(lp1
ccopy_reg
_reconstructor
p2
(cBio.Medline
Record
p3
c__builtin__
dict
p4
(dp5
S'LID'
p6
S'10.1371/journal.pone.0145796 [doi]'
p7
sS'STAT'
p8
S'MEDLINE'
p9
sS'DEP'
p10
S'20151230'
p11
sS'DA'
p12
S'20151231'
p13
sS'AID'
p14
(lp15
S'10.1371/journal.pone.0145796 [doi]'
p16
aS'PONE-D-15-23721 [pii]'
p17
asS'CRDT'
p18
(lp19
S'2015/12/31 06:00'
p20
asS'DP'
p21
S'2015'
p22
sS'AD'
p23
S'Centre for Mathematical Modelling of Infectious Diseases, TB Centre, TB Modeling Group, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom. Amsterdam Institute for Global Health and Development and Department of Global Health, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, United Kingdom. School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, United States of America. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, United States of America. Global Alliance for TB Drug Development, New York, United States of America. Amsterdam Institute for Global Health and Development and Department of Global Health, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. KNCV Tuberculosis Foundation, The Hague, The Netherlands. Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, United Kingdom. Centre for Mathematical Modelling of Infectious Diseases, TB Centre, TB Modeling Group, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.'
p24
sS'OWN'
p25
S'NLM'
p26
sS'PT'
p27
(lp28
S'Journal Article'
p29
aS"Research Support, Non-U.S. Gov't"
p30
asS'LA'
p31
(lp32
S'eng'
p33
asS'FAU'
p34
(lp35
S'Knight, Gwenan M'
p36
aS'Gomez, Gabriela B'
p37
aS'Dodd, Peter J'
p38
aS'Dowdy, David'
p39
aS'Zwerling, Alice'
p40
aS'Wells, William A'
p41
aS'Cobelens, Frank'
p42
aS'Vassall, Anna'
p43
aS'White, Richard G'
p44
asS'JT'
p45
S'PloS one'
p46
sS'LR'
p47
S'20160301'
p48
sS'PG'
p49
S'e0145796'
p50
sS'TI'
p51
S'The Impact and Cost-Effectiveness of a Four-Month Regimen for First-Line Treatment of Active Tuberculosis in South Africa.'
p52
sS'RN'
p53
(lp54
S'0 (Antitubercular Agents)'
p55
asS'PL'
p56
S'United States'
p57
sS'TA'
p58
S'PLoS One'
p59
sS'JID'
p60
S'101285081'
p61
sS'AB'
p62
S'BACKGROUND: A 4-month first-line treatment regimen for tuberculosis disease (TB) is expected to have a direct impact on patient outcomes and societal costs, as well as an indirect impact on Mycobacterium tuberculosis transmission. We aimed to estimate this combined impact in a high TB-burden country: South Africa. METHOD: An individual based M. tb transmission model was fitted to the TB burden of South Africa using a standard TB natural history framework. We measured the impact on TB burden from 2015-2035 of introduction of a non-inferior 4-month regimen replacing the standard 6-month regimen as first-line therapy. Impact was measured with respect to three separate baselines (Guidelines, Policy and Current), reflecting differences in adherence to TB and HIV treatment guidelines. Further scenario analyses considered the variation in treatment-related parameters and resistance levels. Impact was measured in terms of differences in TB burden and Disability Adjusted Life Years (DALYs) averted. We also examined the highest cost at which the new regimen would be cost-effective for several willingness-to-pay thresholds. RESULTS: It was estimated that a 4-month regimen would avert less than 1% of the predicted 6 million person years with TB disease in South Africa between 2015 and 2035. A similarly small impact was seen on deaths and DALYs averted. Despite this small impact, with the health systems and patient cost savings from regimen shortening, the 4-month regimen could be cost-effective at $436 [NA, 5983] (mean [range]) per month at a willingness-to-pay threshold of one GDP per capita ($6,618). CONCLUSION: The introduction of a non-inferior 4-month first-line TB regimen into South Africa would have little impact on the TB burden. However, under several scenarios, it is likely that the averted societal costs would make such a regimen cost-effective in South Africa.'
p63
sS'GR'
p64
(lp65
S'MR/J005088/1/Medical Research Council/United Kingdom'
p66
aS'MR/J005088/1/Medical Research Council/United Kingdom'
p67
asS'IP'
p68
S'12'
p69
sS'IS'
p70
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p71
sS'PMC'
p72
S'PMC4696677'
p73
sS'DCOM'
p74
S'20160627'
p75
sS'AU'
p76
(lp77
S'Knight GM'
p78
aS'Gomez GB'
p79
aS'Dodd PJ'
p80
aS'Dowdy D'
p81
aS'Zwerling A'
p82
aS'Wells WA'
p83
aS'Cobelens F'
p84
aS'Vassall A'
p85
aS'White RG'
p86
asS'VI'
p87
S'10'
p88
sS'MHDA'
p89
S'2016/06/28 06:00'
p90
sS'PHST'
p91
(lp92
S'2015 [ecollection]'
p93
aS'2015/06/01 [received]'
p94
aS'2015/12/08 [accepted]'
p95
aS'2015/12/30 [epublish]'
p96
asS'OID'
p97
(lp98
S'NLM: PMC4696677'
p99
asS'MH'
p100
(lp101
S'Antitubercular Agents/*economics/*therapeutic use'
p102
aS'Cost-Benefit Analysis'
p103
aS'Health Care Costs'
p104
aS'Humans'
p105
aS'Models, Economic'
p106
aS'Mycobacterium tuberculosis/drug effects'
p107
aS'Quality-Adjusted Life Years'
p108
aS'South Africa'
p109
aS'Tuberculosis/*drug therapy/*economics/radionuclide imaging'
p110
asS'EDAT'
p111
S'2015/12/31 06:00'
p112
sS'SO'
p113
S'PLoS One. 2015 Dec 30;10(12):e0145796. doi: 10.1371/journal.pone.0145796. eCollection 2015.'
p114
sS'SB'
p115
S'IM'
p116
sS'PMID'
p117
S'26717007'
p118
sS'PST'
p119
S'epublish'
p120
stRp121
ag2
(g3
g4
(dp122
S'LID'
p123
S'10.1186/s13104-015-1804-6 [doi]'
p124
sS'STAT'
p125
S'MEDLINE'
p126
sS'DEP'
p127
S'20151224'
p128
sS'DA'
p129
S'20151225'
p130
sS'AID'
p131
(lp132
S'10.1186/s13104-015-1804-6 [doi]'
p133
aS'10.1186/s13104-015-1804-6 [pii]'
p134
asS'CRDT'
p135
(lp136
S'2015/12/26 06:00'
p137
asS'DP'
p138
S'2015'
p139
sS'AD'
p140
S'Uganda Research Unit on AIDS, Medical Research Council/Uganda Virus Research Institute (MRC/UVRI), P.O Box 49, Entebbe, Uganda. Andrew.Abaasa@mrcuganda.org. Uganda Research Unit on AIDS, Medical Research Council/Uganda Virus Research Institute (MRC/UVRI), P.O Box 49, Entebbe, Uganda. Gershim.Asiki@mrcuganda.org. Uganda Virus Research Institute/International AIDS Vaccine Initiative (UVRI/IAVI)-HIV Vaccine Program, Entebbe, Uganda. jmpendo@iavi.or.ug. Uganda Research Unit on AIDS, Medical Research Council/Uganda Virus Research Institute (MRC/UVRI), P.O Box 49, Entebbe, Uganda. Jonathan.Levin@wits.ac.za. Faculty of Health Sciences, School of Public Health, University of the Witwatersrand, Johannesburg, South Africa. Jonathan.Levin@wits.ac.za. Uganda Research Unit on AIDS, Medical Research Council/Uganda Virus Research Institute (MRC/UVRI), P.O Box 49, Entebbe, Uganda. Janet.Seeley@mrcuganda.org. London School of Hygiene and Tropical Medicine, London, UK. Janet.Seeley@mrcuganda.org. International AIDS Vaccine Initiative, New York, USA. lnielsen@iavi.org. Uganda Virus Research Institute/International AIDS Vaccine Initiative (UVRI/IAVI)-HIV Vaccine Program, Entebbe, Uganda. assetaala@iavi.or.ug. Uganda Virus Research Institute/International AIDS Vaccine Initiative (UVRI/IAVI)-HIV Vaccine Program, Entebbe, Uganda. ANanvubya@iavi.or.ug. International AIDS Vaccine Initiative, New York, USA. jdebont@iavi.org. Uganda Research Unit on AIDS, Medical Research Council/Uganda Virus Research Institute (MRC/UVRI), P.O Box 49, Entebbe, Uganda. Pontiano.Kaleebu@mrcuganda.org. London School of Hygiene and Tropical Medicine, London, UK. Pontiano.Kaleebu@mrcuganda.org. Uganda Research Unit on AIDS, Medical Research Council/Uganda Virus Research Institute (MRC/UVRI), P.O Box 49, Entebbe, Uganda. Anatoli.Kamali@mrcuganda.org.'
p141
sS'OWN'
p142
S'NLM'
p143
sS'PT'
p144
(lp145
S'Journal Article'
p146
aS'Observational Study'
p147
aS"Research Support, Non-U.S. Gov't"
p148
aS"Research Support, U.S. Gov't, Non-P.H.S."
p149
asS'LA'
p150
(lp151
S'eng'
p152
asS'DCOM'
p153
S'20160926'
p154
sS'JT'
p155
S'BMC research notes'
p156
sS'LR'
p157
S'20160308'
p158
sS'FAU'
p159
(lp160
S'Abaasa, Andrew'
p161
aS'Asiki, Gershim'
p162
aS'Mpendo, Juliet'
p163
aS'Levin, Jonathan'
p164
aS'Seeley, Janet'
p165
aS'Nielsen, Leslie'
p166
aS'Ssetaala, Ali'
p167
aS'Nanvubya, Annet'
p168
aS'De Bont, Jan'
p169
aS'Kaleebu, Pontiano'
p170
aS'Kamali, Anatoli'
p171
asS'TI'
p172
S'Factors associated with dropout in a long term observational cohort of fishing communities around lake Victoria, Uganda.'
p173
sS'PL'
p174
S'England'
p175
sS'PG'
p176
S'815'
p177
sS'JID'
p178
S'101462768'
p179
sS'AB'
p180
S'BACKGROUND: Fishing communities are potentially suitable for Human immunodeficiency virus (HIV) efficacy trials due to their high risk profile. However, high mobility and attrition could decrease statistical power to detect the impact of a given intervention. We report dropout and associated factors in a fisher-folk observational cohort in Uganda. METHODS: Human immunodeficiency virus-uninfected high-risk volunteers aged 13-49 years living in five fishing communities around Lake Victoria were enrolled and followed every 6 months for 18 months at clinics located within each community. Volunteers from two of the five communities had their follow-up periods extended to 30 months and were invited to attend clinics 10-40 km (km) away from their communities. Human immunodeficiency virus counseling and testing was provided, and data on sexual behaviour collected at all study visits. Study completion was defined as completion of 18 or 30 months or visits up to the date of sero-conversion and dropout as missing one or more visits. Discrete time survival models were fitted to find factors independently associated with dropout. RESULTS: A total of 1000 volunteers (55% men) were enrolled. Of these, 91.9% completed 6 months, 85.2% completed 12 months and 76.0% completed 18 months of follow-up. In the two communities with additional follow-up, 76.9% completed 30 months. In total 299 (29.9%) volunteers missed at least one visit (dropped out). Dropout was independently associated with age (volunteers aged 13-24 being most likely to dropout), gender [men being more likely to dropout than women [adjusted hazard ratio (aHR) 1.4; 95% confidence interval (CI) 1.1-1.8)], time spent in the fishing community (those who stayed <1 year being most likely to dropout), History of marijuana use (users being more likely to dropout than non-users [1.7; (1.2-2.5)], ethnicity (non-Baganda being more likely to dropout than Baganda [1.5; (1.2-1.9)], dropout varied between the five fishing communities, having a new sexual partner in the previous 3 months [1.3 (1.0-1.7)] and being away from home for >/=2 nights in the month preceding the interview [1.4 (1.1-1.8)]. CONCLUSION: Despite a substantial proportion dropping out, retention was sufficient to suggest that by incorporating retention strategies it will be possible to conduct HIV prevention efficacy trials in this community.'
p181
sS'GR'
p182
(lp183
S'MC_U950097152/Medical Research Council/United Kingdom'
p184
aS'MC_U950097154/Medical Research Council/United Kingdom'
p185
asS'VI'
p186
S'8'
sS'IS'
p187
S'1756-0500 (Electronic) 1756-0500 (Linking)'
p188
sS'PMC'
p189
S'PMC4690385'
p190
sS'AU'
p191
(lp192
S'Abaasa A'
p193
aS'Asiki G'
p194
aS'Mpendo J'
p195
aS'Levin J'
p196
aS'Seeley J'
p197
aS'Nielsen L'
p198
aS'Ssetaala A'
p199
aS'Nanvubya A'
p200
aS'De Bont J'
p201
aS'Kaleebu P'
p202
aS'Kamali A'
p203
asS'MHDA'
p204
S'2016/09/27 06:00'
p205
sS'PHST'
p206
(lp207
S'2015/01/23 [received]'
p208
aS'2015/12/14 [accepted]'
p209
aS'2015/12/24 [aheadofprint]'
p210
asS'OID'
p211
(lp212
S'NLM: PMC4690385'
p213
asS'MH'
p214
(lp215
S'Adolescent'
p216
aS'Adult'
p217
aS'Animals'
p218
aS'Cohort Studies'
p219
aS'Female'
p220
aS'Fishes'
p221
aS'Follow-Up Studies'
p222
aS'HIV Infections/epidemiology/*prevention & control'
p223
aS'Humans'
p224
aS'Lakes'
p225
aS'Male'
p226
aS'Middle Aged'
p227
aS'Patient Dropouts/statistics & numerical data'
p228
aS'Risk-Taking'
p229
aS'Sexual Behavior'
p230
aS'Uganda/epidemiology'
p231
aS'Young Adult'
p232
asS'EDAT'
p233
S'2015/12/26 06:00'
p234
sS'SO'
p235
S'BMC Res Notes. 2015 Dec 24;8:815. doi: 10.1186/s13104-015-1804-6.'
p236
sS'SB'
p237
S'IM'
p238
sS'PMID'
p239
S'26703879'
p240
sS'TA'
p241
S'BMC Res Notes'
p242
sS'PST'
p243
S'epublish'
p244
stRp245
ag2
(g3
g4
(dp246
S'LID'
p247
S'10.1371/journal.pone.0145536 [doi]'
p248
sS'STAT'
p249
S'MEDLINE'
p250
sS'DEP'
p251
S'20151223'
p252
sS'DA'
p253
S'20151224'
p254
sS'AID'
p255
(lp256
S'10.1371/journal.pone.0145536 [doi]'
p257
aS'PONE-D-15-34596 [pii]'
p258
asS'CRDT'
p259
(lp260
S'2015/12/25 06:00'
p261
asS'DP'
p262
S'2015'
p263
sS'GR'
p264
(lp265
S'1U2GGH000785-01/PEPFAR/United States'
p266
aS'3U2GPS000586-05S1/PEPFAR/United States'
p267
aS'MC_U950080938/Medical Research Council/United Kingdom'
p268
aS'Medical Research Council/United Kingdom'
p269
asS'OWN'
p270
S'NLM'
p271
sS'PT'
p272
(lp273
S'Journal Article'
p274
aS"Research Support, Non-U.S. Gov't"
p275
aS"Research Support, U.S. Gov't, Non-P.H.S."
p276
asS'LA'
p277
(lp278
S'eng'
p279
asS'FAU'
p280
(lp281
S'Kaleebu, Pontiano'
p282
aS'Kirungi, Wilford'
p283
aS'Watera, Christine'
p284
aS'Asio, Juliet'
p285
aS'Lyagoba, Fred'
p286
aS'Lutalo, Tom'
p287
aS'Kapaata, Anne A'
p288
aS'Nanyonga, Faith'
p289
aS'Parry, Chris M'
p290
aS'Magambo, Brian'
p291
aS'Nazziwa, Jamirah'
p292
aS'Nannyonjo, Maria'
p293
aS'Hughes, Peter'
p294
aS'Hladik, Wolfgang'
p295
aS'Ruberantwari, Anthony'
p296
aS'Namuwenge, Norah'
p297
aS'Musinguzi, Joshua'
p298
aS'Downing, Robert'
p299
aS'Katongole-Mbidde, Edward'
p300
asS'JT'
p301
S'PloS one'
p302
sS'LR'
p303
S'20160322'
p304
sS'PG'
p305
S'e0145536'
p306
sS'TI'
p307
S'Virological Response and Antiretroviral Drug Resistance Emerging during Antiretroviral Therapy at Three Treatment Centers in Uganda.'
p308
sS'RN'
p309
(lp310
S'0 (Anti-HIV Agents)'
p311
asS'PL'
p312
S'United States'
p313
sS'TA'
p314
S'PLoS One'
p315
sS'FIR'
p316
(lp317
S'Kaleebu, Pontiano'
p318
aS'Kirungi, Wilford'
p319
aS'Munderi, Paula'
p320
aS'Ssali, Francis'
p321
aS'Lutalo, Tom'
p322
aS'Etukoit, Bernard'
p323
aS'Namayanja, Grace'
p324
aS'Downing, Robert'
p325
aS'Watera, Christine'
p326
aS'Byomire, Helen'
p327
aS'Kambugu, Andrew'
p328
aS'Kityo, Cissy'
p329
aS'Namuwenge, Norah'
p330
aS'Namagala, Elizabeth'
p331
asS'JID'
p332
S'101285081'
p333
sS'AB'
p334
S'BACKGROUND: With the scale-up of antiretroviral therapy (ART), monitoring programme performance is needed to maximize ART efficacy and limit HIV drug resistance (HIVDR). METHODS: We implemented a WHO HIVDR prospective survey protocol at three treatment centers between 2012 and 2013. Data were abstracted from patient records at ART start (T1) and after 12 months (T2). Genotyping was performed in the HIV pol region at the two time points. RESULTS: Of the 425 patients enrolled, at T2, 20 (4.7%) had died, 66 (15.5%) were lost to follow-up, 313 (73.6%) were still on first-line, 8 (1.9%) had switched to second-line, 17 (4.0%) had transferred out and 1 (0.2%) had stopped treatment. At T2, 272 out of 321 on first and second line (84.7%) suppressed below 1000 copies/ml and the HIV DR prevention rate was 70.1%, just within the WHO threshold of >/= 70%. The proportion of participants with potential HIVDR was 20.9%, which is higher than the 18.8% based on pooled analyses from African studies. Of the 35 patients with mutations at T2, 80% had M184V/I, 65.7% Y181C, and 48.6% (54.8% excluding those not on Tenofovir) had K65R mutations. 22.9% had Thymidine Analogue Mutations (TAMs). Factors significantly associated with HIVDR prevention at T2 were: baseline viral load (VL) <100,000 copies/ml [Adjusted odds ratio (AOR) 3.13, 95% confidence interval (CI): 1.36-7.19] and facility. Independent baseline predictors for HIVDR mutations at T2 were: CD4 count < 250 cells/mul (AOR 2.80, 95% CI: 1.08-7.29) and viral load >/= 100,000 copies/ml (AOR 2.48, 95% CI: 1.00-6.14). CONCLUSION: Strengthening defaulter tracing, intensified follow-up for patients with low CD4 counts and/or high VL at ART initiation together with early treatment initiation above 250 CD4 cells/ul and adequate patient counselling would improve ART efficacy and HIVDR prevention. The high rate of K65R and TAMs could compromise second line regimens including NRTIs.'
p335
sS'AD'
p336
S'Uganda Virus Research Institute, Entebbe, Uganda. MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda. London School of Hygiene and Tropical Medicine, London, United Kingdom. Ministry of Health, AIDS Control Programme, Kampala, Uganda. Uganda Virus Research Institute, Entebbe, Uganda. Uganda Virus Research Institute, Entebbe, Uganda. Uganda Virus Research Institute, Entebbe, Uganda. MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda. Uganda Virus Research Institute, Entebbe, Uganda. MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda. Uganda Virus Research Institute, Entebbe, Uganda. MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda. Uganda Virus Research Institute, Entebbe, Uganda. MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda. MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda. MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda. MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda. U.S. Centers for Disease Control and Prevention, Entebbe, Uganda. Uganda Virus Research Institute, Entebbe, Uganda. Ministry of Health, AIDS Control Programme, Kampala, Uganda. Ministry of Health, AIDS Control Programme, Kampala, Uganda. Uganda Virus Research Institute, Entebbe, Uganda. Uganda Virus Research Institute, Entebbe, Uganda.'
p337
sS'CN'
p338
(lp339
S'HIV Drug Resistance Working group'
p340
asS'IP'
p341
S'12'
p342
sS'IS'
p343
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p344
sS'IR'
p345
(lp346
S'Kaleebu P'
p347
aS'Kirungi W'
p348
aS'Munderi P'
p349
aS'Ssali F'
p350
aS'Lutalo T'
p351
aS'Etukoit B'
p352
aS'Namayanja G'
p353
aS'Downing R'
p354
aS'Watera C'
p355
aS'Byomire H'
p356
aS'Kambugu A'
p357
aS'Kityo C'
p358
aS'Namuwenge N'
p359
aS'Namagala E'
p360
asS'DCOM'
p361
S'20160817'
p362
sS'AU'
p363
(lp364
S'Kaleebu P'
p365
aS'Kirungi W'
p366
aS'Watera C'
p367
aS'Asio J'
p368
aS'Lyagoba F'
p369
aS'Lutalo T'
p370
aS'Kapaata AA'
p371
aS'Nanyonga F'
p372
aS'Parry CM'
p373
aS'Magambo B'
p374
aS'Nazziwa J'
p375
aS'Nannyonjo M'
p376
aS'Hughes P'
p377
aS'Hladik W'
p378
aS'Ruberantwari A'
p379
aS'Namuwenge N'
p380
aS'Musinguzi J'
p381
aS'Downing R'
p382
aS'Katongole-Mbidde E'
p383
asS'VI'
p384
S'10'
p385
sS'MHDA'
p386
S'2016/08/18 06:00'
p387
sS'PHST'
p388
(lp389
S'2015 [ecollection]'
p390
aS'2015/08/06 [received]'
p391
aS'2015/12/04 [accepted]'
p392
aS'2015/12/23 [epublish]'
p393
asS'OID'
p394
(lp395
S'NLM: PMC4689474'
p396
asS'MH'
p397
(lp398
S'Adult'
p399
aS'Anti-HIV Agents/*therapeutic use'
p400
aS'*Antiretroviral Therapy, Highly Active'
p401
aS'*Drug Resistance, Viral'
p402
aS'Female'
p403
aS'HIV Infections/drug therapy/epidemiology/*virology'
p404
aS'HIV-1/*drug effects'
p405
aS'Humans'
p406
aS'Male'
p407
aS'Middle Aged'
p408
aS'Prognosis'
p409
aS'Prospective Studies'
p410
aS'Uganda/epidemiology'
p411
aS'Viral Load'
p412
asS'EDAT'
p413
S'2015/12/25 06:00'
p414
sS'PMC'
p415
S'PMC4689474'
p416
sS'SO'
p417
S'PLoS One. 2015 Dec 23;10(12):e0145536. doi: 10.1371/journal.pone.0145536. eCollection 2015.'
p418
sS'SB'
p419
S'IM'
p420
sS'PMID'
p421
S'26700639'
p422
sS'PST'
p423
S'epublish'
p424
stRp425
ag2
(g3
g4
(dp426
S'LID'
p427
S'10.7448/IAS.18.1.20303 [doi]'
p428
sS'STAT'
p429
S'MEDLINE'
p430
sS'DEP'
p431
S'20151218'
p432
sS'DA'
p433
S'20151222'
p434
sS'AID'
p435
(lp436
S'20303 [pii]'
p437
asS'CRDT'
p438
(lp439
S'2015/12/23 06:00'
p440
asS'DP'
p441
S'2015'
p442
sS'GR'
p443
(lp444
S'5U2GPS001537/PHS HHS/United States'
p445
aS'5U62PS223540/PS/NCHHSTP CDC HHS/United States'
p446
asS'OWN'
p447
S'NLM'
p448
sS'PT'
p449
(lp450
S'Journal Article'
p451
aS'Practice Guideline'
p452
aS"Research Support, U.S. Gov't, P.H.S."
p453
asS'LA'
p454
(lp455
S'eng'
p456
asS'DCOM'
p457
S'20160816'
p458
sS'JT'
p459
S'Journal of the International AIDS Society'
p460
sS'LR'
p461
S'20151224'
p462
sS'FAU'
p463
(lp464
S'Nuwagaba-Biribonwoha, Harriet'
p465
aS'Wang, Chunhui'
p466
aS'Kilama, Bonita'
p467
aS'Jowhar, Farhat K'
p468
aS'Antelman, Gretchen'
p469
aS'Panya, Milembe F'
p470
aS'Abrams, Elaine J'
p471
asS'TI'
p472
S'Implementation of antiretroviral therapy guidelines for under-five children in Tanzania: translating recommendations into practice.'
p473
sS'RN'
p474
(lp475
S'0 (Anti-HIV Agents)'
p476
asS'PL'
p477
S'Switzerland'
p478
sS'PG'
p479
S'20303'
p480
sS'JID'
p481
S'101478566'
p482
sS'AB'
p483
S'INTRODUCTION: Paediatric antiretroviral therapy (ART) guidelines have been updated several times in recent years. We assessed implementation of ART guidelines among under-five children to inform the transition to universal paediatric ART in Tanzania. METHODS: We conducted a retrospective cohort analysis of infants (0 to 11 months) and children (12 to 59 months) enrolled between 2010 and 2012 using routinely collected data. Infants and children were initiated on ART according to the 2008 World Health Organization (WHO) recommendations/2009 Tanzania guidelines (universal ART for infants). Cumulative ART initiation incidence and correlates of ART initiation were examined using competing risk methods accounting for attrition (death or loss to follow-up). Kaplan-Meier methods and Cox regression models were used to examine attrition on ART and its correlates. RESULTS: A total of 1679 children were enrolled at 69 clinics: 469 (28%) infants and 1210 (74%) children. Infant cumulative ART initiation incidence was 59.6, 71.3 and 78.0% at one, three and six months of follow-up. Infants were more likely to start ART if enrolled in 2012 [adjusted sub-hazard ratio (AsHR)=2.2, 95% confidence interval (CI): 1.7 to 2.8] or 2011 (AsHR=1.8, 95% CI: 1.4 to 2.3) compared to 2010; they were more likely to start ART from prevention of mother-to-child HIV transmission (AsHR=1.6, 95% CI: 1.3 to 2.1) and inpatient wards (AsHR=1.5, 95% CI: 1.2 to 2.0) versus being enrolled from voluntary counselling and testing centres. Attrition at 12 months on ART was 33.9% and was more likely among infants with WHO Stage 4 [adjusted hazard ratio (AHR)=3.1. 95% CI: 1.8 to 5.2] and severe malnutrition (AHR=1.4, 95% CI: 1.0 to 1.9).Among 599 children eligible for ART at enrollment, cumulative ART initiation incidence was 51.8, 68.6 and 76.1% at one, three, and six months. Children were more likely to start ART if enrolled in 2012 (AsHR=1.8, 95% CI: 1.4 to 2.3) or 2011 (AsHR=1.5, 95% CI: 1.2 to 1.8) compared to 2010; they were more likely to start ART at primary health facilities (AsHR=1.5, 95% CI: 1.1 to 2.0) and less likely at urban facilities (AsHR=0.6, 95% CI: 0.5 to 0.9) and facilities without CD4 testing on site (AsHR=0.7, 95% CI: 0.5 to 0.9). Attrition at 12 months on ART was 23.1% and was more likely with severe malnutrition (AHR=1.8, 95% CI: 1.1 to 3.0), WHO Stage 4 (AHR=3.0, 95% CI: 1.0 to 8.5) and outpatient enrolees (AHR=1.7, 95% CI: 1.1 to 2.7). CONCLUSIONS: Our findings suggest the gradual adoption of guidelines over calendar time. Interventions to expedite ART initiation and support retention on ART are needed.'
p484
sS'AD'
p485
S'ICAP at Columbia University, Mailman School of Public Health, Columbia University, New York, NY, USA. Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA; hn2158@cumc.columbia.edu. ICAP at Columbia University, Mailman School of Public Health, Columbia University, New York, NY, USA. National AIDS Control Program, Dar Es Salaam, Tanzania. Zanzibar AIDS Control Program, Zanzibar, Tanzania. ICAP at Columbia University, Mailman School of Public Health, Columbia University, New York, NY, USA. ICAP at Columbia University, Mailman School of Public Health, Columbia University, New York, NY, USA. ICAP at Columbia University, Mailman School of Public Health, Columbia University, New York, NY, USA. Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.'
p486
sS'CN'
p487
(lp488
S'Identifying Optimal Models of HIV Care in Africa: Tanzania and Zanzibar'
p489
aS'Consortium'
p490
asS'VI'
p491
S'18'
p492
sS'IS'
p493
S'1758-2652 (Electronic) 1758-2652 (Linking)'
p494
sS'PMC'
p495
S'PMC4685962'
p496
sS'AU'
p497
(lp498
S'Nuwagaba-Biribonwoha H'
p499
aS'Wang C'
p500
aS'Kilama B'
p501
aS'Jowhar FK'
p502
aS'Antelman G'
p503
aS'Panya MF'
p504
aS'Abrams EJ'
p505
asS'MHDA'
p506
S'2016/08/17 06:00'
p507
sS'PHST'
p508
(lp509
S'2015 [ecollection]'
p510
aS'2015/05/16 [received]'
p511
aS'2015/10/15 [revised]'
p512
aS'2015/11/02 [accepted]'
p513
asS'OT'
p514
(lp515
S'ART cascade'
p516
aS'HIV-infected children'
p517
aS'Tanzania'
p518
aS'antiretroviral therapy'
p519
aS'infants'
p520
asS'OTO'
p521
(lp522
S'NOTNLM'
p523
asS'OID'
p524
(lp525
S'NLM: PMC4685962'
p526
asS'MH'
p527
(lp528
S'Anti-HIV Agents/*therapeutic use'
p529
aS'CD4 Lymphocyte Count'
p530
aS'Child, Preschool'
p531
aS'Cohort Studies'
p532
aS'Female'
p533
aS'HIV Infections/*drug therapy/immunology'
p534
aS'Humans'
p535
aS'Infant'
p536
aS'Male'
p537
aS'Retrospective Studies'
p538
asS'EDAT'
p539
S'2015/12/23 06:00'
p540
sS'SO'
p541
S'J Int AIDS Soc. 2015 Dec 18;18:20303. doi: 10.7448/IAS.18.1.20303. eCollection 2015.'
p542
sS'SB'
p543
S'IM X'
p544
sS'PMID'
p545
S'26690303'
p546
sS'TA'
p547
S'J Int AIDS Soc'
p548
sS'PST'
p549
S'epublish'
p550
stRp551
ag2
(g3
g4
(dp552
S'LID'
p553
S'10.1089/apc.2015.0213 [doi]'
p554
sS'STAT'
p555
S'MEDLINE'
p556
sS'DEP'
p557
S'20151218'
p558
sS'DA'
p559
S'20160109'
p560
sS'AID'
p561
(lp562
S'10.1089/apc.2015.0213 [doi]'
p563
asS'CRDT'
p564
(lp565
S'2015/12/20 06:00'
p566
asS'DP'
p567
S'2016 Jan'
p568
sS'AD'
p569
S'1 Department of Internal Medicine, Mbarara University of Science and Technology , Mbarara, Uganda . 1 Department of Internal Medicine, Mbarara University of Science and Technology , Mbarara, Uganda . 1 Department of Internal Medicine, Mbarara University of Science and Technology , Mbarara, Uganda . 2 Department of Internal Medicine, Mbarara Regional Referral Hospital , Mbarara, Uganda . 3 Department of Infectious Disease and Center for Global Health, Massachusetts General Hospital , Boston, Massachusetts. 4 Harvard Medical School , Boston, Massachusetts.'
p570
sS'OWN'
p571
S'NLM'
p572
sS'PT'
p573
(lp574
S'Journal Article'
p575
aS'Research Support, N.I.H., Extramural'
p576
aS"Research Support, Non-U.S. Gov't"
p577
asS'LA'
p578
(lp579
S'eng'
p580
asS'FAU'
p581
(lp582
S'Muyanja, Daniel'
p583
aS'Muzoora, Conrad'
p584
aS'Muyingo, Anthony'
p585
aS'Muyindike, Winnie'
p586
aS'Siedner, Mark J'
p587
asS'JT'
p588
S'AIDS patient care and STDs'
p589
sS'LR'
p590
S'20160209'
p591
sS'PG'
p592
S'4-10'
p593
sS'TI'
p594
S'High Prevalence of Metabolic Syndrome and Cardiovascular Disease Risk Among People with HIV on Stable ART in Southwestern Uganda.'
p595
sS'RN'
p596
(lp597
S'0 (Blood Glucose)'
p598
aS'0 (Cholesterol, HDL)'
p599
asS'IS'
p600
S'1557-7449 (Electronic) 1087-2914 (Linking)'
p601
sS'PL'
p602
S'United States'
p603
sS'TA'
p604
S'AIDS Patient Care STDS'
p605
sS'JID'
p606
S'9607225'
p607
sS'AB'
p608
S'The objectives of this study were to determine the epidemiology and correlates of cardiovascular disease (CVD) risk among Ugandans on first-line antiretroviral therapy (ART). We conducted a cross-sectional study at an HIV clinic in southwestern Uganda. We enrolled adult patients on non-nucleoside-based ART regimens for a minimum of 2 years. We collected anthropometric and clinical measurements, smoking history, and blood for fasting lipid profile and blood sugar (FBS). Outcomes of interest were (1) presence of metabolic syndrome (at least two of the following: FBS >100 mg/dL, blood pressure of >/=130/85 mmHg, triglycerides >/=150 mg/dL, HDL <40 mg/DL, or waist circumference >/=94 cm in males or >/=80 cm in females); and (2) a Framingham score correlating to >5% 10-year CVD risk. Of the 250 participants enrolled, metabolic syndrome was detected in 145/250 (58%) of participants (62% in females and 50% in males). Forty-three participants (17%) had a Framingham risk correlating to a 5% or greater risk for CVD within 10 years (26% in males and 13% in females). In multivariate analyses, being female (AOR 3.13; 95% CI: 1.0-9.70; p = 0.04) and over 40 years of age (AOR 1.78; 95% CI: 1.00-3.17; p = 0.05) was independently associated with having metabolic syndrome. We found no independent risk factors for a Framingham risk score 10-year risk exceeding 5%, or associations between ART regimen and CVD risk profiles. We conclude that metabolic abnormalities are common among patients on first-line ART in rural Uganda, and appear to be more common in women than men.'
p609
sS'GR'
p610
(lp611
S'K23 MH099916/MH/NIMH NIH HHS/United States'
p612
aS'K23MH 099916/MH/NIMH NIH HHS/United States'
p613
asS'IP'
p614
S'1'
sS'PMCR'
p615
(lp616
S'2017/01/01 00:00'
p617
asS'PMC'
p618
S'PMC4717524'
p619
sS'DCOM'
p620
S'20160223'
p621
sS'AU'
p622
(lp623
S'Muyanja D'
p624
aS'Muzoora C'
p625
aS'Muyingo A'
p626
aS'Muyindike W'
p627
aS'Siedner MJ'
p628
asS'VI'
p629
S'30'
p630
sS'MHDA'
p631
S'2016/02/26 06:00'
p632
sS'PHST'
p633
(lp634
S'2015/12/18 [aheadofprint]'
p635
asS'OID'
p636
(lp637
S'NLM: PMC4717524 [Available on 01/01/17]'
p638
asS'MH'
p639
(lp640
S'Adult'
p641
aS'Age Distribution'
p642
aS'*Antiretroviral Therapy, Highly Active'
p643
aS'Blood Glucose/*analysis'
p644
aS'Body Mass Index'
p645
aS'Cardiovascular Diseases/*epidemiology'
p646
aS'Cholesterol, HDL/blood'
p647
aS'Cross-Sectional Studies'
p648
aS'Female'
p649
aS'HIV Infections/*drug therapy/epidemiology'
p650
aS'Humans'
p651
aS'Hypertension/*epidemiology'
p652
aS'Male'
p653
aS'Metabolic Syndrome X/blood/*epidemiology'
p654
aS'Multivariate Analysis'
p655
aS'Obesity/epidemiology'
p656
aS'Prevalence'
p657
aS'Risk Factors'
p658
aS'Sex Distribution'
p659
aS'Uganda/epidemiology'
p660
asS'EDAT'
p661
S'2015/12/20 06:00'
p662
sS'SO'
p663
S'AIDS Patient Care STDS. 2016 Jan;30(1):4-10. doi: 10.1089/apc.2015.0213. Epub 2015 Dec 18.'
p664
sS'SB'
p665
S'IM X'
p666
sS'PMID'
p667
S'26683587'
p668
sS'PST'
p669
S'ppublish'
p670
stRp671
ag2
(g3
g4
(dp672
S'LID'
p673
S'10.1186/s12913-015-1213-5 [doi]'
p674
sS'STAT'
p675
S'MEDLINE'
p676
sS'DEP'
p677
S'20151215'
p678
sS'DA'
p679
S'20151215'
p680
sS'AID'
p681
(lp682
S'10.1186/s12913-015-1213-5 [doi]'
p683
aS'10.1186/s12913-015-1213-5 [pii]'
p684
asS'CRDT'
p685
(lp686
S'2015/12/16 06:00'
p687
asS'DP'
p688
S'2015'
p689
sS'AD'
p690
S"Makerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Upper Mulago Hill Road, P.O. BOX 23491, Kampala, Uganda. znamukwaya@mujhu.org. Makerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Upper Mulago Hill Road, P.O. BOX 23491, Kampala, Uganda. lbarlow@mujhu.org. Makerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Upper Mulago Hill Road, P.O. BOX 23491, Kampala, Uganda. pmudiope@gmail.com. Baylor College of Medicine Children's Foundation, Kampala, Uganda. akekitiinwa@baylor-uganda.org. Makerere University College of Health Sciences, Pediatrics and Child Health, Kampala, Uganda. akekitiinwa@baylor-uganda.org. Makerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Upper Mulago Hill Road, P.O. BOX 23491, Kampala, Uganda. jmatovu@mujhu.org. Makerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Upper Mulago Hill Road, P.O. BOX 23491, Kampala, Uganda. emusingye@yahoo.com. Makerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Upper Mulago Hill Road, P.O. BOX 23491, Kampala, Uganda. jssebaggala@mujhu.org. Makerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Upper Mulago Hill Road, P.O. BOX 23491, Kampala, Uganda. tnakyanzi@mujhu.org. Mpigi Health Centre IV, Mpigi, Uganda. jubileejohn@yahoo.co.uk. Makerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Upper Mulago Hill Road, P.O. BOX 23491, Kampala, Uganda. dmirembe@mujhu.org. Makerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Upper Mulago Hill Road, P.O. BOX 23491, Kampala, Uganda. jetima@mujhu.org. Elizabeth Glaser Pediatric AIDS Foundation, Kampala, Uganda. ebitarakwate@pedaids.org. Makerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Upper Mulago Hill Road, P.O. BOX 23491, Kampala, Uganda. mgfowler@mujhu.org. Makerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Upper Mulago Hill Road, P.O. BOX 23491, Kampala, Uganda. pmusoke@mujhu.org. Makerere University College of Health Sciences, Pediatrics and Child Health, Kampala, Uganda. pmusoke@mujhu.org."
p691
sS'OWN'
p692
S'NLM'
p693
sS'PT'
p694
(lp695
S'Journal Article'
p696
aS'Multicenter Study'
p697
aS"Research Support, Non-U.S. Gov't"
p698
asS'LA'
p699
(lp700
S'eng'
p701
asS'DCOM'
p702
S'20160926'
p703
sS'JT'
p704
S'BMC health services research'
p705
sS'FAU'
p706
(lp707
S'Namukwaya, Zikulah'
p708
aS'Barlow-Mosha, Linda'
p709
aS'Mudiope, Peter'
p710
aS'Kekitiinwa, Adeodata'
p711
aS'Matovu, Joyce Namale'
p712
aS'Musingye, Ezra'
p713
aS'Ssebaggala, Jane Ntongo'
p714
aS'Nakyanzi, Teopista'
p715
aS'Abwooli, Jubilee John'
p716
aS'Mirembe, Dorothy'
p717
aS'Etima, Juliane'
p718
aS'Bitarakwate, Edward'
p719
aS'Fowler, Mary Glenn'
p720
aS'Musoke, Philippa Martha'
p721
asS'TI'
p722
S'Use of peers, community lay persons and Village Health Team (VHT) members improves six-week postnatal clinic (PNC) follow-up and Early Infant HIV Diagnosis (EID) in urban and rural health units in Uganda: A one-year implementation study.'
p723
sS'PL'
p724
S'England'
p725
sS'PG'
p726
S'555'
p727
sS'JID'
p728
S'101088677'
p729
sS'AB'
p730
S'BACKGROUND: Effective Prevention of Mother to child Transmission of HIV (PMTCT) relies heavily on follow-up of HIV-infected women and infants from antenatal, through postnatal, to the end of the breastfeeding period. In Uganda, postnatal (PNC) follow-up remains below 50 % creating a missed opportunity for linkage to comprehensive HIV care and early infant diagnosis (EID). We evaluated the use of HIV infected peer mothers (peers), community lay persons and Village health team (VHT) members to improve PNC follow up and EID in urban and rural health units. METHODS: Study participants were HIV-infected women recruited from antenatal clinics at three urban clinics (Mulago, Rubaga and Mengo hospitals) and one rural health centre (Mpigi Health centre IV) between January and September 2010. The women were followed through delivery and the mother-infant pairs for the 6-week postnatal visit and up to 14 weeks for EID. Peers, community lay persons and VHT members were identified and trained in basic PMTCT and reproductive health (RH). They were then assigned to study clinic to support and follow study participants, their partners and infants through provision of health education, counseling, home visits, and phone call reminders. Six week PNC attendance was measured as a proportion of mother-infant pairs that returned for the 6-week postnatal follow up visit (5-8 weeks) while EID was measured as the proportion of HIV-exposed live birth that had an HIV test done by 14 weeks of age. Data at baseline (one year before the intervention) was compared with that during the one year study period among study participants and HIV infected women and their HIV-exposed infants in the whole clinic population. RESULTS: A total of 558 HIV-infected pregnant women were recruited for the study, 47 mother-infant pairs were censured before 6 weeks due to stillbirth (14), infant death < 6 weeks (23), death of participant (04) and loss to follow up before delivery (6). 401/511 (78.5 %) of mother-infant pairs returned to the study clinics at six-week, while 441/511 (86.3 %) infants were tested for HIV infection by 14 weeks of age. The baseline six-week PNC follow up was 37.7 % and increased during the study period to 78.5 % and 39.1 % among study participants and whole clinic population respectively, an incremental difference of 39.4 % (P < 0.001). EID increased from a baseline of 53.6 % to 86.3 % and 65.8 % among study and whole clinic population respectively during the study period, an incremental difference of 20.5 % (P < 0.001). CONCLUSIONS: Use of peers, community lay persons and VHT members led to a significant increase in six-week postnatal follow up of HIV infected women and EID among HIV exposed infants in the four study clinics. Our study supports the use of peers to improve early postnatal follow up and EID and should be implemented in other health units to support the PMTCT cascade.'
p731
sS'CN'
p732
(lp733
S'Peer-senga study Group at Mulago, Mengo, Rubaga and Mpigi Health Units'
p734
asS'VI'
p735
S'15'
p736
sS'IS'
p737
S'1472-6963 (Electronic) 1472-6963 (Linking)'
p738
sS'PMC'
p739
S'PMC4678627'
p740
sS'AU'
p741
(lp742
S'Namukwaya Z'
p743
aS'Barlow-Mosha L'
p744
aS'Mudiope P'
p745
aS'Kekitiinwa A'
p746
aS'Matovu JN'
p747
aS'Musingye E'
p748
aS'Ssebaggala JN'
p749
aS'Nakyanzi T'
p750
aS'Abwooli JJ'
p751
aS'Mirembe D'
p752
aS'Etima J'
p753
aS'Bitarakwate E'
p754
aS'Fowler MG'
p755
aS'Musoke PM'
p756
asS'MHDA'
p757
S'2016/09/27 06:00'
p758
sS'PHST'
p759
(lp760
S'2015/02/05 [received]'
p761
aS'2015/12/04 [accepted]'
p762
aS'2015/12/15 [aheadofprint]'
p763
asS'MH'
p764
(lp765
S'Adult'
p766
aS'Ambulatory Care Facilities'
p767
aS'Breast Feeding'
p768
aS'Directive Counseling'
p769
aS'Early Diagnosis'
p770
aS'Female'
p771
aS'Follow-Up Studies'
p772
aS'HIV Infections/*diagnosis/drug therapy/prevention & control'
p773
aS'Humans'
p774
aS'Infant'
p775
aS'Infant, Newborn'
p776
aS'Infectious Disease Transmission, Vertical/prevention & control'
p777
aS'Male'
p778
aS'*Mothers'
p779
aS'Postnatal Care/methods/*organization & administration'
p780
aS'Pregnancy'
p781
aS'Preventive Health Services/*organization & administration'
p782
aS'Program Evaluation'
p783
aS'Rural Population'
p784
aS'Social Support'
p785
aS'Uganda/epidemiology'
p786
aS'Urban Population'
p787
asS'EDAT'
p788
S'2015/12/17 06:00'
p789
sS'SO'
p790
S'BMC Health Serv Res. 2015 Dec 15;15:555. doi: 10.1186/s12913-015-1213-5.'
p791
sS'SB'
p792
S'IM'
p793
sS'PMID'
p794
S'26666331'
p795
sS'TA'
p796
S'BMC Health Serv Res'
p797
sS'PST'
p798
S'epublish'
p799
stRp800
ag2
(g3
g4
(dp801
S'LID'
p802
S'10.1111/j.1728-4465.2015.00040.x [doi]'
p803
sS'STAT'
p804
S'MEDLINE'
p805
sS'JT'
p806
S'Studies in family planning'
p807
sS'CI'
p808
(lp809
S'(c) 2015 The Population Council, Inc.'
p810
asS'DA'
p811
S'20151208'
p812
sS'AID'
p813
(lp814
S'10.1111/j.1728-4465.2015.00040.x [doi]'
p815
asS'CRDT'
p816
(lp817
S'2015/12/09 06:00'
p818
asS'DP'
p819
S'2015 Dec'
p820
sS'OWN'
p821
S'NLM'
p822
sS'PT'
p823
(lp824
S'Journal Article'
p825
aS"Research Support, Non-U.S. Gov't"
p826
asS'LA'
p827
(lp828
S'eng'
p829
asS'FAU'
p830
(lp831
S'Keogh, Sarah C'
p832
aS'Urassa, Mark'
p833
aS'Kumogola, Yusufu'
p834
aS'Kalongoji, Samwel'
p835
aS'Kimaro, Daniel'
p836
aS'Zaba, Basia'
p837
asS'PG'
p838
S'405-22'
p839
sS'TI'
p840
S'Postpartum Contraception in Northern Tanzania: Patterns of Use, Relationship to Antenatal Intentions, and Impact of Antenatal Counseling.'
p841
sS'RN'
p842
(lp843
S'0 (Contraceptive Agents)'
p844
asS'PL'
p845
S'United States'
p846
sS'TA'
p847
S'Stud Fam Plann'
p848
sS'JID'
p849
S'7810364'
p850
sS'AB'
p851
S'In Tanzania, unmet need for contraception is high, particularly in the postpartum period. Contraceptive counseling during routine antenatal HIV testing could reach 97 percent of pregnant women with much-needed information, but requires an understanding of postpartum contraceptive use and its relationship to antenatal intentions. We conducted a baseline survey of reproductive behavior among 5,284 antenatal clients in Northern Tanzania, followed by an intervention offering contraceptive counseling to half the respondents. A follow-up survey at 6-15 months postpartum examined patterns and determinants of postpartum contraceptive use, assessed their correspondence with antenatal intentions, and evaluated the impact of the intervention. Despite high loss to follow-up, our findings indicate that condoms and hormonal methods had particular and distinct roles in the postpartum period, based on understandings of postpartum fertility. Antenatal intentions were poor predictors of postpartum reproductive behavior. Antenatal counseling had an effect on postpartum contraceptive intentions, but not on use. Different antenatal/contraceptive service integration models should be tested to determine how and when antenatal counseling can be most effective.'
p852
sS'AD'
p853
S'Postdoctoral Fellow, Department of Anthropology, University College London, Gower Street, London WC1E 6BT, United Kingdom. Senior Research Scientist, National Institute for Medical Research, Mwanza, Tanzania. Clinical Officer, National Institute for Medical Research, Mwanza, Tanzania. Samwel Kalongoji is District Medical Officer, Magu District Council, Tanzania. Daniel Kimaro is City Medical Officer, Mwanza City Council, Tanzania. Basia Zaba is Professor of Medical Demography, Department of Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.'
p854
sS'IP'
p855
S'4'
sS'IS'
p856
S'1728-4465 (Electronic) 0039-3665 (Linking)'
p857
sS'DCOM'
p858
S'20160914'
p859
sS'AU'
p860
(lp861
S'Keogh SC'
p862
aS'Urassa M'
p863
aS'Kumogola Y'
p864
aS'Kalongoji S'
p865
aS'Kimaro D'
p866
aS'Zaba B'
p867
asS'VI'
p868
S'46'
p869
sS'MHDA'
p870
S'2016/09/15 06:00'
p871
sS'MH'
p872
(lp873
S'Adolescent'
p874
aS'Adult'
p875
aS'Condoms/*utilization'
p876
aS'Contraception Behavior/psychology/*statistics & numerical data'
p877
aS'Contraceptive Agents/*therapeutic use'
p878
aS'*Counseling'
p879
aS'Family Planning Services'
p880
aS'Female'
p881
aS'Humans'
p882
aS'*Intention'
p883
aS'*Postpartum Period'
p884
aS'Pregnancy'
p885
aS'*Prenatal Care'
p886
aS'Tanzania'
p887
aS'Young Adult'
p888
asS'EDAT'
p889
S'2015/12/09 06:00'
p890
sS'SO'
p891
S'Stud Fam Plann. 2015 Dec;46(4):405-22. doi: 10.1111/j.1728-4465.2015.00040.x.'
p892
sS'SB'
p893
S'IM'
p894
sS'PMID'
p895
S'26643490'
p896
sS'PST'
p897
S'ppublish'
p898
stRp899
ag2
(g3
g4
(dp900
S'LID'
p901
S'10.1371/journal.pone.0142722 [doi]'
p902
sS'STAT'
p903
S'MEDLINE'
p904
sS'DEP'
p905
S'20151207'
p906
sS'DA'
p907
S'20151208'
p908
sS'AID'
p909
(lp910
S'10.1371/journal.pone.0142722 [doi]'
p911
aS'PONE-D-15-20963 [pii]'
p912
asS'CRDT'
p913
(lp914
S'2015/12/08 06:00'
p915
asS'DP'
p916
S'2015'
p917
sS'OWN'
p918
S'NLM'
p919
sS'PT'
p920
(lp921
S'Journal Article'
p922
aS"Research Support, Non-U.S. Gov't"
p923
asS'LA'
p924
(lp925
S'eng'
p926
asS'FAU'
p927
(lp928
S'Castelnuovo, Barbara'
p929
aS'Kiragga, Agnes'
p930
aS'Musaazi, Joseph'
p931
aS'Sempa, Joseph'
p932
aS'Mubiru, Frank'
p933
aS'Wanyama, Jane'
p934
aS'Wandera, Bonnie'
p935
aS'Kamya, Moses Robert'
p936
aS'Kambugu, Andrew'
p937
asS'JT'
p938
S'PloS one'
p939
sS'LR'
p940
S'20151214'
p941
sS'PG'
p942
S'e0142722'
p943
sS'TI'
p944
S'Outcomes in a Cohort of Patients Started on Antiretroviral Treatment and Followed up for a Decade in an Urban Clinic in Uganda.'
p945
sS'RN'
p946
(lp947
S'0 (Anti-HIV Agents)'
p948
aS'0 (Reverse Transcriptase Inhibitors)'
p949
asS'PL'
p950
S'United States'
p951
sS'TA'
p952
S'PLoS One'
p953
sS'JID'
p954
S'101285081'
p955
sS'AB'
p956
S'BACKGROUND: Short-medium term studies from sub-Saharan Africa show that, despite high early mortality, substantial loss to program, and high rates toxicity, patients on antiretroviral treatment have achieved outcomes comparable to those in developed settings. However, these studies were unable to account for long term outcomes of patients as they stayed longer on treatment. OBJECTIVES: We aim to describe ten years outcomes of one of the first cohort of HIV positive patients started on antiretroviral treatment (ART) in Sub-Saharan Africa. METHODS: We report 10-years outcomes including mortality, retention, CD4-count response, virological outcomes, ART regimens change from a prospective cohort of 559 patients initiating ART and followed up for 10 years Uganda. RESULTS: Of 559 patients, 69.1% were female, median age (IQR) was 38 (33-44) years, median CD4-count (IQR) 98 (21-163) cell/muL; 74% were started on stavudine, lamivudine and nevirapine, 26% on zidovudine, lamivudine and efavirenz. After 10 years 361 (65%) patients were still in the study; 127 (22.7%) had died; 30 (5%) were lost to follow-up; 27 (5%) transferred; 18 (3%) withdrew consent. The probability of death was high in the first year (0.15, 95%, CI 0.12-0.18). The median CD4 count increased from 98 to 589 cell/muL (IQR: 450-739 cell/muL) with a median increase of 357 cells/muL (IQR: 128-600 cells/muL); 7.4% never attained initial viral suppression and of those who did 31.7% experienced viral failure. Three hundred and two patients had at least one drug substitution while on first line after a median of 40 months; 66 (11.9%) of the patients were switched to a second line PI-based regimen due to confirmed treatment failure. CONCLUSIONS: Despite the high rate of early mortality due to advanced disease at presentation the outcomes from this cohort are encouraging, particularly the remarkable and incremental immune-recovery and a satisfactory rate of virologic suppression.'
p957
sS'AD'
p958
S'Infectious Diseases Institute, Makerere University, Mulago Hospital, Kampala, Uganda. Infectious Diseases Institute, Makerere University, Mulago Hospital, Kampala, Uganda. Infectious Diseases Institute, Makerere University, Mulago Hospital, Kampala, Uganda. Infectious Diseases Institute, Makerere University, Mulago Hospital, Kampala, Uganda. Infectious Diseases Institute, Makerere University, Mulago Hospital, Kampala, Uganda. Infectious Diseases Institute, Makerere University, Mulago Hospital, Kampala, Uganda. Infectious Diseases Institute, Makerere University, Mulago Hospital, Kampala, Uganda. School of medicine, Makerere University, Mulago Hospital, Kampala, Uganda. Infectious Diseases Institute, Makerere University, Mulago Hospital, Kampala, Uganda.'
p959
sS'IP'
p960
S'12'
p961
sS'IS'
p962
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p963
sS'PMC'
p964
S'PMC4671641'
p965
sS'DCOM'
p966
S'20160621'
p967
sS'AU'
p968
(lp969
S'Castelnuovo B'
p970
aS'Kiragga A'
p971
aS'Musaazi J'
p972
aS'Sempa J'
p973
aS'Mubiru F'
p974
aS'Wanyama J'
p975
aS'Wandera B'
p976
aS'Kamya MR'
p977
aS'Kambugu A'
p978
asS'VI'
p979
S'10'
p980
sS'MHDA'
p981
S'2016/06/22 06:00'
p982
sS'PHST'
p983
(lp984
S'2015 [ecollection]'
p985
aS'2015/05/14 [received]'
p986
aS'2015/10/25 [accepted]'
p987
aS'2015/12/07 [epublish]'
p988
asS'OID'
p989
(lp990
S'NLM: PMC4671641'
p991
asS'MH'
p992
(lp993
S'Adult'
p994
aS'Anti-HIV Agents/*therapeutic use'
p995
aS'CD4 Lymphocyte Count/methods'
p996
aS'Drug Administration Schedule'
p997
aS'Female'
p998
aS'Follow-Up Studies'
p999
aS'HIV Infections/*drug therapy'
p1000
aS'HIV-1/drug effects'
p1001
aS'Humans'
p1002
aS'Lost to Follow-Up'
p1003
aS'Male'
p1004
aS'Prospective Studies'
p1005
aS'Reverse Transcriptase Inhibitors/therapeutic use'
p1006
aS'Uganda'
p1007
aS'Viral Load/methods'
p1008
asS'EDAT'
p1009
S'2015/12/08 06:00'
p1010
sS'SO'
p1011
S'PLoS One. 2015 Dec 7;10(12):e0142722. doi: 10.1371/journal.pone.0142722. eCollection 2015.'
p1012
sS'SB'
p1013
S'IM'
p1014
sS'PMID'
p1015
S'26642214'
p1016
sS'PST'
p1017
S'epublish'
p1018
stRp1019
ag2
(g3
g4
(dp1020
S'LID'
p1021
S'10.1038/nature16046 [doi]'
p1022
sS'STAT'
p1023
S'MEDLINE'
p1024
sS'JT'
p1025
S'Nature'
p1026
sS'MID'
p1027
(lp1028
S'NIHMS792639'
p1029
asS'DA'
p1030
S'20151204'
p1031
sS'AID'
p1032
(lp1033
S'nature16046 [pii]'
p1034
aS'10.1038/nature16046 [doi]'
p1035
asS'CRDT'
p1036
(lp1037
S'2015/12/04 06:00'
p1038
asS'DP'
p1039
S'2015 Dec 3'
p1040
sS'GR'
p1041
(lp1042
S'MR/K010174/1/Medical Research Council/United Kingdom'
p1043
aS'P30 AI045008/AI/NIAID NIH HHS/United States'
p1044
asS'OWN'
p1045
S'NLM'
p1046
sS'PT'
p1047
(lp1048
S'Journal Article'
p1049
aS"Research Support, Non-U.S. Gov't"
p1050
asS'LA'
p1051
(lp1052
S'eng'
p1053
asS'FAU'
p1054
(lp1055
S'Phillips, Andrew'
p1056
aS'Shroufi, Amir'
p1057
aS'Vojnov, Lara'
p1058
aS'Cohn, Jennifer'
p1059
aS'Roberts, Teri'
p1060
aS'Ellman, Tom'
p1061
aS'Bonner, Kimberly'
p1062
aS'Rousseau, Christine'
p1063
aS'Garnett, Geoff'
p1064
aS'Cambiano, Valentina'
p1065
aS'Nakagawa, Fumiyo'
p1066
aS'Ford, Deborah'
p1067
aS'Bansi-Matharu, Loveleen'
p1068
aS'Miners, Alec'
p1069
aS'Lundgren, Jens D'
p1070
aS'Eaton, Jeffrey W'
p1071
aS'Parkes-Ratanshi, Rosalind'
p1072
aS'Katz, Zachary'
p1073
aS'Maman, David'
p1074
aS'Ford, Nathan'
p1075
aS'Vitoria, Marco'
p1076
aS'Doherty, Meg'
p1077
aS'Dowdy, David'
p1078
aS'Nichols, Brooke'
p1079
aS'Murtagh, Maurine'
p1080
aS'Wareham, Meghan'
p1081
aS'Palamountain, Kara M'
p1082
aS'Chakanyuka Musanhu, Christine'
p1083
aS'Stevens, Wendy'
p1084
aS'Katzenstein, David'
p1085
aS'Ciaranello, Andrea'
p1086
aS'Barnabas, Ruanne'
p1087
aS'Braithwaite, R Scott'
p1088
aS'Bendavid, Eran'
p1089
aS'Nathoo, Kusum J'
p1090
aS'van de Vijver, David'
p1091
aS'Wilson, David P'
p1092
aS'Holmes, Charles'
p1093
aS'Bershteyn, Anna'
p1094
aS'Walker, Simon'
p1095
aS'Raizes, Elliot'
p1096
aS'Jani, Ilesh'
p1097
aS'Nelson, Lisa J'
p1098
aS'Peeling, Rosanna'
p1099
aS'Terris-Prestholt, Fern'
p1100
aS'Murungu, Joseph'
p1101
aS'Mutasa-Apollo, Tsitsi'
p1102
aS'Hallett, Timothy B'
p1103
aS'Revill, Paul'
p1104
asS'LR'
p1105
S'20160708'
p1106
sS'PG'
p1107
S'S68-76'
p1108
sS'TI'
p1109
S'Sustainable HIV treatment in Africa through viral-load-informed differentiated care.'
p1110
sS'RN'
p1111
(lp1112
S'0 (Anti-HIV Agents)'
p1113
asS'PL'
p1114
S'England'
p1115
sS'TA'
p1116
S'Nature'
p1117
sS'JID'
p1118
S'0410462'
p1119
sS'AB'
p1120
S'There are inefficiencies in current approaches to monitoring patients on antiretroviral therapy in sub-Saharan Africa. Patients typically attend clinics every 1 to 3 months for clinical assessment. The clinic costs are comparable with the costs of the drugs themselves and CD4 counts are measured every 6 months, but patients are rarely switched to second-line therapies. To ensure sustainability of treatment programmes, a transition to more cost-effective delivery of antiretroviral therapy is needed. In contrast to the CD4 count, measurement of the level of HIV RNA in plasma (the viral load) provides a direct measure of the current treatment effect. Viral-load-informed differentiated care is a means of tailoring care so that those with suppressed viral load visit the clinic less frequently and attention is focussed on those with unsuppressed viral load to promote adherence and timely switching to a second-line regimen. The most feasible approach to measuring viral load in many countries is to collect dried blood spot samples for testing in regional laboratories; however, there have been concerns over the sensitivity and specificity of this approach to define treatment failure and the delay in returning results to the clinic. We use modelling to synthesize evidence and evaluate the cost-effectiveness of viral-load-informed differentiated care, accounting for limitations of dried blood sample testing. We find that viral-load-informed differentiated care using dried blood sample testing is cost-effective and is a recommended strategy for patient monitoring, although further empirical evidence as the approach is rolled out would be of value. We also explore the potential benefits of point-of-care viral load tests that may become available in the future.'
p1121
sS'CN'
p1122
(lp1123
S'Working Group on Modelling of Antiretroviral Therapy Monitoring Strategies in'
p1124
aS'Sub-Saharan Africa'
p1125
asS'IP'
p1126
S'7580'
p1127
sS'IS'
p1128
S'1476-4687 (Electronic) 0028-0836 (Linking)'
p1129
sS'PMC'
p1130
S'PMC4932825'
p1131
sS'DCOM'
p1132
S'20151229'
p1133
sS'AU'
p1134
(lp1135
S'Phillips A'
p1136
aS'Shroufi A'
p1137
aS'Vojnov L'
p1138
aS'Cohn J'
p1139
aS'Roberts T'
p1140
aS'Ellman T'
p1141
aS'Bonner K'
p1142
aS'Rousseau C'
p1143
aS'Garnett G'
p1144
aS'Cambiano V'
p1145
aS'Nakagawa F'
p1146
aS'Ford D'
p1147
aS'Bansi-Matharu L'
p1148
aS'Miners A'
p1149
aS'Lundgren JD'
p1150
aS'Eaton JW'
p1151
aS'Parkes-Ratanshi R'
p1152
aS'Katz Z'
p1153
aS'Maman D'
p1154
aS'Ford N'
p1155
aS'Vitoria M'
p1156
aS'Doherty M'
p1157
aS'Dowdy D'
p1158
aS'Nichols B'
p1159
aS'Murtagh M'
p1160
aS'Wareham M'
p1161
aS'Palamountain KM'
p1162
aS'Chakanyuka Musanhu C'
p1163
aS'Stevens W'
p1164
aS'Katzenstein D'
p1165
aS'Ciaranello A'
p1166
aS'Barnabas R'
p1167
aS'Braithwaite RS'
p1168
aS'Bendavid E'
p1169
aS'Nathoo KJ'
p1170
aS'van de Vijver D'
p1171
aS'Wilson DP'
p1172
aS'Holmes C'
p1173
aS'Bershteyn A'
p1174
aS'Walker S'
p1175
aS'Raizes E'
p1176
aS'Jani I'
p1177
aS'Nelson LJ'
p1178
aS'Peeling R'
p1179
aS'Terris-Prestholt F'
p1180
aS'Murungu J'
p1181
aS'Mutasa-Apollo T'
p1182
aS'Hallett TB'
p1183
aS'Revill P'
p1184
asS'AD'
p1185
S"Department of Infection and Population Health, University College London, Rowland Hill Street, London NW3 2PF, UK. Southern Africa Medical Unit (SAMU), Medecins sans Frontieres (MSF) SA, Waverley Business Park, Wyecroft Rd, Mowbray 7700, Cape Town, South Africa. Clinton Health Access Initiative, 383 Dorchester Avenue, Boston, Massachusetts 02127, USA. Medecins Sans Frontieres, Access Campaign, rue du Lausanne 82, 1202 Geneva Switzerland. Medecins Sans Frontieres, Access Campaign, rue du Lausanne 82, 1202 Geneva Switzerland. Southern Africa Medical Unit (SAMU), Medecins sans Frontieres (MSF) SA, Waverley Business Park, Wyecroft Rd, Mowbray 7700, Cape Town, South Africa. Medecins Sans Frontieres, 78 rue de Lausanne, Case Postale 116, 1211 Geneva 21, Switzerland. Bill and Melinda Gates Foundation, PO Box 23350, Seattle, Washington 98199, USA. Bill and Melinda Gates Foundation, PO Box 23350, Seattle, Washington 98199, USA. Department of Infection and Population Health, University College London, Rowland Hill Street, London NW3 2PF, UK. Department of Infection and Population Health, University College London, Rowland Hill Street, London NW3 2PF, UK. MRC Clinical Trials Unit at UCL, Institute of Clinical Trials &Methodology, Aviation House, 125 Kingsway, London WC2B 6NH, UK. Department of Infection and Population Health, University College London, Rowland Hill Street, London NW3 2PF, UK. Health Services Research &Policy, London School of Hygiene and Tropical Medicine, Room 134, 15-17 Tavistock Place, London WC1H 9SY, UK. CHIP, Department of infectious diseases, Rigshospitalet, University of Copenhagen, Blegdamsvej 92100 Copenhagen, Denmark. Department of Infectious Disease Epidemiology, Imperial College London, St Mary's Campus, Norfolk Place, London W2 1PG, UK. Infectious Diseases Institute (IDI), College of Health Sciences, Makerere University, PO Box 22418, Kampala, Uganda. Clinton Health Access Initiative, 383 Dorchester Avenue, Boston, Massachusetts 02127, USA. Southern Africa Medical Unit (SAMU), Medecins sans Frontieres (MSF) SA, Waverley Business Park, Wyecroft Rd, Mowbray 7700, Cape Town, South Africa. HIV/AIDS and Global Hepatitis Programme, World Health Organization, 20 Ave Appia 1211, Geneva, Switzerland. HIV/AIDS and Global Hepatitis Programme, World Health Organization, 20 Ave Appia 1211, Geneva, Switzerland. HIV/AIDS and Global Hepatitis Programme, World Health Organization, 20 Ave Appia 1211, Geneva, Switzerland. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street E6531, Baltimore, Maryland 21205, USA. Department of Viroscience, Erasmus Medical Center, PO Box 20403000CA Rotterdam, the Netherlands. International Diagnostics Centre, London School of Hygiene &Tropical, Medicine, Keppel Street, London WC1E 7HT, UK. Clinton Health Access Initiative, 383 Dorchester Avenue, Boston, Massachusetts 02127, USA. Kellogg School of Management, Northwestern University, 2001 Sheridan Road Evanston, Illinois 60208, USA. WHO Country Office 86 Enterprise Road Cnr, Glenara PO Box CY 348, Causeway Harare, Zimbabwe. Department of Molecular Medicine and Haematology, University of the Witwatersrand, South Africa. Division of Infectious Disease, Laboratory Grant Building S-146, Office Lane 154, Stanford University Medical Center, 300 Pasteur Drive, Stanford, California 94305-5107, USA. Massachusetts General Hospital Division of Infectious Diseases, 50 Staniford Street, 936 Boston, Massachusetts 02114, USA. Medicine, Global Health and Epidemiology, University of Washington (UW), 325 9th Avenue, Seattle, Washington 98104, USA. Department of Population Health, New York University School of Medicine, 227 East 30th Street Office 615, New York, New York 10016, USA. Division of General Medical Disciplines, Department of Medicine Stanford University, MSOB 1265 Welch Road x332 Stanford, California 94305, USA. University of Zimbabwe, College of Health Sciences, Department of Paediatrics and Child Health, PO Box A178, Avondale, Harare, Zimbabwe. Department of Viroscience, Erasmus Medical Center, PO Box 20403000CA Rotterdam, the Netherlands. University of New South Wales, Level 6, Wallace Wurth Building, UNSW Campus, Sydney, New South Wales 2052, Australia. Centre for Infectious Disease Research in Zambia, 5032 Great North Road, Lusaka, Zambia. Institute for Disease Modeling, 3150 139th Avenue SE, Bellevue, Washington 98005, USA. Centre for Health Economics, University of York, Heslington, York YO10 5DD, UK. Care and Treatment Branch Center for Global Health, Division of Global HIV/AIDS (GAP), CDC, MS-E04, 1600 Clifton Road NE, Atlanta, Georgia 30333, USA. Instituto Nacional de Saude (INS), Ministry of Health, PO Box 264, Maputo, Mozambique. The Office of the US Global AIDS Coordinator and Health Diplomacy (S/GAC), U.S. Department of State, SA-22, Suite 10300, 2201 C Street, Washington DC 20520, USA. Clinical Research Department, London School of Hygiene and Tropical Medicine, Keppel St, London WC1E 7HT, UK. Department of Global Health and Development, London School of Hygiene and Tropical Medicine, 15-17 Tavistock Place, London WC1H 9SH, UK. Ministry of Health and Child Care, P. O CY 1122, Causeway, Harare, Zimbabwe. Ministry of Health and Child Care, P. O CY 1122, Causeway, Harare, Zimbabwe. Department of Infectious Disease Epidemiology, Imperial College London, St Mary's Campus, Norfolk Place, London W2 1PG, UK. Centre for Health Economics, University of York, Heslington, York YO10 5DD, UK."
p1186
sS'VI'
p1187
S'528'
p1188
sS'MHDA'
p1189
S'2015/12/30 06:00'
p1190
sS'OID'
p1191
(lp1192
S'NLM: NIHMS792639'
p1193
aS'NLM: PMC4932825'
p1194
asS'MH'
p1195
(lp1196
S'Adolescent'
p1197
aS'Adult'
p1198
aS'Africa'
p1199
aS'Aged'
p1200
aS'Anti-HIV Agents/economics/pharmacology/therapeutic use'
p1201
aS'Cost-Benefit Analysis'
p1202
aS'HIV Infections/diagnosis/*drug therapy/economics/*virology'
p1203
aS'Humans'
p1204
aS'Middle Aged'
p1205
aS'Precision Medicine/economics/*methods'
p1206
aS'*Viral Load/drug effects'
p1207
aS'Young Adult'
p1208
asS'EDAT'
p1209
S'2015/12/04 06:00'
p1210
sS'SO'
p1211
S'Nature. 2015 Dec 3;528(7580):S68-76. doi: 10.1038/nature16046.'
p1212
sS'SB'
p1213
S'IM'
p1214
sS'PMID'
p1215
S'26633768'
p1216
sS'PST'
p1217
S'ppublish'
p1218
stRp1219
ag2
(g3
g4
(dp1220
S'LID'
p1221
S'10.1093/infdis/jiv568 [doi]'
p1222
sS'STAT'
p1223
S'MEDLINE'
p1224
sS'DEP'
p1225
S'20151125'
p1226
sS'CI'
p1227
(lp1228
S'(c) The Author 2015. Published by Oxford University Press for the Infectious'
p1229
aS'Diseases Society of America. All rights reserved. For permissions, e-mail'
p1230
aS'journals.permissions@oup.com.'
p1231
asS'DA'
p1232
S'20160307'
p1233
sS'AID'
p1234
(lp1235
S'jiv568 [pii]'
p1236
aS'10.1093/infdis/jiv568 [doi]'
p1237
asS'CRDT'
p1238
(lp1239
S'2015/11/27 06:00'
p1240
asS'DP'
p1241
S'2016 Apr 1'
p1242
sS'OWN'
p1243
S'NLM'
p1244
sS'PT'
p1245
(lp1246
S'Journal Article'
p1247
aS"Research Support, Non-U.S. Gov't"
p1248
asS'LA'
p1249
(lp1250
S'eng'
p1251
asS'FAU'
p1252
(lp1253
S'Boillat-Blanco, Noemie'
p1254
aS'Ramaiya, Kaushik L'
p1255
aS'Mganga, Maliwasa'
p1256
aS'Minja, Lilian T'
p1257
aS'Bovet, Pascal'
p1258
aS'Schindler, Christian'
p1259
aS'Von Eckardstein, Arnold'
p1260
aS'Gagneux, Sebastien'
p1261
aS'Daubenberger, Claudia'
p1262
aS'Reither, Klaus'
p1263
aS'Probst-Hensch, Nicole'
p1264
asS'JT'
p1265
S'The Journal of infectious diseases'
p1266
sS'PG'
p1267
S'1163-72'
p1268
sS'TI'
p1269
S'Transient Hyperglycemia in Patients With Tuberculosis in Tanzania: Implications for Diabetes Screening Algorithms.'
p1270
sS'RN'
p1271
(lp1272
S'0 (Antitubercular Agents)'
p1273
aS'0 (Blood Glucose)'
p1274
aS'0 (Hemoglobin A, Glycosylated)'
p1275
asS'PL'
p1276
S'United States'
p1277
sS'TA'
p1278
S'J Infect Dis'
p1279
sS'JID'
p1280
S'0413675'
p1281
sS'AB'
p1282
S'BACKGROUND: Diabetes mellitus (DM) increases tuberculosis risk while tuberculosis, as an infectious disease, leads to hyperglycemia. We compared hyperglycemia screening strategies in controls and patients with tuberculosis in Dar es Salaam, Tanzania. METHODS: Consecutive adults with tuberculosis and sex- and age-matched volunteers were included in a case-control study between July 2012 and June 2014. All underwent DM screening tests (fasting capillary glucose [FCG] level, 2-hour CG [2-hCG] level, and glycated hemoglobin A1c [HbA1c] level) at enrollment, and cases were tested again after receipt of tuberculosis treatment. Association of tuberculosis and its outcome with hyperglycemia was assessed using logistic regression analysis adjusted for sex, age, body mass index, human immunodeficiency virus infection status, and socioeconomic status. Patients with tuberculosis and newly diagnosed DM were not treated for hyperglycemia. RESULTS: At enrollment, DM prevalence was significantly higher among patients with tuberculosis (n = 539; FCG level > 7 mmol/L, 4.5% of patients, 2-hCG level > 11 mmol/L, 6.8%; and HbA1c level > 6.5%, 9.3%), compared with controls (n = 496; 1.2%, 3.1%, and 2.2%, respectively). The association between hyperglycemia and tuberculosis disappeared after tuberculosis treatment (adjusted odds ratio [aOR] for the FCG level: 9.6 [95% confidence interval {CI}, 3.7-24.7] at enrollment vs 2.4 [95% CI, .7-8.7] at follow-up; aOR for the 2-hCG level: 6.6 [95% CI, 4.0-11.1] vs 1.6 [95% CI, .8-2.9]; and aOR for the HbA1c level, 4.2 [95% CI, 2.9-6.0] vs 1.4 [95% CI, .9-2.0]). Hyperglycemia, based on the FCG level, at enrollment was associated with tuberculosis treatment failure or death (aOR, 3.3; 95% CI, 1.2-9.3). CONCLUSIONS: Transient hyperglycemia is frequent during tuberculosis, and DM needs confirmation after tuberculosis treatment. Performance of DM screening at tuberculosis diagnosis gives the opportunity to detect patients at risk of adverse outcome.'
p1283
sS'AD'
p1284
S'Ifakara Health Institute Swiss Tropical and Public Health Institute Department of Sciences, University of Basel Infectious Diseases Service. Shree Hindu Mandal Hospital Muhimbili University of Health Sciences. Kinondoni Municipal Council, National Tuberculosis Program, Dar es Salaam, United Republic of Tanzania. Ifakara Health Institute. Institute of Social and Preventive Medicine, Lausanne University Hospital. Swiss Tropical and Public Health Institute Department of Sciences, University of Basel. Institute of Clinical Chemistry, University of Zurich, University Hospital of Zurich, Switzerland. Swiss Tropical and Public Health Institute Department of Sciences, University of Basel. Swiss Tropical and Public Health Institute Department of Sciences, University of Basel. Ifakara Health Institute Swiss Tropical and Public Health Institute Department of Sciences, University of Basel. Swiss Tropical and Public Health Institute Department of Sciences, University of Basel.'
p1285
sS'IP'
p1286
S'7'
sS'IS'
p1287
S'1537-6613 (Electronic) 0022-1899 (Linking)'
p1288
sS'DCOM'
p1289
S'20160726'
p1290
sS'AU'
p1291
(lp1292
S'Boillat-Blanco N'
p1293
aS'Ramaiya KL'
p1294
aS'Mganga M'
p1295
aS'Minja LT'
p1296
aS'Bovet P'
p1297
aS'Schindler C'
p1298
aS'Von Eckardstein A'
p1299
aS'Gagneux S'
p1300
aS'Daubenberger C'
p1301
aS'Reither K'
p1302
aS'Probst-Hensch N'
p1303
asS'VI'
p1304
S'213'
p1305
sS'MHDA'
p1306
S'2016/07/28 06:00'
p1307
sS'PHST'
p1308
(lp1309
S'2015/09/23 [received]'
p1310
aS'2015/11/19 [accepted]'
p1311
aS'2015/11/25 [aheadofprint]'
p1312
asS'OTO'
p1313
(lp1314
S'NOTNLM'
p1315
asS'MH'
p1316
(lp1317
S'Adult'
p1318
aS'Algorithms'
p1319
aS'Antitubercular Agents/administration & dosage/therapeutic use'
p1320
aS'Blood Glucose/metabolism'
p1321
aS'Case-Control Studies'
p1322
aS'Cross-Sectional Studies'
p1323
aS'Diabetes Mellitus/blood/*diagnosis/epidemiology'
p1324
aS'Female'
p1325
aS'Hemoglobin A, Glycosylated/metabolism'
p1326
aS'Humans'
p1327
aS'Hyperglycemia/*blood/etiology'
p1328
aS'Longitudinal Studies'
p1329
aS'Male'
p1330
aS'Middle Aged'
p1331
aS'Prevalence'
p1332
aS'Tanzania/epidemiology'
p1333
aS'Time Factors'
p1334
aS'Tuberculosis, Pulmonary/*blood/*complications/epidemiology'
p1335
aS'Young Adult'
p1336
asS'EDAT'
p1337
S'2015/11/27 06:00'
p1338
sS'SO'
p1339
S'J Infect Dis. 2016 Apr 1;213(7):1163-72. doi: 10.1093/infdis/jiv568. Epub 2015 Nov 25.'
p1340
sS'SB'
p1341
S'AIM IM'
p1342
sS'PMID'
p1343
S'26609005'
p1344
sS'OT'
p1345
(lp1346
S'diabetes mellitus'
p1347
aS'stress-induced hyperglycemia'
p1348
aS'sub-Saharan Africa'
p1349
aS'transient hyperglycemia'
p1350
aS'tuberculosis'
p1351
asS'PST'
p1352
S'ppublish'
p1353
stRp1354
ag2
(g3
g4
(dp1355
S'LID'
p1356
S'10.15585/mmwr.mm6446a3 [doi]'
p1357
sS'STAT'
p1358
S'MEDLINE'
p1359
sS'AB'
p1360
S"To achieve global targets for universal treatment set forth by the Joint United Nations Programme on human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) (UNAIDS), viral load monitoring for HIV-infected persons receiving antiretroviral therapy (ART) must become the standard of care in low- and middle-income countries (LMIC) (1). CDC and other U.S. government agencies, as part of the President's Emergency Plan for AIDS Relief, are supporting multiple countries in sub-Saharan Africa to change from the use of CD4 cell counts for monitoring of clinical response to ART to the use of viral load monitoring, which is the standard of care in developed countries. Viral load monitoring is the preferred method for immunologic monitoring because it enables earlier and more accurate detection of treatment failure before immunologic decline. This report highlights the initial successes and challenges of viral load monitoring in seven countries that have chosen to scale up viral load testing as a national monitoring strategy for patients on ART in response to World Health Organization (WHO) recommendations. Countries initiating viral load scale-up in 2014 observed increases in coverage after scale-up, and countries initiating in 2015 are anticipating similar trends. However, in six of the seven countries, viral load testing coverage in 2015 remained below target levels. Inefficient specimen transport, need for training, delays in procurement and distribution, and limited financial resources to support scale-up hindered progress. Country commitment and effective partnerships are essential to address the financial, operational, technical, and policy challenges of the rising demand for viral load monitoring."
p1361
sS'JID'
p1362
S'7802429'
p1363
sS'DEP'
p1364
S'20151127'
p1365
sS'IP'
p1366
S'46'
p1367
sS'IS'
p1368
S'1545-861X (Electronic) 0149-2195 (Linking)'
p1369
sS'DCOM'
p1370
S'20160304'
p1371
sS'DA'
p1372
S'20151126'
p1373
sS'AU'
p1374
(lp1375
S'Lecher S'
p1376
aS'Ellenberger D'
p1377
aS'Kim AA'
p1378
aS'Fonjungo PN'
p1379
aS'Agolory S'
p1380
aS'Borget MY'
p1381
aS'Broyles L'
p1382
aS'Carmona S'
p1383
aS'Chipungu G'
p1384
aS'De Cock KM'
p1385
aS'Deyde V'
p1386
aS'Downer M'
p1387
aS'Gupta S'
p1388
aS'Kaplan JE'
p1389
aS'Kiyaga C'
p1390
aS'Knight N'
p1391
aS'MacLeod W'
p1392
aS'Makumbi B'
p1393
aS'Muttai H'
p1394
aS'Mwangi C'
p1395
aS'Mwangi JW'
p1396
aS'Mwasekaga M'
p1397
aS"Ng'Ang'A LW"
p1398
aS'Pillay Y'
p1399
aS'Sarr A'
p1400
aS'Sawadogo S'
p1401
aS'Singer D'
p1402
aS'Stevens W'
p1403
aS'Toure CA'
p1404
aS'Nkengasong J'
p1405
asS'PST'
p1406
S'epublish'
p1407
sS'AID'
p1408
(lp1409
S'10.15585/mmwr.mm6446a3 [doi]'
p1410
asS'CRDT'
p1411
(lp1412
S'2015/11/26 06:00'
p1413
asS'VI'
p1414
S'64'
p1415
sS'PMID'
p1416
S'26605986'
p1417
sS'DP'
p1418
S'2015 Nov 27'
p1419
sS'MHDA'
p1420
S'2016/03/05 06:00'
p1421
sS'OWN'
p1422
S'NLM'
p1423
sS'PT'
p1424
(lp1425
S'Journal Article'
p1426
asS'LA'
p1427
(lp1428
S'eng'
p1429
asS'MH'
p1430
(lp1431
S'Africa South of the Sahara'
p1432
aS'Anti-HIV Agents/therapeutic use'
p1433
aS'HIV Infections/drug therapy/*virology'
p1434
aS'Humans'
p1435
aS'*Population Surveillance'
p1436
aS'*Viral Load'
p1437
asS'FAU'
p1438
(lp1439
S'Lecher, Shirley'
p1440
aS'Ellenberger, Dennis'
p1441
aS'Kim, Andrea A'
p1442
aS'Fonjungo, Peter N'
p1443
aS'Agolory, Simon'
p1444
aS'Borget, Marie Yolande'
p1445
aS'Broyles, Laura'
p1446
aS'Carmona, Sergio'
p1447
aS'Chipungu, Geoffrey'
p1448
aS'De Cock, Kevin M'
p1449
aS'Deyde, Varough'
p1450
aS'Downer, Marie'
p1451
aS'Gupta, Sundeep'
p1452
aS'Kaplan, Jonathan E'
p1453
aS'Kiyaga, Charles'
p1454
aS'Knight, Nancy'
p1455
aS'MacLeod, William'
p1456
aS'Makumbi, Boniface'
p1457
aS'Muttai, Hellen'
p1458
aS'Mwangi, Christina'
p1459
aS'Mwangi, Jane W'
p1460
aS'Mwasekaga, Michael'
p1461
aS"Ng'Ang'A, Lucy W"
p1462
aS'Pillay, Yogan'
p1463
aS'Sarr, Abdoulaye'
p1464
aS'Sawadogo, Souleymane'
p1465
aS'Singer, Daniel'
p1466
aS'Stevens, Wendy'
p1467
aS'Toure, Christiane Adje'
p1468
aS'Nkengasong, John'
p1469
asS'EDAT'
p1470
S'2015/11/26 06:00'
p1471
sS'JT'
p1472
S'MMWR. Morbidity and mortality weekly report'
p1473
sS'SO'
p1474
S'MMWR Morb Mortal Wkly Rep. 2015 Nov 27;64(46):1287-90. doi: 10.15585/mmwr.mm6446a3.'
p1475
sS'PG'
p1476
S'1287-90'
p1477
sS'TI'
p1478
S'Scale-up of HIV Viral Load Monitoring--Seven Sub-Saharan African Countries.'
p1479
sS'SB'
p1480
S'IM'
p1481
sS'RN'
p1482
(lp1483
S'0 (Anti-HIV Agents)'
p1484
asS'PL'
p1485
S'United States'
p1486
sS'TA'
p1487
S'MMWR Morb Mortal Wkly Rep'
p1488
stRp1489
ag2
(g3
g4
(dp1490
S'LID'
p1491
S'10.11604/pamj.2015.22.4.6075 [doi]'
p1492
sS'STAT'
p1493
S'MEDLINE'
p1494
sS'DEP'
p1495
S'20150903'
p1496
sS'DA'
p1497
S'20151125'
p1498
sS'AID'
p1499
(lp1500
S'10.11604/pamj.2015.22.4.6075 [doi]'
p1501
aS'PAMJ-22-4 [pii]'
p1502
asS'CRDT'
p1503
(lp1504
S'2015/11/25 06:00'
p1505
asS'DP'
p1506
S'2015'
p1507
sS'OWN'
p1508
S'NLM'
p1509
sS'PT'
p1510
(lp1511
S'Journal Article'
p1512
aS"Research Support, Non-U.S. Gov't"
p1513
aS"Research Support, U.S. Gov't, Non-P.H.S."
p1514
asS'LA'
p1515
(lp1516
S'eng'
p1517
asS'DCOM'
p1518
S'20160617'
p1519
sS'JT'
p1520
S'The Pan African medical journal'
p1521
sS'LR'
p1522
S'20151126'
p1523
sS'FAU'
p1524
(lp1525
S"d'Elia, Alexander"
p1526
aS'Evans, Denise'
p1527
aS'McNamara, Lynne'
p1528
aS'Berhanu, Rebecca'
p1529
aS'Sanne, Ian'
p1530
aS'Lonnermark, Elisabet'
p1531
asS'TI'
p1532
S'Predictive and prognostic properties of TB-LAM among HIV-positive patients initiating ART in Johannesburg, South Africa.'
p1533
sS'RN'
p1534
(lp1535
S'0 (Lipopolysaccharides)'
p1536
aS'0 (lipoarabinomannan)'
p1537
asS'PL'
p1538
S'Uganda'
p1539
sS'PG'
p1540
S'4'
sS'JID'
p1541
S'101517926'
p1542
sS'AB'
p1543
S'While the diagnostic properties of the TB LAM urine assay (LAM) have been well-described, little is known about its predictive and prognostic properties at ART initiation in a routine clinic setting. We describe the predictive and prognostic properties of LAM in HIV-positive patients initiating ART at an urban hospital in Johannesburg, South Africa. Retrospective study of HIV-positive adults (>18 years) who initiated standard first-line ART between February 2012 and April 2013 and had a LAM test at initiation. In HIV-positive patients with no known TB at ART initiation, we assessed the sensitivity, specificity and positive/negative likelihood ratios of LAM to predict incident TB within 6 months of ART initiation. In addition, in patients with a TB diagnosis and on TB treatment <3 months at ART initiation, we measured the CD4 response at 6 months on ART. Of the 274 patients without TB at ART initiation, 65% were female with median CD4 count of 213 cells/mm(3). Among the 14 (5.1%) patients who developed active TB, none were urine LAM +ve at baseline. LAM had poor sensitivity (0.0% 95% CI 0.00-23.2) to predict incident TB within 6 months of initiation. We analyzed 22 patients with a confirmed TB diagnosis at initiation separately. Of these, LAM +ve patients (27%) showed lower CD4 gains compared to LAM negative patients (median increase 103 vs 199 cells/mm(3); p = 0.08). LAM has limited value for accurately predicting incident TB in patients with higher CD4 counts after ART initiation. LAM may help identify TB/HIV co-infected patients at ART initiation who respond more slowly to treatment and require targeted interventions to improve treatment outcomes. Larger studies with longer patient follow-up are needed.'
p1544
sS'AD'
p1545
S'Department of Infectious Diseases, Sahlgrenska University Hospital, Gothenburg, 40032, Sweden. Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, 2193, South Africa. Clinical HIV Research Unit, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, 2193, South Africa. Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, 2193, South Africa ; Right To Care, Helen Joseph Hospital, Perth Road, Johannesburg, 2092, South Africa. Clinical HIV Research Unit, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, 2193, South Africa ; Right To Care, Helen Joseph Hospital, Perth Road, Johannesburg, 2092, South Africa. Department of Infectious Diseases, Sahlgrenska University Hospital, Gothenburg, 40032, Sweden.'
p1546
sS'VI'
p1547
S'22'
p1548
sS'IS'
p1549
S'1937-8688 (Electronic)'
p1550
sS'PMC'
p1551
S'PMC4643149'
p1552
sS'AU'
p1553
(lp1554
S"d'Elia A"
p1555
aS'Evans D'
p1556
aS'McNamara L'
p1557
aS'Berhanu R'
p1558
aS'Sanne I'
p1559
aS'Lonnermark E'
p1560
asS'MHDA'
p1561
S'2016/06/18 06:00'
p1562
sS'PHST'
p1563
(lp1564
S'2015 [ecollection]'
p1565
aS'2015/01/05 [received]'
p1566
aS'2015/08/26 [accepted]'
p1567
aS'2015/09/03 [epublish]'
p1568
asS'OT'
p1569
(lp1570
S'Antiretroviral therapy'
p1571
aS'HIV'
p1572
aS'Mycobacterium'
p1573
aS'South Africa'
p1574
aS'TB LAM'
p1575
aS'lipoarabinomannan'
p1576
asS'OTO'
p1577
(lp1578
S'NOTNLM'
p1579
asS'OID'
p1580
(lp1581
S'NLM: PMC4643149'
p1582
asS'MH'
p1583
(lp1584
S'Adult'
p1585
aS'CD4 Lymphocyte Count'
p1586
aS'Coinfection'
p1587
aS'Female'
p1588
aS'HIV Infections/*complications'
p1589
aS'Humans'
p1590
aS'Lipopolysaccharides/*urine'
p1591
aS'Male'
p1592
aS'Predictive Value of Tests'
p1593
aS'Prognosis'
p1594
aS'Retrospective Studies'
p1595
aS'Sensitivity and Specificity'
p1596
aS'South Africa'
p1597
aS'Tuberculosis/complications/*diagnosis'
p1598
asS'EDAT'
p1599
S'2015/11/26 06:00'
p1600
sS'SO'
p1601
S'Pan Afr Med J. 2015 Sep 3;22:4. doi: 10.11604/pamj.2015.22.4.6075. eCollection 2015.'
p1602
sS'SB'
p1603
S'IM'
p1604
sS'PMID'
p1605
S'26600904'
p1606
sS'TA'
p1607
S'Pan Afr Med J'
p1608
sS'PST'
p1609
S'epublish'
p1610
stRp1611
ag2
(g3
g4
(dp1612
S'LID'
p1613
S'10.1111/tmi.12639 [doi]'
p1614
sS'STAT'
p1615
S'MEDLINE'
p1616
sS'DEP'
p1617
S'20151210'
p1618
sS'CI'
p1619
(lp1620
S'(c) 2015 John Wiley & Sons Ltd.'
p1621
asS'DA'
p1622
S'20160202'
p1623
sS'AID'
p1624
(lp1625
S'10.1111/tmi.12639 [doi]'
p1626
asS'CRDT'
p1627
(lp1628
S'2015/11/21 06:00'
p1629
asS'DP'
p1630
S'2016 Feb'
p1631
sS'OWN'
p1632
S'NLM'
p1633
sS'PT'
p1634
(lp1635
S'Journal Article'
p1636
asS'LA'
p1637
(lp1638
S'eng'
p1639
asS'FAU'
p1640
(lp1641
S'Hoffmann, Christopher J'
p1642
aS'Maritz, Jean'
p1643
aS'van Zyl, Gert U'
p1644
asS'JT'
p1645
S'Tropical medicine & international health : TM & IH'
p1646
sS'PG'
p1647
S'219-23'
p1648
sS'TI'
p1649
S'CD4 count-based failure criteria combined with viral load monitoring may trigger worse switch decisions than viral load monitoring alone.'
p1650
sS'RN'
p1651
(lp1652
S'0 (Anti-HIV Agents)'
p1653
asS'PL'
p1654
S'England'
p1655
sS'TA'
p1656
S'Trop Med Int Health'
p1657
sS'JID'
p1658
S'9610576'
p1659
sS'AB'
p1660
S'OBJECTIVE: CD4 count decline often triggers antiretroviral regimen switches in resource-limited settings, even when viral load testing is available. We therefore compared CD4 failure and CD4 trends in patients with viraemia with or without antiretroviral resistance. METHODS: Retrospective cohort study investigating the association of HIV drug resistance with CD4 failure or CD4 trends in patients on first-line antiretroviral regimens during viraemia. Patients with viraemia (HIV RNA >1000 copies/ml) from two HIV treatment programmes in South Africa (n = 350) were included. We investigated the association of M184V and NNRTI resistance with WHO immunological failure criteria and CD4 count trends, using chi-square tests and linear mixed models. RESULTS: Fewer patients with the M184V mutation reached immunologic failure criteria than those without: 51 of 151(34%) vs. 90 of 199 (45%) (P = 0.03). Similarly, 79 of 220 (36%) patients, who had major NNRTI resistance, had immunological failure, whereas 62 of 130 (48%) without (chi-square P = 0.03) did. The CD4 count decline among patients with the M184V mutation was 2.5 cells/mm(3) /year, whereas in those without M184V it was 14 cells/mm(3) /year (P = 0.1), but the difference in CD4 count decline with and without NNRTI resistance was marginal. CONCLUSION: Our data suggest that CD4 count monitoring may lead to inappropriate delayed therapy switches for patients with HIV drug resistance. Conversely, patients with viraemia but no drug resistance are more likely to have a CD4 count decline and thus may be more likely to be switched to a second-line regimen.'
p1661
sS'AD'
p1662
S'Johns Hopkins University School of Medicine, Baltimore, MD, USA. Aurum Institute, Johannesburg, South Africa. National Health Laboratory Service, Tygerberg, Cape Town, South Africa. Division of Medical Virology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. National Health Laboratory Service, Tygerberg, Cape Town, South Africa. Division of Medical Virology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.'
p1663
sS'IP'
p1664
S'2'
sS'IS'
p1665
S'1365-3156 (Electronic) 1360-2276 (Linking)'
p1666
sS'DCOM'
p1667
S'20160609'
p1668
sS'AU'
p1669
(lp1670
S'Hoffmann CJ'
p1671
aS'Maritz J'
p1672
aS'van Zyl GU'
p1673
asS'VI'
p1674
S'21'
p1675
sS'MHDA'
p1676
S'2016/06/10 06:00'
p1677
sS'PHST'
p1678
(lp1679
S'2015/12/10 [aheadofprint]'
p1680
asS'OTO'
p1681
(lp1682
S'NOTNLM'
p1683
asS'MH'
p1684
(lp1685
S'Adult'
p1686
aS'Anti-HIV Agents/*therapeutic use'
p1687
aS'Antiretroviral Therapy, Highly Active'
p1688
aS'*CD4 Lymphocyte Count'
p1689
aS'*Decision Making'
p1690
aS'*Drug Monitoring'
p1691
aS'*Drug Resistance, Viral'
p1692
aS'Female'
p1693
aS'HIV Infections/blood/*drug therapy/virology'
p1694
aS'HIV-1'
p1695
aS'Humans'
p1696
aS'Male'
p1697
aS'Middle Aged'
p1698
aS'Retrospective Studies'
p1699
aS'South Africa'
p1700
aS'Treatment Failure'
p1701
aS'*Viral Load'
p1702
aS'Viremia/drug therapy'
p1703
asS'EDAT'
p1704
S'2015/11/21 06:00'
p1705
sS'SO'
p1706
S'Trop Med Int Health. 2016 Feb;21(2):219-23. doi: 10.1111/tmi.12639. Epub 2015 Dec 10.'
p1707
sS'SB'
p1708
S'IM'
p1709
sS'PMID'
p1710
S'26584666'
p1711
sS'OT'
p1712
(lp1713
S'HIV-1 drug resistance'
p1714
aS'HIV-1 viral load testing'
p1715
aS'M184V'
p1716
aS'M184V, Major NNRTI drug resistance mutations'
p1717
aS'adherence'
p1718
aS'adherencia'
p1719
aS'compliance'
p1720
aS"criteres d'echec immunologique"
p1721
aS'determination de la charge virale du VIH-1'
p1722
aS'fallo inmunologico'
p1723
aS'first-line antiretroviral therapy'
p1724
aS'immunologic failure criteria'
p1725
aS'mutaciones de resistencia a medicamentos NNRTI'
p1726
aS'mutations NNRTI de resistance majeure aux medicaments'
p1727
aS'prueba de carga viral VIH-1'
p1728
aS'resistencia a medicamentos VIH-1'
p1729
aS'resistance aux medicaments du VIH-1'
p1730
aS'terapia antirretroviral de primera linea'
p1731
aS'traitement antiretroviral de premiere ligne'
p1732
asS'PST'
p1733
S'ppublish'
p1734
stRp1735
ag2
(g3
g4
(dp1736
S'LID'
p1737
S'10.1080/09540121.2015.1110234 [doi]'
p1738
sS'STAT'
p1739
S'MEDLINE'
p1740
sS'DEP'
p1741
S'20151112'
p1742
sS'DA'
p1743
S'20160223'
p1744
sS'AID'
p1745
(lp1746
S'10.1080/09540121.2015.1110234 [doi]'
p1747
asS'CRDT'
p1748
(lp1749
S'2015/11/14 06:00'
p1750
asS'DP'
p1751
S'2016'
p1752
sS'AD'
p1753
S'a Family AIDS Care & Education Services (FACES) , Centre for Microbiology Research (CMR), Kenya Medical Research Institute (KEMRI) , Nairobi , Kenya. a Family AIDS Care & Education Services (FACES) , Centre for Microbiology Research (CMR), Kenya Medical Research Institute (KEMRI) , Nairobi , Kenya. b Department of Family Practice , University of British Columbia , Vancouver , Canada. a Family AIDS Care & Education Services (FACES) , Centre for Microbiology Research (CMR), Kenya Medical Research Institute (KEMRI) , Nairobi , Kenya. c Department of Obstetrics, Gynaecology & Reproductive Sciences , University of California , San Francisco , CA , USA. d Impact Research and Development Organization , Kisumu , Kenya. a Family AIDS Care & Education Services (FACES) , Centre for Microbiology Research (CMR), Kenya Medical Research Institute (KEMRI) , Nairobi , Kenya. a Family AIDS Care & Education Services (FACES) , Centre for Microbiology Research (CMR), Kenya Medical Research Institute (KEMRI) , Nairobi , Kenya. c Department of Obstetrics, Gynaecology & Reproductive Sciences , University of California , San Francisco , CA , USA.'
p1754
sS'OWN'
p1755
S'NLM'
p1756
sS'PT'
p1757
(lp1758
S'Journal Article'
p1759
aS"Research Support, U.S. Gov't, Non-P.H.S."
p1760
aS"Research Support, U.S. Gov't, P.H.S."
p1761
asS'LA'
p1762
(lp1763
S'eng'
p1764
asS'FAU'
p1765
(lp1766
S"Ojwang', V O"
p1767
aS'Penner, J'
p1768
aS'Blat, C'
p1769
aS'Agot, K'
p1770
aS'Bukusi, E A'
p1771
aS'Cohen, C R'
p1772
asS'JT'
p1773
S'AIDS care'
p1774
sS'PG'
p1775
S'500-7'
p1776
sS'TI'
p1777
S'Loss to follow-up among youth accessing outpatient HIV care and treatment services in Kisumu, Kenya.'
p1778
sS'RN'
p1779
(lp1780
S'0 (Anti-HIV Agents)'
p1781
asS'PL'
p1782
S'England'
p1783
sS'TA'
p1784
S'AIDS Care'
p1785
sS'JID'
p1786
S'8915313'
p1787
sS'AB'
p1788
S'Youth are particularly vulnerable to acquiring HIV, yet reaching them with HIV prevention interventions and engaging and retaining those infected in care and treatment remains a challenge. We sought to determine the incidence rate of loss to follow-up (LTFU) and explore socio-demographic and clinical characteristics associated with LTFU among HIV-positive youth aged 15-21 years accessing outpatient care and treatment clinics in Kisumu, Kenya. Between July 2007 and September 2010, youth were enrolled into two different HIV care and treatment clinics, one youth specific and the other family oriented. An individual was defined as LTFU when absent from the HIV treatment clinic for >/= 4 months regardless of their antiretroviral treatment status. The incidence rate of LTFU was calculated and Cox regression analysis used to identify factors associated with LTFU. A total of 924 youth (79% female) were enrolled, with a median age of 20 years (IQR 18-21). Over half, (529 (57%)), were documented as LTFU, of whom 139 (26%) were LTFU immediately after enrolment. The overall incidence rate of LTFU was 52.9 per 100 person-years (p-y). Factors associated with LTFU were pregnancy during the study period (crude HR 0.68, 95% CI 0.53-0.89); CD4 cell count >350 (adjusted hazard ratios (AHR) 0.59, 95% CI 0.39-0.90); not being on antiretroviral therapy (AHR 4.0, 95% CI 2.70-5.88); and non-disclosure of HIV infection status (AHR 1.43, 95% CI 1.10-1.89). The clinic of enrolment, age, marital status, employment status, WHO clinical disease stage and education level were not associated with LTFU. Interventions to identify and enrol youth into care earlier, support disclosure, and initiate ART earlier may improve retention of youth and need further investigation. Further research is also needed to explore the reasons for LTFU from care among HIV-infected youth and the true outcomes of these patients.'
p1789
sS'GR'
p1790
(lp1791
S'PS001913/PS/NCHHSTP CDC HHS/United States'
p1792
aS'PEPFAR/United States'
p1793
asS'IP'
p1794
S'4'
sS'IS'
p1795
S'1360-0451 (Electronic) 0954-0121 (Linking)'
p1796
sS'DCOM'
p1797
S'20160929'
p1798
sS'AU'
p1799
(lp1800
S"Ojwang' VO"
p1801
aS'Penner J'
p1802
aS'Blat C'
p1803
aS'Agot K'
p1804
aS'Bukusi EA'
p1805
aS'Cohen CR'
p1806
asS'VI'
p1807
S'28'
p1808
sS'MHDA'
p1809
S'2016/09/30 06:00'
p1810
sS'PHST'
p1811
(lp1812
S'2015/11/12 [aheadofprint]'
p1813
asS'OTO'
p1814
(lp1815
S'NOTNLM'
p1816
asS'MH'
p1817
(lp1818
S'Adolescent'
p1819
aS'Anti-HIV Agents/*therapeutic use'
p1820
aS'Continuity of Patient Care'
p1821
aS'Female'
p1822
aS'HIV Infections/*drug therapy/epidemiology'
p1823
aS'Health Services Accessibility'
p1824
aS'Humans'
p1825
aS'Incidence'
p1826
aS'Kenya/epidemiology'
p1827
aS'*Lost to Follow-Up'
p1828
aS'Male'
p1829
aS'*No-Show Patients'
p1830
aS'Patient Dropouts/*statistics & numerical data'
p1831
aS'Pregnancy'
p1832
aS'Regression Analysis'
p1833
aS'Retrospective Studies'
p1834
aS'Socioeconomic Factors'
p1835
aS'Truth Disclosure'
p1836
aS'Young Adult'
p1837
asS'EDAT'
p1838
S'2015/11/14 06:00'
p1839
sS'SO'
p1840
S'AIDS Care. 2016;28(4):500-7. doi: 10.1080/09540121.2015.1110234. Epub 2015 Nov 12.'
p1841
sS'SB'
p1842
S'IM X'
p1843
sS'PMID'
p1844
S'26565428'
p1845
sS'OT'
p1846
(lp1847
S'Africa'
p1848
aS'HIV'
p1849
aS'antiretroviral therapy'
p1850
aS'loss to follow-up'
p1851
aS'resource-limited settings'
p1852
aS'youth'
p1853
asS'PST'
p1854
S'ppublish'
p1855
stRp1856
ag2
(g3
g4
(dp1857
S'LID'
p1858
S'10.1097/QAD.0000000000000897 [doi]'
p1859
sS'STAT'
p1860
S'MEDLINE'
p1861
sS'JT'
p1862
S'AIDS (London, England)'
p1863
sS'MID'
p1864
(lp1865
S'NIHMS748728'
p1866
asS'DA'
p1867
S'20151113'
p1868
sS'AID'
p1869
(lp1870
S'10.1097/QAD.0000000000000897 [doi]'
p1871
aS'00002030-201512003-00007 [pii]'
p1872
asS'CRDT'
p1873
(lp1874
S'2015/11/13 06:00'
p1875
asS'DP'
p1876
S'2015 Dec'
p1877
sS'AD'
p1878
S'aDepartment of Medicine bDepartment of Global Health cDepartment of Epidemiology, University of Washington, Seattle, Washington, USA dCentre for Geographic Medicine Research - Coast, Kenya Medical Research Institute, Kilifi, Kenya eDepartment of Psychology, University of Washington, Seattle, Washington, USA fNuffield Department of Medicine, University of Oxford, Headington, UK gDepartment of Global Health, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands.'
p1879
sS'OWN'
p1880
S'NLM'
p1881
sS'PT'
p1882
(lp1883
S'Evaluation Studies'
p1884
aS'Journal Article'
p1885
aS'Research Support, N.I.H., Extramural'
p1886
aS"Research Support, Non-U.S. Gov't"
p1887
asS'LA'
p1888
(lp1889
S'eng'
p1890
asS'DCOM'
p1891
S'20160713'
p1892
sS'LR'
p1893
S'20160326'
p1894
sS'FAU'
p1895
(lp1896
S'Graham, Susan M'
p1897
aS'Micheni, Murugi'
p1898
aS'Kombo, Bernadette'
p1899
aS'Van Der Elst, Elisabeth M'
p1900
aS'Mugo, Peter M'
p1901
aS'Kivaya, Esther'
p1902
aS'Aunon, Frances'
p1903
aS'Kutner, Bryan'
p1904
aS'Sanders, Eduard J'
p1905
aS'Simoni, Jane M'
p1906
asS'TI'
p1907
S'Development and pilot testing of an intervention to promote care engagement and adherence among HIV-positive Kenyan MSM.'
p1908
sS'RN'
p1909
(lp1910
S'0 (Anti-HIV Agents)'
p1911
asS'PL'
p1912
S'England'
p1913
sS'PG'
p1914
S'S241-9'
p1915
sS'JID'
p1916
S'8710219'
p1917
sS'AB'
p1918
S'OBJECTIVES: In many African settings, MSM are a stigmatized group whose access to and engagement in HIV care may be challenging. Our aim was to design a targeted, culturally appropriate intervention to promote care engagement and antiretroviral therapy (ART) adherence for MSM in coastal Kenya, and describe intervention safety, feasibility, and acceptability based upon a small pilot study. DESIGN: Based on qualitative work including in-depth interviews with HIV-positive MSM and focus groups with providers, we developed a tailored intervention and conducted a pilot test to refine intervention materials and procedures. METHODS: The Shikamana intervention combines modified Next-Step Counseling by trained providers, support from a trained peer navigator, and tailored use of SMS messaging, phone calls, and discrete pill carriers. Providers, including counselors and clinicians, work together with peer navigators as a case management team. RESULTS: Forty HIV-positive MSM aged 19-51 participated in intervention development and testing. Six counselors, three clinical officers, and four MSM peers were trained in intervention procedures. Of 10 ART-naive participants who enrolled in the pilot, eight completed follow-up with no adverse events reported. One participant was lost to follow-up after 2 months and another failed to initiate ART despite ongoing counseling. No adverse events were reported. Staff feedback and exit interviews rated the intervention as feasible and acceptable. CONCLUSION: This adherence support intervention tailored for Kenyan MSM was well tolerated, feasible, and acceptable in the pilot phase. A randomized controlled trial of a scaled-up programme to estimate intervention efficacy is ongoing.'
p1919
sS'GR'
p1920
(lp1921
S'077092/Wellcome Trust/United Kingdom'
p1922
aS'092654/Wellcome Trust/United Kingdom'
p1923
aS'K24 MH093243/MH/NIMH NIH HHS/United States'
p1924
aS'P30 AI027757/AI/NIAID NIH HHS/United States'
p1925
aS'P30AI027757/AI/NIAID NIH HHS/United States'
p1926
aS'R34 MH099946/MH/NIMH NIH HHS/United States'
p1927
aS'R34MH099946/MH/NIMH NIH HHS/United States'
p1928
asS'VI'
p1929
S'29 Suppl 3'
p1930
sS'IS'
p1931
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p1932
sS'PMC'
p1933
S'PMC4706368'
p1934
sS'AU'
p1935
(lp1936
S'Graham SM'
p1937
aS'Micheni M'
p1938
aS'Kombo B'
p1939
aS'Van Der Elst EM'
p1940
aS'Mugo PM'
p1941
aS'Kivaya E'
p1942
aS'Aunon F'
p1943
aS'Kutner B'
p1944
aS'Sanders EJ'
p1945
aS'Simoni JM'
p1946
asS'MHDA'
p1947
S'2016/07/14 06:00'
p1948
sS'OID'
p1949
(lp1950
S'NLM: NIHMS748728'
p1951
aS'NLM: PMC4706368'
p1952
asS'MH'
p1953
(lp1954
S'Adult'
p1955
aS'Anti-HIV Agents/therapeutic use'
p1956
aS'Counseling'
p1957
aS'Focus Groups'
p1958
aS'HIV Infections/*prevention & control'
p1959
aS'Homosexuality, Male/*psychology'
p1960
aS'Humans'
p1961
aS'Kenya'
p1962
aS'Male'
p1963
aS'Middle Aged'
p1964
aS'*Patient Compliance'
p1965
aS'Peer Group'
p1966
aS'Pilot Projects'
p1967
aS'*Primary Prevention'
p1968
aS'*Secondary Prevention'
p1969
aS'Stereotyping'
p1970
aS'Young Adult'
p1971
asS'EDAT'
p1972
S'2015/11/13 06:00'
p1973
sS'SO'
p1974
S'AIDS. 2015 Dec;29 Suppl 3:S241-9. doi: 10.1097/QAD.0000000000000897.'
p1975
sS'SB'
p1976
S'IM X'
p1977
sS'PMID'
p1978
S'26562813'
p1979
sS'TA'
p1980
S'AIDS'
p1981
sS'PST'
p1982
S'ppublish'
p1983
stRp1984
ag2
(g3
g4
(dp1985
S'LID'
p1986
S'10.1586/14787210.2016.1116383 [doi]'
p1987
sS'STAT'
p1988
S'MEDLINE'
p1989
sS'DEP'
p1990
S'20151203'
p1991
sS'DA'
p1992
S'20160109'
p1993
sS'AID'
p1994
(lp1995
S'10.1586/14787210.2016.1116383 [doi]'
p1996
asS'CRDT'
p1997
(lp1998
S'2015/11/13 06:00'
p1999
asS'DP'
p2000
S'2016'
p2001
sS'OWN'
p2002
S'NLM'
p2003
sS'PT'
p2004
(lp2005
S'Journal Article'
p2006
aS'Review'
p2007
asS'LA'
p2008
(lp2009
S'ENG'
p2010
asS'FAU'
p2011
(lp2012
S'De Nardo, Pasquale'
p2013
aS'Gentilotti, Elisa'
p2014
aS'Nguhuni, Boniface'
p2015
aS'Vairo, Francesco'
p2016
aS'Chaula, Zainab'
p2017
aS'Nicastri, Emanuele'
p2018
aS'Ippolito, Giuseppe'
p2019
asS'JT'
p2020
S'Expert review of anti-infective therapy'
p2021
sS'LR'
p2022
S'20161008'
p2023
sS'PG'
p2024
S'19-27'
p2025
sS'TI'
p2026
S'Efavirenz-based antiretroviral therapy versus nevirapine-including regimens for prevention of mother-to-child transmission of HIV option B plus in resource-limited settings: is there anything missing?'
p2027
sS'RN'
p2028
(lp2029
S'0 (Benzoxazines)'
p2030
aS'0 (Reverse Transcriptase Inhibitors)'
p2031
aS'99DK7FVK1H (Nevirapine)'
p2032
aS'JE6H2O27P8 (efavirenz)'
p2033
asS'PL'
p2034
S'England'
p2035
sS'TA'
p2036
S'Expert Rev Anti Infect Ther'
p2037
sS'JID'
p2038
S'101181284'
p2039
sS'AB'
p2040
S'In 2013, an estimated 1.5 million HIV-positive pregnant women gave birth, with 240,000 children worldwide acquiring HIV. More than 90% of new pediatric infections occurred in Sub-Saharan Africa. The latest WHO guidelines recommended efavirenz (EFV)-based antiretroviral therapy as the first-line regimen for prevention of mother-to-child transmission of HIV (PMTCT). On the other hand, some data suggest that nevirapine (NVP), a well-known antiretroviral, could still play a relevant role in PMTCT, especially in resource-limited settings (RLSs) where the fertility rate is dramatically high compared to developed countries. Given the lack of an unanimous consensus and definitive opinions, this paper goes through the reasons for WHO decisions and aims at refreshing the debate about NVP and EFV pros and cons for PMTCT in RLSs.'
p2041
sS'AD'
p2042
S'a Resource Centre for Infectious Diseases , Clinical Department, Dodoma Regional Referral Hospital , Dodoma , Tanzania. b National Institute for Infectious Diseases "Lazzaro Spallanzani" , Rome , Italy. a Resource Centre for Infectious Diseases , Clinical Department, Dodoma Regional Referral Hospital , Dodoma , Tanzania. c Department of Infectious Diseases , University Hospital Tor Vergata , Rome , Italy. a Resource Centre for Infectious Diseases , Clinical Department, Dodoma Regional Referral Hospital , Dodoma , Tanzania. b National Institute for Infectious Diseases "Lazzaro Spallanzani" , Rome , Italy. b National Institute for Infectious Diseases "Lazzaro Spallanzani" , Rome , Italy. a Resource Centre for Infectious Diseases , Clinical Department, Dodoma Regional Referral Hospital , Dodoma , Tanzania. b National Institute for Infectious Diseases "Lazzaro Spallanzani" , Rome , Italy. b National Institute for Infectious Diseases "Lazzaro Spallanzani" , Rome , Italy.'
p2043
sS'IP'
p2044
S'1'
sS'IS'
p2045
S'1744-8336 (Electronic) 1478-7210 (Linking)'
p2046
sS'DCOM'
p2047
S'20161006'
p2048
sS'AU'
p2049
(lp2050
S'De Nardo P'
p2051
aS'Gentilotti E'
p2052
aS'Nguhuni B'
p2053
aS'Vairo F'
p2054
aS'Chaula Z'
p2055
aS'Nicastri E'
p2056
aS'Ippolito G'
p2057
asS'VI'
p2058
S'14'
p2059
sS'MHDA'
p2060
S'2016/10/08 06:00'
p2061
sS'OTO'
p2062
(lp2063
S'NOTNLM'
p2064
asS'MH'
p2065
(lp2066
S'Adult'
p2067
aS'Africa South of the Sahara'
p2068
aS'Benzoxazines/economics/*therapeutic use'
p2069
aS'Clinical Trials as Topic'
p2070
aS'Developing Countries'
p2071
aS'Female'
p2072
aS'HIV Infections/*drug therapy/economics/pathology/transmission/virology'
p2073
aS'HIV-1/drug effects/enzymology/pathogenicity'
p2074
aS'Humans'
p2075
aS'Infant'
p2076
aS'Infectious Disease Transmission, Vertical/*prevention & control'
p2077
aS'Nevirapine/economics/*therapeutic use'
p2078
aS'Practice Guidelines as Topic'
p2079
aS'Pregnancy'
p2080
aS'Pregnancy Complications, Infectious/economics/*prevention & control'
p2081
aS'Reverse Transcriptase Inhibitors/economics/*therapeutic use'
p2082
asS'EDAT'
p2083
S'2015/11/13 06:00'
p2084
sS'SO'
p2085
S'Expert Rev Anti Infect Ther. 2016;14(1):19-27. doi: 10.1586/14787210.2016.1116383. Epub 2015 Dec 3.'
p2086
sS'SB'
p2087
S'IM'
p2088
sS'PMID'
p2089
S'26559430'
p2090
sS'OT'
p2091
(lp2092
S'HIV'
p2093
aS'HIV-positive pregnant women'
p2094
aS'PMTCT'
p2095
aS'Sub-Saharan Africa'
p2096
aS'efavirenz'
p2097
aS'nevirapine'
p2098
aS'option B plus'
p2099
aS'resource-limited settings'
p2100
asS'PST'
p2101
S'ppublish'
p2102
stRp2103
ag2
(g3
g4
(dp2104
S'LID'
p2105
S'10.1371/journal.pone.0141414 [doi]'
p2106
sS'STAT'
p2107
S'MEDLINE'
p2108
sS'DEP'
p2109
S'20151110'
p2110
sS'DA'
p2111
S'20151111'
p2112
sS'AID'
p2113
(lp2114
S'10.1371/journal.pone.0141414 [doi]'
p2115
aS'PONE-D-15-18321 [pii]'
p2116
asS'CRDT'
p2117
(lp2118
S'2015/11/12 06:00'
p2119
asS'DP'
p2120
S'2015'
p2121
sS'OWN'
p2122
S'NLM'
p2123
sS'PT'
p2124
(lp2125
S'Journal Article'
p2126
aS'Observational Study'
p2127
aS"Research Support, Non-U.S. Gov't"
p2128
asS'LA'
p2129
(lp2130
S'eng'
p2131
asS'FAU'
p2132
(lp2133
S'van Lettow, Monique'
p2134
aS'Bedell, Richard'
p2135
aS'Maosa, Sonia'
p2136
aS'Phiri, Kenneth'
p2137
aS'Chan, Adrienne K'
p2138
aS'Mwinjiwa, Edson'
p2139
aS'Kwekwesa, Aunex'
p2140
aS'Kawonga, Harry'
p2141
aS'Joshua, Martias'
p2142
aS'Harries, Anthony D'
p2143
aS'van Oosterhout, Joep J'
p2144
asS'JT'
p2145
S'PloS one'
p2146
sS'LR'
p2147
S'20151116'
p2148
sS'PG'
p2149
S'e0141414'
p2150
sS'TI'
p2151
S'Outcomes and Diagnostic Processes in Outpatients with Presumptive Tuberculosis in Zomba District, Malawi.'
p2152
sS'PL'
p2153
S'United States'
p2154
sS'TA'
p2155
S'PLoS One'
p2156
sS'JID'
p2157
S'101285081'
p2158
sS'AB'
p2159
S'BACKGROUND: In Malawi, outpatients who have presumptive tuberculosis (TB), i.e. fever, night sweats, weight loss and/or any-duration cough (HIV-infected) or cough of at least 2 weeks (HIV-uninfected), are registered in chronic cough registers. They should receive a diagnostic work-up with first-step provider-initiated HIV testing and sputum testing which includes XpertMTB/RIF, following a national algorithm introduced in 2012. METHODS: An operational study, in which we prospectively studied 6-month outcomes of adult outpatients who were registered in chronic cough registers in Zomba Central Hospital and Matawale peri-urban Health Center, between February and September 2013. We recorded implementation of the diagnostic protocol and outcomes at 6 months from registration. RESULTS: Of 348 patients enrolled, 165(47%) were male, median age was 40 years, 72(21%) had previous TB. At registration 154(44%) were known HIV-positive, 34(10%) HIV-negative (26 unconfirmed) and 160(46%) had unknown HIV status; 104(56%) patients with unknown/unconfirmed HIV status underwent HIV testing. At 6 months 191(55%) were HIV-positive, 87(25%) HIV-negative (26 unconfirmed) and 70(20%) still had unknown HIV status. Higher age and registration in Matawale were independently associated with remaining unknown HIV status after 6 months. 62% of patients had sputum tested, including XpertMTB/RIF, according to the algorithm. TB was diagnosed in 54(15%) patients. This was based on XpertMTB/RIF results in 8(15%) diagnosed cases. In 26(48%) TB was diagnosed on clinical grounds. Coverage of ART in HIV-positive patients was 89%. At 6 months, 236(68%) were asymptomatic, 48(14%) symptomatic, 25(7%) had been lost-to-follow-up and 39(11%) had died. Mortality among those HIV-positive, HIV-negative and with unknown HIV-status was 15%, 2% and 10%, respectively. Male gender, being HIV-positive-not-on-ART and not receiving antibiotics were independent risk factors for mortality. CONCLUSION: HIV prevalence among patients with presumptive TB was high (55%). One quarter was not HIV tested and mortality in this group was substantial (10%). The impact of XpertMTB/RIF on TB diagnosis was limited.'
p2160
sS'AD'
p2161
S'Dignitas International, Zomba, Malawi. Dalla Lana School of Public Health, University of Toronto, Toronto, Canada. Dignitas International, Zomba, Malawi. Dignitas International, Zomba, Malawi. Dignitas International, Zomba, Malawi. Dignitas International, Zomba, Malawi. Dalla Lana School of Public Health, University of Toronto, Toronto, Canada. Division of Infectious Diseases, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada. Dignitas International, Zomba, Malawi. Dignitas International, Zomba, Malawi. Dignitas International, Zomba, Malawi. Zomba Central Hospital, Ministry of Health, Zomba, Malawi. The International Union against Tuberculosis and Lung Disease, Paris, France. London School of Hygiene and Tropical Medicine, London, United Kingdom. Dignitas International, Zomba, Malawi. Department of Medicine, College of Medicine, University of Malawi, Blantyre, Malawi.'
p2162
sS'IP'
p2163
S'11'
p2164
sS'IS'
p2165
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p2166
sS'PMC'
p2167
S'PMC4640882'
p2168
sS'DCOM'
p2169
S'20160626'
p2170
sS'AU'
p2171
(lp2172
S'van Lettow M'
p2173
aS'Bedell R'
p2174
aS'Maosa S'
p2175
aS'Phiri K'
p2176
aS'Chan AK'
p2177
aS'Mwinjiwa E'
p2178
aS'Kwekwesa A'
p2179
aS'Kawonga H'
p2180
aS'Joshua M'
p2181
aS'Harries AD'
p2182
aS'van Oosterhout JJ'
p2183
asS'VI'
p2184
S'10'
p2185
sS'MHDA'
p2186
S'2016/06/28 06:00'
p2187
sS'PHST'
p2188
(lp2189
S'2015 [ecollection]'
p2190
aS'2015/05/07 [received]'
p2191
aS'2015/10/08 [accepted]'
p2192
aS'2015/11/10 [epublish]'
p2193
asS'OID'
p2194
(lp2195
S'NLM: PMC4640882'
p2196
asS'MH'
p2197
(lp2198
S'Adult'
p2199
aS'Age Factors'
p2200
aS'Antiretroviral Therapy, Highly Active'
p2201
aS'Comorbidity'
p2202
aS'Cough/*etiology'
p2203
aS'Female'
p2204
aS'HIV Infections/drug therapy/epidemiology'
p2205
aS'HIV Seroprevalence'
p2206
aS'Humans'
p2207
aS'Malawi/epidemiology'
p2208
aS'Male'
p2209
aS'Middle Aged'
p2210
aS'Mycobacterium tuberculosis/isolation & purification'
p2211
aS'*Outpatients'
p2212
aS'Prospective Studies'
p2213
aS'Sputum/microbiology'
p2214
aS'Survival Analysis'
p2215
aS'Treatment Outcome'
p2216
aS'Tuberculosis/*diagnosis/epidemiology'
p2217
asS'EDAT'
p2218
S'2015/11/12 06:00'
p2219
sS'SO'
p2220
S'PLoS One. 2015 Nov 10;10(11):e0141414. doi: 10.1371/journal.pone.0141414. eCollection 2015.'
p2221
sS'SB'
p2222
S'IM'
p2223
sS'PMID'
p2224
S'26556045'
p2225
sS'PST'
p2226
S'epublish'
p2227
stRp2228
ag2
(g3
g4
(dp2229
S'LID'
p2230
S'10.1111/tmi.12637 [doi]'
p2231
sS'STAT'
p2232
S'MEDLINE'
p2233
sS'DEP'
p2234
S'20151208'
p2235
sS'CI'
p2236
(lp2237
S'(c) 2015 John Wiley & Sons Ltd.'
p2238
asS'DA'
p2239
S'20160202'
p2240
sS'AID'
p2241
(lp2242
S'10.1111/tmi.12637 [doi]'
p2243
asS'CRDT'
p2244
(lp2245
S'2015/11/12 06:00'
p2246
asS'DP'
p2247
S'2016 Feb'
p2248
sS'OWN'
p2249
S'NLM'
p2250
sS'PT'
p2251
(lp2252
S'Evaluation Studies'
p2253
aS'Journal Article'
p2254
aS"Research Support, Non-U.S. Gov't"
p2255
asS'LA'
p2256
(lp2257
S'eng'
p2258
asS'FAU'
p2259
(lp2260
S'Dzangare, Janet'
p2261
aS'Takarinda, Kudakwashe C'
p2262
aS'Harries, Anthony D'
p2263
aS'Tayler-Smith, Katie'
p2264
aS'Mhangara, Mutsa'
p2265
aS'Apollo, Tsitsi Mutasa'
p2266
aS'Mushavi, Angela'
p2267
aS'Chimwaza, Anesu'
p2268
aS'Sithole, Ngwarai'
p2269
aS'Magure, Tapiwa'
p2270
aS'Mpofu, Amon'
p2271
aS'Dube, Freeman'
p2272
aS'Mugurungi, Owen'
p2273
asS'JT'
p2274
S'Tropical medicine & international health : TM & IH'
p2275
sS'PG'
p2276
S'202-9'
p2277
sS'TI'
p2278
S"HIV testing uptake and retention in care of HIV-infected pregnant and breastfeeding women initiated on 'Option B+' in rural Zimbabwe."
p2279
sS'RN'
p2280
(lp2281
S'0 (Anti-HIV Agents)'
p2282
asS'PL'
p2283
S'England'
p2284
sS'TA'
p2285
S'Trop Med Int Health'
p2286
sS'JID'
p2287
S'9610576'
p2288
sS'AB'
p2289
S'OBJECTIVES: Zimbabwe has started to scale up Option B+ for the prevention of mother-to-child transmission of HIV, but there is little published information about uptake or retention in care. This study determined the number and proportion of pregnant and lactating women in rural districts diagnosed with HIV infection and started on Option B+ along with six-month antiretroviral treatment (ART) outcomes. METHODS: This was a retrospective record review of women presenting to antenatal care or maternal and child health services at 34 health facilities in Chikomba and Gutu rural districts, Zimbabwe, between January and March 2014. RESULTS: A total of 2728 women presented to care of whom 2598 were eligible for HIV testing: 76% presented to antenatal care, 20% during labour and delivery and 4% while breastfeeding. Of 2097 (81%) HIV-tested women, 7% were HIV positive. Lower HIV testing uptake was found with increasing parity, late presentation to antenatal care, health centre attendance and in women tested during labour. Ninety-one per cent of the HIV-positive women were started on Option B+. Six-month ART retention in care, including transfers, was 83%. Loss to follow-up was the main cause of attrition. Increasing age and gravida status >/=2 were associated with higher six-month attrition. CONCLUSION: The uptake of HIV testing and Option B+ is high in women attending antenatal and post-natal clinics in rural Zimbabwe, suggesting that the strategy is feasible for national scale-up in the country.'
p2290
sS'AD'
p2291
S'National AIDS and Tuberculosis Unit, Ministry of Health and Child Care, Harare, Zimbabwe. National AIDS and Tuberculosis Unit, Ministry of Health and Child Care, Harare, Zimbabwe. International Union Against Tuberculosis and Lung Disease, Paris, France. International Union Against Tuberculosis and Lung Disease, Paris, France. London School of Hygiene & Tropical Medicine, London, UK. Operational Centre Brussels, Medecins Sans Frontieres, 68 Rue de Gasperich, Luxembourg. National AIDS and Tuberculosis Unit, Ministry of Health and Child Care, Harare, Zimbabwe. National AIDS and Tuberculosis Unit, Ministry of Health and Child Care, Harare, Zimbabwe. National AIDS and Tuberculosis Unit, Ministry of Health and Child Care, Harare, Zimbabwe. National AIDS and Tuberculosis Unit, Ministry of Health and Child Care, Harare, Zimbabwe. National AIDS and Tuberculosis Unit, Ministry of Health and Child Care, Harare, Zimbabwe. National AIDS Council, Harare, Zimbabwe. National AIDS Council, Harare, Zimbabwe. National AIDS Council, Harare, Zimbabwe. National AIDS and Tuberculosis Unit, Ministry of Health and Child Care, Harare, Zimbabwe.'
p2292
sS'IP'
p2293
S'2'
sS'IS'
p2294
S'1365-3156 (Electronic) 1360-2276 (Linking)'
p2295
sS'DCOM'
p2296
S'20160609'
p2297
sS'AU'
p2298
(lp2299
S'Dzangare J'
p2300
aS'Takarinda KC'
p2301
aS'Harries AD'
p2302
aS'Tayler-Smith K'
p2303
aS'Mhangara M'
p2304
aS'Apollo TM'
p2305
aS'Mushavi A'
p2306
aS'Chimwaza A'
p2307
aS'Sithole N'
p2308
aS'Magure T'
p2309
aS'Mpofu A'
p2310
aS'Dube F'
p2311
aS'Mugurungi O'
p2312
asS'VI'
p2313
S'21'
p2314
sS'MHDA'
p2315
S'2016/06/10 06:00'
p2316
sS'PHST'
p2317
(lp2318
S'2015/12/08 [aheadofprint]'
p2319
asS'OTO'
p2320
(lp2321
S'NOTNLM'
p2322
asS'MH'
p2323
(lp2324
S'Adolescent'
p2325
aS'Adult'
p2326
aS'Anti-HIV Agents/*therapeutic use'
p2327
aS'Breast Feeding'
p2328
aS'Female'
p2329
aS'Gravidity'
p2330
aS'*HIV Infections/diagnosis/drug therapy'
p2331
aS'Humans'
p2332
aS'Infectious Disease Transmission, Vertical/*prevention & control'
p2333
aS'Lactation'
p2334
aS'Lost to Follow-Up'
p2335
aS'*Mass Screening'
p2336
aS'*Maternal Health Services'
p2337
aS'Parity'
p2338
aS'*Patient Acceptance of Health Care'
p2339
aS'Pregnancy'
p2340
aS'*Pregnancy Complications, Infectious/diagnosis/drug therapy'
p2341
aS'Retrospective Studies'
p2342
aS'Rural Population'
p2343
aS'Young Adult'
p2344
aS'Zimbabwe'
p2345
asS'EDAT'
p2346
S'2015/11/12 06:00'
p2347
sS'SO'
p2348
S'Trop Med Int Health. 2016 Feb;21(2):202-9. doi: 10.1111/tmi.12637. Epub 2015 Dec 8.'
p2349
sS'SB'
p2350
S'IM'
p2351
sS'PMID'
p2352
S'26555353'
p2353
sS'OT'
p2354
(lp2355
S'Investigacion de Operaciones'
p2356
aS'Opcion B+'
p2357
aS'Operational Research'
p2358
aS'Option B+'
p2359
aS'SORT IT'
p2360
aS'Zimbabue'
p2361
aS'Zimbabwe'
p2362
aS'recherche operationnelle'
p2363
asS'PST'
p2364
S'ppublish'
p2365
stRp2366
ag2
(g3
g4
(dp2367
S'LID'
p2368
S'10.1371/journal.pone.0142873 [doi]'
p2369
sS'STAT'
p2370
S'MEDLINE'
p2371
sS'DEP'
p2372
S'20151110'
p2373
sS'DA'
p2374
S'20151111'
p2375
sS'AID'
p2376
(lp2377
S'10.1371/journal.pone.0142873 [doi]'
p2378
aS'PONE-D-15-37230 [pii]'
p2379
asS'CRDT'
p2380
(lp2381
S'2015/11/12 06:00'
p2382
asS'DP'
p2383
S'2015'
p2384
sS'OWN'
p2385
S'NLM'
p2386
sS'PT'
p2387
(lp2388
S'Journal Article'
p2389
asS'LA'
p2390
(lp2391
S'eng'
p2392
asS'FAU'
p2393
(lp2394
S'Daniels, Johnny Flippie'
p2395
aS'Khogali, Mohammed'
p2396
aS'Mohr, Erika'
p2397
aS'Cox, Vivian'
p2398
aS'Moyo, Sizulu'
p2399
aS'Edginton, Mary'
p2400
aS'Hinderaker, Sven Gudmund'
p2401
aS'Meintjes, Graeme'
p2402
aS'Hughes, Jennifer'
p2403
aS'De Azevedo, Virginia'
p2404
aS'van Cutsem, Gilles'
p2405
aS'Cox, Helen Suzanne'
p2406
asS'JT'
p2407
S'PloS one'
p2408
sS'LR'
p2409
S'20151116'
p2410
sS'PG'
p2411
S'e0142873'
p2412
sS'TI'
p2413
S'Time to ART Initiation among Patients Treated for Rifampicin-Resistant Tuberculosis in Khayelitsha, South Africa: Impact on Mortality and Treatment Success.'
p2414
sS'RN'
p2415
(lp2416
S'0 (Anti-HIV Agents)'
p2417
aS'0 (Antitubercular Agents)'
p2418
aS'VJT6J7R4TR (Rifampin)'
p2419
asS'PL'
p2420
S'United States'
p2421
sS'TA'
p2422
S'PLoS One'
p2423
sS'JID'
p2424
S'101285081'
p2425
sS'AB'
p2426
S'SETTING: Khayelitsha, South Africa, with high burdens of rifampicin-resistant tuberculosis (RR-TB) and HIV co-infection. OBJECTIVE: To describe time to antiretroviral treatment (ART) initiation among HIV-infected RR-TB patients initiating RR-TB treatment and to assess the association between time to ART initiation and treatment outcomes. DESIGN: A retrospective cohort study of patients with RR-TB and HIV co-infection not on ART at RR-TB treatment initiation. RESULTS: Of the 696 RR-TB and HIV-infected patients initiated on RR-TB treatment between 2009 and 2013, 303 (44%) were not on ART when RR-TB treatment was initiated. The median CD4 cell count was 126 cells/mm3. Overall 257 (85%) patients started ART during RR-TB treatment, 33 (11%) within 2 weeks, 152 (50%) between 2-8 weeks and 72 (24%) after 8 weeks. Of the 46 (15%) who never started ART, 10 (21%) died or stopped RR-TB treatment within 4 weeks and 16 (37%) had at least 4 months of RR-TB treatment. Treatment success and mortality during treatment did not vary by time to ART initiation: treatment success was 41%, 43%, and 50% among patients who started ART within 2 weeks, between 2-8 weeks, and after 8 weeks (p = 0.62), while mortality was 21%, 13% and 15% respectively (p = 0.57). Mortality was associated with never receiving ART (adjusted hazard ratio (aHR) 6.0, CI 2.1-18.1), CD4 count </=100 (aHR 2.1, CI 1.0-4.5), and multidrug-resistant tuberculosis (MDR-TB) with second-line resistance (aHR 2.5, CI 1.1-5.4). CONCLUSIONS: Despite wide variation in time to ART initiation among RR-TB patients, no differences in mortality or treatment success were observed. However, a significant proportion of patients did not initiate ART despite receiving >4 months of RR-TB treatment. Programmatic priorities should focus on ensuring all patients with RR-TB/HIV co-infection initiate ART regardless of CD4 count, with special attention for patients with CD4 counts </= 100 to initiate ART as soon as possible after RR-TB treatment initiation.'
p2427
sS'AD'
p2428
S'Medecins sans Frontieres, Khayelitsha, Cape Town, South Africa. Medecins sans Frontieres, Luxembourg, Luxembourg. Medecins sans Frontieres, Khayelitsha, Cape Town, South Africa. Medecins sans Frontieres, Khayelitsha, Cape Town, South Africa. Medecins sans Frontieres, Khayelitsha, Cape Town, South Africa. Human Sciences Research Council, HIV/AIDS, STIs and TB programme, Cape Town, South Africa. International Union against TB and Lung Disease, Paris, France. School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. University of Bergen, Bergen, Norway. Institute of Infectious Disease and Molecular Medicine and Department of Medicine, University of Cape Town, Cape Town, South Africa. Medecins sans Frontieres, Khayelitsha, Cape Town, South Africa. City of Cape Town Department of Health, Cape Town, South Africa. Medecins sans Frontieres, Khayelitsha, Cape Town, South Africa. Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa. Division of Medical Microbiology and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.'
p2429
sS'IP'
p2430
S'11'
p2431
sS'IS'
p2432
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p2433
sS'PMC'
p2434
S'PMC4640533'
p2435
sS'DCOM'
p2436
S'20160613'
p2437
sS'AU'
p2438
(lp2439
S'Daniels JF'
p2440
aS'Khogali M'
p2441
aS'Mohr E'
p2442
aS'Cox V'
p2443
aS'Moyo S'
p2444
aS'Edginton M'
p2445
aS'Hinderaker SG'
p2446
aS'Meintjes G'
p2447
aS'Hughes J'
p2448
aS'De Azevedo V'
p2449
aS'van Cutsem G'
p2450
aS'Cox HS'
p2451
asS'VI'
p2452
S'10'
p2453
sS'MHDA'
p2454
S'2016/06/14 06:00'
p2455
sS'PHST'
p2456
(lp2457
S'2015 [ecollection]'
p2458
aS'2015/08/24 [received]'
p2459
aS'2015/10/27 [accepted]'
p2460
aS'2015/11/10 [epublish]'
p2461
asS'OID'
p2462
(lp2463
S'NLM: PMC4640533'
p2464
asS'MH'
p2465
(lp2466
S'AIDS-Related Opportunistic Infections/complications/*drug therapy/mortality'
p2467
aS'Adolescent'
p2468
aS'Adult'
p2469
aS'Anti-HIV Agents/*administration & dosage'
p2470
aS'Antitubercular Agents/*therapeutic use'
p2471
aS'Child'
p2472
aS'Child, Preschool'
p2473
aS'Female'
p2474
aS'Humans'
p2475
aS'Infant'
p2476
aS'Infant, Newborn'
p2477
aS'Male'
p2478
aS'Rifampin/*therapeutic use'
p2479
aS'South Africa'
p2480
aS'Treatment Outcome'
p2481
aS'Tuberculosis, Multidrug-Resistant/complications/*drug therapy/mortality'
p2482
aS'Young Adult'
p2483
asS'EDAT'
p2484
S'2015/11/12 06:00'
p2485
sS'SI'
p2486
(lp2487
S'figshare/10.6084/M9.FIGSHARE.1585000'
p2488
asS'SO'
p2489
S'PLoS One. 2015 Nov 10;10(11):e0142873. doi: 10.1371/journal.pone.0142873. eCollection 2015.'
p2490
sS'SB'
p2491
S'IM'
p2492
sS'PMID'
p2493
S'26555134'
p2494
sS'PST'
p2495
S'epublish'
p2496
stRp2497
ag2
(g3
g4
(dp2498
S'LID'
p2499
S'10.1001/jama.2015.13631 [doi]'
p2500
sS'STAT'
p2501
S'MEDLINE'
p2502
sS'JT'
p2503
S'JAMA'
p2504
sS'CIN'
p2505
(lp2506
S'JAMA. 2015 Nov 3;314(17):1801-2. PMID: 26529157'
p2507
asS'DA'
p2508
S'20151104'
p2509
sS'AID'
p2510
(lp2511
S'2467551 [pii]'
p2512
aS'10.1001/jama.2015.13631 [doi]'
p2513
asS'CRDT'
p2514
(lp2515
S'2015/11/04 06:00'
p2516
asS'DP'
p2517
S'2015 Nov 3'
p2518
sS'AD'
p2519
S'Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. ICAP, Mailman School of Public Health, Columbia University, New York, New York3Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York. Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York4Gertrude H. Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, New York. Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Center for HIV and STIs, National Institute for Communicable Diseases, Johannesburg, South Africa. Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, New York. Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York4Gertrude H. Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, New York.'
p2520
sS'OWN'
p2521
S'NLM'
p2522
sS'PT'
p2523
(lp2524
S'Journal Article'
p2525
aS'Randomized Controlled Trial'
p2526
aS'Research Support, N.I.H., Extramural'
p2527
asS'LA'
p2528
(lp2529
S'eng'
p2530
asS'FAU'
p2531
(lp2532
S'Coovadia, Ashraf'
p2533
aS'Abrams, Elaine J'
p2534
aS'Strehlau, Renate'
p2535
aS'Shiau, Stephanie'
p2536
aS'Pinillos, Francoise'
p2537
aS'Martens, Leigh'
p2538
aS'Patel, Faeezah'
p2539
aS'Hunt, Gillian'
p2540
aS'Tsai, Wei-Yann'
p2541
aS'Kuhn, Louise'
p2542
asS'LR'
p2543
S'20151201'
p2544
sS'PG'
p2545
S'1808-17'
p2546
sS'TI'
p2547
S'Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial.'
p2548
sS'RN'
p2549
(lp2550
S'0 (Anti-Retroviral Agents)'
p2551
aS'0 (Benzoxazines)'
p2552
aS'2494G1JF75 (Lopinavir)'
p2553
aS'99DK7FVK1H (Nevirapine)'
p2554
aS'JE6H2O27P8 (efavirenz)'
p2555
asS'PL'
p2556
S'United States'
p2557
sS'TA'
p2558
S'JAMA'
p2559
sS'JID'
p2560
S'7501160'
p2561
sS'AB'
p2562
S'IMPORTANCE: Advantages of using efavirenz as part of treatment for children infected with human immunodeficiency virus (HIV) include once-daily dosing, simplification of co-treatment for tuberculosis, preservation of ritonavir-boosted lopinavir for second-line treatment, and harmonization of adult and pediatric treatment regimens. However, there have been concerns about possible reduced viral efficacy of efavirenz in children exposed to nevirapine for prevention of mother-to-child transmission. OBJECTIVE: To evaluate whether nevirapine-exposed children achieving initial viral suppression with ritonavir-boosted lopinavir-based therapy can transition to efavirenz-based therapy without risk of viral failure. DESIGN, SETTING, AND PARTICIPANTS: Randomized, open-label noninferiority trial conducted at Rahima Moosa Mother and Child Hospital, Johannesburg, South Africa, from June 2010 to December 2013, enrolling 300 HIV-infected children exposed to nevirapine for prevention of mother-to-child transmission who were aged 3 years or older and had plasma HIV RNA of less than 50 copies/mL during ritonavir-boosted lopinavir-based therapy; 298 were randomized and 292 (98%) were followed up to 48 weeks after randomization. INTERVENTIONS: Participants were randomly assigned to switch to efavirenz-based therapy (n = 150) or continue ritonavir-boosted lopinavir-based therapy (n = 148). MAIN OUTCOMES AND MEASURES: Risk difference between groups in (1) viral rebound (ie, >/=1 HIV RNA measurement of >50 copies/mL) and (2) viral failure (ie, confirmed HIV RNA >1000 copies/mL) with a noninferiority bound of -0.10. Immunologic and clinical responses were secondary end points. RESULTS: The Kaplan-Meier probability of viral rebound by 48 weeks was 0.176 (n = 26) in the efavirenz group and 0.284 (n = 42) in the ritonavir-boosted lopinavir group. Probabilities of viral failure were 0.027 (n = 4) in the efavirenz group and 0.020 (n = 3) in the ritonavir-boosted lopinavir group. The risk difference for viral rebound was 0.107 (1-sided 95% CI, 0.028 to infinity) and for viral failure was -0.007 (1-sided 95% CI, -0.036 to infinity). We rejected the null hypothesis that efavirenz is inferior to ritonavir-boosted lopinavir (P < .001) for both end points. By 48 weeks, CD4 cell percentage was 2.88% (95% CI, 1.26%-4.49%) higher in the efavirenz group than in the ritonavir-boosted lopinavir group. CONCLUSIONS AND RELEVANCE: Among HIV-infected children exposed to nevirapine for prevention of mother-to-child transmission and with initial viral suppression with ritonavir-boosted lopinavir-based therapy, switching to efavirenz-based therapy compared with continuing ritonavir-boosted lopinavir-based therapy did not result in significantly higher rates of viral rebound or viral failure. This therapeutic approach may offer advantages in children such as these. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01146873.'
p2563
sS'GR'
p2564
(lp2565
S'HD061255/HD/NICHD NIH HHS/United States'
p2566
aS'R01 HD061255/HD/NICHD NIH HHS/United States'
p2567
asS'IP'
p2568
S'17'
p2569
sS'IS'
p2570
S'1538-3598 (Electronic) 0098-7484 (Linking)'
p2571
sS'PMC'
p2572
S'PMC4655876'
p2573
sS'DCOM'
p2574
S'20151116'
p2575
sS'MID'
p2576
(lp2577
S'NIHMS736799'
p2578
asS'AU'
p2579
(lp2580
S'Coovadia A'
p2581
aS'Abrams EJ'
p2582
aS'Strehlau R'
p2583
aS'Shiau S'
p2584
aS'Pinillos F'
p2585
aS'Martens L'
p2586
aS'Patel F'
p2587
aS'Hunt G'
p2588
aS'Tsai WY'
p2589
aS'Kuhn L'
p2590
asS'VI'
p2591
S'314'
p2592
sS'MHDA'
p2593
S'2015/11/17 06:00'
p2594
sS'OID'
p2595
(lp2596
S'NLM: NIHMS736799'
p2597
aS'NLM: PMC4655876'
p2598
asS'MH'
p2599
(lp2600
S'Anti-Retroviral Agents/*administration & dosage'
p2601
aS'Benzoxazines/*administration & dosage'
p2602
aS'Child'
p2603
aS'Child, Preschool'
p2604
aS'Drug Therapy, Combination'
p2605
aS'Female'
p2606
aS'HIV Infections/*drug therapy/prevention & control/transmission'
p2607
aS'Humans'
p2608
aS'Infectious Disease Transmission, Vertical/*prevention & control'
p2609
aS'Lopinavir/*administration & dosage'
p2610
aS'Male'
p2611
aS'Nevirapine/*administration & dosage'
p2612
aS'South Africa'
p2613
aS'Viral Load'
p2614
asS'EDAT'
p2615
S'2015/11/04 06:00'
p2616
sS'SI'
p2617
(lp2618
S'ClinicalTrials.gov/NCT01146873'
p2619
asS'SO'
p2620
S'JAMA. 2015 Nov 3;314(17):1808-17. doi: 10.1001/jama.2015.13631.'
p2621
sS'SB'
p2622
S'AIM IM'
p2623
sS'PMID'
p2624
S'26529159'
p2625
sS'PST'
p2626
S'ppublish'
p2627
stRp2628
ag2
(g3
g4
(dp2629
S'LID'
p2630
S'10.1257/aer.20121607 [doi]'
p2631
sS'STAT'
p2632
S'MEDLINE'
p2633
sS'JT'
p2634
S'The American economic review'
p2635
sS'MID'
p2636
(lp2637
S'NIHMS691942'
p2638
asS'DA'
p2639
S'20151103'
p2640
sS'AID'
p2641
(lp2642
S'10.1257/aer.20121607 [doi]'
p2643
asS'CRDT'
p2644
(lp2645
S'2015/11/03 06:00'
p2646
asS'DP'
p2647
S'2015 Sep'
p2648
sS'AD'
p2649
S'MIT Economics Department, 50 Memorial Drive, Building E52 room 252G, Cambridge, MA 02142. Stanford Economics Department, 579 Serra Mall, CA 94306. Harvard University Department of Economics, Littauer Center, 1805 Cambridge Street, Cambridge, MA 02138.'
p2650
sS'OWN'
p2651
S'HSR'
p2652
sS'PT'
p2653
(lp2654
S'Journal Article'
p2655
asS'LA'
p2656
(lp2657
S'eng'
p2658
asS'FAU'
p2659
(lp2660
S'Duflo, Esther'
p2661
aS'Dupas, Pascaline'
p2662
aS'Kremer, Michael'
p2663
asS'LR'
p2664
S'20151215'
p2665
sS'PG'
p2666
S'2757-97'
p2667
sS'TI'
p2668
S'Education, HIV, and Early Fertility: Experimental Evidence from Kenya.'
p2669
sS'PL'
p2670
S'United States'
p2671
sS'TA'
p2672
S'Am Econ Rev'
p2673
sS'JID'
p2674
S'14810500R'
p2675
sS'AB'
p2676
S"A seven-year randomized evaluation suggests education subsidies reduce adolescent girls' dropout, pregnancy, and marriage but not sexually transmitted infection (STI). The government's HIV curriculum, which stresses abstinence until marriage, does not reduce pregnancy or STI. Both programs combined reduce STI more, but cut dropout and pregnancy less, than education subsidies alone. These results are inconsistent with a model of schooling and sexual behavior in which both pregnancy and STI are determined by one factor (unprotected sex), but consistent with a two-factor model in which choices between committed and casual relationships also affect these outcomes."
p2677
sS'GR'
p2678
(lp2679
S'R01 HD039922/HD/NICHD NIH HHS/United States'
p2680
asS'IP'
p2681
S'9'
sS'IS'
p2682
S'0002-8282 (Print) 0002-8282 (Linking)'
p2683
sS'PMC'
p2684
S'PMC4624413'
p2685
sS'DCOM'
p2686
S'20160111'
p2687
sS'AU'
p2688
(lp2689
S'Duflo E'
p2690
aS'Dupas P'
p2691
aS'Kremer M'
p2692
asS'VI'
p2693
S'105'
p2694
sS'MHDA'
p2695
S'2016/01/12 06:00'
p2696
sS'OTO'
p2697
(lp2698
S'NOTNLM'
p2699
asS'OID'
p2700
(lp2701
S'NLM: NIHMS691942'
p2702
aS'NLM: PMC4624413'
p2703
asS'MH'
p2704
(lp2705
S'Adolescent'
p2706
aS'Clothing/economics'
p2707
aS'Condoms/utilization'
p2708
aS'Education/*economics'
p2709
aS'Educational Status'
p2710
aS'Extramarital Relations'
p2711
aS'Female'
p2712
aS'Fertility'
p2713
aS'HIV Infections/*prevention & control'
p2714
aS'Herpes Genitalis/prevention & control'
p2715
aS'Humans'
p2716
aS'Kenya'
p2717
aS'Male'
p2718
aS'*Marital Status'
p2719
aS'Pregnancy'
p2720
aS'*Pregnancy in Adolescence'
p2721
aS'*Program Evaluation'
p2722
aS'Sex Education/*economics'
p2723
aS'Sexual Abstinence'
p2724
aS'*Sexual Behavior'
p2725
aS'Sexual Partners'
p2726
aS'Sexually Transmitted Diseases/epidemiology/*prevention & control'
p2727
aS'Unsafe Sex'
p2728
aS'Young Adult'
p2729
asS'EDAT'
p2730
S'2015/11/03 06:00'
p2731
sS'SO'
p2732
S'Am Econ Rev. 2015 Sep;105(9):2757-97. doi: 10.1257/aer.20121607.'
p2733
sS'SB'
p2734
S'T'
sS'PMID'
p2735
S'26523067'
p2736
sS'OT'
p2737
(lp2738
S'Sexually Transmitted Infections'
p2739
aS'information'
p2740
aS'prevention'
p2741
aS'sexual behavior'
p2742
aS'subsidies'
p2743
asS'PST'
p2744
S'ppublish'
p2745
stRp2746
ag2
(g3
g4
(dp2747
S'LID'
p2748
S'10.1177/2325957415614642 [doi]'
p2749
sS'STAT'
p2750
S'MEDLINE'
p2751
sS'DEP'
p2752
S'20151029'
p2753
sS'CI'
p2754
(lp2755
S'(c) The Author(s) 2015.'
p2756
asS'DA'
p2757
S'20160317'
p2758
sS'AID'
p2759
(lp2760
S'2325957415614642 [pii]'
p2761
aS'10.1177/2325957415614642 [doi]'
p2762
asS'CRDT'
p2763
(lp2764
S'2015/10/31 06:00'
p2765
asS'DP'
p2766
S'2016 Mar-Apr'
p2767
sS'OWN'
p2768
S'NLM'
p2769
sS'PT'
p2770
(lp2771
S'Journal Article'
p2772
aS"Research Support, Non-U.S. Gov't"
p2773
asS'LA'
p2774
(lp2775
S'eng'
p2776
asS'FAU'
p2777
(lp2778
S'Ombeni, Walter'
p2779
aS'Kamuhabwa, Appolinary R'
p2780
asS'JT'
p2781
S'Journal of the International Association of Providers of AIDS Care'
p2782
sS'PG'
p2783
S'164-71'
p2784
sS'TI'
p2785
S'Lipid Profile in HIV-Infected Patients Using First-Line Antiretroviral Drugs.'
p2786
sS'RN'
p2787
(lp2788
S'0 (Anti-HIV Agents)'
p2789
aS'0 (Drug Combinations)'
p2790
aS'0 (lamivudine, zidovudine drug combination)'
p2791
aS'2T8Q726O95 (Lamivudine)'
p2792
aS'4B9XT59T7S (Zidovudine)'
p2793
asS'PL'
p2794
S'United States'
p2795
sS'TA'
p2796
S'J Int Assoc Provid AIDS Care'
p2797
sS'JID'
p2798
S'101603896'
p2799
sS'AB'
p2800
S'OBJECTIVE: To determine the prevalence of dyslipidemia in HIV-infected patients using the first-line antiretroviral (ARV) drugs triple regimen. METHODS: HIV-infected patients aged >/=15 years and attending Care and Treatment Clinic (CTC) at Muhimbili National Hospital, in Dar es Salaam, Tanzania, were recruited for the study. Blood samples from patients were collected during their regular visits at the CTC and assayed for determination of total cholesterol, triglycerides (TGs), high-density lipoprotein, low-density lipoprotein cholesterol, and CD4 counts. RESULTS: The median CD4 count was 346 cells/mm(3) (2-2600). Triple therapy combinations of ARV drugs used by patients included zidovudine (ZDV)/lamivudine (3TC)/efavirenz (EFV; 42.4%), ZDV/3TC/nevirapine (NVP; 33.8%), tenofovir (TDF)/emtricitabine/EFV (19.9%), and TDF/3TC/EFV (3.9%). The overall prevalence of dyslipidemia in patients was 77.5%. There were varied prevalence of derangement of individual lipids among patients. Age, body mass index, CD4 count, sex, and duration of ARV drug use were the predictors of poor lipid profiles. CONCLUSION: The findings of this study indicate the need for routine monitoring of lipids among HIV-infected patients.'
p2801
sS'AD'
p2802
S'Unit of Pharmacology and Therapeutics, School of Pharmacy, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania. Unit of Pharmacology and Therapeutics, School of Pharmacy, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania akamuhabwa@muhas.ac.tz enali2012@gmail.com.'
p2803
sS'IP'
p2804
S'2'
sS'IS'
p2805
S'2325-9574 (Print) 2325-9574 (Linking)'
p2806
sS'DCOM'
p2807
S'20160630'
p2808
sS'AU'
p2809
(lp2810
S'Ombeni W'
p2811
aS'Kamuhabwa AR'
p2812
asS'VI'
p2813
S'15'
p2814
sS'MHDA'
p2815
S'2016/07/01 06:00'
p2816
sS'PHST'
p2817
(lp2818
S'2015/10/29 [aheadofprint]'
p2819
asS'OTO'
p2820
(lp2821
S'NOTNLM'
p2822
asS'MH'
p2823
(lp2824
S'Adolescent'
p2825
aS'Adult'
p2826
aS'Aged'
p2827
aS'Anti-HIV Agents/*adverse effects/therapeutic use'
p2828
aS'CD4 Lymphocyte Count'
p2829
aS'Cross-Sectional Studies'
p2830
aS'Drug Combinations'
p2831
aS'Female'
p2832
aS'HIV Infections/*drug therapy/metabolism/physiopathology'
p2833
aS'Humans'
p2834
aS'Lamivudine/*adverse effects/therapeutic use'
p2835
aS'Lipid Metabolism/*drug effects'
p2836
aS'Male'
p2837
aS'Middle Aged'
p2838
aS'Tanzania/epidemiology'
p2839
aS'Young Adult'
p2840
aS'Zidovudine/*adverse effects/therapeutic use'
p2841
asS'EDAT'
p2842
S'2015/10/31 06:00'
p2843
sS'SO'
p2844
S'J Int Assoc Provid AIDS Care. 2016 Mar-Apr;15(2):164-71. doi: 10.1177/2325957415614642. Epub 2015 Oct 29.'
p2845
sS'SB'
p2846
S'IM'
p2847
sS'PMID'
p2848
S'26514630'
p2849
sS'OT'
p2850
(lp2851
S'ARV drugs'
p2852
aS'HIV'
p2853
aS'dyslipidemia'
p2854
asS'PST'
p2855
S'ppublish'
p2856
stRp2857
ag2
(g3
g4
(dp2858
S'LID'
p2859
S'10.1186/s12879-015-1214-3 [doi]'
p2860
sS'STAT'
p2861
S'MEDLINE'
p2862
sS'DEP'
p2863
S'20151028'
p2864
sS'DA'
p2865
S'20151029'
p2866
sS'AID'
p2867
(lp2868
S'10.1186/s12879-015-1214-3 [doi]'
p2869
aS'10.1186/s12879-015-1214-3 [pii]'
p2870
asS'CRDT'
p2871
(lp2872
S'2015/10/30 06:00'
p2873
asS'DP'
p2874
S'2015'
p2875
sS'OWN'
p2876
S'NLM'
p2877
sS'PT'
p2878
(lp2879
S'Journal Article'
p2880
asS'LA'
p2881
(lp2882
S'eng'
p2883
asS'DCOM'
p2884
S'20160422'
p2885
sS'JT'
p2886
S'BMC infectious diseases'
p2887
sS'LR'
p2888
S'20151031'
p2889
sS'FAU'
p2890
(lp2891
S'Umanah, Teye'
p2892
aS'Ncayiyana, Jabulani'
p2893
aS'Padanilam, Xavier'
p2894
aS'Nyasulu, Peter S'
p2895
asS'TI'
p2896
S'Treatment outcomes in multidrug resistant tuberculosis-human immunodeficiency virus Co-infected patients on anti-retroviral therapy at Sizwe Tropical Disease Hospital Johannesburg, South Africa.'
p2897
sS'RN'
p2898
(lp2899
S'0 (Anti-Retroviral Agents)'
p2900
aS'0 (Antitubercular Agents)'
p2901
asS'PL'
p2902
S'England'
p2903
sS'PG'
p2904
S'478'
p2905
sS'JID'
p2906
S'100968551'
p2907
sS'AB'
p2908
S'BACKGROUND: Multidrug resistant-tuberculosis (MDR-TB) is a threat to global tuberculosis control which is worsened by human immune-deficiency virus (HIV) co-infection. There is however paucity of data on the effects of antiretroviral treatment (ART) before or after starting MDR-TB treatment. This study determined predictors of mortality and treatment failure among HIV co-infected MDR-TB patients on ART. METHODS: A retrospective medical record review of 1200 HIV co-infected MDR-TB patients admitted at Sizwe Tropical Disease Hospital, Johannesburg from 2007 to 2010 was performed. Chi-square test was used to determine treatment outcomes in HIV co-infected MDR-TB patients on ART. Multivariable logistic regression and Poisson models were used to determine predictors of mortality and treatment failure respectively. RESULTS: Mortality was higher (21.8% vs. 15.4%) among patients who started ART before initiating MDR-TB treatment compared with patients initiated on ART after commencing MDR-TB treatment (p = 0.013). Factors significantly associated with mortality included: the use of ART before starting MDR-TB treatment (OR 1.65, 95% CI 1.02-2.73), severely-underweight (OR 3.71, 95% CI 1.89-7.29) and underweight (OR 2.35, 95% CI 1.30-4.26), cavities on chest x-rays at baseline (OR 1.76, 95% CI 1.08-2.94), presence of other opportunistic infections (OR 1.80, 95% CI 1.10-2.94) and presence of other co-morbidities (OR 2.26, 95% CI 1.20-4.21). Factors predicting failure were severe anaemia (IRR (OR 4.72, 95% CI 1.47-15), other co-morbidities (OR 2.39, 95% CI 1.05-5.43) and modified individualised regimen at baseline (OR 2.15, 95% CI 0.98-4.71). CONCLUSIONS: High mortality among patients already on ART before initiating MDR-TB treatment is a worrisome development. Management of adverse-events, opportunistic infections and co-morbidities in these patients is important if the protective benefits of being on ART are to be maximized. There is the need to intensify intervention programmes targeted at early identification of MDR-TB, treatment initiation, drug monitoring and increasing adherence among HIV co-infected MDR-TB patients.'
p2909
sS'AD'
p2910
S'Division of Epidemiology and Biostatistics, School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. teyeumanah@yahoo.com. Division of Epidemiology and Biostatistics, School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. jabulani.ncayiyana@wits.ac.za. Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. jabulani.ncayiyana@wits.ac.za. Sizwe Tropical Disease Hospital, Gauteng Department of Health, Sandringham, Johannesburg. cmosizwe@gmail.com. Division of Epidemiology and Biostatistics, School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. peter.nyasulu@monash.edu. Department of Public Health, School of Health Sciences, Monash University, 144 Peter Road, Rumsuig, Johannesburg, South Africa. peter.nyasulu@monash.edu.'
p2911
sS'VI'
p2912
S'15'
p2913
sS'IS'
p2914
S'1471-2334 (Electronic) 1471-2334 (Linking)'
p2915
sS'PMC'
p2916
S'PMC4625623'
p2917
sS'AU'
p2918
(lp2919
S'Umanah T'
p2920
aS'Ncayiyana J'
p2921
aS'Padanilam X'
p2922
aS'Nyasulu PS'
p2923
asS'MHDA'
p2924
S'2016/04/23 06:00'
p2925
sS'PHST'
p2926
(lp2927
S'2015/03/27 [received]'
p2928
aS'2015/10/14 [accepted]'
p2929
aS'2015/10/28 [aheadofprint]'
p2930
asS'OID'
p2931
(lp2932
S'NLM: PMC4625623'
p2933
asS'MH'
p2934
(lp2935
S'Adult'
p2936
aS'Anti-Retroviral Agents/*therapeutic use'
p2937
aS'Antitubercular Agents/therapeutic use'
p2938
aS'Chi-Square Distribution'
p2939
aS'Coinfection/drug therapy'
p2940
aS'Comorbidity'
p2941
aS'Female'
p2942
aS'HIV Infections/*drug therapy/epidemiology/mortality'
p2943
aS'Humans'
p2944
aS'Logistic Models'
p2945
aS'Male'
p2946
aS'Retrospective Studies'
p2947
aS'South Africa/epidemiology'
p2948
aS'Treatment Failure'
p2949
aS'Treatment Outcome'
p2950
aS'Tuberculosis, Multidrug-Resistant/*drug therapy/epidemiology/mortality'
p2951
asS'EDAT'
p2952
S'2015/10/30 06:00'
p2953
sS'SO'
p2954
S'BMC Infect Dis. 2015 Oct 28;15:478. doi: 10.1186/s12879-015-1214-3.'
p2955
sS'SB'
p2956
S'IM'
p2957
sS'PMID'
p2958
S'26511616'
p2959
sS'TA'
p2960
S'BMC Infect Dis'
p2961
sS'PST'
p2962
S'epublish'
p2963
stRp2964
ag2
(g3
g4
(dp2965
S'LID'
p2966
S'10.3390/ijerph121013224 [doi]'
p2967
sS'STAT'
p2968
S'MEDLINE'
p2969
sS'DEP'
p2970
S'20151021'
p2971
sS'DA'
p2972
S'20151028'
p2973
sS'AID'
p2974
(lp2975
S'ijerph121013224 [pii]'
p2976
aS'10.3390/ijerph121013224 [doi]'
p2977
asS'CRDT'
p2978
(lp2979
S'2015/10/28 06:00'
p2980
asS'DP'
p2981
S'2015 Oct'
p2982
sS'OWN'
p2983
S'NLM'
p2984
sS'PT'
p2985
(lp2986
S'Journal Article'
p2987
aS'Review'
p2988
asS'LA'
p2989
(lp2990
S'eng'
p2991
asS'FAU'
p2992
(lp2993
S'Liotta, Giuseppe'
p2994
aS'Marazzi, Maria Cristina'
p2995
aS'Mothibi, Khethimipilo E'
p2996
aS'Zimba, Ines'
p2997
aS'Amangoua, Evelyne E'
p2998
aS'Bonje, Esther K'
p2999
aS'Bossiky, Bernard N B'
p3000
aS'Robinson, Precious A'
p3001
aS'Scarcella, Paola'
p3002
aS'Musokotwane, Kebby'
p3003
aS'Palombi, Leonardo'
p3004
aS'Germano, Paola'
p3005
aS'Narciso, Pasquale'
p3006
aS'de Luca, Andrea'
p3007
aS'Alumando, Elard'
p3008
aS'Mamary, Sangare H'
p3009
aS'Magid, Nurja A'
p3010
aS'Guidotti, Giovanni'
p3011
aS'Mancinelli, Sandro'
p3012
aS'Orlando, Stefano'
p3013
aS'Peroni, Marco'
p3014
aS'Buonomo, Ersilia'
p3015
aS'Nielsen-Saines, Karin'
p3016
asS'JT'
p3017
S'International journal of environmental research and public health'
p3018
sS'LR'
p3019
S'20151113'
p3020
sS'PG'
p3021
S'13224-39'
p3022
sS'TI'
p3023
S'Elimination of Mother-To-Child Transmission of HIV Infection: The Drug Resource Enhancement against AIDS and Malnutrition Model.'
p3024
sS'RN'
p3025
(lp3026
S'0 (Anti-HIV Agents)'
p3027
asS'PL'
p3028
S'Switzerland'
p3029
sS'TA'
p3030
S'Int J Environ Res Public Health'
p3031
sS'JID'
p3032
S'101238455'
p3033
sS'AB'
p3034
S'The Drug Resource Enhancement against AIDS and Malnutrition Program (DREAM) gathered professionals in the field of Elimination of HIV-Mother-To-Child Transmission (EMTCT) in Maputo in 2013 to discuss obstacles and solutions for the elimination of HIV vertical transmission in sub-Saharan Africa. During this workshop, the benefits of administrating combined antiretroviral therapy (cART) to HIV positive women from pregnancy throughout breastfeeding were reviewed. cART is capable of reducing vertical transmission to less than 5% at 24 months of age, as well as maternal mortality and infant mortality in both HIV infected and exposed populations to levels similar to those of uninfected individuals. The challenge for programs targeting eMTCT in developing countries is retention in care and treatment adherence. Both are intrinsically related to the model of care. The drop-out from eMTCT programs before cART initiation ranges from 33%-88% while retention rates at 18-24 months are less than 50%. Comprehensive strategies including peer-to-peer education, social support and laboratory monitoring can reduce refusals to less than 5% and attain retention rates approaching 90%. Several components of the model of care for reduction of HIV-1 MTCT are feasible and implementable in scale-up strategies. A review of this model of care for HIV eMTCT is provided.'
p3035
sS'AD'
p3036
S'University of Tor Vergata, 18-00173 Rome, Italy. giuseppeliotta@hotmail.com. LUMSA University, 18-00173 Rome, Italy. mcmarazzi@gmail.com. Health Services Cluster, Cite du Djoue, P.O. Box 06 Brazzaville, South Africa. eula.mothibi@khethimpilo.org. Community of S.Egidio-DREAM program, Avenida de Julho 7, Maputo, Mozambique. ineszimba@dream.org.mz. Ministere de la Sante et de la lutte contre le SIDA, B.P. 2091, Abidjan, Ivory Coast. evaehua@yahoo.fr. Cameroon Baptist Convention Health Services, P.O. Box 1 Bamenda, Cameroon. kunibonje@yahoo.com. Programme National Multisectoriel de Lutte contre le Sida, Blvd Triomphal and 24 Novembre Kinshasa, Congo (RDC). bernardbossiky@yahoo.fr. National Department of Health, Private Bag X9070, South Africa. robinsonprecious@gmail.com. University of Tor Vergata, 18-00173 Rome, Italy. paola.scarcella@gmail.com. Ministry of Health, Ndeke House, P.O. Box 30205, Lusaka, Zambia. University of Tor Vergata, 18-00173 Rome, Italy. leonardo.palombi@gmail.com. INMI L. Spallanzani, 00149 Rome, Italy. paolagermano1@gmail.com. INMI L. Spallanzani, 00149 Rome, Italy. pasquale.narciso@inmi.it. Division of Infectious Diseases, Department of Medical Biotechnologies, University of Siena, Siena University Hospital, Siena 53100, Italy. andrea.deluca@unisi.it. Community of S.Egidio-DREAM program, P.O. Box 30355, Blantyre, Malawi. eladarmando@yahoo.com. Community of S.Egidio-DREAM program, P.O. Box 30355, Blantyre, Malawi. drsangarehawa@gmail.com. Community of S.Egidio-DREAM program, Avenida de Julho 7, Maputo, Mozambique. nurjamajid@yahoo.com. Community of S.Egidio-DREAM program, Rome 00153, Italy. gianniguidotti1@gmail.com. University of Tor Vergata, 18-00173 Rome, Italy. sandro.mancinelli@gmail.com. Community of S.Egidio-DREAM program, Rome 00153, Italy. stefano.orlando@dreameurope.org. Community of S.Egidio-DREAM program, Rome 00153, Italy. peronimarco@gmail.com. University of Tor Vergata, 18-00173 Rome, Italy. ersiliabuonomo@gmail.com. David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, USA. knielsen@mednet.ucla.edu.'
p3037
sS'IP'
p3038
S'10'
p3039
sS'IS'
p3040
S'1660-4601 (Electronic) 1660-4601 (Linking)'
p3041
sS'PMC'
p3042
S'PMC4627027'
p3043
sS'DCOM'
p3044
S'20160523'
p3045
sS'AU'
p3046
(lp3047
S'Liotta G'
p3048
aS'Marazzi MC'
p3049
aS'Mothibi KE'
p3050
aS'Zimba I'
p3051
aS'Amangoua EE'
p3052
aS'Bonje EK'
p3053
aS'Bossiky BN'
p3054
aS'Robinson PA'
p3055
aS'Scarcella P'
p3056
aS'Musokotwane K'
p3057
aS'Palombi L'
p3058
aS'Germano P'
p3059
aS'Narciso P'
p3060
aS'de Luca A'
p3061
aS'Alumando E'
p3062
aS'Mamary SH'
p3063
aS'Magid NA'
p3064
aS'Guidotti G'
p3065
aS'Mancinelli S'
p3066
aS'Orlando S'
p3067
aS'Peroni M'
p3068
aS'Buonomo E'
p3069
aS'Nielsen-Saines K'
p3070
asS'VI'
p3071
S'12'
p3072
sS'MHDA'
p3073
S'2016/05/24 06:00'
p3074
sS'PHST'
p3075
(lp3076
S'2015/08/14 [received]'
p3077
aS'2015/10/01 [revised]'
p3078
aS'2015/10/15 [accepted]'
p3079
asS'OTO'
p3080
(lp3081
S'NOTNLM'
p3082
asS'OID'
p3083
(lp3084
S'NLM: PMC4627027'
p3085
asS'MH'
p3086
(lp3087
S'Acquired Immunodeficiency Syndrome'
p3088
aS'Africa South of the Sahara'
p3089
aS'Anti-HIV Agents/*therapeutic use'
p3090
aS'Child'
p3091
aS'Female'
p3092
aS'HIV Infections/*drug therapy/*transmission'
p3093
aS'HIV-1'
p3094
aS'Humans'
p3095
aS'Infectious Disease Transmission, Vertical/*prevention & control'
p3096
aS'Malnutrition'
p3097
aS'*Models, Theoretical'
p3098
aS'Mothers'
p3099
aS'Pregnancy'
p3100
aS'Pregnancy Complications, Infectious/*prevention & control'
p3101
asS'EDAT'
p3102
S'2015/10/28 06:00'
p3103
sS'SO'
p3104
S'Int J Environ Res Public Health. 2015 Oct 21;12(10):13224-39. doi: 10.3390/ijerph121013224.'
p3105
sS'SB'
p3106
S'IM'
p3107
sS'PMID'
p3108
S'26506365'
p3109
sS'OT'
p3110
(lp3111
S'DREAM program'
p3112
aS'elimination of HIV MTCT'
p3113
asS'PST'
p3114
S'epublish'
p3115
stRp3116
ag2
(g3
g4
(dp3117
S'LID'
p3118
S'10.1371/journal.pone.0141002 [doi]'
p3119
sS'STAT'
p3120
S'MEDLINE'
p3121
sS'DEP'
p3122
S'20151026'
p3123
sS'DA'
p3124
S'20151027'
p3125
sS'AID'
p3126
(lp3127
S'10.1371/journal.pone.0141002 [doi]'
p3128
aS'PONE-D-14-19585 [pii]'
p3129
asS'CRDT'
p3130
(lp3131
S'2015/10/27 06:00'
p3132
asS'DP'
p3133
S'2015'
p3134
sS'AD'
p3135
S'Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. Department of Infectious Diseases, Odense University Hospital, Odense, Denmark; National Institute for Medical Research, Mwanza Medical Research Centre, Mwanza, Tanzania. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark. National Institute for Medical Research, Mwanza Medical Research Centre, Mwanza, Tanzania. National Institute for Medical Research, Muhimbili Research Centre, Dar Es Salaam, Tanzania. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. Department for Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark. Department for Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark. National Institute for Medical Research, Mwanza Medical Research Centre, Mwanza, Tanzania. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark. Department of Infectious Diseases, Odense University Hospital, Odense, Denmark; Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark.'
p3136
sS'OWN'
p3137
S'NLM'
p3138
sS'PT'
p3139
(lp3140
S'Journal Article'
p3141
aS'Randomized Controlled Trial'
p3142
aS'Research Support, N.I.H., Extramural'
p3143
aS"Research Support, Non-U.S. Gov't"
p3144
asS'LA'
p3145
(lp3146
S'eng'
p3147
asS'FAU'
p3148
(lp3149
S'Denti, Paolo'
p3150
aS'Jeremiah, Kidola'
p3151
aS'Chigutsa, Emmanuel'
p3152
aS'Faurholt-Jepsen, Daniel'
p3153
aS'PrayGod, George'
p3154
aS'Range, Nyagosya'
p3155
aS'Castel, Sandra'
p3156
aS'Wiesner, Lubbe'
p3157
aS'Hagen, Christian Munch'
p3158
aS'Christiansen, Michael'
p3159
aS'Changalucha, John'
p3160
aS'McIlleron, Helen'
p3161
aS'Friis, Henrik'
p3162
aS'Andersen, Aase Bengaard'
p3163
asS'JT'
p3164
S'PloS one'
p3165
sS'LR'
p3166
S'20151030'
p3167
sS'PG'
p3168
S'e0141002'
p3169
sS'TI'
p3170
S'Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania.'
p3171
sS'RN'
p3172
(lp3173
S'0 (Antitubercular Agents)'
p3174
aS'2KNI5N06TI (Pyrazinamide)'
p3175
aS'8G167061QZ (Ethambutol)'
p3176
aS'V83O1VOZ8L (Isoniazid)'
p3177
asS'PL'
p3178
S'United States'
p3179
sS'TA'
p3180
S'PLoS One'
p3181
sS'JID'
p3182
S'101285081'
p3183
sS'AB'
p3184
S'Exposure to lower-than-therapeutic levels of anti-tuberculosis drugs is likely to cause selection of resistant strains of Mycobacterium tuberculosis and treatment failure. The first-line anti-tuberculosis (TB) regimen consists of rifampicin, isoniazid, pyrazinamide, and ethambutol, and correct management reduces risk of TB relapse and development of drug resistance. In this study we aimed to investigate the effect of standard of care plus nutritional supplementation versus standard care on the pharmacokinetics of isoniazid, pyrazinamide and ethambutol among sputum smear positive TB patients with and without HIV. In a clinical trial in 100 Tanzanian TB patients, with or without HIV infection, drug concentrations were determined at 1 week and 2 months post initiation of anti-TB medication. Data was analysed using population pharmacokinetic modelling. The effect of body size was described using allometric scaling, and the effects of nutritional supplementation, HIV, age, sex, CD4+ count, weight-adjusted dose, NAT2 genotype, and time on TB treatment were investigated. The kinetics of all drugs was well characterised using first-order elimination and transit compartment absorption, with isoniazid and ethambutol described by two-compartment disposition models, and pyrazinamide by a one-compartment model. Patients with a slow NAT2 genotype had higher isoniazid exposure and a lower estimate of oral clearance (15.5 L/h) than rapid/intermediate NAT2 genotype (26.1 L/h). Pyrazinamide clearance had an estimated typical value of 3.32 L/h, and it was found to increase with time on treatment, with a 16.3% increase after the first 2 months of anti-TB treatment. The typical clearance of ethambutol was estimated to be 40.7 L/h, and was found to decrease with age, at a rate of 1.41% per year. Neither HIV status nor nutritional supplementations were found to affect the pharmacokinetics of these drugs in our cohort of patients.'
p3185
sS'GR'
p3186
(lp3187
S'UM1 AI068634/AI/NIAID NIH HHS/United States'
p3188
aS'UM1 AI068636/AI/NIAID NIH HHS/United States'
p3189
aS'UM1 AI106701/AI/NIAID NIH HHS/United States'
p3190
asS'IP'
p3191
S'10'
p3192
sS'IS'
p3193
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p3194
sS'PMC'
p3195
S'PMC4621059'
p3196
sS'DCOM'
p3197
S'20160620'
p3198
sS'AU'
p3199
(lp3200
S'Denti P'
p3201
aS'Jeremiah K'
p3202
aS'Chigutsa E'
p3203
aS'Faurholt-Jepsen D'
p3204
aS'PrayGod G'
p3205
aS'Range N'
p3206
aS'Castel S'
p3207
aS'Wiesner L'
p3208
aS'Hagen CM'
p3209
aS'Christiansen M'
p3210
aS'Changalucha J'
p3211
aS'McIlleron H'
p3212
aS'Friis H'
p3213
aS'Andersen AB'
p3214
asS'VI'
p3215
S'10'
p3216
sS'MHDA'
p3217
S'2016/06/21 06:00'
p3218
sS'PHST'
p3219
(lp3220
S'2015 [ecollection]'
p3221
aS'2014/05/01 [received]'
p3222
aS'2015/10/02 [accepted]'
p3223
aS'2015/10/26 [epublish]'
p3224
asS'OID'
p3225
(lp3226
S'NLM: PMC4621059'
p3227
asS'MH'
p3228
(lp3229
S'Adult'
p3230
aS'Antitubercular Agents'
p3231
aS'Ethambutol/*pharmacokinetics/therapeutic use'
p3232
aS'Female'
p3233
aS'Humans'
p3234
aS'Isoniazid/*pharmacokinetics/therapeutic use'
p3235
aS'Male'
p3236
aS'Pyrazinamide/*pharmacokinetics/therapeutic use'
p3237
aS'Tanzania'
p3238
aS'Tuberculosis, Pulmonary/*blood/drug therapy/metabolism'
p3239
asS'EDAT'
p3240
S'2015/10/27 06:00'
p3241
sS'SO'
p3242
S'PLoS One. 2015 Oct 26;10(10):e0141002. doi: 10.1371/journal.pone.0141002. eCollection 2015.'
p3243
sS'SB'
p3244
S'IM'
p3245
sS'PMID'
p3246
S'26501782'
p3247
sS'PST'
p3248
S'epublish'
p3249
stRp3250
ag2
(g3
g4
(dp3251
S'LID'
p3252
S'10.1016/S1473-3099(15)00319-9 [doi] S1473-3099(15)00319-9 [pii]'
p3253
sS'STAT'
p3254
S'MEDLINE'
p3255
sS'DEP'
p3256
S'20151005'
p3257
sS'CI'
p3258
(lp3259
S'Copyright (c) 2016 Walker et al. Open Access article distributed under the terms'
p3260
aS'of CC BY. Published by Elsevier Ltd.. All rights reserved.'
p3261
asS'DA'
p3262
S'20160212'
p3263
sS'AID'
p3264
(lp3265
S'S1473-3099(15)00319-9 [pii]'
p3266
aS'10.1016/S1473-3099(15)00319-9 [doi]'
p3267
asS'CRDT'
p3268
(lp3269
S'2015/10/21 06:00'
p3270
asS'DP'
p3271
S'2016 Feb'
p3272
sS'GR'
p3273
(lp3274
S'100714/Wellcome Trust/United Kingdom'
p3275
asS'OWN'
p3276
S'NLM'
p3277
sS'PT'
p3278
(lp3279
S'Clinical Trial'
p3280
aS'Comparative Study'
p3281
aS'Journal Article'
p3282
aS'Randomized Controlled Trial'
p3283
aS"Research Support, Non-U.S. Gov't"
p3284
asS'LA'
p3285
(lp3286
S'eng'
p3287
asS'FAU'
p3288
(lp3289
S'Mulenga, Veronica'
p3290
aS'Musiime, Victor'
p3291
aS'Kekitiinwa, Adeodata'
p3292
aS'Cook, Adrian D'
p3293
aS'Abongomera, George'
p3294
aS'Kenny, Julia'
p3295
aS'Chabala, Chisala'
p3296
aS'Mirembe, Grace'
p3297
aS'Asiimwe, Alice'
p3298
aS'Owen-Powell, Ellen'
p3299
aS'Burger, David'
p3300
aS'McIlleron, Helen'
p3301
aS'Klein, Nigel'
p3302
aS'Chintu, Chifumbe'
p3303
aS'Thomason, Margaret J'
p3304
aS'Kityo, Cissy'
p3305
aS'Walker, A Sarah'
p3306
aS'Gibb, Diana M'
p3307
asS'JT'
p3308
S'The Lancet. Infectious diseases'
p3309
sS'LR'
p3310
S'20160713'
p3311
sS'PG'
p3312
S'169-79'
p3313
sS'TI'
p3314
S'Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.'
p3315
sS'RN'
p3316
(lp3317
S'0 (Anti-HIV Agents)'
p3318
aS'0 (Benzoxazines)'
p3319
aS'0 (Dideoxynucleosides)'
p3320
aS'0 (Tablets)'
p3321
aS'2T8Q726O95 (Lamivudine)'
p3322
aS'4B9XT59T7S (Zidovudine)'
p3323
aS'99DK7FVK1H (Nevirapine)'
p3324
aS'BO9LE4QFZF (Stavudine)'
p3325
aS'JE6H2O27P8 (efavirenz)'
p3326
aS'WR2TIP26VS (abacavir)'
p3327
asS'PL'
p3328
S'United States'
p3329
sS'TA'
p3330
S'Lancet Infect Dis'
p3331
sS'JID'
p3332
S'101130150'
p3333
sS'AB'
p3334
S'BACKGROUND: WHO 2013 guidelines recommend universal treatment for HIV-infected children younger than 5 years. No paediatric trials have compared nucleoside reverse-transcriptase inhibitors (NRTIs) in first-line antiretroviral therapy (ART) in Africa, where most HIV-infected children live. We aimed to compare stavudine, zidovudine, or abacavir as dual or triple fixed-dose-combination paediatric tablets with lamivudine and nevirapine or efavirenz. METHODS: In this open-label, parallel-group, randomised trial (CHAPAS-3), we enrolled children from one centre in Zambia and three in Uganda who were previously untreated (ART naive) or on stavudine for more than 2 years with viral load less than 50 copies per mL (ART experienced). Computer-generated randomisation tables were incorporated securely within the database. The primary endpoint was grade 2-4 clinical or grade 3/4 laboratory adverse events. Analysis was intention to treat. This trial is registered with the ISRCTN Registry number, 69078957. FINDINGS: Between Nov 8, 2010, and Dec 28, 2011, 480 children were randomised: 156 to stavudine, 159 to zidovudine, and 165 to abacavir. After two were excluded due to randomisation error, 156 children were analysed in the stavudine group, 158 in the zidovudine group, and 164 in the abacavir group, and followed for median 2.3 years (5% lost to follow-up). 365 (76%) were ART naive (median age 2.6 years vs 6.2 years in ART experienced). 917 grade 2-4 clinical or grade 3/4 laboratory adverse events (835 clinical [634 grade 2]; 40 laboratory) occurred in 104 (67%) children on stavudine, 103 (65%) on zidovudine, and 105 (64%), on abacavir (p=0.63; zidovudine vs stavudine: hazard ratio [HR] 0.99 [95% CI 0.75-1.29]; abacavir vs stavudine: HR 0.88 [0.67-1.15]). At 48 weeks, 98 (85%), 81 (80%) and 95 (81%) ART-naive children in the stavudine, zidovudine, and abacavir groups, respectively, had viral load less than 400 copies per mL (p=0.58); most ART-experienced children maintained suppression (p=1.00). INTERPRETATION: All NRTIs had low toxicity and good clinical, immunological, and virological responses. Clinical and subclinical lipodystrophy was not noted in those younger than 5 years and anaemia was no more frequent with zidovudine than with the other drugs. Absence of hypersensitivity reactions, superior resistance profile and once-daily dosing favours abacavir for African children, supporting WHO 2013 guidelines. FUNDING: European Developing Countries Clinical Trials Partnership.'
p3335
sS'AD'
p3336
S'Department of Paediatrics, University Teaching Hospital, Lusaka, Zambia. Joint Clinical Research Centre, Kampala, Uganda. Baylor-Uganda, Mulago, Uganda. Medical Research Council Clinical Trials Unit at University College London, London, UK. Joint Clinical Research Centre, Gulu, Uganda. Institute of Child Health, University College London, London, UK. Department of Paediatrics, University Teaching Hospital, Lusaka, Zambia. Joint Clinical Research Centre, Kampala, Uganda. Baylor-Uganda, Mulago, Uganda. Medical Research Council Clinical Trials Unit at University College London, London, UK. Department of Pharmacy, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. Institute of Child Health, University College London, London, UK. Department of Paediatrics, University Teaching Hospital, Lusaka, Zambia. Medical Research Council Clinical Trials Unit at University College London, London, UK. Joint Clinical Research Centre, Kampala, Uganda. Medical Research Council Clinical Trials Unit at University College London, London, UK. Electronic address: rmjlasw@ucl.ac.uk. Medical Research Council Clinical Trials Unit at University College London, London, UK. Electronic address: diana.gibb@ucl.ac.uk.'
p3337
sS'CN'
p3338
(lp3339
S'CHAPAS-3 trial team'
p3340
asS'IP'
p3341
S'2'
sS'IS'
p3342
S'1474-4457 (Electronic) 1473-3099 (Linking)'
p3343
sS'PMC'
p3344
S'PMC4726762'
p3345
sS'DCOM'
p3346
S'20160706'
p3347
sS'CIN'
p3348
(lp3349
S'Lancet Infect Dis. 2016 Feb;16(2):133-4. PMID: 26481927'
p3350
asS'AU'
p3351
(lp3352
S'Mulenga V'
p3353
aS'Musiime V'
p3354
aS'Kekitiinwa A'
p3355
aS'Cook AD'
p3356
aS'Abongomera G'
p3357
aS'Kenny J'
p3358
aS'Chabala C'
p3359
aS'Mirembe G'
p3360
aS'Asiimwe A'
p3361
aS'Owen-Powell E'
p3362
aS'Burger D'
p3363
aS'McIlleron H'
p3364
aS'Klein N'
p3365
aS'Chintu C'
p3366
aS'Thomason MJ'
p3367
aS'Kityo C'
p3368
aS'Walker AS'
p3369
aS'Gibb DM'
p3370
asS'VI'
p3371
S'16'
p3372
sS'MHDA'
p3373
S'2016/07/07 06:00'
p3374
sS'PHST'
p3375
(lp3376
S'2015/07/28 [received]'
p3377
aS'2015/09/01 [revised]'
p3378
aS'2015/09/03 [accepted]'
p3379
aS'2015/10/05 [aheadofprint]'
p3380
asS'OID'
p3381
(lp3382
S'NLM: PMC4726762'
p3383
asS'MH'
p3384
(lp3385
S'Anti-HIV Agents/*administration & dosage'
p3386
aS'Antiretroviral Therapy, Highly Active'
p3387
aS'Benzoxazines/administration & dosage'
p3388
aS'Child'
p3389
aS'Child, Preschool'
p3390
aS'Dideoxynucleosides/administration & dosage'
p3391
aS'Drug Therapy, Combination'
p3392
aS'Female'
p3393
aS'HIV Infections/*drug therapy'
p3394
aS'Humans'
p3395
aS'Infant'
p3396
aS'Lamivudine/administration & dosage'
p3397
aS'Male'
p3398
aS'Nevirapine/administration & dosage'
p3399
aS'Stavudine/administration & dosage'
p3400
aS'Tablets/*administration & dosage'
p3401
aS'Uganda'
p3402
aS'Zambia'
p3403
aS'Zidovudine/administration & dosage'
p3404
asS'EDAT'
p3405
S'2015/10/21 06:00'
p3406
sS'SO'
p3407
S'Lancet Infect Dis. 2016 Feb;16(2):169-79. doi: 10.1016/S1473-3099(15)00319-9. Epub 2015 Oct 5.'
p3408
sS'SB'
p3409
S'IM'
p3410
sS'PMID'
p3411
S'26481928'
p3412
sS'PST'
p3413
S'ppublish'
p3414
stRp3415
ag2
(g3
g4
(dp3416
S'LID'
p3417
S'10.5588/ijtld.15.0015 [doi]'
p3418
sS'STAT'
p3419
S'MEDLINE'
p3420
sS'AB'
p3421
S'BACKGROUND: The World Health Organization recommends tuberculin skin tests (TSTs) where feasible to identify individuals most likely to benefit from isoniazid preventive therapy (IPT). The requirement for TST reading after 48-72 h by a trained nurse is a barrier to implementation and increases loss to follow-up. METHODS: Patients with human immunodeficiency virus (HIV) infection were recruited from a primary care clinic in South Africa and trained by a lay counsellor to interpret their own TST. The TST was placed by a nurse, and the patient was asked to return 2 days later with their self-reading result, followed by blinded reading by a trained nurse (reference). RESULTS: Of 227 patients, 210 returned for TST reading; 78% interpreted their test correctly: those interpreting it as negative were more likely to be correct (negative predictive value 93%) than those interpreting it as positive (positive predictive value 42%); 10/36 (28%) positive TST results were read as negative by the patient. CONCLUSIONS: Patients with HIV in low-resource settings can be trained to interpret their own TST. Those interpreting it as positive should return to the clinic within 48-72 h for confirmatory reading and IPT initiation; those with a negative interpretation can return at their next scheduled visit and initiate IPT at that time if appropriate.'
p3422
sS'JID'
p3423
S'9706389'
p3424
sS'AD'
p3425
S'Medecins Sans Frontieres, Khayelitsha, South Africa. City of Cape Town Health Department, Khayelitsha, South Africa. Medecins Sans Frontieres, Khayelitsha, South Africa; Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa. Medecins Sans Frontieres, Khayelitsha, South Africa. Centre for Infectious Disease Epidemiology, Department of Infection and Population Health, University College London, London, UK. Division of Infectious Diseases and HIV Medicine, Department of Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.'
p3426
sS'JT'
p3427
S'The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease'
p3428
sS'IP'
p3429
S'11'
p3430
sS'IS'
p3431
S'1815-7920 (Electronic) 1027-3719 (Linking)'
p3432
sS'DCOM'
p3433
S'20160801'
p3434
sS'DA'
p3435
S'20151015'
p3436
sS'AU'
p3437
(lp3438
S'Cox V'
p3439
aS'de Azevedo V'
p3440
aS'Stinson K'
p3441
aS'Wilkinson L'
p3442
aS'Rangaka M'
p3443
aS'Boyles TH'
p3444
asS'AID'
p3445
(lp3446
S'10.5588/ijtld.15.0015 [doi]'
p3447
asS'CRDT'
p3448
(lp3449
S'2015/10/16 06:00'
p3450
asS'VI'
p3451
S'19'
p3452
sS'DP'
p3453
S'2015 Nov'
p3454
sS'MHDA'
p3455
S'2016/08/02 06:00'
p3456
sS'OWN'
p3457
S'NLM'
p3458
sS'PT'
p3459
(lp3460
S'Comparative Study'
p3461
aS'Journal Article'
p3462
aS"Research Support, Non-U.S. Gov't"
p3463
asS'LA'
p3464
(lp3465
S'eng'
p3466
asS'MH'
p3467
(lp3468
S'Adult'
p3469
aS'*Diagnostic Self Evaluation'
p3470
aS'Female'
p3471
aS'HIV Infections/*complications'
p3472
aS'Humans'
p3473
aS'Male'
p3474
aS'Predictive Value of Tests'
p3475
aS'South Africa'
p3476
aS'*Tuberculin Test'
p3477
aS'Tuberculosis/*diagnosis'
p3478
aS'World Health Organization'
p3479
asS'FAU'
p3480
(lp3481
S'Cox, V'
p3482
aS'de Azevedo, V'
p3483
aS'Stinson, K'
p3484
aS'Wilkinson, L'
p3485
aS'Rangaka, M'
p3486
aS'Boyles, T H'
p3487
asS'EDAT'
p3488
S'2015/10/16 06:00'
p3489
sS'PST'
p3490
S'ppublish'
p3491
sS'SO'
p3492
S'Int J Tuberc Lung Dis. 2015 Nov;19(11):1300-4. doi: 10.5588/ijtld.15.0015.'
p3493
sS'PG'
p3494
S'1300-4'
p3495
sS'TI'
p3496
S'Diagnostic accuracy of tuberculin skin test self-reading by HIV patients in a low-resource setting.'
p3497
sS'SB'
p3498
S'IM'
p3499
sS'PMID'
p3500
S'26467581'
p3501
sS'PL'
p3502
S'France'
p3503
sS'TA'
p3504
S'Int J Tuberc Lung Dis'
p3505
stRp3506
ag2
(g3
g4
(dp3507
S'LID'
p3508
S'10.1186/s12884-015-0697-7 [doi]'
p3509
sS'STAT'
p3510
S'MEDLINE'
p3511
sS'DEP'
p3512
S'20151012'
p3513
sS'DA'
p3514
S'20151013'
p3515
sS'AID'
p3516
(lp3517
S'10.1186/s12884-015-0697-7 [doi]'
p3518
aS'10.1186/s12884-015-0697-7 [pii]'
p3519
asS'CRDT'
p3520
(lp3521
S'2015/10/14 06:00'
p3522
asS'DP'
p3523
S'2015'
p3524
sS'OWN'
p3525
S'NLM'
p3526
sS'PT'
p3527
(lp3528
S'Journal Article'
p3529
aS"Research Support, Non-U.S. Gov't"
p3530
asS'LA'
p3531
(lp3532
S'eng'
p3533
asS'DCOM'
p3534
S'20160623'
p3535
sS'JT'
p3536
S'BMC pregnancy and childbirth'
p3537
sS'LR'
p3538
S'20151017'
p3539
sS'FAU'
p3540
(lp3541
S'Okawa, Sumiyo'
p3542
aS'Chirwa, Mable'
p3543
aS'Ishikawa, Naoko'
p3544
aS'Kapyata, Henry'
p3545
aS'Msiska, Charles Yekha'
p3546
aS'Syakantu, Gardner'
p3547
aS'Miyano, Shinsuke'
p3548
aS'Komada, Kenichi'
p3549
aS'Jimba, Masamine'
p3550
aS'Yasuoka, Junko'
p3551
asS'TI'
p3552
S'Longitudinal adherence to antiretroviral drugs for preventing mother-to-child transmission of HIV in Zambia.'
p3553
sS'RN'
p3554
(lp3555
S'0 (Anti-HIV Agents)'
p3556
aS'4B9XT59T7S (Zidovudine)'
p3557
aS'99DK7FVK1H (Nevirapine)'
p3558
asS'PL'
p3559
S'England'
p3560
sS'PG'
p3561
S'258'
p3562
sS'JID'
p3563
S'100967799'
p3564
sS'AB'
p3565
S"BACKGROUND: Adherence to antiretroviral (ARV) drugs is essential for eliminating new pediatric infections of human immunodeficiency virus (HIV). Since the Zambian government revised the national guidelines based on option A (i.e., maternal zidovudine and infant ARV prophylaxis) of the World Health Organization's 2010 guidelines, no studies have assessed adherence to ARVs during pregnancy up to the postpartum period. This study aimed to examine adherence to ARVs and identify the associated risk factors. METHODS: A prospective cohort study was conducted in the Chongwe district from June 2011 to January 2014. Self-reported adherence to ARVs was examined during pregnancy and at one week, six weeks, and 24 weeks postpartum among 321 HIV-positive women. The probability of remaining adherent to ARVs was estimated using the Kaplan-Meier method, and the risk factors for non-adherence were identified using the Cox proportional hazard regressions--treating loss to follow-up as non-adherence. The statuses of HIV in HIV-exposed infants were assessed in January 2014. RESULTS: During the study period, 326 infants were born to HIV-positive women, 262 (80.4%) underwent HIV testing, and 11 (3.4%) had their HIV infection detected at the time that they had the latest HIV testing as of January 2014. The ARV adherence rate was 82.5% during pregnancy, 84.2% at one week postpartum, 81.5% at six weeks postpartum, and 70.5% at 24 weeks postpartum. The probability of remaining adherent to ARVs was 0.61 at day 50, 0.35 at day 100, 0.18 at day 200, and 0.06 at day 300. Attending a referral health center (HC) was a risk factor for non-adherence compared with attending rural HCs that provided HIV care/treatment (adjusted hazard ratio [aHR] 0.71, 95% confidence interval [CI] 0.57-0.88) and those that did not provide HIV care/treatment (aHR 0.58, 95% CI 0.46-0.74). A new diagnosis of HIV infection compared to a known HIV-positive status before pregnancy was another risk factor for non-adherence (aHR 1.24, 95% CI 1.03-1.50). CONCLUSIONS: Maintaining adherence to ARVs through pregnancy to the postpartum period remains a crucial challenge in Zambia. To maximize the treatment benefits, adherence to ARVs and retention in care should be improved at all health facilities."
p3566
sS'AD'
p3567
S'Department of Community and Global Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. sumiyo@m.u-tokyo.ac.jp. Chongwe District Community Health Office, Chongwe, Zambia. chirwamable@yahoo.com. Ministry of Health Zambia-Japan International Cooperation Agency SHIMA project, Lusaka, Zambia. chirwamable@yahoo.com. National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan. n-ishikawa@it.ncgm.go.jp. Chongwe District Community Health Office, Chongwe, Zambia. kapyata2012@gmail.com. Ministry of Health Zambia-Japan International Cooperation Agency SHIMA project, Lusaka, Zambia. kapyata2012@gmail.com. Chongwe District Community Health Office, Chongwe, Zambia. myekha@yahoo.com. Ministry of Health Zambia-Japan International Cooperation Agency SHIMA project, Lusaka, Zambia. myekha@yahoo.com. Ministry of Health, Lusaka, Zambia. gsyakantu@yahoo.com. National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan. s-miyano@it.ncgm.go.jp. Ministry of Health Zambia-Japan International Cooperation Agency SHIMA project, Lusaka, Zambia. k-komada@it.ncgm.go.jp. National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan. k-komada@it.ncgm.go.jp. Department of Community and Global Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. mjimba@m.u-tokyo.ac.jp. Department of Community and Global Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. jyasuoka@m.u-tokyo.ac.jp.'
p3568
sS'VI'
p3569
S'15'
p3570
sS'IS'
p3571
S'1471-2393 (Electronic) 1471-2393 (Linking)'
p3572
sS'PMC'
p3573
S'PMC4603915'
p3574
sS'AU'
p3575
(lp3576
S'Okawa S'
p3577
aS'Chirwa M'
p3578
aS'Ishikawa N'
p3579
aS'Kapyata H'
p3580
aS'Msiska CY'
p3581
aS'Syakantu G'
p3582
aS'Miyano S'
p3583
aS'Komada K'
p3584
aS'Jimba M'
p3585
aS'Yasuoka J'
p3586
asS'MHDA'
p3587
S'2016/06/24 06:00'
p3588
sS'PHST'
p3589
(lp3590
S'2015/01/29 [received]'
p3591
aS'2015/10/06 [accepted]'
p3592
aS'2015/10/12 [aheadofprint]'
p3593
asS'OID'
p3594
(lp3595
S'NLM: PMC4603915'
p3596
asS'MH'
p3597
(lp3598
S'Adult'
p3599
aS'Anti-HIV Agents/*therapeutic use'
p3600
aS'Female'
p3601
aS'HIV Infections/*drug therapy/prevention & control/*transmission'
p3602
aS'Humans'
p3603
aS'Infant, Newborn'
p3604
aS'Infectious Disease Transmission, Vertical/*prevention & control'
p3605
aS'Medication Adherence/*statistics & numerical data'
p3606
aS'Nevirapine/therapeutic use'
p3607
aS'Postpartum Period'
p3608
aS'Pregnancy'
p3609
aS'Pregnancy Complications, Infectious/*drug therapy'
p3610
aS'Probability'
p3611
aS'Prospective Studies'
p3612
aS'Referral and Consultation'
p3613
aS'Risk Factors'
p3614
aS'Rural Health Services/utilization'
p3615
aS'Self Report'
p3616
aS'Time Factors'
p3617
aS'Young Adult'
p3618
aS'Zambia'
p3619
aS'Zidovudine/therapeutic use'
p3620
asS'EDAT'
p3621
S'2015/10/16 06:00'
p3622
sS'SO'
p3623
S'BMC Pregnancy Childbirth. 2015 Oct 12;15:258. doi: 10.1186/s12884-015-0697-7.'
p3624
sS'SB'
p3625
S'IM'
p3626
sS'PMID'
p3627
S'26459335'
p3628
sS'TA'
p3629
S'BMC Pregnancy Childbirth'
p3630
sS'PST'
p3631
S'epublish'
p3632
stRp3633
ag2
(g3
g4
(dp3634
S'LID'
p3635
S'10.1186/s12889-015-2355-4 [doi]'
p3636
sS'STAT'
p3637
S'MEDLINE'
p3638
sS'DEP'
p3639
S'20151003'
p3640
sS'DA'
p3641
S'20151005'
p3642
sS'AID'
p3643
(lp3644
S'10.1186/s12889-015-2355-4 [doi]'
p3645
aS'10.1186/s12889-015-2355-4 [pii]'
p3646
asS'CRDT'
p3647
(lp3648
S'2015/10/05 06:00'
p3649
asS'DP'
p3650
S'2015'
p3651
sS'AD'
p3652
S'Kenya Medical Research Institute/Wellcome Trust Research Programme, Centre for Geographic Medicine Research Coast, Kilifi, Kenya. ENduati@kemri-wellcome.org. Kenya Medical Research Institute/Wellcome Trust Research Programme, Centre for Geographic Medicine Research Coast, Kilifi, Kenya. AHassan@kemri-wellcome.org. Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK. Miguel.garciaknight@ndm.ox.ac.uk. Kenya Medical Research Institute/Wellcome Trust Research Programme, Centre for Geographic Medicine Research Coast, Kilifi, Kenya. DMuema@kemri-wellcome.org. Kilifi County Hospital, Kilifi, Kenya. knasim06@yahoo.com. Kenya Medical Research Institute/Wellcome Trust Research Programme, Centre for Geographic Medicine Research Coast, Kilifi, Kenya. SMwaringa@kemri-wellcome.org. Kenya Medical Research Institute/Wellcome Trust Research Programme, Centre for Geographic Medicine Research Coast, Kilifi, Kenya. TEtyang@kemri-wellcome.org. Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK. sarah.rowland-jones@ndm.ox.ac.uk. Kenya Medical Research Institute/Wellcome Trust Research Programme, Centre for Geographic Medicine Research Coast, Kilifi, Kenya. Britta.Urban@lstmed.ac.uk. Liverpool School of Tropical Medicine, Liverpool, UK. Britta.Urban@lstmed.ac.uk. Kenya Medical Research Institute/Wellcome Trust Research Programme, Centre for Geographic Medicine Research Coast, Kilifi, Kenya. JBerkley@kemri-wellcome.org. Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK. JBerkley@kemri-wellcome.org.'
p3653
sS'OWN'
p3654
S'NLM'
p3655
sS'PT'
p3656
(lp3657
S'Evaluation Studies'
p3658
aS'Journal Article'
p3659
aS"Research Support, Non-U.S. Gov't"
p3660
asS'LA'
p3661
(lp3662
S'eng'
p3663
asS'DCOM'
p3664
S'20160512'
p3665
sS'JT'
p3666
S'BMC public health'
p3667
sS'LR'
p3668
S'20160112'
p3669
sS'FAU'
p3670
(lp3671
S'Nduati, Eunice Wambui'
p3672
aS'Hassan, Amin Shaban'
p3673
aS'Knight, Miguel Garcia'
p3674
aS'Muema, Daniel Muli'
p3675
aS'Jahangir, Margaret Nassim'
p3676
aS'Mwaringa, Shalton Lwambi'
p3677
aS'Etyang, Timothy Juma'
p3678
aS'Rowland-Jones, Sarah'
p3679
aS'Urban, Britta Christina'
p3680
aS'Berkley, James Alexander'
p3681
asS'TI'
p3682
S'Outcomes of prevention of mother to child transmission of the human immunodeficiency virus-1 in rural Kenya--a cohort study.'
p3683
sS'PL'
p3684
S'England'
p3685
sS'PG'
p3686
S'1008'
p3687
sS'JID'
p3688
S'100968562'
p3689
sS'AB'
p3690
S"BACKGROUND: Success in prevention of mother-to-child transmission (PMTCT) raises the prospect of eliminating pediatric HIV infection. To achieve global elimination, however, strategies are needed to strengthen PMTCT interventions. This study aimed to determine PMTCT outcomes and identify challenges facing its successful implementation in a rural setting in Kenya. METHODS: A retrospective cohort design was used. Routine demographic and clinical data for infants and mothers enrolling for PMTCT care at a rural hospital in Kenya were analysed. Cox and logistic regression were used to determine factors associated with retention and vertical transmission respectively. RESULTS: Between 2006 and 2012, 1338 infants were enrolled and followed up for PMTCT care with earlier age of enrollment and improved retention observed over time. Mother to child transmission of HIV declined from 19.4 % in 2006 to 8.9 % in 2012 (non-parametric test for trend p = 0.024). From 2009 to 2012, enrolling for care after 6 months of age, adjusted Odds Ratio [aOR]: 23.3 [95 % confidence interval (CI): 8.3-65.4], presence of malnutrition ([aOR]: 2.3 [95 % CI: 1.1-5.2]) and lack of maternal use of highly active antiretroviral therapy (HAART) (aOR: 6.5 [95 % CI: 1.4-29.4]) was associated with increased risk of HIV infection. Infant's older age at enrollment, malnutrition and maternal HAART status, were also associated with drop out from care. Infants who were not actively followed up were more likely to drop out from care (adjusted Hazard Ratio: 6.6 [95 % CI: 2.9-14.6]). DISCUSSION: We report a temporal increase in the proportion of infants enrolling for PMTCT care before 3 months of age, improved retention in PMTCT and a significant reduction in the proportion of infants enrolled who became HIV-infected, emphasizing the benefits of PMTCT. CONCLUSION: A simple set of risk factors at enrollment can identify mother-infant pairs most at risk of infection or drop out for targeted intervention."
p3691
sS'GR'
p3692
(lp3693
S'092654/Wellcome Trust/United Kingdom'
p3694
aS'WT079082/Wellcome Trust/United Kingdom'
p3695
aS'WT083579MA/Wellcome Trust/United Kingdom'
p3696
aS'WT089351MA/Wellcome Trust/United Kingdom'
p3697
aS'WT095068/Wellcome Trust/United Kingdom'
p3698
asS'VI'
p3699
S'15'
p3700
sS'IS'
p3701
S'1471-2458 (Electronic) 1471-2458 (Linking)'
p3702
sS'PMC'
p3703
S'PMC4592570'
p3704
sS'AU'
p3705
(lp3706
S'Nduati EW'
p3707
aS'Hassan AS'
p3708
aS'Knight MG'
p3709
aS'Muema DM'
p3710
aS'Jahangir MN'
p3711
aS'Mwaringa SL'
p3712
aS'Etyang TJ'
p3713
aS'Rowland-Jones S'
p3714
aS'Urban BC'
p3715
aS'Berkley JA'
p3716
asS'MHDA'
p3717
S'2016/05/14 06:00'
p3718
sS'PHST'
p3719
(lp3720
S'2015/04/13 [received]'
p3721
aS'2015/09/25 [accepted]'
p3722
aS'2015/10/03 [aheadofprint]'
p3723
asS'OID'
p3724
(lp3725
S'NLM: PMC4592570'
p3726
asS'MH'
p3727
(lp3728
S'Adult'
p3729
aS'*Antiretroviral Therapy, Highly Active'
p3730
aS'Female'
p3731
aS'HIV Infections/drug therapy/*prevention & control/transmission/virology'
p3732
aS'*HIV-1'
p3733
aS'Humans'
p3734
aS'Infant'
p3735
aS'Infant, Newborn'
p3736
aS'Infectious Disease Transmission, Vertical/*prevention & control'
p3737
aS'Kenya'
p3738
aS'Male'
p3739
aS'Malnutrition/complications'
p3740
aS'*Maternal-Child Health Services/utilization'
p3741
aS'Mothers'
p3742
aS'Odds Ratio'
p3743
aS'Pregnancy'
p3744
aS'*Pregnancy Complications, Infectious/drug therapy/virology'
p3745
aS'Retrospective Studies'
p3746
aS'Risk Factors'
p3747
aS'*Rural Population'
p3748
aS'Young Adult'
p3749
asS'EDAT'
p3750
S'2015/10/05 06:00'
p3751
sS'SO'
p3752
S'BMC Public Health. 2015 Oct 3;15:1008. doi: 10.1186/s12889-015-2355-4.'
p3753
sS'SB'
p3754
S'IM'
p3755
sS'PMID'
p3756
S'26433396'
p3757
sS'TA'
p3758
S'BMC Public Health'
p3759
sS'PST'
p3760
S'epublish'
p3761
stRp3762
ag2
(g3
g4
(dp3763
S'LID'
p3764
S'10.1016/S2352-3018(15)00002-8 [doi] S2352-3018(15)00002-8 [pii]'
p3765
sS'STAT'
p3766
S'MEDLINE'
p3767
sS'DEP'
p3768
S'20150128'
p3769
sS'CI'
p3770
(lp3771
S'Copyright (c) 2015 Elsevier Ltd. All rights reserved.'
p3772
asS'DA'
p3773
S'20151001'
p3774
sS'AID'
p3775
(lp3776
S'S2352-3018(15)00002-8 [pii]'
p3777
aS'10.1016/S2352-3018(15)00002-8 [doi]'
p3778
asS'CRDT'
p3779
(lp3780
S'2015/10/02 06:00'
p3781
asS'DP'
p3782
S'2015 Mar'
p3783
sS'AD'
p3784
S'Division of HIV/AIDS at San Francisco General Hospital in the Department of Medicine, University of California, San Francisco, CA, USA; East Africa International Epidemiologic Databases to Evaluate AIDS (EA-IeDEA) Consortium. Electronic address: genge@php.ucsf.edu. Kenya Medical Research Institute and the Family AIDS Care and Education Services Program, Kisumu, Kenya; East Africa International Epidemiologic Databases to Evaluate AIDS (EA-IeDEA) Consortium. National AIDS Control Program, Dar Es Salaam, Tanzania; East Africa International Epidemiologic Databases to Evaluate AIDS (EA-IeDEA) Consortium. Infectious Diseases Institute, Kampala, Uganda; East Africa International Epidemiologic Databases to Evaluate AIDS (EA-IeDEA) Consortium. College of Health Sciences, School of Medicine, Department of Medicine, Moi University, Eldoret, Kenya; East Africa International Epidemiologic Databases to Evaluate AIDS (EA-IeDEA) Consortium. Mbarara University of Science and Technology, Mbarara, Uganda; East Africa International Epidemiologic Databases to Evaluate AIDS (EA-IeDEA) Consortium. Mbarara University of Science and Technology, Mbarara, Uganda; East Africa International Epidemiologic Databases to Evaluate AIDS (EA-IeDEA) Consortium. College of Health Sciences, School of Medicine, Department of Medicine, Moi University, Eldoret, Kenya; Department of Medicine, School of Medicine, Indiana University School of Public Health, Indiana University, Indianapolis, IN, USA; East Africa International Epidemiologic Databases to Evaluate AIDS (EA-IeDEA) Consortium. National AIDS Control Program, Dar Es Salaam, Tanzania; East Africa International Epidemiologic Databases to Evaluate AIDS (EA-IeDEA) Consortium. Infectious Diseases Institute, Kampala, Uganda; East Africa International Epidemiologic Databases to Evaluate AIDS (EA-IeDEA) Consortium. Kenya Medical Research Institute and the Family AIDS Care and Education Services Program, Kisumu, Kenya; East Africa International Epidemiologic Databases to Evaluate AIDS (EA-IeDEA) Consortium. Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA; East Africa International Epidemiologic Databases to Evaluate AIDS (EA-IeDEA) Consortium. Department of Medicine, School of Medicine, Indiana University School of Public Health, Indiana University, Indianapolis, IN, USA; East Africa International Epidemiologic Databases to Evaluate AIDS (EA-IeDEA) Consortium. Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA; East Africa International Epidemiologic Databases to Evaluate AIDS (EA-IeDEA) Consortium. Department of Biostatistics, Indiana University School of Public Health, Indiana University, Indianapolis, IN, USA; East Africa International Epidemiologic Databases to Evaluate AIDS (EA-IeDEA) Consortium. Division of HIV/AIDS at San Francisco General Hospital in the Department of Medicine, University of California, San Francisco, CA, USA; Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA; East Africa International Epidemiologic Databases to Evaluate AIDS (EA-IeDEA) Consortium.'
p3785
sS'OWN'
p3786
S'NLM'
p3787
sS'PT'
p3788
(lp3789
S'Journal Article'
p3790
aS'Multicenter Study'
p3791
aS'Observational Study'
p3792
aS'Research Support, N.I.H., Extramural'
p3793
asS'LA'
p3794
(lp3795
S'eng'
p3796
asS'FAU'
p3797
(lp3798
S'Geng, Elvin H'
p3799
aS'Odeny, Thomas A'
p3800
aS'Lyamuya, Rita E'
p3801
aS'Nakiwogga-Muwanga, Alice'
p3802
aS'Diero, Lameck'
p3803
aS'Bwana, Mwebesa'
p3804
aS'Muyindike, Winnie'
p3805
aS'Braitstein, Paula'
p3806
aS'Somi, Geoffrey R'
p3807
aS'Kambugu, Andrew'
p3808
aS'Bukusi, Elizabeth A'
p3809
aS'Wenger, Megan'
p3810
aS'Wools-Kaloustian, Kara K'
p3811
aS'Glidden, David V'
p3812
aS'Yiannoutsos, Constantin T'
p3813
aS'Martin, Jeffrey N'
p3814
asS'JT'
p3815
S'The lancet. HIV'
p3816
sS'LR'
p3817
S'20160701'
p3818
sS'PG'
p3819
S'e107-16'
p3820
sS'TI'
p3821
S'Estimation of mortality among HIV-infected people on antiretroviral treatment in East Africa: a sampling based approach in an observational, multisite, cohort study.'
p3822
sS'RN'
p3823
(lp3824
S'0 (Anti-HIV Agents)'
p3825
asS'PL'
p3826
S'Netherlands'
p3827
sS'TA'
p3828
S'Lancet HIV'
p3829
sS'JID'
p3830
S'101645355'
p3831
sS'AB'
p3832
S"BACKGROUND: Mortality in HIV-infected people after initiation of antiretroviral treatment (ART) in resource-limited settings is an important measure of the effectiveness and comparative effectiveness of the global public health response. Substantial loss to follow-up precludes accurate accounting of deaths and limits our understanding of effectiveness. We aimed to provide a better understanding of mortality at scale and, by extension, the effectiveness and comparative effectiveness of public health ART treatment in east Africa. METHODS: In 14 clinics in five settings in Kenya, Uganda, and Tanzania, we intensively traced a sample of patients randomly selected using a random number generator, who were infected with HIV and on ART and who were lost to follow-up (>90 days late for last scheduled visit). We incorporated the vital status outcomes for these patients into analyses of the entire clinic population through probability-weighted survival analyses. FINDINGS: We followed 34 277 adults on ART from Mbarara and Kampala in Uganda, Eldoret, and Kisumu in Kenya, and Morogoro in Tanzania. The median age was 35 years (IQR 30-42), 11 628 (34%) were men, and median CD4 count count before therapy was 154 cells per muL (IQR 70-234). 5780 patients (17%) were lost to follow-up, 991 (17%) were selected for tracing between June 10, 2011, and Aug 27, 2012, and vital status was ascertained for 860 (87%). With incorporation of outcomes from the patients lost to follow-up, estimated 3 year mortality increased from 3.9% (95% CI 3.6-4.2) to 12.5% (11.8-13.3). The sample-corrected, unadjusted 3 year mortality across settings was lowest in Mbarara (7.2%) and highest in Morogoro (23.6%). After adjustment for age, sex, CD4 count before therapy, and WHO stage, the sample-corrected hazard ratio comparing the settings with highest and lowest mortalities was 2.2 (95% CI 1.5-3.4) and the risk difference for death at 3 years was 11% (95% CI 5.0-17.7). INTERPRETATION: A sampling-based approach is widely feasible and important to an understanding of mortality after initiation of ART. After adjustment for measured biological drivers, mortality differs substantially across settings despite delivery of a similar clinical package of treatment. Implementation research to understand the systems, community, and patients' behaviours driving these differences is urgently needed. FUNDING: The US National Institutes of Health and President's Emergency Fund for AIDS Relief."
p3833
sS'GR'
p3834
(lp3835
S'K23AI084544/AI/NIAID NIH HHS/United States'
p3836
aS'P30 AI027763/AI/NIAID NIH HHS/United States'
p3837
aS'P30AI027763/AI/NIAID NIH HHS/United States'
p3838
aS'R01 AI102710/AI/NIAID NIH HHS/United States'
p3839
aS'U01AI069918/AI/NIAID NIH HHS/United States'
p3840
aS'PEPFAR/United States'
p3841
asS'IP'
p3842
S'3'
sS'IS'
p3843
S'2352-3018 (Electronic) 2352-3018 (Linking)'
p3844
sS'DCOM'
p3845
S'20160406'
p3846
sS'CIN'
p3847
(lp3848
S'Lancet HIV. 2015 Mar;2(3):e78-9. PMID: 26424547'
p3849
asS'AU'
p3850
(lp3851
S'Geng EH'
p3852
aS'Odeny TA'
p3853
aS'Lyamuya RE'
p3854
aS'Nakiwogga-Muwanga A'
p3855
aS'Diero L'
p3856
aS'Bwana M'
p3857
aS'Muyindike W'
p3858
aS'Braitstein P'
p3859
aS'Somi GR'
p3860
aS'Kambugu A'
p3861
aS'Bukusi EA'
p3862
aS'Wenger M'
p3863
aS'Wools-Kaloustian KK'
p3864
aS'Glidden DV'
p3865
aS'Yiannoutsos CT'
p3866
aS'Martin JN'
p3867
asS'VI'
p3868
S'2'
sS'MHDA'
p3869
S'2016/04/07 06:00'
p3870
sS'PHST'
p3871
(lp3872
S'2014/10/08 [received]'
p3873
aS'2014/12/29 [accepted]'
p3874
aS'2015/01/28 [aheadofprint]'
p3875
asS'MH'
p3876
(lp3877
S'Adult'
p3878
aS'Anti-HIV Agents/*administration & dosage'
p3879
aS'Antiretroviral Therapy, Highly Active'
p3880
aS'CD4 Lymphocyte Count'
p3881
aS'Cohort Studies'
p3882
aS'Data Collection/*methods'
p3883
aS'Female'
p3884
aS'HIV Infections/*drug therapy/epidemiology/immunology/*mortality'
p3885
aS'Humans'
p3886
aS'Kenya/epidemiology'
p3887
aS'Male'
p3888
aS'Sampling Studies'
p3889
aS'Tanzania/epidemiology'
p3890
aS'Uganda/epidemiology'
p3891
aS'United States'
p3892
aS'Young Adult'
p3893
asS'EDAT'
p3894
S'2015/10/02 06:00'
p3895
sS'SO'
p3896
S'Lancet HIV. 2015 Mar;2(3):e107-16. doi: 10.1016/S2352-3018(15)00002-8. Epub 2015 Jan 28.'
p3897
sS'SB'
p3898
S'IM X'
p3899
sS'PMID'
p3900
S'26424542'
p3901
sS'PST'
p3902
S'ppublish'
p3903
stRp3904
ag2
(g3
g4
(dp3905
S'LID'
p3906
S'10.1016/S2352-3018(14)00007-1 [doi] S2352-3018(14)00007-1 [pii]'
p3907
sS'STAT'
p3908
S'MEDLINE'
p3909
sS'DEP'
p3910
S'20141211'
p3911
sS'CI'
p3912
(lp3913
S'Copyright (c) 2015 Elsevier Ltd. All rights reserved.'
p3914
asS'DA'
p3915
S'20151001'
p3916
sS'AID'
p3917
(lp3918
S'S2352-3018(14)00007-1 [pii]'
p3919
aS'10.1016/S2352-3018(14)00007-1 [doi]'
p3920
asS'CRDT'
p3921
(lp3922
S'2015/10/02 06:00'
p3923
asS'DP'
p3924
S'2015 Jan'
p3925
sS'GR'
p3926
(lp3927
S'2UM1AI069438-08/AI/NIAID NIH HHS/United States'
p3928
aS'2UMIAI069456-08/PHS HHS/United States'
p3929
aS'7UM1AI069455/AI/NIAID NIH HHS/United States'
p3930
aS'AI 069421/AI/NIAID NIH HHS/United States'
p3931
aS'AI069438/AI/NIAID NIH HHS/United States'
p3932
aS'AI069463/AI/NIAID NIH HHS/United States'
p3933
aS'AI069476/AI/NIAID NIH HHS/United States'
p3934
aS'U01-A1069501/PHS HHS/United States'
p3935
aS'U01-AI069467/AI/NIAID NIH HHS/United States'
p3936
aS'UL1 TR000077/TR/NCATS NIH HHS/United States'
p3937
aS'UM 1AI069436/AI/NIAID NIH HHS/United States'
p3938
aS'UM1AI068634/AI/NIAID NIH HHS/United States'
p3939
aS'UM1AI068636/AI/NIAID NIH HHS/United States'
p3940
aS'UM1AI069434/AI/NIAID NIH HHS/United States'
p3941
aS'UM1AI069481/AI/NIAID NIH HHS/United States'
p3942
asS'OWN'
p3943
S'NLM'
p3944
sS'PT'
p3945
(lp3946
S'Journal Article'
p3947
aS'Multicenter Study'
p3948
aS'Randomized Controlled Trial'
p3949
aS'Research Support, N.I.H., Extramural'
p3950
asS'LA'
p3951
(lp3952
S'eng'
p3953
asS'FAU'
p3954
(lp3955
S'Gross, Robert'
p3956
aS'Zheng, Lu'
p3957
aS'La Rosa, Alberto'
p3958
aS'Sun, Xin'
p3959
aS'Rosenkranz, Susan L'
p3960
aS'Cardoso, Sandra Wagner'
p3961
aS'Ssali, Francis'
p3962
aS'Camp, Rob'
p3963
aS'Godfrey, Catherine'
p3964
aS'Cohn, Susan E'
p3965
aS'Robbins, Gregory K'
p3966
aS'Chisada, Anthony'
p3967
aS'Wallis, Carole L'
p3968
aS'Reynolds, Nancy R'
p3969
aS'Lu, Darlene'
p3970
aS'Safren, Steven A'
p3971
aS'Hosey, Lara'
p3972
aS'Severe, Patrice'
p3973
aS'Collier, Ann C'
p3974
asS'JT'
p3975
S'The lancet. HIV'
p3976
sS'LR'
p3977
S'20160225'
p3978
sS'PG'
p3979
S'e12-9'
p3980
sS'TI'
p3981
S'Partner-based adherence intervention for second-line antiretroviral therapy (ACTG A5234): a multinational randomised trial.'
p3982
sS'RN'
p3983
(lp3984
S'0 (Anti-HIV Agents)'
p3985
asS'PL'
p3986
S'Netherlands'
p3987
sS'TA'
p3988
S'Lancet HIV'
p3989
sS'JID'
p3990
S'101645355'
p3991
sS'AB'
p3992
S'BACKGROUND: Adherence is key to the success of antiretroviral therapy. Enhanced partner support might benefit patients with previous treatment failure. We aimed to assess whether an enhanced partner-based support intervention with modified directly observed therapy would improve outcomes with second-line therapy in HIV-infected patients for whom first-line therapy had failed. METHODS: We did a multicentre, international, randomised clinical trial at nine sites in Botswana, Brazil, Haiti, Peru, South Africa, Uganda, Zambia, and Zimbabwe. Participants aged 18 years or older for whom first-line therapy had failed, with HIV RNA concentrations greater than 1000 copies per mL and with a willing partner, were randomly assigned (1:1), via computer-generated randomisation, to receive partner-based modified directly observed therapy or standard of care. Randomisation was stratified by screening HIV RNA concentration (</=10 000 copies per mL vs >10 000 copies per mL). Participants and site investigators were not masked to group assignment. Primary outcome was confirmed virological failure (viral load >400 copies per mL) by week 48. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00608569. FINDINGS: Between April 23, 2009, and Sept 29, 2011, we randomly assigned 259 participants to the modified directly observed therapy group (n=129) or the standard-of-care group (n=130). 34 (26%) participants in the modified directly observed therapy group achieved the primary endpoint of virological failure by week 48 compared with 23 (18%) participants in the standard-of-care group. The Kaplan-Meier estimated cumulative probability of virological failure by week 48 was 25.1% (95% CI 17.7-32.4) in the modified directly observed therapy group and 17.3% (10.8-23.7) in the standard-of-care group, for a weighted difference in standard of care versus modified directly observed therapy of -6.6% (95% CI -16.5% to 3.2%; p=0.19). 36 (14%) participants reported at least one grade 3 or higher adverse event or laboratory abnormality (n=21 in the modified directly observed therapy group and n=15 in the standard-of-care group). INTERPRETATION: Partner-based training with modified directly observed therapy had no effect on virological suppression. The intervention does not therefore seem to be a promising strategy to increase adherence. Intensive follow-up with clinic staff might be a viable approach in this setting. FUNDING: AIDS Clinical Trials Group and the National Institute of Allergy and Infectious Diseases, US National Institutes of Health.'
p3993
sS'AD'
p3994
S'University of Pennsylvania Perelman School of Medicine, Medicine (Infectious Diseases) and Epidemiology, Philadelphia, PA, USA. Electronic address: grossr@mail.med.upenn.edu. Harvard School of Public Health, Biostatistics, Boston, MA, USA. Asociacion Civil IMPACTA Salud y Educacion, Lima, Peru. Harvard School of Public Health, Biostatistics, Boston, MA, USA. Harvard School of Public Health, Biostatistics, Boston, MA, USA. FIOCRUZ, Rio de Janeiro, Brazil. Joint Clinical Research Centre, Kampala, Uganda. EUPATI, Barcelona, Spain. National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA. Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. University of Zimbabwe, Harare, Zimbabwe. Lancet Laboratories, Johannesburg, South Africa. Yale University School of Nursing, New Haven, CT USA. Harvard School of Public Health, Biostatistics, Boston, MA, USA. Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. Social and Scientific Systems, Silver Spring, MD, USA. GHESKIO, Port au Prince, Haiti. University of Washington, Seattle, WA, USA.'
p3995
sS'CN'
p3996
(lp3997
S'ACTG 5234 team'
p3998
asS'IP'
p3999
S'1'
sS'IS'
p4000
S'2352-3018 (Electronic) 2352-3018 (Linking)'
p4001
sS'DCOM'
p4002
S'20160808'
p4003
sS'CIN'
p4004
(lp4005
S'Lancet HIV. 2015 Jan;2(1):e2-3. PMID: 26424233'
p4006
asS'AU'
p4007
(lp4008
S'Gross R'
p4009
aS'Zheng L'
p4010
aS'La Rosa A'
p4011
aS'Sun X'
p4012
aS'Rosenkranz SL'
p4013
aS'Cardoso SW'
p4014
aS'Ssali F'
p4015
aS'Camp R'
p4016
aS'Godfrey C'
p4017
aS'Cohn SE'
p4018
aS'Robbins GK'
p4019
aS'Chisada A'
p4020
aS'Wallis CL'
p4021
aS'Reynolds NR'
p4022
aS'Lu D'
p4023
aS'Safren SA'
p4024
aS'Hosey L'
p4025
aS'Severe P'
p4026
aS'Collier AC'
p4027
asS'VI'
p4028
S'2'
sS'MHDA'
p4029
S'2016/08/09 06:00'
p4030
sS'PHST'
p4031
(lp4032
S'2014/10/15 [received]'
p4033
aS'2014/11/12 [accepted]'
p4034
aS'2014/12/11 [aheadofprint]'
p4035
asS'MH'
p4036
(lp4037
S'Adult'
p4038
aS'Anti-HIV Agents/*administration & dosage'
p4039
aS'*Antiretroviral Therapy, Highly Active/methods'
p4040
aS'Appointments and Schedules'
p4041
aS'Botswana'
p4042
aS'Brazil'
p4043
aS'Female'
p4044
aS'HIV Infections/*drug therapy/virology'
p4045
aS'Haiti'
p4046
aS'Humans'
p4047
aS'Male'
p4048
aS'Medication Adherence/*psychology'
p4049
aS'Middle Aged'
p4050
aS'Peru'
p4051
aS'Research Personnel'
p4052
aS'South Africa'
p4053
aS'Standard of Care'
p4054
aS'Treatment Failure'
p4055
aS'Uganda'
p4056
aS'United States'
p4057
aS'Viral Load/drug effects'
p4058
aS'Zimbabwe'
p4059
asS'EDAT'
p4060
S'2015/10/02 06:00'
p4061
sS'SI'
p4062
(lp4063
S'ClinicalTrials.gov/NCT00608569'
p4064
asS'SO'
p4065
S'Lancet HIV. 2015 Jan;2(1):e12-9. doi: 10.1016/S2352-3018(14)00007-1. Epub 2014 Dec 11.'
p4066
sS'SB'
p4067
S'IM X'
p4068
sS'PMID'
p4069
S'26424232'
p4070
sS'PST'
p4071
S'ppublish'
p4072
stRp4073
ag2
(g3
g4
(dp4074
S'LID'
p4075
S'10.1016/S2352-3018(15)00113-7 [doi] S2352-3018(15)00113-7 [pii]'
p4076
sS'STAT'
p4077
S'MEDLINE'
p4078
sS'DEP'
p4079
S'20150804'
p4080
sS'MID'
p4081
(lp4082
S'NIHMS714623'
p4083
asS'DA'
p4084
S'20151001'
p4085
sS'AID'
p4086
(lp4087
S'S2352-3018(15)00113-7 [pii]'
p4088
aS'10.1016/S2352-3018(15)00113-7 [doi]'
p4089
asS'CRDT'
p4090
(lp4091
S'2015/10/02 06:00'
p4092
asS'DP'
p4093
S'2015 Sep'
p4094
sS'GR'
p4095
(lp4096
S'097410/Wellcome Trust/United Kingdom'
p4097
aS'U01 AI069924/AI/NIAID NIH HHS/United States'
p4098
aS'U01AI069924/AI/NIAID NIH HHS/United States'
p4099
asS'OWN'
p4100
S'NLM'
p4101
sS'PT'
p4102
(lp4103
S'Journal Article'
p4104
aS'Multicenter Study'
p4105
aS'Observational Study'
p4106
aS'Research Support, N.I.H., Extramural'
p4107
aS"Research Support, Non-U.S. Gov't"
p4108
aS"Research Support, U.S. Gov't, Non-P.H.S."
p4109
asS'LA'
p4110
(lp4111
S'eng'
p4112
asS'FAU'
p4113
(lp4114
S'Cornell, Morna'
p4115
aS'Johnson, Leigh F'
p4116
aS'Schomaker, Michael'
p4117
aS'Tanser, Frank'
p4118
aS'Maskew, Mhairi'
p4119
aS'Wood, Robin'
p4120
aS'Prozesky, Hans'
p4121
aS'Giddy, Janet'
p4122
aS'Stinson, Kathryn'
p4123
aS'Egger, Matthias'
p4124
aS'Boulle, Andrew'
p4125
aS'Myer, Landon'
p4126
asS'JT'
p4127
S'The lancet. HIV'
p4128
sS'LR'
p4129
S'20160901'
p4130
sS'PG'
p4131
S'e368-75'
p4132
sS'TI'
p4133
S'Age in antiretroviral therapy programmes in South Africa: a retrospective, multicentre, observational cohort study.'
p4134
sS'RN'
p4135
(lp4136
S'0 (Anti-HIV Agents)'
p4137
asS'PL'
p4138
S'Netherlands'
p4139
sS'TA'
p4140
S'Lancet HIV'
p4141
sS'JID'
p4142
S'101645355'
p4143
sS'AB'
p4144
S"BACKGROUND: As access to antiretroviral therapy (ART) expands, increasing numbers of older patients will start treatment and need specialised long-term care. However, the effect of age in ART programmes in resource-constrained settings is poorly understood. The HIV epidemic is ageing rapidly and South Africa has one of the highest HIV population prevalences worldwide. We explored the effect of age on mortality of patients on ART in South Africa and whether this effect is mediated by baseline immunological status. METHODS: In this retrospective cohort analysis, we studied HIV-positive patients aged 16-80 years who started ART for the first time in six large South African cohorts of the International Epidemiologic Databases to Evaluate AIDS-Southern Africa collaboration, in KwaZulu-Natal, Gauteng, and Western Cape (two primary care clinics, three hospitals, and a large rural cohort). The primary outcome was mortality. We ascertained patients' vital status through linkage to the National Population Register. We used inverse probability weighting to correct mortality for loss to follow-up. We estimated mortality using Cox's proportional hazards and competing risks regression. We tested the interaction between baseline CD4 cell count and age. FINDINGS: Between Jan 1, 2004, and Dec 31, 2013, 84,078 eligible adults started ART. Of these, we followed up 83,566 patients for 174,640 patient-years. 8% (1817 of 23,258) of patients aged 16-29 years died compared with 19% (93 of 492) of patients aged 65 years or older. The age adjusted mortality hazard ratio was 2.52 (95% CI 2.01-3.17) for people aged 65 years or older compared with those 16-29 years of age. In patients starting ART with a CD4 count of less than 50 cells per muL, the adjusted mortality hazard ratio was 2.52 (2.04-3.11) for people aged 50 years or older compared with those 16-39 years old. Mortality was highest in patients with CD4 counts of less than 50 cells per muL, and 15% (1103 of 7295) of all patients aged 50 years or older starting ART were in this group. The proportion of patients aged 50 years or older enrolling in ART increased with successive years, from 6% (290 of 4999) in 2004 to 10% (961 of 9657) in 2012-13, comprising 9% of total enrolment (7295 of 83 566). At the end of the study, 6304 (14%) of 44,909 patients still alive and in care were aged 50 years or older. INTERPRETATION: Health services need reorientation towards HIV diagnosis and starting of ART in older individuals. Policies are needed for long-term care of older people with HIV. FUNDING: National Institutes of Health (National Institute of Allergy and Infectious Diseases), US Agency for International Development, and South African Centre for Epidemiological Modelling and Analysis."
p4145
sS'AD'
p4146
S'Centre for Infectious Disease Epidemiology and Research, Cape Town, South Africa; Division of Epidemiology and Biostatistics, Cape Town, South Africa. Electronic address: morna.cornell@uct.ac.za. Centre for Infectious Disease Epidemiology and Research, Cape Town, South Africa. Centre for Infectious Disease Epidemiology and Research, Cape Town, South Africa. Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa; Wellcome Trust Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Mtubatuba, South Africa. Health Economics and Epidemiology Research Office, Wits Health Consortium, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. School of Public Health and Family Medicine, Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, Cape Town, South Africa. Division of Infectious Diseases, Department of Medicine, University of Stellenbosch and Tygerberg Academic Hospital, Tygerberg, Cape Town, South Africa. McCord Hospital, Durban, South Africa. Centre for Infectious Disease Epidemiology and Research, Cape Town, South Africa; Medecins Sans Frontieres, Khayelitsha, Cape Town, South Africa. Centre for Infectious Disease Epidemiology and Research, Cape Town, South Africa; Division of International and Environmental Health, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. Centre for Infectious Disease Epidemiology and Research, Cape Town, South Africa. Centre for Infectious Disease Epidemiology and Research, Cape Town, South Africa; Division of Epidemiology and Biostatistics, Cape Town, South Africa.'
p4147
sS'CN'
p4148
(lp4149
S'International Epidemiologic Databases to Evaluate AIDS-Southern Africa'
p4150
aS'Collaboration'
p4151
asS'IP'
p4152
S'9'
sS'IS'
p4153
S'2352-3018 (Electronic) 2352-3018 (Linking)'
p4154
sS'PMC'
p4155
S'PMC4603282'
p4156
sS'DCOM'
p4157
S'20160926'
p4158
sS'CIN'
p4159
(lp4160
S'Lancet HIV. 2015 Sep;2(9):e352-3. PMID: 26423539'
p4161
asS'AU'
p4162
(lp4163
S'Cornell M'
p4164
aS'Johnson LF'
p4165
aS'Schomaker M'
p4166
aS'Tanser F'
p4167
aS'Maskew M'
p4168
aS'Wood R'
p4169
aS'Prozesky H'
p4170
aS'Giddy J'
p4171
aS'Stinson K'
p4172
aS'Egger M'
p4173
aS'Boulle A'
p4174
aS'Myer L'
p4175
asS'VI'
p4176
S'2'
sS'MHDA'
p4177
S'2016/09/27 06:00'
p4178
sS'PHST'
p4179
(lp4180
S'2015/03/13 [received]'
p4181
aS'2015/06/02 [revised]'
p4182
aS'2015/06/02 [accepted]'
p4183
aS'2015/08/04 [aheadofprint]'
p4184
asS'OID'
p4185
(lp4186
S'NLM: NIHMS714623'
p4187
aS'NLM: PMC4603282'
p4188
asS'CI'
p4189
(lp4190
S'Copyright (c) 2015 Elsevier Ltd. All rights reserved.'
p4191
asS'MH'
p4192
(lp4193
S'Adult'
p4194
aS'Age Factors'
p4195
aS'Anti-HIV Agents/*therapeutic use'
p4196
aS'Antiretroviral Therapy, Highly Active'
p4197
aS'CD4 Lymphocyte Count'
p4198
aS'Female'
p4199
aS'Follow-Up Studies'
p4200
aS'HIV Infections/*drug therapy/mortality'
p4201
aS'Humans'
p4202
aS'Male'
p4203
aS'Needs Assessment/organization & administration'
p4204
aS'*Program Development'
p4205
aS'*Public Health'
p4206
aS'Retrospective Studies'
p4207
aS'Risk Factors'
p4208
aS'South Africa/epidemiology'
p4209
aS'Treatment Outcome'
p4210
asS'EDAT'
p4211
S'2015/10/02 06:00'
p4212
sS'SO'
p4213
S'Lancet HIV. 2015 Sep;2(9):e368-75. doi: 10.1016/S2352-3018(15)00113-7. Epub 2015 Aug 4.'
p4214
sS'SB'
p4215
S'IM X'
p4216
sS'PMID'
p4217
S'26423550'
p4218
sS'PST'
p4219
S'ppublish'
p4220
stRp4221
ag2
(g3
g4
(dp4222
S'LID'
p4223
S'10.1016/S2352-3018(15)00087-9 [doi] S2352-3018(15)00087-9 [pii]'
p4224
sS'STAT'
p4225
S'MEDLINE'
p4226
sS'DEP'
p4227
S'20150616'
p4228
sS'MID'
p4229
(lp4230
S'NIHMS704369'
p4231
asS'DA'
p4232
S'20151001'
p4233
sS'AID'
p4234
(lp4235
S'S2352-3018(15)00087-9 [pii]'
p4236
aS'10.1016/S2352-3018(15)00087-9 [doi]'
p4237
asS'CRDT'
p4238
(lp4239
S'2015/10/02 06:00'
p4240
asS'DP'
p4241
S'2015 Jul'
p4242
sS'GR'
p4243
(lp4244
S'5U01-AI069924/AI/NIAID NIH HHS/United States'
p4245
aS'U01 AI069911/AI/NIAID NIH HHS/United States'
p4246
aS'U01 AI069919/AI/NIAID NIH HHS/United States'
p4247
aS'U01 AI069924/AI/NIAID NIH HHS/United States'
p4248
aS'U01AI069911/AI/NIAID NIH HHS/United States'
p4249
aS'U01AI069919/AI/NIAID NIH HHS/United States'
p4250
aS'Intramural NIH HHS/United States'
p4251
asS'OWN'
p4252
S'NLM'
p4253
sS'PT'
p4254
(lp4255
S'Journal Article'
p4256
aS'Research Support, N.I.H., Extramural'
p4257
aS'Research Support, N.I.H., Intramural'
p4258
aS"Research Support, Non-U.S. Gov't"
p4259
asS'LA'
p4260
(lp4261
S'eng'
p4262
asS'FAU'
p4263
(lp4264
S'Haas, Andreas D'
p4265
aS'Keiser, Olivia'
p4266
aS'Balestre, Eric'
p4267
aS'Brown, Steve'
p4268
aS'Bissagnene, Emmanuel'
p4269
aS'Chimbetete, Cleophas'
p4270
aS'Dabis, Francois'
p4271
aS'Davies, Mary-Ann'
p4272
aS'Hoffmann, Christopher J'
p4273
aS'Oyaro, Patrick'
p4274
aS'Parkes-Ratanshi, Rosalind'
p4275
aS'Reynolds, Steven J'
p4276
aS'Sikazwe, Izukanji'
p4277
aS'Wools-Kaloustian, Kara'
p4278
aS'Zannou, D Marcel'
p4279
aS'Wandeler, Gilles'
p4280
aS'Egger, Matthias'
p4281
asS'JT'
p4282
S'The lancet. HIV'
p4283
sS'LR'
p4284
S'20160701'
p4285
sS'PG'
p4286
S'e271-8'
p4287
sS'TI'
p4288
S'Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.'
p4289
sS'RN'
p4290
(lp4291
S'0 (Anti-HIV Agents)'
p4292
aS'0 (HIV Protease Inhibitors)'
p4293
aS'0 (Reverse Transcriptase Inhibitors)'
p4294
asS'PL'
p4295
S'Netherlands'
p4296
sS'TA'
p4297
S'Lancet HIV'
p4298
sS'FIR'
p4299
(lp4300
S'Tanser, Frank'
p4301
aS'Hoffmann, Christopher'
p4302
aS'Chi, Benjamin'
p4303
aS'Naniche, Denise'
p4304
aS'Wood, Robin'
p4305
aS'Tutu, Desmond'
p4306
aS'Stinson, Kathryn'
p4307
aS'Fatti, Geoffrey'
p4308
aS'Phiri, Sam'
p4309
aS'Giddy, Janet'
p4310
aS'Chimbetete, Cleophas'
p4311
aS'Malisita, Kennedy'
p4312
aS'Eley, Brian'
p4313
aS'Hobbins, Michael'
p4314
aS'Kamenova, Kamelia'
p4315
aS'Faturiyele, Olatunbosun'
p4316
aS'Lesotho, Maseru'
p4317
aS'Fox, Matthew'
p4318
aS'Prozesky, Hans'
p4319
aS'Technau, Karl'
p4320
aS'Sawry, Shobna'
p4321
aS'Egger, Matthias'
p4322
aS'Bohlius, Julia'
p4323
aS'Blaser, Nello'
p4324
aS'Estill, Janne'
p4325
aS'Keiser, Olivia'
p4326
aS'Wandeler, Gilles'
p4327
aS'Salazar-Vizcaya, Luisa'
p4328
aS'Haas, Andreas'
p4329
aS'Ballif, Marie'
p4330
aS'Rohner, Eliane'
p4331
aS'Wyss, Natascha'
p4332
aS'Baranczuk, Zofia'
p4333
aS'Goodwin, Kelly'
p4334
aS'Ostinelli, Cam Ha Dao'
p4335
aS'Davies, Mary-Ann'
p4336
aS'Boulle, Andrew'
p4337
aS'Campbell, Lucy'
p4338
aS'Cornell, Morna'
p4339
aS'Johnson, Leigh'
p4340
aS'Maxwell, Nicola'
p4341
aS'Myer, Landon'
p4342
aS'Schomaker, Michael'
p4343
aS'Porter, Mireille'
p4344
aS'Ayaya, Samuel'
p4345
aS'Diero, Lameck'
p4346
aS'Sang, Edwin'
p4347
aS'Rotich, Elyne'
p4348
aS'Bukusi, Elizabeth'
p4349
aS'Somi, Geoffrey R'
p4350
aS'Lyamuya, Rita'
p4351
aS'Lugina, Edward'
p4352
aS'Urassa, Mark'
p4353
aS'Mkwasa, Denna Michael'
p4354
aS'Ngonyani, Kapella'
p4355
aS'Kambugu, Andrew'
p4356
aS'Easterbrook, Philippa'
p4357
aS'Achieng-Kariuki, Marion'
p4358
aS'Nalugoda, Fred'
p4359
aS'Ssali, John'
p4360
aS'Bwana, Mwebesa Bosco'
p4361
aS'Muyindike, Winnie'
p4362
aS'Yiannoutsos, Constantin T'
p4363
aS'Musick, Beverly S'
p4364
aS'Kuhn, Yee Yee H'
p4365
aS'Zannou, Marcel'
p4366
aS'Maga, Hubert'
p4367
aS'Drabo, Joseph'
p4368
aS'Sawadogo, Adrien Bruno'
p4369
aS'Messou, Eugene'
p4370
aS'Bosse, Clarisse Amani'
p4371
aS'Chenal, Henri'
p4372
aS'Minga, Albert'
p4373
aS'Tanon, Aristophane Koffi'
p4374
aS'Koule, Serge Olivier'
p4375
aS'Wejse, Christian'
p4376
aS'Leuenberger, David'
p4377
aS'Hebelamou, Jean'
p4378
aS'Maiga, Moussa Y'
p4379
aS'Traore, Hamar Alassane'
p4380
aS'Minta, Daouda'
p4381
aS'Kwaghe, Vivian'
p4382
aS'Igbinoba, Festus'
p4383
aS'Benson, Okwara'
p4384
aS'Adebamowo, Clement'
p4385
aS'Seydi, Moussa'
p4386
aS'Patassi, Akessiwe'
p4387
aS'Dabis, Francois'
p4388
aS'Arrive, Elise'
p4389
aS'de Rekeneire, Nathalie'
p4390
aS'Jaquet, Antoine'
p4391
aS'Leroy, Valeriane'
p4392
aS'Lewden, Charlotte'
p4393
aS'Sasco, Annie'
p4394
aS'Bissagnene, Emmanuel'
p4395
aS'Coffie, Patrick'
p4396
aS'Ekouevi, Didier'
p4397
aS'Charurat, Man'
p4398
asS'JID'
p4399
S'101645355'
p4400
sS'AB'
p4401
S'BACKGROUND: HIV-1 viral load testing is recommended to monitor antiretroviral therapy (ART) but is not universally available. The aim of our study was to assess monitoring of first-line ART and switching to second-line ART in sub-Saharan Africa. METHODS: We did a collaborative analysis of cohort studies from 16 countries in east Africa, southern Africa, and west Africa that participate in the international epidemiological database to evaluate AIDS (IeDEA). We included adults infected with HIV-1 who started combination ART between January, 2004, and January, 2013. We defined switching of ART as a change from a non-nucleoside reverse-transcriptase inhibitor (NNRTI)-based regimen to one including a protease inhibitor, with adjustment of one or more nucleoside reverse-transcriptase inhibitors (NRTIs). Virological and immunological failures were defined according to WHO criteria. We calculated cumulative probabilities of switching and hazard ratios with 95% CIs comparing routine viral load monitoring, targeted viral load monitoring, CD4 monitoring, and clinical monitoring, adjusting for programme and individual characteristics. FINDINGS: Of 297,825 eligible patients, 10,352 (3%) switched to second-line ART during 782 ,412 person-years of follow-up. Compared with CD4 monitoring, hazard ratios for switching were 3.15 (95% CI 2.92-3.40) for routine viral load monitoring, 1.21 (1.13-1.30) for targeted viral load monitoring, and 0.49 (0.43-0.56) for clinical monitoring. Of 6450 patients with confirmed virological failure, 58.0% (95% CI 56.5-59.6) switched by 2 years, and of 15,892 patients with confirmed immunological failure, 19.3% (18.5-20.0) switched by 2 years. Of 10,352 patients who switched, evidence of treatment failure based on one CD4 count or viral load measurement ranged from 86 (32%) of 268 patients with clinical monitoring to 3754 (84%) of 4452 with targeted viral load monitoring. Median CD4 counts at switching were 215 cells per muL (IQR 117-335) with routine viral load monitoring, but were lower with other types of monitoring (range 114-133 cells per muL). INTERPRETATION: Overall, few patients switched to second-line ART and switching happened late in the absence of routine viral load monitoring. Switching was more common and happened earlier after initiation of ART with targeted or routine viral load testing. FUNDING: National Institute of Allergy and Infectious Diseases, Swiss National Science Foundation.'
p4402
sS'AD'
p4403
S"Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. Centre de Recherche INSERM U897, Epidemiologie-Biostatistique, Institut de Sante Publique, Epidemiologie et Developpement, Universite de Bordeaux, Bordeaux, France. Indiana University School of Medicine, Indianapolis, IN, USA. Service de Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Treichville, Abidjan, Cote d'Ivoire. Newlands Clinic, Harare, Zimbabwe. Centre de Recherche INSERM U897, Epidemiologie-Biostatistique, Institut de Sante Publique, Epidemiologie et Developpement, Universite de Bordeaux, Bordeaux, France. Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa. Johns Hopkins University, Baltimore, MD, USA; Aurum Institute, Johannesburg, South Africa. Kenya Medical Research Institute - RCTP FACES Program, Kisumu, Kenya. Infectious Diseases Institute, Mulago Hospital Complex, Kampala, Uganda. Rakai Health Sciences Program, Entebbe, Uganda; Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA; Johns Hopkins University School of Medicine, Baltimore, MD, USA. Centre for Infectious Disease Research in Zambia, Lusaka, Zambia. Indiana University School of Medicine, Indianapolis, IN, USA. Faculte des Sciences de la Sante de l'Universite d'Abomey-Calavi, and Centre de Traitement Ambulatoire du Centre National Hospitalier Universitaire Hubert Koutoukou Maga, Cotonou, Benin. Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Department of Infectious Diseases, Bern University Hospital and University of Bern, Bern, Switzerland. Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa. Electronic address: egger@ispm.unibe.ch."
p4404
sS'CN'
p4405
(lp4406
S'IeDEA southern Africa, east Africa, and west Africa'
p4407
asS'IP'
p4408
S'7'
sS'IS'
p4409
S'2352-3018 (Electronic) 2352-3018 (Linking)'
p4410
sS'IR'
p4411
(lp4412
S'Tanser F'
p4413
aS'Hoffmann C'
p4414
aS'Chi B'
p4415
aS'Naniche D'
p4416
aS'Wood R'
p4417
aS'Tutu D'
p4418
aS'Stinson K'
p4419
aS'Fatti G'
p4420
aS'Phiri S'
p4421
aS'Giddy J'
p4422
aS'Chimbetete C'
p4423
aS'Malisita K'
p4424
aS'Eley B'
p4425
aS'Hobbins M'
p4426
aS'Kamenova K'
p4427
aS'Faturiyele O'
p4428
aS'Lesotho M'
p4429
aS'Fox M'
p4430
aS'Prozesky H'
p4431
aS'Technau K'
p4432
aS'Sawry S'
p4433
aS'Egger M'
p4434
aS'Bohlius J'
p4435
aS'Blaser N'
p4436
aS'Estill J'
p4437
aS'Keiser O'
p4438
aS'Wandeler G'
p4439
aS'Salazar-Vizcaya L'
p4440
aS'Haas A'
p4441
aS'Ballif M'
p4442
aS'Rohner E'
p4443
aS'Wyss N'
p4444
aS'Baranczuk Z'
p4445
aS'Goodwin K'
p4446
aS'Ostinelli CH'
p4447
aS'Davies MA'
p4448
aS'Boulle A'
p4449
aS'Campbell L'
p4450
aS'Cornell M'
p4451
aS'Johnson L'
p4452
aS'Maxwell N'
p4453
aS'Myer L'
p4454
aS'Schomaker M'
p4455
aS'Porter M'
p4456
aS'Ayaya S'
p4457
aS'Diero L'
p4458
aS'Sang E'
p4459
aS'Rotich E'
p4460
aS'Bukusi E'
p4461
aS'Somi GR'
p4462
aS'Lyamuya R'
p4463
aS'Lugina E'
p4464
aS'Urassa M'
p4465
aS'Mkwasa DM'
p4466
aS'Ngonyani K'
p4467
aS'Kambugu A'
p4468
aS'Easterbrook P'
p4469
aS'Achieng-Kariuki M'
p4470
aS'Nalugoda F'
p4471
aS'Ssali J'
p4472
aS'Bwana MB'
p4473
aS'Muyindike W'
p4474
aS'Yiannoutsos CT'
p4475
aS'Musick BS'
p4476
aS'Kuhn YY'
p4477
aS'Zannou M'
p4478
aS'Maga H'
p4479
aS'Drabo J'
p4480
aS'Sawadogo AB'
p4481
aS'Messou E'
p4482
aS'Bosse CA'
p4483
aS'Chenal H'
p4484
aS'Minga A'
p4485
aS'Tanon AK'
p4486
aS'Koule SO'
p4487
aS'Wejse C'
p4488
aS'Leuenberger D'
p4489
aS'Hebelamou J'
p4490
aS'Maiga MY'
p4491
aS'Traore HA'
p4492
aS'Minta D'
p4493
aS'Kwaghe V'
p4494
aS'Igbinoba F'
p4495
aS'Benson O'
p4496
aS'Adebamowo C'
p4497
aS'Seydi M'
p4498
aS'Patassi A'
p4499
aS'Dabis F'
p4500
aS'Arrive E'
p4501
aS'de Rekeneire N'
p4502
aS'Jaquet A'
p4503
aS'Leroy V'
p4504
aS'Lewden C'
p4505
aS'Sasco A'
p4506
aS'Bissagnene E'
p4507
aS'Coffie P'
p4508
aS'Ekouevi D'
p4509
aS'Charurat M'
p4510
asS'DCOM'
p4511
S'20160808'
p4512
sS'CIN'
p4513
(lp4514
S'Lancet HIV. 2015 Jul;2(7):e261-2. PMID: 26423247'
p4515
asS'AU'
p4516
(lp4517
S'Haas AD'
p4518
aS'Keiser O'
p4519
aS'Balestre E'
p4520
aS'Brown S'
p4521
aS'Bissagnene E'
p4522
aS'Chimbetete C'
p4523
aS'Dabis F'
p4524
aS'Davies MA'
p4525
aS'Hoffmann CJ'
p4526
aS'Oyaro P'
p4527
aS'Parkes-Ratanshi R'
p4528
aS'Reynolds SJ'
p4529
aS'Sikazwe I'
p4530
aS'Wools-Kaloustian K'
p4531
aS'Zannou DM'
p4532
aS'Wandeler G'
p4533
aS'Egger M'
p4534
asS'VI'
p4535
S'2'
sS'MHDA'
p4536
S'2016/08/09 06:00'
p4537
sS'PHST'
p4538
(lp4539
S'2015/01/22 [received]'
p4540
aS'2015/05/08 [revised]'
p4541
aS'2015/05/11 [accepted]'
p4542
aS'2015/06/16 [aheadofprint]'
p4543
asS'OID'
p4544
(lp4545
S'NLM: NIHMS704369'
p4546
aS'NLM: PMC4500741'
p4547
asS'CI'
p4548
(lp4549
S'Copyright (c) 2015 Elsevier Ltd. All rights reserved.'
p4550
asS'MH'
p4551
(lp4552
S'Adult'
p4553
aS'Africa South of the Sahara/epidemiology'
p4554
aS'Anti-HIV Agents/administration & dosage/*therapeutic use'
p4555
aS'Antiretroviral Therapy, Highly Active/statistics & numerical data'
p4556
aS'CD4 Lymphocyte Count'
p4557
aS'Cohort Studies'
p4558
aS'*Drug Monitoring'
p4559
aS'Drug Substitution/*statistics & numerical data'
p4560
aS'Female'
p4561
aS'HIV Infections/*drug therapy/epidemiology'
p4562
aS'HIV Protease Inhibitors/*therapeutic use'
p4563
aS'HIV-1/immunology'
p4564
aS'Humans'
p4565
aS'Male'
p4566
aS'Reverse Transcriptase Inhibitors/*therapeutic use'
p4567
aS'Treatment Failure'
p4568
aS'Viral Load/drug effects'
p4569
asS'EDAT'
p4570
S'2015/10/02 06:00'
p4571
sS'PMC'
p4572
S'PMC4500741'
p4573
sS'SO'
p4574
S'Lancet HIV. 2015 Jul;2(7):e271-8. doi: 10.1016/S2352-3018(15)00087-9. Epub 2015 Jun 16.'
p4575
sS'SB'
p4576
S'IM X'
p4577
sS'PMID'
p4578
S'26423252'
p4579
sS'PST'
p4580
S'ppublish'
p4581
stRp4582
ag2
(g3
g4
(dp4583
S'LID'
p4584
S'10.1371/journal.pmed.1001880 [doi]'
p4585
sS'STAT'
p4586
S'MEDLINE'
p4587
sS'DEP'
p4588
S'20150929'
p4589
sS'DA'
p4590
S'20150930'
p4591
sS'AID'
p4592
(lp4593
S'10.1371/journal.pmed.1001880 [doi]'
p4594
aS'PMEDICINE-D-15-00672 [pii]'
p4595
asS'CRDT'
p4596
(lp4597
S'2015/09/30 06:00'
p4598
asS'DP'
p4599
S'2015 Sep'
p4600
sS'AD'
p4601
S"Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America; KwaZulu-Natal Research Institute for TB and HIV (K-RITH), Durban, South Africa. Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America; Delft Bioinformatics Lab, Delft University of Technology, Delft, The Netherlands. Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America. Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America. KwaZulu-Natal Research Institute for TB and HIV (K-RITH), Durban, South Africa. Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America. Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America. Medical Research Council, Durban, South Africa. KwaZulu-Natal Research Institute for TB and HIV (K-RITH), Durban, South Africa; Center for Tuberculosis Research, Johns Hopkins School of Medicine, Baltimore, Maryland, United States of America. Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America. Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America. School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa; National Health Laboratory Service, Durban, South Africa. KwaZulu-Natal Research Institute for TB and HIV (K-RITH), Durban, South Africa. Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America. KwaZulu-Natal Research Institute for TB and HIV (K-RITH), Durban, South Africa. Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America. Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America. Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America. Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America. KwaZulu-Natal Research Institute for TB and HIV (K-RITH), Durban, South Africa. Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America. Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America. Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America. Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa. KwaZulu-Natal Research Institute for TB and HIV (K-RITH), Durban, South Africa; Center for Tuberculosis Research, Johns Hopkins School of Medicine, Baltimore, Maryland, United States of America. Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America. Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America. School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa; National Health Laboratory Service, Durban, South Africa. Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa; Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University College of Physicians and Surgeons, New York, United States of America; Department of Epidemiology, Columbia Mailman School of Public Health, New York, United States of America. Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America. Center for Tuberculosis Research, Johns Hopkins School of Medicine, Baltimore, Maryland, United States of America. KwaZulu-Natal Research Institute for TB and HIV (K-RITH), Durban, South Africa. Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America."
p4602
sS'OWN'
p4603
S'NLM'
p4604
sS'PT'
p4605
(lp4606
S'Journal Article'
p4607
aS'Research Support, N.I.H., Extramural'
p4608
aS"Research Support, Non-U.S. Gov't"
p4609
asS'LA'
p4610
(lp4611
S'eng'
p4612
asS'FAU'
p4613
(lp4614
S'Cohen, Keira A'
p4615
aS'Abeel, Thomas'
p4616
aS'Manson McGuire, Abigail'
p4617
aS'Desjardins, Christopher A'
p4618
aS'Munsamy, Vanisha'
p4619
aS'Shea, Terrance P'
p4620
aS'Walker, Bruce J'
p4621
aS'Bantubani, Nonkqubela'
p4622
aS'Almeida, Deepak V'
p4623
aS'Alvarado, Lucia'
p4624
aS'Chapman, Sinead B'
p4625
aS'Mvelase, Nomonde R'
p4626
aS'Duffy, Eamon Y'
p4627
aS'Fitzgerald, Michael G'
p4628
aS'Govender, Pamla'
p4629
aS'Gujja, Sharvari'
p4630
aS'Hamilton, Susanna'
p4631
aS'Howarth, Clinton'
p4632
aS'Larimer, Jeffrey D'
p4633
aS'Maharaj, Kashmeel'
p4634
aS'Pearson, Matthew D'
p4635
aS'Priest, Margaret E'
p4636
aS'Zeng, Qiandong'
p4637
aS'Padayatchi, Nesri'
p4638
aS'Grosset, Jacques'
p4639
aS'Young, Sarah K'
p4640
aS'Wortman, Jennifer'
p4641
aS'Mlisana, Koleka P'
p4642
aS"O'Donnell, Max R"
p4643
aS'Birren, Bruce W'
p4644
aS'Bishai, William R'
p4645
aS'Pym, Alexander S'
p4646
aS'Earl, Ashlee M'
p4647
asS'JT'
p4648
S'PLoS medicine'
p4649
sS'LR'
p4650
S'20160126'
p4651
sS'PG'
p4652
S'e1001880'
p4653
sS'TI'
p4654
S'Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal.'
p4655
sS'RN'
p4656
(lp4657
S'0 (Antitubercular Agents)'
p4658
asS'PL'
p4659
S'United States'
p4660
sS'TA'
p4661
S'PLoS Med'
p4662
sS'JID'
p4663
S'101231360'
p4664
sS'AB'
p4665
S'BACKGROUND: The continued advance of antibiotic resistance threatens the treatment and control of many infectious diseases. This is exemplified by the largest global outbreak of extensively drug-resistant (XDR) tuberculosis (TB) identified in Tugela Ferry, KwaZulu-Natal, South Africa, in 2005 that continues today. It is unclear whether the emergence of XDR-TB in KwaZulu-Natal was due to recent inadequacies in TB control in conjunction with HIV or other factors. Understanding the origins of drug resistance in this fatal outbreak of XDR will inform the control and prevention of drug-resistant TB in other settings. In this study, we used whole genome sequencing and dating analysis to determine if XDR-TB had emerged recently or had ancient antecedents. METHODS AND FINDINGS: We performed whole genome sequencing and drug susceptibility testing on 337 clinical isolates of Mycobacterium tuberculosis collected in KwaZulu-Natal from 2008 to 2013, in addition to three historical isolates, collected from patients in the same province and including an isolate from the 2005 Tugela Ferry XDR outbreak, a multidrug-resistant (MDR) isolate from 1994, and a pansusceptible isolate from 1995. We utilized an array of whole genome comparative techniques to assess the relatedness among strains, to establish the order of acquisition of drug resistance mutations, including the timing of acquisitions leading to XDR-TB in the LAM4 spoligotype, and to calculate the number of independent evolutionary emergences of MDR and XDR. Our sequencing and analysis revealed a 50-member clone of XDR M. tuberculosis that was highly related to the Tugela Ferry XDR outbreak strain. We estimated that mutations conferring isoniazid and streptomycin resistance in this clone were acquired 50 y prior to the Tugela Ferry outbreak (katG S315T [isoniazid]; gidB 130 bp deletion [streptomycin]; 1957 [95% highest posterior density (HPD): 1937-1971]), with the subsequent emergence of MDR and XDR occurring 20 y (rpoB L452P [rifampicin]; pncA 1 bp insertion [pyrazinamide]; 1984 [95% HPD: 1974-1992]) and 10 y (rpoB D435G [rifampicin]; rrs 1400 [kanamycin]; gyrA A90V [ofloxacin]; 1995 [95% HPD: 1988-1999]) prior to the outbreak, respectively. We observed frequent de novo evolution of MDR and XDR, with 56 and nine independent evolutionary events, respectively. Isoniazid resistance evolved before rifampicin resistance 46 times, whereas rifampicin resistance evolved prior to isoniazid only twice. We identified additional putative compensatory mutations to rifampicin in this dataset. One major limitation of this study is that the conclusions with respect to ordering and timing of acquisition of mutations may not represent universal patterns of drug resistance emergence in other areas of the globe. CONCLUSIONS: In the first whole genome-based analysis of the emergence of drug resistance among clinical isolates of M. tuberculosis, we show that the ancestral precursor of the LAM4 XDR outbreak strain in Tugela Ferry gained mutations to first-line drugs at the beginning of the antibiotic era. Subsequent accumulation of stepwise resistance mutations, occurring over decades and prior to the explosion of HIV in this region, yielded MDR and XDR, permitting the emergence of compensatory mutations. Our results suggest that drug-resistant strains circulating today reflect not only vulnerabilities of current TB control efforts but also those that date back 50 y. In drug-resistant TB, isoniazid resistance was overwhelmingly the initial resistance mutation to be acquired, which would not be detected by current rapid molecular diagnostics employed in South Africa that assess only rifampicin resistance.'
p4666
sS'GR'
p4667
(lp4668
S'K23 AI098479-01A1/AI/NIAID NIH HHS/United States'
p4669
aS'T32HL007633/HL/NHLBI NIH HHS/United States'
p4670
aS'U19 AI110818/AI/NIAID NIH HHS/United States'
p4671
aS'U19 AI51794/AI/NIAID NIH HHS/United States'
p4672
aS'U19AI110818/AI/NIAID NIH HHS/United States'
p4673
asS'IP'
p4674
S'9'
sS'IS'
p4675
S'1549-1676 (Electronic) 1549-1277 (Linking)'
p4676
sS'PMC'
p4677
S'PMC4587932'
p4678
sS'DCOM'
p4679
S'20160404'
p4680
sS'AU'
p4681
(lp4682
S'Cohen KA'
p4683
aS'Abeel T'
p4684
aS'Manson McGuire A'
p4685
aS'Desjardins CA'
p4686
aS'Munsamy V'
p4687
aS'Shea TP'
p4688
aS'Walker BJ'
p4689
aS'Bantubani N'
p4690
aS'Almeida DV'
p4691
aS'Alvarado L'
p4692
aS'Chapman SB'
p4693
aS'Mvelase NR'
p4694
aS'Duffy EY'
p4695
aS'Fitzgerald MG'
p4696
aS'Govender P'
p4697
aS'Gujja S'
p4698
aS'Hamilton S'
p4699
aS'Howarth C'
p4700
aS'Larimer JD'
p4701
aS'Maharaj K'
p4702
aS'Pearson MD'
p4703
aS'Priest ME'
p4704
aS'Zeng Q'
p4705
aS'Padayatchi N'
p4706
aS'Grosset J'
p4707
aS'Young SK'
p4708
aS'Wortman J'
p4709
aS'Mlisana KP'
p4710
aS"O'Donnell MR"
p4711
aS'Birren BW'
p4712
aS'Bishai WR'
p4713
aS'Pym AS'
p4714
aS'Earl AM'
p4715
asS'VI'
p4716
S'12'
p4717
sS'MHDA'
p4718
S'2016/04/05 06:00'
p4719
sS'PHST'
p4720
(lp4721
S'2015/09 [ecollection]'
p4722
aS'2015/03/03 [received]'
p4723
aS'2015/08/20 [accepted]'
p4724
aS'2015/09/29 [epublish]'
p4725
asS'OID'
p4726
(lp4727
S'NLM: PMC4587932'
p4728
asS'MH'
p4729
(lp4730
S'Adult'
p4731
aS'Antitubercular Agents/*pharmacology'
p4732
aS'Disease Outbreaks'
p4733
aS'Extensively Drug-Resistant Tuberculosis/drug therapy/epidemiology/*genetics'
p4734
aS'Female'
p4735
aS'*Genome, Bacterial'
p4736
aS'Humans'
p4737
aS'Male'
p4738
aS'Microbial Sensitivity Tests'
p4739
aS'Mutation'
p4740
aS'Mycobacterium tuberculosis/drug effects/*genetics/isolation & purification'
p4741
aS'Sequence Analysis, DNA'
p4742
aS'South Africa/epidemiology'
p4743
asS'EDAT'
p4744
S'2015/09/30 06:00'
p4745
sS'SO'
p4746
S'PLoS Med. 2015 Sep 29;12(9):e1001880. doi: 10.1371/journal.pmed.1001880. eCollection 2015 Sep.'
p4747
sS'SB'
p4748
S'IM'
p4749
sS'PMID'
p4750
S'26418737'
p4751
sS'PST'
p4752
S'epublish'
p4753
stRp4754
ag2
(g3
g4
(dp4755
S'LID'
p4756
S'10.1089/AID.2015.0039 [doi]'
p4757
sS'STAT'
p4758
S'MEDLINE'
p4759
sS'DEP'
p4760
S'20151008'
p4761
sS'DA'
p4762
S'20151125'
p4763
sS'AID'
p4764
(lp4765
S'10.1089/AID.2015.0039 [doi]'
p4766
asS'CRDT'
p4767
(lp4768
S'2015/09/29 06:00'
p4769
asS'DP'
p4770
S'2015 Dec'
p4771
sS'OWN'
p4772
S'NLM'
p4773
sS'PT'
p4774
(lp4775
S'Journal Article'
p4776
aS"Research Support, Non-U.S. Gov't"
p4777
asS'LA'
p4778
(lp4779
S'eng'
p4780
asS'FAU'
p4781
(lp4782
S'Cheriro, Winfrida'
p4783
aS'Kiptoo, Michael'
p4784
aS'Kikuvi, Gideon'
p4785
aS'Mining, Simeon'
p4786
aS'Emonyi, Wilfred'
p4787
aS'Songok, Elijah'
p4788
asS'JT'
p4789
S'AIDS research and human retroviruses'
p4790
sS'PG'
p4791
S'1274-7'
p4792
sS'TI'
p4793
S'High Prevalence of HIV Low Abundance Drug-Resistant Variants in a Treatment-Naive Population in North Rift Kenya.'
p4794
sS'RN'
p4795
(lp4796
S'0 (DNA, Viral)'
p4797
asS'PL'
p4798
S'United States'
p4799
sS'TA'
p4800
S'AIDS Res Hum Retroviruses'
p4801
sS'JID'
p4802
S'8709376'
p4803
sS'AB'
p4804
S'The advent of antiretroviral treatment (ART) has resulted in a dramatic reduction in AIDS-related morbidity and mortality. However, the emergence and spread of antiretroviral drug resistance (DR) threaten to negatively impact treatment regimens and compromise efforts to control the epidemic. It is recommended that surveillance of drug resistance occur in conjunction with scale-up efforts to ensure that appropriate first-line therapy is offered relative to the resistance that exists. However, standard resistance testing methods used in Sub-Saharan Africa rely on techniques that do not include low abundance DR variants (LADRVs) that have been documented to contribute to treatment failure. The use of next generation sequencing (NGS) has been shown to be more sensitive to LADRVS. We have carried out a preliminary investigation using NGS to determine the prevalence of LDRVS among a drug-naive population in North Rift Kenya. Antiretroviral-naive patients attending a care clinic in North Rift Kenya were requested to provide and with consent provided blood samples for DR analysis. DNA was extracted and amplified and nested PCR was conducted on the pol RT region using primers tagged with multiplex identifiers (MID). Resulting PCR amplicons were purified, quantified, and pyrosequenced using a GS FLX Titanium PicoTiterPlate (Roche). Valid pyrosequencing reads were aligned with HXB-2 and the frequency and distribution of nucleotide and amino acid changes were determined using an in-house Perl script. DR mutations were identified using the IAS-USA HIV DR mutation database. Sixty samples were successfully sequenced of which 26 were subtype A, 9 were subtype D, 2 were subtype C, and the remaining were recombinants. Forty-six (76.6%) had at least one drug resistance mutation, with 25 (41.6%) indicated as major and the remaining 21 (35%) indicated as minor. The most prevalent mutation was NRTI position K219Q/R (11/46, 24%) followed by NRTI M184V (5/46, 11%) and NNRTI K103N (4/46, 9%). Our use of NGS technology revealed a high prevalence of LADRVs among drug-naive populations in Kenya, a region with predominantly non-B subtypes. The impact of these mutations on the clinical outcome of ART can be ascertained only through long-term follow-up.'
p4805
sS'AD'
p4806
S'1 Institute of Tropical Medicine and Infectious Diseases, Jomo Kenyatta University of Agriculture and Technology (JKUAT), Nairobi, Kenya . 2 Moi Teaching and Referral Hospital, Eldoret, Kenya . 1 Institute of Tropical Medicine and Infectious Diseases, Jomo Kenyatta University of Agriculture and Technology (JKUAT), Nairobi, Kenya . 3 Kenya Medical Research Institute, Nairobi, Kenya . 1 Institute of Tropical Medicine and Infectious Diseases, Jomo Kenyatta University of Agriculture and Technology (JKUAT), Nairobi, Kenya . 4 School of Medicine, Moi University, Eldoret, Kenya . 4 School of Medicine, Moi University, Eldoret, Kenya . 1 Institute of Tropical Medicine and Infectious Diseases, Jomo Kenyatta University of Agriculture and Technology (JKUAT), Nairobi, Kenya . 3 Kenya Medical Research Institute, Nairobi, Kenya . 5 Department of Medical Microbiology, University of Manitoba, Winnipeg, MN, Canada .'
p4807
sS'IP'
p4808
S'12'
p4809
sS'IS'
p4810
S'1931-8405 (Electronic) 0889-2229 (Linking)'
p4811
sS'DCOM'
p4812
S'20160829'
p4813
sS'AU'
p4814
(lp4815
S'Cheriro W'
p4816
aS'Kiptoo M'
p4817
aS'Kikuvi G'
p4818
aS'Mining S'
p4819
aS'Emonyi W'
p4820
aS'Songok E'
p4821
asS'VI'
p4822
S'31'
p4823
sS'MHDA'
p4824
S'2016/08/30 06:00'
p4825
sS'PHST'
p4826
(lp4827
S'2015/10/08 [aheadofprint]'
p4828
asS'MH'
p4829
(lp4830
S'Adult'
p4831
aS'Aged'
p4832
aS'Blood/virology'
p4833
aS'Child'
p4834
aS'DNA, Viral/chemistry/genetics/isolation & purification'
p4835
aS'*Drug Resistance, Viral'
p4836
aS'Female'
p4837
aS'*Genotype'
p4838
aS'HIV/*drug effects/*genetics/isolation & purification'
p4839
aS'HIV Infections/*epidemiology/*virology'
p4840
aS'High-Throughput Nucleotide Sequencing'
p4841
aS'Humans'
p4842
aS'Infant'
p4843
aS'Kenya/epidemiology'
p4844
aS'Male'
p4845
aS'Middle Aged'
p4846
aS'*Mutation, Missense'
p4847
aS'Polymerase Chain Reaction'
p4848
aS'Prevalence'
p4849
asS'EDAT'
p4850
S'2015/09/29 06:00'
p4851
sS'SO'
p4852
S'AIDS Res Hum Retroviruses. 2015 Dec;31(12):1274-7. doi: 10.1089/AID.2015.0039. Epub 2015 Oct 8.'
p4853
sS'SB'
p4854
S'IM X'
p4855
sS'PMID'
p4856
S'26414430'
p4857
sS'PST'
p4858
S'ppublish'
p4859
stRp4860
ag2
(g3
g4
(dp4861
S'LID'
p4862
S'10.1371/journal.pone.0139242 [doi]'
p4863
sS'STAT'
p4864
S'MEDLINE'
p4865
sS'DEP'
p4866
S'20150925'
p4867
sS'DA'
p4868
S'20150926'
p4869
sS'AID'
p4870
(lp4871
S'10.1371/journal.pone.0139242 [doi]'
p4872
aS'PONE-D-14-55634 [pii]'
p4873
asS'CRDT'
p4874
(lp4875
S'2015/09/26 06:00'
p4876
asS'DP'
p4877
S'2015'
p4878
sS'AD'
p4879
S'Johns Hopkins Medical Institutions, Baltimore, Maryland, United States of America. Jhpiego, an affiliate of Johns Hopkins University, Baltimore, Maryland, United States of America. Jhpiego, an affiliate of Johns Hopkins University, Baltimore, Maryland, United States of America. Jhpiego/Tanzania, an affiliate of Johns Hopkins University, Dar es Salaam, Tanzania. Jhpiego, an affiliate of Johns Hopkins University, Baltimore, Maryland, United States of America. Jhpiego, an affiliate of Johns Hopkins University, Baltimore, Maryland, United States of America. Johns Hopkins Medical Institutions, Baltimore, Maryland, United States of America. Jhpiego, an affiliate of Johns Hopkins University, Baltimore, Maryland, United States of America.'
p4880
sS'OWN'
p4881
S'NLM'
p4882
sS'PT'
p4883
(lp4884
S'Journal Article'
p4885
aS"Research Support, U.S. Gov't, Non-P.H.S."
p4886
aS"Research Support, U.S. Gov't, P.H.S."
p4887
asS'LA'
p4888
(lp4889
S'eng'
p4890
asS'FAU'
p4891
(lp4892
S'Anderson, Jean'
p4893
aS'Wysong, Megan'
p4894
aS'Estep, Deb'
p4895
aS'Besana, Giulia'
p4896
aS'Kibwana, Sharon'
p4897
aS'Varallo, John'
p4898
aS'Sun, Kai'
p4899
aS'Lu, Enriquito'
p4900
asS'JT'
p4901
S'PloS one'
p4902
sS'LR'
p4903
S'20151003'
p4904
sS'PG'
p4905
S'e0139242'
p4906
sS'TI'
p4907
S"Evaluation of Cervical Cancer Screening Programs in Cote d'Ivoire, Guyana, and Tanzania: Effect of HIV Status."
p4908
sS'PL'
p4909
S'United States'
p4910
sS'TA'
p4911
S'PLoS One'
p4912
sS'JID'
p4913
S'101285081'
p4914
sS'AB'
p4915
S"BACKGROUND: HIV infection increases a woman's risk for cervical cancer, and cervical cancer incidence and mortality rates are higher in countries with high HIV prevalence and limited resources for screening. Visual inspection with acetic acid (VIA) allows screening and treatment of cervical lesions in a single-visit approach (SVA), but data on its performance in HIV-infected women are limited. This study's objective was to examine cervical cancer screening using VIA/SVA in programs serving HIV-infected women. METHODS: A VIA/SVA program with cryotherapy for VIA-positive lesions was implemented in Cote d'Ivoire, Guyana, and Tanzania from 2009 to 2012. The effect of HIV status on VIA positivity and on presence of cryotherapy-eligible lesions was examined using a cross-sectional study design, with Chi-square tests for comparisons and constructed multivariate logistic regression models. A P-value of < 0.05 was significant. FINDINGS: VIA was performed on 34,921 women, 10% (3,580) were VIA positive; 2,508 (85%) eligible women received cryotherapy during the same visit; only 234 (52%) of those who postponed returned for treatment; 622 (17%) VIA-positive women had lesions too large to be treated with cryotherapy and were referred for excisional treatment. In multivariate analysis-controlling for HIV status, location of the screening clinic, facility location, facility type, and country-compared to HIV-uninfected/unknown women, HIV-infected women had higher odds of being VIA positive (OR 1.95, 95% CI 1.76, 2.16, P<0.0001) and of having large lesions requiring referral (OR 1.93, 95% CI 1.49, 2.51, P< 0.0001). Minor treatment complications occurred in 19 of 3,032 (0.63%) women; none required further intervention. CONCLUSIONS: This study found that compared to HIV-uninfected/unknown women, HIV-infected women had nearly twice the odds of being VIA-positive and to require referral for large lesions. SVA was safe and resulted in significant reductions in loss to follow-up. There is increased need for excisional treatment in countries with high HIV prevalence."
p4916
sS'GR'
p4917
(lp4918
S'5U2GPS001463/PHS HHS/United States'
p4919
asS'IP'
p4920
S'9'
sS'IS'
p4921
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p4922
sS'PMC'
p4923
S'PMC4583505'
p4924
sS'DCOM'
p4925
S'20160530'
p4926
sS'AU'
p4927
(lp4928
S'Anderson J'
p4929
aS'Wysong M'
p4930
aS'Estep D'
p4931
aS'Besana G'
p4932
aS'Kibwana S'
p4933
aS'Varallo J'
p4934
aS'Sun K'
p4935
aS'Lu E'
p4936
asS'VI'
p4937
S'10'
p4938
sS'MHDA'
p4939
S'2016/05/31 06:00'
p4940
sS'PHST'
p4941
(lp4942
S'2015 [ecollection]'
p4943
aS'2015/03/08 [received]'
p4944
aS'2015/09/09 [accepted]'
p4945
aS'2015/09/25 [epublish]'
p4946
asS'OID'
p4947
(lp4948
S'NLM: PMC4583505'
p4949
asS'MH'
p4950
(lp4951
S"Cote d'Ivoire/epidemiology"
p4952
aS'Early Detection of Cancer/*methods'
p4953
aS'Female'
p4954
aS'Guyana/epidemiology'
p4955
aS'HIV Infections/*epidemiology'
p4956
aS'Humans'
p4957
aS'Logistic Models'
p4958
aS'Multivariate Analysis'
p4959
aS'Tanzania/epidemiology'
p4960
aS'Treatment Outcome'
p4961
aS'Uterine Cervical Neoplasms/complications/*diagnosis/therapy/*virology'
p4962
asS'EDAT'
p4963
S'2015/09/26 06:00'
p4964
sS'SO'
p4965
S'PLoS One. 2015 Sep 25;10(9):e0139242. doi: 10.1371/journal.pone.0139242. eCollection 2015.'
p4966
sS'SB'
p4967
S'IM'
p4968
sS'PMID'
p4969
S'26405784'
p4970
sS'PST'
p4971
S'epublish'
p4972
stRp4973
ag2
(g3
g4
(dp4974
S'LID'
p4975
S'10.1097/QAI.0000000000000745 [doi]'
p4976
sS'STAT'
p4977
S'MEDLINE'
p4978
sS'JT'
p4979
S'Journal of acquired immune deficiency syndromes (1999)'
p4980
sS'DA'
p4981
S'20150917'
p4982
sS'AID'
p4983
(lp4984
S'10.1097/QAI.0000000000000745 [doi]'
p4985
aS'00126334-201510010-00016 [pii]'
p4986
asS'CRDT'
p4987
(lp4988
S'2015/09/17 06:00'
p4989
asS'DP'
p4990
S'2015 Oct 1'
p4991
sS'GR'
p4992
(lp4993
S'5U2GPS001537/PHS HHS/United States'
p4994
aS'5U62PS223540/PS/NCHHSTP CDC HHS/United States'
p4995
asS'OWN'
p4996
S'NLM'
p4997
sS'PT'
p4998
(lp4999
S'Journal Article'
p5000
aS"Research Support, U.S. Gov't, P.H.S."
p5001
asS'LA'
p5002
(lp5003
S'eng'
p5004
asS'FAU'
p5005
(lp5006
S'McNairy, Margaret L'
p5007
aS'Lamb, Matthew R'
p5008
aS'Abrams, Elaine J'
p5009
aS'Elul, Batya'
p5010
aS'Sahabo, Ruben'
p5011
aS'Hawken, Mark P'
p5012
aS'Mussa, Antonio'
p5013
aS'Zwede, Ayele'
p5014
aS'Justman, Jessica'
p5015
aS'El-Sadr, Wafaa M'
p5016
asS'PG'
p5017
S'e44-51'
p5018
sS'TI'
p5019
S'Use of a Comprehensive HIV Care Cascade for Evaluating HIV Program Performance: Findings From 4 Sub-Saharan African Countries.'
p5020
sS'RN'
p5021
(lp5022
S'0 (Anti-HIV Agents)'
p5023
asS'PL'
p5024
S'United States'
p5025
sS'TA'
p5026
S'J Acquir Immune Defic Syndr'
p5027
sS'JID'
p5028
S'100892005'
p5029
sS'AB'
p5030
S'BACKGROUND: The traditional HIV treatment cascade has been noted to have limitations. A proposed comprehensive HIV care cascade that uses cohort methodology offers additional information as it accounts for all patients. Using data from 4 countries, we compare patient outcomes using both approaches. METHODS: Data from 390,603 HIV-infected adults (>15 years) enrolled at 217 facilities in Kenya, Mozambique, Rwanda, and Tanzania from 2005 to 2011 were included. Outcomes of all patients at 3, 6, and 12 months after enrollment were categorized as optimal, suboptimal, or poor. Optimal outcomes included retention in care, antiretroviral therapy (ART) initiation, and documented transfer. Suboptimal outcomes included retention in care without ART initiation among eligible patients or those without eligibility data. Poor outcomes included loss to follow-up and death. RESULTS: The comprehensive HIV care cascade demonstrated that at 3, 6 and 12 months, 58%, 51%, and 49% of patients had optimal outcomes; 22%, 12%, and 7% had suboptimal outcomes, and 20%, 37% and 44% had poor outcomes. Of all patients enrolled in care, 56% were retained in care at 12 months after enrollment. In comparison, the traditional HIV treatment cascade found 89% of patients enrolled in HIV care were assessed for ART eligibility, of whom 48% were determined to be ART-eligible with 70% initiating ART, and 78% of those initiated on ART retained at 12 months. CONCLUSIONS: The comprehensive HIV care cascade follows outcomes of all patients, including pre-ART patients, who enroll in HIV care over time and uses quality of care parameters for categorizing outcomes. The comprehensive HIV care cascade provides complementary information to that of the traditional HIV treatment cascade and is a valuable tool for monitoring HIV program performance.'
p5031
sS'AD'
p5032
S'*ICAP at Columbia University, New York, NY; daggerDepartment of Medicine, Weill-Cornell Medical College, New York, NY; double daggerDepartment of Epidemiology, Mailman School of Public Health, New York, NY; and section signDepartment of Pediatrics, College of Physicians & Surgeons, Columbia University, New York, NY.'
p5033
sS'CN'
p5034
(lp5035
S'Identifying Optimal Models of HIV Care and Treatment in Sub-Saharan Africa Study'
p5036
asS'IP'
p5037
S'2'
sS'IS'
p5038
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p5039
sS'DCOM'
p5040
S'20151215'
p5041
sS'AU'
p5042
(lp5043
S'McNairy ML'
p5044
aS'Lamb MR'
p5045
aS'Abrams EJ'
p5046
aS'Elul B'
p5047
aS'Sahabo R'
p5048
aS'Hawken MP'
p5049
aS'Mussa A'
p5050
aS'Zwede A'
p5051
aS'Justman J'
p5052
aS'El-Sadr WM'
p5053
asS'VI'
p5054
S'70'
p5055
sS'MHDA'
p5056
S'2015/12/17 06:00'
p5057
sS'MH'
p5058
(lp5059
S'Adolescent'
p5060
aS'Adult'
p5061
aS'Africa South of the Sahara/epidemiology'
p5062
aS'Aged'
p5063
aS'Anti-HIV Agents/*therapeutic use'
p5064
aS'CD4 Lymphocyte Count'
p5065
aS'Community Health Services'
p5066
aS'Female'
p5067
aS'Government Programs'
p5068
aS'HIV Infections/*drug therapy'
p5069
aS'Humans'
p5070
aS'Male'
p5071
aS'Middle Aged'
p5072
aS'Treatment Outcome'
p5073
aS'Young Adult'
p5074
asS'EDAT'
p5075
S'2015/09/17 06:00'
p5076
sS'SO'
p5077
S'J Acquir Immune Defic Syndr. 2015 Oct 1;70(2):e44-51. doi: 10.1097/QAI.0000000000000745.'
p5078
sS'SB'
p5079
S'IM X'
p5080
sS'PMID'
p5081
S'26375466'
p5082
sS'PST'
p5083
S'ppublish'
p5084
stRp5085
ag2
(g3
g4
(dp5086
S'LID'
p5087
S'10.1186/s13104-015-1348-9 [doi]'
p5088
sS'STAT'
p5089
S'MEDLINE'
p5090
sS'AB'
p5091
S"BACKGROUND: Kaposi's Sarcoma is the most common sarcoma and second most prevalent cancer seen in Tanzania. Little is known about Kaposi's sarcoma in our setting as there is paucity of recent published data regarding this condition. This study describes the clinicopathological pattern and treatment outcome of Kaposi's sarcoma at Bugando Medical Centre, a tertiary care hospital in northwestern Tanzania. METHODS: This was a prospective study of histologically confirmed Kaposi's sarcoma that was conducted at Bugando Medical Center between July 2004 and June 2014. RESULTS: A total of 248 patients (M:F = 1.4:1) representing 2.4% of all malignancies during the study period were enrolled into the study. The median age at presentation was 36 years. Females were younger than males (p = 0.04). Out of 248 patients, 122 (49.2%) were HIV positive. Of these, 46 (37.7%) were males and 76 (62.3%) females. AIDS-related Kaposi's sarcoma were younger than HIV negative Kaposi's sarcoma patients (p = 0.011). Median duration of symptoms was 6 months. Kaposi's sarcoma was the AIDS defining disease in 82 (67.2%) patients while in the remaining 40 (32.8%) it was diagnosed between 1 and 14 months after the initial diagnosis of AIDS. The lower limb was most frequently involved site in 28.9% of patient. Females had more disseminated lesions compared with more localized lesions in the males (p = 0.001). The treatment modalities in this study included chemotherapy, radiotherapy, surgery and highly active antiretroviral therapy. Overall 126 (53.4%) patients had significant improvement in quality of life at the end of 1 year follow up. Treatment related complication and mortality rates were 25.8 and 24.2% respectively. Poor ACTG stage, CD4+ count <200 cells/microl, associated co-morbid illness, disseminated disease and poor adherent to chemotherapy were the significant independent factors associated with deaths (p < 0.001). Patient's follow-up was generally poor and data on long-term survivals were not available as more than two-thirds of patients were lost to follow up. CONCLUSION: Kaposi's sarcoma is the most common malignant vascular tumor and HIV/AIDS- related cancer in our region. There is an urgent need to develop health education programmes to enhance the understanding of this disease and how it spreads, particularly among the younger generation."
p5092
sS'AD'
p5093
S'Department of Surgery, Bugando Medical Centre, Mwanza, Tanzania. drphillipoleo@yahoo.com. Department of Surgery, Bugando Medical Centre, Mwanza, Tanzania. fidelismbunda@ymail.com. Department of Pathology, Catholic University of Health and Allied Science-Bugando, Mwanza, Tanzania. prambau@bugando.ac.tz. Department of Internal Medicine, Catholic University of Health and Allied Science-Bugando, Mwanza, Tanzania. hjaka2@hotmail.com. Department of Oncology, Bugando Medical Centre, Mwanza, Tanzania. pnmasalu4@gmail.com. Department of Microbiology, Catholic University of Health and Allied Science-Bugando, Mwanza, Tanzania. mmmirambo@gmail.com. Department of Microbiology, Catholic University of Health and Allied Science-Bugando, Mwanza, Tanzania. mushimartha@gmail.com. Department of Internal Medicine, Catholic University of Health and Allied Science-Bugando, Mwanza, Tanzania. samuelkalluvya@yahoo.com.'
p5094
sS'DEP'
p5095
S'20150915'
p5096
sS'VI'
p5097
S'8'
sS'IS'
p5098
S'1756-0500 (Electronic) 1756-0500 (Linking)'
p5099
sS'JID'
p5100
S'101462768'
p5101
sS'DA'
p5102
S'20150916'
p5103
sS'AU'
p5104
(lp5105
S'Chalya PL'
p5106
aS'Mbunda F'
p5107
aS'Rambau PF'
p5108
aS'Jaka H'
p5109
aS'Masalu N'
p5110
aS'Mirambo M'
p5111
aS'Mushi MF'
p5112
aS'Kalluvya SE'
p5113
asS'PST'
p5114
S'epublish'
p5115
sS'AID'
p5116
(lp5117
S'10.1186/s13104-015-1348-9 [doi]'
p5118
aS'10.1186/s13104-015-1348-9 [pii]'
p5119
asS'CRDT'
p5120
(lp5121
S'2015/09/17 06:00'
p5122
asS'DP'
p5123
S'2015'
p5124
sS'MHDA'
p5125
S'2016/06/14 06:00'
p5126
sS'PHST'
p5127
(lp5128
S'2014/11/12 [received]'
p5129
aS'2015/08/17 [accepted]'
p5130
aS'2015/09/15 [aheadofprint]'
p5131
asS'OWN'
p5132
S'NLM'
p5133
sS'PT'
p5134
(lp5135
S'Journal Article'
p5136
asS'LA'
p5137
(lp5138
S'eng'
p5139
asS'MH'
p5140
(lp5141
S'Adolescent'
p5142
aS'Adult'
p5143
aS'Aged'
p5144
aS'Child'
p5145
aS'Child, Preschool'
p5146
aS'Female'
p5147
aS'Follow-Up Studies'
p5148
aS'*Hospitals'
p5149
aS'Humans'
p5150
aS'Male'
p5151
aS'Middle Aged'
p5152
aS'Sarcoma, Kaposi/epidemiology/pathology'
p5153
aS'Tanzania/epidemiology'
p5154
aS'*Tertiary Healthcare'
p5155
aS'Treatment Outcome'
p5156
aS'Young Adult'
p5157
asS'DCOM'
p5158
S'20160613'
p5159
sS'EDAT'
p5160
S'2015/09/17 06:00'
p5161
sS'JT'
p5162
S'BMC research notes'
p5163
sS'SO'
p5164
S'BMC Res Notes. 2015 Sep 15;8:440. doi: 10.1186/s13104-015-1348-9.'
p5165
sS'FAU'
p5166
(lp5167
S'Chalya, Phillipo L'
p5168
aS'Mbunda, Fidelis'
p5169
aS'Rambau, Peter F'
p5170
aS'Jaka, Hyasinta'
p5171
aS'Masalu, Nestory'
p5172
aS'Mirambo, Mariam'
p5173
aS'Mushi, Martha F'
p5174
aS'Kalluvya, Samuel E'
p5175
asS'TI'
p5176
S"Kaposi's sarcoma: a 10-year experience with 248 patients at a single tertiary care hospital in Tanzania."
p5177
sS'SB'
p5178
S'IM'
p5179
sS'PMID'
p5180
S'26374100'
p5181
sS'TA'
p5182
S'BMC Res Notes'
p5183
sS'PL'
p5184
S'England'
p5185
sS'PG'
p5186
S'440'
p5187
stRp5188
ag2
(g3
g4
(dp5189
S'LID'
p5190
S'10.1371/journal.pone.0137666 [doi]'
p5191
sS'STAT'
p5192
S'MEDLINE'
p5193
sS'DEP'
p5194
S'20150914'
p5195
sS'DA'
p5196
S'20150915'
p5197
sS'AID'
p5198
(lp5199
S'10.1371/journal.pone.0137666 [doi]'
p5200
aS'PONE-D-15-23819 [pii]'
p5201
asS'CRDT'
p5202
(lp5203
S'2015/09/15 06:00'
p5204
asS'DP'
p5205
S'2015'
p5206
sS'AD'
p5207
S'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America. Desmond Tutu HIV Foundation, University of Cape Town, Cape Town, South Africa. Aurum Institute for Health Research, Johannesburg, South Africa; School of Public Health, University of Witwatersrand, Johannesburg, South Africa; London School of Hygiene and Tropical Medicine, London, United Kingdom. Mecru Clinical Research Unit, Sefako Makgatho Health Sciences University, Pretoria, South Africa. School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal and National Health Laboratory Service, Durban, South Africa. Perinatal HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa. Desmond Tutu HIV Foundation, University of Cape Town, Cape Town, South Africa. Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa; School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal and National Health Laboratory Service, Durban, South Africa. Aurum Institute Clinical Research Site, Klerksdorp, South Africa. Mecru Clinical Research Unit, Sefako Makgatho Health Sciences University, Pretoria, South Africa. Vaccine Research Program, Division of AIDS, NIAID, NIH, Rockville, United States of America. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America. Merck Research Laboratories, West Point, Pennsylvania, United States of America. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America. Perinatal HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa; South African Medical Research Council, Cape Town, South Africa.'
p5208
sS'OWN'
p5209
S'NLM'
p5210
sS'PT'
p5211
(lp5212
S'Clinical Trial, Phase II'
p5213
aS'Journal Article'
p5214
aS'Randomized Controlled Trial'
p5215
aS'Research Support, N.I.H., Extramural'
p5216
asS'LA'
p5217
(lp5218
S'eng'
p5219
asS'FAU'
p5220
(lp5221
S'Moodie, Zoe'
p5222
aS'Metch, Barbara'
p5223
aS'Bekker, Linda-Gail'
p5224
aS'Churchyard, Gavin'
p5225
aS'Nchabeleng, Maphoshane'
p5226
aS'Mlisana, Koleka'
p5227
aS'Laher, Fatima'
p5228
aS'Roux, Surita'
p5229
aS'Mngadi, Kathryn'
p5230
aS'Innes, Craig'
p5231
aS'Mathebula, Matsontso'
p5232
aS'Allen, Mary'
p5233
aS'Bentley, Carter'
p5234
aS'Gilbert, Peter B'
p5235
aS'Robertson, Michael'
p5236
aS'Kublin, James'
p5237
aS'Corey, Lawrence'
p5238
aS'Gray, Glenda E'
p5239
asS'JT'
p5240
S'PloS one'
p5241
sS'LR'
p5242
S'20160909'
p5243
sS'PG'
p5244
S'e0137666'
p5245
sS'TI'
p5246
S'Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men.'
p5247
sS'RN'
p5248
(lp5249
S'0 (AIDS Vaccines)'
p5250
asS'PL'
p5251
S'United States'
p5252
sS'TA'
p5253
S'PLoS One'
p5254
sS'JID'
p5255
S'101285081'
p5256
sS'AB'
p5257
S'BACKGROUND: The Phase 2b double-blinded, randomized Phambili/HVTN 503 trial evaluated safety and efficacy of the MRK Ad5 gag/pol/nef subtype B HIV-1 preventive vaccine vs placebo in sexually active HIV-1 seronegative participants in South Africa. Enrollment and vaccinations stopped and participants were unblinded but continued follow-up when the Step study evaluating the same vaccine in the Americas, Caribbean, and Australia was unblinded for non-efficacy. Final Phambili analyses found more HIV-1 infections amongst vaccine than placebo recipients, impelling the HVTN 503-S recall study. METHODS: HVTN 503-S sought to enroll all 695 HIV-1 uninfected Phambili participants, provide HIV testing, risk reduction counseling, physical examination, risk behavior assessment and treatment assignment recall. After adding HVTN 503-S data, HIV-1 infection hazard ratios (HR vaccine vs. placebo) were estimated by Cox models. RESULTS: Of the 695 eligible, 465 (67%) enrolled with 230 from the vaccine group and 235 from the placebo group. 38% of the 184 Phambili dropouts were enrolled. Enrollment did not differ by treatment group, gender, or baseline HSV-2. With the additional 1286 person years of 503-S follow-up, the estimated HR over Phambili and HVTN 503-S follow-up was 1.52 (95% CI 1.08-2.15, p = 0.02, 82 vaccine/54 placebo infections). The HR was significant for men (HR = 2.75, 95% CI 1.49, 5.06, p = 0.001) but not for women (HR = 1.12, 95% CI 0.73, 1.72, p = 0.62). CONCLUSION: The additional follow-up from HVTN 503-S supported the Phambili finding of increased HIV-1 acquisition among vaccinated men and strengthened the evidence of lack of vaccine effect among women. TRIAL REGISTRATION: clinicaltrials.gov NCT00413725 SA National Health Research Database DOH-27-0207-1539.'
p5258
sS'GR'
p5259
(lp5260
S'UM1 AI068614/AI/NIAID NIH HHS/United States'
p5261
aS'UM1 AI068614/AI/NIAID NIH HHS/United States'
p5262
aS'UM1 AI068618/AI/NIAID NIH HHS/United States'
p5263
aS'UM1 AI068618/AI/NIAID NIH HHS/United States'
p5264
aS'UM1 AI068635/AI/NIAID NIH HHS/United States'
p5265
aS'UM1 AI068635/AI/NIAID NIH HHS/United States'
p5266
aS'UM1 AI069453/AI/NIAID NIH HHS/United States'
p5267
aS'UM1 AI069453/AI/NIAID NIH HHS/United States'
p5268
aS'UM1 AI069469/AI/NIAID NIH HHS/United States'
p5269
aS'UM1 AI069519/AI/NIAID NIH HHS/United States'
p5270
asS'IP'
p5271
S'9'
sS'IS'
p5272
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p5273
sS'PMC'
p5274
S'PMC4569275'
p5275
sS'DCOM'
p5276
S'20160606'
p5277
sS'AU'
p5278
(lp5279
S'Moodie Z'
p5280
aS'Metch B'
p5281
aS'Bekker LG'
p5282
aS'Churchyard G'
p5283
aS'Nchabeleng M'
p5284
aS'Mlisana K'
p5285
aS'Laher F'
p5286
aS'Roux S'
p5287
aS'Mngadi K'
p5288
aS'Innes C'
p5289
aS'Mathebula M'
p5290
aS'Allen M'
p5291
aS'Bentley C'
p5292
aS'Gilbert PB'
p5293
aS'Robertson M'
p5294
aS'Kublin J'
p5295
aS'Corey L'
p5296
aS'Gray GE'
p5297
asS'VI'
p5298
S'10'
p5299
sS'MHDA'
p5300
S'2016/06/09 06:00'
p5301
sS'PHST'
p5302
(lp5303
S'2015 [ecollection]'
p5304
aS'2015/06/02 [received]'
p5305
aS'2015/08/19 [accepted]'
p5306
aS'2015/09/14 [epublish]'
p5307
asS'OID'
p5308
(lp5309
S'NLM: PMC4569275'
p5310
asS'MH'
p5311
(lp5312
S'AIDS Vaccines/*administration & dosage/adverse effects/immunology'
p5313
aS'Double-Blind Method'
p5314
aS'Female'
p5315
aS'Follow-Up Studies'
p5316
aS'HIV Infections/*epidemiology/immunology/prevention & control'
p5317
aS'Humans'
p5318
aS'Male'
p5319
aS'Proportional Hazards Models'
p5320
aS'Risk Factors'
p5321
aS'South Africa'
p5322
aS'Treatment Outcome'
p5323
asS'EDAT'
p5324
S'2015/09/15 06:00'
p5325
sS'SI'
p5326
(lp5327
S'ClinicalTrials.gov/NCT00413725'
p5328
asS'SO'
p5329
S'PLoS One. 2015 Sep 14;10(9):e0137666. doi: 10.1371/journal.pone.0137666. eCollection 2015.'
p5330
sS'SB'
p5331
S'IM'
p5332
sS'PMID'
p5333
S'26368824'
p5334
sS'PST'
p5335
S'epublish'
p5336
stRp5337
ag2
(g3
g4
(dp5338
S'LID'
p5339
S'10.1016/j.ijid.2015.09.002 [doi] S1201-9712(15)00212-X [pii]'
p5340
sS'STAT'
p5341
S'MEDLINE'
p5342
sS'DEP'
p5343
S'20150907'
p5344
sS'CI'
p5345
(lp5346
S'Copyright (c) 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.'
p5347
asS'DA'
p5348
S'20151014'
p5349
sS'AID'
p5350
(lp5351
S'S1201-9712(15)00212-X [pii]'
p5352
aS'10.1016/j.ijid.2015.09.002 [doi]'
p5353
asS'CRDT'
p5354
(lp5355
S'2015/09/12 06:00'
p5356
asS'DP'
p5357
S'2015 Oct'
p5358
sS'OWN'
p5359
S'NLM'
p5360
sS'PT'
p5361
(lp5362
S'Journal Article'
p5363
aS"Research Support, U.S. Gov't, Non-P.H.S."
p5364
asS'LA'
p5365
(lp5366
S'eng'
p5367
asS'DCOM'
p5368
S'20160916'
p5369
sS'JT'
p5370
S'International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases'
p5371
sS'FAU'
p5372
(lp5373
S'Schnippel, Kathryn'
p5374
aS'Shearer, Kate'
p5375
aS'Evans, Denise'
p5376
aS'Berhanu, Rebecca'
p5377
aS"Dlamini, S'celo"
p5378
aS'Ndjeka, Norbert'
p5379
asS'TI'
p5380
S'Predictors of mortality and treatment success during treatment for rifampicin-resistant tuberculosis within the South African National TB Programme, 2009 to 2011: a cohort analysis of the national case register.'
p5381
sS'RN'
p5382
(lp5383
S'0 (Antitubercular Agents)'
p5384
aS'VJT6J7R4TR (Rifampin)'
p5385
asS'PL'
p5386
S'Canada'
p5387
sS'PG'
p5388
S'89-94'
p5389
sS'JID'
p5390
S'9610933'
p5391
sS'AB'
p5392
S'BACKGROUND: The South African Electronic Drug-Resistant Tuberculosis Register (EDRweb) is the national database of registered drug-resistant tuberculosis (DR-TB) cases. METHODS: This study was a retrospective, de-identified secondary analysis of EDRweb patients initiating treatment for rifampicin-resistant TB (January 2009 to September 2011). The relative risks of death and treatment success were estimated using modified Poisson regression with robust error estimation. RESULTS: Seventeen thousand six hundred and ninety-seven cases of DR-TB were registered and met the inclusion criteria; 52.0% (n=9207) were male and the median age was 35 years (interquartile range 27-43 years). Of the 9419 cases with HIV infection (53.2%), 7157 (76.0%) were on antiretroviral therapy. Most had undergone previous TB treatment (76.5%, n=13531). Multidrug-resistant TB was the most common diagnosis, at 80.6% (n=14272). No treatment outcome was available for 6934 patients (39.2%). For patients with outcomes, 4227 (39.4%) were successfully treated, 2987 (27.8%) died, 2533 (23.7%) were lost to follow-up, and 996 (9.3%) failed. Second-line drug resistance was the strongest predictor of death during DR-TB treatment; extensively drug-resistant TB patients were more likely to have died during treatment (adjusted relative risk 2.63, 95% confidence interval 2.45-2.84). CONCLUSIONS: Testing for second-line drug resistance at initiation of DR-TB treatment can identify patients most at risk of treatment failure and death and most in need of individualized treatment.'
p5393
sS'AD'
p5394
S'Right to Care, 5(th) floor Outspan House, 1006 Lenchen Avenue North, Centurion 0157, South Africa. Electronic address: kschnipp@gmail.com. Health Economics and Epidemiology Research Office, Department of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Health Economics and Epidemiology Research Office, Department of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Right to Care, 5(th) floor Outspan House, 1006 Lenchen Avenue North, Centurion 0157, South Africa; Health Economics and Epidemiology Research Office, Department of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. National TB Programme, South African National Department of Health, Pretoria, South Africa. National TB Programme, South African National Department of Health, Pretoria, South Africa.'
p5395
sS'VI'
p5396
S'39'
p5397
sS'IS'
p5398
S'1878-3511 (Electronic) 1201-9712 (Linking)'
p5399
sS'AU'
p5400
(lp5401
S'Schnippel K'
p5402
aS'Shearer K'
p5403
aS'Evans D'
p5404
aS'Berhanu R'
p5405
aS'Dlamini S'
p5406
aS'Ndjeka N'
p5407
asS'MHDA'
p5408
S'2016/09/17 06:00'
p5409
sS'PHST'
p5410
(lp5411
S'2015/06/20 [received]'
p5412
aS'2015/08/11 [revised]'
p5413
aS'2015/09/01 [accepted]'
p5414
aS'2015/09/07 [aheadofprint]'
p5415
asS'OT'
p5416
(lp5417
S'Extensively drug-resistant tuberculosis'
p5418
aS'Sub-Saharan Africa'
p5419
aS'TB/HIV co-infection'
p5420
asS'OTO'
p5421
(lp5422
S'NOTNLM'
p5423
asS'MH'
p5424
(lp5425
S'Adolescent'
p5426
aS'Adult'
p5427
aS'Antitubercular Agents/*therapeutic use'
p5428
aS'Cohort Studies'
p5429
aS'Female'
p5430
aS'HIV Infections/complications'
p5431
aS'Humans'
p5432
aS'Male'
p5433
aS'Middle Aged'
p5434
aS'Registries'
p5435
aS'Retrospective Studies'
p5436
aS'Rifampin/*therapeutic use'
p5437
aS'Treatment Outcome'
p5438
aS'Tuberculosis/complications/*drug therapy/mortality'
p5439
aS'Tuberculosis, Multidrug-Resistant/drug therapy'
p5440
aS'Young Adult'
p5441
asS'EDAT'
p5442
S'2015/09/12 06:00'
p5443
sS'SO'
p5444
S'Int J Infect Dis. 2015 Oct;39:89-94. doi: 10.1016/j.ijid.2015.09.002. Epub 2015 Sep 7.'
p5445
sS'SB'
p5446
S'IM'
p5447
sS'PMID'
p5448
S'26358856'
p5449
sS'TA'
p5450
S'Int J Infect Dis'
p5451
sS'PST'
p5452
S'ppublish'
p5453
stRp5454
ag2
(g3
g4
(dp5455
S'LID'
p5456
S'10.1186/s12889-015-2195-2 [doi]'
p5457
sS'STAT'
p5458
S'MEDLINE'
p5459
sS'DEP'
p5460
S'20150902'
p5461
sS'DA'
p5462
S'20150902'
p5463
sS'AID'
p5464
(lp5465
S'10.1186/s12889-015-2195-2 [doi]'
p5466
aS'10.1186/s12889-015-2195-2 [pii]'
p5467
asS'CRDT'
p5468
(lp5469
S'2015/09/03 06:00'
p5470
asS'DP'
p5471
S'2015'
p5472
sS'OWN'
p5473
S'NLM'
p5474
sS'PT'
p5475
(lp5476
S'Journal Article'
p5477
aS"Research Support, Non-U.S. Gov't"
p5478
asS'LA'
p5479
(lp5480
S'eng'
p5481
asS'DCOM'
p5482
S'20160321'
p5483
sS'JT'
p5484
S'BMC public health'
p5485
sS'LR'
p5486
S'20150905'
p5487
sS'FAU'
p5488
(lp5489
S'Nabukenya-Mudiope, Mary G'
p5490
aS'Kawuma, Herman Joseph'
p5491
aS'Brouwer, Miranda'
p5492
aS'Mudiope, Peter'
p5493
aS'Vassall, Anna'
p5494
asS'TI'
p5495
S"Tuberculosis retreatment 'others' in comparison with classical retreatment cases; a retrospective cohort review."
p5496
sS'RN'
p5497
(lp5498
S'0 (Antitubercular Agents)'
p5499
asS'PL'
p5500
S'England'
p5501
sS'PG'
p5502
S'840'
p5503
sS'JID'
p5504
S'100968562'
p5505
sS'AB'
p5506
S"BACKGROUND: Many of the countries in sub-Saharan Africa are still largely dependent on microscopy as the mainstay for diagnosis of tuberculosis (TB) including patients with previous history of TB treatment. The available guidance in management of TB retreatment cases is focused on bacteriologically confirmed TB retreatment cases leaving out those classified as retreatment 'others'. Retreatment 'others' refer to all TB cases who were previously treated but with unknown outcome of that previous treatment or who have returned to treatment with bacteriologically negative pulmonary or extra-pulmonary TB. This study was conducted in 11 regional referral hospitals (RRHs) serving high burden TB districts in Uganda to determine the profile and treatment success of TB retreatment 'others' in comparison with the classical retreatment cases. METHODS: A retrospective cohort review of routinely collected National TB and Leprosy Program (NTLP) facility data from 1 January to 31 December 2010. This study uses the term classical retreatment cases to refer to a combined group of bacteriologically confirmed relapse, return after failure and return after loss to follow-up cases as a distinct group from retreatment 'others'. Distribution of categorical characteristics were compared using Chi-squared test for difference between proportions. The log likelihood ratio test was used to assess the independent contribution of type of retreatment, human immunodeficiency virus (HIV) status, age group and sex to the models. RESULTS: Of the 6244 TB cases registered at the study sites, 733 (11.7%) were retreatment cases. Retreatment 'others' constituted 45.5% of retreatment cases. Co-infection with HIV was higher among retreatment 'others' (70.9%) than classical retreatment cases (53.5%). Treatment was successful in 410 (56.2%) retreatment cases. Retreatment 'others' were associated with reduced odds of success (AOR = 0.44, 95% CI 0.22,0.88) compared to classical cases. Lost to follow up was the commonest adverse outcome (38% of adverse outcomes) in all retreatment cases. Type of retreatment case, HIV status, and age were independently associated with treatment success. CONCLUSION: TB retreatment 'others' constitute a significant proportion of retreatment cases, with higher HIV prevalence and worse treatment success. There is need to review the diagnosis and management of retreatment 'others'."
p5507
sS'AD'
p5508
S'Track Tuberculosis Activity Project-Management Sciences for Health, Plot no. 15, Princess Anne Drive Bugolobi, P.O. Box 71419, Kampala, Uganda. marygmudiope@gmail.com. German Leprosy and Tuberculosis Relief Association, Kampala, Uganda. kawumahjs@gmail.com. Public Health and Tuberculosis Consultancy, Tilburg, The Netherlands. mbrouwer@phtbconsult.org. Uganda AIDS Commission, Kampala, Uganda. pmudiope@gmail.com. London School of Hygiene and Tropical Medicine, London, United Kingdom. Anna.Vassall@lshtm.ac.uk.'
p5509
sS'VI'
p5510
S'15'
p5511
sS'IS'
p5512
S'1471-2458 (Electronic) 1471-2458 (Linking)'
p5513
sS'PMC'
p5514
S'PMC4556407'
p5515
sS'AU'
p5516
(lp5517
S'Nabukenya-Mudiope MG'
p5518
aS'Kawuma HJ'
p5519
aS'Brouwer M'
p5520
aS'Mudiope P'
p5521
aS'Vassall A'
p5522
asS'MHDA'
p5523
S'2016/03/22 06:00'
p5524
sS'PHST'
p5525
(lp5526
S'2014/11/11 [received]'
p5527
aS'2015/08/27 [accepted]'
p5528
aS'2015/09/02 [aheadofprint]'
p5529
asS'OID'
p5530
(lp5531
S'NLM: PMC4556407'
p5532
asS'MH'
p5533
(lp5534
S'Adolescent'
p5535
aS'Adult'
p5536
aS'Aged, 80 and over'
p5537
aS'Antitubercular Agents/therapeutic use'
p5538
aS'*Drug Resistance, Bacterial'
p5539
aS'Female'
p5540
aS'Humans'
p5541
aS'Male'
p5542
aS'Middle Aged'
p5543
aS'Practice Guidelines as Topic'
p5544
aS'Prevalence'
p5545
aS'Retreatment'
p5546
aS'Retrospective Studies'
p5547
aS'Treatment Outcome'
p5548
aS'Tuberculosis, Multidrug-Resistant/*diagnosis/*drug therapy/epidemiology'
p5549
aS'Tuberculosis, Pulmonary/*diagnosis/*drug therapy/epidemiology'
p5550
aS'Uganda/epidemiology'
p5551
aS'Young Adult'
p5552
asS'EDAT'
p5553
S'2015/09/04 06:00'
p5554
sS'SO'
p5555
S'BMC Public Health. 2015 Sep 2;15:840. doi: 10.1186/s12889-015-2195-2.'
p5556
sS'SB'
p5557
S'IM'
p5558
sS'PMID'
p5559
S'26330223'
p5560
sS'TA'
p5561
S'BMC Public Health'
p5562
sS'PST'
p5563
S'epublish'
p5564
stRp5565
ag2
(g3
g4
(dp5566
S'LID'
p5567
S'10.1093/aje/kwv083 [doi]'
p5568
sS'STAT'
p5569
S'MEDLINE'
p5570
sS'DEP'
p5571
S'20150826'
p5572
sS'CI'
p5573
(lp5574
S'(c) The Author 2015. Published by Oxford University Press on behalf of the Johns'
p5575
aS'Hopkins Bloomberg School of Public Health.'
p5576
asS'DA'
p5577
S'20150925'
p5578
sS'AID'
p5579
(lp5580
S'kwv083 [pii]'
p5581
aS'10.1093/aje/kwv083 [doi]'
p5582
asS'CRDT'
p5583
(lp5584
S'2015/08/29 06:00'
p5585
asS'DP'
p5586
S'2015 Oct 1'
p5587
sS'CN'
p5588
(lp5589
S'DART Trial Team'
p5590
asS'OWN'
p5591
S'NLM'
p5592
sS'PT'
p5593
(lp5594
S'Journal Article'
p5595
aS'Randomized Controlled Trial'
p5596
aS'Research Support, N.I.H., Extramural'
p5597
aS"Research Support, Non-U.S. Gov't"
p5598
asS'LA'
p5599
(lp5600
S'eng'
p5601
asS'FAU'
p5602
(lp5603
S'Ford, Deborah'
p5604
aS'Robins, James M'
p5605
aS'Petersen, Maya L'
p5606
aS'Gibb, Diana M'
p5607
aS'Gilks, Charles F'
p5608
aS'Mugyenyi, Peter'
p5609
aS'Grosskurth, Heiner'
p5610
aS'Hakim, James'
p5611
aS'Katabira, Elly'
p5612
aS'Babiker, Abdel G'
p5613
aS'Walker, A Sarah'
p5614
asS'JT'
p5615
S'American journal of epidemiology'
p5616
sS'LR'
p5617
S'20160322'
p5618
sS'PG'
p5619
S'633-43'
p5620
sS'TI'
p5621
S'The Impact of Different CD4 Cell-Count Monitoring and Switching Strategies on Mortality in HIV-Infected African Adults on Antiretroviral Therapy: An Application of Dynamic Marginal Structural Models.'
p5622
sS'RN'
p5623
(lp5624
S'0 (Anti-Retroviral Agents)'
p5625
asS'PL'
p5626
S'United States'
p5627
sS'TA'
p5628
S'Am J Epidemiol'
p5629
sS'FIR'
p5630
(lp5631
S'Grosskurth, H'
p5632
aS'Munderi, P'
p5633
aS'Kabuye, G'
p5634
aS'Nsibambi, D'
p5635
aS'Kasirye, R'
p5636
aS'Zalwango, E'
p5637
aS'Nakazibwe, M'
p5638
aS'Kikaire, B'
p5639
aS'Nassuna, G'
p5640
aS'Massa, R'
p5641
aS'Fadhiru, K'
p5642
aS'Namyalo, M'
p5643
aS'Zalwango, A'
p5644
aS'Generous, L'
p5645
aS'Khauka, P'
p5646
aS'Rutikarayo, N'
p5647
aS'Nakahima, W'
p5648
aS'Mugisha, A'
p5649
aS'Todd, J'
p5650
aS'Levin, J'
p5651
aS'Muyingo, S'
p5652
aS'Ruberantwari, A'
p5653
aS'Kaleebu, P'
p5654
aS'Yirrell, D'
p5655
aS'Ndembi, N'
p5656
aS'Lyagoba, F'
p5657
aS'Hughes, P'
p5658
aS'Aber, M'
p5659
aS'Medina Lara, A'
p5660
aS'Foster, S'
p5661
aS'Amurwon, J'
p5662
aS'Nyanzi Wakholi, B'
p5663
aS'Mugyenyi, P'
p5664
aS'Kityo, C'
p5665
aS'Ssali, F'
p5666
aS'Tumukunde, D'
p5667
aS'Otim, T'
p5668
aS'Kabanda, J'
p5669
aS'Musana, H'
p5670
aS'Akao, J'
p5671
aS'Kyomugisha, H'
p5672
aS'Byamukama, A'
p5673
aS'Sabiiti, J'
p5674
aS'Komugyena, J'
p5675
aS'Wavamunno, P'
p5676
aS'Mukiibi, S'
p5677
aS'Drasiku, A'
p5678
aS'Byaruhanga, R'
p5679
aS'Labeja, O'
p5680
aS'Katundu, P'
p5681
aS'Tugume, S'
p5682
aS'Awio, P'
p5683
aS'Namazzi, A'
p5684
aS'Bakeinyaga, G T'
p5685
aS'Katabira, H'
p5686
aS'Abaine, D'
p5687
aS'Tukamushaba, J'
p5688
aS'Anywar, W'
p5689
aS'Ojiambo, W'
p5690
aS'Angweng, E'
p5691
aS'Murungi, S'
p5692
aS'Haguma, W'
p5693
aS'Atwiine, S'
p5694
aS'Kigozi, J'
p5695
aS'Latif, A'
p5696
aS'Hakim, J'
p5697
aS'Robertson, V'
p5698
aS'Reid, A'
p5699
aS'Chidziva, E'
p5700
aS'Bulaya-Tembo, R'
p5701
aS'Musoro, G'
p5702
aS'Taziwa, F'
p5703
aS'Chimbetete, C'
p5704
aS'Chakonza, L'
p5705
aS'Mawora, A'
p5706
aS'Muvirimi, C'
p5707
aS'Tinago, G'
p5708
aS'Svovanapasis, P'
p5709
aS'Simango, M'
p5710
aS'Chirema, O'
p5711
aS'Machingura, J'
p5712
aS'Mutsai, S'
p5713
aS'Phiri, M'
p5714
aS'Bafana, T'
p5715
aS'Chirara, M'
p5716
aS'Muchabaiwa, L'
p5717
aS'Muzambi, M'
p5718
aS'Katabira, E'
p5719
aS'Ronald, A'
p5720
aS'Kambungu, A'
p5721
aS'Lutwama, F'
p5722
aS'Nanfuka, A'
p5723
aS'Walusimbi, J'
p5724
aS'Nabankema, E'
p5725
aS'Nalumenya, R'
p5726
aS'Namuli, T'
p5727
aS'Kulume, R'
p5728
aS'Namata, I'
p5729
aS'Nyachwo, L'
p5730
aS'Florence, A'
p5731
aS'Kusiima, A'
p5732
aS'Lubwama, E'
p5733
aS'Nairuba, R'
p5734
aS'Oketta, F'
p5735
aS'Buluma, E'
p5736
aS'Waita, R'
p5737
aS'Ojiambo, H'
p5738
aS'Sadik, F'
p5739
aS'Wanyama, J'
p5740
aS'Nabongo, P'
p5741
aS'Ochai, R'
p5742
aS'Muhweezi, D'
p5743
aS'Gilks, C'
p5744
aS'Boocock, K'
p5745
aS'Puddephatt, C'
p5746
aS'Winogron, D'
p5747
aS'Bohannon, J'
p5748
aS'Darbyshire, J'
p5749
aS'Gibb, D M'
p5750
aS'Burke, A'
p5751
aS'Bray, D'
p5752
aS'Babiker, A'
p5753
aS'Walker, A S'
p5754
aS'Wilkes, H'
p5755
aS'Rauchenberger, M'
p5756
aS'Sheehan, S'
p5757
aS'Peto, L'
p5758
aS'Taylor, K'
p5759
aS'Spyer, M'
p5760
aS'Ferrier, A'
p5761
aS'Naidoo, B'
p5762
aS'Dunn, D'
p5763
aS'Goodall, R'
p5764
aS'Nanfuka, R'
p5765
aS'Mufuka-Kapuya, C'
p5766
aS'Kaleebu, P'
p5767
aS'Pillay, D'
p5768
aS'Robertson, V'
p5769
aS'Yirrell, D'
p5770
aS'Tugume, S'
p5771
aS'Chirara, M'
p5772
aS'Katundu, P'
p5773
aS'Ndembi, N'
p5774
aS'Lyagoba, F'
p5775
aS'Dunn, D'
p5776
aS'Goodall, R'
p5777
aS'McCormick, A'
p5778
aS'Medina Lara, A'
p5779
aS'Foster, S'
p5780
aS'Amurwon, J'
p5781
aS'Nyanzi Wakholi, B'
p5782
aS'Kigozi, J'
p5783
aS'Muchabaiwa, L'
p5784
aS'Muzambi, M'
p5785
aS'Weller, I'
p5786
aS'Babiker, A'
p5787
aS'Bahendeka, S'
p5788
aS'Bassett, M'
p5789
aS'Chogo Wapakhabulo, A'
p5790
aS'Darbyshire, J'
p5791
aS'Gazzard, B'
p5792
aS'Gilks, C'
p5793
aS'Grosskurth, H'
p5794
aS'Hakim, J'
p5795
aS'Latif, A'
p5796
aS'Mapuchere, C'
p5797
aS'Mugurungi, O'
p5798
aS'Mugyenyi, P'
p5799
aS'Burke, C'
p5800
aS'Jones, S'
p5801
aS'Newland, C'
p5802
aS'Rahim, S'
p5803
aS'Rooney, J'
p5804
aS'Smith, M'
p5805
aS'Snowden, W'
p5806
aS'Steens, J-M'
p5807
aS'Breckenridge, A'
p5808
aS'McLaren, A'
p5809
aS'Hill, C'
p5810
aS'Matenga, J'
p5811
aS'Pozniak, A'
p5812
aS'Serwadda, D'
p5813
aS'Peto, T'
p5814
aS'Palfreeman, A'
p5815
aS'Borok, M'
p5816
aS'Katabira, E'
p5817
asS'JID'
p5818
S'7910653'
p5819
sS'AB'
p5820
S'In Africa, antiretroviral therapy (ART) is delivered with limited laboratory monitoring, often none. In 2003-2004, investigators in the Development of Antiretroviral Therapy in Africa (DART) Trial randomized persons initiating ART in Uganda and Zimbabwe to either laboratory and clinical monitoring (LCM) or clinically driven monitoring (CDM). CD4 cell counts were measured every 12 weeks in both groups but were only returned to treating clinicians for management in the LCM group. Follow-up continued through 2008. In observational analyses, dynamic marginal structural models on pooled randomized groups were used to estimate survival under different monitoring-frequency and clinical/immunological switching strategies. Assumptions included no direct effect of randomized group on mortality or confounders and no unmeasured confounders which influenced treatment switch and mortality or treatment switch and time-dependent covariates. After 48 weeks of first-line ART, 2,946 individuals contributed 11,351 person-years of follow-up, 625 switches, and 179 deaths. The estimated survival probability after a further 240 weeks for post-48-week switch at the first CD4 cell count less than 100 cells/mm(3) or non-Candida World Health Organization stage 4 event (with CD4 count <250) was 0.96 (95% confidence interval (CI): 0.94, 0.97) with 12-weekly CD4 testing, 0.96 (95% CI: 0.95, 0.97) with 24-weekly CD4 testing, 0.95 (95% CI: 0.93, 0.96) with a single CD4 test at 48 weeks (baseline), and 0.92 (95% CI: 0.91, 0.94) with no CD4 testing. Comparing randomized groups by 48-week CD4 count, the mortality risk associated with CDM versus LCM was greater in persons with CD4 counts of <100 (hazard ratio = 2.4, 95% CI: 1.3, 4.3) than in those with CD4 counts of >/=100 (hazard ratio = 1.1, 95% CI: 0.8, 1.7; interaction P = 0.04). These findings support a benefit from identifying patients immunologically failing first-line ART at 48 weeks.'
p5821
sS'GR'
p5822
(lp5823
S'5 R37 AI032475/AI/NIAID NIH HHS/United States'
p5824
aS'MC_U122886352/Medical Research Council/United Kingdom'
p5825
aS'Medical Research Council/United Kingdom'
p5826
asS'IP'
p5827
S'7'
sS'IS'
p5828
S'1476-6256 (Electronic) 0002-9262 (Linking)'
p5829
sS'IR'
p5830
(lp5831
S'Grosskurth H'
p5832
aS'Munderi P'
p5833
aS'Kabuye G'
p5834
aS'Nsibambi D'
p5835
aS'Kasirye R'
p5836
aS'Zalwango E'
p5837
aS'Nakazibwe M'
p5838
aS'Kikaire B'
p5839
aS'Nassuna G'
p5840
aS'Massa R'
p5841
aS'Fadhiru K'
p5842
aS'Namyalo M'
p5843
aS'Zalwango A'
p5844
aS'Generous L'
p5845
aS'Khauka P'
p5846
aS'Rutikarayo N'
p5847
aS'Nakahima W'
p5848
aS'Mugisha A'
p5849
aS'Todd J'
p5850
aS'Levin J'
p5851
aS'Muyingo S'
p5852
aS'Ruberantwari A'
p5853
aS'Kaleebu P'
p5854
aS'Yirrell D'
p5855
aS'Ndembi N'
p5856
aS'Lyagoba F'
p5857
aS'Hughes P'
p5858
aS'Aber M'
p5859
aS'Medina Lara A'
p5860
aS'Foster S'
p5861
aS'Amurwon J'
p5862
aS'Nyanzi Wakholi B'
p5863
aS'Mugyenyi P'
p5864
aS'Kityo C'
p5865
aS'Ssali F'
p5866
aS'Tumukunde D'
p5867
aS'Otim T'
p5868
aS'Kabanda J'
p5869
aS'Musana H'
p5870
aS'Akao J'
p5871
aS'Kyomugisha H'
p5872
aS'Byamukama A'
p5873
aS'Sabiiti J'
p5874
aS'Komugyena J'
p5875
aS'Wavamunno P'
p5876
aS'Mukiibi S'
p5877
aS'Drasiku A'
p5878
aS'Byaruhanga R'
p5879
aS'Labeja O'
p5880
aS'Katundu P'
p5881
aS'Tugume S'
p5882
aS'Awio P'
p5883
aS'Namazzi A'
p5884
aS'Bakeinyaga GT'
p5885
aS'Katabira H'
p5886
aS'Abaine D'
p5887
aS'Tukamushaba J'
p5888
aS'Anywar W'
p5889
aS'Ojiambo W'
p5890
aS'Angweng E'
p5891
aS'Murungi S'
p5892
aS'Haguma W'
p5893
aS'Atwiine S'
p5894
aS'Kigozi J'
p5895
aS'Latif A'
p5896
aS'Hakim J'
p5897
aS'Robertson V'
p5898
aS'Reid A'
p5899
aS'Chidziva E'
p5900
aS'Bulaya-Tembo R'
p5901
aS'Musoro G'
p5902
aS'Taziwa F'
p5903
aS'Chimbetete C'
p5904
aS'Chakonza L'
p5905
aS'Mawora A'
p5906
aS'Muvirimi C'
p5907
aS'Tinago G'
p5908
aS'Svovanapasis P'
p5909
aS'Simango M'
p5910
aS'Chirema O'
p5911
aS'Machingura J'
p5912
aS'Mutsai S'
p5913
aS'Phiri M'
p5914
aS'Bafana T'
p5915
aS'Chirara M'
p5916
aS'Muchabaiwa L'
p5917
aS'Muzambi M'
p5918
aS'Katabira E'
p5919
aS'Ronald A'
p5920
aS'Kambungu A'
p5921
aS'Lutwama F'
p5922
aS'Nanfuka A'
p5923
aS'Walusimbi J'
p5924
aS'Nabankema E'
p5925
aS'Nalumenya R'
p5926
aS'Namuli T'
p5927
aS'Kulume R'
p5928
aS'Namata I'
p5929
aS'Nyachwo L'
p5930
aS'Florence A'
p5931
aS'Kusiima A'
p5932
aS'Lubwama E'
p5933
aS'Nairuba R'
p5934
aS'Oketta F'
p5935
aS'Buluma E'
p5936
aS'Waita R'
p5937
aS'Ojiambo H'
p5938
aS'Sadik F'
p5939
aS'Wanyama J'
p5940
aS'Nabongo P'
p5941
aS'Ochai R'
p5942
aS'Muhweezi D'
p5943
aS'Gilks C'
p5944
aS'Boocock K'
p5945
aS'Puddephatt C'
p5946
aS'Winogron D'
p5947
aS'Bohannon J'
p5948
aS'Darbyshire J'
p5949
aS'Gibb DM'
p5950
aS'Burke A'
p5951
aS'Bray D'
p5952
aS'Babiker A'
p5953
aS'Walker AS'
p5954
aS'Wilkes H'
p5955
aS'Rauchenberger M'
p5956
aS'Sheehan S'
p5957
aS'Peto L'
p5958
aS'Taylor K'
p5959
aS'Spyer M'
p5960
aS'Ferrier A'
p5961
aS'Naidoo B'
p5962
aS'Dunn D'
p5963
aS'Goodall R'
p5964
aS'Nanfuka R'
p5965
aS'Mufuka-Kapuya C'
p5966
aS'Kaleebu P'
p5967
aS'Pillay D'
p5968
aS'Robertson V'
p5969
aS'Yirrell D'
p5970
aS'Tugume S'
p5971
aS'Chirara M'
p5972
aS'Katundu P'
p5973
aS'Ndembi N'
p5974
aS'Lyagoba F'
p5975
aS'Dunn D'
p5976
aS'Goodall R'
p5977
aS'McCormick A'
p5978
aS'Medina Lara A'
p5979
aS'Foster S'
p5980
aS'Amurwon J'
p5981
aS'Nyanzi Wakholi B'
p5982
aS'Kigozi J'
p5983
aS'Muchabaiwa L'
p5984
aS'Muzambi M'
p5985
aS'Weller I'
p5986
aS'Babiker A'
p5987
aS'Bahendeka S'
p5988
aS'Bassett M'
p5989
aS'Chogo Wapakhabulo A'
p5990
aS'Darbyshire J'
p5991
aS'Gazzard B'
p5992
aS'Gilks C'
p5993
aS'Grosskurth H'
p5994
aS'Hakim J'
p5995
aS'Latif A'
p5996
aS'Mapuchere C'
p5997
aS'Mugurungi O'
p5998
aS'Mugyenyi P'
p5999
aS'Burke C'
p6000
aS'Jones S'
p6001
aS'Newland C'
p6002
aS'Rahim S'
p6003
aS'Rooney J'
p6004
aS'Smith M'
p6005
aS'Snowden W'
p6006
aS'Steens JM'
p6007
aS'Breckenridge A'
p6008
aS'McLaren A'
p6009
aS'Hill C'
p6010
aS'Matenga J'
p6011
aS'Pozniak A'
p6012
aS'Serwadda D'
p6013
aS'Peto T'
p6014
aS'Palfreeman A'
p6015
aS'Borok M'
p6016
aS'Katabira E'
p6017
asS'DCOM'
p6018
S'20160108'
p6019
sS'AU'
p6020
(lp6021
S'Ford D'
p6022
aS'Robins JM'
p6023
aS'Petersen ML'
p6024
aS'Gibb DM'
p6025
aS'Gilks CF'
p6026
aS'Mugyenyi P'
p6027
aS'Grosskurth H'
p6028
aS'Hakim J'
p6029
aS'Katabira E'
p6030
aS'Babiker AG'
p6031
aS'Walker AS'
p6032
asS'VI'
p6033
S'182'
p6034
sS'MHDA'
p6035
S'2016/01/09 06:00'
p6036
sS'PHST'
p6037
(lp6038
S'2014/08/30 [received]'
p6039
aS'2015/03/27 [accepted]'
p6040
aS'2015/08/26 [aheadofprint]'
p6041
asS'OTO'
p6042
(lp6043
S'NOTNLM'
p6044
asS'OID'
p6045
(lp6046
S'NLM: PMC4581589'
p6047
asS'MH'
p6048
(lp6049
S'Adult'
p6050
aS'Anti-Retroviral Agents/*administration & dosage'
p6051
aS'CD4 Lymphocyte Count'
p6052
aS'Female'
p6053
aS'HIV Infections/*drug therapy/mortality'
p6054
aS'Humans'
p6055
aS'Male'
p6056
aS'Models, Statistical'
p6057
aS'Uganda/epidemiology'
p6058
aS'Zimbabwe/epidemiology'
p6059
asS'EDAT'
p6060
S'2015/09/01 06:00'
p6061
sS'PMC'
p6062
S'PMC4581589'
p6063
sS'SO'
p6064
S'Am J Epidemiol. 2015 Oct 1;182(7):633-43. doi: 10.1093/aje/kwv083. Epub 2015 Aug 26.'
p6065
sS'SB'
p6066
S'IM'
p6067
sS'PMID'
p6068
S'26316598'
p6069
sS'OT'
p6070
(lp6071
S'Africa'
p6072
aS'HIV'
p6073
aS'antiretroviral therapy'
p6074
aS'drug switching'
p6075
aS'dynamic marginal structural models'
p6076
aS'monitoring'
p6077
asS'PST'
p6078
S'ppublish'
p6079
stRp6080
ag2
(g3
g4
(dp6081
S'LID'
p6082
S'10.1371/journal.pone.0136839 [doi]'
p6083
sS'STAT'
p6084
S'MEDLINE'
p6085
sS'DEP'
p6086
S'20150827'
p6087
sS'DA'
p6088
S'20150828'
p6089
sS'AID'
p6090
(lp6091
S'10.1371/journal.pone.0136839 [doi]'
p6092
aS'PONE-D-15-22477 [pii]'
p6093
asS'CRDT'
p6094
(lp6095
S'2015/08/28 06:00'
p6096
asS'DP'
p6097
S'2015'
p6098
sS'EIN'
p6099
(lp6100
S'PLoS One. 2015;10(9):e0139295. Izadnegahdar, Raza [corrected to Izadnegahdar,'
p6101
aS'Rasa]. PMID: 26402716'
p6102
asS'OWN'
p6103
S'NLM'
p6104
sS'PT'
p6105
(lp6106
S'Journal Article'
p6107
aS'Research Support, N.I.H., Extramural'
p6108
aS"Research Support, Non-U.S. Gov't"
p6109
asS'LA'
p6110
(lp6111
S'eng'
p6112
asS'FAU'
p6113
(lp6114
S'King, Carina'
p6115
aS'McCollum, Eric D'
p6116
aS'Mankhambo, Limangeni'
p6117
aS'Colbourn, Tim'
p6118
aS'Beard, James'
p6119
aS'Hay Burgess, Debbie C'
p6120
aS'Costello, Anthony'
p6121
aS'Izadnegahdar, Rasa'
p6122
aS'Lufesi, Norman'
p6123
aS'Masache, Gibson'
p6124
aS'Mwansambo, Charles'
p6125
aS'Nambiar, Bejoy'
p6126
aS'Johnson, Eric'
p6127
aS'Platt, Robert'
p6128
aS'Mukanga, David'
p6129
asS'JT'
p6130
S'PloS one'
p6131
sS'LR'
p6132
S'20150904'
p6133
sS'PG'
p6134
S'e0136839'
p6135
sS'TI'
p6136
S'Can We Predict Oral Antibiotic Treatment Failure in Children with Fast-Breathing Pneumonia Managed at the Community Level? A Prospective Cohort Study in Malawi.'
p6137
sS'RN'
p6138
(lp6139
S'0 (Anti-Bacterial Agents)'
p6140
aS'8064-90-2 (Trimethoprim, Sulfamethoxazole Drug Combination)'
p6141
asS'PL'
p6142
S'United States'
p6143
sS'TA'
p6144
S'PLoS One'
p6145
sS'JID'
p6146
S'101285081'
p6147
sS'AB'
p6148
S'BACKGROUND: Pneumonia is the leading cause of infectious death amongst children globally, with the highest burden in Africa. Early identification of children at risk of treatment failure in the community and prompt referral could lower mortality. A number of clinical markers have been independently associated with oral antibiotic failure in childhood pneumonia. This study aimed to develop a prognostic model for fast-breathing pneumonia treatment failure in sub-Saharan Africa. METHOD: We prospectively followed a cohort of children (2-59 months), diagnosed by community health workers with fast-breathing pneumonia using World Health Organisation (WHO) integrated community case management guidelines. Cases were followed at days 5 and 14 by study data collectors, who assessed a range of pre-determined clinical features for treatment outcome. We built the prognostic model using eight pre-defined parameters, using multivariable logistic regression, validated through bootstrapping. RESULTS: We assessed 1,542 cases of which 769 were included (32% ineligible; 19% defaulted). The treatment failure rate was 15% at day 5 and relapse was 4% at day 14. Concurrent malaria diagnosis (OR: 1.62; 95% CI: 1.06, 2.47) and moderate malnutrition (OR: 1.88; 95% CI: 1.09, 3.26) were associated with treatment failure. The model demonstrated poor calibration and discrimination (c-statistic: 0.56). CONCLUSION: This study suggests that it may be difficult to create a pragmatic community-level prognostic child pneumonia tool based solely on clinical markers and pulse oximetry in an HIV and malaria endemic setting. Further work is needed to identify more accurate and reliable referral algorithms that remain feasible for use by community health workers.'
p6149
sS'GR'
p6150
(lp6151
S'T32 HL072748/HL/NHLBI NIH HHS/United States'
p6152
aS'T32 HL072748-11/HL/NHLBI NIH HHS/United States'
p6153
asS'IP'
p6154
S'8'
sS'IS'
p6155
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p6156
sS'PMC'
p6157
S'PMC4551481'
p6158
sS'DCOM'
p6159
S'20160524'
p6160
sS'AU'
p6161
(lp6162
S'King C'
p6163
aS'McCollum ED'
p6164
aS'Mankhambo L'
p6165
aS'Colbourn T'
p6166
aS'Beard J'
p6167
aS'Hay Burgess DC'
p6168
aS'Costello A'
p6169
aS'Izadnegahdar R'
p6170
aS'Lufesi N'
p6171
aS'Masache G'
p6172
aS'Mwansambo C'
p6173
aS'Nambiar B'
p6174
aS'Johnson E'
p6175
aS'Platt R'
p6176
aS'Mukanga D'
p6177
asS'AD'
p6178
S'Institute for Global Health, University College London, London, United Kingdom. Institute for Global Health, University College London, London, United Kingdom; Department of Pediatrics, Division of Pulmonology, Johns Hopkins School of Medicine, Baltimore, Maryland, United States of America. Parent and Child Health Initiative, Lilongwe, Malawi. Institute for Global Health, University College London, London, United Kingdom. Institute for Global Health, University College London, London, United Kingdom. Bill & Melinda Gates Foundation, Seattle, Washington, United States of America. Institute for Global Health, University College London, London, United Kingdom. Bill & Melinda Gates Foundation, Seattle, Washington, United States of America. Acute Respiratory Infection Unit, Ministry of Health, Lilongwe, Malawi. Parent and Child Health Initiative, Lilongwe, Malawi. Ministry of Health, Lilongwe, Malawi. Institute for Global Health, University College London, London, United Kingdom. Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon, United States of America. McGill University, Montreal, Canada. Bill & Melinda Gates Foundation, Seattle, Washington, United States of America.'
p6179
sS'VI'
p6180
S'10'
p6181
sS'MHDA'
p6182
S'2016/05/25 06:00'
p6183
sS'PHST'
p6184
(lp6185
S'2015 [ecollection]'
p6186
aS'2015/06/02 [received]'
p6187
aS'2015/08/10 [accepted]'
p6188
aS'2015/08/27 [epublish]'
p6189
asS'OID'
p6190
(lp6191
S'NLM: PMC4551481'
p6192
asS'MH'
p6193
(lp6194
S'Administration, Oral'
p6195
aS'Anti-Bacterial Agents/administration & dosage/*therapeutic use'
p6196
aS'Child, Preschool'
p6197
aS'Cohort Studies'
p6198
aS'Community Health Workers'
p6199
aS'Humans'
p6200
aS'Infant'
p6201
aS'Malawi'
p6202
aS'*Models, Biological'
p6203
aS'Patient Compliance'
p6204
aS'Pneumonia/*drug therapy'
p6205
aS'Prospective Studies'
p6206
aS'Respiration'
p6207
aS'Treatment Failure'
p6208
aS'Trimethoprim, Sulfamethoxazole Drug Combination/administration & dosage/*therapeutic use'
p6209
asS'EDAT'
p6210
S'2015/08/28 06:00'
p6211
sS'SO'
p6212
S'PLoS One. 2015 Aug 27;10(8):e0136839. doi: 10.1371/journal.pone.0136839. eCollection 2015.'
p6213
sS'SB'
p6214
S'IM'
p6215
sS'PMID'
p6216
S'26313752'
p6217
sS'PST'
p6218
S'epublish'
p6219
stRp6220
ag2
(g3
g4
(dp6221
S'LID'
p6222
S'10.3402/gha.v8.26652 [doi]'
p6223
sS'STAT'
p6224
S'MEDLINE'
p6225
sS'DEP'
p6226
S'20150817'
p6227
sS'DA'
p6228
S'20150820'
p6229
sS'AID'
p6230
(lp6231
S'26652 [pii]'
p6232
asS'CRDT'
p6233
(lp6234
S'2015/08/20 06:00'
p6235
asS'DP'
p6236
S'2015'
p6237
sS'OWN'
p6238
S'NLM'
p6239
sS'PT'
p6240
(lp6241
S'Journal Article'
p6242
asS'LA'
p6243
(lp6244
S'eng'
p6245
asS'DCOM'
p6246
S'20160323'
p6247
sS'JT'
p6248
S'Global health action'
p6249
sS'LR'
p6250
S'20150911'
p6251
sS'FAU'
p6252
(lp6253
S'Walter, Jan'
p6254
aS'Molfino, Lucas'
p6255
aS'Moreno, Verena'
p6256
aS'Edwards, Celeste G'
p6257
aS'Chissano, Mafalda'
p6258
aS'Prieto, Angels'
p6259
aS'Bocharnikova, Tatiana'
p6260
aS'Antierens, Annick'
p6261
aS'Lujan, Johnny'
p6262
asS'TI'
p6263
S'Long-term outcomes of a pediatric HIV treatment program in Maputo, Mozambique: a cohort study.'
p6264
sS'RN'
p6265
(lp6266
S'0 (Anti-HIV Agents)'
p6267
asS'PL'
p6268
S'Sweden'
p6269
sS'PG'
p6270
S'26652'
p6271
sS'JID'
p6272
S'101496665'
p6273
sS'AB'
p6274
S'OBJECTIVE: To describe long-term treatment outcomes of a pediatric HIV cohort in Mozambique. DESIGN: Retrospective analysis of routine monitoring data. SETTING: Secondary health care facilities in the Chamanculo Health District of Maputo. SUBJECTS: A total of 1,335 antiretroviral treatment (ART) naive children <15 years of age enrolled in HIV care between 2002 and 2010. INTERVENTION: HIV care, ART (since 2003), task shifting to lower cadre nurses, counseling by lay counselors, active patient tracing, nutritional support, support by a psychologist, targeted viral load testing, and switch to second-line treatment. MAIN OUTCOME MEASURES: Kaplan-Meier estimates for retention in care (RIC), CD4 cell percentage, body mass index for age z-score, and adjusted incidence rate ratios for attrition (death or loss to follow-up) as calculated by Poisson regression. RESULTS: The RIC at 6 years in the pre-ART cohort was 44% (95% confidence interval: 38-49), and the one at 8 years in the ART cohort was 70% (64-75). Risk factors for attrition included young age, low CD4 percentage, underweight, active tuberculosis, and enrollment/treatment initiation after 2006. The mean CD4 percentage increased strongly at 1 year on treatment and remained high thereafter. The body mass index for age z-score sharply increased at 1 year after treatment initiation before stabilizing at pre-ART levels thereafter. CONCLUSIONS: Good clinical and immunological treatment outcomes up to 8 years of follow-up on ART can be achieved in a context of shortage of health workers and a high level of task-shifting approach.'
p6275
sS'AD'
p6276
S'Medecins Sans Frontieres, Maputo, Mozambique. Medecins Sans Frontieres, Maputo, Mozambique; lucasmolfino@yahoo.com.ar. Medecins Sans Frontieres, Maputo, Mozambique. Medecins Sans Frontieres, Maputo, Mozambique. Medecins Sans Frontieres, Maputo, Mozambique. Medecins Sans Frontieres, Maputo, Mozambique. Ministry of Health, Maputo, Mozambique. Medecins Sans Frontieres, Geneva, Switzerland. Medecins Sans Frontieres, Geneva, Switzerland.'
p6277
sS'VI'
p6278
S'8'
sS'IS'
p6279
S'1654-9880 (Electronic) 1654-9880 (Linking)'
p6280
sS'PMC'
p6281
S'PMC4541076'
p6282
sS'AU'
p6283
(lp6284
S'Walter J'
p6285
aS'Molfino L'
p6286
aS'Moreno V'
p6287
aS'Edwards CG'
p6288
aS'Chissano M'
p6289
aS'Prieto A'
p6290
aS'Bocharnikova T'
p6291
aS'Antierens A'
p6292
aS'Lujan J'
p6293
asS'MHDA'
p6294
S'2016/03/24 06:00'
p6295
sS'PHST'
p6296
(lp6297
S'2015 [ecollection]'
p6298
aS'2014/11/16 [received]'
p6299
aS'2015/06/30 [revised]'
p6300
aS'2015/07/14 [accepted]'
p6301
asS'OT'
p6302
(lp6303
S'CD4 cell count'
p6304
aS'HIV'
p6305
aS'Mozambique'
p6306
aS'anthropometric scores'
p6307
aS'pediatric HIV care'
p6308
aS'task shifting'
p6309
asS'OTO'
p6310
(lp6311
S'NOTNLM'
p6312
asS'OID'
p6313
(lp6314
S'NLM: PMC4541076'
p6315
asS'MH'
p6316
(lp6317
S'AIDS-Related Opportunistic Infections/epidemiology'
p6318
aS'Adolescent'
p6319
aS'Age Factors'
p6320
aS'Anti-HIV Agents/*therapeutic use'
p6321
aS'Body Mass Index'
p6322
aS'CD4 Lymphocyte Count'
p6323
aS'Child'
p6324
aS'Child, Preschool'
p6325
aS'Counseling'
p6326
aS'Diet'
p6327
aS'Female'
p6328
aS'HIV Infections/epidemiology/*mortality/psychology/*therapy'
p6329
aS'Humans'
p6330
aS'Infant'
p6331
aS'Kaplan-Meier Estimate'
p6332
aS'Lost to Follow-Up'
p6333
aS'Male'
p6334
aS'Mozambique/epidemiology'
p6335
aS'Patient Education as Topic/*organization & administration'
p6336
aS'Retrospective Studies'
p6337
aS'Risk Factors'
p6338
aS'Tuberculosis/epidemiology'
p6339
aS'Viral Load'
p6340
asS'EDAT'
p6341
S'2015/08/20 06:00'
p6342
sS'SO'
p6343
S'Glob Health Action. 2015 Aug 17;8:26652. doi: 10.3402/gha.v8.26652. eCollection 2015.'
p6344
sS'SB'
p6345
S'IM'
p6346
sS'PMID'
p6347
S'26287397'
p6348
sS'TA'
p6349
S'Glob Health Action'
p6350
sS'PST'
p6351
S'epublish'
p6352
stRp6353
ag2
(g3
g4
(dp6354
S'LID'
p6355
S'10.1186/s12879-015-1082-x [doi]'
p6356
sS'STAT'
p6357
S'MEDLINE'
p6358
sS'DEP'
p6359
S'20150819'
p6360
sS'DA'
p6361
S'20150819'
p6362
sS'AID'
p6363
(lp6364
S'10.1186/s12879-015-1082-x [doi]'
p6365
aS'10.1186/s12879-015-1082-x [pii]'
p6366
asS'CRDT'
p6367
(lp6368
S'2015/08/20 06:00'
p6369
asS'DP'
p6370
S'2015'
p6371
sS'AD'
p6372
S'School of Public Health, Makerere University College of Health Sciences, Kampala, Uganda. dguwatudde@musph.ac.ug. Departments of Epidemiology and Biostatistics, Harvard School of Public Health, Channing Division of Network Medicine, Harvard Medical School, Boston, MA, USA. stmow@channing.harvard.edu. Department of Epidemiology and Biostatistics, University of Georgia, Athens, GA, USA. aezeamam@uga.edu. School of Public Health, Makerere University College of Health Sciences, Kampala, Uganda. dbagenda@hsph.harvard.edu. Department of Global Health and Population, Harvard School of Public Health, Boston, MA, USA. dbagenda@hsph.harvard.edu. Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda. smilin.rasasa@gmail.com. School of Public Health, Makerere University College of Health Sciences, Kampala, Uganda. hwamani@musph.ac.ug. Division of Infectious Diseases, Department of Medicine, John Hopkins University, Baltimore, MD, USA. ymanabe@jhmi.edu. Departments of Global Health and Population, Nutrition and Epidemiology, Harvard School of Public Health, Boston, MA, USA. mina@hsph.harvard.edu.'
p6373
sS'OWN'
p6374
S'NLM'
p6375
sS'PT'
p6376
(lp6377
S'Journal Article'
p6378
aS'Randomized Controlled Trial'
p6379
aS'Research Support, N.I.H., Extramural'
p6380
asS'LA'
p6381
(lp6382
S'eng'
p6383
asS'DCOM'
p6384
S'20160309'
p6385
sS'JT'
p6386
S'BMC infectious diseases'
p6387
sS'LR'
p6388
S'20150823'
p6389
sS'FAU'
p6390
(lp6391
S'Guwatudde, David'
p6392
aS'Wang, Molin'
p6393
aS'Ezeamama, Amara E'
p6394
aS'Bagenda, Danstan'
p6395
aS'Kyeyune, Rachel'
p6396
aS'Wamani, Henry'
p6397
aS'Manabe, Yukari C'
p6398
aS'Fawzi, Wafaie W'
p6399
asS'TI'
p6400
S'The effect of standard dose multivitamin supplementation on disease progression in HIV-infected adults initiating HAART: a randomized double blind placebo-controlled trial in Uganda.'
p6401
sS'RN'
p6402
(lp6403
S'0 (Vitamins)'
p6404
asS'PL'
p6405
S'England'
p6406
sS'PG'
p6407
S'348'
p6408
sS'JID'
p6409
S'100968551'
p6410
sS'AB'
p6411
S'BACKGROUND: Efficacy trials investigating the effect of multivitamin (MV) supplementations among patients on Highly Active Antiretroviral Therapy (HAART) have so far been inconclusive. We conducted a randomized, double blind, placebo controlled trial to determine the effect of one recommended daily allowance (RDA) of MV supplementation on disease progression in patients initiating HAART. METHODS: Eligible subjects were randomized to receive placebo or MV supplementation including vitamins B-complex, C and E. Participants were followed for up to 18 months. Primary endpoints were: change in CD4 cell count, weight and quality of life (QoL). Secondary endpoints were: i) development of a new or recurrent HIV disease progression event, including all-cause mortality; ii) switching from first- to second-line antiretroviral therapy (ART); and iii) occurrence of an adverse event. Intent-to-treat analysis, using linear regression mixed effects models were used to compare changes over time in the primary endpoints between the study arms. Kaplan-Meier time-to-event analysis and the log-rank test was used to compare HIV disease progression events and all-cause mortality. RESULTS: Four hundred participants were randomized, 200 onto MV and 200 onto placebo. By month 18, the average change in CD4 cell count in the MV arm was 141 cells/uL compared to 147 cells/uL in the placebo arm, a mean difference of -6 . 17 [95 % CI -29 . 3, 16 . 9]. The average change in weight in the MV arm was 3 . 9 kg compared to 3 . 3 kg in the placebo arm, a mean difference of 0 . 54 [95 % CI -0 . 40, 1 . 48]; whereas average change in QoL scores in the MV arm was 6 . 8 compared to 8 . 8 in the placebo arm, a mean difference of -2.16 [95 % CI -4 . 59,0 . 27]. No significant differences were observed in these primary endpoints, or in occurrence of adverse events between the trial arms. CONCLUSIONS: One RDA of MV supplementation was safe but did not have an effect on indicators of disease progression among HIV infected adults initiating HAART. TRIAL REGISTRATION: Clinical trials NCT01228578 , registered on 15th October 2010.'
p6412
sS'GR'
p6413
(lp6414
S'R01HD060333/HD/NICHD NIH HHS/United States'
p6415
asS'VI'
p6416
S'15'
p6417
sS'IS'
p6418
S'1471-2334 (Electronic) 1471-2334 (Linking)'
p6419
sS'PMC'
p6420
S'PMC4545778'
p6421
sS'AU'
p6422
(lp6423
S'Guwatudde D'
p6424
aS'Wang M'
p6425
aS'Ezeamama AE'
p6426
aS'Bagenda D'
p6427
aS'Kyeyune R'
p6428
aS'Wamani H'
p6429
aS'Manabe YC'
p6430
aS'Fawzi WW'
p6431
asS'MHDA'
p6432
S'2016/03/10 06:00'
p6433
sS'PHST'
p6434
(lp6435
S'2015/03/11 [received]'
p6436
aS'2015/08/04 [accepted]'
p6437
aS'2015/08/19 [aheadofprint]'
p6438
asS'OID'
p6439
(lp6440
S'NLM: PMC4545778'
p6441
asS'MH'
p6442
(lp6443
S'Adolescent'
p6444
aS'Adult'
p6445
aS'*Antiretroviral Therapy, Highly Active'
p6446
aS'Body Weight'
p6447
aS'CD4 Lymphocyte Count'
p6448
aS'*Dietary Supplements'
p6449
aS'Disease Progression'
p6450
aS'Double-Blind Method'
p6451
aS'Female'
p6452
aS'HIV Infections/*drug therapy/immunology'
p6453
aS'Humans'
p6454
aS'Kaplan-Meier Estimate'
p6455
aS'Linear Models'
p6456
aS'Male'
p6457
aS'Middle Aged'
p6458
aS'Quality of Life'
p6459
aS'Recommended Dietary Allowances'
p6460
aS'Treatment Outcome'
p6461
aS'Uganda'
p6462
aS'Vitamins/*therapeutic use'
p6463
aS'Young Adult'
p6464
asS'EDAT'
p6465
S'2015/08/20 06:00'
p6466
sS'SI'
p6467
(lp6468
S'ClinicalTrials.gov/NCT01228578'
p6469
asS'SO'
p6470
S'BMC Infect Dis. 2015 Aug 19;15:348. doi: 10.1186/s12879-015-1082-x.'
p6471
sS'SB'
p6472
S'IM'
p6473
sS'PMID'
p6474
S'26285704'
p6475
sS'TA'
p6476
S'BMC Infect Dis'
p6477
sS'PST'
p6478
S'epublish'
p6479
stRp6480
ag2
(g3
g4
(dp6481
S'LID'
p6482
S'10.1080/09540121.2015.1058896 [doi]'
p6483
sS'STAT'
p6484
S'MEDLINE'
p6485
sS'DEP'
p6486
S'20150817'
p6487
sS'MID'
p6488
(lp6489
S'NIHMS697837'
p6490
asS'DA'
p6491
S'20160115'
p6492
sS'AID'
p6493
(lp6494
S'10.1080/09540121.2015.1058896 [doi]'
p6495
asS'CRDT'
p6496
(lp6497
S'2015/08/18 06:00'
p6498
asS'DP'
p6499
S'2016'
p6500
sS'AD'
p6501
S'a Department of Health Policy and Management , University of North Carolina at Chapel Hill , Chapel Hill , NC , USA. b Department of Medicine , University of North Carolina at Chapel Hill , Chapel Hill , NC , USA. c Department of Health Behavior , University of North Carolina at Chapel Hill , Chapel Hill , NC , USA. a Department of Health Policy and Management , University of North Carolina at Chapel Hill , Chapel Hill , NC , USA. d UNC Project , Lilongwe , Malawi. b Department of Medicine , University of North Carolina at Chapel Hill , Chapel Hill , NC , USA. d UNC Project , Lilongwe , Malawi. a Department of Health Policy and Management , University of North Carolina at Chapel Hill , Chapel Hill , NC , USA. b Department of Medicine , University of North Carolina at Chapel Hill , Chapel Hill , NC , USA. e Department of Epidemiology , University of North Carolina at Chapel Hill , Chapel Hill , NC , USA. a Department of Health Policy and Management , University of North Carolina at Chapel Hill , Chapel Hill , NC , USA. d UNC Project , Lilongwe , Malawi. f School of Public Health , Loma Linda University , Loma Linda , CA , USA. g Ministry of Health , Lilongwe , Malawi. h Centers for Disease Control , Lilongwe , Malawi. h Centers for Disease Control , Lilongwe , Malawi. f School of Public Health , Loma Linda University , Loma Linda , CA , USA.'
p6502
sS'OWN'
p6503
S'NLM'
p6504
sS'PT'
p6505
(lp6506
S'Journal Article'
p6507
aS'Research Support, N.I.H., Extramural'
p6508
aS"Research Support, U.S. Gov't, P.H.S."
p6509
asS'LA'
p6510
(lp6511
S'eng'
p6512
asS'FAU'
p6513
(lp6514
S'Rutstein, S E'
p6515
aS'Golin, C E'
p6516
aS'Wheeler, S B'
p6517
aS'Kamwendo, D'
p6518
aS'Hosseinipour, M C'
p6519
aS'Weinberger, M'
p6520
aS'Miller, W C'
p6521
aS'Biddle, A K'
p6522
aS'Soko, A'
p6523
aS'Mkandawire, M'
p6524
aS'Mwenda, R'
p6525
aS'Sarr, A'
p6526
aS'Gupta, S'
p6527
aS'Mataya, R'
p6528
asS'JT'
p6529
S'AIDS care'
p6530
sS'LR'
p6531
S'20160417'
p6532
sS'PG'
p6533
S'1-10'
p6534
sS'TI'
p6535
S'On the front line of HIV virological monitoring: barriers and facilitators from a provider perspective in resource-limited settings.'
p6536
sS'RN'
p6537
(lp6538
S'0 (Anti-HIV Agents)'
p6539
asS'IS'
p6540
S'1360-0451 (Electronic) 0954-0121 (Linking)'
p6541
sS'PL'
p6542
S'England'
p6543
sS'TA'
p6544
S'AIDS Care'
p6545
sS'JID'
p6546
S'8915313'
p6547
sS'AB'
p6548
S"Scale-up of viral load (VL) monitoring for HIV-infected patients on antiretroviral therapy (ART) is a priority in many resource-limited settings, and ART providers are critical to effective program implementation. We explored provider-perceived barriers and facilitators of VL monitoring. We interviewed all providers (n = 17) engaged in a public health evaluation of dried blood spots for VL monitoring at five ART clinics in Malawi. All ART clinics were housed within district hospitals. We grouped themes at patient, provider, facility, system, and policy levels. Providers emphasized their desire for improved ART monitoring strategies, and frustration in response to restrictive policies for determining which patients were eligible to receive VL monitoring. Although many providers pled for expansion of monitoring to include all persons on ART, regardless of time on ART, the most salient provider-perceived barrier to VL monitoring implementation was the pressure of work associated with monitoring activities. The work burden was exacerbated by inefficient data management systems, highlighting a critical interaction between provider-, facility-, and system-level factors. Lack of integration between laboratory and clinical systems complicated the process for alerting providers when results were available, and these communication gaps were intensified by poor facility connectivity. Centralized second-line ART distribution was also noted as a barrier: providers reported that the time and expenses required for patients to collect second-line ART frequently obstructed referral. However, provider empowerment emerged as an unexpected facilitator of VL monitoring. For many providers, this was the first time they used an objective marker of ART response to guide clinical management. Providers' knowledge of a patient's virological status increased confidence in adherence counseling and clinical decision-making. Results from our study provide unique insight into provider perceptions of VL monitoring and indicate the importance of policies responsive to individual and environmental challenges of VL monitoring program implementation. Findings may inform scale-up by helping policy-makers identify strategies to improve feasibility and sustainability of VL monitoring."
p6549
sS'GR'
p6550
(lp6551
S'F30 MH098731/MH/NIMH NIH HHS/United States'
p6552
aS'F30 MH098731-01/MH/NIMH NIH HHS/United States'
p6553
aS'MW.10.1433/PHS HHS/United States'
p6554
aS'P30 AI050410/AI/NIAID NIH HHS/United States'
p6555
aS'P30AI50410/AI/NIAID NIH HHS/United States'
p6556
aS'T32 GM008719/GM/NIGMS NIH HHS/United States'
p6557
aS'T32 GM008719/GM/NIGMS NIH HHS/United States'
p6558
aS'U2G PS001965/PS/NCHHSTP CDC HHS/United States'
p6559
asS'IP'
p6560
S'1'
sS'PMCR'
p6561
(lp6562
S'2017/01/01 00:00'
p6563
asS'PMC'
p6564
S'PMC4834050'
p6565
sS'DCOM'
p6566
S'20160720'
p6567
sS'AU'
p6568
(lp6569
S'Rutstein SE'
p6570
aS'Golin CE'
p6571
aS'Wheeler SB'
p6572
aS'Kamwendo D'
p6573
aS'Hosseinipour MC'
p6574
aS'Weinberger M'
p6575
aS'Miller WC'
p6576
aS'Biddle AK'
p6577
aS'Soko A'
p6578
aS'Mkandawire M'
p6579
aS'Mwenda R'
p6580
aS'Sarr A'
p6581
aS'Gupta S'
p6582
aS'Mataya R'
p6583
asS'VI'
p6584
S'28'
p6585
sS'MHDA'
p6586
S'2016/07/21 06:00'
p6587
sS'PHST'
p6588
(lp6589
S'2015/08/17 [aheadofprint]'
p6590
asS'OTO'
p6591
(lp6592
S'NOTNLM'
p6593
asS'OID'
p6594
(lp6595
S'NLM: NIHMS697837 [Available on 01/01/17]'
p6596
aS'NLM: PMC4834050 [Available on 01/01/17]'
p6597
asS'MH'
p6598
(lp6599
S'Adult'
p6600
aS'Anti-HIV Agents/economics/*therapeutic use'
p6601
aS'Antiretroviral Therapy, Highly Active'
p6602
aS'Drug Monitoring/*methods'
p6603
aS'Female'
p6604
aS'HIV Infections/*drug therapy/economics/virology'
p6605
aS'*Health Care Costs'
p6606
aS'Health Personnel/*psychology'
p6607
aS'*Health Resources'
p6608
aS'Humans'
p6609
aS'Interviews as Topic'
p6610
aS'Malawi'
p6611
aS'Male'
p6612
aS'Perception'
p6613
aS'Viral Load/*drug effects'
p6614
aS'Workload'
p6615
asS'EDAT'
p6616
S'2015/08/19 06:00'
p6617
sS'SO'
p6618
S'AIDS Care. 2016;28(1):1-10. doi: 10.1080/09540121.2015.1058896. Epub 2015 Aug 17.'
p6619
sS'SB'
p6620
S'IM X'
p6621
sS'PMID'
p6622
S'26278724'
p6623
sS'OT'
p6624
(lp6625
S'HIV'
p6626
aS'provider perceptions'
p6627
aS'resource-limited settings'
p6628
aS'viral load monitoring'
p6629
asS'PST'
p6630
S'ppublish'
p6631
stRp6632
ag2
(g3
g4
(dp6633
S'LID'
p6634
S'10.1128/AAC.01193-15 [doi]'
p6635
sS'STAT'
p6636
S'MEDLINE'
p6637
sS'DEP'
p6638
S'20150727'
p6639
sS'CI'
p6640
(lp6641
S'Copyright (c) 2015, van Oosterhout et al.'
p6642
asS'DA'
p6643
S'20150919'
p6644
sS'AID'
p6645
(lp6646
S'AAC.01193-15 [pii]'
p6647
aS'10.1128/AAC.01193-15 [doi]'
p6648
asS'CRDT'
p6649
(lp6650
S'2015/08/07 06:00'
p6651
asS'DP'
p6652
S'2015 Oct'
p6653
sS'AD'
p6654
S'Dignitas International, Medical and Research Department, Zomba, Malawi College of Medicine, Department of Medicine, Blantyre, Malawi joepvanoosterhout@gmail.com. College of Medicine, Department of Pharmacy, Blantyre, Malawi. National Tuberculosis Control Program, Lilongwe, Malawi. Liverpool School of Tropical Medicine, Liverpool, United Kingdom. Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi University of Liverpool, Liverpool, United Kingdom. College of Medicine, Department of Medicine, Blantyre, Malawi. Liverpool School of Tropical Medicine, Liverpool, United Kingdom Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi. College of Medicine, University of Malawi, Department of Pediatrics, Blantyre, Malawi. Liverpool School of Tropical Medicine, Liverpool, United Kingdom.'
p6655
sS'OWN'
p6656
S'NLM'
p6657
sS'PT'
p6658
(lp6659
S'Clinical Trial'
p6660
aS'Journal Article'
p6661
aS"Research Support, Non-U.S. Gov't"
p6662
asS'LA'
p6663
(lp6664
S'eng'
p6665
asS'FAU'
p6666
(lp6667
S'van Oosterhout, J J'
p6668
aS'Dzinjalamala, F K'
p6669
aS'Dimba, A'
p6670
aS'Waterhouse, D'
p6671
aS'Davies, G'
p6672
aS'Zijlstra, E E'
p6673
aS'Molyneux, M E'
p6674
aS'Molyneux, E M'
p6675
aS'Ward, S'
p6676
asS'JT'
p6677
S'Antimicrobial agents and chemotherapy'
p6678
sS'LR'
p6679
S'20150923'
p6680
sS'PG'
p6681
S'6175-80'
p6682
sS'TI'
p6683
S'Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi.'
p6684
sS'RN'
p6685
(lp6686
S'0 (Antitubercular Agents)'
p6687
aS'2KNI5N06TI (Pyrazinamide)'
p6688
aS'8G167061QZ (Ethambutol)'
p6689
aS'V83O1VOZ8L (Isoniazid)'
p6690
aS'VJT6J7R4TR (Rifampin)'
p6691
asS'PL'
p6692
S'United States'
p6693
sS'TA'
p6694
S'Antimicrob Agents Chemother'
p6695
sS'JID'
p6696
S'0315061'
p6697
sS'AB'
p6698
S'Limited data address the impact of HIV coinfection on the pharmacokinetics (PK) of antituberculosis drugs in sub-Saharan Africa. A total of 47 Malawian adults underwent rich pharmacokinetic sampling at 0, 0.5, 1, 2, 3, 4, 6, 8, and 24 h postdose. Of the subjects, 51% were male, their mean age was 34 years, and 65% were HIV-positive with a mean CD4 count of 268 cells/mul. Antituberculosis drugs were administered as fixed-dose combinations (150 mg rifampin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol) according to recommended weight bands. Plasma drug concentrations were determined by high-performance liquid chromatography (rifampin and pyrazinamide) or liquid chromatography-mass spectrometry (isoniazid and ethambutol). Data were analyzed by noncompartmental methods and analysis of variance of log-transformed summary parameters. The pharmacokinetic parameters were as follows (median [interquartile range]): for rifampin, maximum concentration of drug in plasma (Cmax) of 4.129 mug/ml (2.474 to 5.596 mug/ml), area under the curve from 0 to 24 h (AUC0-infinity) of 21.32 mug/ml . h (13.57 to 28.60 mug/ml . h), and half-life of 2.45 h (1.86 to 3.08 h); for isoniazid, Cmax of 3.97 mug/ml (2.979 to 4.544 mug/ml), AUC0-24 of 22.5 (14.75 to 34.59 mug/ml . h), and half-life of 3.93 h (3.18 to 4.73 h); for pyrazinamide, Cmax of 34.21 mug/ml (30.00 to 41.60 mug/ml), AUC0-24 of 386.6 mug/ml . h (320.0 to 463.7 mug/ml . h), and half-life of 6.821 h (5.71 to 8.042 h); and for ethambutol, Cmax of 2.278 mug/ml (1.694 to 3.098 mug/ml), AUC0-24 of 20.41 mug/ml . h (16.18 to 26.27 mug/ml . h), and half-life of 7.507 (6.517 to 8.696 h). The isoniazid PK data analysis suggested that around two-thirds of the participants were slow acetylators. Dose, weight, and weight-adjusted dose were not significant predictors of PK exposure, probably due to weight-banded dosing. In this first pharmacokinetic study of antituberculosis drugs in Malawian adults, measures of pharmacokinetic exposure were comparable with those of other studies for all first-line drugs except for rifampin, for which the Cmax and AUC0-24 values were notably lower. Contrary to some earlier observations, HIV status did not significantly affect the AUC of any of the drugs. Increasing the dose of rifampin might be beneficial in African adults, irrespective of HIV status. Current co-trimoxazole prophylaxis was associated with an increase in the half-life of isoniazid of 41% (P = 0.022). Possible competitive interactions between isoniazid and sulfamethoxazole mediated by the N-acetyltransferase pathway should therefore be explored further.'
p6699
sS'GR'
p6700
(lp6701
S'Wellcome Trust/United Kingdom'
p6702
asS'IP'
p6703
S'10'
p6704
sS'IS'
p6705
S'1098-6596 (Electronic) 0066-4804 (Linking)'
p6706
sS'PMC'
p6707
S'PMC4576091'
p6708
sS'DCOM'
p6709
S'20160706'
p6710
sS'AU'
p6711
(lp6712
S'van Oosterhout JJ'
p6713
aS'Dzinjalamala FK'
p6714
aS'Dimba A'
p6715
aS'Waterhouse D'
p6716
aS'Davies G'
p6717
aS'Zijlstra EE'
p6718
aS'Molyneux ME'
p6719
aS'Molyneux EM'
p6720
aS'Ward S'
p6721
asS'VI'
p6722
S'59'
p6723
sS'MHDA'
p6724
S'2016/07/07 06:00'
p6725
sS'PHST'
p6726
(lp6727
S'2015/05/21 [received]'
p6728
aS'2015/07/12 [accepted]'
p6729
aS'2015/07/27 [aheadofprint]'
p6730
asS'OID'
p6731
(lp6732
S'NLM: PMC4576091'
p6733
asS'MH'
p6734
(lp6735
S'Adolescent'
p6736
aS'Adult'
p6737
aS'Antitubercular Agents/*blood/*pharmacokinetics'
p6738
aS'Ethambutol/blood/pharmacokinetics'
p6739
aS'Female'
p6740
aS'HIV Infections/*blood/*metabolism'
p6741
aS'Humans'
p6742
aS'Isoniazid/blood/pharmacokinetics'
p6743
aS'Malawi'
p6744
aS'Male'
p6745
aS'Middle Aged'
p6746
aS'Pyrazinamide/blood/pharmacokinetics'
p6747
aS'Rifampin/blood/pharmacokinetics'
p6748
aS'Young Adult'
p6749
asS'EDAT'
p6750
S'2015/08/08 06:00'
p6751
sS'SO'
p6752
S'Antimicrob Agents Chemother. 2015 Oct;59(10):6175-80. doi: 10.1128/AAC.01193-15. Epub 2015 Jul 27.'
p6753
sS'SB'
p6754
S'IM'
p6755
sS'PMID'
p6756
S'26248378'
p6757
sS'PST'
p6758
S'ppublish'
p6759
stRp6760
ag2
(g3
g4
(dp6761
S'LID'
p6762
S'10.1097/QAI.0000000000000782 [doi]'
p6763
sS'STAT'
p6764
S'MEDLINE'
p6765
sS'JT'
p6766
S'Journal of acquired immune deficiency syndromes (1999)'
p6767
sS'MID'
p6768
(lp6769
S'NIHMS710738'
p6770
asS'DA'
p6771
S'20151017'
p6772
sS'AID'
p6773
(lp6774
S'10.1097/QAI.0000000000000782 [doi]'
p6775
asS'CRDT'
p6776
(lp6777
S'2015/08/07 06:00'
p6778
asS'DP'
p6779
S'2015 Nov 1'
p6780
sS'AD'
p6781
S"Departments of *Epidemiology; daggerGlobal Health and Population, Harvard School of Public Health, Boston, MA; double daggerManagement and Development for Health, Dar es Salaam, Tanzania; section signDepartment of Pediatrics and Child Health, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania; ||Division of GI/Nutrition, Clinical Nutrition Service, Children's Hospital, Boston, MA; paragraph signDepartments of Global Health and Population, Epidemiology, and Nutrition, Harvard School of Public Health, Boston, MA; and #Departments of Epidemiology, Biostatistics, Global Health and Population, and Nutrition, Harvard School of Public Health, Boston, MA."
p6782
sS'OWN'
p6783
S'NLM'
p6784
sS'PT'
p6785
(lp6786
S'Journal Article'
p6787
aS'Research Support, N.I.H., Extramural'
p6788
aS"Research Support, U.S. Gov't, P.H.S."
p6789
asS'LA'
p6790
(lp6791
S'eng'
p6792
asS'FAU'
p6793
(lp6794
S'McCormick, Nora M'
p6795
aS'Li, Nan'
p6796
aS'Sando, David'
p6797
aS'Muya, Aisa'
p6798
aS'Manji, Karim P'
p6799
aS'Kisenge, Rodrick'
p6800
aS'Duggan, Christopher'
p6801
aS'Chalamilla, Guerino'
p6802
aS'Fawzi, Wafaie W'
p6803
aS'Spiegelman, Donna'
p6804
asS'LR'
p6805
S'20160329'
p6806
sS'PG'
p6807
S'e73-83'
p6808
sS'TI'
p6809
S'Implementation and Operational Research: Risk Factors of Loss to Follow-up Among HIV-Positive Pediatric Patients in Dar es Salaam, Tanzania.'
p6810
sS'RN'
p6811
(lp6812
S'0 (Anti-HIV Agents)'
p6813
aS'0 (Dietary Proteins)'
p6814
aS'8064-90-2 (Trimethoprim, Sulfamethoxazole Drug Combination)'
p6815
asS'IS'
p6816
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p6817
sS'PL'
p6818
S'United States'
p6819
sS'TA'
p6820
S'J Acquir Immune Defic Syndr'
p6821
sS'JID'
p6822
S'100892005'
p6823
sS'AB'
p6824
S'OBJECTIVE: To identify risk factors for loss to follow-up (LTFU) in an HIV-infected pediatric population in Dar es Salaam, Tanzania, between 2004 and 2011. DESIGN: Longitudinal analysis of 6236 HIV-infected children. METHODS: We conducted a prospective cohort study of 6236 pediatric patients enrolled in care and treatment in Dar es Salaam from October 2004 to September 2011. LTFU was defined as missing a clinic visit for >90 days for patients on ART and for >180 days for patients in care and monitoring. The relationship of baseline and time-varying characteristics to the risk of LTFU was examined using a Cox proportional hazards model. RESULTS: A total of 2130 children (34%) were LTFU over a median follow-up of 16.7 months (interquartile range, 3.4-36.9). Factors independently associated with a higher risk of LTFU were age </=2 years (relative risk [RR] = 1.59, 95% CI: 1.40 to 1.80), diarrhea at enrollment (RR = 1.20, 95% CI: 1.03 to 1.41), a low mid-upper arm circumference for age (RR = 1.20, CI: 1.05 to 1.37), eating protein-rich foods </=3 times a week (RR = 1.39, 95% CI: 1.05 to 1.90), taking cotrimoxazole (RR = 1.39, 95% CI: 1.06 to 1.81), initiating onto antiretrovirals (RR = 1.37, 95% CI: 1.17 to 1.61), receiving treatment at a hospital instead of a local facility (RR = 1.39, 95% CI: 1.06 to 1.41), and starting treatment in 2006 or later (RR = 1.10, 95% CI: 1.04 to 1.16). CONCLUSIONS: Health workers should be aware of pediatric patients who are at a greatest risk of LTFU, such as younger and undernourished patients, so that they can proactively counsel families about the importance of visit adherence. Findings support decentralization of HIV care to local facilities as opposed to hospitals.'
p6825
sS'GR'
p6826
(lp6827
S'5U2GPS001966-04/PHS HHS/United States'
p6828
aS'K24 DK104676/DK/NIDDK NIH HHS/United States'
p6829
aS'K24 HD058795/HD/NICHD NIH HHS/United States'
p6830
aS'K24HD058795/HD/NICHD NIH HHS/United States'
p6831
aS'R01 HD043688/HD/NICHD NIH HHS/United States'
p6832
aS'R01 HD043688-01/HD/NICHD NIH HHS/United States'
p6833
aS'U2G PS001966/PS/NCHHSTP CDC HHS/United States'
p6834
asS'IP'
p6835
S'3'
sS'PMCR'
p6836
(lp6837
S'2016/11/01 00:00'
p6838
asS'PMC'
p6839
S'PMC4650894'
p6840
sS'DCOM'
p6841
S'20160128'
p6842
sS'AU'
p6843
(lp6844
S'McCormick NM'
p6845
aS'Li N'
p6846
aS'Sando D'
p6847
aS'Muya A'
p6848
aS'Manji KP'
p6849
aS'Kisenge R'
p6850
aS'Duggan C'
p6851
aS'Chalamilla G'
p6852
aS'Fawzi WW'
p6853
aS'Spiegelman D'
p6854
asS'VI'
p6855
S'70'
p6856
sS'MHDA'
p6857
S'2016/01/29 06:00'
p6858
sS'OID'
p6859
(lp6860
S'NLM: NIHMS710738 [Available on 11/01/16]'
p6861
aS'NLM: PMC4650894 [Available on 11/01/16]'
p6862
asS'MH'
p6863
(lp6864
S'Anti-HIV Agents/*therapeutic use'
p6865
aS'Child'
p6866
aS'Child Nutritional Physiological Phenomena'
p6867
aS'Child, Preschool'
p6868
aS'Dietary Proteins'
p6869
aS'Female'
p6870
aS'HIV Infections/*epidemiology'
p6871
aS'Humans'
p6872
aS'*Lost to Follow-Up'
p6873
aS'Male'
p6874
aS'Malnutrition'
p6875
aS'Risk Factors'
p6876
aS'Tanzania/epidemiology'
p6877
aS'Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use'
p6878
asS'EDAT'
p6879
S'2015/08/08 06:00'
p6880
sS'SO'
p6881
S'J Acquir Immune Defic Syndr. 2015 Nov 1;70(3):e73-83. doi: 10.1097/QAI.0000000000000782.'
p6882
sS'SB'
p6883
S'IM X'
p6884
sS'PMID'
p6885
S'26247894'
p6886
sS'PST'
p6887
S'ppublish'
p6888
stRp6889
ag2
(g3
g4
(dp6890
S'LID'
p6891
S'10.7196/samj.8217 [doi]'
p6892
sS'STAT'
p6893
S'MEDLINE'
p6894
sS'DEP'
p6895
S'20150407'
p6896
sS'DA'
p6897
S'20150805'
p6898
sS'CRDT'
p6899
(lp6900
S'2015/08/06 06:00'
p6901
asS'DP'
p6902
S'2015 May'
p6903
sS'OWN'
p6904
S'NLM'
p6905
sS'PT'
p6906
(lp6907
S'Journal Article'
p6908
asS'LA'
p6909
(lp6910
S'eng'
p6911
asS'FAU'
p6912
(lp6913
S'Naidoo, Sashelin'
p6914
aS'Evans, Denise'
p6915
aS'Jong, Eefje'
p6916
aS'Mellet, Karla'
p6917
aS'Berhanu, Rebecca'
p6918
asS'JT'
p6919
S'South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde'
p6920
sS'PG'
p6921
S'393-6'
p6922
sS'TI'
p6923
S'Outcomes of TB/HIV co-infected patients presenting with antituberculosis drug-induced liver injury.'
p6924
sS'RN'
p6925
(lp6926
S'0 (Antitubercular Agents)'
p6927
asS'PL'
p6928
S'South Africa'
p6929
sS'TA'
p6930
S'S Afr Med J'
p6931
sS'JID'
p6932
S'0404520'
p6933
sS'AB'
p6934
S'BACKGROUND: South Africa has a significant burden of tuberculosis (TB). Anti-TB drug-induced liver injury (TB DILI) is one of the most serious adverse events that can arise from TB treatment (TBT). There are limited data on TB DILI among HIV-infected patients and those on antiretroviral therapy (ART). OBJECTIVE: To describe characteristics of HIV-infected patients presenting with TB DILI and the proportion reintroduced on standard or modified TBT after DILI. METHODS: This was a retrospective study of TB/HIV co-infected patients with DILI between 1 July 2009 and 30 September 2012. The primary focus of interest was HIV-infected patients with TB DILI on ART (ART/TB DILI) v. not on ART (TB DILI). RESULTS: A total of 94 patients were included, 41 with TB DILI and 53 with ART/TB DILI. Compared with patients with TB DILI, patients with ART/TB DILI were more likely to present with symptomatic DILI (71.2% v. 51.2%; p=0.03) and had a lower median alanine aminotransferase level at diagnosis (89 IU/L v. 118 IU/L; p=0.008), a lower rate of ALT decline (-23 IU/L v. -76 IU/L; p=0.047) and longer duration of TBT at DILI diagnosis (53 days v. 11 days; p&lt;0.001). In 71.8% of patients, standard TBT was reintroduced. More patients with ART/TB DILI than TB DILI required modified TBT (37.2% v.17.1%; p=0.05; crude odds ratio 2.17; 95% confidence interval 0.95 - 4.96). The rate of death/loss to follow-up was higher in the ART/TB DILI group (18.9% v. 14.5%). CONCLUSION: A significant number of TB/HIV co-infected patients were not able to tolerate standard TBT. Furthermore, ART appears to complicate TBT, with relatively few patients reintroduced on standard TBT.'
p6935
sS'AD'
p6936
S'Helen Joseph Hospital, Johannesburg, South Africa. sashelin@gmail.com.'
p6937
sS'IP'
p6938
S'5'
sS'IS'
p6939
S'0256-9574 (Print)'
p6940
sS'DCOM'
p6941
S'20150908'
p6942
sS'AU'
p6943
(lp6944
S'Naidoo S'
p6945
aS'Evans D'
p6946
aS'Jong E'
p6947
aS'Mellet K'
p6948
aS'Berhanu R'
p6949
asS'VI'
p6950
S'105'
p6951
sS'MHDA'
p6952
S'2015/09/09 06:00'
p6953
sS'PHST'
p6954
(lp6955
S'2015/04/16 [received]'
p6956
asS'MH'
p6957
(lp6958
S'Adult'
p6959
aS'Antitubercular Agents/*adverse effects'
p6960
aS'*Coinfection'
p6961
aS'Drug-Induced Liver Injury/*epidemiology/etiology'
p6962
aS'Female'
p6963
aS'Follow-Up Studies'
p6964
aS'HIV Infections/*complications/drug therapy'
p6965
aS'Humans'
p6966
aS'Incidence'
p6967
aS'Kaplan-Meier Estimate'
p6968
aS'Male'
p6969
aS'Middle Aged'
p6970
aS'Odds Ratio'
p6971
aS'Prognosis'
p6972
aS'Retrospective Studies'
p6973
aS'South Africa/epidemiology'
p6974
aS'Survival Rate/trends'
p6975
aS'Tuberculosis/*complications/drug therapy/epidemiology'
p6976
asS'EDAT'
p6977
S'2015/08/06 06:00'
p6978
sS'SO'
p6979
S'S Afr Med J. 2015 Apr 7;105(5):393-6. doi: 10.7196/samj.8217.'
p6980
sS'SB'
p6981
S'IM'
p6982
sS'PMID'
p6983
S'26242667'
p6984
sS'PST'
p6985
S'epublish'
p6986
stRp6987
ag2
(g3
g4
(dp6988
S'LID'
p6989
S'10.1093/cid/civ656 [doi]'
p6990
sS'STAT'
p6991
S'MEDLINE'
p6992
sS'DEP'
p6993
S'20150803'
p6994
sS'CI'
p6995
(lp6996
S'(c) The Author 2015. Published by Oxford University Press on behalf of the'
p6997
aS'Infectious Diseases Society of America. All rights reserved. For Permissions,'
p6998
aS'please e-mail: journals.permissions@oup.com.'
p6999
asS'DA'
p7000
S'20151114'
p7001
sS'AID'
p7002
(lp7003
S'civ656 [pii]'
p7004
aS'10.1093/cid/civ656 [doi]'
p7005
asS'CRDT'
p7006
(lp7007
S'2015/08/05 06:00'
p7008
asS'DP'
p7009
S'2015 Dec 1'
p7010
sS'OWN'
p7011
S'NLM'
p7012
sS'PT'
p7013
(lp7014
S'Journal Article'
p7015
aS"Research Support, Non-U.S. Gov't"
p7016
asS'LA'
p7017
(lp7018
S'eng'
p7019
asS'FAU'
p7020
(lp7021
S'Boender, T Sonia'
p7022
aS'Hoenderboom, Bernice M'
p7023
aS'Sigaloff, Kim C E'
p7024
aS'Hamers, Raph L'
p7025
aS'Wellington, Maureen'
p7026
aS'Shamu, Tinei'
p7027
aS'Siwale, Margaret'
p7028
aS'Labib Maksimos, Eman E F'
p7029
aS'Nankya, Immaculate'
p7030
aS'Kityo, Cissy M'
p7031
aS'Adeyemo, Titilope A'
p7032
aS'Akanmu, Alani Sulaimon'
p7033
aS'Mandaliya, Kishor'
p7034
aS'Botes, Mariette E'
p7035
aS'Ondoa, Pascale'
p7036
aS'Rinke de Wit, Tobias F'
p7037
asS'JT'
p7038
S'Clinical infectious diseases : an official publication of the Infectious Diseases Society of America'
p7039
sS'PG'
p7040
S'1749-58'
p7041
sS'TI'
p7042
S'Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa.'
p7043
sS'RN'
p7044
(lp7045
S'0 (Anti-HIV Agents)'
p7046
asS'PL'
p7047
S'United States'
p7048
sS'TA'
p7049
S'Clin Infect Dis'
p7050
sS'JID'
p7051
S'9203213'
p7052
sS'AB'
p7053
S'BACKGROUND: After the scale-up of antiretroviral therapy (ART) for human immunodeficiency virus (HIV) infection in Africa, increasing numbers of patients have pretreatment drug resistance. METHODS: In a large multicountry cohort of patients starting standard first-line ART in six African countries, pol genotyping was retrospectively performed if viral load (VL) >/=1000 cps/mL. Pretreatment drug resistance was defined as a decreased susceptibility to >/=1 prescribed drug. We assessed the effect of pretreatment drug resistance on all-cause mortality, new AIDS events and switch to second-line ART due to presumed treatment failure, using Cox models. RESULTS: Among 2579 participants for whom a pretreatment genotype was available, 5.5% had pretreatment drug resistance. Pretreatment drug resistance was associated with an increased risk of regimen switch (adjusted hazard ratio [aHR] 3.80; 95% confidence interval [CI], 1.49-9.68; P = .005) but was not associated with mortality (aHR 0.75, 95% CI, .24-2.35; P = .617) or new AIDS events (aHR 1.06, 95% CI, .68-1.64; P = .807). During three years of follow up, 106 (4.1%) participants switched to second-line, of whom 18 (17.0%) switched with VL < 1000 cps/mL, 7 (6.6%) with VL >/= 1000 cps/mL and no drug resistance mutations (DRMs), 46 (43.4%) with VL >/= 1000 cps/mL and >/=1 DRMs; no HIV RNA data was available for 32 (30.2%) participants. CONCLUSIONS: Given rising pretreatment HIV drug resistance levels in sub-Saharan Africa, these findings underscore the need for expanded access to second-line ART. VL monitoring can improve the accuracy of failure detection and efficiency of switching practices.'
p7054
sS'AD'
p7055
S'Amsterdam Institute for Global Health and Development and Department of Global Health. Amsterdam Institute for Global Health and Development and Department of Global Health. Amsterdam Institute for Global Health and Development and Department of Global Health Department of Internal Medicine, Division of Infectious Diseases, Academic Medical Center of the University of Amsterdam, The Netherlands. Amsterdam Institute for Global Health and Development and Department of Global Health Department of Internal Medicine, Division of Infectious Diseases, Academic Medical Center of the University of Amsterdam, The Netherlands. Newlands Clinic, Harare, Zimbabwe. Newlands Clinic, Harare, Zimbabwe. Lusaka Trust Hospital. Coptic Hospital, Lusaka, Zambia. Joint Clinical Research Centre, Kampala, Uganda. Joint Clinical Research Centre, Kampala, Uganda. Department of Haematology and Blood Transfusion, University of Lagos, Nigeria University Teaching Hospital, Nigeria. Department of Haematology and Blood Transfusion, University of Lagos, Nigeria University Teaching Hospital, Nigeria. Coast Province General Hospital, Mombasa, Kenya. Muelmed Hospital, Pretoria, South Africa. Amsterdam Institute for Global Health and Development and Department of Global Health. Amsterdam Institute for Global Health and Development and Department of Global Health.'
p7056
sS'IP'
p7057
S'11'
p7058
sS'IS'
p7059
S'1537-6591 (Electronic) 1058-4838 (Linking)'
p7060
sS'DCOM'
p7061
S'20160810'
p7062
sS'AU'
p7063
(lp7064
S'Boender TS'
p7065
aS'Hoenderboom BM'
p7066
aS'Sigaloff KC'
p7067
aS'Hamers RL'
p7068
aS'Wellington M'
p7069
aS'Shamu T'
p7070
aS'Siwale M'
p7071
aS'Labib Maksimos EE'
p7072
aS'Nankya I'
p7073
aS'Kityo CM'
p7074
aS'Adeyemo TA'
p7075
aS'Akanmu AS'
p7076
aS'Mandaliya K'
p7077
aS'Botes ME'
p7078
aS'Ondoa P'
p7079
aS'Rinke de Wit TF'
p7080
asS'VI'
p7081
S'61'
p7082
sS'MHDA'
p7083
S'2016/08/11 06:00'
p7084
sS'PHST'
p7085
(lp7086
S'2015/06/11 [received]'
p7087
aS'2015/07/23 [accepted]'
p7088
aS'2015/08/03 [aheadofprint]'
p7089
asS'OTO'
p7090
(lp7091
S'NOTNLM'
p7092
asS'MH'
p7093
(lp7094
S'Acquired Immunodeficiency Syndrome/drug therapy'
p7095
aS'Adolescent'
p7096
aS'Adult'
p7097
aS'Africa South of the Sahara/epidemiology'
p7098
aS'Anti-HIV Agents/pharmacology/*therapeutic use'
p7099
aS'Antiretroviral Therapy, Highly Active/standards'
p7100
aS'CD4 Lymphocyte Count'
p7101
aS'Cohort Studies'
p7102
aS'*Drug Resistance, Viral/genetics'
p7103
aS'Female'
p7104
aS'Follow-Up Studies'
p7105
aS'Genes, pol'
p7106
aS'Genotype'
p7107
aS'HIV Infections/*drug therapy/epidemiology/mortality/*virology'
p7108
aS'HIV-1/*drug effects/genetics'
p7109
aS'Humans'
p7110
aS'Male'
p7111
aS'Mutation'
p7112
aS'Proportional Hazards Models'
p7113
aS'Treatment Failure'
p7114
aS'Treatment Outcome'
p7115
aS'Viral Load/*drug effects'
p7116
aS'Young Adult'
p7117
asS'EDAT'
p7118
S'2015/08/05 06:00'
p7119
sS'SO'
p7120
S'Clin Infect Dis. 2015 Dec 1;61(11):1749-58. doi: 10.1093/cid/civ656. Epub 2015 Aug 3.'
p7121
sS'SB'
p7122
S'IM'
p7123
sS'PMID'
p7124
S'26240203'
p7125
sS'OT'
p7126
(lp7127
S'HIV-1 drug resistance'
p7128
aS'antiretroviral therapy'
p7129
aS'mortality'
p7130
aS'regimen switch'
p7131
aS'sub-Saharan Africa'
p7132
asS'PST'
p7133
S'ppublish'
p7134
stRp7135
ag2
(g3
g4
(dp7136
S'LID'
p7137
S'10.1179/2047773215Y.0000000027 [doi]'
p7138
sS'STAT'
p7139
S'MEDLINE'
p7140
sS'DEP'
p7141
S'20150804'
p7142
sS'DA'
p7143
S'20150925'
p7144
sS'AID'
p7145
(lp7146
S'10.1179/2047773215Y.0000000027 [doi]'
p7147
asS'CRDT'
p7148
(lp7149
S'2015/08/05 06:00'
p7150
asS'DP'
p7151
S'2015 Jul'
p7152
sS'OWN'
p7153
S'NLM'
p7154
sS'PT'
p7155
(lp7156
S'Journal Article'
p7157
asS'LA'
p7158
(lp7159
S'eng'
p7160
asS'FAU'
p7161
(lp7162
S'Wikman-Jorgensen, Philip Erik'
p7163
aS'Morales-Cartagena, Alejandra'
p7164
aS'Llenas-Garcia, Jara'
p7165
aS'Perez-Porcuna, Tomas Maria'
p7166
aS'Hobbins, Michael'
p7167
aS'Ehmer, Jochen'
p7168
aS'Mussa, Manuel Aly'
p7169
aS'Abellana, Rosa'
p7170
aS'Ascaso, Carlos'
p7171
asS'JT'
p7172
S'Pathogens and global health'
p7173
sS'LR'
p7174
S'20160701'
p7175
sS'PG'
p7176
S'221-7'
p7177
sS'TI'
p7178
S'Implementation challenges of a TB programme in rural northern mozambique: evaluation of 2012-2013 outcomes.'
p7179
sS'PL'
p7180
S'England'
p7181
sS'TA'
p7182
S'Pathog Glob Health'
p7183
sS'JID'
p7184
S'101583421'
p7185
sS'AB'
p7186
S'BACKGROUND: We aimed to identify challenges and to propose solutions for the implementation of tuberculosis (TB) programmes in rural Sub-Saharan Africa (SSA) by evaluating the outcomes of the TB programme in the Ancuabe district in rural Northern Mozambique. METHODS: Retrospective descriptive study of the patients included in the TB programme in 2012-2013. Follow-up was continued till June 2014. RESULTS: Three hundred nineteen patients were registered, 62.1% male, mean age 36.3 (SD 14.4), estimated case detection rate (eCDR) of 24.24%. Two hundred seventy-two were new cases, 21 transferred-in, 11 back after lost to follow-up (LTFU), 10 relapsing TB, 5 previous treatment failures. 94.4% were tested for Human immunodeficiency virus (HIV), 41.9% HIV-positive. 87.5% of the new cases were pulmonary TB (PTB), 43.4% were HIV co-infected. Initial sputum results were available in 207 cases, with 145 smear-positive (SP) cases. Outcomes of new cases: 122 (44.9%) LTFU, 55 (20.2%) cured, 43 (15.8%) treatment completed (98-36%-treatment success), 31 (11.4%) died, 19 (7%) transferred out and 2 (0.7%) failures. CONCLUSIONS: A low eCDR and high proportion of LTFU demonstrate that few patients were identified and had a low probability of complete treatment, suggesting a fragile health system. This raises the hypothesis that, probably, to improve TB health care in rural SSA, interventions should aim at improving health systems. Special attention should be given to social protection and compensation of the financial burden associated with TB.'
p7187
sS'IP'
p7188
S'5'
sS'IS'
p7189
S'2047-7732 (Electronic) 2047-7724 (Linking)'
p7190
sS'PMC'
p7191
S'PMC4727574'
p7192
sS'DCOM'
p7193
S'20160622'
p7194
sS'AU'
p7195
(lp7196
S'Wikman-Jorgensen PE'
p7197
aS'Morales-Cartagena A'
p7198
aS'Llenas-Garcia J'
p7199
aS'Perez-Porcuna TM'
p7200
aS'Hobbins M'
p7201
aS'Ehmer J'
p7202
aS'Mussa MA'
p7203
aS'Abellana R'
p7204
aS'Ascaso C'
p7205
asS'VI'
p7206
S'109'
p7207
sS'MHDA'
p7208
S'2016/06/23 06:00'
p7209
sS'PHST'
p7210
(lp7211
S'2015/08/04 [aheadofprint]'
p7212
asS'OTO'
p7213
(lp7214
S'NOTNLM'
p7215
asS'OID'
p7216
(lp7217
S'NLM: PMC4727574'
p7218
asS'MH'
p7219
(lp7220
S'Adult'
p7221
aS'Communicable Disease Control/*methods/*organization & administration'
p7222
aS'Female'
p7223
aS'Health Services Research'
p7224
aS'Humans'
p7225
aS'Lost to Follow-Up'
p7226
aS'Male'
p7227
aS'Middle Aged'
p7228
aS'Mozambique'
p7229
aS'Retrospective Studies'
p7230
aS'*Rural Population'
p7231
aS'Treatment Outcome'
p7232
aS'Tuberculosis/*diagnosis/*drug therapy'
p7233
asS'EDAT'
p7234
S'2015/08/05 06:00'
p7235
sS'SO'
p7236
S'Pathog Glob Health. 2015 Jul;109(5):221-7. doi: 10.1179/2047773215Y.0000000027. Epub 2015 Aug 4.'
p7237
sS'SB'
p7238
S'IM'
p7239
sS'PMID'
p7240
S'26239760'
p7241
sS'OT'
p7242
(lp7243
S'Directly observed treatment,'
p7244
aS'Epidemiology,'
p7245
aS'Mozambique'
p7246
aS'Tuberculosis,'
p7247
asS'PST'
p7248
S'ppublish'
p7249
stRp7250
ag2
(g3
g4
(dp7251
S'LID'
p7252
S'10.1186/s12913-015-0959-0 [doi]'
p7253
sS'STAT'
p7254
S'MEDLINE'
p7255
sS'DEP'
p7256
S'20150728'
p7257
sS'DA'
p7258
S'20150728'
p7259
sS'AID'
p7260
(lp7261
S'10.1186/s12913-015-0959-0 [doi]'
p7262
aS'10.1186/s12913-015-0959-0 [pii]'
p7263
asS'CRDT'
p7264
(lp7265
S'2015/07/29 06:00'
p7266
asS'DP'
p7267
S'2015'
p7268
sS'AD'
p7269
S'Department of Medicine, Makerere College of Health Sciences, P.O.Box 7072, Kampala, Uganda. dorismutabazi@yahoo.com. Department of Health Policy and Management, John Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. awu@jhu.edu. Department of Psychology, University of Bath, Bath, United Kingdom. psmfm@bath.ac.uk. Department of Medicine, Makerere College of Health Sciences, P.O.Box 7072, Kampala, Uganda. akatamba@yahoo.com. MRC/UVRI Uganda Research Unit on AIDS, Uganda Virus Research Institute, Entebbe, Uganda. janet.seeley@mrcuganda.co.ug.'
p7270
sS'OWN'
p7271
S'NLM'
p7272
sS'PT'
p7273
(lp7274
S'Journal Article'
p7275
aS"Research Support, Non-U.S. Gov't"
p7276
asS'LA'
p7277
(lp7278
S'eng'
p7279
asS'DCOM'
p7280
S'20160317'
p7281
sS'JT'
p7282
S'BMC health services research'
p7283
sS'LR'
p7284
S'20160308'
p7285
sS'FAU'
p7286
(lp7287
S'Mwesigire, Doris Mutabazi'
p7288
aS'Wu, Albert W'
p7289
aS'Martin, Faith'
p7290
aS'Katamba, Achilles'
p7291
aS'Seeley, Janet'
p7292
asS'TI'
p7293
S'Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine or efavirenz in Uganda: a prospective non-randomized study.'
p7294
sS'RN'
p7295
(lp7296
S'0 (Anti-HIV Agents)'
p7297
aS'0 (Benzoxazines)'
p7298
aS'0 (Reverse Transcriptase Inhibitors)'
p7299
aS'99DK7FVK1H (Nevirapine)'
p7300
aS'JE6H2O27P8 (efavirenz)'
p7301
asS'PL'
p7302
S'England'
p7303
sS'PG'
p7304
S'292'
p7305
sS'JID'
p7306
S'101088677'
p7307
sS'AB'
p7308
S'BACKGROUND: The goal of antiretroviral therapy (ART) is to suppress viral replication, reduce morbidity and mortality, and improve quality of life (QoL). For resource-limited settings, the World Health Organization recommends a first-line regimen of two-nucleoside reverse-transcriptase inhibitors and one non-nucleoside transcriptase inhibitor (nevirapine (NVP) or efavirenz (EFV)). There are few data comparing the QoL impact of NVP versus EFV. This study assessed the change in QoL and factors associated with QoL among HIV patients receiving ART regimens based on EFV or NVP. METHODS: We enrolled 640 people with HIV eligible for ART who received regimens including either NVP or EFV. QoL was assessed at baseline, three months and six months using Physical Health Summary (PHS) and Mental Health Summary (MHS) scores and the Global Person Generated Index (GPGI). Data were analyzed using generalized estimating equations, with ART regimen as the primary exposure, to identify associations between patient and disease factors and QoL. RESULTS: QoL increased on ART. The mean QoL scores did not differ significantly for regimens based on NVP versus EFV during follow-up for MHS and GPGI regardless of CD4 stratum and for PHS among patients with a CD4 count >250 cells/muL. The PHS-adjusted beta coefficients for ART regimens based on EFV versus NVP by CD4 count strata were as follows: -1.61 (95% CI -2.74, -0.49) for CD4 count <100 cells/muL; 0.82 (0.22, 1.43) for CD4 count 101-250 cells/muL; and -1.33 (-5.66, 3.00) for CD4 count >250 cells/muL. The corresponding MHS-adjusted beta coefficients were as follows: -0.39 (-1.40, 0.62) for CD4 < 100 cells/muL; 0.16 (-0.66, 0.98) for CD4 count 101-250 cells/muL; and -0.75 (-2.01, 0.51) for CD4 count >250 cells/muL. The GPGI-adjusted odds ratios for EFV versus NVP were 0.51 (0.25, 1.04) for CD4 count <100 cells/muL, 0.98 (0.60, 1.58) for CD4 count 101-250 cells/muL, 1.39 (0.66, 2.90) for CD4 > 250 cells/muL. QoL improved among patients on EFV over the 6-month follow-up period (MHS p < 0.001; PHS p = 0.04, p = 0.028). Overall, patients with depression (PHS p < 0.001; GPGI p < 0.001) had lower scores and women had lower MHS (on NVP, p = 0.001). Other factors associated with lower QoL included alcohol use, low education level and advanced HIV disease. CONCLUSIONS: ART improves QoL. The results support use of either NVP or EFV. Patients initiating ART should be assessed for depression and managed appropriately. Women may require extra support to improve their QoL.'
p7309
sS'GR'
p7310
(lp7311
S'087540/Wellcome Trust/United Kingdom'
p7312
aS'MC_U950097150/Medical Research Council/United Kingdom'
p7313
asS'VI'
p7314
S'15'
p7315
sS'IS'
p7316
S'1472-6963 (Electronic) 1472-6963 (Linking)'
p7317
sS'PMC'
p7318
S'PMC4517416'
p7319
sS'AU'
p7320
(lp7321
S'Mwesigire DM'
p7322
aS'Wu AW'
p7323
aS'Martin F'
p7324
aS'Katamba A'
p7325
aS'Seeley J'
p7326
asS'MHDA'
p7327
S'2016/03/18 06:00'
p7328
sS'PHST'
p7329
(lp7330
S'2015/01/27 [received]'
p7331
aS'2015/07/14 [accepted]'
p7332
aS'2015/07/28 [aheadofprint]'
p7333
asS'OID'
p7334
(lp7335
S'NLM: PMC4517416'
p7336
asS'MH'
p7337
(lp7338
S'Adult'
p7339
aS'Anti-HIV Agents/*therapeutic use'
p7340
aS'Benzoxazines/*therapeutic use'
p7341
aS'CD4 Lymphocyte Count'
p7342
aS'Depression'
p7343
aS'Female'
p7344
aS'HIV Infections/*drug therapy/*psychology'
p7345
aS'Humans'
p7346
aS'Interviews as Topic'
p7347
aS'Male'
p7348
aS'Mental Health'
p7349
aS'Nevirapine/*therapeutic use'
p7350
aS'Prospective Studies'
p7351
aS'*Quality of Life'
p7352
aS'Reverse Transcriptase Inhibitors/*therapeutic use'
p7353
aS'Treatment Outcome'
p7354
aS'Uganda'
p7355
aS'World Health Organization'
p7356
asS'EDAT'
p7357
S'2015/07/29 06:00'
p7358
sS'SO'
p7359
S'BMC Health Serv Res. 2015 Jul 28;15:292. doi: 10.1186/s12913-015-0959-0.'
p7360
sS'SB'
p7361
S'IM'
p7362
sS'PMID'
p7363
S'26216221'
p7364
sS'TA'
p7365
S'BMC Health Serv Res'
p7366
sS'PST'
p7367
S'epublish'
p7368
stRp7369
ag2
(g3
g4
(dp7370
S'LID'
p7371
S'10.7448/IAS.18.1.20090 [doi]'
p7372
sS'STAT'
p7373
S'MEDLINE'
p7374
sS'DEP'
p7375
S'20150723'
p7376
sS'DA'
p7377
S'20150725'
p7378
sS'AID'
p7379
(lp7380
S'20090 [pii]'
p7381
asS'CRDT'
p7382
(lp7383
S'2015/07/26 06:00'
p7384
asS'DP'
p7385
S'2015'
p7386
sS'OWN'
p7387
S'NLM'
p7388
sS'PT'
p7389
(lp7390
S'Journal Article'
p7391
aS"Research Support, Non-U.S. Gov't"
p7392
asS'LA'
p7393
(lp7394
S'eng'
p7395
asS'DCOM'
p7396
S'20160331'
p7397
sS'JT'
p7398
S'Journal of the International AIDS Society'
p7399
sS'LR'
p7400
S'20150729'
p7401
sS'FAU'
p7402
(lp7403
S'Bernheimer, Jonathan M'
p7404
aS'Patten, Gem'
p7405
aS'Makeleni, Thembisa'
p7406
aS'Mantangana, Nompumelelo'
p7407
aS'Dumile, Nombasa'
p7408
aS'Goemaere, Eric'
p7409
aS'Cox, Vivian'
p7410
asS'TI'
p7411
S'Paediatric HIV treatment failure: a silent epidemic.'
p7412
sS'RN'
p7413
(lp7414
S'0 (Anti-HIV Agents)'
p7415
asS'PL'
p7416
S'Switzerland'
p7417
sS'PG'
p7418
S'20090'
p7419
sS'JID'
p7420
S'101478566'
p7421
sS'AB'
p7422
S'Paediatric antiretroviral treatment (ART) failure is an under-recognized issue that receives inadequate attention in the field of paediatrics and within HIV treatment programmes. With paediatric ART failure rates ranging from 19.3% to over 32% in resource limited settings, a comprehensive evaluation of the causes of failure along with approaches to address barriers to treatment adherence are urgently needed. In partnership with the local Department of Health, a pilot programme has been established by Medecins Sans Frontieres (MSF) in Khayelitsha, South Africa, to identify and support paediatric HIV patients with high viral loads and potential treatment failure. Through detailed clinical and psychosocial evaluations and adherence support with an innovative counselling model, treatment barriers are identified and addressed. Demographic and clinical characteristics from the cohort show a delayed median start date for ART, prolonged viraemia including a large number of patients who have never achieved viral load (VL) suppression, a low rate of regimen changes despite failure, and a high percentage of pre-adolescent and adolescent patients who have not gone through the disclosure process. Stemming this epidemic of paediatric treatment failure requires programmatic responses to high viral loads in children, starting with improved "case finding" of previously undiagnosed HIV-infected children and adolescents. Viral load testing needs to be prioritized over CD4 count monitoring, and flagging systems to identify high VL results should be developed in clinics. Clinicians must understand that successful treatment begins with good adherence, and that simple adherence support strategies can often dramatically improve adherence. Moreover, appropriate adherence counselling should begin not when the child fails to respond to treatment. Establishing good adherence from the beginning of treatment, and supporting ongoing adherence during the milestones in these children\'s lives is key to sustaining treatment success in this vulnerable HIV-infected patient population.'
p7423
sS'AD'
p7424
S'Medecins Sans Frontieres, Khayelitsha, South Africa; mscocb-khayelitsha-pedsdoc@brussels.msf.org. Medecins Sans Frontieres, Khayelitsha, South Africa. Medecins Sans Frontieres, Khayelitsha, South Africa. Medecins Sans Frontieres, Khayelitsha, South Africa. Medecins Sans Frontieres, Khayelitsha, South Africa. Medecins Sans Frontieres, Khayelitsha, South Africa. Medecins Sans Frontieres, Khayelitsha, South Africa.'
p7425
sS'VI'
p7426
S'18'
p7427
sS'IS'
p7428
S'1758-2652 (Electronic) 1758-2652 (Linking)'
p7429
sS'PMC'
p7430
S'PMC4514899'
p7431
sS'AU'
p7432
(lp7433
S'Bernheimer JM'
p7434
aS'Patten G'
p7435
aS'Makeleni T'
p7436
aS'Mantangana N'
p7437
aS'Dumile N'
p7438
aS'Goemaere E'
p7439
aS'Cox V'
p7440
asS'MHDA'
p7441
S'2016/04/01 06:00'
p7442
sS'PHST'
p7443
(lp7444
S'2015 [ecollection]'
p7445
aS'2015/03/03 [received]'
p7446
aS'2015/05/13 [accepted]'
p7447
asS'OT'
p7448
(lp7449
S'HIV'
p7450
aS'Khayelitsha'
p7451
aS'paediatrics'
p7452
aS'primary care'
p7453
aS'treatment failure'
p7454
aS'viral load'
p7455
asS'OTO'
p7456
(lp7457
S'NOTNLM'
p7458
asS'OID'
p7459
(lp7460
S'NLM: PMC4514899'
p7461
asS'MH'
p7462
(lp7463
S'Adolescent'
p7464
aS'Anti-HIV Agents/*therapeutic use'
p7465
aS'CD4 Lymphocyte Count'
p7466
aS'Child'
p7467
aS'Child, Preschool'
p7468
aS'Female'
p7469
aS'HIV Infections/*drug therapy/epidemiology/immunology/virology'
p7470
aS'Humans'
p7471
aS'Male'
p7472
aS'Treatment Failure'
p7473
aS'Viral Load'
p7474
asS'EDAT'
p7475
S'2015/07/26 06:00'
p7476
sS'SO'
p7477
S'J Int AIDS Soc. 2015 Jul 23;18:20090. doi: 10.7448/IAS.18.1.20090. eCollection 2015.'
p7478
sS'SB'
p7479
S'IM X'
p7480
sS'PMID'
p7481
S'26208630'
p7482
sS'TA'
p7483
S'J Int AIDS Soc'
p7484
sS'PST'
p7485
S'epublish'
p7486
stRp7487
ag2
(g3
g4
(dp7488
S'LID'
p7489
S'10.1097/QAI.0000000000000760 [doi]'
p7490
sS'STAT'
p7491
S'MEDLINE'
p7492
sS'JT'
p7493
S'Journal of acquired immune deficiency syndromes (1999)'
p7494
sS'DA'
p7495
S'20151029'
p7496
sS'AID'
p7497
(lp7498
S'10.1097/QAI.0000000000000760 [doi]'
p7499
asS'CRDT'
p7500
(lp7501
S'2015/07/17 06:00'
p7502
asS'DP'
p7503
S'2015 Dec 1'
p7504
sS'AD'
p7505
S'*Center for Global Health and Development, Boston University School of Public Health, Boston, MA; daggerDepartment of Pediatrics, Boston Medical Center, Boston, MA; double daggerDepartment of Global Health, Boston University School of Public Health, Boston, MA; section signDepartment of Pediatrics, University of California Davis, Sacramento, CA; ||Zambia Center for Applied Health Research and Development, Lusaka, Zambia; paragraph signMarie Stopes International, Lilongwe, Malawi; #Centers for Disease Control and Prevention, Lusaka, Zambia; **Ministry of Community Development, Mother and Child Health, Government of the Republic of Zambia, Lusaka, Zambia; and daggerdaggerPerinatal HIV Research Unit, University of Witwatersrand, Johannesburg, South Africa.'
p7506
sS'OWN'
p7507
S'NLM'
p7508
sS'PT'
p7509
(lp7510
S'Journal Article'
p7511
aS"Research Support, U.S. Gov't, P.H.S."
p7512
asS'LA'
p7513
(lp7514
S'eng'
p7515
asS'FAU'
p7516
(lp7517
S'Herlihy, Julie M'
p7518
aS'Hamomba, Leoda'
p7519
aS'Bonawitz, Rachael'
p7520
aS'Goggin, Caitlin E'
p7521
aS'Sambambi, Kennedy'
p7522
aS'Mwale, Jonas'
p7523
aS'Musonda, Victor'
p7524
aS'Musokatwane, Kebby'
p7525
aS'Hopkins, Kathryn L'
p7526
aS'Semrau, Katherine'
p7527
aS'Hammond, Emily E'
p7528
aS'Duncan, Julie'
p7529
aS'Knapp, Anna B'
p7530
aS'Thea, Donald M'
p7531
asS'LR'
p7532
S'20151029'
p7533
sS'PG'
p7534
S'e123-9'
p7535
sS'TI'
p7536
S'Implementation and Operational Research: Integration of PMTCT and Antenatal Services Improves Combination Antiretroviral Therapy Uptake for HIV-Positive Pregnant Women in Southern Zambia: A Prototype for Option B+?'
p7537
sS'RN'
p7538
(lp7539
S'0 (Anti-Retroviral Agents)'
p7540
asS'PL'
p7541
S'United States'
p7542
sS'TA'
p7543
S'J Acquir Immune Defic Syndr'
p7544
sS'JID'
p7545
S'100892005'
p7546
sS'AB'
p7547
S'BACKGROUND: Early initiation of combination antiretroviral therapy (cART) for HIV-positive pregnant women can decrease vertical transmission to less than 5%. Programmatic barriers to early cART include decentralized care, disease-stage assessment delays, and loss to follow-up. INTERVENTION: Our intervention had 3 components: integrated HIV and antenatal services in 1 location with 1 provider, laboratory courier to expedite CD4 counts, and community-based follow-up of women-infant pairs to improve prevention of mother-to-child transmission attendance. Preintervention HIV-positive pregnant women were referred to HIV clinics for disease-stage assessment and cART initiation for advanced disease (CD4 count <350 cells/muL or WHO stage >2). METHODS: We used a quasi-experimental design with preintervention/postintervention evaluations at 6 government antenatal clinics (ANCs) in Southern Province, Zambia. Retrospective clinical data were collected from clinic registers during a 7-month baseline period. Postintervention data were collected from all antiretroviral therapy-naive, HIV-positive pregnant women and their infants presenting to ANC from December 2011 to June 2013. RESULTS: Data from 510 baseline women-infant pairs were analyzed and 624 pregnant women were enrolled during the intervention period. The proportion of HIV-positive pregnant women receiving CD4 counts increased from 50.6% to 77.2% [relative risk (RR) = 1.81; 95% confidence interval (CI): 1.57 to 2.08; P < 0.01]. The proportion of cART-eligible pregnant women initiated on cART increased from 27.5% to 71.5% (RR = 2.25; 95% CI: 1.78 to 2.83; P < 0.01). The proportion of eligible HIV-exposed infants with documented 6-week HIV PCR test increased from 41.9% to 55.8% (RR = 1.33; 95% CI: 1.18 to 1.51; P < 0.01). CONCLUSIONS: Integration of HIV care into ANC and community-based support improved uptake of CD4 counts, proportion of cART-eligible women initiated on cART, and infants tested.'
p7548
sS'GR'
p7549
(lp7550
S'5U2GPS001418/PHS HHS/United States'
p7551
aS'U2G PS001418/PS/NCHHSTP CDC HHS/United States'
p7552
asS'IP'
p7553
S'4'
sS'IS'
p7554
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p7555
sS'DCOM'
p7556
S'20160202'
p7557
sS'AU'
p7558
(lp7559
S'Herlihy JM'
p7560
aS'Hamomba L'
p7561
aS'Bonawitz R'
p7562
aS'Goggin CE'
p7563
aS'Sambambi K'
p7564
aS'Mwale J'
p7565
aS'Musonda V'
p7566
aS'Musokatwane K'
p7567
aS'Hopkins KL'
p7568
aS'Semrau K'
p7569
aS'Hammond EE'
p7570
aS'Duncan J'
p7571
aS'Knapp AB'
p7572
aS'Thea DM'
p7573
asS'VI'
p7574
S'70'
p7575
sS'MHDA'
p7576
S'2016/02/03 06:00'
p7577
sS'MH'
p7578
(lp7579
S'Adult'
p7580
aS'Anti-Retroviral Agents/*therapeutic use'
p7581
aS'Cohort Studies'
p7582
aS'Controlled Before-After Studies'
p7583
aS'Female'
p7584
aS'HIV Infections/*drug therapy/*transmission'
p7585
aS'Humans'
p7586
aS'Infant'
p7587
aS'Infant, Newborn'
p7588
aS'Infectious Disease Transmission, Vertical/*prevention & control'
p7589
aS'Male'
p7590
aS'*Medication Adherence'
p7591
aS'Pregnancy'
p7592
aS'Pregnancy Complications, Infectious/*drug therapy'
p7593
aS'Prenatal Care/methods/*organization & administration'
p7594
aS'Retrospective Studies'
p7595
aS'Young Adult'
p7596
aS'Zambia'
p7597
asS'EDAT'
p7598
S'2015/07/17 06:00'
p7599
sS'SO'
p7600
S'J Acquir Immune Defic Syndr. 2015 Dec 1;70(4):e123-9. doi: 10.1097/QAI.0000000000000760.'
p7601
sS'SB'
p7602
S'IM X'
p7603
sS'PMID'
p7604
S'26181813'
p7605
sS'PST'
p7606
S'ppublish'
p7607
stRp7608
ag2
(g3
g4
(dp7609
S'LID'
p7610
S'10.7448/IAS.18.1.20016 [doi]'
p7611
sS'STAT'
p7612
S'MEDLINE'
p7613
sS'DEP'
p7614
S'20150710'
p7615
sS'DA'
p7616
S'20150713'
p7617
sS'AID'
p7618
(lp7619
S'20016 [pii]'
p7620
asS'CRDT'
p7621
(lp7622
S'2015/07/14 06:00'
p7623
asS'DP'
p7624
S'2015'
p7625
sS'AD'
p7626
S"Instituto de Medicina Tropical Alexander von Humboldt, Lima, Peru; gabriela.carriquiry.c@upch.pe; gabriela.carriquiry@yahoo.com. Fundacion Huesped, Buenos Aires, Argentina. Department of Medicine, Vanderbilt University Nashville, TN, USA. Department of Biostatistics, Vanderbilt University Nashville, TN, USA. Department of Medicine, Vanderbilt University Nashville, TN, USA. Department of Biostatistics, Vanderbilt University Nashville, TN, USA. Fundacion Huesped, Buenos Aires, Argentina. Instituto de Pesquisa Clinica Evandro Chagas-Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil. Fundacion Arriaran, Santiago, Chile. Le Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes, Port-au-Prince, Haiti. Weill Cornell Medical College, New York, NY, USA. Instituto Hondureno de Seguridad Social and Hospital Escuela, Tegucigalpa, Honduras. Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico. Instituto de Medicina Tropical Alexander von Humboldt, Lima, Peru. Department of Medicine, Vanderbilt University Nashville, TN, USA. Department of Biostatistics, Vanderbilt University Nashville, TN, USA."
p7627
sS'OWN'
p7628
S'NLM'
p7629
sS'PT'
p7630
(lp7631
S'Journal Article'
p7632
aS'Research Support, N.I.H., Extramural'
p7633
asS'LA'
p7634
(lp7635
S'eng'
p7636
asS'DCOM'
p7637
S'20160331'
p7638
sS'JT'
p7639
S'Journal of the International AIDS Society'
p7640
sS'LR'
p7641
S'20151001'
p7642
sS'FAU'
p7643
(lp7644
S'Carriquiry, Gabriela'
p7645
aS'Fink, Valeria'
p7646
aS'Koethe, John Robert'
p7647
aS'Giganti, Mark Joseph'
p7648
aS'Jayathilake, Karu'
p7649
aS'Blevins, Meridith'
p7650
aS'Cahn, Pedro'
p7651
aS'Grinsztejn, Beatriz'
p7652
aS'Wolff, Marcelo'
p7653
aS'Pape, Jean William'
p7654
aS'Padgett, Denis'
p7655
aS'Madero, Juan Sierra'
p7656
aS'Gotuzzo, Eduardo'
p7657
aS'McGowan, Catherine Carey'
p7658
aS'Shepherd, Bryan Earl'
p7659
asS'TI'
p7660
S'Mortality and loss to follow-up among HIV-infected persons on long-term antiretroviral therapy in Latin America and the Caribbean.'
p7661
sS'PL'
p7662
S'Switzerland'
p7663
sS'PG'
p7664
S'20016'
p7665
sS'JID'
p7666
S'101478566'
p7667
sS'AB'
p7668
S'INTRODUCTION: Long-term survival of HIV patients after initiating highly active antiretroviral therapy (ART) has not been sufficiently described in Latin America and the Caribbean, as compared to other regions. The aim of this study was to describe the incidence of mortality, loss to follow-up (LTFU) and associated risk factors for patients enrolled in the Caribbean, Central and South America Network (CCASAnet). METHODS: We assessed time from ART initiation (baseline) to death or LTFU between 2000 and 2014 among ART-naive adults (>/=18 years) from sites in seven countries included in CCASAnet: Argentina, Brazil, Chile, Haiti, Honduras, Mexico and Peru. Kaplan-Meier techniques were used to estimate the probability of mortality over time. Risk factors for death were assessed using Cox regression models stratified by site and adjusted for sex, baseline age, nadir pre-ART CD4 count, calendar year of ART initiation, clinical AIDS at baseline and type of ART regimen. RESULTS: A total of 16,996 ART initiators were followed for a median of 3.5 years (interquartile range (IQR): 1.6-6.2). The median age at ART initiation was 36 years (IQR: 30-44), subjects were predominantly male (63%), median CD4 count was 156 cells/microL (IQR: 60-251) and 26% of subjects had clinical AIDS prior to starting ART. Initial ART regimens were predominantly non-nucleoside reverse transcriptase inhibitor based (86%). The cumulative incidence of LTFU five years after ART initiation was 18.2% (95% confidence interval (CI) 17.5-18.8%). A total of 1582 (9.3%) subjects died; the estimated probability of death one, three and five years after ART initiation was 5.4, 8.3 and 10.3%, respectively. The estimated five-year mortality probability varied substantially across sites, from 3.5 to 14.0%. Risk factors for death were clinical AIDS at baseline (adjusted hazard ratio (HR)=1.65 (95% CI 1.47-1.87); p<0.001), lower baseline CD4 (HR=1.95 (95% CI 1.63-2.32) for 50 vs. 350 cells/microL; p<0.001) and older age (HR=1.47 (95% CI 1.29-1.69) for 50 vs. 30 years at ART initiation; p<0.001). CONCLUSIONS: In this large, long-term study of mortality among HIV-positive adults initiating ART in Latin America and the Caribbean, overall estimates of mortality were heterogeneous, generally falling between those reported in high-income countries and sub-Saharan Africa.'
p7669
sS'GR'
p7670
(lp7671
S'U01 AI069923/AI/NIAID NIH HHS/United States'
p7672
aS'UM1 AI069421/AI/NIAID NIH HHS/United States'
p7673
aS'UM1 AI069476/AI/NIAID NIH HHS/United States'
p7674
asS'VI'
p7675
S'18'
p7676
sS'IS'
p7677
S'1758-2652 (Electronic) 1758-2652 (Linking)'
p7678
sS'PMC'
p7679
S'PMC4499577'
p7680
sS'AU'
p7681
(lp7682
S'Carriquiry G'
p7683
aS'Fink V'
p7684
aS'Koethe JR'
p7685
aS'Giganti MJ'
p7686
aS'Jayathilake K'
p7687
aS'Blevins M'
p7688
aS'Cahn P'
p7689
aS'Grinsztejn B'
p7690
aS'Wolff M'
p7691
aS'Pape JW'
p7692
aS'Padgett D'
p7693
aS'Madero JS'
p7694
aS'Gotuzzo E'
p7695
aS'McGowan CC'
p7696
aS'Shepherd BE'
p7697
asS'MHDA'
p7698
S'2016/04/01 06:00'
p7699
sS'PHST'
p7700
(lp7701
S'2015 [ecollection]'
p7702
aS'2015/01/14 [received]'
p7703
aS'2015/05/04 [revised]'
p7704
aS'2015/06/01 [accepted]'
p7705
asS'OT'
p7706
(lp7707
S'AIDS'
p7708
aS'ART'
p7709
aS'HIV'
p7710
aS'Latin America'
p7711
aS'long-term mortality'
p7712
aS'the Caribbean'
p7713
asS'OTO'
p7714
(lp7715
S'NOTNLM'
p7716
asS'OID'
p7717
(lp7718
S'NLM: PMC4499577'
p7719
asS'MH'
p7720
(lp7721
S'Adult'
p7722
aS'*Antiretroviral Therapy, Highly Active'
p7723
aS'CD4 Lymphocyte Count'
p7724
aS'Caribbean Region'
p7725
aS'Female'
p7726
aS'Follow-Up Studies'
p7727
aS'HIV Infections/*drug therapy/immunology/mortality'
p7728
aS'Humans'
p7729
aS'Latin America'
p7730
aS'Male'
p7731
aS'Middle Aged'
p7732
aS'Proportional Hazards Models'
p7733
asS'EDAT'
p7734
S'2015/07/15 06:00'
p7735
sS'SO'
p7736
S'J Int AIDS Soc. 2015 Jul 10;18:20016. doi: 10.7448/IAS.18.1.20016. eCollection 2015.'
p7737
sS'SB'
p7738
S'IM X'
p7739
sS'PMID'
p7740
S'26165322'
p7741
sS'TA'
p7742
S'J Int AIDS Soc'
p7743
sS'PST'
p7744
S'epublish'
p7745
stRp7746
ag2
(g3
g4
(dp7747
S'LID'
p7748
S'10.5588/ijtld.14.0944 [doi]'
p7749
sS'STAT'
p7750
S'MEDLINE'
p7751
sS'AB'
p7752
S'BACKGROUND: South Africa has a large burden of extensively drug-resistant tuberculosis (XDR-TB); only 15% of XDR-TB patients have successful outcomes. OBJECTIVE: To describe the safety and effectiveness of bedaquiline (BDQ) in the South African BDQ Clinical Access Programme. DESIGN: An interim cohort analysis. RESULTS: Of the first 91 patients enrolled between March 2013 and July 2014 (with follow-up until August 2014), 54 (59%) were human immunodeficiency virus (HIV) infected. The median CD4 count was 239 cells/mul, and all patients were on antiretroviral therapy (ART) at initiation of BDQ; 33 had XDR-TB, 41 were pre-XDR-TB with fluoroquinolone resistance and 17 were pre-XDR-TB with resistance to an injectable. Of the 91 patients, 58 (64%) had completed 24 weeks of BDQ, 28 were still on BDQ, 3 were lost to follow-up, 1 had died and 1 had BDQ withdrawn following atrial fibrillation. Of the 63 patients with 6 months follow-up, 48 (76%) had either culture-converted or remained culture-negative after initiation of BDQ. QTcF was monitored monthly and exceeded 500 ms in three participants; this resolved in all three. CONCLUSION: Interim safety and culture conversion outcomes for patients accessing BDQ in South Africa, including HIV-infected patients on ART and patients with pre-XDR- and XDR-TB, suggest that BDQ may be both efficacious and safe.'
p7753
sS'JID'
p7754
S'9706389'
p7755
sS'AD'
p7756
S'National Department of Health, Pretoria, South Africa. Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Right to Care, Johannesburg, South Africa. Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Right to Care, Johannesburg, South Africa. Medecins sans Frontieres, Khayelitsha, Cape Town, South Africa. TB/HIV Investigative Network of Kwazulu-Natal, Durban, South Africa. Klerksdorp Tshepong Hospital Complex, Klerksdorp, South Africa. Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa; Department of Medicine, University of Cape Town, Cape Town, South Africa. National Department of Health, Pretoria, South Africa. Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa; Department of Medicine, University of Cape Town, Cape Town, South Africa. Sizwe Tropical Disease Hospital, Johannesburg, South Africa. Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Klerksdorp Tshepong Hospital Complex, Klerksdorp, South Africa. Kwazulu-Natal Research Institute for TB and HIV, Durban, South Africa. National Department of Health, Pretoria, South Africa.'
p7757
sS'JT'
p7758
S'The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease'
p7759
sS'IP'
p7760
S'8'
sS'IS'
p7761
S'1815-7920 (Electronic) 1027-3719 (Linking)'
p7762
sS'DCOM'
p7763
S'20160418'
p7764
sS'DA'
p7765
S'20150711'
p7766
sS'AU'
p7767
(lp7768
S'Ndjeka N'
p7769
aS'Conradie F'
p7770
aS'Schnippel K'
p7771
aS'Hughes J'
p7772
aS'Bantubani N'
p7773
aS'Ferreira H'
p7774
aS'Maartens G'
p7775
aS'Mametja D'
p7776
aS'Meintjes G'
p7777
aS'Padanilam X'
p7778
aS'Variava E'
p7779
aS'Pym A'
p7780
aS'Pillay Y'
p7781
asS'AID'
p7782
(lp7783
S'10.5588/ijtld.14.0944 [doi]'
p7784
asS'CRDT'
p7785
(lp7786
S'2015/07/12 06:00'
p7787
asS'VI'
p7788
S'19'
p7789
sS'PMID'
p7790
S'26162365'
p7791
sS'DP'
p7792
S'2015 Aug'
p7793
sS'MHDA'
p7794
S'2016/04/19 06:00'
p7795
sS'OWN'
p7796
S'NLM'
p7797
sS'PT'
p7798
(lp7799
S'Journal Article'
p7800
asS'LA'
p7801
(lp7802
S'eng'
p7803
asS'MH'
p7804
(lp7805
S'Adult'
p7806
aS'Anti-HIV Agents/therapeutic use'
p7807
aS'Antitubercular Agents/adverse effects/*therapeutic use'
p7808
aS'Cohort Studies'
p7809
aS'Diarylquinolines/adverse effects/*therapeutic use'
p7810
aS'Extensively Drug-Resistant Tuberculosis/*drug therapy/epidemiology/microbiology'
p7811
aS'Female'
p7812
aS'Fluoroquinolones/pharmacology'
p7813
aS'Follow-Up Studies'
p7814
aS'HIV Infections/drug therapy/*epidemiology'
p7815
aS'Humans'
p7816
aS'Male'
p7817
aS'Middle Aged'
p7818
aS'Prevalence'
p7819
aS'Prospective Studies'
p7820
aS'South Africa/epidemiology'
p7821
aS'Treatment Outcome'
p7822
asS'FAU'
p7823
(lp7824
S'Ndjeka, N'
p7825
aS'Conradie, F'
p7826
aS'Schnippel, K'
p7827
aS'Hughes, J'
p7828
aS'Bantubani, N'
p7829
aS'Ferreira, H'
p7830
aS'Maartens, G'
p7831
aS'Mametja, D'
p7832
aS'Meintjes, G'
p7833
aS'Padanilam, X'
p7834
aS'Variava, E'
p7835
aS'Pym, A'
p7836
aS'Pillay, Y'
p7837
asS'EDAT'
p7838
S'2015/07/15 06:00'
p7839
sS'PST'
p7840
S'ppublish'
p7841
sS'SO'
p7842
S'Int J Tuberc Lung Dis. 2015 Aug;19(8):979-85. doi: 10.5588/ijtld.14.0944.'
p7843
sS'PG'
p7844
S'979-85'
p7845
sS'TI'
p7846
S'Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis.'
p7847
sS'SB'
p7848
S'IM'
p7849
sS'RN'
p7850
(lp7851
S'0 (Anti-HIV Agents)'
p7852
aS'0 (Antitubercular Agents)'
p7853
aS'0 (Diarylquinolines)'
p7854
aS'0 (Fluoroquinolones)'
p7855
aS'78846I289Y (bedaquiline)'
p7856
asS'PL'
p7857
S'France'
p7858
sS'TA'
p7859
S'Int J Tuberc Lung Dis'
p7860
stRp7861
ag2
(g3
g4
(dp7862
S'LID'
p7863
S'10.1186/s12879-015-0967-z [doi]'
p7864
sS'STAT'
p7865
S'MEDLINE'
p7866
sS'DEP'
p7867
S'20150709'
p7868
sS'DA'
p7869
S'20150709'
p7870
sS'AID'
p7871
(lp7872
S'10.1186/s12879-015-0967-z [doi]'
p7873
aS'10.1186/s12879-015-0967-z [pii]'
p7874
asS'CRDT'
p7875
(lp7876
S'2015/07/10 06:00'
p7877
asS'DP'
p7878
S'2015'
p7879
sS'AD'
p7880
S'Lung Infection and Immunity Unit, Division of Pulmonology & UCT Lung Institute, Department of Medicine, University of Cape Town, Cape Town, South Africa. Jonny.Peter@uct.ac.za. TB Vaccine group, Jenner Institute, University of Oxford, Oxford, UK. Jonny.Peter@uct.ac.za. Department of Medicine, University of Cape Town, Cape Town, South Africa. Jonny.Peter@uct.ac.za. Lung Infection and Immunity Unit, Division of Pulmonology & UCT Lung Institute, Department of Medicine, University of Cape Town, Cape Town, South Africa. Grant.Theron@uct.ac.za. Lung Infection and Immunity Unit, Division of Pulmonology & UCT Lung Institute, Department of Medicine, University of Cape Town, Cape Town, South Africa. duncanchanda@gmail.com. Institute for Medical Research & Training (IMReT), University Teaching Hospital, Lusaka, Zambia. duncanchanda@gmail.com. National Institute of Medical Research, Mbeya Medical Research Centre, Mbeya, Tanzania. pclowes@nimr-mmrc.org. Division of Infectious Diseases and Tropical Medicine, Medical Centre of the University of Munich (LMU), Munich, Germany. pclowes@nimr-mmrc.org. Division of Infectious Diseases and Tropical Medicine, Medical Centre of the University of Munich (LMU), Munich, Germany. arachow@mmrp.org. German Centre for Infection Research (DZIF), Munich, Germany. arachow@mmrp.org. Department of Medicine, University of Cape Town, Cape Town, South Africa. lesosky@gmail.com. Division of Infectious Diseases and Tropical Medicine, Medical Centre of the University of Munich (LMU), Munich, Germany. hoelscher@lrz.uni-muenchen.de. German Centre for Infection Research (DZIF), Munich, Germany. hoelscher@lrz.uni-muenchen.de. Institute for Medical Research & Training (IMReT), University Teaching Hospital, Lusaka, Zambia. pbmwaba2000@yahoo.com. South African Medical Research Council, Durban, South Africa, KwaZulu Research Institute for Tuberculosis and HIV (K-RITH), Durban, South Africa. alexanderpym@hotmail.com. Lung Infection and Immunity Unit, Division of Pulmonology & UCT Lung Institute, Department of Medicine, University of Cape Town, Cape Town, South Africa. keertan.dheda@uct.ac.za. Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa. keertan.dheda@uct.ac.za.'
p7881
sS'OWN'
p7882
S'NLM'
p7883
sS'PT'
p7884
(lp7885
S'Journal Article'
p7886
asS'LA'
p7887
(lp7888
S'eng'
p7889
asS'DCOM'
p7890
S'20160107'
p7891
sS'JT'
p7892
S'BMC infectious diseases'
p7893
sS'LR'
p7894
S'20150712'
p7895
sS'FAU'
p7896
(lp7897
S'Peter, Jonny'
p7898
aS'Theron, Grant'
p7899
aS'Chanda, Duncan'
p7900
aS'Clowes, Petra'
p7901
aS'Rachow, Andrea'
p7902
aS'Lesosky, Maia'
p7903
aS'Hoelscher, Michael'
p7904
aS'Mwaba, Peter'
p7905
aS'Pym, Alex'
p7906
aS'Dheda, Keertan'
p7907
asS'TI'
p7908
S'Test characteristics and potential impact of the urine LAM lateral flow assay in HIV-infected outpatients under investigation for TB and able to self-expectorate sputum for diagnostic testing.'
p7909
sS'RN'
p7910
(lp7911
S'0 (Lipopolysaccharides)'
p7912
aS'0 (lipoarabinomannan)'
p7913
asS'PL'
p7914
S'England'
p7915
sS'PG'
p7916
S'262'
p7917
sS'FIR'
p7918
(lp7919
S'Pretorius, M'
p7920
aS'Pascoe, M'
p7921
aS'Soetwater, B'
p7922
aS'Wyngard, M'
p7923
aS'Pool, L'
p7924
aS'Viny, C'
p7925
aS'Kasonde, M'
p7926
aS'Manjeta, L'
p7927
aS'Mthiyane, T'
p7928
aS'Ntshuba, N'
p7929
aS'Gumede, S'
p7930
aS'Mvuyane, T'
p7931
aS'Mbambo, P'
p7932
aS'Mangu, C'
p7933
aS'Kayombo, F'
p7934
aS'Temihanga, A'
p7935
aS'Kimaro, M'
p7936
aS'Mnyanyi, B'
p7937
aS'Mgogo, I'
p7938
aS'Ambukege, B'
p7939
aS'Sanga, T'
p7940
aS'Meldau, R'
p7941
aS'Woodbourne, V'
p7942
aS'Hope, P'
p7943
aS'Mzyece, J'
p7944
aS'Madaar, F'
p7945
aS'Kayombo, F'
p7946
aS'Mbilinyi, H'
p7947
aS'Rojas-Ponce, G'
p7948
aS'Mapamba, D'
p7949
aS'Lueer, C'
p7950
aS'Bauer, A'
p7951
aS'Njovu, L'
p7952
aS'Cogill, D'
p7953
aS'Louw, V'
p7954
aS'Kapotwe, V'
p7955
aS'Connolly, C'
p7956
aS'Kowuor, D'
p7957
aS'Chiwerengo, N'
p7958
aS'Edwards, S'
p7959
asS'JID'
p7960
S'100968551'
p7961
sS'AB'
p7962
S'BACKGROUND: The commercially available urine LAM strip test, a point-of-care tuberculosis (TB) assay, requires evaluation in a primary care setting where it is most needed. There is currently inadequate data to guide implementation in TB and HIV-endemic settings. METHODS: Adult HIV-infected outpatients with suspected pulmonary TB able to self-expectorate sputum from four primary clinics in South Africa, Zambia and Tanzania underwent diagnostic evaluation [sputum smear microscopy, Xpert-MTB/RIF, and culture (reference standard)] as part of a prospective parent study. Urine LAM testing (grade-2 cut-point) was performed on archived samples. Performance characteristics of LAM alone or in combination with sputum-based diagnostics were evaluated. Potential impact on 2 and 6-month morbidity (TBscore), patient dropout rates, and prognosis (death/ loss to follow-up) were evaluated. RESULTS: Among 583 participants with suspected TB that were HIV-infected or refused testing, the overall LAM sensitivity (95 % CI; n/N) and in the CD4 </= 100 cells/mm(3) sub-group was 22.7 % (16.6-28.7; 41/181) and 30.4 % (17.1-43.7; 14/46), respectively. Overall specificity was 93.0 % (90.5-95.6; 361/388). Amongst culture-positive TB cases, adjunctive LAM testing did not improve the sensitivity of either sputum Xpert-MTB/RIF [78.2 % (69.8-86.7; 72/92) versus 76.1 % (67.4-84.8; 70/92), p = 0.7] or smear-microscopy [56.2 % (45.9-66.5; 50/89) versus 43.8 % (33.5-54.1; 39/89), p = 0.1). Clinic-based LAM, as an adjunct to either smear microscopy or Xpert MTB/RIF same-day testing, would neither have decreased patient dropout, nor increased same-day treatment initiation in this clinical setting where same-day chest radiography was available. LAM positivity was associated with 6-month lost-to-follow-up/death (AOR 4.4; p = 0.002) but not TBscore (at baseline or change in TBscore 2-months post-treatment) (p = 0.17). CONCLUSIONS: In African HIV-TB co-infected outpatients able to self-expectorate sputum LAM had limited sensitivity even at low CD4 counts, and offered no significant incremental diagnostic yield over Xpert-MTB/RIF or smear microscopy. In primary care clinics with chest radiography and where empiric TB treatment is common, LAM seems unlikely to improve rates of same-day treatment initiation and patient dropout, however, the ability of LAM to identify patients at high risk of death or lost-to-follow-up may offer important prognostic value.'
p7963
sS'CN'
p7964
(lp7965
S'TB-NEAT team'
p7966
asS'VI'
p7967
S'15'
p7968
sS'IS'
p7969
S'1471-2334 (Electronic) 1471-2334 (Linking)'
p7970
sS'IR'
p7971
(lp7972
S'Pretorius M'
p7973
aS'Pascoe M'
p7974
aS'Soetwater B'
p7975
aS'Wyngard M'
p7976
aS'Pool L'
p7977
aS'Viny C'
p7978
aS'Kasonde M'
p7979
aS'Manjeta L'
p7980
aS'Mthiyane T'
p7981
aS'Ntshuba N'
p7982
aS'Gumede S'
p7983
aS'Mvuyane T'
p7984
aS'Mbambo P'
p7985
aS'Mangu C'
p7986
aS'Kayombo F'
p7987
aS'Temihanga A'
p7988
aS'Kimaro M'
p7989
aS'Mnyanyi B'
p7990
aS'Mgogo I'
p7991
aS'Ambukege B'
p7992
aS'Sanga T'
p7993
aS'Meldau R'
p7994
aS'Woodbourne V'
p7995
aS'Hope P'
p7996
aS'Mzyece J'
p7997
aS'Madaar F'
p7998
aS'Kayombo F'
p7999
aS'Mbilinyi H'
p8000
aS'Rojas-Ponce G'
p8001
aS'Mapamba D'
p8002
aS'Lueer C'
p8003
aS'Bauer A'
p8004
aS'Njovu L'
p8005
aS'Cogill D'
p8006
aS'Louw V'
p8007
aS'Kapotwe V'
p8008
aS'Connolly C'
p8009
aS'Kowuor D'
p8010
aS'Chiwerengo N'
p8011
aS'Edwards S'
p8012
asS'AU'
p8013
(lp8014
S'Peter J'
p8015
aS'Theron G'
p8016
aS'Chanda D'
p8017
aS'Clowes P'
p8018
aS'Rachow A'
p8019
aS'Lesosky M'
p8020
aS'Hoelscher M'
p8021
aS'Mwaba P'
p8022
aS'Pym A'
p8023
aS'Dheda K'
p8024
asS'MHDA'
p8025
S'2016/01/08 06:00'
p8026
sS'PHST'
p8027
(lp8028
S'2014/11/27 [received]'
p8029
aS'2015/05/29 [accepted]'
p8030
aS'2015/07/09 [aheadofprint]'
p8031
asS'OID'
p8032
(lp8033
S'NLM: PMC4495934'
p8034
asS'MH'
p8035
(lp8036
S'Adult'
p8037
aS'Aged'
p8038
aS'Ambulatory Care Facilities'
p8039
aS'Biological Assay'
p8040
aS'CD4 Lymphocyte Count'
p8041
aS'Coinfection'
p8042
aS'Cross-Sectional Studies'
p8043
aS'Diagnostic Tests, Routine'
p8044
aS'Female'
p8045
aS'HIV Infections/complications/*immunology'
p8046
aS'Humans'
p8047
aS'Lipopolysaccharides/*urine'
p8048
aS'Male'
p8049
aS'Middle Aged'
p8050
aS'Outpatients'
p8051
aS'Point-of-Care Systems'
p8052
aS'Prospective Studies'
p8053
aS'Sensitivity and Specificity'
p8054
aS'South Africa'
p8055
aS'Sputum/*microbiology'
p8056
aS'Tanzania'
p8057
aS'Tuberculosis/diagnosis'
p8058
aS'Tuberculosis, Pulmonary/complications/*diagnosis/immunology'
p8059
aS'Urinalysis'
p8060
aS'Young Adult'
p8061
aS'Zambia'
p8062
asS'EDAT'
p8063
S'2015/07/15 06:00'
p8064
sS'PMC'
p8065
S'PMC4495934'
p8066
sS'SO'
p8067
S'BMC Infect Dis. 2015 Jul 9;15:262. doi: 10.1186/s12879-015-0967-z.'
p8068
sS'SB'
p8069
S'IM'
p8070
sS'PMID'
p8071
S'26156025'
p8072
sS'TA'
p8073
S'BMC Infect Dis'
p8074
sS'PST'
p8075
S'epublish'
p8076
stRp8077
ag2
(g3
g4
(dp8078
S'LID'
p8079
S'10.1371/journal.pone.0130580 [doi]'
p8080
sS'STAT'
p8081
S'MEDLINE'
p8082
sS'DEP'
p8083
S'20150707'
p8084
sS'DA'
p8085
S'20150708'
p8086
sS'AID'
p8087
(lp8088
S'10.1371/journal.pone.0130580 [doi]'
p8089
aS'PONE-D-14-25452 [pii]'
p8090
asS'CRDT'
p8091
(lp8092
S'2015/07/08 06:00'
p8093
asS'DP'
p8094
S'2015'
p8095
sS'OWN'
p8096
S'NLM'
p8097
sS'PT'
p8098
(lp8099
S'Journal Article'
p8100
aS'Observational Study'
p8101
aS"Research Support, Non-U.S. Gov't"
p8102
asS'LA'
p8103
(lp8104
S'eng'
p8105
asS'FAU'
p8106
(lp8107
S'Bila, Dulce Celina Adolfo'
p8108
aS'Boullosa, Lidia Teodoro'
p8109
aS'Vubil, Adolfo Salvador'
p8110
aS'Mabunda, Nedio Jonas'
p8111
aS'Abreu, Celina Monteiro'
p8112
aS'Ismael, Nalia'
p8113
aS'Jani, Ilesh Vinodrai'
p8114
aS'Tanuri, Amilcar'
p8115
asS'JT'
p8116
S'PloS one'
p8117
sS'LR'
p8118
S'20150719'
p8119
sS'PG'
p8120
S'e0130580'
p8121
sS'TI'
p8122
S'Trends in Prevalence of HIV-1 Drug Resistance in a Public Clinic in Maputo, Mozambique.'
p8123
sS'RN'
p8124
(lp8125
S'0 (Anti-Retroviral Agents)'
p8126
asS'PL'
p8127
S'United States'
p8128
sS'TA'
p8129
S'PLoS One'
p8130
sS'JID'
p8131
S'101285081'
p8132
sS'AB'
p8133
S'BACKGROUND: An observational study was conducted in Maputo, Mozambique, to investigate trends in prevalence of HIV drug resistance (HIVDR) in antiretroviral (ART) naive subjects initiating highly active antiretroviral treatment (HAART). METHODOLOGY/PRINCIPAL FINDINGS: To evaluate the pattern of drug resistance mutations (DRMs) found in adults on ART failing first-line HAART [patients with detectable viral load (VL)]. Untreated subjects [Group 1 (G1; n=99)] and 274 treated subjects with variable length of exposure to ARV s [6-12 months, Group 2 (G2;n=93); 12-24 months, Group 3 (G3;n=81); >24 months (G4;n=100)] were enrolled. Virological and immunological failure (VF and IF) were measured based on viral load (VL) and T lymphocyte CD4+ cells (TCD4+) count and genotypic resistance was also performed. Major subtype found was C (untreated: n=66, 97,06%; treated: n=36, 91.7%). Maximum virological suppression was observed in G3, and significant differences intragroup were observed between VF and IF in G4 (p=0.022). Intergroup differences were observed between G3 and G4 for VF (p=0.023) and IF between G2 and G4 (p=0.0018). Viral suppression (<50 copies/ml) ranged from 84.9% to 90.1%, and concordant VL and DRM ranged from 25% to 57%. WHO cut-off for determining VF as given by 2010 guidelines (>5000 copies/ml) identified 50% of subjects carrying DRM compared to 100% when lower VL cut-off was used (<50 copies/ml). Length of exposure to ARVs was directly proportional to the complexity of DRM patterns. In Mozambique, VL suppression was achieved in 76% of individuals after 24 months on HAART. This is in agreement with WHO target for HIVDR prevention target (70%). CONCLUSIONS: We demonstrated that the best way to determine therapeutic failure is VL compared to CD4 counts. The rationalized use of VL testing is needed to ensure timely detection of treatment failures preventing the occurrence of TDR and new infections.'
p8134
sS'AD'
p8135
S'National Institute of Health of Mozambique, Maputo, Mozambique; Department of Genetic, Molecular Virology Laboratory, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil; Department of Institute of Biophysics Carlos Chagas Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. Department of Genetic, Molecular Virology Laboratory, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. National Institute of Health of Mozambique, Maputo, Mozambique. National Institute of Health of Mozambique, Maputo, Mozambique. Department of Genetic, Molecular Virology Laboratory, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. National Institute of Health of Mozambique, Maputo, Mozambique. National Institute of Health of Mozambique, Maputo, Mozambique. Department of Genetic, Molecular Virology Laboratory, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.'
p8136
sS'IP'
p8137
S'7'
sS'IS'
p8138
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p8139
sS'PMC'
p8140
S'PMC4494809'
p8141
sS'DCOM'
p8142
S'20160418'
p8143
sS'AU'
p8144
(lp8145
S'Bila DC'
p8146
aS'Boullosa LT'
p8147
aS'Vubil AS'
p8148
aS'Mabunda NJ'
p8149
aS'Abreu CM'
p8150
aS'Ismael N'
p8151
aS'Jani IV'
p8152
aS'Tanuri A'
p8153
asS'VI'
p8154
S'10'
p8155
sS'MHDA'
p8156
S'2016/04/19 06:00'
p8157
sS'PHST'
p8158
(lp8159
S'2015 [ecollection]'
p8160
aS'2014/06/10 [received]'
p8161
aS'2015/05/22 [accepted]'
p8162
aS'2015/07/07 [epublish]'
p8163
asS'OID'
p8164
(lp8165
S'NLM: PMC4494809'
p8166
asS'MH'
p8167
(lp8168
S'Adult'
p8169
aS'Ambulatory Care Facilities'
p8170
aS'Anti-Retroviral Agents/*therapeutic use'
p8171
aS'*Antiretroviral Therapy, Highly Active'
p8172
aS'CD4 Lymphocyte Count'
p8173
aS'Drug Resistance, Viral/genetics'
p8174
aS'Female'
p8175
aS'Genotype'
p8176
aS'HIV Infections/*drug therapy/epidemiology/virology'
p8177
aS'HIV-1/*drug effects/genetics/physiology'
p8178
aS'Host-Pathogen Interactions/drug effects'
p8179
aS'Humans'
p8180
aS'Male'
p8181
aS'Mozambique/epidemiology'
p8182
aS'Mutation'
p8183
aS'Prevalence'
p8184
aS'Time Factors'
p8185
aS'Treatment Failure'
p8186
aS'Viral Load/drug effects/genetics'
p8187
asS'EDAT'
p8188
S'2015/07/08 06:00'
p8189
sS'SO'
p8190
S'PLoS One. 2015 Jul 7;10(7):e0130580. doi: 10.1371/journal.pone.0130580. eCollection 2015.'
p8191
sS'SB'
p8192
S'IM'
p8193
sS'PMID'
p8194
S'26151752'
p8195
sS'PST'
p8196
S'epublish'
p8197
stRp8198
ag2
(g3
g4
(dp8199
S'LID'
p8200
S'10.1371/journal.pone.0132425 [doi]'
p8201
sS'STAT'
p8202
S'MEDLINE'
p8203
sS'DEP'
p8204
S'20150706'
p8205
sS'DA'
p8206
S'20150707'
p8207
sS'AID'
p8208
(lp8209
S'10.1371/journal.pone.0132425 [doi]'
p8210
aS'PONE-D-15-01967 [pii]'
p8211
asS'CRDT'
p8212
(lp8213
S'2015/07/07 06:00'
p8214
asS'DP'
p8215
S'2015'
p8216
sS'AD'
p8217
S"Health Systems Research Unit, Medical Research Council, Cape Town, South Africa. School of Public Health, University of the Western Cape, Cape Town, South Africa; United Nations Children's Fund, New York, United States of America. Health Systems Research Unit, Medical Research Council, Cape Town, South Africa. Centers for Disease Control and Prevention, Center for Global Health, Division of Global HIV/AIDS, Atlanta, Georgia, United States of America. National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa; Division of Virology and Communicable Diseases, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa. National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa; Department of Paediatrics and Child Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Health Systems Research Unit, Medical Research Council, Cape Town, South Africa. Health Systems Research Unit, Medical Research Council, Cape Town, South Africa; School of Public Health, University of the Western Cape, Cape Town, South Africa; School of Public Health, University of the Witwatersrand, Johannesburg, South Africa. Centers for Disease Control and Prevention, Center for Global Health, Division of Global HIV/AIDS, Pretoria, South Africa. United Nations Children's Fund, Pretoria, South Africa. School of Public Health, University of the Western Cape, Cape Town, South Africa; United Nations Children's Fund, New York, United States of America. World Health Organization, Geneva, Switzerland. National Department of Health, Pretoria, South Africa. Department of Paediatrics and Child Health, University of Pretoria, Pretoria, South Africa; Health Systems Research Unit, Medical Research Council, Pretoria, South Africa."
p8218
sS'OWN'
p8219
S'NLM'
p8220
sS'PT'
p8221
(lp8222
S'Journal Article'
p8223
aS"Research Support, Non-U.S. Gov't"
p8224
asS'LA'
p8225
(lp8226
S'eng'
p8227
asS'FAU'
p8228
(lp8229
S'Woldesenbet, Selamawit'
p8230
aS'Jackson, Debra'
p8231
aS'Lombard, Carl'
p8232
aS'Dinh, Thu-Ha'
p8233
aS'Puren, Adrian'
p8234
aS'Sherman, Gayle'
p8235
aS'Ramokolo, Vundli'
p8236
aS'Doherty, Tanya'
p8237
aS'Mogashoa, Mary'
p8238
aS'Bhardwaj, Sanjana'
p8239
aS'Chopra, Mickey'
p8240
aS'Shaffer, Nathan'
p8241
aS'Pillay, Yogan'
p8242
aS'Goga, Ameena'
p8243
asS'JT'
p8244
S'PloS one'
p8245
sS'LR'
p8246
S'20150719'
p8247
sS'PG'
p8248
S'e0132425'
p8249
sS'TI'
p8250
S'Missed Opportunities along the Prevention of Mother-to-Child Transmission Services Cascade in South Africa: Uptake, Determinants, and Attributable Risk (the SAPMTCTE).'
p8251
sS'RN'
p8252
(lp8253
S'0 (Anti-HIV Agents)'
p8254
aS'4B9XT59T7S (Zidovudine)'
p8255
aS'99DK7FVK1H (Nevirapine)'
p8256
asS'PL'
p8257
S'United States'
p8258
sS'TA'
p8259
S'PLoS One'
p8260
sS'JID'
p8261
S'101285081'
p8262
sS'AB'
p8263
S"OBJECTIVES: We examined uptake of prevention of mother-to-child HIV transmission (PMTCT) services, predictors of missed opportunities, and infant HIV transmission attributable to missed opportunities along the PMTCT cascade across South Africa. METHODS: A cross-sectional survey was conducted among 4-8 week old infants receiving first immunisations in 580 nationally representative public health facilities in 2010. This included maternal interviews and testing infants' dried blood spots for HIV. A weighted analysis was performed to assess uptake of antenatal and perinatal PMTCT services along the PMTCT cascade (namely: maternal HIV testing, CD4 count test/result, and receiving maternal and infant antiretroviral treatment) and predictors of dropout. The population attributable fraction associated with dropouts at each service point are estimated. RESULTS: Of 9,803 mothers included, 31.7% were HIV-positive as identified by reactive infant antibody tests. Of these 80.4% received some form of maternal and infant antiretroviral treatment. More than a third (34.9%) of mothers dropped out from one or more steps in the PMTCT service cascade. In a multivariable analysis, the following characteristics were associated with increased dropout from the PMTCT cascade: adolescent (<20 years) mothers, low socioeconomic score, low education level, primiparous mothers, delayed first antenatal visit, homebirth, and non-disclosure of HIV status. Adolescent mothers were twice (adjusted odds ratio: 2.2, 95% confidence interval: 1.5-3.3) as likely to be unaware of their HIV-positive status and had a significantly higher rate (85.2%) of unplanned pregnancies compared to adults aged >/=20 years (55.5%, p = 0.0001). A third (33.8%) of infant HIV infections were attributable to dropout in one or more steps in the cascade. CONCLUSION: A third of transmissions attributable to missed opportunities of PMTCT services can be prevented by optimizing the uptake of PMTCT services. Identified risk factors for low PMTCT service uptake should be addressed through health facility and community-level interventions, including raising awareness, promoting women education, adolescent focused interventions, and strengthening linkages/referral-system between communities and health facilities."
p8264
sS'CN'
p8265
(lp8266
S'South African PMTCT Evaluation (SAPMCTE) Team'
p8267
asS'IP'
p8268
S'7'
sS'IS'
p8269
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p8270
sS'PMC'
p8271
S'PMC4492960'
p8272
sS'DCOM'
p8273
S'20160510'
p8274
sS'AU'
p8275
(lp8276
S'Woldesenbet S'
p8277
aS'Jackson D'
p8278
aS'Lombard C'
p8279
aS'Dinh TH'
p8280
aS'Puren A'
p8281
aS'Sherman G'
p8282
aS'Ramokolo V'
p8283
aS'Doherty T'
p8284
aS'Mogashoa M'
p8285
aS'Bhardwaj S'
p8286
aS'Chopra M'
p8287
aS'Shaffer N'
p8288
aS'Pillay Y'
p8289
aS'Goga A'
p8290
asS'VI'
p8291
S'10'
p8292
sS'MHDA'
p8293
S'2016/05/11 06:00'
p8294
sS'PHST'
p8295
(lp8296
S'2015 [ecollection]'
p8297
aS'2015/01/15 [received]'
p8298
aS'2015/06/12 [accepted]'
p8299
aS'2015/07/06 [epublish]'
p8300
asS'OID'
p8301
(lp8302
S'NLM: PMC4492960'
p8303
asS'MH'
p8304
(lp8305
S'AIDS Serodiagnosis/utilization'
p8306
aS'Adolescent'
p8307
aS'Adult'
p8308
aS'Anti-HIV Agents/therapeutic use'
p8309
aS'CD4 Lymphocyte Count/utilization'
p8310
aS'Cross-Sectional Studies'
p8311
aS'Developing Countries'
p8312
aS'Female'
p8313
aS'HIV Infections/congenital/diagnosis/drug therapy/epidemiology/*prevention & control/transmission'
p8314
aS'Home Childbirth/statistics & numerical data'
p8315
aS'Humans'
p8316
aS'Infant, Newborn'
p8317
aS'Infectious Disease Transmission, Vertical/*prevention & control'
p8318
aS'Maternal Age'
p8319
aS'Maternal Health Services/organization & administration/*statistics & numerical data'
p8320
aS'Nevirapine/therapeutic use'
p8321
aS'Parity'
p8322
aS'Patient Dropouts'
p8323
aS'Pregnancy'
p8324
aS'*Pregnancy Complications, Infectious/diagnosis/drug therapy/epidemiology'
p8325
aS'Pregnancy in Adolescence'
p8326
aS'Prenatal Care/*statistics & numerical data'
p8327
aS'Risk Factors'
p8328
aS'Socioeconomic Factors'
p8329
aS'South Africa/epidemiology'
p8330
aS'Zidovudine/therapeutic use'
p8331
asS'EDAT'
p8332
S'2015/07/07 06:00'
p8333
sS'SO'
p8334
S'PLoS One. 2015 Jul 6;10(7):e0132425. doi: 10.1371/journal.pone.0132425. eCollection 2015.'
p8335
sS'SB'
p8336
S'IM'
p8337
sS'PMID'
p8338
S'26147598'
p8339
sS'PST'
p8340
S'epublish'
p8341
stRp8342
ag2
(g3
g4
(dp8343
S'LID'
p8344
S'10.1186/s12913-015-0912-2 [doi]'
p8345
sS'STAT'
p8346
S'MEDLINE'
p8347
sS'DEP'
p8348
S'20150704'
p8349
sS'DA'
p8350
S'20150704'
p8351
sS'AID'
p8352
(lp8353
S'10.1186/s12913-015-0912-2 [doi]'
p8354
aS'10.1186/s12913-015-0912-2 [pii]'
p8355
asS'CRDT'
p8356
(lp8357
S'2015/07/05 06:00'
p8358
asS'DP'
p8359
S'2015'
p8360
sS'OWN'
p8361
S'NLM'
p8362
sS'PT'
p8363
(lp8364
S'Journal Article'
p8365
aS'Observational Study'
p8366
aS"Research Support, Non-U.S. Gov't"
p8367
asS'LA'
p8368
(lp8369
S'eng'
p8370
asS'DCOM'
p8371
S'20160105'
p8372
sS'JT'
p8373
S'BMC health services research'
p8374
sS'LR'
p8375
S'20150707'
p8376
sS'FAU'
p8377
(lp8378
S'Mberi, Mazvita Naome'
p8379
aS'Kuonza, Lazarus Rugare'
p8380
aS'Dube, Nomathemba Michelle'
p8381
aS'Nattey, Cornelius'
p8382
aS'Manda, Samuel'
p8383
aS'Summers, Robert'
p8384
asS'TI'
p8385
S'Determinants of loss to follow-up in patients on antiretroviral treatment, South Africa, 2004-2012: a cohort study.'
p8386
sS'RN'
p8387
(lp8388
S'0 (Anti-Retroviral Agents)'
p8389
asS'PL'
p8390
S'England'
p8391
sS'PG'
p8392
S'259'
p8393
sS'JID'
p8394
S'101088677'
p8395
sS'AB'
p8396
S'BACKGROUND: The number of Human Immunodeficiency Virus (HIV) infected people eligible for initiation on antiretroviral Therapy (ART) is increasing. ART programmatic success requires that patients who are taking ART remain on treatment and are followed up regularly. This study investigated factors associated with being lost to follow-up, in a cohort of patients enrolled in a pharmacovigilance study in South Africa. METHODS: This was a retrospective observational cohort study performed at one of the Medunsa National Pharmacovigilance Centre\'s (MNPC) ART sentinel surveillance sites. Loss to Follow-up (LTFU) was defined as "a patient who had been followed up at the sentinel site, who had not had contact with the health facility for 180 days or more since their last recorded expected date of return or if there were 180 days or more between the expected date of return and the next clinic visit". RESULTS: Out of 595 patients, 65.5% (n = 390) were female and 23.4% (n = 139) were LTFU. The median time on ART before LTFU was 21.5 months (interquartile range: 12.9 - 34.7 months). The incidence rate of LTFU was 103 per 1000 person-years in the first year on ART and increased to 405 per 1000 person-years in the eighth year of taking ART. Factors associated with becoming LTFU included not having a committed partner (Adjusted Hazard Ratio (aHR): 2.9, 95% Confidence Interval (CI):1.19-6.97, p = 0.019), being self-employed (aHR: 13.9, 95% CI:2.81 - 69.06, p = 0.001), baseline CD4 count > 200 cells/ml (aHR: 3.8, 95% CI: 1.85-7.85, p < 0.001), detectable last known Viral Load (VL) (aHR: 3.6, 95% CI:1.98-6.52, p < 0.001) and a last known World Health Organisation clinical stage three or four (aHR: 2.0, 95% CI:1.22-3.27, p = 0.006). Patients that previously had an ART adverse event had a lower risk (aHR: 0.6, 95% CI: 0.38 - 0.99, p = 0.044) of becoming LTFU than those that had not. CONCLUSION: The incidence rate of LTFU increases with additional years on ART. Intensified measures to improve patient retention on ART must be prioritised with increasing patient time on ART and in patients that are at increased risk of becoming lost to follow-up.'
p8397
sS'AD'
p8398
S'South African Field Epidemiology Training Programme, National Institute for Communicable Diseases of the National Health Laboratory Services, 1 Modderfontein Road, Monument Park 0105, Post net suite 179, P/bag X27923, Sandringham, South Africa. mazvita1979@gmail.com. School of Health Systems and Public Health, Faculty of Health Sciences, University of Pretoria, Pretoria, Dr Savage Road 0084 Pinshof 349, Pretoria, South Africa. mazvita1979@gmail.com. Medunsa National Pharmacovigilance Centre, Medunsa Campus, University of Limpopo, Pretoria, South Africa. mazvita1979@gmail.com. Wits Reproductive Health and HIV Institute, 22 Esselen Street, Hillbrow, South Africa. mazvita1979@gmail.com. South African Field Epidemiology Training Programme, National Institute for Communicable Diseases of the National Health Laboratory Services, 1 Modderfontein Road, Monument Park 0105, Post net suite 179, P/bag X27923, Sandringham, South Africa. LazarusK@nicd.ac.za. School of Health Systems and Public Health, Faculty of Health Sciences, University of Pretoria, Pretoria, Dr Savage Road 0084 Pinshof 349, Pretoria, South Africa. LazarusK@nicd.ac.za. South African Field Epidemiology Training Programme, National Institute for Communicable Diseases of the National Health Laboratory Services, 1 Modderfontein Road, Monument Park 0105, Post net suite 179, P/bag X27923, Sandringham, South Africa. ngumede@yahoo.com. National Institute for Occupational Health, Smit Street, Braamfontein, South Africa. Cornelius.nattey@nioh.nhls.ac.za. Global Partnership Initiated Academia for the control of health threats, Bernard Nocht Institute for Tropical Medicine, Bernad-Nocht Street 74, 20259, Hamburg, Germany. Cornelius.nattey@nioh.nhls.ac.za. Biostatistics Research unit, South African Medical Research Council, 1 Soutpansberg Road, Pretoria, South Africa. Samuel.Manda@mrc.ac.za. Division of Epidemiology and biostatistics, School of Public Health, University of the Witwatersrand, 27 St Andrews Road Parktown, Johannesburg, South Africa. Samuel.Manda@mrc.ac.za. Medunsa National Pharmacovigilance Centre, Medunsa Campus, University of Limpopo, Pretoria, South Africa. randbsummers@mweb.ac.za. Department of Pharmacy, Faculty of Health Sciences, MEDUNSA Campus, University of Limpopo, Pretoria, South Africa. randbsummers@mweb.ac.za.'
p8399
sS'VI'
p8400
S'15'
p8401
sS'IS'
p8402
S'1472-6963 (Electronic) 1472-6963 (Linking)'
p8403
sS'PMC'
p8404
S'PMC4491264'
p8405
sS'AU'
p8406
(lp8407
S'Mberi MN'
p8408
aS'Kuonza LR'
p8409
aS'Dube NM'
p8410
aS'Nattey C'
p8411
aS'Manda S'
p8412
aS'Summers R'
p8413
asS'MHDA'
p8414
S'2016/01/06 06:00'
p8415
sS'PHST'
p8416
(lp8417
S'2014/09/04 [received]'
p8418
aS'2015/06/08 [accepted]'
p8419
aS'2015/07/04 [aheadofprint]'
p8420
asS'OID'
p8421
(lp8422
S'NLM: PMC4491264'
p8423
asS'MH'
p8424
(lp8425
S'Adult'
p8426
aS'Anti-Retroviral Agents/*therapeutic use'
p8427
aS'CD4 Lymphocyte Count'
p8428
aS'Female'
p8429
aS'HIV Infections/*drug therapy/epidemiology'
p8430
aS'Humans'
p8431
aS'*Lost to Follow-Up'
p8432
aS'Male'
p8433
aS'Middle Aged'
p8434
aS'Pharmacovigilance'
p8435
aS'Retrospective Studies'
p8436
aS'Sexual Partners'
p8437
aS'South Africa/epidemiology'
p8438
aS'Viral Load'
p8439
aS'World Health Organization'
p8440
asS'EDAT'
p8441
S'2015/07/05 06:00'
p8442
sS'SO'
p8443
S'BMC Health Serv Res. 2015 Jul 4;15:259. doi: 10.1186/s12913-015-0912-2.'
p8444
sS'SB'
p8445
S'IM'
p8446
sS'PMID'
p8447
S'26141729'
p8448
sS'TA'
p8449
S'BMC Health Serv Res'
p8450
sS'PST'
p8451
S'epublish'
p8452
stRp8453
ag2
(g3
g4
(dp8454
S'LID'
p8455
S'10.1097/QAI.0000000000000724 [doi]'
p8456
sS'STAT'
p8457
S'MEDLINE'
p8458
sS'JT'
p8459
S'Journal of acquired immune deficiency syndromes (1999)'
p8460
sS'MID'
p8461
(lp8462
S'NIHMS707001'
p8463
asS'DA'
p8464
S'20151016'
p8465
sS'AID'
p8466
(lp8467
S'10.1097/QAI.0000000000000724 [doi]'
p8468
asS'CRDT'
p8469
(lp8470
S'2015/07/03 06:00'
p8471
asS'DP'
p8472
S'2015 Nov 1'
p8473
sS'AD'
p8474
S'*HIV, STD and Hepatitis Branch of Public Health Services, Health and Human Services, County of San Diego, San Diego, CA; daggerUniversity of California, San Diego, La Jolla, CA; double daggerDepartment of Microbiology, Universidade Eduardo Mondlane, Maputo, Mozambique; section signDepartment of Biostatistics, University of Washington, Seattle, WA; and ||Veterans Affairs San Diego Healthcare System, San Diego, CA.'
p8475
sS'OWN'
p8476
S'NLM'
p8477
sS'PT'
p8478
(lp8479
S'Journal Article'
p8480
aS'Research Support, N.I.H., Extramural'
p8481
aS"Research Support, Non-U.S. Gov't"
p8482
asS'LA'
p8483
(lp8484
S'eng'
p8485
asS'FAU'
p8486
(lp8487
S'Tilghman, Myres'
p8488
aS'Tsai, Daniel'
p8489
aS'Buene, Titos P'
p8490
aS'Tomas, Manuel'
p8491
aS'Amade, Salma'
p8492
aS'Gehlbach, Daniel'
p8493
aS'Chang, Stephanie'
p8494
aS'Ignacio, Caroline'
p8495
aS'Caballero, Gemma'
p8496
aS'Espitia, Stephen'
p8497
aS'May, Susanne'
p8498
aS'Noormahomed, Emilia V'
p8499
aS'Smith, Davey M'
p8500
asS'LR'
p8501
S'20151016'
p8502
sS'PG'
p8503
S'256-61'
p8504
sS'TI'
p8505
S'Pooled Nucleic Acid Testing to Detect Antiretroviral Treatment Failure in HIV-Infected Patients in Mozambique.'
p8506
sS'RN'
p8507
(lp8508
S'0 (Anti-HIV Agents)'
p8509
aS'0 (RNA, Viral)'
p8510
asS'IS'
p8511
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p8512
sS'PL'
p8513
S'United States'
p8514
sS'TA'
p8515
S'J Acquir Immune Defic Syndr'
p8516
sS'JID'
p8517
S'100892005'
p8518
sS'AB'
p8519
S'BACKGROUND: In resource-limited settings, viral load monitoring of HIV-infected patients receiving antiretroviral therapy (ART) is not readily available because of high costs. Here, we compared the accuracy and costs of quantitative and qualitative pooled methods with standard viral load testing. METHODS: Blood was collected prospectively from 461 patients receiving first-line ART in Mozambique who had not been evaluated previously with viral load testing. Screening for virologic failure of ART was performed quantitatively (ie, standard viral loads) and qualitatively [one and 2 rounds of polymerase chain reaction (PCR)]. Individual samples and minipools of 5 samples were then analyzed using both methods. The relative efficiency, accuracy, and costs of each method were calculated based on viral load thresholds for ART failure. RESULTS: Standard viral load testing of individual samples revealed a high rate of ART failure (19%-23%) across all virologic failure thresholds, and the majority of the patients (93%) with viral loads >1500 copies per milliliter had genotypic resistance to drugs in their ART regimen. Pooled quantitative screening and deconvolution testing had positive and negative predictive values exceeding 95% with cost savings of $11,250 compared with quantitative testing of each sample individually. Pooled qualitative screening and deconvolution testing had a higher cost savings of $30,147 for 1 PCR round and $25,535 for 2 PCR rounds compared with quantitative testing each sample individually. Both pooled qualitative PCR methods had positive and negative predictive values >/=90%, but the pooled 1-round PCR method had a sensitivity of 64%. CONCLUSIONS: Given the high rate of undiagnosed ART failure and drug resistance in this cohort, it is clear that virologic monitoring is urgently needed in this population. Here, we compared alternative methods of virologic monitoring with standard viral load testing of individual samples and found these methods to be cost saving and accurate. The test characteristics of each method will likely need to be considered for each local population before it is adopted.'
p8520
sS'GR'
p8521
(lp8522
S'AI100665/AI/NIAID NIH HHS/United States'
p8523
aS'AI36214/AI/NIAID NIH HHS/United States'
p8524
aS'AI69432/AI/NIAID NIH HHS/United States'
p8525
aS'EB015365/EB/NIBIB NIH HHS/United States'
p8526
aS'K24 AI100665/AI/NIAID NIH HHS/United States'
p8527
aS'P30 AI036214/AI/NIAID NIH HHS/United States'
p8528
aS'P30 MH062512/MH/NIMH NIH HHS/United States'
p8529
aS'R03 EB015365/EB/NIBIB NIH HHS/United States'
p8530
aS'R24TW008908/TW/FIC NIH HHS/United States'
p8531
aS'R24TW008910/TW/FIC NIH HHS/United States'
p8532
asS'IP'
p8533
S'3'
sS'PMCR'
p8534
(lp8535
S'2016/11/01 00:00'
p8536
asS'PMC'
p8537
S'PMC4607635'
p8538
sS'DCOM'
p8539
S'20160128'
p8540
sS'AU'
p8541
(lp8542
S'Tilghman M'
p8543
aS'Tsai D'
p8544
aS'Buene TP'
p8545
aS'Tomas M'
p8546
aS'Amade S'
p8547
aS'Gehlbach D'
p8548
aS'Chang S'
p8549
aS'Ignacio C'
p8550
aS'Caballero G'
p8551
aS'Espitia S'
p8552
aS'May S'
p8553
aS'Noormahomed EV'
p8554
aS'Smith DM'
p8555
asS'VI'
p8556
S'70'
p8557
sS'MHDA'
p8558
S'2016/01/29 06:00'
p8559
sS'OID'
p8560
(lp8561
S'NLM: NIHMS707001 [Available on 11/01/16]'
p8562
aS'NLM: PMC4607635 [Available on 11/01/16]'
p8563
asS'MH'
p8564
(lp8565
S'Anti-HIV Agents/*therapeutic use'
p8566
aS'HIV Infections/blood/*drug therapy/epidemiology/virology'
p8567
aS'Humans'
p8568
aS'Mozambique/epidemiology'
p8569
aS'Polymerase Chain Reaction/*methods'
p8570
aS'RNA, Viral/*isolation & purification'
p8571
aS'Treatment Failure'
p8572
aS'Viral Load'
p8573
asS'EDAT'
p8574
S'2015/07/03 06:00'
p8575
sS'SO'
p8576
S'J Acquir Immune Defic Syndr. 2015 Nov 1;70(3):256-61. doi: 10.1097/QAI.0000000000000724.'
p8577
sS'SB'
p8578
S'IM X'
p8579
sS'PMID'
p8580
S'26135327'
p8581
sS'PST'
p8582
S'ppublish'
p8583
stRp8584
ag2
(g3
g4
(dp8585
S'LID'
p8586
S'10.1097/QAI.0000000000000737 [doi]'
p8587
sS'STAT'
p8588
S'MEDLINE'
p8589
sS'JT'
p8590
S'Journal of acquired immune deficiency syndromes (1999)'
p8591
sS'MID'
p8592
(lp8593
S'NIHMS701309'
p8594
asS'DA'
p8595
S'20151028'
p8596
sS'AID'
p8597
(lp8598
S'10.1097/QAI.0000000000000737 [doi]'
p8599
asS'CRDT'
p8600
(lp8601
S'2015/06/26 06:00'
p8602
asS'DP'
p8603
S'2015 Dec 1'
p8604
sS'AD'
p8605
S'*Center for Global Health, Massachusetts General Hospital, Boston, MA; daggerDepartment of Medicine, Harvard Medical School, Boston, MA; double daggerGlobal Health Collaboration, Mbarara University of Science and Technology, Mbarara, Uganda; section signEpiCentre/Medecins Sans Frontieres, Mbarara, Uganda; ||Department of Medical Laboratory Sciences, Mbarara University of Science and Technology, Mbarara, Uganda; Departments of paragraph signEpidemiology and Biostatistics; #Medicine, University of California, San Francisco, CA; and **Department of Global Health and Populations, Harvard T.H. Chan School of Public Health, Boston, MA.'
p8606
sS'OWN'
p8607
S'NLM'
p8608
sS'PT'
p8609
(lp8610
S'Journal Article'
p8611
aS'Observational Study'
p8612
aS'Research Support, N.I.H., Extramural'
p8613
asS'LA'
p8614
(lp8615
S'eng'
p8616
asS'FAU'
p8617
(lp8618
S'Haberer, Jessica E'
p8619
aS'Musinguzi, Nicholas'
p8620
aS'Boum, Yap 2nd'
p8621
aS'Siedner, Mark J'
p8622
aS'Mocello, A Rain'
p8623
aS'Hunt, Peter W'
p8624
aS'Martin, Jeffrey N'
p8625
aS'Bangsberg, David R'
p8626
asS'LR'
p8627
S'20160701'
p8628
sS'PG'
p8629
S'386-92'
p8630
sS'TI'
p8631
S'Duration of Antiretroviral Therapy Adherence Interruption Is Associated With Risk of Virologic Rebound as Determined by Real-Time Adherence Monitoring in Rural Uganda.'
p8632
sS'RN'
p8633
(lp8634
S'0 (Anti-Retroviral Agents)'
p8635
aS'0 (RNA, Viral)'
p8636
asS'IS'
p8637
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p8638
sS'PL'
p8639
S'United States'
p8640
sS'TA'
p8641
S'J Acquir Immune Defic Syndr'
p8642
sS'JID'
p8643
S'100892005'
p8644
sS'AB'
p8645
S'BACKGROUND: Antiretroviral therapy (ART) adherence interruptions have been associated with viral rebound; however, the true risk is unknown because HIV RNA has never been measured during ongoing interruptions. METHODS: The Uganda AIDS Rural Treatment Outcomes Study is an observational longitudinal cohort of adults initiating ART. We monitored adherence with the device that wirelessly transmits records of device openings, and routinely assessed HIV RNA quarterly. When lapses of 48+ hours between device openings were detected, we made unannounced visits to participants to investigate the cause and assess HIV RNA. Generalized estimating equation logistic regressions were used to assess factors associated with viral rebound. RESULTS: We followed 479 participants (median: 25 months per participant). Most were women (72%), median age was 36 years, median pre-ART CD4 count was 198 cells per microliter, median pre-ART HIV RNA level was 5.0 log10 copies per milliliter, and median duration of prior viral suppression was 13 months. A total of 587 adherence interruptions followed confirmed prior viral suppression, of which 13 (2%) had detectable viral rebound. Viral rebound was associated with duration of adherence interruption (odds ratio: 1.25 for each day beyond 48 hours; P = 0.007) and 30-day adherence before the interruption (odds ratio: 0.73; P = 0.02). DISCUSSION: This article is the first demonstration of HIV RNA rebound during adherence interruptions objectively measured in real time. Odds of viral rebound increased by 25% with each day beyond 48 hours. Real-time adherence monitoring was feasible in a sub-Saharan African setting. Further research should assess the potential for real-time adherence interventions to sustain adherence to affordable first-line regimens.'
p8646
sS'GR'
p8647
(lp8648
S'K23 MH087228/MH/NIMH NIH HHS/United States'
p8649
aS'K23 MH099916/MH/NIMH NIH HHS/United States'
p8650
aS'K23MH087228/MH/NIMH NIH HHS/United States'
p8651
aS'K23MH099916/MH/NIMH NIH HHS/United States'
p8652
aS'P30 AI027763/AI/NIAID NIH HHS/United States'
p8653
aS'P30AI027763/AI/NIAID NIH HHS/United States'
p8654
aS'R01 MH054907/MH/NIMH NIH HHS/United States'
p8655
aS'R01MH054907/MH/NIMH NIH HHS/United States'
p8656
aS'UM1CA181255/CA/NCI NIH HHS/United States'
p8657
asS'IP'
p8658
S'4'
sS'PMCR'
p8659
(lp8660
S'2016/12/01 00:00'
p8661
asS'PMC'
p8662
S'PMC4624495'
p8663
sS'DCOM'
p8664
S'20160202'
p8665
sS'AU'
p8666
(lp8667
S'Haberer JE'
p8668
aS'Musinguzi N'
p8669
aS'Boum Y 2nd'
p8670
aS'Siedner MJ'
p8671
aS'Mocello AR'
p8672
aS'Hunt PW'
p8673
aS'Martin JN'
p8674
aS'Bangsberg DR'
p8675
asS'VI'
p8676
S'70'
p8677
sS'MHDA'
p8678
S'2016/02/03 06:00'
p8679
sS'OID'
p8680
(lp8681
S'NLM: NIHMS701309 [Available on 12/01/16]'
p8682
aS'NLM: PMC4624495 [Available on 12/01/16]'
p8683
asS'MH'
p8684
(lp8685
S'Adolescent'
p8686
aS'Adult'
p8687
aS'Anti-Retroviral Agents/*therapeutic use'
p8688
aS'Cohort Studies'
p8689
aS'Drug Monitoring'
p8690
aS'Female'
p8691
aS'HIV Infections/*drug therapy/*virology'
p8692
aS'Humans'
p8693
aS'Longitudinal Studies'
p8694
aS'Male'
p8695
aS'*Medication Adherence'
p8696
aS'RNA, Viral/*blood'
p8697
aS'Rural Population'
p8698
aS'Time Factors'
p8699
aS'Treatment Outcome'
p8700
aS'Uganda'
p8701
aS'*Viral Load'
p8702
aS'Young Adult'
p8703
asS'EDAT'
p8704
S'2015/06/26 06:00'
p8705
sS'SO'
p8706
S'J Acquir Immune Defic Syndr. 2015 Dec 1;70(4):386-92. doi: 10.1097/QAI.0000000000000737.'
p8707
sS'SB'
p8708
S'IM X'
p8709
sS'PMID'
p8710
S'26110445'
p8711
sS'PST'
p8712
S'ppublish'
p8713
stRp8714
ag2
(g3
g4
(dp8715
S'LID'
p8716
S'10.11604/pamj.2015.20.63.4865 [doi]'
p8717
sS'STAT'
p8718
S'MEDLINE'
p8719
sS'DEP'
p8720
S'20150122'
p8721
sS'DA'
p8722
S'20150619'
p8723
sS'AID'
p8724
(lp8725
S'10.11604/pamj.2015.20.63.4865 [doi]'
p8726
aS'PAMJ-20-63 [pii]'
p8727
asS'CRDT'
p8728
(lp8729
S'2015/06/20 06:00'
p8730
asS'DP'
p8731
S'2015'
p8732
sS'AD'
p8733
S'African Medical and Research Foundation (AMREF) Kenya. University of Maryland, School of Medicine-Institute of HumanVirology,Baltimore. Independent Public Health Research Consultants, Addis Ababa, Ethiopia. African Medical and Research Foundation (AMREF) Kenya. African Medical and Research Foundation (AMREF) Kenya.'
p8734
sS'OWN'
p8735
S'NLM'
p8736
sS'PT'
p8737
(lp8738
S'Journal Article'
p8739
aS"Research Support, U.S. Gov't, Non-P.H.S."
p8740
aS"Research Support, U.S. Gov't, P.H.S."
p8741
asS'LA'
p8742
(lp8743
S'eng'
p8744
asS'DCOM'
p8745
S'20160519'
p8746
sS'JT'
p8747
S'The Pan African medical journal'
p8748
sS'LR'
p8749
S'20150621'
p8750
sS'FAU'
p8751
(lp8752
S'Muhula, Samuel Opondo'
p8753
aS'Peter, Memiah'
p8754
aS'Sibhatu, Biadgilign'
p8755
aS'Meshack, Ndirangu'
p8756
aS'Lennie, Kyomuhangi'
p8757
asS'TI'
p8758
S'Effects of highly active antiretroviral therapy on the survival of HIV-infected adult patients in urban slums of Kenya.'
p8759
sS'RN'
p8760
(lp8761
S'0 (Anti-HIV Agents)'
p8762
aS'4B9XT59T7S (Zidovudine)'
p8763
asS'PL'
p8764
S'Uganda'
p8765
sS'PG'
p8766
S'63'
p8767
sS'JID'
p8768
S'101517926'
p8769
sS'AB'
p8770
S'Recent improvements in access to Anti-Retroviral Therapy (ART) have radically reduced hospitalizations and deaths associated with HIV infection in both developed countries and sub-Saharan Africa. Not much is known about survival of patients on ART in slums. The objective of this study was to identify factors associated with mortality among adult patients on ART in resource poor, urban, sub-Saharan African setting. A prospective open cohort study was conducted with adult patients on ART at a clinic in Kibera slums, Nairobi, Kenya. The patients\' enrollment to care was between March 2005 and November 2011. Descriptive statistics were computed and Kaplan-Meier (KM) methods used to estimate survival time while Cox\'s proportional hazards (CPH) model fitted to determine mortality predictors. A total of 2,011 adult patients were studied, 69% being female. Female gender (p=0.0016), zidovudine-based regimen patients (p<0.0001), CD4 count>351 patients (p<0.0001), WHO stage I patients (p<0.0001) and "Working" functional status patients recorded better survival probability on ART. In CPH analysis, the hazard of dying was higher in patients on Stavudine-based regimen(hazard ratio (HR)=.8; 95% CI, 1.5-2.2; p<0.0001),CD4 count<50 cells/microl (HR=1.6; 95% CI, 1.5-1.7;p<0.0001), WHO Stage IV at ART initiation (HR=1.3; 95% CI, 1.1-1.6; p=0.016) and bedridden patients (HR=2.7; 95% CI, 1.7-4.4;p<0.0001). There was increased mortality among the males, those with advanced Immunosuppression, late WHO stage and bedridden patients. The findings further justify the need to switch patients on Stavudine-based regimen as per the WHO recommendations.'
p8771
sS'GR'
p8772
(lp8773
S'PEPFAR/United States'
p8774
asS'VI'
p8775
S'20'
p8776
sS'IS'
p8777
S'1937-8688 (Electronic)'
p8778
sS'PMC'
p8779
S'PMC4450049'
p8780
sS'AU'
p8781
(lp8782
S'Muhula SO'
p8783
aS'Peter M'
p8784
aS'Sibhatu B'
p8785
aS'Meshack N'
p8786
aS'Lennie K'
p8787
asS'MHDA'
p8788
S'2016/05/20 06:00'
p8789
sS'PHST'
p8790
(lp8791
S'2015 [ecollection]'
p8792
aS'2014/06/22 [received]'
p8793
aS'2014/10/27 [accepted]'
p8794
aS'2015/01/22 [epublish]'
p8795
asS'OT'
p8796
(lp8797
S'Haart'
p8798
aS'Kenya'
p8799
aS'slums'
p8800
aS'survival'
p8801
asS'OTO'
p8802
(lp8803
S'NOTNLM'
p8804
asS'OID'
p8805
(lp8806
S'NLM: PMC4450049'
p8807
asS'MH'
p8808
(lp8809
S'Adolescent'
p8810
aS'Adult'
p8811
aS'Anti-HIV Agents/administration & dosage/*therapeutic use'
p8812
aS'Antiretroviral Therapy, Highly Active/methods'
p8813
aS'CD4 Lymphocyte Count'
p8814
aS'Cohort Studies'
p8815
aS'Female'
p8816
aS'HIV Infections/*drug therapy/mortality'
p8817
aS'Humans'
p8818
aS'Kenya'
p8819
aS'Male'
p8820
aS'Middle Aged'
p8821
aS'*Poverty Areas'
p8822
aS'Proportional Hazards Models'
p8823
aS'Prospective Studies'
p8824
aS'Sex Factors'
p8825
aS'Survival Rate'
p8826
aS'Treatment Outcome'
p8827
aS'Young Adult'
p8828
aS'Zidovudine/administration & dosage/therapeutic use'
p8829
asS'EDAT'
p8830
S'2015/06/20 06:00'
p8831
sS'SO'
p8832
S'Pan Afr Med J. 2015 Jan 22;20:63. doi: 10.11604/pamj.2015.20.63.4865. eCollection 2015.'
p8833
sS'SB'
p8834
S'IM'
p8835
sS'PMID'
p8836
S'26090021'
p8837
sS'TA'
p8838
S'Pan Afr Med J'
p8839
sS'PST'
p8840
S'epublish'
p8841
stRp8842
ag2
(g3
g4
(dp8843
S'LID'
p8844
S'10.1093/jac/dkv143 [doi]'
p8845
sS'STAT'
p8846
S'MEDLINE'
p8847
sS'DEP'
p8848
S'20150616'
p8849
sS'CI'
p8850
(lp8851
S'(c) The Author 2015. Published by Oxford University Press on behalf of the'
p8852
aS'British Society for Antimicrobial Chemotherapy. All rights reserved. For'
p8853
aS'Permissions, please e-mail: journals.permissions@oup.com.'
p8854
asS'DA'
p8855
S'20150818'
p8856
sS'AID'
p8857
(lp8858
S'dkv143 [pii]'
p8859
aS'10.1093/jac/dkv143 [doi]'
p8860
asS'CRDT'
p8861
(lp8862
S'2015/06/19 06:00'
p8863
asS'DP'
p8864
S'2015 Sep'
p8865
sS'OWN'
p8866
S'NLM'
p8867
sS'PT'
p8868
(lp8869
S'Journal Article'
p8870
aS"Research Support, Non-U.S. Gov't"
p8871
asS'LA'
p8872
(lp8873
S'eng'
p8874
asS'FAU'
p8875
(lp8876
S'Ruperez, Maria'
p8877
aS'Pou, Christian'
p8878
aS'Maculuve, Sonia'
p8879
aS'Cedeno, Samandhy'
p8880
aS'Luis, Leopoldina'
p8881
aS'Rodriguez, Judith'
p8882
aS'Letang, Emilio'
p8883
aS'Molto, Jose'
p8884
aS'Macete, Eusebio'
p8885
aS'Clotet, Bonaventura'
p8886
aS'Alonso, Pedro'
p8887
aS'Menendez, Clara'
p8888
aS'Naniche, Denise'
p8889
aS'Paredes, Roger'
p8890
asS'JT'
p8891
S'The Journal of antimicrobial chemotherapy'
p8892
sS'PG'
p8893
S'2639-47'
p8894
sS'TI'
p8895
S'Determinants of virological failure and antiretroviral drug resistance in Mozambique.'
p8896
sS'RN'
p8897
(lp8898
S'0 (Anti-Retroviral Agents)'
p8899
asS'PL'
p8900
S'England'
p8901
sS'TA'
p8902
S'J Antimicrob Chemother'
p8903
sS'JID'
p8904
S'7513617'
p8905
sS'AB'
p8906
S"OBJECTIVES: The objective of this study was to inform public health actions to limit first-line ART failure and HIV drug resistance in Mozambique. METHODS: This was a cross-sectional study. HIV-1-infected adults on first-line ART for at least 1 year attending routine visits in the Manhica District Hospital, in a semi-rural area in southern Mozambique with no HIV-1 RNA monitoring available, were evaluated for clinical, socio-demographic, therapeutic, immunological and virological characteristics. Factors associated with HIV-1 RNA >/=1000 copies/mL and HIV drug resistance were determined using multivariate logistic regression. RESULTS: The study included 334 adults on first-line ART for a median of 3 years, of which 65% (214/332) had suppressed viraemia, 11% (37/332) had low-level viraemia (HIV-1 RNA 150-999 copies/mL) and 24% (81/332) had overt virological failure (HIV-1 RNA >/=1000 copies/mL). HIV drug resistance was detected in 89% of subjects with virological failure, but in none with low-level viraemia. Younger age [OR = 0.97 per additional year (95% CI = 0.94-1.00), P = 0.039], ART initiation at WHO stage III/IV [OR = 2.10 (95% CI = 1.23-3.57), P = 0.003] and low ART adherence [OR = 2.69 (95% CI = 1.39-5.19), P = 0.003] were associated with virological failure. Longer time on ART [OR = 1.55 per additional year (95% CI = 1.00-2.43), P = 0.052] and illiteracy [OR = 0.24 (95% CI = 0.07-0.89), P = 0.033] were associated with HIV drug resistance. Compared with HIV-1 RNA, clinician's judgement of ART failure, based on clinical and immunological outcomes, only achieved 29% sensitivity and misdiagnosed 1 out of every 4.5 subjects. CONCLUSIONS: Public health programmes in Mozambique should focus on early HIV diagnosis, early ART initiation and adherence support. Virological monitoring drastically improves the diagnosis of ART failure, enabling a better use of resources."
p8907
sS'AD'
p8908
S'Manhica Health Research Center (CISM), Manhica, Maputo, Mozambique Barcelona Centre for International Health Research (CRESIB, Hospital Clinic-Universitat de Barcelona), ISGlobal, Barcelona Institute for Global Health, Barcelona, Spain maria.ruperez@isglobal.org. IrsiCaixa AIDS Research Institute, Badalona, Catalonia, Spain. Manhica Health Research Center (CISM), Manhica, Maputo, Mozambique. IrsiCaixa AIDS Research Institute, Badalona, Catalonia, Spain. Manhica Health Research Center (CISM), Manhica, Maputo, Mozambique. IrsiCaixa AIDS Research Institute, Badalona, Catalonia, Spain. Barcelona Centre for International Health Research (CRESIB, Hospital Clinic-Universitat de Barcelona), ISGlobal, Barcelona Institute for Global Health, Barcelona, Spain Swiss Tropical and Public Health Institute (Swiss TPH), Basel, Switzerland. Lluita Contra la Sida Foundation, HIV Unit, Hosp Univ Germans Trias i Pujol, Badalona, Catalonia, Spain. Manhica Health Research Center (CISM), Manhica, Maputo, Mozambique. IrsiCaixa AIDS Research Institute, Badalona, Catalonia, Spain Lluita Contra la Sida Foundation, HIV Unit, Hosp Univ Germans Trias i Pujol, Badalona, Catalonia, Spain Universitat de Vic-Universitat Central de Catalunya, Vic, Catalonia, Spain. Manhica Health Research Center (CISM), Manhica, Maputo, Mozambique Barcelona Centre for International Health Research (CRESIB, Hospital Clinic-Universitat de Barcelona), ISGlobal, Barcelona Institute for Global Health, Barcelona, Spain. Manhica Health Research Center (CISM), Manhica, Maputo, Mozambique Barcelona Centre for International Health Research (CRESIB, Hospital Clinic-Universitat de Barcelona), ISGlobal, Barcelona Institute for Global Health, Barcelona, Spain. Manhica Health Research Center (CISM), Manhica, Maputo, Mozambique Barcelona Centre for International Health Research (CRESIB, Hospital Clinic-Universitat de Barcelona), ISGlobal, Barcelona Institute for Global Health, Barcelona, Spain. IrsiCaixa AIDS Research Institute, Badalona, Catalonia, Spain Lluita Contra la Sida Foundation, HIV Unit, Hosp Univ Germans Trias i Pujol, Badalona, Catalonia, Spain Universitat de Vic-Universitat Central de Catalunya, Vic, Catalonia, Spain.'
p8909
sS'IP'
p8910
S'9'
sS'IS'
p8911
S'1460-2091 (Electronic) 0305-7453 (Linking)'
p8912
sS'DCOM'
p8913
S'20160509'
p8914
sS'AU'
p8915
(lp8916
S'Ruperez M'
p8917
aS'Pou C'
p8918
aS'Maculuve S'
p8919
aS'Cedeno S'
p8920
aS'Luis L'
p8921
aS'Rodriguez J'
p8922
aS'Letang E'
p8923
aS'Molto J'
p8924
aS'Macete E'
p8925
aS'Clotet B'
p8926
aS'Alonso P'
p8927
aS'Menendez C'
p8928
aS'Naniche D'
p8929
aS'Paredes R'
p8930
asS'VI'
p8931
S'70'
p8932
sS'MHDA'
p8933
S'2016/05/10 06:00'
p8934
sS'PHST'
p8935
(lp8936
S'2015/02/02 [received]'
p8937
aS'2015/05/01 [accepted]'
p8938
aS'2015/06/16 [aheadofprint]'
p8939
asS'OTO'
p8940
(lp8941
S'NOTNLM'
p8942
asS'MH'
p8943
(lp8944
S'Adult'
p8945
aS'Anti-Retroviral Agents/*therapeutic use'
p8946
aS'Cross-Sectional Studies'
p8947
aS'Drug Monitoring'
p8948
aS'*Drug Resistance, Viral'
p8949
aS'Female'
p8950
aS'*Genotype'
p8951
aS'Genotyping Techniques'
p8952
aS'HIV Infections/*drug therapy/*virology'
p8953
aS'HIV-1/classification/*genetics/isolation & purification'
p8954
aS'Humans'
p8955
aS'Male'
p8956
aS'Middle Aged'
p8957
aS'Mozambique'
p8958
aS'Suburban Population'
p8959
aS'Treatment Failure'
p8960
asS'EDAT'
p8961
S'2015/06/19 06:00'
p8962
sS'SO'
p8963
S'J Antimicrob Chemother. 2015 Sep;70(9):2639-47. doi: 10.1093/jac/dkv143. Epub 2015 Jun 16.'
p8964
sS'SB'
p8965
S'IM'
p8966
sS'PMID'
p8967
S'26084302'
p8968
sS'OT'
p8969
(lp8970
S'HIV-1'
p8971
aS'antiretroviral treatment'
p8972
aS'low-income countries'
p8973
aS'public health'
p8974
asS'PST'
p8975
S'ppublish'
p8976
stRp8977
ag2
(g3
g4
(dp8978
S'LID'
p8979
S'10.3402/gha.v8.27942 [doi]'
p8980
sS'STAT'
p8981
S'MEDLINE'
p8982
sS'DEP'
p8983
S'20150615'
p8984
sS'DA'
p8985
S'20150617'
p8986
sS'AID'
p8987
(lp8988
S'27942 [pii]'
p8989
asS'CRDT'
p8990
(lp8991
S'2015/06/18 06:00'
p8992
asS'DP'
p8993
S'2015'
p8994
sS'AD'
p8995
S'Department of Epidemiology, University of Washington School of Public Health, Seattle, WA, USA. Health Alliance International, Seattle, WA, USA; wagenaarb@gmail.com. Department of Epidemiology, University of Washington School of Public Health, Seattle, WA, USA. Department of Global Health, University of Washington School of Public Health, Seattle, WA, USA. Global Medicines Program, University of Washington, Seattle, WA, USA. Department of Global Health, University of Washington School of Public Health, Seattle, WA, USA. Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA. Health Alliance International, Beira, Mozambique. Beira Operations Research Center, Ministry of Health, Beira, Mozambique. Department of Mental Health, Ministry of Health, Beira, Mozambique. Psychiatric Services, Department of Medicine, Beira Central Hospital, Beira, Mozambique. Beira Operations Research Center, Ministry of Health, Beira, Mozambique. Health Alliance International, Seattle, WA, USA. Department of Global Health, University of Washington School of Public Health, Seattle, WA, USA.'
p8996
sS'OWN'
p8997
S'NLM'
p8998
sS'PT'
p8999
(lp9000
S'Journal Article'
p9001
aS'Research Support, N.I.H., Extramural'
p9002
aS"Research Support, Non-U.S. Gov't"
p9003
asS'LA'
p9004
(lp9005
S'eng'
p9006
asS'DCOM'
p9007
S'20160126'
p9008
sS'JT'
p9009
S'Global health action'
p9010
sS'LR'
p9011
S'20150730'
p9012
sS'FAU'
p9013
(lp9014
S'Wagenaar, Bradley H'
p9015
aS'Stergachis, Andy'
p9016
aS'Rao, Deepa'
p9017
aS'Hoek, Roxanne'
p9018
aS'Cumbe, Vasco'
p9019
aS'Napua, Manuel'
p9020
aS'Sherr, Kenneth'
p9021
asS'TI'
p9022
S'The availability of essential medicines for mental healthcare in Sofala, Mozambique.'
p9023
sS'RN'
p9024
(lp9025
S'0 (Drugs, Essential)'
p9026
aS'0 (Psychotropic Drugs)'
p9027
asS'PL'
p9028
S'Sweden'
p9029
sS'PG'
p9030
S'27942'
p9031
sS'JID'
p9032
S'101496665'
p9033
sS'AB'
p9034
S'OBJECTIVE: We assessed the availability of essential medicines for mental healthcare (MH) across levels of the public healthcare system to aid in future systems planning. DESIGN: Non-expired MH medications were assessed in 24 public health facilities and 13 district warehouses across Sofala Province, Mozambique, from July to August 2014. Medication categories included: antipsychotics, antidepressants, benzodiazepines, antiepileptics and mood stabilizers, and anticholinergics and antihistamines. RESULTS: Only 7 of 12 (58.3%) district warehouses, 11 of 24 (45.8%) of all health facilities, and 10 of 12 (83.3%) of facilities with trained MH staff had availability of at least one medication of each category. Thioridazine was the most commonly available antipsychotic across all facilities (9 of 24, 37.5%), while chlorpromazine and thioridazine were most common at facilities providing MH care (8 of 12, 66.7%). The atypical antipsychotic risperidone was not available at any facility or district warehouse. Amitriptyline was the most commonly available antidepressant (10 of 12 districts; 12 of 24 overall facilities; 9 or 12 MH facilities). Despite being on the national essential drug list, fluoxetine was only available at one quaternary-level facility and no district warehouses. CONCLUSIONS: Essential psychotropic medicines are routinely unavailable at public health facilities. Current essential drug lists include six typical but no atypical antipsychotics, which is concerning given the side-effect profiles of typical antipsychotics. Ensuring consistent availability of at least one selective serotonin reuptake inhibitor should also be a priority, as they are essential for the treatment of individuals with underlying cardiovascular disease and/or suicidal ideation. Similar to successful task-sharing approaches used for HIV/AIDS, mid-level providers could be retrained and certified to prescribe and monitor first-line psychotropic regimens.'
p9035
sS'GR'
p9036
(lp9037
S'K02 TW009207/TW/FIC NIH HHS/United States'
p9038
aS'K02TW009207/TW/FIC NIH HHS/United States'
p9039
asS'VI'
p9040
S'8'
sS'IS'
p9041
S'1654-9880 (Electronic) 1654-9880 (Linking)'
p9042
sS'PMC'
p9043
S'PMC4469619'
p9044
sS'AU'
p9045
(lp9046
S'Wagenaar BH'
p9047
aS'Stergachis A'
p9048
aS'Rao D'
p9049
aS'Hoek R'
p9050
aS'Cumbe V'
p9051
aS'Napua M'
p9052
aS'Sherr K'
p9053
asS'MHDA'
p9054
S'2016/01/27 06:00'
p9055
sS'PHST'
p9056
(lp9057
S'2015 [ecollection]'
p9058
aS'2015/03/22 [received]'
p9059
aS'2015/05/06 [revised]'
p9060
aS'2015/05/07 [accepted]'
p9061
asS'OT'
p9062
(lp9063
S'Mozambique'
p9064
aS'delivery of mental healthcare'
p9065
aS'health planning'
p9066
aS'mental health systems'
p9067
aS'pharmaceutical services'
p9068
asS'OTO'
p9069
(lp9070
S'NOTNLM'
p9071
asS'OID'
p9072
(lp9073
S'NLM: PMC4469619'
p9074
asS'MH'
p9075
(lp9076
S'Drugs, Essential/*supply & distribution'
p9077
aS'Humans'
p9078
aS'*Mental Health Services'
p9079
aS'Mozambique'
p9080
aS'Psychotropic Drugs/*supply & distribution'
p9081
aS'Residence Characteristics'
p9082
asS'EDAT'
p9083
S'2015/06/18 06:00'
p9084
sS'SO'
p9085
S'Glob Health Action. 2015 Jun 15;8:27942. doi: 10.3402/gha.v8.27942. eCollection 2015.'
p9086
sS'SB'
p9087
S'IM'
p9088
sS'PMID'
p9089
S'26081970'
p9090
sS'TA'
p9091
S'Glob Health Action'
p9092
sS'PST'
p9093
S'epublish'
p9094
stRp9095
ag2
(g3
g4
(dp9096
S'LID'
p9097
S'10.1097/QAI.0000000000000723 [doi]'
p9098
sS'STAT'
p9099
S'MEDLINE'
p9100
sS'JT'
p9101
S'Journal of acquired immune deficiency syndromes (1999)'
p9102
sS'DA'
p9103
S'20150916'
p9104
sS'AID'
p9105
(lp9106
S'10.1097/QAI.0000000000000723 [doi]'
p9107
asS'CRDT'
p9108
(lp9109
S'2015/06/17 06:00'
p9110
asS'DP'
p9111
S'2015 Oct 1'
p9112
sS'AD'
p9113
S"*District Health Office, Iganga District Administration, Iganga, Uganda; daggerIganga/Mayuge Health and Demographic Surveillance System, Makerere University, Kampala, Uganda; double daggerDepartment of Health Policy Planning and Management, Makerere University School of Public Health, Kampala, Uganda; section signInstitute of Health Sciences, Busoga University, Iganga, Uganda; ||Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; paragraph signJohns Hopkins University School of Medicine, Baltimore, MD; #Department of Epidemiology and Biostatistics, Makerere University School of Public Health, Kampala, Uganda; **Department of Public Health Sciences/Global Health (IHCAR), Karolinska Institutet, Solna, Sweden; daggerdaggerDepartment of Women's and Children's Health, IMCH, Uppsala University, Uppsala, Sweden; and double daggerdouble daggerDepartment of Infectious Diseases, Karolinska University Hospital, Solna, Sweden."
p9114
sS'OWN'
p9115
S'NLM'
p9116
sS'PT'
p9117
(lp9118
S'Journal Article'
p9119
aS'Randomized Controlled Trial'
p9120
aS'Research Support, N.I.H., Intramural'
p9121
aS"Research Support, Non-U.S. Gov't"
p9122
asS'LA'
p9123
(lp9124
S'eng'
p9125
asS'FAU'
p9126
(lp9127
S'Lubega, Muhamadi'
p9128
aS'Tumwesigye, Nazarius Mbona'
p9129
aS'Kadobera, Daniel'
p9130
aS'Marrone, Gaetano'
p9131
aS'Wabwire-Mangen, Fred'
p9132
aS'Peterson, Stefan'
p9133
aS'Reynolds, Steven J'
p9134
aS'Ekstrom, Anna Mia'
p9135
asS'PG'
p9136
S'e36-43'
p9137
sS'TI'
p9138
S'Effect of Community Support Agents on Retention of People Living With HIV in Pre-antiretroviral Care: A Randomized Controlled Trial in Eastern Uganda.'
p9139
sS'PL'
p9140
S'United States'
p9141
sS'TA'
p9142
S'J Acquir Immune Defic Syndr'
p9143
sS'JID'
p9144
S'100892005'
p9145
sS'AB'
p9146
S'BACKGROUND: Over 50% of people living with HIV (PLHIV) in sub-Saharan Africa are lost to follow-up between diagnosis and initiation of antiretroviral treatment during pre-antiretroviral (pre-ARV) care. The effect of providing home counseling visits by community support agents on 2-year retention in pre-ARV care was evaluated through a randomized controlled trial in eastern Uganda. METHODS: Four hundred newly screened HIV-positive patients were randomly assigned to receive posttest counseling alone (routine arm) or posttest counseling and monthly home counseling visits by community support agents to encourage them go back for routine pre-ARV care (intervention arm). The outcome measure was the proportion of new PLHIV in either arm who attended their scheduled pre-ARV care visits for at least 6 of the anticipated 8 visits in the first 24 months after HIV diagnosis. The difference between the 2 study arms was assessed using the chi and T tests. Mantel-Haenszel Risk Ratios and multivariate logistic models were used to assess the adjusted effect of the intervention on the outcome. RESULTS: In all models generated, participants receiving monthly home counseling visits were 2.5 times more likely to be retained in pre-ARV compared with those in standard care over a period of 24 months (adjusted risk ratio, 2.5; 95% confidence interval: 2.0 to 3.0). CONCLUSION: Monthly follow-up home visits by community workers more than doubled the retention of PLHIV in pre-ARV care in rural Uganda and can be applicable in similar resource-poor settings.'
p9147
sS'GR'
p9148
(lp9149
S'Intramural NIH HHS/United States'
p9150
asS'IP'
p9151
S'2'
sS'IS'
p9152
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p9153
sS'DCOM'
p9154
S'20151215'
p9155
sS'AU'
p9156
(lp9157
S'Lubega M'
p9158
aS'Tumwesigye NM'
p9159
aS'Kadobera D'
p9160
aS'Marrone G'
p9161
aS'Wabwire-Mangen F'
p9162
aS'Peterson S'
p9163
aS'Reynolds SJ'
p9164
aS'Ekstrom AM'
p9165
asS'VI'
p9166
S'70'
p9167
sS'MHDA'
p9168
S'2015/12/17 06:00'
p9169
sS'MH'
p9170
(lp9171
S'Adolescent'
p9172
aS'Adult'
p9173
aS'Aged'
p9174
aS'*Community Health Services'
p9175
aS'*Counseling'
p9176
aS'Female'
p9177
aS'HIV Infections/*diagnosis/*drug therapy/psychology'
p9178
aS'Humans'
p9179
aS'Male'
p9180
aS'Middle Aged'
p9181
aS'Patient Compliance'
p9182
aS'*Time Factors'
p9183
aS'Treatment Outcome'
p9184
aS'Uganda/epidemiology'
p9185
aS'Young Adult'
p9186
asS'EDAT'
p9187
S'2015/06/17 06:00'
p9188
sS'SI'
p9189
(lp9190
S'ISRCTN/ISRCTN94133652'
p9191
asS'SO'
p9192
S'J Acquir Immune Defic Syndr. 2015 Oct 1;70(2):e36-43. doi: 10.1097/QAI.0000000000000723.'
p9193
sS'SB'
p9194
S'IM X'
p9195
sS'PMID'
p9196
S'26079842'
p9197
sS'PST'
p9198
S'ppublish'
p9199
stRp9200
ag2
(g3
g4
(dp9201
S'LID'
p9202
S'10.1097/QAI.0000000000000719 [doi]'
p9203
sS'STAT'
p9204
S'MEDLINE'
p9205
sS'AB'
p9206
S"The objective of this study was to quantify the impact of a new technology to communicate the results of an infant HIV diagnostic test on test turnaround time and to quantify the association between late delivery of test results and patient loss to follow-up. We used data collected during a pilot implementation of Global Package Radio Service (GPRS) printers for communicating results in the early infant diagnosis program in Mozambique from 2008 through 2010. Our dataset comprised 1757 patient records, of which 767 were from before implementation and 990 from after implementation of expedited results delivery system. We used multivariate logistic regression model to determine the association between late result delivery (more than 30 days between sample collection and result delivery to the health facility) and the probability of result collection by the infant's caregiver. We used a sample selection model to determine the association between late result delivery to the facility and further delay in collection of results by the caregiver. The mean test turnaround time reduced from 68.13 to 41.05 days post-expedited results delivery system. Caregivers collected only 665 (37.8%) of the 1757 results. After controlling for confounders, the late delivery of results was associated with a reduction of approximately 18% (0.44 vs. 0.36; P < 0.01) in the probability of results collected by the caregivers (odds ratio = 0.67, P < 0.05). Late delivery of results was also associated with a further average increase in 20.91 days of delay in collection of results (P < 0.01). Early infant diagnosis program managers should further evaluate the cost-effectiveness of operational interventions (eg, GPRS printers) that reduce delays."
p9207
sS'JID'
p9208
S'100892005'
p9209
sS'AD'
p9210
S'*Indian School of Business, Hyderabad, India; daggerClinton Health Access Initiative, Maputo, Mozambique; and double daggerInstituto Nacional da Saude, Maputo, Mozambique.'
p9211
sS'JT'
p9212
S'Journal of acquired immune deficiency syndromes (1999)'
p9213
sS'IP'
p9214
S'1'
sS'IS'
p9215
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p9216
sS'DCOM'
p9217
S'20151117'
p9218
sS'DA'
p9219
S'20150902'
p9220
sS'AU'
p9221
(lp9222
S'Deo S'
p9223
aS'Crea L'
p9224
aS'Quevedo J'
p9225
aS'Lehe J'
p9226
aS'Vojnov L'
p9227
aS'Peter T'
p9228
aS'Jani I'
p9229
asS'AID'
p9230
(lp9231
S'10.1097/QAI.0000000000000719 [doi]'
p9232
asS'CRDT'
p9233
(lp9234
S'2015/06/13 06:00'
p9235
asS'VI'
p9236
S'70'
p9237
sS'DP'
p9238
S'2015 Sep 1'
p9239
sS'MHDA'
p9240
S'2015/11/18 06:00'
p9241
sS'OWN'
p9242
S'NLM'
p9243
sS'PT'
p9244
(lp9245
S'Journal Article'
p9246
aS'Observational Study'
p9247
aS"Research Support, Non-U.S. Gov't"
p9248
asS'LA'
p9249
(lp9250
S'eng'
p9251
asS'MH'
p9252
(lp9253
S'Delayed Diagnosis'
p9254
aS'Female'
p9255
aS'HIV Infections/*diagnosis'
p9256
aS'Health Information Management/*methods'
p9257
aS'Humans'
p9258
aS'Infant'
p9259
aS'Infant, Newborn'
p9260
aS'*Lost to Follow-Up'
p9261
aS'Male'
p9262
aS'Mozambique'
p9263
aS'*Radio'
p9264
aS'Telemedicine/*methods'
p9265
aS'Time Factors'
p9266
asS'FAU'
p9267
(lp9268
S'Deo, Sarang'
p9269
aS'Crea, Lindy'
p9270
aS'Quevedo, Jorge'
p9271
aS'Lehe, Jonathan'
p9272
aS'Vojnov, Lara'
p9273
aS'Peter, Trevor'
p9274
aS'Jani, Ilesh'
p9275
asS'EDAT'
p9276
S'2015/06/13 06:00'
p9277
sS'PST'
p9278
S'ppublish'
p9279
sS'SO'
p9280
S'J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):e1-4. doi: 10.1097/QAI.0000000000000719.'
p9281
sS'PG'
p9282
S'e1-4'
p9283
sS'TI'
p9284
S'Implementation and Operational Research: Expedited Results Delivery Systems Using GPRS Technology Significantly Reduce Early Infant Diagnosis Test Turnaround Times.'
p9285
sS'SB'
p9286
S'IM X'
p9287
sS'PMID'
p9288
S'26068719'
p9289
sS'PL'
p9290
S'United States'
p9291
sS'TA'
p9292
S'J Acquir Immune Defic Syndr'
p9293
stRp9294
ag2
(g3
g4
(dp9295
S'LID'
p9296
S'10.7448/IAS.18.1.19929 [doi]'
p9297
sS'STAT'
p9298
S'MEDLINE'
p9299
sS'DEP'
p9300
S'20150529'
p9301
sS'DA'
p9302
S'20150601'
p9303
sS'AID'
p9304
(lp9305
S'19929 [pii]'
p9306
asS'CRDT'
p9307
(lp9308
S'2015/06/02 06:00'
p9309
asS'DP'
p9310
S'2015'
p9311
sS'AD'
p9312
S"Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA. Abwenzi Pa Za Umoyo, Neno, Malawi. Partners In Health, Boston, MA, USA; michael_herce@med.unc.edu. Abwenzi Pa Za Umoyo, Neno, Malawi. Partners In Health, Boston, MA, USA. Abwenzi Pa Za Umoyo, Neno, Malawi. Partners In Health, Boston, MA, USA. Department of Medicine, Brigham & Women's Hospital, Boston, MA, USA. Abwenzi Pa Za Umoyo, Neno, Malawi. Partners In Health, Boston, MA, USA. Department of Family Medicine, Tufts University School of Medicine, Boston, MA, USA. Neno District Health Office, Malawi Ministry of Health, Neno, Malawi. Neno District Health Office, Malawi Ministry of Health, Neno, Malawi. Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA. Abwenzi Pa Za Umoyo, Neno, Malawi. Partners In Health, Boston, MA, USA. Abwenzi Pa Za Umoyo, Neno, Malawi. Partners In Health, Boston, MA, USA. Abwenzi Pa Za Umoyo, Neno, Malawi. Partners In Health, Boston, MA, USA. Abwenzi Pa Za Umoyo, Neno, Malawi. Partners In Health, Boston, MA, USA. Division of Allergy & Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA. Harvard Medical School, Boston, MA, USA. Abwenzi Pa Za Umoyo, Neno, Malawi. Department of Medicine, Beth Israel Deaconess Hospital, Boston, MA, USA. Abwenzi Pa Za Umoyo, Neno, Malawi. Partners In Health, Boston, MA, USA. Haiti Assistance Program, American Red Cross, Washington, DC, USA."
p9313
sS'OWN'
p9314
S'NLM'
p9315
sS'PT'
p9316
(lp9317
S'Journal Article'
p9318
aS'Research Support, N.I.H., Extramural'
p9319
asS'LA'
p9320
(lp9321
S'eng'
p9322
asS'DCOM'
p9323
S'20160516'
p9324
sS'JT'
p9325
S'Journal of the International AIDS Society'
p9326
sS'LR'
p9327
S'20160513'
p9328
sS'FAU'
p9329
(lp9330
S'Herce, Michael E'
p9331
aS'Kalanga, Noel'
p9332
aS'Wroe, Emily B'
p9333
aS'Keck, James W'
p9334
aS'Chingoli, Felix'
p9335
aS'Tengatenga, Listern'
p9336
aS'Gopal, Satish'
p9337
aS'Phiri, Atupere'
p9338
aS'Mailosi, Bright'
p9339
aS'Bazile, Junior'
p9340
aS'Beste, Jason A'
p9341
aS'Elmore, Shekinah N'
p9342
aS'Crocker, Jonathan T'
p9343
aS'Rigodon, Jonas'
p9344
asS'TI'
p9345
S'Excellent clinical outcomes and retention in care for adults with HIV-associated Kaposi sarcoma treated with systemic chemotherapy and integrated antiretroviral therapy in rural Malawi.'
p9346
sS'RN'
p9347
(lp9348
S'0 (stavudine, lamivudine, nevirapine drug combination)'
p9349
aS'2T8Q726O95 (Lamivudine)'
p9350
aS'99DK7FVK1H (Nevirapine)'
p9351
aS'BO9LE4QFZF (Stavudine)'
p9352
asS'PL'
p9353
S'Switzerland'
p9354
sS'PG'
p9355
S'19929'
p9356
sS'JID'
p9357
S'101478566'
p9358
sS'AB'
p9359
S'INTRODUCTION: HIV-associated Kaposi sarcoma (HIV-KS) is the most common cancer in Malawi. In 2008, the non-governmental organization, Partners In Health, and the Ministry of Health established the Neno Kaposi Sarcoma Clinic (NKSC) to treat HIV-KS in rural Neno district. We aimed to evaluate 12-month clinical outcomes and retention in care for HIV-KS patients in the NKSC, and to describe our implementation model, which featured protocol-guided chemotherapy, integrated antiretroviral therapy (ART) and psychosocial support delivered by community health workers. METHODS: We conducted a retrospective cohort study using routine clinical data from 114 adult HIV-KS patients who received ART and >/=1 chemotherapy cycle in the NKSC between March 2008 and February 2012. RESULTS: At enrolment 97% of patients (n/N=103/106) had advanced HIV-KS (stage T1). Most patients were male (n/N=85/114, 75%) with median age 36 years (interquartile range, IQR: 29-42). Patients started ART a median of 77 days prior to chemotherapy (IQR: 36-252), with 97% (n/N=105/108) receiving nevirapine/lamivudine/stavudine. Following standardized protocols, we treated 20 patients (18%) with first-line paclitaxel and 94 patients (82%) with bleomycin plus vincristine (BV). Of the 94 BV patients, 24 (26%) failed to respond to BV requiring change to second-line paclitaxel. A Division of AIDS grade 3/4 adverse event occurred in 29% of patients (n/N=30/102). Neutropenia was the most common grade 3/4 event (n/N=17/102, 17%). Twelve months after chemotherapy initiation, 83% of patients (95% CI: 74-89%) were alive, including 88 (77%) retained in care. Overall survival (OS) at 12 months did not differ by initial chemotherapy regimen (p=0.6). Among patients with T1 disease, low body mass index (BMI) (adjusted hazard ratio, aHR=4.10, 95% CI: 1.06-15.89) and 1 g/dL decrease in baseline haemoglobin (aHR=1.52, 95% CI: 1.03-2.25) were associated with increased death or loss to follow-up at 12 months. CONCLUSIONS: The NKSC model resulted in infrequent adverse events, low loss to follow-up and excellent OS. Our results suggest it is safe, effective and feasible to provide standard-of-care chemotherapy regimens from the developed world, integrated with ART, to treat HIV-KS in rural Malawi. Baseline BMI and haemoglobin may represent important patient characteristics associated with HIV-KS survival in rural sub-Saharan Africa.'
p9360
sS'GR'
p9361
(lp9362
S'K01 TW009488/TW/FIC NIH HHS/United States'
p9363
aS'K01TW009488/TW/FIC NIH HHS/United States'
p9364
aS'P30 AI050410/AI/NIAID NIH HHS/United States'
p9365
aS'P30CA016086/CA/NCI NIH HHS/United States'
p9366
aS'R21CA180815/CA/NCI NIH HHS/United States'
p9367
aS'R25TW009340/TW/FIC NIH HHS/United States'
p9368
aS'T32 AI007001-36/AI/NIAID NIH HHS/United States'
p9369
aS'U01CA121947/CA/NCI NIH HHS/United States'
p9370
aS'U54 CA190152/CA/NCI NIH HHS/United States'
p9371
aS'U54CA190152/CA/NCI NIH HHS/United States'
p9372
aS'UL1TR000083/TR/NCATS NIH HHS/United States'
p9373
asS'VI'
p9374
S'18'
p9375
sS'IS'
p9376
S'1758-2652 (Electronic) 1758-2652 (Linking)'
p9377
sS'PMC'
p9378
S'PMC4450240'
p9379
sS'AU'
p9380
(lp9381
S'Herce ME'
p9382
aS'Kalanga N'
p9383
aS'Wroe EB'
p9384
aS'Keck JW'
p9385
aS'Chingoli F'
p9386
aS'Tengatenga L'
p9387
aS'Gopal S'
p9388
aS'Phiri A'
p9389
aS'Mailosi B'
p9390
aS'Bazile J'
p9391
aS'Beste JA'
p9392
aS'Elmore SN'
p9393
aS'Crocker JT'
p9394
aS'Rigodon J'
p9395
asS'MHDA'
p9396
S'2016/05/18 06:00'
p9397
sS'PHST'
p9398
(lp9399
S'2015 [ecollection]'
p9400
aS'2014/11/23 [received]'
p9401
aS'2015/04/02 [revised]'
p9402
aS'2015/04/22 [accepted]'
p9403
asS'OT'
p9404
(lp9405
S'Kaposi sarcoma'
p9406
aS'Malawi'
p9407
aS'antiretroviral therapy'
p9408
aS'bleomycin'
p9409
aS'community health worker'
p9410
aS'paclitaxel'
p9411
aS'psychosocial support'
p9412
aS'vincristine'
p9413
asS'OTO'
p9414
(lp9415
S'NOTNLM'
p9416
asS'OID'
p9417
(lp9418
S'NLM: PMC4450240'
p9419
asS'MH'
p9420
(lp9421
S'Adult'
p9422
aS'Cohort Studies'
p9423
aS'Female'
p9424
aS'HIV Infections/*complications/drug therapy'
p9425
aS'Humans'
p9426
aS'Lamivudine/*therapeutic use'
p9427
aS'Malawi'
p9428
aS'Male'
p9429
aS'Nevirapine/*therapeutic use'
p9430
aS'Retrospective Studies'
p9431
aS'Rural Population'
p9432
aS'Sarcoma, Kaposi/*drug therapy'
p9433
aS'Stavudine/*therapeutic use'
p9434
asS'EDAT'
p9435
S'2015/06/02 06:00'
p9436
sS'SO'
p9437
S'J Int AIDS Soc. 2015 May 29;18:19929. doi: 10.7448/IAS.18.1.19929. eCollection 2015.'
p9438
sS'SB'
p9439
S'IM X'
p9440
sS'PMID'
p9441
S'26028156'
p9442
sS'TA'
p9443
S'J Int AIDS Soc'
p9444
sS'PST'
p9445
S'epublish'
p9446
stRp9447
ag2
(g3
g4
(dp9448
S'LID'
p9449
S'10.1371/journal.pone.0127235 [doi]'
p9450
sS'STAT'
p9451
S'MEDLINE'
p9452
sS'DEP'
p9453
S'20150526'
p9454
sS'DA'
p9455
S'20150527'
p9456
sS'AID'
p9457
(lp9458
S'10.1371/journal.pone.0127235 [doi]'
p9459
aS'PONE-D-14-51478 [pii]'
p9460
asS'CRDT'
p9461
(lp9462
S'2015/05/27 06:00'
p9463
asS'DP'
p9464
S'2015'
p9465
sS'AD'
p9466
S'Johns Hopkins School of Medicine, Baltimore, Maryland; Rakai Health Sciences Program, Rakai, Uganda. Rakai Health Sciences Program, Rakai, Uganda. Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland. Johns Hopkins School of Medicine, Baltimore, Maryland; Rakai Health Sciences Program, Rakai, Uganda; Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. Johns Hopkins School of Medicine, Baltimore, Maryland; Rakai Health Sciences Program, Rakai, Uganda; National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland. Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. Rakai Health Sciences Program, Rakai, Uganda. Rakai Health Sciences Program, Rakai, Uganda. Rakai Health Sciences Program, Rakai, Uganda. Rakai Health Sciences Program, Rakai, Uganda; Makerere University College of Health Sciences, School of Public Health, Kampala, Uganda. Johns Hopkins School of Medicine, Baltimore, Maryland; Rakai Health Sciences Program, Rakai, Uganda; National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.'
p9467
sS'OWN'
p9468
S'NLM'
p9469
sS'PT'
p9470
(lp9471
S'Journal Article'
p9472
aS'Research Support, N.I.H., Extramural'
p9473
aS'Research Support, N.I.H., Intramural'
p9474
asS'LA'
p9475
(lp9476
S'eng'
p9477
asS'FAU'
p9478
(lp9479
S'Billioux, Alexander'
p9480
aS'Nakigozi, Gertrude'
p9481
aS'Newell, Kevin'
p9482
aS'Chang, Larry W'
p9483
aS'Quinn, Thomas C'
p9484
aS'Gray, Ron H'
p9485
aS'Ndyanabo, Anthony'
p9486
aS'Galiwango, Ronald'
p9487
aS'Kiggundu, Valerian'
p9488
aS'Serwadda, David'
p9489
aS'Reynolds, Steven J'
p9490
asS'JT'
p9491
S'PloS one'
p9492
sS'LR'
p9493
S'20160227'
p9494
sS'PG'
p9495
S'e0127235'
p9496
sS'TI'
p9497
S'Durable Suppression of HIV-1 after Virologic Monitoring-Based Antiretroviral Adherence Counseling in Rakai, Uganda.'
p9498
sS'PL'
p9499
S'United States'
p9500
sS'TA'
p9501
S'PLoS One'
p9502
sS'JID'
p9503
S'101285081'
p9504
sS'AB'
p9505
S'OBJECTIVES: HIV viral load is recommended for monitoring antiretroviral treatment and identifying treatment failure. We assessed the durability of viral suppression after viral load-triggered adherence counseling among patients with HIV viremia 6 months after ART initiation. DESIGN: Observational cohort enrolled in an antiretroviral treatment program in rural Uganda. METHODS: Participants who underwent routine viral load determination every 24 weeks and had at least 48 weeks of follow-up were included in this analysis. Patients with viral loads >400 copies/ml at 24 weeks of treatment were given additional adherence counseling, and all patients were followed to assess the duration of viral suppression and development of virologic failure. RESULTS: 1,841 participants initiating antiretroviral therapy were enrolled in the Rakai Health Sciences Program between June 2005 and June 2011 and were followed with viral load monitoring every 24 weeks. 148 (8%) of patients did not achieve viral suppression at 24 weeks and were given additional adherence counseling. 85 (60%) of these patients had undetectable viral loads at 48 weeks, with a median duration of viral suppression of 240 weeks (IQR 193-288 weeks). Failure to achieve an undetectable viral load at 48 weeks was associated with age <30 years and 24 week viral load >2,000 copies/ml in multivariate logistic regression analysis. CONCLUSIONS: The majority of patients with persistent viremia who were provided adherence counseling achieved robust viral suppression for a median 4.6 years. Access to virologic monitoring and adherence counseling is a priority in resource-limited settings.'
p9506
sS'GR'
p9507
(lp9508
S'HHSN261200800001E/PHS HHS/United States'
p9509
aS'K23MH086338/MH/NIMH NIH HHS/United States'
p9510
aS'P30 AI094189/AI/NIAID NIH HHS/United States'
p9511
aS'Intramural NIH HHS/United States'
p9512
asS'IP'
p9513
S'5'
sS'IS'
p9514
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p9515
sS'PMC'
p9516
S'PMC4444255'
p9517
sS'DCOM'
p9518
S'20160418'
p9519
sS'AU'
p9520
(lp9521
S'Billioux A'
p9522
aS'Nakigozi G'
p9523
aS'Newell K'
p9524
aS'Chang LW'
p9525
aS'Quinn TC'
p9526
aS'Gray RH'
p9527
aS'Ndyanabo A'
p9528
aS'Galiwango R'
p9529
aS'Kiggundu V'
p9530
aS'Serwadda D'
p9531
aS'Reynolds SJ'
p9532
asS'VI'
p9533
S'10'
p9534
sS'MHDA'
p9535
S'2016/04/19 06:00'
p9536
sS'PHST'
p9537
(lp9538
S'2015 [ecollection]'
p9539
aS'2014/11/24 [received]'
p9540
aS'2015/04/12 [accepted]'
p9541
aS'2015/05/26 [epublish]'
p9542
asS'OID'
p9543
(lp9544
S'NLM: PMC4444255'
p9545
asS'MH'
p9546
(lp9547
S'Adult'
p9548
aS'*Antiretroviral Therapy, Highly Active'
p9549
aS'Counseling'
p9550
aS'Female'
p9551
aS'HIV Infections/*drug therapy/*virology'
p9552
aS'HIV-1/*physiology'
p9553
aS'Humans'
p9554
aS'Male'
p9555
aS'*Patient Compliance'
p9556
aS'Uganda'
p9557
aS'Viral Load/*physiology'
p9558
asS'EDAT'
p9559
S'2015/05/27 06:00'
p9560
sS'SO'
p9561
S'PLoS One. 2015 May 26;10(5):e0127235. doi: 10.1371/journal.pone.0127235. eCollection 2015.'
p9562
sS'SB'
p9563
S'IM'
p9564
sS'PMID'
p9565
S'26011158'
p9566
sS'PST'
p9567
S'epublish'
p9568
stRp9569
ag2
(g3
g4
(dp9570
S'LID'
p9571
S'10.1097/QAI.0000000000000580 [doi]'
p9572
sS'STAT'
p9573
S'MEDLINE'
p9574
sS'JT'
p9575
S'Journal of acquired immune deficiency syndromes (1999)'
p9576
sS'MID'
p9577
(lp9578
S'EMS62165'
p9579
asS'DA'
p9580
S'20150527'
p9581
sS'AID'
p9582
(lp9583
S'10.1097/QAI.0000000000000580 [doi]'
p9584
aS'00126334-201506010-00019 [pii]'
p9585
asS'CRDT'
p9586
(lp9587
S'2015/05/27 06:00'
p9588
asS'DP'
p9589
S'2015 Jun 1'
p9590
sS'AD'
p9591
S'*Center for Research in Therapeutic Sciences and the Institute of Healthcare Management, Strathmore University, Nairobi, Kenya; daggerKenya Medical Research Institute, Nairobi, Kenya; double daggerInstitute of Tropical Medicine and Infectious Diseases at JKUAT, Nairobi, Kenya; section signMCPHS University, Worcester, MA; ||Center for Global Public Health, Tufts University School of Medicine, Boston, MA; and paragraph signAfrican Centre for Clinical Trials, Nairobi, Kenya.'
p9592
sS'OWN'
p9593
S'NLM'
p9594
sS'PT'
p9595
(lp9596
S'Journal Article'
p9597
aS'Multicenter Study'
p9598
aS"Research Support, Non-U.S. Gov't"
p9599
asS'LA'
p9600
(lp9601
S'eng'
p9602
asS'FAU'
p9603
(lp9604
S'Ochieng, Washingtone'
p9605
aS'Kitawi, Rose C'
p9606
aS'Nzomo, Timothy J'
p9607
aS'Mwatelah, Ruth S'
p9608
aS'Kimulwo, Maureen J'
p9609
aS'Ochieng, Dorothy J'
p9610
aS'Kinyua, Joyceline'
p9611
aS'Lagat, Nancy'
p9612
aS'Onyango, Kevin O'
p9613
aS'Lwembe, Raphael M'
p9614
aS'Mwamburi, Mkaya'
p9615
aS'Ogutu, Bernhards R'
p9616
aS'Oloo, Florence A'
p9617
aS'Aman, Rashid'
p9618
asS'LR'
p9619
S'20151203'
p9620
sS'PG'
p9621
S'e49-56'
p9622
sS'TI'
p9623
S'Implementation and Operational Research: Correlates of Adherence and Treatment Failure Among Kenyan Patients on Long-term Highly Active Antiretroviral Therapy.'
p9624
sS'RN'
p9625
(lp9626
S'0 (Anti-Retroviral Agents)'
p9627
asS'PL'
p9628
S'United States'
p9629
sS'TA'
p9630
S'J Acquir Immune Defic Syndr'
p9631
sS'JID'
p9632
S'100892005'
p9633
sS'AB'
p9634
S'BACKGROUND: Universal access to highly active antiretroviral therapy (HAART) is still elusive in most developing nations. We asked whether peer support influenced adherence and treatment outcome and if a single viral load (VL) could define treatment failure in a resource-limited setting. METHODS: A multicenter longitudinal and cross-sectional survey of VL, CD4 T cells, and adherence in 546 patients receiving HAART for up to 228 months. VL and CD4 counts were determined using m2000 Abbott RealTime HIV-1 assay and FACS counters, respectively. Adherence was assessed based on pill count and on self-report. RESULTS: Of the patients, 55.8%, 22.2%, and 22% had good, fair, and poor adherence, respectively. Adherence, peer support, and regimen, but not HIV disclosure, age, or gender, independently correlated with VL and durability of treatment in a multivariate analysis (P < 0.001). Treatment failure was 35.9% using sequential VL but ranged between 27% and 35% using alternate single VL cross-sectional definitions. More patients failed stavudine (41.2%) than zidovudine (37.4%) or tenofovir (28.8%, P = 0.043) treatment arms. Peer support correlated positively with adherence (chi(2), P < 0.001), with nonadherence being highest in the stavudine arm. VL before the time of regimen switch was comparable between patients switching and not switching treatment. Moreover, 36% of those switching still failed the second-line regimen. CONCLUSION: Weak adherence support and inaccessible VL testing threaten to compromise the success of HAART scale-up in Kenya. To hasten antiretroviral therapy monitoring and decision making, we suggest strengthening patient-focused adherence programs, optimizing and aligning regimen to WHO standards, and a single point-of-care VL testing when multiple tests are unavailable.'
p9635
sS'GR'
p9636
(lp9637
S'080883KOKWARO/Wellcome Trust/United Kingdom'
p9638
aS'WT080883/Wellcome Trust/United Kingdom'
p9639
asS'IP'
p9640
S'2'
sS'IS'
p9641
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p9642
sS'PMC'
p9643
S'PMC4445604'
p9644
sS'DCOM'
p9645
S'20150810'
p9646
sS'AU'
p9647
(lp9648
S'Ochieng W'
p9649
aS'Kitawi RC'
p9650
aS'Nzomo TJ'
p9651
aS'Mwatelah RS'
p9652
aS'Kimulwo MJ'
p9653
aS'Ochieng DJ'
p9654
aS'Kinyua J'
p9655
aS'Lagat N'
p9656
aS'Onyango KO'
p9657
aS'Lwembe RM'
p9658
aS'Mwamburi M'
p9659
aS'Ogutu BR'
p9660
aS'Oloo FA'
p9661
aS'Aman R'
p9662
asS'VI'
p9663
S'69'
p9664
sS'MHDA'
p9665
S'2015/08/11 06:00'
p9666
sS'OID'
p9667
(lp9668
S'NLM: EMS62165'
p9669
aS'NLM: PMC4445604'
p9670
asS'MH'
p9671
(lp9672
S'Adolescent'
p9673
aS'Adult'
p9674
aS'Aged'
p9675
aS'Anti-Retroviral Agents/*therapeutic use'
p9676
aS'Antiretroviral Therapy, Highly Active/*methods'
p9677
aS'Child'
p9678
aS'Child, Preschool'
p9679
aS'Cohort Studies'
p9680
aS'Cross-Sectional Studies'
p9681
aS'Drug Monitoring'
p9682
aS'Female'
p9683
aS'HIV Infections/*diagnosis/*drug therapy'
p9684
aS'Health Services Accessibility'
p9685
aS'Humans'
p9686
aS'Kenya'
p9687
aS'Longitudinal Studies'
p9688
aS'Male'
p9689
aS'*Medication Adherence'
p9690
aS'Middle Aged'
p9691
aS'Treatment Failure'
p9692
aS'Viral Load'
p9693
aS'Young Adult'
p9694
asS'EDAT'
p9695
S'2015/05/27 06:00'
p9696
sS'SO'
p9697
S'J Acquir Immune Defic Syndr. 2015 Jun 1;69(2):e49-56. doi: 10.1097/QAI.0000000000000580.'
p9698
sS'SB'
p9699
S'IM X'
p9700
sS'PMID'
p9701
S'26009836'
p9702
sS'PST'
p9703
S'ppublish'
p9704
stRp9705
ag2
(g3
g4
(dp9706
S'LID'
p9707
S'10.1371/journal.pone.0126878 [doi]'
p9708
sS'STAT'
p9709
S'MEDLINE'
p9710
sS'DEP'
p9711
S'20150522'
p9712
sS'DA'
p9713
S'20150524'
p9714
sS'AID'
p9715
(lp9716
S'10.1371/journal.pone.0126878 [doi]'
p9717
aS'PONE-D-14-58064 [pii]'
p9718
asS'CRDT'
p9719
(lp9720
S'2015/05/23 06:00'
p9721
asS'DP'
p9722
S'2015'
p9723
sS'OWN'
p9724
S'NLM'
p9725
sS'PT'
p9726
(lp9727
S'Journal Article'
p9728
aS"Research Support, Non-U.S. Gov't"
p9729
asS'LA'
p9730
(lp9731
S'eng'
p9732
asS'FAU'
p9733
(lp9734
S'Napierala Mavedzenge, Sue'
p9735
aS'Davey, Calum'
p9736
aS'Chirenje, Tarisai'
p9737
aS'Mushati, Phyllis'
p9738
aS'Mtetwa, Sibongile'
p9739
aS'Dirawo, Jeffrey'
p9740
aS'Mudenge, Boniface'
p9741
aS'Phillips, Andrew'
p9742
aS'Cowan, Frances M'
p9743
asS'JT'
p9744
S'PloS one'
p9745
sS'LR'
p9746
S'20150529'
p9747
sS'PG'
p9748
S'e0126878'
p9749
sS'TI'
p9750
S'Finger Prick Dried Blood Spots for HIV Viral Load Measurement in Field Conditions in Zimbabwe.'
p9751
sS'PL'
p9752
S'United States'
p9753
sS'TA'
p9754
S'PLoS One'
p9755
sS'JID'
p9756
S'101285081'
p9757
sS'AB'
p9758
S'BACKGROUND: In the context of a community-randomized trial of antiretrovirals for HIV prevention and treatment among sex workers in Zimbabwe (the SAPPH-IRe trial), we will measure the proportion of women with HIV viral load (VL) above 1000 copies/mL ("VL>1000") as our primary endpoint. We sought to characterize VL assay performance by comparing results from finger prick dried blood spots (DBS) collected in the field with plasma samples, to determine whether finger prick DBS is an acceptable sample for VL quantification in the setting. METHODS: We collected whole blood from a finger prick onto filter paper and plasma samples using venipuncture from women in two communities. VL quantification was run on samples in parallel using NucliSENS EasyQ HIV-1 v2.0. Our trial outcome is the proportion of women with VL>1000, consistent with WHO guidelines relating to regimen switching. We therefore focused on this cut-off level for assessing sensitivity and specificity. Results were log transformed and the mean difference and standard deviation calculated, and correlation between VL quantification across sample types was evaluated. RESULTS: A total of 149 HIV-positive women provided DBS and plasma samples; 56 (63%) reported being on antiretroviral therapy. VL ranged from undetectable-6.08 log10 using DBS and undetectable-6.40 log10 using plasma. The mean difference in VL (plasma-DBS) was 0.077 log10 (95%CI = 0.025-0.18 log10; standard deviation = 0.63 log10,). 78 (52%) DBS and 87 (58%) plasma samples had a VL>1000. Based on plasma \'gold-standard\', DBS sensitivity for detection of VL>1000 was 87.4%, and specificity was 96.8%. CONCLUSION: There was generally good agreement between DBS and plasma VL for detection of VL>1000. Overall, finger prick DBS appeared to be an acceptable sample for classifying VL as above or below 1000 copies/mL using the NucliSENS assay.'
p9759
sS'AD'
p9760
S"Women's Global Health Imperative, RTI International, San Francisco, California, United States of America. London School of Hygiene and Tropical Medicine, London, United Kingdom. Centre for Sexual Health and HIV/AIDS Research Zimbabwe, Harare, Zimbabwe. Centre for Sexual Health and HIV/AIDS Research Zimbabwe, Harare, Zimbabwe. Centre for Sexual Health and HIV/AIDS Research Zimbabwe, Harare, Zimbabwe. Centre for Sexual Health and HIV/AIDS Research Zimbabwe, Harare, Zimbabwe. Flowcytometry Laboratory, Harare, Zimbabwe. University College London, London, United Kingdom. Centre for Sexual Health and HIV/AIDS Research Zimbabwe, Harare, Zimbabwe; University College London, London, United Kingdom."
p9761
sS'IP'
p9762
S'5'
sS'IS'
p9763
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p9764
sS'PMC'
p9765
S'PMC4441418'
p9766
sS'DCOM'
p9767
S'20160413'
p9768
sS'AU'
p9769
(lp9770
S'Napierala Mavedzenge S'
p9771
aS'Davey C'
p9772
aS'Chirenje T'
p9773
aS'Mushati P'
p9774
aS'Mtetwa S'
p9775
aS'Dirawo J'
p9776
aS'Mudenge B'
p9777
aS'Phillips A'
p9778
aS'Cowan FM'
p9779
asS'VI'
p9780
S'10'
p9781
sS'MHDA'
p9782
S'2016/04/14 06:00'
p9783
sS'PHST'
p9784
(lp9785
S'2015 [ecollection]'
p9786
aS'2015/02/09 [received]'
p9787
aS'2015/04/08 [accepted]'
p9788
aS'2015/05/22 [epublish]'
p9789
asS'OID'
p9790
(lp9791
S'NLM: PMC4441418'
p9792
asS'MH'
p9793
(lp9794
S'*Blood Specimen Collection'
p9795
aS'Desiccation'
p9796
aS'Female'
p9797
aS'HIV Infections/*virology'
p9798
aS'*HIV-1'
p9799
aS'Humans'
p9800
aS'Sensitivity and Specificity'
p9801
aS'*Serologic Tests'
p9802
aS'Specimen Handling'
p9803
aS'*Viral Load'
p9804
aS'Zimbabwe'
p9805
asS'EDAT'
p9806
S'2015/05/23 06:00'
p9807
sS'SO'
p9808
S'PLoS One. 2015 May 22;10(5):e0126878. doi: 10.1371/journal.pone.0126878. eCollection 2015.'
p9809
sS'SB'
p9810
S'IM'
p9811
sS'PMID'
p9812
S'26001044'
p9813
sS'PST'
p9814
S'epublish'
p9815
stRp9816
ag2
(g3
g4
(dp9817
S'LID'
p9818
S'10.1371/journal.pone.0127024 [doi]'
p9819
sS'STAT'
p9820
S'MEDLINE'
p9821
sS'DEP'
p9822
S'20150519'
p9823
sS'DA'
p9824
S'20150521'
p9825
sS'AID'
p9826
(lp9827
S'10.1371/journal.pone.0127024 [doi]'
p9828
aS'PONE-D-14-50518 [pii]'
p9829
asS'CRDT'
p9830
(lp9831
S'2015/05/21 06:00'
p9832
asS'DP'
p9833
S'2015'
p9834
sS'AD'
p9835
S'Icahn School of Medicine at Mount Sinai, New York, New York, United States of America. Church of Scotland Hospital, Tugela Ferry, KwaZulu-Natal, South Africa. Department of Medicine, Section of Infectious Diseases, AIDS Program, Yale University School of Medicine, New Haven, Connecticut, United States of America. Department of Medicine, Section of Infectious Diseases, AIDS Program, Yale University School of Medicine, New Haven, Connecticut, United States of America.'
p9836
sS'OWN'
p9837
S'NLM'
p9838
sS'PT'
p9839
(lp9840
S'Journal Article'
p9841
aS'Research Support, N.I.H., Extramural'
p9842
aS"Research Support, Non-U.S. Gov't"
p9843
asS'LA'
p9844
(lp9845
S'eng'
p9846
asS'FAU'
p9847
(lp9848
S'Jacobson, Karen B'
p9849
aS'Moll, Anthony P'
p9850
aS'Friedland, Gerald H'
p9851
aS'Shenoi, Sheela V'
p9852
asS'JT'
p9853
S'PloS one'
p9854
sS'LR'
p9855
S'20160115'
p9856
sS'PG'
p9857
S'e0127024'
p9858
sS'TI'
p9859
S'Successful Tuberculosis Treatment Outcomes among HIV/TB Coinfected Patients Down-Referred from a District Hospital to Primary Health Clinics in Rural South Africa.'
p9860
sS'RN'
p9861
(lp9862
S'0 (Antitubercular Agents)'
p9863
asS'PL'
p9864
S'United States'
p9865
sS'TA'
p9866
S'PLoS One'
p9867
sS'JID'
p9868
S'101285081'
p9869
sS'AB'
p9870
S"BACKGROUND: HIV and tuberculosis (TB) coinfection remains a major public health threat in sub-Saharan Africa. Integration and decentralization of HIV and TB treatment services are being implemented, but data on outcomes of this strategy are lacking in rural, resource-limited settings. We evaluated TB treatment outcomes in TB/HIV coinfected patients in an integrated and decentralized system in rural KwaZulu-Natal, South Africa. METHODS: We retrospectively studied a cohort of HIV/TB coinfected patients initiating treatment for drug-susceptible TB at a district hospital HIV clinic from January 2012-June 2013. Patients were eligible for down-referral to primary health clinics(PHCs) for TB treatment completion if they met specific clinical criteria. Records were reviewed for patients' demographic, baseline clinical and laboratory information, past HIV and TB history, and TB treatment outcomes. RESULTS: Of 657(88.7%) patients, 322(49.0%) were female, 558(84.9%) were new TB cases, and 572(87.1%) had pulmonary TB. After TB treatment initiation, 280(42.6%) were down-referred from the district level HIV clinic to PHCs for treatment completion; 377(57.4%) remained at the district hospital. Retained patients possessed characteristics indicative of more severe disease. In total, 540(82.2%) patients experienced treatment success, 69(10.5%) died, and 46(7.0%) defaulted. Down-referred patients experienced higher treatment success, and lower mortality, but were more likely to default, primarily at the time of transfer to PHC. CONCLUSION: Decentralization of TB treatment to the primary care level is feasible in rural South Africa. Treatment outcomes are favorable when patients are carefully chosen for down-referral. Higher mortality in retained patients reflects increased baseline disease severity while higher default among down-referred patients reflects failed linkage of care. Better linkage mechanisms are needed including improved identification of potential defaulters, increased patient education, active communication between hospitals and PHCs, and tracing of patients lost to follow up. Decentralized and integrated care is successful for carefully selected TB/HIV coinfected patients and should be expanded."
p9871
sS'GR'
p9872
(lp9873
S'#5K23AI089260-03/AI/NIAID NIH HHS/United States'
p9874
aS'K23 AI089260/AI/NIAID NIH HHS/United States'
p9875
aS'P30 MH062294/MH/NIMH NIH HHS/United States'
p9876
asS'IP'
p9877
S'5'
sS'IS'
p9878
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p9879
sS'PMC'
p9880
S'PMC4438008'
p9881
sS'DCOM'
p9882
S'20160415'
p9883
sS'AU'
p9884
(lp9885
S'Jacobson KB'
p9886
aS'Moll AP'
p9887
aS'Friedland GH'
p9888
aS'Shenoi SV'
p9889
asS'VI'
p9890
S'10'
p9891
sS'MHDA'
p9892
S'2016/04/16 06:00'
p9893
sS'PHST'
p9894
(lp9895
S'2015 [ecollection]'
p9896
aS'2014/11/15 [received]'
p9897
aS'2015/04/10 [accepted]'
p9898
aS'2015/05/19 [epublish]'
p9899
asS'OID'
p9900
(lp9901
S'NLM: PMC4438008'
p9902
asS'MH'
p9903
(lp9904
S'Adult'
p9905
aS'Antitubercular Agents/*therapeutic use'
p9906
aS'Female'
p9907
aS'HIV Infections/*complications'
p9908
aS'*Hospitals, District'
p9909
aS'Humans'
p9910
aS'Male'
p9911
aS'*Primary Health Care'
p9912
aS'*Referral and Consultation'
p9913
aS'*Rural Population'
p9914
aS'South Africa'
p9915
aS'Tuberculosis/complications/*drug therapy'
p9916
asS'EDAT'
p9917
S'2015/05/21 06:00'
p9918
sS'SO'
p9919
S'PLoS One. 2015 May 19;10(5):e0127024. doi: 10.1371/journal.pone.0127024. eCollection 2015.'
p9920
sS'SB'
p9921
S'IM'
p9922
sS'PMID'
p9923
S'25993636'
p9924
sS'PST'
p9925
S'epublish'
p9926
stRp9927
ag2
(g3
g4
(dp9928
S'LID'
p9929
S'10.1093/trstmh/trv037 [doi]'
p9930
sS'STAT'
p9931
S'MEDLINE'
p9932
sS'DEP'
p9933
S'20150515'
p9934
sS'CI'
p9935
(lp9936
S'(c) The Author 2015. Published by Oxford University Press on behalf of Royal'
p9937
aS'Society of Tropical Medicine and Hygiene. All rights reserved. For permissions,'
p9938
aS'please e-mail: journals.permissions@oup.com.'
p9939
asS'DA'
p9940
S'20150613'
p9941
sS'AID'
p9942
(lp9943
S'trv037 [pii]'
p9944
aS'10.1093/trstmh/trv037 [doi]'
p9945
asS'CRDT'
p9946
(lp9947
S'2015/05/17 06:00'
p9948
asS'DP'
p9949
S'2015 Jul'
p9950
sS'AD'
p9951
S'Medecins Sans Frontieres (MSF), Khayelitsha, Cape Town, South Africa msfocb-khayelitsha-drtb-epi@brussels.msf.org. Medecins Sans Frontieres (MSF), Khayelitsha, Cape Town, South Africa. Medecins Sans Frontieres (MSF), Khayelitsha, Cape Town, South Africa. Medecins Sans Frontieres (MSF), Khayelitsha, Cape Town, South Africa. Medecins Sans Frontieres (MSF), Khayelitsha, Cape Town, South Africa. Medecins Sans Frontieres (MSF), Khayelitsha, Cape Town, South Africa. Medecins Sans Frontieres (MSF), Khayelitsha, Cape Town, South Africa. University of Cape Town, Division of Medical Microbiology and Institute of Infectious Disease and Molecular Medicine, Cape Town, South Africa.'
p9952
sS'OWN'
p9953
S'NLM'
p9954
sS'PT'
p9955
(lp9956
S'Journal Article'
p9957
aS"Research Support, Non-U.S. Gov't"
p9958
asS'LA'
p9959
(lp9960
S'eng'
p9961
asS'FAU'
p9962
(lp9963
S'Mohr, Erika'
p9964
aS'Cox, Vivian'
p9965
aS'Wilkinson, Lynne'
p9966
aS'Moyo, Sizulu'
p9967
aS'Hughes, Jennifer'
p9968
aS'Daniels, Johnny'
p9969
aS'Muller, Odelia'
p9970
aS'Cox, Helen'
p9971
asS'JT'
p9972
S'Transactions of the Royal Society of Tropical Medicine and Hygiene'
p9973
sS'PG'
p9974
S'425-32'
p9975
sS'TI'
p9976
S'Programmatic treatment outcomes in HIV-infected and uninfected drug-resistant TB patients in Khayelitsha, South Africa.'
p9977
sS'RN'
p9978
(lp9979
S'0 (Antitubercular Agents)'
p9980
asS'PL'
p9981
S'England'
p9982
sS'TA'
p9983
S'Trans R Soc Trop Med Hyg'
p9984
sS'JID'
p9985
S'7506129'
p9986
sS'AB'
p9987
S'BACKGROUND: South Africa has high burdens of HIV, TB and drug-resistant TB (DR-TB, rifampicin-resistance). Treatment outcome data for HIV-infected versus uninfected patients is limited. We assessed the impact of HIV and other factors on DR-TB treatment success, time to culture conversion, loss-from-treatment and overall mortality after second-line treatment initiation. METHODS: A retrospective cohort analysis was conducted for patients initiated on DR-TB treatment from 2008 to 2012, within a community-based, decentralised programme in Khayelitsha, South Africa. RESULTS: Among 853 confirmed DR-TB patients initiating second-line treatment, 605 (70.9%) were HIV infected. HIV status did not impact on time to sputum culture conversion nor did it impact treatment success; 48.1% (259/539) and 45.9% (100/218), respectively (p=0.59). In a multivariate model, HIV was not associated with treatment success. Death during treatment was higher among HIV-infected patients, but overall mortality was not significantly higher. HIV-infected patients with CD4 <=100 cells/ml were significantly more likely to die after starting treatment. CONCLUSIONS: Response to DR-TB treatment did not differ with HIV infection in a programmatic setting with access to antiretroviral treatment (ART). Earlier ART initiation at a primary care level could reduce mortality among HIV-infected patients presenting with low CD4 counts.'
p9988
sS'GR'
p9989
(lp9990
S'085215/Wellcome Trust/United Kingdom'
p9991
asS'IP'
p9992
S'7'
sS'IS'
p9993
S'1878-3503 (Electronic) 0035-9203 (Linking)'
p9994
sS'DCOM'
p9995
S'20160222'
p9996
sS'AU'
p9997
(lp9998
S'Mohr E'
p9999
aS'Cox V'
p10000
aS'Wilkinson L'
p10001
aS'Moyo S'
p10002
aS'Hughes J'
p10003
aS'Daniels J'
p10004
aS'Muller O'
p10005
aS'Cox H'
p10006
asS'VI'
p10007
S'109'
p10008
sS'MHDA'
p10009
S'2016/02/24 06:00'
p10010
sS'PHST'
p10011
(lp10012
S'2014/08/20 [received]'
p10013
aS'2015/04/20 [accepted]'
p10014
aS'2015/05/15 [aheadofprint]'
p10015
asS'OTO'
p10016
(lp10017
S'NOTNLM'
p10018
asS'MH'
p10019
(lp10020
S'Adolescent'
p10021
aS'Adult'
p10022
aS'Antitubercular Agents/*therapeutic use'
p10023
aS'CD4 Lymphocyte Count'
p10024
aS'Coinfection'
p10025
aS'Female'
p10026
aS'*HIV Infections/epidemiology'
p10027
aS'Humans'
p10028
aS'Logistic Models'
p10029
aS'Male'
p10030
aS'Middle Aged'
p10031
aS'Outcome Assessment (Health Care)'
p10032
aS'Retrospective Studies'
p10033
aS'South Africa/epidemiology'
p10034
aS'Tuberculosis, Multidrug-Resistant/*drug therapy/mortality'
p10035
aS'Young Adult'
p10036
asS'EDAT'
p10037
S'2015/05/17 06:00'
p10038
sS'SO'
p10039
S'Trans R Soc Trop Med Hyg. 2015 Jul;109(7):425-32. doi: 10.1093/trstmh/trv037. Epub 2015 May 15.'
p10040
sS'SB'
p10041
S'IM'
p10042
sS'PMID'
p10043
S'25979526'
p10044
sS'OT'
p10045
(lp10046
S'ART'
p10047
aS'DR-TB'
p10048
aS'HIV'
p10049
aS'Programmatic treatment outcomes'
p10050
asS'PST'
p10051
S'ppublish'
p10052
stRp10053
ag2
(g3
g4
(dp10054
S'LID'
p10055
S'10.1093/humrep/dev109 [doi]'
p10056
sS'STAT'
p10057
S'MEDLINE'
p10058
sS'DEP'
p10059
S'20150515'
p10060
sS'CI'
p10061
(lp10062
S'(c) The Author 2015. Published by Oxford University Press on behalf of the'
p10063
aS'European Society of Human Reproduction and Embryology. All rights reserved. For'
p10064
aS'Permissions, please email: journals.permissions@oup.com.'
p10065
asS'DA'
p10066
S'20150619'
p10067
sS'AID'
p10068
(lp10069
S'dev109 [pii]'
p10070
aS'10.1093/humrep/dev109 [doi]'
p10071
asS'CRDT'
p10072
(lp10073
S'2015/05/17 06:00'
p10074
asS'DP'
p10075
S'2015 Jul'
p10076
sS'AD'
p10077
S"Department of Obstetrics and Gynaecology, Makerere University College of Health Sciences, Mulago Hospital Complex, PO Box 7072, Old Mulago Hill, Kampala, Uganda kakaireothman@hotmail.com. Department of Obstetrics and Gynaecology, Makerere University College of Health Sciences, Mulago Hospital Complex, PO Box 7072, Old Mulago Hill, Kampala, Uganda. School of Public Health, Makerere University College of Health Sciences, Mulago Hospital Complex, Old Mulago Hill, Kampala, Uganda. Department of Women's and Children's Health, Division of Obstetrics and Gynaecology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden."
p10078
sS'OWN'
p10079
S'NLM'
p10080
sS'PT'
p10081
(lp10082
S'Journal Article'
p10083
aS'Randomized Controlled Trial'
p10084
aS'Research Support, N.I.H., Extramural'
p10085
asS'LA'
p10086
(lp10087
S'eng'
p10088
asS'FAU'
p10089
(lp10090
S'Kakaire, Othman'
p10091
aS'Byamugisha, Josaphat Kayogoza'
p10092
aS'Tumwesigye, Nazarius Mbona'
p10093
aS'Gemzell-Danielsson, Kristina'
p10094
asS'JT'
p10095
S'Human reproduction (Oxford, England)'
p10096
sS'LR'
p10097
S'20160701'
p10098
sS'PG'
p10099
S'1573-9'
p10100
sS'TI'
p10101
S'Clinical versus laboratory screening for sexually transmitted infections prior to insertion of intrauterine contraception among women living with HIV/AIDS: a randomized controlled trial.'
p10102
sS'PL'
p10103
S'England'
p10104
sS'TA'
p10105
S'Hum Reprod'
p10106
sS'JID'
p10107
S'8701199'
p10108
sS'AB'
p10109
S'STUDY QUESTION: Does laboratory testing after syndromic screening for sexually transmitted infections (STIs) reduce the rate of intrauterine contraception (IUC) removal among women living with HIV/AIDS (WLHA)? SUMMARY ANSWER: Additional laboratory testing after syndromic screening for STIs did not affect the likelihood that a woman would remove an IUC immediately or within 1 year of IUC use or the frequency of post-insertion unscheduled clinic visits. In low-risk WLHA, the incidence rate of IUC removal is low with or without laboratory testing. WHAT IS KNOWN ALREADY: Fear of infectious morbidity remains an obstacle to uptake of IUC by WLHA. The value of laboratory testing after syndromic screening for STI before the insertion of IUC remains uncertain. STUDY DESIGN, SIZE, DURATION: We enrolled WLHA from 2 September to 6 December 2013 and followed them up to 31 December 2014. After syndromic screening, 703 women free of STIs were randomized to either additional laboratory screening or no additional screening for STI before IUC insertion. The randomization sequence was generated by an independent statistician and randomization numbers placed in opaque sequentially numbered sealed envelopes. All women randomized had an IUC inserted and in all 672 participants completed the 1-year follow-up. The study staff who followed up the participants were blinded to the study allocation groups. Incidence rate ratios (IRRs) were used to compare the incidence rates of IUC removal, unscheduled clinic attendance and IUC continuation between the two groups. PARTICIPANTS/MATERIALS, SETTING, METHODS: Women eligible to participate were 18-49 years old at study entry, in a relationship with a male partner, wanted to avoid pregnancy for at least 1 year and were undergoing HIV/AIDS care at Mulago Hospital, Uganda. Participants completed a baseline questionnaire and up to four follow-up questionnaires until discontinuation of IUC, loss to follow-up or end of study observation after 12 months. MAIN RESULTS AND THE ROLE OF CHANCE: The rate of IUC removal was 8.8% (29/331) in the no additional screening group and 8.0% (27/341) in the additional laboratory screening group [IRR 1.1 (95% CI 0.63-1.93)]. Unscheduled clinic attendances were similar in the two groups at 1 year of IUC insertion: 13.6% (45/331) in the no additional screening group and 12.3% (42/241) in the additional laboratory screening group. During the 1-year follow-up, only five women, three from the no additional screening group and two from the additional laboratory screening group, developed pelvic inflammatory disease (PID), as defined by established diagnostic criteria. LIMITATIONS, REASONS FOR CAUTION: We were not able to carry out STI risk assessment directly from the men thus women with high-risk partners could have been included in the study and this may be responsible for the lack of a demonstrable effect of additional laboratory screening on incidence rates of IUC removals and unscheduled clinic attendance. The diagnosis of PID was based on clinical signs and symptoms; therefore, subclinical PID could have been missed. WIDER IMPLICATIONS OF THE FINDINGS: Among WLHA, the incidence rate of IUC removal is low and IUC continuation high. Syndromic screening for STIs could be sufficient in indentifying WLHA who are suitable for IUC use. However, our findings are only generalizable to women in HIV/AIDS care who have access to good follow-up. STUDY FUNDING/COMPETING INTERESTS: The study was supported by Medical Education for Equitable Services to all Ugandans, a Medical Education Partnership Initiative grant number 5R24TW008886 from the office of Global AIDS Coordinator and the US Department of Health and Human Services, Health Resources and Services Administration and National Institutes of Health. Additional funding was from the Swedish International Development Agency, Swedish Research Council (SIDA/VR). The authors have no competing interests to declare. TRIAL REGISTRATION NUMBER: This trial was registered at Pan African Clinical Trial, Registry. PACTR 201308000561212.'
p10110
sS'GR'
p10111
(lp10112
S'5R24TW008886/TW/FIC NIH HHS/United States'
p10113
aS'R24 TW008886/TW/FIC NIH HHS/United States'
p10114
asS'IP'
p10115
S'7'
sS'IS'
p10116
S'1460-2350 (Electronic) 0268-1161 (Linking)'
p10117
sS'PMC'
p10118
S'PMC4472322'
p10119
sS'DCOM'
p10120
S'20160404'
p10121
sS'AU'
p10122
(lp10123
S'Kakaire O'
p10124
aS'Byamugisha JK'
p10125
aS'Tumwesigye NM'
p10126
aS'Gemzell-Danielsson K'
p10127
asS'VI'
p10128
S'30'
p10129
sS'MHDA'
p10130
S'2016/04/05 06:00'
p10131
sS'PHST'
p10132
(lp10133
S'2015/03/02 [received]'
p10134
aS'2015/04/20 [accepted]'
p10135
aS'2015/05/15 [aheadofprint]'
p10136
asS'OTO'
p10137
(lp10138
S'NOTNLM'
p10139
asS'OID'
p10140
(lp10141
S'NLM: PMC4472322'
p10142
asS'MH'
p10143
(lp10144
S'Adult'
p10145
aS'Device Removal/*statistics & numerical data'
p10146
aS'Female'
p10147
aS'Follow-Up Studies'
p10148
aS'*HIV Infections/epidemiology'
p10149
aS'Humans'
p10150
aS'Intrauterine Devices/adverse effects/*statistics & numerical data'
p10151
aS'Pelvic Inflammatory Disease/epidemiology/etiology'
p10152
aS'Sexually Transmitted Diseases/*diagnosis'
p10153
aS'Single-Blind Method'
p10154
aS'Uganda/epidemiology'
p10155
aS'Young Adult'
p10156
asS'EDAT'
p10157
S'2015/05/17 06:00'
p10158
sS'SI'
p10159
(lp10160
S'PACTR/PACTR201308000561212'
p10161
asS'SO'
p10162
S'Hum Reprod. 2015 Jul;30(7):1573-9. doi: 10.1093/humrep/dev109. Epub 2015 May 15.'
p10163
sS'SB'
p10164
S'IM'
p10165
sS'PMID'
p10166
S'25979373'
p10167
sS'OT'
p10168
(lp10169
S'IUC removal'
p10170
aS'acquired immunodeficiency syndrome'
p10171
aS'intrauterine contraceptive device'
p10172
aS'laboratory screening'
p10173
aS'sexually transmitted infections'
p10174
asS'PST'
p10175
S'ppublish'
p10176
stRp10177
ag2
(g3
g4
(dp10178
S'LID'
p10179
S'10.1111/tmi.12544 [doi]'
p10180
sS'STAT'
p10181
S'MEDLINE'
p10182
sS'DEP'
p10183
S'20150601'
p10184
sS'CI'
p10185
(lp10186
S'(c) 2015 The Authors. Tropical Medicine & International Health Published by John'
p10187
aS'Wiley & Sons Ltd.'
p10188
asS'DA'
p10189
S'20150905'
p10190
sS'AID'
p10191
(lp10192
S'10.1111/tmi.12544 [doi]'
p10193
asS'CRDT'
p10194
(lp10195
S'2015/05/16 06:00'
p10196
asS'DP'
p10197
S'2015 Oct'
p10198
sS'OWN'
p10199
S'NLM'
p10200
sS'PT'
p10201
(lp10202
S'Journal Article'
p10203
asS'LA'
p10204
(lp10205
S'eng'
p10206
asS'FAU'
p10207
(lp10208
S'Cox, Helen'
p10209
aS'Ramma, Lebogang'
p10210
aS'Wilkinson, Lynne'
p10211
aS'Azevedo, Virginia'
p10212
aS'Sinanovic, Edina'
p10213
asS'JT'
p10214
S'Tropical medicine & international health : TM & IH'
p10215
sS'LR'
p10216
S'20160626'
p10217
sS'PG'
p10218
S'1337-45'
p10219
sS'TI'
p10220
S'Cost per patient of treatment for rifampicin-resistant tuberculosis in a community-based programme in Khayelitsha, South Africa.'
p10221
sS'RN'
p10222
(lp10223
S'0 (Antibiotics, Antitubercular)'
p10224
aS'VJT6J7R4TR (Rifampin)'
p10225
asS'PL'
p10226
S'England'
p10227
sS'TA'
p10228
S'Trop Med Int Health'
p10229
sS'JID'
p10230
S'9610576'
p10231
sS'AB'
p10232
S'OBJECTIVES: The high cost of rifampicin-resistant tuberculosis (RR-TB) treatment hinders treatment access. South Africa has a high RR-TB burden, and national policy outlines decentralisation to improve access and reduce costs. We analysed health system costs associated with RR-TB treatment by drug resistance profile and treatment outcome in a decentralised programme. METHODS: Retrospective, routinely collected patient-level data were combined with unit cost data to determine costs for each patient in a cohort treated between January 2009 and December 2011. Drug costs were based on recommended regimens according to drug resistance and treatment duration. Hospitalisation costs were estimated based on admission/discharge dates, while clinic visit and diagnostic/monitoring costs were estimated according to recommendations and treatment duration. Missing data were imputed. RESULTS: Among 467 patients (72% HIV infected), 49% were successfully treated. Treatment was initiated in primary care for 62%, with the remainder as inpatients. The mean cost per patient treated was $7916 (range 260-87,140), ranging from $5369 among patients who did not complete treatment to $23,006 for treatment failure. Mean cost for successful treatment was $8359 (2585-32,506). Second-line drug resistance was associated with a mean cost of $15,567 vs. $6852 for only first-line resistance, with the major cost difference due to hospitalisation. Costs are reported in 2013 USD. CONCLUSIONS: RR-TB treatment cost was high and varied according to treatment outcome. Despite decentralisation, hospitalisation remained a significant cost, particularly among those with more extensive resistance and those with treatment failure. These cost estimates can be used to model the impact of new interventions to improve patient outcomes.'
p10233
sS'AD'
p10234
S'Division of Medical Microbiology and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa. Health Economics Unit, University of Cape Town, Cape Town, South Africa. Medecins Sans Frontieres (MSF), Khayelitsha, South Africa. City of Cape Town Health Department, Khayelitsha, South Africa. Health Economics Unit, University of Cape Town, Cape Town, South Africa.'
p10235
sS'IP'
p10236
S'10'
p10237
sS'IS'
p10238
S'1365-3156 (Electronic) 1360-2276 (Linking)'
p10239
sS'PMC'
p10240
S'PMC4864411'
p10241
sS'DCOM'
p10242
S'20151124'
p10243
sS'AU'
p10244
(lp10245
S'Cox H'
p10246
aS'Ramma L'
p10247
aS'Wilkinson L'
p10248
aS'Azevedo V'
p10249
aS'Sinanovic E'
p10250
asS'VI'
p10251
S'20'
p10252
sS'MHDA'
p10253
S'2015/12/15 06:00'
p10254
sS'PHST'
p10255
(lp10256
S'2015/06/01 [aheadofprint]'
p10257
asS'OTO'
p10258
(lp10259
S'NOTNLM'
p10260
asS'OID'
p10261
(lp10262
S'NLM: PMC4864411'
p10263
asS'MH'
p10264
(lp10265
S'Adolescent'
p10266
aS'Adult'
p10267
aS'Aged'
p10268
aS'Antibiotics, Antitubercular/therapeutic use'
p10269
aS'Child'
p10270
aS'Child, Preschool'
p10271
aS'*Costs and Cost Analysis'
p10272
aS'Female'
p10273
aS'Health Care Costs/*statistics & numerical data'
p10274
aS'Hospitalization/*economics'
p10275
aS'Humans'
p10276
aS'Infant'
p10277
aS'Male'
p10278
aS'Middle Aged'
p10279
aS'Primary Health Care/*economics'
p10280
aS'Retrospective Studies'
p10281
aS'Rifampin/therapeutic use'
p10282
aS'South Africa'
p10283
aS'Time Factors'
p10284
aS'Treatment Failure'
p10285
aS'Treatment Outcome'
p10286
aS'Tuberculosis, Multidrug-Resistant/drug therapy/*economics'
p10287
aS'Young Adult'
p10288
asS'EDAT'
p10289
S'2015/05/16 06:00'
p10290
sS'SO'
p10291
S'Trop Med Int Health. 2015 Oct;20(10):1337-45. doi: 10.1111/tmi.12544. Epub 2015 Jun 1.'
p10292
sS'SB'
p10293
S'IM'
p10294
sS'PMID'
p10295
S'25975868'
p10296
sS'OT'
p10297
(lp10298
S'Afrique du Sud'
p10299
aS'South Africa'
p10300
aS'Sudafrica'
p10301
aS'TB - MDR'
p10302
aS'TB-MDR'
p10303
aS'TB-RR'
p10304
aS'cost'
p10305
aS'costes'
p10306
aS'cout'
p10307
aS'decentralisation'
p10308
aS'descentralizacion'
p10309
aS'decentralisation'
p10310
aS'multidrug-resistant tuberculosis'
p10311
aS'rifampicin-resistant tuberculosis'
p10312
aS'traitement'
p10313
aS'tratamiento'
p10314
aS'treatment'
p10315
asS'PST'
p10316
S'ppublish'
p10317
stRp10318
ag2
(g3
g4
(dp10319
S'LID'
p10320
S'10.1111/tmi.12539 [doi]'
p10321
sS'STAT'
p10322
S'MEDLINE'
p10323
sS'DEP'
p10324
S'20150615'
p10325
sS'CI'
p10326
(lp10327
S'(c) 2015 The Authors. Tropical Medicine & International Health Published by John'
p10328
aS'Wiley & Sons Ltd.'
p10329
asS'DA'
p10330
S'20150905'
p10331
sS'AID'
p10332
(lp10333
S'10.1111/tmi.12539 [doi]'
p10334
asS'CRDT'
p10335
(lp10336
S'2015/05/13 06:00'
p10337
asS'DP'
p10338
S'2015 Oct'
p10339
sS'OWN'
p10340
S'NLM'
p10341
sS'PT'
p10342
(lp10343
S'Journal Article'
p10344
asS'LA'
p10345
(lp10346
S'eng'
p10347
asS'FAU'
p10348
(lp10349
S'Khabala, Kelly B'
p10350
aS'Edwards, Jeffrey K'
p10351
aS'Baruani, Bienvenu'
p10352
aS'Sirengo, Martin'
p10353
aS'Musembi, Phylles'
p10354
aS'Kosgei, Rose J'
p10355
aS'Walter, Kizito'
p10356
aS'Kibachio, Joseph M'
p10357
aS'Tondoi, Monique'
p10358
aS'Ritter, Helga'
p10359
aS'Wilkinson, Ewan'
p10360
aS'Reid, Tony'
p10361
asS'JT'
p10362
S'Tropical medicine & international health : TM & IH'
p10363
sS'LR'
p10364
S'20160221'
p10365
sS'PG'
p10366
S'1265-70'
p10367
sS'TI'
p10368
S'Medication Adherence Clubs: a potential solution to managing large numbers of stable patients with multiple chronic diseases in informal settlements.'
p10369
sS'PL'
p10370
S'England'
p10371
sS'TA'
p10372
S'Trop Med Int Health'
p10373
sS'JID'
p10374
S'9610576'
p10375
sS'AB'
p10376
S'OBJECTIVES: To assess the care of hypertension, diabetes mellitus and/or HIV patients enrolled into Medication Adherence Clubs (MACs). METHODS: Retrospective descriptive study was carried out using routinely collected programme data from a primary healthcare clinic at informal settlement in Nairobi, Kenya. All patients enrolled into MACs were selected for the study. MACs are nurse-facilitated mixed groups of 25-35 stable hypertension, diabetes mellitus and/or HIV patients who met quarterly to confirm their clinical stability, have brief health discussions and receive medication. Clinical officer reviewed MACs yearly, when a patient developed complications or no longer met stable criteria. RESULTS: A total of 1432 patients were enrolled into 47 clubs with 109 sessions conducted between August 2013 and August 2014. There were 1020 (71%) HIV and 412 (29%) non-communicable disease patients. Among those with NCD, 352 (85%) had hypertension and 60 (15%) had DM, while 12 had HIV concurrent with hypertension. A total of 2208 consultations were offloaded from regular clinic. During MAC attendance, blood pressure, weight and laboratory testing were completed correctly in 98-99% of consultations. Only 43 (2%) consultations required referral for clinical officer review before their routine yearly appointment. Loss to follow-up from the MACs was 3.5%. CONCLUSIONS: This study demonstrates the feasibility and early efficacy of MACs for mixed chronic disease in a resource-limited setting. It supports burden reduction and flexibility of regular clinical review for stable patients. Further assessment regarding long-term outcomes of this model should be completed to increase confidence for deployment in similar contexts.'
p10377
sS'AD'
p10378
S'Medecins Sans Frontieres, Nairobi, Kenya. Medecins Sans Frontieres, Nairobi, Kenya. Medecins Sans Frontieres, Nairobi, Kenya. National AIDs and STI Control Programme, Nairobi, Kenya. MOH Langata sub-County, Nairobi, Kenya. Department of Obstetrics and Gynaecology, College of Health Sciences, University of Nairobi, Nairobi, Kenya. Medecins Sans Frontieres, Nairobi, Kenya. Noncommunicable Diseases Control Unit, Kenya Ministry of Health, Nairobi, Kenya. Medecins Sans Frontieres, Nairobi, Kenya. Medecins Sans Frontieres, Nairobi, Kenya. Chester University, Chester, UK. Operational Research Unit, Medecins Sans Frontieres, Luxembourg, Luxembourg.'
p10379
sS'IP'
p10380
S'10'
p10381
sS'IS'
p10382
S'1365-3156 (Electronic) 1360-2276 (Linking)'
p10383
sS'PMC'
p10384
S'PMC4744994'
p10385
sS'DCOM'
p10386
S'20151124'
p10387
sS'AU'
p10388
(lp10389
S'Khabala KB'
p10390
aS'Edwards JK'
p10391
aS'Baruani B'
p10392
aS'Sirengo M'
p10393
aS'Musembi P'
p10394
aS'Kosgei RJ'
p10395
aS'Walter K'
p10396
aS'Kibachio JM'
p10397
aS'Tondoi M'
p10398
aS'Ritter H'
p10399
aS'Wilkinson E'
p10400
aS'Reid T'
p10401
asS'VI'
p10402
S'20'
p10403
sS'MHDA'
p10404
S'2015/12/15 06:00'
p10405
sS'PHST'
p10406
(lp10407
S'2015/06/15 [aheadofprint]'
p10408
asS'OTO'
p10409
(lp10410
S'NOTNLM'
p10411
asS'OID'
p10412
(lp10413
S'NLM: PMC4744994'
p10414
asS'MH'
p10415
(lp10416
S'Adult'
p10417
aS'Aged'
p10418
aS'Chronic Disease'
p10419
aS'Diabetes Mellitus/*drug therapy'
p10420
aS'Female'
p10421
aS'HIV Infections/complications/*drug therapy'
p10422
aS'Humans'
p10423
aS'Hypertension/*drug therapy'
p10424
aS'Kenya'
p10425
aS'Male'
p10426
aS'*Medication Adherence'
p10427
aS'Middle Aged'
p10428
aS'Primary Health Care/*methods'
p10429
aS'Retrospective Studies'
p10430
asS'EDAT'
p10431
S'2015/05/13 06:00'
p10432
sS'SO'
p10433
S'Trop Med Int Health. 2015 Oct;20(10):1265-70. doi: 10.1111/tmi.12539. Epub 2015 Jun 15.'
p10434
sS'SB'
p10435
S'IM'
p10436
sS'PMID'
p10437
S'25962952'
p10438
sS'OT'
p10439
(lp10440
S'Diabetes Mellitus'
p10441
aS'Hipertension'
p10442
aS'Hypertension'
p10443
aS'SORT IT'
p10444
aS'SORT-IT'
p10445
aS'diabete sucre'
p10446
aS'hypertension'
p10447
aS'investigacion de operaciones'
p10448
aS'operational research'
p10449
aS'recherche operationnelle'
p10450
asS'PST'
p10451
S'ppublish'
p10452
stRp10453
ag2
(g3
g4
(dp10454
S'LID'
p10455
S'10.1186/s12889-015-1814-2 [doi]'
p10456
sS'STAT'
p10457
S'MEDLINE'
p10458
sS'DEP'
p10459
S'20150510'
p10460
sS'DA'
p10461
S'20150514'
p10462
sS'AID'
p10463
(lp10464
S'10.1186/s12889-015-1814-2 [doi]'
p10465
aS'10.1186/s12889-015-1814-2 [pii]'
p10466
asS'CRDT'
p10467
(lp10468
S'2015/05/10 06:00'
p10469
asS'DP'
p10470
S'2015'
p10471
sS'AD'
p10472
S'KEMRI/Wellcome Trust Research Programme, Kilifi, Kenya. ahassan@kemri-wellcome.org. KEMRI/Wellcome Trust Research Programme, Kilifi, Kenya. smwaringa@kemri-wellcome.org. Kilifi District Hospital, Kilifi, Kenya. placbo1@gmail.com. KEMRI/Wellcome Trust Research Programme, Kilifi, Kenya. esanders@kemri-wellcome.org. Centre for Clinical Vaccinology & Tropical Medicine, University of Oxford, Oxford, UK. esanders@kemri-wellcome.org. Amsterdam Institute for Global health and Development, Department of Global Health, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands. t.rinkedewit@pharmaccess.org. KEMRI/Wellcome Trust Research Programme, Kilifi, Kenya. jberkley@kemri-wellcome.org. Centre for Clinical Vaccinology & Tropical Medicine, University of Oxford, Oxford, UK. jberkley@kemri-wellcome.org.'
p10473
sS'OWN'
p10474
S'NLM'
p10475
sS'PT'
p10476
(lp10477
S'Journal Article'
p10478
aS"Research Support, Non-U.S. Gov't"
p10479
asS'LA'
p10480
(lp10481
S'eng'
p10482
asS'DCOM'
p10483
S'20151214'
p10484
sS'JT'
p10485
S'BMC public health'
p10486
sS'LR'
p10487
S'20160112'
p10488
sS'FAU'
p10489
(lp10490
S'Hassan, Amin S'
p10491
aS'Mwaringa, Shalton M'
p10492
aS'Ndirangu, Kennedy K'
p10493
aS'Sanders, Eduard J'
p10494
aS'de Wit, Tobias F Rinke'
p10495
aS'Berkley, James A'
p10496
asS'TI'
p10497
S'Incidence and predictors of attrition from antiretroviral care among adults in a rural HIV clinic in Coastal Kenya: a retrospective cohort study.'
p10498
sS'RN'
p10499
(lp10500
S'0 (Anti-Retroviral Agents)'
p10501
asS'PL'
p10502
S'England'
p10503
sS'PG'
p10504
S'478'
p10505
sS'JID'
p10506
S'100968562'
p10507
sS'AB'
p10508
S'BACKGROUND: Scale up of antiretroviral therapy (ART) has led to substantial declines in HIV related morbidity and mortality. However, attrition from ART care remains a major public health concern and has been identified as one of the key reportable indicators in assessing the success of ART programs. This study describes the incidence and predictors of attrition among adults initiating ART in a rural HIV clinic in Coastal Kenya. METHODS: A retrospective cohort study design was used. Adults (>/= 15 years) initiated ART between January 2008 and December 2010 were followed up for two years. Attrition was defined as individuals who were either reported dead or lost to follow up (LFU, >/= 180 days late since the last clinic visit). Kaplan Meier survival probabilities and Weibull baseline hazard regression analyses were used to model the incidence and predictors of time to attrition. RESULTS: Of the 928 eligible participants, 308 (33.2% [95% CI, 30.2 - 36.3]) underwent attrition at an incident rate of 23.1 (95% CI, 20.6 - 25.8)/100 pyo. Attrition at 6 and 12 months was 18.4% (95% CI, 16.0 - 21.1) and 23.2% (95% CI, 19.9 - 25.3) respectively. Gender (male vs. female, adjusted hazard ratio [95% CI], p-value: 1.5 [1.1 - 2.0], p = 0.014), age (15 - 24 vs. >/= 45 years, 2.2 [1.3 - 3.7], p = 0.034) and baseline CD4 T-cell count (100 - 350 cells/uL vs. < 100 cells/uL, 0.5 [0.3 - 0.7], p = 0.002) were independent predictors of time to attrition. CONCLUSIONS: A third of individuals initiating ART were either reported dead or LFU during two years of care, with more than a half of these occurring within six months of treatment initiation. Practical and sustainable biomedical interventions and psychosocial support systems are warranted to improve ART retention in this setting.'
p10509
sS'GR'
p10510
(lp10511
S'092654/Wellcome Trust/United Kingdom'
p10512
aS'WT083579MA/Wellcome Trust/United Kingdom'
p10513
aS'WT089351MA/Wellcome Trust/United Kingdom'
p10514
asS'VI'
p10515
S'15'
p10516
sS'IS'
p10517
S'1471-2458 (Electronic) 1471-2458 (Linking)'
p10518
sS'PMC'
p10519
S'PMC4431376'
p10520
sS'AU'
p10521
(lp10522
S'Hassan AS'
p10523
aS'Mwaringa SM'
p10524
aS'Ndirangu KK'
p10525
aS'Sanders EJ'
p10526
aS'de Wit TF'
p10527
aS'Berkley JA'
p10528
asS'MHDA'
p10529
S'2015/12/15 06:00'
p10530
sS'PHST'
p10531
(lp10532
S'2014/06/04 [received]'
p10533
aS'2015/04/29 [accepted]'
p10534
aS'2015/05/10 [aheadofprint]'
p10535
asS'OID'
p10536
(lp10537
S'NLM: PMC4431376'
p10538
asS'MH'
p10539
(lp10540
S'Adult'
p10541
aS'Ambulatory Care Facilities'
p10542
aS'Anti-Retroviral Agents/*therapeutic use'
p10543
aS'*Attitude to Health'
p10544
aS'CD4 Lymphocyte Count'
p10545
aS'Cohort Studies'
p10546
aS'Female'
p10547
aS'Follow-Up Studies'
p10548
aS'HIV Infections/*drug therapy/epidemiology/*psychology'
p10549
aS'Humans'
p10550
aS'Incidence'
p10551
aS'Kenya/epidemiology'
p10552
aS'Male'
p10553
aS'Medication Adherence/psychology/*statistics & numerical data'
p10554
aS'Middle Aged'
p10555
aS'Public Health'
p10556
aS'Retrospective Studies'
p10557
aS'Rural Population/*statistics & numerical data'
p10558
aS'Sex Distribution'
p10559
aS'Social Support'
p10560
asS'EDAT'
p10561
S'2015/05/10 06:00'
p10562
sS'SO'
p10563
S'BMC Public Health. 2015 May 10;15:478. doi: 10.1186/s12889-015-1814-2.'
p10564
sS'SB'
p10565
S'IM'
p10566
sS'PMID'
p10567
S'25957077'
p10568
sS'TA'
p10569
S'BMC Public Health'
p10570
sS'PST'
p10571
S'epublish'
p10572
stRp10573
ag2
(g3
g4
(dp10574
S'LID'
p10575
S'10.1097/INF.0000000000000741 [doi]'
p10576
sS'STAT'
p10577
S'MEDLINE'
p10578
sS'JT'
p10579
S'The Pediatric infectious disease journal'
p10580
sS'DA'
p10581
S'20150917'
p10582
sS'AID'
p10583
(lp10584
S'10.1097/INF.0000000000000741 [doi]'
p10585
asS'CRDT'
p10586
(lp10587
S'2015/05/09 06:00'
p10588
asS'DP'
p10589
S'2015 Aug'
p10590
sS'AD'
p10591
S'From the *Division of Global HIV/AIDS, Centers For Disease Control and Prevention, Atlanta, Georgia; daggerDivision of Global HIV/AIDS, Centers For Disease Control and Prevention, Maputo, Mozambique; double daggerMinisterio Da Saude, Programa TARV Pediatrico, Maputo, Mozambique; and section signFundacao Ariel Glaser Contra O SIDA Pediatrico, Maputo, Mozambique.'
p10592
sS'OWN'
p10593
S'NLM'
p10594
sS'PT'
p10595
(lp10596
S'Journal Article'
p10597
aS"Research Support, Non-U.S. Gov't"
p10598
aS"Research Support, U.S. Gov't, P.H.S."
p10599
asS'LA'
p10600
(lp10601
S'eng'
p10602
asS'FAU'
p10603
(lp10604
S'Auld, Andrew F'
p10605
aS'Alfredo, Charity'
p10606
aS'Macassa, Eugenia'
p10607
aS'Jobarteh, Kebba'
p10608
aS'Shiraishi, Ray W'
p10609
aS'Rivadeneira, Emilia D'
p10610
aS'Houston, James'
p10611
aS'Spira, Thomas J'
p10612
aS'Ellerbrock, Tedd V'
p10613
aS'Vaz, Paula'
p10614
asS'PG'
p10615
S'e191-9'
p10616
sS'TI'
p10617
S"Temporal Trends in Patient Characteristics and Outcomes Among Children Enrolled in Mozambique's National Antiretroviral Therapy Program."
p10618
sS'RN'
p10619
(lp10620
S'0 (Anti-Retroviral Agents)'
p10621
asS'PL'
p10622
S'United States'
p10623
sS'TA'
p10624
S'Pediatr Infect Dis J'
p10625
sS'JID'
p10626
S'8701858'
p10627
sS'AB'
p10628
S'BACKGROUND: During 2004-2009, >12,000 children (<15 years old) initiated antiretroviral therapy (ART) in Mozambique. Nationally representative outcomes and temporal trends in outcomes were investigated. METHODS: Rates of death, loss to follow-up (LTFU) and attrition (death or LTFU) were evaluated in a nationally representative sample of 1054 children, who initiated ART during 2004-2009 at 25 facilities randomly selected using probability-proportional-to-size sampling. RESULTS: At ART initiation during 2004-2009, 50% were male; median age was 3.3 years; median CD4% was 13%; median CD4 count was 375 cells/muL; median weight-for-age Z score was -2.1. During 2004-2009, median time from HIV diagnosis to care initiation declined from 33 to 0 days (P = 0.001); median time from care to ART declined from 93 to 62 days (P = 0.004); the percentage aged <2 at ART initiation increased from 16% to 48% (P = 0.021); the percentage of patients with prior tuberculosis declined from 50% to 10% (P = 0.009); and the percentage with prior lymphocytic interstitial pneumonia declined from 16% to 1% (P < 0.001). Over 2652 person-years of ART, 183 children became LTFU and 26 died. Twelve-month attrition was 11% overall but increased from 3% to 22% during 2004-2009, mainly because of increases in 12-month LTFU (from 3% to 18%). CONCLUSION: Declines in the prevalence of markers of advanced HIV disease at ART initiation probably reflect increasing ART access. However, 12-month LTFU increased during program expansion, and this negated any program improvements in outcomes that might have resulted from earlier ART initiation.'
p10629
sS'GR'
p10630
(lp10631
S'PEPFAR/United States'
p10632
asS'IP'
p10633
S'8'
sS'IS'
p10634
S'1532-0987 (Electronic) 0891-3668 (Linking)'
p10635
sS'DCOM'
p10636
S'20160615'
p10637
sS'AU'
p10638
(lp10639
S'Auld AF'
p10640
aS'Alfredo C'
p10641
aS'Macassa E'
p10642
aS'Jobarteh K'
p10643
aS'Shiraishi RW'
p10644
aS'Rivadeneira ED'
p10645
aS'Houston J'
p10646
aS'Spira TJ'
p10647
aS'Ellerbrock TV'
p10648
aS'Vaz P'
p10649
asS'VI'
p10650
S'34'
p10651
sS'MHDA'
p10652
S'2016/06/16 06:00'
p10653
sS'MH'
p10654
(lp10655
S'Adolescent'
p10656
aS'Anti-Retroviral Agents/administration & dosage/*therapeutic use'
p10657
aS'Child'
p10658
aS'Child, Preschool'
p10659
aS'Female'
p10660
aS'HIV Infections/*drug therapy/*epidemiology/mortality'
p10661
aS'Humans'
p10662
aS'Infant'
p10663
aS'Infant, Newborn'
p10664
aS'Lost to Follow-Up'
p10665
aS'Male'
p10666
aS'Mozambique/epidemiology'
p10667
aS'Retrospective Studies'
p10668
asS'EDAT'
p10669
S'2015/05/09 06:00'
p10670
sS'SO'
p10671
S'Pediatr Infect Dis J. 2015 Aug;34(8):e191-9. doi: 10.1097/INF.0000000000000741.'
p10672
sS'SB'
p10673
S'IM'
p10674
sS'PMID'
p10675
S'25955836'
p10676
sS'PST'
p10677
S'ppublish'
p10678
stRp10679
ag2
(g3
g4
(dp10680
S'LID'
p10681
S'10.1177/0956462415585450 [doi]'
p10682
sS'STAT'
p10683
S'MEDLINE'
p10684
sS'DEP'
p10685
S'20150506'
p10686
sS'CI'
p10687
(lp10688
S'(c) The Author(s) 2016.'
p10689
asS'DA'
p10690
S'20160408'
p10691
sS'AID'
p10692
(lp10693
S'0956462415585450 [pii]'
p10694
aS'10.1177/0956462415585450 [doi]'
p10695
asS'CRDT'
p10696
(lp10697
S'2015/05/09 06:00'
p10698
asS'DP'
p10699
S'2016 May'
p10700
sS'OWN'
p10701
S'NLM'
p10702
sS'PT'
p10703
(lp10704
S'Journal Article'
p10705
aS"Research Support, Non-U.S. Gov't"
p10706
asS'LA'
p10707
(lp10708
S'eng'
p10709
asS'FAU'
p10710
(lp10711
S'Giuliano, Marina'
p10712
aS'Liotta, Giuseppe'
p10713
aS'Andreotti, Mauro'
p10714
aS'Mancinelli, Sandro'
p10715
aS'Buonomo, Ersilia'
p10716
aS'Scarcella, Paola'
p10717
aS'Amici, Roberta'
p10718
aS'Jere, Haswel'
p10719
aS'Sagno, Jean-Baptiste'
p10720
aS'Di Gregorio, Massimiliano'
p10721
aS'Marazzi, Maria Cristina'
p10722
aS'Vella, Stefano'
p10723
aS'Palombi, Leonardo'
p10724
asS'JT'
p10725
S'International journal of STD & AIDS'
p10726
sS'PG'
p10727
S'462-8'
p10728
sS'TI'
p10729
S'Retention, transfer out and loss to follow-up two years after delivery in a cohort of HIV+ pregnant women in Malawi.'
p10730
sS'RN'
p10731
(lp10732
S'0 (Anti-Retroviral Agents)'
p10733
asS'PL'
p10734
S'England'
p10735
sS'TA'
p10736
S'Int J STD AIDS'
p10737
sS'JID'
p10738
S'9007917'
p10739
sS'AB'
p10740
S'In this study, we analysed in a cohort of pregnant women followed for two years the proportion of women remaining at the same clinic, those who transferred to other clinics, and those lost to follow-up. The possible determinants of the loss to follow-up were also assessed in a setting of postpartum discontinuation based on CD4+ count. A total of 311 pregnant women received antiretroviral therapy from week 25 of gestational age until six months postpartum (end of breastfeeding period), or indefinitely if meeting the criteria for treatment (baseline CD4+ <350 cells/mm(3)). Twenty-four months after delivery, six women had died, 247 were in active follow-up, 21 had transferred to another antiretroviral therapy clinic and 37 were lost to follow-up (rate of loss to follow-up 13%, 95% CI 9.1-16.9%). The presence of a baseline CD4+ count above 350 cells/mm(3) was associated with a ten-fold higher risk of loss to follow-up after six months of delivery (hazard ratio: 9.8, 95% CI 2.2-42.7, for baseline CD4 >350 cells/mm(3) versus baseline CD4+ count below 350 cells/mm(3), p = 0.002). This finding suggests that discontinuation of drugs when the risk of transmission has ceased can have a negative impact on the retention in care of these women.'
p10741
sS'AD'
p10742
S'Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Rome, Italy marina.giuliano@iss.it. Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy. Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Rome, Italy. Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy. Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy. Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy. Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Rome, Italy. DREAM Program, Community of S. Egidio, Blantyre, Malawi. DREAM Program, Community of S. Egidio, Blantyre, Malawi. Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Rome, Italy. LUMSA University, Rome, Italy. Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Rome, Italy. Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.'
p10743
sS'IP'
p10744
S'6'
sS'IS'
p10745
S'1758-1052 (Electronic) 0956-4624 (Linking)'
p10746
sS'DCOM'
p10747
S'20160906'
p10748
sS'AU'
p10749
(lp10750
S'Giuliano M'
p10751
aS'Liotta G'
p10752
aS'Andreotti M'
p10753
aS'Mancinelli S'
p10754
aS'Buonomo E'
p10755
aS'Scarcella P'
p10756
aS'Amici R'
p10757
aS'Jere H'
p10758
aS'Sagno JB'
p10759
aS'Di Gregorio M'
p10760
aS'Marazzi MC'
p10761
aS'Vella S'
p10762
aS'Palombi L'
p10763
asS'VI'
p10764
S'27'
p10765
sS'MHDA'
p10766
S'2016/09/07 06:00'
p10767
sS'PHST'
p10768
(lp10769
S'2015/02/17 [received]'
p10770
aS'2015/04/13 [accepted]'
p10771
aS'2015/05/06 [aheadofprint]'
p10772
asS'OTO'
p10773
(lp10774
S'NOTNLM'
p10775
asS'MH'
p10776
(lp10777
S'Adult'
p10778
aS'Anti-Retroviral Agents/administration & dosage/*therapeutic use'
p10779
aS'Antiretroviral Therapy, Highly Active'
p10780
aS'CD4 Lymphocyte Count'
p10781
aS'Female'
p10782
aS'Follow-Up Studies'
p10783
aS'HIV Infections/*drug therapy/mortality/prevention & control'
p10784
aS'Humans'
p10785
aS'Infectious Disease Transmission, Vertical/*prevention & control'
p10786
aS'Lost to Follow-Up'
p10787
aS'Malawi/epidemiology'
p10788
aS'Male'
p10789
aS'Medication Adherence/statistics & numerical data'
p10790
aS'Patient Acceptance of Health Care/statistics & numerical data'
p10791
aS'Patient Transfer'
p10792
aS'Postpartum Period'
p10793
aS'Pregnancy'
p10794
aS'Pregnancy Complications, Infectious/*drug therapy'
p10795
aS'Pregnant Women/*psychology'
p10796
aS'Proportional Hazards Models'
p10797
aS'Treatment Outcome'
p10798
aS'Viral Load'
p10799
aS'Young Adult'
p10800
asS'EDAT'
p10801
S'2015/05/09 06:00'
p10802
sS'SO'
p10803
S'Int J STD AIDS. 2016 May;27(6):462-8. doi: 10.1177/0956462415585450. Epub 2015 May 6.'
p10804
sS'SB'
p10805
S'IM X'
p10806
sS'PMID'
p10807
S'25953961'
p10808
sS'OT'
p10809
(lp10810
S'AIDS'
p10811
aS'Africa'
p10812
aS'HAART'
p10813
aS'HIV'
p10814
aS'antenatal care'
p10815
aS'pregnancy'
p10816
aS'prevention'
p10817
aS'retention in care'
p10818
aS'treatment'
p10819
aS'women'
p10820
asS'PST'
p10821
S'ppublish'
p10822
stRp10823
ag2
(g3
g4
(dp10824
S'LID'
p10825
S'10.1186/s13256-015-0557-0 [doi]'
p10826
sS'STAT'
p10827
S'MEDLINE'
p10828
sS'DEP'
p10829
S'20150507'
p10830
sS'DA'
p10831
S'20150519'
p10832
sS'AID'
p10833
(lp10834
S'10.1186/s13256-015-0557-0 [doi]'
p10835
aS'10.1186/s13256-015-0557-0 [pii]'
p10836
asS'CRDT'
p10837
(lp10838
S'2015/05/08 06:00'
p10839
asS'DP'
p10840
S'2015'
p10841
sS'OWN'
p10842
S'NLM'
p10843
sS'PT'
p10844
(lp10845
S'Case Reports'
p10846
aS'Journal Article'
p10847
asS'LA'
p10848
(lp10849
S'eng'
p10850
asS'DCOM'
p10851
S'20160119'
p10852
sS'JT'
p10853
S'Journal of medical case reports'
p10854
sS'LR'
p10855
S'20150521'
p10856
sS'FAU'
p10857
(lp10858
S'Sogbanmu, Olufunso Oladipo'
p10859
aS'Adeniyi, Oladele Vincent'
p10860
aS'Fuentes, Yusimi Ordaz'
p10861
aS'Ter Goon, Daniel'
p10862
asS'TI'
p10863
S'Very early virological failure and drug resistance mutations in a woman on antiretroviral therapy in Eastern Cape, South Africa: a case report.'
p10864
sS'RN'
p10865
(lp10866
S'0 (Anti-HIV Agents)'
p10867
aS'0 (HIV Protease Inhibitors)'
p10868
aS'4B9XT59T7S (Zidovudine)'
p10869
asS'PL'
p10870
S'England'
p10871
sS'PG'
p10872
S'106'
p10873
sS'JID'
p10874
S'101293382'
p10875
sS'AB'
p10876
S"INTRODUCTION: Rapid scale-up of antiretroviral therapy rollout in Sub-Saharan African countries faces the challenge of virological failure. This could be the consequence of transmitted drug-resistant human immunodeficiency virus strains at the population level. While a pre-antiretroviral therapy genotypic test has been a major component of the human immunodeficiency virus management programme in developed nations, it is yet to be incorporated into the antiretroviral therapy programme in resource-poor countries. CASE PRESENTATION: A 32-year-old Black African woman was seen for her six-month routine review. Her viral load after initiation of fixed drug combination of tenofovir, emtricitabine and efavirenz was 31,397 RNA copies/mL. Adherence was assessed to be good based on pharmacy pick-up dates, on-time clinic appointment records, medical file review, self-reporting and treatment supporter's report. Her viral load was repeated after another two months of close monitoring; the result showed viral load of 31,159 RNA copies/mL. She was assessed as virological failure to her first-line antiretrovirals and commenced on second-line antiretrovirals: zidovudine/lamivudine/Aluvia((R)) (lopinavir and ritonavir). A human immunodeficiency virus drug genotypic testing showed she was only susceptible to zidovudine and protease inhibitors. At third month on the new regimen, her viral load was suppressed. CONCLUSIONS: This case report demonstrates the possibility of a silent epidemic within the human immunodeficiency virus pandemic in resource-poor settings like Eastern Cape, South Africa. We described a case of early virological failure in a highly motivated young woman. Although, a pre-antiretroviral therapy genotypic test is yet to be incorporated into a human immunodeficiency virus programme in resource-poor countries, the need for it might become evident as the programme expands. Close monitoring of the viral load of patients according to national guidelines will enable early detection of a failing regimen and prompt intervention can be instituted to prevent morbidity and mortality. There is an urgent need to strengthen the human immunodeficiency virus programme in resource-poor countries to prevent the emergence of an epidemic of transmitted drug-resistant human immunodeficiency virus strains within the existing human immunodeficiency virus pandemic."
p10877
sS'AD'
p10878
S'Department of Family Medicine, Division of HIV Care, Cecilia Makiwane Hospital, East London Hospital Complex, East London, Eastern Cape Province, South Africa. dudumela@yahoo.com. Department of Family Medicine, Division of HIV Care, Cecilia Makiwane Hospital, East London Hospital Complex, East London, Eastern Cape Province, South Africa. vincoladele@gmail.com. Department of Family Medicine, Division of HIV Care, Cecilia Makiwane Hospital, East London Hospital Complex, East London, Eastern Cape Province, South Africa. yusilanof@gmail.com. School of Health Sciences, University of Fort Hare, East London, South Africa. dgoon@ufh.ac.za.'
p10879
sS'VI'
p10880
S'9'
sS'IS'
p10881
S'1752-1947 (Electronic) 1752-1947 (Linking)'
p10882
sS'PMC'
p10883
S'PMC4437671'
p10884
sS'AU'
p10885
(lp10886
S'Sogbanmu OO'
p10887
aS'Adeniyi OV'
p10888
aS'Fuentes YO'
p10889
aS'Ter Goon D'
p10890
asS'MHDA'
p10891
S'2016/01/20 06:00'
p10892
sS'PHST'
p10893
(lp10894
S'2014/12/16 [received]'
p10895
aS'2015/02/26 [accepted]'
p10896
aS'2015/05/07 [aheadofprint]'
p10897
asS'OID'
p10898
(lp10899
S'NLM: PMC4437671'
p10900
asS'MH'
p10901
(lp10902
S'Adult'
p10903
aS'Anti-HIV Agents/therapeutic use'
p10904
aS'*Antiretroviral Therapy, Highly Active'
p10905
aS'Drug Resistance, Multiple, Viral/*genetics'
p10906
aS'Female'
p10907
aS'Genotype'
p10908
aS'HIV Infections/*drug therapy/virology'
p10909
aS'HIV Protease Inhibitors/therapeutic use'
p10910
aS'Humans'
p10911
aS'*Mutation'
p10912
aS'South Africa'
p10913
aS'Treatment Failure'
p10914
aS'Viral Load'
p10915
aS'Zidovudine/therapeutic use'
p10916
asS'EDAT'
p10917
S'2015/05/08 06:00'
p10918
sS'SO'
p10919
S'J Med Case Rep. 2015 May 7;9:106. doi: 10.1186/s13256-015-0557-0.'
p10920
sS'SB'
p10921
S'IM'
p10922
sS'PMID'
p10923
S'25947544'
p10924
sS'TA'
p10925
S'J Med Case Rep'
p10926
sS'PST'
p10927
S'epublish'
p10928
stRp10929
ag2
(g3
g4
(dp10930
S'LID'
p10931
S'10.1097/QAI.0000000000000535 [doi]'
p10932
sS'STAT'
p10933
S'MEDLINE'
p10934
sS'AB'
p10935
S'BACKGROUND: More than 4.7 million voluntary medical male circumcisions (VMMCs) had been provided by HIV prevention programs in sub-Saharan Africa through 2013. All VMMC clients are recommended to return to the clinic for postoperative follow-up, although adherence is variable. The clinical status of clients who do not return is largely unknown. METHODS: VMMC clients from Nyanza Province, Kenya, aged older than or equal to 13 years, were recruited immediately after surgery from April to October 2012 from high-volume sites. Medical record reviews at 13-14 days after surgery indicated which clients had been adherent with recommended follow-up (ADFU) and which were lost-to-follow-up (LTFU). Clients in the LTFU group received clinical evaluations at home approximately 2 weeks postsurgery. Adverse events (AEs) and AE rates were compared between the ADFU and LTFU groups. RESULTS: Of 4504 males approached in 50 VMMC sites, 1699 (37.7%) were eligible and enrolled and 1600 of 1699 (94.2%) contributed to follow-up and AE data. Medical record review indicated 897 of 1600 (56.1%) were LTFU, and 762 (84.9%) of these received home-based clinical evaluations. The rate of moderate or severe AE diagnosis was 6.8% in the LTFU group vs. 3.3% in the ADFU group (relative risk = 2.1, 95% confidence interval: 1.3 to 3.4). CONCLUSIONS: The moderate or severe AE diagnosis rate was approximately 2 times higher in the LTFU group. National programs should consider instituting surveillance systems to detect AEs that might otherwise go unnoticed. Providers should emphasize the importance of follow-up and actively contact LTFU clients to ensure care is provided throughout the entire postoperative course for all.'
p10936
sS'JID'
p10937
S'100892005'
p10938
sS'GR'
p10939
(lp10940
S'PEPFAR/United States'
p10941
asS'JT'
p10942
S'Journal of acquired immune deficiency syndromes (1999)'
p10943
sS'IP'
p10944
S'1'
sS'IS'
p10945
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p10946
sS'DCOM'
p10947
S'20150723'
p10948
sS'DA'
p10949
S'20150506'
p10950
sS'AU'
p10951
(lp10952
S'Reed JB'
p10953
aS'Grund J'
p10954
aS'Liu Y'
p10955
aS'Mwandi Z'
p10956
aS'Howard AA'
p10957
aS'McNairy ML'
p10958
aS'Chesang K'
p10959
aS'Cherutich P'
p10960
aS'Bock N'
p10961
asS'AID'
p10962
(lp10963
S'10.1097/QAI.0000000000000535 [doi]'
p10964
aS'00126334-201505010-00018 [pii]'
p10965
asS'CRDT'
p10966
(lp10967
S'2015/05/06 06:00'
p10968
asS'VI'
p10969
S'69'
p10970
sS'DP'
p10971
S'2015 May 1'
p10972
sS'AD'
p10973
S'*Division of Global HIV AIDS, Center for Global Health, US Centers for Disease Control and Prevention, Atlanta, GA; daggerDivision of Global HIV AIDS, Center for Global Health, US Centers for Disease Control and Prevention, Nairobi, Kenya; double daggerICAP, Columbia University, New York, NY; and section signNational AIDS and Sexually Transmitted Infection Control Programme, Ministry of Health, Nairobi, Kenya.'
p10974
sS'MHDA'
p10975
S'2015/07/24 06:00'
p10976
sS'OWN'
p10977
S'NLM'
p10978
sS'PT'
p10979
(lp10980
S'Journal Article'
p10981
aS"Research Support, U.S. Gov't, P.H.S."
p10982
asS'LA'
p10983
(lp10984
S'eng'
p10985
asS'MH'
p10986
(lp10987
S'Adolescent'
p10988
aS'Adult'
p10989
aS'Circumcision, Male/*adverse effects'
p10990
aS'HIV Infections/*prevention & control'
p10991
aS'Humans'
p10992
aS'Kenya'
p10993
aS'*Lost to Follow-Up'
p10994
aS'Male'
p10995
aS'*National Health Programs'
p10996
aS'Postoperative Complications/epidemiology'
p10997
aS'Young Adult'
p10998
asS'FAU'
p10999
(lp11000
S'Reed, Jason Bailey'
p11001
aS'Grund, Jonathan'
p11002
aS'Liu, Yang'
p11003
aS'Mwandi, Zebedee'
p11004
aS'Howard, Andrea A'
p11005
aS'McNairy, Margaret L'
p11006
aS'Chesang, Kipruto'
p11007
aS'Cherutich, Peter'
p11008
aS'Bock, Naomi'
p11009
asS'EDAT'
p11010
S'2015/05/06 06:00'
p11011
sS'PST'
p11012
S'ppublish'
p11013
sS'SO'
p11014
S'J Acquir Immune Defic Syndr. 2015 May 1;69(1):e13-23. doi: 10.1097/QAI.0000000000000535.'
p11015
sS'PG'
p11016
S'e13-23'
p11017
sS'TI'
p11018
S'Implementation and Operational Research: Evaluation of Loss-to-Follow-up and Postoperative Adverse Events in a Voluntary Medical Male Circumcision Program in Nyanza Province, Kenya.'
p11019
sS'SB'
p11020
S'IM X'
p11021
sS'PMID'
p11022
S'25942466'
p11023
sS'PL'
p11024
S'United States'
p11025
sS'TA'
p11026
S'J Acquir Immune Defic Syndr'
p11027
stRp11028
ag2
(g3
g4
(dp11029
S'LID'
p11030
S'10.1097/QAI.0000000000000553 [doi]'
p11031
sS'STAT'
p11032
S'MEDLINE'
p11033
sS'JT'
p11034
S'Journal of acquired immune deficiency syndromes (1999)'
p11035
sS'CIN'
p11036
(lp11037
S'J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):e27. PMID: 26039932'
p11038
asS'DA'
p11039
S'20150506'
p11040
sS'AID'
p11041
(lp11042
S'10.1097/QAI.0000000000000553 [doi]'
p11043
aS'00126334-201505010-00014 [pii]'
p11044
asS'CRDT'
p11045
(lp11046
S'2015/05/06 06:00'
p11047
asS'DP'
p11048
S'2015 May 1'
p11049
sS'AD'
p11050
S'*Center for Global Health & Development, Boston University, Boston, MA; daggerCenter for Global Health & Development Boston University School of Public Health, Boston, MA; and double daggerHealth Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.'
p11051
sS'OWN'
p11052
S'NLM'
p11053
sS'PT'
p11054
(lp11055
S'Journal Article'
p11056
aS'Meta-Analysis'
p11057
aS'Research Support, N.I.H., Extramural'
p11058
aS"Research Support, Non-U.S. Gov't"
p11059
aS'Review'
p11060
asS'LA'
p11061
(lp11062
S'eng'
p11063
asS'FAU'
p11064
(lp11065
S'Fox, Matthew P'
p11066
aS'Rosen, Sydney'
p11067
asS'LR'
p11068
S'20160501'
p11069
sS'PG'
p11070
S'98-108'
p11071
sS'TI'
p11072
S'Retention of Adult Patients on Antiretroviral Therapy in Low- and Middle-Income Countries: Systematic Review and Meta-analysis 2008-2013.'
p11073
sS'RN'
p11074
(lp11075
S'0 (Anti-Retroviral Agents)'
p11076
asS'PL'
p11077
S'United States'
p11078
sS'TA'
p11079
S'J Acquir Immune Defic Syndr'
p11080
sS'JID'
p11081
S'100892005'
p11082
sS'AB'
p11083
S'BACKGROUND: We previously published systematic reviews of retention in care after antiretroviral therapy initiation among general adult populations in sub-Saharan Africa. We estimated 36-month retention at 73% for publications from 2007 to 2010. This report extends the review to cover 2008-2013 and expands it to all low- and middle-income countries. METHODS: We searched PubMed, Embase, Cochrane Register, and ISI Web of Science from January 1, 2008, to December 31, 2013, and abstracts from AIDS and IAS from 2008-2013. We estimated retention across cohorts using simple averages and interpolated missing times through the last time reported. We estimated all-cause attrition (death, loss to follow-up) for patients receiving first-line antiretroviral therapy in routine settings in low- and middle-income countries. RESULTS: We found 123 articles and abstracts reporting retention for 154 patient cohorts and 1,554,773 patients in 42 countries. Overall, 43% of all patients not retained were known to have died. Unweighted averages of reported retention were 78%, 71%, and 69% at 12, 24, and 36 months, after treatment initiation, respectively. We estimated 36-month retention at 65% in Africa, 80% in Asia, and 64% in Latin America and the Caribbean. From lifetable analysis, we estimated retention at 12, 24, 36, 48, and 60 months at 83%, 74%, 68%, 64%, and 60%, respectively. CONCLUSIONS: Retention at 36 months on treatment averages 65%-70%. There are several important gaps in the evidence base, which could be filled by further research, especially in terms of geographic coverage and duration of follow-up.'
p11084
sS'GR'
p11085
(lp11086
S'K01 AI083097/AI/NIAID NIH HHS/United States'
p11087
asS'IP'
p11088
S'1'
sS'IS'
p11089
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p11090
sS'PMC'
p11091
S'PMC4422218'
p11092
sS'DCOM'
p11093
S'20150723'
p11094
sS'MID'
p11095
(lp11096
S'NIHMS657470'
p11097
asS'AU'
p11098
(lp11099
S'Fox MP'
p11100
aS'Rosen S'
p11101
asS'VI'
p11102
S'69'
p11103
sS'MHDA'
p11104
S'2015/07/24 06:00'
p11105
sS'OID'
p11106
(lp11107
S'NLM: NIHMS657470'
p11108
aS'NLM: PMC4422218'
p11109
asS'MH'
p11110
(lp11111
S'Adolescent'
p11112
aS'Adult'
p11113
aS'Africa'
p11114
aS'Anti-Retroviral Agents/*therapeutic use'
p11115
aS'Antiretroviral Therapy, Highly Active/*methods'
p11116
aS'Asia'
p11117
aS'Caribbean Region'
p11118
aS'Developing Countries'
p11119
aS'Female'
p11120
aS'HIV Infections/*drug therapy'
p11121
aS'Humans'
p11122
aS'Latin America'
p11123
aS'Male'
p11124
aS'*Medication Adherence'
p11125
aS'Middle Aged'
p11126
aS'Young Adult'
p11127
asS'EDAT'
p11128
S'2015/05/06 06:00'
p11129
sS'SO'
p11130
S'J Acquir Immune Defic Syndr. 2015 May 1;69(1):98-108. doi: 10.1097/QAI.0000000000000553.'
p11131
sS'SB'
p11132
S'IM X'
p11133
sS'PMID'
p11134
S'25942461'
p11135
sS'PST'
p11136
S'ppublish'
p11137
stRp11138
ag2
(g3
g4
(dp11139
S'LID'
p11140
S'10.1177/0956462415584487 [doi]'
p11141
sS'STAT'
p11142
S'MEDLINE'
p11143
sS'DEP'
p11144
S'20150504'
p11145
sS'CI'
p11146
(lp11147
S'(c) The Author(s) 2015.'
p11148
asS'DA'
p11149
S'20160303'
p11150
sS'AID'
p11151
(lp11152
S'0956462415584487 [pii]'
p11153
aS'10.1177/0956462415584487 [doi]'
p11154
asS'CRDT'
p11155
(lp11156
S'2015/05/06 06:00'
p11157
asS'DP'
p11158
S'2016 Apr'
p11159
sS'OWN'
p11160
S'NLM'
p11161
sS'PT'
p11162
(lp11163
S'Evaluation Studies'
p11164
aS'Journal Article'
p11165
asS'LA'
p11166
(lp11167
S'eng'
p11168
asS'FAU'
p11169
(lp11170
S'Bowman, Alex S'
p11171
aS'Lerebours, Leonel'
p11172
aS'Amesty, Silvia'
p11173
aS'de la Rosa, Milagros'
p11174
aS'Gil, Elizabeth'
p11175
aS'Halpern, Mina'
p11176
aS'Nicholas, Stephen'
p11177
aS'Lamb, Matthew R'
p11178
asS'JT'
p11179
S'International journal of STD & AIDS'
p11180
sS'PG'
p11181
S'394-401'
p11182
sS'TI'
p11183
S'Evaluation of patient care cascade for HIV-positive patients diagnosed in La Romana, Dominican Republic in 2011: a retrospective cohort study.'
p11184
sS'RN'
p11185
(lp11186
S'0 (Anti-HIV Agents)'
p11187
asS'PL'
p11188
S'England'
p11189
sS'TA'
p11190
S'Int J STD AIDS'
p11191
sS'JID'
p11192
S'9007917'
p11193
sS'AB'
p11194
S'The Caribbean has the highest adult HIV prevalence in the world after sub-Saharan Africa (2011). One sub-population in the Dominican Republic is the migratory Batey community primarily comprised of Haitian immigrants with limited access to healthcare and HIV prevalence rates of between 3.0% and 9.0%, compared to 0.7% nationally. This retrospective cohort study describes the cumulative retention from diagnosis to virological suppression for newly-diagnosed HIV-infected adults presenting to the Clinica de Familia and its Batey programme in La Romana, during 2011. Of the patients diagnosed with HIV, 65% entered into care, 59% completed immunologic testing, 53% were eligible for antiretroviral therapy (ART) initiation, 36% initiated ART within three months of eligibility and 27% were retained in care. Seventeen per cent of those retained on ART with a 12-month viral load measure had undetectable viral load. Attrition primarily occurred before ART initiation. The Batey programme had a first step lost-to-follow-up of 88% compared to 20% at the clinic (p < 0.001). This retrospective study details the continuum of care and indicates where structural changes must occur to increase continuity between steps. The manuscript results are important to help implement programmes to enhance engagement and retention in HIV primary care.'
p11195
sS'AD'
p11196
S'Columbia University Mailman School of Public Health, New York, USA asb2227@cumc.columbia.edu. Clinica de Familia, La Romana, Dominican Republic. Columbia University Mailman School of Public Health, New York, USA Columbia University Medical Center College of Physicians & Surgeons, New York, NY, USA. Clinica de Familia, La Romana, Dominican Republic. Clinica de Familia, La Romana, Dominican Republic. Clinica de Familia, La Romana, Dominican Republic. Columbia University Mailman School of Public Health, New York, USA Columbia University Medical Center College of Physicians & Surgeons, New York, NY, USA. Columbia University Mailman School of Public Health, New York, USA.'
p11197
sS'IP'
p11198
S'5'
sS'IS'
p11199
S'1758-1052 (Electronic) 0956-4624 (Linking)'
p11200
sS'DCOM'
p11201
S'20160715'
p11202
sS'AU'
p11203
(lp11204
S'Bowman AS'
p11205
aS'Lerebours L'
p11206
aS'Amesty S'
p11207
aS'de la Rosa M'
p11208
aS'Gil E'
p11209
aS'Halpern M'
p11210
aS'Nicholas S'
p11211
aS'Lamb MR'
p11212
asS'VI'
p11213
S'27'
p11214
sS'MHDA'
p11215
S'2016/07/16 06:00'
p11216
sS'PHST'
p11217
(lp11218
S'2014/12/23 [received]'
p11219
aS'2015/04/05 [accepted]'
p11220
aS'2015/05/04 [aheadofprint]'
p11221
asS'OTO'
p11222
(lp11223
S'NOTNLM'
p11224
asS'MH'
p11225
(lp11226
S'Adolescent'
p11227
aS'Adult'
p11228
aS'Anti-HIV Agents/*therapeutic use'
p11229
aS'CD4 Lymphocyte Count'
p11230
aS'*Continuity of Patient Care'
p11231
aS'Dominican Republic/epidemiology'
p11232
aS'Female'
p11233
aS'HIV Infections/*diagnosis/*drug therapy/ethnology'
p11234
aS'Humans'
p11235
aS'Male'
p11236
aS'Middle Aged'
p11237
aS'*Patient Acceptance of Health Care'
p11238
aS'Patient Compliance'
p11239
aS'Prevalence'
p11240
aS'Program Evaluation'
p11241
aS'Retrospective Studies'
p11242
aS'Viral Load'
p11243
aS'Young Adult'
p11244
asS'EDAT'
p11245
S'2015/05/06 06:00'
p11246
sS'SO'
p11247
S'Int J STD AIDS. 2016 Apr;27(5):394-401. doi: 10.1177/0956462415584487. Epub 2015 May 4.'
p11248
sS'SB'
p11249
S'IM X'
p11250
sS'PMID'
p11251
S'25941055'
p11252
sS'OT'
p11253
(lp11254
S'AIDS'
p11255
aS'Caribbean'
p11256
aS'HAART'
p11257
aS'HIV'
p11258
aS'antiretroviral therapy'
p11259
aS'care cascade'
p11260
aS'epidemiology'
p11261
aS'treatment'
p11262
asS'PST'
p11263
S'ppublish'
p11264
stRp11265
ag2
(g3
g4
(dp11266
S'LID'
p11267
S'10.1371/journal.pone.0126267 [doi]'
p11268
sS'STAT'
p11269
S'MEDLINE'
p11270
sS'DEP'
p11271
S'20150504'
p11272
sS'DA'
p11273
S'20150505'
p11274
sS'AID'
p11275
(lp11276
S'10.1371/journal.pone.0126267 [doi]'
p11277
aS'PONE-D-14-51547 [pii]'
p11278
asS'CRDT'
p11279
(lp11280
S'2015/05/05 06:00'
p11281
asS'DP'
p11282
S'2015'
p11283
sS'AD'
p11284
S'Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, United States of America; Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, CT, United States of America. Anderson School of Management, University of California Los Angeles, Los Angeles, CA, United States of America. Department of Medicine, Section of Infectious Diseases, AIDS Program, Yale University School of Medicine, New Haven, CT, United States of America. Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, United States of America; Department of Medicine, Section of Infectious Diseases, AIDS Program, Yale University School of Medicine, New Haven, CT, United States of America. Department of Medicine, Section of Infectious Diseases, AIDS Program, Yale University School of Medicine, New Haven, CT, United States of America; Church of Scotland Hospital, Tugela Ferry, KwaZulu-Natal, South Africa. Department of Biostatistics, Yale University, New Haven, CT, United States of America; Department of Ecology and Evolutionary Biology, Yale University, New Haven, CT, United States of America; Program in Computational Biology and Informatics, Yale University, New Haven, CT, United States of America. Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, United States of America; Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, CT, United States of America; Department of Ecology and Evolutionary Biology, Yale University, New Haven, CT, United States of America; Program in Computational Biology and Informatics, Yale University, New Haven, CT, United States of America. Department of Medicine, Section of Infectious Diseases, AIDS Program, Yale University School of Medicine, New Haven, CT, United States of America.'
p11285
sS'OWN'
p11286
S'NLM'
p11287
sS'PT'
p11288
(lp11289
S'Journal Article'
p11290
aS'Research Support, N.I.H., Extramural'
p11291
aS"Research Support, U.S. Gov't, P.H.S."
p11292
asS'LA'
p11293
(lp11294
S'eng'
p11295
asS'FAU'
p11296
(lp11297
S'Gilbert, Jennifer A'
p11298
aS'Long, Elisa F'
p11299
aS'Brooks, Ralph P'
p11300
aS'Friedland, Gerald H'
p11301
aS'Moll, Anthony P'
p11302
aS'Townsend, Jeffrey P'
p11303
aS'Galvani, Alison P'
p11304
aS'Shenoi, Sheela V'
p11305
asS'JT'
p11306
S'PloS one'
p11307
sS'LR'
p11308
S'20160115'
p11309
sS'PG'
p11310
S'e0126267'
p11311
sS'TI'
p11312
S'Integrating Community-Based Interventions to Reverse the Convergent TB/HIV Epidemics in Rural South Africa.'
p11313
sS'RN'
p11314
(lp11315
S'0 (Anti-HIV Agents)'
p11316
aS'0 (Antitubercular Agents)'
p11317
asS'PL'
p11318
S'United States'
p11319
sS'TA'
p11320
S'PLoS One'
p11321
sS'JID'
p11322
S'101285081'
p11323
sS'AB'
p11324
S"The WHO recommends integrating interventions to address the devastating TB/HIV co-epidemics in South Africa, yet integration has been poorly implemented and TB/HIV control efforts need strengthening. Identifying infected individuals is particularly difficult in rural settings. We used mathematical modeling to predict the impact of community-based, integrated TB/HIV case finding and additional control strategies on South Africa's TB/HIV epidemics. We developed a model incorporating TB and HIV transmission to evaluate the effectiveness of integrating TB and HIV interventions in rural South Africa over 10 years. We modeled the impact of a novel screening program that integrates case finding for TB and HIV in the community, comparing it to status quo and recommended TB/HIV control strategies, including GeneXpert, MDR-TB treatment decentralization, improved first-line TB treatment cure rate, isoniazid preventive therapy, and expanded ART. Combining recommended interventions averted 27% of expected TB cases (95% CI 18-40%) 18% HIV (95% CI 13-24%), 60% MDR-TB (95% CI 34-83%), 69% XDR-TB (95% CI 34-90%), and 16% TB/HIV deaths (95% CI 12-29). Supplementing these interventions with annual community-based TB/HIV case finding averted a further 17% of TB cases (44% total; 95% CI 31-56%), 5% HIV (23% total; 95% CI 17-29%), 8% MDR-TB (68% total; 95% CI 40-88%), 4% XDR-TB (73% total; 95% CI 38-91%), and 8% TB/HIV deaths (24% total; 95% CI 16-39%). In addition to increasing screening frequency, we found that improving TB symptom questionnaire sensitivity, second-line TB treatment delays, default before initiating TB treatment or ART, and second-line TB drug efficacy were significantly associated with even greater reductions in TB and HIV cases. TB/HIV epidemics in South Africa were most effectively curtailed by simultaneously implementing interventions that integrated community-based TB/HIV control strategies and targeted drug-resistant TB. Strengthening existing TB and HIV treatment programs is needed to further reduce disease incidence."
p11325
sS'GR'
p11326
(lp11327
S'1K23AI089260/AI/NIAID NIH HHS/United States'
p11328
aS'1U01GH000524-01/GH/CGH CDC HHS/United States'
p11329
aS'2U01GM087719/GM/NIGMS NIH HHS/United States'
p11330
aS'5U01GM105627/GM/NIGMS NIH HHS/United States'
p11331
aS'K23 AI089260/AI/NIAID NIH HHS/United States'
p11332
aS'P30 MH062294/MH/NIMH NIH HHS/United States'
p11333
aS'R01DA015612/DA/NIDA NIH HHS/United States'
p11334
aS'R01DA025932/DA/NIDA NIH HHS/United States'
p11335
aS'R24TW007988/TW/FIC NIH HHS/United States'
p11336
asS'IP'
p11337
S'5'
sS'IS'
p11338
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p11339
sS'PMC'
p11340
S'PMC4418809'
p11341
sS'DCOM'
p11342
S'20160425'
p11343
sS'AU'
p11344
(lp11345
S'Gilbert JA'
p11346
aS'Long EF'
p11347
aS'Brooks RP'
p11348
aS'Friedland GH'
p11349
aS'Moll AP'
p11350
aS'Townsend JP'
p11351
aS'Galvani AP'
p11352
aS'Shenoi SV'
p11353
asS'VI'
p11354
S'10'
p11355
sS'MHDA'
p11356
S'2016/04/26 06:00'
p11357
sS'PHST'
p11358
(lp11359
S'2015 [ecollection]'
p11360
aS'2014/11/16 [received]'
p11361
aS'2015/03/31 [accepted]'
p11362
aS'2015/05/04 [epublish]'
p11363
asS'OID'
p11364
(lp11365
S'NLM: PMC4418809'
p11366
asS'MH'
p11367
(lp11368
S'Adolescent'
p11369
aS'Adult'
p11370
aS'Anti-HIV Agents/therapeutic use'
p11371
aS'Antitubercular Agents/therapeutic use'
p11372
aS'HIV Infections/*drug therapy/*epidemiology'
p11373
aS'Humans'
p11374
aS'Middle Aged'
p11375
aS'South Africa/epidemiology'
p11376
aS'Tuberculosis/*drug therapy/*epidemiology'
p11377
aS'Young Adult'
p11378
asS'EDAT'
p11379
S'2015/05/06 06:00'
p11380
sS'SO'
p11381
S'PLoS One. 2015 May 4;10(5):e0126267. doi: 10.1371/journal.pone.0126267. eCollection 2015.'
p11382
sS'SB'
p11383
S'IM'
p11384
sS'PMID'
p11385
S'25938501'
p11386
sS'PST'
p11387
S'epublish'
p11388
stRp11389
ag2
(g3
g4
(dp11390
S'LID'
p11391
S'10.1371/journal.pone.0125665 [doi]'
p11392
sS'STAT'
p11393
S'MEDLINE'
p11394
sS'DEP'
p11395
S'20150501'
p11396
sS'DA'
p11397
S'20150502'
p11398
sS'AID'
p11399
(lp11400
S'10.1371/journal.pone.0125665 [doi]'
p11401
aS'PONE-D-14-44634 [pii]'
p11402
asS'CRDT'
p11403
(lp11404
S'2015/05/02 06:00'
p11405
asS'DP'
p11406
S'2015'
p11407
sS'OWN'
p11408
S'NLM'
p11409
sS'PT'
p11410
(lp11411
S'Journal Article'
p11412
asS'LA'
p11413
(lp11414
S'eng'
p11415
asS'FAU'
p11416
(lp11417
S'Ogoina, Dimie'
p11418
aS'Finomo, Finomo'
p11419
aS'Harry, Tubonye'
p11420
aS'Inatimi, Otonyo'
p11421
aS'Ebuenyi, Ikenna'
p11422
aS'Tariladei, Wolo-wolo'
p11423
aS'Afolayan, Abimbola Anne'
p11424
asS'JT'
p11425
S'PloS one'
p11426
sS'LR'
p11427
S'20150508'
p11428
sS'PG'
p11429
S'e0125665'
p11430
sS'TI'
p11431
S'Factors Associated with Timing of Initiation of Antiretroviral Therapy among HIV-1 Infected Adults in the Niger Delta Region of Nigeria.'
p11432
sS'RN'
p11433
(lp11434
S'0 (Anti-HIV Agents)'
p11435
asS'PL'
p11436
S'United States'
p11437
sS'TA'
p11438
S'PLoS One'
p11439
sS'JID'
p11440
S'101285081'
p11441
sS'AB'
p11442
S'INTRODUCTION: Based on growing evidence mainly from countries outside Sub-Saharan Africa, the World Health Organisation (WHO) now recommends initiation of antiretroviral therapy (ART) in HIV-infected individuals in developing countries when CD4 cell count (CD4+) is </= 500 cells/ul. Nigeria accounts for about 14% of the estimated HIV/AIDS burden in Sub-Saharan Africa. We evaluated the factors associated with timing of initiation of ART among treatment-ineligible HIV-infected adults from Nigeria. METHODS: We retrospectively reviewed the hospital records of ART ineligible HIV-infected adults who enrolled into HIV care between January 2008 and December 2012 at two major tertiary hospitals in Bayelsa State, South-South Nigeria. Demographic, clinical and laboratories data were obtained at presentation, at each subsequent visit at 6 monthly intervals and at time of initiation of ART. Cox proportional regression and Kaplan-Meier survival analysis were used to evaluate independent predictors of time to initiation of ART. RESULTS: Amongst the 280 study participants, 70.6% were females, 62.6% had CD4+ >/=500 cells/ul, 48.4% had WHO HIV Stage 1 disease and 34.3% were lost to follow up. In a cohort of 180 participants followed up for >/=3 months, participants with CD4+ of 351-500 cells/ul and stage 2 disease were more likely to start ART earlier than those with CD4+ > 500 cells/ul (Hazard ratio [HR]-1.7, 95% confidence interval [CI] of 1.0-2.9) and stage 1 disease (HR-2.3 (95% CI-1.3-4.2) respectively. HIV-infected adults with faster CD4+ decay required earlier ART initiation, especially in the first year of follow up. CONCLUSION: ART-ineligible HIV-infected adults on follow up in South-South Nigeria are more likely to require earlier initiation of ART if they have stage 2 HIV disease or CD4+ </=500 cells/ul at presentation. Our findings suggest faster progression of HIV-disease in these groups of individuals and corroborate the growing evidence in support for earlier initiation of ART.'
p11443
sS'AD'
p11444
S'Department of Internal Medicine, Niger Delta University Teaching Hospital, Okolobiri, Bayelsa state, Nigeria. Department of Medicine, Federal Medical Centre, Yenagoa, Bayelsa State, Nigeria. Department of Internal Medicine, Niger Delta University Teaching Hospital, Okolobiri, Bayelsa state, Nigeria. Department of Internal Medicine, Niger Delta University Teaching Hospital, Okolobiri, Bayelsa state, Nigeria. Department of Internal Medicine, Niger Delta University Teaching Hospital, Okolobiri, Bayelsa state, Nigeria. Department of Medicine, Federal Medical Centre, Yenagoa, Bayelsa State, Nigeria. Department of Medicine, Federal Medical Centre, Yenagoa, Bayelsa State, Nigeria.'
p11445
sS'IP'
p11446
S'5'
sS'IS'
p11447
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p11448
sS'PMC'
p11449
S'PMC4416715'
p11450
sS'DCOM'
p11451
S'20160204'
p11452
sS'AU'
p11453
(lp11454
S'Ogoina D'
p11455
aS'Finomo F'
p11456
aS'Harry T'
p11457
aS'Inatimi O'
p11458
aS'Ebuenyi I'
p11459
aS'Tariladei WW'
p11460
aS'Afolayan AA'
p11461
asS'VI'
p11462
S'10'
p11463
sS'MHDA'
p11464
S'2016/02/05 06:00'
p11465
sS'PHST'
p11466
(lp11467
S'2015 [ecollection]'
p11468
aS'2014/10/06 [received]'
p11469
aS'2015/03/23 [accepted]'
p11470
aS'2015/05/01 [epublish]'
p11471
asS'OID'
p11472
(lp11473
S'NLM: PMC4416715'
p11474
asS'MH'
p11475
(lp11476
S'Adult'
p11477
aS'Anti-HIV Agents/therapeutic use'
p11478
aS'CD4 Lymphocyte Count'
p11479
aS'CD4-Positive T-Lymphocytes/immunology/pathology/*virology'
p11480
aS'Disease Progression'
p11481
aS'Female'
p11482
aS'HIV Infections/drug therapy/mortality/pathology/*virology'
p11483
aS'HIV-1/immunology/pathogenicity'
p11484
aS'Humans'
p11485
aS'Male'
p11486
aS'Nigeria'
p11487
aS'Retrospective Studies'
p11488
aS'Survival Analysis'
p11489
aS'Tertiary Care Centers'
p11490
aS'*Time-to-Treatment'
p11491
asS'EDAT'
p11492
S'2015/05/02 06:00'
p11493
sS'SO'
p11494
S'PLoS One. 2015 May 1;10(5):e0125665. doi: 10.1371/journal.pone.0125665. eCollection 2015.'
p11495
sS'SB'
p11496
S'IM'
p11497
sS'PMID'
p11498
S'25933356'
p11499
sS'PST'
p11500
S'epublish'
p11501
stRp11502
ag2
(g3
g4
(dp11503
S'LID'
p11504
S'10.1371/journal.pntd.0003748 [doi]'
p11505
sS'STAT'
p11506
S'MEDLINE'
p11507
sS'DEP'
p11508
S'20150424'
p11509
sS'DA'
p11510
S'20150427'
p11511
sS'AID'
p11512
(lp11513
S'10.1371/journal.pntd.0003748 [doi]'
p11514
aS'PNTD-D-15-00131 [pii]'
p11515
asS'CRDT'
p11516
(lp11517
S'2015/04/25 06:00'
p11518
asS'DP'
p11519
S'2015 Apr'
p11520
sS'AD'
p11521
S'Malawi Liverpool Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi; Liverpool School of Tropical Medicine, Liverpool, United Kingdom; Wellcome Trust Sanger Institute, Hinxton, United Kingdom. Malawi Liverpool Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi. Wellcome Trust Sanger Institute, Hinxton, United Kingdom. Malawi Liverpool Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi; University of Malawi College of Medicine, Blantyre, Malawi. Malawi Liverpool Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi. University of Malawi, The Polytechnic, Blantyre, Malawi. University of Malawi College of Medicine, Blantyre, Malawi. Malawi Liverpool Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi; University of Malawi College of Medicine, Blantyre, Malawi. University of Malawi College of Medicine, Blantyre, Malawi. Malawi Liverpool Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi; Institute for Infection and Global Health, University of Liverpool, Liverpool, United Kingdom. University of Malawi College of Medicine, Blantyre, Malawi. University of Malawi College of Medicine, Blantyre, Malawi. University of Malawi College of Medicine, Blantyre, Malawi. Wellcome Trust Sanger Institute, Hinxton, United Kingdom. Wellcome Trust Sanger Institute, Hinxton, United Kingdom. Institute for Infection and Global Health, University of Liverpool, Liverpool, United Kingdom. Malawi Liverpool Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi; Liverpool School of Tropical Medicine, Liverpool, United Kingdom.'
p11522
sS'OWN'
p11523
S'NLM'
p11524
sS'PT'
p11525
(lp11526
S'Journal Article'
p11527
aS"Research Support, Non-U.S. Gov't"
p11528
asS'LA'
p11529
(lp11530
S'eng'
p11531
asS'FAU'
p11532
(lp11533
S'Feasey, Nicholas A'
p11534
aS'Gaskell, Katherine'
p11535
aS'Wong, Vanessa'
p11536
aS'Msefula, Chisomo'
p11537
aS'Selemani, George'
p11538
aS'Kumwenda, Save'
p11539
aS'Allain, Theresa J'
p11540
aS'Mallewa, Jane'
p11541
aS'Kennedy, Neil'
p11542
aS'Bennett, Aisleen'
p11543
aS'Nyirongo, Joram O'
p11544
aS'Nyondo, Patience A'
p11545
aS'Zulu, Madalitso D'
p11546
aS'Parkhill, Julian'
p11547
aS'Dougan, Gordon'
p11548
aS'Gordon, Melita A'
p11549
aS'Heyderman, Robert S'
p11550
asS'JT'
p11551
S'PLoS neglected tropical diseases'
p11552
sS'LR'
p11553
S'20160713'
p11554
sS'PG'
p11555
S'e0003748'
p11556
sS'TI'
p11557
S'Rapid emergence of multidrug resistant, H58-lineage Salmonella typhi in Blantyre, Malawi.'
p11558
sS'PL'
p11559
S'United States'
p11560
sS'TA'
p11561
S'PLoS Negl Trop Dis'
p11562
sS'JID'
p11563
S'101291488'
p11564
sS'AB'
p11565
S'INTRODUCTION: Between 1998 and 2010, S. Typhi was an uncommon cause of bloodstream infection (BSI) in Blantyre, Malawi and it was usually susceptible to first-line antimicrobial therapy. In 2011 an increase in a multidrug resistant (MDR) strain was detected through routine bacteriological surveillance conducted at Queen Elizabeth Central Hospital (QECH). METHODS: Longitudinal trends in culture-confirmed Typhoid admissions at QECH were described between 1998-2014. A retrospective review of patient cases notes was conducted, focusing on clinical presentation, prevalence of HIV and case-fatality. Isolates of S. Typhi were sequenced and the phylogeny of Typhoid in Blantyre was reconstructed and placed in a global context. RESULTS: Between 1998-2010, there were a mean of 14 microbiological diagnoses of Typhoid/year at QECH, of which 6.8% were MDR. This increased to 67 in 2011 and 782 in 2014 at which time 97% were MDR. The disease predominantly affected children and young adults (median age 11 [IQR 6-21] in 2014). The prevalence of HIV in adult patients was 16.7% [8/48], similar to that of the general population (17.8%). Overall, the case fatality rate was 2.5% (3/94). Complications included anaemia, myocarditis, pneumonia and intestinal perforation. 112 isolates were sequenced and the phylogeny demonstrated the introduction and clonal expansion of the H58 lineage of S. Typhi. CONCLUSIONS: Since 2011, there has been a rapid increase in the incidence of multidrug resistant, H58-lineage Typhoid in Blantyre. This is one of a number of reports of the re-emergence of Typhoid in Southern and Eastern Africa. There is an urgent need to understand the reservoirs and transmission of disease and how to arrest this regional increase.'
p11566
sS'GR'
p11567
(lp11568
S'098051/Wellcome Trust/United Kingdom'
p11569
aS'100890/Wellcome Trust/United Kingdom'
p11570
aS'101113/Z/13/Z084/Wellcome Trust/United Kingdom'
p11571
aS'WT092152MA/Wellcome Trust/United Kingdom'
p11572
asS'IP'
p11573
S'4'
sS'IS'
p11574
S'1935-2735 (Electronic) 1935-2727 (Linking)'
p11575
sS'PMC'
p11576
S'PMC4409211'
p11577
sS'DCOM'
p11578
S'20160126'
p11579
sS'AU'
p11580
(lp11581
S'Feasey NA'
p11582
aS'Gaskell K'
p11583
aS'Wong V'
p11584
aS'Msefula C'
p11585
aS'Selemani G'
p11586
aS'Kumwenda S'
p11587
aS'Allain TJ'
p11588
aS'Mallewa J'
p11589
aS'Kennedy N'
p11590
aS'Bennett A'
p11591
aS'Nyirongo JO'
p11592
aS'Nyondo PA'
p11593
aS'Zulu MD'
p11594
aS'Parkhill J'
p11595
aS'Dougan G'
p11596
aS'Gordon MA'
p11597
aS'Heyderman RS'
p11598
asS'VI'
p11599
S'9'
sS'MHDA'
p11600
S'2016/01/27 06:00'
p11601
sS'PHST'
p11602
(lp11603
S'2015/04 [ecollection]'
p11604
aS'2015/01/27 [received]'
p11605
aS'2015/04/08 [accepted]'
p11606
aS'2015/04/24 [epublish]'
p11607
asS'OID'
p11608
(lp11609
S'NLM: PMC4409211'
p11610
asS'MH'
p11611
(lp11612
S'Adolescent'
p11613
aS'Adult'
p11614
aS'Base Sequence'
p11615
aS'Child'
p11616
aS'Drug Resistance, Multiple, Bacterial/*genetics'
p11617
aS'Female'
p11618
aS'Humans'
p11619
aS'Incidence'
p11620
aS'Malawi/epidemiology'
p11621
aS'Male'
p11622
aS'Molecular Sequence Data'
p11623
aS'Phylogeny'
p11624
aS'Prevalence'
p11625
aS'Retrospective Studies'
p11626
aS'Salmonella typhi/*genetics'
p11627
aS'Sequence Analysis, DNA'
p11628
aS'Typhoid Fever/*epidemiology/*microbiology'
p11629
asS'EDAT'
p11630
S'2015/04/25 06:00'
p11631
sS'SO'
p11632
S'PLoS Negl Trop Dis. 2015 Apr 24;9(4):e0003748. doi: 10.1371/journal.pntd.0003748. eCollection 2015 Apr.'
p11633
sS'SB'
p11634
S'IM'
p11635
sS'PMID'
p11636
S'25909750'
p11637
sS'PST'
p11638
S'epublish'
p11639
stRp11640
ag2
(g3
g4
(dp11641
S'LID'
p11642
S'10.1186/s12957-015-0482-0 [doi]'
p11643
sS'STAT'
p11644
S'MEDLINE'
p11645
sS'DEP'
p11646
S'20150222'
p11647
sS'DA'
p11648
S'20150419'
p11649
sS'AID'
p11650
(lp11651
S'10.1186/s12957-015-0482-0 [doi]'
p11652
aS'10.1186/s12957-015-0482-0 [pii]'
p11653
asS'CRDT'
p11654
(lp11655
S'2015/04/19 06:00'
p11656
asS'DP'
p11657
S'2015'
p11658
sS'OWN'
p11659
S'NLM'
p11660
sS'PT'
p11661
(lp11662
S'Journal Article'
p11663
asS'LA'
p11664
(lp11665
S'eng'
p11666
asS'DCOM'
p11667
S'20160119'
p11668
sS'JT'
p11669
S'World journal of surgical oncology'
p11670
sS'LR'
p11671
S'20150420'
p11672
sS'FAU'
p11673
(lp11674
S'Chalya, Phillipo L'
p11675
aS'Rambau, Peter F'
p11676
aS'Masalu, Nestory'
p11677
aS'Simbila, Samson'
p11678
asS'TI'
p11679
S'Ten-year surgical experiences with penile cancer at a tertiary care hospital in northwestern Tanzania: a retrospective study of 236 patients.'
p11680
sS'PL'
p11681
S'England'
p11682
sS'PG'
p11683
S'71'
p11684
sS'JID'
p11685
S'101170544'
p11686
sS'AB'
p11687
S"BACKGROUND: Penile cancer is an uncommon malignancy in developed countries, but the incidence is as high as 10% to 20% of all male cancers in some developing countries. There is a paucity of published data on this subject in our setting. This study describes the clinicopathological presentation and treatment outcome of this condition in our environment, and highlights challenges associated with the care of these patients and proffers solutions for improved outcome. METHODS: This was a retrospective study of histologically confirmed cases of penile cancer seen at Bugando Medical Centre between January 2004 and December 2013. RESULTS: There were 236 penile cancer patients representing 2.2% of all male malignancies during the study period. The median age was 47 years with a modal age group of 41 to 50 years. Of the 236 patients, 147 (62.3%) had severe phimosis. The majority of patients (89.8%) were uncircumcised. A history of human papilloma virus (HPV) was reported in 12 (5.1%) cases. One hundred eighty-two (77.1%) patients reported history of cigarette smoking. Seven (6.7%) patients were human immunodeficiency virus (HIV) positive. The majority of the patients (68.6%) presented with Jackson's stages III and IV. Squamous cell carcinoma was the most common histopathological type (99.2%). Lymph node metastasis was recorded in 65.3% of cases, and it was significantly associated with the tumor size, histopathological subtype, histopathological grade, lympho-vascular invasion, positive resection margins, and urethral involvement (P < 0.001). Distant metastasis accounted for 4.2% of cases. The majority of patients (63.1%) underwent partial penectomy. Chemotherapy and radiotherapy were given in 14 (5.9%) and 12 (5.1%) patients, respectively. Complication and mortality rates were 22.0% and 4.2%, respectively. HIV positivity, histopathological stage and grade of the tumor, and presence of metastases at the time of diagnosis were the main predictors of death (P < 0.001). The median length of hospitalization was 14 days. Local recurrence was reported in 12 (5.3%) patients. Data on long-term survivals were not available as the majority of patients were lost to follow-up. CONCLUSIONS: Penile cancer is not rare in our environment. The majority of patients present late with advanced stage of the disease. Early detection of primary cancer at an early stage may improve the prognosis."
p11688
sS'AD'
p11689
S'Department of Surgery, Bugando Medical Centre, P.O. Box 1370, Mwanza, Tanzania. drphillipoleo@yahoo.com. Department of Pathology, Catholic University of Health and Allied Science-Bugando, P.O. Box 1464, Mwanza, Tanzania. prambau@bugando.ac.tz. Department of Oncology, Bugando Medical Centre, P.O. Box 1370, Mwanza, Tanzania. nmasalu4@gmail.com. Department of Urology, Bugando Medical Centre, P.O. Box 1370, Mwanza, Tanzania. samsimbila50@gmail.com.'
p11690
sS'VI'
p11691
S'13'
p11692
sS'IS'
p11693
S'1477-7819 (Electronic) 1477-7819 (Linking)'
p11694
sS'PMC'
p11695
S'PMC4341227'
p11696
sS'AU'
p11697
(lp11698
S'Chalya PL'
p11699
aS'Rambau PF'
p11700
aS'Masalu N'
p11701
aS'Simbila S'
p11702
asS'MHDA'
p11703
S'2016/01/20 06:00'
p11704
sS'PHST'
p11705
(lp11706
S'2014/11/01 [received]'
p11707
aS'2015/01/22 [accepted]'
p11708
aS'2015/02/22 [aheadofprint]'
p11709
asS'OID'
p11710
(lp11711
S'NLM: PMC4341227'
p11712
asS'MH'
p11713
(lp11714
S'Adult'
p11715
aS'Carcinoma, Small Cell/mortality/secondary/*surgery'
p11716
aS'Carcinoma, Squamous Cell/mortality/secondary/*surgery'
p11717
aS'Follow-Up Studies'
p11718
aS'Humans'
p11719
aS'Lymphatic Metastasis'
p11720
aS'Male'
p11721
aS'Middle Aged'
p11722
aS'Neoplasm Invasiveness'
p11723
aS'Neoplasm Recurrence, Local/mortality/pathology/*surgery'
p11724
aS'Neoplasm Staging'
p11725
aS'Penile Neoplasms/mortality/pathology/*surgery'
p11726
aS'Prognosis'
p11727
aS'Retrospective Studies'
p11728
aS'Sarcoma/mortality/secondary/*surgery'
p11729
aS'Survival Rate'
p11730
aS'Tanzania'
p11731
aS'Tertiary Healthcare'
p11732
aS'Time Factors'
p11733
asS'EDAT'
p11734
S'2015/04/19 06:00'
p11735
sS'SO'
p11736
S'World J Surg Oncol. 2015 Feb 22;13:71. doi: 10.1186/s12957-015-0482-0.'
p11737
sS'SB'
p11738
S'IM'
p11739
sS'PMID'
p11740
S'25889238'
p11741
sS'TA'
p11742
S'World J Surg Oncol'
p11743
sS'PST'
p11744
S'epublish'
p11745
stRp11746
ag2
(g3
g4
(dp11747
S'LID'
p11748
S'10.1186/s12960-015-0006-6 [doi]'
p11749
sS'STAT'
p11750
S'MEDLINE'
p11751
sS'DEP'
p11752
S'20150328'
p11753
sS'DA'
p11754
S'20150418'
p11755
sS'AID'
p11756
(lp11757
S'10.1186/s12960-015-0006-6 [doi]'
p11758
aS'10.1186/s12960-015-0006-6 [pii]'
p11759
asS'CRDT'
p11760
(lp11761
S'2015/04/18 06:00'
p11762
asS'DP'
p11763
S'2015'
p11764
sS'AD'
p11765
S'EnCompass LLC, 7200 Wisconsin Ave., Bethesda, MD, 20814, USA. ssmith@urc-chs.com. University Research Co, LLC, 7200 Wisconsin Ave., Bethesda, MD, 20814, USA. kfatta@urc-chs.com. University Research Co, LLC, 7200 Wisconsin Ave., Bethesda, MD, 20814, USA. kethier@urc-chs.com. University Research Co, LLC, 7200 Wisconsin Ave., Bethesda, MD, 20814, USA. rshrestha@urc-chs.com.'
p11766
sS'OWN'
p11767
S'NLM'
p11768
sS'PT'
p11769
(lp11770
S'Journal Article'
p11771
aS"Research Support, U.S. Gov't, Non-P.H.S."
p11772
asS'LA'
p11773
(lp11774
S'eng'
p11775
asS'DCOM'
p11776
S'20160111'
p11777
sS'JT'
p11778
S'Human resources for health'
p11779
sS'LR'
p11780
S'20150420'
p11781
sS'FAU'
p11782
(lp11783
S'Lunsford, Sarah Smith'
p11784
aS'Fatta, Kate'
p11785
aS'Stover, Kim Ethier'
p11786
aS'Shrestha, Ram'
p11787
asS'TI'
p11788
S'Supporting close-to-community providers through a community health system approach: case examples from Ethiopia and Tanzania.'
p11789
sS'PL'
p11790
S'England'
p11791
sS'PG'
p11792
S'12'
p11793
sS'JID'
p11794
S'101170535'
p11795
sS'AB'
p11796
S"INTRODUCTION: Close-to-community (CTC) providers, including community health workers or volunteers or health extension workers, can be effective in promoting access to and utilization of health services. Tasks are often shifted to these providers with limited resources and support from CTC programmes or communities. The Community Health System Strengthening (CHSS) model is part of an improvement approach which draws on existing formal and informal networks within a community, such as agricultural or women's groups, to support CTC providers and address gaps in community-based health services. The model offers a framework for bringing representatives from existing community networks, CTC providers, and health facility staff together to form a community team charged with identifying challenges in service delivery, testing solutions, and monitoring changes. CTC providers draw upon fellow community team members to disseminate health messages and refer community members in need of services. CASES: Two cases are presented. In Ethiopia, the CHSS model was applied in 18 communities to increase HIV testing among pregnant women and antenatal care service utilization and improve sanitation. Prior to implementation, representatives from community groups were unaware of health extension workers or were uncomfortable making referrals. By participating on the community team, representatives became familiar with and comfortable referring people to health extension workers and spreading health messages. During implementation, more pregnant women registered for antenatal care and tested for HIV; health extension workers conducted more postnatal visits; and more households had functioning latrines and proper latrine use increased. In Tanzania, the CHSS model was applied in five communities to improve HIV testing and retention into care. Community team members talked to their families and social networks about HIV testing and, when they identified someone who had dropped out of treatment, they referred those individuals to the home-based care volunteer. Increases in HIV testing and a reduction in patients lost to follow-up were observed. DISCUSSION AND CONCLUSION: The CHSS model brings together existing networks within communities to support and lend legitimacy to CTC providers. This approach may result in sustainable community-based programmes, especially in HIV where the continuum of care extends beyond the facility and into the community."
p11797
sS'GR'
p11798
(lp11799
S'PEPFAR/United States'
p11800
asS'VI'
p11801
S'13'
p11802
sS'IS'
p11803
S'1478-4491 (Electronic) 1478-4491 (Linking)'
p11804
sS'PMC'
p11805
S'PMC4387620'
p11806
sS'AU'
p11807
(lp11808
S'Lunsford SS'
p11809
aS'Fatta K'
p11810
aS'Stover KE'
p11811
aS'Shrestha R'
p11812
asS'MHDA'
p11813
S'2016/01/12 06:00'
p11814
sS'PHST'
p11815
(lp11816
S'2014/11/25 [received]'
p11817
aS'2015/03/08 [accepted]'
p11818
aS'2015/03/28 [aheadofprint]'
p11819
asS'OID'
p11820
(lp11821
S'NLM: PMC4387620'
p11822
asS'MH'
p11823
(lp11824
S'*Community Health Planning'
p11825
aS'Community Health Services/*manpower'
p11826
aS'*Community Health Workers'
p11827
aS'Community Networks'
p11828
aS'Delivery of Health Care/*manpower'
p11829
aS'Ethiopia'
p11830
aS'Female'
p11831
aS'HIV Infections/complications/diagnosis'
p11832
aS'Humans'
p11833
aS'Male'
p11834
aS'Maternal Health Services/manpower'
p11835
aS'Pregnancy'
p11836
aS'Pregnancy Complications/diagnosis'
p11837
aS'*Residence Characteristics'
p11838
aS'Tanzania'
p11839
asS'EDAT'
p11840
S'2015/04/18 06:00'
p11841
sS'SO'
p11842
S'Hum Resour Health. 2015 Mar 28;13:12. doi: 10.1186/s12960-015-0006-6.'
p11843
sS'SB'
p11844
S'IM'
p11845
sS'PMID'
p11846
S'25884699'
p11847
sS'TA'
p11848
S'Hum Resour Health'
p11849
sS'PST'
p11850
S'epublish'
p11851
stRp11852
ag2
(g3
g4
(dp11853
S'LID'
p11854
S'10.1097/QAD.0000000000000672 [doi]'
p11855
sS'STAT'
p11856
S'MEDLINE'
p11857
sS'JT'
p11858
S'AIDS (London, England)'
p11859
sS'CIN'
p11860
(lp11861
S'AIDS. 2015 Jun 19;29(10):1261-2. PMID: 26035324'
p11862
asS'DA'
p11863
S'20150603'
p11864
sS'AID'
p11865
(lp11866
S'10.1097/QAD.0000000000000672 [doi]'
p11867
asS'CRDT'
p11868
(lp11869
S'2015/04/15 06:00'
p11870
asS'DP'
p11871
S'2015 Jun 19'
p11872
sS'AD'
p11873
S"aDivision of Infectious Diseases bDivision of General Medicine cMedical Practice Evaluation Center, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA dThe Medical Research Council Clinical Trials Unit, London, UK eWorld Health Organization, Geneva, Switzerland fCenter for Biostatistics in AIDS Research gDepartment of Health Policy and Management, Harvard School of Public Health hDivision of Infectious Diseases, Department of Medicine iDepartment of Orthopedic Surgery, Brigham and Women's Hospital, Boston jCenter for AIDS Research, Harvard University, Cambridge, Massachusetts kClinton Health Access Initiative, New York lDepartments of Biostatistics and Epidemiology, Boston University School of Public Health, Boston, Massachusetts mDivision of Infectious Diseases, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA nDepartment of Child Health and Pediatrics, Moi University, Eldoret, Kenya oDepartment of Medicine and Department of Pediatrics16, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA."
p11874
sS'OWN'
p11875
S'NLM'
p11876
sS'PT'
p11877
(lp11878
S'Journal Article'
p11879
aS'Research Support, N.I.H., Extramural'
p11880
aS"Research Support, Non-U.S. Gov't"
p11881
asS'LA'
p11882
(lp11883
S'eng'
p11884
asS'FAU'
p11885
(lp11886
S'Ciaranello, Andrea L'
p11887
aS'Doherty, Kathleen'
p11888
aS'Penazzato, Martina'
p11889
aS'Lindsey, Jane C'
p11890
aS'Harrison, Linda'
p11891
aS'Kelly, Kathleen'
p11892
aS'Walensky, Rochelle P'
p11893
aS'Essajee, Shaffiq'
p11894
aS'Losina, Elena'
p11895
aS'Muhe, Lulu'
p11896
aS'Wools-Kaloustian, Kara'
p11897
aS'Ayaya, Samuel'
p11898
aS'Weinstein, Milton C'
p11899
aS'Palumbo, Paul'
p11900
aS'Freedberg, Kenneth A'
p11901
asS'LR'
p11902
S'20160506'
p11903
sS'PG'
p11904
S'1247-59'
p11905
sS'TI'
p11906
S'Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age.'
p11907
sS'RN'
p11908
(lp11909
S'0 (Anti-Retroviral Agents)'
p11910
aS'2494G1JF75 (Lopinavir)'
p11911
aS'99DK7FVK1H (Nevirapine)'
p11912
aS'O3J8G9O825 (Ritonavir)'
p11913
asS'PL'
p11914
S'England'
p11915
sS'TA'
p11916
S'AIDS'
p11917
sS'JID'
p11918
S'8710219'
p11919
sS'AB'
p11920
S"BACKGROUND: The International Maternal, Pediatric, and Adolescent Clinical Trials P1060 trial demonstrated superior outcomes for HIV-infected children less than 3 years old initiating antiretroviral therapy (ART) with lopinavir/ritonavir compared to nevirapine, but lopinavir/ritonavir is four-fold costlier. DESIGN/METHODS: We used the Cost-Effectiveness of Preventing AIDS Complications (CEPAC)-Pediatric model, with published and P1060 data, to project outcomes under three strategies: no ART; first-line nevirapine (with second-line lopinavir/ritonavir); and first-line lopinavir/ritonavir (second-line nevirapine). The base-case examined South African children initiating ART at age 12 months; sensitivity analyses varied all key model parameters. Outcomes included life expectancy, lifetime costs, and incremental cost-effectiveness ratios [ICERs; dollars/year of life saved ($/YLS)]. We considered interventions with ICERs less than 1x per-capita gross domestic product (South Africa: $7500)/YLS as 'very cost-effective,' interventions with ICERs below 3x gross domestic product/YLS as 'cost-effective,' and interventions leading to longer life expectancy and lower lifetime costs as 'cost-saving'. RESULTS: Projected life expectancy was 2.8 years with no ART. Both ART regimens markedly improved life expectancy and were very cost-effective, compared to no ART. First-line lopinavir/ritonavir led to longer life expectancy (28.8 years) and lower lifetime costs ($41 350/person, from lower second-line costs) than first-line nevirapine (27.6 years, $44 030). First-line lopinavir/ritonavir remained cost-saving or very cost-effective compared to first-line nevirapine unless: liquid lopinavir/ritonavir led to two-fold higher virologic failure rates or 15-fold greater costs than in the base-case, or second-line ART following first-line lopinavir/ritonavir was very ineffective. CONCLUSIONS: On the basis of P1060 data, first-line lopinavir/ritonavir leads to longer life expectancy and is cost-saving or very cost-effective compared to first-line nevirapine. This supports WHO guidelines, but increasing access to pediatric ART is critical regardless of the regimen used."
p11921
sS'GR'
p11922
(lp11923
S'K01 AI078754/AI/NIAID NIH HHS/United States'
p11924
aS'K01 AI078754/AI/NIAID NIH HHS/United States'
p11925
aS'K24 AI062476/AI/NIAID NIH HHS/United States'
p11926
aS'K24 AI062476/AI/NIAID NIH HHS/United States'
p11927
aS'N01-DK-9-001/HHSN267200800001C/DK/NIDDK NIH HHS/United States'
p11928
aS'R01 AI058736/AI/NIAID NIH HHS/United States'
p11929
aS'R01 AI058736/AI/NIAID NIH HHS/United States'
p11930
aS'R01 AI093269/AI/NIAID NIH HHS/United States'
p11931
aS'R01 AI093269/AI/NIAID NIH HHS/United States'
p11932
aS'R01 HD079214/HD/NICHD NIH HHS/United States'
p11933
aS'R01 HD079214/HD/NICHD NIH HHS/United States'
p11934
aS'U01 AI069911/AI/NIAID NIH HHS/United States'
p11935
aS'U01 AI069911/AI/NIAID NIH HHS/United States'
p11936
aS'U01 AI069919/AI/NIAID NIH HHS/United States'
p11937
aS'U01AI09919/AI/NIAID NIH HHS/United States'
p11938
aS'UM1 AI068616/AI/NIAID NIH HHS/United States'
p11939
aS'UM1 AI068632/AI/NIAID NIH HHS/United States'
p11940
aS'UM1AI068616/AI/NIAID NIH HHS/United States'
p11941
aS'UM1AI068632/AI/NIAID NIH HHS/United States'
p11942
asS'IP'
p11943
S'10'
p11944
sS'IS'
p11945
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p11946
sS'PMC'
p11947
S'PMC4536981'
p11948
sS'DCOM'
p11949
S'20160223'
p11950
sS'AU'
p11951
(lp11952
S'Ciaranello AL'
p11953
aS'Doherty K'
p11954
aS'Penazzato M'
p11955
aS'Lindsey JC'
p11956
aS'Harrison L'
p11957
aS'Kelly K'
p11958
aS'Walensky RP'
p11959
aS'Essajee S'
p11960
aS'Losina E'
p11961
aS'Muhe L'
p11962
aS'Wools-Kaloustian K'
p11963
aS'Ayaya S'
p11964
aS'Weinstein MC'
p11965
aS'Palumbo P'
p11966
aS'Freedberg KA'
p11967
asS'VI'
p11968
S'29'
p11969
sS'MHDA'
p11970
S'2016/02/26 06:00'
p11971
sS'OID'
p11972
(lp11973
S'NLM: PMC4536981'
p11974
asS'MH'
p11975
(lp11976
S'Anti-Retroviral Agents/*economics/*therapeutic use'
p11977
aS'Antiretroviral Therapy, Highly Active/*economics/*methods'
p11978
aS'Child, Preschool'
p11979
aS'Clinical Trials as Topic'
p11980
aS'Cost-Benefit Analysis'
p11981
aS'HIV Infections/*drug therapy/*economics'
p11982
aS'Health Care Costs'
p11983
aS'Humans'
p11984
aS'Infant'
p11985
aS'Infant, Newborn'
p11986
aS'Life Expectancy'
p11987
aS'Lopinavir/economics/therapeutic use'
p11988
aS'Male'
p11989
aS'Nevirapine/economics/therapeutic use'
p11990
aS'Ritonavir/economics/therapeutic use'
p11991
aS'South Africa'
p11992
asS'EDAT'
p11993
S'2015/04/15 06:00'
p11994
sS'SO'
p11995
S'AIDS. 2015 Jun 19;29(10):1247-59. doi: 10.1097/QAD.0000000000000672.'
p11996
sS'SB'
p11997
S'IM X'
p11998
sS'PMID'
p11999
S'25870982'
p12000
sS'PST'
p12001
S'ppublish'
p12002
stRp12003
ag2
(g3
g4
(dp12004
S'LID'
p12005
S'10.1371/journal.pone.0122514 [doi]'
p12006
sS'STAT'
p12007
S'MEDLINE'
p12008
sS'DEP'
p12009
S'20150407'
p12010
sS'DA'
p12011
S'20150408'
p12012
sS'AID'
p12013
(lp12014
S'10.1371/journal.pone.0122514 [doi]'
p12015
aS'PONE-D-14-50603 [pii]'
p12016
asS'CRDT'
p12017
(lp12018
S'2015/04/08 06:00'
p12019
asS'DP'
p12020
S'2015'
p12021
sS'AD'
p12022
S'TB Modelling Group, Centre for the Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom; TB Centre, London School of Hygiene and Tropical Medicine, London, United Kingdom. School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom. TB Centre, London School of Hygiene and Tropical Medicine, London, United Kingdom. TB Centre, London School of Hygiene and Tropical Medicine, London, United Kingdom. TB Centre, London School of Hygiene and Tropical Medicine, London, United Kingdom; Aurum Institute, Johannesburg, South Africa; School of Public Health, University of Witwatersrand, Johannesburg, South Africa. TB Modelling Group, Centre for the Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom; TB Centre, London School of Hygiene and Tropical Medicine, London, United Kingdom.'
p12023
sS'OWN'
p12024
S'NLM'
p12025
sS'PT'
p12026
(lp12027
S'Journal Article'
p12028
aS"Research Support, Non-U.S. Gov't"
p12029
asS'LA'
p12030
(lp12031
S'eng'
p12032
asS'FAU'
p12033
(lp12034
S'Knight, Gwenan M'
p12035
aS'Dodd, Peter J'
p12036
aS'Grant, Alison D'
p12037
aS'Fielding, Katherine L'
p12038
aS'Churchyard, Gavin J'
p12039
aS'White, Richard G'
p12040
asS'JT'
p12041
S'PloS one'
p12042
sS'LR'
p12043
S'20150422'
p12044
sS'PG'
p12045
S'e0122514'
p12046
sS'TI'
p12047
S'Tuberculosis prevention in South Africa.'
p12048
sS'RN'
p12049
(lp12050
S'0 (Anti-HIV Agents)'
p12051
aS'0 (Antitubercular Agents)'
p12052
aS'V83O1VOZ8L (Isoniazid)'
p12053
asS'PL'
p12054
S'United States'
p12055
sS'TA'
p12056
S'PLoS One'
p12057
sS'JID'
p12058
S'101285081'
p12059
sS'AB'
p12060
S'BACKGROUND: South Africa has one of the highest per capita rates of tuberculosis (TB) incidence in the world. In 2012, the South African government produced a National Strategic Plan (NSP) to control the spread of TB with the ambitious aim of zero new TB infections and deaths by 2032, and a halving of the 2012 rates by 2016. METHODS: We used a transmission model to investigate whether the NSP targets could be reached if immediate scale up of control methods had happened in 2014. We explored the potential impact of four intervention portfolios; 1) "NSP" represents the NSP strategy, 2) "WHO" investigates increasing antiretroviral therapy eligibility, 3) "Novel Strategies" considers new isoniazid preventive therapy strategies and HIV "Universal Test and Treat" and 4) "Optimised" contains the most effective interventions. FINDINGS: We find that even with this scale-up, the NSP targets are unlikely to be achieved. The portfolio that achieved the greatest impact was "Optimised", followed closely by "NSP". The "WHO" and "Novel Strategies" had little impact on TB incidence by 2050. Of the individual interventions explored, the most effective were active case finding and reductions in pre-treatment loss to follow up which would have a large impact on TB burden. CONCLUSION: Use of existing control strategies has the potential to have a large impact on TB disease burden in South Africa. However, our results suggest that the South African TB targets are unlikely to be reached without new technologies. Despite this, TB incidence could be dramatically reduced by finding and starting more TB cases on treatment.'
p12061
sS'GR'
p12062
(lp12063
S'MR/J005088/1/Medical Research Council/United Kingdom'
p12064
asS'IP'
p12065
S'4'
sS'IS'
p12066
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p12067
sS'PMC'
p12068
S'PMC4388715'
p12069
sS'DCOM'
p12070
S'20151229'
p12071
sS'AU'
p12072
(lp12073
S'Knight GM'
p12074
aS'Dodd PJ'
p12075
aS'Grant AD'
p12076
aS'Fielding KL'
p12077
aS'Churchyard GJ'
p12078
aS'White RG'
p12079
asS'VI'
p12080
S'10'
p12081
sS'MHDA'
p12082
S'2015/12/30 06:00'
p12083
sS'PHST'
p12084
(lp12085
S'2015 [ecollection]'
p12086
aS'2014/11/10 [received]'
p12087
aS'2015/02/11 [accepted]'
p12088
aS'2015/04/07 [epublish]'
p12089
asS'OID'
p12090
(lp12091
S'NLM: PMC4388715'
p12092
asS'MH'
p12093
(lp12094
S'Anti-HIV Agents/therapeutic use'
p12095
aS'Antitubercular Agents/therapeutic use'
p12096
aS'HIV Infections/complications/drug therapy'
p12097
aS'Humans'
p12098
aS'Incidence'
p12099
aS'Isoniazid/therapeutic use'
p12100
aS'*Models, Theoretical'
p12101
aS'South Africa/epidemiology'
p12102
aS'Tuberculosis/complications/epidemiology/*prevention & control'
p12103
asS'EDAT'
p12104
S'2015/04/08 06:00'
p12105
sS'SO'
p12106
S'PLoS One. 2015 Apr 7;10(4):e0122514. doi: 10.1371/journal.pone.0122514. eCollection 2015.'
p12107
sS'SB'
p12108
S'IM'
p12109
sS'PMID'
p12110
S'25849558'
p12111
sS'PST'
p12112
S'epublish'
p12113
stRp12114
ag2
(g3
g4
(dp12115
S'LID'
p12116
S'10.1371/journal.pmed.1001810 [doi]'
p12117
sS'STAT'
p12118
S'MEDLINE'
p12119
sS'DEP'
p12120
S'20150407'
p12121
sS'DA'
p12122
S'20150408'
p12123
sS'AID'
p12124
(lp12125
S'10.1371/journal.pmed.1001810 [doi]'
p12126
aS'PMEDICINE-D-14-02307 [pii]'
p12127
asS'CRDT'
p12128
(lp12129
S'2015/04/08 06:00'
p12130
asS'DP'
p12131
S'2015 Apr'
p12132
sS'EIN'
p12133
(lp12134
S'PLoS Med. 2015 Jun;12(6):e1001845. PMID: 26030872'
p12135
asS'OWN'
p12136
S'NLM'
p12137
sS'PT'
p12138
(lp12139
S'Journal Article'
p12140
aS'Meta-Analysis'
p12141
aS'Research Support, N.I.H., Extramural'
p12142
aS"Research Support, Non-U.S. Gov't"
p12143
asS'LA'
p12144
(lp12145
S'eng'
p12146
asS'FAU'
p12147
(lp12148
S'Rhee, Soo-Yon'
p12149
aS'Blanco, Jose Luis'
p12150
aS'Jordan, Michael R'
p12151
aS'Taylor, Jonathan'
p12152
aS'Lemey, Philippe'
p12153
aS'Varghese, Vici'
p12154
aS'Hamers, Raph L'
p12155
aS'Bertagnolio, Silvia'
p12156
aS'Rinke de Wit, Tobias F'
p12157
aS'Aghokeng, Avelin F'
p12158
aS'Albert, Jan'
p12159
aS'Avi, Radko'
p12160
aS'Avila-Rios, Santiago'
p12161
aS'Bessong, Pascal O'
p12162
aS'Brooks, James I'
p12163
aS'Boucher, Charles A B'
p12164
aS'Brumme, Zabrina L'
p12165
aS'Busch, Michael P'
p12166
aS'Bussmann, Hermann'
p12167
aS'Chaix, Marie-Laure'
p12168
aS'Chin, Bum Sik'
p12169
aS"D'Aquin, Toni T"
p12170
aS'De Gascun, Cillian F'
p12171
aS'Derache, Anne'
p12172
aS'Descamps, Diane'
p12173
aS'Deshpande, Alaka K'
p12174
aS'Djoko, Cyrille F'
p12175
aS'Eshleman, Susan H'
p12176
aS'Fleury, Herve'
p12177
aS'Frange, Pierre'
p12178
aS'Fujisaki, Seiichiro'
p12179
aS'Harrigan, P Richard'
p12180
aS'Hattori, Junko'
p12181
aS'Holguin, Africa'
p12182
aS'Hunt, Gillian M'
p12183
aS'Ichimura, Hiroshi'
p12184
aS'Kaleebu, Pontiano'
p12185
aS'Katzenstein, David'
p12186
aS'Kiertiburanakul, Sasisopin'
p12187
aS'Kim, Jerome H'
p12188
aS'Kim, Sung Soon'
p12189
aS'Li, Yanpeng'
p12190
aS'Lutsar, Irja'
p12191
aS'Morris, Lynn'
p12192
aS'Ndembi, Nicaise'
p12193
aS'Ng, Kee Peng'
p12194
aS'Paranjape, Ramesh S'
p12195
aS'Peeters, Martine'
p12196
aS'Poljak, Mario'
p12197
aS'Price, Matt A'
p12198
aS'Ragonnet-Cronin, Manon L'
p12199
aS'Reyes-Teran, Gustavo'
p12200
aS'Rolland, Morgane'
p12201
aS'Sirivichayakul, Sunee'
p12202
aS'Smith, Davey M'
p12203
aS'Soares, Marcelo A'
p12204
aS'Soriano, Vincent V'
p12205
aS'Ssemwanga, Deogratius'
p12206
aS'Stanojevic, Maja'
p12207
aS'Stefani, Mariane A'
p12208
aS'Sugiura, Wataru'
p12209
aS'Sungkanuparph, Somnuek'
p12210
aS'Tanuri, Amilcar'
p12211
aS'Tee, Kok Keng'
p12212
aS'Truong, Hong-Ha M'
p12213
aS'van de Vijver, David A M C'
p12214
aS'Vidal, Nicole'
p12215
aS'Yang, Chunfu'
p12216
aS'Yang, Rongge'
p12217
aS'Yebra, Gonzalo'
p12218
aS'Ioannidis, John P A'
p12219
aS'Vandamme, Anne-Mieke'
p12220
aS'Shafer, Robert W'
p12221
asS'JT'
p12222
S'PLoS medicine'
p12223
sS'LR'
p12224
S'20160428'
p12225
sS'PG'
p12226
S'e1001810'
p12227
sS'TI'
p12228
S'Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis.'
p12229
sS'RN'
p12230
(lp12231
S'0 (Anti-HIV Agents)'
p12232
aS'EC 2.7.7.- (reverse transcriptase, Human immunodeficiency virus 1)'
p12233
aS'EC 2.7.7.49 (HIV Reverse Transcriptase)'
p12234
asS'PL'
p12235
S'United States'
p12236
sS'TA'
p12237
S'PLoS Med'
p12238
sS'JID'
p12239
S'101231360'
p12240
sS'AB'
p12241
S'BACKGROUND: Regional and subtype-specific mutational patterns of HIV-1 transmitted drug resistance (TDR) are essential for informing first-line antiretroviral (ARV) therapy guidelines and designing diagnostic assays for use in regions where standard genotypic resistance testing is not affordable. We sought to understand the molecular epidemiology of TDR and to identify the HIV-1 drug-resistance mutations responsible for TDR in different regions and virus subtypes. METHODS AND FINDINGS: We reviewed all GenBank submissions of HIV-1 reverse transcriptase sequences with or without protease and identified 287 studies published between March 1, 2000, and December 31, 2013, with more than 25 recently or chronically infected ARV-naive individuals. These studies comprised 50,870 individuals from 111 countries. Each set of study sequences was analyzed for phylogenetic clustering and the presence of 93 surveillance drug-resistance mutations (SDRMs). The median overall TDR prevalence in sub-Saharan Africa (SSA), south/southeast Asia (SSEA), upper-income Asian countries, Latin America/Caribbean, Europe, and North America was 2.8%, 2.9%, 5.6%, 7.6%, 9.4%, and 11.5%, respectively. In SSA, there was a yearly 1.09-fold (95% CI: 1.05-1.14) increase in odds of TDR since national ARV scale-up attributable to an increase in non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance. The odds of NNRTI-associated TDR also increased in Latin America/Caribbean (odds ratio [OR] = 1.16; 95% CI: 1.06-1.25), North America (OR = 1.19; 95% CI: 1.12-1.26), Europe (OR = 1.07; 95% CI: 1.01-1.13), and upper-income Asian countries (OR = 1.33; 95% CI: 1.12-1.55). In SSEA, there was no significant change in the odds of TDR since national ARV scale-up (OR = 0.97; 95% CI: 0.92-1.02). An analysis limited to sequences with mixtures at less than 0.5% of their nucleotide positions-a proxy for recent infection-yielded trends comparable to those obtained using the complete dataset. Four NNRTI SDRMs-K101E, K103N, Y181C, and G190A-accounted for >80% of NNRTI-associated TDR in all regions and subtypes. Sixteen nucleoside reverse transcriptase inhibitor (NRTI) SDRMs accounted for >69% of NRTI-associated TDR in all regions and subtypes. In SSA and SSEA, 89% of NNRTI SDRMs were associated with high-level resistance to nevirapine or efavirenz, whereas only 27% of NRTI SDRMs were associated with high-level resistance to zidovudine, lamivudine, tenofovir, or abacavir. Of 763 viruses with TDR in SSA and SSEA, 725 (95%) were genetically dissimilar; 38 (5%) formed 19 sequence pairs. Inherent limitations of this study are that some cohorts may not represent the broader regional population and that studies were heterogeneous with respect to duration of infection prior to sampling. CONCLUSIONS: Most TDR strains in SSA and SSEA arose independently, suggesting that ARV regimens with a high genetic barrier to resistance combined with improved patient adherence may mitigate TDR increases by reducing the generation of new ARV-resistant strains. A small number of NNRTI-resistance mutations were responsible for most cases of high-level resistance, suggesting that inexpensive point-mutation assays to detect these mutations may be useful for pre-therapy screening in regions with high levels of TDR. In the context of a public health approach to ARV therapy, a reliable point-of-care genotypic resistance test could identify which patients should receive standard first-line therapy and which should receive a protease-inhibitor-containing regimen.'
p12242
sS'GR'
p12243
(lp12244
S'1P30A142853/PHS HHS/United States'
p12245
aS'MC_U950097144/Medical Research Council/United Kingdom'
p12246
aS'P30 MH062512/MH/NIMH NIH HHS/United States'
p12247
aS'R01 AI068581/AI/NIAID NIH HHS/United States'
p12248
aS'R01 AI068581/AI/NIAID NIH HHS/United States'
p12249
aS'R56 AI068581/AI/NIAID NIH HHS/United States'
p12250
asS'IP'
p12251
S'4'
sS'IS'
p12252
S'1549-1676 (Electronic) 1549-1277 (Linking)'
p12253
sS'PMC'
p12254
S'PMC4388826'
p12255
sS'DCOM'
p12256
S'20160418'
p12257
sS'AU'
p12258
(lp12259
S'Rhee SY'
p12260
aS'Blanco JL'
p12261
aS'Jordan MR'
p12262
aS'Taylor J'
p12263
aS'Lemey P'
p12264
aS'Varghese V'
p12265
aS'Hamers RL'
p12266
aS'Bertagnolio S'
p12267
aS'Rinke de Wit TF'
p12268
aS'Aghokeng AF'
p12269
aS'Albert J'
p12270
aS'Avi R'
p12271
aS'Avila-Rios S'
p12272
aS'Bessong PO'
p12273
aS'Brooks JI'
p12274
aS'Boucher CA'
p12275
aS'Brumme ZL'
p12276
aS'Busch MP'
p12277
aS'Bussmann H'
p12278
aS'Chaix ML'
p12279
aS'Chin BS'
p12280
aS"D'Aquin TT"
p12281
aS'De Gascun CF'
p12282
aS'Derache A'
p12283
aS'Descamps D'
p12284
aS'Deshpande AK'
p12285
aS'Djoko CF'
p12286
aS'Eshleman SH'
p12287
aS'Fleury H'
p12288
aS'Frange P'
p12289
aS'Fujisaki S'
p12290
aS'Harrigan PR'
p12291
aS'Hattori J'
p12292
aS'Holguin A'
p12293
aS'Hunt GM'
p12294
aS'Ichimura H'
p12295
aS'Kaleebu P'
p12296
aS'Katzenstein D'
p12297
aS'Kiertiburanakul S'
p12298
aS'Kim JH'
p12299
aS'Kim SS'
p12300
aS'Li Y'
p12301
aS'Lutsar I'
p12302
aS'Morris L'
p12303
aS'Ndembi N'
p12304
aS'Ng KP'
p12305
aS'Paranjape RS'
p12306
aS'Peeters M'
p12307
aS'Poljak M'
p12308
aS'Price MA'
p12309
aS'Ragonnet-Cronin ML'
p12310
aS'Reyes-Teran G'
p12311
aS'Rolland M'
p12312
aS'Sirivichayakul S'
p12313
aS'Smith DM'
p12314
aS'Soares MA'
p12315
aS'Soriano VV'
p12316
aS'Ssemwanga D'
p12317
aS'Stanojevic M'
p12318
aS'Stefani MA'
p12319
aS'Sugiura W'
p12320
aS'Sungkanuparph S'
p12321
aS'Tanuri A'
p12322
aS'Tee KK'
p12323
aS'Truong HM'
p12324
aS'van de Vijver DA'
p12325
aS'Vidal N'
p12326
aS'Yang C'
p12327
aS'Yang R'
p12328
aS'Yebra G'
p12329
aS'Ioannidis JP'
p12330
aS'Vandamme AM'
p12331
aS'Shafer RW'
p12332
asS'AD'
p12333
S"Department of Medicine, Stanford University, Stanford, California, United States of America. Leuven-University of Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Clinical and Epidemiological Virology, Leuven, Belgium. Hospital Clinic Universitari-Institut d'Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain. Tufts University School of Medicine, Boston, Massachusetts, United States of America. Department of Statistics, Stanford University, Stanford, California, United States of America. KU Leuven-University of Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Clinical and Epidemiological Virology, Leuven, Belgium. Department of Medicine, Stanford University, Stanford, California, United States of America. Department of Global Health and Internal Medicine, Academic Medical Center of the University of Amsterdam, and Amsterdam Institute for Global Health and Development, Amsterdam, the Netherlands. World Health Organization, Geneva, Switzerland. Department of Global Health and Internal Medicine, Academic Medical Center of the University of Amsterdam, and Amsterdam Institute for Global Health and Development, Amsterdam, the Netherlands. Virology Laboratory CREMER-IMPM, Yaounde, Cameroon. Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden; Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden. Department of Microbiology, University of Tartu, Tartu, Estonia. National Institute of Respiratory Diseases, Centre for Research in Infectious Diseases, Mexico City, Mexico. HIV/AIDS & Global Health Research Programme, Department of Microbiology, University of Venda, Thohoyandou, South Africa. National HIV and Retrovirology Laboratories, Public Health Agency of Canada, Ottawa, Ontario, Canada. Department of Viroscience, Erasmus Medical Centre, Erasmus University, Rotterdam, Netherlands. British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada; Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada. Blood Systems Research Institute, San Francisco, California, United States of America. Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana. Laboratoire de Virologie, Hopital Saint Louis, Universite Paris Diderot, INSERM U941, Paris, France. Center for Infectious Diseases, National Medical Center, Seoul, Republic of Korea. CIRBA-Programme PACCI, Abidjan, Cote d'Ivoire. UCD National Virus Reference Laboratory, University College Dublin, Dublin, Ireland. Department of Virology, Pitie-Salpetriere Hospital, Paris, France. Laboratoire de Virologie, Assistance Publique-Hopitaux de Paris Hopital Bichat-Claude Bernard, INSERM UMR 1137, Universite Paris Diderot, Paris, France. Department of Medicine, Grant Medical College and Sir Jamshedjee Jeejeebhoy Group of Hospitals, Mumbai, India. Global Viral Cameroon, Intendance Round About, EMAT/CRESAR, Yaounde, Cameroon. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America. Laboratoire de Virologie, Centre Hospitalier Universitaire de Bordeaux, CNRS UMR 5234, Universite de Bordeaux, Bordeaux, France. Microbiology Department, Hopital Necker-Enfants Malades, Paris, France. Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan. British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada. National Hospital Organization Nagoya Medical Center, Nagoya, Japan. Department of Microbiology, Hospital Universitario Ramon y Cajal, Instituto Ramon y Cajal de Investigacion Sanitaria, Madrid, Spain. Centre for HIV and STIs, National Institute for Communicable Diseases, Johannesburg, South Africa. Department of Viral Infection and International Health, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan. MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda. Department of Medicine, Stanford University, Stanford, California, United States of America. Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America. Division of AIDS, Korea National Institute of Health, Osong, Chungcheongbuk-do, Republic of Korea. State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China. Department of Microbiology, University of Tartu, Tartu, Estonia. Centre for HIV and STIs, National Institute for Communicable Diseases, Johannesburg, South Africa. Institute of Human Virology, Abuja, Nigeria. Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. National AIDS Research Institute, Indian Council of Medical Research, Pune, India. Unite Mixte Internationale 233, Institut de Recherche pour le Developpement, INSERM U1175, and University of Montpellier, 34394 Montpellier, France; Computational Biology Institute, Montpellier, France. Institute of Microbiology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. Department of Medical Affairs, International AIDS Vaccine Initiative, New York, New York, United States of America; Department of Epidemiology and Biostatistics, School of Medicine, University of California, San Francisco, California, United States of America. University of Edinburgh, Edinburgh, Scotland, United Kingdom. National Institute of Respiratory Diseases, Centre for Research in Infectious Diseases, Mexico City, Mexico. US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America. Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. University of California San Diego, La Jolla, California, United States of America. Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain. MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda. Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia. Federal University of Goias, Goias, Brazil. National Hospital Organization Nagoya Medical Center, Nagoya, Japan. Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. Department of Medicine, University of California, San Francisco, California, United States of America. Department of Viroscience, Erasmus Medical Centre, Erasmus University, Rotterdam, Netherlands. Institut de Recherche pour le Developpement, University of Montpellier 1, Montpellier, France. International Laboratory Branch, Division of Global HIV/AIDS, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America. State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China. Department of Microbiology, Hospital Universitario Ramon y Cajal, Instituto Ramon y Cajal de Investigacion Sanitaria, Madrid, Spain. Stanford Prevention Research Center, Department of Medicine, Stanford University, Stanford, California, United States of America; Meta-Research Innovation Center at Stanford, Stanford University, Stanford, California, United States of America. KU Leuven-University of Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Clinical and Epidemiological Virology, Leuven, Belgium; Global Health and Tropical Medicine, Unidade de Microbiologia, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisbon, Portugal. Department of Medicine, Stanford University, Stanford, California, United States of America."
p12334
sS'VI'
p12335
S'12'
p12336
sS'MHDA'
p12337
S'2016/04/19 06:00'
p12338
sS'PHST'
p12339
(lp12340
S'2015/04 [ecollection]'
p12341
aS'2014/07/17 [received]'
p12342
aS'2015/02/27 [accepted]'
p12343
aS'2015/04/07 [epublish]'
p12344
asS'OID'
p12345
(lp12346
S'NLM: PMC4388826'
p12347
asS'MH'
p12348
(lp12349
S'Africa'
p12350
aS'Americas'
p12351
aS'Anti-HIV Agents/pharmacology/*therapeutic use'
p12352
aS'Asia'
p12353
aS'*Base Sequence'
p12354
aS'*Drug Resistance, Viral'
p12355
aS'Europe'
p12356
aS'HIV Infections/*drug therapy/virology'
p12357
aS'HIV Reverse Transcriptase/antagonists & inhibitors/*genetics'
p12358
aS'HIV-1/drug effects/*genetics'
p12359
aS'Humans'
p12360
aS'Molecular Epidemiology'
p12361
aS'*Mutation'
p12362
aS'Phylogeny'
p12363
asS'EDAT'
p12364
S'2015/04/08 06:00'
p12365
sS'SO'
p12366
S'PLoS Med. 2015 Apr 7;12(4):e1001810. doi: 10.1371/journal.pmed.1001810. eCollection 2015 Apr.'
p12367
sS'SB'
p12368
S'IM'
p12369
sS'PMID'
p12370
S'25849352'
p12371
sS'PST'
p12372
S'epublish'
p12373
stRp12374
ag2
(g3
g4
(dp12375
S'LID'
p12376
S'10.1111/tmi.12509 [doi]'
p12377
sS'STAT'
p12378
S'MEDLINE'
p12379
sS'DEP'
p12380
S'20150402'
p12381
sS'CI'
p12382
(lp12383
S'(c) 2015 John Wiley & Sons Ltd.'
p12384
asS'DA'
p12385
S'20150602'
p12386
sS'AID'
p12387
(lp12388
S'10.1111/tmi.12509 [doi]'
p12389
asS'CRDT'
p12390
(lp12391
S'2015/03/19 06:00'
p12392
asS'DP'
p12393
S'2015 Jul'
p12394
sS'OWN'
p12395
S'NLM'
p12396
sS'PT'
p12397
(lp12398
S'Comparative Study'
p12399
aS'Journal Article'
p12400
aS"Research Support, Non-U.S. Gov't"
p12401
asS'LA'
p12402
(lp12403
S'eng'
p12404
asS'FAU'
p12405
(lp12406
S'Labhardt, Niklaus D'
p12407
aS'Bader, Joelle'
p12408
aS'Lejone, Thabo Ismael'
p12409
aS'Ringera, Isaac'
p12410
aS'Puga, Daniel'
p12411
aS'Glass, Tracy R'
p12412
aS'Klimkait, Thomas'
p12413
asS'JT'
p12414
S'Tropical medicine & international health : TM & IH'
p12415
sS'LR'
p12416
S'20151119'
p12417
sS'PG'
p12418
S'914-8'
p12419
sS'TI'
p12420
S'Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?'
p12421
sS'RN'
p12422
(lp12423
S'0 (Anti-HIV Agents)'
p12424
aS'0 (Benzoxazines)'
p12425
aS'0 (Organophosphonates)'
p12426
aS'2T8Q726O95 (Lamivudine)'
p12427
aS'4B9XT59T7S (Zidovudine)'
p12428
aS'99YXE507IL (Tenofovir)'
p12429
aS'JAC85A2161 (Adenine)'
p12430
aS'JE6H2O27P8 (efavirenz)'
p12431
asS'PL'
p12432
S'England'
p12433
sS'TA'
p12434
S'Trop Med Int Health'
p12435
sS'JID'
p12436
S'9610576'
p12437
sS'AB'
p12438
S"OBJECTIVE: To compare virologic success between adult patients on tenofovir (TDF) and zidovudine (AZT)-containing first-line antiretroviral (ART) regimens in 10 rural clinics in Lesotho, Southern Africa. METHODS: Multicentre cross-sectional study, patients >/=16 years, on first-line ART >/=6 months, receiving AZT/lamivudine (3TC) or TDF/3TC combined with efavirenz (EFV) or nevirapine (NVP). Patient characteristics and clinical/therapeutic history were collected on the day of blood draw for viral load (VL). Analysis was stratified for non-nucleoside reverse transcriptase inhibitor (EFV or NVP). A logistic regression model weighted for patients' baseline characteristics was used to assess the likelihood of virologic success (<80 copies/ml) in patients with TDF- as compared to AZT-backbones. RESULTS: In total 1539 patients were included in the analysis. Most were clinically and immunologically stable (clinical failure: 2.7% (AZT) and 2.8% (TDF); immunological failure: 4.6% (AZT) and 4.8% (TDF)). In EFV-based regimens (n = 1162), TDF was significantly associated with higher rates of virologic suppression than AZT (93.8% vs. 88.1%; weighted odds ratio: 2.15 (95% CI: 1.29-3.58; P = 0.003)). In NVP-based regimens, a similar trend was observed, but not significant (89.4% vs. 86.7%; 1.99 (0.83-4.75, P = 0.121)). CONCLUSION: These findings support the WHO recommendation to use TDF/3TC/EFV as first-line regimen. They do, however, not support the recommendation that patients who are clinically stable on AZT should continue on this first-line regimen."
p12439
sS'AD'
p12440
S'Medical Services and Diagnostics, Clinical Research Unit, Swiss Tropical and Public Health Institute, Basel, Switzerland. University of Basel, Basel, Switzerland. Molecular Virology, Department Biomedicine - Petersplatz, University of Basel, Basel, Switzerland. SolidarMed, Swiss Organization for Health in Africa, Maseru, Lesotho. SolidarMed, Swiss Organization for Health in Africa, Maseru, Lesotho. SolidarMed, Swiss Organization for Health in Africa, Maseru, Lesotho. University of Basel, Basel, Switzerland. Biostatistics Department, Epidemiology and Public Health Unit, Swiss Tropical and Public Health Institute, Basel, Switzerland. Molecular Virology, Department Biomedicine - Petersplatz, University of Basel, Basel, Switzerland.'
p12441
sS'IP'
p12442
S'7'
sS'IS'
p12443
S'1365-3156 (Electronic) 1360-2276 (Linking)'
p12444
sS'DCOM'
p12445
S'20150807'
p12446
sS'AU'
p12447
(lp12448
S'Labhardt ND'
p12449
aS'Bader J'
p12450
aS'Lejone TI'
p12451
aS'Ringera I'
p12452
aS'Puga D'
p12453
aS'Glass TR'
p12454
aS'Klimkait T'
p12455
asS'VI'
p12456
S'20'
p12457
sS'MHDA'
p12458
S'2015/08/08 06:00'
p12459
sS'PHST'
p12460
(lp12461
S'2015/04/02 [aheadofprint]'
p12462
asS'OTO'
p12463
(lp12464
S'NOTNLM'
p12465
asS'MH'
p12466
(lp12467
S'Adenine/*analogs & derivatives/pharmacology/therapeutic use'
p12468
aS'Adult'
p12469
aS'Anti-HIV Agents/pharmacology/*therapeutic use'
p12470
aS'*Antiretroviral Therapy, Highly Active'
p12471
aS'Benzoxazines/therapeutic use'
p12472
aS'Cross-Sectional Studies'
p12473
aS'Female'
p12474
aS'HIV/*drug effects'
p12475
aS'HIV Infections/*drug therapy/virology'
p12476
aS'Health Resources'
p12477
aS'Humans'
p12478
aS'Lamivudine/therapeutic use'
p12479
aS'Lesotho'
p12480
aS'Logistic Models'
p12481
aS'Male'
p12482
aS'Middle Aged'
p12483
aS'Organophosphonates/pharmacology/*therapeutic use'
p12484
aS'Tenofovir'
p12485
aS'*Viral Load'
p12486
aS'Zidovudine/pharmacology/*therapeutic use'
p12487
asS'EDAT'
p12488
S'2015/03/19 06:00'
p12489
sS'SO'
p12490
S'Trop Med Int Health. 2015 Jul;20(7):914-8. doi: 10.1111/tmi.12509. Epub 2015 Apr 2.'
p12491
sS'SB'
p12492
S'IM'
p12493
sS'PMID'
p12494
S'25782332'
p12495
sS'OT'
p12496
(lp12497
S'Africa'
p12498
aS'Carga Viral'
p12499
aS'HIV'
p12500
aS'Inhibidor Nucleosido de la Transcriptasa Inversa'
p12501
aS'Tenofovir'
p12502
aS'Terapia Antirretroviral'
p12503
aS'VIH'
p12504
aS'Zidovudina'
p12505
aS'anti-retroviral therapy'
p12506
aS'charge virale'
p12507
aS'inhibiteur de la transcriptase inverse nucleosidique'
p12508
aS"l'Afrique"
p12509
aS'nucleoside reverse transcriptase inhibitor'
p12510
aS'tenofovir'
p12511
aS'therapie antiretrovirale'
p12512
aS'tenofovir'
p12513
aS'viral load'
p12514
aS'zidovudine'
p12515
aS'Africa'
p12516
asS'PST'
p12517
S'ppublish'
p12518
stRp12519
ag2
(g3
g4
(dp12520
S'LID'
p12521
S'10.1371/journal.pmed.1001801 [doi]'
p12522
sS'STAT'
p12523
S'MEDLINE'
p12524
sS'DEP'
p12525
S'20150317'
p12526
sS'CIN'
p12527
(lp12528
S'PLoS Med. 2015 Mar;12(3):e1001803. PMID: 25781617'
p12529
asS'DA'
p12530
S'20150318'
p12531
sS'AID'
p12532
(lp12533
S'10.1371/journal.pmed.1001801 [doi]'
p12534
aS'PMEDICINE-D-14-01583 [pii]'
p12535
asS'CRDT'
p12536
(lp12537
S'2015/03/18 06:00'
p12538
asS'DP'
p12539
S'2015 Mar'
p12540
sS'AD'
p12541
S'Center for Computational Biology and Bioinformatics, The University of Texas at Austin, Austin, Texas, United States of America. Department of Biology, McMaster University, Hamilton, Ontario, Canada. Yale School of Public Health, Yale University, New Haven, Connecticut, United States of America; Department of Ecology and Evolution, Yale University, New Haven, Connecticut, United States of America. Department of Integrative Biology, The University of Texas at Austin, Austin, Texas, United States of America; The Santa Fe Institute, Santa Fe, New Mexico, United States of America.'
p12542
sS'OWN'
p12543
S'NLM'
p12544
sS'PT'
p12545
(lp12546
S'Journal Article'
p12547
aS'Research Support, N.I.H., Extramural'
p12548
aS"Research Support, Non-U.S. Gov't"
p12549
asS'LA'
p12550
(lp12551
S'eng'
p12552
asS'FAU'
p12553
(lp12554
S'Bellan, Steve E'
p12555
aS'Dushoff, Jonathan'
p12556
aS'Galvani, Alison P'
p12557
aS'Meyers, Lauren Ancel'
p12558
asS'JT'
p12559
S'PLoS medicine'
p12560
sS'LR'
p12561
S'20150415'
p12562
sS'PG'
p12563
S'e1001801'
p12564
sS'TI'
p12565
S'Reassessment of HIV-1 acute phase infectivity: accounting for heterogeneity and study design with simulated cohorts.'
p12566
sS'PL'
p12567
S'United States'
p12568
sS'TA'
p12569
S'PLoS Med'
p12570
sS'JID'
p12571
S'101231360'
p12572
sS'AB'
p12573
S"BACKGROUND: The infectivity of the HIV-1 acute phase has been directly measured only once, from a retrospectively identified cohort of serodiscordant heterosexual couples in Rakai, Uganda. Analyses of this cohort underlie the widespread view that the acute phase is highly infectious, even more so than would be predicted from its elevated viral load, and that transmission occurring shortly after infection may therefore compromise interventions that rely on diagnosis and treatment, such as antiretroviral treatment as prevention (TasP). Here, we re-estimate the duration and relative infectivity of the acute phase, while accounting for several possible sources of bias in published estimates, including the retrospective cohort exclusion criteria and unmeasured heterogeneity in risk. METHODS AND FINDINGS: We estimated acute phase infectivity using two approaches. First, we combined viral load trajectories and viral load-infectivity relationships to estimate infectivity trajectories over the course of infection, under the assumption that elevated acute phase infectivity is caused by elevated viral load alone. Second, we estimated the relative hazard of transmission during the acute phase versus the chronic phase (RHacute) and the acute phase duration (dacute) by fitting a couples transmission model to the Rakai retrospective cohort using approximate Bayesian computation. Our model fit the data well and accounted for characteristics overlooked by previous analyses, including individual heterogeneity in infectiousness and susceptibility and the retrospective cohort's exclusion of couples that were recorded as serodiscordant only once before being censored by loss to follow-up, couple dissolution, or study termination. Finally, we replicated two highly cited analyses of the Rakai data on simulated data to identify biases underlying the discrepancies between previous estimates and our own. From the Rakai data, we estimated RHacute = 5.3 (95% credibility interval [95% CrI]: 0.79-57) and dacute = 1.7 mo (95% CrI: 0.55-6.8). The wide credibility intervals reflect an inability to distinguish a long, mildly infectious acute phase from a short, highly infectious acute phase, given the 10-mo Rakai observation intervals. The total additional risk, measured as excess hazard-months attributable to the acute phase (EHMacute) can be estimated more precisely: EHMacute = (RHacute - 1) x dacute, and should be interpreted with respect to the 120 hazard-months generated by a constant untreated chronic phase infectivity over 10 y of infection. From the Rakai data, we estimated that EHMacute = 8.4 (95% CrI: -0.27 to 64). This estimate is considerably lower than previously published estimates, and consistent with our independent estimate from viral load trajectories, 5.6 (95% confidence interval: 3.3-9.1). We found that previous overestimates likely stemmed from failure to account for risk heterogeneity and bias resulting from the retrospective cohort study design. Our results reflect the interaction between the retrospective cohort exclusion criteria and high (47%) rates of censorship amongst incident serodiscordant couples in the Rakai study due to loss to follow-up, couple dissolution, or study termination. We estimated excess physiological infectivity during the acute phase from couples data, but not the proportion of transmission attributable to the acute phase, which would require data on the broader population's sexual network structure. CONCLUSIONS: Previous EHMacute estimates relying on the Rakai retrospective cohort data range from 31 to 141. Our results indicate that these are substantial overestimates of HIV-1 acute phase infectivity, biased by unmodeled heterogeneity in transmission rates between couples and by inconsistent censoring. Elevated acute phase infectivity is therefore less likely to undermine TasP interventions than previously thought. Heterogeneity in infectiousness and susceptibility may still play an important role in intervention success and deserves attention in future analyses."
p12574
sS'GR'
p12575
(lp12576
S'R25 GM102149/GM/NIGMS NIH HHS/United States'
p12577
aS'R25GM102149/GM/NIGMS NIH HHS/United States'
p12578
aS'U01 GM087719/GM/NIGMS NIH HHS/United States'
p12579
aS'U01GM087719/GM/NIGMS NIH HHS/United States'
p12580
asS'IP'
p12581
S'3'
sS'IS'
p12582
S'1549-1676 (Electronic) 1549-1277 (Linking)'
p12583
sS'PMC'
p12584
S'PMC4363602'
p12585
sS'DCOM'
p12586
S'20160113'
p12587
sS'AU'
p12588
(lp12589
S'Bellan SE'
p12590
aS'Dushoff J'
p12591
aS'Galvani AP'
p12592
aS'Meyers LA'
p12593
asS'VI'
p12594
S'12'
p12595
sS'MHDA'
p12596
S'2016/01/14 06:00'
p12597
sS'PHST'
p12598
(lp12599
S'2015/03 [ecollection]'
p12600
aS'2014/05/13 [received]'
p12601
aS'2015/02/04 [accepted]'
p12602
aS'2015/03/17 [epublish]'
p12603
asS'OID'
p12604
(lp12605
S'NLM: PMC4363602'
p12606
asS'MH'
p12607
(lp12608
S'Acute Disease'
p12609
aS'*Acute-Phase Reaction'
p12610
aS'Bayes Theorem'
p12611
aS'*Bias (Epidemiology)'
p12612
aS'Cohort Studies'
p12613
aS'Computer Simulation'
p12614
aS'Family Characteristics'
p12615
aS'HIV Infections/pathology/*transmission/virology'
p12616
aS'HIV Seropositivity/virology'
p12617
aS'*HIV-1'
p12618
aS'Heterosexuality'
p12619
aS'Humans'
p12620
aS'Patient Selection'
p12621
aS'*Research Design/statistics & numerical data'
p12622
aS'Retrospective Studies'
p12623
aS'Risk'
p12624
aS'Sexual Behavior'
p12625
aS'*Sexual Partners'
p12626
aS'Uganda'
p12627
aS'*Viral Load'
p12628
asS'EDAT'
p12629
S'2015/03/18 06:00'
p12630
sS'SO'
p12631
S'PLoS Med. 2015 Mar 17;12(3):e1001801. doi: 10.1371/journal.pmed.1001801. eCollection 2015 Mar.'
p12632
sS'SB'
p12633
S'IM'
p12634
sS'PMID'
p12635
S'25781323'
p12636
sS'PST'
p12637
S'epublish'
p12638
stRp12639
ag2
(g3
g4
(dp12640
S'LID'
p12641
S'10.1111/tmi.12507 [doi]'
p12642
sS'STAT'
p12643
S'MEDLINE'
p12644
sS'DEP'
p12645
S'20150402'
p12646
sS'CI'
p12647
(lp12648
S'(c) 2015 The Authors. Tropical Medicine & International Health Published by John'
p12649
aS'Wiley & Sons Ltd.'
p12650
asS'DA'
p12651
S'20150602'
p12652
sS'AID'
p12653
(lp12654
S'10.1111/tmi.12507 [doi]'
p12655
asS'CRDT'
p12656
(lp12657
S'2015/03/18 06:00'
p12658
asS'DP'
p12659
S'2015 Jul'
p12660
sS'OWN'
p12661
S'NLM'
p12662
sS'PT'
p12663
(lp12664
S'Journal Article'
p12665
aS"Research Support, Non-U.S. Gov't"
p12666
asS'LA'
p12667
(lp12668
S'eng'
p12669
asS'FAU'
p12670
(lp12671
S'Vanobberghen, Fiona M'
p12672
aS'Kilama, Bonita'
p12673
aS'Wringe, Alison'
p12674
aS'Ramadhani, Angela'
p12675
aS'Zaba, Basia'
p12676
aS'Mmbando, Donan'
p12677
aS'Todd, Jim'
p12678
asS'JT'
p12679
S'Tropical medicine & international health : TM & IH'
p12680
sS'LR'
p12681
S'20160217'
p12682
sS'PG'
p12683
S'880-92'
p12684
sS'TI'
p12685
S'Immunological failure of first-line and switch to second-line antiretroviral therapy among HIV-infected persons in Tanzania: analysis of routinely collected national data.'
p12686
sS'RN'
p12687
(lp12688
S'0 (Anti-HIV Agents)'
p12689
asS'PL'
p12690
S'England'
p12691
sS'TA'
p12692
S'Trop Med Int Health'
p12693
sS'JID'
p12694
S'9610576'
p12695
sS'AB'
p12696
S'OBJECTIVES: Rates of first-line treatment failure and switches to second-line therapy are key indicators for national HIV programmes. We assessed immunological treatment failure defined by WHO criteria in the Tanzanian national HIV programme. METHODS: We included adults initiating first-line therapy in 2004-2011 with a pre-treatment CD4 count, and >/=6-months of follow-up. We assessed subhazard ratios (SHR) for immunological treatment failure, and subsequent switch to second-line therapy, using competing risks methods to account for deaths. RESULTS: Of 121 308 adults, 7% experienced immunological treatment failure, and 2% died without observed immunological treatment failure, over a median 1.7 years. The 6-year cumulative probability of immunological treatment failure was 19.0% (95% CI 18.5, 19.7) and of death, 5.1% (4.8, 5.4). Immunological treatment failure predictors included earlier year of treatment initiation (P < 0.001), initiation in lower level facilities (SHR = 2.23 [2.03, 2.45] for dispensaries vs. hospitals), being male (1.27 [1.19, 1.33]) and initiation at low or high CD4 counts (for example, 1.78 [1.65, 1.92] and 5.33 [4.65, 6.10] for <50 and >/=500 vs. 200-349 cells/mm(3) , respectively). Of 7382 participants in the time-to-switch analysis, 6% switched and 5% died before switching. Four years after immunological treatment failure, the cumulative probability of switching was 7.3% (6.6, 8.0) and of death, 6.8% (6.0, 7.6). Those who immunologically failed in dispensaries, health centres and government facilities were least likely to switch. CONCLUSIONS: Immunological treatment failure rates and unmet need for second-line therapy are high in Tanzania; virological monitoring, at least for persons with immunological treatment failure, is required to minimise unnecessary switches to second-line therapy. Lower level government health facilities need more support to reduce treatment failure rates and improve second-line therapy uptake to sustain the benefits of increased coverage.'
p12697
sS'AD'
p12698
S'London School of Hygiene & Tropical Medicine, London, UK. Mwanza Intervention Trials Unit, National Institute for Medical Research, Mwanza, Tanzania. National AIDS Control Program, Dar es Salaam, Tanzania. London School of Hygiene & Tropical Medicine, London, UK. National AIDS Control Program, Dar es Salaam, Tanzania. London School of Hygiene & Tropical Medicine, London, UK. Ministry of Health and Social Welfare, Dar es Salaam, Tanzania. London School of Hygiene & Tropical Medicine, London, UK. Kilimanjaro Christian Medical University College, Moshi, Tanzania.'
p12699
sS'IP'
p12700
S'7'
sS'IS'
p12701
S'1365-3156 (Electronic) 1360-2276 (Linking)'
p12702
sS'PMC'
p12703
S'PMC4672690'
p12704
sS'DCOM'
p12705
S'20150807'
p12706
sS'AU'
p12707
(lp12708
S'Vanobberghen FM'
p12709
aS'Kilama B'
p12710
aS'Wringe A'
p12711
aS'Ramadhani A'
p12712
aS'Zaba B'
p12713
aS'Mmbando D'
p12714
aS'Todd J'
p12715
asS'VI'
p12716
S'20'
p12717
sS'MHDA'
p12718
S'2015/08/08 06:00'
p12719
sS'PHST'
p12720
(lp12721
S'2015/04/02 [aheadofprint]'
p12722
asS'OTO'
p12723
(lp12724
S'NOTNLM'
p12725
asS'MH'
p12726
(lp12727
S'Adolescent'
p12728
aS'Adult'
p12729
aS'Anti-HIV Agents/*therapeutic use'
p12730
aS'*Antiretroviral Therapy, Highly Active'
p12731
aS'CD4 Lymphocyte Count'
p12732
aS'Female'
p12733
aS'HIV Infections/*drug therapy/immunology/mortality'
p12734
aS'Humans'
p12735
aS'Male'
p12736
aS'Middle Aged'
p12737
aS'Tanzania/epidemiology'
p12738
aS'Treatment Failure'
p12739
aS'Viral Load'
p12740
aS'Young Adult'
p12741
asS'EDAT'
p12742
S'2015/03/18 06:00'
p12743
sS'SO'
p12744
S'Trop Med Int Health. 2015 Jul;20(7):880-92. doi: 10.1111/tmi.12507. Epub 2015 Apr 2.'
p12745
sS'SB'
p12746
S'IM'
p12747
sS'PMID'
p12748
S'25779383'
p12749
sS'OT'
p12750
(lp12751
S'Adulto'
p12752
aS'CD4 lymphocyte count'
p12753
aS'Tanzania'
p12754
aS'Tanzanie'
p12755
aS'adult'
p12756
aS'adulte'
p12757
aS'antiretroviral therapy'
p12758
aS'facteurs de risque'
p12759
aS'factores de riesgo'
p12760
aS'fallo terapeutico'
p12761
aS'numeration des lymphocytes CD4'
p12762
aS'risk factors'
p12763
aS'terapia antirretroviral, conteo de linfocitos CD4'
p12764
aS'therapie antiretrovirale'
p12765
aS'treatment failure'
p12766
aS'echec du traitement'
p12767
asS'PST'
p12768
S'ppublish'
p12769
stRp12770
ag2
(g3
g4
(dp12771
S'LID'
p12772
S'10.1093/cid/civ195 [doi]'
p12773
sS'STAT'
p12774
S'MEDLINE'
p12775
sS'DEP'
p12776
S'20150316'
p12777
sS'CI'
p12778
(lp12779
S'(c) The Author 2015. Published by Oxford University Press on behalf of the'
p12780
aS'Infectious Diseases Society of America.'
p12781
asS'DA'
p12782
S'20150613'
p12783
sS'AID'
p12784
(lp12785
S'civ195 [pii]'
p12786
aS'10.1093/cid/civ195 [doi]'
p12787
asS'CRDT'
p12788
(lp12789
S'2015/03/18 06:00'
p12790
asS'DP'
p12791
S'2015 Jul 1'
p12792
sS'AD'
p12793
S'Malawi Liverpool Wellcome Trust Clinical Research Programme, College of Medicine, University of Malawi, Blantyre Liverpool Heart and Chest Hospital Liverpool School of Tropical Medicine, United Kingdom Department of Microbiology Department of Medicine, College of Medicine, University of Malawi, Blantyre. Malawi Liverpool Wellcome Trust Clinical Research Programme, College of Medicine, University of Malawi, Blantyre Department of Microbiology Department of Medicine, College of Medicine, University of Malawi, Blantyre. Department of Infection, Immunity and Inflammation, University of Leicester. Department of Pharmacology, University of Liverpool. Department of Microbiology London School of Hygiene and Tropical Medicine. Department of Medicine, College of Medicine, University of Malawi, Blantyre. Malawi Liverpool Wellcome Trust Clinical Research Programme, College of Medicine, University of Malawi, Blantyre Department of Medicine, College of Medicine, University of Malawi, Blantyre. Malawi Liverpool Wellcome Trust Clinical Research Programme, College of Medicine, University of Malawi, Blantyre Department of Microbiology London School of Hygiene and Tropical Medicine. Department of Infection, Immunity and Inflammation, University of Leicester. Malawi Liverpool Wellcome Trust Clinical Research Programme, College of Medicine, University of Malawi, Blantyre Department of Medicine, College of Medicine, University of Malawi, Blantyre Institute of Infection and Global Health, University of Liverpool, United Kingdom.'
p12794
sS'OWN'
p12795
S'NLM'
p12796
sS'PT'
p12797
(lp12798
S'Journal Article'
p12799
aS"Research Support, Non-U.S. Gov't"
p12800
asS'LA'
p12801
(lp12802
S'eng'
p12803
asS'FAU'
p12804
(lp12805
S'Sloan, Derek J'
p12806
aS'Mwandumba, Henry C'
p12807
aS'Garton, Natalie J'
p12808
aS'Khoo, Saye H'
p12809
aS'Butterworth, Anthony E'
p12810
aS'Allain, Theresa J'
p12811
aS'Heyderman, Robert S'
p12812
aS'Corbett, Elizabeth L'
p12813
aS'Barer, Mike R'
p12814
aS'Davies, Geraint R'
p12815
asS'JT'
p12816
S'Clinical infectious diseases : an official publication of the Infectious Diseases Society of America'
p12817
sS'LR'
p12818
S'20160713'
p12819
sS'PG'
p12820
S'1-8'
p12821
sS'TI'
p12822
S'Pharmacodynamic Modeling of Bacillary Elimination Rates and Detection of Bacterial Lipid Bodies in Sputum to Predict and Understand Outcomes in Treatment of Pulmonary Tuberculosis.'
p12823
sS'PL'
p12824
S'United States'
p12825
sS'TA'
p12826
S'Clin Infect Dis'
p12827
sS'JID'
p12828
S'9203213'
p12829
sS'AB'
p12830
S'BACKGROUND: Antibiotic-tolerant bacterial persistence prevents treatment shortening in drug-susceptible tuberculosis, and accumulation of intracellular lipid bodies has been proposed to identify a persister phenotype of Mycobacterium tuberculosis cells. In Malawi, we modeled bacillary elimination rates (BERs) from sputum cultures and calculated the percentage of lipid body-positive acid-fast bacilli (%LB + AFB) on sputum smears. We assessed whether these putative measurements of persistence predict unfavorable outcomes (treatment failure/relapse). METHODS: Adults with pulmonary tuberculosis received standard 6-month therapy. Sputum samples were collected during the first 8 weeks for serial sputum colony counting (SSCC) on agar and time-to positivity (TTP) measurement in mycobacterial growth indicator tubes. BERs were extracted from nonlinear and linear mixed-effects models, respectively, fitted to these datasets. The %LB + AFB counts were assessed by fluorescence microscopy. Patients were followed until 1 year posttreatment. Individual BERs and %LB + AFB counts were related to final outcomes. RESULTS: One hundred and thirty-three patients (56% HIV coinfected) participated, and 15 unfavorable outcomes were reported. These were inversely associated with faster sterilization phase bacillary elimination from the SSCC model (odds ratio [OR], 0.39; 95% confidence interval [CI], .22-.70) and a faster BER from the TTP model (OR, 0.71; 95% CI, .55-.94). Higher %LB + AFB counts on day 21-28 were recorded in patients who suffered unfavorable final outcomes compared with those who achieved stable cure (P = .008). CONCLUSIONS: Modeling BERs predicts final outcome, and high %LB + AFB counts 3-4 weeks into therapy may identify a persister bacterial phenotype. These methods deserve further evaluation as surrogate endpoints for clinical trials.'
p12831
sS'GR'
p12832
(lp12833
S'086757/Z/08//Wellcome Trust/United Kingdom'
p12834
aS'091769/Wellcome Trust/United Kingdom'
p12835
aS'100714/Wellcome Trust/United Kingdom'
p12836
aS'100890/Wellcome Trust/United Kingdom'
p12837
aS'G0300403/Medical Research Council/United Kingdom'
p12838
aS'G0901364/Medical Research Council/United Kingdom'
p12839
asS'IP'
p12840
S'1'
sS'IS'
p12841
S'1537-6591 (Electronic) 1058-4838 (Linking)'
p12842
sS'PMC'
p12843
S'PMC4463005'
p12844
sS'DCOM'
p12845
S'20160229'
p12846
sS'AU'
p12847
(lp12848
S'Sloan DJ'
p12849
aS'Mwandumba HC'
p12850
aS'Garton NJ'
p12851
aS'Khoo SH'
p12852
aS'Butterworth AE'
p12853
aS'Allain TJ'
p12854
aS'Heyderman RS'
p12855
aS'Corbett EL'
p12856
aS'Barer MR'
p12857
aS'Davies GR'
p12858
asS'VI'
p12859
S'61'
p12860
sS'MHDA'
p12861
S'2016/03/02 06:00'
p12862
sS'PHST'
p12863
(lp12864
S'2014/11/30 [received]'
p12865
aS'2015/02/26 [accepted]'
p12866
aS'2015/03/16 [aheadofprint]'
p12867
asS'OTO'
p12868
(lp12869
S'NOTNLM'
p12870
asS'OID'
p12871
(lp12872
S'NLM: PMC4463005'
p12873
asS'MH'
p12874
(lp12875
S'Adolescent'
p12876
aS'Adult'
p12877
aS'Aged'
p12878
aS'Colony Count, Microbial'
p12879
aS'Drug Monitoring/*methods'
p12880
aS'Female'
p12881
aS'Humans'
p12882
aS'*Lipid Droplets'
p12883
aS'Malawi'
p12884
aS'Male'
p12885
aS'Middle Aged'
p12886
aS'Models, Theoretical'
p12887
aS'Mycobacterium tuberculosis/*isolation & purification/*ultrastructure'
p12888
aS'Prospective Studies'
p12889
aS'Sputum/*cytology/*microbiology'
p12890
aS'Treatment Outcome'
p12891
aS'Tuberculosis, Pulmonary/*drug therapy'
p12892
aS'Young Adult'
p12893
asS'EDAT'
p12894
S'2015/03/18 06:00'
p12895
sS'SO'
p12896
S'Clin Infect Dis. 2015 Jul 1;61(1):1-8. doi: 10.1093/cid/civ195. Epub 2015 Mar 16.'
p12897
sS'SB'
p12898
S'IM'
p12899
sS'PMID'
p12900
S'25778753'
p12901
sS'OT'
p12902
(lp12903
S'clinical trials'
p12904
aS'lipid bodies'
p12905
aS'persistence'
p12906
aS'sterilizing activity'
p12907
aS'tuberculosis'
p12908
asS'PST'
p12909
S'ppublish'
p12910
stRp12911
ag2
(g3
g4
(dp12912
S'LID'
p12913
S'10.3390/ijms16035830 [doi]'
p12914
sS'STAT'
p12915
S'MEDLINE'
p12916
sS'DEP'
p12917
S'20150312'
p12918
sS'DA'
p12919
S'20150317'
p12920
sS'AID'
p12921
(lp12922
S'ijms16035830 [pii]'
p12923
aS'10.3390/ijms16035830 [doi]'
p12924
asS'CRDT'
p12925
(lp12926
S'2015/03/17 06:00'
p12927
asS'DP'
p12928
S'2015'
p12929
sS'OWN'
p12930
S'NLM'
p12931
sS'PT'
p12932
(lp12933
S'Journal Article'
p12934
asS'LA'
p12935
(lp12936
S'eng'
p12937
asS'FAU'
p12938
(lp12939
S'Ciccacci, Cinzia'
p12940
aS'Rufini, Sara'
p12941
aS'Mancinelli, Sandro'
p12942
aS'Buonomo, Ersilia'
p12943
aS'Giardina, Emiliano'
p12944
aS'Scarcella, Paola'
p12945
aS'Marazzi, Maria C'
p12946
aS'Novelli, Giuseppe'
p12947
aS'Palombi, Leonardo'
p12948
aS'Borgiani, Paola'
p12949
asS'JT'
p12950
S'International journal of molecular sciences'
p12951
sS'LR'
p12952
S'20150522'
p12953
sS'PG'
p12954
S'5830-8'
p12955
sS'TI'
p12956
S'A pharmacogenetics study in Mozambican patients treated with nevirapine: full resequencing of TRAF3IP2 gene shows a novel association with SJS/TEN susceptibility.'
p12957
sS'RN'
p12958
(lp12959
S'0 (Anti-HIV Agents)'
p12960
aS'0 (TRAF3IP2 protein, human)'
p12961
aS'0 (Tumor Necrosis Factor Receptor-Associated Peptides and Proteins)'
p12962
aS'99DK7FVK1H (Nevirapine)'
p12963
asS'PL'
p12964
S'Switzerland'
p12965
sS'TA'
p12966
S'Int J Mol Sci'
p12967
sS'JID'
p12968
S'101092791'
p12969
sS'AB'
p12970
S'Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are severe adverse drug reactions, characterized by extensive epidermal detachment and erosions of mucous membrane. SJS/TEN is one of the most serious adverse reactions to Nevirapine (NVP) treatment, commonly used in developing countries as first-line treatment of human immunodeficiency virus infection. In the last years TRAF3IP2 gene variants had been described as associated with susceptibility to several diseases such as psoriasis and psoriatic arthritis. We hypothesized that this gene, involved in immune response and in NF-kappaB activation, could also be implicated in the SJS/TEN susceptibility. We performed a full resequencing of TRAF3IP2 gene in a population of patients treated with NVP. Twenty-seven patients with NVP-induced SJS/TEN and 78 controls, all from Mozambique, were enrolled. We identified eight exonic and three intronic already described variants. The case/control association analysis highlighted an association between the rs76228616 SNP in exon 2 and the SJS/TEN susceptibility. In particular, the variant allele (C) resulted significantly associated with a higher risk to develop SJS/TEN (p = 0.012 and OR = 3.65 (95% CI 1.33-10.01)). A multivariate analysis by logistic regression confirmed its significant contribution (p = 0.027, OR = 4.39 (95% CI 1.19-16.23)). In conclusion, our study suggests that a variant in TRAF3IP2 gene could be involved in susceptibility to SJS/TEN.'
p12971
sS'AD'
p12972
S'Department of Biomedicine and Prevention, Genetics Section, University of Rome "Tor Vergata", Rome 00133, Italy. cinziaciccacci@libero.it. Department of Biomedicine and Prevention, Genetics Section, University of Rome "Tor Vergata", Rome 00133, Italy. sara.rufini@hotmail.it. Department of Biomedicine and Prevention, Epidemiology Section, University of Rome "Tor Vergata", Rome 00133, Italy. sandro.mancinelli@uniroma2.it. Department of Biomedicine and Prevention, Epidemiology Section, University of Rome "Tor Vergata", Rome 00133, Italy. ersilia.buonomo@uniroma2.it. Department of Biomedicine and Prevention, Genetics Section, University of Rome "Tor Vergata", Rome 00133, Italy. emiliano.giardina@uniroma2.it. Laboratory of Molecular Genetics UILDM, Fondazione Santa Lucia, Rome 00179, Italy. emiliano.giardina@uniroma2.it. Department of Biomedicine and Prevention, Epidemiology Section, University of Rome "Tor Vergata", Rome 00133, Italy. paola.scarcella@uniroma2.it. Department of Human Sciences, LUMSA University, Rome 00193, Italy. marazzi@lumsa.it. Department of Biomedicine and Prevention, Genetics Section, University of Rome "Tor Vergata", Rome 00133, Italy. novelli@med.uniroma2.it. Department of Biomedicine and Prevention, Epidemiology Section, University of Rome "Tor Vergata", Rome 00133, Italy. leonardo.palombi@gmail.com. Department of Biomedicine and Prevention, Genetics Section, University of Rome "Tor Vergata", Rome 00133, Italy. borgiani@med.uniroma2.it.'
p12973
sS'IP'
p12974
S'3'
sS'IS'
p12975
S'1422-0067 (Electronic) 1422-0067 (Linking)'
p12976
sS'PMC'
p12977
S'PMC4394508'
p12978
sS'DCOM'
p12979
S'20151202'
p12980
sS'AU'
p12981
(lp12982
S'Ciccacci C'
p12983
aS'Rufini S'
p12984
aS'Mancinelli S'
p12985
aS'Buonomo E'
p12986
aS'Giardina E'
p12987
aS'Scarcella P'
p12988
aS'Marazzi MC'
p12989
aS'Novelli G'
p12990
aS'Palombi L'
p12991
aS'Borgiani P'
p12992
asS'VI'
p12993
S'16'
p12994
sS'MHDA'
p12995
S'2015/12/15 06:00'
p12996
sS'PHST'
p12997
(lp12998
S'2015/01/22 [received]'
p12999
aS'2015/03/06 [revised]'
p13000
aS'2015/03/07 [accepted]'
p13001
asS'OID'
p13002
(lp13003
S'NLM: PMC4394508'
p13004
asS'MH'
p13005
(lp13006
S'Adult'
p13007
aS'African Continental Ancestry Group/*genetics'
p13008
aS'Alleles'
p13009
aS'Anti-HIV Agents/*adverse effects/therapeutic use'
p13010
aS'Exons'
p13011
aS'*Genetic Predisposition to Disease'
p13012
aS'Genotype'
p13013
aS'HIV Infections/drug therapy'
p13014
aS'Haplotypes'
p13015
aS'Humans'
p13016
aS'Logistic Models'
p13017
aS'Mozambique'
p13018
aS'Nevirapine/*adverse effects/therapeutic use'
p13019
aS'Odds Ratio'
p13020
aS'Pharmacogenetics'
p13021
aS'Polymorphism, Single Nucleotide'
p13022
aS'Stevens-Johnson Syndrome/etiology/*genetics/pathology'
p13023
aS'Tumor Necrosis Factor Receptor-Associated Peptides and Proteins/*genetics'
p13024
asS'EDAT'
p13025
S'2015/03/17 06:00'
p13026
sS'SO'
p13027
S'Int J Mol Sci. 2015 Mar 12;16(3):5830-8. doi: 10.3390/ijms16035830.'
p13028
sS'SB'
p13029
S'IM'
p13030
sS'PMID'
p13031
S'25775161'
p13032
sS'PST'
p13033
S'epublish'
p13034
stRp13035
ag2
(g3
g4
(dp13036
S'LID'
p13037
S'10.1016/S0140-6736(15)60164-7 [doi] S0140-6736(15)60164-7 [pii]'
p13038
sS'STAT'
p13039
S'MEDLINE'
p13040
sS'DEP'
p13041
S'20150310'
p13042
sS'CI'
p13043
(lp13044
S'Copyright (c) 2015 Elsevier Ltd. All rights reserved.'
p13045
asS'DA'
p13046
S'20150613'
p13047
sS'AID'
p13048
(lp13049
S'S0140-6736(15)60164-7 [pii]'
p13050
aS'10.1016/S0140-6736(15)60164-7 [doi]'
p13051
asS'CRDT'
p13052
(lp13053
S'2015/03/14 06:00'
p13054
asS'DP'
p13055
S'2015 May 30'
p13056
sS'AD'
p13057
S'National Institute for Medical Research, Muhimbili Medical Research Centre, Dar es Salaam, Tanzania. Institute for Medical Research and Training, University Teaching Hospital, Lusaka, Zambia. National Institute for Medical Research, Muhimbili Medical Research Centre, Dar es Salaam, Tanzania. Faculty of Public Health Policy, London School of Hygiene & Tropical Medicine, London, UK. Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK. Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK. Institute for Medical Research and Training, University Teaching Hospital, Lusaka, Zambia. National Institute for Medical Research, Muhimbili Medical Research Centre, Dar es Salaam, Tanzania. National Institute for Medical Research, Muhimbili Medical Research Centre, Dar es Salaam, Tanzania. National Institute for Medical Research, Muhimbili Medical Research Centre, Dar es Salaam, Tanzania. National Institute for Medical Research, Muhimbili Medical Research Centre, Dar es Salaam, Tanzania. Institute for Medical Research and Training, University Teaching Hospital, Lusaka, Zambia. Institute for Infection and Immunity, St Georges University of London, London, UK. National Tuberculosis and Leprosy Control Program, Ministry of Health and Socio-Welfare, Dar es Salaam, Tanzania. Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK. Electronic address: shabbar.jaffar@lshtm.ac.uk.'
p13058
sS'OWN'
p13059
S'NLM'
p13060
sS'PT'
p13061
(lp13062
S'Journal Article'
p13063
aS'Multicenter Study'
p13064
aS'Randomized Controlled Trial'
p13065
aS"Research Support, Non-U.S. Gov't"
p13066
asS'LA'
p13067
(lp13068
S'eng'
p13069
asS'FAU'
p13070
(lp13071
S'Mfinanga, Sayoki'
p13072
aS'Chanda, Duncan'
p13073
aS'Kivuyo, Sokoine L'
p13074
aS'Guinness, Lorna'
p13075
aS'Bottomley, Christian'
p13076
aS'Simms, Victoria'
p13077
aS'Chijoka, Carol'
p13078
aS'Masasi, Ayubu'
p13079
aS'Kimaro, Godfather'
p13080
aS'Ngowi, Bernard'
p13081
aS'Kahwa, Amos'
p13082
aS'Mwaba, Peter'
p13083
aS'Harrison, Thomas S'
p13084
aS'Egwaga, Saidi'
p13085
aS'Jaffar, Shabbar'
p13086
asS'JT'
p13087
S'Lancet (London, England)'
p13088
sS'PG'
p13089
S'2173-82'
p13090
sS'TI'
p13091
S'Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial.'
p13092
sS'RN'
p13093
(lp13094
S'0 (Anti-HIV Agents)'
p13095
aS'0 (Antifungal Agents)'
p13096
asS'PL'
p13097
S'England'
p13098
sS'TA'
p13099
S'Lancet'
p13100
sS'FIR'
p13101
(lp13102
S'Chale, Paulina'
p13103
aS"Kigocha, Okeng'o"
p13104
aS'Shirima, Raymond Phillips'
p13105
aS'Lema, Yacobo'
p13106
aS'Kasubi, Mabula'
p13107
aS'Mathania, Milka'
p13108
aS'Makuchilo, Magreth'
p13109
aS'Mziray, Flora'
p13110
aS'Alway, Clement'
p13111
aS'Rwezaura, Ladislaus'
p13112
aS'Mgohamwenda, Joyce'
p13113
aS'Minde, John'
p13114
aS'Luhimbo, Theophilla'
p13115
aS'Biseko, Maijo'
p13116
aS'Kapesa, Emmanuel'
p13117
aS'Shoo, Walter'
p13118
aS'Barankena, Asheri'
p13119
aS'Mzyece, Judy'
p13120
aS'Chanda, Raphael'
p13121
aS'Salim, Elias'
p13122
aS'Kashongore, Gershon'
p13123
aS'Kapotwe, Vincent'
p13124
aS'Manan, Diana'
p13125
asS'JID'
p13126
S'2985213R'
p13127
sS'AB'
p13128
S'BACKGROUND: Mortality in people in Africa with HIV infection starting antiretroviral therapy (ART) is high, particularly in those with advanced disease. We assessed the effect of a short period of community support to supplement clinic-based services combined with serum cryptococcal antigen screening. METHODS: We did an open-label, randomised controlled trial in six urban clinics in Dar es Salaam, Tanzania, and Lusaka, Zambia. From February, 2012, we enrolled eligible individuals with HIV infection (age >/=18 years, CD4 count of <200 cells per muL, ART naive) and randomly assigned them to either the standard clinic-based care supplemented with community support or standard clinic-based care alone, stratified by country and clinic, in permuted block sizes of ten. Clinic plus community support consisted of screening for serum cryptococcal antigen combined with antifungal therapy for patients testing antigen positive, weekly home visits for the first 4 weeks on ART by lay workers to provide support, and in Tanzania alone, re-screening for tuberculosis at 6-8 weeks after ART initiation. The primary endpoint was all-cause mortality at 12 months, analysed by intention to treat. This trial is registered with the International Standard Randomised Controlled Trial Number registry, number ISCRTN 20410413. FINDINGS: Between Feb 9, 2012, and Sept 30, 2013, 1001 patients were randomly assigned to clinic plus community support and 998 to standard care. 89 (9%) of 1001 participants in the clinic plus community support group did not receive their assigned intervention, and 11 (1%) of 998 participants in the standard care group received a home visit or a cryptococcal antigen screen rather than only standard care. At 12 months, 25 (2%) of 1001 participants in the clinic plus community support group and 24 (2%) of 998 participants in the standard care group had been lost to follow-up, and were censored at their last visit for the primary analysis. At 12 months, 134 (13%) of 1001 participants in the clinic plus community support group had died compared with 180 (18%) of 998 in the standard care group. Mortality was 28% (95% CI 10-43) lower in the clinic plus community support group than in standard care group (p=0.004). INTERPRETATION: Screening and pre-emptive treatment for cryptococcal infection combined with a short initial period of adherence support after initiation of ART could substantially reduce mortality in HIV programmes in Africa. FUNDING: European and Developing Countries Clinical Trials Partnership.'
p13129
sS'CN'
p13130
(lp13131
S'REMSTART trial team'
p13132
asS'IP'
p13133
S'9983'
p13134
sS'IS'
p13135
S'1474-547X (Electronic) 0140-6736 (Linking)'
p13136
sS'IR'
p13137
(lp13138
S'Chale P'
p13139
aS'Kigocha O'
p13140
aS'Shirima RP'
p13141
aS'Lema Y'
p13142
aS'Kasubi M'
p13143
aS'Mathania M'
p13144
aS'Makuchilo M'
p13145
aS'Mziray F'
p13146
aS'Alway C'
p13147
aS'Rwezaura L'
p13148
aS'Mgohamwenda J'
p13149
aS'Minde J'
p13150
aS'Luhimbo T'
p13151
aS'Biseko M'
p13152
aS'Kapesa E'
p13153
aS'Shoo W'
p13154
aS'Barankena A'
p13155
aS'Mzyece J'
p13156
aS'Chanda R'
p13157
aS'Salim E'
p13158
aS'Kashongore G'
p13159
aS'Kapotwe V'
p13160
aS'Manan D'
p13161
asS'DCOM'
p13162
S'20150629'
p13163
sS'CIN'
p13164
(lp13165
S'Lancet. 2015 May 30;385(9983):2128-9. PMID: 25765697'
p13166
asS'AU'
p13167
(lp13168
S'Mfinanga S'
p13169
aS'Chanda D'
p13170
aS'Kivuyo SL'
p13171
aS'Guinness L'
p13172
aS'Bottomley C'
p13173
aS'Simms V'
p13174
aS'Chijoka C'
p13175
aS'Masasi A'
p13176
aS'Kimaro G'
p13177
aS'Ngowi B'
p13178
aS'Kahwa A'
p13179
aS'Mwaba P'
p13180
aS'Harrison TS'
p13181
aS'Egwaga S'
p13182
aS'Jaffar S'
p13183
asS'VI'
p13184
S'385'
p13185
sS'MHDA'
p13186
S'2015/06/30 06:00'
p13187
sS'PHST'
p13188
(lp13189
S'2015/03/10 [aheadofprint]'
p13190
asS'MH'
p13191
(lp13192
S'Adult'
p13193
aS'Anti-HIV Agents/*therapeutic use'
p13194
aS'Antifungal Agents/therapeutic use'
p13195
aS'Community Health Services/*methods'
p13196
aS'Female'
p13197
aS'HIV Infections/*drug therapy/*mortality'
p13198
aS'Humans'
p13199
aS'Male'
p13200
aS'Meningitis, Cryptococcal/*diagnosis/drug therapy/*mortality'
p13201
aS'Middle Aged'
p13202
aS'Patient Compliance'
p13203
aS'Tanzania/epidemiology'
p13204
aS'Treatment Outcome'
p13205
aS'Zambia/epidemiology'
p13206
asS'EDAT'
p13207
S'2015/03/15 06:00'
p13208
sS'SI'
p13209
(lp13210
S'ISRCTN/ISRCTN20410413'
p13211
asS'SO'
p13212
S'Lancet. 2015 May 30;385(9983):2173-82. doi: 10.1016/S0140-6736(15)60164-7. Epub 2015 Mar 10.'
p13213
sS'SB'
p13214
S'AIM IM'
p13215
sS'PMID'
p13216
S'25765698'
p13217
sS'PST'
p13218
S'ppublish'
p13219
stRp13220
ag2
(g3
g4
(dp13221
S'LID'
p13222
S'10.1002/jmv.24162 [doi]'
p13223
sS'STAT'
p13224
S'MEDLINE'
p13225
sS'DEP'
p13226
S'20150305'
p13227
sS'CI'
p13228
(lp13229
S'(c) 2015 Wiley Periodicals, Inc.'
p13230
asS'DA'
p13231
S'20150506'
p13232
sS'AID'
p13233
(lp13234
S'10.1002/jmv.24162 [doi]'
p13235
asS'CRDT'
p13236
(lp13237
S'2015/03/11 06:00'
p13238
asS'DP'
p13239
S'2015 Jul'
p13240
sS'AD'
p13241
S'School of Medicine, University of Alabama at Birmingham, Alabama; Centre for Infectious Disease Research Zambia, Lusaka, Zambia.'
p13242
sS'OWN'
p13243
S'NLM'
p13244
sS'PT'
p13245
(lp13246
S'Journal Article'
p13247
aS'Research Support, N.I.H., Extramural'
p13248
aS"Research Support, Non-U.S. Gov't"
p13249
aS"Research Support, U.S. Gov't, P.H.S."
p13250
asS'LA'
p13251
(lp13252
S'eng'
p13253
asS'FAU'
p13254
(lp13255
S'Seu, Lillian'
p13256
aS'Mulenga, Lloyd B'
p13257
aS'Siwingwa, Mpanji'
p13258
aS'Sikazwe, Izukanji'
p13259
aS'Lambwe, Nason'
p13260
aS'Guffey, M Bradford'
p13261
aS'Chi, Benjamin H'
p13262
asS'JT'
p13263
S'Journal of medical virology'
p13264
sS'LR'
p13265
S'20151027'
p13266
sS'PG'
p13267
S'1149-57'
p13268
sS'TI'
p13269
S'Characterization of HIV drug resistance mutations among patients failing first-line antiretroviral therapy from a tertiary referral center in Lusaka, Zambia.'
p13270
sS'RN'
p13271
(lp13272
S'0 (Anti-HIV Agents)'
p13273
aS'EC 3.4.23.- (HIV Protease)'
p13274
asS'PL'
p13275
S'United States'
p13276
sS'TA'
p13277
S'J Med Virol'
p13278
sS'JID'
p13279
S'7705876'
p13280
sS'AB'
p13281
S'In settings of resource constraint, an understanding of HIV drug resistance can guide antiretroviral therapy (ART) at switch to second-line therapy. To determine the prevalence of such HIV drug resistance mutations (HIV DRM), we used an in-house sequencing assay in the pol gene (protease and partial reverse transcriptase) in a cohort of patients suspected of failing a first-line regimen, which in Zambia comprises two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and one non-nucleoside reverse transcriptase inhibitor (NNRTI). Our analysis cohort (n = 68) was referred to the University Teaching Hospital in Lusaka from November 2009 to October 2012. Median duration on first-line ART to suspected treatment failure was 3.2 years (IQR 1.7-4.7 years). The majority of patients (95%) harbored HIV-1 subtype C virus. Analysis of reverse transcriptase revealed M184V (88%), K103N/S (32%), and Y181C/I/V (41%) DRMs, with the latter conferring reduced susceptibility to the salvage therapy candidates etravirine and rilpivirine. Three patients (5%) had major protease inhibitor (PI) resistance mutations: all three had the V82A mutation, and one patient (Clade J virus) had a concurrent M46I, Q58E, and L76V DRM. HIV-1 genotyping revealed major and minor DRMs as well as high levels of polymorphisms in subtype C isolates from patients failing first-line antiretroviral therapy. Closer monitoring of DRM mutations at first-line failure can inform clinicians about future options for salvage therapy.'
p13282
sS'GR'
p13283
(lp13284
S'R24 TW007988/TW/FIC NIH HHS/United States'
p13285
aS'R24TW007988/TW/FIC NIH HHS/United States'
p13286
aS'U2G GH000078/GH/CGH CDC HHS/United States'
p13287
asS'IP'
p13288
S'7'
sS'IS'
p13289
S'1096-9071 (Electronic) 0146-6615 (Linking)'
p13290
sS'PMC'
p13291
S'PMC4489546'
p13292
sS'DCOM'
p13293
S'20151009'
p13294
sS'MID'
p13295
(lp13296
S'NIHMS703622'
p13297
asS'AU'
p13298
(lp13299
S'Seu L'
p13300
aS'Mulenga LB'
p13301
aS'Siwingwa M'
p13302
aS'Sikazwe I'
p13303
aS'Lambwe N'
p13304
aS'Guffey MB'
p13305
aS'Chi BH'
p13306
asS'VI'
p13307
S'87'
p13308
sS'MHDA'
p13309
S'2015/10/10 06:00'
p13310
sS'PHST'
p13311
(lp13312
S'2015/01/19 [accepted]'
p13313
aS'2015/03/05 [aheadofprint]'
p13314
asS'OTO'
p13315
(lp13316
S'NOTNLM'
p13317
asS'OID'
p13318
(lp13319
S'NLM: NIHMS703622'
p13320
aS'NLM: PMC4489546'
p13321
asS'MH'
p13322
(lp13323
S'Adult'
p13324
aS'Anti-HIV Agents/*pharmacology/therapeutic use'
p13325
aS'Antiretroviral Therapy, Highly Active'
p13326
aS'*Drug Resistance, Viral'
p13327
aS'Female'
p13328
aS'Genotype'
p13329
aS'HIV Infections/drug therapy/epidemiology/*virology'
p13330
aS'HIV Protease/genetics'
p13331
aS'HIV-1/classification/*drug effects/*genetics'
p13332
aS'Humans'
p13333
aS'Male'
p13334
aS'*Mutation'
p13335
aS'Phylogeny'
p13336
aS'Prevalence'
p13337
aS'Retrospective Studies'
p13338
aS'*Tertiary Care Centers'
p13339
aS'Treatment Failure'
p13340
aS'Viral Load'
p13341
aS'Zambia/epidemiology'
p13342
asS'EDAT'
p13343
S'2015/03/11 06:00'
p13344
sS'SO'
p13345
S'J Med Virol. 2015 Jul;87(7):1149-57. doi: 10.1002/jmv.24162. Epub 2015 Mar 5.'
p13346
sS'SB'
p13347
S'IM'
p13348
sS'PMID'
p13349
S'25754408'
p13350
sS'OT'
p13351
(lp13352
S'HIV drug resistance'
p13353
aS'NNRTI'
p13354
aS'Zambia'
p13355
aS'diversity'
p13356
aS'pol'
p13357
asS'PST'
p13358
S'ppublish'
p13359
stRp13360
ag2
(g3
g4
(dp13361
S'LID'
p13362
S'10.1097/INF.0000000000000625 [doi]'
p13363
sS'STAT'
p13364
S'MEDLINE'
p13365
sS'AB'
p13366
S'HIV-infected women seeking early infant HIV diagnosis (EID) services in Malawi were asked about factors potentially associated with returning for EID results. Many (33.3%) infants failed to complete the EID process because of time and costs required for multiple visits. Infants of mothers receiving antiretroviral treatment were less likely to drop out (adjusted risk ratio 0.51), suggesting that EID completion may improve in programs providing antiretroviral treatment to all pregnant women.'
p13367
sS'JID'
p13368
S'8701858'
p13369
sS'GR'
p13370
(lp13371
S'R01 HD053216/HD/NICHD NIH HHS/United States'
p13372
aS'Wellcome Trust/United Kingdom'
p13373
asS'JT'
p13374
S'The Pediatric infectious disease journal'
p13375
sS'IP'
p13376
S'3'
sS'IS'
p13377
S'1532-0987 (Electronic) 0891-3668 (Linking)'
p13378
sS'DCOM'
p13379
S'20160112'
p13380
sS'DA'
p13381
S'20150306'
p13382
sS'AU'
p13383
(lp13384
S'Cromwell EA'
p13385
aS'Dow AE'
p13386
aS'Low D'
p13387
aS'Chirambo C'
p13388
aS'Heyderman RS'
p13389
aS'Dube Q'
p13390
aS'Van Rie A'
p13391
asS'AID'
p13392
(lp13393
S'10.1097/INF.0000000000000625 [doi]'
p13394
aS'00006454-201503000-00012 [pii]'
p13395
asS'CRDT'
p13396
(lp13397
S'2015/03/06 06:00'
p13398
asS'VI'
p13399
S'34'
p13400
sS'DP'
p13401
S'2015 Mar'
p13402
sS'AD'
p13403
S'From the *Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina; daggerMalawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi; double daggerDepartment of Pediatrics & Child Health, Queen Elizabeth Central Hospital, Blantyre, Malawi; and section signSchool of Medicine, University of Washington, Seattle, Washington.'
p13404
sS'MHDA'
p13405
S'2016/01/13 06:00'
p13406
sS'OWN'
p13407
S'NLM'
p13408
sS'PT'
p13409
(lp13410
S'Journal Article'
p13411
aS'Research Support, N.I.H., Extramural'
p13412
aS"Research Support, Non-U.S. Gov't"
p13413
asS'LA'
p13414
(lp13415
S'eng'
p13416
asS'MH'
p13417
(lp13418
S'Early Diagnosis'
p13419
aS'Female'
p13420
aS'HIV Infections/*diagnosis/*epidemiology/transmission'
p13421
aS'Health Services Accessibility'
p13422
aS'Humans'
p13423
aS'Infant'
p13424
aS'Infectious Disease Transmission, Vertical'
p13425
aS'Malawi/epidemiology'
p13426
aS'Pregnancy'
p13427
aS'Pregnancy Complications, Infectious'
p13428
aS'*Primary Health Care'
p13429
aS'Prospective Studies'
p13430
aS'Public Health Surveillance'
p13431
aS'Time Factors'
p13432
asS'FAU'
p13433
(lp13434
S'Cromwell, Elizabeth A'
p13435
aS'Dow, Anna E'
p13436
aS'Low, Daniel'
p13437
aS'Chirambo, Chawanangwa'
p13438
aS'Heyderman, Robert S'
p13439
aS'Dube, Queen'
p13440
aS'Van Rie, Annelies'
p13441
asS'EDAT'
p13442
S'2015/03/06 06:00'
p13443
sS'PST'
p13444
S'ppublish'
p13445
sS'SO'
p13446
S'Pediatr Infect Dis J. 2015 Mar;34(3):273-5. doi: 10.1097/INF.0000000000000625.'
p13447
sS'PG'
p13448
S'273-5'
p13449
sS'TI'
p13450
S'Barriers to successful early infant diagnosis of HIV infection at primary care level in Malawi.'
p13451
sS'SB'
p13452
S'IM'
p13453
sS'PMID'
p13454
S'25742076'
p13455
sS'PL'
p13456
S'United States'
p13457
sS'TA'
p13458
S'Pediatr Infect Dis J'
p13459
stRp13460
ag2
(g3
g4
(dp13461
S'LID'
p13462
S'10.3402/gha.v8.26308 [doi]'
p13463
sS'STAT'
p13464
S'MEDLINE'
p13465
sS'DEP'
p13466
S'20150227'
p13467
sS'DA'
p13468
S'20150302'
p13469
sS'AID'
p13470
(lp13471
S'26308 [pii]'
p13472
asS'CRDT'
p13473
(lp13474
S'2015/03/03 06:00'
p13475
asS'DP'
p13476
S'2015'
p13477
sS'OWN'
p13478
S'NLM'
p13479
sS'PT'
p13480
(lp13481
S'Journal Article'
p13482
asS'LA'
p13483
(lp13484
S'eng'
p13485
asS'DCOM'
p13486
S'20160127'
p13487
sS'JT'
p13488
S'Global health action'
p13489
sS'LR'
p13490
S'20150314'
p13491
sS'FAU'
p13492
(lp13493
S'Larsson, Elin C'
p13494
aS'Ekstrom, Anna Mia'
p13495
aS'Pariyo, George'
p13496
aS'Tomson, Goran'
p13497
aS'Sarowar, Mohammad'
p13498
aS'Baluka, Rose'
p13499
aS'Galiwango, Edward'
p13500
aS'Thorson, Anna Ekeus'
p13501
asS'TI'
p13502
S'Prevention of mother-to-child transmission of HIV in rural Uganda: modelling effectiveness and impact of scaling-up PMTCT services.'
p13503
sS'RN'
p13504
(lp13505
S'0 (Anti-Retroviral Agents)'
p13506
asS'PL'
p13507
S'Sweden'
p13508
sS'PG'
p13509
S'26308'
p13510
sS'JID'
p13511
S'101496665'
p13512
sS'AB'
p13513
S'BACKGROUND: The reported coverage of any antiretroviral (ARV) prophylaxis for prevention of mother-to-child transmission (PMTCT) has increased in sub-Saharan Africa in recent years, but was still only 60% in 2010. However, the coverage estimate is subject to overestimations since it only considers enrolment and not completion of the PMTCT programme. The PMTCT programme is complex as it builds on a cascade of sequential interventions that should take place to reduce mother-to-child transmission (MTCT) of HIV: starting with antenatal care (ANC), HIV testing, and ARVs for the woman and the baby. OBJECTIVE: The objective was to estimate the number of children infected with HIV in a district population, using empirical data on uptake of PMTCT components combined with data on MTCT rates. DESIGN: This study is based on a population-based cohort of pregnant women recruited in the Iganga-Mayuge Health and Demographic Surveillance Site in rural Uganda 2008-2010. We later modelled different scenarios assuming increased uptake of specific PMTCT components to estimate the impact on MTCT for each scenario. RESULTS: In this setting, HIV infections in children could be reduced by 28% by increasing HIV testing capacity at health facilities to ensure 100% testing among women seeking ANC. Providing ART to all women who received ARV prophylaxis would give an 18% MTCT reduction. CONCLUSIONS: Our results highlight the urgency in scaling-up universal access to HIV testing at all ANC facilities, and the potential gains of early enrolment of all pregnant women on antiretroviral treatment for PMTCT. Further, to determine the effectiveness of PMTCT programmes in different settings, it is crucial to analyse at what stages of the PMTCT cascade that dropouts occur to target interventions accordingly.'
p13514
sS'AD'
p13515
S"Department of Public Health Sciences Global Health/IHCAR, Karolinska Institutet, Stockholm, Sweden. Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden; elin.larsson@ki.se. Department of Public Health Sciences Global Health/IHCAR, Karolinska Institutet, Stockholm, Sweden. Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden. Deptartment of Health Policy, Planning and Management, Makerere University School of Public Health, Kampala, Uganda. Iganga-Mayuge Health and Demographic Surveillance Site, Iganga, Uganda. Department of Public Health Sciences Global Health/IHCAR, Karolinska Institutet, Stockholm, Sweden. Department of Learning, Informatics, Management and Ethics (MMC), Karolinska Institutet, Stockholm, Sweden. Department of Public Health Sciences Global Health/IHCAR, Karolinska Institutet, Stockholm, Sweden. Iganga-Mayuge Health and Demographic Surveillance Site, Iganga, Uganda. Deptartment of Health Policy, Planning and Management, Makerere University School of Public Health, Kampala, Uganda. Iganga-Mayuge Health and Demographic Surveillance Site, Iganga, Uganda. Department of Public Health Sciences Global Health/IHCAR, Karolinska Institutet, Stockholm, Sweden. Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden."
p13516
sS'VI'
p13517
S'8'
sS'IS'
p13518
S'1654-9880 (Electronic) 1654-9880 (Linking)'
p13519
sS'PMC'
p13520
S'PMC4345173'
p13521
sS'AU'
p13522
(lp13523
S'Larsson EC'
p13524
aS'Ekstrom AM'
p13525
aS'Pariyo G'
p13526
aS'Tomson G'
p13527
aS'Sarowar M'
p13528
aS'Baluka R'
p13529
aS'Galiwango E'
p13530
aS'Thorson AE'
p13531
asS'MHDA'
p13532
S'2016/01/28 06:00'
p13533
sS'PHST'
p13534
(lp13535
S'2015 [ecollection]'
p13536
aS'2014/10/13 [received]'
p13537
aS'2015/01/12 [revised]'
p13538
aS'2015/01/20 [accepted]'
p13539
asS'OT'
p13540
(lp13541
S'HIV'
p13542
aS'cohort'
p13543
aS'effectiveness'
p13544
aS'population-based'
p13545
aS'prevention of mother-to-child transmission'
p13546
asS'OTO'
p13547
(lp13548
S'NOTNLM'
p13549
asS'OID'
p13550
(lp13551
S'NLM: PMC4345173'
p13552
asS'MH'
p13553
(lp13554
S'Adult'
p13555
aS'Anti-Retroviral Agents/therapeutic use'
p13556
aS'Child'
p13557
aS'Cohort Studies'
p13558
aS'Early Diagnosis'
p13559
aS'Female'
p13560
aS'HIV Infections/diagnosis/*drug therapy/*transmission'
p13561
aS'Humans'
p13562
aS'Infant'
p13563
aS'Infant, Newborn'
p13564
aS'Infectious Disease Transmission, Vertical/*prevention & control/statistics & numerical data'
p13565
aS'Mass Screening'
p13566
aS'*Models, Organizational'
p13567
aS'Pregnancy'
p13568
aS'Pregnancy Complications, Infectious/*diagnosis/*drug therapy'
p13569
aS'Prenatal Care/*organization & administration'
p13570
aS'Rural Population'
p13571
aS'Uganda'
p13572
aS'Young Adult'
p13573
asS'EDAT'
p13574
S'2015/03/03 06:00'
p13575
sS'SO'
p13576
S'Glob Health Action. 2015 Feb 27;8:26308. doi: 10.3402/gha.v8.26308. eCollection 2015.'
p13577
sS'SB'
p13578
S'IM'
p13579
sS'PMID'
p13580
S'25726836'
p13581
sS'TA'
p13582
S'Glob Health Action'
p13583
sS'PST'
p13584
S'epublish'
p13585
stRp13586
ag2
(g3
g4
(dp13587
S'STAT'
p13588
S'MEDLINE'
p13589
sS'AB'
p13590
S'BACKGROUND: A HIV positive-to-positive program was started in South Africa in 2008. The program was started because dialysis is not freely available to everyone, but severely limited and only available to a selected group of patients. PATIENTS AND METHODS: Between September 2008 and March 2015, 29 patients were transplanted from HIV-positive brain-dead donors at Groote Schuur Hospital transplant team. Donors were either naive to anti-retroviral therapy or on first line therapy. The recipients were selected to have undetectable plasma HIV type 1 RNA levels and be on a stable antiretroviral regimen. CD4+ T-cell counts of at least 200/mm3 in last 6 months prior to transplant, with no previous serious opportunistic infections. RESULTS: Survivors in the study were followed for a median of 2.4 years. The rate of patient survival was 84% at 1 year and 74% at 5 years. The corresponding graft survival rate was 93% and 84%. CONCLUSION: Using HIV-positive donors might resolve some of the problems we are experiencing in getting enough donors for our patients wit ESRD. In the USA the HOPE act was accepted in 2014 and this might now also impact on the use of HIV positive donors elsewhere in the world.'
p13591
sS'JID'
p13592
S'0364441'
p13593
sS'AD'
p13594
S'Groote Schuur Hospital, University of Cape Town, South Africa.'
p13595
sS'JT'
p13596
S'Clinical nephrology'
p13597
sS'IP'
p13598
S'7 Suppl 1'
p13599
sS'IS'
p13600
S'0301-0430 (Print) 0301-0430 (Linking)'
p13601
sS'DCOM'
p13602
S'20160524'
p13603
sS'DA'
p13604
S'20150301'
p13605
sS'AU'
p13606
(lp13607
S'Muller E'
p13608
asS'AID'
p13609
(lp13610
S'13139 [pii]'
p13611
asS'CRDT'
p13612
(lp13613
S'2015/03/01 06:00'
p13614
asS'VI'
p13615
S'83'
p13616
sS'DP'
p13617
S'2015'
p13618
sS'MHDA'
p13619
S'2016/05/25 06:00'
p13620
sS'OWN'
p13621
S'NLM'
p13622
sS'PT'
p13623
(lp13624
S'Journal Article'
p13625
aS'Review'
p13626
asS'LA'
p13627
(lp13628
S'eng'
p13629
asS'MH'
p13630
(lp13631
S'Graft Survival'
p13632
aS'HIV/*immunology'
p13633
aS'*HIV Seropositivity'
p13634
aS'Humans'
p13635
aS'Kidney Failure, Chronic/complications/*surgery'
p13636
aS'Kidney Transplantation/*methods'
p13637
aS'South Africa'
p13638
aS'*Tissue Donors'
p13639
asS'FAU'
p13640
(lp13641
S'Muller, Elmi'
p13642
asS'EDAT'
p13643
S'2015/03/01 06:00'
p13644
sS'PST'
p13645
S'ppublish'
p13646
sS'SO'
p13647
S'Clin Nephrol. 2015;83(7 Suppl 1):39-41.'
p13648
sS'PG'
p13649
S'39-41'
p13650
sS'TI'
p13651
S'Transplantation in resource-limited setting: using HIV-positive donors for HIV-positive patients.'
p13652
sS'SB'
p13653
S'IM'
p13654
sS'PMID'
p13655
S'25725240'
p13656
sS'PL'
p13657
S'Germany'
p13658
sS'TA'
p13659
S'Clin Nephrol'
p13660
stRp13661
ag2
(g3
g4
(dp13662
S'LID'
p13663
S'10.1111/hiv.12214 [doi]'
p13664
sS'STAT'
p13665
S'MEDLINE'
p13666
sS'DEP'
p13667
S'20150227'
p13668
sS'CI'
p13669
(lp13670
S'(c) 2015 British HIV Association.'
p13671
asS'DA'
p13672
S'20150622'
p13673
sS'AID'
p13674
(lp13675
S'10.1111/hiv.12214 [doi]'
p13676
asS'CRDT'
p13677
(lp13678
S'2015/02/28 06:00'
p13679
asS'DP'
p13680
S'2015 Jul'
p13681
sS'OWN'
p13682
S'NLM'
p13683
sS'PT'
p13684
(lp13685
S'Journal Article'
p13686
aS"Research Support, Non-U.S. Gov't"
p13687
asS'LA'
p13688
(lp13689
S'eng'
p13690
asS'FAU'
p13691
(lp13692
S'Selvam, A'
p13693
aS'Buhimschi, I A'
p13694
aS'Makin, J D'
p13695
aS'Pattinson, R C'
p13696
aS'Anderson, R'
p13697
aS'Forsyth, B W'
p13698
asS'JT'
p13699
S'HIV medicine'
p13700
sS'PG'
p13701
S'375-80'
p13702
sS'TI'
p13703
S'Hyperferritinemia and markers of inflammation and oxidative stress in the cord blood of HIV-exposed, uninfected (HEU) infants.'
p13704
sS'RN'
p13705
(lp13706
S'0 (Biomarkers)'
p13707
aS'0 (IL6 protein, human)'
p13708
aS'0 (Interleukin-6)'
p13709
aS'0 (Transferrins)'
p13710
aS'9007-41-4 (C-Reactive Protein)'
p13711
aS'9007-73-2 (Ferritins)'
p13712
aS'E1UOL152H7 (Iron)'
p13713
asS'PL'
p13714
S'England'
p13715
sS'TA'
p13716
S'HIV Med'
p13717
sS'JID'
p13718
S'100897392'
p13719
sS'AB'
p13720
S'OBJECTIVES: The purpose of this study was to evaluate markers of iron status and inflammation/oxidative stress in maternal and cord blood (CB) of HIV-infected and HIV-uninfected women as potential mechanisms for poor outcomes among HIV-exposed, uninfected (HEU) infants. METHODS: Maternal venous blood and CB specimens were obtained from 87 pregnant women (45 HIV-infected and 42 HIV-uninfected) enrolled at Kalafong Hospital, Pretoria, South Africa. Iron status [serum iron, ferritin and transferrin concentrations, transferrin saturation, soluble transferrin receptor (sTfR) concentration and the sTfR/log ferritin (sTfR/F) index], antenatal exposure to inflammation (CB C-reactive protein and interleukin-6 concentrations and haptoglobin switch-on status) and oxidative stress [total radical trapping ability of CB plasma (TRAP) and chronic oxidative stress (soluble receptor of advanced glycation end-products (sRAGE) concentration] were assessed in laboratory studies. RESULTS: There were no differences between the HIV-infected and HIV-uninfected groups in maternal haematological and iron indices, except that HIV-infected mothers had decreased white blood cell counts (P = 0.048) and increased serum ferritin concentrations (P = 0.032). Ferritin levels were significantly higher in CB than in maternal blood (P < 0.001) in both groups and further elevated in the CB of HEU infants (P = 0.044). There was also an inverse relationship between CB sTfR/F index and sRAGE (r = -0.43; P = 0.003) in the HIV-infected but not in the HIV-uninfected group. CONCLUSIONS: Our study showed for the first time that ferritin was significantly elevated in CB of HEU infants. The inverse relationship between sTfR/F index and sRAGE in CB suggests that chronic oxidative stress or RAGE axis activation in HIV-infected mothers may play a role in modulating ferritin levels.'
p13721
sS'AD'
p13722
S"Department of Emergency Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA. Center for Perinatal Research, Nationwide Children's Hospital, Ohio State University, Columbus, OH, USA. Department of Obstetrics and Gynaecology, Kalafong Hospital, University of Pretoria, Pretoria, South Africa. Department of Obstetrics and Gynaecology, Kalafong Hospital, University of Pretoria, Pretoria, South Africa. Medical Research Council Unit for Inflammation and Immunity, Department of Immunology, University of Pretoria, Pretoria, South Africa. Department of Pediatrics, Yale University School of Medicine, New Haven, CT, USA."
p13723
sS'IP'
p13724
S'6'
sS'IS'
p13725
S'1468-1293 (Electronic) 1464-2662 (Linking)'
p13726
sS'DCOM'
p13727
S'20160303'
p13728
sS'AU'
p13729
(lp13730
S'Selvam A'
p13731
aS'Buhimschi IA'
p13732
aS'Makin JD'
p13733
aS'Pattinson RC'
p13734
aS'Anderson R'
p13735
aS'Forsyth BW'
p13736
asS'VI'
p13737
S'16'
p13738
sS'MHDA'
p13739
S'2016/03/05 06:00'
p13740
sS'PHST'
p13741
(lp13742
S'2014/10/15 [accepted]'
p13743
aS'2015/02/27 [aheadofprint]'
p13744
asS'OTO'
p13745
(lp13746
S'NOTNLM'
p13747
asS'MH'
p13748
(lp13749
S'Adult'
p13750
aS'Biomarkers/blood'
p13751
aS'C-Reactive Protein/analysis'
p13752
aS'Case-Control Studies'
p13753
aS'Female'
p13754
aS'Ferritins/*blood'
p13755
aS'Fetal Blood/*chemistry'
p13756
aS'HIV Infections/*blood'
p13757
aS'Humans'
p13758
aS'Infant, Newborn'
p13759
aS'Inflammation/blood'
p13760
aS'Interleukin-6/blood'
p13761
aS'Iron/*blood'
p13762
aS'Oxidative Stress/*physiology'
p13763
aS'Pregnancy'
p13764
aS'Pregnancy Complications, Infectious/*blood'
p13765
aS'Transferrins/*blood'
p13766
asS'EDAT'
p13767
S'2015/02/28 06:00'
p13768
sS'SO'
p13769
S'HIV Med. 2015 Jul;16(6):375-80. doi: 10.1111/hiv.12214. Epub 2015 Feb 27.'
p13770
sS'SB'
p13771
S'IM'
p13772
sS'PMID'
p13773
S'25721379'
p13774
sS'OT'
p13775
(lp13776
S'HIV-exposed'
p13777
aS'cord blood markers'
p13778
aS'ferritin'
p13779
aS'inflammation in HIV infection'
p13780
aS'iron status in HIV infection'
p13781
aS'oxidative stress in HIV infection'
p13782
aS'uninfected (HEU) infants'
p13783
asS'PST'
p13784
S'ppublish'
p13785
stRp13786
ag2
(g3
g4
(dp13787
S'LID'
p13788
S'10.7448/IAS.18.1.19247 [doi]'
p13789
sS'STAT'
p13790
S'MEDLINE'
p13791
sS'DEP'
p13792
S'20150223'
p13793
sS'DA'
p13794
S'20150225'
p13795
sS'AID'
p13796
(lp13797
S'19247 [pii]'
p13798
asS'CRDT'
p13799
(lp13800
S'2015/02/26 06:00'
p13801
asS'DP'
p13802
S'2015'
p13803
sS'AD'
p13804
S'Medecins Sans Frontieres, Harare, Zimbabwe; amir.shroufi@doctors.org.uk. Mpilo OI/ART Clinic, Bulawayo, Zimbabwe. Faculty of Medicine, National University of Science and Technology, Bulawayo, Zimbabwe. Mpilo OI/ART Clinic, Bulawayo, Zimbabwe. Mpilo OI/ART Clinic, Bulawayo, Zimbabwe. Faculty of Medicine, National University of Science and Technology, Bulawayo, Zimbabwe. Mpilo OI/ART Clinic, Bulawayo, Zimbabwe. Faculty of Medicine, National University of Science and Technology, Bulawayo, Zimbabwe. Medecins Sans Frontieres, Harare, Zimbabwe. Medecins Sans Frontieres, Harare, Zimbabwe. Medecins Sans Frontieres, Harare, Zimbabwe. Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK.'
p13805
sS'OWN'
p13806
S'NLM'
p13807
sS'PT'
p13808
(lp13809
S'Journal Article'
p13810
aS"Research Support, Non-U.S. Gov't"
p13811
asS'LA'
p13812
(lp13813
S'eng'
p13814
asS'DCOM'
p13815
S'20160516'
p13816
sS'JT'
p13817
S'Journal of the International AIDS Society'
p13818
sS'LR'
p13819
S'20160713'
p13820
sS'FAU'
p13821
(lp13822
S'Shroufi, Amir'
p13823
aS'Ndebele, Wedu'
p13824
aS'Nyathi, Mary'
p13825
aS'Gunguwo, Hilary'
p13826
aS'Dixon, Mark'
p13827
aS'Saint-Sauveur, Jean F'
p13828
aS'Taziwa, Fabian'
p13829
aS'Vinoles, Mari C'
p13830
aS'Ferrand, Rashida A'
p13831
asS'TI'
p13832
S'Risk of death among those awaiting treatment for HIV infection in Zimbabwe: adolescents are at particular risk.'
p13833
sS'RN'
p13834
(lp13835
S'0 (Anti-HIV Agents)'
p13836
asS'PL'
p13837
S'Switzerland'
p13838
sS'PG'
p13839
S'19247'
p13840
sS'JID'
p13841
S'101478566'
p13842
sS'AB'
p13843
S'INTRODUCTION: Mortality among HIV-positive adults awaiting antiretroviral therapy (ART) has previously been found to be high. Here, we compare adolescent pre-ART mortality to that of adults in a public sector HIV care programme in Bulawayo, Zimbabwe. METHODS: In this retrospective cohort study, we compared adolescent pre-ART outcomes with those of adults enrolled for HIV care in the same clinic. Adolescents were defined as those aged 10-19 at the time of registration. Comparisons of means and proportions were carried out using two-tailed sample t-tests and chi-square tests respectively, for normally distributed data, and the Mann-Whitney U-tests for non-normally distributed data. Loss to follow-up (LTFU) was defined as missing a scheduled appointment by three or more months. RESULTS: Between 2004 and 2010, 1382 of 1628 adolescents and 7557 of 11,106 adults who registered for HIV care met the eligibility criteria for ART. Adolescents registered at a more advanced disease stage than did adults (83% vs. 73% WHO stage III/IV, respectively, p<0.001), and the median time to ART initiation was longer for adolescents than for adults [21 (10-55) days vs. 15 (7-42) days, p<0.001]. Among the 138 adolescents and 942 adults who never commenced ART, 39 (28%) of adolescents and 135 (14%) of adults died, the remainder being LTFU. Mortality among treatment-eligible adolescents awaiting ART was significantly higher than among adults (3% vs. 1.8%, respectively, p=0.004). CONCLUSIONS: Adolescents present to ART services at a later clinical stage than adults and are at an increased risk of death prior to commencing ART. Improved and innovative HIV case-finding approaches and emphasis on prompt ART initiation in adolescents are urgently needed. Following registration, defaulter tracing should be used, whether or not ART has been commenced.'
p13844
sS'GR'
p13845
(lp13846
S'100714/Wellcome Trust/United Kingdom'
p13847
asS'VI'
p13848
S'18'
p13849
sS'IS'
p13850
S'1758-2652 (Electronic) 1758-2652 (Linking)'
p13851
sS'PMC'
p13852
S'PMC4339242'
p13853
sS'AU'
p13854
(lp13855
S'Shroufi A'
p13856
aS'Ndebele W'
p13857
aS'Nyathi M'
p13858
aS'Gunguwo H'
p13859
aS'Dixon M'
p13860
aS'Saint-Sauveur JF'
p13861
aS'Taziwa F'
p13862
aS'Vinoles MC'
p13863
aS'Ferrand RA'
p13864
asS'MHDA'
p13865
S'2016/05/18 06:00'
p13866
sS'PHST'
p13867
(lp13868
S'2015 [ecollection]'
p13869
aS'2014/04/26 [received]'
p13870
aS'2014/12/14 [revised]'
p13871
aS'2015/01/13 [accepted]'
p13872
asS'OT'
p13873
(lp13874
S'ART'
p13875
aS'Africa'
p13876
aS'HIV/AIDS'
p13877
aS'adolescent'
p13878
aS'pre-ART'
p13879
asS'OTO'
p13880
(lp13881
S'NOTNLM'
p13882
asS'OID'
p13883
(lp13884
S'NLM: PMC4339242'
p13885
asS'MH'
p13886
(lp13887
S'Adolescent'
p13888
aS'Adult'
p13889
aS'Anti-HIV Agents/*therapeutic use'
p13890
aS'Cohort Studies'
p13891
aS'Female'
p13892
aS'HIV Infections/drug therapy/*mortality'
p13893
aS'Humans'
p13894
aS'Male'
p13895
aS'Retrospective Studies'
p13896
aS'Risk'
p13897
aS'Zimbabwe'
p13898
asS'EDAT'
p13899
S'2015/02/26 06:00'
p13900
sS'SO'
p13901
S'J Int AIDS Soc. 2015 Feb 23;18:19247. doi: 10.7448/IAS.18.1.19247. eCollection 2015.'
p13902
sS'SB'
p13903
S'IM X'
p13904
sS'PMID'
p13905
S'25712590'
p13906
sS'TA'
p13907
S'J Int AIDS Soc'
p13908
sS'PST'
p13909
S'epublish'
p13910
stRp13911
ag2
(g3
g4
(dp13912
S'LID'
p13913
S'10.1111/tmi.12488 [doi]'
p13914
sS'STAT'
p13915
S'MEDLINE'
p13916
sS'DEP'
p13917
S'20150327'
p13918
sS'CI'
p13919
(lp13920
S'(c) 2015 John Wiley & Sons Ltd.'
p13921
asS'DA'
p13922
S'20150505'
p13923
sS'AID'
p13924
(lp13925
S'10.1111/tmi.12488 [doi]'
p13926
asS'CRDT'
p13927
(lp13928
S'2015/02/24 06:00'
p13929
asS'DP'
p13930
S'2015 Jun'
p13931
sS'AD'
p13932
S'Mirembe Hospital, Dodoma, Tanzania; Kilimanjaro Christian Medical University College, Moshi, Tanzania.'
p13933
sS'OWN'
p13934
S'NLM'
p13935
sS'PT'
p13936
(lp13937
S'Journal Article'
p13938
aS"Research Support, Non-U.S. Gov't"
p13939
asS'LA'
p13940
(lp13941
S'eng'
p13942
asS'FAU'
p13943
(lp13944
S'Tweve, Escor N'
p13945
aS'Kayabu, David'
p13946
aS'Nassari, Nahum O'
p13947
aS'Todd, Jim'
p13948
asS'JT'
p13949
S'Tropical medicine & international health : TM & IH'
p13950
sS'PG'
p13951
S'791-6'
p13952
sS'TI'
p13953
S'Improvement in mortality and retention among adult HIV-infected patients in the first 12 months of antiretroviral therapy in Dodoma urban district, Tanzania.'
p13954
sS'RN'
p13955
(lp13956
S'0 (Anti-HIV Agents)'
p13957
asS'PL'
p13958
S'England'
p13959
sS'TA'
p13960
S'Trop Med Int Health'
p13961
sS'JID'
p13962
S'9610576'
p13963
sS'AB'
p13964
S'OBJECTIVE: To determine mortality and retention in ART programmes in Tanzania, between 2010 and 2013. METHODS: Retrospective routinely collected data were analysed from people starting ART in the period 2010-2013. Mortality and retention over the first 12 months on ART were compared across the 4 years, and adjustment was made for individual level potential confounders. RESULTS: Data from 3844 people (70.6% female) starting ART were analysed. Mortality in the first year declined from 11.4% in 2010 to 4.9% in 2013, and retention after 12 months increased from 77.8% in 2010 to 98.1% in 2013. Mortality was inversely associated with CD4 count, lowest among those with CD4 350+ cells/mul [adjusted odds ratio (AOR) = 0.03, 95% CI 0.01-0.03], associated with male sex (AOR = 1.79, 95% CI 1.39-2.31), but not age. Lost to follow-up (LTFU) was lowest among those with CD4 = 350+ cells/mul AOR = 0.20, 95% CI 0.10-0.30), but not associated with age or sex, and higher in urban health facilities (AOR = 1.88, 95% CI 1.15-3.09). After adjustment for individual level characteristics, there was a statistically significant yearly improvement in mortality (AOR = 0.31, 95% CI (0.21-0.44) and LTFU (AOR = 0.06, 95% CI 0.04-0.10). CONCLUSION: Mortality and retention in the first 12 months on ART have significantly improved over the 4 years from 2010 to 2013. These improvements may indicate better services, earlier initiation on ART, and strengthened systems to provide ART in Tanzania. These results refute the worries that earlier initiation on ART might lead to lower retention in the ART programme.'
p13965
sS'GR'
p13966
(lp13967
S'PEPFAR/United States'
p13968
asS'IP'
p13969
S'6'
sS'IS'
p13970
S'1365-3156 (Electronic) 1360-2276 (Linking)'
p13971
sS'DCOM'
p13972
S'20150706'
p13973
sS'AU'
p13974
(lp13975
S'Tweve EN'
p13976
aS'Kayabu D'
p13977
aS'Nassari NO'
p13978
aS'Todd J'
p13979
asS'VI'
p13980
S'20'
p13981
sS'MHDA'
p13982
S'2015/07/07 06:00'
p13983
sS'PHST'
p13984
(lp13985
S'2015/03/27 [aheadofprint]'
p13986
asS'OTO'
p13987
(lp13988
S'NOTNLM'
p13989
asS'MH'
p13990
(lp13991
S'Adolescent'
p13992
aS'Adult'
p13993
aS'Anti-HIV Agents/*therapeutic use'
p13994
aS'CD4 Lymphocyte Count'
p13995
aS'Female'
p13996
aS'HIV Infections/*drug therapy/*mortality'
p13997
aS'Humans'
p13998
aS'*Lost to Follow-Up'
p13999
aS'Male'
p14000
aS'Medication Adherence/*statistics & numerical data'
p14001
aS'Middle Aged'
p14002
aS'Retrospective Studies'
p14003
aS'Risk Factors'
p14004
aS'Survival Rate'
p14005
aS'Tanzania/epidemiology'
p14006
aS'Time Factors'
p14007
aS'Treatment Outcome'
p14008
aS'Urban Population'
p14009
asS'EDAT'
p14010
S'2015/02/24 06:00'
p14011
sS'SO'
p14012
S'Trop Med Int Health. 2015 Jun;20(6):791-6. doi: 10.1111/tmi.12488. Epub 2015 Mar 27.'
p14013
sS'SB'
p14014
S'IM'
p14015
sS'PMID'
p14016
S'25706518'
p14017
sS'OT'
p14018
(lp14019
S'HIV-infected patients'
p14020
aS'Tanzania'
p14021
aS'Tanzanie'
p14022
aS'antiretroviral therapy'
p14023
aS'mortalidad'
p14024
aS'mortality'
p14025
aS'mortalite'
p14026
aS'pacientes infectados con VIH'
p14027
aS'patients infectes par le VIH'
p14028
aS'retencion'
p14029
aS'retention'
p14030
aS'retention'
p14031
aS'terapia antirretroviral'
p14032
aS'traitement antiretroviral'
p14033
asS'PST'
p14034
S'ppublish'
p14035
stRp14036
ag2
(g3
g4
(dp14037
S'LID'
p14038
S'10.1097/QAI.0000000000000492 [doi]'
p14039
sS'STAT'
p14040
S'MEDLINE'
p14041
sS'JT'
p14042
S'Journal of acquired immune deficiency syndromes (1999)'
p14043
sS'MID'
p14044
(lp14045
S'NIHMS650908'
p14046
asS'DA'
p14047
S'20150219'
p14048
sS'AID'
p14049
(lp14050
S'10.1097/QAI.0000000000000492 [doi]'
p14051
aS'00126334-201504010-00017 [pii]'
p14052
asS'CRDT'
p14053
(lp14054
S'2015/02/19 06:00'
p14055
asS'DP'
p14056
S'2015 Apr 1'
p14057
sS'AD'
p14058
S'*Academic Model Providing Access To Healthcare, Eldoret, Kenya; daggerDivision of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada; double daggerDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA; section signMoi University School of Public Health, Kenya; Departments of ||Behavioral Sciences; and paragraph signMedicine, School of Medicine, College of Health Sciences, Moi University, Eldoret, Kenya.'
p14059
sS'OWN'
p14060
S'NLM'
p14061
sS'PT'
p14062
(lp14063
S'Journal Article'
p14064
aS'Research Support, N.I.H., Extramural'
p14065
asS'LA'
p14066
(lp14067
S'eng'
p14068
asS'FAU'
p14069
(lp14070
S'Rachlis, Beth'
p14071
aS'Ochieng, Daniel'
p14072
aS'Geng, Elvin'
p14073
aS'Rotich, Elyne'
p14074
aS'Ochieng, Vincent'
p14075
aS'Maritim, Beryl'
p14076
aS'Ndege, Samson'
p14077
aS'Naanyu, Violet'
p14078
aS'Martin, Jeffrey N'
p14079
aS'Keter, Alfred'
p14080
aS'Ayuo, Paul'
p14081
aS'Diero, Lameck'
p14082
aS'Nyambura, Monicah'
p14083
aS'Braitstein, Paula'
p14084
asS'LR'
p14085
S'20160401'
p14086
sS'PG'
p14087
S'e46-55'
p14088
sS'TI'
p14089
S'Implementation and operational research: evaluating outcomes of patients lost to follow-up in a large comprehensive care treatment program in western Kenya.'
p14090
sS'PL'
p14091
S'United States'
p14092
sS'TA'
p14093
S'J Acquir Immune Defic Syndr'
p14094
sS'JID'
p14095
S'100892005'
p14096
sS'AB'
p14097
S'BACKGROUND: Academic Model Providing Access To Healthcare (AMPATH) program provides comprehensive HIV care and treatment services. Approximately, 30% of patients have become lost to follow-up (LTFU). We sought to actively trace and identify outcomes for a sample of these patients. METHODS: LTFU was defined as missing a scheduled visit by >/=3 months. A randomly selected sample of 17% of patients identified as LTFU between January 2009 and June 2011 was generated, with sample stratification on age, antiretroviral therapy (ART) status at last visit, and facility. Chart reviews were conducted followed by active tracing. Tracing was completed by trained HIV-positive outreach workers July 2011 to February 2012. Outcomes were compared between adults and children and by ART status. RESULTS: Of 14,811 LTFU patients, 2540 were randomly selected for tracing (2179 adults, 1071 on ART). The chart reviews indicated that 326 (12.8%) patients were not actually LTFU. Outcomes for 71% of sampled patients were determined including 85% of those physically traced. Of those with known outcomes, 21% had died, whereas 29% had disengaged from care for various reasons. The remaining patients had moved away (n = 458, 25%) or were still receiving HIV care (n = 443 total, 25%). CONCLUSIONS: Our findings demonstrate the feasibility of a large-scale sampling-based approach. A significant proportion of patients were found not to be LTFU, and further, high numbers of patients who were LTFU could not be located. Over a quarter of patients disengaged from care for various reasons including access challenges and familial influences.'
p14098
sS'GR'
p14099
(lp14100
S'2U01AI069911-06/AI/NIAID NIH HHS/United States'
p14101
aS'P30 AI027763/AI/NIAID NIH HHS/United States'
p14102
aS'P30 AI027763/AI/NIAID NIH HHS/United States'
p14103
aS'P30A1027763/PHS HHS/United States'
p14104
aS'U01 AI069911/AI/NIAID NIH HHS/United States'
p14105
aS'U01AI069911/AI/NIAID NIH HHS/United States'
p14106
asS'IP'
p14107
S'4'
sS'IS'
p14108
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p14109
sS'PMC'
p14110
S'PMC4348019'
p14111
sS'DCOM'
p14112
S'20150421'
p14113
sS'AU'
p14114
(lp14115
S'Rachlis B'
p14116
aS'Ochieng D'
p14117
aS'Geng E'
p14118
aS'Rotich E'
p14119
aS'Ochieng V'
p14120
aS'Maritim B'
p14121
aS'Ndege S'
p14122
aS'Naanyu V'
p14123
aS'Martin JN'
p14124
aS'Keter A'
p14125
aS'Ayuo P'
p14126
aS'Diero L'
p14127
aS'Nyambura M'
p14128
aS'Braitstein P'
p14129
asS'VI'
p14130
S'68'
p14131
sS'MHDA'
p14132
S'2015/04/22 06:00'
p14133
sS'OID'
p14134
(lp14135
S'NLM: NIHMS650908'
p14136
aS'NLM: PMC4348019'
p14137
asS'MH'
p14138
(lp14139
S'Adolescent'
p14140
aS'Adult'
p14141
aS'Child'
p14142
aS'Child, Preschool'
p14143
aS'Female'
p14144
aS'HIV Infections/*drug therapy'
p14145
aS'Humans'
p14146
aS'Infant'
p14147
aS'Infant, Newborn'
p14148
aS'Kenya'
p14149
aS'*Lost to Follow-Up'
p14150
aS'Male'
p14151
aS'Middle Aged'
p14152
aS'Young Adult'
p14153
asS'EDAT'
p14154
S'2015/02/19 06:00'
p14155
sS'SO'
p14156
S'J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):e46-55. doi: 10.1097/QAI.0000000000000492.'
p14157
sS'SB'
p14158
S'IM X'
p14159
sS'PMID'
p14160
S'25692336'
p14161
sS'PST'
p14162
S'ppublish'
p14163
stRp14164
ag2
(g3
g4
(dp14165
S'LID'
p14166
S'10.1111/hiv.12245 [doi]'
p14167
sS'STAT'
p14168
S'MEDLINE'
p14169
sS'DEP'
p14170
S'20150217'
p14171
sS'CI'
p14172
(lp14173
S'(c) 2015 British HIV Association.'
p14174
asS'DA'
p14175
S'20150806'
p14176
sS'AID'
p14177
(lp14178
S'10.1111/hiv.12245 [doi]'
p14179
asS'CRDT'
p14180
(lp14181
S'2015/02/18 06:00'
p14182
asS'DP'
p14183
S'2015 Sep'
p14184
sS'OWN'
p14185
S'NLM'
p14186
sS'PT'
p14187
(lp14188
S'Journal Article'
p14189
aS"Research Support, Non-U.S. Gov't"
p14190
asS'LA'
p14191
(lp14192
S'eng'
p14193
asS'FAU'
p14194
(lp14195
S'Govender, N P'
p14196
aS'Roy, M'
p14197
aS'Mendes, J F'
p14198
aS'Zulu, T G'
p14199
aS'Chiller, T M'
p14200
aS'Karstaedt, A S'
p14201
asS'JT'
p14202
S'HIV medicine'
p14203
sS'PG'
p14204
S'468-76'
p14205
sS'TI'
p14206
S'Evaluation of screening and treatment of cryptococcal antigenaemia among HIV-infected persons in Soweto, South Africa.'
p14207
sS'RN'
p14208
(lp14209
S'0 (Antifungal Agents)'
p14210
aS'0 (Antigens, Fungal)'
p14211
asS'PL'
p14212
S'England'
p14213
sS'TA'
p14214
S'HIV Med'
p14215
sS'JID'
p14216
S'100897392'
p14217
sS'AB'
p14218
S'OBJECTIVES: We retrospectively evaluated clinic-based screening to determine the prevalence of cryptococcal antigenaemia and management and outcome of patients with antigenaemia. METHODS: Cryptococcal antigen (CrAg) screening of HIV-infected adults who attended the HIV clinic at Chris Hani Baragwanath Hospital was conducted over 19 months. Data collected from CrAg-positive patients included CD4 T-lymphocyte count at screening, prior or subsequent cryptococcal meningitis (CM), antifungal and antiretroviral treatment and outcome after at least 8 months. RESULTS: Of 1460 patients with no prior CM, 30 (2.1%) had a positive CrAg test. The prevalence of antigenaemia among patients with a CD4 count < 100 cells/mul and no prior CM was 2.8% (20 of 708). Of 29 evaluable CrAg-positive patients with no prior CM, 14 (48%) did not return for post-screening follow-up. Of these 14, five developed CM and one (7%) was known to be alive at follow-up. Of 15 patients who returned for follow-up, two already had evidence of nonmeningeal cryptococcosis. Overall, 11 received fluconazole, one did not and fluconazole treatment was unknown for three. Among these 15, one developed CM and 10 (67%) were known to be alive at follow-up. Overall, 18 (62%) of 29 CrAg-positive patients died or were lost to follow-up. Seven (0.5%) of 1430 CrAg-negative patients developed CM a median of 83 days post-screening (range 34 to 219 days). CONCLUSIONS: Loss to follow-up is the major operational issue relevant to scale-up of screen-and-treat. Patient outcomes may be improved by rapid access to CrAg results and focus on linkage to and retention in HIV care.'
p14219
sS'AD'
p14220
S'National Institute for Communicable Diseases (Centre for Opportunistic, Tropical and Hospital Infections), a Division of the National Health Laboratory Service, Johannesburg, South Africa. Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA. Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Department of Community Health, Gauteng Department of Health, Johannesburg, South Africa. National Institute for Communicable Diseases (Centre for Opportunistic, Tropical and Hospital Infections), a Division of the National Health Laboratory Service, Johannesburg, South Africa. Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA. Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Division of Infectious Diseases, Department of Medicine, Chris Hani Baragwanath Hospital, Soweto, South Africa.'
p14221
sS'IP'
p14222
S'8'
sS'IS'
p14223
S'1468-1293 (Electronic) 1464-2662 (Linking)'
p14224
sS'DCOM'
p14225
S'20160427'
p14226
sS'AU'
p14227
(lp14228
S'Govender NP'
p14229
aS'Roy M'
p14230
aS'Mendes JF'
p14231
aS'Zulu TG'
p14232
aS'Chiller TM'
p14233
aS'Karstaedt AS'
p14234
asS'VI'
p14235
S'16'
p14236
sS'MHDA'
p14237
S'2016/04/28 06:00'
p14238
sS'PHST'
p14239
(lp14240
S'2014/11/25 [accepted]'
p14241
aS'2015/02/17 [aheadofprint]'
p14242
asS'OTO'
p14243
(lp14244
S'NOTNLM'
p14245
asS'MH'
p14246
(lp14247
S'AIDS-Related Opportunistic Infections/diagnosis/drug therapy/*epidemiology'
p14248
aS'Adult'
p14249
aS'Antifungal Agents/therapeutic use'
p14250
aS'Antigens, Fungal/analysis/blood'
p14251
aS'CD4 Lymphocyte Count'
p14252
aS'Cryptococcus neoformans/immunology/isolation & purification'
p14253
aS'Female'
p14254
aS'HIV Infections/*complications'
p14255
aS'Humans'
p14256
aS'Male'
p14257
aS'Meningitis, Cryptococcal/diagnosis/drug therapy/*epidemiology'
p14258
aS'Middle Aged'
p14259
aS'Prevalence'
p14260
aS'Retrospective Studies'
p14261
aS'South Africa/epidemiology'
p14262
asS'EDAT'
p14263
S'2015/02/18 06:00'
p14264
sS'SO'
p14265
S'HIV Med. 2015 Sep;16(8):468-76. doi: 10.1111/hiv.12245. Epub 2015 Feb 17.'
p14266
sS'SB'
p14267
S'IM'
p14268
sS'PMID'
p14269
S'25689352'
p14270
sS'OT'
p14271
(lp14272
S'South Africa'
p14273
aS'cryptococcal antigen'
p14274
aS'cryptococcal meningitis'
p14275
aS'evaluation'
p14276
aS'screen-and-treat'
p14277
asS'PST'
p14278
S'ppublish'
p14279
stRp14280
ag2
(g3
g4
(dp14281
S'LID'
p14282
S'10.1056/NEJMoa1408896 [doi]'
p14283
sS'STAT'
p14284
S'MEDLINE'
p14285
sS'JT'
p14286
S'The New England journal of medicine'
p14287
sS'CIN'
p14288
(lp14289
S'N Engl J Med. 2015 May 21;372(21):2070. PMID: 25992756'
p14290
aS'N Engl J Med. 2015 May 21;372(21):2069-70. PMID: 25992755'
p14291
aS'N Engl J Med. 2015 May 21;372(21):2069. PMID: 25992754'
p14292
aS'Transplantation. 2015 Sep;99(9):1744-5. PMID: 26308409'
p14293
aS'N Engl J Med. 2015 May 21;372(21):2070-1. PMID: 25992753'
p14294
aS'Nat Rev Nephrol. 2015 Apr;11(4):197. PMID: 25708167'
p14295
aS'N Engl J Med. 2015 Feb 12;372(7):663-5. PMID: 25671260'
p14296
asS'DA'
p14297
S'20150212'
p14298
sS'AID'
p14299
(lp14300
S'10.1056/NEJMoa1408896 [doi]'
p14301
asS'CRDT'
p14302
(lp14303
S'2015/02/12 06:00'
p14304
asS'DP'
p14305
S'2015 Feb 12'
p14306
sS'OWN'
p14307
S'NLM'
p14308
sS'PT'
p14309
(lp14310
S'Clinical Trial'
p14311
aS'Journal Article'
p14312
aS"Research Support, Non-U.S. Gov't"
p14313
asS'LA'
p14314
(lp14315
S'eng'
p14316
asS'FAU'
p14317
(lp14318
S'Muller, Elmi'
p14319
aS'Barday, Zunaid'
p14320
aS'Mendelson, Marc'
p14321
aS'Kahn, Delawir'
p14322
asS'LR'
p14323
S'20151103'
p14324
sS'PG'
p14325
S'613-20'
p14326
sS'TI'
p14327
S'HIV-positive-to-HIV-positive kidney transplantation--results at 3 to 5 years.'
p14328
sS'RN'
p14329
(lp14330
S'0 (Anti-Retroviral Agents)'
p14331
asS'PL'
p14332
S'United States'
p14333
sS'TA'
p14334
S'N Engl J Med'
p14335
sS'JID'
p14336
S'0255562'
p14337
sS'AB'
p14338
S'BACKGROUND: The outcome of kidney transplantation in human immunodeficiency virus (HIV)-positive patients who receive organs from HIV-negative donors has been reported to be similar to the outcome in HIV-negative recipients. We report the outcomes at 3 to 5 years in HIV-positive patients who received kidneys from HIV-positive deceased donors. METHODS: We conducted a prospective, nonrandomized study of kidney transplantation in HIV-infected patients who had a CD4 T-cell count of 200 per cubic millimeter or higher and an undetectable plasma HIV RNA level. All the patients were receiving antiretroviral therapy (ART). The patients received kidneys from deceased donors who tested positive for HIV with the use of fourth-generation enzyme-linked immunosorbent assay at the time of referral. All the donors either had received no ART previously or had received only first-line ART. RESULTS: From September 2008 through February 2014, a total of 27 HIV-positive patients underwent kidney transplantation. Survivors were followed for a median of 2.4 years. The rate of survival among the patients was 84% at 1 year, 84% at 3 years, and 74% at 5 years. The corresponding rates of graft survival were 93%, 84%, and 84%. (If a patient died with a functioning graft, the calculation was performed as if the graft had survived.) Rejection rates were 8% at 1 year and 22% at 3 years. HIV infection remained well controlled, with undetectable virus in blood after the transplantation. CONCLUSIONS: Kidney transplantation from an HIV-positive donor appears to be an additional treatment option for HIV-infected patients requiring renal-replacement therapy. (Funded by Sanofi South Africa and the Roche Organ Transplantation Research Foundation.).'
p14339
sS'AD'
p14340
S'From the Transplant Unit, Department of Surgery (E.M.), Division of Nephrology, Department of Medicine (Z.B.), Division of Infectious Diseases and HIV Medicine, Department of Medicine (M.M.), and the Department of Surgery (D.K.), University of Cape Town, Groote Schuur Hospital, Cape Town, South Africa.'
p14341
sS'IP'
p14342
S'7'
sS'IS'
p14343
S'1533-4406 (Electronic) 0028-4793 (Linking)'
p14344
sS'DCOM'
p14345
S'20150218'
p14346
sS'AU'
p14347
(lp14348
S'Muller E'
p14349
aS'Barday Z'
p14350
aS'Mendelson M'
p14351
aS'Kahn D'
p14352
asS'VI'
p14353
S'372'
p14354
sS'MHDA'
p14355
S'2015/02/19 06:00'
p14356
sS'MH'
p14357
(lp14358
S'Adult'
p14359
aS'Allografts'
p14360
aS'Anti-Retroviral Agents/therapeutic use'
p14361
aS'Antibiotic Prophylaxis'
p14362
aS'CD4 Lymphocyte Count'
p14363
aS'Disease Progression'
p14364
aS'Female'
p14365
aS'Follow-Up Studies'
p14366
aS'Graft Rejection'
p14367
aS'*HIV Seropositivity/complications/drug therapy'
p14368
aS'Humans'
p14369
aS'*Kidney Transplantation'
p14370
aS'Male'
p14371
aS'Middle Aged'
p14372
aS'Postoperative Complications'
p14373
aS'Renal Insufficiency, Chronic/complications/*surgery'
p14374
aS'South Africa'
p14375
aS'*Tissue Donors'
p14376
asS'EDAT'
p14377
S'2015/02/12 06:00'
p14378
sS'SO'
p14379
S'N Engl J Med. 2015 Feb 12;372(7):613-20. doi: 10.1056/NEJMoa1408896.'
p14380
sS'SB'
p14381
S'AIM IM'
p14382
sS'PMID'
p14383
S'25671253'
p14384
sS'PST'
p14385
S'ppublish'
p14386
stRp14387
ag2
(g3
g4
(dp14388
S'LID'
p14389
S'10.1371/journal.pone.0118145 [doi]'
p14390
sS'STAT'
p14391
S'MEDLINE'
p14392
sS'DEP'
p14393
S'20150206'
p14394
sS'DA'
p14395
S'20150209'
p14396
sS'AID'
p14397
(lp14398
S'10.1371/journal.pone.0118145 [doi]'
p14399
aS'PONE-D-14-43606 [pii]'
p14400
asS'CRDT'
p14401
(lp14402
S'2015/02/07 06:00'
p14403
asS'DP'
p14404
S'2015'
p14405
sS'OWN'
p14406
S'NLM'
p14407
sS'PT'
p14408
(lp14409
S'Journal Article'
p14410
asS'LA'
p14411
(lp14412
S'eng'
p14413
asS'FAU'
p14414
(lp14415
S'Skhosana, Lindiwe'
p14416
aS'Steegen, Kim'
p14417
aS'Bronze, Michelle'
p14418
aS'Lukhwareni, Azwidowi'
p14419
aS'Letsoalo, Esrom'
p14420
aS'Papathanasopoulos, Maria A'
p14421
aS'Carmona, Sergio C'
p14422
aS'Stevens, Wendy S'
p14423
asS'JT'
p14424
S'PloS one'
p14425
sS'LR'
p14426
S'20151119'
p14427
sS'PG'
p14428
S'e0118145'
p14429
sS'TI'
p14430
S'High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa.'
p14431
sS'RN'
p14432
(lp14433
S'0 (Anti-HIV Agents)'
p14434
aS'0 (Organophosphonates)'
p14435
aS'99YXE507IL (Tenofovir)'
p14436
aS'JAC85A2161 (Adenine)'
p14437
asS'PL'
p14438
S'United States'
p14439
sS'TA'
p14440
S'PLoS One'
p14441
sS'JID'
p14442
S'101285081'
p14443
sS'AB'
p14444
S'BACKGROUND: Tenofovir (TDF) has replaced stavudine (d4T) as the preferred nucleoside reverse transcriptase inhibitor (NRTI) in first-line regimens in South Africa, but limited information is available on the resistance patterns that develop after the introduction of TDF. This study investigated the antiretroviral drug resistance patterns in South African HIV-1 subtype C-infected patients failing stavudine- (d4T) and tenofovir- (TDF) based first-line regimens and assess the suitability of TDF as the preferred first-line nucleotide reverse transcriptase inhibitor (NRTI). METHODS: Resistance patterns of HIV-1 from 160 adult patients virologically failing TDF- (n = 80) and d4T- (n = 80) based first-line regimens were retrospectively analyzed. The pol gene was sequenced using an in-house protocol and mutations were analysed using the IAS-USA 2014 Drug Resistance Mutation list. RESULTS: Compared to d4T-exposed patients (n = 7), patients failing on a TDF-containing regimen (n = 43) were almost 5 times more likely to present with a K65R mutation (aRR 4.86 95% CI 2.29 - 10.34). Y115F was absent in the d4T group, and detected in 13.8% (n = 11) of TDF-exposed patients, p = 0.0007. Virus from 9 of the 11 patients (82.0%) who developed the Y115F mutation also developed K65R. Intermediate or high-level resistance to most NRTIs was common in the TDF-treatment group, but these patients twice more likely to remain susceptible to AZT as compared to those exposed to d4T (aRR 2.09 95% CI 1.13 - 3.90). CONCLUSION: The frequency of the TDF induced K65R mutation was higher in our setting compared to non-subtype C dominated countries. However, despite the higher frequency of cross-resistance to NRTIs, most patients remained susceptible to AZT, which is reflected in the South African treatment guidelines that recommend AZT as an essential component of second-line regimens.'
p14445
sS'AD'
p14446
S'Department of Haematology and Molecular Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Department of Haematology and Molecular Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Department of Haematology and Molecular Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. National Health Laboratory Services, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa. Department of Haematology and Molecular Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Department of Haematology and Molecular Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Department of Haematology and Molecular Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; National Health Laboratory Services, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa. Department of Haematology and Molecular Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; National Health Laboratory Services, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa.'
p14447
sS'IP'
p14448
S'2'
sS'IS'
p14449
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p14450
sS'PMC'
p14451
S'PMC4320083'
p14452
sS'DCOM'
p14453
S'20151022'
p14454
sS'AU'
p14455
(lp14456
S'Skhosana L'
p14457
aS'Steegen K'
p14458
aS'Bronze M'
p14459
aS'Lukhwareni A'
p14460
aS'Letsoalo E'
p14461
aS'Papathanasopoulos MA'
p14462
aS'Carmona SC'
p14463
aS'Stevens WS'
p14464
asS'VI'
p14465
S'10'
p14466
sS'MHDA'
p14467
S'2015/10/23 06:00'
p14468
sS'PHST'
p14469
(lp14470
S'2015 [ecollection]'
p14471
aS'2014/10/02 [received]'
p14472
aS'2015/01/05 [accepted]'
p14473
aS'2015/02/06 [epublish]'
p14474
asS'OID'
p14475
(lp14476
S'NLM: PMC4320083'
p14477
asS'MH'
p14478
(lp14479
S'Adenine/analogs & derivatives/pharmacology/therapeutic use'
p14480
aS'Adolescent'
p14481
aS'Adult'
p14482
aS'Anti-HIV Agents/pharmacology/therapeutic use'
p14483
aS'Antiretroviral Therapy, Highly Active'
p14484
aS'CD4 Lymphocyte Count'
p14485
aS'Drug Resistance, Viral'
p14486
aS'Female'
p14487
aS'*Genotype'
p14488
aS'HIV Infections/drug therapy/epidemiology/*virology'
p14489
aS'HIV-1/drug effects/*genetics'
p14490
aS'Humans'
p14491
aS'Male'
p14492
aS'Middle Aged'
p14493
aS'Molecular Sequence Data'
p14494
aS'*Mutation'
p14495
aS'Organophosphonates/pharmacology/therapeutic use'
p14496
aS'Prevalence'
p14497
aS'South Africa/epidemiology'
p14498
aS'Tenofovir'
p14499
aS'Viral Load'
p14500
aS'Young Adult'
p14501
asS'EDAT'
p14502
S'2015/02/07 06:00'
p14503
sS'SI'
p14504
(lp14505
S'GENBANK/KM115717'
p14506
aS'GENBANK/KM115718'
p14507
aS'GENBANK/KM115719'
p14508
aS'GENBANK/KM115720'
p14509
aS'GENBANK/KM115721'
p14510
aS'GENBANK/KM115722'
p14511
aS'GENBANK/KM115723'
p14512
aS'GENBANK/KM115724'
p14513
aS'GENBANK/KM115725'
p14514
aS'GENBANK/KM115726'
p14515
aS'GENBANK/KM115727'
p14516
aS'GENBANK/KM115728'
p14517
aS'GENBANK/KM115729'
p14518
aS'GENBANK/KM115730'
p14519
aS'GENBANK/KM115731'
p14520
aS'GENBANK/KM115732'
p14521
aS'GENBANK/KM115733'
p14522
aS'GENBANK/KM115734'
p14523
aS'GENBANK/KM115735'
p14524
aS'GENBANK/KM115736'
p14525
aS'GENBANK/KM115737'
p14526
aS'GENBANK/KM115738'
p14527
aS'GENBANK/KM115739'
p14528
aS'GENBANK/KM115740'
p14529
aS'GENBANK/KM115741'
p14530
aS'GENBANK/KM115742'
p14531
aS'GENBANK/KM115743'
p14532
aS'GENBANK/KM115744'
p14533
aS'GENBANK/KM115745'
p14534
aS'GENBANK/KM115746'
p14535
aS'GENBANK/KM115747'
p14536
aS'GENBANK/KM115748'
p14537
aS'GENBANK/KM115749'
p14538
aS'GENBANK/KM115750'
p14539
aS'GENBANK/KM115751'
p14540
aS'GENBANK/KM115752'
p14541
aS'GENBANK/KM115753'
p14542
aS'GENBANK/KM115754'
p14543
aS'GENBANK/KM115755'
p14544
aS'GENBANK/KM115756'
p14545
aS'GENBANK/KM115757'
p14546
aS'GENBANK/KM115758'
p14547
aS'GENBANK/KM115759'
p14548
aS'GENBANK/KM115760'
p14549
aS'GENBANK/KM115761'
p14550
aS'GENBANK/KM115762'
p14551
aS'GENBANK/KM115763'
p14552
aS'GENBANK/KM115764'
p14553
aS'GENBANK/KM115765'
p14554
aS'GENBANK/KM115766'
p14555
aS'GENBANK/KM115767'
p14556
aS'GENBANK/KM115768'
p14557
aS'GENBANK/KM115769'
p14558
aS'GENBANK/KM115770'
p14559
aS'GENBANK/KM115771'
p14560
aS'GENBANK/KM115772'
p14561
aS'GENBANK/KM115773'
p14562
aS'GENBANK/KM115774'
p14563
aS'GENBANK/KM115775'
p14564
aS'GENBANK/KM115776'
p14565
aS'GENBANK/KM115777'
p14566
aS'GENBANK/KM115778'
p14567
aS'GENBANK/KM115779'
p14568
aS'GENBANK/KM115780'
p14569
aS'GENBANK/KM115781'
p14570
aS'GENBANK/KM115782'
p14571
aS'GENBANK/KM115783'
p14572
aS'GENBANK/KM115784'
p14573
aS'GENBANK/KM115785'
p14574
aS'GENBANK/KM115786'
p14575
aS'GENBANK/KM115787'
p14576
aS'GENBANK/KM115788'
p14577
aS'GENBANK/KM115789'
p14578
aS'GENBANK/KM115790'
p14579
aS'GENBANK/KM115791'
p14580
aS'GENBANK/KM115792'
p14581
aS'GENBANK/KM115793'
p14582
aS'GENBANK/KM115794'
p14583
aS'GENBANK/KM115795'
p14584
aS'GENBANK/KM115796'
p14585
aS'GENBANK/KM115797'
p14586
aS'GENBANK/KM115798'
p14587
aS'GENBANK/KM115799'
p14588
aS'GENBANK/KM115800'
p14589
aS'GENBANK/KM115801'
p14590
aS'GENBANK/KM115802'
p14591
aS'GENBANK/KM115803'
p14592
aS'GENBANK/KM115804'
p14593
aS'GENBANK/KM115805'
p14594
aS'GENBANK/KM115806'
p14595
aS'GENBANK/KM115807'
p14596
aS'GENBANK/KM115808'
p14597
aS'GENBANK/KM115809'
p14598
aS'GENBANK/KM115810'
p14599
aS'GENBANK/KM115811'
p14600
aS'GENBANK/KM115812'
p14601
aS'GENBANK/KM115813'
p14602
aS'GENBANK/KM115814'
p14603
aS'GENBANK/KM115815'
p14604
aS'GENBANK/KM115816'
p14605
aS'GENBANK/KM115817'
p14606
aS'GENBANK/KM115818'
p14607
aS'GENBANK/KM115819'
p14608
aS'GENBANK/KM115820'
p14609
aS'GENBANK/KM115821'
p14610
aS'GENBANK/KM115822'
p14611
aS'GENBANK/KM115823'
p14612
aS'GENBANK/KM115824'
p14613
aS'GENBANK/KM115825'
p14614
aS'GENBANK/KM115826'
p14615
aS'GENBANK/KM115827'
p14616
aS'GENBANK/KM115828'
p14617
aS'GENBANK/KM115829'
p14618
aS'GENBANK/KM115830'
p14619
aS'GENBANK/KM115831'
p14620
aS'GENBANK/KM115832'
p14621
aS'GENBANK/KM115833'
p14622
aS'GENBANK/KM115834'
p14623
aS'GENBANK/KM115835'
p14624
aS'GENBANK/KM115836'
p14625
aS'GENBANK/KM115837'
p14626
aS'GENBANK/KM115838'
p14627
aS'GENBANK/KM115839'
p14628
aS'GENBANK/KM115840'
p14629
aS'GENBANK/KM115841'
p14630
aS'GENBANK/KM115842'
p14631
aS'GENBANK/KM115843'
p14632
aS'GENBANK/KM115844'
p14633
aS'GENBANK/KM115845'
p14634
aS'GENBANK/KM115846'
p14635
aS'GENBANK/KM115847'
p14636
aS'GENBANK/KM115848'
p14637
aS'GENBANK/KM115849'
p14638
aS'GENBANK/KM115850'
p14639
aS'GENBANK/KM115851'
p14640
aS'GENBANK/KM115852'
p14641
aS'GENBANK/KM115853'
p14642
aS'GENBANK/KM115854'
p14643
aS'GENBANK/KM115855'
p14644
aS'GENBANK/KM115856'
p14645
aS'GENBANK/KM115857'
p14646
aS'GENBANK/KM115858'
p14647
aS'GENBANK/KM115859'
p14648
aS'GENBANK/KM115860'
p14649
aS'GENBANK/KM115861'
p14650
aS'GENBANK/KM115862'
p14651
aS'GENBANK/KM115863'
p14652
aS'GENBANK/KM115864'
p14653
aS'GENBANK/KM115865'
p14654
aS'GENBANK/KM115866'
p14655
aS'GENBANK/KM115867'
p14656
aS'GENBANK/KM115868'
p14657
aS'GENBANK/KM115869'
p14658
aS'GENBANK/KM115870'
p14659
aS'GENBANK/KM115871'
p14660
aS'GENBANK/KM115872'
p14661
aS'GENBANK/KM115873'
p14662
aS'GENBANK/KM115874'
p14663
aS'GENBANK/KM115875'
p14664
aS'GENBANK/KM115876'
p14665
asS'SO'
p14666
S'PLoS One. 2015 Feb 6;10(2):e0118145. doi: 10.1371/journal.pone.0118145. eCollection 2015.'
p14667
sS'SB'
p14668
S'IM'
p14669
sS'PMID'
p14670
S'25659108'
p14671
sS'PST'
p14672
S'epublish'
p14673
stRp14674
ag2
(g3
g4
(dp14675
S'LID'
p14676
S'10.1371/journal.pone.0118191 [doi]'
p14677
sS'STAT'
p14678
S'MEDLINE'
p14679
sS'DEP'
p14680
S'20150206'
p14681
sS'DA'
p14682
S'20150209'
p14683
sS'AID'
p14684
(lp14685
S'10.1371/journal.pone.0118191 [doi]'
p14686
aS'PONE-D-14-52851 [pii]'
p14687
asS'CRDT'
p14688
(lp14689
S'2015/02/07 06:00'
p14690
asS'DP'
p14691
S'2015'
p14692
sS'AD'
p14693
S'Epicentre Mbarara Research Centre, Mbarara, Uganda; Department of Microbiology, Mbarara University of Science and Technology, Mbarara, Uganda. Department of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda. Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, United States of America. Epicentre Mbarara Research Centre, Mbarara, Uganda. Department of Microbiology, Mbarara University of Science and Technology, Mbarara, Uganda. Department of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda; Department of Medicine, Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, Virginia, United States of America. Department of Medicine, Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, Virginia, United States of America. Epicentre Paris, Paris, France. Epicentre Paris, Paris, France. Department of Microbiology, Mbarara University of Science and Technology, Mbarara, Uganda. Epicentre Mbarara Research Centre, Mbarara, Uganda; Department of Microbiology, Mbarara University of Science and Technology, Mbarara, Uganda.'
p14694
sS'OWN'
p14695
S'NLM'
p14696
sS'PT'
p14697
(lp14698
S'Journal Article'
p14699
aS'Research Support, N.I.H., Extramural'
p14700
aS"Research Support, Non-U.S. Gov't"
p14701
aS"Research Support, U.S. Gov't, P.H.S."
p14702
asS'LA'
p14703
(lp14704
S'eng'
p14705
asS'FAU'
p14706
(lp14707
S'Orikiriza, Patrick'
p14708
aS'Tibenderana, Becky'
p14709
aS'Siedner, Mark J'
p14710
aS'Mueller, Yolanda'
p14711
aS'Byarugaba, Frederick'
p14712
aS'Moore, Christopher C'
p14713
aS'Evans, Emily E'
p14714
aS'Bonnet, Maryline'
p14715
aS'Page, Anne-Laure'
p14716
aS'Bazira, Joel'
p14717
aS'Boum, Yap 2nd'
p14718
asS'JT'
p14719
S'PloS one'
p14720
sS'LR'
p14721
S'20151028'
p14722
sS'PG'
p14723
S'e0118191'
p14724
sS'TI'
p14725
S'Low resistance to first and second line anti-tuberculosis drugs among treatment naive pulmonary tuberculosis patients in southwestern Uganda.'
p14726
sS'RN'
p14727
(lp14728
S'0 (Antitubercular Agents)'
p14729
asS'PL'
p14730
S'United States'
p14731
sS'TA'
p14732
S'PLoS One'
p14733
sS'JID'
p14734
S'101285081'
p14735
sS'AB'
p14736
S'BACKGROUND: There are limited data on region-specific drug susceptibility of tuberculosis (TB) in Uganda. We performed resistance testing on specimens collected from treatment-naive patients with pulmonary TB in Southwestern Uganda for first and second line anti-TB drugs. We sought to provide data to guide regional recommendations for empiric TB therapy. METHODS: Archived isolates, obtained from patients at Mbarara Regional Referral Hospital from February 2009 to February 2013, were tested for resistance to isoniazid and rifampicin using the MTBDRplus and Xpert MTB/RIF assays. A subset of randomly selected isolates was tested for second line agents, including fluoroquinolones (FQs), aminoglycosides, cyclic peptides, and ethambutol using the MTBDRsl assay. We performed confirmatory testing for FQ resistance using repeated MTBDRsl, the Mycobacteria growth indicator tube (MGIT) assay, and sequencing of the gyrA and gyrB genes. RESULTS: We tested isolates from 190 patients. The cohort had a median age of 33 years (IQR 26-43), 69% (131/190) were male, and the HIV prevalence was 42% (80/190). No isolates (0/190) were rifampicin-resistant and only 1/190 (0.5%) was isoniazid-resistant. Among 92 isolates tested for second-line drug resistance, 71 (77%) had interpretable results, of which none were resistant to aminoglycosides, cyclic peptides or ethambutol. Although 7 (10%) initially tested as resistant to FQs by the MTBDRsl assay, they were confirmed as susceptible by repeat MTBDRsl testing as well as by MGIT and gyrase gene sequencing. CONCLUSION: We found no MDR-TB and no resistance to ethambutol, FQs, or injectable anti-TB drugs in treatment naive patients with pulmonary TB in Southwestern Uganda. Standard treatment guidelines for susceptible TB should be adequate for most patients with TB in this population. Where possible, molecular susceptibility testing methods should be routinely validated by culture methods.'
p14737
sS'GR'
p14738
(lp14739
S'5R24TW008886/TW/FIC NIH HHS/United States'
p14740
aS'K23 MH099916/MH/NIMH NIH HHS/United States'
p14741
aS'K23 MH099916/MH/NIMH NIH HHS/United States'
p14742
aS'R24 TW008886/TW/FIC NIH HHS/United States'
p14743
asS'IP'
p14744
S'2'
sS'IS'
p14745
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p14746
sS'PMC'
p14747
S'PMC4320102'
p14748
sS'DCOM'
p14749
S'20151022'
p14750
sS'AU'
p14751
(lp14752
S'Orikiriza P'
p14753
aS'Tibenderana B'
p14754
aS'Siedner MJ'
p14755
aS'Mueller Y'
p14756
aS'Byarugaba F'
p14757
aS'Moore CC'
p14758
aS'Evans EE'
p14759
aS'Bonnet M'
p14760
aS'Page AL'
p14761
aS'Bazira J'
p14762
aS'Boum Y 2nd'
p14763
asS'VI'
p14764
S'10'
p14765
sS'MHDA'
p14766
S'2015/10/23 06:00'
p14767
sS'PHST'
p14768
(lp14769
S'2015 [ecollection]'
p14770
aS'2014/11/24 [received]'
p14771
aS'2015/01/06 [accepted]'
p14772
aS'2015/02/06 [epublish]'
p14773
asS'OID'
p14774
(lp14775
S'NLM: PMC4320102'
p14776
asS'MH'
p14777
(lp14778
S'Adult'
p14779
aS'Antitubercular Agents/*pharmacology/*therapeutic use'
p14780
aS'*Drug Resistance, Bacterial'
p14781
aS'Female'
p14782
aS'Humans'
p14783
aS'Male'
p14784
aS'Microbial Sensitivity Tests'
p14785
aS'Mycobacterium tuberculosis/*drug effects'
p14786
aS'Tuberculosis, Pulmonary/*drug therapy/epidemiology/*microbiology'
p14787
aS'Uganda/epidemiology'
p14788
asS'EDAT'
p14789
S'2015/02/07 06:00'
p14790
sS'SO'
p14791
S'PLoS One. 2015 Feb 6;10(2):e0118191. doi: 10.1371/journal.pone.0118191. eCollection 2015.'
p14792
sS'SB'
p14793
S'IM'
p14794
sS'PMID'
p14795
S'25658921'
p14796
sS'PST'
p14797
S'epublish'
p14798
stRp14799
ag2
(g3
g4
(dp14800
S'LID'
p14801
S'10.1186/s12879-015-0778-2 [doi]'
p14802
sS'STAT'
p14803
S'MEDLINE'
p14804
sS'DEP'
p14805
S'20150206'
p14806
sS'DA'
p14807
S'20150418'
p14808
sS'AID'
p14809
(lp14810
S'10.1186/s12879-015-0778-2 [doi]'
p14811
aS's12879-015-0778-2 [pii]'
p14812
asS'CRDT'
p14813
(lp14814
S'2015/02/07 06:00'
p14815
asS'DP'
p14816
S'2015'
p14817
sS'OWN'
p14818
S'NLM'
p14819
sS'PT'
p14820
(lp14821
S'Journal Article'
p14822
aS'Observational Study'
p14823
aS"Research Support, Non-U.S. Gov't"
p14824
aS"Research Support, U.S. Gov't, Non-P.H.S."
p14825
asS'LA'
p14826
(lp14827
S'eng'
p14828
asS'DCOM'
p14829
S'20151218'
p14830
sS'JT'
p14831
S'BMC infectious diseases'
p14832
sS'LR'
p14833
S'20150420'
p14834
sS'FAU'
p14835
(lp14836
S'Schnippel, Kathryn'
p14837
aS'Mongwenyana, Constance'
p14838
aS'Long, Lawrence C'
p14839
aS'Larson, Bruce A'
p14840
asS'TI'
p14841
S'Delays, interruptions, and losses from prevention of mother-to-child transmission of HIV services during antenatal care in Johannesburg, South Africa: a cohort analysis.'
p14842
sS'PL'
p14843
S'England'
p14844
sS'PG'
p14845
S'46'
p14846
sS'JID'
p14847
S'100968551'
p14848
sS'AB'
p14849
S"BACKGROUND: Between 2010-2013, South Africa implemented WHO 'Option A' for prevention of mother to child transmission (PMTCT), where all HIV-infected pregnant women (from 14 weeks gestation) received zidovudine (AZT) as ARV prophylaxis and initiated CD4 testing at their first antenatal care (ANC) visit. After returning for a second visit to collect CD4 results, women with CD4 counts </= 350 were referred to the ART clinic and fast-tracked for initiation on lifelong ART while continuing to visit the ANC clinic every four weeks. Women with CD4 counts >350 were dispensed daily AZT prophylaxis at monthly follow up visits (every 4 weeks). The primary objective of this study was to evaluate adherence of HIV-infected pregnant women to recommended PMTCT services at and after their first antenatal care (ANC) visit. METHODS: We conducted an observational cohort study from August 2012 to February 2013 at two primary health care clinics in Johannesburg, South Africa using routinely collected clinic data from first ANC visit for up to 60 days. RESULTS: Of the 158 patients newly diagnosed with HIV at their first ANC visit, records indicated that 139 women initiated CD4 testing during their first ANC visit. 52 patients (33% of 158) did not return again to the clinic within 60 days. Of the 118 (84% of 139) women with known gestational age > 13 weeks and known Hb >/= 8 g/dl who should have received a 4-week supply of daily AZT at first ANC visit, 81 women (69% of 118) had a record of AZT being dispensed. Among the 139 women with CD4 results, 72 (52%) were eligible for lifelong ART (CD4 count </=350); however, only 2 initiated ART within 30 days. CONCLUSIONS: Loss to initiation of both single and triple ARV therapy, loss to follow-up, and treatment interruptions were common during ANC care for pregnant women with HIV after their first ANC visit."
p14850
sS'AD'
p14851
S'Health Economics and Epidemiology Research Office (HE2RO), School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. kschnipp@gmail.com. Health Economics and Epidemiology Research Office (HE2RO), School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. cmongwenyana@heroza.org. Health Economics and Epidemiology Research Office (HE2RO), School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. llong@heroza.org. Department of Global Health and the Center for Global Health and Development, Boston University School of Public Health, Boston, MA, USA. blarson@bu.edu.'
p14852
sS'VI'
p14853
S'15'
p14854
sS'IS'
p14855
S'1471-2334 (Electronic) 1471-2334 (Linking)'
p14856
sS'PMC'
p14857
S'PMC4322445'
p14858
sS'AU'
p14859
(lp14860
S'Schnippel K'
p14861
aS'Mongwenyana C'
p14862
aS'Long LC'
p14863
aS'Larson BA'
p14864
asS'MHDA'
p14865
S'2015/12/19 06:00'
p14866
sS'PHST'
p14867
(lp14868
S'2014/07/29 [received]'
p14869
aS'2015/01/23 [accepted]'
p14870
aS'2015/02/06 [aheadofprint]'
p14871
asS'OID'
p14872
(lp14873
S'NLM: PMC4322445'
p14874
asS'MH'
p14875
(lp14876
S'Adolescent'
p14877
aS'Adult'
p14878
aS'Cohort Studies'
p14879
aS'Female'
p14880
aS'HIV Infections/drug therapy/*prevention & control/*transmission'
p14881
aS'HIV-1'
p14882
aS'Humans'
p14883
aS'Infectious Disease Transmission, Vertical/*prevention & control/statistics & numerical data'
p14884
aS'Mothers'
p14885
aS'Patient Dropouts/statistics & numerical data'
p14886
aS'Patient Participation/statistics & numerical data'
p14887
aS'Pregnancy'
p14888
aS'Pregnancy Complications, Infectious/*drug therapy/epidemiology'
p14889
aS'Prenatal Care/standards/statistics & numerical data'
p14890
aS'South Africa/epidemiology'
p14891
aS'Time-to-Treatment/statistics & numerical data'
p14892
aS'Young Adult'
p14893
asS'EDAT'
p14894
S'2015/02/07 06:00'
p14895
sS'SO'
p14896
S'BMC Infect Dis. 2015 Feb 6;15:46. doi: 10.1186/s12879-015-0778-2.'
p14897
sS'SB'
p14898
S'IM'
p14899
sS'PMID'
p14900
S'25656597'
p14901
sS'TA'
p14902
S'BMC Infect Dis'
p14903
sS'PST'
p14904
S'epublish'
p14905
stRp14906
ag2
(g3
g4
(dp14907
S'LID'
p14908
S'10.1097/QAI.0000000000000565 [doi]'
p14909
sS'STAT'
p14910
S'MEDLINE'
p14911
sS'JT'
p14912
S'Journal of acquired immune deficiency syndromes (1999)'
p14913
sS'MID'
p14914
(lp14915
S'NIHMS659318'
p14916
asS'DA'
p14917
S'20150527'
p14918
sS'AID'
p14919
(lp14920
S'10.1097/QAI.0000000000000565 [doi]'
p14921
asS'CRDT'
p14922
(lp14923
S'2015/02/04 06:00'
p14924
asS'DP'
p14925
S'2015 Jun 1'
p14926
sS'AD'
p14927
S'*Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, CA; daggerDepartment of Epidemiology, University of California, Berkeley, CA; and double daggerCenter for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya.'
p14928
sS'OWN'
p14929
S'NLM'
p14930
sS'PT'
p14931
(lp14932
S'Journal Article'
p14933
aS'Research Support, N.I.H., Extramural'
p14934
asS'LA'
p14935
(lp14936
S'eng'
p14937
asS'FAU'
p14938
(lp14939
S'Huchko, Megan J'
p14940
aS'Leslie, Hannah'
p14941
aS'Maloba, May'
p14942
aS'Zakaras, Jennifer'
p14943
aS'Bukusi, Elizabeth'
p14944
aS'Cohen, Craig R'
p14945
asS'LR'
p14946
S'20160601'
p14947
sS'PG'
p14948
S'200-5'
p14949
sS'TI'
p14950
S'Outcomes Up to 12 Months After Treatment With Loop Electrosurgical Excision Procedure for Cervical Intraepithelial Neoplasia Among HIV-Infected Women.'
p14951
sS'PL'
p14952
S'United States'
p14953
sS'TA'
p14954
S'J Acquir Immune Defic Syndr'
p14955
sS'JID'
p14956
S'100892005'
p14957
sS'AB'
p14958
S'INTRODUCTION: HIV-infected women may have higher rates of recurrent cervical precancer after treatment. Knowledge about rates and predictors of recurrence could impact guidelines and program planning, especially in low-resource settings. METHODS: In this prospective cohort study in Western Kenya, we followed HIV-infected women at 6 and 12 months after treatment for cervical intraepithelial neoplasia 2 or greater (CIN2+) after treatment with loop electrosurgical excision procedure (LEEP). All women underwent follow-up colposcopy with biopsy as indicated for the diagnosis of CIN2+. We calculated the incidence and predictors of primary disease recurrence after treatment. RESULTS: Among the 284 women who underwent LEEP and had at least 1 follow-up visit, there were 37 (13%) cases of CIN2+ detected by 12-month follow-up. Four (10.8%) of the recurrences were invasive cancer, all stage IA1. The 6- and 12-month rates of recurrence were 13.7 and 12.8 cases per 100 person-years of follow-up, respectively. Antiretroviral therapy use did not significantly impact the rate of recurrence (hazard ratio: 1.24, 95% confidence interval: 0.59 to 2.79). The only significant predictor of recurrence in the multivariate analysis was CD4(+) nadir <200 cells per cubic millimeter (adjusted hazard ratio: 3.14, 95% confidence interval: 1.22 to 8.08). DISCUSSION: The overall rate of treatment failure within a year of LEEP was low in this cohort of HIV-infected women. Among the women with recurrence, there was a significant amount of invasive cancer. The relatively high rate of cancer after treatment suggests that HIV-infected women merit continued close follow-up after treatment.'
p14959
sS'GR'
p14960
(lp14961
S'KL2 TR000143/TR/NCATS NIH HHS/United States'
p14962
aS'KL2 TR000143/TR/NCATS NIH HHS/United States'
p14963
aS'L30 AI075944/AI/NIAID NIH HHS/United States'
p14964
aS'P30 MH062246/MH/NIMH NIH HHS/United States'
p14965
asS'IP'
p14966
S'2'
sS'IS'
p14967
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p14968
sS'PMC'
p14969
S'PMC4446153'
p14970
sS'DCOM'
p14971
S'20150810'
p14972
sS'AU'
p14973
(lp14974
S'Huchko MJ'
p14975
aS'Leslie H'
p14976
aS'Maloba M'
p14977
aS'Zakaras J'
p14978
aS'Bukusi E'
p14979
aS'Cohen CR'
p14980
asS'VI'
p14981
S'69'
p14982
sS'MHDA'
p14983
S'2015/08/11 06:00'
p14984
sS'OID'
p14985
(lp14986
S'NLM: NIHMS659318'
p14987
aS'NLM: PMC4446153'
p14988
asS'MH'
p14989
(lp14990
S'Adult'
p14991
aS'Biopsy'
p14992
aS'Carcinoma/epidemiology'
p14993
aS'Cervical Intraepithelial Neoplasia/*surgery'
p14994
aS'Cohort Studies'
p14995
aS'Electrosurgery/*methods'
p14996
aS'Female'
p14997
aS'HIV Infections/*complications'
p14998
aS'Humans'
p14999
aS'Kenya'
p15000
aS'Prospective Studies'
p15001
aS'Recurrence'
p15002
aS'Treatment Outcome'
p15003
asS'EDAT'
p15004
S'2015/02/04 06:00'
p15005
sS'SO'
p15006
S'J Acquir Immune Defic Syndr. 2015 Jun 1;69(2):200-5. doi: 10.1097/QAI.0000000000000565.'
p15007
sS'SB'
p15008
S'IM X'
p15009
sS'PMID'
p15010
S'25647529'
p15011
sS'PST'
p15012
S'ppublish'
p15013
stRp15014
ag2
(g3
g4
(dp15015
S'LID'
p15016
S'10.1007/s13365-014-0311-1 [doi]'
p15017
sS'STAT'
p15018
S'MEDLINE'
p15019
sS'DEP'
p15020
S'20150121'
p15021
sS'DA'
p15022
S'20150325'
p15023
sS'AID'
p15024
(lp15025
S'10.1007/s13365-014-0311-1 [doi]'
p15026
asS'CRDT'
p15027
(lp15028
S'2015/01/22 06:00'
p15029
asS'DP'
p15030
S'2015 Apr'
p15031
sS'OWN'
p15032
S'NLM'
p15033
sS'PT'
p15034
(lp15035
S'Journal Article'
p15036
aS"Research Support, Non-U.S. Gov't"
p15037
asS'LA'
p15038
(lp15039
S'eng'
p15040
asS'FAU'
p15041
(lp15042
S'Hoare, Jacqueline'
p15043
aS'Fouche, Jean-Paul'
p15044
aS'Phillips, Nicole'
p15045
aS'Joska, John A'
p15046
aS'Donald, Kirsten A'
p15047
aS'Thomas, Kevin'
p15048
aS'Stein, Dan J'
p15049
asS'JT'
p15050
S'Journal of neurovirology'
p15051
sS'PG'
p15052
S'120-8'
p15053
sS'TI'
p15054
S'Clinical associations of white matter damage in cART-treated HIV-positive children in South Africa.'
p15055
sS'RN'
p15056
(lp15057
S'0 (Anti-HIV Agents)'
p15058
asS'PL'
p15059
S'United States'
p15060
sS'TA'
p15061
S'J Neurovirol'
p15062
sS'JID'
p15063
S'9508123'
p15064
sS'AB'
p15065
S'A range of factors contributes to white matter damage in vertically infected HIV-positive children. These may include combination antiretroviral treatment (cART) regimen, sociodemographic factors, nutritional-hematological status, HIV-relevant clinical variables, and cognitive functioning. We explored associations between a number of these factors and diffusion tensor imaging (DTI) measures in 50 cART-treated children aged 6 to 15 years. Fractional anisotropy (FA), mean diffusion (MD), radial diffusion (RD), and axial diffusion (AD) were derived from 48 cerebral white matter regions. Significant associations between a number of the clinical variables and white matter integrity were found. Decreased FA, a measure of neuronal damage, was associated with being on second-line cART, low hemoglobin, and younger age. Children with increased MD, a measure of neuronal damage, were younger, had reduced albumin and hemoglobin, and increased viral load. Decreased AD, a measure of axonal damage, was associated with increased viral load and total protein, decreased albumin and hemoglobin, younger age, poorer fronto-striatal cognition, and being on second-line cART. Increased RD, a measure of myelin loss, was associated with younger age, low current CD4 count, low albumin and hemoglobin, and higher viral load and total protein. The current findings underline the possible association of first-line treatment failure with white matter brain dysfunction in pediatric neuroHIV and the importance of examining the effects of HIV disease in the context of treatable clinical variables such as anemia and nutritional status.'
p15066
sS'AD'
p15067
S'Division of Liaison Psychiatry, Department of Psychiatry and Mental Health, University of Cape Town, Anzio Road Observatory, Cape Town, 7925, South Africa, hoare.jax@gmail.com.'
p15068
sS'IP'
p15069
S'2'
sS'IS'
p15070
S'1538-2443 (Electronic) 1355-0284 (Linking)'
p15071
sS'DCOM'
p15072
S'20151229'
p15073
sS'AU'
p15074
(lp15075
S'Hoare J'
p15076
aS'Fouche JP'
p15077
aS'Phillips N'
p15078
aS'Joska JA'
p15079
aS'Donald KA'
p15080
aS'Thomas K'
p15081
aS'Stein DJ'
p15082
asS'VI'
p15083
S'21'
p15084
sS'MHDA'
p15085
S'2015/12/30 06:00'
p15086
sS'PHST'
p15087
(lp15088
S'2014/08/05 [received]'
p15089
aS'2014/12/26 [accepted]'
p15090
aS'2014/11/14 [revised]'
p15091
aS'2015/01/21 [aheadofprint]'
p15092
asS'MH'
p15093
(lp15094
S'Adolescent'
p15095
aS'Anti-HIV Agents/*therapeutic use'
p15096
aS'Brain/*pathology'
p15097
aS'Child'
p15098
aS'Diffusion Tensor Imaging'
p15099
aS'Female'
p15100
aS'HIV Infections/drug therapy/*pathology'
p15101
aS'Humans'
p15102
aS'Image Interpretation, Computer-Assisted'
p15103
aS'Male'
p15104
aS'Neuropsychological Tests'
p15105
aS'South Africa'
p15106
aS'White Matter/*pathology'
p15107
asS'EDAT'
p15108
S'2015/01/22 06:00'
p15109
sS'SO'
p15110
S'J Neurovirol. 2015 Apr;21(2):120-8. doi: 10.1007/s13365-014-0311-1. Epub 2015 Jan 21.'
p15111
sS'SB'
p15112
S'IM'
p15113
sS'PMID'
p15114
S'25604496'
p15115
sS'PST'
p15116
S'ppublish'
p15117
stRp15118
ag2
(g3
g4
(dp15119
S'LID'
p15120
S'10.1186/1742-4755-12-5 [doi]'
p15121
sS'STAT'
p15122
S'MEDLINE'
p15123
sS'DEP'
p15124
S'20150115'
p15125
sS'DA'
p15126
S'20150120'
p15127
sS'AID'
p15128
(lp15129
S'1742-4755-12-5 [pii]'
p15130
aS'10.1186/1742-4755-12-5 [doi]'
p15131
asS'CRDT'
p15132
(lp15133
S'2015/01/17 06:00'
p15134
asS'DP'
p15135
S'2015'
p15136
sS'AD'
p15137
S'Institute of Tropical Medicine, Antwerp, Belgium. udalessandro@mrc.gm.'
p15138
sS'OWN'
p15139
S'NLM'
p15140
sS'PT'
p15141
(lp15142
S'Comparative Study'
p15143
aS'Journal Article'
p15144
aS'Multicenter Study'
p15145
aS'Randomized Controlled Trial'
p15146
aS"Research Support, Non-U.S. Gov't"
p15147
asS'LA'
p15148
(lp15149
S'eng'
p15150
asS'DCOM'
p15151
S'20150914'
p15152
sS'JT'
p15153
S'Reproductive health'
p15154
sS'LR'
p15155
S'20151028'
p15156
sS'FAU'
p15157
(lp15158
S'Nambozi, Michael'
p15159
aS'Mulenga, Modest'
p15160
aS'Halidou, Tinto'
p15161
aS'Tagbor, Harry'
p15162
aS'Mwapasa, Victor'
p15163
aS'Phiri, Linda Kalilani'
p15164
aS'Kalanda, Gertrude'
p15165
aS'Valea, Innocent'
p15166
aS'Traore, Maminata'
p15167
aS'Mwakazanga, David'
p15168
aS'Claeys, Yves'
p15169
aS'Schurmans, Celine'
p15170
aS'De Crop, Maaike'
p15171
aS'Menten, Joris'
p15172
aS'Ravinetto, Raffaella'
p15173
aS'Thriemer, Kamala'
p15174
aS'Van Geertruyden, Jean-Pierre'
p15175
aS'Mutabingwa, Theonest'
p15176
aS"D'Alessandro, Umberto"
p15177
asS'TI'
p15178
S'Safe and efficacious artemisinin-based combination treatments for African pregnant women with malaria: a multicentre randomized control trial.'
p15179
sS'RN'
p15180
(lp15181
S'0 (Antimalarials)'
p15182
aS'0 (Artemisinins)'
p15183
aS'0 (Drug Combinations)'
p15184
aS'0 (Ethanolamines)'
p15185
aS'0 (Fluorenes)'
p15186
aS'0 (Quinolines)'
p15187
aS'0 (amodiaquine, artesunate drug combination)'
p15188
aS'0 (artemether-lumefantrine combination)'
p15189
aS'220236ED28 (Amodiaquine)'
p15190
aS'60W3249T9M (artesunate)'
p15191
aS'6A9O50735X (dihydroartemisinin)'
p15192
aS'A0HV2Q956Y (piperaquine)'
p15193
aS'TML814419R (Mefloquine)'
p15194
asS'PL'
p15195
S'England'
p15196
sS'PG'
p15197
S'5'
sS'JID'
p15198
S'101224380'
p15199
sS'AB'
p15200
S"BACKGROUND: Asymptomatic and symptomatic malaria during pregnancy has consequences for both mother and her offspring. Unfortunately, there is insufficient information on the safety and efficacy of most antimalarials in pregnancy. Indeed, clinical trials assessing antimalarial treatments systematically exclude pregnancy for fear of teratogenicity and embryotoxicity. The little available information originates from South East Asia while in sub-Saharan Africa such information is still limited and needs to be provided. DESIGN: A Phase 3, non-inferiority, multicentre, randomized, open-label clinical trial on safety and efficacy of 4 ACT when administered during pregnancy was carried out in 4 African countries: Burkina Faso, Ghana, Malawi and Zambia. This is a four arm trial using a balanced incomplete block design. Pregnant women diagnosed with malaria are randomised to receive either amodiaquine-artesunate (AQ-AS), dihydroartemisinin-piperaquine (DHA-PQ), artemether-lumefantrine (AL), or mefloquine-artesunate (MQAS). They are actively followed up until day 63 post-treatment and then monthly until 4-6 weeks post-delivery. The offspring is visited at the time of the first birthday. The primary endpoint is treatment failure (PCR adjusted) at day 63 and safety profiles. Secondary endpoints included PCR unadjusted treatment failure up to day 63, gametocyte carriage, Hb changes, placenta malaria, mean birth weight and low birth weight. The primary statistical analysis will use the combined data from all 4 centres, with adjustment for any centre effects, using an additive model for the response rates. This will allow the assessment of all 6 possible pair-wise treatment comparisons using all available data. DISCUSSION: The strength of this trial is the involvement of several African countries, increasing the generalisability of the results. In addition, it assesses most ACTs currently available, determining their relative '-value-' compared to others. The balanced incomplete block design was chosen because using all 4-arms in each site would have increased complexity in terms of implementation. Excluding HIV-positive pregnant women on antiretroviral drugs may be seen as a limitation because of the possible interactions between antiretroviral and antimalarial treatments. Nevertheless, the results of this trial will provide the evidence base for the formulation of malaria treatment policy for pregnant women in sub-Saharan Africa."
p15201
sS'CN'
p15202
(lp15203
S'Pregact Group'
p15204
asS'VI'
p15205
S'12'
p15206
sS'IS'
p15207
S'1742-4755 (Electronic) 1742-4755 (Linking)'
p15208
sS'PMC'
p15209
S'PMC4326323'
p15210
sS'AU'
p15211
(lp15212
S'Nambozi M'
p15213
aS'Mulenga M'
p15214
aS'Halidou T'
p15215
aS'Tagbor H'
p15216
aS'Mwapasa V'
p15217
aS'Phiri LK'
p15218
aS'Kalanda G'
p15219
aS'Valea I'
p15220
aS'Traore M'
p15221
aS'Mwakazanga D'
p15222
aS'Claeys Y'
p15223
aS'Schurmans C'
p15224
aS'De Crop M'
p15225
aS'Menten J'
p15226
aS'Ravinetto R'
p15227
aS'Thriemer K'
p15228
aS'Van Geertruyden JP'
p15229
aS'Mutabingwa T'
p15230
aS"D'Alessandro U"
p15231
asS'MHDA'
p15232
S'2015/09/15 06:00'
p15233
sS'PHST'
p15234
(lp15235
S'2014/12/02 [received]'
p15236
aS'2015/01/12 [accepted]'
p15237
aS'2015/01/15 [aheadofprint]'
p15238
asS'OID'
p15239
(lp15240
S'NLM: PMC4326323'
p15241
asS'MH'
p15242
(lp15243
S'Adult'
p15244
aS'Amodiaquine/adverse effects/therapeutic use'
p15245
aS'Antimalarials/adverse effects/*therapeutic use'
p15246
aS'Artemisinins/adverse effects/*therapeutic use'
p15247
aS'Birth Weight/drug effects'
p15248
aS'Burkina Faso'
p15249
aS'Drug Combinations'
p15250
aS'Ethanolamines/adverse effects/therapeutic use'
p15251
aS'Female'
p15252
aS'Fetal Development/drug effects'
p15253
aS'Fluorenes/adverse effects/therapeutic use'
p15254
aS'Follow-Up Studies'
p15255
aS'Ghana'
p15256
aS'Humans'
p15257
aS'Infant, Newborn'
p15258
aS'Malaria/*drug therapy'
p15259
aS'Malawi'
p15260
aS'Mefloquine/adverse effects/therapeutic use'
p15261
aS'Placentation/drug effects'
p15262
aS'Pregnancy'
p15263
aS'Pregnancy Complications, Parasitic/*drug therapy'
p15264
aS'Prenatal Exposure Delayed Effects'
p15265
aS'Quinolines/adverse effects/therapeutic use'
p15266
aS'Zambia'
p15267
asS'EDAT'
p15268
S'2015/01/17 06:00'
p15269
sS'SI'
p15270
(lp15271
S'ClinicalTrials.gov/NCT00852423'
p15272
asS'SO'
p15273
S'Reprod Health. 2015 Jan 15;12:5. doi: 10.1186/1742-4755-12-5.'
p15274
sS'SB'
p15275
S'IM'
p15276
sS'PMID'
p15277
S'25592254'
p15278
sS'TA'
p15279
S'Reprod Health'
p15280
sS'PST'
p15281
S'epublish'
p15282
stRp15283
ag2
(g3
g4
(dp15284
S'LID'
p15285
S'10.1097/QAI.0000000000000513 [doi]'
p15286
sS'STAT'
p15287
S'MEDLINE'
p15288
sS'JT'
p15289
S'Journal of acquired immune deficiency syndromes (1999)'
p15290
sS'DA'
p15291
S'20150312'
p15292
sS'AID'
p15293
(lp15294
S'10.1097/QAI.0000000000000513 [doi]'
p15295
asS'CRDT'
p15296
(lp15297
S'2015/01/14 06:00'
p15298
asS'DP'
p15299
S'2015 Apr 15'
p15300
sS'AD'
p15301
S'*Clinical Research, Epicentre, Paris, France; daggerMedical Department, Medecins Sans Frontieres, Paris, France; double daggerMedical Department, Medecins Sans Frontieres, Barcelona, Spain; and section signDepartment of Epidemiology and Public Health, University College London, London, United Kingdom.'
p15302
sS'OWN'
p15303
S'NLM'
p15304
sS'PT'
p15305
(lp15306
S'Journal Article'
p15307
aS'Multicenter Study'
p15308
aS"Research Support, Non-U.S. Gov't"
p15309
asS'LA'
p15310
(lp15311
S'eng'
p15312
asS'FAU'
p15313
(lp15314
S'Pinoges, Loretxu'
p15315
aS'Schramm, Birgit'
p15316
aS'Poulet, Elisabeth'
p15317
aS'Balkan, Suna'
p15318
aS'Szumilin, Elisabeth'
p15319
aS'Ferreyra, Cecilia'
p15320
aS'Pujades-Rodriguez, Mar'
p15321
asS'LR'
p15322
S'20160308'
p15323
sS'PG'
p15324
S'527-35'
p15325
sS'TI'
p15326
S'Risk factors and mortality associated with resistance to first-line antiretroviral therapy: multicentric cross-sectional and longitudinal analyses.'
p15327
sS'PL'
p15328
S'United States'
p15329
sS'TA'
p15330
S'J Acquir Immune Defic Syndr'
p15331
sS'JID'
p15332
S'100892005'
p15333
sS'AB'
p15334
S'BACKGROUND: Understanding the factors associated with HIV drug resistance development and subsequent mortality is important to improve clinical patient management. METHODS: Analysis of individual electronic health records from 4 HIV programs in Malawi, Kenya, Uganda, and Cambodia, linked to data from 5 cross-sectional virological studies conducted among patients receiving first-line antiretroviral therapy (ART) for >/=6 months. Adjusted logistic and Cox-regression models were used to identify risk factors for drug resistance and subsequent mortality. RESULTS: A total of 2257 patients (62% women) were included. At ART initiation, median CD4 cell count was 100 cells per microliter (interquartile range, 40-165). A median of 25.1 months after therapy start, 18% of patients had >/=400 and 12.4% >/=1000 HIV RNA copies per milliliter. Of 180 patients with drug resistance data, 83.9% had major resistance(s) to nucleoside or nonnucleoside reverse transcriptase inhibitors, and 74.4% dual resistance. Resistance to nevirapine, lamivudine, and efavirenz was common, and 6% had etravirine cross-resistance. Risk factors for resistance were young age (<35 years), low CD4 cell count (<200 cells/muL), and poor treatment adherence. During 4978 person-years of follow-up after virological testing (median = 31.8 months), 57 deaths occurred [rate = 1.14/100 person-years; 95% confidence interval (CI): 0.88 to 1.48]. Mortality was higher in patients with resistance (hazard ratio = 2.08; 95% CI: 1.07 to 4.07 vs. <400 copies/mL), and older age (hazard ratio = 2.41; 95% CI: 1.24 to 4.71 for >/=43 vs. </=34 years), and lower in those receiving ART for >30 months. CONCLUSIONS: Our findings underline the importance of optimal treatment adherence and adequate virological response monitoring and emphasize the need for resistance surveillance initiatives even in HIV programs achieving high virological suppression rates.'
p15335
sS'GR'
p15336
(lp15337
S'MR/L01629X/1/Medical Research Council/United Kingdom'
p15338
asS'IP'
p15339
S'5'
sS'IS'
p15340
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p15341
sS'DCOM'
p15342
S'20150518'
p15343
sS'AU'
p15344
(lp15345
S'Pinoges L'
p15346
aS'Schramm B'
p15347
aS'Poulet E'
p15348
aS'Balkan S'
p15349
aS'Szumilin E'
p15350
aS'Ferreyra C'
p15351
aS'Pujades-Rodriguez M'
p15352
asS'VI'
p15353
S'68'
p15354
sS'MHDA'
p15355
S'2015/05/20 06:00'
p15356
sS'MH'
p15357
(lp15358
S'Adult'
p15359
aS'Africa/epidemiology'
p15360
aS'Antiretroviral Therapy, Highly Active/*methods'
p15361
aS'Cambodia/epidemiology'
p15362
aS'Cross-Sectional Studies'
p15363
aS'Drug Monitoring'
p15364
aS'*Drug Resistance, Viral'
p15365
aS'Female'
p15366
aS'HIV Infections/*drug therapy/epidemiology/*mortality/virology'
p15367
aS'Humans'
p15368
aS'Longitudinal Studies'
p15369
aS'Male'
p15370
aS'Medication Adherence'
p15371
aS'Risk Factors'
p15372
aS'Survival Analysis'
p15373
aS'Viral Load'
p15374
asS'EDAT'
p15375
S'2015/01/15 06:00'
p15376
sS'SO'
p15377
S'J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):527-35. doi: 10.1097/QAI.0000000000000513.'
p15378
sS'SB'
p15379
S'IM X'
p15380
sS'PMID'
p15381
S'25585301'
p15382
sS'PST'
p15383
S'ppublish'
p15384
stRp15385
ag2
(g3
g4
(dp15386
S'LID'
p15387
S'10.1097/QAI.0000000000000509 [doi]'
p15388
sS'STAT'
p15389
S'MEDLINE'
p15390
sS'JT'
p15391
S'Journal of acquired immune deficiency syndromes (1999)'
p15392
sS'MID'
p15393
(lp15394
S'NIHMS651406'
p15395
asS'DA'
p15396
S'20150219'
p15397
sS'AID'
p15398
(lp15399
S'10.1097/QAI.0000000000000509 [doi]'
p15400
asS'CRDT'
p15401
(lp15402
S'2015/01/08 06:00'
p15403
asS'DP'
p15404
S'2015 Apr 1'
p15405
sS'AD'
p15406
S'*Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, MA; daggerDivision of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, MA; double daggerRepublic of Namibia Ministry of Health and Social Services, Windhoek, Namibia; section signMolecular Diagnosis Unit, Namibia Institute of Pathology, Windhoek, Namibia; ||World Health Organization, Klein Windhoek, Windhoek, Namibia; and paragraph signCentre for HIV & STIs: HIV Virology Section, National Institute for Communicable Diseases, Johannesburg, South Africa.'
p15407
sS'OWN'
p15408
S'NLM'
p15409
sS'PT'
p15410
(lp15411
S'Journal Article'
p15412
aS'Research Support, N.I.H., Extramural'
p15413
aS"Research Support, Non-U.S. Gov't"
p15414
asS'LA'
p15415
(lp15416
S'eng'
p15417
asS'FAU'
p15418
(lp15419
S'Hong, Steven Y'
p15420
aS'Jonas, Anna'
p15421
aS'DeKlerk, Michael'
p15422
aS'Shiningavamwe, Andreas'
p15423
aS'Desta, Tiruneh'
p15424
aS'Badi, Alfons'
p15425
aS'Morris, Lynn'
p15426
aS'Hunt, Gillian M'
p15427
aS'Ledwaba, Johanna'
p15428
aS'Sheehan, Heidi B'
p15429
aS'Lau, Kiger'
p15430
aS'Trotter, Andrew'
p15431
aS'Tang, Alice M'
p15432
aS'Wanke, Christine'
p15433
aS'Jordan, Michael R'
p15434
asS'LR'
p15435
S'20160401'
p15436
sS'PG'
p15437
S'463-71'
p15438
sS'TI'
p15439
S'Population-based surveillance of HIV drug resistance emerging on treatment and associated factors at sentinel antiretroviral therapy sites in Namibia.'
p15440
sS'RN'
p15441
(lp15442
S'0 (Anti-Retroviral Agents)'
p15443
asS'PL'
p15444
S'United States'
p15445
sS'TA'
p15446
S'J Acquir Immune Defic Syndr'
p15447
sS'JID'
p15448
S'100892005'
p15449
sS'AB'
p15450
S'OBJECTIVE: The World Health Organization (WHO) prospective surveys of acquired HIV drug resistance (HIVDR) evaluate HIVDR emerging after the first year of antiretroviral therapy (ART) and associated factors. METHODS: Consecutive ART starters in 2009 were enrolled at 3 sentinel sites in Namibia. Genotyping was performed at start and after 12 months in patients with HIV viral load (VL) >1000 copies per mL. HIVDR outcomes were: HIVDR prevention (VL </=1000 copies/mL), possible HIVDR (VL >1000 copies/mL without detectable HIVDR or loss to follow-up or ART stop), and HIVDR (VL >1000 copies/mL with detectable HIVDR). Adherence was assessed using medication possession ratio (MPR). RESULTS: Of 394 starters, at 12 months, 80% were on first-line ART, 1% died, 4% transferred out, 1% stopped ART, <1% switched to second-line, and 15% were lost to follow-up. Among patients on first-line, 77% had VL testing, and 94% achieved VL </=1000 copies per mL. At baseline, 7% had HIVDR. After 12 months, among patients with VL testing, 5% had HIVDR. A majority of patients failing therapy had high-level resistance to nonnucleoside reverse transcriptase inhibitors but none to protease inhibitors. All sites achieved the WHO target of >/=70% HIVDR prevention. Factors associated with not achieving HIVDR prevention were: baseline resistance to nonnucleoside reverse transcriptase inhibitors [odds ratio (OR) 3.0, P = 0.023], WHO stage 3 or 4 at baseline (OR 2.0, P = 0.012), and MPR <75% (OR 4.9, P = 0.021). CONCLUSIONS: Earlier ART initiation and removal of barriers to on-time drug pickups may help to prevent HIVDR. These data inform decisions at national and global levels on the effectiveness of first- and second-line regimens.'
p15451
sS'GR'
p15452
(lp15453
S'1K23AI097010-01A1/AI/NIAID NIH HHS/United States'
p15454
aS'K23 AI074423/AI/NIAID NIH HHS/United States'
p15455
aS'K23 AI097010/AI/NIAID NIH HHS/United States'
p15456
aS'K23 AIO74423-05/PHS HHS/United States'
p15457
aS'L30 AI080268/AI/NIAID NIH HHS/United States'
p15458
aS'L30 AI080268-02/AI/NIAID NIH HHS/United States'
p15459
aS'P30 AI042853/AI/NIAID NIH HHS/United States'
p15460
aS'P30 AI042853/AI/NIAID NIH HHS/United States'
p15461
aS'T32 AI007438/AI/NIAID NIH HHS/United States'
p15462
aS'T32 AI007438-16/AI/NIAID NIH HHS/United States'
p15463
asS'IP'
p15464
S'4'
sS'IS'
p15465
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p15466
sS'PMC'
p15467
S'PMC4334707'
p15468
sS'DCOM'
p15469
S'20150421'
p15470
sS'AU'
p15471
(lp15472
S'Hong SY'
p15473
aS'Jonas A'
p15474
aS'DeKlerk M'
p15475
aS'Shiningavamwe A'
p15476
aS'Desta T'
p15477
aS'Badi A'
p15478
aS'Morris L'
p15479
aS'Hunt GM'
p15480
aS'Ledwaba J'
p15481
aS'Sheehan HB'
p15482
aS'Lau K'
p15483
aS'Trotter A'
p15484
aS'Tang AM'
p15485
aS'Wanke C'
p15486
aS'Jordan MR'
p15487
asS'VI'
p15488
S'68'
p15489
sS'MHDA'
p15490
S'2015/04/22 06:00'
p15491
sS'OID'
p15492
(lp15493
S'NLM: NIHMS651406'
p15494
aS'NLM: PMC4334707'
p15495
asS'MH'
p15496
(lp15497
S'Adult'
p15498
aS'Anti-Retroviral Agents/supply & distribution/*therapeutic use'
p15499
aS'Antiretroviral Therapy, Highly Active/methods'
p15500
aS'*Drug Resistance, Viral'
p15501
aS'Female'
p15502
aS'Genotype'
p15503
aS'Genotyping Techniques'
p15504
aS'HIV/classification/genetics/isolation & purification'
p15505
aS'HIV Infections/*drug therapy/*virology'
p15506
aS'Humans'
p15507
aS'Male'
p15508
aS'Namibia'
p15509
aS'Prospective Studies'
p15510
aS'Sentinel Surveillance'
p15511
asS'EDAT'
p15512
S'2015/01/08 06:00'
p15513
sS'SO'
p15514
S'J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):463-71. doi: 10.1097/QAI.0000000000000509.'
p15515
sS'SB'
p15516
S'IM X'
p15517
sS'PMID'
p15518
S'25564107'
p15519
sS'PST'
p15520
S'ppublish'
p15521
stRp15522
ag2
(g3
g4
(dp15523
S'LID'
p15524
S'10.2989/16085906.2014.961939 [doi]'
p15525
sS'STAT'
p15526
S'MEDLINE'
p15527
sS'JT'
p15528
S'African journal of AIDS research : AJAR'
p15529
sS'DA'
p15530
S'20150103'
p15531
sS'AID'
p15532
(lp15533
S'10.2989/16085906.2014.961939 [doi]'
p15534
asS'CRDT'
p15535
(lp15536
S'2015/01/03 06:00'
p15537
asS'DP'
p15538
S'2014'
p15539
sS'AD'
p15540
S'a British Columbia Centre for Disease Control , 655 West 12th Avenue, Vancouver , British Columbia , Canada , V5Z 4R4.'
p15541
sS'OWN'
p15542
S'NLM'
p15543
sS'PT'
p15544
(lp15545
S'Journal Article'
p15546
aS'Randomized Controlled Trial'
p15547
aS'Research Support, N.I.H., Extramural'
p15548
asS'LA'
p15549
(lp15550
S'eng'
p15551
asS'FAU'
p15552
(lp15553
S'Smillie, Kirsten'
p15554
aS'Van Borek, Natasha'
p15555
aS'van der Kop, Mia L'
p15556
aS'Lukhwaro, Abigael'
p15557
aS'Li, Neville'
p15558
aS'Karanja, Sarah'
p15559
aS'Patel, Anik R'
p15560
aS'Ojakaa, David'
p15561
aS'Lester, Richard T'
p15562
asS'PG'
p15563
S'331-8'
p15564
sS'TI'
p15565
S'Mobile health for early retention in HIV care: a qualitative study in Kenya (WelTel Retain).'
p15566
sS'PL'
p15567
S'South Africa'
p15568
sS'TA'
p15569
S'Afr J AIDS Res'
p15570
sS'JID'
p15571
S'101146510'
p15572
sS'AB'
p15573
S'Many people newly diagnosed with HIV are lost to follow-up before timely initiation of antiretroviral therapy (ART). A randomised controlled trial (RCT), WelTel Kenya1, demonstrated the effectiveness of the WelTel text messaging intervention to improve clinical outcomes among patients initiating ART. In preparation for WelTel Retain, an RCT that will evaluate the effect of the intervention to retain patients in care immediately following HIV diagnosis, we conducted an informative qualitative study with people living with HIV (n = 15) and healthcare providers (HCP) (n = 5) in October 2012. Study objectives included exploring the experiences of people living with HIV who have attempted to engage in HIV care, the use of cell phones in everyday life, and perceptions of communicating via text message with HCP. Participants were recruited through convenience sampling. Semi-structured, qualitative interviews were conducted and recorded, transcribed verbatim and analysed using NVivo software. Analysis was guided by the Theory of Reasoned Action and the Technology Acceptance Model. Results indicate that while individuals have many motivators for engaging in care after diagnosis, structural and individual barriers including poverty, depression and fear of stigma prevent them from doing so. All participants had access to a mobile phone, and most were comfortable communicating through text messages, or were willing to learn. Both people living with HIV and HCP felt that increased communication via the text messaging intervention has the potential to enable early identification of problems, leading to timely problem solving that may improve retention and engagement in care during the first year after diagnosis.'
p15574
sS'GR'
p15575
(lp15576
S'R01MH097558-01/MH/NIMH NIH HHS/United States'
p15577
asS'IP'
p15578
S'4'
sS'IS'
p15579
S'1727-9445 (Electronic) 1608-5906 (Linking)'
p15580
sS'DCOM'
p15581
S'20150902'
p15582
sS'AU'
p15583
(lp15584
S'Smillie K'
p15585
aS'Van Borek N'
p15586
aS'van der Kop ML'
p15587
aS'Lukhwaro A'
p15588
aS'Li N'
p15589
aS'Karanja S'
p15590
aS'Patel AR'
p15591
aS'Ojakaa D'
p15592
aS'Lester RT'
p15593
asS'VI'
p15594
S'13'
p15595
sS'MHDA'
p15596
S'2015/09/04 06:00'
p15597
sS'OTO'
p15598
(lp15599
S'NOTNLM'
p15600
asS'MH'
p15601
(lp15602
S'Adult'
p15603
aS'Communication'
p15604
aS'Female'
p15605
aS'Follow-Up Studies'
p15606
aS'HIV Infections/drug therapy/*psychology'
p15607
aS'Humans'
p15608
aS'Kenya'
p15609
aS'Male'
p15610
aS'Middle Aged'
p15611
aS'*Patient Compliance'
p15612
aS'Qualitative Research'
p15613
aS'*Telemedicine/instrumentation/methods'
p15614
aS'Text Messaging/utilization'
p15615
aS'Young Adult'
p15616
asS'EDAT'
p15617
S'2015/01/03 06:00'
p15618
sS'SO'
p15619
S'Afr J AIDS Res. 2014;13(4):331-8. doi: 10.2989/16085906.2014.961939.'
p15620
sS'SB'
p15621
S'IM X'
p15622
sS'PMID'
p15623
S'25555099'
p15624
sS'OT'
p15625
(lp15626
S'HIV'
p15627
aS'engagement in care'
p15628
aS'mobile health'
p15629
aS'sub-Saharan Africa'
p15630
asS'PST'
p15631
S'ppublish'
p15632
stRp15633
ag2
(g3
g4
(dp15634
S'LID'
p15635
S'10.1186/s12879-014-0703-0 [doi]'
p15636
sS'STAT'
p15637
S'MEDLINE'
p15638
sS'DEP'
p15639
S'20141219'
p15640
sS'DA'
p15641
S'20150427'
p15642
sS'AID'
p15643
(lp15644
S'10.1186/s12879-014-0703-0 [doi]'
p15645
aS's12879-014-0703-0 [pii]'
p15646
asS'CRDT'
p15647
(lp15648
S'2014/12/20 06:00'
p15649
asS'DP'
p15650
S'2014'
p15651
sS'AD'
p15652
S'National Tuberculosis and Leprosy Program, Kampala, Uganda. ezatinick@yahoo.co.uk. National Tuberculosis and Leprosy Program, Kampala, Uganda. deuslukoye@gmail.com. Department of Medical Microbiology, Makerere University College of Health Sciences, Kampala, Uganda. wamps@covab.mak.ac.ug. Department of Bio-molecular Resources and Biolab Sciences, College of Veterinary Medicine, Animal Resources and Bio Security, Makerere University, Kampala, Uganda. wamps@covab.mak.ac.ug. National Tuberculosis Reference Laboratory (NTRL), Kampala, Uganda. kenmusisi@yahoo.co.uk. National Tuberculosis Reference Laboratory (NTRL), Kampala, Uganda. kasulegw@gmail.com. Department of Global health and Amsterdam Institute for Global Heath and Development, Academic Medical Center, Amsterdam, The Netherlands KNCV Tuberculosis Foundation, The Hague, The Netherlands. f.cobelens@aighd.org. Department of Medical Microbiology, Makerere University College of Health Sciences, Kampala, Uganda. davidkateete@gmail.com. National Tuberculosis Reference Laboratory (NTRL), Kampala, Uganda. mlj10@case.edu. Department of Medical Microbiology, Makerere University College of Health Sciences, Kampala, Uganda. mlj10@case.edu.'
p15653
sS'OWN'
p15654
S'NLM'
p15655
sS'PT'
p15656
(lp15657
S'Journal Article'
p15658
aS'Research Support, N.I.H., Extramural'
p15659
asS'LA'
p15660
(lp15661
S'eng'
p15662
asS'DCOM'
p15663
S'20151028'
p15664
sS'JT'
p15665
S'BMC infectious diseases'
p15666
sS'LR'
p15667
S'20150430'
p15668
sS'FAU'
p15669
(lp15670
S'Ezati, Nicholas'
p15671
aS'Lukoye, Deus'
p15672
aS'Wampande, Eddie M'
p15673
aS'Musisi, Kenneth'
p15674
aS'Kasule, George W'
p15675
aS'Cobelens, Frank G J'
p15676
aS'Kateete, David P'
p15677
aS'Joloba, Moses L'
p15678
asS'TI'
p15679
S'The Mycobacterium tuberculosis Uganda II family and resistance to first-line anti-tuberculosis drugs in Uganda.'
p15680
sS'RN'
p15681
(lp15682
S'0 (Antitubercular Agents)'
p15683
aS'0 (Bacterial Proteins)'
p15684
asS'PL'
p15685
S'England'
p15686
sS'PG'
p15687
S'703'
p15688
sS'JID'
p15689
S'100968551'
p15690
sS'AB'
p15691
S"BACKGROUND: The global increase in the burden of multidrug-resistant tuberculosis (MDR-TB) underscores an urgent need for data on factors involved in generation and spread of TB drug resistance. We performed molecular analyses on a representative sample of Mycobacterium tuberculosis (MTB) isolates. Basing on findings of the molecular epidemiological study in Kampala, we hypothesized that the predominant MTB strain lineage in Uganda is negatively associated with anti-TB drug resistance and we set out to test this hypothesis. METHODS: We extracted DNA from mycobacterial isolates collected from smear-positive TB patients in the national TB drug resistance survey and carried out IS6110-PCR. To identify MTB lineages/sub lineages RT-PCR SNP was performed using specific primers and hybridization probes and the 'melting curve' analysis was done to distinguish the Uganda II family from other MTB families. The primary outcome was the distribution of the Uganda II family and its associations with anti-TB drug resistance and HIV infection. RESULTS: Out of the 1537 patients enrolled, MTB isolates for 1001 patients were available for SNP analysis for identification of Uganda II family, of which 973 (97%) had conclusive RT-PCR results. Of these 422 (43.4%) were of the Uganda II family, mostly distributed in the south west zone (55.0%; OR = 4.6 for comparison with other zones; 95% CI 2.83-7.57; p < 0.001) but occurred in each of the other seven geographic zones at varying levels. Compared to the Uganda II family, other genotypes as a group were more likely to be resistant to any anti-TB drug (OR(adj) =2.9; 95% CI 1.63-5.06; p = 0.001) or MDR (OR(adj) 4.9; 95% CI, 1.15-20.60; p = 0.032), even after adjusting for geographic zone, patient category, sex, residence and HIV status. It was commonest in the 25-34 year age group 159/330 (48.2%). No association was observed between Uganda II family and HIV infection. CONCLUSION: The Uganda II family is a major cause of morbidity due to TB in all NTLP zones in Uganda. It is less likely to be resistant to anti-TB drugs than other MTB strain lineages."
p15692
sS'GR'
p15693
(lp15694
S'HHSN266200700022C/NO1-AI-70022/AI/NIAID NIH HHS/United States'
p15695
aS'N01-AI-95383/AI/NIAID NIH HHS/United States'
p15696
aS'R01 AI075637/AI/NIAID NIH HHS/United States'
p15697
aS'R03 AI062849/AI/NIAID NIH HHS/United States'
p15698
asS'VI'
p15699
S'14'
p15700
sS'IS'
p15701
S'1471-2334 (Electronic) 1471-2334 (Linking)'
p15702
sS'PMC'
p15703
S'PMC4367914'
p15704
sS'AU'
p15705
(lp15706
S'Ezati N'
p15707
aS'Lukoye D'
p15708
aS'Wampande EM'
p15709
aS'Musisi K'
p15710
aS'Kasule GW'
p15711
aS'Cobelens FG'
p15712
aS'Kateete DP'
p15713
aS'Joloba ML'
p15714
asS'MHDA'
p15715
S'2015/10/29 06:00'
p15716
sS'PHST'
p15717
(lp15718
S'2014/07/17 [received]'
p15719
aS'2014/12/11 [accepted]'
p15720
aS'2014/12/19 [aheadofprint]'
p15721
asS'OID'
p15722
(lp15723
S'NLM: PMC4367914'
p15724
asS'MH'
p15725
(lp15726
S'Adolescent'
p15727
aS'Adult'
p15728
aS'Antitubercular Agents/pharmacology'
p15729
aS'Bacterial Proteins/*genetics'
p15730
aS'Coinfection'
p15731
aS'Drug Resistance, Multiple, Bacterial/*genetics'
p15732
aS'Female'
p15733
aS'Genotype'
p15734
aS'HIV Infections/*epidemiology'
p15735
aS'Humans'
p15736
aS'Male'
p15737
aS'Microbial Sensitivity Tests'
p15738
aS'Middle Aged'
p15739
aS'Molecular Epidemiology'
p15740
aS'Mycobacterium tuberculosis/drug effects/*genetics'
p15741
aS'Polymorphism, Single Nucleotide'
p15742
aS'Reverse Transcriptase Polymerase Chain Reaction'
p15743
aS'Tuberculosis/drug therapy/epidemiology/microbiology'
p15744
aS'Tuberculosis, Multidrug-Resistant/drug therapy/*epidemiology/microbiology'
p15745
aS'Uganda/epidemiology'
p15746
aS'Young Adult'
p15747
asS'EDAT'
p15748
S'2014/12/20 06:00'
p15749
sS'SO'
p15750
S'BMC Infect Dis. 2014 Dec 19;14:703. doi: 10.1186/s12879-014-0703-0.'
p15751
sS'SB'
p15752
S'IM'
p15753
sS'PMID'
p15754
S'25523472'
p15755
sS'TA'
p15756
S'BMC Infect Dis'
p15757
sS'PST'
p15758
S'epublish'
p15759
stRp15760
ag2
(g3
g4
(dp15761
S'LID'
p15762
S'10.1097/QAD.0000000000000473 [doi]'
p15763
sS'STAT'
p15764
S'MEDLINE'
p15765
sS'JT'
p15766
S'AIDS (London, England)'
p15767
sS'DA'
p15768
S'20150116'
p15769
sS'AID'
p15770
(lp15771
S'10.1097/QAD.0000000000000473 [doi]'
p15772
aS'00002030-201411280-00011 [pii]'
p15773
asS'CRDT'
p15774
(lp15775
S'2014/12/11 06:00'
p15776
asS'DP'
p15777
S'2014 Nov 28'
p15778
sS'AD'
p15779
S'aICAP-Columbia University, New York bDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York, USA cNational AIDS & STI Control Program, Ministry of Health, Nairobi, Kenya dCollege of Physicians & Surgeons, Columbia University, New York, USA.'
p15780
sS'OWN'
p15781
S'NLM'
p15782
sS'PT'
p15783
(lp15784
S'Journal Article'
p15785
aS"Research Support, U.S. Gov't, Non-P.H.S."
p15786
aS"Research Support, U.S. Gov't, P.H.S."
p15787
asS'LA'
p15788
(lp15789
S'eng'
p15790
asS'FAU'
p15791
(lp15792
S'Koech, Emily'
p15793
aS'Teasdale, Chloe A'
p15794
aS'Wang, Chunhui'
p15795
aS'Fayorsey, Ruby'
p15796
aS'Alwar, Terezah'
p15797
aS'Mukui, Irene N'
p15798
aS'Hawken, Mark'
p15799
aS'Abrams, Elaine J'
p15800
asS'PG'
p15801
S'2729-38'
p15802
sS'TI'
p15803
S'Characteristics and outcomes of HIV-infected youth and young adolescents enrolled in HIV care in Kenya.'
p15804
sS'RN'
p15805
(lp15806
S'0 (Anti-Retroviral Agents)'
p15807
asS'PL'
p15808
S'England'
p15809
sS'TA'
p15810
S'AIDS'
p15811
sS'JID'
p15812
S'8710219'
p15813
sS'AB'
p15814
S'BACKGROUND: The number of youth and adolescents (10-24 years) with HIV infection has increased substantially presenting unique challenges to effective health service delivery. METHODS: We examined routinely collected patient-level data for antiretroviral treatment (ART)-naive HIV-infected patients, aged 10-24 years, enrolled in care during 2006-2011 at 109 ICAP-supported health facilities in three provinces in Kenya. Loss to follow-up (LTF) was defined as having no clinic visit for 12 months prior to ART initiation (pre-ART) and 6 months for ART patients. Competing risk and Kaplan-Meier estimators were used to calculate LTF and death rates. Sub-distributional and Cox proportional-hazards models were used to identify potential predictors of death and LTF. RESULTS: Overall 22 832 patients were enrolled in care at 10-24 years of age, 69.5% were aged 20-24 years, and 82% were female. Median CD4(+) cell count was 332 cells/mul (interquartile range 153-561); 70.8% were WHO stage I/II. Young adolescents (10-14 years) had more advanced WHO stage and lower median CD4(+) cell count compared to youth (15-24 years) at enrollment (284 vs. 340 cells/mul; P < 0.0001). Cumulative incidence of LTF and death at 24 months for pre-ART patients was 46.1% [95% confidence interval (CI) 45.4-46.8%) and 2.1% (95% CI 1.9-2.3%), respectively. For those on ART, 32.2% (95% CI 31.1-33.3%) were LTF and 3.9% (95% CI 1.7-2.3%) died within 24 months. LTF among pre-ART and ART patients was twice as high among youth compared to young adolescents. CONCLUSION: LTF of young people with HIV in this Kenyan cohort was high and notably greater among youth compared to young adolescents. Novel strategies targeting these populations are urgently needed to improve retention.'
p15815
sS'GR'
p15816
(lp15817
S'5U2GPS001537/PHS HHS/United States'
p15818
aS'5U62PS223540/PS/NCHHSTP CDC HHS/United States'
p15819
aS'PEPFAR/United States'
p15820
asS'IP'
p15821
S'18'
p15822
sS'IS'
p15823
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p15824
sS'DCOM'
p15825
S'20150721'
p15826
sS'AU'
p15827
(lp15828
S'Koech E'
p15829
aS'Teasdale CA'
p15830
aS'Wang C'
p15831
aS'Fayorsey R'
p15832
aS'Alwar T'
p15833
aS'Mukui IN'
p15834
aS'Hawken M'
p15835
aS'Abrams EJ'
p15836
asS'VI'
p15837
S'28'
p15838
sS'MHDA'
p15839
S'2015/07/22 06:00'
p15840
sS'MH'
p15841
(lp15842
S'Adolescent'
p15843
aS'Anti-Retroviral Agents/*therapeutic use'
p15844
aS'Child'
p15845
aS'Female'
p15846
aS'HIV Infections/*drug therapy/*mortality/pathology'
p15847
aS'Humans'
p15848
aS'Incidence'
p15849
aS'Kenya'
p15850
aS'Lost to Follow-Up'
p15851
aS'Male'
p15852
aS'Retrospective Studies'
p15853
aS'Survival Analysis'
p15854
aS'Treatment Outcome'
p15855
aS'Young Adult'
p15856
asS'EDAT'
p15857
S'2014/12/11 06:00'
p15858
sS'SO'
p15859
S'AIDS. 2014 Nov 28;28(18):2729-38. doi: 10.1097/QAD.0000000000000473.'
p15860
sS'SB'
p15861
S'IM X'
p15862
sS'PMID'
p15863
S'25493599'
p15864
sS'PST'
p15865
S'ppublish'
p15866
stRp15867
ag2
(g3
g4
(dp15868
S'LID'
p15869
S'10.7448/IAS.17.1.19164 [doi]'
p15870
sS'STAT'
p15871
S'MEDLINE'
p15872
sS'DEP'
p15873
S'20141205'
p15874
sS'DA'
p15875
S'20141210'
p15876
sS'AID'
p15877
(lp15878
S'19164 [pii]'
p15879
asS'CRDT'
p15880
(lp15881
S'2014/12/11 06:00'
p15882
asS'DP'
p15883
S'2014'
p15884
sS'AD'
p15885
S'Department of Viroscience, Erasmus Medical Center, University Medical Center, Rotterdam, The Netherlands; b.nichols@erasmusmc.nl. Department of Global Health, Academic Medical Centre, Amsterdam Institute for Global Health and Development (AIGHD), University of Amsterdam, Amsterdam, The Netherlands. Joint Clinical Research Centre (JCRC), Kampala, Uganda. Department of Global Health, Academic Medical Centre, Amsterdam Institute for Global Health and Development (AIGHD), University of Amsterdam, Amsterdam, The Netherlands. Department of Primary and Community Care, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands. HIV Department, World Health Organization, Geneva, Switzerland. Department of Geographic Medicine and Infectious Disease, Tufts University School of Medicine, Boston, MA, USA. Department of Infectious Disease Epidemiology, Imperial College London, London, UK. Department of Viroscience, Erasmus Medical Center, University Medical Center, Rotterdam, The Netherlands. Department of Global Health, Academic Medical Centre, Amsterdam Institute for Global Health and Development (AIGHD), University of Amsterdam, Amsterdam, The Netherlands; PharmAccess Foundation, Amsterdam, The Netherlands. Department of Viroscience, Erasmus Medical Center, University Medical Center, Rotterdam, The Netherlands.'
p15886
sS'OWN'
p15887
S'NLM'
p15888
sS'PT'
p15889
(lp15890
S'Journal Article'
p15891
aS'Research Support, N.I.H., Extramural'
p15892
aS"Research Support, Non-U.S. Gov't"
p15893
asS'LA'
p15894
(lp15895
S'eng'
p15896
asS'DCOM'
p15897
S'20150629'
p15898
sS'JT'
p15899
S'Journal of the International AIDS Society'
p15900
sS'LR'
p15901
S'20151028'
p15902
sS'FAU'
p15903
(lp15904
S'Nichols, Brooke E'
p15905
aS'Sigaloff, Kim C E'
p15906
aS'Kityo, Cissy'
p15907
aS'Hamers, Raph L'
p15908
aS'Baltussen, Rob'
p15909
aS'Bertagnolio, Silvia'
p15910
aS'Jordan, Michael R'
p15911
aS'Hallett, Timothy B'
p15912
aS'Boucher, Charles A B'
p15913
aS'de Wit, Tobias F Rinke'
p15914
aS'van de Vijver, David A M C'
p15915
asS'TI'
p15916
S'Increasing the use of second-line therapy is a cost-effective approach to prevent the spread of drug-resistant HIV: a mathematical modelling study.'
p15917
sS'RN'
p15918
(lp15919
S'0 (Anti-HIV Agents)'
p15920
asS'PL'
p15921
S'Switzerland'
p15922
sS'PG'
p15923
S'19164'
p15924
sS'JID'
p15925
S'101478566'
p15926
sS'AB'
p15927
S'INTRODUCTION: Earlier antiretroviral therapy (ART) initiation reduces HIV-1 incidence. This benefit may be offset by increased transmitted drug resistance (TDR), which could limit future HIV treatment options. We analyze the epidemiological impact and cost-effectiveness of strategies to reduce TDR. METHODS: We develop a deterministic mathematical model representing Kampala, Uganda, to predict the prevalence of TDR over a 10-year period. We then compare the impact on TDR and cost-effectiveness of: (1) introduction of pre-therapy genotyping; (2) doubling use of second-line treatment to 80% (50-90%) of patients with confirmed virological failure on first-line ART; and (3) increasing viral load monitoring from yearly to twice yearly. An intervention can be considered cost-effective if it costs less than three times the gross domestic product per capita per quality adjusted life year (QALY) gained, or less than $3420 in Uganda. RESULTS: The prevalence of TDR is predicted to rise from 6.7% (interquartile range [IQR] 6.2-7.2%) in 2014, to 6.8% (IQR 6.1-7.6%), 10.0% (IQR 8.9-11.5%) and 11.1% (IQR 9.7-13.0%) in 2024 if treatment is initiated at a CD4 <350, <500, or immediately, respectively. The absolute number of TDR cases is predicted to decrease 4.4-8.1% when treating earlier compared to treating at CD4 <350 due to the preventative effects of earlier treatment. Most cases of TDR can be averted by increasing second-line treatment (additional 7.1-10.2% reduction), followed by increased viral load monitoring (<2.7%) and pre-therapy genotyping (<1.0%). Only increasing second-line treatment is cost-effective, ranging from $1612 to $2234 (IQR $450-dominated) per QALY gained. CONCLUSIONS: While earlier treatment initiation will result in a predicted increase in the proportion of patients infected with drug-resistant HIV, the absolute numbers of patients infected with drug-resistant HIV is predicted to decrease. Increasing use of second-line treatment to all patients with confirmed failure on first-line therapy is a cost-effective approach to reduce TDR. Improving access to second-line ART is therefore a major priority.'
p15928
sS'GR'
p15929
(lp15930
S'1P30A142853/PHS HHS/United States'
p15931
asS'VI'
p15932
S'17'
p15933
sS'IS'
p15934
S'1758-2652 (Electronic) 1758-2652 (Linking)'
p15935
sS'PMC'
p15936
S'PMC4260459'
p15937
sS'AU'
p15938
(lp15939
S'Nichols BE'
p15940
aS'Sigaloff KC'
p15941
aS'Kityo C'
p15942
aS'Hamers RL'
p15943
aS'Baltussen R'
p15944
aS'Bertagnolio S'
p15945
aS'Jordan MR'
p15946
aS'Hallett TB'
p15947
aS'Boucher CA'
p15948
aS'de Wit TF'
p15949
aS'van de Vijver DA'
p15950
asS'MHDA'
p15951
S'2015/06/30 06:00'
p15952
sS'PHST'
p15953
(lp15954
S'2014 [ecollection]'
p15955
aS'2014/03/31 [received]'
p15956
aS'2014/10/14 [revised]'
p15957
aS'2014/10/30 [accepted]'
p15958
asS'OT'
p15959
(lp15960
S'antiretroviral therapy'
p15961
aS'cost-effectiveness'
p15962
aS'drug resistance'
p15963
aS'pre-therapy genotyping'
p15964
aS'second-line treatment'
p15965
aS'viral load monitoring'
p15966
asS'OTO'
p15967
(lp15968
S'NOTNLM'
p15969
asS'OID'
p15970
(lp15971
S'NLM: PMC4260459'
p15972
asS'MH'
p15973
(lp15974
S'Anti-HIV Agents/*economics/*therapeutic use'
p15975
aS'Antiretroviral Therapy, Highly Active/*economics/*methods'
p15976
aS'Cost-Benefit Analysis'
p15977
aS'Drug Monitoring/economics/utilization'
p15978
aS'*Drug Resistance, Viral'
p15979
aS'HIV Infections/*drug therapy/transmission/virology'
p15980
aS'Humans'
p15981
aS'*Models, Theoretical'
p15982
aS'Uganda'
p15983
asS'EDAT'
p15984
S'2014/12/11 06:00'
p15985
sS'SO'
p15986
S'J Int AIDS Soc. 2014 Dec 5;17:19164. doi: 10.7448/IAS.17.1.19164. eCollection 2014.'
p15987
sS'SB'
p15988
S'IM X'
p15989
sS'PMID'
p15990
S'25491351'
p15991
sS'TA'
p15992
S'J Int AIDS Soc'
p15993
sS'PST'
p15994
S'epublish'
p15995
stRp15996
ag2
(g3
g4
(dp15997
S'LID'
p15998
S'10.1186/1756-0500-7-890 [doi]'
p15999
sS'STAT'
p16000
S'MEDLINE'
p16001
sS'DEP'
p16002
S'20141209'
p16003
sS'DA'
p16004
S'20141220'
p16005
sS'AID'
p16006
(lp16007
S'1756-0500-7-890 [pii]'
p16008
aS'10.1186/1756-0500-7-890 [doi]'
p16009
asS'CRDT'
p16010
(lp16011
S'2014/12/10 06:00'
p16012
asS'DP'
p16013
S'2014'
p16014
sS'OWN'
p16015
S'NLM'
p16016
sS'PT'
p16017
(lp16018
S'Journal Article'
p16019
aS"Research Support, Non-U.S. Gov't"
p16020
asS'LA'
p16021
(lp16022
S'eng'
p16023
asS'DCOM'
p16024
S'20150811'
p16025
sS'JT'
p16026
S'BMC research notes'
p16027
sS'LR'
p16028
S'20151028'
p16029
sS'FAU'
p16030
(lp16031
S'Koigi, Peter'
p16032
aS'Ngayo, Musa Otieno'
p16033
aS'Khamadi, Samoel'
p16034
aS'Ngugi, Caroline'
p16035
aS'Nyamache, Anthony Kebira'
p16036
asS'TI'
p16037
S'HIV type 1 drug resistance patterns among patients failing first and second line antiretroviral therapy in Nairobi, Kenya.'
p16038
sS'RN'
p16039
(lp16040
S'0 (Anti-HIV Agents)'
p16041
asS'PL'
p16042
S'England'
p16043
sS'PG'
p16044
S'890'
p16045
sS'JID'
p16046
S'101462768'
p16047
sS'AB'
p16048
S'BACKGROUND: The ever-expanding rollout of antiretroviral therapy in poor resource settings without routine virological monitoring has been accompanied with development of drug resistance that has resulted in limited treatment success. METHODS: A cross-sectional study with one time viral load was conducted during the period between 2012 and 2013 to determine treatment failure and drug resistance mutations among adults receiving first-line (44) (3TC_d4T/AZT_NVP/EFV) and second-line (20) (3TC/AZT/LPV/r) in Nairobi, Kenya. HIV-1 pol-RT genotyping for drug resistance was performed using an in-house protocol. RESULTS: A total of 64 patients were recruited (mean age 36.9 yrs.) during the period between 2012 and 2013 of the 44 adult patients failing first-line 24 (40.9%) had drug resistance mutations. Eight (8) patients had NRTI resistance mutations with NAMS M184V (54.2%) and K65R (8.4%) mutations being the highest followed by TAMs T215Y and K70R (12.5%). In addition, among patients failing second-line (20), six patients (30%) had NNRTI resistance; two patients on K103N and G190A mutations while V106A, Y184V, A98G, Y181C mutations per patient were also detected. However, for NRTI two patients had TAM T215Y. M184V mutation occurred in one patient. CONCLUSIONS: The study findings showed that HIV-1 drug resistance was significantly high in the study population. The detected accumulated resistance strains show that emergence of HIV drug resistance will continue to be a big challenge and should be given more attention as the scale up of treatment in the country continues.'
p16049
sS'AD'
p16050
S'Centre for Virus Research, Kenya Medical Research Institute, Nairobi, Kenya. akibera2000@gmail.com.'
p16051
sS'VI'
p16052
S'7'
sS'IS'
p16053
S'1756-0500 (Electronic) 1756-0500 (Linking)'
p16054
sS'PMC'
p16055
S'PMC4295353'
p16056
sS'AU'
p16057
(lp16058
S'Koigi P'
p16059
aS'Ngayo MO'
p16060
aS'Khamadi S'
p16061
aS'Ngugi C'
p16062
aS'Nyamache AK'
p16063
asS'MHDA'
p16064
S'2015/08/12 06:00'
p16065
sS'PHST'
p16066
(lp16067
S'2014/08/29 [received]'
p16068
aS'2014/11/21 [accepted]'
p16069
aS'2014/12/09 [aheadofprint]'
p16070
asS'OID'
p16071
(lp16072
S'NLM: PMC4295353'
p16073
asS'MH'
p16074
(lp16075
S'Adult'
p16076
aS'Anti-HIV Agents/*therapeutic use'
p16077
aS'CD4 Lymphocyte Count'
p16078
aS'Drug Resistance, Viral/*genetics'
p16079
aS'Female'
p16080
aS'HIV Infections/*drug therapy/immunology/virology'
p16081
aS'HIV-1/*drug effects'
p16082
aS'Humans'
p16083
aS'Kenya'
p16084
aS'Male'
p16085
aS'Molecular Sequence Data'
p16086
aS'Mutation'
p16087
aS'Polymerase Chain Reaction'
p16088
asS'EDAT'
p16089
S'2014/12/10 06:00'
p16090
sS'SI'
p16091
(lp16092
S'GENBANK/KJ502113'
p16093
aS'GENBANK/KJ502114'
p16094
aS'GENBANK/KJ502115'
p16095
aS'GENBANK/KJ502116'
p16096
aS'GENBANK/KJ502117'
p16097
aS'GENBANK/KJ502118'
p16098
aS'GENBANK/KJ502119'
p16099
aS'GENBANK/KJ502120'
p16100
aS'GENBANK/KJ502121'
p16101
aS'GENBANK/KJ502122'
p16102
aS'GENBANK/KJ502123'
p16103
aS'GENBANK/KJ502124'
p16104
aS'GENBANK/KJ502125'
p16105
aS'GENBANK/KJ502126'
p16106
aS'GENBANK/KJ502127'
p16107
aS'GENBANK/KJ502128'
p16108
aS'GENBANK/KJ502129'
p16109
aS'GENBANK/KJ502130'
p16110
aS'GENBANK/KJ502131'
p16111
aS'GENBANK/KJ502132'
p16112
aS'GENBANK/KJ502133'
p16113
aS'GENBANK/KJ502134'
p16114
aS'GENBANK/KJ502135'
p16115
aS'GENBANK/KJ502136'
p16116
aS'GENBANK/KJ502137'
p16117
aS'GENBANK/KJ502138'
p16118
aS'GENBANK/KJ502139'
p16119
aS'GENBANK/KJ502140'
p16120
aS'GENBANK/KJ502141'
p16121
aS'GENBANK/KJ502142'
p16122
aS'GENBANK/KJ502143'
p16123
aS'GENBANK/KJ502144'
p16124
aS'GENBANK/KJ502145'
p16125
aS'GENBANK/KJ502146'
p16126
aS'GENBANK/KJ502147'
p16127
aS'GENBANK/KJ502148'
p16128
aS'GENBANK/KJ502149'
p16129
aS'GENBANK/KJ502150'
p16130
aS'GENBANK/KJ502151'
p16131
aS'GENBANK/KJ502152'
p16132
aS'GENBANK/KJ502153'
p16133
aS'GENBANK/KJ502154'
p16134
aS'GENBANK/KJ502155'
p16135
aS'GENBANK/KJ502156'
p16136
aS'GENBANK/KJ502157'
p16137
aS'GENBANK/KJ502158'
p16138
aS'GENBANK/KJ502159'
p16139
aS'GENBANK/KJ502160'
p16140
aS'GENBANK/KJ502161'
p16141
aS'GENBANK/KJ502162'
p16142
aS'GENBANK/KJ502163'
p16143
aS'GENBANK/KJ502164'
p16144
aS'GENBANK/KJ502165'
p16145
aS'GENBANK/KJ502166'
p16146
aS'GENBANK/KJ502167'
p16147
aS'GENBANK/KJ502168'
p16148
aS'GENBANK/KJ502169'
p16149
aS'GENBANK/KJ502170'
p16150
aS'GENBANK/KJ502171'
p16151
aS'GENBANK/KJ502172'
p16152
aS'GENBANK/KJ502173'
p16153
asS'SO'
p16154
S'BMC Res Notes. 2014 Dec 9;7:890. doi: 10.1186/1756-0500-7-890.'
p16155
sS'SB'
p16156
S'IM'
p16157
sS'PMID'
p16158
S'25487529'
p16159
sS'TA'
p16160
S'BMC Res Notes'
p16161
sS'PST'
p16162
S'epublish'
p16163
stRp16164
ag2
(g3
g4
(dp16165
S'LID'
p16166
S'10.1097/QAD.0000000000000550 [doi]'
p16167
sS'STAT'
p16168
S'MEDLINE'
p16169
sS'JT'
p16170
S'AIDS (London, England)'
p16171
sS'MID'
p16172
(lp16173
S'NIHMS675217'
p16174
asS'DA'
p16175
S'20150128'
p16176
sS'AID'
p16177
(lp16178
S'10.1097/QAD.0000000000000550 [doi]'
p16179
asS'CRDT'
p16180
(lp16181
S'2014/12/09 06:00'
p16182
asS'DP'
p16183
S'2015 Feb 20'
p16184
sS'AD'
p16185
S'Yale School of Public Health, New Haven, Connecticut, USA.'
p16186
sS'OWN'
p16187
S'NLM'
p16188
sS'PT'
p16189
(lp16190
S'Journal Article'
p16191
aS'Research Support, N.I.H., Extramural'
p16192
asS'LA'
p16193
(lp16194
S'eng'
p16195
asS'FAU'
p16196
(lp16197
S'Greenhalgh, Scott'
p16198
aS'Ndeffo, Martial'
p16199
aS'Galvani, Alison P'
p16200
aS'Parikh, Sunil'
p16201
asS'LR'
p16202
S'20160220'
p16203
sS'PG'
p16204
S'473-82'
p16205
sS'TI'
p16206
S'The epidemiological impact of HIV antiretroviral therapy on malaria in children.'
p16207
sS'RN'
p16208
(lp16209
S'0 (Antimalarials)'
p16210
aS'0 (Artemisinins)'
p16211
aS'0 (Drug Combinations)'
p16212
aS'0 (Ethanolamines)'
p16213
aS'0 (Fluorenes)'
p16214
aS'0 (HIV Protease Inhibitors)'
p16215
aS'0 (artemether-lumefantrine combination)'
p16216
asS'PL'
p16217
S'England'
p16218
sS'TA'
p16219
S'AIDS'
p16220
sS'JID'
p16221
S'8710219'
p16222
sS'AB'
p16223
S'OBJECTIVE: The objective of this study is to determine the epidemiological effectiveness of a first-line antiretroviral regimen with HIV protease inhibitor for preventing recurrent malaria in children under the range of HIV prevalence levels and malaria transmission intensities encountered in sub-Saharan Africa. DESIGN: A dynamic model of malaria transmission was developed using clinical data on the protease inhibitor extended posttreatment prophylactic effect of the antimalarial treatment, artemether-lumefantrine, in addition to parameter estimates from the literature. METHODS: To evaluate the benefits of HIV protease inhibitors on the health burden of recurrent malaria among children, we constructed a dynamic model of malaria transmission to both HIV-positive and HIV-negative children, parameterized by data from a recent clinical trial. The model was then evaluated under varying malaria transmission and HIV prevalence settings to determine the health benefits of HIV protease inhibitors in the context of artemether-lumefantrine treatment of malaria in children. RESULTS: Comparing scenarios of low, intermediate and high newborn HIV prevalence, in a range of malaria transmission settings, our dynamic model predicts that artemether-lumefantrine with HIV protease inhibitor based regimens prevents 0.03-0.10, 5.2-13.0 and 25.5-65.8 annual incidences of malaria per 1000 children, respectively. In addition, HIV protease inhibitors save 0.002-0.006, 0.22-0.8, 1.04-4.3 disability-adjusted life-years per 1000 children annually. Considering only HIV-infected children, HIV protease inhibitors avert between 278 and 1043 annual incidences of malaria per 1000 children. CONCLUSION: The use of HIV protease inhibitor based regimens as first-line antiretroviral therapy for HIV is an effective measure for reducing recurrent malaria among HIV-infected children in areas where HIV and malaria are coendemic, and artemether-lumefantrine is a first-line antimalarial.'
p16224
sS'GR'
p16225
(lp16226
S'5R01HD068174/HD/NICHD NIH HHS/United States'
p16227
aS'R01 HD068174/HD/NICHD NIH HHS/United States'
p16228
aS'U01 GM087719/GM/NIGMS NIH HHS/United States'
p16229
aS'U01 GM087719/GM/NIGMS NIH HHS/United States'
p16230
asS'IP'
p16231
S'4'
sS'IS'
p16232
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p16233
sS'PMC'
p16234
S'PMC4391884'
p16235
sS'DCOM'
p16236
S'20151221'
p16237
sS'AU'
p16238
(lp16239
S'Greenhalgh S'
p16240
aS'Ndeffo M'
p16241
aS'Galvani AP'
p16242
aS'Parikh S'
p16243
asS'VI'
p16244
S'29'
p16245
sS'MHDA'
p16246
S'2015/12/22 06:00'
p16247
sS'OID'
p16248
(lp16249
S'NLM: NIHMS675217'
p16250
aS'NLM: PMC4391884'
p16251
asS'MH'
p16252
(lp16253
S'Africa South of the Sahara/epidemiology'
p16254
aS'Animals'
p16255
aS'Antimalarials/*therapeutic use'
p16256
aS'Artemisinins/*therapeutic use'
p16257
aS'Child'
p16258
aS'Child, Preschool'
p16259
aS'Drug Combinations'
p16260
aS'Ethanolamines/*therapeutic use'
p16261
aS'Fluorenes/*therapeutic use'
p16262
aS'HIV Infections/*drug therapy/epidemiology/immunology'
p16263
aS'HIV Protease Inhibitors/*therapeutic use'
p16264
aS'Humans'
p16265
aS'Malaria/*drug therapy/epidemiology/prevention & control'
p16266
aS'Recurrence'
p16267
aS'Treatment Outcome'
p16268
asS'EDAT'
p16269
S'2014/12/09 06:00'
p16270
sS'SO'
p16271
S'AIDS. 2015 Feb 20;29(4):473-82. doi: 10.1097/QAD.0000000000000550.'
p16272
sS'SB'
p16273
S'IM X'
p16274
sS'PMID'
p16275
S'25486414'
p16276
sS'PST'
p16277
S'ppublish'
p16278
stRp16279
ag2
(g3
g4
(dp16280
S'LID'
p16281
S'10.1186/s12913-014-0627-9 [doi]'
p16282
sS'STAT'
p16283
S'MEDLINE'
p16284
sS'DEP'
p16285
S'20141203'
p16286
sS'DA'
p16287
S'20150427'
p16288
sS'AID'
p16289
(lp16290
S'10.1186/s12913-014-0627-9 [doi]'
p16291
aS's12913-014-0627-9 [pii]'
p16292
asS'CRDT'
p16293
(lp16294
S'2014/12/04 06:00'
p16295
asS'DP'
p16296
S'2014'
p16297
sS'AD'
p16298
S'Department of Internal Medicine, Bugando Medical Centre, Bugando Hill Road, Box 1370, Mwanza, Tanzania. wajangabmk@gmail.com. Department of Internal Medicine, Catholic University of Health and Allied Sciences, Bugando, Mwanza, Tanzania. wajangabmk@gmail.com. Weill Cornell Medical College, New York, NY, USA. laurenwebs@gmail.com. Department of Internal Medicine, Bugando Medical Centre, Bugando Hill Road, Box 1370, Mwanza, Tanzania. rnp2002@gmail.com. Department of Internal Medicine, Catholic University of Health and Allied Sciences, Bugando, Mwanza, Tanzania. rnp2002@gmail.com. Weill Cornell Medical College, New York, NY, USA. rnp2002@gmail.com. Department of Internal Medicine, Bugando Medical Centre, Bugando Hill Road, Box 1370, Mwanza, Tanzania. jna2002@med.cornell.edu. Department of Internal Medicine, Catholic University of Health and Allied Sciences, Bugando, Mwanza, Tanzania. jna2002@med.cornell.edu. Weill Cornell Medical College, New York, NY, USA. jna2002@med.cornell.edu. Weill Cornell Medical College, New York, NY, USA. kmate@ihi.org. Department of Internal Medicine, Bugando Medical Centre, Bugando Hill Road, Box 1370, Mwanza, Tanzania. smart.luke@gmail.com. Department of Internal Medicine, Catholic University of Health and Allied Sciences, Bugando, Mwanza, Tanzania. smart.luke@gmail.com. Weill Cornell Medical College, New York, NY, USA. smart.luke@gmail.com. Weill Cornell Medical College, New York, NY, USA. dfitzgerald@gheskio.org.'
p16299
sS'OWN'
p16300
S'NLM'
p16301
sS'PT'
p16302
(lp16303
S'Journal Article'
p16304
aS'Review'
p16305
asS'LA'
p16306
(lp16307
S'eng'
p16308
asS'DCOM'
p16309
S'20160411'
p16310
sS'JT'
p16311
S'BMC health services research'
p16312
sS'LR'
p16313
S'20150427'
p16314
sS'FAU'
p16315
(lp16316
S'Wajanga, Bahati Mk'
p16317
aS'Webster, Lauren E'
p16318
aS'Peck, Robert N'
p16319
aS'Downs, Jennifer A'
p16320
aS'Mate, Kedar'
p16321
aS'Smart, Luke R'
p16322
aS'Fitzgerald, Daniel W'
p16323
asS'TI'
p16324
S'Inpatient mortality of HIV-infected adults in sub-Saharan Africa and possible interventions: a mixed methods review.'
p16325
sS'PL'
p16326
S'England'
p16327
sS'PG'
p16328
S'627'
p16329
sS'JID'
p16330
S'101088677'
p16331
sS'AB'
p16332
S'BACKGROUND: Despite the increased availability of anti-retroviral therapy, in-hospital HIV mortality remains high in sub-Saharan Africa. Reports from Senegal, Malawi, and Tanzania show rates of in-hospital, HIV-related mortality ranging from 24.2% to 44%. This mixed methods review explored the potential causes of preventable in-hospital mortality associated with HIV infections in sub-Saharan Africa in the anti-retroviral era. RESULTS: Based on our experience as healthcare providers in Africa and a review of the literature we identified 5 health systems failures which may cause preventable in-hospital mortality, including: 1) late presentation of HIV cases, 2) low rates of in-hospital HIV testing, 3) poor laboratory capacity which limits CD4 T-cell testing and the diagnosis of opportunistic infections, 4) delay in initiation of anti-retroviral therapy in-hospital, and 5) problems associated with loss to follow-up upon discharge from hospital. CONCLUSION: Our findings, together with the current available literature, should be used to develop practical interventions that can be implemented to reduce in-hospital mortality.'
p16333
sS'GR'
p16334
(lp16335
S'R25 TW009337/TW/FIC NIH HHS/United States'
p16336
asS'VI'
p16337
S'14'
p16338
sS'IS'
p16339
S'1472-6963 (Electronic) 1472-6963 (Linking)'
p16340
sS'PMC'
p16341
S'PMC4265398'
p16342
sS'AU'
p16343
(lp16344
S'Wajanga BM'
p16345
aS'Webster LE'
p16346
aS'Peck RN'
p16347
aS'Downs JA'
p16348
aS'Mate K'
p16349
aS'Smart LR'
p16350
aS'Fitzgerald DW'
p16351
asS'MHDA'
p16352
S'2016/04/12 06:00'
p16353
sS'PHST'
p16354
(lp16355
S'2013/09/23 [received]'
p16356
aS'2014/11/24 [accepted]'
p16357
aS'2014/12/03 [aheadofprint]'
p16358
asS'OID'
p16359
(lp16360
S'NLM: PMC4265398'
p16361
asS'MH'
p16362
(lp16363
S'Adult'
p16364
aS'Africa South of the Sahara'
p16365
aS'CD4-Positive T-Lymphocytes'
p16366
aS'Female'
p16367
aS'HIV Infections/*mortality'
p16368
aS'*Hospital Mortality'
p16369
aS'Humans'
p16370
aS'*Inpatients'
p16371
aS'Male'
p16372
asS'EDAT'
p16373
S'2014/12/04 06:00'
p16374
sS'SO'
p16375
S'BMC Health Serv Res. 2014 Dec 3;14:627. doi: 10.1186/s12913-014-0627-9.'
p16376
sS'SB'
p16377
S'IM'
p16378
sS'PMID'
p16379
S'25465206'
p16380
sS'TA'
p16381
S'BMC Health Serv Res'
p16382
sS'PST'
p16383
S'epublish'
p16384
stRp16385
ag2
(g3
g4
(dp16386
S'LID'
p16387
S'10.1097/QAI.0000000000000379 [doi]'
p16388
sS'STAT'
p16389
S'MEDLINE'
p16390
sS'JT'
p16391
S'Journal of acquired immune deficiency syndromes (1999)'
p16392
sS'DA'
p16393
S'20141202'
p16394
sS'AID'
p16395
(lp16396
S'10.1097/QAI.0000000000000379 [doi]'
p16397
aS'00126334-201412011-00011 [pii]'
p16398
asS'CRDT'
p16399
(lp16400
S'2014/12/02 06:00'
p16401
asS'DP'
p16402
S'2014 Dec 1'
p16403
sS'OWN'
p16404
S'NLM'
p16405
sS'PT'
p16406
(lp16407
S'Comparative Study'
p16408
aS'Journal Article'
p16409
aS"Research Support, Non-U.S. Gov't"
p16410
aS"Research Support, U.S. Gov't, Non-P.H.S."
p16411
asS'LA'
p16412
(lp16413
S'eng'
p16414
asS'DCOM'
p16415
S'20150130'
p16416
sS'LR'
p16417
S'20151028'
p16418
sS'FAU'
p16419
(lp16420
S'Myer, Landon'
p16421
aS'Abrams, Elaine J'
p16422
aS'Zhang, Yuan'
p16423
aS'Duong, Jimmy'
p16424
aS'El-Sadr, Wafaa M'
p16425
aS'Carter, Rosalind J'
p16426
asS'TI'
p16427
S'Family matters: Co-enrollment of family members into care is associated with improved outcomes for HIV-infected women initiating antiretroviral therapy.'
p16428
sS'RN'
p16429
(lp16430
S'0 (Anti-HIV Agents)'
p16431
asS'PL'
p16432
S'United States'
p16433
sS'PG'
p16434
S'S243-9'
p16435
sS'JID'
p16436
S'100892005'
p16437
sS'AB'
p16438
S"BACKGROUND: Although there is widespread interest in understanding how models of care for delivering antiretroviral therapy (ART) may influence patient outcomes, family-focused approaches have received little attention. In particular, there have been few investigations of whether the co-enrollment of HIV-infected family members may improve adult ART outcomes over time. METHODS: We examined the association between co-enrollment of HIV-infected family members into care and outcomes of women initiating ART in 12 HIV care and treatment programs across sub-Saharan Africa. Using data from the mother-to-child transmission-(MTCT) Plus Initiative, women starting ART were categorized according to the co-enrollment of an HIV-infected partner and/or HIV-infected child within the same program. Mortality and loss to follow-up were assessed for up to 5 years after women's ART initiation. RESULTS: Of the 2877 women initiating ART included in the analysis, 31% (n = 880) had at least 1 HIV-infected family member enrolled into care at the same program, including 24% (n = 689) who had an HIV-infected male partner, and 10% (n = 295) who had an HIV-infected child co-enrolled. There was no significant difference in the risk of death of women by family co-enrollment status (P = 0.286). However, the risk of loss to follow-up was greatest among women who did not have an HIV-infected family member co-enrolled (19% after 36 months on ART) compared with women who had an HIV-infected family member co-enrolled (3%-8% after 36 months on ART) (P < 0.001). These associations persisted after adjustment for demographic and clinical covariates and were consistent across countries and care programs. DISCUSSION: These data provide novel evidence for the association between adult outcomes on ART and co-enrollment of HIV-infected family members into care at the same program. Interventions that build on women's family contexts warrant further consideration in both research and policies to promote retention in ART services across sub-Saharan Africa."
p16439
sS'AD'
p16440
S'*Division of Epidemiology & Biostatistics, School of Public Health & Family Medicine, University of Cape Town, Cape Town, South Africa; daggerDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY; double daggerICAP at Columbia University and Department of Epidemiology, Mailman School of Public Health, New York, NY; section signCollege of Physicians & Surgeons, Columbia University, New York, NY; ||Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY; and paragraph signUNICEF, New York, NY.'
p16441
sS'VI'
p16442
S'67 Suppl 4'
p16443
sS'IS'
p16444
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p16445
sS'PMC'
p16446
S'PMC4252141'
p16447
sS'AU'
p16448
(lp16449
S'Myer L'
p16450
aS'Abrams EJ'
p16451
aS'Zhang Y'
p16452
aS'Duong J'
p16453
aS'El-Sadr WM'
p16454
aS'Carter RJ'
p16455
asS'MHDA'
p16456
S'2015/01/31 06:00'
p16457
sS'OID'
p16458
(lp16459
S'NLM: PMC4252141'
p16460
asS'MH'
p16461
(lp16462
S'Adolescent'
p16463
aS'Adult'
p16464
aS'Africa South of the Sahara'
p16465
aS'Anti-HIV Agents/*therapeutic use'
p16466
aS'Child'
p16467
aS'Child, Preschool'
p16468
aS'Family/*psychology'
p16469
aS'Female'
p16470
aS'Follow-Up Studies'
p16471
aS'HIV Infections/*drug therapy/*psychology'
p16472
aS'Humans'
p16473
aS'*Interpersonal Relations'
p16474
aS'Male'
p16475
aS'Young Adult'
p16476
asS'EDAT'
p16477
S'2014/12/02 06:00'
p16478
sS'SO'
p16479
S'J Acquir Immune Defic Syndr. 2014 Dec 1;67 Suppl 4:S243-9. doi: 10.1097/QAI.0000000000000379.'
p16480
sS'SB'
p16481
S'IM X'
p16482
sS'PMID'
p16483
S'25436824'
p16484
sS'TA'
p16485
S'J Acquir Immune Defic Syndr'
p16486
sS'PST'
p16487
S'ppublish'
p16488
stRp16489
ag2
(g3
g4
(dp16490
S'STAT'
p16491
S'MEDLINE'
p16492
sS'JT'
p16493
S'Current HIV research'
p16494
sS'MID'
p16495
(lp16496
S'NIHMS728486'
p16497
asS'DA'
p16498
S'20141127'
p16499
sS'AID'
p16500
(lp16501
S'CHR-63500 [pii]'
p16502
asS'CRDT'
p16503
(lp16504
S'2014/11/27 06:00'
p16505
asS'DP'
p16506
S'2014'
p16507
sS'AD'
p16508
S'341 Ponce de Leon Avenue, Atlanta, GA, 30308, USA. vcmarco@emory.edu.'
p16509
sS'OWN'
p16510
S'NLM'
p16511
sS'PT'
p16512
(lp16513
S'Journal Article'
p16514
asS'LA'
p16515
(lp16516
S'eng'
p16517
asS'FAU'
p16518
(lp16519
S'Wu, Peng'
p16520
aS'Johnson, Brent A'
p16521
aS'Nachega, Jean B'
p16522
aS'Wu, Baohua'
p16523
aS'Ordonez, Claudia E'
p16524
aS'Hare, Anna Q'
p16525
aS'Kearns, Rachel'
p16526
aS'Murphy, Richard'
p16527
aS'Sunpath, Henry'
p16528
aS'Marconi, Vincent C'
p16529
asS'LR'
p16530
S'20151119'
p16531
sS'PG'
p16532
S'366-75'
p16533
sS'TI'
p16534
S'The combination of pill count and self-reported adherence is a strong predictor of first-line ART failure for adults in South Africa.'
p16535
sS'RN'
p16536
(lp16537
S'0 (Anti-HIV Agents)'
p16538
asS'PL'
p16539
S'Netherlands'
p16540
sS'TA'
p16541
S'Curr HIV Res'
p16542
sS'JID'
p16543
S'101156990'
p16544
sS'AB'
p16545
S'BACKGROUND: Suboptimal adherence to antiretroviral therapy (ART) is a strong predictor of virologic failure (VF) among people with HIV. Various methods such as patient self-report, pill counts and pharmacy refills have been utilized to monitor adherence. However, there are limited data on the accuracy of combining methods to better predict VF in routine clinical settings. We examined various methods to assess adherence including pill count, medication possession ratio (MPR), and self-reported adherence in order to determine which was most highly associated with VF after > 6 months on ART. METHODS: We conducted a secondary analysis of data from a case-control study. At enrollment, pharmacy refill data were collected retrospectively from the medical chart, pill counts were completed to derive a pill count adherence ratio (PCAR) and a self-report questionnaire was administered to all participants. Parametric smooth splines and receiver operator characteristic (ROC) analyses were carried out to assess the accuracy of the adherence methods. RESULTS: 458 patients were enrolled from October 2010 to June 2012. Of these, 158 (34.50%) experienced VF (cases) and 300 (65.50%) were controls. The median (IQR) PCAR was 1.10 (0.99-1.14) for cases and 1.13 (1.08-1.18) for controls (p < 0.0001). The median MPR was 1.00 (0.97-1.07) for cases and 1.03 (0.96-1.07) for controls (p = 0.83). Combination of PCAR and self-reported questions was highly associated with VF. CONCLUSION: In this setting, a combination of pill count adherence and self-report adherence questions had the highest diagnostic accuracy for VF. Further validation of this simple, low-cost combination is warranted in large prospective studies.'
p16546
sS'GR'
p16547
(lp16548
S'P30 AI050409/AI/NIAID NIH HHS/United States'
p16549
aS'R01 AI098558/AI/NIAID NIH HHS/United States'
p16550
asS'IP'
p16551
S'5'
sS'IS'
p16552
S'1873-4251 (Electronic) 1570-162X (Linking)'
p16553
sS'PMC'
p16554
S'PMC4608026'
p16555
sS'DCOM'
p16556
S'20150630'
p16557
sS'AU'
p16558
(lp16559
S'Wu P'
p16560
aS'Johnson BA'
p16561
aS'Nachega JB'
p16562
aS'Wu B'
p16563
aS'Ordonez CE'
p16564
aS'Hare AQ'
p16565
aS'Kearns R'
p16566
aS'Murphy R'
p16567
aS'Sunpath H'
p16568
aS'Marconi VC'
p16569
asS'VI'
p16570
S'12'
p16571
sS'MHDA'
p16572
S'2015/07/01 06:00'
p16573
sS'PHST'
p16574
(lp16575
S'2014/01/07 [received]'
p16576
aS'2014/08/28 [revised]'
p16577
aS'2014/09/19 [accepted]'
p16578
asS'OID'
p16579
(lp16580
S'NLM: NIHMS728486'
p16581
aS'NLM: PMC4608026'
p16582
asS'MH'
p16583
(lp16584
S'Adult'
p16585
aS'Anti-HIV Agents/therapeutic use'
p16586
aS'*Antiretroviral Therapy, Highly Active'
p16587
aS'Case-Control Studies'
p16588
aS'Female'
p16589
aS'HIV Infections/*drug therapy/virology'
p16590
aS'Humans'
p16591
aS'Male'
p16592
aS'Medication Adherence/*statistics & numerical data'
p16593
aS'Middle Aged'
p16594
aS'Predictive Value of Tests'
p16595
aS'ROC Curve'
p16596
aS'Retrospective Studies'
p16597
aS'Risk Factors'
p16598
aS'Self Report'
p16599
aS'South Africa'
p16600
aS'Surveys and Questionnaires'
p16601
aS'Treatment Failure'
p16602
aS'Viral Load'
p16603
asS'EDAT'
p16604
S'2014/11/27 06:00'
p16605
sS'SO'
p16606
S'Curr HIV Res. 2014;12(5):366-75.'
p16607
sS'SB'
p16608
S'IM'
p16609
sS'PMID'
p16610
S'25426940'
p16611
sS'PST'
p16612
S'ppublish'
p16613
stRp16614
ag2
(g3
g4
(dp16615
S'LID'
p16616
S'10.1111/tmi.12434 [doi]'
p16617
sS'STAT'
p16618
S'MEDLINE'
p16619
sS'DEP'
p16620
S'20150106'
p16621
sS'CI'
p16622
(lp16623
S'(c) 2014 The Authors. Tropical Medicine & International Health Published by John'
p16624
aS'Wiley & Sons Ltd.'
p16625
asS'DA'
p16626
S'20150127'
p16627
sS'AID'
p16628
(lp16629
S'10.1111/tmi.12434 [doi]'
p16630
asS'CRDT'
p16631
(lp16632
S'2014/11/25 06:00'
p16633
asS'DP'
p16634
S'2015 Mar'
p16635
sS'OWN'
p16636
S'NLM'
p16637
sS'PT'
p16638
(lp16639
S'Journal Article'
p16640
aS'Meta-Analysis'
p16641
aS'Review'
p16642
asS'LA'
p16643
(lp16644
S'eng'
p16645
asS'FAU'
p16646
(lp16647
S'Wilkinson, Lynne S'
p16648
aS'Skordis-Worrall, Jolene'
p16649
aS'Ajose, Olawale'
p16650
aS'Ford, Nathan'
p16651
asS'JT'
p16652
S'Tropical medicine & international health : TM & IH'
p16653
sS'PG'
p16654
S'365-79'
p16655
sS'TI'
p16656
S'Self-transfer and mortality amongst adults lost to follow-up in ART programmes in low- and middle-income countries: systematic review and meta-analysis.'
p16657
sS'RN'
p16658
(lp16659
S'0 (Anti-HIV Agents)'
p16660
asS'PL'
p16661
S'England'
p16662
sS'TA'
p16663
S'Trop Med Int Health'
p16664
sS'JID'
p16665
S'9610576'
p16666
sS'AB'
p16667
S'OBJECTIVE: To ascertain estimates of adult patients, recorded as lost to follow-up (LTFU) within antiretroviral treatment (ART) programmes, who have self-transferred care, died or truly stopped ART in low- and middle-income countries. METHODS: PubMed, EMBASE, Web of Science, Science Direct, LILACS, IndMed and AIM databases (2003-2013) and IAS/AIDS conference abstracts (2011-2013) were searched for tracing studies reporting the proportion of traced patients found to have self-transferred, died or stopped ART. These estimates were then combined using random-effects meta-analysis. Risk of bias was assessed through subgroup and sensitivity analyses. RESULTS: Twenty eight studies were eligible for inclusion, reporting true outcomes for 10,806 traced patients attending approximately 258 ART facilities. None were from outside sub-Saharan Africa. Twenty three studies reported 4.5-54.4% traced LTFU patients self-transferring care, providing a pooled estimate of 18.6% (95% CI 15.8-22.0%). A significant positive association was found between rates of self-transfer and LTFU in the ART cohort. The pooled estimates for unreported deaths were 38.8% (95% CI 30.8-46.8%; 27 studies) and 28.6% (95% CI 21.9-36.0%; 20 studies) for patients stopping ART. A significant decrease in unreported deaths from 50.0% (95% CI 41.5-58.4%) to 30.0% (95% CI 21.1-38.9%) was found comparing study periods before and after 31 December 2007. CONCLUSIONS: Substantial unaccounted for transfers and deaths amongst patients LTFU confirms that retention and mortality is underestimated where the true outcomes of LTFU patients are not ascertained.'
p16668
sS'AD'
p16669
S'UCL Institute for Global Health, London, UK; Medecins Sans Frontieres, Khayelitsha, South Africa.'
p16670
sS'IP'
p16671
S'3'
sS'IS'
p16672
S'1365-3156 (Electronic) 1360-2276 (Linking)'
p16673
sS'DCOM'
p16674
S'20150406'
p16675
sS'AU'
p16676
(lp16677
S'Wilkinson LS'
p16678
aS'Skordis-Worrall J'
p16679
aS'Ajose O'
p16680
aS'Ford N'
p16681
asS'VI'
p16682
S'20'
p16683
sS'MHDA'
p16684
S'2015/04/07 06:00'
p16685
sS'PHST'
p16686
(lp16687
S'2015/01/06 [aheadofprint]'
p16688
asS'OTO'
p16689
(lp16690
S'NOTNLM'
p16691
asS'MH'
p16692
(lp16693
S'Adult'
p16694
aS'Africa South of the Sahara'
p16695
aS'Anti-HIV Agents/*therapeutic use'
p16696
aS'Developing Countries/*statistics & numerical data'
p16697
aS'*HIV Infections/drug therapy/mortality'
p16698
aS'Humans'
p16699
aS'*Lost to Follow-Up'
p16700
aS'Outcome Assessment (Health Care)'
p16701
aS'Patient Acceptance of Health Care/*statistics & numerical data'
p16702
aS'Patient Transfer/statistics & numerical data'
p16703
asS'EDAT'
p16704
S'2014/11/25 06:00'
p16705
sS'SO'
p16706
S'Trop Med Int Health. 2015 Mar;20(3):365-79. doi: 10.1111/tmi.12434. Epub 2015 Jan 6.'
p16707
sS'SB'
p16708
S'IM'
p16709
sS'PMID'
p16710
S'25418366'
p16711
sS'OT'
p16712
(lp16713
S'Human immunodeficiency virus'
p16714
aS'VIH'
p16715
aS'analyse systematique'
p16716
aS'antiretroviral therapy'
p16717
aS'continuidad de cuidados'
p16718
aS'continuity of care'
p16719
aS'continuite des soins'
p16720
aS'lost to follow-up'
p16721
aS'mortalidad'
p16722
aS'mortality'
p16723
aS'mortalite'
p16724
aS'perdu au suivi'
p16725
aS'perdida durante el seguimiento'
p16726
aS'revision sistematica'
p16727
aS'systematic review'
p16728
aS'terapia antirretroviral'
p16729
aS'therapie antiretrovirale'
p16730
asS'PST'
p16731
S'ppublish'
p16732
stRp16733
ag2
(g3
g4
(dp16734
S'LID'
p16735
S'10.7448/IAS.17.1.19262 [doi]'
p16736
sS'STAT'
p16737
S'MEDLINE'
p16738
sS'DEP'
p16739
S'20141118'
p16740
sS'DA'
p16741
S'20141121'
p16742
sS'AID'
p16743
(lp16744
S'19262 [pii]'
p16745
asS'CRDT'
p16746
(lp16747
S'2014/11/22 06:00'
p16748
asS'DP'
p16749
S'2014'
p16750
sS'AD'
p16751
S'Division of Infectious Diseases, Alpert Medical School, Brown University, Providence, RI, USA; rkantor@brown.edu. Center for Statistical Sciences, Brown University, Providence, RI, USA. Division of Infectious Diseases, Alpert Medical School, Brown University, Providence, RI, USA; Division of Infectious Diseases, Stanford University, Stanford, CA, USA. Division of Infectious Diseases, Alpert Medical School, Brown University, Providence, RI, USA. Research Think Tank, Inc., Buford, GA, USA. Department of Medicine, School of Medicine, College of Health Sciences, Moi University, Eldoret, Kenya; Academic Model Providing Access To Health Care (AMPATH), Eldoret, Kenya. Department of Medicine, School of Medicine, College of Health Sciences, Moi University, Eldoret, Kenya; Academic Model Providing Access To Health Care (AMPATH), Eldoret, Kenya. Department of Medicine, School of Medicine, College of Health Sciences, Moi University, Eldoret, Kenya; Academic Model Providing Access To Health Care (AMPATH), Eldoret, Kenya. Department of Medicine, School of Medicine, College of Health Sciences, Moi University, Eldoret, Kenya; Academic Model Providing Access To Health Care (AMPATH), Eldoret, Kenya. Division of Infectious Diseases, Stanford University, Stanford, CA, USA. Center for Statistical Sciences, Brown University, Providence, RI, USA. Department of Medicine, School of Medicine, College of Health Sciences, Moi University, Eldoret, Kenya; Department of Hematology and Blood Transfusion, College of Health Sciences, Moi University, Eldoret, Kenya. Department of Medicine, School of Medicine, College of Health Sciences, Moi University, Eldoret, Kenya; Academic Model Providing Access To Health Care (AMPATH), Eldoret, Kenya.'
p16752
sS'OWN'
p16753
S'NLM'
p16754
sS'PT'
p16755
(lp16756
S'Comparative Study'
p16757
aS'Evaluation Studies'
p16758
aS'Journal Article'
p16759
aS'Research Support, N.I.H., Extramural'
p16760
aS"Research Support, Non-U.S. Gov't"
p16761
asS'LA'
p16762
(lp16763
S'eng'
p16764
asS'DCOM'
p16765
S'20150629'
p16766
sS'JT'
p16767
S'Journal of the International AIDS Society'
p16768
sS'LR'
p16769
S'20151028'
p16770
sS'FAU'
p16771
(lp16772
S'Kantor, Rami'
p16773
aS'DeLong, Allison'
p16774
aS'Balamane, Maya'
p16775
aS'Schreier, Leeann'
p16776
aS'Lloyd, Robert M Jr'
p16777
aS'Injera, Wilfred'
p16778
aS'Kamle, Lydia'
p16779
aS'Mambo, Fidelis'
p16780
aS'Muyonga, Sarah'
p16781
aS'Katzenstein, David'
p16782
aS'Hogan, Joseph'
p16783
aS'Buziba, Nathan'
p16784
aS'Diero, Lameck'
p16785
asS'TI'
p16786
S'HIV diversity and drug resistance from plasma and non-plasma analytes in a large treatment programme in western Kenya.'
p16787
sS'RN'
p16788
(lp16789
S'0 (Anti-Retroviral Agents)'
p16790
asS'PL'
p16791
S'Switzerland'
p16792
sS'PG'
p16793
S'19262'
p16794
sS'JID'
p16795
S'101478566'
p16796
sS'AB'
p16797
S'INTRODUCTION: Antiretroviral resistance leads to treatment failure and resistance transmission. Resistance data in western Kenya are limited. Collection of non-plasma analytes may provide additional resistance information. METHODS: We assessed HIV diversity using the REGA tool, transmitted resistance by the WHO mutation list and acquired resistance upon first-line failure by the IAS-USA mutation list, at the Academic Model Providing Access to Healthcare (AMPATH), a major treatment programme in western Kenya. Plasma and four non-plasma analytes, dried blood-spots (DBS), dried plasma-spots (DPS), ViveST(TM)-plasma (STP) and ViveST-blood (STB), were compared to identify diversity and evaluate sequence concordance. RESULTS: Among 122 patients, 62 were treatment-naive and 60 treatment-experienced; 61% were female, median age 35 years, median CD4 182 cells/microL, median viral-load 4.6 log10 copies/mL. One hundred and ninety-six sequences were available for 107/122 (88%) patients, 58/62 (94%) treatment-naive and 49/60 (82%) treated; 100/122 (82%) plasma, 37/78 (47%) attempted DBS, 16/45 (36%) attempted DPS, 14/44 (32%) attempted STP from fresh plasma and 23/34 (68%) from frozen plasma, and 5/42 (12%) attempted STB. Plasma and DBS genotyping success increased at higher VL and shorter shipment-to-genotyping time. Main subtypes were A (62%), D (15%) and C (6%). Transmitted resistance was found in 1.8% of plasma sequences, and 7% combining analytes. Plasma resistance mutations were identified in 91% of treated patients, 76% NRTI, 91% NNRTI; 76% dual-class; 60% with intermediate-high predicted resistance to future treatment options; with novel mutation co-occurrence patterns. Nearly 88% of plasma mutations were identified in DBS, 89% in DPS and 94% in STP. Of 23 discordant mutations, 92% in plasma and 60% in non-plasma analytes were mixtures. Mean whole-sequence discordance from frozen plasma reference was 1.1% for plasma-DBS, 1.2% plasma-DPS, 2.0% plasma-STP and 2.3% plasma-STB. Of 23 plasma-STP discordances, one mutation was identified in plasma and 22 in STP (p<0.05). Discordance was inversely significantly related to VL for DBS. CONCLUSIONS: In a large treatment programme in western Kenya, we report high HIV-1 subtype diversity; low plasma transmitted resistance, increasing when multiple analytes were combined; and high-acquired resistance with unique mutation patterns. Resistance surveillance may be augmented by using non-plasma analytes for lower-cost genotyping in resource-limited settings.'
p16798
sS'GR'
p16799
(lp16800
S'P30 AI042853/AI/NIAID NIH HHS/United States'
p16801
aS'P30AI42853/AI/NIAID NIH HHS/United States'
p16802
aS'R01AI066922/AI/NIAID NIH HHS/United States'
p16803
aS'R24 HD041020/HD/NICHD NIH HHS/United States'
p16804
asS'VI'
p16805
S'17'
p16806
sS'IS'
p16807
S'1758-2652 (Electronic) 1758-2652 (Linking)'
p16808
sS'PMC'
p16809
S'PMC4238965'
p16810
sS'AU'
p16811
(lp16812
S'Kantor R'
p16813
aS'DeLong A'
p16814
aS'Balamane M'
p16815
aS'Schreier L'
p16816
aS'Lloyd RM Jr'
p16817
aS'Injera W'
p16818
aS'Kamle L'
p16819
aS'Mambo F'
p16820
aS'Muyonga S'
p16821
aS'Katzenstein D'
p16822
aS'Hogan J'
p16823
aS'Buziba N'
p16824
aS'Diero L'
p16825
asS'MHDA'
p16826
S'2015/06/30 06:00'
p16827
sS'PHST'
p16828
(lp16829
S'2014 [ecollection]'
p16830
aS'2014/05/06 [received]'
p16831
aS'2014/09/23 [revised]'
p16832
aS'2014/10/10 [accepted]'
p16833
asS'OT'
p16834
(lp16835
S'AMPATH'
p16836
aS'HIV'
p16837
aS'Kenya'
p16838
aS'analyte'
p16839
aS'diversity'
p16840
aS'drug resistance'
p16841
aS'subtype'
p16842
asS'OTO'
p16843
(lp16844
S'NOTNLM'
p16845
asS'OID'
p16846
(lp16847
S'NLM: PMC4238965'
p16848
asS'MH'
p16849
(lp16850
S'Adult'
p16851
aS'Aged'
p16852
aS'Anti-Retroviral Agents/*pharmacology'
p16853
aS'Blood/*virology'
p16854
aS'*Drug Resistance, Viral'
p16855
aS'Female'
p16856
aS'*Genetic Variation'
p16857
aS'Genotype'
p16858
aS'Genotyping Techniques/*methods'
p16859
aS'HIV Infections/*virology'
p16860
aS'HIV-1/classification/*drug effects/genetics/isolation & purification'
p16861
aS'Humans'
p16862
aS'Kenya'
p16863
aS'Male'
p16864
aS'Microbial Sensitivity Tests/methods'
p16865
aS'Middle Aged'
p16866
aS'Specimen Handling/methods'
p16867
aS'Young Adult'
p16868
asS'EDAT'
p16869
S'2014/11/22 06:00'
p16870
sS'SO'
p16871
S'J Int AIDS Soc. 2014 Nov 18;17:19262. doi: 10.7448/IAS.17.1.19262. eCollection 2014.'
p16872
sS'SB'
p16873
S'IM X'
p16874
sS'PMID'
p16875
S'25413893'
p16876
sS'TA'
p16877
S'J Int AIDS Soc'
p16878
sS'PST'
p16879
S'epublish'
p16880
stRp16881
ag2
(g3
g4
(dp16882
S'LID'
p16883
S'10.1186/1745-6215-15-441 [doi]'
p16884
sS'STAT'
p16885
S'MEDLINE'
p16886
sS'DEP'
p16887
S'20141112'
p16888
sS'DA'
p16889
S'20141202'
p16890
sS'AID'
p16891
(lp16892
S'1745-6215-15-441 [pii]'
p16893
aS'10.1186/1745-6215-15-441 [doi]'
p16894
asS'CRDT'
p16895
(lp16896
S'2014/11/14 06:00'
p16897
asS'DP'
p16898
S'2014'
p16899
sS'AD'
p16900
S'Oxford University Clinical Research Unit, Wellcome Trust Major Overseas Programme Vietnam, Ho Chi Minh City, Vietnam. jbeardsley@oucru.org.'
p16901
sS'OWN'
p16902
S'NLM'
p16903
sS'PT'
p16904
(lp16905
S'Clinical Trial, Phase III'
p16906
aS'Journal Article'
p16907
aS'Multicenter Study'
p16908
aS'Randomized Controlled Trial'
p16909
aS"Research Support, Non-U.S. Gov't"
p16910
asS'LA'
p16911
(lp16912
S'eng'
p16913
asS'DCOM'
p16914
S'20150708'
p16915
sS'JT'
p16916
S'Trials'
p16917
sS'LR'
p16918
S'20160202'
p16919
sS'FAU'
p16920
(lp16921
S'Day, Jeremy'
p16922
aS'Imran, Darma'
p16923
aS'Ganiem, Ahmed Rizal'
p16924
aS'Tjahjani, Natriana'
p16925
aS'Wahyuningsih, Retno'
p16926
aS'Adawiyah, Robiatul'
p16927
aS'Dance, David'
p16928
aS'Mayxay, Mayfong'
p16929
aS'Newton, Paul'
p16930
aS'Phetsouvanh, Rattanaphone'
p16931
aS'Rattanavong, Sayaphet'
p16932
aS'Chan, Adrienne K'
p16933
aS'Heyderman, Robert'
p16934
aS'van Oosterhout, Joep J'
p16935
aS'Chierakul, Wirongrong'
p16936
aS'Day, Nick'
p16937
aS'Kamali, Anatoli'
p16938
aS'Kibengo, Freddie'
p16939
aS'Ruzagira, Eugene'
p16940
aS'Gray, Alastair'
p16941
aS'Lalloo, David G'
p16942
aS'Beardsley, Justin'
p16943
aS'Binh, Tran Quang'
p16944
aS'Chau, Tran Thi Hong'
p16945
aS'Chau, Nguyen Van Vinh'
p16946
aS'Cuc, Ngo Thi Kim'
p16947
aS'Farrar, Jeremy'
p16948
aS'Hien, Tran Tinh'
p16949
aS'Van Kinh, Nguyen'
p16950
aS'Merson, Laura'
p16951
aS'Phuong, Lan'
p16952
aS'Tho, Loc Truong'
p16953
aS'Thuy, Pham Thanh'
p16954
aS'Thwaites, Guy'
p16955
aS'Wertheim, Heiman'
p16956
aS'Wolbers, Marcel'
p16957
asS'TI'
p16958
S'CryptoDex: a randomised, double-blind, placebo-controlled phase III trial of adjunctive dexamethasone in HIV-infected adults with cryptococcal meningitis: study protocol for a randomised control trial.'
p16959
sS'RN'
p16960
(lp16961
S'0 (Anti-Inflammatory Agents)'
p16962
aS'0 (Antifungal Agents)'
p16963
aS'7S5I7G3JQL (Dexamethasone)'
p16964
asS'PL'
p16965
S'England'
p16966
sS'PG'
p16967
S'441'
p16968
sS'JID'
p16969
S'101263253'
p16970
sS'AB'
p16971
S"BACKGROUND: Cryptococcal meningitis (CM) is a severe AIDS-defining illness with 90-day case mortality as high as 70% in sub-Saharan Africa, despite treatment. It is the leading cause of death in HIV patients in Asia and Africa.No major advance has been made in the treatment of CM since the 1970s. The mainstays of induction therapy are amphotericin B and flucytosine, but these are often poorly available where the disease burden is highest. Adjunctive treatments, such as dexamethasone, have had dramatic effects on mortality in other neurologic infections, but are untested in CM. Given the high death rates in patients receiving current optimal treatment, and the lack of new agents on the horizon, adjuvant treatments, which offer the potential to reduce mortality in CM, should be tested.The principal research question posed by this study is as follows: does adding dexamethasone to standard antifungal therapy for CM reduce mortality? Dexamethasone is a cheap, readily available, and practicable intervention. METHOD: A double-blind placebo-controlled trial with parallel arms in which patients are randomised to receive either dexamethasone or placebo, in addition to local standard of care. The study recruits patients in both Asia and Africa to ensure the relevance of its results to the populations in which the disease burden is highest. The 10-week mortality risk in the control group is expected to be between 30% and 50%, depending on location, and the target hazard ratio of 0.7 corresponds to absolute risk reductions in mortality from 30% to 22%, or from 50% to 38%. Assuming an overall 10-week mortality of at least 30% in our study population, recruitment of 824 patients will be sufficient to observe the expected number of deaths. Allowing for some loss to follow-up, the total sample size for this study is 880 patients. To generate robust evidence across both continents, we aim to recruit roughly similar numbers of patients from each continent. The primary end point is 10-week mortality. Ethical approval has been obtained from Oxford University's Tropical Research Ethics Committee (OxTREC), and as locally mandated at each site. TRIAL REGISTRATION: International Standard Randomised Controlled Trial Number: ISRCTN59144167 26-July-2012."
p16972
sS'GR'
p16973
(lp16974
S'089276/Wellcome Trust/United Kingdom'
p16975
aS'G1100684/Medical Research Council/United Kingdom'
p16976
aS'Medical Research Council/United Kingdom'
p16977
aS'Wellcome Trust/United Kingdom'
p16978
asS'VI'
p16979
S'15'
p16980
sS'IS'
p16981
S'1745-6215 (Electronic) 1745-6215 (Linking)'
p16982
sS'PMC'
p16983
S'PMC4289250'
p16984
sS'AU'
p16985
(lp16986
S'Day J'
p16987
aS'Imran D'
p16988
aS'Ganiem AR'
p16989
aS'Tjahjani N'
p16990
aS'Wahyuningsih R'
p16991
aS'Adawiyah R'
p16992
aS'Dance D'
p16993
aS'Mayxay M'
p16994
aS'Newton P'
p16995
aS'Phetsouvanh R'
p16996
aS'Rattanavong S'
p16997
aS'Chan AK'
p16998
aS'Heyderman R'
p16999
aS'van Oosterhout JJ'
p17000
aS'Chierakul W'
p17001
aS'Day N'
p17002
aS'Kamali A'
p17003
aS'Kibengo F'
p17004
aS'Ruzagira E'
p17005
aS'Gray A'
p17006
aS'Lalloo DG'
p17007
aS'Beardsley J'
p17008
aS'Binh TQ'
p17009
aS'Chau TT'
p17010
aS'Chau NV'
p17011
aS'Cuc NT'
p17012
aS'Farrar J'
p17013
aS'Hien TT'
p17014
aS'Van Kinh N'
p17015
aS'Merson L'
p17016
aS'Phuong L'
p17017
aS'Tho LT'
p17018
aS'Thuy PT'
p17019
aS'Thwaites G'
p17020
aS'Wertheim H'
p17021
aS'Wolbers M'
p17022
asS'MHDA'
p17023
S'2015/07/15 06:00'
p17024
sS'PHST'
p17025
(lp17026
S'2014/05/16 [received]'
p17027
aS'2014/09/16 [accepted]'
p17028
aS'2014/11/12 [aheadofprint]'
p17029
asS'OID'
p17030
(lp17031
S'NLM: PMC4289250'
p17032
asS'MH'
p17033
(lp17034
S'AIDS-Related Opportunistic Infections/diagnosis/*drug therapy/microbiology/mortality'
p17035
aS'Anti-Inflammatory Agents/adverse effects/*therapeutic use'
p17036
aS'Antifungal Agents/adverse effects/*therapeutic use'
p17037
aS'Asia'
p17038
aS'Clinical Protocols'
p17039
aS'Dexamethasone/adverse effects/*therapeutic use'
p17040
aS'Double-Blind Method'
p17041
aS'Drug Therapy, Combination'
p17042
aS'HIV Infections/*complications/diagnosis/mortality/virology'
p17043
aS'Humans'
p17044
aS'Malawi'
p17045
aS'Meningitis, Cryptococcal/diagnosis/*drug therapy/microbiology/mortality'
p17046
aS'*Research Design'
p17047
aS'Time Factors'
p17048
aS'Treatment Outcome'
p17049
aS'Uganda'
p17050
asS'EDAT'
p17051
S'2014/11/14 06:00'
p17052
sS'SI'
p17053
(lp17054
S'ISRCTN/ISRCTN59144167'
p17055
asS'SO'
p17056
S'Trials. 2014 Nov 12;15:441. doi: 10.1186/1745-6215-15-441.'
p17057
sS'SB'
p17058
S'IM'
p17059
sS'PMID'
p17060
S'25391338'
p17061
sS'TA'
p17062
S'Trials'
p17063
sS'PST'
p17064
S'epublish'
p17065
stRp17066
ag2
(g3
g4
(dp17067
S'LID'
p17068
S'10.1371/journal.pone.0108304 [doi]'
p17069
sS'STAT'
p17070
S'MEDLINE'
p17071
sS'DEP'
p17072
S'20141112'
p17073
sS'DA'
p17074
S'20141113'
p17075
sS'AID'
p17076
(lp17077
S'10.1371/journal.pone.0108304 [doi]'
p17078
aS'PONE-D-13-48190 [pii]'
p17079
asS'CRDT'
p17080
(lp17081
S'2014/11/13 06:00'
p17082
asS'DP'
p17083
S'2014'
p17084
sS'OWN'
p17085
S'NLM'
p17086
sS'PT'
p17087
(lp17088
S'Comparative Study'
p17089
aS'Journal Article'
p17090
aS"Research Support, Non-U.S. Gov't"
p17091
asS'LA'
p17092
(lp17093
S'eng'
p17094
asS'FAU'
p17095
(lp17096
S'Tagar, Elya'
p17097
aS'Sundaram, Maaya'
p17098
aS'Condliffe, Kate'
p17099
aS'Matatiyo, Blackson'
p17100
aS'Chimbwandira, Frank'
p17101
aS'Chilima, Ben'
p17102
aS'Mwanamanga, Robert'
p17103
aS'Moyo, Crispin'
p17104
aS'Chitah, Bona Mukosha'
p17105
aS'Nyemazi, Jean Pierre'
p17106
aS'Assefa, Yibeltal'
p17107
aS'Pillay, Yogan'
p17108
aS'Mayer, Sam'
p17109
aS'Shear, Lauren'
p17110
aS'Dain, Mary'
p17111
aS'Hurley, Raphael'
p17112
aS'Kumar, Ritu'
p17113
aS'McCarthy, Thomas'
p17114
aS'Batra, Parul'
p17115
aS'Gwinnell, Dan'
p17116
aS'Diamond, Samantha'
p17117
aS'Over, Mead'
p17118
asS'JT'
p17119
S'PloS one'
p17120
sS'LR'
p17121
S'20151029'
p17122
sS'PG'
p17123
S'e108304'
p17124
sS'TI'
p17125
S'Multi-country analysis of treatment costs for HIV/AIDS (MATCH): facility-level ART unit cost analysis in Ethiopia, Malawi, Rwanda, South Africa and Zambia.'
p17126
sS'RN'
p17127
(lp17128
S'0 (Anti-Retroviral Agents)'
p17129
asS'PL'
p17130
S'United States'
p17131
sS'TA'
p17132
S'PLoS One'
p17133
sS'JID'
p17134
S'101285081'
p17135
sS'AB'
p17136
S"BACKGROUND: Today's uncertain HIV funding landscape threatens to slow progress towards treatment goals. Understanding the costs of antiretroviral therapy (ART) will be essential for governments to make informed policy decisions about the pace of scale-up under the 2013 WHO HIV Treatment Guidelines, which increase the number of people eligible for treatment from 17.6 million to 28.6 million. The study presented here is one of the largest of its kind and the first to describe the facility-level cost of ART in a random sample of facilities in Ethiopia, Malawi, Rwanda, South Africa and Zambia. METHODS & FINDINGS: In 2010-2011, comprehensive data on one year of facility-level ART costs and patient outcomes were collected from 161 facilities, selected using stratified random sampling. Overall, facility-level ART costs were significantly lower than expected in four of the five countries, with a simple average of $208 per patient-year (ppy) across Ethiopia, Malawi, Rwanda and Zambia. Costs were higher in South Africa, at $682 ppy. This included medications, laboratory services, direct and indirect personnel, patient support, equipment and administrative services. Facilities demonstrated the ability to retain patients alive and on treatment at these costs, although outcomes for established patients (2-8% annual loss to follow-up or death) were better than outcomes for new patients in their first year of ART (77-95% alive and on treatment). CONCLUSIONS: This study illustrated that the facility-level costs of ART are lower than previously understood in these five countries. While limitations must be considered, and costs will vary across countries, this suggests that expanded treatment coverage may be affordable. Further research is needed to understand investment costs of treatment scale-up, non-facility costs and opportunities for more efficient resource allocation."
p17137
sS'AD'
p17138
S'HIV, TB and Health Financing, Clinton Health Access Initiative, Boston, Massachusetts, United States of America. HIV, TB and Health Financing, Clinton Health Access Initiative, Boston, Massachusetts, United States of America. HIV, TB and Health Financing, Clinton Health Access Initiative, Boston, Massachusetts, United States of America. Planning, Monitoring, Evaluation and Research, National AIDS Commission, Lilongwe, Malawi. Department for HIV and AIDS, Ministry of Health, Lilongwe, Malawi. Community Health Sciences Unit, Ministry of Health, Lilongwe, Malawi. Department of Planning and Policy Development, Ministry of Health, Lilongwe, Malawi. National ART Program, Ministry of Health, Lusaka, Zambia. Department of Economics, University of Zambia, Lusaka, Zambia. Planning, Monitoring and Evaluation Division, Ministry of Health, Kigali, Rwanda. Planning, Monitoring and Evaluation Directorate, Federal HIV/AIDS Prevention and Control Office, Addis Ababa, Ethiopia. HIV/AIDS, TB and MCWH, National Department of Health, Pretoria, South Africa. HIV, TB and Health Financing, Clinton Health Access Initiative, Boston, Massachusetts, United States of America. HIV, TB and Health Financing, Clinton Health Access Initiative, Lilongwe, Malawi. HIV, TB and Health Financing, Clinton Health Access Initiative, Kigali, Rwanda. HIV, TB and Health Financing, Clinton Health Access Initiative, Addis Ababa, Ethiopia. HIV, TB and Health Financing, Clinton Health Access Initiative, Lusaka, Zambia. HIV, TB and Health Financing, Clinton Health Access Initiative, Pretoria, South Africa. HIV, TB and Health Financing, Clinton Health Access Initiative, Boston, Massachusetts, United States of America. HIV, TB and Health Financing, Clinton Health Access Initiative, Boston, Massachusetts, United States of America. HIV, TB and Health Financing, Clinton Health Access Initiative, Boston, Massachusetts, United States of America. Center for Global Development, Washington, District of Columbia, United States of America.'
p17139
sS'IP'
p17140
S'11'
p17141
sS'IS'
p17142
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p17143
sS'PMC'
p17144
S'PMC4229087'
p17145
sS'DCOM'
p17146
S'20150713'
p17147
sS'AU'
p17148
(lp17149
S'Tagar E'
p17150
aS'Sundaram M'
p17151
aS'Condliffe K'
p17152
aS'Matatiyo B'
p17153
aS'Chimbwandira F'
p17154
aS'Chilima B'
p17155
aS'Mwanamanga R'
p17156
aS'Moyo C'
p17157
aS'Chitah BM'
p17158
aS'Nyemazi JP'
p17159
aS'Assefa Y'
p17160
aS'Pillay Y'
p17161
aS'Mayer S'
p17162
aS'Shear L'
p17163
aS'Dain M'
p17164
aS'Hurley R'
p17165
aS'Kumar R'
p17166
aS'McCarthy T'
p17167
aS'Batra P'
p17168
aS'Gwinnell D'
p17169
aS'Diamond S'
p17170
aS'Over M'
p17171
asS'VI'
p17172
S'9'
sS'MHDA'
p17173
S'2015/07/15 06:00'
p17174
sS'PHST'
p17175
(lp17176
S'2014 [ecollection]'
p17177
aS'2013/11/25 [received]'
p17178
aS'2014/08/27 [accepted]'
p17179
aS'2014/11/12 [epublish]'
p17180
asS'OID'
p17181
(lp17182
S'NLM: PMC4229087'
p17183
asS'MH'
p17184
(lp17185
S'Acquired Immunodeficiency Syndrome/drug therapy/*economics'
p17186
aS'Anti-Retroviral Agents/*economics/therapeutic use'
p17187
aS'CD4-Positive T-Lymphocytes/cytology'
p17188
aS'Communicable Disease Control'
p17189
aS'Communicable Diseases/economics'
p17190
aS'Developing Countries/economics'
p17191
aS'Ethiopia'
p17192
aS'HIV Infections/drug therapy/*economics'
p17193
aS'Health Care Costs'
p17194
aS'Health Services Accessibility'
p17195
aS'Health Services Needs and Demand/economics'
p17196
aS'Humans'
p17197
aS'Malawi'
p17198
aS'Models, Economic'
p17199
aS'Rwanda'
p17200
aS'South Africa'
p17201
aS'Treatment Outcome'
p17202
aS'Zambia'
p17203
asS'EDAT'
p17204
S'2014/11/13 06:00'
p17205
sS'SO'
p17206
S'PLoS One. 2014 Nov 12;9(11):e108304. doi: 10.1371/journal.pone.0108304. eCollection 2014.'
p17207
sS'SB'
p17208
S'IM'
p17209
sS'PMID'
p17210
S'25389777'
p17211
sS'PST'
p17212
S'epublish'
p17213
stRp17214
ag2
(g3
g4
(dp17215
S'LID'
p17216
S'10.1089/AID.2014.0007 [doi]'
p17217
sS'STAT'
p17218
S'MEDLINE'
p17219
sS'DEP'
p17220
S'20141217'
p17221
sS'DA'
p17222
S'20150214'
p17223
sS'AID'
p17224
(lp17225
S'10.1089/AID.2014.0007 [doi]'
p17226
asS'CRDT'
p17227
(lp17228
S'2014/11/11 06:00'
p17229
asS'DP'
p17230
S'2015 Feb'
p17231
sS'AD'
p17232
S'1 Vanderbilt Institute for Global Health, Vanderbilt University School of Medicine , Nashville, Tennessee.'
p17233
sS'OWN'
p17234
S'NLM'
p17235
sS'PT'
p17236
(lp17237
S'Journal Article'
p17238
aS'Observational Study'
p17239
aS"Research Support, U.S. Gov't, P.H.S."
p17240
asS'LA'
p17241
(lp17242
S'eng'
p17243
asS'FAU'
p17244
(lp17245
S'Blevins, Meridith'
p17246
aS'Jose, Eurico'
p17247
aS'Bilhete, Fernandes R'
p17248
aS'Vaz, Lara M E'
p17249
aS'Shepherd, Bryan E'
p17250
aS'Audet, Carolyn M'
p17251
aS'Vermund, Sten H'
p17252
aS'Moon, Troy D'
p17253
asS'JT'
p17254
S'AIDS research and human retroviruses'
p17255
sS'LR'
p17256
S'20160409'
p17257
sS'PG'
p17258
S'198-207'
p17259
sS'TI'
p17260
S'Two-year death and loss to follow-up outcomes by source of referral to HIV care for HIV-infected patients initiating antiretroviral therapy in rural Mozambique.'
p17261
sS'RN'
p17262
(lp17263
S'0 (Anti-Retroviral Agents)'
p17264
asS'PL'
p17265
S'United States'
p17266
sS'TA'
p17267
S'AIDS Res Hum Retroviruses'
p17268
sS'JID'
p17269
S'8709376'
p17270
sS'AB'
p17271
S"We studied patient outcomes by type of referral site following 2 years of combination antiretroviral therapy (cART) during scale-up from June 2006 to July 2011 in Mozambique's rural Zambezia Province. Loss to follow-up (LTFU) was defined as no contact within 60 days after scheduled medication pickup. Endpoints included LTFU, mortality, and combined mortality/LTFU; we used Kaplan-Meier and cumulative incidence estimates. The referral site was the source of HIV testing. We modeled 2-year outcomes using Cox regression stratified by district, adjusting for sociodemographics and health status. Of 7,615 HIV-infected patients >/=15 years starting cART, 61% were female and the median age was 30 years. Two-year LTFU was 38.1% (95% CI: 36.9-39.3%) and mortality was 14.2% (95% CI 13.2-15.2%). Patients arrived from voluntary counseling and testing (VCT) sites (51%), general outpatient clinics (21%), antenatal care (8%), inpatient care (3%), HIV/tuberculosis/laboratory facilities (<4%), or other sources of referral (14%). Compared with VCT, patients referred from inpatient, tuberculosis, or antenatal care had higher hazards of LTFU. Adjusted hazard ratios (AHR; 95% CI) for 2-year mortality by referral site (VCT as referent) were inpatient 1.87 (1.36-2.58), outpatient 1.44 (1.11-1.85), and antenatal care 0.69 (0.43-1.11) and for mortality/LTFU were inpatient 1.60 (1.34-1.91), outpatient 1.17 (1.02-1.33), tuberculosis care 1.38 (1.08-1.75), and antenatal care 1.24 (1.06-1.44). That source of referral was associated with mortality/LTFU after adjusting for patient characteristics at cART initiation suggests that (1) additional unmeasured factors are influential, and (2) retention programs may benefit from targeting patient populations based on source of referral with focused counseling and/or social support."
p17272
sS'GR'
p17273
(lp17274
S'KL2 TR000446/TR/NCATS NIH HHS/United States'
p17275
aS'P30 AI110527/AI/NIAID NIH HHS/United States'
p17276
aS'U2G PS000631/PS/NCHHSTP CDC HHS/United States'
p17277
aS'U2GPS000631/PHS HHS/United States'
p17278
asS'IP'
p17279
S'2'
sS'IS'
p17280
S'1931-8405 (Electronic) 0889-2229 (Linking)'
p17281
sS'PMC'
p17282
S'PMC4532902'
p17283
sS'DCOM'
p17284
S'20151102'
p17285
sS'AU'
p17286
(lp17287
S'Blevins M'
p17288
aS'Jose E'
p17289
aS'Bilhete FR'
p17290
aS'Vaz LM'
p17291
aS'Shepherd BE'
p17292
aS'Audet CM'
p17293
aS'Vermund SH'
p17294
aS'Moon TD'
p17295
asS'VI'
p17296
S'31'
p17297
sS'MHDA'
p17298
S'2015/11/03 06:00'
p17299
sS'PHST'
p17300
(lp17301
S'2014/12/17 [aheadofprint]'
p17302
asS'OID'
p17303
(lp17304
S'NLM: PMC4532902'
p17305
asS'MH'
p17306
(lp17307
S'Adolescent'
p17308
aS'Adult'
p17309
aS'Anti-Retroviral Agents/*therapeutic use'
p17310
aS'Cohort Studies'
p17311
aS'Female'
p17312
aS'HIV Infections/*drug therapy/epidemiology/*mortality'
p17313
aS'Humans'
p17314
aS'Incidence'
p17315
aS'*Lost to Follow-Up'
p17316
aS'Male'
p17317
aS'Mozambique/epidemiology'
p17318
aS'Rural Population'
p17319
aS'Survival Analysis'
p17320
aS'Young Adult'
p17321
asS'EDAT'
p17322
S'2014/11/11 06:00'
p17323
sS'SO'
p17324
S'AIDS Res Hum Retroviruses. 2015 Feb;31(2):198-207. doi: 10.1089/AID.2014.0007. Epub 2014 Dec 17.'
p17325
sS'SB'
p17326
S'IM X'
p17327
sS'PMID'
p17328
S'25381732'
p17329
sS'PST'
p17330
S'ppublish'
p17331
stRp17332
ag2
(g3
g4
(dp17333
S'LID'
p17334
S'10.2471/BLT.13.126532 [doi]'
p17335
sS'STAT'
p17336
S'MEDLINE'
p17337
sS'OAB'
p17338
(lp17339
S'Publisher: Abstract available from the publisher.'
p17340
aS'Publisher: Abstract available from the publisher.'
p17341
aS'Publisher: Abstract available from the publisher.'
p17342
aS'Publisher: Abstract available from the publisher.'
p17343
aS'Publisher: Abstract available from the publisher.'
p17344
asS'DEP'
p17345
S'20140918'
p17346
sS'DA'
p17347
S'20141107'
p17348
sS'AID'
p17349
(lp17350
S'10.2471/BLT.13.126532 [doi]'
p17351
aS'BLT.13.126532 [pii]'
p17352
asS'CRDT'
p17353
(lp17354
S'2014/11/08 06:00'
p17355
asS'DP'
p17356
S'2014 Nov 1'
p17357
sS'OWN'
p17358
S'NLM'
p17359
sS'PT'
p17360
(lp17361
S'Journal Article'
p17362
aS"Research Support, U.S. Gov't, Non-P.H.S."
p17363
asS'LA'
p17364
(lp17365
S'eng'
p17366
asS'FAU'
p17367
(lp17368
S'Abouyannis, Michael'
p17369
aS'Dacombe, Russell'
p17370
aS'Dambe, Isaias'
p17371
aS'Mpunga, James'
p17372
aS'Faragher, Brian'
p17373
aS'Gausi, Francis'
p17374
aS'Ndhlovu, Henry'
p17375
aS'Kachiza, Chifundo'
p17376
aS'Suarez, Pedro'
p17377
aS'Mundy, Catherine'
p17378
aS'Banda, Hastings T'
p17379
aS'Nyasulu, Ishmael'
p17380
aS'Squire, S Bertel'
p17381
asS'JT'
p17382
S'Bulletin of the World Health Organization'
p17383
sS'PG'
p17384
S'798-806'
p17385
sS'TI'
p17386
S'Drug resistance of Mycobacterium tuberculosis in Malawi: a cross-sectional survey.'
p17387
sS'RN'
p17388
(lp17389
S'0 (Antitubercular Agents)'
p17390
asS'PL'
p17391
S'Switzerland'
p17392
sS'TA'
p17393
S'Bull World Health Organ'
p17394
sS'JID'
p17395
S'7507052'
p17396
sS'AB'
p17397
S"OBJECTIVE: To document the prevalence of multidrug resistance among people newly diagnosed with - and those retreated for - tuberculosis in Malawi. METHODS: We conducted a nationally representative survey of people with sputum-smear-positive tuberculosis between 2010 and 2011. For all consenting participants, we collected demographic and clinical data, two sputum samples and tested for human immunodeficiency virus (HIV).The samples underwent resistance testing at the Central Reference Laboratory in Lilongwe, Malawi. All Mycobacterium tuberculosis isolates found to be multidrug-resistant were retested for resistance to first-line drugs - and tested for resistance to second-line drugs - at a Supranational Tuberculosis Reference Laboratory in South Africa. FINDINGS: Overall, M. tuberculosis was isolated from 1777 (83.8%) of the 2120 smear-positive tuberculosis patients. Multidrug resistance was identified in five (0.4%) of 1196 isolates from new cases and 28 (4.8%) of 581 isolates from people undergoing retreatment. Of the 31 isolates from retreatment cases who had previously failed treatment, nine (29.0%) showed multidrug resistance. Although resistance to second-line drugs was found, no cases of extensive drug-resistant tuberculosis were detected. HIV testing of people from whom M. tuberculosis isolates were obtained showed that 577 (48.2%) of people newly diagnosed and 386 (66.4%) of people undergoing retreatment were positive. CONCLUSION: The prevalence of multidrug resistance among people with smear-positive tuberculosis was low for sub-Saharan Africa - probably reflecting the strength of Malawi's tuberculosis control programme. The relatively high prevalence of such resistance observed among those with previous treatment failure may highlight a need for a change in the national policy for retreating this subgroup of people with tuberculosis."
p17398
sS'AD'
p17399
S'Centre for Applied Health Research & Delivery, Department of Clinical Sciences, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, England . Centre for Applied Health Research & Delivery, Department of Clinical Sciences, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, England . National Tuberculosis Control Programme, Lilongwe, Malawi . National Tuberculosis Control Programme, Lilongwe, Malawi . Centre for Applied Health Research & Delivery, Department of Clinical Sciences, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, England . National Tuberculosis Control Programme, Lilongwe, Malawi . Research for Equity and Community Health Trust, Lilongwe, Malawi . Tuberculosis Control Assistance Programme, Management Sciences for Health, Lilongwe, Malawi . Management Sciences for Health, Arlington, United States of America . Management Sciences for Health, Arlington, United States of America . Research for Equity and Community Health Trust, Lilongwe, Malawi . World Health Organization, Lilongwe, Malawi . Centre for Applied Health Research & Delivery, Department of Clinical Sciences, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, England .'
p17400
sS'IP'
p17401
S'11'
p17402
sS'IS'
p17403
S'1564-0604 (Electronic) 0042-9686 (Linking)'
p17404
sS'PMC'
p17405
S'PMC4221759'
p17406
sS'DCOM'
p17407
S'20160923'
p17408
sS'AU'
p17409
(lp17410
S'Abouyannis M'
p17411
aS'Dacombe R'
p17412
aS'Dambe I'
p17413
aS'Mpunga J'
p17414
aS'Faragher B'
p17415
aS'Gausi F'
p17416
aS'Ndhlovu H'
p17417
aS'Kachiza C'
p17418
aS'Suarez P'
p17419
aS'Mundy C'
p17420
aS'Banda HT'
p17421
aS'Nyasulu I'
p17422
aS'Squire SB'
p17423
asS'OABL'
p17424
(lp17425
S'ara'
p17426
aS'chi'
p17427
aS'fre'
p17428
aS'rus'
p17429
aS'spa'
p17430
asS'VI'
p17431
S'92'
p17432
sS'MHDA'
p17433
S'2016/09/24 06:00'
p17434
sS'PHST'
p17435
(lp17436
S'2013/07/04 [received]'
p17437
aS'2014/07/31 [revised]'
p17438
aS'2014/08/07 [accepted]'
p17439
aS'2014/09/18 [epublish]'
p17440
asS'OID'
p17441
(lp17442
S'NLM: PMC4221759'
p17443
asS'MH'
p17444
(lp17445
S'Adult'
p17446
aS'Antitubercular Agents/*therapeutic use'
p17447
aS'Cross-Sectional Studies'
p17448
aS'*Drug Resistance, Multiple, Bacterial'
p17449
aS'Female'
p17450
aS'Humans'
p17451
aS'Malawi/epidemiology'
p17452
aS'Male'
p17453
aS'Mycobacterium tuberculosis/*drug effects/isolation & purification'
p17454
aS'Prevalence'
p17455
aS'Prospective Studies'
p17456
aS'Tuberculosis/*drug therapy/*epidemiology'
p17457
aS'Tuberculosis, Multidrug-Resistant/*drug therapy/*epidemiology'
p17458
asS'EDAT'
p17459
S'2014/11/08 06:00'
p17460
sS'SO'
p17461
S'Bull World Health Organ. 2014 Nov 1;92(11):798-806. doi: 10.2471/BLT.13.126532. Epub 2014 Sep 18.'
p17462
sS'SB'
p17463
S'IM'
p17464
sS'PMID'
p17465
S'25378741'
p17466
sS'PST'
p17467
S'ppublish'
p17468
stRp17469
ag2
(g3
g4
(dp17470
S'LID'
p17471
S'10.1186/1471-2458-14-1154 [doi]'
p17472
sS'STAT'
p17473
S'MEDLINE'
p17474
sS'DEP'
p17475
S'20141106'
p17476
sS'DA'
p17477
S'20141113'
p17478
sS'AID'
p17479
(lp17480
S'1471-2458-14-1154 [pii]'
p17481
aS'10.1186/1471-2458-14-1154 [doi]'
p17482
asS'CRDT'
p17483
(lp17484
S'2014/11/08 06:00'
p17485
asS'DP'
p17486
S'2014'
p17487
sS'AD'
p17488
S'Department of Pediatrics, Georgetown University Medical Center, 4200 Wisconsin Ave, NW, Washington, DC 20026, USA. Hilary.T.Wolf@gunet.georgetown.edu.'
p17489
sS'OWN'
p17490
S'NLM'
p17491
sS'PT'
p17492
(lp17493
S'Journal Article'
p17494
aS'Research Support, N.I.H., Extramural'
p17495
aS"Research Support, Non-U.S. Gov't"
p17496
asS'LA'
p17497
(lp17498
S'eng'
p17499
asS'DCOM'
p17500
S'20150908'
p17501
sS'JT'
p17502
S'BMC public health'
p17503
sS'LR'
p17504
S'20151029'
p17505
sS'FAU'
p17506
(lp17507
S'Wolf, Hilary T'
p17508
aS'Halpern-Felsher, Bonnie L'
p17509
aS'Bukusi, Elizabeth A'
p17510
aS'Agot, Kawango E'
p17511
aS'Cohen, Craig R'
p17512
aS'Auerswald, Colette L'
p17513
asS'TI'
p17514
S'"It is all about the fear of being discriminated [against]...the person suffering from HIV will not be accepted": a qualitative study exploring the reasons for loss to follow-up among HIV-positive youth in Kisumu, Kenya.'
p17515
sS'PL'
p17516
S'England'
p17517
sS'PG'
p17518
S'1154'
p17519
sS'JID'
p17520
S'100968562'
p17521
sS'AB'
p17522
S"BACKGROUND: Youth represent 40% of all new HIV infections in the world, 80% of which live in sub-Saharan Africa. Youth living with HIV (YLWH) are more likely to become lost to follow-up (LTFU) from care compared to all other age groups. This study explored the reasons for LTFU among YLWH in Kenya. METHODS: Data was collected from: (1) Focus group Discussions (n = 18) with community health workers who work with LTFU youth. (2) Semi-structured interviews (n = 27) with HIV + youth (15-21 years old) that had not received HIV care for at least four months. (3) Semi-structured interviews (n = 10) with educators selected from schools attended by LTFU interview participants. Transcripts were coded and analyzed employing grounded theory. RESULTS: HIV-related stigma was the overarching factor that led to LTFU among HIV + youth. Stigma operated on multiple levels to influence LTFU, including in the home/family, at school, and at the clinic. In all three settings, participants' fear of stigma due to disclosure of their HIV status contributed to LTFU. Likewise, in the three settings, the dependent relationships between youth and the key adult figures in their lives were also adversely impacted by stigma and resultant lack of disclosure. Thus, at all three settings stigma influenced fear of disclosure, which in turn impacted negatively on dependent relationships with adults on whom they rely (i.e. parents, teachers and clinicians) leading to LTFU. CONCLUSIONS: Interventions focusing on reduction of stigma, increasing safe disclosure of HIV status, and improved dependent relationships may improve retention in care of YLWH."
p17523
sS'GR'
p17524
(lp17525
S'1R25TW009343-01/TW/FIC NIH HHS/United States'
p17526
aS'5T32AI065388-05/AI/NIAID NIH HHS/United States'
p17527
aS'R25 TW009343/TW/FIC NIH HHS/United States'
p17528
asS'VI'
p17529
S'14'
p17530
sS'IS'
p17531
S'1471-2458 (Electronic) 1471-2458 (Linking)'
p17532
sS'PMC'
p17533
S'PMC4232620'
p17534
sS'AU'
p17535
(lp17536
S'Wolf HT'
p17537
aS'Halpern-Felsher BL'
p17538
aS'Bukusi EA'
p17539
aS'Agot KE'
p17540
aS'Cohen CR'
p17541
aS'Auerswald CL'
p17542
asS'MHDA'
p17543
S'2015/09/09 06:00'
p17544
sS'PHST'
p17545
(lp17546
S'2014/04/23 [received]'
p17547
aS'2014/10/15 [accepted]'
p17548
aS'2014/11/06 [aheadofprint]'
p17549
asS'OID'
p17550
(lp17551
S'NLM: PMC4232620'
p17552
asS'MH'
p17553
(lp17554
S'Adolescent'
p17555
aS'Adolescent Health Services'
p17556
aS'Female'
p17557
aS'Follow-Up Studies'
p17558
aS'HIV Infections/*psychology'
p17559
aS'Health Services Accessibility'
p17560
aS'Humans'
p17561
aS'Kenya'
p17562
aS'*Lost to Follow-Up'
p17563
aS'Male'
p17564
aS'*Social Stigma'
p17565
aS'Young Adult'
p17566
asS'EDAT'
p17567
S'2014/11/08 06:00'
p17568
sS'SO'
p17569
S'BMC Public Health. 2014 Nov 6;14:1154. doi: 10.1186/1471-2458-14-1154.'
p17570
sS'SB'
p17571
S'IM'
p17572
sS'PMID'
p17573
S'25377362'
p17574
sS'TA'
p17575
S'BMC Public Health'
p17576
sS'PST'
p17577
S'epublish'
p17578
stRp17579
ag2
(g3
g4
(dp17580
S'LID'
p17581
S'10.1186/s12879-014-0567-3 [doi]'
p17582
sS'STAT'
p17583
S'MEDLINE'
p17584
sS'DEP'
p17585
S'20141107'
p17586
sS'DA'
p17587
S'20141110'
p17588
sS'AID'
p17589
(lp17590
S's12879-014-0567-3 [pii]'
p17591
aS'10.1186/s12879-014-0567-3 [doi]'
p17592
asS'CRDT'
p17593
(lp17594
S'2014/11/07 06:00'
p17595
asS'DP'
p17596
S'2014'
p17597
sS'AD'
p17598
S'Division of Pediatric Infectious Diseases, Department of Pediatrics, Duke University Medical Center, Durham, NC, USA. dorothy.dow@duke.edu.'
p17599
sS'OWN'
p17600
S'NLM'
p17601
sS'PT'
p17602
(lp17603
S'Journal Article'
p17604
asS'LA'
p17605
(lp17606
S'eng'
p17607
asS'DCOM'
p17608
S'20150518'
p17609
sS'JT'
p17610
S'BMC infectious diseases'
p17611
sS'LR'
p17612
S'20160506'
p17613
sS'FAU'
p17614
(lp17615
S'Dow, Dorothy E'
p17616
aS'Shayo, Aisa M'
p17617
aS'Cunningham, Coleen K'
p17618
aS'Reddy, Elizabeth A'
p17619
asS'TI'
p17620
S'Durability of antiretroviral therapy and predictors of virologic failure among perinatally HIV-infected children in Tanzania: a four-year follow-up.'
p17621
sS'RN'
p17622
(lp17623
S'0 (Anti-HIV Agents)'
p17624
aS'0 (RNA, Viral)'
p17625
asS'PL'
p17626
S'England'
p17627
sS'PG'
p17628
S'567'
p17629
sS'JID'
p17630
S'100968551'
p17631
sS'AB'
p17632
S'BACKGROUND: In Tanzania, HIV-1 RNA testing is rarely available and not standard of care. Determining virologic failure is challenging and resistance mutations accumulate, thereby compromising second-line therapy. We evaluated durability of antiretroviral therapy (ART) and predictors of virologic failure among a pediatric cohort at four-year follow-up. METHODS: This was a prospective cross-sectional study with retrospective chart review evaluating a perinatally HIV-infected Tanzanian cohort enrolled in 2008-09 with repeat HIV-1 RNA in 2012-13. Demographic, clinical, and laboratory data were extracted from charts, resistance mutations from 2008-9 were analyzed, and prospective HIV RNA was obtained. RESULTS: 161 (78%) participants of the original cohort consented to repeat HIV RNA. The average age was 12.2 years (55% adolescents >/=12 years). Average time on ART was 6.4 years with 41% receiving second-line (protease inhibitor based) therapy. Among those originally suppressed on a first-line (non-nucleoside reverse transcriptase based regimen) 76% remained suppressed. Of those originally failing first-line, 88% were switched to second-line and 72% have suppressed virus. Increased level of viremia and duration of ART trended with an increased number of thymidine analogue mutations (TAMs). Increased TAMs increased the odds of virologic failure (p = 0.18), as did adolescent age (p < 0.01). CONCLUSIONS: After viral load testing in 2008-09 many participants switched to second-line therapy. The majority achieved virologic suppression despite multiple resistance mutations. Though virologic testing would likely hasten the switch to second-line among those failing, methods to improve adherence is critical to maximize durability of ART and improve virologic outcomes among youth in resource-limited settings.'
p17633
sS'GR'
p17634
(lp17635
S'R25 TW009337/TW/FIC NIH HHS/United States'
p17636
aS'T32 HD060558/HD/NICHD NIH HHS/United States'
p17637
asS'VI'
p17638
S'14'
p17639
sS'IS'
p17640
S'1471-2334 (Electronic) 1471-2334 (Linking)'
p17641
sS'PMC'
p17642
S'PMC4225040'
p17643
sS'AU'
p17644
(lp17645
S'Dow DE'
p17646
aS'Shayo AM'
p17647
aS'Cunningham CK'
p17648
aS'Reddy EA'
p17649
asS'MHDA'
p17650
S'2015/05/20 06:00'
p17651
sS'PHST'
p17652
(lp17653
S'2014/04/08 [received]'
p17654
aS'2014/10/16 [accepted]'
p17655
aS'2014/11/07 [aheadofprint]'
p17656
asS'OID'
p17657
(lp17658
S'NLM: PMC4225040'
p17659
asS'MH'
p17660
(lp17661
S'Adolescent'
p17662
aS'Anti-HIV Agents/pharmacology/*therapeutic use'
p17663
aS'Child'
p17664
aS'Cross-Sectional Studies'
p17665
aS'Drug Resistance, Viral/genetics'
p17666
aS'Female'
p17667
aS'Follow-Up Studies'
p17668
aS'HIV Infections/blood/*drug therapy/transmission'
p17669
aS'HIV-1/*genetics'
p17670
aS'Humans'
p17671
aS'*Infectious Disease Transmission, Vertical'
p17672
aS'Male'
p17673
aS'Prospective Studies'
p17674
aS'RNA, Viral/blood'
p17675
aS'Retrospective Studies'
p17676
aS'Tanzania'
p17677
aS'Treatment Failure'
p17678
aS'Viral Load'
p17679
asS'EDAT'
p17680
S'2014/11/07 06:00'
p17681
sS'SO'
p17682
S'BMC Infect Dis. 2014 Nov 7;14:567. doi: 10.1186/s12879-014-0567-3.'
p17683
sS'SB'
p17684
S'IM'
p17685
sS'PMID'
p17686
S'25373425'
p17687
sS'TA'
p17688
S'BMC Infect Dis'
p17689
sS'PST'
p17690
S'epublish'
p17691
stRp17692
ag2
(g3
g4
(dp17693
S'LID'
p17694
S'10.1371/journal.pone.0111421 [doi]'
p17695
sS'STAT'
p17696
S'MEDLINE'
p17697
sS'DEP'
p17698
S'20141105'
p17699
sS'DA'
p17700
S'20141106'
p17701
sS'AID'
p17702
(lp17703
S'10.1371/journal.pone.0111421 [doi]'
p17704
aS'PONE-D-14-14916 [pii]'
p17705
asS'CRDT'
p17706
(lp17707
S'2014/11/06 06:00'
p17708
asS'DP'
p17709
S'2014'
p17710
sS'OWN'
p17711
S'NLM'
p17712
sS'PT'
p17713
(lp17714
S'Journal Article'
p17715
aS'Meta-Analysis'
p17716
aS"Research Support, U.S. Gov't, Non-P.H.S."
p17717
aS'Review'
p17718
asS'LA'
p17719
(lp17720
S'eng'
p17721
asS'FAU'
p17722
(lp17723
S'Hodgson, Ian'
p17724
aS'Plummer, Mary L'
p17725
aS'Konopka, Sarah N'
p17726
aS'Colvin, Christopher J'
p17727
aS'Jonas, Edna'
p17728
aS'Albertini, Jennifer'
p17729
aS'Amzel, Anouk'
p17730
aS'Fogg, Karen P'
p17731
asS'JT'
p17732
S'PloS one'
p17733
sS'LR'
p17734
S'20151029'
p17735
sS'PG'
p17736
S'e111421'
p17737
sS'TI'
p17738
S'A systematic review of individual and contextual factors affecting ART initiation, adherence, and retention for HIV-infected pregnant and postpartum women.'
p17739
sS'PL'
p17740
S'United States'
p17741
sS'TA'
p17742
S'PLoS One'
p17743
sS'JID'
p17744
S'101285081'
p17745
sS'AB'
p17746
S"BACKGROUND: Despite progress reducing maternal mortality, HIV-related maternal deaths remain high, accounting, for example, for up to 24 percent of all pregnancy-related deaths in sub-Saharan Africa. Antiretroviral therapy (ART) is effective in improving outcomes among HIV-infected pregnant and postpartum women, yet rates of initiation, adherence, and retention remain low. This systematic literature review synthesized evidence about individual and contextual factors affecting ART use among HIV-infected pregnant and postpartum women. METHODS: Searches were conducted for studies addressing the population (HIV-infected pregnant and postpartum women), intervention (ART), and outcomes of interest (initiation, adherence, and retention). Quantitative and qualitative studies published in English since January 2008 were included. Individual and contextual enablers and barriers to ART use were extracted and organized thematically within a framework of individual, interpersonal, community, and structural categories. RESULTS: Thirty-four studies were included in the review. Individual-level factors included both those within and outside a woman's awareness and control (e.g., commitment to child's health or age). Individual-level barriers included poor understanding of HIV, ART, and prevention of mother-to-child transmission, and difficulty managing practical demands of ART. At an interpersonal level, disclosure to a spouse and spousal involvement in treatment were associated with improved initiation, adherence, and retention. Fear of negative consequences was a barrier to disclosure. At a community level, stigma was a major barrier. Key structural barriers and enablers were related to health system use and engagement, including access to services and health worker attitudes. CONCLUSIONS: To be successful, programs seeking to expand access to and continued use of ART by integrating maternal health and HIV services must identify and address the relevant barriers and enablers in their own context that are described in this review. Further research on this population, including those who drop out of or never access health services, is needed to inform effective implementation."
p17747
sS'AD'
p17748
S'Independent Consultant, Bingley, United Kingdom. Independent Consultant, Dar es Salaam, Tanzania. Center for Health Services, Management Sciences for Health, Arlington, Virginia, USA. Centre for Infectious Disease Epidemiology and Research (CIDER), Division of Social and Behavioural Sciences, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa. Center for Health Services, Management Sciences for Health, Arlington, Virginia, USA. United States Agency for International Development (USAID)/Africa Bureau, Washington, D.C., USA. USAID/Bureau for Global Health (BGH)/Office of HIV/AIDS, Washington, D.C., USA. USAID/BGH/Office of Health, Infectious Diseases, and Nutrition, Washington, D.C., USA.'
p17749
sS'IP'
p17750
S'11'
p17751
sS'IS'
p17752
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p17753
sS'PMC'
p17754
S'PMC4221025'
p17755
sS'DCOM'
p17756
S'20150629'
p17757
sS'AU'
p17758
(lp17759
S'Hodgson I'
p17760
aS'Plummer ML'
p17761
aS'Konopka SN'
p17762
aS'Colvin CJ'
p17763
aS'Jonas E'
p17764
aS'Albertini J'
p17765
aS'Amzel A'
p17766
aS'Fogg KP'
p17767
asS'VI'
p17768
S'9'
sS'MHDA'
p17769
S'2015/06/30 06:00'
p17770
sS'PHST'
p17771
(lp17772
S'2014 [ecollection]'
p17773
aS'2014/04/03 [received]'
p17774
aS'2014/09/15 [accepted]'
p17775
aS'2014/11/05 [epublish]'
p17776
asS'OID'
p17777
(lp17778
S'NLM: PMC4221025'
p17779
asS'MH'
p17780
(lp17781
S'Adult'
p17782
aS'*Antiretroviral Therapy, Highly Active'
p17783
aS'Culture'
p17784
aS'Female'
p17785
aS'HIV Infections/*drug therapy/epidemiology'
p17786
aS'Health Knowledge, Attitudes, Practice'
p17787
aS'Humans'
p17788
aS'*Medication Adherence'
p17789
aS'Postpartum Period'
p17790
aS'Pregnancy'
p17791
aS'Pregnancy Complications, Infectious/*drug therapy/epidemiology'
p17792
aS'Risk Factors'
p17793
asS'EDAT'
p17794
S'2014/11/06 06:00'
p17795
sS'SO'
p17796
S'PLoS One. 2014 Nov 5;9(11):e111421. doi: 10.1371/journal.pone.0111421. eCollection 2014.'
p17797
sS'SB'
p17798
S'IM'
p17799
sS'PMID'
p17800
S'25372479'
p17801
sS'PST'
p17802
S'epublish'
p17803
stRp17804
ag2
(g3
g4
(dp17805
S'LID'
p17806
S'10.7448/IAS.17.1.19065 [doi]'
p17807
sS'STAT'
p17808
S'MEDLINE'
p17809
sS'DEP'
p17810
S'20141022'
p17811
sS'DA'
p17812
S'20141101'
p17813
sS'AID'
p17814
(lp17815
S'19065 [pii]'
p17816
asS'CRDT'
p17817
(lp17818
S'2014/11/02 06:00'
p17819
asS'DP'
p17820
S'2014'
p17821
sS'AD'
p17822
S'Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; kshearer@heroza.org. Center for Global Health & Development, Boston University, Boston, MA, USA. Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Right to Care, Johannesburg, South Africa. Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Center for Global Health & Development, Boston University, Boston, MA, USA; Right to Care, Johannesburg, South Africa; Clinical HIV Research Unit, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Center for Global Health & Development, Boston University, Boston, MA, USA; Department of Epidemiology, School of Public Health, Boston University, Boston, MA, USA.'
p17823
sS'OWN'
p17824
S'NLM'
p17825
sS'PT'
p17826
(lp17827
S'Comparative Study'
p17828
aS'Journal Article'
p17829
aS'Research Support, N.I.H., Extramural'
p17830
aS"Research Support, Non-U.S. Gov't"
p17831
aS"Research Support, U.S. Gov't, Non-P.H.S."
p17832
asS'LA'
p17833
(lp17834
S'eng'
p17835
asS'DCOM'
p17836
S'20150304'
p17837
sS'JT'
p17838
S'Journal of the International AIDS Society'
p17839
sS'LR'
p17840
S'20151029'
p17841
sS'FAU'
p17842
(lp17843
S'Shearer, Kate'
p17844
aS'Brennan, Alana T'
p17845
aS'Maskew, Mhairi'
p17846
aS'Long, Lawrence'
p17847
aS'Berhanu, Rebecca'
p17848
aS'Sanne, Ian'
p17849
aS'Fox, Matthew P'
p17850
asS'TI'
p17851
S'The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa.'
p17852
sS'RN'
p17853
(lp17854
S'0 (Anti-HIV Agents)'
p17855
aS'0 (Benzoxazines)'
p17856
aS'99DK7FVK1H (Nevirapine)'
p17857
aS'JE6H2O27P8 (efavirenz)'
p17858
asS'PL'
p17859
S'Switzerland'
p17860
sS'PG'
p17861
S'19065'
p17862
sS'JID'
p17863
S'101478566'
p17864
sS'AB'
p17865
S'INTRODUCTION: Previous research has raised concerns that patients given nevirapine (NVP)-based regimens experience more virologic failure than patients given efavirenz (EFV)-based regimens. We investigated this hypothesis in a cohort of HIV-positive patients at a large HIV treatment clinic in South Africa. METHODS: All antiretroviral therapy (ART)-naive non-pregnant patients, >/= 18 years old, without tuberculosis, who initiated treatment with either NVP or EFV from April 2004 to August 2011 at the Themba Lethu Clinic in Johannesburg, South Africa, were included. Log-binomial regression and modified Poisson regression were used to estimate risk ratios (RR) with 95% confidence intervals (CI) for predictors of virologic failure, virologic suppression, and loss to follow-up (LTF), whereas a Cox proportional hazards model was used to estimate the risk of death, all within one year. RESULTS: Of 12,840 included patients, 62.0% were female and the median baseline CD4 count was 98 cells/mm(3) (36-169). Of these patients, 93.2% initiated an EFV-based regimen. After adjusting for baseline characteristics, no difference in death (adjusted Hazards Ratio (aHR): 0.92; 95% CI: 0.68-1.25), LTF (adjusted Risk Ratio (aRR): 1.00; 95% CI: 0.79-1.25), nor suppression (aRR: 0.98; 95% CI: 0.95-1.00) at one year was found between regimens. Among patients with >/= 1 viral load >/= 4 months after ART initiation, 4% (n=350) experienced virologic failure within 12 months of initiation. Patients initiating NVP-based regimens were 60% more likely to fail than patients initiating EFV-based regimens (aRR: 1.58; 95% CI: 1.13-2.22). CONCLUSIONS: In this cohort, patients initiating NVP-based regimens experienced more virologic failure than patients initiating EFV-based regimens. Future guidelines should consider the implications of different efficacy profiles when making recommendations for which drugs to prioritize.'
p17866
sS'GR'
p17867
(lp17868
S'K01AI083097/AI/NIAID NIH HHS/United States'
p17869
aS'T32 AI102623/AI/NIAID NIH HHS/United States'
p17870
asS'VI'
p17871
S'17'
p17872
sS'IS'
p17873
S'1758-2652 (Electronic) 1758-2652 (Linking)'
p17874
sS'PMC'
p17875
S'PMC4215701'
p17876
sS'AU'
p17877
(lp17878
S'Shearer K'
p17879
aS'Brennan AT'
p17880
aS'Maskew M'
p17881
aS'Long L'
p17882
aS'Berhanu R'
p17883
aS'Sanne I'
p17884
aS'Fox MP'
p17885
asS'MHDA'
p17886
S'2015/03/05 06:00'
p17887
sS'PHST'
p17888
(lp17889
S'2014 [ecollection]'
p17890
aS'2014/02/14 [received]'
p17891
aS'2014/08/28 [revised]'
p17892
aS'2014/09/16 [accepted]'
p17893
asS'OT'
p17894
(lp17895
S'efavirenz'
p17896
aS'loss to follow-up'
p17897
aS'mortality'
p17898
aS'nevirapine'
p17899
aS'resource-limited settings'
p17900
aS'viral suppression'
p17901
aS'virologic failure'
p17902
asS'OTO'
p17903
(lp17904
S'NOTNLM'
p17905
asS'OID'
p17906
(lp17907
S'NLM: PMC4215701'
p17908
asS'MH'
p17909
(lp17910
S'Adolescent'
p17911
aS'Adult'
p17912
aS'Anti-HIV Agents/*therapeutic use'
p17913
aS'Benzoxazines/*therapeutic use'
p17914
aS'Female'
p17915
aS'Follow-Up Studies'
p17916
aS'HIV/isolation & purification'
p17917
aS'HIV Infections/*drug therapy'
p17918
aS'Humans'
p17919
aS'Male'
p17920
aS'Middle Aged'
p17921
aS'Nevirapine/*therapeutic use'
p17922
aS'South Africa'
p17923
aS'Treatment Failure'
p17924
aS'Viremia'
p17925
aS'Young Adult'
p17926
asS'EDAT'
p17927
S'2014/11/02 06:00'
p17928
sS'SO'
p17929
S'J Int AIDS Soc. 2014 Oct 22;17:19065. doi: 10.7448/IAS.17.1.19065. eCollection 2014.'
p17930
sS'SB'
p17931
S'IM X'
p17932
sS'PMID'
p17933
S'25361827'
p17934
sS'TA'
p17935
S'J Int AIDS Soc'
p17936
sS'PST'
p17937
S'epublish'
p17938
stRp17939
ag2
(g3
g4
(dp17940
S'LID'
p17941
S'10.1002/14651858.CD010385.pub2 [doi]'
p17942
sS'STAT'
p17943
S'MEDLINE'
p17944
sS'AB'
p17945
S"BACKGROUND: Each year about two million pregnant women are infected with preventable syphilis infection, mostly in developing countries. Despite the expansion of antenatal syphilis screening programmes over the past few decades, syphilis continues to be a major public health concern in developing countries. Point-of-care syphilis testing may be a useful strategy to substantially prevent syphilis-associated perinatal mortality and other negative consequences in resource-poor settings. However, the evidence on effectiveness has been generated mostly from observational study designs or has been reported as a mixed-intervention effect. OBJECTIVES: To assess the effectiveness of antenatal syphilis screening in improving the uptake of screening tests and treatment, and reducing perinatal mortality. SEARCH METHODS: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (30 September 2014) and the reference lists of retrieved studies. SELECTION CRITERIA: Randomised (individual and cluster) controlled trials comparing different screening tests conducted during routine antenatal check-ups versus no screening test. Cross-over trials and quasi-randomised experimental study designs were not eligible for inclusion. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed trials for inclusion and risk of bias, extracted data and checked for accuracy. MAIN RESULTS: We included two cluster-randomised controlled trials (three reports). Both trials assessed point-of-care syphilis testing with conventional testing methods and together involved a total of 8493 pregnant women. Data from these trials were not amenable to meta-analysis as the measure of effectiveness was assessed in a non-comparable way.One trial randomised 14 antenatal clinics (including 7700 pregnant women) and was carried out at in Ulaanbaatar, Mongolia. The trial assessed one-stop syphilis testing using a rapid treponemal test, and was judged to have unclear methods of random sequence generation, allocation concealment, selective reporting, and other bias and low risk of bias for incomplete outcome data. Blinding was not reported and was assessed as high risk. The point-of-care testing provided screening, test results and treatment within the same day. The trial appears to have adjusted their results to account for clustering. We entered the data into RevMan using the generic inverse variance method. The incidence of congenital syphilis was lower in the clusters receiving on-site screening (adjusted odds ratio (AOR) 0.09, 95% confidence interval (CI) 0.01 to 0.71) and the proportion of women tested for syphilis was higher in the clusters receiving on-site screening at both the first antenatal visit and at the third trimester visit (OR 989.80, 95% CI 16.27 to 60233.05; OR 617.88, 95% CI 13.44 to 28399.01). Adequate treatment and partner treatment was higher with the on-site screening (AOR 10.44, 95% CI 1.00 to 108.99; AOR 18.17, 95% CI 3.23 to 101.20) and more syphilis cases were detected at first and third trimester visits with the on-site screening (AOR 2.45, 95% CI 1.44 to 4.18; AOR 6.27, 95% CI 1.47 to 26.69). Perinatal mortality, incidence of HIV/AIDS, obstacles in uptake of screening, any other adverse effects, or healthcare resource usage were not reported in this trial.The second trial divided clinics into seven matched pairs (including 7618 pregnant women, although results were only presented for the positive cases (793 women)), and within each pair one clinic was randomised to receive the on-site screening and the other to continue routine laboratory testing. The trial was conducted in primary healthcare clinics in KwaZulu-Natal, South Africa. Random sequence generation were judged to be at low risk of bias, but allocation concealment and incomplete outcome data were judged to be high risk. Other bias and selective reporting bias remain unclear. Blinding was not reported and was assessed as high risk of bias. This trial assessed the primary outcome of this review (perinatal mortality) and the secondary outcomes (adverse outcomes; adequate treatment; syphilis prevalence) in the subset of women (793 women) who tested positive for syphilis. Only one outcome, adequate treatment, was adjusted to account for cluster design. However, not enough information was provided to include this in an analysis using the generic inverse variance method. Where possible, results have therefore been presented in forest plots (perinatal mortality; adequate treatment), as if the data are from a parallel randomised controlled trial. These results should therefore be interpreted with caution.The trial reported on perinatal mortality in women with positive test results and showed that on-site screening using a rapid plasma reagin test had no clear evidence of an effect on perinatal mortality reduction (odds ratio (OR) 0.63; 95% CI 0.27 to 1.48; 18/549 (3.3%) versus 8/157 (5.1%)). After loss to follow up, 396/618 (64.1%) women with positive test results received adequate treatment (two or more doses of 2.4 mega units of benzathine penicillin) in the intervention cluster versus 120/175 (68.6%) in the control (OR 0.82; 95% CI 0.57 to 1.17). It was not possible to include any other data on reported outcomes in forest plots (adverse outcomes; syphilis prevalence). Incidence of congenital syphilis, proportion of women test for syphilis, incidence of HIV/AIDS, obstacles in uptake of screening, partner treatment, or healthcare resource usage were not reported in this trial. AUTHORS' CONCLUSIONS: This review included evidence from two cluster-randomised trials at high or unclear risk of bias for most of the 'Risk of bias' domains. Data were not combined in meta-analysis because the trials used non-comparable measures of effectiveness.Point-of-care syphilis testing showed some promising results for syphilis detection and treatment rates and for use in different settings. In Mongolia point-of-care testing was found to be effective in increasing the proportion of pregnant women tested for syphilis and treatment provided, reducing congenital syphilis, and improving access to treatment for both women and their partners. In contrast, in rural South Africa, among women with positive test results, there was no clear evidence of an effect of point-of-care syphilis testing in increasing adequate syphilis treatment rates, and reducing perinatal mortality, but point-of-care testing was found to reduce delay in seeking treatment.More trials are therefore warranted to determine the effectiveness of available testing strategies for improving syphilis-associated adverse outcomes in pregnant women and neonates, especially in high-risk regions."
p17946
sS'AD'
p17947
S'Department of Health Policy, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, Tokyo, Japan, 157 8535.'
p17948
sS'DEP'
p17949
S'20141029'
p17950
sS'IP'
p17951
S'10'
p17952
sS'IS'
p17953
S'1469-493X (Electronic) 1361-6137 (Linking)'
p17954
sS'JID'
p17955
S'100909747'
p17956
sS'DA'
p17957
S'20141101'
p17958
sS'AU'
p17959
(lp17960
S'Shahrook S'
p17961
aS'Mori R'
p17962
aS'Ochirbat T'
p17963
aS'Gomi H'
p17964
asS'SB'
p17965
S'IM'
p17966
sS'AID'
p17967
(lp17968
S'10.1002/14651858.CD010385.pub2 [doi]'
p17969
asS'CRDT'
p17970
(lp17971
S'2014/10/30 06:00'
p17972
asS'DP'
p17973
S'2014'
p17974
sS'MHDA'
p17975
S'2014/12/20 06:00'
p17976
sS'OWN'
p17977
S'NLM'
p17978
sS'PT'
p17979
(lp17980
S'Journal Article'
p17981
aS"Research Support, Non-U.S. Gov't"
p17982
aS'Review'
p17983
asS'LA'
p17984
(lp17985
S'eng'
p17986
asS'MH'
p17987
(lp17988
S'Female'
p17989
aS'Humans'
p17990
aS'*Point-of-Care Systems'
p17991
aS'Pregnancy'
p17992
aS'Pregnancy Complications, Infectious/*diagnosis'
p17993
aS'Prenatal Diagnosis/*methods'
p17994
aS'Randomized Controlled Trials as Topic'
p17995
aS'Syphilis/*diagnosis'
p17996
aS'Syphilis, Congenital/diagnosis'
p17997
asS'DCOM'
p17998
S'20141219'
p17999
sS'EDAT'
p18000
S'2014/10/30 06:00'
p18001
sS'JT'
p18002
S'The Cochrane database of systematic reviews'
p18003
sS'LR'
p18004
S'20160602'
p18005
sS'FAU'
p18006
(lp18007
S'Shahrook, Sadequa'
p18008
aS'Mori, Rintaro'
p18009
aS'Ochirbat, Tumendemberel'
p18010
aS'Gomi, Harumi'
p18011
asS'TI'
p18012
S'Strategies of testing for syphilis during pregnancy.'
p18013
sS'SO'
p18014
S'Cochrane Database Syst Rev. 2014 Oct 29;(10):CD010385. doi: 10.1002/14651858.CD010385.pub2.'
p18015
sS'PMID'
p18016
S'25352226'
p18017
sS'TA'
p18018
S'Cochrane Database Syst Rev'
p18019
sS'PST'
p18020
S'epublish'
p18021
sS'PL'
p18022
S'England'
p18023
sS'PG'
p18024
S'CD010385'
p18025
stRp18026
ag2
(g3
g4
(dp18027
S'LID'
p18028
S'10.1371/journal.pone.0110116 [doi]'
p18029
sS'STAT'
p18030
S'MEDLINE'
p18031
sS'DEP'
p18032
S'20141020'
p18033
sS'DA'
p18034
S'20141021'
p18035
sS'AID'
p18036
(lp18037
S'10.1371/journal.pone.0110116 [doi]'
p18038
aS'PONE-D-13-45953 [pii]'
p18039
asS'CRDT'
p18040
(lp18041
S'2014/10/21 06:00'
p18042
asS'DP'
p18043
S'2014'
p18044
sS'AD'
p18045
S'Vanderbilt Institute for Global Health, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America; Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America; Friends in Global Health, Quelimane and Maputo, Mozambique. Vanderbilt Institute for Global Health, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America; Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America. Vanderbilt Institute for Global Health, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America; Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America; Friends in Global Health, Quelimane and Maputo, Mozambique. Friends in Global Health, Quelimane and Maputo, Mozambique. Friends in Global Health, Quelimane and Maputo, Mozambique. Vanderbilt Institute for Global Health, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America; Friends in Global Health, Quelimane and Maputo, Mozambique. School of Medicine, Universidade Eduardo Mondlane, Maputo, Mozambique. Vanderbilt Institute for Global Health, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America. Vanderbilt Institute for Global Health, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America; Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America. Vanderbilt Institute for Global Health, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America; Department of Preventive Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America; Friends in Global Health, Quelimane and Maputo, Mozambique.'
p18046
sS'OWN'
p18047
S'NLM'
p18048
sS'PT'
p18049
(lp18050
S'Journal Article'
p18051
aS'Research Support, N.I.H., Extramural'
p18052
aS"Research Support, U.S. Gov't, P.H.S."
p18053
asS'LA'
p18054
(lp18055
S'eng'
p18056
asS'FAU'
p18057
(lp18058
S'Vermund, Sten H'
p18059
aS'Blevins, Meridith'
p18060
aS'Moon, Troy D'
p18061
aS'Jose, Eurico'
p18062
aS'Moiane, Linda'
p18063
aS'Tique, Jose A'
p18064
aS'Sidat, Mohsin'
p18065
aS'Ciampa, Philip J'
p18066
aS'Shepherd, Bryan E'
p18067
aS'Vaz, Lara M E'
p18068
asS'JT'
p18069
S'PloS one'
p18070
sS'LR'
p18071
S'20151029'
p18072
sS'PG'
p18073
S'e110116'
p18074
sS'TI'
p18075
S'Poor clinical outcomes for HIV infected children on antiretroviral therapy in rural Mozambique: need for program quality improvement and community engagement.'
p18076
sS'RN'
p18077
(lp18078
S'0 (Anti-HIV Agents)'
p18079
asS'PL'
p18080
S'United States'
p18081
sS'TA'
p18082
S'PLoS One'
p18083
sS'JID'
p18084
S'101285081'
p18085
sS'AB'
p18086
S'INTRODUCTION: Residents of Zambezia Province, Mozambique live from rural subsistence farming and fishing. The 2009 provincial HIV prevalence for adults 15-49 years was 12.6%, higher among women (15.3%) than men (8.9%). We reviewed clinical data to assess outcomes for HIV-infected children on combination antiretroviral therapy (cART) in a highly resource-limited setting. METHODS: We studied rates of 2-year mortality and loss to follow-up (LTFU) for children <15 years of age initiating cART between June 2006-July 2011 in 10 rural districts. National guidelines define LTFU as >60 days following last-scheduled medication pickup. Kaplan-Meier estimates to compute mortality assumed non-informative censoring. Cumulative LTFU incidence calculations treated death as a competing risk. RESULTS: Of 753 children, 29.0% (95% CI: 24.5, 33.2) were confirmed dead by 2 years and 39.0% (95% CI: 34.8, 42.9) were LTFU with unknown clinical outcomes. The cohort mortality rate was 8.4% (95% CI: 6.3, 10.4) after 90 days on cART and 19.2% (95% CI: 16.0, 22.3) after 365 days. Higher hemoglobin at cART initiation was associated with being alive and on cART at 2 years (alive: 9.3 g/dL vs. dead or LTFU: 8.3-8.4 g/dL, p<0.01). Cotrimoxazole use within 90 days of ART initiation was associated with improved 2-year outcomes Treatment was initiated late (WHO stage III/IV) among 48% of the children with WHO stage recorded in their records. Marked heterogeneity in outcomes by district was noted (p<0.001). CONCLUSIONS: We found poor clinical and programmatic outcomes among children taking cART in rural Mozambique. Expanded testing, early infant diagnosis, counseling/support services, case finding, and outreach are insufficiently implemented. Our quality improvement efforts seek to better link pregnancy and HIV services, expand coverage and timeliness of infant diagnosis and treatment, and increase follow-up and adherence.'
p18087
sS'GR'
p18088
(lp18089
S'D43TW001035/TW/FIC NIH HHS/United States'
p18090
aS'U2GPS000631/PHS HHS/United States'
p18091
aS'PEPFAR/United States'
p18092
asS'IP'
p18093
S'10'
p18094
sS'IS'
p18095
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p18096
sS'PMC'
p18097
S'PMC4203761'
p18098
sS'DCOM'
p18099
S'20150702'
p18100
sS'AU'
p18101
(lp18102
S'Vermund SH'
p18103
aS'Blevins M'
p18104
aS'Moon TD'
p18105
aS'Jose E'
p18106
aS'Moiane L'
p18107
aS'Tique JA'
p18108
aS'Sidat M'
p18109
aS'Ciampa PJ'
p18110
aS'Shepherd BE'
p18111
aS'Vaz LM'
p18112
asS'VI'
p18113
S'9'
sS'MHDA'
p18114
S'2015/07/03 06:00'
p18115
sS'PHST'
p18116
(lp18117
S'2014 [ecollection]'
p18118
aS'2013/11/01 [received]'
p18119
aS'2014/09/16 [accepted]'
p18120
aS'2014/10/20 [epublish]'
p18121
asS'OID'
p18122
(lp18123
S'NLM: PMC4203761'
p18124
asS'MH'
p18125
(lp18126
S'Adolescent'
p18127
aS'Anti-HIV Agents/*therapeutic use'
p18128
aS'Child'
p18129
aS'Child, Preschool'
p18130
aS'Female'
p18131
aS'HIV Infections/*drug therapy/*epidemiology/mortality'
p18132
aS'Health Resources/supply & distribution'
p18133
aS'Health Services Needs and Demand'
p18134
aS'Humans'
p18135
aS'Infant'
p18136
aS'Lost to Follow-Up'
p18137
aS'Male'
p18138
aS'Mozambique/epidemiology'
p18139
aS'*Quality Improvement'
p18140
aS'*Residence Characteristics'
p18141
aS'Rural Population/*statistics & numerical data'
p18142
aS'Treatment Outcome'
p18143
asS'EDAT'
p18144
S'2014/10/21 06:00'
p18145
sS'SO'
p18146
S'PLoS One. 2014 Oct 20;9(10):e110116. doi: 10.1371/journal.pone.0110116. eCollection 2014.'
p18147
sS'SB'
p18148
S'IM'
p18149
sS'PMID'
p18150
S'25330113'
p18151
sS'PST'
p18152
S'epublish'
p18153
stRp18154
ag2
(g3
g4
(dp18155
S'STAT'
p18156
S'MEDLINE'
p18157
sS'JT'
p18158
S'Current HIV research'
p18159
sS'DA'
p18160
S'20141127'
p18161
sS'AID'
p18162
(lp18163
S'CHRE-EPUB-62896 [pii]'
p18164
asS'CRDT'
p18165
(lp18166
S'2014/10/18 06:00'
p18167
asS'DP'
p18168
S'2014'
p18169
sS'AD'
p18170
S'African Institute of Biomedical Science and Technology, 211 Dominion House, Cnr H. Chitepo and Parklane, Harare, Zimbabwe. benjiechim@yahoo.com.'
p18171
sS'OWN'
p18172
S'NLM'
p18173
sS'PT'
p18174
(lp18175
S'Journal Article'
p18176
aS'Research Support, N.I.H., Extramural'
p18177
aS"Research Support, Non-U.S. Gov't"
p18178
asS'LA'
p18179
(lp18180
S'eng'
p18181
asS'FAU'
p18182
(lp18183
S'Chimukangara, Benjamin'
p18184
aS'Gwanzura, Lovemore'
p18185
aS'Mitchell, Rebecca'
p18186
aS'Katzenstein, David'
p18187
aS'Masimirembwa, Collen'
p18188
asS'PG'
p18189
S'309-16'
p18190
sS'TI'
p18191
S'Drug resistance mutations from whole blood proviral DNA among patients on antiretroviral drugs in Zimbabwe.'
p18192
sS'RN'
p18193
(lp18194
S'0 (Anti-HIV Agents)'
p18195
aS'0 (Reverse Transcriptase Inhibitors)'
p18196
aS'EC 2.7.7.49 (HIV Reverse Transcriptase)'
p18197
asS'PL'
p18198
S'Netherlands'
p18199
sS'TA'
p18200
S'Curr HIV Res'
p18201
sS'JID'
p18202
S'101156990'
p18203
sS'AB'
p18204
S'INTRODUCTION: There are more than 500 000 HIV-infected people on antiretroviral treatment (ART) in Zimbabwe with very limited laboratory monitoring. To ensure effective treatment and prevent transmission of drug resistance, affordable treatment monitoring is needed to guide individual treatment. METHODS: 125 whole blood samples from patients on first-line ART were investigated for drug resistance mutations using an in-house genotypic testing method. Patients had been on HIV reverse transcriptase inhibitors only, with some having been on both HIV and TB treatment. DNA was extracted from whole blood; amplicons were generated by nested PCR and sequenced. Drug resistance mutations were determined using the Stanford HIV drug resistance database. Exact statistics were used to investigate relationships between drug resistance and predisposing factors. RESULTS: From 125 samples, 108 were successfully analyzed for drug resistance mutations. 11 of the 108 sequences had drug resistance mutations; predominantly M184V and Y181C. For a 100-cell increase in CD4 count, the odds of being resistant were 61% lower than those with the baseline CD4 count (p = 0.04, CI: 0.34-0.98). There was no association between concurrent HIV/TB treatment and drug resistance (p = 0.41). DISCUSSION AND CONCLUSION: Although plasma samples are recommended for genotypic testing, the cost of analyzing plasma RNA makes it less feasible in resource limited settings. Lower cost DNA drug resistance testing from whole blood samples was assessed as a treatment-monitoring tool among patients followed by CD4 and clinical monitoring only. The infrequent detection of resistance and higher CD4 is consistent with effective first-line treatment. Further investigation of proviral DNA as a tool to identify drug resistance mutations is warranted.'
p18205
sS'GR'
p18206
(lp18207
S'U2R TW006878/TW/FIC NIH HHS/United States'
p18208
asS'IP'
p18209
S'5'
sS'IS'
p18210
S'1873-4251 (Electronic) 1570-162X (Linking)'
p18211
sS'DCOM'
p18212
S'20150630'
p18213
sS'AU'
p18214
(lp18215
S'Chimukangara B'
p18216
aS'Gwanzura L'
p18217
aS'Mitchell R'
p18218
aS'Katzenstein D'
p18219
aS'Masimirembwa C'
p18220
asS'VI'
p18221
S'12'
p18222
sS'MHDA'
p18223
S'2015/07/01 06:00'
p18224
sS'PHST'
p18225
(lp18226
S'2014/04/08 [received]'
p18227
aS'2014/09/19 [revised]'
p18228
aS'2014/10/09 [accepted]'
p18229
asS'MH'
p18230
(lp18231
S'Adult'
p18232
aS'Anti-HIV Agents/*therapeutic use'
p18233
aS'CD4 Lymphocyte Count'
p18234
aS'Drug Resistance, Viral/*genetics'
p18235
aS'Female'
p18236
aS'HIV Infections/*drug therapy/virology'
p18237
aS'HIV Reverse Transcriptase/genetics'
p18238
aS'HIV-1/drug effects/*genetics'
p18239
aS'Humans'
p18240
aS'Male'
p18241
aS'Middle Aged'
p18242
aS'Regression Analysis'
p18243
aS'Reverse Transcriptase Inhibitors/*therapeutic use'
p18244
aS'Young Adult'
p18245
aS'Zimbabwe'
p18246
asS'EDAT'
p18247
S'2014/10/18 06:00'
p18248
sS'SO'
p18249
S'Curr HIV Res. 2014;12(5):309-16.'
p18250
sS'SB'
p18251
S'IM'
p18252
sS'PMID'
p18253
S'25323793'
p18254
sS'PST'
p18255
S'ppublish'
p18256
stRp18257
ag2
(g3
g4
(dp18258
S'LID'
p18259
S'10.1097/QAD.0000000000000409 [doi]'
p18260
sS'STAT'
p18261
S'MEDLINE'
p18262
sS'JT'
p18263
S'AIDS (London, England)'
p18264
sS'MID'
p18265
(lp18266
S'NIHMS665068'
p18267
asS'DA'
p18268
S'20141015'
p18269
sS'AID'
p18270
(lp18271
S'10.1097/QAD.0000000000000409 [doi]'
p18272
aS'00002030-201409240-00014 [pii]'
p18273
asS'CRDT'
p18274
(lp18275
S'2014/10/15 06:00'
p18276
asS'DP'
p18277
S'2014 Sep 24'
p18278
sS'AD'
p18279
S'aKenya Medical Research Institute (KEMRI), Nairobi, Kenya bDepartment of Epidemiology cDepartment of Global Health dDepartment of Obstetrics and Gynecology, University of Washington, Seattle, Washington eDepartment of Obstetrics, Gynecology & Reproductive Sciences, University of California San Francisco, San Francisco, California fDepartment of Medicine, University of Washington, Seattle, Washington, USA gInstitute of Tropical and Infectious Diseases, University of Nairobi, Nairobi, Kenya.'
p18280
sS'OWN'
p18281
S'NLM'
p18282
sS'PT'
p18283
(lp18284
S'Journal Article'
p18285
aS'Randomized Controlled Trial'
p18286
aS'Research Support, N.I.H., Extramural'
p18287
asS'LA'
p18288
(lp18289
S'eng'
p18290
asS'FAU'
p18291
(lp18292
S'Odeny, Thomas A'
p18293
aS'Bukusi, Elizabeth A'
p18294
aS'Cohen, Craig R'
p18295
aS'Yuhas, Krista'
p18296
aS'Camlin, Carol S'
p18297
aS'McClelland, R Scott'
p18298
asS'LR'
p18299
S'20160518'
p18300
sS'PG'
p18301
S'2307-12'
p18302
sS'TI'
p18303
S'Texting improves testing: a randomized trial of two-way SMS to increase postpartum prevention of mother-to-child transmission retention and infant HIV testing.'
p18304
sS'PL'
p18305
S'England'
p18306
sS'TA'
p18307
S'AIDS'
p18308
sS'JID'
p18309
S'8710219'
p18310
sS'AB'
p18311
S'OBJECTIVE: Many sub-Saharan African countries report high postpartum loss to follow-up of mother-baby pairs. We aimed to determine whether interactive text messages improved rates of clinic attendance and early infant HIV testing in the Nyanza region of Kenya. DESIGN: Parallel-group, unblinded, randomized controlled trial. METHODS: HIV-positive pregnant women at least 18 years old and enrolled in the prevention of mother-to-child transmission of HIV programme were randomized to receive either text messages (SMS group, n = 195) or usual care (n = 193). Messages were developed using formative focus group research informed by constructs of the Health Belief Model. The SMS group received up to eight text messages before delivery (depending on gestational age), and six messages postpartum. Primary outcomes included maternal postpartum clinic attendance and virological infant HIV testing by 8 weeks postpartum. The primary analyses were intention-to-treat. RESULTS: Of the 388 enrolled women, 381 (98.2%) had final outcome information. In the SMS group, 38 of 194 (19.6%) women attended a maternal postpartum clinic compared to 22 of 187 (11.8%) in the control group (relative risk 1.66, 95% confidence interval 1.02-2.70). HIV testing within 8 weeks was performed in 172 of 187 (92.0%) infants in the SMS group compared to 154 of 181 (85.1%) in the control group (relative risk 1.08, 95% confidence interval 1.00-1.16). CONCLUSIONS: Text messaging significantly improved maternal postpartum visit attendance, but overall return rates for these visits remained low. In contrast, high rates of early infant HIV testing were achieved in both arms, with significantly higher testing rates in the SMS compared to the control infants.'
p18312
sS'GR'
p18313
(lp18314
S'K01 MH093205/MH/NIMH NIH HHS/United States'
p18315
aS'K01MH093205/MH/NIMH NIH HHS/United States'
p18316
aS'P30 AI027757/AI/NIAID NIH HHS/United States'
p18317
aS'P30AI027757/AI/NIAID NIH HHS/United States'
p18318
aS'R24 TW007988/TW/FIC NIH HHS/United States'
p18319
aS'R24 TW007988/TW/FIC NIH HHS/United States'
p18320
asS'IP'
p18321
S'15'
p18322
sS'IS'
p18323
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p18324
sS'PMC'
p18325
S'PMC4834137'
p18326
sS'DCOM'
p18327
S'20150616'
p18328
sS'AU'
p18329
(lp18330
S'Odeny TA'
p18331
aS'Bukusi EA'
p18332
aS'Cohen CR'
p18333
aS'Yuhas K'
p18334
aS'Camlin CS'
p18335
aS'McClelland RS'
p18336
asS'VI'
p18337
S'28'
p18338
sS'MHDA'
p18339
S'2015/06/17 06:00'
p18340
sS'OID'
p18341
(lp18342
S'NLM: NIHMS665068'
p18343
aS'NLM: PMC4834137'
p18344
asS'MH'
p18345
(lp18346
S'Adult'
p18347
aS'Female'
p18348
aS'HIV Infections/*diagnosis/*prevention & control'
p18349
aS'Humans'
p18350
aS'Infant'
p18351
aS'Infant, Newborn'
p18352
aS'Infectious Disease Transmission, Vertical/*prevention & control'
p18353
aS'Kenya'
p18354
aS'Male'
p18355
aS'*Postpartum Period'
p18356
aS'Pregnancy'
p18357
aS'*Professional-Patient Relations'
p18358
aS'Text Messaging/*utilization'
p18359
aS'Young Adult'
p18360
asS'EDAT'
p18361
S'2014/10/15 06:00'
p18362
sS'SO'
p18363
S'AIDS. 2014 Sep 24;28(15):2307-12. doi: 10.1097/QAD.0000000000000409.'
p18364
sS'SB'
p18365
S'IM X'
p18366
sS'PMID'
p18367
S'25313586'
p18368
sS'PST'
p18369
S'ppublish'
p18370
stRp18371
ag2
(g3
g4
(dp18372
S'STAT'
p18373
S'MEDLINE'
p18374
sS'AB'
p18375
S'The detection and clinical significance of HIV-1 minority drug-resistant variants is a major topic of current HIV research. Whereas much attention has been placed on the clinical impact of minority drug-resistant variants in patients initiating antiretroviral therapy, their possible influence on the effectiveness of antiretroviral therapy following prevention of mother-to-child transmission strategies in resource-limited settings remains largely unexplored. This review outlines the clinical significance and detection of minority drug-resistant variants, focusing primarily on studies of minority variants in the context of prevention of mother-to-child transmission and their possible influence on current regimens, especially those available in resource-limited countries. The clinical impact of minority nevirapine-resistant variants that arise in the context of prevention of mother-to-child transmission, for example, is an important factor to consider when these women initiate antiretroviral therapy that may include nevirapine or efavirenz. Minority nonnucleoside reverse transcriptase inhibitor-resistant variants have been associated with treatment failure in women exposed to single-dose nevirapine. In countries like South Africa, with its longstanding use of single-dose nevirapine, this question is relevant as it is for other resource-limited countries where single-dose nevirapine is used. In the same context, various other minority drug-resistant variants (e.g. Y181C, K65R and thymidine analogue mutations etc.) are discussed. The field of next generation sequencing is very dynamic, with rapid improvements on present technologies and the introduction of novel technologies as discussed in this review. As the impact of minority drug-resistant variants in the setting of prevention of mother-to-child transmission becomes more evident, guidelines for this, especially in resource-limited countries, will need revision in order to optimize the clinical benefit from future antiretroviral therapy.'
p18376
sS'JID'
p18377
S'101134876'
p18378
sS'AD'
p18379
S'Department of Virology, National Health Laboratory Service, University of KwaZulu-Natal, Durban, South Africa. IrsiCaixa AIDS Research Institute, Badalona, Catalonia, Spain; HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain; Universitat Autonoma de Barcelona, Barcelona, Catalonia, Spain; Universitat de Vic, Vic, Catalonia, Spain. Department of Virology, National Health Laboratory Service, University of KwaZulu-Natal, Durban, South Africa. Department of Virology, National Health Laboratory Service, University of KwaZulu-Natal, Durban, South Africa. Department of Virology, HIV Pathogenesis Programme Laboratory, Nelson R Mandela Medical School, University of KwaZulu-Natal, Durban, South Africa.'
p18380
sS'JT'
p18381
S'AIDS reviews'
p18382
sS'IP'
p18383
S'4'
sS'IS'
p18384
S'1698-6997 (Electronic) 1139-6121 (Linking)'
p18385
sS'DCOM'
p18386
S'20150825'
p18387
sS'DA'
p18388
S'20141106'
p18389
sS'AU'
p18390
(lp18391
S'Samuel R'
p18392
aS'Paredes R'
p18393
aS'Parboosing R'
p18394
aS'Moodley P'
p18395
aS'Gordon M'
p18396
asS'AID'
p18397
(lp18398
S's113961211413 [pii]'
p18399
asS'CRDT'
p18400
(lp18401
S'2014/10/11 06:00'
p18402
asS'VI'
p18403
S'16'
p18404
sS'PMID'
p18405
S'25300623'
p18406
sS'DP'
p18407
S'2014 Oct-Dec'
p18408
sS'MHDA'
p18409
S'2015/08/26 06:00'
p18410
sS'OWN'
p18411
S'NLM'
p18412
sS'PT'
p18413
(lp18414
S'Journal Article'
p18415
aS'Review'
p18416
asS'LA'
p18417
(lp18418
S'eng'
p18419
asS'MH'
p18420
(lp18421
S'Anti-HIV Agents/administration & dosage'
p18422
aS'Benzoxazines/administration & dosage'
p18423
aS'Developing Countries'
p18424
aS'Drug Resistance, Viral/*genetics'
p18425
aS'Female'
p18426
aS'Genotype'
p18427
aS'HIV Infections/*drug therapy/transmission'
p18428
aS'HIV Reverse Transcriptase/genetics'
p18429
aS'HIV-1/*genetics/isolation & purification'
p18430
aS'Health Services Accessibility'
p18431
aS'Humans'
p18432
aS'Infant, Newborn'
p18433
aS'Infectious Disease Transmission, Vertical/*prevention & control'
p18434
aS'Mothers'
p18435
aS'Mutagenicity Tests'
p18436
aS'Mutation/genetics'
p18437
aS'Nevirapine/administration & dosage'
p18438
aS'Pregnancy'
p18439
aS'Pregnancy Complications, Infectious/*drug therapy'
p18440
aS'Public Health'
p18441
aS'RNA, Viral/genetics'
p18442
aS'Treatment Failure'
p18443
asS'FAU'
p18444
(lp18445
S'Samuel, Reshmi'
p18446
aS'Paredes, Roger'
p18447
aS'Parboosing, Raveen'
p18448
aS'Moodley, Pravi'
p18449
aS'Gordon, Michelle'
p18450
asS'EDAT'
p18451
S'2014/10/11 06:00'
p18452
sS'PST'
p18453
S'ppublish'
p18454
sS'SO'
p18455
S'AIDS Rev. 2014 Oct-Dec;16(4):187-98.'
p18456
sS'PG'
p18457
S'187-98'
p18458
sS'TI'
p18459
S'Minority HIV-1 drug-resistant mutations and prevention of mother-to-child transmission: perspectives for resource-limited countries.'
p18460
sS'SB'
p18461
S'IM'
p18462
sS'RN'
p18463
(lp18464
S'0 (Anti-HIV Agents)'
p18465
aS'0 (Benzoxazines)'
p18466
aS'0 (RNA, Viral)'
p18467
aS'99DK7FVK1H (Nevirapine)'
p18468
aS'EC 2.7.7.49 (HIV Reverse Transcriptase)'
p18469
aS'JE6H2O27P8 (efavirenz)'
p18470
asS'PL'
p18471
S'Spain'
p18472
sS'TA'
p18473
S'AIDS Rev'
p18474
stRp18475
ag2
(g3
g4
(dp18476
S'LID'
p18477
S'10.1371/journal.pone.0109148 [doi]'
p18478
sS'STAT'
p18479
S'MEDLINE'
p18480
sS'DEP'
p18481
S'20141007'
p18482
sS'DA'
p18483
S'20141008'
p18484
sS'AID'
p18485
(lp18486
S'10.1371/journal.pone.0109148 [doi]'
p18487
aS'PONE-D-14-21290 [pii]'
p18488
asS'CRDT'
p18489
(lp18490
S'2014/10/08 06:00'
p18491
asS'DP'
p18492
S'2014'
p18493
sS'EIN'
p18494
(lp18495
S'PLoS One. 2014;9(12):e115079. Magubu, Travor [corrected to Mabugu, Travor]'
p18496
asS'OWN'
p18497
S'NLM'
p18498
sS'PT'
p18499
(lp18500
S'Journal Article'
p18501
aS"Research Support, Non-U.S. Gov't"
p18502
asS'LA'
p18503
(lp18504
S'eng'
p18505
asS'FAU'
p18506
(lp18507
S'Phillips, Andrew'
p18508
aS'Cambiano, Valentina'
p18509
aS'Nakagawa, Fumiyo'
p18510
aS'Mabugu, Travor'
p18511
aS'Miners, Alec'
p18512
aS'Ford, Debbie'
p18513
aS'Pillay, Deenan'
p18514
aS'De Luca, Andrea'
p18515
aS'Lundgren, Jens'
p18516
aS'Revill, Paul'
p18517
asS'JT'
p18518
S'PloS one'
p18519
sS'LR'
p18520
S'20151029'
p18521
sS'PG'
p18522
S'e109148'
p18523
sS'TI'
p18524
S'Cost-effectiveness of HIV drug resistance testing to inform switching to second line antiretroviral therapy in low income settings.'
p18525
sS'RN'
p18526
(lp18527
S'0 (Anti-HIV Agents)'
p18528
asS'PL'
p18529
S'United States'
p18530
sS'TA'
p18531
S'PLoS One'
p18532
sS'JID'
p18533
S'101285081'
p18534
sS'AB'
p18535
S'BACKGROUND: To guide future need for cheap resistance tests for use in low income settings, we assessed cost-effectiveness of drug resistance testing as part of monitoring of people on first line ART - with switching from first to second line ART being conditional on NNRTI drug resistance mutations being identified. METHODS: An individual level simulation model of HIV transmission, progression and the effect of ART which accounts for adherence and resistance development was used to compare outcomes of various potential monitoring strategies in a typical low income setting in sub-Saharan Africa. Underlying monitoring strategies considered were based on clinical disease, CD4 count or viral load. Within each we considered a strategy in which no further measures are performed, one with a viral load measure to confirm failure, and one with both a viral load measure and a resistance test. Predicted outcomes were assessed over 2015-2025 in terms of viral suppression, first line failure, switching to second line regimen, death, HIV incidence, disability-adjusted-life-years averted and costs. Potential future low costs of resistance tests ($30) were used. RESULTS: The most effective strategy, in terms of DALYs averted, was one using viral load monitoring without confirmation. The incremental cost-effectiveness ratio for this strategy was $2113 (the same as that for viral load monitoring with confirmation). ART monitoring strategies which involved resistance testing did not emerge as being more effective or cost effective than strategies not using it. The slightly reduced ART costs resulting from use of resistance testing, due to less use of second line regimens, was of similar magnitude to the costs of resistance tests. CONCLUSION: Use of resistance testing at the time of first line failure as part of the decision whether to switch to second line therapy was not cost-effective, even though the test was assumed to be very inexpensive.'
p18536
sS'GR'
p18537
(lp18538
S'MC_U122886353/Medical Research Council/United Kingdom'
p18539
asS'IP'
p18540
S'10'
p18541
sS'IS'
p18542
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p18543
sS'PMC'
p18544
S'PMC4188574'
p18545
sS'DCOM'
p18546
S'20150610'
p18547
sS'AU'
p18548
(lp18549
S'Phillips A'
p18550
aS'Cambiano V'
p18551
aS'Nakagawa F'
p18552
aS'Mabugu T'
p18553
aS'Miners A'
p18554
aS'Ford D'
p18555
aS'Pillay D'
p18556
aS'De Luca A'
p18557
aS'Lundgren J'
p18558
aS'Revill P'
p18559
asS'AD'
p18560
S'Research Department of Infection & Population Health, UCL, London, United Kingdom. Research Department of Infection & Population Health, UCL, London, United Kingdom. Research Department of Infection & Population Health, UCL, London, United Kingdom. University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe. Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom. MRC Clinical Trials Unit, UCL, London, United Kingdom. Africa Centre, KwaZulu Natal, South Africa. University Division of Infectious Diseases, Siena University Hospital, Siena, Italy. Dept of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. Centre for Health Economics, University of York, York, United Kingdom.'
p18561
sS'VI'
p18562
S'9'
sS'MHDA'
p18563
S'2015/06/11 06:00'
p18564
sS'PHST'
p18565
(lp18566
S'2014 [ecollection]'
p18567
aS'2014/05/13 [received]'
p18568
aS'2014/08/19 [accepted]'
p18569
aS'2014/10/07 [epublish]'
p18570
asS'OID'
p18571
(lp18572
S'NLM: PMC4188574'
p18573
asS'MH'
p18574
(lp18575
S'Adolescent'
p18576
aS'Adult'
p18577
aS'*Anti-HIV Agents/pharmacology/therapeutic use'
p18578
aS'*Cost-Benefit Analysis'
p18579
aS'Drug Resistance, Viral/genetics'
p18580
aS'Drug Substitution'
p18581
aS'HIV Infections/*diagnosis/drug therapy/*epidemiology'
p18582
aS'*HIV-1/drug effects/genetics'
p18583
aS'Humans'
p18584
aS'Incidence'
p18585
aS'Microbial Sensitivity Tests/*economics'
p18586
aS'Middle Aged'
p18587
aS'*Poverty'
p18588
aS'Prevalence'
p18589
aS'Treatment Failure'
p18590
aS'Treatment Outcome'
p18591
aS'Young Adult'
p18592
asS'EDAT'
p18593
S'2014/10/08 06:00'
p18594
sS'SO'
p18595
S'PLoS One. 2014 Oct 7;9(10):e109148. doi: 10.1371/journal.pone.0109148. eCollection 2014.'
p18596
sS'SB'
p18597
S'IM'
p18598
sS'PMID'
p18599
S'25290340'
p18600
sS'PST'
p18601
S'epublish'
p18602
stRp18603
ag2
(g3
g4
(dp18604
S'LID'
p18605
S'10.1371/journal.pone.0108305 [doi]'
p18606
sS'STAT'
p18607
S'MEDLINE'
p18608
sS'DEP'
p18609
S'20140925'
p18610
sS'DA'
p18611
S'20140926'
p18612
sS'AID'
p18613
(lp18614
S'10.1371/journal.pone.0108305 [doi]'
p18615
aS'PONE-D-13-54691 [pii]'
p18616
asS'CRDT'
p18617
(lp18618
S'2014/09/26 06:00'
p18619
asS'DP'
p18620
S'2014'
p18621
sS'OWN'
p18622
S'NLM'
p18623
sS'PT'
p18624
(lp18625
S'Journal Article'
p18626
aS"Research Support, Non-U.S. Gov't"
p18627
asS'LA'
p18628
(lp18629
S'eng'
p18630
asS'FAU'
p18631
(lp18632
S'Zulu, Joseph Mumba'
p18633
aS'Lisulo, Mpala Mwanza'
p18634
aS'Besa, Ellen'
p18635
aS'Kaonga, Patrick'
p18636
aS'Chisenga, Caroline C'
p18637
aS'Chomba, Mumba'
p18638
aS'Simuyandi, Michelo'
p18639
aS'Banda, Rosemary'
p18640
aS'Kelly, Paul'
p18641
asS'JT'
p18642
S'PloS one'
p18643
sS'PG'
p18644
S'e108305'
p18645
sS'TI'
p18646
S'Improving validity of informed consent for biomedical research in Zambia using a laboratory exposure intervention.'
p18647
sS'PL'
p18648
S'United States'
p18649
sS'TA'
p18650
S'PLoS One'
p18651
sS'JID'
p18652
S'101285081'
p18653
sS'AB'
p18654
S'BACKGROUND: Complex biomedical research can lead to disquiet in communities with limited exposure to scientific discussions, leading to rumours or to high drop-out rates. We set out to test an intervention designed to address apprehensions commonly encountered in a community where literacy is uncommon, and where complex biomedical research has been conducted for over a decade. We aimed to determine if it could improve the validity of consent. METHODS: Data were collected using focus group discussions, key informant interviews and observations. We designed an intervention that exposed participants to a detailed demonstration of laboratory processes. Each group was interviewed twice in a day, before and after exposure to the intervention in order to assess changes in their views. RESULTS: Factors that motivated people to participate in invasive biomedical research included a desire to stay healthy because of the screening during the recruitment process, regular advice from doctors, free medical services, and trust in the researchers. Inhibiting factors were limited knowledge about samples taken from their bodies during endoscopic procedures, the impact of endoscopy on the function of internal organs, and concerns about the use of biomedical samples. The belief that blood can be used for Satanic practices also created insecurities about drawing of blood samples. Further inhibiting factors included a fear of being labelled as HIV positive if known to consult heath workers repeatedly, and gender inequality. Concerns about the use and storage of blood and tissue samples were overcome by a laboratory exposure intervention. CONCLUSION: Selecting a group of members from target community and engaging them in a laboratory exposure intervention could be a useful tool for enhancing specific aspects of consent for biomedical research. Further work is needed to determine the extent to which improved understanding permeates beyond the immediate group participating in the intervention.'
p18655
sS'AD'
p18656
S'Departments of Community and Internal Medicine, University of Zambia (School of Medicine), Lusaka City, Lusaka Province, Zambia. Departments of Community and Internal Medicine, University of Zambia (School of Medicine), Lusaka City, Lusaka Province, Zambia. Departments of Community and Internal Medicine, University of Zambia (School of Medicine), Lusaka City, Lusaka Province, Zambia. Departments of Community and Internal Medicine, University of Zambia (School of Medicine), Lusaka City, Lusaka Province, Zambia. Departments of Community and Internal Medicine, University of Zambia (School of Medicine), Lusaka City, Lusaka Province, Zambia. Departments of Community and Internal Medicine, University of Zambia (School of Medicine), Lusaka City, Lusaka Province, Zambia. Departments of Community and Internal Medicine, University of Zambia (School of Medicine), Lusaka City, Lusaka Province, Zambia. Departments of Community and Internal Medicine, University of Zambia (School of Medicine), Lusaka City, Lusaka Province, Zambia. Departments of Community and Internal Medicine, University of Zambia (School of Medicine), Lusaka City, Lusaka Province, Zambia; Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.'
p18657
sS'IP'
p18658
S'9'
sS'IS'
p18659
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p18660
sS'PMC'
p18661
S'PMC4178004'
p18662
sS'DCOM'
p18663
S'20151204'
p18664
sS'AU'
p18665
(lp18666
S'Zulu JM'
p18667
aS'Lisulo MM'
p18668
aS'Besa E'
p18669
aS'Kaonga P'
p18670
aS'Chisenga CC'
p18671
aS'Chomba M'
p18672
aS'Simuyandi M'
p18673
aS'Banda R'
p18674
aS'Kelly P'
p18675
asS'VI'
p18676
S'9'
sS'MHDA'
p18677
S'2015/12/15 06:00'
p18678
sS'PHST'
p18679
(lp18680
S'2014 [ecollection]'
p18681
aS'2014/01/01 [received]'
p18682
aS'2014/08/27 [accepted]'
p18683
aS'2014/09/25 [epublish]'
p18684
asS'OID'
p18685
(lp18686
S'NLM: PMC4178004'
p18687
asS'MH'
p18688
(lp18689
S'Adult'
p18690
aS'Biomedical Research/*ethics/*standards'
p18691
aS'Female'
p18692
aS'Focus Groups'
p18693
aS'Humans'
p18694
aS'Informed Consent/*ethics'
p18695
aS'Male'
p18696
aS'Middle Aged'
p18697
aS'Motivation'
p18698
aS'Qualitative Research'
p18699
aS'*Research Subjects'
p18700
aS'Surveys and Questionnaires'
p18701
aS'Trust'
p18702
aS'Young Adult'
p18703
asS'EDAT'
p18704
S'2014/09/26 06:00'
p18705
sS'SO'
p18706
S'PLoS One. 2014 Sep 25;9(9):e108305. doi: 10.1371/journal.pone.0108305. eCollection 2014.'
p18707
sS'SB'
p18708
S'IM'
p18709
sS'PMID'
p18710
S'25254378'
p18711
sS'PST'
p18712
S'epublish'
p18713
stRp18714
ag2
(g3
g4
(dp18715
S'LID'
p18716
S'10.1111/tmi.12387 [doi]'
p18717
sS'STAT'
p18718
S'MEDLINE'
p18719
sS'DEP'
p18720
S'20140922'
p18721
sS'CI'
p18722
(lp18723
S'(c) 2014 John Wiley & Sons Ltd.'
p18724
asS'DA'
p18725
S'20141112'
p18726
sS'AID'
p18727
(lp18728
S'10.1111/tmi.12387 [doi]'
p18729
asS'CRDT'
p18730
(lp18731
S'2014/09/23 06:00'
p18732
asS'DP'
p18733
S'2014 Dec'
p18734
sS'OWN'
p18735
S'NLM'
p18736
sS'PT'
p18737
(lp18738
S'Comparative Study'
p18739
aS'Journal Article'
p18740
asS'LA'
p18741
(lp18742
S'eng'
p18743
asS'FAU'
p18744
(lp18745
S'Clouse, Kate'
p18746
aS'Hanrahan, Colleen F'
p18747
aS'Bassett, Jean'
p18748
aS'Fox, Matthew P'
p18749
aS'Sanne, Ian'
p18750
aS'Van Rie, Annelies'
p18751
asS'JT'
p18752
S'Tropical medicine & international health : TM & IH'
p18753
sS'PG'
p18754
S'1411-9'
p18755
sS'TI'
p18756
S'Impact of systematic HIV testing on case finding and retention in care at a primary care clinic in South Africa.'
p18757
sS'RN'
p18758
(lp18759
S'0 (Anti-HIV Agents)'
p18760
asS'PL'
p18761
S'England'
p18762
sS'TA'
p18763
S'Trop Med Int Health'
p18764
sS'JID'
p18765
S'9610576'
p18766
sS'AB'
p18767
S'OBJECTIVE: Systematic, opt-out HIV counselling and testing (HCT) may diagnose individuals at lower levels of immunodeficiency but may impact loss to follow-up (LTFU) if healthier people are less motivated to engage and remain in HIV care. We explored LTFU and patient clinical outcomes under two different HIV testing strategies. METHODS: We compared patient characteristics and retention in care between adults newly diagnosed with HIV by either voluntary counselling and testing (VCT) plus targeted provider-initiated counselling and testing (PITC) or systematic HCT at a primary care clinic in Johannesburg, South Africa. RESULTS: One thousand one hundred and forty-four adults were newly diagnosed by VCT/PITC and 1124 by systematic HCT. Two-thirds of diagnoses were in women. Median CD4 count at HIV diagnosis (251 vs. 264 cells/mul, P = 0.19) and proportion of individuals eligible for antiretroviral therapy (ART) (67.2% vs. 66.7%, P = 0.80) did not differ by HCT strategy. Within 1 year of HIV diagnosis, half were LTFU: 50.5% under VCT/PITC and 49.6% under systematic HCT (P = 0.64). The overall hazard of LTFU was not affected by testing policy (aHR 0.98, 95%CI: 0.87-1.10). Independent of HCT strategy, males, younger adults and those ineligible for ART were at higher risk of LTFU. CONCLUSIONS: Implementation of systematic HCT did not increase baseline CD4 count. Overall retention in the first year after HIV diagnosis was low (37.9%), especially among those ineligible for ART, but did not differ by testing strategy. Expansion of HIV testing should coincide with effective strategies to increase retention in care, especially among those not yet eligible for ART at initial diagnosis.'
p18768
sS'AD'
p18769
S'Department of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC, USA.'
p18770
sS'IP'
p18771
S'12'
p18772
sS'IS'
p18773
S'1365-3156 (Electronic) 1360-2276 (Linking)'
p18774
sS'DCOM'
p18775
S'20150309'
p18776
sS'AU'
p18777
(lp18778
S'Clouse K'
p18779
aS'Hanrahan CF'
p18780
aS'Bassett J'
p18781
aS'Fox MP'
p18782
aS'Sanne I'
p18783
aS'Van Rie A'
p18784
asS'VI'
p18785
S'19'
p18786
sS'MHDA'
p18787
S'2015/03/10 06:00'
p18788
sS'PHST'
p18789
(lp18790
S'2014/09/22 [aheadofprint]'
p18791
asS'OTO'
p18792
(lp18793
S'NOTNLM'
p18794
asS'MH'
p18795
(lp18796
S'Adult'
p18797
aS'Age Factors'
p18798
aS'*Ambulatory Care Facilities'
p18799
aS'Anti-HIV Agents/*therapeutic use'
p18800
aS'*CD4 Lymphocyte Count'
p18801
aS'Counseling'
p18802
aS'Female'
p18803
aS'HIV Infections/*diagnosis/epidemiology/therapy'
p18804
aS'HIV Seropositivity/diagnosis'
p18805
aS'Humans'
p18806
aS'*Lost to Follow-Up'
p18807
aS'Male'
p18808
aS'*Mass Screening'
p18809
aS'*Patient Acceptance of Health Care'
p18810
aS'Patient Selection'
p18811
aS'Prevalence'
p18812
aS'Primary Health Care'
p18813
aS'Risk Factors'
p18814
aS'South Africa/epidemiology'
p18815
asS'EDAT'
p18816
S'2014/09/23 06:00'
p18817
sS'SO'
p18818
S'Trop Med Int Health. 2014 Dec;19(12):1411-9. doi: 10.1111/tmi.12387. Epub 2014 Sep 22.'
p18819
sS'SB'
p18820
S'IM'
p18821
sS'PMID'
p18822
S'25244155'
p18823
sS'OT'
p18824
(lp18825
S'HIV counselling and testing'
p18826
aS'HIV/AIDS'
p18827
aS'VIH/SIDA'
p18828
aS'aconsejamiento y prueba voluntarios (APV)'
p18829
aS'asesoramiento y prueba iniciado por el proveedor (APIP)'
p18830
aS'conseil et depistage (CD) du VIH'
p18831
aS"conseil et depistage du VIH a l'initiative du prestataire (CDIP)"
p18832
aS'conseil et depistage volontaire (CDV)'
p18833
aS'loss to follow-up'
p18834
aS'perte au suivi'
p18835
aS'provider-initiated HIV counselling and testing'
p18836
aS'perdida durante el seguimiento (PDS)'
p18837
aS'retencion en cuidados'
p18838
aS'retention in care'
p18839
aS'retention dans les soins'
p18840
aS'voluntary counselling and testing'
p18841
asS'PST'
p18842
S'ppublish'
p18843
stRp18844
ag2
(g3
g4
(dp18845
S'LID'
p18846
S'10.1111/tmi.12386 [doi]'
p18847
sS'STAT'
p18848
S'MEDLINE'
p18849
sS'DEP'
p18850
S'20140917'
p18851
sS'CI'
p18852
(lp18853
S'(c) 2014 John Wiley & Sons Ltd.'
p18854
asS'DA'
p18855
S'20141112'
p18856
sS'AID'
p18857
(lp18858
S'10.1111/tmi.12386 [doi]'
p18859
asS'CRDT'
p18860
(lp18861
S'2014/09/18 06:00'
p18862
asS'DP'
p18863
S'2014 Dec'
p18864
sS'AD'
p18865
S'Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK; Clinical Sciences Department, Institute of Tropical Medicine, Antwerp, Belgium.'
p18866
sS'OWN'
p18867
S'NLM'
p18868
sS'PT'
p18869
(lp18870
S'Journal Article'
p18871
aS"Research Support, Non-U.S. Gov't"
p18872
asS'LA'
p18873
(lp18874
S'eng'
p18875
asS'FAU'
p18876
(lp18877
S'Koole, Olivier'
p18878
aS'Tsui, Sharon'
p18879
aS'Wabwire-Mangen, Fred'
p18880
aS'Kwesigabo, Gideon'
p18881
aS'Menten, Joris'
p18882
aS'Mulenga, Modest'
p18883
aS'Auld, Andrew'
p18884
aS'Agolory, Simon'
p18885
aS'Mukadi, Ya Diul'
p18886
aS'Colebunders, Robert'
p18887
aS'Bangsberg, David R'
p18888
aS'van Praag, Eric'
p18889
aS'Torpey, Kwasi'
p18890
aS'Williams, Seymour'
p18891
aS'Kaplan, Jonathan'
p18892
aS'Zee, Aaron'
p18893
aS'Denison, Julie'
p18894
asS'JT'
p18895
S'Tropical medicine & international health : TM & IH'
p18896
sS'LR'
p18897
S'20160218'
p18898
sS'PG'
p18899
S'1397-410'
p18900
sS'TI'
p18901
S'Retention and risk factors for attrition among adults in antiretroviral treatment programmes in Tanzania, Uganda and Zambia.'
p18902
sS'RN'
p18903
(lp18904
S'0 (Anti-HIV Agents)'
p18905
asS'PL'
p18906
S'England'
p18907
sS'TA'
p18908
S'Trop Med Int Health'
p18909
sS'JID'
p18910
S'9610576'
p18911
sS'AB'
p18912
S'OBJECTIVES: We assessed retention and predictors of attrition (recorded death or loss to follow-up) in antiretroviral treatment (ART) clinics in Tanzania, Uganda and Zambia. METHODS: We conducted a retrospective cohort study among adults (>/=18 years) starting ART during 2003-2010. We purposefully selected six health facilities per country and randomly selected 250 patients from each facility. Patients who visited clinics at least once during the 90 days before data abstraction were defined as retained. Data on individual and programme level risk factors for attrition were obtained through chart review and clinic manager interviews. Kaplan-Meier curves for retention across sites were created. Predictors of attrition were assessed using a multivariable Cox-proportional hazards model, adjusted for site-level clustering. RESULTS: From 17 facilities, 4147 patients were included. Retention ranged from 52.0% to 96.2% at 1 year to 25.8%-90.4% at 4 years. Multivariable analysis of ART initiation characteristics found the following independent risk factors for attrition: younger age [adjusted hazard ratio (aHR) and 95% confidence interval (95%CI) = 1.30 (1.14-1.47)], WHO stage 4 ([aHR (95% CI): 1.56 (1.29-1.88)], >10% bodyweight loss [aHR (95%CI) = 1.17 (1.00-1.38)], poor functional status [ambulatory aHR (95%CI) = 1.29 (1.09-1.54); bedridden aHR1.54 (1.15-2.07)], and increasing years of clinic operation prior to ART initiation in government facilities [aHR (95%CI) = 1.17 (1.10-1.23)]. Patients with higher CD4 cell count were less likely to experience attrition [aHR (95%CI) = 0.88 (0.78-1.00)] for every log (tenfold) increase. Sites offering community ART dispensing [aHR (95%CI) = 0.55 (0.30-1.01) for women; 0.40 (0.21-0.75) for men] had significantly less attrition. CONCLUSIONS: Patient retention to an individual programme worsened over time especially among males, younger persons and those with poor clinical indicators. Community ART drug dispensing programmes could improve retention.'
p18913
sS'GR'
p18914
(lp18915
S'CC999999/Intramural CDC HHS/United States'
p18916
aS'F31 MH095665/MH/NIMH NIH HHS/United States'
p18917
asS'IP'
p18918
S'12'
p18919
sS'IS'
p18920
S'1365-3156 (Electronic) 1360-2276 (Linking)'
p18921
sS'PMC'
p18922
S'PMC4724698'
p18923
sS'DCOM'
p18924
S'20150309'
p18925
sS'MID'
p18926
(lp18927
S'HHSPA751516'
p18928
asS'AU'
p18929
(lp18930
S'Koole O'
p18931
aS'Tsui S'
p18932
aS'Wabwire-Mangen F'
p18933
aS'Kwesigabo G'
p18934
aS'Menten J'
p18935
aS'Mulenga M'
p18936
aS'Auld A'
p18937
aS'Agolory S'
p18938
aS'Mukadi YD'
p18939
aS'Colebunders R'
p18940
aS'Bangsberg DR'
p18941
aS'van Praag E'
p18942
aS'Torpey K'
p18943
aS'Williams S'
p18944
aS'Kaplan J'
p18945
aS'Zee A'
p18946
aS'Denison J'
p18947
asS'VI'
p18948
S'19'
p18949
sS'MHDA'
p18950
S'2015/03/10 06:00'
p18951
sS'PHST'
p18952
(lp18953
S'2014/09/17 [aheadofprint]'
p18954
asS'OTO'
p18955
(lp18956
S'NOTNLM'
p18957
asS'OID'
p18958
(lp18959
S'NLM: HHSPA751516'
p18960
aS'NLM: PMC4724698'
p18961
asS'MH'
p18962
(lp18963
S'Adolescent'
p18964
aS'Adult'
p18965
aS'Age Factors'
p18966
aS'*Ambulatory Care Facilities'
p18967
aS'Anti-HIV Agents/*therapeutic use'
p18968
aS'CD4 Lymphocyte Count'
p18969
aS'Disease Progression'
p18970
aS'Female'
p18971
aS'HIV Infections/*drug therapy'
p18972
aS'*Health Services'
p18973
aS'Humans'
p18974
aS'Male'
p18975
aS'*Medication Adherence'
p18976
aS'Patient Dropouts'
p18977
aS'Residence Characteristics'
p18978
aS'Retrospective Studies'
p18979
aS'Risk Factors'
p18980
aS'Tanzania'
p18981
aS'Uganda'
p18982
aS'Weight Loss'
p18983
aS'Young Adult'
p18984
aS'Zambia'
p18985
asS'EDAT'
p18986
S'2014/09/18 06:00'
p18987
sS'SO'
p18988
S'Trop Med Int Health. 2014 Dec;19(12):1397-410. doi: 10.1111/tmi.12386. Epub 2014 Sep 17.'
p18989
sS'SB'
p18990
S'IM'
p18991
sS'PMID'
p18992
S'25227621'
p18993
sS'OT'
p18994
(lp18995
S'ART'
p18996
aS'Afrique subsaharienne'
p18997
aS'HIV'
p18998
aS'TAR'
p18999
aS'VIH'
p19000
aS'retencion'
p19001
aS'retention'
p19002
aS'retention'
p19003
aS'sub-Saharan Africa'
p19004
aS'Africa sub-Sahariana'
p19005
asS'PST'
p19006
S'ppublish'
p19007
stRp19008
ag2
(g3
g4
(dp19009
S'LID'
p19010
S'10.7196/samj.7926 [doi]'
p19011
sS'STAT'
p19012
S'MEDLINE'
p19013
sS'DEP'
p19014
S'20140617'
p19015
sS'DA'
p19016
S'20140912'
p19017
sS'CRDT'
p19018
(lp19019
S'2014/09/13 06:00'
p19020
asS'DP'
p19021
S'2014 Jul'
p19022
sS'OWN'
p19023
S'NLM'
p19024
sS'PT'
p19025
(lp19026
S'Journal Article'
p19027
asS'LA'
p19028
(lp19029
S'eng'
p19030
asS'FAU'
p19031
(lp19032
S'Khwitshana, Alicia Khululwa'
p19033
aS'Greeff, Oppel B W'
p19034
aS'Hurrell, Tracey'
p19035
asS'JT'
p19036
S'South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde'
p19037
sS'LR'
p19038
S'20151119'
p19039
sS'PG'
p19040
S'495-500'
p19041
sS'TI'
p19042
S'Assessing adherence to the 2010 antiretroviral guidelines at the antiretroviral rollout clinic in 1 military hospital, South Africa: a retrospective, cross sectional study.'
p19043
sS'RN'
p19044
(lp19045
S'0 (Anti-Retroviral Agents)'
p19046
aS'0 (Organophosphonates)'
p19047
aS'99YXE507IL (Tenofovir)'
p19048
aS'BO9LE4QFZF (Stavudine)'
p19049
aS'JAC85A2161 (Adenine)'
p19050
asS'PL'
p19051
S'South Africa'
p19052
sS'TA'
p19053
S'S Afr Med J'
p19054
sS'JID'
p19055
S'0404520'
p19056
sS'AB'
p19057
S"BACKGROUND: HIV research is a therapeutic area for which well-defined population-specific treatment and prophylaxis guidelines exist. However, there are limited objective, evidence-based data for assessing adherence to these guidelines. OBJECTIVE: To conduct a retrospective, cross sectional study of adult HIV-infected patients receiving treatment at the antiretroviral (ARV) roll-out clinic of the Infectious Diseases Clinic Pharmacy at 1 Military Hospital (1MH) over a period of 3 years to assess clinicians' adherence to the 2010 ARV guidelines. METHODS: Pharmacy files from the pool of adult patients receiving treatment at the ARV roll-out clinic between 1 April 2009 and 31 March 2012 were selected. Variables used to establish adherence were assessed through evaluation of pharmacy scripts and laboratory tests. RESULTS: In accordance with the ARV guidelines, we found a switch in the first-line regimen from stavudine to tenofovir in the period following implementation. There was no difference in baseline blood tests conducted, suggesting that clinicians were recommending a standardised test panel. Notably, similar blood tests were routinely done during follow-up visits, despite no indication for doing so. While the number of blood tests was found to decrease over time, the type of blood tests requested for specific treatment regimens was not in accordance with ARV guidelines. CONCLUSION: We used an evidence-based approach to critically assess variations from the delineated ARV guidelines. Adherence to clinical guidelines at 1MH, while demonstrating improvement in patient outcomes, highlighted the need for increased vigilance in monitoring failure of prescribers to comply with ARV guidelines."
p19058
sS'AD'
p19059
S'Infectious Disease Clinic,1 Military Hospital, Pretoria, South Africa. k.sima@ymail.com.'
p19060
sS'IP'
p19061
S'7'
sS'IS'
p19062
S'0256-9574 (Print)'
p19063
sS'DCOM'
p19064
S'20141121'
p19065
sS'AU'
p19066
(lp19067
S'Khwitshana AK'
p19068
aS'Greeff OB'
p19069
aS'Hurrell T'
p19070
asS'VI'
p19071
S'104'
p19072
sS'MHDA'
p19073
S'2014/12/15 06:00'
p19074
sS'PHST'
p19075
(lp19076
S'2014/01/08 [received]'
p19077
aS'2014/02/24 [accepted]'
p19078
asS'MH'
p19079
(lp19080
S'Adenine/administration & dosage/adverse effects/*analogs & derivatives'
p19081
aS'Adult'
p19082
aS'Anti-Retroviral Agents/administration & dosage/adverse effects'
p19083
aS'Cross-Sectional Studies'
p19084
aS'Drug Monitoring/methods'
p19085
aS'Drug Substitution/methods'
p19086
aS'Female'
p19087
aS'Guideline Adherence/*statistics & numerical data'
p19088
aS'*HIV Infections/blood/drug therapy/epidemiology'
p19089
aS'Hospitals, Military/statistics & numerical data'
p19090
aS'Humans'
p19091
aS'Male'
p19092
aS'*Organophosphonates/administration & dosage/adverse effects'
p19093
aS'Outcome Assessment (Health Care)'
p19094
aS'Practice Guidelines as Topic'
p19095
aS"Practice Patterns, Physicians'/*statistics & numerical data"
p19096
aS'Retrospective Studies'
p19097
aS'South Africa/epidemiology'
p19098
aS'*Stavudine/administration & dosage/adverse effects'
p19099
aS'Tenofovir'
p19100
asS'EDAT'
p19101
S'2014/09/13 06:00'
p19102
sS'SO'
p19103
S'S Afr Med J. 2014 Jun 17;104(7):495-500. doi: 10.7196/samj.7926.'
p19104
sS'SB'
p19105
S'IM'
p19106
sS'PMID'
p19107
S'25214052'
p19108
sS'PST'
p19109
S'epublish'
p19110
stRp19111
ag2
(g3
g4
(dp19112
S'LID'
p19113
S'10.1371/journal.pmed.1001718 [doi]'
p19114
sS'STAT'
p19115
S'MEDLINE'
p19116
sS'DEP'
p19117
S'20140909'
p19118
sS'CIN'
p19119
(lp19120
S'PLoS Med. 2014 Sep;11(9):e1001719. PMID: 25202913'
p19121
asS'DA'
p19122
S'20140910'
p19123
sS'AID'
p19124
(lp19125
S'10.1371/journal.pmed.1001718 [doi]'
p19126
aS'PMEDICINE-D-13-04124 [pii]'
p19127
asS'CRDT'
p19128
(lp19129
S'2014/09/10 06:00'
p19130
asS'DP'
p19131
S'2014 Sep'
p19132
sS'AD'
p19133
S'Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa; Department of Health, Provincial Government of the Western Cape, Cape Town, South Africa. Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa. School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom. Division of Epidemiology and Population Health, British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada; Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada. Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America. Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, Madrid, Spain. University of Bern, Institute for Social and Preventive Medicine, Bern, Switzerland. Research Department of Infection and Population Health, UCL Medical School, London, United Kingdom. McCord Hospital, Durban, South Africa. Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Somkhele, South Africa. Medecins Sans Frontieres, Khayelitsha, South Africa. Center for Global Health and Development, Boston University, Boston, Massachusetts, United States of America. School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom. Stichting HIV Monitoring, Amsterdam, The Netherlands; Department of Global Health and Division of Infectious Diseases, Academic Medical Center, University of Amsterdam, and Amsterdam Institute for Global health and Development, Amsterdam, the Netherlands. INSERM, Centre INSERM U897 "Epidemiologie et Biostatistique", Bordeaux, France; Universite Bordeaux, Institut de Sante Publique Epidemiologie Developpement (ISPED), Bordeaux, France. Sorbonne Universites, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d\'Epidemiologie et de Sante Publique, Paris, France; INSERM, UMR_S 1136, Institut Pierre Louis d\'Epidemiologie et de Sante Publique, Paris, France. Infectious Diseases Department, San Raffaele Scientific Institute, Milan, Italy. First Department of Internal Medicine, University Hospital of Cologne, Germany. Centre d\'Estudis Epidemiologics sobre les Infeccions de Transmissio Sexual i Sida de Catalunya (CEEISCAT), Institut catala d\'Oncologia (ICO), Agencia Salut Publica de Catalunya (ASPC), Generalitat de Catalunya, Badalona, Spain; CIBER Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain. Division of Infectious Diseases, University of Calgary, Calgary, Canada. Division of Infectious Disease, Department of Medicine, University of Alabama, Birmingham, Alabama, United States of America. Yale University School of Medicine, New Haven, Connecticut, United States of America; VA Connecticut Healthcare System, West Haven, Connecticut, United States of America. HIV Atlanta VA Cohort Study (HAVACS), Atlanta Veterans Affairs Medical Center, Decatur, Georgia, United States of America. Center for AIDS Research, University of Washington, Seattle, Washington, United States of America. Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa; University of Bern, Institute for Social and Preventive Medicine, Bern, Switzerland. School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom.'
p19134
sS'OWN'
p19135
S'NLM'
p19136
sS'PT'
p19137
(lp19138
S'Journal Article'
p19139
aS'Research Support, N.I.H., Extramural'
p19140
aS"Research Support, Non-U.S. Gov't"
p19141
aS"Research Support, U.S. Gov't, Non-P.H.S."
p19142
asS'LA'
p19143
(lp19144
S'eng'
p19145
asS'FAU'
p19146
(lp19147
S'Boulle, Andrew'
p19148
aS'Schomaker, Michael'
p19149
aS'May, Margaret T'
p19150
aS'Hogg, Robert S'
p19151
aS'Shepherd, Bryan E'
p19152
aS'Monge, Susana'
p19153
aS'Keiser, Olivia'
p19154
aS'Lampe, Fiona C'
p19155
aS'Giddy, Janet'
p19156
aS'Ndirangu, James'
p19157
aS'Garone, Daniela'
p19158
aS'Fox, Matthew'
p19159
aS'Ingle, Suzanne M'
p19160
aS'Reiss, Peter'
p19161
aS'Dabis, Francois'
p19162
aS'Costagliola, Dominique'
p19163
aS'Castagna, Antonella'
p19164
aS'Ehren, Kathrin'
p19165
aS'Campbell, Colin'
p19166
aS'Gill, M John'
p19167
aS'Saag, Michael'
p19168
aS'Justice, Amy C'
p19169
aS'Guest, Jodie'
p19170
aS'Crane, Heidi M'
p19171
aS'Egger, Matthias'
p19172
aS'Sterne, Jonathan A C'
p19173
asS'JT'
p19174
S'PLoS medicine'
p19175
sS'LR'
p19176
S'20151222'
p19177
sS'PG'
p19178
S'e1001718'
p19179
sS'TI'
p19180
S'Mortality in patients with HIV-1 infection starting antiretroviral therapy in South Africa, Europe, or North America: a collaborative analysis of prospective studies.'
p19181
sS'RN'
p19182
(lp19183
S'0 (Anti-HIV Agents)'
p19184
asS'PL'
p19185
S'United States'
p19186
sS'TA'
p19187
S'PLoS Med'
p19188
sS'JID'
p19189
S'101231360'
p19190
sS'AB'
p19191
S"BACKGROUND: High early mortality in patients with HIV-1 starting antiretroviral therapy (ART) in sub-Saharan Africa, compared to Europe and North America, is well documented. Longer-term comparisons between settings have been limited by poor ascertainment of mortality in high burden African settings. This study aimed to compare mortality up to four years on ART between South Africa, Europe, and North America. METHODS AND FINDINGS: Data from four South African cohorts in which patients lost to follow-up (LTF) could be linked to the national population register to determine vital status were combined with data from Europe and North America. Cumulative mortality, crude and adjusted (for characteristics at ART initiation) mortality rate ratios (relative to South Africa), and predicted mortality rates were described by region at 0-3, 3-6, 6-12, 12-24, and 24-48 months on ART for the period 2001-2010. Of the adults included (30,467 [South Africa], 29,727 [Europe], and 7,160 [North America]), 20,306 (67%), 9,961 (34%), and 824 (12%) were women. Patients began treatment with markedly more advanced disease in South Africa (median CD4 count 102, 213, and 172 cells/microl in South Africa, Europe, and North America, respectively). High early mortality after starting ART in South Africa occurred mainly in patients starting ART with CD4 count <50 cells/microl. Cumulative mortality at 4 years was 16.6%, 4.7%, and 15.3% in South Africa, Europe, and North America, respectively. Mortality was initially much lower in Europe and North America than South Africa, but the differences were reduced or reversed (North America) at longer durations on ART (adjusted rate ratios 0.46, 95% CI 0.37-0.58, and 1.62, 95% CI 1.27-2.05 between 24 and 48 months on ART comparing Europe and North America to South Africa). While bias due to under-ascertainment of mortality was minimised through death registry linkage, residual bias could still be present due to differing approaches to and frequency of linkage. CONCLUSIONS: After accounting for under-ascertainment of mortality, with increasing duration on ART, the mortality rate on HIV treatment in South Africa declines to levels comparable to or below those described in participating North American cohorts, while substantially narrowing the differential with the European cohorts. Please see later in the article for the Editors' Summary."
p19192
sS'GR'
p19193
(lp19194
S'5U01AI069924-05/AI/NIAID NIH HHS/United States'
p19195
aS'G0700820/Medical Research Council/United Kingdom'
p19196
aS'MR/J002380/1/Medical Research Council/United Kingdom'
p19197
aS'P30 AI027757/AI/NIAID NIH HHS/United States'
p19198
aS'P30 AI54999/AI/NIAID NIH HHS/United States'
p19199
aS'P30-AI027767/AI/NIAID NIH HHS/United States'
p19200
aS'U01 AI069924/AI/NIAID NIH HHS/United States'
p19201
aS'U10-AA13566/AA/NIAAA NIH HHS/United States'
p19202
aS'U24-AA020794/AA/NIAAA NIH HHS/United States'
p19203
aS'Canadian Institutes of Health Research/Canada'
p19204
asS'IP'
p19205
S'9'
sS'IS'
p19206
S'1549-1676 (Electronic) 1549-1277 (Linking)'
p19207
sS'PMC'
p19208
S'PMC4159124'
p19209
sS'DCOM'
p19210
S'20150615'
p19211
sS'AU'
p19212
(lp19213
S'Boulle A'
p19214
aS'Schomaker M'
p19215
aS'May MT'
p19216
aS'Hogg RS'
p19217
aS'Shepherd BE'
p19218
aS'Monge S'
p19219
aS'Keiser O'
p19220
aS'Lampe FC'
p19221
aS'Giddy J'
p19222
aS'Ndirangu J'
p19223
aS'Garone D'
p19224
aS'Fox M'
p19225
aS'Ingle SM'
p19226
aS'Reiss P'
p19227
aS'Dabis F'
p19228
aS'Costagliola D'
p19229
aS'Castagna A'
p19230
aS'Ehren K'
p19231
aS'Campbell C'
p19232
aS'Gill MJ'
p19233
aS'Saag M'
p19234
aS'Justice AC'
p19235
aS'Guest J'
p19236
aS'Crane HM'
p19237
aS'Egger M'
p19238
aS'Sterne JA'
p19239
asS'VI'
p19240
S'11'
p19241
sS'MHDA'
p19242
S'2015/06/16 06:00'
p19243
sS'PHST'
p19244
(lp19245
S'2014/09 [ecollection]'
p19246
aS'2013/12/20 [received]'
p19247
aS'2014/07/24 [accepted]'
p19248
aS'2014/09/09 [epublish]'
p19249
asS'OID'
p19250
(lp19251
S'NLM: PMC4159124'
p19252
asS'MH'
p19253
(lp19254
S'Adult'
p19255
aS'Anti-HIV Agents/therapeutic use'
p19256
aS'Antiretroviral Therapy, Highly Active/*mortality/*trends'
p19257
aS'Cohort Studies'
p19258
aS'*Cooperative Behavior'
p19259
aS'Europe/epidemiology'
p19260
aS'Female'
p19261
aS'Follow-Up Studies'
p19262
aS'HIV Infections/*drug therapy/*mortality'
p19263
aS'*HIV-1'
p19264
aS'Humans'
p19265
aS'Male'
p19266
aS'Middle Aged'
p19267
aS'Mortality/trends'
p19268
aS'North America/epidemiology'
p19269
aS'Prospective Studies'
p19270
aS'South Africa/epidemiology'
p19271
asS'EDAT'
p19272
S'2014/09/10 06:00'
p19273
sS'SO'
p19274
S'PLoS Med. 2014 Sep 9;11(9):e1001718. doi: 10.1371/journal.pmed.1001718. eCollection 2014 Sep.'
p19275
sS'SB'
p19276
S'IM'
p19277
sS'PMID'
p19278
S'25203931'
p19279
sS'PST'
p19280
S'epublish'
p19281
stRp19282
ag2
(g3
g4
(dp19283
S'LID'
p19284
S'10.1186/1471-2334-14-479 [doi]'
p19285
sS'STAT'
p19286
S'MEDLINE'
p19287
sS'DEP'
p19288
S'20140904'
p19289
sS'DA'
p19290
S'20140909'
p19291
sS'AID'
p19292
(lp19293
S'1471-2334-14-479 [pii]'
p19294
aS'10.1186/1471-2334-14-479 [doi]'
p19295
asS'CRDT'
p19296
(lp19297
S'2014/09/05 06:00'
p19298
asS'DP'
p19299
S'2014'
p19300
sS'OWN'
p19301
S'NLM'
p19302
sS'PT'
p19303
(lp19304
S'Journal Article'
p19305
aS"Research Support, Non-U.S. Gov't"
p19306
asS'LA'
p19307
(lp19308
S'eng'
p19309
asS'DCOM'
p19310
S'20141124'
p19311
sS'JT'
p19312
S'BMC infectious diseases'
p19313
sS'LR'
p19314
S'20150804'
p19315
sS'FAU'
p19316
(lp19317
S'Bhembe, Nolwazi L'
p19318
aS'Nwodo, Uchechukwu U'
p19319
aS'Govender, Sharlene'
p19320
aS'Hayes, Cindy'
p19321
aS'Ndip, Roland N'
p19322
aS'Okoh, Anthony I'
p19323
aS'Green, Ezekiel'
p19324
asS'TI'
p19325
S'Molecular detection and characterization of resistant genes in Mycobacterium tuberculosis complex from DNA isolated from tuberculosis patients in the Eastern Cape province South Africa.'
p19326
sS'RN'
p19327
(lp19328
S'0 (Anti-Bacterial Agents)'
p19329
aS'0 (DNA, Bacterial)'
p19330
aS'V83O1VOZ8L (Isoniazid)'
p19331
aS'VJT6J7R4TR (Rifampin)'
p19332
asS'PL'
p19333
S'England'
p19334
sS'PG'
p19335
S'479'
p19336
sS'JID'
p19337
S'100968551'
p19338
sS'AB'
p19339
S'BACKGROUND: Tuberculosis (TB) in both animals and humans is caused by Mycobacterium tuberculosis complex (MTBC) primarily transmitted by inhalation of aerosolized droplets containing the organism. Multi-drug resistance (MDR) and extensive drug resistance (XDR) are evolutionary features of Mycobacterium tuberculosis to subvert the antibiotic regimes in place. The heavy burden of TB worsened by HIV endemic in South Africa motivated for the investigation of MTBC prevalence among TB patients in Port Elizabeth and the amplification and sequencing of the DNA amplicons known to confer resistance to TB drugs. METHODS: Three thousand eight hundred and ten (3810) sputum specimens were processed and DNA was isolated from sputum specimens collected from different hospitals and health care places in the Eastern Cape Province, South Africa. DNA was amplified using the Seeplex(R) MTB Nested ACE detection assay. The agar-dilution proportion method was used to perform drug-sensitivity testing using 7H10 Middlebrook medium. Target genes known to confer resistance to first and second-line drugs were amplified and the amplicons sequenced. RESULTS: One hundred and ninety (5%) DNA samples tested positive for MTBC and from the resistant profiles of the 190 positive samples, we noted that multidrug-resistant TB was identified in 189 (99.5%) with 190 (100%) patients infected with MTB resistant to isoniazid and 189 (99.5%) having MTB resistant to rifampicin. Other percentages of drug resistance observed including 40% pre-XDR and 60% of XDR. CONCLUSION: This study provides valuable data on the different kinds of mutations occurring at various target loci in resistant MTBC strains isolated from samples obtained from the Eastern Cape Province. The results obtained reveal a high incidence of MDR amongst the positive samples from Eastern Cape Province, South Africa.'
p19340
sS'AD'
p19341
S'Department of Biochemistry and Microbiology, Faculty of Science and Agriculture, University of Fort Hare, PMB X1314, Alice 5700, South Africa. egreen@ufh.ac.za.'
p19342
sS'VI'
p19343
S'14'
p19344
sS'IS'
p19345
S'1471-2334 (Electronic) 1471-2334 (Linking)'
p19346
sS'PMC'
p19347
S'PMC4161913'
p19348
sS'AU'
p19349
(lp19350
S'Bhembe NL'
p19351
aS'Nwodo UU'
p19352
aS'Govender S'
p19353
aS'Hayes C'
p19354
aS'Ndip RN'
p19355
aS'Okoh AI'
p19356
aS'Green E'
p19357
asS'MHDA'
p19358
S'2014/12/15 06:00'
p19359
sS'PHST'
p19360
(lp19361
S'2014/04/30 [received]'
p19362
aS'2014/09/01 [accepted]'
p19363
aS'2014/09/04 [aheadofprint]'
p19364
asS'OID'
p19365
(lp19366
S'NLM: PMC4161913'
p19367
asS'MH'
p19368
(lp19369
S'Adolescent'
p19370
aS'Adult'
p19371
aS'Aged'
p19372
aS'Anti-Bacterial Agents/chemistry'
p19373
aS'Child'
p19374
aS'Child, Preschool'
p19375
aS'DNA, Bacterial/isolation & purification'
p19376
aS'Female'
p19377
aS'HIV Infections/drug therapy'
p19378
aS'Humans'
p19379
aS'Infant'
p19380
aS'Infant, Newborn'
p19381
aS'Isoniazid/therapeutic use'
p19382
aS'Male'
p19383
aS'Microbial Sensitivity Tests'
p19384
aS'Middle Aged'
p19385
aS'*Mutation'
p19386
aS'Mycobacterium tuberculosis/*isolation & purification'
p19387
aS'Prevalence'
p19388
aS'Rifampin/therapeutic use'
p19389
aS'South Africa/epidemiology'
p19390
aS'Sputum'
p19391
aS'Tuberculosis, Multidrug-Resistant/*drug therapy/*microbiology'
p19392
aS'Young Adult'
p19393
asS'EDAT'
p19394
S'2014/09/05 06:00'
p19395
sS'SO'
p19396
S'BMC Infect Dis. 2014 Sep 4;14:479. doi: 10.1186/1471-2334-14-479.'
p19397
sS'SB'
p19398
S'IM'
p19399
sS'PMID'
p19400
S'25186245'
p19401
sS'TA'
p19402
S'BMC Infect Dis'
p19403
sS'PST'
p19404
S'epublish'
p19405
stRp19406
ag2
(g3
g4
(dp19407
S'LID'
p19408
S'10.1093/trstmh/tru130 [doi]'
p19409
sS'STAT'
p19410
S'MEDLINE'
p19411
sS'DEP'
p19412
S'20140826'
p19413
sS'CI'
p19414
(lp19415
S'(c) The Author 2014. Published by Oxford University Press on behalf of Royal'
p19416
aS'Society of Tropical Medicine and Hygiene. All rights reserved. For permissions,'
p19417
aS'please e-mail: journals.permissions@oup.com.'
p19418
asS'DA'
p19419
S'20141010'
p19420
sS'AID'
p19421
(lp19422
S'tru130 [pii]'
p19423
aS'10.1093/trstmh/tru130 [doi]'
p19424
asS'CRDT'
p19425
(lp19426
S'2014/08/29 06:00'
p19427
asS'DP'
p19428
S'2014 Nov'
p19429
sS'OWN'
p19430
S'NLM'
p19431
sS'PT'
p19432
(lp19433
S'Journal Article'
p19434
aS"Research Support, Non-U.S. Gov't"
p19435
asS'LA'
p19436
(lp19437
S'eng'
p19438
asS'FAU'
p19439
(lp19440
S'Djarma, Oumaima'
p19441
aS'Nguyen, Yohan'
p19442
aS'Renois, Fanny'
p19443
aS'Djimassal, Alain'
p19444
aS'Banisadr, Firouze'
p19445
aS'Andreoletti, Laurent'
p19446
asS'JT'
p19447
S'Transactions of the Royal Society of Tropical Medicine and Hygiene'
p19448
sS'PG'
p19449
S'735-8'
p19450
sS'TI'
p19451
S"Continuous free access to HAART could be one of the potential factors impacting on loss to follow-up in HAART-eligible patients living in a resource-limited setting: N'djamena, Chad."
p19452
sS'PL'
p19453
S'England'
p19454
sS'TA'
p19455
S'Trans R Soc Trop Med Hyg'
p19456
sS'JID'
p19457
S'7506129'
p19458
sS'AB'
p19459
S'BACKGROUND: Retention of HAART-eligible HIV-infected patients in clinical follow-up systems are now becoming an important issue in sub-Saharan African countries. METHODS: In this retrospective study (April 2008 to November 2011), we assessed the attrition rate variations in a cohort of 509 HAART-eligible patients in Chad. RESULTS: Decrease in levels of loss to follow-up were observed during the implementation of continuous free access to HAART (72.5 vs 10%; p<0.001) and was independent of gender, age, WHO clinical stage and CD4+ T cell count at inclusion and of the time delay to initiate HAART (p>0.48). CONCLUSIONS: These data suggest that the implementation of free access to HAART without any interruption of supply, from autumn 2009, could be the factor that potentially changed the HIV patient attrition rate in this resource-limited setting.'
p19460
sS'AD'
p19461
S"Service de Medecine interne, Hopital Le Bon Samaritain, CHU Walia, N'Djamena, Chad. Laboratoire de Virologie medicale et moleculaire Hopital Robert Debre, CHU Reims & EA-4684, Faculte de Medecine, Reims, France Service de Medecine interne, Maladies infectieuses et Immunologie Clinique, Hopital Robert Debre, CHU Reims, France. Laboratoire de Virologie medicale et moleculaire Hopital Robert Debre, CHU Reims & EA-4684, Faculte de Medecine, Reims, France. Service de Medecine interne, Hopital Le Bon Samaritain, CHU Walia, N'Djamena, Chad. Laboratoire de Virologie medicale et moleculaire Hopital Robert Debre, CHU Reims & EA-4684, Faculte de Medecine, Reims, France Service de Medecine interne, Maladies infectieuses et Immunologie Clinique, Hopital Robert Debre, CHU Reims, France. Service de Medecine interne, Hopital Le Bon Samaritain, CHU Walia, N'Djamena, Chad Laboratoire de Virologie medicale et moleculaire Hopital Robert Debre, CHU Reims & EA-4684, Faculte de Medecine, Reims, France landreoletti@chu-reims.fr."
p19462
sS'IP'
p19463
S'11'
p19464
sS'IS'
p19465
S'1878-3503 (Electronic) 0035-9203 (Linking)'
p19466
sS'DCOM'
p19467
S'20150603'
p19468
sS'AU'
p19469
(lp19470
S'Djarma O'
p19471
aS'Nguyen Y'
p19472
aS'Renois F'
p19473
aS'Djimassal A'
p19474
aS'Banisadr F'
p19475
aS'Andreoletti L'
p19476
asS'VI'
p19477
S'108'
p19478
sS'MHDA'
p19479
S'2015/06/04 06:00'
p19480
sS'PHST'
p19481
(lp19482
S'2014/08/26 [aheadofprint]'
p19483
asS'OTO'
p19484
(lp19485
S'NOTNLM'
p19486
asS'MH'
p19487
(lp19488
S'Adolescent'
p19489
aS'Adult'
p19490
aS'Africa/epidemiology'
p19491
aS'Aged'
p19492
aS'Antiretroviral Therapy, Highly Active/*economics'
p19493
aS'CD4 Lymphocyte Count'
p19494
aS'Chad/epidemiology'
p19495
aS'Cohort Studies'
p19496
aS'Female'
p19497
aS'Follow-Up Studies'
p19498
aS'HIV Infections/*drug therapy/epidemiology'
p19499
aS'Health Services Accessibility/*economics'
p19500
aS'Humans'
p19501
aS'Longitudinal Studies'
p19502
aS'*Lost to Follow-Up'
p19503
aS'Male'
p19504
aS'Middle Aged'
p19505
aS'Resource Allocation/supply & distribution'
p19506
aS'Retrospective Studies'
p19507
aS'Viral Load'
p19508
aS'Young Adult'
p19509
asS'EDAT'
p19510
S'2014/08/29 06:00'
p19511
sS'SO'
p19512
S'Trans R Soc Trop Med Hyg. 2014 Nov;108(11):735-8. doi: 10.1093/trstmh/tru130. Epub 2014 Aug 26.'
p19513
sS'SB'
p19514
S'IM'
p19515
sS'PMID'
p19516
S'25163753'
p19517
sS'OT'
p19518
(lp19519
S'Chad'
p19520
aS'HAART'
p19521
aS'HIV'
p19522
aS'Loss to follow-up'
p19523
aS'Sub-Saharan Africa'
p19524
asS'PST'
p19525
S'ppublish'
p19526
stRp19527
ag2
(g3
g4
(dp19528
S'LID'
p19529
S'10.1128/JCM.02063-14 [doi]'
p19530
sS'STAT'
p19531
S'MEDLINE'
p19532
sS'DEP'
p19533
S'20140820'
p19534
sS'CI'
p19535
(lp19536
S'Copyright (c) 2014, American Society for Microbiology. All Rights Reserved.'
p19537
asS'DA'
p19538
S'20141017'
p19539
sS'AID'
p19540
(lp19541
S'JCM.02063-14 [pii]'
p19542
aS'10.1128/JCM.02063-14 [doi]'
p19543
asS'CRDT'
p19544
(lp19545
S'2014/08/22 06:00'
p19546
asS'DP'
p19547
S'2014 Nov'
p19548
sS'AD'
p19549
S'Division of Global HIV/AIDS, U.S. Centers for Disease Control and Prevention, Windhoek, Namibia ssawadogo@cdc.gov. Namibia Institute of Pathology, Windhoek, Namibia. Division of Global HIV/AIDS, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Division of Global HIV/AIDS, U.S. Centers for Disease Control and Prevention, Windhoek, Namibia. Division of Global HIV/AIDS, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Division of Global HIV/AIDS, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Namibia Institute of Pathology, Windhoek, Namibia. Namibia Institute of Pathology, Windhoek, Namibia. Division of Global HIV/AIDS, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Division of Global HIV/AIDS, U.S. Centers for Disease Control and Prevention, Windhoek, Namibia.'
p19550
sS'OWN'
p19551
S'NLM'
p19552
sS'PT'
p19553
(lp19554
S'Evaluation Studies'
p19555
aS'Journal Article'
p19556
aS"Research Support, Non-U.S. Gov't"
p19557
aS"Research Support, U.S. Gov't, P.H.S."
p19558
asS'LA'
p19559
(lp19560
S'eng'
p19561
asS'FAU'
p19562
(lp19563
S'Sawadogo, Souleymane'
p19564
aS'Shiningavamwe, Andreas'
p19565
aS'Chang, Joy'
p19566
aS'Maher, Andrew D'
p19567
aS'Zhang, Guoqing'
p19568
aS'Yang, Chunfu'
p19569
aS'Gaeb, Esegiel'
p19570
aS'Kaura, Harold'
p19571
aS'Ellenberger, Dennis'
p19572
aS'Lowrance, David W'
p19573
asS'JT'
p19574
S'Journal of clinical microbiology'
p19575
sS'LR'
p19576
S'20150501'
p19577
sS'PG'
p19578
S'3878-83'
p19579
sS'TI'
p19580
S'Limited utility of dried-blood- and plasma spot-based screening for antiretroviral treatment failure with Cobas Ampliprep/TaqMan HIV-1 version 2.0.'
p19581
sS'RN'
p19582
(lp19583
S'0 (Anti-Retroviral Agents)'
p19584
asS'PL'
p19585
S'United States'
p19586
sS'TA'
p19587
S'J Clin Microbiol'
p19588
sS'JID'
p19589
S'7505564'
p19590
sS'AB'
p19591
S'The 2013 WHO antiretroviral therapy (ART) guidelines recommend dried blood spots (DBS) as an alternative specimen type for viral load (VL) monitoring. We assessed the programmatic utility of screening for antiretroviral (ARV) treatment failure (TF) at 5,000 and 1,000 copies/ml using DBS and dried plasma spots (DPS) with a commonly used VL assay, the Roche Cobas Ampliprep/Cobas TaqMan V.2.0 (CAP/CTM). Plasma, DBS, and DPS were prepared from 839 whole-blood specimens collected from patients on ART for >/= 6 months at three public facilities in Namibia. Using the CAP/CTM test, VL were measured in plasma, DBS, and DPS, and the results were compared using the plasma VL as the reference standard. The clinical sensitivities, specificities, and positive (PPV) and negative predictive values (NPV) of DBS at ARV TF diagnostic thresholds of 5,000 copies/ml and 1,000 copies/ml were 0.99, 0.55, 0.33, and 0.99 and 0.99, 0.26, 0.29, and 0.99, respectively, and for DPS at TF diagnostic thresholds of 5,000 copies/ml and 1,000 copies/ml, they were 0.88, 0.98, 0.92, and 0.97 and 0.91, 0.96, 0.89, and 0.97, respectively. The prevalences of TF were overestimated in DBS by 33% and 57% at these two thresholds, respectively. A high rate of false-positive results would occur if the CAP/CTM with DBS were to be used to screen for ARV TF. WHO recommendations for DBS-based VL monitoring should be specific to the VL assay version and type. Despite the better performance of DPS, the programmatic utility for TF screening may be limited by requirements for processing the whole blood at the collection site.'
p19592
sS'GR'
p19593
(lp19594
S'PEPFAR/United States'
p19595
asS'IP'
p19596
S'11'
p19597
sS'IS'
p19598
S'1098-660X (Electronic) 0095-1137 (Linking)'
p19599
sS'PMC'
p19600
S'PMC4313218'
p19601
sS'DCOM'
p19602
S'20151012'
p19603
sS'AU'
p19604
(lp19605
S'Sawadogo S'
p19606
aS'Shiningavamwe A'
p19607
aS'Chang J'
p19608
aS'Maher AD'
p19609
aS'Zhang G'
p19610
aS'Yang C'
p19611
aS'Gaeb E'
p19612
aS'Kaura H'
p19613
aS'Ellenberger D'
p19614
aS'Lowrance DW'
p19615
asS'VI'
p19616
S'52'
p19617
sS'MHDA'
p19618
S'2015/10/13 06:00'
p19619
sS'PHST'
p19620
(lp19621
S'2014/08/20 [aheadofprint]'
p19622
asS'OID'
p19623
(lp19624
S'NLM: PMC4313218'
p19625
asS'MH'
p19626
(lp19627
S'Adolescent'
p19628
aS'Adult'
p19629
aS'Aged'
p19630
aS'Aged, 80 and over'
p19631
aS'Anti-Retroviral Agents/*therapeutic use'
p19632
aS'Blood/*virology'
p19633
aS'Drug Monitoring/*methods'
p19634
aS'Female'
p19635
aS'HIV Infections/*drug therapy'
p19636
aS'HIV-1/genetics/*isolation & purification'
p19637
aS'Humans'
p19638
aS'Male'
p19639
aS'Mass Screening/methods'
p19640
aS'Middle Aged'
p19641
aS'Namibia'
p19642
aS'Sensitivity and Specificity'
p19643
aS'Specimen Handling/*methods'
p19644
aS'Treatment Failure'
p19645
aS'Viral Load/*methods'
p19646
aS'Young Adult'
p19647
asS'EDAT'
p19648
S'2014/08/22 06:00'
p19649
sS'SO'
p19650
S'J Clin Microbiol. 2014 Nov;52(11):3878-83. doi: 10.1128/JCM.02063-14. Epub 2014 Aug 20.'
p19651
sS'SB'
p19652
S'IM'
p19653
sS'PMID'
p19654
S'25143579'
p19655
sS'PST'
p19656
S'ppublish'
p19657
stRp19658
ag2
(g3
g4
(dp19659
S'LID'
p19660
S'10.1097/QAI.0000000000000312 [doi]'
p19661
sS'STAT'
p19662
S'MEDLINE'
p19663
sS'JT'
p19664
S'Journal of acquired immune deficiency syndromes (1999)'
p19665
sS'MID'
p19666
(lp19667
S'NIHMS618891'
p19668
asS'DA'
p19669
S'20141014'
p19670
sS'AID'
p19671
(lp19672
S'10.1097/QAI.0000000000000312 [doi]'
p19673
asS'CRDT'
p19674
(lp19675
S'2014/08/21 06:00'
p19676
asS'DP'
p19677
S'2014 Nov 1'
p19678
sS'AD'
p19679
S"Departments of *Global Health; daggerMedicine; double daggerEpidemiology, University of Washington, Seattle, WA; section signCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA; ||Department of Obstetrics and Gynaecology, University of Nairobi, Nairobi, Kenya; paragraph signDepartment of Biostatistics, University of Washington, Seattle, WA; #Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA; **Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA; daggerdaggerCoptic Hospital, Nairobi, Kenya; Departments of double daggerdouble daggerPediatrics; and section sign section signLaboratory Medicine, University of Washington, Seattle, WA."
p19680
sS'OWN'
p19681
S'NLM'
p19682
sS'PT'
p19683
(lp19684
S'Journal Article'
p19685
aS'Research Support, American Recovery and Reinvestment Act'
p19686
aS'Research Support, N.I.H., Extramural'
p19687
aS"Research Support, U.S. Gov't, P.H.S."
p19688
asS'LA'
p19689
(lp19690
S'eng'
p19691
asS'FAU'
p19692
(lp19693
S'Chung, Michael H'
p19694
aS'Beck, Ingrid A'
p19695
aS'Dross, Sandra'
p19696
aS'Tapia, Kenneth'
p19697
aS'Kiarie, James N'
p19698
aS'Richardson, Barbra A'
p19699
aS'Overbaugh, Julie'
p19700
aS'Sakr, Samah R'
p19701
aS'John-Stewart, Grace C'
p19702
aS'Frenkel, Lisa M'
p19703
asS'LR'
p19704
S'20151119'
p19705
sS'PG'
p19706
S'246-53'
p19707
sS'TI'
p19708
S'Oligonucleotide ligation assay detects HIV drug resistance associated with virologic failure among antiretroviral-naive adults in Kenya.'
p19709
sS'RN'
p19710
(lp19711
S'0 (Anti-HIV Agents)'
p19712
aS'0 (DNA, Viral)'
p19713
aS'0 (Oligonucleotide Probes)'
p19714
aS'0 (Reverse Transcriptase Inhibitors)'
p19715
asS'PL'
p19716
S'United States'
p19717
sS'TA'
p19718
S'J Acquir Immune Defic Syndr'
p19719
sS'JID'
p19720
S'100892005'
p19721
sS'AB'
p19722
S'BACKGROUND: Transmitted drug resistance (TDR) is increasing in some areas of Africa. Detection of TDR may predict virologic failure of first-line nonnucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy (ART). We evaluated the utility of a relatively inexpensive oligonucleotide ligation assay (OLA) to detect clinically relevant TDR at the time of ART initiation. METHODS: Pre-ART plasmas from ART-naive Kenyans initiating an NNRTI-based fixed-dose combination ART in a randomized adherence trial conducted in 2006 were retrospectively analyzed by OLA for mutations conferring resistance to NNRTI (K103N, Y181C, and G190A) and lamivudine (M184V). Post-ART plasmas were analyzed for virologic failure (>/=1000 copies/mL) at 6-month intervals over 18-month follow-up. Pre-ART plasmas of those with virologic failure were evaluated for drug resistance by consensus and 454-pyrosequencing. RESULTS: Among 386 participants, TDR was detected by OLA in 3.89% (95% confidence interval: 2.19 to 6.33) and was associated with a 10-fold higher rate of virologic failure (hazard ratio: 10.39; 95% confidence interval: 3.23 to 32.41; P < 0.001) compared with those without TDR. OLA detected 24 TDR mutations (K103N: n = 13; Y181C: n = 5; G190A: n = 3; M184V: n = 3) in 15 subjects (NNRTI: n = 15; 3TC: n = 3). Among 51 participants who developed virologic failure, consensus sequencing did not detect additional TDR mutations conferring high-level resistance, and pyrosequencing only detected additional mutations at frequencies <2%. Mutant frequencies <2% at ART initiation were significantly less likely to be found at the time of virologic failure compared with frequencies >/=2% (22% vs. 63%; P < 0.001). CONCLUSIONS: Detection of TDR by a point mutation assay may prevent the use of suboptimal ART.'
p19723
sS'GR'
p19724
(lp19725
S'K23 AI065222/AI/NIAID NIH HHS/United States'
p19726
aS'K23-AI065222/AI/NIAID NIH HHS/United States'
p19727
aS'K24 HD054314/HD/NICHD NIH HHS/United States'
p19728
aS'P30 AI027757/AI/NIAID NIH HHS/United States'
p19729
aS'P30AI027757/AI/NIAID NIH HHS/United States'
p19730
aS'R01 AI058723/AI/NIAID NIH HHS/United States'
p19731
aS'R01-AI058723/AI/NIAID NIH HHS/United States'
p19732
aS'U62/CCU024512/PHS HHS/United States'
p19733
asS'IP'
p19734
S'3'
sS'IS'
p19735
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p19736
sS'PMC'
p19737
S'PMC4197120'
p19738
sS'DCOM'
p19739
S'20141215'
p19740
sS'AU'
p19741
(lp19742
S'Chung MH'
p19743
aS'Beck IA'
p19744
aS'Dross S'
p19745
aS'Tapia K'
p19746
aS'Kiarie JN'
p19747
aS'Richardson BA'
p19748
aS'Overbaugh J'
p19749
aS'Sakr SR'
p19750
aS'John-Stewart GC'
p19751
aS'Frenkel LM'
p19752
asS'VI'
p19753
S'67'
p19754
sS'MHDA'
p19755
S'2014/12/17 06:00'
p19756
sS'OID'
p19757
(lp19758
S'NLM: NIHMS618891'
p19759
aS'NLM: PMC4197120'
p19760
asS'MH'
p19761
(lp19762
S'Adult'
p19763
aS'Anti-HIV Agents/*therapeutic use'
p19764
aS'*Antiretroviral Therapy, Highly Active'
p19765
aS'DNA, Viral/analysis'
p19766
aS'*Drug Resistance, Viral'
p19767
aS'Female'
p19768
aS'HIV Infections/*drug therapy/virology'
p19769
aS'HIV-1/*drug effects/genetics/isolation & purification'
p19770
aS'Humans'
p19771
aS'Kenya'
p19772
aS'Ligase Chain Reaction/methods'
p19773
aS'Male'
p19774
aS'Middle Aged'
p19775
aS'Molecular Diagnostic Techniques/*methods'
p19776
aS'Mutation'
p19777
aS'Oligonucleotide Probes/genetics'
p19778
aS'Retrospective Studies'
p19779
aS'Reverse Transcriptase Inhibitors/*therapeutic use'
p19780
aS'Treatment Failure'
p19781
aS'Viral Load'
p19782
asS'EDAT'
p19783
S'2014/08/21 06:00'
p19784
sS'SO'
p19785
S'J Acquir Immune Defic Syndr. 2014 Nov 1;67(3):246-53. doi: 10.1097/QAI.0000000000000312.'
p19786
sS'SB'
p19787
S'IM X'
p19788
sS'PMID'
p19789
S'25140907'
p19790
sS'PST'
p19791
S'ppublish'
p19792
stRp19793
ag2
(g3
g4
(dp19794
S'LID'
p19795
S'10.7448/IAS.17.1.18957 [doi]'
p19796
sS'STAT'
p19797
S'MEDLINE'
p19798
sS'DEP'
p19799
S'20140814'
p19800
sS'DA'
p19801
S'20140818'
p19802
sS'AID'
p19803
(lp19804
S'18957 [pii]'
p19805
asS'CRDT'
p19806
(lp19807
S'2014/08/19 06:00'
p19808
asS'DP'
p19809
S'2014'
p19810
sS'GR'
p19811
(lp19812
S'R01 AI100762/AI/NIAID NIH HHS/United States'
p19813
aS'R01 AI102710/AI/NIAID NIH HHS/United States'
p19814
aS'R01AI100762/AI/NIAID NIH HHS/United States'
p19815
aS'U01 AI069911/AI/NIAID NIH HHS/United States'
p19816
aS'U01AI069911/AI/NIAID NIH HHS/United States'
p19817
aS'UL1 TR001108/TR/NCATS NIH HHS/United States'
p19818
aS'Wellcome Trust/United Kingdom'
p19819
asS'OWN'
p19820
S'NLM'
p19821
sS'PT'
p19822
(lp19823
S'Journal Article'
p19824
aS'Research Support, N.I.H., Extramural'
p19825
aS"Research Support, Non-U.S. Gov't"
p19826
asS'LA'
p19827
(lp19828
S'eng'
p19829
asS'DCOM'
p19830
S'20150304'
p19831
sS'JT'
p19832
S'Journal of the International AIDS Society'
p19833
sS'LR'
p19834
S'20160227'
p19835
sS'FAU'
p19836
(lp19837
S'Kiragga, Agnes N'
p19838
aS'Lok, Judith J'
p19839
aS'Musick, Beverly S'
p19840
aS'Bosch, Ronald J'
p19841
aS'Mwangi, Ann'
p19842
aS'Wools-Kaloustian, Kara K'
p19843
aS'Yiannoutsos, Constantin T'
p19844
asS'TI'
p19845
S'CD4 trajectory adjusting for dropout among HIV-positive patients receiving combination antiretroviral therapy in an East African HIV care centre.'
p19846
sS'RN'
p19847
(lp19848
S'0 (Anti-Retroviral Agents)'
p19849
asS'PL'
p19850
S'Switzerland'
p19851
sS'PG'
p19852
S'18957'
p19853
sS'JID'
p19854
S'101478566'
p19855
sS'AB'
p19856
S'OBJECTIVE: Estimates of CD4 response to antiretroviral therapy (ART) obtained by averaging data from patients in care, overestimate population CD4 response and treatment program effectiveness because they do not consider data from patients who are deceased or not in care. We use mathematical methods to assess and adjust for this bias based on patient characteristics. DESIGN: We examined data from 25,261 HIV-positive patients from the East Africa IeDEA Consortium. METHODS: We used inverse probability of censoring weighting (IPCW) to represent patients not in care by patients in care with similar characteristics. We address two questions: What would the median CD4 be "had everyone starting ART remained on observation?" and "were everyone starting ART maintained on treatment?" RESULTS: Routine CD4 count estimates were higher than adjusted estimates even under the best-case scenario of maintaining all patients on treatment. Two years after starting ART, differences between estimates diverged from 30 cells/microL, assuming similar mortality and treatment access among dropouts as patients in care, to over 100 cells/microL assuming 20% lower survival and 50% lower treatment access among dropouts. When considering only patients in care, the proportion of patients with CD4 above 350 cells/microL was 50% adjusted to below 30% when accounting for patients not in care. One-year mortality diverged 6-14% from the naive estimates depending on assumptions about access to care among lost patients. CONCLUSIONS: Ignoring mortality and loss to care results in over-estimation of ART response for patients starting treatment and exaggerates the efficacy of treatment programs administering it.'
p19857
sS'AD'
p19858
S'Infectious Diseases Institute, Kampala, Uganda. Department of Biostatistics, Harvard School of Public Health, Boston, MA, USA. Department of Biostatistics, Indiana University School of Medicine, Indianapolis, IN, USA. Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA, USA. School of Medicine, Moi University, Eldoret, Kenya. Division of Infectious Diseases, Indiana University School of Medicine, Indianapolis, IN, USA. Department of Biostatistics, Fairbanks School of Public Health, Indiana University, Indianapolis, IN, USA; cyiannou@iupui.edu.'
p19859
sS'CN'
p19860
(lp19861
S'East Africa IeDEA Regional Consortium'
p19862
asS'VI'
p19863
S'17'
p19864
sS'IS'
p19865
S'1758-2652 (Electronic) 1758-2652 (Linking)'
p19866
sS'PMC'
p19867
S'PMC4136415'
p19868
sS'AU'
p19869
(lp19870
S'Kiragga AN'
p19871
aS'Lok JJ'
p19872
aS'Musick BS'
p19873
aS'Bosch RJ'
p19874
aS'Mwangi A'
p19875
aS'Wools-Kaloustian KK'
p19876
aS'Yiannoutsos CT'
p19877
asS'MHDA'
p19878
S'2015/03/05 06:00'
p19879
sS'PHST'
p19880
(lp19881
S'2014 [ecollection]'
p19882
aS'2013/11/11 [received]'
p19883
aS'2014/05/09 [revised]'
p19884
aS'2014/06/11 [accepted]'
p19885
asS'OT'
p19886
(lp19887
S'CD4 count'
p19888
aS'HIV/AIDS'
p19889
aS'IPCW'
p19890
aS'Mathematical modeling'
p19891
aS'Resource-limited setting'
p19892
aS'sub-Saharan Africa'
p19893
asS'OTO'
p19894
(lp19895
S'NOTNLM'
p19896
asS'OID'
p19897
(lp19898
S'NLM: PMC4136415'
p19899
asS'MH'
p19900
(lp19901
S'Adolescent'
p19902
aS'Adult'
p19903
aS'Africa, Eastern'
p19904
aS'Anti-Retroviral Agents/*therapeutic use'
p19905
aS'CD4 Lymphocyte Count'
p19906
aS'CD4-Positive T-Lymphocytes/*immunology'
p19907
aS'Female'
p19908
aS'HIV Infections/*drug therapy/*immunology'
p19909
aS'Humans'
p19910
aS'Male'
p19911
aS'Models, Theoretical'
p19912
aS'*Patient Dropouts'
p19913
aS'Treatment Outcome'
p19914
aS'Young Adult'
p19915
asS'EDAT'
p19916
S'2014/08/19 06:00'
p19917
sS'SO'
p19918
S'J Int AIDS Soc. 2014 Aug 14;17:18957. doi: 10.7448/IAS.17.1.18957. eCollection 2014.'
p19919
sS'SB'
p19920
S'IM X'
p19921
sS'PMID'
p19922
S'25131801'
p19923
sS'TA'
p19924
S'J Int AIDS Soc'
p19925
sS'PST'
p19926
S'epublish'
p19927
stRp19928
ag2
(g3
g4
(dp19929
S'LID'
p19930
S'10.1111/hiv.12177 [doi]'
p19931
sS'STAT'
p19932
S'MEDLINE'
p19933
sS'DEP'
p19934
S'20140815'
p19935
sS'CI'
p19936
(lp19937
S'(c) 2014 British HIV Association.'
p19938
asS'DA'
p19939
S'20150119'
p19940
sS'AID'
p19941
(lp19942
S'10.1111/hiv.12177 [doi]'
p19943
asS'CRDT'
p19944
(lp19945
S'2014/08/16 06:00'
p19946
asS'DP'
p19947
S'2015 Feb'
p19948
sS'AD'
p19949
S'U.S. Military HIV Research Program (MHRP), Global Health Programs, Walter Reed Army Institute of Research, Bethesda, MD, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.'
p19950
sS'OWN'
p19951
S'NLM'
p19952
sS'PT'
p19953
(lp19954
S'Journal Article'
p19955
aS'Multicenter Study'
p19956
aS'Observational Study'
p19957
aS'Randomized Controlled Trial'
p19958
aS"Research Support, Non-U.S. Gov't"
p19959
aS"Research Support, U.S. Gov't, Non-P.H.S."
p19960
asS'LA'
p19961
(lp19962
S'eng'
p19963
asS'FAU'
p19964
(lp19965
S'Crawford, K W'
p19966
aS'Wakabi, S'
p19967
aS'Magala, F'
p19968
aS'Kibuuka, H'
p19969
aS'Liu, M'
p19970
aS'Hamm, T E'
p19971
asS'JT'
p19972
S'HIV medicine'
p19973
sS'PG'
p19974
S'95-104'
p19975
sS'TI'
p19976
S"Evaluation of treatment outcomes for patients on first-line regimens in US President's Emergency Plan for AIDS Relief (PEPFAR) clinics in Uganda: predictors of virological and immunological response from RV288 analyses."
p19977
sS'RN'
p19978
(lp19979
S'0 (Anti-HIV Agents)'
p19980
aS'0 (RNA, Viral)'
p19981
asS'PL'
p19982
S'England'
p19983
sS'TA'
p19984
S'HIV Med'
p19985
sS'JID'
p19986
S'100897392'
p19987
sS'AB'
p19988
S"OBJECTIVES: Viral load (VL) monitoring is recommended, but seldom performed, in resource-constrained countries. RV288 is a US President's Emergency Plan for AIDS Relief (PEPFAR) basic programme evaluation to determine the proportion of patients on treatment who are virologically suppressed and to identify predictors of virological suppression and recovery of CD4 cell count. Analyses from Uganda are presented here. METHODS: In this cross-sectional, observational study, patients on first-line antiretroviral therapy (ART) (efavirenz or nevirapine+zidovudine/lamivudine) from Kayunga District Hospital and Kagulamira Health Center were randomly selected for a study visit that included determination of viral load (HIV-1 RNA), CD4 cell count and clinical chemistry tests. Subjects were recruited by time on treatment: 6-12, 13-24 or >24 months. Logistic regression modelling identified predictors of virological suppression. Linear regression modelling identified predictors of CD4 cell count recovery on ART. RESULTS: We found that 85.2% of 325 subjects were virologically suppressed (viral load<47 HIV-1 RNA copies/ml). There was no difference in the proportion of virologically suppressed subjects by time on treatment, yet CD4 counts were higher in each successive stratum. Women had higher median CD4 counts than men overall (406 vs. 294 cells/muL, respectively; P<0.0001) and in each time-on-treatment stratum. In a multivariate logistic regression model, predictors of virological suppression included efavirenz use [odds ratio (OR) 0.47; 95% confidence interval (CI) 0.22-1.02; P=0.057], lower cost of clinic visits (OR 0.815; 95% CI 0.66-1.00; P=0.05), improvement in CD4 percentage (OR 1.06; 95% CI 1.014-1.107; P=0.009), and care at Kayunga vs. Kangulamira (OR 0.47; 95% CI 0.23-0.92; P=0.035). In a multivariate linear regression model of covariates associated with CD4 count recovery, time on highly active antiretroviral therapy (ART) (P<0.0001), patient satisfaction with care (P=0.038), improvements in total lymphocyte count (P<0.0001) and haemoglobin concentration (P=0.05) were positively associated, whereas age at start of ART (P=0.0045) was negatively associated with this outcome. CONCLUSIONS: High virological suppression rates are achievable on first-line ART in Uganda. The odds of virological suppression were positively associated with efavirenz use and improvements in CD4 cell percentage and total lymphocyte count and negatively associated with the cost of travel to the clinic. CD4 cell reconstitution was positively associated with CD4 count at study visit, time on ART, satisfaction with care at clinic, haemoglobin concentration and total lymphocyte count and negatively associated with age."
p19989
sS'GR'
p19990
(lp19991
S'PEPFAR/United States'
p19992
asS'IP'
p19993
S'2'
sS'IS'
p19994
S'1468-1293 (Electronic) 1464-2662 (Linking)'
p19995
sS'DCOM'
p19996
S'20150825'
p19997
sS'AU'
p19998
(lp19999
S'Crawford KW'
p20000
aS'Wakabi S'
p20001
aS'Magala F'
p20002
aS'Kibuuka H'
p20003
aS'Liu M'
p20004
aS'Hamm TE'
p20005
asS'VI'
p20006
S'16'
p20007
sS'MHDA'
p20008
S'2015/08/26 06:00'
p20009
sS'PHST'
p20010
(lp20011
S'2014/05/11 [accepted]'
p20012
aS'2014/08/15 [aheadofprint]'
p20013
asS'OTO'
p20014
(lp20015
S'NOTNLM'
p20016
asS'MH'
p20017
(lp20018
S'Acquired Immunodeficiency Syndrome/*drug therapy/immunology/transmission'
p20019
aS'Adult'
p20020
aS'Age Factors'
p20021
aS'Anti-HIV Agents/*administration & dosage'
p20022
aS'CD4 Lymphocyte Count/methods'
p20023
aS'Cross-Sectional Studies'
p20024
aS'Delivery of Health Care/*organization & administration'
p20025
aS'Disease Progression'
p20026
aS'Drug Administration Schedule'
p20027
aS'Drug Therapy, Combination'
p20028
aS'Female'
p20029
aS'Government Programs/*organization & administration'
p20030
aS'Humans'
p20031
aS'International Cooperation'
p20032
aS'Male'
p20033
aS'Medication Adherence/statistics & numerical data'
p20034
aS'Middle Aged'
p20035
aS'*National Institutes of Health (U.S.)'
p20036
aS'Organizations, Nonprofit/organization & administration'
p20037
aS'Program Evaluation'
p20038
aS'RNA, Viral/drug effects/isolation & purification'
p20039
aS'Treatment Outcome'
p20040
aS'Uganda/epidemiology'
p20041
aS'United States'
p20042
aS'Viral Load/drug effects'
p20043
asS'EDAT'
p20044
S'2014/08/16 06:00'
p20045
sS'SO'
p20046
S'HIV Med. 2015 Feb;16(2):95-104. doi: 10.1111/hiv.12177. Epub 2014 Aug 15.'
p20047
sS'SB'
p20048
S'IM'
p20049
sS'PMID'
p20050
S'25124078'
p20051
sS'OT'
p20052
(lp20053
S"US President's Emergency Plan for AIDS Relief (PEPFAR)"
p20054
aS'Uganda'
p20055
aS'first-line regimen'
p20056
aS'sub-Saharan Africa'
p20057
aS'treatment outcomes'
p20058
aS'virological suppression'
p20059
asS'PST'
p20060
S'ppublish'
p20061
stRp20062
ag2
(g3
g4
(dp20063
S'LID'
p20064
S'10.1128/JCM.01989-14 [doi]'
p20065
sS'STAT'
p20066
S'MEDLINE'
p20067
sS'DEP'
p20068
S'20140813'
p20069
sS'CI'
p20070
(lp20071
S'Copyright (c) 2014, American Society for Microbiology. All Rights Reserved.'
p20072
asS'DA'
p20073
S'20140917'
p20074
sS'AID'
p20075
(lp20076
S'JCM.01989-14 [pii]'
p20077
aS'10.1128/JCM.01989-14 [doi]'
p20078
asS'CRDT'
p20079
(lp20080
S'2014/08/15 06:00'
p20081
asS'DP'
p20082
S'2014 Oct'
p20083
sS'AD'
p20084
S'Division of Global HIV/AIDS, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. ICAP, Mailman School of Public Health, Columbia University, New York, New York, USA. Division of Global HIV/AIDS, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Division of Global HIV/AIDS, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. ICAP, Mailman School of Public Health, Columbia University, New York, New York, USA. Ministry of Health, Mbabane, Swaziland. Division of Global HIV/AIDS, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. ICAP, Mailman School of Public Health, Columbia University, New York, New York, USA. Statistical Center for HIV/AIDS Research and Prevention (SCHARP), Fred Hutchison Cancer Research Center, Seattle, Washington, USA. Statistical Center for HIV/AIDS Research and Prevention (SCHARP), Fred Hutchison Cancer Research Center, Seattle, Washington, USA. Division of Global HIV/AIDS, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Division of Global HIV/AIDS, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Ministry of Health, Mbabane, Swaziland. ICAP, Mailman School of Public Health, Columbia University, New York, New York, USA. Division of Global HIV/AIDS, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Centers for Disease Control and Prevention, Mbabane, Swaziland. Division of Global HIV/AIDS, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Division of Global HIV/AIDS, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Division of Global HIV/AIDS, Centers for Disease Control and Prevention, Atlanta, Georgia, USA bparekh@cdc.gov.'
p20085
sS'OWN'
p20086
S'NLM'
p20087
sS'PT'
p20088
(lp20089
S'Evaluation Studies'
p20090
aS'Journal Article'
p20091
aS"Research Support, U.S. Gov't, P.H.S."
p20092
asS'LA'
p20093
(lp20094
S'eng'
p20095
asS'FAU'
p20096
(lp20097
S'Duong, Yen T'
p20098
aS'Mavengere, Yvonne'
p20099
aS'Patel, Hetal'
p20100
aS'Moore, Carole'
p20101
aS'Manjengwa, Julius'
p20102
aS'Sibandze, Dumile'
p20103
aS'Rasberry, Christopher'
p20104
aS'Mlambo, Charmaine'
p20105
aS'Li, Zhi'
p20106
aS'Emel, Lynda'
p20107
aS'Bock, Naomi'
p20108
aS'Moore, Jan'
p20109
aS'Nkambule, Rejoice'
p20110
aS'Justman, Jessica'
p20111
aS'Reed, Jason'
p20112
aS'Bicego, George'
p20113
aS'Ellenberger, Dennis L'
p20114
aS'Nkengasong, John N'
p20115
aS'Parekh, Bharat S'
p20116
asS'JT'
p20117
S'Journal of clinical microbiology'
p20118
sS'LR'
p20119
S'20150401'
p20120
sS'PG'
p20121
S'3743-8'
p20122
sS'TI'
p20123
S'Poor performance of the determine HIV-1/2 Ag/Ab combo fourth-generation rapid test for detection of acute infections in a National Household Survey in Swaziland.'
p20124
sS'RN'
p20125
(lp20126
S'0 (HIV Antibodies)'
p20127
aS'0 (HIV Antigens)'
p20128
asS'PL'
p20129
S'United States'
p20130
sS'TA'
p20131
S'J Clin Microbiol'
p20132
sS'JID'
p20133
S'7505564'
p20134
sS'AB'
p20135
S'Fourth-generation HIV rapid tests (RTs) claim to detect both p24 antigen (Ag) and HIV antibodies (Ab) for early identification of acute infections, important for targeting prevention and reducing HIV transmission. In a nationally representative household survey in Swaziland, 18,172 adults, age 18 to 49 years, received home-based HIV rapid testing in 2010 and 2011. Of the 18,172 individuals, 5,822 (32.0%) were Ab positive (Ab(+)) by the Determine HIV-1/2 Ab/Ab combo test, and 5,789 (99.4%) of those were confirmed to be reactive in the Uni-Gold test. Determine combo identified 12 individuals as having acute infections (Ag(+)/Ab negative [Ab(-)]); however, none had detectable HIV-1 RNA and 8 of 12 remained HIV negative at their 6-week follow-up visit (4 were lost to follow-up). All RT-nonreactive samples were pooled and tested by nucleic acid amplification testing (NAAT) to identify acute infections. NAAT identified 13 (0.1%) of the 12,338 HIV antibody-negative specimens as HIV RNA positive, with RNA levels ranging from 300 to >10,000,000 copies/ml. However, none of them were Ag(+) by Determine combo. Follow-up testing of 12 of the 13 NAAT-positive individuals at 6 months demonstrated 12 seroconversions (1 individual was lost to follow-up). Therefore, the Determine combo test had a sensitivity of 0% (95% confidence interval, 0 to 28) and positive predictive value of 0% for the detection of acute infections. The ability of the 4th-generation Determine combo to detect antigen was very poor in Swaziland. Thus, the Determine combo test does not add any value to the current testing algorithm; rather, it adds additional costs and complexity to HIV diagnosis. The detection of acute HIV infections may need to rely on other testing strategies.'
p20136
sS'GR'
p20137
(lp20138
S'5U2GPS002005/PHS HHS/United States'
p20139
asS'IP'
p20140
S'10'
p20141
sS'IS'
p20142
S'1098-660X (Electronic) 0095-1137 (Linking)'
p20143
sS'PMC'
p20144
S'PMC4187782'
p20145
sS'DCOM'
p20146
S'20151014'
p20147
sS'AU'
p20148
(lp20149
S'Duong YT'
p20150
aS'Mavengere Y'
p20151
aS'Patel H'
p20152
aS'Moore C'
p20153
aS'Manjengwa J'
p20154
aS'Sibandze D'
p20155
aS'Rasberry C'
p20156
aS'Mlambo C'
p20157
aS'Li Z'
p20158
aS'Emel L'
p20159
aS'Bock N'
p20160
aS'Moore J'
p20161
aS'Nkambule R'
p20162
aS'Justman J'
p20163
aS'Reed J'
p20164
aS'Bicego G'
p20165
aS'Ellenberger DL'
p20166
aS'Nkengasong JN'
p20167
aS'Parekh BS'
p20168
asS'VI'
p20169
S'52'
p20170
sS'MHDA'
p20171
S'2015/10/16 06:00'
p20172
sS'PHST'
p20173
(lp20174
S'2014/08/13 [aheadofprint]'
p20175
asS'OID'
p20176
(lp20177
S'NLM: PMC4187782'
p20178
asS'MH'
p20179
(lp20180
S'Adolescent'
p20181
aS'Adult'
p20182
aS'Cross-Sectional Studies'
p20183
aS'Family Characteristics'
p20184
aS'Female'
p20185
aS'HIV Antibodies/*blood'
p20186
aS'HIV Antigens/*blood'
p20187
aS'HIV Infections/*diagnosis'
p20188
aS'HIV-1/*immunology'
p20189
aS'HIV-2/*immunology'
p20190
aS'Humans'
p20191
aS'Male'
p20192
aS'Middle Aged'
p20193
aS'Predictive Value of Tests'
p20194
aS'Sensitivity and Specificity'
p20195
aS'Swaziland'
p20196
aS'Time Factors'
p20197
aS'Young Adult'
p20198
asS'EDAT'
p20199
S'2014/08/15 06:00'
p20200
sS'SO'
p20201
S'J Clin Microbiol. 2014 Oct;52(10):3743-8. doi: 10.1128/JCM.01989-14. Epub 2014 Aug 13.'
p20202
sS'SB'
p20203
S'IM'
p20204
sS'PMID'
p20205
S'25122853'
p20206
sS'PST'
p20207
S'ppublish'
p20208
stRp20209
ag2
(g3
g4
(dp20210
S'LID'
p20211
S'10.1177/0956462414548460 [doi]'
p20212
sS'STAT'
p20213
S'MEDLINE'
p20214
sS'DEP'
p20215
S'20140813'
p20216
sS'CI'
p20217
(lp20218
S'(c) The Author(s) 2014.'
p20219
asS'DA'
p20220
S'20150703'
p20221
sS'AID'
p20222
(lp20223
S'0956462414548460 [pii]'
p20224
aS'10.1177/0956462414548460 [doi]'
p20225
asS'CRDT'
p20226
(lp20227
S'2014/08/15 06:00'
p20228
asS'DP'
p20229
S'2015 Aug'
p20230
sS'OWN'
p20231
S'NLM'
p20232
sS'PT'
p20233
(lp20234
S'Journal Article'
p20235
aS"Research Support, Non-U.S. Gov't"
p20236
asS'LA'
p20237
(lp20238
S'eng'
p20239
asS'FAU'
p20240
(lp20241
S'Pettersen, Pernille S'
p20242
aS'Brox, Ida K'
p20243
aS'Naman, Ezra'
p20244
aS'Bruun, Johan N'
p20245
aS'Dyrhol-Riise, Anne M'
p20246
aS'Troseid, Marius'
p20247
aS'Johannessen, Asgeir'
p20248
asS'JT'
p20249
S'International journal of STD & AIDS'
p20250
sS'PG'
p20251
S'633-9'
p20252
sS'TI'
p20253
S'Antiretroviral treatment failure predicts mortality in rural Tanzania.'
p20254
sS'RN'
p20255
(lp20256
S'0 (Anti-HIV Agents)'
p20257
asS'PL'
p20258
S'England'
p20259
sS'TA'
p20260
S'Int J STD AIDS'
p20261
sS'JID'
p20262
S'9007917'
p20263
sS'AB'
p20264
S'Virological monitoring of HIV-infected patients on antiretroviral treatment (ART) is rarely available in resource-limited settings and many patients experience unrecognized virological failure. We studied the long-term consequences of virological failure in rural Tanzania. Previously, virological efficacy was measured in a cohort treated with ART. In the present study, patients with virological failure (VF; HIV-RNA >400 copies/ml) were followed up and compared to those with virological response (VR; HIV-RNA <400 copies/ml) with regard to mortality, CD4 change and subsequent virological outcome. Fifty-six patients with VF had a median CD4 count of 358 cells/microl (interquartile range [IQR] 223-635) and a median HIV-RNA of 13,573 copies/ml (IQR 2326-129,736). Median CD4 count for those with VR was 499 cells/microl (IQR 290-636). During a median follow-up time of 39 months (IQR 18-42), 8 of 56 patients (14.3%) with VF died, compared to 1 of 63 patients (1.6%) with VR (p = 0.009). All registered deaths were HIV-related. Of 55 patients with subsequent HIV-RNA measurements, only 12 of 30 (40%) patients with VF achieved virological suppression, compared to 20 of 25 (80%) patients with VR (p = 0.003). Virological failure predicted death and subsequent virological failure in patients on ART in a resource-limited setting.'
p20265
sS'AD'
p20266
S'Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. HIV Care and Treatment Center, Haydom Lutheran Hospital, Mbulu, Tanzania. University Hospital of Northern Norway, Tromso, Norway. Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway. Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway. Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway Vestre Viken HF, Drammen Hospital, Drammen, Norway johannessen.asgeir@gmail.com.'
p20267
sS'IP'
p20268
S'9'
sS'IS'
p20269
S'1758-1052 (Electronic) 0956-4624 (Linking)'
p20270
sS'DCOM'
p20271
S'20160518'
p20272
sS'AU'
p20273
(lp20274
S'Pettersen PS'
p20275
aS'Brox IK'
p20276
aS'Naman E'
p20277
aS'Bruun JN'
p20278
aS'Dyrhol-Riise AM'
p20279
aS'Troseid M'
p20280
aS'Johannessen A'
p20281
asS'VI'
p20282
S'26'
p20283
sS'MHDA'
p20284
S'2016/05/19 06:00'
p20285
sS'PHST'
p20286
(lp20287
S'2014/04/02 [received]'
p20288
aS'2014/07/24 [accepted]'
p20289
aS'2014/08/13 [aheadofprint]'
p20290
asS'OTO'
p20291
(lp20292
S'NOTNLM'
p20293
asS'MH'
p20294
(lp20295
S'Adolescent'
p20296
aS'Adult'
p20297
aS'Anti-HIV Agents/*therapeutic use'
p20298
aS'*Antiretroviral Therapy, Highly Active'
p20299
aS'CD4 Lymphocyte Count'
p20300
aS'Drug Resistance, Viral/genetics'
p20301
aS'Female'
p20302
aS'Follow-Up Studies'
p20303
aS'HIV Infections/*drug therapy/mortality/virology'
p20304
aS'HIV-1/drug effects/genetics'
p20305
aS'Humans'
p20306
aS'Male'
p20307
aS'Middle Aged'
p20308
aS'Risk Factors'
p20309
aS'Rural Population'
p20310
aS'Tanzania/epidemiology'
p20311
aS'Treatment Failure'
p20312
aS'Viral Load'
p20313
aS'Young Adult'
p20314
asS'EDAT'
p20315
S'2014/08/15 06:00'
p20316
sS'SO'
p20317
S'Int J STD AIDS. 2015 Aug;26(9):633-9. doi: 10.1177/0956462414548460. Epub 2014 Aug 13.'
p20318
sS'SB'
p20319
S'IM X'
p20320
sS'PMID'
p20321
S'25122578'
p20322
sS'OT'
p20323
(lp20324
S'AIDS'
p20325
aS'ART'
p20326
aS'CD4'
p20327
aS'HIV'
p20328
aS'antiretroviral therapy'
p20329
aS'long-term outcome'
p20330
aS'mortality'
p20331
aS'resource-limited settings'
p20332
aS'treatment'
p20333
aS'treatment failure'
p20334
aS'viral load'
p20335
asS'PST'
p20336
S'ppublish'
p20337
stRp20338
ag2
(g3
g4
(dp20339
S'LID'
p20340
S'10.1097/QAI.0000000000000209 [doi]'
p20341
sS'STAT'
p20342
S'MEDLINE'
p20343
sS'JT'
p20344
S'Journal of acquired immune deficiency syndromes (1999)'
p20345
sS'DA'
p20346
S'20140814'
p20347
sS'AID'
p20348
(lp20349
S'10.1097/QAI.0000000000000209 [doi]'
p20350
aS'00126334-201409010-00018 [pii]'
p20351
asS'CRDT'
p20352
(lp20353
S'2014/08/15 06:00'
p20354
asS'DP'
p20355
S'2014 Sep 1'
p20356
sS'AD'
p20357
S'*Elizabeth Glaser Pediatric AIDS Foundation, Maseru, Lesotho; daggerStellenbosch University, Cape Town, South Africa; double daggerNew York Department of Health; section signMinistry of Health Lesotho, Maseru, Lesotho; ||Center for Tuberculosis Research, Johns Hopkins University, Baltimore, MD; paragraph signElizabeth Glaser Pediatric AIDS Foundation Washington, DC; #Department of Epidemiology/Biostatistics, Milken Institute School of Public Health, The George Washington University, Washington, DC; and **Georgetown University, Washington, DC.'
p20358
sS'OWN'
p20359
S'NLM'
p20360
sS'PT'
p20361
(lp20362
S'Journal Article'
p20363
aS'Research Support, N.I.H., Extramural'
p20364
aS"Research Support, Non-U.S. Gov't"
p20365
asS'LA'
p20366
(lp20367
S'eng'
p20368
asS'FAU'
p20369
(lp20370
S'Tiam, Appolinaire'
p20371
aS'Machekano, Rhoderick'
p20372
aS'Gounder, Celine R'
p20373
aS'Maama-Maime, Llang B M'
p20374
aS'Ntene-Sealiete, Keletso'
p20375
aS'Sahu, Maitreyi'
p20376
aS'Isavwa, Anthony'
p20377
aS'Oyebanji, Oyebola'
p20378
aS'Ahimbisibwe, Allan'
p20379
aS'Mokone, Majoalane'
p20380
aS'Barnes, Grace L'
p20381
aS'Chaisson, Richard E'
p20382
aS'Guay, Laura'
p20383
aS'Kassaye, Seble'
p20384
asS'LR'
p20385
S'20160610'
p20386
sS'PG'
p20387
S'e5-e11'
p20388
sS'TI'
p20389
S'Preventing tuberculosis among HIV-infected pregnant women in Lesotho: the case for rolling out active case finding and isoniazid preventive therapy.'
p20390
sS'RN'
p20391
(lp20392
S'0 (Antitubercular Agents)'
p20393
aS'V83O1VOZ8L (Isoniazid)'
p20394
asS'PL'
p20395
S'United States'
p20396
sS'TA'
p20397
S'J Acquir Immune Defic Syndr'
p20398
sS'JID'
p20399
S'100892005'
p20400
sS'AB'
p20401
S'BACKGROUND: The Lesotho Ministry of Health issued guidelines on active case finding (ACF) for tuberculosis (TB) and isoniazid preventive therapy (IPT) in April 2011. ACF has been recommended in maternal and child health (MCH) settings globally, however, the feasibility of implementing IPT within MCH in countries with high concurrent HIV and TB epidemics is unknown. DESIGN/METHODS: The study evaluated the implementation of ACF and IPT guidelines in MCH settings in 2 health facilities in Lesotho. This descriptive prospective study analyzed data collected during routine services. Categorical data and continuous variables were summarized using descriptive statistics. The chi test or Wilcoxon rank-sum test was used to ascertain significant associations between categorical and continuous variables, respectively. RESULTS: Data from 160 HIV-positive and 640 HIV-negative women were reviewed. Within this study population, 99.8% of women were screened for TB, and 11.4% HIV-positive women compared with 2.3% HIV-negative women were reported to have symptoms of TB (P < 0.001). IPT was initiated in 124/158 (78.5%) HIV-positive pregnant women, 64.5% women completed a 6-month IPT regimen, 2 (1.6%) died of causes unrelated to IPT/TB, and 31.5% were lost to follow-up. Predictors of IPT initiation among HIV-positive women included gestational age at the first antenatal visit (unadjusted odds ratio, -0.93; 95% confidence interval: -0.88 to 0.98), and receipt of antiretroviral therapy for treatment rather than for prevention of mother-to-child transmission prophylaxis only (odds ratio, 4.59; 95% confidence interval: 1.32 to 15.93). CONCLUSIONS: Implementation of ACF and IPT is feasible within the MCH setting. Uptake of IPT during pregnancy among HIV-positive women was high, but with a high rate of loss to follow-up.'
p20402
sS'GR'
p20403
(lp20404
S'D43TW00003/TW/FIC NIH HHS/United States'
p20405
aS'P30 AI094189/AI/NIAID NIH HHS/United States'
p20406
aS'P30 MH062246/MH/NIMH NIH HHS/United States'
p20407
aS'R25MH064712-08/MH/NIMH NIH HHS/United States'
p20408
asS'IP'
p20409
S'1'
sS'IS'
p20410
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p20411
sS'DCOM'
p20412
S'20150113'
p20413
sS'AU'
p20414
(lp20415
S'Tiam A'
p20416
aS'Machekano R'
p20417
aS'Gounder CR'
p20418
aS'Maama-Maime LB'
p20419
aS'Ntene-Sealiete K'
p20420
aS'Sahu M'
p20421
aS'Isavwa A'
p20422
aS'Oyebanji O'
p20423
aS'Ahimbisibwe A'
p20424
aS'Mokone M'
p20425
aS'Barnes GL'
p20426
aS'Chaisson RE'
p20427
aS'Guay L'
p20428
aS'Kassaye S'
p20429
asS'VI'
p20430
S'67'
p20431
sS'MHDA'
p20432
S'2015/01/15 06:00'
p20433
sS'MH'
p20434
(lp20435
S'Adult'
p20436
aS'Antitubercular Agents/*administration & dosage'
p20437
aS'Female'
p20438
aS'HIV Infections/*microbiology/virology'
p20439
aS'Humans'
p20440
aS'Isoniazid/*administration & dosage'
p20441
aS'Lesotho'
p20442
aS'Logistic Models'
p20443
aS'Pregnancy'
p20444
aS'Pregnancy Complications, Infectious/microbiology/*prevention & control/virology'
p20445
aS'Prenatal Care/methods'
p20446
aS'Prospective Studies'
p20447
aS'Tuberculosis/diagnosis/microbiology/*prevention & control/*virology'
p20448
aS'Young Adult'
p20449
asS'EDAT'
p20450
S'2014/08/15 06:00'
p20451
sS'SO'
p20452
S'J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):e5-e11. doi: 10.1097/QAI.0000000000000209.'
p20453
sS'SB'
p20454
S'IM X'
p20455
sS'PMID'
p20456
S'25118796'
p20457
sS'PST'
p20458
S'ppublish'
p20459
stRp20460
ag2
(g3
g4
(dp20461
S'LID'
p20462
S'10.1097/QAI.0000000000000253 [doi]'
p20463
sS'STAT'
p20464
S'MEDLINE'
p20465
sS'JT'
p20466
S'Journal of acquired immune deficiency syndromes (1999)'
p20467
sS'MID'
p20468
(lp20469
S'NIHMS651542'
p20470
asS'DA'
p20471
S'20140813'
p20472
sS'AID'
p20473
(lp20474
S'10.1097/QAI.0000000000000253 [doi]'
p20475
aS'00126334-201409011-00003 [pii]'
p20476
asS'CRDT'
p20477
(lp20478
S'2014/08/14 06:00'
p20479
asS'DP'
p20480
S'2014 Sep 1'
p20481
sS'AD'
p20482
S'*Division of Biostatistics, Berkeley School of Public Health, Berkeley, CA; daggerDepartment of Biostatistics, Indiana University R. M. Fairbanks School of Public Health, Indianapolis, IN; double daggerSection of General Internal Medicine, Yale University Schools of Medicine and Public Health and Veterans Affairs (VA) Connecticut Healthcare System, West Haven, CT; section signCentre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa; and ||HIV/AIDS Research Group Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland.'
p20483
sS'OWN'
p20484
S'NLM'
p20485
sS'PT'
p20486
(lp20487
S'Journal Article'
p20488
aS'Research Support, N.I.H., Extramural'
p20489
aS"Research Support, Non-U.S. Gov't"
p20490
aS'Review'
p20491
asS'LA'
p20492
(lp20493
S'eng'
p20494
asS'DCOM'
p20495
S'20141006'
p20496
sS'LR'
p20497
S'20160227'
p20498
sS'FAU'
p20499
(lp20500
S'Petersen, Maya'
p20501
aS'Yiannoutsos, Constantin T'
p20502
aS'Justice, Amy'
p20503
aS'Egger, Matthias'
p20504
asS'TI'
p20505
S'Observational research on NCDs in HIV-positive populations: conceptual and methodological considerations.'
p20506
sS'RN'
p20507
(lp20508
S'0 (Anti-Retroviral Agents)'
p20509
asS'PL'
p20510
S'United States'
p20511
sS'PG'
p20512
S'S8-16'
p20513
sS'JID'
p20514
S'100892005'
p20515
sS'AB'
p20516
S'Noncommunicable diseases (NCDs) account for a growing burden of morbidity and mortality among people living with HIV in low- and middle-income countries (LMICs). HIV infection and antiretroviral therapy interact with NCD risk factors in complex ways, and research into this "web of causation" has so far been largely based on data from high-income countries. However, improving the understanding, treatment, and prevention of NCDs in LMICs requires region-specific evidence. Priority research areas include: (1) defining the burden of NCDs among people living with HIV, (2) understanding the impact of modifiable risk factors, (3) evaluating effective and efficient care strategies at individual and health systems levels, and (4) evaluating cost-effective prevention strategies. Meeting these needs will require observational data, both to inform the design of randomized trials and to replace trials that would be unethical or infeasible. Focusing on Sub-Saharan Africa, we discuss data resources currently available to inform this effort and consider key limitations and methodological challenges. Existing data resources often lack population-based samples; HIV-negative, HIV-positive, and antiretroviral therapy-naive comparison groups; and measurements of key NCD risk factors and outcomes. Other challenges include loss to follow-up, competing risk of death, incomplete outcome ascertainment and measurement of factors affecting clinical decision making, and the need to control for (time-dependent) confounding. We review these challenges and discuss strategies for overcoming them through augmented data collection and appropriate analysis. We conclude with recommendations to improve the quality of data and analyses available to inform the response to HIV and NCD comorbidity in LMICs.'
p20517
sS'GR'
p20518
(lp20519
S'5U01AI069911-07/AI/NIAID NIH HHS/United States'
p20520
aS'5U01AI069924-08/AI/NIAID NIH HHS/United States'
p20521
aS'P30 MH062294/MH/NIMH NIH HHS/United States'
p20522
aS'R01 AI102710/AI/NIAID NIH HHS/United States'
p20523
aS'U01-AA020790/AA/NIAAA NIH HHS/United States'
p20524
aS'U01-AA020795/AA/NIAAA NIH HHS/United States'
p20525
aS'U01-AA020799/AA/NIAAA NIH HHS/United States'
p20526
aS'U24-AA020794/AA/NIAAA NIH HHS/United States'
p20527
aS'UL1 TR001108/TR/NCATS NIH HHS/United States'
p20528
asS'VI'
p20529
S'67 Suppl 1'
p20530
sS'IS'
p20531
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p20532
sS'PMC'
p20533
S'PMC4317266'
p20534
sS'AU'
p20535
(lp20536
S'Petersen M'
p20537
aS'Yiannoutsos CT'
p20538
aS'Justice A'
p20539
aS'Egger M'
p20540
asS'MHDA'
p20541
S'2014/10/07 06:00'
p20542
sS'OID'
p20543
(lp20544
S'NLM: NIHMS651542'
p20545
aS'NLM: PMC4317266'
p20546
asS'MH'
p20547
(lp20548
S'Africa South of the Sahara/epidemiology'
p20549
aS'Anti-Retroviral Agents/adverse effects/therapeutic use'
p20550
aS'Biomedical Research/*methods/trends'
p20551
aS'Comorbidity/*trends'
p20552
aS'Delivery of Health Care, Integrated'
p20553
aS'Developing Countries'
p20554
aS'Diagnostic Tests, Routine/methods'
p20555
aS'HIV Infections/drug therapy/*epidemiology'
p20556
aS'Humans'
p20557
aS'Prevalence'
p20558
aS'Preventive Health Services'
p20559
aS'Risk Factors'
p20560
asS'EDAT'
p20561
S'2014/08/15 06:00'
p20562
sS'SO'
p20563
S'J Acquir Immune Defic Syndr. 2014 Sep 1;67 Suppl 1:S8-16. doi: 10.1097/QAI.0000000000000253.'
p20564
sS'SB'
p20565
S'IM X'
p20566
sS'PMID'
p20567
S'25117964'
p20568
sS'TA'
p20569
S'J Acquir Immune Defic Syndr'
p20570
sS'PST'
p20571
S'ppublish'
p20572
stRp20573
ag2
(g3
g4
(dp20574
S'LID'
p20575
S'10.1016/S2214-109X(13)70149-9 [doi] S2214-109X(13)70149-9 [pii]'
p20576
sS'STAT'
p20577
S'MEDLINE'
p20578
sS'DEP'
p20579
S'20131211'
p20580
sS'CI'
p20581
(lp20582
S'Copyright (c) 2014 Farahani et al. Open Access article distributed under the'
p20583
aS'terms of CC BY-NC-ND. Published by .. All rights reserved.'
p20584
asS'DA'
p20585
S'20140808'
p20586
sS'AID'
p20587
(lp20588
S'S2214-109X(13)70149-9 [pii]'
p20589
aS'10.1016/S2214-109X(13)70149-9 [doi]'
p20590
asS'CRDT'
p20591
(lp20592
S'2014/08/09 06:00'
p20593
asS'DP'
p20594
S'2014 Jan'
p20595
sS'OWN'
p20596
S'NLM'
p20597
sS'PT'
p20598
(lp20599
S'Journal Article'
p20600
aS"Research Support, Non-U.S. Gov't"
p20601
asS'LA'
p20602
(lp20603
S'eng'
p20604
asS'FAU'
p20605
(lp20606
S'Farahani, Mansour'
p20607
aS'Vable, Anusha'
p20608
aS'Lebelonyane, Refeletswe'
p20609
aS'Seipone, Khumo'
p20610
aS'Anderson, Marina'
p20611
aS'Avalos, Ava'
p20612
aS'Chadborn, Tim'
p20613
aS'Tilahun, Hailu'
p20614
aS'Roumis, Danae'
p20615
aS'Moeti, Themba'
p20616
aS'Musuka, Godfrey'
p20617
aS'Busang, Lesego'
p20618
aS'Gaolathe, Tendani'
p20619
aS'Malefho, Kolaatamo C S'
p20620
aS'Marlink, Richard'
p20621
asS'JT'
p20622
S'The Lancet. Global health'
p20623
sS'PG'
p20624
S'e44-50'
p20625
sS'TI'
p20626
S'Outcomes of the Botswana national HIV/AIDS treatment programme from 2002 to 2010: a longitudinal analysis.'
p20627
sS'RN'
p20628
(lp20629
S'0 (Anti-HIV Agents)'
p20630
asS'PL'
p20631
S'England'
p20632
sS'TA'
p20633
S'Lancet Glob Health'
p20634
sS'JID'
p20635
S'101613665'
p20636
sS'AB'
p20637
S"BACKGROUND: Short-term mortality rates among patients with HIV receiving antiretroviral therapy (ART) in sub-Saharan Africa are higher than those recorded in high-income countries, but systematic long-term comparisons have not been made because of the scarcity of available data. We analysed the effect of the implementation of Botswana's national ART programme, known as Masa, from 2002 to 2010. METHODS: The Masa programme started on Jan 21, 2002. Patients who were eligible for ART according to national guidelines had their data collected prospectively through a clinical information system developed by the Botswana Ministry of Health. A dataset of all available electronic records for adults (>/=18 years) who had enrolled by April 30, 2010, was extracted and sent to the study team. All data were anonymised before analysis. The primary outcome was mortality. To assess the effect of loss to follow-up, we did a series of sensitivity analyses assuming varying proportions of the population lost to follow-up to be dead. FINDINGS: We analysed the records of 126,263 patients, of whom 102,713 had documented initiation of ART. Median follow-up time was 35 months (IQR 14-56), with a median of eight follow-up visits (4-14). 15,270 patients were deemed lost to follow-up by the end of the study. 63% (78,866) of the study population were women; median age at baseline was 34 years for women (IQR 29-41) and 38 years for men (33-45). 10,230 (8%) deaths were documented during the 9 years of the study. Mortality was highest during the first 3 months after treatment initiation at 12.8 deaths per 100 person-years (95% CI 12.4-13.2), but decreased to 1.16 deaths per 100 person-years (1.12-1.2) in the second year of treatment, and to 0.15 deaths per 100 person-years (0.09-0.25) over the next 7 years of follow-up. In each calendar year after the start of the Masa programme in 2002, average CD4 cell counts at enrolment increased (from 101 cells/muL [IQR 44-156] in 2002, to 191 cells/muL [115-239] in 2010). In each year, the proportion of the total enrolled population who died in that year decreased, from 63% (88 of 140) in 2002, to 0.8% (13 of 1599) in 2010. A sensitivity analysis assuming that 60% of the population lost to follow-up had died gave 3000 additional deaths, increasing overall mortality from 8% to 11-13%. INTERPRETATION: The Botswana national HIV/AIDS treatment programme reduced mortality among adults with HIV to levels much the same as in other low-income or middle-income countries. FUNDING: The African Comprehensive HIV/AIDS Partnerships."
p20638
sS'AD'
p20639
S'Harvard School of Public Health, Boston, MA, USA. Electronic address: mfarahan@hsph.harvard.edu. Harvard School of Public Health, Boston, MA, USA. Ministry of Health, Gaborone, Botswana. Ministry of Health, Gaborone, Botswana. Ministry of Health, Gaborone, Botswana. Ministry of Health, Gaborone, Botswana. Ministry of Health, Gaborone, Botswana. Harvard School of Public Health, Boston, MA, USA. Harvard School of Public Health, Boston, MA, USA. African Comprehensive HIV/AIDS Partnerships, Gaborone, Botswana. African Comprehensive HIV/AIDS Partnerships, Gaborone, Botswana. African Comprehensive HIV/AIDS Partnerships, Gaborone, Botswana. Botswana-Harvard Partnership, Gaborone, Botswana. Ministry of Health, Gaborone, Botswana. Harvard School of Public Health, Boston, MA, USA; Botswana-Harvard Partnership, Gaborone, Botswana.'
p20640
sS'IP'
p20641
S'1'
sS'IS'
p20642
S'2214-109X (Electronic) 2214-109X (Linking)'
p20643
sS'DCOM'
p20644
S'20150511'
p20645
sS'CIN'
p20646
(lp20647
S'Lancet Glob Health. 2014 Jan;2(1):e6. PMID: 25104637'
p20648
asS'AU'
p20649
(lp20650
S'Farahani M'
p20651
aS'Vable A'
p20652
aS'Lebelonyane R'
p20653
aS'Seipone K'
p20654
aS'Anderson M'
p20655
aS'Avalos A'
p20656
aS'Chadborn T'
p20657
aS'Tilahun H'
p20658
aS'Roumis D'
p20659
aS'Moeti T'
p20660
aS'Musuka G'
p20661
aS'Busang L'
p20662
aS'Gaolathe T'
p20663
aS'Malefho KC'
p20664
aS'Marlink R'
p20665
asS'VI'
p20666
S'2'
sS'MHDA'
p20667
S'2015/05/12 06:00'
p20668
sS'PHST'
p20669
(lp20670
S'2013/12/11 [aheadofprint]'
p20671
asS'MH'
p20672
(lp20673
S'Adult'
p20674
aS'Anti-HIV Agents/*therapeutic use'
p20675
aS'Botswana/epidemiology'
p20676
aS'CD4 Lymphocyte Count'
p20677
aS'Female'
p20678
aS'HIV Infections/*drug therapy/mortality'
p20679
aS'HIV-1'
p20680
aS'Humans'
p20681
aS'Longitudinal Studies'
p20682
aS'Lost to Follow-Up'
p20683
aS'Male'
p20684
aS'Middle Aged'
p20685
aS'Viral Load'
p20686
aS'Young Adult'
p20687
asS'EDAT'
p20688
S'2014/08/12 06:00'
p20689
sS'SO'
p20690
S'Lancet Glob Health. 2014 Jan;2(1):e44-50. doi: 10.1016/S2214-109X(13)70149-9. Epub 2013 Dec 11.'
p20691
sS'SB'
p20692
S'IM'
p20693
sS'PMID'
p20694
S'25104635'
p20695
sS'PST'
p20696
S'ppublish'
p20697
stRp20698
ag2
(g3
g4
(dp20699
S'LID'
p20700
S'10.1016/S2214-109X(13)70067-6 [doi] S2214-109X(13)70067-6 [pii]'
p20701
sS'STAT'
p20702
S'MEDLINE'
p20703
sS'DEP'
p20704
S'20130823'
p20705
sS'MID'
p20706
(lp20707
S'NIHMS603741'
p20708
asS'DA'
p20709
S'20140808'
p20710
sS'AID'
p20711
(lp20712
S'S2214-109X(13)70067-6 [pii]'
p20713
aS'10.1016/S2214-109X(13)70067-6 [doi]'
p20714
asS'CRDT'
p20715
(lp20716
S'2014/08/09 06:00'
p20717
asS'DP'
p20718
S'2013 Sep'
p20719
sS'AD'
p20720
S'Department of Disease Control and Environmental Health, Makerere University School of Public Health, Kampala, Uganda. Electronic address: rwanyenze@hotmail.com. Department of Medicine, Makerere University School of Medicine, Kampala, Uganda. Department of Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, CA, USA. Department of Medicine, Makerere University School of Medicine, Kampala, Uganda. Department of Medicine, Makerere University School of Medicine, Kampala, Uganda. Division of Infectious Diseases, University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA, USA. Massachusetts General Hospital Center for Global Health and Harvard Medical School, Boston, MA, USA. Division of Infectious Diseases, University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA, USA. Department of Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, CA, USA.'
p20721
sS'OWN'
p20722
S'NLM'
p20723
sS'PT'
p20724
(lp20725
S'Journal Article'
p20726
aS'Randomized Controlled Trial'
p20727
aS'Research Support, N.I.H., Extramural'
p20728
asS'LA'
p20729
(lp20730
S'eng'
p20731
asS'FAU'
p20732
(lp20733
S'Wanyenze, Rhoda K'
p20734
aS'Kamya, Moses R'
p20735
aS'Fatch, Robin'
p20736
aS'Mayanja-Kizza, Harriet'
p20737
aS'Baveewo, Steven'
p20738
aS'Szekeres, Gregory'
p20739
aS'Bangsberg, David R'
p20740
aS'Coates, Thomas'
p20741
aS'Hahn, Judith A'
p20742
asS'JT'
p20743
S'The Lancet. Global health'
p20744
sS'LR'
p20745
S'20141205'
p20746
sS'PG'
p20747
S'e137-45'
p20748
sS'TI'
p20749
S'Abbreviated HIV counselling and testing and enhanced referral to care in Uganda: a factorial randomised controlled trial.'
p20750
sS'PL'
p20751
S'England'
p20752
sS'TA'
p20753
S'Lancet Glob Health'
p20754
sS'JID'
p20755
S'101613665'
p20756
sS'AB'
p20757
S'BACKGROUND: HIV counselling and testing and linkage to care are crucial for successful HIV prevention and treatment. Abbreviated counselling could save time; however, its effect on HIV risk is uncertain and methods to improve linkage to care have not been studied. METHODS: We did this factorial randomised controlled study at Mulago Hospital, Uganda. Participants were randomly assigned to abbreviated or traditional HIV counselling and testing; HIV-infected patients were randomly assigned to enhanced linkage to care or standard linkage to care. All study personnel except counsellors and the data officer were masked to study group assignment. Participants had structured interviews, given once every 3 months. We compared sexual risk behaviour by counselling strategy with a 6.5% non-inferiority margin. We used Cox proportional hazards analyses to compare HIV outcomes by linkage to care over 1 year and tested for interaction by sex. This trial is registered with ClinicalTrials.gov (NCT00648232). FINDINGS: We enrolled 3415 participants; 1707 assigned to abbreviated counselling versus 1708 assigned to traditional. Unprotected sex with an HIV discordant or status unknown partner was similar in each group (232/823 [27.9%] vs 251/890 [28.2%], difference -0.3%, one-sided 95% CI 3.2). Loss to follow-up was lower for traditional counselling than for abbreviated counselling (adjusted hazard ratio [HR] 0.61, 95% CI 0.44-0.83). 1003 HIV-positive participants were assigned to enhanced linkage (n=504) or standard linkage to care (n=499). Linkage to care did not have a significant effect on mortality or receipt of co-trimoxazole. Time to treatment in men with CD4 cell counts of 250 cells per muL or fewer was lower for enhanced linkage versus standard linkage (adjusted HR 0.60, 95% CI 0.41-0.87) and time to HIV care was decreased among women (0.80, 0.66-0.96). INTERPRETATION: Abbreviated HIV counselling and testing did not adversely affect risk behaviour. Linkage to care interventions might decrease time to enrolment in HIV care and antiretroviral treatment and thus might affect secondary HIV transmission and improve treatment outcomes. FUNDING: US National Institute of Mental Health.'
p20758
sS'GR'
p20759
(lp20760
S'1 R01 MH077512/MH/NIMH NIH HHS/United States'
p20761
aS'P30 AI028697/AI/NIAID NIH HHS/United States'
p20762
aS'P30 MH058107/MH/NIMH NIH HHS/United States'
p20763
aS'R01 MH077512/MH/NIMH NIH HHS/United States'
p20764
aS'UL1 TR000124/TR/NCATS NIH HHS/United States'
p20765
asS'IP'
p20766
S'3'
sS'IS'
p20767
S'2214-109X (Electronic) 2214-109X (Linking)'
p20768
sS'PMC'
p20769
S'PMC4129546'
p20770
sS'DCOM'
p20771
S'20151016'
p20772
sS'CIN'
p20773
(lp20774
S'Lancet Glob Health. 2013 Sep;1(3):e117-8. PMID: 25104249'
p20775
asS'AU'
p20776
(lp20777
S'Wanyenze RK'
p20778
aS'Kamya MR'
p20779
aS'Fatch R'
p20780
aS'Mayanja-Kizza H'
p20781
aS'Baveewo S'
p20782
aS'Szekeres G'
p20783
aS'Bangsberg DR'
p20784
aS'Coates T'
p20785
aS'Hahn JA'
p20786
asS'VI'
p20787
S'1'
sS'MHDA'
p20788
S'2015/10/17 06:00'
p20789
sS'PHST'
p20790
(lp20791
S'2013/08/23 [aheadofprint]'
p20792
asS'OID'
p20793
(lp20794
S'NLM: NIHMS603741'
p20795
aS'NLM: PMC4129546'
p20796
asS'CI'
p20797
(lp20798
S'Copyright (c) 2013 Wanyenze et al. Open Access article distributed under the'
p20799
aS'terms of CC BY. Published by .. All rights reserved.'
p20800
asS'MH'
p20801
(lp20802
S'Adult'
p20803
aS'CD4 Lymphocyte Count'
p20804
aS'Counseling/*methods'
p20805
aS'Disease Management'
p20806
aS'Female'
p20807
aS'HIV Infections/blood/*diagnosis/therapy'
p20808
aS'Humans'
p20809
aS'Male'
p20810
aS'Proportional Hazards Models'
p20811
aS'*Referral and Consultation'
p20812
aS'Risk Assessment'
p20813
aS'*Risk-Taking'
p20814
aS'Sex Factors'
p20815
aS'Sexual Behavior'
p20816
aS'*Time-to-Treatment'
p20817
aS'Uganda'
p20818
aS'Unsafe Sex'
p20819
aS'Young Adult'
p20820
asS'EDAT'
p20821
S'2014/08/12 06:00'
p20822
sS'SO'
p20823
S'Lancet Glob Health. 2013 Sep;1(3):e137-45. doi: 10.1016/S2214-109X(13)70067-6. Epub 2013 Aug 23.'
p20824
sS'SB'
p20825
S'IM'
p20826
sS'PMID'
p20827
S'25104262'
p20828
sS'PST'
p20829
S'ppublish'
p20830
stRp20831
ag2
(g3
g4
(dp20832
S'LID'
p20833
S'10.1093/cid/ciu630 [doi]'
p20834
sS'STAT'
p20835
S'MEDLINE'
p20836
sS'DEP'
p20837
S'20140806'
p20838
sS'CI'
p20839
(lp20840
S'(c) The Author 2014. Published by Oxford University Press on behalf of the'
p20841
aS'Infectious Diseases Society of America. All rights reserved. For Permissions,'
p20842
aS'please e-mail: journals.permissions@oup.com.'
p20843
asS'DA'
p20844
S'20141112'
p20845
sS'AID'
p20846
(lp20847
S'ciu630 [pii]'
p20848
aS'10.1093/cid/ciu630 [doi]'
p20849
asS'CRDT'
p20850
(lp20851
S'2014/08/08 06:00'
p20852
asS'DP'
p20853
S'2014 Dec 1'
p20854
sS'AD'
p20855
S'Division of Infection & Immunity and London Centre for Nanotechnology. Department of Infectious Diseases, University of Liverpool/Malawi Liverpool Wellcome Trust, United Kingdom. Division of Infection & Immunity and London Centre for Nanotechnology. Department of Infection & Population Health, University College London. IrsiCaixa & AIDS Unit, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain. Institute of Infection and Global Health. Department of Virology. Institute of Translational Medicine, University of Liverpool, United Kingdom. College of Medicine, University of Malawi, Blantyre Dignitas International, Zomba, Malawi. Institute of Infection and Global Health.'
p20856
sS'OWN'
p20857
S'NLM'
p20858
sS'PT'
p20859
(lp20860
S'Journal Article'
p20861
aS"Research Support, Non-U.S. Gov't"
p20862
asS'LA'
p20863
(lp20864
S'eng'
p20865
asS'FAU'
p20866
(lp20867
S'Aoudjane, Samir'
p20868
aS'Chaponda, Mas'
p20869
aS'Gonzalez Del Castillo, Antonio Adrian'
p20870
aS"O'Connor, Jemma"
p20871
aS'Noguera, Marc'
p20872
aS'Beloukas, Apostolos'
p20873
aS'Hopkins, Mark'
p20874
aS'Khoo, Saye'
p20875
aS'van Oosterhout, Joep J'
p20876
aS'Geretti, Anna Maria'
p20877
asS'JT'
p20878
S'Clinical infectious diseases : an official publication of the Infectious Diseases Society of America'
p20879
sS'LR'
p20880
S'20160713'
p20881
sS'PG'
p20882
S'1618-26'
p20883
sS'TI'
p20884
S'Hepatitis B virus sub-genotype A1 infection is characterized by high replication levels and rapid emergence of drug resistance in HIV-positive adults receiving first-line antiretroviral therapy in Malawi.'
p20885
sS'RN'
p20886
(lp20887
S'0 (Anti-HIV Agents)'
p20888
aS'0 (DNA, Viral)'
p20889
aS'0 (stavudine, lamivudine, nevirapine drug combination)'
p20890
aS'2T8Q726O95 (Lamivudine)'
p20891
aS'99DK7FVK1H (Nevirapine)'
p20892
aS'BO9LE4QFZF (Stavudine)'
p20893
asS'PL'
p20894
S'United States'
p20895
sS'TA'
p20896
S'Clin Infect Dis'
p20897
sS'JID'
p20898
S'9203213'
p20899
sS'AB'
p20900
S'BACKGROUND: It has been proposed that hepatitis B virus (HBV) sub-genotype A1 infections have mild outcomes and a low risk of drug-resistance among patients infected with human immunodeficiency virus (HIV) receiving lamivudine-containing antiretroviral therapy (ART) without tenofovir in Africa. METHODS: The virologic expression of HBV sub-genotype A1 coinfection was studied over 12 months in HIV-positive adults starting stavudine/lamivudine/nevirapine in Malawi, using Sanger, deep, clonal, and single full-genome sequencing for the sensitive characterization of HBV resistance-associated mutations (RAMs). RESULTS: Among 1117 subjects, 133 (12%) tested HBsAg-positive. After starting ART, retention rates were 96/133 (72%) at 6 months and 54/133 (41%) at 12 months. Based upon the last available follow-up, 92/96 (96%) subjects achieved HIV-1 RNA <40 copies/mL, 48/96 (50%) showed HBV DNA <14 IU/mL, and 24/96 (25%) acquired HBV RAMs. At 6 months, M204I was detected in 8/46 (17%) and 16/17 (94%) subjects using Sanger and deep sequencing, respectively. At 12 months, all viremic patients had multiple resistance and compensatory mutations coexisting on the same HBV genomes. Comparing HBeA-positive (67/133, 50%) with HBeAg-negative subjects, 64/67 (96%) vs 35/66 (55%) showed baseline HBV DNA >2000 IU/mL (P = .0006), 39/47 (17%) vs 9/49 (82%) had persistent HBV DNA detection during follow-up (P < .0001), and 23/47 (49%) vs 2/49 (4%) acquired HBV RAMs (P < .0001). Baseline HBV DNA levels were median 8.1 vs 5.3 log10 IU/mL in subjects with vs those without treatment-emergent RAMs (P < .0001). CONCLUSIONS: HBV sub-genotype A1 infections showed a severe virologic expression in HIV-positive Malawians. The findings strengthen the urgency of interventions to improve ascertainment and management of chronic hepatitis B in the region.'
p20901
sS'GR'
p20902
(lp20903
S'100890/Wellcome Trust/United Kingdom'
p20904
aS'Wellcome Trust/United Kingdom'
p20905
asS'IP'
p20906
S'11'
p20907
sS'IS'
p20908
S'1537-6591 (Electronic) 1058-4838 (Linking)'
p20909
sS'PMC'
p20910
S'PMC4650769'
p20911
sS'DCOM'
p20912
S'20150702'
p20913
sS'AU'
p20914
(lp20915
S'Aoudjane S'
p20916
aS'Chaponda M'
p20917
aS'Gonzalez Del Castillo AA'
p20918
aS"O'Connor J"
p20919
aS'Noguera M'
p20920
aS'Beloukas A'
p20921
aS'Hopkins M'
p20922
aS'Khoo S'
p20923
aS'van Oosterhout JJ'
p20924
aS'Geretti AM'
p20925
asS'VI'
p20926
S'59'
p20927
sS'MHDA'
p20928
S'2015/07/03 06:00'
p20929
sS'PHST'
p20930
(lp20931
S'2014/08/06 [aheadofprint]'
p20932
asS'OTO'
p20933
(lp20934
S'NOTNLM'
p20935
asS'OID'
p20936
(lp20937
S'NLM: PMC4650769'
p20938
asS'MH'
p20939
(lp20940
S'Adult'
p20941
aS'Anti-HIV Agents/adverse effects/*therapeutic use'
p20942
aS'DNA, Viral/genetics'
p20943
aS'Drug Resistance, Viral'
p20944
aS'Female'
p20945
aS'HIV Infections/*drug therapy/virology'
p20946
aS'Hepatitis B/drug therapy/*virology'
p20947
aS'Hepatitis B virus/classification/genetics/*physiology'
p20948
aS'Humans'
p20949
aS'Lamivudine/adverse effects/therapeutic use'
p20950
aS'Malawi'
p20951
aS'Male'
p20952
aS'Nevirapine/adverse effects/therapeutic use'
p20953
aS'Phylogeny'
p20954
aS'Retrospective Studies'
p20955
aS'Sequence Analysis, DNA'
p20956
aS'Stavudine/adverse effects/therapeutic use'
p20957
aS'Viral Load/drug effects'
p20958
aS'Virus Replication/drug effects'
p20959
asS'EDAT'
p20960
S'2014/08/08 06:00'
p20961
sS'SO'
p20962
S'Clin Infect Dis. 2014 Dec 1;59(11):1618-26. doi: 10.1093/cid/ciu630. Epub 2014 Aug 6.'
p20963
sS'SB'
p20964
S'IM'
p20965
sS'PMID'
p20966
S'25100867'
p20967
sS'OT'
p20968
(lp20969
S'Africa'
p20970
aS'lamivudine'
p20971
aS'resistance'
p20972
aS'sub-genotype A1'
p20973
aS'viral load'
p20974
asS'PST'
p20975
S'ppublish'
p20976
stRp20977
ag2
(g3
g4
(dp20978
S'LID'
p20979
S'10.1007/s10461-014-0874-0 [doi]'
p20980
sS'STAT'
p20981
S'MEDLINE'
p20982
sS'AB'
p20983
S"Within Mozambique's current HIV care system, there are numerous opportunities for a person to become lost to follow-up (LTFU) prior to initiating antiretroviral therapy (pre-ART). We explored pre-ART LTFU in Zambezia province utilizing quantitative and qualitative methods. Patients were deemed LTFU if they were more than 60 days late for either a scheduled appointment or a CD4+ cell count blood draw, according to national guidelines. Among 13,968 adult patients registered for care, 211 (1.8 %) died, one transferred, 2,196 (15.7 %) initiated ART, and 9,195 (65.8 %) were LTFU during the first year. Being male, younger, less educated, and/or having no home electricity were associated with LTFU. Qualitative interviews revealed that poor clinical care, logistics and competing priorities contribute to attrition. In addition, many expressed fears of stigma and/or rejection by family or community members because they were HIV-infected. At 66 %, pre-ART LTFU in Zambezia, Mozambique is a significant problem. This study highlights characteristics of lost patients and discusses barriers requiring consideration to improve retention."
p20984
sS'JID'
p20985
S'9712133'
p20986
sS'GR'
p20987
(lp20988
S'U2GPS000631/PHS HHS/United States'
p20989
aS'PEPFAR/United States'
p20990
asS'JT'
p20991
S'AIDS and behavior'
p20992
sS'IP'
p20993
S'4'
sS'IS'
p20994
S'1573-3254 (Electronic) 1090-7165 (Linking)'
p20995
sS'DCOM'
p20996
S'20151231'
p20997
sS'DA'
p20998
S'20150411'
p20999
sS'AU'
p21000
(lp21001
S'da Silva M'
p21002
aS'Blevins M'
p21003
aS'Wester CW'
p21004
aS'Manjolo J'
p21005
aS'Jose E'
p21006
aS'Gonzalez LC'
p21007
aS'Shepherd BE'
p21008
aS'Moon TD'
p21009
aS'Vaz LM'
p21010
asS'AID'
p21011
(lp21012
S'10.1007/s10461-014-0874-0 [doi]'
p21013
asS'CRDT'
p21014
(lp21015
S'2014/08/07 06:00'
p21016
asS'VI'
p21017
S'19'
p21018
sS'DP'
p21019
S'2015 Apr'
p21020
sS'AD'
p21021
S'Vanderbilt Institute for Global Health (VIGH), 2525 West End Avenue, Suite 750, Nashville, TN, 37203, USA, monica.l.da.silva@vanderbilt.edu.'
p21022
sS'MHDA'
p21023
S'2016/01/01 06:00'
p21024
sS'OWN'
p21025
S'NLM'
p21026
sS'PT'
p21027
(lp21028
S'Journal Article'
p21029
aS'Observational Study'
p21030
aS"Research Support, U.S. Gov't, P.H.S."
p21031
asS'LA'
p21032
(lp21033
S'eng'
p21034
asS'MH'
p21035
(lp21036
S'Adult'
p21037
aS'Age Factors'
p21038
aS'*Antiretroviral Therapy, Highly Active'
p21039
aS'Cohort Studies'
p21040
aS'Educational Status'
p21041
aS'Female'
p21042
aS'HIV Infections/diagnosis/*drug therapy/psychology'
p21043
aS'Humans'
p21044
aS'*Lost to Follow-Up'
p21045
aS'Male'
p21046
aS'Mozambique'
p21047
aS'Qualitative Research'
p21048
aS'Rural Population'
p21049
aS'Sex Factors'
p21050
aS'Social Distance'
p21051
aS'Social Stigma'
p21052
aS'Young Adult'
p21053
asS'FAU'
p21054
(lp21055
S'da Silva, Monica'
p21056
aS'Blevins, Meridith'
p21057
aS'Wester, C William'
p21058
aS'Manjolo, Jose'
p21059
aS'Jose, Eurico'
p21060
aS'Gonzalez, Lazaro C'
p21061
aS'Shepherd, Bryan E'
p21062
aS'Moon, Troy D'
p21063
aS'Vaz, Lara M E'
p21064
asS'EDAT'
p21065
S'2014/08/07 06:00'
p21066
sS'PST'
p21067
S'ppublish'
p21068
sS'SO'
p21069
S'AIDS Behav. 2015 Apr;19(4):666-78. doi: 10.1007/s10461-014-0874-0.'
p21070
sS'PG'
p21071
S'666-78'
p21072
sS'TI'
p21073
S'Patient loss to follow-up before antiretroviral therapy initiation in rural Mozambique.'
p21074
sS'SB'
p21075
S'IM'
p21076
sS'PMID'
p21077
S'25096897'
p21078
sS'PL'
p21079
S'United States'
p21080
sS'TA'
p21081
S'AIDS Behav'
p21082
stRp21083
ag2
(g3
g4
(dp21084
S'LID'
p21085
S'10.1186/1477-7819-12-246 [doi]'
p21086
sS'STAT'
p21087
S'MEDLINE'
p21088
sS'DEP'
p21089
S'20140802'
p21090
sS'DA'
p21091
S'20140808'
p21092
sS'AID'
p21093
(lp21094
S'1477-7819-12-246 [pii]'
p21095
aS'10.1186/1477-7819-12-246 [doi]'
p21096
asS'CRDT'
p21097
(lp21098
S'2014/08/03 06:00'
p21099
asS'DP'
p21100
S'2014'
p21101
sS'OWN'
p21102
S'NLM'
p21103
sS'PT'
p21104
(lp21105
S'Journal Article'
p21106
asS'LA'
p21107
(lp21108
S'eng'
p21109
asS'DCOM'
p21110
S'20150330'
p21111
sS'JT'
p21112
S'World journal of surgical oncology'
p21113
sS'LR'
p21114
S'20150805'
p21115
sS'FAU'
p21116
(lp21117
S'Jaka, Hyasinta'
p21118
aS'Mshana, Stephen E'
p21119
aS'Rambau, Peter F'
p21120
aS'Masalu, Nestory'
p21121
aS'Chalya, Phillipo L'
p21122
aS'Kalluvya, Samuel E'
p21123
asS'TI'
p21124
S'Hepatocellular carcinoma: clinicopathological profile and challenges of management in a resource-limited setting.'
p21125
sS'PL'
p21126
S'England'
p21127
sS'PG'
p21128
S'246'
p21129
sS'JID'
p21130
S'101170544'
p21131
sS'AB'
p21132
S'BACKGROUND: Hepatocellular carcinoma is one of the most common cancers worldwide and its incidence is reported to be increasing in resource-limited countries. There is a paucity of published data regarding hepatocellular carcinoma in Tanzania, and the study area in particular. This study describes the clinicopathological profile of hepatocellular carcinoma in our local setting and highlights the challenging problems in the management of this disease. METHODS: This was a retrospective study of histopathologically confirmed cases of hepatocellular carcinoma seen at Bugando Medical Center between March 2009 and February 2013. RESULTS: A total of 142 patients (M: F = 2.2: 1) were studied representing 4.6% of all malignancies. The median age of patients was 45 years. Hepatitis B virus infection (66.2%) and heavy alcohol consumption (60.6%) were the most frequently identified risk factors for hepatocellular carcinoma. The majority of patients (88.0%) presented late with advanced stages. HBsAg was positive in 66.2% of the patients and Hepatitis C Virus antibody in 16.9%. Thirteen (9.2%) patients tested positive for HIV infection. Most patients (52.8%) had both right and left lobe involvement. The trabecular pattern (47.9%) was the most frequent histopathological type. None of patients had curative therapy because of the advanced nature of the disease. Coagulopathy (45.7%) was the most common complications. The overall mortality rate was 46.5% and it was significantly associated with comorbidity, HIV positivity, CD4+ count <200 cells/mul, high histological grade, advanced stage of the tumor, presence of distant metastases at the time of diagnosis, and associated complications (P < 0.001). The overall median duration of hospital stay was 14 days. The majority of patients (71.1%) were lost to follow-up at the end of the follow-up period. CONCLUSIONS: Hepatocellular carcinoma patients in this region are relatively young at diagnosis and the majority of them present late with an advanced stage and high rate of distant metastasis. Lack of awareness of the disease, poor accessibility to healthcare facilities, and lack of screening programs in this region may contribute to advanced disease at the time of diagnosis. There is a need for early detection, adequate treatment, and proper follow-up to improve treatment outcome.'
p21133
sS'AD'
p21134
S'Department of Surgery, Catholic University of Health and Allied Sciences- Bugando, Bugando, P,O, Box 1464, Mwanza, Tanzania. drphillipoleo@yahoo.com.'
p21135
sS'VI'
p21136
S'12'
p21137
sS'IS'
p21138
S'1477-7819 (Electronic) 1477-7819 (Linking)'
p21139
sS'PMC'
p21140
S'PMC4121298'
p21141
sS'AU'
p21142
(lp21143
S'Jaka H'
p21144
aS'Mshana SE'
p21145
aS'Rambau PF'
p21146
aS'Masalu N'
p21147
aS'Chalya PL'
p21148
aS'Kalluvya SE'
p21149
asS'MHDA'
p21150
S'2015/03/31 06:00'
p21151
sS'PHST'
p21152
(lp21153
S'2013/08/09 [received]'
p21154
aS'2014/07/04 [accepted]'
p21155
aS'2014/08/02 [aheadofprint]'
p21156
asS'OID'
p21157
(lp21158
S'NLM: PMC4121298'
p21159
asS'MH'
p21160
(lp21161
S'Adolescent'
p21162
aS'Adult'
p21163
aS'Aged'
p21164
aS'Carcinoma, Hepatocellular/*economics/mortality/*secondary/therapy'
p21165
aS'Combined Modality Therapy'
p21166
aS'Developing Countries'
p21167
aS'Disease Management'
p21168
aS'Female'
p21169
aS'Follow-Up Studies'
p21170
aS'Health Resources/*economics'
p21171
aS'Health Services Accessibility/*economics'
p21172
aS'Humans'
p21173
aS'Length of Stay/*economics'
p21174
aS'Liver Neoplasms/*economics/mortality/*pathology/therapy'
p21175
aS'Male'
p21176
aS'Middle Aged'
p21177
aS'Neoplasm Metastasis'
p21178
aS'Neoplasm Staging'
p21179
aS'Prognosis'
p21180
aS'Risk Factors'
p21181
aS'Survival Rate'
p21182
aS'Young Adult'
p21183
asS'EDAT'
p21184
S'2014/08/03 06:00'
p21185
sS'SO'
p21186
S'World J Surg Oncol. 2014 Aug 2;12:246. doi: 10.1186/1477-7819-12-246.'
p21187
sS'SB'
p21188
S'IM'
p21189
sS'PMID'
p21190
S'25085449'
p21191
sS'TA'
p21192
S'World J Surg Oncol'
p21193
sS'PST'
p21194
S'epublish'
p21195
stRp21196
ag2
(g3
g4
(dp21197
S'LID'
p21198
S'10.1371/journal.pone.0102960 [doi]'
p21199
sS'STAT'
p21200
S'MEDLINE'
p21201
sS'DEP'
p21202
S'20140730'
p21203
sS'DA'
p21204
S'20140731'
p21205
sS'AID'
p21206
(lp21207
S'10.1371/journal.pone.0102960 [doi]'
p21208
aS'PONE-D-13-53708 [pii]'
p21209
asS'CRDT'
p21210
(lp21211
S'2014/07/31 06:00'
p21212
asS'DP'
p21213
S'2014'
p21214
sS'AD'
p21215
S'University of Washington, Seattle, Washington, United States of America. Harvard School of Public Health, Boston, Massachusetts, United States of America. University of California San Francisco, San Francisco, California, United States of America. Asociacion Civil Impacta Salud y Educacion, Lima, Peru San Francisco Department of Public Health, California, United States of America. Asociacion Civil Impacta Salud y Educacion, Lima, Peru San Francisco Department of Public Health, California, United States of America.'
p21216
sS'OWN'
p21217
S'NLM'
p21218
sS'PT'
p21219
(lp21220
S'Journal Article'
p21221
aS'Research Support, N.I.H., Extramural'
p21222
aS"Research Support, U.S. Gov't, Non-P.H.S."
p21223
asS'LA'
p21224
(lp21225
S'eng'
p21226
asS'FAU'
p21227
(lp21228
S'Goodreau, Steven M'
p21229
aS'Carnegie, Nicole B'
p21230
aS'Vittinghoff, Eric'
p21231
aS'Lama, Javier R'
p21232
aS'Fuchs, Jonathan D'
p21233
aS'Sanchez, Jorge'
p21234
aS'Buchbinder, Susan P'
p21235
asS'JT'
p21236
S'PloS one'
p21237
sS'LR'
p21238
S'20150701'
p21239
sS'PG'
p21240
S'e102960'
p21241
sS'TI'
p21242
S'Can male circumcision have an impact on the HIV epidemic in men who have sex with men?'
p21243
sS'PL'
p21244
S'United States'
p21245
sS'TA'
p21246
S'PLoS One'
p21247
sS'JID'
p21248
S'101285081'
p21249
sS'AB'
p21250
S'BACKGROUND: Three trials have demonstrated the prophylactic effect of male circumcision (MC) for HIV acquisition among heterosexuals, and MC interventions are underway throughout sub-Saharan Africa. Similar efforts for men who have sex with men (MSM) are stymied by the potential for circumcised MSM to acquire HIV easily through receptive sex and transmit easily through insertive sex. Existing work suggests that MC for MSM should reach its maximum potential in settings where sexual role segregation is historically high and relatively stable across the lifecourse; HIV incidence among MSM is high; reported willingness for prophylactic circumcision is high; and pre-existing circumcision rates are low. We aim to identify the likely public health impact that MC interventions among MSM would have in one setting that fulfills these conditions-Peru-as a theoretical upper bound for their effectiveness among MSM generally. METHODS AND FINDINGS: We use a dynamic, stochastic sexual network model based in exponential-family random graph modeling and parameterized from multiple behavioral surveys of Peruvian MSM. We consider three enrollment criteria (insertive during 100%, >80% or >60% of UAI) and two levels of uptake (25% and 50% of eligible men); we explore sexual role proportions from two studies and different frequencies of switching among role categories. Each scenario is simulated 10 times. We estimate that efficiency could reach one case averted per 6 circumcisions. However, the population-level impact of an optimistic MSM-MC intervention in this setting would likely be at most approximately 5-10% incidence and prevalence reductions over 25 years. CONCLUSIONS: Roll-out of MC for MSM in Peru would not result in a substantial reduction in new HIV infections, despite characteristics in this population that could maximize such effects. Additional studies are needed to confirm these results for other MSM populations, and providers may consider the individual health benefits of offering MC to their MSM patients.'
p21251
sS'GR'
p21252
(lp21253
S'P30 MH062246/MH/NIMH NIH HHS/United States'
p21254
aS'R01 AI083060/AI/NIAID NIH HHS/United States'
p21255
aS'R01 AI083060/AI/NIAID NIH HHS/United States'
p21256
aS'R01 AI52054/AI/NIAID NIH HHS/United States'
p21257
aS'R01 HD068395/HD/NICHD NIH HHS/United States'
p21258
aS'R01 HD068395/HD/NICHD NIH HHS/United States'
p21259
aS'R24 HD042828/HD/NICHD NIH HHS/United States'
p21260
aS'R37 AI051164/AI/NIAID NIH HHS/United States'
p21261
aS'UM1 AI069496/AI/NIAID NIH HHS/United States'
p21262
asS'IP'
p21263
S'7'
sS'IS'
p21264
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p21265
sS'PMC'
p21266
S'PMC4116164'
p21267
sS'DCOM'
p21268
S'20151109'
p21269
sS'AU'
p21270
(lp21271
S'Goodreau SM'
p21272
aS'Carnegie NB'
p21273
aS'Vittinghoff E'
p21274
aS'Lama JR'
p21275
aS'Fuchs JD'
p21276
aS'Sanchez J'
p21277
aS'Buchbinder SP'
p21278
asS'VI'
p21279
S'9'
sS'MHDA'
p21280
S'2015/11/10 06:00'
p21281
sS'PHST'
p21282
(lp21283
S'2014 [ecollection]'
p21284
aS'2013/12/19 [received]'
p21285
aS'2014/06/25 [accepted]'
p21286
aS'2014/07/30 [epublish]'
p21287
asS'OID'
p21288
(lp21289
S'NLM: PMC4116164'
p21290
asS'MH'
p21291
(lp21292
S'*Circumcision, Male'
p21293
aS'Disease Outbreaks/*prevention & control'
p21294
aS'HIV Infections/epidemiology/*prevention & control'
p21295
aS'*Homosexuality, Male'
p21296
aS'Humans'
p21297
aS'Male'
p21298
aS'Models, Statistical'
p21299
aS'Peru'
p21300
asS'EDAT'
p21301
S'2014/07/31 06:00'
p21302
sS'SO'
p21303
S'PLoS One. 2014 Jul 30;9(7):e102960. doi: 10.1371/journal.pone.0102960. eCollection 2014.'
p21304
sS'SB'
p21305
S'IM'
p21306
sS'PMID'
p21307
S'25076493'
p21308
sS'PST'
p21309
S'epublish'
p21310
stRp21311
ag2
(g3
g4
(dp21312
S'LID'
p21313
S'10.1371/journal.pone.0103864 [doi]'
p21314
sS'STAT'
p21315
S'MEDLINE'
p21316
sS'DEP'
p21317
S'20140730'
p21318
sS'DA'
p21319
S'20140731'
p21320
sS'AID'
p21321
(lp21322
S'10.1371/journal.pone.0103864 [doi]'
p21323
aS'PONE-D-14-15977 [pii]'
p21324
asS'CRDT'
p21325
(lp21326
S'2014/07/31 06:00'
p21327
asS'DP'
p21328
S'2014'
p21329
sS'AD'
p21330
S'Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, United States of America. Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, United States of America; ICAP, Mailman School of Public Health, Columbia University, New York, New York, United States of America. ICAP, Mailman School of Public Health, Columbia University, New York, New York, United States of America. Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, United States of America; ICAP, Mailman School of Public Health, Columbia University, New York, New York, United States of America. ICAP, Mailman School of Public Health, Columbia University, New York, New York, United States of America. National AIDS and STI Control Programme, Ministry of Health, Nairobi, Kenya. National AIDS Control Program, Ministry of Health and Social Welfare, Dar es Salaam, Tanzania. Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, United States of America; ICAP, Mailman School of Public Health, Columbia University, New York, New York, United States of America. Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, United States of America; ICAP, Mailman School of Public Health, Columbia University, New York, New York, United States of America.'
p21331
sS'OWN'
p21332
S'NLM'
p21333
sS'PT'
p21334
(lp21335
S'Journal Article'
p21336
aS"Research Support, U.S. Gov't, P.H.S."
p21337
asS'LA'
p21338
(lp21339
S'eng'
p21340
asS'FAU'
p21341
(lp21342
S'Eduardo, Eduard'
p21343
aS'Lamb, Matthew R'
p21344
aS'Kandula, Sasi'
p21345
aS'Howard, Andrea'
p21346
aS'Mugisha, Veronicah'
p21347
aS'Kimanga, Davies'
p21348
aS'Kilama, Bonita'
p21349
aS'El-Sadr, Wafaa'
p21350
aS'Elul, Batya'
p21351
asS'JT'
p21352
S'PloS one'
p21353
sS'PG'
p21354
S'e103864'
p21355
sS'TI'
p21356
S'Characteristics and outcomes among older HIV-positive adults enrolled in HIV programs in four sub-Saharan African countries.'
p21357
sS'RN'
p21358
(lp21359
S'0 (Anti-HIV Agents)'
p21360
asS'PL'
p21361
S'United States'
p21362
sS'TA'
p21363
S'PLoS One'
p21364
sS'JID'
p21365
S'101285081'
p21366
sS'AB'
p21367
S'BACKGROUND: Limited information exists on adults >/=50 years receiving HIV care in sub-Saharan Africa. METHODOLOGY: Using routinely-collected longitudinal patient-level data among 391,111 adults >/=15 years enrolling in HIV care from January 2005-December 2010 and 184,689 initiating ART, we compared characteristics and outcomes between older (>/=50 years) and younger adults at 199 clinics in Kenya, Mozambique, Rwanda, and Tanzania. We calculated proportions over time of newly enrolled and active adults receiving HIV care and initiating ART who were >/=50 years; cumulative incidence of loss to follow-up (LTF) and recorded death one year after enrollment and ART initiation, and CD4+ response following ART initiation. FINDINGS: From 2005-2010, the percentage of adults >/=50 years newly enrolled in HIV care remained stable at 10%, while the percentage of adults >/=50 years newly initiating ART (10% [2005]-12% [2010]), active in follow-up (10% [2005]-14% (2010]), and active on ART (10% [2005]-16% [2010]) significantly increased. One year after enrollment, older patients had significantly lower incidence of LTF (33.1% vs. 32.6%[40-49 years], 40.5%[25-39 years], and 56.3%[15-24 years]; p-value<0.0001), but significantly higher incidence of recorded death (6.0% vs. 5.0% [40-49 years], 4.1% [25-39 years], and 2.8% [15-24 years]; p-valve<0.0001). LTF was lower after vs. before ART initiation for all ages, with older adults experiencing less LTF than younger adults. Among 85,763 ART patients with baseline and follow-up CD4+ counts, adjusted average 12-month CD4+ response for older adults was 20.6 cells/mm3 lower than for adults 25-39 years of age (95% CI: 17.1-24.1). CONCLUSIONS: The proportion of patients who are >/=50 years has increased over time and been driven by aging of the existing patient population. Older patients experienced less LTF, higher recorded mortality and less robust CD4+ response after ART initiation. Increased programmatic attention on older adults receiving HIV care in sub-Saharan Africa is warranted.'
p21368
sS'GR'
p21369
(lp21370
S'5U2GPS001537-03/PHS HHS/United States'
p21371
asS'IP'
p21372
S'7'
sS'IS'
p21373
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p21374
sS'PMC'
p21375
S'PMC4116238'
p21376
sS'DCOM'
p21377
S'20151112'
p21378
sS'AU'
p21379
(lp21380
S'Eduardo E'
p21381
aS'Lamb MR'
p21382
aS'Kandula S'
p21383
aS'Howard A'
p21384
aS'Mugisha V'
p21385
aS'Kimanga D'
p21386
aS'Kilama B'
p21387
aS'El-Sadr W'
p21388
aS'Elul B'
p21389
asS'VI'
p21390
S'9'
sS'MHDA'
p21391
S'2015/11/13 06:00'
p21392
sS'PHST'
p21393
(lp21394
S'2014 [ecollection]'
p21395
aS'2014/04/10 [received]'
p21396
aS'2014/07/03 [accepted]'
p21397
aS'2014/07/30 [epublish]'
p21398
asS'OID'
p21399
(lp21400
S'NLM: PMC4116238'
p21401
asS'MH'
p21402
(lp21403
S'Adolescent'
p21404
aS'Adult'
p21405
aS'Ambulatory Care Facilities'
p21406
aS'Anti-HIV Agents/*therapeutic use'
p21407
aS'CD4 Lymphocyte Count'
p21408
aS'Female'
p21409
aS'Government Programs'
p21410
aS'HIV Infections/*drug therapy/epidemiology/immunology'
p21411
aS'Humans'
p21412
aS'Kenya/epidemiology'
p21413
aS'Lost to Follow-Up'
p21414
aS'Male'
p21415
aS'Middle Aged'
p21416
aS'Mozambique/epidemiology'
p21417
aS'Rwanda/epidemiology'
p21418
aS'Tanzania/epidemiology'
p21419
aS'Treatment Outcome'
p21420
aS'Young Adult'
p21421
asS'EDAT'
p21422
S'2014/07/31 06:00'
p21423
sS'SO'
p21424
S'PLoS One. 2014 Jul 30;9(7):e103864. doi: 10.1371/journal.pone.0103864. eCollection 2014.'
p21425
sS'SB'
p21426
S'IM'
p21427
sS'PMID'
p21428
S'25075743'
p21429
sS'PST'
p21430
S'epublish'
p21431
stRp21432
ag2
(g3
g4
(dp21433
S'LID'
p21434
S'10.1097/INF.0000000000000491 [doi]'
p21435
sS'STAT'
p21436
S'MEDLINE'
p21437
sS'JT'
p21438
S'The Pediatric infectious disease journal'
p21439
sS'MID'
p21440
(lp21441
S'EMS62531'
p21442
asS'DA'
p21443
S'20150309'
p21444
sS'AID'
p21445
(lp21446
S'10.1097/INF.0000000000000491 [doi]'
p21447
asS'CRDT'
p21448
(lp21449
S'2014/07/29 06:00'
p21450
asS'DP'
p21451
S'2015 Feb'
p21452
sS'GR'
p21453
(lp21454
S'093768/Wellcome Trust/United Kingdom'
p21455
aS'100714/Wellcome Trust/United Kingdom'
p21456
aS'MC_EX_G0300400/Medical Research Council/United Kingdom'
p21457
aS'MC_U122886353/Medical Research Council/United Kingdom'
p21458
aS'WT 093768/z/10/z/Wellcome Trust/United Kingdom'
p21459
aS'Medical Research Council/United Kingdom'
p21460
asS'OWN'
p21461
S'NLM'
p21462
sS'PT'
p21463
(lp21464
S'Journal Article'
p21465
aS"Research Support, Non-U.S. Gov't"
p21466
asS'LA'
p21467
(lp21468
S'eng'
p21469
asS'FAU'
p21470
(lp21471
S'Bwakura-Dangarembizi, Mutsawashe'
p21472
aS'Musiime, Victor'
p21473
aS'Szubert, Alexander J'
p21474
aS'Prendergast, Andrew J'
p21475
aS'Gomo, Zvenyika A'
p21476
aS'Thomason, Margaret J'
p21477
aS'Musarurwa, Cuthbert'
p21478
aS'Mugyenyi, Peter'
p21479
aS'Nahirya, Patricia'
p21480
aS'Kekitiinwa, Adeodata'
p21481
aS'Gibb, Diana M'
p21482
aS'Walker, Ann S'
p21483
aS'Nathoo, Kusum'
p21484
asS'LR'
p21485
S'20160713'
p21486
sS'PG'
p21487
S'e23-31'
p21488
sS'TI'
p21489
S'Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy.'
p21490
sS'RN'
p21491
(lp21492
S'0 (Anti-Retroviral Agents)'
p21493
aS'0 (Lipids)'
p21494
asS'PL'
p21495
S'United States'
p21496
sS'TA'
p21497
S'Pediatr Infect Dis J'
p21498
sS'FIR'
p21499
(lp21500
S'Munderi, P'
p21501
aS'Nahirya-Ntege, P'
p21502
aS'Katuramu, R'
p21503
aS'Lutaakome, J'
p21504
aS'Nankya, F'
p21505
aS'Nabulime, G'
p21506
aS'Sekamatte, I'
p21507
aS'Kyarimpa, J'
p21508
aS'Ruberantwari, A'
p21509
aS'Sebukyu, R'
p21510
aS'Tushabe, G'
p21511
aS'Wangi, D'
p21512
aS'Musinguzi, M'
p21513
aS'Aber, M'
p21514
aS'Matama, L'
p21515
aS'Nakitto-Kesi, D'
p21516
aS'Mugyenyi, P'
p21517
aS'Musiime, V'
p21518
aS'Keishanyu, R'
p21519
aS'Afayo, V D'
p21520
aS'Bwomezi, J'
p21521
aS'Byaruhanga, J'
p21522
aS'Erimu, P'
p21523
aS'Karungi, C'
p21524
aS'Kizito, H'
p21525
aS'Namala, W S'
p21526
aS'Namusanje, J'
p21527
aS'Nandugwa, R'
p21528
aS'Najjuko, T K'
p21529
aS'Natukunda, E'
p21530
aS'Ndigendawani, M'
p21531
aS'Nsiyona, S O'
p21532
aS'Kibenge, R'
p21533
aS'Bainomuhwezi, B'
p21534
aS'Sseremba, D'
p21535
aS'Tezikyabbiri, J'
p21536
aS'Tumusiime, C S'
p21537
aS'Balaba, A'
p21538
aS'Mugumya, A'
p21539
aS'Nghania, F'
p21540
aS'Mwebesa, D'
p21541
aS'Mutumba, M'
p21542
aS'Bagurukira, E'
p21543
aS'Odongo, F'
p21544
aS'Mubokyi, S'
p21545
aS'Ssenyonga, M'
p21546
aS'Kasango, M'
p21547
aS'Lutalo, E'
p21548
aS'Oronon, P'
p21549
aS'Nathoo, K J'
p21550
aS'Bwakura-Dangarembizi, M F'
p21551
aS'Mapinge, F'
p21552
aS'Chidziva, E'
p21553
aS'Mhute, T'
p21554
aS'Vhembo, T'
p21555
aS'Mandidewa, R'
p21556
aS'Chipiti, M'
p21557
aS'Dzapasi, R'
p21558
aS'Katanda, C'
p21559
aS'Nyoni, D'
p21560
aS'Tinago, G C'
p21561
aS'Bhiri, J'
p21562
aS'Mudzingwa, S'
p21563
aS'Muchabaiwa, D'
p21564
aS'Phiri, M'
p21565
aS'Masore, V'
p21566
aS'Marozva, C C'
p21567
aS'Maturure, S J'
p21568
aS'Tsikirayi, S'
p21569
aS'Munetsi, L'
p21570
aS'Rashirai, K M'
p21571
aS'Steamer, J'
p21572
aS'Nhema, R'
p21573
aS'Bikwa, W'
p21574
aS'Tambawoga, B'
p21575
aS'Mufuka, E'
p21576
aS'Kekitiinwa, A'
p21577
aS'Musoke, P'
p21578
aS'Bakeera-Kitaka, S'
p21579
aS'Namuddu, R'
p21580
aS'Kasirye, P'
p21581
aS'Babirye, A'
p21582
aS'Asello, J'
p21583
aS'Nakalanzi, S'
p21584
aS'Nakafeero, J'
p21585
aS'Tikabibamu, J'
p21586
aS'Musoba, G'
p21587
aS'Ssanyu, J'
p21588
aS'Kisekka, M'
p21589
aS'Gibb, D M'
p21590
aS'Thomason, M J'
p21591
aS'Walker, A S'
p21592
aS'Cook, A D'
p21593
aS'Szubert, A J'
p21594
aS'Naidoo-James, B'
p21595
aS'Spyer, M J'
p21596
aS'Male, C'
p21597
aS'Glabay, A J'
p21598
aS'Kendall, L K'
p21599
aS'Crawley, J'
p21600
aS'Prendergast, A J'
p21601
aS'Machingura, I'
p21602
aS'Ssenyonjo, S'
p21603
aS'Weller, I'
p21604
aS'Luyirika, E'
p21605
aS'Lyall, H'
p21606
aS'Malianga, E'
p21607
aS'Mwansambo, C'
p21608
aS'Nyathi, M'
p21609
aS'Miiro, F'
p21610
aS'Gibb, D M'
p21611
aS'Kekitiinwa, A'
p21612
aS'Mugyenyi, P'
p21613
aS'Munderi, P'
p21614
aS'Nathoo, K J'
p21615
aS'Walker, A S'
p21616
aS'Kinn, S'
p21617
aS'McNeil, M'
p21618
aS'Roberts, M'
p21619
aS'Snowden, W'
p21620
aS'Breckenridge, A'
p21621
aS'Pozniak, A'
p21622
aS'Hill, C'
p21623
aS'Matenga, J'
p21624
aS'Tumwine, J'
p21625
aS'Tudor-Williams, G'
p21626
aS'Barigye, H'
p21627
aS'Mujuru, H A'
p21628
aS'Ndeezi, G'
p21629
aS'Bakeera-Kitaka, S'
p21630
aS'Bwakura-Dangarembizi, M F'
p21631
aS'Crawley, J'
p21632
aS'Musiime, V'
p21633
aS'Nahirya-Ntege, P'
p21634
aS'Prendergast, A'
p21635
aS'Spyer, M'
p21636
aS'Revill, P'
p21637
aS'Mabugu, T'
p21638
aS'Mirimo, F'
p21639
aS'Walker, S'
p21640
aS'Sculpher, M J'
p21641
asS'JID'
p21642
S'8701858'
p21643
sS'AB'
p21644
S'BACKGROUND: Most pediatric lipodystrophy data come from high-income/middle-income countries, but most HIV-infected children live in sub-Saharan Africa, where lipodystrophy studies have predominantly investigated stavudine-based regimens. METHODS: Three years after antiretroviral therapy (ART) initiation, body circumferences and skinfold thicknesses were measured (n = 590), and fasted lipid profile assayed (n = 325), in children from 2 ARROW trial centres in Uganda/Zimbabwe. Analyses compared randomization to long-term versus short-term versus no zidovudine from ART initiation [unadjusted; latter 2 groups receiving abacavir+lamivudine+non-nucleoside-reverse-transciptase-inhibitor (nNRTI) long-term], and nonrandomized (confounder-adjusted) receipt of nevirapine versus efavirenz. RESULTS: Body circumferences and skinfold thicknesses were similar regardless of zidovudine exposure (P > 0.1), except for subscapular and supra-iliac skinfolds-for-age which were greater with long-term zidovudine (0.006 < P < 0.047). Circumferences/skinfolds were also similar with efavirenz and nevirapine (adjusted P > 0.09; 0.02 < P < 0.03 for waist/waist-hip-ratio). Total and high-density lipoprotein (HDL)-cholesterol, HDL/triglyceride-ratio (P < 0.0001) and triglycerides (P = 0.01) were lower with long-term zidovudine. Low-density lipoprotein (LDL)-cholesterol was higher with efavirenz than nevirapine (P < 0.001). Most lipids remained within normal ranges (75% cholesterol, 85% LDL and 100% triglycerides) but more on long-term zidovudine (3 NRTI) had abnormal HDL-cholesterol (88% vs. 40% short/no-zidovudine, P < 0.0001). Only 8/579(1.4%) children had clinical fat wasting (5 grade 1; 3 grade 2); 2(0.3%) had grade 1 fat accumulation. CONCLUSIONS: Long-term zidovudine-based ART is associated with similar body circumferences and skinfold thicknesses to abacavir-based ART, with low rates of lipid abnormalities and clinical lipodystrophy, providing reassurance where national programs now recommend long-term zidovudine. Efavirenz and nevirapine were also similar; however, the higher LDL observed with efavirenz and lower HDL observed with zidovudine suggests that zidovudine+lamivudine+efavirenz should be investigated in future.'
p21645
sS'AD'
p21646
S'*University of Zimbabwe, College of Health Sciences, Harare, Zimbabwe; daggerJoint Clinical Research Centre; double daggerMakerere University, College of Health Sciences, Kampala, Uganda; section signMedical Research Council Clinical Trials Unit; paragraph sign Centre for Paediatrics, Blizard Institute, Queen Mary University of London, London, United Kingdom; ||Medical Research Council/Uganda Virus Research Institute Uganda Research Unit on AIDS, Entebbe, Uganda; and **Pediatric Infectious Diseases Clinic/Baylor - Uganda, Mulago Hospital, Kampala, Uganda.'
p21647
sS'CN'
p21648
(lp21649
S'ARROW Trial Team'
p21650
asS'IP'
p21651
S'2'
sS'IS'
p21652
S'1532-0987 (Electronic) 0891-3668 (Linking)'
p21653
sS'IR'
p21654
(lp21655
S'Munderi P'
p21656
aS'Nahirya-Ntege P'
p21657
aS'Katuramu R'
p21658
aS'Lutaakome J'
p21659
aS'Nankya F'
p21660
aS'Nabulime G'
p21661
aS'Sekamatte I'
p21662
aS'Kyarimpa J'
p21663
aS'Ruberantwari A'
p21664
aS'Sebukyu R'
p21665
aS'Tushabe G'
p21666
aS'Wangi D'
p21667
aS'Musinguzi M'
p21668
aS'Aber M'
p21669
aS'Matama L'
p21670
aS'Nakitto-Kesi D'
p21671
aS'Mugyenyi P'
p21672
aS'Musiime V'
p21673
aS'Keishanyu R'
p21674
aS'Afayo VD'
p21675
aS'Bwomezi J'
p21676
aS'Byaruhanga J'
p21677
aS'Erimu P'
p21678
aS'Karungi C'
p21679
aS'Kizito H'
p21680
aS'Namala WS'
p21681
aS'Namusanje J'
p21682
aS'Nandugwa R'
p21683
aS'Najjuko TK'
p21684
aS'Natukunda E'
p21685
aS'Ndigendawani M'
p21686
aS'Nsiyona SO'
p21687
aS'Kibenge R'
p21688
aS'Bainomuhwezi B'
p21689
aS'Sseremba D'
p21690
aS'Tezikyabbiri J'
p21691
aS'Tumusiime CS'
p21692
aS'Balaba A'
p21693
aS'Mugumya A'
p21694
aS'Nghania F'
p21695
aS'Mwebesa D'
p21696
aS'Mutumba M'
p21697
aS'Bagurukira E'
p21698
aS'Odongo F'
p21699
aS'Mubokyi S'
p21700
aS'Ssenyonga M'
p21701
aS'Kasango M'
p21702
aS'Lutalo E'
p21703
aS'Oronon P'
p21704
aS'Nathoo KJ'
p21705
aS'Bwakura-Dangarembizi MF'
p21706
aS'Mapinge F'
p21707
aS'Chidziva E'
p21708
aS'Mhute T'
p21709
aS'Vhembo T'
p21710
aS'Mandidewa R'
p21711
aS'Chipiti M'
p21712
aS'Dzapasi R'
p21713
aS'Katanda C'
p21714
aS'Nyoni D'
p21715
aS'Tinago GC'
p21716
aS'Bhiri J'
p21717
aS'Mudzingwa S'
p21718
aS'Muchabaiwa D'
p21719
aS'Phiri M'
p21720
aS'Masore V'
p21721
aS'Marozva CC'
p21722
aS'Maturure SJ'
p21723
aS'Tsikirayi S'
p21724
aS'Munetsi L'
p21725
aS'Rashirai KM'
p21726
aS'Steamer J'
p21727
aS'Nhema R'
p21728
aS'Bikwa W'
p21729
aS'Tambawoga B'
p21730
aS'Mufuka E'
p21731
aS'Kekitiinwa A'
p21732
aS'Musoke P'
p21733
aS'Bakeera-Kitaka S'
p21734
aS'Namuddu R'
p21735
aS'Kasirye P'
p21736
aS'Babirye A'
p21737
aS'Asello J'
p21738
aS'Nakalanzi S'
p21739
aS'Nakafeero J'
p21740
aS'Tikabibamu J'
p21741
aS'Musoba G'
p21742
aS'Ssanyu J'
p21743
aS'Kisekka M'
p21744
aS'Gibb DM'
p21745
aS'Thomason MJ'
p21746
aS'Walker AS'
p21747
aS'Cook AD'
p21748
aS'Szubert AJ'
p21749
aS'Naidoo-James B'
p21750
aS'Spyer MJ'
p21751
aS'Male C'
p21752
aS'Glabay AJ'
p21753
aS'Kendall LK'
p21754
aS'Crawley J'
p21755
aS'Prendergast AJ'
p21756
aS'Machingura I'
p21757
aS'Ssenyonjo S'
p21758
aS'Weller I'
p21759
aS'Luyirika E'
p21760
aS'Lyall H'
p21761
aS'Malianga E'
p21762
aS'Mwansambo C'
p21763
aS'Nyathi M'
p21764
aS'Miiro F'
p21765
aS'Gibb DM'
p21766
aS'Kekitiinwa A'
p21767
aS'Mugyenyi P'
p21768
aS'Munderi P'
p21769
aS'Nathoo KJ'
p21770
aS'Walker AS'
p21771
aS'Kinn S'
p21772
aS'McNeil M'
p21773
aS'Roberts M'
p21774
aS'Snowden W'
p21775
aS'Breckenridge A'
p21776
aS'Pozniak A'
p21777
aS'Hill C'
p21778
aS'Matenga J'
p21779
aS'Tumwine J'
p21780
aS'Tudor-Williams G'
p21781
aS'Barigye H'
p21782
aS'Mujuru HA'
p21783
aS'Ndeezi G'
p21784
aS'Bakeera-Kitaka S'
p21785
aS'Bwakura-Dangarembizi MF'
p21786
aS'Crawley J'
p21787
aS'Musiime V'
p21788
aS'Nahirya-Ntege P'
p21789
aS'Prendergast A'
p21790
aS'Spyer M'
p21791
aS'Revill P'
p21792
aS'Mabugu T'
p21793
aS'Mirimo F'
p21794
aS'Walker S'
p21795
aS'Sculpher MJ'
p21796
asS'DCOM'
p21797
S'20151113'
p21798
sS'AU'
p21799
(lp21800
S'Bwakura-Dangarembizi M'
p21801
aS'Musiime V'
p21802
aS'Szubert AJ'
p21803
aS'Prendergast AJ'
p21804
aS'Gomo ZA'
p21805
aS'Thomason MJ'
p21806
aS'Musarurwa C'
p21807
aS'Mugyenyi P'
p21808
aS'Nahirya P'
p21809
aS'Kekitiinwa A'
p21810
aS'Gibb DM'
p21811
aS'Walker AS'
p21812
aS'Nathoo K'
p21813
asS'VI'
p21814
S'34'
p21815
sS'MHDA'
p21816
S'2015/11/14 06:00'
p21817
sS'OID'
p21818
(lp21819
S'NLM: EMS62531'
p21820
aS'NLM: PMC4369579'
p21821
asS'MH'
p21822
(lp21823
S'Adolescent'
p21824
aS'Anti-Retroviral Agents/adverse effects/*therapeutic use'
p21825
aS'Antiretroviral Therapy, Highly Active/adverse effects/*methods'
p21826
aS'Body Fat Distribution'
p21827
aS'Child'
p21828
aS'Child, Preschool'
p21829
aS'Female'
p21830
aS'HIV Infections/*complications/*drug therapy'
p21831
aS'Humans'
p21832
aS'Infant'
p21833
aS'Lipids/blood'
p21834
aS'Lipodystrophy/chemically induced/*epidemiology'
p21835
aS'Male'
p21836
aS'Prevalence'
p21837
aS'Uganda/epidemiology'
p21838
aS'Zimbabwe/epidemiology'
p21839
asS'EDAT'
p21840
S'2014/07/30 06:00'
p21841
sS'PMC'
p21842
S'PMC4369579'
p21843
sS'SO'
p21844
S'Pediatr Infect Dis J. 2015 Feb;34(2):e23-31. doi: 10.1097/INF.0000000000000491.'
p21845
sS'SB'
p21846
S'IM'
p21847
sS'PMID'
p21848
S'25068287'
p21849
sS'PST'
p21850
S'ppublish'
p21851
stRp21852
ag2
(g3
g4
(dp21853
S'LID'
p21854
S'10.1111/tmi.12346 [doi]'
p21855
sS'STAT'
p21856
S'MEDLINE'
p21857
sS'DEP'
p21858
S'20140708'
p21859
sS'CI'
p21860
(lp21861
S'(c) 2014 John Wiley & Sons Ltd.'
p21862
asS'DA'
p21863
S'20140808'
p21864
sS'AID'
p21865
(lp21866
S'10.1111/tmi.12346 [doi]'
p21867
asS'CRDT'
p21868
(lp21869
S'2014/07/22 06:00'
p21870
asS'DP'
p21871
S'2014 Sep'
p21872
sS'AD'
p21873
S'Division of Epidemiology & Biostatistics, School of Public Health & Family Medicine, University of Cape Town, Cape Town, South Africa.'
p21874
sS'OWN'
p21875
S'NLM'
p21876
sS'PT'
p21877
(lp21878
S'Comparative Study'
p21879
aS'Journal Article'
p21880
aS"Research Support, Non-U.S. Gov't"
p21881
asS'LA'
p21882
(lp21883
S'eng'
p21884
asS'FAU'
p21885
(lp21886
S'Grimsrud, Anna'
p21887
aS'Kaplan, Richard'
p21888
aS'Bekker, Linda-Gail'
p21889
aS'Myer, Landon'
p21890
asS'JT'
p21891
S'Tropical medicine & international health : TM & IH'
p21892
sS'PG'
p21893
S'1029-39'
p21894
sS'TI'
p21895
S'Outcomes of a nurse-managed service for stable HIV-positive patients in a large South African public sector antiretroviral therapy programme.'
p21896
sS'RN'
p21897
(lp21898
S'0 (Anti-HIV Agents)'
p21899
asS'PL'
p21900
S'England'
p21901
sS'TA'
p21902
S'Trop Med Int Health'
p21903
sS'JID'
p21904
S'9610576'
p21905
sS'AB'
p21906
S'OBJECTIVES: Models of care utilizing task shifting and decentralization are needed to support growing ART programmes. We compared patient outcomes between a doctor-managed clinic and a nurse-managed down-referral site in Cape Town, South Africa. METHODS: Analysis included all adults who initiated ART between 2002 and 2011 within a large public sector ART service. Stable patients were eligible for down-referral. Outcomes [mortality, loss to follow-up (LTFU), virologic failure] were compared under different models of care using proportional hazards models with time-dependent covariates. RESULTS: Five thousand seven hundred and forty-six patients initiated ART and over 5 years 41% (n = 2341) were down-referred; the median time on ART before down-referral was 1.6 years (interquartile range, 0.9-2.6). The nurse-managed down-referral site reported lower crude rates of mortality, LTFU and virologic failure compared with the doctor-managed clinic. After adjustment, there was no difference in the risk of mortality or virologic failure by model of care. However, patients who were down-referred were more likely to be LTFU than those retained at the doctor-managed site (adjusted hazard ratio, 1.36; 95% CI, 1.09-1.69). Increased levels of LTFU in the nurse-managed vs. doctor-managed service were observed in subgroups of male patients, those with advanced disease at initiation and those who started ART in the early years of the programme. CONCLUSION: Reorganization of ART maintenance by down-referral to nurse-managed services is associated with programme outcomes similar to those achieved using doctor-driven primary care services. Further research is necessary to identify optimal models of care to support long-term retention of patients on ART in resource-limited settings.'
p21907
sS'GR'
p21908
(lp21909
S'Canadian Institutes of Health Research/Canada'
p21910
asS'IP'
p21911
S'9'
sS'IS'
p21912
S'1365-3156 (Electronic) 1360-2276 (Linking)'
p21913
sS'DCOM'
p21914
S'20140929'
p21915
sS'AU'
p21916
(lp21917
S'Grimsrud A'
p21918
aS'Kaplan R'
p21919
aS'Bekker LG'
p21920
aS'Myer L'
p21921
asS'VI'
p21922
S'19'
p21923
sS'MHDA'
p21924
S'2014/09/30 06:00'
p21925
sS'PHST'
p21926
(lp21927
S'2014/07/08 [aheadofprint]'
p21928
asS'OTO'
p21929
(lp21930
S'NOTNLM'
p21931
asS'MH'
p21932
(lp21933
S'Adult'
p21934
aS'Ambulatory Care Facilities'
p21935
aS'Anti-HIV Agents/*therapeutic use'
p21936
aS'Delivery of Health Care/*organization & administration'
p21937
aS'Female'
p21938
aS'HIV'
p21939
aS'HIV Infections/*drug therapy/virology'
p21940
aS'Health Resources'
p21941
aS'Health Services/*manpower'
p21942
aS'Humans'
p21943
aS'*Lost to Follow-Up'
p21944
aS'Male'
p21945
aS'*Nurses'
p21946
aS'Physicians'
p21947
aS'Politics'
p21948
aS'Primary Health Care'
p21949
aS'Proportional Hazards Models'
p21950
aS'Public Sector'
p21951
aS'*Referral and Consultation'
p21952
aS'South Africa'
p21953
aS'Treatment Failure'
p21954
asS'EDAT'
p21955
S'2014/07/22 06:00'
p21956
sS'SO'
p21957
S'Trop Med Int Health. 2014 Sep;19(9):1029-39. doi: 10.1111/tmi.12346. Epub 2014 Jul 8.'
p21958
sS'SB'
p21959
S'IM'
p21960
sS'PMID'
p21961
S'25041716'
p21962
sS'OT'
p21963
(lp21964
S'Terapia antirretroviral (altamente activa)'
p21965
aS'antiretroviral therapy (highly active)'
p21966
aS'decentralization'
p21967
aS'descentralizacion'
p21968
aS'decentralisation'
p21969
aS'delegation des taches'
p21970
aS'loss to follow-up'
p21971
aS'perdu au suivi'
p21972
aS'programme outcomes'
p21973
aS'perdida durante el seguimiento'
p21974
aS'resultados de programa'
p21975
aS'retencion'
p21976
aS'retention'
p21977
aS'rotacion de tareas'
p21978
aS'resultats du programme'
p21979
aS'retention'
p21980
aS'task shifting'
p21981
aS'therapie antiretrovirale (tres active)'
p21982
asS'PST'
p21983
S'ppublish'
p21984
stRp21985
ag2
(g3
g4
(dp21986
S'LID'
p21987
S'10.1007/s10461-014-0849-1 [doi]'
p21988
sS'STAT'
p21989
S'MEDLINE'
p21990
sS'JT'
p21991
S'AIDS and behavior'
p21992
sS'MID'
p21993
(lp21994
S'NIHMS614840'
p21995
asS'DA'
p21996
S'20141014'
p21997
sS'AID'
p21998
(lp21999
S'10.1007/s10461-014-0849-1 [doi]'
p22000
asS'CRDT'
p22001
(lp22002
S'2014/07/20 06:00'
p22003
asS'DP'
p22004
S'2014 Nov'
p22005
sS'AD'
p22006
S'Emory University School of Medicine, Atlanta, GA, USA.'
p22007
sS'OWN'
p22008
S'NLM'
p22009
sS'PT'
p22010
(lp22011
S'Journal Article'
p22012
aS'Research Support, N.I.H., Extramural'
p22013
aS"Research Support, Non-U.S. Gov't"
p22014
asS'LA'
p22015
(lp22016
S'eng'
p22017
asS'FAU'
p22018
(lp22019
S'Hare, Anna Q'
p22020
aS'Ordonez, Claudia E'
p22021
aS'Johnson, Brent A'
p22022
aS'Del Rio, Carlos'
p22023
aS'Kearns, Rachel A'
p22024
aS'Wu, Baohua'
p22025
aS'Hampton, Jane'
p22026
aS'Wu, Peng'
p22027
aS'Sunpath, Henry'
p22028
aS'Marconi, Vincent C'
p22029
asS'LR'
p22030
S'20151101'
p22031
sS'PG'
p22032
S'2219-29'
p22033
sS'TI'
p22034
S'Gender-specific risk factors for virologic failure in KwaZulu-Natal: automobile ownership and financial insecurity.'
p22035
sS'PL'
p22036
S'United States'
p22037
sS'TA'
p22038
S'AIDS Behav'
p22039
sS'JID'
p22040
S'9712133'
p22041
sS'AB'
p22042
S'We sought to examine which socioeconomic indicators are risk factors for virologic failure among HIV-1 infected patients receiving antiretroviral therapy (ART) in KwaZulu-Natal, South Africa. A case-control study of virologic failure was conducted among patients recruited from the outpatient clinic at McCord Hospital in Durban, South Africa between October 1, 2010 and June 30, 2012. Cases were those failing first-line ART, defined as viral load >1,000 copies/mL. Univariate logistic regression was performed on sociodemographic data for the outcome of virologic failure. Variables found significant (p < 0.05) were used in multivariate models and all models were stratified by gender. Of 158 cases and 300 controls, 35 % were male and median age was 40 years. Gender stratification of models revealed automobile ownership was a risk factor among males, while variables of financial insecurity (unemployment, non-spouse family paying for care, staying with family) were risk factors for women. In this cohort, financial insecurity among women and automobile ownership among men were risk factors for virologic failure. Risk factor differences between genders demonstrate limitations of generalized risk factor analysis.'
p22043
sS'GR'
p22044
(lp22045
S'P30AI050409/AI/NIAID NIH HHS/United States'
p22046
aS'R01 AI098558/AI/NIAID NIH HHS/United States'
p22047
aS'R01 AI098558-01A1/AI/NIAID NIH HHS/United States'
p22048
aS'UL1 TR000454/TR/NCATS NIH HHS/United States'
p22049
aS'UL1RR025008/RR/NCRR NIH HHS/United States'
p22050
asS'IP'
p22051
S'11'
p22052
sS'IS'
p22053
S'1573-3254 (Electronic) 1090-7165 (Linking)'
p22054
sS'PMC'
p22055
S'PMC4198463'
p22056
sS'DCOM'
p22057
S'20150622'
p22058
sS'AU'
p22059
(lp22060
S'Hare AQ'
p22061
aS'Ordonez CE'
p22062
aS'Johnson BA'
p22063
aS'Del Rio C'
p22064
aS'Kearns RA'
p22065
aS'Wu B'
p22066
aS'Hampton J'
p22067
aS'Wu P'
p22068
aS'Sunpath H'
p22069
aS'Marconi VC'
p22070
asS'VI'
p22071
S'18'
p22072
sS'MHDA'
p22073
S'2015/06/24 06:00'
p22074
sS'OID'
p22075
(lp22076
S'NLM: NIHMS614840'
p22077
aS'NLM: PMC4198463'
p22078
asS'MH'
p22079
(lp22080
S'Adolescent'
p22081
aS'Adult'
p22082
aS'Aged'
p22083
aS'Automobiles/*statistics & numerical data'
p22084
aS'Case-Control Studies'
p22085
aS'Female'
p22086
aS'HIV Infections/*drug therapy/virology'
p22087
aS'Humans'
p22088
aS'Male'
p22089
aS'Middle Aged'
p22090
aS'Ownership/statistics & numerical data'
p22091
aS'Risk Factors'
p22092
aS'Sex Factors'
p22093
aS'Socioeconomic Factors'
p22094
aS'South Africa/epidemiology'
p22095
aS'Treatment Failure'
p22096
aS'Unemployment/statistics & numerical data'
p22097
aS'Viral Load/statistics & numerical data'
p22098
aS'Young Adult'
p22099
asS'EDAT'
p22100
S'2014/07/20 06:00'
p22101
sS'SO'
p22102
S'AIDS Behav. 2014 Nov;18(11):2219-29. doi: 10.1007/s10461-014-0849-1.'
p22103
sS'SB'
p22104
S'IM'
p22105
sS'PMID'
p22106
S'25037488'
p22107
sS'PST'
p22108
S'ppublish'
p22109
stRp22110
ag2
(g3
g4
(dp22111
S'LID'
p22112
S'10.1080/17441692.2014.934266 [doi]'
p22113
sS'STAT'
p22114
S'MEDLINE'
p22115
sS'DEP'
p22116
S'20140718'
p22117
sS'MID'
p22118
(lp22119
S'NIHMS627138'
p22120
asS'DA'
p22121
S'20141014'
p22122
sS'AID'
p22123
(lp22124
S'10.1080/17441692.2014.934266 [doi]'
p22125
asS'CRDT'
p22126
(lp22127
S'2014/07/19 06:00'
p22128
asS'DP'
p22129
S'2014'
p22130
sS'AD'
p22131
S'a ICAP, Mailman School of Public Health , Columbia University , New York , NY , USA.'
p22132
sS'OWN'
p22133
S'NLM'
p22134
sS'PT'
p22135
(lp22136
S'Journal Article'
p22137
aS'Research Support, N.I.H., Extramural'
p22138
aS"Research Support, Non-U.S. Gov't"
p22139
asS'LA'
p22140
(lp22141
S'eng'
p22142
asS'FAU'
p22143
(lp22144
S'Daftary, Amrita'
p22145
aS'Padayatchi, Nesri'
p22146
aS"O'Donnell, Max"
p22147
asS'JT'
p22148
S'Global public health'
p22149
sS'LR'
p22150
S'20151001'
p22151
sS'PG'
p22152
S'1107-16'
p22153
sS'TI'
p22154
S'Preferential adherence to antiretroviral therapy over tuberculosis treatment: a qualitative study of drug-resistant TB/HIV co-infected patients in South Africa.'
p22155
sS'RN'
p22156
(lp22157
S'0 (Anti-HIV Agents)'
p22158
aS'0 (Antitubercular Agents)'
p22159
asS'PL'
p22160
S'England'
p22161
sS'TA'
p22162
S'Glob Public Health'
p22163
sS'JID'
p22164
S'101256323'
p22165
sS'AB'
p22166
S"Adherence to antiretroviral therapy (ART) and second-line antituberculosis medications is essential to achieve successful outcomes among individuals co-infected with HIV and multi or extensively drug-resistant TB (M/XDR-TB). In 2012-2013, we designed a qualitative study to explore barriers to adherence in KwaZulu-Natal, South Africa. We conducted six focus groups comprising 23 adults receiving treatment for either MDR-TB (n = 2) or XDR-TB (n = 21); 17 were on concurrent ART. Participants expressed a preference for ART over M/XDR-TB treatment as a result of greater tolerability, lower pill burden and a commitment to ART. Treatment outcomes and the social morbidity associated with M/XDR-TB, characterised by public notification, stigma and social isolation, were perceived to be worse than with HIV. Poor communication, low patient involvement and provider supervision of treatment exacerbated participants' negative experiences with TB care. To improve adherence, it is critical that new regimens for drug-resistant TB be developed with better efficacy, lower pill burden and fewer adverse effects. For the first time, such improved regimens are on the horizon. In parallel and equally important is the implementation of a cohesive approach that promotes patient involvement, empowerment and treatment literacy for HIV and for TB."
p22167
sS'GR'
p22168
(lp22169
S'5K23AI098479/AI/NIAID NIH HHS/United States'
p22170
aS'AI51794/AI/NIAID NIH HHS/United States'
p22171
aS'D43 TW000231/TW/FIC NIH HHS/United States'
p22172
aS'D43TW000231-16S1/TW/FIC NIH HHS/United States'
p22173
aS'K23 AI098479/AI/NIAID NIH HHS/United States'
p22174
aS'U19 AI051794/AI/NIAID NIH HHS/United States'
p22175
asS'IP'
p22176
S'9'
sS'IS'
p22177
S'1744-1706 (Electronic) 1744-1692 (Linking)'
p22178
sS'PMC'
p22179
S'PMC4198425'
p22180
sS'DCOM'
p22181
S'20150616'
p22182
sS'AU'
p22183
(lp22184
S'Daftary A'
p22185
aS'Padayatchi N'
p22186
aS"O'Donnell M"
p22187
asS'VI'
p22188
S'9'
sS'MHDA'
p22189
S'2015/06/17 06:00'
p22190
sS'PHST'
p22191
(lp22192
S'2014/07/18 [aheadofprint]'
p22193
asS'OTO'
p22194
(lp22195
S'NOTNLM'
p22196
asS'OID'
p22197
(lp22198
S'NLM: NIHMS627138'
p22199
aS'NLM: PMC4198425'
p22200
asS'MH'
p22201
(lp22202
S'Adolescent'
p22203
aS'Adult'
p22204
aS'Anti-HIV Agents/*administration & dosage'
p22205
aS'Antitubercular Agents/*administration & dosage'
p22206
aS'Extensively Drug-Resistant Tuberculosis/*complications/*drug therapy'
p22207
aS'Female'
p22208
aS'Focus Groups'
p22209
aS'HIV Infections/*complications/*drug therapy'
p22210
aS'Humans'
p22211
aS'Male'
p22212
aS'Medication Adherence/*psychology'
p22213
aS'Middle Aged'
p22214
aS'Qualitative Research'
p22215
aS'South Africa'
p22216
asS'EDAT'
p22217
S'2014/07/19 06:00'
p22218
sS'SO'
p22219
S'Glob Public Health. 2014;9(9):1107-16. doi: 10.1080/17441692.2014.934266. Epub 2014 Jul 18.'
p22220
sS'SB'
p22221
S'IM'
p22222
sS'PMID'
p22223
S'25035943'
p22224
sS'OT'
p22225
(lp22226
S'HIV/AIDS'
p22227
aS'adherence'
p22228
aS'co-infection'
p22229
aS'drug-resistant tuberculosis'
p22230
aS'qualitative methods'
p22231
asS'PST'
p22232
S'ppublish'
p22233
stRp22234
ag2
(g3
g4
(dp22235
S'LID'
p22236
S'10.1097/QAI.0000000000000280 [doi]'
p22237
sS'STAT'
p22238
S'MEDLINE'
p22239
sS'AB'
p22240
S"BACKGROUND: Socioeconomic support reduced nonretention in a community-based antiretroviral therapy (ART) program in Uganda. However, resource implications of expanding socioeconomic support are large, and cost-effectiveness analysis can inform budget priorities. We compared the incremental benefits and costs of providing education, food, or both forms of support (dual support) with existing ART services from a health care provider's perspective. METHODS: Costs and outcome data were collected from a cohort of 2371 adult patients with HIV receiving education, food, or dual support from Reach Out Mbuya between 2004 and 2010. The primary outcome was averted loss to follow-up. The number of follow-up days was calculated for each patient along with accrued service and fixed program costs for the alternative forms of socioeconomic support in USD by standard costing methods. The socioeconomic support types were compared incrementally over the study period. RESULTS: After 7 years, 762 (33%) of the patients were loss to follow-up with 42% of them receiving food. In the presence of providing ART, education support was less costly and more effective than the alternatives. The average unit cost for education, food, and dual support were $237, $538, and $776, respectively. The average total annual costs were $88,643 for education, $538,005 for food, and $103,045 for dual support. CONCLUSIONS: Compared with food or dual support, investing in education of the children of ART patients is less costly and more effective in improving patient retention. Reach Out Mbuya should embrace this paradigm shift and channel its resources more efficiently and effectively by focusing on education support."
p22241
sS'JID'
p22242
S'100892005'
p22243
sS'AD'
p22244
S'*Executive Directors Office, Reach Out Mbuya HIV/AIDS Initiative, Kampala, Uganda; daggerCenter for Health Economics Research & Modeling Infectious Diseases (CHERMID, Vaccine & Infectious Disease Institute [Vaxinfectio]), University of Antwerp, Antwerp, Belgium; and double daggerInstitute of Tropical Medicine Antwerp, Antwerp, Belgium.'
p22245
sS'JT'
p22246
S'Journal of acquired immune deficiency syndromes (1999)'
p22247
sS'IP'
p22248
S'2'
sS'IS'
p22249
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p22250
sS'DCOM'
p22251
S'20150106'
p22252
sS'DA'
p22253
S'20140912'
p22254
sS'AU'
p22255
(lp22256
S'Stella-Talisuna A'
p22257
aS'Bilcke J'
p22258
aS'Colebunders R'
p22259
aS'Beutels P'
p22260
asS'AID'
p22261
(lp22262
S'10.1097/QAI.0000000000000280 [doi]'
p22263
asS'CRDT'
p22264
(lp22265
S'2014/07/18 06:00'
p22266
asS'VI'
p22267
S'67'
p22268
sS'DP'
p22269
S'2014 Oct 1'
p22270
sS'MHDA'
p22271
S'2015/01/07 06:00'
p22272
sS'OWN'
p22273
S'NLM'
p22274
sS'PT'
p22275
(lp22276
S'Journal Article'
p22277
asS'LA'
p22278
(lp22279
S'eng'
p22280
asS'MH'
p22281
(lp22282
S'Adolescent'
p22283
aS'Adult'
p22284
aS'Child'
p22285
aS'Cohort Studies'
p22286
aS'Cost-Benefit Analysis'
p22287
aS'Female'
p22288
aS'*Financial Support'
p22289
aS'Food Supply/economics'
p22290
aS'HIV Infections/*drug therapy'
p22291
aS'Health Education/economics'
p22292
aS'Humans'
p22293
aS'Male'
p22294
aS'*Social Support'
p22295
aS'Treatment Outcome'
p22296
aS'Uganda'
p22297
aS'Urban Population'
p22298
asS'FAU'
p22299
(lp22300
S'Stella-Talisuna, Alamo'
p22301
aS'Bilcke, Joke'
p22302
aS'Colebunders, Robert'
p22303
aS'Beutels, Philippe'
p22304
asS'EDAT'
p22305
S'2014/07/18 06:00'
p22306
sS'PST'
p22307
S'ppublish'
p22308
sS'SO'
p22309
S'J Acquir Immune Defic Syndr. 2014 Oct 1;67(2):e76-83. doi: 10.1097/QAI.0000000000000280.'
p22310
sS'PG'
p22311
S'e76-83'
p22312
sS'TI'
p22313
S'Cost-effectiveness of socioeconomic support as part of HIV care for the poor in an urban community-based antiretroviral program in Uganda.'
p22314
sS'SB'
p22315
S'IM X'
p22316
sS'PMID'
p22317
S'25032486'
p22318
sS'PL'
p22319
S'United States'
p22320
sS'TA'
p22321
S'J Acquir Immune Defic Syndr'
p22322
stRp22323
ag2
(g3
g4
(dp22324
S'LID'
p22325
S'10.3855/jidc.3879 [doi]'
p22326
sS'STAT'
p22327
S'MEDLINE'
p22328
sS'DEP'
p22329
S'20140714'
p22330
sS'DA'
p22331
S'20140715'
p22332
sS'CRDT'
p22333
(lp22334
S'2014/07/16 06:00'
p22335
asS'DP'
p22336
S'2014 Jul'
p22337
sS'OWN'
p22338
S'NLM'
p22339
sS'PT'
p22340
(lp22341
S'Journal Article'
p22342
aS"Research Support, Non-U.S. Gov't"
p22343
aS"Research Support, U.S. Gov't, P.H.S."
p22344
asS'LA'
p22345
(lp22346
S'eng'
p22347
asS'FAU'
p22348
(lp22349
S'Mosha, Fausta'
p22350
aS'Ledwaba, Johanna'
p22351
aS'Ndugulile, Faustine'
p22352
aS"Ng'ang'a, Zipora"
p22353
aS'Nsubuga, Peter'
p22354
aS'Morris, Lynn'
p22355
aS'Kasubi, Mabula'
p22356
aS'Swai, Andrew'
p22357
aS'Vercauteren, Jurgen'
p22358
aS'Vandamme, Anne-Mieke'
p22359
asS'JT'
p22360
S'Journal of infection in developing countries'
p22361
sS'PG'
p22362
S'845-52'
p22363
sS'TI'
p22364
S'Clinical and virological response to antiretroviral drugs among HIV patients on first-line treatment in Dar-es-Salaam, Tanzania.'
p22365
sS'RN'
p22366
(lp22367
S'0 (Anti-HIV Agents)'
p22368
aS'8VZV102JFY (Fluconazole)'
p22369
asS'PL'
p22370
S'Italy'
p22371
sS'TA'
p22372
S'J Infect Dev Ctries'
p22373
sS'JID'
p22374
S'101305410'
p22375
sS'AB'
p22376
S"INTRODUCTION: In Tanzania, the follow-up on antiretroviral therapy (ART) response is based on clinical outcomes. We investigated virological response and ARV resistance mutations in relation to clinical response in ARV-treated patients. METHODOLOGY: A cross-sectional study of a cohort of 150 patients taking first-line ART in Dar-es-Salaam was conducted. Data were collected using standardized questionnaires and patients' blood samples. HIV viral load testing and genotyping was performed on all viremic samples. Statistical analyses compared clinical responders and non-responders. RESULTS: The median time on ART was 20 months; 71 (47%) patients were ART clinical responders. Clinical non-responders were more likely to have started ART with advanced disease with significantly lower median percentage weight gain (6% versus 20%) with respect to pre-treatment levels. Sixty-one (86%) and 64 (81%) of clinical responders and non-responders, respectively, had undetectable viral loads. Genotyping was successful in 24 (96%) virologically failing patients, among whom 83% had resistance mutations; 67% had dual nucleoside reverse transcriptase inhibitor (NRTI)/non-NRTI (NNRTI) resistance mutations. Seventeen (71%) and 19 (79%) patients had NRTI and NNRTI resistance mutations, respectively, which were related to the ART in use, with no difference between clinical responders and non-responders. The most prevalent subtypes were A and C, found in 9 (38%) and 7 (29%) patients, respectively. CONCLUSIONS: The observed virological response was high and did not correlate with clinical response. The prevalence of ARV resistance mutations was high in viraemic patients and was related to the ARV prescribed. We recommend use of viral load monitoring during ART in Tanzania."
p22377
sS'AD'
p22378
S'Ministry of Health and Social Welfare, Tanzania. fausta_mosha@yahoo.com.'
p22379
sS'IP'
p22380
S'7'
sS'IS'
p22381
S'1972-2680 (Electronic) 1972-2680 (Linking)'
p22382
sS'DCOM'
p22383
S'20160513'
p22384
sS'AU'
p22385
(lp22386
S'Mosha F'
p22387
aS'Ledwaba J'
p22388
aS'Ndugulile F'
p22389
aS"Ng'ang'a Z"
p22390
aS'Nsubuga P'
p22391
aS'Morris L'
p22392
aS'Kasubi M'
p22393
aS'Swai A'
p22394
aS'Vercauteren J'
p22395
aS'Vandamme AM'
p22396
asS'VI'
p22397
S'8'
sS'MHDA'
p22398
S'2016/05/14 06:00'
p22399
sS'PHST'
p22400
(lp22401
S'2013/06/15 [received]'
p22402
aS'2013/09/08 [accepted]'
p22403
asS'MH'
p22404
(lp22405
S'AIDS-Related Opportunistic Infections/drug therapy'
p22406
aS'Anti-HIV Agents/*therapeutic use'
p22407
aS'Antiretroviral Therapy, Highly Active/methods'
p22408
aS'Cross-Sectional Studies'
p22409
aS'Drug Resistance, Viral/*genetics'
p22410
aS'Female'
p22411
aS'Fluconazole/therapeutic use'
p22412
aS'HIV Infections/*drug therapy/*virology'
p22413
aS'HIV-1/*drug effects/*genetics'
p22414
aS'Humans'
p22415
aS'Male'
p22416
aS'Mutation'
p22417
aS'Patient Compliance'
p22418
aS'Tanzania'
p22419
aS'Treatment Outcome'
p22420
aS'Viral Load'
p22421
aS'Viremia/drug therapy/virology'
p22422
asS'EDAT'
p22423
S'2014/07/16 06:00'
p22424
sS'SO'
p22425
S'J Infect Dev Ctries. 2014 Jul 14;8(7):845-52. doi: 10.3855/jidc.3879.'
p22426
sS'SB'
p22427
S'IM'
p22428
sS'PMID'
p22429
S'25022294'
p22430
sS'PST'
p22431
S'epublish'
p22432
stRp22433
ag2
(g3
g4
(dp22434
S'LID'
p22435
S'10.1056/NEJMoa1311274 [doi]'
p22436
sS'STAT'
p22437
S'MEDLINE'
p22438
sS'JT'
p22439
S'The New England journal of medicine'
p22440
sS'DA'
p22441
S'20140712'
p22442
sS'AID'
p22443
(lp22444
S'10.1056/NEJMoa1311274 [doi]'
p22445
asS'CRDT'
p22446
(lp22447
S'2014/07/12 06:00'
p22448
asS'DP'
p22449
S'2014 Jul 17'
p22450
sS'GR'
p22451
(lp22452
S'PDF-2012-05-305/Department of Health/United Kingdom'
p22453
aS'Wellcome Trust/United Kingdom'
p22454
aS'Medical Research Council/United Kingdom'
p22455
asS'OWN'
p22456
S'NLM'
p22457
sS'PT'
p22458
(lp22459
S'Journal Article'
p22460
aS'Randomized Controlled Trial'
p22461
aS"Research Support, Non-U.S. Gov't"
p22462
asS'LA'
p22463
(lp22464
S'eng'
p22465
asS'FAU'
p22466
(lp22467
S'Paton, Nicholas I'
p22468
aS'Kityo, Cissy'
p22469
aS'Hoppe, Anne'
p22470
aS'Reid, Andrew'
p22471
aS'Kambugu, Andrew'
p22472
aS'Lugemwa, Abbas'
p22473
aS'van Oosterhout, Joep J'
p22474
aS'Kiconco, Mary'
p22475
aS'Siika, Abraham'
p22476
aS'Mwebaze, Raymond'
p22477
aS'Abwola, Mary'
p22478
aS'Abongomera, George'
p22479
aS'Mweemba, Aggrey'
p22480
aS'Alima, Hillary'
p22481
aS'Atwongyeire, Dickens'
p22482
aS'Nyirenda, Rose'
p22483
aS'Boles, Justine'
p22484
aS'Thompson, Jennifer'
p22485
aS'Tumukunde, Dinah'
p22486
aS'Chidziva, Ennie'
p22487
aS'Mambule, Ivan'
p22488
aS'Arribas, Jose R'
p22489
aS'Easterbrook, Philippa J'
p22490
aS'Hakim, James'
p22491
aS'Walker, A Sarah'
p22492
aS'Mugyenyi, Peter'
p22493
asS'LR'
p22494
S'20151119'
p22495
sS'PG'
p22496
S'234-47'
p22497
sS'TI'
p22498
S'Assessment of second-line antiretroviral regimens for HIV therapy in Africa.'
p22499
sS'RN'
p22500
(lp22501
S'0 (HIV Protease Inhibitors)'
p22502
aS'0 (Pyrrolidinones)'
p22503
aS'0 (Reverse Transcriptase Inhibitors)'
p22504
aS'43Y000U234 (Raltegravir Potassium)'
p22505
asS'PL'
p22506
S'United States'
p22507
sS'TA'
p22508
S'N Engl J Med'
p22509
sS'FIR'
p22510
(lp22511
S'Agweng, E'
p22512
aS'Awio, P'
p22513
aS'Bakeinyaga, G'
p22514
aS'Isabirye, C'
p22515
aS'Kabuga, U'
p22516
aS'Kasuswa, S'
p22517
aS'Katuramu, M'
p22518
aS'Kityo, C'
p22519
aS'Kiweewa, F'
p22520
aS'Kyomugisha, H'
p22521
aS'Lutalo, E'
p22522
aS'Mugyenyi, P'
p22523
aS'Mulima, D'
p22524
aS'Musana, H'
p22525
aS'Musitwa, G'
p22526
aS'Musiime, V'
p22527
aS'Ndigendawan, M'
p22528
aS'Namata, H'
p22529
aS'Nkalubo, J'
p22530
aS'Ocitti Labejja, P'
p22531
aS'Okello, P'
p22532
aS'Olal, P'
p22533
aS'Pimundu, G'
p22534
aS'Segonga, P'
p22535
aS'Ssali, F'
p22536
aS'Tamale, Z'
p22537
aS'Tumukunde, D'
p22538
aS'Namala, W'
p22539
aS'Byaruhanga, R'
p22540
aS'Kayiwa, J'
p22541
aS'Tukamushaba, J'
p22542
aS'Bihabwa, G'
p22543
aS'Buluma, E'
p22544
aS'Easterbrook, P'
p22545
aS'Elbireer, A'
p22546
aS'Kambugu, A'
p22547
aS'Kamya, D'
p22548
aS'Katwere, M'
p22549
aS'Kiggundu, R'
p22550
aS'Komujuni, C'
p22551
aS'Laker, E'
p22552
aS'Lubwama, E'
p22553
aS'Mambule, I'
p22554
aS'Matovu, J'
p22555
aS'Nakajubi, A'
p22556
aS'Nakku, J'
p22557
aS'Nalumenya, R'
p22558
aS'Namuyimbwa, L'
p22559
aS'Semitala, F'
p22560
aS'Wandera, B'
p22561
aS'Wanyama, J'
p22562
aS'Mugerwa, H'
p22563
aS'Lugemwa, A'
p22564
aS'Ninsiima, E'
p22565
aS'Ssenkindu, T'
p22566
aS'Mwebe, S'
p22567
aS'Atwine, L'
p22568
aS'William, H'
p22569
aS'Katemba, C'
p22570
aS'Abunyang, S'
p22571
aS'Acaku, M'
p22572
aS'Ssebutinde, P'
p22573
aS'Kitizo, H'
p22574
aS'Kukundakwe, J'
p22575
aS'Naluguza, M'
p22576
aS'Ssegawa, K'
p22577
aS'Namayanja'
p22578
aS'Nsibuka, F'
p22579
aS'Tuhirirwe, P'
p22580
aS'Fortunate, M'
p22581
aS'Acen, J'
p22582
aS'Achidri, J'
p22583
aS'Amone, A'
p22584
aS'Chamai, M'
p22585
aS'Ditai, J'
p22586
aS'Kemigisa, M'
p22587
aS'Kiconco, M'
p22588
aS'Matama, C'
p22589
aS'Mbanza, D'
p22590
aS'Nambaziira, F'
p22591
aS'Owor Odoi, M'
p22592
aS'Rweyora, A'
p22593
aS'Tumwebaze, G'
p22594
aS'Kalanzi, H'
p22595
aS'Katabaazi, J'
p22596
aS'Kiyingi, A'
p22597
aS'Mbidde, M'
p22598
aS'Mugenyi, M'
p22599
aS'Mwebaze, R'
p22600
aS'Okong, P'
p22601
aS'Senoga, I'
p22602
aS'Abwola, M'
p22603
aS'Baliruno, D'
p22604
aS'Bwomezi, J'
p22605
aS'Kasede, A'
p22606
aS'Mudoola, M'
p22607
aS'Namisi, R'
p22608
aS'Ssennono, F'
p22609
aS'Tuhirwe, S'
p22610
aS'Abongomera, G'
p22611
aS'Amone, G'
p22612
aS'Abach, J'
p22613
aS'Aciro, I'
p22614
aS'Arach, B'
p22615
aS'Kidega, P'
p22616
aS'Omongin, J'
p22617
aS'Ocung, E'
p22618
aS'Odong, W'
p22619
aS'Philliam, A'
p22620
aS'Alima, H'
p22621
aS'Ahimbisibwe, B'
p22622
aS'Atuhaire, E'
p22623
aS'Atukunda, F'
p22624
aS'Bekusike, G'
p22625
aS'Bulegyeya, A'
p22626
aS'Kahatano, D'
p22627
aS'Kamukama, S'
p22628
aS'Kyoshabire, J'
p22629
aS'Nassali, A'
p22630
aS'Mbonye, A'
p22631
aS'Naturinda, T M'
p22632
aS'Ndukukire'
p22633
aS'Nshabohurira, A'
p22634
aS'Ntawiha, H'
p22635
aS'Rogers, A'
p22636
aS'Tibyasa, M'
p22637
aS'Kiirya, S'
p22638
aS'Atwongyeire, D'
p22639
aS'Nankya, A'
p22640
aS'Draleku, C'
p22641
aS'Nakiboneka, D'
p22642
aS'Odoch, D'
p22643
aS'Lakidi, L'
p22644
aS'Ruganda, R'
p22645
aS'Abiriga, R'
p22646
aS'Mulindwa, M'
p22647
aS'Balmoi, F'
p22648
aS'Kafuma, S'
p22649
aS'Moriku, E'
p22650
aS'Hakim, J'
p22651
aS'Reid, A'
p22652
aS'Chidziva, E'
p22653
aS'Musoro, G'
p22654
aS'Warambwa, C'
p22655
aS'Tinago, G'
p22656
aS'Mutsai, S'
p22657
aS'Phiri, M'
p22658
aS'Mudzingwa, S'
p22659
aS'Bafana, T'
p22660
aS'Masore, V'
p22661
aS'Moyo, C'
p22662
aS'Nhema, R'
p22663
aS'Chitongo, S'
p22664
aS'Heyderman, R'
p22665
aS'Kabanga, L'
p22666
aS'Kaunda, S'
p22667
aS'Kudzala, A'
p22668
aS'Lifa, L'
p22669
aS'Mallewa, J'
p22670
aS'Moore, M'
p22671
aS'Mtali, C'
p22672
aS'Musowa, G'
p22673
aS'Mwimaniwa, G'
p22674
aS'Sikwese, R'
p22675
aS'van Oosterhout, J'
p22676
aS'Ziwoya, M'
p22677
aS'Chimbaka, H'
p22678
aS'Chitete, B'
p22679
aS'Kamanga, S'
p22680
aS'Kayinga, T'
p22681
aS'Makwakwa, E'
p22682
aS'Mbiya, R'
p22683
aS'Mlenga, M'
p22684
aS'Mphande, T'
p22685
aS'Mtika, C'
p22686
aS'Mushani, G'
p22687
aS'Ndhlovu, O'
p22688
aS'Ngonga, M'
p22689
aS'Nkhana, I'
p22690
aS'Nyirenda, R'
p22691
aS'Cheruiyot, P'
p22692
aS'Kwobah, C'
p22693
aS'Lokitala Ekiru, W'
p22694
aS'Mokaya, M'
p22695
aS'Mudogo, A'
p22696
aS'Nzioka, A'
p22697
aS'Siika, A'
p22698
aS'Tanui, M'
p22699
aS'Wachira, S'
p22700
aS'Wools-Kaloustian, K'
p22701
aS'Alipalli, P'
p22702
aS'Chikatula, E'
p22703
aS'Kipaila, J'
p22704
aS'Kunda, I'
p22705
aS'Lakhi, S'
p22706
aS'Malama, J'
p22707
aS'Mufwambi, W'
p22708
aS'Mulenga, L'
p22709
aS'Mwaba, P'
p22710
aS'Mwamba, E'
p22711
aS'Mweemba, A'
p22712
aS'Namfukwe, M'
p22713
aS'Kerukadho, E'
p22714
aS'Ngwatu, B'
p22715
aS'Birungi, J'
p22716
aS'Paton, N'
p22717
aS'Boles, J'
p22718
aS'Burke, A'
p22719
aS'Castle, L'
p22720
aS'Ghuman, S'
p22721
aS'Kendall, L'
p22722
aS'Hoppe, A'
p22723
aS'Tebbs, S'
p22724
aS'Thomason, M'
p22725
aS'Thompson, J'
p22726
aS'Walker, S'
p22727
aS'Whittle, J'
p22728
aS'Wilkes, H'
p22729
aS'Young, N'
p22730
aS'Kapuya, C'
p22731
aS'Kyomuhendo, F'
p22732
aS'Kyakundi, D'
p22733
aS'Mkandawire, N'
p22734
aS'Mulambo, S'
p22735
aS'Senyonjo, S'
p22736
aS'Angus, B'
p22737
aS'Arenas-Pinto, A'
p22738
aS'Palfreeman, A'
p22739
aS'Post, F'
p22740
aS'Ishola, D'
p22741
aS'Arribas, J'
p22742
aS'Colebunders, R'
p22743
aS'Floridia, M'
p22744
aS'Giuliano, M'
p22745
aS'Mallon, P'
p22746
aS'Walsh, P'
p22747
aS'De Rosa, M'
p22748
aS'Rinaldi, E'
p22749
aS'Bertagnolio, S'
p22750
aS'Weller, I'
p22751
aS'Gilks, C'
p22752
aS'Hakim, J'
p22753
aS'Kangewende, A'
p22754
aS'Lakhi, S'
p22755
aS'Luyirika, E'
p22756
aS'Miiro, F'
p22757
aS'Mwamba, P'
p22758
aS'Mugyenyi, P'
p22759
aS'Ojoo, S'
p22760
aS'Paton, N'
p22761
aS'Phiri, S'
p22762
aS'van Oosterhout, J'
p22763
aS'Siika, A'
p22764
aS'Walker, S'
p22765
aS'Wapakabulo, A'
p22766
aS'Peto, T'
p22767
aS'French, N'
p22768
aS'Matenga, J'
p22769
aS'Cloherty, G'
p22770
aS'van Wyk, J'
p22771
aS'Norton, M'
p22772
aS'Lehrman, S'
p22773
aS'Lamba, P'
p22774
aS'Malik, K'
p22775
aS'Rooney, J'
p22776
aS'Snowden, W'
p22777
aS'Villacian, J'
p22778
asS'JID'
p22779
S'0255562'
p22780
sS'AB'
p22781
S'BACKGROUND: The efficacy and toxic effects of nucleoside reverse-transcriptase inhibitors (NRTIs) are uncertain when these agents are used with a protease inhibitor in second-line therapy for human immunodeficiency virus (HIV) infection in resource-limited settings. Removing the NRTIs or replacing them with raltegravir may provide a benefit. METHODS: In this open-label trial in sub-Saharan Africa, we randomly assigned 1277 adults and adolescents with HIV infection and first-line treatment failure to receive a ritonavir-boosted protease inhibitor (lopinavir-ritonavir) plus clinician-selected NRTIs (NRTI group, 426 patients), a protease inhibitor plus raltegravir in a superiority comparison (raltegravir group, 433 patients), or protease-inhibitor monotherapy after 12 weeks of induction therapy with raltegravir in a noninferiority comparison (monotherapy group, 418 patients). The primary composite end point, good HIV disease control, was defined as survival with no new World Health Organization stage 4 events, a CD4+ count of more than 250 cells per cubic millimeter, and a viral load of less than 10,000 copies per milliliter or 10,000 copies or more with no protease resistance mutations at week 96 and was analyzed with the use of imputation of data (</=4%). RESULTS: Good HIV disease control was achieved in 60% of the patients (mean, 255 patients) in the NRTI group, 64% of the patients (mean, 277) in the raltegravir group (P=0.21 for the comparison with the NRTI group; superiority of raltegravir not shown), and 55% of the patients (mean, 232) in the monotherapy group (noninferiority of monotherapy not shown, based on a 10-percentage-point margin). There was no significant difference in rates of grade 3 or 4 adverse events among the three groups (P=0.82). The viral load was less than 400 copies per milliliter in 86% of patients in the NRTI group, 86% in the raltegravir group (P=0.97), and 61% in the monotherapy group (P<0.001). CONCLUSIONS: When given with a protease inhibitor in second-line therapy, NRTIs retained substantial virologic activity without evidence of increased toxicity, and there was no advantage to replacing them with raltegravir. Virologic control was inferior with protease-inhibitor monotherapy. (Funded by European and Developing Countries Clinical Trials Partnership and others; EARNEST Current Controlled Trials number, ISRCTN37737787, and ClinicalTrials.gov number, NCT00988039.).'
p22782
sS'AD'
p22783
S'From the Medical Research Council Clinical Trials Unit at University College London, London (N.I.P., A.H., J.B., J.T., A.S.W.); Yong Loo Lin School of Medicine, National University of Singapore, Singapore (N.I.P.); Joint Clinical Research Centre (JCRC) (C.K., D.T., P.M.), Infectious Diseases Institute (A.K., I.M., P.J.E.), and St. Francis of Nsambya Hospital (R.M.), Kampala, JCRC, Mbarara (A.L.), JCRC, Fort Portal (M.K.), JCRC, Mbale (M.A.), JCRC, Gulu (G.A.), JCRC, Kabale (H.A.), and JCRC, Kakira (D.A.) - all in Uganda; University of Zimbabwe Clinical Research Centre, Harare (A.R., E.C., J.H.); Malawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine, Blantyre (J.J.O.), Dignitas International, Zomba (J.J.O.), and Mzuzu Central Hospital, Mzuzu (R.N.) - all in Malawi; Moi University School of Medicine, Eldoret, Kenya (A.S.); University Teaching Hospital, Lusaka, Zambia (A.M.); and Hospital La Paz, Madrid (J.R.A.).'
p22784
sS'CN'
p22785
(lp22786
S'EARNEST Trial Team'
p22787
asS'IP'
p22788
S'3'
sS'IS'
p22789
S'1533-4406 (Electronic) 0028-4793 (Linking)'
p22790
sS'IR'
p22791
(lp22792
S'Agweng E'
p22793
aS'Awio P'
p22794
aS'Bakeinyaga G'
p22795
aS'Isabirye C'
p22796
aS'Kabuga U'
p22797
aS'Kasuswa S'
p22798
aS'Katuramu M'
p22799
aS'Kityo C'
p22800
aS'Kiweewa F'
p22801
aS'Kyomugisha H'
p22802
aS'Lutalo E'
p22803
aS'Mugyenyi P'
p22804
aS'Mulima D'
p22805
aS'Musana H'
p22806
aS'Musitwa G'
p22807
aS'Musiime V'
p22808
aS'Ndigendawan M'
p22809
aS'Namata H'
p22810
aS'Nkalubo J'
p22811
aS'Ocitti Labejja P'
p22812
aS'Okello P'
p22813
aS'Olal P'
p22814
aS'Pimundu G'
p22815
aS'Segonga P'
p22816
aS'Ssali F'
p22817
aS'Tamale Z'
p22818
aS'Tumukunde D'
p22819
aS'Namala W'
p22820
aS'Byaruhanga R'
p22821
aS'Kayiwa J'
p22822
aS'Tukamushaba J'
p22823
aS'Bihabwa G'
p22824
aS'Buluma E'
p22825
aS'Easterbrook P'
p22826
aS'Elbireer A'
p22827
aS'Kambugu A'
p22828
aS'Kamya D'
p22829
aS'Katwere M'
p22830
aS'Kiggundu R'
p22831
aS'Komujuni C'
p22832
aS'Laker E'
p22833
aS'Lubwama E'
p22834
aS'Mambule I'
p22835
aS'Matovu J'
p22836
aS'Nakajubi A'
p22837
aS'Nakku J'
p22838
aS'Nalumenya R'
p22839
aS'Namuyimbwa L'
p22840
aS'Semitala F'
p22841
aS'Wandera B'
p22842
aS'Wanyama J'
p22843
aS'Mugerwa H'
p22844
aS'Lugemwa A'
p22845
aS'Ninsiima E'
p22846
aS'Ssenkindu T'
p22847
aS'Mwebe S'
p22848
aS'Atwine L'
p22849
aS'William H'
p22850
aS'Katemba C'
p22851
aS'Abunyang S'
p22852
aS'Acaku M'
p22853
aS'Ssebutinde P'
p22854
aS'Kitizo H'
p22855
aS'Kukundakwe J'
p22856
aS'Naluguza M'
p22857
aS'Ssegawa K'
p22858
aS'Namayanja'
p22859
aS'Nsibuka F'
p22860
aS'Tuhirirwe P'
p22861
aS'Fortunate M'
p22862
aS'Acen J'
p22863
aS'Achidri J'
p22864
aS'Amone A'
p22865
aS'Chamai M'
p22866
aS'Ditai J'
p22867
aS'Kemigisa M'
p22868
aS'Kiconco M'
p22869
aS'Matama C'
p22870
aS'Mbanza D'
p22871
aS'Nambaziira F'
p22872
aS'Owor Odoi M'
p22873
aS'Rweyora A'
p22874
aS'Tumwebaze G'
p22875
aS'Kalanzi H'
p22876
aS'Katabaazi J'
p22877
aS'Kiyingi A'
p22878
aS'Mbidde M'
p22879
aS'Mugenyi M'
p22880
aS'Mwebaze R'
p22881
aS'Okong P'
p22882
aS'Senoga I'
p22883
aS'Abwola M'
p22884
aS'Baliruno D'
p22885
aS'Bwomezi J'
p22886
aS'Kasede A'
p22887
aS'Mudoola M'
p22888
aS'Namisi R'
p22889
aS'Ssennono F'
p22890
aS'Tuhirwe S'
p22891
aS'Abongomera G'
p22892
aS'Amone G'
p22893
aS'Abach J'
p22894
aS'Aciro I'
p22895
aS'Arach B'
p22896
aS'Kidega P'
p22897
aS'Omongin J'
p22898
aS'Ocung E'
p22899
aS'Odong W'
p22900
aS'Philliam A'
p22901
aS'Alima H'
p22902
aS'Ahimbisibwe B'
p22903
aS'Atuhaire E'
p22904
aS'Atukunda F'
p22905
aS'Bekusike G'
p22906
aS'Bulegyeya A'
p22907
aS'Kahatano D'
p22908
aS'Kamukama S'
p22909
aS'Kyoshabire J'
p22910
aS'Nassali A'
p22911
aS'Mbonye A'
p22912
aS'Naturinda TM'
p22913
aS'Ndukukire'
p22914
aS'Nshabohurira A'
p22915
aS'Ntawiha H'
p22916
aS'Rogers A'
p22917
aS'Tibyasa M'
p22918
aS'Kiirya S'
p22919
aS'Atwongyeire D'
p22920
aS'Nankya A'
p22921
aS'Draleku C'
p22922
aS'Nakiboneka D'
p22923
aS'Odoch D'
p22924
aS'Lakidi L'
p22925
aS'Ruganda R'
p22926
aS'Abiriga R'
p22927
aS'Mulindwa M'
p22928
aS'Balmoi F'
p22929
aS'Kafuma S'
p22930
aS'Moriku E'
p22931
aS'Hakim J'
p22932
aS'Reid A'
p22933
aS'Chidziva E'
p22934
aS'Musoro G'
p22935
aS'Warambwa C'
p22936
aS'Tinago G'
p22937
aS'Mutsai S'
p22938
aS'Phiri M'
p22939
aS'Mudzingwa S'
p22940
aS'Bafana T'
p22941
aS'Masore V'
p22942
aS'Moyo C'
p22943
aS'Nhema R'
p22944
aS'Chitongo S'
p22945
aS'Heyderman R'
p22946
aS'Kabanga L'
p22947
aS'Kaunda S'
p22948
aS'Kudzala A'
p22949
aS'Lifa L'
p22950
aS'Mallewa J'
p22951
aS'Moore M'
p22952
aS'Mtali C'
p22953
aS'Musowa G'
p22954
aS'Mwimaniwa G'
p22955
aS'Sikwese R'
p22956
aS'van Oosterhout J'
p22957
aS'Ziwoya M'
p22958
aS'Chimbaka H'
p22959
aS'Chitete B'
p22960
aS'Kamanga S'
p22961
aS'Kayinga T'
p22962
aS'Makwakwa E'
p22963
aS'Mbiya R'
p22964
aS'Mlenga M'
p22965
aS'Mphande T'
p22966
aS'Mtika C'
p22967
aS'Mushani G'
p22968
aS'Ndhlovu O'
p22969
aS'Ngonga M'
p22970
aS'Nkhana I'
p22971
aS'Nyirenda R'
p22972
aS'Cheruiyot P'
p22973
aS'Kwobah C'
p22974
aS'Lokitala Ekiru W'
p22975
aS'Mokaya M'
p22976
aS'Mudogo A'
p22977
aS'Nzioka A'
p22978
aS'Siika A'
p22979
aS'Tanui M'
p22980
aS'Wachira S'
p22981
aS'Wools-Kaloustian K'
p22982
aS'Alipalli P'
p22983
aS'Chikatula E'
p22984
aS'Kipaila J'
p22985
aS'Kunda I'
p22986
aS'Lakhi S'
p22987
aS'Malama J'
p22988
aS'Mufwambi W'
p22989
aS'Mulenga L'
p22990
aS'Mwaba P'
p22991
aS'Mwamba E'
p22992
aS'Mweemba A'
p22993
aS'Namfukwe M'
p22994
aS'Kerukadho E'
p22995
aS'Ngwatu B'
p22996
aS'Birungi J'
p22997
aS'Paton N'
p22998
aS'Boles J'
p22999
aS'Burke A'
p23000
aS'Castle L'
p23001
aS'Ghuman S'
p23002
aS'Kendall L'
p23003
aS'Hoppe A'
p23004
aS'Tebbs S'
p23005
aS'Thomason M'
p23006
aS'Thompson J'
p23007
aS'Walker S'
p23008
aS'Whittle J'
p23009
aS'Wilkes H'
p23010
aS'Young N'
p23011
aS'Kapuya C'
p23012
aS'Kyomuhendo F'
p23013
aS'Kyakundi D'
p23014
aS'Mkandawire N'
p23015
aS'Mulambo S'
p23016
aS'Senyonjo S'
p23017
aS'Angus B'
p23018
aS'Arenas-Pinto A'
p23019
aS'Palfreeman A'
p23020
aS'Post F'
p23021
aS'Ishola D'
p23022
aS'Arribas J'
p23023
aS'Colebunders R'
p23024
aS'Floridia M'
p23025
aS'Giuliano M'
p23026
aS'Mallon P'
p23027
aS'Walsh P'
p23028
aS'De Rosa M'
p23029
aS'Rinaldi E'
p23030
aS'Bertagnolio S'
p23031
aS'Weller I'
p23032
aS'Gilks C'
p23033
aS'Hakim J'
p23034
aS'Kangewende A'
p23035
aS'Lakhi S'
p23036
aS'Luyirika E'
p23037
aS'Miiro F'
p23038
aS'Mwamba P'
p23039
aS'Mugyenyi P'
p23040
aS'Ojoo S'
p23041
aS'Paton N'
p23042
aS'Phiri S'
p23043
aS'van Oosterhout J'
p23044
aS'Siika A'
p23045
aS'Walker S'
p23046
aS'Wapakabulo A'
p23047
aS'Peto T'
p23048
aS'French N'
p23049
aS'Matenga J'
p23050
aS'Cloherty G'
p23051
aS'van Wyk J'
p23052
aS'Norton M'
p23053
aS'Lehrman S'
p23054
aS'Lamba P'
p23055
aS'Malik K'
p23056
aS'Rooney J'
p23057
aS'Snowden W'
p23058
aS'Villacian J'
p23059
asS'DCOM'
p23060
S'20140723'
p23061
sS'AU'
p23062
(lp23063
S'Paton NI'
p23064
aS'Kityo C'
p23065
aS'Hoppe A'
p23066
aS'Reid A'
p23067
aS'Kambugu A'
p23068
aS'Lugemwa A'
p23069
aS'van Oosterhout JJ'
p23070
aS'Kiconco M'
p23071
aS'Siika A'
p23072
aS'Mwebaze R'
p23073
aS'Abwola M'
p23074
aS'Abongomera G'
p23075
aS'Mweemba A'
p23076
aS'Alima H'
p23077
aS'Atwongyeire D'
p23078
aS'Nyirenda R'
p23079
aS'Boles J'
p23080
aS'Thompson J'
p23081
aS'Tumukunde D'
p23082
aS'Chidziva E'
p23083
aS'Mambule I'
p23084
aS'Arribas JR'
p23085
aS'Easterbrook PJ'
p23086
aS'Hakim J'
p23087
aS'Walker AS'
p23088
aS'Mugyenyi P'
p23089
asS'VI'
p23090
S'371'
p23091
sS'MHDA'
p23092
S'2014/07/24 06:00'
p23093
sS'MH'
p23094
(lp23095
S'Adolescent'
p23096
aS'Adult'
p23097
aS'Africa South of the Sahara'
p23098
aS'Aged'
p23099
aS'CD4 Lymphocyte Count'
p23100
aS'Child'
p23101
aS'Drug Resistance, Viral/genetics'
p23102
aS'Drug Therapy, Combination'
p23103
aS'Female'
p23104
aS'HIV/immunology'
p23105
aS'HIV Infections/*drug therapy'
p23106
aS'HIV Protease Inhibitors/adverse effects/*therapeutic use'
p23107
aS'Humans'
p23108
aS'Male'
p23109
aS'Middle Aged'
p23110
aS'Pyrrolidinones/therapeutic use'
p23111
aS'Raltegravir Potassium'
p23112
aS'Reverse Transcriptase Inhibitors/adverse effects/*therapeutic use'
p23113
aS'Viral Load/drug effects'
p23114
aS'Young Adult'
p23115
asS'EDAT'
p23116
S'2014/07/12 06:00'
p23117
sS'SI'
p23118
(lp23119
S'ClinicalTrials.gov/NCT00988039'
p23120
aS'ISRCTN/ISRCTN37737787'
p23121
asS'SO'
p23122
S'N Engl J Med. 2014 Jul 17;371(3):234-47. doi: 10.1056/NEJMoa1311274.'
p23123
sS'SB'
p23124
S'AIM IM'
p23125
sS'PMID'
p23126
S'25014688'
p23127
sS'PST'
p23128
S'ppublish'
p23129
stRp23130
ag2
(g3
g4
(dp23131
S'LID'
p23132
S'10.1016/j.jad.2014.05.005 [doi] S0165-0327(14)00277-8 [pii]'
p23133
sS'STAT'
p23134
S'MEDLINE'
p23135
sS'DEP'
p23136
S'20140510'
p23137
sS'CI'
p23138
(lp23139
S'Copyright (c) 2014 Elsevier B.V. All rights reserved.'
p23140
asS'DA'
p23141
S'20140711'
p23142
sS'AID'
p23143
(lp23144
S'S0165-0327(14)00277-8 [pii]'
p23145
aS'10.1016/j.jad.2014.05.005 [doi]'
p23146
asS'CRDT'
p23147
(lp23148
S'2014/07/12 06:00'
p23149
asS'DP'
p23150
S'2014 Sep'
p23151
sS'OWN'
p23152
S'NLM'
p23153
sS'PT'
p23154
(lp23155
S'Journal Article'
p23156
aS"Research Support, Non-U.S. Gov't"
p23157
asS'LA'
p23158
(lp23159
S'eng'
p23160
asS'DCOM'
p23161
S'20141205'
p23162
sS'JT'
p23163
S'Journal of affective disorders'
p23164
sS'LR'
p23165
S'20151119'
p23166
sS'FAU'
p23167
(lp23168
S'Nakimuli-Mpungu, Etheldreda'
p23169
aS'Wamala, Kizito'
p23170
aS'Okello, James'
p23171
aS'Alderman, Stephen'
p23172
aS'Odokonyero, Raymond'
p23173
aS'Musisi, Seggane'
p23174
aS'Mojtabai, Ramin'
p23175
aS'Mills, Edward J'
p23176
asS'TI'
p23177
S'Outcomes, feasibility and acceptability of a group support psychotherapeutic intervention for depressed HIV-affected Ugandan adults: a pilot study.'
p23178
sS'PL'
p23179
S'Netherlands'
p23180
sS'PG'
p23181
S'144-50'
p23182
sS'JID'
p23183
S'7906073'
p23184
sS'AB'
p23185
S'BACKGROUND: Psychotherapy is the recommended first line treatment for mild to moderate depression. However, its availability in low resource settings is limited. We developed a manualized culturally sensitive group support psychotherapeutic intervention for depressed HIV affected Ugandan adults. In this study, we aimed to assess its feasibility, acceptability and impact on depression, functioning, social support and self-esteem. METHODS: A total of 77 depressed individuals were assigned to the group intervention (n=48) and a wait-list control group (n=29), and assessed before, during and at the end of the intervention. The self-reporting questionnaire, a locally relevant function assessment instrument, the Rosenberg self-esteem scale, and the multiple dimensions perceived social support scale were administered to assess depression symptoms, functioning, self-esteem and social support at three assessment periods. Multivariate longitudinal regression models were used to determine change in outcomes over time between the two groups. Participants were asked to evaluate the intervention. RESULTS: Post -intervention assessments indicate that, in comparison to the wait-list control group, the intervention group had a faster reduction in depression symptom scores [OR=0.00,95% CI, 0.00-0.003] and faster increase in functioning scores [OR=4.82, 95% CI, 2.39 to 9.75], social support scores [OR=2.68, 95% CI, 1.50-4.78] and self-esteem [OR=1.90, 95% CI 1.48-2.44]. Sixty-three percent of participants strongly agreed that the intervention had reduced their depression and would recommend it to other depressed individuals. LIMITATIONS: Inadequate study power due to small sample sizes may result in imprecise confidence intervals even when there are significant differences. The use of non-random samples could have resulted in selection bias. CONCLUSIONS: This intervention appears feasible, acceptable and promising in treating depression and restoring function, enhancing social support and self-esteem. Larger and randomized evaluations are warranted.'
p23186
sS'AD'
p23187
S'Makerere University, College of Health Sciences, Kampala, Uganda; Peter C. Alderman Foundation, NY, USA. Electronic address: ethelmpungu@yahoo.com. African Center for Tortured Victims, Kampala, Uganda. Peter C. Alderman Foundation, NY, USA; Gulu University, Department of Psychiatry, Gulu, Uganda. Peter C. Alderman Foundation, NY, USA. Makerere University, College of Health Sciences, Kampala, Uganda; Peter C. Alderman Foundation, NY, USA. Makerere University, College of Health Sciences, Kampala, Uganda; Peter C. Alderman Foundation, NY, USA. Johns Hopkins School of Public Health, Department of Mental Health, Baltimore, USA. Faculty of Health Sciences, University of Ottawa, Canada.'
p23188
sS'VI'
p23189
S'166'
p23190
sS'IS'
p23191
S'1573-2517 (Electronic) 0165-0327 (Linking)'
p23192
sS'AU'
p23193
(lp23194
S'Nakimuli-Mpungu E'
p23195
aS'Wamala K'
p23196
aS'Okello J'
p23197
aS'Alderman S'
p23198
aS'Odokonyero R'
p23199
aS'Musisi S'
p23200
aS'Mojtabai R'
p23201
aS'Mills EJ'
p23202
asS'MHDA'
p23203
S'2014/12/15 06:00'
p23204
sS'PHST'
p23205
(lp23206
S'2013/12/04 [received]'
p23207
aS'2014/03/26 [revised]'
p23208
aS'2014/05/02 [accepted]'
p23209
aS'2014/05/10 [aheadofprint]'
p23210
asS'OT'
p23211
(lp23212
S'Depression'
p23213
aS'Function'
p23214
aS'Group support psychotherapy'
p23215
aS'HIV/AIDS'
p23216
aS'Northern Uganda'
p23217
aS'Social support'
p23218
asS'OTO'
p23219
(lp23220
S'NOTNLM'
p23221
asS'MH'
p23222
(lp23223
S'Adult'
p23224
aS'Cultural Characteristics'
p23225
aS'Depression/etiology/*therapy'
p23226
aS'Feasibility Studies'
p23227
aS'Female'
p23228
aS'HIV Infections/*psychology'
p23229
aS'Humans'
p23230
aS'Male'
p23231
aS'Middle Aged'
p23232
aS'*Patient Acceptance of Health Care'
p23233
aS'Pilot Projects'
p23234
aS'*Psychotherapy, Group'
p23235
aS'*Self Concept'
p23236
aS'*Social Support'
p23237
aS'Surveys and Questionnaires'
p23238
aS'Treatment Outcome'
p23239
aS'Uganda/epidemiology'
p23240
asS'EDAT'
p23241
S'2014/07/12 06:00'
p23242
sS'SO'
p23243
S'J Affect Disord. 2014 Sep;166:144-50. doi: 10.1016/j.jad.2014.05.005. Epub 2014 May 10.'
p23244
sS'SB'
p23245
S'IM'
p23246
sS'PMID'
p23247
S'25012423'
p23248
sS'TA'
p23249
S'J Affect Disord'
p23250
sS'PST'
p23251
S'ppublish'
p23252
stRp23253
ag2
(g3
g4
(dp23254
S'LID'
p23255
S'10.1089/AID.2014.0046 [doi]'
p23256
sS'STAT'
p23257
S'MEDLINE'
p23258
sS'DEP'
p23259
S'20140805'
p23260
sS'DA'
p23261
S'20141001'
p23262
sS'AID'
p23263
(lp23264
S'10.1089/AID.2014.0046 [doi]'
p23265
asS'CRDT'
p23266
(lp23267
S'2014/07/08 06:00'
p23268
asS'DP'
p23269
S'2014 Oct'
p23270
sS'AD'
p23271
S'1 Centre for Infectious Disease Research in Zambia , Lusaka, Zambia .'
p23272
sS'OWN'
p23273
S'NLM'
p23274
sS'PT'
p23275
(lp23276
S'Journal Article'
p23277
aS'Research Support, N.I.H., Extramural'
p23278
asS'LA'
p23279
(lp23280
S'eng'
p23281
asS'FAU'
p23282
(lp23283
S'Vinikoor, Michael J'
p23284
aS'Joseph, Jessica'
p23285
aS'Mwale, Jonas'
p23286
aS'Marx, Melissa A'
p23287
aS'Goma, Fastone M'
p23288
aS'Mulenga, Lloyd B'
p23289
aS'Stringer, Jeffrey S A'
p23290
aS'Eron, Joseph J'
p23291
aS'Chi, Benjamin H'
p23292
asS'JT'
p23293
S'AIDS research and human retroviruses'
p23294
sS'LR'
p23295
S'20151001'
p23296
sS'PG'
p23297
S'949-55'
p23298
sS'TI'
p23299
S'Age at antiretroviral therapy initiation predicts immune recovery, death, and loss to follow-up among HIV-infected adults in urban Zambia.'
p23300
sS'RN'
p23301
(lp23302
S'0 (Anti-HIV Agents)'
p23303
asS'PL'
p23304
S'United States'
p23305
sS'TA'
p23306
S'AIDS Res Hum Retroviruses'
p23307
sS'JID'
p23308
S'8709376'
p23309
sS'AB'
p23310
S'We analyzed the association of age at antiretroviral therapy (ART) initiation with CD4(+) T cell count recovery, death, and loss to follow-up (LTFU) among HIV-infected adults in Zambia. We compared baseline characteristics of patients by sex and age at ART initiation [categorized as 16-29 years, 30-39 years, 40-49 years, 50-59 years, and 60 years and older]. We used the medication possession ratio to assess adherence and analysis of covariance to measure the adjusted change in CD4(+) T cell count during ART. Using Cox proportional hazard regression, we examined the association of age with death and LTFU. In a secondary analysis, we repeated models with age as a continuous variable. Among 92,130 HIV-infected adults who initiated ART, the median age was 34 years and 6,281 (6.8%) were aged >/=50 years. Compared with 16-29 year olds, 40-49 year olds (-46 cells/mm(3)), 50-59 year olds (-53 cells/mm(3)), and 60+ year olds (-60 cells/mm(3)) had reduced CD4(+) T cell gains during ART. The adjusted hazard ratio (AHR) for death was increased for individuals aged >/=40 years (AHR 1.25 for 40-49 year olds, 1.56 for 50-59 year olds, and 2.97 for 60+ year olds). Adherence and retention in care were poorest among 16-29 year olds but similar in other groups. As a continuous variable, a 5-year increase in age predicted reduced CD4(+) T cell count recovery and increased risk of death. Increased age at ART initiation was associated with poorer clinical outcomes, while age <30 years was associated with a higher likelihood of being lost to follow-up. HIV treatment guidelines should consider age-specific recommendations.'
p23311
sS'GR'
p23312
(lp23313
S'D43TW001035/TW/FIC NIH HHS/United States'
p23314
aS'P30 AI050410/AI/NIAID NIH HHS/United States'
p23315
aS'R25 TW009340/TW/FIC NIH HHS/United States'
p23316
aS'R25TW009340/TW/FIC NIH HHS/United States'
p23317
asS'IP'
p23318
S'10'
p23319
sS'IS'
p23320
S'1931-8405 (Electronic) 0889-2229 (Linking)'
p23321
sS'PMC'
p23322
S'PMC4179921'
p23323
sS'DCOM'
p23324
S'20150330'
p23325
sS'AU'
p23326
(lp23327
S'Vinikoor MJ'
p23328
aS'Joseph J'
p23329
aS'Mwale J'
p23330
aS'Marx MA'
p23331
aS'Goma FM'
p23332
aS'Mulenga LB'
p23333
aS'Stringer JS'
p23334
aS'Eron JJ'
p23335
aS'Chi BH'
p23336
asS'VI'
p23337
S'30'
p23338
sS'MHDA'
p23339
S'2015/03/31 06:00'
p23340
sS'PHST'
p23341
(lp23342
S'2014/08/05 [aheadofprint]'
p23343
asS'OID'
p23344
(lp23345
S'NLM: PMC4179921'
p23346
asS'MH'
p23347
(lp23348
S'Adolescent'
p23349
aS'Adult'
p23350
aS'*Age Factors'
p23351
aS'Anti-HIV Agents/*administration & dosage/therapeutic use'
p23352
aS'CD4 Lymphocyte Count'
p23353
aS'HIV Infections/*drug therapy/immunology/mortality'
p23354
aS'Humans'
p23355
aS'Middle Aged'
p23356
aS'Patient Compliance'
p23357
aS'Prognosis'
p23358
aS'*Urban Population'
p23359
aS'Young Adult'
p23360
aS'Zambia'
p23361
asS'EDAT'
p23362
S'2014/07/08 06:00'
p23363
sS'SO'
p23364
S'AIDS Res Hum Retroviruses. 2014 Oct;30(10):949-55. doi: 10.1089/AID.2014.0046. Epub 2014 Aug 5.'
p23365
sS'SB'
p23366
S'IM X'
p23367
sS'PMID'
p23368
S'24998881'
p23369
sS'PST'
p23370
S'ppublish'
p23371
stRp23372
ag2
(g3
g4
(dp23373
S'LID'
p23374
S'10.1186/1471-2458-14-676 [doi]'
p23375
sS'STAT'
p23376
S'MEDLINE'
p23377
sS'DEP'
p23378
S'20140703'
p23379
sS'DA'
p23380
S'20140723'
p23381
sS'AID'
p23382
(lp23383
S'1471-2458-14-676 [pii]'
p23384
aS'10.1186/1471-2458-14-676 [doi]'
p23385
asS'CRDT'
p23386
(lp23387
S'2014/07/04 06:00'
p23388
asS'DP'
p23389
S'2014'
p23390
sS'OWN'
p23391
S'NLM'
p23392
sS'PT'
p23393
(lp23394
S'Journal Article'
p23395
aS"Research Support, Non-U.S. Gov't"
p23396
asS'LA'
p23397
(lp23398
S'eng'
p23399
asS'DCOM'
p23400
S'20150723'
p23401
sS'JT'
p23402
S'BMC public health'
p23403
sS'LR'
p23404
S'20150805'
p23405
sS'FAU'
p23406
(lp23407
S'Nglazi, Mweete D'
p23408
aS'West, Sacha J'
p23409
aS'Dave, Joel A'
p23410
aS'Levitt, Naomi S'
p23411
aS'Lambert, Estelle V'
p23412
asS'TI'
p23413
S'Quality of life in individuals living with HIV/AIDS attending a public sector antiretroviral service in Cape Town, South Africa.'
p23414
sS'RN'
p23415
(lp23416
S'0 (Anti-HIV Agents)'
p23417
asS'PL'
p23418
S'England'
p23419
sS'PG'
p23420
S'676'
p23421
sS'JID'
p23422
S'100968562'
p23423
sS'AB'
p23424
S'BACKGROUND: Health related quality of life (HRQoL) is an important outcome helping to understand the impact of antiretroviral therapy (ART). We examined and compared the HRQoL in relation to ART status among HIV-infected patients in a public sector service in Cape Town, South Africa. In addition, we aimed to examine the relationship between ART status and HRQoL according to CD4 count strata. METHODS: A cross sectional study sample of 903 HIV-infected patients who were categorized as not receiving ART (ART-naive) or receiving first-line ART for > 6 months (ART). HRQoL outcomes were compared in the two groups. HRQoL was assessed using the EQ-5D (five domains) and Visual Analogue Scale (EQ-5D VAS). RESULTS: Of the total sample, 435 were categorised as ART naive (76% women) and 468 were on ART (78% women). There were no significant associations between groups for most of the EQ-5D domains, however ART-naive experienced a significantly greater problem with mobility than the ART group. Being ART-naive (adjusted odds ratio (aOR) 3.08 95% confidence interval (CI) 1.63- 7.89) and obese 2.78 (95% CI 1.24- 6.22) were identified as predictors for increased mobility problems in multivariate analysis. In addition, receiving ART (5.61 difference; 95% CI 2.50 - 8.72) and having some source of income (4.76; 95% CI 1.63 -7.89) were identified as predictors for a higher EQ-5D VAS score. When grouped according to CD4 count strata, there were no significant difference between groups for most of the EQ-5D domains, however the ART-naive group indicated having significantly greater problems under the CD4 count of >500 cells/muL in the anxiety/depression domain (22.4% vs 8.8%, p = 0.018) and significantly lower EQ-5D VAS scores under the CD4 counts of </= 200 cells/muL (median 80 (IQR 60-90) vs 90 (IQR 80-100), p = 0.0003) and 201-350 cells/muL (median 80 (IQR 70-90) vs 90 (80-100), p = 0.0004) compared to ART group. CONCLUSIONS: HRQoL (self-rated health state) was improved with ART use, including those with immunocompromised status, which may be relevant to the public sector ART program in South Africa.'
p23425
sS'AD'
p23426
S'MRC/UCT Research Unit for Exercise Science and Sports Medicine, Department of Human Biology, University of Cape Town, Cape Town, South Africa. mweete.nglazi@gmail.com.'
p23427
sS'VI'
p23428
S'14'
p23429
sS'IS'
p23430
S'1471-2458 (Electronic) 1471-2458 (Linking)'
p23431
sS'PMC'
p23432
S'PMC4227123'
p23433
sS'AU'
p23434
(lp23435
S'Nglazi MD'
p23436
aS'West SJ'
p23437
aS'Dave JA'
p23438
aS'Levitt NS'
p23439
aS'Lambert EV'
p23440
asS'MHDA'
p23441
S'2015/07/24 06:00'
p23442
sS'PHST'
p23443
(lp23444
S'2013/12/20 [received]'
p23445
aS'2014/06/19 [accepted]'
p23446
aS'2014/07/03 [aheadofprint]'
p23447
asS'OID'
p23448
(lp23449
S'NLM: PMC4227123'
p23450
asS'MH'
p23451
(lp23452
S'Acquired Immunodeficiency Syndrome/complications/drug therapy'
p23453
aS'Adult'
p23454
aS'Anti-HIV Agents/*therapeutic use'
p23455
aS'Anxiety/*etiology'
p23456
aS'CD4 Lymphocyte Count'
p23457
aS'Communicable Diseases/complications/drug therapy'
p23458
aS'Cross-Sectional Studies'
p23459
aS'Depression/*etiology'
p23460
aS'Female'
p23461
aS'*HIV Infections/complications/drug therapy'
p23462
aS'Humans'
p23463
aS'Income'
p23464
aS'Male'
p23465
aS'Mobility Limitation'
p23466
aS'Odds Ratio'
p23467
aS'Pain/*etiology'
p23468
aS'Pain Measurement'
p23469
aS'Public Sector'
p23470
aS'*Quality of Life'
p23471
aS'South Africa'
p23472
asS'EDAT'
p23473
S'2014/07/06 06:00'
p23474
sS'SO'
p23475
S'BMC Public Health. 2014 Jul 3;14:676. doi: 10.1186/1471-2458-14-676.'
p23476
sS'SB'
p23477
S'IM'
p23478
sS'PMID'
p23479
S'24990360'
p23480
sS'TA'
p23481
S'BMC Public Health'
p23482
sS'PST'
p23483
S'epublish'
p23484
stRp23485
ag2
(g3
g4
(dp23486
S'LID'
p23487
S'10.1097/QAI.0000000000000264 [doi]'
p23488
sS'STAT'
p23489
S'MEDLINE'
p23490
sS'JT'
p23491
S'Journal of acquired immune deficiency syndromes (1999)'
p23492
sS'DA'
p23493
S'20140813'
p23494
sS'AID'
p23495
(lp23496
S'10.1097/QAI.0000000000000264 [doi]'
p23497
asS'CRDT'
p23498
(lp23499
S'2014/07/01 06:00'
p23500
asS'DP'
p23501
S'2014 Sep 1'
p23502
sS'GR'
p23503
(lp23504
S'U62/CCU223540-07/PHS HHS/United States'
p23505
asS'OWN'
p23506
S'NLM'
p23507
sS'PT'
p23508
(lp23509
S'Journal Article'
p23510
aS"Research Support, U.S. Gov't, P.H.S."
p23511
asS'LA'
p23512
(lp23513
S'eng'
p23514
asS'FAU'
p23515
(lp23516
S'Reidy, William J'
p23517
aS'Sheriff, Muhsin'
p23518
aS'Wang, Chunhui'
p23519
aS'Hawken, Mark'
p23520
aS'Koech, Emily'
p23521
aS'Elul, Batya'
p23522
aS'Kimanga, Davies'
p23523
aS'Abrams, Elaine J'
p23524
asS'LR'
p23525
S'20151119'
p23526
sS'PG'
p23527
S'e34-40'
p23528
sS'TI'
p23529
S'Decentralization of HIV care and treatment services in Central Province, Kenya.'
p23530
sS'RN'
p23531
(lp23532
S'0 (Anti-HIV Agents)'
p23533
asS'PL'
p23534
S'United States'
p23535
sS'TA'
p23536
S'J Acquir Immune Defic Syndr'
p23537
sS'JID'
p23538
S'100892005'
p23539
sS'AB'
p23540
S'BACKGROUND: Since 2006, the government of Kenya began decentralizing HIV care from secondary health facilities (SHF) to an expanded network, including primary health facilities (PHF). We evaluated the impact of this strategy on enrollment, care, and outcomes among adult patients in Central Province, Kenya, from 2006 to 2010. METHODS: We analyzed electronic patient-level data for 26,690 patients at 15 SHF and 22 PHF. Enrollment, patient, and facility characteristics and patterns in CD4 testing, World Health Organization staging, and antiretroviral treatment (ART) initiation were compared between SHF and PHF. Survival analysis was used to estimate cumulative death and loss to follow-up (LTF) rates in PHF and SHF. Multivariate competing risks regression and Cox proportional hazards models were constructed to identify correlates of LTF and death. RESULTS: Enrollment in PHF increased mainly between 2007 and 2009, representing 5% and 25% of all new enrollments, respectively. CD4 test provision and World Health Organization staging, time to ART initiation, and CD4 count at ART initiation were for the most part similar between PHF and SHF. In multivariate analyses, pre-ART patients enrolled in PHF had a lower risk of LTF than those enrolled in SHF (SHR = 0.77, 95% confidence interval: 0.61 to 0.96). No differences in risk of death among pre-ART patients or in LTF or death among ART patients were observed. CONCLUSIONS: Enrollment at PHF increased substantially during the period; death rates were comparable between PHF and SHF, whereas LTF among pre-ART patients was lower at PHF. This suggests that decentralization can be a successful strategy for expanding HIV care.'
p23541
sS'AD'
p23542
S'*ICAP, Mailman School of Public Health, Columbia University, New York, NY; and daggerCentres for Health and Education Programmes, Nairobi, Kenya; and double daggerMinistry of Health, Kenya.'
p23543
sS'CN'
p23544
(lp23545
S'Identifying Optimal Models of HIV Care in Africa: Kenya Consortium'
p23546
asS'IP'
p23547
S'1'
sS'IS'
p23548
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p23549
sS'DCOM'
p23550
S'20150113'
p23551
sS'AU'
p23552
(lp23553
S'Reidy WJ'
p23554
aS'Sheriff M'
p23555
aS'Wang C'
p23556
aS'Hawken M'
p23557
aS'Koech E'
p23558
aS'Elul B'
p23559
aS'Kimanga D'
p23560
aS'Abrams EJ'
p23561
asS'VI'
p23562
S'67'
p23563
sS'MHDA'
p23564
S'2015/01/15 06:00'
p23565
sS'MH'
p23566
(lp23567
S'Adolescent'
p23568
aS'Adult'
p23569
aS'Anti-HIV Agents/*therapeutic use'
p23570
aS'CD4 Lymphocyte Count'
p23571
aS'Delivery of Health Care/*organization & administration'
p23572
aS'Female'
p23573
aS'HIV Infections/*drug therapy/epidemiology/mortality'
p23574
aS'Health Facilities'
p23575
aS'Humans'
p23576
aS'Kaplan-Meier Estimate'
p23577
aS'Kenya/epidemiology'
p23578
aS'Lost to Follow-Up'
p23579
aS'Male'
p23580
aS'Middle Aged'
p23581
aS'Politics'
p23582
aS'Proportional Hazards Models'
p23583
aS'Rural Population'
p23584
aS'Surveys and Questionnaires'
p23585
aS'Young Adult'
p23586
asS'EDAT'
p23587
S'2014/07/01 06:00'
p23588
sS'SO'
p23589
S'J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):e34-40. doi: 10.1097/QAI.0000000000000264.'
p23590
sS'SB'
p23591
S'IM X'
p23592
sS'PMID'
p23593
S'24977728'
p23594
sS'PST'
p23595
S'ppublish'
p23596
stRp23597
ag2
(g3
g4
(dp23598
S'STAT'
p23599
S'MEDLINE'
p23600
sS'JT'
p23601
S'AIDS (London, England)'
p23602
sS'MID'
p23603
(lp23604
S'NIHMS651544'
p23605
asS'DA'
p23606
S'20141028'
p23607
sS'AID'
p23608
(lp23609
S'10.1097/QAD.0000000000000349 [doi]'
p23610
asS'CRDT'
p23611
(lp23612
S'2014/07/01 06:00'
p23613
asS'DP'
p23614
S'2014 Sep 10'
p23615
sS'OWN'
p23616
S'NLM'
p23617
sS'PT'
p23618
(lp23619
S'Journal Article'
p23620
aS'Multicenter Study'
p23621
aS'Observational Study'
p23622
aS'Research Support, N.I.H., Extramural'
p23623
aS'Research Support, N.I.H., Intramural'
p23624
aS"Research Support, Non-U.S. Gov't"
p23625
asS'LA'
p23626
(lp23627
S'eng'
p23628
asS'FAU'
p23629
(lp23630
S'Petersen, Maya L'
p23631
aS'Tran, Linh'
p23632
aS'Geng, Elvin H'
p23633
aS'Reynolds, Steven J'
p23634
aS'Kambugu, Andrew'
p23635
aS'Wood, Robin'
p23636
aS'Bangsberg, David R'
p23637
aS'Yiannoutsos, Constantin T'
p23638
aS'Deeks, Steven G'
p23639
aS'Martin, Jeffrey N'
p23640
asS'LR'
p23641
S'20150813'
p23642
sS'PG'
p23643
S'2097-107'
p23644
sS'TI'
p23645
S'Delayed switch of antiretroviral therapy after virologic failure associated with elevated mortality among HIV-infected adults in Africa.'
p23646
sS'RN'
p23647
(lp23648
S'0 (Anti-HIV Agents)'
p23649
aS'0 (RNA, Viral)'
p23650
asS'PL'
p23651
S'England'
p23652
sS'TA'
p23653
S'AIDS'
p23654
sS'JID'
p23655
S'8710219'
p23656
sS'AB'
p23657
S'OBJECTIVE: Routine monitoring of plasma HIV RNA among HIV-infected patients on antiretroviral therapy (ART) is unavailable in many resource-limited settings. Alternative monitoring approaches correlate poorly with virologic failure and can substantially delay switch to second-line therapy. We evaluated the impact of delayed switch on mortality among patients with virologic failure in Africa. DESIGN: A cohort. METHODS: We examined patients with confirmed virologic failure on first-line nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens from four cohorts with serial HIV RNA monitoring in Uganda and South Africa. Marginal structural models aimed to estimate the effect of delayed switch on mortality in a hypothetical trial in which switch time was randomly assigned. Inverse probability weights adjusted for measured confounders including time-updated CD4+ T-cell count and HIV RNA. Results: Among 823 patients with confirmed virologic failure, the cumulative incidence of switch 180 days after failure was 30% [95% confidence interval (CI) 27-33]. The majority of patients (74%) had not failed immunologically as defined by WHO criteria by the time of virologic failure. Adjusted mortality was higher for individuals who remained on first-line therapy than for those who had switched [odds ratio (OR) 2.1, 95% CI 1.1-4.2]. Among those without immunologic failure, the relative harm of failure to switch was similar (OR 2.4; 95% CI 0.99-5.8) to that of the entire cohort, although of borderline statistical significance. CONCLUSION: Among HIV-infected patients with confirmed virologic failure on first-line ART, remaining on first-line therapy led to an increase in mortality relative to switching. Our results suggest that detection and response to confirmed virologic failure could decrease mortality.'
p23658
sS'GR'
p23659
(lp23660
S'K23 AI084544/AI/NIAID NIH HHS/United States'
p23661
aS'K24 AI069994/AI/NIAID NIH HHS/United States'
p23662
aS'K24 MH87227/MH/NIMH NIH HHS/United States'
p23663
aS'P30 AI027763/AI/NIAID NIH HHS/United States'
p23664
aS'P30 AI027763/AI/NIAID NIH HHS/United States'
p23665
aS'R01 AI102710/AI/NIAID NIH HHS/United States'
p23666
aS'R01 MH054907/MH/NIMH NIH HHS/United States'
p23667
aS'U01 AI069911/AI/NIAID NIH HHS/United States'
p23668
aS'U01 AI069911/AI/NIAID NIH HHS/United States'
p23669
aS'U01 CA066529/CA/NCI NIH HHS/United States'
p23670
aS'Intramural NIH HHS/United States'
p23671
asS'IP'
p23672
S'14'
p23673
sS'IS'
p23674
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p23675
sS'PMC'
p23676
S'PMC4317283'
p23677
sS'DCOM'
p23678
S'20150601'
p23679
sS'AU'
p23680
(lp23681
S'Petersen ML'
p23682
aS'Tran L'
p23683
aS'Geng EH'
p23684
aS'Reynolds SJ'
p23685
aS'Kambugu A'
p23686
aS'Wood R'
p23687
aS'Bangsberg DR'
p23688
aS'Yiannoutsos CT'
p23689
aS'Deeks SG'
p23690
aS'Martin JN'
p23691
asS'VI'
p23692
S'28'
p23693
sS'MHDA'
p23694
S'2015/06/02 06:00'
p23695
sS'OID'
p23696
(lp23697
S'NLM: NIHMS651544'
p23698
aS'NLM: PMC4317283'
p23699
asS'MH'
p23700
(lp23701
S'Anti-HIV Agents/*administration & dosage'
p23702
aS'Antiretroviral Therapy, Highly Active'
p23703
aS'CD4-Positive T-Lymphocytes/*drug effects/immunology'
p23704
aS'Cohort Studies'
p23705
aS'Drug Administration Schedule'
p23706
aS'HIV Infections/drug therapy/immunology/*mortality'
p23707
aS'Humans'
p23708
aS'Prospective Studies'
p23709
aS'RNA, Viral/*drug effects/immunology'
p23710
aS'South Africa/epidemiology'
p23711
aS'Time Factors'
p23712
aS'Treatment Failure'
p23713
aS'Uganda/epidemiology'
p23714
aS'Viral Load/*drug effects/immunology'
p23715
asS'EDAT'
p23716
S'2014/07/01 06:00'
p23717
sS'SO'
p23718
S'AIDS. 2014 Sep 10;28(14):2097-107.'
p23719
sS'SB'
p23720
S'IM X'
p23721
sS'PMID'
p23722
S'24977440'
p23723
sS'PST'
p23724
S'ppublish'
p23725
stRp23726
ag2
(g3
g4
(dp23727
S'LID'
p23728
S'10.1097/QAI.0000000000000263 [doi]'
p23729
sS'STAT'
p23730
S'MEDLINE'
p23731
sS'JT'
p23732
S'Journal of acquired immune deficiency syndromes (1999)'
p23733
sS'DA'
p23734
S'20140813'
p23735
sS'AID'
p23736
(lp23737
S'10.1097/QAI.0000000000000263 [doi]'
p23738
asS'CRDT'
p23739
(lp23740
S'2014/07/01 06:00'
p23741
asS'DP'
p23742
S'2014 Sep 1'
p23743
sS'AD'
p23744
S'*Department of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC; daggerInstitute for Global Health and Infectious Diseases, University of North Carolina, Chapel Hill, NC; and double daggerWitkoppen Health and Welfare Centre, Johannesburg, South Africa.'
p23745
sS'OWN'
p23746
S'NLM'
p23747
sS'PT'
p23748
(lp23749
S'Journal Article'
p23750
aS'Research Support, N.I.H., Extramural'
p23751
aS"Research Support, U.S. Gov't, Non-P.H.S."
p23752
asS'LA'
p23753
(lp23754
S'eng'
p23755
asS'FAU'
p23756
(lp23757
S'Clouse, Kate'
p23758
aS'Schwartz, Sheree'
p23759
aS'Van Rie, Annelies'
p23760
aS'Bassett, Jean'
p23761
aS'Yende, Nompumelelo'
p23762
aS'Pettifor, Audrey'
p23763
asS'LR'
p23764
S'20150710'
p23765
sS'PG'
p23766
S'e12-8'
p23767
sS'TI'
p23768
S'"What they wanted was to give birth; nothing else": barriers to retention in option B+ HIV care among postpartum women in South Africa.'
p23769
sS'RN'
p23770
(lp23771
S'0 (Anti-HIV Agents)'
p23772
asS'PL'
p23773
S'United States'
p23774
sS'TA'
p23775
S'J Acquir Immune Defic Syndr'
p23776
sS'JID'
p23777
S'100892005'
p23778
sS'AB'
p23779
S'BACKGROUND: Women initiating antiretroviral therapy during pregnancy have high rates of dropout, particularly after delivery. We aimed to identify challenges to postpartum retention in care under Option B+, which expands antiretroviral therapy access to all HIV-positive pregnant women regardless of CD4 count. METHODOLOGY: We performed 2 semi-structured interviews (SSI, n = 50) and 1 focus group discussion (n = 8) with HIV-positive women at Witkoppen Health and Welfare Centre, a primary care facility in Johannesburg, South Africa, that is one of the only clinics offering Option B+ in South Africa. RESULTS: Fifty women completed the SSI before delivery, and 48 (96%) completed the second SSI within 3 months of delivery. Median age was 28 years (interquartile range: 26-34); most women worked (62%) or had worked in the previous year (18%). Postpartum women attending HIV care perceived that barriers to HIV care after delivery among other women included the belief that mothers care more about the baby\'s health than their own (29.2%, 14/48), women were "ignorant" or "irresponsible" (16.7%, 8/48), negative clinic staff treatment (12.5%, 6/48), and denial or lack of disclosure of HIV status (10.4% each, 5/48). Experienced barriers included lack of money (18.0%, 9/50), work conflict (6.0%, 3/50), and negative staff treatment (6.0%, 3/50). During the focus group discussion, 3 main themes emerged: conflict with work commitment, negative treatment from health-care workers, and lack of disclosure related to stigma. CONCLUSIONS: We identified a complex set of interconnected barriers to retaining postpartum women in HIV care under Option B+, including structural, personal, and societal barriers. The importance of postpartum HIV care for the mother\'s own health must be embraced by health-care workers and public health programs.'
p23780
sS'GR'
p23781
(lp23782
S'1UL1TR001111/TR/NCATS NIH HHS/United States'
p23783
aS'P30 AI050410/AI/NIAID NIH HHS/United States'
p23784
asS'IP'
p23785
S'1'
sS'IS'
p23786
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p23787
sS'DCOM'
p23788
S'20150113'
p23789
sS'AU'
p23790
(lp23791
S'Clouse K'
p23792
aS'Schwartz S'
p23793
aS'Van Rie A'
p23794
aS'Bassett J'
p23795
aS'Yende N'
p23796
aS'Pettifor A'
p23797
asS'VI'
p23798
S'67'
p23799
sS'MHDA'
p23800
S'2015/01/15 06:00'
p23801
sS'MH'
p23802
(lp23803
S'Adult'
p23804
aS'Anti-HIV Agents/*therapeutic use'
p23805
aS'Female'
p23806
aS'Focus Groups'
p23807
aS'HIV Infections/*drug therapy'
p23808
aS'Humans'
p23809
aS'Interviews as Topic'
p23810
aS'Patient Acceptance of Health Care/*psychology'
p23811
aS'Pilot Projects'
p23812
aS'Postpartum Period/psychology'
p23813
aS'Pregnancy'
p23814
aS'Pregnancy Complications, Infectious/*drug therapy/psychology/*virology'
p23815
aS'South Africa'
p23816
asS'EDAT'
p23817
S'2014/07/01 06:00'
p23818
sS'SO'
p23819
S'J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):e12-8. doi: 10.1097/QAI.0000000000000263.'
p23820
sS'SB'
p23821
S'IM X'
p23822
sS'PMID'
p23823
S'24977376'
p23824
sS'PST'
p23825
S'ppublish'
p23826
stRp23827
ag2
(g3
g4
(dp23828
S'LID'
p23829
S'10.3390/v6062495 [doi]'
p23830
sS'STAT'
p23831
S'MEDLINE'
p23832
sS'DEP'
p23833
S'20140623'
p23834
sS'DA'
p23835
S'20140625'
p23836
sS'AID'
p23837
(lp23838
S'v6062495 [pii]'
p23839
aS'10.3390/v6062495 [doi]'
p23840
asS'CRDT'
p23841
(lp23842
S'2014/06/25 06:00'
p23843
asS'DP'
p23844
S'2014 Jun'
p23845
sS'OWN'
p23846
S'NLM'
p23847
sS'PT'
p23848
(lp23849
S'Journal Article'
p23850
aS"Research Support, Non-U.S. Gov't"
p23851
asS'LA'
p23852
(lp23853
S'eng'
p23854
asS'FAU'
p23855
(lp23856
S'Boullosa, Jose'
p23857
aS'Bachu, Mahesh'
p23858
aS'Bila, Dulce'
p23859
aS'Ranga, Udaykumar'
p23860
aS'Suffert, Theodoro'
p23861
aS'Sasazawa, Tomoko'
p23862
aS'Tanuri, Amilcar'
p23863
asS'JT'
p23864
S'Viruses'
p23865
sS'LR'
p23866
S'20150805'
p23867
sS'PG'
p23868
S'2495-504'
p23869
sS'TI'
p23870
S'Genetic diversity in HIV-1 subtype C LTR from Brazil and Mozambique generates new transcription factor-binding sites.'
p23871
sS'RN'
p23872
(lp23873
S'0 (Transcription Factors)'
p23874
asS'PL'
p23875
S'Switzerland'
p23876
sS'TA'
p23877
S'Viruses'
p23878
sS'JID'
p23879
S'101509722'
p23880
sS'AB'
p23881
S'The HIV-1 subtype C has been substituting the subtype B population in southern Brazil. This phenomenon has been previously described in other countries, suggesting that subtype C may possess greater fitness than other subtypes. The HIV-1 long-terminal repeat (LTR) is an important regulatory region critical for the viral life cycle. Sequence insertions immediately upstream of the viral enhancer are known as the most frequent naturally occurring length polimorphisms (MFNLP). Previous reports demonstrated that the MFNLP could lead to the duplication of transcription factor binding sites (TFBS) enhancing the activity of the HIV-1 subtype C LTR. Here, we amplified and sequenced the LTR obtained from proviral DNA samples collected from patients infected with subtype C from the Southern Region of Brazil (naive or treatment failure) and Mozambique (only naive). We confirm the presence of different types of insertions in the LTR sequences of both the countries leading to the creation of additional TFBS. In the Brazilian clinical samples, the frequency of the sequence insertion was significantly higher in subjects experiencing treatment failure than in antiretroviral naive patients.'
p23882
sS'AD'
p23883
S'Department of Genetics, Universidade Federal do Rio de Janeiro, Avenida Carlos Chagas Filho, 373. Edificio do Centro de Ciencias da Saude, Bloco A, sala A2-121, Cidade Universitaria, Cep: 21.941-902, Brazil. joseneto@biologia.ufrj.br. Jawaharlal Nehru Centre for Advanced Scientific Research, 560 064, Jakkur Post, Bangalore, India. bmahesh07@gmail.com. Department of Genetics, Universidade Federal do Rio de Janeiro, Avenida Carlos Chagas Filho, 373. Edificio do Centro de Ciencias da Saude, Bloco A, sala A2-121, Cidade Universitaria, Cep: 21.941-902, Brazil. dulcebila@gmail.com. Jawaharlal Nehru Centre for Advanced Scientific Research, 560 064, Jakkur Post, Bangalore, India. udaykumar@jncasr.ac.in. Prefeitura Municipal de Porto Alegre, Rio Grande do Sul, 90010-170, Brazil. tasuffert@terra.com.br. Prefeitura Municipal de Curitiba, Parana, 80000-000, Brazil. tito@sms.curitiba.pr.gov.br. Department of Genetics, Universidade Federal do Rio de Janeiro, Avenida Carlos Chagas Filho, 373. Edificio do Centro de Ciencias da Saude, Bloco A, sala A2-121, Cidade Universitaria, Cep: 21.941-902, Brazil. atanuri@biologia.ufrj.br.'
p23884
sS'IP'
p23885
S'6'
sS'IS'
p23886
S'1999-4915 (Electronic) 1999-4915 (Linking)'
p23887
sS'PMC'
p23888
S'PMC4074939'
p23889
sS'DCOM'
p23890
S'20150123'
p23891
sS'AU'
p23892
(lp23893
S'Boullosa J'
p23894
aS'Bachu M'
p23895
aS'Bila D'
p23896
aS'Ranga U'
p23897
aS'Suffert T'
p23898
aS'Sasazawa T'
p23899
aS'Tanuri A'
p23900
asS'VI'
p23901
S'6'
sS'MHDA'
p23902
S'2015/01/24 06:00'
p23903
sS'PHST'
p23904
(lp23905
S'2013/11/13 [received]'
p23906
aS'2014/01/12 [revised]'
p23907
aS'2014/01/24 [accepted]'
p23908
asS'OID'
p23909
(lp23910
S'NLM: PMC4074939'
p23911
asS'MH'
p23912
(lp23913
S'Base Sequence'
p23914
aS'*Binding Sites'
p23915
aS'Brazil'
p23916
aS'Gene Expression Regulation, Viral'
p23917
aS'*Genetic Variation'
p23918
aS'*Genotype'
p23919
aS'HIV Infections/*virology'
p23920
aS'HIV Long Terminal Repeat/*genetics'
p23921
aS'HIV-1/*genetics'
p23922
aS'Humans'
p23923
aS'Molecular Sequence Data'
p23924
aS'Mozambique'
p23925
aS'Promoter Regions, Genetic'
p23926
aS'Transcription Factors/*metabolism'
p23927
aS'Transcription, Genetic'
p23928
asS'EDAT'
p23929
S'2014/06/25 06:00'
p23930
sS'SO'
p23931
S'Viruses. 2014 Jun 23;6(6):2495-504. doi: 10.3390/v6062495.'
p23932
sS'SB'
p23933
S'IM'
p23934
sS'PMID'
p23935
S'24960272'
p23936
sS'PST'
p23937
S'epublish'
p23938
stRp23939
ag2
(g3
g4
(dp23940
S'LID'
p23941
S'10.1089/AID.2014.0043 [doi]'
p23942
sS'STAT'
p23943
S'MEDLINE'
p23944
sS'DEP'
p23945
S'20140729'
p23946
sS'DA'
p23947
S'20140904'
p23948
sS'AID'
p23949
(lp23950
S'10.1089/AID.2014.0043 [doi]'
p23951
asS'CRDT'
p23952
(lp23953
S'2014/06/25 06:00'
p23954
asS'DP'
p23955
S'2014 Sep'
p23956
sS'AD'
p23957
S'1 B.C. Centre for Excellence in HIV/AIDS , Vancouver, BC, Canada .'
p23958
sS'OWN'
p23959
S'NLM'
p23960
sS'PT'
p23961
(lp23962
S'Journal Article'
p23963
aS'Research Support, N.I.H., Extramural'
p23964
aS"Research Support, Non-U.S. Gov't"
p23965
asS'LA'
p23966
(lp23967
S'eng'
p23968
asS'FAU'
p23969
(lp23970
S'Lee, Guinevere Q'
p23971
aS'Bangsberg, David R'
p23972
aS'Muzoora, Conrad'
p23973
aS'Boum, Yap'
p23974
aS'Oyugi, Jessica H'
p23975
aS'Emenyonu, Nneka'
p23976
aS'Bennett, John'
p23977
aS'Hunt, Peter W'
p23978
aS'Knapp, David'
p23979
aS'Brumme, Chanson J'
p23980
aS'Harrigan, P Richard'
p23981
aS'Martin, Jeffrey N'
p23982
asS'JT'
p23983
S'AIDS research and human retroviruses'
p23984
sS'LR'
p23985
S'20160701'
p23986
sS'PG'
p23987
S'896-906'
p23988
sS'TI'
p23989
S'Prevalence and virologic consequences of transmitted HIV-1 drug resistance in Uganda.'
p23990
sS'PL'
p23991
S'United States'
p23992
sS'TA'
p23993
S'AIDS Res Hum Retroviruses'
p23994
sS'JID'
p23995
S'8709376'
p23996
sS'AB'
p23997
S'Few reports have examined the impact of HIV-1 transmitted drug resistance (TDR) in resource-limited settings where there are fewer regimen choices and limited pretherapy/posttherapy resistance testing. In this study, we examined TDR prevalence in Kampala and Mbarara, Uganda and assessed its virologic consequences after antiretroviral therapy initiation. We sequenced the HIV-1 protease/reverse transcriptase from n=81 and n=491 treatment-naive participants of the Uganda AIDS Rural Treatment Outcomes (UARTO) pilot study in Kampala (AMU 2002-2004) and main cohort in Mbarara (MBA 2005-2010). TDR-associated mutations were defined by the WHO 2009 surveillance mutation list. Posttreatment viral load data were available for both populations. Overall TDR prevalence was 7% (Kampala) and 3% (Mbarara) with no significant time trend. There was a slight but statistically nonsignificant trend indicating that the presence of TDR was associated with a worse treatment outcome. Virologic suppression (</=400 copies/ml within 6 months posttherapy initiation) was achieved in 87% and 96% of participants with wildtype viruses versus 67% and 83% of participants with TDR (AMU, MBA p=0.2 and 0.1); time to suppression (log-rank p=0.3 and p=0.05). Overall, 85% and 96% of study participants achieved suppression regardless of TDR status. Surprisingly, among the TDR cases, approximately half still achieved suppression; the presence of pretherapy K103N while on nevirapine and fewer active drugs in the first regimen were most often observed with failures. The majority of patients benefited from the local HIV care system even without resistance monitoring. Overall, TDR prevalence was relatively low and its presence did not always imply treatment failure.'
p23998
sS'GR'
p23999
(lp24000
S'P30 AI027763/AI/NIAID NIH HHS/United States'
p24001
aS'P30 AI27763/AI/NIAID NIH HHS/United States'
p24002
aS'R-21 014784/PHS HHS/United States'
p24003
aS'R0-1 54907/PHS HHS/United States'
p24004
aS'U01 CA066529/CA/NCI NIH HHS/United States'
p24005
aS'Canadian Institutes of Health Research/Canada'
p24006
asS'IP'
p24007
S'9'
sS'IS'
p24008
S'1931-8405 (Electronic) 0889-2229 (Linking)'
p24009
sS'PMC'
p24010
S'PMC4151058'
p24011
sS'DCOM'
p24012
S'20150330'
p24013
sS'AU'
p24014
(lp24015
S'Lee GQ'
p24016
aS'Bangsberg DR'
p24017
aS'Muzoora C'
p24018
aS'Boum Y'
p24019
aS'Oyugi JH'
p24020
aS'Emenyonu N'
p24021
aS'Bennett J'
p24022
aS'Hunt PW'
p24023
aS'Knapp D'
p24024
aS'Brumme CJ'
p24025
aS'Harrigan PR'
p24026
aS'Martin JN'
p24027
asS'VI'
p24028
S'30'
p24029
sS'MHDA'
p24030
S'2015/03/31 06:00'
p24031
sS'PHST'
p24032
(lp24033
S'2014/07/29 [aheadofprint]'
p24034
asS'OID'
p24035
(lp24036
S'NLM: PMC4151058'
p24037
asS'MH'
p24038
(lp24039
S'Adult'
p24040
aS'Cross-Sectional Studies'
p24041
aS'*Drug Resistance, Viral'
p24042
aS'Female'
p24043
aS'HIV Infections/*drug therapy'
p24044
aS'HIV-1'
p24045
aS'Humans'
p24046
aS'Male'
p24047
aS'Polymerase Chain Reaction'
p24048
aS'Prevalence'
p24049
aS'Uganda'
p24050
asS'EDAT'
p24051
S'2014/06/25 06:00'
p24052
sS'SO'
p24053
S'AIDS Res Hum Retroviruses. 2014 Sep;30(9):896-906. doi: 10.1089/AID.2014.0043. Epub 2014 Jul 29.'
p24054
sS'SB'
p24055
S'IM X'
p24056
sS'PMID'
p24057
S'24960249'
p24058
sS'PST'
p24059
S'ppublish'
p24060
stRp24061
ag2
(g3
g4
(dp24062
S'LID'
p24063
S'10.4314/ahs.v13i4.17 [doi]'
p24064
sS'STAT'
p24065
S'MEDLINE'
p24066
sS'JT'
p24067
S'African health sciences'
p24068
sS'DA'
p24069
S'20140618'
p24070
sS'AID'
p24071
(lp24072
S'10.4314/ahs.v13i4.17 [doi]'
p24073
aS'jAFHS.v13.i4.pg977 [pii]'
p24074
asS'CRDT'
p24075
(lp24076
S'2014/06/19 06:00'
p24077
asS'DP'
p24078
S'2013 Dec'
p24079
sS'OWN'
p24080
S'NLM'
p24081
sS'PT'
p24082
(lp24083
S'Journal Article'
p24084
aS"Research Support, Non-U.S. Gov't"
p24085
asS'LA'
p24086
(lp24087
S'eng'
p24088
asS'FAU'
p24089
(lp24090
S'Namutebi, A M N'
p24091
aS'Kamya, M R K'
p24092
aS'Byakika-Kibwika, P'
p24093
asS'LR'
p24094
S'20150805'
p24095
sS'PG'
p24096
S'977-85'
p24097
sS'TI'
p24098
S'Causes and outcome of hospitalization among HIV-infected adults receiving antiretroviral therapy in Mulago hospital, Uganda.'
p24099
sS'RN'
p24100
(lp24101
S'0 (Anti-Retroviral Agents)'
p24102
asS'PL'
p24103
S'Uganda'
p24104
sS'TA'
p24105
S'Afr Health Sci'
p24106
sS'JID'
p24107
S'101149451'
p24108
sS'AB'
p24109
S"BACKGROUND: Cohorts describing cause specific mortality in HIV-infected patients initiating antiretroviral therapy (ART) operate on an outpatient basis. Hospitalized patients represent the spectrum and burden of severe morbidity and mortality in patients on ART. OBJECTIVE: To determine the causes and outcomes of hospitalization among adults receiving ART. METHODS: A prospective cohort study. We enrolled 201 participants (50% female) with median (IQR) age and CD4 count of 34 (28-40) years and 91(29-211) cells/uL respectively. RESULTS: The most frequent causes of hospitalization were tuberculosis (TB) (37, 18%), cryptococcal meningitis (22, 11%), zidovudine (AZT) - associated anemia (19, 10%), sepsis (10, 5%) and Kaposi's sarcoma (10, 5%). Forty two patients (21%) died: 10 (24%) had TB, 8 (19%) had cryptococcal meningitis and 5 (12%) had sepsis, 9 (21%) had undiagnosed neurological syndromes while 10 (24%) had other illnesses. Predictors of death included low Karnofsky performance score of < 40 (OR, 21.1; CI 1.43- 31.6) and age >34 years (OR, 7.65; CI 1.09- 53.8). CONCLUSIONS: Opportunistic infections, malignancy and AZT-associated anemia contributed to most hospitalizations and mortality. It is important to intensify prevention, screening, and treatment for these opportunistic diseases and early ART initiation in HIV-infected patients. Tenofovir-based regimens, unless contraindicated should be scaled up to replace AZT-based regimens as first line ART drugs."
p24110
sS'AD'
p24111
S'Department of Medicine, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda. Department of Medicine, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda. Department of Medicine, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.'
p24112
sS'IP'
p24113
S'4'
sS'IS'
p24114
S'1729-0503 (Electronic) 1680-6905 (Linking)'
p24115
sS'PMC'
p24116
S'PMC4056514'
p24117
sS'DCOM'
p24118
S'20150413'
p24119
sS'AU'
p24120
(lp24121
S'Namutebi AM'
p24122
aS'Kamya MR'
p24123
aS'Byakika-Kibwika P'
p24124
asS'VI'
p24125
S'13'
p24126
sS'MHDA'
p24127
S'2015/04/14 06:00'
p24128
sS'OID'
p24129
(lp24130
S'NLM: PMC4056514'
p24131
asS'MH'
p24132
(lp24133
S'AIDS-Related Opportunistic Infections/*epidemiology'
p24134
aS'Adult'
p24135
aS'Anti-Retroviral Agents/*therapeutic use'
p24136
aS'CD4 Lymphocyte Count'
p24137
aS'Female'
p24138
aS'HIV Infections/complications/*drug therapy/*mortality'
p24139
aS'Hospitalization/*statistics & numerical data'
p24140
aS'Humans'
p24141
aS'Male'
p24142
aS'Meningitis, Cryptococcal/complications/diagnosis/mortality'
p24143
aS'Middle Aged'
p24144
aS'Prospective Studies'
p24145
aS'Sepsis/complications/diagnosis/mortality'
p24146
aS'Treatment Outcome'
p24147
aS'Tuberculosis/complications/diagnosis/mortality'
p24148
aS'Uganda/epidemiology'
p24149
asS'EDAT'
p24150
S'2014/06/19 06:00'
p24151
sS'SO'
p24152
S'Afr Health Sci. 2013 Dec;13(4):977-85. doi: 10.4314/ahs.v13i4.17.'
p24153
sS'SB'
p24154
S'IM'
p24155
sS'PMID'
p24156
S'24940321'
p24157
sS'PST'
p24158
S'ppublish'
p24159
stRp24160
ag2
(g3
g4
(dp24161
S'LID'
p24162
S'10.1186/1475-2875-13-227 [doi]'
p24163
sS'STAT'
p24164
S'MEDLINE'
p24165
sS'DEP'
p24166
S'20140609'
p24167
sS'DA'
p24168
S'20140612'
p24169
sS'AID'
p24170
(lp24171
S'1475-2875-13-227 [pii]'
p24172
aS'10.1186/1475-2875-13-227 [doi]'
p24173
asS'CRDT'
p24174
(lp24175
S'2014/06/10 06:00'
p24176
asS'DP'
p24177
S'2014'
p24178
sS'OWN'
p24179
S'NLM'
p24180
sS'PT'
p24181
(lp24182
S'Journal Article'
p24183
aS"Research Support, U.S. Gov't, Non-P.H.S."
p24184
asS'LA'
p24185
(lp24186
S'eng'
p24187
asS'DCOM'
p24188
S'20150126'
p24189
sS'JT'
p24190
S'Malaria journal'
p24191
sS'LR'
p24192
S'20150805'
p24193
sS'FAU'
p24194
(lp24195
S'Tan, Kathrine R'
p24196
aS'Katalenich, Bonnie L'
p24197
aS'Mace, Kimberly E'
p24198
aS'Nambozi, Michael'
p24199
aS'Taylor, Steve M'
p24200
aS'Meshnick, Steven R'
p24201
aS'Wiegand, Ryan E'
p24202
aS'Chalwe, Victor'
p24203
aS'Filler, Scott J'
p24204
aS'Kamuliwo, Mulakwa'
p24205
aS'Craig, Allen S'
p24206
asS'TI'
p24207
S'Efficacy of sulphadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy, Mansa, Zambia.'
p24208
sS'RN'
p24209
(lp24210
S'0 (Antimalarials)'
p24211
aS'0 (Drug Combinations)'
p24212
aS'37338-39-9 (fanasil, pyrimethamine drug combination)'
p24213
aS'88463U4SM5 (Sulfadoxine)'
p24214
aS'Z3614QOX8W (Pyrimethamine)'
p24215
asS'PL'
p24216
S'England'
p24217
sS'PG'
p24218
S'227'
p24219
sS'JID'
p24220
S'101139802'
p24221
sS'AB'
p24222
S'BACKGROUND: Intermittent preventive treatment of malaria in pregnancy (IPTp) with sulphadoxine-pyrimethamine (SP) decreases adverse effects of malaria during pregnancy. Zambia implemented its IPTp-SP programme in 2003. Emergence of SP-resistant Plasmodium falciparum threatens this strategy. The quintuple mutant haplotype (substitutions in N51I, C59R, S108N in dhfr and A437G and K540E in dhps genes), is associated with SP treatment failure in non-pregnant patients with malaria. This study examined efficacy of IPTp-SP and presence of the quintuple mutant among pregnant women in Mansa, Zambia. METHODS: In Mansa, an area with high malaria transmission, HIV-negative pregnant women presenting to two antenatal clinics for the 1st dose of IPTp-SP with asymptomatic parasitaemia were enrolled and microscopy for parasitaemia was done weekly for five weeks. Outcomes were parasitological failure and adequate parasitological response (no parasitaemia during follow-up). Polymerase chain reaction assays were employed to distinguish recrudescence from reinfection, and identify molecular markers of SP resistance. Survival analysis included those who had reinfection and incomplete follow-up (missed at least one follow-up). RESULTS: Of the 109 women included in the study, 58 (53%) completed all follow-up, 34 (31%) had incomplete follow-up, and 17 (16%) were lost to follow-up after day 0. Of those who had complete follow-up, 15 (26%, 95% confidence interval [CI] [16-38]) had parasitological failure. For the 92 women included in the survival analysis, median age was 20 years (interquartile range [IQR] 18-22), median gestational age was 22 weeks (IQR range 20-24), and 57% were primigravid. There was no difference in time to failure in primigravid versus multigravid women. Of the 84 women with complete haplotype data for the aforementioned loci of the dhfr and dhps genes, 53 (63%, 95% CI [50-70]) had quintuple mutants (two with an additional mutation in A581G of dhps). Among women with complete follow-up and quintuple mutants, 22% had parasitological failure versus 0% without (p = 0.44). CONCLUSIONS: While underpowered, this study found 26% failure rates of SP given the moderate prevalence of the quintuple mutant haplotype. Despite the presence of resistance, SP retained some efficacy in clearing parasites in pregnant women, and may remain a viable option for IPTp in Zambia.'
p24223
sS'AD'
p24224
S'Malaria Branch, US Centers for Disease Control and Prevention, Atlanta, GA, USA. ktan@cdc.gov.'
p24225
sS'VI'
p24226
S'13'
p24227
sS'IS'
p24228
S'1475-2875 (Electronic) 1475-2875 (Linking)'
p24229
sS'PMC'
p24230
S'PMC4053579'
p24231
sS'AU'
p24232
(lp24233
S'Tan KR'
p24234
aS'Katalenich BL'
p24235
aS'Mace KE'
p24236
aS'Nambozi M'
p24237
aS'Taylor SM'
p24238
aS'Meshnick SR'
p24239
aS'Wiegand RE'
p24240
aS'Chalwe V'
p24241
aS'Filler SJ'
p24242
aS'Kamuliwo M'
p24243
aS'Craig AS'
p24244
asS'MHDA'
p24245
S'2015/01/27 06:00'
p24246
sS'PHST'
p24247
(lp24248
S'2014/03/20 [received]'
p24249
aS'2014/05/25 [accepted]'
p24250
aS'2014/06/09 [aheadofprint]'
p24251
asS'OID'
p24252
(lp24253
S'NLM: PMC4053579'
p24254
asS'MH'
p24255
(lp24256
S'Adolescent'
p24257
aS'Adult'
p24258
aS'Animals'
p24259
aS'Antimalarials/*therapeutic use'
p24260
aS'Drug Combinations'
p24261
aS'Drug Resistance'
p24262
aS'Drug Therapy, Combination/methods'
p24263
aS'Female'
p24264
aS'Humans'
p24265
aS'Malaria, Falciparum/*prevention & control'
p24266
aS'Mutation'
p24267
aS'Plasmodium falciparum/drug effects'
p24268
aS'Pregnancy'
p24269
aS'Pregnancy Complications, Infectious/*prevention & control'
p24270
aS'Pyrimethamine/*therapeutic use'
p24271
aS'Sulfadoxine/*therapeutic use'
p24272
aS'Survival Analysis'
p24273
aS'Treatment Failure'
p24274
aS'Young Adult'
p24275
aS'Zambia'
p24276
asS'EDAT'
p24277
S'2014/06/10 06:00'
p24278
sS'SO'
p24279
S'Malar J. 2014 Jun 9;13:227. doi: 10.1186/1475-2875-13-227.'
p24280
sS'SB'
p24281
S'IM'
p24282
sS'PMID'
p24283
S'24909578'
p24284
sS'TA'
p24285
S'Malar J'
p24286
sS'PST'
p24287
S'epublish'
p24288
stRp24289
ag2
(g3
g4
(dp24290
S'LID'
p24291
S'10.1016/j.jcv.2014.05.005 [doi] S1386-6532(14)00182-6 [pii]'
p24292
sS'STAT'
p24293
S'MEDLINE'
p24294
sS'DEP'
p24295
S'20140522'
p24296
sS'CI'
p24297
(lp24298
S'Copyright (c) 2014 Elsevier B.V. All rights reserved.'
p24299
asS'DA'
p24300
S'20140624'
p24301
sS'AID'
p24302
(lp24303
S'S1386-6532(14)00182-6 [pii]'
p24304
aS'10.1016/j.jcv.2014.05.005 [doi]'
p24305
asS'CRDT'
p24306
(lp24307
S'2014/06/08 06:00'
p24308
asS'DP'
p24309
S'2014 Aug'
p24310
sS'AD'
p24311
S'Department of Health Policy and Management, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States. Electronic address: srutstein@unc.edu. UNC Project, Lilongwe, Malawi. Johns Hopkins University, United States. UNC Project, Lilongwe, Malawi. UNC Project, Lilongwe, Malawi. UNC Center for AIDS Research and Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States. UNC Center for AIDS Research and Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States. Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; UNC Project, Lilongwe, Malawi. Centers for Disease Control, Malawi. Centers for Disease Control, Malawi. Ministry of Health, Lilongwe, Malawi. Ministry of Health, Lilongwe, Malawi. School of Public Health, Loma Linda University, United States.'
p24312
sS'OWN'
p24313
S'NLM'
p24314
sS'PT'
p24315
(lp24316
S'Comparative Study'
p24317
aS'Journal Article'
p24318
aS'Research Support, N.I.H., Extramural'
p24319
aS"Research Support, U.S. Gov't, P.H.S."
p24320
asS'LA'
p24321
(lp24322
S'eng'
p24323
asS'FAU'
p24324
(lp24325
S'Rutstein, Sarah E'
p24326
aS'Kamwendo, Deborah'
p24327
aS'Lugali, Lebah'
p24328
aS'Thengolose, Isaac'
p24329
aS'Tegha, Gerald'
p24330
aS'Fiscus, Susan A'
p24331
aS'Nelson, Julie A E'
p24332
aS'Hosseinipour, Mina C'
p24333
aS'Sarr, Abdoulaye'
p24334
aS'Gupta, Sundeep'
p24335
aS'Chimbwandira, Frank'
p24336
aS'Mwenda, Reuben'
p24337
aS'Mataya, Ronald'
p24338
asS'JT'
p24339
S'Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology'
p24340
sS'LR'
p24341
S'20150805'
p24342
sS'PG'
p24343
S'392-8'
p24344
sS'TI'
p24345
S'Measures of viral load using Abbott RealTime HIV-1 Assay on venous and fingerstick dried blood spots from provider-collected specimens in Malawian District Hospitals.'
p24346
sS'RN'
p24347
(lp24348
S'0 (Anti-HIV Agents)'
p24349
aS'0 (RNA, Viral)'
p24350
asS'PL'
p24351
S'Netherlands'
p24352
sS'TA'
p24353
S'J Clin Virol'
p24354
sS'JID'
p24355
S'9815671'
p24356
sS'AB'
p24357
S'BACKGROUND: Viral suppression is a key indicator of antiretroviral therapy (ART) response among HIV-infected patients. Dried blood spots (DBS) are an appealing alternative to conventional plasma-based virologic testing, improving access to monitoring in resource-limited settings. However, validity of DBS obtained from fingerstick in field settings remains unknown. OBJECTIVES: Investigate feasibility and accuracy of DBS vs plasma collected by healthcare workers in real-world settings of remote hospitals in Malawi. Compare venous DBS to fingerstick DBS for identifying treatment failure. STUDY DESIGN: We recruited patients from ART clinics at two district hospitals in Malawi, collecting plasma, venous DBS (vDBS), and fingerstick DBS (fsDBS) cards for the first 149 patients, and vDBS and fsDBS only for the subsequent 398 patients. Specimens were tested using Abbott RealTime HIV-1 Assay (lower detection limit 40 copies/ml (plasma) and 550 copies/ml (DBS)). RESULTS: 21/149 (14.1%) had detectable viremia (>1.6 log copies/ml), 13 of which were detectable for plasma, vDBS, and fsDBS. Linear regression demonstrated high correlation for plasma vs. DBS (vDBS: beta=1.19, R(2)=0.93 (p<0.0001); fsDBS beta=1.20, R(2)=0.90 (p<0.0001)) and vDBS vs. fsDBS (beta=0.88, R(2)=0.73, (p<0.0001)). Mean difference between plasma and vDBS was 1.1 log copies/ml [SD: 0.27] and plasma and fsDBS 1.1 log copies/ml [SD: 0.31]. At 5000 copies/ml, sensitivity was 100%, and specificity was 98.6% and 97.8% for vDBS and fsDBS, respectively, compared to plasma. CONCLUSIONS: DBS from venipuncture and fingerstick perform well at the failure threshold of 5000 copies/ml. Fingerstick specimen source may improve access to virologic treatment monitoring in resource-limited settings given task-shifting in high-volume, low-resource facilities.'
p24358
sS'GR'
p24359
(lp24360
S'F30 MH098731/MH/NIMH NIH HHS/United States'
p24361
aS'F30MH098731-01/MH/NIMH NIH HHS/United States'
p24362
aS'MW.10.1433/PHS HHS/United States'
p24363
aS'P30 AI050410/AI/NIAID NIH HHS/United States'
p24364
aS'P30 AI50410/AI/NIAID NIH HHS/United States'
p24365
aS'T32 GM008719/GM/NIGMS NIH HHS/United States'
p24366
asS'IP'
p24367
S'4'
sS'IS'
p24368
S'1873-5967 (Electronic) 1386-6532 (Linking)'
p24369
sS'PMC'
p24370
S'PMC4073118'
p24371
sS'DCOM'
p24372
S'20150416'
p24373
sS'MID'
p24374
(lp24375
S'NIHMS600317'
p24376
asS'AU'
p24377
(lp24378
S'Rutstein SE'
p24379
aS'Kamwendo D'
p24380
aS'Lugali L'
p24381
aS'Thengolose I'
p24382
aS'Tegha G'
p24383
aS'Fiscus SA'
p24384
aS'Nelson JA'
p24385
aS'Hosseinipour MC'
p24386
aS'Sarr A'
p24387
aS'Gupta S'
p24388
aS'Chimbwandira F'
p24389
aS'Mwenda R'
p24390
aS'Mataya R'
p24391
asS'VI'
p24392
S'60'
p24393
sS'MHDA'
p24394
S'2015/04/17 06:00'
p24395
sS'PHST'
p24396
(lp24397
S'2014/03/04 [received]'
p24398
aS'2014/05/06 [revised]'
p24399
aS'2014/05/10 [accepted]'
p24400
aS'2014/05/22 [aheadofprint]'
p24401
asS'OID'
p24402
(lp24403
S'NLM: NIHMS600317'
p24404
aS'NLM: PMC4073118'
p24405
asS'MH'
p24406
(lp24407
S'Adult'
p24408
aS'Anti-HIV Agents/therapeutic use'
p24409
aS'Antiretroviral Therapy, Highly Active'
p24410
aS'Blood Specimen Collection'
p24411
aS'Dried Blood Spot Testing/*methods'
p24412
aS'Female'
p24413
aS'HIV Infections/*blood/*diagnosis/drug therapy/virology'
p24414
aS'HIV-1/genetics'
p24415
aS'Hospitals'
p24416
aS'Humans'
p24417
aS'Malawi'
p24418
aS'Male'
p24419
aS'Phlebotomy/methods'
p24420
aS'RNA, Viral/blood'
p24421
aS'Sensitivity and Specificity'
p24422
aS'Viral Load/*methods'
p24423
aS'Viremia/blood/virology'
p24424
asS'EDAT'
p24425
S'2014/06/08 06:00'
p24426
sS'SO'
p24427
S'J Clin Virol. 2014 Aug;60(4):392-8. doi: 10.1016/j.jcv.2014.05.005. Epub 2014 May 22.'
p24428
sS'SB'
p24429
S'IM'
p24430
sS'PMID'
p24431
S'24906641'
p24432
sS'PST'
p24433
S'ppublish'
p24434
stRp24435
ag2
(g3
g4
(dp24436
S'LID'
p24437
S'10.5588/ijtld.13.0492 [doi]'
p24438
sS'STAT'
p24439
S'MEDLINE'
p24440
sS'AB'
p24441
S"BACKGROUND: The optimal treatment for tuberculosis (TB) in human immunodeficiency virus (HIV) infected patients in resource-poor settings receiving lopinavir-ritonavir (LPV/r) based second-line antiretroviral therapy (ART) has yet to be determined. In South Africa, clinicians are advised to use 'double-dose' LPV/r dosed at 800 mg/200 mg twice daily during anti-tuberculosis treatment. METHODOLOGY AND PRINCIPLE FINDINGS: We conducted a retrospective study of HIV-infected patients who received >/=2 months of double-dose LPV/r-based ART during concomitant rifampicin-containing anti-tuberculosis treatment. We used standard definitions for TB and HIV outcomes; virological failure was defined as a viral load >1000 copies/ml. During co-administration, gastro-intestinal toxicity occurred in 9/25 (36%) patients, a symptomatic rise in aspartate aminotransferase or alanine aminotransferase of any grade was noted in 3 (12%), with two Grade 3 events, and 3 (12%) patients required treatment discontinuation. Outcomes were favourable, with 20/25 (80%) patients achieving TB treatment success and virological failure observed among 3 (12%) patients during co-administration. CONCLUSION: We found the use of double-dose LPV/r during simultaneous standard anti-tuberculosis treatment to be an effective and reasonably well tolerated interim strategy."
p24442
sS'JID'
p24443
S'9706389'
p24444
sS'AD'
p24445
S'McCord Hospital, Durban, South Africa. St. Vincent Hospital, Indianapolis, Indiana, USA. Department of Medicine New York University School of Medicine, New York, New York, USA. University of Edinburgh, Edinburgh, Scotland, UK. McCord Hospital, Durban, South Africa. Massachusetts General Hospital, Boston, Massachusetts, USA;;Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard, Boston, Massachusetts, USA. Albert Einstein College of Medicine, New York, New York, USA.'
p24446
sS'JT'
p24447
S'The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease'
p24448
sS'IP'
p24449
S'6'
sS'IS'
p24450
S'1815-7920 (Electronic) 1027-3719 (Linking)'
p24451
sS'DCOM'
p24452
S'20150202'
p24453
sS'DA'
p24454
S'20140606'
p24455
sS'AU'
p24456
(lp24457
S'Sunpath H'
p24458
aS'Winternheimer P'
p24459
aS'Cohen S'
p24460
aS'Tennant I'
p24461
aS'Chelin N'
p24462
aS'Gandhi RT'
p24463
aS'Murphy RA'
p24464
asS'AID'
p24465
(lp24466
S'10.5588/ijtld.13.0492 [doi]'
p24467
asS'CRDT'
p24468
(lp24469
S'2014/06/07 06:00'
p24470
asS'VI'
p24471
S'18'
p24472
sS'PMID'
p24473
S'24903940'
p24474
sS'DP'
p24475
S'2014 Jun'
p24476
sS'MHDA'
p24477
S'2015/02/03 06:00'
p24478
sS'OWN'
p24479
S'NLM'
p24480
sS'PT'
p24481
(lp24482
S'Journal Article'
p24483
aS"Research Support, Non-U.S. Gov't"
p24484
asS'LA'
p24485
(lp24486
S'eng'
p24487
asS'MH'
p24488
(lp24489
S'Adult'
p24490
aS'Antibiotics, Antitubercular/*administration & dosage/adverse effects'
p24491
aS'Coinfection'
p24492
aS'Drug Combinations'
p24493
aS'Drug Interactions'
p24494
aS'Drug Therapy, Combination'
p24495
aS'Female'
p24496
aS'HIV Infections/diagnosis/*drug therapy/epidemiology/virology'
p24497
aS'HIV Protease Inhibitors/*administration & dosage/adverse effects'
p24498
aS'Humans'
p24499
aS'Lopinavir/*administration & dosage/adverse effects'
p24500
aS'Male'
p24501
aS'Middle Aged'
p24502
aS'Retrospective Studies'
p24503
aS'Rifampin/*administration & dosage/adverse effects'
p24504
aS'Ritonavir/*administration & dosage/adverse effects'
p24505
aS'South Africa/epidemiology'
p24506
aS'Treatment Outcome'
p24507
aS'Tuberculosis/diagnosis/*drug therapy/epidemiology/microbiology'
p24508
aS'Viral Load'
p24509
aS'Young Adult'
p24510
asS'FAU'
p24511
(lp24512
S'Sunpath, H'
p24513
aS'Winternheimer, P'
p24514
aS'Cohen, S'
p24515
aS'Tennant, I'
p24516
aS'Chelin, N'
p24517
aS'Gandhi, R T'
p24518
aS'Murphy, R A'
p24519
asS'EDAT'
p24520
S'2014/06/07 06:00'
p24521
sS'PST'
p24522
S'ppublish'
p24523
sS'SO'
p24524
S'Int J Tuberc Lung Dis. 2014 Jun;18(6):689-93. doi: 10.5588/ijtld.13.0492.'
p24525
sS'PG'
p24526
S'689-93'
p24527
sS'TI'
p24528
S'Double-dose lopinavir-ritonavir in combination with rifampicin-based anti-tuberculosis treatment in South Africa.'
p24529
sS'SB'
p24530
S'IM'
p24531
sS'RN'
p24532
(lp24533
S'0 (Antibiotics, Antitubercular)'
p24534
aS'0 (Drug Combinations)'
p24535
aS'0 (HIV Protease Inhibitors)'
p24536
aS'0 (lopinavir-ritonavir drug combination)'
p24537
aS'2494G1JF75 (Lopinavir)'
p24538
aS'O3J8G9O825 (Ritonavir)'
p24539
aS'VJT6J7R4TR (Rifampin)'
p24540
asS'PL'
p24541
S'France'
p24542
sS'TA'
p24543
S'Int J Tuberc Lung Dis'
p24544
stRp24545
ag2
(g3
g4
(dp24546
S'LID'
p24547
S'10.5588/ijtld.13.0934 [doi]'
p24548
sS'STAT'
p24549
S'MEDLINE'
p24550
sS'JT'
p24551
S'The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease'
p24552
sS'CIN'
p24553
(lp24554
S'Int J Tuberc Lung Dis. 2014 Jul;18(7):758-9. PMID: 24902546'
p24555
asS'DA'
p24556
S'20140606'
p24557
sS'AID'
p24558
(lp24559
S'10.5588/ijtld.13.0934 [doi]'
p24560
asS'CRDT'
p24561
(lp24562
S'2014/06/07 06:00'
p24563
asS'DP'
p24564
S'2014 Jul'
p24565
sS'AD'
p24566
S'<label>*</label>Epidemic Intelligence Service, Division of Global HIV/AIDS, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA. <label><sup>dagger</sup></label>Uganda Prisons Service, Kampala. <label><sup>double dagger</sup></label>Division of Global HIV/AIDS, Center for Global Health, CDC, Entebbe, Uganda. <label><sup>double dagger</sup></label>Division of Global HIV/AIDS, Center for Global Health, CDC, Entebbe, Uganda. <label><sup>dagger</sup></label>Uganda Prisons Service, Kampala. <label><sup>double dagger</sup></label>Division of Global HIV/AIDS, Center for Global Health, CDC, Entebbe, Uganda.'
p24567
sS'OWN'
p24568
S'NLM'
p24569
sS'PT'
p24570
(lp24571
S'Journal Article'
p24572
aS"Research Support, Non-U.S. Gov't"
p24573
aS"Research Support, U.S. Gov't, P.H.S."
p24574
asS'LA'
p24575
(lp24576
S'eng'
p24577
asS'FAU'
p24578
(lp24579
S'Schwitters, A'
p24580
aS'Kaggwa, M'
p24581
aS'Omiel, P'
p24582
aS'Nagadya, G'
p24583
aS'Kisa, N'
p24584
aS'Dalal, S'
p24585
asS'LR'
p24586
S'20160706'
p24587
sS'PG'
p24588
S'781-6'
p24589
sS'TI'
p24590
S'Tuberculosis incidence and treatment completion among Ugandan prison inmates.'
p24591
sS'RN'
p24592
(lp24593
S'0 (Antitubercular Agents)'
p24594
asS'PL'
p24595
S'France'
p24596
sS'TA'
p24597
S'Int J Tuberc Lung Dis'
p24598
sS'JID'
p24599
S'9706389'
p24600
sS'AB'
p24601
S'BACKGROUND: The Uganda Prisons Service (UPS) is responsible for the health of approximately 32 500 inmates in 233 prisons. In 2008 a rapid UPS assessment estimated TB prevalence at 654/100 000, three times that of the general population (183/100 000). Although treatment programs exist, little is known about treatment completion in sub-Saharan African prisons. METHODS: We conducted a retrospective study of Ugandan prisoners diagnosed with TB from June 2011 to November 2012. We analyzed TB diagnosis, TB-HIV comorbidity and treatment completion from national registers and tracked prison transfers and releases. RESULTS: A total of 469 prisoners were diagnosed with TB over the 1.5-year period (incidence 955/100 000 person-years). Of 466 prisoners starting treatment, 48% completed treatment, 43% defaulted, 5% died and 4% were currently on treatment. During treatment, 12% of prisoners remaining in the same prison defaulted, 53% of transfers defaulted and 81% of those released were lost to follow-up. The odds of defaulting were 8.36 times greater among prisoners who were transferred during treatment. CONCLUSIONS: TB incidence and treatment default are high among Ugandan prisoners. Strategies to improve treatment completion and prevent multidrug resistance could include avoiding transfer of TB patients, improving communications between prisons to ensure treatment follow-up after transfer and facilitating transfer to community clinics for released prisoners.'
p24602
sS'GR'
p24603
(lp24604
S'5U2GPS001315/PHS HHS/United States'
p24605
aS'CC999999/Intramural CDC HHS/United States'
p24606
aS'PEPFAR/United States'
p24607
asS'IP'
p24608
S'7'
sS'IS'
p24609
S'1815-7920 (Electronic) 1027-3719 (Linking)'
p24610
sS'PMC'
p24611
S'PMC4922131'
p24612
sS'DCOM'
p24613
S'20150302'
p24614
sS'MID'
p24615
(lp24616
S'HHSPA793880'
p24617
asS'AU'
p24618
(lp24619
S'Schwitters A'
p24620
aS'Kaggwa M'
p24621
aS'Omiel P'
p24622
aS'Nagadya G'
p24623
aS'Kisa N'
p24624
aS'Dalal S'
p24625
asS'VI'
p24626
S'18'
p24627
sS'MHDA'
p24628
S'2015/03/03 06:00'
p24629
sS'OID'
p24630
(lp24631
S'NLM: HHSPA793880'
p24632
aS'NLM: PMC4922131'
p24633
asS'MH'
p24634
(lp24635
S'Adolescent'
p24636
aS'Adult'
p24637
aS'Antitubercular Agents/therapeutic use'
p24638
aS'Female'
p24639
aS'Follow-Up Studies'
p24640
aS'HIV Infections/*epidemiology'
p24641
aS'Humans'
p24642
aS'Incidence'
p24643
aS'Male'
p24644
aS'Medication Adherence'
p24645
aS'Prevalence'
p24646
aS'Prisoners/*statistics & numerical data'
p24647
aS'*Prisons'
p24648
aS'Retrospective Studies'
p24649
aS'Time Factors'
p24650
aS'Tuberculosis/drug therapy/*epidemiology'
p24651
aS'Uganda/epidemiology'
p24652
aS'Young Adult'
p24653
asS'EDAT'
p24654
S'2014/06/07 06:00'
p24655
sS'SO'
p24656
S'Int J Tuberc Lung Dis. 2014 Jul;18(7):781-6. doi: 10.5588/ijtld.13.0934.'
p24657
sS'SB'
p24658
S'IM'
p24659
sS'PMID'
p24660
S'24902552'
p24661
sS'PST'
p24662
S'ppublish'
p24663
stRp24664
ag2
(g3
g4
(dp24665
S'LID'
p24666
S'10.5588/ijtld.13.0069 [doi]'
p24667
sS'STAT'
p24668
S'MEDLINE'
p24669
sS'AB'
p24670
S'Childhood tuberculosis (TB) is a marker of TB transmission within a community. We present the fourth consecutive survey of children with culture-confirmed TB at a hospital in Cape Town, South Africa, from 2009 to 2011. In comparison to the previous survey, the rate of multidrug-resistant TB (MDR-TB) has stabilised and the human immunodeficiency virus infection rate has declined. We also report on the first systematic surveillance of resistance to second-line drugs. Two concerns following from this are the high rate (22%) of ofloxacin resistance in MDR-TB isolates, and the discordance between isolates with an inhA promoter region mutation, usually implying ethionamide (ETH) resistance, and phenotypic ETH results in these isolates showing ETH susceptibility.'
p24671
sS'JID'
p24672
S'9706389'
p24673
sS'AD'
p24674
S'<label>*</label>Department of Paediatrics and Child Health, Desmond Tutu TB Centre, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa. <label>*</label>Department of Paediatrics and Child Health, Desmond Tutu TB Centre, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa. <label><sup>double dagger</sup></label>National Health Laboratory Service, Tygerberg Academic Hospital, Tygerberg, South Africa. <label>*</label>Department of Paediatrics and Child Health, Desmond Tutu TB Centre, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.'
p24675
sS'JT'
p24676
S'The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease'
p24677
sS'IP'
p24678
S'7'
sS'IS'
p24679
S'1815-7920 (Electronic) 1027-3719 (Linking)'
p24680
sS'DCOM'
p24681
S'20150302'
p24682
sS'DA'
p24683
S'20140606'
p24684
sS'AU'
p24685
(lp24686
S'Schaaf HS'
p24687
aS'Hesseling AC'
p24688
aS'Rautenbach C'
p24689
aS'Seddon JA'
p24690
asS'AID'
p24691
(lp24692
S'10.5588/ijtld.13.0069 [doi]'
p24693
asS'CRDT'
p24694
(lp24695
S'2014/06/07 06:00'
p24696
asS'VI'
p24697
S'18'
p24698
sS'PMID'
p24699
S'24902550'
p24700
sS'DP'
p24701
S'2014 Jul'
p24702
sS'MHDA'
p24703
S'2015/03/03 06:00'
p24704
sS'OWN'
p24705
S'NLM'
p24706
sS'PT'
p24707
(lp24708
S'Journal Article'
p24709
aS"Research Support, Non-U.S. Gov't"
p24710
asS'LA'
p24711
(lp24712
S'eng'
p24713
asS'MH'
p24714
(lp24715
S'Age Factors'
p24716
aS'Antitubercular Agents/*pharmacology'
p24717
aS'Bacterial Proteins'
p24718
aS'Child'
p24719
aS'Child, Preschool'
p24720
aS'Drug Resistance, Multiple, Bacterial'
p24721
aS'Ethionamide/pharmacology'
p24722
aS'Female'
p24723
aS'HIV Infections/*epidemiology'
p24724
aS'Humans'
p24725
aS'Infant'
p24726
aS'Male'
p24727
aS'Mycobacterium tuberculosis/drug effects/isolation & purification'
p24728
aS'Ofloxacin/pharmacology'
p24729
aS'Oxidoreductases'
p24730
aS'Promoter Regions, Genetic'
p24731
aS'South Africa/epidemiology'
p24732
aS'Tuberculosis, Multidrug-Resistant/drug therapy/*epidemiology/microbiology'
p24733
asS'FAU'
p24734
(lp24735
S'Schaaf, H S'
p24736
aS'Hesseling, A C'
p24737
aS'Rautenbach, C'
p24738
aS'Seddon, J A'
p24739
asS'EDAT'
p24740
S'2014/06/07 06:00'
p24741
sS'PST'
p24742
S'ppublish'
p24743
sS'SO'
p24744
S'Int J Tuberc Lung Dis. 2014 Jul;18(7):770-3. doi: 10.5588/ijtld.13.0069.'
p24745
sS'PG'
p24746
S'770-3'
p24747
sS'TI'
p24748
S'Trends in childhood drug-resistant tuberculosis in South Africa: a window into the wider epidemic?'
p24749
sS'SB'
p24750
S'IM'
p24751
sS'RN'
p24752
(lp24753
S'0 (Antitubercular Agents)'
p24754
aS'0 (Bacterial Proteins)'
p24755
aS'A4P49JAZ9H (Ofloxacin)'
p24756
aS'EC 1.- (Oxidoreductases)'
p24757
aS'EC 1.3.1.9 (InhA protein, Mycobacterium)'
p24758
aS'OAY8ORS3CQ (Ethionamide)'
p24759
asS'PL'
p24760
S'France'
p24761
sS'TA'
p24762
S'Int J Tuberc Lung Dis'
p24763
stRp24764
ag2
(g3
g4
(dp24765
S'LID'
p24766
S'10.1111/tmi.12278 [doi]'
p24767
sS'STAT'
p24768
S'MEDLINE'
p24769
sS'DEP'
p24770
S'20140212'
p24771
sS'CI'
p24772
(lp24773
S'(c) 2014 John Wiley & Sons Ltd.'
p24774
asS'DA'
p24775
S'20140606'
p24776
sS'AID'
p24777
(lp24778
S'10.1111/tmi.12278 [doi]'
p24779
asS'CRDT'
p24780
(lp24781
S'2014/06/06 06:00'
p24782
asS'DP'
p24783
S'2014 May'
p24784
sS'OWN'
p24785
S'NLM'
p24786
sS'PT'
p24787
(lp24788
S'Journal Article'
p24789
asS'LA'
p24790
(lp24791
S'eng'
p24792
asS'FAU'
p24793
(lp24794
S'Decroo, Tom'
p24795
aS'Koole, Olivier'
p24796
aS'Remartinez, Daniel'
p24797
aS'dos Santos, Natacha'
p24798
aS'Dezembro, Sergio'
p24799
aS'Jofrisse, Mariano'
p24800
aS'Rasschaert, Freya'
p24801
aS'Biot, Marc'
p24802
aS'Laga, Marie'
p24803
asS'JT'
p24804
S'Tropical medicine & international health : TM & IH'
p24805
sS'PG'
p24806
S'514-21'
p24807
sS'TI'
p24808
S'Four-year retention and risk factors for attrition among members of community ART groups in Tete, Mozambique.'
p24809
sS'RN'
p24810
(lp24811
S'0 (Anti-Retroviral Agents)'
p24812
asS'PL'
p24813
S'England'
p24814
sS'TA'
p24815
S'Trop Med Int Health'
p24816
sS'JID'
p24817
S'9610576'
p24818
sS'AB'
p24819
S'OBJECTIVE: Community ART groups (CAG), peer support groups involved in community ART distribution and mutual psychosocial support, were piloted to respond to staggering antiretroviral treatment (ART) attrition in Mozambique. To understand the impact of CAG on long-term retention, we estimated mortality and lost-to-follow-up (LTFU) rates and assessed predictors for attrition. METHODS: Retrospective cohort study. Kaplan-Meier techniques were used to estimate mortality and LTFU in CAG. Individual- and CAG-level predictors of attrition were assessed using a multivariable Cox proportional hazards model, adjusted for site-level clustering. RESULTS: Mortality and LTFU rates among 5729 CAG members were, respectively, 2.1 and 0.1 per 100 person-years. Retention was 97.7% at 12 months, 96.0% at 24 months, 93.4% at 36 months and 91.8% at 48 months. At individual level, attrition in CAG was significantly associated with immunosuppression when joining a CAG, and being male. At CAG level, attrition was associated with lack of rotational representation at the clinic, lack of a regular CD4 count among fellow members and linkage to a rural or district clinic compared with linkage to a peri-urban clinic. CONCLUSIONS: Long-term retention in this community-based ART model compares favourably with published data on stable ART patients. Nevertheless, to reduce attrition, further efforts need to be made to enroll patients earlier on ART, promote health-seeking behaviour, especially for men, promote a strong peer dynamic to assure rotational representation at the clinic and regular CD4 follow-up and reinforce referral of sick patients.'
p24820
sS'AD'
p24821
S'Medecins Sans Frontieres, Tete, Mozambique; Departement of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.'
p24822
sS'IP'
p24823
S'5'
sS'IS'
p24824
S'1365-3156 (Electronic) 1360-2276 (Linking)'
p24825
sS'DCOM'
p24826
S'20140630'
p24827
sS'AU'
p24828
(lp24829
S'Decroo T'
p24830
aS'Koole O'
p24831
aS'Remartinez D'
p24832
aS'dos Santos N'
p24833
aS'Dezembro S'
p24834
aS'Jofrisse M'
p24835
aS'Rasschaert F'
p24836
aS'Biot M'
p24837
aS'Laga M'
p24838
asS'VI'
p24839
S'19'
p24840
sS'MHDA'
p24841
S'2014/07/01 06:00'
p24842
sS'PHST'
p24843
(lp24844
S'2014/02/12 [aheadofprint]'
p24845
asS'OTO'
p24846
(lp24847
S'NOTNLM'
p24848
asS'MH'
p24849
(lp24850
S'Adult'
p24851
aS'Anti-Retroviral Agents/*therapeutic use'
p24852
aS'Cohort Studies'
p24853
aS'Community Health Services/statistics & numerical data'
p24854
aS'Female'
p24855
aS'Follow-Up Studies'
p24856
aS'HIV Infections/*drug therapy/mortality/*psychology'
p24857
aS'*Health Behavior'
p24858
aS'Health Services Accessibility/statistics & numerical data'
p24859
aS'Humans'
p24860
aS'Kaplan-Meier Estimate'
p24861
aS'Lost to Follow-Up'
p24862
aS'Male'
p24863
aS'Mozambique'
p24864
aS'Patient Participation/statistics & numerical data'
p24865
aS'Peer Group'
p24866
aS'Proportional Hazards Models'
p24867
aS'Retrospective Studies'
p24868
aS'Risk Factors'
p24869
aS'Rural Population/statistics & numerical data'
p24870
aS'Sex Distribution'
p24871
aS'*Social Support'
p24872
aS'Urban Population/statistics & numerical data'
p24873
asS'EDAT'
p24874
S'2014/06/06 06:00'
p24875
sS'SO'
p24876
S'Trop Med Int Health. 2014 May;19(5):514-21. doi: 10.1111/tmi.12278. Epub 2014 Feb 12.'
p24877
sS'SB'
p24878
S'IM'
p24879
sS'PMID'
p24880
S'24898272'
p24881
sS'OT'
p24882
(lp24883
S'HIV'
p24884
aS'antiretroviral therapy'
p24885
aS'community participation'
p24886
aS'health services accessibility'
p24887
aS'peer support'
p24888
asS'PST'
p24889
S'ppublish'
p24890
stRp24891
ag2
(g3
g4
(dp24892
S'LID'
p24893
S'10.1186/1475-2875-13-181 [doi]'
p24894
sS'STAT'
p24895
S'MEDLINE'
p24896
sS'DEP'
p24897
S'20140511'
p24898
sS'DA'
p24899
S'20140604'
p24900
sS'AID'
p24901
(lp24902
S'1475-2875-13-181 [pii]'
p24903
aS'10.1186/1475-2875-13-181 [doi]'
p24904
asS'CRDT'
p24905
(lp24906
S'2014/06/03 06:00'
p24907
asS'DP'
p24908
S'2014'
p24909
sS'OWN'
p24910
S'NLM'
p24911
sS'PT'
p24912
(lp24913
S'Journal Article'
p24914
aS"Research Support, Non-U.S. Gov't"
p24915
asS'LA'
p24916
(lp24917
S'eng'
p24918
asS'DCOM'
p24919
S'20150114'
p24920
sS'JT'
p24921
S'Malaria journal'
p24922
sS'LR'
p24923
S'20150805'
p24924
sS'FAU'
p24925
(lp24926
S'Mikkelsen-Lopez, Inez'
p24927
aS'Shango, Winna'
p24928
aS'Barrington, Jim'
p24929
aS'Ziegler, Rene'
p24930
aS'Smith, Tom'
p24931
aS'deSavigny, Don'
p24932
asS'TI'
p24933
S'The challenge to avoid anti-malarial medicine stock-outs in an era of funding partners: the case of Tanzania.'
p24934
sS'RN'
p24935
(lp24936
S'0 (Antimalarials)'
p24937
aS'0 (Artemisinins)'
p24938
aS'0 (Drug Combinations)'
p24939
aS'0 (Ethanolamines)'
p24940
aS'0 (Fluorenes)'
p24941
aS'0 (artemether-lumefantrine combination)'
p24942
asS'PL'
p24943
S'England'
p24944
sS'PG'
p24945
S'181'
p24946
sS'JID'
p24947
S'101139802'
p24948
sS'AB'
p24949
S'BACKGROUND: Between 2007 and 2013, the Tanzanian public sector received 93.1 million doses of first-line anti-malarial artemisinin-based combination therapy (ACT) in the form of artemether-lumefantrine entirely supplied by funding partners. The introduction of a health facility ACT stock monitoring system using SMS technology by the National Malaria Control Programme in mid 2011 revealed a high frequency of stock-outs of ACT in primary care public health facilities. The objective of this study was to determine the pattern of availability of ACT and possible causes of observed stock-outs across public health facilities in Tanzania since mid-2011. METHODS: Data were collected weekly by the mobile phone reporting tool SMS for Life on ACT availability from over 5,000 public health facilities in Tanzania starting from September 2011 to December 2012. Stock data for all four age-dose levels of ACT across health facilities were summarized and supply of ACT at the national level was also documented. RESULTS: Over the period of 15 months, on average 29% of health facilities in Tanzania were completely stocked out of all four-age dose levels of the first-line anti-malarial with a median duration of total stock-out of six weeks. Patterns of total stock-out by region ranged from a low of 9% to a high of 52%. The ACT stock-outs were most likely caused by: a) insufficient ACT supplies entering Tanzania (e.g. in 2012 Tanzania received 10.9 million ACT doses compared with a forecast demand of 14.4 million doses); and b) irregular pattern of ACT supply (several months with no ACT stock). CONCLUSION: The reduced ACT availability and irregular pattern of supply were due to cumbersome bureaucratic processes and delays both within the country and from the main donor, the Global Fund to Fight AIDS, Tuberculosis and Malaria. Tanzania should invest in strengthening both the supply system and the health information system using mHealth solutions such as SMS for Life. This will continue to assist in tracking ACT availability across the country where all partners work towards more streamlined, demand driven and accountable procurement and supply chain systems.'
p24950
sS'AD'
p24951
S'Swiss Tropical and Public Health Institute, Basel, Switzerland. i.mikkelsen-lopez@unibas.ch.'
p24952
sS'VI'
p24953
S'13'
p24954
sS'IS'
p24955
S'1475-2875 (Electronic) 1475-2875 (Linking)'
p24956
sS'PMC'
p24957
S'PMC4030285'
p24958
sS'AU'
p24959
(lp24960
S'Mikkelsen-Lopez I'
p24961
aS'Shango W'
p24962
aS'Barrington J'
p24963
aS'Ziegler R'
p24964
aS'Smith T'
p24965
aS'deSavigny D'
p24966
asS'MHDA'
p24967
S'2015/01/15 06:00'
p24968
sS'PHST'
p24969
(lp24970
S'2014/01/05 [received]'
p24971
aS'2014/04/27 [accepted]'
p24972
aS'2014/05/11 [aheadofprint]'
p24973
asS'OID'
p24974
(lp24975
S'NLM: PMC4030285'
p24976
asS'MH'
p24977
(lp24978
S'Antimalarials/*supply & distribution'
p24979
aS'Artemisinins/*supply & distribution'
p24980
aS'Child, Preschool'
p24981
aS'Drug Combinations'
p24982
aS'Ethanolamines/*supply & distribution'
p24983
aS'Female'
p24984
aS'Fluorenes/*supply & distribution'
p24985
aS'Health Facilities'
p24986
aS'Health Information Management/methods/organization & administration'
p24987
aS'Humans'
p24988
aS'Infant'
p24989
aS'Infant, Newborn'
p24990
aS'Malaria/*drug therapy'
p24991
aS'Male'
p24992
aS'Public Health Administration'
p24993
aS'Public Sector'
p24994
aS'Tanzania'
p24995
asS'EDAT'
p24996
S'2014/06/03 06:00'
p24997
sS'SO'
p24998
S'Malar J. 2014 May 11;13:181. doi: 10.1186/1475-2875-13-181.'
p24999
sS'SB'
p25000
S'IM'
p25001
sS'PMID'
p25002
S'24885420'
p25003
sS'TA'
p25004
S'Malar J'
p25005
sS'PST'
p25006
S'epublish'
p25007
stRp25008
ag2
(g3
g4
(dp25009
S'LID'
p25010
S'10.1097/QAI.0000000000000221 [doi]'
p25011
sS'STAT'
p25012
S'MEDLINE'
p25013
sS'JT'
p25014
S'Journal of acquired immune deficiency syndromes (1999)'
p25015
sS'MID'
p25016
(lp25017
S'NIHMS594209'
p25018
asS'DA'
p25019
S'20140813'
p25020
sS'AID'
p25021
(lp25022
S'10.1097/QAI.0000000000000221 [doi]'
p25023
asS'CRDT'
p25024
(lp25025
S'2014/05/30 06:00'
p25026
asS'DP'
p25027
S'2014 Sep 1'
p25028
sS'AD'
p25029
S'*Division of Pulmonary, Allergy and Critical Care Medicine, Columbia University Medical Center, New York, NY; daggerDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY; double daggerCentre for Aids Program of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa; section signDepartment of Epidemiology, Boston University School of Public Health, Boston, MA; and ||University of KwaZulu-Natal, Durban, South Africa.'
p25030
sS'OWN'
p25031
S'NLM'
p25032
sS'PT'
p25033
(lp25034
S'Journal Article'
p25035
aS'Research Support, N.I.H., Extramural'
p25036
aS"Research Support, Non-U.S. Gov't"
p25037
asS'LA'
p25038
(lp25039
S'eng'
p25040
asS'FAU'
p25041
(lp25042
S"O'Donnell, Max R"
p25043
aS'Wolf, Allison'
p25044
aS'Werner, Lise'
p25045
aS'Horsburgh, C Robert'
p25046
aS'Padayatchi, Nesri'
p25047
asS'LR'
p25048
S'20151119'
p25049
sS'PG'
p25050
S'22-9'
p25051
sS'TI'
p25052
S'Adherence in the treatment of patients with extensively drug-resistant tuberculosis and HIV in South Africa: a prospective cohort study.'
p25053
sS'RN'
p25054
(lp25055
S'0 (Anti-HIV Agents)'
p25056
aS'0 (Antitubercular Agents)'
p25057
asS'PL'
p25058
S'United States'
p25059
sS'TA'
p25060
S'J Acquir Immune Defic Syndr'
p25061
sS'JID'
p25062
S'100892005'
p25063
sS'AB'
p25064
S'OBJECTIVE: Extensively drug-resistant tuberculosis (XDR-TB)/HIV coinfection is difficult to treat with frequent adverse drug reactions and associated with high mortality. Adherence to antiretroviral therapy (ARV) and second-line TB medications may reduce mortality, prevent amplification of drug resistance, and improve outcomes. METHODS: Prospective cohort study of XDR-TB patients on treatment in KwaZulu-Natal, South Africa. Adherence to ARV and TB medications was assessed separately at baseline and monthly. Knowledge, attitudes, and beliefs were assessed at baseline. Optimal adherence was defined as self-report of taking all pills in the previous 7 days; missing any pills was defined as suboptimal adherence. Primary outcome was optimal adherence 6 months after initiation of XDR-TB treatment to TB medications, ARV, and both ("dual adherence"). RESULTS: One hundred four XDR-TB patients (79.8% HIV coinfected, 84.3% on ARV at enrollment) were enrolled and followed monthly (median 8 visits; interquartile range: 4-12). Six-month optimal adherence was higher for ARV (88.2%) than TB medications (67.7%) (P < 0.001). Low educational attainment, male gender, and year of enrollment were independently associated with dual suboptimal adherence. At baseline, participants indicated that XDR-TB was curable (76.0%), HIV and TB were linked (81.7%), and ARV improves TB outcomes (72.1%). Baseline knowledge, attitudes, and beliefs did not predict subsequent adherence. CONCLUSIONS: Medication adherence was significantly higher for ARV than for TB medications in this cohort. Short-course treatment regimens for drug-resistant TB with lower pill burden may increase adherence and improve outcomes in XDR-TB/HIV. Programmatic support for dual adherence is critical in the treatment of drug-resistant TB and HIV.'
p25065
sS'GR'
p25066
(lp25067
S'5K23AI098479/AI/NIAID NIH HHS/United States'
p25068
aS'K23 AI098479/AI/NIAID NIH HHS/United States'
p25069
asS'IP'
p25070
S'1'
sS'IS'
p25071
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p25072
sS'PMC'
p25073
S'PMC4410008'
p25074
sS'DCOM'
p25075
S'20150113'
p25076
sS'AU'
p25077
(lp25078
S"O'Donnell MR"
p25079
aS'Wolf A'
p25080
aS'Werner L'
p25081
aS'Horsburgh CR'
p25082
aS'Padayatchi N'
p25083
asS'VI'
p25084
S'67'
p25085
sS'MHDA'
p25086
S'2015/01/15 06:00'
p25087
sS'OID'
p25088
(lp25089
S'NLM: NIHMS594209'
p25090
aS'NLM: PMC4410008'
p25091
asS'MH'
p25092
(lp25093
S'Adolescent'
p25094
aS'Adult'
p25095
aS'Anti-HIV Agents/*administration & dosage'
p25096
aS'Antitubercular Agents/*administration & dosage'
p25097
aS'Cohort Studies'
p25098
aS'Extensively Drug-Resistant Tuberculosis/*drug therapy/immunology/microbiology'
p25099
aS'Female'
p25100
aS'HIV Infections/*drug therapy/immunology/virology'
p25101
aS'HIV-1/*isolation & purification'
p25102
aS'Humans'
p25103
aS'Logistic Models'
p25104
aS'Male'
p25105
aS'*Medication Adherence'
p25106
aS'Middle Aged'
p25107
aS'Mycobacterium tuberculosis/*isolation & purification'
p25108
aS'Prospective Studies'
p25109
aS'Socioeconomic Factors'
p25110
aS'South Africa'
p25111
aS'Surveys and Questionnaires'
p25112
aS'Young Adult'
p25113
asS'EDAT'
p25114
S'2014/05/30 06:00'
p25115
sS'SO'
p25116
S'J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):22-9. doi: 10.1097/QAI.0000000000000221.'
p25117
sS'SB'
p25118
S'IM X'
p25119
sS'PMID'
p25120
S'24872138'
p25121
sS'PST'
p25122
S'ppublish'
p25123
stRp25124
ag2
(g3
g4
(dp25125
S'LID'
p25126
S'10.1111/joim.12264 [doi]'
p25127
sS'STAT'
p25128
S'MEDLINE'
p25129
sS'DEP'
p25130
S'20140618'
p25131
sS'CI'
p25132
(lp25133
S'(c) 2014 The Association for the Publication of the Journal of Internal Medicine.'
p25134
asS'DA'
p25135
S'20150326'
p25136
sS'AID'
p25137
(lp25138
S'10.1111/joim.12264 [doi]'
p25139
asS'CRDT'
p25140
(lp25141
S'2014/05/10 06:00'
p25142
asS'DP'
p25143
S'2015 Apr'
p25144
sS'AD'
p25145
S'Therapeutic Immunology Division, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.'
p25146
sS'OWN'
p25147
S'NLM'
p25148
sS'PT'
p25149
(lp25150
S'Journal Article'
p25151
aS"Research Support, Non-U.S. Gov't"
p25152
aS'Review'
p25153
asS'LA'
p25154
(lp25155
S'eng'
p25156
asS'FAU'
p25157
(lp25158
S'Parida, S K'
p25159
aS'Axelsson-Robertson, R'
p25160
aS'Rao, M V'
p25161
aS'Singh, N'
p25162
aS'Master, I'
p25163
aS'Lutckii, A'
p25164
aS'Keshavjee, S'
p25165
aS'Andersson, J'
p25166
aS'Zumla, A'
p25167
aS'Maeurer, M'
p25168
asS'JT'
p25169
S'Journal of internal medicine'
p25170
sS'PG'
p25171
S'388-405'
p25172
sS'TI'
p25173
S'Totally drug-resistant tuberculosis and adjunct therapies.'
p25174
sS'RN'
p25175
(lp25176
S'0 (Nitroimidazoles)'
p25177
aS'0 (Oxazolidinones)'
p25178
asS'PL'
p25179
S'England'
p25180
sS'TA'
p25181
S'J Intern Med'
p25182
sS'JID'
p25183
S'8904841'
p25184
sS'AB'
p25185
S"The first cases of totally drug-resistant (TDR) tuberculosis (TB) were reported in Italy 10 years ago; more recently, cases have also been reported in Iran, India and South Africa. Although there is no consensus on terminology, it is most commonly described as 'resistance to all first- and second-line drugs used to treat TB'. Mycobacterium tuberculosis (M.tb) acquires drug resistance mutations in a sequential fashion under suboptimal drug pressure due to monotherapy, inadequate dosing, treatment interruptions and drug interactions. The treatment of TDR-TB includes antibiotics with disputed or minimal effectiveness against M.tb, and the fatality rate is high. Comorbidities such as diabetes and infection with human immunodeficiency virus further impact on TB treatment options and survival rates. Several new drug candidates with novel modes of action are under late-stage clinical evaluation (e.g., delamanid, bedaquiline, SQ109 and sutezolid). 'Repurposed' antibiotics have also recently been included in the treatment of extensively drug resistant TB. However, because of mutations in M.tb, drugs will not provide a cure for TB in the long term. Adjunct TB therapies, including therapeutic vaccines, vitamin supplementation and/or repurposing of drugs targeting biologically and clinically relevant molecular pathways, may achieve better clinical outcomes in combination with standard chemotherapy. Here, we review broader perspectives of drug resistance in TB and potential adjunct treatment options."
p25186
sS'GR'
p25187
(lp25188
S'Medical Research Council/United Kingdom'
p25189
asS'IP'
p25190
S'4'
sS'IS'
p25191
S'1365-2796 (Electronic) 0954-6820 (Linking)'
p25192
sS'DCOM'
p25193
S'20150601'
p25194
sS'AU'
p25195
(lp25196
S'Parida SK'
p25197
aS'Axelsson-Robertson R'
p25198
aS'Rao MV'
p25199
aS'Singh N'
p25200
aS'Master I'
p25201
aS'Lutckii A'
p25202
aS'Keshavjee S'
p25203
aS'Andersson J'
p25204
aS'Zumla A'
p25205
aS'Maeurer M'
p25206
asS'VI'
p25207
S'277'
p25208
sS'MHDA'
p25209
S'2015/06/02 06:00'
p25210
sS'PHST'
p25211
(lp25212
S'2014/06/18 [aheadofprint]'
p25213
asS'OTO'
p25214
(lp25215
S'NOTNLM'
p25216
asS'MH'
p25217
(lp25218
S'Drug Resistance, Bacterial/genetics'
p25219
aS'Extensively Drug-Resistant Tuberculosis/diagnosis/epidemiology/etiology/immunology/*therapy'
p25220
aS'Genotype'
p25221
aS'Global Health'
p25222
aS'Host-Pathogen Interactions'
p25223
aS'Humans'
p25224
aS'Mutation'
p25225
aS'Mycobacterium tuberculosis/drug effects/genetics/physiology'
p25226
aS'Nitroimidazoles/therapeutic use'
p25227
aS'Oxazolidinones/therapeutic use'
p25228
asS'EDAT'
p25229
S'2014/05/09 06:00'
p25230
sS'SO'
p25231
S'J Intern Med. 2015 Apr;277(4):388-405. doi: 10.1111/joim.12264. Epub 2014 Jun 18.'
p25232
sS'SB'
p25233
S'IM'
p25234
sS'PMID'
p25235
S'24809736'
p25236
sS'OT'
p25237
(lp25238
S'Mycobacterium tuberculosis'
p25239
aS'adjunct therapies'
p25240
aS'drug resistance'
p25241
aS'extensively drug resistant'
p25242
aS'genotype'
p25243
aS'multidrug resistant'
p25244
asS'PST'
p25245
S'ppublish'
p25246
stRp25247
ag2
(g3
g4
(dp25248
S'LID'
p25249
S'10.1089/AID.2013.0294 [doi]'
p25250
sS'STAT'
p25251
S'MEDLINE'
p25252
sS'DEP'
p25253
S'20140606'
p25254
sS'DA'
p25255
S'20140801'
p25256
sS'AID'
p25257
(lp25258
S'10.1089/AID.2013.0294 [doi]'
p25259
asS'CRDT'
p25260
(lp25261
S'2014/05/07 06:00'
p25262
asS'DP'
p25263
S'2014 Aug'
p25264
sS'AD'
p25265
S'1 Global Health Programs, U.S. Military HIV Research Program (MHRP)/Walter Reed Army Institute of Research (WRAIR) , Bethesda, Maryland.'
p25266
sS'OWN'
p25267
S'NLM'
p25268
sS'PT'
p25269
(lp25270
S'Journal Article'
p25271
aS'Randomized Controlled Trial'
p25272
aS"Research Support, U.S. Gov't, Non-P.H.S."
p25273
asS'LA'
p25274
(lp25275
S'eng'
p25276
asS'FAU'
p25277
(lp25278
S'Crawford, Keith W'
p25279
aS'Wakabi, Salim'
p25280
aS'Kibuuka, Hannah'
p25281
aS'Magala, Fred'
p25282
aS'Keshinro, Babajide'
p25283
aS'Okoye, Ifeanyi'
p25284
aS'Akintunde, Ezekiel'
p25285
aS'Hamm, Tiffany E'
p25286
asS'JT'
p25287
S'AIDS research and human retroviruses'
p25288
sS'PG'
p25289
S'796-9'
p25290
sS'TI'
p25291
S'Short communication: east meets west: a description of HIV-1 drug resistance mutation patterns of patients failing first line therapy in PEPFAR clinics from Uganda and Nigeria.'
p25292
sS'RN'
p25293
(lp25294
S'0 (Anti-Retroviral Agents)'
p25295
aS'0 (Viral Proteins)'
p25296
asS'PL'
p25297
S'United States'
p25298
sS'TA'
p25299
S'AIDS Res Hum Retroviruses'
p25300
sS'JID'
p25301
S'8709376'
p25302
sS'AB'
p25303
S'HIV-1 viral load (VL) monitoring is recommended but seldom performed in resource-constrained countries. An evaluation of patients receiving first-line antiretroviral therapy in a multicountry PEPFAR program (RV288) was performed to determine the rates and predictors of virologic suppression. Resistance data from treatment failures are available from Uganda and Nigeria. Each country enrolled 325 subjects into this cross-sectional study. Subjects on first-line therapy were randomly selected for HIV RNA testing (viral load). Regimens included efavirenz or nevirapine with zidovudine/lamivudine or tenofovir/lamivudine. VL was determined from plasma using the Roche COBAS TaqMan HIV-1 Test, High Pure System v1.0 (47 copies/ml). Genotypic resistance testing was performed on samples with VL>1,000 copies/ml. From Uganda, 85% of subjects were undetectable while 7% (23/325) had VL>1,000 copies/ml. The HIV-1 subtype distribution was as follows: A=47.6%, C=14.3%, and D=38.1%. No resistance mutations were found in 14% of subjects. All subjects with resistance had the M184V mutation. Of subjects failing a zidovudine regimen less than 1 year, 88% (7/8) had no thymidine analogue mutations (TAMs), compared to 50% (4/8) failing greater than 1 year. Four subjects (25%) had more than two mutations from the TAM-1 pathway (41L, 210W, 215Y). In Nigeria, 82% were undetectable while 14% (45/325) had VL>1,000 copies/ml. HIV-1 subtype distribution was as follows: 62.8%=CRF02_AG, 34%=pure G, and 2.8%=A. Of the 35 genotyped subjects, 14% (5/35) had no resistance mutations. Of the remainder, 10% (3/30) had no nucleoside analogue mutations while 33% (10/30) had only M184V along with nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations. Forty percent (10/25) of subjects on zidovudine failed without TAMs. Another 25% (5/25) of subjects failing on zidovudine had more than two TAM-1 mutations. Individuals failing first-line antiretroviral therapy (ART) may retain sensitivity to one or more nucleoside analogues from the regimen. Knowledge of drug resistance patterns allow for selection of drugs that can be recycled in future regimens. Accumulation of resistance mutations may compromise future treatment options.'
p25304
sS'GR'
p25305
(lp25306
S'PEPFAR/United States'
p25307
asS'IP'
p25308
S'8'
sS'IS'
p25309
S'1931-8405 (Electronic) 0889-2229 (Linking)'
p25310
sS'DCOM'
p25311
S'20150330'
p25312
sS'AU'
p25313
(lp25314
S'Crawford KW'
p25315
aS'Wakabi S'
p25316
aS'Kibuuka H'
p25317
aS'Magala F'
p25318
aS'Keshinro B'
p25319
aS'Okoye I'
p25320
aS'Akintunde E'
p25321
aS'Hamm TE'
p25322
asS'VI'
p25323
S'30'
p25324
sS'MHDA'
p25325
S'2015/03/31 06:00'
p25326
sS'PHST'
p25327
(lp25328
S'2014/06/06 [aheadofprint]'
p25329
asS'MH'
p25330
(lp25331
S'Anti-Retroviral Agents/pharmacology/*therapeutic use'
p25332
aS'Cross-Sectional Studies'
p25333
aS'*Drug Resistance, Viral'
p25334
aS'Genotyping Techniques/methods'
p25335
aS'HIV Infections/*drug therapy/*virology'
p25336
aS'HIV-1/*drug effects/genetics/isolation & purification'
p25337
aS'Humans'
p25338
aS'*Mutation, Missense'
p25339
aS'Nigeria'
p25340
aS'Treatment Failure'
p25341
aS'Uganda'
p25342
aS'Viral Load'
p25343
aS'Viral Proteins/*genetics'
p25344
asS'EDAT'
p25345
S'2014/05/07 06:00'
p25346
sS'SO'
p25347
S'AIDS Res Hum Retroviruses. 2014 Aug;30(8):796-9. doi: 10.1089/AID.2013.0294. Epub 2014 Jun 6.'
p25348
sS'SB'
p25349
S'IM X'
p25350
sS'PMID'
p25351
S'24798614'
p25352
sS'PST'
p25353
S'ppublish'
p25354
stRp25355
ag2
(g3
g4
(dp25356
S'LID'
p25357
S'10.1371/journal.pone.0095469 [doi]'
p25358
sS'STAT'
p25359
S'MEDLINE'
p25360
sS'DEP'
p25361
S'20140505'
p25362
sS'DA'
p25363
S'20140506'
p25364
sS'AID'
p25365
(lp25366
S'10.1371/journal.pone.0095469 [doi]'
p25367
aS'PONE-D-14-06460 [pii]'
p25368
asS'CRDT'
p25369
(lp25370
S'2014/05/07 06:00'
p25371
asS'DP'
p25372
S'2014'
p25373
sS'AD'
p25374
S'Department of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, North Carolina, United States of America. Department of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, North Carolina, United States of America. Department of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, North Carolina, United States of America; Center for Health Policy & Inequalities Research, Duke Global Health Institute, Department of Community and Family Medicine, Duke University, Durham, North Carolina, United States of America. Tanzania Women Research Foundation, Moshi, Tanzania. Kilimanjaro Christian Medical Center, Moshi, Tanzania. Center for Health Policy & Inequalities Research, Duke Global Health Institute, Department of Community and Family Medicine, Duke University, Durham, North Carolina, United States of America.'
p25375
sS'OWN'
p25376
S'NLM'
p25377
sS'PT'
p25378
(lp25379
S'Clinical Trial'
p25380
aS'Journal Article'
p25381
aS'Observational Study'
p25382
aS'Research Support, N.I.H., Extramural'
p25383
asS'LA'
p25384
(lp25385
S'eng'
p25386
asS'FAU'
p25387
(lp25388
S'Belenky, Nadya M'
p25389
aS'Cole, Stephen R'
p25390
aS'Pence, Brian W'
p25391
aS'Itemba, Dafrosa'
p25392
aS'Maro, Venance'
p25393
aS'Whetten, Kathryn'
p25394
asS'JT'
p25395
S'PloS one'
p25396
sS'LR'
p25397
S'20160301'
p25398
sS'PG'
p25399
S'e95469'
p25400
sS'TI'
p25401
S'Depressive symptoms, HIV medication adherence, and HIV clinical outcomes in Tanzania: a prospective, observational study.'
p25402
sS'PL'
p25403
S'United States'
p25404
sS'TA'
p25405
S'PLoS One'
p25406
sS'JID'
p25407
S'101285081'
p25408
sS'AB'
p25409
S'Depressive symptoms have been shown to independently affect both antiretroviral therapy (ART) adherence and HIV clinical outcomes in high-income countries. We examined the prospective relationship between depressive symptoms and adherence, virologic failure, and suppressed immune function in people living with HIV/AIDS in Tanzania. Data from 403 study participants who were on stable ART and engaged in HIV clinical care were analyzed. We assessed crude and adjusted associations of depressive symptoms and ART adherence, both at baseline and at 12 months, using logistic regression. We used logistic generalized estimating equations to assess the association and 95% confidence intervals (CI) between depressive symptoms and both virologic failure and suppressed immune function. Ten percent of participants reported moderate or severe depressive symptoms at baseline and 31% of participants experienced virologic failure (>150 copies/ml) over two years. Depressive symptoms were associated with greater odds of reported medication nonadherence at both baseline (Odds Ratio [OR] per 1-unit increase = 1.18, 95% CI [1.12, 1.24]) and 12 months (OR = 1.08, 95% CI [1.03, 1.14]). By contrast, increases in depressive symptom score were inversely related to both virologic failure (OR = 0.93, 95% CI [0.87, 1.00]) and immune system suppression (OR = 0.88, 95% CI [0.79, 0.99]), though the association between depressive symptoms and clinical outcomes was less precise than for the association with nonadherence. Findings indicate a positive association between depressive symptoms and nonadherence, and also an inverse relationship between depressive symptoms and clinical outcomes, possibly due to informative loss to follow-up.'
p25410
sS'GR'
p25411
(lp25412
S'5R01MH078756/MH/NIMH NIH HHS/United States'
p25413
aS'P30 AI050410/AI/NIAID NIH HHS/United States'
p25414
aS'P30 AI064518/AI/NIAID NIH HHS/United States'
p25415
aS'R01 MH078756/MH/NIMH NIH HHS/United States'
p25416
asS'IP'
p25417
S'5'
sS'IS'
p25418
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p25419
sS'PMC'
p25420
S'PMC4010413'
p25421
sS'DCOM'
p25422
S'20150612'
p25423
sS'AU'
p25424
(lp25425
S'Belenky NM'
p25426
aS'Cole SR'
p25427
aS'Pence BW'
p25428
aS'Itemba D'
p25429
aS'Maro V'
p25430
aS'Whetten K'
p25431
asS'VI'
p25432
S'9'
sS'MHDA'
p25433
S'2015/06/13 06:00'
p25434
sS'PHST'
p25435
(lp25436
S'2014 [ecollection]'
p25437
aS'2014/02/11 [received]'
p25438
aS'2014/03/25 [accepted]'
p25439
aS'2014/05/05 [epublish]'
p25440
asS'OID'
p25441
(lp25442
S'NLM: PMC4010413'
p25443
asS'MH'
p25444
(lp25445
S'Acquired Immunodeficiency Syndrome/*drug therapy/*epidemiology'
p25446
aS'Adult'
p25447
aS'Depression/*epidemiology'
p25448
aS'Female'
p25449
aS'Humans'
p25450
aS'Male'
p25451
aS'*Medication Adherence'
p25452
aS'Middle Aged'
p25453
aS'Prospective Studies'
p25454
aS'Tanzania/epidemiology'
p25455
asS'EDAT'
p25456
S'2014/05/07 06:00'
p25457
sS'SO'
p25458
S'PLoS One. 2014 May 5;9(5):e95469. doi: 10.1371/journal.pone.0095469. eCollection 2014.'
p25459
sS'SB'
p25460
S'IM'
p25461
sS'PMID'
p25462
S'24798428'
p25463
sS'PST'
p25464
S'epublish'
p25465
stRp25466
ag2
(g3
g4
(dp25467
S'LID'
p25468
S'10.1093/cid/ciu314 [doi]'
p25469
sS'STAT'
p25470
S'MEDLINE'
p25471
sS'DEP'
p25472
S'20140501'
p25473
sS'CI'
p25474
(lp25475
S'(c) The Author 2014. Published by Oxford University Press on behalf of the'
p25476
aS'Infectious Diseases Society of America. All rights reserved. For Permissions,'
p25477
aS'please e-mail: journals.permissions@oup.com.'
p25478
asS'DA'
p25479
S'20140813'
p25480
sS'AID'
p25481
(lp25482
S'ciu314 [pii]'
p25483
aS'10.1093/cid/ciu314 [doi]'
p25484
asS'CRDT'
p25485
(lp25486
S'2014/05/06 06:00'
p25487
asS'DP'
p25488
S'2014 Sep 1'
p25489
sS'GR'
p25490
(lp25491
S'AI068634/AI/NIAID NIH HHS/United States'
p25492
aS'U01069484/PHS HHS/United States'
p25493
aS'U01AI068636/AI/NIAID NIH HHS/United States'
p25494
aS'U01AI069432/AI/NIAID NIH HHS/United States'
p25495
aS'U01AI069518/AI/NIAID NIH HHS/United States'
p25496
aS'U01AI38858/AI/NIAID NIH HHS/United States'
p25497
aS'UM1 AI068634/AI/NIAID NIH HHS/United States'
p25498
aS'UM1 AI068636/AI/NIAID NIH HHS/United States'
p25499
aS'UM1 AI069399/AI/NIAID NIH HHS/United States'
p25500
aS'UM1 AI069432/AI/NIAID NIH HHS/United States'
p25501
aS'UM1 AI106701/AI/NIAID NIH HHS/United States'
p25502
asS'OWN'
p25503
S'NLM'
p25504
sS'PT'
p25505
(lp25506
S'Journal Article'
p25507
aS'Multicenter Study'
p25508
aS'Research Support, N.I.H., Extramural'
p25509
asS'LA'
p25510
(lp25511
S'eng'
p25512
asS'FAU'
p25513
(lp25514
S'Wallis, Carole L'
p25515
aS'Aga, Evgenia'
p25516
aS'Ribaudo, Heather'
p25517
aS'Saravanan, Shanmugam'
p25518
aS'Norton, Michael'
p25519
aS'Stevens, Wendy'
p25520
aS'Kumarasamy, Nagalingeswaran'
p25521
aS'Bartlett, John'
p25522
aS'Katzenstein, David'
p25523
asS'JT'
p25524
S'Clinical infectious diseases : an official publication of the Infectious Diseases Society of America'
p25525
sS'LR'
p25526
S'20150902'
p25527
sS'PG'
p25528
S'706-15'
p25529
sS'TI'
p25530
S'Drug susceptibility and resistance mutations after first-line failure in resource limited settings.'
p25531
sS'RN'
p25532
(lp25533
S'0 (Anti-HIV Agents)'
p25534
aS'0 (Pyridazines)'
p25535
aS'0 (Reverse Transcriptase Inhibitors)'
p25536
aS'0C50HW4FO1 (etravirine)'
p25537
aS'2494G1JF75 (Lopinavir)'
p25538
aS'O3J8G9O825 (Ritonavir)'
p25539
asS'PL'
p25540
S'United States'
p25541
sS'TA'
p25542
S'Clin Infect Dis'
p25543
sS'JID'
p25544
S'9203213'
p25545
sS'AB'
p25546
S'BACKGROUND: The development of drug resistance to nucleoside reverse transcriptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) has been associated with baseline human immunodeficiency virus (HIV)-1 RNA level (VL), CD4 cell counts (CD4), subtype, and treatment failure duration. This study describes drug resistance and levels of susceptibility after first-line virologic failure in individuals from Thailand, South Africa, India, Malawi, Tanzania. METHODS: CD4 and VL were captured at AIDs Clinical Trial Group (ACTG) A5230 study entry, a study of lopinavir/ritonavir (LPV/r) monotherapy after first-line virologic failure on an NNRTI regimen. HIV drug-resistance mutation associations with subtype, site, study entry VL, and CD4 were evaluated using Fisher exact and Kruskall-Wallis tests. RESULTS: Of the 207 individuals who were screened for A5230, sequence data were available for 148 individuals. Subtypes observed: subtype C (n = 97, 66%) AE (n = 27, 18%), A1 (n = 12, 8%), and D (n = 10, 7%). Of the 148 individuals, 93% (n = 138) and 96% (n = 142) had at least 1 reverse transcriptase (RT) mutation associated with NRTI and NNRTI resistance, respectively. The number of NRTI mutations was significantly associated with a higher study screening VL and lower study screening CD4 (P < .001). Differences in drug-resistance patterns in both NRTI and NNRTI were observed by site. CONCLUSIONS: The degree of NNRTI and NRTI resistance after first-line virologic failure was associated with higher VL at study entry. Thirty-two percent of individuals remained fully susceptible to etravirine and rilpivirine, protease inhibitor resistance was rare. Some level of susceptibility to NRTI remained; however, VL monitoring and earlier virologic failure detection may result in lower NRTI resistance.'
p25547
sS'AD'
p25548
S'Lancet Laboratories, Johannesburg, South Africa. Statistical Data Analysis Center, Harvard School of Public Health, Boston, Massachusetts. Statistical Data Analysis Center, Harvard School of Public Health, Boston, Massachusetts. YRG Centre for AIDS Research and Education, Chennai, India. Medical Affairs Therapeutic Area, Virology and Nanotechnology, Global Pharmaceutical Research and Development, AbbVie, Chicago, Illinois. University of Witwatersrand, Johannesburg, South Africa. YRG Centre for AIDS Research and Education, Chennai, India. Duke Global Health Institute, Duke University, Durham, North Carolina Kilimanjaro Christian Medical Centre, Moshi, Tanzania. Division of Infectious Diseases, Stanford University, Palo Alto, California.'
p25549
sS'CN'
p25550
(lp25551
S'A5230 team'
p25552
asS'IP'
p25553
S'5'
sS'IS'
p25554
S'1537-6591 (Electronic) 1058-4838 (Linking)'
p25555
sS'PMC'
p25556
S'PMC4148601'
p25557
sS'DCOM'
p25558
S'20160310'
p25559
sS'AU'
p25560
(lp25561
S'Wallis CL'
p25562
aS'Aga E'
p25563
aS'Ribaudo H'
p25564
aS'Saravanan S'
p25565
aS'Norton M'
p25566
aS'Stevens W'
p25567
aS'Kumarasamy N'
p25568
aS'Bartlett J'
p25569
aS'Katzenstein D'
p25570
asS'VI'
p25571
S'59'
p25572
sS'MHDA'
p25573
S'2016/03/11 06:00'
p25574
sS'PHST'
p25575
(lp25576
S'2014/05/01 [aheadofprint]'
p25577
asS'OTO'
p25578
(lp25579
S'NOTNLM'
p25580
asS'OID'
p25581
(lp25582
S'NLM: PMC4148601'
p25583
asS'MH'
p25584
(lp25585
S'Adult'
p25586
aS'Anti-HIV Agents/*therapeutic use'
p25587
aS'CD4 Lymphocyte Count'
p25588
aS'*Drug Resistance, Viral/genetics'
p25589
aS'Female'
p25590
aS'HIV Infections/*drug therapy/virology'
p25591
aS'HIV-1/*drug effects/genetics'
p25592
aS'*Health Resources'
p25593
aS'Humans'
p25594
aS'India'
p25595
aS'Lopinavir/therapeutic use'
p25596
aS'Malawi/epidemiology'
p25597
aS'Male'
p25598
aS'Middle Aged'
p25599
aS'Mutation Rate'
p25600
aS'Pilot Projects'
p25601
aS'Pyridazines/therapeutic use'
p25602
aS'Reverse Transcriptase Inhibitors/therapeutic use'
p25603
aS'Ritonavir/therapeutic use'
p25604
aS'South Africa'
p25605
aS'Tanzania'
p25606
aS'Thailand'
p25607
aS'Treatment Failure'
p25608
aS'Young Adult'
p25609
asS'EDAT'
p25610
S'2014/05/06 06:00'
p25611
sS'SO'
p25612
S'Clin Infect Dis. 2014 Sep 1;59(5):706-15. doi: 10.1093/cid/ciu314. Epub 2014 May 1.'
p25613
sS'SB'
p25614
S'IM'
p25615
sS'PMID'
p25616
S'24795328'
p25617
sS'OT'
p25618
(lp25619
S'HIV-1 drug resistance'
p25620
aS'first-line failure'
p25621
aS'nonsubtype B'
p25622
aS'resource limited setting'
p25623
asS'PST'
p25624
S'ppublish'
p25625
stRp25626
ag2
(g3
g4
(dp25627
S'LID'
p25628
S'10.1128/JCM.00961-14 [doi]'
p25629
sS'STAT'
p25630
S'MEDLINE'
p25631
sS'DEP'
p25632
S'20140430'
p25633
sS'CI'
p25634
(lp25635
S'Copyright (c) 2014, American Society for Microbiology. All Rights Reserved.'
p25636
asS'DA'
p25637
S'20140627'
p25638
sS'AID'
p25639
(lp25640
S'JCM.00961-14 [pii]'
p25641
aS'10.1128/JCM.00961-14 [doi]'
p25642
asS'CRDT'
p25643
(lp25644
S'2014/05/03 06:00'
p25645
asS'DP'
p25646
S'2014 Jul'
p25647
sS'OWN'
p25648
S'NLM'
p25649
sS'PT'
p25650
(lp25651
S'Evaluation Studies'
p25652
aS'Journal Article'
p25653
aS"Research Support, Non-U.S. Gov't"
p25654
asS'LA'
p25655
(lp25656
S'eng'
p25657
asS'FAU'
p25658
(lp25659
S'Costenaro, Paola'
p25660
aS'Lundin, Rebecca'
p25661
aS'Petrara, Maria Raffaella'
p25662
aS'Penazzato, Martina'
p25663
aS'Massavon, William'
p25664
aS'Kizito, Susan'
p25665
aS'Nabachwa, Sandra Monica'
p25666
aS'Nannyonga Musoke, Maria'
p25667
aS'Namisi, Charles'
p25668
aS'Morelli, Erika'
p25669
aS'Bilardi, Davide'
p25670
aS'Mazza, Antonio'
p25671
aS'Zanchetta, Marisa'
p25672
aS'Giaquinto, Carlo'
p25673
aS'De Rossi, Anita'
p25674
asS'JT'
p25675
S'Journal of clinical microbiology'
p25676
sS'LR'
p25677
S'20150806'
p25678
sS'PG'
p25679
S'2665-7'
p25680
sS'TI'
p25681
S'Viral load detection using dried blood spots in a cohort of HIV-1-infected children in Uganda: correlations with clinical and immunological criteria for treatment failure.'
p25682
sS'RN'
p25683
(lp25684
S'0 (Anti-Retroviral Agents)'
p25685
asS'PL'
p25686
S'United States'
p25687
sS'TA'
p25688
S'J Clin Microbiol'
p25689
sS'JID'
p25690
S'7505564'
p25691
sS'AB'
p25692
S'Correlations between clinical/immunological treatment failure and viral load (VL) detected by dried blood spot (DBS) sampling were explored in HIV-1-infected children in Uganda. Of 104 children on combined antiretroviral treatment (cART), 12.5% experienced clinical and/or immunological failure, while 28.8%, 44.2%, and 26.9% had VLs of <1,000, 1,000 to 5,000, and >5,000 copies/ml, respectively. Clinical/immunological failure poorly predicted virological failure.'
p25693
sS'AD'
p25694
S'Department of Pediatrics, University of Padua, Padua, Italy paolacoste@gmail.com. Department of Pediatrics, University of Padua, Padua, Italy. Department of Surgery, Oncology and Gastroenterology, Section of Oncology and Immunology, AIDS Reference Center, University of Padua, Padua, Italy. Department of Pediatrics, University of Padua, Padua, Italy. Department of Pediatrics, University of Padua, Padua, Italy. Nsambya Home Care Department of St. Raphael of St. Francis Nsambya Hospital, Kampala, Uganda. Nsambya Home Care Department of St. Raphael of St. Francis Nsambya Hospital, Kampala, Uganda. Nsambya Home Care Department of St. Raphael of St. Francis Nsambya Hospital, Kampala, Uganda. Nsambya Home Care Department of St. Raphael of St. Francis Nsambya Hospital, Kampala, Uganda. Department of Pediatrics, University of Padua, Padua, Italy. Department of Pediatrics, University of Padua, Padua, Italy. Associazione Casa Accoglienza alla Vita Padre Angelo, Trento, Italy. Department of Surgery, Oncology and Gastroenterology, Section of Oncology and Immunology, AIDS Reference Center, University of Padua, Padua, Italy. Department of Pediatrics, University of Padua, Padua, Italy. Department of Surgery, Oncology and Gastroenterology, Section of Oncology and Immunology, AIDS Reference Center, University of Padua, Padua, Italy Istituto Oncologico Veneto (IOV)-IRCCS, Padua, Italy.'
p25695
sS'IP'
p25696
S'7'
sS'IS'
p25697
S'1098-660X (Electronic) 0095-1137 (Linking)'
p25698
sS'PMC'
p25699
S'PMC4097737'
p25700
sS'DCOM'
p25701
S'20150213'
p25702
sS'AU'
p25703
(lp25704
S'Costenaro P'
p25705
aS'Lundin R'
p25706
aS'Petrara MR'
p25707
aS'Penazzato M'
p25708
aS'Massavon W'
p25709
aS'Kizito S'
p25710
aS'Nabachwa SM'
p25711
aS'Nannyonga Musoke M'
p25712
aS'Namisi C'
p25713
aS'Morelli E'
p25714
aS'Bilardi D'
p25715
aS'Mazza A'
p25716
aS'Zanchetta M'
p25717
aS'Giaquinto C'
p25718
aS'De Rossi A'
p25719
asS'VI'
p25720
S'52'
p25721
sS'MHDA'
p25722
S'2015/02/14 06:00'
p25723
sS'PHST'
p25724
(lp25725
S'2014/04/30 [aheadofprint]'
p25726
asS'OID'
p25727
(lp25728
S'NLM: PMC4097737'
p25729
asS'MH'
p25730
(lp25731
S'Anti-Retroviral Agents/therapeutic use'
p25732
aS'Antiretroviral Therapy, Highly Active'
p25733
aS'Blood/*virology'
p25734
aS'Child'
p25735
aS'Child, Preschool'
p25736
aS'Cohort Studies'
p25737
aS'Desiccation/*methods'
p25738
aS'Female'
p25739
aS'HIV Infections/diagnosis/drug therapy/immunology/*virology'
p25740
aS'HIV-1/*isolation & purification'
p25741
aS'Humans'
p25742
aS'Male'
p25743
aS'Sensitivity and Specificity'
p25744
aS'Specimen Handling/*methods'
p25745
aS'Treatment Failure'
p25746
aS'Uganda'
p25747
aS'Viral Load/*methods'
p25748
asS'EDAT'
p25749
S'2014/05/03 06:00'
p25750
sS'SO'
p25751
S'J Clin Microbiol. 2014 Jul;52(7):2665-7. doi: 10.1128/JCM.00961-14. Epub 2014 Apr 30.'
p25752
sS'SB'
p25753
S'IM'
p25754
sS'PMID'
p25755
S'24789197'
p25756
sS'PST'
p25757
S'ppublish'
p25758
stRp25759
ag2
(g3
g4
(dp25760
S'LID'
p25761
S'10.1093/jac/dku104 [doi]'
p25762
sS'STAT'
p25763
S'MEDLINE'
p25764
sS'DEP'
p25765
S'20140430'
p25766
sS'CI'
p25767
(lp25768
S'(c) The Author 2014. Published by Oxford University Press on behalf of the'
p25769
aS'British Society for Antimicrobial Chemotherapy. All rights reserved. For'
p25770
aS'Permissions, please e-mail: journals.permissions@oup.com.'
p25771
asS'DA'
p25772
S'20140717'
p25773
sS'AID'
p25774
(lp25775
S'dku104 [pii]'
p25776
aS'10.1093/jac/dku104 [doi]'
p25777
asS'CRDT'
p25778
(lp25779
S'2014/05/03 06:00'
p25780
asS'DP'
p25781
S'2014 Aug'
p25782
sS'OWN'
p25783
S'NLM'
p25784
sS'PT'
p25785
(lp25786
S'Journal Article'
p25787
aS"Research Support, Non-U.S. Gov't"
p25788
aS'Review'
p25789
asS'LA'
p25790
(lp25791
S'eng'
p25792
asS'FAU'
p25793
(lp25794
S'Rojas Sanchez, Patricia'
p25795
aS'Holguin, Africa'
p25796
asS'JT'
p25797
S'The Journal of antimicrobial chemotherapy'
p25798
sS'PG'
p25799
S'2032-42'
p25800
sS'TI'
p25801
S'Drug resistance in the HIV-1-infected paediatric population worldwide: a systematic review.'
p25802
sS'RN'
p25803
(lp25804
S'0 (Anti-HIV Agents)'
p25805
aS'0 (pol Gene Products, Human Immunodeficiency Virus)'
p25806
asS'PL'
p25807
S'England'
p25808
sS'TA'
p25809
S'J Antimicrob Chemother'
p25810
sS'JID'
p25811
S'7513617'
p25812
sS'AB'
p25813
S"BACKGROUND: Drug resistance monitoring of the paediatric HIV-1-infected population is required to optimize treatment success and preserve future treatment options. OBJECTIVES: To explore the current knowledge of HIV drug resistance (HIVDR) in naive and pretreated HIV-1-infected paediatric populations across diverse settings and sampling time periods. METHODS: PubMed database screened until May 2013. We selected publications including data on transmitted (TDR) and acquired drug resistance mutation (DRM) rates and/or pol sequences for HIVDR testing in paediatric patients. We recorded the children's country, age, study period, number of children with pol sequences, presence or absence of antiretroviral treatment (ART) at sampling time, viral region sequenced, HIVDR rate to the three main drug classes (single, double or triple), the considered resistance mutation list and performed assay, specimen type, HIV-1 variants and subtyping methodology when available. RESULTS: Forty-one selected studies showed HIVDR data from 2538 paediatric HIV-1-infected patients (558 naive and 1980 pretreated) from 30 countries in Africa (11), Asia (6), America (10) and Europe (3). Both TDR and DRM prevalence were reported in 9 studies, only TDR in 6 and only DRM in 26. HIVDR prevalence varied across countries and periods. Most studies used in-house resistance assays using plasma or infected cells. HIV-1 non-B variants were prevalent in 18 paediatric cohorts of the 24 countries with reported subtypes. Only five countries (Uganda, Spain, the UK, Brazil and Thailand) presented resistance data in >/=200 patients. CONCLUSIONS: Systematic and periodic studies among infected children are crucial to design a more suitable first- or second-line therapy."
p25814
sS'AD'
p25815
S'HIV-1 Molecular Epidemiology Laboratory, Microbiology Department, Hospital Ramon y Cajal-IRYCIS and CIBERESP, Madrid, Spain. HIV-1 Molecular Epidemiology Laboratory, Microbiology Department, Hospital Ramon y Cajal-IRYCIS and CIBERESP, Madrid, Spain africa.holguin@salud.madrid.org.'
p25816
sS'IP'
p25817
S'8'
sS'IS'
p25818
S'1460-2091 (Electronic) 0305-7453 (Linking)'
p25819
sS'DCOM'
p25820
S'20150930'
p25821
sS'AU'
p25822
(lp25823
S'Rojas Sanchez P'
p25824
aS'Holguin A'
p25825
asS'VI'
p25826
S'69'
p25827
sS'MHDA'
p25828
S'2015/10/01 06:00'
p25829
sS'PHST'
p25830
(lp25831
S'2014/04/30 [aheadofprint]'
p25832
asS'OTO'
p25833
(lp25834
S'NOTNLM'
p25835
asS'MH'
p25836
(lp25837
S'Anti-HIV Agents/*therapeutic use'
p25838
aS'Antiretroviral Therapy, Highly Active'
p25839
aS'Child'
p25840
aS'Drug Monitoring'
p25841
aS'Drug Resistance, Multiple, Viral/*genetics'
p25842
aS'HIV Infections/*drug therapy'
p25843
aS'HIV-1/*drug effects'
p25844
aS'Humans'
p25845
aS'Microbial Sensitivity Tests'
p25846
aS'Mutation'
p25847
aS'pol Gene Products, Human Immunodeficiency Virus/*genetics'
p25848
asS'EDAT'
p25849
S'2014/05/03 06:00'
p25850
sS'SO'
p25851
S'J Antimicrob Chemother. 2014 Aug;69(8):2032-42. doi: 10.1093/jac/dku104. Epub 2014 Apr 30.'
p25852
sS'SB'
p25853
S'IM'
p25854
sS'PMID'
p25855
S'24788658'
p25856
sS'OT'
p25857
(lp25858
S'HIV-1'
p25859
aS'antiretroviral therapy'
p25860
aS'children'
p25861
aS'resistance mutations'
p25862
asS'PST'
p25863
S'ppublish'
p25864
stRp25865
ag2
(g3
g4
(dp25866
S'LID'
p25867
S'10.1097/QAD.0000000000000261 [doi]'
p25868
sS'STAT'
p25869
S'MEDLINE'
p25870
sS'JT'
p25871
S'AIDS (London, England)'
p25872
sS'MID'
p25873
(lp25874
S'NIHMS715195'
p25875
asS'DA'
p25876
S'20140920'
p25877
sS'AID'
p25878
(lp25879
S'10.1097/QAD.0000000000000261 [doi]'
p25880
asS'CRDT'
p25881
(lp25882
S'2014/05/03 06:00'
p25883
asS'DP'
p25884
S'2014 Jul 17'
p25885
sS'AD'
p25886
S'aGertrude H. Sergievsky Center, College of Physicians and Surgeons, and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, USA bNational Institute for Communicable Diseases of the National Health Laboratory Services cFaculty of Health Sciences, Empilweni Services and Research Unit, Department of Paediatrics & Child Health, Rahima Moosa Mother and Child Hospital, University of the Witwatersrand, Johannesburg, South Africa dMRC Clinical Trial Unit, University College London, London, UK eHIV Department, World Health Organization, Geneva, Switzerland fHIV Center for Clinical and Behavioral Studies in the Division of Gender Sexuality and Health, Department of Psychiatry, Columbia University and the New York State Psychiatric Institute, New York, New York, USA gFaculty of Health Sciences, Wits Reproductive Health and HIV Institute, University of Witwatersrand, Johannesburg, South Africa hICAP, Mailman School of Public Health, and Department of Pediatrics, College of Physicians & Surgeons, Columbia University, New York, New York, USA.'
p25887
sS'OWN'
p25888
S'NLM'
p25889
sS'PT'
p25890
(lp25891
S'Journal Article'
p25892
aS'Research Support, N.I.H., Extramural'
p25893
aS"Research Support, Non-U.S. Gov't"
p25894
asS'LA'
p25895
(lp25896
S'eng'
p25897
asS'FAU'
p25898
(lp25899
S'Kuhn, Louise'
p25900
aS'Hunt, Gillian'
p25901
aS'Technau, Karl-Gunter'
p25902
aS'Coovadia, Ashraf'
p25903
aS'Ledwaba, Johanna'
p25904
aS'Pickerill, Sam'
p25905
aS'Penazzato, Martina'
p25906
aS'Bertagnolio, Silvia'
p25907
aS'Mellins, Claude A'
p25908
aS'Black, Vivian'
p25909
aS'Morris, Lynn'
p25910
aS'Abrams, Elaine J'
p25911
asS'LR'
p25912
S'20160223'
p25913
sS'PG'
p25914
S'1673-8'
p25915
sS'TI'
p25916
S'Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis.'
p25917
sS'RN'
p25918
(lp25919
S'0 (Anti-HIV Agents)'
p25920
aS'0 (RNA, Viral)'
p25921
asS'PL'
p25922
S'England'
p25923
sS'TA'
p25924
S'AIDS'
p25925
sS'JID'
p25926
S'8710219'
p25927
sS'AB'
p25928
S'BACKGROUND: In the era of more efficacious prevention of mother-to-child transmission (PMTCT) regimens, documenting the profile of drug resistance in HIV-infected infants and young children is critical to our efforts to improve care and treatment for children. METHODS: HIV drug resistance mutations in plasma virus were ascertained using population sequencing among 230 newly diagnosed HIV-infected children under 2 years of age recruited in Johannesburg, South Africa, during 2011. By this time, more effective PMTCT regimens, including combination antiretroviral therapy for pregnant women, were being implemented. RESULTS: Two-thirds (67.4%) of HIV-infected children had been exposed to some form of maternal (89%) and/or infant (97%) PMTCT. Among PMTCT-exposed, 56.8% had nonnucleoside reverse transcriptase inhibitor (NNRTI), 14.8% nucleoside reverse transcriptase inhibitor (NRTI), and 1.3% protease inhibitor mutations. NNRTI mutations were strongly related to younger age. The remaining third (32.6%) had no reported or recorded PMTCT exposures, but resistance to NNRTI was detected in 24.0%, NRTI in 10.7%, and protease inhibitor in 1.3%. CONCLUSION: The new PMTCT strategies dramatically reduce the number of children who acquire infection, but among those who do become infected, NNRTI resistance prevalence is high. In this South African setting with high PMTCT coverage, almost a quarter of children with no reported or recorded PMTCT also have drug resistance mutations. PMTCT history is an inadequate means of ruling out pretreatment drug resistance. Our results support the use of protease inhibitor-based first-line regimens in HIV-infected infants and young children regardless of PMTCT history.'
p25929
sS'GR'
p25930
(lp25931
S'HD 61255/HD/NICHD NIH HHS/United States'
p25932
aS'P30 MH043520/MH/NIMH NIH HHS/United States'
p25933
aS'R01 HD047177/HD/NICHD NIH HHS/United States'
p25934
aS'R01 HD061255/HD/NICHD NIH HHS/United States'
p25935
asS'IP'
p25936
S'11'
p25937
sS'IS'
p25938
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p25939
sS'PMC'
p25940
S'PMC4539942'
p25941
sS'DCOM'
p25942
S'20150518'
p25943
sS'AU'
p25944
(lp25945
S'Kuhn L'
p25946
aS'Hunt G'
p25947
aS'Technau KG'
p25948
aS'Coovadia A'
p25949
aS'Ledwaba J'
p25950
aS'Pickerill S'
p25951
aS'Penazzato M'
p25952
aS'Bertagnolio S'
p25953
aS'Mellins CA'
p25954
aS'Black V'
p25955
aS'Morris L'
p25956
aS'Abrams EJ'
p25957
asS'VI'
p25958
S'28'
p25959
sS'MHDA'
p25960
S'2015/05/20 06:00'
p25961
sS'OID'
p25962
(lp25963
S'NLM: NIHMS715195'
p25964
aS'NLM: PMC4539942'
p25965
asS'MH'
p25966
(lp25967
S'Anti-HIV Agents/therapeutic use'
p25968
aS'Chemoprevention/methods'
p25969
aS'*Drug Resistance, Viral'
p25970
aS'Female'
p25971
aS'HIV/drug effects/*genetics/*isolation & purification'
p25972
aS'HIV Infections/prevention & control/*virology'
p25973
aS'Humans'
p25974
aS'Infant'
p25975
aS'Infant, Newborn'
p25976
aS'Male'
p25977
aS'*Mutation'
p25978
aS'Plasma/virology'
p25979
aS'Pregnancy'
p25980
aS'Prevalence'
p25981
aS'RNA, Viral/*genetics'
p25982
aS'South Africa/epidemiology'
p25983
asS'EDAT'
p25984
S'2014/05/03 06:00'
p25985
sS'SO'
p25986
S'AIDS. 2014 Jul 17;28(11):1673-8. doi: 10.1097/QAD.0000000000000261.'
p25987
sS'SB'
p25988
S'IM X'
p25989
sS'PMID'
p25990
S'24785949'
p25991
sS'PST'
p25992
S'ppublish'
p25993
stRp25994
ag2
(g3
g4
(dp25995
S'STAT'
p25996
S'MEDLINE'
p25997
sS'AB'
p25998
S'BACKGROUND: Risk factors for treatment failure in HIV positive adults have not been studied extensively in Zimbabwe. AIM: To investigate socio-demographic, psychosocial and antiretroviral drug related factors as possible risk factors for treatment failure. OBJECTIVE: To compare the accuracy and reliability of CD4 count results in diagnosing treatment failure versus viral load results. DESIGN: A descriptive cross-sectional survey. SETTING: Harare Central Hospital adult opportunistic infections clinic. PARTICIPANTS: One hundred and eighteen (118) HIV positive participants on 1st line antiretroviral therapy (any 1 of stavudine, tenofovir or zidovudine combined with lamivudine and nevirapine or efavirenz) for at least 1 year. Participants were conveniently sampled. MAIN OUTCOME MEASURES: First line treatment failure as defined according to World Health Organisation (WHO) 2010 guidelines. RESULTS: Factors associated with higher odds of treatment failure were severe depression [OR 3.7; p-value 0.002; 95% CI 1.6-8.5] and discontinuing ART [OR 4.4; p-value 0.02; 95% CI 1.3-14.7]. Factors associated with lower odds of treatment failure were age = 42 [OR 0.3; p-value 0.007; 95% CI 0.1-0.7], taking ART on time [OR 0.2; p-value 0.02; 95% CI 0.05-0.8], time on ART > 4 years [OR 0.6; p-value 0.02; 95% CI 0.3-0.9] and female sex [OR 0.4; p-value 0.02; 95% CI 0.2-0.8]. There was statistically significant difference between CD4 count and viral load results in diagnosing treatment failure [OR 8.7; p-value 0.0005; 95% CI 3.6-21.2]. CONCLUSION: Severe depression and discontinuing ART predisposed to treatment failure. CD4 counts were not as reliable as viral load measurements in diagnosing treatment failure.'
p25999
sS'JID'
p26000
S'0372566'
p26001
sS'JT'
p26002
S'The Central African journal of medicine'
p26003
sS'IP'
p26004
S'5-8'
p26005
sS'IS'
p26006
S'0008-9176 (Print) 0008-9176 (Linking)'
p26007
sS'DCOM'
p26008
S'20160301'
p26009
sS'DA'
p26010
S'20160212'
p26011
sS'AU'
p26012
(lp26013
S'Chawana TD'
p26014
aS'Reid A'
p26015
aS'Bwakura T'
p26016
aS'Gavi S'
p26017
aS'Nhachi CF'
p26018
asS'CRDT'
p26019
(lp26020
S'2016/02/13 06:00'
p26021
asS'VI'
p26022
S'60'
p26023
sS'PMID'
p26024
S'26867253'
p26025
sS'DP'
p26026
S'2014 May-Aug'
p26027
sS'MHDA'
p26028
S'2016/03/02 06:00'
p26029
sS'OWN'
p26030
S'NLM'
p26031
sS'PT'
p26032
(lp26033
S'Journal Article'
p26034
asS'LA'
p26035
(lp26036
S'eng'
p26037
asS'MH'
p26038
(lp26039
S'Adult'
p26040
aS'Aged'
p26041
aS'Anti-Retroviral Agents/*therapeutic use'
p26042
aS'CD4 Lymphocyte Count'
p26043
aS'Cross-Sectional Studies'
p26044
aS'Female'
p26045
aS'HIV Infections/*drug therapy/immunology/psychology'
p26046
aS'Humans'
p26047
aS'Male'
p26048
aS'Medication Adherence'
p26049
aS'Middle Aged'
p26050
aS'Risk Factors'
p26051
aS'Socioeconomic Factors'
p26052
aS'Treatment Failure'
p26053
aS'Viral Load'
p26054
aS'Zimbabwe'
p26055
asS'FAU'
p26056
(lp26057
S'Chawana, T D'
p26058
aS'Reid, A'
p26059
aS'Bwakura, T'
p26060
aS'Gavi, S'
p26061
aS'Nhachi, C F B'
p26062
asS'EDAT'
p26063
S'2014/05/01 00:00'
p26064
sS'PST'
p26065
S'ppublish'
p26066
sS'SO'
p26067
S'Cent Afr J Med. 2014 May-Aug;60(5-8):29-36.'
p26068
sS'PG'
p26069
S'29-36'
p26070
sS'TI'
p26071
S'Factors influencing treatment failure in HIV positive adult patients on first line antiretroviral therapy.'
p26072
sS'SB'
p26073
S'IM'
p26074
sS'RN'
p26075
(lp26076
S'0 (Anti-Retroviral Agents)'
p26077
asS'PL'
p26078
S'Zimbabwe'
p26079
sS'TA'
p26080
S'Cent Afr J Med'
p26081
stRp26082
ag2
(g3
g4
(dp26083
S'LID'
p26084
S'10.1371/journal.pone.0095603 [doi]'
p26085
sS'STAT'
p26086
S'MEDLINE'
p26087
sS'DEP'
p26088
S'20140422'
p26089
sS'DA'
p26090
S'20140423'
p26091
sS'AID'
p26092
(lp26093
S'10.1371/journal.pone.0095603 [doi]'
p26094
aS'PONE-D-13-54228 [pii]'
p26095
asS'CRDT'
p26096
(lp26097
S'2014/04/24 06:00'
p26098
asS'DP'
p26099
S'2014'
p26100
sS'OWN'
p26101
S'NLM'
p26102
sS'PT'
p26103
(lp26104
S'Journal Article'
p26105
aS"Research Support, Non-U.S. Gov't"
p26106
asS'LA'
p26107
(lp26108
S'eng'
p26109
asS'FAU'
p26110
(lp26111
S'Ade, Serge'
p26112
aS'Harries, Anthony D'
p26113
aS'Trebucq, Arnaud'
p26114
aS'Ade, Gabriel'
p26115
aS'Agodokpessi, Gildas'
p26116
aS'Adjonou, Christine'
p26117
aS'Azon, Sophie'
p26118
aS'Anagonou, Severin'
p26119
asS'JT'
p26120
S'PloS one'
p26121
sS'LR'
p26122
S'20150806'
p26123
sS'PG'
p26124
S'e95603'
p26125
sS'TI'
p26126
S'National profile and treatment outcomes of patients with extrapulmonary tuberculosis in Benin.'
p26127
sS'RN'
p26128
(lp26129
S'0 (Antitubercular Agents)'
p26130
asS'PL'
p26131
S'United States'
p26132
sS'TA'
p26133
S'PLoS One'
p26134
sS'JID'
p26135
S'101285081'
p26136
sS'AB'
p26137
S'BACKGROUND: In sub-Saharan Africa, there is a dearth of published literature on extrapulmonary tuberculosis (EPTB). OBJECTIVE: To describe demographic, diagnostic and HIV-status characteristics of patients with EPTB in Benin, their treatment outcomes, and among those who completed their treatment in the Centre National Hospitalier de Pneumo-Phtisiologie (CNHP-P), the proportion whose bodyweight increased during treatment. MATERIAL AND FINDINGS: This was a retrospective cohort study with comparisons made between EPTB and new smear-positive pulmonary tuberculosis (NPTB) patients diagnosed in the country from January to December 2011. There were 383 EPTB patients (9% of all TB cases) with a mean age of 35 years, male/female ratio of 1.3 and important regional variation. There were significantly more females (p = 0.001), children <15 years (p<0.001) and HIV-positive patients (p = 0.005) with EPTB compared with NPTB. Pleural effusion, spinal and lymph node tuberculosis accounted for 66% of all EPTB. Children <15 years represented 16% of cases, with lymph node disease being most common among them (p<0.001). Of 130 EPTB patients registered in CNHP-P, 7% had a confirmed bacteriological/histological diagnosis. There were 331 (86%) patients who successfully completed treatment. More patients with EPTB were lost-to-follow-up compared with NPTB (p<0.001) with all these patients from one region. The best treatment completion rates were in children <15 years (OR:3.5, 95%CI:1.0-14.8) while patients with pleural effusion and ascites had the worst outcomes. Of 72 HIV-coinfected patients, 88% were on antiretroviral therapy (ART). HIV-positive status was associated with poor outcomes while those on ART fared better. In the CNHP-P, more than 80% who completed their treatment showed an increase in bodyweight and this was more evident in HIV-positive compared with HIV-negative patients (p = 0.03). CONCLUSION: Patients with EPTB generally do well in Benin, although the TB Programme would benefit through more attention to accurate diagnosis and earlier start of ART in HIV-infected patients.'
p26138
sS'AD'
p26139
S'National TB Programme, Cotonou, Benin. International Union against Tuberculosis and Lung Disease, Paris, France; London School of Hygiene and Tropical Medicine, London, United Kingdom. International Union against Tuberculosis and Lung Disease, Paris, France. National TB Programme, Cotonou, Benin. National TB Programme, Cotonou, Benin. National TB Programme, Cotonou, Benin. National TB Programme, Cotonou, Benin. National TB Programme, Cotonou, Benin.'
p26140
sS'IP'
p26141
S'4'
sS'IS'
p26142
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p26143
sS'PMC'
p26144
S'PMC3995824'
p26145
sS'DCOM'
p26146
S'20150114'
p26147
sS'AU'
p26148
(lp26149
S'Ade S'
p26150
aS'Harries AD'
p26151
aS'Trebucq A'
p26152
aS'Ade G'
p26153
aS'Agodokpessi G'
p26154
aS'Adjonou C'
p26155
aS'Azon S'
p26156
aS'Anagonou S'
p26157
asS'VI'
p26158
S'9'
sS'MHDA'
p26159
S'2015/01/15 06:00'
p26160
sS'PHST'
p26161
(lp26162
S'2014 [ecollection]'
p26163
aS'2013/12/26 [received]'
p26164
aS'2014/03/27 [accepted]'
p26165
aS'2014/04/22 [epublish]'
p26166
asS'OID'
p26167
(lp26168
S'NLM: PMC3995824'
p26169
asS'MH'
p26170
(lp26171
S'Adult'
p26172
aS'Antiretroviral Therapy, Highly Active'
p26173
aS'Antitubercular Agents/therapeutic use'
p26174
aS'Benin/epidemiology'
p26175
aS'Body Weight'
p26176
aS'Coinfection'
p26177
aS'Female'
p26178
aS'HIV Infections/drug therapy/epidemiology'
p26179
aS'HIV Seropositivity'
p26180
aS'Humans'
p26181
aS'Male'
p26182
aS'Middle Aged'
p26183
aS'National Health Programs'
p26184
aS'Retrospective Studies'
p26185
aS'Treatment Outcome'
p26186
aS'Tuberculosis/diagnosis/*drug therapy/*epidemiology'
p26187
aS'Tuberculosis, Pulmonary/drug therapy/epidemiology'
p26188
aS'Young Adult'
p26189
asS'EDAT'
p26190
S'2014/04/24 06:00'
p26191
sS'SO'
p26192
S'PLoS One. 2014 Apr 22;9(4):e95603. doi: 10.1371/journal.pone.0095603. eCollection 2014.'
p26193
sS'SB'
p26194
S'IM'
p26195
sS'PMID'
p26196
S'24755603'
p26197
sS'PST'
p26198
S'epublish'
p26199
stRp26200
ag2
(g3
g4
(dp26201
S'LID'
p26202
S'10.1097/QAI.0000000000000166 [doi]'
p26203
sS'STAT'
p26204
S'MEDLINE'
p26205
sS'JT'
p26206
S'Journal of acquired immune deficiency syndromes (1999)'
p26207
sS'MID'
p26208
(lp26209
S'NIHMS584195'
p26210
asS'DA'
p26211
S'20140828'
p26212
sS'AID'
p26213
(lp26214
S'10.1097/QAI.0000000000000166 [doi]'
p26215
asS'CRDT'
p26216
(lp26217
S'2014/04/16 06:00'
p26218
asS'DP'
p26219
S'2014 Jul 1'
p26220
sS'AD'
p26221
S"*Centre Inserm 897, University of Bordeaux, Bordeaux, France; daggerISPED, University of Bordeaux, Bordeaux, France; double daggerProgramme PAC-CI/ANRS Research Site, CHU de Treichville, Abidjan, Cote d'Ivoire; section signDivision of General Medicine and the Medical Practice Evaluation Center, Department of Medicine, Massachusetts General Hospital, Boston, MA; ||Department of Infectious and Tropical Diseases, Bichat-Claude Bernard University Hospital, Paris, France; paragraph signEquipe Atip/Avenir Inserm U738, University Paris Diderot, Paris, France; #Department of Orthopedics, Brigham and Women's Hospital, Boston, MA; **Center for AIDS Research, Harvard University, Boston, MA; daggerdaggerHarvard Medical School, Boston, MA; double daggerdouble daggerDepartments of Biostatistics, Boston University School of Public Health, Boston, MA; section sign section signDepartment of Infectious and Tropical Diseases, Treichville University Hospital, Abidjan, Cote d'Ivoire; || ||Divisions of Infectious Disease and the Medical Practice Evaluation Center, Department of Medicine, Massachusetts General Hospital, Boston, MA; paragraph sign paragraph signDivision of Infectious Disease, Brigham and Women's Hospital, Boston, MA; ##Department of Epidemiology and Public Health, Yale School of Public Health, New Haven, CT; ***Department of Epidemiology, Boston University School of Public Health, Boston, MA; and daggerdaggerdaggerDepartment of Health Policy and Management, Harvard School of Public Health, Boston, MA."
p26222
sS'OWN'
p26223
S'NLM'
p26224
sS'PT'
p26225
(lp26226
S'Journal Article'
p26227
aS'Research Support, N.I.H., Extramural'
p26228
aS"Research Support, Non-U.S. Gov't"
p26229
asS'LA'
p26230
(lp26231
S'eng'
p26232
asS'FAU'
p26233
(lp26234
S'Ouattara, Eric N'
p26235
aS'Ross, Eric L'
p26236
aS'Yazdanpanah, Yazdan'
p26237
aS'Wong, Angela Y'
p26238
aS'Robine, Marion'
p26239
aS'Losina, Elena'
p26240
aS'Moh, Raoul'
p26241
aS'Walensky, Rochelle P'
p26242
aS'Danel, Christine'
p26243
aS'Paltiel, A David'
p26244
aS'Eholie, Serge P'
p26245
aS'Freedberg, Kenneth A'
p26246
aS'Anglaret, Xavier'
p26247
asS'LR'
p26248
S'20151119'
p26249
sS'PG'
p26250
S'294-302'
p26251
sS'TI'
p26252
S"Clinical impact and cost-effectiveness of making third-line antiretroviral therapy available in sub-Saharan Africa: a model-based analysis in Cote d'Ivoire."
p26253
sS'RN'
p26254
(lp26255
S'0 (Pyrrolidinones)'
p26256
aS'0 (Sulfonamides)'
p26257
aS'43Y000U234 (Raltegravir Potassium)'
p26258
aS'YO603Y8113 (Darunavir)'
p26259
asS'PL'
p26260
S'United States'
p26261
sS'TA'
p26262
S'J Acquir Immune Defic Syndr'
p26263
sS'JID'
p26264
S'100892005'
p26265
sS'AB'
p26266
S"OBJECTIVE: In sub-Saharan Africa, HIV-infected adults who fail second-line antiretroviral therapy (ART) often do not have access to third-line ART. We examined the clinical impact and cost-effectiveness of making third-line ART available in Cote d'Ivoire. METHODS: We used a simulation model to compare 4 strategies after second-line ART failure: continue second-line ART (C-ART2), continue second-line ART with an adherence reinforcement intervention (AR-ART2), immediate switch to third-line ART (IS-ART3), and continue second-line ART with adherence reinforcement, switching patients with persistent failure to third-line ART (AR-ART3). Third-line ART consisted of a boosted-darunavir plus raltegravir-based regimen. Primary outcomes were 10-year survival and lifetime incremental cost-effectiveness ratios (ICERs), in $/year of life saved (YLS). ICERs below $3585 (3 times the country per capita gross domestic product) were considered cost-effective. RESULTS: Ten-year survival was 6.0% with C-ART2, 17.0% with AR-ART2, 35.4% with IS-ART3, and 37.2% with AR-ART3. AR-ART2 was cost-effective ($1100/YLS). AR-ART3 had an ICER of $3600/YLS and became cost-effective if the cost of third-line ART decreased by <1%. IS-ART3 was less effective and more costly than AR-ART3. Results were robust to wide variations in the efficacy of third-line ART and of the adherence reinforcement, as well as in the cost of second-line ART. CONCLUSIONS: Access to third-line ART combined with an intense adherence reinforcement phase, used as a tool to distinguish between patients who can still benefit from their current second-line regimen and those who truly need third-line ART would provide substantial survival benefits. With minor decreases in drug costs, this strategy would be cost-effective."
p26267
sS'GR'
p26268
(lp26269
S'R01 AI058736/AI/NIAID NIH HHS/United States'
p26270
aS'R01 AI058736/AI/NIAID NIH HHS/United States'
p26271
asS'IP'
p26272
S'3'
sS'IS'
p26273
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p26274
sS'PMC'
p26275
S'PMC4146647'
p26276
sS'DCOM'
p26277
S'20141229'
p26278
sS'AU'
p26279
(lp26280
S'Ouattara EN'
p26281
aS'Ross EL'
p26282
aS'Yazdanpanah Y'
p26283
aS'Wong AY'
p26284
aS'Robine M'
p26285
aS'Losina E'
p26286
aS'Moh R'
p26287
aS'Walensky RP'
p26288
aS'Danel C'
p26289
aS'Paltiel AD'
p26290
aS'Eholie SP'
p26291
aS'Freedberg KA'
p26292
aS'Anglaret X'
p26293
asS'VI'
p26294
S'66'
p26295
sS'MHDA'
p26296
S'2014/12/30 06:00'
p26297
sS'OID'
p26298
(lp26299
S'NLM: NIHMS584195'
p26300
aS'NLM: PMC4146647'
p26301
asS'MH'
p26302
(lp26303
S'Adult'
p26304
aS'Africa South of the Sahara'
p26305
aS'Antiretroviral Therapy, Highly Active'
p26306
aS'Cost-Benefit Analysis'
p26307
aS'Darunavir'
p26308
aS'Drug Costs'
p26309
aS'Female'
p26310
aS'HIV Infections/*drug therapy/economics'
p26311
aS'Health Resources/economics'
p26312
aS'Humans'
p26313
aS'Male'
p26314
aS'Medication Adherence'
p26315
aS'Middle Aged'
p26316
aS'Models, Theoretical'
p26317
aS'Pyrrolidinones/economics/*therapeutic use'
p26318
aS'Raltegravir Potassium'
p26319
aS'Sulfonamides/economics/*therapeutic use'
p26320
aS'Survival Analysis'
p26321
aS'Treatment Failure'
p26322
asS'EDAT'
p26323
S'2014/04/16 06:00'
p26324
sS'SO'
p26325
S'J Acquir Immune Defic Syndr. 2014 Jul 1;66(3):294-302. doi: 10.1097/QAI.0000000000000166.'
p26326
sS'SB'
p26327
S'IM X'
p26328
sS'PMID'
p26329
S'24732870'
p26330
sS'PST'
p26331
S'ppublish'
p26332
stRp26333
ag2
(g3
g4
(dp26334
S'LID'
p26335
S'10.1186/1471-2334-14-196 [doi]'
p26336
sS'STAT'
p26337
S'MEDLINE'
p26338
sS'DEP'
p26339
S'20140411'
p26340
sS'DA'
p26341
S'20140428'
p26342
sS'AID'
p26343
(lp26344
S'1471-2334-14-196 [pii]'
p26345
aS'10.1186/1471-2334-14-196 [doi]'
p26346
asS'CRDT'
p26347
(lp26348
S'2014/04/15 06:00'
p26349
asS'DP'
p26350
S'2014'
p26351
sS'OWN'
p26352
S'NLM'
p26353
sS'PT'
p26354
(lp26355
S'Journal Article'
p26356
asS'LA'
p26357
(lp26358
S'eng'
p26359
asS'DCOM'
p26360
S'20150128'
p26361
sS'JT'
p26362
S'BMC infectious diseases'
p26363
sS'LR'
p26364
S'20150806'
p26365
sS'FAU'
p26366
(lp26367
S'Juma, James M'
p26368
aS'Tiberio, Jenny K'
p26369
aS'Abuya, Mathias I'
p26370
aS'Kilama, Bonita K'
p26371
aS'Somi, Geoffrey R'
p26372
aS'Sambu, Veryeh'
p26373
aS'Banda, Richard'
p26374
aS'Jullu, Boniphace S'
p26375
aS'Ramadhani, Angela A'
p26376
asS'TI'
p26377
S'Monitoring prevention or emergence of HIV drug resistance: results of a population-based foundational survey of early warning indicators in mainland Tanzania.'
p26378
sS'PL'
p26379
S'England'
p26380
sS'PG'
p26381
S'196'
p26382
sS'JID'
p26383
S'100968551'
p26384
sS'AB'
p26385
S"BACKGROUND: In Tanzania, routine individual-level testing for HIV drug resistance (HIVDR) using laboratory genotyping and phenotyping is not feasible due to resource constraints. To monitor the prevention or emergence of HIVDR at a population level, WHO developed generic strategies to be adapted by countries, which include a set of early warning indicators (EWIs). METHODS: To establish a baseline of EWIs, we conducted a retrospective longitudinal survey of 35 purposively sampled care and treatment clinics in 17 regions of mainland Tanzania. We extracted data relevant for four EWIs (ART prescribing practices, patients lost to follow-up 12 months after ART initiation, retention on first-line ART at 12 months, and ART clinic appointment keeping in the first 12 months) from the patient monitoring system on patients who initiated ART at each respective facility in 2010. We uploaded patient information into WHO HIVResNet excel-based tool to compute national and facility averages of the EWIs and tested for associations between various programmatic factors and EWI performance using Fisher's Exact Test. RESULTS: All sampled facilities met the WHO EWI target (100%) for ART prescribing practices. However, the national averages for patients lost to follow-up 12 months after ART initiation, retention on first-line ART at 12 months, and ART clinic appointment keeping in the first 12 months fell short, at 26%, 54% and 38%, respectively, compared to the WHO targets </= 20%, >/= 70%, and >/= 80%. Clinics with fewer patients lost to follow-up 12 months after ART initiation and more patients retained on first-line-ART at 12 months were more likely to have their patients spend the longest time in the facility (including wait-time and time with providers), (p = 0.011 and 0.007, respectively). CONCLUSION: Tanzania performed very well in EWI 1a, ART prescribing practices. However, its performance in other three EWIs was far below the WHO targets. This study provides a baseline for future monitoring of EWIs in Tanzania and highlights areas for improvement in the management of ART patients in order not only to prevent emergence of HIVDR due to programmatic factors, but also to improve the quality of life for ART patients."
p26386
sS'AD'
p26387
S'Ministry of Health and Social Welfare, The National AIDS Control Programme (NACP), P,O, Box 11857, Dar es Salaam, Tanzania. jj162us@yahoo.com.'
p26388
sS'VI'
p26389
S'14'
p26390
sS'IS'
p26391
S'1471-2334 (Electronic) 1471-2334 (Linking)'
p26392
sS'PMC'
p26393
S'PMC3999848'
p26394
sS'AU'
p26395
(lp26396
S'Juma JM'
p26397
aS'Tiberio JK'
p26398
aS'Abuya MI'
p26399
aS'Kilama BK'
p26400
aS'Somi GR'
p26401
aS'Sambu V'
p26402
aS'Banda R'
p26403
aS'Jullu BS'
p26404
aS'Ramadhani AA'
p26405
asS'MHDA'
p26406
S'2015/01/30 06:00'
p26407
sS'PHST'
p26408
(lp26409
S'2013/06/25 [received]'
p26410
aS'2014/04/03 [accepted]'
p26411
aS'2014/04/11 [aheadofprint]'
p26412
asS'OID'
p26413
(lp26414
S'NLM: PMC3999848'
p26415
asS'MH'
p26416
(lp26417
S'Drug Resistance, Viral'
p26418
aS'HIV/*drug effects'
p26419
aS'HIV Infections/epidemiology/*virology'
p26420
aS'Health Facilities'
p26421
aS'Humans'
p26422
aS'Public Health Surveillance/*methods'
p26423
aS'Retrospective Studies'
p26424
aS'Tanzania/epidemiology'
p26425
asS'EDAT'
p26426
S'2014/04/15 06:00'
p26427
sS'SO'
p26428
S'BMC Infect Dis. 2014 Apr 11;14:196. doi: 10.1186/1471-2334-14-196.'
p26429
sS'SB'
p26430
S'IM'
p26431
sS'PMID'
p26432
S'24725750'
p26433
sS'TA'
p26434
S'BMC Infect Dis'
p26435
sS'PST'
p26436
S'epublish'
p26437
stRp26438
ag2
(g3
g4
(dp26439
S'LID'
p26440
S'10.1016/S2213-2600(14)70031-1 [doi] S2213-2600(14)70031-1 [pii]'
p26441
sS'STAT'
p26442
S'MEDLINE'
p26443
sS'DEP'
p26444
S'20140324'
p26445
sS'CI'
p26446
(lp26447
S'Copyright (c) 2014 Elsevier Ltd. All rights reserved.'
p26448
asS'DA'
p26449
S'20140410'
p26450
sS'AID'
p26451
(lp26452
S'S2213-2600(14)70031-1 [pii]'
p26453
aS'10.1016/S2213-2600(14)70031-1 [doi]'
p26454
asS'CRDT'
p26455
(lp26456
S'2014/04/11 06:00'
p26457
asS'DP'
p26458
S'2014 Apr'
p26459
sS'OWN'
p26460
S'NLM'
p26461
sS'PT'
p26462
(lp26463
S'Journal Article'
p26464
aS'Review'
p26465
asS'LA'
p26466
(lp26467
S'eng'
p26468
asS'FAU'
p26469
(lp26470
S'Dheda, Keertan'
p26471
aS'Gumbo, Tawanda'
p26472
aS'Gandhi, Neel R'
p26473
aS'Murray, Megan'
p26474
aS'Theron, Grant'
p26475
aS'Udwadia, Zarir'
p26476
aS'Migliori, G B'
p26477
aS'Warren, Robin'
p26478
asS'JT'
p26479
S'The Lancet. Respiratory medicine'
p26480
sS'PG'
p26481
S'321-38'
p26482
sS'TI'
p26483
S'Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis.'
p26484
sS'PL'
p26485
S'England'
p26486
sS'TA'
p26487
S'Lancet Respir Med'
p26488
sS'JID'
p26489
S'101605555'
p26490
sS'AB'
p26491
S'Extensively drug-resistant tuberculosis is a burgeoning global health crisis mainly affecting economically active young adults, and has high mortality irrespective of HIV status. In some countries such as South Africa, drug-resistant tuberculosis represents less than 3% of all cases but consumes more than a third of the total national budget for tuberculosis, which is unsustainable and threatens to destabilise national tuberculosis programmes. However, concern about drug-resistant tuberculosis has been eclipsed by that of totally and extremely drug-resistant tuberculosis--ie, resistance to all or nearly all conventional first-line and second-line antituberculosis drugs. In this Review, we discuss the epidemiology, pathogenesis, diagnosis, management, implications for health-care workers, and ethical and medicolegal aspects of extensively drug-resistant tuberculosis and other resistant strains. Finally, we discuss the emerging problem of functionally untreatable tuberculosis, and the issues and challenges that it poses to public health and clinical practice. The emergence and growth of highly resistant strains of tuberculosis make the development of new drugs and rapid diagnostics for tuberculosis--and increased funding to strengthen global control efforts, research, and advocacy--even more pressing.'
p26492
sS'AD'
p26493
S'Lung Infection and Immunity Unit, Division of Pulmonology and UCT Lung Institute, Department of Medicine, University of Cape Town, Cape Town, South Africa; Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa. Electronic address: keertan.dheda@uct.ac.za. Office of Global Health and Department of Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA. Departments of Epidemiology, Global Health, and Infectious Diseases, Rollins School of Public Health, Emory University, Atlanta, GA, USA. Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA. Lung Infection and Immunity Unit, Division of Pulmonology and UCT Lung Institute, Department of Medicine, University of Cape Town, Cape Town, South Africa. Hinduja Hospital and Research Center, Mumbai, India. WHO Collaborating Centre for TB and Lung Diseases, Fondazione S Maugeri, Care and Research Institute, Tradate, Italy. DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, MRC Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.'
p26494
sS'IP'
p26495
S'4'
sS'IS'
p26496
S'2213-2619 (Electronic) 2213-2600 (Linking)'
p26497
sS'DCOM'
p26498
S'20150126'
p26499
sS'AU'
p26500
(lp26501
S'Dheda K'
p26502
aS'Gumbo T'
p26503
aS'Gandhi NR'
p26504
aS'Murray M'
p26505
aS'Theron G'
p26506
aS'Udwadia Z'
p26507
aS'Migliori GB'
p26508
aS'Warren R'
p26509
asS'VI'
p26510
S'2'
sS'MHDA'
p26511
S'2015/01/27 06:00'
p26512
sS'PHST'
p26513
(lp26514
S'2014/03/24 [aheadofprint]'
p26515
asS'MH'
p26516
(lp26517
S'*Extensively Drug-Resistant Tuberculosis/diagnosis/epidemiology/therapy'
p26518
aS'*Global Health'
p26519
aS'Humans'
p26520
aS'Infectious Disease Transmission, Patient-to-Professional/prevention & control'
p26521
aS'Mycobacterium tuberculosis/*pathogenicity'
p26522
aS'Treatment Outcome'
p26523
aS'Tuberculosis, Multidrug-Resistant/diagnosis/epidemiology/therapy'
p26524
asS'EDAT'
p26525
S'2014/04/11 06:00'
p26526
sS'SO'
p26527
S'Lancet Respir Med. 2014 Apr;2(4):321-38. doi: 10.1016/S2213-2600(14)70031-1. Epub 2014 Mar 24.'
p26528
sS'SB'
p26529
S'IM'
p26530
sS'PMID'
p26531
S'24717628'
p26532
sS'PST'
p26533
S'ppublish'
p26534
stRp26535
ag2
(g3
g4
(dp26536
S'LID'
p26537
S'10.3402/gha.v7.23758 [doi]'
p26538
sS'STAT'
p26539
S'MEDLINE'
p26540
sS'DEP'
p26541
S'20140408'
p26542
sS'DA'
p26543
S'20140410'
p26544
sS'AID'
p26545
(lp26546
S'23758 [pii]'
p26547
asS'CRDT'
p26548
(lp26549
S'2014/04/11 06:00'
p26550
asS'DP'
p26551
S'2014'
p26552
sS'OWN'
p26553
S'NLM'
p26554
sS'PT'
p26555
(lp26556
S'Journal Article'
p26557
aS"Research Support, Non-U.S. Gov't"
p26558
asS'LA'
p26559
(lp26560
S'eng'
p26561
asS'DCOM'
p26562
S'20141002'
p26563
sS'JT'
p26564
S'Global health action'
p26565
sS'LR'
p26566
S'20150806'
p26567
sS'FAU'
p26568
(lp26569
S'Molfino, Lucas'
p26570
aS'Kumar, Ajay M V'
p26571
aS'Isaakidis, Petros'
p26572
aS'Van den Bergh, Rafael'
p26573
aS'Khogali, Mohamed'
p26574
aS'Hinderaker, Sven G'
p26575
aS'Magaia, Alice'
p26576
aS'Lobo, Sheila'
p26577
aS'Edwards, Celeste Gracia'
p26578
aS'Walter, Jan'
p26579
asS'TI'
p26580
S'High attrition among HIV-infected patients with advanced disease treated in an intermediary referral center in Maputo, Mozambique.'
p26581
sS'RN'
p26582
(lp26583
S'0 (Anti-HIV Agents)'
p26584
asS'PL'
p26585
S'Sweden'
p26586
sS'PG'
p26587
S'23758'
p26588
sS'JID'
p26589
S'101496665'
p26590
sS'AB'
p26591
S"BACKGROUND: In Mozambique, antiretroviral therapy (ART) scale-up has been successfully implemented. However, attrition in care remains a major programmatic challenge. In 2009, an intermediary-level HIV referral center was created in Maputo to ensure access to specialized care for HIV-infected patients with complications (advanced clinical-immunological stage, Kaposi sarcoma, or suspected ART failure). OBJECTIVE: To determine the attrition from care and to identify risk factors that lead to high attrition among patients referred to an intermediary-level HIV referral center. DESIGN: This was a retrospective cohort study from 2009 to 2011. RESULTS: A total of 1,657 patients were enrolled, 847 (51%) were men, the mean age was 36 years (standard deviation: 11), the mean CD4 count was 27 cells/microl (interquartile range: 11-44), and one-third were severely malnourished. The main reasons for referral were advanced clinical stages (WHO stages 3 and 4, and CD4 count <50 cells/microl) in 70% of the cases, and 19% had Kaposi sarcoma. The overall attrition rate was 28.7 per 100 person-years (PYs) - the mortality rate was 5.0 (95% confidence interval [CI]: 4.2-5.9) per 100 PYs, and the loss-to-follow-up rate was 23.7 (95% CI: 21.9-25.6) per 100 PYs. There were 793 attritions - 137 deaths and 656 lost to follow-up (LTFU); 77% of all attrition happened within the first year. The factors independently associated with attrition were male sex (adjusted hazard ratio [aHR]: 1.15, 95% CI: 1.0-1.3), low body mass index (aHR: 1.51, 95% CI: 1.2-1.8), WHO clinical stage 3 or 4 (aHR: 1.30, 95% CI: 1.0-1.6; and aHR: 1.91, 95% CI: 1.4-2.5), later year of enrollment (aHR 1.61, 95% CI 1.3-1.9), and 'being already on ART' at enrollment (aHR 13.71, 95% CI 11.4-16.4). CONCLUSIONS: Attrition rates among HIV-infected patients enrolled in an intermediary referral center were high, mainly related to advanced stage of clinical disease. Measures are required to address this, including innovative strategies for HIV-testing uptake, earlier ART initiation and nutritional supplementation, and special attention to men and those who are already on ART at enrolment. Qualitative research is required to understand the reasons for being LTFU and design informed evidence-based interventions."
p26592
sS'AD'
p26593
S'Medecins Sans Frontieres, Maputo, Mozambique; lucasmolfino@yahoo.com.ar. International Union Against Tuberculosis and Lung Disease, South-East Asia Regional Office, New Delhi, India. Medecins Sans Frontieres (MSF), Operational Research Unit, Luxembourg City, Luxembourg. Medecins Sans Frontieres (MSF), Operational Research Unit, Luxembourg City, Luxembourg. Medecins Sans Frontieres (MSF), Operational Research Unit, Luxembourg City, Luxembourg. Centre for International Health, University of Bergen, Bergen, Norway. Direccao de Saude da Cidade de Maputo (DSCM), Ministry of Health, Maputo, Mozambique. Direccao de Saude da Cidade de Maputo (DSCM), Ministry of Health, Maputo, Mozambique. Medecins Sans Frontieres, Maputo, Mozambique. Medecins Sans Frontieres, Maputo, Mozambique.'
p26594
sS'VI'
p26595
S'7'
sS'IS'
p26596
S'1654-9880 (Electronic) 1654-9880 (Linking)'
p26597
sS'PMC'
p26598
S'PMC3982117'
p26599
sS'AU'
p26600
(lp26601
S'Molfino L'
p26602
aS'Kumar AM'
p26603
aS'Isaakidis P'
p26604
aS'Van den Bergh R'
p26605
aS'Khogali M'
p26606
aS'Hinderaker SG'
p26607
aS'Magaia A'
p26608
aS'Lobo S'
p26609
aS'Edwards CG'
p26610
aS'Walter J'
p26611
asS'MHDA'
p26612
S'2014/10/03 06:00'
p26613
sS'PHST'
p26614
(lp26615
S'2014 [ecollection]'
p26616
aS'2014/01/06 [received]'
p26617
aS'2014/02/24 [revised]'
p26618
aS'2014/03/08 [accepted]'
p26619
asS'OT'
p26620
(lp26621
S'HIV referral center'
p26622
aS'attrition'
p26623
aS'operational research'
p26624
aS'resource-limited settings'
p26625
aS'retention in care'
p26626
asS'OTO'
p26627
(lp26628
S'NOTNLM'
p26629
asS'OID'
p26630
(lp26631
S'NLM: PMC3982117'
p26632
asS'MH'
p26633
(lp26634
S'Adult'
p26635
aS'Anti-HIV Agents/*therapeutic use'
p26636
aS'CD4 Lymphocyte Count'
p26637
aS'Female'
p26638
aS'HIV Infections/*drug therapy/mortality/psychology'
p26639
aS'Humans'
p26640
aS'Male'
p26641
aS'Medication Adherence/psychology/*statistics & numerical data'
p26642
aS'Middle Aged'
p26643
aS'Mozambique/epidemiology'
p26644
aS'Retrospective Studies'
p26645
aS'Risk Factors'
p26646
aS'Secondary Care Centers/statistics & numerical data'
p26647
aS'Young Adult'
p26648
asS'EDAT'
p26649
S'2014/04/11 06:00'
p26650
sS'SO'
p26651
S'Glob Health Action. 2014 Apr 8;7:23758. doi: 10.3402/gha.v7.23758. eCollection 2014.'
p26652
sS'SB'
p26653
S'IM'
p26654
sS'PMID'
p26655
S'24717189'
p26656
sS'TA'
p26657
S'Glob Health Action'
p26658
sS'PST'
p26659
S'epublish'
p26660
stRp26661
ag2
(g3
g4
(dp26662
S'LID'
p26663
S'10.1136/sextrans-2013-051336 [doi]'
p26664
sS'STAT'
p26665
S'MEDLINE'
p26666
sS'DEP'
p26667
S'20140408'
p26668
sS'CI'
p26669
(lp26670
S'Published by the BMJ Publishing Group Limited. For permission to use (where not'
p26671
aS'already granted under a licence) please go to'
p26672
aS'http://group.bmj.com/group/rights-licensing/permissions.'
p26673
asS'DA'
p26674
S'20140515'
p26675
sS'AID'
p26676
(lp26677
S'sextrans-2013-051336 [pii]'
p26678
aS'10.1136/sextrans-2013-051336 [doi]'
p26679
asS'CRDT'
p26680
(lp26681
S'2014/04/10 06:00'
p26682
asS'DP'
p26683
S'2014 Jun'
p26684
sS'AD'
p26685
S'London School of Hygiene and Tropical Medicine, London, UK. Malawi Ministry of Health, Lilongwe, Malawi. London School of Hygiene and Tropical Medicine, London, UK. Malawi Ministry of Health, Lilongwe, Malawi. Malawi Ministry of Health, Lilongwe, Malawi. Malawi Ministry of Health, Lilongwe, Malawi. London School of Hygiene and Tropical Medicine, London, UK. Karonga Prevention Study, Chilumba, Malawi. London School of Hygiene and Tropical Medicine, London, UK. London School of Hygiene and Tropical Medicine, London, UK. London School of Hygiene and Tropical Medicine, London, UK. London School of Hygiene and Tropical Medicine, London, UK.'
p26686
sS'OWN'
p26687
S'NLM'
p26688
sS'PT'
p26689
(lp26690
S'Journal Article'
p26691
aS"Research Support, Non-U.S. Gov't"
p26692
asS'LA'
p26693
(lp26694
S'eng'
p26695
asS'FAU'
p26696
(lp26697
S'Price, Alison J'
p26698
aS'Kayange, Michael'
p26699
aS'Zaba, Basia'
p26700
aS'Chimbwandira, Frank M'
p26701
aS'Jahn, Andreas'
p26702
aS'Chirwa, Zengani'
p26703
aS'Dasgupta, Aisha Nz'
p26704
aS'Katundu, Cynthia'
p26705
aS'Saul, Jacqueline L'
p26706
aS'Glynn, Judith R'
p26707
aS'Koole, Olivier'
p26708
aS'Crampin, Amelia C'
p26709
asS'JT'
p26710
S'Sexually transmitted infections'
p26711
sS'LR'
p26712
S'20160713'
p26713
sS'PG'
p26714
S'309-14'
p26715
sS'TI'
p26716
S'Uptake of prevention of mother-to-child-transmission using Option B+ in northern rural Malawi: a retrospective cohort study.'
p26717
sS'RN'
p26718
(lp26719
S'0 (Anti-HIV Agents)'
p26720
aS'0 (Benzoxazines)'
p26721
aS'0 (Organophosphonates)'
p26722
aS'2T8Q726O95 (Lamivudine)'
p26723
aS'99DK7FVK1H (Nevirapine)'
p26724
aS'99YXE507IL (Tenofovir)'
p26725
aS'JAC85A2161 (Adenine)'
p26726
aS'JE6H2O27P8 (efavirenz)'
p26727
asS'PL'
p26728
S'England'
p26729
sS'TA'
p26730
S'Sex Transm Infect'
p26731
sS'JID'
p26732
S'9805554'
p26733
sS'AB'
p26734
S"To identify points of dropout on the pathway from offering HIV testing to maintenance on antiretroviral therapy (ART), following the introduction of the Option B+ policy for pregnant women in Malawi (lifelong ART for HIV-positive mothers and 6 weeks nevirapine for the infants), a retrospective cohort study within a demographic surveillance system in northern Malawi. Women living in the demographic surveillance system who initiated antenatal care (ANC) between July 2011 (date of policy change) and January 2013, were eligible for inclusion. Women who consented were interviewed at home about their health facility attendance and care since pregnancy, including antenatal clinic (ANC) visits, delivery and postpartum care. Women's reports, patient-held health records and clinic health records were manually linked to ascertain service use. Among 395 women, 86% had tested for HIV before the pregnancy, 90% tested or re-tested at the ANC visit, and <1% had never tested. Among 53 mothers known to be HIV-positive before attending ANC, 15 (28%) were already on ART prior to pregnancy. Ten women tested HIV-positive for the first time during pregnancy. Of the 47 HIV-positive mothers not already on ART, 26/47 (55%) started treatment during pregnancy. All but five women who started ART were still on treatment at the time of study interview. HIV testing was almost universal and most women who initiated ART were retained in care. However, nearly half of eligible pregnant women not on ART at the start of ANC had not taken up the invitation to initiate (lifelong) ART by the time of delivery, leaving their infants potentially HIV-exposed."
p26735
sS'GR'
p26736
(lp26737
S'096249/Z/11/A/Wellcome Trust/United Kingdom'
p26738
aS'098610/Wellcome Trust/United Kingdom'
p26739
asS'IP'
p26740
S'4'
sS'IS'
p26741
S'1472-3263 (Electronic) 1368-4973 (Linking)'
p26742
sS'PMC'
p26743
S'PMC4033143'
p26744
sS'DCOM'
p26745
S'20140626'
p26746
sS'CIN'
p26747
(lp26748
S'Sex Transm Infect. 2014 Dec;90(8):640. PMID: 25398730'
p26749
asS'AU'
p26750
(lp26751
S'Price AJ'
p26752
aS'Kayange M'
p26753
aS'Zaba B'
p26754
aS'Chimbwandira FM'
p26755
aS'Jahn A'
p26756
aS'Chirwa Z'
p26757
aS'Dasgupta AN'
p26758
aS'Katundu C'
p26759
aS'Saul JL'
p26760
aS'Glynn JR'
p26761
aS'Koole O'
p26762
aS'Crampin AC'
p26763
asS'VI'
p26764
S'90'
p26765
sS'MHDA'
p26766
S'2014/06/27 06:00'
p26767
sS'PHST'
p26768
(lp26769
S'2014/04/08 [aheadofprint]'
p26770
asS'OTO'
p26771
(lp26772
S'NOTNLM'
p26773
asS'OID'
p26774
(lp26775
S'NLM: PMC4033143'
p26776
asS'MH'
p26777
(lp26778
S'Adenine/*analogs & derivatives/therapeutic use'
p26779
aS'Adult'
p26780
aS'Anti-HIV Agents/*therapeutic use'
p26781
aS'Antiretroviral Therapy, Highly Active'
p26782
aS'Benzoxazines/*therapeutic use'
p26783
aS'Chemoprevention'
p26784
aS'Cohort Studies'
p26785
aS'Female'
p26786
aS'HIV Infections/*transmission'
p26787
aS'Humans'
p26788
aS'Infant, Newborn'
p26789
aS'Infectious Disease Transmission, Vertical/*prevention & control'
p26790
aS'Lamivudine/*therapeutic use'
p26791
aS'Malawi'
p26792
aS'Nevirapine/*therapeutic use'
p26793
aS'Organophosphonates/*therapeutic use'
p26794
aS'Pregnancy'
p26795
aS'Pregnancy Complications, Infectious/*drug therapy'
p26796
aS'Prenatal Care'
p26797
aS'Retrospective Studies'
p26798
aS'Rural Population/*statistics & numerical data'
p26799
aS'Tenofovir'
p26800
aS'Young Adult'
p26801
asS'EDAT'
p26802
S'2014/04/10 06:00'
p26803
sS'SO'
p26804
S'Sex Transm Infect. 2014 Jun;90(4):309-14. doi: 10.1136/sextrans-2013-051336. Epub 2014 Apr 8.'
p26805
sS'SB'
p26806
S'IM'
p26807
sS'PMID'
p26808
S'24714445'
p26809
sS'OT'
p26810
(lp26811
S'ANTENATAL HIV'
p26812
aS'CHILDREN'
p26813
aS'PREVENTION'
p26814
asS'PST'
p26815
S'ppublish'
p26816
stRp26817
ag2
(g3
g4
(dp26818
S'LID'
p26819
S'10.1186/1471-2334-14-181 [doi]'
p26820
sS'STAT'
p26821
S'MEDLINE'
p26822
sS'DEP'
p26823
S'20140404'
p26824
sS'DA'
p26825
S'20140410'
p26826
sS'AID'
p26827
(lp26828
S'1471-2334-14-181 [pii]'
p26829
aS'10.1186/1471-2334-14-181 [doi]'
p26830
asS'CRDT'
p26831
(lp26832
S'2014/04/09 06:00'
p26833
asS'DP'
p26834
S'2014'
p26835
sS'OWN'
p26836
S'NLM'
p26837
sS'PT'
p26838
(lp26839
S'Journal Article'
p26840
aS'Randomized Controlled Trial'
p26841
aS"Research Support, Non-U.S. Gov't"
p26842
asS'LA'
p26843
(lp26844
S'eng'
p26845
asS'DCOM'
p26846
S'20150128'
p26847
sS'JT'
p26848
S'BMC infectious diseases'
p26849
sS'LR'
p26850
S'20150806'
p26851
sS'FAU'
p26852
(lp26853
S'Abdissa, Alemseged'
p26854
aS'Yilma, Daniel'
p26855
aS'Fonager, Jannik'
p26856
aS'Audelin, Anne M'
p26857
aS'Christensen, Lone H'
p26858
aS'Olsen, Mette F'
p26859
aS'Tesfaye, Markos'
p26860
aS'Kaestel, Pernille'
p26861
aS'Girma, Tsinuel'
p26862
aS'Aseffa, Abraham'
p26863
aS'Friis, Henrik'
p26864
aS'Pedersen, Court'
p26865
aS'Andersen, Aase B'
p26866
asS'TI'
p26867
S'Drug resistance in HIV patients with virological failure or slow virological response to antiretroviral therapy in Ethiopia.'
p26868
sS'RN'
p26869
(lp26870
S'0 (Anti-Retroviral Agents)'
p26871
asS'PL'
p26872
S'England'
p26873
sS'PG'
p26874
S'181'
p26875
sS'JID'
p26876
S'100968551'
p26877
sS'AB'
p26878
S'BACKGROUND: The ongoing scale-up of antiretroviral therapy (ART) in sub-Saharan Africa has prompted the interest in surveillance of transmitted and acquired HIV drug resistance. Resistance data on virological failure and mutations in HIV infected populations initiating treatment in sub-Saharan Africa is sparse. METHODS: HIV viral load (VL) and resistance mutations pre-ART and after 6 months were determined in a prospective cohort study of ART-naive HIV patients initiating first-line therapy in Jimma, Ethiopia. VL measurements were done at baseline and after 3 and 6 months. Genotypic HIV drug resistance (HIVDR) was performed on patients exhibiting virological failure (>1000 copies/mL at 6 months) or slow virological response (>5000 copies/mL at 3 months and <1000 copies/mL at 6 months). RESULTS: Two hundred sixty five patients had VL data available at baseline and at 6 months. Virological failure was observed among 14 (5.3%) participants out of 265 patients. Twelve samples were genotyped and six had HIV drug resistance (HIVDR) mutations at baseline. Among virological failures, 9/11 (81.8%) harbored one or more HIVDR mutations at 6 months. The most frequent mutations were K103N and M184VI. CONCLUSIONS: Our data confirm that the currently recommended first-line ART regimen is efficient in the vast majority of individuals initiating therapy in Jimma, Ethiopia eight years after the introduction of ART. However, the documented occurrence of transmitted resistance and accumulation of acquired HIVDR mutations among failing patients justify increased vigilance by improving the availability and systematic use of VL testing to monitor ART response, and underlines the need for rapid, inexpensive tests to identify the most common drug resistance mutations.'
p26879
sS'AD'
p26880
S'Department of Medical Laboratory Sciences & Pathology, Jimma University, Jimma, Ethiopia. alemseged.abdisssa@ju.edu.et.'
p26881
sS'VI'
p26882
S'14'
p26883
sS'IS'
p26884
S'1471-2334 (Electronic) 1471-2334 (Linking)'
p26885
sS'PMC'
p26886
S'PMC4234735'
p26887
sS'AU'
p26888
(lp26889
S'Abdissa A'
p26890
aS'Yilma D'
p26891
aS'Fonager J'
p26892
aS'Audelin AM'
p26893
aS'Christensen LH'
p26894
aS'Olsen MF'
p26895
aS'Tesfaye M'
p26896
aS'Kaestel P'
p26897
aS'Girma T'
p26898
aS'Aseffa A'
p26899
aS'Friis H'
p26900
aS'Pedersen C'
p26901
aS'Andersen AB'
p26902
asS'MHDA'
p26903
S'2015/01/30 06:00'
p26904
sS'PHST'
p26905
(lp26906
S'2014/01/03 [received]'
p26907
aS'2014/03/31 [accepted]'
p26908
aS'2014/04/04 [aheadofprint]'
p26909
asS'OID'
p26910
(lp26911
S'NLM: PMC4234735'
p26912
asS'MH'
p26913
(lp26914
S'Adult'
p26915
aS'Anti-Retroviral Agents/*therapeutic use'
p26916
aS'Drug Resistance, Viral'
p26917
aS'Ethiopia'
p26918
aS'Female'
p26919
aS'HIV/*isolation & purification'
p26920
aS'HIV Infections/*drug therapy/*virology'
p26921
aS'Humans'
p26922
aS'Male'
p26923
aS'Middle Aged'
p26924
aS'Young Adult'
p26925
asS'EDAT'
p26926
S'2014/04/09 06:00'
p26927
sS'SI'
p26928
(lp26929
S'ISRCTN/ISRCTN32453477'
p26930
asS'SO'
p26931
S'BMC Infect Dis. 2014 Apr 4;14:181. doi: 10.1186/1471-2334-14-181.'
p26932
sS'SB'
p26933
S'IM'
p26934
sS'PMID'
p26935
S'24708645'
p26936
sS'TA'
p26937
S'BMC Infect Dis'
p26938
sS'PST'
p26939
S'epublish'
p26940
stRp26941
ag2
(g3
g4
(dp26942
S'LID'
p26943
S'10.1007/s00431-014-2303-9 [doi]'
p26944
sS'STAT'
p26945
S'MEDLINE'
p26946
sS'DEP'
p26947
S'20140402'
p26948
sS'DA'
p26949
S'20140815'
p26950
sS'AID'
p26951
(lp26952
S'10.1007/s00431-014-2303-9 [doi]'
p26953
asS'CRDT'
p26954
(lp26955
S'2014/04/03 06:00'
p26956
asS'DP'
p26957
S'2014 Sep'
p26958
sS'AD'
p26959
S'Anova Health Institute, Johannesburg and Tzaneen, 21A Peace Street, PO Box 2243, Tzaneen, 0850, South Africa, rph.peters@gmail.com.'
p26960
sS'OWN'
p26961
S'NLM'
p26962
sS'PT'
p26963
(lp26964
S'Journal Article'
p26965
aS'Multicenter Study'
p26966
aS"Research Support, U.S. Gov't, Non-P.H.S."
p26967
asS'LA'
p26968
(lp26969
S'eng'
p26970
asS'FAU'
p26971
(lp26972
S'Peters, Remco P H'
p26973
aS'Van Ramshorst, Mette S'
p26974
aS'Struthers, Helen E'
p26975
aS'McIntyre, James A'
p26976
asS'JT'
p26977
S'European journal of pediatrics'
p26978
sS'PG'
p26979
S'1245-8'
p26980
sS'TI'
p26981
S'Clinical assessment of peripheral neuropathy in HIV-infected children on antiretroviral therapy in rural South Africa.'
p26982
sS'RN'
p26983
(lp26984
S'0 (Anti-HIV Agents)'
p26985
aS'0 (Reverse Transcriptase Inhibitors)'
p26986
asS'PL'
p26987
S'Germany'
p26988
sS'TA'
p26989
S'Eur J Pediatr'
p26990
sS'JID'
p26991
S'7603873'
p26992
sS'AB'
p26993
S'Peripheral neuropathy is a well-known side effect of antiretroviral therapy (ART) in adult patients and is particularly related to the use of nucleoside reverse transcriptase inhibitors. This class of drugs is included in all first-line paediatric ART regimens in Africa, but data on the prevalence of neuropathy in children are scarce. In this cross-sectional study, 182 HIV-infected children on ART in rural South Africa were assessed for peripheral neuropathy using the neuropathy symptom score (NSS) and neuropathy disability score (NDS). Peripheral neuropathy was defined as NSS >/= 5 or NDS >/= 3. Neurological assessment was completed for 174 children (96 %). Symptoms of neuropathy were reported in NSS by 48 children (28 %; 95 % confidence interval (CI) 21-34 %), and signs were observed in NDS in 25 children (14 %; 95 % CI 12-16 %). A diagnosis of peripheral neuropathy was established in 42 children (24 %; 95 % CI 18-30 %). Independent risk factors for peripheral neuropathy were co-trimoxazole prophylaxis (adjusted odds ratio 0.45; 95 % CI 0.21-0.95, p = 0.036) and didanosine use (adjusted odds ratio 12; 95 % CI 1.3-116, p = 0.030). CONCLUSION: Peripheral neuropathy as determined by clinical assessment is a common condition in African children on ART.'
p26994
sS'GR'
p26995
(lp26996
S'PEPFAR/United States'
p26997
asS'IP'
p26998
S'9'
sS'IS'
p26999
S'1432-1076 (Electronic) 0340-6199 (Linking)'
p27000
sS'DCOM'
p27001
S'20150602'
p27002
sS'AU'
p27003
(lp27004
S'Peters RP'
p27005
aS'Van Ramshorst MS'
p27006
aS'Struthers HE'
p27007
aS'McIntyre JA'
p27008
asS'VI'
p27009
S'173'
p27010
sS'MHDA'
p27011
S'2015/06/03 06:00'
p27012
sS'PHST'
p27013
(lp27014
S'2013/12/28 [received]'
p27015
aS'2014/03/24 [accepted]'
p27016
aS'2014/03/04 [revised]'
p27017
aS'2014/04/02 [aheadofprint]'
p27018
asS'MH'
p27019
(lp27020
S'Adolescent'
p27021
aS'Anti-HIV Agents/administration & dosage/*adverse effects'
p27022
aS'Child'
p27023
aS'Child, Preschool'
p27024
aS'Cross-Sectional Studies'
p27025
aS'Female'
p27026
aS'HIV Infections/*drug therapy'
p27027
aS'Humans'
p27028
aS'Male'
p27029
aS'Peripheral Nervous System Diseases/*chemically induced/diagnosis/*epidemiology/prevention & control'
p27030
aS'Prevalence'
p27031
aS'Reverse Transcriptase Inhibitors/administration & dosage/*adverse effects'
p27032
aS'Risk Factors'
p27033
aS'Rural Population/*statistics & numerical data'
p27034
aS'South Africa/epidemiology'
p27035
asS'EDAT'
p27036
S'2014/04/03 06:00'
p27037
sS'SO'
p27038
S'Eur J Pediatr. 2014 Sep;173(9):1245-8. doi: 10.1007/s00431-014-2303-9. Epub 2014 Apr 2.'
p27039
sS'SB'
p27040
S'IM'
p27041
sS'PMID'
p27042
S'24691679'
p27043
sS'PST'
p27044
S'ppublish'
p27045
stRp27046
ag2
(g3
g4
(dp27047
S'LID'
p27048
S'10.1186/1471-2458-14-296 [doi]'
p27049
sS'STAT'
p27050
S'MEDLINE'
p27051
sS'DEP'
p27052
S'20140331'
p27053
sS'DA'
p27054
S'20140423'
p27055
sS'AID'
p27056
(lp27057
S'1471-2458-14-296 [pii]'
p27058
aS'10.1186/1471-2458-14-296 [doi]'
p27059
asS'CRDT'
p27060
(lp27061
S'2014/04/02 06:00'
p27062
asS'DP'
p27063
S'2014'
p27064
sS'AD'
p27065
S'Center for Global Health and Development, Boston University, Crosstown Center, 3rd Floor, 801 Massachusetts Avenue, Boston, MA 02118, USA. blarson@bu.edu.'
p27066
sS'OWN'
p27067
S'NLM'
p27068
sS'PT'
p27069
(lp27070
S'Journal Article'
p27071
aS"Research Support, U.S. Gov't, P.H.S."
p27072
asS'LA'
p27073
(lp27074
S'eng'
p27075
asS'DCOM'
p27076
S'20150622'
p27077
sS'JT'
p27078
S'BMC public health'
p27079
sS'LR'
p27080
S'20151119'
p27081
sS'FAU'
p27082
(lp27083
S'Scott, Callie A'
p27084
aS'Iyer, Hari S'
p27085
aS'McCoy, Kelly'
p27086
aS'Moyo, Crispin'
p27087
aS'Long, Lawrence'
p27088
aS'Larson, Bruce A'
p27089
aS'Rosen, Sydney'
p27090
asS'TI'
p27091
S'Retention in care, resource utilization, and costs for adults receiving antiretroviral therapy in Zambia: a retrospective cohort study.'
p27092
sS'RN'
p27093
(lp27094
S'0 (Anti-HIV Agents)'
p27095
aS'0 (Organophosphonates)'
p27096
aS'99YXE507IL (Tenofovir)'
p27097
aS'JAC85A2161 (Adenine)'
p27098
asS'PL'
p27099
S'England'
p27100
sS'PG'
p27101
S'296'
p27102
sS'JID'
p27103
S'100968562'
p27104
sS'AB'
p27105
S"BACKGROUND: Of the estimated 800,000 adults living with HIV in Zambia in 2011, roughly half were receiving antiretroviral therapy (ART). As treatment scale up continues, information on the care provided to patients after initiating ART can help guide decision-making. We estimated retention in care, the quantity of resources utilized, and costs for a retrospective cohort of adults initiating ART under routine clinical conditions in Zambia. METHODS: Data on resource utilization (antiretroviral [ARV] and non-ARV drugs, laboratory tests, outpatient clinic visits, and fixed resources) and retention in care were extracted from medical records for 846 patients who initiated ART at >/=15 years of age at six treatment sites between July 2007 and October 2008. Unit costs were estimated from the provider's perspective using site- and country-level data and are reported in 2011 USD. RESULTS: Patients initiated ART at a median CD4 cell count of 145 cells/muL. Fifty-nine percent of patients initiated on a tenofovir-containing regimen, ranging from 15% to 86% depending on site. One year after ART initiation, 75% of patients were retained in care. The average cost per patient retained in care one year after ART initiation was $243 (95% CI, $194-$293), ranging from $184 (95% CI, $172-$195) to $304 (95% CI, $290-$319) depending on site. Patients retained in care one year after ART initiation received, on average, 11.4 months' worth of ARV drugs, 1.5 CD4 tests, 1.3 blood chemistry tests, 1.4 full blood count tests, and 6.5 clinic visits with a doctor or clinical officer. At all sites, ARV drugs were the largest cost component, ranging from 38% to 84% of total costs, depending on site. CONCLUSIONS: Patients initiate ART late in the course of disease progression and a large proportion drop out of care after initiation. The quantity of resources utilized and costs vary widely by site, and patients utilize a different mix of resources under routine clinical conditions than if they were receiving fully guideline-concordant care. Improving retention in care and guideline concordance, including increasing the use of tenofovir in first-line ART regimens, may lead to increases in overall treatment costs."
p27106
sS'GR'
p27107
(lp27108
S'5U2GPS001418-00/PHS HHS/United States'
p27109
asS'VI'
p27110
S'14'
p27111
sS'IS'
p27112
S'1471-2458 (Electronic) 1471-2458 (Linking)'
p27113
sS'PMC'
p27114
S'PMC3995515'
p27115
sS'AU'
p27116
(lp27117
S'Scott CA'
p27118
aS'Iyer HS'
p27119
aS'McCoy K'
p27120
aS'Moyo C'
p27121
aS'Long L'
p27122
aS'Larson BA'
p27123
aS'Rosen S'
p27124
asS'MHDA'
p27125
S'2015/06/24 06:00'
p27126
sS'PHST'
p27127
(lp27128
S'2013/07/26 [received]'
p27129
aS'2014/03/14 [accepted]'
p27130
aS'2014/03/31 [aheadofprint]'
p27131
asS'OID'
p27132
(lp27133
S'NLM: PMC3995515'
p27134
asS'MH'
p27135
(lp27136
S'Adenine/analogs & derivatives/therapeutic use'
p27137
aS'Adult'
p27138
aS'Ambulatory Care Facilities'
p27139
aS'Anti-HIV Agents/*therapeutic use'
p27140
aS'CD4 Lymphocyte Count'
p27141
aS'Delivery of Health Care/*economics'
p27142
aS'Female'
p27143
aS'Guideline Adherence'
p27144
aS'HIV Infections/drug therapy/*economics'
p27145
aS'*Health Care Costs'
p27146
aS'*Health Resources'
p27147
aS'Humans'
p27148
aS'Male'
p27149
aS'Office Visits'
p27150
aS'Organophosphonates/therapeutic use'
p27151
aS'*Patient Dropouts'
p27152
aS'Retrospective Studies'
p27153
aS'Tenofovir'
p27154
aS'Zambia'
p27155
asS'EDAT'
p27156
S'2014/04/02 06:00'
p27157
sS'SO'
p27158
S'BMC Public Health. 2014 Mar 31;14:296. doi: 10.1186/1471-2458-14-296.'
p27159
sS'SB'
p27160
S'IM'
p27161
sS'PMID'
p27162
S'24684772'
p27163
sS'TA'
p27164
S'BMC Public Health'
p27165
sS'PST'
p27166
S'epublish'
p27167
stRp27168
ag2
(g3
g4
(dp27169
S'LID'
p27170
S'10.1016/j.ijid.2013.10.016 [doi] S1201-9712(13)00346-9 [pii]'
p27171
sS'STAT'
p27172
S'MEDLINE'
p27173
sS'DEP'
p27174
S'20140325'
p27175
sS'CI'
p27176
(lp27177
S'Copyright (c) 2013 The Authors. Published by Elsevier Ltd.. All rights reserved.'
p27178
asS'DA'
p27179
S'20140526'
p27180
sS'AID'
p27181
(lp27182
S'S1201-9712(13)00346-9 [pii]'
p27183
aS'10.1016/j.ijid.2013.10.016 [doi]'
p27184
asS'CRDT'
p27185
(lp27186
S'2014/04/01 06:00'
p27187
asS'DP'
p27188
S'2014 Jun'
p27189
sS'AD'
p27190
S'Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand,, Johannesburg, South Africa. Electronic address: kshearer@heroza.org. Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand,, Johannesburg, South Africa. Center for Global Health and Development, Boston University, Boston, Massachusetts, USA. Right to Care, Johannesburg, South Africa. Right to Care, Johannesburg, South Africa. Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand,, Johannesburg, South Africa; Right to Care, Johannesburg, South Africa; Clinical HIV Research Unit, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand,, Johannesburg, South Africa; Center for Global Health and Development, Boston University, Boston, Massachusetts, USA; Department of Epidemiology, School of Public Health, Boston University, Boston, Massachusetts, USA.'
p27191
sS'OWN'
p27192
S'NLM'
p27193
sS'PT'
p27194
(lp27195
S'Journal Article'
p27196
aS'Research Support, N.I.H., Extramural'
p27197
aS"Research Support, U.S. Gov't, Non-P.H.S."
p27198
asS'LA'
p27199
(lp27200
S'eng'
p27201
asS'DCOM'
p27202
S'20150120'
p27203
sS'JT'
p27204
S'International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases'
p27205
sS'LR'
p27206
S'20150601'
p27207
sS'FAU'
p27208
(lp27209
S'Shearer, Kate'
p27210
aS'Maskew, Mhairi'
p27211
aS'Ajayi, Toyin'
p27212
aS'Berhanu, Rebecca'
p27213
aS'Majuba, Pappie'
p27214
aS'Sanne, Ian'
p27215
aS'Fox, Matthew P'
p27216
asS'TI'
p27217
S'Incidence and predictors of herpes zoster among antiretroviral therapy-naive patients initiating HIV treatment in Johannesburg, South Africa.'
p27218
sS'RN'
p27219
(lp27220
S'0 (Anti-HIV Agents)'
p27221
asS'PL'
p27222
S'Canada'
p27223
sS'PG'
p27224
S'56-62'
p27225
sS'JID'
p27226
S'9610933'
p27227
sS'AB'
p27228
S'OBJECTIVES: To describe the characteristics of HIV-infected patients experiencing herpes zoster after antiretroviral therapy (ART) initiation and to describe the incidence and predictors of a herpes zoster diagnosis. METHODS: Adult patients initiating ART from April 2004 to September 2011 at the Themba Lethu Clinic in Johannesburg, South Africa were included. Patients were followed from ART initiation until the date of first herpes zoster diagnosis, or death, transfer, loss to follow-up, or dataset closure. Herpes zoster is described using incidence rates (IR) and predictors of herpes zoster are presented as subdistribution hazard ratios (sHR) and 95% confidence intervals (95% CI). RESULTS: Fifteen thousand and twenty-five patients were included; 62% were female, the median age was 36.6 years, and the median baseline CD4 count was 98 cells/mm(3). Three hundred and forty patients (2.3%) experienced herpes zoster in a median of 26.1 weeks after ART initiation. Most (71.5%) occurred within 1 year of initiation, for a 1-year IR of 18.1/1000 person-years. In an adjusted model, patients with low CD4 counts (<50 vs. >/=200 cells/mm(3); sHR: 1.71, 95% CI: 1.21-2.47) and with a prior episode of herpes zoster (sHR: 1.53, 95% CI: 0.97-2.28) were at increased risk of incident herpes zoster. CONCLUSIONS: While only 2% of patients were diagnosed with herpes zoster in this cohort, patients with low CD4 counts and those with prior episodes of herpes zoster were at higher risk for a herpes zoster diagnosis.'
p27229
sS'GR'
p27230
(lp27231
S'K01 AI083097/AI/NIAID NIH HHS/United States'
p27232
aS'K01AI083097/AI/NIAID NIH HHS/United States'
p27233
asS'VI'
p27234
S'23'
p27235
sS'IS'
p27236
S'1878-3511 (Electronic) 1201-9712 (Linking)'
p27237
sS'PMC'
p27238
S'PMC4092228'
p27239
sS'MID'
p27240
(lp27241
S'NIHMS579595'
p27242
asS'AU'
p27243
(lp27244
S'Shearer K'
p27245
aS'Maskew M'
p27246
aS'Ajayi T'
p27247
aS'Berhanu R'
p27248
aS'Majuba P'
p27249
aS'Sanne I'
p27250
aS'Fox MP'
p27251
asS'MHDA'
p27252
S'2015/01/21 06:00'
p27253
sS'PHST'
p27254
(lp27255
S'2013/09/01 [received]'
p27256
aS'2013/10/22 [revised]'
p27257
aS'2013/10/27 [accepted]'
p27258
aS'2014/03/25 [aheadofprint]'
p27259
asS'OT'
p27260
(lp27261
S'Attrition'
p27262
aS'HIV infection'
p27263
aS'Herpes zoster'
p27264
aS'Resource-limited settings'
p27265
aS'Shingles'
p27266
asS'OTO'
p27267
(lp27268
S'NOTNLM'
p27269
asS'OID'
p27270
(lp27271
S'NLM: NIHMS579595'
p27272
aS'NLM: PMC4092228'
p27273
asS'MH'
p27274
(lp27275
S'Adult'
p27276
aS'Anti-HIV Agents/therapeutic use'
p27277
aS'Antiretroviral Therapy, Highly Active'
p27278
aS'Body Mass Index'
p27279
aS'CD4 Lymphocyte Count'
p27280
aS'Coinfection/virology'
p27281
aS'Female'
p27282
aS'HIV Infections/complications/*drug therapy/*epidemiology'
p27283
aS'Herpes Zoster/complications/*diagnosis/*epidemiology'
p27284
aS'Humans'
p27285
aS'Incidence'
p27286
aS'Middle Aged'
p27287
aS'Retrospective Studies'
p27288
aS'Risk Factors'
p27289
aS'South Africa/epidemiology'
p27290
aS'Viral Load'
p27291
asS'EDAT'
p27292
S'2014/04/01 06:00'
p27293
sS'SO'
p27294
S'Int J Infect Dis. 2014 Jun;23:56-62. doi: 10.1016/j.ijid.2013.10.016. Epub 2014 Mar 25.'
p27295
sS'SB'
p27296
S'IM'
p27297
sS'PMID'
p27298
S'24680820'
p27299
sS'TA'
p27300
S'Int J Infect Dis'
p27301
sS'PST'
p27302
S'ppublish'
p27303
stRp27304
ag2
(g3
g4
(dp27305
S'STAT'
p27306
S'MEDLINE'
p27307
sS'AB'
p27308
S'BACKGROUND: The efficacy of anti-retroviral Therapy (ART) depends on adherence to the prescribed regimen. However, lack of adherence leads to treatment failure and drug resistance among other negative outcomes. OBJECTIVE: To determine factors influencing adherence to ARVS among patients attending the Comprehensive Care Clinic (CCC) within Jomo Kenyatta University of Agriculture and Technology (JKUAT). DESIGN: A descriptive cross sectional study. SETTING: Comprehensive Care Clinic within JKUAT. SUBJECTS: Three hundred HIV positive patients, undergoing ART treatment and follow up at the JKUAT clinic for a minimum duration of one month before the study, were recruited. RESULTS: Of the 300 patients enrolled for the study (70% females and 30% males), 81% were adhering to ARV treatment. The factors that were significantly associated with adherence included; Support (encouragement and reminder to take drugs) (P = 0.025); the number of meals respondents took in a day (P = 0.001); pill burden (P = 0.002) and forgetfulness (P = 0.001). However, there was no significant relationship between adherence and age, marital status, education, employment status or time taken to travel to the clinic. CONCLUSION: This study concluded that, the observed level of sub-optimal adherence to ART (19%) is of public health concern. These patients are vulnerable to treatment failure and development of resistant viral strains. Consequently the modifiable factors (Support, Number of meals taken, pill burden, and forgetfulness, should be addressed to change the current tread.'
p27309
sS'JID'
p27310
S'0372766'
p27311
sS'JT'
p27312
S'East African medical journal'
p27313
sS'IP'
p27314
S'4'
sS'IS'
p27315
S'0012-835X (Print) 0012-835X (Linking)'
p27316
sS'DCOM'
p27317
S'20160301'
p27318
sS'DA'
p27319
S'20160209'
p27320
sS'AU'
p27321
(lp27322
S'Mwangi AN'
p27323
aS"Ng'ang'a Z"
p27324
aS'Wanzala P'
p27325
aS'Karanja SM'
p27326
asS'CRDT'
p27327
(lp27328
S'2016/02/10 06:00'
p27329
asS'VI'
p27330
S'91'
p27331
sS'PMID'
p27332
S'26859028'
p27333
sS'DP'
p27334
S'2014 Apr'
p27335
sS'MHDA'
p27336
S'2016/03/02 06:00'
p27337
sS'OWN'
p27338
S'NLM'
p27339
sS'PT'
p27340
(lp27341
S'Journal Article'
p27342
aS"Research Support, Non-U.S. Gov't"
p27343
asS'LA'
p27344
(lp27345
S'eng'
p27346
asS'MH'
p27347
(lp27348
S'Adolescent'
p27349
aS'Adult'
p27350
aS'Ambulatory Care Facilities'
p27351
aS'Anti-Retroviral Agents/*therapeutic use'
p27352
aS'Cross-Sectional Studies'
p27353
aS'Female'
p27354
aS'HIV Infections/*drug therapy/psychology'
p27355
aS'Humans'
p27356
aS'Kenya'
p27357
aS'Male'
p27358
aS'*Medication Adherence'
p27359
aS'Middle Aged'
p27360
aS'Socioeconomic Factors'
p27361
aS'Young Adult'
p27362
asS'FAU'
p27363
(lp27364
S'Mwangi, A N'
p27365
aS"Ng'ang'a, Z"
p27366
aS'Wanzala, P'
p27367
aS'Karanja, S M'
p27368
asS'EDAT'
p27369
S'2014/04/01 00:00'
p27370
sS'PST'
p27371
S'ppublish'
p27372
sS'SO'
p27373
S'East Afr Med J. 2014 Apr;91(4):109-14.'
p27374
sS'PG'
p27375
S'109-14'
p27376
sS'TI'
p27377
S'FACTORS INFLUENCING ADHERENCE TO ARVS AMONG PATIENTS ATTENDING COMPREHENSIVE CARE CLINIC WITHIN JOMO KENYATTA UNIVERSITY OF AGRICULTURE AND TECHNOLOGY, KIAMBU COUNTY, KENYA.'
p27378
sS'SB'
p27379
S'IM'
p27380
sS'RN'
p27381
(lp27382
S'0 (Anti-Retroviral Agents)'
p27383
asS'PL'
p27384
S'Kenya'
p27385
sS'TA'
p27386
S'East Afr Med J'
p27387
stRp27388
ag2
(g3
g4
(dp27389
S'LID'
p27390
S'10.5588/ijtld.13.0742 [doi]'
p27391
sS'STAT'
p27392
S'MEDLINE'
p27393
sS'AB'
p27394
S'SETTING: Khayelitsha, South Africa, a peri-urban township with high burdens of tuberculosis (TB), drug-resistant tuberculosis (DR-TB), and human immunodeficiency virus (HIV) infection. OBJECTIVE: To describe case detection and patient outcomes in a community-based DR-TB programme. DESIGN: DR-TB management was integrated into primary health care in Khayelitsha from 2007 onwards. Implementation was incremental, and included training and clinician support, counselling and home visits, tuberculous infection control, a local in-patient service, and routine monitoring. Patients received treatment rapidly through their local clinic, and were only hospitalised if clinically unwell. RESULTS: DR-TB case notification (any rifampicin resistance) increased from 28 per 100 000 population per year (2005-2007) to 55/100 000/year in 2009-2011 (72% HIV-infected). From 2008 to 2011, 754 patients received treatment (86% of those diagnosed). The median time between diagnostic sputum and treatment decreased over the years of implementation to 27 days in 2011 (P < 0.001). Treatment success was 52% in 2010, with 31% default, 13% death and 4% treatment failure. Two-year survival was 65%, with poorer survival in those with HIV (HR 2.0, 95%CI 1.4-2.8), second-line drug resistance (HR 3.3, 95%CI 2.2-4.8), and diagnosis in earlier programme years (HR 1.4, 95%CI 1.1-2.0). CONCLUSION: Community-based DR-TB management is feasible, and contributes to improved case detection, reduced treatment delay and improved survival. Treatment outcomes remain poor, highlighting the poor efficacy, tolerability and lengthy duration of current treatment.'
p27395
sS'JID'
p27396
S'9706389'
p27397
sS'AD'
p27398
S'Medecins Sans Frontieres, Khayelitsha, Cape Town, South Africa. Medecins Sans Frontieres, Khayelitsha, Cape Town, South Africa. Medecins Sans Frontieres, Khayelitsha, Cape Town, South Africa. City of Cape Town Health Department, Khayelitsha, Cape Town, South Africa. Medecins Sans Frontieres, Khayelitsha, Cape Town, South Africa. Western Cape Province Department of Health, Cape Town, South Africa South Africa. Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa. Medecins Sans Frontieres, Khayelitsha, Cape Town, South Africa. Medecins Sans Frontieres, Khayelitsha, Cape Town, South Africa.'
p27399
sS'JT'
p27400
S'The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease'
p27401
sS'IP'
p27402
S'4'
sS'IS'
p27403
S'1815-7920 (Electronic) 1027-3719 (Linking)'
p27404
sS'DCOM'
p27405
S'20141124'
p27406
sS'DA'
p27407
S'20140327'
p27408
sS'AU'
p27409
(lp27410
S'Cox H'
p27411
aS'Hughes J'
p27412
aS'Daniels J'
p27413
aS'Azevedo V'
p27414
aS'McDermid C'
p27415
aS'Poolman M'
p27416
aS'Boulle A'
p27417
aS'Goemaere E'
p27418
aS'van Cutsem G'
p27419
asS'AID'
p27420
(lp27421
S'10.5588/ijtld.13.0742 [doi]'
p27422
asS'CRDT'
p27423
(lp27424
S'2014/03/28 06:00'
p27425
asS'VI'
p27426
S'18'
p27427
sS'PMID'
p27428
S'24670700'
p27429
sS'DP'
p27430
S'2014 Apr'
p27431
sS'MHDA'
p27432
S'2014/12/15 06:00'
p27433
sS'OWN'
p27434
S'NLM'
p27435
sS'PT'
p27436
(lp27437
S'Journal Article'
p27438
aS"Research Support, Non-U.S. Gov't"
p27439
asS'LA'
p27440
(lp27441
S'eng'
p27442
asS'MH'
p27443
(lp27444
S'Adolescent'
p27445
aS'Adult'
p27446
aS'Antitubercular Agents/*therapeutic use'
p27447
aS'Coinfection'
p27448
aS'*Community Health Services'
p27449
aS'*Drug Resistance, Multiple, Bacterial'
p27450
aS'Feasibility Studies'
p27451
aS'Female'
p27452
aS'HIV Infections/epidemiology'
p27453
aS'Humans'
p27454
aS'Male'
p27455
aS'Mycobacterium tuberculosis/*drug effects/isolation & purification'
p27456
aS'Pilot Projects'
p27457
aS'Prevalence'
p27458
aS'Program Evaluation'
p27459
aS'Retrospective Studies'
p27460
aS'South Africa/epidemiology'
p27461
aS'Sputum/microbiology'
p27462
aS'Time Factors'
p27463
aS'Time-to-Treatment'
p27464
aS'Treatment Outcome'
p27465
aS'Tuberculosis, Multidrug-Resistant/diagnosis/*drug therapy/epidemiology/microbiology'
p27466
aS'Tuberculosis, Pulmonary/diagnosis/*drug therapy/microbiology/mortality'
p27467
aS'*Urban Health Services'
p27468
aS'Young Adult'
p27469
asS'FAU'
p27470
(lp27471
S'Cox, H'
p27472
aS'Hughes, J'
p27473
aS'Daniels, J'
p27474
aS'Azevedo, V'
p27475
aS'McDermid, C'
p27476
aS'Poolman, M'
p27477
aS'Boulle, A'
p27478
aS'Goemaere, E'
p27479
aS'van Cutsem, G'
p27480
asS'EDAT'
p27481
S'2014/03/29 06:00'
p27482
sS'PST'
p27483
S'ppublish'
p27484
sS'SO'
p27485
S'Int J Tuberc Lung Dis. 2014 Apr;18(4):441-8. doi: 10.5588/ijtld.13.0742.'
p27486
sS'PG'
p27487
S'441-8'
p27488
sS'TI'
p27489
S'Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa.'
p27490
sS'SB'
p27491
S'IM'
p27492
sS'RN'
p27493
(lp27494
S'0 (Antitubercular Agents)'
p27495
asS'PL'
p27496
S'France'
p27497
sS'TA'
p27498
S'Int J Tuberc Lung Dis'
p27499
stRp27500
ag2
(g3
g4
(dp27501
S'LID'
p27502
S'10.5588/ijtld.13.0184 [doi]'
p27503
sS'STAT'
p27504
S'MEDLINE'
p27505
sS'AB'
p27506
S'SETTING: Public health clinics in Cape Town, South Africa. OBJECTIVE: To examine the influence of integrated tuberculosis (TB) and human immunodeficiency virus (HIV) service delivery on mortality, TB cure and successful treatment completion and loss to follow-up of TB-HIV co-infected patients on concurrent anti-tuberculosis and antiretroviral treatment (ART). DESIGN: A survey instrument was used to measure the degree to which TB and HIV services were jointly delivered, and patient data were collected retrospectively from clinic sites and the Department of Health. Six domains measuring integrated TB and HIV service delivery were modelled to assess their relationship with patient outcomes. RESULTS: Two domains, integrated TB and ART service delivery and the delivery of TB and HIV care by one clinical team, were associated with lowered odds of death. Care by the same clinical team was also associated with reduced loss to follow-up. CONCLUSION: Overall, these findings show that the organization and delivery of health services are important factors that influence health outcomes. These findings strongly support efforts by local governments to integrate TB and ART services, and may help to alleviate concerns that restructuring of TB programs could have a negative impact on long-standing gains.'
p27507
sS'JID'
p27508
S'9706389'
p27509
sS'AD'
p27510
S'School of Medicine, Department of Population Health, Section on Value and Effectiveness, New York University, New York, New York, USA; Department of Nutrition, Food Studies, and Public Health, Steinhardt School of Culture, Education, and Human Development, New York University, New York, New York, USA. School of Public Health and Family Medicine, Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa. Department of Nutrition, Food Studies, and Public Health, Steinhardt School of Culture, Education, and Human Development, New York University, New York, New York, USA. Department of Humanities and Social Sciences, Steinhardt School of Culture, Education, and Human Development, New York University, New York, New York, USA. Department of Nutrition, Food Studies, and Public Health, Steinhardt School of Culture, Education, and Human Development, New York University, New York, New York, USA.'
p27511
sS'JT'
p27512
S'The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease'
p27513
sS'IP'
p27514
S'3'
sS'IS'
p27515
S'1815-7920 (Electronic) 1027-3719 (Linking)'
p27516
sS'DCOM'
p27517
S'20151123'
p27518
sS'DA'
p27519
S'20140327'
p27520
sS'AU'
p27521
(lp27522
S'Uyei J'
p27523
aS'Coetzee D'
p27524
aS'Macinko J'
p27525
aS'Weinberg SL'
p27526
aS'Guttmacher S'
p27527
asS'AID'
p27528
(lp27529
S'10.5588/ijtld.13.0184 [doi]'
p27530
asS'CRDT'
p27531
(lp27532
S'2014/03/28 06:00'
p27533
asS'VI'
p27534
S'18'
p27535
sS'PMID'
p27536
S'24670569'
p27537
sS'DP'
p27538
S'2014 Mar'
p27539
sS'MHDA'
p27540
S'2015/12/15 06:00'
p27541
sS'OWN'
p27542
S'NLM'
p27543
sS'PT'
p27544
(lp27545
S'Journal Article'
p27546
aS'Multicenter Study'
p27547
aS"Research Support, Non-U.S. Gov't"
p27548
asS'LA'
p27549
(lp27550
S'eng'
p27551
asS'MH'
p27552
(lp27553
S'Adult'
p27554
aS'Ambulatory Care Facilities'
p27555
aS'Anti-HIV Agents/*therapeutic use'
p27556
aS'Antitubercular Agents/*therapeutic use'
p27557
aS'*Coinfection'
p27558
aS'*Delivery of Health Care, Integrated/organization & administration'
p27559
aS'Female'
p27560
aS'HIV Infections/diagnosis/*drug therapy/mortality'
p27561
aS'Health Care Surveys'
p27562
aS'Humans'
p27563
aS'Logistic Models'
p27564
aS'Male'
p27565
aS'Multivariate Analysis'
p27566
aS'Odds Ratio'
p27567
aS'*Outcome and Process Assessment (Health Care)/organization & administration'
p27568
aS'Public Health'
p27569
aS'Retrospective Studies'
p27570
aS'Risk Factors'
p27571
aS'South Africa/epidemiology'
p27572
aS'Treatment Outcome'
p27573
aS'Tuberculosis/diagnosis/*drug therapy/mortality'
p27574
asS'FAU'
p27575
(lp27576
S'Uyei, J'
p27577
aS'Coetzee, D'
p27578
aS'Macinko, J'
p27579
aS'Weinberg, S L'
p27580
aS'Guttmacher, S'
p27581
asS'EDAT'
p27582
S'2014/03/29 06:00'
p27583
sS'PST'
p27584
S'ppublish'
p27585
sS'SO'
p27586
S'Int J Tuberc Lung Dis. 2014 Mar;18(3):315-21. doi: 10.5588/ijtld.13.0184.'
p27587
sS'PG'
p27588
S'315-21'
p27589
sS'TI'
p27590
S'The influence of integrated tuberculosis and human immunodeficiency virus service delivery on patient outcomes.'
p27591
sS'SB'
p27592
S'IM'
p27593
sS'RN'
p27594
(lp27595
S'0 (Anti-HIV Agents)'
p27596
aS'0 (Antitubercular Agents)'
p27597
asS'PL'
p27598
S'France'
p27599
sS'TA'
p27600
S'Int J Tuberc Lung Dis'
p27601
stRp27602
ag2
(g3
g4
(dp27603
S'LID'
p27604
S'10.1097/QAD.0000000000000140 [doi]'
p27605
sS'STAT'
p27606
S'MEDLINE'
p27607
sS'JT'
p27608
S'AIDS (London, England)'
p27609
sS'DA'
p27610
S'20140327'
p27611
sS'AID'
p27612
(lp27613
S'10.1097/QAD.0000000000000140 [doi]'
p27614
aS'00002030-201401280-00018 [pii]'
p27615
asS'CRDT'
p27616
(lp27617
S'2014/03/28 06:00'
p27618
asS'DP'
p27619
S'2014 Jan 28'
p27620
sS'AD'
p27621
S'aU.S. Military HIV Research Program, Global Health Programs, Walter Reed Army Institute of Research, Silver Spring bHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA cKenya Defense Forces (KDF), United States Army Medical Research Unit - Kenya (USAMRU-K), Nairobi, Kenya dKenya Medical Research Institute (KEMRI)/Walter Reed Program, South Rift Valley (SRV), US Army Medical Research Unit-Kenya (USAMRU-K), Kerich, Kenya eSouthern Highlands Walter Reed Program, Mbeya, Tanzania.'
p27622
sS'OWN'
p27623
S'NLM'
p27624
sS'PT'
p27625
(lp27626
S'Journal Article'
p27627
aS"Research Support, U.S. Gov't, Non-P.H.S."
p27628
asS'LA'
p27629
(lp27630
S'eng'
p27631
asS'FAU'
p27632
(lp27633
S'Crawford, Keith W'
p27634
aS'Njeru, Dorothy'
p27635
aS'Maswai, Jonah'
p27636
aS'Omondi, Milton'
p27637
aS'Apollo, Duncan'
p27638
aS'Kimetto, Jane'
p27639
aS'Gitonga, Lawrence'
p27640
aS'Munyao, James'
p27641
aS'Langat, Raphael'
p27642
aS'Aoko, Appolonia'
p27643
aS'Tarus, Jemutai'
p27644
aS'Khamadi, Samoel'
p27645
aS'Hamm, Tiffany E'
p27646
asS'PG'
p27647
S'442-5'
p27648
sS'TI'
p27649
S'Occurrence of etravirine/rilpivirine-specific resistance mutations selected by efavirenz and nevirapine in Kenyan patients with non-B HIV-1 subtypes failing antiretroviral therapy.'
p27650
sS'RN'
p27651
(lp27652
S'0 (Anti-HIV Agents)'
p27653
asS'PL'
p27654
S'England'
p27655
sS'TA'
p27656
S'AIDS'
p27657
sS'JID'
p27658
S'8710219'
p27659
sS'AB'
p27660
S"Resistance to efavirenz and nevirapine has not been associated with mutations at position 138 of reverse transcriptase. In an evaluation of virologic suppression rates in PEPFAR (President's Emergency Plan For AIDS Relief) clinics in Kenya among patients on first-line therapy (RV288), 63% (617/975) of randomly selected patients on antiretroviral therapy were suppressed (HIV RNA<400 copies/ml). Among those with non-nucleoside reverse transcriptase inhibitor resistance (n = 101), 14 (13.8%) had substitutions at 138 (A, G, K or Q), mutations selected only by etravirine and rilpivirine in subtype B viruses. All 14 patients received efavirenz or nevirapine, not etravirine or rilpivirine, and were predominantly subtype A1. This may be the first report of efavirenz and nevirapine selecting these mutations in these subtypes."
p27661
sS'GR'
p27662
(lp27663
S'W81XWH-11-2-0174/PEPFAR/United States'
p27664
asS'IP'
p27665
S'3'
sS'IS'
p27666
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p27667
sS'DCOM'
p27668
S'20141027'
p27669
sS'AU'
p27670
(lp27671
S'Crawford KW'
p27672
aS'Njeru D'
p27673
aS'Maswai J'
p27674
aS'Omondi M'
p27675
aS'Apollo D'
p27676
aS'Kimetto J'
p27677
aS'Gitonga L'
p27678
aS'Munyao J'
p27679
aS'Langat R'
p27680
aS'Aoko A'
p27681
aS'Tarus J'
p27682
aS'Khamadi S'
p27683
aS'Hamm TE'
p27684
asS'VI'
p27685
S'28'
p27686
sS'MHDA'
p27687
S'2014/10/28 06:00'
p27688
sS'MH'
p27689
(lp27690
S'Anti-HIV Agents/*pharmacology'
p27691
aS'Cross-Sectional Studies'
p27692
aS'*Drug Resistance, Viral'
p27693
aS'HIV Infections/drug therapy/*virology'
p27694
aS'HIV-1/*drug effects/*genetics/isolation & purification'
p27695
aS'Humans'
p27696
aS'Kenya'
p27697
aS'Molecular Sequence Data'
p27698
aS'*Mutation, Missense'
p27699
aS'Selection, Genetic'
p27700
aS'Sequence Analysis, DNA'
p27701
aS'Treatment Failure'
p27702
asS'EDAT'
p27703
S'2014/03/29 06:00'
p27704
sS'SI'
p27705
(lp27706
S'GENBANK/KF781826'
p27707
aS'GENBANK/KF781827'
p27708
aS'GENBANK/KF781828'
p27709
aS'GENBANK/KF781829'
p27710
aS'GENBANK/KF781830'
p27711
aS'GENBANK/KF781831'
p27712
aS'GENBANK/KF781832'
p27713
aS'GENBANK/KF781833'
p27714
aS'GENBANK/KF781834'
p27715
aS'GENBANK/KF781835'
p27716
aS'GENBANK/KF781836'
p27717
aS'GENBANK/KF781837'
p27718
aS'GENBANK/KF781838'
p27719
aS'GENBANK/KF781839'
p27720
aS'GENBANK/KF781840'
p27721
aS'GENBANK/KF781841'
p27722
aS'GENBANK/KF781842'
p27723
aS'GENBANK/KF781843'
p27724
aS'GENBANK/KF781844'
p27725
aS'GENBANK/KF781845'
p27726
aS'GENBANK/KF781846'
p27727
aS'GENBANK/KF781847'
p27728
aS'GENBANK/KF781848'
p27729
aS'GENBANK/KF781849'
p27730
aS'GENBANK/KF781850'
p27731
aS'GENBANK/KF781851'
p27732
aS'GENBANK/KJ764861'
p27733
aS'GENBANK/KJ764862'
p27734
asS'SO'
p27735
S'AIDS. 2014 Jan 28;28(3):442-5. doi: 10.1097/QAD.0000000000000140.'
p27736
sS'SB'
p27737
S'IM X'
p27738
sS'PMID'
p27739
S'24670527'
p27740
sS'PST'
p27741
S'ppublish'
p27742
stRp27743
ag2
(g3
g4
(dp27744
S'LID'
p27745
S'10.1179/2046905514Y.0000000119 [doi]'
p27746
sS'STAT'
p27747
S'MEDLINE'
p27748
sS'DEP'
p27749
S'20140324'
p27750
sS'DA'
p27751
S'20140729'
p27752
sS'AID'
p27753
(lp27754
S'10.1179/2046905514Y.0000000119 [doi]'
p27755
asS'CRDT'
p27756
(lp27757
S'2014/03/25 06:00'
p27758
asS'DP'
p27759
S'2014 Aug'
p27760
sS'OWN'
p27761
S'NLM'
p27762
sS'PT'
p27763
(lp27764
S'Journal Article'
p27765
asS'LA'
p27766
(lp27767
S'eng'
p27768
asS'FAU'
p27769
(lp27770
S'Smith, Sara-Jane'
p27771
aS'Nimmo, Camus'
p27772
aS'Fredlund, Victor'
p27773
aS'Moodley, Pravi'
p27774
asS'JT'
p27775
S'Paediatrics and international child health'
p27776
sS'PG'
p27777
S'203-7'
p27778
sS'TI'
p27779
S'Early infant diagnosis of HIV and fast initiation of anti-retroviral therapy in a rural African setting: how well are we doing?'
p27780
sS'RN'
p27781
(lp27782
S'0 (Anti-Retroviral Agents)'
p27783
asS'PL'
p27784
S'England'
p27785
sS'TA'
p27786
S'Paediatr Int Child Health'
p27787
sS'JID'
p27788
S'101582666'
p27789
sS'AB'
p27790
S'BACKGROUND: In South Africa, current estimates indicate that 1% of infants will be HIV PCR-positive by 2 months of age. WHO recommends early infant diagnosis (EID) and immediate initiation of antiretroviral therapy (ART) in infants who are diagnosed with HIV infection within the first year of life. AIMS: To investigate rates of EID and subsequent ART initiation in infants attending the Primary Health Care (PHC) clinics which fed Mseleni Hospital during 2012. OBJECTIVES: To measure the number of infants (<1 year of age) testing HIV PCR-positive who are currently collecting ART and those lost to follow-up. METHODS: HIV PCR test results from Mseleni Hospital in 2012 were cross-referenced with the national database (TIER.net) for ART initiation and follow-up from the National Health Laboratory Service (NHLS) database. RESULTS: 455 of 843 (54%) HIV-exposed infants (<2 months) were tested by HIV PCR, 11 of whom (2.4%) tested positive, reflecting the national prevalence. Of 897 HIV PCR tests undertaken in infants <1 year, 51 (5.7%) were positive, and 36 were included for analysis. Only 13 (36.1%) of these infants are currently collecting ART; seven (19.4%) commenced ART but were lost to follow-up, and 16 (44.5%) never started ART. CONCLUSION: 16 (44.5%) HIV PCR-positive infants in Mseleni Hospital and its feeder PHCs were not commenced on ART. This may reflect a similar problem in other rural hospitals in South Africa. Specific interventions are required to rapidly up-scale early initiation of ART in this vulnerable group of infants.'
p27791
sS'IP'
p27792
S'3'
sS'IS'
p27793
S'2046-9055 (Electronic) 2046-9047 (Linking)'
p27794
sS'DCOM'
p27795
S'20150330'
p27796
sS'AU'
p27797
(lp27798
S'Smith SJ'
p27799
aS'Nimmo C'
p27800
aS'Fredlund V'
p27801
aS'Moodley P'
p27802
asS'VI'
p27803
S'34'
p27804
sS'MHDA'
p27805
S'2015/03/31 06:00'
p27806
sS'PHST'
p27807
(lp27808
S'2014/03/24 [aheadofprint]'
p27809
asS'OTO'
p27810
(lp27811
S'NOTNLM'
p27812
asS'MH'
p27813
(lp27814
S'Anti-Retroviral Agents/*therapeutic use'
p27815
aS'Early Diagnosis'
p27816
aS'Female'
p27817
aS'HIV Infections/*diagnosis/*drug therapy'
p27818
aS'*Health Services Research'
p27819
aS'Humans'
p27820
aS'Infant'
p27821
aS'Male'
p27822
aS'Rural Population'
p27823
aS'South Africa'
p27824
asS'EDAT'
p27825
S'2014/03/25 06:00'
p27826
sS'SO'
p27827
S'Paediatr Int Child Health. 2014 Aug;34(3):203-7. doi: 10.1179/2046905514Y.0000000119. Epub 2014 Mar 24.'
p27828
sS'SB'
p27829
S'IM'
p27830
sS'PMID'
p27831
S'24655116'
p27832
sS'OT'
p27833
(lp27834
S'AIDS,'
p27835
aS'Anti-retroviral therapy,'
p27836
aS'Early infant diagnosis,'
p27837
aS'HIV,'
p27838
aS'Initiation,'
p27839
aS'PCR'
p27840
aS'Rural setting,'
p27841
asS'PST'
p27842
S'ppublish'
p27843
stRp27844
ag2
(g3
g4
(dp27845
S'LID'
p27846
S'10.1177/0956462414529098 [doi]'
p27847
sS'STAT'
p27848
S'MEDLINE'
p27849
sS'DEP'
p27850
S'20140319'
p27851
sS'CI'
p27852
(lp27853
S'(c) The Author(s) 2014 Reprints and permissions:'
p27854
aS'sagepub.co.uk/journalsPermissions.nav.'
p27855
asS'DA'
p27856
S'20141210'
p27857
sS'AID'
p27858
(lp27859
S'0956462414529098 [pii]'
p27860
aS'10.1177/0956462414529098 [doi]'
p27861
asS'CRDT'
p27862
(lp27863
S'2014/03/21 06:00'
p27864
asS'DP'
p27865
S'2015 Jan'
p27866
sS'OWN'
p27867
S'NLM'
p27868
sS'PT'
p27869
(lp27870
S'Journal Article'
p27871
aS"Research Support, Non-U.S. Gov't"
p27872
asS'LA'
p27873
(lp27874
S'eng'
p27875
asS'FAU'
p27876
(lp27877
S'Nakiwogga-Muwanga, A'
p27878
aS'Musaazi, J'
p27879
aS'Katabira, E'
p27880
aS'Worodria, W'
p27881
aS'Talisuna, S Alamo'
p27882
aS'Colebunders, R'
p27883
asS'JT'
p27884
S'International journal of STD & AIDS'
p27885
sS'PG'
p27886
S'42-7'
p27887
sS'TI'
p27888
S'Patients who return to care after tracking remain at high risk of attrition: experience from a large HIV clinic, Uganda.'
p27889
sS'RN'
p27890
(lp27891
S'0 (Anti-HIV Agents)'
p27892
asS'PL'
p27893
S'England'
p27894
sS'TA'
p27895
S'Int J STD AIDS'
p27896
sS'JID'
p27897
S'9007917'
p27898
sS'AB'
p27899
S"We determined the retention rate of patients infected with HIV who resumed care after being tracked at the Infectious Diseases Clinic (IDC) in Kampala, Uganda. Between April 2011 and September 2013, patients who missed their clinic appointment for 8-90 days were tracked, and those who returned to the clinic within 120 days were followed up. The proportion of patients retained among tracked patients, and those who resumed care before tracking started was compared. At 18 months of follow up, 33 (39%) of the tracked patients and 72 (61%) of those who had resumed care before tracking started were retained in care. The most important cause of attrition among the traceable was self-transfer to another clinic (38 [73%] patients), whereas among those who resumed care before tracking was loss to follow up (LTFU) (32 [71%] patients). Tracked patients who resume care following a missed appointment are at high risk of attrition. To increase retention, antiretroviral therapy clinics need to adopt a chronic care model which takes into consideration patients' changing needs and their preference for self-management."
p27900
sS'AD'
p27901
S'Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda nakiwoalice@gmail.com. Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda. Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda. Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda. Reach Out Mbuya Parish HIV/AIDS Initiative, Kampala, Uganda. Department of Epidemiology and Social Medicine, University of Antwerp, Antwerp, Belgium Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.'
p27902
sS'IP'
p27903
S'1'
sS'IS'
p27904
S'1758-1052 (Electronic) 0956-4624 (Linking)'
p27905
sS'DCOM'
p27906
S'20150417'
p27907
sS'AU'
p27908
(lp27909
S'Nakiwogga-Muwanga A'
p27910
aS'Musaazi J'
p27911
aS'Katabira E'
p27912
aS'Worodria W'
p27913
aS'Talisuna SA'
p27914
aS'Colebunders R'
p27915
asS'VI'
p27916
S'26'
p27917
sS'MHDA'
p27918
S'2015/04/18 06:00'
p27919
sS'PHST'
p27920
(lp27921
S'2014/03/19 [aheadofprint]'
p27922
asS'OTO'
p27923
(lp27924
S'NOTNLM'
p27925
asS'MH'
p27926
(lp27927
S'Adult'
p27928
aS'Ambulatory Care Facilities'
p27929
aS'Anti-HIV Agents/*therapeutic use'
p27930
aS'Antiretroviral Therapy, Highly Active'
p27931
aS'Appointments and Schedules'
p27932
aS'CD4 Lymphocyte Count'
p27933
aS'Continuity of Patient Care/*organization & administration'
p27934
aS'Female'
p27935
aS'Follow-Up Studies'
p27936
aS'HIV Infections/*drug therapy/psychology'
p27937
aS'Humans'
p27938
aS'*Lost to Follow-Up'
p27939
aS'Male'
p27940
aS'Middle Aged'
p27941
aS'Patient Compliance/psychology/*statistics & numerical data'
p27942
aS'Patient Dropouts/psychology/*statistics & numerical data'
p27943
aS'Socioeconomic Factors'
p27944
aS'Time Factors'
p27945
aS'Treatment Outcome'
p27946
aS'Treatment Refusal'
p27947
asS'EDAT'
p27948
S'2014/03/22 06:00'
p27949
sS'SO'
p27950
S'Int J STD AIDS. 2015 Jan;26(1):42-7. doi: 10.1177/0956462414529098. Epub 2014 Mar 19.'
p27951
sS'SB'
p27952
S'IM X'
p27953
sS'PMID'
p27954
S'24648320'
p27955
sS'OT'
p27956
(lp27957
S'AIDS'
p27958
aS'HIV'
p27959
aS'Uganda'
p27960
aS'antiretroviral therapy'
p27961
aS'loss to follow up'
p27962
aS'missed appointment'
p27963
aS"patients' retention"
p27964
aS'resource-limited setting'
p27965
aS'resuming care'
p27966
aS'risk of attrition'
p27967
aS'tracking'
p27968
aS'treatment'
p27969
asS'PST'
p27970
S'ppublish'
p27971
stRp27972
ag2
(g3
g4
(dp27973
S'LID'
p27974
S'10.1371/journal.pone.0089764 [doi]'
p27975
sS'STAT'
p27976
S'MEDLINE'
p27977
sS'DEP'
p27978
S'20140319'
p27979
sS'DA'
p27980
S'20140320'
p27981
sS'AID'
p27982
(lp27983
S'10.1371/journal.pone.0089764 [doi]'
p27984
aS'PONE-D-13-23971 [pii]'
p27985
asS'CRDT'
p27986
(lp27987
S'2014/03/21 06:00'
p27988
asS'DP'
p27989
S'2014'
p27990
sS'AD'
p27991
S'Institute for Global Health, University of Southern California, Los Angeles, California, United States of America; MRC Tropical Epidemiology Group, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom; University of Nairobi Institute for Tropical and Infectious Diseases, Nairobi, Kenya. Clinical Research Department, London School of Hygiene & Tropical Medicine, London, United Kingdom. MRC Tropical Epidemiology Group, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom. Institute for International Health & Development, Queen Margaret University, Edinburgh, United Kingdom. Clinical Research Department, London School of Hygiene & Tropical Medicine, London, United Kingdom; Mwanza Intervention Trials Unit, National Institute for Medical Research, Mwanza, Tanzania. University of Nairobi Institute for Tropical and Infectious Diseases, Nairobi, Kenya. University of Nairobi Institute for Tropical and Infectious Diseases, Nairobi, Kenya; Department of Obstetrics and Gynaecology, University of Nairobi, Nairobi, Kenya. MRC Tropical Epidemiology Group, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.'
p27992
sS'OWN'
p27993
S'NLM'
p27994
sS'PT'
p27995
(lp27996
S'Journal Article'
p27997
aS"Research Support, Non-U.S. Gov't"
p27998
asS'LA'
p27999
(lp28000
S'eng'
p28001
asS'FAU'
p28002
(lp28003
S'Ferguson, Laura'
p28004
aS'Grant, Alison D'
p28005
aS'Lewis, James'
p28006
aS'Kielmann, Karina'
p28007
aS'Watson-Jones, Deborah'
p28008
aS'Vusha, Sophie'
p28009
aS"Ong'ech, John O"
p28010
aS'Ross, David A'
p28011
asS'JT'
p28012
S'PloS one'
p28013
sS'LR'
p28014
S'20151119'
p28015
sS'PG'
p28016
S'e89764'
p28017
sS'TI'
p28018
S'Linking women who test HIV-positive in pregnancy-related services to HIV care and treatment services in Kenya: a mixed methods prospective cohort study.'
p28019
sS'RN'
p28020
(lp28021
S'0 (Anti-HIV Agents)'
p28022
asS'PL'
p28023
S'United States'
p28024
sS'TA'
p28025
S'PLoS One'
p28026
sS'JID'
p28027
S'101285081'
p28028
sS'AB'
p28029
S"INTRODUCTION: There has been insufficient attention to long-term care and treatment for pregnant women diagnosed with HIV. OBJECTIVE AND METHODS: This prospective cohort study of 100 HIV-positive women recruited within pregnancy-related services in a district hospital in Kenya employed quantitative methods to assess attrition between women testing HIV-positive in pregnancy-related services and accessing long-term HIV care and treatment services. Qualitative methods were used to explore barriers and facilitators to navigating these services. Structured questionnaires were administered to cohort participants at enrolment and 90+ days later. Participants' medical records were monitored prospectively. Semi-structured qualitative interviews were carried out with a sub-set of 19 participants. FINDINGS: Only 53/100 (53%) women registered at an HIV clinic within 90 days of HIV diagnosis, of whom 27/53 (51%) had a CD4 count result in their file. 11/27 (41%) women were eligible for immediate antiretroviral therapy (ART); only 6/11 (55%) started ART during study follow-up. In multivariable logistic regression analysis, factors associated with registration at the HIV clinic within 90 days of HIV diagnosis were: having cared for someone with HIV (aOR:3.67(95%CI:1.22, 11.09)), not having to pay for transport to the hospital (aOR:2.73(95%CI:1.09, 6.84)), and having received enough information to decide to have an HIV test (aOR:3.61(95%CI:0.83, 15.71)). Qualitative data revealed multiple factors underlying high patient drop-out related to women's social support networks (e.g. partner's attitude to HIV status), interactions with health workers (e.g. being given unclear/incorrect HIV-related information) and health services characteristics (e.g. restricted opening hours, long waiting times). CONCLUSION: HIV testing within pregnancy-related services is an important entry point to HIV care and treatment services, but few women successfully completed the steps needed for assessment of their treatment needs within three months of diagnosis. Programmatic recommendations include simplified pathways to care, better-tailored counselling, integration of ART into antenatal services, and facilitation of social support."
p28030
sS'GR'
p28031
(lp28032
S'MR/K012126/1/Medical Research Council/United Kingdom'
p28033
aS'Medical Research Council/United Kingdom'
p28034
asS'IP'
p28035
S'3'
sS'IS'
p28036
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p28037
sS'PMC'
p28038
S'PMC3960101'
p28039
sS'DCOM'
p28040
S'20141223'
p28041
sS'AU'
p28042
(lp28043
S'Ferguson L'
p28044
aS'Grant AD'
p28045
aS'Lewis J'
p28046
aS'Kielmann K'
p28047
aS'Watson-Jones D'
p28048
aS'Vusha S'
p28049
aS"Ong'ech JO"
p28050
aS'Ross DA'
p28051
asS'VI'
p28052
S'9'
sS'MHDA'
p28053
S'2014/12/24 06:00'
p28054
sS'PHST'
p28055
(lp28056
S'2014 [ecollection]'
p28057
aS'2013/06/09 [received]'
p28058
aS'2014/01/25 [accepted]'
p28059
aS'2014/03/19 [epublish]'
p28060
asS'OID'
p28061
(lp28062
S'NLM: PMC3960101'
p28063
asS'MH'
p28064
(lp28065
S'Adolescent'
p28066
aS'Adult'
p28067
aS'Anti-HIV Agents/therapeutic use'
p28068
aS'Counseling'
p28069
aS'Delivery of Health Care/organization & administration'
p28070
aS'Female'
p28071
aS'HIV Infections/diagnosis/drug therapy/*psychology'
p28072
aS'Health Services Needs and Demand/*utilization'
p28073
aS'Humans'
p28074
aS'Kenya'
p28075
aS'Long-Term Care/organization & administration'
p28076
aS'Patient Acceptance of Health Care/psychology/*statistics & numerical data'
p28077
aS'Pregnancy'
p28078
aS'Prospective Studies'
p28079
aS'Surveys and Questionnaires'
p28080
asS'EDAT'
p28081
S'2014/03/22 06:00'
p28082
sS'SO'
p28083
S'PLoS One. 2014 Mar 19;9(3):e89764. doi: 10.1371/journal.pone.0089764. eCollection 2014.'
p28084
sS'SB'
p28085
S'IM'
p28086
sS'PMID'
p28087
S'24646492'
p28088
sS'PST'
p28089
S'epublish'
p28090
stRp28091
ag2
(g3
g4
(dp28092
S'LID'
p28093
S'10.1111/bjd.12721 [doi]'
p28094
sS'STAT'
p28095
S'MEDLINE'
p28096
sS'JT'
p28097
S'The British journal of dermatology'
p28098
sS'CI'
p28099
(lp28100
S'(c) 2013 British Association of Dermatologists.'
p28101
asS'DA'
p28102
S'20140416'
p28103
sS'AID'
p28104
(lp28105
S'10.1111/bjd.12721 [doi]'
p28106
asS'CRDT'
p28107
(lp28108
S'2014/03/20 06:00'
p28109
asS'DP'
p28110
S'2014 Apr'
p28111
sS'AD'
p28112
S'Department of Dermatology, Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Birmingham, B15 2WB, U.K.'
p28113
sS'OWN'
p28114
S'NLM'
p28115
sS'PT'
p28116
(lp28117
S'Journal Article'
p28118
aS'Research Support, N.I.H., Extramural'
p28119
aS"Research Support, Non-U.S. Gov't"
p28120
asS'LA'
p28121
(lp28122
S'eng'
p28123
asS'FAU'
p28124
(lp28125
S'Chua, S L'
p28126
aS'Amerson, E H'
p28127
aS'Leslie, K S'
p28128
aS'McCalmont, T H'
p28129
aS'Leboit, P E'
p28130
aS'Martin, J N'
p28131
aS'Bangsberg, D'
p28132
aS'Maurer, T A'
p28133
asS'LR'
p28134
S'20150401'
p28135
sS'PG'
p28136
S'832-9'
p28137
sS'TI'
p28138
S'Factors associated with pruritic papular eruption of human immunodeficiency virus infection in the antiretroviral therapy era.'
p28139
sS'RN'
p28140
(lp28141
S'0 (Anti-HIV Agents)'
p28142
aS'0 (RNA, Viral)'
p28143
asS'PL'
p28144
S'England'
p28145
sS'TA'
p28146
S'Br J Dermatol'
p28147
sS'JID'
p28148
S'0004041'
p28149
sS'AB'
p28150
S'BACKGROUND: Pruritic papular eruption (PPE) of HIV is common in HIV-infected populations living in the tropics. Its aetiology has been attributed to insect bite reactions and it is reported to improve with antiretroviral therapy (ART). Its presence after at least 6 months of ART has been proposed as one of several markers of treatment failure. OBJECTIVES: To determine factors associated with PPE in HIV-infected persons receiving ART. METHODS: A case-control study nested within a 500-person cohort from a teaching hospital in Mbarara, Uganda. Forty-five cases and 90 controls were enrolled. Cases had received ART for >/= 15 months and had an itchy papular rash for at least 1 month with microscopic correlation by skin biopsy. Each case was individually matched with two controls for age, sex and ART duration. RESULTS: Twenty-five of 45 cases (56%) had microscopic findings consistent with PPE. At skin examination and biopsy (study enrolment), a similar proportion of PPE cases and matched controls had plasma HIV RNA < 400 copies mL(-1) (96% vs. 85%, P = 0.31). The odds of having PPE increased fourfold with every log increase in viral load at ART initiation (P = 0.02) but not at study enrolment. CD4 counts at ART initiation and study enrolment, and CD4 gains and CD8(+) T-cell activation measured 6 and 12 months after ART commencement were not associated with PPE. Study participants who reported daily insect bites had greater odds of being cases [odds ratio (OR) 8.3, P < 0.001] or PPE cases (OR 8.6, P = 0.01). CONCLUSIONS: Pruritic papular eruption in HIV-infected persons receiving ART for >/= 15 months was associated with greater HIV viraemia at ART commencement, independent of CD4 count. Skin biopsies are important to distinguish between PPE and other itchy papular eruptions.'
p28151
sS'GR'
p28152
(lp28153
S'K24 MH087227/MH/NIMH NIH HHS/United States'
p28154
aS'K24 MH87227/MH/NIMH NIH HHS/United States'
p28155
aS'P30 AI027763/AI/NIAID NIH HHS/United States'
p28156
aS'P30 AI027763/AI/NIAID NIH HHS/United States'
p28157
aS'R01 MH054907/MH/NIMH NIH HHS/United States'
p28158
aS'R01 MH054907/MH/NIMH NIH HHS/United States'
p28159
asS'IP'
p28160
S'4'
sS'IS'
p28161
S'1365-2133 (Electronic) 0007-0963 (Linking)'
p28162
sS'PMC'
p28163
S'PMC4217043'
p28164
sS'DCOM'
p28165
S'20150528'
p28166
sS'MID'
p28167
(lp28168
S'NIHMS541342'
p28169
asS'AU'
p28170
(lp28171
S'Chua SL'
p28172
aS'Amerson EH'
p28173
aS'Leslie KS'
p28174
aS'McCalmont TH'
p28175
aS'Leboit PE'
p28176
aS'Martin JN'
p28177
aS'Bangsberg D'
p28178
aS'Maurer TA'
p28179
asS'VI'
p28180
S'170'
p28181
sS'MHDA'
p28182
S'2015/05/29 06:00'
p28183
sS'PHST'
p28184
(lp28185
S'2013/11/02 [accepted]'
p28186
asS'OID'
p28187
(lp28188
S'NLM: NIHMS541342'
p28189
aS'NLM: PMC4217043'
p28190
asS'MH'
p28191
(lp28192
S'Adult'
p28193
aS'Anti-HIV Agents/*therapeutic use'
p28194
aS'Bites and Stings/complications'
p28195
aS'CD4 Lymphocyte Count'
p28196
aS'Case-Control Studies'
p28197
aS'Female'
p28198
aS'HIV Infections/complications/*drug therapy'
p28199
aS'Humans'
p28200
aS'Male'
p28201
aS'Pruritus/*etiology'
p28202
aS'RNA, Viral/metabolism'
p28203
aS'Risk Factors'
p28204
aS'Socioeconomic Factors'
p28205
asS'EDAT'
p28206
S'2014/03/20 06:00'
p28207
sS'SO'
p28208
S'Br J Dermatol. 2014 Apr;170(4):832-9. doi: 10.1111/bjd.12721.'
p28209
sS'SB'
p28210
S'IM'
p28211
sS'PMID'
p28212
S'24641299'
p28213
sS'PST'
p28214
S'ppublish'
p28215
stRp28216
ag2
(g3
g4
(dp28217
S'LID'
p28218
S'10.1093/jac/dku052 [doi]'
p28219
sS'STAT'
p28220
S'MEDLINE'
p28221
sS'DEP'
p28222
S'20140314'
p28223
sS'CI'
p28224
(lp28225
S'(c) The Author 2014. Published by Oxford University Press on behalf of the'
p28226
aS'British Society for Antimicrobial Chemotherapy.'
p28227
asS'DA'
p28228
S'20140620'
p28229
sS'AID'
p28230
(lp28231
S'dku052 [pii]'
p28232
aS'10.1093/jac/dku052 [doi]'
p28233
asS'CRDT'
p28234
(lp28235
S'2014/03/18 06:00'
p28236
asS'DP'
p28237
S'2014 Jul'
p28238
sS'GR'
p28239
(lp28240
S'MC_U950080931/Medical Research Council/United Kingdom'
p28241
aS'MC_U950080938/Medical Research Council/United Kingdom'
p28242
aS'Medical Research Council/United Kingdom'
p28243
asS'OWN'
p28244
S'NLM'
p28245
sS'PT'
p28246
(lp28247
S'Journal Article'
p28248
aS'Randomized Controlled Trial'
p28249
aS"Research Support, Non-U.S. Gov't"
p28250
asS'LA'
p28251
(lp28252
S'eng'
p28253
asS'FAU'
p28254
(lp28255
S'Goodall, R L'
p28256
aS'Dunn, D T'
p28257
aS'Pattery, T'
p28258
aS'van Cauwenberge, A'
p28259
aS'Nkurunziza, P'
p28260
aS'Awio, P'
p28261
aS'Ndembi, N'
p28262
aS'Munderi, P'
p28263
aS'Kityo, C'
p28264
aS'Gilks, C F'
p28265
aS'Kaleebu, P'
p28266
aS'Pillay, D'
p28267
asS'JT'
p28268
S'The Journal of antimicrobial chemotherapy'
p28269
sS'LR'
p28270
S'20151119'
p28271
sS'PG'
p28272
S'1938-44'
p28273
sS'TI'
p28274
S'Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda.'
p28275
sS'RN'
p28276
(lp28277
S'0 (Anti-HIV Agents)'
p28278
aS'0 (Organophosphonates)'
p28279
aS'4B9XT59T7S (Zidovudine)'
p28280
aS'99YXE507IL (Tenofovir)'
p28281
aS'EC 2.7.7.- (reverse transcriptase, Human immunodeficiency virus 1)'
p28282
aS'EC 2.7.7.49 (HIV Reverse Transcriptase)'
p28283
aS'JAC85A2161 (Adenine)'
p28284
asS'PL'
p28285
S'England'
p28286
sS'TA'
p28287
S'J Antimicrob Chemother'
p28288
sS'FIR'
p28289
(lp28290
S'Kaleebu, P'
p28291
aS'Pillay, D'
p28292
aS'Awio, P'
p28293
aS'Chirara, M'
p28294
aS'Dunn, D'
p28295
aS'Gibb, D M'
p28296
aS'Gilks, C'
p28297
aS'Goodall, R'
p28298
aS'Kapaata, A'
p28299
aS'Katuramur, M'
p28300
aS'Lyagoba, F'
p28301
aS'Magala, R'
p28302
aS'Magambo, B'
p28303
aS'Mataruka, K'
p28304
aS'McCormick, A'
p28305
aS'Mugarura, L'
p28306
aS'Musunga, T'
p28307
aS'Nabankkema, M'
p28308
aS'Nkalubo, J'
p28309
aS'Nkurunziza, P'
p28310
aS'Parry, C'
p28311
aS'Robertson, V'
p28312
aS'Spyer, M'
p28313
aS'Yirrell, D'
p28314
aS'Grosskurth, H'
p28315
aS'Munderi, P'
p28316
aS'Kabuye, G'
p28317
aS'Nsibambi, D'
p28318
aS'Kasirye, R'
p28319
aS'Zalwango, E'
p28320
aS'Nakazibwe, M'
p28321
aS'Kikaire, B'
p28322
aS'Nassuna, G'
p28323
aS'Massa, R'
p28324
aS'Fadhiru, K'
p28325
aS'Namyalo, M'
p28326
aS'Zalwango, A'
p28327
aS'Generous, L'
p28328
aS'Khauka, P'
p28329
aS'Rutikarayo, N'
p28330
aS'Nakahima, W'
p28331
aS'Mugisha, A'
p28332
aS'Todd, J'
p28333
aS'Levin, J'
p28334
aS'Muyingo, S'
p28335
aS'Ruberantwari, A'
p28336
aS'Kaleebu, P'
p28337
aS'Yirrell, D'
p28338
aS'Ndembi, N'
p28339
aS'Lyagoba, F'
p28340
aS'Hughes, P'
p28341
aS'Aber, M'
p28342
aS'Medina Lara, A'
p28343
aS'Foster, S'
p28344
aS'Amurwon, J'
p28345
aS'Nyanzi Wakholi, B'
p28346
aS'Mugyenyi, P'
p28347
aS'Kityo, C'
p28348
aS'Ssali, F'
p28349
aS'Tumukunde, D'
p28350
aS'Otim, T'
p28351
aS'Kabanda, J'
p28352
aS'Musana, H'
p28353
aS'Akao, J'
p28354
aS'Kyomugisha, H'
p28355
aS'Byamukama, A'
p28356
aS'Sabiiti, J'
p28357
aS'Komugyena, J'
p28358
aS'Wavamunno, P'
p28359
aS'Mukiibi, S'
p28360
aS'Drasiku, A'
p28361
aS'Byaruhanga, R'
p28362
aS'Labeja, O'
p28363
aS'Katundu, P'
p28364
aS'Tugume, S'
p28365
aS'Awio, P'
p28366
aS'Namazzi, A'
p28367
aS'Bakeinyaga, G T'
p28368
aS'Katabira, H'
p28369
aS'Abaine, D'
p28370
aS'Tukamushaba, J'
p28371
aS'Anywar, W'
p28372
aS'Ojiambo, W'
p28373
aS'Angweng, E'
p28374
aS'Murungi, S'
p28375
aS'Haguma, W'
p28376
aS'Atwiine, S'
p28377
aS'Kigozi, J'
p28378
aS'Latif, A'
p28379
aS'Hakim, J'
p28380
aS'Robertson, V'
p28381
aS'Reid, A'
p28382
aS'Chidziva, E'
p28383
aS'Bulaya-Tembo, R'
p28384
aS'Musoro, G'
p28385
aS'Taziwa, F'
p28386
aS'Chimbetete, C'
p28387
aS'Chakonza, L'
p28388
aS'Mawora, A'
p28389
aS'Muvirimi, C'
p28390
aS'Tinago, G'
p28391
aS'Svovanapasis, P'
p28392
aS'Simango, M'
p28393
aS'Chirema, O'
p28394
aS'Machingura, J'
p28395
aS'Mutsai, S'
p28396
aS'Phiri, M'
p28397
aS'Bafana, T'
p28398
aS'Chirara, M'
p28399
aS'Muchabaiwa, L'
p28400
aS'Muzambi, M'
p28401
aS'Katabira, E'
p28402
aS'Ronald, A'
p28403
aS'Kambungu, A'
p28404
aS'Lutwama, F'
p28405
aS'Nanfuka, A'
p28406
aS'Walusimbi, J'
p28407
aS'Nabankema, E'
p28408
aS'Nalumenya, R'
p28409
aS'Namuli, T'
p28410
aS'Kulume, R'
p28411
aS'Namata, I'
p28412
aS'Nyachwo, L'
p28413
aS'Florence, A'
p28414
aS'Kusiima, A'
p28415
aS'Lubwama, E'
p28416
aS'Nairuba, R'
p28417
aS'Oketta, F'
p28418
aS'Buluma, E'
p28419
aS'Waita, R'
p28420
aS'Ojiambo, H'
p28421
aS'Sadik, F'
p28422
aS'Wanyama, J'
p28423
aS'Nabongo, P'
p28424
asS'JID'
p28425
S'7513617'
p28426
sS'AB'
p28427
S'OBJECTIVES: We investigated phenotypic and genotypic resistance after 2 years of first-line therapy with two HIV treatment regimens in the absence of virological monitoring. METHODS: NORA [Nevirapine OR Abacavir study, a sub-study of the Development of AntiRetroviral Therapy in Africa (DART) trial] randomized 600 symptomatic HIV-infected Ugandan adults (CD4 cell count <200 cells/mm(3)) to receive zidovudine/lamivudine plus abacavir (cABC arm) or nevirapine (cNVP arm). All virological tests were performed retrospectively, including resistance tests on week 96 plasma samples with HIV RNA levels >/=1000 copies/mL. Phenotypic resistance was expressed as fold-change in IC(50) (FC) relative to wild-type virus. RESULTS: HIV-1 RNA viral load >/=1000 copies/mL at week 96 was seen in 58/204 (28.4%) cABC participants and 21/159 (13.2%) cNVP participants. Resistance results were available in 35 cABC and 17 cNVP participants; 31 (89%) cABC and 16 (94%) cNVP isolates had a week 96 FC below the biological cut-off for tenofovir (2.2). In the cNVP arm, 16/17 participants had resistance mutations synonymous with high-level resistance to nevirapine and efavirenz; FC values for etravirine were above the biological cut-off in 9 (53%) isolates. In multivariate regression models, K65R, Y115F and the presence of thymidine analogue-associated mutations were associated with increased susceptibility to etravirine in the cABC arm. CONCLUSIONS: Our data support the use of tenofovir following failure of a first-line zidovudine-containing regimen and shed further light on non-nucleoside reverse transcriptase inhibitor hypersusceptibility.'
p28428
sS'AD'
p28429
S'MRC Clinical Trials Unit, London, UK r.goodall@ctu.mrc.ac.uk. MRC Clinical Trials Unit, London, UK. Virco BVBA, Beerse, Belgium. Virco BVBA, Beerse, Belgium. MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda. Joint Clinical Research Centre, Kampala, Uganda. Institute of Human Virology, Abuja, Nigeria. MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda. Joint Clinical Research Centre, Kampala, Uganda. School of Population Health, University of Queensland, Brisbane, Australia. MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda. Department of Infection, University College London, London, UK Centres for Infection, Public Health England, Colindale, UK.'
p28430
sS'CN'
p28431
(lp28432
S'DART Virology Group and Trial Teams'
p28433
asS'IP'
p28434
S'7'
sS'IS'
p28435
S'1460-2091 (Electronic) 0305-7453 (Linking)'
p28436
sS'IR'
p28437
(lp28438
S'Kaleebu P'
p28439
aS'Pillay D'
p28440
aS'Awio P'
p28441
aS'Chirara M'
p28442
aS'Dunn D'
p28443
aS'Gibb DM'
p28444
aS'Gilks C'
p28445
aS'Goodall R'
p28446
aS'Kapaata A'
p28447
aS'Katuramur M'
p28448
aS'Lyagoba F'
p28449
aS'Magala R'
p28450
aS'Magambo B'
p28451
aS'Mataruka K'
p28452
aS'McCormick A'
p28453
aS'Mugarura L'
p28454
aS'Musunga T'
p28455
aS'Nabankkema M'
p28456
aS'Nkalubo J'
p28457
aS'Nkurunziza P'
p28458
aS'Parry C'
p28459
aS'Robertson V'
p28460
aS'Spyer M'
p28461
aS'Yirrell D'
p28462
aS'Grosskurth H'
p28463
aS'Munderi P'
p28464
aS'Kabuye G'
p28465
aS'Nsibambi D'
p28466
aS'Kasirye R'
p28467
aS'Zalwango E'
p28468
aS'Nakazibwe M'
p28469
aS'Kikaire B'
p28470
aS'Nassuna G'
p28471
aS'Massa R'
p28472
aS'Fadhiru K'
p28473
aS'Namyalo M'
p28474
aS'Zalwango A'
p28475
aS'Generous L'
p28476
aS'Khauka P'
p28477
aS'Rutikarayo N'
p28478
aS'Nakahima W'
p28479
aS'Mugisha A'
p28480
aS'Todd J'
p28481
aS'Levin J'
p28482
aS'Muyingo S'
p28483
aS'Ruberantwari A'
p28484
aS'Kaleebu P'
p28485
aS'Yirrell D'
p28486
aS'Ndembi N'
p28487
aS'Lyagoba F'
p28488
aS'Hughes P'
p28489
aS'Aber M'
p28490
aS'Medina Lara A'
p28491
aS'Foster S'
p28492
aS'Amurwon J'
p28493
aS'Nyanzi Wakholi B'
p28494
aS'Mugyenyi P'
p28495
aS'Kityo C'
p28496
aS'Ssali F'
p28497
aS'Tumukunde D'
p28498
aS'Otim T'
p28499
aS'Kabanda J'
p28500
aS'Musana H'
p28501
aS'Akao J'
p28502
aS'Kyomugisha H'
p28503
aS'Byamukama A'
p28504
aS'Sabiiti J'
p28505
aS'Komugyena J'
p28506
aS'Wavamunno P'
p28507
aS'Mukiibi S'
p28508
aS'Drasiku A'
p28509
aS'Byaruhanga R'
p28510
aS'Labeja O'
p28511
aS'Katundu P'
p28512
aS'Tugume S'
p28513
aS'Awio P'
p28514
aS'Namazzi A'
p28515
aS'Bakeinyaga GT'
p28516
aS'Katabira H'
p28517
aS'Abaine D'
p28518
aS'Tukamushaba J'
p28519
aS'Anywar W'
p28520
aS'Ojiambo W'
p28521
aS'Angweng E'
p28522
aS'Murungi S'
p28523
aS'Haguma W'
p28524
aS'Atwiine S'
p28525
aS'Kigozi J'
p28526
aS'Latif A'
p28527
aS'Hakim J'
p28528
aS'Robertson V'
p28529
aS'Reid A'
p28530
aS'Chidziva E'
p28531
aS'Bulaya-Tembo R'
p28532
aS'Musoro G'
p28533
aS'Taziwa F'
p28534
aS'Chimbetete C'
p28535
aS'Chakonza L'
p28536
aS'Mawora A'
p28537
aS'Muvirimi C'
p28538
aS'Tinago G'
p28539
aS'Svovanapasis P'
p28540
aS'Simango M'
p28541
aS'Chirema O'
p28542
aS'Machingura J'
p28543
aS'Mutsai S'
p28544
aS'Phiri M'
p28545
aS'Bafana T'
p28546
aS'Chirara M'
p28547
aS'Muchabaiwa L'
p28548
aS'Muzambi M'
p28549
aS'Katabira E'
p28550
aS'Ronald A'
p28551
aS'Kambungu A'
p28552
aS'Lutwama F'
p28553
aS'Nanfuka A'
p28554
aS'Walusimbi J'
p28555
aS'Nabankema E'
p28556
aS'Nalumenya R'
p28557
aS'Namuli T'
p28558
aS'Kulume R'
p28559
aS'Namata I'
p28560
aS'Nyachwo L'
p28561
aS'Florence A'
p28562
aS'Kusiima A'
p28563
aS'Lubwama E'
p28564
aS'Nairuba R'
p28565
aS'Oketta F'
p28566
aS'Buluma E'
p28567
aS'Waita R'
p28568
aS'Ojiambo H'
p28569
aS'Sadik F'
p28570
aS'Wanyama J'
p28571
aS'Nabongo P'
p28572
asS'DCOM'
p28573
S'20150202'
p28574
sS'AU'
p28575
(lp28576
S'Goodall RL'
p28577
aS'Dunn DT'
p28578
aS'Pattery T'
p28579
aS'van Cauwenberge A'
p28580
aS'Nkurunziza P'
p28581
aS'Awio P'
p28582
aS'Ndembi N'
p28583
aS'Munderi P'
p28584
aS'Kityo C'
p28585
aS'Gilks CF'
p28586
aS'Kaleebu P'
p28587
aS'Pillay D'
p28588
asS'VI'
p28589
S'69'
p28590
sS'MHDA'
p28591
S'2015/02/03 06:00'
p28592
sS'PHST'
p28593
(lp28594
S'2014/03/14 [aheadofprint]'
p28595
asS'OTO'
p28596
(lp28597
S'NOTNLM'
p28598
asS'OID'
p28599
(lp28600
S'NLM: PMC4054985'
p28601
asS'MH'
p28602
(lp28603
S'Adenine/analogs & derivatives/pharmacology/therapeutic use'
p28604
aS'Adult'
p28605
aS'Anti-HIV Agents/pharmacology/*therapeutic use'
p28606
aS'Antiretroviral Therapy, Highly Active/methods'
p28607
aS'*Drug Resistance, Viral'
p28608
aS'HIV Infections/*drug therapy/*virology'
p28609
aS'HIV Reverse Transcriptase/*genetics'
p28610
aS'HIV-1/*drug effects/*genetics/isolation & purification'
p28611
aS'Humans'
p28612
aS'Inhibitory Concentration 50'
p28613
aS'Microbial Sensitivity Tests'
p28614
aS'Organophosphonates/pharmacology/therapeutic use'
p28615
aS'Tenofovir'
p28616
aS'Uganda'
p28617
aS'Zidovudine/pharmacology/therapeutic use'
p28618
asS'EDAT'
p28619
S'2014/03/19 06:00'
p28620
sS'PMC'
p28621
S'PMC4054985'
p28622
sS'SO'
p28623
S'J Antimicrob Chemother. 2014 Jul;69(7):1938-44. doi: 10.1093/jac/dku052. Epub 2014 Mar 14.'
p28624
sS'SB'
p28625
S'IM'
p28626
sS'PMID'
p28627
S'24633208'
p28628
sS'OT'
p28629
(lp28630
S'Africa'
p28631
aS'hypersusceptibility'
p28632
aS'resistance'
p28633
asS'PST'
p28634
S'ppublish'
p28635
stRp28636
ag2
(g3
g4
(dp28637
S'LID'
p28638
S'10.1111/nyas.12380 [doi]'
p28639
sS'STAT'
p28640
S'MEDLINE'
p28641
sS'DEP'
p28642
S'20140314'
p28643
sS'CI'
p28644
(lp28645
S'(c) 2014 New York Academy of Sciences.'
p28646
asS'DA'
p28647
S'20140908'
p28648
sS'AID'
p28649
(lp28650
S'10.1111/nyas.12380 [doi]'
p28651
asS'CRDT'
p28652
(lp28653
S'2014/03/18 06:00'
p28654
asS'DP'
p28655
S'2014 Sep'
p28656
sS'AD'
p28657
S'Centre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya; Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom.'
p28658
sS'OWN'
p28659
S'NLM'
p28660
sS'PT'
p28661
(lp28662
S'Journal Article'
p28663
aS'Research Support, N.I.H., Extramural'
p28664
aS"Research Support, Non-U.S. Gov't"
p28665
aS'Review'
p28666
asS'LA'
p28667
(lp28668
S'eng'
p28669
asS'DCOM'
p28670
S'20141027'
p28671
sS'JT'
p28672
S'Annals of the New York Academy of Sciences'
p28673
sS'LR'
p28674
S'20160713'
p28675
sS'FAU'
p28676
(lp28677
S'Kariuki, Samuel'
p28678
aS'Dougan, Gordon'
p28679
asS'TI'
p28680
S'Antibacterial resistance in sub-Saharan Africa: an underestimated emergency.'
p28681
sS'RN'
p28682
(lp28683
S'0 (Anti-Bacterial Agents)'
p28684
asS'PL'
p28685
S'United States'
p28686
sS'PG'
p28687
S'43-55'
p28688
sS'JID'
p28689
S'7506858'
p28690
sS'AB'
p28691
S'Antibacterial resistance-associated infections are known to increase morbidity, mortality, and cost of treatment, and to potentially put others in the community at higher risk of infections. In high-income countries, where the burden of infectious diseases is relatively modest, resistance to first-line antibacterial agents is usually overcome by use of second- and third-line agents. However, in developing countries where the burden of infectious diseases is high, patients with antibacterial-resistant infections may be unable to obtain or afford effective second-line treatments. In sub-Saharan Africa (SSA), the situation is aggravated by poor hygiene, unreliable water supplies, civil conflicts, and increasing numbers of immunocompromised people, such as those with HIV, which facilitate both the evolution of resistant pathogens and their rapid spread in the community. Because of limited capacity for disease detection and surveillance, the burden of illnesses due to treatable bacterial infections, their specific etiologies, and the awareness of antibacterial resistance are less well established in most of SSA, and therefore the ability to mitigate their consequences is significantly limited.'
p28692
sS'GR'
p28693
(lp28694
S'100891/Wellcome Trust/United Kingdom'
p28695
aS'R01 AI099525/AI/NIAID NIH HHS/United States'
p28696
aS'Wellcome Trust/United Kingdom'
p28697
asS'VI'
p28698
S'1323'
p28699
sS'IS'
p28700
S'1749-6632 (Electronic) 0077-8923 (Linking)'
p28701
sS'PMC'
p28702
S'PMC4159419'
p28703
sS'MID'
p28704
(lp28705
S'NIHMS558484'
p28706
asS'AU'
p28707
(lp28708
S'Kariuki S'
p28709
aS'Dougan G'
p28710
asS'MHDA'
p28711
S'2014/10/28 06:00'
p28712
sS'PHST'
p28713
(lp28714
S'2014/03/14 [aheadofprint]'
p28715
asS'OT'
p28716
(lp28717
S'antibacterial resistance'
p28718
aS'bacterial pathogens'
p28719
aS'sub-Saharan Africa'
p28720
asS'OTO'
p28721
(lp28722
S'NOTNLM'
p28723
asS'OID'
p28724
(lp28725
S'NLM: NIHMS558484'
p28726
aS'NLM: PMC4159419'
p28727
asS'MH'
p28728
(lp28729
S'Africa South of the Sahara/epidemiology'
p28730
aS'Anti-Bacterial Agents/*therapeutic use'
p28731
aS'Bacterial Infections/drug therapy/epidemiology'
p28732
aS'Drug Resistance, Microbial'
p28733
aS'Humans'
p28734
asS'EDAT'
p28735
S'2014/03/19 06:00'
p28736
sS'SO'
p28737
S'Ann N Y Acad Sci. 2014 Sep;1323:43-55. doi: 10.1111/nyas.12380. Epub 2014 Mar 14.'
p28738
sS'SB'
p28739
S'IM'
p28740
sS'PMID'
p28741
S'24628272'
p28742
sS'TA'
p28743
S'Ann N Y Acad Sci'
p28744
sS'PST'
p28745
S'ppublish'
p28746
stRp28747
ag2
(g3
g4
(dp28748
S'LID'
p28749
S'10.1371/journal.pone.0090614 [doi]'
p28750
sS'STAT'
p28751
S'MEDLINE'
p28752
sS'DEP'
p28753
S'20140307'
p28754
sS'DA'
p28755
S'20140310'
p28756
sS'AID'
p28757
(lp28758
S'10.1371/journal.pone.0090614 [doi]'
p28759
aS'PONE-D-13-54034 [pii]'
p28760
asS'CRDT'
p28761
(lp28762
S'2014/03/11 06:00'
p28763
asS'DP'
p28764
S'2014'
p28765
sS'AD'
p28766
S'Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda. Medical Research Council-Uganda Virus Research Institute, Uganda Research Unit on AIDS, Entebbe, Uganda; School of Public Health, University of the Witwatersrand, Johannesburg, Gauteng, South Africa. Makerere University - Boston Medical Center Research Collaboration, Kampala, Uganda. Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda. Department of Medicine, New Jersey Medical School - Rutgers University, Newark, New Jersey, United States of America. Department of Microbiology, Makerere University College of Health Sciences, Kampala, Uganda. Makerere University - Boston Medical Center Research Collaboration, Kampala, Uganda. Makerere University - Boston Medical Center Research Collaboration, Kampala, Uganda. Southeastern National Tuberculosis Center, Division of Mycobacteriology, Department of Medicine, University of Florida, Gainesville, Florida, United States of America; Makerere University - Boston Medical Center Research Collaboration, Kampala, Uganda. Medical Research Council-Uganda Virus Research Institute, Uganda Research Unit on AIDS, Entebbe, Uganda. Department of Microbiology, Makerere University College of Health Sciences, Kampala, Uganda. Medical Research Council-Uganda Virus Research Institute, Uganda Research Unit on AIDS, Entebbe, Uganda; Mulago Hospital Tuberculosis Clinic, Mulago Hospital, Kampala, Uganda. Departments of Pathology and, Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America. Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, England. Medical Research Council-Uganda Virus Research Institute, Uganda Research Unit on AIDS, Entebbe, Uganda; Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda; Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, England. Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda; Makerere University - Boston Medical Center Research Collaboration, Kampala, Uganda. MRC Tropical Epidemiology Group, London School of Hygiene & Tropical Medicine, London, England. Section of Infectious Diseases, Department of Medicine, Boston Medical Center and Boston University School of Medicine, Boston, Massachusetts, United States of America; Makerere University - Boston Medical Center Research Collaboration, Kampala, Uganda. Section of Infectious Diseases, Department of Medicine, Boston Medical Center and Boston University School of Medicine, Boston, Massachusetts, United States of America; Makerere University - Boston Medical Center Research Collaboration, Kampala, Uganda.'
p28767
sS'OWN'
p28768
S'NLM'
p28769
sS'PT'
p28770
(lp28771
S'Journal Article'
p28772
aS"Research Support, Non-U.S. Gov't"
p28773
asS'LA'
p28774
(lp28775
S'eng'
p28776
asS'FAU'
p28777
(lp28778
S'Kirenga, Bruce J'
p28779
aS'Levin, Jonathan'
p28780
aS'Ayakaka, Irene'
p28781
aS'Worodria, William'
p28782
aS'Reilly, Nancy'
p28783
aS'Mumbowa, Francis'
p28784
aS'Nabanjja, Helen'
p28785
aS'Nyakoojo, Grace'
p28786
aS'Fennelly, Kevin'
p28787
aS'Nakubulwa, Susan'
p28788
aS'Joloba, Moses'
p28789
aS'Okwera, Alphonse'
p28790
aS'Eisenach, Kathleen D'
p28791
aS'McNerney, Ruth'
p28792
aS'Elliott, Alison M'
p28793
aS'Mugerwa, Roy D'
p28794
aS'Smith, Peter G'
p28795
aS'Ellner, Jerrold J'
p28796
aS'Jones-Lopez, Edward C'
p28797
asS'JT'
p28798
S'PloS one'
p28799
sS'LR'
p28800
S'20160713'
p28801
sS'PG'
p28802
S'e90614'
p28803
sS'TI'
p28804
S'Treatment outcomes of new tuberculosis patients hospitalized in Kampala, Uganda: a prospective cohort study.'
p28805
sS'RN'
p28806
(lp28807
S'0 (Anti-HIV Agents)'
p28808
asS'PL'
p28809
S'United States'
p28810
sS'TA'
p28811
S'PLoS One'
p28812
sS'JID'
p28813
S'101285081'
p28814
sS'AB'
p28815
S'BACKGROUND: In most resource limited settings, new tuberculosis (TB) patients are usually treated as outpatients. We sought to investigate the reasons for hospitalisation and the predictors of poor treatment outcomes and mortality in a cohort of hospitalized new TB patients in Kampala, Uganda. METHODS AND FINDINGS: Ninety-six new TB patients hospitalised between 2003 and 2006 were enrolled and followed for two years. Thirty two were HIV-uninfected and 64 were HIV-infected. Among the HIV-uninfected, the commonest reasons for hospitalization were low Karnofsky score (47%) and need for diagnostic evaluation (25%). HIV-infected patients were commonly hospitalized due to low Karnofsky score (72%), concurrent illness (16%) and diagnostic evaluation (14%). Eleven HIV uninfected patients died (mortality rate 19.7 per 100 person-years) while 41 deaths occurred among the HIV-infected patients (mortality rate 46.9 per 100 person years). In all patients an unsuccessful treatment outcome (treatment failure, death during the treatment period or an unknown outcome) was associated with duration of TB symptoms, with the odds of an unsuccessful outcome decreasing with increasing duration. Among HIV-infected patients, an unsuccessful treatment outcome was also associated with male sex (P = 0.004) and age (P = 0.034). Low Karnofsky score (aHR = 8.93, 95% CI 1.88 - 42.40, P = 0.001) was the only factor significantly associated with mortality among the HIV-uninfected. Mortality among the HIV-infected was associated with the composite variable of CD4 and ART use, with patients with baseline CD4 below 200 cells/microL who were not on ART at a greater risk of death than those who were on ART, and low Karnofsky score (aHR = 2.02, 95% CI 1.02 - 4.01, P = 0.045). CONCLUSION: Poor health status is a common cause of hospitalisation for new TB patients. Mortality in this study was very high and associated with advanced HIV Disease and no use of ART.'
p28816
sS'GR'
p28817
(lp28818
S'063410/ABC/00/Z/Wellcome Trust/United Kingdom'
p28819
aS'095778/Wellcome Trust/United Kingdom'
p28820
aS'100714/Wellcome Trust/United Kingdom'
p28821
aS'MR/K012126/1/Medical Research Council/United Kingdom'
p28822
aS'Medical Research Council/United Kingdom'
p28823
asS'IP'
p28824
S'3'
sS'IS'
p28825
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p28826
sS'PMC'
p28827
S'PMC3948371'
p28828
sS'DCOM'
p28829
S'20141230'
p28830
sS'AU'
p28831
(lp28832
S'Kirenga BJ'
p28833
aS'Levin J'
p28834
aS'Ayakaka I'
p28835
aS'Worodria W'
p28836
aS'Reilly N'
p28837
aS'Mumbowa F'
p28838
aS'Nabanjja H'
p28839
aS'Nyakoojo G'
p28840
aS'Fennelly K'
p28841
aS'Nakubulwa S'
p28842
aS'Joloba M'
p28843
aS'Okwera A'
p28844
aS'Eisenach KD'
p28845
aS'McNerney R'
p28846
aS'Elliott AM'
p28847
aS'Mugerwa RD'
p28848
aS'Smith PG'
p28849
aS'Ellner JJ'
p28850
aS'Jones-Lopez EC'
p28851
asS'VI'
p28852
S'9'
sS'MHDA'
p28853
S'2014/12/31 06:00'
p28854
sS'PHST'
p28855
(lp28856
S'2014 [ecollection]'
p28857
aS'2013/12/21 [received]'
p28858
aS'2014/02/02 [accepted]'
p28859
aS'2014/03/07 [epublish]'
p28860
asS'OID'
p28861
(lp28862
S'NLM: PMC3948371'
p28863
asS'MH'
p28864
(lp28865
S'Adult'
p28866
aS'Anti-HIV Agents/therapeutic use'
p28867
aS'Female'
p28868
aS'HIV Infections/*drug therapy/*mortality'
p28869
aS'Humans'
p28870
aS'Male'
p28871
aS'Prospective Studies'
p28872
aS'Treatment Outcome'
p28873
aS'Tuberculosis/*drug therapy/*mortality'
p28874
aS'Uganda'
p28875
aS'Young Adult'
p28876
asS'EDAT'
p28877
S'2014/03/13 06:00'
p28878
sS'SO'
p28879
S'PLoS One. 2014 Mar 7;9(3):e90614. doi: 10.1371/journal.pone.0090614. eCollection 2014.'
p28880
sS'SB'
p28881
S'IM'
p28882
sS'PMID'
p28883
S'24608875'
p28884
sS'PST'
p28885
S'epublish'
p28886
stRp28887
ag2
(g3
g4
(dp28888
S'LID'
p28889
S'10.1186/1472-6963-14-116 [doi]'
p28890
sS'STAT'
p28891
S'MEDLINE'
p28892
sS'DEP'
p28893
S'20140307'
p28894
sS'DA'
p28895
S'20140314'
p28896
sS'AID'
p28897
(lp28898
S'1472-6963-14-116 [pii]'
p28899
aS'10.1186/1472-6963-14-116 [doi]'
p28900
asS'CRDT'
p28901
(lp28902
S'2014/03/11 06:00'
p28903
asS'DP'
p28904
S'2014'
p28905
sS'GR'
p28906
(lp28907
S'082384/Z/07/Z/Wellcome Trust/United Kingdom'
p28908
aS'090999/Z/09/Z/Wellcome Trust/United Kingdom'
p28909
aS'097410/Wellcome Trust/United Kingdom'
p28910
aS'100714/Wellcome Trust/United Kingdom'
p28911
aS'674-A-00-08-00001-00/PEPFAR/United States'
p28912
aS'D43TW00231-16S1/TW/FIC NIH HHS/United States'
p28913
asS'OWN'
p28914
S'NLM'
p28915
sS'PT'
p28916
(lp28917
S'Journal Article'
p28918
aS'Research Support, N.I.H., Extramural'
p28919
aS"Research Support, Non-U.S. Gov't"
p28920
aS"Research Support, U.S. Gov't, Non-P.H.S."
p28921
aS"Research Support, U.S. Gov't, P.H.S."
p28922
asS'LA'
p28923
(lp28924
S'eng'
p28925
asS'DCOM'
p28926
S'20141124'
p28927
sS'JT'
p28928
S'BMC health services research'
p28929
sS'LR'
p28930
S'20160713'
p28931
sS'FAU'
p28932
(lp28933
S'Lessells, Richard J'
p28934
aS'Stott, Katharine E'
p28935
aS'Manasa, Justen'
p28936
aS'Naidu, Kevindra K'
p28937
aS'Skingsley, Andrew'
p28938
aS'Rossouw, Theresa'
p28939
aS'de Oliveira, Tulio'
p28940
asS'TI'
p28941
S'Implementing antiretroviral resistance testing in a primary health care HIV treatment programme in rural KwaZulu-Natal, South Africa: early experiences, achievements and challenges.'
p28942
sS'RN'
p28943
(lp28944
S'0 (Anti-HIV Agents)'
p28945
asS'PL'
p28946
S'England'
p28947
sS'PG'
p28948
S'116'
p28949
sS'JID'
p28950
S'101088677'
p28951
sS'AB'
p28952
S'BACKGROUND: Antiretroviral drug resistance is becoming increasingly common with the expansion of human immunodeficiency virus (HIV) treatment programmes in high prevalence settings. Genotypic resistance testing could have benefit in guiding individual-level treatment decisions but successful models for delivering resistance testing in low- and middle-income countries have not been reported. METHODS: An HIV Treatment Failure Clinic model was implemented within a large primary health care HIV treatment programme in northern KwaZulu-Natal, South Africa. Genotypic resistance testing was offered to adults (>/=16 years) with virological failure on first-line antiretroviral therapy (one viral load >1000 copies/ml after at least 12 months on a standard first-line regimen). A genotypic resistance test report was generated with treatment recommendations from a specialist HIV clinician and sent to medical officers at the clinics who were responsible for patient management. A quantitative process evaluation was conducted to determine how the model was implemented and to provide feedback regarding barriers and challenges to delivery. RESULTS: A total of 508 specimens were submitted for genotyping between 8 April 2011 and 31 January 2013; in 438 cases (86.2%) a complete genotype report with recommendations from the specialist clinician was sent to the medical officer. The median turnaround time from specimen collection to receipt of final report was 18 days (interquartile range (IQR) 13-29). In 114 (26.0%) cases the recommended treatment differed from what would be given in the absence of drug resistance testing. In the majority of cases (n = 315, 71.9%), the subsequent treatment prescribed was in line with the recommendations of the report. CONCLUSIONS: Genotypic resistance testing was successfully implemented in this large primary health care HIV programme and the system functioned well enough for the results to influence clinical management decisions in real time. Further research will explore the impact and cost-effectiveness of different implementation models in different settings.'
p28953
sS'AD'
p28954
S'Africa Centre for Health and Population Studies, University of KwaZulu-Natal, PO Box 198, Mtubatuba, KwaZulu-Natal 3935, South Africa. rlessells@africacentre.ac.za.'
p28955
sS'CN'
p28956
(lp28957
S'Southern African Treatment and Resistance Network (SATuRN)'
p28958
asS'VI'
p28959
S'14'
p28960
sS'IS'
p28961
S'1472-6963 (Electronic) 1472-6963 (Linking)'
p28962
sS'PMC'
p28963
S'PMC3973961'
p28964
sS'AU'
p28965
(lp28966
S'Lessells RJ'
p28967
aS'Stott KE'
p28968
aS'Manasa J'
p28969
aS'Naidu KK'
p28970
aS'Skingsley A'
p28971
aS'Rossouw T'
p28972
aS'de Oliveira T'
p28973
asS'MHDA'
p28974
S'2014/12/15 06:00'
p28975
sS'PHST'
p28976
(lp28977
S'2013/08/21 [received]'
p28978
aS'2014/02/28 [accepted]'
p28979
aS'2014/03/07 [aheadofprint]'
p28980
asS'OID'
p28981
(lp28982
S'NLM: PMC3973961'
p28983
asS'MH'
p28984
(lp28985
S'Adult'
p28986
aS'Anti-HIV Agents/administration & dosage/*therapeutic use'
p28987
aS'Drug Resistance, Viral'
p28988
aS'Female'
p28989
aS'Genotype'
p28990
aS'HIV Infections/*drug therapy/virology'
p28991
aS'HIV-1/drug effects/genetics'
p28992
aS'Humans'
p28993
aS'Male'
p28994
aS'*Microbial Sensitivity Tests/methods'
p28995
aS'Primary Health Care/organization & administration'
p28996
aS'Rural Health Services/organization & administration'
p28997
aS'South Africa/epidemiology'
p28998
aS'Treatment Failure'
p28999
asS'EDAT'
p29000
S'2014/03/13 06:00'
p29001
sS'SO'
p29002
S'BMC Health Serv Res. 2014 Mar 7;14:116. doi: 10.1186/1472-6963-14-116.'
p29003
sS'SB'
p29004
S'IM'
p29005
sS'PMID'
p29006
S'24606875'
p29007
sS'TA'
p29008
S'BMC Health Serv Res'
p29009
sS'PST'
p29010
S'epublish'
p29011
stRp29012
ag2
(g3
g4
(dp29013
S'LID'
p29014
S'10.1371/journal.pone.0088235 [doi]'
p29015
sS'STAT'
p29016
S'MEDLINE'
p29017
sS'DEP'
p29018
S'20140220'
p29019
sS'DA'
p29020
S'20140303'
p29021
sS'AID'
p29022
(lp29023
S'10.1371/journal.pone.0088235 [doi]'
p29024
aS'PONE-D-13-38191 [pii]'
p29025
asS'CRDT'
p29026
(lp29027
S'2014/03/04 06:00'
p29028
asS'DP'
p29029
S'2014'
p29030
sS'AD'
p29031
S'Department of Psychology, Royal Holloway University of London, United Kingdom. Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Somkhele, South Africa ; Faculty of Medicine, University of Southampton, Southampton, United Kingdom. Human Sciences Research Council, Durban, South Africa. Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Somkhele, South Africa ; Academic Unit of Primary Care and Population Sciences and Division of Social Statistics and Demography, University of Southampton, Southampton, United Kingdom.'
p29032
sS'OWN'
p29033
S'NLM'
p29034
sS'PT'
p29035
(lp29036
S'Journal Article'
p29037
aS"Research Support, Non-U.S. Gov't"
p29038
asS'LA'
p29039
(lp29040
S'eng'
p29041
asS'FAU'
p29042
(lp29043
S'Evangeli, Michael'
p29044
aS'Newell, Marie-Louise'
p29045
aS'Richter, Linda'
p29046
aS'McGrath, Nuala'
p29047
asS'JT'
p29048
S'PloS one'
p29049
sS'LR'
p29050
S'20160202'
p29051
sS'PG'
p29052
S'e88235'
p29053
sS'TI'
p29054
S'The association between self-reported stigma and loss-to-follow up in treatment eligible HIV positive adults in rural Kwazulu-Natal, South Africa.'
p29055
sS'PL'
p29056
S'United States'
p29057
sS'TA'
p29058
S'PLoS One'
p29059
sS'JID'
p29060
S'101285081'
p29061
sS'AB'
p29062
S'BACKGROUND: The relationship between loss-to-follow-up (LTFU) in HIV treatment and care programmes and psychosocial factors, including self-reported stigma, is important to understand. This prospective cohort study explored stigma and LTFU in treatment eligible adults who had yet not started antiretroviral therapy (ART). METHODS: Psychosocial, clinical and demographic data were collected at a baseline interview. Self-reported stigma was measured with a multi-item scale. LTFU was defined as not attending clinic in the 90 days since last appointment or before death. Data was collected between January 2009 and January 2013 and analysed using Cox Regression. RESULTS: 380 individuals were recruited (median time in study 3.35 years, total time at risk 1065.81 person-years). 203 were retained (53.4%), 109 were LTFU (28.7%), 48 had died and were not LTFU at death (12.6%) and 20 had transferred out (5.3%). The LTFU rate was 10.65 per 100 person-years (95% CI: 8.48-12.34). 362 individuals (95.3%) started ART. Stigma total score (categorised in quartiles) was not significantly associated with LTFU in either univariable or multivariable analysis (adjusting for other variables in the final model): second quartile aHR 0.77 (95%CI: 0.41-1.46), third quartile aHR 1.20(95%CI: 0.721-2.04), fourth quartile aHR 0.62 (95%CI: 0.35-1.11). In the final multivariable model, higher LTFU rates were associated with male gender, increased openness with friends/family and believing that community problems would be solved at higher levels. Lower LTFU rates were independently associated with increased year of age, greater reliance on family/friends, and having children. CONCLUSIONS: Demographic and other psychosocial factors were more closely related to LTFU than self-reported stigma. This may be consistent with high levels of social exposure to HIV and ART and with stigma affecting LTFU less than other stages of care. Research and clinical implications are discussed.'
p29063
sS'GR'
p29064
(lp29065
S'097410/Wellcome Trust/United Kingdom'
p29066
aS'WT083495MA/Wellcome Trust/United Kingdom'
p29067
asS'IP'
p29068
S'2'
sS'IS'
p29069
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p29070
sS'PMC'
p29071
S'PMC3930529'
p29072
sS'DCOM'
p29073
S'20150102'
p29074
sS'AU'
p29075
(lp29076
S'Evangeli M'
p29077
aS'Newell ML'
p29078
aS'Richter L'
p29079
aS'McGrath N'
p29080
asS'VI'
p29081
S'9'
sS'MHDA'
p29082
S'2015/01/03 06:00'
p29083
sS'PHST'
p29084
(lp29085
S'2014 [ecollection]'
p29086
aS'2013/09/16 [received]'
p29087
aS'2014/01/06 [accepted]'
p29088
aS'2014/02/20 [epublish]'
p29089
asS'OID'
p29090
(lp29091
S'NLM: PMC3930529'
p29092
asS'MH'
p29093
(lp29094
S'Adult'
p29095
aS'Cohort Studies'
p29096
aS'Female'
p29097
aS'HIV Infections/*drug therapy/*epidemiology'
p29098
aS'Humans'
p29099
aS'*Lost to Follow-Up'
p29100
aS'Male'
p29101
aS'Proportional Hazards Models'
p29102
aS'Prospective Studies'
p29103
aS'Psychology'
p29104
aS'Regression Analysis'
p29105
aS'Rural Population'
p29106
aS'*Social Stigma'
p29107
aS'South Africa/epidemiology'
p29108
asS'EDAT'
p29109
S'2014/03/04 06:00'
p29110
sS'SO'
p29111
S'PLoS One. 2014 Feb 20;9(2):e88235. doi: 10.1371/journal.pone.0088235. eCollection 2014.'
p29112
sS'SB'
p29113
S'IM'
p29114
sS'PMID'
p29115
S'24586310'
p29116
sS'PST'
p29117
S'epublish'
p29118
stRp29119
ag2
(g3
g4
(dp29120
S'LID'
p29121
S'10.1007/s10461-014-0729-8 [doi]'
p29122
sS'STAT'
p29123
S'MEDLINE'
p29124
sS'JT'
p29125
S'AIDS and behavior'
p29126
sS'MID'
p29127
(lp29128
S'NIHMS569793'
p29129
asS'DA'
p29130
S'20140604'
p29131
sS'AID'
p29132
(lp29133
S'10.1007/s10461-014-0729-8 [doi]'
p29134
asS'CRDT'
p29135
(lp29136
S'2014/02/25 06:00'
p29137
asS'DP'
p29138
S'2014 Jul'
p29139
sS'AD'
p29140
S'Departments of Internal Medicine and Pediatrics, University of Pennsylvania, Philadelphia, PA, USA, alexlankowski@gmail.com.'
p29141
sS'OWN'
p29142
S'NLM'
p29143
sS'PT'
p29144
(lp29145
S'Journal Article'
p29146
aS'Research Support, N.I.H., Extramural'
p29147
aS"Research Support, Non-U.S. Gov't"
p29148
aS'Review'
p29149
asS'LA'
p29150
(lp29151
S'eng'
p29152
asS'FAU'
p29153
(lp29154
S'Lankowski, Alexander J'
p29155
aS'Siedner, Mark J'
p29156
aS'Bangsberg, David R'
p29157
aS'Tsai, Alexander C'
p29158
asS'LR'
p29159
S'20160226'
p29160
sS'PG'
p29161
S'1199-223'
p29162
sS'TI'
p29163
S'Impact of geographic and transportation-related barriers on HIV outcomes in sub-Saharan Africa: a systematic review.'
p29164
sS'RN'
p29165
(lp29166
S'0 (Anti-HIV Agents)'
p29167
asS'PL'
p29168
S'United States'
p29169
sS'TA'
p29170
S'AIDS Behav'
p29171
sS'JID'
p29172
S'9712133'
p29173
sS'AB'
p29174
S'Difficulty obtaining reliable transportation to clinic is frequently cited as a barrier to HIV care in sub-Saharan Africa (SSA). Numerous studies have sought to characterize the impact of geographic and transportation-related barriers on HIV outcomes in SSA, but to date there has been no systematic attempt to summarize these findings. In this systematic review, we summarized this body of literature. We searched for studies conducted in SSA examining the following outcomes in the HIV care continuum: (1) voluntary counseling and testing, (2) pre-antiretroviral therapy (ART) linkage to care, (3) loss to follow-up and mortality, and (4) ART adherence and/or viral suppression. We identified 34 studies containing 52 unique estimates of association between a geographic or transportation-related barrier and an HIV outcome. There was an inverse effect in 23 estimates (44 %), a null association in 26 (50 %), and a paradoxical beneficial impact in 3 (6 %). We conclude that geographic and transportation-related barriers are associated with poor outcomes across the continuum of HIV care.'
p29175
sS'GR'
p29176
(lp29177
S'K23 MH096620/MH/NIMH NIH HHS/United States'
p29178
aS'K23 MH099916/MH/NIMH NIH HHS/United States'
p29179
aS'K23MH096620/MH/NIMH NIH HHS/United States'
p29180
aS'K23MH099916/MH/NIMH NIH HHS/United States'
p29181
aS'K24 MH087227/MH/NIMH NIH HHS/United States'
p29182
aS'K24MH087227/MH/NIMH NIH HHS/United States'
p29183
aS'R24TW007988/TW/FIC NIH HHS/United States'
p29184
asS'IP'
p29185
S'7'
sS'IS'
p29186
S'1573-3254 (Electronic) 1090-7165 (Linking)'
p29187
sS'PMC'
p29188
S'PMC4047127'
p29189
sS'DCOM'
p29190
S'20150210'
p29191
sS'AU'
p29192
(lp29193
S'Lankowski AJ'
p29194
aS'Siedner MJ'
p29195
aS'Bangsberg DR'
p29196
aS'Tsai AC'
p29197
asS'VI'
p29198
S'18'
p29199
sS'MHDA'
p29200
S'2015/02/11 06:00'
p29201
sS'OID'
p29202
(lp29203
S'NLM: NIHMS569793'
p29204
aS'NLM: PMC4047127'
p29205
asS'MH'
p29206
(lp29207
S'Africa South of the Sahara'
p29208
aS'Anti-HIV Agents/therapeutic use'
p29209
aS'Chemoprevention'
p29210
aS'Continuity of Patient Care'
p29211
aS'Counseling/*organization & administration/statistics & numerical data'
p29212
aS'Female'
p29213
aS'HIV Infections/drug therapy/*epidemiology'
p29214
aS'Health Services Accessibility/*organization & administration'
p29215
aS'Humans'
p29216
aS'Infectious Disease Transmission, Vertical/*prevention & control'
p29217
aS'Medication Adherence/*statistics & numerical data'
p29218
aS'Pregnancy'
p29219
aS'Transportation/*standards'
p29220
asS'EDAT'
p29221
S'2014/02/25 06:00'
p29222
sS'SO'
p29223
S'AIDS Behav. 2014 Jul;18(7):1199-223. doi: 10.1007/s10461-014-0729-8.'
p29224
sS'SB'
p29225
S'IM'
p29226
sS'PMID'
p29227
S'24563115'
p29228
sS'PST'
p29229
S'ppublish'
p29230
stRp29231
ag2
(g3
g4
(dp29232
S'LID'
p29233
S'10.1016/S1473-3099(14)70020-9 [doi] S1473-3099(14)70020-9 [pii]'
p29234
sS'STAT'
p29235
S'MEDLINE'
p29236
sS'DEP'
p29237
S'20140220'
p29238
sS'MID'
p29239
(lp29240
S'NIHMS588579'
p29241
asS'DA'
p29242
S'20140424'
p29243
sS'AID'
p29244
(lp29245
S'S1473-3099(14)70020-9 [pii]'
p29246
aS'10.1016/S1473-3099(14)70020-9 [doi]'
p29247
asS'CRDT'
p29248
(lp29249
S'2014/02/25 06:00'
p29250
asS'DP'
p29251
S'2014 May'
p29252
sS'GR'
p29253
(lp29254
S'5U01 AI068614/AI/NIAID NIH HHS/United States'
p29255
aS'5U01 AI068618/AI/NIAID NIH HHS/United States'
p29256
aS'5U01 AI068635/AI/NIAID NIH HHS/United States'
p29257
aS'5U01 AI069453/AI/NIAID NIH HHS/United States'
p29258
aS'5U01 AI069469/AI/NIAID NIH HHS/United States'
p29259
aS'5U01 AI069519/AI/NIAID NIH HHS/United States'
p29260
aS'UM1 AI068614/AI/NIAID NIH HHS/United States'
p29261
aS'UM1 AI068618/AI/NIAID NIH HHS/United States'
p29262
aS'UM1 AI068635/AI/NIAID NIH HHS/United States'
p29263
aS'UM1 AI069453/AI/NIAID NIH HHS/United States'
p29264
aS'UM1 AI069469/AI/NIAID NIH HHS/United States'
p29265
aS'UM1 AI069519/AI/NIAID NIH HHS/United States'
p29266
asS'OWN'
p29267
S'NLM'
p29268
sS'PT'
p29269
(lp29270
S'Clinical Trial, Phase II'
p29271
aS'Journal Article'
p29272
aS'Randomized Controlled Trial'
p29273
aS'Research Support, N.I.H., Extramural'
p29274
aS"Research Support, Non-U.S. Gov't"
p29275
asS'LA'
p29276
(lp29277
S'eng'
p29278
asS'FAU'
p29279
(lp29280
S'Gray, Glenda E'
p29281
aS'Moodie, Zoe'
p29282
aS'Metch, Barbara'
p29283
aS'Gilbert, Peter B'
p29284
aS'Bekker, Linda-Gail'
p29285
aS'Churchyard, Gavin'
p29286
aS'Nchabeleng, Maphoshane'
p29287
aS'Mlisana, Koleka'
p29288
aS'Laher, Fatima'
p29289
aS'Roux, Surita'
p29290
aS'Mngadi, Kathryn'
p29291
aS'Innes, Craig'
p29292
aS'Mathebula, Matsontso'
p29293
aS'Allen, Mary'
p29294
aS'McElrath, M Julie'
p29295
aS'Robertson, Michael'
p29296
aS'Kublin, James'
p29297
aS'Corey, Lawrence'
p29298
asS'JT'
p29299
S'The Lancet. Infectious diseases'
p29300
sS'LR'
p29301
S'20150515'
p29302
sS'PG'
p29303
S'388-96'
p29304
sS'TI'
p29305
S'Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study.'
p29306
sS'RN'
p29307
(lp29308
S'0 (AIDS Vaccines)'
p29309
aS'0 (Protein Precursors)'
p29310
aS'0 (Vaccines, Synthetic)'
p29311
aS'0 (gag Gene Products, Human Immunodeficiency Virus)'
p29312
aS'0 (nef Gene Products, Human Immunodeficiency Virus)'
p29313
aS'0 (nef protein, Human immunodeficiency virus 1)'
p29314
aS'0 (pol Gene Products, Human Immunodeficiency Virus)'
p29315
aS'0 (pr160 gag-pol precursor protein, Human immunodeficiency virus 1)'
p29316
asS'PL'
p29317
S'United States'
p29318
sS'TA'
p29319
S'Lancet Infect Dis'
p29320
sS'FIR'
p29321
(lp29322
S'Alexander, Sarah'
p29323
aS'Corey, Larry'
p29324
aS'Ducar, Constance'
p29325
aS'Duerr, Ann'
p29326
aS'Eaton, Niles'
p29327
aS'McElrath, Julie'
p29328
aS'Holt, Renee'
p29329
aS'Hural, John'
p29330
aS'Kublin, Jim'
p29331
aS'Wecker, Margaret'
p29332
aS'Escamilla, Gina'
p29333
aS'Holman, Drienna'
p29334
aS'Metch, Barbara'
p29335
aS'Moodie, Zoe'
p29336
aS'Self, Steve'
p29337
aS'Allen, Mary'
p29338
aS'Fix, Alan'
p29339
aS'Follman, Dean'
p29340
aS'Johnston, Peggy'
p29341
aS'Luzar, Mary Anne'
p29342
aS'Martinez, Ana'
p29343
aS'Casimiro, Danny'
p29344
aS'Isaacs, Robin'
p29345
aS'Kierstead, Lisa'
p29346
aS'Leavitt, Randi'
p29347
aS'Mehrotra, Devan'
p29348
aS'Robertson, Mike'
p29349
aS'DeBruyn, Guy'
p29350
aS'Gray, Glenda'
p29351
aS'Nkala, Busi'
p29352
aS'Magopane, Tebogo'
p29353
aS'Mkhise, Baningi'
p29354
aS'Lehobye, Innocentia'
p29355
aS'Mathebula, Matsontso Peter'
p29356
aS'Nchabeleng, Maphoshane'
p29357
aS'Bekker, Desmond Tutu Linda-Gail'
p29358
aS'Ronan, Agnes'
p29359
aS'Roux, Surita'
p29360
aS'Churchyard, Gavin'
p29361
aS'Latka, Mary'
p29362
aS'Mngadi, Kathy'
p29363
aS'Nielson, Tanya'
p29364
aS'Selepe, Pearl'
p29365
aS'Bennie, Thola'
p29366
aS'Mlisana, Koleka'
p29367
aS'Naicker, Nivashnee'
p29368
aS'Puren, Adrian'
p29369
aS'Galetta, David'
p29370
aS'Levendal, Elise'
p29371
asS'JID'
p29372
S'101130150'
p29373
sS'AB'
p29374
S'BACKGROUND: The HVTN 503/Phambili study, which assessed the efficacy of the Merck Ad5 gag/pol/nef subtype B HIV-1 preventive vaccine in South Africa, was stopped when futility criteria in the Step study (assessing the same vaccine in the Americas, Caribbean, and Australia) were met. Here we report long-term follow-up data. METHODS: HVTN 503/Phambili was a double-blind, placebo-controlled, randomised trial that recruited HIV-1 uninfected, sexually active adults aged 18-35 years from five sites in South Africa. Eligible participants were randomly assigned (1:1) by computer-generated random numbers to either vaccine or placebo, stratified by site and sex. Cox proportional hazards models were used to estimate HIV-1 infection in the modified intention-to-treat cohort, all of whom were unmasked early in follow-up. The trial is registered with ClinicalTrials.gov, number NCT00413725 and the South African National Health Research Database, number DOH-27-0207-1539. FINDINGS: Between Jan 24, 2007, and Sept 19, 2007, 801 participants (26.7%) of a planned 3000 were randomly assigned (400 to vaccine, 401 to placebo); 216 (27%) received only one injection, 529 (66%) received only two injections, and 56 (7%) received three injections. At a median follow-up of 42 months (IQR 31-42), 63 vaccine recipients (16%) had HIV-1 infection compared with 37 placebo recipients (9%; adjusted HR 1.70, 95% CI 1.13-2.55; p=0.01). Risk for HIV-1 infection did not differ according to the number of vaccinations received, sex, circumcision, or adenovirus type 5 (Ad5) serostatus. Differences in risk behaviour at baseline or during the study, or annualised dropout rate (7.7% [95% CI 6.2-9.5] for vaccine recipients vs 8.8% [7.1-10.7] for placebo recipients; p=0.40) are unlikely explanations for the increased rate of HIV-1 infections seen in vaccine recipients. INTERPRETATION: The increased risk of HIV-1 acquisition in vaccine recipients, irrespective of number of doses received, warrants further investigation to understand the biological mechanism. We caution against further use of the Ad5 vector for HIV vaccines. FUNDING: National Institute of Allergy and Infectious Diseases, Merck, and South African Medical Research Council.'
p29375
sS'AD'
p29376
S'Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa; South African Medical Research Council, Cape Town, South Africa. Electronic address: gray@pixie.co.za. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Desmond Tutu HIV Foundation, University of Cape Town, Cape Town, South Africa. Aurum Institute for Health Research, Johannesburg, South Africa. MEDUNSA HIV Clinical Research Unit, University of Limpopo, Mankweng-E, South Africa. Centre for AIDS Programme for Research in South Africa, University of KwaZulu-Natal, Durban, South Africa. Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa. Desmond Tutu HIV Foundation, University of Cape Town, Cape Town, South Africa. Centre for AIDS Programme for Research in South Africa, University of KwaZulu-Natal, Durban, South Africa. Aurum Institute for Health Research, Johannesburg, South Africa. MEDUNSA HIV Clinical Research Unit, University of Limpopo, Mankweng-E, South Africa. Vaccine Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Infectious Diseases and Vaccines Clinical Research, Merck and Company, North Wales, PA, USA. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'
p29377
sS'CN'
p29378
(lp29379
S'HVTN 503/Phambili study team'
p29380
asS'IP'
p29381
S'5'
sS'IS'
p29382
S'1474-4457 (Electronic) 1473-3099 (Linking)'
p29383
sS'IR'
p29384
(lp29385
S'Alexander S'
p29386
aS'Corey L'
p29387
aS'Ducar C'
p29388
aS'Duerr A'
p29389
aS'Eaton N'
p29390
aS'McElrath J'
p29391
aS'Holt R'
p29392
aS'Hural J'
p29393
aS'Kublin J'
p29394
aS'Wecker M'
p29395
aS'Escamilla G'
p29396
aS'Holman D'
p29397
aS'Metch B'
p29398
aS'Moodie Z'
p29399
aS'Self S'
p29400
aS'Allen M'
p29401
aS'Fix A'
p29402
aS'Follman D'
p29403
aS'Johnston P'
p29404
aS'Luzar MA'
p29405
aS'Martinez A'
p29406
aS'Casimiro D'
p29407
aS'Isaacs R'
p29408
aS'Kierstead L'
p29409
aS'Leavitt R'
p29410
aS'Mehrotra D'
p29411
aS'Robertson M'
p29412
aS'DeBruyn G'
p29413
aS'Gray G'
p29414
aS'Nkala B'
p29415
aS'Magopane T'
p29416
aS'Mkhise B'
p29417
aS'Lehobye I'
p29418
aS'Mathebula MP'
p29419
aS'Nchabeleng M'
p29420
aS'Bekker DT'
p29421
aS'Ronan A'
p29422
aS'Roux S'
p29423
aS'Churchyard G'
p29424
aS'Latka M'
p29425
aS'Mngadi K'
p29426
aS'Nielson T'
p29427
aS'Selepe P'
p29428
aS'Bennie T'
p29429
aS'Mlisana K'
p29430
aS'Naicker N'
p29431
aS'Puren A'
p29432
aS'Galetta D'
p29433
aS'Levendal E'
p29434
asS'DCOM'
p29435
S'20140612'
p29436
sS'CIN'
p29437
(lp29438
S'Lancet Infect Dis. 2014 May;14(5):361-2. PMID: 24560542'
p29439
asS'AU'
p29440
(lp29441
S'Gray GE'
p29442
aS'Moodie Z'
p29443
aS'Metch B'
p29444
aS'Gilbert PB'
p29445
aS'Bekker LG'
p29446
aS'Churchyard G'
p29447
aS'Nchabeleng M'
p29448
aS'Mlisana K'
p29449
aS'Laher F'
p29450
aS'Roux S'
p29451
aS'Mngadi K'
p29452
aS'Innes C'
p29453
aS'Mathebula M'
p29454
aS'Allen M'
p29455
aS'McElrath MJ'
p29456
aS'Robertson M'
p29457
aS'Kublin J'
p29458
aS'Corey L'
p29459
asS'VI'
p29460
S'14'
p29461
sS'MHDA'
p29462
S'2014/06/13 06:00'
p29463
sS'PHST'
p29464
(lp29465
S'2014/02/20 [aheadofprint]'
p29466
asS'OID'
p29467
(lp29468
S'NLM: NIHMS588579'
p29469
aS'NLM: PMC4174314'
p29470
asS'CI'
p29471
(lp29472
S'Copyright (c) 2014 Elsevier Ltd. All rights reserved.'
p29473
asS'MH'
p29474
(lp29475
S'AIDS Vaccines/*administration & dosage'
p29476
aS'Adenoviridae/*genetics'
p29477
aS'Adolescent'
p29478
aS'Adult'
p29479
aS'Double-Blind Method'
p29480
aS'Female'
p29481
aS'Follow-Up Studies'
p29482
aS'*Genetic Vectors'
p29483
aS'HIV Infections/epidemiology/*prevention & control'
p29484
aS'Humans'
p29485
aS'Incidence'
p29486
aS'Male'
p29487
aS'Proportional Hazards Models'
p29488
aS'Protein Precursors/*immunology'
p29489
aS'Risk Assessment'
p29490
aS'South Africa'
p29491
aS'Vaccines, Synthetic/immunology'
p29492
aS'Young Adult'
p29493
aS'gag Gene Products, Human Immunodeficiency Virus/*immunology'
p29494
aS'nef Gene Products, Human Immunodeficiency Virus/*immunology'
p29495
aS'pol Gene Products, Human Immunodeficiency Virus/*immunology'
p29496
asS'EDAT'
p29497
S'2014/02/25 06:00'
p29498
sS'PMC'
p29499
S'PMC4174314'
p29500
sS'SI'
p29501
(lp29502
S'ClinicalTrials.gov/NCT00413725'
p29503
asS'SO'
p29504
S'Lancet Infect Dis. 2014 May;14(5):388-96. doi: 10.1016/S1473-3099(14)70020-9. Epub 2014 Feb 20.'
p29505
sS'SB'
p29506
S'IM'
p29507
sS'PMID'
p29508
S'24560541'
p29509
sS'PST'
p29510
S'ppublish'
p29511
stRp29512
ag2
(g3
g4
(dp29513
S'LID'
p29514
S'10.1371/journal.pone.0088437 [doi]'
p29515
sS'STAT'
p29516
S'MEDLINE'
p29517
sS'DEP'
p29518
S'20140218'
p29519
sS'DA'
p29520
S'20140221'
p29521
sS'AID'
p29522
(lp29523
S'10.1371/journal.pone.0088437 [doi]'
p29524
aS'PONE-D-13-35284 [pii]'
p29525
asS'CRDT'
p29526
(lp29527
S'2014/02/22 06:00'
p29528
asS'DP'
p29529
S'2014'
p29530
sS'AD'
p29531
S"Department of Psychiatry, School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia ; Centre for Global Mental Health, Institute of Psychiatry, King's College London, London, United Kingdom. Transcultural Psychosocial Organization Nepal, Kathmandu, Nepal. School of Psychology, University of KwaZulu-Natal, Durban, South Africa. PRIME India team, Sangath Non-Governmental Organisation, Goa, India. PRIME India team, Sangath Non-Governmental Organisation, Goa, India. Aklilu-Lemma Institute of Pathobiology, Addis Ababa University, Addis Ababa, Ethiopia. Butabika National Mental Hospital, Kampala, Uganda. Department of Psychiatry, School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia. Centre for Mental Health, Public Health Foundation of India, New Delhi, India. School of Psychology, University of KwaZulu-Natal, Durban, South Africa. Department of Research and Development, HealthNet Transcultural Psychosocial Organisation, Amsterdam, The Netherlands ; Centre for Global Mental Health, London School of Hygiene and Tropical Medicine, London, United Kingdom. Butabika National Mental Hospital, Kampala, Uganda. Health Service and Population Research Department, Institute of Psychiatry, King's College London, London, United Kingdom. Sangath Non-Governmental Organisation, Goa, India ; Centre for Global Mental Health, London School of Hygiene and Tropical Medicine, London, United Kingdom. Centre for Public Mental Health, Department of Psychology, Stellenbosch University and Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa. Alan J Flisher Centre for Public Mental Health, Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa. Alan J Flisher Centre for Public Mental Health, Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa. Centre for Global Mental Health, London School of Hygiene and Tropical Medicine, London, United Kingdom. Centre for Global Mental Health, Institute of Psychiatry, King's College London, London, United Kingdom."
p29532
sS'OWN'
p29533
S'NLM'
p29534
sS'PT'
p29535
(lp29536
S'Journal Article'
p29537
aS"Research Support, Non-U.S. Gov't"
p29538
asS'LA'
p29539
(lp29540
S'eng'
p29541
asS'FAU'
p29542
(lp29543
S'Hanlon, Charlotte'
p29544
aS'Luitel, Nagendra P'
p29545
aS'Kathree, Tasneem'
p29546
aS'Murhar, Vaibhav'
p29547
aS'Shrivasta, Sanjay'
p29548
aS'Medhin, Girmay'
p29549
aS'Ssebunnya, Joshua'
p29550
aS'Fekadu, Abebaw'
p29551
aS'Shidhaye, Rahul'
p29552
aS'Petersen, Inge'
p29553
aS'Jordans, Mark'
p29554
aS'Kigozi, Fred'
p29555
aS'Thornicroft, Graham'
p29556
aS'Patel, Vikram'
p29557
aS'Tomlinson, Mark'
p29558
aS'Lund, Crick'
p29559
aS'Breuer, Erica'
p29560
aS'De Silva, Mary'
p29561
aS'Prince, Martin'
p29562
asS'JT'
p29563
S'PloS one'
p29564
sS'LR'
p29565
S'20160713'
p29566
sS'PG'
p29567
S'e88437'
p29568
sS'TI'
p29569
S'Challenges and opportunities for implementing integrated mental health care: a district level situation analysis from five low- and middle-income countries.'
p29570
sS'PL'
p29571
S'United States'
p29572
sS'TA'
p29573
S'PLoS One'
p29574
sS'JID'
p29575
S'101285081'
p29576
sS'AB'
p29577
S'BACKGROUND: Little is known about how to tailor implementation of mental health services in low- and middle-income countries (LMICs) to the diverse settings encountered within and between countries. In this paper we compare the baseline context, challenges and opportunities in districts in five LMICs (Ethiopia, India, Nepal, South Africa and Uganda) participating in the PRogramme for Improving Mental health carE (PRIME). The purpose was to inform development and implementation of a comprehensive district plan to integrate mental health into primary care. METHODS: A situation analysis tool was developed for the study, drawing on existing tools and expert consensus. Cross-sectional information obtained was largely in the public domain in all five districts. RESULTS: The PRIME study districts face substantial contextual and health system challenges many of which are common across sites. Reliable information on existing treatment coverage for mental disorders was unavailable. Particularly in the low-income countries, many health service organisational requirements for mental health care were absent, including specialist mental health professionals to support the service and reliable supplies of medication. Across all sites, community mental health literacy was low and there were no models of multi-sectoral working or collaborations with traditional or religious healers. Nonetheless health system opportunities were apparent. In each district there was potential to apply existing models of care for tuberculosis and HIV or non-communicable disorders, which have established mechanisms for detection of drop-out from care, outreach and adherence support. The extensive networks of community-based health workers and volunteers in most districts provide further opportunities to expand mental health care. CONCLUSIONS: The low level of baseline health system preparedness across sites underlines that interventions at the levels of health care organisation, health facility and community will all be essential for sustainable delivery of quality mental health care integrated into primary care.'
p29578
sS'GR'
p29579
(lp29580
S'084674/Wellcome Trust/United Kingdom'
p29581
aS'100714/Wellcome Trust/United Kingdom'
p29582
asS'IP'
p29583
S'2'
sS'IS'
p29584
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p29585
sS'PMC'
p29586
S'PMC3928234'
p29587
sS'DCOM'
p29588
S'20150113'
p29589
sS'AU'
p29590
(lp29591
S'Hanlon C'
p29592
aS'Luitel NP'
p29593
aS'Kathree T'
p29594
aS'Murhar V'
p29595
aS'Shrivasta S'
p29596
aS'Medhin G'
p29597
aS'Ssebunnya J'
p29598
aS'Fekadu A'
p29599
aS'Shidhaye R'
p29600
aS'Petersen I'
p29601
aS'Jordans M'
p29602
aS'Kigozi F'
p29603
aS'Thornicroft G'
p29604
aS'Patel V'
p29605
aS'Tomlinson M'
p29606
aS'Lund C'
p29607
aS'Breuer E'
p29608
aS'De Silva M'
p29609
aS'Prince M'
p29610
asS'VI'
p29611
S'9'
sS'MHDA'
p29612
S'2015/01/15 06:00'
p29613
sS'PHST'
p29614
(lp29615
S'2014 [ecollection]'
p29616
aS'2013/08/25 [received]'
p29617
aS'2014/01/12 [accepted]'
p29618
aS'2014/02/18 [epublish]'
p29619
asS'OID'
p29620
(lp29621
S'NLM: PMC3928234'
p29622
asS'MH'
p29623
(lp29624
S'Community Health Workers'
p29625
aS'Community Mental Health Services/*economics/*organization & administration'
p29626
aS'Cross-Sectional Studies'
p29627
aS'Developing Countries'
p29628
aS'Ethiopia'
p29629
aS'HIV Infections/therapy'
p29630
aS'Health Services Accessibility'
p29631
aS'Humans'
p29632
aS'India'
p29633
aS'Nepal'
p29634
aS'Poverty'
p29635
aS'Primary Health Care/organization & administration'
p29636
aS'Program Evaluation'
p29637
aS'Public Health'
p29638
aS'South Africa'
p29639
aS'Tuberculosis/therapy'
p29640
aS'Uganda'
p29641
asS'EDAT'
p29642
S'2014/02/22 06:00'
p29643
sS'SO'
p29644
S'PLoS One. 2014 Feb 18;9(2):e88437. doi: 10.1371/journal.pone.0088437. eCollection 2014.'
p29645
sS'SB'
p29646
S'IM'
p29647
sS'PMID'
p29648
S'24558389'
p29649
sS'PST'
p29650
S'epublish'
p29651
stRp29652
ag2
(g3
g4
(dp29653
S'STAT'
p29654
S'MEDLINE'
p29655
sS'AB'
p29656
S'The 2011 prevalence of human immunodeficiency virus (HIV) among pregnant women in Botswana was 30.4%. High coverage rates of HIV testing and antiretroviral prophylaxis have reduced the rate of mother-to-child transmission of HIV in Botswana from as high as 40% with no prophylaxis to <4% in 2011. In June 2005, the national Early Infant Diagnosis (EID) Program began testing HIV-exposed infants (i.e., those born to HIV-infected mothers) for HIV using polymerase chain reaction (PCR) at 6 weeks postpartum. During 2005-2012, follow-up of all HIV-infected infants diagnosed in all 13 postnatal care facilities in Francistown, Botswana, was conducted to ascertain patient outcomes. A total of 202 infants were diagnosed with HIV. As of September 2013, 82 (41%) children were alive and on antiretroviral therapy (ART), 79 (39%) had died, and 41 (20%) were either lost to follow-up, had transferred, or their mothers declined ART. Despite success in preventing mother-to-child transmission in Botswana, results of the EID program highlight the need for early diagnosis of HIV-infected infants, prompt initiation of ART, and retention in care.'
p29657
sS'JID'
p29658
S'7802429'
p29659
sS'CN'
p29660
(lp29661
S'Centers for Disease Control and Prevention (CDC)'
p29662
asS'JT'
p29663
S'MMWR. Morbidity and mortality weekly report'
p29664
sS'IP'
p29665
S'7'
sS'IS'
p29666
S'1545-861X (Electronic) 0149-2195 (Linking)'
p29667
sS'DCOM'
p29668
S'20140403'
p29669
sS'DA'
p29670
S'20140220'
p29671
sS'AU'
p29672
(lp29673
S'Motswere-Chirwa C'
p29674
aS'Voetsch A'
p29675
aS'Lu L'
p29676
aS'Letsholathebe V'
p29677
aS'Lekone P'
p29678
aS'Machakaire E'
p29679
aS'Legwaila K'
p29680
aS'Matambo S'
p29681
aS'Maruping M'
p29682
aS'Kolobe T'
p29683
aS'Petlo C'
p29684
aS'Lebelonyane R'
p29685
aS'Glenshaw M'
p29686
aS'Dale H'
p29687
aS'Davis M'
p29688
aS'El Halabi S'
p29689
aS'Pelletier A'
p29690
asS'AID'
p29691
(lp29692
S'mm6307a5 [pii]'
p29693
asS'CRDT'
p29694
(lp29695
S'2014/02/21 06:00'
p29696
asS'VI'
p29697
S'63'
p29698
sS'PMID'
p29699
S'24553200'
p29700
sS'DP'
p29701
S'2014 Feb 21'
p29702
sS'MHDA'
p29703
S'2014/04/04 06:00'
p29704
sS'OWN'
p29705
S'NLM'
p29706
sS'PT'
p29707
(lp29708
S'Journal Article'
p29709
asS'LA'
p29710
(lp29711
S'eng'
p29712
asS'MH'
p29713
(lp29714
S'Anti-HIV Agents/therapeutic use'
p29715
aS'Botswana'
p29716
aS'Counseling/statistics & numerical data'
p29717
aS'Female'
p29718
aS'Follow-Up Studies'
p29719
aS'HIV Infections/*diagnosis/*drug therapy/mortality/transmission'
p29720
aS'Humans'
p29721
aS'Infant'
p29722
aS'Infectious Disease Transmission, Vertical/*prevention & control'
p29723
aS'Male'
p29724
aS'Polymerase Chain Reaction'
p29725
aS'Pregnancy'
p29726
aS'Pregnancy Complications, Infectious/*prevention & control'
p29727
aS'Program Evaluation'
p29728
aS'Survival Rate'
p29729
aS'Treatment Outcome'
p29730
asS'FAU'
p29731
(lp29732
S'Motswere-Chirwa, Catherine'
p29733
aS'Voetsch, Andrew'
p29734
aS'Lu, Lydia'
p29735
aS'Letsholathebe, Victor'
p29736
aS'Lekone, Phenyo'
p29737
aS'Machakaire, Esther'
p29738
aS'Legwaila, Keitumetse'
p29739
aS'Matambo, Stembile'
p29740
aS'Maruping, Maruping'
p29741
aS'Kolobe, Thatayotlhe'
p29742
aS'Petlo, Chipo'
p29743
aS'Lebelonyane, Refeletswe'
p29744
aS'Glenshaw, Mary'
p29745
aS'Dale, Helen'
p29746
aS'Davis, Margarett'
p29747
aS'El Halabi, Shenaaz'
p29748
aS'Pelletier, Andrew'
p29749
asS'EDAT'
p29750
S'2014/02/21 06:00'
p29751
sS'PST'
p29752
S'ppublish'
p29753
sS'SO'
p29754
S'MMWR Morb Mortal Wkly Rep. 2014 Feb 21;63(7):158-60.'
p29755
sS'PG'
p29756
S'158-60'
p29757
sS'TI'
p29758
S'Follow-up of infants diagnosed with HIV - Early Infant Diagnosis Program, Francistown, Botswana, 2005-2012.'
p29759
sS'SB'
p29760
S'IM'
p29761
sS'RN'
p29762
(lp29763
S'0 (Anti-HIV Agents)'
p29764
asS'PL'
p29765
S'United States'
p29766
sS'TA'
p29767
S'MMWR Morb Mortal Wkly Rep'
p29768
stRp29769
ag2
(g3
g4
(dp29770
S'LID'
p29771
S'10.1186/1471-2334-14-90 [doi]'
p29772
sS'STAT'
p29773
S'MEDLINE'
p29774
sS'DEP'
p29775
S'20140220'
p29776
sS'DA'
p29777
S'20140226'
p29778
sS'AID'
p29779
(lp29780
S'1471-2334-14-90 [pii]'
p29781
aS'10.1186/1471-2334-14-90 [doi]'
p29782
asS'CRDT'
p29783
(lp29784
S'2014/02/21 06:00'
p29785
asS'DP'
p29786
S'2014'
p29787
sS'OWN'
p29788
S'NLM'
p29789
sS'PT'
p29790
(lp29791
S'Journal Article'
p29792
aS"Research Support, Non-U.S. Gov't"
p29793
asS'LA'
p29794
(lp29795
S'eng'
p29796
asS'DCOM'
p29797
S'20141218'
p29798
sS'JT'
p29799
S'BMC infectious diseases'
p29800
sS'LR'
p29801
S'20150515'
p29802
sS'FAU'
p29803
(lp29804
S'Franzeck, Fabian Christoph'
p29805
aS'Letang, Emilio'
p29806
aS'Mwaigomole, Geoffrey'
p29807
aS'Jullu, Boniphace'
p29808
aS'Glass, Tracy R'
p29809
aS'Nyogea, Daniel'
p29810
aS'Hatz, Christoph'
p29811
aS'Tanner, Marcel'
p29812
aS'Battegay, Manuel'
p29813
asS'TI'
p29814
S'cART prescription trends in a prospective HIV cohort in rural Tanzania from 2007 to 2011.'
p29815
sS'RN'
p29816
(lp29817
S'0 (Anti-HIV Agents)'
p29818
aS'BO9LE4QFZF (Stavudine)'
p29819
asS'PL'
p29820
S'England'
p29821
sS'PG'
p29822
S'90'
p29823
sS'JID'
p29824
S'100968551'
p29825
sS'AB'
p29826
S'BACKGROUND: Since 2010, World Health Organization (WHO) guidelines discourage using stavudine in first-line regimens due to frequent and severe side effects. This study describes the implementation of this recommendation and trends in usage of antiretroviral therapy combinations in a cohort of HIV-positive patients in rural Tanzania. METHODS: We analyzed longitudinal, prospectively collected clinical data of HIV-1 infected adults initiating antiretroviral therapy within the Kilombero Ulanga Antiretroviral Cohort (KIULARCO) in Ifakara, Tanzania from 2007-2011. RESULTS: This analysis included data of 3008 patients. Median age was 38 (interquartile range [IQR] 31-45) years, 1962 (65.2%) of all subjects were female, and median CD4+ cell count at enrollment was 168 cells/mm3 (IQR 81-273). The percentage of prescriptions containing stavudine in initial regimens fell from a maximum of 75.3% in 2008 to 10.7% in 2011. TDF/FTC/EFV became available in 2009 and was used in 41.9% of patients initiating cART in 2011. An overall on-treatment analysis revealed that d4T/3TC/NVP and AZT/3TC/EFV were the most prescribed combinations in each year, including 2011 (674 [36.5%] and 641 [34.7%] patients, respectively). Of those receiving stavudine in 2011, 659 (89.1%) initiated it before 2011. CONCLUSIONS: Initial cART with stavudine declined to low levels according to recommendations but the overall use of stavudine remained substantial, as individuals already on cART containing stavudine were not changed to alternative drugs. Our findings highlight the critical need to exchange stavudine in treatment regimens of patients who initiated therapy in earlier years.'
p29827
sS'AD'
p29828
S'Swiss Tropical and Public Health Institute (SwissTPH), Socinstrasse 57, CH-4051 Basel, Switzerland. fcfranzeck@gmail.com.'
p29829
sS'VI'
p29830
S'14'
p29831
sS'IS'
p29832
S'1471-2334 (Electronic) 1471-2334 (Linking)'
p29833
sS'PMC'
p29834
S'PMC3936899'
p29835
sS'AU'
p29836
(lp29837
S'Franzeck FC'
p29838
aS'Letang E'
p29839
aS'Mwaigomole G'
p29840
aS'Jullu B'
p29841
aS'Glass TR'
p29842
aS'Nyogea D'
p29843
aS'Hatz C'
p29844
aS'Tanner M'
p29845
aS'Battegay M'
p29846
asS'MHDA'
p29847
S'2014/12/19 06:00'
p29848
sS'PHST'
p29849
(lp29850
S'2013/06/19 [received]'
p29851
aS'2014/02/18 [accepted]'
p29852
aS'2014/02/20 [aheadofprint]'
p29853
asS'OID'
p29854
(lp29855
S'NLM: PMC3936899'
p29856
asS'MH'
p29857
(lp29858
S'Adult'
p29859
aS'Anti-HIV Agents/*therapeutic use'
p29860
aS'CD4 Lymphocyte Count'
p29861
aS'CD4-Positive T-Lymphocytes/cytology'
p29862
aS'Drug Prescriptions/*statistics & numerical data'
p29863
aS'Female'
p29864
aS'HIV Infections/*drug therapy'
p29865
aS'HIV Seropositivity/drug therapy'
p29866
aS'HIV-1'
p29867
aS'Humans'
p29868
aS'Longitudinal Studies'
p29869
aS'Male'
p29870
aS'Middle Aged'
p29871
aS'Practice Guidelines as Topic'
p29872
aS'Prospective Studies'
p29873
aS'Rural Population'
p29874
aS'Stavudine/*therapeutic use'
p29875
aS'Tanzania'
p29876
asS'EDAT'
p29877
S'2014/02/21 06:00'
p29878
sS'SO'
p29879
S'BMC Infect Dis. 2014 Feb 20;14:90. doi: 10.1186/1471-2334-14-90.'
p29880
sS'SB'
p29881
S'IM'
p29882
sS'PMID'
p29883
S'24552395'
p29884
sS'TA'
p29885
S'BMC Infect Dis'
p29886
sS'PST'
p29887
S'epublish'
p29888
stRp29889
ag2
(g3
g4
(dp29890
S'LID'
p29891
S'10.1186/1471-2431-14-39 [doi]'
p29892
sS'STAT'
p29893
S'MEDLINE'
p29894
sS'DEP'
p29895
S'20140212'
p29896
sS'DA'
p29897
S'20140219'
p29898
sS'AID'
p29899
(lp29900
S'1471-2431-14-39 [pii]'
p29901
aS'10.1186/1471-2431-14-39 [doi]'
p29902
asS'CRDT'
p29903
(lp29904
S'2014/02/14 06:00'
p29905
asS'DP'
p29906
S'2014'
p29907
sS'AD'
p29908
S'Gertrude H, Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, NY USA. sma2@columbia.edu.'
p29909
sS'OWN'
p29910
S'NLM'
p29911
sS'PT'
p29912
(lp29913
S'Comparative Study'
p29914
aS'Journal Article'
p29915
aS'Randomized Controlled Trial'
p29916
aS'Research Support, N.I.H., Extramural'
p29917
aS"Research Support, Non-U.S. Gov't"
p29918
asS'LA'
p29919
(lp29920
S'eng'
p29921
asS'DCOM'
p29922
S'20141020'
p29923
sS'JT'
p29924
S'BMC pediatrics'
p29925
sS'LR'
p29926
S'20150812'
p29927
sS'FAU'
p29928
(lp29929
S'Shiau, Stephanie'
p29930
aS'Kuhn, Louise'
p29931
aS'Strehlau, Renate'
p29932
aS'Martens, Leigh'
p29933
aS'McIlleron, Helen'
p29934
aS'Meredith, Sandra'
p29935
aS'Wiesner, Lubbe'
p29936
aS'Coovadia, Ashraf'
p29937
aS'Abrams, Elaine J'
p29938
aS'Arpadi, Stephen M'
p29939
asS'TI'
p29940
S'Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment.'
p29941
sS'RN'
p29942
(lp29943
S'0 (Anti-HIV Agents)'
p29944
aS'2494G1JF75 (Lopinavir)'
p29945
aS'99DK7FVK1H (Nevirapine)'
p29946
aS'O3J8G9O825 (Ritonavir)'
p29947
asS'PL'
p29948
S'England'
p29949
sS'PG'
p29950
S'39'
p29951
sS'JID'
p29952
S'100967804'
p29953
sS'AB'
p29954
S'BACKGROUND: While studies of HIV-infected adults on antiretroviral treatment (ART) report no sex differences in immune recovery and virologic response but more ART-associated complications in women, sex differences in disease progression and response to ART among children have not been well assessed. The objective of this study was to evaluate for sex differences in response to ART in South African HIV-infected children who were randomized to continue ritonavir-boosted lopinavir (LPV/r)-based ART or switch to nevirapine-based ART. METHODS: ART outcomes in HIV-infected boys and girls in Johannesburg, South Africa from 2005-2010 were compared. Children initiated ritonavir-boosted lopinavir (LPV/r)-based ART before 24 months of age and were randomized to remain on LPV/r or switch to nevirapine-based ART after achieving viral suppression. Children were followed for 76 weeks post-randomization and then long-term follow up continued for a minimum of 99 weeks and maximum of 245 weeks after randomization. Viral load, CD4 count, lipids, anthropometrics, drug concentrations, and adherence were measured at regular intervals. Outcomes were compared between sexes within treatment strata. RESULTS: A total of 323 children (median age 8.8 months, IQR 5.1-13.5), including 168 boys and 155 girls, initiated LPV/r-based ART and 195 children were randomized. No sex differences in risk of virological failure (confirmed viral load >1000 copies/mL) by 156 weeks post-randomization were observed within either treatment group. Girls switched to nevirapine had more robust CD4 count improvement relative to boys in this group through 112 weeks post-randomization. In addition, girls remaining on LPV/r had higher plasma concentrations of ritonavir than boys during post-randomization visits. After a mean of 3.4 years post-randomization, girls remaining on LPV/r also had a higher total cholesterol:HDL ratio and lower mean HDL than boys on LPV/r. CONCLUSIONS: Sex differences are noted in treated HIV-infected children even at a young age, and appear to depend on treatment regimen. Future studies are warranted to determine biological mechanisms and clinical significance of these differences. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00117728.'
p29955
sS'GR'
p29956
(lp29957
S'HD 073952/HD/NICHD NIH HHS/United States'
p29958
aS'HD 073977/HD/NICHD NIH HHS/United States'
p29959
aS'HD 47177/HD/NICHD NIH HHS/United States'
p29960
aS'HD 61255/HD/NICHD NIH HHS/United States'
p29961
aS'R01 HD047177/HD/NICHD NIH HHS/United States'
p29962
aS'R01 HD061255/HD/NICHD NIH HHS/United States'
p29963
aS'R01 HD073952/HD/NICHD NIH HHS/United States'
p29964
asS'VI'
p29965
S'14'
p29966
sS'IS'
p29967
S'1471-2431 (Electronic) 1471-2431 (Linking)'
p29968
sS'PMC'
p29969
S'PMC3927631'
p29970
sS'AU'
p29971
(lp29972
S'Shiau S'
p29973
aS'Kuhn L'
p29974
aS'Strehlau R'
p29975
aS'Martens L'
p29976
aS'McIlleron H'
p29977
aS'Meredith S'
p29978
aS'Wiesner L'
p29979
aS'Coovadia A'
p29980
aS'Abrams EJ'
p29981
aS'Arpadi SM'
p29982
asS'MHDA'
p29983
S'2014/10/21 06:00'
p29984
sS'PHST'
p29985
(lp29986
S'2013/10/16 [received]'
p29987
aS'2014/02/06 [accepted]'
p29988
aS'2014/02/12 [aheadofprint]'
p29989
asS'OID'
p29990
(lp29991
S'NLM: PMC3927631'
p29992
asS'MH'
p29993
(lp29994
S'Anti-HIV Agents/*therapeutic use'
p29995
aS'Child, Preschool'
p29996
aS'Drug Therapy, Combination'
p29997
aS'Female'
p29998
aS'HIV Infections/*drug therapy'
p29999
aS'Humans'
p30000
aS'Infant'
p30001
aS'Lopinavir/*therapeutic use'
p30002
aS'Male'
p30003
aS'Nevirapine/*therapeutic use'
p30004
aS'Ritonavir/*therapeutic use'
p30005
aS'Sex Factors'
p30006
aS'South Africa'
p30007
aS'Treatment Outcome'
p30008
asS'EDAT'
p30009
S'2014/02/14 06:00'
p30010
sS'SI'
p30011
(lp30012
S'ClinicalTrials.gov/NCT00117728'
p30013
asS'SO'
p30014
S'BMC Pediatr. 2014 Feb 12;14:39. doi: 10.1186/1471-2431-14-39.'
p30015
sS'SB'
p30016
S'IM'
p30017
sS'PMID'
p30018
S'24521425'
p30019
sS'TA'
p30020
S'BMC Pediatr'
p30021
sS'PST'
p30022
S'epublish'
p30023
stRp30024
ag2
(g3
g4
(dp30025
S'LID'
p30026
S'10.1080/09540121.2014.882493 [doi]'
p30027
sS'STAT'
p30028
S'MEDLINE'
p30029
sS'DEP'
p30030
S'20140211'
p30031
sS'MID'
p30032
(lp30033
S'NIHMS563967'
p30034
asS'DA'
p30035
S'20140805'
p30036
sS'AID'
p30037
(lp30038
S'10.1080/09540121.2014.882493 [doi]'
p30039
asS'CRDT'
p30040
(lp30041
S'2014/02/13 06:00'
p30042
asS'DP'
p30043
S'2014'
p30044
sS'EIN'
p30045
(lp30046
S'AIDS Care. 2014;26(11):i'
p30047
asS'OWN'
p30048
S'NLM'
p30049
sS'PT'
p30050
(lp30051
S'Journal Article'
p30052
aS'Observational Study'
p30053
aS'Research Support, N.I.H., Extramural'
p30054
asS'LA'
p30055
(lp30056
S'eng'
p30057
asS'FAU'
p30058
(lp30059
S'Ostermann, Jan'
p30060
aS'Whetten, Kathryn'
p30061
aS'Reddy, Elizabeth'
p30062
aS'Pence, Brian'
p30063
aS'Weinhold, Andrew'
p30064
aS'Itemba, Dafrosa'
p30065
aS'Maro, Venance'
p30066
aS'Mosille, Eligy'
p30067
aS'Thielman, Nathan'
p30068
asS'JT'
p30069
S'AIDS care'
p30070
sS'LR'
p30071
S'20151101'
p30072
sS'PG'
p30073
S'1352-8'
p30074
sS'TI'
p30075
S'Treatment retention and care transitions during and after the scale-up of HIV care and treatment in Northern Tanzania.'
p30076
sS'RN'
p30077
(lp30078
S'0 (Anti-HIV Agents)'
p30079
asS'PL'
p30080
S'England'
p30081
sS'TA'
p30082
S'AIDS Care'
p30083
sS'JID'
p30084
S'8915313'
p30085
sS'AB'
p30086
S'Decentralization of HIV care is promoted to improve access to antiretroviral therapy in sub-Saharan Africa. This study describes care transitions among HIV-infected persons in Northern Tanzania during a period of rapid decentralization of HIV care and treatment centers (CTCs) from hospitals to local health centers. Between November 2008 and June 2009, 492 HIV-infected patients in established care at two referral hospitals in Moshi, Tanzania, and 262 persons newly diagnosed with HIV were selected for participation in a prospective cohort study entitled Coping with HIV/AIDS in Tanzania. Clinical records and participant self-reports, collected between June and November 2012, were used to describe retention in care and transitions between CTCs during the study period. After a mean follow-up period of 3.5 years, 10% of participants had died, 9% were lost to follow-up, and 11% had moved. Of the remaining participants enrolled from CTCs, more than 90% reported at least one CTC visit during the previous six months, with 98% still in care at the CTC at which they were enrolled. Nearly three out of four newly diagnosed clients listed a referral hospital as their primary CTC. Fewer than 10% of participants ever sought care at another CTC in the study area; nearly 90% of those in care bypassed their closest CTC. Administrative data from all facilities in the study area indicate that new clients, even after the scale-up from 8 CTCs in 2006 to 21 CTCs in 2008, disproportionately selected established CTCs, and client volume at newly approved facilities was highly variable. Despite the decentralization of HIV care and treatment in this setting, many patients continue to bypass their closest CTC to seek care at established facilities. Patient preferences for decentralized HIV care, which may inform optimal resource utilization, are largely unknown and warrant further investigation.'
p30087
sS'AD'
p30088
S'a Duke Global Health Institute , Duke University , Durham , NC , USA.'
p30089
sS'CN'
p30090
(lp30091
S'CHAT Research Team'
p30092
asS'IP'
p30093
S'11'
p30094
sS'IS'
p30095
S'1360-0451 (Electronic) 0954-0121 (Linking)'
p30096
sS'PMC'
p30097
S'PMC4122642'
p30098
sS'DCOM'
p30099
S'20150123'
p30100
sS'AU'
p30101
(lp30102
S'Ostermann J'
p30103
aS'Whetten K'
p30104
aS'Reddy E'
p30105
aS'Pence B'
p30106
aS'Weinhold A'
p30107
aS'Itemba D'
p30108
aS'Maro V'
p30109
aS'Mosille E'
p30110
aS'Thielman N'
p30111
asS'VI'
p30112
S'26'
p30113
sS'MHDA'
p30114
S'2015/01/24 06:00'
p30115
sS'PHST'
p30116
(lp30117
S'2014/02/11 [aheadofprint]'
p30118
asS'OTO'
p30119
(lp30120
S'NOTNLM'
p30121
asS'OID'
p30122
(lp30123
S'NLM: NIHMS563967'
p30124
aS'NLM: PMC4122642'
p30125
asS'MH'
p30126
(lp30127
S'Adult'
p30128
aS'Anti-HIV Agents/*therapeutic use'
p30129
aS'Community Health Services/statistics & numerical data/*utilization'
p30130
aS'Continuity of Patient Care/*statistics & numerical data'
p30131
aS'Female'
p30132
aS'Follow-Up Studies'
p30133
aS'HIV Infections/*drug therapy'
p30134
aS'Health Services Accessibility'
p30135
aS'Humans'
p30136
aS'Lost to Follow-Up'
p30137
aS'Male'
p30138
aS'Middle Aged'
p30139
aS'Patient Acceptance of Health Care/*statistics & numerical data'
p30140
aS'Prospective Studies'
p30141
aS'Tanzania'
p30142
aS'Treatment Outcome'
p30143
asS'EDAT'
p30144
S'2014/02/13 06:00'
p30145
sS'GR'
p30146
(lp30147
S'5P30 AI064518/AI/NIAID NIH HHS/United States'
p30148
aS'5R01MH078756/MH/NIMH NIH HHS/United States'
p30149
aS'KL2 RR024127/RR/NCRR NIH HHS/United States'
p30150
aS'KL2RR024127-04/RR/NCRR NIH HHS/United States'
p30151
aS'P30 AI064518/AI/NIAID NIH HHS/United States'
p30152
aS'R01 MH078756/MH/NIMH NIH HHS/United States'
p30153
asS'SO'
p30154
S'AIDS Care. 2014;26(11):1352-8. doi: 10.1080/09540121.2014.882493. Epub 2014 Feb 11.'
p30155
sS'SB'
p30156
S'IM X'
p30157
sS'PMID'
p30158
S'24517083'
p30159
sS'OT'
p30160
(lp30161
S'HIV/AIDS'
p30162
aS'Tanzania'
p30163
aS'antiretroviral therapy'
p30164
aS'decentralization'
p30165
aS'treatment retention'
p30166
asS'PST'
p30167
S'ppublish'
p30168
stRp30169
ag2
(g3
g4
(dp30170
S'LID'
p30171
S'10.1186/2046-4053-3-9 [doi]'
p30172
sS'STAT'
p30173
S'MEDLINE'
p30174
sS'DEP'
p30175
S'20140210'
p30176
sS'DA'
p30177
S'20140213'
p30178
sS'AID'
p30179
(lp30180
S'2046-4053-3-9 [pii]'
p30181
aS'10.1186/2046-4053-3-9 [doi]'
p30182
asS'CRDT'
p30183
(lp30184
S'2014/02/12 06:00'
p30185
asS'DP'
p30186
S'2014'
p30187
sS'AD'
p30188
S'Research Center of the Montreal University Hospital Center (CRCHUM), 850 rue St-Denis, tour St-Antoine, Montreal, QC H2X 0A9, Canada. maryline.sicotte@umontreal.ca.'
p30189
sS'OWN'
p30190
S'NLM'
p30191
sS'PT'
p30192
(lp30193
S'Journal Article'
p30194
aS"Research Support, Non-U.S. Gov't"
p30195
aS'Review'
p30196
asS'LA'
p30197
(lp30198
S'eng'
p30199
asS'DCOM'
p30200
S'20140926'
p30201
sS'JT'
p30202
S'Systematic reviews'
p30203
sS'LR'
p30204
S'20150515'
p30205
sS'FAU'
p30206
(lp30207
S'Sicotte, Maryline'
p30208
aS'Langlois, Etienne V'
p30209
aS'Aho, Josephine'
p30210
aS'Ziegler, Daniela'
p30211
aS'Zunzunegui, Maria Victoria'
p30212
asS'TI'
p30213
S'Association between nutritional status and the immune response in HIV + patients under HAART: protocol for a systematic review.'
p30214
sS'RN'
p30215
(lp30216
S'0 (Anti-HIV Agents)'
p30217
asS'PL'
p30218
S'England'
p30219
sS'PG'
p30220
S'9'
sS'JID'
p30221
S'101580575'
p30222
sS'AB'
p30223
S'BACKGROUND: Over 850 million people worldwide and 200 million adults in Sub-Saharan Africa suffer from malnutrition. Countries most affected by HIV are also stricken by elevated rates of food insecurity and malnutrition. HIV infection and insufficient nutritional intake are part of a vicious cycle that contributes to immunodeficiency and negative health outcomes. However, the effect of the overlap between HIV infection and undernutrition on the immune response following antiretroviral initiation remains unclear. A possible explanation could be the lack of consensus concerning the definition and assessment of nutritional status. Our objectives are to investigate the existence of an association between undernutrition and immune response at antiretroviral treatment initiation and the following year in low- and middle-income countries where malnutrition is most prevalent. METHODS/DESIGN: Our systematic review will identify studies originating from low- and middle-income countries (LMICs) published from 1996 onwards, through searches in MEDLINE (PubMed interface), EMBASE (OVID interface), Cochrane Central (OVID interface) and grey literature. No language restrictions will be applied. We will seek out studies of any design investigating the association between the nutritional status (for example, undernourished versus well nourished) and the immune response, either in terms of CD4 count or immune failure, in seropositive patients initiating antiretroviral therapy or in their first year of treatment. Two reviewers will independently screen articles, extract data and assess scientific quality using standardized forms and published quality assessment tools tailored for each study design. Where feasible, pooled measures of association will be obtained through meta-analyses. Results will be reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement. This protocol has been registered in the PROSPERO database (registration number: CRD42014005961). CONCLUSION: Undernutrition and weight loss are prevalent amongst highly active antiretroviral therapy (HAART)-treated patients in LMICs and contribute to excess early mortality. A possible intermediate pathway could be poor immune reconstitution secondary to deficient nutritional status. In the face of limited access to second line treatments, raising HIV resistance and cut backs to HIV programs, it is crucial to identify the factors associated with suboptimal response and therapeutic failure in order to better customize the care strategies employed in LMICs.'
p30224
sS'GR'
p30225
(lp30226
S'Canadian Institutes of Health Research/Canada'
p30227
asS'VI'
p30228
S'3'
sS'IS'
p30229
S'2046-4053 (Electronic) 2046-4053 (Linking)'
p30230
sS'PMC'
p30231
S'PMC3922999'
p30232
sS'AU'
p30233
(lp30234
S'Sicotte M'
p30235
aS'Langlois EV'
p30236
aS'Aho J'
p30237
aS'Ziegler D'
p30238
aS'Zunzunegui MV'
p30239
asS'MHDA'
p30240
S'2014/09/27 06:00'
p30241
sS'PHST'
p30242
(lp30243
S'2013/11/13 [received]'
p30244
aS'2014/02/03 [accepted]'
p30245
aS'2014/02/10 [aheadofprint]'
p30246
asS'OID'
p30247
(lp30248
S'NLM: PMC3922999'
p30249
asS'MH'
p30250
(lp30251
S'Anti-HIV Agents/administration & dosage/*therapeutic use'
p30252
aS'*Antiretroviral Therapy, Highly Active'
p30253
aS'HIV Infections/complications/*drug therapy/immunology'
p30254
aS'Humans'
p30255
aS'Nutrition Disorders/complications'
p30256
aS'*Nutritional Status/immunology'
p30257
aS'Treatment Outcome'
p30258
asS'EDAT'
p30259
S'2014/02/12 06:00'
p30260
sS'SO'
p30261
S'Syst Rev. 2014 Feb 10;3:9. doi: 10.1186/2046-4053-3-9.'
p30262
sS'SB'
p30263
S'IM'
p30264
sS'PMID'
p30265
S'24513015'
p30266
sS'TA'
p30267
S'Syst Rev'
p30268
sS'PST'
p30269
S'epublish'
p30270
stRp30271
ag2
(g3
g4
(dp30272
S'LID'
p30273
S'10.1093/database/bat082 [doi]'
p30274
sS'STAT'
p30275
S'MEDLINE'
p30276
sS'DEP'
p30277
S'20140206'
p30278
sS'DA'
p30279
S'20140207'
p30280
sS'AID'
p30281
(lp30282
S'bat082 [pii]'
p30283
aS'10.1093/database/bat082 [doi]'
p30284
asS'CRDT'
p30285
(lp30286
S'2014/02/08 06:00'
p30287
asS'DP'
p30288
S'2014'
p30289
sS'AD'
p30290
S'Africa Centre for Health and Population Studies, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Mtubatuba, South Africa, Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK, Immunology department, University of Pretoria, Pretoria, South Africa, Infectious Diseases, Internal Medicine, University of the Free State School of Medicine, Bloemfontein, South Africa and Division of Medical Virology, Stellenbosch University, Stellenbosch, South Africa, National Health Laboratory Service Tygerberg, Cape Town, South Africa, Department of Virology, National Health Laboratory Service, University of KwaZulu-Natal, Durban, South Africa, The Brighton Doctoral College, Brighton and Sussex Medical School, UK, Academic Unit of primary Care and Population Science, Division of Social Statistics and Geography, University of Southampton, Southampton, UK, Jembi Health Systems, Cape Town, South Africa, School of Mathematics, Statistics and Computer Science, University of KwaZulu-Natal, Westville, South Africa and Research Department of Infection, University College of London (UCL), London, UK.'
p30291
sS'OWN'
p30292
S'NLM'
p30293
sS'PT'
p30294
(lp30295
S'Journal Article'
p30296
aS"Research Support, Non-U.S. Gov't"
p30297
aS"Research Support, U.S. Gov't, Non-P.H.S."
p30298
aS"Research Support, U.S. Gov't, P.H.S."
p30299
asS'LA'
p30300
(lp30301
S'eng'
p30302
asS'DCOM'
p30303
S'20140826'
p30304
sS'JT'
p30305
S'Database : the journal of biological databases and curation'
p30306
sS'LR'
p30307
S'20150310'
p30308
sS'FAU'
p30309
(lp30310
S'Manasa, Justen'
p30311
aS'Lessells, Richard'
p30312
aS'Rossouw, Theresa'
p30313
aS'Naidu, Kevindra'
p30314
aS'Van Vuuren, Cloete'
p30315
aS'Goedhals, Dominique'
p30316
aS'van Zyl, Gert'
p30317
aS'Bester, Armand'
p30318
aS'Skingsley, Andrew'
p30319
aS'Stott, Katharine'
p30320
aS'Danaviah, Siva'
p30321
aS'Chetty, Terusha'
p30322
aS'Singh, Lavanya'
p30323
aS'Moodley, Pravi'
p30324
aS'Iwuji, Collins'
p30325
aS'McGrath, Nuala'
p30326
aS'Seebregts, Christopher J'
p30327
aS'de Oliveira, Tulio'
p30328
asS'TI'
p30329
S'Southern African Treatment Resistance Network (SATuRN) RegaDB HIV drug resistance and clinical management database: supporting patient management, surveillance and research in southern Africa.'
p30330
sS'RN'
p30331
(lp30332
S'0 (Anti-HIV Agents)'
p30333
asS'PL'
p30334
S'England'
p30335
sS'PG'
p30336
S'bat082'
p30337
sS'JID'
p30338
S'101517697'
p30339
sS'AB'
p30340
S'Substantial amounts of data have been generated from patient management and academic exercises designed to better understand the human immunodeficiency virus (HIV) epidemic and design interventions to control it. A number of specialized databases have been designed to manage huge data sets from HIV cohort, vaccine, host genomic and drug resistance studies. Besides databases from cohort studies, most of the online databases contain limited curated data and are thus sequence repositories. HIV drug resistance has been shown to have a great potential to derail the progress made thus far through antiretroviral therapy. Thus, a lot of resources have been invested in generating drug resistance data for patient management and surveillance purposes. Unfortunately, most of the data currently available relate to subtype B even though >60% of the epidemic is caused by HIV-1 subtype C. A consortium of clinicians, scientists, public health experts and policy markers working in southern Africa came together and formed a network, the Southern African Treatment and Resistance Network (SATuRN), with the aim of increasing curated HIV-1 subtype C and tuberculosis drug resistance data. This article describes the HIV-1 data curation process using the SATuRN Rega database. The data curation is a manual and time-consuming process done by clinical, laboratory and data curation specialists. Access to the highly curated data sets is through applications that are reviewed by the SATuRN executive committee. Examples of research outputs from the analysis of the curated data include trends in the level of transmitted drug resistance in South Africa, analysis of the levels of acquired resistance among patients failing therapy and factors associated with the absence of genotypic evidence of drug resistance among patients failing therapy. All these studies have been important for informing first- and second-line therapy. This database is a free password-protected open source database available on www.bioafrica.net. Database URL: http://www.bioafrica.net/regadb/'
p30341
sS'GR'
p30342
(lp30343
S'082384/Z/07/Z/Wellcome Trust/United Kingdom'
p30344
aS'090999/Wellcome Trust/United Kingdom'
p30345
aS'090999/Z/09/Z/Wellcome Trust/United Kingdom'
p30346
aS'097410/Wellcome Trust/United Kingdom'
p30347
aS'WT083495MA/Wellcome Trust/United Kingdom'
p30348
asS'VI'
p30349
S'2014'
p30350
sS'IS'
p30351
S'1758-0463 (Electronic) 1758-0463 (Linking)'
p30352
sS'AU'
p30353
(lp30354
S'Manasa J'
p30355
aS'Lessells R'
p30356
aS'Rossouw T'
p30357
aS'Naidu K'
p30358
aS'Van Vuuren C'
p30359
aS'Goedhals D'
p30360
aS'van Zyl G'
p30361
aS'Bester A'
p30362
aS'Skingsley A'
p30363
aS'Stott K'
p30364
aS'Danaviah S'
p30365
aS'Chetty T'
p30366
aS'Singh L'
p30367
aS'Moodley P'
p30368
aS'Iwuji C'
p30369
aS'McGrath N'
p30370
aS'Seebregts CJ'
p30371
aS'de Oliveira T'
p30372
asS'MHDA'
p30373
S'2014/08/27 06:00'
p30374
sS'PHST'
p30375
(lp30376
S'2014 [ppublish]'
p30377
asS'MH'
p30378
(lp30379
S'Africa, Southern'
p30380
aS'Anti-HIV Agents/*pharmacology/*therapeutic use'
p30381
aS'Data Mining'
p30382
aS'*Databases, Genetic'
p30383
aS'Drug Resistance, Viral/*drug effects'
p30384
aS'HIV Infections/*drug therapy'
p30385
aS'HIV-1/drug effects/genetics'
p30386
aS'Humans'
p30387
aS'*Patient Care Management'
p30388
aS'*Population Surveillance'
p30389
aS'Research'
p30390
asS'EDAT'
p30391
S'2014/02/08 06:00'
p30392
sS'SO'
p30393
S'Database (Oxford). 2014 Feb 6;2014:bat082. doi: 10.1093/database/bat082. Print 2014.'
p30394
sS'SB'
p30395
S'IM'
p30396
sS'PMID'
p30397
S'24504151'
p30398
sS'TA'
p30399
S'Database (Oxford)'
p30400
sS'PST'
p30401
S'epublish'
p30402
stRp30403
ag2
(g3
g4
(dp30404
S'LID'
p30405
S'10.7554/eLife.01604 [doi]'
p30406
sS'STAT'
p30407
S'MEDLINE'
p30408
sS'DEP'
p30409
S'20140128'
p30410
sS'DA'
p30411
S'20140129'
p30412
sS'AID'
p30413
(lp30414
S'3/0/e01604 [pii]'
p30415
aS'10.7554/eLife.01604 [doi]'
p30416
asS'CRDT'
p30417
(lp30418
S'2014/01/30 06:00'
p30419
asS'DP'
p30420
S'2014'
p30421
sS'AD'
p30422
S'Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.'
p30423
sS'OWN'
p30424
S'NLM'
p30425
sS'PT'
p30426
(lp30427
S'Comparative Study'
p30428
aS'Journal Article'
p30429
aS"Research Support, Non-U.S. Gov't"
p30430
asS'LA'
p30431
(lp30432
S'eng'
p30433
asS'DCOM'
p30434
S'20151124'
p30435
sS'JT'
p30436
S'eLife'
p30437
sS'LR'
p30438
S'20160713'
p30439
sS'FAU'
p30440
(lp30441
S'Glynn, Judith R'
p30442
aS'Kayuni, Ndoliwe'
p30443
aS'Gondwe, Levie'
p30444
aS'Price, Alison J'
p30445
aS'Crampin, Amelia C'
p30446
asS'TI'
p30447
S'Earlier menarche is associated with a higher prevalence of Herpes simplex type-2 (HSV-2) in young women in rural Malawi.'
p30448
sS'PL'
p30449
S'United States'
p30450
sS'PG'
p30451
S'e01604'
p30452
sS'JID'
p30453
S'101579614'
p30454
sS'AB'
p30455
S'Remarkably little is known about associations between age at menarche and sexually transmitted infections, although girls with earlier menarche tend to have earlier sexual debut and school drop-out, so an association might be expected. In a population-based survey of >3000 women aged 15-30 in northern Malawi we show that those with earlier menarche had earlier sexual debut, earlier marriage and were more often Herpes simplex type-2 (HSV-2) positive. Compared to those with menarche aged <14, the age-adjusted odds ratios for HSV-2 were 0.89 (95%CI 0.71-1.1), 0.71 (0.57-0.89) and 0.69 (0.54-0.89) for menarche aged 14, 15 and 16+ respectively. This association persisted after adjusting for socio-economic factors, including schooling, and for sexual behaviour. No such association was seen with HIV infection, which is much less common and less uniformly distributed than HSV-2 in this population. The extra vulnerability of girls with earlier menarche needs to be recognised. DOI: http://dx.doi.org/10.7554/eLife.01604.001.'
p30456
sS'GR'
p30457
(lp30458
S'079828/Z/06/Wellcome Trust/United Kingdom'
p30459
aS'098610/Wellcome Trust/United Kingdom'
p30460
asS'VI'
p30461
S'3'
sS'IS'
p30462
S'2050-084X (Electronic) 2050-084X (Linking)'
p30463
sS'PMC'
p30464
S'PMC3901398'
p30465
sS'AU'
p30466
(lp30467
S'Glynn JR'
p30468
aS'Kayuni N'
p30469
aS'Gondwe L'
p30470
aS'Price AJ'
p30471
aS'Crampin AC'
p30472
asS'GN'
p30473
(lp30474
S'NLM: Original DateCompleted: 20140129'
p30475
asS'MHDA'
p30476
S'2014/01/30 06:01'
p30477
sS'OT'
p30478
(lp30479
S'Africa'
p30480
aS'Herpes simplex type 2'
p30481
aS'sexual health'
p30482
asS'OTO'
p30483
(lp30484
S'NOTNLM'
p30485
asS'OID'
p30486
(lp30487
S'NLM: PMC3901398'
p30488
asS'MH'
p30489
(lp30490
S'Adolescent'
p30491
aS'Adult'
p30492
aS'Age Distribution'
p30493
aS'Age Factors'
p30494
aS'Child'
p30495
aS'Female'
p30496
aS'Health Surveys'
p30497
aS'Herpes Genitalis/diagnosis/*epidemiology/transmission/virology'
p30498
aS'Herpesvirus 2, Human/*isolation & purification'
p30499
aS'Humans'
p30500
aS'Malawi/epidemiology'
p30501
aS'Marriage'
p30502
aS'*Menarche'
p30503
aS'Multivariate Analysis'
p30504
aS'Odds Ratio'
p30505
aS'Prevalence'
p30506
aS'Puberty, Precocious/diagnosis/*epidemiology/physiopathology'
p30507
aS'Risk Factors'
p30508
aS'*Rural Health'
p30509
aS'Sex Distribution'
p30510
aS'Sex Factors'
p30511
aS'Sexual Behavior'
p30512
aS'Socioeconomic Factors'
p30513
aS'Young Adult'
p30514
asS'EDAT'
p30515
S'2014/01/30 06:00'
p30516
sS'SO'
p30517
S'Elife. 2014 Jan 28;3:e01604. doi: 10.7554/eLife.01604.'
p30518
sS'SB'
p30519
S'IM'
p30520
sS'PMID'
p30521
S'24473074'
p30522
sS'TA'
p30523
S'Elife'
p30524
sS'PST'
p30525
S'epublish'
p30526
stRp30527
ag2
(g3
g4
(dp30528
S'LID'
p30529
S'10.1097/QAD.0000000000000143 [doi]'
p30530
sS'STAT'
p30531
S'MEDLINE'
p30532
sS'JT'
p30533
S'AIDS (London, England)'
p30534
sS'CIN'
p30535
(lp30536
S'AIDS. 2014 Feb 20;28(4):599-601. PMID: 24469000'
p30537
asS'DA'
p30538
S'20140128'
p30539
sS'AID'
p30540
(lp30541
S'10.1097/QAD.0000000000000143 [doi]'
p30542
aS'00002030-201402200-00015 [pii]'
p30543
asS'CRDT'
p30544
(lp30545
S'2014/01/29 06:00'
p30546
asS'DP'
p30547
S'2014 Feb 20'
p30548
sS'GR'
p30549
(lp30550
S'AID-OAA-A-11-00012/PHS HHS/United States'
p30551
aS'U01 AI069924/AI/NIAID NIH HHS/United States'
p30552
aS'U01 AI069924/AI/NIAID NIH HHS/United States'
p30553
asS'OWN'
p30554
S'NLM'
p30555
sS'PT'
p30556
(lp30557
S'Journal Article'
p30558
aS'Research Support, N.I.H., Extramural'
p30559
aS"Research Support, Non-U.S. Gov't"
p30560
aS"Research Support, U.S. Gov't, Non-P.H.S."
p30561
asS'LA'
p30562
(lp30563
S'eng'
p30564
asS'FAU'
p30565
(lp30566
S'Tenthani, Lyson'
p30567
aS'Haas, Andreas D'
p30568
aS'Tweya, Hannock'
p30569
aS'Jahn, Andreas'
p30570
aS'van Oosterhout, Joep J'
p30571
aS'Chimbwandira, Frank'
p30572
aS'Chirwa, Zengani'
p30573
aS"Ng'ambi, Wingston"
p30574
aS'Bakali, Alan'
p30575
aS'Phiri, Sam'
p30576
aS'Myer, Landon'
p30577
aS'Valeri, Fabio'
p30578
aS'Zwahlen, Marcel'
p30579
aS'Wandeler, Gilles'
p30580
aS'Keiser, Olivia'
p30581
asS'LR'
p30582
S'20150515'
p30583
sS'PG'
p30584
S'589-98'
p30585
sS'TI'
p30586
S"Retention in care under universal antiretroviral therapy for HIV-infected pregnant and breastfeeding women ('Option B+') in Malawi."
p30587
sS'RN'
p30588
(lp30589
S'0 (Anti-Retroviral Agents)'
p30590
asS'PL'
p30591
S'England'
p30592
sS'TA'
p30593
S'AIDS'
p30594
sS'JID'
p30595
S'8710219'
p30596
sS'AB'
p30597
S"OBJECTIVE: To explore the levels and determinants of loss to follow-up (LTF) under universal lifelong antiretroviral therapy (ART) for pregnant and breastfeeding women ('Option B+') in Malawi. DESIGN, SETTING, AND PARTICIPANTS: We examined retention in care, from the date of ART initiation up to 6 months, for women in the Option B+ program. We analysed nationwide facility-level data on women who started ART at 540 facilities (n = 21,939), as well as individual-level data on patients who started ART at 19 large facilities (n = 11,534). RESULTS: Of the women who started ART under Option B+ (n = 21,939), 17% appeared to be lost to follow-up 6 months after ART initiation. Most losses occurred in the first 3 months of therapy. Option B+ patients who started therapy during pregnancy were five times more likely than women who started ART in WHO stage 3/4 or with a CD4 cell count 350 cells/mul or less, to never return after their initial clinic visit [odds ratio (OR) 5.0, 95% confidence interval (CI) 4.2-6.1]. Option B+ patients who started therapy while breastfeeding were twice as likely to miss their first follow-up visit (OR 2.2, 95% CI 1.8-2.8). LTF was highest in pregnant Option B+ patients who began ART at large clinics on the day they were diagnosed with HIV. LTF varied considerably between facilities, ranging from 0 to 58%. CONCLUSION: Decreasing LTF will improve the effectiveness of the Option B+ approach. Tailored interventions, like community or family-based models of care could improve its effectiveness."
p30598
sS'AD'
p30599
S'aDepartment of HIV and AIDS, Ministry of Health, Lilongwe, Malawi bInstitute of Social and Preventive Medicine, University of Bern, Switzerland cInternational Training and Education Centre for Health/Department for Global Health, University of Washington, Seattle, USA dLighthouse Trust Clinic, Lilongwe, Malawi eThe International Union Against Tuberculosis and Lung Disease, Paris, France fDignitas International, Zomba gBaobab Trust, Lilongwe, Malawi hDivision of Epidemiology & Biostatistics, School of Public Health & Family Medicine, University of Cape Town, South Africa iDepartment of Infectious Diseases, University Hospital Bern, Switzerland jDepartment of Infectious Diseases, University of Dakar, Dakar, Senegal. *Lyson Tenthani, Andreas D. Haas and Olivia Keiser contributed equally to the writing of this article.'
p30600
sS'CN'
p30601
(lp30602
S'Ministry of Health in Malawi and IeDEA Southern Africa'
p30603
asS'IP'
p30604
S'4'
sS'IS'
p30605
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p30606
sS'PMC'
p30607
S'PMC4009400'
p30608
sS'DCOM'
p30609
S'20140917'
p30610
sS'MID'
p30611
(lp30612
S'NIHMS574602'
p30613
asS'AU'
p30614
(lp30615
S'Tenthani L'
p30616
aS'Haas AD'
p30617
aS'Tweya H'
p30618
aS'Jahn A'
p30619
aS'van Oosterhout JJ'
p30620
aS'Chimbwandira F'
p30621
aS'Chirwa Z'
p30622
aS"Ng'ambi W"
p30623
aS'Bakali A'
p30624
aS'Phiri S'
p30625
aS'Myer L'
p30626
aS'Valeri F'
p30627
aS'Zwahlen M'
p30628
aS'Wandeler G'
p30629
aS'Keiser O'
p30630
asS'VI'
p30631
S'28'
p30632
sS'MHDA'
p30633
S'2014/09/18 06:00'
p30634
sS'OID'
p30635
(lp30636
S'NLM: NIHMS574602'
p30637
aS'NLM: PMC4009400'
p30638
asS'MH'
p30639
(lp30640
S'Adolescent'
p30641
aS'Adult'
p30642
aS'Anti-Retroviral Agents/*therapeutic use'
p30643
aS'*Antiretroviral Therapy, Highly Active'
p30644
aS'*Breast Feeding'
p30645
aS'Female'
p30646
aS'HIV Infections/*drug therapy'
p30647
aS'Health Services Research'
p30648
aS'Humans'
p30649
aS'*Lost to Follow-Up'
p30650
aS'Malawi'
p30651
aS'Middle Aged'
p30652
aS'Pregnancy'
p30653
aS'Pregnancy Complications, Infectious/*drug therapy'
p30654
aS'Young Adult'
p30655
asS'EDAT'
p30656
S'2014/01/29 06:00'
p30657
sS'SO'
p30658
S'AIDS. 2014 Feb 20;28(4):589-98. doi: 10.1097/QAD.0000000000000143.'
p30659
sS'SB'
p30660
S'IM X'
p30661
sS'PMID'
p30662
S'24468999'
p30663
sS'PST'
p30664
S'ppublish'
p30665
stRp30666
ag2
(g3
g4
(dp30667
S'LID'
p30668
S'10.1097/QAD.0000000000000110 [doi]'
p30669
sS'STAT'
p30670
S'MEDLINE'
p30671
sS'JT'
p30672
S'AIDS (London, England)'
p30673
sS'MID'
p30674
(lp30675
S'NIHMS594861'
p30676
asS'DA'
p30677
S'20140128'
p30678
sS'AID'
p30679
(lp30680
S'10.1097/QAD.0000000000000110 [doi]'
p30681
aS'00002030-201401001-00008 [pii]'
p30682
asS'CRDT'
p30683
(lp30684
S'2014/01/29 06:00'
p30685
asS'DP'
p30686
S'2014 Jan'
p30687
sS'AD'
p30688
S'aDepartment of Population Health, New York University School of Medicine, New York, New York, USA bSouth African Department of Science and Technology/National Research Foundation Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa cImperial College London, London, UK.'
p30689
sS'OWN'
p30690
S'NLM'
p30691
sS'PT'
p30692
(lp30693
S'Journal Article'
p30694
aS'Research Support, N.I.H., Extramural'
p30695
asS'LA'
p30696
(lp30697
S'eng'
p30698
asS'DCOM'
p30699
S'20140916'
p30700
sS'LR'
p30701
S'20150515'
p30702
sS'FAU'
p30703
(lp30704
S'Scott Braithwaite, Ronald'
p30705
aS'Nucifora, Kimberly A'
p30706
aS'Toohey, Christopher'
p30707
aS'Kessler, Jason'
p30708
aS'Uhler, Lauren M'
p30709
aS'Mentor, Sherry M'
p30710
aS'Keebler, Daniel'
p30711
aS'Hallett, Timothy'
p30712
asS'TI'
p30713
S'How do different eligibility guidelines for antiretroviral therapy affect the cost-effectiveness of routine viral load testing in sub-Saharan Africa?'
p30714
sS'RN'
p30715
(lp30716
S'0 (Anti-Retroviral Agents)'
p30717
asS'PL'
p30718
S'England'
p30719
sS'PG'
p30720
S'S73-83'
p30721
sS'JID'
p30722
S'8710219'
p30723
sS'AB'
p30724
S'BACKGROUND: Increased eligibility guidelines of antiretroviral therapy (ART) may lead to greater routine viral load monitoring. However, in resource-constrained settings, the additional resources required by greater routine viral load monitoring may impair ability to comply with expanded eligibility guidelines for ART. OBJECTIVE: We use a published validated computer simulation of the HIV epidemic in East African countries (expanded to include transmission as well as disease progression) to evaluate the cost-effectiveness of routine viral load monitoring. METHODS: We explored alternative scenarios regarding cost, frequency, and switching threshold of routine viral load monitoring (including every 6 or every 12 months; and switching thresholds of 1000, or 10 000 copies/ml), as well as alternative scenarios regarding ART initiation (200, 350, 500 cells/mul, and no CD4 cell threshold). For each ART initiation strategy, we sought to identify the viral load monitoring strategy at which the incremental cost-effectiveness ratio (ICER) of more frequent routine viral load testing became more favorable than the ICER of more expansive ART eligibility. Cost inputs were based on data provided by the Academic Model Providing Access to Healthcare (AMPATH), and disease progression inputs were based on prior published work. We used a discount rate of 3%, a time horizon of 20 years, and a payer perspective. RESULTS: Across a wide range of scenarios, and even when considering the beneficial effect of virological monitoring at reducing HIV transmission, earlier ART initiation conferred far greater health benefits for resources spent than routine virological testing, with ICERs of approximately $1000 to $2000 for earlier ART initiation, versus ICERs of approximately $5000 to $25 000 for routine virological monitoring. ICERs of viral load testing were insensitive to the cost of the viral load test, because most of the costs originated from the downstream higher costs of later regimens. ICERs of viral load testing were very sensitive to the relative cost of second-line compared with first-line regimens, assuming favorable value when the costs of these regimens were equal. CONCLUSION: If all HIV patients are not yet treated with ART starting at 500 cells/mul and costs of second regimens remain substantially more expensive than first-line regimens, resources would buy more population health if they are spent on earlier ART rather than being spent on routine virological testing.'
p30725
sS'GR'
p30726
(lp30727
S'R01 AA017385/AA/NIAAA NIH HHS/United States'
p30728
aS'R01 AA017385/AA/NIAAA NIH HHS/United States'
p30729
aS'U01AI069911-01/AI/NIAID NIH HHS/United States'
p30730
asS'VI'
p30731
S'28 Suppl 1'
p30732
sS'IS'
p30733
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p30734
sS'PMC'
p30735
S'PMC4089870'
p30736
sS'AU'
p30737
(lp30738
S'Scott Braithwaite R'
p30739
aS'Nucifora KA'
p30740
aS'Toohey C'
p30741
aS'Kessler J'
p30742
aS'Uhler LM'
p30743
aS'Mentor SM'
p30744
aS'Keebler D'
p30745
aS'Hallett T'
p30746
asS'MHDA'
p30747
S'2014/09/17 06:00'
p30748
sS'OID'
p30749
(lp30750
S'NLM: NIHMS594861'
p30751
aS'NLM: PMC4089870'
p30752
asS'MH'
p30753
(lp30754
S'Adult'
p30755
aS'Africa South of the Sahara/epidemiology'
p30756
aS'Anti-Retroviral Agents/*therapeutic use'
p30757
aS'Antiretroviral Therapy, Highly Active/*economics/*standards'
p30758
aS'Computer Simulation'
p30759
aS'Cost-Benefit Analysis'
p30760
aS'Female'
p30761
aS'HIV Infections/*diagnosis/drug therapy/epidemiology/*virology'
p30762
aS'Humans'
p30763
aS'Male'
p30764
aS'Middle Aged'
p30765
aS'Viral Load/*economics'
p30766
asS'EDAT'
p30767
S'2014/01/29 06:00'
p30768
sS'SO'
p30769
S'AIDS. 2014 Jan;28 Suppl 1:S73-83. doi: 10.1097/QAD.0000000000000110.'
p30770
sS'SB'
p30771
S'IM X'
p30772
sS'PMID'
p30773
S'24468949'
p30774
sS'TA'
p30775
S'AIDS'
p30776
sS'PST'
p30777
S'ppublish'
p30778
stRp30779
ag2
(g3
g4
(dp30780
S'LID'
p30781
S'10.1097/QAD.0000000000000081 [doi]'
p30782
sS'STAT'
p30783
S'MEDLINE'
p30784
sS'AB'
p30785
S"OBJECTIVE: EMOD-HIV v0.8 has been used to estimate the potential impact of expanding treatment guidelines to allow earlier initiation of antiretroviral therapy (ART) in sub-Saharan Africa with current or improved treatment coverage. In generating these results, a model must additionally make assumptions about the rates of dropout and re-initiation into ART programs before and after the program change, about which little is known. The objective of this work is to rigorously analyze modeling assumptions and the sensitivity of model results with respect to relevant mechanisms and parameters. METHODS: We varied key model assumptions pertaining to ART dropout and re-enrollment to analyze their effect on the cost, impact, and cost-effectiveness of expanding treatment guidelines, and of expanding coverage via improved testing and linkage to care. Additionally, we performed a sensitivity analysis of 17 relevant model parameters. SETTING: South Africa. RESULTS: Allowing re-initiation of ART irrespective of prior treatment doubled the cost and impact of expanding treatment guidelines, as compared with a scenario in which re-initiation could only be triggered by a health event (AIDS symptoms, diagnosis of a partner, or an antenatal care visit). Increasing the probability of 'voluntary' re-initiation (not triggered by a health event) was the most cost-effective way to improve the treatment program, especially in the short term because it provided immediate benefits to those who would otherwise have delayed re-initiation until the onset of AIDS symptoms. However, the maximum impact of this change was limited compared with expanding coverage through improvements in testing and linkage to care. Beyond improvements in coverage and re-initiation, further gains could be made by improving retention in care. Only with optimal retention in care was expansion of guidelines cost-saving after 20 years due to reductions in transmission. Re-initiation did not reduce transmission sufficiently to make a guideline change cost-effective due to transmission that occurred while patients were away from care. Sensitivity analysis suggested that enormous health benefits could be attained by improving treatment regimens to have higher efficacy at preventing transmission, increasing the proportion of the population with access to improved healthcare, and reducing 'leaks' in the 'cascade of care.' Increasing the proportion of individuals who receive CD4 cell results was particularly cost-effective at baseline levels of coverage, and increasing retention on ART was particularly cost-effective with expanded coverage. CONCLUSION: This analysis provides a sense of the magnitude of uncertainty in program cost and impact that policy-makers could anticipate in the face of uncertain future programmatic changes. Our findings suggest that increasing re-initiation is the most cost-effective means of initial program improvement, especially in the short term, but that improvements in retention are necessary in order to reap the full transmission-blocking benefits of a test-and-treat program in the long term."
p30786
sS'AD'
p30787
S'*Daniel J. Klein and Anna Bershteyn contributed equally to this work.'
p30788
sS'JT'
p30789
S'AIDS (London, England)'
p30790
sS'VI'
p30791
S'28 Suppl 1'
p30792
sS'IS'
p30793
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p30794
sS'JID'
p30795
S'8710219'
p30796
sS'DA'
p30797
S'20140128'
p30798
sS'AU'
p30799
(lp30800
S'Klein DJ'
p30801
aS'Bershteyn A'
p30802
aS'Eckhoff PA'
p30803
asS'AID'
p30804
(lp30805
S'10.1097/QAD.0000000000000081 [doi]'
p30806
aS'00002030-201401001-00006 [pii]'
p30807
asS'CRDT'
p30808
(lp30809
S'2014/01/29 06:00'
p30810
asS'PMID'
p30811
S'24468946'
p30812
sS'DP'
p30813
S'2014 Jan'
p30814
sS'MHDA'
p30815
S'2014/09/17 06:00'
p30816
sS'OWN'
p30817
S'NLM'
p30818
sS'PT'
p30819
(lp30820
S'Journal Article'
p30821
aS"Research Support, Non-U.S. Gov't"
p30822
asS'LA'
p30823
(lp30824
S'eng'
p30825
asS'MH'
p30826
(lp30827
S'Adolescent'
p30828
aS'Adult'
p30829
aS'Aged'
p30830
aS'Anti-Retroviral Agents/*therapeutic use'
p30831
aS'Child, Preschool'
p30832
aS'Cost-Benefit Analysis'
p30833
aS'Disease Transmission, Infectious/prevention & control'
p30834
aS'Female'
p30835
aS'HIV Infections/*drug therapy/economics/*epidemiology/transmission'
p30836
aS'Humans'
p30837
aS'Infant'
p30838
aS'Infant, Newborn'
p30839
aS'Male'
p30840
aS'Middle Aged'
p30841
aS'Patient Dropouts/*statistics & numerical data'
p30842
aS'Pregnancy'
p30843
aS'Projection'
p30844
aS'South Africa/epidemiology'
p30845
aS'Young Adult'
p30846
asS'DCOM'
p30847
S'20140916'
p30848
sS'EDAT'
p30849
S'2014/01/29 06:00'
p30850
sS'PST'
p30851
S'ppublish'
p30852
sS'SO'
p30853
S'AIDS. 2014 Jan;28 Suppl 1:S47-59. doi: 10.1097/QAD.0000000000000081.'
p30854
sS'FAU'
p30855
(lp30856
S'Klein, Daniel J'
p30857
aS'Bershteyn, Anna'
p30858
aS'Eckhoff, Philip A'
p30859
asS'TI'
p30860
S'Dropout and re-enrollment: implications for epidemiological projections of treatment programs.'
p30861
sS'SB'
p30862
S'IM X'
p30863
sS'RN'
p30864
(lp30865
S'0 (Anti-Retroviral Agents)'
p30866
asS'TA'
p30867
S'AIDS'
p30868
sS'PL'
p30869
S'England'
p30870
sS'PG'
p30871
S'S47-59'
p30872
stRp30873
ag2
(g3
g4
(dp30874
S'LID'
p30875
S'10.1097/QAD.0000000000000084 [doi]'
p30876
sS'STAT'
p30877
S'MEDLINE'
p30878
sS'JT'
p30879
S'AIDS (London, England)'
p30880
sS'DA'
p30881
S'20140128'
p30882
sS'AID'
p30883
(lp30884
S'10.1097/QAD.0000000000000084 [doi]'
p30885
aS'00002030-201401001-00005 [pii]'
p30886
asS'CRDT'
p30887
(lp30888
S'2014/01/29 06:00'
p30889
asS'DP'
p30890
S'2014 Jan'
p30891
sS'AD'
p30892
S"aSchool of Social and Community Medicine, University of Bristol, Bristol bSocial and Mathematical Epidemiology Group, London School of Hygiene and Tropical Medicine cDepartment of Health Services Research and Policy, London School of Hygiene and Tropical Medicine dDepartment of Infectious Disease Epidemiology, Imperial College London eBlizard Institute of Molecular Medicine, Queen Mary's University of London, London, UK fKirby Institute, University of New South Wales, Sydney, Australia gDepartment of HIV/AIDS, World Health Organization, Geneva, Switzerland."
p30893
sS'OWN'
p30894
S'NLM'
p30895
sS'PT'
p30896
(lp30897
S'Journal Article'
p30898
aS"Research Support, Non-U.S. Gov't"
p30899
asS'LA'
p30900
(lp30901
S'eng'
p30902
asS'DCOM'
p30903
S'20140916'
p30904
sS'LR'
p30905
S'20150708'
p30906
sS'FAU'
p30907
(lp30908
S'Martin, Natasha K'
p30909
aS'Devine, Angela'
p30910
aS'Eaton, Jeffrey W'
p30911
aS'Miners, Alec'
p30912
aS'Hallett, Timothy B'
p30913
aS'Foster, Graham R'
p30914
aS'Dore, Gregory J'
p30915
aS'Easterbrook, Philippa J'
p30916
aS'Legood, Rosa'
p30917
aS'Vickerman, Peter'
p30918
asS'TI'
p30919
S'Modeling the impact of early antiretroviral therapy for adults coinfected with HIV and hepatitis B or C in South Africa.'
p30920
sS'RN'
p30921
(lp30922
S'0 (Anti-Retroviral Agents)'
p30923
aS'0 (Antiviral Agents)'
p30924
asS'PL'
p30925
S'England'
p30926
sS'PG'
p30927
S'S35-46'
p30928
sS'JID'
p30929
S'8710219'
p30930
sS'AB'
p30931
S'OBJECTIVE: There has been discussion about whether individuals coinfected with HIV and hepatitis C virus (HCV) or hepatitis B virus (HBV) ( approximately 30% of all people living with HIV) should be prioritized for early HIV antiretroviral therapy (ART). We assess the relative benefits of providing ART at CD4 count below 500 cells/mul or immediate ART to HCV/HIV or HBV/HIV-coinfected adults compared with HIV-monoinfected adults. We evaluate individual outcomes (HIV/liver disease progression) and preventive benefits in a generalized HIV epidemic setting. METHODS: We modeled disease progression for HIV-monoinfected, HBV/HIV-coinfected, and HCV/HIV-coinfected adults for differing ART eligibility thresholds (CD4 <350 cells/mul, CD4 <500 cells/mul, immediate ART eligibility upon infection). We report disability-adjusted life-years averted per 100 person-years on ART (DALYaverted/100PYonART) as a measure of the health benefits generated from incremental changes in ART eligibility. Sensitivity analyses explored impact on sexual HIV and vertical HIV, HCV, and HBV transmission. RESULTS: For HBV/HIV-coinfected adults, a switch to ART initiation at CD4 count below 500 cells/mul from CD4 below 350 cells/mul generates 9% greater health benefits per year on ART (48 DALYaverted/100PYonART) than for HIV-monoinfected adults (44 DALYaverted/100PYonART). Additionally, ART at CD4 below 500 cells/mul could prevent 25% and 32% of vertical transmissions of HIV and HBV, respectively. For HCV/HIV-coinfected adults, ART at CD4 below 500 cells/mul generates 10% fewer health benefits (40 DALYaverted/100PYonART) than for HIV monoinfection, unless ART reduces progression to cirrhosis by more than 70% (33% in base-case). CONCLUSIONS: The additional therapeutic benefits of ART for HBV-related liver disease results in ART generating more health benefits among HBV/HIV-coinfected adults than HIV-monoinfected individuals, whereas less health benefits are generated amongst HCV/HIV coinfection in a generalized HIV epidemic setting.'
p30932
sS'GR'
p30933
(lp30934
S'G0801627/Medical Research Council/United Kingdom'
p30935
aS'MR/K010174/1/Medical Research Council/United Kingdom'
p30936
aS'PDF-2011-04-049/Department of Health/United Kingdom'
p30937
aS'Wellcome Trust/United Kingdom'
p30938
asS'VI'
p30939
S'28 Suppl 1'
p30940
sS'IS'
p30941
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p30942
sS'AU'
p30943
(lp30944
S'Martin NK'
p30945
aS'Devine A'
p30946
aS'Eaton JW'
p30947
aS'Miners A'
p30948
aS'Hallett TB'
p30949
aS'Foster GR'
p30950
aS'Dore GJ'
p30951
aS'Easterbrook PJ'
p30952
aS'Legood R'
p30953
aS'Vickerman P'
p30954
asS'MHDA'
p30955
S'2014/09/17 06:00'
p30956
sS'MH'
p30957
(lp30958
S'Adult'
p30959
aS'Aged'
p30960
aS'Aged, 80 and over'
p30961
aS'Anti-Retroviral Agents/*administration & dosage'
p30962
aS'Antiviral Agents/*administration & dosage'
p30963
aS'Drug Therapy, Combination/methods'
p30964
aS'Female'
p30965
aS'HIV Infections/complications/*drug therapy/epidemiology/transmission'
p30966
aS'Hepatitis B/complications/*drug therapy/epidemiology'
p30967
aS'Hepatitis C/complications/*drug therapy/epidemiology'
p30968
aS'Humans'
p30969
aS'Male'
p30970
aS'Middle Aged'
p30971
aS'Models, Theoretical'
p30972
aS'Secondary Prevention/methods'
p30973
aS'South Africa/epidemiology'
p30974
aS'Treatment Outcome'
p30975
asS'EDAT'
p30976
S'2014/01/29 06:00'
p30977
sS'SO'
p30978
S'AIDS. 2014 Jan;28 Suppl 1:S35-46. doi: 10.1097/QAD.0000000000000084.'
p30979
sS'SB'
p30980
S'IM X'
p30981
sS'PMID'
p30982
S'24468945'
p30983
sS'TA'
p30984
S'AIDS'
p30985
sS'PST'
p30986
S'ppublish'
p30987
stRp30988
ag2
(g3
g4
(dp30989
S'LID'
p30990
S'10.1002/14651858.CD009826.pub2 [doi]'
p30991
sS'STAT'
p30992
S'MEDLINE'
p30993
sS'DEP'
p30994
S'20140127'
p30995
sS'DA'
p30996
S'20140203'
p30997
sS'AID'
p30998
(lp30999
S'10.1002/14651858.CD009826.pub2 [doi]'
p31000
asS'CRDT'
p31001
(lp31002
S'2014/01/28 06:00'
p31003
asS'DP'
p31004
S'2014'
p31005
sS'AD'
p31006
S'Global Health Sciences, University of California, San Francisco, San Francisco, California, USA, 94105.'
p31007
sS'OWN'
p31008
S'NLM'
p31009
sS'PT'
p31010
(lp31011
S'Journal Article'
p31012
aS'Meta-Analysis'
p31013
aS'Review'
p31014
asS'LA'
p31015
(lp31016
S'eng'
p31017
asS'DCOM'
p31018
S'20140701'
p31019
sS'JT'
p31020
S'The Cochrane database of systematic reviews'
p31021
sS'LR'
p31022
S'20160602'
p31023
sS'FAU'
p31024
(lp31025
S'Anglemyer, Andrew'
p31026
aS'Agrawal, Anurag K'
p31027
aS'Rutherford, George W'
p31028
asS'TI'
p31029
S'Treatment of Kaposi sarcoma in children with HIV-1 infection.'
p31030
sS'RN'
p31031
(lp31032
S'0 (Anti-HIV Agents)'
p31033
aS'AIDS-related Kaposi sarcoma'
p31034
asS'PL'
p31035
S'England'
p31036
sS'PG'
p31037
S'CD009826'
p31038
sS'JID'
p31039
S'100909747'
p31040
sS'AB'
p31041
S"BACKGROUND: Kaposi sarcoma (KS) remains the second most frequently diagnosed HIV-related malignancy (HRM) worldwide and most common HRM in sub-Saharan Africa where HIV is most prevalent and human herpesvirus 8 (HHV-8), the precipitating agent for the development of KS, is endemic. The majority of KS patients would likely benefit from systemic chemotherapy in addition to the initiation of antiretroviral therapy (ART). However, as paediatric staging and treatment criteria are not readily available, there are no uniform treatment criteria. OBJECTIVES: To describe the efficacy and effectiveness of current treatment options for HIV-associated KS in ART-treated paediatric populations. SEARCH METHODS: We used standard Cochrane methods to search electronic databases and conference proceedings with relevant search terms without limits to language. SELECTION CRITERIA: Randomised controlled trials, cohort studies, and case-control studies of HIV-infected infants and children <18 years old treated with ART and diagnosed with KS. DATA COLLECTION AND ANALYSIS: Abstracts of all studies identified by electronic or bibliographic scanning were examined independently by two authors. We initially identified 920 references and examined 15 in detail for study eligibility. Data were abstracted independently using a standardised abstraction form. MAIN RESULTS: After initially screening 920 titles, 15 full-text articles were closely examined by two authors. We identified four cohort studies that met our inclusion criteria for data extraction, coding, and potential meta-analysis.Using the Newcastle-Ottawa Scale and Cochrane risk of bias assessments, all observational studies had cohorts that were representative of average (treated and untreated) HIV-infected children with Kaposi sarcoma. For all outcomes of interest, no study adjusted for any other potential confounders. Two of four observational studies either explicitly described complete follow up of the study participants and/or described the characteristics of the participants lost to follow up.The use of ART together with a chemotherapeutic regimen versus ART alone appears to increase the likelihood of KS remission in HIV-infected children diagnosed with KS, although data are sparse and not adequately adjusted for staging of disease and comorbidities. Additionally, though data are sparse, the use of ART together with a chemotherapeutic regimen versus chemotherapy alone in some analyses appears to increase the likelihood of KS remission and reduce the risk of death in HIV-infected children diagnosed with KS.In this analysis, we found that the quality of evidence was very low due to small sample sizes and a paucity of paediatric literature. AUTHORS' CONCLUSIONS: Data describing the efficacy of different treatment options for pediatric KS, to include chemotherapy and ART, are sparse. However, the use of ART together with a chemotherapy regimen may be superior to the use of ART alone or of chemotherapy alone."
p31042
sS'GR'
p31043
(lp31044
S'P30 MH062246/MH/NIMH NIH HHS/United States'
p31045
asS'IP'
p31046
S'1'
sS'IS'
p31047
S'1469-493X (Electronic) 1361-6137 (Linking)'
p31048
sS'AU'
p31049
(lp31050
S'Anglemyer A'
p31051
aS'Agrawal AK'
p31052
aS'Rutherford GW'
p31053
asS'MHDA'
p31054
S'2014/07/02 06:00'
p31055
sS'MH'
p31056
(lp31057
S'AIDS-Related Opportunistic Infections/*drug therapy'
p31058
aS'Anti-HIV Agents/*therapeutic use'
p31059
aS'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use'
p31060
aS'Child'
p31061
aS'Cohort Studies'
p31062
aS'Drug Therapy, Combination/methods'
p31063
aS'HIV Infections/drug therapy'
p31064
aS'*HIV-1'
p31065
aS'Humans'
p31066
aS'Induction Chemotherapy/methods'
p31067
aS'Randomized Controlled Trials as Topic'
p31068
aS'Sarcoma, Kaposi/*drug therapy'
p31069
asS'EDAT'
p31070
S'2014/01/28 06:00'
p31071
sS'SO'
p31072
S'Cochrane Database Syst Rev. 2014 Jan 27;(1):CD009826. doi: 10.1002/14651858.CD009826.pub2.'
p31073
sS'SB'
p31074
S'IM'
p31075
sS'PMID'
p31076
S'24464843'
p31077
sS'TA'
p31078
S'Cochrane Database Syst Rev'
p31079
sS'PST'
p31080
S'epublish'
p31081
stRp31082
ag2
(g3
g4
(dp31083
S'LID'
p31084
S'10.7448/IAS.17.1.18646 [doi]'
p31085
sS'STAT'
p31086
S'MEDLINE'
p31087
sS'DEP'
p31088
S'20140115'
p31089
sS'DA'
p31090
S'20140117'
p31091
sS'AID'
p31092
(lp31093
S'18646 [pii]'
p31094
asS'CRDT'
p31095
(lp31096
S'2014/01/18 06:00'
p31097
asS'DP'
p31098
S'2014'
p31099
sS'OWN'
p31100
S'NLM'
p31101
sS'PT'
p31102
(lp31103
S'Journal Article'
p31104
aS"Research Support, Non-U.S. Gov't"
p31105
asS'LA'
p31106
(lp31107
S'eng'
p31108
asS'DCOM'
p31109
S'20140926'
p31110
sS'JT'
p31111
S'Journal of the International AIDS Society'
p31112
sS'LR'
p31113
S'20150515'
p31114
sS'FAU'
p31115
(lp31116
S'Penot, Pauline'
p31117
aS'Hema, Arsene'
p31118
aS'Bado, Guillaume'
p31119
aS'Kabore, Firmin'
p31120
aS'Sore, Ibrahim'
p31121
aS'Sombie, Diamasso'
p31122
aS'Traore, Jean-Richard'
p31123
aS'Guiard-Schmid, Jean-Baptiste'
p31124
aS'Fontanet, Arnaud'
p31125
aS'Slama, Laurence'
p31126
aS'Bruno Sawadogo, Adrien'
p31127
aS'Laurent, Christian'
p31128
asS'TI'
p31129
S'The vulnerability of men to virologic failure during antiretroviral therapy in a public routine clinic in Burkina Faso.'
p31130
sS'RN'
p31131
(lp31132
S'0 (Anti-HIV Agents)'
p31133
asS'PL'
p31134
S'Switzerland'
p31135
sS'PG'
p31136
S'18646'
p31137
sS'JID'
p31138
S'101478566'
p31139
sS'AB'
p31140
S'INTRODUCTION: Gender differences in antiretroviral therapy (ART) outcomes are critical in sub-Saharan Africa. We assessed the association between gender and virologic failure among adult patients treated in a public routine clinic (one of the largest in West Africa) in Burkina Faso. METHODS: We performed a case-control study between July and October 2012 among patients who had received ART at the Bobo Dioulasso Day Care Unit. Patients were eligible if they were 15 years or older, positive for HIV-1 or HIV-1+2, and on first-line ART for at least six months. Cases were all patients with two consecutive HIV loads >1000 copies/mL (Biocentric Generic or Abbott Real Time assays), or one HIV load >1000 copies/mL associated with immunologic or clinical failure criteria. Controls were all patients who only had HIV loads <300 copies/mL. The association between gender and virologic failure was assessed using a multivariate logistic regression, adjusted on age, level of education, baseline CD4+ T cell count, first and current antiretroviral regimens and time on ART. RESULTS: Of 2303 patients (74.2% women; median age: 40 years; median time on ART: 34 months), 172 had virologic failure and 2131 had virologic success. Among the former, 130 (75.6%) had confirmed virologic failure, 38 (22.1%) had viro-immunologic failure, and four (2.3%) had viro-clinical failure. The proportion of men was significantly higher among the cases than among the controls (37.2% vs. 24.9%; p<0.001). Compared to controls, cases were also younger, more immunodeficient at ART initiation, less likely to receive a protease inhibitor-based antiretroviral regimen and had spent a longer period of time on ART. After adjustment, male gender remained strongly associated with virologic failure (odds ratio 2.52, 95% CI: 1.77-3.60; p<0.001). CONCLUSIONS: Men on ART appeared more vulnerable to virologic failure than women. Additional studies are needed to confirm the poorer prognosis of men in this setting and to determine the causes for their vulnerability in order to optimize HIV care. From now on, efforts should be made to support the adherence of men to ART in the African setting.'
p31141
sS'AD'
p31142
S'Hopital de jour du service de medecine interne du CHU Sanou Souro, Bobo-Dioulasso, Burkina Faso; UMI 233, Institut de Recherche pour le Developpement (IRD), Universite Montpellier 1, Montpellier, France; penotpauline@gmail.com. Hopital de jour du service de medecine interne du CHU Sanou Souro, Bobo-Dioulasso, Burkina Faso. Hopital de jour du service de medecine interne du CHU Sanou Souro, Bobo-Dioulasso, Burkina Faso. Hopital de jour du service de medecine interne du CHU Sanou Souro, Bobo-Dioulasso, Burkina Faso. Hopital de jour du service de medecine interne du CHU Sanou Souro, Bobo-Dioulasso, Burkina Faso. Hopital de jour du service de medecine interne du CHU Sanou Souro, Bobo-Dioulasso, Burkina Faso. Hopital de jour du service de medecine interne du CHU Sanou Souro, Bobo-Dioulasso, Burkina Faso. Initiatives Conseil International - Sante, Ouagadougou, Burkina Faso. Emerging Diseases Epidemiology Unit, Institut Pasteur, Paris, France; Conservatoire National des Arts et Metiers, Paris, France. Service des maladies infectieuses et tropicales, hopital Tenon, Paris, France. Hopital de jour du service de medecine interne du CHU Sanou Souro, Bobo-Dioulasso, Burkina Faso. UMI 233, Institut de Recherche pour le Developpement (IRD), Universite Montpellier 1, Montpellier, France.'
p31143
sS'VI'
p31144
S'17'
p31145
sS'IS'
p31146
S'1758-2652 (Electronic) 1758-2652 (Linking)'
p31147
sS'PMC'
p31148
S'PMC3895258'
p31149
sS'AU'
p31150
(lp31151
S'Penot P'
p31152
aS'Hema A'
p31153
aS'Bado G'
p31154
aS'Kabore F'
p31155
aS'Sore I'
p31156
aS'Sombie D'
p31157
aS'Traore JR'
p31158
aS'Guiard-Schmid JB'
p31159
aS'Fontanet A'
p31160
aS'Slama L'
p31161
aS'Bruno Sawadogo A'
p31162
aS'Laurent C'
p31163
asS'MHDA'
p31164
S'2014/09/27 06:00'
p31165
sS'PHST'
p31166
(lp31167
S'2014 [ecollection]'
p31168
aS'2013/04/17 [received]'
p31169
aS'2013/11/15 [revised]'
p31170
aS'2013/11/27 [accepted]'
p31171
asS'OT'
p31172
(lp31173
S'Africa'
p31174
aS'HIV'
p31175
aS'antiretroviral'
p31176
aS'efficacy'
p31177
aS'gender'
p31178
aS'virologic failure'
p31179
asS'OTO'
p31180
(lp31181
S'NOTNLM'
p31182
asS'OID'
p31183
(lp31184
S'NLM: PMC3895258'
p31185
asS'MH'
p31186
(lp31187
S'Adult'
p31188
aS'Anti-HIV Agents/*therapeutic use'
p31189
aS'Burkina Faso/epidemiology'
p31190
aS'CD4 Lymphocyte Count'
p31191
aS'Case-Control Studies'
p31192
aS'Female'
p31193
aS'HIV Infections/*drug therapy/virology'
p31194
aS'HIV-1/drug effects'
p31195
aS'HIV-2/drug effects'
p31196
aS'Humans'
p31197
aS'Male'
p31198
aS'Middle Aged'
p31199
aS'Sex Factors'
p31200
aS'Treatment Failure'
p31201
aS'Viral Load/drug effects'
p31202
asS'EDAT'
p31203
S'2014/01/18 06:00'
p31204
sS'SO'
p31205
S'J Int AIDS Soc. 2014 Jan 15;17:18646. doi: 10.7448/IAS.17.1.18646. eCollection 2014.'
p31206
sS'SB'
p31207
S'IM X'
p31208
sS'PMID'
p31209
S'24433983'
p31210
sS'TA'
p31211
S'J Int AIDS Soc'
p31212
sS'PST'
p31213
S'epublish'
p31214
stRp31215
ag2
(g3
g4
(dp31216
S'LID'
p31217
S'10.5588/ijtld.13.0627 [doi]'
p31218
sS'STAT'
p31219
S'MEDLINE'
p31220
sS'JT'
p31221
S'The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease'
p31222
sS'MID'
p31223
(lp31224
S'NIHMS762197'
p31225
asS'DA'
p31226
S'20140116'
p31227
sS'AID'
p31228
(lp31229
S'10.5588/ijtld.13.0627 [doi]'
p31230
asS'CRDT'
p31231
(lp31232
S'2014/01/17 06:00'
p31233
asS'DP'
p31234
S'2014 Feb'
p31235
sS'AD'
p31236
S'Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa. Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa. Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa. Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa. Departments of Internal Medicine and Epidemiology, Yale University School of Medicine, New Haven, Connecticut, USA.'
p31237
sS'OWN'
p31238
S'NLM'
p31239
sS'PT'
p31240
(lp31241
S'Comparative Study'
p31242
aS'Journal Article'
p31243
aS'Randomized Controlled Trial'
p31244
aS'Research Support, N.I.H., Extramural'
p31245
aS"Research Support, Non-U.S. Gov't"
p31246
aS"Research Support, U.S. Gov't, Non-P.H.S."
p31247
asS'LA'
p31248
(lp31249
S'eng'
p31250
asS'FAU'
p31251
(lp31252
S'Padayatchi, N'
p31253
aS'Abdool Karim, S S'
p31254
aS'Naidoo, K'
p31255
aS'Grobler, A'
p31256
aS'Friedland, G'
p31257
asS'LR'
p31258
S'20160303'
p31259
sS'PG'
p31260
S'147-54'
p31261
sS'TI'
p31262
S'Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial.'
p31263
sS'RN'
p31264
(lp31265
S'0 (Anti-HIV Agents)'
p31266
aS'0 (Antitubercular Agents)'
p31267
asS'PL'
p31268
S'France'
p31269
sS'TA'
p31270
S'Int J Tuberc Lung Dis'
p31271
sS'JID'
p31272
S'9706389'
p31273
sS'AB'
p31274
S'BACKGROUND: The therapeutic effects of antiretroviral treatment (ART) in patients with multidrug-resistant tuberculosis (MDR-TB) and human immunodeficiency virus (HIV) infection have not been established. OBJECTIVE: To assess therapeutic outcomes of integrating ART with treatment for MDR-TB. DESIGN: A subgroup of MDR-TB patients from a randomised controlled trial, the SAPiT (Starting Antiretroviral Therapy at Three Points in Tuberculosis) study, conducted in an out-patient clinic in Durban, South Africa, from 2008 to 2012. METHODS: Clinical outcomes at 18 months were compared in patients randomised to receive ART within 12 weeks of initiating standard first-line anti-tuberculosis treatment with those who commenced ART after completing anti-tuberculosis treatment. RESULTS: Mycobacterium tuberculosis drug susceptibility results were available in 489 (76%) of 642 SAPiT patients: 23 had MDR-TB, 14 in the integrated treatment arm and 9 in the sequential treatment arm. At 18 months, the mortality rate was 11.9/100 person-years (py; 95%CI 1.4-42.8) in the combined integrated treatment arm and 56.0/100 py (95%CI 18.2-130.8) in the sequential treatment arm (hazard ratio adjusted for baseline CD4 count and whether MDR-TB treatment was initiated: 0.14; 95%CI 0.02-0.94, P = 0.04). CONCLUSION: Despite the small sample size, the 86% reduction in mortality due to early initiation of ART in MDR-TB patients was statistically significant.'
p31275
sS'GR'
p31276
(lp31277
S'5U26PS001350/PS/NCHHSTP CDC HHS/United States'
p31278
aS'D43 TW000231/TW/FIC NIH HHS/United States'
p31279
aS'D43TW00231/TW/FIC NIH HHS/United States'
p31280
aS'U19 AI051794/AI/NIAID NIH HHS/United States'
p31281
aS'U2G PS001350/PS/NCHHSTP CDC HHS/United States'
p31282
aS'PEPFAR/United States'
p31283
asS'IP'
p31284
S'2'
sS'IS'
p31285
S'1815-7920 (Electronic) 1027-3719 (Linking)'
p31286
sS'PMC'
p31287
S'PMC4770013'
p31288
sS'DCOM'
p31289
S'20140929'
p31290
sS'AU'
p31291
(lp31292
S'Padayatchi N'
p31293
aS'Abdool Karim SS'
p31294
aS'Naidoo K'
p31295
aS'Grobler A'
p31296
aS'Friedland G'
p31297
asS'VI'
p31298
S'18'
p31299
sS'MHDA'
p31300
S'2014/09/30 06:00'
p31301
sS'OID'
p31302
(lp31303
S'NLM: NIHMS762197'
p31304
aS'NLM: PMC4770013'
p31305
asS'MH'
p31306
(lp31307
S'Adult'
p31308
aS'Aged'
p31309
aS'Anti-HIV Agents/*therapeutic use'
p31310
aS'Antitubercular Agents/*therapeutic use'
p31311
aS'CD4 Lymphocyte Count'
p31312
aS'*Coinfection'
p31313
aS'Female'
p31314
aS'HIV Infections/diagnosis/*drug therapy/mortality'
p31315
aS'Humans'
p31316
aS'Kaplan-Meier Estimate'
p31317
aS'Male'
p31318
aS'Middle Aged'
p31319
aS'South Africa/epidemiology'
p31320
aS'Time Factors'
p31321
aS'Treatment Outcome'
p31322
aS'Tuberculosis, Multidrug-Resistant/diagnosis/*drug therapy/mortality'
p31323
asS'EDAT'
p31324
S'2014/01/17 06:00'
p31325
sS'SO'
p31326
S'Int J Tuberc Lung Dis. 2014 Feb;18(2):147-54. doi: 10.5588/ijtld.13.0627.'
p31327
sS'SB'
p31328
S'IM'
p31329
sS'PMID'
p31330
S'24429305'
p31331
sS'PST'
p31332
S'ppublish'
p31333
stRp31334
ag2
(g3
g4
(dp31335
S'LID'
p31336
S'10.1002/sim.6087 [doi]'
p31337
sS'STAT'
p31338
S'MEDLINE'
p31339
sS'DEP'
p31340
S'20140110'
p31341
sS'CI'
p31342
(lp31343
S'Copyright (c) 2014 John Wiley & Sons, Ltd.'
p31344
asS'DA'
p31345
S'20140506'
p31346
sS'AID'
p31347
(lp31348
S'10.1002/sim.6087 [doi]'
p31349
asS'CRDT'
p31350
(lp31351
S'2014/01/11 06:00'
p31352
asS'DP'
p31353
S'2014 May 30'
p31354
sS'AD'
p31355
S'Department of Mathematics, Vassar College, Poughkeepsie, NY 12604, U.S.A.'
p31356
sS'OWN'
p31357
S'NLM'
p31358
sS'PT'
p31359
(lp31360
S'Journal Article'
p31361
aS'Research Support, N.I.H., Extramural'
p31362
aS"Research Support, Non-U.S. Gov't"
p31363
aS"Research Support, U.S. Gov't, Non-P.H.S."
p31364
asS'LA'
p31365
(lp31366
S'eng'
p31367
asS'FAU'
p31368
(lp31369
S'An, Ming-Wen'
p31370
aS'Frangakis, Constantine E'
p31371
aS'Yiannoutsos, Constantin T'
p31372
asS'JT'
p31373
S'Statistics in medicine'
p31374
sS'LR'
p31375
S'20150530'
p31376
sS'PG'
p31377
S'2017-29'
p31378
sS'TI'
p31379
S"Choosing profile double-sampling designs for survival estimation with application to President's Emergency Plan for AIDS Relief evaluation."
p31380
sS'PL'
p31381
S'England'
p31382
sS'TA'
p31383
S'Stat Med'
p31384
sS'JID'
p31385
S'8215016'
p31386
sS'AB'
p31387
S"Most studies that follow subjects over time are challenged by having some subjects who dropout. Double sampling is a design that selects and devotes resources to intensively pursue and find a subset of these dropouts, then uses data obtained from these to adjust naive estimates, which are potentially biased by the dropout. Existing methods to estimate survival from double sampling assume a random sample. In limited-resource settings, however, generating accurate estimates using a minimum of resources is important. We propose using double-sampling designs that oversample certain profiles of dropouts as more efficient alternatives to random designs. First, we develop a framework to estimate the survival function under these profile double-sampling designs. We then derive the precision of these designs as a function of the rule for selecting different profiles, in order to identify more efficient designs. We illustrate using data from the United States President's Emergency Plan for AIDS Relief-funded HIV care and treatment program in western Kenya. Our results show why and how more efficient designs should oversample patients with shorter dropout times. Further, our work suggests generalizable practice for more efficient double-sampling designs, which can help maximize efficiency in resource-limited settings."
p31388
sS'GR'
p31389
(lp31390
S'R01 AI102710/AI/NIAID NIH HHS/United States'
p31391
aS'U01 AI069911/AI/NIAID NIH HHS/United States'
p31392
aS'U01-AI0669911/AI/NIAID NIH HHS/United States'
p31393
aS'PEPFAR/United States'
p31394
asS'IP'
p31395
S'12'
p31396
sS'IS'
p31397
S'1097-0258 (Electronic) 0277-6715 (Linking)'
p31398
sS'PMC'
p31399
S'PMC4013226'
p31400
sS'DCOM'
p31401
S'20150113'
p31402
sS'MID'
p31403
(lp31404
S'NIHMS551061'
p31405
asS'AU'
p31406
(lp31407
S'An MW'
p31408
aS'Frangakis CE'
p31409
aS'Yiannoutsos CT'
p31410
asS'VI'
p31411
S'33'
p31412
sS'MHDA'
p31413
S'2015/01/15 06:00'
p31414
sS'PHST'
p31415
(lp31416
S'2012/04/10 [received]'
p31417
aS'2013/12/05 [revised]'
p31418
aS'2013/12/11 [accepted]'
p31419
aS'2014/01/10 [aheadofprint]'
p31420
asS'OTO'
p31421
(lp31422
S'NOTNLM'
p31423
asS'OID'
p31424
(lp31425
S'NLM: NIHMS551061'
p31426
aS'NLM: PMC4013226'
p31427
asS'MH'
p31428
(lp31429
S'Acquired Immunodeficiency Syndrome/*mortality'
p31430
aS'Algorithms'
p31431
aS'Humans'
p31432
aS'*International Cooperation'
p31433
aS'Kenya/epidemiology'
p31434
aS'*Research Design'
p31435
aS'*Sampling Studies'
p31436
aS'*Survival Analysis'
p31437
aS'United States'
p31438
asS'EDAT'
p31439
S'2014/01/11 06:00'
p31440
sS'SO'
p31441
S'Stat Med. 2014 May 30;33(12):2017-29. doi: 10.1002/sim.6087. Epub 2014 Jan 10.'
p31442
sS'SB'
p31443
S'IM'
p31444
sS'PMID'
p31445
S'24408038'
p31446
sS'OT'
p31447
(lp31448
S'HIV'
p31449
aS'PEPFAR'
p31450
aS'covariates'
p31451
aS'double sampling'
p31452
aS'dropouts'
p31453
aS'loss to follow-up'
p31454
aS'potential outcomes'
p31455
aS'profile sampling'
p31456
aS'survival'
p31457
asS'PST'
p31458
S'ppublish'
p31459
stRp31460
ag2
(g3
g4
(dp31461
S'LID'
p31462
S'10.1371/journal.pone.0083524 [doi]'
p31463
sS'STAT'
p31464
S'MEDLINE'
p31465
sS'DEP'
p31466
S'20131231'
p31467
sS'DA'
p31468
S'20140106'
p31469
sS'AID'
p31470
(lp31471
S'10.1371/journal.pone.0083524 [doi]'
p31472
aS'PONE-D-13-27460 [pii]'
p31473
asS'CRDT'
p31474
(lp31475
S'2014/01/07 06:00'
p31476
asS'DP'
p31477
S'2013'
p31478
sS'AD'
p31479
S'Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda. Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda. Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda. Medical Research Council/Uganda Virus Research Institute Uganda Research Unit on AIDS, Entebbe, Uganda. Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda. School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America. Indiana University Richard M. Fairbanks School of Public Health, Department of Biostatistics, Indianapolis, Indiana, United States of America. School of Public Health, College of Health Sciences, Makerere University Kampala, Uganda.'
p31480
sS'OWN'
p31481
S'NLM'
p31482
sS'PT'
p31483
(lp31484
S'Comparative Study'
p31485
aS'Journal Article'
p31486
aS"Research Support, Non-U.S. Gov't"
p31487
aS'Validation Studies'
p31488
asS'LA'
p31489
(lp31490
S'eng'
p31491
asS'FAU'
p31492
(lp31493
S'Kiragga, Agnes N'
p31494
aS'Castelnuovo, Barbara'
p31495
aS'Musomba, Rachel'
p31496
aS'Levin, Jonathan'
p31497
aS'Kambugu, Andrew'
p31498
aS'Manabe, Yukari C'
p31499
aS'Yiannoutsos, Constantin T'
p31500
aS'Kiwanuka, Noah'
p31501
asS'JT'
p31502
S'PloS one'
p31503
sS'LR'
p31504
S'20150528'
p31505
sS'PG'
p31506
S'e83524'
p31507
sS'TI'
p31508
S'Comparison of methods for correction of mortality estimates for loss to follow-up after ART initiation: a case of the Infectious Diseases Institute, Uganda.'
p31509
sS'RN'
p31510
(lp31511
S'0 (Anti-HIV Agents)'
p31512
asS'PL'
p31513
S'United States'
p31514
sS'TA'
p31515
S'PLoS One'
p31516
sS'JID'
p31517
S'101285081'
p31518
sS'AB'
p31519
S'BACKGROUND: In sub-Saharan Africa, a large proportion of HIV positive patients on antiretroviral therapy (ART) are lost to follow-up, some of whom are dead. The objective of this study was to validate methods used to correct mortality estimates for loss-to-follow-up using a cohort with complete death ascertainment. METHODS: Routinely collected data from HIV patients initiating first line antiretroviral therapy (ART) at the Infectious Diseases Institute (IDI) (Routine Cohort) was used. Three methods to estimate mortality after initiation were: 1) standard Kaplan-Meier estimation (uncorrected method) that uses passively observed data; 2) double-sampling methods by Frangakis and Rubin (F&R) where deaths obtained from patient tracing studies are given a higher weight than those passively ascertained; 3) Nomogram proposed by Egger et al. Corrected mortality estimates in the Routine Cohort, were compared with the estimates from the IDI research observational cohort (Research Cohort), which was used as the "gold-standard". RESULTS: We included 5,633 patients from the Routine Cohort and 559 from the Research Cohort. Uncorrected mortality estimates (95% confidence interval [1]) in the Routine Cohort at 1, 2 and 3 years were 5.5% (4.9%-6.3%), 6.6% (5.9%-7.5%) and 7.4% (6.5%-8.5%), respectively. The F&R corrected estimates at 1, 2 and 3 years were 11.2% (5.8%-21.2%), 15.8% (9.9%-24.8%) and 18.5% (12.3% -27.2%) respectively. The estimates obtained from the Research Cohort were 15.6% (12.8%-18.9%), 17.5% (14.6%-21.0%) and 19.0% (15.3%-21.9%) at 1, 2 and 3 years respectively. Using the nomogram method in the Routine Cohort, the corrected programme-level mortality estimate in year 1 was 11.9% (8.0%-15.7%). CONCLUSION: Mortality adjustments provided by the F&R and nomogram methods are adequate and should be employed to correct mortality for loss-to-follow-up in large HIV care centres in Sub-Saharan Africa.'
p31520
sS'GR'
p31521
(lp31522
S'R01 AI102710/AI/NIAID NIH HHS/United States'
p31523
aS'Wellcome Trust/United Kingdom'
p31524
asS'IP'
p31525
S'12'
p31526
sS'IS'
p31527
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p31528
sS'PMC'
p31529
S'PMC3877043'
p31530
sS'DCOM'
p31531
S'20140825'
p31532
sS'AU'
p31533
(lp31534
S'Kiragga AN'
p31535
aS'Castelnuovo B'
p31536
aS'Musomba R'
p31537
aS'Levin J'
p31538
aS'Kambugu A'
p31539
aS'Manabe YC'
p31540
aS'Yiannoutsos CT'
p31541
aS'Kiwanuka N'
p31542
asS'VI'
p31543
S'8'
sS'MHDA'
p31544
S'2014/08/26 06:00'
p31545
sS'PHST'
p31546
(lp31547
S'2013 [ecollection]'
p31548
aS'2013/07/03 [received]'
p31549
aS'2013/11/05 [accepted]'
p31550
aS'2013/12/31 [epublish]'
p31551
asS'OID'
p31552
(lp31553
S'NLM: PMC3877043'
p31554
asS'MH'
p31555
(lp31556
S'Adult'
p31557
aS'Anti-HIV Agents/*therapeutic use'
p31558
aS'Cohort Studies'
p31559
aS'Confidence Intervals'
p31560
aS'Female'
p31561
aS'Follow-Up Studies'
p31562
aS'HIV Infections/*drug therapy/*mortality'
p31563
aS'Humans'
p31564
aS'Kaplan-Meier Estimate'
p31565
aS'Lost to Follow-Up'
p31566
aS'Male'
p31567
aS'Uganda/epidemiology'
p31568
asS'EDAT'
p31569
S'2014/01/07 06:00'
p31570
sS'SO'
p31571
S'PLoS One. 2013 Dec 31;8(12):e83524. doi: 10.1371/journal.pone.0083524. eCollection 2013.'
p31572
sS'SB'
p31573
S'IM'
p31574
sS'PMID'
p31575
S'24391780'
p31576
sS'PST'
p31577
S'epublish'
p31578
stRp31579
ag2
(g3
g4
(dp31580
S'LID'
p31581
S'10.1111/tmi.12255 [doi]'
p31582
sS'STAT'
p31583
S'MEDLINE'
p31584
sS'DEP'
p31585
S'20140106'
p31586
sS'CI'
p31587
(lp31588
S'(c) 2014 John Wiley & Sons Ltd.'
p31589
asS'DA'
p31590
S'20140220'
p31591
sS'AID'
p31592
(lp31593
S'10.1111/tmi.12255 [doi]'
p31594
asS'CRDT'
p31595
(lp31596
S'2014/01/07 06:00'
p31597
asS'DP'
p31598
S'2014 Mar'
p31599
sS'AD'
p31600
S'Kilimanjaro Christian Medical University College, Moshi, Tanzania; National Institute for Medical Research, Mwanza, Tanzania.'
p31601
sS'OWN'
p31602
S'NLM'
p31603
sS'PT'
p31604
(lp31605
S'Journal Article'
p31606
aS"Research Support, Non-U.S. Gov't"
p31607
asS'LA'
p31608
(lp31609
S'eng'
p31610
asS'FAU'
p31611
(lp31612
S'Mwendo, Emanuel M'
p31613
aS'Mtuy, Tara B'
p31614
aS'Renju, Jenny'
p31615
aS'Rutherford, George W'
p31616
aS'Nondi, Joseph'
p31617
aS'Sichalwe, Aifello W'
p31618
aS'Todd, Jim'
p31619
asS'JT'
p31620
S'Tropical medicine & international health : TM & IH'
p31621
sS'LR'
p31622
S'20150528'
p31623
sS'PG'
p31624
S'267-74'
p31625
sS'TI'
p31626
S'Effectiveness of prevention of mother-to-child HIV transmission programmes in Kilimanjaro region, northern Tanzania.'
p31627
sS'RN'
p31628
(lp31629
S'0 (Anti-HIV Agents)'
p31630
asS'PL'
p31631
S'England'
p31632
sS'TA'
p31633
S'Trop Med Int Health'
p31634
sS'JID'
p31635
S'9610576'
p31636
sS'AB'
p31637
S'OBJECTIVE: To monitor the effectiveness of the prevention of mother-to-child transmission (PMTCT) components in reducing mother-to-child transmission of HIV in Kilimanjaro region, Tanzania. METHODS: We conducted a retrospective registry-based cohort study of HIV-exposed children aged 4 weeks to 18 months. Eligible children had a DNA polymerase chain reaction HIV antigen test between January 2009 and August 2012. We collected and analysed the data on the PMTCT components provided. We used logistic regression to explore factors associated with successful PMTCT usage and with infant infection. RESULTS: We studied 561 children; 283 (50.5%) were from rural areas. Breastfeeding was reported by 519 (92.5%) of mothers. In 469 (83.6%) mother-baby pairs, both received chemoprophylaxis, whereas in 9 (1.6%) pairs, neither mother nor baby received any chemoprophylaxis. Of the 522 (93.0%) infants with known outcomes at 6 months, 227 (43.5%) were alive, 258 (49.4%) were lost to follow-up, 34 (6.5%) had transferred and 3 (0.6%) had died. A total of 54 (9.6%) children were infected. Transmission rates of HIV when only the mother (adjusted odds ratio [aOR] 1.49, 95% CI: 0.47-4.77) or only the baby (aOR 1.06, 95% CI: 0.23-5.01) received chemoprophylaxis were not significantly different from transmission rates when both mother and baby received antiretroviral chemoprophylaxis. Mixed feeding practices were not associated with significantly increased risk (aOR 4.09, 95% CI: 0.58-28.76) compared with exclusive breastfeeding. CONCLUSION: This study showed that rate of MTCT of HIV was 9.6% in Tanzania between 2009 and 2012. The intrapartum and child chemoprophylaxis components of the PMTCT programme were well implemented with 84% of both mothers and their babies getting full chemoprophylaxis, and effective in reducing mother-to-child transmission.'
p31638
sS'GR'
p31639
(lp31640
S'P30 MH062246/MH/NIMH NIH HHS/United States'
p31641
asS'IP'
p31642
S'3'
sS'IS'
p31643
S'1365-3156 (Electronic) 1360-2276 (Linking)'
p31644
sS'DCOM'
p31645
S'20140414'
p31646
sS'AU'
p31647
(lp31648
S'Mwendo EM'
p31649
aS'Mtuy TB'
p31650
aS'Renju J'
p31651
aS'Rutherford GW'
p31652
aS'Nondi J'
p31653
aS'Sichalwe AW'
p31654
aS'Todd J'
p31655
asS'VI'
p31656
S'19'
p31657
sS'MHDA'
p31658
S'2014/04/15 06:00'
p31659
sS'PHST'
p31660
(lp31661
S'2014/01/06 [aheadofprint]'
p31662
asS'OTO'
p31663
(lp31664
S'NOTNLM'
p31665
asS'MH'
p31666
(lp31667
S'Anti-HIV Agents/therapeutic use'
p31668
aS'Breast Feeding/statistics & numerical data'
p31669
aS'Child, Preschool'
p31670
aS'Early Diagnosis'
p31671
aS'Female'
p31672
aS'*HIV Infections/epidemiology/prevention & control/transmission'
p31673
aS'Humans'
p31674
aS'Infant'
p31675
aS'Infectious Disease Transmission, Vertical/*prevention & control/statistics & numerical data'
p31676
aS'Logistic Models'
p31677
aS'Lost to Follow-Up'
p31678
aS'Mothers'
p31679
aS'Outcome Assessment (Health Care)/*statistics & numerical data'
p31680
aS'Patient Compliance/statistics & numerical data'
p31681
aS'Polymerase Chain Reaction'
p31682
aS'Postnatal Care/*methods'
p31683
aS'Practice Guidelines as Topic'
p31684
aS'Pregnancy'
p31685
aS'Pregnancy Complications, Infectious/drug therapy/epidemiology'
p31686
aS'Program Evaluation'
p31687
aS'*Registries'
p31688
aS'Regression Analysis'
p31689
aS'Retrospective Studies'
p31690
aS'Risk Reduction Behavior'
p31691
aS'Tanzania/epidemiology'
p31692
asS'EDAT'
p31693
S'2014/01/07 06:00'
p31694
sS'SO'
p31695
S'Trop Med Int Health. 2014 Mar;19(3):267-74. doi: 10.1111/tmi.12255. Epub 2014 Jan 6.'
p31696
sS'SB'
p31697
S'IM'
p31698
sS'PMID'
p31699
S'24386998'
p31700
sS'OT'
p31701
(lp31702
S'HIV'
p31703
aS'Tanzania'
p31704
aS'antiretroviral'
p31705
aS'breastfeeding'
p31706
aS'infants'
p31707
aS'vertical transmission'
p31708
asS'PST'
p31709
S'ppublish'
p31710
stRp31711
ag2
(g3
g4
(dp31712
S'LID'
p31713
S'10.1371/journal.pone.0083591 [doi]'
p31714
sS'STAT'
p31715
S'MEDLINE'
p31716
sS'DEP'
p31717
S'20131230'
p31718
sS'DA'
p31719
S'20140103'
p31720
sS'AID'
p31721
(lp31722
S'10.1371/journal.pone.0083591 [doi]'
p31723
aS'PONE-D-13-30874 [pii]'
p31724
asS'CRDT'
p31725
(lp31726
S'2014/01/04 06:00'
p31727
asS'DP'
p31728
S'2013'
p31729
sS'AD'
p31730
S'Vanderbilt Institute for Global Health, Nashville, Tennessee, United States of America ; Friends in Global Health, Maputo, Mozambique. Friends in Global Health, Maputo, Mozambique. Friends in Global Health, Maputo, Mozambique. Friends in Global Health, Maputo, Mozambique. Friends in Global Health, Maputo, Mozambique. Vanderbilt Institute for Global Health, Nashville, Tennessee, United States of America ; Friends in Global Health, Maputo, Mozambique. Friends in Global Health, Maputo, Mozambique.'
p31731
sS'OWN'
p31732
S'NLM'
p31733
sS'PT'
p31734
(lp31735
S'Journal Article'
p31736
aS'Observational Study'
p31737
aS'Research Support, N.I.H., Extramural'
p31738
aS"Research Support, Non-U.S. Gov't"
p31739
aS"Research Support, U.S. Gov't, P.H.S."
p31740
asS'LA'
p31741
(lp31742
S'eng'
p31743
asS'FAU'
p31744
(lp31745
S'Moon, Troy D'
p31746
aS'Silva, Wilson P'
p31747
aS'Buene, Manuel'
p31748
aS'Morais, Luis'
p31749
aS'Valverde, Emilio'
p31750
aS'Vermund, Sten H'
p31751
aS'Brentlinger, Paula E'
p31752
asS'JT'
p31753
S'PloS one'
p31754
sS'LR'
p31755
S'20150515'
p31756
sS'PG'
p31757
S'e83591'
p31758
sS'TI'
p31759
S'Bacteremia as a cause of fever in ambulatory, HIV-infected Mozambican adults: results and policy implications from a prospective observational study.'
p31760
sS'PL'
p31761
S'United States'
p31762
sS'TA'
p31763
S'PLoS One'
p31764
sS'JID'
p31765
S'101285081'
p31766
sS'AB'
p31767
S'Fever is typically treated empirically in rural Mozambique. We examined the distribution and antimicrobial susceptibility patterns of bacterial pathogens isolated from blood-culture specimens, and clinical characteristics of ambulatory HIV-infected febrile patients with and without bacteremia. This analysis was nested within a larger prospective observational study to evaluate the performance of new Mozambican guidelines for fever and anemia in HIV-infected adults (clinical trial registration NCT01681914, www.clinicaltrials.gov); the guidelines were designed to be used by non-physician clinicians who attended ambulatory HIV-infected patients in very resource-constrained peripheral health units. In 2012 (April-September), we recruited 258 HIV-infected adults with documented fever or history of recent fever in three sites within Zambezia Province, Mozambique. Although febrile patients were routinely tested for malaria, blood culture capacity was unavailable in Zambezia prior to study initiation. We confirmed bacteremia in 39 (15.1%) of 258 patients. The predominant organisms were non-typhoid Salmonella, nearly all resistant to multiple first-line antibiotics (ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole). Features most associated with bacteremia included higher temperature, lower CD4+ T-lymphocyte count, lower hemoglobin, and headache. Introduction of blood cultures allowed us to: 1) confirm bacteremia in a substantial proportion of patients; 2) tailor specific antimicrobial therapy for confirmed bacteremia based on known susceptibilities; 3) make informed choices of presumptive antibiotics for patients with suspected bacteremia; and 4) construct a preliminary clinical profile to help clinicians determine who would most likely benefit from presumptive bacteremia treatment. Our findings demonstrate that in resource-limited settings, there is urgent need to expand local microbiologic capacity to better identify and treat cases of bacteremia in HIV-infected and other patients, and to support surveillance. Data on the prevalence and susceptibility patterns of important pathogens can guide national formulary and prescribing practices.'
p31768
sS'GR'
p31769
(lp31770
S'U2GPS000631/PHS HHS/United States'
p31771
aS'UL1 TR000445/TR/NCATS NIH HHS/United States'
p31772
aS'PEPFAR/United States'
p31773
asS'IP'
p31774
S'12'
p31775
sS'IS'
p31776
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p31777
sS'PMC'
p31778
S'PMC3875454'
p31779
sS'DCOM'
p31780
S'20140916'
p31781
sS'AU'
p31782
(lp31783
S'Moon TD'
p31784
aS'Silva WP'
p31785
aS'Buene M'
p31786
aS'Morais L'
p31787
aS'Valverde E'
p31788
aS'Vermund SH'
p31789
aS'Brentlinger PE'
p31790
asS'VI'
p31791
S'8'
sS'MHDA'
p31792
S'2014/09/17 06:00'
p31793
sS'PHST'
p31794
(lp31795
S'2013 [ecollection]'
p31796
aS'2013/07/25 [received]'
p31797
aS'2013/11/13 [accepted]'
p31798
aS'2013/12/30 [epublish]'
p31799
asS'OID'
p31800
(lp31801
S'NLM: PMC3875454'
p31802
asS'MH'
p31803
(lp31804
S'*Ambulatory Care'
p31805
aS'Bacteremia/*complications/diagnosis/epidemiology'
p31806
aS'*Coinfection'
p31807
aS'Female'
p31808
aS'Fever/diagnosis/epidemiology/*microbiology'
p31809
aS'Geography'
p31810
aS'HIV Infections/*complications/epidemiology'
p31811
aS'Humans'
p31812
aS'Male'
p31813
aS'Microbial Sensitivity Tests'
p31814
aS'Mozambique/epidemiology'
p31815
aS'Outcome Assessment (Health Care)'
p31816
aS'Prospective Studies'
p31817
aS'Public Health Surveillance'
p31818
asS'EDAT'
p31819
S'2014/01/05 06:00'
p31820
sS'SI'
p31821
(lp31822
S'ClinicalTrials.gov/NCT01681914'
p31823
asS'SO'
p31824
S'PLoS One. 2013 Dec 30;8(12):e83591. doi: 10.1371/journal.pone.0083591. eCollection 2013.'
p31825
sS'SB'
p31826
S'IM'
p31827
sS'PMID'
p31828
S'24386229'
p31829
sS'PST'
p31830
S'epublish'
p31831
stRp31832
ag2
(g3
g4
(dp31833
S'LID'
p31834
S'10.1371/journal.pone.0083193 [doi]'
p31835
sS'STAT'
p31836
S'MEDLINE'
p31837
sS'DEP'
p31838
S'20131230'
p31839
sS'DA'
p31840
S'20140103'
p31841
sS'AID'
p31842
(lp31843
S'10.1371/journal.pone.0083193 [doi]'
p31844
aS'PONE-D-13-30009 [pii]'
p31845
asS'CRDT'
p31846
(lp31847
S'2014/01/04 06:00'
p31848
asS'DP'
p31849
S'2013'
p31850
sS'AD'
p31851
S'Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, United Kingdom. Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, United Kingdom. Wits Reproductive Health and HIV Institute, Hillbrow, Johannesburg, Gauteng, South Africa ; Collaborative Research Network for Mental Health and Wellbeing in Rural and Regional Communities (CRN), University of New England, Armidale, NSW, Australia. Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, United Kingdom. Wits Reproductive Health and HIV Institute, Hillbrow, Johannesburg, Gauteng, South Africa. Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, United Kingdom.'
p31852
sS'OWN'
p31853
S'NLM'
p31854
sS'PT'
p31855
(lp31856
S'Journal Article'
p31857
aS"Research Support, Non-U.S. Gov't"
p31858
asS'LA'
p31859
(lp31860
S'eng'
p31861
asS'FAU'
p31862
(lp31863
S'Terris-Prestholt, Fern'
p31864
aS'Hanson, Kara'
p31865
aS'MacPhail, Catherine'
p31866
aS'Vickerman, Peter'
p31867
aS'Rees, Helen'
p31868
aS'Watts, Charlotte'
p31869
asS'JT'
p31870
S'PloS one'
p31871
sS'LR'
p31872
S'20150515'
p31873
sS'PG'
p31874
S'e83193'
p31875
sS'TI'
p31876
S'How much demand for New HIV prevention technologies can we really expect? Results from a discrete choice experiment in South Africa.'
p31877
sS'PL'
p31878
S'United States'
p31879
sS'TA'
p31880
S'PLoS One'
p31881
sS'JID'
p31882
S'101285081'
p31883
sS'AB'
p31884
S"BACKGROUND: For the first time in the history of HIV, new bio-medical interventions have been shown to be effective in preventing HIV transmission. For these new HIV prevention technologies (NPTs) to have an impact on the epidemic, they must be widely used. This study uses a discrete choice experiment (DCE) to: understand the relative strength of women's preferences for product characteristics, understand the implications for substitution away from male condoms, and inform realistic modelling of their potential impact and cost-effectiveness. METHODS: A DCE was conducted among 1017 women in urban South Africa. Women were presented with choices between potential women's NPTs (microbicides, diaphragm, female condom) and 'what I did last time' (use or not use a condom) with different HIV and pregnancy prevention effectiveness' and prices. Choice probabilities are estimated using the nested logit model and used to predict uptake. RESULTS: In this high HIV prevalence setting, HIV prevention effectiveness is the main driver of uptake followed by pregnancy prevention effectiveness. For example a microbicide with poor effectiveness would have niche appeal at just 11% predicted uptake, while a highly effective microbicide (95% effective against HIV and pregnancy) would have far wider appeal (56% predicted uptake). Though women who reported not using condoms were more likely to choose the NPTs, at current very high rates of male condom use in South Africa (60%), about half of microbicide uptake is projected to be among those currently not using condoms. CONCLUSIONS: Women are very interested in NPTs, especially if highly effective in preventing HIV and pregnancy. Women in greatest need were also most likely to switch to the new products. Where products are not yet available for distribution, proxy data, such as that generated by DCEs, can bring realism to overly optimistic uptake scenarios found in many current impact models."
p31885
sS'GR'
p31886
(lp31887
S'Medical Research Council/United Kingdom'
p31888
asS'IP'
p31889
S'12'
p31890
sS'IS'
p31891
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p31892
sS'PMC'
p31893
S'PMC3875434'
p31894
sS'DCOM'
p31895
S'20140930'
p31896
sS'AU'
p31897
(lp31898
S'Terris-Prestholt F'
p31899
aS'Hanson K'
p31900
aS'MacPhail C'
p31901
aS'Vickerman P'
p31902
aS'Rees H'
p31903
aS'Watts C'
p31904
asS'VI'
p31905
S'8'
sS'MHDA'
p31906
S'2014/10/01 06:00'
p31907
sS'PHST'
p31908
(lp31909
S'2013 [ecollection]'
p31910
aS'2013/07/19 [received]'
p31911
aS'2013/11/11 [accepted]'
p31912
aS'2013/12/30 [epublish]'
p31913
asS'OID'
p31914
(lp31915
S'NLM: PMC3875434'
p31916
asS'MH'
p31917
(lp31918
S'*Choice Behavior'
p31919
aS'Contraceptive Devices'
p31920
aS'Female'
p31921
aS'HIV Infections/*prevention & control/transmission'
p31922
aS'Humans'
p31923
aS'South Africa'
p31924
asS'EDAT'
p31925
S'2014/01/05 06:00'
p31926
sS'SO'
p31927
S'PLoS One. 2013 Dec 30;8(12):e83193. doi: 10.1371/journal.pone.0083193. eCollection 2013.'
p31928
sS'SB'
p31929
S'IM'
p31930
sS'PMID'
p31931
S'24386160'
p31932
sS'PST'
p31933
S'epublish'
p31934
stRp31935
ag2
(g3
g4
(dp31936
S'LID'
p31937
S'10.1097/INF.0000000000000214 [doi]'
p31938
sS'STAT'
p31939
S'MEDLINE'
p31940
sS'JT'
p31941
S'The Pediatric infectious disease journal'
p31942
sS'MID'
p31943
(lp31944
S'NIHMS540908'
p31945
asS'DA'
p31946
S'20140516'
p31947
sS'AID'
p31948
(lp31949
S'10.1097/INF.0000000000000214 [doi]'
p31950
asS'CRDT'
p31951
(lp31952
S'2014/01/01 06:00'
p31953
asS'DP'
p31954
S'2014 Jun'
p31955
sS'GR'
p31956
(lp31957
S'2U01AI069924/AI/NIAID NIH HHS/United States'
p31958
aS'MR/J002380/1/Medical Research Council/United Kingdom'
p31959
aS'U01 AI069924/AI/NIAID NIH HHS/United States'
p31960
asS'OWN'
p31961
S'NLM'
p31962
sS'PT'
p31963
(lp31964
S'Journal Article'
p31965
aS'Research Support, N.I.H., Extramural'
p31966
aS"Research Support, Non-U.S. Gov't"
p31967
asS'LA'
p31968
(lp31969
S'eng'
p31970
asS'FAU'
p31971
(lp31972
S'Davies, Mary-Ann'
p31973
aS'May, Margaret'
p31974
aS'Bolton-Moore, Carolyn'
p31975
aS'Chimbetete, Cleophas'
p31976
aS'Eley, Brian'
p31977
aS'Garone, Daniela'
p31978
aS'Giddy, Janet'
p31979
aS'Moultrie, Harry'
p31980
aS'Ndirangu, James'
p31981
aS'Phiri, Sam'
p31982
aS'Rabie, Helena'
p31983
aS'Technau, Karl-Gunter'
p31984
aS'Wood, Robin'
p31985
aS'Boulle, Andrew'
p31986
aS'Egger, Matthias'
p31987
aS'Keiser, Olivia'
p31988
asS'LR'
p31989
S'20150601'
p31990
sS'PG'
p31991
S'608-16'
p31992
sS'TI'
p31993
S'Prognosis of children with HIV-1 infection starting antiretroviral therapy in Southern Africa: a collaborative analysis of treatment programs.'
p31994
sS'RN'
p31995
(lp31996
S'0 (Anti-Retroviral Agents)'
p31997
asS'PL'
p31998
S'United States'
p31999
sS'TA'
p32000
S'Pediatr Infect Dis J'
p32001
sS'FIR'
p32002
(lp32003
S'Wellington, Maureen'
p32004
aS'Eley, Brian'
p32005
aS'Fritz, Christiane'
p32006
aS'Stinson, Kathryn'
p32007
aS'Giddy, Janet'
p32008
aS'Fox, Matthew'
p32009
aS'Joseph, Helen'
p32010
aS'Heinrich, Sabine'
p32011
aS'Hoffmann, Christopher'
p32012
aS'Ndirangu, James'
p32013
aS'Pestilli, Sabrina'
p32014
aS'Phiri, Sam'
p32015
aS'Prozesky, Hans'
p32016
aS'Chi, Benjamin'
p32017
aS'Technau, Karl'
p32018
aS'Wood, Robin'
p32019
asS'JID'
p32020
S'8701858'
p32021
sS'AB'
p32022
S'BACKGROUND: Prognostic models for children starting antiretroviral therapy (ART) in Africa are lacking. We developed models to estimate the probability of death during the first year receiving ART in Southern Africa. METHODS: We analyzed data from children </=10 years of age who started ART in Malawi, South Africa, Zambia or Zimbabwe from 2004 to 2010. Children lost to follow up or transferred were excluded. The primary outcome was all-cause mortality in the first year of ART. We used Weibull survival models to construct 2 prognostic models: 1 with CD4%, age, World Health Organization clinical stage, weight-for-age z-score (WAZ) and anemia and the other without CD4%, because it is not routinely measured in many programs. We used multiple imputation to account for missing data. RESULTS: Among 12,655 children, 877 (6.9%) died in the first year of ART. We excluded 1780 children who were lost to follow up/transferred from main analyses; 10,875 children were therefore included. With the CD4% model probability of death at 1 year ranged from 1.8% [95% confidence interval (CI): 1.5-2.3] in children 5-10 years with CD4% >/=10%, World Health Organization stage I/II, WAZ >/= -2 and without severe anemia to 46.3% (95% CI: 38.2-55.2) in children <1 year with CD4% < 5%, stage III/IV, WAZ< -3 and severe anemia. The corresponding range for the model without CD4% was 2.2% (95% CI: 1.8-2.7) to 33.4% (95% CI: 28.2-39.3). Agreement between predicted and observed mortality was good (C-statistics = 0.753 and 0.745 for models with and without CD4%, respectively). CONCLUSIONS: These models may be useful to counsel children/caregivers, for program planning and to assess program outcomes after allowing for differences in patient disease severity characteristics.'
p32023
sS'AD'
p32024
S"From the *School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa; daggerSchool of Social and Community Medicine, University of Bristol, Bristol, United Kingdom; double daggerCentre for Infectious Disease Research in Zambia, Lusaka, Zambia; section signUniversity of North Carolina, Chapel Hill, NC; paragraph signNewlands clinic, Harare, Zimbabwe; ||Red Cross Children's Hospital and School of Child and Adolescent Health, University of Cape Town; **Medecins Sans Frontieres (MSF) South Africa and Khayelitsha ART Programme, Cape Town; daggerdaggerSinikithemba Clinic, McCord Hospital, Durban; double daggerdouble daggerWits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg; section sign section signHarriet Shezi Children's Clinic, Chris Hani Baragwanath Hospital, Soweto; paragraph sign paragraph signAfrica Centre for Health and Population Studies, University of Kwazulu-Natal, Somkhele, South Africa; || ||Lighthouse Trust Clinic, Kamuzu Central Hospital, Lilongwe, Malawi and Liverpool School of Tropical Medicine, Liverpool, United Kingdom; ***Tygerberg Academic Hospital, University of Stellenbosch, Stellenbosch; daggerdaggerdaggerEmpilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital, and University of the Witwatersrand, Johannesburg; double daggerdouble daggerdouble daggerGugulethu ART Programme and Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa; and section sign section sign section signInstitute of Social and Preventive Medicine (ISPM), University of Bern, Switzerland."
p32025
sS'CN'
p32026
(lp32027
S'IeDEA Southern Africa Collaboration'
p32028
asS'IP'
p32029
S'6'
sS'IS'
p32030
S'1532-0987 (Electronic) 0891-3668 (Linking)'
p32031
sS'IR'
p32032
(lp32033
S'Wellington M'
p32034
aS'Eley B'
p32035
aS'Fritz C'
p32036
aS'Stinson K'
p32037
aS'Giddy J'
p32038
aS'Fox M'
p32039
aS'Joseph H'
p32040
aS'Heinrich S'
p32041
aS'Hoffmann C'
p32042
aS'Ndirangu J'
p32043
aS'Pestilli S'
p32044
aS'Phiri S'
p32045
aS'Prozesky H'
p32046
aS'Chi B'
p32047
aS'Technau K'
p32048
aS'Wood R'
p32049
asS'DCOM'
p32050
S'20150223'
p32051
sS'AU'
p32052
(lp32053
S'Davies MA'
p32054
aS'May M'
p32055
aS'Bolton-Moore C'
p32056
aS'Chimbetete C'
p32057
aS'Eley B'
p32058
aS'Garone D'
p32059
aS'Giddy J'
p32060
aS'Moultrie H'
p32061
aS'Ndirangu J'
p32062
aS'Phiri S'
p32063
aS'Rabie H'
p32064
aS'Technau KG'
p32065
aS'Wood R'
p32066
aS'Boulle A'
p32067
aS'Egger M'
p32068
aS'Keiser O'
p32069
asS'VI'
p32070
S'33'
p32071
sS'MHDA'
p32072
S'2015/02/24 06:00'
p32073
sS'OID'
p32074
(lp32075
S'NLM: NIHMS540908'
p32076
aS'NLM: PMC4349941'
p32077
asS'MH'
p32078
(lp32079
S'Africa, Southern/epidemiology'
p32080
aS'Anti-Retroviral Agents/*therapeutic use'
p32081
aS'Child'
p32082
aS'Child, Preschool'
p32083
aS'Female'
p32084
aS'HIV Infections/*drug therapy/epidemiology/mortality'
p32085
aS'HIV-1/*isolation & purification'
p32086
aS'Humans'
p32087
aS'Infant'
p32088
aS'Infant, Newborn'
p32089
aS'Male'
p32090
aS'Prognosis'
p32091
aS'Treatment Outcome'
p32092
asS'EDAT'
p32093
S'2014/01/01 06:00'
p32094
sS'PMC'
p32095
S'PMC4349941'
p32096
sS'SO'
p32097
S'Pediatr Infect Dis J. 2014 Jun;33(6):608-16. doi: 10.1097/INF.0000000000000214.'
p32098
sS'SB'
p32099
S'IM'
p32100
sS'PMID'
p32101
S'24378936'
p32102
sS'PST'
p32103
S'ppublish'
p32104
stRp32105
ag2
(g3
g4
(dp32106
S'LID'
p32107
S'10.1097/QAI.0000000000000094 [doi]'
p32108
sS'STAT'
p32109
S'MEDLINE'
p32110
sS'JT'
p32111
S'Journal of acquired immune deficiency syndromes (1999)'
p32112
sS'MID'
p32113
(lp32114
S'NIHMS558603'
p32115
asS'DA'
p32116
S'20140408'
p32117
sS'AID'
p32118
(lp32119
S'10.1097/QAI.0000000000000094 [doi]'
p32120
asS'CRDT'
p32121
(lp32122
S'2014/01/01 06:00'
p32123
asS'DP'
p32124
S'2014 May 1'
p32125
sS'AD'
p32126
S'*Division of Child and Adolescent Psychiatry, Department of Psychiatry and Behavioral Sciences, Johns Hopkins Hospital, Johns Hopkins School of Medicine, Baltimore, MD; daggerDivision of HIV/AIDS and Center for AIDS Prevention Studies, University of California, San Francisco, CA; double daggerThe Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH; section signReach Out-Mbuya, Kampala, Uganda; ||Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; paragraph signDivision of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD; and #Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.'
p32127
sS'OWN'
p32128
S'NLM'
p32129
sS'PT'
p32130
(lp32131
S'Journal Article'
p32132
aS'Research Support, N.I.H., Extramural'
p32133
aS"Research Support, Non-U.S. Gov't"
p32134
asS'LA'
p32135
(lp32136
S'eng'
p32137
asS'FAU'
p32138
(lp32139
S'Burkey, Matthew D'
p32140
aS'Weiser, Sheri D'
p32141
aS'Fehmie, Desiree'
p32142
aS'Alamo-Talisuna, Stella'
p32143
aS'Sunday, Pamella'
p32144
aS'Nannyunja, Joy'
p32145
aS'Reynolds, Steven J'
p32146
aS'Chang, Larry W'
p32147
asS'LR'
p32148
S'20150701'
p32149
sS'PG'
p32150
S'41-7'
p32151
sS'TI'
p32152
S'Socioeconomic determinants of mortality in HIV: evidence from a clinical cohort in Uganda.'
p32153
sS'PL'
p32154
S'United States'
p32155
sS'TA'
p32156
S'J Acquir Immune Defic Syndr'
p32157
sS'JID'
p32158
S'100892005'
p32159
sS'AB'
p32160
S'OBJECTIVE: To delineate the association between baseline socioeconomic status (SES) indicators and mortality and lost to follow-up (LTFU) in a cohort of HIV-infected individuals enrolled in antiretroviral therapy (ART) in urban Uganda. DESIGN: Retrospective cohort study nested in an antiretroviral clinic-based cohort. METHODS: SES indicators including education, employment status, and a standardized wealth index, and other demographic and clinical variables were assessed at baseline among ART-treated patients in a clinic-based cohort in Kampala, Uganda. Confirmed mortality (primary outcome) and LTFU (secondary outcome) were actively ascertained over a 4-year follow-up period from 2005 to 2009. RESULTS: Among 1763 adults [70.5% female; mean age, 36.2 years (SD = 8.4)] enrolled in ART, 14.4% (n = 253) were confirmed dead and 19.7% (n = 346) were LTFU at 4-year follow-up. No formal education [adjusted odds ratio (AOR) 1.76; 95% confidence interval (CI): 1.19 to 2.59], having fewer than 6 dependents (AOR 1.39; 95% CI: 1.04 to 1.86), unemployment (AOR 1.98; 95% CI: 1.48 to 2.66), and housing tenure index score (a component of the wealth index) (AOR 1.11; 95% CI: 1.00 to 1.23) were significantly associated with confirmed mortality at 4 years. SES indicators were not associated with LTFU at 4 years. CONCLUSIONS: Baseline SES indicators, including education, number of dependents, employment status, and components of a standard wealth index may indicate long-term vulnerability to mortality in patients with HIV/AIDS, despite uniform access to ART. Future studies delineating the pathways through which poverty and limited assets affect clinical outcomes may lead to more effective HIV interventions in low-resource settings.'
p32161
sS'GR'
p32162
(lp32163
S'5K23MH086338/MH/NIMH NIH HHS/United States'
p32164
aS'K23 MH086338/MH/NIMH NIH HHS/United States'
p32165
aS'KL2 TR001077/TR/NCATS NIH HHS/United States'
p32166
aS'R01 MH095683/MH/NIMH NIH HHS/United States'
p32167
aS'R01MH095683/MH/NIMH NIH HHS/United States'
p32168
aS'Z01 AI000862-08/Intramural NIH HHS/United States'
p32169
aS'Z01 AI000862-09/Intramural NIH HHS/United States'
p32170
aS'Z99 AI999999/Intramural NIH HHS/United States'
p32171
aS'ZIA AI000862-10/Intramural NIH HHS/United States'
p32172
aS'ZIA AI000862-11/Intramural NIH HHS/United States'
p32173
asS'IP'
p32174
S'1'
sS'IS'
p32175
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p32176
sS'PMC'
p32177
S'PMC3981890'
p32178
sS'DCOM'
p32179
S'20140602'
p32180
sS'AU'
p32181
(lp32182
S'Burkey MD'
p32183
aS'Weiser SD'
p32184
aS'Fehmie D'
p32185
aS'Alamo-Talisuna S'
p32186
aS'Sunday P'
p32187
aS'Nannyunja J'
p32188
aS'Reynolds SJ'
p32189
aS'Chang LW'
p32190
asS'VI'
p32191
S'66'
p32192
sS'MHDA'
p32193
S'2014/06/03 06:00'
p32194
sS'OID'
p32195
(lp32196
S'NLM: NIHMS558603'
p32197
aS'NLM: PMC3981890'
p32198
asS'MH'
p32199
(lp32200
S'Adolescent'
p32201
aS'Adult'
p32202
aS'Cohort Studies'
p32203
aS'Female'
p32204
aS'HIV Infections/epidemiology/*mortality'
p32205
aS'Humans'
p32206
aS'Male'
p32207
aS'Middle Aged'
p32208
aS'Retrospective Studies'
p32209
aS'Socioeconomic Factors'
p32210
aS'Survival Analysis'
p32211
aS'Uganda/epidemiology'
p32212
aS'Young Adult'
p32213
asS'EDAT'
p32214
S'2014/01/01 06:00'
p32215
sS'SO'
p32216
S'J Acquir Immune Defic Syndr. 2014 May 1;66(1):41-7. doi: 10.1097/QAI.0000000000000094.'
p32217
sS'SB'
p32218
S'IM X'
p32219
sS'PMID'
p32220
S'24378727'
p32221
sS'PST'
p32222
S'ppublish'
p32223
stRp32224
ag2
(g3
g4
(dp32225
S'LID'
p32226
S'10.1186/1471-2334-13-607 [doi]'
p32227
sS'STAT'
p32228
S'MEDLINE'
p32229
sS'DEP'
p32230
S'20131227'
p32231
sS'DA'
p32232
S'20140106'
p32233
sS'AID'
p32234
(lp32235
S'1471-2334-13-607 [pii]'
p32236
aS'10.1186/1471-2334-13-607 [doi]'
p32237
asS'CRDT'
p32238
(lp32239
S'2013/12/31 06:00'
p32240
asS'DP'
p32241
S'2013'
p32242
sS'AD'
p32243
S"Programme PAC-CI, Centre Hospitalier Universitaire (CHU) de Treichville, 18 BP 1954, Abidjan, Cote d'Ivoire. aysonabo@gmail.com."
p32244
sS'OWN'
p32245
S'NLM'
p32246
sS'PT'
p32247
(lp32248
S'Journal Article'
p32249
aS'Research Support, N.I.H., Extramural'
p32250
asS'LA'
p32251
(lp32252
S'eng'
p32253
asS'DCOM'
p32254
S'20140623'
p32255
sS'JT'
p32256
S'BMC infectious diseases'
p32257
sS'LR'
p32258
S'20150521'
p32259
sS'FAU'
p32260
(lp32261
S'Abo, Yao'
p32262
aS'Minga, Albert'
p32263
aS'Menan, Herve'
p32264
aS'Danel, Christine'
p32265
aS'Ouassa, Timothee'
p32266
aS'Dohoun, Lambert'
p32267
aS'Bomisso, Germain'
p32268
aS'Tanoh, Anthony'
p32269
aS'Messou, Eugene'
p32270
aS'Eholie, Serge'
p32271
aS'Lewden, Charlotte'
p32272
aS'Anglaret, Xavier'
p32273
asS'TI'
p32274
S'Incidence of serious morbidity in HIV-infected adults on antiretroviral therapy in a West African care centre, 2003-2008.'
p32275
sS'RN'
p32276
(lp32277
S'0 (Anti-HIV Agents)'
p32278
asS'PL'
p32279
S'England'
p32280
sS'PG'
p32281
S'607'
p32282
sS'JID'
p32283
S'100968551'
p32284
sS'AB'
p32285
S"BACKGROUND: In resource-limited settings, scaling-up antiretroviral treatment (ART) has required the involvement of decentralized health facilities with limited equipment. We estimated the incidence of serious morbidity among HIV-infected adults receiving ART in one of these HIV routine care center in sub-Saharan Africa. METHODS: We conducted a prospective study at the Centre Medical de Suivi des Donneurs de Sang (CMSDS), which is affiliated with the National Centre for Blood Transfusion in Abidjan, Cote d'Ivoire. Adult patients infected with HIV-1 or HIV-1/HIV-2 who initiated ART between January 2003 and December 2008 were eligible for the study. Standardized clinical data were collected at each visit. Serious morbidity was defined as a new episode of malaria, WHO stage 3-4 event, ANRS grade 3-4 adverse event, or any event leading to death or to hospitalization. RESULTS: 1008 adults, 67% women, with a median age of 35 years, and a median pre-ART CD4 count of 186/mm3 started ART and were followed for a median of 17.3 months. The overall incidences of loss to follow-up, death, and attrition were 6.2/100 person-years (PY) [95% CI 5.1-7.2], 2.3/100 PY [95% CI 1.6-2.9], and 8.1/100 PY [95% CI 7.0-9.4], respectively. The incidence of first serious event was 11.5/100 PY overall, 15.9/100 PY within the first year and 8.3/100 PY thereafter. The most frequently documented specific diagnoses were malaria, tuberculosis, bacterial septicemia and bacterial pneumonia. CONCLUSION: Among HIV-infected adults followed in routine conditions in a West African primary care clinic, we recorded a high incidence of serious morbidity during the first year on ART. Providing care centers with diagnostic tools and standardizing data collection are necessary steps to improve the quality of care in primary care facilities in sub-Saharan Africa."
p32286
sS'GR'
p32287
(lp32288
S'U01 AI069919/AI/NIAID NIH HHS/United States'
p32289
aS'U01AI069919./AI/NIAID NIH HHS/United States'
p32290
asS'VI'
p32291
S'13'
p32292
sS'IS'
p32293
S'1471-2334 (Electronic) 1471-2334 (Linking)'
p32294
sS'PMC'
p32295
S'PMC3880348'
p32296
sS'AU'
p32297
(lp32298
S'Abo Y'
p32299
aS'Minga A'
p32300
aS'Menan H'
p32301
aS'Danel C'
p32302
aS'Ouassa T'
p32303
aS'Dohoun L'
p32304
aS'Bomisso G'
p32305
aS'Tanoh A'
p32306
aS'Messou E'
p32307
aS'Eholie S'
p32308
aS'Lewden C'
p32309
aS'Anglaret X'
p32310
asS'MHDA'
p32311
S'2014/06/24 06:00'
p32312
sS'PHST'
p32313
(lp32314
S'2013/05/06 [received]'
p32315
aS'2013/12/20 [accepted]'
p32316
aS'2013/12/27 [aheadofprint]'
p32317
asS'OID'
p32318
(lp32319
S'NLM: PMC3880348'
p32320
asS'MH'
p32321
(lp32322
S'Adult'
p32323
aS'Anti-HIV Agents/*therapeutic use'
p32324
aS'Antiretroviral Therapy, Highly Active'
p32325
aS'Community Health Centers/statistics & numerical data'
p32326
aS"Cote d'Ivoire/epidemiology"
p32327
aS'Female'
p32328
aS'HIV Infections/*drug therapy/epidemiology/*mortality'
p32329
aS'HIV-1'
p32330
aS'Humans'
p32331
aS'Incidence'
p32332
aS'Male'
p32333
aS'Middle Aged'
p32334
aS'Morbidity'
p32335
aS'Prospective Studies'
p32336
aS'Young Adult'
p32337
asS'EDAT'
p32338
S'2014/01/01 06:00'
p32339
sS'SO'
p32340
S'BMC Infect Dis. 2013 Dec 27;13:607. doi: 10.1186/1471-2334-13-607.'
p32341
sS'SB'
p32342
S'IM'
p32343
sS'PMID'
p32344
S'24373303'
p32345
sS'TA'
p32346
S'BMC Infect Dis'
p32347
sS'PST'
p32348
S'epublish'
p32349
stRp32350
ag2
(g3
g4
(dp32351
S'LID'
p32352
S'10.7448/IAS.16.4.18753 [doi]'
p32353
sS'STAT'
p32354
S'MEDLINE'
p32355
sS'DEP'
p32356
S'20131202'
p32357
sS'DA'
p32358
S'20131210'
p32359
sS'AID'
p32360
(lp32361
S'18753 [pii]'
p32362
asS'CRDT'
p32363
(lp32364
S'2013/12/11 06:00'
p32365
asS'DP'
p32366
S'2013'
p32367
sS'AD'
p32368
S'Universite Gaston Berger/Enda Sante, Dakar, Senegal.'
p32369
sS'OWN'
p32370
S'NLM'
p32371
sS'PT'
p32372
(lp32373
S'Journal Article'
p32374
aS"Research Support, U.S. Gov't, Non-P.H.S."
p32375
aS"Research Support, U.S. Gov't, P.H.S."
p32376
asS'LA'
p32377
(lp32378
S'eng'
p32379
asS'DCOM'
p32380
S'20140717'
p32381
sS'JT'
p32382
S'Journal of the International AIDS Society'
p32383
sS'LR'
p32384
S'20151119'
p32385
sS'FAU'
p32386
(lp32387
S'Drame, Fatou Maria'
p32388
aS'Crawford, Emily E'
p32389
aS'Diouf, Daouda'
p32390
aS'Beyrer, Chris'
p32391
aS'Baral, Stefan D'
p32392
asS'TI'
p32393
S'A pilot cohort study to assess the feasibility of HIV prevention science research among men who have sex with men in Dakar, Senegal.'
p32394
sS'PL'
p32395
S'Switzerland'
p32396
sS'PG'
p32397
S'18753'
p32398
sS'JID'
p32399
S'101478566'
p32400
sS'AB'
p32401
S'INTRODUCTION: Men who have sex with men (MSM) are disproportionately burdened by HIV in Senegal, across sub-Saharan Africa and throughout the world. This is driven in part by stigma, and limits health achievements and social capital among these populations. To date, there is a limited understanding of the feasibility of prospective HIV prevention studies among MSM in Senegal, including HIV incidence and cohort retention rates. METHODS: One hundred and nineteen men who reported having anal sex with another man in the past 12 months were randomly selected from a sampling frame of 450 unique members of community groups serving MSM in Dakar. These men were enrolled in a 15-month pilot cohort study implemented by a community-based partner. The study included a structured survey instrument and biological testing for HIV, syphilis and hepatitis B virus at two time points. RESULTS: Baseline HIV prevalence was 36.0% (43/114), with cumulative HIV prevalence at study end being 47.2% (51/108). The annualized incidence rate was 16% (8/40 at risk for seroconversion over 15 months of follow-up, 95% confidence interval 4.6-27.4%). Thirty-seven men were lost to follow up, including at least four deaths. Men who were able to confide in someone about health, emotional distress and sex were less likely to be HIV positive (OR 0.36, p < 0.05, 95% CI 0.13, 0.97). CONCLUSIONS: High HIV prevalence and incidence, as well as mortality in this young population of Senegalese MSM indicate a public health emergency. Moreover, given the high burden of HIV and rate of incident HIV infections, this population appears to be appropriate for the evaluation of novel HIV prevention, treatment and care approaches. Using a study implemented by community-based organizations, there appears to be feasibility in implementing interventions addressing the multiple levels of HIV risk among MSM in this setting. However, low retention across arms of this pilot intervention, and in the cohort, will need to be addressed for larger-scale efficacy trials to be feasible.'
p32402
sS'GR'
p32403
(lp32404
S'PEPFAR/United States'
p32405
asS'VI'
p32406
S'16 Suppl 3'
p32407
sS'IS'
p32408
S'1758-2652 (Electronic) 1758-2652 (Linking)'
p32409
sS'PMC'
p32410
S'PMC3852354'
p32411
sS'AU'
p32412
(lp32413
S'Drame FM'
p32414
aS'Crawford EE'
p32415
aS'Diouf D'
p32416
aS'Beyrer C'
p32417
aS'Baral SD'
p32418
asS'MHDA'
p32419
S'2014/07/18 06:00'
p32420
sS'PHST'
p32421
(lp32422
S'2013/05/22 [received]'
p32423
aS'2013/09/30 [revised]'
p32424
aS'2013/10/09 [accepted]'
p32425
asS'OT'
p32426
(lp32427
S'Africa'
p32428
aS'HIV'
p32429
aS'men who have sex with men'
p32430
aS'prevention'
p32431
aS'socio-economic status'
p32432
asS'OTO'
p32433
(lp32434
S'NOTNLM'
p32435
asS'OID'
p32436
(lp32437
S'NLM: PMC3852354'
p32438
asS'MH'
p32439
(lp32440
S'Adolescent'
p32441
aS'Cohort Studies'
p32442
aS'HIV/isolation & purification'
p32443
aS'HIV Infections/*epidemiology/prevention & control/*transmission'
p32444
aS'Hepatitis B/diagnosis'
p32445
aS'*Homosexuality, Male'
p32446
aS'Humans'
p32447
aS'Incidence'
p32448
aS'Male'
p32449
aS'Pilot Projects'
p32450
aS'Prevalence'
p32451
aS'Prospective Studies'
p32452
aS'Risk Assessment'
p32453
aS'Risk Management'
p32454
aS'Senegal'
p32455
aS'Surveys and Questionnaires'
p32456
aS'Syphilis/diagnosis'
p32457
aS'Young Adult'
p32458
asS'EDAT'
p32459
S'2014/01/01 06:00'
p32460
sS'SO'
p32461
S'J Int AIDS Soc. 2013 Dec 2;16 Suppl 3:18753. doi: 10.7448/IAS.16.4.18753.'
p32462
sS'SB'
p32463
S'IM X'
p32464
sS'PMID'
p32465
S'24321115'
p32466
sS'TA'
p32467
S'J Int AIDS Soc'
p32468
sS'PST'
p32469
S'epublish'
p32470
stRp32471
ag2
(g3
g4
(dp32472
S'LID'
p32473
S'10.4102/phcfm.v6i1.586 [doi]'
p32474
sS'STAT'
p32475
S'MEDLINE'
p32476
sS'DEP'
p32477
S'20140926'
p32478
sS'DA'
p32479
S'20150806'
p32480
sS'AID'
p32481
(lp32482
S'586 [pii]'
p32483
asS'CRDT'
p32484
(lp32485
S'2015/08/07 06:00'
p32486
asS'DP'
p32487
S'2014'
p32488
sS'OWN'
p32489
S'NLM'
p32490
sS'PT'
p32491
(lp32492
S'Journal Article'
p32493
asS'LA'
p32494
(lp32495
S'eng'
p32496
asS'FAU'
p32497
(lp32498
S'Samuel, Oladoyinbo O'
p32499
aS'de Villiers, Pierre J T'
p32500
asS'JT'
p32501
S'African journal of primary health care & family medicine'
p32502
sS'LR'
p32503
S'20160204'
p32504
sS'PG'
p32505
S'E1-5'
p32506
sS'TI'
p32507
S"Compliance of St Joseph's Hospital Roma, Lesotho with the National Tuberculosis Programme of Lesotho, 2007 and 2008."
p32508
sS'RN'
p32509
(lp32510
S'0 (Antitubercular Agents)'
p32511
asS'PL'
p32512
S'South Africa'
p32513
sS'TA'
p32514
S'Afr J Prim Health Care Fam Med'
p32515
sS'JID'
p32516
S'101520860'
p32517
sS'AB'
p32518
S"BACKGROUND: In 2009 Lesotho had an estimated TB prevalence of 696 cases/100 000 population - the 4th highest in the world. This epidemic was characterised by high rates of death, treatment failure and unknown treatment outcomes. These adverse outcomes were attributable to a high rate of TB and/or HIV co-infection and weaknesses in the implementation of Lesotho's National Tuberculosis Programme (NTP). This study was conducted in St Joseph's Hospital, Roma (SJHR) to assess the implementation of the NTP. METHOD: Records of 993 patients entered into the SJHR TB register between 2007 and 2008 were reviewed. Patients' treatment details were extracted from the register, validated and analysed by STATA 10.0. RESULTS: Of 993 patients registered: 88% were new patients, 37% were diagnosed on sputum smear microscopy alone, 35% were diagnosed on sputum smear microscopy with chest X-ray, whilst 25% were diagnosed on chest X-ray alone. In addition: 33% were sputum smear positive, 45% were sputum smear negative, and 22% had extra-pulmonary TB. As to treatment outcome: 26% were cured, 51% completed treatment, and 51% converted from sputum smear positive to sputum smear negative over six months, whilst 16% died. Regarding HIV, 77% of patients were tested for HIV and 59% had TB and/or HIV co-infection. Of ten NTP targets only the defaulter and treatment failure rate targets were met. CONCLUSION: Whilst only two out of ten NTP targets were met at SJHR in 2007-2008, improvements in TB case management were noted in 2008 which were probably due to the positive effects of audit on staff performance."
p32519
sS'AD'
p32520
S'Division of Family Medicine and Primary Care, Stellenbosch University. pierre@aosis.co.za.'
p32521
sS'IP'
p32522
S'1'
sS'IS'
p32523
S'2071-2936 (Electronic) 2071-2928 (Linking)'
p32524
sS'PMC'
p32525
S'PMC4502872'
p32526
sS'DCOM'
p32527
S'20160307'
p32528
sS'AU'
p32529
(lp32530
S'Samuel OO'
p32531
aS'de Villiers PJ'
p32532
asS'VI'
p32533
S'6'
sS'MHDA'
p32534
S'2016/03/08 06:00'
p32535
sS'PHST'
p32536
(lp32537
S'2013/09/05 [received]'
p32538
aS'2013/11/13 [accepted]'
p32539
aS'2014/09/01 [revised]'
p32540
asS'OID'
p32541
(lp32542
S'NLM: PMC4502872'
p32543
asS'MH'
p32544
(lp32545
S'Adult'
p32546
aS'Antitubercular Agents/*therapeutic use'
p32547
aS'Female'
p32548
aS'*Guideline Adherence'
p32549
aS'Humans'
p32550
aS'Lesotho/epidemiology'
p32551
aS'Male'
p32552
aS'Prevalence'
p32553
aS'Retrospective Studies'
p32554
aS'Treatment Outcome'
p32555
aS'Tuberculosis, Pulmonary/*drug therapy/epidemiology'
p32556
asS'EDAT'
p32557
S'2014/01/01 00:00'
p32558
sS'SO'
p32559
S'Afr J Prim Health Care Fam Med. 2014 Sep 26;6(1):E1-5. doi: 10.4102/phcfm.v6i1.586.'
p32560
sS'SB'
p32561
S'IM'
p32562
sS'PMID'
p32563
S'26245409'
p32564
sS'PST'
p32565
S'epublish'
p32566
stRp32567
ag2
(g3
g4
(dp32568
S'LID'
p32569
S'10.1371/journal.pone.0081037 [doi]'
p32570
sS'STAT'
p32571
S'MEDLINE'
p32572
sS'DEP'
p32573
S'20131209'
p32574
sS'DA'
p32575
S'20131223'
p32576
sS'AID'
p32577
(lp32578
S'10.1371/journal.pone.0081037 [doi]'
p32579
aS'PONE-D-13-17883 [pii]'
p32580
asS'CRDT'
p32581
(lp32582
S'2013/12/24 06:00'
p32583
asS'DP'
p32584
S'2013'
p32585
sS'GR'
p32586
(lp32587
S'2U01AI069924/AI/NIAID NIH HHS/United States'
p32588
aS'U01 AI069924/AI/NIAID NIH HHS/United States'
p32589
asS'OWN'
p32590
S'NLM'
p32591
sS'PT'
p32592
(lp32593
S'Journal Article'
p32594
aS'Research Support, N.I.H., Extramural'
p32595
asS'LA'
p32596
(lp32597
S'eng'
p32598
asS'FAU'
p32599
(lp32600
S'Davies, Mary-Ann'
p32601
aS'Phiri, Sam'
p32602
aS'Wood, Robin'
p32603
aS'Wellington, Maureen'
p32604
aS'Cox, Vivian'
p32605
aS'Bolton-Moore, Carolyn'
p32606
aS'Timmerman, Venessa'
p32607
aS'Moultrie, Harry'
p32608
aS'Ndirangu, James'
p32609
aS'Rabie, Helena'
p32610
aS'Technau, Karl'
p32611
aS'Giddy, Janet'
p32612
aS'Maxwell, Nicola'
p32613
aS'Boulle, Andrew'
p32614
aS'Keiser, Olivia'
p32615
aS'Egger, Matthias'
p32616
aS'Eley, Brian'
p32617
asS'JT'
p32618
S'PloS one'
p32619
sS'LR'
p32620
S'20150422'
p32621
sS'PG'
p32622
S'e81037'
p32623
sS'TI'
p32624
S'Temporal trends in the characteristics of children at antiretroviral therapy initiation in southern Africa: the IeDEA-SA Collaboration.'
p32625
sS'RN'
p32626
(lp32627
S'0 (Anti-HIV Agents)'
p32628
asS'PL'
p32629
S'United States'
p32630
sS'TA'
p32631
S'PLoS One'
p32632
sS'FIR'
p32633
(lp32634
S'Wellington, Maureen'
p32635
aS'Eley, Brian'
p32636
aS'Fritz, Christiane'
p32637
aS'Stinson, Kathryn'
p32638
aS'Giddy, Janet'
p32639
aS'Fox, Matthew'
p32640
aS'Heinrich, Sabine'
p32641
aS'Hoffmann, Christopher'
p32642
aS'Moultrie, Harry'
p32643
aS'Ndirangu, James'
p32644
aS'van Oosterhout, Joep'
p32645
aS'Pestilli, Sabrina'
p32646
aS'Phiri, Sam'
p32647
aS'Prozesky, Hans'
p32648
aS'Chi, Benjamin'
p32649
aS'Technau, Karl'
p32650
aS'Wood, Robin'
p32651
asS'JID'
p32652
S'101285081'
p32653
sS'AB'
p32654
S"BACKGROUND: Since 2005, increasing numbers of children have started antiretroviral therapy (ART) in sub-Saharan Africa and, in recent years, WHO and country treatment guidelines have recommended ART initiation for all infants and very young children, and at higher CD4 thresholds for older children. We examined temporal changes in patient and regimen characteristics at ART start using data from 12 cohorts in 4 countries participating in the IeDEA-SA collaboration. METHODOLOGY/PRINCIPAL FINDINGS: Data from 30,300 ART-naive children aged <16 years at ART initiation who started therapy between 2005 and 2010 were analysed. We examined changes in median values for continuous variables using the Cuzick's test for trend over time. We also examined changes in the proportions of patients with particular disease severity characteristics (expressed as a binary variable e.g. WHO Stage III/IV vs I/II) using logistic regression. Between 2005 and 2010 the number of children starting ART each year increased and median age declined from 63 months (2006) to 56 months (2010). Both the proportion of children <1 year and >/=10 years of age increased from 12 to 19% and 18 to 22% respectively. Children had less severe disease at ART initiation in later years with significant declines in the percentage with severe immunosuppression (81 to 63%), WHO Stage III/IV disease (75 to 62%), severe anemia (12 to 7%) and weight-for-age z-score<-3 (31 to 28%). Similar results were seen when restricting to infants with significant declines in the proportion with severe immunodeficiency (98 to 82%) and Stage III/IV disease (81 to 63%). First-line regimen use followed country guidelines. CONCLUSIONS/SIGNIFICANCE: Between 2005 and 2010 increasing numbers of children have initiated ART with a decline in disease severity at start of therapy. However, even in 2010, a substantial number of infants and children started ART with advanced disease. These results highlight the importance of efforts to improve access to HIV diagnostic testing and ART in children."
p32655
sS'AD'
p32656
S"School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa. Lighthouse Trust Clinic, Kamuzu Central Hospital, Lilongwe, Malawi. Gugulethu Community Health Centre and Desmond Tutu HIV Centre, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa. Newlands Clinic, Harare, Zimbabwe. Medecins Sans Frontieres South Africa and Khayelitsha ART Programme, Khayelitsha, Cape Town, South Africa. Centre for Infectious Disease Research in Zambia, Lusaka, Zambia and University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America. Knowledge Translation Unit, University of Cape Town Lung Institute, Cape Town, South Africa. Wits Reproductive Health and HIV Institute, Harriet Shezi Children's Clinic, Chris Hani Baragwanath Hospital, Faculty of Health Sciences, University of Witwatersrand, Soweto, Johannesburg, South Africa. Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Somkhele, South Africa. Tygerberg Academic Hospital, University of Stellenbosch, Stellenbosch, South Africa. Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital and University of Witwatersrand, Johannesburg, South Africa. Sinikithemba Clinic, McCord Hospital, Durban, South Africa. School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa. School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa. Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland. Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland. Red Cross Children's Hospital and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa."
p32657
sS'CN'
p32658
(lp32659
S'IeDEA Southern Africa Steering Group'
p32660
asS'IP'
p32661
S'12'
p32662
sS'IS'
p32663
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p32664
sS'IR'
p32665
(lp32666
S'Wellington M'
p32667
aS'Eley B'
p32668
aS'Fritz C'
p32669
aS'Stinson K'
p32670
aS'Giddy J'
p32671
aS'Fox M'
p32672
aS'Heinrich S'
p32673
aS'Hoffmann C'
p32674
aS'Moultrie H'
p32675
aS'Ndirangu J'
p32676
aS'van Oosterhout J'
p32677
aS'Pestilli S'
p32678
aS'Phiri S'
p32679
aS'Prozesky H'
p32680
aS'Chi B'
p32681
aS'Technau K'
p32682
aS'Wood R'
p32683
asS'DCOM'
p32684
S'20140728'
p32685
sS'AU'
p32686
(lp32687
S'Davies MA'
p32688
aS'Phiri S'
p32689
aS'Wood R'
p32690
aS'Wellington M'
p32691
aS'Cox V'
p32692
aS'Bolton-Moore C'
p32693
aS'Timmerman V'
p32694
aS'Moultrie H'
p32695
aS'Ndirangu J'
p32696
aS'Rabie H'
p32697
aS'Technau K'
p32698
aS'Giddy J'
p32699
aS'Maxwell N'
p32700
aS'Boulle A'
p32701
aS'Keiser O'
p32702
aS'Egger M'
p32703
aS'Eley B'
p32704
asS'VI'
p32705
S'8'
sS'MHDA'
p32706
S'2014/07/30 06:00'
p32707
sS'PHST'
p32708
(lp32709
S'2013 [ecollection]'
p32710
aS'2013/05/01 [received]'
p32711
aS'2013/10/18 [accepted]'
p32712
aS'2013/12/09 [epublish]'
p32713
asS'OID'
p32714
(lp32715
S'NLM: PMC3867284'
p32716
asS'MH'
p32717
(lp32718
S'Africa, Southern/epidemiology'
p32719
aS'Anemia/*epidemiology/etiology'
p32720
aS'Anti-HIV Agents/*therapeutic use'
p32721
aS'CD4 Lymphocyte Count'
p32722
aS'Child'
p32723
aS'Child, Preschool'
p32724
aS'Databases, Factual'
p32725
aS'Female'
p32726
aS'HIV Infections/complications/*drug therapy/*epidemiology/immunology'
p32727
aS'Humans'
p32728
aS'Infant'
p32729
aS'Logistic Models'
p32730
aS'Male'
p32731
aS'Time Factors'
p32732
asS'EDAT'
p32733
S'2013/12/24 06:00'
p32734
sS'PMC'
p32735
S'PMC3867284'
p32736
sS'SO'
p32737
S'PLoS One. 2013 Dec 9;8(12):e81037. doi: 10.1371/journal.pone.0081037. eCollection 2013.'
p32738
sS'SB'
p32739
S'IM'
p32740
sS'PMID'
p32741
S'24363808'
p32742
sS'PST'
p32743
S'epublish'
p32744
stRp32745
ag2
(g3
g4
(dp32746
S'LID'
p32747
S'10.1007/s15010-013-0572-2 [doi]'
p32748
sS'STAT'
p32749
S'MEDLINE'
p32750
sS'DEP'
p32751
S'20131221'
p32752
sS'DA'
p32753
S'20140328'
p32754
sS'AID'
p32755
(lp32756
S'10.1007/s15010-013-0572-2 [doi]'
p32757
asS'CRDT'
p32758
(lp32759
S'2013/12/24 06:00'
p32760
asS'DP'
p32761
S'2014 Apr'
p32762
sS'AD'
p32763
S'Department of Clinical Microbiology and Infectious Diseases, School of Pathology, University of the Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa, else.marais@gmail.com.'
p32764
sS'OWN'
p32765
S'NLM'
p32766
sS'PT'
p32767
(lp32768
S'Journal Article'
p32769
aS'Research Support, N.I.H., Extramural'
p32770
aS"Research Support, Non-U.S. Gov't"
p32771
asS'LA'
p32772
(lp32773
S'eng'
p32774
asS'FAU'
p32775
(lp32776
S'Marais, E'
p32777
aS'Mlambo, C K'
p32778
aS'Lewis, J J'
p32779
aS'Rastogi, N'
p32780
aS'Zozio, T'
p32781
aS'Grobusch, M P'
p32782
aS'Duse, A'
p32783
aS'Victor, T'
p32784
aS'Warren, R W'
p32785
asS'JT'
p32786
S'Infection'
p32787
sS'LR'
p32788
S'20160322'
p32789
sS'PG'
p32790
S'405-13'
p32791
sS'TI'
p32792
S'Treatment outcomes of multidrug-resistant tuberculosis patients in Gauteng, South Africa.'
p32793
sS'RN'
p32794
(lp32795
S'0 (Antitubercular Agents)'
p32796
asS'PL'
p32797
S'Germany'
p32798
sS'TA'
p32799
S'Infection'
p32800
sS'JID'
p32801
S'0365307'
p32802
sS'AB'
p32803
S'PURPOSE: Multidrug-resistant tuberculosis (MDR-TB) is associated with lengthy treatment, expensive and potentially toxic regimens, and high rates of treatment failure and death. This study describes the outcomes of 351 MDR-TB patients who started treatment between 2004 and 2007 at the provincial MDR-TB referral hospital in Johannesburg, South Africa, and investigates risk factors associated with death. METHODS: The study involved the assessment of factors associated with treatment outcomes using a retrospective review of patient records, drug-susceptibility data and spoligotyping of isolates. RESULTS: Treatment success (completion/cure) was recorded in 158 (48.8 %) patients, while 65 (20 %) died, 93 (28.7 %) defaulted, 8 (2.5 %) failed treatment, 11(3.1 %) were transferred out to other health facilities and 16 (4.6 %) had no recorded final outcome. The proportion of successful treatment increased significantly over time. Univariable and multivariable analysis (P = 0.05) identified the year of MDR-TB diagnosis and spoligotype-defined families as factors associated with treatment outcome. No associations were found between treatment outcome and human immunodeficiency virus (HIV) status, previous TB and additional MDR resistance to streptomycin or ethambutol. Molecular typing of the strains revealed a diverse group of spoligotypes, with Beijing, LAM4 and H3 making up the largest groups. CONCLUSIONS: This is the first published study to investigate treatment outcomes at this facility and to find a link between genotype and treatment outcome, suggesting that genotype determination could potentially serve as a prognostic factor.'
p32804
sS'GR'
p32805
(lp32806
S'1U2RTW007370/3/PHS HHS/United States'
p32807
aS'MR/K007467/1/Medical Research Council/United Kingdom'
p32808
aS'MR/K012126/1/Medical Research Council/United Kingdom'
p32809
asS'IP'
p32810
S'2'
sS'IS'
p32811
S'1439-0973 (Electronic) 0300-8126 (Linking)'
p32812
sS'DCOM'
p32813
S'20141215'
p32814
sS'AU'
p32815
(lp32816
S'Marais E'
p32817
aS'Mlambo CK'
p32818
aS'Lewis JJ'
p32819
aS'Rastogi N'
p32820
aS'Zozio T'
p32821
aS'Grobusch MP'
p32822
aS'Duse A'
p32823
aS'Victor T'
p32824
aS'Warren RW'
p32825
asS'VI'
p32826
S'42'
p32827
sS'MHDA'
p32828
S'2014/12/17 06:00'
p32829
sS'PHST'
p32830
(lp32831
S'2013/09/08 [received]'
p32832
aS'2013/12/10 [accepted]'
p32833
aS'2013/12/21 [aheadofprint]'
p32834
asS'MH'
p32835
(lp32836
S'Adolescent'
p32837
aS'Adult'
p32838
aS'Antitubercular Agents/*pharmacology/*therapeutic use'
p32839
aS'Female'
p32840
aS'Genotype'
p32841
aS'Humans'
p32842
aS'Male'
p32843
aS'Mycobacterium tuberculosis/*drug effects/genetics'
p32844
aS'Retrospective Studies'
p32845
aS'Risk Factors'
p32846
aS'South Africa/epidemiology'
p32847
aS'Treatment Failure'
p32848
aS'Treatment Outcome'
p32849
aS'Tuberculosis, Multidrug-Resistant/*drug therapy/epidemiology/microbiology'
p32850
aS'Young Adult'
p32851
asS'EDAT'
p32852
S'2013/12/24 06:00'
p32853
sS'SO'
p32854
S'Infection. 2014 Apr;42(2):405-13. doi: 10.1007/s15010-013-0572-2. Epub 2013 Dec 21.'
p32855
sS'SB'
p32856
S'IM'
p32857
sS'PMID'
p32858
S'24363208'
p32859
sS'PST'
p32860
S'ppublish'
p32861
stRp32862
ag2
(g3
g4
(dp32863
S'LID'
p32864
S'10.1371/journal.pone.0067259 [doi]'
p32865
sS'STAT'
p32866
S'MEDLINE'
p32867
sS'DEP'
p32868
S'20131205'
p32869
sS'DA'
p32870
S'20131216'
p32871
sS'AID'
p32872
(lp32873
S'10.1371/journal.pone.0067259 [doi]'
p32874
aS'PONE-D-12-14856 [pii]'
p32875
asS'CRDT'
p32876
(lp32877
S'2013/12/17 06:00'
p32878
asS'DP'
p32879
S'2013'
p32880
sS'AD'
p32881
S'A.I.C. Kijabe Hospital, Kijabe, Kenya ; University of Nairobi, Nairobi, Kenya.'
p32882
sS'OWN'
p32883
S'NLM'
p32884
sS'PT'
p32885
(lp32886
S'Journal Article'
p32887
aS'Observational Study'
p32888
aS'Research Support, N.I.H., Extramural'
p32889
asS'LA'
p32890
(lp32891
S'eng'
p32892
asS'FAU'
p32893
(lp32894
S'Achieng, Loice'
p32895
aS'Musangi, Helen'
p32896
aS'Billingsley, Katherine'
p32897
aS'Onguit, Sharon'
p32898
aS'Ombegoh, Edwin'
p32899
aS'Bryant, LeeAnn'
p32900
aS'Mwiindi, Jonathan'
p32901
aS'Smith, Nathaniel'
p32902
aS'Keiser, Philip'
p32903
asS'JT'
p32904
S'PloS one'
p32905
sS'LR'
p32906
S'20150422'
p32907
sS'PG'
p32908
S'e67259'
p32909
sS'TI'
p32910
S'The use of pill counts as a facilitator of adherence with antiretroviral therapy in resource limited settings.'
p32911
sS'RN'
p32912
(lp32913
S'0 (Anti-HIV Agents)'
p32914
asS'PL'
p32915
S'United States'
p32916
sS'TA'
p32917
S'PLoS One'
p32918
sS'JID'
p32919
S'101285081'
p32920
sS'AB'
p32921
S'BACKGROUND: Pill counts are often used to measure adherence to ART, but there is little data on how they affect adherence. We previously showed a bivariate relationship between clinicians counting pills and adherence in patients receiving HIV care in Kenya. We present a secondary analysis of the relationship between numbers of pill counts and clinical outcomes in resource limited settings. METHODS: Patients initiating ART at Kijabe Hospital were monitored for the number of discretionary pill counts performed by their clinician in the first 6 months of ART. Subjects were followed for at least 1 year after enrollment. The number of clinician pill counts was correlated to ART adherence. The primary endpoints were time to treatment failure, defined as a detectable HIV-1 viral load, death; or loss to follow-up. RESULTS: Clinician pill counts were done at 68% of clinic visits for 304 subjects. There was a positive correlation between the number of clinician pill counts and ART adherence (r = 0.21, p <0.001). Patients were divided into 3 groups (0 counts, 1 to 3 counts, 4 to 7 counts) and exhibited adherence of 76%, 84%, and 92%, respectively (p = 0.004). Time to treatment failure for these groups was 220 days, 438 days, and 497 days (P<0.01), respectively. Time to virologic failure in living patients remaining in the cohort was longer in those with more pill count (P =0.02). Multi-variate analysis adjusting for co-variates affecting time to treatment failure found that that clinician pill counts were associated with a decreased risk of treatment failure (HR = 0.69, p =0.04). CONCLUSIONS: The number of clinician pill count performed was independently associated with better adherence and a decreased risk of treatment failure. The use of clinician pill counts should be further studied as an adherence promoter through a randomized clinical trial.'
p32922
sS'GR'
p32923
(lp32924
S'R25TW008129/TW/FIC NIH HHS/United States'
p32925
asS'IP'
p32926
S'12'
p32927
sS'IS'
p32928
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p32929
sS'PMC'
p32930
S'PMC3855050'
p32931
sS'DCOM'
p32932
S'20150302'
p32933
sS'AU'
p32934
(lp32935
S'Achieng L'
p32936
aS'Musangi H'
p32937
aS'Billingsley K'
p32938
aS'Onguit S'
p32939
aS'Ombegoh E'
p32940
aS'Bryant L'
p32941
aS'Mwiindi J'
p32942
aS'Smith N'
p32943
aS'Keiser P'
p32944
asS'VI'
p32945
S'8'
sS'MHDA'
p32946
S'2015/03/03 06:00'
p32947
sS'PHST'
p32948
(lp32949
S'2013 [ecollection]'
p32950
aS'2012/05/23 [received]'
p32951
aS'2013/05/21 [accepted]'
p32952
aS'2013/12/05 [epublish]'
p32953
asS'OID'
p32954
(lp32955
S'NLM: PMC3855050'
p32956
asS'MH'
p32957
(lp32958
S'Anti-HIV Agents/*therapeutic use'
p32959
aS'Cohort Studies'
p32960
aS'Female'
p32961
aS'HIV Infections/*drug therapy'
p32962
aS'Health Resources/*supply & distribution'
p32963
aS'Humans'
p32964
aS'Male'
p32965
aS'Multivariate Analysis'
p32966
aS'Patient Compliance/*statistics & numerical data'
p32967
aS'Treatment Failure'
p32968
asS'EDAT'
p32969
S'2013/12/18 06:00'
p32970
sS'SO'
p32971
S'PLoS One. 2013 Dec 5;8(12):e67259. doi: 10.1371/journal.pone.0067259. eCollection 2013.'
p32972
sS'SB'
p32973
S'IM'
p32974
sS'PMID'
p32975
S'24339861'
p32976
sS'PST'
p32977
S'epublish'
p32978
stRp32979
ag2
(g3
g4
(dp32980
S'LID'
p32981
S'10.1097/QAI.0000000000000081 [doi]'
p32982
sS'STAT'
p32983
S'MEDLINE'
p32984
sS'JT'
p32985
S'Journal of acquired immune deficiency syndromes (1999)'
p32986
sS'MID'
p32987
(lp32988
S'NIHMS544105'
p32989
asS'DA'
p32990
S'20140514'
p32991
sS'AID'
p32992
(lp32993
S'10.1097/QAI.0000000000000081 [doi]'
p32994
asS'CRDT'
p32995
(lp32996
S'2013/12/12 06:00'
p32997
asS'DP'
p32998
S'2014 Jun 1'
p32999
sS'AD'
p33000
S'*Department of Epidemiology, University of Washington, Seattle, WA; daggerHealth Alliance International, Seattle, WA; double daggerDepartment of Global Health, University of Washington, Seattle, WA; section signMinistry of Health, Mozambique; and ||Department of Family Child Nursing, University of Washington, Seattle, WA (Micek is now with the Department of Medicine, University of Wisconsin-Madison, Madison, WI, USA).'
p33001
sS'OWN'
p33002
S'NLM'
p33003
sS'PT'
p33004
(lp33005
S'Journal Article'
p33006
aS'Research Support, N.I.H., Extramural'
p33007
asS'LA'
p33008
(lp33009
S'eng'
p33010
asS'FAU'
p33011
(lp33012
S'Gerdts, Sarah E'
p33013
aS'Wagenaar, Bradley H'
p33014
aS'Micek, Mark A'
p33015
aS'Farquhar, Carey'
p33016
aS'Kariaganis, Marina'
p33017
aS'Amos, Juvenal'
p33018
aS'Gimbel, Sarah'
p33019
aS'Pfeiffer, James'
p33020
aS'Gloyd, Stephen'
p33021
aS'Sherr, Kenneth'
p33022
asS'LR'
p33023
S'20150601'
p33024
sS'PG'
p33025
S'e37-44'
p33026
sS'TI'
p33027
S'Linkage to HIV care and antiretroviral therapy by HIV testing service type in Central Mozambique: a retrospective cohort study.'
p33028
sS'RN'
p33029
(lp33030
S'0 (Anti-HIV Agents)'
p33031
asS'PL'
p33032
S'United States'
p33033
sS'TA'
p33034
S'J Acquir Immune Defic Syndr'
p33035
sS'JID'
p33036
S'100892005'
p33037
sS'AB'
p33038
S'BACKGROUND: Access to antiretroviral therapy (ART) has increased dramatically in resource-limited settings since its introduction a decade ago. However, ART coverage remains low in countries with the highest disease burden, which may be partially explained by poor testing to care linkages. HIV testing service may impact early attrition in the HIV treatment cascade. METHODS: A retrospective cohort study was conducted in 18 clinics in central Mozambique using routine patient data and monthly reports. Patients referred from voluntary counseling and testing (VCT) were compared with those referred from prevention of mother-to-child transmission (PMTCT) for 3 outcomes: (1) enrollment at an HIV clinic </=30 days after testing HIV positive, (2) CD4 test </=30 days after enrollment, and (3) ART initiation </=90 days after first CD4 test. RESULTS: Patient retention in the HIV care system dropped at each step from HIV testing to ART initiation. Enrollment in HIV care was not significantly different between PMTCT and VCT [risk ratio (RR) = 0.84, 0.72 < RR < 1.02]. Women tested in PMTCT were less likely to have a CD4 test </=30 days after enrollment when adjusting for age, education level, and marital status (adjusted RR = 0.84, 0.70 < RR < 1.00), and were less likely to initiate ART </=90 days after their first CD4 test when adjusting for age, education, and marital status (adjusted RR = 0.56, 0.44 < RR < 0.71). CONCLUSIONS: Poor linkages between HIV testing and care hamper efforts to improve coverage for HIV care and treatment services. Increased loss to follow-up among women diagnosed in PMTCT relative to VCT is worrisome and merits further qualitative research and programmatic attention.'
p33039
sS'GR'
p33040
(lp33041
S'K02 TW009207/TW/FIC NIH HHS/United States'
p33042
aS'K02TW009207/TW/FIC NIH HHS/United States'
p33043
aS'P30 AI027757/AI/NIAID NIH HHS/United States'
p33044
aS'P30AI027757/AI/NIAID NIH HHS/United States'
p33045
asS'IP'
p33046
S'2'
sS'IS'
p33047
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p33048
sS'PMC'
p33049
S'PMC4020956'
p33050
sS'DCOM'
p33051
S'20140703'
p33052
sS'AU'
p33053
(lp33054
S'Gerdts SE'
p33055
aS'Wagenaar BH'
p33056
aS'Micek MA'
p33057
aS'Farquhar C'
p33058
aS'Kariaganis M'
p33059
aS'Amos J'
p33060
aS'Gimbel S'
p33061
aS'Pfeiffer J'
p33062
aS'Gloyd S'
p33063
aS'Sherr K'
p33064
asS'VI'
p33065
S'66'
p33066
sS'MHDA'
p33067
S'2014/07/06 06:00'
p33068
sS'OID'
p33069
(lp33070
S'NLM: NIHMS544105'
p33071
aS'NLM: PMC4020956'
p33072
asS'MH'
p33073
(lp33074
S'Adolescent'
p33075
aS'Adult'
p33076
aS'Anti-HIV Agents/*therapeutic use'
p33077
aS'CD4 Lymphocyte Count'
p33078
aS'Delivery of Health Care/*methods'
p33079
aS'Female'
p33080
aS'Follow-Up Studies'
p33081
aS'HIV Infections/*diagnosis/*drug therapy/prevention & control'
p33082
aS'Humans'
p33083
aS'*Infectious Disease Transmission, Vertical/prevention & control'
p33084
aS'Lost to Follow-Up'
p33085
aS'Male'
p33086
aS'Mass Screening'
p33087
aS'Mozambique'
p33088
aS'Odds Ratio'
p33089
aS'Referral and Consultation'
p33090
aS'Retrospective Studies'
p33091
aS'Socioeconomic Factors'
p33092
aS'Young Adult'
p33093
asS'EDAT'
p33094
S'2013/12/12 06:00'
p33095
sS'SO'
p33096
S'J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):e37-44. doi: 10.1097/QAI.0000000000000081.'
p33097
sS'SB'
p33098
S'IM X'
p33099
sS'PMID'
p33100
S'24326605'
p33101
sS'PST'
p33102
S'ppublish'
p33103
stRp33104
ag2
(g3
g4
(dp33105
S'LID'
p33106
S'10.1097/QAI.0000000000000075 [doi]'
p33107
sS'STAT'
p33108
S'MEDLINE'
p33109
sS'JT'
p33110
S'Journal of acquired immune deficiency syndromes (1999)'
p33111
sS'MID'
p33112
(lp33113
S'NIHMS542698'
p33114
asS'DA'
p33115
S'20140424'
p33116
sS'AID'
p33117
(lp33118
S'10.1097/QAI.0000000000000075 [doi]'
p33119
asS'CRDT'
p33120
(lp33121
S'2013/12/12 06:00'
p33122
asS'DP'
p33123
S'2014 Apr 15'
p33124
sS'AD'
p33125
S'*Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland; daggerThe International Union Against Tuberculosis and Lung Disease, Paris, France; double daggerLighthouse Trust, Lilongwe, Malawi; section signCentre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa; ||Department of Infectious Diseases, University Hospital Bern, Bern, Switzerland; paragraph signDepartment of Infectious Diseases, University of Dakar, Dakar, Senegal; #International Training and Education Center for Health, University of Washington, Seattle, WA.'
p33126
sS'OWN'
p33127
S'NLM'
p33128
sS'PT'
p33129
(lp33130
S'Journal Article'
p33131
aS'Research Support, N.I.H., Extramural'
p33132
aS"Research Support, Non-U.S. Gov't"
p33133
asS'LA'
p33134
(lp33135
S'eng'
p33136
asS'FAU'
p33137
(lp33138
S'Estill, Janne'
p33139
aS'Tweya, Hannock'
p33140
aS'Egger, Matthias'
p33141
aS'Wandeler, Gilles'
p33142
aS'Feldacker, Caryl'
p33143
aS'Johnson, Leigh F'
p33144
aS'Blaser, Nello'
p33145
aS'Vizcaya, Luisa Salazar'
p33146
aS'Phiri, Sam'
p33147
aS'Keiser, Olivia'
p33148
asS'LR'
p33149
S'20150422'
p33150
sS'PG'
p33151
S'e179-86'
p33152
sS'TI'
p33153
S'Tracing of patients lost to follow-up and HIV transmission: mathematical modeling study based on 2 large ART programs in Malawi.'
p33154
sS'RN'
p33155
(lp33156
S'0 (Anti-Retroviral Agents)'
p33157
asS'PL'
p33158
S'United States'
p33159
sS'TA'
p33160
S'J Acquir Immune Defic Syndr'
p33161
sS'JID'
p33162
S'100892005'
p33163
sS'AB'
p33164
S'OBJECTIVE: Treatment as prevention depends on retaining HIV-infected patients in care. We investigated the effect on HIV transmission of bringing patients lost to follow-up (LTFU) back into care. DESIGN: Mathematical model. METHODS: Stochastic mathematical model of cohorts of 1000 HIV-infected patients on antiretroviral therapy, based on the data from 2 clinics in Lilongwe, Malawi. We calculated cohort viral load (sum of individual mean viral loads each year) and used a mathematical relationship between viral load and transmission probability to estimate the number of new HIV infections. We simulated 4 scenarios: "no LTFU" (all patients stay in care), "no tracing" (patients LTFU are not traced), "immediate tracing" (after missed clinic appointment), and "delayed tracing" (after 6 months). RESULTS: About 440 of 1000 patients were LTFU over 5 years. Cohort viral loads (million copies/mL per 1000 patients) were 3.7 [95% prediction interval (PrI), 2.9-4.9] for no LTFU, 8.6 (95% PrI, 7.3-10.0) for no tracing, 7.7 (95% PrI, 6.2-9.1) for immediate, and 8.0 (95% PrI, 6.7-9.5) for delayed tracing. Comparing no LTFU with no tracing, the number of new infections increased from 33 (95% PrI, 29-38) to 54 (95% PrI, 47-60) per 1000 patients. Immediate tracing prevented 3.6 (95% PrI, -3.3 to 12.8) and delayed tracing 2.5 (95% PrI, -5.8 to 11.1) new infections per 1000. Immediate tracing was more efficient than delayed tracing: to 116 and 142 tracing efforts, respectively, were needed prevent 1 new infection. CONCLUSIONS: Tracing of patients LTFU enhances the preventive effect of antiretroviral therapy, but the number of transmissions prevented is small.'
p33165
sS'GR'
p33166
(lp33167
S'5U01-AI069924/AI/NIAID NIH HHS/United States'
p33168
aS'U01 AI069924/AI/NIAID NIH HHS/United States'
p33169
asS'IP'
p33170
S'5'
sS'IS'
p33171
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p33172
sS'PMC'
p33173
S'PMC3999218'
p33174
sS'DCOM'
p33175
S'20140625'
p33176
sS'AU'
p33177
(lp33178
S'Estill J'
p33179
aS'Tweya H'
p33180
aS'Egger M'
p33181
aS'Wandeler G'
p33182
aS'Feldacker C'
p33183
aS'Johnson LF'
p33184
aS'Blaser N'
p33185
aS'Vizcaya LS'
p33186
aS'Phiri S'
p33187
aS'Keiser O'
p33188
asS'VI'
p33189
S'65'
p33190
sS'MHDA'
p33191
S'2014/06/26 06:00'
p33192
sS'OID'
p33193
(lp33194
S'NLM: NIHMS542698'
p33195
aS'NLM: PMC3999218'
p33196
asS'MH'
p33197
(lp33198
S'Adolescent'
p33199
aS'Adult'
p33200
aS'Aged'
p33201
aS'Anti-Retroviral Agents/therapeutic use'
p33202
aS'Antiretroviral Therapy, Highly Active/methods'
p33203
aS'Disease Transmission, Infectious/*prevention & control'
p33204
aS'Female'
p33205
aS'HIV Infections/*drug therapy/*prevention & control/transmission'
p33206
aS'Humans'
p33207
aS'*Lost to Follow-Up'
p33208
aS'Malawi'
p33209
aS'Male'
p33210
aS'Middle Aged'
p33211
aS'Models, Theoretical'
p33212
aS'Viral Load'
p33213
aS'Young Adult'
p33214
asS'EDAT'
p33215
S'2013/12/12 06:00'
p33216
sS'SO'
p33217
S'J Acquir Immune Defic Syndr. 2014 Apr 15;65(5):e179-86. doi: 10.1097/QAI.0000000000000075.'
p33218
sS'SB'
p33219
S'IM X'
p33220
sS'PMID'
p33221
S'24326599'
p33222
sS'PST'
p33223
S'ppublish'
p33224
stRp33225
ag2
(g3
g4
(dp33226
S'LID'
p33227
S'10.1186/1471-2458-13-1149 [doi]'
p33228
sS'STAT'
p33229
S'MEDLINE'
p33230
sS'DEP'
p33231
S'20131209'
p33232
sS'DA'
p33233
S'20140117'
p33234
sS'AID'
p33235
(lp33236
S'1471-2458-13-1149 [pii]'
p33237
aS'10.1186/1471-2458-13-1149 [doi]'
p33238
asS'CRDT'
p33239
(lp33240
S'2013/12/11 06:00'
p33241
asS'DP'
p33242
S'2013'
p33243
sS'OWN'
p33244
S'NLM'
p33245
sS'PT'
p33246
(lp33247
S'Clinical Trial, Phase I'
p33248
aS'Clinical Trial, Phase II'
p33249
aS'Journal Article'
p33250
aS'Randomized Controlled Trial'
p33251
aS"Research Support, Non-U.S. Gov't"
p33252
aS"Research Support, U.S. Gov't, Non-P.H.S."
p33253
asS'LA'
p33254
(lp33255
S'eng'
p33256
asS'DCOM'
p33257
S'20140825'
p33258
sS'JT'
p33259
S'BMC public health'
p33260
sS'LR'
p33261
S'20150422'
p33262
sS'FAU'
p33263
(lp33264
S'Bakari, Muhammad'
p33265
aS'Munseri, Patricia'
p33266
aS'Francis, Joel'
p33267
aS'Aris, Eric'
p33268
aS'Moshiro, Candida'
p33269
aS'Siyame, David'
p33270
aS'Janabi, Mohamed'
p33271
aS'Ngatoluwa, Mary'
p33272
aS'Aboud, Said'
p33273
aS'Lyamuya, Eligius'
p33274
aS'Sandstrom, Eric'
p33275
aS'Mhalu, Fred'
p33276
asS'TI'
p33277
S'Experiences on recruitment and retention of volunteers in the first HIV vaccine trial in Dar es Salam, Tanzania - the phase I/II HIVIS 03 trial.'
p33278
sS'RN'
p33279
(lp33280
S'0 (AIDS Vaccines)'
p33281
asS'PL'
p33282
S'England'
p33283
sS'PG'
p33284
S'1149'
p33285
sS'JID'
p33286
S'100968562'
p33287
sS'AB'
p33288
S'BACKGROUND: Eventual control of HIV/AIDS is believed to be ultimately dependent on a safe, effective and affordable vaccine. Participation of sub-Saharan Africa in the conduct of HIV trials is crucial as this region still experiences high HIV incidences. We describe the experience of recruiting and retaining volunteers in the first HIV vaccine trial (HIVIS03) in Tanzania. METHODS: In this trial enrolled volunteers from amongst Police Officers (POs) in Dar es Salaam were primed with HIV-1 DNA vaccine at months 0, 1 and 3; and boosted with HIV-1 MVA vaccine at months 9 and 21. A stepwise education provision/sensitization approach was employed to eventual recruitment. Having identified a "core" group of POs keen on HIV prevention activities, those interested to participate in the vaccine trial were invited for a first screening session that comprised of provision of detailed study information and medical evaluation. In the second screening session results of the initial assessment were provided and those eligible were assessed for willingness to participate (WTP). Those willing were consented and eventually randomized into the trial having met the eligibility criteria. Voluntary participation was emphasized throughout. RESULTS: Out of 408 POs who formed the core group, 364 (89.0%) attended the educational sessions. 263 out of 364 (72.2%) indicated willingness to participate in the HIV vaccine trial. 98% of those indicating WTP attended the pre-screening workshops. 220 (85.0%) indicated willingness to undergo first screening and 177 POs attended for initial screenings, of whom 162 (91.5%) underwent both clinical and laboratory screenings. 119 volunteers (73.5%) were eligible for the study. 79 were randomized into the trial, while 19 did not turn up, the major reason being partner/family advice. 60 volunteers including 15 females were recruited during a one-year period. All participated in the planned progress updates workshops. Retention into the schedule was: 98% for the 3 DNA/placebo vaccinations, while it was 83% and 73% for the first and second MVA/placebo vaccinations respectively. CONCLUSION: In this first HIV vaccine trial in Tanzania, we successfully recruited the volunteers and there was no significant loss to follow up. Close contact and updates on study progress facilitated the observed retention rates. TRIAL REGISTRATION NUMBERS: ISRCTN90053831 ISRNCT01132976 and ATMR2009040001075080.'
p33289
sS'AD'
p33290
S'Muhimbili University of Health and Allied Sciences, P,O, Box 65001, Dar es Salaam, Tanzania. drbakari@yahoo.com.'
p33291
sS'VI'
p33292
S'13'
p33293
sS'IS'
p33294
S'1471-2458 (Electronic) 1471-2458 (Linking)'
p33295
sS'PMC'
p33296
S'PMC4029747'
p33297
sS'AU'
p33298
(lp33299
S'Bakari M'
p33300
aS'Munseri P'
p33301
aS'Francis J'
p33302
aS'Aris E'
p33303
aS'Moshiro C'
p33304
aS'Siyame D'
p33305
aS'Janabi M'
p33306
aS'Ngatoluwa M'
p33307
aS'Aboud S'
p33308
aS'Lyamuya E'
p33309
aS'Sandstrom E'
p33310
aS'Mhalu F'
p33311
asS'MHDA'
p33312
S'2014/08/26 06:00'
p33313
sS'PHST'
p33314
(lp33315
S'2013/04/26 [received]'
p33316
aS'2013/12/02 [accepted]'
p33317
aS'2013/12/09 [aheadofprint]'
p33318
asS'OID'
p33319
(lp33320
S'NLM: PMC4029747'
p33321
asS'MH'
p33322
(lp33323
S'AIDS Vaccines/*therapeutic use'
p33324
aS'Adult'
p33325
aS'Female'
p33326
aS'HIV Infections/*prevention & control'
p33327
aS'Humans'
p33328
aS'Male'
p33329
aS'Middle Aged'
p33330
aS'Patient Dropouts/psychology/*statistics & numerical data'
p33331
aS'*Patient Selection'
p33332
aS'Tanzania/epidemiology'
p33333
aS'Young Adult'
p33334
asS'EDAT'
p33335
S'2013/12/11 06:00'
p33336
sS'SI'
p33337
(lp33338
S'ISRCTN/ISRCTN90053831'
p33339
asS'SO'
p33340
S'BMC Public Health. 2013 Dec 9;13:1149. doi: 10.1186/1471-2458-13-1149.'
p33341
sS'SB'
p33342
S'IM'
p33343
sS'PMID'
p33344
S'24321091'
p33345
sS'TA'
p33346
S'BMC Public Health'
p33347
sS'PST'
p33348
S'epublish'
p33349
stRp33350
ag2
(g3
g4
(dp33351
S'LID'
p33352
S'10.4103/1596-3519.122692 [doi]'
p33353
sS'STAT'
p33354
S'MEDLINE'
p33355
sS'AB'
p33356
S'BACKGROUND: The prevalence of human immunodeficiency virus (HIV) infection is rising in Sub- Saharan Africa. The various indirect tests readily available have not been helpful in neonatal and early infant diagnosis of the disease. Polymerase chain reaction (PCR) is a direct test that can be used in these groups of children. Early infant diagnosis is important in achieving good outcome in the management of HIV infection. The aim of this article was to examine the role of PCR in the evaluation HIV-infected infants, with a view to achieve early diagnosis, early treatment, and good outcome. MATERIALS AND METHODS: This was a prospective review of 174 infants delivered by HIV-infected mothers in a rural hospital from January 2007 to September 2008. The blood samples of the patients were collected and subjected to PCR analysis for detection of viral antigen. Two samples were collected, the first at 6 weeks and the second 6 weeks after that. The results were recorded, collated, and analyzed using SPSS version 17. RESULTS: There were 174 infants, 100 boys, and 74 girls. The age range was 6-8 weeks (median 6 weeks). PCR was positive for both the samples in 12 (6.9%) infants. PCR was negative in both samples in 162 (93.1%) infants. All infants who were negative in the first sampling were found to be negative in the second sampling as well. None of the infant was positive for only one sample. Analysis of 12 positive infants revealed that 5 (2.9%) infants were placed on anti-retroviral drugs, 3 (1.7%) infants were not placed on anti-retroviral drugs because of low CD+ count, and 1 (1.0%) infant was lost to follow-up, while 3 (1.7%) infants died from sepsis. CONCLUSION: PCR has a role as a direct test in early diagnosis of HIV infection in infancy, particularly where the other direct test are not readily available.'
p33357
sS'JID'
p33358
S'101231417'
p33359
sS'AD'
p33360
S'Department of Surgery, Paediatric Surgery Unit, Usmanu Danfodiyo University, Sokoto, Nigeria.'
p33361
sS'JT'
p33362
S'Annals of African medicine'
p33363
sS'IP'
p33364
S'4'
sS'IS'
p33365
S'0975-5764 (Electronic) 0975-5764 (Linking)'
p33366
sS'DCOM'
p33367
S'20140212'
p33368
sS'DA'
p33369
S'20131206'
p33370
sS'AU'
p33371
(lp33372
S'Lukong CS'
p33373
aS'Tshimwanga ED'
p33374
aS'Mfuh AY'
p33375
asS'AID'
p33376
(lp33377
S'AnnAfrMed_2013_12_4_232_122692 [pii]'
p33378
aS'10.4103/1596-3519.122692 [doi]'
p33379
asS'CRDT'
p33380
(lp33381
S'2013/12/07 06:00'
p33382
asS'VI'
p33383
S'12'
p33384
sS'DP'
p33385
S'2013 Oct-Dec'
p33386
sS'MHDA'
p33387
S'2014/02/13 06:00'
p33388
sS'OWN'
p33389
S'NLM'
p33390
sS'PT'
p33391
(lp33392
S'Journal Article'
p33393
asS'LA'
p33394
(lp33395
S'eng'
p33396
asS'MH'
p33397
(lp33398
S'CD4 Lymphocyte Count'
p33399
aS'Cameroon'
p33400
aS'*Early Diagnosis'
p33401
aS'Enzyme-Linked Immunosorbent Assay'
p33402
aS'Female'
p33403
aS'HIV Infections/blood/*diagnosis/transmission'
p33404
aS'HIV-1/genetics/*isolation & purification'
p33405
aS'Hospitals, Rural'
p33406
aS'Humans'
p33407
aS'Infant, Newborn'
p33408
aS'Infectious Disease Transmission, Vertical'
p33409
aS'Male'
p33410
aS'Polymerase Chain Reaction/*methods'
p33411
aS'Prospective Studies'
p33412
asS'FAU'
p33413
(lp33414
S'Lukong, Christopher S'
p33415
aS'Tshimwanga, Edourd D'
p33416
aS'Mfuh, Anita Y'
p33417
asS'EDAT'
p33418
S'2013/12/07 06:00'
p33419
sS'PST'
p33420
S'ppublish'
p33421
sS'SO'
p33422
S'Ann Afr Med. 2013 Oct-Dec;12(4):232-5. doi: 10.4103/1596-3519.122692.'
p33423
sS'PG'
p33424
S'232-5'
p33425
sS'TI'
p33426
S'The role of polymerase chain reaction in early diagnosis of human immunodeficiency virus infection in infants.'
p33427
sS'SB'
p33428
S'IM'
p33429
sS'PMID'
p33430
S'24309412'
p33431
sS'PL'
p33432
S'India'
p33433
sS'TA'
p33434
S'Ann Afr Med'
p33435
stRp33436
ag2
(g3
g4
(dp33437
S'LID'
p33438
S'10.1093/infdis/jit584 [doi]'
p33439
sS'STAT'
p33440
S'MEDLINE'
p33441
sS'DEP'
p33442
S'20131203'
p33443
sS'CIN'
p33444
(lp33445
S'J Infect Dis. 2014 Feb 15;209(4):483-5. PMID: 24307740'
p33446
asS'DA'
p33447
S'20140128'
p33448
sS'AID'
p33449
(lp33450
S'jit584 [pii]'
p33451
aS'10.1093/infdis/jit584 [doi]'
p33452
asS'CRDT'
p33453
(lp33454
S'2013/12/06 06:00'
p33455
asS'DP'
p33456
S'2014 Feb 15'
p33457
sS'AD'
p33458
S'Department of Emergency Medicine, San Antonio Uniformed Services Health Education Consortium, Texas.'
p33459
sS'OWN'
p33460
S'NLM'
p33461
sS'PT'
p33462
(lp33463
S'Journal Article'
p33464
aS'Research Support, N.I.H., Extramural'
p33465
aS"Research Support, Non-U.S. Gov't"
p33466
asS'LA'
p33467
(lp33468
S'eng'
p33469
asS'FAU'
p33470
(lp33471
S'April, Michael D'
p33472
aS'Wood, Robin'
p33473
aS'Berkowitz, Bethany K'
p33474
aS'Paltiel, A David'
p33475
aS'Anglaret, Xavier'
p33476
aS'Losina, Elena'
p33477
aS'Freedberg, Kenneth A'
p33478
aS'Walensky, Rochelle P'
p33479
asS'JT'
p33480
S'The Journal of infectious diseases'
p33481
sS'LR'
p33482
S'20150428'
p33483
sS'PG'
p33484
S'491-9'
p33485
sS'TI'
p33486
S'The survival benefits of antiretroviral therapy in South Africa.'
p33487
sS'RN'
p33488
(lp33489
S'0 (Anti-HIV Agents)'
p33490
asS'PL'
p33491
S'United States'
p33492
sS'TA'
p33493
S'J Infect Dis'
p33494
sS'JID'
p33495
S'0413675'
p33496
sS'AB'
p33497
S'BACKGROUND: We sought to quantify the survival benefits attributable to antiretroviral therapy (ART) in South Africa since 2004. METHODS: We used the Cost-Effectiveness of Preventing AIDS Complications-International model (CEPAC) to simulate 8 cohorts of human immunodeficiency virus (HIV)-infected patients initiating ART each year during 2004-2011. Model inputs included cohort-specific mean CD4(+) T-cell count at ART initiation (112-178 cells/microL), 24-week ART suppressive efficacy (78%), second-line ART availability (2.4% of ART recipients), and cohort-specific 36-month retention rate (55%-71%). CEPAC simulated survival twice for each cohort, once with and once without ART. The sum of the products of per capita survival differences and the total numbers of persons initiating ART for each cohort yielded the total survival benefits. RESULTS: Lifetime per capita survival benefits ranged from 9.3 to 10.2 life-years across the 8 cohorts. Total estimated population lifetime survival benefit for all persons starting ART during 2004-2011 was 21.7 million life-years, of which 2.8 million life-years (12.7%) had been realized by December 2012. By 2030, benefits reached 17.9 million life-years under current policies, 21.7 million life-years with universal second-line ART, 23.3 million life-years with increased linkage to care of eligible untreated patients, and 28.0 million life-years with both linkage to care and universal second-line ART. CONCLUSIONS: We found dramatic past and potential future survival benefits attributable to ART, justifying international support of ART rollout in South Africa.'
p33498
sS'GR'
p33499
(lp33500
S'P30 AI060354/AI/NIAID NIH HHS/United States'
p33501
aS'P30 AI060354/AI/NIAID NIH HHS/United States'
p33502
aS'P30 MH062294/MH/NIMH NIH HHS/United States'
p33503
aS'R01 AI058736/AI/NIAID NIH HHS/United States'
p33504
aS'R01 AI093269/AI/NIAID NIH HHS/United States'
p33505
aS'R01 AI093269/AI/NIAID NIH HHS/United States'
p33506
asS'IP'
p33507
S'4'
sS'IS'
p33508
S'1537-6613 (Electronic) 0022-1899 (Linking)'
p33509
sS'PMC'
p33510
S'PMC3903379'
p33511
sS'DCOM'
p33512
S'20140414'
p33513
sS'AU'
p33514
(lp33515
S'April MD'
p33516
aS'Wood R'
p33517
aS'Berkowitz BK'
p33518
aS'Paltiel AD'
p33519
aS'Anglaret X'
p33520
aS'Losina E'
p33521
aS'Freedberg KA'
p33522
aS'Walensky RP'
p33523
asS'VI'
p33524
S'209'
p33525
sS'MHDA'
p33526
S'2014/04/15 06:00'
p33527
sS'PHST'
p33528
(lp33529
S'2013/12/03 [aheadofprint]'
p33530
asS'OTO'
p33531
(lp33532
S'NOTNLM'
p33533
asS'OID'
p33534
(lp33535
S'NLM: PMC3903379'
p33536
asS'MH'
p33537
(lp33538
S'Adult'
p33539
aS'Analysis of Variance'
p33540
aS'Anti-HIV Agents/*therapeutic use'
p33541
aS'Antiretroviral Therapy, Highly Active'
p33542
aS'CD4 Lymphocyte Count'
p33543
aS'Computer Simulation'
p33544
aS'Cost-Benefit Analysis'
p33545
aS'Female'
p33546
aS'HIV Infections/*drug therapy/*economics/epidemiology'
p33547
aS'Humans'
p33548
aS'Male'
p33549
aS'Middle Aged'
p33550
aS'Models, Theoretical'
p33551
aS'South Africa/epidemiology'
p33552
aS'Viral Load'
p33553
asS'EDAT'
p33554
S'2013/12/07 06:00'
p33555
sS'SO'
p33556
S'J Infect Dis. 2014 Feb 15;209(4):491-9. doi: 10.1093/infdis/jit584. Epub 2013 Dec 3.'
p33557
sS'SB'
p33558
S'AIM IM'
p33559
sS'PMID'
p33560
S'24307741'
p33561
sS'OT'
p33562
(lp33563
S'HIV'
p33564
aS'South Africa'
p33565
aS'highly active antiretroviral therapy'
p33566
asS'PST'
p33567
S'ppublish'
p33568
stRp33569
ag2
(g3
g4
(dp33570
S'LID'
p33571
S'10.1093/trstmh/trt105 [doi]'
p33572
sS'STAT'
p33573
S'MEDLINE'
p33574
sS'DEP'
p33575
S'20131126'
p33576
sS'DA'
p33577
S'20131224'
p33578
sS'AID'
p33579
(lp33580
S'trt105 [pii]'
p33581
aS'10.1093/trstmh/trt105 [doi]'
p33582
asS'CRDT'
p33583
(lp33584
S'2013/11/29 06:00'
p33585
asS'DP'
p33586
S'2014 Jan'
p33587
sS'AD'
p33588
S'Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.'
p33589
sS'OWN'
p33590
S'NLM'
p33591
sS'PT'
p33592
(lp33593
S'Journal Article'
p33594
asS'LA'
p33595
(lp33596
S'eng'
p33597
asS'FAU'
p33598
(lp33599
S'Govindasamy, Darshini'
p33600
aS'Kranzer, Katharina'
p33601
aS'Ford, Nathan'
p33602
asS'JT'
p33603
S'Transactions of the Royal Society of Tropical Medicine and Hygiene'
p33604
sS'LR'
p33605
S'20160713'
p33606
sS'PG'
p33607
S'1-3'
p33608
sS'TI'
p33609
S'Strengthening the HIV cascade to ensure an effective future ART response in sub-Saharan Africa.'
p33610
sS'RN'
p33611
(lp33612
S'0 (Anti-Retroviral Agents)'
p33613
asS'PL'
p33614
S'England'
p33615
sS'TA'
p33616
S'Trans R Soc Trop Med Hyg'
p33617
sS'JID'
p33618
S'7506129'
p33619
sS'AB'
p33620
S'Timely linkage to antiretroviral therapy (ART) care is critical for reducing HIV-related morbidity, mortality and transmission. Studies investigating interventions to improve linkage to, and retention in, pre-ART care in sub-Saharan Africa were reviewed. Certain interventions used to overcome economic barriers for ART-patients (i.e. integration of services, medical and food incentives, intensified counselling and peer support) have also shown favourable results in the pre-ART period. A combined package of interventions found to be effective in the pre-ART and ART period might be effective for reducing attrition in both periods. Further operational research in this area is needed to identify local solutions.'
p33621
sS'GR'
p33622
(lp33623
S'100714/Wellcome Trust/United Kingdom'
p33624
asS'IP'
p33625
S'1'
sS'IS'
p33626
S'1878-3503 (Electronic) 0035-9203 (Linking)'
p33627
sS'DCOM'
p33628
S'20140728'
p33629
sS'AU'
p33630
(lp33631
S'Govindasamy D'
p33632
aS'Kranzer K'
p33633
aS'Ford N'
p33634
asS'VI'
p33635
S'108'
p33636
sS'MHDA'
p33637
S'2014/07/30 06:00'
p33638
sS'PHST'
p33639
(lp33640
S'2013/11/26 [aheadofprint]'
p33641
asS'OTO'
p33642
(lp33643
S'NOTNLM'
p33644
asS'MH'
p33645
(lp33646
S'Africa South of the Sahara'
p33647
aS'Anti-Retroviral Agents/*therapeutic use'
p33648
aS'Delivery of Health Care/*organization & administration'
p33649
aS'HIV Infections/*drug therapy'
p33650
aS'Health Services Accessibility/standards'
p33651
aS'Humans'
p33652
aS'Patient Acceptance of Health Care'
p33653
asS'EDAT'
p33654
S'2013/11/29 06:00'
p33655
sS'SO'
p33656
S'Trans R Soc Trop Med Hyg. 2014 Jan;108(1):1-3. doi: 10.1093/trstmh/trt105. Epub 2013 Nov 26.'
p33657
sS'SB'
p33658
S'IM'
p33659
sS'PMID'
p33660
S'24284954'
p33661
sS'OT'
p33662
(lp33663
S'ART'
p33664
aS'Attrition'
p33665
aS'HIV'
p33666
aS'Loss to follow-up'
p33667
aS'Pre-ART'
p33668
aS'Retention'
p33669
asS'PST'
p33670
S'ppublish'
p33671
stRp33672
ag2
(g3
g4
(dp33673
S'STAT'
p33674
S'MEDLINE'
p33675
sS'AB'
p33676
S"Evaluation of differences between human immunodeficiency virus (HIV)-infected men and women in antiretroviral therapy (ART) enrollment characteristics and outcomes might identify opportunities to improve ART program patient outcomes and prevention impact. During September 2008-February 2012, retrospective cohort studies to estimate attrition of enrollees (i.e., from death, stopping ART, or loss to follow-up) at 6-month intervals after ART initiation were completed among samples of adult men and women (defined as aged >/=15 years or aged >/=18 years) who initiated ART during 2004-2010 in six African countries: Cote d'Ivoire in western Africa; Swaziland, Mozambique, and Zambia in southern Africa; and Uganda and Tanzania in eastern Africa. Records for 13,175 ART enrollees were analyzed; sample sizes among the six countries ranged from 1,457 to 3,682. In each country, women comprised 61%-67% of ART enrollees. Median CD4 count range was 119-141 cells/microL for men and 137-161 cells/microL for women. Compared with women, a greater percentage of men initiated ART who had World Health Organization (WHO) HIV stage IV disease. In cohorts from western Africa and southern Africa, the risk for attrition was 15%-26% lower among women compared with men in multivariable analysis. However, in eastern Africa, differences between men and women in risk for attrition were not statistically significant. Research to identify country-specific causes for increased attrition and delayed initiation of care among men could identify strategies to improve ART program outcomes among men, which might contribute to prevention of new HIV infections in female partners."
p33677
sS'CN'
p33678
(lp33679
S'Centers for Disease Control and Prevention (CDC)'
p33680
asS'JT'
p33681
S'MMWR. Morbidity and mortality weekly report'
p33682
sS'IP'
p33683
S'47'
p33684
sS'IS'
p33685
S'1545-861X (Electronic) 0149-2195 (Linking)'
p33686
sS'JID'
p33687
S'7802429'
p33688
sS'DA'
p33689
S'20131127'
p33690
sS'AID'
p33691
(lp33692
S'mm6247a2 [pii]'
p33693
asS'DCOM'
p33694
S'20140115'
p33695
sS'VI'
p33696
S'62'
p33697
sS'PMID'
p33698
S'24280913'
p33699
sS'DP'
p33700
S'2013 Nov 29'
p33701
sS'MHDA'
p33702
S'2014/01/16 06:00'
p33703
sS'OWN'
p33704
S'NLM'
p33705
sS'PT'
p33706
(lp33707
S'Journal Article'
p33708
asS'LA'
p33709
(lp33710
S'eng'
p33711
asS'MH'
p33712
(lp33713
S'Adult'
p33714
aS'Africa'
p33715
aS'Anti-HIV Agents/*therapeutic use'
p33716
aS'Female'
p33717
aS'HIV Infections/*drug therapy'
p33718
aS'*Health Status Disparities'
p33719
aS'Humans'
p33720
aS'Male'
p33721
aS'Sex Factors'
p33722
aS'Treatment Outcome'
p33723
asS'CRDT'
p33724
(lp33725
S'2013/11/28 06:00'
p33726
asS'EDAT'
p33727
S'2013/11/28 06:00'
p33728
sS'PST'
p33729
S'ppublish'
p33730
sS'SO'
p33731
S'MMWR Morb Mortal Wkly Rep. 2013 Nov 29;62(47):945-52.'
p33732
sS'PG'
p33733
S'945-52'
p33734
sS'TI'
p33735
S'Differences between HIV-Infected men and women in antiretroviral therapy outcomes - six African countries, 2004-2012.'
p33736
sS'SB'
p33737
S'IM'
p33738
sS'RN'
p33739
(lp33740
S'0 (Anti-HIV Agents)'
p33741
asS'PL'
p33742
S'United States'
p33743
sS'TA'
p33744
S'MMWR Morb Mortal Wkly Rep'
p33745
stRp33746
ag2
(g3
g4
(dp33747
S'LID'
p33748
S'10.7448/IAS.16.1.18616 [doi]'
p33749
sS'STAT'
p33750
S'MEDLINE'
p33751
sS'DEP'
p33752
S'20131121'
p33753
sS'DA'
p33754
S'20131125'
p33755
sS'AID'
p33756
(lp33757
S'18616 [pii]'
p33758
asS'CRDT'
p33759
(lp33760
S'2013/11/26 06:00'
p33761
asS'DP'
p33762
S'2013'
p33763
sS'GR'
p33764
(lp33765
S'1 U01AI069924-01/AI/NIAID NIH HHS/United States'
p33766
aS'U01 AI069924/AI/NIAID NIH HHS/United States'
p33767
asS'OWN'
p33768
S'NLM'
p33769
sS'PT'
p33770
(lp33771
S'Comparative Study'
p33772
aS'Journal Article'
p33773
aS'Research Support, N.I.H., Extramural'
p33774
aS"Research Support, Non-U.S. Gov't"
p33775
asS'LA'
p33776
(lp33777
S'eng'
p33778
asS'DCOM'
p33779
S'20140602'
p33780
sS'JT'
p33781
S'Journal of the International AIDS Society'
p33782
sS'LR'
p33783
S'20150422'
p33784
sS'FAU'
p33785
(lp33786
S'Labhardt, Niklaus Daniel'
p33787
aS'Keiser, Olivia'
p33788
aS'Sello, Motlalepula'
p33789
aS'Lejone, Thabo Ishmael'
p33790
aS'Pfeiffer, Karolin'
p33791
aS'Davies, Mary-Ann'
p33792
aS'Egger, Matthias'
p33793
aS'Ehmer, Jochen'
p33794
aS'Wandeler, Gilles'
p33795
asS'TI'
p33796
S'Outcomes of antiretroviral treatment programmes in rural Lesotho: health centres and hospitals compared.'
p33797
sS'RN'
p33798
(lp33799
S'0 (Anti-Retroviral Agents)'
p33800
asS'PL'
p33801
S'Switzerland'
p33802
sS'PG'
p33803
S'18616'
p33804
sS'JID'
p33805
S'101478566'
p33806
sS'AB'
p33807
S'INTRODUCTION: Lesotho was among the first countries to adopt decentralization of care from hospitals to nurse-led health centres (HCs) to scale up the provision of antiretroviral therapy (ART). We compared outcomes between patients who started ART at HCs and hospitals in two rural catchment areas in Lesotho. METHODS: The two catchment areas comprise two hospitals and 12 HCs. Patients >/=16 years starting ART at a hospital or HC between 2008 and 2011 were included. Loss to follow-up (LTFU) was defined as not returning to the facility for >/=180 days after the last visit, no follow-up (no FUP) as not returning after starting ART, and retention in care as alive and on ART at the facility. The data were analysed using logistic regression, competing risk regression and Kaplan-Meier methods. Multivariable analyses were adjusted for sex, age, CD4 cell count, World Health Organization stage, catchment area and type of ART. All analyses were stratified by gender. RESULTS: Of 3747 patients, 2042 (54.5%) started ART at HCs. Both women and men at hospitals had more advanced clinical and immunological stages of disease than those at HCs. Over 5445 patient-years, 420 died and 475 were LTFU. Kaplan-Meier estimates for three-year retention were 68.7 and 69.7% at HCs and hospitals, respectively, among women (p=0.81) and 68.8% at HCs versus 54.7% at hospitals among men (p<0.001). These findings persisted in adjusted analyses, with similar retention at HCs and hospitals among women (odds ratio (OR): 0.89, 95% confidence interval (CI): 0.73-1.09) and higher retention at HCs among men (OR: 1.53, 95% CI: 1.20-1.96). The latter result was mainly driven by a lower proportion of patients LTFU at HCs (OR: 0.68, 95% CI: 0.51-0.93). CONCLUSIONS: In rural Lesotho, overall retention in care did not differ significantly between nurse-led HCs and hospitals. However, men seemed to benefit most from starting ART at HCs, as they were more likely to remain in care in these facilities compared to hospitals.'
p33808
sS'AD'
p33809
S'SolidarMed Lesotho, Maseru, Lesotho; University Medical Clinic, Kantonsspital Baselland, Liestal, Switzerland; niklaus.labhardt@gmail.com.'
p33810
sS'CN'
p33811
(lp33812
S'SolidarMed ART Program and IeDEA-Southern Africa'
p33813
asS'VI'
p33814
S'16'
p33815
sS'IS'
p33816
S'1758-2652 (Electronic) 1758-2652 (Linking)'
p33817
sS'PMC'
p33818
S'PMC3838571'
p33819
sS'AU'
p33820
(lp33821
S'Labhardt ND'
p33822
aS'Keiser O'
p33823
aS'Sello M'
p33824
aS'Lejone TI'
p33825
aS'Pfeiffer K'
p33826
aS'Davies MA'
p33827
aS'Egger M'
p33828
aS'Ehmer J'
p33829
aS'Wandeler G'
p33830
asS'MHDA'
p33831
S'2014/06/03 06:00'
p33832
sS'PHST'
p33833
(lp33834
S'2013/03/17 [received]'
p33835
aS'2013/09/20 [revised]'
p33836
aS'2013/10/18 [accepted]'
p33837
asS'OT'
p33838
(lp33839
S'HIV'
p33840
aS'antiretroviral treatment'
p33841
aS'decentralization'
p33842
aS'nurse-based care'
p33843
aS'retention in care'
p33844
aS'rural Southern Africa'
p33845
aS'task shifting'
p33846
asS'OTO'
p33847
(lp33848
S'NOTNLM'
p33849
asS'OID'
p33850
(lp33851
S'NLM: PMC3838571'
p33852
asS'MH'
p33853
(lp33854
S'Adult'
p33855
aS'Anti-Retroviral Agents/*therapeutic use'
p33856
aS'*Community Health Centers'
p33857
aS'Female'
p33858
aS'HIV Infections/*drug therapy'
p33859
aS'*Hospitals'
p33860
aS'Humans'
p33861
aS'Lesotho'
p33862
aS'Male'
p33863
aS'Medication Adherence/*statistics & numerical data'
p33864
aS'Middle Aged'
p33865
aS'Rural Population'
p33866
aS'Treatment Outcome'
p33867
asS'EDAT'
p33868
S'2013/11/26 06:00'
p33869
sS'SO'
p33870
S'J Int AIDS Soc. 2013 Nov 21;16:18616. doi: 10.7448/IAS.16.1.18616.'
p33871
sS'SB'
p33872
S'IM X'
p33873
sS'PMID'
p33874
S'24267671'
p33875
sS'TA'
p33876
S'J Int AIDS Soc'
p33877
sS'PST'
p33878
S'epublish'
p33879
stRp33880
ag2
(g3
g4
(dp33881
S'LID'
p33882
S'10.4314/ahs.v13i2.16 [doi]'
p33883
sS'STAT'
p33884
S'MEDLINE'
p33885
sS'JT'
p33886
S'African health sciences'
p33887
sS'DA'
p33888
S'20131115'
p33889
sS'AID'
p33890
(lp33891
S'10.4314/ahs.v13i2.16 [doi]'
p33892
aS'jAFHS.v13.i2.pg311 [pii]'
p33893
asS'CRDT'
p33894
(lp33895
S'2013/11/16 06:00'
p33896
asS'DP'
p33897
S'2013 Jun'
p33898
sS'AD'
p33899
S'MRC/UVRI -Uganda Research Unit on AIDS. P.O. Box 49, Entebbe, Uganda.'
p33900
sS'OWN'
p33901
S'NLM'
p33902
sS'PT'
p33903
(lp33904
S'Case Reports'
p33905
aS'Journal Article'
p33906
aS"Research Support, Non-U.S. Gov't"
p33907
asS'LA'
p33908
(lp33909
S'eng'
p33910
asS'FAU'
p33911
(lp33912
S'Mayanja, B N'
p33913
aS'Kabunga, E'
p33914
aS'Masiira, B'
p33915
aS'Lubega, R'
p33916
aS'Kaleebu, P'
p33917
aS'Seeley, J'
p33918
asS'LR'
p33919
S'20150422'
p33920
sS'PG'
p33921
S'311-9'
p33922
sS'TI'
p33923
S'Personal barriers to antiretroviral therapy adherence: case studies from a rural Uganda prospective clinical cohort.'
p33924
sS'RN'
p33925
(lp33926
S'0 (Anti-Retroviral Agents)'
p33927
asS'PL'
p33928
S'Uganda'
p33929
sS'TA'
p33930
S'Afr Health Sci'
p33931
sS'JID'
p33932
S'101149451'
p33933
sS'AB'
p33934
S"BACKGROUND: Although good adherence to antiretroviral therapy (ART) is essential for successful treatment outcomes, some patients may have specific personal barriers to ART adherence. OBJECTIVES: To study specific personal barriers to ART adherence. METHODS: Quantitative data on patients' health status, ART adherence, CD4 cell counts and viral loads were collected, and qualitative data on life experiences of five patients with poor ART outcomes and adherence were also collected. RESULTS: Out of 35 patients with poor immunological and virological ART outcomes, 17 (49%) also had poor ART adherence. Patient 1 had no living child and did not disclose her HIV serostatus to her spouse because she wanted to have a child. Patient 2 was an orphan with neither social nor family support. Patient 3 stopped ART when she conceived, returned to the study clinic when pregnant again and was sickly. She was switched to second-line ART with satisfactory outcomes. Patient 4, a 14 year old orphan had missed ART for 2 months when his treatment supporter was away. Patient 5 aged 66 years stopped ART which he blamed for his erectile dysfunction. CONCLUSION: ART adherence counselling should target specific personal barriers to ART adherence like: lack of family support, health and sexual life concerns, desire to have children and family instability."
p33935
sS'GR'
p33936
(lp33937
S'MC_U950080938/Medical Research Council/United Kingdom'
p33938
aS'Medical Research Council/United Kingdom'
p33939
asS'IP'
p33940
S'2'
sS'IS'
p33941
S'1729-0503 (Electronic) 1680-6905 (Linking)'
p33942
sS'PMC'
p33943
S'PMC3824501'
p33944
sS'DCOM'
p33945
S'20140904'
p33946
sS'AU'
p33947
(lp33948
S'Mayanja BN'
p33949
aS'Kabunga E'
p33950
aS'Masiira B'
p33951
aS'Lubega R'
p33952
aS'Kaleebu P'
p33953
aS'Seeley J'
p33954
asS'VI'
p33955
S'13'
p33956
sS'MHDA'
p33957
S'2014/09/05 06:00'
p33958
sS'OTO'
p33959
(lp33960
S'NOTNLM'
p33961
asS'OID'
p33962
(lp33963
S'NLM: PMC3824501'
p33964
asS'MH'
p33965
(lp33966
S'Adolescent'
p33967
aS'Adult'
p33968
aS'Anti-Retroviral Agents/*therapeutic use'
p33969
aS'CD4 Lymphocyte Count'
p33970
aS'Female'
p33971
aS'HIV Infections/drug therapy/epidemiology'
p33972
aS'HIV-1/drug effects'
p33973
aS'Humans'
p33974
aS'Male'
p33975
aS'Medication Adherence/*psychology'
p33976
aS'Pregnancy'
p33977
aS'Prospective Studies'
p33978
aS'*Rural Population'
p33979
aS'Uganda/epidemiology'
p33980
aS'Viral Load'
p33981
aS'Young Adult'
p33982
asS'EDAT'
p33983
S'2013/11/16 06:00'
p33984
sS'SO'
p33985
S'Afr Health Sci. 2013 Jun;13(2):311-9. doi: 10.4314/ahs.v13i2.16.'
p33986
sS'SB'
p33987
S'IM'
p33988
sS'PMID'
p33989
S'24235929'
p33990
sS'OT'
p33991
(lp33992
S'ART adherence'
p33993
aS'Personal barriers'
p33994
aS'children desire'
p33995
aS'disclosure'
p33996
aS'sexual dysfunction'
p33997
aS'stigma'
p33998
asS'PST'
p33999
S'ppublish'
p34000
stRp34001
ag2
(g3
g4
(dp34002
S'LID'
p34003
S'10.1128/AAC.02069-13 [doi]'
p34004
sS'STAT'
p34005
S'MEDLINE'
p34006
sS'DEP'
p34007
S'20131111'
p34008
sS'DA'
p34009
S'20140128'
p34010
sS'AID'
p34011
(lp34012
S'AAC.02069-13 [pii]'
p34013
aS'10.1128/AAC.02069-13 [doi]'
p34014
asS'CRDT'
p34015
(lp34016
S'2013/11/13 06:00'
p34017
asS'DP'
p34018
S'2014'
p34019
sS'AD'
p34020
S'Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom.'
p34021
sS'OWN'
p34022
S'NLM'
p34023
sS'PT'
p34024
(lp34025
S'Journal Article'
p34026
aS"Research Support, Non-U.S. Gov't"
p34027
asS'LA'
p34028
(lp34029
S'eng'
p34030
asS'FAU'
p34031
(lp34032
S'Dickinson, Laura'
p34033
aS'Chaponda, Masautso'
p34034
aS'Carr, Daniel F'
p34035
aS'van Oosterhout, Joep J'
p34036
aS'Kumwenda, Johnstone'
p34037
aS'Lalloo, David G'
p34038
aS'Pirmohamed, Munir'
p34039
aS'Heyderman, Robert S'
p34040
aS'Khoo, Saye H'
p34041
asS'JT'
p34042
S'Antimicrobial agents and chemotherapy'
p34043
sS'LR'
p34044
S'20160713'
p34045
sS'PG'
p34046
S'706-12'
p34047
sS'TI'
p34048
S'Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi.'
p34049
sS'RN'
p34050
(lp34051
S'0 (Anti-HIV Agents)'
p34052
aS'99DK7FVK1H (Nevirapine)'
p34053
aS'EC 1.14.14.1 (Aryl Hydrocarbon Hydroxylases)'
p34054
aS'EC 1.14.14.1 (CYP2B6 protein, human)'
p34055
aS'EC 1.14.14.1 (Cytochrome P-450 CYP2B6)'
p34056
asS'PL'
p34057
S'United States'
p34058
sS'TA'
p34059
S'Antimicrob Agents Chemother'
p34060
sS'JID'
p34061
S'0315061'
p34062
sS'AB'
p34063
S'We modeled nevirapine (NVP) pharmacokinetics in HIV-infected Malawian patients to assess the relationship between drug exposure and patient characteristics, genetic polymorphisms, and development of hypersensitivity reaction (HSR). One thousand one hundred seventeen patients were prospectively recruited and followed for 26 weeks with multiple or single serum samples obtained in a subset of patients for NVP quantification. Single nucleotide polymorphisms (SNPs) within CYP2B6 and CYP3A4 genes were typed. Nonlinear mixed effects modeling was utilized to assess the influence of patient characteristics and host genetics on NVP apparent oral clearance (CL/F) and to explore the relationship between NVP CL/F and HSR. Published haplotype distributions were used to simulate NVP concentrations in Caucasians versus Africans. One hundred eighty patients (101 female) were included in the model; 25 experienced HSR. No associations between patient demographics or HSR and NVP CL/F were evident. A significant relationship between CYP2B6 c.983T>C and CYP2B6 c.516G>T and NVP CL/F was observed (P < 0.01). NVP CL/F was reduced by 23% and 36% in patients with CYP2B6 983TT/516TT and 983TC/516GG or GT, respectively, compared to the reference genotype. Simulated exposures suggested similar proportions (13 to 17%) of patients with subtherapeutic NVP among Caucasians and an African population. Influence of CYP2B6 polymorphisms on NVP CL/F in this population is in agreement with other reports. Our data indicate a lack of association between NVP exposure and HSR. Based on these data, dose optimization based solely on ethnicity (without individual gene testing) is unlikely to impact on risk of treatment failure or toxicity even in an African population with high carriage of poor metabolizer mutations.'
p34064
sS'GR'
p34065
(lp34066
S'100890/Wellcome Trust/United Kingdom'
p34067
aS'101113/Wellcome Trust/United Kingdom'
p34068
aS'G0901364/Medical Research Council/United Kingdom'
p34069
aS'MR/L006758/1/Medical Research Council/United Kingdom'
p34070
aS'WT078857MA/Wellcome Trust/United Kingdom'
p34071
asS'IP'
p34072
S'2'
sS'IS'
p34073
S'1098-6596 (Electronic) 0066-4804 (Linking)'
p34074
sS'PMC'
p34075
S'PMC3910846'
p34076
sS'DCOM'
p34077
S'20140922'
p34078
sS'AU'
p34079
(lp34080
S'Dickinson L'
p34081
aS'Chaponda M'
p34082
aS'Carr DF'
p34083
aS'van Oosterhout JJ'
p34084
aS'Kumwenda J'
p34085
aS'Lalloo DG'
p34086
aS'Pirmohamed M'
p34087
aS'Heyderman RS'
p34088
aS'Khoo SH'
p34089
asS'VI'
p34090
S'58'
p34091
sS'MHDA'
p34092
S'2014/09/23 06:00'
p34093
sS'PHST'
p34094
(lp34095
S'2013/11/11 [aheadofprint]'
p34096
asS'OID'
p34097
(lp34098
S'NLM: PMC3910846'
p34099
asS'MH'
p34100
(lp34101
S'Adult'
p34102
aS'African Continental Ancestry Group'
p34103
aS'Anti-HIV Agents/metabolism/*pharmacokinetics/therapeutic use'
p34104
aS'Aryl Hydrocarbon Hydroxylases/*genetics/metabolism'
p34105
aS'Biotransformation'
p34106
aS'Cytochrome P-450 CYP2B6'
p34107
aS'Drug Hypersensitivity/drug therapy/ethnology/*genetics/metabolism'
p34108
aS'European Continental Ancestry Group'
p34109
aS'Female'
p34110
aS'*HIV'
p34111
aS'HIV Infections/drug therapy/ethnology/*genetics/metabolism'
p34112
aS'Haplotypes'
p34113
aS'Humans'
p34114
aS'Malawi'
p34115
aS'Male'
p34116
aS'Middle Aged'
p34117
aS'Nevirapine/metabolism/*pharmacokinetics/therapeutic use'
p34118
aS'Pharmacogenetics'
p34119
aS'Polymorphism, Single Nucleotide'
p34120
aS'Prospective Studies'
p34121
asS'EDAT'
p34122
S'2013/11/13 06:00'
p34123
sS'SO'
p34124
S'Antimicrob Agents Chemother. 2014;58(2):706-12. doi: 10.1128/AAC.02069-13. Epub 2013 Nov 11.'
p34125
sS'SB'
p34126
S'IM'
p34127
sS'PMID'
p34128
S'24217698'
p34129
sS'PST'
p34130
S'ppublish'
p34131
stRp34132
ag2
(g3
g4
(dp34133
S'LID'
p34134
S'10.1089/AID.2013.0244 [doi]'
p34135
sS'STAT'
p34136
S'MEDLINE'
p34137
sS'DEP'
p34138
S'20131221'
p34139
sS'DA'
p34140
S'20140606'
p34141
sS'AID'
p34142
(lp34143
S'10.1089/aid.2013.0244 [doi]'
p34144
asS'CRDT'
p34145
(lp34146
S'2013/11/06 06:00'
p34147
asS'DP'
p34148
S'2014 Jun'
p34149
sS'OWN'
p34150
S'NLM'
p34151
sS'PT'
p34152
(lp34153
S'Journal Article'
p34154
aS"Research Support, Non-U.S. Gov't"
p34155
asS'LA'
p34156
(lp34157
S'eng'
p34158
asS'FAU'
p34159
(lp34160
S'Ismael, Nalia'
p34161
aS'Bila, Dulce'
p34162
aS'Mariani, Diana'
p34163
aS'Vubil, Adolfo'
p34164
aS'Mabunda, Nedio'
p34165
aS'Abreu, Celina'
p34166
aS'Jani, Ilesh'
p34167
aS'Tanuri, Amilcar'
p34168
asS'JT'
p34169
S'AIDS research and human retroviruses'
p34170
sS'LR'
p34171
S'20150601'
p34172
sS'PG'
p34173
S'603-9'
p34174
sS'TI'
p34175
S'Genetic analysis and natural polymorphisms in HIV-1 gp41 isolates from Maputo City, Mozambique.'
p34176
sS'RN'
p34177
(lp34178
S'0 (Anti-HIV Agents)'
p34179
aS'0 (HIV Envelope Protein gp41)'
p34180
aS'0 (Peptide Fragments)'
p34181
aS'0 (RNA, Viral)'
p34182
aS'0 (gp41 protein, Human immunodeficiency virus 1)'
p34183
aS'19OWO1T3ZE (enfuvirtide)'
p34184
asS'PL'
p34185
S'United States'
p34186
sS'TA'
p34187
S'AIDS Res Hum Retroviruses'
p34188
sS'JID'
p34189
S'8709376'
p34190
sS'AB'
p34191
S'Enfuvirtide was the first fusion inhibitor approved by the Food and Drug Administration (FDA) in 2003 for HIV-1 infection in treatment-experienced patient. It is the first approved antiviral agent to attack the HIV life cycle in its early stages. For HIV fusion to occur, the HR1 and HR2 domains in the gp41 region need to interact. Enfuvirtide is a synthetic peptide that corresponds to 36 amino acids of the HR2, which competitively binds to HR1 inhibiting the interaction with the HR2 domain thus preventing fusogenic conformation and inhibiting viral entry into host cells. Resistance to enfuvirtide is conferred by mutations occurring in the HR1 region involving residues 36-45. Mozambique, a sub-Saharan country, with an HIV prevalence of 11.5%, provides first line and second line antiretroviral therapy (ART)-based treatment. In poor resource settings such as Mozambique the lack of adequate infrastructures, the high costs of viral load tests, and the availability of salvage treatment have hindered the intended objective of monitoring HIV treatment, suggesting an important concern regarding the development of drug resistance. The general aim of this study was to evaluate naturally occurring polymorphisms and resistance-associated mutations in the gp41 region of HIV-1 isolates from Mozambique. The study included 78 patients naive to ARV treatment and 28 patients failing first line regimen recruited from Centro de Saude Alto-Mae situated in Maputo. The gp41 gene from 103 patients was sequenced and resistance-associated mutations for enfuvirtide were screened. Subtype analysis revealed that 96% of the sequences were classified as subtype C, 2% as subtype G, 1% as subtype A1, and the other 1% as a mosaic form composed of A1/C. No enfuvirtide resistance-associated mutations in HR1 of gp41 were detected. The major polymorphisms in the HR1 were N42S, L54M, A67T, and V72I. This study suggests that this new class of antiviral drug may be effective as a salvage therapy in patients failing first line regimens in Mozambique. However, further phenotypic studies are required to determine the clinical relevance of the polymorphisms detected in this study.'
p34192
sS'AD'
p34193
S'1 Instituto Nacional de Saude , Maputo, Mozambique .'
p34194
sS'IP'
p34195
S'6'
sS'IS'
p34196
S'1931-8405 (Electronic) 0889-2229 (Linking)'
p34197
sS'PMC'
p34198
S'PMC4046211'
p34199
sS'DCOM'
p34200
S'20150124'
p34201
sS'AU'
p34202
(lp34203
S'Ismael N'
p34204
aS'Bila D'
p34205
aS'Mariani D'
p34206
aS'Vubil A'
p34207
aS'Mabunda N'
p34208
aS'Abreu C'
p34209
aS'Jani I'
p34210
aS'Tanuri A'
p34211
asS'VI'
p34212
S'30'
p34213
sS'MHDA'
p34214
S'2015/01/27 06:00'
p34215
sS'PHST'
p34216
(lp34217
S'2013/12/21 [aheadofprint]'
p34218
asS'OID'
p34219
(lp34220
S'NLM: PMC4046211'
p34221
asS'MH'
p34222
(lp34223
S'Adolescent'
p34224
aS'Adult'
p34225
aS'Amino Acid Sequence'
p34226
aS'Anti-HIV Agents/therapeutic use'
p34227
aS'Child'
p34228
aS'Child, Preschool'
p34229
aS'Cluster Analysis'
p34230
aS'Drug Resistance, Viral'
p34231
aS'Female'
p34232
aS'Genotype'
p34233
aS'HIV Envelope Protein gp41/*genetics/therapeutic use'
p34234
aS'HIV Infections/drug therapy/*virology'
p34235
aS'HIV-1/*classification/*genetics/isolation & purification'
p34236
aS'Humans'
p34237
aS'Male'
p34238
aS'Middle Aged'
p34239
aS'Molecular Sequence Data'
p34240
aS'Mozambique'
p34241
aS'Mutation, Missense'
p34242
aS'Peptide Fragments/therapeutic use'
p34243
aS'Phylogeny'
p34244
aS'*Polymorphism, Genetic'
p34245
aS'RNA, Viral/genetics'
p34246
aS'Sequence Alignment'
p34247
aS'Sequence Analysis, DNA'
p34248
aS'Treatment Failure'
p34249
aS'Young Adult'
p34250
asS'EDAT'
p34251
S'2013/11/06 06:00'
p34252
sS'SO'
p34253
S'AIDS Res Hum Retroviruses. 2014 Jun;30(6):603-9. doi: 10.1089/AID.2013.0244. Epub 2013 Dec 21.'
p34254
sS'SB'
p34255
S'IM X'
p34256
sS'PMID'
p34257
S'24188582'
p34258
sS'PST'
p34259
S'ppublish'
p34260
stRp34261
ag2
(g3
g4
(dp34262
S'LID'
p34263
S'10.1097/QAD.0000000000000039 [doi]'
p34264
sS'STAT'
p34265
S'MEDLINE'
p34266
sS'JT'
p34267
S'AIDS (London, England)'
p34268
sS'MID'
p34269
(lp34270
S'NIHMS584246'
p34271
asS'DA'
p34272
S'20131003'
p34273
sS'AID'
p34274
(lp34275
S'10.1097/QAD.0000000000000039 [doi]'
p34276
aS'00002030-201310001-00011 [pii]'
p34277
asS'CRDT'
p34278
(lp34279
S'2013/10/04 06:00'
p34280
asS'DP'
p34281
S'2013 Oct'
p34282
sS'AD'
p34283
S'aRwanda Zambia HIV Research Group, Department of Pathology & Laboratory Medicine, School of Medicine bDepartment of Gynecology and Obstetrics, Emory University, School of Medicine cDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA dDepartment of Gynecology and Obstetrics, School of Medicine, University of Zambia, Lusaka, Zambia eDepartment of Epidemiology, Ryals School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama fHubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA gMinistry of Community Development, Mother and Child Health, Lusaka, Zambia.'
p34284
sS'OWN'
p34285
S'NLM'
p34286
sS'PT'
p34287
(lp34288
S'Journal Article'
p34289
aS'Randomized Controlled Trial'
p34290
aS'Research Support, N.I.H., Extramural'
p34291
aS"Research Support, Non-U.S. Gov't"
p34292
asS'LA'
p34293
(lp34294
S'eng'
p34295
asS'DCOM'
p34296
S'20140529'
p34297
sS'LR'
p34298
S'20150422'
p34299
sS'FAU'
p34300
(lp34301
S'Haddad, Lisa'
p34302
aS'Wall, Kristin M'
p34303
aS'Vwalika, Bellington'
p34304
aS'Khu, Naw Htee'
p34305
aS'Brill, Ilene'
p34306
aS'Kilembe, William'
p34307
aS'Stephenson, Rob'
p34308
aS'Chomba, Elwyn'
p34309
aS'Vwalika, Cheswa'
p34310
aS'Tichacek, Amanda'
p34311
aS'Allen, Susan'
p34312
asS'TI'
p34313
S'Contraceptive discontinuation and switching among couples receiving integrated HIV and family planning services in Lusaka, Zambia.'
p34314
sS'RN'
p34315
(lp34316
S'0 (Contraceptive Agents)'
p34317
asS'PL'
p34318
S'England'
p34319
sS'PG'
p34320
S'S93-103'
p34321
sS'JID'
p34322
S'8710219'
p34323
sS'AB'
p34324
S"OBJECTIVE: To describe predictors of contraceptive method discontinuation and switching behaviours among HIV-positive couples receiving couples' voluntary HIV counselling and testing services in Lusaka, Zambia. DESIGN: Couples were randomized in a factorial design to two-family planning educational intervention videos, received comprehensive family planning services and were assessed every 3 months for contraceptive initiation, discontinuation and switching. METHODS: We modelled factors associated with contraceptive method upgrading and downgrading via multivariate Andersen-Gill models. RESULTS: Most women continued the initial method selected after randomization. The highest rates of discontinuation/switching were observed for injectable contraceptive and intrauterine device users. Time to discontinuing the more effective contraceptive methods or downgrading to oral contraceptives or condoms was associated with the women's younger age, desire for more children within the next year, heavy menstrual bleeding, bleeding between periods and cystitis/dysuria. Health concerns among women about contraceptive implants and male partners not wanting more children were associated with upgrading from oral contraceptives or condoms. HIV status of the woman or the couple was not predictive of switching or stopping. CONCLUSION: We found complicated patterns of contraceptive use. The predictors of contraception switching indicate that interventions targeted to younger couples that address common contraception-related misconceptions could improve effective family planning utilization. We recommend these findings be used to increase the uptake and continuation of contraception, especially long-acting reversible contraceptive (LARC) methods, and that fertility goal based, LARC-focused family planning be offered as an integral part of HIV prevention services."
p34325
sS'GR'
p34326
(lp34327
S'D43 TW001042/TW/FIC NIH HHS/United States'
p34328
aS'NIAID R01 AI51231/PHS HHS/United States'
p34329
aS'NIMH R01 66767/PHS HHS/United States'
p34330
aS'P30 AI027767/AI/NIAID NIH HHS/United States'
p34331
aS'P30 AI050409/AI/NIAID NIH HHS/United States'
p34332
aS'P30 AI050409/AI/NIAID NIH HHS/United States'
p34333
aS'R01 HD040125/HD/NICHD NIH HHS/United States'
p34334
aS'R01 HD072659/HD/NICHD NIH HHS/United States'
p34335
aS'R01 HD40125/HD/NICHD NIH HHS/United States'
p34336
aS'R01 MH066767/MH/NIMH NIH HHS/United States'
p34337
aS'R01 MH095503/MH/NIMH NIH HHS/United States'
p34338
asS'VI'
p34339
S'27 Suppl 1'
p34340
sS'IS'
p34341
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p34342
sS'PMC'
p34343
S'PMC4070372'
p34344
sS'AU'
p34345
(lp34346
S'Haddad L'
p34347
aS'Wall KM'
p34348
aS'Vwalika B'
p34349
aS'Khu NH'
p34350
aS'Brill I'
p34351
aS'Kilembe W'
p34352
aS'Stephenson R'
p34353
aS'Chomba E'
p34354
aS'Vwalika C'
p34355
aS'Tichacek A'
p34356
aS'Allen S'
p34357
asS'MHDA'
p34358
S'2014/05/30 06:00'
p34359
sS'OID'
p34360
(lp34361
S'NLM: NIHMS584246'
p34362
aS'NLM: PMC4070372'
p34363
asS'MH'
p34364
(lp34365
S'Adolescent'
p34366
aS'Adult'
p34367
aS'Aged'
p34368
aS'Behavior Therapy/methods'
p34369
aS'Contraception/*methods/utilization'
p34370
aS'Contraceptive Agents/*administration & dosage'
p34371
aS'Delivery of Health Care, Integrated/*methods'
p34372
aS'*Family Characteristics'
p34373
aS'Family Planning Services/*methods'
p34374
aS'Female'
p34375
aS'HIV Infections/*diagnosis/drug therapy/prevention & control'
p34376
aS'Health Education/methods'
p34377
aS'Health Services Research'
p34378
aS'Humans'
p34379
aS'Infectious Disease Transmission, Vertical/*prevention & control'
p34380
aS'Male'
p34381
aS'Middle Aged'
p34382
aS'Pregnancy'
p34383
aS'Young Adult'
p34384
aS'Zambia'
p34385
asS'EDAT'
p34386
S'2013/10/23 06:00'
p34387
sS'SI'
p34388
(lp34389
S'ClinicalTrials.gov/NCT00067522'
p34390
asS'SO'
p34391
S'AIDS. 2013 Oct;27 Suppl 1:S93-103. doi: 10.1097/QAD.0000000000000039.'
p34392
sS'SB'
p34393
S'IM X'
p34394
sS'PMID'
p34395
S'24088689'
p34396
sS'TA'
p34397
S'AIDS'
p34398
sS'PST'
p34399
S'ppublish'
p34400
stRp34401
ag2
(g3
g4
(dp34402
S'LID'
p34403
S'10.1097/QAD.0000000000000040 [doi]'
p34404
sS'STAT'
p34405
S'MEDLINE'
p34406
sS'JT'
p34407
S'AIDS (London, England)'
p34408
sS'MID'
p34409
(lp34410
S'NIHMS606073'
p34411
asS'DA'
p34412
S'20131003'
p34413
sS'AID'
p34414
(lp34415
S'10.1097/QAD.0000000000000040 [doi]'
p34416
aS'00002030-201310001-00012 [pii]'
p34417
asS'CRDT'
p34418
(lp34419
S'2013/10/04 06:00'
p34420
asS'DP'
p34421
S'2013 Oct'
p34422
sS'AD'
p34423
S'aDivision of Infectious Disease, Massachusetts General Hospital, Center for Global Health bDivision of Infectious Disease, Beth Israel Deaconess Medical Center, Boston, Massachusetts cSimon Fraser University, Faculty of Health Sciences, Burnaby, Canada dDepartment of Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, California eUniversity of British Columbia, School of Population and Public Health, Vancouver, Canada fMbarara University of Science and Technology, Mbarara, Uganda gDepartment of Medicine, Massachusetts General Hospital, Center for Global Health, Boston, Massachusetts hUniversity of California at San Francisco, Department of Medicine, San Francisco, California, USA.'
p34424
sS'OWN'
p34425
S'NLM'
p34426
sS'PT'
p34427
(lp34428
S'Journal Article'
p34429
aS'Research Support, N.I.H., Extramural'
p34430
asS'LA'
p34431
(lp34432
S'eng'
p34433
asS'DCOM'
p34434
S'20140529'
p34435
sS'LR'
p34436
S'20160708'
p34437
sS'FAU'
p34438
(lp34439
S'Matthews, Lynn T'
p34440
aS'Kaida, Angela'
p34441
aS'Kanters, Steven'
p34442
aS'Byakwagamd, Helen'
p34443
aS'Mocello, A Rain'
p34444
aS'Muzoora, Conrad'
p34445
aS'Kembabazi, Annet'
p34446
aS'Haberer, Jessica E'
p34447
aS'Martin, Jeffrey N'
p34448
aS'Bangsberg, David R'
p34449
aS'Hunt, Peter W'
p34450
asS'TI'
p34451
S'HIV-infected women on antiretroviral treatment have increased mortality during pregnant and postpartum periods.'
p34452
sS'RN'
p34453
(lp34454
S'0 (Anti-Retroviral Agents)'
p34455
aS'0 (RNA, Viral)'
p34456
asS'PL'
p34457
S'England'
p34458
sS'PG'
p34459
S'S105-12'
p34460
sS'JID'
p34461
S'8710219'
p34462
sS'AB'
p34463
S"OBJECTIVE: To assess the impact of pregnancy on mortality among HIV-infected Ugandan women initiating ART. DESIGN: Prospective cohort study. METHODS: HIV-infected women initiating ART in the Uganda AIDS Rural Treatment Outcomes study were assessed quarterly for self-reported pregnancy. The association between pregnancy and postpartum ('pregnancy-related') follow-up periods and mortality was assessed with Cox proportional hazards models adjusted for age, CD4 cell count, plasma HIV-1 RNA levels, and ART duration. RESULTS: Three hundred and fifty-four women with median age 33 years (IQR: 27-37) and CD4 142 cells/mul (IQR: 82-213) were followed for a median of 4.0 years (IQR: 2.5-4.8) after ART initiation, with 3 and 7% loss-to-follow-up at years 1 and 5. One hundred and nine women experienced pregnancy. Five deaths occurred during pregnancy-related follow-up and 16 during nonpregnancy-related follow-up, for crude mortality rates during the first year after ART initiation of 12.57/100 PYs and 3.53/100 PYs (rate ratio 3.56, 95% CI: 0.97-11.07). In adjusted models, the impact of pregnancy-related follow-up on mortality was highest at ART initiation (aHR: 21.48, 95% CI: 3.73-123.51), decreasing to 13.44 (95% CI 3.28-55.11) after 4 months, 8.28 (95% CI 2.38-28.88) after 8 months, 5.18 (95% CI: 1.36-19.71) after 1 year, and 1.25 (95% CI: 0.10-15.58) after 2 years on ART. Four of five maternal deaths occurred postpartum. CONCLUSION: Pregnancy and the postpartum period were associated with increased mortality in HIV-infected women initiating ART, particularly during early ART. Contraception proximate to ART initiation, earlier ART initiation, and careful monitoring during the postpartum period may reduce maternal mortality in this setting."
p34464
sS'GR'
p34465
(lp34466
S'087228/PHS HHS/United States'
p34467
aS'AI100765/AI/NIAID NIH HHS/United States'
p34468
aS'HD069194/HD/NICHD NIH HHS/United States'
p34469
aS'K23 MH087228/MH/NIMH NIH HHS/United States'
p34470
aS'K23 MH095655/MH/NIMH NIH HHS/United States'
p34471
aS'K24 MH087227/MH/NIMH NIH HHS/United States'
p34472
aS'MH54907/MH/NIMH NIH HHS/United States'
p34473
aS'NIAID P30 027763/PHS HHS/United States'
p34474
aS'NIMH 095655/PHS HHS/United States'
p34475
aS'NIMH 87227/PHS HHS/United States'
p34476
aS'P30 AI027763/AI/NIAID NIH HHS/United States'
p34477
aS'R01 MH054907/MH/NIMH NIH HHS/United States'
p34478
aS'R21 HD069194/HD/NICHD NIH HHS/United States'
p34479
aS'R56 AI100765/AI/NIAID NIH HHS/United States'
p34480
asS'VI'
p34481
S'27 Suppl 1'
p34482
sS'IS'
p34483
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p34484
sS'PMC'
p34485
S'PMC4142689'
p34486
sS'AU'
p34487
(lp34488
S'Matthews LT'
p34489
aS'Kaida A'
p34490
aS'Kanters S'
p34491
aS'Byakwagamd H'
p34492
aS'Mocello AR'
p34493
aS'Muzoora C'
p34494
aS'Kembabazi A'
p34495
aS'Haberer JE'
p34496
aS'Martin JN'
p34497
aS'Bangsberg DR'
p34498
aS'Hunt PW'
p34499
asS'MHDA'
p34500
S'2014/05/30 06:00'
p34501
sS'OID'
p34502
(lp34503
S'NLM: NIHMS606073'
p34504
aS'NLM: PMC4142689'
p34505
asS'MH'
p34506
(lp34507
S'Adult'
p34508
aS'Anti-Retroviral Agents/*therapeutic use'
p34509
aS'CD4 Lymphocyte Count'
p34510
aS'Cohort Studies'
p34511
aS'Female'
p34512
aS'HIV Infections/*drug therapy/*mortality'
p34513
aS'HIV-1/isolation & purification'
p34514
aS'Humans'
p34515
aS'*Postpartum Period'
p34516
aS'Pregnancy'
p34517
aS'Pregnancy Complications, Infectious/*drug therapy/*mortality'
p34518
aS'Prospective Studies'
p34519
aS'RNA, Viral/blood'
p34520
aS'Survival Analysis'
p34521
aS'Uganda'
p34522
aS'Viral Load'
p34523
asS'EDAT'
p34524
S'2013/10/23 06:00'
p34525
sS'SO'
p34526
S'AIDS. 2013 Oct;27 Suppl 1:S105-12. doi: 10.1097/QAD.0000000000000040.'
p34527
sS'SB'
p34528
S'IM X'
p34529
sS'PMID'
p34530
S'24088676'
p34531
sS'TA'
p34532
S'AIDS'
p34533
sS'PST'
p34534
S'ppublish'
p34535
stRp34536
ag2
(g3
g4
(dp34537
S'LID'
p34538
S'10.1016/j.ijgo.2013.06.035 [doi] S0020-7292(13)00493-1 [pii]'
p34539
sS'STAT'
p34540
S'MEDLINE'
p34541
sS'DEP'
p34542
S'20130925'
p34543
sS'CI'
p34544
(lp34545
S'(c) 2013. Published by Elsevier Ireland Ltd on behalf of International Federation'
p34546
aS'of Gynecology and Obstetrics. All rights reserved.'
p34547
asS'DA'
p34548
S'20131224'
p34549
sS'AID'
p34550
(lp34551
S'S0020-7292(13)00493-1 [pii]'
p34552
aS'10.1016/j.ijgo.2013.06.035 [doi]'
p34553
asS'CRDT'
p34554
(lp34555
S'2013/10/22 06:00'
p34556
asS'DP'
p34557
S'2014 Jan'
p34558
sS'OWN'
p34559
S'NLM'
p34560
sS'PT'
p34561
(lp34562
S'Journal Article'
p34563
aS"Research Support, Non-U.S. Gov't"
p34564
asS'LA'
p34565
(lp34566
S'eng'
p34567
asS'FAU'
p34568
(lp34569
S'Khozaim, Kareem'
p34570
aS"Orang'o, Elkanah"
p34571
aS'Christoffersen-Deb, Astrid'
p34572
aS'Itsura, Peter'
p34573
aS'Oguda, John'
p34574
aS'Muliro, Hellen'
p34575
aS'Ndiema, Jackline'
p34576
aS'Mwangi, Grace'
p34577
aS'Strother, Matthew'
p34578
aS'Cu-Uvin, Susan'
p34579
aS'Rosen, Barry'
p34580
aS'Washington, Sierra'
p34581
asS'JT'
p34582
S'International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics'
p34583
sS'PG'
p34584
S'12-8'
p34585
sS'TI'
p34586
S'Successes and challenges of establishing a cervical cancer screening and treatment program in western Kenya.'
p34587
sS'PL'
p34588
S'Ireland'
p34589
sS'TA'
p34590
S'Int J Gynaecol Obstet'
p34591
sS'JID'
p34592
S'0210174'
p34593
sS'AB'
p34594
S'OBJECTIVE: To describe the challenges and successes of integrating a public-sector cervical screening program into a large HIV care system in western Kenya. METHODS: The present study was a programmatic description and a retrospective chart review of data collected from a cervical screening program based on visual inspection with acetic acid (VIA) between June 2009 and October 2011. RESULTS: In total, 6787 women were screened: 1331 (19.6%) were VIA-positive, of whom 949 (71.3%) had HIV. Overall, 206 women underwent cryotherapy, 754 colposcopy, 143 loop electrical excision procedure (LEEP), and 27 hysterectomy. Among the colposcopy-guided biopsies, 27.9% had severe dysplasia and 10.9% had invasive cancer. There were 68 cases of cancer, equating to approximately 414 per 100000 women per year. Despite aggressive strategies, the overall loss to follow-up was 31.5%: 27.9% were lost after a positive VIA screen, 49.3% between biopsy and LEEP, and 59.6% between biopsy and hysterectomy/chemotherapy. CONCLUSION: The established infrastructure of an HIV treatment program was successfully used to build capacity for cervical screening in a low-resource setting. By using task-shifting and evidence-based, low-cost approaches, population-based cervical screening in a rural African clinical network was found to feasible; however, loss to follow-up and poor pathology infrastructure remain important obstacles.'
p34595
sS'AD'
p34596
S'Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, USA. Electronic address: kkhozaim@iupui.edu. Moi Teaching and Referral Hospital, Eldoret, Kenya; Department of Reproductive Health, College of Health Sciences, Moi University, Eldoret, Kenya. Department of Obstetrics and Gynecology, University of Toronto, Toronto, Canada. Moi Teaching and Referral Hospital, Eldoret, Kenya; Department of Reproductive Health, College of Health Sciences, Moi University, Eldoret, Kenya. Moi Teaching and Referral Hospital, Eldoret, Kenya. Moi Teaching and Referral Hospital, Eldoret, Kenya. Moi Teaching and Referral Hospital, Eldoret, Kenya. Moi Teaching and Referral Hospital, Eldoret, Kenya. Department of Internal Medicine, Indiana University School of Medicine, Indianapolis, USA. Department of Obstetrics and Gynecology and Department of Medicine, Brown University School of Medicine, Providence, USA. Department of Obstetrics and Gynecology, University of Toronto, Toronto, Canada. Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, USA; Moi Teaching and Referral Hospital, Eldoret, Kenya.'
p34597
sS'IP'
p34598
S'1'
sS'IS'
p34599
S'1879-3479 (Electronic) 0020-7292 (Linking)'
p34600
sS'DCOM'
p34601
S'20140902'
p34602
sS'AU'
p34603
(lp34604
S'Khozaim K'
p34605
aS"Orang'o E"
p34606
aS'Christoffersen-Deb A'
p34607
aS'Itsura P'
p34608
aS'Oguda J'
p34609
aS'Muliro H'
p34610
aS'Ndiema J'
p34611
aS'Mwangi G'
p34612
aS'Strother M'
p34613
aS'Cu-Uvin S'
p34614
aS'Rosen B'
p34615
aS'Washington S'
p34616
asS'VI'
p34617
S'124'
p34618
sS'MHDA'
p34619
S'2014/09/03 06:00'
p34620
sS'PHST'
p34621
(lp34622
S'2013/01/29 [received]'
p34623
aS'2013/06/22 [revised]'
p34624
aS'2013/09/17 [accepted]'
p34625
aS'2013/09/25 [aheadofprint]'
p34626
asS'OTO'
p34627
(lp34628
S'NOTNLM'
p34629
asS'MH'
p34630
(lp34631
S'Adolescent'
p34632
aS'Adult'
p34633
aS'Aged'
p34634
aS'Cervical Intraepithelial Neoplasia/*diagnosis/epidemiology/therapy'
p34635
aS'Female'
p34636
aS'Humans'
p34637
aS'Kenya/epidemiology'
p34638
aS'Mass Screening/*statistics & numerical data'
p34639
aS'Middle Aged'
p34640
aS'Retrospective Studies'
p34641
aS'Uterine Cervical Dysplasia/*diagnosis/epidemiology/therapy'
p34642
aS'Uterine Cervical Neoplasms/*diagnosis/epidemiology/therapy'
p34643
aS'Young Adult'
p34644
asS'EDAT'
p34645
S'2013/10/22 06:00'
p34646
sS'SO'
p34647
S'Int J Gynaecol Obstet. 2014 Jan;124(1):12-8. doi: 10.1016/j.ijgo.2013.06.035. Epub 2013 Sep 25.'
p34648
sS'SB'
p34649
S'IM'
p34650
sS'PMID'
p34651
S'24140218'
p34652
sS'OT'
p34653
(lp34654
S'Cervical cancer screening'
p34655
aS'Loss to follow-up'
p34656
aS'Sub-Saharan Africa'
p34657
aS'Visual inspection with acetic acid'
p34658
asS'PST'
p34659
S'ppublish'
p34660
stRp34661
ag2
(g3
g4
(dp34662
S'LID'
p34663
S'10.1177/0956462413506892 [doi]'
p34664
sS'STAT'
p34665
S'MEDLINE'
p34666
sS'DEP'
p34667
S'20131008'
p34668
sS'MID'
p34669
(lp34670
S'NIHMS538329'
p34671
asS'DA'
p34672
S'20140326'
p34673
sS'AID'
p34674
(lp34675
S'0956462413506892 [pii]'
p34676
aS'10.1177/0956462413506892 [doi]'
p34677
asS'CRDT'
p34678
(lp34679
S'2013/10/10 06:00'
p34680
asS'DP'
p34681
S'2014 Apr'
p34682
sS'AD'
p34683
S'Bridge HIV, Department of Public Health, San Francisco, CA, USA.'
p34684
sS'OWN'
p34685
S'NLM'
p34686
sS'PT'
p34687
(lp34688
S'Comparative Study'
p34689
aS'Journal Article'
p34690
asS'LA'
p34691
(lp34692
S'eng'
p34693
asS'FAU'
p34694
(lp34695
S'Volk, Jonathan E'
p34696
aS'Hessol, Nancy A'
p34697
aS'Gray, Glenda E'
p34698
aS'Kublin, James G'
p34699
aS'Churchyard, Gavin J'
p34700
aS'Mlisana, Koleka'
p34701
aS'Nchabeleng, Maphoshane'
p34702
aS'Buchbinder, Susan P'
p34703
aS'Bekker, Linda-Gail'
p34704
asS'JT'
p34705
S'International journal of STD & AIDS'
p34706
sS'LR'
p34707
S'20160701'
p34708
sS'PG'
p34709
S'332-40'
p34710
sS'TI'
p34711
S'The HVTN503/Phambili HIV vaccine trial: a comparison of younger and older participants.'
p34712
sS'RN'
p34713
(lp34714
S'0 (AIDS Vaccines)'
p34715
asS'PL'
p34716
S'England'
p34717
sS'TA'
p34718
S'Int J STD AIDS'
p34719
sS'JID'
p34720
S'9007917'
p34721
sS'AB'
p34722
S'By comparing younger to older participants enrolled in a HIV vaccine efficacy trial, we aimed to gain insights into the inclusion of adolescents in future trials. This was a sub-analysis of a multisite HIV vaccine randomized clinical trial in South Africa, conducted January-September 2007. Motivations for trial enrolment, social harms, adverse events and loss to follow-up were compared between younger (18-20 years old) and older participants (21-35 years old). Both younger (n = 238) and older participants (n = 563) were equally likely to report enrolling for altruistic reasons. Younger females were less likely than older participants to join for trial reimbursement (p = 0.005), while younger males were more likely to enrol because the vaccine may provide protection from HIV-acquisition (p < 0.001). There were no significant differences in the number of social harms reported. Compared to males over 20 years old, 18-20-year-old females were less likely to experience adverse events (OR = 0.1, CI 0.01-0.80) and no more likely to be lost to follow-up (OR = 0.7, CI 0.39-1.25), while 18-20-year-old males were no more likely to experience adverse events (OR = 1.3, CI 0.58-2.83) or loss to follow-up (OR = 0.8, CI 0.51-1.41). Our data support the inclusion of younger participants who are at risk for HIV in future HIV vaccine efficacy trials.'
p34723
sS'GR'
p34724
(lp34725
S'P30 AI027763/AI/NIAID NIH HHS/United States'
p34726
aS'U01 AI068614/AI/NIAID NIH HHS/United States'
p34727
aS'U01 AI068618/AI/NIAID NIH HHS/United States'
p34728
aS'U01 AI068635/AI/NIAID NIH HHS/United States'
p34729
aS'U01 AI069453/AI/NIAID NIH HHS/United States'
p34730
aS'U01 AI069469/AI/NIAID NIH HHS/United States'
p34731
aS'U01 AI069519/AI/NIAID NIH HHS/United States'
p34732
aS'UM1 AI068614/AI/NIAID NIH HHS/United States'
p34733
asS'IP'
p34734
S'5'
sS'IS'
p34735
S'1758-1052 (Electronic) 0956-4624 (Linking)'
p34736
sS'PMC'
p34737
S'PMC3968181'
p34738
sS'DCOM'
p34739
S'20140512'
p34740
sS'AU'
p34741
(lp34742
S'Volk JE'
p34743
aS'Hessol NA'
p34744
aS'Gray GE'
p34745
aS'Kublin JG'
p34746
aS'Churchyard GJ'
p34747
aS'Mlisana K'
p34748
aS'Nchabeleng M'
p34749
aS'Buchbinder SP'
p34750
aS'Bekker LG'
p34751
asS'VI'
p34752
S'25'
p34753
sS'MHDA'
p34754
S'2014/05/13 06:00'
p34755
sS'PHST'
p34756
(lp34757
S'2013/10/08 [aheadofprint]'
p34758
asS'OTO'
p34759
(lp34760
S'NOTNLM'
p34761
asS'OID'
p34762
(lp34763
S'NLM: NIHMS538329'
p34764
aS'NLM: PMC3968181'
p34765
asS'MH'
p34766
(lp34767
S'AIDS Vaccines/*administration & dosage/immunology'
p34768
aS'Adolescent'
p34769
aS'Adult'
p34770
aS'Age Distribution'
p34771
aS'*Clinical Trials as Topic'
p34772
aS'Female'
p34773
aS'HIV Infections/*prevention & control'
p34774
aS'Humans'
p34775
aS'Male'
p34776
aS'Motivation'
p34777
aS'Patient Participation/*statistics & numerical data'
p34778
aS'Patient Selection'
p34779
aS'South Africa'
p34780
aS'Young Adult'
p34781
asS'EDAT'
p34782
S'2013/10/10 06:00'
p34783
sS'SO'
p34784
S'Int J STD AIDS. 2014 Apr;25(5):332-40. doi: 10.1177/0956462413506892. Epub 2013 Oct 8.'
p34785
sS'SB'
p34786
S'IM X'
p34787
sS'PMID'
p34788
S'24104693'
p34789
sS'OT'
p34790
(lp34791
S'AIDS'
p34792
aS'HIV'
p34793
aS'South Africa'
p34794
aS'clinical trials'
p34795
aS'prevention'
p34796
aS'vaccination'
p34797
aS'vaccine trials'
p34798
aS'youth'
p34799
asS'PST'
p34800
S'ppublish'
p34801
stRp34802
ag2
(g3
g4
(dp34803
S'LID'
p34804
S'10.1080/09540121.2013.841829 [doi]'
p34805
sS'STAT'
p34806
S'MEDLINE'
p34807
sS'DEP'
p34808
S'20131004'
p34809
sS'DA'
p34810
S'20140110'
p34811
sS'AID'
p34812
(lp34813
S'10.1080/09540121.2013.841829 [doi]'
p34814
asS'CRDT'
p34815
(lp34816
S'2013/10/05 06:00'
p34817
asS'DP'
p34818
S'2014 Apr'
p34819
sS'AD'
p34820
S'a Department of Medicine , NYU School of Medicine , New York , NY , USA.'
p34821
sS'OWN'
p34822
S'NLM'
p34823
sS'PT'
p34824
(lp34825
S'Journal Article'
p34826
aS'Research Support, N.I.H., Extramural'
p34827
aS"Research Support, Non-U.S. Gov't"
p34828
aS"Research Support, U.S. Gov't, P.H.S."
p34829
asS'LA'
p34830
(lp34831
S'eng'
p34832
asS'FAU'
p34833
(lp34834
S'Sivapalasingam, Sumathi'
p34835
aS'Mendillo, Megan'
p34836
aS'Ahmed, Aabid'
p34837
aS'Mwamzuka, Musa'
p34838
aS'Said, Swale'
p34839
aS'Marshed, Fatma'
p34840
aS'Luhar Abdulaziz, Farhad'
p34841
aS'Fajans, Mark'
p34842
aS'Holzman, Robert'
p34843
asS'JT'
p34844
S'AIDS care'
p34845
sS'PG'
p34846
S'425-33'
p34847
sS'TI'
p34848
S'The importance of caregivers in the outcome of pediatric HIV management, Mombasa, Kenya.'
p34849
sS'RN'
p34850
(lp34851
S'0 (Anti-HIV Agents)'
p34852
asS'PL'
p34853
S'England'
p34854
sS'TA'
p34855
S'AIDS Care'
p34856
sS'JID'
p34857
S'8915313'
p34858
sS'AB'
p34859
S'We assessed programmatic gaps that prevent the optimal treatment of pediatric HIV infection despite free antiretroviral care in Kenya. Of 626 HIV-infected Kenyan children, the median age was five years, 54% were male and the mortality rate was 3.2 per 100 person-years. A total of 380 (61%) children initiated antiretroviral therapy (ART) during the study period. Among the 246 children who never started ART, 129 (52%) met the criteria for ART initiation. Immunologic failure occurred in 20% of children who received ART for >24 weeks. In multivariate analysis, immunological failure was associated with having nonimmediate relative or unrelated caregivers accompanying the child to clinic (AOR = 69.16, p = 0.008). Having >/= 3 types of accompanying caregivers was also associated with virologic failure in multivariate analysis (AOR = 3.84, p = 0.03). The lost to follow-up rate was 8.7/100 persons-years for the entire cohort, and significantly higher (17.7/100 persons-years) among children not on ART (p < 0.001). Among children who do initiate ART, those with the best treatment outcomes were those who had a limited number of close relatives as caregivers and good adherence to ART. Focus on early ART initiation and education of the right caregiver will likely improve retention and quality of pediatric HIV care in Kenya.'
p34860
sS'GR'
p34861
(lp34862
S'5U62PS224509-04/PS/NCHHSTP CDC HHS/United States'
p34863
aS'P30 AI027742/AI/NIAID NIH HHS/United States'
p34864
asS'IP'
p34865
S'4'
sS'IS'
p34866
S'1360-0451 (Electronic) 0954-0121 (Linking)'
p34867
sS'DCOM'
p34868
S'20140407'
p34869
sS'AU'
p34870
(lp34871
S'Sivapalasingam S'
p34872
aS'Mendillo M'
p34873
aS'Ahmed A'
p34874
aS'Mwamzuka M'
p34875
aS'Said S'
p34876
aS'Marshed F'
p34877
aS'Luhar Abdulaziz F'
p34878
aS'Fajans M'
p34879
aS'Holzman R'
p34880
asS'VI'
p34881
S'26'
p34882
sS'MHDA'
p34883
S'2014/04/08 06:00'
p34884
sS'PHST'
p34885
(lp34886
S'2013/10/04 [aheadofprint]'
p34887
asS'MH'
p34888
(lp34889
S'Adolescent'
p34890
aS'Anti-HIV Agents/administration & dosage/*therapeutic use'
p34891
aS'*Antiretroviral Therapy, Highly Active'
p34892
aS'CD4 Lymphocyte Count'
p34893
aS'Caregivers/*psychology'
p34894
aS'Child'
p34895
aS'Child, Preschool'
p34896
aS'Disease Progression'
p34897
aS'Female'
p34898
aS'HIV Infections/*drug therapy/immunology/virology'
p34899
aS'HIV-1/drug effects'
p34900
aS'Humans'
p34901
aS'Infant'
p34902
aS'Infant, Newborn'
p34903
aS'Kenya'
p34904
aS'Logistic Models'
p34905
aS'Male'
p34906
aS'Multivariate Analysis'
p34907
aS'*Patient Compliance'
p34908
aS'Retrospective Studies'
p34909
aS'Treatment Outcome'
p34910
aS'Viral Load'
p34911
asS'EDAT'
p34912
S'2013/10/05 06:00'
p34913
sS'SO'
p34914
S'AIDS Care. 2014 Apr;26(4):425-33. doi: 10.1080/09540121.2013.841829. Epub 2013 Oct 4.'
p34915
sS'SB'
p34916
S'IM X'
p34917
sS'PMID'
p34918
S'24090313'
p34919
sS'PST'
p34920
S'ppublish'
p34921
stRp34922
ag2
(g3
g4
(dp34923
S'LID'
p34924
S'10.1186/1471-2458-13-910 [doi]'
p34925
sS'STAT'
p34926
S'MEDLINE'
p34927
sS'DEP'
p34928
S'20131002'
p34929
sS'DA'
p34930
S'20131115'
p34931
sS'AID'
p34932
(lp34933
S'1471-2458-13-910 [pii]'
p34934
aS'10.1186/1471-2458-13-910 [doi]'
p34935
asS'CRDT'
p34936
(lp34937
S'2013/10/04 06:00'
p34938
asS'DP'
p34939
S'2013'
p34940
sS'OWN'
p34941
S'NLM'
p34942
sS'PT'
p34943
(lp34944
S'Journal Article'
p34945
aS"Research Support, Non-U.S. Gov't"
p34946
asS'LA'
p34947
(lp34948
S'eng'
p34949
asS'DCOM'
p34950
S'20150709'
p34951
sS'JT'
p34952
S'BMC public health'
p34953
sS'FAU'
p34954
(lp34955
S'Chiduo, Mercy G'
p34956
aS'Mmbando, Bruno P'
p34957
aS'Theilgaard, Zahra P'
p34958
aS'Bygbjerg, Ib C'
p34959
aS'Gerstoft, Jan'
p34960
aS'Lemnge, Martha'
p34961
aS'Katzenstein, Terese L'
p34962
asS'TI'
p34963
S'Early infant diagnosis of HIV in three regions in Tanzania; successes and challenges.'
p34964
sS'PL'
p34965
S'England'
p34966
sS'PG'
p34967
S'910'
p34968
sS'JID'
p34969
S'100968562'
p34970
sS'AB'
p34971
S'BACKGROUND: By the end of 2009 an estimated 2.5 million children worldwide were living with HIV-1, mostly as a consequence of vertical transmission, and more than 90% of these children live in sub-Saharan Africa. In 2008 the World Health Organization (WHO), recommended early initiation of Highly Active Antiretroviral Therapy (HAART) to all HIV infected infants diagnosed within the first year of life, and since 2010, within the first two years of life, irrespective of CD4 count or WHO clinical stage. The study aims were to describe implementation of EID programs in three Tanzanian regions with differences in HIV prevalences and logistical set-up with regard to HIV DNA testing. METHODS: Data were obtained by review of the prevention from mother to child transmission of HIV (PMTCT) registers from 2009-2011 at the Reproductive and Child Health Clinics (RCH) and from the databases from the Care and Treatment Clinics (CTC) in all the three regions; Kilimanjaro, Mbeya and Tanga. Statistical tests used were Poisson regression model and rank sum test. RESULTS: During the period of 2009 - 2011 a total of 4,860 exposed infants were registered from the reviewed sites, of whom 4,292 (88.3%) were screened for HIV infection. Overall proportion of tested infants in the three regions increased from 77.2% in 2009 to 97.8% in 2011. A total of 452 (10.5%) were found to be HIV infected (judged by the result of the first test). The prevalence of HIV infection among infants was higher in Mbeya when compared to Kilimanjaro region RR = 1.872 (95%CI = 1.408 - 2.543) p < 0.001. However sample turnaround time was significantly shorter in both Mbeya (2.7 weeks) and Tanga (5.0 weeks) as compared to Kilimanjaro (7.0 weeks), p=<0.001. A substantial of loss to follow-up (LTFU) was evident at all stages of EID services in the period of 2009 to 2011. Among the infants who were receiving treatment, 61% were found to be LFTU during the review period. CONCLUSION: The study showed an increase in testing of HIV exposed infants within the three years, there is large variations of HIV prevalence among the regions. Challenges like; sample turnaround time and LTFU must be overcome before this can translate into the intended goal of early initiation of lifelong lifesaving antiretroviral therapy for the infants.'
p34972
sS'AD'
p34973
S'National Institute for Medical Research Tanga Centre, Bombo Road, Box 5004, Tanga, Tanzania. mercy_chiduo@yahoo.com.'
p34974
sS'VI'
p34975
S'13'
p34976
sS'IS'
p34977
S'1471-2458 (Electronic) 1471-2458 (Linking)'
p34978
sS'PMC'
p34979
S'PMC3852479'
p34980
sS'AU'
p34981
(lp34982
S'Chiduo MG'
p34983
aS'Mmbando BP'
p34984
aS'Theilgaard ZP'
p34985
aS'Bygbjerg IC'
p34986
aS'Gerstoft J'
p34987
aS'Lemnge M'
p34988
aS'Katzenstein TL'
p34989
asS'MHDA'
p34990
S'2015/07/15 06:00'
p34991
sS'PHST'
p34992
(lp34993
S'2012/11/30 [received]'
p34994
aS'2013/09/25 [accepted]'
p34995
aS'2013/10/02 [aheadofprint]'
p34996
asS'OID'
p34997
(lp34998
S'NLM: PMC3852479'
p34999
asS'MH'
p35000
(lp35001
S'Antiretroviral Therapy, Highly Active'
p35002
aS'CD4 Lymphocyte Count'
p35003
aS'Early Diagnosis'
p35004
aS'Female'
p35005
aS'HIV Infections/*diagnosis/drug therapy/epidemiology'
p35006
aS'*HIV-1'
p35007
aS'Humans'
p35008
aS'Infant'
p35009
aS'*Infectious Disease Transmission, Vertical'
p35010
aS'Lost to Follow-Up'
p35011
aS'Male'
p35012
aS'*Mass Screening'
p35013
aS'Prevalence'
p35014
aS'*Program Evaluation'
p35015
aS'Tanzania/epidemiology'
p35016
asS'EDAT'
p35017
S'2013/10/04 06:00'
p35018
sS'SO'
p35019
S'BMC Public Health. 2013 Oct 2;13:910. doi: 10.1186/1471-2458-13-910.'
p35020
sS'SB'
p35021
S'IM'
p35022
sS'PMID'
p35023
S'24088196'
p35024
sS'TA'
p35025
S'BMC Public Health'
p35026
sS'PST'
p35027
S'epublish'
p35028
stRp35029
ag2
(g3
g4
(dp35030
S'LID'
p35031
S'10.1371/journal.pone.0075761 [doi]'
p35032
sS'STAT'
p35033
S'MEDLINE'
p35034
sS'DEP'
p35035
S'20130926'
p35036
sS'DA'
p35037
S'20131002'
p35038
sS'AID'
p35039
(lp35040
S'10.1371/journal.pone.0075761 [doi]'
p35041
aS'PONE-D-13-13201 [pii]'
p35042
asS'CRDT'
p35043
(lp35044
S'2013/10/03 06:00'
p35045
asS'DP'
p35046
S'2013'
p35047
sS'OWN'
p35048
S'NLM'
p35049
sS'PT'
p35050
(lp35051
S'Journal Article'
p35052
aS'Research Support, N.I.H., Extramural'
p35053
aS"Research Support, Non-U.S. Gov't"
p35054
asS'LA'
p35055
(lp35056
S'eng'
p35057
asS'FAU'
p35058
(lp35059
S'Tweya, Hannock'
p35060
aS'Feldacker, Caryl'
p35061
aS'Estill, Janne'
p35062
aS'Jahn, Andreas'
p35063
aS"Ng'ambi, Wingston"
p35064
aS'Ben-Smith, Anne'
p35065
aS'Keiser, Olivia'
p35066
aS'Bokosi, Mphatso'
p35067
aS'Egger, Matthias'
p35068
aS'Speight, Colin'
p35069
aS'Gumulira, Joe'
p35070
aS'Phiri, Sam'
p35071
asS'JT'
p35072
S'PloS one'
p35073
sS'LR'
p35074
S'20150422'
p35075
sS'PG'
p35076
S'e75761'
p35077
sS'TI'
p35078
S'Are they really lost? "true" status and reasons for treatment discontinuation among HIV infected patients on antiretroviral therapy considered lost to follow up in Urban Malawi.'
p35079
sS'RN'
p35080
(lp35081
S'0 (Anti-HIV Agents)'
p35082
aS'0 (Anti-Retroviral Agents)'
p35083
asS'PL'
p35084
S'United States'
p35085
sS'TA'
p35086
S'PLoS One'
p35087
sS'JID'
p35088
S'101285081'
p35089
sS'AB'
p35090
S'INTRODUCTION: Patients who are lost to follow-up (LTFU) while on antiretroviral therapy (ART) pose challenges to the long-term success of ART programs. We describe the extent to which patients considered LTFU are misclassified as true disengagement from care when they are still alive on ART and explain reasons for ART discontinuation using our active tracing program to further improve ART retention programs and policies. METHODS: We identified adult ART patients who missed clinic appointment by more than 3 weeks between January 2006 and December 2010, assuming that such patients would miss their doses of antiretroviral drugs. Patients considered LTFU who consented during ART registration were traced by phone or home visits; true ART status after tracing was documented. Reasons for ART discontinuation were also recorded for those who stopped ART. RESULTS: Of the 4,560 suspected LTFU cases, 1,384 (30%) could not be traced. Of the 3,176 successfully traced patients, 952 (30%) were dead and 2,224 (70%) were alive, of which 2,183 (99.5%) started ART according to phone-based self-reports or physical verification during in-person interviews. Of those who started ART, 957 (44%) stopped ART and 1,226 (56%) reported still taking ART at the time of interview by sourcing drugs from another clinic, using alternative ART sources or making brief ART interruptions. Among 940 cases with reasons for ART discontinuations, failure to remember (17%), too weak/sick (12%), travel (46%), and lack of transport to the clinic (16%) were frequently cited; reasons differed by gender. CONCLUSION: The LTFU category comprises sizeable proportions of patients still taking ART that may potentially bias retention estimates and misdirect resources at the clinic and national levels if not properly accounted for. Clinics should consider further decentralization efforts, increasing drug allocations for frequent travels, and improving communication on patient transfers between clinics to increase retention and adherence.'
p35091
sS'AD'
p35092
S'The International Union Against Tuberculosis and Lung Disease, Paris, France ; Lighthouse Trust, Lilongwe, Malawi ; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.'
p35093
sS'IP'
p35094
S'9'
sS'IS'
p35095
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p35096
sS'PMC'
p35097
S'PMC3784425'
p35098
sS'DCOM'
p35099
S'20140714'
p35100
sS'AU'
p35101
(lp35102
S'Tweya H'
p35103
aS'Feldacker C'
p35104
aS'Estill J'
p35105
aS'Jahn A'
p35106
aS"Ng'ambi W"
p35107
aS'Ben-Smith A'
p35108
aS'Keiser O'
p35109
aS'Bokosi M'
p35110
aS'Egger M'
p35111
aS'Speight C'
p35112
aS'Gumulira J'
p35113
aS'Phiri S'
p35114
asS'VI'
p35115
S'8'
sS'MHDA'
p35116
S'2014/07/16 06:00'
p35117
sS'PHST'
p35118
(lp35119
S'2013 [ecollection]'
p35120
aS'2013/03/30 [received]'
p35121
aS'2013/08/19 [accepted]'
p35122
aS'2013/09/26 [epublish]'
p35123
asS'OID'
p35124
(lp35125
S'NLM: PMC3784425'
p35126
asS'MH'
p35127
(lp35128
S'Adolescent'
p35129
aS'Adult'
p35130
aS'Anti-HIV Agents/*therapeutic use'
p35131
aS'Anti-Retroviral Agents/*therapeutic use'
p35132
aS'Antiretroviral Therapy, Highly Active/methods'
p35133
aS'Female'
p35134
aS'HIV Infections/*drug therapy'
p35135
aS'Humans'
p35136
aS'Lost to Follow-Up'
p35137
aS'Malawi'
p35138
aS'Male'
p35139
aS'Middle Aged'
p35140
aS'Retrospective Studies'
p35141
aS'Young Adult'
p35142
asS'EDAT'
p35143
S'2013/10/03 06:00'
p35144
sS'SO'
p35145
S'PLoS One. 2013 Sep 26;8(9):e75761. doi: 10.1371/journal.pone.0075761. eCollection 2013.'
p35146
sS'SB'
p35147
S'IM'
p35148
sS'PMID'
p35149
S'24086627'
p35150
sS'PST'
p35151
S'epublish'
p35152
stRp35153
ag2
(g3
g4
(dp35154
S'LID'
p35155
S'10.1093/jac/dkt372 [doi]'
p35156
sS'STAT'
p35157
S'MEDLINE'
p35158
sS'DEP'
p35159
S'20130929'
p35160
sS'DA'
p35161
S'20140110'
p35162
sS'AID'
p35163
(lp35164
S'dkt372 [pii]'
p35165
aS'10.1093/jac/dkt372 [doi]'
p35166
asS'CRDT'
p35167
(lp35168
S'2013/10/02 06:00'
p35169
asS'DP'
p35170
S'2014 Feb'
p35171
sS'AD'
p35172
S'Department of Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana.'
p35173
sS'OWN'
p35174
S'NLM'
p35175
sS'PT'
p35176
(lp35177
S'Journal Article'
p35178
aS"Research Support, Non-U.S. Gov't"
p35179
asS'LA'
p35180
(lp35181
S'eng'
p35182
asS'FAU'
p35183
(lp35184
S'Sarfo, Fred S'
p35185
aS'Zhang, Yuan'
p35186
aS'Egan, Deirdre'
p35187
aS'Tetteh, Lambert A'
p35188
aS'Phillips, Richard'
p35189
aS'Bedu-Addo, George'
p35190
aS'Sarfo, Maame Anima'
p35191
aS'Khoo, Saye'
p35192
aS'Owen, Andrew'
p35193
aS'Chadwick, David R'
p35194
asS'JT'
p35195
S'The Journal of antimicrobial chemotherapy'
p35196
sS'LR'
p35197
S'20141125'
p35198
sS'PG'
p35199
S'491-9'
p35200
sS'TI'
p35201
S'Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients.'
p35202
sS'RN'
p35203
(lp35204
S'0 (Anti-HIV Agents)'
p35205
aS'0 (Benzoxazines)'
p35206
aS'0 (CYP2A6 protein, human)'
p35207
aS'EC 1.14.13.- (Cytochrome P-450 CYP2A6)'
p35208
aS'EC 1.14.14.1 (Aryl Hydrocarbon Hydroxylases)'
p35209
aS'EC 1.14.14.1 (CYP2B6 protein, human)'
p35210
aS'EC 1.14.14.1 (Cytochrome P-450 CYP2B6)'
p35211
aS'EC 2.4.1.- (UGT2B7 protein, human)'
p35212
aS'EC 2.4.1.17 (Glucuronosyltransferase)'
p35213
aS'JE6H2O27P8 (efavirenz)'
p35214
asS'PL'
p35215
S'England'
p35216
sS'TA'
p35217
S'J Antimicrob Chemother'
p35218
sS'JID'
p35219
S'7513617'
p35220
sS'AB'
p35221
S'OBJECTIVES: Efavirenz is widely used in first-line antiretroviral therapy in sub-Saharan Africa. However, exposure to efavirenz shows marked interindividual variability that is genetically mediated with potential for important pharmacodynamic consequences. The aims of this study were to assess the frequencies of CYP2B6, CYP2A6, UGT2B7 and CAR single nucleotide polymorphisms (SNPs) and their impact on plasma efavirenz concentration and clinical/immunological responses in Ghanaian patients. METHODS: Genomic DNA from 800 HIV-infected patients was genotyped for selected SNPs by real-time PCR-based allelic discrimination. Mid-dose plasma efavirenz concentrations were measured for 521 patients using HPLC with UV detection. Clinical outcomes in 299 patients on efavirenz were retrospectively assessed. Univariate and multivariate linear regression were performed using best subset selection. Time-to-event outcomes were analysed using a Cox proportional hazards regression model. RESULTS: The variant allele frequencies for CYP2B6 516G>T (rs3745274), CYP2B6 983T>C (rs28399499), CYP2A6 -48T>G (CYP2B6*9B; rs28399433), UGT2B7 802C>T (UGT2B7*2; rs7439366), UGT2B7 735A>G (UGT2B7*1c; rs28365062) and CAR 540C>T (rs2307424) were 48%, 4%, 3%, 23%, 15% and 7%, respectively. CYP2B6 516G>T, CYP2B6 983T>C and CYP2A6 -48T>G were associated with significantly elevated efavirenz concentrations. A trend towards association between plasma efavirenz concentration and CAR 540C>T was observed. CYP2B6 516G homozygosity was associated with immunological failure [adjusted hazards ratio compared with T homozygosity, 1.70 (1.04-2.76); P = 0.03]. CONCLUSIONS: CYP2B6 and CYP2A6 SNPs were associated with higher plasma efavirenz concentrations due to reduction in major and minor phase I routes of elimination, respectively. Further prospective studies are needed to validate the pharmacodynamic correlates of these polymorphisms in this population.'
p35222
sS'GR'
p35223
(lp35224
S'G0800247/Medical Research Council/United Kingdom'
p35225
aS'G0901364/Medical Research Council/United Kingdom'
p35226
aS'MR/J01477X/1/Medical Research Council/United Kingdom'
p35227
asS'IP'
p35228
S'2'
sS'IS'
p35229
S'1460-2091 (Electronic) 0305-7453 (Linking)'
p35230
sS'DCOM'
p35231
S'20140908'
p35232
sS'AU'
p35233
(lp35234
S'Sarfo FS'
p35235
aS'Zhang Y'
p35236
aS'Egan D'
p35237
aS'Tetteh LA'
p35238
aS'Phillips R'
p35239
aS'Bedu-Addo G'
p35240
aS'Sarfo MA'
p35241
aS'Khoo S'
p35242
aS'Owen A'
p35243
aS'Chadwick DR'
p35244
asS'VI'
p35245
S'69'
p35246
sS'MHDA'
p35247
S'2014/09/10 06:00'
p35248
sS'PHST'
p35249
(lp35250
S'2013/09/29 [aheadofprint]'
p35251
asS'OTO'
p35252
(lp35253
S'NOTNLM'
p35254
asS'MH'
p35255
(lp35256
S'Adolescent'
p35257
aS'Adult'
p35258
aS'Aged'
p35259
aS'Anti-HIV Agents/*therapeutic use'
p35260
aS'Aryl Hydrocarbon Hydroxylases/genetics'
p35261
aS'Benzoxazines/*therapeutic use'
p35262
aS'Cohort Studies'
p35263
aS'Cytochrome P-450 CYP2A6'
p35264
aS'Cytochrome P-450 CYP2B6'
p35265
aS'Female'
p35266
aS'Ghana/epidemiology'
p35267
aS'Glucuronosyltransferase/genetics'
p35268
aS'HIV Infections/*drug therapy/epidemiology/*genetics'
p35269
aS'Humans'
p35270
aS'Male'
p35271
aS'Middle Aged'
p35272
aS'Polymorphism, Single Nucleotide/*genetics'
p35273
aS'Retrospective Studies'
p35274
aS'Young Adult'
p35275
asS'EDAT'
p35276
S'2013/10/02 06:00'
p35277
sS'SO'
p35278
S'J Antimicrob Chemother. 2014 Feb;69(2):491-9. doi: 10.1093/jac/dkt372. Epub 2013 Sep 29.'
p35279
sS'SB'
p35280
S'IM'
p35281
sS'PMID'
p35282
S'24080498'
p35283
sS'OT'
p35284
(lp35285
S'Africa'
p35286
aS'non-nucleoside reverse transcriptase inhibitors'
p35287
aS'pharmacodynamics'
p35288
aS'pharmacokinetics'
p35289
asS'PST'
p35290
S'ppublish'
p35291
stRp35292
ag2
(g3
g4
(dp35293
S'LID'
p35294
S'10.1177/2325957413501719 [doi]'
p35295
sS'STAT'
p35296
S'MEDLINE'
p35297
sS'DEP'
p35298
S'20130930'
p35299
sS'CI'
p35300
(lp35301
S'(c) The Author(s) 2013.'
p35302
asS'DA'
p35303
S'20141111'
p35304
sS'AID'
p35305
(lp35306
S'2325957413501719 [pii]'
p35307
aS'10.1177/2325957413501719 [doi]'
p35308
asS'CRDT'
p35309
(lp35310
S'2013/10/02 06:00'
p35311
asS'DP'
p35312
S'2014 Nov-Dec'
p35313
sS'OWN'
p35314
S'NLM'
p35315
sS'PT'
p35316
(lp35317
S'Journal Article'
p35318
asS'LA'
p35319
(lp35320
S'eng'
p35321
asS'FAU'
p35322
(lp35323
S'Nakiwogga-Muwanga, Alice'
p35324
aS'Alamo-Talisuna, Stella'
p35325
aS'Musaazi, Joseph'
p35326
aS'Kambugu, Andrew'
p35327
aS'Ssekawungu, P'
p35328
aS'Katabira, Elly'
p35329
aS'Colebunders, Robert'
p35330
asS'JT'
p35331
S'Journal of the International Association of Providers of AIDS Care'
p35332
sS'LR'
p35333
S'20160517'
p35334
sS'PG'
p35335
S'547-54'
p35336
sS'TI'
p35337
S'Inadequate monitoring in advanced stages of disease with lack of supportive counseling increases attrition among patients on antiretroviral treatment at a large urban clinic in Uganda.'
p35338
sS'RN'
p35339
(lp35340
S'0 (Anti-Retroviral Agents)'
p35341
asS'PL'
p35342
S'United States'
p35343
sS'TA'
p35344
S'J Int Assoc Provid AIDS Care'
p35345
sS'JID'
p35346
S'101603896'
p35347
sS'AB'
p35348
S'BACKGROUND: The purpose of this case-control study was to identify risk factors for loss to follow-up (LTFU). METHODS: Cases and controls were selected from HIV-positive patients, aged 18 years and older, on antiretroviral therapy (ART) at the Infectious Diseases Clinic (IDC) in January 2008. As cases, we selected 209 patients who in 2008 did not return to the clinic within 90 days of their scheduled appointment date. As controls, we randomly selected 626 patients from the 5872 patients who were following up at the end of December 2008. RESULTS: In multivariable logistic regression analysis, urban or semiurban residence, World Health Organization disease stage III or IV at ART initiation, a median CD4 count at last visit <200 cells/mm(3), tuberculosis (TB) in the 6 months before the last visit, absence of counseling before ART initiation, and no disclosure of HIV status were associated with LTFU. CONCLUSION: This study demonstrates the importance of close patient monitoring in advanced stages of disease, supportive counseling for patients initiating ART, extra psychosocial support for patients with TB and HIV coinfection, assisting patients with disclosure, and setting up a good referral system to retain patients on ART.'
p35349
sS'AD'
p35350
S'Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda nakiwoalice@gmail.com. Reach Out Mbuya Parish HIV/AIDS Initiative, Kampala, Uganda. Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda. Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda. Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda. Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda. Department of Epidemiology and Social Medicine, University of Antwerp, Antwerp, Belgium Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.'
p35351
sS'IP'
p35352
S'6'
sS'IS'
p35353
S'2325-9574 (Print) 2325-9574 (Linking)'
p35354
sS'DCOM'
p35355
S'20150108'
p35356
sS'AU'
p35357
(lp35358
S'Nakiwogga-Muwanga A'
p35359
aS'Alamo-Talisuna S'
p35360
aS'Musaazi J'
p35361
aS'Kambugu A'
p35362
aS'Ssekawungu P'
p35363
aS'Katabira E'
p35364
aS'Colebunders R'
p35365
asS'VI'
p35366
S'13'
p35367
sS'MHDA'
p35368
S'2015/01/09 06:00'
p35369
sS'PHST'
p35370
(lp35371
S'2013/09/30 [aheadofprint]'
p35372
asS'OTO'
p35373
(lp35374
S'NOTNLM'
p35375
asS'MH'
p35376
(lp35377
S'Adult'
p35378
aS'Ambulatory Care Facilities'
p35379
aS'Anti-Retroviral Agents/*therapeutic use'
p35380
aS'Case-Control Studies'
p35381
aS'*Directive Counseling'
p35382
aS'Female'
p35383
aS'HIV Infections/*diagnosis/psychology/*therapy'
p35384
aS'Humans'
p35385
aS'Lost to Follow-Up'
p35386
aS'Male'
p35387
aS'Patient Compliance'
p35388
aS'Risk Factors'
p35389
aS'*Social Support'
p35390
aS'Uganda'
p35391
aS'*Urban Health Services'
p35392
asS'EDAT'
p35393
S'2013/10/02 06:00'
p35394
sS'SO'
p35395
S'J Int Assoc Provid AIDS Care. 2014 Nov-Dec;13(6):547-54. doi: 10.1177/2325957413501719. Epub 2013 Sep 30.'
p35396
sS'SB'
p35397
S'IM'
p35398
sS'PMID'
p35399
S'24080478'
p35400
sS'OT'
p35401
(lp35402
S'HIV-positive patients'
p35403
aS'Uganda'
p35404
aS'advanced disease'
p35405
aS'counseling'
p35406
aS'inadequate monitoring'
p35407
aS'patient attrition'
p35408
asS'PST'
p35409
S'ppublish'
p35410
stRp35411
ag2
(g3
g4
(dp35412
S'LID'
p35413
S'10.7196/samj.6677 [doi]'
p35414
sS'STAT'
p35415
S'MEDLINE'
p35416
sS'DEP'
p35417
S'20130918'
p35418
sS'DA'
p35419
S'20131001'
p35420
sS'CRDT'
p35421
(lp35422
S'2013/10/02 06:00'
p35423
asS'DP'
p35424
S'2013 Oct'
p35425
sS'OWN'
p35426
S'NLM'
p35427
sS'PT'
p35428
(lp35429
S'Comparative Study'
p35430
aS'Journal Article'
p35431
aS'Multicenter Study'
p35432
asS'LA'
p35433
(lp35434
S'eng'
p35435
asS'FAU'
p35436
(lp35437
S'Cross, H M'
p35438
aS'Combrinck, M I'
p35439
aS'Joska, J A'
p35440
asS'JT'
p35441
S'South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde'
p35442
sS'LR'
p35443
S'20140912'
p35444
sS'PG'
p35445
S'758-62'
p35446
sS'TI'
p35447
S'HIV-associated neurocognitive disorders: antiretroviral regimen, central nervous system penetration effectiveness, and cognitive outcomes.'
p35448
sS'RN'
p35449
(lp35450
S'0 (Anti-Retroviral Agents)'
p35451
asS'PL'
p35452
S'South Africa'
p35453
sS'TA'
p35454
S'S Afr Med J'
p35455
sS'JID'
p35456
S'0404520'
p35457
sS'AB'
p35458
S"BACKGROUND: The human immunodeficiency virus (HIV) can give rise to a spectrum of neuropsychological impairments known collectively as HIV-associated neurocognitive disorders (HAND). Although antiretroviral therapy (ART) has reduced the incidence of HIV dementia, the prevalence of milder forms of HAND has increased. It has been postulated that incomplete central nervous system (CNS) viral suppression or potential drug toxicity, both of which could be related to the CNS penetration effectiveness (CPE) of ART regimens, may contribute to this phenomenon. OBJECTIVE: This study compared cognitive outcomes in clade C-infected HIV patients in South Africa treated for 1 year with ART regimens with differing CPE scores. METHODS: We assessed 111 HIV-positive patients with varying levels of cognitive function at baseline (pre-ART) and then a year later. A neuropsychological battery was administered at both visits to derive global deficit scores. ART regimen data were collected at the follow-up visit. Some participants remained ART-naive during this period, thus providing a non-treatment control group. RESULTS: Significantly more ART recipients maintained or improved cognitive function compared with patients not on ART (p=0.017). There was no significant difference in cognitive outcomes between higher and lower CPE regimen groups (p=0.473). CONCLUSIONS: ART preserves or improves cognition in HIV-infected patients after 1 year, irrespective of the regimen's CPE. South Africa's current low CPE-scored first-line regimen performed as well as higher CPE-scored regimens. These findings are reassuring for South Africa, but larger, longer-term studies would be more definitive."
p35459
sS'AD'
p35460
S'Division of Neurology, Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa. helenmargot@gmail.com.'
p35461
sS'IP'
p35462
S'10'
p35463
sS'IS'
p35464
S'0256-9574 (Print)'
p35465
sS'DCOM'
p35466
S'20131219'
p35467
sS'AU'
p35468
(lp35469
S'Cross HM'
p35470
aS'Combrinck MI'
p35471
aS'Joska JA'
p35472
asS'VI'
p35473
S'103'
p35474
sS'MHDA'
p35475
S'2013/12/20 06:00'
p35476
sS'PHST'
p35477
(lp35478
S'2013/01/08 [received]'
p35479
aS'2013/03/14 [accepted]'
p35480
asS'MH'
p35481
(lp35482
S'Anti-Retroviral Agents/adverse effects/*pharmacokinetics'
p35483
aS'Central Nervous System/drug effects/*metabolism'
p35484
aS'Cognition/*drug effects/physiology'
p35485
aS'Cognition Disorders/epidemiology/*etiology/physiopathology'
p35486
aS'Follow-Up Studies'
p35487
aS'HIV Infections/*complications/drug therapy/metabolism'
p35488
aS'Humans'
p35489
aS'Incidence'
p35490
aS'Retrospective Studies'
p35491
aS'South Africa/epidemiology'
p35492
asS'EDAT'
p35493
S'2013/10/02 06:00'
p35494
sS'SO'
p35495
S'S Afr Med J. 2013 Sep 18;103(10):758-62. doi: 10.7196/samj.6677.'
p35496
sS'SB'
p35497
S'IM'
p35498
sS'PMID'
p35499
S'24079630'
p35500
sS'PST'
p35501
S'epublish'
p35502
stRp35503
ag2
(g3
g4
(dp35504
S'LID'
p35505
S'10.1097/QAD.0000000000000054 [doi]'
p35506
sS'STAT'
p35507
S'MEDLINE'
p35508
sS'JT'
p35509
S'AIDS (London, England)'
p35510
sS'MID'
p35511
(lp35512
S'HHSPA707278'
p35513
asS'DA'
p35514
S'20140128'
p35515
sS'AID'
p35516
(lp35517
S'10.1097/QAD.0000000000000054 [doi]'
p35518
asS'CRDT'
p35519
(lp35520
S'2013/10/01 06:00'
p35521
asS'DP'
p35522
S'2014 Feb 20'
p35523
sS'AD'
p35524
S'aICAP-Columbia University bDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, USA cRwanda Biomedical Center, Kigali, Rwanda.'
p35525
sS'OWN'
p35526
S'NLM'
p35527
sS'PT'
p35528
(lp35529
S'Journal Article'
p35530
aS"Research Support, U.S. Gov't, P.H.S."
p35531
asS'LA'
p35532
(lp35533
S'eng'
p35534
asS'FAU'
p35535
(lp35536
S'Lamb, Matthew R'
p35537
aS'Fayorsey, Ruby'
p35538
aS'Nuwagaba-Biribonwoha, Harriet'
p35539
aS'Viola, Violante'
p35540
aS'Mutabazi, Vincent'
p35541
aS'Alwar, Teresa'
p35542
aS'Casalini, Caterina'
p35543
aS'Elul, Batya'
p35544
asS'LR'
p35545
S'20160229'
p35546
sS'PG'
p35547
S'559-68'
p35548
sS'TI'
p35549
S'High attrition before and after ART initiation among youth (15-24 years of age) enrolled in HIV care.'
p35550
sS'RN'
p35551
(lp35552
S'0 (Anti-Retroviral Agents)'
p35553
asS'PL'
p35554
S'England'
p35555
sS'TA'
p35556
S'AIDS'
p35557
sS'JID'
p35558
S'8710219'
p35559
sS'AB'
p35560
S'OBJECTIVES: To compare pre and post-ART attrition between youth (15-24 years) and other patients in HIV care, and to investigate factors associated with attrition among youth. DESIGN: Cohort study utilizing routinely collected patient-level data from 160 HIV clinics in Kenya, Mozambique, Tanzania, and Rwanda. METHODS: Patients at least 10 years of age enrolling in HIV care between 01/05 and 09/10 were included. Attrition (loss to follow-up or death 1 year after enrollment or ART initiation) was compared between youth and other patients using multivariate competing risk (pre-ART) and traditional (post-ART) Cox proportional hazards methods accounting for within-clinic correlation. Among youth, patient-level and clinic-level factors associated with attrition were similarly assessed. RESULTS: A total of 312,335 patients at least 10 years of age enrolled in HIV care; 147,936 (47%) initiated ART, 17% enrolling in care and 10% initiating ART were youth. Attrition before and after ART initiation was substantially higher among youth compared with other age groups. Among youth, nonpregnant women experienced lower pre-ART attrition than men [sub-division hazard ratio = 0.90, 95% confidence interval (CI): 0.86-0.94], while both pregnant [adjusted hazard ratio (AHR) = 0.85, 95% CI: 0.74-0.97] and nonpregnant (AHR = 0.79, 95% CI: 0.73-0.86) female youth experienced lower post-ART attrition than men. Youth attending clinics providing sexual and reproductive health services including condoms (AHR = 0.47, 95% CI: 0.32-0.70) and clinics offering adolescent support groups (AHR = 0.73, 95% CI: 0.52-1.0) experienced significantly lower attrition after ART initiation. CONCLUSION: Youth experienced substantially higher attrition before and after ART initiation compared with younger adolescents and older adults. Adolescent-friendly services were associated with reduced attrition among youth, particularly after ART initiation.'
p35561
sS'GR'
p35562
(lp35563
S'5U2GPS001537-03/PHS HHS/United States'
p35564
aS'U2G PS001537/PS/NCHHSTP CDC HHS/United States'
p35565
asS'IP'
p35566
S'4'
sS'IS'
p35567
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p35568
sS'PMC'
p35569
S'PMC4517438'
p35570
sS'DCOM'
p35571
S'20140917'
p35572
sS'AU'
p35573
(lp35574
S'Lamb MR'
p35575
aS'Fayorsey R'
p35576
aS'Nuwagaba-Biribonwoha H'
p35577
aS'Viola V'
p35578
aS'Mutabazi V'
p35579
aS'Alwar T'
p35580
aS'Casalini C'
p35581
aS'Elul B'
p35582
asS'VI'
p35583
S'28'
p35584
sS'MHDA'
p35585
S'2014/09/18 06:00'
p35586
sS'OID'
p35587
(lp35588
S'NLM: HHSPA707278'
p35589
aS'NLM: PMC4517438'
p35590
asS'MH'
p35591
(lp35592
S'Adolescent'
p35593
aS'Adult'
p35594
aS'Africa'
p35595
aS'Ambulatory Care/methods'
p35596
aS'Anti-Retroviral Agents/*therapeutic use'
p35597
aS'Antiretroviral Therapy, Highly Active/*methods'
p35598
aS'Child'
p35599
aS'Cohort Studies'
p35600
aS'Female'
p35601
aS'HIV Infections/*drug therapy/*pathology'
p35602
aS'Humans'
p35603
aS'Incidence'
p35604
aS'*Lost to Follow-Up'
p35605
aS'Male'
p35606
aS'Middle Aged'
p35607
aS'Pregnancy'
p35608
aS'Young Adult'
p35609
asS'EDAT'
p35610
S'2013/10/01 06:00'
p35611
sS'SO'
p35612
S'AIDS. 2014 Feb 20;28(4):559-68. doi: 10.1097/QAD.0000000000000054.'
p35613
sS'SB'
p35614
S'IM X'
p35615
sS'PMID'
p35616
S'24076661'
p35617
sS'PST'
p35618
S'ppublish'
p35619
stRp35620
ag2
(g3
g4
(dp35621
S'LID'
p35622
S'10.1155/2013/858023 [doi]'
p35623
sS'STAT'
p35624
S'MEDLINE'
p35625
sS'DEP'
p35626
S'20130829'
p35627
sS'DA'
p35628
S'20130926'
p35629
sS'AID'
p35630
(lp35631
S'10.1155/2013/858023 [doi]'
p35632
asS'CRDT'
p35633
(lp35634
S'2013/09/27 06:00'
p35635
asS'DP'
p35636
S'2013'
p35637
sS'OWN'
p35638
S'NLM'
p35639
sS'PT'
p35640
(lp35641
S'Journal Article'
p35642
asS'LA'
p35643
(lp35644
S'eng'
p35645
asS'DCOM'
p35646
S'20140415'
p35647
sS'JT'
p35648
S'BioMed research international'
p35649
sS'LR'
p35650
S'20150422'
p35651
sS'FAU'
p35652
(lp35653
S'Alvarez-Uria, Gerardo'
p35654
aS'Midde, Manoranjan'
p35655
aS'Pakam, Raghavakalyan'
p35656
aS'Naik, Praveen Kumar'
p35657
asS'TI'
p35658
S'Predictors of attrition in patients ineligible for antiretroviral therapy after being diagnosed with HIV: data from an HIV cohort study in India.'
p35659
sS'PL'
p35660
S'United States'
p35661
sS'PG'
p35662
S'858023'
p35663
sS'JID'
p35664
S'101600173'
p35665
sS'AB'
p35666
S'In newly HIV-diagnosed patients, the CD4+ lymphocyte count is measured to determine the need for antiretroviral therapy (ART). Studies from Sub-Saharan Africa have shown that patients who are ART ineligible at the first assessment have poor retention in care, but data from other low- or middle-income countries are scarce. In this study we describe the retention in pre-ART care of 1696 patients who were ineligible for ART after being diagnosed with HIV in a cohort study in India. More than one-third of ART ineligible patients had poor retention in care, and the attrition was higher in those with longer follow-up periods. Of those patients with poor retention, only 10% came back to the clinics, and their CD4 cell counts were lower than the ones of patients retained in care. After 4.5 years of follow-up, the cumulative incidence of loss to follow-up was 50%. Factors associated with attrition were being homeless, being illiterate, belonging to a disadvantaged community, being symptomatic at the time of the HIV diagnosis, male gender, and not living near a town. Widows were given nutritional support and, therefore, had better retention in care. The results of this study highlight the need to improve the retention in care of ART ineligible patients in India.'
p35667
sS'AD'
p35668
S'Department of Infectious Diseases, RDT Bathalapalli Hospital, Kadiri Road, Bathalapalli 515661, India.'
p35669
sS'VI'
p35670
S'2013'
p35671
sS'IS'
p35672
S'2314-6141 (Electronic)'
p35673
sS'PMC'
p35674
S'PMC3773413'
p35675
sS'AU'
p35676
(lp35677
S'Alvarez-Uria G'
p35678
aS'Midde M'
p35679
aS'Pakam R'
p35680
aS'Naik PK'
p35681
asS'MHDA'
p35682
S'2014/04/16 06:00'
p35683
sS'PHST'
p35684
(lp35685
S'2013/04/30 [received]'
p35686
aS'2013/08/01 [accepted]'
p35687
aS'2013/08/29 [epublish]'
p35688
asS'OID'
p35689
(lp35690
S'NLM: PMC3773413'
p35691
asS'MH'
p35692
(lp35693
S'Adult'
p35694
aS'*Antiretroviral Therapy, Highly Active'
p35695
aS'CD4 Lymphocyte Count'
p35696
aS'Cohort Studies'
p35697
aS'Female'
p35698
aS'Follow-Up Studies'
p35699
aS'HIV Infections/*diagnosis/*drug therapy/immunology'
p35700
aS'Humans'
p35701
aS'India'
p35702
aS'Male'
p35703
aS'Middle Aged'
p35704
asS'EDAT'
p35705
S'2013/09/27 06:00'
p35706
sS'SO'
p35707
S'Biomed Res Int. 2013;2013:858023. doi: 10.1155/2013/858023. Epub 2013 Aug 29.'
p35708
sS'SB'
p35709
S'IM'
p35710
sS'PMID'
p35711
S'24069604'
p35712
sS'TA'
p35713
S'Biomed Res Int'
p35714
sS'PST'
p35715
S'ppublish'
p35716
stRp35717
ag2
(g3
g4
(dp35718
S'LID'
p35719
S'10.1186/1471-2482-13-41 [doi]'
p35720
sS'STAT'
p35721
S'MEDLINE'
p35722
sS'DEP'
p35723
S'20130925'
p35724
sS'DA'
p35725
S'20131115'
p35726
sS'AID'
p35727
(lp35728
S'1471-2482-13-41 [pii]'
p35729
aS'10.1186/1471-2482-13-41 [doi]'
p35730
asS'CRDT'
p35731
(lp35732
S'2013/09/27 06:00'
p35733
asS'DP'
p35734
S'2013'
p35735
sS'OWN'
p35736
S'NLM'
p35737
sS'PT'
p35738
(lp35739
S'Journal Article'
p35740
aS'Observational Study'
p35741
asS'LA'
p35742
(lp35743
S'eng'
p35744
asS'DCOM'
p35745
S'20140421'
p35746
sS'JT'
p35747
S'BMC surgery'
p35748
sS'LR'
p35749
S'20150422'
p35750
sS'FAU'
p35751
(lp35752
S'Jaka, Hyasinta'
p35753
aS'Mchembe, Mabula D'
p35754
aS'Rambau, Peter F'
p35755
aS'Chalya, Phillipo L'
p35756
asS'TI'
p35757
S'Gastric outlet obstruction at Bugando Medical Centre in Northwestern Tanzania: a prospective review of 184 cases.'
p35758
sS'PL'
p35759
S'England'
p35760
sS'PG'
p35761
S'41'
p35762
sS'JID'
p35763
S'100968567'
p35764
sS'AB'
p35765
S'BACKGROUND: Gastric outlet obstruction poses diagnostic and therapeutic challenges to general surgeons practicing in resource-limited countries. There is a paucity of published data on this subject in our setting. This study was undertaken to highlight the etiological spectrum and treatment outcome of gastric outlet obstruction in our setting and to identify prognostic factors for morbidity and mortality. METHODS: This was a descriptive prospective study which was conducted at Bugando Medical Centre between March 2009 and February 2013. All patients with a clinical diagnosis of gastric outlet obstruction were, after informed consent for the study, consecutively enrolled into the study. Statistical data analysis was done using SPSS computer software version 17.0. RESULTS: A total of 184 patients were studied. More than two-third of patients were males. Patients with malignant gastric outlet obstruction were older than those of benign type. This difference was statistically significant (p < 0.001). Gastric cancer was the commonest malignant cause of gastric outlet obstruction where as peptic ulcer disease was the commonest benign cause. In children, the commonest cause of gastric outlet obstruction was congenital pyloric stenosis (13.0%). Non-bilious vomiting (100%) and weight loss (93.5%) were the most frequent symptoms. Eighteen (9.8%) patients were HIV positive with the median CD 4+ count of 282 cells/mul. A total of 168 (91.3%) patients underwent surgery. Of these, gastro-jejunostomy (61.9%) was the most common surgical procedure performed. The complication rate was 32.1 % mainly surgical site infections (38.2%). The median hospital stay and mortality rate were 14 days and 18.5% respectively. The presence of postoperative complication was the main predictor of hospital stay (p = 0.002), whereas the age > 60 years, co-existing medical illness, malignant cause, HIV positivity, low CD 4 count (<200 cells/mul), high ASA class and presence of surgical site infection significantly predicted mortality ( p< 0.001). The follow up of patients was generally poor as more than 60% of patients were lost to follow up. CONCLUSION: Gastric outlet obstruction in our setting is more prevalent in males and the cause is mostly malignant. The majority of patients present late with poor general condition. Early recognition of the diagnosis, aggressive resuscitation and early institution of surgical management is of paramount importance if morbidity and mortality associated with gastric outlet obstruction are to be avoided.'
p35766
sS'AD'
p35767
S'Department of Surgery, Catholic University of Health and Allied Sciences- Bugando, Mwanza, Tanzania. drphillipoleo@yahoo.com.'
p35768
sS'VI'
p35769
S'13'
p35770
sS'IS'
p35771
S'1471-2482 (Electronic) 1471-2482 (Linking)'
p35772
sS'PMC'
p35773
S'PMC3849005'
p35774
sS'AU'
p35775
(lp35776
S'Jaka H'
p35777
aS'Mchembe MD'
p35778
aS'Rambau PF'
p35779
aS'Chalya PL'
p35780
asS'MHDA'
p35781
S'2014/04/22 06:00'
p35782
sS'PHST'
p35783
(lp35784
S'2013/05/12 [received]'
p35785
aS'2013/09/23 [accepted]'
p35786
aS'2013/09/25 [aheadofprint]'
p35787
asS'OID'
p35788
(lp35789
S'NLM: PMC3849005'
p35790
asS'MH'
p35791
(lp35792
S'Adolescent'
p35793
aS'Adult'
p35794
aS'Aged'
p35795
aS'Child'
p35796
aS'Child, Preschool'
p35797
aS'*Developing Countries'
p35798
aS'Female'
p35799
aS'Gastrectomy'
p35800
aS'Gastric Outlet Obstruction/diagnosis/etiology/mortality/*surgery'
p35801
aS'Gastroenterostomy'
p35802
aS'Humans'
p35803
aS'Infant'
p35804
aS'Infant, Newborn'
p35805
aS'Length of Stay/statistics & numerical data'
p35806
aS'Male'
p35807
aS'Middle Aged'
p35808
aS'Postoperative Complications/epidemiology'
p35809
aS'Prognosis'
p35810
aS'Prospective Studies'
p35811
aS'Pylorus/surgery'
p35812
aS'Tanzania'
p35813
aS'Treatment Outcome'
p35814
aS'Young Adult'
p35815
asS'EDAT'
p35816
S'2013/09/27 06:00'
p35817
sS'SO'
p35818
S'BMC Surg. 2013 Sep 25;13:41. doi: 10.1186/1471-2482-13-41.'
p35819
sS'SB'
p35820
S'IM'
p35821
sS'PMID'
p35822
S'24067148'
p35823
sS'TA'
p35824
S'BMC Surg'
p35825
sS'PST'
p35826
S'epublish'
p35827
stRp35828
ag2
(g3
g4
(dp35829
S'LID'
p35830
S'10.1371/journal.pone.0074090 [doi]'
p35831
sS'STAT'
p35832
S'MEDLINE'
p35833
sS'DEP'
p35834
S'20130916'
p35835
sS'DA'
p35836
S'20130925'
p35837
sS'AID'
p35838
(lp35839
S'10.1371/journal.pone.0074090 [doi]'
p35840
aS'PONE-D-13-16805 [pii]'
p35841
asS'CRDT'
p35842
(lp35843
S'2013/09/26 06:00'
p35844
asS'DP'
p35845
S'2013'
p35846
sS'OWN'
p35847
S'NLM'
p35848
sS'PT'
p35849
(lp35850
S'Journal Article'
p35851
asS'LA'
p35852
(lp35853
S'eng'
p35854
asS'FAU'
p35855
(lp35856
S'McGuire, Megan'
p35857
aS'Ben Farhat, Jihane'
p35858
aS'Pedrono, Gaelle'
p35859
aS'Szumilin, Elisabeth'
p35860
aS'Heinzelmann, Annette'
p35861
aS'Chinyumba, Yamikani Ntakwile'
p35862
aS'Goossens, Sylvie'
p35863
aS'Makombe, Simon'
p35864
aS'Pujades-Rodriguez, Mar'
p35865
asS'JT'
p35866
S'PloS one'
p35867
sS'LR'
p35868
S'20150422'
p35869
sS'PG'
p35870
S'e74090'
p35871
sS'TI'
p35872
S'Task-sharing of HIV care and ART initiation: evaluation of a mixed-care non-physician provider model for ART delivery in rural Malawi.'
p35873
sS'RN'
p35874
(lp35875
S'0 (Anti-HIV Agents)'
p35876
asS'PL'
p35877
S'United States'
p35878
sS'TA'
p35879
S'PLoS One'
p35880
sS'JID'
p35881
S'101285081'
p35882
sS'AB'
p35883
S'BACKGROUND: Expanding access to antiretroviral therapy (ART) in sub-Saharan Africa requires implementation of alternative care delivery models to traditional physician-centered approaches. This longitudinal analysis compares outcomes of patients initiated on antiretroviral therapy (ART) by non-physician and physician providers. METHODS: Adults (>/=15 years) initiating ART between September 2007 and March 2010, and with >1 follow-up visit were included and classified according to the proportion of clinical visits performed by nurses or by clinical officers (>/= 80% of visits). Multivariable Poisson models were used to compare 2-year program attrition (mortality and lost to follow-up) and mortality by type of provider. In sensitivity analyses only patients with less severe disease were included. RESULTS: A total of 10,112 patients contributed 14,012 person-years to the analysis: 3386 (33.5%) in the clinical officer group, 1901 (18.8%) in the nurse care group and 4825 (47.7%) in the mixed care group. Overall 2-year program retention was 81.8%. Attrition was lower in the mixed care and higher in the clinical officer group, compared to the nurse group (adjusted incidence rate ratio [aIRR]=0.54, 95%CI 0.45-0.65; and aIRR=3.03, 95%CI 2.56-3.59, respectively). While patients initiated on ART by clinical officers in the mixed care group had lower attrition (aIRR=0.36, 95%CI 0.29-0.44) than those in the overall nurse care group; no differences in attrition were found between patients initiated on ART by nurses in the mixed care group and those included in the nurse group (aIRR=1.18, 95%CI 0.95-1.47). Two-year mortality estimates were aIRR=0.72, 95%CI 0.49-1.09 and aIRR=5.04, 95%CI 3.56-7.15, respectively. Slightly higher estimates were observed when analyses were restricted to patients with less severe disease. CONCLUSION: The findings of this study support the use of a mixed care model with well trained and regularly supervised nurses and medical assistants to provide HIV care in countries with high HIV prevalence.'
p35884
sS'AD'
p35885
S'Epicentre, Paris, France ; Medecins sans Frontieres, Medical Unit, New York, New York, United States of America.'
p35886
sS'IP'
p35887
S'9'
sS'IS'
p35888
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p35889
sS'PMC'
p35890
S'PMC3774791'
p35891
sS'DCOM'
p35892
S'20140526'
p35893
sS'AU'
p35894
(lp35895
S'McGuire M'
p35896
aS'Ben Farhat J'
p35897
aS'Pedrono G'
p35898
aS'Szumilin E'
p35899
aS'Heinzelmann A'
p35900
aS'Chinyumba YN'
p35901
aS'Goossens S'
p35902
aS'Makombe S'
p35903
aS'Pujades-Rodriguez M'
p35904
asS'VI'
p35905
S'8'
sS'MHDA'
p35906
S'2014/05/27 06:00'
p35907
sS'PHST'
p35908
(lp35909
S'2013 [ecollection]'
p35910
aS'2013/04/24 [received]'
p35911
aS'2013/07/26 [accepted]'
p35912
aS'2013/09/16 [epublish]'
p35913
asS'OID'
p35914
(lp35915
S'NLM: PMC3774791'
p35916
asS'MH'
p35917
(lp35918
S'Adult'
p35919
aS'Anti-HIV Agents/*therapeutic use'
p35920
aS'Delivery of Health Care/*statistics & numerical data'
p35921
aS'Female'
p35922
aS'HIV Infections/*drug therapy'
p35923
aS'Humans'
p35924
aS'Malawi'
p35925
aS'Male'
p35926
aS'Treatment Outcome'
p35927
asS'EDAT'
p35928
S'2013/09/26 06:00'
p35929
sS'SO'
p35930
S'PLoS One. 2013 Sep 16;8(9):e74090. doi: 10.1371/journal.pone.0074090. eCollection 2013.'
p35931
sS'SB'
p35932
S'IM'
p35933
sS'PMID'
p35934
S'24066099'
p35935
sS'PST'
p35936
S'epublish'
p35937
stRp35938
ag2
(g3
g4
(dp35939
S'LID'
p35940
S'10.1136/thoraxjnl-2013-203900 [doi]'
p35941
sS'STAT'
p35942
S'MEDLINE'
p35943
sS'DEP'
p35944
S'20130924'
p35945
sS'DA'
p35946
S'20140414'
p35947
sS'AID'
p35948
(lp35949
S'thoraxjnl-2013-203900 [pii]'
p35950
aS'10.1136/thoraxjnl-2013-203900 [doi]'
p35951
asS'CRDT'
p35952
(lp35953
S'2013/09/26 06:00'
p35954
asS'DP'
p35955
S'2014 May'
p35956
sS'OWN'
p35957
S'NLM'
p35958
sS'PT'
p35959
(lp35960
S'Journal Article'
p35961
aS'Observational Study'
p35962
aS"Research Support, Non-U.S. Gov't"
p35963
aS"Research Support, U.S. Gov't, Non-P.H.S."
p35964
asS'LA'
p35965
(lp35966
S'eng'
p35967
asS'FAU'
p35968
(lp35969
S'Seddon, James A'
p35970
aS'Hesseling, Anneke C'
p35971
aS'Godfrey-Faussett, Peter'
p35972
aS'Schaaf, H Simon'
p35973
asS'JT'
p35974
S'Thorax'
p35975
sS'PG'
p35976
S'458-64'
p35977
sS'TI'
p35978
S'High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study.'
p35979
sS'RN'
p35980
(lp35981
S'0 (Antitubercular Agents)'
p35982
asS'PL'
p35983
S'England'
p35984
sS'TA'
p35985
S'Thorax'
p35986
sS'JID'
p35987
S'0417353'
p35988
sS'AB'
p35989
S'BACKGROUND: Few studies have described the management of multidrug-resistant (MDR) tuberculosis (TB) in children and evidence-based guidance on management is lacking. We describe the presentation, treatment and outcome in children treated for severe and non-severe MDR-TB in Cape Town, South Africa. METHODS: We conducted an observational cohort study of all children (<15 years) treated for MDR-TB if routinely initiated on treatment between January 2009 and December 2010. Treatment was based on local standard of care, based on international guidelines. Data were collected through family interviews and folder review. Standardised definitions were used for diagnosis, severity of disease, adverse events and outcome. RESULTS: Of 149 children started on MDR-TB treatment, the median age was 36 months (IQR 16-66), 32 (22%; of 146 tested) had HIV infection and 59 (40%) had a confirmed diagnosis. Ninety-four (66%) children were treated with an injectable drug and the median total duration of treatment was 13 months (IQR 11-18). Thirty-six (24%) children were cured, 101 (68%) probably cured, 1 (1%) was transferred out, 8 (5%) were lost to follow-up and 3 (2%) died. Children with severe disease were older (54 months (IQR 18-142) vs 31.5 months (IQR 17.5-53.5); p=0.012), more commonly had HIV infection (OR 6.25; 95% CI 2.50 to 15.6; p<0.001) and were more likely to die (p=0.008). DISCUSSION: A confirmed diagnosis of MDR-TB is not possible in all cases but this should not impede the treatment of MDR-TB in children. More than 90% of children with MDR-TB can be successfully treated. Non-severe disease could be successfully treated with reduced treatment duration.'
p35990
sS'AD'
p35991
S'Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Desmond Tutu TB Centre, Stellenbosch University, , Tygerberg, South Africa.'
p35992
sS'IP'
p35993
S'5'
sS'IS'
p35994
S'1468-3296 (Electronic) 0040-6376 (Linking)'
p35995
sS'DCOM'
p35996
S'20140527'
p35997
sS'AU'
p35998
(lp35999
S'Seddon JA'
p36000
aS'Hesseling AC'
p36001
aS'Godfrey-Faussett P'
p36002
aS'Schaaf HS'
p36003
asS'VI'
p36004
S'69'
p36005
sS'MHDA'
p36006
S'2014/05/28 06:00'
p36007
sS'PHST'
p36008
(lp36009
S'2013/09/24 [aheadofprint]'
p36010
asS'OTO'
p36011
(lp36012
S'NOTNLM'
p36013
asS'MH'
p36014
(lp36015
S'Antitubercular Agents/*administration & dosage'
p36016
aS'Child, Preschool'
p36017
aS'Dose-Response Relationship, Drug'
p36018
aS'Female'
p36019
aS'Follow-Up Studies'
p36020
aS'Humans'
p36021
aS'Incidence'
p36022
aS'Infant'
p36023
aS'Male'
p36024
aS'Mycobacterium tuberculosis/*isolation & purification'
p36025
aS'Retrospective Studies'
p36026
aS'South Africa/epidemiology'
p36027
aS'Treatment Outcome'
p36028
aS'Tuberculosis, Multidrug-Resistant/diagnosis/*drug therapy/epidemiology'
p36029
asS'EDAT'
p36030
S'2013/09/26 06:00'
p36031
sS'SO'
p36032
S'Thorax. 2014 May;69(5):458-64. doi: 10.1136/thoraxjnl-2013-203900. Epub 2013 Sep 24.'
p36033
sS'SB'
p36034
S'IM'
p36035
sS'PMID'
p36036
S'24064441'
p36037
sS'OT'
p36038
(lp36039
S'Paediatric Lung Disaese'
p36040
aS'Respiratory Infection'
p36041
aS'Tuberculosis'
p36042
asS'PST'
p36043
S'ppublish'
p36044
stRp36045
ag2
(g3
g4
(dp36046
S'LID'
p36047
S'10.1371/journal.pone.0075118 [doi]'
p36048
sS'STAT'
p36049
S'MEDLINE'
p36050
sS'DEP'
p36051
S'20130910'
p36052
sS'DA'
p36053
S'20130923'
p36054
sS'AID'
p36055
(lp36056
S'10.1371/journal.pone.0075118 [doi]'
p36057
aS'PONE-D-13-25447 [pii]'
p36058
asS'CRDT'
p36059
(lp36060
S'2013/09/24 06:00'
p36061
asS'DP'
p36062
S'2013'
p36063
sS'OWN'
p36064
S'NLM'
p36065
sS'PT'
p36066
(lp36067
S'Clinical Trial'
p36068
aS'Journal Article'
p36069
aS'Multicenter Study'
p36070
aS"Research Support, Non-U.S. Gov't"
p36071
asS'LA'
p36072
(lp36073
S'eng'
p36074
asS'FAU'
p36075
(lp36076
S'Gunda, Daniel W'
p36077
aS'Kasang, Christa'
p36078
aS'Kidenya, Benson R'
p36079
aS'Kabangila, Rodrick'
p36080
aS'Mshana, Stephen E'
p36081
aS'Kidola, Jeremiah'
p36082
aS'Kalluvya, Samuel E'
p36083
aS'Kongola, Gilbert W'
p36084
aS'Klinker, Hartwig'
p36085
asS'JT'
p36086
S'PloS one'
p36087
sS'LR'
p36088
S'20150422'
p36089
sS'PG'
p36090
S'e75118'
p36091
sS'TI'
p36092
S'Plasma concentrations of efavirenz and nevirapine among HIV-infected patients with immunological failure attending a tertiary hospital in North-western Tanzania.'
p36093
sS'RN'
p36094
(lp36095
S'0 (Benzoxazines)'
p36096
aS'0 (Reverse Transcriptase Inhibitors)'
p36097
aS'99DK7FVK1H (Nevirapine)'
p36098
aS'JE6H2O27P8 (efavirenz)'
p36099
asS'PL'
p36100
S'United States'
p36101
sS'TA'
p36102
S'PLoS One'
p36103
sS'JID'
p36104
S'101285081'
p36105
sS'AB'
p36106
S'BACKGROUND: Sub-therapeutic and supra-therapeutic plasma concentrations of antriretrovirals are the significant causes of treatment failure and toxicity respectively among HIV-infected patients. We conducted this study to determine the pattern of efavirenz and nevirapine plasma drug concentrations among adult HIV-infected patients with immunological failure attending at a tertiary hospital in North-western Tanzania. MATERIALS AND METHODS: A cross-sectional study was conducted among adult HIV-infected patients with immunological failure who have been on either efavirenz or nevirapine based antiretroviral regimen for more than 6 months. Patients were serially enrolled through routine Care and Treatment Clinic (CTC) activities. Plasma drug concentrations for efavirenz and nevirapine were determined by high performance liquid chromatography (HPLC) and Gas Chromatography (GC) respectively. Demographic, clinical and laboratory data such as viral load and CD4 counts were collected. Data analysis was done using STATA 12. RESULTS: Of the 152 patients with immunological failure enrolled, the sub-therapeutic, therapeutic and supra-therapeutic plasma antiretroviral drug concentrations were found in 43/152 (28.3%), 76/152 (50.0%) and 33/152 (21.7%) respectively. Half of the patients were outside therapeutic window with either sub-therapeutic or supra-therapeutic plasma ARV drug concentrations. There was a significant difference in distribution of ARV adherence (p-value<0.001), NRTI backbone (p-value = 0.039), HIV stage (p-value = 0.026) and viral load (p-value = 0.007) within sub-therapeutic, therapeutic and supra-therapeutic ARV plasma drug concentrations. CONCLUSION: There is a wide inter-individual variability of plasma ARV concentrations among HIV patients with immunological failure, with a large proportion of patients being outside therapeutic window. This variability is significant based on ARV adherence, NRTI backbone, viral load and HIV stage. Routine therapeutic drug monitoring (TDM) could assist identifying these patients early and making timely correction to avoid virological failure, poor immunological outcome and prevent associated drug toxicities. Nonetheless, ARV adherence should be strictly emphasized on HIV patients with immunological failure.'
p36107
sS'AD'
p36108
S'Department of Internal Medicine, School of Medicine, Catholic University of Health and Allied Sciences, Mwanza, Tanzania.'
p36109
sS'IP'
p36110
S'9'
sS'IS'
p36111
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p36112
sS'PMC'
p36113
S'PMC3769243'
p36114
sS'DCOM'
p36115
S'20140930'
p36116
sS'AU'
p36117
(lp36118
S'Gunda DW'
p36119
aS'Kasang C'
p36120
aS'Kidenya BR'
p36121
aS'Kabangila R'
p36122
aS'Mshana SE'
p36123
aS'Kidola J'
p36124
aS'Kalluvya SE'
p36125
aS'Kongola GW'
p36126
aS'Klinker H'
p36127
asS'VI'
p36128
S'8'
sS'MHDA'
p36129
S'2014/10/01 06:00'
p36130
sS'PHST'
p36131
(lp36132
S'2013 [ecollection]'
p36133
aS'2013/06/20 [received]'
p36134
aS'2013/08/08 [accepted]'
p36135
aS'2013/09/10 [epublish]'
p36136
asS'OID'
p36137
(lp36138
S'NLM: PMC3769243'
p36139
asS'MH'
p36140
(lp36141
S'Adult'
p36142
aS'Benzoxazines/administration & dosage/*pharmacokinetics'
p36143
aS'*Drug Monitoring'
p36144
aS'Female'
p36145
aS'HIV Infections/*blood/drug therapy/epidemiology'
p36146
aS'*HIV-1'
p36147
aS'Humans'
p36148
aS'Male'
p36149
aS'Middle Aged'
p36150
aS'Nevirapine/administration & dosage/*pharmacokinetics'
p36151
aS'Reverse Transcriptase Inhibitors/administration & dosage/*pharmacokinetics'
p36152
aS'Tanzania/epidemiology'
p36153
aS'Viral Load/drug effects'
p36154
asS'EDAT'
p36155
S'2013/09/24 06:00'
p36156
sS'SO'
p36157
S'PLoS One. 2013 Sep 10;8(9):e75118. doi: 10.1371/journal.pone.0075118. eCollection 2013.'
p36158
sS'SB'
p36159
S'IM'
p36160
sS'PMID'
p36161
S'24058655'
p36162
sS'PST'
p36163
S'epublish'
p36164
stRp36165
ag2
(g3
g4
(dp36166
S'LID'
p36167
S'10.1097/QAD.0000000000000027 [doi]'
p36168
sS'STAT'
p36169
S'MEDLINE'
p36170
sS'JT'
p36171
S'AIDS (London, England)'
p36172
sS'DA'
p36173
S'20140103'
p36174
sS'AID'
p36175
(lp36176
S'10.1097/QAD.0000000000000027 [doi]'
p36177
asS'CRDT'
p36178
(lp36179
S'2013/09/24 06:00'
p36180
asS'DP'
p36181
S'2013 Nov 13'
p36182
sS'AD'
p36183
S'aCentre for Sexual Health and HIV/AIDS Research (CeSHHAR Zimbabwe), Harare, Zimbabwe bUniversity College London Centre for Sexual Health & HIV Research, London, UK cDepartment of Medicine, College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe.'
p36184
sS'OWN'
p36185
S'NLM'
p36186
sS'PT'
p36187
(lp36188
S'Journal Article'
p36189
aS'Meta-Analysis'
p36190
aS"Research Support, Non-U.S. Gov't"
p36191
aS'Review'
p36192
asS'LA'
p36193
(lp36194
S'eng'
p36195
asS'FAU'
p36196
(lp36197
S'Sibanda, Euphemia L'
p36198
aS'Weller, Ian V D'
p36199
aS'Hakim, James G'
p36200
aS'Cowan, Frances M'
p36201
asS'LR'
p36202
S'20150422'
p36203
sS'PG'
p36204
S'2787-97'
p36205
sS'TI'
p36206
S'The magnitude of loss to follow-up of HIV-exposed infants along the prevention of mother-to-child HIV transmission continuum of care: a systematic review and meta-analysis.'
p36207
sS'PL'
p36208
S'England'
p36209
sS'TA'
p36210
S'AIDS'
p36211
sS'JID'
p36212
S'8710219'
p36213
sS'AB'
p36214
S'INTRODUCTION: Although prevention of mother-to-child HIV transmission (PMTCT) programs are widely implemented, many children do not benefit from them because of loss to follow-up (LTFU). We conducted a systematic review to determine the magnitude of infant/baby LTFU along the PMTCT cascade. METHODS: Eligible publications reported infant LTFU outcomes from standard care PMTCT programs (not intervention studies) at any stage of the cascade. Literature searches were conducted in Medline, Embase, Web of Knowledge, CINAHL Plus, and Maternity and Infant Care. Extracted data included setting, methods of follow-up, PMTCT regimens, and proportion and timing of LTFU. For programs in sub-Saharan Africa, random-effects meta-analysis was done using Stata v10. Because of heterogeneity, predictive intervals (PrIs; approximate 95% confidence intervals of a future study based on extent of observed heterogeneity) were computed. RESULTS: A total of 826 papers were identified; 25 publications were eligible. Studies were published from 2001 to 2012 and were mostly from sub-Saharan Africa (three were from India, one from UK and one from Ireland). There was extensive heterogeneity in findings. Eight studies reported on LTFU of pregnant HIV-positive women between antenatal care (ANC) registration and delivery, which ranged from 10.9 to 68.1%, pooled proportion 49.08% [95% confidence interval (CI) 39.6-60.9%], and PrI 22.0-100%. Fourteen studies reported LTFU of infants within 3 months of delivery, range 4.8-75%, pooled proportion 33.9% (27.6-41.5), and PrI 15.4-74.2. Children were also lost after HIV testing; this was reported in five studies, pooled estimate 45.5% (35.9-57.6), PrI 18.7-100%. Programs that actively tracked defaulters had better retention outcomes. CONCLUSION: There is unacceptable infant LTFU from PMTCT programs. Countries should incorporate defaulter-tracking as standard to improve retention.'
p36215
sS'GR'
p36216
(lp36217
S'Wellcome Trust/United Kingdom'
p36218
asS'IP'
p36219
S'17'
p36220
sS'IS'
p36221
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p36222
sS'PMC'
p36223
S'PMC3814628'
p36224
sS'DCOM'
p36225
S'20140707'
p36226
sS'AU'
p36227
(lp36228
S'Sibanda EL'
p36229
aS'Weller IV'
p36230
aS'Hakim JG'
p36231
aS'Cowan FM'
p36232
asS'VI'
p36233
S'27'
p36234
sS'MHDA'
p36235
S'2014/07/08 06:00'
p36236
sS'OID'
p36237
(lp36238
S'NLM: PMC3814628'
p36239
asS'MH'
p36240
(lp36241
S'Continuity of Patient Care/*statistics & numerical data'
p36242
aS'Female'
p36243
aS'HIV Infections/*diagnosis/*drug therapy/prevention & control'
p36244
aS'Humans'
p36245
aS'Infant'
p36246
aS'Infant, Newborn'
p36247
aS'Infectious Disease Transmission, Vertical/*prevention & control'
p36248
aS'*Lost to Follow-Up'
p36249
aS'Pregnancy'
p36250
asS'EDAT'
p36251
S'2013/09/24 06:00'
p36252
sS'SO'
p36253
S'AIDS. 2013 Nov 13;27(17):2787-97. doi: 10.1097/QAD.0000000000000027.'
p36254
sS'SB'
p36255
S'IM X'
p36256
sS'PMID'
p36257
S'24056068'
p36258
sS'PST'
p36259
S'ppublish'
p36260
stRp36261
ag2
(g3
g4
(dp36262
S'LID'
p36263
S'10.1186/1471-2334-13-439 [doi]'
p36264
sS'STAT'
p36265
S'MEDLINE'
p36266
sS'DEP'
p36267
S'20130921'
p36268
sS'DA'
p36269
S'20131115'
p36270
sS'AID'
p36271
(lp36272
S'1471-2334-13-439 [pii]'
p36273
aS'10.1186/1471-2334-13-439 [doi]'
p36274
asS'CRDT'
p36275
(lp36276
S'2013/09/24 06:00'
p36277
asS'DP'
p36278
S'2013'
p36279
sS'AD'
p36280
S'"L, Spallanzani" National Institute for Infectious Diseases- INMI, Via Portuense 292, 00149 Rome, Italy. francvairo@gmail.com.'
p36281
sS'OWN'
p36282
S'NLM'
p36283
sS'PT'
p36284
(lp36285
S'Journal Article'
p36286
aS"Research Support, Non-U.S. Gov't"
p36287
asS'LA'
p36288
(lp36289
S'eng'
p36290
asS'DCOM'
p36291
S'20140623'
p36292
sS'JT'
p36293
S'BMC infectious diseases'
p36294
sS'LR'
p36295
S'20150422'
p36296
sS'FAU'
p36297
(lp36298
S'Vairo, Francesco'
p36299
aS'Nicastri, Emanuele'
p36300
aS'Liuzzi, Giuseppina'
p36301
aS'Chaula, Zainab'
p36302
aS'Nguhuni, Boniface'
p36303
aS'Bevilacqua, Nazario'
p36304
aS'Forbici, Federica'
p36305
aS'Amendola, Alessandra'
p36306
aS'Fabeni, Lavinia'
p36307
aS'De Nardo, Pasquale'
p36308
aS'Perno, Carlo Federico'
p36309
aS'Cannas, Angela'
p36310
aS'Sakhoo, Calistus'
p36311
aS'Capobianchi, Maria Rosaria'
p36312
aS'Ippolito, Giuseppe'
p36313
asS'TI'
p36314
S"HIV-1 drug resistance in recently HIV-infected pregnant mother's naive to antiretroviral therapy in Dodoma urban, Tanzania."
p36315
sS'RN'
p36316
(lp36317
S'0 (Anti-HIV Agents)'
p36318
asS'PL'
p36319
S'England'
p36320
sS'PG'
p36321
S'439'
p36322
sS'JID'
p36323
S'100968551'
p36324
sS'AB'
p36325
S'BACKGROUND: HIV resistance affects virological response to therapy and efficacy of prophylaxis in mother-to-child-transmission. The study aims to assess the prevalence of HIV primary resistance in pregnant women naive to antiretrovirals. METHODS: Cross sectional baseline analysis of a cohort of HIV + pregnant women (HPW) enrolled in the study entitled Antiretroviral Management of Antenatal and Natal HIV Infection (AMANI, peace in Kiswahili language). The AMANI study began in May 2010 in Dodoma, Tanzania. In this observational cohort, antiretroviral treatment was provided to all women from the 28th week of gestation until the end of the breastfeeding period. Baseline CD4 cell count, viral load and HIV drug-resistance genotype were collected. RESULTS: Drug-resistance analysis was performed on 97 naive infected-mothers. The prevalence of all primary drug resistance and primary non-nucleoside reverse-transcriptase inhibitors resistance was 11.9% and 7.5%, respectively. K103S was found in two women with no M184V detection. HIV-1 subtype A was the most commonly identified, with a high prevalence of subtype A1, followed by C, D, C/D recombinant, A/C recombinant and A/D recombinant. HIV drug- resistance mutations were detected in A1 and C subtypes. CONCLUSION: Our study reports an 11.9% prevalence rate of primary drug resistance in naive HIV-infected pregnant women from a remote area of Tanzania. Considering that the non-nucleoside reverse-transcriptase inhibitors are part of the first-line antiretroviral regimen in Tanzania and all of Africa, resistance surveys should be prioritized in settings where antiretroviral therapy programs are scaled up.'
p36326
sS'CN'
p36327
(lp36328
S'AMANI Study Group'
p36329
asS'VI'
p36330
S'13'
p36331
sS'IS'
p36332
S'1471-2334 (Electronic) 1471-2334 (Linking)'
p36333
sS'PMC'
p36334
S'PMC3849050'
p36335
sS'AU'
p36336
(lp36337
S'Vairo F'
p36338
aS'Nicastri E'
p36339
aS'Liuzzi G'
p36340
aS'Chaula Z'
p36341
aS'Nguhuni B'
p36342
aS'Bevilacqua N'
p36343
aS'Forbici F'
p36344
aS'Amendola A'
p36345
aS'Fabeni L'
p36346
aS'De Nardo P'
p36347
aS'Perno CF'
p36348
aS'Cannas A'
p36349
aS'Sakhoo C'
p36350
aS'Capobianchi MR'
p36351
aS'Ippolito G'
p36352
asS'MHDA'
p36353
S'2014/06/24 06:00'
p36354
sS'PHST'
p36355
(lp36356
S'2013/08/07 [received]'
p36357
aS'2013/09/18 [accepted]'
p36358
aS'2013/09/21 [aheadofprint]'
p36359
asS'OID'
p36360
(lp36361
S'NLM: PMC3849050'
p36362
asS'MH'
p36363
(lp36364
S'Adult'
p36365
aS'Anti-HIV Agents/*therapeutic use'
p36366
aS'Cohort Studies'
p36367
aS'Cross-Sectional Studies'
p36368
aS'*Drug Resistance, Viral'
p36369
aS'Female'
p36370
aS'HIV Infections/*drug therapy/epidemiology/transmission/*virology'
p36371
aS'HIV-1/classification/*drug effects/genetics/isolation & purification'
p36372
aS'Humans'
p36373
aS'Molecular Sequence Data'
p36374
aS'Mothers'
p36375
aS'Phylogeny'
p36376
aS'Pregnancy'
p36377
aS'Pregnancy Complications/*drug therapy/virology'
p36378
aS'Tanzania/epidemiology'
p36379
aS'Urban Health'
p36380
aS'Young Adult'
p36381
asS'EDAT'
p36382
S'2013/09/24 06:00'
p36383
sS'SO'
p36384
S'BMC Infect Dis. 2013 Sep 21;13:439. doi: 10.1186/1471-2334-13-439.'
p36385
sS'SB'
p36386
S'IM'
p36387
sS'PMID'
p36388
S'24053581'
p36389
sS'TA'
p36390
S'BMC Infect Dis'
p36391
sS'PST'
p36392
S'epublish'
p36393
stRp36394
ag2
(g3
g4
(dp36395
S'LID'
p36396
S'10.1111/tmi.12183 [doi]'
p36397
sS'STAT'
p36398
S'MEDLINE'
p36399
sS'DEP'
p36400
S'20130911'
p36401
sS'CI'
p36402
(lp36403
S'(c) 2013 John Wiley & Sons Ltd.'
p36404
asS'DA'
p36405
S'20140303'
p36406
sS'AID'
p36407
(lp36408
S'10.1111/tmi.12183 [doi]'
p36409
asS'CRDT'
p36410
(lp36411
S'2013/09/17 06:00'
p36412
asS'DP'
p36413
S'2013 Nov'
p36414
sS'OWN'
p36415
S'NLM'
p36416
sS'PT'
p36417
(lp36418
S'Journal Article'
p36419
aS"Research Support, Non-U.S. Gov't"
p36420
asS'LA'
p36421
(lp36422
S'eng'
p36423
asS'FAU'
p36424
(lp36425
S'Kapata, Nathan'
p36426
aS'Chanda-Kapata, Pascalina'
p36427
aS'Bates, Matthew'
p36428
aS'Mwaba, Peter'
p36429
aS'Cobelens, Frank'
p36430
aS'Grobusch, Martin P'
p36431
aS'Zumla, Alimuddin'
p36432
asS'JT'
p36433
S'Tropical medicine & international health : TM & IH'
p36434
sS'PG'
p36435
S'1386-91'
p36436
sS'TI'
p36437
S'Multidrug-resistant TB in Zambia: review of national data from 2000 to 2011.'
p36438
sS'RN'
p36439
(lp36440
S'0 (Antibiotics, Antitubercular)'
p36441
aS'0 (Antitubercular Agents)'
p36442
aS'VJT6J7R4TR (Rifampin)'
p36443
asS'PL'
p36444
S'England'
p36445
sS'TA'
p36446
S'Trop Med Int Health'
p36447
sS'JID'
p36448
S'9610576'
p36449
sS'AB'
p36450
S'BACKGROUND: Multidrug-resistant tuberculosis (MDR-TB) is posing a great threat to global TB control. The burden in Zambia is not well defined because routine surveillance data are scarce. We reviewed national MDR-TB data for the last decade to inform future public health policy with respect to MDR-TB in Zambia. METHOD: Retrospective review of national surveillance of MDR-TB data, TB programme and laboratory reports between 2000 and 2011. RESULTS: The total number of DSTs performed during this 11-year period was 2,038 and accounted for 2.6% (2,038/78,639) of all the retreatment cases notified. The total number of diagnosed MDR-TB cases for this period was 446, of which 56.3% (251/446) were male and 41.7% (186/446) female. Only one child was found to have MDR-TB. Poly-drug resistance accounted for 18.9% (172/911) of the DR-TB cases and 8.4% of the total DSTs. 8.8% (80/911) of the DR-TB cases showed either rifampicin mono- or poly-resistance other than MDR-TB. No XDR-TB was reported. There were no data available on DR-TB and HIV co-infection. Only 65 MDR-TB patients were notified and put on second-line treatment according to WHO guidelines. CONCLUSIONS: Multidrug-resistant tuberculosis may be an emerging challenge in Zambia. There is a need to invest in improving the capacity of the TB programme to detect and manage MDR-TB.'
p36451
sS'AD'
p36452
S'Ministry of Health, Lusaka, Zambia; National TB and Leprosy Control Programme, Ministry of Health, Lusaka, Zambia; University of Zambia-University College London Medical School Research and Training Programme, Lusaka, Zambia; Center for Tropical Medicine and Travel Medicine, University of Amsterdam, Amsterdam, The Netherlands.'
p36453
sS'IP'
p36454
S'11'
p36455
sS'IS'
p36456
S'1365-3156 (Electronic) 1360-2276 (Linking)'
p36457
sS'DCOM'
p36458
S'20140421'
p36459
sS'AU'
p36460
(lp36461
S'Kapata N'
p36462
aS'Chanda-Kapata P'
p36463
aS'Bates M'
p36464
aS'Mwaba P'
p36465
aS'Cobelens F'
p36466
aS'Grobusch MP'
p36467
aS'Zumla A'
p36468
asS'VI'
p36469
S'18'
p36470
sS'MHDA'
p36471
S'2014/04/22 06:00'
p36472
sS'PHST'
p36473
(lp36474
S'2013/09/11 [aheadofprint]'
p36475
asS'OTO'
p36476
(lp36477
S'NOTNLM'
p36478
asS'MH'
p36479
(lp36480
S'Adult'
p36481
aS'Antibiotics, Antitubercular/therapeutic use'
p36482
aS'Antitubercular Agents/*therapeutic use'
p36483
aS'Child'
p36484
aS'Disease Management'
p36485
aS'Extensively Drug-Resistant Tuberculosis/epidemiology'
p36486
aS'Female'
p36487
aS'HIV Infections/complications'
p36488
aS'Humans'
p36489
aS'Incidence'
p36490
aS'Male'
p36491
aS'*Population Surveillance'
p36492
aS'Retrospective Studies'
p36493
aS'Rifampin/therapeutic use'
p36494
aS'Sex Factors'
p36495
aS'Tuberculosis, Multidrug-Resistant/*drug therapy/epidemiology'
p36496
aS'Zambia/epidemiology'
p36497
asS'EDAT'
p36498
S'2013/09/17 06:00'
p36499
sS'SO'
p36500
S'Trop Med Int Health. 2013 Nov;18(11):1386-91. doi: 10.1111/tmi.12183. Epub 2013 Sep 11.'
p36501
sS'SB'
p36502
S'IM'
p36503
sS'PMID'
p36504
S'24033538'
p36505
sS'OT'
p36506
(lp36507
S'Zambia'
p36508
aS'diagnosis'
p36509
aS'multidrug-resistant tuberculosis'
p36510
aS'retreatments'
p36511
aS'surveillance'
p36512
aS'tuberculosis'
p36513
asS'PST'
p36514
S'ppublish'
p36515
stRp36516
ag2
(g3
g4
(dp36517
S'LID'
p36518
S'10.1093/inthealth/iht002 [doi]'
p36519
sS'STAT'
p36520
S'MEDLINE'
p36521
sS'JT'
p36522
S'International health'
p36523
sS'DA'
p36524
S'20130913'
p36525
sS'AID'
p36526
(lp36527
S'iht002 [pii]'
p36528
aS'10.1093/inthealth/iht002 [doi]'
p36529
asS'CRDT'
p36530
(lp36531
S'2013/09/14 06:00'
p36532
asS'DP'
p36533
S'2013 Jun'
p36534
sS'OWN'
p36535
S'NLM'
p36536
sS'PT'
p36537
(lp36538
S'Clinical Trial'
p36539
aS'Comparative Study'
p36540
aS'Journal Article'
p36541
aS'Multicenter Study'
p36542
asS'LA'
p36543
(lp36544
S'eng'
p36545
asS'FAU'
p36546
(lp36547
S'Bock, Peter'
p36548
aS'Fatti, Geoffrey'
p36549
aS'Grimwood, Ashraf'
p36550
asS'LR'
p36551
S'20160511'
p36552
sS'PG'
p36553
S'132-8'
p36554
sS'TI'
p36555
S'Comparing the effectiveness of efavirenz and nevirapine for first-line antiretroviral therapy in a South African multicentre cohort.'
p36556
sS'RN'
p36557
(lp36558
S'0 (Anti-HIV Agents)'
p36559
aS'0 (Benzoxazines)'
p36560
aS'0 (Reverse Transcriptase Inhibitors)'
p36561
aS'99DK7FVK1H (Nevirapine)'
p36562
aS'JE6H2O27P8 (efavirenz)'
p36563
asS'PL'
p36564
S'England'
p36565
sS'TA'
p36566
S'Int Health'
p36567
sS'JID'
p36568
S'101517095'
p36569
sS'AB'
p36570
S'INTRODUCTION: Current WHO guidelines for developing countries recommend efavirenz (EFV) and nevirapine (NVP) for first-line antiretroviral treatment (ART). This paper compares the effectiveness of EFV and NVP among ART-naive patients initiating treatment at 56 public health facilities in South Africa between January 2004 and December 2007. METHODS: Participants were assigned to the EFV or NVP cohorts depending on their baseline ART regimen. Mortality, viral load suppression after 6 months and ART regimen change were compared between the cohorts using Cox proportional hazards models and logistic regression. RESULTS: At initiation, 19 441 (71.1%) patients started EFV and 7909 (28.9%) started NVP treatment. The median follow-up period was 9.5 months (IQR 4.6-17.7). After adjustment, mortality was similar in the two cohorts, (adjusted HR = 1.07, 95% CI 0.89-1.28). Viral load suppression at 6 months was higher in the EFV cohort overall (adjusted odds ratio [AOR] = 1.29, 95% CI 1.05-1.59) and in women aged 16-40 years (AOR = 1.35, 95% CI 1.11-1.63) and women with CD4 counts <25 cells/microL (AOR = 1.95, 95% CI 1.01-3.76). Patients starting on EFV were 47% less likely to change regimen (AOR = 0.53, 95% CI 0.48-0.59). DISCUSSION: These findings suggest the superior effectiveness of EFV for first-line ART compared with NVP and should be considered during development of future ART guidelines for high-burden regions.'
p36571
sS'AD'
p36572
S"Kheth'Impilo, Green Square, 37 Hares Crescent, Woodstock, 7925, Cape Town, South Africa."
p36573
sS'IP'
p36574
S'2'
sS'IS'
p36575
S'1876-3405 (Electronic) 1876-3405 (Linking)'
p36576
sS'DCOM'
p36577
S'20140826'
p36578
sS'AU'
p36579
(lp36580
S'Bock P'
p36581
aS'Fatti G'
p36582
aS'Grimwood A'
p36583
asS'VI'
p36584
S'5'
sS'MHDA'
p36585
S'2014/08/27 06:00'
p36586
sS'OTO'
p36587
(lp36588
S'NOTNLM'
p36589
asS'MH'
p36590
(lp36591
S'Adolescent'
p36592
aS'Adult'
p36593
aS'Anti-HIV Agents/pharmacology/*therapeutic use'
p36594
aS'Benzoxazines/adverse effects/pharmacology/*therapeutic use'
p36595
aS'*CD4 Lymphocyte Count'
p36596
aS'Cohort Studies'
p36597
aS'Female'
p36598
aS'HIV Infections/*drug therapy/mortality/virology'
p36599
aS'Humans'
p36600
aS'Male'
p36601
aS'Middle Aged'
p36602
aS'Nevirapine/pharmacology/*therapeutic use'
p36603
aS'Pregnancy'
p36604
aS'Proportional Hazards Models'
p36605
aS'Reverse Transcriptase Inhibitors/adverse effects/pharmacology/*therapeutic use'
p36606
aS'South Africa'
p36607
aS'Treatment Outcome'
p36608
aS'Viral Load/*drug effects'
p36609
aS'Young Adult'
p36610
asS'EDAT'
p36611
S'2013/09/14 06:00'
p36612
sS'SO'
p36613
S'Int Health. 2013 Jun;5(2):132-8. doi: 10.1093/inthealth/iht002.'
p36614
sS'SB'
p36615
S'IM'
p36616
sS'PMID'
p36617
S'24030113'
p36618
sS'OT'
p36619
(lp36620
S'AIDS'
p36621
aS'Antiretrovirals'
p36622
aS'Efavirenz'
p36623
aS'Guidelines'
p36624
aS'Nevirapine'
p36625
aS'Teratogencity'
p36626
asS'PST'
p36627
S'ppublish'
p36628
stRp36629
ag2
(g3
g4
(dp36630
S'LID'
p36631
S'10.3402/gha.v6i0.21682 [doi]'
p36632
sS'STAT'
p36633
S'MEDLINE'
p36634
sS'DEP'
p36635
S'20130912'
p36636
sS'DA'
p36637
S'20130913'
p36638
sS'AID'
p36639
(lp36640
S'21682 [pii]'
p36641
asS'CRDT'
p36642
(lp36643
S'2013/09/14 06:00'
p36644
asS'DP'
p36645
S'2013'
p36646
sS'OWN'
p36647
S'NLM'
p36648
sS'PT'
p36649
(lp36650
S'Journal Article'
p36651
asS'LA'
p36652
(lp36653
S'eng'
p36654
asS'DCOM'
p36655
S'20140131'
p36656
sS'JT'
p36657
S'Global health action'
p36658
sS'LR'
p36659
S'20150422'
p36660
sS'FAU'
p36661
(lp36662
S'Alvarez-Uria, Gerardo'
p36663
aS'Naik, Praveen K'
p36664
aS'Pakam, Raghavakalyan'
p36665
aS'Midde, Manoranjan'
p36666
asS'TI'
p36667
S'Factors associated with attrition, mortality, and loss to follow up after antiretroviral therapy initiation: data from an HIV cohort study in India.'
p36668
sS'RN'
p36669
(lp36670
S'0 (Anti-HIV Agents)'
p36671
asS'PL'
p36672
S'Sweden'
p36673
sS'PG'
p36674
S'21682'
p36675
sS'JID'
p36676
S'101496665'
p36677
sS'AB'
p36678
S'BACKGROUND: Studies from sub-Saharan Africa have shown high incidence of attrition due to mortality or loss to follow-up (LTFU) after initiating antiretroviral therapy (ART). India is the third largest country in the world in terms of HIV infected people, but predictors of attrition after ART initiation are not well known. DESIGN: We describe factors associated with attrition, mortality, and LTFU in 3,159 HIV infected patients who initiated ART between 1 January 2007 and 4 November 2011 in an HIV cohort study in India. The study included 6,852 person-years with a mean follow-up of 2.17 years. RESULTS: After 5 years of follow-up, the estimated cumulative incidence of attrition was 37.7%. There was no significant difference between attrition due to mortality and attrition due to LTFU. Having CD4 counts <100 cells/microl and being homeless [adjusted hazard ratio (aHR) 3.1, 95% confidence interval (CI) 2.6-3.8] were associated with a higher risk of attrition, and female gender (aHR 0.64, 95% CI 0.6-0.8) was associated with a reduced risk of attrition. Living near a town (aHR 0.82, 95% CI 0.7-0.999) was associated with a reduced risk of mortality. Being single (aHR 1.6, 95% CI 1.2-2.3), illiteracy (aHR 1.3, 95% CI 1.1-1.6), and age <25 years (aHR 1.3, 95% CI 1-1.8) were associated with an increased risk of LTFU. Although the cumulative incidence of attrition in patients diagnosed with tuberculosis after ART initiation was 47.4%, patients who started anti-tuberculous treatment before ART had similar attrition to patients without tuberculosis (36 vs. 35.2%, P=0.19) after four years of follow-up. CONCLUSIONS: In this cohort study, the attrition was similar to the one found in sub-Saharan Africa. Earlier initiation of ART, improving the diagnosis of tuberculosis before initiating ART, and giving more support to those patients at higher risk of attrition could potentially reduce the mortality and LTFU after ART initiation.'
p36679
sS'AD'
p36680
S'Department of Infectious Diseases, Rural Development Trust Hospital, Bathalapalli, India; gerardouria@gmail.com.'
p36681
sS'VI'
p36682
S'6'
sS'IS'
p36683
S'1654-9880 (Electronic) 1654-9880 (Linking)'
p36684
sS'PMC'
p36685
S'PMC3773168'
p36686
sS'AU'
p36687
(lp36688
S'Alvarez-Uria G'
p36689
aS'Naik PK'
p36690
aS'Pakam R'
p36691
aS'Midde M'
p36692
asS'MHDA'
p36693
S'2014/02/01 06:00'
p36694
sS'PHST'
p36695
(lp36696
S'2013/06/12 [received]'
p36697
aS'2013/08/22 [revised]'
p36698
aS'2013/08/23 [accepted]'
p36699
asS'OT'
p36700
(lp36701
S'attrition'
p36702
aS'developing countries'
p36703
aS'highly active antiretroviral therapy'
p36704
aS'lost to follow up'
p36705
aS'mortality'
p36706
aS'rural health'
p36707
asS'OTO'
p36708
(lp36709
S'NOTNLM'
p36710
asS'OID'
p36711
(lp36712
S'NLM: PMC3773168'
p36713
asS'MH'
p36714
(lp36715
S'Adult'
p36716
aS'Age Factors'
p36717
aS'Anti-HIV Agents/*therapeutic use'
p36718
aS'CD4 Lymphocyte Count/statistics & numerical data'
p36719
aS'Cohort Studies'
p36720
aS'Female'
p36721
aS'HIV Infections/*drug therapy/epidemiology/mortality'
p36722
aS'Humans'
p36723
aS'India/epidemiology'
p36724
aS'*Lost to Follow-Up'
p36725
aS'Male'
p36726
aS'Medication Adherence/statistics & numerical data'
p36727
aS'Middle Aged'
p36728
aS'Prevalence'
p36729
aS'Proportional Hazards Models'
p36730
aS'Risk Factors'
p36731
aS'Sex Factors'
p36732
aS'Young Adult'
p36733
asS'EDAT'
p36734
S'2013/09/14 06:00'
p36735
sS'SO'
p36736
S'Glob Health Action. 2013 Sep 12;6:21682. doi: 10.3402/gha.v6i0.21682.'
p36737
sS'SB'
p36738
S'IM'
p36739
sS'PMID'
p36740
S'24028937'
p36741
sS'TA'
p36742
S'Glob Health Action'
p36743
sS'PST'
p36744
S'epublish'
p36745
stRp36746
ag2
(g3
g4
(dp36747
S'LID'
p36748
S'10.5588/ijtld.12.0861 [doi]'
p36749
sS'STAT'
p36750
S'MEDLINE'
p36751
sS'JT'
p36752
S'The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease'
p36753
sS'MID'
p36754
(lp36755
S'NIHMS612899'
p36756
asS'DA'
p36757
S'20130912'
p36758
sS'AID'
p36759
(lp36760
S'10.5588/ijtld.12.0861 [doi]'
p36761
asS'CRDT'
p36762
(lp36763
S'2013/09/13 06:00'
p36764
asS'DP'
p36765
S'2013 Oct'
p36766
sS'AD'
p36767
S'New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, USA.'
p36768
sS'OWN'
p36769
S'NLM'
p36770
sS'PT'
p36771
(lp36772
S'Comparative Study'
p36773
aS'Journal Article'
p36774
aS"Research Support, Non-U.S. Gov't"
p36775
asS'LA'
p36776
(lp36777
S'eng'
p36778
asS'FAU'
p36779
(lp36780
S'Schwartz, A B'
p36781
aS'Tamuhla, N'
p36782
aS'Steenhoff, A P'
p36783
aS'Nkakana, K'
p36784
aS'Letlhogile, R'
p36785
aS'Chadborn, T R'
p36786
aS'Kestler, M'
p36787
aS'Zetola, N M'
p36788
aS'Ravimohan, S'
p36789
aS'Bisson, G P'
p36790
asS'LR'
p36791
S'20150422'
p36792
sS'PG'
p36793
S'1298-303'
p36794
sS'TI'
p36795
S'Outcomes in HIV-infected adults with tuberculosis at clinics with and without co-located HIV clinics in Botswana.'
p36796
sS'RN'
p36797
(lp36798
S'0 (Anti-HIV Agents)'
p36799
aS'0 (Antitubercular Agents)'
p36800
asS'PL'
p36801
S'France'
p36802
sS'TA'
p36803
S'Int J Tuberc Lung Dis'
p36804
sS'JID'
p36805
S'9706389'
p36806
sS'AB'
p36807
S'SETTING: Gaborone, Botswana. OBJECTIVE: To determine if starting anti-tuberculosis treatment at clinics in Gaborone without co-located human immunodeficiency virus (HIV) clinics would delay time to highly active antiretroviral therapy (HAART) initiation and be associated with lower survival compared to starting anti-tuberculosis treatment at clinics with on-site HIV clinics. DESIGN: Retrospective cohort study. Subjects were HAART-naive, aged >/= 21 years with pulmonary tuberculosis (TB), HIV and CD4 counts </= 250 cells/mm(3) initiating anti-tuberculosis treatment between 2005 and 2010. Survival at completion of anti-tuberculosis treatment or at 6 months post-treatment initiation and time to HAART after anti-tuberculosis treatment initiation were compared by clinic type. RESULTS: Respectively 259 and 80 patients from clinics without and with on-site HIV facilities qualified for the study. Age, sex, CD4, baseline sputum smears and loss to follow-up rate were similar by clinic type. Mortality did not differ between clinics without or with on-site HIV clinics (20/250, 8.0% vs. 8/79, 10.1%, relative risk 0.79, 95%CI 0.36-1.72), nor did median time to HAART initiation (respectively 63 and 66 days, P = 0.53). CONCLUSION: In urban areas where TB and HIV programs are separate, geographic co-location alone without further integration may not reduce mortality or time to HAART initiation among co-infected patients.'
p36808
sS'GR'
p36809
(lp36810
S'R01 AI097045/AI/NIAID NIH HHS/United States'
p36811
asS'IP'
p36812
S'10'
p36813
sS'IS'
p36814
S'1815-7920 (Electronic) 1027-3719 (Linking)'
p36815
sS'PMC'
p36816
S'PMC4104161'
p36817
sS'DCOM'
p36818
S'20140506'
p36819
sS'AU'
p36820
(lp36821
S'Schwartz AB'
p36822
aS'Tamuhla N'
p36823
aS'Steenhoff AP'
p36824
aS'Nkakana K'
p36825
aS'Letlhogile R'
p36826
aS'Chadborn TR'
p36827
aS'Kestler M'
p36828
aS'Zetola NM'
p36829
aS'Ravimohan S'
p36830
aS'Bisson GP'
p36831
asS'VI'
p36832
S'17'
p36833
sS'MHDA'
p36834
S'2014/05/07 06:00'
p36835
sS'OID'
p36836
(lp36837
S'NLM: NIHMS612899'
p36838
aS'NLM: PMC4104161'
p36839
asS'MH'
p36840
(lp36841
S'Adult'
p36842
aS'Ambulatory Care Facilities/organization & administration'
p36843
aS'Anti-HIV Agents/administration & dosage/*therapeutic use'
p36844
aS'Antiretroviral Therapy, Highly Active/methods'
p36845
aS'Antitubercular Agents/administration & dosage/*therapeutic use'
p36846
aS'Botswana/epidemiology'
p36847
aS'Cohort Studies'
p36848
aS'Female'
p36849
aS'Follow-Up Studies'
p36850
aS'HIV Infections/*drug therapy/epidemiology/mortality'
p36851
aS'Humans'
p36852
aS'Male'
p36853
aS'Middle Aged'
p36854
aS'Retrospective Studies'
p36855
aS'Survival Rate'
p36856
aS'Time Factors'
p36857
aS'Treatment Outcome'
p36858
aS'Tuberculosis/*drug therapy/epidemiology/mortality'
p36859
aS'Urban Health Services/organization & administration'
p36860
aS'Young Adult'
p36861
asS'EDAT'
p36862
S'2013/09/13 06:00'
p36863
sS'SO'
p36864
S'Int J Tuberc Lung Dis. 2013 Oct;17(10):1298-303. doi: 10.5588/ijtld.12.0861.'
p36865
sS'SB'
p36866
S'IM'
p36867
sS'PMID'
p36868
S'24025381'
p36869
sS'PST'
p36870
S'ppublish'
p36871
stRp36872
ag2
(g3
g4
(dp36873
S'LID'
p36874
S'10.1371/journal.pone.0072444 [doi]'
p36875
sS'STAT'
p36876
S'MEDLINE'
p36877
sS'DEP'
p36878
S'20130828'
p36879
sS'DA'
p36880
S'20130909'
p36881
sS'AID'
p36882
(lp36883
S'10.1371/journal.pone.0072444 [doi]'
p36884
aS'PONE-D-13-23050 [pii]'
p36885
asS'CRDT'
p36886
(lp36887
S'2013/09/10 06:00'
p36888
asS'DP'
p36889
S'2013'
p36890
sS'AD'
p36891
S'Center for Global Health and Development, Boston University, Boston, Massachusetts, United States of America ; Zambia Center for Applied Health Research and Development, Lusaka, Zambia.'
p36892
sS'OWN'
p36893
S'NLM'
p36894
sS'PT'
p36895
(lp36896
S'Journal Article'
p36897
aS"Research Support, U.S. Gov't, Non-P.H.S."
p36898
aS"Research Support, U.S. Gov't, P.H.S."
p36899
asS'LA'
p36900
(lp36901
S'eng'
p36902
asS'FAU'
p36903
(lp36904
S'Scott, Callie A'
p36905
aS'Iyer, Hari S'
p36906
aS'Lembela Bwalya, Deophine'
p36907
aS'Bweupe, Maximillian'
p36908
aS'Rosen, Sydney B'
p36909
aS'Scott, Nancy'
p36910
aS'Larson, Bruce A'
p36911
asS'JT'
p36912
S'PloS one'
p36913
sS'LR'
p36914
S'20150422'
p36915
sS'PG'
p36916
S'e72444'
p36917
sS'TI'
p36918
S'Uptake, outcomes, and costs of antenatal, well-baby, and prevention of mother-to-child transmission of HIV services under routine care conditions in Zambia.'
p36919
sS'RN'
p36920
(lp36921
S'0 (Anti-HIV Agents)'
p36922
asS'PL'
p36923
S'United States'
p36924
sS'TA'
p36925
S'PLoS One'
p36926
sS'JID'
p36927
S'101285081'
p36928
sS'AB'
p36929
S"BACKGROUND: Zambia adopted Option A for prevention of mother-to-child transmission of HIV (PMTCT) in 2010 and announced a move to Option B+ in 2013. We evaluated the uptake, outcomes, and costs of antenatal, well-baby, and PMTCT services under routine care conditions in Zambia after the adoption of Option A. METHODS: We enrolled 99 HIV-infected/HIV-exposed (index) mother/baby pairs with a first antenatal visit in April-September 2011 at four study sites and 99 HIV-uninfected/HIV-unexposed (comparison) mother/baby pairs matched on site, gestational age, and calendar month at first visit. Data on patient outcomes and resources utilized from the first antenatal visit through six months postpartum were extracted from site registers. Costs in 2011 USD were estimated from the provider's perspective. RESULTS: Index mothers presented for antenatal care at a mean 23.6 weeks gestation; 55% were considered to have initiated triple-drug antiretroviral therapy (ART) based on information recorded in site registers. Six months postpartum, 62% of index and 30% of comparison mother/baby pairs were retained in care; 67% of index babies retained had an unknown HIV status. Comparison and index mother/baby pairs utilized fewer resources than under fully guideline-concordant care; index babies utilized more well-baby resources than comparison babies. The average cost per comparison pair retained in care six months postpartum was $52 for antenatal and well-baby services. The average cost per index pair retained was $88 for antenatal, well-baby, and PMTCT services and increased to $185 when costs of triple-drug ART services were included. CONCLUSIONS: HIV-infected mothers present to care late in pregnancy and many are lost to follow up by six months postpartum. HIV-exposed babies are more likely to remain in care and receive non-HIV, well-baby care than HIV-unexposed babies. Improving retention in care, guideline concordance, and moving to Option B+ will result in increased service delivery costs in the short term."
p36930
sS'GR'
p36931
(lp36932
S'5U2GPS001418-00/PHS HHS/United States'
p36933
aS'PEPFAR/United States'
p36934
asS'IP'
p36935
S'8'
sS'IS'
p36936
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p36937
sS'PMC'
p36938
S'PMC3756060'
p36939
sS'DCOM'
p36940
S'20140522'
p36941
sS'AU'
p36942
(lp36943
S'Scott CA'
p36944
aS'Iyer HS'
p36945
aS'Lembela Bwalya D'
p36946
aS'Bweupe M'
p36947
aS'Rosen SB'
p36948
aS'Scott N'
p36949
aS'Larson BA'
p36950
asS'VI'
p36951
S'8'
sS'MHDA'
p36952
S'2014/05/23 06:00'
p36953
sS'PHST'
p36954
(lp36955
S'2013 [ecollection]'
p36956
aS'2013/06/03 [received]'
p36957
aS'2013/07/05 [accepted]'
p36958
aS'2013/08/28 [epublish]'
p36959
asS'OID'
p36960
(lp36961
S'NLM: PMC3756060'
p36962
asS'MH'
p36963
(lp36964
S'Adult'
p36965
aS'Anti-HIV Agents/economics/therapeutic use'
p36966
aS'Case-Control Studies'
p36967
aS'Communicable Disease Control/economics'
p36968
aS'Drug Therapy, Combination'
p36969
aS'Female'
p36970
aS'HIV Infections/drug therapy/*prevention & control/transmission'
p36971
aS'Health Resources/economics/utilization'
p36972
aS'Humans'
p36973
aS'Infant'
p36974
aS'Infectious Disease Transmission, Vertical/economics/*prevention & control'
p36975
aS'Patient Acceptance of Health Care'
p36976
aS'Postnatal Care/*economics/utilization'
p36977
aS'Pregnancy'
p36978
aS'Prenatal Care/economics'
p36979
aS'Treatment Outcome'
p36980
aS'Young Adult'
p36981
aS'Zambia'
p36982
asS'EDAT'
p36983
S'2013/09/10 06:00'
p36984
sS'SO'
p36985
S'PLoS One. 2013 Aug 28;8(8):e72444. doi: 10.1371/journal.pone.0072444. eCollection 2013.'
p36986
sS'SB'
p36987
S'IM'
p36988
sS'PMID'
p36989
S'24015245'
p36990
sS'PST'
p36991
S'epublish'
p36992
stRp36993
ag2
(g3
g4
(dp36994
S'LID'
p36995
S'10.1371/journal.pone.0072152 [doi]'
p36996
sS'STAT'
p36997
S'MEDLINE'
p36998
sS'DEP'
p36999
S'20130821'
p37000
sS'DA'
p37001
S'20130830'
p37002
sS'AID'
p37003
(lp37004
S'10.1371/journal.pone.0072152 [doi]'
p37005
aS'PONE-D-13-13545 [pii]'
p37006
asS'CRDT'
p37007
(lp37008
S'2013/08/31 06:00'
p37009
asS'DP'
p37010
S'2013'
p37011
sS'GR'
p37012
(lp37013
S'082384/Z/07/Z/PHS HHS/United States'
p37014
aS'090999/Wellcome Trust/United Kingdom'
p37015
aS'097410/Wellcome Trust/United Kingdom'
p37016
aS'100714/Wellcome Trust/United Kingdom'
p37017
asS'OWN'
p37018
S'NLM'
p37019
sS'PT'
p37020
(lp37021
S'Journal Article'
p37022
aS'Research Support, N.I.H., Extramural'
p37023
asS'LA'
p37024
(lp37025
S'eng'
p37026
asS'FAU'
p37027
(lp37028
S'Manasa, Justen'
p37029
aS'Lessells, Richard J'
p37030
aS'Skingsley, Andrew'
p37031
aS'Naidu, Kevindra K'
p37032
aS'Newell, Marie-Louise'
p37033
aS'McGrath, Nuala'
p37034
aS'de Oliveira, Tulio'
p37035
asS'JT'
p37036
S'PloS one'
p37037
sS'LR'
p37038
S'20160713'
p37039
sS'PG'
p37040
S'e72152'
p37041
sS'TI'
p37042
S'High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa.'
p37043
sS'RN'
p37044
(lp37045
S'0 (Anti-HIV Agents)'
p37046
aS'0 (Benzoxazines)'
p37047
aS'2T8Q726O95 (Lamivudine)'
p37048
aS'4B9XT59T7S (Zidovudine)'
p37049
aS'99DK7FVK1H (Nevirapine)'
p37050
aS'BO9LE4QFZF (Stavudine)'
p37051
aS'JE6H2O27P8 (efavirenz)'
p37052
asS'PL'
p37053
S'United States'
p37054
sS'TA'
p37055
S'PLoS One'
p37056
sS'JID'
p37057
S'101285081'
p37058
sS'AB'
p37059
S'OBJECTIVE: To determine the frequency and patterns of acquired antiretroviral drug resistance in a rural primary health care programme in South Africa. DESIGN: Cross-sectional study nested within HIV treatment programme. METHODS: Adult (>/= 18 years) HIV-infected individuals initially treated with a first-line stavudine- or zidovudine-based antiretroviral therapy (ART) regimen and with evidence of virological failure (one viral load >1000 copies/ml) were enrolled from 17 rural primary health care clinics. Genotypic resistance testing was performed using the in-house SATuRN/Life Technologies system. Sequences were analysed and genotypic susceptibility scores (GSS) for standard second-line regimens were calculated using the Stanford HIVDB 6.0.5 algorithms. RESULTS: A total of 222 adults were successfully genotyped for HIV drug resistance between December 2010 and March 2012. The most common regimens at time of genotype were stavudine, lamivudine and efavirenz (51%); and stavudine, lamivudine and nevirapine (24%). Median duration of ART was 42 months (interquartile range (IQR) 32-53) and median duration of antiretroviral failure was 27 months (IQR 17-40). One hundred and ninety one (86%) had at least one drug resistance mutation. For 34 individuals (15%), the GSS for the standard second-line regimen was <2, suggesting a significantly compromised regimen. In univariate analysis, individuals with a prior nucleoside reverse-transcriptase inhibitor (NRTI) substitution were more likely to have a GSS <2 than those on the same NRTIs throughout (odds ratio (OR) 5.70, 95% confidence interval (CI) 2.60-12.49). CONCLUSIONS: There are high levels of drug resistance in adults with failure of first-line antiretroviral therapy in this rural primary health care programme. Standard second-line regimens could potentially have had reduced efficacy in about one in seven adults involved.'
p37060
sS'AD'
p37061
S'Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Somkhele, South Africa.'
p37062
sS'CN'
p37063
(lp37064
S'Southern African Treatment and Resistance Network'
p37065
asS'IP'
p37066
S'8'
sS'IS'
p37067
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p37068
sS'PMC'
p37069
S'PMC3749184'
p37070
sS'DCOM'
p37071
S'20140421'
p37072
sS'AU'
p37073
(lp37074
S'Manasa J'
p37075
aS'Lessells RJ'
p37076
aS'Skingsley A'
p37077
aS'Naidu KK'
p37078
aS'Newell ML'
p37079
aS'McGrath N'
p37080
aS'de Oliveira T'
p37081
asS'VI'
p37082
S'8'
sS'MHDA'
p37083
S'2014/04/22 06:00'
p37084
sS'PHST'
p37085
(lp37086
S'2013 [ecollection]'
p37087
aS'2013/04/02 [received]'
p37088
aS'2013/07/05 [accepted]'
p37089
aS'2013/08/21 [epublish]'
p37090
asS'OID'
p37091
(lp37092
S'NLM: PMC3749184'
p37093
asS'MH'
p37094
(lp37095
S'Adolescent'
p37096
aS'Adult'
p37097
aS'Analysis of Variance'
p37098
aS'Anti-HIV Agents/pharmacology/*therapeutic use'
p37099
aS'Benzoxazines/pharmacology/therapeutic use'
p37100
aS'Cross-Sectional Studies'
p37101
aS'Drug Resistance, Viral/*drug effects/genetics'
p37102
aS'Drug Therapy, Combination'
p37103
aS'Female'
p37104
aS'Genotype'
p37105
aS'HIV Infections/*drug therapy/epidemiology/virology'
p37106
aS'HIV-1/*drug effects/genetics'
p37107
aS'Humans'
p37108
aS'Lamivudine/pharmacology/therapeutic use'
p37109
aS'Male'
p37110
aS'Middle Aged'
p37111
aS'Mutation'
p37112
aS'Nevirapine/pharmacology/therapeutic use'
p37113
aS'Outcome Assessment (Health Care)'
p37114
aS'Prevalence'
p37115
aS'South Africa/epidemiology'
p37116
aS'Stavudine/pharmacology/therapeutic use'
p37117
aS'Young Adult'
p37118
aS'Zidovudine/pharmacology/therapeutic use'
p37119
asS'EDAT'
p37120
S'2013/08/31 06:00'
p37121
sS'SO'
p37122
S'PLoS One. 2013 Aug 21;8(8):e72152. doi: 10.1371/journal.pone.0072152. eCollection 2013.'
p37123
sS'SB'
p37124
S'IM'
p37125
sS'PMID'
p37126
S'23991055'
p37127
sS'PST'
p37128
S'epublish'
p37129
stRp37130
ag2
(g3
g4
(dp37131
S'STAT'
p37132
S'MEDLINE'
p37133
sS'AB'
p37134
S'OBJECTIVE: Hepatitis B virus (HBV) and HIV are endemic infections in many African countries. The objectives of this study were to determine the levels of exposure to, and protection from, HBV, as well as the prevalence of HIV/HBV co-infection and the response of HBV to highly active anti-retroviral therapy (HAART) in a cross-section of HIV-infected patients in north-eastern South Africa. STUDY DESIGN: This was a laboratory-based, unmatched study. Three hundred and eighty patients were screened by ELISA for HBsAg, anti-HBc and anti-HBs. Samples non-reactive for HBsAg but reactive for anti-HBc were examined for occult HBV infection. Response to HAART was assessed by measuring HBV viral loads, seroconversion from HBeAg to anti-HBe, and levels of aminotransferase. RESULTS: Of the study population of 380, 60% (95% CI 54.8 - 64.9) were exposed to HBV based on HBsAg, anti-HBs or anti-HBc; 20% (95% CI 16.1 - 24.4) had active HBV infection, based on HBsAg serology, and 30% (95% CI 25.2 - 35.2) were protected, based on anti-HBs levels > or = 10 IU/l. Of 181 HBsAg-negative individuals, 61 had HBV occult infection (33.7%, 95% CI 26.9 - 41.1). The differences in prevalence were not statistically significant when gender, marital status and CD4+ cell counts were considered. Of 21 patients analysed, 80% showed adequate response to the first-line HAART regimen (stavudine/lamivudine/efavirenz or nevirapine) after 12 months of use. CONCLUSION: The study confirms the higher level (60%) of exposure to HBV in HIV patients in Limpopo Province, as well as the high (20%) prevalence of HBsAg positivity and occult hepatitis B (33.7%). However, further studies are warranted to corroborate the benefit of lamivudine-containing HAART regimens, as HIV/HBV co-infected patients have a higher liver-related mortality if hepatitis B is not treated.'
p37135
sS'JID'
p37136
S'0404520'
p37137
sS'AD'
p37138
S'Division of Community Health, Faculty of Health Sciences, Stellenbosch University, Stellenbosch, South Africa.'
p37139
sS'JT'
p37140
S'South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde'
p37141
sS'IP'
p37142
S'5'
sS'IS'
p37143
S'0256-9574 (Print)'
p37144
sS'DCOM'
p37145
S'20130919'
p37146
sS'DA'
p37147
S'20130823'
p37148
sS'AU'
p37149
(lp37150
S'Ayuk J'
p37151
aS'Mphahlele J'
p37152
aS'Bessong P'
p37153
asS'SB'
p37154
S'IM'
p37155
sS'CRDT'
p37156
(lp37157
S'2013/08/24 06:00'
p37158
asS'VI'
p37159
S'103'
p37160
sS'DP'
p37161
S'2013 May'
p37162
sS'MHDA'
p37163
S'2013/09/21 06:00'
p37164
sS'OWN'
p37165
S'NLM'
p37166
sS'PT'
p37167
(lp37168
S'Journal Article'
p37169
aS"Research Support, Non-U.S. Gov't"
p37170
asS'LA'
p37171
(lp37172
S'eng'
p37173
asS'MH'
p37174
(lp37175
S'Adult'
p37176
aS'*Antiretroviral Therapy, Highly Active'
p37177
aS'Cross-Sectional Studies'
p37178
aS'Enzyme-Linked Immunosorbent Assay'
p37179
aS'Female'
p37180
aS'HIV Infections/*complications/*drug therapy/epidemiology'
p37181
aS'Hepatitis B/*complications/epidemiology'
p37182
aS'Humans'
p37183
aS'Male'
p37184
aS'Prevalence'
p37185
aS'South Africa/epidemiology'
p37186
aS'Treatment Outcome'
p37187
asS'FAU'
p37188
(lp37189
S'Ayuk, J'
p37190
aS'Mphahlele, J'
p37191
aS'Bessong, P'
p37192
asS'EDAT'
p37193
S'2013/08/24 06:00'
p37194
sS'PST'
p37195
S'ppublish'
p37196
sS'LR'
p37197
S'20140912'
p37198
sS'PG'
p37199
S'330-3'
p37200
sS'TI'
p37201
S'Hepatitis B virus in HIV-infected patients in northeastern South Africa: prevalence, exposure, protection and response to HAART.'
p37202
sS'SO'
p37203
S'S Afr Med J. 2013 May;103(5):330-3.'
p37204
sS'PMID'
p37205
S'23971125'
p37206
sS'PL'
p37207
S'South Africa'
p37208
sS'TA'
p37209
S'S Afr Med J'
p37210
stRp37211
ag2
(g3
g4
(dp37212
S'LID'
p37213
S'10.1177/0956462413497702 [doi]'
p37214
sS'STAT'
p37215
S'MEDLINE'
p37216
sS'DEP'
p37217
S'20130719'
p37218
sS'MID'
p37219
(lp37220
S'NIHMS571802'
p37221
asS'DA'
p37222
S'20140217'
p37223
sS'AID'
p37224
(lp37225
S'0956462413497702 [pii]'
p37226
aS'10.1177/0956462413497702 [doi]'
p37227
asS'CRDT'
p37228
(lp37229
S'2013/08/24 06:00'
p37230
asS'DP'
p37231
S'2014 Mar'
p37232
sS'AD'
p37233
S'Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, USA.'
p37234
sS'OWN'
p37235
S'NLM'
p37236
sS'PT'
p37237
(lp37238
S'Journal Article'
p37239
aS'Research Support, N.I.H., Extramural'
p37240
aS"Research Support, Non-U.S. Gov't"
p37241
asS'LA'
p37242
(lp37243
S'eng'
p37244
asS'FAU'
p37245
(lp37246
S'Drain, Paul K'
p37247
aS'Mosam, Anisa'
p37248
aS'Gounder, Lilishia'
p37249
aS'Gosnell, Bernadett'
p37250
aS'Manzini, Thandekile'
p37251
aS'Moosa, Mahomed-Yunus S'
p37252
asS'JT'
p37253
S'International journal of STD & AIDS'
p37254
sS'LR'
p37255
S'20150423'
p37256
sS'PG'
p37257
S'235-8'
p37258
sS'TI'
p37259
S'Recurrent giant molluscum contagiosum immune reconstitution inflammatory syndrome (IRIS) after initiation of antiretroviral therapy in an HIV-infected man.'
p37260
sS'PL'
p37261
S'England'
p37262
sS'TA'
p37263
S'Int J STD AIDS'
p37264
sS'JID'
p37265
S'9007917'
p37266
sS'AB'
p37267
S'We describe an HIV-infected South African man who experienced two distinct episodes of disseminated giant molluscum contagiosum immune reconstitution inflammatory syndrome (IRIS) over a six-year period. The first episode of molluscum contagiosum IRIS occurred with rapid virologic suppression following antiretroviral therapy initiation. The second episode occurred during a rapid increase in CD4 cells following stable viral suppression with second-line antiretroviral therapy. His molluscum contagiosum lesions then completely resolved during a reduction in CD4 count, despite maintaining virologic suppression. Nearly one year after the resolution of his giant molluscum contagiosum IRIS lesions, he maintains an undetectable viral load, but his level of immune deficiency has not improved. In the absence of well-controlled therapeutic trials, molluscum contagiosum IRIS presents important management challenges.'
p37268
sS'GR'
p37269
(lp37270
S'R24 TW007988/TW/FIC NIH HHS/United States'
p37271
aS'R24 TW007988/TW/FIC NIH HHS/United States'
p37272
aS'T32 AI007433/AI/NIAID NIH HHS/United States'
p37273
aS'T32 AI007433/AI/NIAID NIH HHS/United States'
p37274
asS'IP'
p37275
S'3'
sS'IS'
p37276
S'1758-1052 (Electronic) 0956-4624 (Linking)'
p37277
sS'PMC'
p37278
S'PMC4000481'
p37279
sS'DCOM'
p37280
S'20140421'
p37281
sS'AU'
p37282
(lp37283
S'Drain PK'
p37284
aS'Mosam A'
p37285
aS'Gounder L'
p37286
aS'Gosnell B'
p37287
aS'Manzini T'
p37288
aS'Moosa MY'
p37289
asS'VI'
p37290
S'25'
p37291
sS'MHDA'
p37292
S'2014/04/22 06:00'
p37293
sS'PHST'
p37294
(lp37295
S'2013/07/19 [aheadofprint]'
p37296
asS'OTO'
p37297
(lp37298
S'NOTNLM'
p37299
asS'OID'
p37300
(lp37301
S'NLM: NIHMS571802'
p37302
aS'NLM: PMC4000481'
p37303
asS'MH'
p37304
(lp37305
S'AIDS-Related Opportunistic Infections/complications/virology'
p37306
aS'Adult'
p37307
aS'Antiretroviral Therapy, Highly Active/*adverse effects'
p37308
aS'CD4-Positive T-Lymphocytes'
p37309
aS'HIV Infections/*drug therapy/immunology/virology'
p37310
aS'Humans'
p37311
aS'Immune Reconstitution Inflammatory Syndrome/*chemically induced'
p37312
aS'Immunocompromised Host'
p37313
aS'Male'
p37314
aS'Molluscum Contagiosum/chemically induced/*immunology/virology'
p37315
aS'Recurrence'
p37316
aS'South Africa'
p37317
aS'Treatment Outcome'
p37318
aS'Viral Load/drug effects'
p37319
asS'EDAT'
p37320
S'2013/08/24 06:00'
p37321
sS'SO'
p37322
S'Int J STD AIDS. 2014 Mar;25(3):235-8. doi: 10.1177/0956462413497702. Epub 2013 Jul 19.'
p37323
sS'SB'
p37324
S'IM X'
p37325
sS'PMID'
p37326
S'23970647'
p37327
sS'OT'
p37328
(lp37329
S'HIV/AIDS'
p37330
aS'IRIS'
p37331
aS'Molluscum contagiosum'
p37332
aS'South Africa'
p37333
aS'antiretroviral therapy'
p37334
aS'immune reconstitution inflammatory syndrome'
p37335
asS'PST'
p37336
S'ppublish'
p37337
stRp37338
ag2
(g3
g4
(dp37339
S'LID'
p37340
S'10.1371/journal.pone.0071719 [doi]'
p37341
sS'STAT'
p37342
S'MEDLINE'
p37343
sS'DEP'
p37344
S'20130807'
p37345
sS'DA'
p37346
S'20130813'
p37347
sS'AID'
p37348
(lp37349
S'10.1371/journal.pone.0071719 [doi]'
p37350
aS'PONE-D-13-23030 [pii]'
p37351
asS'CRDT'
p37352
(lp37353
S'2013/08/14 06:00'
p37354
asS'DP'
p37355
S'2013'
p37356
sS'AD'
p37357
S'Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. kshearer@heroza.org'
p37358
sS'OWN'
p37359
S'NLM'
p37360
sS'PT'
p37361
(lp37362
S'Journal Article'
p37363
aS'Research Support, N.I.H., Extramural'
p37364
aS"Research Support, Non-U.S. Gov't"
p37365
asS'LA'
p37366
(lp37367
S'eng'
p37368
asS'FAU'
p37369
(lp37370
S'Shearer, Kate'
p37371
aS'Fox, Matthew P'
p37372
aS'Maskew, Mhairi'
p37373
aS'Berhanu, Rebecca'
p37374
aS'Long, Lawrence'
p37375
aS'Sanne, Ian'
p37376
asS'JT'
p37377
S'PloS one'
p37378
sS'LR'
p37379
S'20151119'
p37380
sS'PG'
p37381
S'e71719'
p37382
sS'TI'
p37383
S'The impact of choice of NNRTI on short-term treatment outcomes among HIV-infected patients prescribed tenofovir and lamivudine in Johannesburg, South Africa.'
p37384
sS'RN'
p37385
(lp37386
S'0 (Anti-HIV Agents)'
p37387
aS'0 (Organophosphonates)'
p37388
aS'0 (Reverse Transcriptase Inhibitors)'
p37389
aS'2T8Q726O95 (Lamivudine)'
p37390
aS'99YXE507IL (Tenofovir)'
p37391
aS'JAC85A2161 (Adenine)'
p37392
asS'PL'
p37393
S'United States'
p37394
sS'TA'
p37395
S'PLoS One'
p37396
sS'JID'
p37397
S'101285081'
p37398
sS'AB'
p37399
S"INTRODUCTION: Recent WHO guidelines for resource-limited settings recommend tenofovir in first-line antiretroviral therapy (ART) yet there are suggestions that patients receiving nevirapine with tenofovir have worse outcomes than those receiving efavirenz. We sought to compare outcomes among those taking nevirapine vs. efavirenz with tenofovir and lamivudine. METHODS: We analyzed data on ART naive, non-pregnant patients, >/= 18 years old without tuberculosis co-infection, initiating tenofovir with lamivudine and either nevirapine or efavirenz between April 1, 2010 and July 31, 2011 (when South Africa's public-sector use of tenofovir began) at Themba Lethu Clinic in South Africa. We measured virologic suppression (viral load <400 copies/ml), virologic failure (2 consecutive viral loads >1000 copies/ml), and attrition (death/loss to follow-up) all at 12 months after ART initiation. Modified Poisson regression with robust error estimation was used to estimate risk ratios (RR) and 95% confidence intervals (CI) for predictors of each outcome. RESULTS: 2,254 patients were prescribed efavirenz, 131 nevirapine. Patients were followed a median (range) of 12.0 (0.1-12.0) person-months. 62.2% were female and median (IQR) age was 37.7 years (31.5-44.1). Patients prescribed efavirenz had similar initiating CD4 counts (median 132 for both regimens) but were somewhat more likely to be WHO Stage III or IV (39.6% vs. 33.6%) than those prescribed nevirapine. No difference in attrition was found (aRR: 0.83; 95% CI: 0.49-1.41). Among patients with >/= 1 viral load within 1 year on ART, those prescribed nevirapine were as likely to reach virologic suppression (aRR: 0.97; 95% CI: 0.88-1.07) but more likely to experience virologic failure (aRR: 1.84; 95% CI: 1.02-3.31) than those prescribed efavirenz. CONCLUSIONS: Our results support the notion that, among patients prescribed tenofovir and lamivudine, virologic failure is more common among those taking nevirapine than among those taking efavirenz. Longer-term follow up and larger studies will be needed to confirm this finding."
p37400
sS'GR'
p37401
(lp37402
S'K01AI083097/AI/NIAID NIH HHS/United States'
p37403
asS'IP'
p37404
S'8'
sS'IS'
p37405
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p37406
sS'PMC'
p37407
S'PMC3737125'
p37408
sS'DCOM'
p37409
S'20140303'
p37410
sS'AU'
p37411
(lp37412
S'Shearer K'
p37413
aS'Fox MP'
p37414
aS'Maskew M'
p37415
aS'Berhanu R'
p37416
aS'Long L'
p37417
aS'Sanne I'
p37418
asS'VI'
p37419
S'8'
sS'MHDA'
p37420
S'2014/03/04 06:00'
p37421
sS'PHST'
p37422
(lp37423
S'2013 [ppublish]'
p37424
aS'2013/06/04 [received]'
p37425
aS'2013/07/09 [accepted]'
p37426
aS'2013/08/07 [epublish]'
p37427
asS'OID'
p37428
(lp37429
S'NLM: PMC3737125'
p37430
asS'MH'
p37431
(lp37432
S'Adenine/administration & dosage/*analogs & derivatives'
p37433
aS'Adult'
p37434
aS'Anti-HIV Agents/*administration & dosage'
p37435
aS'Drug Therapy, Combination'
p37436
aS'Female'
p37437
aS'HIV Infections/*drug therapy/mortality/virology'
p37438
aS'Humans'
p37439
aS'Lamivudine/*administration & dosage'
p37440
aS'Male'
p37441
aS'Middle Aged'
p37442
aS'Organophosphonates/*administration & dosage'
p37443
aS'Retrospective Studies'
p37444
aS'Reverse Transcriptase Inhibitors/*administration & dosage'
p37445
aS'South Africa'
p37446
aS'Tenofovir'
p37447
aS'Treatment Outcome'
p37448
aS'Viral Load'
p37449
asS'EDAT'
p37450
S'2013/08/14 06:00'
p37451
sS'SO'
p37452
S'PLoS One. 2013 Aug 7;8(8):e71719. doi: 10.1371/journal.pone.0071719. Print 2013.'
p37453
sS'SB'
p37454
S'IM'
p37455
sS'PMID'
p37456
S'23940782'
p37457
sS'PST'
p37458
S'epublish'
p37459
stRp37460
ag2
(g3
g4
(dp37461
S'LID'
p37462
S'10.1371/journal.pone.0070763 [doi]'
p37463
sS'STAT'
p37464
S'MEDLINE'
p37465
sS'DEP'
p37466
S'20130801'
p37467
sS'DA'
p37468
S'20130812'
p37469
sS'AID'
p37470
(lp37471
S'10.1371/journal.pone.0070763 [doi]'
p37472
aS'PONE-D-13-09460 [pii]'
p37473
asS'CRDT'
p37474
(lp37475
S'2013/08/13 06:00'
p37476
asS'DP'
p37477
S'2013'
p37478
sS'AD'
p37479
S'National Tuberculosis/Leprosy Program Ministry of Health, Kampala, Uganda.'
p37480
sS'OWN'
p37481
S'NLM'
p37482
sS'PT'
p37483
(lp37484
S'Journal Article'
p37485
aS"Research Support, Non-U.S. Gov't"
p37486
aS"Research Support, U.S. Gov't, P.H.S."
p37487
asS'LA'
p37488
(lp37489
S'eng'
p37490
asS'FAU'
p37491
(lp37492
S'Lukoye, Deus'
p37493
aS'Adatu, Francis'
p37494
aS'Musisi, Kenneth'
p37495
aS'Kasule, George William'
p37496
aS'Were, Willy'
p37497
aS'Odeke, Rosemary'
p37498
aS'Kalamya, Julius Namonyo'
p37499
aS'Awor, Ann'
p37500
aS'Date, Anand'
p37501
aS'Joloba, Moses L'
p37502
asS'JT'
p37503
S'PloS one'
p37504
sS'LR'
p37505
S'20150423'
p37506
sS'PG'
p37507
S'e70763'
p37508
sS'TI'
p37509
S'Anti-tuberculosis drug resistance among new and previously treated sputum smear-positive tuberculosis patients in Uganda: results of the first national survey.'
p37510
sS'RN'
p37511
(lp37512
S'0 (Antitubercular Agents)'
p37513
asS'PL'
p37514
S'United States'
p37515
sS'TA'
p37516
S'PLoS One'
p37517
sS'JID'
p37518
S'101285081'
p37519
sS'AB'
p37520
S'BACKGROUND: Multidrug resistant and extensively drug resistant tuberculosis (TB) have become major threats to control of tuberculosis globally. The rates of anti-TB drug resistance in Uganda are not known. We conducted a national drug resistance survey to investigate the levels and patterns of resistance to first and second line anti-TB drugs among new and previously treated sputum smear-positive TB cases. METHODS: Sputum samples were collected from a nationally representative sample of new and previously treated sputum smear-positive TB patients registered at TB diagnostic centers during December 2009 to February 2011 using a weighted cluster sampling method. Culture and drug susceptibility testing was performed at the national TB reference laboratory. RESULTS: A total of 1537 patients (1397 new and 140 previously treated) were enrolled in the survey from 44 health facilities. HIV test result and complete drug susceptibility testing (DST) results were available for 1524 (96.8%) and 1325 (85.9%) patients, respectively. Of the 1209 isolates from new cases, resistance to any anti-TB drug was 10.3%, 5% were resistant to isoniazid, 1.9% to rifampicin, and 1.4% were multi drug resistant. Among the 116 isolates from previously treated cases, the prevalence of resistance was 25.9%, 23.3%, 12.1% and 12.1% respectively. Of the 1524 patients who had HIV testing 469 (30.7%) tested positive. There was no association between anti-TB drug resistance (including MDR) and HIV infection. CONCLUSION: The prevalence of anti-TB drug resistance among new patients in Uganda is low relative to WHO estimates. The higher levels of MDR-TB (12.1%) and resistance to any drug (25.3%) among previously treated patients raises concerns about the quality of directly observed therapy (DOT) and adherence to treatment. This calls for strengthening existing TB control measures, especially DOT, routine DST among the previously treated TB patients or periodic drug resistance surveys, to prevent and monitor development and transmission of drug resistant TB.'
p37521
sS'GR'
p37522
(lp37523
S'PEPFAR/United States'
p37524
asS'IP'
p37525
S'8'
sS'IS'
p37526
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p37527
sS'PMC'
p37528
S'PMC3731251'
p37529
sS'DCOM'
p37530
S'20140318'
p37531
sS'AU'
p37532
(lp37533
S'Lukoye D'
p37534
aS'Adatu F'
p37535
aS'Musisi K'
p37536
aS'Kasule GW'
p37537
aS'Were W'
p37538
aS'Odeke R'
p37539
aS'Kalamya JN'
p37540
aS'Awor A'
p37541
aS'Date A'
p37542
aS'Joloba ML'
p37543
asS'VI'
p37544
S'8'
sS'MHDA'
p37545
S'2014/03/19 06:00'
p37546
sS'PHST'
p37547
(lp37548
S'2013 [ppublish]'
p37549
aS'2013/03/07 [received]'
p37550
aS'2013/06/21 [accepted]'
p37551
aS'2013/08/01 [epublish]'
p37552
asS'OID'
p37553
(lp37554
S'NLM: PMC3731251'
p37555
asS'MH'
p37556
(lp37557
S'Adolescent'
p37558
aS'Adult'
p37559
aS'Antitubercular Agents/*pharmacology/therapeutic use'
p37560
aS'*Data Collection'
p37561
aS'*Drug Resistance, Bacterial'
p37562
aS'Drug Resistance, Multiple'
p37563
aS'Female'
p37564
aS'HIV Infections/complications'
p37565
aS'Humans'
p37566
aS'Male'
p37567
aS'Middle Aged'
p37568
aS'Risk'
p37569
aS'Sputum/*microbiology'
p37570
aS'Tuberculosis/complications/*drug therapy/*epidemiology'
p37571
aS'Uganda/epidemiology'
p37572
aS'World Health Organization'
p37573
aS'Young Adult'
p37574
asS'EDAT'
p37575
S'2013/08/13 06:00'
p37576
sS'SO'
p37577
S'PLoS One. 2013 Aug 1;8(8):e70763. doi: 10.1371/journal.pone.0070763. Print 2013.'
p37578
sS'SB'
p37579
S'IM'
p37580
sS'PMID'
p37581
S'23936467'
p37582
sS'PST'
p37583
S'epublish'
p37584
stRp37585
ag2
(g3
g4
(dp37586
S'LID'
p37587
S'10.1371/journal.pone.0068213 [doi]'
p37588
sS'STAT'
p37589
S'MEDLINE'
p37590
sS'DEP'
p37591
S'20130730'
p37592
sS'DA'
p37593
S'20130812'
p37594
sS'AID'
p37595
(lp37596
S'10.1371/journal.pone.0068213 [doi]'
p37597
aS'PONE-D-13-10984 [pii]'
p37598
asS'CRDT'
p37599
(lp37600
S'2013/08/13 06:00'
p37601
asS'DP'
p37602
S'2013'
p37603
sS'AD'
p37604
S'Instituto Nacional de Saude, Maputo, Mozambique ; Laboratorio de Virologia Molecular, Universidade Federal do Rio de Janeiro,Rio de Janeiro, Brazil. dulcebila@gmail.com'
p37605
sS'OWN'
p37606
S'NLM'
p37607
sS'PT'
p37608
(lp37609
S'Journal Article'
p37610
aS"Research Support, Non-U.S. Gov't"
p37611
aS"Research Support, U.S. Gov't, P.H.S."
p37612
asS'LA'
p37613
(lp37614
S'eng'
p37615
asS'FAU'
p37616
(lp37617
S'Bila, Dulce Celina Adolfo'
p37618
aS'Young, Peter'
p37619
aS'Merks, Harriet'
p37620
aS'Vubil, Adolfo Salvador'
p37621
aS'Mahomed, Mussagy'
p37622
aS'Augusto, Angelo'
p37623
aS'Abreu, Celina Monteiro'
p37624
aS'Mabunda, Nedio Jonas'
p37625
aS'Brooks, James I'
p37626
aS'Tanuri, Amilcar'
p37627
aS'Jani, Ilesh Vinodrai'
p37628
asS'JT'
p37629
S'PloS one'
p37630
sS'LR'
p37631
S'20150423'
p37632
sS'PG'
p37633
S'e68213'
p37634
sS'TI'
p37635
S'Evolution of primary HIV drug resistance in a subtype C dominated epidemic in Mozambique.'
p37636
sS'RN'
p37637
(lp37638
S'0 (Anti-HIV Agents)'
p37639
asS'PL'
p37640
S'United States'
p37641
sS'TA'
p37642
S'PLoS One'
p37643
sS'JID'
p37644
S'101285081'
p37645
sS'AB'
p37646
S'OBJECTIVE: In Mozambique, highly active antiretroviral treatment (HAART) was introduced in 2004 followed by decentralization and expansion, resulting in a more than 20-fold increase in coverage by 2009. Implementation of HIV drug resistance threshold surveys (HIVDR-TS) is crucial in order to monitor the emergence of transmitted viral resistance, and to produce evidence-based recommendations to support antiretroviral (ARV) policy in Mozambique. METHODS: World Health Organization (WHO) methodology was used to evaluate transmitted drug resistance (TDR) in newly diagnosed HIV-1 infected pregnant women attending ante-natal clinics in Maputo and Beira to non-nucleoside reverse transcriptase inhibitors (NNRTI), nucleoside reverse transcriptase inhibitors (NRTI) and protease inhibitors (PI). Subtypes were assigned using REGA HIV-1 subtyping tool and phylogenetic trees constructed using MEGA version 5. RESULTS: Although mutations associated with resistance to all three drug were detected in these surveys, transmitted resistance was analyzed and classified as <5% in Maputo in both surveys for all three drug classes. Transmitted resistance to NNRTI in Beira in 2009 was classified between 5-15%, an increase from 2007 when no NNRTI mutations were found. All sequences clustered with subtype C. CONCLUSIONS: Our results show that the epidemic is dominated by subtype C, where the first-line option based on two NRTI and one NNRTI is still effective for treatment of HIV infection, but intermediate levels of TDR found in Beira reinforce the need for constant evaluation with continuing treatment expansion in Mozambique.'
p37647
sS'GR'
p37648
(lp37649
S'1U2GPS001093/PHS HHS/United States'
p37650
aS'PEPFAR/United States'
p37651
asS'IP'
p37652
S'7'
sS'IS'
p37653
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p37654
sS'PMC'
p37655
S'PMC3728366'
p37656
sS'DCOM'
p37657
S'20140401'
p37658
sS'AU'
p37659
(lp37660
S'Bila DC'
p37661
aS'Young P'
p37662
aS'Merks H'
p37663
aS'Vubil AS'
p37664
aS'Mahomed M'
p37665
aS'Augusto A'
p37666
aS'Abreu CM'
p37667
aS'Mabunda NJ'
p37668
aS'Brooks JI'
p37669
aS'Tanuri A'
p37670
aS'Jani IV'
p37671
asS'VI'
p37672
S'8'
sS'MHDA'
p37673
S'2014/04/02 06:00'
p37674
sS'PHST'
p37675
(lp37676
S'2013 [ppublish]'
p37677
aS'2013/03/15 [received]'
p37678
aS'2013/05/28 [accepted]'
p37679
aS'2013/07/30 [epublish]'
p37680
asS'OID'
p37681
(lp37682
S'NLM: PMC3728366'
p37683
asS'MH'
p37684
(lp37685
S'Adolescent'
p37686
aS'Adult'
p37687
aS'Anti-HIV Agents/*pharmacology/therapeutic use'
p37688
aS'Antiretroviral Therapy, Highly Active'
p37689
aS'*Drug Resistance, Viral/genetics'
p37690
aS'Female'
p37691
aS'*Genotype'
p37692
aS'HIV Infections/drug therapy/epidemiology/*virology'
p37693
aS'HIV-1/classification/*drug effects/*genetics'
p37694
aS'Humans'
p37695
aS'Male'
p37696
aS'Mozambique/epidemiology'
p37697
aS'Mutation'
p37698
aS'Phylogeny'
p37699
aS'Pregnancy'
p37700
aS'Young Adult'
p37701
asS'EDAT'
p37702
S'2013/08/13 06:00'
p37703
sS'SO'
p37704
S'PLoS One. 2013 Jul 30;8(7):e68213. doi: 10.1371/journal.pone.0068213. Print 2013.'
p37705
sS'SB'
p37706
S'IM'
p37707
sS'PMID'
p37708
S'23935858'
p37709
sS'PST'
p37710
S'epublish'
p37711
stRp37712
ag2
(g3
g4
(dp37713
S'LID'
p37714
S'10.1089/AID.2013.0167 [doi]'
p37715
sS'STAT'
p37716
S'MEDLINE'
p37717
sS'DEP'
p37718
S'20130830'
p37719
sS'DA'
p37720
S'20140107'
p37721
sS'AID'
p37722
(lp37723
S'10.1089/AID.2013.0167 [doi]'
p37724
asS'CRDT'
p37725
(lp37726
S'2013/08/09 06:00'
p37727
asS'DP'
p37728
S'2014 Jan'
p37729
sS'AD'
p37730
S'1 Centre for Infectious Disease Research in Zambia , Lusaka, Zambia .'
p37731
sS'OWN'
p37732
S'NLM'
p37733
sS'PT'
p37734
(lp37735
S'Journal Article'
p37736
aS'Research Support, N.I.H., Extramural'
p37737
asS'LA'
p37738
(lp37739
S'eng'
p37740
asS'FAU'
p37741
(lp37742
S'Vinikoor, Michael J'
p37743
aS'Schuttner, Linnaea'
p37744
aS'Moyo, Crispin'
p37745
aS'Li, Michelle'
p37746
aS'Musonda, Patrick'
p37747
aS'Hachaambwa, Lottie M'
p37748
aS'Stringer, Jeffrey S A'
p37749
aS'Chi, Benjamin H'
p37750
asS'JT'
p37751
S'AIDS research and human retroviruses'
p37752
sS'LR'
p37753
S'20150604'
p37754
sS'PG'
p37755
S'74-7'
p37756
sS'TI'
p37757
S'Short communication: Late refills during the first year of antiretroviral therapy predict mortality and program failure among HIV-infected adults in urban Zambia.'
p37758
sS'RN'
p37759
(lp37760
S'0 (Anti-HIV Agents)'
p37761
asS'PL'
p37762
S'United States'
p37763
sS'TA'
p37764
S'AIDS Res Hum Retroviruses'
p37765
sS'JID'
p37766
S'8709376'
p37767
sS'AB'
p37768
S'We evaluated the association of the number of late antiretroviral therapy (ART) refills with patient outcomes in a large public-sector human immunodeficiency virus treatment program in Lusaka, Zambia. Using pharmacy data routinely collected during 2004-2010, we calculated the number of late refills during the initial year of ART. We used multivariable Cox proportional hazard regression to examine the association between the number of late refills and death or program failure (i.e., death, loss to follow-up, or program withdrawal) >12 months after ART initiation, with and without stratification by the medication possession ratio (MPR) during the initial year of ART. Of 53,015 adults who received ART for >/=12 months (median follow-up duration, 86.1 months; interquartile range, 53.2-128.2 months), 26,847 (50.6%) had 0 late refills, 16,762 (31.6%) had 1, 6,505 (12.3%) had 2, and 2,901 (5.5%) had >/=3. Kaplan-Meier analysis revealed that >/=3 late refills was associated with a greater mortality risk than 1 and 2 late refills (p<0.001, by the log-rank test). The mortality risk was greater for patients with 2 late refills [adjusted hazard ratio (HR), 1.17; 95% confidence interval (CI), 0.99-1.38] or >/=3 late refills (adjusted HR, 1.51; 95% CI, 1.23-1.87), compared with that for patients with 0-1 late refills. Program failure was associated with >/=2 late refills. An MPR of <80% was associated with similar increases in mortality risk across late-refill strata. Monitoring late refills during the initial period of ART may help resource- and time-constrained clinics identify patients at risk for program failure.'
p37769
sS'GR'
p37770
(lp37771
S'D43TW001035/TW/FIC NIH HHS/United States'
p37772
aS'R24TW007988/TW/FIC NIH HHS/United States'
p37773
aS'R25 TW009340/TW/FIC NIH HHS/United States'
p37774
aS'R25TW009340/TW/FIC NIH HHS/United States'
p37775
asS'IP'
p37776
S'1'
sS'IS'
p37777
S'1931-8405 (Electronic) 0889-2229 (Linking)'
p37778
sS'PMC'
p37779
S'PMC3887398'
p37780
sS'DCOM'
p37781
S'20140828'
p37782
sS'AU'
p37783
(lp37784
S'Vinikoor MJ'
p37785
aS'Schuttner L'
p37786
aS'Moyo C'
p37787
aS'Li M'
p37788
aS'Musonda P'
p37789
aS'Hachaambwa LM'
p37790
aS'Stringer JS'
p37791
aS'Chi BH'
p37792
asS'VI'
p37793
S'30'
p37794
sS'MHDA'
p37795
S'2014/08/29 06:00'
p37796
sS'PHST'
p37797
(lp37798
S'2013/08/30 [aheadofprint]'
p37799
asS'OID'
p37800
(lp37801
S'NLM: PMC3887398'
p37802
asS'MH'
p37803
(lp37804
S'Adult'
p37805
aS'Anti-HIV Agents/*therapeutic use'
p37806
aS'Antiretroviral Therapy, Highly Active'
p37807
aS'Female'
p37808
aS'HIV Infections/*drug therapy/*mortality'
p37809
aS'HIV-1/drug effects'
p37810
aS'Humans'
p37811
aS'Male'
p37812
aS'Risk'
p37813
aS'Treatment Failure'
p37814
aS'Young Adult'
p37815
aS'Zambia'
p37816
asS'EDAT'
p37817
S'2013/08/09 06:00'
p37818
sS'SO'
p37819
S'AIDS Res Hum Retroviruses. 2014 Jan;30(1):74-7. doi: 10.1089/AID.2013.0167. Epub 2013 Aug 30.'
p37820
sS'SB'
p37821
S'IM X'
p37822
sS'PMID'
p37823
S'23924188'
p37824
sS'PST'
p37825
S'ppublish'
p37826
stRp37827
ag2
(g3
g4
(dp37828
S'LID'
p37829
S'10.1097/01.aids.0000433239.01611.52 [doi]'
p37830
sS'STAT'
p37831
S'MEDLINE'
p37832
sS'JT'
p37833
S'AIDS (London, England)'
p37834
sS'DA'
p37835
S'20140113'
p37836
sS'AID'
p37837
(lp37838
S'10.1097/01.aids.0000433239.01611.52 [doi]'
p37839
asS'CRDT'
p37840
(lp37841
S'2013/08/08 06:00'
p37842
asS'DP'
p37843
S'2014 Jan 2'
p37844
sS'AD'
p37845
S'aDepartment of Virology, Erasmus Medical Center, Rotterdam bPharmAccess Foundation cDepartment of Global Health, Academic Medical Centre of the University of Amsterdam, Amsterdam Institute for Global Health and Development (AIGHD), Amsterdam, The Netherlands dJoint Clinical Research Centre (JCRC), Kampala, Uganda eCoast Province General Hospital, International Center for Reproductive Health (ICRH), Mombasa, Kenya fHIV Department, World Health Organization, Geneva, Switzerland gDepartment of Geographic Medicine and Infectious Disease, Tufts University School of Medicine, Boston, Massachusetts, USA.'
p37846
sS'OWN'
p37847
S'NLM'
p37848
sS'PT'
p37849
(lp37850
S'Journal Article'
p37851
aS'Research Support, N.I.H., Extramural'
p37852
aS"Research Support, Non-U.S. Gov't"
p37853
asS'LA'
p37854
(lp37855
S'eng'
p37856
asS'FAU'
p37857
(lp37858
S'Nichols, Brooke E'
p37859
aS'Sigaloff, Kim C E'
p37860
aS'Kityo, Cissy'
p37861
aS'Mandaliya, Kishor'
p37862
aS'Hamers, Raph L'
p37863
aS'Bertagnolio, Silvia'
p37864
aS'Jordan, Michael R'
p37865
aS'Boucher, Charles A B'
p37866
aS'Rinke de Wit, Tobias F'
p37867
aS'van de Vijver, David A M C'
p37868
asS'PG'
p37869
S'73-83'
p37870
sS'TI'
p37871
S'Averted HIV infections due to expanded antiretroviral treatment eligibility offsets risk of transmitted drug resistance: a modeling study.'
p37872
sS'RN'
p37873
(lp37874
S'0 (Anti-HIV Agents)'
p37875
asS'PL'
p37876
S'England'
p37877
sS'TA'
p37878
S'AIDS'
p37879
sS'JID'
p37880
S'8710219'
p37881
sS'AB'
p37882
S'BACKGROUND: Earlier antiretroviral therapy initiation can reduce the incidence of HIV-1. This benefit can be offset by increased transmitted drug resistance (TDR). We compared the preventive benefits of reducing incident infections with the potential TDR increase in East Africa. METHODS: A mathematical model was constructed to represent Kampala, Uganda, and Mombasa, Kenya. We predicted the effect of initiating treatment at different immunological thresholds (<350, <500 CD4 cells/mul) on infections averted and mutation-specific TDR prevalence over 10 years compared to initiating treatment at CD4 cell count below 200 cells/mul. RESULTS: When initiating treatment at CD4 cell count below 350 cells/mul, we predict 18 [interquartile range (IQR) 11-31] and 46 (IQR 30-83) infections averted for each additional case of TDR in Kampala and Mombasa, respectively, and 22 (IQR 17-35) and 32 (IQR 21-57) infections averted when initiating at below 500. TDR is predicted to increase most strongly when initiating treatment at CD4 cell count below 500 cells/mul, from 8.3% (IQR 7.7-9.0%) and 12.3% (IQR 11.7-13.1%) in 2012 to 19.0% (IQR 16.5-21.8%) and 19.2% (IQR 17.1-21.5%) in 10 years in Kampala and Mombasa, respectively. The TDR epidemic at all immunological thresholds was comprised mainly of resistance to non-nucleoside reverse transcriptase inhibitors. When 80-100% of individuals with virological failure are timely switched to second-line therapy, TDR is predicted to decline irrespective of treatment initiation threshold. CONCLUSION: Averted HIV infections due to the expansion of antiretroviral treatment eligibility offset the risk of transmitted drug resistance, as defined by more infections averted than TDR gained. The effectiveness of first-line non-nucleoside reverse transcriptase inhibitor-based therapy can be preserved by improving switching practices to second-line therapy.'
p37883
sS'GR'
p37884
(lp37885
S'K23 AI074423-05/AI/NIAID NIH HHS/United States'
p37886
asS'IP'
p37887
S'1'
sS'IS'
p37888
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p37889
sS'DCOM'
p37890
S'20140828'
p37891
sS'AU'
p37892
(lp37893
S'Nichols BE'
p37894
aS'Sigaloff KC'
p37895
aS'Kityo C'
p37896
aS'Mandaliya K'
p37897
aS'Hamers RL'
p37898
aS'Bertagnolio S'
p37899
aS'Jordan MR'
p37900
aS'Boucher CA'
p37901
aS'Rinke de Wit TF'
p37902
aS'van de Vijver DA'
p37903
asS'VI'
p37904
S'28'
p37905
sS'MHDA'
p37906
S'2014/08/29 06:00'
p37907
sS'MH'
p37908
(lp37909
S'Adult'
p37910
aS'Anti-HIV Agents/*therapeutic use'
p37911
aS'CD4 Lymphocyte Count'
p37912
aS'*Drug Resistance, Viral'
p37913
aS'Female'
p37914
aS'HIV Infections/*drug therapy/epidemiology/transmission/*virology'
p37915
aS'Humans'
p37916
aS'Incidence'
p37917
aS'Kenya/epidemiology'
p37918
aS'Male'
p37919
aS'Models, Theoretical'
p37920
aS'Time Factors'
p37921
aS'Uganda/epidemiology'
p37922
aS'Young Adult'
p37923
asS'EDAT'
p37924
S'2013/08/08 06:00'
p37925
sS'SO'
p37926
S'AIDS. 2014 Jan 2;28(1):73-83. doi: 10.1097/01.aids.0000433239.01611.52.'
p37927
sS'SB'
p37928
S'IM X'
p37929
sS'PMID'
p37930
S'23921620'
p37931
sS'PST'
p37932
S'ppublish'
p37933
stRp37934
ag2
(g3
g4
(dp37935
S'LID'
p37936
S'10.1097/01.aids.0000432534.47217.b4 [doi]'
p37937
sS'STAT'
p37938
S'MEDLINE'
p37939
sS'JT'
p37940
S'AIDS (London, England)'
p37941
sS'CI'
p37942
(lp37943
S'(c) 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins'
p37944
asS'DA'
p37945
S'20130913'
p37946
sS'AID'
p37947
(lp37948
S'10.1097/01.aids.0000432534.47217.b4 [doi]'
p37949
asS'CRDT'
p37950
(lp37951
S'2013/08/08 06:00'
p37952
asS'DP'
p37953
S'2013 Sep 24'
p37954
sS'AD'
p37955
S'aThe Kirby Institute, University of New South Wales, Sydney, Australia bUCD School of Medicine and Medical Science, Dublin, Ireland cThe Alfred Hospital, Melbourne, Australia dCICAL, Buenos Aires, Argentina eThai Red Cross AIDS Research Center, Bangkok, Thailand fHopital Saint-Louis, Paris, France.'
p37956
sS'OWN'
p37957
S'NLM'
p37958
sS'PT'
p37959
(lp37960
S'Comparative Study'
p37961
aS'Journal Article'
p37962
aS'Randomized Controlled Trial'
p37963
aS"Research Support, Non-U.S. Gov't"
p37964
asS'LA'
p37965
(lp37966
S'eng'
p37967
asS'FAU'
p37968
(lp37969
S'Martin, Allison'
p37970
aS'Moore, Cecilia'
p37971
aS'Mallon, Patrick W G'
p37972
aS'Hoy, Jennifer'
p37973
aS'Emery, Sean'
p37974
aS'Belloso, Waldo'
p37975
aS'Phanuphak, Praphan'
p37976
aS'Ferret, Samuel'
p37977
aS'Cooper, David A'
p37978
aS'Boyd, Mark A'
p37979
asS'LR'
p37980
S'20151119'
p37981
sS'PG'
p37982
S'2403-11'
p37983
sS'TI'
p37984
S'Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy.'
p37985
sS'RN'
p37986
(lp37987
S'0 (HIV Protease Inhibitors)'
p37988
aS'0 (Pyrrolidinones)'
p37989
aS'0 (Reverse Transcriptase Inhibitors)'
p37990
aS'2494G1JF75 (Lopinavir)'
p37991
aS'43Y000U234 (Raltegravir Potassium)'
p37992
aS'O3J8G9O825 (Ritonavir)'
p37993
asS'PL'
p37994
S'England'
p37995
sS'TA'
p37996
S'AIDS'
p37997
sS'FIR'
p37998
(lp37999
S'Kumarasamy, Nagalingeswaran'
p38000
aS'Foulkes, Sharne'
p38001
aS'Wood, Robin'
p38002
aS'Chetchotisakd, Ploenchan'
p38003
aS'Phanuphak, Praphan'
p38004
aS'Mohapi, Lerato'
p38005
aS'Kamarulzaman, Adeeba'
p38006
aS'Messina, Oscar'
p38007
asS'JID'
p38008
S'8710219'
p38009
sS'AB'
p38010
S'OBJECTIVE: To compare changes over 48 weeks in bone mineral density (BMD) between participants randomized to lopinavir/ritonavir (LPV/r) + raltegravir (RAL) or LPV/r + 2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTIs) as second line therapy. DESIGN: 48-week open-label sub-study of the Second Line trial conducted in South Africa, India, Thailand, Malaysia and Argentina. METHODS: Dual energy X-ray absorptiometry scans of proximal femur and lumbar spine were performed at baseline and week 48. Linear regression was used to compare means of differences between arms. McNemars test compared osteopenia and osteoporosis. Associations between percentage BMD changes and baseline variables were assessed by multivariate linear regression. RESULTS: Two hundred and ten participants were randomized. Analyses were adjusted for sex, BMI and smoking status. Mean (95% CI) proximal femur BMD% reduced over 48 weeks by -5.2% (-6.7 to -3.8%) in the LPV/r+2-3N(t)RTIs arm and by -2.9% (-4.3 to -1.5%) in the LPV/r+RAL arm (P = 0.0001). Lumbar spine BMD reduced by -4.2% (-5.7 to -2.7%) in the LPV/r+2-3N(t)RTIs arm and by -2.0% (-3.5 to -0.6%) in the LPV/r+RAL arm (P = 0.0006). The incidence of osteopenia (7.6%) and osteoporosis (2.0%) assessed over 48 weeks were similar between arms. Reduced BMD over 48 weeks was significantly associated with longer duration of tenofovir on study [% change (SE) -1.58 (0.38) femur, -1.65 (0.38) spine, P = 0.0001] and low baseline BMI [% change (SE) 0.5 (0.13) femur, 0.17 (0.07) spine; P < 0.01]. CONCLUSION: An N(t)RTI-sparing antiretroviral regimen of LPV/r and raltegravir as second line therapy is associated with less bone loss than a LPV/r regimen containing N(t)RTIs.'
p38011
sS'CN'
p38012
(lp38013
S'Second Line study team'
p38014
asS'IP'
p38015
S'15'
p38016
sS'IS'
p38017
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p38018
sS'IR'
p38019
(lp38020
S'Kumarasamy N'
p38021
aS'Foulkes S'
p38022
aS'Wood R'
p38023
aS'Chetchotisakd P'
p38024
aS'Phanuphak P'
p38025
aS'Mohapi L'
p38026
aS'Kamarulzaman A'
p38027
aS'Messina O'
p38028
asS'DCOM'
p38029
S'20140331'
p38030
sS'AU'
p38031
(lp38032
S'Martin A'
p38033
aS'Moore C'
p38034
aS'Mallon PW'
p38035
aS'Hoy J'
p38036
aS'Emery S'
p38037
aS'Belloso W'
p38038
aS'Phanuphak P'
p38039
aS'Ferret S'
p38040
aS'Cooper DA'
p38041
aS'Boyd MA'
p38042
asS'VI'
p38043
S'27'
p38044
sS'MHDA'
p38045
S'2014/04/01 06:00'
p38046
sS'OID'
p38047
(lp38048
S'NLM: PMC3815006'
p38049
asS'MH'
p38050
(lp38051
S'Absorptiometry, Photon'
p38052
aS'Adult'
p38053
aS'Argentina/epidemiology'
p38054
aS'Bone Density/*drug effects'
p38055
aS'Bone Diseases, Metabolic/complications/*epidemiology'
p38056
aS'Female'
p38057
aS'Femur/radiography'
p38058
aS'HIV Infections/complications/*drug therapy'
p38059
aS'HIV Protease Inhibitors/administration & dosage/*adverse effects'
p38060
aS'Humans'
p38061
aS'India/epidemiology'
p38062
aS'Lopinavir/adverse effects'
p38063
aS'Lumbar Vertebrae/radiography'
p38064
aS'Malaysia/epidemiology'
p38065
aS'Male'
p38066
aS'Osteoporosis/complications/*epidemiology'
p38067
aS'Prevalence'
p38068
aS'Pyrrolidinones/adverse effects'
p38069
aS'Raltegravir Potassium'
p38070
aS'Reverse Transcriptase Inhibitors/administration & dosage/*adverse effects'
p38071
aS'Risk Factors'
p38072
aS'Ritonavir/adverse effects'
p38073
aS'South Africa/epidemiology'
p38074
aS'Thailand/epidemiology'
p38075
aS'Treatment Outcome'
p38076
asS'EDAT'
p38077
S'2013/08/08 06:00'
p38078
sS'PMC'
p38079
S'PMC3815006'
p38080
sS'SO'
p38081
S'AIDS. 2013 Sep 24;27(15):2403-11. doi: 10.1097/01.aids.0000432534.47217.b4.'
p38082
sS'SB'
p38083
S'IM X'
p38084
sS'PMID'
p38085
S'23921615'
p38086
sS'PST'
p38087
S'ppublish'
p38088
stRp38089
ag2
(g3
g4
(dp38090
S'LID'
p38091
S'10.1007/s40264-013-0091-1 [doi]'
p38092
sS'STAT'
p38093
S'MEDLINE'
p38094
sS'JT'
p38095
S'Drug safety'
p38096
sS'DA'
p38097
S'20131024'
p38098
sS'AID'
p38099
(lp38100
S'10.1007/s40264-013-0091-1 [doi]'
p38101
asS'CRDT'
p38102
(lp38103
S'2013/08/07 06:00'
p38104
asS'DP'
p38105
S'2013 Nov'
p38106
sS'OWN'
p38107
S'NLM'
p38108
sS'PT'
p38109
(lp38110
S'Journal Article'
p38111
aS"Research Support, Non-U.S. Gov't"
p38112
asS'LA'
p38113
(lp38114
S'eng'
p38115
asS'FAU'
p38116
(lp38117
S'Sagwa, Evans'
p38118
aS'Ruswa, Nunurai'
p38119
aS'Musasa, Jean Paul'
p38120
aS'Mantel-Teeuwisse, Aukje K'
p38121
asS'LR'
p38122
S'20160909'
p38123
sS'PG'
p38124
S'1087-96'
p38125
sS'TI'
p38126
S'Adverse events during treatment of drug-resistant tuberculosis: a comparison between patients with or without human immunodeficiency virus co-infection.'
p38127
sS'RN'
p38128
(lp38129
S'0 (Anti-HIV Agents)'
p38130
aS'0 (Antitubercular Agents)'
p38131
asS'PL'
p38132
S'New Zealand'
p38133
sS'TA'
p38134
S'Drug Saf'
p38135
sS'JID'
p38136
S'9002928'
p38137
sS'AB'
p38138
S"INTRODUCTION: In settings such as Namibia with a high prevalence of human immunodeficiency virus (HIV) and drug-resistant (DR) tuberculosis (TB) co-infection, interactions and adverse events associated with second-line anti-TB and antiretroviral medicines pose a unique challenge in the treatment of both infections. OBJECTIVE: The main objective of this study was to compare the absolute risks and risk factors for commonly observed adverse events (occurring in >20 % of patients) during DR-TB treatment in HIV-infected and HIV-uninfected patients. METHODS: This was a retrospective cohort analysis of patients treated for DR-TB between January 2008 and February 2010 at the Kondja DR-TB ward in Walvis Bay, Namibia. Data were anonymously collected from patients' treatment records, using a structured form. The data were then analyzed using descriptive statistics, while 2 x 2 contingency tables stratified by HIV status were employed to examine specific risk factor and adverse event relationships, using Epi Info 3.4.3 statistical software. Eighteen adverse events were studied but, because of the small sample size of patients, only the four most frequent ones (occurring in >20 % of patients) were included in the risk factor analysis. The risk factors were a treatment period of <4 weeks; treatment with any highly active antiretroviral therapy (HAART) regimen; specific treatment with a zidovudine (AZT)-based HAART regimen, a cycloserine-based DR-TB regimen or an amikacin-based DR-TB regimen; female gender; baseline body weight </= 45 kg; and age 30 >/= years. RESULTS: Of the 57 DR-TB patients who were included in the analysis, 31 (53 %) were co-infected with HIV. When stratified by HIV status, DR-TB patients had similar exposure to specific DR-TB medicines and comparable demographic and clinical characteristics, except for age, as HIV-infected patients were on average 6.5 years older than HIV-uninfected patients (P = 0.007). Of the 18 studied adverse events, tinnitus (40 %), joint pain (26 %), hearing loss (23 %) and nausea (21 %) were the four most commonly observed events. Only for abdominal pain was there a statistically significant difference in the risk of occurrence between HIV-infected patients and HIV-uninfected patients (26 versus 4 %, P = 0.02). The risk ratios (RRs) for the association between treatment with a cycloserine-based DR-TB regimen and occurrence of joint pain did not differ much between HIV-infected and HIV-uninfected patients (RR 4.3 in HIV-infected patients, P = 0.03; RR 5 in HIV-uninfected patients, P = 0.08). Similarly, although some differences in the RRs were observed between the two HIV status groups, the differences were not statistically significant for tinnitus, hearing loss or nausea. In some instances, HIV status appeared to modify the effect of the association of some of the risk factors and adverse event occurrence, but the wide and overlapping confidence intervals were inconclusive. CONCLUSION: Generally, the absolute risks and risk factors for adverse events were similar between HIV-infected and HIV-uninfected patients treated for DR-TB in our Namibian cohort of 57 patients. Although our findings of comparable adverse event risks between DR-TB and DR-TB/HIV co-infected patients are encouraging, they are inconclusive because of the low statistical power of our study. We recommend a prospective study with a larger sample size that would increase the power and therefore the confidence in the results."
p38139
sS'AD'
p38140
S'School of Public Health, University of the Western Cape, Cape Town, South Africa, esagwa@gmail.com.'
p38141
sS'IP'
p38142
S'11'
p38143
sS'IS'
p38144
S'1179-1942 (Electronic) 0114-5916 (Linking)'
p38145
sS'DCOM'
p38146
S'20140606'
p38147
sS'AU'
p38148
(lp38149
S'Sagwa E'
p38150
aS'Ruswa N'
p38151
aS'Musasa JP'
p38152
aS'Mantel-Teeuwisse AK'
p38153
asS'VI'
p38154
S'36'
p38155
sS'MHDA'
p38156
S'2014/06/07 06:00'
p38157
sS'MH'
p38158
(lp38159
S'AIDS-Related Opportunistic Infections/complications/*drug therapy/epidemiology/virology'
p38160
aS'Adult'
p38161
aS'Anti-HIV Agents/administration & dosage/*adverse effects/therapeutic use'
p38162
aS'Antitubercular Agents/administration & dosage/*adverse effects/therapeutic use'
p38163
aS'Cohort Studies'
p38164
aS'Drug-Related Side Effects and Adverse Reactions/epidemiology/*etiology'
p38165
aS'Female'
p38166
aS'HIV Infections/complications/*drug therapy/epidemiology'
p38167
aS'Humans'
p38168
aS'Male'
p38169
aS'Middle Aged'
p38170
aS'Namibia/epidemiology'
p38171
aS'Retrospective Studies'
p38172
aS'Risk Factors'
p38173
aS'Tuberculosis, Multidrug-Resistant/complications/*drug therapy/epidemiology/virology'
p38174
aS'Young Adult'
p38175
asS'EDAT'
p38176
S'2013/08/07 06:00'
p38177
sS'SO'
p38178
S'Drug Saf. 2013 Nov;36(11):1087-96. doi: 10.1007/s40264-013-0091-1.'
p38179
sS'SB'
p38180
S'IM'
p38181
sS'PMID'
p38182
S'23917883'
p38183
sS'PST'
p38184
S'ppublish'
p38185
stRp38186
ag2
(g3
g4
(dp38187
S'LID'
p38188
S'10.1093/cid/cit490 [doi]'
p38189
sS'STAT'
p38190
S'MEDLINE'
p38191
sS'DEP'
p38192
S'20130729'
p38193
sS'DA'
p38194
S'20131009'
p38195
sS'AID'
p38196
(lp38197
S'cit490 [pii]'
p38198
aS'10.1093/cid/cit490 [doi]'
p38199
asS'CRDT'
p38200
(lp38201
S'2013/08/01 06:00'
p38202
asS'DP'
p38203
S'2013 Nov'
p38204
sS'AD'
p38205
S'Makerere University Joint AIDS Program.'
p38206
sS'OWN'
p38207
S'NLM'
p38208
sS'PT'
p38209
(lp38210
S'Journal Article'
p38211
aS'Research Support, N.I.H., Extramural'
p38212
aS"Research Support, U.S. Gov't, Non-P.H.S."
p38213
asS'LA'
p38214
(lp38215
S'eng'
p38216
asS'FAU'
p38217
(lp38218
S'Namusobya, Jennifer'
p38219
aS'Semitala, Fred C'
p38220
aS'Amanyire, Gideon'
p38221
aS'Kabami, Jane'
p38222
aS'Chamie, Gabriel'
p38223
aS'Bogere, John'
p38224
aS'Jain, Vivek'
p38225
aS'Clark, Tamara D'
p38226
aS'Charlebois, Edwin'
p38227
aS'Havlir, Diane V'
p38228
aS'Kamya, Moses'
p38229
aS'Geng, Elvin H'
p38230
asS'JT'
p38231
S'Clinical infectious diseases : an official publication of the Infectious Diseases Society of America'
p38232
sS'LR'
p38233
S'20160316'
p38234
sS'PG'
p38235
S'1343-50'
p38236
sS'TI'
p38237
S'High retention in care among HIV-infected patients entering care with CD4 levels >350 cells/muL under routine program conditions in Uganda.'
p38238
sS'RN'
p38239
(lp38240
S'0 (Anti-Retroviral Agents)'
p38241
asS'PL'
p38242
S'United States'
p38243
sS'TA'
p38244
S'Clin Infect Dis'
p38245
sS'JID'
p38246
S'9203213'
p38247
sS'AB'
p38248
S'BACKGROUND: In Africa, human immunodeficiency virus (HIV)-infected patients who present to care with CD4 levels >350 cells/microL (ie, current antiretroviral treatment thresholds) are often thought to be poorly retained in care, but most estimates do not account for outcomes among patients lost to follow-up. METHODS: We evaluated HIV-infected adults who had made a visit in the last 2.5 years in a program in Uganda. We identified a random sample of patients lost to follow-up (9 months without a visit). Ascertainers sought patients in the community in this sample and outcomes were incorporated into revised survival estimates of mortality and retention for the clinic population using a probability weight. RESULTS: Of 6473 patients, (29% male, median age 29 years, median CD4 count 550 cells/microL), 1294 (20%) became lost to follow-up over 2.5 years. Two hundred seven (16%) randomly selected lost patients were sought, and in 175 (85%) vital status was ascertained. In 19 of 175 (11%), the patient had died. Of the 156 (89%) alive, 74 (47%) were interviewed in person, and 38 of 74 (51%) reported HIV care elsewhere, whereas 36 of 74 (49%) were not in care. Application of weights derived from sampling found that at 2.5 years, retention among patients who enrolled with CD4 levels >350 cells/microL was 88.2% and mortality was 2.5%. Lower income, unemployment, and rural residence were associated with failure to be retained. CONCLUSIONS: Retention in patients entering care with high CD4 counts under routine program conditions in Africa is high in a Ugandan care program and may be systematically underestimated in many other settings.'
p38249
sS'GR'
p38250
(lp38251
S'K23 AI084544/AI/NIAID NIH HHS/United States'
p38252
aS'P30 AI027763/AI/NIAID NIH HHS/United States'
p38253
aS'U01 AI099959/AI/NIAID NIH HHS/United States'
p38254
asS'IP'
p38255
S'9'
sS'IS'
p38256
S'1537-6591 (Electronic) 1058-4838 (Linking)'
p38257
sS'PMC'
p38258
S'PMC3792723'
p38259
sS'DCOM'
p38260
S'20140505'
p38261
sS'AU'
p38262
(lp38263
S'Namusobya J'
p38264
aS'Semitala FC'
p38265
aS'Amanyire G'
p38266
aS'Kabami J'
p38267
aS'Chamie G'
p38268
aS'Bogere J'
p38269
aS'Jain V'
p38270
aS'Clark TD'
p38271
aS'Charlebois E'
p38272
aS'Havlir DV'
p38273
aS'Kamya M'
p38274
aS'Geng EH'
p38275
asS'VI'
p38276
S'57'
p38277
sS'MHDA'
p38278
S'2014/05/06 06:00'
p38279
sS'PHST'
p38280
(lp38281
S'2013/07/29 [aheadofprint]'
p38282
aS'2013/08/23 [aheadofprint]'
p38283
asS'OTO'
p38284
(lp38285
S'NOTNLM'
p38286
asS'OID'
p38287
(lp38288
S'NLM: PMC3792723'
p38289
asS'MH'
p38290
(lp38291
S'Adult'
p38292
aS'Anti-Retroviral Agents/*therapeutic use'
p38293
aS'CD4 Lymphocyte Count'
p38294
aS'CD4-Positive T-Lymphocytes/*immunology'
p38295
aS'Female'
p38296
aS'HIV Infections/*drug therapy/*immunology'
p38297
aS'Humans'
p38298
aS'Male'
p38299
aS'Medication Adherence/*statistics & numerical data'
p38300
aS'Uganda'
p38301
asS'EDAT'
p38302
S'2013/08/01 06:00'
p38303
sS'SO'
p38304
S'Clin Infect Dis. 2013 Nov;57(9):1343-50. doi: 10.1093/cid/cit490. Epub 2013 Jul 29.'
p38305
sS'SB'
p38306
S'IM'
p38307
sS'PMID'
p38308
S'23899683'
p38309
sS'OT'
p38310
(lp38311
S'Africa'
p38312
aS'CD4'
p38313
aS'HIV'
p38314
aS'retention'
p38315
asS'PST'
p38316
S'ppublish'
p38317
stRp38318
ag2
(g3
g4
(dp38319
S'LID'
p38320
S'10.1097/QAI.0b013e3182a61e8d [doi]'
p38321
sS'STAT'
p38322
S'MEDLINE'
p38323
sS'AB'
p38324
S'BACKGROUND: Gaining understanding of the period before antiretroviral therapy (ART) is needed to improve treatment outcomes and to reduce HIV transmission. This study describes the cascade of enrollment in HIV care, pre-ART follow-up, and predictors of mortality and lost to follow-up (LTFU) before ART initiation. METHODS: We conducted a cohort study among HIV-infected adult patients not yet started on ART in 4 HIV Sub-Saharan African programs. Patient follow-up began at enrollment and ended at the earliest of death, transfer-out, ART initiation, last visit date, or 60 months postenrollment. Risk factors for death and LTFU were investigated during the periods 0-6 and 6-60 months. RESULTS: A total of 55,789 patients (65.4% women) were included as follows: 44.2% in clinical stage 3 or 4, with median CD4 of 261 cells per microliter [interquartile range (IQR): 125-447]. Patient care started with a median of 3 days (IQR: 0-11) after HIV diagnosis, and 31,104 of 55,789 (55.8%) patients had CD4 counts performed within 1 month of enrollment. Of 47,283 patients with known ART eligibility status at enrollment, 36,969 (78.2%) patients required ART and 27,798 of 36,969 (75.7%) patients initiated therapy. Median follow-up was 2.5 months (IQR: 0.9-13.1). Mortality and LTFU rates were 3.9 per 100 person-years [95% confidence interval (CI): 3.7 to 4.1] and 28.3 per 100 person-years (95% CI: 27.8 to 28.8), respectively. Regardless of period, increased mortality and LTFU were associated with male, lower body mass index, advanced clinical stage, and lower CD4 cell count. CONCLUSIONS: Short delays between HIV testing and care enrollment were observed in our HIV programs, but delays to determine ART eligibility were long. Interventions to initiate ART earlier, specifically targeted to men, are needed to improve patient retention in Africa.'
p38325
sS'JID'
p38326
S'100892005'
p38327
sS'AD'
p38328
S'*Clinical Research Department, Epicentre, Paris, France; daggerMedecins Sans Frontieres, Medical Department, Paris, France; and double daggerUniversity College London, London, United Kingdom.'
p38329
sS'JT'
p38330
S'Journal of acquired immune deficiency syndromes (1999)'
p38331
sS'IP'
p38332
S'5'
sS'IS'
p38333
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p38334
sS'DCOM'
p38335
S'20140103'
p38336
sS'DA'
p38337
S'20131114'
p38338
sS'AU'
p38339
(lp38340
S'Bastard M'
p38341
aS'Nicolay N'
p38342
aS'Szumilin E'
p38343
aS'Balkan S'
p38344
aS'Poulet E'
p38345
aS'Pujades-Rodriguez M'
p38346
asS'AID'
p38347
(lp38348
S'10.1097/QAI.0b013e3182a61e8d [doi]'
p38349
asS'CRDT'
p38350
(lp38351
S'2013/07/30 06:00'
p38352
asS'VI'
p38353
S'64'
p38354
sS'DP'
p38355
S'2013 Dec 15'
p38356
sS'MHDA'
p38357
S'2014/01/05 06:00'
p38358
sS'OWN'
p38359
S'NLM'
p38360
sS'PT'
p38361
(lp38362
S'Journal Article'
p38363
asS'LA'
p38364
(lp38365
S'eng'
p38366
asS'MH'
p38367
(lp38368
S'Adult'
p38369
aS'Africa South of the Sahara/epidemiology'
p38370
aS'Cohort Studies'
p38371
aS'Female'
p38372
aS'HIV Infections/*therapy/transmission'
p38373
aS'Humans'
p38374
aS'Longitudinal Studies'
p38375
aS'Male'
p38376
aS'Patient Care/*methods'
p38377
aS'Risk Factors'
p38378
aS'Treatment Outcome'
p38379
asS'FAU'
p38380
(lp38381
S'Bastard, Mathieu'
p38382
aS'Nicolay, Nathalie'
p38383
aS'Szumilin, Elisabeth'
p38384
aS'Balkan, Suna'
p38385
aS'Poulet, Elisabeth'
p38386
aS'Pujades-Rodriguez, Mar'
p38387
asS'EDAT'
p38388
S'2013/07/31 06:00'
p38389
sS'PST'
p38390
S'ppublish'
p38391
sS'SO'
p38392
S'J Acquir Immune Defic Syndr. 2013 Dec 15;64(5):455-63. doi: 10.1097/QAI.0b013e3182a61e8d.'
p38393
sS'PG'
p38394
S'455-63'
p38395
sS'TI'
p38396
S'Adults receiving HIV care before the start of antiretroviral therapy in sub-Saharan Africa: patient outcomes and associated risk factors.'
p38397
sS'SB'
p38398
S'IM X'
p38399
sS'PMID'
p38400
S'23892242'
p38401
sS'PL'
p38402
S'United States'
p38403
sS'TA'
p38404
S'J Acquir Immune Defic Syndr'
p38405
stRp38406
ag2
(g3
g4
(dp38407
S'LID'
p38408
S'10.1097/QAI.0b013e3182a60f7d [doi]'
p38409
sS'STAT'
p38410
S'MEDLINE'
p38411
sS'JT'
p38412
S'Journal of acquired immune deficiency syndromes (1999)'
p38413
sS'DA'
p38414
S'20130919'
p38415
sS'AID'
p38416
(lp38417
S'10.1097/QAI.0b013e3182a60f7d [doi]'
p38418
asS'CRDT'
p38419
(lp38420
S'2013/07/30 06:00'
p38421
asS'DP'
p38422
S'2013 Oct 1'
p38423
sS'AD'
p38424
S'*Department of Global Health, Academic Medical Center of the University of Amsterdam, Amsterdam, The Netherlands; daggerPharmAccess Foundation, Amsterdam, The Netherlands; double daggerAmsterdam Institute for Global Health and Development, Amsterdam, The Netherlands; section signDepartment of Blood-Borne Infections, Sanquin, Amsterdam, The Netherlands; ||Department of Medical Microbiology, Academic Medical Center of the University of Amsterdam, Amsterdam, The Netherlands; paragraph signDepartment of Molecular Medicine and Hematology, University of the Witwatersrand, Johannesburg, South Africa; #Lancet Laboratories, Johannesburg, South Africa; **Lusaka Trust Hospital, Lusaka, Zambia; daggerdaggerClinical HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa; double daggerdouble daggerMuelmed Hospital, Pretoria, South Africa; and section sign section signDepartment of Internal Medicine and Infectious Diseases, University Medical Center Utrecht, Utrecht, The Netherlands.'
p38425
sS'OWN'
p38426
S'NLM'
p38427
sS'PT'
p38428
(lp38429
S'Journal Article'
p38430
aS'Multicenter Study'
p38431
aS"Research Support, Non-U.S. Gov't"
p38432
asS'LA'
p38433
(lp38434
S'eng'
p38435
asS'FAU'
p38436
(lp38437
S'Hamers, Raph L'
p38438
aS'Zaaijer, Hans L'
p38439
aS'Wallis, Carole L'
p38440
aS'Siwale, Margaret'
p38441
aS'Ive, Prudence'
p38442
aS'Botes, Mariette E'
p38443
aS'Sigaloff, Kim C E'
p38444
aS'Hoepelman, Andy I M'
p38445
aS'Stevens, Wendy S'
p38446
aS'Rinke de Wit, Tobias F'
p38447
asS'LR'
p38448
S'20151119'
p38449
sS'PG'
p38450
S'174-82'
p38451
sS'TI'
p38452
S'HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes.'
p38453
sS'RN'
p38454
(lp38455
S'0 (Anti-HIV Agents)'
p38456
aS'0 (DNA, Viral)'
p38457
aS'0 (Organophosphonates)'
p38458
aS'0 (Reverse Transcriptase Inhibitors)'
p38459
aS'2T8Q726O95 (Lamivudine)'
p38460
aS'99YXE507IL (Tenofovir)'
p38461
aS'JAC85A2161 (Adenine)'
p38462
asS'PL'
p38463
S'United States'
p38464
sS'TA'
p38465
S'J Acquir Immune Defic Syndr'
p38466
sS'JID'
p38467
S'100892005'
p38468
sS'AB'
p38469
S'BACKGROUND: This study assessed HIV-hepatitis B virus (HBV) coinfection in southern Africa in terms of prevalence, viral characteristics, occult HBV, and the effect of lamivudine- versus tenofovir-containing first-line combination antiretroviral treatment (cART) on HBV-related outcomes. METHODS: A multicenter prospective cohort of HIV-infected adults in Zambia and South Africa who initiated cART. Outcomes by month 12 on cART were immunological recovery, hepatitis B surface antigen (HBsAg) loss, viral suppression, and drug resistance. We used descriptive statistics, logistic regression, and linear mixed models. RESULTS: Of the 1087 participants, 92 were HBsAg seropositive, yielding a sample-weighted prevalence of 7.4% (95% confidence interval: 5.6 to 9.2), with 76% genotype HBV-A1. The estimated CD4 recovery on cART was similar between HIV monoinfection and HIV-HBV coinfection groups and between lamivudine- and tenofovir-treated participants. HBsAg loss was documented in 20% (4/20) of lamivudine-treated and 18% (3/17) of tenofovir-treated participants (P = 0.305). Viral suppression (HBV-DNA < 20 IU/mL) was achieved in 61.5% (16/26) of lamivudine-treated and 71.4% (15/21) of tenofovir-treated participants (P = 0.477). HBV pol sequencing demonstrated M204I (n = 3) and N236T (n = 1) resistance-associated mutations in 4 of 8 (50%) lamivudine-treated participants and none in tenofovir-treated participants. Occult HBV infection was present in 13.3% before cART, but by month 12, HBV-DNA was below the limit of detection (<15 IU/mL) in 90.5% (19/21) of lamivudine-treated and 100% (18/18) of tenofovir-treated participants (P = 0.179). CONCLUSIONS: Tenofovir-containing first-line cART is preferred for HIV-HBV coinfection in Africa because of a superior resistance profile relative to lamivudine monotherapy. Extended follow-up will be needed to determine long-term complications of occult HBV coinfection. Improved access to HBsAg screening and tenofovir is needed.'
p38470
sS'CN'
p38471
(lp38472
S'PharmAccess African Studies to Evaluate Resistance (PASER)'
p38473
asS'IP'
p38474
S'2'
sS'IS'
p38475
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p38476
sS'DCOM'
p38477
S'20131113'
p38478
sS'AU'
p38479
(lp38480
S'Hamers RL'
p38481
aS'Zaaijer HL'
p38482
aS'Wallis CL'
p38483
aS'Siwale M'
p38484
aS'Ive P'
p38485
aS'Botes ME'
p38486
aS'Sigaloff KC'
p38487
aS'Hoepelman AI'
p38488
aS'Stevens WS'
p38489
aS'Rinke de Wit TF'
p38490
asS'VI'
p38491
S'64'
p38492
sS'MHDA'
p38493
S'2013/11/14 06:00'
p38494
sS'MH'
p38495
(lp38496
S'Adenine/administration & dosage/*analogs & derivatives/therapeutic use'
p38497
aS'Adult'
p38498
aS'*Anti-HIV Agents/administration & dosage/therapeutic use'
p38499
aS'Antiretroviral Therapy, Highly Active'
p38500
aS'Cohort Studies'
p38501
aS'Coinfection/*drug therapy/epidemiology/virology'
p38502
aS'DNA, Viral/analysis/genetics'
p38503
aS'Drug Resistance, Viral/drug effects/genetics'
p38504
aS'Drug Therapy, Combination'
p38505
aS'Female'
p38506
aS'HIV Infections/*complications/drug therapy/epidemiology/virology'
p38507
aS'HIV-1/drug effects'
p38508
aS'Hepatitis B/*complications/*drug therapy/epidemiology/virology'
p38509
aS'Hepatitis B virus/drug effects/genetics'
p38510
aS'Humans'
p38511
aS'*Lamivudine/administration & dosage/therapeutic use'
p38512
aS'Male'
p38513
aS'Middle Aged'
p38514
aS'Mutation'
p38515
aS'*Organophosphonates/administration & dosage/therapeutic use'
p38516
aS'Prospective Studies'
p38517
aS'*Reverse Transcriptase Inhibitors/administration & dosage/therapeutic use'
p38518
aS'South Africa'
p38519
aS'Tenofovir'
p38520
aS'Treatment Outcome'
p38521
aS'Zambia/epidemiology'
p38522
asS'EDAT'
p38523
S'2013/07/31 06:00'
p38524
sS'SO'
p38525
S'J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):174-82. doi: 10.1097/QAI.0b013e3182a60f7d.'
p38526
sS'SB'
p38527
S'IM X'
p38528
sS'PMID'
p38529
S'23892239'
p38530
sS'PST'
p38531
S'ppublish'
p38532
stRp38533
ag2
(g3
g4
(dp38534
S'LID'
p38535
S'10.1186/1471-2334-13-349 [doi]'
p38536
sS'STAT'
p38537
S'MEDLINE'
p38538
sS'DEP'
p38539
S'20130726'
p38540
sS'DA'
p38541
S'20140723'
p38542
sS'AID'
p38543
(lp38544
S'1471-2334-13-349 [pii]'
p38545
aS'10.1186/1471-2334-13-349 [doi]'
p38546
asS'CRDT'
p38547
(lp38548
S'2013/07/30 06:00'
p38549
asS'DP'
p38550
S'2013'
p38551
sS'OWN'
p38552
S'NLM'
p38553
sS'PT'
p38554
(lp38555
S'Journal Article'
p38556
aS"Research Support, Non-U.S. Gov't"
p38557
asS'LA'
p38558
(lp38559
S'eng'
p38560
asS'DCOM'
p38561
S'20141113'
p38562
sS'JT'
p38563
S'BMC infectious diseases'
p38564
sS'LR'
p38565
S'20150423'
p38566
sS'FAU'
p38567
(lp38568
S'Waako, James'
p38569
aS'Verver, Suzanne'
p38570
aS'Wajja, Anne'
p38571
aS'Ssengooba, Willy'
p38572
aS'Joloba, Moses L'
p38573
aS'Colebunders, Robert'
p38574
aS'Musoke, Philippa'
p38575
aS'Mayanja-Kizza, Harriet'
p38576
asS'TI'
p38577
S'Burden of tuberculosis disease among adolescents in a rural cohort in Eastern Uganda.'
p38578
sS'PL'
p38579
S'England'
p38580
sS'PG'
p38581
S'349'
p38582
sS'JID'
p38583
S'100968551'
p38584
sS'AB'
p38585
S'BACKGROUND: The world health organization (WHO) declared tuberculosis (TB) a global emergency, mainly affecting people in sub-Saharan Africa. However there is little data about the burden of TB among adolescents. We estimated the prevalence and incidence of TB and assessed factors associated with TB among adolescents aged 12-18 years in a rural population in Uganda in order to prepare the site for phase III clinical trials with novel TB vaccines among adolescents. METHODS: In a prospective cohort study, we recruited 5000 adolescents and followed them actively, every 6 months, for 1-2 years. Participants suspected of having TB were those who had any of; TB signs and symptoms, history of TB contact or a positive tuberculin skin test (TST) of >/=10 mm. Laboratory investigations included sputum smear microscopy and culture. RESULTS: Of the 5000 participants, eight culture confirmed cases of TB were found at baseline: a prevalence of 160/100,000 (95% confidence interval (CI), 69-315). There were 13 incident TB cases detected in an average of 1.1 person years: an incidence of 235/100,000 person years (95% CI, 125-402). None of the confirmed TB cases were HIV infected. Predictors for prevalent TB disease were: a history of TB contact and a cough >/= 2 weeks at baseline and being out of school, while the only predictor for incident TB was a positive TST during follow-up. CONCLUSION: The TB incidence among adolescents in this rural part of Uganda seemed too low for a phase III TB vaccine trial. However, the study site demonstrated capability to handle a large number of participants with minimal loss to follow-up and its suitability for future clinical trials. Improved contact tracing in TB program activities is likely to increase TB case detection among adolescents. Future studies should explore possible pockets of higher TB incidence in urban areas and among out of school youth.'
p38586
sS'VI'
p38587
S'13'
p38588
sS'IS'
p38589
S'1471-2334 (Electronic) 1471-2334 (Linking)'
p38590
sS'PMC'
p38591
S'PMC3735406'
p38592
sS'AU'
p38593
(lp38594
S'Waako J'
p38595
aS'Verver S'
p38596
aS'Wajja A'
p38597
aS'Ssengooba W'
p38598
aS'Joloba ML'
p38599
aS'Colebunders R'
p38600
aS'Musoke P'
p38601
aS'Mayanja-Kizza H'
p38602
asS'MHDA'
p38603
S'2014/11/14 06:00'
p38604
sS'PHST'
p38605
(lp38606
S'2013/03/14 [received]'
p38607
aS'2013/07/24 [accepted]'
p38608
aS'2013/07/26 [aheadofprint]'
p38609
asS'OID'
p38610
(lp38611
S'NLM: PMC3735406'
p38612
asS'MH'
p38613
(lp38614
S'Adolescent'
p38615
aS'Child'
p38616
aS'Cost of Illness'
p38617
aS'Female'
p38618
aS'Humans'
p38619
aS'Incidence'
p38620
aS'Male'
p38621
aS'Prevalence'
p38622
aS'Prospective Studies'
p38623
aS'Risk Factors'
p38624
aS'Rural Population/statistics & numerical data'
p38625
aS'Tuberculosis/*epidemiology'
p38626
aS'Uganda/epidemiology'
p38627
asS'EDAT'
p38628
S'2013/07/31 06:00'
p38629
sS'SO'
p38630
S'BMC Infect Dis. 2013 Jul 26;13:349. doi: 10.1186/1471-2334-13-349.'
p38631
sS'SB'
p38632
S'IM'
p38633
sS'PMID'
p38634
S'23890464'
p38635
sS'TA'
p38636
S'BMC Infect Dis'
p38637
sS'PST'
p38638
S'epublish'
p38639
stRp38640
ag2
(g3
g4
(dp38641
S'LID'
p38642
S'10.1186/1472-698X-13-32 [doi]'
p38643
sS'STAT'
p38644
S'MEDLINE'
p38645
sS'DEP'
p38646
S'20130725'
p38647
sS'DA'
p38648
S'20130729'
p38649
sS'AID'
p38650
(lp38651
S'1472-698X-13-32 [pii]'
p38652
aS'10.1186/1472-698X-13-32 [doi]'
p38653
asS'CRDT'
p38654
(lp38655
S'2013/07/27 06:00'
p38656
asS'DP'
p38657
S'2013'
p38658
sS'OWN'
p38659
S'NLM'
p38660
sS'PT'
p38661
(lp38662
S'Journal Article'
p38663
aS"Research Support, Non-U.S. Gov't"
p38664
asS'LA'
p38665
(lp38666
S'eng'
p38667
asS'DCOM'
p38668
S'20140217'
p38669
sS'JT'
p38670
S'BMC international health and human rights'
p38671
sS'LR'
p38672
S'20150423'
p38673
sS'FAU'
p38674
(lp38675
S'Juma, Milka'
p38676
aS'Alaii, Jane'
p38677
aS'Bartholomew, L Kay'
p38678
aS'Askew, Ian'
p38679
aS'Van den Born, Bart'
p38680
asS'TI'
p38681
S"Understanding orphan and non-orphan adolescents' sexual risks in the context of poverty: a qualitative study in Nyanza Province, Kenya."
p38682
sS'PL'
p38683
S'England'
p38684
sS'PG'
p38685
S'32'
p38686
sS'JID'
p38687
S'101088678'
p38688
sS'AB'
p38689
S"BACKGROUND: Some studies show orphanhood to be associated with increased sexual risk-taking while others have not established this relationship, but have found factors other than orphanhood as predictors of sexual risk behaviours and outcomes among adolescents. This study examines community members' perceptions of how poverty influences adolescent sexual behaviour and outcomes in four districts of Nyanza Province, Kenya. METHODS: Eight study sites within the four districts were randomly selected. Focus group discussions were conducted with a purposive sample of adolescents, parents and caregivers. Key informant interviews were undertaken with a purposive sample of community leaders, child welfare and healthcare workers, and adolescents. The two methods elicited information on factors perceived to predispose adolescent orphans and non-orphans to sexual risks. Data were analysed through line-by-line coding, grouped into families and retrieved as themes and sub-themes. RESULTS: Participants included 147 adolescents and parents/caregivers in 14 focus groups and 13 key informants. Poverty emerged as a key predisposing factor to sexual risk behaviour among orphans and non-orphans. Poverty was associated with lack of food, poor housing, school dropout, and engaging in income generating activities, all of which increase their vulnerability to transactional sex, early marriage, sexual experimentation, and the eventual consequences of increased risk of unintended pregnancies and STI/HIV. CONCLUSION: Poverty was perceived to contribute to increasing sexual risks among orphan and non-orphan adolescents through survival strategies adopted to be able to meet their basic needs. Policies for prevention and intervention that target adolescents in a generalized poverty and HIV epidemic should integrate economic empowerment for caregivers and life skills for adolescents to reduce vulnerabilities of orphan and non-orphan adolescents to sexual risk behaviour."
p38690
sS'AD'
p38691
S'Department of Health Promotion, Maastricht University, Maastricht, The Netherlands. milka.juma@maastrichtuniversity.nl'
p38692
sS'VI'
p38693
S'13'
p38694
sS'IS'
p38695
S'1472-698X (Electronic) 1472-698X (Linking)'
p38696
sS'PMC'
p38697
S'PMC3725178'
p38698
sS'AU'
p38699
(lp38700
S'Juma M'
p38701
aS'Alaii J'
p38702
aS'Bartholomew LK'
p38703
aS'Askew I'
p38704
aS'Van den Born B'
p38705
asS'MHDA'
p38706
S'2014/02/18 06:00'
p38707
sS'PHST'
p38708
(lp38709
S'2012/12/12 [received]'
p38710
aS'2013/07/19 [accepted]'
p38711
aS'2013/07/25 [aheadofprint]'
p38712
asS'OID'
p38713
(lp38714
S'NLM: PMC3725178'
p38715
asS'MH'
p38716
(lp38717
S'Adolescent'
p38718
aS'Adult'
p38719
aS'Aged'
p38720
aS'Caregivers/psychology'
p38721
aS'Child, Orphaned/*psychology'
p38722
aS'Evaluation Studies as Topic'
p38723
aS'Female'
p38724
aS'Focus Groups'
p38725
aS'Humans'
p38726
aS'Kenya'
p38727
aS'Male'
p38728
aS'Middle Aged'
p38729
aS'Parents/psychology'
p38730
aS'*Poverty'
p38731
aS'*Psychology, Adolescent'
p38732
aS'Risk Factors'
p38733
aS'Sexual Behavior/*psychology'
p38734
aS'Socioeconomic Factors'
p38735
aS'Young Adult'
p38736
asS'EDAT'
p38737
S'2013/07/28 06:00'
p38738
sS'SO'
p38739
S'BMC Int Health Hum Rights. 2013 Jul 25;13:32. doi: 10.1186/1472-698X-13-32.'
p38740
sS'SB'
p38741
S'IM'
p38742
sS'PMID'
p38743
S'23886019'
p38744
sS'TA'
p38745
S'BMC Int Health Hum Rights'
p38746
sS'PST'
p38747
S'epublish'
p38748
stRp38749
ag2
(g3
g4
(dp38750
S'LID'
p38751
S'10.1097/INF.0b013e31828c3738 [doi]'
p38752
sS'STAT'
p38753
S'MEDLINE'
p38754
sS'JT'
p38755
S'The Pediatric infectious disease journal'
p38756
sS'MID'
p38757
(lp38758
S'NIHMS454903'
p38759
asS'DA'
p38760
S'20130717'
p38761
sS'AID'
p38762
(lp38763
S'10.1097/INF.0b013e31828c3738 [doi]'
p38764
aS'00006454-201308000-00014 [pii]'
p38765
asS'CRDT'
p38766
(lp38767
S'2013/07/18 06:00'
p38768
asS'DP'
p38769
S'2013 Aug'
p38770
sS'AD'
p38771
S'Empilweni Services and Research Unit, Department of Paediatrics & Child Health, Rahima Moosa Mother and Child Hospital, Coronationville, Johannesburg, Gauteng, South Africa. karltechnau@gmail.com'
p38772
sS'OWN'
p38773
S'NLM'
p38774
sS'PT'
p38775
(lp38776
S'Journal Article'
p38777
aS'Research Support, N.I.H., Extramural'
p38778
aS"Research Support, Non-U.S. Gov't"
p38779
asS'LA'
p38780
(lp38781
S'eng'
p38782
asS'FAU'
p38783
(lp38784
S'Technau, Karl-Gunter'
p38785
aS'Lazarus, Erica'
p38786
aS'Kuhn, Louise'
p38787
aS'Abrams, Elaine J'
p38788
aS'Sorour, Gillian'
p38789
aS'Strehlau, Renate'
p38790
aS'Reubenson, Gary'
p38791
aS'Davies, Mary-Ann'
p38792
aS'Coovadia, Ashraf'
p38793
asS'LR'
p38794
S'20150423'
p38795
sS'PG'
p38796
S'851-5'
p38797
sS'TI'
p38798
S'Poor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children.'
p38799
sS'RN'
p38800
(lp38801
S'0 (Anti-HIV Agents)'
p38802
aS'0 (Dideoxynucleosides)'
p38803
aS'WR2TIP26VS (abacavir)'
p38804
asS'PL'
p38805
S'United States'
p38806
sS'TA'
p38807
S'Pediatr Infect Dis J'
p38808
sS'JID'
p38809
S'8701858'
p38810
sS'AB'
p38811
S'BACKGROUND: Concerns about stavudine (d4T) toxicity have led to increased use of abacavir (ABC) in first-line pediatric antiretroviral treatment (ART) regimens. Field experience with ABC in ART-naive children is limited. METHODS: Deidentified demographic, clinical and laboratory data on HIV-infected children initiating ART between 2004 and 2011 in a large pediatric HIV treatment program in Johannesburg, South Africa, were used to compare viral suppression at 6 and 12 months by initial treatment regimen, time to suppression (<400 copies/mL) and rebound (>1000 copies/mL after initial suppression). Adjusted logistic regression was used to investigate confounders and calendar effects. RESULTS: Two thousand thirty-six children initiated either d4T/3TC- or ABC/3TC-based first-line regimens in combination with either boosted lopinavir (LPV/r) or efavirenz (EFV). 1634 received d4T regimens (LPV/r n = 672; EFV n = 962) and 402 ABC regimens (LPV/r n = 192; EFV n = 210). At 6 and 12 months on ART, viral suppression rate was poorer in ABC versus d4T groups within both the LPV/r and EFV groups (P < 0.0001 for all points). In ABC groups, time to suppression was significantly slower (log-rank P < 0.0001 and P = 0.0092 for LPV/r- and EFV-based, respectively) and time to rebound after suppression significantly faster (log-rank P = 0.014 and P = 0.0001 for LPV/r- and EFV-based, respectively). Logistic regression confirmed the worse outcomes in the ABC groups even after adjustment for confounders. CONCLUSION: Data from this urban pediatric ART service program show significantly poorer virological performance of ABC compared with d4T-based regimens, a signal that urgently warrants further investigation.'
p38812
sS'GR'
p38813
(lp38814
S'2U01AI069924-06/AI/NIAID NIH HHS/United States'
p38815
aS'RFA-A-00-08-00005-00/PHS HHS/United States'
p38816
aS'U01 AI069924/AI/NIAID NIH HHS/United States'
p38817
aS'U01AI069924/AI/NIAID NIH HHS/United States'
p38818
aS'PEPFAR/United States'
p38819
asS'IP'
p38820
S'8'
sS'IS'
p38821
S'1532-0987 (Electronic) 0891-3668 (Linking)'
p38822
sS'PMC'
p38823
S'PMC3717192'
p38824
sS'DCOM'
p38825
S'20140509'
p38826
sS'AU'
p38827
(lp38828
S'Technau KG'
p38829
aS'Lazarus E'
p38830
aS'Kuhn L'
p38831
aS'Abrams EJ'
p38832
aS'Sorour G'
p38833
aS'Strehlau R'
p38834
aS'Reubenson G'
p38835
aS'Davies MA'
p38836
aS'Coovadia A'
p38837
asS'VI'
p38838
S'32'
p38839
sS'MHDA'
p38840
S'2014/05/10 06:00'
p38841
sS'OID'
p38842
(lp38843
S'NLM: NIHMS454903'
p38844
aS'NLM: PMC3717192'
p38845
asS'MH'
p38846
(lp38847
S'Anti-HIV Agents/*therapeutic use'
p38848
aS'Child'
p38849
aS'Child, Preschool'
p38850
aS'Dideoxynucleosides/*therapeutic use'
p38851
aS'Female'
p38852
aS'HIV Infections/*drug therapy/*virology'
p38853
aS'Humans'
p38854
aS'Infant'
p38855
aS'Male'
p38856
aS'Retrospective Studies'
p38857
aS'Treatment Outcome'
p38858
aS'Viral Load'
p38859
asS'EDAT'
p38860
S'2013/07/19 06:00'
p38861
sS'SO'
p38862
S'Pediatr Infect Dis J. 2013 Aug;32(8):851-5. doi: 10.1097/INF.0b013e31828c3738.'
p38863
sS'SB'
p38864
S'IM'
p38865
sS'PMID'
p38866
S'23860481'
p38867
sS'PST'
p38868
S'ppublish'
p38869
stRp38870
ag2
(g3
g4
(dp38871
S'LID'
p38872
S'10.11604/pamj.2013.15.5.1889 [doi]'
p38873
sS'STAT'
p38874
S'MEDLINE'
p38875
sS'DEP'
p38876
S'20130503'
p38877
sS'DA'
p38878
S'20130712'
p38879
sS'AID'
p38880
(lp38881
S'10.11604/pamj.2013.15.5.1889 [doi]'
p38882
aS'PAMJ-15-5 [pii]'
p38883
asS'CRDT'
p38884
(lp38885
S'2013/07/13 06:00'
p38886
asS'DP'
p38887
S'2013'
p38888
sS'OWN'
p38889
S'NLM'
p38890
sS'PT'
p38891
(lp38892
S'Comparative Study'
p38893
aS'Journal Article'
p38894
asS'LA'
p38895
(lp38896
S'eng'
p38897
asS'DCOM'
p38898
S'20140210'
p38899
sS'JT'
p38900
S'The Pan African medical journal'
p38901
sS'LR'
p38902
S'20150423'
p38903
sS'FAU'
p38904
(lp38905
S'Takuva, Simbarashe'
p38906
aS'Evans, Denise'
p38907
aS'Zuma, Khangelani'
p38908
aS'Okello, Velephi'
p38909
aS'Louwagie, Goedele'
p38910
asS'TI'
p38911
S'Comparative durability of nevirapine versus efavirenz in first-line regimens during the first year of initiating antiretroviral therapy among Swaziland HIV-infected adults.'
p38912
sS'RN'
p38913
(lp38914
S'0 (Anti-HIV Agents)'
p38915
aS'0 (Benzoxazines)'
p38916
aS'0 (Reverse Transcriptase Inhibitors)'
p38917
aS'99DK7FVK1H (Nevirapine)'
p38918
aS'JE6H2O27P8 (efavirenz)'
p38919
asS'PL'
p38920
S'Uganda'
p38921
sS'PG'
p38922
S'5'
sS'JID'
p38923
S'101517926'
p38924
sS'AB'
p38925
S'Nevirapine (NVP) and Efavirenz (EFV) have generally comparable clinical and virologic efficacy. However, data comparing NVP durability to EFV are imprecise. We analyzed cohort data to compare durability of NVP to EFV among patients initiating ART in Mbabane, Swaziland. The primary outcome was poor regimen durability defined as any modification of NVP or EFV to the ART regimen. Multivariate Cox proportional hazards models were employed to estimate the risk of poor regimen durability (all-cause) for the two regimens and also separately to estimate risk of drug-related toxicity. We analyzed records for 769 patients initiating ART in Mbabane, Swaziland from March 2006 to December 2007. 30 patients (3.9%) changed their NVP or EFV-based regimen during follow up. Cumulative incidence for poor regimen durability was 5.3% and 2.7% for NVP and EFV, respectively. Cumulative incidence for drug-related toxicity was 1.9% and 2.7% for NVP and EFV, respectively. Burden of TB was high and 14 (46.7%) modifications were due to patients substituting NVP due to beginning TB treatment. Though the estimates were imprecise, use of NVP - based regimens seemed to be associated with higher risk of modifications compared to use of EFV - based regimens (HR 2.03 95%CI 0.58 - 7.05) and NVP - based regimens had a small advantage over EFV - based regimens with regard to toxicity - related modifications (HR 0.87 95%CI 0.26 - 2.90). Due to the high burden of TB and a significant proportion of patients changing their ART regimen after starting TB treatment, use of EFV as the preferred NNRTI over NVP in high TB endemic settings may result in improved first-line regimen tolerance. Further studies comparing the cost-effectiveness of delivering these two NNRTIs in light of their different limitations are required.'
p38926
sS'AD'
p38927
S'Clinical HIV Research Unit, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, South Africa.'
p38928
sS'VI'
p38929
S'15'
p38930
sS'IS'
p38931
S'1937-8688 (Electronic)'
p38932
sS'PMC'
p38933
S'PMC3708322'
p38934
sS'AU'
p38935
(lp38936
S'Takuva S'
p38937
aS'Evans D'
p38938
aS'Zuma K'
p38939
aS'Okello V'
p38940
aS'Louwagie G'
p38941
asS'MHDA'
p38942
S'2014/02/11 06:00'
p38943
sS'PHST'
p38944
(lp38945
S'2013 [ppublish]'
p38946
aS'2012/07/18 [received]'
p38947
aS'2013/01/03 [accepted]'
p38948
aS'2013/05/03 [epublish]'
p38949
asS'OT'
p38950
(lp38951
S'Antiretroviral therapy'
p38952
aS'Efavirenz'
p38953
aS'Nevirapine'
p38954
aS'Resource limited setting'
p38955
aS'Swaziland'
p38956
aS'Tolerability'
p38957
aS'Toxicity'
p38958
asS'OTO'
p38959
(lp38960
S'NOTNLM'
p38961
asS'OID'
p38962
(lp38963
S'NLM: PMC3708322'
p38964
asS'MH'
p38965
(lp38966
S'Adult'
p38967
aS'Anti-HIV Agents/administration & dosage/adverse effects/*therapeutic use'
p38968
aS'Benzoxazines/administration & dosage/adverse effects/*therapeutic use'
p38969
aS'Cohort Studies'
p38970
aS'Female'
p38971
aS'Follow-Up Studies'
p38972
aS'HIV Infections/*drug therapy'
p38973
aS'Humans'
p38974
aS'Incidence'
p38975
aS'Male'
p38976
aS'Multivariate Analysis'
p38977
aS'Nevirapine/administration & dosage/adverse effects/*therapeutic use'
p38978
aS'Proportional Hazards Models'
p38979
aS'Retrospective Studies'
p38980
aS'Reverse Transcriptase Inhibitors/administration & dosage/adverse effects/therapeutic use'
p38981
aS'Swaziland'
p38982
aS'Treatment Outcome'
p38983
aS'Tuberculosis/epidemiology'
p38984
asS'EDAT'
p38985
S'2013/07/13 06:00'
p38986
sS'SO'
p38987
S'Pan Afr Med J. 2013 May 3;15:5. doi: 10.11604/pamj.2013.15.5.1889. Print 2013.'
p38988
sS'SB'
p38989
S'IM'
p38990
sS'PMID'
p38991
S'23847702'
p38992
sS'TA'
p38993
S'Pan Afr Med J'
p38994
sS'PST'
p38995
S'epublish'
p38996
stRp38997
ag2
(g3
g4
(dp38998
S'LID'
p38999
S'10.1097/01.aids.0000432451.75980.1b [doi]'
p39000
sS'STAT'
p39001
S'MEDLINE'
p39002
sS'JT'
p39003
S'AIDS (London, England)'
p39004
sS'DA'
p39005
S'20131007'
p39006
sS'AID'
p39007
(lp39008
S'10.1097/01.aids.0000432451.75980.1b [doi]'
p39009
asS'CRDT'
p39010
(lp39011
S'2013/07/12 06:00'
p39012
asS'DP'
p39013
S'2013 Oct 23'
p39014
sS'AD'
p39015
S"aDepartment of Paediatric Infectious Diseases, Emma Children's Hospital AMC bHIV Monitoring Foundation, Amsterdam cDepartment of Paediatrics, Sophia Children's Hospital, ErasmusMC dDepartment of Paediatrics, Sophia Children's Hospital/Viroscience Lab, ErasmusMC, Rotterdam eDepartment of Paediatrics, Wilhelmina Children's Hospital, Utrecht fDepartment of Paediatrics, University of Groningen, University Medical Centre Groningen gRadboud University Medical Centre, Nijmegen and the Nijmegen Institute for Infection, Inflammation and Immunity, The Netherlands. *S.C. and C.S. contributed equally to the writing of this article."
p39016
sS'OWN'
p39017
S'NLM'
p39018
sS'PT'
p39019
(lp39020
S'Journal Article'
p39021
asS'LA'
p39022
(lp39023
S'eng'
p39024
asS'FAU'
p39025
(lp39026
S'Cohen, Sophie'
p39027
aS'Smit, Colette'
p39028
aS'van Rossum, Annemarie M C'
p39029
aS'Fraaij, Pieter L A'
p39030
aS'Wolfs, Tom F W'
p39031
aS'Geelen, Sibyl P M'
p39032
aS'Scholvinck, Elisabeth H'
p39033
aS'Warris, Adilia'
p39034
aS'Scherpbier, Henriette J'
p39035
aS'Pajkrt, Dasja'
p39036
asS'PG'
p39037
S'2567-75'
p39038
sS'TI'
p39039
S'Long-term response to combination antiretroviral therapy in HIV-infected children in the Netherlands registered from 1996 to 2012.'
p39040
sS'RN'
p39041
(lp39042
S'0 (Anti-Retroviral Agents)'
p39043
asS'PL'
p39044
S'England'
p39045
sS'TA'
p39046
S'AIDS'
p39047
sS'FIR'
p39048
(lp39049
S'Cohen, S'
p39050
aS'Pajkrt, D'
p39051
aS'Kuijpers, T W'
p39052
aS'van der Plas, A'
p39053
aS'Scherpbier, H J'
p39054
aS'Weijsenfeld, A'
p39055
aS'Doedens, R A'
p39056
aS'de Groot-de Jonge, H'
p39057
aS'Scholvinck, E H'
p39058
aS'Burger, D M'
p39059
aS'van der Flier, M'
p39060
aS'Strik-Albers, R'
p39061
aS'Warris, A'
p39062
aS'Driessen, G J A'
p39063
aS'Fraaij, P L A'
p39064
aS'de Groot, R'
p39065
aS'Hartwig, N G'
p39066
aS'van Jaarsveld, P'
p39067
aS'van der Knaap, L'
p39068
aS'van Rossum, A M C'
p39069
aS'Bont, L'
p39070
aS'Geelen, S P M'
p39071
aS'Nauta, N'
p39072
aS'Wolfs, T F W'
p39073
asS'JID'
p39074
S'8710219'
p39075
sS'AB'
p39076
S'OBJECTIVES: To describe demographic and treatment characteristics of the Dutch vertically HIV-infected paediatric population from 1996 to 2012, and to investigate the long-term virological and immunological response to combination antiretroviral therapy (cART), with emphasis on the influence of age at cART initiation and initial CD4 cell counts. DESIGN: Descriptive cohort study. METHODS: From 1996 to 2012, all paediatric HIV clinics in the Netherlands provided data on their HIV-infected population. Descriptive statistics, parametric and non-parametric comparative tests, and random-effects linear regression models were performed to investigate the different aspects of this cohort. RESULTS: A total of 229 vertically HIV-infected children were included. The majority of all mothers (64%) and almost half of the children (43%) originated from sub-Saharan Africa. Ritonavir-boosted lopinavir and efavirenz have replaced indinavir, nelfinavir and nevirapine as preferred first-line cART regimens. Long-term CD4 T-cell reconstitution (with CD4 cell counts corrected for age) was independent of age and CD4 cell count at cART initiation. The decline in HIV viral load after cART introduction occurred faster over the studied time period. The percentage of children with an undetectable viral load rose substantially from 1996 to 2012. Mortality was 0.3 per 100 person-years. CONCLUSION: A sustained immunological response in the Dutch paediatric HIV-infected population was independent of age as well as CD4 cell count at cART initiation, despite a higher initial HIV viral load in the youngest children. The percentage of children with an undetectable HIV viral load rose substantially over the years and there was a low mortality rate in comparison with reports from other industrialized countries.'
p39077
sS'CN'
p39078
(lp39079
S'Dutch Paediatric HIV Study Group'
p39080
asS'IP'
p39081
S'16'
p39082
sS'IS'
p39083
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p39084
sS'IR'
p39085
(lp39086
S'Cohen S'
p39087
aS'Pajkrt D'
p39088
aS'Kuijpers TW'
p39089
aS'van der Plas A'
p39090
aS'Scherpbier HJ'
p39091
aS'Weijsenfeld A'
p39092
aS'Doedens RA'
p39093
aS'de Groot-de Jonge H'
p39094
aS'Scholvinck EH'
p39095
aS'Burger DM'
p39096
aS'van der Flier M'
p39097
aS'Strik-Albers R'
p39098
aS'Warris A'
p39099
aS'Driessen GJ'
p39100
aS'Fraaij PL'
p39101
aS'de Groot R'
p39102
aS'Hartwig NG'
p39103
aS'van Jaarsveld P'
p39104
aS'van der Knaap L'
p39105
aS'van Rossum AM'
p39106
aS'Bont L'
p39107
aS'Geelen SP'
p39108
aS'Nauta N'
p39109
aS'Wolfs TF'
p39110
asS'DCOM'
p39111
S'20140430'
p39112
sS'AU'
p39113
(lp39114
S'Cohen S'
p39115
aS'Smit C'
p39116
aS'van Rossum AM'
p39117
aS'Fraaij PL'
p39118
aS'Wolfs TF'
p39119
aS'Geelen SP'
p39120
aS'Scholvinck EH'
p39121
aS'Warris A'
p39122
aS'Scherpbier HJ'
p39123
aS'Pajkrt D'
p39124
asS'VI'
p39125
S'27'
p39126
sS'MHDA'
p39127
S'2014/05/03 06:00'
p39128
sS'MH'
p39129
(lp39130
S'Adolescent'
p39131
aS'Anti-Retroviral Agents/*therapeutic use'
p39132
aS'Antiretroviral Therapy, Highly Active/*methods'
p39133
aS'CD4 Lymphocyte Count'
p39134
aS'Child'
p39135
aS'Child, Preschool'
p39136
aS'Cohort Studies'
p39137
aS'Female'
p39138
aS'HIV Infections/*drug therapy/immunology/virology'
p39139
aS'Humans'
p39140
aS'Infant'
p39141
aS'Male'
p39142
aS'Netherlands'
p39143
aS'Treatment Outcome'
p39144
aS'Viral Load'
p39145
asS'EDAT'
p39146
S'2013/07/12 06:00'
p39147
sS'SO'
p39148
S'AIDS. 2013 Oct 23;27(16):2567-75. doi: 10.1097/01.aids.0000432451.75980.1b.'
p39149
sS'SB'
p39150
S'IM X'
p39151
sS'PMID'
p39152
S'23842124'
p39153
sS'PST'
p39154
S'ppublish'
p39155
stRp39156
ag2
(g3
g4
(dp39157
S'LID'
p39158
S'10.1371/journal.pone.0067311 [doi]'
p39159
sS'STAT'
p39160
S'MEDLINE'
p39161
sS'DEP'
p39162
S'20130628'
p39163
sS'DA'
p39164
S'20130710'
p39165
sS'AID'
p39166
(lp39167
S'10.1371/journal.pone.0067311 [doi]'
p39168
aS'PONE-D-13-14167 [pii]'
p39169
asS'CRDT'
p39170
(lp39171
S'2013/07/11 06:00'
p39172
asS'DP'
p39173
S'2013'
p39174
sS'AD'
p39175
S'Department of Medicine, University of Malawi, College of Medicine, Blantyre, Malawi.'
p39176
sS'OWN'
p39177
S'NLM'
p39178
sS'PT'
p39179
(lp39180
S'Journal Article'
p39181
aS"Research Support, Non-U.S. Gov't"
p39182
asS'LA'
p39183
(lp39184
S'eng'
p39185
asS'FAU'
p39186
(lp39187
S'Rothe, Camilla'
p39188
aS'Sloan, Derek J'
p39189
aS'Goodson, Patrick'
p39190
aS'Chikafa, Jean'
p39191
aS'Mukaka, Mavuto'
p39192
aS'Denis, Brigitte'
p39193
aS'Harrison, Tom'
p39194
aS'van Oosterhout, Joep J'
p39195
aS'Heyderman, Robert S'
p39196
aS'Lalloo, David G'
p39197
aS'Allain, Theresa'
p39198
aS'Feasey, Nicholas A'
p39199
asS'JT'
p39200
S'PloS one'
p39201
sS'LR'
p39202
S'20160713'
p39203
sS'PG'
p39204
S'e67311'
p39205
sS'TI'
p39206
S'A prospective longitudinal study of the clinical outcomes from cryptococcal meningitis following treatment induction with 800 mg oral fluconazole in Blantyre, Malawi.'
p39207
sS'RN'
p39208
(lp39209
S'0 (Antifungal Agents)'
p39210
aS'8VZV102JFY (Fluconazole)'
p39211
asS'PL'
p39212
S'United States'
p39213
sS'TA'
p39214
S'PLoS One'
p39215
sS'JID'
p39216
S'101285081'
p39217
sS'AB'
p39218
S'INTRODUCTION: Cryptococcal meningitis is the most common neurological infection in HIV infected patients in Sub Saharan Africa, where gold standard treatment with intravenous amphotericin B and 5 flucytosine is often unavailable or difficult to administer. Fluconazole monotherapy is frequently recommended in national guidelines but is a fungistatic drug compromised by uncertainty over optimal dosing and a paucity of clinical end-point outcome data. METHODS: From July 2010 until March 2011, HIV infected adults with a first episode of cryptococcal meningitis were recruited at Queen Elizabeth Central Hospital, Blantyre, Malawi. Patients were treated with oral fluconazole monotherapy 800 mg daily, as per national guidelines. ART was started at 4 weeks. Outcomes and factors associated with treatment failure were assessed 4, 10 and 52 weeks after fluconazole initiation. RESULTS: Sixty patients were recruited. 26/60 (43%) died by 4 weeks. 35/60 (58.0%) and 43/56 (77%) died or failed treatment by 10 or 52 weeks respectively. Reduced consciousness (Glasgow Coma Score <14 of 15), moderate/severe neurological disability (modified Rankin Score >3 of 5) and confusion (Abbreviated Mental Test Score <8 of 10) were all common at baseline and associated with death or treatment failure. ART prior to recruitment was not associated with better outcomes. CONCLUSIONS: Mortality and treatment failure from cryptococcal meningitis following initiation of treatment with 800 mg oral fluconazole is unacceptably high. To improve outcomes, there is an urgent need for better therapeutic strategies and point-of-care diagnostics, allowing earlier diagnosis before development of neurological deficit.'
p39219
sS'GR'
p39220
(lp39221
S'084679/Z/08/Z/Wellcome Trust/United Kingdom'
p39222
aS'100890/Wellcome Trust/United Kingdom'
p39223
aS'101113/Wellcome Trust/United Kingdom'
p39224
aS'G1100814/Medical Research Council/United Kingdom'
p39225
asS'IP'
p39226
S'6'
sS'IS'
p39227
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p39228
sS'PMC'
p39229
S'PMC3696104'
p39230
sS'DCOM'
p39231
S'20140121'
p39232
sS'AU'
p39233
(lp39234
S'Rothe C'
p39235
aS'Sloan DJ'
p39236
aS'Goodson P'
p39237
aS'Chikafa J'
p39238
aS'Mukaka M'
p39239
aS'Denis B'
p39240
aS'Harrison T'
p39241
aS'van Oosterhout JJ'
p39242
aS'Heyderman RS'
p39243
aS'Lalloo DG'
p39244
aS'Allain T'
p39245
aS'Feasey NA'
p39246
asS'VI'
p39247
S'8'
sS'MHDA'
p39248
S'2014/01/22 06:00'
p39249
sS'PHST'
p39250
(lp39251
S'2013 [ppublish]'
p39252
aS'2013/03/29 [received]'
p39253
aS'2013/05/17 [accepted]'
p39254
aS'2013/06/28 [epublish]'
p39255
asS'OID'
p39256
(lp39257
S'NLM: PMC3696104'
p39258
asS'MH'
p39259
(lp39260
S'Adolescent'
p39261
aS'Adult'
p39262
aS'Antifungal Agents/*therapeutic use'
p39263
aS'Female'
p39264
aS'Fluconazole/*therapeutic use'
p39265
aS'HIV Infections/*complications/mortality'
p39266
aS'Humans'
p39267
aS'Induction Chemotherapy'
p39268
aS'Kaplan-Meier Estimate'
p39269
aS'Longitudinal Studies'
p39270
aS'Malawi'
p39271
aS'Male'
p39272
aS'Meningitis, Cryptococcal/*drug therapy/mortality'
p39273
aS'Middle Aged'
p39274
aS'Multivariate Analysis'
p39275
aS'Proportional Hazards Models'
p39276
aS'Prospective Studies'
p39277
aS'Treatment Failure'
p39278
aS'Young Adult'
p39279
asS'EDAT'
p39280
S'2013/07/11 06:00'
p39281
sS'SO'
p39282
S'PLoS One. 2013 Jun 28;8(6):e67311. doi: 10.1371/journal.pone.0067311. Print 2013.'
p39283
sS'SB'
p39284
S'IM'
p39285
sS'PMID'
p39286
S'23840659'
p39287
sS'PST'
p39288
S'epublish'
p39289
stRp39290
ag2
(g3
g4
(dp39291
S'LID'
p39292
S'10.7448/IAS.16.1.18445 [doi]'
p39293
sS'STAT'
p39294
S'MEDLINE'
p39295
sS'DEP'
p39296
S'20130703'
p39297
sS'DA'
p39298
S'20130705'
p39299
sS'AID'
p39300
(lp39301
S'18445 [pii]'
p39302
asS'CRDT'
p39303
(lp39304
S'2013/07/06 06:00'
p39305
asS'DP'
p39306
S'2013'
p39307
sS'OWN'
p39308
S'NLM'
p39309
sS'PT'
p39310
(lp39311
S'Journal Article'
p39312
aS'Meta-Analysis'
p39313
aS"Research Support, Non-U.S. Gov't"
p39314
aS'Review'
p39315
asS'LA'
p39316
(lp39317
S'eng'
p39318
asS'DCOM'
p39319
S'20131111'
p39320
sS'JT'
p39321
S'Journal of the International AIDS Society'
p39322
sS'LR'
p39323
S'20150423'
p39324
sS'FAU'
p39325
(lp39326
S'Emdin, Connor A'
p39327
aS'Chong, Nicholas J'
p39328
aS'Millson, Peggy E'
p39329
asS'TI'
p39330
S'Non-physician clinician provided HIV treatment results in equivalent outcomes as physician-provided care: a meta-analysis.'
p39331
sS'RN'
p39332
(lp39333
S'0 (Anti-HIV Agents)'
p39334
asS'PL'
p39335
S'Switzerland'
p39336
sS'PG'
p39337
S'18445'
p39338
sS'JID'
p39339
S'101478566'
p39340
sS'AB'
p39341
S'INTRODUCTION: A severe healthcare worker shortage in sub-Saharan Africa is inhibiting the expansion of HIV treatment. Task shifting, the transfer of antiretroviral therapy (ART) management and initiation from doctors to nurses and other non-physician clinicians, has been proposed to address this problem. However, many health officials remain wary about implementing task shifting policies due to concerns that non-physicians will provide care inferior to physicians. To determine if non-physician-provided HIV care does result in equivalent outcomes to physician-provided care, a meta-analysis was performed. METHODS: Online databases were searched using a predefined strategy. The results for four primary outcomes were combined using a random effects model with sub-groups of non-physician-managed ART and -initiated ART. TB diagnosis rates, adherence, weight gain and patient satisfaction were summarized qualitatively. RESULTS: Mortality (N=59,666) had similar outcomes for non-physicians and physicians, with a hazard ratio of 1.05 (CI: 0.88-1.26). The increase in CD4 levels at one year, as a difference in means of 2.3 (N=17,142, CI: -12.7-17.3), and viral failure at one year, as a risk ratio of 0.89 (N=10,344, CI: 0.65-1.23), were similar for physicians and non-physicians. Interestingly, loss to follow-up (LTFU) (N=53,435) was reduced for non-physicians with a hazard ratio of 0.72 (CI: 0.56-0.94). TB diagnosis rates, adherence and weight gain were similar for non-physicians and physicians. Patient satisfaction appeared higher for non-physicians in qualitative components of studies and was attributed to non-physicians spending more time with patients as well as providing more holistic care. CONCLUSIONS: Non-physician-provided HIV care results in equivalent outcomes to care provided by physicians and may result in decreased LTFU rates.'
p39342
sS'AD'
p39343
S'Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. connor.emdin@mail.utoronto.ca'
p39344
sS'VI'
p39345
S'16'
p39346
sS'IS'
p39347
S'1758-2652 (Electronic) 1758-2652 (Linking)'
p39348
sS'PMC'
p39349
S'PMC3702014'
p39350
sS'AU'
p39351
(lp39352
S'Emdin CA'
p39353
aS'Chong NJ'
p39354
aS'Millson PE'
p39355
asS'MHDA'
p39356
S'2013/11/12 06:00'
p39357
sS'PHST'
p39358
(lp39359
S'2012/09/30 [received]'
p39360
aS'2013/05/02 [revised]'
p39361
aS'2013/06/06 [accepted]'
p39362
asS'OT'
p39363
(lp39364
S'ART'
p39365
aS'HIV treatment'
p39366
aS'antiretroviral therapy'
p39367
aS'non-physician'
p39368
aS'substitution of physicians'
p39369
aS'task shifting'
p39370
asS'OTO'
p39371
(lp39372
S'NOTNLM'
p39373
asS'OID'
p39374
(lp39375
S'NLM: PMC3702014'
p39376
asS'MH'
p39377
(lp39378
S'Africa South of the Sahara'
p39379
aS'Anti-HIV Agents/*therapeutic use'
p39380
aS'Body Weight'
p39381
aS'HIV Infections/complications/*drug therapy/pathology'
p39382
aS'Humans'
p39383
aS'Medication Adherence/statistics & numerical data'
p39384
aS'*Nurses'
p39385
aS'Patient Satisfaction/statistics & numerical data'
p39386
aS'*Physicians'
p39387
aS'Survival Analysis'
p39388
aS'Treatment Outcome'
p39389
aS'Tuberculosis/diagnosis'
p39390
asS'EDAT'
p39391
S'2013/07/06 06:00'
p39392
sS'SO'
p39393
S'J Int AIDS Soc. 2013 Jul 3;16:18445. doi: 10.7448/IAS.16.1.18445.'
p39394
sS'SB'
p39395
S'IM X'
p39396
sS'PMID'
p39397
S'23827470'
p39398
sS'TA'
p39399
S'J Int AIDS Soc'
p39400
sS'PST'
p39401
S'epublish'
p39402
stRp39403
ag2
(g3
g4
(dp39404
S'LID'
p39405
S'10.1080/17441692.2013.810297 [doi]'
p39406
sS'STAT'
p39407
S'MEDLINE'
p39408
sS'DEP'
p39409
S'20130704'
p39410
sS'DA'
p39411
S'20130725'
p39412
sS'AID'
p39413
(lp39414
S'10.1080/17441692.2013.810297 [doi]'
p39415
asS'CRDT'
p39416
(lp39417
S'2013/07/06 06:00'
p39418
asS'DP'
p39419
S'2013 Jul'
p39420
sS'OWN'
p39421
S'NLM'
p39422
sS'PT'
p39423
(lp39424
S'Journal Article'
p39425
aS"Research Support, Non-U.S. Gov't"
p39426
asS'LA'
p39427
(lp39428
S'eng'
p39429
asS'FAU'
p39430
(lp39431
S'Reynolds, Joanna'
p39432
aS'Mangesho, Peter'
p39433
aS'Lemnge, Martha M'
p39434
aS'Vestergaard, Lasse S'
p39435
aS'Chandler, Clare I R'
p39436
asS'JT'
p39437
S'Global public health'
p39438
sS'PG'
p39439
S'670-84'
p39440
sS'TI'
p39441
S"'... in the project they really care for us': meaning and experiences of participating in a clinical study of first-line treatment for malaria and HIV in Tanzanian adults."
p39442
sS'PL'
p39443
S'England'
p39444
sS'TA'
p39445
S'Glob Public Health'
p39446
sS'JID'
p39447
S'101256323'
p39448
sS'AB'
p39449
S"Critiques of biomedical research in low-resource settings typically centre on clinical trials and the 'dissymmetries of power' between the researched and those benefiting from the products of research. It is important to extend this critical lens to other forms of global health research. We conducted a qualitative study in Tanzania to explore meaning and experiences of participating in a clinical observational study evaluating the safety and efficacy of current practice for treating HIV and malaria co-infection. Focus group discussions and in-depth interviews were undertaken with 124 study participants, study staff and health workers. Participants' understanding of the study's research aims was limited, but the practice of participation - engaging with research staff and materials - appeared to facilitate interpretations of the study's value, conceptualised as a 'service'. For those peripheral to the study, however, interpretations of it reflected existing suspicions of experimental research. Our findings indicate the importance of considering the expectations, roles and responsibilities constructed through the practice of participation in different types of research, and how they relate to legacies of research. Understanding how networks of research practice intersect local social and historical contexts can extend discussions of collaboration and engagement with research in low-resource settings."
p39450
sS'AD'
p39451
S'Department of Global Health and Development, London School of Hygiene & Tropical Medicine, London, UK. Joanna.Reynolds@lshtm.ac.uk'
p39452
sS'IP'
p39453
S'6'
sS'IS'
p39454
S'1744-1706 (Electronic) 1744-1692 (Linking)'
p39455
sS'DCOM'
p39456
S'20140401'
p39457
sS'AU'
p39458
(lp39459
S'Reynolds J'
p39460
aS'Mangesho P'
p39461
aS'Lemnge MM'
p39462
aS'Vestergaard LS'
p39463
aS'Chandler CI'
p39464
asS'VI'
p39465
S'8'
sS'MHDA'
p39466
S'2014/04/02 06:00'
p39467
sS'PHST'
p39468
(lp39469
S'2013/07/04 [aheadofprint]'
p39470
asS'MH'
p39471
(lp39472
S'Adult'
p39473
aS'Attitude of Health Personnel'
p39474
aS'Attitude to Health'
p39475
aS'Coinfection'
p39476
aS'Developing Countries'
p39477
aS'Female'
p39478
aS'HIV Infections/drug therapy'
p39479
aS'Humans'
p39480
aS'Malaria/drug therapy'
p39481
aS'Male'
p39482
aS'Narration'
p39483
aS'*Professional Role'
p39484
aS'Qualitative Research'
p39485
aS'*Researcher-Subject Relations'
p39486
aS'*Social Responsibility'
p39487
aS'Tanzania'
p39488
aS'Therapeutic Human Experimentation/*ethics'
p39489
aS'*Vulnerable Populations'
p39490
asS'EDAT'
p39491
S'2013/07/06 06:00'
p39492
sS'SO'
p39493
S'Glob Public Health. 2013 Jul;8(6):670-84. doi: 10.1080/17441692.2013.810297. Epub 2013 Jul 4.'
p39494
sS'SB'
p39495
S'IM'
p39496
sS'PMID'
p39497
S'23826948'
p39498
sS'PST'
p39499
S'ppublish'
p39500
stRp39501
ag2
(g3
g4
(dp39502
S'LID'
p39503
S'10.1186/1475-2875-12-223 [doi]'
p39504
sS'STAT'
p39505
S'MEDLINE'
p39506
sS'DEP'
p39507
S'20130701'
p39508
sS'DA'
p39509
S'20130708'
p39510
sS'AID'
p39511
(lp39512
S'1475-2875-12-223 [pii]'
p39513
aS'10.1186/1475-2875-12-223 [doi]'
p39514
asS'CRDT'
p39515
(lp39516
S'2013/07/03 06:00'
p39517
asS'DP'
p39518
S'2013'
p39519
sS'GR'
p39520
(lp39521
S'U19 AI089680/AI/NIAID NIH HHS/United States'
p39522
asS'OWN'
p39523
S'NLM'
p39524
sS'PT'
p39525
(lp39526
S'Journal Article'
p39527
aS'Research Support, N.I.H., Extramural'
p39528
asS'LA'
p39529
(lp39530
S'eng'
p39531
asS'DCOM'
p39532
S'20131112'
p39533
sS'JT'
p39534
S'Malaria journal'
p39535
sS'LR'
p39536
S'20150423'
p39537
sS'FAU'
p39538
(lp39539
S'Mharakurwa, Sungano'
p39540
aS'Mutambu, Susan L'
p39541
aS'Mberikunashe, Joseph'
p39542
aS'Thuma, Philip E'
p39543
aS'Moss, William J'
p39544
aS'Mason, Peter R'
p39545
asS'TI'
p39546
S'Changes in the burden of malaria following scale up of malaria control interventions in Mutasa District, Zimbabwe.'
p39547
sS'RN'
p39548
(lp39549
S'0 (Antimalarials)'
p39550
asS'PL'
p39551
S'England'
p39552
sS'PG'
p39553
S'223'
p39554
sS'FIR'
p39555
(lp39556
S'Agre, Peter'
p39557
aS'Gwanzura, Lovemore'
p39558
aS'Kobayashi, Tamaki'
p39559
aS'Lukwa, Nzira'
p39560
aS'Madinga, Munashe'
p39561
aS'Mamini, Edmore'
p39562
aS'Munyati, Shungu'
p39563
aS'Musana, Bhiza J'
p39564
aS'Norris, Douglas E'
p39565
aS'Shiff, Clive'
p39566
asS'JID'
p39567
S'101139802'
p39568
sS'AB'
p39569
S"BACKGROUND: To better understand trends in the burden of malaria and their temporal relationship to control activities, a survey was conducted to assess reported cases of malaria and malaria control activities in Mutasa District, Zimbabwe. METHODS: Data on reported malaria cases were abstracted from available records at all three district hospitals, three rural hospitals and 25 rural health clinics in Mutasa District from 2003 to 2011. RESULTS: Malaria control interventions were scaled up through the support of the Roll Back Malaria Partnership, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and The President's Malaria Initiative. The recommended first-line treatment regimen changed from chloroquine or a combination of chloroquine plus sulphadoxine/pyrimethamine to artemisinin-based combination therapy, the latter adopted by 70%, 95% and 100% of health clinics by 2008, 2009 and 2010, respectively. Diagnostic capacity improved, with rapid diagnostic tests (RDTs) available in all health clinics by 2008. Vector control consisted of indoor residual spraying and distribution of long-lasting insecticidal nets. The number of reported malaria cases initially increased from levels in 2003 to a peak in 2008 but then declined 39% from 2008 to 2010. The proportion of suspected cases of malaria in older children and adults remained high, ranging from 75% to 80%. From 2008 to 2010, the number of RDT positive cases of malaria decreased 35% but the decrease was greater for children younger than five years of age (60%) compared to older children and adults (26%). CONCLUSIONS: The burden of malaria in Mutasa District decreased following the scale up of malaria control interventions. However, the persistent high number of cases in older children and adults highlights the need for strategies to identify locally effective control measures that target all age groups."
p39570
sS'AD'
p39571
S'Johns Hopkins Malaria Research Institute, Bloomberg School of Public Health, Johns Hopkins University, 615 North Wolfe Street, Baltimore, MD 21205, USA.'
p39572
sS'CN'
p39573
(lp39574
S'Southern Africa ICEMR Team'
p39575
asS'VI'
p39576
S'12'
p39577
sS'IS'
p39578
S'1475-2875 (Electronic) 1475-2875 (Linking)'
p39579
sS'IR'
p39580
(lp39581
S'Agre P'
p39582
aS'Gwanzura L'
p39583
aS'Kobayashi T'
p39584
aS'Lukwa N'
p39585
aS'Madinga M'
p39586
aS'Mamini E'
p39587
aS'Munyati S'
p39588
aS'Musana BJ'
p39589
aS'Norris DE'
p39590
aS'Shiff C'
p39591
asS'AU'
p39592
(lp39593
S'Mharakurwa S'
p39594
aS'Mutambu SL'
p39595
aS'Mberikunashe J'
p39596
aS'Thuma PE'
p39597
aS'Moss WJ'
p39598
aS'Mason PR'
p39599
asS'MHDA'
p39600
S'2013/11/13 06:00'
p39601
sS'PHST'
p39602
(lp39603
S'2013/03/04 [received]'
p39604
aS'2013/06/24 [accepted]'
p39605
aS'2013/07/01 [aheadofprint]'
p39606
asS'OID'
p39607
(lp39608
S'NLM: PMC3703256'
p39609
asS'MH'
p39610
(lp39611
S'Adolescent'
p39612
aS'Adult'
p39613
aS'Aged'
p39614
aS'Aged, 80 and over'
p39615
aS'Animals'
p39616
aS'Antimalarials/*therapeutic use'
p39617
aS'Child'
p39618
aS'Child, Preschool'
p39619
aS'Clinical Laboratory Techniques/methods'
p39620
aS'Drug Therapy, Combination/methods'
p39621
aS'Female'
p39622
aS'Humans'
p39623
aS'Incidence'
p39624
aS'Infant'
p39625
aS'Infant, Newborn'
p39626
aS'Malaria/diagnosis/drug therapy/*epidemiology/*prevention & control'
p39627
aS'Male'
p39628
aS'Middle Aged'
p39629
aS'Mosquito Control/*methods'
p39630
aS'Parasitology/methods'
p39631
aS'Point-of-Care Systems'
p39632
aS'Prevalence'
p39633
aS'Young Adult'
p39634
aS'Zimbabwe/epidemiology'
p39635
asS'EDAT'
p39636
S'2013/07/03 06:00'
p39637
sS'PMC'
p39638
S'PMC3703256'
p39639
sS'SO'
p39640
S'Malar J. 2013 Jul 1;12:223. doi: 10.1186/1475-2875-12-223.'
p39641
sS'SB'
p39642
S'IM'
p39643
sS'PMID'
p39644
S'23815862'
p39645
sS'TA'
p39646
S'Malar J'
p39647
sS'PST'
p39648
S'epublish'
p39649
stRp39650
ag2
(g3
g4
(dp39651
S'LID'
p39652
S'10.1089/AID.2011.0367 [doi]'
p39653
sS'STAT'
p39654
S'MEDLINE'
p39655
sS'JT'
p39656
S'AIDS research and human retroviruses'
p39657
sS'DA'
p39658
S'20130820'
p39659
sS'AID'
p39660
(lp39661
S'10.1089/AID.2011.0367 [doi]'
p39662
asS'CRDT'
p39663
(lp39664
S'2013/06/29 06:00'
p39665
asS'DP'
p39666
S'2013 Sep'
p39667
sS'OWN'
p39668
S'NLM'
p39669
sS'PT'
p39670
(lp39671
S'Journal Article'
p39672
aS"Research Support, Non-U.S. Gov't"
p39673
asS'LA'
p39674
(lp39675
S'eng'
p39676
asS'FAU'
p39677
(lp39678
S'Masimba, Pax'
p39679
aS'Kituma, Elimsaada'
p39680
aS'Klimkait, Thomas'
p39681
aS'Horvath, Edit'
p39682
aS'Stoeckle, Marcel'
p39683
aS'Hatz, Christoph'
p39684
aS'Mossdorf, Erick'
p39685
aS'Mwaigomole, Emmanuel'
p39686
aS'Khamis, Salim'
p39687
aS'Jullu, Boniphace'
p39688
aS'Abdulla, Salim'
p39689
aS'Tanner, Marcel'
p39690
aS'Felger, Ingrid'
p39691
asS'LR'
p39692
S'20150423'
p39693
sS'PG'
p39694
S'1229-36'
p39695
sS'TI'
p39696
S'Prevalence of drug resistance mutations and HIV type 1 subtypes in an HIV type 1-infected cohort in rural Tanzania.'
p39697
sS'RN'
p39698
(lp39699
S'0 (Anti-HIV Agents)'
p39700
aS'0 (RNA, Viral)'
p39701
aS'EC 2.7.7.- (reverse transcriptase, Human immunodeficiency virus 1)'
p39702
aS'EC 2.7.7.49 (HIV Reverse Transcriptase)'
p39703
aS'EC 3.4.- (Peptide Hydrolases)'
p39704
asS'PL'
p39705
S'United States'
p39706
sS'TA'
p39707
S'AIDS Res Hum Retroviruses'
p39708
sS'JID'
p39709
S'8709376'
p39710
sS'AB'
p39711
S'The development of resistance mutations in drug-targeted HIV-1 genes compromises the success of antiretroviral therapy (ART) programs. Genotyping of these mutations enables adjusted therapeutic decisions both at the individual and population level. We investigated over time the prevalence of HIV-1 primary drug resistance mutations in treatment-naive patients and described the HIV-1 subtype distribution in a cohort in rural Tanzania at the beginning of the ART rollout in 2005-2007 and later in 2009. Viral RNA was analyzed in 387 baseline plasma samples from treatment-naive patients over a period of 5 years. The reverse transcriptase (RT) and protease genes were reversely transcribed, polymerase chain reaction (PCR) amplified, and directly sequenced to identify HIV-1 subtypes and single nucleotide polymorphisms associated with drug resistance (DR-SNPs). The prevalence of major DR-SNPs in 2005-2007 in the RT gene was determined: K103N (5.0%), Y181C (2.5%), M184V (2.5%), and G190A (1.7%), and M41L, K65KR, K70KR, and L74LV (0.8%). In samples from 2009 only K103N (3.3%), M184V, and T215FY (0.8%) were detected. Initial frequencies of subtypes C, A, D, and recombinants were 43%, 32%, 18%, and 7%, respectively. Later similar frequencies were found except for the recombinants, which were found twice as often (15%), highlighting the subtype diversity and a relatively stable subtype frequency in the area. DR-SNPs were found at initiation of the cohort despite very low previous ART use in the area. Statistically, frequencies of major mutations did not change significantly over the studied 5-year interval. These mutations could reflect primary resistances and may indicate a possible risk for treatment failure.'
p39712
sS'AD'
p39713
S'Swiss Tropical and Public Health Institute, Basel, Switzerland.'
p39714
sS'IP'
p39715
S'9'
sS'IS'
p39716
S'1931-8405 (Electronic) 0889-2229 (Linking)'
p39717
sS'PMC'
p39718
S'PMC3749719'
p39719
sS'DCOM'
p39720
S'20140120'
p39721
sS'AU'
p39722
(lp39723
S'Masimba P'
p39724
aS'Kituma E'
p39725
aS'Klimkait T'
p39726
aS'Horvath E'
p39727
aS'Stoeckle M'
p39728
aS'Hatz C'
p39729
aS'Mossdorf E'
p39730
aS'Mwaigomole E'
p39731
aS'Khamis S'
p39732
aS'Jullu B'
p39733
aS'Abdulla S'
p39734
aS'Tanner M'
p39735
aS'Felger I'
p39736
asS'VI'
p39737
S'29'
p39738
sS'MHDA'
p39739
S'2014/01/21 06:00'
p39740
sS'OID'
p39741
(lp39742
S'NLM: PMC3749719'
p39743
asS'MH'
p39744
(lp39745
S'Anti-HIV Agents/*therapeutic use'
p39746
aS'Antiretroviral Therapy, Highly Active'
p39747
aS'Cohort Studies'
p39748
aS'Drug Resistance, Viral/*genetics'
p39749
aS'Female'
p39750
aS'Genetic Variation'
p39751
aS'HIV Infections/*drug therapy/virology'
p39752
aS'HIV Reverse Transcriptase/genetics'
p39753
aS'HIV-1/classification/*drug effects/*genetics'
p39754
aS'Humans'
p39755
aS'Male'
p39756
aS'Molecular Sequence Data'
p39757
aS'Mutation'
p39758
aS'Peptide Hydrolases/genetics'
p39759
aS'Polymorphism, Single Nucleotide'
p39760
aS'RNA, Viral/genetics'
p39761
aS'Tanzania/epidemiology'
p39762
asS'EDAT'
p39763
S'2013/06/29 06:00'
p39764
sS'SI'
p39765
(lp39766
S'GENBANK/KC537065'
p39767
aS'GENBANK/KC537066'
p39768
aS'GENBANK/KC537067'
p39769
aS'GENBANK/KC537068'
p39770
aS'GENBANK/KC537069'
p39771
aS'GENBANK/KC537070'
p39772
aS'GENBANK/KC537071'
p39773
aS'GENBANK/KC537072'
p39774
aS'GENBANK/KC537073'
p39775
aS'GENBANK/KC537074'
p39776
aS'GENBANK/KC537075'
p39777
aS'GENBANK/KC537076'
p39778
aS'GENBANK/KC537077'
p39779
aS'GENBANK/KC537078'
p39780
aS'GENBANK/KC537079'
p39781
aS'GENBANK/KC537080'
p39782
aS'GENBANK/KC537081'
p39783
aS'GENBANK/KC537082'
p39784
aS'GENBANK/KC537083'
p39785
aS'GENBANK/KC537084'
p39786
aS'GENBANK/KC537085'
p39787
aS'GENBANK/KC537086'
p39788
aS'GENBANK/KC537087'
p39789
aS'GENBANK/KC537088'
p39790
aS'GENBANK/KC537089'
p39791
aS'GENBANK/KC537090'
p39792
aS'GENBANK/KC537091'
p39793
aS'GENBANK/KC537092'
p39794
aS'GENBANK/KC537093'
p39795
aS'GENBANK/KC537094'
p39796
aS'GENBANK/KC537095'
p39797
aS'GENBANK/KC537096'
p39798
aS'GENBANK/KC537097'
p39799
aS'GENBANK/KC537098'
p39800
aS'GENBANK/KC537099'
p39801
aS'GENBANK/KC537100'
p39802
aS'GENBANK/KC537101'
p39803
aS'GENBANK/KC537102'
p39804
aS'GENBANK/KC537103'
p39805
aS'GENBANK/KC537104'
p39806
aS'GENBANK/KC537105'
p39807
aS'GENBANK/KC537106'
p39808
aS'GENBANK/KC537107'
p39809
aS'GENBANK/KC537108'
p39810
aS'GENBANK/KC537109'
p39811
aS'GENBANK/KC537110'
p39812
aS'GENBANK/KC537111'
p39813
aS'GENBANK/KC537112'
p39814
aS'GENBANK/KC537113'
p39815
aS'GENBANK/KC537114'
p39816
aS'GENBANK/KC537115'
p39817
aS'GENBANK/KC537116'
p39818
aS'GENBANK/KC537117'
p39819
aS'GENBANK/KC537118'
p39820
aS'GENBANK/KC537119'
p39821
aS'GENBANK/KC537120'
p39822
aS'GENBANK/KC537121'
p39823
aS'GENBANK/KC537122'
p39824
aS'GENBANK/KC537123'
p39825
aS'GENBANK/KC537124'
p39826
aS'GENBANK/KC537125'
p39827
aS'GENBANK/KC537126'
p39828
aS'GENBANK/KC537127'
p39829
aS'GENBANK/KC537128'
p39830
aS'GENBANK/KC537129'
p39831
aS'GENBANK/KC537130'
p39832
aS'GENBANK/KC537131'
p39833
aS'GENBANK/KC537132'
p39834
aS'GENBANK/KC537133'
p39835
aS'GENBANK/KC537134'
p39836
aS'GENBANK/KC537135'
p39837
aS'GENBANK/KC537136'
p39838
aS'GENBANK/KC537137'
p39839
aS'GENBANK/KC537138'
p39840
aS'GENBANK/KC537139'
p39841
aS'GENBANK/KC537140'
p39842
aS'GENBANK/KC537141'
p39843
aS'GENBANK/KC537142'
p39844
aS'GENBANK/KC537143'
p39845
aS'GENBANK/KC537144'
p39846
aS'GENBANK/KC537145'
p39847
aS'GENBANK/KC537146'
p39848
aS'GENBANK/KC537147'
p39849
aS'GENBANK/KC537148'
p39850
aS'GENBANK/KC537149'
p39851
aS'GENBANK/KC537150'
p39852
aS'GENBANK/KC537151'
p39853
aS'GENBANK/KC537152'
p39854
aS'GENBANK/KC537153'
p39855
aS'GENBANK/KC537154'
p39856
aS'GENBANK/KC537155'
p39857
aS'GENBANK/KC537156'
p39858
aS'GENBANK/KC537157'
p39859
aS'GENBANK/KC537158'
p39860
aS'GENBANK/KC537159'
p39861
aS'GENBANK/KC537160'
p39862
aS'GENBANK/KC537161'
p39863
aS'GENBANK/KC537162'
p39864
aS'GENBANK/KC537163'
p39865
aS'GENBANK/KC537164'
p39866
aS'GENBANK/KC537165'
p39867
aS'GENBANK/KC537166'
p39868
aS'GENBANK/KC537167'
p39869
aS'GENBANK/KC537168'
p39870
aS'GENBANK/KC537169'
p39871
aS'GENBANK/KC537170'
p39872
aS'GENBANK/KC537171'
p39873
aS'GENBANK/KC537172'
p39874
aS'GENBANK/KC537173'
p39875
aS'GENBANK/KC537174'
p39876
aS'GENBANK/KC537175'
p39877
aS'GENBANK/KC537176'
p39878
aS'GENBANK/KC537177'
p39879
aS'GENBANK/KC537178'
p39880
aS'GENBANK/KC537179'
p39881
aS'GENBANK/KC537180'
p39882
aS'GENBANK/KC537181'
p39883
aS'GENBANK/KC537182'
p39884
aS'GENBANK/KC537183'
p39885
aS'GENBANK/KC537184'
p39886
aS'GENBANK/KC537185'
p39887
aS'GENBANK/KC537186'
p39888
aS'GENBANK/KC537187'
p39889
aS'GENBANK/KC537188'
p39890
aS'GENBANK/KC537189'
p39891
aS'GENBANK/KC537190'
p39892
aS'GENBANK/KC537191'
p39893
aS'GENBANK/KC537192'
p39894
aS'GENBANK/KC537193'
p39895
aS'GENBANK/KC537194'
p39896
aS'GENBANK/KC537195'
p39897
aS'GENBANK/KC537196'
p39898
aS'GENBANK/KC537197'
p39899
aS'GENBANK/KC537198'
p39900
aS'GENBANK/KC537199'
p39901
aS'GENBANK/KC537200'
p39902
aS'GENBANK/KC537201'
p39903
aS'GENBANK/KC537202'
p39904
aS'GENBANK/KC537203'
p39905
aS'GENBANK/KC537204'
p39906
aS'GENBANK/KC537205'
p39907
aS'GENBANK/KC537206'
p39908
aS'GENBANK/KC537207'
p39909
aS'GENBANK/KC537208'
p39910
aS'GENBANK/KC537209'
p39911
aS'GENBANK/KC537210'
p39912
aS'GENBANK/KC537211'
p39913
aS'GENBANK/KC537212'
p39914
aS'GENBANK/KC537213'
p39915
aS'GENBANK/KC537214'
p39916
aS'GENBANK/KC537215'
p39917
aS'GENBANK/KC537216'
p39918
aS'GENBANK/KC537217'
p39919
aS'GENBANK/KC537218'
p39920
aS'GENBANK/KC537219'
p39921
aS'GENBANK/KC537220'
p39922
aS'GENBANK/KC537221'
p39923
aS'GENBANK/KC537222'
p39924
aS'GENBANK/KC537223'
p39925
aS'GENBANK/KC537224'
p39926
aS'GENBANK/KC537225'
p39927
aS'GENBANK/KC537226'
p39928
aS'GENBANK/KC537227'
p39929
aS'GENBANK/KC537228'
p39930
aS'GENBANK/KC537229'
p39931
aS'GENBANK/KC537230'
p39932
aS'GENBANK/KC537231'
p39933
aS'GENBANK/KC537232'
p39934
aS'GENBANK/KC537233'
p39935
aS'GENBANK/KC537234'
p39936
aS'GENBANK/KC537235'
p39937
aS'GENBANK/KC537236'
p39938
aS'GENBANK/KC537237'
p39939
aS'GENBANK/KC537238'
p39940
aS'GENBANK/KC537239'
p39941
aS'GENBANK/KC537240'
p39942
aS'GENBANK/KC537241'
p39943
aS'GENBANK/KC537242'
p39944
aS'GENBANK/KC537243'
p39945
aS'GENBANK/KC537244'
p39946
aS'GENBANK/KC537245'
p39947
aS'GENBANK/KC537246'
p39948
aS'GENBANK/KC537247'
p39949
aS'GENBANK/KC537248'
p39950
aS'GENBANK/KC537249'
p39951
aS'GENBANK/KC537250'
p39952
aS'GENBANK/KC537251'
p39953
aS'GENBANK/KC537252'
p39954
aS'GENBANK/KC537253'
p39955
aS'GENBANK/KC537254'
p39956
aS'GENBANK/KC537255'
p39957
aS'GENBANK/KC537256'
p39958
aS'GENBANK/KC537257'
p39959
aS'GENBANK/KC537258'
p39960
aS'GENBANK/KC537259'
p39961
aS'GENBANK/KC537260'
p39962
aS'GENBANK/KC537261'
p39963
aS'GENBANK/KC537262'
p39964
aS'GENBANK/KC537263'
p39965
aS'GENBANK/KC537264'
p39966
aS'GENBANK/KC537265'
p39967
aS'GENBANK/KC537266'
p39968
aS'GENBANK/KC537267'
p39969
aS'GENBANK/KC537268'
p39970
aS'GENBANK/KC537269'
p39971
aS'GENBANK/KC537270'
p39972
aS'GENBANK/KC537271'
p39973
aS'GENBANK/KC537272'
p39974
aS'GENBANK/KC537273'
p39975
aS'GENBANK/KC537274'
p39976
aS'GENBANK/KC537275'
p39977
aS'GENBANK/KC537276'
p39978
aS'GENBANK/KC537277'
p39979
aS'GENBANK/KC537278'
p39980
aS'GENBANK/KC537279'
p39981
aS'GENBANK/KC537280'
p39982
aS'GENBANK/KC537281'
p39983
aS'GENBANK/KC537282'
p39984
aS'GENBANK/KC537283'
p39985
aS'GENBANK/KC537284'
p39986
aS'GENBANK/KC537285'
p39987
aS'GENBANK/KC537286'
p39988
aS'GENBANK/KC537287'
p39989
aS'GENBANK/KC537288'
p39990
aS'GENBANK/KC537289'
p39991
aS'GENBANK/KC537290'
p39992
asS'SO'
p39993
S'AIDS Res Hum Retroviruses. 2013 Sep;29(9):1229-36. doi: 10.1089/AID.2011.0367.'
p39994
sS'SB'
p39995
S'IM X'
p39996
sS'PMID'
p39997
S'23806135'
p39998
sS'PST'
p39999
S'ppublish'
p40000
stRp40001
ag2
(g3
g4
(dp40002
S'LID'
p40003
S'10.1097/INF.0b013e3182a0994b [doi]'
p40004
sS'STAT'
p40005
S'MEDLINE'
p40006
sS'AB'
p40007
S"BACKGROUND: HIV-infected children have less access to combination antiretroviral therapy as compared with adults in resource-limited settings. Growth faltering, loss to follow-up (LTFU) and high mortality are frequently seen. METHODS: A retrospective cohort study was performed with parameters extracted from the Drug Resource Enhancement against AIDS and Malnutrition database for HIV-infected, antiretroviral naive children under 15 years presenting for care at 17 Drug Resource Enhancement against AIDS and Malnutrition centers in Mozambique, Malawi and Guinea between January 2005 to December 2008. Predictors of time-to-death, time-to-LTFU and persistence of malnutrition by Cox's regression and Kaplan-Meier were determined. RESULTS: 2215 children presented to care with 1343 (61%) being </= 5 years. At baseline, stunting and malnutrition occurred in 40% and 25%, respectively; 75% of 2149 children had CD4 cell percentages less than 20; median HIV RNA, log10 cp/mL, was 4.97 in 1927 patients. Over time 238 children died (10.7%; 2.7% person-years [PY]) 63 were LTFU (2.8%; 0.7% PY). By multivariate analysis, mortality was associated with virus load (hazards ratio: 1.19; confidence interval: 1.01-1.402, P = 0.038) and reduced weight-for-age Z scores (hazards ratio: 0.590; confidence interval: 0.53-0.66, P < 0.001). LTFU was associated with low weight-for-height Z scores (hazards ratio: 0.71; confidence interval: 0.51-0.97, P = 0.031). At 12 months after combination antiretroviral therapy, anthropometric parameters significantly improved in 1226 children (P < 0.001); virus load declined to <400 copies/mL in over 60%. CONCLUSIONS: Despite advanced HIV disease, children initiating combination antiretroviral therapy had mortality rates of 2.7% p/PY with overall attrition rates of 11.7% p/100 PY, with significant reversal of negative anthropometric markers, and improvement of immunological and virological parameters in children with 12 months of follow-up."
p40008
sS'JID'
p40009
S'8701858'
p40010
sS'AD'
p40011
S'From the *Department of Preventive Medicine, LUMSA University (Libera Universita Maria SS. Assunta); daggerDREAM Program; double daggerDepartment of Biomedicine and Prevention, Tor Vergata University, via Montpellier, Rome, Italy; section signDepartment of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA; paragraph signAzienda Ospedaliedra Universitaria Senese, Siena; ||Universita Cattolica Sacro Cuore, Rome, Italy; and **DREAM Program Mozambique, Maputo, Mozambique.'
p40012
sS'JT'
p40013
S'The Pediatric infectious disease journal'
p40014
sS'IP'
p40015
S'3'
sS'IS'
p40016
S'1532-0987 (Electronic) 0891-3668 (Linking)'
p40017
sS'DCOM'
p40018
S'20150330'
p40019
sS'DA'
p40020
S'20140226'
p40021
sS'AU'
p40022
(lp40023
S'Marazzi MC'
p40024
aS'De Luca S'
p40025
aS'Palombi L'
p40026
aS'Scarcella P'
p40027
aS'Ciccacci F'
p40028
aS'Ceffa S'
p40029
aS'Nielsen-Saines K'
p40030
aS'De Luca A'
p40031
aS'Mancinelli S'
p40032
aS'Gennaro E'
p40033
aS'Zimba I'
p40034
aS'Liotta G'
p40035
aS'Buonomo E'
p40036
asS'AID'
p40037
(lp40038
S'10.1097/INF.0b013e3182a0994b [doi]'
p40039
asS'CRDT'
p40040
(lp40041
S'2013/06/27 06:00'
p40042
asS'VI'
p40043
S'33'
p40044
sS'PMID'
p40045
S'23799517'
p40046
sS'DP'
p40047
S'2014 Mar'
p40048
sS'MHDA'
p40049
S'2015/03/31 06:00'
p40050
sS'OWN'
p40051
S'NLM'
p40052
sS'PT'
p40053
(lp40054
S'Journal Article'
p40055
aS"Research Support, Non-U.S. Gov't"
p40056
asS'LA'
p40057
(lp40058
S'eng'
p40059
asS'MH'
p40060
(lp40061
S'Adolescent'
p40062
aS'Africa South of the Sahara/epidemiology'
p40063
aS'Anti-Retroviral Agents/therapeutic use'
p40064
aS'Body Height'
p40065
aS'Body Weight'
p40066
aS'Child'
p40067
aS'Child, Preschool'
p40068
aS'Drug Therapy, Combination'
p40069
aS'Female'
p40070
aS'*HIV Infections/drug therapy/epidemiology/mortality'
p40071
aS'Humans'
p40072
aS'Infant'
p40073
aS'Infant, Newborn'
p40074
aS'Kaplan-Meier Estimate'
p40075
aS'Male'
p40076
aS'Malnutrition'
p40077
aS'Retrospective Studies'
p40078
aS'Risk Factors'
p40079
aS'Treatment Outcome'
p40080
aS'Tuberculosis'
p40081
asS'FAU'
p40082
(lp40083
S'Marazzi, Maria Cristina'
p40084
aS'De Luca, Simona'
p40085
aS'Palombi, Leonardo'
p40086
aS'Scarcella, Paola'
p40087
aS'Ciccacci, Fausto'
p40088
aS'Ceffa, Susanna'
p40089
aS'Nielsen-Saines, Karin'
p40090
aS'De Luca, Andrea'
p40091
aS'Mancinelli, Sandro'
p40092
aS'Gennaro, Elisabetta'
p40093
aS'Zimba, Ines'
p40094
aS'Liotta, Giuseppe'
p40095
aS'Buonomo, Ersilia'
p40096
asS'EDAT'
p40097
S'2013/06/27 06:00'
p40098
sS'PST'
p40099
S'ppublish'
p40100
sS'SO'
p40101
S'Pediatr Infect Dis J. 2014 Mar;33(3):295-300. doi: 10.1097/INF.0b013e3182a0994b.'
p40102
sS'PG'
p40103
S'295-300'
p40104
sS'TI'
p40105
S'Predictors of adverse outcomes in HIV-1-infected children receiving combination antiretroviral treatment: results from a DREAM cohort in sub-Saharan Africa.'
p40106
sS'SB'
p40107
S'IM'
p40108
sS'RN'
p40109
(lp40110
S'0 (Anti-Retroviral Agents)'
p40111
asS'PL'
p40112
S'United States'
p40113
sS'TA'
p40114
S'Pediatr Infect Dis J'
p40115
stRp40116
ag2
(g3
g4
(dp40117
S'LID'
p40118
S'10.1097/QAI.0b013e3182a009e4 [doi]'
p40119
sS'STAT'
p40120
S'MEDLINE'
p40121
sS'JT'
p40122
S'Journal of acquired immune deficiency syndromes (1999)'
p40123
sS'MID'
p40124
(lp40125
S'NIHMS505913'
p40126
asS'DA'
p40127
S'20130917'
p40128
sS'AID'
p40129
(lp40130
S'10.1097/QAI.0b013e3182a009e4 [doi]'
p40131
asS'CRDT'
p40132
(lp40133
S'2013/06/26 06:00'
p40134
asS'DP'
p40135
S'2013 Oct 1'
p40136
sS'AD'
p40137
S"*Programme PAC-CI/ANRS, Abidjan, Cote d'Ivoire; daggerINSERM, Centre 897, France; double daggerUniversity of Bordeaux, ISPED, France; section signLaboratoire de Virologie, Universite Paris Descartes, Sorbonne Paris Cite, AP-HP, CHU Necker-Enfants Malades, Paris; ||CeDReS, CHU de Treichville, Abidjan, Cote d'Ivoire; and paragraph signService des Maladies Infectieuses et Tropicales, CHU de Treichville, Abidjan, Cote d'Ivoire."
p40138
sS'OWN'
p40139
S'NLM'
p40140
sS'PT'
p40141
(lp40142
S'Journal Article'
p40143
aS'Research Support, N.I.H., Extramural'
p40144
aS"Research Support, Non-U.S. Gov't"
p40145
asS'LA'
p40146
(lp40147
S'eng'
p40148
asS'FAU'
p40149
(lp40150
S'Messou, Eugene'
p40151
aS'Chaix, Marie-Laure'
p40152
aS'Gabillard, Delphine'
p40153
aS'Yapo, Vincent'
p40154
aS"Toni, Thomas-d'Aquin"
p40155
aS'Minga, Albert'
p40156
aS'Kouakou, Martial Guillaume'
p40157
aS'Ouattara, Eric'
p40158
aS'Rouzioux, Christine'
p40159
aS'Danel, Christine'
p40160
aS'Eholie, Serge P'
p40161
aS'Anglaret, Xavier'
p40162
asS'LR'
p40163
S'20150423'
p40164
sS'PG'
p40165
S'211-9'
p40166
sS'TI'
p40167
S"Increasing rate of TAMs and etravirine resistance in HIV-1-infected adults between 12 and 24 months of treatment: the VOLTART cohort study in Cote d'Ivoire, West Africa."
p40168
sS'RN'
p40169
(lp40170
S'0 (Anti-HIV Agents)'
p40171
aS'0 (Pyridazines)'
p40172
aS'0 (RNA, Viral)'
p40173
aS'0 (Reverse Transcriptase Inhibitors)'
p40174
aS'0C50HW4FO1 (etravirine)'
p40175
aS'VC2W18DGKR (Thymidine)'
p40176
asS'PL'
p40177
S'United States'
p40178
sS'TA'
p40179
S'J Acquir Immune Defic Syndr'
p40180
sS'JID'
p40181
S'100892005'
p40182
sS'AB'
p40183
S'BACKGROUND: In sub-Saharan Africa, most HIV-infected patients receive antiretroviral therapy (ART) without virological monitoring. Longitudinal data on secondary resistance are rare. METHODS: We conducted a prospective cohort study of HIV-1-infected adults initiating ART in 3 clinics using computerized monitoring systems. Patients had plasma HIV-1 RNA viral load (VL) tests at months 12 (M12) and 24 (M24) after ART initiation and HIV-1 resistance genotype tests if VL was detectable (>/=300 copies/mL). RESULTS: Overall, 1573 patients initiated ART with stavudine/zidovudine plus lamivudine plus nevirapine/efavirenz. At M12 and M24, 944 and 844 patients, respectively, remained in active follow-up. Among them, 25% (M12) and 27% (M24) had detectable VLs and 12% (M12) and 19% (M24) had virus resistant to at least 1 antiretroviral drug, accounting for 54% (M12) and 75% (M24) of patients with detectable VLs. Among the resistant strains, 95% (M12) and 97% (M24) were resistant to lamivudine/emtricitabine, efavirenz, and/or nevirapine, the frequency of thymidine analog mutations increased from 8.1% (M12) to 14.7% (M24) and etravirine resistance increased from 13.5% (M12) to 24.5% (M24). CONCLUSIONS: Of the patients with detectable VLs at M24, 25% still did not harbor resistant virus. Preventing mutations from emerging with adherence reinforcement in patients with detectable VLs remains important beyond M24. Switching therapy early in patients with resistance to 3 TC/FTC and/or to nonnucleoside reverse transcriptase inhibitors to prevent extended resistance to nucleoside reverse transcriptase inhibitors and etravirine resistance from occurring is also a major challenge.'
p40184
sS'GR'
p40185
(lp40186
S'K24 AI062476/AI/NIAID NIH HHS/United States'
p40187
aS'K24-AI062476/AI/NIAID NIH HHS/United States'
p40188
aS'R01 AI058736/AI/NIAID NIH HHS/United States'
p40189
aS'R01 AI058736/AI/NIAID NIH HHS/United States'
p40190
asS'IP'
p40191
S'2'
sS'IS'
p40192
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p40193
sS'PMC'
p40194
S'PMC3834582'
p40195
sS'DCOM'
p40196
S'20131113'
p40197
sS'AU'
p40198
(lp40199
S'Messou E'
p40200
aS'Chaix ML'
p40201
aS'Gabillard D'
p40202
aS'Yapo V'
p40203
aS'Toni TD'
p40204
aS'Minga A'
p40205
aS'Kouakou MG'
p40206
aS'Ouattara E'
p40207
aS'Rouzioux C'
p40208
aS'Danel C'
p40209
aS'Eholie SP'
p40210
aS'Anglaret X'
p40211
asS'VI'
p40212
S'64'
p40213
sS'MHDA'
p40214
S'2013/11/14 06:00'
p40215
sS'OID'
p40216
(lp40217
S'NLM: NIHMS505913'
p40218
aS'NLM: PMC3834582'
p40219
asS'MH'
p40220
(lp40221
S'Adult'
p40222
aS'Anti-HIV Agents/administration & dosage/*pharmacology/therapeutic use'
p40223
aS'Cohort Studies'
p40224
aS"Cote d'Ivoire"
p40225
aS'Drug Monitoring/methods'
p40226
aS'Drug Resistance, Viral/*genetics'
p40227
aS'Female'
p40228
aS'HIV Infections/*drug therapy/epidemiology/virology'
p40229
aS'HIV-1/*drug effects/genetics'
p40230
aS'Humans'
p40231
aS'Male'
p40232
aS'*Mutation'
p40233
aS'Prospective Studies'
p40234
aS'Pyridazines/administration & dosage/*pharmacology/therapeutic use'
p40235
aS'RNA, Viral/blood'
p40236
aS'Reverse Transcriptase Inhibitors/administration & dosage/pharmacology/therapeutic use'
p40237
aS'Thymidine/*analogs & derivatives/pharmacology'
p40238
aS'Time Factors'
p40239
aS'Viral Load'
p40240
asS'EDAT'
p40241
S'2013/06/26 06:00'
p40242
sS'SO'
p40243
S'J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):211-9. doi: 10.1097/QAI.0b013e3182a009e4.'
p40244
sS'SB'
p40245
S'IM X'
p40246
sS'PMID'
p40247
S'23797690'
p40248
sS'PST'
p40249
S'ppublish'
p40250
stRp40251
ag2
(g3
g4
(dp40252
S'LID'
p40253
S'10.1093/aje/kwt030 [doi]'
p40254
sS'STAT'
p40255
S'MEDLINE'
p40256
sS'DEP'
p40257
S'20130619'
p40258
sS'DA'
p40259
S'20130829'
p40260
sS'AID'
p40261
(lp40262
S'kwt030 [pii]'
p40263
aS'10.1093/aje/kwt030 [doi]'
p40264
asS'CRDT'
p40265
(lp40266
S'2013/06/21 06:00'
p40267
asS'DP'
p40268
S'2013 Sep 1'
p40269
sS'AD'
p40270
S'Vanderbilt University School of Medicine, 1161 21st Avenue South, Nashville,TN 37232-2158, USA. bryan.shepherd@vanderbilt.edu'
p40271
sS'OWN'
p40272
S'NLM'
p40273
sS'PT'
p40274
(lp40275
S'Journal Article'
p40276
aS"Research Support, U.S. Gov't, P.H.S."
p40277
asS'LA'
p40278
(lp40279
S'eng'
p40280
asS'FAU'
p40281
(lp40282
S'Shepherd, Bryan E'
p40283
aS'Blevins, Meridith'
p40284
aS'Vaz, Lara M E'
p40285
aS'Moon, Troy D'
p40286
aS'Kipp, Aaron M'
p40287
aS'Jose, Eurico'
p40288
aS'Ferreira, Ferreira G'
p40289
aS'Vermund, Sten H'
p40290
asS'JT'
p40291
S'American journal of epidemiology'
p40292
sS'LR'
p40293
S'20150424'
p40294
sS'PG'
p40295
S'819-28'
p40296
sS'TI'
p40297
S'Impact of definitions of loss to follow-up on estimates of retention, disease progression, and mortality: application to an HIV program in Mozambique.'
p40298
sS'RN'
p40299
(lp40300
S'0 (Anti-Retroviral Agents)'
p40301
asS'PL'
p40302
S'United States'
p40303
sS'TA'
p40304
S'Am J Epidemiol'
p40305
sS'JID'
p40306
S'7910653'
p40307
sS'AB'
p40308
S"Patient retention is critical to the management of chronic diseases such as human immunodeficiency virus (HIV); hence, accurate measures of loss to follow-up (LTF) are important. Many different LTF definitions have been proposed. In a cohort of 9,692 HIV-infected patients initiating antiretroviral therapy in Mozambique from 2006 to 2011, we investigated the impact of the definition of LTF on estimated rates of LTF, acquired immunodeficiency syndrome (AIDS)-defining events, and death by applying 17 different definitions of LTF gleaned from HIV literature. We further investigated the impact of 4 specific components of the LTF definitions. Cumulative incidences of LTF and AIDS-defining events were estimated by treating death as a competing risk; Kaplan-Meier techniques and variations to account for informative censoring were used to estimate rates of mortality. Estimates of LTF 2 years after treatment initiation were high and varied substantially, from 22% to 84% depending on the LTF definition used. Estimates of 2-year mortality varied from 11% to 16%, and estimates of 2-year AIDS-defining events varied from 6% to 8%. As seen here, the choice of LTF definition can greatly affect study conclusions and program evaluations. Selection of LTF definitions should be based on the study outcome, available data on clinical encounters, and the patients' visit schedules; we suggest some general guidelines."
p40309
sS'GR'
p40310
(lp40311
S'1R01 AI093234-01/AI/NIAID NIH HHS/United States'
p40312
aS'R01 AI093234/AI/NIAID NIH HHS/United States'
p40313
aS'PEPFAR/United States'
p40314
asS'IP'
p40315
S'5'
sS'IS'
p40316
S'1476-6256 (Electronic) 0002-9262 (Linking)'
p40317
sS'PMC'
p40318
S'PMC3755641'
p40319
sS'DCOM'
p40320
S'20131104'
p40321
sS'AU'
p40322
(lp40323
S'Shepherd BE'
p40324
aS'Blevins M'
p40325
aS'Vaz LM'
p40326
aS'Moon TD'
p40327
aS'Kipp AM'
p40328
aS'Jose E'
p40329
aS'Ferreira FG'
p40330
aS'Vermund SH'
p40331
asS'VI'
p40332
S'178'
p40333
sS'MHDA'
p40334
S'2013/11/05 06:00'
p40335
sS'PHST'
p40336
(lp40337
S'2013/06/19 [aheadofprint]'
p40338
asS'OTO'
p40339
(lp40340
S'NOTNLM'
p40341
asS'OID'
p40342
(lp40343
S'NLM: PMC3755641'
p40344
asS'MH'
p40345
(lp40346
S'Acquired Immunodeficiency Syndrome/drug therapy/epidemiology'
p40347
aS'Adult'
p40348
aS'Anti-Retroviral Agents/therapeutic use'
p40349
aS'Data Collection/methods'
p40350
aS'Data Interpretation, Statistical'
p40351
aS'Disease Progression'
p40352
aS'Female'
p40353
aS'Follow-Up Studies'
p40354
aS'HIV Infections/drug therapy/*epidemiology/mortality'
p40355
aS'Humans'
p40356
aS'Kaplan-Meier Estimate'
p40357
aS'Male'
p40358
aS'Mozambique/epidemiology'
p40359
aS'Patient Acceptance of Health Care/statistics & numerical data'
p40360
aS'*Research Design'
p40361
aS'Time Factors'
p40362
asS'EDAT'
p40363
S'2013/06/21 06:00'
p40364
sS'SO'
p40365
S'Am J Epidemiol. 2013 Sep 1;178(5):819-28. doi: 10.1093/aje/kwt030. Epub 2013 Jun 19.'
p40366
sS'SB'
p40367
S'IM'
p40368
sS'PMID'
p40369
S'23785113'
p40370
sS'OT'
p40371
(lp40372
S'HIV'
p40373
aS'chronic disease'
p40374
aS'cohort studies'
p40375
aS'long-term care'
p40376
aS'lost to follow-up'
p40377
aS'program evaluation'
p40378
asS'PST'
p40379
S'ppublish'
p40380
stRp40381
ag2
(g3
g4
(dp40382
S'LID'
p40383
S'10.5539/gjhs.v5n4p200 [doi]'
p40384
sS'STAT'
p40385
S'MEDLINE'
p40386
sS'DEP'
p40387
S'20130515'
p40388
sS'DA'
p40389
S'20130619'
p40390
sS'AID'
p40391
(lp40392
S'10.5539/gjhs.v5n4p200 [doi]'
p40393
asS'CRDT'
p40394
(lp40395
S'2013/06/20 06:00'
p40396
asS'DP'
p40397
S'2013 Jul'
p40398
sS'OWN'
p40399
S'NLM'
p40400
sS'PT'
p40401
(lp40402
S'Journal Article'
p40403
asS'LA'
p40404
(lp40405
S'eng'
p40406
asS'FAU'
p40407
(lp40408
S'Menon, Sonia'
p40409
asS'JT'
p40410
S'Global journal of health science'
p40411
sS'LR'
p40412
S'20160422'
p40413
sS'PG'
p40414
S'200-10'
p40415
sS'TI'
p40416
S'Preventing nosocomial MDR TB transmission in sub Saharan Africa: where are we at?'
p40417
sS'RN'
p40418
(lp40419
S'0 (Antitubercular Agents)'
p40420
asS'PL'
p40421
S'Canada'
p40422
sS'TA'
p40423
S'Glob J Health Sci'
p40424
sS'JID'
p40425
S'101519495'
p40426
sS'AB'
p40427
S'BACKGROUND: In sub Saharan Africa, the cocktail of many advanced HIV-infected susceptible hosts, poor TB treatment success rates, a lack of airborne infection control, limited drug-resistance testing (DST) have resulted in HIV-infected individuals being disproportionately represented in Multi drug resistant Tuberculosis (MDR-TB) cases. The prevailing application of the WHO re-treatment protocol indiscriminately to all re-treatment cases sets the stage for an increase in mortality and MDR-TB nosocomial transmission. METHOD: A comprehensive search was performed of the Cochrane Infectious Diseases Group Specialized Register and Medline database including the bibliographies of the retrieved reference. FINDINGS: The TB diagnosis paradigm which for decades relied on smear sputum and culture is likely to change with the advent of the point-of-care diagnostic, Xpert MTB/RIF assay. Until the new DST infrastructure is available, along with clinical trials for both, current and new approaches to retreatment TB in areas heavily affected by HIV and TB, there are cost effective administrative, environmental, and protective measures that may be immediately instituted. CONCLUSION: The severe lack of infection control practices in sub Saharan Africa may jeopardise the recent strides in MDR-TB management. Cost effective infection control measures must be immediately implemented, otherwise the development of further drug resistance may offset recent strides in MDR-TB management. Indiscriminate use of the WHO standardized retreatment protocol can lead to nosocomial transmission of MDR-TB by: -Precluding early diagnosis and prompt separation of patients who experienced treatment failure category and thereby more likely to have MDR-TB. -Leaving patients from the treatment failure category in health establishments on ineffective standard retreatment regimen until the DST results are known. -targeting only patients who have had prior TB therapy, new severely debilitated TB patients having primary unrecognized MDR-TB may continue spreading resistant organisms.'
p40428
sS'AD'
p40429
S'University of Ghent, Ghent, Belgium. soniamenon1@yahoo.com'
p40430
sS'IP'
p40431
S'4'
sS'IS'
p40432
S'1916-9736 (Print) 1916-9736 (Linking)'
p40433
sS'PMC'
p40434
S'PMC4776863'
p40435
sS'DCOM'
p40436
S'20130904'
p40437
sS'AU'
p40438
(lp40439
S'Menon S'
p40440
asS'VI'
p40441
S'5'
sS'MHDA'
p40442
S'2013/09/05 06:00'
p40443
sS'PHST'
p40444
(lp40445
S'2013/02/17 [received]'
p40446
aS'2013/04/10 [accepted]'
p40447
aS'2013/03/18 [revised]'
p40448
asS'OID'
p40449
(lp40450
S'NLM: PMC4776863'
p40451
asS'MH'
p40452
(lp40453
S'Africa South of the Sahara/epidemiology'
p40454
aS'Antitubercular Agents/*administration & dosage'
p40455
aS'Cross Infection/*epidemiology/*prevention & control'
p40456
aS'Environment'
p40457
aS'Guideline Adherence'
p40458
aS'Humans'
p40459
aS'Infection Control/methods/statistics & numerical data'
p40460
aS'Practice Guidelines as Topic'
p40461
aS'Tuberculosis, Multidrug-Resistant/*epidemiology/*prevention & control'
p40462
aS'World Health Organization'
p40463
asS'EDAT'
p40464
S'2013/06/20 06:00'
p40465
sS'SO'
p40466
S'Glob J Health Sci. 2013 May 15;5(4):200-10. doi: 10.5539/gjhs.v5n4p200.'
p40467
sS'SB'
p40468
S'IM'
p40469
sS'PMID'
p40470
S'23777736'
p40471
sS'PST'
p40472
S'epublish'
p40473
stRp40474
ag2
(g3
g4
(dp40475
S'LID'
p40476
S'10.1186/1471-2431-13-95 [doi]'
p40477
sS'STAT'
p40478
S'MEDLINE'
p40479
sS'DEP'
p40480
S'20130615'
p40481
sS'DA'
p40482
S'20130626'
p40483
sS'AID'
p40484
(lp40485
S'1471-2431-13-95 [pii]'
p40486
aS'10.1186/1471-2431-13-95 [doi]'
p40487
asS'CRDT'
p40488
(lp40489
S'2013/06/18 06:00'
p40490
asS'DP'
p40491
S'2013'
p40492
sS'OWN'
p40493
S'NLM'
p40494
sS'PT'
p40495
(lp40496
S'Journal Article'
p40497
aS"Research Support, Non-U.S. Gov't"
p40498
asS'LA'
p40499
(lp40500
S'eng'
p40501
asS'DCOM'
p40502
S'20131203'
p40503
sS'JT'
p40504
S'BMC pediatrics'
p40505
sS'LR'
p40506
S'20151119'
p40507
sS'FAU'
p40508
(lp40509
S'Mghamba, Frida William'
p40510
aS'Minzi, Omary M S'
p40511
aS'Massawe, Augustine'
p40512
aS'Sasi, Philip'
p40513
asS'TI'
p40514
S'Adherence to antiretroviral therapy among HIV infected children measured by caretaker report, medication return, and drug level in Dar Es Salaam, Tanzania.'
p40515
sS'RN'
p40516
(lp40517
S'0 (Anti-HIV Agents)'
p40518
aS'0 (Drug Combinations)'
p40519
aS'0 (stavudine, lamivudine, nevirapine drug combination)'
p40520
aS'2T8Q726O95 (Lamivudine)'
p40521
aS'4B9XT59T7S (Zidovudine)'
p40522
aS'99DK7FVK1H (Nevirapine)'
p40523
aS'BO9LE4QFZF (Stavudine)'
p40524
asS'PL'
p40525
S'England'
p40526
sS'PG'
p40527
S'95'
p40528
sS'JID'
p40529
S'100967804'
p40530
sS'AB'
p40531
S"BACKGROUND: Adherence to antiretroviral drugs in the treatment of paediatric HIV infection is complicated because of many factors including stigma and drug intake logistics. It is therefore important to identify children with non-adherence in order to intervene before they become at risk of developing treatment failure or drug resistance. The aim of this study was to determine the level of adherence to antiretroviral therapy (ART), measured by caretaker report, medication return and nevirapine plasma concentration. In addition, the association between level of adherence and patient's immune status was compared across the three methods of measuring adherence. METHODS: This was a descriptive cross-sectional study involving HIV infected children aged 2-14 years, on nevirapine- based antiretroviral treatment for at least six months, attending care and treatment clinic in three municipal hospitals in Dar- Es- Salaam City. Eligible patients and their accompanying caretakers were consecutively enrolled after obtaining written informed consent. Structured questionnaires were administered to caretakers to assess patient's adherence by caretaker report and medication return whereas a single blood sample for CD4 cell count/percent and determination of nevirapine plasma concentration was taken from patients on the day of assessment. RESULTS: A total of 300 patients and accompanying caretakers were enrolled and the mean patient age (SD) was 8 (3) years. Caretakers' report and medication return showed good adherence (98% and 97%) respectively. However, the level of adherence assessed by nevirapine plasma concentration (85%) was significantly lower than caretaker report and medication return (p < 0.001). The agreement between nevirapine plasma concentration and medication return and between nevirapine plasma concentration and caretaker report was weak (k = 0. 131) (k = 0. 09) respectively. Nevirapine plasma concentration below 3 mug/ml was associated with immunosuppression (p = 0. 021) whereas medication return (>5% of prescribed doses) and caretaker reported missing more than one dose within 72 hours prior to interview were not associated with immunosuppression (p = 0. 474), (p = 0. 569) respectively. CONCLUSION: Lower adherence level observed using nevirapine plasma concentration and its association with immunological response supports the validity of the method and indicates that adherence data obtained from caretaker report and medication return may overestimate the true adherence in paediatric antiretroviral therapy."
p40532
sS'AD'
p40533
S'Department of Paediatrics and Child Health, School of Medicine, Muhimbili University of Health and Allied Sciences, P.O. BOX 65001, Dar-Es-Salaam, Tanzania. fwmghamba@gmail.com'
p40534
sS'VI'
p40535
S'13'
p40536
sS'IS'
p40537
S'1471-2431 (Electronic) 1471-2431 (Linking)'
p40538
sS'PMC'
p40539
S'PMC3691638'
p40540
sS'AU'
p40541
(lp40542
S'Mghamba FW'
p40543
aS'Minzi OM'
p40544
aS'Massawe A'
p40545
aS'Sasi P'
p40546
asS'MHDA'
p40547
S'2013/12/16 06:00'
p40548
sS'PHST'
p40549
(lp40550
S'2013/01/05 [received]'
p40551
aS'2013/06/13 [accepted]'
p40552
aS'2013/06/15 [aheadofprint]'
p40553
asS'OID'
p40554
(lp40555
S'NLM: PMC3691638'
p40556
asS'MH'
p40557
(lp40558
S'Adolescent'
p40559
aS'Adult'
p40560
aS'Aged'
p40561
aS'Anti-HIV Agents/blood/*therapeutic use'
p40562
aS'CD4 Lymphocyte Count'
p40563
aS'Caregivers'
p40564
aS'Child'
p40565
aS'Child, Preschool'
p40566
aS'Cross-Sectional Studies'
p40567
aS'Drug Administration Schedule'
p40568
aS'Drug Combinations'
p40569
aS'Female'
p40570
aS'HIV Infections/blood/*drug therapy/immunology'
p40571
aS'Humans'
p40572
aS'Lamivudine/therapeutic use'
p40573
aS'Logistic Models'
p40574
aS'Male'
p40575
aS'Medication Adherence/*statistics & numerical data'
p40576
aS'Middle Aged'
p40577
aS'Nevirapine/blood/*therapeutic use'
p40578
aS'Odds Ratio'
p40579
aS'Stavudine/therapeutic use'
p40580
aS'Surveys and Questionnaires'
p40581
aS'Tanzania'
p40582
aS'Young Adult'
p40583
aS'Zidovudine/therapeutic use'
p40584
asS'EDAT'
p40585
S'2013/06/19 06:00'
p40586
sS'SO'
p40587
S'BMC Pediatr. 2013 Jun 15;13:95. doi: 10.1186/1471-2431-13-95.'
p40588
sS'SB'
p40589
S'IM'
p40590
sS'PMID'
p40591
S'23768248'
p40592
sS'TA'
p40593
S'BMC Pediatr'
p40594
sS'PST'
p40595
S'epublish'
p40596
stRp40597
ag2
(g3
g4
(dp40598
S'LID'
p40599
S'10.1371/journal.pone.0065653 [doi]'
p40600
sS'STAT'
p40601
S'MEDLINE'
p40602
sS'DEP'
p40603
S'20130607'
p40604
sS'DA'
p40605
S'20130613'
p40606
sS'AID'
p40607
(lp40608
S'10.1371/journal.pone.0065653 [doi]'
p40609
aS'PONE-D-13-00059 [pii]'
p40610
asS'CRDT'
p40611
(lp40612
S'2013/06/14 06:00'
p40613
asS'DP'
p40614
S'2013'
p40615
sS'AD'
p40616
S'Directorate of Special Programmes, Republic of Namibia Ministry of Health and Social Services, Windhoek, Namibia.'
p40617
sS'OWN'
p40618
S'NLM'
p40619
sS'PT'
p40620
(lp40621
S'Journal Article'
p40622
aS"Research Support, Non-U.S. Gov't"
p40623
asS'LA'
p40624
(lp40625
S'eng'
p40626
asS'FAU'
p40627
(lp40628
S'Jonas, Anna'
p40629
aS'Gweshe, Justice'
p40630
aS'Siboleka, Milner'
p40631
aS'Deklerk, Michael'
p40632
aS'Gawanab, Michael'
p40633
aS'Badi, Alfons'
p40634
aS'Sumbi, Victor'
p40635
aS'Pereko, Dawn'
p40636
aS'Blom, Abraham'
p40637
aS'Mwinga, Samson'
p40638
aS'Jordan, Michael R'
p40639
aS'Jerger, Logan'
p40640
aS'Lau, Kiger'
p40641
aS'Hong, Steven Y'
p40642
asS'JT'
p40643
S'PloS one'
p40644
sS'LR'
p40645
S'20151119'
p40646
sS'PG'
p40647
S'e65653'
p40648
sS'TI'
p40649
S'HIV drug resistance early warning indicators in Namibia for public health action.'
p40650
sS'RN'
p40651
(lp40652
S'0 (Anti-HIV Agents)'
p40653
asS'PL'
p40654
S'United States'
p40655
sS'TA'
p40656
S'PLoS One'
p40657
sS'JID'
p40658
S'101285081'
p40659
sS'AB'
p40660
S'BACKGROUND: HIV drug resistance (HIVDR) testing is not routinely available in many resource-limited settings, therefore antiretroviral therapy (ART) program and site factors known to be associated with emergence of HIVDR should be monitored to optimize the quality of patient care and minimize the emergence of preventable HIVDR. METHODS: In 2010, Namibia selected five World Health Organization Early Warning Indicators (EWIs) and scaled-up monitoring from 9 to 33 ART sites: ART prescribing practices, Patients lost to follow-up (LTFU) at 12 months, Patients switched to a second-line regimen at 12 months, On-time antiretroviral (ARV) drug pick-up, and ARV drug-supply continuity. RESULTS: Records allowed reporting on three of the five selected EWIs. 22 of 33 (67%) sites met the target of 100% initiated on appropriate first-line regimens. 17 of 33 (52%) sites met the target of </=20% LTFU. 15 of 33 (45%) sites met the target of 0% switched to a second-line regimen. CONCLUSIONS: EWI monitoring directly resulted in public health action which will optimize the quality of care, specifically the strengthening of ART record systems, engagement of ART sites, and operational research for improved adherence assessment and ART patient defaulter tracing.'
p40661
sS'GR'
p40662
(lp40663
S'K23 AI097010/AI/NIAID NIH HHS/United States'
p40664
asS'IP'
p40665
S'6'
sS'IS'
p40666
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p40667
sS'PMC'
p40668
S'PMC3676318'
p40669
sS'DCOM'
p40670
S'20140122'
p40671
sS'AU'
p40672
(lp40673
S'Jonas A'
p40674
aS'Gweshe J'
p40675
aS'Siboleka M'
p40676
aS'Deklerk M'
p40677
aS'Gawanab M'
p40678
aS'Badi A'
p40679
aS'Sumbi V'
p40680
aS'Pereko D'
p40681
aS'Blom A'
p40682
aS'Mwinga S'
p40683
aS'Jordan MR'
p40684
aS'Jerger L'
p40685
aS'Lau K'
p40686
aS'Hong SY'
p40687
asS'VI'
p40688
S'8'
sS'MHDA'
p40689
S'2014/01/23 06:00'
p40690
sS'PHST'
p40691
(lp40692
S'2013 [ppublish]'
p40693
aS'2012/12/20 [received]'
p40694
aS'2013/04/25 [accepted]'
p40695
aS'2013/06/07 [epublish]'
p40696
asS'OID'
p40697
(lp40698
S'NLM: PMC3676318'
p40699
asS'MH'
p40700
(lp40701
S'Anti-HIV Agents/*pharmacology/supply & distribution/*therapeutic use'
p40702
aS'Antiretroviral Therapy, Highly Active'
p40703
aS'Drug Resistance, Viral/*drug effects'
p40704
aS'Geography'
p40705
aS'HIV Infections/*drug therapy/*virology'
p40706
aS'*Health Status Indicators'
p40707
aS'Humans'
p40708
aS'Lost to Follow-Up'
p40709
aS'Namibia'
p40710
aS"Practice Patterns, Physicians'"
p40711
aS'*Public Health'
p40712
aS'World Health Organization'
p40713
asS'EDAT'
p40714
S'2013/06/14 06:00'
p40715
sS'SO'
p40716
S'PLoS One. 2013 Jun 7;8(6):e65653. doi: 10.1371/journal.pone.0065653. Print 2013.'
p40717
sS'SB'
p40718
S'IM'
p40719
sS'PMID'
p40720
S'23762406'
p40721
sS'PST'
p40722
S'epublish'
p40723
stRp40724
ag2
(g3
g4
(dp40725
S'LID'
p40726
S'10.1097/QAI.0b013e31829ceb14 [doi]'
p40727
sS'STAT'
p40728
S'MEDLINE'
p40729
sS'JT'
p40730
S'Journal of acquired immune deficiency syndromes (1999)'
p40731
sS'MID'
p40732
(lp40733
S'EMS54781'
p40734
asS'DA'
p40735
S'20140114'
p40736
sS'AID'
p40737
(lp40738
S'10.1097/QAI.0b013e31829ceb14 [doi]'
p40739
asS'CRDT'
p40740
(lp40741
S'2013/06/13 06:00'
p40742
asS'DP'
p40743
S'2014 Jan 1'
p40744
sS'AD'
p40745
S'*Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Somkhele, South Africa; daggerDepartment of Clinical Research, London School of Hygiene and Tropical Medicine, London, United Kingdom; double daggerDepartment of Infection and Population Health, University College London, London, United Kingdom; section signThe Brighton Doctoral College, Brighton and Sussex Medical School, United Kingdom; and ||University College London Institute of Child Health, London, United Kingdom.'
p40746
sS'OWN'
p40747
S'NLM'
p40748
sS'PT'
p40749
(lp40750
S'Journal Article'
p40751
aS"Research Support, Non-U.S. Gov't"
p40752
aS"Research Support, U.S. Gov't, Non-P.H.S."
p40753
asS'LA'
p40754
(lp40755
S'eng'
p40756
asS'FAU'
p40757
(lp40758
S'Lessells, Richard J'
p40759
aS'Mutevedzi, Portia C'
p40760
aS'Iwuji, Collins C'
p40761
aS'Newell, Marie-Louise'
p40762
asS'LR'
p40763
S'20160713'
p40764
sS'PG'
p40765
S'e17-24'
p40766
sS'TI'
p40767
S'Reduction in early mortality on antiretroviral therapy for adults in rural South Africa since change in CD4+ cell count eligibility criteria.'
p40768
sS'RN'
p40769
(lp40770
S'0 (Anti-HIV Agents)'
p40771
asS'PL'
p40772
S'United States'
p40773
sS'TA'
p40774
S'J Acquir Immune Defic Syndr'
p40775
sS'JID'
p40776
S'100892005'
p40777
sS'AB'
p40778
S'OBJECTIVE: To explore the impact of expanded eligibility criteria for antiretroviral therapy (ART) on median CD4(+) cell count at ART initiation and early mortality on ART. METHODS: Analyses included all adults (>/=16 years) initiated on first-line ART between August 2004 and July 2012. CD4(+) cell count threshold 350 cells per microliter for all adults was implemented in August 2011. Early mortality was defined as any death within 91 days of ART initiation. Trends in baseline CD4(+) cell count and early mortality were examined by year (August to July) of ART initiation. Competing risks analysis was used to examine early mortality. RESULTS: A total of 19,080 adults (67.6% female) initiated ART. Median CD4(+) cell count at ART initiation was 110-120 cells per microliter over the first 6 years, increasing marginally to 145 cells per microliter in 2010-2011 and more significantly to 199 cells per microliter in 2011-2012. Overall, there were 875 deaths within 91 days of ART initiation; early mortality rate was 19.4 per 100 person-years [95% confidence interval (CI) 18.2 to 20.7]. After adjustment for sex, age, baseline CD4(+) cell count, and concurrent tuberculosis (TB), there was a 46% decrease in early mortality for those who initiated ART in 2011-2012 compared with the reference period 2008-2009 (subhazard ratio, 0.54; 95% CI: 0.41 to 0.71). CONCLUSIONS: Since the expansion of eligibility criteria, there is evidence of earlier access to ART and a significant reduction in early mortality rate in this primary health care programme. These findings provide strong support for national ART policies and highlight the importance of earlier ART initiation for achieving reductions in HIV-related mortality.'
p40779
sS'GR'
p40780
(lp40781
S'082384/Z/07/Z/Wellcome Trust/United Kingdom'
p40782
aS'090999/Wellcome Trust/United Kingdom'
p40783
aS'090999/Z/09/Z/Wellcome Trust/United Kingdom'
p40784
aS'097410/Wellcome Trust/United Kingdom'
p40785
aS'100714/Wellcome Trust/United Kingdom'
p40786
aS'674-A-00-08-00-001-00/PEPFAR/United States'
p40787
asS'IP'
p40788
S'1'
sS'IS'
p40789
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p40790
sS'PMC'
p40791
S'PMC3867341'
p40792
sS'DCOM'
p40793
S'20140321'
p40794
sS'AU'
p40795
(lp40796
S'Lessells RJ'
p40797
aS'Mutevedzi PC'
p40798
aS'Iwuji CC'
p40799
aS'Newell ML'
p40800
asS'VI'
p40801
S'65'
p40802
sS'MHDA'
p40803
S'2014/03/22 06:00'
p40804
sS'OID'
p40805
(lp40806
S'NLM: EMS54781'
p40807
aS'NLM: PMC3867341'
p40808
asS'MH'
p40809
(lp40810
S'Adult'
p40811
aS'Age Factors'
p40812
aS'Anti-HIV Agents/administration & dosage/*therapeutic use'
p40813
aS'*CD4 Lymphocyte Count/statistics & numerical data'
p40814
aS'Eligibility Determination'
p40815
aS'Female'
p40816
aS'HIV Infections/drug therapy/immunology/*mortality'
p40817
aS'Humans'
p40818
aS'Male'
p40819
aS'Risk Factors'
p40820
aS'Rural Population/statistics & numerical data'
p40821
aS'Sex Factors'
p40822
aS'South Africa/epidemiology'
p40823
asS'EDAT'
p40824
S'2013/06/13 06:00'
p40825
sS'SO'
p40826
S'J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):e17-24. doi: 10.1097/QAI.0b013e31829ceb14.'
p40827
sS'SB'
p40828
S'IM X'
p40829
sS'PMID'
p40830
S'23756374'
p40831
sS'PST'
p40832
S'ppublish'
p40833
stRp40834
ag2
(g3
g4
(dp40835
S'LID'
p40836
S'10.3851/IMP2652 [doi]'
p40837
sS'STAT'
p40838
S'MEDLINE'
p40839
sS'DEP'
p40840
S'20130610'
p40841
sS'MID'
p40842
(lp40843
S'NIHMS592459'
p40844
asS'DA'
p40845
S'20140116'
p40846
sS'AID'
p40847
(lp40848
S'10.3851/IMP2652 [doi]'
p40849
asS'CRDT'
p40850
(lp40851
S'2013/06/12 06:00'
p40852
asS'DP'
p40853
S'2013'
p40854
sS'AD'
p40855
S'Johns Hopkins University School of Medicine, Baltimore, MD, USA. choffmann@jhmi.edu.'
p40856
sS'OWN'
p40857
S'NLM'
p40858
sS'PT'
p40859
(lp40860
S'Journal Article'
p40861
aS'Research Support, N.I.H., Extramural'
p40862
aS"Research Support, Non-U.S. Gov't"
p40863
asS'LA'
p40864
(lp40865
S'eng'
p40866
asS'FAU'
p40867
(lp40868
S'Hoffmann, Christopher J'
p40869
aS'Ledwaba, Johanna'
p40870
aS'Li, Jin-Fen'
p40871
aS'Johnston, Victoria'
p40872
aS'Hunt, Gillian'
p40873
aS'Fielding, Katherine L'
p40874
aS'Chaisson, Richard E'
p40875
aS'Churchyard, Gavin J'
p40876
aS'Grant, Alison D'
p40877
aS'Johnson, Jeffrey A'
p40878
aS'Charalambous, Salome'
p40879
aS'Morris, Lynn'
p40880
asS'JT'
p40881
S'Antiviral therapy'
p40882
sS'LR'
p40883
S'20160610'
p40884
sS'PG'
p40885
S'915-20'
p40886
sS'TI'
p40887
S'Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa.'
p40888
sS'RN'
p40889
(lp40890
S'0 (Anti-HIV Agents)'
p40891
aS'0 (Organophosphonates)'
p40892
aS'0 (Reverse Transcriptase Inhibitors)'
p40893
aS'99YXE507IL (Tenofovir)'
p40894
aS'JAC85A2161 (Adenine)'
p40895
asS'PL'
p40896
S'England'
p40897
sS'TA'
p40898
S'Antivir Ther'
p40899
sS'JID'
p40900
S'9815705'
p40901
sS'AB'
p40902
S'BACKGROUND: Tenofovir disoproxil fumarate (TDF) is increasingly available for patients infected with subtype C HIV-1. This subtype is reported to develop the principal TDF resistance mutation in the HIV reverse transcriptase, K65R, with greater propensity than other subtypes. We sought to describe K65R development during TDF use in a cohort of patients infected with subtype C HIV. METHODS: Using a prospectively followed cohort with 6 monthly HIV RNA assays, we identified virological failure (defined as an HIV RNA > 1,000 copies/ml) during treatment that included TDF. Residual serum, stored at the time of the HIV RNA assay, was used for consensus sequencing and allele-specific PCR. We assessed prevalence of resistance at failure during TDF-containing treatment and associated factors. RESULTS: Among 1,682 patients on a TDF-containing regimen, 270 developed failure of which 40 were assessed for resistance. By sequencing, the K65R was identified in 5 (12%), major non-nucleoside reverse transcriptase inhibitor mutations in 24 (57%) and the M184V/I in 12 (28%) patients. The K65R was associated with lower HIV RNA at failure (HIV RNA 3.3 versus 4.2 log10 copies/ml) and prior stavudine exposure. An additional five patients had minority K65R populations identified by allele-specific PCR. CONCLUSIONS: These data suggest that the K65R prevalence at virological failure is moderately higher in our subtype C population than some non-subtype C HIV cohorts. However, we did not find that the K65R was highly selected in HIV-1 subtype-C-infected patients with up to 6 months of failure of a TDF-containing regimen.'
p40903
sS'GR'
p40904
(lp40905
S'AI016137/AI/NIAID NIH HHS/United States'
p40906
aS'AI083099/AI/NIAID NIH HHS/United States'
p40907
aS'AI5535901/AI/NIAID NIH HHS/United States'
p40908
aS'K23 AI083099/AI/NIAID NIH HHS/United States'
p40909
aS'P30 AI094189/AI/NIAID NIH HHS/United States'
p40910
aS'Wellcome Trust/United Kingdom'
p40911
asS'IP'
p40912
S'7'
sS'IS'
p40913
S'2040-2058 (Electronic) 1359-6535 (Linking)'
p40914
sS'PMC'
p40915
S'PMC4046272'
p40916
sS'DCOM'
p40917
S'20140911'
p40918
sS'AU'
p40919
(lp40920
S'Hoffmann CJ'
p40921
aS'Ledwaba J'
p40922
aS'Li JF'
p40923
aS'Johnston V'
p40924
aS'Hunt G'
p40925
aS'Fielding KL'
p40926
aS'Chaisson RE'
p40927
aS'Churchyard GJ'
p40928
aS'Grant AD'
p40929
aS'Johnson JA'
p40930
aS'Charalambous S'
p40931
aS'Morris L'
p40932
asS'VI'
p40933
S'18'
p40934
sS'MHDA'
p40935
S'2014/09/12 06:00'
p40936
sS'PHST'
p40937
(lp40938
S'2013/05/18 [accepted]'
p40939
aS'2013/06/10 [aheadofprint]'
p40940
asS'OID'
p40941
(lp40942
S'NLM: NIHMS592459'
p40943
aS'NLM: PMC4046272'
p40944
asS'MH'
p40945
(lp40946
S'Adenine/*analogs & derivatives/therapeutic use'
p40947
aS'Adult'
p40948
aS'Anti-HIV Agents/*therapeutic use'
p40949
aS'Antiretroviral Therapy, Highly Active'
p40950
aS'CD4 Lymphocyte Count'
p40951
aS'Drug Resistance, Viral/*genetics'
p40952
aS'Female'
p40953
aS'Genotype'
p40954
aS'HIV Infections/*drug therapy/*virology'
p40955
aS'HIV-1/*drug effects/*genetics'
p40956
aS'Humans'
p40957
aS'Male'
p40958
aS'Middle Aged'
p40959
aS'Mutation'
p40960
aS'Organophosphonates/*therapeutic use'
p40961
aS'Reverse Transcriptase Inhibitors/*therapeutic use'
p40962
aS'South Africa'
p40963
aS'Tenofovir'
p40964
aS'Treatment Failure'
p40965
aS'Viral Load'
p40966
asS'EDAT'
p40967
S'2013/06/12 06:00'
p40968
sS'SO'
p40969
S'Antivir Ther. 2013;18(7):915-20. doi: 10.3851/IMP2652. Epub 2013 Jun 10.'
p40970
sS'SB'
p40971
S'IM'
p40972
sS'PMID'
p40973
S'23751421'
p40974
sS'PST'
p40975
S'ppublish'
p40976
stRp40977
ag2
(g3
g4
(dp40978
S'LID'
p40979
S'10.1371/journal.pone.0064745 [doi]'
p40980
sS'STAT'
p40981
S'MEDLINE'
p40982
sS'DEP'
p40983
S'20130531'
p40984
sS'DA'
p40985
S'20130606'
p40986
sS'AID'
p40987
(lp40988
S'10.1371/journal.pone.0064745 [doi]'
p40989
aS'PONE-D-13-08529 [pii]'
p40990
asS'CRDT'
p40991
(lp40992
S'2013/06/07 06:00'
p40993
asS'DP'
p40994
S'2013'
p40995
sS'OWN'
p40996
S'NLM'
p40997
sS'PT'
p40998
(lp40999
S'Journal Article'
p41000
aS"Research Support, Non-U.S. Gov't"
p41001
asS'LA'
p41002
(lp41003
S'eng'
p41004
asS'FAU'
p41005
(lp41006
S'Muwonge, Adrian'
p41007
aS'Malama, Sydney'
p41008
aS'Johansen, Tone B'
p41009
aS'Kankya, Clovice'
p41010
aS'Biffa, Demelash'
p41011
aS'Ssengooba, Willy'
p41012
aS'Godfroid, Jacques'
p41013
aS'Djonne, Berit'
p41014
aS'Skjerve, Eystein'
p41015
asS'JT'
p41016
S'PloS one'
p41017
sS'LR'
p41018
S'20150426'
p41019
sS'PG'
p41020
S'e64745'
p41021
sS'TI'
p41022
S'Molecular epidemiology, drug susceptibility and economic aspects of tuberculosis in Mubende district, Uganda.'
p41023
sS'RN'
p41024
(lp41025
S'0 (Antitubercular Agents)'
p41026
aS'0 (DNA, Bacterial)'
p41027
asS'PL'
p41028
S'United States'
p41029
sS'TA'
p41030
S'PLoS One'
p41031
sS'JID'
p41032
S'101285081'
p41033
sS'AB'
p41034
S'BACKGROUND: Tuberculosis (TB) remains a global public health problem whose effects have major impact in developing countries like Uganda. This study aimed at investigating genotypic characteristics and drug resistance profiles of Mycobacterium tuberculosis isolated from suspected TB patients. Furthermore, risk factors and economic burdens that could affect the current control strategies were studied. METHODS: TB suspected patients were examined in a cross-sectional study at the Mubende regional referral hospital between February and July 2011. A questionnaire was administered to each patient to obtain information associated with TB prevalence. Isolates of M. tuberculosis recovered during sampling were examined for drug resistance to first line anti-TB drugs using the BACTEC-MGIT960(TM) system. All isolates were further characterized using deletion analysis, spoligotyping and MIRU-VNTR analysis. Data were analyzed using different software; MIRU-VNTR plus, SITVITWEB, BioNumerics and multivariable regression models. RESULTS: M. tuberculosis was isolated from 74 out of 344 patients, 48 of these were co-infected with HIV. Results from the questionnaire showed that previously treated TB, co-infection with HIV, cigarette smoking, and overcrowding were risk factors associated with TB, while high medical related transport bills were identified as an economic burden. Out of the 67 isolates that gave interpretable results, 23 different spoligopatterns were detected, nine of which were novel patterns. T2 with the sub types Uganda-I and Uganda-II was the most predominant lineage detected. Antibiotic resistance was detected in 19% and multidrug resistance was detected in 3% of the isolates. CONCLUSION: The study detected M. tuberculosis from 21% of examined TB patients, 62% of whom were also HIV positive. There is a heterogeneous pool of genotypes that circulate in this area, with the T2 lineage being the most predominant. High medical related transport bills and drug resistance could undermine the usefulness of the current TB strategic interventions.'
p41035
sS'AD'
p41036
S'Department of Food Safety and Infection Biology, Centre for Epidemiology and Biostatistics, Norwegian School of Veterinary Science, Oslo, Norway. Adrian.Muwonge@roslin.ed.ac.uk'
p41037
sS'IP'
p41038
S'5'
sS'IS'
p41039
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p41040
sS'PMC'
p41041
S'PMC3669366'
p41042
sS'DCOM'
p41043
S'20140218'
p41044
sS'AU'
p41045
(lp41046
S'Muwonge A'
p41047
aS'Malama S'
p41048
aS'Johansen TB'
p41049
aS'Kankya C'
p41050
aS'Biffa D'
p41051
aS'Ssengooba W'
p41052
aS'Godfroid J'
p41053
aS'Djonne B'
p41054
aS'Skjerve E'
p41055
asS'VI'
p41056
S'8'
sS'MHDA'
p41057
S'2014/02/19 06:00'
p41058
sS'PHST'
p41059
(lp41060
S'2013 [ppublish]'
p41061
aS'2013/02/22 [received]'
p41062
aS'2013/04/17 [accepted]'
p41063
aS'2013/05/31 [epublish]'
p41064
asS'OID'
p41065
(lp41066
S'NLM: PMC3669366'
p41067
asS'MH'
p41068
(lp41069
S'Adult'
p41070
aS'Antitubercular Agents/therapeutic use'
p41071
aS'Bacterial Typing Techniques'
p41072
aS'Coinfection'
p41073
aS'Cross-Sectional Studies'
p41074
aS'DNA, Bacterial/genetics/*isolation & purification'
p41075
aS'Drug Resistance, Bacterial'
p41076
aS'Female'
p41077
aS'HIV/*isolation & purification'
p41078
aS'HIV Infections/diagnosis/*epidemiology/microbiology'
p41079
aS'Humans'
p41080
aS'Male'
p41081
aS'Middle Aged'
p41082
aS'Molecular Epidemiology'
p41083
aS'Mycobacterium tuberculosis/genetics/*isolation & purification'
p41084
aS'Tuberculosis, Pulmonary/diagnosis/drug therapy/*epidemiology/microbiology'
p41085
aS'Uganda/epidemiology'
p41086
asS'EDAT'
p41087
S'2013/06/07 06:00'
p41088
sS'SO'
p41089
S'PLoS One. 2013 May 31;8(5):e64745. doi: 10.1371/journal.pone.0064745. Print 2013.'
p41090
sS'SB'
p41091
S'IM'
p41092
sS'PMID'
p41093
S'23741382'
p41094
sS'PST'
p41095
S'epublish'
p41096
stRp41097
ag2
(g3
g4
(dp41098
S'LID'
p41099
S'10.1016/S1473-3099(13)70078-1 [doi] S1473-3099(13)70078-1 [pii]'
p41100
sS'STAT'
p41101
S'MEDLINE'
p41102
sS'DEP'
p41103
S'20130602'
p41104
sS'CI'
p41105
(lp41106
S'Copyright (c) 2013 Elsevier Ltd. All rights reserved.'
p41107
asS'DA'
p41108
S'20130701'
p41109
sS'AID'
p41110
(lp41111
S'S1473-3099(13)70078-1 [pii]'
p41112
aS'10.1016/S1473-3099(13)70078-1 [doi]'
p41113
asS'CRDT'
p41114
(lp41115
S'2013/06/06 06:00'
p41116
asS'DP'
p41117
S'2013 Jul'
p41118
sS'AD'
p41119
S"Cryptococcal Meningitis Group, Research Centre for Infection and Immunity, Division of Clinical Sciences, St George's University of London, UK. angelaloyse@hotmail.com"
p41120
sS'OWN'
p41121
S'NLM'
p41122
sS'PT'
p41123
(lp41124
S'Journal Article'
p41125
aS"Research Support, Non-U.S. Gov't"
p41126
aS'Review'
p41127
asS'LA'
p41128
(lp41129
S'eng'
p41130
asS'FAU'
p41131
(lp41132
S'Loyse, Angela'
p41133
aS'Thangaraj, Harry'
p41134
aS'Easterbrook, Philippa'
p41135
aS'Ford, Nathan'
p41136
aS'Roy, Monika'
p41137
aS'Chiller, Tom'
p41138
aS'Govender, Nelesh'
p41139
aS'Harrison, Thomas S'
p41140
aS'Bicanic, Tihana'
p41141
asS'JT'
p41142
S'The Lancet. Infectious diseases'
p41143
sS'LR'
p41144
S'20140815'
p41145
sS'PG'
p41146
S'629-37'
p41147
sS'TI'
p41148
S'Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries.'
p41149
sS'RN'
p41150
(lp41151
S'0 (Antifungal Agents)'
p41152
asS'PL'
p41153
S'United States'
p41154
sS'TA'
p41155
S'Lancet Infect Dis'
p41156
sS'JID'
p41157
S'101130150'
p41158
sS'AB'
p41159
S'Cryptococcal meningitis is the leading cause of adult meningitis in sub-Saharan Africa, and contributes up to 20% of AIDS-related mortality in low-income and middle-income countries every year. Antifungal treatment for cryptococcal meningitis relies on three old, off-patent antifungal drugs: amphotericin B deoxycholate, flucytosine, and fluconazole. Widely accepted treatment guidelines recommend amphotericin B and flucytosine as first-line induction treatment for cryptococcal meningitis. However, flucytosine is unavailable in Africa and most of Asia, and safe amphotericin B administration requires patient hospitalisation and careful laboratory monitoring to identify and treat common side-effects. Therefore, fluconazole monotherapy is widely used in low-income and middle-income countries for induction therapy, but treatment is associated with significantly increased rates of mortality. We review the antifungal drugs used to treat cryptococcal meningitis with respect to clinical effectiveness and access issues specific to low-income and middle-income countries. Each drug poses unique access challenges: amphotericin B through cost, toxic effects, and insufficiently coordinated distribution; flucytosine through cost and scarcity of registration; and fluconazole through challenges in maintenance of local stocks--eg, sustainability of donations or insufficient generic supplies. We advocate ten steps that need to be taken to improve access to safe and effective antifungal therapy for cryptococcal meningitis.'
p41160
sS'GR'
p41161
(lp41162
S'WT 089966/Wellcome Trust/United Kingdom'
p41163
asS'IP'
p41164
S'7'
sS'IS'
p41165
S'1474-4457 (Electronic) 1473-3099 (Linking)'
p41166
sS'DCOM'
p41167
S'20130904'
p41168
sS'CIN'
p41169
(lp41170
S'Lancet Infect Dis. 2014 May;14(5):371. PMID: 24758994'
p41171
aS'Lancet Infect Dis. 2014 May;14(5):370-1. PMID: 24758992'
p41172
asS'AU'
p41173
(lp41174
S'Loyse A'
p41175
aS'Thangaraj H'
p41176
aS'Easterbrook P'
p41177
aS'Ford N'
p41178
aS'Roy M'
p41179
aS'Chiller T'
p41180
aS'Govender N'
p41181
aS'Harrison TS'
p41182
aS'Bicanic T'
p41183
asS'VI'
p41184
S'13'
p41185
sS'MHDA'
p41186
S'2013/09/05 06:00'
p41187
sS'PHST'
p41188
(lp41189
S'2013/06/02 [aheadofprint]'
p41190
asS'MH'
p41191
(lp41192
S'AIDS-Related Opportunistic Infections/drug therapy/epidemiology'
p41193
aS'Africa South of the Sahara/epidemiology'
p41194
aS'Antifungal Agents/*therapeutic use'
p41195
aS'Developing Countries'
p41196
aS'Health Services Accessibility/*trends'
p41197
aS'Humans'
p41198
aS'Meningitis, Cryptococcal/*drug therapy/*epidemiology'
p41199
aS'Treatment Outcome'
p41200
asS'EDAT'
p41201
S'2013/06/06 06:00'
p41202
sS'SO'
p41203
S'Lancet Infect Dis. 2013 Jul;13(7):629-37. doi: 10.1016/S1473-3099(13)70078-1. Epub 2013 Jun 2.'
p41204
sS'SB'
p41205
S'IM'
p41206
sS'PMID'
p41207
S'23735626'
p41208
sS'PST'
p41209
S'ppublish'
p41210
stRp41211
ag2
(g3
g4
(dp41212
S'LID'
p41213
S'10.1111/tmi.12135 [doi]'
p41214
sS'STAT'
p41215
S'MEDLINE'
p41216
sS'DEP'
p41217
S'20130603'
p41218
sS'CI'
p41219
(lp41220
S'(c) 2013 John Wiley & Sons Ltd.'
p41221
asS'DA'
p41222
S'20130710'
p41223
sS'AID'
p41224
(lp41225
S'10.1111/tmi.12135 [doi]'
p41226
asS'CRDT'
p41227
(lp41228
S'2013/06/05 06:00'
p41229
asS'DP'
p41230
S'2013 Aug'
p41231
sS'AD'
p41232
S'Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Somkhele, South Africa. pmutevedzi@africacentre.ac.za'
p41233
sS'OWN'
p41234
S'NLM'
p41235
sS'PT'
p41236
(lp41237
S'Journal Article'
p41238
aS"Research Support, Non-U.S. Gov't"
p41239
asS'LA'
p41240
(lp41241
S'eng'
p41242
asS'FAU'
p41243
(lp41244
S'Mutevedzi, Portia C'
p41245
aS'Lessells, Richard J'
p41246
aS'Newell, Marie-Louise'
p41247
asS'JT'
p41248
S'Tropical medicine & international health : TM & IH'
p41249
sS'LR'
p41250
S'20160713'
p41251
sS'PG'
p41252
S'934-41'
p41253
sS'TI'
p41254
S'Disengagement from care in a decentralised primary health care antiretroviral treatment programme: cohort study in rural South Africa.'
p41255
sS'RN'
p41256
(lp41257
S'0 (Anti-Retroviral Agents)'
p41258
asS'PL'
p41259
S'England'
p41260
sS'TA'
p41261
S'Trop Med Int Health'
p41262
sS'JID'
p41263
S'9610576'
p41264
sS'AB'
p41265
S'OBJECTIVE: To determine rates of, and factors associated with, disengagement from care in a decentralised antiretroviral programme. METHODS: Adults (>/=16 years) who initiated antiretroviral therapy (ART) in the Hlabisa HIV Treatment and Care Programme August 2004-March 2011 were included. Disengagement from care was defined as no clinic visit for 180 days, after adjustment for mortality. Cumulative incidence functions for disengagement from care, stratified by year of ART initiation, were obtained; competing-risks regression was used to explore factors associated with disengagement from care. RESULTS: A total of 4,674 individuals (median age 34 years, 29% male) contributed 13 610 person-years of follow-up. After adjustment for mortality, incidence of disengagement from care was 3.4 per 100 person-years (95% confidence interval (CI) 3.1-3.8). Estimated retention at 5 years was 61%. The risk of disengagement from care increased with each calendar year of ART initiation (P for trend <0.001). There was a strong association between disengagement from care and higher baseline CD4+ cell count (subhazard ratio (SHR) 1.94 (P < 0.001) and 2.35 (P < 0.001) for CD4+ cell count 150-200 cells/mul and >200 cells/mul respectively, compared with CD4 count <50 cells/mul). Of those disengaged from care with known outcomes, the majority (206/303, 68.0%) remained resident within the local community. CONCLUSIONS: Increasing disengagement from care threatens to limit the population impact of expanded antiretroviral coverage. The influence of both individual and programmatic factors suggests that alternative service delivery strategies will be required to achieve high rates of long-term retention.'
p41266
sS'GR'
p41267
(lp41268
S'082384/Wellcome Trust/United Kingdom'
p41269
aS'090999/Wellcome Trust/United Kingdom'
p41270
aS'090999/Wellcome Trust/United Kingdom'
p41271
aS'097410/Wellcome Trust/United Kingdom'
p41272
aS'100714/Wellcome Trust/United Kingdom'
p41273
aS'674-A-00-08-00001-00./PEPFAR/United States'
p41274
asS'IP'
p41275
S'8'
sS'IS'
p41276
S'1365-3156 (Electronic) 1360-2276 (Linking)'
p41277
sS'PMC'
p41278
S'PMC3775257'
p41279
sS'DCOM'
p41280
S'20130916'
p41281
sS'MID'
p41282
(lp41283
S'EMS54780'
p41284
asS'AU'
p41285
(lp41286
S'Mutevedzi PC'
p41287
aS'Lessells RJ'
p41288
aS'Newell ML'
p41289
asS'VI'
p41290
S'18'
p41291
sS'MHDA'
p41292
S'2013/09/17 06:00'
p41293
sS'PHST'
p41294
(lp41295
S'2013/06/03 [aheadofprint]'
p41296
asS'OTO'
p41297
(lp41298
S'NOTNLM'
p41299
asS'OID'
p41300
(lp41301
S'NLM: EMS54780'
p41302
aS'NLM: PMC3775257'
p41303
asS'MH'
p41304
(lp41305
S'Adolescent'
p41306
aS'Adult'
p41307
aS'Ambulatory Care/*statistics & numerical data'
p41308
aS'Anti-Retroviral Agents/*therapeutic use'
p41309
aS'CD4 Lymphocyte Count'
p41310
aS'Cohort Studies'
p41311
aS'Delivery of Health Care/organization & administration'
p41312
aS'Demography'
p41313
aS'Female'
p41314
aS'HIV Infections/*drug therapy/epidemiology/immunology'
p41315
aS'Humans'
p41316
aS'Incidence'
p41317
aS'*Lost to Follow-Up'
p41318
aS'Male'
p41319
aS'Middle Aged'
p41320
aS'Regression Analysis'
p41321
aS'Rural Health Services/*statistics & numerical data'
p41322
aS'Rural Population/statistics & numerical data'
p41323
aS'South Africa/epidemiology'
p41324
aS'Treatment Refusal/*statistics & numerical data'
p41325
aS'Young Adult'
p41326
asS'EDAT'
p41327
S'2013/06/05 06:00'
p41328
sS'SO'
p41329
S'Trop Med Int Health. 2013 Aug;18(8):934-41. doi: 10.1111/tmi.12135. Epub 2013 Jun 3.'
p41330
sS'SB'
p41331
S'IM'
p41332
sS'PMID'
p41333
S'23731253'
p41334
sS'OT'
p41335
(lp41336
S'HIV-1'
p41337
aS'antiretroviral agents'
p41338
aS'delivery of health care'
p41339
aS'disengagement from care'
p41340
aS'lost to follow-up'
p41341
aS'primary health care'
p41342
asS'PST'
p41343
S'ppublish'
p41344
stRp41345
ag2
(g3
g4
(dp41346
S'STAT'
p41347
S'MEDLINE'
p41348
sS'JT'
p41349
S'AIDS (London, England)'
p41350
sS'MID'
p41351
(lp41352
S'NIHMS605725'
p41353
asS'DA'
p41354
S'20131031'
p41355
sS'AID'
p41356
(lp41357
S'10.1097/QAD.0b013e3283610ec7 [doi]'
p41358
asS'CRDT'
p41359
(lp41360
S'2013/06/04 06:00'
p41361
asS'DP'
p41362
S'2013 Jul 31'
p41363
sS'CN'
p41364
(lp41365
S'JCRC Drug Resistance Working Group'
p41366
asS'OWN'
p41367
S'NLM'
p41368
sS'PT'
p41369
(lp41370
S'Journal Article'
p41371
aS'Research Support, N.I.H., Extramural'
p41372
asS'LA'
p41373
(lp41374
S'eng'
p41375
asS'FAU'
p41376
(lp41377
S'Kyeyune, Fred'
p41378
aS'Nankya, Immaculate'
p41379
aS'Metha, Samar'
p41380
aS'Akao, Juliet'
p41381
aS'Ndashimye, Emmanuel'
p41382
aS'Tebit, Denis M'
p41383
aS'Rodriguez, Benigno'
p41384
aS'Kityo, Cissy'
p41385
aS'Salata, Robert A'
p41386
aS'Mugyenyi, Peter'
p41387
aS'Arts, Eric'
p41388
asS'LR'
p41389
S'20160303'
p41390
sS'PG'
p41391
S'1899-909'
p41392
sS'TI'
p41393
S'Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period.'
p41394
sS'RN'
p41395
(lp41396
S'0 (Anti-HIV Agents)'
p41397
asS'PL'
p41398
S'England'
p41399
sS'TA'
p41400
S'AIDS'
p41401
sS'FIR'
p41402
(lp41403
S'Bagenda, Leonard'
p41404
aS'Nanyonjo, Hannah'
p41405
aS'Immonen, Taina'
p41406
aS'Ssali, Francis'
p41407
aS'Semanda, Michael'
p41408
aS'Bukuru, Aggrey'
p41409
asS'JID'
p41410
S'8710219'
p41411
sS'AB'
p41412
S'OBJECTIVES: To determine the impact of HIV-1 subtype on treatment outcomes and the emergence of drug resistance in the resource limited setting of Kampala, Uganda. DESIGN: The Joint Clinical Research Centre (JCRC) in Kampala, Uganda has provided over 2000 drug-resistant genotypes (DRGs) over the past 10 years as standard of care for patients failing therapy and 1403 from treatment-naive and experienced patients over the past 10 years have been analyzed for this study. METHOD: Viral loads, CD4 cell count, treatment histories and other relevant clinical data was compared with the infecting HIV-1 subtype and DRGs of Ugandan patients failing treatment. RESULTS: Patients failing HAART with DRGs (n = 937) were more frequently infected with subtype D than expected on the basis of the subtype distribution in the treatment-naive population (n = 655) in Kampala (P < 0.001). Higher proportions of treatment failures among subtype D-infected patients were driven by resistance to nucleoside reverse transcriptase inhibitors (NRTI) (P < 0.0002) more than to non-NRTIs (P > 0.04) or protease inhibitors. CONCLUSION: Higher rates of treatment failure among subtype D as compared with subtype A-infected Ugandans was analogous to the faster disease progression in subtype D-infected patients. The mechanism(s) by which drug resistance may emerge faster in subtype D HIV-1 may relate to higher replicative fitness and increased propensity for a CXCR4 tropism.'
p41413
sS'GR'
p41414
(lp41415
S'AI025879/AI/NIAID NIH HHS/United States'
p41416
aS'AI36219/AI/NIAID NIH HHS/United States'
p41417
aS'AI49170/AI/NIAID NIH HHS/United States'
p41418
aS'P30 AI036219/AI/NIAID NIH HHS/United States'
p41419
aS'R01 AI049170/AI/NIAID NIH HHS/United States'
p41420
aS'U01 AI025879/AI/NIAID NIH HHS/United States'
p41421
asS'IP'
p41422
S'12'
p41423
sS'IS'
p41424
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p41425
sS'IR'
p41426
(lp41427
S'Bagenda L'
p41428
aS'Nanyonjo H'
p41429
aS'Immonen T'
p41430
aS'Ssali F'
p41431
aS'Semanda M'
p41432
aS'Bukuru A'
p41433
asS'DCOM'
p41434
S'20140421'
p41435
sS'AU'
p41436
(lp41437
S'Kyeyune F'
p41438
aS'Nankya I'
p41439
aS'Metha S'
p41440
aS'Akao J'
p41441
aS'Ndashimye E'
p41442
aS'Tebit DM'
p41443
aS'Rodriguez B'
p41444
aS'Kityo C'
p41445
aS'Salata RA'
p41446
aS'Mugyenyi P'
p41447
aS'Arts E'
p41448
asS'VI'
p41449
S'27'
p41450
sS'MHDA'
p41451
S'2014/04/22 06:00'
p41452
sS'OID'
p41453
(lp41454
S'NLM: NIHMS605725'
p41455
aS'NLM: PMC4494684'
p41456
asS'MH'
p41457
(lp41458
S'Anti-HIV Agents/*therapeutic use'
p41459
aS'CD4 Lymphocyte Count'
p41460
aS'*Drug Resistance, Viral'
p41461
aS'Genotype'
p41462
aS'HIV Infections/*drug therapy/epidemiology/immunology/*virology'
p41463
aS'HIV-1/*classification/*drug effects/genetics/isolation & purification'
p41464
aS'Humans'
p41465
aS'Treatment Failure'
p41466
aS'Uganda/epidemiology'
p41467
aS'Viral Load'
p41468
asS'EDAT'
p41469
S'2013/06/04 06:00'
p41470
sS'PMC'
p41471
S'PMC4494684'
p41472
sS'SO'
p41473
S'AIDS. 2013 Jul 31;27(12):1899-909.'
p41474
sS'SB'
p41475
S'IM X'
p41476
sS'PMID'
p41477
S'23727942'
p41478
sS'PST'
p41479
S'ppublish'
p41480
stRp41481
ag2
(g3
g4
(dp41482
S'LID'
p41483
S'10.1371/journal.pone.0063596 [doi]'
p41484
sS'STAT'
p41485
S'MEDLINE'
p41486
sS'DEP'
p41487
S'20130522'
p41488
sS'DA'
p41489
S'20130529'
p41490
sS'AID'
p41491
(lp41492
S'10.1371/journal.pone.0063596 [doi]'
p41493
aS'PONE-D-13-09929 [pii]'
p41494
asS'CRDT'
p41495
(lp41496
S'2013/05/30 06:00'
p41497
asS'DP'
p41498
S'2013'
p41499
sS'AD'
p41500
S'Desmond Tutu HIV Centre, Institute for Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa. christine_njuguna@yahoo.co.uk'
p41501
sS'OWN'
p41502
S'NLM'
p41503
sS'PT'
p41504
(lp41505
S'Journal Article'
p41506
aS'Research Support, N.I.H., Extramural'
p41507
aS"Research Support, Non-U.S. Gov't"
p41508
asS'LA'
p41509
(lp41510
S'eng'
p41511
asS'FAU'
p41512
(lp41513
S'Njuguna, Christine'
p41514
aS'Orrell, Catherine'
p41515
aS'Kaplan, Richard'
p41516
aS'Bekker, Linda-Gail'
p41517
aS'Wood, Robin'
p41518
aS'Lawn, Stephen D'
p41519
asS'JT'
p41520
S'PloS one'
p41521
sS'LR'
p41522
S'20151119'
p41523
sS'PG'
p41524
S'e63596'
p41525
sS'TI'
p41526
S'Rates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovir.'
p41527
sS'RN'
p41528
(lp41529
S'0 (Anti-Retroviral Agents)'
p41530
aS'0 (Organophosphonates)'
p41531
aS'99YXE507IL (Tenofovir)'
p41532
aS'JAC85A2161 (Adenine)'
p41533
asS'PL'
p41534
S'United States'
p41535
sS'TA'
p41536
S'PLoS One'
p41537
sS'JID'
p41538
S'101285081'
p41539
sS'AB'
p41540
S'INTRODUCTION: Antiretroviral changes (single drug substitutions and regimen switches) limit treatment options and introduce challenges such as increased cost, monitoring and adherence difficulties. Patterns of drug substitutions and regimen switches from stavudine (d4T) and zidovudine (AZT) regimens have been well described but data on tenofovir (TDF) are more limited. This study describes the patterns and risk factors for drug changes of these antiretroviral drugs in adults. METHOD: This retrospective cohort study included HIV positive, antiretroviral treatment (ART) naive adults aged >/=18 years who started ART with two nucleoside reverse transcriptase inhibitors (NRTIs) and a non-nucleoside reverse transcriptase inhibitor. Follow-up was censored at first drug change and analysis focused on NRTI changes only. RESULTS: Between September 2002 and April 2011, 5095 adults initiated ART in Gugulethu. This comprised 948 subjects on TDF, 3438 on d4T and 709 subjects on AZT. Virological suppression rates at 1 year, regimen switching due to virological failure and overall losses to the programme were similar across the three groups. TDF had the lowest incidence rate of drug substitutions (2.6 per 100 P/Ys) compared to 17.9 for d4T and 8.5 per 100 P/Ys for AZT. Adverse drug reactions (ADRs) accounted for the majority of drug substitutions of d4T. Multivariate analysis showed that increasing age, female sex and d4T exposure were associated with increased hazard of drug substitution due to ADRs. Conversely, TDF exposure was associated with a substantially lower risk of substitution (adjusted hazards ratio 0.38; 95% CI 0.20-0.72). CONCLUSION: Regimen switches and virological suppression were similar for patients exposed to TDF, d4T and AZT, suggesting all regimens were equally effective. However, TDF was better tolerated with a substantially lower rate of drug substitutions due to ADRs.'
p41541
sS'GR'
p41542
(lp41543
S'5D43TW007115-06/TW/FIC NIH HHS/United States'
p41544
aS'Wellcome Trust/United Kingdom'
p41545
asS'IP'
p41546
S'5'
sS'IS'
p41547
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p41548
sS'PMC'
p41549
S'PMC3661537'
p41550
sS'DCOM'
p41551
S'20140417'
p41552
sS'AU'
p41553
(lp41554
S'Njuguna C'
p41555
aS'Orrell C'
p41556
aS'Kaplan R'
p41557
aS'Bekker LG'
p41558
aS'Wood R'
p41559
aS'Lawn SD'
p41560
asS'VI'
p41561
S'8'
sS'MHDA'
p41562
S'2014/04/18 06:00'
p41563
sS'PHST'
p41564
(lp41565
S'2013 [ppublish]'
p41566
aS'2013/03/06 [received]'
p41567
aS'2013/04/01 [accepted]'
p41568
aS'2013/05/22 [epublish]'
p41569
asS'OID'
p41570
(lp41571
S'NLM: PMC3661537'
p41572
asS'MH'
p41573
(lp41574
S'Adenine/adverse effects/*analogs & derivatives/therapeutic use'
p41575
aS'Adult'
p41576
aS'Anti-Retroviral Agents/*adverse effects/*therapeutic use'
p41577
aS'Antiretroviral Therapy, Highly Active/adverse effects/methods'
p41578
aS'Cohort Studies'
p41579
aS'*Drug Substitution'
p41580
aS'Drug-Related Side Effects and Adverse Reactions/etiology'
p41581
aS'Female'
p41582
aS'HIV/drug effects'
p41583
aS'HIV Infections/*drug therapy'
p41584
aS'Humans'
p41585
aS'Male'
p41586
aS'Organophosphonates/*adverse effects/*therapeutic use'
p41587
aS'Primary Health Care'
p41588
aS'Retrospective Studies'
p41589
aS'Risk Factors'
p41590
aS'South Africa'
p41591
aS'Tenofovir'
p41592
asS'EDAT'
p41593
S'2013/05/30 06:00'
p41594
sS'SO'
p41595
S'PLoS One. 2013 May 22;8(5):e63596. doi: 10.1371/journal.pone.0063596. Print 2013.'
p41596
sS'SB'
p41597
S'IM'
p41598
sS'PMID'
p41599
S'23717451'
p41600
sS'PST'
p41601
S'epublish'
p41602
stRp41603
ag2
(g3
g4
(dp41604
S'LID'
p41605
S'10.1186/1471-2334-13-237 [doi]'
p41606
sS'STAT'
p41607
S'MEDLINE'
p41608
sS'DEP'
p41609
S'20130523'
p41610
sS'DA'
p41611
S'20130603'
p41612
sS'AID'
p41613
(lp41614
S'1471-2334-13-237 [pii]'
p41615
aS'10.1186/1471-2334-13-237 [doi]'
p41616
asS'CRDT'
p41617
(lp41618
S'2013/05/25 06:00'
p41619
asS'DP'
p41620
S'2013'
p41621
sS'OWN'
p41622
S'NLM'
p41623
sS'PT'
p41624
(lp41625
S'Journal Article'
p41626
aS"Research Support, Non-U.S. Gov't"
p41627
asS'LA'
p41628
(lp41629
S'eng'
p41630
asS'DCOM'
p41631
S'20140303'
p41632
sS'JT'
p41633
S'BMC infectious diseases'
p41634
sS'LR'
p41635
S'20150426'
p41636
sS'FAU'
p41637
(lp41638
S'Mbonye, Anthony K'
p41639
aS'Birungi, Josephine'
p41640
aS'Yanow, Stephanie'
p41641
aS'Magnussen, Pascal'
p41642
asS'TI'
p41643
S'Prescription patterns and drug use among pregnant women with febrile Illnesses in Uganda: a survey in out-patient clinics.'
p41644
sS'RN'
p41645
(lp41646
S'0 (Anti-Retroviral Agents)'
p41647
aS'0 (Antimalarials)'
p41648
asS'PL'
p41649
S'England'
p41650
sS'PG'
p41651
S'237'
p41652
sS'JID'
p41653
S'100968551'
p41654
sS'AB'
p41655
S'BACKGROUND: Malaria is a public health problem in Uganda; affecting mainly women and children. Effective treatment has been hampered by over-diagnosis and over-treatment with anti-malarial drugs among patients presenting with fever. In order to understand the effect of drug pressure on sulfadoxine-pyrimethamine (SP) resistance in pregnancy, a sample of pregnant women presenting with fever in out-patient clinics was studied. The main objective was to assess prescription patterns and drug use in pregnancy especially SP; and draw implications on the efficacy of SP for intermittent preventive treatment of malaria in pregnancy (IPTp). METHODS: A total of 998 pregnant women with a history of fever were interviewed and blood samples taken for diagnosis of malaria and HIV infections. Data were captured on the drugs prescribed for the current febrile episode and previous use of drugs especially SP, anti-retroviral drugs (ARVs) and cotrimoxazole. RESULTS: Few pregnant women, 128 (12.8%) were parasitaemic for P.falciparum; and of these, 72 (56.3%) received first-line treatment with Artemether-lumefantrine (Coartem(R)) 14 (10.9%) SP and 33 (25.8%) quinine. Of the parasite negative patients (non-malarial fevers), 186 (21.4%) received Coartem, 423 (48.6%) SP and 19 (2.1%) cotrimoxazole. Overall, malaria was appropriately treated in 35.5% of cases. Almost all febrile pregnant women, 91.1%, were sleeping under a mosquito net. The majority of them, 911 (91.3%), accepted to have an HIV test done and 92 (9.2%) were HIV positive. Of the HIV positive women, 23 (25.0%) were on ARVs, 10 (10.9%) on cotrimoxazole and 30 (32.6%) on SP. A significant proportion of women, 40 (43.5%), were on both SP and cotrimoxazole. Age and occupation were associated with diagnosis and treatment of malaria and HIV infections. CONCLUSION: There is inappropriate treatment of malaria and non-malarial fevers among pregnant women in these facilities. This is due to non-adherence to the guidelines. Over-prescription and use of anti-malarial drugs, especially SP may have implications on resistance against SP for malaria prevention in pregnancy. The policy implications of these findings are to evaluate SP efficacy as IPTp; and the need to enforce adherence to the current clinical treatment guidelines.'
p41656
sS'AD'
p41657
S'School of Public Health, Makerere University and Commissioner Health Services, Ministry of Health, Box 7272, Kampala, Uganda. vpadmn@infocom.co.ug'
p41658
sS'VI'
p41659
S'13'
p41660
sS'IS'
p41661
S'1471-2334 (Electronic) 1471-2334 (Linking)'
p41662
sS'PMC'
p41663
S'PMC3668983'
p41664
sS'AU'
p41665
(lp41666
S'Mbonye AK'
p41667
aS'Birungi J'
p41668
aS'Yanow S'
p41669
aS'Magnussen P'
p41670
asS'MHDA'
p41671
S'2014/03/04 06:00'
p41672
sS'PHST'
p41673
(lp41674
S'2012/12/05 [received]'
p41675
aS'2013/05/13 [accepted]'
p41676
aS'2013/05/23 [aheadofprint]'
p41677
asS'OID'
p41678
(lp41679
S'NLM: PMC3668983'
p41680
asS'MH'
p41681
(lp41682
S'Adolescent'
p41683
aS'Adult'
p41684
aS'Ambulatory Care Facilities/statistics & numerical data'
p41685
aS'Analysis of Variance'
p41686
aS'Anti-Retroviral Agents/therapeutic use'
p41687
aS'Antimalarials/*therapeutic use'
p41688
aS'Cohort Studies'
p41689
aS'Female'
p41690
aS'Fever/*drug therapy/microbiology/parasitology'
p41691
aS'HIV Infections/*diagnosis/drug therapy'
p41692
aS'Humans'
p41693
aS'Inappropriate Prescribing/statistics & numerical data'
p41694
aS'Malaria/diagnosis/*drug therapy'
p41695
aS'Middle Aged'
p41696
aS'Pregnancy'
p41697
aS'Pregnancy Complications, Infectious/*drug therapy/microbiology/parasitology'
p41698
aS'Uganda'
p41699
asS'EDAT'
p41700
S'2013/05/25 06:00'
p41701
sS'SO'
p41702
S'BMC Infect Dis. 2013 May 23;13:237. doi: 10.1186/1471-2334-13-237.'
p41703
sS'SB'
p41704
S'IM'
p41705
sS'PMID'
p41706
S'23702003'
p41707
sS'TA'
p41708
S'BMC Infect Dis'
p41709
sS'PST'
p41710
S'epublish'
p41711
stRp41712
ag2
(g3
g4
(dp41713
S'LID'
p41714
S'10.1093/infdis/jit112 [doi]'
p41715
sS'STAT'
p41716
S'MEDLINE'
p41717
sS'JT'
p41718
S'The Journal of infectious diseases'
p41719
sS'DA'
p41720
S'20130520'
p41721
sS'AID'
p41722
(lp41723
S'jit112 [pii]'
p41724
aS'10.1093/infdis/jit112 [doi]'
p41725
asS'CRDT'
p41726
(lp41727
S'2013/05/21 06:00'
p41728
asS'DP'
p41729
S'2013 Jun 15'
p41730
sS'OWN'
p41731
S'NLM'
p41732
sS'PT'
p41733
(lp41734
S'Journal Article'
p41735
aS'Meta-Analysis'
p41736
aS"Research Support, Non-U.S. Gov't"
p41737
asS'LA'
p41738
(lp41739
S'eng'
p41740
asS'DCOM'
p41741
S'20130802'
p41742
sS'FAU'
p41743
(lp41744
S'Hill, Andrew'
p41745
aS'McBride, Angela'
p41746
aS'Sawyer, A William'
p41747
aS'Clumeck, Nathan'
p41748
aS'Gupta, Ravindra K'
p41749
asS'TI'
p41750
S'Resistance at virological failure using boosted protease inhibitors versus nonnucleoside reverse transcriptase inhibitors as first-line antiretroviral therapy--implications for sustained efficacy of ART in resource-limited settings.'
p41751
sS'RN'
p41752
(lp41753
S'0 (Anti-Retroviral Agents)'
p41754
aS'0 (HIV Protease Inhibitors)'
p41755
aS'0 (RNA, Viral)'
p41756
aS'0 (Reverse Transcriptase Inhibitors)'
p41757
asS'PL'
p41758
S'United States'
p41759
sS'PG'
p41760
S'S78-84'
p41761
sS'JID'
p41762
S'0413675'
p41763
sS'AB'
p41764
S'BACKGROUND: Increases in the prevalence of resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs) have been observed among previously untreated individuals in all areas of sub-Saharan Africa. We aimed to examine whether first-line use of 2 NRTIs plus a boosted protease inhibitor (bPI) could protect against emergence of NRTI resistance mutations, compared to the use of 2 NRTIs plus 1 NNRTI. METHODS: We carried out a weighted meta-analysis of randomized clinical trials comparing bPI- with NNRTI-based first-line antiretroviral therapy regimens using random effects modeling. RESULTS: In intention to treat analyses, there was no difference in the risk of viral failure at week 48 between NNRTI and bPI (P = .19). At week 48, the overall difference between NNRTI- and PI-based regimens in selection of any major NRTI resistance mutation (crude unweighted prevalence 3.3% vs 1.6%) was 1.7% (95% confidence interval [CI], .4-3.0; P = .00927). There was a statistically significant difference in prevalence of K65R when comparing NNRTI (1.3%) with PI (0.67%); absolute weighted difference 1.0% (95% CI, .3-1.7; P = .00447). There was also a significant difference in prevalence of M184V/I between NNRTI and PI (crude unweighted prevalence 3.2% vs 1.4%); difference 1.6% (95% CI 0.1-3.1; P = .0368). CONCLUSIONS: Despite the equivalent efficacy and more favorable resistance implications of PI- versus NNRTI-based first line therapy, widespread use of PI-based first-line therapy is not warranted at this time, due to resource limitations and predicted increased risk of resistance-related failure of NNRTI/NRTI second-line regimens. PI-based first-line therapy could be reconsidered when antiretroviral agents from other classes become available for second-line regimens in resource-limited settings.'
p41765
sS'AD'
p41766
S'Pharmacology Research Laboratories, Liverpool University, United Kingdom.'
p41767
sS'VI'
p41768
S'207 Suppl 2'
p41769
sS'IS'
p41770
S'1537-6613 (Electronic) 0022-1899 (Linking)'
p41771
sS'AU'
p41772
(lp41773
S'Hill A'
p41774
aS'McBride A'
p41775
aS'Sawyer AW'
p41776
aS'Clumeck N'
p41777
aS'Gupta RK'
p41778
asS'MHDA'
p41779
S'2013/08/03 06:00'
p41780
sS'OT'
p41781
(lp41782
S'ART'
p41783
aS'HIV'
p41784
aS'NNRTI'
p41785
aS'PI'
p41786
aS'antiretroviral therapy'
p41787
aS'protease'
p41788
aS'resistance'
p41789
aS'reverse transcriptase'
p41790
asS'OTO'
p41791
(lp41792
S'NOTNLM'
p41793
asS'MH'
p41794
(lp41795
S'Anti-Retroviral Agents/*administration & dosage'
p41796
aS'Developing Countries'
p41797
aS'*Drug Resistance, Viral'
p41798
aS'Drug Therapy, Combination'
p41799
aS'Female'
p41800
aS'Follow-Up Studies'
p41801
aS'Genotype'
p41802
aS'HIV Infections/*drug therapy/virology'
p41803
aS'HIV Protease Inhibitors/administration & dosage'
p41804
aS'HIV-1/*drug effects/genetics/physiology'
p41805
aS'Humans'
p41806
aS'Male'
p41807
aS'Mutation, Missense'
p41808
aS'Poverty'
p41809
aS'Prevalence'
p41810
aS'RNA, Viral/analysis/genetics'
p41811
aS'Regression Analysis'
p41812
aS'Reverse Transcriptase Inhibitors/administration & dosage'
p41813
aS'Treatment Outcome'
p41814
aS'Viral Load'
p41815
asS'EDAT'
p41816
S'2013/05/25 06:00'
p41817
sS'SO'
p41818
S'J Infect Dis. 2013 Jun 15;207 Suppl 2:S78-84. doi: 10.1093/infdis/jit112.'
p41819
sS'SB'
p41820
S'AIM IM'
p41821
sS'PMID'
p41822
S'23687293'
p41823
sS'TA'
p41824
S'J Infect Dis'
p41825
sS'PST'
p41826
S'ppublish'
p41827
stRp41828
ag2
(g3
g4
(dp41829
S'LID'
p41830
S'10.1371/journal.pone.0064459 [doi]'
p41831
sS'STAT'
p41832
S'MEDLINE'
p41833
sS'DEP'
p41834
S'20130514'
p41835
sS'DA'
p41836
S'20130521'
p41837
sS'AID'
p41838
(lp41839
S'10.1371/journal.pone.0064459 [doi]'
p41840
aS'PONE-D-12-33991 [pii]'
p41841
asS'CRDT'
p41842
(lp41843
S'2013/05/22 06:00'
p41844
asS'DP'
p41845
S'2013'
p41846
sS'AD'
p41847
S'The Aurum Institute, Johannesburg, South Africa.'
p41848
sS'OWN'
p41849
S'NLM'
p41850
sS'PT'
p41851
(lp41852
S'Comparative Study'
p41853
aS'Journal Article'
p41854
aS'Research Support, N.I.H., Extramural'
p41855
aS"Research Support, Non-U.S. Gov't"
p41856
asS'LA'
p41857
(lp41858
S'eng'
p41859
asS'FAU'
p41860
(lp41861
S'Velen, Kavindhran'
p41862
aS'Lewis, James J'
p41863
aS'Charalambous, Salome'
p41864
aS'Grant, Alison D'
p41865
aS'Churchyard, Gavin J'
p41866
aS'Hoffmann, Christopher J'
p41867
asS'JT'
p41868
S'PloS one'
p41869
sS'LR'
p41870
S'20151119'
p41871
sS'PG'
p41872
S'e64459'
p41873
sS'TI'
p41874
S'Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study.'
p41875
sS'RN'
p41876
(lp41877
S'0 (Anti-HIV Agents)'
p41878
aS'0 (Organophosphonates)'
p41879
aS'0 (RNA, Viral)'
p41880
aS'4B9XT59T7S (Zidovudine)'
p41881
aS'99YXE507IL (Tenofovir)'
p41882
aS'BO9LE4QFZF (Stavudine)'
p41883
aS'JAC85A2161 (Adenine)'
p41884
asS'PL'
p41885
S'United States'
p41886
sS'TA'
p41887
S'PLoS One'
p41888
sS'JID'
p41889
S'101285081'
p41890
sS'AB'
p41891
S'BACKGROUND: Tenofovir (TDF) is part of the WHO recommended first-line antiretroviral therapy (ART); however, there are limited data comparing TDF to other nucleoside reverse transcriptase inhibitors in resource-limited-settings. Using a routine workplace and community-based ART cohort in South Africa, we assessed single drug substitution, HIV RNA suppression, CD4 count increase, loss-from-care, and mortality between TDF, stavudine (d4T) 30 mg dose, and zidovudine (AZT). METHODS: In a prospective cohort study we included ART naive patients aged >/=17 years-old who initiated ART containing TDF, d4T, or AZT between 2007 and 2009. For analysis of single drug substitutions we used a competing-risks time-to-event analysis; for loss-from-care, mixed-effect Poisson modeling; for HIV RNA suppression, competing-risks logistic regression; for CD4 count slope, mixed-effects linear regression; and for mortality, proportional hazards modeling. RESULTS: Of 6,196 patients, the initial drug was TDF for 665 (11%), d4T for 4,179 (68%), and AZT for 1,352 (22%). During the first 6 months of ART, the adjusted hazard ratio for a single drug substitution was 2.3 for d4T (95% confidence interval [CI]: 0.27, 19) and 5.2 for AZT (95% CI: 1.1, 23), compared to TDF; whereas, after 6 months, it was 10 (95% CI: 5.8, 18) and 4.4 (95% CI: 2.5, 7.8) for d4T and AZT, respectively. Virologic suppression was similar by agent; however, CD4 count rise was lowest for AZT. The adjusted hazard ratio for loss-from-care, when compared to TDF, was 1.5 (95% CI: 1.1, 1.9) for d4T and 1.2 (95% CI: 1.1, 1.4) for AZT. The adjusted hazard ratio for mortality, when compared to TDF, was 2.7 (95% CI: 2.0, 3.5) and 1.4 (95% CI: 1.3, 1.5) and for d4T and AZT, respectively. DISCUSSION: In routine care, TDF appeared to perform better than either d4T or AZT, most notably with less drug substitution and mortality than for either other agent.'
p41892
sS'GR'
p41893
(lp41894
S'AI083099/AI/NIAID NIH HHS/United States'
p41895
aS'MR/K007467/1/Medical Research Council/United Kingdom'
p41896
asS'IP'
p41897
S'5'
sS'IS'
p41898
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p41899
sS'PMC'
p41900
S'PMC3653880'
p41901
sS'DCOM'
p41902
S'20131230'
p41903
sS'AU'
p41904
(lp41905
S'Velen K'
p41906
aS'Lewis JJ'
p41907
aS'Charalambous S'
p41908
aS'Grant AD'
p41909
aS'Churchyard GJ'
p41910
aS'Hoffmann CJ'
p41911
asS'VI'
p41912
S'8'
sS'MHDA'
p41913
S'2014/01/01 06:00'
p41914
sS'PHST'
p41915
(lp41916
S'2013 [ppublish]'
p41917
aS'2012/10/26 [received]'
p41918
aS'2013/04/15 [accepted]'
p41919
aS'2013/05/14 [epublish]'
p41920
asS'OID'
p41921
(lp41922
S'NLM: PMC3653880'
p41923
asS'MH'
p41924
(lp41925
S'Adenine/analogs & derivatives/pharmacology/therapeutic use'
p41926
aS'Adolescent'
p41927
aS'Adult'
p41928
aS'Anti-HIV Agents/*pharmacology/therapeutic use'
p41929
aS'CD4 Lymphocyte Count'
p41930
aS'Cohort Studies'
p41931
aS'Female'
p41932
aS'HIV/drug effects/physiology'
p41933
aS'HIV Infections/*drug therapy/immunology/mortality'
p41934
aS'Health Resources/*supply & distribution'
p41935
aS'Humans'
p41936
aS'Male'
p41937
aS'Middle Aged'
p41938
aS'Organophosphonates/pharmacology/therapeutic use'
p41939
aS'RNA, Viral/metabolism'
p41940
aS'Residence Characteristics'
p41941
aS'Stavudine/pharmacology/therapeutic use'
p41942
aS'Tenofovir'
p41943
aS'Young Adult'
p41944
aS'Zidovudine/pharmacology/therapeutic use'
p41945
asS'EDAT'
p41946
S'2013/05/22 06:00'
p41947
sS'SO'
p41948
S'PLoS One. 2013 May 14;8(5):e64459. doi: 10.1371/journal.pone.0064459. Print 2013.'
p41949
sS'SB'
p41950
S'IM'
p41951
sS'PMID'
p41952
S'23691224'
p41953
sS'PST'
p41954
S'epublish'
p41955
stRp41956
ag2
(g3
g4
(dp41957
S'LID'
p41958
S'10.1371/journal.pone.0062034 [doi]'
p41959
sS'STAT'
p41960
S'MEDLINE'
p41961
sS'DEP'
p41962
S'20130513'
p41963
sS'DA'
p41964
S'20130515'
p41965
sS'AID'
p41966
(lp41967
S'10.1371/journal.pone.0062034 [doi]'
p41968
aS'PONE-D-12-31309 [pii]'
p41969
asS'CRDT'
p41970
(lp41971
S'2013/05/16 06:00'
p41972
asS'DP'
p41973
S'2013'
p41974
sS'AD'
p41975
S"Kibong'oto National Tuberculosis Hospital, Kilimanjaro, Tanzania. s.mpagama@kcri.ac.tz"
p41976
sS'OWN'
p41977
S'NLM'
p41978
sS'PT'
p41979
(lp41980
S'Journal Article'
p41981
aS'Research Support, N.I.H., Extramural'
p41982
aS"Research Support, Non-U.S. Gov't"
p41983
asS'LA'
p41984
(lp41985
S'eng'
p41986
asS'FAU'
p41987
(lp41988
S'Mpagama, Stellah G'
p41989
aS'Heysell, Scott K'
p41990
aS'Ndusilo, Nora D'
p41991
aS'Kumburu, Happiness H'
p41992
aS'Lekule, Isack A'
p41993
aS'Kisonga, Riziki M'
p41994
aS'Gratz, Jean'
p41995
aS'Boeree, Martin J'
p41996
aS'Houpt, Eric R'
p41997
aS'Kibiki, Gibson S'
p41998
asS'JT'
p41999
S'PloS one'
p42000
sS'LR'
p42001
S'20150426'
p42002
sS'PG'
p42003
S'e62034'
p42004
sS'TI'
p42005
S'Diagnosis and interim treatment outcomes from the first cohort of multidrug-resistant tuberculosis patients in Tanzania.'
p42006
sS'RN'
p42007
(lp42008
S'0 (Aminoglycosides)'
p42009
aS'0 (Antitubercular Agents)'
p42010
aS'0 (Fluoroquinolones)'
p42011
aS'5B2658E0N2 (Aminosalicylic Acid)'
p42012
aS'OAY8ORS3CQ (Ethionamide)'
p42013
asS'PL'
p42014
S'United States'
p42015
sS'TA'
p42016
S'PLoS One'
p42017
sS'JID'
p42018
S'101285081'
p42019
sS'AB'
p42020
S"SETTING: Kibong'oto National Tuberculosis Hospital (KNTH), Kilimanjaro, Tanzania. OBJECTIVE: Characterize the diagnostic process and interim treatment outcomes from patients treated for multidrug-resistant tuberculosis (MDR-TB) in Tanzania. DESIGN: A retrospective cohort study was performed among all patients treated at KNTH for pulmonary MDR-TB between November 2009 and September 2011. RESULTS: Sixty-one culture-positive MDR-TB patients initiated therapy, 60 (98%) with a prior history of TB treatment. Forty-one (67%) were male and 9 (14%) were HIV infected with a mean CD4 count of 424 (+/-106) cells/microl. The median time from specimen collection to MDR-TB diagnosis and from diagnosis to initiation of MDR-TB treatment was 138 days (IQR 101-159) and 131 days (IQR 32-233), respectively. Following treatment initiation four (7%) patients died (all HIV negative), 3 (5%) defaulted, and the remaining 54 (89%) completed the intensive phase. Most adverse drug reactions were mild to moderate and did not require discontinuation of treatment. Median time to culture conversion was 2 months (IQR 1-3) and did not vary by HIV status. In 28 isolates available for additional second-line drug susceptibility testing, fluoroquinolone, aminoglycoside and para-aminosalicylic acid resistance was rare yet ethionamide resistance was present in 9 (32%). CONCLUSION: The majority of MDR-TB patients from this cohort had survived a prolonged referral process, had multiple episodes of prior TB treatment, but did not have advanced AIDS and converted to culture negative early while completing an intensive inpatient regimen without serious adverse event. Further study is required to determine the clinical impact of second-line drug susceptibility testing and the feasibility of alternatives to prolonged hospitalization."
p42021
sS'GR'
p42022
(lp42023
S'D43 TW008270/TW/FIC NIH HHS/United States'
p42024
aS'K23 AI099019/AI/NIAID NIH HHS/United States'
p42025
aS'K23 AI099019/AI/NIAID NIH HHS/United States'
p42026
aS'R01 AI093358/AI/NIAID NIH HHS/United States'
p42027
aS'R01 AI093358/AI/NIAID NIH HHS/United States'
p42028
asS'IP'
p42029
S'5'
sS'IS'
p42030
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p42031
sS'PMC'
p42032
S'PMC3652861'
p42033
sS'DCOM'
p42034
S'20131209'
p42035
sS'AU'
p42036
(lp42037
S'Mpagama SG'
p42038
aS'Heysell SK'
p42039
aS'Ndusilo ND'
p42040
aS'Kumburu HH'
p42041
aS'Lekule IA'
p42042
aS'Kisonga RM'
p42043
aS'Gratz J'
p42044
aS'Boeree MJ'
p42045
aS'Houpt ER'
p42046
aS'Kibiki GS'
p42047
asS'VI'
p42048
S'8'
sS'MHDA'
p42049
S'2013/12/16 06:00'
p42050
sS'PHST'
p42051
(lp42052
S'2013 [ppublish]'
p42053
aS'2012/10/11 [received]'
p42054
aS'2013/03/15 [accepted]'
p42055
aS'2013/05/13 [epublish]'
p42056
asS'OID'
p42057
(lp42058
S'NLM: PMC3652861'
p42059
asS'MH'
p42060
(lp42061
S'Adult'
p42062
aS'Aminoglycosides/therapeutic use'
p42063
aS'Aminosalicylic Acid/therapeutic use'
p42064
aS'Antitubercular Agents/*therapeutic use'
p42065
aS'Comorbidity'
p42066
aS'Drug Resistance, Multiple, Bacterial'
p42067
aS'Ethionamide/therapeutic use'
p42068
aS'Female'
p42069
aS'Fluoroquinolones/therapeutic use'
p42070
aS'*HIV'
p42071
aS'HIV Infections/diagnosis/*epidemiology/virology'
p42072
aS'Humans'
p42073
aS'Male'
p42074
aS'Middle Aged'
p42075
aS'Mycobacterium tuberculosis/*isolation & purification'
p42076
aS'Retrospective Studies'
p42077
aS'Tanzania/epidemiology'
p42078
aS'Treatment Outcome'
p42079
aS'Tuberculosis, Multidrug-Resistant/diagnosis/drug therapy/*epidemiology/microbiology'
p42080
asS'EDAT'
p42081
S'2013/05/16 06:00'
p42082
sS'SO'
p42083
S'PLoS One. 2013 May 13;8(5):e62034. doi: 10.1371/journal.pone.0062034. Print 2013.'
p42084
sS'SB'
p42085
S'IM'
p42086
sS'PMID'
p42087
S'23675411'
p42088
sS'PST'
p42089
S'epublish'
p42090
stRp42091
ag2
(g3
g4
(dp42092
S'LID'
p42093
S'10.7448/IAS.16.1.18059 [doi]'
p42094
sS'STAT'
p42095
S'MEDLINE'
p42096
sS'DEP'
p42097
S'20130430'
p42098
sS'DA'
p42099
S'20130503'
p42100
sS'AID'
p42101
(lp42102
S'18059 [pii]'
p42103
asS'CRDT'
p42104
(lp42105
S'2013/05/04 06:00'
p42106
asS'DP'
p42107
S'2013'
p42108
sS'OWN'
p42109
S'NLM'
p42110
sS'PT'
p42111
(lp42112
S'Journal Article'
p42113
aS'Multicenter Study'
p42114
aS'Randomized Controlled Trial'
p42115
aS"Research Support, Non-U.S. Gov't"
p42116
asS'LA'
p42117
(lp42118
S'eng'
p42119
asS'DCOM'
p42120
S'20131111'
p42121
sS'JT'
p42122
S'Journal of the International AIDS Society'
p42123
sS'LR'
p42124
S'20151119'
p42125
sS'FAU'
p42126
(lp42127
S'Ouattara, Eric'
p42128
aS'Danel, Christine'
p42129
aS'Moh, Raoul'
p42130
aS'Gabillard, Delphine'
p42131
aS'Peytavin, Gilles'
p42132
aS'Konan, Romuald'
p42133
aS'Carrou, Jerome Le'
p42134
aS'Bohoussou, Franck'
p42135
aS'Eholie, Serge P'
p42136
aS'Anglaret, Xavier'
p42137
asS'TI'
p42138
S'Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts.'
p42139
sS'RN'
p42140
(lp42141
S'0 (Anti-HIV Agents)'
p42142
aS'0 (Organophosphonates)'
p42143
aS'0W860991D6 (Deoxycytidine)'
p42144
aS'4B9XT59T7S (Zidovudine)'
p42145
aS'99YXE507IL (Tenofovir)'
p42146
aS'G70B4ETF4S (Emtricitabine)'
p42147
aS'JAC85A2161 (Adenine)'
p42148
asS'PL'
p42149
S'Switzerland'
p42150
sS'PG'
p42151
S'18059'
p42152
sS'JID'
p42153
S'101478566'
p42154
sS'AB'
p42155
S"INTRODUCTION: Tenofovir (TDF) with emtricitabine (FTC) and zidovudine (ZDV) is a recognized alternate first-line antiretroviral (ART) regimen for patients who cannot start treatment with non-nucleoside reverse transcriptase inhibitors (NNRTIs). Clinical studies comparing TDF+FTC+ZDV to other regimens are lacking. METHODS: Participants in a trial of early ART in Cote d'Ivoire (Temprano ANRS 12136) started treatment with TDF/FTC plus either efavirenz (EFV) or ZDV (HIV-1+2 dually infected patients and women refusing contraception or previously treated with nevirapine). We compared rates of upper digestive serious adverse events (sAEs) between TDF/FTC+EFV and TDF/FTC+ZDV patients during the first six months of treatment. sAEs were defined as either grade 3-4 AEs or persistent grade 1-2 AEs leading to drug discontinuation. RESULTS: A total of 197 patients (76% women, median CD4 count 395/mm(3)) started therapy with TDF/FTC, 126 with EFV and 71 with ZDV. During the first six months of ART, 94 patients had digestive AEs (nausea/vomiting) of any grade (EFV 36/126, 29%; ZDV 58/71, 82%, p<0.0001), including 20 sAEs (EFV 3/126, 5%; ZDV 17/71, 24%, p<0.0001). In-patients on TDF/FTC+ZDV with digestive AEs, the median time to the first symptom was two days (IQR: 1-4). Plasma ZDV (Cmax) distributions and pill ZDV dosages were normal. Patients with digestive AEs had higher haemoglobin levels and tended to have higher body mass indices and more frequent past histories of cotrimoxazole (CTX) prophylaxis. CONCLUSIONS: We observed an unexpectedly high rate of digestive sAEs in West African adults, mostly women, who started a 3-nuc ART with TDF/FTC+ZDV in Cote d'Ivoire. These adults were participating in a trial of early ART and had much higher CD4 counts than those who currently routinely start ART in sub-Saharan Africa. They all received CTX concomitantly with ZDV. We suggest that further early prescriptions of TDF+XTC+ZDV should be carefully monitored and that whenever possible, the rate of early upper digestive adverse events should be compared to that occurring in-patients taking other drug regimens. CLINICAL TRIAL NUMBER: NCT00495651."
p42156
sS'AD'
p42157
S"Programme PACCI, Abidjan, Cote d'Ivoire; Univ. Bordeaux, ISPED, F-33000 Bordeaux, France."
p42158
sS'VI'
p42159
S'16'
p42160
sS'IS'
p42161
S'1758-2652 (Electronic) 1758-2652 (Linking)'
p42162
sS'PMC'
p42163
S'PMC3643089'
p42164
sS'AU'
p42165
(lp42166
S'Ouattara E'
p42167
aS'Danel C'
p42168
aS'Moh R'
p42169
aS'Gabillard D'
p42170
aS'Peytavin G'
p42171
aS'Konan R'
p42172
aS'Carrou JL'
p42173
aS'Bohoussou F'
p42174
aS'Eholie SP'
p42175
aS'Anglaret X'
p42176
asS'MHDA'
p42177
S'2013/11/12 06:00'
p42178
sS'PHST'
p42179
(lp42180
S'2012/09/14 [received]'
p42181
aS'2013/03/19 [revised]'
p42182
aS'2013/03/22 [accepted]'
p42183
asS'OT'
p42184
(lp42185
S'3 nucleoside reverse transcriptase inhibitors'
p42186
aS'HIV infection'
p42187
aS'adults'
p42188
aS'antiretroviral treatment'
p42189
aS'early treatment'
p42190
aS'side effects'
p42191
aS'sub-Saharan Africa'
p42192
aS'tolerance'
p42193
asS'OTO'
p42194
(lp42195
S'NOTNLM'
p42196
asS'OID'
p42197
(lp42198
S'NLM: PMC3643089'
p42199
asS'MH'
p42200
(lp42201
S'Adenine/administration & dosage/adverse effects/*analogs & derivatives'
p42202
aS'Adult'
p42203
aS'Anti-HIV Agents/administration & dosage/*adverse effects'
p42204
aS'CD4 Lymphocyte Count'
p42205
aS"Cote d'Ivoire"
p42206
aS'Deoxycytidine/administration & dosage/adverse effects/*analogs & derivatives'
p42207
aS'Drug Therapy, Combination/adverse effects/methods'
p42208
aS'Drug-Related Side Effects and Adverse Reactions/*epidemiology/pathology'
p42209
aS'Emtricitabine'
p42210
aS'Female'
p42211
aS'Gastrointestinal Diseases/*chemically induced/epidemiology'
p42212
aS'HIV Infections/*complications/drug therapy/immunology'
p42213
aS'Humans'
p42214
aS'Male'
p42215
aS'Middle Aged'
p42216
aS'Organophosphonates/administration & dosage/*adverse effects'
p42217
aS'Tenofovir'
p42218
aS'Zidovudine/administration & dosage/*adverse effects'
p42219
asS'EDAT'
p42220
S'2013/05/04 06:00'
p42221
sS'SI'
p42222
(lp42223
S'ClinicalTrials.gov/NCT00495651'
p42224
asS'SO'
p42225
S'J Int AIDS Soc. 2013 Apr 30;16:18059. doi: 10.7448/IAS.16.1.18059.'
p42226
sS'SB'
p42227
S'IM X'
p42228
sS'PMID'
p42229
S'23639243'
p42230
sS'TA'
p42231
S'J Int AIDS Soc'
p42232
sS'PST'
p42233
S'epublish'
p42234
stRp42235
ag2
(g3
g4
(dp42236
S'LID'
p42237
S'10.1001/jama.2013.3710 [doi]'
p42238
sS'STAT'
p42239
S'MEDLINE'
p42240
sS'JT'
p42241
S'JAMA'
p42242
sS'MID'
p42243
(lp42244
S'NIHMS505218'
p42245
asS'DA'
p42246
S'20130501'
p42247
sS'AID'
p42248
(lp42249
S'1682940 [pii]'
p42250
aS'10.1001/jama.2013.3710 [doi]'
p42251
asS'CRDT'
p42252
(lp42253
S'2013/05/02 06:00'
p42254
asS'DP'
p42255
S'2013 May 1'
p42256
sS'AD'
p42257
S'Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. lowenthale@email.chop.edu'
p42258
sS'OWN'
p42259
S'NLM'
p42260
sS'PT'
p42261
(lp42262
S'Journal Article'
p42263
aS'Research Support, N.I.H., Extramural'
p42264
aS"Research Support, Non-U.S. Gov't"
p42265
aS"Research Support, U.S. Gov't, P.H.S."
p42266
asS'LA'
p42267
(lp42268
S'eng'
p42269
asS'FAU'
p42270
(lp42271
S'Lowenthal, Elizabeth D'
p42272
aS'Ellenberg, Jonas H'
p42273
aS'Machine, Edwin'
p42274
aS'Sagdeo, Aditi'
p42275
aS'Boiditswe, Sefelani'
p42276
aS'Steenhoff, Andrew P'
p42277
aS'Rutstein, Richard'
p42278
aS'Anabwani, Gabriel'
p42279
aS'Gross, Robert'
p42280
asS'LR'
p42281
S'20150517'
p42282
sS'PG'
p42283
S'1803-9'
p42284
sS'TI'
p42285
S'Association between efavirenz-based compared with nevirapine-based antiretroviral regimens and virological failure in HIV-infected children.'
p42286
sS'RN'
p42287
(lp42288
S'0 (Anti-Retroviral Agents)'
p42289
aS'0 (Benzoxazines)'
p42290
aS'0 (RNA, Viral)'
p42291
aS'99DK7FVK1H (Nevirapine)'
p42292
aS'JE6H2O27P8 (efavirenz)'
p42293
asS'PL'
p42294
S'United States'
p42295
sS'TA'
p42296
S'JAMA'
p42297
sS'JID'
p42298
S'7501160'
p42299
sS'AB'
p42300
S'IMPORTANCE: Worldwide, the nonnucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz and nevirapine are commonly used in first-line antiretroviral regimens in both adults and children with human immunodeficiency virus (HIV) infection. Data on the comparative effectiveness of these medications in children are limited. OBJECTIVE: To investigate whether virological failure is more likely among children who initiated 1 or the other NNRTI-based HIV treatment. DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study of children (aged 3-16 years) who initiated efavirenz-based (n = 421) or nevirapine-based (n = 383) treatment between April 2002 and January 2011 at a large pediatric HIV care setting in Botswana. MAIN OUTCOMES AND MEASURES: The primary outcome was time from initiation of therapy to virological failure. Virological failure was defined as lack of plasma HIV RNA suppression to less than 400 copies/mL by 6 months or confirmed HIV RNA of 400 copies/mL or greater after suppression. Cox proportional hazards regression analysis compared time to virological failure by regimen. Multivariable Cox regression controlled for age, sex, baseline immunologic category, baseline clinical category, baseline viral load, nutritional status, NRTIs used, receipt of single-dose nevirapine, and treatment for tuberculosis. RESULTS: With a median follow-up time of 69 months (range, 6-112 months; interquartile range, 23-87 months), 57 children (13.5%; 95% CI, 10.4%-17.2%) initiating treatment with efavirenz and 101 children (26.4%; 95% CI, 22.0%-31.1%) initiating treatment with nevirapine had virological failure. There were 11 children (2.6%; 95% CI, 1.3%-4.6%) receiving efavirenz and 20 children (5.2%; 95% CI, 3.2%-7.9%) receiving nevirapine who never achieved virological suppression. The Cox proportional hazard ratio for the combined virological failure end point was 2.0 (95% CI, 1.4-2.7; log rank P < .001, favoring efavirenz). None of the measured covariates affected the estimated hazard ratio in the multivariable analyses. CONCLUSIONS AND RELEVANCE: Among children aged 3 to 16 years infected with HIV and treated at a clinic in Botswana, the use of efavirenz compared with nevirapine as initial antiretroviral treatment was associated with less virological failure. These findings may warrant additional research evaluating the use of efavirenz and nevirapine for pediatric patients.'
p42301
sS'GR'
p42302
(lp42303
S'K23 MH095669/MH/NIMH NIH HHS/United States'
p42304
aS'K23 MH095669/MH/NIMH NIH HHS/United States'
p42305
aS'P30 AI 045008/AI/NIAID NIH HHS/United States'
p42306
aS'P30 AI045008/AI/NIAID NIH HHS/United States'
p42307
aS'T32 HP10026/PHS HHS/United States'
p42308
asS'IP'
p42309
S'17'
p42310
sS'IS'
p42311
S'1538-3598 (Electronic) 0098-7484 (Linking)'
p42312
sS'PMC'
p42313
S'PMC3748602'
p42314
sS'DCOM'
p42315
S'20130502'
p42316
sS'AU'
p42317
(lp42318
S'Lowenthal ED'
p42319
aS'Ellenberg JH'
p42320
aS'Machine E'
p42321
aS'Sagdeo A'
p42322
aS'Boiditswe S'
p42323
aS'Steenhoff AP'
p42324
aS'Rutstein R'
p42325
aS'Anabwani G'
p42326
aS'Gross R'
p42327
asS'VI'
p42328
S'309'
p42329
sS'MHDA'
p42330
S'2013/05/03 06:00'
p42331
sS'OID'
p42332
(lp42333
S'NLM: NIHMS505218'
p42334
aS'NLM: PMC3748602'
p42335
asS'MH'
p42336
(lp42337
S'Adolescent'
p42338
aS'Anti-Retroviral Agents/*therapeutic use'
p42339
aS'Benzoxazines/*therapeutic use'
p42340
aS'Botswana'
p42341
aS'Child'
p42342
aS'Child, Preschool'
p42343
aS'Cohort Studies'
p42344
aS'Drug Therapy, Combination'
p42345
aS'Female'
p42346
aS'HIV Infections/*drug therapy'
p42347
aS'Humans'
p42348
aS'Male'
p42349
aS'Nevirapine/*therapeutic use'
p42350
aS'RNA, Viral/*blood'
p42351
aS'Regression Analysis'
p42352
aS'Retrospective Studies'
p42353
aS'Treatment Failure'
p42354
aS'Viral Load'
p42355
asS'EDAT'
p42356
S'2013/05/02 06:00'
p42357
sS'SO'
p42358
S'JAMA. 2013 May 1;309(17):1803-9. doi: 10.1001/jama.2013.3710.'
p42359
sS'SB'
p42360
S'AIM IM'
p42361
sS'PMID'
p42362
S'23632724'
p42363
sS'PST'
p42364
S'ppublish'
p42365
stRp42366
ag2
(g3
g4
(dp42367
S'LID'
p42368
S'10.3201/eid1903.120998 [doi]'
p42369
sS'STAT'
p42370
S'MEDLINE'
p42371
sS'JT'
p42372
S'Emerging infectious diseases'
p42373
sS'DA'
p42374
S'20130429'
p42375
sS'AID'
p42376
(lp42377
S'10.3201/eid1903.120998 [doi]'
p42378
asS'CRDT'
p42379
(lp42380
S'2013/04/30 06:00'
p42381
asS'DP'
p42382
S'2013 Mar'
p42383
sS'AD'
p42384
S'Albert Einstein College of Medicine, Bronx, NY 10461, USA. max.odonnell@einstein.yu.edu'
p42385
sS'OWN'
p42386
S'NLM'
p42387
sS'PT'
p42388
(lp42389
S'Journal Article'
p42390
aS'Research Support, N.I.H., Extramural'
p42391
aS"Research Support, Non-U.S. Gov't"
p42392
asS'LA'
p42393
(lp42394
S'eng'
p42395
asS'FAU'
p42396
(lp42397
S"O'Donnell, Max R"
p42398
aS'Padayatchi, Nesri'
p42399
aS'Kvasnovsky, Charlotte'
p42400
aS'Werner, Lise'
p42401
aS'Master, Iqbal'
p42402
aS'Horsburgh, C Robert Jr'
p42403
asS'LR'
p42404
S'20150427'
p42405
sS'PG'
p42406
S'416-24'
p42407
sS'TI'
p42408
S'Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection.'
p42409
sS'RN'
p42410
(lp42411
S'0 (Antitubercular Agents)'
p42412
aS'2KNI5N06TI (Pyrazinamide)'
p42413
aS'8G167061QZ (Ethambutol)'
p42414
aS'95IK5KI84Z (Cycloserine)'
p42415
aS'OAY8ORS3CQ (Ethionamide)'
p42416
asS'PL'
p42417
S'United States'
p42418
sS'TA'
p42419
S'Emerg Infect Dis'
p42420
sS'JID'
p42421
S'9508155'
p42422
sS'AB'
p42423
S'High mortality rates have been reported for patients co-infected with extensively drug-resistant tuberculosis (XDR-TB) and HIV, but treatment outcomes have not been reported. We report treatment outcomes for adult XDR TB patients in KwaZulu-Natal Province, South Africa. Initial data were obtained retrospectively, and outcomes were obtained prospectively during 24 months of treatment. A total of 114 XDR TB patients were treated (median 6 drugs, range 3-9 drugs); 82 (73%) were HIV positive and 50 (61%) were receiving antiretroviral therapy. After receiving treatment for 24 months, 48 (42%) of 114 patients died, 25 (22%) were cured or successfully completed treatment, 19 (17%) withdrew from the study, and 22 (19%) showed treatment failure. A higher number of deaths occurred among HIV-positive patients not receiving antiretroviral therapy and among patients who did not show sputum culture conversion. Culture conversion was a major predictor of survival but was poorly predictive (51%) of successful treatment outcome.'
p42424
sS'GR'
p42425
(lp42426
S'K23 AI098479/AI/NIAID NIH HHS/United States'
p42427
asS'IP'
p42428
S'3'
sS'IS'
p42429
S'1080-6059 (Electronic) 1080-6040 (Linking)'
p42430
sS'PMC'
p42431
S'PMC3647656'
p42432
sS'DCOM'
p42433
S'20131021'
p42434
sS'AU'
p42435
(lp42436
S"O'Donnell MR"
p42437
aS'Padayatchi N'
p42438
aS'Kvasnovsky C'
p42439
aS'Werner L'
p42440
aS'Master I'
p42441
aS'Horsburgh CR Jr'
p42442
asS'VI'
p42443
S'19'
p42444
sS'MHDA'
p42445
S'2013/10/22 06:00'
p42446
sS'OTO'
p42447
(lp42448
S'NOTNLM'
p42449
asS'OID'
p42450
(lp42451
S'NLM: PMC3647656'
p42452
asS'MH'
p42453
(lp42454
S'Adolescent'
p42455
aS'Adult'
p42456
aS'Antitubercular Agents/*therapeutic use'
p42457
aS'Coinfection/*drug therapy/mortality'
p42458
aS'Cycloserine/therapeutic use'
p42459
aS'Drug Therapy, Combination'
p42460
aS'Ethambutol/therapeutic use'
p42461
aS'Ethionamide/therapeutic use'
p42462
aS'Extensively Drug-Resistant Tuberculosis/*drug therapy/mortality'
p42463
aS'Female'
p42464
aS'HIV Infections/*drug therapy/mortality'
p42465
aS'Humans'
p42466
aS'Kaplan-Meier Estimate'
p42467
aS'Male'
p42468
aS'Middle Aged'
p42469
aS'Pyrazinamide/therapeutic use'
p42470
aS'Retrospective Studies'
p42471
aS'Treatment Outcome'
p42472
aS'Tuberculosis, Pulmonary/*drug therapy/mortality'
p42473
aS'Young Adult'
p42474
asS'EDAT'
p42475
S'2013/04/30 06:00'
p42476
sS'SO'
p42477
S'Emerg Infect Dis. 2013 Mar;19(3):416-24. doi: 10.3201/eid1903.120998.'
p42478
sS'SB'
p42479
S'IM'
p42480
sS'PMID'
p42481
S'23622055'
p42482
sS'OT'
p42483
(lp42484
S'HIV'
p42485
aS'South Africa'
p42486
aS'XDR TB'
p42487
aS'bacteria'
p42488
aS'co-infection'
p42489
aS'extensively drug-resistant tuberculosis'
p42490
aS'treatment outcomes'
p42491
aS'tuberculosis and other mycobacteria'
p42492
aS'viruses'
p42493
asS'PST'
p42494
S'ppublish'
p42495
stRp42496
ag2
(g3
g4
(dp42497
S'LID'
p42498
S'10.1089/AID.2012.0284 [doi]'
p42499
sS'STAT'
p42500
S'MEDLINE'
p42501
sS'DEP'
p42502
S'20130521'
p42503
sS'DA'
p42504
S'20130719'
p42505
sS'AID'
p42506
(lp42507
S'10.1089/aid.2012.0284 [doi]'
p42508
asS'CRDT'
p42509
(lp42510
S'2013/04/27 06:00'
p42511
asS'DP'
p42512
S'2013 Aug'
p42513
sS'OWN'
p42514
S'NLM'
p42515
sS'PT'
p42516
(lp42517
S'Journal Article'
p42518
aS"Research Support, Non-U.S. Gov't"
p42519
asS'LA'
p42520
(lp42521
S'eng'
p42522
asS'FAU'
p42523
(lp42524
S'Nyamache, Anthony Kebira'
p42525
aS'Muigai, Anne W T'
p42526
aS"Ng'ang'a, Zipporah"
p42527
aS'Khamadi, Samoel A'
p42528
asS'JT'
p42529
S'AIDS research and human retroviruses'
p42530
sS'LR'
p42531
S'20150427'
p42532
sS'PG'
p42533
S'1105-9'
p42534
sS'TI'
p42535
S'Profile of HIV type 1 coreceptor tropism among Kenyan patients from 2009 to 2010.'
p42536
sS'RN'
p42537
(lp42538
S'0 (CCR5 Receptor Antagonists)'
p42539
aS'0 (Cyclohexanes)'
p42540
aS'0 (HIV Envelope Protein gp120)'
p42541
aS'0 (Receptors, CCR5)'
p42542
aS'0 (Receptors, CXCR4)'
p42543
aS'0 (Triazoles)'
p42544
aS'MD6P741W8A (maraviroc)'
p42545
asS'PL'
p42546
S'United States'
p42547
sS'TA'
p42548
S'AIDS Res Hum Retroviruses'
p42549
sS'JID'
p42550
S'8709376'
p42551
sS'AB'
p42552
S'A switch of HIV coreceptor usage from CCR5 to CXCR4 occurs in AIDS pathogenesis and may play a critical role in the use of entry inhibitors. To determine the potential usefulness of maraviroc and other CCR5 antagonists among drug-naive and experienced patients in Kenya, the env-C2-V3 gene was successfully sequenced in samples from 176 (98 men and 78 female) consenting subjects between January 2009 and December 2012. In silico CPSSM, webPSSM/, and (ds) Kernel tools were used in predicting coreceptor usage. On the basis of the env V3 loop sequences, 84.1% (148) were reported with R-5 tropism, 4.5% (5) were dual tropic, while 13.4% (23) were of X4 tropism. However, similar to previous studies conducted in Kenya on genetic diversity, HIV-1 subtype A1 (73.9%; 130/176) still remains the most dominant subtype. The high levels of R5 tropism among the studied Kenyan infected populations suggested the potential use of CCR5 antagonists as new therapeutic options in Kenya.'
p42553
sS'AD'
p42554
S'Department of Plant and Microbial Sciences, Kenyatta University, Nairobi, Kenya.'
p42555
sS'IP'
p42556
S'8'
sS'IS'
p42557
S'1931-8405 (Electronic) 0889-2229 (Linking)'
p42558
sS'PMC'
p42559
S'PMC3715788'
p42560
sS'DCOM'
p42561
S'20131112'
p42562
sS'AU'
p42563
(lp42564
S'Nyamache AK'
p42565
aS'Muigai AW'
p42566
aS"Ng'ang'a Z"
p42567
aS'Khamadi SA'
p42568
asS'VI'
p42569
S'29'
p42570
sS'MHDA'
p42571
S'2013/11/13 06:00'
p42572
sS'PHST'
p42573
(lp42574
S'2013/05/21 [aheadofprint]'
p42575
asS'OID'
p42576
(lp42577
S'NLM: PMC3715788'
p42578
asS'MH'
p42579
(lp42580
S'Adolescent'
p42581
aS'Adult'
p42582
aS'Aged'
p42583
aS'CCR5 Receptor Antagonists'
p42584
aS'Child'
p42585
aS'Child, Preschool'
p42586
aS'Cyclohexanes/*therapeutic use'
p42587
aS'Female'
p42588
aS'HIV Envelope Protein gp120/*genetics'
p42589
aS'HIV Infections/*genetics/virology'
p42590
aS'HIV-1/*physiology'
p42591
aS'Humans'
p42592
aS'Kenya'
p42593
aS'Male'
p42594
aS'Middle Aged'
p42595
aS'Molecular Sequence Data'
p42596
aS'Receptors, CCR5/*genetics'
p42597
aS'Receptors, CXCR4/*genetics'
p42598
aS'Sequence Analysis, DNA'
p42599
aS'Triazoles/*therapeutic use'
p42600
aS'*Viral Tropism'
p42601
aS'Young Adult'
p42602
asS'EDAT'
p42603
S'2013/04/27 06:00'
p42604
sS'SI'
p42605
(lp42606
S'GENBANK/JN381630'
p42607
aS'GENBANK/JN381631'
p42608
aS'GENBANK/JN381632'
p42609
aS'GENBANK/JN381633'
p42610
aS'GENBANK/JN381634'
p42611
aS'GENBANK/JN381635'
p42612
aS'GENBANK/JN381636'
p42613
aS'GENBANK/JN381637'
p42614
aS'GENBANK/JN381638'
p42615
aS'GENBANK/JN381639'
p42616
aS'GENBANK/JN381640'
p42617
aS'GENBANK/JN381641'
p42618
aS'GENBANK/JN381642'
p42619
aS'GENBANK/JN381643'
p42620
aS'GENBANK/JN381644'
p42621
aS'GENBANK/JN381645'
p42622
aS'GENBANK/JN381646'
p42623
aS'GENBANK/JN381647'
p42624
aS'GENBANK/JN381648'
p42625
aS'GENBANK/JN381649'
p42626
aS'GENBANK/JN381650'
p42627
aS'GENBANK/JN381651'
p42628
aS'GENBANK/JN381652'
p42629
aS'GENBANK/JN381653'
p42630
aS'GENBANK/JN381654'
p42631
aS'GENBANK/JN381655'
p42632
aS'GENBANK/JN381656'
p42633
aS'GENBANK/JN381657'
p42634
aS'GENBANK/JN381658'
p42635
aS'GENBANK/JN381659'
p42636
aS'GENBANK/JN381660'
p42637
aS'GENBANK/JN381661'
p42638
aS'GENBANK/JN381662'
p42639
aS'GENBANK/JN381663'
p42640
aS'GENBANK/JN381664'
p42641
aS'GENBANK/JN381665'
p42642
aS'GENBANK/JN381666'
p42643
aS'GENBANK/JN381667'
p42644
aS'GENBANK/JN381668'
p42645
aS'GENBANK/JN381669'
p42646
aS'GENBANK/JN381670'
p42647
aS'GENBANK/JN381671'
p42648
aS'GENBANK/JN381672'
p42649
aS'GENBANK/JN381673'
p42650
aS'GENBANK/JN381674'
p42651
aS'GENBANK/JN381675'
p42652
aS'GENBANK/JN381676'
p42653
aS'GENBANK/JN381677'
p42654
aS'GENBANK/JN381678'
p42655
aS'GENBANK/JN381679'
p42656
aS'GENBANK/JN381680'
p42657
aS'GENBANK/JN381681'
p42658
aS'GENBANK/JN381682'
p42659
aS'GENBANK/JN381683'
p42660
aS'GENBANK/JN381684'
p42661
aS'GENBANK/JN381685'
p42662
aS'GENBANK/JN381686'
p42663
aS'GENBANK/JN381687'
p42664
aS'GENBANK/JN381688'
p42665
aS'GENBANK/JN381689'
p42666
aS'GENBANK/JN381690'
p42667
aS'GENBANK/JN381691'
p42668
aS'GENBANK/JN381692'
p42669
aS'GENBANK/JN381693'
p42670
aS'GENBANK/JN381694'
p42671
aS'GENBANK/JN381695'
p42672
aS'GENBANK/JN381696'
p42673
aS'GENBANK/JN381697'
p42674
aS'GENBANK/JN381698'
p42675
aS'GENBANK/JN381699'
p42676
aS'GENBANK/JN381700'
p42677
aS'GENBANK/JN381701'
p42678
aS'GENBANK/JN381702'
p42679
aS'GENBANK/JN381703'
p42680
aS'GENBANK/JN381704'
p42681
aS'GENBANK/JN381705'
p42682
aS'GENBANK/JN381706'
p42683
aS'GENBANK/JN381707'
p42684
aS'GENBANK/JN381708'
p42685
aS'GENBANK/JN381709'
p42686
aS'GENBANK/JN381710'
p42687
aS'GENBANK/JN381711'
p42688
aS'GENBANK/JN381712'
p42689
aS'GENBANK/JN381713'
p42690
aS'GENBANK/JN381714'
p42691
aS'GENBANK/JN381715'
p42692
aS'GENBANK/JN381716'
p42693
aS'GENBANK/JN381717'
p42694
aS'GENBANK/JN381718'
p42695
aS'GENBANK/JN381719'
p42696
aS'GENBANK/JN381720'
p42697
aS'GENBANK/JN381721'
p42698
aS'GENBANK/JN381722'
p42699
aS'GENBANK/JN381723'
p42700
aS'GENBANK/JN381724'
p42701
aS'GENBANK/JN381725'
p42702
aS'GENBANK/JN381726'
p42703
aS'GENBANK/JN381727'
p42704
aS'GENBANK/JN381728'
p42705
aS'GENBANK/JN381729'
p42706
aS'GENBANK/JN381730'
p42707
aS'GENBANK/JN381731'
p42708
aS'GENBANK/JN381732'
p42709
aS'GENBANK/JN381733'
p42710
aS'GENBANK/JN381734'
p42711
aS'GENBANK/JN381735'
p42712
aS'GENBANK/JN381736'
p42713
aS'GENBANK/JN381737'
p42714
aS'GENBANK/JN381738'
p42715
aS'GENBANK/JN381739'
p42716
aS'GENBANK/JN381740'
p42717
aS'GENBANK/JN381741'
p42718
aS'GENBANK/JN381742'
p42719
aS'GENBANK/JN381743'
p42720
aS'GENBANK/JN381744'
p42721
aS'GENBANK/JN381745'
p42722
aS'GENBANK/JN381746'
p42723
aS'GENBANK/JN381747'
p42724
aS'GENBANK/JN381748'
p42725
aS'GENBANK/JN381749'
p42726
aS'GENBANK/JN381750'
p42727
aS'GENBANK/JN381751'
p42728
aS'GENBANK/JN381752'
p42729
aS'GENBANK/JN381753'
p42730
aS'GENBANK/JN381754'
p42731
aS'GENBANK/JN381755'
p42732
aS'GENBANK/JN381756'
p42733
aS'GENBANK/JN381757'
p42734
aS'GENBANK/JN381758'
p42735
aS'GENBANK/JN381759'
p42736
aS'GENBANK/JN381760'
p42737
aS'GENBANK/JN381761'
p42738
aS'GENBANK/JN381762'
p42739
aS'GENBANK/JN381763'
p42740
aS'GENBANK/JN381764'
p42741
aS'GENBANK/JN381765'
p42742
aS'GENBANK/JN381766'
p42743
aS'GENBANK/JN381767'
p42744
aS'GENBANK/JN381768'
p42745
aS'GENBANK/JN381769'
p42746
aS'GENBANK/JN381770'
p42747
aS'GENBANK/JN381771'
p42748
aS'GENBANK/JN381772'
p42749
aS'GENBANK/JN381773'
p42750
aS'GENBANK/JN381774'
p42751
aS'GENBANK/JN381775'
p42752
aS'GENBANK/JN381776'
p42753
aS'GENBANK/JN381777'
p42754
aS'GENBANK/JN381778'
p42755
aS'GENBANK/JN381779'
p42756
aS'GENBANK/JN381780'
p42757
aS'GENBANK/JN381781'
p42758
aS'GENBANK/JN381782'
p42759
aS'GENBANK/JN381783'
p42760
aS'GENBANK/JN381784'
p42761
aS'GENBANK/JN381785'
p42762
aS'GENBANK/JN381786'
p42763
aS'GENBANK/JN381787'
p42764
aS'GENBANK/JN381788'
p42765
aS'GENBANK/JN381789'
p42766
aS'GENBANK/JN381790'
p42767
aS'GENBANK/JN381791'
p42768
aS'GENBANK/JN381792'
p42769
aS'GENBANK/JN381793'
p42770
aS'GENBANK/JN381794'
p42771
aS'GENBANK/JN381795'
p42772
aS'GENBANK/JN381796'
p42773
aS'GENBANK/JN381797'
p42774
aS'GENBANK/JN381798'
p42775
aS'GENBANK/JN381799'
p42776
aS'GENBANK/JN381800'
p42777
aS'GENBANK/JN381801'
p42778
aS'GENBANK/JN381802'
p42779
aS'GENBANK/JN381803'
p42780
aS'GENBANK/JN381804'
p42781
aS'GENBANK/JN381805'
p42782
aS'GENBANK/JN381806'
p42783
aS'GENBANK/JN381807'
p42784
aS'GENBANK/JN381808'
p42785
aS'GENBANK/JN381809'
p42786
aS'GENBANK/JN381810'
p42787
asS'SO'
p42788
S'AIDS Res Hum Retroviruses. 2013 Aug;29(8):1105-9. doi: 10.1089/AID.2012.0284. Epub 2013 May 21.'
p42789
sS'SB'
p42790
S'IM X'
p42791
sS'PMID'
p42792
S'23617327'
p42793
sS'PST'
p42794
S'ppublish'
p42795
stRp42796
ag2
(g3
g4
(dp42797
S'LID'
p42798
S'10.1128/JCM.03305-12 [doi]'
p42799
sS'STAT'
p42800
S'MEDLINE'
p42801
sS'DEP'
p42802
S'20130417'
p42803
sS'DA'
p42804
S'20130517'
p42805
sS'AID'
p42806
(lp42807
S'JCM.03305-12 [pii]'
p42808
aS'10.1128/JCM.03305-12 [doi]'
p42809
asS'CRDT'
p42810
(lp42811
S'2013/04/19 06:00'
p42812
asS'DP'
p42813
S'2013 Jun'
p42814
sS'AD'
p42815
S'University Medical Centre Utrecht, Utrecht, the Netherlands. s.c.aitken@umcutrecht.nl'
p42816
sS'OWN'
p42817
S'NLM'
p42818
sS'PT'
p42819
(lp42820
S'Evaluation Studies'
p42821
aS'Journal Article'
p42822
aS"Research Support, Non-U.S. Gov't"
p42823
asS'LA'
p42824
(lp42825
S'eng'
p42826
asS'FAU'
p42827
(lp42828
S'Aitken, Susan C'
p42829
aS'Kliphuis, Aletta'
p42830
aS'Bronze, Michelle'
p42831
aS'Wallis, Carole L'
p42832
aS'Kityo, Cissy'
p42833
aS'Balinda, Sheila'
p42834
aS'Stevens, Wendy'
p42835
aS'Spieker, Nicole'
p42836
aS'de Oliveira, Tulio'
p42837
aS'Rinke de Wit, Tobias F'
p42838
aS'Schuurman, Rob'
p42839
asS'JT'
p42840
S'Journal of clinical microbiology'
p42841
sS'LR'
p42842
S'20150427'
p42843
sS'PG'
p42844
S'1899-905'
p42845
sS'TI'
p42846
S'Development and evaluation of an affordable real-time qualitative assay for determining HIV-1 virological failure in plasma and dried blood spots.'
p42847
sS'PL'
p42848
S'United States'
p42849
sS'TA'
p42850
S'J Clin Microbiol'
p42851
sS'JID'
p42852
S'7505564'
p42853
sS'AB'
p42854
S'Virological failure (VF) has been identified as the earliest, most predictive determinant of HIV-1 antiretroviral treatment (ART) failure. Due to the high cost and complexity of virological monitoring, VF assays are rarely performed in resource-limited settings (RLS). Rather, ART failure is determined by clinical monitoring and to a large extent immunological monitoring. This paper describes the development and evaluation of a low-cost, dried blood spot (DBS)-compatible qualitative assay to determine VF, in accordance with current WHO guideline recommendations for therapy switching in RLS. The assay described here is an internally controlled qualitative real-time PCR targeting the conserved long terminal repeat domain of HIV-1. This assay was applied to HIV-1 subtypes A to H and further evaluated on HIV-1 clinical plasma samples from South Africa (n = 191) and Tanzania (n = 42). Field evaluation was performed in Uganda using local clinical plasma samples (n = 176). Furthermore, assay performance was evaluated for DBS. This assay is able to identify VF for all major HIV-1 group M subtypes with equal specificity and has a lower detection limit of 1.00E+03 copies/ml for plasma samples and 5.00E+03 copies/ml for DBS. Comparative testing yielded accurate VF determination for therapy switching in 89% to 96% of samples compared to gold standards. The assay is robust and flexible, allowing for "open platform" applications and producing results comparable to those of commercial assays. Assay design enables application in laboratories that can accommodate real-time PCR equipment, allowing decentralization of testing to some extent. Compatibility with DBS extends access of sampling and thus access to this test to remote settings.'
p42855
sS'GR'
p42856
(lp42857
S'097410/Wellcome Trust/United Kingdom'
p42858
asS'IP'
p42859
S'6'
sS'IS'
p42860
S'1098-660X (Electronic) 0095-1137 (Linking)'
p42861
sS'PMC'
p42862
S'PMC3716048'
p42863
sS'DCOM'
p42864
S'20131118'
p42865
sS'AU'
p42866
(lp42867
S'Aitken SC'
p42868
aS'Kliphuis A'
p42869
aS'Bronze M'
p42870
aS'Wallis CL'
p42871
aS'Kityo C'
p42872
aS'Balinda S'
p42873
aS'Stevens W'
p42874
aS'Spieker N'
p42875
aS'de Oliveira T'
p42876
aS'Rinke de Wit TF'
p42877
aS'Schuurman R'
p42878
asS'VI'
p42879
S'51'
p42880
sS'MHDA'
p42881
S'2013/11/19 06:00'
p42882
sS'PHST'
p42883
(lp42884
S'2013/04/17 [aheadofprint]'
p42885
asS'OID'
p42886
(lp42887
S'NLM: PMC3716048'
p42888
asS'MH'
p42889
(lp42890
S'Blood/*virology'
p42891
aS'*Desiccation'
p42892
aS'Drug Monitoring/methods'
p42893
aS'HIV Infections/drug therapy/*virology'
p42894
aS'HIV-1/*isolation & purification'
p42895
aS'Humans'
p42896
aS'Real-Time Polymerase Chain Reaction/*methods'
p42897
aS'Sensitivity and Specificity'
p42898
aS'South Africa'
p42899
aS'Specimen Handling/*methods'
p42900
aS'Tanzania'
p42901
aS'Uganda'
p42902
aS'Viral Load/*methods'
p42903
asS'EDAT'
p42904
S'2013/04/19 06:00'
p42905
sS'SO'
p42906
S'J Clin Microbiol. 2013 Jun;51(6):1899-905. doi: 10.1128/JCM.03305-12. Epub 2013 Apr 17.'
p42907
sS'SB'
p42908
S'IM'
p42909
sS'PMID'
p42910
S'23596235'
p42911
sS'PST'
p42912
S'ppublish'
p42913
stRp42914
ag2
(g3
g4
(dp42915
S'LID'
p42916
S'10.1097/INF.0b013e318294c922 [doi]'
p42917
sS'STAT'
p42918
S'MEDLINE'
p42919
sS'JT'
p42920
S'The Pediatric infectious disease journal'
p42921
sS'DA'
p42922
S'20130926'
p42923
sS'AID'
p42924
(lp42925
S'10.1097/INF.0b013e318294c922 [doi]'
p42926
asS'CRDT'
p42927
(lp42928
S'2013/04/17 06:00'
p42929
asS'DP'
p42930
S'2013 Oct'
p42931
sS'AD'
p42932
S"From the Botswana-Baylor Children's Clinical Centre of Excellence, Gaborone, Botswana, and Baylor College of Medicine, Houston, TX."
p42933
sS'OWN'
p42934
S'NLM'
p42935
sS'PT'
p42936
(lp42937
S'Journal Article'
p42938
asS'LA'
p42939
(lp42940
S'eng'
p42941
asS'FAU'
p42942
(lp42943
S'Gomila, Andres'
p42944
aS'Kirk, Brianna'
p42945
aS'Marape, Marape'
p42946
aS'Anabwani, Gabriel'
p42947
aS'Tolle, Michael'
p42948
asS'LR'
p42949
S'20150721'
p42950
sS'PG'
p42951
S'1086-8'
p42952
sS'TI'
p42953
S'Protease genotypes in patients failing protease inhibitor-based antiretroviral therapy at a pediatric center in Botswana.'
p42954
sS'RN'
p42955
(lp42956
S'0 (Protease Inhibitors)'
p42957
aS'EC 3.4.23.- (HIV Protease)'
p42958
asS'PL'
p42959
S'United States'
p42960
sS'TA'
p42961
S'Pediatr Infect Dis J'
p42962
sS'JID'
p42963
S'8701858'
p42964
sS'AB'
p42965
S'With increasing use of protease inhibitors (PI) in Botswana, a large proportion of HIV-infected children are now exposed to PI-based regimens. There is limited protease genotype data from African children and adolescents who have failed PI-based antiretroviral therapy. We describe a cohort of pediatric HIV-infected patients experiencing virologic failure at time of second-line or salvage PI-based regimens and analyze associated PI mutations.'
p42966
sS'GR'
p42967
(lp42968
S'P30 AI036211/AI/NIAID NIH HHS/United States'
p42969
asS'IP'
p42970
S'10'
p42971
sS'IS'
p42972
S'1532-0987 (Electronic) 0891-3668 (Linking)'
p42973
sS'DCOM'
p42974
S'20140617'
p42975
sS'AU'
p42976
(lp42977
S'Gomila A'
p42978
aS'Kirk B'
p42979
aS'Marape M'
p42980
aS'Anabwani G'
p42981
aS'Tolle M'
p42982
asS'VI'
p42983
S'32'
p42984
sS'MHDA'
p42985
S'2014/06/18 06:00'
p42986
sS'MH'
p42987
(lp42988
S'Adolescent'
p42989
aS'Botswana'
p42990
aS'Child'
p42991
aS'Child, Preschool'
p42992
aS'Genotype'
p42993
aS'HIV Infections/*drug therapy/virology'
p42994
aS'HIV Protease/*genetics'
p42995
aS'HIV-1/*enzymology/*genetics'
p42996
aS'Humans'
p42997
aS'Mutation'
p42998
aS'Protease Inhibitors/*therapeutic use'
p42999
aS'Retrospective Studies'
p43000
aS'Treatment Failure'
p43001
asS'EDAT'
p43002
S'2013/04/17 06:00'
p43003
sS'SO'
p43004
S'Pediatr Infect Dis J. 2013 Oct;32(10):1086-8. doi: 10.1097/INF.0b013e318294c922.'
p43005
sS'SB'
p43006
S'IM'
p43007
sS'PMID'
p43008
S'23587981'
p43009
sS'PST'
p43010
S'ppublish'
p43011
stRp43012
ag2
(g3
g4
(dp43013
S'LID'
p43014
S'10.1371/journal.pone.0059787 [doi]'
p43015
sS'STAT'
p43016
S'MEDLINE'
p43017
sS'DEP'
p43018
S'20130409'
p43019
sS'DA'
p43020
S'20130415'
p43021
sS'AID'
p43022
(lp43023
S'10.1371/journal.pone.0059787 [doi]'
p43024
aS'PONE-D-12-31887 [pii]'
p43025
asS'CRDT'
p43026
(lp43027
S'2013/04/16 06:00'
p43028
asS'DP'
p43029
S'2013'
p43030
sS'EIN'
p43031
(lp43032
S'PLoS One. 2014;9(1). doi:10.1371/annotation/8096d24f-06de-4e42-8834-b5d3e116253c.'
p43033
aS'IPTc Taskforce [corrected to MTN-009 Protocol Team]'
p43034
asS'OWN'
p43035
S'NLM'
p43036
sS'PT'
p43037
(lp43038
S'Journal Article'
p43039
aS'Multicenter Study'
p43040
aS'Research Support, N.I.H., Extramural'
p43041
asS'LA'
p43042
(lp43043
S'eng'
p43044
asS'FAU'
p43045
(lp43046
S'Parikh, Urvi M'
p43047
aS'Kiepiela, Photini'
p43048
aS'Ganesh, Shayhana'
p43049
aS'Gomez, Kailazarid'
p43050
aS'Horn, Stephanie'
p43051
aS'Eskay, Krista'
p43052
aS'Kelly, Cliff'
p43053
aS'Mensch, Barbara'
p43054
aS'Gorbach, Pamina'
p43055
aS'Soto-Torres, Lydia'
p43056
aS'Ramjee, Gita'
p43057
aS'Mellors, John W'
p43058
asS'JT'
p43059
S'PloS one'
p43060
sS'LR'
p43061
S'20150427'
p43062
sS'PG'
p43063
S'e59787'
p43064
sS'TI'
p43065
S'Prevalence of HIV-1 drug resistance among women screening for HIV prevention trials in KwaZulu-Natal, South Africa (MTN-009).'
p43066
sS'RN'
p43067
(lp43068
S'0 (Anti-HIV Agents)'
p43069
aS'0 (RNA, Viral)'
p43070
aS'EC 2.7.7.49 (HIV Reverse Transcriptase)'
p43071
aS'EC 3.4.23.- (HIV Protease)'
p43072
asS'PL'
p43073
S'United States'
p43074
sS'TA'
p43075
S'PLoS One'
p43076
sS'JID'
p43077
S'101285081'
p43078
sS'AB'
p43079
S'BACKGROUND: A major concern with using antiretroviral (ARV)-based products for HIV prevention is the potential spread of drug resistance, particularly from individuals who are HIV-infected but unaware of their status. Limited data exist on the prevalence of HIV infection or drug resistance among potential users of ARV-based prevention products. METHODS: A cross-sectional study of reproductive-aged women who presented to screen for an HIV prevention trial was conducted at 7 clinical sites in Durban, South Africa. CD4+T cell counts, HIV-1 RNA levels and population sequencing of the protease and reverse transcriptase genes were performed for all women with 2 positive HIV rapid tests. Resistance mutations were identified using the Stanford Calibrated Population Resistance Tool. RESULTS: Of the 1073 evaluable women, 400(37%) were confirmed as HIV-infected. Of those, plasma HIV-1 RNA was detectable in 365/400(91%) and undetectable(<40 copies/ml) in 35/400(9%) women. 156 women(39%) were eligible for antiretroviral therapy (CD4+T cell counts<350 cells/mm(3)) and 50(13%) met criteria for AIDS(CD4<200 cells/mm(3)). Of 352 plasma samples(>200 copies/ml) analyzed for drug resistance, 26(7.4%) had nucleoside reverse transcriptase inhibitor (NRTI), non-nucleoside reverse transcriptase inhibitor (NNRTI) or protease inhibitor (PI) drug resistance mutations. Among those with resistance, 18/26 participants(62%) had single-class NNRTI resistance and 5/26(19%) had dual-class NRTI/NNRTI. Major mutations in reverse transcriptase included K65R(n = 1), L74I(n = 1), K103N(n = 19), V106M(n = 4), Y181C(n = 2), M184V(n = 4), and K219E/R(n = 2). Major PI-resistance mutations were rare: M46L(n = 1) and I85V(n = 1). All participants were infected with subtype C virus, except one infected with subtype A. CONCLUSIONS: In women from Durban, South Africa screening for an HIV prevention trial, the HIV prevalence was high (37%) and HIV drug resistance prevalence was above 5%. This study highlights the potential challenges faced when implementing an ARV-based prevention product that overlaps with first-line antiretroviral therapy. Effective screening to exclude HIV infection among women interested in uptake of ARV-based HIV prevention will be essential in limiting the spread of ARV resistance.'
p43080
sS'AD'
p43081
S'Department of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America. ump3@pitt.edu'
p43082
sS'CN'
p43083
(lp43084
S'MTN-009 Protocol Team'
p43085
aS'IPTc Taskforce'
p43086
asS'IP'
p43087
S'4'
sS'IS'
p43088
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p43089
sS'PMC'
p43090
S'PMC3621859'
p43091
sS'DCOM'
p43092
S'20131022'
p43093
sS'AU'
p43094
(lp43095
S'Parikh UM'
p43096
aS'Kiepiela P'
p43097
aS'Ganesh S'
p43098
aS'Gomez K'
p43099
aS'Horn S'
p43100
aS'Eskay K'
p43101
aS'Kelly C'
p43102
aS'Mensch B'
p43103
aS'Gorbach P'
p43104
aS'Soto-Torres L'
p43105
aS'Ramjee G'
p43106
aS'Mellors JW'
p43107
asS'VI'
p43108
S'8'
sS'MHDA'
p43109
S'2013/10/23 06:00'
p43110
sS'PHST'
p43111
(lp43112
S'2013 [ppublish]'
p43113
aS'2012/10/11 [received]'
p43114
aS'2013/02/18 [accepted]'
p43115
aS'2013/04/09 [epublish]'
p43116
asS'OID'
p43117
(lp43118
S'NLM: PMC3621859'
p43119
asS'MH'
p43120
(lp43121
S'Adult'
p43122
aS'Anti-HIV Agents/*therapeutic use'
p43123
aS'CD4 Lymphocyte Count'
p43124
aS'Cross-Sectional Studies'
p43125
aS'Drug Resistance, Viral/*genetics'
p43126
aS'Female'
p43127
aS'HIV Infections/diagnosis/*epidemiology/prevention & control/virology'
p43128
aS'HIV Protease/genetics'
p43129
aS'HIV Reverse Transcriptase/genetics'
p43130
aS'HIV Seropositivity/diagnosis/*epidemiology/virology'
p43131
aS'HIV-1/*genetics/isolation & purification'
p43132
aS'Humans'
p43133
aS'Mass Screening'
p43134
aS'Mutation'
p43135
aS'Prevalence'
p43136
aS'RNA, Viral/*genetics/isolation & purification'
p43137
aS'South Africa/epidemiology'
p43138
aS'Viral Load'
p43139
asS'EDAT'
p43140
S'2013/04/16 06:00'
p43141
sS'GR'
p43142
(lp43143
S'5UM1AI068633/AI/NIAID NIH HHS/United States'
p43144
aS'U01 AI068633/AI/NIAID NIH HHS/United States'
p43145
asS'SO'
p43146
S'PLoS One. 2013 Apr 9;8(4):e59787. doi: 10.1371/journal.pone.0059787. Print 2013.'
p43147
sS'SB'
p43148
S'IM'
p43149
sS'PMID'
p43150
S'23585827'
p43151
sS'PST'
p43152
S'epublish'
p43153
stRp43154
ag2
(g3
g4
(dp43155
S'LID'
p43156
S'10.1371/journal.pone.0058817 [doi]'
p43157
sS'STAT'
p43158
S'MEDLINE'
p43159
sS'DEP'
p43160
S'20130403'
p43161
sS'DA'
p43162
S'20130410'
p43163
sS'AID'
p43164
(lp43165
S'10.1371/journal.pone.0058817 [doi]'
p43166
aS'PONE-D-12-33124 [pii]'
p43167
asS'CRDT'
p43168
(lp43169
S'2013/04/11 06:00'
p43170
asS'DP'
p43171
S'2013'
p43172
sS'OWN'
p43173
S'NLM'
p43174
sS'PT'
p43175
(lp43176
S'Journal Article'
p43177
aS"Research Support, Non-U.S. Gov't"
p43178
asS'LA'
p43179
(lp43180
S'eng'
p43181
asS'FAU'
p43182
(lp43183
S'Van der Walt, Martha'
p43184
aS'Lancaster, Johanna'
p43185
aS'Odendaal, Ronel'
p43186
aS'Davis, Jeanne Garcia'
p43187
aS'Shean, Karen'
p43188
aS'Farley, Jason'
p43189
asS'JT'
p43190
S'PloS one'
p43191
sS'LR'
p43192
S'20150427'
p43193
sS'PG'
p43194
S'e58817'
p43195
sS'TI'
p43196
S'Serious treatment related adverse drug reactions amongst anti-retroviral naive MDR-TB patients.'
p43197
sS'RN'
p43198
(lp43199
S'0 (Antitubercular Agents)'
p43200
aS'0 (Isoxazoles)'
p43201
aS'0 (Oxazolidinones)'
p43202
aS'1199LEX5N8 (terizidone)'
p43203
aS'95IK5KI84Z (Cycloserine)'
p43204
aS'A4P49JAZ9H (Ofloxacin)'
p43205
asS'PL'
p43206
S'United States'
p43207
sS'TA'
p43208
S'PLoS One'
p43209
sS'JID'
p43210
S'101285081'
p43211
sS'AB'
p43212
S'BACKGROUND: Globally treatment outcomes for multidrug-resistant Mycobacterium tuberculosis (MDR-TB) remain poor and this is compounded by high drug toxicity. Little is known about the influence of adverse drug reactions (ADRs) on treatment outcomes in South Africa. METHODS: We evaluated the impact of severe ADRs among a prospective cohort of MDR-TB patients in South Africa (2000-2004). The HIV-infected study participants were anti-retroviral naive. RESULTS: Of 2,079 patients enrolled, 1,390 (66.8%) were included in this analysis based on known HIV test results (39.1% HIV-infected). At least one severe ADR was reported in 83 (6.9%) patients with ototoxicity being the most frequent ADR experienced (38.9%). CONCLUSIONS: We found that being HIV-infected but antiretroviral naive did not increase occurrence of SADRs in patients on second-line anti-tuberculosis drugs. Early screening and proactive management of ADRs in this patient population is essential, especially given the rollout of decentralized care and the potential for overlapping toxicity of concomitant MDR-TB and HIV treatment.'
p43213
sS'AD'
p43214
S'Tuberculosis Epidemiology and Intervention Research Unit, South African Medical Research Council, Pretoria, South Africa. vdwalt@mrc.ac.za'
p43215
sS'IP'
p43216
S'4'
sS'IS'
p43217
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p43218
sS'PMC'
p43219
S'PMC3615995'
p43220
sS'DCOM'
p43221
S'20131022'
p43222
sS'AU'
p43223
(lp43224
S'Van der Walt M'
p43225
aS'Lancaster J'
p43226
aS'Odendaal R'
p43227
aS'Davis JG'
p43228
aS'Shean K'
p43229
aS'Farley J'
p43230
asS'VI'
p43231
S'8'
sS'MHDA'
p43232
S'2013/10/23 06:00'
p43233
sS'PHST'
p43234
(lp43235
S'2012/10/24 [received]'
p43236
aS'2013/02/07 [accepted]'
p43237
aS'2013/04/03 [epublish]'
p43238
asS'OID'
p43239
(lp43240
S'NLM: PMC3615995'
p43241
asS'MH'
p43242
(lp43243
S'Adult'
p43244
aS'Antitubercular Agents/*adverse effects/therapeutic use'
p43245
aS'Coinfection'
p43246
aS'Cycloserine/*adverse effects/therapeutic use'
p43247
aS'Drug Resistance, Multiple, Bacterial'
p43248
aS'Female'
p43249
aS'HIV Infections/*complications/drug therapy'
p43250
aS'Hearing Loss/chemically induced'
p43251
aS'Humans'
p43252
aS'Isoxazoles/*adverse effects/therapeutic use'
p43253
aS'Male'
p43254
aS'Middle Aged'
p43255
aS'Mycobacterium tuberculosis'
p43256
aS'Ofloxacin/*adverse effects/therapeutic use'
p43257
aS'Oxazolidinones/*adverse effects/therapeutic use'
p43258
aS'Prospective Studies'
p43259
aS'Psychoses, Substance-Induced/etiology'
p43260
aS'South Africa'
p43261
aS'Treatment Outcome'
p43262
aS'Tuberculosis, Multidrug-Resistant/complications/*drug therapy'
p43263
aS'Tuberculosis, Pulmonary/complications/*drug therapy'
p43264
asS'EDAT'
p43265
S'2013/04/11 06:00'
p43266
sS'SO'
p43267
S'PLoS One. 2013;8(4):e58817. doi: 10.1371/journal.pone.0058817. Epub 2013 Apr 3.'
p43268
sS'SB'
p43269
S'IM'
p43270
sS'PMID'
p43271
S'23573193'
p43272
sS'PST'
p43273
S'ppublish'
p43274
stRp43275
ag2
(g3
g4
(dp43276
S'LID'
p43277
S'10.1089/AID.2013.0024 [doi]'
p43278
sS'STAT'
p43279
S'MEDLINE'
p43280
sS'DEP'
p43281
S'20130430'
p43282
sS'DA'
p43283
S'20130719'
p43284
sS'AID'
p43285
(lp43286
S'10.1089/AID.2013.0024 [doi]'
p43287
asS'CRDT'
p43288
(lp43289
S'2013/04/05 06:00'
p43290
asS'DP'
p43291
S'2013 Aug'
p43292
sS'OWN'
p43293
S'NLM'
p43294
sS'PT'
p43295
(lp43296
S'Journal Article'
p43297
aS"Research Support, Non-U.S. Gov't"
p43298
asS'LA'
p43299
(lp43300
S'eng'
p43301
asS'FAU'
p43302
(lp43303
S'Liegeois, Florian'
p43304
aS'Reteno, Dorine Gaelle Ikanga'
p43305
aS'Mouinga-Ondeme, Augustin'
p43306
aS'Sica, Jeanne'
p43307
aS'Rouet, Francois'
p43308
asS'JT'
p43309
S'AIDS research and human retroviruses'
p43310
sS'PG'
p43311
S'1179-82'
p43312
sS'TI'
p43313
S'Short communication: high natural polymorphism in the gag gene cleavage sites of non-B HIV type 1 isolates from Gabon.'
p43314
sS'RN'
p43315
(lp43316
S'0 (Anti-Retroviral Agents)'
p43317
asS'PL'
p43318
S'United States'
p43319
sS'TA'
p43320
S'AIDS Res Hum Retroviruses'
p43321
sS'JID'
p43322
S'8709376'
p43323
sS'AB'
p43324
S'The main goal of the present study was to determine the frequency of substitutions in the cleavage sites (CS) of gag gene among non-B HIV-1 isolates from Gabon. Fifty plasma specimens, collected in 2010-2011, from HIV-1-infected patients failing first-line antiretroviral (ARV) regimens (constituted of two nucleoside reverse transcriptase inhibitors+one nonnucleoside reverse transcriptase inhibitor) (n=38) and from HIV-1-infected individuals untreated with ARV (n=12) were analyzed in the gag and gag-pol cleavage sites. Compared to HXB2 reference sequence, the total median number of substitutions in gag and gag-pol CS was 10 (range, 5-18). The cleavage site p2/NC was the most variable of the four gag CS with 100% (50/50) isolates carrying at least 1 substitution (range, 1-9). The two gag-pol TFP/p6pol and p6pol/PR CS sites were also highly variable (at least one substitution, 50/50, 100% in both cases). Substitutions at position G381 (p2/NC), L449 (p1/p6gag), and K444 (TFP/p6pol) were significantly more frequent in CRF02_AG strains, compared to other non-B strains (30.4% vs. 3.7%, p=0.03; 87.0% vs. 59.3%, p=0.03; and 91.3% vs. 59.3%, p=0.01, respectively). Other non-B subtypes were significantly more likely to harbor substitutions at position N487 (p6pol) (70.4%) than CRF02_AG (39.1%) (p=0.02). In Gabon, gag and gag-pol cleavage sites were highly polymorphic in protease inhibitor-naive patients harboring non-B HIV-1 strains. In sub-Saharan Africa, further studies are definitively required to better understand the impact of gag mutations among subjects receiving second-line LPV/r-containing regimens (monotherapy or triple combinations).'
p43325
sS'AD'
p43326
S'Laboratoire de Retrovirologie, CIRMF, BP769, Franceville, Gabon.'
p43327
sS'IP'
p43328
S'8'
sS'IS'
p43329
S'1931-8405 (Electronic) 0889-2229 (Linking)'
p43330
sS'DCOM'
p43331
S'20131112'
p43332
sS'AU'
p43333
(lp43334
S'Liegeois F'
p43335
aS'Reteno DG'
p43336
aS'Mouinga-Ondeme A'
p43337
aS'Sica J'
p43338
aS'Rouet F'
p43339
asS'VI'
p43340
S'29'
p43341
sS'MHDA'
p43342
S'2013/11/13 06:00'
p43343
sS'PHST'
p43344
(lp43345
S'2013/04/30 [aheadofprint]'
p43346
asS'MH'
p43347
(lp43348
S'Adult'
p43349
aS'Anti-Retroviral Agents/therapeutic use'
p43350
aS'Gabon'
p43351
aS'Genes, gag/*genetics'
p43352
aS'*Genes, pol'
p43353
aS'HIV Infections/drug therapy/*virology'
p43354
aS'HIV-1/drug effects/*genetics/isolation & purification'
p43355
aS'Humans'
p43356
aS'Mutation'
p43357
aS'Polymorphism, Genetic'
p43358
asS'EDAT'
p43359
S'2013/04/05 06:00'
p43360
sS'SO'
p43361
S'AIDS Res Hum Retroviruses. 2013 Aug;29(8):1179-82. doi: 10.1089/AID.2013.0024. Epub 2013 Apr 30.'
p43362
sS'SB'
p43363
S'IM X'
p43364
sS'PMID'
p43365
S'23551028'
p43366
sS'PST'
p43367
S'ppublish'
p43368
stRp43369
ag2
(g3
g4
(dp43370
S'LID'
p43371
S'10.1128/JCM.00118-13 [doi]'
p43372
sS'STAT'
p43373
S'MEDLINE'
p43374
sS'DEP'
p43375
S'20130327'
p43376
sS'DA'
p43377
S'20130517'
p43378
sS'AID'
p43379
(lp43380
S'JCM.00118-13 [pii]'
p43381
aS'10.1128/JCM.00118-13 [doi]'
p43382
asS'CRDT'
p43383
(lp43384
S'2013/03/29 06:00'
p43385
asS'DP'
p43386
S'2013 Jun'
p43387
sS'OWN'
p43388
S'NLM'
p43389
sS'PT'
p43390
(lp43391
S'Evaluation Studies'
p43392
aS'Journal Article'
p43393
aS"Research Support, Non-U.S. Gov't"
p43394
asS'LA'
p43395
(lp43396
S'eng'
p43397
asS'FAU'
p43398
(lp43399
S'Aitken, Susan C'
p43400
aS'Bronze, Michelle'
p43401
aS'Wallis, Carole L'
p43402
aS'Stuyver, Lieven'
p43403
aS'Steegen, Kim'
p43404
aS'Balinda, Sheila'
p43405
aS'Kityo, Cissy'
p43406
aS'Stevens, Wendy'
p43407
aS'Rinke de Wit, Tobias F'
p43408
aS'Schuurman, Rob'
p43409
asS'JT'
p43410
S'Journal of clinical microbiology'
p43411
sS'LR'
p43412
S'20150427'
p43413
sS'PG'
p43414
S'1757-61'
p43415
sS'TI'
p43416
S'A pragmatic approach to HIV-1 drug resistance determination in resource-limited settings by use of a novel genotyping assay targeting the reverse transcriptase-encoding region only.'
p43417
sS'RN'
p43418
(lp43419
S'0 (DNA Primers)'
p43420
aS'0 (RNA, Viral)'
p43421
aS'EC 2.7.7.- (reverse transcriptase, Human immunodeficiency virus 1)'
p43422
aS'EC 2.7.7.49 (HIV Reverse Transcriptase)'
p43423
asS'PL'
p43424
S'United States'
p43425
sS'TA'
p43426
S'J Clin Microbiol'
p43427
sS'JID'
p43428
S'7505564'
p43429
sS'AB'
p43430
S'In resource-limited settings (RLS), reverse transcriptase (RT) inhibitors form the backbone of first-line treatment regimens. We have developed a simplified HIV-1 drug resistance genotyping assay targeting the region of RT harboring all major RT inhibitor resistance mutation positions, thus providing all relevant susceptibility data for first-line failures, coupled with minimal cost and labor. The assay comprises a one-step RT-PCR amplification reaction, followed by sequencing using one forward and one reverse primer, generating double-stranded coverage of RT amino acids (aa) 41 to 238. The assay was optimized for all major HIV-1 group M subtypes in plasma and dried blood spot (DBS) samples using a panel of reference viruses for HIV-1 subtypes A to D, F to H, and circulating recombinant form 01_AE (CRF01_AE) and applied to 212 clinical plasma samples and 25 DBS samples from HIV-1-infected individuals from Africa and Europe. The assay was subsequently transferred to Uganda and applied locally on clinical plasma samples. All major HIV-1 subtypes could be detected with an analytical sensitivity of 5.00E+3 RNA copies/ml for plasma and DBS. Application of the assay on 212 clinical samples from African subjects comprising subtypes A to D, F to H (rare), CRF01_AE, and CRF02_AG at a viral load (VL) range of 6.71E+2 to 1.00E+7 (median, 1.48E+5) RNA copies/ml was 94.8% (n = 201) successful. Application on clinical samples in Uganda demonstrated a comparable success rate. Genotyping of clinical DBS samples, all subtype C with a VL range of 1.02E+3 to 4.49E+5 (median, 1.42E+4) RNA copies/ml, was 84.0% successful. The described assay greatly reduces hands-on time and the costs required for genotyping and is ideal for use in RLS, as demonstrated in a reference laboratory in Uganda and its successful application on DBS samples.'
p43431
sS'AD'
p43432
S'University Medical Centre, Utrecht, The Netherlands. s.c.aitken@umcutrecht.nl'
p43433
sS'IP'
p43434
S'6'
sS'IS'
p43435
S'1098-660X (Electronic) 0095-1137 (Linking)'
p43436
sS'PMC'
p43437
S'PMC3716103'
p43438
sS'DCOM'
p43439
S'20131118'
p43440
sS'AU'
p43441
(lp43442
S'Aitken SC'
p43443
aS'Bronze M'
p43444
aS'Wallis CL'
p43445
aS'Stuyver L'
p43446
aS'Steegen K'
p43447
aS'Balinda S'
p43448
aS'Kityo C'
p43449
aS'Stevens W'
p43450
aS'Rinke de Wit TF'
p43451
aS'Schuurman R'
p43452
asS'VI'
p43453
S'51'
p43454
sS'MHDA'
p43455
S'2013/11/19 06:00'
p43456
sS'PHST'
p43457
(lp43458
S'2013/03/27 [aheadofprint]'
p43459
asS'OID'
p43460
(lp43461
S'NLM: PMC3716103'
p43462
asS'MH'
p43463
(lp43464
S'Africa'
p43465
aS'Child'
p43466
aS'DNA Primers/genetics'
p43467
aS'Developing Countries'
p43468
aS'*Drug Resistance, Viral'
p43469
aS'Europe'
p43470
aS'Genotype'
p43471
aS'HIV Infections/*virology'
p43472
aS'HIV Reverse Transcriptase/*genetics'
p43473
aS'HIV-1/*genetics'
p43474
aS'Humans'
p43475
aS'Microbial Sensitivity Tests/methods'
p43476
aS'Molecular Diagnostic Techniques/*methods'
p43477
aS'Plasma/virology'
p43478
aS'RNA, Viral/genetics'
p43479
aS'Reverse Transcriptase Polymerase Chain Reaction'
p43480
aS'Sequence Analysis, DNA'
p43481
asS'EDAT'
p43482
S'2013/03/29 06:00'
p43483
sS'SO'
p43484
S'J Clin Microbiol. 2013 Jun;51(6):1757-61. doi: 10.1128/JCM.00118-13. Epub 2013 Mar 27.'
p43485
sS'SB'
p43486
S'IM'
p43487
sS'PMID'
p43488
S'23536405'
p43489
sS'PST'
p43490
S'ppublish'
p43491
stRp43492
ag2
(g3
g4
(dp43493
S'STAT'
p43494
S'MEDLINE'
p43495
sS'JT'
p43496
S'AIDS (London, England)'
p43497
sS'DA'
p43498
S'20131031'
p43499
sS'AID'
p43500
(lp43501
S'10.1097/QAD.0b013e32836149ea [doi]'
p43502
asS'CRDT'
p43503
(lp43504
S'2013/03/26 06:00'
p43505
asS'DP'
p43506
S'2013 Jul 31'
p43507
sS'OWN'
p43508
S'NLM'
p43509
sS'PT'
p43510
(lp43511
S'Comparative Study'
p43512
aS'Journal Article'
p43513
aS"Research Support, Non-U.S. Gov't"
p43514
asS'LA'
p43515
(lp43516
S'eng'
p43517
asS'FAU'
p43518
(lp43519
S'Shroufi, Amir'
p43520
aS'Gunguwo, Hilary'
p43521
aS'Dixon, Mark'
p43522
aS'Nyathi, Mary'
p43523
aS'Ndebele, Wedu'
p43524
aS'Saint-Sauveur, Jean-Francois'
p43525
aS'Taziwa, Fabian'
p43526
aS'Ferreyra, Cecilia'
p43527
aS'Vinoles, Mari-Carmen'
p43528
aS'Ferrand, Rashida A'
p43529
asS'LR'
p43530
S'20150427'
p43531
sS'PG'
p43532
S'1971-8'
p43533
sS'TI'
p43534
S'HIV-infected adolescents in southern Africa can achieve good treatment outcomes: results from a retrospective cohort study.'
p43535
sS'RN'
p43536
(lp43537
S'0 (Anti-HIV Agents)'
p43538
asS'PL'
p43539
S'England'
p43540
sS'TA'
p43541
S'AIDS'
p43542
sS'JID'
p43543
S'8710219'
p43544
sS'AB'
p43545
S'OBJECTIVES: In this study we examine whether adolescents treated for HIV/AIDS in southern Africa can achieve similar treatment outcomes to adults. DESIGN: We have used a retrospective cohort study design to compare outcomes for adolescents and adults commencing antiretroviral therapy (ART) between 2004 and 2010 in a public sector hospital clinic in Bulawayo, Zimbabwe. METHODS: Cox proportional hazards modelling was used to investigate risk factors for death and loss to follow-up (LTFU) (defined as missing a scheduled appointment by >/=3months). RESULTS: One thousand, seven hundred and seventy-six adolescents commenced ART, 94% having had no previous history of ART. The median age at ART initiation was 13.3 years. HIV diagnosis in 97% of adolescents occurred after presentation with clinical disease and a higher proportion had advanced HIV disease at presentation compared with adults [WHO Stage 3/4 disease (79.3 versus 65.2%, P < 0.001)]. Despite this, adolescents had no worse mortality than adults, assuming 50% mortality among those LTFU (6.4 versus 7.3 per 100 person-years, P = 0.75) with rates of loss to follow-up significantly lower than in adults (4.8 versus 9.2 per 100 person-years, P < 0.001). Among those who were followed for 5 years or more, 5.8% of adolescents switched to a second-line regimen as a result of treatment failure, compared with 2.1% of adults (P < 0.001). CONCLUSION: With adolescent-focused services, it is feasible to achieve good outcomes for adolescents in large-scale ART programs in sub-Saharan Africa. However, adolescents are at high risk of treatment failure, which compromises future drug options. Interventions to address poor adherence in adolescence should be prioritized.'
p43546
sS'IP'
p43547
S'12'
p43548
sS'IS'
p43549
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p43550
sS'PMC'
p43551
S'PMC3713766'
p43552
sS'DCOM'
p43553
S'20140421'
p43554
sS'AU'
p43555
(lp43556
S'Shroufi A'
p43557
aS'Gunguwo H'
p43558
aS'Dixon M'
p43559
aS'Nyathi M'
p43560
aS'Ndebele W'
p43561
aS'Saint-Sauveur JF'
p43562
aS'Taziwa F'
p43563
aS'Ferreyra C'
p43564
aS'Vinoles MC'
p43565
aS'Ferrand RA'
p43566
asS'VI'
p43567
S'27'
p43568
sS'MHDA'
p43569
S'2014/04/22 06:00'
p43570
sS'OID'
p43571
(lp43572
S'NLM: PMC3713766'
p43573
asS'MH'
p43574
(lp43575
S'Adolescent'
p43576
aS'Adult'
p43577
aS'Age Factors'
p43578
aS'Anti-HIV Agents/*therapeutic use'
p43579
aS'Child'
p43580
aS'Cohort Studies'
p43581
aS'Female'
p43582
aS'HIV Infections/*drug therapy'
p43583
aS'Humans'
p43584
aS'Male'
p43585
aS'Patient Compliance'
p43586
aS'Retrospective Studies'
p43587
aS'Survival Analysis'
p43588
aS'Treatment Outcome'
p43589
aS'Zimbabwe'
p43590
asS'EDAT'
p43591
S'2013/03/26 06:00'
p43592
sS'SO'
p43593
S'AIDS. 2013 Jul 31;27(12):1971-8.'
p43594
sS'SB'
p43595
S'IM X'
p43596
sS'PMID'
p43597
S'23525033'
p43598
sS'PST'
p43599
S'ppublish'
p43600
stRp43601
ag2
(g3
g4
(dp43602
S'LID'
p43603
S'10.1371/journal.pone.0058117 [doi]'
p43604
sS'STAT'
p43605
S'MEDLINE'
p43606
sS'DEP'
p43607
S'20130308'
p43608
sS'DA'
p43609
S'20130322'
p43610
sS'AID'
p43611
(lp43612
S'10.1371/journal.pone.0058117 [doi]'
p43613
aS'PONE-D-12-20032 [pii]'
p43614
asS'CRDT'
p43615
(lp43616
S'2013/03/23 06:00'
p43617
asS'DP'
p43618
S'2013'
p43619
sS'AD'
p43620
S'Department of Obstetrics and Gynecology and Duke Global Health Institute, Duke University, Durham, North Carolina, United States of America. Erica.Pierce@ucdenver.edu'
p43621
sS'OWN'
p43622
S'NLM'
p43623
sS'PT'
p43624
(lp43625
S'Clinical Trial'
p43626
aS'Journal Article'
p43627
aS'Multicenter Study'
p43628
aS'Research Support, N.I.H., Extramural'
p43629
aS"Research Support, Non-U.S. Gov't"
p43630
aS"Research Support, U.S. Gov't, Non-P.H.S."
p43631
asS'LA'
p43632
(lp43633
S'eng'
p43634
asS'FAU'
p43635
(lp43636
S'Westreich, Daniel'
p43637
aS'Maskew, Mhairi'
p43638
aS'Evans, Denise'
p43639
aS'Firnhaber, Cindy'
p43640
aS'Majuba, Pappie'
p43641
aS'Sanne, Ian'
p43642
asS'JT'
p43643
S'PloS one'
p43644
sS'LR'
p43645
S'20150427'
p43646
sS'PG'
p43647
S'e58117'
p43648
sS'TI'
p43649
S'Incident pregnancy and time to death or AIDS among HIV-positive women receiving antiretroviral therapy.'
p43650
sS'PL'
p43651
S'United States'
p43652
sS'TA'
p43653
S'PLoS One'
p43654
sS'JID'
p43655
S'101285081'
p43656
sS'AB'
p43657
S'BACKGROUND: Little is known about the impact of pregnancy on response to highly active antiretroviral therapy (HAART) in sub-Saharan Africa. We examined the effect of incident pregnancy after HAART initiation on clinical response to HAART. METHODS: We evaluated a prospective clinical cohort of adult women initiating HAART in Johannesburg, South Africa between 1 April 2004 and 31 March 2011, and followed up until an event, transfer, drop-out, or administrative end of follow-up on 30 September 2011. Women over age 45 and women who were pregnant at HAART initiation were excluded from the study. Main exposure was having experienced pregnancy after HAART initiation; main outcome was death and (separately) death or new AIDS event. We calculated adjusted hazard ratios (HRs) and 95% confidence limits (CL) using marginal structural Cox proportional hazards models. RESULTS: The study included 7,534 women, and 20,813 person-years of follow-up; 918 women had at least one recognized pregnancy during follow-up. For death alone, the weighted (adjusted) HR was 0.84 (95% CL 0.44, 1.60). Sensitivity analyses confirmed main results, and results were similar for analysis of death or new AIDS event. Incident pregnancy was associated with a substantially reduced hazard of drop-out (HR = 0.62, 95% CL 0.51, 0.75). CONCLUSIONS: Recognized incident pregnancy after HAART initiation was not associated with increases in hazard of clinical events, but was associated with a decreased hazard of drop-out. High rates of pregnancy after initiation of HAART may point to a need to better integrate family planning services into clinical care for HIV-infected women.'
p43658
sS'GR'
p43659
(lp43660
S'P30 AI064518/AI/NIAID NIH HHS/United States'
p43661
aS'P30-AI-064518/AI/NIAID NIH HHS/United States'
p43662
aS'R00 HD063961/HD/NICHD NIH HHS/United States'
p43663
aS'R00-HD-06-3961/HD/NICHD NIH HHS/United States'
p43664
aS'PEPFAR/United States'
p43665
asS'IP'
p43666
S'3'
sS'IS'
p43667
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p43668
sS'PMC'
p43669
S'PMC3592862'
p43670
sS'DCOM'
p43671
S'20130910'
p43672
sS'AU'
p43673
(lp43674
S'Westreich D'
p43675
aS'Maskew M'
p43676
aS'Evans D'
p43677
aS'Firnhaber C'
p43678
aS'Majuba P'
p43679
aS'Sanne I'
p43680
asS'VI'
p43681
S'8'
sS'MHDA'
p43682
S'2013/09/11 06:00'
p43683
sS'PHST'
p43684
(lp43685
S'2012/07/06 [received]'
p43686
aS'2013/02/03 [accepted]'
p43687
aS'2013/03/08 [epublish]'
p43688
asS'OID'
p43689
(lp43690
S'NLM: PMC3592862'
p43691
asS'MH'
p43692
(lp43693
S'Acquired Immunodeficiency Syndrome/*drug therapy/*mortality'
p43694
aS'Adult'
p43695
aS'*Antiretroviral Therapy, Highly Active'
p43696
aS'Female'
p43697
aS'Follow-Up Studies'
p43698
aS'HIV Seropositivity/*drug therapy/*mortality'
p43699
aS'Humans'
p43700
aS'Incidence'
p43701
aS'Pregnancy'
p43702
aS'Pregnancy Complications, Infectious/*drug therapy/*mortality'
p43703
aS'Retrospective Studies'
p43704
asS'EDAT'
p43705
S'2013/03/23 06:00'
p43706
sS'SO'
p43707
S'PLoS One. 2013;8(3):e58117. doi: 10.1371/journal.pone.0058117. Epub 2013 Mar 8.'
p43708
sS'SB'
p43709
S'IM'
p43710
sS'PMID'
p43711
S'23520489'
p43712
sS'PST'
p43713
S'ppublish'
p43714
stRp43715
ag2
(g3
g4
(dp43716
S'LID'
p43717
S'10.1089/AID.2012.0218 [doi]'
p43718
sS'STAT'
p43719
S'MEDLINE'
p43720
sS'DEP'
p43721
S'20130417'
p43722
sS'DA'
p43723
S'20130513'
p43724
sS'AID'
p43725
(lp43726
S'10.1089/AID.2012.0218 [doi]'
p43727
asS'CRDT'
p43728
(lp43729
S'2013/03/23 06:00'
p43730
asS'DP'
p43731
S'2013 Jun'
p43732
sS'OWN'
p43733
S'NLM'
p43734
sS'PT'
p43735
(lp43736
S'Journal Article'
p43737
aS"Research Support, Non-U.S. Gov't"
p43738
asS'LA'
p43739
(lp43740
S'eng'
p43741
asS'FAU'
p43742
(lp43743
S'Sigaloff, Kim C E'
p43744
aS'Kayiwa, Joshua'
p43745
aS'Musiime, Victor'
p43746
aS'Calis, Job C J'
p43747
aS'Kaudha, Elizabeth'
p43748
aS'Mukuye, Andrew'
p43749
aS'Matama, Christine'
p43750
aS'Nankya, Immaculate'
p43751
aS'Nakatudde, Lillian'
p43752
aS'Dekker, John T'
p43753
aS'Hamers, Raph L'
p43754
aS'Mugyenyi, Peter'
p43755
aS'Rinke De Wit, Tobias F'
p43756
aS'Kityo, Cissy'
p43757
asS'JT'
p43758
S'AIDS research and human retroviruses'
p43759
sS'LR'
p43760
S'20131121'
p43761
sS'PG'
p43762
S'925-30'
p43763
sS'TI'
p43764
S'Short communication: high rates of thymidine analogue mutations and dual-class resistance among HIV-infected Ugandan children failing first-line antiretroviral therapy.'
p43765
sS'RN'
p43766
(lp43767
S'0 (Anti-HIV Agents)'
p43768
aS'VC2W18DGKR (Thymidine)'
p43769
asS'PL'
p43770
S'United States'
p43771
sS'TA'
p43772
S'AIDS Res Hum Retroviruses'
p43773
sS'JID'
p43774
S'8709376'
p43775
sS'AB'
p43776
S'HIV-infected children are at high risk of acquiring drug-resistant viruses, which is of particular concern in settings where antiretroviral drug options are limited. We aimed to assess resistance patterns and predict viral drug susceptibility among children with first-line antiretroviral therapy (ART) failure in Uganda. A cross-sectional analysis of children switching ART regimens due to first-line failure was performed at three clinical sites in Uganda. HIV-RNA determination and genotypic resistance testing on all specimens with HIV-RNA >1,000 copies/ml were performed. Major drug resistance mutations were scored using the 2011 International Antiviral Society-USA list. The Stanford algorithm was used to predict drug susceptibility. At the time of switch, 44 genotypic resistance tests were available for 50 children. All children harbored virus with nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance [95% confidence interval (CI) 92-100%] and NRTI resistance was present in 98% (95% CI 88-100%). Forty-six percent (95% CI 30-61%) of children harbored >/=2 thymidine analog mutations. M184V was identified as the only NRTI mutation in 27% (95% CI 15-43%). HIV susceptibility to NRTIs, with the exception of tenofovir, was reduced in >/=60% of children. Ugandan children experiencing first-line ART failure in our study harbored high rates of dual-class and accumulated HIV drug resistance. Methods to prevent treatment failure, including adequate pediatric formulations and alternative second-line treatment options, are urgently needed.'
p43777
sS'AD'
p43778
S'PharmAccess Foundation, Amsterdam, The Netherlands. k.sigaloff@aighd.org'
p43779
sS'IP'
p43780
S'6'
sS'IS'
p43781
S'1931-8405 (Electronic) 0889-2229 (Linking)'
p43782
sS'DCOM'
p43783
S'20130830'
p43784
sS'AU'
p43785
(lp43786
S'Sigaloff KC'
p43787
aS'Kayiwa J'
p43788
aS'Musiime V'
p43789
aS'Calis JC'
p43790
aS'Kaudha E'
p43791
aS'Mukuye A'
p43792
aS'Matama C'
p43793
aS'Nankya I'
p43794
aS'Nakatudde L'
p43795
aS'Dekker JT'
p43796
aS'Hamers RL'
p43797
aS'Mugyenyi P'
p43798
aS'Rinke De Wit TF'
p43799
aS'Kityo C'
p43800
asS'VI'
p43801
S'29'
p43802
sS'MHDA'
p43803
S'2013/08/31 06:00'
p43804
sS'PHST'
p43805
(lp43806
S'2013/04/17 [aheadofprint]'
p43807
asS'MH'
p43808
(lp43809
S'Amino Acid Substitution/*genetics'
p43810
aS'Anti-HIV Agents/*therapeutic use'
p43811
aS'Child'
p43812
aS'Child, Preschool'
p43813
aS'Cross-Sectional Studies'
p43814
aS'Drug Resistance, Multiple, Viral/genetics'
p43815
aS'Drug Resistance, Viral/genetics'
p43816
aS'Female'
p43817
aS'Genotype'
p43818
aS'HIV/*drug effects/genetics'
p43819
aS'HIV Infections/*drug therapy/virology'
p43820
aS'Humans'
p43821
aS'Male'
p43822
aS'Molecular Sequence Data'
p43823
aS'Thymidine'
p43824
aS'Treatment Failure'
p43825
aS'Uganda/epidemiology'
p43826
aS'Viral Load/drug effects/genetics'
p43827
asS'EDAT'
p43828
S'2013/03/23 06:00'
p43829
sS'SI'
p43830
(lp43831
S'GENBANK/JX181983'
p43832
aS'GENBANK/JX181984'
p43833
aS'GENBANK/JX181985'
p43834
aS'GENBANK/JX181986'
p43835
aS'GENBANK/JX181987'
p43836
aS'GENBANK/JX181988'
p43837
aS'GENBANK/JX181989'
p43838
aS'GENBANK/JX181990'
p43839
aS'GENBANK/JX181991'
p43840
aS'GENBANK/JX181992'
p43841
aS'GENBANK/JX181993'
p43842
aS'GENBANK/JX181994'
p43843
aS'GENBANK/JX181995'
p43844
aS'GENBANK/JX181996'
p43845
aS'GENBANK/JX181997'
p43846
aS'GENBANK/JX181998'
p43847
aS'GENBANK/JX181999'
p43848
aS'GENBANK/JX182000'
p43849
aS'GENBANK/JX182001'
p43850
aS'GENBANK/JX182002'
p43851
aS'GENBANK/JX182003'
p43852
aS'GENBANK/JX182004'
p43853
aS'GENBANK/JX182005'
p43854
aS'GENBANK/JX182006'
p43855
aS'GENBANK/JX182007'
p43856
aS'GENBANK/JX182008'
p43857
aS'GENBANK/JX182009'
p43858
aS'GENBANK/JX182010'
p43859
aS'GENBANK/JX182011'
p43860
aS'GENBANK/JX182012'
p43861
aS'GENBANK/JX182013'
p43862
aS'GENBANK/JX182014'
p43863
aS'GENBANK/JX182015'
p43864
aS'GENBANK/JX182016'
p43865
aS'GENBANK/JX182017'
p43866
aS'GENBANK/JX182018'
p43867
aS'GENBANK/JX182019'
p43868
aS'GENBANK/JX182020'
p43869
aS'GENBANK/JX182021'
p43870
aS'GENBANK/JX182022'
p43871
aS'GENBANK/JX182023'
p43872
aS'GENBANK/JX182024'
p43873
aS'GENBANK/JX182025'
p43874
aS'GENBANK/JX182026'
p43875
asS'SO'
p43876
S'AIDS Res Hum Retroviruses. 2013 Jun;29(6):925-30. doi: 10.1089/AID.2012.0218. Epub 2013 Apr 17.'
p43877
sS'SB'
p43878
S'IM X'
p43879
sS'PMID'
p43880
S'23517497'
p43881
sS'PST'
p43882
S'ppublish'
p43883
stRp43884
ag2
(g3
g4
(dp43885
S'LID'
p43886
S'10.1128/JVI.00178-13 [doi]'
p43887
sS'STAT'
p43888
S'MEDLINE'
p43889
sS'DEP'
p43890
S'20130320'
p43891
sS'DA'
p43892
S'20130508'
p43893
sS'AID'
p43894
(lp43895
S'JVI.00178-13 [pii]'
p43896
aS'10.1128/JVI.00178-13 [doi]'
p43897
asS'CRDT'
p43898
(lp43899
S'2013/03/22 06:00'
p43900
asS'DP'
p43901
S'2013 Jun'
p43902
sS'AD'
p43903
S'Aaron Diamond AIDS Research Center, New York, New York, USA.'
p43904
sS'OWN'
p43905
S'NLM'
p43906
sS'PT'
p43907
(lp43908
S'Journal Article'
p43909
aS'Research Support, N.I.H., Extramural'
p43910
aS"Research Support, Non-U.S. Gov't"
p43911
asS'LA'
p43912
(lp43913
S'eng'
p43914
asS'FAU'
p43915
(lp43916
S'Ren, Wuze'
p43917
aS'Mumbauer, Alexandra'
p43918
aS'Gettie, Agegnehu'
p43919
aS'Seaman, Michael S'
p43920
aS'Russell-Lodrigue, Kasi'
p43921
aS'Blanchard, James'
p43922
aS'Westmoreland, Susan'
p43923
aS'Cheng-Mayer, Cecilia'
p43924
asS'JT'
p43925
S'Journal of virology'
p43926
sS'LR'
p43927
S'20151119'
p43928
sS'PG'
p43929
S'6137-49'
p43930
sS'TI'
p43931
S'Generation of lineage-related, mucosally transmissible subtype C R5 simian-human immunodeficiency viruses capable of AIDS development, induction of neurological disease, and coreceptor switching in rhesus macaques.'
p43932
sS'RN'
p43933
(lp43934
S'0 (Receptors, CCR5)'
p43935
aS'0 (Receptors, HIV)'
p43936
asS'PL'
p43937
S'United States'
p43938
sS'TA'
p43939
S'J Virol'
p43940
sS'JID'
p43941
S'0113724'
p43942
sS'AB'
p43943
S'Most human immunodeficiency virus (HIV) transmissions are initiated with CCR5 (R5)-using viruses across mucosal surfaces, with the majority in regions where HIV type 1 (HIV-1) clade C predominates. Mucosally transmissible, highly replication competent, pathogenic R5 simian-human immunodeficiency viruses (SHIVs) encoding biologically relevant clade C envelopes are therefore needed as challenge viruses in vaccine efficacy studies with nonhuman primates. Here we describe the generation of three lineage-related subtype C SHIVs through four successive rapid transfers in rhesus macaques of SHIVC109F.PB4, a molecular clone expressing the soluble-CD4 (sCD4)-sensitive CCR5-tropic clade C envelope of a recently infected subject in Zambia. The viruses differed in their monkey passage histories and neutralization sensitivities but remained R5 tropic. SHIVC109P3 and SHIVC109P3N were recovered from a passage-3 rapid-progressor animal during chronic infection (24 weeks postinfection [wpi]) and at end-stage disease (34 wpi), respectively, and are classified as tier 1B strains, whereas SHIVC109P4 was recovered from a passage-4 normal-progressor macaque at 22 wpi and is a tier 2 virus, more difficult to neutralize. All three viruses were transmitted efficiently via intrarectal inoculation, reaching peak viral loads of 10(7) to 10(9) RNA copies/ml plasma and establishing viremia at various set points. Notably, one of seven (GC98) and two of six (CL31, FI08) SHIVC109P3- and SHIVC109P3N-infected macaques, respectively, progressed to AIDS, with neuropathologies observed in GC98 and FI08, as well as coreceptor switching in the latter. These findings support the use of these new SHIVC109F.PB4-derived viruses to study the immunopathology of HIV-1 clade C infection and to evaluate envelope-based AIDS vaccines in nonhuman primates.'
p43944
sS'GR'
p43945
(lp43946
S'R01AI46980/AI/NIAID NIH HHS/United States'
p43947
asS'IP'
p43948
S'11'
p43949
sS'IS'
p43950
S'1098-5514 (Electronic) 0022-538X (Linking)'
p43951
sS'PMC'
p43952
S'PMC3648099'
p43953
sS'DCOM'
p43954
S'20130730'
p43955
sS'AU'
p43956
(lp43957
S'Ren W'
p43958
aS'Mumbauer A'
p43959
aS'Gettie A'
p43960
aS'Seaman MS'
p43961
aS'Russell-Lodrigue K'
p43962
aS'Blanchard J'
p43963
aS'Westmoreland S'
p43964
aS'Cheng-Mayer C'
p43965
asS'VI'
p43966
S'87'
p43967
sS'MHDA'
p43968
S'2013/07/31 06:00'
p43969
sS'PHST'
p43970
(lp43971
S'2013/03/20 [aheadofprint]'
p43972
asS'OID'
p43973
(lp43974
S'NLM: PMC3648099'
p43975
asS'MH'
p43976
(lp43977
S'Acquired Immunodeficiency Syndrome/metabolism/pathology/transmission/*virology'
p43978
aS'Amino Acid Sequence'
p43979
aS'Animals'
p43980
aS'Brain/pathology/virology'
p43981
aS'Disease Models, Animal'
p43982
aS'HIV Infections/immunology'
p43983
aS'HIV-1/classification/*genetics/*physiology'
p43984
aS'Humans'
p43985
aS'Macaca mulatta'
p43986
aS'Molecular Sequence Data'
p43987
aS'Receptors, CCR5/genetics/*metabolism'
p43988
aS'Receptors, HIV/genetics/*metabolism'
p43989
aS'Recombination, Genetic'
p43990
aS'Simian Acquired Immunodeficiency Syndrome'
p43991
aS'Simian Immunodeficiency Virus/classification/genetics/*physiology'
p43992
asS'EDAT'
p43993
S'2013/03/22 06:00'
p43994
sS'SO'
p43995
S'J Virol. 2013 Jun;87(11):6137-49. doi: 10.1128/JVI.00178-13. Epub 2013 Mar 20.'
p43996
sS'SB'
p43997
S'IM'
p43998
sS'PMID'
p43999
S'23514895'
p44000
sS'PST'
p44001
S'ppublish'
p44002
stRp44003
ag2
(g3
g4
(dp44004
S'LID'
p44005
S'10.1371/journal.pone.0058526 [doi]'
p44006
sS'STAT'
p44007
S'MEDLINE'
p44008
sS'DEP'
p44009
S'20130311'
p44010
sS'DA'
p44011
S'20130318'
p44012
sS'AID'
p44013
(lp44014
S'10.1371/journal.pone.0058526 [doi]'
p44015
aS'PONE-D-12-35938 [pii]'
p44016
asS'CRDT'
p44017
(lp44018
S'2013/03/19 06:00'
p44019
asS'DP'
p44020
S'2013'
p44021
sS'OWN'
p44022
S'NLM'
p44023
sS'PT'
p44024
(lp44025
S'Journal Article'
p44026
asS'LA'
p44027
(lp44028
S'eng'
p44029
asS'FAU'
p44030
(lp44031
S'Schoffelen, Annelot F'
p44032
aS'Wensing, Annemarie M J'
p44033
aS'Tempelman, Hugo A'
p44034
aS'Geelen, Sibyl P M'
p44035
aS'Hoepelman, Andy I M'
p44036
aS'Barth, Roos E'
p44037
asS'JT'
p44038
S'PloS one'
p44039
sS'LR'
p44040
S'20150427'
p44041
sS'PG'
p44042
S'e58526'
p44043
sS'TI'
p44044
S'Sustained virological response on second-line antiretroviral therapy following virological failure in HIV-infected patients in rural South Africa.'
p44045
sS'RN'
p44046
(lp44047
S'0 (Anti-HIV Agents)'
p44048
asS'PL'
p44049
S'United States'
p44050
sS'TA'
p44051
S'PLoS One'
p44052
sS'JID'
p44053
S'101285081'
p44054
sS'AB'
p44055
S'OBJECTIVE: This study aims to describe the virological, immunological and clinical efficacy of protease inhibitor (PI)-based second-line antiretroviral therapy (ART) in rural South Africa. METHODS: An observational cohort study was performed on 210 patients (including 39 children) who initiated PI-based second-line therapy at least 12 months prior to data collection. Biannual clinical, immunological and virological monitoring was performed. Primary endpoints were adequate virological response (plasma HIV-1 RNA<400 copies/ml), full virological suppression (plasma HIV-1 RNA<50 copies/ml) and treatment failure (virological failure (plasma HIV-1 RNA>1000 after initial virological response) or on-going viremia (plasma HIV-1 RNA never<400 copies/ml for more than six months)). Data were analyzed by an on-treatment (OT) and intention-to-treat (ITT) approach. Analyses were primarily performed on the group of patients who switched following first-line virological failure. RESULTS: Median duration of follow-up after switch to second-line treatment was 20 months [IQR 11-35]. 191 patients had switched to second-line ART due to first-line virological failure. 139/191 of them (72.8%, ITT) were in care and on treatment at the end of follow-up and 11/191 (5.8%, ITT) had died. After twelve months, an adequate virological response was seen in 92/128 patients (71.9%, OT), of which 78/128 (60.9%, OT) experienced full virological suppression. Virological response remained stable after 24 months. Virological efficacy was similar amongst adult and pediatric patients. As in first-line ART, we observed a lack of correlation between virological failure and WHO-defined immunological failure. CONCLUSIONS: Good virological outcomes following first-line failure can be achieved with PI-based, second-line antiretroviral therapy in both adult and pediatric patients in rural South Africa. Retention rates were high and virological outcomes were sustainable during the two-year follow-up period, although persisting low-level viremia occurred in a subset of patients. The observed viro-immunological dissociation emphasizes the need for virological monitoring.'
p44056
sS'AD'
p44057
S'Department of Internal Medicine and Infectious Diseases, University Medical Centre Utrecht, Utrecht, The Netherlands. A.F.Schoffelen@umcutrecht.nl'
p44058
sS'IP'
p44059
S'3'
sS'IS'
p44060
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p44061
sS'PMC'
p44062
S'PMC3594302'
p44063
sS'DCOM'
p44064
S'20130906'
p44065
sS'AU'
p44066
(lp44067
S'Schoffelen AF'
p44068
aS'Wensing AM'
p44069
aS'Tempelman HA'
p44070
aS'Geelen SP'
p44071
aS'Hoepelman AI'
p44072
aS'Barth RE'
p44073
asS'VI'
p44074
S'8'
sS'MHDA'
p44075
S'2013/09/07 06:00'
p44076
sS'PHST'
p44077
(lp44078
S'2012/11/06 [received]'
p44079
aS'2013/02/05 [accepted]'
p44080
aS'2013/03/11 [epublish]'
p44081
asS'OID'
p44082
(lp44083
S'NLM: PMC3594302'
p44084
asS'MH'
p44085
(lp44086
S'Adolescent'
p44087
aS'Adult'
p44088
aS'Anti-HIV Agents/*therapeutic use'
p44089
aS'Antiretroviral Therapy, Highly Active'
p44090
aS'CD4 Lymphocyte Count'
p44091
aS'Child'
p44092
aS'Child, Preschool'
p44093
aS'Cross-Sectional Studies'
p44094
aS'Female'
p44095
aS'Follow-Up Studies'
p44096
aS'HIV Infections/*drug therapy/immunology/*virology'
p44097
aS'HIV-1/immunology'
p44098
aS'Humans'
p44099
aS'Infant'
p44100
aS'Male'
p44101
aS'*Rural Population'
p44102
aS'South Africa'
p44103
aS'Treatment Failure'
p44104
aS'Treatment Outcome'
p44105
aS'Viral Load'
p44106
aS'Young Adult'
p44107
asS'EDAT'
p44108
S'2013/03/19 06:00'
p44109
sS'SO'
p44110
S'PLoS One. 2013;8(3):e58526. doi: 10.1371/journal.pone.0058526. Epub 2013 Mar 11.'
p44111
sS'SB'
p44112
S'IM'
p44113
sS'PMID'
p44114
S'23505529'
p44115
sS'PST'
p44116
S'ppublish'
p44117
stRp44118
ag2
(g3
g4
(dp44119
S'LID'
p44120
S'10.1371/journal.pone.0057611 [doi]'
p44121
sS'STAT'
p44122
S'MEDLINE'
p44123
sS'DEP'
p44124
S'20130228'
p44125
sS'DA'
p44126
S'20130307'
p44127
sS'AID'
p44128
(lp44129
S'10.1371/journal.pone.0057611 [doi]'
p44130
aS'PONE-D-12-26345 [pii]'
p44131
asS'CRDT'
p44132
(lp44133
S'2013/03/08 06:00'
p44134
asS'DP'
p44135
S'2013'
p44136
sS'GR'
p44137
(lp44138
S'5U01-AI069924-05/AI/NIAID NIH HHS/United States'
p44139
aS'U01 AI069924/AI/NIAID NIH HHS/United States'
p44140
asS'OWN'
p44141
S'NLM'
p44142
sS'PT'
p44143
(lp44144
S'Journal Article'
p44145
aS'Research Support, N.I.H., Extramural'
p44146
aS"Research Support, Non-U.S. Gov't"
p44147
asS'LA'
p44148
(lp44149
S'eng'
p44150
asS'FAU'
p44151
(lp44152
S'Estill, Janne'
p44153
aS'Egger, Matthias'
p44154
aS'Johnson, Leigh F'
p44155
aS'Gsponer, Thomas'
p44156
aS'Wandeler, Gilles'
p44157
aS'Davies, Mary-Ann'
p44158
aS'Boulle, Andrew'
p44159
aS'Wood, Robin'
p44160
aS'Garone, Daniela'
p44161
aS'Stringer, Jeffrey S A'
p44162
aS'Hallett, Timothy B'
p44163
aS'Keiser, Olivia'
p44164
asS'JT'
p44165
S'PloS one'
p44166
sS'LR'
p44167
S'20150218'
p44168
sS'PG'
p44169
S'e57611'
p44170
sS'TI'
p44171
S'Monitoring of antiretroviral therapy and mortality in HIV programmes in Malawi, South Africa and Zambia: mathematical modelling study.'
p44172
sS'RN'
p44173
(lp44174
S'0 (Anti-HIV Agents)'
p44175
asS'PL'
p44176
S'United States'
p44177
sS'TA'
p44178
S'PLoS One'
p44179
sS'JID'
p44180
S'101285081'
p44181
sS'AB'
p44182
S'OBJECTIVES: Mortality in patients starting antiretroviral therapy (ART) is higher in Malawi and Zambia than in South Africa. We examined whether different monitoring of ART (viral load [VL] in South Africa and CD4 count in Malawi and Zambia) could explain this mortality difference. DESIGN: Mathematical modelling study based on data from ART programmes. METHODS: We used a stochastic simulation model to study the effect of VL monitoring on mortality over 5 years. In baseline scenario A all parameters were identical between strategies except for more timely and complete detection of treatment failure with VL monitoring. Additional scenarios introduced delays in switching to second-line ART (scenario B) or higher virologic failure rates (due to worse adherence) when monitoring was based on CD4 counts only (scenario C). Results are presented as relative risks (RR) with 95% prediction intervals and percent of observed mortality difference explained. RESULTS: RRs comparing VL with CD4 cell count monitoring were 0.94 (0.74-1.03) in scenario A, 0.94 (0.77-1.02) with delayed switching (scenario B) and 0.80 (0.44-1.07) when assuming a 3-times higher rate of failure (scenario C). The observed mortality at 3 years was 10.9% in Malawi and Zambia and 8.6% in South Africa (absolute difference 2.3%). The percentage of the mortality difference explained by VL monitoring ranged from 4% (scenario A) to 32% (scenarios B and C combined, assuming a 3-times higher failure rate). Eleven percent was explained by non-HIV related mortality. CONCLUSIONS: VL monitoring reduces mortality moderately when assuming improved adherence and decreased failure rates.'
p44183
sS'AD'
p44184
S'Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland. jestill@ispm.unibe.ch'
p44185
sS'CN'
p44186
(lp44187
S'IeDEA Southern Africa Collaboration'
p44188
asS'IP'
p44189
S'2'
sS'IS'
p44190
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p44191
sS'PMC'
p44192
S'PMC3585414'
p44193
sS'DCOM'
p44194
S'20130829'
p44195
sS'AU'
p44196
(lp44197
S'Estill J'
p44198
aS'Egger M'
p44199
aS'Johnson LF'
p44200
aS'Gsponer T'
p44201
aS'Wandeler G'
p44202
aS'Davies MA'
p44203
aS'Boulle A'
p44204
aS'Wood R'
p44205
aS'Garone D'
p44206
aS'Stringer JS'
p44207
aS'Hallett TB'
p44208
aS'Keiser O'
p44209
asS'VI'
p44210
S'8'
sS'MHDA'
p44211
S'2013/08/30 06:00'
p44212
sS'PHST'
p44213
(lp44214
S'2012/09/03 [received]'
p44215
aS'2013/01/24 [accepted]'
p44216
aS'2013/02/28 [epublish]'
p44217
asS'OID'
p44218
(lp44219
S'NLM: PMC3585414'
p44220
asS'MH'
p44221
(lp44222
S'Adult'
p44223
aS'Anti-HIV Agents/pharmacology/*therapeutic use'
p44224
aS'HIV Infections/*drug therapy/*mortality'
p44225
aS'Humans'
p44226
aS'Malawi/epidemiology'
p44227
aS'Middle Aged'
p44228
aS'*Models, Statistical'
p44229
aS'South Africa/epidemiology'
p44230
aS'Viral Load/drug effects'
p44231
aS'Zambia/epidemiology'
p44232
asS'EDAT'
p44233
S'2013/03/08 06:00'
p44234
sS'SO'
p44235
S'PLoS One. 2013;8(2):e57611. doi: 10.1371/journal.pone.0057611. Epub 2013 Feb 28.'
p44236
sS'SB'
p44237
S'IM'
p44238
sS'PMID'
p44239
S'23469035'
p44240
sS'PST'
p44241
S'ppublish'
p44242
stRp44243
ag2
(g3
g4
(dp44244
S'LID'
p44245
S'10.1177/0956462412472312 [doi]'
p44246
sS'STAT'
p44247
S'MEDLINE'
p44248
sS'DEP'
p44249
S'20130506'
p44250
sS'DA'
p44251
S'20131122'
p44252
sS'AID'
p44253
(lp44254
S'0956462412472312 [pii]'
p44255
aS'10.1177/0956462412472312 [doi]'
p44256
asS'CRDT'
p44257
(lp44258
S'2013/03/08 06:00'
p44259
asS'DP'
p44260
S'2013 Jan'
p44261
sS'OWN'
p44262
S'NLM'
p44263
sS'PT'
p44264
(lp44265
S'Journal Article'
p44266
asS'LA'
p44267
(lp44268
S'eng'
p44269
asS'FAU'
p44270
(lp44271
S'Johnson, D C'
p44272
aS'Feldacker, C'
p44273
aS'Tweya, H'
p44274
aS'Phiri, S'
p44275
aS'Hosseinipour, M C'
p44276
asS'JT'
p44277
S'International journal of STD & AIDS'
p44278
sS'PG'
p44279
S'42-9'
p44280
sS'TI'
p44281
S'Factors associated with timely initiation of antiretroviral therapy in two HIV clinics in Lilongwe, Malawi.'
p44282
sS'RN'
p44283
(lp44284
S'0 (Anti-HIV Agents)'
p44285
asS'PL'
p44286
S'England'
p44287
sS'TA'
p44288
S'Int J STD AIDS'
p44289
sS'JID'
p44290
S'9007917'
p44291
sS'AB'
p44292
S'The World Health Organization (WHO) estimates that only 30% of eligible, HIV-infected individuals start antiretroviral therapy (ART). This study seeks to explore the geographic and individual factors associated with starting ART on time. This retrospective study includes 15,734 HIV-positive adults initiating ART at two HIV clinics in Lilongwe, Malawi. The outcome was starting ART within two weeks of meeting ART eligibility as defined by the Malawi ART guidelines. Euclidean distance from patient neighbourhood to their clinic was calculated using Google Earth. Logistic regression models assessed factors influencing starting ART on time. Of 15,734 adults initiating ART, 8178 were from Lighthouse (LH) and 7556 were from Martin Preuss Center (MPC). Combined, 68.7% started treatment on time. Patients who were eligible for ART based on a CD4 cell count <250 cells/mm(3) versus WHO stage were less likely to begin ART on time at both LH (odds ratio [OR] 0.16; 95% CI 0.13-0.19) and MPC (OR 0.24; 95% CI 0.21-0.28). Likelihood of starting on time decreased with each kilometer further from clinic location among LH patients (OR 0.97; 95% CI 0.94-0.99); distance was not significant at MPC. In conclusion, predictors differed by clinic. Distance to clinic and type of eligibility for ART significantly influence starting ART on time.'
p44293
sS'AD'
p44294
S'University of North Carolina.'
p44295
sS'IP'
p44296
S'1'
sS'IS'
p44297
S'1758-1052 (Electronic) 0956-4624 (Linking)'
p44298
sS'DCOM'
p44299
S'20140609'
p44300
sS'AU'
p44301
(lp44302
S'Johnson DC'
p44303
aS'Feldacker C'
p44304
aS'Tweya H'
p44305
aS'Phiri S'
p44306
aS'Hosseinipour MC'
p44307
asS'VI'
p44308
S'24'
p44309
sS'MHDA'
p44310
S'2014/06/10 06:00'
p44311
sS'PHST'
p44312
(lp44313
S'2013/05/06 [aheadofprint]'
p44314
asS'OTO'
p44315
(lp44316
S'NOTNLM'
p44317
asS'MH'
p44318
(lp44319
S'Adult'
p44320
aS'Anti-HIV Agents/*therapeutic use'
p44321
aS'Antiretroviral Therapy, Highly Active/*statistics & numerical data'
p44322
aS'CD4 Lymphocyte Count'
p44323
aS'Eligibility Determination'
p44324
aS'Female'
p44325
aS'Geographic Information Systems'
p44326
aS'HIV Infections/diagnosis/*drug therapy/epidemiology'
p44327
aS'Health Services Accessibility'
p44328
aS'Humans'
p44329
aS'Logistic Models'
p44330
aS'Malawi/epidemiology'
p44331
aS'Male'
p44332
aS'Middle Aged'
p44333
aS'Multivariate Analysis'
p44334
aS'Retrospective Studies'
p44335
aS'Socioeconomic Factors'
p44336
aS'Time Factors'
p44337
aS'*Time-to-Treatment'
p44338
aS'Treatment Outcome'
p44339
asS'EDAT'
p44340
S'2013/03/08 06:00'
p44341
sS'SO'
p44342
S'Int J STD AIDS. 2013 Jan;24(1):42-9. doi: 10.1177/0956462412472312. Epub 2013 May 6.'
p44343
sS'SB'
p44344
S'IM X'
p44345
sS'PMID'
p44346
S'23467293'
p44347
sS'OT'
p44348
(lp44349
S'ART eligibility'
p44350
aS'Africa'
p44351
aS'GIS'
p44352
aS'HIV'
p44353
aS'access to care'
p44354
aS'antiretroviral therapy'
p44355
aS'geographic information systems'
p44356
aS'loss to follow-up'
p44357
aS'time to start treatment'
p44358
aS'treatment'
p44359
asS'PST'
p44360
S'ppublish'
p44361
stRp44362
ag2
(g3
g4
(dp44363
S'LID'
p44364
S'10.1097/QAI.0b013e31828e1e2c [doi]'
p44365
sS'STAT'
p44366
S'MEDLINE'
p44367
sS'JT'
p44368
S'Journal of acquired immune deficiency syndromes (1999)'
p44369
sS'DA'
p44370
S'20130515'
p44371
sS'AID'
p44372
(lp44373
S'10.1097/QAI.0b013e31828e1e2c [doi]'
p44374
asS'CRDT'
p44375
(lp44376
S'2013/03/08 06:00'
p44377
asS'DP'
p44378
S'2013 Jun 1'
p44379
sS'AD'
p44380
S'Department of Child Health and Pediatrics, School of Medicine, College of Health Sciences, Moi University, Eldoret, Kenya. nyandikom@yahoo.com'
p44381
sS'OWN'
p44382
S'NLM'
p44383
sS'PT'
p44384
(lp44385
S'Journal Article'
p44386
aS"Research Support, U.S. Gov't, Non-P.H.S."
p44387
asS'LA'
p44388
(lp44389
S'eng'
p44390
asS'FAU'
p44391
(lp44392
S'Nyandiko, Winstone'
p44393
aS'Vreeman, Rachel'
p44394
aS'Liu, Hai'
p44395
aS'Shangani, Sylvia'
p44396
aS'Sang, Edwin'
p44397
aS'Ayaya, Samuel'
p44398
aS'Braitstein, Paula'
p44399
asS'PG'
p44400
S'e49-55'
p44401
sS'TI'
p44402
S'Nonadherence to clinic appointments among HIV-infected children in an ambulatory care program in western Kenya.'
p44403
sS'RN'
p44404
(lp44405
S'0 (Anti-HIV Agents)'
p44406
asS'PL'
p44407
S'United States'
p44408
sS'TA'
p44409
S'J Acquir Immune Defic Syndr'
p44410
sS'JID'
p44411
S'100892005'
p44412
sS'AB'
p44413
S'BACKGROUND: Nonadherence to clinic appointments is associated with poor outcomes in HIV-infected adults. We describe the effect of cumulative clinic adherence (CCA) to clinic appointments on mortality and loss to follow-up (LTFU) among HIV-infected children in Kenya. METHODS: We analyzed retrospective clinical data from HIV-infected children in the United States Agency for International Development-Academic Model Providing Access to Healthcare Partnership in Kenya between 2001 and 2009. We defined CCA as the proportion of days adherent to clinic visits after enrollment. We examined the effects of CCA on both death and LTFU, controlling for demographic and clinical factors at enrollment and over time. Cox proportional hazards models with time-varying coefficients were used to calculate adjusted hazard ratios (AHR) associated with each 10% increase in CCA on mortality and LTFU. RESULTS: Among 3255 HIV-infected children, 1668 (51.2%) were male, median enrollment age of 5.2 years (interquartile range: 3.6-7.4). Of 2393 children with CD4 within 3 months after enrollment, 1125 (47.0%) were severely immune suppressed, 567 became LTFU, and 88 died. Children with higher CCA had a higher risk of both mortality and LTFU at 3 and 6 months. Higher CCA became protective at 24 months for mortality, AHR at 24 months: 0.7 (95% confidence interval: 0.6 to 0.9), and at 12 months for LTFU, AHR at 24 months: 0.7 (95% confidence interval: 0.7 to 0.7). CONCLUSIONS: Children adherence to clinic visits during the first 6 months of HIV care was associated with a higher risk of death and LTFU, but by 24 months, children with better CCA had a reduced risk of LTFU and mortality.'
p44414
sS'GR'
p44415
(lp44416
S'623-A-00-08-00003-00/PEPFAR/United States'
p44417
asS'IP'
p44418
S'2'
sS'IS'
p44419
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p44420
sS'DCOM'
p44421
S'20130708'
p44422
sS'AU'
p44423
(lp44424
S'Nyandiko W'
p44425
aS'Vreeman R'
p44426
aS'Liu H'
p44427
aS'Shangani S'
p44428
aS'Sang E'
p44429
aS'Ayaya S'
p44430
aS'Braitstein P'
p44431
asS'VI'
p44432
S'63'
p44433
sS'MHDA'
p44434
S'2013/07/09 06:00'
p44435
sS'MH'
p44436
(lp44437
S'Acquired Immunodeficiency Syndrome/drug therapy/*mortality'
p44438
aS'Ambulatory Care'
p44439
aS'Ambulatory Care Facilities'
p44440
aS'Anti-HIV Agents/therapeutic use'
p44441
aS'Child'
p44442
aS'Child, Preschool'
p44443
aS'Female'
p44444
aS'Humans'
p44445
aS'Kenya'
p44446
aS'Male'
p44447
aS'Medication Adherence'
p44448
aS'*Patient Compliance'
p44449
aS'Retrospective Studies'
p44450
aS'Treatment Outcome'
p44451
asS'EDAT'
p44452
S'2013/03/08 06:00'
p44453
sS'SO'
p44454
S'J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):e49-55. doi: 10.1097/QAI.0b013e31828e1e2c.'
p44455
sS'SB'
p44456
S'IM X'
p44457
sS'PMID'
p44458
S'23466646'
p44459
sS'PST'
p44460
S'ppublish'
p44461
stRp44462
ag2
(g3
g4
(dp44463
S'LID'
p44464
S'10.1097/QAD.0b013e328360a4e5 [doi]'
p44465
sS'STAT'
p44466
S'MEDLINE'
p44467
sS'JT'
p44468
S'AIDS (London, England)'
p44469
sS'CIN'
p44470
(lp44471
S'AIDS. 2013 Jun 1;27(9):1509-11. PMID: 23759750'
p44472
asS'DA'
p44473
S'20130816'
p44474
sS'AID'
p44475
(lp44476
S'10.1097/QAD.0b013e328360a4e5 [doi]'
p44477
asS'CRDT'
p44478
(lp44479
S'2013/03/07 06:00'
p44480
asS'DP'
p44481
S'2013 Jun 1'
p44482
sS'GR'
p44483
(lp44484
S'5U01-AI069924-05/AI/NIAID NIH HHS/United States'
p44485
aS'G0600719/Medical Research Council/United Kingdom'
p44486
aS'MR/K010174/1/Medical Research Council/United Kingdom'
p44487
aS'U01 AI069924/AI/NIAID NIH HHS/United States'
p44488
asS'OWN'
p44489
S'NLM'
p44490
sS'PT'
p44491
(lp44492
S'Journal Article'
p44493
aS'Research Support, N.I.H., Extramural'
p44494
aS"Research Support, Non-U.S. Gov't"
p44495
asS'LA'
p44496
(lp44497
S'eng'
p44498
asS'FAU'
p44499
(lp44500
S'Estill, Janne'
p44501
aS'Egger, Matthias'
p44502
aS'Blaser, Nello'
p44503
aS'Vizcaya, Luisa Salazar'
p44504
aS'Garone, Daniela'
p44505
aS'Wood, Robin'
p44506
aS'Campbell, Jennifer'
p44507
aS'Hallett, Timothy B'
p44508
aS'Keiser, Olivia'
p44509
asS'LR'
p44510
S'20150922'
p44511
sS'PG'
p44512
S'1483-92'
p44513
sS'TI'
p44514
S'Cost-effectiveness of point-of-care viral load monitoring of antiretroviral therapy in resource-limited settings: mathematical modelling study.'
p44515
sS'RN'
p44516
(lp44517
S'0 (Anti-HIV Agents)'
p44518
asS'PL'
p44519
S'England'
p44520
sS'TA'
p44521
S'AIDS'
p44522
sS'JID'
p44523
S'8710219'
p44524
sS'AB'
p44525
S'BACKGROUND: Monitoring of HIV viral load in patients on combination antiretroviral therapy (ART) is not generally available in resource-limited settings. We examined the cost-effectiveness of qualitative point-of-care viral load tests (POC-VL) in sub-Saharan Africa. DESIGN: Mathematical model based on longitudinal data from the Gugulethu and Khayelitsha township ART programmes in Cape Town, South Africa. METHODS: Cohorts of patients on ART monitored by POC-VL, CD4 cell count or clinically were simulated. Scenario A considered the more accurate detection of treatment failure with POC-VL only, and scenario B also considered the effect on HIV transmission. Scenario C further assumed that the risk of virologic failure is halved with POC-VL due to improved adherence. We estimated the change in costs per quality-adjusted life-year gained (incremental cost-effectiveness ratios, ICERs) of POC-VL compared with CD4 and clinical monitoring. RESULTS: POC-VL tests with detection limits less than 1000 copies/ml increased costs due to unnecessary switches to second-line ART, without improving survival. Assuming POC-VL unit costs between US$5 and US$20 and detection limits between 1000 and 10,000 copies/ml, the ICER of POC-VL was US$4010-US$9230 compared with clinical and US$5960-US$25540 compared with CD4 cell count monitoring. In Scenario B, the corresponding ICERs were US$2450-US$5830 and US$2230-US$10380. In Scenario C, the ICER ranged between US$960 and US$2500 compared with clinical monitoring and between cost-saving and US$2460 compared with CD4 monitoring. CONCLUSION: The cost-effectiveness of POC-VL for monitoring ART is improved by a higher detection limit, by taking the reduction in new HIV infections into account and assuming that failure of first-line ART is reduced due to targeted adherence counselling.'
p44526
sS'AD'
p44527
S'Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. jestill@ispm.unibe.ch'
p44528
sS'CN'
p44529
(lp44530
S'IeDEA Southern Africa'
p44531
asS'IP'
p44532
S'9'
sS'IS'
p44533
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p44534
sS'PMC'
p44535
S'PMC3813830'
p44536
sS'DCOM'
p44537
S'20131031'
p44538
sS'MID'
p44539
(lp44540
S'NIHMS493896'
p44541
asS'AU'
p44542
(lp44543
S'Estill J'
p44544
aS'Egger M'
p44545
aS'Blaser N'
p44546
aS'Vizcaya LS'
p44547
aS'Garone D'
p44548
aS'Wood R'
p44549
aS'Campbell J'
p44550
aS'Hallett TB'
p44551
aS'Keiser O'
p44552
asS'VI'
p44553
S'27'
p44554
sS'MHDA'
p44555
S'2013/11/01 06:00'
p44556
sS'OID'
p44557
(lp44558
S'NLM: NIHMS493896'
p44559
aS'NLM: PMC3813830'
p44560
asS'MH'
p44561
(lp44562
S'Adult'
p44563
aS'Africa South of the Sahara'
p44564
aS'Anti-HIV Agents/*economics/therapeutic use'
p44565
aS'Cohort Studies'
p44566
aS'Cost-Benefit Analysis/economics'
p44567
aS'Female'
p44568
aS'HIV Infections/drug therapy/*economics'
p44569
aS'Humans'
p44570
aS'Male'
p44571
aS'Models, Theoretical'
p44572
aS'Patient Compliance'
p44573
aS'Point-of-Care Systems/*economics'
p44574
aS'Quality-Adjusted Life Years'
p44575
aS'Randomized Controlled Trials as Topic'
p44576
aS'Viral Load/drug effects'
p44577
asS'EDAT'
p44578
S'2013/03/07 06:00'
p44579
sS'SO'
p44580
S'AIDS. 2013 Jun 1;27(9):1483-92. doi: 10.1097/QAD.0b013e328360a4e5.'
p44581
sS'SB'
p44582
S'IM X'
p44583
sS'PMID'
p44584
S'23462219'
p44585
sS'PST'
p44586
S'ppublish'
p44587
stRp44588
ag2
(g3
g4
(dp44589
S'LID'
p44590
S'10.1371/journal.pone.0056248 [doi]'
p44591
sS'STAT'
p44592
S'MEDLINE'
p44593
sS'DEP'
p44594
S'20130215'
p44595
sS'DA'
p44596
S'20130304'
p44597
sS'AID'
p44598
(lp44599
S'10.1371/journal.pone.0056248 [doi]'
p44600
aS'PONE-D-12-31277 [pii]'
p44601
asS'CRDT'
p44602
(lp44603
S'2013/03/05 06:00'
p44604
asS'DP'
p44605
S'2013'
p44606
sS'AD'
p44607
S'The International Union Against Tuberculosis and Lung Disease, Paris, France. h_tweya@lighthouse.org.mw'
p44608
sS'OWN'
p44609
S'NLM'
p44610
sS'PT'
p44611
(lp44612
S'Comparative Study'
p44613
aS'Journal Article'
p44614
aS"Research Support, Non-U.S. Gov't"
p44615
aS"Research Support, U.S. Gov't, P.H.S."
p44616
asS'LA'
p44617
(lp44618
S'eng'
p44619
asS'FAU'
p44620
(lp44621
S'Tweya, Hannock'
p44622
aS'Feldacker, Caryl'
p44623
aS'Phiri, Sam'
p44624
aS'Ben-Smith, Anne'
p44625
aS'Fenner, Lukas'
p44626
aS'Jahn, Andreas'
p44627
aS'Kalulu, Mike'
p44628
aS'Weigel, Ralf'
p44629
aS'Kamba, Chancy'
p44630
aS'Banda, Rabecca'
p44631
aS'Egger, Matthias'
p44632
aS'Keiser, Olivia'
p44633
asS'JT'
p44634
S'PloS one'
p44635
sS'LR'
p44636
S'20150218'
p44637
sS'PG'
p44638
S'e56248'
p44639
sS'TI'
p44640
S'Comparison of treatment outcomes of new smear-positive pulmonary tuberculosis patients by HIV and antiretroviral status in a TB/HIV clinic, Malawi.'
p44641
sS'RN'
p44642
(lp44643
S'0 (Anti-Retroviral Agents)'
p44644
aS'0 (Antitubercular Agents)'
p44645
asS'PL'
p44646
S'United States'
p44647
sS'TA'
p44648
S'PLoS One'
p44649
sS'JID'
p44650
S'101285081'
p44651
sS'AB'
p44652
S"BACKGROUND: Smear-positive pulmonary TB is the most infectious form of TB. Previous studies on the effect of HIV and antiretroviral therapy on TB treatment outcomes among these highly infectious patients demonstrated conflicting results, reducing understanding of important issues. METHODS: All adult smear-positive pulmonary TB patients diagnosed between 2008 and 2010 in Malawi's largest public, integrated TB/HIV clinic were included in the study to assess treatment outcomes by HIV and antiretroviral therapy status using logistic regression. RESULTS: Of 2,361 new smear-positive pulmonary TB patients, 86% had successful treatment outcome (were cured or completed treatment), 5% died, 6% were lost to follow-up, 1% failed treatment, and 2% transferred-out. Overall HIV prevalence was 56%. After adjusting for gender, age and TB registration year, treatment success was higher among HIV-negative than HIV-positive patients (adjusted odds ratio 1.49; 95% CI: 1.14-1.94). Of 1,275 HIV-infected pulmonary TB patients, 492 (38%) received antiretroviral therapy during the study. Pulmonary TB patients on antiretroviral therapy were more likely to have successful treatment outcomes than those not on ART (adjusted odds ratio : 1.83; 95% CI: 1.29-2.60). CONCLUSION: HIV co-infection was associated with poor TB treatment outcomes. Despite high HIV prevalence and the integrated TB/HIV setting, only a minority of patients started antiretroviral therapy. Intensified patient education and provider training on the benefits of antiretroviral therapy could increase antiretroviral therapy uptake and improve TB treatment success among these most infectious patients."
p44653
sS'GR'
p44654
(lp44655
S'3 U01 AI069924-05S1/PEPFAR/United States'
p44656
aS'U01 AI069924/AI/NIAID NIH HHS/United States'
p44657
aS'U01AI069924/AI/NIAID NIH HHS/United States'
p44658
aS'U91HA06801/PHS HHS/United States'
p44659
asS'IP'
p44660
S'2'
sS'IS'
p44661
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p44662
sS'PMC'
p44663
S'PMC3574145'
p44664
sS'DCOM'
p44665
S'20130826'
p44666
sS'AU'
p44667
(lp44668
S'Tweya H'
p44669
aS'Feldacker C'
p44670
aS'Phiri S'
p44671
aS'Ben-Smith A'
p44672
aS'Fenner L'
p44673
aS'Jahn A'
p44674
aS'Kalulu M'
p44675
aS'Weigel R'
p44676
aS'Kamba C'
p44677
aS'Banda R'
p44678
aS'Egger M'
p44679
aS'Keiser O'
p44680
asS'VI'
p44681
S'8'
sS'MHDA'
p44682
S'2013/08/27 06:00'
p44683
sS'PHST'
p44684
(lp44685
S'2012/10/09 [received]'
p44686
aS'2013/01/07 [accepted]'
p44687
aS'2013/02/15 [epublish]'
p44688
asS'OID'
p44689
(lp44690
S'NLM: PMC3574145'
p44691
asS'MH'
p44692
(lp44693
S'Adolescent'
p44694
aS'Adult'
p44695
aS'Anti-Retroviral Agents/*therapeutic use'
p44696
aS'Antitubercular Agents/*therapeutic use'
p44697
aS'Coinfection/complications/drug therapy'
p44698
aS'Female'
p44699
aS'HIV/drug effects/isolation & purification'
p44700
aS'HIV Infections/*complications/*drug therapy/epidemiology'
p44701
aS'Humans'
p44702
aS'Lung/microbiology/virology'
p44703
aS'Malawi/epidemiology'
p44704
aS'Male'
p44705
aS'Middle Aged'
p44706
aS'Mycobacterium tuberculosis/drug effects/isolation & purification'
p44707
aS'Treatment Outcome'
p44708
aS'Tuberculosis, Pulmonary/*complications/diagnosis/*drug therapy/epidemiology'
p44709
aS'Young Adult'
p44710
asS'EDAT'
p44711
S'2013/03/05 06:00'
p44712
sS'SO'
p44713
S'PLoS One. 2013;8(2):e56248. doi: 10.1371/journal.pone.0056248. Epub 2013 Feb 15.'
p44714
sS'SB'
p44715
S'IM'
p44716
sS'PMID'
p44717
S'23457534'
p44718
sS'PST'
p44719
S'ppublish'
p44720
stRp44721
ag2
(g3
g4
(dp44722
S'LID'
p44723
S'10.1371/journal.pone.0054435 [doi]'
p44724
sS'STAT'
p44725
S'MEDLINE'
p44726
sS'DEP'
p44727
S'20130215'
p44728
sS'DA'
p44729
S'20130304'
p44730
sS'AID'
p44731
(lp44732
S'10.1371/journal.pone.0054435 [doi]'
p44733
aS'PONE-D-12-29564 [pii]'
p44734
asS'CRDT'
p44735
(lp44736
S'2013/03/05 06:00'
p44737
asS'DP'
p44738
S'2013'
p44739
sS'OWN'
p44740
S'NLM'
p44741
sS'PT'
p44742
(lp44743
S'Journal Article'
p44744
aS"Research Support, Non-U.S. Gov't"
p44745
asS'LA'
p44746
(lp44747
S'eng'
p44748
asS'FAU'
p44749
(lp44750
S'Schneider, Karen'
p44751
aS'Nwizu, Chidi'
p44752
aS'Kaplan, Richard'
p44753
aS'Anderson, Jonathan'
p44754
aS'Wilson, David P'
p44755
aS'Emery, Sean'
p44756
aS'Cooper, David A'
p44757
aS'Boyd, Mark A'
p44758
asS'JT'
p44759
S'PloS one'
p44760
sS'LR'
p44761
S'20151119'
p44762
sS'PG'
p44763
S'e54435'
p44764
sS'TI'
p44765
S'The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South Africa.'
p44766
sS'RN'
p44767
(lp44768
S'0 (HIV Protease Inhibitors)'
p44769
aS'0 (Pyrrolidinones)'
p44770
aS'2494G1JF75 (Lopinavir)'
p44771
aS'43Y000U234 (Raltegravir Potassium)'
p44772
aS'O3J8G9O825 (Ritonavir)'
p44773
asS'PL'
p44774
S'United States'
p44775
sS'TA'
p44776
S'PLoS One'
p44777
sS'JID'
p44778
S'101285081'
p44779
sS'AB'
p44780
S'BACKGROUND: There is an urgent need to improve the evidence base for provision of second-line antiretroviral therapy (ART) following first-line virological failure. This is particularly the case in Sub-Saharan Africa where 70% of all people living with HIV/AIDS (PHA) reside. The aim of this study was to simulate the potential risks and benefits of treatment simplification in second-line therapy compared to the current standard of care (SOC) in a lower-middle income and an upper-middle income country in Sub-Saharan Africa. METHODS: We developed a microsimulation model to compare outcomes associated with reducing treatment discontinuations between current SOC for second-line therapy in South Africa and Nigeria and an alternative regimen: ritonavir-boosted lopinavir (LPV/r) combined with raltegravir (RAL). We used published studies and collaborating sites to estimate efficacy, adverse effect and cost. Model outcomes were reported as incremental cost effectiveness ratios (ICERs) in 2011 USD per quality adjusted life year ($/QALY) gained. RESULTS: Reducing treatment discontinuations with LPV/r+RAL resulted in an additional 0.4 discounted QALYs and increased the undiscounted life expectancy by 0.8 years per person compared to the current SOC. The average incremental cost was $6,525 per treated patient in Nigeria and $4,409 per treated patient in South Africa. The cost-effectiveness ratios were $16,302/QALY gained and $11,085/QALY gained for Nigeria and South Africa, respectively. Our results were sensitive to the probability of ART discontinuation and the unit cost for RAL. CONCLUSIONS: The combination of raltegravir and ritonavir-boosted lopinavir was projected to be cost-effective in South Africa. However, at its current price, it is unlikely to be cost-effective in Nigeria.'
p44781
sS'AD'
p44782
S'The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, New South Wales, Australia. KSchneider@kirby.unsw.edu.au'
p44783
sS'IP'
p44784
S'2'
sS'IS'
p44785
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p44786
sS'PMC'
p44787
S'PMC3574122'
p44788
sS'DCOM'
p44789
S'20130826'
p44790
sS'AU'
p44791
(lp44792
S'Schneider K'
p44793
aS'Nwizu C'
p44794
aS'Kaplan R'
p44795
aS'Anderson J'
p44796
aS'Wilson DP'
p44797
aS'Emery S'
p44798
aS'Cooper DA'
p44799
aS'Boyd MA'
p44800
asS'VI'
p44801
S'8'
sS'MHDA'
p44802
S'2013/08/27 06:00'
p44803
sS'PHST'
p44804
(lp44805
S'2012/09/25 [received]'
p44806
aS'2012/12/11 [accepted]'
p44807
aS'2013/02/15 [epublish]'
p44808
asS'OID'
p44809
(lp44810
S'NLM: PMC3574122'
p44811
asS'MH'
p44812
(lp44813
S'Antiretroviral Therapy, Highly Active/adverse effects/economics/methods'
p44814
aS'Cost-Benefit Analysis'
p44815
aS'HIV Infections/*drug therapy/*economics'
p44816
aS'HIV Protease Inhibitors/adverse effects/*economics/*therapeutic use'
p44817
aS'Humans'
p44818
aS'Lopinavir/adverse effects/economics/therapeutic use'
p44819
aS'Models, Biological'
p44820
aS'Models, Economic'
p44821
aS'Nigeria'
p44822
aS'Pyrrolidinones/adverse effects/economics/therapeutic use'
p44823
aS'Quality-Adjusted Life Years'
p44824
aS'Raltegravir Potassium'
p44825
aS'Ritonavir/adverse effects/*economics/*therapeutic use'
p44826
aS'South Africa'
p44827
asS'EDAT'
p44828
S'2013/03/05 06:00'
p44829
sS'SO'
p44830
S'PLoS One. 2013;8(2):e54435. doi: 10.1371/journal.pone.0054435. Epub 2013 Feb 15.'
p44831
sS'SB'
p44832
S'IM'
p44833
sS'PMID'
p44834
S'23457450'
p44835
sS'PST'
p44836
S'ppublish'
p44837
stRp44838
ag2
(g3
g4
(dp44839
S'LID'
p44840
S'10.1186/1475-2875-12-81 [doi]'
p44841
sS'STAT'
p44842
S'MEDLINE'
p44843
sS'DEP'
p44844
S'20130301'
p44845
sS'DA'
p44846
S'20130403'
p44847
sS'AID'
p44848
(lp44849
S'1475-2875-12-81 [pii]'
p44850
aS'10.1186/1475-2875-12-81 [doi]'
p44851
asS'CRDT'
p44852
(lp44853
S'2013/03/05 06:00'
p44854
asS'DP'
p44855
S'2013'
p44856
sS'AD'
p44857
S'Malaria Public Health Department, Kenya Medical Research Institute-Wellcome Trust Research Programme, Nairobi, Kenya. bethkangwana@gmail.com'
p44858
sS'OWN'
p44859
S'NLM'
p44860
sS'PT'
p44861
(lp44862
S'Journal Article'
p44863
aS'Randomized Controlled Trial'
p44864
aS"Research Support, Non-U.S. Gov't"
p44865
asS'LA'
p44866
(lp44867
S'eng'
p44868
asS'DCOM'
p44869
S'20130909'
p44870
sS'JT'
p44871
S'Malaria journal'
p44872
sS'LR'
p44873
S'20150218'
p44874
sS'FAU'
p44875
(lp44876
S'Kangwana, Beth P'
p44877
aS'Kedenge, Sarah V'
p44878
aS'Noor, Abdisalan M'
p44879
aS'Alegana, Victor A'
p44880
aS'Nyandigisi, Andrew J'
p44881
aS'Pandit, Jayesh'
p44882
aS'Fegan, Greg W'
p44883
aS'Todd, Jim E'
p44884
aS'Snow, Robert W'
p44885
aS'Goodman, Catherine A'
p44886
asS'TI'
p44887
S'The effect of an anti-malarial subsidy programme on the quality of service provision of artemisinin-based combination therapy in Kenya: a cluster-randomized, controlled trial.'
p44888
sS'RN'
p44889
(lp44890
S'0 (Antimalarials)'
p44891
aS'0 (Artemisinins)'
p44892
aS'9RMU91N5K2 (artemisinine)'
p44893
asS'PL'
p44894
S'England'
p44895
sS'PG'
p44896
S'81'
p44897
sS'JID'
p44898
S'101139802'
p44899
sS'AB'
p44900
S'BACKGROUND: Many patients with suspected malaria in sub-Saharan Africa seek treatment from private providers, but this sector suffers from sub-standard medicine dispensing practices. To improve the quality of care received for presumptive malaria from the highly accessed private retail sector in western Kenya, subsidized pre-packaged artemether-lumefantrine (AL) was provided to private retailers, together with a one day training for retail staff on malaria diagnosis and treatment, job aids and community engagement activities. METHODS: The intervention was assessed using a cluster-randomized, controlled design. Provider and mystery-shopper cross-sectional surveys were conducted at baseline and eight months post-intervention to assess provider practices. Data were analysed based on cluster-level summaries, comparing control and intervention arms. RESULTS: On average, 564 retail outlets were interviewed per year. At follow-up, 43% of respondents reported that at least one staff member had attended the training in the intervention arm. The intervention significantly increased the percentage of providers knowing the first line treatment for uncomplicated malaria by 24.2% points (confidence interval (CI): 14.8%, 33.6%; adjusted p=0.0001); the percentage of outlets stocking AL by 31.7% points (CI: 22.0%, 41.3%; adjusted p=0.0001); and the percentage of providers prescribing AL for presumptive malaria by 23.6% points (CI: 18.7%, 28.6%; adjusted p=0.0001). Generally outlets that received training and job aids performed better than those receiving one or none of these intervention components. CONCLUSION: Overall, subsidizing ACT and retailer training can significantly increase the percentage of outlets stocking and selling AL for the presumptive treatment of malaria, but further research is needed on strategies to improve the provision of counselling advice to retail customers.'
p44901
sS'GR'
p44902
(lp44903
S'#079081/Wellcome Trust/United Kingdom'
p44904
aS'#081829/Wellcome Trust/United Kingdom'
p44905
aS'079080/Wellcome Trust/United Kingdom'
p44906
aS'092654/Wellcome Trust/United Kingdom'
p44907
asS'VI'
p44908
S'12'
p44909
sS'IS'
p44910
S'1475-2875 (Electronic) 1475-2875 (Linking)'
p44911
sS'PMC'
p44912
S'PMC3614520'
p44913
sS'AU'
p44914
(lp44915
S'Kangwana BP'
p44916
aS'Kedenge SV'
p44917
aS'Noor AM'
p44918
aS'Alegana VA'
p44919
aS'Nyandigisi AJ'
p44920
aS'Pandit J'
p44921
aS'Fegan GW'
p44922
aS'Todd JE'
p44923
aS'Snow RW'
p44924
aS'Goodman CA'
p44925
asS'MHDA'
p44926
S'2013/09/10 06:00'
p44927
sS'PHST'
p44928
(lp44929
S'2012/11/16 [received]'
p44930
aS'2013/02/18 [accepted]'
p44931
aS'2013/03/01 [aheadofprint]'
p44932
asS'OID'
p44933
(lp44934
S'NLM: PMC3614520'
p44935
asS'MH'
p44936
(lp44937
S'Antimalarials/*supply & distribution/*therapeutic use'
p44938
aS'Artemisinins/*supply & distribution/*therapeutic use'
p44939
aS'Child, Preschool'
p44940
aS'Cross-Sectional Studies'
p44941
aS'Drug Therapy, Combination/methods/standards'
p44942
aS'Female'
p44943
aS'Health Services Research'
p44944
aS'Humans'
p44945
aS'Infant'
p44946
aS'Kenya'
p44947
aS'Malaria/*drug therapy'
p44948
aS'Male'
p44949
aS'Pharmacies'
p44950
aS'*Quality of Health Care'
p44951
asS'EDAT'
p44952
S'2013/03/05 06:00'
p44953
sS'SO'
p44954
S'Malar J. 2013 Mar 1;12:81. doi: 10.1186/1475-2875-12-81.'
p44955
sS'SB'
p44956
S'IM'
p44957
sS'PMID'
p44958
S'23452547'
p44959
sS'TA'
p44960
S'Malar J'
p44961
sS'PST'
p44962
S'epublish'
p44963
stRp44964
ag2
(g3
g4
(dp44965
S'LID'
p44966
S'10.1093/cid/cit120 [doi]'
p44967
sS'STAT'
p44968
S'MEDLINE'
p44969
sS'DEP'
p44970
S'20130228'
p44971
sS'DA'
p44972
S'20130521'
p44973
sS'AID'
p44974
(lp44975
S'cit120 [pii]'
p44976
aS'10.1093/cid/cit120 [doi]'
p44977
asS'CRDT'
p44978
(lp44979
S'2013/03/02 06:00'
p44980
asS'DP'
p44981
S'2013 Jun'
p44982
sS'OWN'
p44983
S'NLM'
p44984
sS'PT'
p44985
(lp44986
S'Journal Article'
p44987
aS"Research Support, Non-U.S. Gov't"
p44988
aS"Research Support, U.S. Gov't, Non-P.H.S."
p44989
asS'LA'
p44990
(lp44991
S'eng'
p44992
asS'FAU'
p44993
(lp44994
S'Liu, Enju'
p44995
aS'Armstrong, Catharina'
p44996
aS'Spiegelman, Donna'
p44997
aS'Chalamilla, Guerino'
p44998
aS'Njelekela, Marina'
p44999
aS'Hawkins, Claudia'
p45000
aS'Hertzmark, Ellen'
p45001
aS'Li, Nan'
p45002
aS'Aris, Eric'
p45003
aS'Muhihi, Alfa'
p45004
aS'Semu, Helen'
p45005
aS'Fawzi, Wafaie'
p45006
asS'JT'
p45007
S'Clinical infectious diseases : an official publication of the Infectious Diseases Society of America'
p45008
sS'PG'
p45009
S'1820-8'
p45010
sS'TI'
p45011
S'First-line antiretroviral therapy and changes in lipid levels over 3 years among HIV-infected adults in Tanzania.'
p45012
sS'RN'
p45013
(lp45014
S'0 (Anti-Retroviral Agents)'
p45015
aS'0 (Lipids)'
p45016
asS'PL'
p45017
S'United States'
p45018
sS'TA'
p45019
S'Clin Infect Dis'
p45020
sS'JID'
p45021
S'9203213'
p45022
sS'AB'
p45023
S'BACKGROUND: With the rapid rollout of antiretroviral therapy (ART) in sub-Saharan Africa (SSA), there has been an increasing concern about cardiovascular risks related to ART. However, data from human immunodeficiency virus (HIV)-infected populations from this region are very limited. METHODS: Among 6385 HIV-infected adults in Dar es Salaam, Tanzania, we investigated the nonfasting lipid changes over 3 years following ART initiation and their associations with different first-line ART agents that are commonly used in SSA. RESULTS: In the first 6 months of ART, the prevalence of dyslipidemia decreased from 69% to 54%, with triglyceride (TG) decreasing from 127 mg/dL to 113 mg/dL and high-density lipoprotein (HDL) cholesterol increasing from 39 mg/dL to 52 mg/dL. After 6 months, TG returned to its baseline level and increased to 139 mg/dL at 3 years; total cholesterol and low-density lipoprotein cholesterol continued to increase whereas HDL cholesterol leveled off. The prevalence of dyslipidemia increased to 73% after a 3-year follow-up. In multivariate analyses, patients on zidovudine-containing regimens had a greater reduction in TG levels at 6 months (-16.0 vs -6.3 mg/dL), and a lower increase at 3 years compared to patients on stavudine-containing regimens (2.1 vs 11.7 mg/dL, P < .001); patients on nevirapine-based regimens had a higher increase in HDL cholesterol levels at 3 years compared to those on efavirenz-based regimens (13.6 vs 9.5 mg/dL, P = .01). CONCLUSIONS: Our findings support the latest World Health Organization guidelines on the substitution of stavudine in first-line ART in resource-limited settings, and provide further evidence for selection of lipid-friendly ART for patients in SSA.'
p45024
sS'AD'
p45025
S'Department of Global Health and Population, Harvard School of Public Health, 1633 Tremont St, Rm 106, Boston, MA 02120, USA. eliu@hsph.harvard.edu'
p45026
sS'IP'
p45027
S'12'
p45028
sS'IS'
p45029
S'1537-6591 (Electronic) 1058-4838 (Linking)'
p45030
sS'DCOM'
p45031
S'20140312'
p45032
sS'AU'
p45033
(lp45034
S'Liu E'
p45035
aS'Armstrong C'
p45036
aS'Spiegelman D'
p45037
aS'Chalamilla G'
p45038
aS'Njelekela M'
p45039
aS'Hawkins C'
p45040
aS'Hertzmark E'
p45041
aS'Li N'
p45042
aS'Aris E'
p45043
aS'Muhihi A'
p45044
aS'Semu H'
p45045
aS'Fawzi W'
p45046
asS'VI'
p45047
S'56'
p45048
sS'MHDA'
p45049
S'2014/03/13 06:00'
p45050
sS'PHST'
p45051
(lp45052
S'2013/02/28 [aheadofprint]'
p45053
aS'2013/04/02 [aheadofprint]'
p45054
asS'OTO'
p45055
(lp45056
S'NOTNLM'
p45057
asS'MH'
p45058
(lp45059
S'Adult'
p45060
aS'Analysis of Variance'
p45061
aS'Anti-Retroviral Agents/therapeutic use'
p45062
aS'Dyslipidemias/*blood/*virology'
p45063
aS'Female'
p45064
aS'HIV Infections/*blood/*drug therapy'
p45065
aS'Humans'
p45066
aS'Lipids/*blood'
p45067
aS'Longitudinal Studies'
p45068
aS'Male'
p45069
aS'Prevalence'
p45070
aS'Risk Factors'
p45071
aS'Tanzania'
p45072
asS'EDAT'
p45073
S'2013/03/02 06:00'
p45074
sS'SO'
p45075
S'Clin Infect Dis. 2013 Jun;56(12):1820-8. doi: 10.1093/cid/cit120. Epub 2013 Feb 28.'
p45076
sS'SB'
p45077
S'IM'
p45078
sS'PMID'
p45079
S'23449270'
p45080
sS'OT'
p45081
(lp45082
S'HIV'
p45083
aS'adults'
p45084
aS'antiretroviral therapy'
p45085
aS'cholesterol'
p45086
aS'triglyceride'
p45087
asS'PST'
p45088
S'ppublish'
p45089
stRp45090
ag2
(g3
g4
(dp45091
S'LID'
p45092
S'10.1177/2325957412470722 [doi]'
p45093
sS'STAT'
p45094
S'MEDLINE'
p45095
sS'DEP'
p45096
S'20130226'
p45097
sS'CI'
p45098
(lp45099
S'(c) The Author(s) 2013.'
p45100
asS'DA'
p45101
S'20150115'
p45102
sS'AID'
p45103
(lp45104
S'2325957412470722 [pii]'
p45105
aS'10.1177/2325957412470722 [doi]'
p45106
asS'CRDT'
p45107
(lp45108
S'2013/02/28 06:00'
p45109
asS'DP'
p45110
S'2015 Jan-Feb'
p45111
sS'OWN'
p45112
S'NLM'
p45113
sS'PT'
p45114
(lp45115
S'Journal Article'
p45116
asS'LA'
p45117
(lp45118
S'eng'
p45119
asS'FAU'
p45120
(lp45121
S'Tieno, Herve'
p45122
aS'Guira, Oumar'
p45123
aS'Sagna, Yempabou'
p45124
aS'Diendere, Eric Arnaud'
p45125
aS'Diallo, Ismael'
p45126
aS'Bognounou, Rene'
p45127
aS'Zoungrana, Lassane'
p45128
aS'Zida, Seidou'
p45129
aS'Nikiema, Pere'
p45130
aS'Drabo, Youssouf Joseph'
p45131
asS'JT'
p45132
S'Journal of the International Association of Providers of AIDS Care'
p45133
sS'LR'
p45134
S'20160517'
p45135
sS'PG'
p45136
S'40-5'
p45137
sS'TI'
p45138
S'Characteristics and follow-up of newly managed HIV-infected patients in the national referral center in Ouagadougou, Burkina Faso.'
p45139
sS'RN'
p45140
(lp45141
S'0 (Anti-Retroviral Agents)'
p45142
asS'PL'
p45143
S'United States'
p45144
sS'TA'
p45145
S'J Int Assoc Provid AIDS Care'
p45146
sS'JID'
p45147
S'101603896'
p45148
sS'AB'
p45149
S'BACKGROUND: In sub-Saharan countries, HIV testing and treatment facilities are available, especially at subsidized rates for the past few years. METHODS: A prospective and descriptive review was conducted at Yalgado Ouedraogo Teaching Hospital Internal Medicine department in Ouagadougou, using personal case report forms, between June 2009 and August 2010 in all newly diagnosed adults with positive HIV antibody. RESULTS: The study participants consisted of 191 patients at a median age of 37 years (range, 18-65 years) and sex ratio (men/women): 0.66. In all, 110 (57.6%) patients were symptomatic. Fourteen patients were lost to follow-up. Of the 177 patients, 144 had CD4 count <350 cells/mm(3) and all have been treated. At the ninth month, weight gain and immune restoration were significant (P < .01); only 79 of the 144 patients had viral load measurement, and 76 of the 79 were undetectable. Mortality rate of treated patients was 6.25%. CONCLUSION: Laboratory tests and highly active antiretroviral therapy make the management of patients easier, but a majority of them still presented late and were still lost to follow-up. Nevertheless, we have excellent treatment success.'
p45150
sS'AD'
p45151
S'Service de Medecine Interne, Centre Hospitalier Universitaire Yalgado Ouedraogo, Ouagadougou, Burkina Faso. Service de Medecine Interne, Centre Hospitalier Universitaire Yalgado Ouedraogo, Ouagadougou, Burkina Faso. Service de Medecine Interne, Centre Hospitalier Universitaire Yalgado Ouedraogo, Ouagadougou, Burkina Faso my_sagna@yahoo.fr. Service de Medecine Interne, Centre Hospitalier Universitaire Yalgado Ouedraogo, Ouagadougou, Burkina Faso. Service de Medecine Interne, Centre Hospitalier Universitaire Yalgado Ouedraogo, Ouagadougou, Burkina Faso. Service de Medecine Interne, Centre Hospitalier Universitaire Yalgado Ouedraogo, Ouagadougou, Burkina Faso. Service de Medecine Interne, Centre Hospitalier Universitaire Yalgado Ouedraogo, Ouagadougou, Burkina Faso. Service de Medecine Interne, Centre Hospitalier Universitaire Yalgado Ouedraogo, Ouagadougou, Burkina Faso. Service de Medecine Interne, Centre Hospitalier Universitaire Yalgado Ouedraogo, Ouagadougou, Burkina Faso. Service de Medecine Interne, Centre Hospitalier Universitaire Yalgado Ouedraogo, Ouagadougou, Burkina Faso.'
p45152
sS'IP'
p45153
S'1'
sS'IS'
p45154
S'2325-9574 (Print) 2325-9574 (Linking)'
p45155
sS'DCOM'
p45156
S'20150331'
p45157
sS'AU'
p45158
(lp45159
S'Tieno H'
p45160
aS'Guira O'
p45161
aS'Sagna Y'
p45162
aS'Diendere EA'
p45163
aS'Diallo I'
p45164
aS'Bognounou R'
p45165
aS'Zoungrana L'
p45166
aS'Zida S'
p45167
aS'Nikiema P'
p45168
aS'Drabo YJ'
p45169
asS'VI'
p45170
S'14'
p45171
sS'MHDA'
p45172
S'2015/04/01 06:00'
p45173
sS'PHST'
p45174
(lp45175
S'2013/02/26 [aheadofprint]'
p45176
asS'OTO'
p45177
(lp45178
S'NOTNLM'
p45179
asS'MH'
p45180
(lp45181
S'Adolescent'
p45182
aS'Adult'
p45183
aS'Anti-Retroviral Agents/therapeutic use'
p45184
aS'Antiretroviral Therapy, Highly Active'
p45185
aS'Body Mass Index'
p45186
aS'Burkina Faso/epidemiology'
p45187
aS'CD4 Lymphocyte Count'
p45188
aS'Female'
p45189
aS'HIV Infections/drug therapy/*epidemiology/physiopathology'
p45190
aS'Humans'
p45191
aS'Male'
p45192
aS'Middle Aged'
p45193
aS'Prospective Studies'
p45194
aS'Young Adult'
p45195
asS'EDAT'
p45196
S'2013/02/28 06:00'
p45197
sS'SO'
p45198
S'J Int Assoc Provid AIDS Care. 2015 Jan-Feb;14(1):40-5. doi: 10.1177/2325957412470722. Epub 2013 Feb 26.'
p45199
sS'SB'
p45200
S'IM'
p45201
sS'PMID'
p45202
S'23442563'
p45203
sS'OT'
p45204
(lp45205
S'AIDS'
p45206
aS'Burkina Faso'
p45207
aS'HIV'
p45208
aS'newly managed patients'
p45209
aS'sub-Saharan Africa'
p45210
asS'PST'
p45211
S'ppublish'
p45212
stRp45213
ag2
(g3
g4
(dp45214
S'LID'
p45215
S'10.1371/journal.pone.0056446 [doi]'
p45216
sS'STAT'
p45217
S'MEDLINE'
p45218
sS'DEP'
p45219
S'20130220'
p45220
sS'DA'
p45221
S'20130225'
p45222
sS'AID'
p45223
(lp45224
S'10.1371/journal.pone.0056446 [doi]'
p45225
aS'PONE-D-12-19754 [pii]'
p45226
asS'CRDT'
p45227
(lp45228
S'2013/02/26 06:00'
p45229
asS'DP'
p45230
S'2013'
p45231
sS'AD'
p45232
S'Division of International and Environmental Health, Institute of Social and Preventive Medicine, University of Bern, Switzerland.'
p45233
sS'OWN'
p45234
S'NLM'
p45235
sS'PT'
p45236
(lp45237
S'Journal Article'
p45238
aS'Meta-Analysis'
p45239
aS'Research Support, N.I.H., Extramural'
p45240
aS"Research Support, Non-U.S. Gov't"
p45241
asS'LA'
p45242
(lp45243
S'eng'
p45244
asS'FAU'
p45245
(lp45246
S'Mugglin, Catrina'
p45247
aS'Wandeler, Gilles'
p45248
aS'Estill, Janne'
p45249
aS'Egger, Matthias'
p45250
aS'Bender, Nicole'
p45251
aS'Davies, Mary-Ann'
p45252
aS'Keiser, Olivia'
p45253
asS'JT'
p45254
S'PloS one'
p45255
sS'LR'
p45256
S'20150219'
p45257
sS'PG'
p45258
S'e56446'
p45259
sS'TI'
p45260
S'Retention in care of HIV-infected children from HIV test to start of antiretroviral therapy: systematic review.'
p45261
sS'RN'
p45262
(lp45263
S'0 (Anti-HIV Agents)'
p45264
asS'PL'
p45265
S'United States'
p45266
sS'TA'
p45267
S'PLoS One'
p45268
sS'JID'
p45269
S'101285081'
p45270
sS'AB'
p45271
S'BACKGROUND: In adults it is well documented that there are substantial losses to the programme between HIV testing and start of antiretroviral therapy (ART). The magnitude and reasons for loss to follow-up and death between HIV diagnosis and start of ART in children are not well defined. METHODS: We searched the PubMed and EMBASE databases for studies on children followed between HIV diagnosis and start of ART in low-income settings. We examined the proportion of children with a CD4 cell count/percentage after after being diagnosed with HIV infection, the number of treatment-eligible children starting ART and predictors of loss to programme. Data were extracted in duplicate. RESULTS: Eight studies from sub-Saharan Africa and two studies from Asia with a total of 10,741 children were included. Median age ranged from 2.2 to 6.5 years. Between 78.0 and 97.0% of HIV-infected children subsequently had a CD4 cell count/percentage measured, 63.2 to 90.7% of children with an eligibility assessment met the eligibility criteria for the particular setting and time and 39.5 to 99.4% of the eligible children started ART. Three studies reported an association between low CD4 count/percentage and ART initiation while no association was reported for gender. Only two studies reported on pre-ART mortality and found rates of 13 and 6 per 100 person-years. CONCLUSION: Most children who presented for HIV care met eligibility criteria for ART. There is an urgent need for strategies to improve the access to and retention to care of HIV-infected children in resource-limited settings.'
p45272
sS'GR'
p45273
(lp45274
S'5U01-AI069924-05/AI/NIAID NIH HHS/United States'
p45275
aS'U01 AI069924/AI/NIAID NIH HHS/United States'
p45276
asS'IP'
p45277
S'2'
sS'IS'
p45278
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p45279
sS'PMC'
p45280
S'PMC3577897'
p45281
sS'DCOM'
p45282
S'20130910'
p45283
sS'AU'
p45284
(lp45285
S'Mugglin C'
p45286
aS'Wandeler G'
p45287
aS'Estill J'
p45288
aS'Egger M'
p45289
aS'Bender N'
p45290
aS'Davies MA'
p45291
aS'Keiser O'
p45292
asS'VI'
p45293
S'8'
sS'MHDA'
p45294
S'2013/09/11 06:00'
p45295
sS'PHST'
p45296
(lp45297
S'2012/07/06 [received]'
p45298
aS'2013/01/14 [accepted]'
p45299
aS'2013/02/20 [epublish]'
p45300
asS'OID'
p45301
(lp45302
S'NLM: PMC3577897'
p45303
asS'MH'
p45304
(lp45305
S'Adolescent'
p45306
aS'Adult'
p45307
aS'Africa South of the Sahara'
p45308
aS'Anti-HIV Agents/administration & dosage'
p45309
aS'Antiretroviral Therapy, Highly Active'
p45310
aS'Asia'
p45311
aS'CD4 Lymphocyte Count'
p45312
aS'Child'
p45313
aS'Child, Preschool'
p45314
aS'Drug Administration Schedule'
p45315
aS'Female'
p45316
aS'HIV/*isolation & purification/pathogenicity'
p45317
aS'HIV Infections/diagnosis/*drug therapy/*epidemiology/virology'
p45318
aS'HIV Seropositivity/drug therapy/*epidemiology'
p45319
aS'Health Services Needs and Demand'
p45320
aS'Humans'
p45321
aS'Infant'
p45322
aS'Infant, Newborn'
p45323
aS'Male'
p45324
aS'Patient Acceptance of Health Care'
p45325
aS'PubMed'
p45326
aS'Survival Rate'
p45327
asS'EDAT'
p45328
S'2013/02/26 06:00'
p45329
sS'SO'
p45330
S'PLoS One. 2013;8(2):e56446. doi: 10.1371/journal.pone.0056446. Epub 2013 Feb 20.'
p45331
sS'SB'
p45332
S'IM'
p45333
sS'PMID'
p45334
S'23437135'
p45335
sS'PST'
p45336
S'ppublish'
p45337
stRp45338
ag2
(g3
g4
(dp45339
S'LID'
p45340
S'10.1016/S1473-3099(13)70007-0 [doi] S1473-3099(13)70007-0 [pii]'
p45341
sS'STAT'
p45342
S'MEDLINE'
p45343
sS'DEP'
p45344
S'20130220'
p45345
sS'CI'
p45346
(lp45347
S'Copyright (c) 2013 Elsevier Ltd. All rights reserved.'
p45348
asS'DA'
p45349
S'20130329'
p45350
sS'AID'
p45351
(lp45352
S'S1473-3099(13)70007-0 [pii]'
p45353
aS'10.1016/S1473-3099(13)70007-0 [doi]'
p45354
asS'CRDT'
p45355
(lp45356
S'2013/02/26 06:00'
p45357
asS'DP'
p45358
S'2013 Apr'
p45359
sS'AD'
p45360
S'Epicentre, Paris, France. maryline.bonnet@geneva.msf.org'
p45361
sS'OWN'
p45362
S'NLM'
p45363
sS'PT'
p45364
(lp45365
S'Comparative Study'
p45366
aS'Journal Article'
p45367
aS'Multicenter Study'
p45368
aS'Randomized Controlled Trial'
p45369
aS"Research Support, Non-U.S. Gov't"
p45370
asS'LA'
p45371
(lp45372
S'eng'
p45373
asS'FAU'
p45374
(lp45375
S'Bonnet, Maryline'
p45376
aS'Bhatt, Nilesh'
p45377
aS'Baudin, Elisabeth'
p45378
aS'Silva, Carlota'
p45379
aS'Michon, Christophe'
p45380
aS'Taburet, Anne-Marie'
p45381
aS'Ciaffi, Laura'
p45382
aS'Sobry, Agnes'
p45383
aS'Bastos, Rui'
p45384
aS'Nunes, Elizabete'
p45385
aS'Rouzioux, Christine'
p45386
aS'Jani, Ilesh'
p45387
aS'Calmy, Alexandra'
p45388
asS'JT'
p45389
S'The Lancet. Infectious diseases'
p45390
sS'LR'
p45391
S'20140815'
p45392
sS'PG'
p45393
S'303-12'
p45394
sS'TI'
p45395
S'Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial.'
p45396
sS'RN'
p45397
(lp45398
S'0 (Anti-HIV Agents)'
p45399
aS'0 (Antitubercular Agents)'
p45400
aS'0 (Benzoxazines)'
p45401
aS'99DK7FVK1H (Nevirapine)'
p45402
aS'JE6H2O27P8 (efavirenz)'
p45403
asS'PL'
p45404
S'United States'
p45405
sS'TA'
p45406
S'Lancet Infect Dis'
p45407
sS'FIR'
p45408
(lp45409
S'Gudo, Paula Samo'
p45410
aS'Okamura, Josue Limaand Mie'
p45411
aS'Lab, Mariano Lugliand Bruno'
p45412
aS'Barreto, Avertino'
p45413
aS'Diallo, Alpha'
p45414
aS'Nhadzombo, Maria'
p45415
aS'Sitoe, Fernando'
p45416
aS'Nhumaio, Delario'
p45417
aS'Bule, Odete'
p45418
aS'Tandaucane, Jose'
p45419
aS'Guilovica, Vania'
p45420
aS'Meggi, Bindiya'
p45421
aS'Sitoe, Nadia'
p45422
aS'Vubil, Adolfo'
p45423
asS'JID'
p45424
S'101130150'
p45425
sS'AB'
p45426
S'BACKGROUND: In countries with a high incidence of HIV and tuberculosis co-infection, nevirapine and efavirenz are widely used as antiretroviral therapy but both interact with antituberculosis drugs. We aimed to compare efficacy and safety of a nevirapine-based antiretroviral therapy (started at full dose) with an efavirenz-based regimen in co-infected patients. METHODS: We did a multicentre, open-label, randomised, non-inferiority trial at three health centres in Maputo, Mozambique. We enrolled adults (>/=18 years) with tuberculosis and previously untreated HIV infection (CD4 cell counts <250 cells per muL) and alanine aminotransferase and total bilirubin concentrations of less than five times the upper limit of normal. 4-6 weeks after the start of tuberculosis treatment, we randomly allocated patients (1:1) with central randomisation, block sizes of two to six, and stratified by site and CD4 cell count to nevirapine (200 mg twice daily) or efavirenz (600 mg once daily), plus lamivudine and stavudine. The primary endpoint was virological suppression at 48 weeks (HIV-1 RNA <50 copies per mL) in all patients who received at least one dose of study drug (intention-to-treat population); death and loss to follow-up were recorded as treatment failure. The non-inferiority margin for the difference of efficacy was 10%. We assessed efficacy in intention-to-treat and per-protocol populations and safety in all patients who received study drug. This study is registered with ClinicalTrials.gov, number NCT00495326. FINDINGS: Between October, 2007, and March, 2010, we enrolled 285 patients into each group. 242 (85%) patients in the nevirapine group and 233 (82%) patients in the efavirenz group completed follow-up. In the intention-to-treat population, 184 patients (64.6%, 95% CI 58.7-70.1) allocated nevirapine achieved virological suppression at week 48, as did 199 patients (69.8%, 64.1-75.1) allocated efavirenz (one-sided 95% CI of the difference of efficacy 11.7%). In the per-protocol population, 170 (70.0%, 63.8-75.7) of 243 patients allocated nevirapine achieved virological suppression at week 48, as did 194 (78.9%, 73.2-83.8) of 246 patients allocated efavirenz (one-sided 95% CI 15.4%). The median CD4 cell count at randomisation was 89 cells per muL. 15 patients substituted nevirapine with efavirenz and six patients substituted efavirenz with nevirapine. 20 patients allocated nevirapine (7%) had grade 3-4 increase of alanine aminotransferase compared with 17 patients allocated efavirenz (6%). Three patients had severe rash after receipt of nevirapine (1%) but no patients did after receipt of efavirenz. 18 patients in the nevirapine group died, as did 17 patients in the efavirenz group. INTERPRETATION: Although non-inferiority of the nevirapine-regimen was not shown, nevirapine at full dose could be a safe, acceptable alternative for patients unable to tolerate efavirenz. FUNDING: French Research Agency for HIV/AIDS and hepatitis (ANRS).'
p45427
sS'CN'
p45428
(lp45429
S'CARINEMO study group'
p45430
asS'IP'
p45431
S'4'
sS'IS'
p45432
S'1474-4457 (Electronic) 1473-3099 (Linking)'
p45433
sS'IR'
p45434
(lp45435
S'Gudo PS'
p45436
aS'Okamura JL'
p45437
aS'Lab ML'
p45438
aS'Barreto A'
p45439
aS'Diallo A'
p45440
aS'Nhadzombo M'
p45441
aS'Sitoe F'
p45442
aS'Nhumaio D'
p45443
aS'Bule O'
p45444
aS'Tandaucane J'
p45445
aS'Guilovica V'
p45446
aS'Meggi B'
p45447
aS'Sitoe N'
p45448
aS'Vubil A'
p45449
asS'DCOM'
p45450
S'20130510'
p45451
sS'CIN'
p45452
(lp45453
S'Lancet Infect Dis. 2013 Apr;13(4):278-9. PMID: 23433591'
p45454
asS'AU'
p45455
(lp45456
S'Bonnet M'
p45457
aS'Bhatt N'
p45458
aS'Baudin E'
p45459
aS'Silva C'
p45460
aS'Michon C'
p45461
aS'Taburet AM'
p45462
aS'Ciaffi L'
p45463
aS'Sobry A'
p45464
aS'Bastos R'
p45465
aS'Nunes E'
p45466
aS'Rouzioux C'
p45467
aS'Jani I'
p45468
aS'Calmy A'
p45469
asS'VI'
p45470
S'13'
p45471
sS'MHDA'
p45472
S'2013/05/11 06:00'
p45473
sS'PHST'
p45474
(lp45475
S'2013/02/20 [aheadofprint]'
p45476
asS'MH'
p45477
(lp45478
S'AIDS-Related Opportunistic Infections/drug therapy'
p45479
aS'Adult'
p45480
aS'Anti-HIV Agents/administration & dosage/adverse effects/*therapeutic use'
p45481
aS'Antitubercular Agents/*therapeutic use'
p45482
aS'Benzoxazines/administration & dosage/adverse effects/*therapeutic use'
p45483
aS'Coinfection'
p45484
aS'Drug Interactions'
p45485
aS'Drug Therapy, Combination'
p45486
aS'Female'
p45487
aS'HIV Infections/*drug therapy'
p45488
aS'Humans'
p45489
aS'Male'
p45490
aS'Mozambique'
p45491
aS'Nevirapine/administration & dosage/adverse effects/*therapeutic use'
p45492
aS'Treatment Outcome'
p45493
aS'Tuberculosis/*complications/*drug therapy'
p45494
aS'Tuberculosis, Pulmonary/complications/drug therapy'
p45495
asS'EDAT'
p45496
S'2013/02/26 06:00'
p45497
sS'SI'
p45498
(lp45499
S'ClinicalTrials.gov/NCT00495326'
p45500
asS'SO'
p45501
S'Lancet Infect Dis. 2013 Apr;13(4):303-12. doi: 10.1016/S1473-3099(13)70007-0. Epub 2013 Feb 20.'
p45502
sS'SB'
p45503
S'IM'
p45504
sS'PMID'
p45505
S'23433590'
p45506
sS'PST'
p45507
S'ppublish'
p45508
stRp45509
ag2
(g3
g4
(dp45510
S'LID'
p45511
S'10.1097/QAI.0b013e31828af5a6 [doi]'
p45512
sS'STAT'
p45513
S'MEDLINE'
p45514
sS'JT'
p45515
S'Journal of acquired immune deficiency syndromes (1999)'
p45516
sS'MID'
p45517
(lp45518
S'NIHMS452179'
p45519
asS'DA'
p45520
S'20130513'
p45521
sS'AID'
p45522
(lp45523
S'10.1097/QAI.0b013e31828af5a6 [doi]'
p45524
asS'CRDT'
p45525
(lp45526
S'2013/02/23 06:00'
p45527
asS'DP'
p45528
S'2013 Jun 1'
p45529
sS'AD'
p45530
S'Division of HIV/AIDS, San Francisco General Hospital, Department of Medicine, University of California, San Francisco, CA 94110, USA. genge@php.ucsf.edu'
p45531
sS'OWN'
p45532
S'NLM'
p45533
sS'PT'
p45534
(lp45535
S'Journal Article'
p45536
aS'Research Support, N.I.H., Extramural'
p45537
aS"Research Support, U.S. Gov't, Non-P.H.S."
p45538
asS'LA'
p45539
(lp45540
S'eng'
p45541
asS'FAU'
p45542
(lp45543
S'Geng, Elvin H'
p45544
aS'Bwana, Mwebesa B'
p45545
aS'Muyindike, Winnie'
p45546
aS'Glidden, David V'
p45547
aS'Bangsberg, David R'
p45548
aS'Neilands, Torsten B'
p45549
aS'Bernheimer, Ingrid'
p45550
aS'Musinguzi, Nicolas'
p45551
aS'Yiannoutsos, Constantin T'
p45552
aS'Martin, Jeffrey N'
p45553
asS'LR'
p45554
S'20160701'
p45555
sS'PG'
p45556
S'e64-71'
p45557
sS'TI'
p45558
S'Failure to initiate antiretroviral therapy, loss to follow-up and mortality among HIV-infected patients during the pre-ART period in Uganda.'
p45559
sS'RN'
p45560
(lp45561
S'0 (Anti-HIV Agents)'
p45562
asS'PL'
p45563
S'United States'
p45564
sS'TA'
p45565
S'J Acquir Immune Defic Syndr'
p45566
sS'JID'
p45567
S'100892005'
p45568
sS'AB'
p45569
S'BACKGROUND: Delays and failures in initiation of antiretroviral therapy (ART) among treatment eligible patients may compromise the effectiveness of HIV care in Africa. An accurate understanding, however, of the pace and completeness of ART initiation and mortality during the waiting period is obscured by frequent losses to follow-up. METHODS: We evaluated newly ART-eligible HIV-infected adults from 2007 to 2011 in a prototypical clinic in Mbarara, Uganda. A random sample of patients lost to follow-up was tracked in the community to determine vital status and ART initiation after leaving the original clinic. Outcomes among the tracked patients were incorporated using probability weights, and a competing risks approach was used in analyses. RESULTS: Among 2633 ART-eligible patients, 490 were lost to follow-up, of whom a random sample of 132 was tracked and 111 (84.0%) had outcomes ascertained. After incorporating the outcomes among the lost, the cumulative incidence of ART initiation at 30, 90, and 365 days after eligibility was 16.0% [95% confidence interval (CI): 14.2 to 17.7], 64.5% (95% CI: 60.9 to 68.1), and 81.7% (95% CI: 77.7 to 85.6). Death before ART was 7.7% at 1 year. Male sex, higher CD4 count, and no education were associated with delayed ART initiation. Lower CD4 level, malnourishment, and travel time to clinic were associated with mortality. CONCLUSIONS: Using a sampling-based approach to account for losses to follow-up revealed that both the speed and the completeness of ART initiation were suboptimal in a prototypical large clinic in Uganda. Improving the kinetics of ART initiation in Africa is needed to make ART more in real-world populations.'
p45570
sS'GR'
p45571
(lp45572
S'K23 AI084544/AI/NIAID NIH HHS/United States'
p45573
aS'K23 AI084544/AI/NIAID NIH HHS/United States'
p45574
aS'P30 AI027763/AI/NIAID NIH HHS/United States'
p45575
aS'P30 AI027763/AI/NIAID NIH HHS/United States'
p45576
aS'U01 AI069911/AI/NIAID NIH HHS/United States'
p45577
aS'PEPFAR/United States'
p45578
asS'IP'
p45579
S'2'
sS'IS'
p45580
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p45581
sS'PMC'
p45582
S'PMC3654002'
p45583
sS'DCOM'
p45584
S'20130708'
p45585
sS'AU'
p45586
(lp45587
S'Geng EH'
p45588
aS'Bwana MB'
p45589
aS'Muyindike W'
p45590
aS'Glidden DV'
p45591
aS'Bangsberg DR'
p45592
aS'Neilands TB'
p45593
aS'Bernheimer I'
p45594
aS'Musinguzi N'
p45595
aS'Yiannoutsos CT'
p45596
aS'Martin JN'
p45597
asS'VI'
p45598
S'63'
p45599
sS'MHDA'
p45600
S'2013/07/09 06:00'
p45601
sS'OID'
p45602
(lp45603
S'NLM: NIHMS452179'
p45604
aS'NLM: PMC3654002'
p45605
asS'MH'
p45606
(lp45607
S'Adult'
p45608
aS'Anti-HIV Agents/therapeutic use'
p45609
aS'*CD4 Lymphocyte Count'
p45610
aS'CD4-Positive T-Lymphocytes'
p45611
aS'Delivery of Health Care'
p45612
aS'Educational Status'
p45613
aS'*HIV Infections/drug therapy/epidemiology/mortality'
p45614
aS'Humans'
p45615
aS'*Lost to Follow-Up'
p45616
aS'Male'
p45617
aS'*Medication Adherence'
p45618
aS'Treatment Refusal'
p45619
aS'Uganda/epidemiology'
p45620
asS'EDAT'
p45621
S'2013/02/23 06:00'
p45622
sS'SO'
p45623
S'J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):e64-71. doi: 10.1097/QAI.0b013e31828af5a6.'
p45624
sS'SB'
p45625
S'IM X'
p45626
sS'PMID'
p45627
S'23429504'
p45628
sS'PST'
p45629
S'ppublish'
p45630
stRp45631
ag2
(g3
g4
(dp45632
S'LID'
p45633
S'10.3851/IMP2525 [doi]'
p45634
sS'STAT'
p45635
S'MEDLINE'
p45636
sS'DEP'
p45637
S'20130219'
p45638
sS'DA'
p45639
S'20130930'
p45640
sS'AID'
p45641
(lp45642
S'10.3851/IMP2525 [doi]'
p45643
asS'CRDT'
p45644
(lp45645
S'2013/02/21 06:00'
p45646
asS'DP'
p45647
S'2013'
p45648
sS'OWN'
p45649
S'NLM'
p45650
sS'PT'
p45651
(lp45652
S'Journal Article'
p45653
aS"Research Support, Non-U.S. Gov't"
p45654
asS'LA'
p45655
(lp45656
S'eng'
p45657
asS'FAU'
p45658
(lp45659
S'Hermans, Sabine M'
p45660
aS'Manabe, Yukari C'
p45661
aS'Kiragga, Agnes N'
p45662
aS'Hoepelman, Andy I M'
p45663
aS'Lange, Joep M A'
p45664
aS'van Leth, Frank'
p45665
asS'JT'
p45666
S'Antiviral therapy'
p45667
sS'PG'
p45668
S'615-22'
p45669
sS'TI'
p45670
S'Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weighting.'
p45671
sS'RN'
p45672
(lp45673
S'0 (Anti-HIV Agents)'
p45674
aS'0 (Benzoxazines)'
p45675
aS'99DK7FVK1H (Nevirapine)'
p45676
aS'JE6H2O27P8 (efavirenz)'
p45677
asS'PL'
p45678
S'England'
p45679
sS'TA'
p45680
S'Antivir Ther'
p45681
sS'JID'
p45682
S'9815705'
p45683
sS'AB'
p45684
S'BACKGROUND: There is a high incidence of tuberculosis (TB) early after antiretroviral therapy (ART) initiation. This historical cohort study evaluated the association of efavirenz (EFV) compared to nevirapine (NVP) with post-ART TB among patients initiated on first-line ART from 2005 to 2009 in a large, urban HIV clinic in Uganda. METHODS: Hazard ratios (HR) for developing TB were computed using multivariable Cox proportional hazards models with inverse weighting of the probability of being prescribed NVP or EFV (calculated by a multivariable logistic regression model), stratifying by baseline CD4+ T-cell count. Adjustment for time-updated CD4+ T-cell count, restriction of the analysis to patients remaining in follow-up and a TB-free survival analysis were performed as sensitivity analyses. RESULTS: ART was initiated in 5,797 patients; 66% were women with a mean age of 37 years (SD 9) and a median baseline CD4+ T-cell count of 117 cells/mm3 (IQR 43-182). Overall, 60% (n = 3,484) were initiated on NVP and 40% (n = 2,313) on EFV. In the first 2 years of ART, 377 patients developed TB. The use of EFV compared to NVP was independently associated with higher TB incidence in patients with a baseline CD4+ T-cell count < 100 cells/mm3 (HR 2.05 [95% CI 1.29, 3.27]; P = 0.003), but not at higher CD4+ T-cell counts (HR 0.71 [95% CI 0.39, 1.31]; P = 0.428). These estimates were robust to all sensitivity analyses. CONCLUSIONS: There was a higher incidence of TB in patients with baseline CD4+ T-cell counts < 100 cells/mm3 initiated on EFV compared to those initiated on NVP. Further research in a trial setting or a larger multisite observational cohort is needed to confirm these findings.'
p45685
sS'AD'
p45686
S'Department of Global Health, Academic Medical Center, University of Amsterdam, Amsterdam Institute for Global Health and Development, Amsterdam, the Netherlands. s.hermans@aighd.org.'
p45687
sS'IP'
p45688
S'4'
sS'IS'
p45689
S'2040-2058 (Electronic) 1359-6535 (Linking)'
p45690
sS'DCOM'
p45691
S'20140417'
p45692
sS'AU'
p45693
(lp45694
S'Hermans SM'
p45695
aS'Manabe YC'
p45696
aS'Kiragga AN'
p45697
aS'Hoepelman AI'
p45698
aS'Lange JM'
p45699
aS'van Leth F'
p45700
asS'VI'
p45701
S'18'
p45702
sS'MHDA'
p45703
S'2014/04/18 06:00'
p45704
sS'PHST'
p45705
(lp45706
S'2012/12/02 [accepted]'
p45707
aS'2013/02/19 [aheadofprint]'
p45708
asS'MH'
p45709
(lp45710
S'Adult'
p45711
aS'Anti-HIV Agents/*adverse effects'
p45712
aS'Antiretroviral Therapy, Highly Active'
p45713
aS'Benzoxazines/*adverse effects'
p45714
aS'CD4 Lymphocyte Count'
p45715
aS'CD4-Positive T-Lymphocytes/drug effects/immunology'
p45716
aS'Cohort Studies'
p45717
aS'Comorbidity'
p45718
aS'Female'
p45719
aS'HIV Infections/*drug therapy/immunology/mortality/virology'
p45720
aS'HIV-1/drug effects/immunology'
p45721
aS'Humans'
p45722
aS'Male'
p45723
aS'Middle Aged'
p45724
aS'Mycobacterium tuberculosis/immunology'
p45725
aS'Nevirapine/*adverse effects'
p45726
aS'Proportional Hazards Models'
p45727
aS'Risk Factors'
p45728
aS'Survival Analysis'
p45729
aS'Tuberculosis, Pulmonary/*etiology/immunology/microbiology/mortality'
p45730
aS'Uganda/epidemiology'
p45731
aS'Viral Load/drug effects'
p45732
asS'EDAT'
p45733
S'2013/02/21 06:00'
p45734
sS'SO'
p45735
S'Antivir Ther. 2013;18(4):615-22. doi: 10.3851/IMP2525. Epub 2013 Feb 19.'
p45736
sS'SB'
p45737
S'IM'
p45738
sS'PMID'
p45739
S'23423604'
p45740
sS'PST'
p45741
S'ppublish'
p45742
stRp45743
ag2
(g3
g4
(dp45744
S'LID'
p45745
S'10.1097/QAI.0b013e31828bb721 [doi]'
p45746
sS'STAT'
p45747
S'MEDLINE'
p45748
sS'JT'
p45749
S'Journal of acquired immune deficiency syndromes (1999)'
p45750
sS'DA'
p45751
S'20130513'
p45752
sS'AID'
p45753
(lp45754
S'10.1097/QAI.0b013e31828bb721 [doi]'
p45755
asS'CRDT'
p45756
(lp45757
S'2013/02/21 06:00'
p45758
asS'DP'
p45759
S'2013 Jun 1'
p45760
sS'AD'
p45761
S'Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa. marije@sun.ac.za'
p45762
sS'OWN'
p45763
S'NLM'
p45764
sS'PT'
p45765
(lp45766
S'Journal Article'
p45767
aS"Research Support, Non-U.S. Gov't"
p45768
aS"Research Support, U.S. Gov't, Non-P.H.S."
p45769
asS'LA'
p45770
(lp45771
S'eng'
p45772
asS'FAU'
p45773
(lp45774
S'Van Schalkwyk, Marije'
p45775
aS'Andersson, Monique Ingrid'
p45776
aS'Zeier, Michele Desire'
p45777
aS'La Grange, Marina'
p45778
aS'Taljaard, Johannes Jakobus'
p45779
aS'Theron, Gerhard Barnard'
p45780
asS'LR'
p45781
S'20150219'
p45782
sS'PG'
p45783
S'234-8'
p45784
sS'TI'
p45785
S'The impact of revised PMTCT guidelines: a view from a public sector ARV clinic in Cape Town, South Africa.'
p45786
sS'RN'
p45787
(lp45788
S'0 (Anti-HIV Agents)'
p45789
asS'PL'
p45790
S'United States'
p45791
sS'TA'
p45792
S'J Acquir Immune Defic Syndr'
p45793
sS'JID'
p45794
S'100892005'
p45795
sS'AB'
p45796
S'BACKGROUND: In April 2010, revised Prevention of Mother-to-Child Transmission guidelines were implemented in South Africa, advising fast-tracked lifelong highly active antiretroviral therapy (HAART) initiation at a higher CD4 count (</=350 cells per microliter). This study describes the impact of these changes on the management of pregnant women who initiated HAART at Tygerberg Hospital, Cape Town. METHODS: We conducted a retrospective review of all women who initiated HAART in pregnancy at the Tygerberg Hospital between January 2008 and December 2010. Year cohorts were compared. RESULTS: Two hundred and fifty HIV-infected women were included in the study and stratified by HAART initiation year: 2008:N = 82, 2009:N = 71, 2010:N = 97. There were no differences between the groups in age or parity. Median booking CD4 count was 155 cells per microliter [interquartile range (IQR) 107-187], 157 cells per microliter (IQR 104-206) and 208 cells per microliter (IQR 138-270), respectively (P < 0.001). Median gestation at HAART initiation was 31 weeks (IQR 27-35), 30 weeks (IQR 26-34), and 25 weeks (IQR 21-31; P < 0.001). HIV transmission rates were 3/65 (4.6%), 4/57 (7.0%), and 0/90 (0.0%; P = 0.021). Women <8 weeks on HAART before delivery were more likely to transmit than women >/=8 weeks [odds ratio 9.69; 95% confidence interval 1.66 to 56.58; P = 0.017]. Ninety-four (37.6%) women were lost to follow-up, 18.4% within 28 days of delivery. CONCLUSIONS: The positive impact of the new Prevention of Mother-to-Child Transmission program is evident. A longer duration of HAART before delivery was associated with less transmission. However, the lost to follow-up rates remain concerning. Further research is needed to better understand the reasons for nonadherence and mechanisms to improve support for these women.'
p45797
sS'GR'
p45798
(lp45799
S'087859/Wellcome Trust/United Kingdom'
p45800
aS'674-A-00-08-00,009-00/PEPFAR/United States'
p45801
asS'IP'
p45802
S'2'
sS'IS'
p45803
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p45804
sS'PMC'
p45805
S'PMC3707566'
p45806
sS'DCOM'
p45807
S'20130708'
p45808
sS'AU'
p45809
(lp45810
S'Van Schalkwyk M'
p45811
aS'Andersson MI'
p45812
aS'Zeier MD'
p45813
aS'La Grange M'
p45814
aS'Taljaard JJ'
p45815
aS'Theron GB'
p45816
asS'VI'
p45817
S'63'
p45818
sS'MHDA'
p45819
S'2013/07/09 06:00'
p45820
sS'OID'
p45821
(lp45822
S'NLM: PMC3707566'
p45823
asS'MH'
p45824
(lp45825
S'Adult'
p45826
aS'Ambulatory Care Facilities'
p45827
aS'Anti-HIV Agents/*therapeutic use'
p45828
aS'Antiretroviral Therapy, Highly Active'
p45829
aS'CD4 Lymphocyte Count'
p45830
aS'Female'
p45831
aS'Guidelines as Topic'
p45832
aS'*HIV Infections/drug therapy/prevention & control/transmission'
p45833
aS'Humans'
p45834
aS'Infectious Disease Transmission, Vertical/*prevention & control'
p45835
aS'Lost to Follow-Up'
p45836
aS'Patient Compliance'
p45837
aS'Pregnancy'
p45838
aS'Pregnancy Complications, Infectious/drug therapy'
p45839
aS'Retrospective Studies'
p45840
aS'South Africa'
p45841
asS'EDAT'
p45842
S'2013/02/21 06:00'
p45843
sS'SO'
p45844
S'J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):234-8. doi: 10.1097/QAI.0b013e31828bb721.'
p45845
sS'SB'
p45846
S'IM X'
p45847
sS'PMID'
p45848
S'23422849'
p45849
sS'PST'
p45850
S'ppublish'
p45851
stRp45852
ag2
(g3
g4
(dp45853
S'LID'
p45854
S'10.1097/QAI.0b013e31828a3fb8 [doi]'
p45855
sS'STAT'
p45856
S'MEDLINE'
p45857
sS'AB'
p45858
S'BACKGROUND: Retaining patients in clinical care is necessary to ensure successful antiretroviral treatment (ART) outcomes. Among patients who discontinue care, some reenter care at a later stage, whereas others are or will be lost from follow-up. We examined risk factors for health care interruptions and loss to follow-up within a cohort receiving ART in Uganda. METHODS: Using a large hospital cohort providing free universal ART and HIV clinical care, we assessed characteristics and risk factors for treatment interruptions, defined as a 12-month absence from care at Mildmay, and loss to follow-up, defined as absence from care greater than 12 months without reengagement in care at Mildmay. We included patients aged 14 years and above. We assessed these outcomes over time using Kaplan-Meier analysis and multivariable regression. RESULTS: Of 6970 eligible patients, 784 (11.2%) had a health care interruption of at least 12 months and 217 (3.1%) were lost to follow-up. Patients experiencing health care interruptions had higher baseline CD4 T-cell counts at ART initiation, defined as >/= 250 cells per cubic millimeter [odds ratio (OR): 1.29, 95% confidence intervals (CI): 1.11 to 1.50], and lower levels of education (OR: 1.32, 95% CI: 1.09 to 1.61). Adolescents were much more likely to be lost to follow-up (OR: 3.11, 95% CI: 2.23 to 4.34). In contrast, having a partner (OR: 0.22, 95% CI: 0.16 to 0.31) or being sexually active at baseline (OR: 0.40, 95% CI: 0.28 to 0.55) was protective of loss to follow-up. CONCLUSIONS: Within this cohort, long periods of unsupervised health care interruptions were common.'
p45859
sS'JID'
p45860
S'100892005'
p45861
sS'AD'
p45862
S'University of Ottawa, Ottawa, Ontario, Canada. edward.mills@uottawa.ca'
p45863
sS'JT'
p45864
S'Journal of acquired immune deficiency syndromes (1999)'
p45865
sS'IP'
p45866
S'1'
sS'IS'
p45867
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p45868
sS'DCOM'
p45869
S'20130624'
p45870
sS'DA'
p45871
S'20130411'
p45872
sS'AU'
p45873
(lp45874
S'Mills EJ'
p45875
aS'Funk A'
p45876
aS'Kanters S'
p45877
aS'Kawuma E'
p45878
aS'Cooper C'
p45879
aS'Mukasa B'
p45880
aS'Odit M'
p45881
aS'Karamagi Y'
p45882
aS'Mwehire D'
p45883
aS'Nachega J'
p45884
aS'Yaya S'
p45885
aS'Featherstone A'
p45886
aS'Ford N'
p45887
asS'AID'
p45888
(lp45889
S'10.1097/QAI.0b013e31828a3fb8 [doi]'
p45890
asS'CRDT'
p45891
(lp45892
S'2013/02/15 06:00'
p45893
asS'VI'
p45894
S'63'
p45895
sS'PMID'
p45896
S'23406979'
p45897
sS'DP'
p45898
S'2013 May 1'
p45899
sS'MHDA'
p45900
S'2013/06/26 06:00'
p45901
sS'OWN'
p45902
S'NLM'
p45903
sS'PT'
p45904
(lp45905
S'Journal Article'
p45906
asS'LA'
p45907
(lp45908
S'eng'
p45909
asS'MH'
p45910
(lp45911
S'Adult'
p45912
aS'Anti-HIV Agents/*therapeutic use'
p45913
aS'Antiretroviral Therapy, Highly Active'
p45914
aS'CD4 Lymphocyte Count'
p45915
aS'Cohort Studies'
p45916
aS'Female'
p45917
aS'HIV Infections/*drug therapy'
p45918
aS'Humans'
p45919
aS'Lost to Follow-Up'
p45920
aS'Male'
p45921
aS'Medication Adherence/*statistics & numerical data'
p45922
aS'Risk Factors'
p45923
aS'Time Factors'
p45924
aS'Treatment Outcome'
p45925
aS'Uganda'
p45926
asS'FAU'
p45927
(lp45928
S'Mills, Edward J'
p45929
aS'Funk, Anna'
p45930
aS'Kanters, Steve'
p45931
aS'Kawuma, Esther'
p45932
aS'Cooper, Curtis'
p45933
aS'Mukasa, Barbara'
p45934
aS'Odit, Mary'
p45935
aS'Karamagi, Yvonne'
p45936
aS'Mwehire, Daniel'
p45937
aS'Nachega, Jean'
p45938
aS'Yaya, Sanni'
p45939
aS'Featherstone, Amber'
p45940
aS'Ford, Nathan'
p45941
asS'EDAT'
p45942
S'2013/02/15 06:00'
p45943
sS'PST'
p45944
S'ppublish'
p45945
sS'SO'
p45946
S'J Acquir Immune Defic Syndr. 2013 May 1;63(1):e23-7. doi: 10.1097/QAI.0b013e31828a3fb8.'
p45947
sS'PG'
p45948
S'e23-7'
p45949
sS'TI'
p45950
S'Long-term health care interruptions among HIV-positive patients in Uganda.'
p45951
sS'SB'
p45952
S'IM X'
p45953
sS'RN'
p45954
(lp45955
S'0 (Anti-HIV Agents)'
p45956
asS'PL'
p45957
S'United States'
p45958
sS'TA'
p45959
S'J Acquir Immune Defic Syndr'
p45960
stRp45961
ag2
(g3
g4
(dp45962
S'LID'
p45963
S'10.1080/09540121.2013.764391 [doi]'
p45964
sS'STAT'
p45965
S'MEDLINE'
p45966
sS'DEP'
p45967
S'20130206'
p45968
sS'DA'
p45969
S'20130924'
p45970
sS'AID'
p45971
(lp45972
S'10.1080/09540121.2013.764391 [doi]'
p45973
asS'CRDT'
p45974
(lp45975
S'2013/02/07 06:00'
p45976
asS'DP'
p45977
S'2013'
p45978
sS'OWN'
p45979
S'NLM'
p45980
sS'PT'
p45981
(lp45982
S'Journal Article'
p45983
aS'Multicenter Study'
p45984
aS"Research Support, Non-U.S. Gov't"
p45985
asS'LA'
p45986
(lp45987
S'eng'
p45988
asS'FAU'
p45989
(lp45990
S'Musumari, Patou Masika'
p45991
aS'Feldman, Mitchell D'
p45992
aS'Techasrivichien, Teeranee'
p45993
aS'Wouters, Edwin'
p45994
aS'Ono-Kihara, Masako'
p45995
aS'Kihara, Masahiro'
p45996
asS'JT'
p45997
S'AIDS care'
p45998
sS'LR'
p45999
S'20151119'
p46000
sS'PG'
p46001
S'1271-7'
p46002
sS'TI'
p46003
S'"If I have nothing to eat, I get angry and push the pills bottle away from me": A qualitative study of patient determinants of adherence to antiretroviral therapy in the Democratic Republic of Congo.'
p46004
sS'RN'
p46005
(lp46006
S'0 (Anti-Retroviral Agents)'
p46007
asS'PL'
p46008
S'England'
p46009
sS'TA'
p46010
S'AIDS Care'
p46011
sS'JID'
p46012
S'8915313'
p46013
sS'AB'
p46014
S'The global response to the HIV/AIDS epidemic has improved access to antiretroviral therapy (ART) and has contributed to decreased HIV/AIDS morbidity and mortality in sub-Saharan Africa. Patient adherence to ART is crucial to the success of HIV/AIDS treatment. However, little is known about the determinants of adherence to ART among people living with HIV/AIDS (PLWHA) in the Democratic Republic of Congo (DRC). This qualitative study used in-depth semi-structured patient interviews, a purposive sampling strategy and thematic analysis scheme to identify barriers and facilitators of adherence to ART in the DRC. We recruited three categories of participants from the Centre Hospitalier Monkole and the NGO ACS/Amo-Congo including participants on antiretroviral (ARV) treatment (n = 19), on ARV re-treatment (n = 13) and lost to follow-up (n = 6). Among 38 participants interviewed, 24 were female and the median age was 41 years. Food insecurity as a barrier to adherence emerged as a dominant theme across the three categories of participants. Other barriers included financial constraints, forgetfulness and fear of disclosure/stigma. Religious beliefs were both a barrier and a facilitator to ART adherence. We found that food insecurity was a common and an important barrier to ART adherence among patients in the DRC. Our findings suggest that food insecurity should be appropriately addressed and incorporated into ARV treatment programs to ensure patient adherence and ultimately the long-term success of HIV treatment in the region.'
p46015
sS'AD'
p46016
S'a Department of Global Health and Socio-Epidemiology , Kyoto University School of Public Health , Kyoto , Japan.'
p46017
sS'IP'
p46018
S'10'
p46019
sS'IS'
p46020
S'1360-0451 (Electronic) 0954-0121 (Linking)'
p46021
sS'DCOM'
p46022
S'20140226'
p46023
sS'AU'
p46024
(lp46025
S'Musumari PM'
p46026
aS'Feldman MD'
p46027
aS'Techasrivichien T'
p46028
aS'Wouters E'
p46029
aS'Ono-Kihara M'
p46030
aS'Kihara M'
p46031
asS'VI'
p46032
S'25'
p46033
sS'MHDA'
p46034
S'2014/02/27 06:00'
p46035
sS'PHST'
p46036
(lp46037
S'2013/02/06 [aheadofprint]'
p46038
asS'MH'
p46039
(lp46040
S'Adult'
p46041
aS'Anger'
p46042
aS'Anti-Retroviral Agents/*therapeutic use'
p46043
aS'Democratic Republic of the Congo/epidemiology'
p46044
aS'Fear/psychology'
p46045
aS'Female'
p46046
aS'Follow-Up Studies'
p46047
aS'*Food Assistance/statistics & numerical data'
p46048
aS'HIV Infections/*drug therapy/epidemiology/*psychology'
p46049
aS'Health Knowledge, Attitudes, Practice'
p46050
aS'Humans'
p46051
aS'Male'
p46052
aS'Medication Adherence/*psychology/statistics & numerical data'
p46053
aS'Middle Aged'
p46054
aS'*Poverty/statistics & numerical data'
p46055
aS'Qualitative Research'
p46056
aS'Religion'
p46057
aS'Risk Factors'
p46058
aS'Sampling Studies'
p46059
aS'Self Administration'
p46060
aS'Social Stigma'
p46061
aS'Surveys and Questionnaires'
p46062
asS'EDAT'
p46063
S'2013/02/07 06:00'
p46064
sS'SO'
p46065
S'AIDS Care. 2013;25(10):1271-7. doi: 10.1080/09540121.2013.764391. Epub 2013 Feb 6.'
p46066
sS'SB'
p46067
S'IM X'
p46068
sS'PMID'
p46069
S'23383757'
p46070
sS'PST'
p46071
S'ppublish'
p46072
stRp46073
ag2
(g3
g4
(dp46074
S'STAT'
p46075
S'MEDLINE'
p46076
sS'JT'
p46077
S'African health sciences'
p46078
sS'DA'
p46079
S'20130205'
p46080
sS'CRDT'
p46081
(lp46082
S'2013/02/06 06:00'
p46083
asS'DP'
p46084
S'2012 Sep'
p46085
sS'OWN'
p46086
S'NLM'
p46087
sS'PT'
p46088
(lp46089
S'Journal Article'
p46090
aS'Review'
p46091
asS'LA'
p46092
(lp46093
S'eng'
p46094
asS'FAU'
p46095
(lp46096
S'Ubesie, A C'
p46097
asS'LR'
p46098
S'20150219'
p46099
sS'PG'
p46100
S'297-304'
p46101
sS'TI'
p46102
S'Pediatric HIV/AIDS in sub-Saharan Africa: emerging issues and way forward.'
p46103
sS'RN'
p46104
(lp46105
S'0 (Anti-Retroviral Agents)'
p46106
asS'PL'
p46107
S'Uganda'
p46108
sS'TA'
p46109
S'Afr Health Sci'
p46110
sS'JID'
p46111
S'101149451'
p46112
sS'AB'
p46113
S'BACKGROUND: Sub-Saharan Africa has the largest burden of pediatric HIV in the world. Global target has been set for eradication of pediatric HIV by 2015 but there are still so many complex issues facing HIV infected and affected children in the sub-continent. OBJECTIVE: To review the current and emerging challenges facing pediatric HIV care in sub-Saharan Africa; and proffer solutions that could help in tackling these challenges. METHOD: A Medline literature search of recent publications was performed to identify articles on "pediatric HIV", "HIV and children", "HIV and infants", "HIV and adolescents" in sub-Saharan Africa. RESULT: There are a number of challenges and emerging complex issues facing children infected and affected by HIV in sub-Saharan Africa. These include late presentation, limited access to pediatric HIV services, delayed diagnosis, infant feeding choices, malnutrition, limited and complex drug regimen, disclosure, treatment failure and reproductive health concerns. A holistic cost effective preventive, diagnostic and treatment strategies are required in order to eliminate pediatric HIV in SSA. CONCLUSION: HIV infected children and their families in sub-Saharan Africa face myriad of complex medical and psychosocial issues. A holistic health promotional approach is being advocated as the required step for eradication of pediatric HIV in Africa.'
p46114
sS'AD'
p46115
S'Department of Paediatrics, Faculty of Medical Sciences, University of Nigeria/University of Nigeria Teaching Hospital, Enugu, Nigeria. agozie.ubesie@unn.edu.ng'
p46116
sS'IP'
p46117
S'3'
sS'IS'
p46118
S'1729-0503 (Electronic) 1680-6905 (Linking)'
p46119
sS'PMC'
p46120
S'PMC3557677'
p46121
sS'DCOM'
p46122
S'20130918'
p46123
sS'AU'
p46124
(lp46125
S'Ubesie AC'
p46126
asS'VI'
p46127
S'12'
p46128
sS'MHDA'
p46129
S'2013/09/21 06:00'
p46130
sS'OTO'
p46131
(lp46132
S'NOTNLM'
p46133
asS'OID'
p46134
(lp46135
S'NLM: PMC3557677'
p46136
asS'MH'
p46137
(lp46138
S'Africa South of the Sahara'
p46139
aS'Anti-Retroviral Agents/*therapeutic use'
p46140
aS'Child'
p46141
aS'Delayed Diagnosis'
p46142
aS'Female'
p46143
aS'HIV Infections/diagnosis/*drug therapy/*prevention & control/transmission'
p46144
aS'Health Services Accessibility'
p46145
aS'Humans'
p46146
aS'Infectious Disease Transmission, Vertical/*prevention & control'
p46147
aS'Male'
p46148
aS'Patient Compliance'
p46149
aS'Socioeconomic Factors'
p46150
aS'Truth Disclosure'
p46151
asS'EDAT'
p46152
S'2013/02/06 06:00'
p46153
sS'SO'
p46154
S'Afr Health Sci. 2012 Sep;12(3):297-304.'
p46155
sS'SB'
p46156
S'IM'
p46157
sS'PMID'
p46158
S'23382743'
p46159
sS'OT'
p46160
(lp46161
S'Challenges'
p46162
aS'Pediatric HIV'
p46163
aS'sub-Saharan Africa'
p46164
asS'PST'
p46165
S'ppublish'
p46166
stRp46167
ag2
(g3
g4
(dp46168
S'LID'
p46169
S'10.7196/samj.6182 [doi]'
p46170
sS'STAT'
p46171
S'MEDLINE'
p46172
sS'DEP'
p46173
S'20130114'
p46174
sS'CIN'
p46175
(lp46176
S'S Afr Med J. 2013 Jun;103(6):355-6. PMID: 23725947'
p46177
aS'S Afr Med J. 2013 Jul;103(7):436. PMID: 23946950'
p46178
asS'DA'
p46179
S'20130204'
p46180
sS'CRDT'
p46181
(lp46182
S'2013/02/05 06:00'
p46183
asS'DP'
p46184
S'2013 Feb'
p46185
sS'AD'
p46186
S'Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa. kschnippel@heroza.org'
p46187
sS'OWN'
p46188
S'NLM'
p46189
sS'PT'
p46190
(lp46191
S'Comparative Study'
p46192
aS'Journal Article'
p46193
aS'Research Support, N.I.H., Extramural'
p46194
aS"Research Support, Non-U.S. Gov't"
p46195
asS'LA'
p46196
(lp46197
S'eng'
p46198
asS'FAU'
p46199
(lp46200
S'Schnippel, K'
p46201
aS'Meyer-Rath, G'
p46202
aS'Long, L'
p46203
aS'Stevens, W S'
p46204
aS'Sanne, I'
p46205
aS'Rosen, S'
p46206
asS'JT'
p46207
S'South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde'
p46208
sS'LR'
p46209
S'20140912'
p46210
sS'PG'
p46211
S'101-6'
p46212
sS'TI'
p46213
S'Diagnosing Xpert MTB/RIF negative TB: impact and cost of alternative algorithms for South Africa.'
p46214
sS'PL'
p46215
S'South Africa'
p46216
sS'TA'
p46217
S'S Afr Med J'
p46218
sS'JID'
p46219
S'0404520'
p46220
sS'AB'
p46221
S'BACKGROUND: Use of Xpert MTB/RIF is being scaled up throughout South Africa for improved diagnosis of tuberculosis (TB). A large proportion of HIV-infected patients with possible TB are Xpert-negative on their initial test, and the existing diagnostic algorithm calls for these patients to have sputum culture (Xpert followed by culture (X/C)). We modelled the costs and impact of an alternative diagnostic algorithm in which these cultures are replaced with a second Xpert test (Xpert followed by Xpert (X/X)). METHODS: An existing population-level decision model was used. Costs were estimated from Xpert implementation studies and public sector price and salary data. The number of patients requiring diagnosis was estimated from the literature, as were rates of TB treatment uptake and loss to follow-up. TB and HIV positivity rates were estimated from the national TB register and laboratory databases. RESULTS: At national programme scale in 2014, X/X (R969 million/year) is less expensive than X/C R1 095 million/year), potentially saving R126 million/year (US$17.4 million). However, because Xpert is less sensitive than culture, X/X diagnoses 2% fewer TB cases. This is partly offset by higher expected treatment uptake with X/X due to the faster availability of results, resulting in 1% more patients initiating treatment under X/X than X/C. The cost per TB patient initiated on treatment under X/X is R2 682, which is 12% less than under X/C (R3 046). CONCLUSIONS: Modifying the diagnostic algorithm from X/C to X/X could provide rapid results, simplify diagnostic processes, improve HIV/TB treatment outcomes, and generate cost savings.'
p46222
sS'GR'
p46223
(lp46224
S'U2RTW007373/PHS HHS/United States'
p46225
asS'IP'
p46226
S'2'
sS'IS'
p46227
S'0256-9574 (Print)'
p46228
sS'DCOM'
p46229
S'20130402'
p46230
sS'AU'
p46231
(lp46232
S'Schnippel K'
p46233
aS'Meyer-Rath G'
p46234
aS'Long L'
p46235
aS'Stevens WS'
p46236
aS'Sanne I'
p46237
aS'Rosen S'
p46238
asS'VI'
p46239
S'103'
p46240
sS'MHDA'
p46241
S'2013/04/03 06:00'
p46242
sS'PHST'
p46243
(lp46244
S'2012/08/03 [received]'
p46245
aS'2012/09/28 [accepted]'
p46246
asS'MH'
p46247
(lp46248
S'*Algorithms'
p46249
aS'Cost of Illness'
p46250
aS'HIV Infections/*complications/epidemiology'
p46251
aS'Humans'
p46252
aS'Incidence'
p46253
aS'Mycobacterium tuberculosis/isolation & purification'
p46254
aS'Prevalence'
p46255
aS'Prospective Studies'
p46256
aS'South Africa/epidemiology'
p46257
aS'Tuberculosis, Multidrug-Resistant/*diagnosis/economics/epidemiology'
p46258
asS'EDAT'
p46259
S'2013/02/05 06:00'
p46260
sS'SO'
p46261
S'S Afr Med J. 2013 Jan 14;103(2):101-6. doi: 10.7196/samj.6182.'
p46262
sS'SB'
p46263
S'IM'
p46264
sS'PMID'
p46265
S'23374320'
p46266
sS'PST'
p46267
S'epublish'
p46268
stRp46269
ag2
(g3
g4
(dp46270
S'LID'
p46271
S'10.1111/tmi.12072 [doi]'
p46272
sS'STAT'
p46273
S'MEDLINE'
p46274
sS'DEP'
p46275
S'20130203'
p46276
sS'CI'
p46277
(lp46278
S'(c) 2013 Blackwell Publishing Ltd.'
p46279
asS'DA'
p46280
S'20130315'
p46281
sS'AID'
p46282
(lp46283
S'10.1111/tmi.12072 [doi]'
p46284
asS'CRDT'
p46285
(lp46286
S'2013/02/05 06:00'
p46287
asS'DP'
p46288
S'2013 Apr'
p46289
sS'AD'
p46290
S'Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa kclouse@unc.edu'
p46291
sS'OWN'
p46292
S'NLM'
p46293
sS'PT'
p46294
(lp46295
S'Journal Article'
p46296
aS'Research Support, N.I.H., Extramural'
p46297
aS"Research Support, U.S. Gov't, Non-P.H.S."
p46298
asS'LA'
p46299
(lp46300
S'eng'
p46301
asS'FAU'
p46302
(lp46303
S'Clouse, Kate'
p46304
aS'Pettifor, Audrey'
p46305
aS'Shearer, Kate'
p46306
aS'Maskew, Mhairi'
p46307
aS'Bassett, Jean'
p46308
aS'Larson, Bruce'
p46309
aS'Van Rie, Annelies'
p46310
aS'Sanne, Ian'
p46311
aS'Fox, Matthew P'
p46312
asS'JT'
p46313
S'Tropical medicine & international health : TM & IH'
p46314
sS'LR'
p46315
S'20150710'
p46316
sS'PG'
p46317
S'451-60'
p46318
sS'TI'
p46319
S'Loss to follow-up before and after delivery among women testing HIV positive during pregnancy in Johannesburg, South Africa.'
p46320
sS'RN'
p46321
(lp46322
S'0 (Anti-Retroviral Agents)'
p46323
asS'PL'
p46324
S'England'
p46325
sS'TA'
p46326
S'Trop Med Int Health'
p46327
sS'JID'
p46328
S'9610576'
p46329
sS'AB'
p46330
S'OBJECTIVE: HIV-positive pregnant women are at heightened risk of becoming lost to follow-up (LTFU) from HIV care. We examined LTFU before and after delivery among pregnant women newly diagnosed with HIV. METHODS: Observational cohort study of all pregnant women >/=18 years (N = 300) testing HIV positive for the first time at their first ANC visit between January and June 2010, at a primary healthcare clinic in Johannesburg, South Africa. Women (n = 27) whose delivery date could not be determined were excluded. RESULTS: Median (IQR) gestation at HIV testing was 26 weeks (21-30). Ninety-eight per cent received AZT prophylaxis, usually started at the first ANC visit. Of 139 (51.3%) patients who were ART eligible, 66.9% (95% CI 58.8-74.3%) initiated ART prior to delivery; median (IQR) ART duration pre-delivery was 9.5 weeks (5.1-14.2). Among ART-eligible patients, 40.5% (32.3-49.0%) were cumulatively retained through 6 months on ART. Of those ART-ineligible patients at HIV testing, only 22.6% (95% CI 15.9-30.6%) completed CD4 staging and returned for a repeat CD4 test after delivery. LTFU (>/=1 month late for last scheduled visit) before delivery was 20.5% (95% CI 16.0-25.6%) and, among those still in care, 47.9% (95% CI 41.2-54.6%) within 6 months after delivery. Overall, 57.5% (95% CI 51.6-63.3%) were lost between HIV testing and 6 months post-delivery. CONCLUSIONS: Our findings highlight the challenge of continuity of care among HIV-positive pregnant women attending antenatal services, particularly those ineligible for ART.'
p46331
sS'GR'
p46332
(lp46333
S'K01 AI083097/AI/NIAID NIH HHS/United States'
p46334
aS'P30 AI050410/AI/NIAID NIH HHS/United States'
p46335
aS'R24 HD050924/HD/NICHD NIH HHS/United States'
p46336
asS'IP'
p46337
S'4'
sS'IS'
p46338
S'1365-3156 (Electronic) 1360-2276 (Linking)'
p46339
sS'PMC'
p46340
S'PMC3600093'
p46341
sS'DCOM'
p46342
S'20130509'
p46343
sS'MID'
p46344
(lp46345
S'NIHMS437782'
p46346
asS'AU'
p46347
(lp46348
S'Clouse K'
p46349
aS'Pettifor A'
p46350
aS'Shearer K'
p46351
aS'Maskew M'
p46352
aS'Bassett J'
p46353
aS'Larson B'
p46354
aS'Van Rie A'
p46355
aS'Sanne I'
p46356
aS'Fox MP'
p46357
asS'VI'
p46358
S'18'
p46359
sS'MHDA'
p46360
S'2013/05/10 06:00'
p46361
sS'PHST'
p46362
(lp46363
S'2013/02/03 [aheadofprint]'
p46364
asS'OID'
p46365
(lp46366
S'NLM: NIHMS437782'
p46367
aS'NLM: PMC3600093'
p46368
asS'MH'
p46369
(lp46370
S'Adolescent'
p46371
aS'Adult'
p46372
aS'Anti-Retroviral Agents/therapeutic use'
p46373
aS'CD4 Lymphocyte Count'
p46374
aS'Cohort Studies'
p46375
aS'*Continuity of Patient Care'
p46376
aS'Delivery, Obstetric'
p46377
aS'Female'
p46378
aS'Gestational Age'
p46379
aS'HIV Seropositivity/*complications/drug therapy'
p46380
aS'Humans'
p46381
aS'Infectious Disease Transmission, Vertical/prevention & control'
p46382
aS'*Lost to Follow-Up'
p46383
aS'Patient Acceptance of Health Care/psychology'
p46384
aS'Patient Compliance/psychology'
p46385
aS'Postnatal Care/*psychology'
p46386
aS'Pregnancy'
p46387
aS'*Pregnancy Complications, Infectious'
p46388
aS'Prenatal Care/*psychology'
p46389
aS'South Africa'
p46390
aS'Young Adult'
p46391
asS'EDAT'
p46392
S'2013/02/05 06:00'
p46393
sS'SO'
p46394
S'Trop Med Int Health. 2013 Apr;18(4):451-60. doi: 10.1111/tmi.12072. Epub 2013 Feb 3.'
p46395
sS'SB'
p46396
S'IM'
p46397
sS'PMID'
p46398
S'23374278'
p46399
sS'PST'
p46400
S'ppublish'
p46401
stRp46402
ag2
(g3
g4
(dp46403
S'LID'
p46404
S'10.1089/AID.2012.0215 [doi]'
p46405
sS'STAT'
p46406
S'MEDLINE'
p46407
sS'DEP'
p46408
S'20130225'
p46409
sS'DA'
p46410
S'20130513'
p46411
sS'AID'
p46412
(lp46413
S'10.1089/AID.2012.0215 [doi]'
p46414
asS'CRDT'
p46415
(lp46416
S'2013/02/05 06:00'
p46417
asS'DP'
p46418
S'2013 Jun'
p46419
sS'AD'
p46420
S'Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa. devans@witshealth.co.za'
p46421
sS'OWN'
p46422
S'NLM'
p46423
sS'PT'
p46424
(lp46425
S'Journal Article'
p46426
aS'Research Support, N.I.H., Extramural'
p46427
aS"Research Support, Non-U.S. Gov't"
p46428
aS"Research Support, U.S. Gov't, Non-P.H.S."
p46429
asS'LA'
p46430
(lp46431
S'eng'
p46432
asS'FAU'
p46433
(lp46434
S'Evans, Denise'
p46435
aS'Menezes, Colin'
p46436
aS'Mahomed, Kay'
p46437
aS'Macdonald, Philippa'
p46438
aS'Untiedt, Sanlie'
p46439
aS'Levin, Leon'
p46440
aS'Jaffray, Imogen'
p46441
aS'Bhana, Nainisha'
p46442
aS'Firnhaber, Cindy'
p46443
aS'Maskew, Mhairi'
p46444
asS'JT'
p46445
S'AIDS research and human retroviruses'
p46446
sS'LR'
p46447
S'20150219'
p46448
sS'PG'
p46449
S'892-900'
p46450
sS'TI'
p46451
S'Treatment outcomes of HIV-infected adolescents attending public-sector HIV clinics across Gauteng and Mpumalanga, South Africa.'
p46452
sS'PL'
p46453
S'United States'
p46454
sS'TA'
p46455
S'AIDS Res Hum Retroviruses'
p46456
sS'JID'
p46457
S'8709376'
p46458
sS'AB'
p46459
S'There is little evidence comparing treatment outcomes between adolescents and other age groups, particularly in resource-limited settings. A retrospective analysis of data from seven HIV clinics across urban Gauteng (n=5) and rural Mpumalanga (n=2), South Africa was conducted. The analysis compared HIV-positive antiretroviral treatment (ART)-naive young adolescents (10-14 years), older adolescents (15-19), and young adults (20-24 years) to adults (>/=25 years) initiated onto standard first-line ART between April 2004 and August 2010. Log-binomial regression was used to estimate relative risk (RR) of failure to suppress viral load (>/=400 copies/ml) or failure to achieve an adequate CD4 response at 6 or 12 months. The effect of age group on virological failure, mortality, and loss to follow-up (LTFU; >/=90 days since scheduled visit date) was estimated using Cox proportional hazards models. Of 42,427 patients initiating ART, 310 (0.7%) were young adolescents, 342 (0.8%) were older adolescents, and 1599 (3.8%) were young adults. Adolescents were similar to adults in terms of proportion male, baseline CD4 count, hemoglobin, and TB. Compared to adults, both older adolescents (6 months RR 1.75 95% CI 1.25-2.47) and young adults (6 months RR 1.33 95% CI 1.10-1.60 and 12 months RR 1.64 95% CI 1.23-2.19) were more likely to have an unsuppressed viral load and were more likely to fail virologically (HR 2.90 95% CI 1.74-4.86; HR 2.94 95% CI 1.63-5.31). Among those that died or were LTFU, the median time from ART initiation until death or LTFU was 4.7 months (IQR 1.5-13.2) and 10.9 months (IQR 5.0-22.7), respectively. There was no difference in risk of mortality by age category, compared to adults. Young adolescents were less likely to be LTFU at any time period after ART initiation (HR 0.43 95% CI 0.26-0.69) whereas older adolescents and young adults were more likely to be LTFU after ART initiation (HR 1.78 95% CI 1.34-2.36; HR 1.63 95% CI 1.41-1.89) compared to adults. HIV-infected adolescents and young adults between 15 and 24 years have poorer ART treatment outcomes in terms of virological response, LTFU, and virological failure than adults receiving ART. Interventions are needed to help improve outcomes and retention in care in this unique population.'
p46460
sS'GR'
p46461
(lp46462
S'P30AI027767/AI/NIAID NIH HHS/United States'
p46463
asS'IP'
p46464
S'6'
sS'IS'
p46465
S'1931-8405 (Electronic) 0889-2229 (Linking)'
p46466
sS'PMC'
p46467
S'PMC3653371'
p46468
sS'DCOM'
p46469
S'20130830'
p46470
sS'AU'
p46471
(lp46472
S'Evans D'
p46473
aS'Menezes C'
p46474
aS'Mahomed K'
p46475
aS'Macdonald P'
p46476
aS'Untiedt S'
p46477
aS'Levin L'
p46478
aS'Jaffray I'
p46479
aS'Bhana N'
p46480
aS'Firnhaber C'
p46481
aS'Maskew M'
p46482
asS'VI'
p46483
S'29'
p46484
sS'MHDA'
p46485
S'2013/08/31 06:00'
p46486
sS'PHST'
p46487
(lp46488
S'2013/02/25 [aheadofprint]'
p46489
asS'OID'
p46490
(lp46491
S'NLM: PMC3653371'
p46492
asS'MH'
p46493
(lp46494
S'Adolescent'
p46495
aS'Adult'
p46496
aS'Age Factors'
p46497
aS'Female'
p46498
aS'HIV Infections/*drug therapy'
p46499
aS'Humans'
p46500
aS'Logistic Models'
p46501
aS'Male'
p46502
aS'Proportional Hazards Models'
p46503
aS'Retrospective Studies'
p46504
aS'South Africa/epidemiology'
p46505
aS'Treatment Failure'
p46506
aS'Treatment Outcome'
p46507
aS'Viral Load/drug effects'
p46508
aS'Young Adult'
p46509
asS'EDAT'
p46510
S'2013/02/05 06:00'
p46511
sS'SO'
p46512
S'AIDS Res Hum Retroviruses. 2013 Jun;29(6):892-900. doi: 10.1089/AID.2012.0215. Epub 2013 Feb 25.'
p46513
sS'SB'
p46514
S'IM X'
p46515
sS'PMID'
p46516
S'23373540'
p46517
sS'PST'
p46518
S'ppublish'
p46519
stRp46520
ag2
(g3
g4
(dp46521
S'LID'
p46522
S'10.3402/gha.v6i0.19248 [doi]'
p46523
sS'STAT'
p46524
S'MEDLINE'
p46525
sS'DEP'
p46526
S'20130124'
p46527
sS'DA'
p46528
S'20130131'
p46529
sS'AID'
p46530
(lp46531
S'19248 [pii]'
p46532
asS'CRDT'
p46533
(lp46534
S'2013/02/01 06:00'
p46535
asS'DP'
p46536
S'2013'
p46537
sS'OWN'
p46538
S'NLM'
p46539
sS'PT'
p46540
(lp46541
S'Journal Article'
p46542
aS"Research Support, Non-U.S. Gov't"
p46543
aS"Research Support, U.S. Gov't, Non-P.H.S."
p46544
asS'LA'
p46545
(lp46546
S'eng'
p46547
asS'DCOM'
p46548
S'20130722'
p46549
sS'JT'
p46550
S'Global health action'
p46551
sS'LR'
p46552
S'20150219'
p46553
sS'FAU'
p46554
(lp46555
S'Sengayi, Mazvita'
p46556
aS'Dwane, Ntabozuko'
p46557
aS'Marinda, Edmore'
p46558
aS'Sipambo, Nosisa'
p46559
aS'Fairlie, Lee'
p46560
aS'Moultrie, Harry'
p46561
asS'TI'
p46562
S'Predictors of loss to follow-up among children in the first and second years of antiretroviral treatment in Johannesburg, South Africa.'
p46563
sS'RN'
p46564
(lp46565
S'0 (Anti-HIV Agents)'
p46566
asS'PL'
p46567
S'Sweden'
p46568
sS'PG'
p46569
S'19248'
p46570
sS'JID'
p46571
S'101496665'
p46572
sS'AB'
p46573
S"BACKGROUND: Ninety percent of the world's 2.1 million HIV-infected children live in sub-Saharan Africa, and 2.5% of South African children live with HIV. As HIV care and treatment programmes are scaled-up, a rise in loss to follow-up (LTFU) has been observed. OBJECTIVE: The aim of the study was to determine the rate of LTFU in children receiving antiretroviral treatment (ART) and to identify baseline characteristics associated with LTFU in the first year of treatment. We also explored the effect of patient characteristics at 12 months treatment on LTFU in the second year. METHODS: The study is an analysis of prospectively collected routine data of HIV-infected children at the Harriet Shezi Children's Clinic (HSCC) in Soweto, Johannesburg. Cox proportional hazards models were fitted to investigate associations between baseline characteristics and 12-month characteristics with LTFU in the first and second year on ART, respectively. RESULTS: The cumulative probability of LTFU at 12 months was 7.3% (95% CI 7.1-8.8). In the first 12 months on ART, independent predictors of LTFU were age <1 year at initiation, recent year of ART start, mother as a primary caregiver, and being underweight (WAZ </= -2). Among children still on treatment at 1 year from ART initiation, characteristics that predicted LTFU within the second year were recent year of ART start, mother as a primary caregiver, being underweight (WAZ </= -2), and low CD4 cell percentage. CONCLUSIONS: There are similarities between the known predictors of death and the predictors of LTFU in the first and second years of ART. Knowing the vital status of children is important to determine LTFU. Although HIV-positive children cared for by their mothers appear to be at greater risk of becoming LTFU, further research is needed to explore the challenges faced by mothers and other caregivers and their impact on long-term HIV care. There is also a need to investigate the effects of differential access to ART between mothers and children and its impact on ART outcomes in children."
p46574
sS'AD'
p46575
S'Wits Reproductive Health and HIV Research Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. mazvita.sengayi@nhls.ac.za'
p46576
sS'VI'
p46577
S'6'
sS'IS'
p46578
S'1654-9880 (Electronic) 1654-9880 (Linking)'
p46579
sS'PMC'
p46580
S'PMC3556704'
p46581
sS'AU'
p46582
(lp46583
S'Sengayi M'
p46584
aS'Dwane N'
p46585
aS'Marinda E'
p46586
aS'Sipambo N'
p46587
aS'Fairlie L'
p46588
aS'Moultrie H'
p46589
asS'MHDA'
p46590
S'2013/07/23 06:00'
p46591
sS'PHST'
p46592
(lp46593
S'2012/07/31 [received]'
p46594
aS'2012/11/13 [revised]'
p46595
aS'2012/11/13 [accepted]'
p46596
asS'OT'
p46597
(lp46598
S'HIV'
p46599
aS'South Africa'
p46600
aS'antiretroviral treatment'
p46601
aS'children'
p46602
aS'loss to follow-up'
p46603
asS'OTO'
p46604
(lp46605
S'NOTNLM'
p46606
asS'OID'
p46607
(lp46608
S'NLM: PMC3556704'
p46609
asS'MH'
p46610
(lp46611
S'Age Factors'
p46612
aS'Anti-HIV Agents/*therapeutic use'
p46613
aS'CD4 Lymphocyte Count'
p46614
aS'Caregivers/statistics & numerical data'
p46615
aS'Child'
p46616
aS'Child, Preschool'
p46617
aS'Female'
p46618
aS'HIV Infections/drug therapy/*epidemiology'
p46619
aS'Humans'
p46620
aS'Infant'
p46621
aS'*Lost to Follow-Up'
p46622
aS'Male'
p46623
aS'Proportional Hazards Models'
p46624
aS'Prospective Studies'
p46625
aS'South Africa/epidemiology'
p46626
aS'Thinness/epidemiology'
p46627
aS'Time Factors'
p46628
asS'EDAT'
p46629
S'2013/02/01 06:00'
p46630
sS'SO'
p46631
S'Glob Health Action. 2013 Jan 24;6:19248. doi: 10.3402/gha.v6i0.19248.'
p46632
sS'SB'
p46633
S'IM'
p46634
sS'PMID'
p46635
S'23364098'
p46636
sS'TA'
p46637
S'Glob Health Action'
p46638
sS'PST'
p46639
S'epublish'
p46640
stRp46641
ag2
(g3
g4
(dp46642
S'LID'
p46643
S'10.1089/jwh.2012.3585 [doi]'
p46644
sS'STAT'
p46645
S'MEDLINE'
p46646
sS'DEP'
p46647
S'20130125'
p46648
sS'DA'
p46649
S'20130212'
p46650
sS'AID'
p46651
(lp46652
S'10.1089/jwh.2012.3585 [doi]'
p46653
asS'CRDT'
p46654
(lp46655
S'2013/01/29 06:00'
p46656
asS'DP'
p46657
S'2013 Feb'
p46658
sS'AD'
p46659
S'Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. mmaskew@witshealth.co.za'
p46660
sS'OWN'
p46661
S'NLM'
p46662
sS'PT'
p46663
(lp46664
S'Journal Article'
p46665
aS'Research Support, N.I.H., Extramural'
p46666
aS"Research Support, U.S. Gov't, Non-P.H.S."
p46667
asS'LA'
p46668
(lp46669
S'eng'
p46670
asS'FAU'
p46671
(lp46672
S'Maskew, Mhairi'
p46673
aS'Brennan, Alana T'
p46674
aS'Westreich, Daniel'
p46675
aS'McNamara, Lynne'
p46676
aS'MacPhail, A Patrick'
p46677
aS'Fox, Matthew P'
p46678
asS'JT'
p46679
S"Journal of women's health (2002)"
p46680
sS'LR'
p46681
S'20150219'
p46682
sS'PG'
p46683
S'113-20'
p46684
sS'TI'
p46685
S'Gender differences in mortality and CD4 count response among virally suppressed HIV-positive patients.'
p46686
sS'RN'
p46687
(lp46688
S'0 (Anti-HIV Agents)'
p46689
asS'PL'
p46690
S'United States'
p46691
sS'TA'
p46692
S'J Womens Health (Larchmt)'
p46693
sS'JID'
p46694
S'101159262'
p46695
sS'AB'
p46696
S'BACKGROUND: Treatment outcomes for antiretroviral therapy (ART) patients may vary by gender, but estimates from current evidence may be confounded by disease stage and adherence. We investigated the gender differences in treatment response among HIV-positive patients virally suppressed within 6 months of treatment initiation. METHODS: We analyzed data from 7,354 patients initiating ART between April 2004 and April 2010 at Themba Lethu Clinic, a large urban public sector treatment facility in South Africa. We estimated the relations among gender, mortality, and mean CD4 response in HIV-infected adults virally suppressed within 6 months of treatment initiation and used inverse probability of treatment weights to correct estimates for loss to follow-up. RESULTS: Male patients had a 20% greater risk of death at both 24 months and 36 months of follow-up compared to females. Older patients and those with a low hemoglobin level or low body mass index (BMI) were at increased risk of mortality throughout follow-up. Men gained fewer CD4 cells after treatment initiation than did women. The mean differences in CD4 count gains made by women and men between baseline and 12, 24, and 36 months were 28.2 cells/mm(3) (95% confidence interval [CI] 22.2-34.3), 60.8 cells/mm(3) (95% CI 71.1-50.5 cells/mm(3)), and 83.0 cells/mm(3) (95% CI 97.1-68.8 cells/mm(3)), respectively. Additionally, patients with a current detectable viral load (>400 copies/mL) and older patients had a lower mean CD4 increase at the same time points. CONCLUSIONS: In this initially virally suppressed population, women showed consistently better immune response to treatment than did men. Promoting earlier uptake of HIV treatment among men may improve their immunologic outcomes.'
p46697
sS'GR'
p46698
(lp46699
S'2P30 AI064518/AI/NIAID NIH HHS/United States'
p46700
aS'K01 AI083097/AI/NIAID NIH HHS/United States'
p46701
aS'K01AI083097/AI/NIAID NIH HHS/United States'
p46702
aS'K99 HD063961/HD/NICHD NIH HHS/United States'
p46703
aS'K99-HD-06-3961/HD/NICHD NIH HHS/United States'
p46704
aS'P30 AI064518/AI/NIAID NIH HHS/United States'
p46705
aS'R00 HD063961/HD/NICHD NIH HHS/United States'
p46706
asS'IP'
p46707
S'2'
sS'IS'
p46708
S'1931-843X (Electronic) 1540-9996 (Linking)'
p46709
sS'PMC'
p46710
S'PMC3579326'
p46711
sS'DCOM'
p46712
S'20130522'
p46713
sS'AU'
p46714
(lp46715
S'Maskew M'
p46716
aS'Brennan AT'
p46717
aS'Westreich D'
p46718
aS'McNamara L'
p46719
aS'MacPhail AP'
p46720
aS'Fox MP'
p46721
asS'VI'
p46722
S'22'
p46723
sS'MHDA'
p46724
S'2013/05/23 06:00'
p46725
sS'PHST'
p46726
(lp46727
S'2013/01/25 [aheadofprint]'
p46728
asS'OID'
p46729
(lp46730
S'NLM: PMC3579326'
p46731
asS'MH'
p46732
(lp46733
S'Adolescent'
p46734
aS'Adult'
p46735
aS'Age Factors'
p46736
aS'Anti-HIV Agents/*therapeutic use'
p46737
aS'*Antiretroviral Therapy, Highly Active'
p46738
aS'CD4 Lymphocyte Count'
p46739
aS'Female'
p46740
aS'Follow-Up Studies'
p46741
aS'HIV Infections/drug therapy/*immunology/*mortality/virology'
p46742
aS'HIV-1/*drug effects'
p46743
aS'Humans'
p46744
aS'Male'
p46745
aS'Middle Aged'
p46746
aS'Risk Factors'
p46747
aS'Severity of Illness Index'
p46748
aS'Sex Factors'
p46749
aS'Socioeconomic Factors'
p46750
aS'South Africa/epidemiology'
p46751
aS'Time Factors'
p46752
aS'Treatment Outcome'
p46753
aS'Urban Population'
p46754
aS'Viral Load'
p46755
aS'Young Adult'
p46756
asS'EDAT'
p46757
S'2013/01/29 06:00'
p46758
sS'SO'
p46759
S'J Womens Health (Larchmt). 2013 Feb;22(2):113-20. doi: 10.1089/jwh.2012.3585. Epub 2013 Jan 25.'
p46760
sS'SB'
p46761
S'IM'
p46762
sS'PMID'
p46763
S'23350862'
p46764
sS'PST'
p46765
S'ppublish'
p46766
stRp46767
ag2
(g3
g4
(dp46768
S'LID'
p46769
S'10.1371/journal.pmed.1001369 [doi]'
p46770
sS'STAT'
p46771
S'MEDLINE'
p46772
sS'DEP'
p46773
S'20130108'
p46774
sS'DA'
p46775
S'20130123'
p46776
sS'AID'
p46777
(lp46778
S'10.1371/journal.pmed.1001369 [doi]'
p46779
aS'PMEDICINE-D-12-01188 [pii]'
p46780
asS'CRDT'
p46781
(lp46782
S'2013/01/24 06:00'
p46783
asS'DP'
p46784
S'2013'
p46785
sS'AD'
p46786
S'Harvard Medical School, Boston, Massachusetts, USA. norma_ware@hms.harvard.edu'
p46787
sS'OWN'
p46788
S'NLM'
p46789
sS'PT'
p46790
(lp46791
S'Journal Article'
p46792
aS'Research Support, N.I.H., Extramural'
p46793
aS"Research Support, Non-U.S. Gov't"
p46794
asS'LA'
p46795
(lp46796
S'eng'
p46797
asS'FAU'
p46798
(lp46799
S'Ware, Norma C'
p46800
aS'Wyatt, Monique A'
p46801
aS'Geng, Elvin H'
p46802
aS'Kaaya, Sylvia F'
p46803
aS'Agbaji, Oche O'
p46804
aS'Muyindike, Winnie R'
p46805
aS'Chalamilla, Guerino'
p46806
aS'Agaba, Patricia A'
p46807
asS'JT'
p46808
S'PLoS medicine'
p46809
sS'LR'
p46810
S'20160708'
p46811
sS'PG'
p46812
S'e1001369; discussion e1001369'
p46813
sS'TI'
p46814
S'Toward an understanding of disengagement from HIV treatment and care in sub-Saharan Africa: a qualitative study.'
p46815
sS'PL'
p46816
S'United States'
p46817
sS'TA'
p46818
S'PLoS Med'
p46819
sS'JID'
p46820
S'101231360'
p46821
sS'AB'
p46822
S"BACKGROUND: The rollout of antiretroviral therapy in sub-Saharan Africa has brought lifesaving treatment to millions of HIV-infected individuals. Treatment is lifelong, however, and to continue to benefit, patients must remain in care. Despite this, systematic investigations of retention have repeatedly documented high rates of loss to follow-up from HIV treatment programs. This paper introduces an explanation for missed clinic visits and subsequent disengagement among patients enrolled in HIV treatment and care programs in Africa. METHODS AND FINDINGS: Eight-hundred-ninety patients enrolled in HIV treatment programs in Jos, Nigeria; Dar es Salaam, Tanzania; and Mbarara, Uganda who had extended absences from care were tracked for qualitative research interviews. Two-hundred-eighty-seven were located, and 91 took part in the study. Interview data were inductively analyzed to identify reasons for missed visits and to assemble them into a broader explanation of how missed visits may develop into disengagement. Findings reveal unintentional and intentional reasons for missing, along with reluctance to return to care following an absence. Disengagement is interpreted as a process through which missed visits and ensuing reluctance to return over time erode patients' subjective sense of connectedness to care. CONCLUSIONS: Missed visits are inevitable over a lifelong course of HIV care. Efforts to prevent missed clinic visits combined with moves to minimize barriers to re-entry into care are more likely than either approach alone to keep missed visits from turning into long-term disengagement."
p46823
sS'GR'
p46824
(lp46825
S'K24 MH090894/MH/NIMH NIH HHS/United States'
p46826
aS'P30 AI027763/AI/NIAID NIH HHS/United States'
p46827
aS'P30 AI060354/AI/NIAID NIH HHS/United States'
p46828
aS'R21MH085557/MH/NIMH NIH HHS/United States'
p46829
asS'IP'
p46830
S'1'
sS'IS'
p46831
S'1549-1676 (Electronic) 1549-1277 (Linking)'
p46832
sS'PMC'
p46833
S'PMC3541407'
p46834
sS'DCOM'
p46835
S'20130619'
p46836
sS'AU'
p46837
(lp46838
S'Ware NC'
p46839
aS'Wyatt MA'
p46840
aS'Geng EH'
p46841
aS'Kaaya SF'
p46842
aS'Agbaji OO'
p46843
aS'Muyindike WR'
p46844
aS'Chalamilla G'
p46845
aS'Agaba PA'
p46846
asS'VI'
p46847
S'10'
p46848
sS'MHDA'
p46849
S'2013/06/20 06:00'
p46850
sS'PHST'
p46851
(lp46852
S'2012/04/25 [received]'
p46853
aS'2012/11/29 [accepted]'
p46854
aS'2013/01/08 [epublish]'
p46855
asS'OID'
p46856
(lp46857
S'NLM: PMC3541407'
p46858
asS'MH'
p46859
(lp46860
S'Africa South of the Sahara'
p46861
aS'Ambulatory Care'
p46862
aS'Antiretroviral Therapy, Highly Active'
p46863
aS'Comprehension'
p46864
aS'*Delivery of Health Care'
p46865
aS'Female'
p46866
aS'HIV Infections/*drug therapy'
p46867
aS'Humans'
p46868
aS'Male'
p46869
aS'Outcome Assessment (Health Care)'
p46870
aS'Patient Compliance'
p46871
aS'*Qualitative Research'
p46872
asS'EDAT'
p46873
S'2013/01/24 06:00'
p46874
sS'SO'
p46875
S'PLoS Med. 2013;10(1):e1001369; discussion e1001369. doi: 10.1371/journal.pmed.1001369. Epub 2013 Jan 8.'
p46876
sS'SB'
p46877
S'IM'
p46878
sS'PMID'
p46879
S'23341753'
p46880
sS'PST'
p46881
S'ppublish'
p46882
stRp46883
ag2
(g3
g4
(dp46884
S'LID'
p46885
S'10.1097/QAI.0b013e3182869558 [doi]'
p46886
sS'STAT'
p46887
S'MEDLINE'
p46888
sS'JT'
p46889
S'Journal of acquired immune deficiency syndromes (1999)'
p46890
sS'DA'
p46891
S'20130613'
p46892
sS'AID'
p46893
(lp46894
S'10.1097/QAI.0b013e3182869558 [doi]'
p46895
asS'CRDT'
p46896
(lp46897
S'2013/01/23 06:00'
p46898
asS'DP'
p46899
S'2013 Apr 15'
p46900
sS'AD'
p46901
S'Clinical and Training Unit, ICAP, Columbia University Mailman School of Public Health, New York, NY 10031, USA. rf2190@columbia.edu'
p46902
sS'OWN'
p46903
S'NLM'
p46904
sS'PT'
p46905
(lp46906
S'Comparative Study'
p46907
aS'Journal Article'
p46908
aS'Multicenter Study'
p46909
aS"Research Support, U.S. Gov't, Non-P.H.S."
p46910
aS"Research Support, U.S. Gov't, P.H.S."
p46911
asS'LA'
p46912
(lp46913
S'eng'
p46914
asS'FAU'
p46915
(lp46916
S'Fayorsey, Ruby N'
p46917
aS'Saito, Suzue'
p46918
aS'Carter, Rosalind J'
p46919
aS'Gusmao, Eduarda'
p46920
aS'Frederix, Koen'
p46921
aS'Koech-Keter, Emily'
p46922
aS'Tene, Gilbert'
p46923
aS'Panya, Milembe'
p46924
aS'Abrams, Elaine J'
p46925
asS'PG'
p46926
S'e124-30'
p46927
sS'TI'
p46928
S'Decentralization of pediatric HIV care and treatment in five sub-Saharan African countries.'
p46929
sS'RN'
p46930
(lp46931
S'0 (Anti-HIV Agents)'
p46932
asS'PL'
p46933
S'United States'
p46934
sS'TA'
p46935
S'J Acquir Immune Defic Syndr'
p46936
sS'JID'
p46937
S'100892005'
p46938
sS'AB'
p46939
S'BACKGROUND: In resource-limited settings, decentralization of HIV care and treatment is a cornerstone of universal care and rapid scale-up. We compared trends in pediatric enrollment and outcomes at primary (PHFs) vs secondary/tertiary health facilities (SHFs). METHODS: Using aggregate program data reported quarterly from 274 public facilities in Kenya, Lesotho, Mozambique, Rwanda, and Tanzania from January 2008 to March 2010, we examined trends in number of children younger than 15 years of age initiating antiretroviral treatment (ART) by facility type. We compared clinic-level lost to follow-up (LTFU) and mortality per 100 person-years (PYs) on ART during the period by facility type. RESULTS: During the 2-year period, 17,155 children enrolled in HIV care and 8475 initiated ART in 182 (66%) PHFs and 92(34%) SHFs. PHFs increased from 56 to 182, whereas SHFs increased from 72 to 92 sites. SHFs accounted for 71% of children initiating ART; however, the proportion of children initiating ART each quarter at PHFs increased from 17% (129) to 44% (463) in conjunction with an increase in PHFs during observation period. The average LTFU and mortality rates for children on ART were 9.8/100 PYs and 5.2/100 PYs, respectively, at PHFs and 20.2/100 PYs and 6.0/100 PYs, respectively, at SHFs. Adjusted models show PHFs associated with lower LTFU (adjusted rate ratio = 0.55; P = 0.022) and lower mortality (adjusted rate ratio = 0.66; P = 0.028). CONCLUSIONS: The expansion of pediatric services to PHFs has resulted in increased numbers of children on ART. Early findings suggest lower rates of LTFU and mortality at PHFs. Successful scale-up will require further expansion of pediatric services within PHFs.'
p46940
sS'GR'
p46941
(lp46942
S'5U2GPS001537-03/PHS HHS/United States'
p46943
asS'IP'
p46944
S'5'
sS'IS'
p46945
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p46946
sS'DCOM'
p46947
S'20131018'
p46948
sS'AU'
p46949
(lp46950
S'Fayorsey RN'
p46951
aS'Saito S'
p46952
aS'Carter RJ'
p46953
aS'Gusmao E'
p46954
aS'Frederix K'
p46955
aS'Koech-Keter E'
p46956
aS'Tene G'
p46957
aS'Panya M'
p46958
aS'Abrams EJ'
p46959
asS'VI'
p46960
S'62'
p46961
sS'MHDA'
p46962
S'2013/10/19 06:00'
p46963
sS'MH'
p46964
(lp46965
S'Adolescent'
p46966
aS'Africa South of the Sahara'
p46967
aS'Anti-HIV Agents/*therapeutic use'
p46968
aS'CD4 Lymphocyte Count'
p46969
aS'Child'
p46970
aS'Child, Preschool'
p46971
aS'*HIV'
p46972
aS'HIV Infections/*drug therapy/virology'
p46973
aS'Health Facilities/*trends'
p46974
aS'Humans'
p46975
aS'Infant'
p46976
aS'Politics'
p46977
aS'Regression Analysis'
p46978
aS'Retrospective Studies'
p46979
asS'EDAT'
p46980
S'2013/01/23 06:00'
p46981
sS'SO'
p46982
S'J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):e124-30. doi: 10.1097/QAI.0b013e3182869558.'
p46983
sS'SB'
p46984
S'IM X'
p46985
sS'PMID'
p46986
S'23337367'
p46987
sS'PST'
p46988
S'ppublish'
p46989
stRp46990
ag2
(g3
g4
(dp46991
S'LID'
p46992
S'10.7448/IAS.16.1.17998 [doi]'
p46993
sS'STAT'
p46994
S'MEDLINE'
p46995
sS'DEP'
p46996
S'20130115'
p46997
sS'DA'
p46998
S'20130124'
p46999
sS'AID'
p47000
(lp47001
S'17998 [pii]'
p47002
asS'DCOM'
p47003
S'20130703'
p47004
sS'DP'
p47005
S'2013'
p47006
sS'CN'
p47007
(lp47008
S'IeDEA Pediatric Working Group'
p47009
asS'OWN'
p47010
S'NLM'
p47011
sS'PT'
p47012
(lp47013
S'Journal Article'
p47014
aS'Research Support, N.I.H., Extramural'
p47015
asS'LA'
p47016
(lp47017
S'eng'
p47018
asS'CRDT'
p47019
(lp47020
S'2013/01/23 06:00'
p47021
asS'JT'
p47022
S'Journal of the International AIDS Society'
p47023
sS'LR'
p47024
S'20151119'
p47025
sS'PG'
p47026
S'17998'
p47027
sS'TI'
p47028
S'A survey of paediatric HIV programmatic and clinical management practices in Asia and sub-Saharan Africa--the International epidemiologic Databases to Evaluate AIDS (IeDEA).'
p47029
sS'PL'
p47030
S'Switzerland'
p47031
sS'TA'
p47032
S'J Int AIDS Soc'
p47033
sS'FIR'
p47034
(lp47035
S'Saphonn, V'
p47036
aS'Saramony, S'
p47037
aS'Vibol, U'
p47038
aS'Sophan, S'
p47039
aS'Tucker, J'
p47040
aS'Zhang, F J'
p47041
aS'Kumarasamy, N'
p47042
aS'Saghayam, S'
p47043
aS'Gaitonde, Y R'
p47044
aS'Kurniati, N'
p47045
aS'Muktiarti, D'
p47046
aS'Fong, S M'
p47047
aS'Thien, M'
p47048
aS'Yusoff, N K Nik'
p47049
aS'Hai, L C'
p47050
aS'Razali, K A'
p47051
aS'Rahman, N F Abdul'
p47052
aS'Nallusamy, R'
p47053
aS'Chan, K C'
p47054
aS'Sirisanthana, V'
p47055
aS'Aurpibul, L'
p47056
aS'Hansudewechakul, R'
p47057
aS'Taeprasert, P'
p47058
aS'Lumbiganon, P'
p47059
aS'Kosalaraksa, P'
p47060
aS'Tharnprisan, P'
p47061
aS'Jourdain, G'
p47062
aS'Mai, Chiang'
p47063
aS'Ananworanich, J'
p47064
aS'Phasomsap, C'
p47065
aS'Suwanlerk, T'
p47066
aS'Chokephaibulkit, K'
p47067
aS'Phongsamart, W'
p47068
aS'Truong, H K'
p47069
aS'Mai, D A N'
p47070
aS'Do, C V'
p47071
aS'Ha, M T'
p47072
aS'Huy, B V'
p47073
aS'Nguyen, V L'
p47074
aS'Le, N O'
p47075
aS'Sohn, A H'
p47076
aS'Durier, N'
p47077
aS'Pang, J'
p47078
aS'Cooper, D A'
p47079
aS'Law, M G'
p47080
aS'Kariminia, A'
p47081
aS'Niyongabo, Theodore'
p47082
aS'Bukuru, Helene'
p47083
aS'Nduwimana, Martin'
p47084
aS'Kariyo, Pierre'
p47085
aS'Mbaya, Marcel'
p47086
aS'Mukumbi, Henri'
p47087
aS'Ilunga, Beatrice'
p47088
aS'Abena Obama, Marie-Therese'
p47089
aS'Kamgaing, Nelly'
p47090
aS'Akam, Wilfred'
p47091
aS'Atibu, Joseph'
p47092
aS'Azinyue, Innocent'
p47093
aS'Kiumbu, Modeste'
p47094
aS'Konde, Christian'
p47095
aS'Ditekemena, John'
p47096
aS'Mwandagalirwa, Kashamuka'
p47097
aS'Newman, Jamie'
p47098
aS'Hemingway-Foday, Jennifer'
p47099
aS'Ayaya'
p47100
aS'Bukusi'
p47101
aS'Lyamuya'
p47102
aS'Maruchu'
p47103
aS'Otieno'
p47104
aS'Francis, Okong St'
p47105
aS'Wabwire, Deo'
p47106
aS'Masaba'
p47107
aS'Elul'
p47108
aS'Nuwagaba- Biribonwoha'
p47109
aS'Cohen'
p47110
aS'Sang, E'
p47111
aS'Rotich, E'
p47112
aS'Achieng, M'
p47113
aS'Chimbetete, Cleophas'
p47114
aS'Eley, Brian'
p47115
aS'Fritz, Christiane'
p47116
aS'Garone, Daniele'
p47117
aS'Giddy, Janet'
p47118
aS'Hoffmann, Christopher'
p47119
aS'MacPhail, Patrick'
p47120
aS'Moultrie, Harry'
p47121
aS'Ndirangu, James'
p47122
aS'Pestilli, Sabrina'
p47123
aS'Phiri, Sam'
p47124
aS'Prozesky, Hans'
p47125
aS'Rabie, Helena'
p47126
aS'Stringer, Jeff'
p47127
aS'Technau, Karl'
p47128
aS'Mother, Rahima Moosa'
p47129
aS'Vaz, Paula'
p47130
aS'Wood, Robin'
p47131
aS'Tutu, Desmond'
p47132
aS'Egger, Matthias'
p47133
aS'Graber, Claire'
p47134
aS'Kaeser, Fritz'
p47135
aS'Keiser, Olivia'
p47136
aS'Boulle, Andrew'
p47137
aS'Cornell, Morna'
p47138
aS'Davies, Mary-Ann'
p47139
aS'Maxwell, Nicola'
p47140
aS'Dabis, Francois'
p47141
aS'Bissagnene, Emmanuel'
p47142
aS'Akakpo, Jocelyn'
p47143
aS'Azondekon, Alain'
p47144
aS'Bashi, Jules'
p47145
aS'Gratien, Sagbo'
p47146
aS'Koumakpai, Sikiratou'
p47147
aS'Zannou, Marcel D'
p47148
aS'Diarra, Ye'
p47149
aS'Diendere, Eric-Arnaud'
p47150
aS'Drabo, Joseph'
p47151
aS'Koueta, Fla'
p47152
aS'Aka-Addi, Edmond'
p47153
aS'Amani-Bosse, Clarisse'
p47154
aS'Ba-Gomis, Franck- Olivier'
p47155
aS'Eboua-Tanoh, Franois'
p47156
aS'Eholie, Serge-Paul'
p47157
aS'Guehi, Calixte'
p47158
aS'Kouadio, Kouakou'
p47159
aS'Koule, Serge-Olivier'
p47160
aS'Messou, Eugene'
p47161
aS'Minga, Albert'
p47162
aS'Tanon, Aristophane'
p47163
aS'Timite-Konan, Marguerite'
p47164
aS'Toure, Pety'
p47165
aS'Peterson, Kevin'
p47166
aS'Goka, Bamenla'
p47167
aS'Renner, Lorna'
p47168
aS'Coulibaly, Hadizatou'
p47169
aS'Dicko, Fatoumata'
p47170
aS'Maiga, Moussa'
p47171
aS'Minta, Daouda'
p47172
aS'Sylla, Mariam'
p47173
aS'Traore, Hamar Alassane'
p47174
aS'Diop, Bernard'
p47175
aS'Ndiaye, Fatou Ly'
p47176
aS'Sow, Papa Salif'
p47177
aS'Signate, Haby'
p47178
aS'Balestre, Eric'
p47179
aS'Ekouevi, Didier K'
p47180
aS'Jaquet, Antoine'
p47181
aS'Leroy, Valeriane'
p47182
aS'Lewden, Charlotte'
p47183
aS'Malateste, Karen'
p47184
aS'Sasco, Annie'
p47185
aS'Thiebaut, Rodolphe'
p47186
aS'Allou, Gerard'
p47187
aS'Azani, Jean Claude'
p47188
aS'Coffie, Patrick'
p47189
aS'de Gaulle, Charles'
p47190
aS'Doring, Alexandra'
p47191
aS'Rabourdin, Elodie'
p47192
aS'Djetou, Hughes'
p47193
asS'JID'
p47194
S'101478566'
p47195
sS'AB'
p47196
S'INTRODUCTION: There are limited data on paediatric HIV care and treatment programmes in low-resource settings. METHODS: A standardized survey was completed by International epidemiologic Databases to Evaluate AIDS paediatric cohort sites in the regions of Asia-Pacific (AP), Central Africa (CA), East Africa (EA), Southern Africa (SA) and West Africa (WA) to understand operational resource availability and paediatric management practices. Data were collected through January 2010 using a secure, web-based software program (REDCap). RESULTS: A total of 64,552 children were under care at 63 clinics (AP, N=10; CA, N=4; EA, N=29; SA, N=10; WA, N=10). Most were in urban settings (N=41, 65%) and received funding from governments (N=51, 81%), PEPFAR (N=34, 54%), and/or the Global Fund (N=15, 24%). The majority were combined adult-paediatric clinics (N=36, 57%). Prevention of mother-to-child transmission was integrated at 35 (56%) sites; 89% (N=56) had access to DNA PCR for infant diagnosis. African (N=40/53) but not Asian sites recommended exclusive breastfeeding up until 4-6 months. Regular laboratory monitoring included CD4 (N=60, 95%), and viral load (N=24, 38%). Although 42 (67%) sites had the ability to conduct acid-fast bacilli (AFB) smears, 23 (37%) sites could conduct AFB cultures and 18 (29%) sites could conduct tuberculosis drug susceptibility testing. Loss to follow-up was defined as >3 months of lost contact for 25 (40%) sites, >6 months for 27 sites (43%) and >12 months for 6 sites (10%). Telephone calls (N=52, 83%) and outreach worker home visits to trace children lost to follow-up (N=45, 71%) were common. CONCLUSIONS: In general, there was a high level of patient and laboratory monitoring within this multiregional paediatric cohort consortium that will facilitate detailed observational research studies. Practices will continue to be monitored as the WHO/UNAIDS Treatment 2.0 framework is implemented.'
p47197
sS'GR'
p47198
(lp47199
S'R01 AI058736/AI/NIAID NIH HHS/United States'
p47200
aS'U01 AI069907/AI/NIAID NIH HHS/United States'
p47201
aS'U01 AI069919/AI/NIAID NIH HHS/United States'
p47202
aS'U01 AI069924/AI/NIAID NIH HHS/United States'
p47203
aS'U01AI069907/AI/NIAID NIH HHS/United States'
p47204
aS'U01AI069924-05S1/AI/NIAID NIH HHS/United States'
p47205
aS'U01AI09919/AI/NIAID NIH HHS/United States'
p47206
aS'U01AI69924/AI/NIAID NIH HHS/United States'
p47207
asS'VI'
p47208
S'16'
p47209
sS'IS'
p47210
S'1758-2652 (Electronic) 1758-2652 (Linking)'
p47211
sS'IR'
p47212
(lp47213
S'Saphonn V'
p47214
aS'Saramony S'
p47215
aS'Vibol U'
p47216
aS'Sophan S'
p47217
aS'Tucker J'
p47218
aS'Zhang FJ'
p47219
aS'Kumarasamy N'
p47220
aS'Saghayam S'
p47221
aS'Gaitonde YR'
p47222
aS'Kurniati N'
p47223
aS'Muktiarti D'
p47224
aS'Fong SM'
p47225
aS'Thien M'
p47226
aS'Yusoff NK'
p47227
aS'Hai LC'
p47228
aS'Razali KA'
p47229
aS'Rahman NF'
p47230
aS'Nallusamy R'
p47231
aS'Chan KC'
p47232
aS'Sirisanthana V'
p47233
aS'Aurpibul L'
p47234
aS'Hansudewechakul R'
p47235
aS'Taeprasert P'
p47236
aS'Lumbiganon P'
p47237
aS'Kosalaraksa P'
p47238
aS'Tharnprisan P'
p47239
aS'Jourdain G'
p47240
aS'Mai C'
p47241
aS'Ananworanich J'
p47242
aS'Phasomsap C'
p47243
aS'Suwanlerk T'
p47244
aS'Chokephaibulkit K'
p47245
aS'Phongsamart W'
p47246
aS'Truong HK'
p47247
aS'Mai DA'
p47248
aS'Do CV'
p47249
aS'Ha MT'
p47250
aS'Huy BV'
p47251
aS'Nguyen VL'
p47252
aS'Le NO'
p47253
aS'Sohn AH'
p47254
aS'Durier N'
p47255
aS'Pang J'
p47256
aS'Cooper DA'
p47257
aS'Law MG'
p47258
aS'Kariminia A'
p47259
aS'Niyongabo T'
p47260
aS'Bukuru H'
p47261
aS'Nduwimana M'
p47262
aS'Kariyo P'
p47263
aS'Mbaya M'
p47264
aS'Mukumbi H'
p47265
aS'Ilunga B'
p47266
aS'Abena Obama MT'
p47267
aS'Kamgaing N'
p47268
aS'Akam W'
p47269
aS'Atibu J'
p47270
aS'Azinyue I'
p47271
aS'Kiumbu M'
p47272
aS'Konde C'
p47273
aS'Ditekemena J'
p47274
aS'Mwandagalirwa K'
p47275
aS'Newman J'
p47276
aS'Hemingway-Foday J'
p47277
aS'Ayaya'
p47278
aS'Bukusi'
p47279
aS'Lyamuya'
p47280
aS'Maruchu'
p47281
aS'Otieno'
p47282
aS'Francis OS'
p47283
aS'Wabwire D'
p47284
aS'Masaba'
p47285
aS'Elul'
p47286
aS'Nuwagaba- Biribonwoha'
p47287
aS'Cohen'
p47288
aS'Sang E'
p47289
aS'Rotich E'
p47290
aS'Achieng M'
p47291
aS'Chimbetete C'
p47292
aS'Eley B'
p47293
aS'Fritz C'
p47294
aS'Garone D'
p47295
aS'Giddy J'
p47296
aS'Hoffmann C'
p47297
aS'MacPhail P'
p47298
aS'Moultrie H'
p47299
aS'Ndirangu J'
p47300
aS'Pestilli S'
p47301
aS'Phiri S'
p47302
aS'Prozesky H'
p47303
aS'Rabie H'
p47304
aS'Stringer J'
p47305
aS'Technau K'
p47306
aS'Mother RM'
p47307
aS'Vaz P'
p47308
aS'Wood R'
p47309
aS'Tutu D'
p47310
aS'Egger M'
p47311
aS'Graber C'
p47312
aS'Kaeser F'
p47313
aS'Keiser O'
p47314
aS'Boulle A'
p47315
aS'Cornell M'
p47316
aS'Davies MA'
p47317
aS'Maxwell N'
p47318
aS'Dabis F'
p47319
aS'Bissagnene E'
p47320
aS'Akakpo J'
p47321
aS'Azondekon A'
p47322
aS'Bashi J'
p47323
aS'Gratien S'
p47324
aS'Koumakpai S'
p47325
aS'Zannou MD'
p47326
aS'Diarra Y'
p47327
aS'Diendere EA'
p47328
aS'Drabo J'
p47329
aS'Koueta F'
p47330
aS'Aka-Addi E'
p47331
aS'Amani-Bosse C'
p47332
aS'Ba-Gomis F'
p47333
aS'Eboua-Tanoh F'
p47334
aS'Eholie SP'
p47335
aS'Guehi C'
p47336
aS'Kouadio K'
p47337
aS'Koule SO'
p47338
aS'Messou E'
p47339
aS'Minga A'
p47340
aS'Tanon A'
p47341
aS'Timite-Konan M'
p47342
aS'Toure P'
p47343
aS'Peterson K'
p47344
aS'Goka B'
p47345
aS'Renner L'
p47346
aS'Coulibaly H'
p47347
aS'Dicko F'
p47348
aS'Maiga M'
p47349
aS'Minta D'
p47350
aS'Sylla M'
p47351
aS'Traore HA'
p47352
aS'Diop B'
p47353
aS'Ndiaye FL'
p47354
aS'Sow PS'
p47355
aS'Signate H'
p47356
aS'Balestre E'
p47357
aS'Ekouevi DK'
p47358
aS'Jaquet A'
p47359
aS'Leroy V'
p47360
aS'Lewden C'
p47361
aS'Malateste K'
p47362
aS'Sasco A'
p47363
aS'Thiebaut R'
p47364
aS'Allou G'
p47365
aS'Azani JC'
p47366
aS'Coffie P'
p47367
aS'de Gaulle C'
p47368
aS'Doring A'
p47369
aS'Rabourdin E'
p47370
aS'Djetou H'
p47371
asS'MHDA'
p47372
S'2013/07/05 06:00'
p47373
sS'PHST'
p47374
(lp47375
S'2012/06/30 [received]'
p47376
aS'2012/12/05 [accepted]'
p47377
asS'OTO'
p47378
(lp47379
S'NOTNLM'
p47380
asS'OID'
p47381
(lp47382
S'NLM: PMC3547123'
p47383
asS'MH'
p47384
(lp47385
S'Acquired Immunodeficiency Syndrome/diagnosis/drug therapy/*epidemiology/*prevention & control'
p47386
aS'Adolescent'
p47387
aS'Africa South of the Sahara/epidemiology'
p47388
aS'Asia/epidemiology'
p47389
aS'Child'
p47390
aS'Child Health Services/*organization & administration'
p47391
aS'Child, Preschool'
p47392
aS'Female'
p47393
aS'*Health Services Administration'
p47394
aS'Health Services Research'
p47395
aS'Humans'
p47396
aS'Infant'
p47397
aS'Infant, Newborn'
p47398
aS'Male'
p47399
aS'Pregnancy'
p47400
aS'Surveys and Questionnaires'
p47401
asS'EDAT'
p47402
S'2013/01/23 06:00'
p47403
sS'PMC'
p47404
S'PMC3547123'
p47405
sS'SO'
p47406
S'J Int AIDS Soc. 2013 Jan 15;16:17998. doi: 10.7448/IAS.16.1.17998.'
p47407
sS'SB'
p47408
S'IM X'
p47409
sS'PMID'
p47410
S'23336728'
p47411
sS'OT'
p47412
(lp47413
S'Africa'
p47414
aS'Asia'
p47415
aS'cohort'
p47416
aS'observational'
p47417
aS'paediatric HIV'
p47418
asS'PST'
p47419
S'epublish'
p47420
stRp47421
ag2
(g3
g4
(dp47422
S'LID'
p47423
S'10.7448/IAS.15.2.18020 [doi]'
p47424
sS'STAT'
p47425
S'MEDLINE'
p47426
sS'DEP'
p47427
S'20121231'
p47428
sS'DA'
p47429
S'20130124'
p47430
sS'AID'
p47431
(lp47432
S'18020 [pii]'
p47433
asS'CRDT'
p47434
(lp47435
S'2013/01/23 06:00'
p47436
asS'DP'
p47437
S'2012'
p47438
sS'AD'
p47439
S'Clinical Group, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, UK. p.macpherson@liverpool.ac.uk'
p47440
sS'OWN'
p47441
S'NLM'
p47442
sS'PT'
p47443
(lp47444
S'Journal Article'
p47445
aS"Research Support, Non-U.S. Gov't"
p47446
asS'LA'
p47447
(lp47448
S'eng'
p47449
asS'FAU'
p47450
(lp47451
S'MacPherson, Peter'
p47452
aS'MacPherson, Eleanor E'
p47453
aS'Mwale, Daniel'
p47454
aS'Bertel Squire, Stephen'
p47455
aS'Makombe, Simon D'
p47456
aS'Corbett, Elizabeth L'
p47457
aS'Lalloo, David G'
p47458
aS'Desmond, Nicola'
p47459
asS'JT'
p47460
S'Journal of the International AIDS Society'
p47461
sS'LR'
p47462
S'20150219'
p47463
sS'PG'
p47464
S'18020'
p47465
sS'TI'
p47466
S'Barriers and facilitators to linkage to ART in primary care: a qualitative study of patients and providers in Blantyre, Malawi.'
p47467
sS'RN'
p47468
(lp47469
S'0 (Anti-HIV Agents)'
p47470
asS'PL'
p47471
S'Switzerland'
p47472
sS'TA'
p47473
S'J Int AIDS Soc'
p47474
sS'JID'
p47475
S'101478566'
p47476
sS'AB'
p47477
S'INTRODUCTION: Linkage from HIV testing and counselling (HTC) to initiation of antiretroviral therapy (ART) is suboptimal in many national programmes in sub-Saharan Africa, leading to delayed initiation of ART and increased risk of death. Reasons for failure of linkage are poorly understood. METHODS: Semi-structured qualitative interviews were undertaken with health providers and HIV-positive primary care patients as part of a prospective cohort study at primary health centres in Blantyre, Malawi. Patients successful and unsuccessful in linking to ART were included. RESULTS: Progression through the HIV care pathway was strongly influenced by socio-cultural norms, particularly around the perceived need to regain respect lost during a period of visibly declining health. Capacity to call upon the support of networks of families, friends and employers was a key determinant of successful progression. Over-busy clinics, non-functioning laboratories and unsuitable tools used for ART eligibility assessment (WHO clinical staging system and centralized CD4 count measurement) were important health systems determinants of drop-out. CONCLUSIONS: Key interventions that could rapidly improve linkage include guarantee of same-day, same-clinic ART eligibility assessments; utilization of the support offered by peer-groups and community health workers; and integration of HTC and ART programmes.'
p47478
sS'GR'
p47479
(lp47480
S'091769/Wellcome Trust/United Kingdom'
p47481
aS'WT089673/Wellcome Trust/United Kingdom'
p47482
asS'IP'
p47483
S'2'
sS'IS'
p47484
S'1758-2652 (Electronic) 1758-2652 (Linking)'
p47485
sS'PMC'
p47486
S'PMC3535694'
p47487
sS'DCOM'
p47488
S'20130510'
p47489
sS'AU'
p47490
(lp47491
S'MacPherson P'
p47492
aS'MacPherson EE'
p47493
aS'Mwale D'
p47494
aS'Bertel Squire S'
p47495
aS'Makombe SD'
p47496
aS'Corbett EL'
p47497
aS'Lalloo DG'
p47498
aS'Desmond N'
p47499
asS'VI'
p47500
S'15'
p47501
sS'MHDA'
p47502
S'2013/05/11 06:00'
p47503
sS'PHST'
p47504
(lp47505
S'2012/08/08 [received]'
p47506
aS'2012/11/02 [revised]'
p47507
aS'2012/12/05 [accepted]'
p47508
asS'OTO'
p47509
(lp47510
S'NOTNLM'
p47511
asS'OID'
p47512
(lp47513
S'NLM: PMC3535694'
p47514
asS'MH'
p47515
(lp47516
S'Adult'
p47517
aS'Anti-HIV Agents/*therapeutic use'
p47518
aS'CD4 Lymphocyte Count'
p47519
aS'Cohort Studies'
p47520
aS'Data Collection'
p47521
aS'Female'
p47522
aS'HIV Infections/*drug therapy/epidemiology'
p47523
aS'Humans'
p47524
aS'Malawi/epidemiology'
p47525
aS'Male'
p47526
aS'Middle Aged'
p47527
aS'*Primary Health Care'
p47528
aS'Social Support'
p47529
aS'Young Adult'
p47530
asS'EDAT'
p47531
S'2013/01/23 06:00'
p47532
sS'SO'
p47533
S'J Int AIDS Soc. 2012 Dec 31;15(2):18020. doi: 10.7448/IAS.15.2.18020.'
p47534
sS'SB'
p47535
S'IM X'
p47536
sS'PMID'
p47537
S'23336700'
p47538
sS'OT'
p47539
(lp47540
S'HIV testing and counselling'
p47541
aS'antiretroviral therapy'
p47542
aS'linkage to care'
p47543
aS'qualitative studies'
p47544
aS'sub-Saharan Africa'
p47545
asS'PST'
p47546
S'epublish'
p47547
stRp47548
ag2
(g3
g4
(dp47549
S'LID'
p47550
S'10.1186/1471-2458-13-38 [doi]'
p47551
sS'STAT'
p47552
S'MEDLINE'
p47553
sS'DEP'
p47554
S'20130115'
p47555
sS'DA'
p47556
S'20130416'
p47557
sS'AID'
p47558
(lp47559
S'1471-2458-13-38 [pii]'
p47560
aS'10.1186/1471-2458-13-38 [doi]'
p47561
asS'CRDT'
p47562
(lp47563
S'2013/01/17 06:00'
p47564
asS'DP'
p47565
S'2013'
p47566
sS'OWN'
p47567
S'NLM'
p47568
sS'PT'
p47569
(lp47570
S'Journal Article'
p47571
aS"Research Support, Non-U.S. Gov't"
p47572
asS'LA'
p47573
(lp47574
S'eng'
p47575
asS'DCOM'
p47576
S'20130618'
p47577
sS'JT'
p47578
S'BMC public health'
p47579
sS'LR'
p47580
S'20151119'
p47581
sS'FAU'
p47582
(lp47583
S'Mosha, Fausta'
p47584
aS'Muchunguzi, Victor'
p47585
aS'Matee, Mecey'
p47586
aS'Sangeda, Raphael Z'
p47587
aS'Vercauteren, Jurgen'
p47588
aS'Nsubuga, Peter'
p47589
aS'Lyamuya, Eligius'
p47590
aS'Vandamme, Anne-Mieke'
p47591
asS'TI'
p47592
S'Gender differences in HIV disease progression and treatment outcomes among HIV patients one year after starting antiretroviral treatment (ART) in Dar es Salaam, Tanzania.'
p47593
sS'RN'
p47594
(lp47595
S'0 (Anti-HIV Agents)'
p47596
asS'PL'
p47597
S'England'
p47598
sS'PG'
p47599
S'38'
p47600
sS'JID'
p47601
S'100968562'
p47602
sS'AB'
p47603
S'BACKGROUND: We investigated gender differences in treatment outcome during first line antiretroviral treatment (ART) in a hospital setting in Tanzania, assessing clinical, social demographic, virological and immunological factors. METHODS: We conducted a cohort study involving HIV infected patients scheduled to start ART and followed up to 1 year on ART. Structured questionnaires and patients file review were used to collect information and blood was collected for CD4 and viral load testing. Gender differences were assessed using Kruskal-Wallis test and chi-square test for continuous and categorical data respectively. Survival distributions for male and female patients were estimated using the Kaplan-Meier method and compared using Cox proportional hazards models. RESULTS: Of 234 patients recruited in this study, 70% were females. At baseline, women had significantly lower education level; lower monthly income, lower knowledge on ARV, less advanced HIV disease (33% women; 47% men started ART at WHO stage IV, p = 0.04), higher CD4 cell count (median 149 for women, 102 for men, p = 0.02) and higher BMI (p = 0.002). After 1 year of standard ART, a higher proportion of females survived although this was not significant, a significantly higher proportion of females had undetectable plasma viral load (69% women, 45% men, p = 0.003), however females ended at a comparable CD4 cell count (median CD4, 312 women; 321 men) signifying a worse CD4 cell increase (p = 0.05), even though they still had a higher BMI (p = 0.02). The unadjusted relative hazard for death for men compared to women was 1.94. After correcting for confounding factors, the Cox proportional hazards showed no significant difference in the survival rate (relative hazard 1.02). CONCLUSION: We observed women were starting treatment at a less advanced disease stage, but they had a lower socioeconomical status. After one year, both men and women had similar clinical and immunological conditions. It is not clear why women lose their immunological advantage over men despite a better virological treatment response. We recommend continuous follow up of this and more cohorts of patients to better understand the underlying causes for these differences and whether this will translate also in longer term differences.'
p47604
sS'AD'
p47605
S'Ministry of Health and Social Welfare, Box 65545, Dar es Salaam, Tanzania. fausta_mosha@yahoo.com'
p47606
sS'VI'
p47607
S'13'
p47608
sS'IS'
p47609
S'1471-2458 (Electronic) 1471-2458 (Linking)'
p47610
sS'PMC'
p47611
S'PMC3623886'
p47612
sS'AU'
p47613
(lp47614
S'Mosha F'
p47615
aS'Muchunguzi V'
p47616
aS'Matee M'
p47617
aS'Sangeda RZ'
p47618
aS'Vercauteren J'
p47619
aS'Nsubuga P'
p47620
aS'Lyamuya E'
p47621
aS'Vandamme AM'
p47622
asS'MHDA'
p47623
S'2013/06/19 06:00'
p47624
sS'PHST'
p47625
(lp47626
S'2012/10/01 [received]'
p47627
aS'2013/01/11 [accepted]'
p47628
aS'2013/01/15 [aheadofprint]'
p47629
asS'OID'
p47630
(lp47631
S'NLM: PMC3623886'
p47632
asS'MH'
p47633
(lp47634
S'Adult'
p47635
aS'Anti-HIV Agents/*therapeutic use'
p47636
aS'CD4 Lymphocyte Count/statistics & numerical data'
p47637
aS'*Disease Progression'
p47638
aS'Female'
p47639
aS'Follow-Up Studies'
p47640
aS'HIV Infections/*drug therapy/immunology/*pathology/virology'
p47641
aS'*Health Status Disparities'
p47642
aS'Humans'
p47643
aS'Male'
p47644
aS'Proportional Hazards Models'
p47645
aS'Sex Factors'
p47646
aS'Socioeconomic Factors'
p47647
aS'Surveys and Questionnaires'
p47648
aS'Tanzania'
p47649
aS'Time Factors'
p47650
aS'Treatment Outcome'
p47651
aS'Viral Load/statistics & numerical data'
p47652
asS'EDAT'
p47653
S'2013/01/17 06:00'
p47654
sS'SO'
p47655
S'BMC Public Health. 2013 Jan 15;13:38. doi: 10.1186/1471-2458-13-38.'
p47656
sS'SB'
p47657
S'IM'
p47658
sS'PMID'
p47659
S'23320567'
p47660
sS'TA'
p47661
S'BMC Public Health'
p47662
sS'PST'
p47663
S'epublish'
p47664
stRp47665
ag2
(g3
g4
(dp47666
S'LID'
p47667
S'10.1177/1545109712463073 [doi]'
p47668
sS'STAT'
p47669
S'MEDLINE'
p47670
sS'DEP'
p47671
S'20130111'
p47672
sS'DA'
p47673
S'20130322'
p47674
sS'AID'
p47675
(lp47676
S'1545109712463073 [pii]'
p47677
aS'10.1177/1545109712463073 [doi]'
p47678
asS'CRDT'
p47679
(lp47680
S'2013/01/15 06:00'
p47681
asS'DP'
p47682
S'2013 Mar-Apr'
p47683
sS'AD'
p47684
S"Botswana-Baylor Children's Clinical Centre of Excellence, Gaborone, Botswana. briannakirk@me.com"
p47685
sS'OWN'
p47686
S'NLM'
p47687
sS'PT'
p47688
(lp47689
S'Journal Article'
p47690
asS'LA'
p47691
(lp47692
S'eng'
p47693
asS'FAU'
p47694
(lp47695
S'Kirk, Brianna L'
p47696
aS'Gomila, Andres'
p47697
aS'Matshaba, Mogomotsi'
p47698
aS'Marape, Marape'
p47699
aS'Joel, Dipesalema R'
p47700
aS'Anabwani, Gabriel'
p47701
aS'Tolle, Michael A'
p47702
asS'JT'
p47703
S'Journal of the International Association of Providers of AIDS Care'
p47704
sS'LR'
p47705
S'20160517'
p47706
sS'PG'
p47707
S'90-4'
p47708
sS'TI'
p47709
S'Early outcomes of darunavir- and/or raltegravir-based antiretroviral therapy in children with multidrug-resistant HIV at a pediatric center in Botswana.'
p47710
sS'RN'
p47711
(lp47712
S'0 (HIV Protease Inhibitors)'
p47713
aS'0 (Pyrrolidinones)'
p47714
aS'0 (Sulfonamides)'
p47715
aS'43Y000U234 (Raltegravir Potassium)'
p47716
aS'O3J8G9O825 (Ritonavir)'
p47717
aS'YO603Y8113 (Darunavir)'
p47718
asS'PL'
p47719
S'United States'
p47720
sS'TA'
p47721
S'J Int Assoc Provid AIDS Care'
p47722
sS'JID'
p47723
S'101603896'
p47724
sS'AB'
p47725
S'BACKGROUND: Data on the use of ritonavir-boosted darunavir (DRV/r) and/or raltegravir (RAL) in resource-limited settings are rare and there is currently no published data regarding their use among African children. Botswana has recently made DRV/r and RAL available for patients failing second-line antiretroviral therapy (ART). METHODS: Retrospective chart review of 4 multidrug-resistant pediatric patients on DRV/r- and/or RAL-based regimens. Viral load, CD4 count, adherence by pill count, and World Health Organization (WHO) clinical stage prior to and after switch to DRV/r- and/or RAL-based regimen were assessed. Antiretroviral therapy history, duration of virologic failure, and time to viral suppression were also noted. Genotypic resistance assays reviewed for mutations present prior to switch. RESULTS: All patients achieved viral suppression, showed improved/stable CD4 counts, and obtained or maintained WHO clinical treatment stage I, even after long-standing virologic/immunologic failure. CONCLUSIONS: Well tolerated by and effective in our patients, DRV/r and RAL provide potentially lifesaving ART options for children and adolescents in resource-limited settings failing ART due to ritonavir-boosted lopinavir (LPV/r) resistance.'
p47726
sS'GR'
p47727
(lp47728
S'D43 TW001036/TW/FIC NIH HHS/United States'
p47729
asS'IP'
p47730
S'2'
sS'IS'
p47731
S'2325-9574 (Print) 2325-9574 (Linking)'
p47732
sS'DCOM'
p47733
S'20130827'
p47734
sS'AU'
p47735
(lp47736
S'Kirk BL'
p47737
aS'Gomila A'
p47738
aS'Matshaba M'
p47739
aS'Marape M'
p47740
aS'Joel DR'
p47741
aS'Anabwani G'
p47742
aS'Tolle MA'
p47743
asS'VI'
p47744
S'12'
p47745
sS'MHDA'
p47746
S'2013/08/28 06:00'
p47747
sS'PHST'
p47748
(lp47749
S'2013/01/11 [aheadofprint]'
p47750
asS'MH'
p47751
(lp47752
S'Adolescent'
p47753
aS'Antiretroviral Therapy, Highly Active'
p47754
aS'Botswana'
p47755
aS'Child'
p47756
aS'Darunavir'
p47757
aS'*Drug Resistance, Multiple, Viral'
p47758
aS'Female'
p47759
aS'HIV Infections/*drug therapy'
p47760
aS'HIV Protease Inhibitors/*therapeutic use'
p47761
aS'Humans'
p47762
aS'Male'
p47763
aS'Pyrrolidinones/*therapeutic use'
p47764
aS'Raltegravir Potassium'
p47765
aS'Retrospective Studies'
p47766
aS'Ritonavir/*therapeutic use'
p47767
aS'Sulfonamides/*therapeutic use'
p47768
aS'Treatment Outcome'
p47769
aS'Young Adult'
p47770
asS'EDAT'
p47771
S'2013/01/15 06:00'
p47772
sS'SO'
p47773
S'J Int Assoc Provid AIDS Care. 2013 Mar-Apr;12(2):90-4. doi: 10.1177/1545109712463073. Epub 2013 Jan 11.'
p47774
sS'SB'
p47775
S'IM'
p47776
sS'PMID'
p47777
S'23315674'
p47778
sS'PST'
p47779
S'ppublish'
p47780
stRp47781
ag2
(g3
g4
(dp47782
S'STAT'
p47783
S'MEDLINE'
p47784
sS'JT'
p47785
S'Current HIV research'
p47786
sS'MID'
p47787
(lp47788
S'NIHMS575959'
p47789
asS'DA'
p47790
S'20130227'
p47791
sS'AID'
p47792
(lp47793
S'CHIVR-EPUB-20130111-1 [pii]'
p47794
asS'CRDT'
p47795
(lp47796
S'2013/01/12 06:00'
p47797
asS'DP'
p47798
S'2013 Jan'
p47799
sS'AD'
p47800
S'Nebraska Center for Virology, University of Nebraska-Lincoln, 102C Morrison Center, 4240 Fair St, Lincoln, NE 68583-0900, USA.'
p47801
sS'OWN'
p47802
S'NLM'
p47803
sS'PT'
p47804
(lp47805
S'Journal Article'
p47806
aS'Research Support, N.I.H., Extramural'
p47807
asS'LA'
p47808
(lp47809
S'eng'
p47810
asS'FAU'
p47811
(lp47812
S'Gonzalez, Sandra'
p47813
aS'Tully, Damien C'
p47814
aS'Gondwe, Clement'
p47815
aS'Wood, Charles'
p47816
asS'LR'
p47817
S'20150219'
p47818
sS'PG'
p47819
S'43-9'
p47820
sS'TI'
p47821
S'Low-abundance resistant mutations in HIV-1 subtype C antiretroviral therapy-naive individuals as revealed by pyrosequencing.'
p47822
sS'RN'
p47823
(lp47824
S'0 (Anti-HIV Agents)'
p47825
aS'0 (Protease Inhibitors)'
p47826
aS'0 (Reverse Transcriptase Inhibitors)'
p47827
aS'EC 2.7.7.49 (HIV Reverse Transcriptase)'
p47828
asS'PL'
p47829
S'Netherlands'
p47830
sS'TA'
p47831
S'Curr HIV Res'
p47832
sS'JID'
p47833
S'101156990'
p47834
sS'AB'
p47835
S'Given the recent scale-up of antiretroviral therapy (ART) in sub-Saharan Africa, we sought to determine how often and at what levels do drug-resistant mutant variants exist in ART-naive HIV subtype C infected individuals. Samples from 10 ART-naive Zambian individuals were subjected to ultra-deep pyrosequencing (UDPS) to characterize the frequency of low-abundance drug resistance mutations in the pol gene. Low-abundance clinically relevant variants were detected for nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) in eight of the ten subjects. Intermediate to high-level resistance was predicted for the majority of NRTIs. Mutations conferring resistance to most first-line and some second-line therapy drugs were also observed. UDPS detected a number of additional major resistant mutations suggesting that these individuals may have an increased risk of virological failure after initiating ART. Moreover, the effectiveness of first-line and even some secondline ART may be compromised in this setting.'
p47836
sS'GR'
p47837
(lp47838
S'CA75903/CA/NCI NIH HHS/United States'
p47839
aS'D43 TW001429/TW/FIC NIH HHS/United States'
p47840
aS'D43 TW001492/TW/FIC NIH HHS/United States'
p47841
aS'P01AI48240/AI/NIAID NIH HHS/United States'
p47842
aS'P30 GM103509/GM/NIGMS NIH HHS/United States'
p47843
aS'P30GM103509/GM/NIGMS NIH HHS/United States'
p47844
aS'R01 CA075903/CA/NCI NIH HHS/United States'
p47845
aS'T32 AI060547/AI/NIAID NIH HHS/United States'
p47846
aS'T32 AI060547/AI/NIAID NIH HHS/United States'
p47847
asS'IP'
p47848
S'1'
sS'IS'
p47849
S'1873-4251 (Electronic) 1570-162X (Linking)'
p47850
sS'PMC'
p47851
S'PMC4005869'
p47852
sS'DCOM'
p47853
S'20130813'
p47854
sS'AU'
p47855
(lp47856
S'Gonzalez S'
p47857
aS'Tully DC'
p47858
aS'Gondwe C'
p47859
aS'Wood C'
p47860
asS'VI'
p47861
S'11'
p47862
sS'MHDA'
p47863
S'2013/08/14 06:00'
p47864
sS'PHST'
p47865
(lp47866
S'2012/12/05 [received]'
p47867
aS'2012/12/31 [revised]'
p47868
aS'2013/01/02 [accepted]'
p47869
asS'OID'
p47870
(lp47871
S'NLM: NIHMS575959'
p47872
aS'NLM: PMC4005869'
p47873
asS'MH'
p47874
(lp47875
S'Adult'
p47876
aS'Anti-HIV Agents/pharmacology'
p47877
aS'Drug Resistance, Viral/*genetics'
p47878
aS'Female'
p47879
aS'Genotype'
p47880
aS'HIV Infections/*virology'
p47881
aS'HIV Reverse Transcriptase/*antagonists & inhibitors/genetics'
p47882
aS'HIV-1/drug effects/*genetics'
p47883
aS'Humans'
p47884
aS'Male'
p47885
aS'*Mutation'
p47886
aS'Protease Inhibitors/pharmacology'
p47887
aS'Reverse Transcriptase Inhibitors/pharmacology'
p47888
aS'Sequence Analysis, DNA/methods'
p47889
aS'Zambia'
p47890
asS'EDAT'
p47891
S'2013/01/12 06:00'
p47892
sS'SO'
p47893
S'Curr HIV Res. 2013 Jan;11(1):43-9.'
p47894
sS'SB'
p47895
S'IM'
p47896
sS'PMID'
p47897
S'23305169'
p47898
sS'PST'
p47899
S'ppublish'
p47900
stRp47901
ag2
(g3
g4
(dp47902
S'LID'
p47903
S'10.1097/INF.0b013e3182829092 [doi]'
p47904
sS'STAT'
p47905
S'MEDLINE'
p47906
sS'JT'
p47907
S'The Pediatric infectious disease journal'
p47908
sS'MID'
p47909
(lp47910
S'NIHMS435420'
p47911
asS'DA'
p47912
S'20130711'
p47913
sS'AID'
p47914
(lp47915
S'10.1097/INF.0b013e3182829092 [doi]'
p47916
asS'CRDT'
p47917
(lp47918
S'2013/01/11 06:00'
p47919
asS'DP'
p47920
S'2013 Jun'
p47921
sS'AD'
p47922
S'Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town Faculty of Health Sciences, Cape Town, South Africa. catherine.orrell@hiv-research.org.za'
p47923
sS'OWN'
p47924
S'NLM'
p47925
sS'PT'
p47926
(lp47927
S'Journal Article'
p47928
aS'Research Support, American Recovery and Reinvestment Act'
p47929
aS'Research Support, N.I.H., Extramural'
p47930
asS'LA'
p47931
(lp47932
S'eng'
p47933
asS'FAU'
p47934
(lp47935
S'Orrell, Catherine'
p47936
aS'Levison, Julie'
p47937
aS'Ciaranello, Andrea'
p47938
aS'Bekker, Linda-Gail'
p47939
aS'Kuritzkes, Daniel R'
p47940
aS'Freedberg, Kenneth A'
p47941
aS'Wood, Robin'
p47942
asS'LR'
p47943
S'20160226'
p47944
sS'PG'
p47945
S'644-7'
p47946
sS'TI'
p47947
S'Resistance in pediatric patients experiencing virologic failure with first-line and second-line antiretroviral therapy.'
p47948
sS'RN'
p47949
(lp47950
S'0 (Anti-Retroviral Agents)'
p47951
aS'0 (RNA, Viral)'
p47952
aS'O3J8G9O825 (Ritonavir)'
p47953
asS'PL'
p47954
S'United States'
p47955
sS'TA'
p47956
S'Pediatr Infect Dis J'
p47957
sS'JID'
p47958
S'8701858'
p47959
sS'AB'
p47960
S'We examined HIV-1 resistance in children failing first-line and second-line antiretroviral therapy in South Africa, all with clade C virus. Those exposed to full-dose ritonavir had multiple protease resistance mutations. Nineteen percent had wild-type virus. Appropriate antiretroviral therapy sequencing in sub-Saharan African children is essential for prolong treatment options.'
p47961
sS'GR'
p47962
(lp47963
S'K01 AI078754/AI/NIAID NIH HHS/United States'
p47964
aS'K01 AI078754/AI/NIAID NIH HHS/United States'
p47965
aS'R01 AI058736/AI/NIAID NIH HHS/United States'
p47966
aS'R01 AI085736/AI/NIAID NIH HHS/United States'
p47967
aS'UM1 AI068632/AI/NIAID NIH HHS/United States'
p47968
aS'UM1 AI068636/AI/NIAID NIH HHS/United States'
p47969
aS'PEPFAR/United States'
p47970
asS'IP'
p47971
S'6'
sS'IS'
p47972
S'1532-0987 (Electronic) 0891-3668 (Linking)'
p47973
sS'PMC'
p47974
S'PMC3881960'
p47975
sS'DCOM'
p47976
S'20140206'
p47977
sS'AU'
p47978
(lp47979
S'Orrell C'
p47980
aS'Levison J'
p47981
aS'Ciaranello A'
p47982
aS'Bekker LG'
p47983
aS'Kuritzkes DR'
p47984
aS'Freedberg KA'
p47985
aS'Wood R'
p47986
asS'VI'
p47987
S'32'
p47988
sS'MHDA'
p47989
S'2014/02/07 06:00'
p47990
sS'OID'
p47991
(lp47992
S'NLM: NIHMS435420'
p47993
aS'NLM: PMC3881960'
p47994
asS'MH'
p47995
(lp47996
S'Adolescent'
p47997
aS'Anti-Retroviral Agents/pharmacology/*therapeutic use'
p47998
aS'Child'
p47999
aS'Child, Preschool'
p48000
aS'Cohort Studies'
p48001
aS'*Drug Resistance, Viral'
p48002
aS'Female'
p48003
aS'Genotype'
p48004
aS'HIV Infections/*drug therapy/*virology'
p48005
aS'HIV-1/*drug effects/genetics/isolation & purification'
p48006
aS'Humans'
p48007
aS'Infant'
p48008
aS'Male'
p48009
aS'Microbial Sensitivity Tests/methods'
p48010
aS'RNA, Viral/genetics'
p48011
aS'Retrospective Studies'
p48012
aS'Ritonavir/pharmacology/therapeutic use'
p48013
aS'South Africa'
p48014
aS'Treatment Failure'
p48015
asS'EDAT'
p48016
S'2013/01/11 06:00'
p48017
sS'SO'
p48018
S'Pediatr Infect Dis J. 2013 Jun;32(6):644-7. doi: 10.1097/INF.0b013e3182829092.'
p48019
sS'SB'
p48020
S'IM'
p48021
sS'PMID'
p48022
S'23303240'
p48023
sS'PST'
p48024
S'ppublish'
p48025
stRp48026
ag2
(g3
g4
(dp48027
S'LID'
p48028
S'10.1371/journal.pone.0053022 [doi]'
p48029
sS'STAT'
p48030
S'MEDLINE'
p48031
sS'DEP'
p48032
S'20130102'
p48033
sS'DA'
p48034
S'20130109'
p48035
sS'AID'
p48036
(lp48037
S'10.1371/journal.pone.0053022 [doi]'
p48038
aS'PONE-D-12-22199 [pii]'
p48039
asS'CRDT'
p48040
(lp48041
S'2013/01/10 06:00'
p48042
asS'DP'
p48043
S'2013'
p48044
sS'AD'
p48045
S'School of Medicine, College of Health Sciences, Moi University, Eldoret, Kenya.'
p48046
sS'OWN'
p48047
S'NLM'
p48048
sS'PT'
p48049
(lp48050
S'Journal Article'
p48051
aS'Research Support, N.I.H., Extramural'
p48052
aS"Research Support, Non-U.S. Gov't"
p48053
aS"Research Support, U.S. Gov't, Non-P.H.S."
p48054
aS"Research Support, U.S. Gov't, P.H.S."
p48055
asS'LA'
p48056
(lp48057
S'eng'
p48058
asS'FAU'
p48059
(lp48060
S'Siika, Abraham M'
p48061
aS'Yiannoutsos, Constantin T'
p48062
aS'Wools-Kaloustian, Kara K'
p48063
aS'Musick, Beverly S'
p48064
aS'Mwangi, Ann W'
p48065
aS'Diero, Lameck O'
p48066
aS'Kimaiyo, Sylvester N'
p48067
aS'Tierney, William M'
p48068
aS'Carter, Jane E'
p48069
asS'JT'
p48070
S'PloS one'
p48071
sS'LR'
p48072
S'20150528'
p48073
sS'PG'
p48074
S'e53022'
p48075
sS'TI'
p48076
S'Active tuberculosis is associated with worse clinical outcomes in HIV-infected African patients on antiretroviral therapy.'
p48077
sS'RN'
p48078
(lp48079
S'0 (Anti-Retroviral Agents)'
p48080
asS'PL'
p48081
S'United States'
p48082
sS'TA'
p48083
S'PLoS One'
p48084
sS'JID'
p48085
S'101285081'
p48086
sS'AB'
p48087
S"OBJECTIVE: This cohort study utilized data from a large HIV treatment program in western Kenya to describe the impact of active tuberculosis (TB) on clinical outcomes among African patients on antiretroviral therapy (ART). DESIGN: We included all patients initiating ART between March 2004 and November 2007. Clinical (signs and symptoms), radiological (chest radiographs) and laboratory (mycobacterial smears, culture and tissue histology) criteria were used to record the diagnosis of TB disease in the program's electronic medical record system. METHODS: We assessed the impact of TB disease on mortality, loss to follow-up (LTFU) and incident AIDS-defining events (ADEs) through Cox models and CD4 cell and weight response to ART by non-linear mixed models. RESULTS: We studied 21,242 patients initiating ART-5,186 (24%) with TB; 62% female; median age 37 years. There were proportionately more men in the active TB (46%) than in the non-TB (35%) group. Adjusting for baseline HIV-disease severity, TB patients were more likely to die (hazard ratio--HR = 1.32, 95% CI 1.18-1.47) or have incident ADEs (HR = 1.31, 95% CI: 1.19-1.45). They had lower median CD4 cell counts (77 versus 109), weight (52.5 versus 55.0 kg) and higher ADE risk at baseline (CD4-adjusted odds ratio = 1.55, 95% CI: 1.31-1.85). ART adherence was similarly good in both groups. Adjusting for gender and baseline CD4 cell count, TB patients experienced virtually identical rise in CD4 counts after ART initiation as those without. However, the overall CD4 count at one year was lower among patients with TB (251 versus 269 cells/microl). CONCLUSIONS: Clinically detected TB disease is associated with greater mortality and morbidity despite salutary response to ART. Data suggest that identifying HIV patients co-infected with TB earlier in the HIV-disease trajectory may not fully address TB-related morbidity and mortality."
p48088
sS'GR'
p48089
(lp48090
S'AI-069911/AI/NIAID NIH HHS/United States'
p48091
asS'IP'
p48092
S'1'
sS'IS'
p48093
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p48094
sS'PMC'
p48095
S'PMC3534658'
p48096
sS'DCOM'
p48097
S'20130820'
p48098
sS'AU'
p48099
(lp48100
S'Siika AM'
p48101
aS'Yiannoutsos CT'
p48102
aS'Wools-Kaloustian KK'
p48103
aS'Musick BS'
p48104
aS'Mwangi AW'
p48105
aS'Diero LO'
p48106
aS'Kimaiyo SN'
p48107
aS'Tierney WM'
p48108
aS'Carter JE'
p48109
asS'VI'
p48110
S'8'
sS'MHDA'
p48111
S'2013/08/21 06:00'
p48112
sS'PHST'
p48113
(lp48114
S'2012/07/24 [received]'
p48115
aS'2012/11/22 [accepted]'
p48116
aS'2013/01/02 [epublish]'
p48117
asS'OID'
p48118
(lp48119
S'NLM: PMC3534658'
p48120
asS'MH'
p48121
(lp48122
S'Adult'
p48123
aS'Anti-Retroviral Agents/therapeutic use'
p48124
aS'CD4-Positive T-Lymphocytes/cytology'
p48125
aS'Cohort Studies'
p48126
aS'Comorbidity'
p48127
aS'Female'
p48128
aS'HIV Infections/*complications/drug therapy/*mortality'
p48129
aS'Humans'
p48130
aS'Kenya'
p48131
aS'Male'
p48132
aS'Medical Records Systems, Computerized'
p48133
aS'Proportional Hazards Models'
p48134
aS'Retrospective Studies'
p48135
aS'Treatment Outcome'
p48136
aS'Tuberculosis/*complications/drug therapy/*mortality'
p48137
aS'Weight Gain'
p48138
asS'EDAT'
p48139
S'2013/01/10 06:00'
p48140
sS'SO'
p48141
S'PLoS One. 2013;8(1):e53022. doi: 10.1371/journal.pone.0053022. Epub 2013 Jan 2.'
p48142
sS'SB'
p48143
S'IM'
p48144
sS'PMID'
p48145
S'23301015'
p48146
sS'PST'
p48147
S'ppublish'
p48148
stRp48149
ag2
(g3
g4
(dp48150
S'LID'
p48151
S'10.1111/tmi.12054 [doi]'
p48152
sS'STAT'
p48153
S'MEDLINE'
p48154
sS'DEP'
p48155
S'20130104'
p48156
sS'CI'
p48157
(lp48158
S'(c) 2013 Blackwell Publishing Ltd.'
p48159
asS'DA'
p48160
S'20130215'
p48161
sS'AID'
p48162
(lp48163
S'10.1111/tmi.12054 [doi]'
p48164
asS'CRDT'
p48165
(lp48166
S'2013/01/08 06:00'
p48167
asS'DP'
p48168
S'2013 Mar'
p48169
sS'OWN'
p48170
S'NLM'
p48171
sS'PT'
p48172
(lp48173
S'Comparative Study'
p48174
aS'Journal Article'
p48175
aS"Research Support, Non-U.S. Gov't"
p48176
asS'LA'
p48177
(lp48178
S'eng'
p48179
asS'FAU'
p48180
(lp48181
S'Mudiope, Peter K'
p48182
aS'Kim, Soyeon'
p48183
aS'Wabwire, Deo'
p48184
aS'Nyende, Louis'
p48185
aS'Bagenda, Danstan'
p48186
aS'Mubiru, Mike'
p48187
aS'Mulira, Robinah'
p48188
aS'Elbireer, Sawsan'
p48189
aS'Namukwaya, Zikulah'
p48190
aS'Fowler, Mary Glenn'
p48191
aS'Musoke, Philippa'
p48192
asS'JT'
p48193
S'Tropical medicine & international health : TM & IH'
p48194
sS'LR'
p48195
S'20131121'
p48196
sS'PG'
p48197
S'344-51'
p48198
sS'TI'
p48199
S'Long-term clinical and immunologic outcomes of HIV-infected women with and without previous exposure to nevirapine.'
p48200
sS'RN'
p48201
(lp48202
S'0 (Anti-HIV Agents)'
p48203
aS'99DK7FVK1H (Nevirapine)'
p48204
asS'PL'
p48205
S'England'
p48206
sS'TA'
p48207
S'Trop Med Int Health'
p48208
sS'JID'
p48209
S'9610576'
p48210
sS'AB'
p48211
S'OBJECTIVES: To determine and compare the clinical and immunologic outcomes for HIV-infected women initiated on antiretroviral therapy (ART), with and without previous exposure to single-dose nevirapine in the MTCT-Plus programme - Kampala, Uganda, from 2003 to 2011. METHODS: Retrospective comparison of prospectively collected programmatic data of clinical and immunologic treatment outcomes among HIV-infected Ugandan women, with and without prior exposure to sdNVP, who received NNRTI-based ART for a median follow-up of 6 years. RESULTS: Of the 408 women in the programme, 289 (70.8%) were started on ART, of whom 205 (70.9%) had prior exposure to sdNVP. Clinical, immunologic and combined (clinical and or immunologic) treatment failure occurred in 29 (10.0%), 132 (45.7%) and 142 (49.1%) women, respectively. There was no significant difference in the distribution of time to immunologic failure for women by exposure to sdNVP (log-rank P = 0.98). In Cox proportional hazard modelling, exposure to sdNVP was not associated with immunologic failure [adjusted hazard ratio (HR) = 0.89, 95% confidence interval (CI): 0.61-1.30]. CD4 count >100 cells/mm(3) at initiation was associated with reduced incidence of immunologic failure in adjusted analyses (HR = 0.32, 95% CI: 0.22-0.48). CONCLUSIONS: HIV-infected Ugandan women initiated on an NVP-based ART regimen had similar immunologic treatment outcomes irrespective of previous NVP exposure. CD4 cell count prior to initiating HAART was a key prognostic factor for successful long-term immunologic treatment outcomes. In poor settings, regular follow-up of patients on HAART with adequate counselling to promote adherence and safe disclosure may promote low clinical failure rates.'
p48212
sS'AD'
p48213
S'Makerere University - Johns Hopkins University Research Collaboration, Kampala, Uganda. pmudiope@mujhu.org'
p48214
sS'IP'
p48215
S'3'
sS'IS'
p48216
S'1365-3156 (Electronic) 1360-2276 (Linking)'
p48217
sS'DCOM'
p48218
S'20130408'
p48219
sS'AU'
p48220
(lp48221
S'Mudiope PK'
p48222
aS'Kim S'
p48223
aS'Wabwire D'
p48224
aS'Nyende L'
p48225
aS'Bagenda D'
p48226
aS'Mubiru M'
p48227
aS'Mulira R'
p48228
aS'Elbireer S'
p48229
aS'Namukwaya Z'
p48230
aS'Fowler MG'
p48231
aS'Musoke P'
p48232
asS'VI'
p48233
S'18'
p48234
sS'MHDA'
p48235
S'2013/04/09 06:00'
p48236
sS'PHST'
p48237
(lp48238
S'2013/01/04 [aheadofprint]'
p48239
asS'MH'
p48240
(lp48241
S'Adult'
p48242
aS'Anti-HIV Agents/*administration & dosage/pharmacology'
p48243
aS'Antiretroviral Therapy, Highly Active/*methods'
p48244
aS'CD4 Lymphocyte Count'
p48245
aS'Female'
p48246
aS'Follow-Up Studies'
p48247
aS'HIV Infections/*drug therapy/immunology'
p48248
aS'Humans'
p48249
aS'Infectious Disease Transmission, Vertical/*prevention & control'
p48250
aS'Kaplan-Meier Estimate'
p48251
aS'Nevirapine/*administration & dosage/pharmacology'
p48252
aS'Proportional Hazards Models'
p48253
aS'Retrospective Studies'
p48254
aS'Time Factors'
p48255
aS'Treatment Failure'
p48256
aS'Uganda'
p48257
asS'EDAT'
p48258
S'2013/01/08 06:00'
p48259
sS'SO'
p48260
S'Trop Med Int Health. 2013 Mar;18(3):344-51. doi: 10.1111/tmi.12054. Epub 2013 Jan 4.'
p48261
sS'SB'
p48262
S'IM'
p48263
sS'PMID'
p48264
S'23289497'
p48265
sS'PST'
p48266
S'ppublish'
p48267
stRp48268
ag2
(g3
g4
(dp48269
S'LID'
p48270
S'10.1371/journal.pone.0052856 [doi]'
p48271
sS'STAT'
p48272
S'MEDLINE'
p48273
sS'DEP'
p48274
S'20121220'
p48275
sS'DA'
p48276
S'20130103'
p48277
sS'AID'
p48278
(lp48279
S'10.1371/journal.pone.0052856 [doi]'
p48280
aS'PONE-D-12-24034 [pii]'
p48281
asS'CRDT'
p48282
(lp48283
S'2013/01/04 06:00'
p48284
asS'DP'
p48285
S'2012'
p48286
sS'OWN'
p48287
S'NLM'
p48288
sS'PT'
p48289
(lp48290
S'Journal Article'
p48291
asS'LA'
p48292
(lp48293
S'eng'
p48294
asS'FAU'
p48295
(lp48296
S'Bygrave, Helen'
p48297
aS'Mtangirwa, Judith'
p48298
aS'Ncube, Kwenzakwenkosi'
p48299
aS'Ford, Nathan'
p48300
aS'Kranzer, Katharina'
p48301
aS'Munyaradzi, Dhodho'
p48302
asS'JT'
p48303
S'PloS one'
p48304
sS'LR'
p48305
S'20150219'
p48306
sS'PG'
p48307
S'e52856'
p48308
sS'TI'
p48309
S'Antiretroviral therapy outcomes among adolescents and youth in rural Zimbabwe.'
p48310
sS'PL'
p48311
S'United States'
p48312
sS'TA'
p48313
S'PLoS One'
p48314
sS'JID'
p48315
S'101285081'
p48316
sS'AB'
p48317
S'Around 2 million adolescents and 3 million youth are estimated to be living with HIV worldwide. Antiretroviral outcomes for this group appear to be worse compared to adults. We report antiretroviral therapy outcomes from a rural setting in Zimbabwe among patients aged 10-30 years who were initiated on ART between 2005 and 2008. The cohort was stratified into four age groups: 10-15 (young adolescents) 15.1-19 years (adolescents), 19.1-24 years (young adults) and 24.1-29.9 years (older adults). Survival analysis was used to estimate rates of deaths and loss to follow-up stratified by age group. Endpoints were time from ART initiation to death or loss to follow-up. Follow-up of patients on continuous therapy was censored at date of transfer, or study end (31 December 2008). Sex-adjusted Cox proportional hazards models were used to estimate hazard ratios for different age groups. 898 patients were included in the analysis; median duration on ART was 468 days. The risk of death were highest in adults compared to young adolescents (aHR 2.25, 95%CI 1.17-4.35). Young adults and adolescents had a 2-3 times higher risk of loss to follow-up compared to young adolescents. When estimating the risk of attrition combining loss to follow-up and death, young adults had the highest risk (aHR 2.70, 95%CI 1.62-4.52). This study highlights the need for adapted adherence support and service delivery models for both adolescents and young adults.'
p48318
sS'AD'
p48319
S'Southern Africa Medical Unit, Medecins Sans Frontieres, Cape Town, South Africa. Helen.bygrave@joburg.msf.org'
p48320
sS'IP'
p48321
S'12'
p48322
sS'IS'
p48323
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p48324
sS'PMC'
p48325
S'PMC3527625'
p48326
sS'DCOM'
p48327
S'20130627'
p48328
sS'AU'
p48329
(lp48330
S'Bygrave H'
p48331
aS'Mtangirwa J'
p48332
aS'Ncube K'
p48333
aS'Ford N'
p48334
aS'Kranzer K'
p48335
aS'Munyaradzi D'
p48336
asS'VI'
p48337
S'7'
sS'MHDA'
p48338
S'2013/06/29 06:00'
p48339
sS'PHST'
p48340
(lp48341
S'2012/07/30 [received]'
p48342
aS'2012/11/23 [accepted]'
p48343
aS'2012/12/20 [epublish]'
p48344
asS'OID'
p48345
(lp48346
S'NLM: PMC3527625'
p48347
asS'MH'
p48348
(lp48349
S'Adolescent'
p48350
aS'Adult'
p48351
aS'Age Factors'
p48352
aS'Antiretroviral Therapy, Highly Active'
p48353
aS'Child'
p48354
aS'Female'
p48355
aS'HIV Infections/drug therapy/*epidemiology/mortality'
p48356
aS'Humans'
p48357
aS'Male'
p48358
aS'Rural Population'
p48359
aS'Treatment Outcome'
p48360
aS'Young Adult'
p48361
aS'Zimbabwe/epidemiology'
p48362
asS'EDAT'
p48363
S'2013/01/04 06:00'
p48364
sS'SO'
p48365
S'PLoS One. 2012;7(12):e52856. doi: 10.1371/journal.pone.0052856. Epub 2012 Dec 20.'
p48366
sS'SB'
p48367
S'IM'
p48368
sS'PMID'
p48369
S'23285204'
p48370
sS'PST'
p48371
S'ppublish'
p48372
stRp48373
ag2
(g3
g4
(dp48374
S'LID'
p48375
S'10.1371/journal.pone.0051631 [doi]'
p48376
sS'STAT'
p48377
S'MEDLINE'
p48378
sS'DEP'
p48379
S'20121217'
p48380
sS'DA'
p48381
S'20130103'
p48382
sS'AID'
p48383
(lp48384
S'10.1371/journal.pone.0051631 [doi]'
p48385
aS'PONE-D-12-20764 [pii]'
p48386
asS'CRDT'
p48387
(lp48388
S'2013/01/04 06:00'
p48389
asS'DP'
p48390
S'2012'
p48391
sS'OWN'
p48392
S'NLM'
p48393
sS'PT'
p48394
(lp48395
S'Journal Article'
p48396
aS"Research Support, Non-U.S. Gov't"
p48397
asS'LA'
p48398
(lp48399
S'eng'
p48400
asS'FAU'
p48401
(lp48402
S'Castelnuovo, Barbara'
p48403
aS'Kiragga, Agnes'
p48404
aS'Afayo, Victor'
p48405
aS'Ncube, Malisa'
p48406
aS'Orama, Richard'
p48407
aS'Magero, Stephen'
p48408
aS'Okwi, Peter'
p48409
aS'Manabe, Yukari C'
p48410
aS'Kambugu, Andrew'
p48411
asS'JT'
p48412
S'PloS one'
p48413
sS'LR'
p48414
S'20151119'
p48415
sS'PG'
p48416
S'e51631'
p48417
sS'TI'
p48418
S'Implementation of provider-based electronic medical records and improvement of the quality of data in a large HIV program in Sub-Saharan Africa.'
p48419
sS'PL'
p48420
S'United States'
p48421
sS'TA'
p48422
S'PLoS One'
p48423
sS'JID'
p48424
S'101285081'
p48425
sS'AB'
p48426
S"INTRODUCTION: Starting in June 2010 the Infectious Diseases Institute (IDI) clinic (a large urban HIV out-patient facility) switched to provider-based Electronic Medical Records (EMR) from paper EMR entered in the database by data-entry clerks. Standardized clinics forms were eliminated but providers still fill free text clinical notes in physical patients' files. The objective of this study was to compare the rate of errors in the database before and after the introduction of the provider-based EMR. METHODS AND FINDINGS: Data in the database pre and post provider-based EMR was compared with the information in the patients' files and classified as correct, incorrect, and missing. We calculated the proportion of incorrect, missing and total error for key variables (toxicities, opportunistic infections, reasons for treatment change and interruption). Proportions of total errors were compared using chi-square test. A survey of the users of the EMR was also conducted. We compared data from 2,382 visits (from 100 individuals) of a retrospective validation conducted in 2007 with 34,957 visits (from 10,920 individuals) of a prospective validation conducted in April-August 2011. The total proportion of errors decreased from 66.5% in 2007 to 2.1% in 2011 for opportunistic infections, from 51.9% to 3.5% for ART toxicity, from 82.8% to 12.5% for reasons for ART interruption and from 94.1% to 0.9% for reasons for ART switch (all P<0.0001). The survey showed that 83% of the providers agreed that provider-based EMR led to improvement of clinical care, 80% reported improved access to patients' records, and 80% appreciated the automation of providers' tasks. CONCLUSIONS: The introduction of provider-based EMR improved the quality of data collected with a significant reduction in missing and incorrect information. The majority of providers and clients expressed satisfaction with the new system. We recommend the use of provider-based EMR in large HIV programs in Sub-Saharan Africa."
p48427
sS'AD'
p48428
S'Infectious Diseases Institute, Makerere College of Health Sciences, Kampala, Uganda. bcastelnuovo@idi.co.ug'
p48429
sS'IP'
p48430
S'12'
p48431
sS'IS'
p48432
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p48433
sS'PMC'
p48434
S'PMC3524185'
p48435
sS'DCOM'
p48436
S'20130617'
p48437
sS'AU'
p48438
(lp48439
S'Castelnuovo B'
p48440
aS'Kiragga A'
p48441
aS'Afayo V'
p48442
aS'Ncube M'
p48443
aS'Orama R'
p48444
aS'Magero S'
p48445
aS'Okwi P'
p48446
aS'Manabe YC'
p48447
aS'Kambugu A'
p48448
asS'VI'
p48449
S'7'
sS'MHDA'
p48450
S'2013/06/19 06:00'
p48451
sS'PHST'
p48452
(lp48453
S'2012/07/13 [received]'
p48454
aS'2012/11/08 [accepted]'
p48455
aS'2012/12/17 [epublish]'
p48456
asS'OID'
p48457
(lp48458
S'NLM: PMC3524185'
p48459
asS'MH'
p48460
(lp48461
S'Adult'
p48462
aS'Africa South of the Sahara'
p48463
aS'*Decision Support Systems, Clinical'
p48464
aS'Electronic Health Records/*utilization'
p48465
aS'HIV'
p48466
aS'HIV Infections/*therapy'
p48467
aS'Humans'
p48468
aS'*Program Development'
p48469
aS'*Quality Assurance, Health Care'
p48470
aS'Surveys and Questionnaires'
p48471
asS'EDAT'
p48472
S'2013/01/04 06:00'
p48473
sS'SO'
p48474
S'PLoS One. 2012;7(12):e51631. doi: 10.1371/journal.pone.0051631. Epub 2012 Dec 17.'
p48475
sS'SB'
p48476
S'IM'
p48477
sS'PMID'
p48478
S'23284728'
p48479
sS'PST'
p48480
S'ppublish'
p48481
stRp48482
ag2
(g3
g4
(dp48483
S'LID'
p48484
S'10.1093/heapol/czs131 [doi]'
p48485
sS'STAT'
p48486
S'MEDLINE'
p48487
sS'DEP'
p48488
S'20121229'
p48489
sS'DA'
p48490
S'20131226'
p48491
sS'AID'
p48492
(lp48493
S'czs131 [pii]'
p48494
aS'10.1093/heapol/czs131 [doi]'
p48495
asS'CRDT'
p48496
(lp48497
S'2013/01/01 06:00'
p48498
asS'DP'
p48499
S'2014 Jan'
p48500
sS'OWN'
p48501
S'NLM'
p48502
sS'PT'
p48503
(lp48504
S'Journal Article'
p48505
aS"Research Support, Non-U.S. Gov't"
p48506
asS'LA'
p48507
(lp48508
S'eng'
p48509
asS'FAU'
p48510
(lp48511
S'Uyei, Jennifer'
p48512
aS'Coetzee, David'
p48513
aS'Macinko, James'
p48514
aS'Weinberg, Sharon L'
p48515
aS'Guttmacher, Sally'
p48516
asS'JT'
p48517
S'Health policy and planning'
p48518
sS'PG'
p48519
S'42-55'
p48520
sS'TI'
p48521
S'Measuring the degree of integrated tuberculosis and HIV service delivery in Cape Town, South Africa.'
p48522
sS'RN'
p48523
(lp48524
S'0 (Anti-HIV Agents)'
p48525
aS'0 (Antitubercular Agents)'
p48526
asS'PL'
p48527
S'England'
p48528
sS'TA'
p48529
S'Health Policy Plan'
p48530
sS'JID'
p48531
S'8610614'
p48532
sS'AB'
p48533
S'To address the considerable tuberculosis (TB)/HIV co-infected population in Cape Town, a number of clinics have made an effort of varying degrees to integrate TB and HIV services. This article describes the development of a theory-based survey instrument designed to quantify the extent to which services were integrated in 33 clinics and presents the results of the survey. Using principal factor analysis, eight factors were extracted and used to make comparisons across three types of clinics: co-located TB and antiretroviral therapy (ART) services, clinics with TB services only and clinics with ART only. Clinics with co-located services scored highest on measures related to integrated TB/ART service delivery compared to clinics with single services, but within group variability was high indicating that co-location of TB and ART services is a necessary but insufficient condition for integrated service delivery. In addition, we found almost all clinics with only TB services in our sample had highly integrated pre-ART services, suggesting that integration of these services across a large number of clinics is feasible and acceptable to clinic staff. TB clinics with highly integrated pre-ART services appear to be efficient sites for introducing ART given that co-infected patients are already engaged in care, and may potentially facilitate earlier access to treatment and minimize loss to follow-up.'
p48534
sS'AD'
p48535
S'227 East 30th Street, New York, NY 10016, USA. E-mail: jennyuyei@gmail.com.'
p48536
sS'IP'
p48537
S'1'
sS'IS'
p48538
S'1460-2237 (Electronic) 0268-1080 (Linking)'
p48539
sS'DCOM'
p48540
S'20150420'
p48541
sS'AU'
p48542
(lp48543
S'Uyei J'
p48544
aS'Coetzee D'
p48545
aS'Macinko J'
p48546
aS'Weinberg SL'
p48547
aS'Guttmacher S'
p48548
asS'VI'
p48549
S'29'
p48550
sS'MHDA'
p48551
S'2015/04/22 06:00'
p48552
sS'PHST'
p48553
(lp48554
S'2012/12/29 [aheadofprint]'
p48555
asS'OTO'
p48556
(lp48557
S'NOTNLM'
p48558
asS'MH'
p48559
(lp48560
S'Anti-HIV Agents/therapeutic use'
p48561
aS'Antitubercular Agents/therapeutic use'
p48562
aS'Coinfection/drug therapy/therapy'
p48563
aS'Delivery of Health Care, Integrated/organization & administration/*statistics & numerical data'
p48564
aS'Factor Analysis, Statistical'
p48565
aS'HIV Infections/drug therapy/*therapy'
p48566
aS'Health Care Surveys'
p48567
aS'Humans'
p48568
aS'South Africa/epidemiology'
p48569
aS'Tuberculosis, Pulmonary/drug therapy/*therapy'
p48570
asS'EDAT'
p48571
S'2013/01/01 06:00'
p48572
sS'SO'
p48573
S'Health Policy Plan. 2014 Jan;29(1):42-55. doi: 10.1093/heapol/czs131. Epub 2012 Dec 29.'
p48574
sS'SB'
p48575
S'H'
sS'PMID'
p48576
S'23274439'
p48577
sS'OT'
p48578
(lp48579
S'HIV'
p48580
aS'Integrated service delivery'
p48581
aS'South Africa'
p48582
aS'co-infection'
p48583
aS'tuberculosis'
p48584
asS'PST'
p48585
S'ppublish'
p48586
stRp48587
ag2
(g3
g4
(dp48588
S'LID'
p48589
S'10.1371/journal.pmed.1001358 [doi]'
p48590
sS'STAT'
p48591
S'MEDLINE'
p48592
sS'DEP'
p48593
S'20121218'
p48594
sS'DA'
p48595
S'20121228'
p48596
sS'AID'
p48597
(lp48598
S'10.1371/journal.pmed.1001358 [doi]'
p48599
aS'PMEDICINE-D-11-00938 [pii]'
p48600
asS'CRDT'
p48601
(lp48602
S'2012/12/29 06:00'
p48603
asS'DP'
p48604
S'2012'
p48605
sS'OWN'
p48606
S'NLM'
p48607
sS'PT'
p48608
(lp48609
S'Journal Article'
p48610
aS'Review'
p48611
asS'LA'
p48612
(lp48613
S'eng'
p48614
asS'FAU'
p48615
(lp48616
S'Cobelens, Frank'
p48617
aS'van Kampen, Sanne'
p48618
aS'Ochodo, Eleanor'
p48619
aS'Atun, Rifat'
p48620
aS'Lienhardt, Christian'
p48621
asS'JT'
p48622
S'PLoS medicine'
p48623
sS'LR'
p48624
S'20150219'
p48625
sS'PG'
p48626
S'e1001358'
p48627
sS'TI'
p48628
S'Research on implementation of interventions in tuberculosis control in low- and middle-income countries: a systematic review.'
p48629
sS'RN'
p48630
(lp48631
S'0 (Antitubercular Agents)'
p48632
aS'V83O1VOZ8L (Isoniazid)'
p48633
asS'PL'
p48634
S'United States'
p48635
sS'TA'
p48636
S'PLoS Med'
p48637
sS'JID'
p48638
S'101231360'
p48639
sS'AB'
p48640
S'BACKGROUND: Several interventions for tuberculosis (TB) control have been recommended by the World Health Organization (WHO) over the past decade. These include isoniazid preventive therapy (IPT) for HIV-infected individuals and household contacts of infectious TB patients, diagnostic algorithms for rule-in or rule-out of smear-negative pulmonary TB, and programmatic treatment for multidrug-resistant TB. There is no systematically collected data on the type of evidence that is publicly available to guide the scale-up of these interventions in low- and middle-income countries. We investigated the availability of published evidence on their effectiveness, delivery, and cost-effectiveness that policy makers need for scaling-up these interventions at country level. METHODS AND FINDINGS: PubMed, Web of Science, EMBASE, and several regional databases were searched for studies published from 1 January 1990 through 31 March 2012 that assessed health outcomes, delivery aspects, or cost-effectiveness for any of these interventions in low- or middle-income countries. Selected studies were evaluated for their objective(s), design, geographical and institutional setting, and generalizability. Studies reporting health outcomes were categorized as primarily addressing efficacy or effectiveness of the intervention. These criteria were used to draw landscapes of published research. We identified 59 studies on IPT in HIV infection, 14 on IPT in household contacts, 44 on rule-in diagnosis, 19 on rule-out diagnosis, and 72 on second-line treatment. Comparative effectiveness studies were relatively few (n = 9) and limited to South America and sub-Saharan Africa for IPT in HIV-infection, absent for IPT in household contacts, and rare for second-line treatment (n = 3). Evaluations of diagnostic and screening algorithms were more frequent (n = 19) but geographically clustered and mainly of non-comparative design. Fifty-four studies evaluated ways of delivering these interventions, and nine addressed their cost-effectiveness. CONCLUSIONS: There are substantial gaps in published evidence for scale-up for five WHO-recommended TB interventions settings at country level, which for many countries possibly precludes program-wide implementation of these interventions. There is a strong need for rigorous operational research studies to be carried out in programmatic settings to inform on best use of existing and new interventions in TB control.'
p48641
sS'AD'
p48642
S'Department of Global Health, Academic Medical Center, Amsterdam, The Netherlands. f.cobelens@aighd.org'
p48643
sS'IP'
p48644
S'12'
p48645
sS'IS'
p48646
S'1549-1676 (Electronic) 1549-1277 (Linking)'
p48647
sS'PMC'
p48648
S'PMC3525528'
p48649
sS'DCOM'
p48650
S'20130604'
p48651
sS'AU'
p48652
(lp48653
S'Cobelens F'
p48654
aS'van Kampen S'
p48655
aS'Ochodo E'
p48656
aS'Atun R'
p48657
aS'Lienhardt C'
p48658
asS'VI'
p48659
S'9'
sS'MHDA'
p48660
S'2013/06/05 06:00'
p48661
sS'PHST'
p48662
(lp48663
S'2011/04/23 [received]'
p48664
aS'2012/11/08 [accepted]'
p48665
aS'2012/12/18 [epublish]'
p48666
asS'OID'
p48667
(lp48668
S'NLM: PMC3525528'
p48669
asS'MH'
p48670
(lp48671
S'Algorithms'
p48672
aS'Antitubercular Agents/therapeutic use'
p48673
aS'Coinfection/complications'
p48674
aS'Cost-Benefit Analysis'
p48675
aS'*Delivery of Health Care/economics'
p48676
aS'*Developing Countries'
p48677
aS'Evidence-Based Medicine'
p48678
aS'HIV Infections/complications'
p48679
aS'Humans'
p48680
aS'Isoniazid/therapeutic use'
p48681
aS'*Program Development'
p48682
aS'Tuberculosis, Pulmonary/complications/*diagnosis/*prevention & control'
p48683
asS'EDAT'
p48684
S'2012/12/29 06:00'
p48685
sS'SO'
p48686
S'PLoS Med. 2012;9(12):e1001358. doi: 10.1371/journal.pmed.1001358. Epub 2012 Dec 18.'
p48687
sS'SB'
p48688
S'IM'
p48689
sS'PMID'
p48690
S'23271959'
p48691
sS'PST'
p48692
S'ppublish'
p48693
stRp48694
ag2
(g3
g4
(dp48695
S'LID'
p48696
S'10.1258/ijsa.2012.012040 [doi]'
p48697
sS'STAT'
p48698
S'MEDLINE'
p48699
sS'JT'
p48700
S'International journal of STD & AIDS'
p48701
sS'DA'
p48702
S'20121221'
p48703
sS'AID'
p48704
(lp48705
S'23/12/890 [pii]'
p48706
aS'10.1258/ijsa.2012.012040 [doi]'
p48707
asS'CRDT'
p48708
(lp48709
S'2012/12/22 06:00'
p48710
asS'DP'
p48711
S'2012 Dec'
p48712
sS'AD'
p48713
S'Department of Medicine and Centre for Infectious Diseases (CID), Stellenbosch University, Cape Town, South Africa. mdz@iburst.co.za'
p48714
sS'OWN'
p48715
S'NLM'
p48716
sS'PT'
p48717
(lp48718
S'Journal Article'
p48719
aS'Research Support, N.I.H., Extramural'
p48720
aS"Research Support, Non-U.S. Gov't"
p48721
aS"Research Support, U.S. Gov't, Non-P.H.S."
p48722
asS'LA'
p48723
(lp48724
S'eng'
p48725
asS'FAU'
p48726
(lp48727
S'Zeier, M D'
p48728
aS'Nachega, J B'
p48729
aS'Van Der Merwe, F H'
p48730
aS'Eshun-Wilson, I'
p48731
aS'Van Schalkwyk, M'
p48732
aS'La Grange, M'
p48733
aS'Mason, D'
p48734
aS'Louw, M'
p48735
aS'Botha, M H'
p48736
asS'PG'
p48737
S'890-6'
p48738
sS'TI'
p48739
S'Impact of timing of antiretroviral therapy initiation on survival of cervical squamous intraepithelial lesions: a cohort analysis from South Africa.'
p48740
sS'RN'
p48741
(lp48742
S'0 (Anti-Retroviral Agents)'
p48743
asS'PL'
p48744
S'England'
p48745
sS'TA'
p48746
S'Int J STD AIDS'
p48747
sS'JID'
p48748
S'9007917'
p48749
sS'AB'
p48750
S'To determine factors that influence excision treatment outcome and recurrence of cervical squamous intraepithelial lesions (SIL) in women living with HIV infection, we analysed 1848 women who underwent excision treatment of cervical SIL at Tygerberg Hospital, Cape Town, South Africa. We compared treatment failure defined as presence of cervical intraepithelial neoplasia (CIN) I (presence of CIN I or higher at first follow-up after excision treatment) and post-excision recurrence of lesions (at one year or later) between women of HIV-positive, -negative or unknown status and examined factors associated with excision treatment outcome and recurrence. HIV-infected women experienced higher treatment failure than uninfected women (53.8% versus 26.9%, P < 0.001). At treatment failure, more HIV-infected women had low-grade squamous intraepithelial lesion (LSIL) compared with uninfected women (64.9% versus 37.3%, P < 0.001). Treatment failure did not differ with the type of excision used in HIV-infected women. HIV-infected women were more likely to experience recurrence of lesions after excision treatment than uninfected women (hazard ratio 1.95, 95% confidence interval [CI] 1.59-2.39; P < 0.001). Antiretroviral therapy (ART) initiated before excision biopsy had a strong protective effect against recurrence (hazard ratio 0.70, 95% CI 0.55-0.89; P = 0.006). Our data suggest that women with cervical SIL initiated on ART earlier may be expected to have better long-term excision treatment outcome. Close follow-up should be maintained after cervical excision treatment, especially in a setting of high HIV prevalence.'
p48751
sS'GR'
p48752
(lp48753
S'K23 AI 068582-01/AI/NIAID NIH HHS/United States'
p48754
aS'WT087537MA/Wellcome Trust/United Kingdom'
p48755
asS'IP'
p48756
S'12'
p48757
sS'IS'
p48758
S'1758-1052 (Electronic) 0956-4624 (Linking)'
p48759
sS'DCOM'
p48760
S'20130911'
p48761
sS'AU'
p48762
(lp48763
S'Zeier MD'
p48764
aS'Nachega JB'
p48765
aS'Van Der Merwe FH'
p48766
aS'Eshun-Wilson I'
p48767
aS'Van Schalkwyk M'
p48768
aS'La Grange M'
p48769
aS'Mason D'
p48770
aS'Louw M'
p48771
aS'Botha MH'
p48772
asS'VI'
p48773
S'23'
p48774
sS'MHDA'
p48775
S'2013/09/12 06:00'
p48776
sS'MH'
p48777
(lp48778
S'Adult'
p48779
aS'Anti-Retroviral Agents/*administration & dosage'
p48780
aS'Cervical Intraepithelial Neoplasia/*complications/epidemiology/*virology'
p48781
aS'Cohort Studies'
p48782
aS'Female'
p48783
aS'HIV Infections/*complications/*drug therapy/epidemiology'
p48784
aS'Humans'
p48785
aS'Kaplan-Meier Estimate'
p48786
aS'Recurrence'
p48787
aS'Retrospective Studies'
p48788
aS'South Africa/epidemiology'
p48789
aS'Statistics, Nonparametric'
p48790
aS'Treatment Outcome'
p48791
aS'Uterine Cervical Neoplasms/epidemiology/*surgery/*virology'
p48792
asS'EDAT'
p48793
S'2012/12/22 06:00'
p48794
sS'SO'
p48795
S'Int J STD AIDS. 2012 Dec;23(12):890-6. doi: 10.1258/ijsa.2012.012040.'
p48796
sS'SB'
p48797
S'IM X'
p48798
sS'PMID'
p48799
S'23258831'
p48800
sS'PST'
p48801
S'ppublish'
p48802
stRp48803
ag2
(g3
g4
(dp48804
S'LID'
p48805
S'10.7196/samj.6093 [doi]'
p48806
sS'STAT'
p48807
S'MEDLINE'
p48808
sS'DEP'
p48809
S'20121102'
p48810
sS'DA'
p48811
S'20121214'
p48812
sS'CRDT'
p48813
(lp48814
S'2012/12/15 06:00'
p48815
asS'DP'
p48816
S'2013 Jan'
p48817
sS'OWN'
p48818
S'NLM'
p48819
sS'PT'
p48820
(lp48821
S'Comparative Study'
p48822
aS'Journal Article'
p48823
asS'LA'
p48824
(lp48825
S'eng'
p48826
asS'FAU'
p48827
(lp48828
S'Puvaneswaran, B'
p48829
aS'Shoba, B'
p48830
asS'JT'
p48831
S'South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde'
p48832
sS'LR'
p48833
S'20151119'
p48834
sS'PG'
p48835
S'32-3'
p48836
sS'TI'
p48837
S'Misdiagnosis of tuberculosis in patients with lymphoma.'
p48838
sS'PL'
p48839
S'South Africa'
p48840
sS'TA'
p48841
S'S Afr Med J'
p48842
sS'JID'
p48843
S'0404520'
p48844
sS'AB'
p48845
S'BACKGROUND: Since 1970, the incidence of lymphoma, a potentially curable disease, has risen by 80% in the general population and in HIV- positive patients. Given its clinical similarities to tuberculosis (TB), lymphoma may be misdiagnosed and patients treated unnecessarily with potentially harmful TB medication. OBJECTIVES: (i) To identify patients with a histological diagnosis of lymphoma who were previously misdiagnosed with TB; and (ii) to raise awareness of lymphoma as a differential diagnosis when TB has not been confirmed. METHOD: A retrospective study was conducted at Ngwelezane Hospital in rural KwaZulu-Natal, which serves an estimated population of 3 million. Using clinic notes and a questionnaire for patients attending the lymphoma clinic, we identified patients who had undergone failed TB treatment in the 12 months before their histological confirmation of lymphoma. RESULTS: Twenty-one patients were included; 18 had been diagnosed with TB in the 12 months preceding the histological confirmation of lymphoma. All these patients subjectively reported TB treatment failure. CONCLUSIONS: Delay in diagnosing lymphoma or its misdiagnosis is an important clinical problem in South Africa, with the condition often misdiagnosed as TB. This subjects patients to incorrect treatment and potential harm. We propose an algorithm for the work-up of patients presenting with lymphadenopathy +/- constitutional symptoms, to assist diagnosis and management in resource-poor settings.'
p48846
sS'AD'
p48847
S'Department of Internal Medicine, Ngwelezane Hospital, Empangeni, KwaZulu-Natal, South Africa.'
p48848
sS'IP'
p48849
S'1'
sS'IS'
p48850
S'0256-9574 (Print)'
p48851
sS'DCOM'
p48852
S'20130221'
p48853
sS'AU'
p48854
(lp48855
S'Puvaneswaran B'
p48856
aS'Shoba B'
p48857
asS'VI'
p48858
S'103'
p48859
sS'MHDA'
p48860
S'2013/02/22 06:00'
p48861
sS'PHST'
p48862
(lp48863
S'2012/06/27 [received]'
p48864
aS'2012/09/19 [accepted]'
p48865
asS'MH'
p48866
(lp48867
S'Adult'
p48868
aS'Delayed Diagnosis'
p48869
aS'Diagnosis, Differential'
p48870
aS'*Diagnostic Errors'
p48871
aS'Female'
p48872
aS'Humans'
p48873
aS'Lymphoma/*complications/diagnosis'
p48874
aS'Male'
p48875
aS'Middle Aged'
p48876
aS'Retrospective Studies'
p48877
aS'Surveys and Questionnaires'
p48878
aS'Tuberculosis/complications/*diagnosis'
p48879
asS'EDAT'
p48880
S'2012/12/15 06:00'
p48881
sS'SO'
p48882
S'S Afr Med J. 2012 Nov 2;103(1):32-3. doi: 10.7196/samj.6093.'
p48883
sS'SB'
p48884
S'IM'
p48885
sS'PMID'
p48886
S'23237121'
p48887
sS'PST'
p48888
S'epublish'
p48889
stRp48890
ag2
(g3
g4
(dp48891
S'LID'
p48892
S'10.1080/17290376.2012.665255 [doi]'
p48893
sS'STAT'
p48894
S'MEDLINE'
p48895
sS'AB'
p48896
S"OBJECTIVE: With the aim of reducing pediatric loss to follow-up (LTFU) from HIV clinical care programs in sub-Saharan Africa, we sought to understand the personal and socio-cultural factors associated with the behavior of caregivers taking HIV-infected and -exposed children for care in western Kenya. METHODS: Between May and August, 2010, in-depth interviews were conducted with 26 purposively sampled caregivers caring for HIV-infected (7), HIV-exposed (17) and HIV-unknown status (2) children, documented as LTFU from an urban and rural HIV care clinic. All were women with a majority (77%) being biological parents. Interviews were audio-recorded, transcribed and content analyzed. RESULTS: Thematic content analysis of the women's perceptions revealed that their decision about routinely taking their children to HIV care involved multiple levels of factors including: (1) intrapersonal: transport costs, food availability, time constraints due to work commitment, disclosure of HIV status for both mother and child, perception that child is healthy and religious beliefs; (2) interpersonal: unsupportive male partner, stigma by the family and family conflicts; (3) community: cultural norms, changing community dynamics and perceived stigma; (4) health care system: clinic location, lack of patient-centered care, delays at the clinic and different appointment schedules (mother and child). Furthermore, the factors across these different levels interacted with each other in a complex way, illustrating the challenges women face in taking their children to HIV care. CONCLUSION: The complexity and interconnectedness of the factors underlying retention of children in HIV care perceived by these women caregivers suggests that interventions to reduce pediatric LTFU need to be holistic and address multiple socio-ecological levels. Patient-centered care that integrates a family-centered approach to HIV pediatric care is recommended."
p48897
sS'JID'
p48898
S'101226212'
p48899
sS'AD'
p48900
S'Health Behavior, Indiana University, Bloomington, USA. wachirajuddy@gmail.com'
p48901
sS'JT'
p48902
S'SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance / SAHARA , Human Sciences Research Council'
p48903
sS'IP'
p48904
S'1'
sS'IS'
p48905
S'1813-4424 (Electronic) 1729-0376 (Linking)'
p48906
sS'DCOM'
p48907
S'20130625'
p48908
sS'DA'
p48909
S'20121214'
p48910
sS'AU'
p48911
(lp48912
S'Wachira J'
p48913
aS'Middlestadt SE'
p48914
aS'Vreeman R'
p48915
aS'Braitstein P'
p48916
asS'AID'
p48917
(lp48918
S'10.1080/17290376.2012.665255 [doi]'
p48919
asS'CRDT'
p48920
(lp48921
S'2012/12/15 06:00'
p48922
asS'VI'
p48923
S'9'
sS'DP'
p48924
S'2012'
p48925
sS'MHDA'
p48926
S'2013/06/26 06:00'
p48927
sS'OWN'
p48928
S'NLM'
p48929
sS'PT'
p48930
(lp48931
S'Journal Article'
p48932
aS"Research Support, Non-U.S. Gov't"
p48933
asS'LA'
p48934
(lp48935
S'eng'
p48936
asS'MH'
p48937
(lp48938
S'Adult'
p48939
aS'*Caregivers/psychology'
p48940
aS'Child'
p48941
aS'Child Health Services/*methods'
p48942
aS'Child, Preschool'
p48943
aS'Female'
p48944
aS'HIV Infections/*drug therapy/epidemiology/psychology'
p48945
aS'Health Knowledge, Attitudes, Practice'
p48946
aS'Humans'
p48947
aS'Infant'
p48948
aS'Infant, Newborn'
p48949
aS'Kenya/epidemiology'
p48950
aS'*Lost to Follow-Up'
p48951
aS'Male'
p48952
aS'*Medication Adherence/psychology'
p48953
aS'*Mothers/psychology'
p48954
aS'Patient-Centered Care/*methods'
p48955
aS'Qualitative Research'
p48956
aS'Religion'
p48957
aS'Social Stigma'
p48958
aS'Social Support'
p48959
asS'FAU'
p48960
(lp48961
S'Wachira, Juddy'
p48962
aS'Middlestadt, Susan E'
p48963
aS'Vreeman, Rachel'
p48964
aS'Braitstein, Paula'
p48965
asS'EDAT'
p48966
S'2012/12/15 06:00'
p48967
sS'PST'
p48968
S'ppublish'
p48969
sS'SO'
p48970
S'SAHARA J. 2012;9(1):20-9. doi: 10.1080/17290376.2012.665255.'
p48971
sS'PG'
p48972
S'20-9'
p48973
sS'TI'
p48974
S'Factors underlying taking a child to HIV care: implications for reducing loss to follow-up among HIV-infected and -exposed children.'
p48975
sS'SB'
p48976
S'IM X'
p48977
sS'PMID'
p48978
S'23237018'
p48979
sS'PL'
p48980
S'South Africa'
p48981
sS'TA'
p48982
S'SAHARA J'
p48983
stRp48984
ag2
(g3
g4
(dp48985
S'LID'
p48986
S'10.1080/17290376.2011.9725002 [doi]'
p48987
sS'STAT'
p48988
S'MEDLINE'
p48989
sS'JT'
p48990
S'SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance / SAHARA , Human Sciences Research Council'
p48991
sS'DA'
p48992
S'20121214'
p48993
sS'AID'
p48994
(lp48995
S'10.1080/17290376.2011.9725002 [doi]'
p48996
asS'CRDT'
p48997
(lp48998
S'2012/12/15 06:00'
p48999
asS'DP'
p49000
S'2011'
p49001
sS'OWN'
p49002
S'NLM'
p49003
sS'PT'
p49004
(lp49005
S'Journal Article'
p49006
asS'LA'
p49007
(lp49008
S'eng'
p49009
asS'FAU'
p49010
(lp49011
S'Peltzer, Karl'
p49012
aS'Ramlagan, Shandir'
p49013
aS'Khan, Mohamed Salim'
p49014
aS'Gaede, Bernhard'
p49015
asS'LR'
p49016
S'20151119'
p49017
sS'PG'
p49018
S'179-86'
p49019
sS'TI'
p49020
S"The social and clinical characteristics of patients on antiretroviral therapy who are 'lost to follow-up' in KwaZulu-Natal, South Africa: a prospective study."
p49021
sS'RN'
p49022
(lp49023
S'0 (Anti-Retroviral Agents)'
p49024
aS'0 (Plant Preparations)'
p49025
asS'PL'
p49026
S'South Africa'
p49027
sS'TA'
p49028
S'SAHARA J'
p49029
sS'JID'
p49030
S'101226212'
p49031
sS'AB'
p49032
S"A significant proportion of those initiating antiretroviral treatment (ART) for HIV infection are lost to follow-up. Causes (including HIV symptoms, quality of life, depression, herbal treatment and alcohol use) for discontinuing ART follow-up in predominantly rural resource-limited settings are not well understood. This is a prospective study of the treatment-naive patients recruited from three (one urban, one-semi-urban and one rural) public hospitals in Uthukela health district in KwaZulu-Natal from October 2007 to February 2008. The aim of this study was to investigate predictors of loss to follow-up or all caused attrition from an ART programme within a cohort followed up for over 12 months. A total of 735 patients (217 men and 518 women) prior to initiating ART completed a baseline questionnaire and 6- and 12-months' follow-up. At 12-months follow-up 557 (75.9%) individuals continued active ART, 177 (24.1%) were all cause attrition, there were 82 deaths (13.8%), 58 (7.9%) transfers, 7 (1.0%) refused participation, 8 (1.1%) were not yet on ART and 22 (3.0%) could not be traced. Death by 12-months of follow-up was associated with lower CD4 cell counts (risk ratio, RR=2.05, confidence intervals, CI=1.20-3.49) and higher depression levels (RR=1.05, CI=1.01-1.09) at baseline assessment. The high early mortality rates indicate that patients are enrolling into ART programmes with far too advanced immunodeficiency; median CD4 cell counts 119 (IQR=59-163). Causes of late access to the ART programme, such as delays in health care access (delayed health care seeking), health system delays, or inappropriate treatment criteria, need to be addressed. Differences in health status (lower CD4 cell counts and higher depression scores) should be taken into account when initiating patients on ART. Treating depression at ART initiation is recommended to improve treatment outcome."
p49033
sS'AD'
p49034
S'Research Programme HIV/AIDS, STI and TB-HAST, Human Sciences Research Council, South Africa. kpeltzer@hsrc.ac.za'
p49035
sS'IP'
p49036
S'4'
sS'IS'
p49037
S'1813-4424 (Electronic) 1729-0376 (Linking)'
p49038
sS'DCOM'
p49039
S'20130528'
p49040
sS'AU'
p49041
(lp49042
S'Peltzer K'
p49043
aS'Ramlagan S'
p49044
aS'Khan MS'
p49045
aS'Gaede B'
p49046
asS'VI'
p49047
S'8'
sS'MHDA'
p49048
S'2013/05/29 06:00'
p49049
sS'MH'
p49050
(lp49051
S'Adolescent'
p49052
aS'Adult'
p49053
aS'Aged'
p49054
aS'Alcohol Drinking'
p49055
aS'Anti-Retroviral Agents/*therapeutic use'
p49056
aS'CD4 Lymphocyte Count'
p49057
aS'Delayed Diagnosis'
p49058
aS'Depression/complications'
p49059
aS'Female'
p49060
aS'HIV Infections/*drug therapy/immunology/*mortality'
p49061
aS'Health Services Accessibility'
p49062
aS'Humans'
p49063
aS'*Lost to Follow-Up'
p49064
aS'Male'
p49065
aS'*Medication Adherence'
p49066
aS'Middle Aged'
p49067
aS'Patient Acceptance of Health Care'
p49068
aS'Phytotherapy'
p49069
aS'Plant Preparations/therapeutic use'
p49070
aS'Prospective Studies'
p49071
aS'Quality of Life'
p49072
aS'Rural Population'
p49073
aS'Socioeconomic Factors'
p49074
aS'South Africa/epidemiology'
p49075
aS'Surveys and Questionnaires'
p49076
aS'Urban Population'
p49077
aS'Young Adult'
p49078
asS'EDAT'
p49079
S'2012/12/15 06:00'
p49080
sS'SO'
p49081
S'SAHARA J. 2011;8(4):179-86. doi: 10.1080/17290376.2011.9725002.'
p49082
sS'SB'
p49083
S'IM X'
p49084
sS'PMID'
p49085
S'23236959'
p49086
sS'PST'
p49087
S'ppublish'
p49088
stRp49089
ag2
(g3
g4
(dp49090
S'LID'
p49091
S'10.1371/journal.pone.0049564 [doi]'
p49092
sS'STAT'
p49093
S'MEDLINE'
p49094
sS'DEP'
p49095
S'20121207'
p49096
sS'DA'
p49097
S'20121213'
p49098
sS'AID'
p49099
(lp49100
S'10.1371/journal.pone.0049564 [doi]'
p49101
aS'PONE-D-11-09321 [pii]'
p49102
asS'CRDT'
p49103
(lp49104
S'2012/12/14 06:00'
p49105
asS'DP'
p49106
S'2012'
p49107
sS'AD'
p49108
S'Vanderbilt University School of Medicine, Nashville, Tennessee, USA. chris.estopinal@vanderbilt.edu'
p49109
sS'OWN'
p49110
S'NLM'
p49111
sS'PT'
p49112
(lp49113
S'Journal Article'
p49114
aS'Research Support, N.I.H., Extramural'
p49115
aS"Research Support, Non-U.S. Gov't"
p49116
asS'LA'
p49117
(lp49118
S'eng'
p49119
asS'FAU'
p49120
(lp49121
S'Estopinal, Christopher B'
p49122
aS'van Dijk, Janneke H'
p49123
aS'Sitali, Stanley'
p49124
aS'Stewart, Hannah'
p49125
aS'Davidson, Mario A'
p49126
aS'Spurrier, John'
p49127
aS'Vermund, Sten H'
p49128
asS'JT'
p49129
S'PloS one'
p49130
sS'LR'
p49131
S'20150219'
p49132
sS'PG'
p49133
S'e49564'
p49134
sS'TI'
p49135
S'Availability of volunteer-led home-based care system and baseline factors as predictors of clinical outcomes in HIV-infected patients in rural Zambia.'
p49136
sS'RN'
p49137
(lp49138
S'0 (Anti-HIV Agents)'
p49139
asS'PL'
p49140
S'United States'
p49141
sS'TA'
p49142
S'PLoS One'
p49143
sS'JID'
p49144
S'101285081'
p49145
sS'AB'
p49146
S"BACKGROUND: We assessed the impact of home-based care (HBC) for HIV+ patients, comparing outcomes between two groups of Zambians receiving antiretroviral therapy (ART) who lived in villages with and without HBC teams. METHODS: We conducted a retrospective cohort study using medical charts from Macha Mission Hospital, a hospital providing HIV care in Zambia's rural Southern Province. Date of birth, date of ART initiation, place of residence, sex, body mass index (BMI), CD4+ cell count, and hemoglobin (Hgb) were abstracted. Logistic regression was used to test our hypothesis that HBC was associated with treatment outcomes. RESULTS: Of 655 patients, 523 (80%) were eligible and included in the study. There were 428 patients (82%) with favorable outcomes (alive and on ART) and 95 patients (18%) with unfavorable outcomes (died, lost to follow-up, or stopped treatment). A minority of the 523 eligible patients (n = 84, 16%) lived in villages with HBC available. Living in a village with HBC was not significantly associated with treatment outcomes; 80% of patients in a village with HBC had favorable outcomes, compared to 82% of patients in a village without HBC (P = 0.6 by chi(2)). In bivariable analysis, lower BMI (P<0.001), low CD4+ cell count (P = 0.02), low Hgb concentration (P = 0.02), and older age at ART initiation (P = 0.047) were associated with unfavorable outcomes. In multivariable analysis, low BMI remained associated with unfavorable outcomes (P<0.001). CONCLUSIONS: We did not find that living in a village with HBC available was associated with improved treatment outcomes. We speculate that the ART clinic's rigorous treatment preparation before ART initiation and continuous adherence counseling during ART create a motivated group of patients whose outcomes did not improve with additional HBC support. An alternative explanation is that the quality of the HBC program is suboptimal."
p49147
sS'GR'
p49148
(lp49149
S'R25 TW007766/TW/FIC NIH HHS/United States'
p49150
aS'R25TW007766/TW/FIC NIH HHS/United States'
p49151
asS'IP'
p49152
S'12'
p49153
sS'IS'
p49154
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p49155
sS'PMC'
p49156
S'PMC3517597'
p49157
sS'DCOM'
p49158
S'20130524'
p49159
sS'AU'
p49160
(lp49161
S'Estopinal CB'
p49162
aS'van Dijk JH'
p49163
aS'Sitali S'
p49164
aS'Stewart H'
p49165
aS'Davidson MA'
p49166
aS'Spurrier J'
p49167
aS'Vermund SH'
p49168
asS'VI'
p49169
S'7'
sS'MHDA'
p49170
S'2013/05/28 06:00'
p49171
sS'PHST'
p49172
(lp49173
S'2011/05/25 [received]'
p49174
aS'2012/10/14 [accepted]'
p49175
aS'2012/12/07 [epublish]'
p49176
asS'OID'
p49177
(lp49178
S'NLM: PMC3517597'
p49179
asS'MH'
p49180
(lp49181
S'Adult'
p49182
aS'Anti-HIV Agents/*therapeutic use'
p49183
aS'CD4 Lymphocyte Count'
p49184
aS'*Caregivers'
p49185
aS'*Delivery of Health Care'
p49186
aS'Female'
p49187
aS'HIV Infections/*drug therapy'
p49188
aS'*Home Care Services'
p49189
aS'Humans'
p49190
aS'Male'
p49191
aS'Middle Aged'
p49192
aS'Retrospective Studies'
p49193
aS'Rural Population'
p49194
aS'Treatment Outcome'
p49195
aS'*Volunteers'
p49196
aS'Zambia'
p49197
asS'EDAT'
p49198
S'2012/12/14 06:00'
p49199
sS'SO'
p49200
S'PLoS One. 2012;7(12):e49564. doi: 10.1371/journal.pone.0049564. Epub 2012 Dec 7.'
p49201
sS'SB'
p49202
S'IM'
p49203
sS'PMID'
p49204
S'23236351'
p49205
sS'PST'
p49206
S'ppublish'
p49207
stRp49208
ag2
(g3
g4
(dp49209
S'LID'
p49210
S'10.1371/journal.pone.0047391 [doi]'
p49211
sS'STAT'
p49212
S'MEDLINE'
p49213
sS'DEP'
p49214
S'20121206'
p49215
sS'DA'
p49216
S'20121213'
p49217
sS'AID'
p49218
(lp49219
S'10.1371/journal.pone.0047391 [doi]'
p49220
aS'PONE-D-12-15685 [pii]'
p49221
asS'CRDT'
p49222
(lp49223
S'2012/12/14 06:00'
p49224
asS'DP'
p49225
S'2012'
p49226
sS'AD'
p49227
S'Hospital Clinic de Barcelona, IDIBAPS, Barcelona, Spain.'
p49228
sS'OWN'
p49229
S'NLM'
p49230
sS'PT'
p49231
(lp49232
S'Journal Article'
p49233
aS"Research Support, Non-U.S. Gov't"
p49234
asS'LA'
p49235
(lp49236
S'eng'
p49237
asS'FAU'
p49238
(lp49239
S'Arnedo, Mireia'
p49240
aS'Alonso, Elena'
p49241
aS'Eisenberg, Nell'
p49242
aS'Ibanez, Laura'
p49243
aS'Ferreyra, Cecilia'
p49244
aS'Jaen, Angels'
p49245
aS'Flevaud, Laurence'
p49246
aS'Khamadi, Samuel'
p49247
aS'Roddy, Paul'
p49248
aS'Gatell, Jose Maria'
p49249
aS'Dalmau, David'
p49250
asS'JT'
p49251
S'PloS one'
p49252
sS'LR'
p49253
S'20150219'
p49254
sS'PG'
p49255
S'e47391'
p49256
sS'TI'
p49257
S'Monitoring HIV viral load in resource limited settings: still a matter of debate?'
p49258
sS'RN'
p49259
(lp49260
S'0 (Anti-HIV Agents)'
p49261
asS'PL'
p49262
S'United States'
p49263
sS'TA'
p49264
S'PLoS One'
p49265
sS'JID'
p49266
S'101285081'
p49267
sS'AB'
p49268
S"INTRODUCTION: Consequences of lack of viral monitoring in predicting the effects of development of HIV drug resistance mutations during HAART in resource-limited settings (RLS) is still a matter of debate. DESIGN: To assess, among HIV+ patients receiving their first-line HAART, prevalence of virological failure and genotypic resistance mutations pattern in a Medecins Sans Frontieres/Ministry of Health programme in Busia District (Kenya). METHODS: Patients with HAART treatment for >/=12 months were eligible for the study and those with HIV-RNA >/=5000 copies/ml underwent genotypic study. Total HIV-1 RNA from Dried Blood Spots was extracted using Nuclisens method. RESULTS: 926 patients were included. Among 274 (29.6%) patients with detectable viral load, 55 (5.9%) experienced treatment failure (viral load >5.000 copies/ml); 61.8% were female and 10 (18.2%) had clinical failure. Median CD4 cell count was 116 cell/mm3 (IQR: 54-189). Median HIV-RNA was 32,000 copies/ml (IQR: 11000-68000). Eighteen out of 55 (33%) samples could be sequenced on PR and RT genes, with resistance associated mutations (RAMs) in 15 out of 18 samples (83%). Among patients carrying RAMs, 12/15 (81%) harboured RAMs associated to thymidine analogues (TAMs). All of them (100%) showed M184V resistance associated mutation to lamivudine as well as NNRTI's RAMS. CONCLUSIONS: Virological failure rate in resource-limited settings are similar to those observed in developed countries. Resistance mutation patterns were concordant with HAART received by failing patients. Long term detectable viral load confers greater probability of developing resistance and as a consequence, making difficult to find out a cost-effective subsequent treatment regimen."
p49269
sS'CN'
p49270
(lp49271
S'Busia O R Study Group'
p49272
asS'IP'
p49273
S'12'
p49274
sS'IS'
p49275
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p49276
sS'PMC'
p49277
S'PMC3516529'
p49278
sS'DCOM'
p49279
S'20130524'
p49280
sS'AU'
p49281
(lp49282
S'Arnedo M'
p49283
aS'Alonso E'
p49284
aS'Eisenberg N'
p49285
aS'Ibanez L'
p49286
aS'Ferreyra C'
p49287
aS'Jaen A'
p49288
aS'Flevaud L'
p49289
aS'Khamadi S'
p49290
aS'Roddy P'
p49291
aS'Gatell JM'
p49292
aS'Dalmau D'
p49293
asS'VI'
p49294
S'7'
sS'MHDA'
p49295
S'2013/05/28 06:00'
p49296
sS'PHST'
p49297
(lp49298
S'2012/05/27 [received]'
p49299
aS'2012/09/12 [accepted]'
p49300
aS'2012/12/06 [epublish]'
p49301
asS'OID'
p49302
(lp49303
S'NLM: PMC3516529'
p49304
asS'MH'
p49305
(lp49306
S'Adolescent'
p49307
aS'Adult'
p49308
aS'Aged'
p49309
aS'Anti-HIV Agents/*therapeutic use'
p49310
aS'Antiretroviral Therapy, Highly Active'
p49311
aS'CD4 Lymphocyte Count'
p49312
aS'Female'
p49313
aS'HIV Infections/drug therapy/*virology'
p49314
aS'HIV Seropositivity/drug therapy/*virology'
p49315
aS'Humans'
p49316
aS'Kenya'
p49317
aS'Male'
p49318
aS'Medication Adherence'
p49319
aS'Middle Aged'
p49320
aS'Treatment Outcome'
p49321
aS'*Viral Load'
p49322
asS'EDAT'
p49323
S'2012/12/14 06:00'
p49324
sS'SO'
p49325
S'PLoS One. 2012;7(12):e47391. doi: 10.1371/journal.pone.0047391. Epub 2012 Dec 6.'
p49326
sS'SB'
p49327
S'IM'
p49328
sS'PMID'
p49329
S'23236346'
p49330
sS'PST'
p49331
S'ppublish'
p49332
stRp49333
ag2
(g3
g4
(dp49334
S'LID'
p49335
S'10.5588/ijtld.12.0344 [doi]'
p49336
sS'STAT'
p49337
S'MEDLINE'
p49338
sS'AB'
p49339
S'SETTING: Lesotho national multidrug-resistant tuberculosis (MDR-TB) program. OBJECTIVE: To determine the prevalence of drug-resistant TB (DR-TB) among patients registered for MDR-TB treatment after failure or suspected failure of the standard 6-month regimen for new TB patients (Category I). DESIGN: We conducted a retrospective cohort study of patients registered for MDR-TB treatment following failure or suspected failure of Category I. RESULTS: A total of 76 patients were included in the analysis, including 51 Category I treatment failures and 25 suspected Category I treatment failures. The prevalence of resistance to any drug was 92% among the treatment failures and 72% among the suspected failures. The proportion of MDR-TB was respectively 78% and 28% among the treatment failures and suspected failures. Among the subgroup of human immunodeficiency virus (HIV) positive patients, the proportion of MDR-TB was 84% among failures and 23% among suspected failures. CONCLUSION: DR-TB and MDR-TB were common among patients in whom Category I failed. Early initiation of empiric second-line anti-tuberculosis treatment while awaiting culture and drug susceptibility testing (DST) results should be considered for HIV-negative and -positive patients who have failed first-line anti-tuberculosis treatment; patients suspected to be failing a first-line regimen should undergo DST at the end of the intensive phase.'
p49340
sS'JID'
p49341
S'9706389'
p49342
sS'AD'
p49343
S'Partners In Health, Maseru, Lesotho. hsatti@pih.org'
p49344
sS'JT'
p49345
S'The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease'
p49346
sS'IP'
p49347
S'1'
sS'IS'
p49348
S'1815-7920 (Electronic) 1027-3719 (Linking)'
p49349
sS'DCOM'
p49350
S'20130528'
p49351
sS'DA'
p49352
S'20121212'
p49353
sS'AU'
p49354
(lp49355
S'Satti H'
p49356
aS'McLaughlin MM'
p49357
aS'Seung KJ'
p49358
aS'Becerra MC'
p49359
aS'Keshavjee S'
p49360
asS'AID'
p49361
(lp49362
S'10.5588/ijtld.12.0344 [doi]'
p49363
asS'CRDT'
p49364
(lp49365
S'2012/12/13 06:00'
p49366
asS'VI'
p49367
S'17'
p49368
sS'DP'
p49369
S'2013 Jan'
p49370
sS'MHDA'
p49371
S'2013/05/29 06:00'
p49372
sS'OWN'
p49373
S'NLM'
p49374
sS'PT'
p49375
(lp49376
S'Journal Article'
p49377
asS'LA'
p49378
(lp49379
S'eng'
p49380
asS'MH'
p49381
(lp49382
S'Adult'
p49383
aS'Cohort Studies'
p49384
aS'Female'
p49385
aS'HIV Infections/complications/epidemiology'
p49386
aS'Humans'
p49387
aS'Lesotho/epidemiology'
p49388
aS'Male'
p49389
aS'Middle Aged'
p49390
aS'Prevalence'
p49391
aS'Retrospective Studies'
p49392
aS'Risk Factors'
p49393
aS'Treatment Failure'
p49394
aS'Tuberculosis, Multidrug-Resistant/complications/drug therapy/*epidemiology'
p49395
asS'FAU'
p49396
(lp49397
S'Satti, H'
p49398
aS'McLaughlin, M M'
p49399
aS'Seung, K J'
p49400
aS'Becerra, M C'
p49401
aS'Keshavjee, S'
p49402
asS'EDAT'
p49403
S'2012/12/13 06:00'
p49404
sS'PST'
p49405
S'ppublish'
p49406
sS'SO'
p49407
S'Int J Tuberc Lung Dis. 2013 Jan;17(1):100-6. doi: 10.5588/ijtld.12.0344.'
p49408
sS'PG'
p49409
S'100-6'
p49410
sS'TI'
p49411
S'High risk of drug-resistant tuberculosis when first-line therapy fails in a high HIV prevalence setting.'
p49412
sS'SB'
p49413
S'IM'
p49414
sS'PMID'
p49415
S'23232009'
p49416
sS'PL'
p49417
S'France'
p49418
sS'TA'
p49419
S'Int J Tuberc Lung Dis'
p49420
stRp49421
ag2
(g3
g4
(dp49422
S'LID'
p49423
S'10.5588/ijtld.12.0282 [doi]'
p49424
sS'STAT'
p49425
S'MEDLINE'
p49426
sS'JT'
p49427
S'The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease'
p49428
sS'MID'
p49429
(lp49430
S'NIHMS432755'
p49431
asS'DA'
p49432
S'20121212'
p49433
sS'AID'
p49434
(lp49435
S'10.5588/ijtld.12.0282 [doi]'
p49436
asS'CRDT'
p49437
(lp49438
S'2012/12/13 06:00'
p49439
asS'DP'
p49440
S'2013 Jan'
p49441
sS'GR'
p49442
(lp49443
S'AI068632/AI/NIAID NIH HHS/United States'
p49444
aS'N01-DK-9-001/HHSN267200800001C/DK/NIDDK NIH HHS/United States'
p49445
aS'U01 AI041110/AI/NIAID NIH HHS/United States'
p49446
aS'U01 AI068616/AI/NIAID NIH HHS/United States'
p49447
aS'U01 AI068616/AI/NIAID NIH HHS/United States'
p49448
aS'U01 AI068632/AI/NIAID NIH HHS/United States'
p49449
aS'U01 AI068632/AI/NIAID NIH HHS/United States'
p49450
aS'U01 AI41110/AI/NIAID NIH HHS/United States'
p49451
aS'UM1 AI068616/AI/NIAID NIH HHS/United States'
p49452
aS'UM1 AI068632/AI/NIAID NIH HHS/United States'
p49453
asS'OWN'
p49454
S'NLM'
p49455
sS'PT'
p49456
(lp49457
S'Journal Article'
p49458
aS'Randomized Controlled Trial'
p49459
aS'Research Support, N.I.H., Extramural'
p49460
asS'LA'
p49461
(lp49462
S'eng'
p49463
asS'FAU'
p49464
(lp49465
S'Beneri, C A'
p49466
aS'Zeldow, B'
p49467
aS'Nachman, S'
p49468
aS'Van der Linde, M'
p49469
aS'Pillay, E'
p49470
aS'Dittmer, S'
p49471
aS'Kim, S'
p49472
aS'Jean-Philippe, P'
p49473
aS'Coetzee, J'
p49474
aS'Bobat, R'
p49475
aS'Hawkins, E'
p49476
aS'Violari, A'
p49477
asS'LR'
p49478
S'20150219'
p49479
sS'PG'
p49480
S'32-8'
p49481
sS'TI'
p49482
S'Loss to follow-up among infants in a study of isoniazid prophylaxis (P1041) in South Africa.'
p49483
sS'RN'
p49484
(lp49485
S'0 (Antitubercular Agents)'
p49486
aS'V83O1VOZ8L (Isoniazid)'
p49487
asS'PL'
p49488
S'France'
p49489
sS'TA'
p49490
S'Int J Tuberc Lung Dis'
p49491
sS'JID'
p49492
S'9706389'
p49493
sS'AB'
p49494
S'OBJECTIVE: To assess risk factors for loss to follow-up (LFU) from the IMPAACT P1041 study, an isoniazid (INH) prophylaxis study conducted in southern Africa. DESIGN: Infants in two cohorts, human immunodeficiency virus-infected (HIV+) and HIV-exposed but non-infected (HIV-), were randomized to INH or placebo for 96 weeks. LFU was evaluated at week 96. RESULTS: Of 1351 infants, 12.9% were LFU (10.4% HIV+, 14.7% HIV-); 65% of the HIV+ cohort was asymptomatic. Among HIV+ infants, large household size (>6 vs. <4 members, P = 0.035) and presence of an elder (>/=55 years, P = 0.05) were associated with better retention. Although attenuated in adjusted analysis, these associations held among HIV- infants. Among HIV- infants, having a younger mother increased the risk (P = 0.008) and maternal history of TB reduced the risk of LFU, the latter by nearly 70% (P = 0.048 univariate, 0.09 adjusted). LFU was largely due to inability to contact the participant (58% HIV+, 30% HIV-), and inability to attend the clinic and withdrawal of consent (HIV-). CONCLUSIONS: Household support was an important factor in participant retention, particularly for the non-HIV-infected cohort, as young maternal age was a risk factor for LFU. Retaining study participants from this mobile population can be challenging and may warrant additional support.'
p49495
sS'AD'
p49496
S'State University of New York at Stony Brook, Stony Brook, NY 11794-8111, USA. christy.beneri@stonybrook.edu'
p49497
sS'CN'
p49498
(lp49499
S'P1041 Team'
p49500
asS'IP'
p49501
S'1'
sS'IS'
p49502
S'1815-7920 (Electronic) 1027-3719 (Linking)'
p49503
sS'PMC'
p49504
S'PMC3556820'
p49505
sS'DCOM'
p49506
S'20130528'
p49507
sS'AU'
p49508
(lp49509
S'Beneri CA'
p49510
aS'Zeldow B'
p49511
aS'Nachman S'
p49512
aS'Van der Linde M'
p49513
aS'Pillay E'
p49514
aS'Dittmer S'
p49515
aS'Kim S'
p49516
aS'Jean-Philippe P'
p49517
aS'Coetzee J'
p49518
aS'Bobat R'
p49519
aS'Hawkins E'
p49520
aS'Violari A'
p49521
asS'VI'
p49522
S'17'
p49523
sS'MHDA'
p49524
S'2013/05/29 06:00'
p49525
sS'OID'
p49526
(lp49527
S'NLM: NIHMS432755'
p49528
aS'NLM: PMC3556820'
p49529
asS'MH'
p49530
(lp49531
S'Antitubercular Agents/*therapeutic use'
p49532
aS'Double-Blind Method'
p49533
aS'Female'
p49534
aS'Follow-Up Studies'
p49535
aS'HIV Infections/complications'
p49536
aS'Humans'
p49537
aS'Infant'
p49538
aS'Isoniazid/*therapeutic use'
p49539
aS'Male'
p49540
aS'Patient Compliance/*statistics & numerical data'
p49541
aS'Risk Factors'
p49542
aS'South Africa'
p49543
aS'Tuberculosis/etiology/*prevention & control'
p49544
asS'EDAT'
p49545
S'2012/12/13 06:00'
p49546
sS'SO'
p49547
S'Int J Tuberc Lung Dis. 2013 Jan;17(1):32-8. doi: 10.5588/ijtld.12.0282.'
p49548
sS'SB'
p49549
S'IM'
p49550
sS'PMID'
p49551
S'23232002'
p49552
sS'PST'
p49553
S'ppublish'
p49554
stRp49555
ag2
(g3
g4
(dp49556
S'LID'
p49557
S'10.1080/09540121.2012.748168 [doi]'
p49558
sS'STAT'
p49559
S'MEDLINE'
p49560
sS'DEP'
p49561
S'20121211'
p49562
sS'MID'
p49563
(lp49564
S'NIHMS426699'
p49565
asS'DA'
p49566
S'20130717'
p49567
sS'AID'
p49568
(lp49569
S'10.1080/09540121.2012.748168 [doi]'
p49570
asS'CRDT'
p49571
(lp49572
S'2012/12/12 06:00'
p49573
asS'DP'
p49574
S'2013 Aug'
p49575
sS'AD'
p49576
S'Department of Health and Behavioral Sciences, University of Colorado Denver Campus, CO, USA. sara.yeatman@ucdenver.edu'
p49577
sS'OWN'
p49578
S'NLM'
p49579
sS'PT'
p49580
(lp49581
S'Journal Article'
p49582
aS'Research Support, N.I.H., Extramural'
p49583
asS'LA'
p49584
(lp49585
S'eng'
p49586
asS'FAU'
p49587
(lp49588
S'Yeatman, Sara'
p49589
aS'Dovel, Kathryn'
p49590
aS'Conroy, Amy'
p49591
aS'Namadingo, Hazel'
p49592
asS'JT'
p49593
S'AIDS care'
p49594
sS'LR'
p49595
S'20160701'
p49596
sS'PG'
p49597
S'1018-25'
p49598
sS'TI'
p49599
S'HIV treatment optimism and its predictors among young adults in southern Malawi.'
p49600
sS'RN'
p49601
(lp49602
S'0 (Anti-Retroviral Agents)'
p49603
asS'PL'
p49604
S'England'
p49605
sS'TA'
p49606
S'AIDS Care'
p49607
sS'JID'
p49608
S'8915313'
p49609
sS'AB'
p49610
S'This study measures HIV treatment optimism and its predictors in a representative sample of young adults in southern Malawi. In 2010, 1275 women and 470 men between the ages of 16 and 26 were asked about their exposure to people on antiretroviral therapy (ART), sexual risk behavior, HIV status, and beliefs about ART. We used confirmatory factor analysis to develop a 4-item scale of the belief that HIV is a less serious health threat due to ART (reduced-severity optimism) and used a single measure to capture belief in the reduced infectivity of HIV due to ART (reduced-susceptibility optimism). Overall, respondents reported low levels of HIV treatment optimism. Being female and using ART were the largest predictors of both types of treatment optimism. We found a nonlinear relationship between exposure to people on ART and reduced-severity optimism. People who knew someone on ART but did not discuss it with them had lower levels of reduced-severity optimism than people who did not know anyone on ART and people who regularly discussed treatment with someone on ART. In multivariate regression models, HIV treatment optimism was positively associated with all measures of sexual risk behavior among men, but negatively associated with unprotected sex with a nonprimary partner among women. Our findings suggest that the spread of ART in Malawi has not led to widespread HIV treatment optimism. This may reflect the relatively recent spread of ART, the generalized nature of the HIV epidemic, or the fact that access to ART is complicated by structural limitations that delay treatment and limited availability of second-line medicines.'
p49611
sS'GR'
p49612
(lp49613
S'P30 AI027763/AI/NIAID NIH HHS/United States'
p49614
aS'R01 HD058366/HD/NICHD NIH HHS/United States'
p49615
aS'R01 HD077873/HD/NICHD NIH HHS/United States'
p49616
aS'R01-HD058366/HD/NICHD NIH HHS/United States'
p49617
aS'R03 HD067099/HD/NICHD NIH HHS/United States'
p49618
aS'R03-HD067099/HD/NICHD NIH HHS/United States'
p49619
asS'IP'
p49620
S'8'
sS'IS'
p49621
S'1360-0451 (Electronic) 0954-0121 (Linking)'
p49622
sS'PMC'
p49623
S'PMC3604120'
p49624
sS'DCOM'
p49625
S'20131031'
p49626
sS'AU'
p49627
(lp49628
S'Yeatman S'
p49629
aS'Dovel K'
p49630
aS'Conroy A'
p49631
aS'Namadingo H'
p49632
asS'VI'
p49633
S'25'
p49634
sS'MHDA'
p49635
S'2013/11/01 06:00'
p49636
sS'PHST'
p49637
(lp49638
S'2012/12/11 [aheadofprint]'
p49639
asS'OID'
p49640
(lp49641
S'NLM: NIHMS426699'
p49642
aS'NLM: PMC3604120'
p49643
asS'MH'
p49644
(lp49645
S'Adolescent'
p49646
aS'Adult'
p49647
aS'Anti-Retroviral Agents/*therapeutic use'
p49648
aS'Factor Analysis, Statistical'
p49649
aS'Female'
p49650
aS'HIV Infections/*drug therapy/*psychology'
p49651
aS'*Health Knowledge, Attitudes, Practice'
p49652
aS'Humans'
p49653
aS'Malawi'
p49654
aS'Male'
p49655
aS'Risk-Taking'
p49656
aS'Sex Distribution'
p49657
aS'Sexual Behavior/*psychology/*statistics & numerical data'
p49658
aS'Unsafe Sex/psychology/statistics & numerical data'
p49659
aS'Young Adult'
p49660
asS'EDAT'
p49661
S'2012/12/12 06:00'
p49662
sS'SO'
p49663
S'AIDS Care. 2013 Aug;25(8):1018-25. doi: 10.1080/09540121.2012.748168. Epub 2012 Dec 11.'
p49664
sS'SB'
p49665
S'IM X'
p49666
sS'PMID'
p49667
S'23227888'
p49668
sS'PST'
p49669
S'ppublish'
p49670
stRp49671
ag2
(g3
g4
(dp49672
S'LID'
p49673
S'10.1136/archdischild-2012-302633 [doi]'
p49674
sS'STAT'
p49675
S'MEDLINE'
p49676
sS'DEP'
p49677
S'20121205'
p49678
sS'CIN'
p49679
(lp49680
S'Arch Dis Child. 2013 Apr;98(4):245-6. PMID: 23413313'
p49681
asS'DA'
p49682
S'20130313'
p49683
sS'AID'
p49684
(lp49685
S'archdischild-2012-302633 [pii]'
p49686
aS'10.1136/archdischild-2012-302633 [doi]'
p49687
asS'CRDT'
p49688
(lp49689
S'2012/12/11 06:00'
p49690
asS'DP'
p49691
S'2013 Apr'
p49692
sS'AD'
p49693
S'Gertrude H. Sergievsky Center, College of Physicians and Surgeons, Columbia University Medical Center, 630 W. 168th Street, New York, NY 10032, USA. sma2@columbia.edu'
p49694
sS'OWN'
p49695
S'NLM'
p49696
sS'PT'
p49697
(lp49698
S'Journal Article'
p49699
aS'Randomized Controlled Trial'
p49700
aS'Research Support, N.I.H., Extramural'
p49701
aS"Research Support, Non-U.S. Gov't"
p49702
asS'LA'
p49703
(lp49704
S'eng'
p49705
asS'FAU'
p49706
(lp49707
S'Arpadi, Stephen'
p49708
aS'Shiau, Stephanie'
p49709
aS'Strehlau, Renate'
p49710
aS'Martens, Leigh'
p49711
aS'Patel, Faeezah'
p49712
aS'Coovadia, Ashraf'
p49713
aS'Abrams, Elaine J'
p49714
aS'Kuhn, Louise'
p49715
asS'JT'
p49716
S'Archives of disease in childhood'
p49717
sS'LR'
p49718
S'20160307'
p49719
sS'PG'
p49720
S'258-64'
p49721
sS'TI'
p49722
S'Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy.'
p49723
sS'RN'
p49724
(lp49725
S'0 (Anti-HIV Agents)'
p49726
aS'0 (Lipids)'
p49727
aS'2494G1JF75 (Lopinavir)'
p49728
aS'2T8Q726O95 (Lamivudine)'
p49729
aS'99DK7FVK1H (Nevirapine)'
p49730
aS'BO9LE4QFZF (Stavudine)'
p49731
aS'O3J8G9O825 (Ritonavir)'
p49732
asS'PL'
p49733
S'England'
p49734
sS'TA'
p49735
S'Arch Dis Child'
p49736
sS'JID'
p49737
S'0372434'
p49738
sS'AB'
p49739
S'BACKGROUND: Few studies have assessed metabolic and body composition alterations in perinatally HIV-infected African children on antiretroviral therapy (ART). We compared metabolic profiles and regional fat of children on ritonavir-boosted lopinavir (lopinavir/ritonavir), lamivudine and stavudine to those switched to nevirapine, lamivudine and stavudine. METHODS: This study evaluated metabolic and body composition outcomes in 156 HIV-infected children completing a randomised trial that assessed the continued use of lopinavir/ritonavir-based ART or switch to nevirapine-based ART in Johannesburg, South Africa (2005-2010). Fasting total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides total and regional body fat (BF) were measured. A clinical assessment for lipodystrophy (LD) was conducted. RESULTS: 156 children (mean age 5.1+/-0.8 years, mean duration of treatment 4.2+/-0.7 years, mean time since randomisation 3.4+/-0.7 years) were enrolled. 85 were randomised to the lopinavir/ritonavir group and 71 to the nevirapine group. The lopinavir/ritonavir group had lower mean HDL (1.3+/-0.4 vs 1.5+/-0.4 mmol/l, p<0.001) and higher mean TC (4.4+/-1.0 vs 4.1+/-0.8 mmol/l, p=0.097), LDL (2.6+/-0.9 vs 2.3+/-0.7 mmol/l, p=0.018) and triglycerides (1.1+/-0.4 vs 0.8+/-0.3 mmol/l, p<0.001). The lopinavir/ritonavir group had more total BF by mean skinfold sum (43+/-11.1 vs 39+/-10.1 mm, p=0.031) and BF% by bioelectrical impedance analysis (17.0+/-7.0 vs 14.1+/-8.0%, p=0.022). Thirteen (8.4%) met criteria for LD. CONCLUSIONS: Unfavourable alterations in lipid profile and triglycerides, and differences in fat are detectable in young HIV-infected South African children receiving lopinavir/ritonavir-based regimens versus those switched to nevirapine-based regimens. Interventions to mitigate these alterations are warranted to reduce long-term cardiovascular disease risk.'
p49740
sS'GR'
p49741
(lp49742
S'HD 47177/HD/NICHD NIH HHS/United States'
p49743
aS'HD 61255/HD/NICHD NIH HHS/United States'
p49744
aS'R01 HD047177/HD/NICHD NIH HHS/United States'
p49745
aS'R01 HD061255/HD/NICHD NIH HHS/United States'
p49746
asS'IP'
p49747
S'4'
sS'IS'
p49748
S'1468-2044 (Electronic) 0003-9888 (Linking)'
p49749
sS'PMC'
p49750
S'PMC4533934'
p49751
sS'DCOM'
p49752
S'20130501'
p49753
sS'MID'
p49754
(lp49755
S'NIHMS435068'
p49756
asS'AU'
p49757
(lp49758
S'Arpadi S'
p49759
aS'Shiau S'
p49760
aS'Strehlau R'
p49761
aS'Martens L'
p49762
aS'Patel F'
p49763
aS'Coovadia A'
p49764
aS'Abrams EJ'
p49765
aS'Kuhn L'
p49766
asS'VI'
p49767
S'98'
p49768
sS'MHDA'
p49769
S'2013/05/02 06:00'
p49770
sS'PHST'
p49771
(lp49772
S'2012/12/05 [aheadofprint]'
p49773
asS'OID'
p49774
(lp49775
S'NLM: NIHMS435068'
p49776
aS'NLM: PMC4533934'
p49777
asS'MH'
p49778
(lp49779
S'Anti-HIV Agents/*adverse effects/therapeutic use'
p49780
aS'Body Composition/*drug effects'
p49781
aS'Child'
p49782
aS'Child, Preschool'
p49783
aS'Cross-Sectional Studies'
p49784
aS'Drug Therapy, Combination'
p49785
aS'Female'
p49786
aS'HIV Infections/blood/*drug therapy'
p49787
aS'HIV-Associated Lipodystrophy Syndrome/*chemically induced'
p49788
aS'Humans'
p49789
aS'Infant'
p49790
aS'Insulin Resistance/physiology'
p49791
aS'Lamivudine/therapeutic use'
p49792
aS'Lipids/*blood'
p49793
aS'Lopinavir/*adverse effects/therapeutic use'
p49794
aS'Male'
p49795
aS'Nevirapine/*adverse effects/therapeutic use'
p49796
aS'Ritonavir/adverse effects'
p49797
aS'South Africa'
p49798
aS'Stavudine/therapeutic use'
p49799
asS'EDAT'
p49800
S'2012/12/12 06:00'
p49801
sS'SO'
p49802
S'Arch Dis Child. 2013 Apr;98(4):258-64. doi: 10.1136/archdischild-2012-302633. Epub 2012 Dec 5.'
p49803
sS'SB'
p49804
S'AIM IM'
p49805
sS'PMID'
p49806
S'23220209'
p49807
sS'PST'
p49808
S'ppublish'
p49809
stRp49810
ag2
(g3
g4
(dp49811
S'LID'
p49812
S'10.1186/1472-6963-12-444 [doi]'
p49813
sS'STAT'
p49814
S'MEDLINE'
p49815
sS'DEP'
p49816
S'20121205'
p49817
sS'DA'
p49818
S'20130130'
p49819
sS'AID'
p49820
(lp49821
S'1472-6963-12-444 [pii]'
p49822
aS'10.1186/1472-6963-12-444 [doi]'
p49823
asS'CRDT'
p49824
(lp49825
S'2012/12/11 06:00'
p49826
asS'DP'
p49827
S'2012'
p49828
sS'OWN'
p49829
S'NLM'
p49830
sS'PT'
p49831
(lp49832
S'Journal Article'
p49833
aS"Research Support, Non-U.S. Gov't"
p49834
asS'LA'
p49835
(lp49836
S'eng'
p49837
asS'DCOM'
p49838
S'20130612'
p49839
sS'JT'
p49840
S'BMC health services research'
p49841
sS'LR'
p49842
S'20150219'
p49843
sS'FAU'
p49844
(lp49845
S'Rasschaert, Freya'
p49846
aS'Koole, Olivier'
p49847
aS'Zachariah, Rony'
p49848
aS'Lynen, Lut'
p49849
aS'Manzi, Marcel'
p49850
aS'Van Damme, Wim'
p49851
asS'TI'
p49852
S'Short and long term retention in antiretroviral care in health facilities in rural Malawi and Zimbabwe.'
p49853
sS'RN'
p49854
(lp49855
S'0 (Anti-Retroviral Agents)'
p49856
asS'PL'
p49857
S'England'
p49858
sS'PG'
p49859
S'444'
p49860
sS'JID'
p49861
S'101088677'
p49862
sS'AB'
p49863
S"BACKGROUND: Despite the successful scale-up of ART services over the past years, long term retention in ART care remains a major challenge, especially in high HIV prevalence and resource-limited settings. This study analysed the short (<12 months) and long (>12 months) term retention on ART in two ART programmes in Malawi (Thyolo district) and Zimbabwe (Buhera district). METHODS: Retention rates at six-month intervals are reported separately among (1) patients since ART initiation and (2) patients who had been on ART for at least 12 months, according to the site of ART initiation and follow-up, using the Kaplan Meier method. 'Retention' was defined as being alive on ART or transferred out, while 'attrition' was defined as dead, lost to follow-up or stopped ART. RESULTS: In Thyolo and Buhera, a total of 12,004 and 9,721 patients respectively were included in the analysis. The overall retention among the patients since ART initiation was 84%, 80% and 77% in Thyolo and 88%, 84% and 82% in Buhera at 6, 12 and 18 months, respectively. In both programmes the largest drop in ART retention was found during the initial 12 months on ART, mainly related to a high mortality rate in the health centres in Thyolo and a high loss to follow-up rate in the hospital in Buhera. Among the patients who had been on ART for at least 12 months, the retention rates leveled out, with 97%, 95% and 94% in both Thyolo and Buhera, at 18, 24 and 30 months respectively. Loss to follow-up was identified as the main contributor to attrition after 12 months on treatment in both programmes. CONCLUSIONS: To better understand the reasons of attrition and adapt the ART delivery care models accordingly, it is advisable to analyse short and long term retention separately, in order to adapt intervention strategies accordingly. During the initial months on ART more medical follow-up, especially for symptomatic patients, is required to reduce mortality. Once stable on ART, however, the ART care delivery should focus on regular drug refill and adherence support to reduce loss to follow up. Hence, innovative life-long retention strategies, including use of new communication technologies, community based interventions and drug refill outside the health facilities are required."
p49864
sS'AD'
p49865
S'Institute of Tropical Medicine, Nationale straat 155, Antwerpen 2000, Belgium. frasschaert@itg.be'
p49866
sS'VI'
p49867
S'12'
p49868
sS'IS'
p49869
S'1472-6963 (Electronic) 1472-6963 (Linking)'
p49870
sS'PMC'
p49871
S'PMC3558332'
p49872
sS'AU'
p49873
(lp49874
S'Rasschaert F'
p49875
aS'Koole O'
p49876
aS'Zachariah R'
p49877
aS'Lynen L'
p49878
aS'Manzi M'
p49879
aS'Van Damme W'
p49880
asS'MHDA'
p49881
S'2013/06/13 06:00'
p49882
sS'PHST'
p49883
(lp49884
S'2012/02/06 [received]'
p49885
aS'2012/11/25 [accepted]'
p49886
aS'2012/12/05 [aheadofprint]'
p49887
asS'OID'
p49888
(lp49889
S'NLM: PMC3558332'
p49890
asS'MH'
p49891
(lp49892
S'Adolescent'
p49893
aS'Adult'
p49894
aS'Anti-Retroviral Agents/*therapeutic use'
p49895
aS'Confidence Intervals'
p49896
aS'Female'
p49897
aS'Follow-Up Studies'
p49898
aS'HIV Infections/drug therapy'
p49899
aS'Humans'
p49900
aS'Malawi'
p49901
aS'Male'
p49902
aS'Middle Aged'
p49903
aS'Patient Dropouts/*statistics & numerical data'
p49904
aS'Poverty Areas'
p49905
aS'*Rural Health Services'
p49906
aS'Young Adult'
p49907
aS'Zimbabwe'
p49908
asS'EDAT'
p49909
S'2012/12/12 06:00'
p49910
sS'SO'
p49911
S'BMC Health Serv Res. 2012 Dec 5;12:444. doi: 10.1186/1472-6963-12-444.'
p49912
sS'SB'
p49913
S'IM'
p49914
sS'PMID'
p49915
S'23216919'
p49916
sS'TA'
p49917
S'BMC Health Serv Res'
p49918
sS'PST'
p49919
S'epublish'
p49920
stRp49921
ag2
(g3
g4
(dp49922
S'LID'
p49923
S'10.7448/IAS.15.2.17985 [doi]'
p49924
sS'STAT'
p49925
S'MEDLINE'
p49926
sS'DEP'
p49927
S'20121128'
p49928
sS'DA'
p49929
S'20121203'
p49930
sS'AID'
p49931
(lp49932
S'17985 [pii]'
p49933
asS'CRDT'
p49934
(lp49935
S'2012/12/04 06:00'
p49936
asS'DP'
p49937
S'2012'
p49938
sS'OWN'
p49939
S'NLM'
p49940
sS'PT'
p49941
(lp49942
S'Journal Article'
p49943
aS"Research Support, Non-U.S. Gov't"
p49944
asS'LA'
p49945
(lp49946
S'eng'
p49947
asS'FAU'
p49948
(lp49949
S'Liegeois, Florian'
p49950
aS'Vella, Caroline'
p49951
aS'Eymard-Duvernay, Sabrina'
p49952
aS'Sica, Jeanne'
p49953
aS'Makosso, Laurent'
p49954
aS'Mouinga-Ondeme, Augustin'
p49955
aS'Mongo, Arnaud Delis'
p49956
aS'Boue, Vanina'
p49957
aS'Butel, Christelle'
p49958
aS'Peeters, Martine'
p49959
aS'Gonzalez, Jean-Paul'
p49960
aS'Delaporte, Eric'
p49961
aS'Rouet, Francois'
p49962
asS'JT'
p49963
S'Journal of the International AIDS Society'
p49964
sS'LR'
p49965
S'20150219'
p49966
sS'PG'
p49967
S'17985'
p49968
sS'TI'
p49969
S'Virological failure rates and HIV-1 drug resistance patterns in patients on first-line antiretroviral treatment in semirural and rural Gabon.'
p49970
sS'RN'
p49971
(lp49972
S'0 (Anti-HIV Agents)'
p49973
asS'PL'
p49974
S'Switzerland'
p49975
sS'TA'
p49976
S'J Int AIDS Soc'
p49977
sS'JID'
p49978
S'101478566'
p49979
sS'AB'
p49980
S'INTRODUCTION: As antiretroviral treatment (ART) continues to expand in resource-limited countries, the emergence of HIV drug resistance mutations (DRMs) is challenging in these settings. In Gabon (central Africa), no study has yet reported the virological effectiveness of initial ART given through routine HIV care. METHODS: Following the World Health Organization (WHO) recommendations, a cross-sectional study with a one-time HIV-1 RNA viral load (VL) measurement was conducted in Gabon to assess virological failure (VF) defined by a VL result >/=1000 copies/ml and DRMs among adult patients living with non-B HIV-1 strains and receiving first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy for at least 12 months. Risk factors associated with VF and DRMs were assessed. RESULTS: Between March 2010 and March 2011, a total of 375 patients were consecutively enrolled from two decentralized (one semirural and one rural) HIV care centres. Median time on ART was 33.6 months (range, 12-107). Overall, the rate of VF was 41.3% (36.4-46.4). Among viremic patients, 56.7% (80/141) had at least one DRM and 37.6% had dual-class resistance to nucleoside reverse transcriptase inhibitors (NRTIs) and NNRTIs. The most frequent DRMs were K103N/S (46.1%) and M184V/I (37.6%). Thymidine analogue mutations were found in 10.6%. Independent risk factors associated with VF were being followed up at the semirural centre (P=0.033), having experienced unstructured treatment interruptions (P=0.0044), and having low CD4+ counts at enrolment (P<0.0001). A longer time on ART (P=0.0008) and being followed up at the rural centre (P=0.021) were risk factors for DRMs. CONCLUSIONS: This is the first study conducted in Gabon providing VF rates and DRM patterns in adult patients receiving first-line ART. In sub-Saharan Africa, where NNRTI-based regimens are recommended as the standard for first-line ART, strengthening virological monitoring together with preventing unplanned treatment interruptions are a global public health priority.'
p49981
sS'AD'
p49982
S'Laboratoire de Retrovirologie, CIRMF, BP769, Franceville, Gabon.'
p49983
sS'IP'
p49984
S'2'
sS'IS'
p49985
S'1758-2652 (Electronic) 1758-2652 (Linking)'
p49986
sS'PMC'
p49987
S'PMC3510650'
p49988
sS'DCOM'
p49989
S'20130510'
p49990
sS'AU'
p49991
(lp49992
S'Liegeois F'
p49993
aS'Vella C'
p49994
aS'Eymard-Duvernay S'
p49995
aS'Sica J'
p49996
aS'Makosso L'
p49997
aS'Mouinga-Ondeme A'
p49998
aS'Mongo AD'
p49999
aS'Boue V'
p50000
aS'Butel C'
p50001
aS'Peeters M'
p50002
aS'Gonzalez JP'
p50003
aS'Delaporte E'
p50004
aS'Rouet F'
p50005
asS'VI'
p50006
S'15'
p50007
sS'MHDA'
p50008
S'2013/05/11 06:00'
p50009
sS'PHST'
p50010
(lp50011
S'2012/06/05 [received]'
p50012
aS'2012/10/22 [revised]'
p50013
aS'2012/11/06 [accepted]'
p50014
asS'OID'
p50015
(lp50016
S'NLM: PMC3510650'
p50017
asS'MH'
p50018
(lp50019
S'Adult'
p50020
aS'Anti-HIV Agents/pharmacology/*therapeutic use'
p50021
aS'Cross-Sectional Studies'
p50022
aS'*Drug Resistance, Viral'
p50023
aS'Female'
p50024
aS'Gabon/epidemiology'
p50025
aS'HIV Infections/epidemiology/*virology'
p50026
aS'HIV-1/*drug effects/genetics'
p50027
aS'Humans'
p50028
aS'Male'
p50029
aS'Middle Aged'
p50030
aS'Mutation'
p50031
aS'Risk Factors'
p50032
aS'Rural Population'
p50033
asS'EDAT'
p50034
S'2012/12/04 06:00'
p50035
sS'SO'
p50036
S'J Int AIDS Soc. 2012 Nov 28;15(2):17985. doi: 10.7448/IAS.15.2.17985.'
p50037
sS'SB'
p50038
S'IM X'
p50039
sS'PMID'
p50040
S'23199801'
p50041
sS'PST'
p50042
S'epublish'
p50043
stRp50044
ag2
(g3
g4
(dp50045
S'LID'
p50046
S'10.1097/QAI.0b013e31827e818a [doi]'
p50047
sS'STAT'
p50048
S'MEDLINE'
p50049
sS'AB'
p50050
S'Investigating the association between hormonal contraception and HIV is challenging due to high discontinuation rates among users. This secondary analysis of 262 South African adolescent new users of hormonal contraception found continuation rates after 1 year for depot medroxyprogesterone acetate, norethisterone enanthate, or combined oral contraceptives of 40.4%, 64.4%, and 64.6%, respectively. Implications for studies evaluating the association between injectable hormonal contraceptive use and HIV are discussed.'
p50051
sS'JID'
p50052
S'100892005'
p50053
sS'AD'
p50054
S'MatCH, Maternal, Adolescent, and Child Health, Department of Obstetrics and Gynaecology, Faculty of Health Sciences, University of the Witwatersrand, Durban, South Africa. jsmit@match.org.za'
p50055
sS'JT'
p50056
S'Journal of acquired immune deficiency syndromes (1999)'
p50057
sS'IP'
p50058
S'3'
sS'IS'
p50059
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p50060
sS'DCOM'
p50061
S'20130820'
p50062
sS'DA'
p50063
S'20130808'
p50064
sS'AU'
p50065
(lp50066
S'Smit JA'
p50067
aS'Beksinska ME'
p50068
asS'AID'
p50069
(lp50070
S'10.1097/QAI.0b013e31827e818a [doi]'
p50071
asS'CRDT'
p50072
(lp50073
S'2012/11/29 06:00'
p50074
asS'VI'
p50075
S'62'
p50076
sS'PMID'
p50077
S'23187946'
p50078
sS'DP'
p50079
S'2013 Mar 1'
p50080
sS'MHDA'
p50081
S'2013/08/21 06:00'
p50082
sS'OWN'
p50083
S'NLM'
p50084
sS'PT'
p50085
(lp50086
S'Journal Article'
p50087
aS"Research Support, Non-U.S. Gov't"
p50088
asS'LA'
p50089
(lp50090
S'eng'
p50091
asS'MH'
p50092
(lp50093
S'Adolescent'
p50094
aS'Cohort Studies'
p50095
aS'Contraception Behavior/*statistics & numerical data'
p50096
aS'Contraceptive Agents, Female/*administration & dosage'
p50097
aS'Contraceptives, Oral, Hormonal/administration & dosage'
p50098
aS'Drug Substitution/*statistics & numerical data'
p50099
aS'Female'
p50100
aS'HIV Infections/*prevention & control'
p50101
aS'Humans'
p50102
aS'Injections'
p50103
aS'South Africa'
p50104
aS'Young Adult'
p50105
asS'FAU'
p50106
(lp50107
S'Smit, Jennifer A'
p50108
aS'Beksinska, Mags E'
p50109
asS'EDAT'
p50110
S'2012/11/29 06:00'
p50111
sS'PST'
p50112
S'ppublish'
p50113
sS'SO'
p50114
S'J Acquir Immune Defic Syndr. 2013 Mar 1;62(3):363-5. doi: 10.1097/QAI.0b013e31827e818a.'
p50115
sS'PG'
p50116
S'363-5'
p50117
sS'TI'
p50118
S'Hormonal contraceptive continuation and switching in South Africa: implications for evaluating the association of injectable hormonal contraceptive use and HIV.'
p50119
sS'SB'
p50120
S'IM X'
p50121
sS'RN'
p50122
(lp50123
S'0 (Contraceptive Agents, Female)'
p50124
aS'0 (Contraceptives, Oral, Hormonal)'
p50125
asS'PL'
p50126
S'United States'
p50127
sS'TA'
p50128
S'J Acquir Immune Defic Syndr'
p50129
stRp50130
ag2
(g3
g4
(dp50131
S'LID'
p50132
S'10.1371/journal.pone.0049834 [doi]'
p50133
sS'STAT'
p50134
S'MEDLINE'
p50135
sS'DEP'
p50136
S'20121121'
p50137
sS'DA'
p50138
S'20121127'
p50139
sS'AID'
p50140
(lp50141
S'10.1371/journal.pone.0049834 [doi]'
p50142
aS'PONE-D-12-02081 [pii]'
p50143
asS'CRDT'
p50144
(lp50145
S'2012/11/28 06:00'
p50146
asS'DP'
p50147
S'2012'
p50148
sS'OWN'
p50149
S'NLM'
p50150
sS'PT'
p50151
(lp50152
S'Evaluation Studies'
p50153
aS'Journal Article'
p50154
aS"Research Support, Non-U.S. Gov't"
p50155
asS'LA'
p50156
(lp50157
S'eng'
p50158
asS'FAU'
p50159
(lp50160
S'Ferreyra, Cecilia'
p50161
aS'Yun, Oliver'
p50162
aS'Eisenberg, Nell'
p50163
aS'Alonso, Elena'
p50164
aS'Khamadi, Ashimosi S'
p50165
aS'Mwau, Matilu'
p50166
aS'Mugendi, Martha Kihara'
p50167
aS'Alvarez, Ana'
p50168
aS'Velilla, Elena'
p50169
aS'Flevaud, Laurence'
p50170
aS'Arnedo, Mireia'
p50171
aS'Dalmau, David'
p50172
aS'Roddy, Paul'
p50173
aS'Bernasconi, Andrea'
p50174
aS'Palma, Pedro Pablo'
p50175
asS'JT'
p50176
S'PloS one'
p50177
sS'LR'
p50178
S'20151119'
p50179
sS'PG'
p50180
S'e49834'
p50181
sS'TI'
p50182
S'Evaluation of clinical and immunological markers for predicting virological failure in a HIV/AIDS treatment cohort in Busia, Kenya.'
p50183
sS'RN'
p50184
(lp50185
S'0 (Biomarkers)'
p50186
asS'PL'
p50187
S'United States'
p50188
sS'TA'
p50189
S'PLoS One'
p50190
sS'JID'
p50191
S'101285081'
p50192
sS'AB'
p50193
S'BACKGROUND: In resource-limited settings where viral load (VL) monitoring is scarce or unavailable, clinicians must use immunological and clinical criteria to define HIV virological treatment failure. This study examined the performance of World Health Organization (WHO) clinical and immunological failure criteria in predicting virological failure in HIV patients receiving antiretroviral therapy (ART). METHODS: In a HIV/AIDS program in Busia District Hospital, Kenya, a retrospective, cross-sectional cohort analysis was performed in April 2008 for all adult patients (>18 years old) on ART for >/=12 months, treatment-naive at ART start, attending the clinic at least once in last 6 months, and who had given informed consent. Treatment failure was assessed per WHO clinical (disease stage 3 or 4) and immunological (CD4 cell count) criteria, and compared with virological failure (VL >5,000 copies/mL). RESULTS: Of 926 patients, 123 (13.3%) had clinically defined treatment failure, 53 (5.7%) immunologically defined failure, and 55 (6.0%) virological failure. Sensitivity, specificity, positive predictive value, and negative predictive value of both clinical and immunological criteria (combined) in predicting virological failure were 36.4%, 83.5%, 12.3%, and 95.4%, respectively. CONCLUSIONS: In this analysis, clinical and immunological criteria were found to perform relatively poorly in predicting virological failure of ART. VL monitoring and new algorithms for assessing clinical or immunological treatment failure, as well as improved adherence strategies, are required in ART programs in resource-limited settings.'
p50194
sS'AD'
p50195
S'Medecins Sans Frontieres, Operational Center Barcelona Athens, Barcelona, Spain. cecilia.ferreyra@barcelona.msf.org'
p50196
sS'IP'
p50197
S'11'
p50198
sS'IS'
p50199
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p50200
sS'PMC'
p50201
S'PMC3504110'
p50202
sS'DCOM'
p50203
S'20130530'
p50204
sS'AU'
p50205
(lp50206
S'Ferreyra C'
p50207
aS'Yun O'
p50208
aS'Eisenberg N'
p50209
aS'Alonso E'
p50210
aS'Khamadi AS'
p50211
aS'Mwau M'
p50212
aS'Mugendi MK'
p50213
aS'Alvarez A'
p50214
aS'Velilla E'
p50215
aS'Flevaud L'
p50216
aS'Arnedo M'
p50217
aS'Dalmau D'
p50218
aS'Roddy P'
p50219
aS'Bernasconi A'
p50220
aS'Palma PP'
p50221
asS'VI'
p50222
S'7'
sS'MHDA'
p50223
S'2013/06/01 06:00'
p50224
sS'PHST'
p50225
(lp50226
S'2012/01/12 [received]'
p50227
aS'2012/10/15 [accepted]'
p50228
aS'2012/11/21 [epublish]'
p50229
asS'OID'
p50230
(lp50231
S'NLM: PMC3504110'
p50232
asS'MH'
p50233
(lp50234
S'*Acquired Immunodeficiency Syndrome/drug therapy/pathology/virology'
p50235
aS'Adult'
p50236
aS'*Antiretroviral Therapy, Highly Active'
p50237
aS'Biomarkers/*metabolism'
p50238
aS'CD4 Lymphocyte Count'
p50239
aS'Female'
p50240
aS'*HIV/genetics/pathogenicity'
p50241
aS'Humans'
p50242
aS'Kenya'
p50243
aS'Male'
p50244
aS'Middle Aged'
p50245
aS'Prognosis'
p50246
aS'Retrospective Studies'
p50247
aS'Treatment Failure'
p50248
aS'Viral Load'
p50249
aS'World Health Organization'
p50250
asS'EDAT'
p50251
S'2012/11/28 06:00'
p50252
sS'SO'
p50253
S'PLoS One. 2012;7(11):e49834. doi: 10.1371/journal.pone.0049834. Epub 2012 Nov 21.'
p50254
sS'SB'
p50255
S'IM'
p50256
sS'PMID'
p50257
S'23185450'
p50258
sS'PST'
p50259
S'ppublish'
p50260
stRp50261
ag2
(g3
g4
(dp50262
S'LID'
p50263
S'10.1371/journal.pone.0049591 [doi]'
p50264
sS'STAT'
p50265
S'MEDLINE'
p50266
sS'DEP'
p50267
S'20121120'
p50268
sS'DA'
p50269
S'20121127'
p50270
sS'AID'
p50271
(lp50272
S'10.1371/journal.pone.0049591 [doi]'
p50273
aS'PONE-D-12-26761 [pii]'
p50274
asS'CRDT'
p50275
(lp50276
S'2012/11/28 06:00'
p50277
asS'DP'
p50278
S'2012'
p50279
sS'AD'
p50280
S'The Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Charlestown, Massachusetts, United States of America.'
p50281
sS'OWN'
p50282
S'NLM'
p50283
sS'PT'
p50284
(lp50285
S'Journal Article'
p50286
aS"Research Support, Non-U.S. Gov't"
p50287
asS'LA'
p50288
(lp50289
S'eng'
p50290
asS'FAU'
p50291
(lp50292
S'Zanoni, Brian C'
p50293
aS'Sunpath, Henry'
p50294
aS'Feeney, Margaret E'
p50295
asS'JT'
p50296
S'PloS one'
p50297
sS'LR'
p50298
S'20150219'
p50299
sS'PG'
p50300
S'e49591'
p50301
sS'TI'
p50302
S'Pediatric response to second-line antiretroviral therapy in South Africa.'
p50303
sS'RN'
p50304
(lp50305
S'0 (Anti-HIV Agents)'
p50306
aS'0 (Anti-Retroviral Agents)'
p50307
aS'0 (Protease Inhibitors)'
p50308
asS'PL'
p50309
S'United States'
p50310
sS'TA'
p50311
S'PLoS One'
p50312
sS'JID'
p50313
S'101285081'
p50314
sS'AB'
p50315
S"BACKGROUND: With improved access to pediatric antiretroviral therapy (ART) in resource-limited settings, more children could experience first-line ART treatment failure. METHODS: We performed a retrospective cohort analysis using electronic medical records from HIV-infected children who initiated ART at McCord Hospital's Sinikithemba Clinic in KwaZulu-Natal, South Africa, from August 2003 to December 2010. We analyzed all records from children who began second-line ART due to first-line treatment failure. We used logistic regression to compare viral outcomes in Protease Inhibitor (PI)-based versus Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-based second-line ART, controlling for time on first-line ART, sex, and whether HIV genotyping guided the regimen change. RESULTS: Of the 880 children who initiated ART during this time period, 80 (9.1%) switched to second-line ART due to therapeutic failure of first-line ART after a median of 95 weeks (IQR 65-147 weeks). Eight (10%) of the failures received NNRTI-based second-line ART, all of whom failed a PI-based first-line regimen. Seventy (87.5%) received PI-based second-line ART, all of whom failed a NNRTI-based first-line regimen. Two children (2.5%) received non-standard dual therapy as second-line ART. Six months after switching ART regimens, the viral suppression rate was significantly higher in the PI group (82%) than in the NNRTI group (29%; p=0.003). Forty-one children (51%) were tested for genotypic resistance prior to switching to second-line ART. There was no significant difference in six month viral suppression (p=0.38) between children with and without genotype testing. CONCLUSION: NNRTI-based second-line ART carries a high risk of virologic failure compared to PI-based second-line ART."
p50316
sS'GR'
p50317
(lp50318
S'P30 AI060354/AI/NIAID NIH HHS/United States'
p50319
aS'T32 AI052074/AI/NIAID NIH HHS/United States'
p50320
asS'IP'
p50321
S'11'
p50322
sS'IS'
p50323
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p50324
sS'PMC'
p50325
S'PMC3502491'
p50326
sS'DCOM'
p50327
S'20130522'
p50328
sS'AU'
p50329
(lp50330
S'Zanoni BC'
p50331
aS'Sunpath H'
p50332
aS'Feeney ME'
p50333
asS'VI'
p50334
S'7'
sS'MHDA'
p50335
S'2013/05/23 06:00'
p50336
sS'PHST'
p50337
(lp50338
S'2012/09/04 [received]'
p50339
aS'2012/10/12 [accepted]'
p50340
aS'2012/11/20 [epublish]'
p50341
asS'OID'
p50342
(lp50343
S'NLM: PMC3502491'
p50344
asS'MH'
p50345
(lp50346
S'Anti-HIV Agents/*pharmacology'
p50347
aS'Anti-Retroviral Agents/*pharmacology'
p50348
aS'CD4 Lymphocyte Count'
p50349
aS'Child'
p50350
aS'Child, Preschool'
p50351
aS'Cohort Studies'
p50352
aS'*Drug Resistance, Viral'
p50353
aS'Female'
p50354
aS'Genotype'
p50355
aS'HIV Infections/*drug therapy'
p50356
aS'Humans'
p50357
aS'Infant'
p50358
aS'Male'
p50359
aS'Medical Records Systems, Computerized'
p50360
aS'Models, Statistical'
p50361
aS'Protease Inhibitors/pharmacology'
p50362
aS'Regression Analysis'
p50363
aS'Retrospective Studies'
p50364
aS'South Africa'
p50365
aS'Time Factors'
p50366
aS'Treatment Outcome'
p50367
aS'Viral Load'
p50368
asS'EDAT'
p50369
S'2012/11/28 06:00'
p50370
sS'SO'
p50371
S'PLoS One. 2012;7(11):e49591. doi: 10.1371/journal.pone.0049591. Epub 2012 Nov 20.'
p50372
sS'SB'
p50373
S'IM'
p50374
sS'PMID'
p50375
S'23185373'
p50376
sS'PST'
p50377
S'ppublish'
p50378
stRp50379
ag2
(g3
g4
(dp50380
S'LID'
p50381
S'10.1186/1471-2431-12-183 [doi]'
p50382
sS'STAT'
p50383
S'MEDLINE'
p50384
sS'DEP'
p50385
S'20121123'
p50386
sS'DA'
p50387
S'20130301'
p50388
sS'AID'
p50389
(lp50390
S'1471-2431-12-183 [pii]'
p50391
aS'10.1186/1471-2431-12-183 [doi]'
p50392
asS'CRDT'
p50393
(lp50394
S'2012/11/27 06:00'
p50395
asS'DP'
p50396
S'2012'
p50397
sS'AD'
p50398
S"Department of Paediatrics, Children's Infectious Diseases Clinical Research Unit (KID CRU), Tygerberg Children's Hospital, Stellenbosch University, Cape Town, South Africa. innes@sun.ac.za"
p50399
sS'OWN'
p50400
S'NLM'
p50401
sS'PT'
p50402
(lp50403
S'Evaluation Studies'
p50404
aS'Journal Article'
p50405
aS'Research Support, N.I.H., Extramural'
p50406
aS"Research Support, Non-U.S. Gov't"
p50407
aS"Research Support, U.S. Gov't, Non-P.H.S."
p50408
asS'LA'
p50409
(lp50410
S'eng'
p50411
asS'DCOM'
p50412
S'20130516'
p50413
sS'JT'
p50414
S'BMC pediatrics'
p50415
sS'LR'
p50416
S'20150219'
p50417
sS'FAU'
p50418
(lp50419
S'Innes, Steve'
p50420
aS'Cotton, Mark F'
p50421
aS'Haubrich, Richard'
p50422
aS'Conradie, Maria M'
p50423
aS'van Niekerk, Margaret'
p50424
aS'Edson, Clair'
p50425
aS'Rabie, Helena'
p50426
aS'Jain, Sonia'
p50427
aS'Sun, Xiaoying'
p50428
aS'Zollner, Ekkehard W'
p50429
aS'Hough, Stephen'
p50430
aS'Browne, Sara H'
p50431
asS'TI'
p50432
S'High prevalence of lipoatrophy in pre-pubertal South African children on antiretroviral therapy: a cross-sectional study.'
p50433
sS'RN'
p50434
(lp50435
S'0 (Anti-HIV Agents)'
p50436
aS'BO9LE4QFZF (Stavudine)'
p50437
asS'PL'
p50438
S'England'
p50439
sS'PG'
p50440
S'183'
p50441
sS'JID'
p50442
S'100967804'
p50443
sS'AB'
p50444
S'BACKGROUND: Despite changes in WHO guidelines, stavudine is still used extensively for treatment of pediatric HIV in the developing world. Lipoatrophy in sub-Saharan African children can be stigmatizing and have far-reaching consequences. The severity and extent of lipoatrophy in pre-pubertal children living in sub-Saharan Africa is unknown. METHODS: In this cross-sectional study, children who were 3-12 years old, on antiretroviral therapy and pre-pubertal were recruited from a Family HIV Clinic in South Africa. Lipoatrophy was identified and graded by consensus between two HIV pediatricians using a standardized grading scale. A professional dietician performed formal dietary assessment and anthropometric measurements of trunk and limb fat. Previous antiretroviral exposures were recorded. In a Dual-Energy X-ray Absorbtiometry (DXA) substudy body composition was determined in 42 participants. RESULTS: Among 100 recruits, the prevalence of visually obvious lipoatrophy was 36% (95% CI: 27%-45%). Anthropometry and DXA measurements corroborated the clinical diagnosis of lipoatrophy: Both confirmed significant, substantial extremity fat loss in children with visually obvious lipoatrophy, when adjusted for age and sex. Adjusted odds ratio for developing lipoatrophy was 1.9 (95% CI: 1.3 - 2.9) for each additional year of accumulated exposure to standard dose stavudine. Cumulative time on standard dose stavudine was significantly associated with reductions in biceps and triceps skin-fold thickness (p=0.008). CONCLUSIONS: The prevalence of visually obvious lipoatrophy in pre-pubertal South African children on antiretroviral therapy is high. The amount of stavudine that children are exposed to needs review. Resources are needed to enable low-and-middle-income countries to provide suitable pediatric-formulated alternatives to stavudine-based pediatric regimens. The standard stavudine dose for children may need to be reduced. Diagnosis of lipoatrophy at an early stage is important to allow timeous antiretroviral switching to arrest progression and avoid stigmatization. Diagnosis using visual grading requires training and experience, and DXA and comprehensive anthropometry are not commonly available. A simple objective screening tool is needed to identify early lipoatrophy in resource-limited settings where specialized skills and equipment are not available.'
p50445
sS'GR'
p50446
(lp50447
S'5U01AI069521-01/AI/NIAID NIH HHS/United States'
p50448
aS'5U01AI069521-02/AI/NIAID NIH HHS/United States'
p50449
aS'5U01AI069521-03/AI/NIAID NIH HHS/United States'
p50450
aS'5U01AI069521-04/AI/NIAID NIH HHS/United States'
p50451
aS'AI27670/AI/NIAID NIH HHS/United States'
p50452
aS'AI36214/AI/NIAID NIH HHS/United States'
p50453
aS'K08 AI62758/AI/NIAID NIH HHS/United States'
p50454
aS'K24 AI064086/AI/NIAID NIH HHS/United States'
p50455
aS'K24 AI064086/AI/NIAID NIH HHS/United States'
p50456
aS'P30 AI036214/AI/NIAID NIH HHS/United States'
p50457
aS'P30 AI036214-16/AI/NIAID NIH HHS/United States'
p50458
aS'P30-AI36214/AI/NIAID NIH HHS/United States'
p50459
aS'R24-TW007988-01/TW/FIC NIH HHS/United States'
p50460
aS'R43 AI093318-01/AI/NIAID NIH HHS/United States'
p50461
aS'U01 AI069432/AI/NIAID NIH HHS/United States'
p50462
aS'U01-AI38858/AI/NIAID NIH HHS/United States'
p50463
asS'VI'
p50464
S'12'
p50465
sS'IS'
p50466
S'1471-2431 (Electronic) 1471-2431 (Linking)'
p50467
sS'PMC'
p50468
S'PMC3584923'
p50469
sS'AU'
p50470
(lp50471
S'Innes S'
p50472
aS'Cotton MF'
p50473
aS'Haubrich R'
p50474
aS'Conradie MM'
p50475
aS'van Niekerk M'
p50476
aS'Edson C'
p50477
aS'Rabie H'
p50478
aS'Jain S'
p50479
aS'Sun X'
p50480
aS'Zollner EW'
p50481
aS'Hough S'
p50482
aS'Browne SH'
p50483
asS'MHDA'
p50484
S'2013/05/17 06:00'
p50485
sS'PHST'
p50486
(lp50487
S'2012/03/30 [received]'
p50488
aS'2012/10/31 [accepted]'
p50489
aS'2012/11/23 [aheadofprint]'
p50490
asS'OID'
p50491
(lp50492
S'NLM: PMC3584923'
p50493
asS'MH'
p50494
(lp50495
S'Absorptiometry, Photon'
p50496
aS'Adiposity'
p50497
aS'Anti-HIV Agents/*adverse effects'
p50498
aS'Child'
p50499
aS'Child, Preschool'
p50500
aS'Cross-Sectional Studies'
p50501
aS'Female'
p50502
aS'HIV-Associated Lipodystrophy Syndrome/*chemically induced/diagnosis/epidemiology'
p50503
aS'Humans'
p50504
aS'Linear Models'
p50505
aS'Logistic Models'
p50506
aS'Male'
p50507
aS'Prevalence'
p50508
aS'Risk Factors'
p50509
aS'South Africa'
p50510
aS'Stavudine/*adverse effects'
p50511
aS'Time Factors'
p50512
asS'EDAT'
p50513
S'2012/11/28 06:00'
p50514
sS'SO'
p50515
S'BMC Pediatr. 2012 Nov 23;12:183. doi: 10.1186/1471-2431-12-183.'
p50516
sS'SB'
p50517
S'IM'
p50518
sS'PMID'
p50519
S'23176441'
p50520
sS'TA'
p50521
S'BMC Pediatr'
p50522
sS'PST'
p50523
S'epublish'
p50524
stRp50525
ag2
(g3
g4
(dp50526
S'LID'
p50527
S'10.1097/QAD.0b013e32835c54b8 [doi]'
p50528
sS'STAT'
p50529
S'MEDLINE'
p50530
sS'JT'
p50531
S'AIDS (London, England)'
p50532
sS'DA'
p50533
S'20130531'
p50534
sS'AID'
p50535
(lp50536
S'10.1097/QAD.0b013e32835c54b8 [doi]'
p50537
asS'CRDT'
p50538
(lp50539
S'2012/11/22 06:00'
p50540
asS'DP'
p50541
S'2013 Mar 13'
p50542
sS'AD'
p50543
S'Department of Paediatrics, Chris Hani Baragwanath Hospital, Johannesburg, South Africa.'
p50544
sS'OWN'
p50545
S'NLM'
p50546
sS'PT'
p50547
(lp50548
S'Journal Article'
p50549
aS'Research Support, N.I.H., Extramural'
p50550
aS"Research Support, U.S. Gov't, Non-P.H.S."
p50551
asS'LA'
p50552
(lp50553
S'eng'
p50554
asS'FAU'
p50555
(lp50556
S'Palmer, Megan'
p50557
aS'Chersich, Matthew'
p50558
aS'Moultrie, Harry'
p50559
aS'Kuhn, Louise'
p50560
aS'Fairlie, Lee'
p50561
aS'Meyers, Tammy'
p50562
asS'LR'
p50563
S'20140206'
p50564
sS'PG'
p50565
S'781-5'
p50566
sS'TI'
p50567
S'Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa.'
p50568
sS'RN'
p50569
(lp50570
S'0 (Anti-HIV Agents)'
p50571
aS'0 (Benzoxazines)'
p50572
aS'0 (Dideoxynucleosides)'
p50573
aS'2T8Q726O95 (Lamivudine)'
p50574
aS'BO9LE4QFZF (Stavudine)'
p50575
aS'JE6H2O27P8 (efavirenz)'
p50576
aS'WR2TIP26VS (abacavir)'
p50577
asS'PL'
p50578
S'England'
p50579
sS'TA'
p50580
S'AIDS'
p50581
sS'JID'
p50582
S'8710219'
p50583
sS'AB'
p50584
S'INTRODUCTION: Stavudine is a commonly used drug in paediatric antiretroviral treatment (ART) regimens. Due to toxicity concerns, however, the drug abacavir has replaced stavudine in first-line paediatric regimens in many countries. We describe the frequency of stavudine toxicity in children receiving ART at a treatment clinic in Soweto, South Africa. METHODS: Data on patient characteristics and outcomes of ART were collected from a cohort of 2222 HIV-infected children initiating ART between 2004 and 2008 when stavudine-containing regimens were routinely recommended. At several time-points after treatment initiation, we estimate the proportion of children where an attending clinician discontinued stavudine due to lipodystrophy, pancreatitis, lactic acidosis or peripheral neuropathy. Factors associated with stavudine-related toxicities were identified. RESULTS: At ART initiation, most children had advanced disease. The majority initiated an efavirenz/lamivudine/stavudine regimen (n = 1422), and 76% of children remained on their initial ART regimen after a median 19.9 months of ART. Replacement of stavudine due to drug toxicity occurred at a rate of 28.8 per 1000 child years on treatment (95% confidence interval = 23.6-35.2). Rates of toxicity increased with treatment duration (in their first year of ART stavudine was replaced in 0.5% of children, but after 3 years stavudine had been changed to abacavir in 12.6% of children). Toxicity was more common in older children and in girls. Lipodystrophy accounted for 87 of 96 toxic events. CONCLUSION: Stavudine-associated toxicity resulting in single-drug substitution was uncommon in this cohort, though its frequency increased steadily with ART duration, especially with lipodystrophy. Where drug options are limited, stavudine remains a relatively well tolerated and effective option for children.'
p50585
sS'GR'
p50586
(lp50587
S'5U2RTW007370/PHS HHS/United States'
p50588
aS'5U2RTW007373/PHS HHS/United States'
p50589
asS'IP'
p50590
S'5'
sS'IS'
p50591
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p50592
sS'DCOM'
p50593
S'20131029'
p50594
sS'AU'
p50595
(lp50596
S'Palmer M'
p50597
aS'Chersich M'
p50598
aS'Moultrie H'
p50599
aS'Kuhn L'
p50600
aS'Fairlie L'
p50601
aS'Meyers T'
p50602
asS'VI'
p50603
S'27'
p50604
sS'MHDA'
p50605
S'2013/10/30 06:00'
p50606
sS'MH'
p50607
(lp50608
S'Anti-HIV Agents/administration & dosage/*adverse effects'
p50609
aS'Antiretroviral Therapy, Highly Active/*adverse effects'
p50610
aS'Benzoxazines/administration & dosage/adverse effects'
p50611
aS'Child'
p50612
aS'Child, Preschool'
p50613
aS'Cohort Studies'
p50614
aS'Dideoxynucleosides/administration & dosage/adverse effects'
p50615
aS'Drug Substitution'
p50616
aS'Drug Therapy, Combination'
p50617
aS'Drug-Related Side Effects and Adverse Reactions/chemically induced'
p50618
aS'Female'
p50619
aS'HIV Infections/*drug therapy'
p50620
aS'Humans'
p50621
aS'Infant'
p50622
aS'Lamivudine/administration & dosage/adverse effects'
p50623
aS'Male'
p50624
aS'Retrospective Studies'
p50625
aS'Risk Factors'
p50626
aS'South Africa'
p50627
aS'Stavudine/administration & dosage/*adverse effects'
p50628
aS'Time Factors'
p50629
asS'EDAT'
p50630
S'2012/11/22 06:00'
p50631
sS'SO'
p50632
S'AIDS. 2013 Mar 13;27(5):781-5. doi: 10.1097/QAD.0b013e32835c54b8.'
p50633
sS'SB'
p50634
S'IM X'
p50635
sS'PMID'
p50636
S'23169331'
p50637
sS'PST'
p50638
S'ppublish'
p50639
stRp50640
ag2
(g3
g4
(dp50641
S'LID'
p50642
S'10.1186/1471-2334-12-304 [doi]'
p50643
sS'STAT'
p50644
S'MEDLINE'
p50645
sS'DEP'
p50646
S'20121115'
p50647
sS'DA'
p50648
S'20121212'
p50649
sS'AID'
p50650
(lp50651
S'1471-2334-12-304 [pii]'
p50652
aS'10.1186/1471-2334-12-304 [doi]'
p50653
asS'CRDT'
p50654
(lp50655
S'2012/11/16 06:00'
p50656
asS'DP'
p50657
S'2012'
p50658
sS'AD'
p50659
S'School of Public Health, Makerere University College of Health Sciences, PO Box 7072, Kampala, Uganda. dguwatudde@musph.ac.ug'
p50660
sS'OWN'
p50661
S'NLM'
p50662
sS'PT'
p50663
(lp50664
S'Journal Article'
p50665
aS'Randomized Controlled Trial'
p50666
aS'Research Support, N.I.H., Extramural'
p50667
asS'LA'
p50668
(lp50669
S'eng'
p50670
asS'DCOM'
p50671
S'20130429'
p50672
sS'JT'
p50673
S'BMC infectious diseases'
p50674
sS'LR'
p50675
S'20150222'
p50676
sS'FAU'
p50677
(lp50678
S'Guwatudde, David'
p50679
aS'Ezeamama, Amara E'
p50680
aS'Bagenda, Danstan'
p50681
aS'Kyeyune, Rachel'
p50682
aS'Wabwire-Mangen, Fred'
p50683
aS'Wamani, Henry'
p50684
aS'Mugusi, Ferdinand'
p50685
aS'Spiegelman, Donna'
p50686
aS'Wang, Molin'
p50687
aS'Manabe, Yukari C'
p50688
aS'Fawzi, Wafaie W'
p50689
asS'TI'
p50690
S'Multivitamin supplementation in HIV infected adults initiating antiretroviral therapy in Uganda: the protocol for a randomized double blinded placebo controlled efficacy trial.'
p50691
sS'RN'
p50692
(lp50693
S'0 (Placebos)'
p50694
aS'0 (Vitamins)'
p50695
asS'PL'
p50696
S'England'
p50697
sS'PG'
p50698
S'304'
p50699
sS'JID'
p50700
S'100968551'
p50701
sS'AB'
p50702
S'BACKGROUND: Use of multivitamin supplements during the pre-HAART era has been found to reduce viral load, enhance immune response, and generally improve clinical outcomes among HIV-infected adults. However, immune reconstitution is incomplete and significant mortality and opportunistic infections occur in spite of HAART. There is insufficient research information on whether multivitamin supplementation may be beneficial as adjunct therapy for HIV-infected individuals taking HAART. We propose to evaluate the efficacy of a single recommended daily allowance (RDA) of micronutrients (including vitamins B-complex, C, and E) in slowing disease progression among HIV-infected adults receiving HAART in Uganda. METHODS/DESIGN: We are using a randomized, double-blind, placebo-controlled trial study design. Eligible patients are HIV-positive adults aged at least 18 years, and are randomized to receive either a placebo; or multivitamins that include a single RDA of the following vitamins: 1.4 mg B1, 1.4 mg B2, 1.9 mg B6, 2.6 mcg B12, 18 mg niacin, 70 mg C, 10 mg E, and 0.4 mg folic acid. Participants are followed for up to 18 months with evaluations at baseline, 6, 12 and 18 months. The study is primarily powered to examine the effects on immune reconstitution, weight gain, and quality of life. In addition, we will examine the effects on other secondary outcomes including the risks of development of new or recurrent disease progression event, including all-cause mortality; ARV regimen change from first- to second-line therapy; and other adverse events as indicated by incident peripheral neuropathy, severe anemia, or diarrhea. DISCUSSIONS: The conduct of this trial provides an opportunity to evaluate the potential benefits of this affordable adjunct therapy (multivitamin supplementation) among HIV-infected adults receiving HAART in a developing country setting. TRIAL REGISTRATION: Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01228578.'
p50703
sS'GR'
p50704
(lp50705
S'R01 HD060333/HD/NICHD NIH HHS/United States'
p50706
aS'R01HD060333/HD/NICHD NIH HHS/United States'
p50707
asS'VI'
p50708
S'12'
p50709
sS'IS'
p50710
S'1471-2334 (Electronic) 1471-2334 (Linking)'
p50711
sS'PMC'
p50712
S'PMC3519743'
p50713
sS'AU'
p50714
(lp50715
S'Guwatudde D'
p50716
aS'Ezeamama AE'
p50717
aS'Bagenda D'
p50718
aS'Kyeyune R'
p50719
aS'Wabwire-Mangen F'
p50720
aS'Wamani H'
p50721
aS'Mugusi F'
p50722
aS'Spiegelman D'
p50723
aS'Wang M'
p50724
aS'Manabe YC'
p50725
aS'Fawzi WW'
p50726
asS'MHDA'
p50727
S'2013/04/30 06:00'
p50728
sS'PHST'
p50729
(lp50730
S'2012/09/30 [received]'
p50731
aS'2012/11/09 [accepted]'
p50732
aS'2012/11/15 [aheadofprint]'
p50733
asS'OID'
p50734
(lp50735
S'NLM: PMC3519743'
p50736
asS'MH'
p50737
(lp50738
S'Adolescent'
p50739
aS'Adult'
p50740
aS'Antiretroviral Therapy, Highly Active/*methods'
p50741
aS'Body Weight'
p50742
aS'*Clinical Protocols'
p50743
aS'Diet/*methods'
p50744
aS'Female'
p50745
aS'HIV Infections/*drug therapy/immunology'
p50746
aS'Humans'
p50747
aS'Longitudinal Studies'
p50748
aS'Male'
p50749
aS'Middle Aged'
p50750
aS'Placebos/administration & dosage'
p50751
aS'Quality of Life'
p50752
aS'Treatment Outcome'
p50753
aS'Uganda'
p50754
aS'Vitamins/*administration & dosage'
p50755
aS'Young Adult'
p50756
asS'EDAT'
p50757
S'2012/11/16 06:00'
p50758
sS'SI'
p50759
(lp50760
S'ClinicalTrials.gov/NCT01228578'
p50761
asS'SO'
p50762
S'BMC Infect Dis. 2012 Nov 15;12:304. doi: 10.1186/1471-2334-12-304.'
p50763
sS'SB'
p50764
S'IM'
p50765
sS'PMID'
p50766
S'23151221'
p50767
sS'TA'
p50768
S'BMC Infect Dis'
p50769
sS'PST'
p50770
S'epublish'
p50771
stRp50772
ag2
(g3
g4
(dp50773
S'LID'
p50774
S'10.1371/journal.pone.0048531 [doi]'
p50775
sS'STAT'
p50776
S'MEDLINE'
p50777
sS'DEP'
p50778
S'20121029'
p50779
sS'DA'
p50780
S'20121112'
p50781
sS'AID'
p50782
(lp50783
S'10.1371/journal.pone.0048531 [doi]'
p50784
aS'PONE-D-12-10449 [pii]'
p50785
asS'CRDT'
p50786
(lp50787
S'2012/11/13 06:00'
p50788
asS'DP'
p50789
S'2012'
p50790
sS'OWN'
p50791
S'NLM'
p50792
sS'PT'
p50793
(lp50794
S'Journal Article'
p50795
asS'LA'
p50796
(lp50797
S'eng'
p50798
asS'FAU'
p50799
(lp50800
S'Miremba, Penelope'
p50801
aS'Kalyango, Joan N'
p50802
aS'Worodria, William'
p50803
aS'Mugerwa, Henry'
p50804
aS'Nakakawa, Ethel'
p50805
aS'Asiimwe, Benon B'
p50806
asS'JT'
p50807
S'PloS one'
p50808
sS'LR'
p50809
S'20150222'
p50810
sS'PG'
p50811
S'e48531'
p50812
sS'TI'
p50813
S'Performance of frontloading for smear microscopy in the diagnosis of pulmonary tuberculosis: a cross-sectional study at a referral hospital in Uganda.'
p50814
sS'PL'
p50815
S'United States'
p50816
sS'TA'
p50817
S'PLoS One'
p50818
sS'JID'
p50819
S'101285081'
p50820
sS'AB'
p50821
S'OBJECTIVE: To compare the performance of frontloading and the standard WHO method for diagnosis of pulmonary TB at Mulago Hospital in order to validate the technique in this setting. METHODS: This was a cross-sectional study in which 229 adult (>/=18 years) TB suspects were consecutively enrolled. Suspects submitted three sputum samples as follows: at initial presentation, one hour after the first sample, and the next morning. The first and next morning samples formed the standard WHO method, while the first and the one hour later samples formed the frontloading method. Sample processing was by the standard N-acetyl L-cystein (NALC)-NaOH method, and fluorescent microscopy was done for both methods, while cultures of the first sample on Lowenstein-Jensen slants acted as a gold standard. The sensitivity, specificity and predictive values for the WHO standard and frontloading methods were compared. RESULTS: The sensitivity of both the frontloading and standard schemes was 91.1% while their specificities were 86.2% and 91.7% respectively. There was excellent agreement between the diagnostic capacity of the two methods (kappa statistic = 0.87, P<0.0001). The positive predictive value for the frontloading scheme was 87.2% and that for the standard approach was 91.9%, while the negative predictive values were 90.4% and 90.9%, respectively. Among the HIV positive patients, frontloading identified 59/79 (74.7%) culture positive samples while the standard approach identified 55/79 (69.6%). In the HIV sero-negative category, on the other hand, front-loading identified 48/110 (43.6%) culture positive samples compared to 45/110 (40.9%) by the standard approach. CONCLUSION: Frontloading based on smear examination of two same-day sputum samples has a similar performance to the current standard method and would not be associated with any significant missed diagnosis. It may therefore be advocated for use in our setting so as to reduce time to completion of diagnosis and patient loss to follow-up.'
p50822
sS'AD'
p50823
S'Clinical Epidemiology Unit, College of Health Sciences, Makerere University, Kampala, Uganda.'
p50824
sS'IP'
p50825
S'10'
p50826
sS'IS'
p50827
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p50828
sS'PMC'
p50829
S'PMC3483226'
p50830
sS'DCOM'
p50831
S'20140826'
p50832
sS'AU'
p50833
(lp50834
S'Miremba P'
p50835
aS'Kalyango JN'
p50836
aS'Worodria W'
p50837
aS'Mugerwa H'
p50838
aS'Nakakawa E'
p50839
aS'Asiimwe BB'
p50840
asS'VI'
p50841
S'7'
sS'MHDA'
p50842
S'2014/08/27 06:00'
p50843
sS'PHST'
p50844
(lp50845
S'2012/04/12 [received]'
p50846
aS'2012/09/25 [accepted]'
p50847
aS'2012/10/29 [epublish]'
p50848
asS'OID'
p50849
(lp50850
S'NLM: PMC3483226'
p50851
asS'MH'
p50852
(lp50853
S'Adult'
p50854
aS'Cross-Sectional Studies'
p50855
aS'Diagnostic Techniques, Respiratory System/instrumentation/standards'
p50856
aS'Female'
p50857
aS'Humans'
p50858
aS'Male'
p50859
aS'Microscopy/*methods'
p50860
aS'Microscopy, Fluorescence'
p50861
aS'Middle Aged'
p50862
aS'Mycobacterium tuberculosis/*isolation & purification'
p50863
aS'Referral and Consultation'
p50864
aS'Reproducibility of Results'
p50865
aS'Sensitivity and Specificity'
p50866
aS'Sputum/*microbiology'
p50867
aS'Time Factors'
p50868
aS'Tuberculosis, Pulmonary/*diagnosis/microbiology'
p50869
aS'Uganda'
p50870
aS'Young Adult'
p50871
asS'EDAT'
p50872
S'2012/11/13 06:00'
p50873
sS'SO'
p50874
S'PLoS One. 2012;7(10):e48531. doi: 10.1371/journal.pone.0048531. Epub 2012 Oct 29.'
p50875
sS'SB'
p50876
S'IM'
p50877
sS'PMID'
p50878
S'23144768'
p50879
sS'PST'
p50880
S'ppublish'
p50881
stRp50882
ag2
(g3
g4
(dp50883
S'LID'
p50884
S'10.1097/COH.0b013e32835b7f94 [doi]'
p50885
sS'STAT'
p50886
S'MEDLINE'
p50887
sS'AB'
p50888
S'PURPOSE OF REVIEW: This review provides an update of recent data on the development of HIV-1 drug resistance during treatment and its transmission in sub-Saharan Africa after the scale-up of antiretroviral therapy (ART). RECENT FINDINGS: Evidence is accumulating of a rising prevalence of transmitted HIV drug resistance (TDR), predominantly associated with nonnucleoside reverse transcriptase inhibitors (NNRTIs), in east and southern Africa. Pretherapy resistance is associated with first-line therapy failure. Accumulation of resistance mutations during first-line failure can be prevented by early detection and timely switching to second-line ART. Important gaps in service delivery and programme performance, associated with resistance development, affect a considerable proportion of ART programmes, particularly with respect to inadequate supply systems and patient retention. The reduction in new HIV infections associated with earlier use of ART is predicted to outweigh the risk of increasing TDR. Future levels of TDR are estimated to be diminished by improving switching practices to second-line regimens. SUMMARY: TDR is on the rise after the recent scale-up of ART in Africa. To prevent the development and spread of drug resistance and sustain the effectiveness of ART programmes, there is a need to improve drug supply systems, patient retention and access to routine viral load monitoring. Enhanced resistance monitoring is warranted in Africa.'
p50889
sS'JID'
p50890
S'101264945'
p50891
sS'AD'
p50892
S'Department of Global Health, Academic Medical Center of the University of Amsterdam, PharmAccess Foundation, Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands.'
p50893
sS'JT'
p50894
S'Current opinion in HIV and AIDS'
p50895
sS'IP'
p50896
S'1'
sS'IS'
p50897
S'1746-6318 (Electronic) 1746-630X (Linking)'
p50898
sS'DCOM'
p50899
S'20130429'
p50900
sS'DA'
p50901
S'20121205'
p50902
sS'AU'
p50903
(lp50904
S'Hamers RL'
p50905
aS'Sigaloff KC'
p50906
aS'Kityo C'
p50907
aS'Mugyenyi P'
p50908
aS'de Wit TF'
p50909
asS'AID'
p50910
(lp50911
S'10.1097/COH.0b013e32835b7f94 [doi]'
p50912
asS'CRDT'
p50913
(lp50914
S'2012/11/13 06:00'
p50915
asS'VI'
p50916
S'8'
sS'PMID'
p50917
S'23143140'
p50918
sS'DP'
p50919
S'2013 Jan'
p50920
sS'MHDA'
p50921
S'2013/04/30 06:00'
p50922
sS'OWN'
p50923
S'NLM'
p50924
sS'PT'
p50925
(lp50926
S'Journal Article'
p50927
aS"Research Support, Non-U.S. Gov't"
p50928
aS'Review'
p50929
asS'LA'
p50930
(lp50931
S'eng'
p50932
asS'MH'
p50933
(lp50934
S'Africa South of the Sahara'
p50935
aS'Anti-Retroviral Agents/*therapeutic use'
p50936
aS'Drug Resistance, Viral'
p50937
aS'HIV Infections/*drug therapy/*virology'
p50938
aS'Humans'
p50939
asS'FAU'
p50940
(lp50941
S'Hamers, Raph L'
p50942
aS'Sigaloff, Kim C E'
p50943
aS'Kityo, Cissy'
p50944
aS'Mugyenyi, Peter'
p50945
aS'de Wit, Tobias F Rinke'
p50946
asS'EDAT'
p50947
S'2012/11/13 06:00'
p50948
sS'PST'
p50949
S'ppublish'
p50950
sS'SO'
p50951
S'Curr Opin HIV AIDS. 2013 Jan;8(1):19-26. doi: 10.1097/COH.0b013e32835b7f94.'
p50952
sS'PG'
p50953
S'19-26'
p50954
sS'TI'
p50955
S'Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa.'
p50956
sS'SB'
p50957
S'IM X'
p50958
sS'RN'
p50959
(lp50960
S'0 (Anti-Retroviral Agents)'
p50961
asS'PL'
p50962
S'United States'
p50963
sS'TA'
p50964
S'Curr Opin HIV AIDS'
p50965
stRp50966
ag2
(g3
g4
(dp50967
S'STAT'
p50968
S'MEDLINE'
p50969
sS'AB'
p50970
S"OBJECTIVES: Tanzania is one of the nations that are highly affected by HIV/AIDS epidemic. Invention of ARVs (Anti -Retroviral) brought hope of extended life to people living with HIV/AIDS (PLHA). Though ARV's are administered in several clinics particularly in Dar es Salaam, there is a problem to adherence. Some factors associated with non-adherence are investigated and ways to optimize adherence are suggested. METHODS: This study was undertaken at three treatment and care clinics in Dar es Salaam. A sample of 197 individuals on ARV and 30 health care providers were interviewed. The sample comprised of 76 % females and 24% males, with mean age 34. About 74% of individuals on ARV were aged between 25 - 45 years. Logistic Regression and survival analysis models were used in the analysis. RESULTS: Individuals on ARV recommended factors responsible for non-adherence as lack of awareness 63.5%, stigma 56%, side effects 53.3%, and costs 28%. Other factors were being busy 25.4%, away from home 21.3%, forgetting 12.2% and ARVs out of stock 10.2%. Proportion of PLHA lost to follow up was 26%. Awareness and side effects were found to be statistically significant, with p-values of 0.042 and 0.068 respectively (alpha = 0.1). The median survival time for individuals on ARV was 42 months (95% CI: 41-44) with survival rate of above 0.7. Log-rank test showed significant differences between the male and female on having a shorter time to death. Females seemed to survive longer than males suggesting that females adhere more to ART than males. CONCLUSION: This calls for emphasis on HIV/AIDS education to the society especially to sensitize men. Another suggestion is that when a woman gets pregnant, both the expectant mother and father should attend maternal clinic so that they both take HIV test so as to increase man's participation."
p50971
sS'JID'
p50972
S'101302040'
p50973
sS'AD'
p50974
S'Department of Statistics, University of Dar es Salaam, P.O. Box 35047 Dar es Salaam, Tanzania.'
p50975
sS'JT'
p50976
S'East African journal of public health'
p50977
sS'IP'
p50978
S'4'
sS'IS'
p50979
S'0856-8960 (Print) 0856-8960 (Linking)'
p50980
sS'DCOM'
p50981
S'20121211'
p50982
sS'DA'
p50983
S'20121105'
p50984
sS'AU'
p50985
(lp50986
S'Baltazary G'
p50987
aS'Akarro RR'
p50988
aS'Mussa AS'
p50989
asS'SB'
p50990
S'IM'
p50991
sS'CRDT'
p50992
(lp50993
S'2012/11/06 06:00'
p50994
asS'VI'
p50995
S'8'
sS'PMID'
p50996
S'23120930'
p50997
sS'DP'
p50998
S'2011 Dec'
p50999
sS'MHDA'
p51000
S'2012/12/12 06:00'
p51001
sS'OWN'
p51002
S'NLM'
p51003
sS'PT'
p51004
(lp51005
S'Journal Article'
p51006
aS"Research Support, Non-U.S. Gov't"
p51007
asS'LA'
p51008
(lp51009
S'eng'
p51010
asS'MH'
p51011
(lp51012
S'Adult'
p51013
aS'Anti-Retroviral Agents/*therapeutic use'
p51014
aS'Female'
p51015
aS'HIV Infections/*drug therapy/psychology'
p51016
aS'Health Knowledge, Attitudes, Practice'
p51017
aS'Health Services Accessibility'
p51018
aS'Health Surveys'
p51019
aS'Humans'
p51020
aS'Logistic Models'
p51021
aS'Male'
p51022
aS'Medication Adherence/*psychology'
p51023
aS'Middle Aged'
p51024
aS'Pregnancy'
p51025
aS'Risk Factors'
p51026
aS'Sex Factors'
p51027
aS'Socioeconomic Factors'
p51028
aS'Surveys and Questionnaires'
p51029
aS'Survival Analysis'
p51030
aS'Tanzania/epidemiology'
p51031
asS'FAU'
p51032
(lp51033
S'Baltazary, Gasper'
p51034
aS'Akarro, Rocky R J'
p51035
aS'Mussa, A S'
p51036
asS'EDAT'
p51037
S'2012/11/06 06:00'
p51038
sS'PST'
p51039
S'ppublish'
p51040
sS'LR'
p51041
S'20151119'
p51042
sS'PG'
p51043
S'237-46'
p51044
sS'TI'
p51045
S'Some factors associated with non-adherence to antiretroviral therapy (ART) in people living with HIV/AIDS (PLHA) in Tanzania: a case study of Dar es Salaam region.'
p51046
sS'SO'
p51047
S'East Afr J Public Health. 2011 Dec;8(4):237-46.'
p51048
sS'RN'
p51049
(lp51050
S'0 (Anti-Retroviral Agents)'
p51051
asS'PL'
p51052
S'Tanzania'
p51053
sS'TA'
p51054
S'East Afr J Public Health'
p51055
stRp51056
ag2
(g3
g4
(dp51057
S'LID'
p51058
S'10.1371/journal.pone.0046943 [doi]'
p51059
sS'STAT'
p51060
S'MEDLINE'
p51061
sS'DEP'
p51062
S'20121024'
p51063
sS'DA'
p51064
S'20121101'
p51065
sS'AID'
p51066
(lp51067
S'10.1371/journal.pone.0046943 [doi]'
p51068
aS'PONE-D-12-12264 [pii]'
p51069
asS'CRDT'
p51070
(lp51071
S'2012/11/02 06:00'
p51072
asS'DP'
p51073
S'2012'
p51074
sS'OWN'
p51075
S'NLM'
p51076
sS'PT'
p51077
(lp51078
S'Journal Article'
p51079
aS"Research Support, Non-U.S. Gov't"
p51080
asS'LA'
p51081
(lp51082
S'eng'
p51083
asS'FAU'
p51084
(lp51085
S'Satti, Hind'
p51086
aS'McLaughlin, Megan M'
p51087
aS'Hedt-Gauthier, Bethany'
p51088
aS'Atwood, Sidney S'
p51089
aS'Omotayo, David B'
p51090
aS'Ntlamelle, Likhapha'
p51091
aS'Seung, Kwonjune J'
p51092
asS'JT'
p51093
S'PloS one'
p51094
sS'LR'
p51095
S'20150222'
p51096
sS'PG'
p51097
S'e46943'
p51098
sS'TI'
p51099
S'Outcomes of multidrug-resistant tuberculosis treatment with early initiation of antiretroviral therapy for HIV co-infected patients in Lesotho.'
p51100
sS'RN'
p51101
(lp51102
S'0 (Anti-HIV Agents)'
p51103
aS'0 (Antitubercular Agents)'
p51104
asS'PL'
p51105
S'United States'
p51106
sS'TA'
p51107
S'PLoS One'
p51108
sS'JID'
p51109
S'101285081'
p51110
sS'AB'
p51111
S'BACKGROUND: Although the importance of concurrent treatment for multidrug-resistant tuberculosis (MDR-TB) and HIV co-infection has been increasingly recognized, there have been few studies reporting outcomes of MDR-TB and HIV co-treatment. We report final outcomes of comprehensive, integrated MDR-TB and HIV treatment in Lesotho and examine factors associated with death or treatment failure. METHODS: We reviewed clinical charts of all adult patients who initiated MDR-TB treatment in Lesotho between January 2008 and September 2009. We calculated hazard ratios (HR) and used multivariable Cox proportional hazards regression to identify predictors of poor outcomes. RESULTS: Of 134 confirmed MDR-TB patients, 83 (62%) were cured or completed treatment, 46 (34%) died, 3 (2%) transferred, 1 (1%) defaulted, and 1 (1%) failed treatment. Treatment outcomes did not differ significantly by HIV status. Among the 94 (70%) patients with HIV co-infection, 53% were already on antiretroviral therapy (ART) before MDR-TB treatment initiation, and 43% started ART a median of 16 days after the start of the MDR-TB regimen. Among HIV co-infected patients who died, those who had not started ART before MDR-TB treatment had a shorter median time to death (80 days vs. 138 days, p=0.065). In multivariable analysis, predictors of increased hazard of failure or death were low and severely low body mass index (HR 2.75, 95% confidence interval [CI] 1.27-5.93; HR 5.50, 95% CI 2.38-12.69), and a history of working in South Africa (HR 2.37, 95% CI 1.24-4.52). CONCLUSIONS: Favorable outcomes can be achieved in co-infected patients using a community-based treatment model when both MDR-TB and HIV disease are treated concurrently and treatment is initiated promptly.'
p51112
sS'AD'
p51113
S'Partners In Health, Maseru, Lesotho. hsatti@pih.org'
p51114
sS'IP'
p51115
S'10'
p51116
sS'IS'
p51117
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p51118
sS'PMC'
p51119
S'PMC3480376'
p51120
sS'DCOM'
p51121
S'20130423'
p51122
sS'AU'
p51123
(lp51124
S'Satti H'
p51125
aS'McLaughlin MM'
p51126
aS'Hedt-Gauthier B'
p51127
aS'Atwood SS'
p51128
aS'Omotayo DB'
p51129
aS'Ntlamelle L'
p51130
aS'Seung KJ'
p51131
asS'VI'
p51132
S'7'
sS'MHDA'
p51133
S'2013/04/24 06:00'
p51134
sS'PHST'
p51135
(lp51136
S'2012/04/28 [received]'
p51137
aS'2012/09/06 [accepted]'
p51138
aS'2012/10/24 [epublish]'
p51139
asS'OID'
p51140
(lp51141
S'NLM: PMC3480376'
p51142
asS'MH'
p51143
(lp51144
S'AIDS-Related Opportunistic Infections/*drug therapy'
p51145
aS'Anti-HIV Agents/*therapeutic use'
p51146
aS'Antitubercular Agents/*therapeutic use'
p51147
aS'Humans'
p51148
aS'Lesotho'
p51149
aS'*Treatment Outcome'
p51150
aS'Tuberculosis, Multidrug-Resistant/complications/*drug therapy'
p51151
asS'EDAT'
p51152
S'2012/11/02 06:00'
p51153
sS'SO'
p51154
S'PLoS One. 2012;7(10):e46943. doi: 10.1371/journal.pone.0046943. Epub 2012 Oct 24.'
p51155
sS'SB'
p51156
S'IM'
p51157
sS'PMID'
p51158
S'23115633'
p51159
sS'PST'
p51160
S'ppublish'
p51161
stRp51162
ag2
(g3
g4
(dp51163
S'LID'
p51164
S'10.1097/QAI.0b013e318278bcb0 [doi]'
p51165
sS'STAT'
p51166
S'MEDLINE'
p51167
sS'JT'
p51168
S'Journal of acquired immune deficiency syndromes (1999)'
p51169
sS'DA'
p51170
S'20130808'
p51171
sS'AID'
p51172
(lp51173
S'10.1097/QAI.0b013e318278bcb0 [doi]'
p51174
asS'CRDT'
p51175
(lp51176
S'2012/11/01 06:00'
p51177
asS'DP'
p51178
S'2013 Mar 1'
p51179
sS'GR'
p51180
(lp51181
S'5U2GPS001537-03/PHS HHS/United States'
p51182
asS'OWN'
p51183
S'NLM'
p51184
sS'PT'
p51185
(lp51186
S'Journal Article'
p51187
aS"Research Support, Non-U.S. Gov't"
p51188
aS"Research Support, U.S. Gov't, P.H.S."
p51189
asS'LA'
p51190
(lp51191
S'eng'
p51192
asS'FAU'
p51193
(lp51194
S'McNairy, Margaret L'
p51195
aS'Lamb, Matthew R'
p51196
aS'Carter, Rosalind J'
p51197
aS'Fayorsey, Ruby'
p51198
aS'Tene, Gilbert'
p51199
aS'Mutabazi, Vincent'
p51200
aS'Gusmao, Eduarda'
p51201
aS'Panya, Millembe'
p51202
aS'Sheriff, Mushin'
p51203
aS'Abrams, Elaine J'
p51204
asS'PG'
p51205
S'e70-81'
p51206
sS'TI'
p51207
S'Retention of HIV-infected children on antiretroviral treatment in HIV care and treatment programs in Kenya, Mozambique, Rwanda, and Tanzania.'
p51208
sS'PL'
p51209
S'United States'
p51210
sS'TA'
p51211
S'J Acquir Immune Defic Syndr'
p51212
sS'FIR'
p51213
(lp51214
S'Hawkens, Mark'
p51215
aS'Kimanga, Davies'
p51216
aS'Koech, Emily'
p51217
aS'Reidy, William'
p51218
aS'Thiongo, John Elijah'
p51219
aS'Wanjiku, Lucy'
p51220
aS'Fernanda, Maria'
p51221
aS'Alvim, Sardella'
p51222
aS'Assan, Americo Rafi'
p51223
aS'Boore, Amy L'
p51224
aS'Jobarteh, Kebba M'
p51225
aS'Mizela, Jose'
p51226
aS'Mussa, Antonio'
p51227
aS'Xavier, Carla'
p51228
aS'Lahuerta, Maria'
p51229
aS'Lowrance, David'
p51230
aS'Manzi, Emmanuel'
p51231
aS'Micheu, Njeri'
p51232
aS'Morales, Fernando'
p51233
aS'Mugabo, Jules'
p51234
aS'Mugisha, Veronicah'
p51235
aS'Nagaba, William'
p51236
aS'Nyemazi, John Pierre'
p51237
aS'Raghunathan, Pratima'
p51238
aS'Nsanzimana, Sabin'
p51239
aS'Sahabo, Ruben'
p51240
aS'Almeida, Annette'
p51241
aS'Antelman, Gretchen'
p51242
aS'Arthur, Gilly'
p51243
aS'Khatib, Ahmed'
p51244
aS'Kilama, Bonita'
p51245
aS'Mbatia, Redempta'
p51246
aS'Mfaume, Mohammed'
p51247
aS'Nuwabaga-Biribonwoha, Harriet'
p51248
aS'Woldehana, Geoffrey Somi Ayele Zewde'
p51249
asS'JID'
p51250
S'100892005'
p51251
sS'AB'
p51252
S'BACKGROUND: Retention of children in HIV care is essential for prevention of disease progression and mortality. METHODS: Retrospective cohort of children (aged 0 to <15 years) initiating antiretroviral treatment (ART) at health facilities in Kenya, Mozambique, Rwanda, and Tanzania, from January 2005 to June 2011. Retention was defined as the proportion of children known to be alive and attending care at their initiation facility; lost to follow-up (LTF) was defined as no clinic visit for more than 6 months. Cumulative incidence of ascertained survival and retention after ART initiation was estimated through 24 months using Kaplan-Meier methods. Factors associated with LTF and death were assessed using Cox proportional hazard modeling. RESULTS: A total of 17,712 children initiated ART at 192 facilities: median age was 4.6 years [interquartile ratio (IQR), 1.9-8.3], median CD4 percent was 15% (IQR, 10-20) for children younger than 5 years and 265 cells per microliter (IQR, 111-461) for children aged 5 years or older. At 12 and 24 months, 80% and 72% of children were retained with 16% and 22% LTF and 5% and 7% known deaths, respectively. Retention ranged from 71% to 95% at 12 months and from 62% to 93% at 24 months across countries, respectively, and was lowest for children younger than 1 year (51% at 24 months). LTF and death were highest in children younger than 1 year and children with advanced disease. CONCLUSIONS: Retention was lowest in young children and differed across country programs. Young children and those with advanced disease are at highest risk for LTF and death. Further evaluation of patient- and program-level factors is needed to improve health outcomes.'
p51253
sS'AD'
p51254
S'ICAP, Mailman School of Public Health, Columbia University, New York, NY 10031, USA. mm3780@columbia.edu'
p51255
sS'CN'
p51256
(lp51257
S'Identifying Optimal Models of HIV Care and Treatment in Sub-Saharan Africa'
p51258
aS'Consortium'
p51259
asS'IP'
p51260
S'3'
sS'IS'
p51261
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p51262
sS'IR'
p51263
(lp51264
S'Hawkens M'
p51265
aS'Kimanga D'
p51266
aS'Koech E'
p51267
aS'Reidy W'
p51268
aS'Thiongo JE'
p51269
aS'Wanjiku L'
p51270
aS'Fernanda M'
p51271
aS'Alvim S'
p51272
aS'Assan AR'
p51273
aS'Boore AL'
p51274
aS'Jobarteh KM'
p51275
aS'Mizela J'
p51276
aS'Mussa A'
p51277
aS'Xavier C'
p51278
aS'Lahuerta M'
p51279
aS'Lowrance D'
p51280
aS'Manzi E'
p51281
aS'Micheu N'
p51282
aS'Morales F'
p51283
aS'Mugabo J'
p51284
aS'Mugisha V'
p51285
aS'Nagaba W'
p51286
aS'Nyemazi JP'
p51287
aS'Raghunathan P'
p51288
aS'Nsanzimana S'
p51289
aS'Sahabo R'
p51290
aS'Almeida A'
p51291
aS'Antelman G'
p51292
aS'Arthur G'
p51293
aS'Khatib A'
p51294
aS'Kilama B'
p51295
aS'Mbatia R'
p51296
aS'Mfaume M'
p51297
aS'Nuwabaga-Biribonwoha H'
p51298
aS'Woldehana GS'
p51299
asS'DCOM'
p51300
S'20130820'
p51301
sS'AU'
p51302
(lp51303
S'McNairy ML'
p51304
aS'Lamb MR'
p51305
aS'Carter RJ'
p51306
aS'Fayorsey R'
p51307
aS'Tene G'
p51308
aS'Mutabazi V'
p51309
aS'Gusmao E'
p51310
aS'Panya M'
p51311
aS'Sheriff M'
p51312
aS'Abrams EJ'
p51313
asS'VI'
p51314
S'62'
p51315
sS'MHDA'
p51316
S'2013/08/21 06:00'
p51317
sS'MH'
p51318
(lp51319
S'Adolescent'
p51320
aS'*Antiretroviral Therapy, Highly Active'
p51321
aS'Child'
p51322
aS'Child, Preschool'
p51323
aS'Female'
p51324
aS'HIV Infections/*drug therapy/mortality'
p51325
aS'Humans'
p51326
aS'Infant'
p51327
aS'Kaplan-Meier Estimate'
p51328
aS'Kenya/epidemiology'
p51329
aS'Male'
p51330
aS'Mozambique/epidemiology'
p51331
aS'Patient Acceptance of Health Care/*statistics & numerical data'
p51332
aS'Program Evaluation'
p51333
aS'Retrospective Studies'
p51334
aS'Risk Factors'
p51335
aS'Rwanda/epidemiology'
p51336
aS'Tanzania/epidemiology'
p51337
asS'EDAT'
p51338
S'2012/11/01 06:00'
p51339
sS'SO'
p51340
S'J Acquir Immune Defic Syndr. 2013 Mar 1;62(3):e70-81. doi: 10.1097/QAI.0b013e318278bcb0.'
p51341
sS'SB'
p51342
S'IM X'
p51343
sS'PMID'
p51344
S'23111575'
p51345
sS'PST'
p51346
S'ppublish'
p51347
stRp51348
ag2
(g3
g4
(dp51349
S'LID'
p51350
S'10.1093/infdis/jis635 [doi]'
p51351
sS'STAT'
p51352
S'MEDLINE'
p51353
sS'DEP'
p51354
S'20121024'
p51355
sS'CIN'
p51356
(lp51357
S'J Infect Dis. 2013 Jan 1;207(1):4-5. PMID: 23100565'
p51358
asS'DA'
p51359
S'20121220'
p51360
sS'AID'
p51361
(lp51362
S'jis635 [pii]'
p51363
aS'10.1093/infdis/jis635 [doi]'
p51364
asS'CRDT'
p51365
(lp51366
S'2012/10/27 06:00'
p51367
asS'DP'
p51368
S'2013 Jan 1'
p51369
sS'OWN'
p51370
S'NLM'
p51371
sS'PT'
p51372
(lp51373
S'Journal Article'
p51374
aS"Research Support, Non-U.S. Gov't"
p51375
asS'LA'
p51376
(lp51377
S'eng'
p51378
asS'FAU'
p51379
(lp51380
S'Verguet, Stephane'
p51381
aS'Lim, Stephen S'
p51382
aS'Murray, Christopher J L'
p51383
aS'Gakidou, Emmanuela'
p51384
aS'Salomon, Joshua A'
p51385
asS'JT'
p51386
S'The Journal of infectious diseases'
p51387
sS'PG'
p51388
S'72-9'
p51389
sS'TI'
p51390
S'Incorporating loss to follow-up in estimates of survival among HIV-infected individuals in sub-Saharan Africa enrolled in antiretroviral therapy programs.'
p51391
sS'RN'
p51392
(lp51393
S'0 (Anti-HIV Agents)'
p51394
asS'PL'
p51395
S'United States'
p51396
sS'TA'
p51397
S'J Infect Dis'
p51398
sS'JID'
p51399
S'0413675'
p51400
sS'AB'
p51401
S'BACKGROUND: Measuring the survival of human immunodeficiency virus-infected adult patients enrolled in antiretroviral therapy (ART) programs is complicated by short observation periods and loss to follow-up. We synthesized data from treatment cohorts in sub-Saharan Africa to estimate survival over 5 years after initiation of ART. METHODS: We used data on retention, mortality, and loss to follow-up from 34 cohorts, including a total of 102,306 adult patients from 18 sub-Saharan African countries. These data were augmented by data from 13 sub-Saharan African studies tracking death rates among adult patients who were lost to follow-up (LTFU). We used a Poisson regression model to estimate survival over time, incorporating predicted mortality among LTFU patients. RESULTS: Across studies, the median CD4(+) cell count at ART initiation was 104 cells/mm(3), 65% of patients were female, and the median age was 37 years. Survival at 1 year and 5 years were estimated to be 0.87 (95% confidence interval [CI], 0.72-0.94) and 0.70 (95% CI, 0.36-0.86), respectively, after adjustment for loss to follow-up. The life-years gained by a patient during the 5-year period after starting ART were estimated at 2.1 (95% CI, 1.6-2.3) in the adjusted model, compared with 1.7 (95% CI, 1.1-2.0) if there was 100% mortality among LTFU patients and with 2.4 (1.7-2.7) if there was 0% mortality among LTFU patients. CONCLUSIONS: Accounting for loss to follow-up produces substantial changes in the estimated life-years gained during the first 5 years of ART receipt.'
p51402
sS'AD'
p51403
S'Department of Global Health, Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA 98104, USA. verguet@uw.edu'
p51404
sS'IP'
p51405
S'1'
sS'IS'
p51406
S'1537-6613 (Electronic) 0022-1899 (Linking)'
p51407
sS'DCOM'
p51408
S'20130228'
p51409
sS'AU'
p51410
(lp51411
S'Verguet S'
p51412
aS'Lim SS'
p51413
aS'Murray CJ'
p51414
aS'Gakidou E'
p51415
aS'Salomon JA'
p51416
asS'VI'
p51417
S'207'
p51418
sS'MHDA'
p51419
S'2013/03/01 06:00'
p51420
sS'PHST'
p51421
(lp51422
S'2012/10/24 [aheadofprint]'
p51423
aS'2012/12/04 [aheadofprint]'
p51424
asS'MH'
p51425
(lp51426
S'Adult'
p51427
aS'Africa South of the Sahara/epidemiology'
p51428
aS'Anti-HIV Agents/*therapeutic use'
p51429
aS'CD4 Lymphocyte Count'
p51430
aS'Cohort Studies'
p51431
aS'Cost-Benefit Analysis'
p51432
aS'Delivery of Health Care'
p51433
aS'Female'
p51434
aS'HIV/*drug effects'
p51435
aS'HIV Infections/*drug therapy/*mortality/virology'
p51436
aS'Humans'
p51437
aS'Lost to Follow-Up'
p51438
aS'Male'
p51439
aS'Patient Compliance'
p51440
aS'Regression Analysis'
p51441
aS'Survival Analysis'
p51442
asS'EDAT'
p51443
S'2012/10/27 06:00'
p51444
sS'SO'
p51445
S'J Infect Dis. 2013 Jan 1;207(1):72-9. doi: 10.1093/infdis/jis635. Epub 2012 Oct 24.'
p51446
sS'SB'
p51447
S'AIM IM'
p51448
sS'PMID'
p51449
S'23100567'
p51450
sS'PST'
p51451
S'ppublish'
p51452
stRp51453
ag2
(g3
g4
(dp51454
S'LID'
p51455
S'10.1093/cid/cis887 [doi]'
p51456
sS'STAT'
p51457
S'MEDLINE'
p51458
sS'DEP'
p51459
S'20121019'
p51460
sS'DA'
p51461
S'20130124'
p51462
sS'AID'
p51463
(lp51464
S'cis887 [pii]'
p51465
aS'10.1093/cid/cis887 [doi]'
p51466
asS'CRDT'
p51467
(lp51468
S'2012/10/23 06:00'
p51469
asS'DP'
p51470
S'2013 Feb'
p51471
sS'AD'
p51472
S'Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA 02114, USA. jlevison@partners.org'
p51473
sS'OWN'
p51474
S'NLM'
p51475
sS'PT'
p51476
(lp51477
S'Journal Article'
p51478
aS'Research Support, N.I.H., Extramural'
p51479
asS'LA'
p51480
(lp51481
S'eng'
p51482
asS'FAU'
p51483
(lp51484
S'Levison, Julie H'
p51485
aS'Wood, Robin'
p51486
aS'Scott, Callie A'
p51487
aS'Ciaranello, Andrea L'
p51488
aS'Martinson, Neil A'
p51489
aS'Rusu, Corina'
p51490
aS'Losina, Elena'
p51491
aS'Freedberg, Kenneth A'
p51492
aS'Walensky, Rochelle P'
p51493
asS'JT'
p51494
S'Clinical infectious diseases : an official publication of the Infectious Diseases Society of America'
p51495
sS'LR'
p51496
S'20160610'
p51497
sS'PG'
p51498
S'587-97'
p51499
sS'TI'
p51500
S'The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa.'
p51501
sS'RN'
p51502
(lp51503
S'0 (Anti-HIV Agents)'
p51504
asS'PL'
p51505
S'United States'
p51506
sS'TA'
p51507
S'Clin Infect Dis'
p51508
sS'JID'
p51509
S'9203213'
p51510
sS'AB'
p51511
S'BACKGROUND: In resource-limited settings, genotype testing at virologic failure on first-line antiretroviral therapy (ART) may identify patients with wild-type (WT) virus. After adherence counseling, these patients may safely and effectively continue first-line ART, thereby delaying more expensive second-line ART. METHODS: We used the Cost-Effectiveness of Preventing AIDS Complications International model of human immunodeficiency virus (HIV) disease to simulate a South African cohort of HIV-infected adults at first-line ART failure. Two strategies were examined: no genotype vs genotype, assuming availability of protease inhibitor-based second-line ART. Model inputs at first-line ART failure were mean age 38 years, mean CD4 173/microL, and WT virus prevalence 20%; genotype cost was $300 per test and delay to results, 3 months. Outcomes included life expectancy, per-person costs (2010 US dollars), and incremental cost-effectiveness ratios (dollars per years of life saved [YLS]). RESULTS: No genotype had a projected life expectancy of 106.1 months, which with genotype increased to 108.3 months. Per-person discounted lifetime costs were $16 360 and $16 540, respectively. Compared to no genotype, genotype was very cost-effective, by international guidance, at $900/YLS. The cost-effectiveness of genotype was sensitive to prevalence of WT virus (very cost-effective when prevalence >/= 12%), CD4 at first-line ART failure, and ART efficacy. Genotype-associated delays in care >/= 5 months decreased survival and made no genotype the preferred strategy. When the test cost was <$100, genotype became cost-saving. CONCLUSIONS: Genotype resistance testing at first-line ART failure is very cost-effective in South Africa. The cost-effectiveness of this strategy will depend on prevalence of WT virus and timely response to genotype results.'
p51512
sS'GR'
p51513
(lp51514
S'AI48526/AI/NIAID NIH HHS/United States'
p51515
aS'HL090312/HL/NHLBI NIH HHS/United States'
p51516
aS'K01 AI078754/AI/NIAID NIH HHS/United States'
p51517
aS'K01AI078754/AI/NIAID NIH HHS/United States'
p51518
aS'K24 AI062476/AI/NIAID NIH HHS/United States'
p51519
aS'K24 AI062476/AI/NIAID NIH HHS/United States'
p51520
aS'P30 AI060354/AI/NIAID NIH HHS/United States'
p51521
aS'P30 AI060354/AI/NIAID NIH HHS/United States'
p51522
aS'P30 AI094189/AI/NIAID NIH HHS/United States'
p51523
aS'R01 AI048526/AI/NIAID NIH HHS/United States'
p51524
aS'R01 AI058736/AI/NIAID NIH HHS/United States'
p51525
aS'R01 HL090312/HL/NHLBI NIH HHS/United States'
p51526
aS'RTW007370/PHS HHS/United States'
p51527
aS'T32 AI007433/AI/NIAID NIH HHS/United States'
p51528
aS'U2R TW007370/TW/FIC NIH HHS/United States'
p51529
asS'IP'
p51530
S'4'
sS'IS'
p51531
S'1537-6591 (Electronic) 1058-4838 (Linking)'
p51532
sS'PMC'
p51533
S'PMC3552524'
p51534
sS'DCOM'
p51535
S'20130730'
p51536
sS'AU'
p51537
(lp51538
S'Levison JH'
p51539
aS'Wood R'
p51540
aS'Scott CA'
p51541
aS'Ciaranello AL'
p51542
aS'Martinson NA'
p51543
aS'Rusu C'
p51544
aS'Losina E'
p51545
aS'Freedberg KA'
p51546
aS'Walensky RP'
p51547
asS'VI'
p51548
S'56'
p51549
sS'MHDA'
p51550
S'2013/07/31 06:00'
p51551
sS'PHST'
p51552
(lp51553
S'2012/10/19 [aheadofprint]'
p51554
aS'2012/12/12 [aheadofprint]'
p51555
asS'OID'
p51556
(lp51557
S'NLM: PMC3552524'
p51558
asS'MH'
p51559
(lp51560
S'Acquired Immunodeficiency Syndrome/genetics/*prevention & control'
p51561
aS'Adult'
p51562
aS'Anti-HIV Agents/economics/*therapeutic use'
p51563
aS'Clinical Laboratory Techniques/economics'
p51564
aS'Cost-Benefit Analysis'
p51565
aS'Genotype'
p51566
aS'HIV/genetics'
p51567
aS'HIV Infections/*drug therapy/economics/genetics'
p51568
aS'Health Resources/economics'
p51569
aS'Humans'
p51570
aS'Models, Theoretical'
p51571
aS'South Africa'
p51572
aS'Treatment Failure'
p51573
asS'EDAT'
p51574
S'2012/10/23 06:00'
p51575
sS'SO'
p51576
S'Clin Infect Dis. 2013 Feb;56(4):587-97. doi: 10.1093/cid/cis887. Epub 2012 Oct 19.'
p51577
sS'SB'
p51578
S'IM'
p51579
sS'PMID'
p51580
S'23087386'
p51581
sS'PST'
p51582
S'ppublish'
p51583
stRp51584
ag2
(g3
g4
(dp51585
S'STAT'
p51586
S'MEDLINE'
p51587
sS'DEP'
p51588
S'20120723'
p51589
sS'DA'
p51590
S'20121018'
p51591
sS'CRDT'
p51592
(lp51593
S'2012/10/19 06:00'
p51594
asS'DP'
p51595
S'2012'
p51596
sS'OWN'
p51597
S'NLM'
p51598
sS'PT'
p51599
(lp51600
S'Journal Article'
p51601
aS'Multicenter Study'
p51602
aS"Research Support, Non-U.S. Gov't"
p51603
asS'LA'
p51604
(lp51605
S'eng'
p51606
asS'DCOM'
p51607
S'20130308'
p51608
sS'JT'
p51609
S'The Pan African medical journal'
p51610
sS'LR'
p51611
S'20150222'
p51612
sS'FAU'
p51613
(lp51614
S'Mwangi, Joseph'
p51615
aS'Nganga, Zipporah'
p51616
aS'Lihana, Raphael'
p51617
aS'Lagat, Nancy'
p51618
aS'Kinyua, Joyceline'
p51619
aS'Muriuki, Joseph'
p51620
aS'Maiyo, Alex'
p51621
aS'Kinyua, Florence'
p51622
aS'Okoth, Fredrick'
p51623
aS'Mpoke, Solomon'
p51624
asS'TI'
p51625
S'Switch from 200 to 350 CD4 baseline count: what it means to HIV care and treatment programs in Kenya.'
p51626
sS'RN'
p51627
(lp51628
S'0 (Anti-HIV Agents)'
p51629
asS'PL'
p51630
S'Uganda'
p51631
sS'PG'
p51632
S'80'
p51633
sS'JID'
p51634
S'101517926'
p51635
sS'AB'
p51636
S'INTRODUCTION: With the increasing population of infected individuals in Africa and constrained resources for care and treatment, antiretroviral management continues to be an important public health challenge. Since the announcement of World Health Organization recommendation and guidelines for initiation of antiretroviral Treatment at CD4 count below 350, many developing countries are adopting this strategy in their country specific guidelines to care and treatment of HIV and AIDS. Despite the benefits to these recommendations, what does this switch from 200 to 350 CD4 count mean in antiretroviral treatment demand? METHODS: A Multi-centre study involving 1376 patients in health care settings in Kenya. CD4 count was carried out by flow cytometry among the HIV infected individuals in Kenya and results analyzed in view of the In-country and the new CD4 recommendation for initiation of antiretroviral treatment. RESULTS: Across sites, 32% of the individual required antiretroviral at <200 CD4 Baseline, 40% at <250 baseline count and 58% based on the new criteria of <350 CD4 Count. There were more female (68%) than Male (32%).Different from <200 and <250 CD4 baseline criteria, over 50% of all age groups required antiretroviral at 350 CD4 baseline. Age groups between 41-62 led in demand for ART. CONCLUSION: With the new guidelines, demand for ARVs has more than doubled with variations noted within regions and age groups. As A result, HIV Care and Treatment Programs should prepare for this expansion for the benefits to be realized.'
p51637
sS'AD'
p51638
S'Centre for Virus Research, Kenya Medical research Institute, Nairobi, Kenya.'
p51639
sS'VI'
p51640
S'12'
p51641
sS'IS'
p51642
S'1937-8688 (Electronic)'
p51643
sS'PMC'
p51644
S'PMC3473966'
p51645
sS'AU'
p51646
(lp51647
S'Mwangi J'
p51648
aS'Nganga Z'
p51649
aS'Lihana R'
p51650
aS'Lagat N'
p51651
aS'Kinyua J'
p51652
aS'Muriuki J'
p51653
aS'Maiyo A'
p51654
aS'Kinyua F'
p51655
aS'Okoth F'
p51656
aS'Mpoke S'
p51657
asS'MHDA'
p51658
S'2013/03/09 06:00'
p51659
sS'PHST'
p51660
(lp51661
S'2012/01/05 [received]'
p51662
aS'2012/06/06 [accepted]'
p51663
aS'2012/07/23 [epublish]'
p51664
asS'OT'
p51665
(lp51666
S'AIDS'
p51667
aS'ARV initiation'
p51668
aS'CD4'
p51669
aS'HIV'
p51670
aS'New criteria'
p51671
aS'care and treatment'
p51672
asS'OTO'
p51673
(lp51674
S'NOTNLM'
p51675
asS'OID'
p51676
(lp51677
S'NLM: PMC3473966'
p51678
asS'MH'
p51679
(lp51680
S'Adult'
p51681
aS'Age Distribution'
p51682
aS'Aged'
p51683
aS'Anti-HIV Agents/*therapeutic use'
p51684
aS'CD4 Lymphocyte Count/*methods'
p51685
aS'Female'
p51686
aS'Flow Cytometry'
p51687
aS'HIV Infections/*drug therapy'
p51688
aS'Humans'
p51689
aS'Kenya'
p51690
aS'Male'
p51691
aS'Middle Aged'
p51692
aS'*Practice Guidelines as Topic'
p51693
aS'Sex Distribution'
p51694
aS'World Health Organization'
p51695
aS'Young Adult'
p51696
asS'EDAT'
p51697
S'2012/10/19 06:00'
p51698
sS'SO'
p51699
S'Pan Afr Med J. 2012;12:80. Epub 2012 Jul 23.'
p51700
sS'SB'
p51701
S'IM'
p51702
sS'PMID'
p51703
S'23077701'
p51704
sS'TA'
p51705
S'Pan Afr Med J'
p51706
sS'PST'
p51707
S'ppublish'
p51708
stRp51709
ag2
(g3
g4
(dp51710
S'LID'
p51711
S'10.1371/journal.pone.0038044 [doi]'
p51712
sS'STAT'
p51713
S'MEDLINE'
p51714
sS'DEP'
p51715
S'20121015'
p51716
sS'DA'
p51717
S'20121018'
p51718
sS'AID'
p51719
(lp51720
S'10.1371/journal.pone.0038044 [doi]'
p51721
aS'PONE-D-11-21828 [pii]'
p51722
asS'CRDT'
p51723
(lp51724
S'2012/10/19 06:00'
p51725
asS'DP'
p51726
S'2012'
p51727
sS'OWN'
p51728
S'NLM'
p51729
sS'PT'
p51730
(lp51731
S'Journal Article'
p51732
asS'LA'
p51733
(lp51734
S'eng'
p51735
asS'FAU'
p51736
(lp51737
S'McGuire, Megan'
p51738
aS'Pinoges, Loretxu'
p51739
aS'Kanapathipillai, Rupa'
p51740
aS'Munyenyembe, Tamika'
p51741
aS'Huckabee, Martha'
p51742
aS'Makombe, Simon'
p51743
aS'Szumilin, Elisabeth'
p51744
aS'Heinzelmann, Annette'
p51745
aS'Pujades-Rodriguez, Mar'
p51746
asS'JT'
p51747
S'PloS one'
p51748
sS'LR'
p51749
S'20150222'
p51750
sS'PG'
p51751
S'e38044'
p51752
sS'TI'
p51753
S'Treatment initiation, program attrition and patient treatment outcomes associated with scale-up and decentralization of HIV care in rural Malawi.'
p51754
sS'RN'
p51755
(lp51756
S'0 (Anti-HIV Agents)'
p51757
asS'PL'
p51758
S'United States'
p51759
sS'TA'
p51760
S'PLoS One'
p51761
sS'JID'
p51762
S'101285081'
p51763
sS'AB'
p51764
S'OBJECTIVE: To describe patient antiretroviral therapy (cART) outcomes associated with intensive decentralization of services in a rural HIV program in Malawi. METHODS: Longitudinal analysis of data from HIV-infected patients starting cART between August 2001 and December 2008 and of a cross-sectional immunovirological assessment conducted 12 (+/-2) months after therapy start. One-year mortality, lost to follow-up, and attrition (deaths and lost to follow-up) rates were estimated with exact Poisson 95% confidence intervals (CI) by type of care delivery and year of initiation. Association of virological suppression (<50 copies/mL) and immunological success (CD4 gain >/=100 cells/microL), with type of care was investigated using multiple logistic regression. RESULTS: During the study period, 4322 cART patients received centralized care and 11,090 decentralized care. At therapy start, patients treated in decentralized health facilities had higher median CD4 count levels (167 vs. 130 cell/microL, P<0.0001) than other patients. Two years after cART start, program attrition was lower in decentralized than centralized facilities (9.9 per 100 person-years, 95% CI: 9.5-10.4 vs. 20.8 per 100 person-years, 95% CI: 19.7-22.0). One year after treatment start, differences in immunological success (adjusted OR=1.23, 95% CI: 0.83-1.83), and viral suppression (adjusted OR=0.80, 95% CI: 0.56-1.14) between patients followed at centralized and decentralized facilities were not statistically significant. CONCLUSIONS: In rural Malawi, 1- and 2-year program attrition was lower in decentralized than in centralized health facilities and no statistically significant differences in one-year immunovirological outcomes were observed between the two health care levels. Longer follow-up is needed to confirm these results.'
p51765
sS'AD'
p51766
S'Epicentre, Clinical Research Department, Nairobi, Kenya.'
p51767
sS'IP'
p51768
S'10'
p51769
sS'IS'
p51770
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p51771
sS'PMC'
p51772
S'PMC3471893'
p51773
sS'DCOM'
p51774
S'20130320'
p51775
sS'AU'
p51776
(lp51777
S'McGuire M'
p51778
aS'Pinoges L'
p51779
aS'Kanapathipillai R'
p51780
aS'Munyenyembe T'
p51781
aS'Huckabee M'
p51782
aS'Makombe S'
p51783
aS'Szumilin E'
p51784
aS'Heinzelmann A'
p51785
aS'Pujades-Rodriguez M'
p51786
asS'VI'
p51787
S'7'
sS'MHDA'
p51788
S'2013/03/21 06:00'
p51789
sS'PHST'
p51790
(lp51791
S'2011/11/03 [received]'
p51792
aS'2012/05/02 [accepted]'
p51793
aS'2012/10/15 [epublish]'
p51794
asS'OID'
p51795
(lp51796
S'NLM: PMC3471893'
p51797
asS'MH'
p51798
(lp51799
S'Adult'
p51800
aS'Anti-HIV Agents/*therapeutic use'
p51801
aS'CD4 Lymphocyte Count'
p51802
aS'Female'
p51803
aS'HIV Infections/*drug therapy/mortality'
p51804
aS'Humans'
p51805
aS'Longitudinal Studies'
p51806
aS'Malawi/epidemiology'
p51807
aS'Male'
p51808
aS'Middle Aged'
p51809
aS'Patient Dropouts'
p51810
aS'Retrospective Studies'
p51811
aS'Risk Factors'
p51812
aS'Rural Health Services/*organization & administration'
p51813
aS'*Rural Population'
p51814
aS'Treatment Outcome'
p51815
asS'EDAT'
p51816
S'2012/10/19 06:00'
p51817
sS'SO'
p51818
S'PLoS One. 2012;7(10):e38044. doi: 10.1371/journal.pone.0038044. Epub 2012 Oct 15.'
p51819
sS'SB'
p51820
S'IM'
p51821
sS'PMID'
p51822
S'23077473'
p51823
sS'PST'
p51824
S'ppublish'
p51825
stRp51826
ag2
(g3
g4
(dp51827
S'LID'
p51828
S'10.1111/j.1468-1293.2012.01054.x [doi]'
p51829
sS'STAT'
p51830
S'MEDLINE'
p51831
sS'DEP'
p51832
S'20121004'
p51833
sS'CI'
p51834
(lp51835
S'(c) 2012 British HIV Association.'
p51836
asS'DA'
p51837
S'20130301'
p51838
sS'AID'
p51839
(lp51840
S'10.1111/j.1468-1293.2012.01054.x [doi]'
p51841
asS'CRDT'
p51842
(lp51843
S'2012/10/06 06:00'
p51844
asS'DP'
p51845
S'2013 Apr'
p51846
sS'AD'
p51847
S'Division of Infectious Diseases, Department of Internal Medicine, Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa. colin.menezes@wits.ac.za'
p51848
sS'OWN'
p51849
S'NLM'
p51850
sS'PT'
p51851
(lp51852
S'Journal Article'
p51853
aS'Randomized Controlled Trial'
p51854
aS"Research Support, Non-U.S. Gov't"
p51855
asS'LA'
p51856
(lp51857
S'eng'
p51858
asS'FAU'
p51859
(lp51860
S'Menezes, C N'
p51861
aS'Duarte, R'
p51862
aS'Dickens, C'
p51863
aS'Dix-Peek, T'
p51864
aS'Van Amsterdam, D'
p51865
aS'John, M-A'
p51866
aS'Ive, P'
p51867
aS'Maskew, M'
p51868
aS'Macphail, P'
p51869
aS'Fox, M P'
p51870
aS'Raal, F'
p51871
aS'Sanne, I'
p51872
aS'Crowther, N J'
p51873
asS'JT'
p51874
S'HIV medicine'
p51875
sS'LR'
p51876
S'20151119'
p51877
sS'PG'
p51878
S'217-25'
p51879
sS'TI'
p51880
S'The early effects of stavudine compared with tenofovir on adipocyte gene expression, mitochondrial DNA copy number and metabolic parameters in South African HIV-infected patients: a randomized trial.'
p51881
sS'RN'
p51882
(lp51883
S'0 (Anti-HIV Agents)'
p51884
aS'0 (Biomarkers)'
p51885
aS'0 (DNA, Mitochondrial)'
p51886
aS'0 (Organophosphonates)'
p51887
aS'0 (Reverse Transcriptase Inhibitors)'
p51888
aS'99YXE507IL (Tenofovir)'
p51889
aS'BO9LE4QFZF (Stavudine)'
p51890
aS'IY9XDZ35W2 (Glucose)'
p51891
aS'JAC85A2161 (Adenine)'
p51892
asS'PL'
p51893
S'England'
p51894
sS'TA'
p51895
S'HIV Med'
p51896
sS'JID'
p51897
S'100897392'
p51898
sS'AB'
p51899
S'OBJECTIVES: Stavudine is being phased out because of its mitochondrial toxicity and tenofovir (TDF) is recommended as part of first-line highly active antiretroviral therapy (HAART) in South Africa. A prospective, open-label, randomized controlled trial comparing standard- and low-dose stavudine with TDF was performed to assess early differences in adipocyte mtDNA copy number, gene expression and metabolic parameters in Black South African HIV-infected patients. METHODS: Sixty patients were randomized 1:1:1 to either standard-dose (30-40 mg) or low-dose (20-30 mg) stavudine or TDF (300 mg) each combined with lamivudine and efavirenz. Subcutaneous fat biopsies were obtained at weeks 0 and 4. Adipocyte mtDNA copies/cell and gene expression were measured using quantitative polymerase chain reaction (qPCR). Markers of inflammation and lipid and glucose metabolism were also assessed. RESULTS: A 29% and 32% decrease in the mean mtDNA copies/cell was noted in the standard-dose (P < 0.05) and low-dose stavudine (P < 0.005) arms, respectively, when compared with TDF at 4 weeks. Nuclear respiratory factor-1 (NRF1) and mitochondrial cytochrome B (MTCYB) gene expression levels were affected by stavudine, with a significantly (P < 0.05) greater fall in expression observed with the standard, but not the low dose compared with TDF. No significant differences were observed in markers of inflammation and lipid and glucose metabolism. CONCLUSIONS: These results demonstrate early mitochondrial depletion among Black South African patients receiving low and standard doses of stavudine, with preservation of gene expression levels, except for NRF1 and MTCYB, when compared with patients on TDF.'
p51900
sS'GR'
p51901
(lp51902
S'K01 AI083097/AI/NIAID NIH HHS/United States'
p51903
asS'IP'
p51904
S'4'
sS'IS'
p51905
S'1468-1293 (Electronic) 1464-2662 (Linking)'
p51906
sS'DCOM'
p51907
S'20130910'
p51908
sS'AU'
p51909
(lp51910
S'Menezes CN'
p51911
aS'Duarte R'
p51912
aS'Dickens C'
p51913
aS'Dix-Peek T'
p51914
aS'Van Amsterdam D'
p51915
aS'John MA'
p51916
aS'Ive P'
p51917
aS'Maskew M'
p51918
aS'Macphail P'
p51919
aS'Fox MP'
p51920
aS'Raal F'
p51921
aS'Sanne I'
p51922
aS'Crowther NJ'
p51923
asS'VI'
p51924
S'14'
p51925
sS'MHDA'
p51926
S'2013/09/11 06:00'
p51927
sS'PHST'
p51928
(lp51929
S'2012/08/30 [accepted]'
p51930
aS'2012/10/04 [aheadofprint]'
p51931
asS'MH'
p51932
(lp51933
S'Adenine/*analogs & derivatives/therapeutic use'
p51934
aS'Adipocytes/*drug effects/metabolism'
p51935
aS'Adult'
p51936
aS'Anti-HIV Agents/*therapeutic use'
p51937
aS'Antiretroviral Therapy, Highly Active'
p51938
aS'Biomarkers/metabolism'
p51939
aS'DNA Copy Number Variations/drug effects'
p51940
aS'DNA, Mitochondrial/drug effects/genetics'
p51941
aS'Dose-Response Relationship, Drug'
p51942
aS'Female'
p51943
aS'Gene Expression Profiling'
p51944
aS'Glucose/metabolism'
p51945
aS'HIV Infections/*drug therapy/genetics/metabolism'
p51946
aS'Humans'
p51947
aS'Inflammation/metabolism'
p51948
aS'Lipid Metabolism/drug effects'
p51949
aS'Male'
p51950
aS'Middle Aged'
p51951
aS'Organophosphonates/*therapeutic use'
p51952
aS'Prospective Studies'
p51953
aS'Reverse Transcriptase Inhibitors/*therapeutic use'
p51954
aS'South Africa'
p51955
aS'Stavudine/*therapeutic use'
p51956
aS'Tenofovir'
p51957
asS'EDAT'
p51958
S'2012/10/06 06:00'
p51959
sS'SO'
p51960
S'HIV Med. 2013 Apr;14(4):217-25. doi: 10.1111/j.1468-1293.2012.01054.x. Epub 2012 Oct 4.'
p51961
sS'SB'
p51962
S'IM'
p51963
sS'PMID'
p51964
S'23036096'
p51965
sS'PST'
p51966
S'ppublish'
p51967
stRp51968
ag2
(g3
g4
(dp51969
S'LID'
p51970
S'10.7196/samj.5851 [doi]'
p51971
sS'STAT'
p51972
S'MEDLINE'
p51973
sS'DEP'
p51974
S'20120907'
p51975
sS'DA'
p51976
S'20121004'
p51977
sS'CRDT'
p51978
(lp51979
S'2012/10/05 06:00'
p51980
asS'DP'
p51981
S'2012 Oct'
p51982
sS'OWN'
p51983
S'NLM'
p51984
sS'PT'
p51985
(lp51986
S'Journal Article'
p51987
asS'LA'
p51988
(lp51989
S'eng'
p51990
asS'FAU'
p51991
(lp51992
S'Clouse, Kate'
p51993
aS'Page-Shipp, Liesl'
p51994
aS'Dansey, Heather'
p51995
aS'Moatlhodi, Bridgette'
p51996
aS'Scott, Lesley'
p51997
aS'Bassett, Jean'
p51998
aS'Stevens, Wendy'
p51999
aS'Sanne, Ian'
p52000
aS'Van Rie, Annelies'
p52001
asS'JT'
p52002
S'South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde'
p52003
sS'LR'
p52004
S'20140912'
p52005
sS'PG'
p52006
S'805-7'
p52007
sS'TI'
p52008
S'Implementation of Xpert MTB/RIF for routine point-of-care diagnosis of tuberculosis at the primary care level.'
p52009
sS'PL'
p52010
S'South Africa'
p52011
sS'TA'
p52012
S'S Afr Med J'
p52013
sS'JID'
p52014
S'0404520'
p52015
sS'AB'
p52016
S"Xpert MTB/RIF (Xpert) offers rapid detection of Mycobacterium tuberculosis and rifampicin resistance. However, little is known about routine point-of-care (POC) use in high TB/HIV burden settings. We describe our experiences of launching Xpert as the POC, initial diagnostic for all TB suspects at a primary healthcare clinic in Johannesburg, South Africa. Noted important benefits of POC Xpert were fewer clinic visits, rapid detection of TB and rifampicin resistance, real-time assessment of accompanying household members of new TB cases, and increased staff motivation for TB screening. While Xpert results are available within 2 hours, actual turn-around time was longer for most patients because of sample preparation time and clinic congestion. Consequently, a GX4 instrument did not result in a 16-test capacity during an 8-hour working day, and some patients did not receive same-day results. Loss to follow-up was an unforeseen challenge, overcome by clinic flow changes, marking of clinic files, documenting patients' physical description and locating patients in the clinic by cell phone. Staff with high school education successfully performed the assay after minimal training. Human resource requirements were considerable, with a minimum of 2 staff needed to supervise sputum collection, process sputum, perform assays, and document results for an average of 15 TB suspects daily. POC placement of the instrument transferred logistical responsibilities to the clinic, including quality assurance, maintenance, stock control and cartridge disposal. POC use of Xpert is feasible at the primary healthcare level but must be accompanied by financial, operational and logistical support."
p52017
sS'AD'
p52018
S'Clinical HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa. kclouse@unc.edu'
p52019
sS'IP'
p52020
S'10'
p52021
sS'IS'
p52022
S'0256-9574 (Print)'
p52023
sS'DCOM'
p52024
S'20121204'
p52025
sS'AU'
p52026
(lp52027
S'Clouse K'
p52028
aS'Page-Shipp L'
p52029
aS'Dansey H'
p52030
aS'Moatlhodi B'
p52031
aS'Scott L'
p52032
aS'Bassett J'
p52033
aS'Stevens W'
p52034
aS'Sanne I'
p52035
aS'Van Rie A'
p52036
asS'VI'
p52037
S'102'
p52038
sS'MHDA'
p52039
S'2012/12/10 06:00'
p52040
sS'PHST'
p52041
(lp52042
S'2012/04/10 [received]'
p52043
aS'2012/08/16 [accepted]'
p52044
asS'MH'
p52045
(lp52046
S'HIV Infections/*complications'
p52047
aS'Humans'
p52048
aS'Mycobacterium tuberculosis/*isolation & purification'
p52049
aS'Nucleic Acid Amplification Techniques/*methods'
p52050
aS'Outpatient Clinics, Hospital'
p52051
aS'Point-of-Care Systems'
p52052
aS'*Primary Health Care'
p52053
aS'South Africa'
p52054
aS'Tuberculosis, Multidrug-Resistant/diagnosis'
p52055
aS'Tuberculosis, Pulmonary/*complications/diagnosis'
p52056
asS'EDAT'
p52057
S'2012/10/05 06:00'
p52058
sS'SO'
p52059
S'S Afr Med J. 2012 Sep 7;102(10):805-7. doi: 10.7196/samj.5851.'
p52060
sS'SB'
p52061
S'IM'
p52062
sS'PMID'
p52063
S'23034211'
p52064
sS'PST'
p52065
S'epublish'
p52066
stRp52067
ag2
(g3
g4
(dp52068
S'LID'
p52069
S'10.1371/journal.pone.0044793 [doi]'
p52070
sS'STAT'
p52071
S'MEDLINE'
p52072
sS'DEP'
p52073
S'20120928'
p52074
sS'DA'
p52075
S'20121002'
p52076
sS'AID'
p52077
(lp52078
S'10.1371/journal.pone.0044793 [doi]'
p52079
aS'PONE-D-12-09610 [pii]'
p52080
asS'CRDT'
p52081
(lp52082
S'2012/10/03 06:00'
p52083
asS'DP'
p52084
S'2012'
p52085
sS'AD'
p52086
S'Medical Unit, Medecins Sans Frontieres/Doctors Without Borders, New York, New York, United States of America. ramurphy@gmail.com'
p52087
sS'OWN'
p52088
S'NLM'
p52089
sS'PT'
p52090
(lp52091
S'Journal Article'
p52092
aS'Research Support, N.I.H., Extramural'
p52093
aS"Research Support, Non-U.S. Gov't"
p52094
asS'LA'
p52095
(lp52096
S'eng'
p52097
asS'FAU'
p52098
(lp52099
S'Murphy, Richard A'
p52100
aS'Marconi, Vincent C'
p52101
aS'Gandhi, Rajesh T'
p52102
aS'Kuritzkes, Daniel R'
p52103
aS'Sunpath, Henry'
p52104
asS'JT'
p52105
S'PloS one'
p52106
sS'LR'
p52107
S'20150222'
p52108
sS'PG'
p52109
S'e44793'
p52110
sS'TI'
p52111
S'Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa.'
p52112
sS'RN'
p52113
(lp52114
S'0 (Anti-HIV Agents)'
p52115
aS'0 (Antibiotics, Antitubercular)'
p52116
aS'2494G1JF75 (Lopinavir)'
p52117
aS'O3J8G9O825 (Ritonavir)'
p52118
aS'VJT6J7R4TR (Rifampin)'
p52119
asS'PL'
p52120
S'United States'
p52121
sS'TA'
p52122
S'PLoS One'
p52123
sS'JID'
p52124
S'101285081'
p52125
sS'AB'
p52126
S'BACKGROUND: In HIV-infected patients receiving rifampicin-based treatment for tuberculosis (TB), the dosage of lopinavir/ritonavir (LPV/r) is adjusted to prevent sub-therapeutic lopinavir concentrations. In this setting, South African clinicians were advised to administer super-boosted LPV/r (400 mg/400 mg) twice daily, instead of standard dosed LPV/r (400 mg/100 mg) twice daily. We sought to determine--in routine practice--the tolerability and HIV treatment outcomes associated with super-boosted LPV/r compared to unadjusted LPV/r in combination with rifampicin-based TB treatment. METHODOLOGY/PRINCIPLE FINDINGS: We conducted a retrospective review of HIV-infected patients who receiving second-line ART with a LPV/r-containing regimen who required concomitant TB treatment. We identified 29 patients; the median age was 36 years (IQR 29-40), 22 (76%) were female, the median CD4 cell count and viral load at first-line ART failure was 86 cells/mm(3) (IQR 21-159) and 39,457 copies/mL (IQR 6,025-157,500), respectively. According to physician preference, 15 (52%) of 29 patients received super-boosted LPV/r (400 mg/400 mg) every 12 hours during TB treatment and 14 (48%) of 29 patients received standard dose LPV/r (400 mg/100 mg) twice daily during TB treatment. Among patients who received super-boosted LPV/r there was a trend towards a higher rate of symptomatic transaminitis (27% vs. 7%; p = 0.3), gastrointestinal toxicity (20% vs. 0%; p = 0.2) and a significantly increased need for treatment discontinuation (47% vs. 7%; p = 0.035. The durability of coadministered treatment was significantly shorter in patients who received super-boosted lopinavir/ritonavir with TB treatment compared to patients who received standard lopinavir/ritonavir dosing (log rank, P = 0.036). The rate of virologic failure was not higher in patients with unadjusted LPV/r dosing. CONCLUSIONS/SIGNIFICANCE: We observed a high rate of toxicity and need for treatment discontinuation among patients on standard rifampicin-based TB treatment who received super-boosted LPV/r.'
p52127
sS'GR'
p52128
(lp52129
S'K24-RR016482/RR/NCRR NIH HHS/United States'
p52130
aS'P30 AI060354/AI/NIAID NIH HHS/United States'
p52131
aS'P30 AI060354/AI/NIAID NIH HHS/United States'
p52132
asS'IP'
p52133
S'9'
sS'IS'
p52134
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p52135
sS'PMC'
p52136
S'PMC3460963'
p52137
sS'DCOM'
p52138
S'20130305'
p52139
sS'AU'
p52140
(lp52141
S'Murphy RA'
p52142
aS'Marconi VC'
p52143
aS'Gandhi RT'
p52144
aS'Kuritzkes DR'
p52145
aS'Sunpath H'
p52146
asS'VI'
p52147
S'7'
sS'MHDA'
p52148
S'2013/03/06 06:00'
p52149
sS'PHST'
p52150
(lp52151
S'2012/04/01 [received]'
p52152
aS'2012/08/13 [accepted]'
p52153
aS'2012/09/28 [epublish]'
p52154
asS'OID'
p52155
(lp52156
S'NLM: PMC3460963'
p52157
asS'MH'
p52158
(lp52159
S'Adolescent'
p52160
aS'Adult'
p52161
aS'Anti-HIV Agents/*administration & dosage/adverse effects/pharmacology/therapeutic use'
p52162
aS'Antibiotics, Antitubercular/administration & dosage/adverse effects/therapeutic use'
p52163
aS'Child'
p52164
aS'Coinfection/*drug therapy'
p52165
aS'Drug Therapy, Combination'
p52166
aS'Female'
p52167
aS'HIV Infections/complications/*drug therapy'
p52168
aS'HIV-1/drug effects/physiology'
p52169
aS'Humans'
p52170
aS'Kaplan-Meier Estimate'
p52171
aS'Lopinavir/*administration & dosage/adverse effects/pharmacology/therapeutic use'
p52172
aS'Male'
p52173
aS'Middle Aged'
p52174
aS'Retrospective Studies'
p52175
aS'Rifampin/*administration & dosage/adverse effects/therapeutic use'
p52176
aS'Ritonavir/*administration & dosage/adverse effects/pharmacology/therapeutic use'
p52177
aS'South Africa'
p52178
aS'Time Factors'
p52179
aS'Tuberculosis/complications/*drug therapy'
p52180
aS'Young Adult'
p52181
asS'EDAT'
p52182
S'2012/10/03 06:00'
p52183
sS'SO'
p52184
S'PLoS One. 2012;7(9):e44793. doi: 10.1371/journal.pone.0044793. Epub 2012 Sep 28.'
p52185
sS'SB'
p52186
S'IM'
p52187
sS'PMID'
p52188
S'23028623'
p52189
sS'PST'
p52190
S'ppublish'
p52191
stRp52192
ag2
(g3
g4
(dp52193
S'STAT'
p52194
S'MEDLINE'
p52195
sS'AB'
p52196
S'Scaling up of Antiretroviral (ARV) drugs is crucial and should be a perpetual venture in developing countries in-order to increase the survival period of HIV/AIDS individuals. In Tanzania, information on the rate of patients considered as lost to follow up during treatment with ARVs is scarce. The objective of this study was to determine the rate of lost to follow up and treatment outcome among patients attending two care and treatment clinics (CTCs) in Tanga City in north-eastern Tanzania. A descriptive observational study was carried out on cohorts from Tanga AIDS Working Group and Bombo Regional Hospital. The total number of patients identified as "lost to follow up" were 89 of which 14 (15.7%) died. Among those who died, 3 (21.4%) died between the second week and 3 months after ARV initiation. Of those still alive (84.3%; 75/89), 25% (19/75) were still on ARVs, whereas 47 (62.7%) self transferred to other CTCs. Proper patient documentation with actual residence address is a crucial aspect for adherence. Similarly, frequent prompt tracing of patient should be part of any drug interventional programme linking facility and communities.'
p52197
sS'JID'
p52198
S'101479163'
p52199
sS'AD'
p52200
S'National Institute for Medical Research, Tanga Research Centre, P.O. Box 5004, Tanga, Tanzania. hwmakunde@hotmail.com'
p52201
sS'JT'
p52202
S'Tanzania journal of health research'
p52203
sS'IP'
p52204
S'4'
sS'IS'
p52205
S'1821-6404 (Print)'
p52206
sS'DCOM'
p52207
S'20151217'
p52208
sS'DA'
p52209
S'20151120'
p52210
sS'AU'
p52211
(lp52212
S'Makunde WH'
p52213
aS'Francis F'
p52214
aS'Mmbando BP'
p52215
aS'Kamugisha ML'
p52216
aS'Rutta AM'
p52217
aS'Mandara CI'
p52218
aS'Msangeni HA'
p52219
asS'CRDT'
p52220
(lp52221
S'2015/11/24 06:00'
p52222
asS'VI'
p52223
S'14'
p52224
sS'PMID'
p52225
S'26591722'
p52226
sS'DP'
p52227
S'2012 Oct'
p52228
sS'MHDA'
p52229
S'2015/12/19 06:00'
p52230
sS'OWN'
p52231
S'NLM'
p52232
sS'PT'
p52233
(lp52234
S'Journal Article'
p52235
aS'Observational Study'
p52236
aS"Research Support, Non-U.S. Gov't"
p52237
asS'LA'
p52238
(lp52239
S'eng'
p52240
asS'MH'
p52241
(lp52242
S'Adult'
p52243
aS'Anti-Retroviral Agents/*therapeutic use'
p52244
aS'Female'
p52245
aS'HIV Infections/*drug therapy/mortality'
p52246
aS'Humans'
p52247
aS'Lost to Follow-Up'
p52248
aS'Male'
p52249
aS'Middle Aged'
p52250
aS'Surveys and Questionnaires'
p52251
aS'Tanzania/epidemiology'
p52252
aS'Treatment Outcome'
p52253
asS'FAU'
p52254
(lp52255
S'Makunde, Williams H'
p52256
aS'Francis, Filbert'
p52257
aS'Mmbando, Bruno P'
p52258
aS'Kamugisha, Mathias L'
p52259
aS'Rutta, Acleus M'
p52260
aS'Mandara, Celine I'
p52261
aS'Msangeni, Hamis A'
p52262
asS'EDAT'
p52263
S'2012/10/01 00:00'
p52264
sS'PST'
p52265
S'ppublish'
p52266
sS'SO'
p52267
S'Tanzan J Health Res. 2012 Oct;14(4):250-6.'
p52268
sS'PG'
p52269
S'250-6'
p52270
sS'TI'
p52271
S'Lost to follow up and clinical outcomes of HIV adult patients on antiretroviral therapy in care and treatment centres in Tanga City, north-eastern Tanzania.'
p52272
sS'SB'
p52273
S'IM'
p52274
sS'RN'
p52275
(lp52276
S'0 (Anti-Retroviral Agents)'
p52277
asS'PL'
p52278
S'Tanzania'
p52279
sS'TA'
p52280
S'Tanzan J Health Res'
p52281
stRp52282
ag2
(g3
g4
(dp52283
S'STAT'
p52284
S'MEDLINE'
p52285
sS'AB'
p52286
S'Anti-tuberculosis drug resistance is a major problem in tuberculosis (TB) control, particularly multi-drug resistance TB (MDR-TB). The objective of this study was to determine the prevalence of primary and acquired anti-TB drug resistance among newly diagnosed pulmonary TB (PTB) and relapse cases. Sputa were collected from newly diagnosed and relapse PTB patients. Drug susceptibility tests (DST) were performed on sputum culture positive isolates of Mycobacterium tuberculosis using resistance ratio method on four first-line anti-TB drugs: rifampicin, isoniazid, ethambutol and streptomycin. Demographic and anthropometric information was collected and HIV status was determined. Of the 523 culture positive isolates, DST results were available for 503 (96%), 455 were new and 48 were relapse cases. Resistance to at least one of the four drugs was observed in 7.8% (39/503) of the isolates, 7.3% (33/455) were new and 12.5% (6/48) were from relapse cases. Mono resistance to isoniazid was higher in both among new 45.5% (15/33) and relapse 50.0% (3/6) cases. Resistance to rifampicin and streptomycin alone was equal 4/33 (12.1%) and only among new cases. Resistance to ethambutol alone was only one among new cases. Overall MDR-TB prevalence was 2.4% (12/503), nine were new and three were relapse cases. MDR-TB was 17.9% (7/39) for rifampicin and isoniazid. Prevalence of HIV was 43.3% and was similar among new and relapse cases and not risk factor for drug resistance. Majority of PTB patients (52%) had BMI below 18 kg/m2. Those with BMI greater than 18 kg/m2 were more likely to develop drug resistance than those with BMI below 18 kg/m2 (P=0.004). With the resurgence of TB and the high prevalence of HIV among TB patients, prevalence of drug resistance is still low both among new and relapses cases. Despite the current low drug resistance, there is a need for continuous monitoring of the resistance.'
p52287
sS'JID'
p52288
S'101479163'
p52289
sS'AD'
p52290
S'National Institute for Medical Research, Muhimbili Medical Research Centre, Dar es Salaam, Tanzania. hrange08@gmail.com'
p52291
sS'JT'
p52292
S'Tanzania journal of health research'
p52293
sS'IP'
p52294
S'4'
sS'IS'
p52295
S'1821-6404 (Print)'
p52296
sS'DCOM'
p52297
S'20151217'
p52298
sS'DA'
p52299
S'20151120'
p52300
sS'AU'
p52301
(lp52302
S'Range N'
p52303
aS'Friis H'
p52304
aS'Mfaume S'
p52305
aS'Magnussen P'
p52306
aS'Chanualucha J'
p52307
aS'Kilale A'
p52308
aS'Mugomela A'
p52309
aS'Andersen AB'
p52310
asS'CRDT'
p52311
(lp52312
S'2015/11/24 06:00'
p52313
asS'VI'
p52314
S'14'
p52315
sS'PMID'
p52316
S'26591721'
p52317
sS'DP'
p52318
S'2012 Oct'
p52319
sS'MHDA'
p52320
S'2015/12/19 06:00'
p52321
sS'OWN'
p52322
S'NLM'
p52323
sS'PT'
p52324
(lp52325
S'Journal Article'
p52326
aS'Randomized Controlled Trial'
p52327
aS"Research Support, Non-U.S. Gov't"
p52328
asS'LA'
p52329
(lp52330
S'eng'
p52331
asS'MH'
p52332
(lp52333
S'Adolescent'
p52334
aS'Adult'
p52335
aS'Antitubercular Agents/*therapeutic use'
p52336
aS'Female'
p52337
aS'HIV Infections/complications'
p52338
aS'Humans'
p52339
aS'Male'
p52340
aS'Middle Aged'
p52341
aS'Tanzania/epidemiology'
p52342
aS'Tuberculosis, Multidrug-Resistant/complications/*drug therapy/epidemiology'
p52343
aS'Tuberculosis, Pulmonary/complications/*drug therapy/*epidemiology'
p52344
asS'FAU'
p52345
(lp52346
S'Range, Nyagosya'
p52347
aS'Friis, Henrik'
p52348
aS'Mfaume, Said'
p52349
aS'Magnussen, Pascal'
p52350
aS'Chanualucha, John'
p52351
aS'Kilale, Andrew'
p52352
aS'Mugomela, Apolinary'
p52353
aS'Andersen, Aase B'
p52354
asS'EDAT'
p52355
S'2012/10/01 00:00'
p52356
sS'PST'
p52357
S'ppublish'
p52358
sS'SO'
p52359
S'Tanzan J Health Res. 2012 Oct;14(4):243-9.'
p52360
sS'PG'
p52361
S'243-9'
p52362
sS'TI'
p52363
S'Anti-tuberculosis drug resistance pattern among pulmonary tuberculosis patients with or without HIV infection in Mwanza, Tanzania.'
p52364
sS'SB'
p52365
S'IM'
p52366
sS'RN'
p52367
(lp52368
S'0 (Antitubercular Agents)'
p52369
asS'PL'
p52370
S'Tanzania'
p52371
sS'TA'
p52372
S'Tanzan J Health Res'
p52373
stRp52374
ag2
(g3
g4
(dp52375
S'LID'
p52376
S'10.1111/j.1365-3156.2012.03089.x [doi]'
p52377
sS'STAT'
p52378
S'MEDLINE'
p52379
sS'DEP'
p52380
S'20120920'
p52381
sS'CI'
p52382
(lp52383
S'(c) 2012 Blackwell Publishing Ltd.'
p52384
asS'DA'
p52385
S'20131216'
p52386
sS'AID'
p52387
(lp52388
S'10.1111/j.1365-3156.2012.03089.x [doi]'
p52389
asS'CRDT'
p52390
(lp52391
S'2012/09/22 06:00'
p52392
asS'DP'
p52393
S'2012 Dec'
p52394
sS'GR'
p52395
(lp52396
S'U01 AI069924/AI/NIAID NIH HHS/United States'
p52397
asS'OWN'
p52398
S'NLM'
p52399
sS'PT'
p52400
(lp52401
S'Journal Article'
p52402
aS'Meta-Analysis'
p52403
aS'Research Support, N.I.H., Extramural'
p52404
aS"Research Support, Non-U.S. Gov't"
p52405
aS'Review'
p52406
asS'LA'
p52407
(lp52408
S'eng'
p52409
asS'FAU'
p52410
(lp52411
S'Mugglin, Catrina'
p52412
aS'Estill, Janne'
p52413
aS'Wandeler, Gilles'
p52414
aS'Bender, Nicole'
p52415
aS'Egger, Matthias'
p52416
aS'Gsponer, Thomas'
p52417
aS'Keiser, Olivia'
p52418
asS'JT'
p52419
S'Tropical medicine & international health : TM & IH'
p52420
sS'LR'
p52421
S'20150222'
p52422
sS'PG'
p52423
S'1509-20'
p52424
sS'TI'
p52425
S'Loss to programme between HIV diagnosis and initiation of antiretroviral therapy in sub-Saharan Africa: systematic review and meta-analysis.'
p52426
sS'RN'
p52427
(lp52428
S'0 (Anti-HIV Agents)'
p52429
asS'PL'
p52430
S'England'
p52431
sS'TA'
p52432
S'Trop Med Int Health'
p52433
sS'JID'
p52434
S'9610576'
p52435
sS'AB'
p52436
S'OBJECTIVES: To assess the proportion of patients lost to programme (died, lost to follow-up, transferred out) between HIV diagnosis and start of antiretroviral therapy (ART) in sub-Saharan Africa, and determine factors associated with loss to programme. METHODS: Systematic review and meta-analysis. We searched PubMed and EMBASE databases for studies in adults. Outcomes were the percentage of patients dying before starting ART, the percentage lost to follow-up, the percentage with a CD4 cell count, the distribution of first CD4 counts and the percentage of eligible patients starting ART. Data were combined using random-effects meta-analysis. RESULTS: Twenty-nine studies from sub-Saharan Africa including 148,912 patients were analysed. Six studies covered the whole period from HIV diagnosis to ART start. Meta-analysis of these studies showed that of the 100 patients with a positive HIV test, 72 (95% CI 60-84) had a CD4 cell count measured, 40 (95% CI 26-55) were eligible for ART and 25 (95% CI 13-37) started ART. There was substantial heterogeneity between studies (P < 0.0001). Median CD4 cell count at presentation ranged from 154 to 274 cells/mul. Patients eligible for ART were less likely to become lost to programme (25%vs. 54%, P < 0.0001), but eligible patients were more likely to die (11%vs. 5%, P < 0.0001) than ineligible patients. Loss to programme was higher in men, in patients with low CD4 cell counts and low socio-economic status and in recent time periods. CONCLUSIONS: Monitoring and care in the pre-ART time period need improvement, with greater emphasis on patients not yet eligible for ART.'
p52437
sS'AD'
p52438
S'Division of International and Environmental Health, Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland Department of Infectious Diseases, University Hospital Bern, Bern, Switzerland School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.'
p52439
sS'CN'
p52440
(lp52441
S'IeDEA Southern Africa'
p52442
asS'IP'
p52443
S'12'
p52444
sS'IS'
p52445
S'1365-3156 (Electronic) 1360-2276 (Linking)'
p52446
sS'PMC'
p52447
S'PMC3895621'
p52448
sS'DCOM'
p52449
S'20140207'
p52450
sS'MID'
p52451
(lp52452
S'NIHMS494474'
p52453
asS'AU'
p52454
(lp52455
S'Mugglin C'
p52456
aS'Estill J'
p52457
aS'Wandeler G'
p52458
aS'Bender N'
p52459
aS'Egger M'
p52460
aS'Gsponer T'
p52461
aS'Keiser O'
p52462
asS'VI'
p52463
S'17'
p52464
sS'MHDA'
p52465
S'2014/02/08 06:00'
p52466
sS'PHST'
p52467
(lp52468
S'2012/09/20 [aheadofprint]'
p52469
asS'OTO'
p52470
(lp52471
S'NOTNLM'
p52472
asS'OID'
p52473
(lp52474
S'NLM: NIHMS494474'
p52475
aS'NLM: PMC3895621'
p52476
asS'MH'
p52477
(lp52478
S'AIDS Serodiagnosis'
p52479
aS'Adult'
p52480
aS'Africa South of the Sahara'
p52481
aS'Anti-HIV Agents/*therapeutic use'
p52482
aS'CD4 Lymphocyte Count'
p52483
aS'Female'
p52484
aS'HIV Infections/diagnosis/*drug therapy/mortality'
p52485
aS'*Health Services Needs and Demand'
p52486
aS'Humans'
p52487
aS'*Lost to Follow-Up'
p52488
aS'Male'
p52489
aS'Sex Distribution'
p52490
asS'EDAT'
p52491
S'2012/09/22 06:00'
p52492
sS'SO'
p52493
S'Trop Med Int Health. 2012 Dec;17(12):1509-20. doi: 10.1111/j.1365-3156.2012.03089.x. Epub 2012 Sep 20.'
p52494
sS'SB'
p52495
S'IM'
p52496
sS'PMID'
p52497
S'22994151'
p52498
sS'OT'
p52499
(lp52500
S'Afrique subsaharienne'
p52501
aS'liens avec les soins'
p52502
aS'linkage to care'
p52503
aS'loss to follow-up'
p52504
aS'mortalidad'
p52505
aS'mortality'
p52506
aS'mortalite'
p52507
aS'nexo con atencion medica'
p52508
aS'perte au suivi'
p52509
aS'pre-ART'
p52510
aS'pre-TAR'
p52511
aS'pre-ART'
p52512
aS'perdida durante el seguimiento'
p52513
aS'sub-Saharan Africa'
p52514
aS'Africa subsahariana'
p52515
asS'PST'
p52516
S'ppublish'
p52517
stRp52518
ag2
(g3
g4
(dp52519
S'STAT'
p52520
S'MEDLINE'
p52521
sS'AB'
p52522
S"CONTEXT: Recent studies have highlighted the increased risk of adverse outcomes among older patients on antiretroviral therapy (ART). We report on the associations between older age and adverse outcomes in HIV/AIDS antiretroviral programmes across 17 programmes in sub-Saharan Africa. METHODS: We included data from nine countries: Central African Republic, Cote d'Ivoire, Democratic Republic of Congo, Ethiopia, Nigeria, Republic of Congo, Uganda, Zambia and Zimbabwe. We describe survival probability for progression to death and loss to follow-up for patients initiating ART aged less than 50 years and at least 50 years. Multivariate Cox proportional hazards models were used to assess the association between age (15-39, 40-49, 50-59, 60-69 and 70-94 years) and adverse outcomes adjusting for confounders identified a priori. RESULTS: Our analysis included 17,561 patients followed for a median of 12 months. The majority (65%) were female and 6672 (38%) were severely immunosuppressed at baseline. Median age at ART initiation was 36.0 years (interquartile range 30.1-42.8); 11.4% of patients were aged at least 50 years. Median gain in CD4 cell count at 6 and 12 months was significantly higher in patients less than 50 years old compared with those at least 50 years (134 vs. 112 cells/mul at 6 months; 170 vs. 139 cells/mul at 12 months; both P < 0.001). In multivariate analysis, there was a significant increased risk of mortality beyond 3 months after ART initiation in all age groups of at least 40 years of age compared with less than 40 years [40-49 years adjusted hazard ratios (aHRs) 1.59, P < 0.001; 50-59 years aHR 1.58, P = 0.002; 60-69 years aHR 2.63, P < 0.001; 70-94 years aHR 3.64, P = 0.004). CONCLUSION: Older age groups represent an important proportion of the overall treatment cohort in these sub-Saharan Africa programmes, and risk of mortality increased as age increased. Future research should be directed at further understanding the reasons for higher mortality, and defining simple interventions that are feasible in highly under-resourced settings to allow for adapted follow-up and care approaches for older age groups."
p52523
sS'AD'
p52524
S'Medecins Sans Frontieres, London, UK. jane.greig@london.msf.org'
p52525
sS'JT'
p52526
S'AIDS (London, England)'
p52527
sS'VI'
p52528
S'26 Suppl 1'
p52529
sS'IS'
p52530
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p52531
sS'JID'
p52532
S'8710219'
p52533
sS'DA'
p52534
S'20120711'
p52535
sS'AU'
p52536
(lp52537
S'Greig J'
p52538
aS'Casas EC'
p52539
aS"O'Brien DP"
p52540
aS'Mills EJ'
p52541
aS'Ford N'
p52542
asS'AID'
p52543
(lp52544
S'10.1097/QAD.0b013e3283558446 [doi]'
p52545
aS'00002030-201207311-00001 [pii]'
p52546
asS'CRDT'
p52547
(lp52548
S'2012/07/12 06:00'
p52549
asS'PMID'
p52550
S'22781173'
p52551
sS'DP'
p52552
S'2012 Jul 31'
p52553
sS'MHDA'
p52554
S'2012/12/29 06:00'
p52555
sS'OWN'
p52556
S'NLM'
p52557
sS'PT'
p52558
(lp52559
S'Journal Article'
p52560
aS'Multicenter Study'
p52561
asS'LA'
p52562
(lp52563
S'eng'
p52564
asS'MH'
p52565
(lp52566
S'Acquired Immunodeficiency Syndrome/drug therapy/*epidemiology'
p52567
aS'Adolescent'
p52568
aS'Adult'
p52569
aS'Africa South of the Sahara/epidemiology'
p52570
aS'Aged'
p52571
aS'Aged, 80 and over'
p52572
aS'*Aging'
p52573
aS'Anti-HIV Agents/*administration & dosage/*adverse effects'
p52574
aS'CD4 Lymphocyte Count'
p52575
aS'Disease Progression'
p52576
aS'Female'
p52577
aS'Follow-Up Studies'
p52578
aS'Humans'
p52579
aS'Immunosuppression/*statistics & numerical data'
p52580
aS'Kaplan-Meier Estimate'
p52581
aS'Lost to Follow-Up'
p52582
aS'Male'
p52583
aS'Middle Aged'
p52584
aS'*Needs Assessment'
p52585
aS'Treatment Outcome'
p52586
aS'Young Adult'
p52587
asS'DCOM'
p52588
S'20121228'
p52589
sS'EDAT'
p52590
S'2012/09/22 06:00'
p52591
sS'PST'
p52592
S'ppublish'
p52593
sS'SO'
p52594
S'AIDS. 2012 Jul 31;26 Suppl 1:S31-7.'
p52595
sS'FAU'
p52596
(lp52597
S'Greig, Jane'
p52598
aS'Casas, Esther C'
p52599
aS"O'Brien, Daniel P"
p52600
aS'Mills, Edward J'
p52601
aS'Ford, Nathan'
p52602
asS'TI'
p52603
S'Association between older age and adverse outcomes on antiretroviral therapy: a cohort analysis of programme data from nine countries.'
p52604
sS'SB'
p52605
S'IM X'
p52606
sS'RN'
p52607
(lp52608
S'0 (Anti-HIV Agents)'
p52609
asS'TA'
p52610
S'AIDS'
p52611
sS'PL'
p52612
S'England'
p52613
sS'PG'
p52614
S'S31-7'
p52615
stRp52616
ag2
(g3
g4
(dp52617
S'LID'
p52618
S'10.1542/peds.2011-3020 [doi]'
p52619
sS'STAT'
p52620
S'MEDLINE'
p52621
sS'DEP'
p52622
S'20120917'
p52623
sS'DA'
p52624
S'20121004'
p52625
sS'AID'
p52626
(lp52627
S'peds.2011-3020 [pii]'
p52628
aS'10.1542/peds.2011-3020 [doi]'
p52629
asS'CRDT'
p52630
(lp52631
S'2012/09/19 06:00'
p52632
asS'DP'
p52633
S'2012 Oct'
p52634
sS'GR'
p52635
(lp52636
S'097410/Wellcome Trust/United Kingdom'
p52637
aS'5U01-AI069924-05/AI/NIAID NIH HHS/United States'
p52638
aS'U01 AI069924/AI/NIAID NIH HHS/United States'
p52639
asS'OWN'
p52640
S'NLM'
p52641
sS'PT'
p52642
(lp52643
S'Evaluation Studies'
p52644
aS'Journal Article'
p52645
aS'Research Support, N.I.H., Extramural'
p52646
aS"Research Support, Non-U.S. Gov't"
p52647
asS'LA'
p52648
(lp52649
S'eng'
p52650
asS'FAU'
p52651
(lp52652
S'Gsponer, Thomas'
p52653
aS'Weigel, Ralf'
p52654
aS'Davies, Mary-Ann'
p52655
aS'Bolton, Carolyn'
p52656
aS'Moultrie, Harry'
p52657
aS'Vaz, Paula'
p52658
aS'Rabie, Helena'
p52659
aS'Technau, Karl'
p52660
aS'Ndirangu, James'
p52661
aS'Eley, Brian'
p52662
aS'Garone, Daniela'
p52663
aS'Wellington, Maureen'
p52664
aS'Giddy, Janet'
p52665
aS'Ehmer, Jochen'
p52666
aS'Egger, Matthias'
p52667
aS'Keiser, Olivia'
p52668
asS'JT'
p52669
S'Pediatrics'
p52670
sS'LR'
p52671
S'20150223'
p52672
sS'PG'
p52673
S'e966-77'
p52674
sS'TI'
p52675
S'Variability of growth in children starting antiretroviral treatment in southern Africa.'
p52676
sS'RN'
p52677
(lp52678
S'0 (Anti-HIV Agents)'
p52679
asS'PL'
p52680
S'United States'
p52681
sS'TA'
p52682
S'Pediatrics'
p52683
sS'JID'
p52684
S'0376422'
p52685
sS'AB'
p52686
S'BACKGROUND: Poor growth is an indication for antiretroviral therapy (ART) and a criterion for treatment failure. We examined variability in growth response to ART in 12 programs in Malawi, Zambia, Zimbabwe, Mozambique, and South Africa. METHODS: Treatment naive children aged <10 years were included. We calculated weight for age z scores (WAZs), height for age z scores (HAZs), and weight for height z scores (WHZs) up to 3 years after starting ART, by using the World Health Organization standards. Multilevel regression models were used. RESULTS: A total of 17990 children (range, 238-8975) were followed for 36181 person-years. At ART initiation, most children were underweight (50%) and stunted (66%). Lower baseline WAZ, HAZ, and WHZ were the most important determinants of faster catch-up growth on ART. WAZ and WHZ increased rapidly in the first year and stagnated or reversed thereafter, whereas HAZ increased continuously over time. Three years after starting ART, WAZ ranged from -2.80 (95% confidence interval [CI]: -3.66 to -2.02) to -1.98 (95% CI: -2.41 to -1.48) in children with a baseline z score < -3 and from -0.79 (95% CI: -1.62 to 0.02) to 0.05 (95% CI: -0.42 to 0.51) in children with a baseline WAZ >/= -1. For HAZ, the corresponding range was -2.33 (95% CI: -2.62 to -2.02) to -1.27 (95% CI: -1.58 to -1.00) for baseline HAZ < -3 and -0.24 (95% CI: -0.56 to 0.15) to 0.84 (95% CI: 0.53 to 1.16) for HAZ >/= -1. CONCLUSIONS: Despite a sustained growth response and catch-up growth in children with advanced HIV disease treated with ART, normal weights and heights are not achieved over 3 years of ART.'
p52687
sS'AD'
p52688
S'Institute of Social and Preventive Medicine (ISPM), University of Bern, Finkenhubelweg 11, CH-3012 Bern, Switzerland.'
p52689
sS'CN'
p52690
(lp52691
S'IeDEA Southern Africa'
p52692
asS'IP'
p52693
S'4'
sS'IS'
p52694
S'1098-4275 (Electronic) 0031-4005 (Linking)'
p52695
sS'PMC'
p52696
S'PMC3457616'
p52697
sS'DCOM'
p52698
S'20121210'
p52699
sS'AU'
p52700
(lp52701
S'Gsponer T'
p52702
aS'Weigel R'
p52703
aS'Davies MA'
p52704
aS'Bolton C'
p52705
aS'Moultrie H'
p52706
aS'Vaz P'
p52707
aS'Rabie H'
p52708
aS'Technau K'
p52709
aS'Ndirangu J'
p52710
aS'Eley B'
p52711
aS'Garone D'
p52712
aS'Wellington M'
p52713
aS'Giddy J'
p52714
aS'Ehmer J'
p52715
aS'Egger M'
p52716
aS'Keiser O'
p52717
asS'VI'
p52718
S'130'
p52719
sS'MHDA'
p52720
S'2012/12/12 06:00'
p52721
sS'PHST'
p52722
(lp52723
S'2012/09/17 [aheadofprint]'
p52724
asS'OID'
p52725
(lp52726
S'NLM: PMC3457616'
p52727
asS'MH'
p52728
(lp52729
S'Africa, Southern'
p52730
aS'Anti-HIV Agents/pharmacology/*therapeutic use'
p52731
aS'Child'
p52732
aS'Child, Preschool'
p52733
aS'Female'
p52734
aS'Follow-Up Studies'
p52735
aS'Growth/*drug effects'
p52736
aS'Growth Disorders/*etiology'
p52737
aS'HIV Infections/complications/*drug therapy'
p52738
aS'Humans'
p52739
aS'Male'
p52740
aS'Models, Statistical'
p52741
aS'Regression Analysis'
p52742
aS'Thinness/*etiology'
p52743
aS'Treatment Outcome'
p52744
asS'EDAT'
p52745
S'2012/09/19 06:00'
p52746
sS'SO'
p52747
S'Pediatrics. 2012 Oct;130(4):e966-77. doi: 10.1542/peds.2011-3020. Epub 2012 Sep 17.'
p52748
sS'SB'
p52749
S'AIM IM'
p52750
sS'PMID'
p52751
S'22987878'
p52752
sS'PST'
p52753
S'ppublish'
p52754
stRp52755
ag2
(g3
g4
(dp52756
S'STAT'
p52757
S'MEDLINE'
p52758
sS'DEP'
p52759
S'20120618'
p52760
sS'DA'
p52761
S'20120917'
p52762
sS'AID'
p52763
(lp52764
S'10.2471/BLT.11.100776 [doi]'
p52765
aS'BLT.11.100776 [pii]'
p52766
asS'CRDT'
p52767
(lp52768
S'2012/09/18 06:00'
p52769
asS'DP'
p52770
S'2012 Sep 1'
p52771
sS'GR'
p52772
(lp52773
S'R01 HD053216/HD/NICHD NIH HHS/United States'
p52774
asS'OWN'
p52775
S'NLM'
p52776
sS'PT'
p52777
(lp52778
S'Journal Article'
p52779
aS'Research Support, N.I.H., Extramural'
p52780
asS'LA'
p52781
(lp52782
S'eng'
p52783
asS'FAU'
p52784
(lp52785
S'Dube, Queen'
p52786
aS'Dow, Anna'
p52787
aS'Chirambo, Chawanangwa'
p52788
aS'Lebov, Jill'
p52789
aS'Tenthani, Lyson'
p52790
aS'Moore, Michael'
p52791
aS'Heyderman, Robert S'
p52792
aS'Van Rie, Annelies'
p52793
asS'JT'
p52794
S'Bulletin of the World Health Organization'
p52795
sS'LR'
p52796
S'20150223'
p52797
sS'PG'
p52798
S'699-704'
p52799
sS'TI'
p52800
S'Implementing early infant diagnosis of HIV infection at the primary care level: experiences and challenges in Malawi.'
p52801
sS'RN'
p52802
(lp52803
S'0 (Anti-HIV Agents)'
p52804
asS'PL'
p52805
S'Switzerland'
p52806
sS'TA'
p52807
S'Bull World Health Organ'
p52808
sS'JID'
p52809
S'7507052'
p52810
sS'AB'
p52811
S"PROBLEM: Malawi's national guidelines recommend that infants exposed to the human immunodeficiency virus (HIV) be tested at 6 weeks of age. Rollout of services for early infant diagnosis has been limited and has resulted in the initiation of antiretroviral therapy (ART) in very few infants. APPROACH: An early infant diagnosis programme was launched. It included education of pregnant women on infant testing, community sensitization, free infant testing at 6 weeks of age, active tracing of HIV-positive infants and referral for treatment and care. LOCAL SETTING: The programme was established in two primary care facilities in Blantyre, Malawi. RELEVANT CHANGES: Of 1214 HIV-exposed infants, 71.6% presented for early diagnosis, and 14.5% of those who presented tested positive for HIV. Further testing of 103 of these 126 apparently HIV-positive infants confirmed infection in 88; the other 15 results were false positives. The initial polymerase chain reaction testing of dried blood spots had a positive predictive value (PPV) of 85.4%. Despite active tracing, only 87.3% (110/126) of the mothers of infants who initially tested positive were told their infants' test results. ART was initiated in 58% of the infants with confirmed HIV infection. LESSONS LEARNT: Early infant diagnosis of HIV infection at the primary care level in a resource-poor setting is challenging. Many children in the HIV diagnosis and treatment programme were lost to follow-up at various stages. Diagnostic tools with higher PPV and point-of-care capacity and better infrastructures for administering ART are needed to improve the management of HIV-exposed and HIV-infected infants."
p52812
sS'AD'
p52813
S'Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Queen Elizabeth Central Hospital, Blantyre, Malawi.'
p52814
sS'CN'
p52815
(lp52816
S'CHIDEV study team'
p52817
asS'IP'
p52818
S'9'
sS'IS'
p52819
S'1564-0604 (Electronic) 0042-9686 (Linking)'
p52820
sS'PMC'
p52821
S'PMC3442393'
p52822
sS'DCOM'
p52823
S'20130227'
p52824
sS'AU'
p52825
(lp52826
S'Dube Q'
p52827
aS'Dow A'
p52828
aS'Chirambo C'
p52829
aS'Lebov J'
p52830
aS'Tenthani L'
p52831
aS'Moore M'
p52832
aS'Heyderman RS'
p52833
aS'Van Rie A'
p52834
asS'VI'
p52835
S'90'
p52836
sS'MHDA'
p52837
S'2013/02/28 06:00'
p52838
sS'PHST'
p52839
(lp52840
S'2012/01/31 [received]'
p52841
aS'2012/05/05 [revised]'
p52842
aS'2012/05/11 [accepted]'
p52843
aS'2012/06/18 [epublish]'
p52844
asS'OID'
p52845
(lp52846
S'NLM: PMC3442393'
p52847
asS'MH'
p52848
(lp52849
S'AIDS Serodiagnosis/*methods'
p52850
aS'Age Factors'
p52851
aS'Anti-HIV Agents/*therapeutic use'
p52852
aS'Child, Preschool'
p52853
aS'Confidence Intervals'
p52854
aS'Female'
p52855
aS'HIV Infections/*diagnosis/drug therapy'
p52856
aS'Humans'
p52857
aS'Infant'
p52858
aS'*Infant Welfare'
p52859
aS'Infant, Newborn'
p52860
aS'Infectious Disease Transmission, Vertical/prevention & control'
p52861
aS'Malawi'
p52862
aS'Male'
p52863
aS'Polymerase Chain Reaction'
p52864
aS'Predictive Value of Tests'
p52865
aS'Pregnancy'
p52866
aS'Primary Health Care/*methods'
p52867
aS'Time Factors'
p52868
asS'EDAT'
p52869
S'2012/09/18 06:00'
p52870
sS'SO'
p52871
S'Bull World Health Organ. 2012 Sep 1;90(9):699-704. Epub 2012 Jun 18.'
p52872
sS'SB'
p52873
S'IM'
p52874
sS'PMID'
p52875
S'22984315'
p52876
sS'PST'
p52877
S'ppublish'
p52878
stRp52879
ag2
(g3
g4
(dp52880
S'LID'
p52881
S'10.1080/13691058.2012.716166 [doi]'
p52882
sS'STAT'
p52883
S'MEDLINE'
p52884
sS'DEP'
p52885
S'20120913'
p52886
sS'MID'
p52887
(lp52888
S'NIHMS803739'
p52889
asS'DA'
p52890
S'20130212'
p52891
sS'AID'
p52892
(lp52893
S'10.1080/13691058.2012.716166 [doi]'
p52894
asS'CRDT'
p52895
(lp52896
S'2012/09/15 06:00'
p52897
asS'DP'
p52898
S'2013'
p52899
sS'AD'
p52900
S'Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL, USA. OVillar2@med.miami.edu'
p52901
sS'OWN'
p52902
S'NLM'
p52903
sS'PT'
p52904
(lp52905
S'Journal Article'
p52906
aS'Randomized Controlled Trial'
p52907
aS'Research Support, N.I.H., Extramural'
p52908
asS'LA'
p52909
(lp52910
S'eng'
p52911
asS'FAU'
p52912
(lp52913
S'Villar-Loubet, Olga M'
p52914
aS'Bruscantini, Laura'
p52915
aS'Shikwane, Molatelo Elisa'
p52916
aS'Weiss, Stephen'
p52917
aS'Peltzer, Karl'
p52918
aS'Jones, Deborah L'
p52919
asS'JT'
p52920
S'Culture, health & sexuality'
p52921
sS'LR'
p52922
S'20160728'
p52923
sS'PG'
p52924
S'253-68'
p52925
sS'TI'
p52926
S'HIV disclosure, sexual negotiation and male involvement in prevention-of-mother-to-child-transmission in South Africa.'
p52927
sS'PL'
p52928
S'England'
p52929
sS'TA'
p52930
S'Cult Health Sex'
p52931
sS'JID'
p52932
S'100883416'
p52933
sS'AB'
p52934
S"HIV-seroconversion during pregnancy is a serious concern throughout South Africa, where an estimated 35 to 40% of pregnant women have HIV/AIDS and drop-out is high at all stages of the prevention-of-mother-to-child-transmission (PMTCT) process. The likelihood of PMTCT success may be linked to partner support, yet male involvement in antenatal care remains low. This qualitative study examined the influence of pregnant couples' expectations, experiences and perceptions on sexual communication and male involvement in PMTCT. A total of 119 couples participated in a comprehensive intervention in 12 antenatal clinics throughout South Africa. Data were collected between December 2010 to June 2011 and analysed using a grounded theory approach. Findings point to the importance of sexual communication as a factor influencing PMTCT male involvement. Analysis of themes lends support to improving communication between couples, encouraging dialogue among men and increasing male involvement in PMTCT to bridge the gap between knowledge and sexual behaviour change."
p52935
sS'GR'
p52936
(lp52937
S'P30 AI073961/AI/NIAID NIH HHS/United States'
p52938
aS'P30A1073961-S/PHS HHS/United States'
p52939
asS'IP'
p52940
S'3'
sS'IS'
p52941
S'1464-5351 (Electronic) 1369-1058 (Linking)'
p52942
sS'PMC'
p52943
S'PMC4963151'
p52944
sS'DCOM'
p52945
S'20130820'
p52946
sS'AU'
p52947
(lp52948
S'Villar-Loubet OM'
p52949
aS'Bruscantini L'
p52950
aS'Shikwane ME'
p52951
aS'Weiss S'
p52952
aS'Peltzer K'
p52953
aS'Jones DL'
p52954
asS'VI'
p52955
S'15'
p52956
sS'MHDA'
p52957
S'2013/08/21 06:00'
p52958
sS'PHST'
p52959
(lp52960
S'2012/09/13 [aheadofprint]'
p52961
asS'OID'
p52962
(lp52963
S'NLM: NIHMS803739'
p52964
aS'NLM: PMC4963151'
p52965
asS'MH'
p52966
(lp52967
S'Adolescent'
p52968
aS'Adult'
p52969
aS'Condoms/utilization'
p52970
aS'Female'
p52971
aS'HIV Seropositivity/*psychology/transmission'
p52972
aS'Health Education/*methods'
p52973
aS'Humans'
p52974
aS'Infectious Disease Transmission, Vertical/*prevention & control'
p52975
aS'Male'
p52976
aS'Middle Aged'
p52977
aS'*Negotiating/psychology'
p52978
aS'Pregnancy'
p52979
aS'Safe Sex/psychology'
p52980
aS'*Self Disclosure'
p52981
aS'Sexual Behavior/*psychology'
p52982
aS'Sexual Partners/psychology'
p52983
aS'South Africa'
p52984
aS'Young Adult'
p52985
asS'EDAT'
p52986
S'2012/09/15 06:00'
p52987
sS'SO'
p52988
S'Cult Health Sex. 2013;15(3):253-68. doi: 10.1080/13691058.2012.716166. Epub 2012 Sep 13.'
p52989
sS'SB'
p52990
S'IM'
p52991
sS'PMID'
p52992
S'22974414'
p52993
sS'PST'
p52994
S'ppublish'
p52995
stRp52996
ag2
(g3
g4
(dp52997
S'STAT'
p52998
S'MEDLINE'
p52999
sS'DEP'
p53000
S'20120904'
p53001
sS'DA'
p53002
S'20120913'
p53003
sS'AID'
p53004
(lp53005
S'10.1371/journal.pmed.1001304 [doi]'
p53006
aS'PMEDICINE-D-12-00344 [pii]'
p53007
asS'CRDT'
p53008
(lp53009
S'2012/09/14 06:00'
p53010
asS'DP'
p53011
S'2012'
p53012
sS'GR'
p53013
(lp53014
S'090999/Wellcome Trust/United Kingdom'
p53015
aS'097410/Wellcome Trust/United Kingdom'
p53016
aS'5U01AI069924-06/AI/NIAID NIH HHS/United States'
p53017
aS'K23 AI083099/AI/NIAID NIH HHS/United States'
p53018
aS'U01 AI069924/AI/NIAID NIH HHS/United States'
p53019
asS'OWN'
p53020
S'NLM'
p53021
sS'PT'
p53022
(lp53023
S'Journal Article'
p53024
aS'Multicenter Study'
p53025
aS'Research Support, N.I.H., Extramural'
p53026
aS"Research Support, Non-U.S. Gov't"
p53027
asS'LA'
p53028
(lp53029
S'eng'
p53030
asS'FAU'
p53031
(lp53032
S'Cornell, Morna'
p53033
aS'Schomaker, Michael'
p53034
aS'Garone, Daniela Belen'
p53035
aS'Giddy, Janet'
p53036
aS'Hoffmann, Christopher J'
p53037
aS'Lessells, Richard'
p53038
aS'Maskew, Mhairi'
p53039
aS'Prozesky, Hans'
p53040
aS'Wood, Robin'
p53041
aS'Johnson, Leigh F'
p53042
aS'Egger, Matthias'
p53043
aS'Boulle, Andrew'
p53044
aS'Myer, Landon'
p53045
asS'JT'
p53046
S'PLoS medicine'
p53047
sS'LR'
p53048
S'20150223'
p53049
sS'PG'
p53050
S'e1001304'
p53051
sS'TI'
p53052
S'Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study.'
p53053
sS'RN'
p53054
(lp53055
S'0 (Anti-HIV Agents)'
p53056
asS'PL'
p53057
S'United States'
p53058
sS'TA'
p53059
S'PLoS Med'
p53060
sS'FIR'
p53061
(lp53062
S'Ndirangu, James'
p53063
aS'Hoffmann, Christopher J'
p53064
aS'Chi, Benjamin'
p53065
aS'Wood, Robin'
p53066
aS'Dickinson, Diana'
p53067
aS'Garone, Daniela Belen'
p53068
aS'Phiri, Sam'
p53069
aS'Giddy, Janet'
p53070
aS'Chimbetete, Cleophas'
p53071
aS'Oosterhout, Joop'
p53072
aS'Eley, Brian'
p53073
aS'Pestilli, Sabrina'
p53074
aS'Fritz, Christiane'
p53075
aS'MacPhail, Patrick'
p53076
aS'Prozesky, Hans'
p53077
aS'Technau, Karl'
p53078
aS'Moultrie, Harry'
p53079
asS'JID'
p53080
S'101231360'
p53081
sS'AB'
p53082
S"BACKGROUND: Increased mortality among men on antiretroviral therapy (ART) has been documented but remains poorly understood. We examined the magnitude of and risk factors for gender differences in mortality on ART. METHODS AND FINDINGS: Analyses included 46,201 ART-naive adults starting ART between January 2002 and December 2009 in eight ART programmes across South Africa (SA). Patients were followed from initiation of ART to outcome or analysis closure. The primary outcome was mortality; secondary outcomes were loss to follow-up (LTF), virologic suppression, and CD4+ cell count responses. Survival analyses were used to examine the hazard of death on ART by gender. Sensitivity analyses were limited to patients who were virologically suppressed and patients whose CD4+ cell count reached >200 cells/microl. We compared gender differences in mortality among HIV+ patients on ART with mortality in an age-standardised HIV-negative population. Among 46,201 adults (65% female, median age 35 years), during 77,578 person-years of follow-up, men had lower median CD4+ cell counts than women (85 versus 110 cells/microl, p<0.001), were more likely to be classified WHO stage III/IV (86 versus 77%, p<0.001), and had higher mortality in crude (8.5 versus 5.7 deaths/100 person-years, p<0.001) and adjusted analyses (adjusted hazard ratio [AHR] 1.31, 95% CI 1.22-1.41). After 36 months on ART, men were more likely than women to be truly LTF (AHR 1.20, 95% CI 1.12-1.28) but not to die after LTF (AHR 1.04, 95% CI 0.86-1.25). Findings were consistent across all eight programmes. Virologic suppression was similar by gender; women had slightly better immunologic responses than men. Notably, the observed gender differences in mortality on ART were smaller than gender differences in age-standardised death rates in the HIV-negative South African population. Over time, non-HIV mortality appeared to account for an increasing proportion of observed mortality. The analysis was limited by missing data on baseline HIV disease characteristics, and we did not observe directly mortality in HIV-negative populations where the participating cohorts were located. CONCLUSIONS: HIV-infected men have higher mortality on ART than women in South African programmes, but these differences are only partly explained by more advanced HIV disease at the time of ART initiation, differential LTF and subsequent mortality, and differences in responses to treatment. The observed differences in mortality on ART may be best explained by background differences in mortality between men and women in the South African population unrelated to the HIV/AIDS epidemic. Please see later in the article for the Editors' Summary."
p53083
sS'AD'
p53084
S'Centre for Infectious Disease Epidemiology & Research, School of Public Health & Family Medicine, University of Cape Town, Cape Town, South Africa. morna.cornell@uct.ac.za'
p53085
sS'CN'
p53086
(lp53087
S'International Epidemiologic Databases to Evaluate AIDS Southern Africa'
p53088
aS'Collaboration'
p53089
asS'IP'
p53090
S'9'
sS'IS'
p53091
S'1549-1676 (Electronic) 1549-1277 (Linking)'
p53092
sS'IR'
p53093
(lp53094
S'Ndirangu J'
p53095
aS'Hoffmann CJ'
p53096
aS'Chi B'
p53097
aS'Wood R'
p53098
aS'Dickinson D'
p53099
aS'Garone DB'
p53100
aS'Phiri S'
p53101
aS'Giddy J'
p53102
aS'Chimbetete C'
p53103
aS'Oosterhout J'
p53104
aS'Eley B'
p53105
aS'Pestilli S'
p53106
aS'Fritz C'
p53107
aS'MacPhail P'
p53108
aS'Prozesky H'
p53109
aS'Technau K'
p53110
aS'Moultrie H'
p53111
asS'DCOM'
p53112
S'20130204'
p53113
sS'AU'
p53114
(lp53115
S'Cornell M'
p53116
aS'Schomaker M'
p53117
aS'Garone DB'
p53118
aS'Giddy J'
p53119
aS'Hoffmann CJ'
p53120
aS'Lessells R'
p53121
aS'Maskew M'
p53122
aS'Prozesky H'
p53123
aS'Wood R'
p53124
aS'Johnson LF'
p53125
aS'Egger M'
p53126
aS'Boulle A'
p53127
aS'Myer L'
p53128
asS'VI'
p53129
S'9'
sS'MHDA'
p53130
S'2013/02/05 06:00'
p53131
sS'PHST'
p53132
(lp53133
S'2012/02/02 [received]'
p53134
aS'2012/07/20 [accepted]'
p53135
aS'2012/09/04 [epublish]'
p53136
asS'OID'
p53137
(lp53138
S'NLM: PMC3433409'
p53139
asS'MH'
p53140
(lp53141
S'Adolescent'
p53142
aS'Adult'
p53143
aS'Anti-HIV Agents/*therapeutic use'
p53144
aS'Antiretroviral Therapy, Highly Active'
p53145
aS'CD4 Lymphocyte Count'
p53146
aS'Cohort Studies'
p53147
aS'Female'
p53148
aS'HIV Infections/*drug therapy/epidemiology/*mortality'
p53149
aS'Humans'
p53150
aS'Male'
p53151
aS'Middle Aged'
p53152
aS'Risk Factors'
p53153
aS'Sex Factors'
p53154
aS'South Africa/epidemiology'
p53155
aS'Young Adult'
p53156
asS'EDAT'
p53157
S'2012/09/14 06:00'
p53158
sS'PMC'
p53159
S'PMC3433409'
p53160
sS'SO'
p53161
S'PLoS Med. 2012;9(9):e1001304. Epub 2012 Sep 4.'
p53162
sS'SB'
p53163
S'IM'
p53164
sS'PMID'
p53165
S'22973181'
p53166
sS'PST'
p53167
S'ppublish'
p53168
stRp53169
ag2
(g3
g4
(dp53170
S'LID'
p53171
S'10.1080/09540121.2012.722600 [doi]'
p53172
sS'STAT'
p53173
S'MEDLINE'
p53174
sS'DEP'
p53175
S'20120913'
p53176
sS'MID'
p53177
(lp53178
S'NIHMS404942'
p53179
asS'DA'
p53180
S'20130408'
p53181
sS'AID'
p53182
(lp53183
S'10.1080/09540121.2012.722600 [doi]'
p53184
asS'CRDT'
p53185
(lp53186
S'2012/09/14 06:00'
p53187
asS'DP'
p53188
S'2013'
p53189
sS'AD'
p53190
S'Department of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD, USA. lchang8@jhmi.edu'
p53191
sS'OWN'
p53192
S'NLM'
p53193
sS'PT'
p53194
(lp53195
S'Journal Article'
p53196
aS'Research Support, N.I.H., Extramural'
p53197
aS"Research Support, Non-U.S. Gov't"
p53198
asS'LA'
p53199
(lp53200
S'eng'
p53201
asS'FAU'
p53202
(lp53203
S'Chang, Larry W'
p53204
aS'Kagaayi, Joseph'
p53205
aS'Nakigozi, Gertrude'
p53206
aS'Serwada, David'
p53207
aS'Quinn, Thomas C'
p53208
aS'Gray, Ronald H'
p53209
aS'Bollinger, Robert C'
p53210
aS'Reynolds, Steven J'
p53211
aS'Holtgrave, David'
p53212
asS'JT'
p53213
S'AIDS care'
p53214
sS'LR'
p53215
S'20150325'
p53216
sS'PG'
p53217
S'652-6'
p53218
sS'TI'
p53219
S'Cost analyses of peer health worker and mHealth support interventions for improving AIDS care in Rakai, Uganda.'
p53220
sS'PL'
p53221
S'England'
p53222
sS'TA'
p53223
S'AIDS Care'
p53224
sS'JID'
p53225
S'8915313'
p53226
sS'AB'
p53227
S'A cost analysis study calculates resources needed to deliver an intervention and can provide useful information on affordability for service providers and policy-makers. We conducted cost analyses of both a peer health worker (PHW) and a mHealth (mobile phone) support intervention. Excluding supervisory staffing costs, total yearly costs for the PHW intervention was $8475, resulting in a yearly cost per patient of $8.74, per virologic failure averted cost of $189, and per patient lost to follow-up averted cost of $1025. Including supervisory staffing costs increased total yearly costs to $14,991. Yearly costs of the mHealth intervention were an additional $1046, resulting in a yearly cost per patient of $2.35. In a threshold analysis, the PHW intervention was found to be cost saving if it was able to avert 1.50 patients per year from switching to second-line antiretroviral therapy. Other AIDS care programs may find these intervention costs affordable.'
p53228
sS'GR'
p53229
(lp53230
S'1K23MH086338-01A2/MH/NIMH NIH HHS/United States'
p53231
aS'2T32-AI07291/AI/NIAID NIH HHS/United States'
p53232
aS'K23 MH086338/MH/NIMH NIH HHS/United States'
p53233
aS'T32 AI007291/AI/NIAID NIH HHS/United States'
p53234
aS'ZIA AI000361-30/Intramural NIH HHS/United States'
p53235
asS'IP'
p53236
S'5'
sS'IS'
p53237
S'1360-0451 (Electronic) 0954-0121 (Linking)'
p53238
sS'PMC'
p53239
S'PMC3773472'
p53240
sS'DCOM'
p53241
S'20131118'
p53242
sS'AU'
p53243
(lp53244
S'Chang LW'
p53245
aS'Kagaayi J'
p53246
aS'Nakigozi G'
p53247
aS'Serwada D'
p53248
aS'Quinn TC'
p53249
aS'Gray RH'
p53250
aS'Bollinger RC'
p53251
aS'Reynolds SJ'
p53252
aS'Holtgrave D'
p53253
asS'VI'
p53254
S'25'
p53255
sS'MHDA'
p53256
S'2013/11/19 06:00'
p53257
sS'PHST'
p53258
(lp53259
S'2012/09/13 [aheadofprint]'
p53260
asS'OID'
p53261
(lp53262
S'NLM: NIHMS404942'
p53263
aS'NLM: PMC3773472'
p53264
asS'MH'
p53265
(lp53266
S'Acquired Immunodeficiency Syndrome/*therapy'
p53267
aS'Cell Phones/*utilization'
p53268
aS'Community Health Services/methods'
p53269
aS'*Costs and Cost Analysis'
p53270
aS'Humans'
p53271
aS'Patient Care Team/economics'
p53272
aS'Quality of Health Care/economics'
p53273
aS'Retrospective Studies'
p53274
aS'Telemedicine/*economics'
p53275
aS'Uganda'
p53276
asS'EDAT'
p53277
S'2012/09/14 06:00'
p53278
sS'SO'
p53279
S'AIDS Care. 2013;25(5):652-6. doi: 10.1080/09540121.2012.722600. Epub 2012 Sep 13.'
p53280
sS'SB'
p53281
S'IM X'
p53282
sS'PMID'
p53283
S'22971113'
p53284
sS'PST'
p53285
S'ppublish'
p53286
stRp53287
ag2
(g3
g4
(dp53288
S'LID'
p53289
S'10.1186/1471-2431-12-146 [doi]'
p53290
sS'STAT'
p53291
S'MEDLINE'
p53292
sS'DEP'
p53293
S'20120910'
p53294
sS'DA'
p53295
S'20121011'
p53296
sS'AID'
p53297
(lp53298
S'1471-2431-12-146 [pii]'
p53299
aS'10.1186/1471-2431-12-146 [doi]'
p53300
asS'CRDT'
p53301
(lp53302
S'2012/09/12 06:00'
p53303
asS'DP'
p53304
S'2012'
p53305
sS'AD'
p53306
S'Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Mtubatuba, South Africa. tchetty@africacentre.ac.za.'
p53307
sS'OWN'
p53308
S'NLM'
p53309
sS'PT'
p53310
(lp53311
S'Evaluation Studies'
p53312
aS'Journal Article'
p53313
aS"Research Support, Non-U.S. Gov't"
p53314
asS'LA'
p53315
(lp53316
S'eng'
p53317
asS'DCOM'
p53318
S'20121221'
p53319
sS'JT'
p53320
S'BMC pediatrics'
p53321
sS'LR'
p53322
S'20160202'
p53323
sS'FAU'
p53324
(lp53325
S'Chetty, Terusha'
p53326
aS'Knight, Stephen'
p53327
aS'Giddy, Janet'
p53328
aS'Crankshaw, Tamaryn L'
p53329
aS'Butler, Lisa M'
p53330
aS'Newell, Marie-Louise'
p53331
asS'TI'
p53332
S'A retrospective study of Human Immunodeficiency Virus transmission, mortality and loss to follow-up among infants in the first 18 months of life in a prevention of mother-to-child transmission programme in an urban hospital in KwaZulu-Natal, South Africa.'
p53333
sS'RN'
p53334
(lp53335
S'0 (Anti-Retroviral Agents)'
p53336
asS'PL'
p53337
S'England'
p53338
sS'PG'
p53339
S'146'
p53340
sS'JID'
p53341
S'100967804'
p53342
sS'AB'
p53343
S"BACKGROUND: Follow up of Human Immunodeficiency Virus (HIV)-exposed infants is an important component of Prevention of Mother-to-Child Transmission (PMTCT) programmes in order to ascertain infant outcomes post delivery. We determined HIV transmission, mortality and loss to follow-up (LTFU) of HIV-exposed infants attending a postnatal clinic in an urban hospital in Durban, South Africa. METHODS: We conducted a retrospective cohort study of infants born to women in the PMTCT programme at McCord Hospital, where mothers paid a fee for service. Data were abstracted from patient records for live-born infants delivered between 1 May 2008 and 31 May 2009. The infants' LTFU status and age was based on the date of the last visit. HIV transmission was calculated as a proportion of infants followed and tested at six weeks. Mortality rates were analyzed using Kaplan-Meier (K-M), with censoring on 15 January 2010, LTFU or death. RESULTS: Of 260 infants, 155 (59.6%) remained in care at McCord beyond 28 weeks: one died at < 28 days, three died between one to six months; 34 were LTFU within seven days, 60 were LTFU by six months. K-M mortality rate: 1.7% at six months (95% confidence interval (CI): 0.6% to 4.3%). Of 220 (83%) infants tested for HIV at six weeks, six (2.7%, 95% CI: 1.1% to 5.8%) were HIV-infected. In Cox regression analysis, late antenatal attendance (>/= 28 weeks gestation) relative to attending in the first trimester was a predictor for infant LTFU (adjusted hazards ratio = 2.3; 95% CI: 1.0 to 5.1; p = 0.044). CONCLUSION: This urban PMTCT programme achieved low transmission rates at six weeks, but LTFU in the first six months limited our ability to examine HIV transmission up to 18 months and determinants of mortality. The LTFU of infants born to women who attended antenatal care at 28 weeks gestation or later emphasizes the need to identify late antenatal attendees for follow up care to educate and support them regarding the importance of follow up care for themselves and their infants."
p53344
sS'GR'
p53345
(lp53346
S'097410/Wellcome Trust/United Kingdom'
p53347
aS'Wellcome Trust/United Kingdom'
p53348
asS'VI'
p53349
S'12'
p53350
sS'IS'
p53351
S'1471-2431 (Electronic) 1471-2431 (Linking)'
p53352
sS'PMC'
p53353
S'PMC3468389'
p53354
sS'AU'
p53355
(lp53356
S'Chetty T'
p53357
aS'Knight S'
p53358
aS'Giddy J'
p53359
aS'Crankshaw TL'
p53360
aS'Butler LM'
p53361
aS'Newell ML'
p53362
asS'MHDA'
p53363
S'2012/12/22 06:00'
p53364
sS'PHST'
p53365
(lp53366
S'2012/04/04 [received]'
p53367
aS'2012/08/31 [accepted]'
p53368
aS'2012/09/10 [aheadofprint]'
p53369
asS'OID'
p53370
(lp53371
S'NLM: PMC3468389'
p53372
asS'MH'
p53373
(lp53374
S'Adult'
p53375
aS'Anti-Retroviral Agents/therapeutic use'
p53376
aS'Female'
p53377
aS'Follow-Up Studies'
p53378
aS'HIV Infections/diagnosis/mortality/prevention & control/*transmission'
p53379
aS'Hospitals, Urban'
p53380
aS'Humans'
p53381
aS'Infant'
p53382
aS'Infant, Newborn'
p53383
aS'Infectious Disease Transmission, Vertical/*prevention & control/statistics & numerical data'
p53384
aS'Kaplan-Meier Estimate'
p53385
aS'Lost to Follow-Up'
p53386
aS'Male'
p53387
aS'*Postnatal Care'
p53388
aS'Preventive Health Services/*methods'
p53389
aS'Program Evaluation'
p53390
aS'Proportional Hazards Models'
p53391
aS'Retrospective Studies'
p53392
aS'South Africa'
p53393
asS'EDAT'
p53394
S'2012/09/12 06:00'
p53395
sS'SO'
p53396
S'BMC Pediatr. 2012 Sep 10;12:146. doi: 10.1186/1471-2431-12-146.'
p53397
sS'SB'
p53398
S'IM'
p53399
sS'PMID'
p53400
S'22963527'
p53401
sS'TA'
p53402
S'BMC Pediatr'
p53403
sS'PST'
p53404
S'epublish'
p53405
stRp53406
ag2
(g3
g4
(dp53407
S'STAT'
p53408
S'MEDLINE'
p53409
sS'DEP'
p53410
S'20120822'
p53411
sS'DA'
p53412
S'20120910'
p53413
sS'CRDT'
p53414
(lp53415
S'2012/09/11 06:00'
p53416
asS'DP'
p53417
S'2012 Sep'
p53418
sS'OWN'
p53419
S'NLM'
p53420
sS'PT'
p53421
(lp53422
S'Journal Article'
p53423
asS'LA'
p53424
(lp53425
S'eng'
p53426
asS'FAU'
p53427
(lp53428
S'Jones, Martin'
p53429
aS'Stander, Maryna'
p53430
aS'van Zyl, Marlene'
p53431
aS'Cameron, David'
p53432
asS'JT'
p53433
S'South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde'
p53434
sS'LR'
p53435
S'20140912'
p53436
sS'PG'
p53437
S'768-9'
p53438
sS'TI'
p53439
S'Recall of lost-to-follow-up pre-antiretroviral therapy patients in the Eastern Cape: effect of mentoring on patient care.'
p53440
sS'RN'
p53441
(lp53442
S'0 (Anti-HIV Agents)'
p53443
asS'PL'
p53444
S'South Africa'
p53445
sS'TA'
p53446
S'S Afr Med J'
p53447
sS'JID'
p53448
S'0404520'
p53449
sS'AB'
p53450
S'BACKGROUND: In 2011 an experienced HIV nurse from the UK was deployed for 3 months to act as a mentor to nurses learning to initiate antiretroviral therapy (ART) in primary care clinics in a small town in the Eastern Cape, South Africa. METHODS: A review of existing pre-ART patient files (N=286) was carried out and lost-to-follow-up (LTFU) HIV patients were recalled. RESULTS: Only 24% of patients had attended the clinics within the preceding 6 months and 20% had not attended for longer than 2 years. Two lay counsellors visited 222 patients to encourage them to return to care; 65/286 (23%) were untraceable, 11/286 (4%) had relocated, 30/286 (10%) declined, and 8/286 (3%) had died. In the 6 weeks following recall, 51/286 patients (18%) returned to the clinics. CD4 count testing was repeated and screening for tuberculosis (TB) and other opportunistic infections was performed for all patients; ART was initiated in 13/51 (25%), 1 patient tested positive for TB, and isionazid (INH) prophylaxis was initiated in 23/51 (45%). The cost of recall was R130/patient. Within 6 months, all clinics began providing full ART services, 17 professional nurses were mentored and they initiated ART in 55 patients. CONCLUSIONS: Mentoring plays an important role in professional nurse training and support. Recall of LTFU patients is feasible and effective in improving ART services in rural settings.'
p53451
sS'AD'
p53452
S'East Sussex Healthcare NHS Trust, Eastbourne, UK. david.cameron@up.ac.za'
p53453
sS'IP'
p53454
S'9'
sS'IS'
p53455
S'0256-9574 (Print)'
p53456
sS'DCOM'
p53457
S'20121101'
p53458
sS'AU'
p53459
(lp53460
S'Jones M'
p53461
aS'Stander M'
p53462
aS'van Zyl M'
p53463
aS'Cameron D'
p53464
asS'VI'
p53465
S'102'
p53466
sS'MHDA'
p53467
S'2012/11/02 06:00'
p53468
sS'PHST'
p53469
(lp53470
S'2012/04/30 [received]'
p53471
aS'2012/05/09 [accepted]'
p53472
asS'MH'
p53473
(lp53474
S'Anti-HIV Agents/*therapeutic use'
p53475
aS'Antiretroviral Therapy, Highly Active'
p53476
aS'Follow-Up Studies'
p53477
aS'HIV Infections/*drug therapy/*psychology'
p53478
aS'Humans'
p53479
aS'*Patient Compliance'
p53480
aS'*Reminder Systems'
p53481
aS'South Africa'
p53482
asS'EDAT'
p53483
S'2012/09/11 06:00'
p53484
sS'SO'
p53485
S'S Afr Med J. 2012 Aug 22;102(9):768-9.'
p53486
sS'SB'
p53487
S'IM'
p53488
sS'PMID'
p53489
S'22958703'
p53490
sS'PST'
p53491
S'epublish'
p53492
stRp53493
ag2
(g3
g4
(dp53494
S'LID'
p53495
S'10.1371/journal.pone.0041212 [doi]'
p53496
sS'STAT'
p53497
S'MEDLINE'
p53498
sS'DEP'
p53499
S'20120905'
p53500
sS'DA'
p53501
S'20120907'
p53502
sS'AID'
p53503
(lp53504
S'10.1371/journal.pone.0041212 [doi]'
p53505
aS'PONE-D-12-08773 [pii]'
p53506
asS'CRDT'
p53507
(lp53508
S'2012/09/08 06:00'
p53509
asS'DP'
p53510
S'2012'
p53511
sS'AD'
p53512
S'David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America.'
p53513
sS'OWN'
p53514
S'NLM'
p53515
sS'PT'
p53516
(lp53517
S'Journal Article'
p53518
aS'Research Support, N.I.H., Extramural'
p53519
asS'LA'
p53520
(lp53521
S'eng'
p53522
asS'FAU'
p53523
(lp53524
S'Wagner, Bradley G'
p53525
aS'Blower, Sally'
p53526
asS'JT'
p53527
S'PloS one'
p53528
sS'LR'
p53529
S'20150223'
p53530
sS'PG'
p53531
S'e41212'
p53532
sS'TI'
p53533
S"Universal access to HIV treatment versus universal 'test and treat': transmission, drug resistance & treatment costs."
p53534
sS'PL'
p53535
S'United States'
p53536
sS'TA'
p53537
S'PLoS One'
p53538
sS'JID'
p53539
S'101285081'
p53540
sS'AB'
p53541
S"In South Africa (SA) universal access to treatment for HIV-infected individuals in need has yet to be achieved. Currently ~1 million receive treatment, but an additional 1.6 million are in need. It is being debated whether to use a universal 'test and treat' (T&T) strategy to try to eliminate HIV in SA; treatment reduces infectivity and hence transmission. Under a T&T strategy all HIV-infected individuals would receive treatment whether in need or not. This would require treating 5 million individuals almost immediately and providing treatment for several decades. We use a validated mathematical model to predict impact and costs of: (i) a universal T&T strategy and (ii) achieving universal access to treatment. Using modeling the WHO has predicted a universal T&T strategy in SA would eliminate HIV within a decade, and (after 40 years) cost ~$10 billion less than achieving universal access. In contrast, we predict a universal T&T strategy in SA could eliminate HIV, but take 40 years and cost ~$12 billion more than achieving universal access. We determine the difference in predictions is because the WHO has under-estimated survival time on treatment and ignored the risk of resistance. We predict, after 20 years, ~2 million individuals would need second-line regimens if a universal T&T strategy is implemented versus ~1.5 million if universal access is achieved. Costs need to be realistically estimated and multiple evaluation criteria used to compare 'treatment as prevention' with other prevention strategies. Before implementing a universal T&T strategy, which may not be sustainable, we recommend striving to achieve universal access to treatment as quickly as possible. We predict achieving universal access to treatment would be a very effective 'treatment as prevention' approach and bring the HIV epidemic in SA close to elimination, preventing ~4 million infections after 20 years and ~11 million after 40 years."
p53542
sS'GR'
p53543
(lp53544
S'R01 AI041935/AI/NIAID NIH HHS/United States'
p53545
aS'R21 AI086701/AI/NIAID NIH HHS/United States'
p53546
asS'IP'
p53547
S'9'
sS'IS'
p53548
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p53549
sS'PMC'
p53550
S'PMC3434222'
p53551
sS'DCOM'
p53552
S'20130214'
p53553
sS'AU'
p53554
(lp53555
S'Wagner BG'
p53556
aS'Blower S'
p53557
asS'VI'
p53558
S'7'
sS'MHDA'
p53559
S'2013/02/15 06:00'
p53560
sS'PHST'
p53561
(lp53562
S'2012/03/26 [received]'
p53563
aS'2012/06/18 [accepted]'
p53564
aS'2012/09/05 [epublish]'
p53565
asS'OID'
p53566
(lp53567
S'NLM: PMC3434222'
p53568
asS'MH'
p53569
(lp53570
S'CD4-Positive T-Lymphocytes/cytology'
p53571
aS'Communicable Disease Control'
p53572
aS'*Drug Resistance, Viral'
p53573
aS'HIV Infections/diagnosis/economics/epidemiology/*therapy'
p53574
aS'Health Care Costs'
p53575
aS'Health Services Accessibility'
p53576
aS'Health Services Needs and Demand/economics'
p53577
aS'Humans'
p53578
aS'Models, Theoretical'
p53579
aS'Prevalence'
p53580
aS'South Africa'
p53581
aS'World Health Organization'
p53582
asS'EDAT'
p53583
S'2012/09/08 06:00'
p53584
sS'SO'
p53585
S'PLoS One. 2012;7(9):e41212. doi: 10.1371/journal.pone.0041212. Epub 2012 Sep 5.'
p53586
sS'SB'
p53587
S'IM'
p53588
sS'PMID'
p53589
S'22957012'
p53590
sS'PST'
p53591
S'ppublish'
p53592
stRp53593
ag2
(g3
g4
(dp53594
S'LID'
p53595
S'10.7326/0003-4819-157-5-201209040-00004 [doi]'
p53596
sS'STAT'
p53597
S'MEDLINE'
p53598
sS'JT'
p53599
S'Annals of internal medicine'
p53600
sS'MID'
p53601
(lp53602
S'NIHMS422794'
p53603
asS'DA'
p53604
S'20120904'
p53605
sS'AID'
p53606
(lp53607
S'1355683 [pii]'
p53608
aS'10.7326/0003-4819-157-5-201209040-00004 [doi]'
p53609
asS'CRDT'
p53610
(lp53611
S'2012/09/05 06:00'
p53612
asS'DP'
p53613
S'2012 Sep 4'
p53614
sS'AD'
p53615
S'Doris Duke Medical Research Institute, 2nd Floor, University of KwaZulu-Natal, 719 Umbilo Road, Private Bag X7, Congella, 4013, Durban, South Africa.'
p53616
sS'OWN'
p53617
S'NLM'
p53618
sS'PT'
p53619
(lp53620
S'Journal Article'
p53621
aS'Randomized Controlled Trial'
p53622
aS'Research Support, N.I.H., Extramural'
p53623
aS"Research Support, U.S. Gov't, Non-P.H.S."
p53624
asS'LA'
p53625
(lp53626
S'eng'
p53627
asS'FAU'
p53628
(lp53629
S'Naidoo, Kogieleum'
p53630
aS'Yende-Zuma, Nonhlanhla'
p53631
aS'Padayatchi, Nesri'
p53632
aS'Naidoo, Kasavan'
p53633
aS'Jithoo, Niraksha'
p53634
aS'Nair, Gonasagrie'
p53635
aS'Bamber, Sheila'
p53636
aS'Gengiah, Santhana'
p53637
aS'El-Sadr, Wafaa M'
p53638
aS'Friedland, Gerald'
p53639
aS'Abdool Karim, Salim'
p53640
asS'LR'
p53641
S'20150223'
p53642
sS'PG'
p53643
S'313-24'
p53644
sS'TI'
p53645
S'The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial.'
p53646
sS'RN'
p53647
(lp53648
S'0 (Anti-Retroviral Agents)'
p53649
aS'0 (Antibiotics, Antitubercular)'
p53650
aS'VJT6J7R4TR (Rifampin)'
p53651
asS'PL'
p53652
S'United States'
p53653
sS'TA'
p53654
S'Ann Intern Med'
p53655
sS'JID'
p53656
S'0372351'
p53657
sS'AB'
p53658
S'BACKGROUND: Concerns about the immune reconstitution inflammatory syndrome (IRIS) remain a barrier to antiretroviral therapy (ART) initiation during antituberculosis treatment in co-infected patients. OBJECTIVE: To assess IRIS incidence, severity, and outcomes relative to the timing of ART initiation in patients with HIV-related tuberculosis. DESIGN: Randomized, open-label clinical trial. (ClinicalTrials.gov registration number: NCT00398996) SETTING: An outpatient clinic in Durban, South Africa. PATIENTS: 642 patients co-infected with HIV and tuberculosis. MEASUREMENTS: In a secondary analysis of the SAPiT (Starting Antiretroviral Therapy at Three Points in Tuberculosis) trial, IRIS was assessed in patients randomly assigned to initiate ART within 4 weeks of tuberculosis treatment initiation (early integrated treatment group), within 4 weeks of completion of the intensive phase of tuberculosis treatment (late integrated treatment group), or within 4 weeks after tuberculosis therapy completion (sequential treatment group). The syndrome was defined as new-onset or worsening symptoms, signs, or radiographic manifestations temporally related to treatment initiation, accompanied by a treatment response. Severity of IRIS, hospitalization, and time to resolution were monitored. RESULTS: Incidence of IRIS was 19.5 (n = 43), 7.5 (n = 18), and 8.1 (n = 19) per 100 person-years in the early integrated, late integrated, and sequential treatment groups, respectively. Among patients with a baseline CD4+ count less than 0.050 x 109 cells/L, IRIS incidence was 45.5, 9.7, and 19.7 per 100 person-years in the early integrated, late integrated, and sequential treatment groups, respectively. Incidence of IRIS was higher in the early integrated treatment group than in the late integrated (incidence rate ratio, 2.6 [95% CI, 1.5 to 4.8]; P < 0.001) or sequential (incidence rate ratio, 2.4 [CI, 1.4 to 4.4]; P < 0.001) treatment groups. More severe IRIS cases occurred in the early integrated treatment group than in the other 2 groups (35% vs. 19%; P = 0.179), and patients in the early integrated treatment group had significantly higher hospitalization rates (42% vs. 14%; P = 0.007) and longer time to resolution (70.5 vs. 29.0 days; P = 0.001) than patients in the other 2 groups. LIMITATIONS: It was not possible to assess IRIS in more patients in the sequential treatment group (n = 74) than in the late integrated (n = 50) and early integrated (n = 32) treatment groups because of loss to follow-up, withdrawal, or death within 6 months of scheduled ART initiation. This study did not assess IRIS risk in nonambulatory patients or in those with extrapulmonary and smear-negative tuberculosis. CONCLUSION: Initiation of ART in early stages of tuberculosis treatment resulted in significantly higher IRIS rates, longer time to resolution, and more severe cases of IRIS requiring hospitalization. These findings are particularly relevant to patients initiating ART with a CD4+ count less than 0.050 x 109 cells/L, given the increased survival benefit of early ART initiation in this group. PRIMARY FUNDING SOURCE: Comprehensive International Program of Research on AIDS.'
p53659
sS'GR'
p53660
(lp53661
S'AI51794/AI/NIAID NIH HHS/United States'
p53662
aS'D43 TW000231/TW/FIC NIH HHS/United States'
p53663
aS'D43TW00231/TW/FIC NIH HHS/United States'
p53664
aS'U19 AI051794/AI/NIAID NIH HHS/United States'
p53665
asS'IP'
p53666
S'5'
sS'IS'
p53667
S'1539-3704 (Electronic) 0003-4819 (Linking)'
p53668
sS'PMC'
p53669
S'PMC3534856'
p53670
sS'DCOM'
p53671
S'20121112'
p53672
sS'AU'
p53673
(lp53674
S'Naidoo K'
p53675
aS'Yende-Zuma N'
p53676
aS'Padayatchi N'
p53677
aS'Naidoo K'
p53678
aS'Jithoo N'
p53679
aS'Nair G'
p53680
aS'Bamber S'
p53681
aS'Gengiah S'
p53682
aS'El-Sadr WM'
p53683
aS'Friedland G'
p53684
aS'Abdool Karim S'
p53685
asS'VI'
p53686
S'157'
p53687
sS'MHDA'
p53688
S'2012/11/13 06:00'
p53689
sS'OID'
p53690
(lp53691
S'NLM: NIHMS422794'
p53692
aS'NLM: PMC3534856'
p53693
asS'MH'
p53694
(lp53695
S'AIDS-Related Opportunistic Infections/complications/*drug therapy'
p53696
aS'Adult'
p53697
aS'Anti-Retroviral Agents/*adverse effects'
p53698
aS'Antibiotics, Antitubercular/therapeutic use'
p53699
aS'CD4 Lymphocyte Count'
p53700
aS'Female'
p53701
aS'HIV Infections/complications/*drug therapy/immunology'
p53702
aS'Humans'
p53703
aS'Immune Reconstitution Inflammatory Syndrome/epidemiology/*etiology'
p53704
aS'Immunocompromised Host'
p53705
aS'Incidence'
p53706
aS'Kaplan-Meier Estimate'
p53707
aS'Male'
p53708
aS'Prospective Studies'
p53709
aS'Rifampin/therapeutic use'
p53710
aS'Risk Factors'
p53711
aS'Severity of Illness Index'
p53712
aS'Tuberculosis/complications/*drug therapy'
p53713
asS'EDAT'
p53714
S'2012/09/05 06:00'
p53715
sS'SI'
p53716
(lp53717
S'ClinicalTrials.gov/NCT00398996'
p53718
asS'SO'
p53719
S'Ann Intern Med. 2012 Sep 4;157(5):313-24. doi: 10.7326/0003-4819-157-5-201209040-00004.'
p53720
sS'SB'
p53721
S'AIM IM'
p53722
sS'PMID'
p53723
S'22944873'
p53724
sS'PST'
p53725
S'ppublish'
p53726
stRp53727
ag2
(g3
g4
(dp53728
S'LID'
p53729
S'10.1111/j.1365-3156.2011.02889.x [doi]'
p53730
sS'STAT'
p53731
S'MEDLINE'
p53732
sS'DEP'
p53733
S'20110930'
p53734
sS'CI'
p53735
(lp53736
S'(c) 2011 Blackwell Publishing Ltd.'
p53737
asS'DA'
p53738
S'20120904'
p53739
sS'AID'
p53740
(lp53741
S'10.1111/j.1365-3156.2011.02889.x [doi]'
p53742
asS'CRDT'
p53743
(lp53744
S'2012/09/05 06:00'
p53745
asS'DP'
p53746
S'2012 Jan'
p53747
sS'AD'
p53748
S'KEMRI/Wellcome Trust Centre for Geographic Medicine Research (Coast), Kilifi, Kenya. ahassan@kilifi.kemri-wellcome.org'
p53749
sS'OWN'
p53750
S'NLM'
p53751
sS'PT'
p53752
(lp53753
S'Journal Article'
p53754
aS"Research Support, Non-U.S. Gov't"
p53755
asS'LA'
p53756
(lp53757
S'eng'
p53758
asS'FAU'
p53759
(lp53760
S'Hassan, Amin S'
p53761
aS'Fielding, Katherine L'
p53762
aS'Thuo, Nahashon M'
p53763
aS'Nabwera, Helen M'
p53764
aS'Sanders, Eduard J'
p53765
aS'Berkley, James A'
p53766
asS'JT'
p53767
S'Tropical medicine & international health : TM & IH'
p53768
sS'LR'
p53769
S'20150223'
p53770
sS'PG'
p53771
S'82-93'
p53772
sS'TI'
p53773
S'Early loss to follow-up of recently diagnosed HIV-infected adults from routine pre-ART care in a rural district hospital in Kenya: a cohort study.'
p53774
sS'RN'
p53775
(lp53776
S'0 (Anti-HIV Agents)'
p53777
asS'PL'
p53778
S'England'
p53779
sS'TA'
p53780
S'Trop Med Int Health'
p53781
sS'JID'
p53782
S'9610576'
p53783
sS'AB'
p53784
S'OBJECTIVE: To determine the rate and predictors of early loss to follow-up (LTFU) for recently diagnosed HIV-infected, antiretroviral therapy (ART)-ineligible adults in rural Kenya. METHODS: Prospective cohort study. Clients registering for HIV care between July 2008 and August 2009 were followed up for 6 months. Baseline data were used to assess predictors of pre-ART LTFU (not returning for care within 2 months of a scheduled appointment), LTFU before the second visit and LTFU after the second visit. Logistic regression was used to determine factors associated with LTFU before the second visit, while Cox regression was used to assess predictors of time to LTFU and LTFU after the second visit. RESULTS: Of 530 eligible clients, 178 (33.6%) were LTFU from pre-ART care (11.1/100 person-months). Of these, 96 (53.9%) were LTFU before the second visit. Distance (>5 km vs. <1 km: adjusted hazard ratio 2.6 [1.9-3.7], P < 0.01) and marital status (married vs. single: 0.5 [0.3-0.6], P < 0.01) independently predicted pre-ART LTFU. Distance and marital status were independently associated with LTFU before the second visit, while distance, education status and seasonality showed weak evidence of predicting LTFU after the second visit. HIV disease severity did not predict pre-ART LTFU. CONCLUSIONS: A third of recently diagnosed HIV-infected, ART-ineligible clients were LTFU within 6 months of registration. Predictors of LTFU among ART-ineligible clients are different from those among clients on ART. These findings warrant consideration of an enhanced pre-ART care package aimed at improving retention and timely ART initiation.'
p53785
sS'GR'
p53786
(lp53787
S'092654/Wellcome Trust/United Kingdom'
p53788
aS'G0700837/Medical Research Council/United Kingdom'
p53789
aS'Wellcome Trust/United Kingdom'
p53790
asS'IP'
p53791
S'1'
sS'IS'
p53792
S'1365-3156 (Electronic) 1360-2276 (Linking)'
p53793
sS'PMC'
p53794
S'PMC4230408'
p53795
sS'DCOM'
p53796
S'20121119'
p53797
sS'AU'
p53798
(lp53799
S'Hassan AS'
p53800
aS'Fielding KL'
p53801
aS'Thuo NM'
p53802
aS'Nabwera HM'
p53803
aS'Sanders EJ'
p53804
aS'Berkley JA'
p53805
asS'VI'
p53806
S'17'
p53807
sS'MHDA'
p53808
S'2012/12/10 06:00'
p53809
sS'PHST'
p53810
(lp53811
S'2011/09/30 [aheadofprint]'
p53812
asS'OID'
p53813
(lp53814
S'NLM: PMC4230408'
p53815
asS'MH'
p53816
(lp53817
S'Adolescent'
p53818
aS'Adult'
p53819
aS'Aged'
p53820
aS'Anti-HIV Agents/*therapeutic use'
p53821
aS'Educational Status'
p53822
aS'Female'
p53823
aS'Follow-Up Studies'
p53824
aS'HIV Infections/*drug therapy'
p53825
aS'*Health Services Accessibility'
p53826
aS'Hospitals, District'
p53827
aS'Hospitals, Rural'
p53828
aS'Humans'
p53829
aS'Kenya'
p53830
aS'Lost to Follow-Up'
p53831
aS'Male'
p53832
aS'*Marital Status'
p53833
aS'Middle Aged'
p53834
aS'*Patient Compliance'
p53835
aS'Proportional Hazards Models'
p53836
aS'Prospective Studies'
p53837
aS'Seasons'
p53838
aS'Social Class'
p53839
aS'Young Adult'
p53840
asS'EDAT'
p53841
S'2012/09/05 06:00'
p53842
sS'SO'
p53843
S'Trop Med Int Health. 2012 Jan;17(1):82-93. doi: 10.1111/j.1365-3156.2011.02889.x. Epub 2011 Sep 30.'
p53844
sS'SB'
p53845
S'IM'
p53846
sS'PMID'
p53847
S'22943164'
p53848
sS'PST'
p53849
S'ppublish'
p53850
stRp53851
ag2
(g3
g4
(dp53852
S'LID'
p53853
S'10.1186/1471-2458-12-736 [doi]'
p53854
sS'STAT'
p53855
S'MEDLINE'
p53856
sS'DEP'
p53857
S'20120904'
p53858
sS'DA'
p53859
S'20121107'
p53860
sS'AID'
p53861
(lp53862
S'1471-2458-12-736 [pii]'
p53863
aS'10.1186/1471-2458-12-736 [doi]'
p53864
asS'CRDT'
p53865
(lp53866
S'2012/09/05 06:00'
p53867
asS'DP'
p53868
S'2012'
p53869
sS'OWN'
p53870
S'NLM'
p53871
sS'PT'
p53872
(lp53873
S'Journal Article'
p53874
asS'LA'
p53875
(lp53876
S'eng'
p53877
asS'DCOM'
p53878
S'20130506'
p53879
sS'JT'
p53880
S'BMC public health'
p53881
sS'LR'
p53882
S'20150223'
p53883
sS'FAU'
p53884
(lp53885
S'Sempa, Joseph'
p53886
aS'Ssennono, Mark'
p53887
aS'Kuznik, Andreas'
p53888
aS'Lamorde, Mohammed'
p53889
aS'Sowinski, Stefanie'
p53890
aS'Semeere, Aggrey'
p53891
aS'Hermans, Sabine'
p53892
aS'Castelnuovo, Barbara'
p53893
aS'Manabe, Yukari C'
p53894
asS'TI'
p53895
S'Cost-effectiveness of early initiation of first-line combination antiretroviral therapy in Uganda.'
p53896
sS'RN'
p53897
(lp53898
S'0 (Anti-Retroviral Agents)'
p53899
asS'PL'
p53900
S'England'
p53901
sS'PG'
p53902
S'736'
p53903
sS'JID'
p53904
S'100968562'
p53905
sS'AB'
p53906
S"BACKGROUND: Ugandan national guidelines recommend initiation of combination antiretroviral therapy (cART) at CD4+ T cell (CD4) count below 350 cell/mul, but the implementation of this is limited due to availability of medication. However, cART initiation at higher CD4 count increases survival, albeit at higher lifetime treatment cost. This analysis evaluates the cost-effectiveness of initiating cART at a CD4 count between 250-350 cell/mul (early) versus <250 cell/mul (delayed). METHODS: Life expectancy of cART-treated patients, conditional on baseline CD4 count, was modeled based on published literature. First-line cART costs $192 annually, with an additional $113 for patient monitoring. Delaying initiation of cART until the CD4 count falls below 250 cells/mul would incur the cost of the bi-annual CD4 count tests and routine maintenance care at $85 annually. We compared lifetime treatment costs and disability adjusted life-expectancy between early vs. delayed cART for ten baseline CD4 count ranges from 250-350 cell/mul. All costs and benefits were discounted at 3% annually. RESULTS: Treatment delay varied from 6-18 months. Early cART initiation increased life expectancy from 1.5-3.5 years and averted 1.33-3.10 disability adjusted life years (DALY's) per patient. Lifetime treatment costs were $4,300-$5,248 for early initiation and $3,940-$4,435 for delayed initiation. The cost/DALY averted of the early versus delayed start ranged from $260-$270. CONCLUSIONS: In HIV-positive patients presenting with CD4 count between 250-350 cells/mul, immediate initiation of cART is a highly cost-effective strategy using the recommended one-time per capita GDP threshold of $490 reported for Uganda. This would constitute an efficient use of scarce health care funds."
p53907
sS'AD'
p53908
S'Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda. jsempa@idi.co.ug'
p53909
sS'VI'
p53910
S'12'
p53911
sS'IS'
p53912
S'1471-2458 (Electronic) 1471-2458 (Linking)'
p53913
sS'PMC'
p53914
S'PMC3491016'
p53915
sS'AU'
p53916
(lp53917
S'Sempa J'
p53918
aS'Ssennono M'
p53919
aS'Kuznik A'
p53920
aS'Lamorde M'
p53921
aS'Sowinski S'
p53922
aS'Semeere A'
p53923
aS'Hermans S'
p53924
aS'Castelnuovo B'
p53925
aS'Manabe YC'
p53926
asS'MHDA'
p53927
S'2013/05/07 06:00'
p53928
sS'PHST'
p53929
(lp53930
S'2012/02/28 [received]'
p53931
aS'2012/08/29 [accepted]'
p53932
aS'2012/09/04 [aheadofprint]'
p53933
asS'OID'
p53934
(lp53935
S'NLM: PMC3491016'
p53936
asS'MH'
p53937
(lp53938
S'Anti-Retroviral Agents/economics/*therapeutic use'
p53939
aS'Antiretroviral Therapy, Highly Active'
p53940
aS'CD4 Lymphocyte Count'
p53941
aS'Cost-Benefit Analysis'
p53942
aS'Drug Therapy, Combination/*economics'
p53943
aS'Early Diagnosis'
p53944
aS'HIV Infections/drug therapy/mortality'
p53945
aS'Humans'
p53946
aS'Quality-Adjusted Life Years'
p53947
aS'Uganda/epidemiology'
p53948
asS'EDAT'
p53949
S'2012/09/05 06:00'
p53950
sS'SO'
p53951
S'BMC Public Health. 2012 Sep 4;12:736. doi: 10.1186/1471-2458-12-736.'
p53952
sS'SB'
p53953
S'IM'
p53954
sS'PMID'
p53955
S'22943068'
p53956
sS'TA'
p53957
S'BMC Public Health'
p53958
sS'PST'
p53959
S'epublish'
p53960
stRp53961
ag2
(g3
g4
(dp53962
S'LID'
p53963
S'10.1371/journal.pone.0043281 [doi]'
p53964
sS'STAT'
p53965
S'MEDLINE'
p53966
sS'DEP'
p53967
S'20120817'
p53968
sS'DA'
p53969
S'20120822'
p53970
sS'AID'
p53971
(lp53972
S'10.1371/journal.pone.0043281 [doi]'
p53973
aS'PONE-D-12-13853 [pii]'
p53974
asS'CRDT'
p53975
(lp53976
S'2012/08/23 06:00'
p53977
asS'DP'
p53978
S'2012'
p53979
sS'AD'
p53980
S'Harvard Medical School, Boston, Massachusetts, United States of America.'
p53981
sS'OWN'
p53982
S'NLM'
p53983
sS'PT'
p53984
(lp53985
S'Journal Article'
p53986
aS'Research Support, N.I.H., Extramural'
p53987
aS"Research Support, Non-U.S. Gov't"
p53988
asS'LA'
p53989
(lp53990
S'eng'
p53991
asS'FAU'
p53992
(lp53993
S'Hom, Jeffrey K'
p53994
aS'Wang, Bingxia'
p53995
aS'Chetty, Senica'
p53996
aS'Giddy, Janet'
p53997
aS'Mazibuko, Matilda'
p53998
aS'Allen, Jenny'
p53999
aS'Walensky, Rochelle P'
p54000
aS'Losina, Elena'
p54001
aS'Freedberg, Kenneth A'
p54002
aS'Bassett, Ingrid V'
p54003
asS'JT'
p54004
S'PloS one'
p54005
sS'LR'
p54006
S'20150428'
p54007
sS'PG'
p54008
S'e43281'
p54009
sS'TI'
p54010
S'Drug-resistant tuberculosis among HIV-infected patients starting antiretroviral therapy in Durban, South Africa.'
p54011
sS'RN'
p54012
(lp54013
S'0 (Anti-Retroviral Agents)'
p54014
aS'59-01-8 (Kanamycin)'
p54015
aS'8G167061QZ (Ethambutol)'
p54016
aS'V83O1VOZ8L (Isoniazid)'
p54017
aS'VJT6J7R4TR (Rifampin)'
p54018
aS'Y45QSO73OB (Streptomycin)'
p54019
asS'PL'
p54020
S'United States'
p54021
sS'TA'
p54022
S'PLoS One'
p54023
sS'JID'
p54024
S'101285081'
p54025
sS'AB'
p54026
S'OBJECTIVE: To estimate the prevalence of drug-resistant tuberculosis (TB) and describe the resistance patterns in patients commencing antiretroviral therapy (ART) in an HIV clinic in Durban, South Africa. DESIGN: Cross-sectional cohort study. METHODS: Consecutive HIV-infected adults (>/= 18y/o) initiating HIV care were enrolled from May 2007-May 2008, regardless of signs or symptoms of active TB. Prior TB history and current TB treatment status were self-reported. Subjects expectorated sputum for culture (MGIT liquid and 7H11 solid medium). Positive cultures were tested for susceptibility to first- and second-line anti-tuberculous drugs. The prevalence of drug-resistant TB, stratified by prior TB history and current TB treatment status, was assessed. RESULTS: 1,035 subjects had complete culture results. Median CD4 count was 92/microl (IQR 42-150/microl). 267 subjects (26%) reported a prior history of TB and 210 (20%) were receiving TB treatment at enrollment; 191 (18%) subjects had positive sputum cultures, among whom the estimated prevalence of resistance to any antituberculous drug was 7.4% (95% CI 4.0-12.4). Among those with prior TB, the prevalence of resistance was 15.4% (95% CI 5.9-30.5) compared to 5.2% (95% CI 2.1-8.9) among those with no prior TB. 5.1% (95% CI 2.4-9.5) had rifampin or rifampin plus INH resistance. CONCLUSIONS: The prevalence of TB resistance to at least one drug was 7.4% among adults with positive TB cultures initiating ART in Durban, South Africa, with 5.1% having rifampin or rifampin plus INH resistance. Improved tools for diagnosing TB and drug resistance are urgently needed in areas of high HIV/TB prevalence.'
p54027
sS'GR'
p54028
(lp54029
S'K23 AI 068458/AI/NIAID NIH HHS/United States'
p54030
aS'K23 AI068458/AI/NIAID NIH HHS/United States'
p54031
aS'K24 AI062476/AI/NIAID NIH HHS/United States'
p54032
aS'K24 AI062476/AI/NIAID NIH HHS/United States'
p54033
aS'P30 AI060354/AI/NIAID NIH HHS/United States'
p54034
aS'R01 AI058736/AI/NIAID NIH HHS/United States'
p54035
aS'R01 MH073445/MH/NIMH NIH HHS/United States'
p54036
aS'R01 MH073445/MH/NIMH NIH HHS/United States'
p54037
aS'R01 MH090326/MH/NIMH NIH HHS/United States'
p54038
aS'R01MH90326/MH/NIMH NIH HHS/United States'
p54039
aS'PEPFAR/United States'
p54040
asS'IP'
p54041
S'8'
sS'IS'
p54042
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p54043
sS'PMC'
p54044
S'PMC3422270'
p54045
sS'DCOM'
p54046
S'20130501'
p54047
sS'AU'
p54048
(lp54049
S'Hom JK'
p54050
aS'Wang B'
p54051
aS'Chetty S'
p54052
aS'Giddy J'
p54053
aS'Mazibuko M'
p54054
aS'Allen J'
p54055
aS'Walensky RP'
p54056
aS'Losina E'
p54057
aS'Freedberg KA'
p54058
aS'Bassett IV'
p54059
asS'VI'
p54060
S'7'
sS'MHDA'
p54061
S'2013/05/02 06:00'
p54062
sS'PHST'
p54063
(lp54064
S'2012/05/14 [received]'
p54065
aS'2012/07/23 [accepted]'
p54066
aS'2012/08/17 [epublish]'
p54067
asS'OID'
p54068
(lp54069
S'NLM: PMC3422270'
p54070
asS'MH'
p54071
(lp54072
S'Adult'
p54073
aS'Anti-Retroviral Agents/*therapeutic use'
p54074
aS'CD4 Lymphocyte Count'
p54075
aS'Cohort Studies'
p54076
aS'Cross-Sectional Studies'
p54077
aS'Drug Resistance, Multiple, Bacterial/physiology'
p54078
aS'Ethambutol'
p54079
aS'Female'
p54080
aS'HIV Infections/*complications/*drug therapy/*epidemiology'
p54081
aS'Humans'
p54082
aS'Isoniazid'
p54083
aS'Kanamycin'
p54084
aS'Male'
p54085
aS'Prevalence'
p54086
aS'Rifampin'
p54087
aS'South Africa/epidemiology'
p54088
aS'Sputum/microbiology'
p54089
aS'Streptomycin'
p54090
aS'Tuberculosis, Multidrug-Resistant/*complications/*epidemiology'
p54091
asS'EDAT'
p54092
S'2012/08/23 06:00'
p54093
sS'SO'
p54094
S'PLoS One. 2012;7(8):e43281. doi: 10.1371/journal.pone.0043281. Epub 2012 Aug 17.'
p54095
sS'SB'
p54096
S'IM'
p54097
sS'PMID'
p54098
S'22912845'
p54099
sS'PST'
p54100
S'ppublish'
p54101
stRp54102
ag2
(g3
g4
(dp54103
S'LID'
p54104
S'10.1371/journal.pone.0041166 [doi]'
p54105
sS'STAT'
p54106
S'MEDLINE'
p54107
sS'DEP'
p54108
S'20120809'
p54109
sS'DA'
p54110
S'20120822'
p54111
sS'AID'
p54112
(lp54113
S'10.1371/journal.pone.0041166 [doi]'
p54114
aS'PONE-D-12-06910 [pii]'
p54115
asS'CRDT'
p54116
(lp54117
S'2012/08/23 06:00'
p54118
asS'DP'
p54119
S'2012'
p54120
sS'EIN'
p54121
(lp54122
S'PLoS One. 2012;7(9). doi: 10.1371/annotation/71a6d947-c034-4749-a33d-971284ea3408'
p54123
asS'OWN'
p54124
S'NLM'
p54125
sS'PT'
p54126
(lp54127
S'Evaluation Studies'
p54128
aS'Journal Article'
p54129
aS"Research Support, Non-U.S. Gov't"
p54130
aS"Research Support, U.S. Gov't, P.H.S."
p54131
asS'LA'
p54132
(lp54133
S'eng'
p54134
asS'FAU'
p54135
(lp54136
S'Bergeron, Michele'
p54137
aS'Daneau, Geraldine'
p54138
aS'Ding, Tao'
p54139
aS'Sitoe, Nadia E'
p54140
aS'Westerman, Larry E'
p54141
aS'Stokx, Jocelijn'
p54142
aS'Jani, Ilesh V'
p54143
aS'Coetzee, Lindi M'
p54144
aS'Scott, Lesley'
p54145
aS'De Weggheleire, Anja'
p54146
aS'Boel, Luc'
p54147
aS'Stevens, Wendy S'
p54148
aS'Glencross, Deborah K'
p54149
aS'Peter, Trevor F'
p54150
asS'JT'
p54151
S'PloS one'
p54152
sS'LR'
p54153
S'20150223'
p54154
sS'PG'
p54155
S'e41166'
p54156
sS'TI'
p54157
S'Performance of the PointCare NOW system for CD4 counting in HIV patients based on five independent evaluations.'
p54158
sS'RN'
p54159
(lp54160
S'0 (Anti-HIV Agents)'
p54161
asS'PL'
p54162
S'United States'
p54163
sS'TA'
p54164
S'PLoS One'
p54165
sS'JID'
p54166
S'101285081'
p54167
sS'AB'
p54168
S'INTRODUCTION: Point-of-care (POC) CD4 testing can improve access to treatment by enabling decentralization and reducing patient loss-to-follow-up. As new POC CD4 technologies become available, their performance should be assessed before widespread deployment. This study reports the findings of five independent evaluations of the PointCare NOW CD4 system. MATERIALS/METHODS: Evaluations were conducted in Southern Africa (Mozambique, South Africa) and North America (Canada, USA). 492 blood samples (55 from HIV-negative blood donors and 437 from HIV-infected patients, including 20 children aged between 12 and 59 months) were tested with both the PointCare NOW and reference flow cytometry instruments. Assessment of bias, precision and levels of clinical misclassification for absolute and percent CD4 count was conducted. RESULTS: PointCare NOW significantly overestimated CD4 absolute counts with a mean relative bias of +35.0%. Bias was greater in samples with CD4 counts below </= 350 cells/microl (+51.3%) than in the CD4 >350 cells/microl stratum (15.1%). Bias in CD4% had a similar trend with an overall relative mean bias of +25.6% and a larger bias for low CD4 stratum (+40.2%) than the higher CD4 stratum (+5.8%). Relative bias for CD4% in children was -6.8%. In terms of repeatability, PointCare NOW had a coefficient of variation of 11%. Using a threshold of 350 cells/microl, only 47% of patients who qualified for antiretroviral therapy with reference CD4 testing, would have been eligible for treatment with PointCare NOW test results. This was 39% using a 200 cells/microl threshold. Agreement with infant samples was higher, with 90% qualifying at a 25% eligibility threshold. CONCLUSION: The performance of the PointCare NOW instrument for absolute and percent CD4 enumeration was inadequate for HIV clinical management in adults. In children, the small sample size was not large enough to draw a conclusion. This study also highlights the importance of independent evaluation of new diagnostic technology platforms before deployment.'
p54169
sS'AD'
p54170
S'Public Health Agency of Canada, National Laboratory for HIV Immunology, Ottawa, Canada.'
p54171
sS'IP'
p54172
S'8'
sS'IS'
p54173
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p54174
sS'PMC'
p54175
S'PMC3415398'
p54176
sS'DCOM'
p54177
S'20130423'
p54178
sS'AU'
p54179
(lp54180
S'Bergeron M'
p54181
aS'Daneau G'
p54182
aS'Ding T'
p54183
aS'Sitoe NE'
p54184
aS'Westerman LE'
p54185
aS'Stokx J'
p54186
aS'Jani IV'
p54187
aS'Coetzee LM'
p54188
aS'Scott L'
p54189
aS'De Weggheleire A'
p54190
aS'Boel L'
p54191
aS'Stevens WS'
p54192
aS'Glencross DK'
p54193
aS'Peter TF'
p54194
asS'VI'
p54195
S'7'
sS'MHDA'
p54196
S'2013/04/24 06:00'
p54197
sS'PHST'
p54198
(lp54199
S'2012/02/17 [received]'
p54200
aS'2012/06/02 [accepted]'
p54201
aS'2012/08/09 [epublish]'
p54202
asS'OID'
p54203
(lp54204
S'NLM: PMC3415398'
p54205
asS'MH'
p54206
(lp54207
S'Adult'
p54208
aS'Anti-HIV Agents/therapeutic use'
p54209
aS'CD4 Lymphocyte Count/*methods/standards'
p54210
aS'Child, Preschool'
p54211
aS'Eligibility Determination'
p54212
aS'HIV Infections/drug therapy/*immunology'
p54213
aS'Humans'
p54214
aS'Infant'
p54215
aS'*Point-of-Care Systems/standards'
p54216
aS'Quality Control'
p54217
aS'Sensitivity and Specificity'
p54218
asS'EDAT'
p54219
S'2012/08/23 06:00'
p54220
sS'SO'
p54221
S'PLoS One. 2012;7(8):e41166. doi: 10.1371/journal.pone.0041166. Epub 2012 Aug 9.'
p54222
sS'SB'
p54223
S'IM'
p54224
sS'PMID'
p54225
S'22912668'
p54226
sS'PST'
p54227
S'ppublish'
p54228
stRp54229
ag2
(g3
g4
(dp54230
S'STAT'
p54231
S'MEDLINE'
p54232
sS'JT'
p54233
S'Journal of the International AIDS Society'
p54234
sS'DA'
p54235
S'20120817'
p54236
sS'CRDT'
p54237
(lp54238
S'2012/08/21 06:00'
p54239
asS'DP'
p54240
S'2012'
p54241
sS'OWN'
p54242
S'NLM'
p54243
sS'PT'
p54244
(lp54245
S'Journal Article'
p54246
asS'LA'
p54247
(lp54248
S'eng'
p54249
asS'FAU'
p54250
(lp54251
S'Weigel, Ralf'
p54252
aS'Feldacker, Caryl'
p54253
aS'Tweya, Hannock'
p54254
aS'Gondwe, Chimwemwe'
p54255
aS'Chiwoko, Jane'
p54256
aS'Gumulira, Joe'
p54257
aS'Kalulu, Mike'
p54258
aS'Phiri, Sam'
p54259
asS'LR'
p54260
S'20150223'
p54261
sS'PG'
p54262
S'17432'
p54263
sS'TI'
p54264
S'Managing HIV-infected children in a low-resource, public clinic: a comparison of nurse vs. clinical officer practices in ART refill, calculation of adherence and subsequent appointments.'
p54265
sS'RN'
p54266
(lp54267
S'0 (Anti-Retroviral Agents)'
p54268
asS'PL'
p54269
S'Switzerland'
p54270
sS'TA'
p54271
S'J Int AIDS Soc'
p54272
sS'JID'
p54273
S'101478566'
p54274
sS'AB'
p54275
S"BACKGROUND: In Malawi, as in other sub-Saharan African countries, nurses manage patients of all ages on antiretroviral treatment(ART). Nurse management of children is rarely studied.We compare ART prescribing between nurses and clinical officers during routine clinic visits at an urban, public clinic to inform policy in paediatric ART management. METHODS: Caregivers of children on first-line ART provided information about visit dates, pill counts, ART dosage and formulation to a nurse and, subsequently, to a clinical officer. Nurses and clinical officers independently calculated adherence, dosage based on body weight, and set next appointment date. Clinical officers, but not nurses, accessed an electronic data system that made the calculations for them based on information from prior visits, actual and expected pill consumption, and standard drug supplies. Nurses calculated with pen and paper. For numerical variables, Bland-Altman graphs plot differences of each nurse clinical officer pair against the mean, show the 95% limits of agreement (LoA), and also show the mean difference across all reviews. Kappa statistics assess agreement for categorical variables. RESULTS: A total of 704 matched nurse clinical officer reviews of 367 children attending the ART clinics between March and July 2010 were analyzed. Eight nurses and 18 clinical officers were involved; two nurses and five clinical officers managed 100 visits or more. Overall, there was a good agreement between the two cadres. Differences between nurses and clinical officers were within narrow LoA and mean differences showed little deviation from zero, indicating little skewing towards one cadre. LoA of adherence and morning and evening ART dosages varied from -24% to 24%, -0.4 to 0.4 and -0.41 to 0.40 tablets,respectively, with mean differences (95% CI) of 0.003 (-0.9, 0.91), -0.005 (-0.02, 0.01) and -0.009 (-0.02, 0.01). Next appointment calculations differed more between cadres with LoA from -40 to 42 days [mean difference: 0.96 days (95%CI:-0.6 to 2.5)], but agreement in the ART formulation prescribed was very good (kappa 0.93). CONCLUSIONS: Nurses' ART prescribing practices and calculations of adherence and next appointments are similar to clinical officers, although clinical officers used an electronic system. Our findings support the decision of Malawi's health officials to utilize nurses to manage paediatric ART patients."
p54276
sS'AD'
p54277
S'Lighthouse Trust at Kamuzu Central Hospital, Lilongwe, Malawi. Ralf.Weigel@liverpool.ac.uk'
p54278
sS'IP'
p54279
S'2'
sS'IS'
p54280
S'1758-2652 (Electronic) 1758-2652 (Linking)'
p54281
sS'PMC'
p54282
S'PMC3494175'
p54283
sS'DCOM'
p54284
S'20121017'
p54285
sS'AU'
p54286
(lp54287
S'Weigel R'
p54288
aS'Feldacker C'
p54289
aS'Tweya H'
p54290
aS'Gondwe C'
p54291
aS'Chiwoko J'
p54292
aS'Gumulira J'
p54293
aS'Kalulu M'
p54294
aS'Phiri S'
p54295
asS'VI'
p54296
S'15'
p54297
sS'MHDA'
p54298
S'2012/10/18 06:00'
p54299
sS'OID'
p54300
(lp54301
S'NLM: PMC3494175'
p54302
asS'MH'
p54303
(lp54304
S'Anti-Retroviral Agents/*administration & dosage'
p54305
aS'Antiretroviral Therapy, Highly Active/*methods'
p54306
aS'Appointments and Schedules'
p54307
aS'Child'
p54308
aS'Child, Preschool'
p54309
aS'Delivery of Health Care/*methods/organization & administration'
p54310
aS'Female'
p54311
aS'HIV Infections/*drug therapy'
p54312
aS'Health Personnel'
p54313
aS'*Health Services Research'
p54314
aS'Humans'
p54315
aS'Malawi'
p54316
aS'Male'
p54317
aS'Medication Adherence/*statistics & numerical data'
p54318
aS'Urban Population'
p54319
asS'EDAT'
p54320
S'2012/08/21 06:00'
p54321
sS'SO'
p54322
S'J Int AIDS Soc. 2012;15(2):17432.'
p54323
sS'SB'
p54324
S'IM X'
p54325
sS'PMID'
p54326
S'22905359'
p54327
sS'PST'
p54328
S'ppublish'
p54329
stRp54330
ag2
(g3
g4
(dp54331
S'LID'
p54332
S'10.1371/journal.pone.0042834 [doi]'
p54333
sS'STAT'
p54334
S'MEDLINE'
p54335
sS'DEP'
p54336
S'20120808'
p54337
sS'DA'
p54338
S'20120820'
p54339
sS'AID'
p54340
(lp54341
S'10.1371/journal.pone.0042834 [doi]'
p54342
aS'PONE-D-12-03555 [pii]'
p54343
asS'CRDT'
p54344
(lp54345
S'2012/08/21 06:00'
p54346
asS'DP'
p54347
S'2012'
p54348
sS'OWN'
p54349
S'NLM'
p54350
sS'PT'
p54351
(lp54352
S'Journal Article'
p54353
aS"Research Support, Non-U.S. Gov't"
p54354
asS'LA'
p54355
(lp54356
S'eng'
p54357
asS'FAU'
p54358
(lp54359
S'von Wyl, Viktor'
p54360
aS'Cambiano, Valentina'
p54361
aS'Jordan, Michael R'
p54362
aS'Bertagnolio, Silvia'
p54363
aS'Miners, Alec'
p54364
aS'Pillay, Deenan'
p54365
aS'Lundgren, Jens'
p54366
aS'Phillips, Andrew N'
p54367
asS'JT'
p54368
S'PloS one'
p54369
sS'LR'
p54370
S'20151119'
p54371
sS'PG'
p54372
S'e42834'
p54373
sS'TI'
p54374
S'Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring.'
p54375
sS'RN'
p54376
(lp54377
S'0 (Anti-Retroviral Agents)'
p54378
aS'0 (Organophosphonates)'
p54379
aS'4B9XT59T7S (Zidovudine)'
p54380
aS'99YXE507IL (Tenofovir)'
p54381
aS'JAC85A2161 (Adenine)'
p54382
asS'PL'
p54383
S'United States'
p54384
sS'TA'
p54385
S'PLoS One'
p54386
sS'JID'
p54387
S'101285081'
p54388
sS'AB'
p54389
S'BACKGROUND: The most recent World Health Organization (WHO) antiretroviral treatment guidelines recommend the inclusion of zidovudine (ZDV) or tenofovir (TDF) in first-line therapy. We conducted a cost-effectiveness analysis with emphasis on emerging patterns of drug resistance upon treatment failure and their impact on second-line therapy. METHODS: We used a stochastic simulation of a generalized HIV-1 epidemic in sub-Saharan Africa to compare two strategies for first-line combination antiretroviral treatment including lamivudine, nevirapine and either ZDV or TDF. Model input parameters were derived from literature and, for the simulation of resistance pathways, estimated from drug resistance data obtained after first-line treatment failure in settings without virological monitoring. Treatment failure and cost effectiveness were determined based on WHO definitions. Two scenarios with optimistic (no emergence; base) and pessimistic (extensive emergence) assumptions regarding occurrence of multidrug resistance patterns were tested. RESULTS: In the base scenario, cumulative proportions of treatment failure according to WHO criteria were higher among first-line ZDV users (median after six years 36% [95% simulation interval 32%; 39%]) compared with first-line TDF users (31% [29%; 33%]). Consequently, a higher proportion initiated second-line therapy (including lamivudine, boosted protease inhibitors and either ZDV or TDF) in the first-line ZDV user group 34% [31%; 37%] relative to first-line TDF users (30% [27%; 32%]). At the time of second-line initiation, a higher proportion (16%) of first-line ZDV users harboured TDF-resistant HIV compared with ZDV-resistant viruses among first-line TDF users (0% and 6% in base and pessimistic scenarios, respectively). In the base scenario, the incremental cost effectiveness ratio with respect to quality adjusted life years (QALY) was US$83 when TDF instead of ZDV was used in first-line therapy (pessimistic scenario: US$ 315), which was below the WHO threshold for high cost effectiveness (US$ 2154). CONCLUSIONS: Using TDF instead of ZDV in first-line treatment in resource-limited settings is very cost-effective and likely to better preserve future treatment options in absence of virological monitoring.'
p54390
sS'AD'
p54391
S'Research Department of Infection and Population Health, University College London, London, United Kingdom. viktor.vonwyl@css-institut.ch'
p54392
sS'IP'
p54393
S'8'
sS'IS'
p54394
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p54395
sS'PMC'
p54396
S'PMC3414499'
p54397
sS'DCOM'
p54398
S'20130211'
p54399
sS'AU'
p54400
(lp54401
S'von Wyl V'
p54402
aS'Cambiano V'
p54403
aS'Jordan MR'
p54404
aS'Bertagnolio S'
p54405
aS'Miners A'
p54406
aS'Pillay D'
p54407
aS'Lundgren J'
p54408
aS'Phillips AN'
p54409
asS'VI'
p54410
S'7'
sS'MHDA'
p54411
S'2013/02/12 06:00'
p54412
sS'PHST'
p54413
(lp54414
S'2012/02/02 [received]'
p54415
aS'2012/07/12 [accepted]'
p54416
aS'2012/08/08 [epublish]'
p54417
asS'OID'
p54418
(lp54419
S'NLM: PMC3414499'
p54420
asS'MH'
p54421
(lp54422
S'Adenine/*analogs & derivatives/economics/pharmacology'
p54423
aS'Adult'
p54424
aS'Africa South of the Sahara'
p54425
aS'Anti-Retroviral Agents/*economics/pharmacology'
p54426
aS'Cost-Benefit Analysis'
p54427
aS'Drug Resistance, Viral'
p54428
aS'Epidemics'
p54429
aS'Female'
p54430
aS'Genotype'
p54431
aS'HIV Infections/*drug therapy/epidemiology'
p54432
aS'HIV-1/metabolism'
p54433
aS'Humans'
p54434
aS'Male'
p54435
aS'Middle Aged'
p54436
aS'Organophosphonates/*economics/pharmacology'
p54437
aS'Stochastic Processes'
p54438
aS'Tenofovir'
p54439
aS'Treatment Outcome'
p54440
aS'Zidovudine/*economics/pharmacology'
p54441
asS'EDAT'
p54442
S'2012/08/21 06:00'
p54443
sS'SO'
p54444
S'PLoS One. 2012;7(8):e42834. doi: 10.1371/journal.pone.0042834. Epub 2012 Aug 8.'
p54445
sS'SB'
p54446
S'IM'
p54447
sS'PMID'
p54448
S'22905175'
p54449
sS'PST'
p54450
S'ppublish'
p54451
stRp54452
ag2
(g3
g4
(dp54453
S'LID'
p54454
S'10.1007/s10067-012-2058-5 [doi]'
p54455
sS'STAT'
p54456
S'MEDLINE'
p54457
sS'DEP'
p54458
S'20120819'
p54459
sS'DA'
p54460
S'20121030'
p54461
sS'AID'
p54462
(lp54463
S'10.1007/s10067-012-2058-5 [doi]'
p54464
asS'CRDT'
p54465
(lp54466
S'2012/08/21 06:00'
p54467
asS'DP'
p54468
S'2012 Nov'
p54469
sS'OWN'
p54470
S'NLM'
p54471
sS'PT'
p54472
(lp54473
S'Journal Article'
p54474
asS'LA'
p54475
(lp54476
S'eng'
p54477
asS'FAU'
p54478
(lp54479
S'Rachid, Bahiri'
p54480
aS'El Zorkany, Bassel'
p54481
aS'Youseif, Ehab'
p54482
aS'Tikly, Mohammed'
p54483
asS'JT'
p54484
S'Clinical rheumatology'
p54485
sS'PG'
p54486
S'1633-9'
p54487
sS'TI'
p54488
S'Early diagnosis and treatment of ankylosing spondylitis in Africa and the Middle East.'
p54489
sS'RN'
p54490
(lp54491
S'0 (Anti-Inflammatory Agents)'
p54492
aS'0 (HLA-B27 Antigen)'
p54493
asS'PL'
p54494
S'Germany'
p54495
sS'TA'
p54496
S'Clin Rheumatol'
p54497
sS'JID'
p54498
S'8211469'
p54499
sS'AB'
p54500
S'Ankylosing spondylitis (AS) is the prototype for spondyloarthritis primarily affecting young men. Geographic and ethnic variations exist in the prevalence and severity of AS and relate to the wide disparity in the frequency of human leukocyte antigen (HLA)-B27, a major genetic risk factor. The strength of the disease association with HLA-B27 is lower in most Arab populations (25-75 %) than in Western European populations (>90 %), and there is no association in sub-Saharan Africa, where the prevalence of HLA-B27 is <1 %. Other epidemiologic differences between European and African populations are the apparent later age at presentation in sub-Saharan Africa, and the high rate of spondyloarthropathies associated with human immunodeficiency virus infection. Diagnosis of AS is often delayed 8-10 years; potential reasons for the delay in Africa and the Middle East include low awareness among physicians and patients, the requirement for radiographic evidence of sacroiliitis for diagnosis, and limited access to magnetic resonance imaging in some countries. Treatment should be initiated early to prevent or reduce skeletal deformity and physical disability. Nonsteroidal anti-inflammatory drugs are effective first-line treatment and anti-tumor necrosis factor-alpha drugs are indicated for patients who have an inadequate response to first-line therapy. In Africa and the Middle East, such treatments may be precluded either by cost or contraindicated because of the high prevalence of latent tuberculosis infection. Research is sorely needed to develop cost-effective tools to diagnose AS early as well as effective, inexpensive, and safe treatments for these developing regions.'
p54501
sS'AD'
p54502
S'Rheumatology Department, El Ayachi Hospital, Route de la plage, CHU Rabat, Sale, Morocco. bahirirachid@yahoo.fr'
p54503
sS'IP'
p54504
S'11'
p54505
sS'IS'
p54506
S'1434-9949 (Electronic) 0770-3198 (Linking)'
p54507
sS'DCOM'
p54508
S'20130424'
p54509
sS'AU'
p54510
(lp54511
S'Rachid B'
p54512
aS'El Zorkany B'
p54513
aS'Youseif E'
p54514
aS'Tikly M'
p54515
asS'VI'
p54516
S'31'
p54517
sS'MHDA'
p54518
S'2013/04/25 06:00'
p54519
sS'PHST'
p54520
(lp54521
S'2012/05/16 [received]'
p54522
aS'2012/08/05 [accepted]'
p54523
aS'2012/07/12 [revised]'
p54524
aS'2012/08/19 [aheadofprint]'
p54525
asS'MH'
p54526
(lp54527
S'Adult'
p54528
aS'Africa'
p54529
aS'Anti-Inflammatory Agents/pharmacology'
p54530
aS'Cost-Benefit Analysis'
p54531
aS'Early Diagnosis'
p54532
aS'Female'
p54533
aS'HLA-B27 Antigen/blood/genetics'
p54534
aS'Humans'
p54535
aS'Magnetic Resonance Imaging/methods'
p54536
aS'Male'
p54537
aS'Middle Aged'
p54538
aS'Middle East'
p54539
aS'Prevalence'
p54540
aS'Rheumatology/methods'
p54541
aS'Risk Factors'
p54542
aS'Spondylitis, Ankylosing/*therapy'
p54543
aS'Time Factors'
p54544
asS'EDAT'
p54545
S'2012/08/21 06:00'
p54546
sS'SO'
p54547
S'Clin Rheumatol. 2012 Nov;31(11):1633-9. doi: 10.1007/s10067-012-2058-5. Epub 2012 Aug 19.'
p54548
sS'SB'
p54549
S'IM'
p54550
sS'PMID'
p54551
S'22903740'
p54552
sS'PST'
p54553
S'ppublish'
p54554
stRp54555
ag2
(g3
g4
(dp54556
S'LID'
p54557
S'10.1542/peds.2011-1187 [doi]'
p54558
sS'STAT'
p54559
S'MEDLINE'
p54560
sS'DEP'
p54561
S'20120813'
p54562
sS'DA'
p54563
S'20120903'
p54564
sS'AID'
p54565
(lp54566
S'peds.2011-1187 [pii]'
p54567
aS'10.1542/peds.2011-1187 [doi]'
p54568
asS'CRDT'
p54569
(lp54570
S'2012/08/15 06:00'
p54571
asS'DP'
p54572
S'2012 Sep'
p54573
sS'AD'
p54574
S"Baylor College of Medicine Abbott Fund Children's Clinical Centre of Excellence-Malawi, Private Bag B397, Lilongwe 03, Malawi. mmkabue@gmail.com"
p54575
sS'OWN'
p54576
S'NLM'
p54577
sS'PT'
p54578
(lp54579
S'Journal Article'
p54580
aS'Research Support, N.I.H., Extramural'
p54581
aS"Research Support, Non-U.S. Gov't"
p54582
asS'LA'
p54583
(lp54584
S'eng'
p54585
asS'FAU'
p54586
(lp54587
S'Kabue, Mark M'
p54588
aS'Buck, W Chris'
p54589
aS'Wanless, Sebastian R'
p54590
aS'Cox, Carrie M'
p54591
aS'McCollum, Eric D'
p54592
aS'Caviness, A Chantal'
p54593
aS'Ahmed, Saeed'
p54594
aS'Kim, Maria H'
p54595
aS'Thahane, Lineo'
p54596
aS'Devlin, Andrew'
p54597
aS'Kochelani, Duncan'
p54598
aS'Kazembe, Peter N'
p54599
aS'Calles, Nancy R'
p54600
aS'Mizwa, Michael B'
p54601
aS'Schutze, Gordon E'
p54602
aS'Kline, Mark W'
p54603
asS'JT'
p54604
S'Pediatrics'
p54605
sS'LR'
p54606
S'20150721'
p54607
sS'PG'
p54608
S'e591-9'
p54609
sS'TI'
p54610
S'Mortality and clinical outcomes in HIV-infected children on antiretroviral therapy in Malawi, Lesotho, and Swaziland.'
p54611
sS'RN'
p54612
(lp54613
S'0 (Anti-Retroviral Agents)'
p54614
asS'PL'
p54615
S'United States'
p54616
sS'TA'
p54617
S'Pediatrics'
p54618
sS'JID'
p54619
S'0376422'
p54620
sS'AB'
p54621
S'OBJECTIVE: To determine mortality and immune status improvement in HIV-infected pediatric patients on antiretroviral treatment (ART) in Malawi, Lesotho, and Swaziland. METHODS: We conducted a retrospective cohort study of patients aged <12 years at ART initiation at 3 sites in sub-Saharan Africa between 2004 and 2009. Twelve-month and overall mortality were estimated, and factors associated with mortality and immune status improvement were evaluated. RESULTS: Included in the study were 2306 patients with an average follow-up time on ART of 2.3 years (interquartile range 1.5-3.1 years). One hundred four patients (4.5%) died, 9.0% were lost to follow-up, and 1.3% discontinued ART. Of the 104 deaths, 77.9% occurred in the first year of treatment with a 12-month mortality rate of 3.5%. The overall mortality rate was 2.25 deaths/100 person-years (95% confidence interval [CI] 1.84-2.71). Increased 12-month mortality was associated with younger age; <6 months (hazard ratio [HR] = 8.11, CI 4.51-14.58), 6 to <12 months (HR = 3.43, CI 1.96-6.02), and 12 to <36 months (HR = 1.92, CI 1.16-3.19), and World Health Organization stage IV (HR = 4.35, CI 2.19-8.67). Immune status improvement at 12 months was less likely in patients with advanced disease and age <12 months. CONCLUSIONS: Despite challenges associated with pediatric ART in developing countries, low mortality and good treatment outcomes can be achieved. However, outcomes are worse in younger patients and those with advanced disease at the time of ART initiation, highlighting the importance of early diagnosis and treatment.'
p54622
sS'GR'
p54623
(lp54624
S'D43 TW01036/TW/FIC NIH HHS/United States'
p54625
aS'P30 AI036211/AI/NIAID NIH HHS/United States'
p54626
aS'T32 HL072748/HL/NHLBI NIH HHS/United States'
p54627
asS'IP'
p54628
S'3'
sS'IS'
p54629
S'1098-4275 (Electronic) 0031-4005 (Linking)'
p54630
sS'PMC'
p54631
S'PMC3962849'
p54632
sS'DCOM'
p54633
S'20121109'
p54634
sS'AU'
p54635
(lp54636
S'Kabue MM'
p54637
aS'Buck WC'
p54638
aS'Wanless SR'
p54639
aS'Cox CM'
p54640
aS'McCollum ED'
p54641
aS'Caviness AC'
p54642
aS'Ahmed S'
p54643
aS'Kim MH'
p54644
aS'Thahane L'
p54645
aS'Devlin A'
p54646
aS'Kochelani D'
p54647
aS'Kazembe PN'
p54648
aS'Calles NR'
p54649
aS'Mizwa MB'
p54650
aS'Schutze GE'
p54651
aS'Kline MW'
p54652
asS'VI'
p54653
S'130'
p54654
sS'MHDA'
p54655
S'2012/11/10 06:00'
p54656
sS'PHST'
p54657
(lp54658
S'2012/08/13 [aheadofprint]'
p54659
asS'OID'
p54660
(lp54661
S'NLM: PMC3962849'
p54662
asS'MH'
p54663
(lp54664
S'Anti-Retroviral Agents/*therapeutic use'
p54665
aS'CD4 Lymphocyte Count'
p54666
aS'Child'
p54667
aS'Child, Preschool'
p54668
aS'Female'
p54669
aS'HIV Infections/*drug therapy/immunology/*mortality'
p54670
aS'Humans'
p54671
aS'Infant'
p54672
aS'Lesotho/epidemiology'
p54673
aS'Malawi/epidemiology'
p54674
aS'Male'
p54675
aS'Nutritional Status'
p54676
aS'Swaziland/epidemiology'
p54677
asS'EDAT'
p54678
S'2012/08/15 06:00'
p54679
sS'SO'
p54680
S'Pediatrics. 2012 Sep;130(3):e591-9. doi: 10.1542/peds.2011-1187. Epub 2012 Aug 13.'
p54681
sS'SB'
p54682
S'AIM IM'
p54683
sS'PMID'
p54684
S'22891234'
p54685
sS'PST'
p54686
S'ppublish'
p54687
stRp54688
ag2
(g3
g4
(dp54689
S'LID'
p54690
S'10.5588/ijtld.11.0589 [doi]'
p54691
sS'STAT'
p54692
S'MEDLINE'
p54693
sS'DEP'
p54694
S'20120803'
p54695
sS'DA'
p54696
S'20121030'
p54697
sS'AID'
p54698
(lp54699
S'ijtld110589 [pii]'
p54700
aS'10.5588/ijtld.11.0589 [doi]'
p54701
asS'CRDT'
p54702
(lp54703
S'2012/08/07 06:00'
p54704
asS'DP'
p54705
S'2012 Oct'
p54706
sS'AD'
p54707
S'Infectious Diseases Clinic, Mbarara University of Science and Technology, Mbarara, Uganda. dnansera@yahoo.co.uk'
p54708
sS'OWN'
p54709
S'NLM'
p54710
sS'PT'
p54711
(lp54712
S'Comparative Study'
p54713
aS'Journal Article'
p54714
aS'Research Support, N.I.H., Extramural'
p54715
aS"Research Support, Non-U.S. Gov't"
p54716
asS'LA'
p54717
(lp54718
S'eng'
p54719
asS'FAU'
p54720
(lp54721
S'Nansera, D'
p54722
aS'Bajunirwe, F'
p54723
aS'Elyanu, P'
p54724
aS'Asiimwe, C'
p54725
aS'Amanyire, G'
p54726
aS'Graziano, F M'
p54727
asS'JT'
p54728
S'The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease'
p54729
sS'PG'
p54730
S'1371-6'
p54731
sS'TI'
p54732
S'Mortality and loss to follow-up among tuberculosis and HIV co-infected patients in rural southwestern Uganda.'
p54733
sS'RN'
p54734
(lp54735
S'0 (Anti-HIV Agents)'
p54736
asS'PL'
p54737
S'France'
p54738
sS'TA'
p54739
S'Int J Tuberc Lung Dis'
p54740
sS'JID'
p54741
S'9706389'
p54742
sS'AB'
p54743
S"BACKGROUND: We describe the presentation and outcome of care among patients with tuberculosis (TB) and human immunodeficiency virus (HIV) co-infection from a prospective observational cohort in Uganda. METHODS: We analysed basic demographics, CD4+ counts, time of initiating antiretroviral therapy (ART), clinical and haematological parameters and outcome of care of 386 patients enrolled between February 2007 and March 2010. RESULTS: At presentation, 56.7% of the patients were sputum-positive, 89.9% had new TB infection, 62.7% had wasting, 78.7% were anaemic, 72.1% had a CD4+ count of <200 cells/mm(3), 20.2% had pneumonia, 50.3% had oral thrush and 1.3% had Kaposi's sarcoma. Patients developing TB within 3 months of starting ART were less likely to have wasting, to be anaemic or to have a CD4+ count of <100 cells/mm(3). The cure, default and death rates were respectively 54.3%, 24% and 16%. At 8 months, 53 (13.7%) were confirmed dead, 119 (30.8%) were lost to follow-up, 28 (7.3%) were transferred out and 1 (0.3%) had treatment failure. Mortality and loss to follow-up were associated with failure to start ART and having a CD4+ count of <200 cells/mm(3). CONCLUSION: In Uganda, TB-HIV patients present with severe immune suppression and are at increased risk of death and loss to follow-up, particularly those not on ART. There is need for early identification and improved follow-up of TB-HIV co-infected patients."
p54744
sS'GR'
p54745
(lp54746
S'U2RTW006879/PHS HHS/United States'
p54747
asS'IP'
p54748
S'10'
p54749
sS'IS'
p54750
S'1815-7920 (Electronic) 1027-3719 (Linking)'
p54751
sS'DCOM'
p54752
S'20130117'
p54753
sS'AU'
p54754
(lp54755
S'Nansera D'
p54756
aS'Bajunirwe F'
p54757
aS'Elyanu P'
p54758
aS'Asiimwe C'
p54759
aS'Amanyire G'
p54760
aS'Graziano FM'
p54761
asS'VI'
p54762
S'16'
p54763
sS'MHDA'
p54764
S'2013/01/18 06:00'
p54765
sS'PHST'
p54766
(lp54767
S'2012/08/03 [aheadofprint]'
p54768
asS'MH'
p54769
(lp54770
S'Adult'
p54771
aS'Anti-HIV Agents/therapeutic use'
p54772
aS'CD4 Lymphocyte Count'
p54773
aS'Coinfection'
p54774
aS'Female'
p54775
aS'HIV'
p54776
aS'HIV Infections/complications/drug therapy/*mortality'
p54777
aS'Humans'
p54778
aS'*Lost to Follow-Up'
p54779
aS'Male'
p54780
aS'Prospective Studies'
p54781
aS'Risk Factors'
p54782
aS'*Rural Population'
p54783
aS'Tuberculosis/complications/drug therapy/*mortality'
p54784
aS'Uganda/epidemiology'
p54785
asS'EDAT'
p54786
S'2012/08/07 06:00'
p54787
sS'SO'
p54788
S'Int J Tuberc Lung Dis. 2012 Oct;16(10):1371-6. doi: 10.5588/ijtld.11.0589. Epub 2012 Aug 3.'
p54789
sS'SB'
p54790
S'IM'
p54791
sS'PMID'
p54792
S'22863182'
p54793
sS'PST'
p54794
S'ppublish'
p54795
stRp54796
ag2
(g3
g4
(dp54797
S'LID'
p54798
S'10.1089/aid.2011.0300 [doi]'
p54799
sS'STAT'
p54800
S'MEDLINE'
p54801
sS'DEP'
p54802
S'20120803'
p54803
sS'DA'
p54804
S'20130122'
p54805
sS'AID'
p54806
(lp54807
S'10.1089/aid.2011.0300 [doi]'
p54808
asS'CRDT'
p54809
(lp54810
S'2012/08/07 06:00'
p54811
asS'DP'
p54812
S'2013 Feb'
p54813
sS'OWN'
p54814
S'NLM'
p54815
sS'PT'
p54816
(lp54817
S'Journal Article'
p54818
aS"Research Support, Non-U.S. Gov't"
p54819
asS'LA'
p54820
(lp54821
S'eng'
p54822
asS'FAU'
p54823
(lp54824
S'Kebe, Khady'
p54825
aS'Thiam, Moussa'
p54826
aS'Diagne Gueye, Ndeye Rama'
p54827
aS'Diop, Halimatou'
p54828
aS'Dia, Aichatou'
p54829
aS'Signate Sy, Haby'
p54830
aS'Charpentier, Charlotte'
p54831
aS'Belec, Laurent'
p54832
aS'Mboup, Souleymane'
p54833
aS'Toure Kane, Coumba'
p54834
asS'JT'
p54835
S'AIDS research and human retroviruses'
p54836
sS'PG'
p54837
S'242-9'
p54838
sS'TI'
p54839
S'High rate of antiretroviral drug resistance mutations in HIV type 1-infected Senegalese children in virological failure on first-line treatment according to the World Health Organization guidelines.'
p54840
sS'RN'
p54841
(lp54842
S'0 (Anti-Retroviral Agents)'
p54843
aS'0 (RNA, Viral)'
p54844
aS'EC 2.7.7.- (reverse transcriptase, Human immunodeficiency virus 1)'
p54845
aS'EC 2.7.7.49 (HIV Reverse Transcriptase)'
p54846
aS'EC 3.4.23.- (HIV Protease)'
p54847
asS'PL'
p54848
S'United States'
p54849
sS'TA'
p54850
S'AIDS Res Hum Retroviruses'
p54851
sS'JID'
p54852
S'8709376'
p54853
sS'AB'
p54854
S'The rates of virological failure (VF) and HIV-1 drug resistance were evaluated in a cross-sectional study in HIV-1-infected children living in Dakar, and taking antiretroviral treatment (ART) according to WHO recommendations. The plasma HIV-1 RNA load was measured using the Abbott m2000 RealTime HIV-1 assay. The full-length protease gene and partial reverse transcriptase gene were sequenced, and resistance mutations were assessed by reference to the Stanford University HIV drug resistance database. Of 125 included children (median age, 7 years) taking first-line ART for a median duration of 20 months, 82 (66%) showed detectable HIV-1 RNA load, and 70 (56%) met the 2010 revised WHO criteria of VF (defined as plasma HIV-1 RNA load >/=3.7 log(10) copies/ml). Drug resistance results were available for 52 children with plasma HIV-1 RNA load >/=3.0 log(10) copies/ml, and viruses carrying resistance mutations were found in 48 (92%) children. Among these 48, mutations conferring resistance to nucleoside reverse transcriptase inhibitors (NRTIs) or non-NRTIs (NNRTIs) were found in 42 (88%) and 47 (99%) children, respectively. The NRTI-resistant viruses harbored the M184V/I (95%), Q151M (2%), and thymidine-analogue mutations (40%), and the NNRTI-resistant viruses harbored the K103N (34%), Y181C (32%), G190A (23%), and K101E (21%) mutations. A high rate (56%) of VF was demonstrated in Senegalese children after 20 months of first-line ART and therapeutic failure was assessed by the presence of antiretroviral drug resistance mutations in 9 out of 10 children in VF. These findings point out the difficulties of optimizing ART in children living in sub-Saharan Africa, and the crucial need of laboratory monitoring reinforcement.'
p54855
sS'AD'
p54856
S'Laboratoire de Bacteriologie-Virologie , CHU Aristide le Dantec, Dakar, Senegal.'
p54857
sS'IP'
p54858
S'2'
sS'IS'
p54859
S'1931-8405 (Electronic) 0889-2229 (Linking)'
p54860
sS'DCOM'
p54861
S'20130701'
p54862
sS'AU'
p54863
(lp54864
S'Kebe K'
p54865
aS'Thiam M'
p54866
aS'Diagne Gueye NR'
p54867
aS'Diop H'
p54868
aS'Dia A'
p54869
aS'Signate Sy H'
p54870
aS'Charpentier C'
p54871
aS'Belec L'
p54872
aS'Mboup S'
p54873
aS'Toure Kane C'
p54874
asS'VI'
p54875
S'29'
p54876
sS'MHDA'
p54877
S'2013/07/03 06:00'
p54878
sS'PHST'
p54879
(lp54880
S'2012/08/03 [aheadofprint]'
p54881
asS'MH'
p54882
(lp54883
S'Adolescent'
p54884
aS'Anti-Retroviral Agents/*pharmacology/therapeutic use'
p54885
aS'Child'
p54886
aS'Child, Preschool'
p54887
aS'Cross-Sectional Studies'
p54888
aS'*Drug Resistance, Viral'
p54889
aS'Female'
p54890
aS'HIV Infections/*drug therapy/epidemiology/*virology'
p54891
aS'HIV Protease/genetics'
p54892
aS'HIV Reverse Transcriptase/genetics'
p54893
aS'HIV-1/*drug effects/*genetics/isolation & purification'
p54894
aS'Humans'
p54895
aS'Male'
p54896
aS'Molecular Sequence Data'
p54897
aS'*Mutation, Missense'
p54898
aS'RNA, Viral/blood/genetics'
p54899
aS'Senegal/epidemiology'
p54900
aS'Sequence Analysis, DNA'
p54901
aS'Treatment Outcome'
p54902
aS'Viral Load'
p54903
asS'EDAT'
p54904
S'2012/08/07 06:00'
p54905
sS'SI'
p54906
(lp54907
S'GENBANK/HM002496'
p54908
aS'GENBANK/HM002497'
p54909
aS'GENBANK/HM002498'
p54910
aS'GENBANK/HM002499'
p54911
aS'GENBANK/HM002500'
p54912
aS'GENBANK/HM002501'
p54913
aS'GENBANK/HM002502'
p54914
aS'GENBANK/HM002503'
p54915
aS'GENBANK/HM002504'
p54916
aS'GENBANK/HM002505'
p54917
aS'GENBANK/HM002506'
p54918
aS'GENBANK/HM002507'
p54919
aS'GENBANK/HM002508'
p54920
aS'GENBANK/HM002509'
p54921
aS'GENBANK/HM002510'
p54922
aS'GENBANK/HM002511'
p54923
aS'GENBANK/HM002512'
p54924
aS'GENBANK/HM002513'
p54925
aS'GENBANK/HM002514'
p54926
aS'GENBANK/HM002515'
p54927
aS'GENBANK/HM002516'
p54928
aS'GENBANK/HM002517'
p54929
aS'GENBANK/HM002518'
p54930
aS'GENBANK/HM002519'
p54931
aS'GENBANK/HM002520'
p54932
aS'GENBANK/HM002521'
p54933
aS'GENBANK/HM002522'
p54934
aS'GENBANK/HM002523'
p54935
aS'GENBANK/HM002524'
p54936
aS'GENBANK/HM002525'
p54937
aS'GENBANK/HM002526'
p54938
aS'GENBANK/HM002527'
p54939
aS'GENBANK/HM002528'
p54940
aS'GENBANK/HM002529'
p54941
aS'GENBANK/HM002530'
p54942
aS'GENBANK/HM002531'
p54943
aS'GENBANK/HM002532'
p54944
aS'GENBANK/HM002533'
p54945
aS'GENBANK/HM002534'
p54946
aS'GENBANK/HM002535'
p54947
aS'GENBANK/HM002536'
p54948
aS'GENBANK/HM002537'
p54949
aS'GENBANK/HM002538'
p54950
aS'GENBANK/HM002539'
p54951
aS'GENBANK/HM002540'
p54952
aS'GENBANK/HM002541'
p54953
aS'GENBANK/HM002542'
p54954
aS'GENBANK/HM002543'
p54955
aS'GENBANK/HM002544'
p54956
aS'GENBANK/HM002545'
p54957
aS'GENBANK/JN193483'
p54958
aS'GENBANK/JN193484'
p54959
aS'GENBANK/JN193485'
p54960
aS'GENBANK/JN193486'
p54961
aS'GENBANK/JN193487'
p54962
aS'GENBANK/JN193488'
p54963
aS'GENBANK/JN193489'
p54964
aS'GENBANK/JN193490'
p54965
aS'GENBANK/JN193491'
p54966
aS'GENBANK/JN193492'
p54967
aS'GENBANK/JN193493'
p54968
aS'GENBANK/JN193494'
p54969
aS'GENBANK/JN193495'
p54970
aS'GENBANK/JN193496'
p54971
aS'GENBANK/JN193497'
p54972
aS'GENBANK/JN193498'
p54973
aS'GENBANK/JN193499'
p54974
aS'GENBANK/JN193500'
p54975
aS'GENBANK/JN193501'
p54976
asS'SO'
p54977
S'AIDS Res Hum Retroviruses. 2013 Feb;29(2):242-9. doi: 10.1089/aid.2011.0300. Epub 2012 Aug 3.'
p54978
sS'SB'
p54979
S'IM X'
p54980
sS'PMID'
p54981
S'22860571'
p54982
sS'PST'
p54983
S'ppublish'
p54984
stRp54985
ag2
(g3
g4
(dp54986
S'LID'
p54987
S'10.1371/journal.pone.0041011 [doi]'
p54988
sS'STAT'
p54989
S'MEDLINE'
p54990
sS'DEP'
p54991
S'20120727'
p54992
sS'DA'
p54993
S'20120731'
p54994
sS'AID'
p54995
(lp54996
S'10.1371/journal.pone.0041011 [doi]'
p54997
aS'PONE-D-11-08927 [pii]'
p54998
asS'CRDT'
p54999
(lp55000
S'2012/08/01 06:00'
p55001
asS'DP'
p55002
S'2012'
p55003
sS'OWN'
p55004
S'NLM'
p55005
sS'PT'
p55006
(lp55007
S'Clinical Trial'
p55008
aS'Journal Article'
p55009
aS'Multicenter Study'
p55010
aS'Research Support, N.I.H., Extramural'
p55011
asS'LA'
p55012
(lp55013
S'eng'
p55014
asS'FAU'
p55015
(lp55016
S'Johnson, Derek C'
p55017
aS'Chasela, Charles'
p55018
aS'Maliwichi, Madalitso'
p55019
aS'Mwafongo, Albert'
p55020
aS'Akinkuotu, Adesola'
p55021
aS'Moses, Agness'
p55022
aS'Jamieson, Denise J'
p55023
aS'Kourtis, Athena P'
p55024
aS'King, Caroline C'
p55025
aS'van der Horst, Charlie'
p55026
aS'Hosseinipour, Mina C'
p55027
asS'JT'
p55028
S'PloS one'
p55029
sS'LR'
p55030
S'20151119'
p55031
sS'PG'
p55032
S'e41011'
p55033
sS'TI'
p55034
S'Tenofovir use and renal insufficiency among pregnant and general adult population of HIV-infected, ART-naive individuals in Lilongwe, Malawi.'
p55035
sS'RN'
p55036
(lp55037
S'0 (Anti-HIV Agents)'
p55038
aS'0 (Benzoxazines)'
p55039
aS'0 (Drug Combinations)'
p55040
aS'0 (Organophosphonates)'
p55041
aS'2T8Q726O95 (Lamivudine)'
p55042
aS'99YXE507IL (Tenofovir)'
p55043
aS'AYI8EX34EU (Creatinine)'
p55044
aS'JAC85A2161 (Adenine)'
p55045
aS'JE6H2O27P8 (efavirenz)'
p55046
asS'PL'
p55047
S'United States'
p55048
sS'TA'
p55049
S'PLoS One'
p55050
sS'JID'
p55051
S'101285081'
p55052
sS'AB'
p55053
S'BACKGROUND: The Malawian government recently changed its prevention of mother-to-child transmission (PMTCT) regimen and plans to change its first-line antiretroviral therapy (ART) regimen to Tenofovir(TDF)/Lamivudine/Efavirenz as a fixed-dose combination tablet. Implementation could be challenging if baseline creatinine clearance (CrCl) screening were required to assess renal function prior to TDF therapy. Our goal is to determine predictors of CrCl<50 ml/min among HIV-infected, ART-naive individuals. METHODOLOGY: Data on HIV-infected, ART-naive adults screened for enrollment into 5 HIV clinical trials in Lilongwe, Malawi were combined for a pooled analysis of predictors for CrCl<50 ml/min. CrCl was derived from the Cockroft-Gault equation. Multivariable logistic regression modeled the association of age, body mass index (BMI), hemoglobin, CD4 cell count <350 cells/mm(3), gender, and pregnancy with CrCl<50 ml/min. RESULTS: The analysis included 3508 patients with values for creatinine clearance. Most subjects were female (90.6%) with a median age of 26 years (IQR 22-29). The median CD4 cell count was 444 (IQR 298.0-561.0), and 85.2% percent of women in our study were pregnant. Few patients had CrCl<50 ml/min (n = 38, 1.1%). A BMI less than 18.5 in non-pregnant females (OR = 8.87, 95% CI = 2.45-32.09)) was associated with CrCl<50 ml/min. Hemoglobin level higher than 10 g/dL in males (OR = 0.69, 95% CI = 0.56-0.86) and non-pregnant females (OR = 0.21, 95% CI = 0.04-0.97) was protective against CrCl<50 ml/min. DISCUSSION: Our findings indicate few patients would be excluded from a TDF-based antiretroviral regimen, suggesting baseline creatinine clearance assessment may not be necessary for implementation. However, in ART settings individuals with low BMI or anemia could potentially be at increased risk for lower CrCl.'
p55054
sS'AD'
p55055
S'University of North Carolina Project Malawi, Lilongwe, Malawi. Frg1@uab.edu'
p55056
sS'IP'
p55057
S'7'
sS'IS'
p55058
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p55059
sS'PMC'
p55060
S'PMC3407169'
p55061
sS'DCOM'
p55062
S'20130402'
p55063
sS'AU'
p55064
(lp55065
S'Johnson DC'
p55066
aS'Chasela C'
p55067
aS'Maliwichi M'
p55068
aS'Mwafongo A'
p55069
aS'Akinkuotu A'
p55070
aS'Moses A'
p55071
aS'Jamieson DJ'
p55072
aS'Kourtis AP'
p55073
aS'King CC'
p55074
aS'van der Horst C'
p55075
aS'Hosseinipour MC'
p55076
asS'VI'
p55077
S'7'
sS'MHDA'
p55078
S'2013/04/03 06:00'
p55079
sS'PHST'
p55080
(lp55081
S'2012/02/22 [received]'
p55082
aS'2012/06/15 [accepted]'
p55083
aS'2012/07/27 [epublish]'
p55084
asS'OID'
p55085
(lp55086
S'NLM: PMC3407169'
p55087
asS'MH'
p55088
(lp55089
S'Adenine/administration & dosage/adverse effects/*analogs & derivatives'
p55090
aS'Adolescent'
p55091
aS'Adult'
p55092
aS'*Anti-HIV Agents/administration & dosage/adverse effects'
p55093
aS'Benzoxazines/administration & dosage/adverse effects'
p55094
aS'Body Mass Index'
p55095
aS'CD4 Lymphocyte Count'
p55096
aS'Creatinine/urine'
p55097
aS'Drug Combinations'
p55098
aS'Female'
p55099
aS'HIV Infections/blood/*drug therapy/epidemiology/urine'
p55100
aS'Humans'
p55101
aS'Lamivudine/administration & dosage/adverse effects'
p55102
aS'Malawi/epidemiology'
p55103
aS'Male'
p55104
aS'*Organophosphonates/administration & dosage/adverse effects'
p55105
aS'Pregnancy'
p55106
aS'Pregnancy Complications, Infectious/blood/*drug therapy/epidemiology/urine'
p55107
aS'Renal Insufficiency/blood/*chemically induced/epidemiology/urine'
p55108
aS'Tenofovir'
p55109
asS'EDAT'
p55110
S'2012/08/01 06:00'
p55111
sS'SO'
p55112
S'PLoS One. 2012;7(7):e41011. doi: 10.1371/journal.pone.0041011. Epub 2012 Jul 27.'
p55113
sS'SB'
p55114
S'IM'
p55115
sS'PMID'
p55116
S'22848422'
p55117
sS'PST'
p55118
S'ppublish'
p55119
stRp55120
ag2
(g3
g4
(dp55121
S'LID'
p55122
S'10.1111/j.1365-3156.2012.03051.x [doi]'
p55123
sS'STAT'
p55124
S'MEDLINE'
p55125
sS'DEP'
p55126
S'20120729'
p55127
sS'CI'
p55128
(lp55129
S'(c) 2012 Blackwell Publishing Ltd.'
p55130
asS'DA'
p55131
S'20131112'
p55132
sS'AID'
p55133
(lp55134
S'10.1111/j.1365-3156.2012.03051.x [doi]'
p55135
asS'CRDT'
p55136
(lp55137
S'2012/08/01 06:00'
p55138
asS'DP'
p55139
S'2012 Oct'
p55140
sS'OWN'
p55141
S'NLM'
p55142
sS'PT'
p55143
(lp55144
S'Comparative Study'
p55145
aS'Journal Article'
p55146
asS'LA'
p55147
(lp55148
S'eng'
p55149
asS'FAU'
p55150
(lp55151
S'Labhardt, Niklaus D'
p55152
aS'Sello, Motlalepula'
p55153
aS'Lejone, Thabo'
p55154
aS'Ehmer, Jochen'
p55155
aS'Mokhantso, Mohlaba'
p55156
aS'Lynen, Lutgarde'
p55157
aS'Pfeiffer, Karolin'
p55158
asS'JT'
p55159
S'Tropical medicine & international health : TM & IH'
p55160
sS'LR'
p55161
S'20140731'
p55162
sS'PG'
p55163
S'1245-54'
p55164
sS'TI'
p55165
S'Adoption of new HIV treatment guidelines and drug substitutions within first-line as a measure of quality of care in rural Lesotho: health centers and hospitals compared.'
p55166
sS'RN'
p55167
(lp55168
S'0 (Anti-HIV Agents)'
p55169
asS'PL'
p55170
S'England'
p55171
sS'TA'
p55172
S'Trop Med Int Health'
p55173
sS'JID'
p55174
S'9610576'
p55175
sS'AB'
p55176
S'OBJECTIVE: In 2007, Lesotho launched new national antiretroviral treatment (ART) guidelines, prioritising tenofovir and zidovudine over stavudine as a backbone together with lamivudine. We compared the rate of adoption of these new guidelines and substitution of first-line drugs by health centers (HC) and hospitals in two catchment areas in rural Lesotho. METHODS: Retrospective cohort analysis. Patients aged >/=16 years were stratified into a HC- and a hospital-group. MAIN OUTCOME VARIABLES: Type of backbone at ART-initiation (i), substitutions within first line (ii) and type of backbone among patients retained by December 2010 (iii). A multiple logistic regression model including HC vs. hospital, patient characteristics (sex, age, WHO-stage, baseline CD4-count, concurrent pregnancy, concurrent tuberculosis treatment) and year of ART-start, was used. RESULTS: Of 3936 adult patients initiated on ART between 2007 and 2010, 1971 started at hospitals and 1965 at HCs. Hospitals were more likely to follow the new guidelines as measured by prescription of backbones without stavudine (Odds-ratio 1.55; 95%CI: 1.32-1.81) and had a higher rate of drug substitutions while on first-line ART (2.39; 1.83-3.13). By December 2010, patients followed at health centres were more likely to still receive stavudine (2.28; 1.83-2.84). CONCLUSIONS: Health centers took longer to adopt the new guidelines and substituted drugs less frequently. Decentralised ART-programmes need close support, supervision and mentoring to absorb new guidelines and to adhere to them.'
p55177
sS'AD'
p55178
S'SolidarMed, Maseru, Lesotho Seboche Hospital, Botha-Bothe, Lesotho SolidarMed, Lucerne, Switzerland Institute of Tropical Medicine, Antwerp, Belgium.'
p55179
sS'IP'
p55180
S'10'
p55181
sS'IS'
p55182
S'1365-3156 (Electronic) 1360-2276 (Linking)'
p55183
sS'DCOM'
p55184
S'20131230'
p55185
sS'AU'
p55186
(lp55187
S'Labhardt ND'
p55188
aS'Sello M'
p55189
aS'Lejone T'
p55190
aS'Ehmer J'
p55191
aS'Mokhantso M'
p55192
aS'Lynen L'
p55193
aS'Pfeiffer K'
p55194
asS'VI'
p55195
S'17'
p55196
sS'MHDA'
p55197
S'2014/01/01 06:00'
p55198
sS'PHST'
p55199
(lp55200
S'2012/07/29 [aheadofprint]'
p55201
asS'OTO'
p55202
(lp55203
S'NOTNLM'
p55204
asS'MH'
p55205
(lp55206
S'Adolescent'
p55207
aS'Adult'
p55208
aS'Anti-HIV Agents/*therapeutic use'
p55209
aS'Cohort Studies'
p55210
aS'*Drug Substitution'
p55211
aS'Female'
p55212
aS'*Guideline Adherence'
p55213
aS'HIV Infections/*drug therapy'
p55214
aS'Health Facilities/*standards'
p55215
aS'Hospitals/*standards'
p55216
aS'Humans'
p55217
aS'Lesotho'
p55218
aS'Logistic Models'
p55219
aS'Male'
p55220
aS'Middle Aged'
p55221
aS'Practice Guidelines as Topic'
p55222
aS'Pregnancy'
p55223
aS'*Quality of Health Care'
p55224
aS'Retrospective Studies'
p55225
aS'Rural Population'
p55226
aS'Young Adult'
p55227
asS'EDAT'
p55228
S'2012/08/01 06:00'
p55229
sS'SO'
p55230
S'Trop Med Int Health. 2012 Oct;17(10):1245-54. doi: 10.1111/j.1365-3156.2012.03051.x. Epub 2012 Jul 29.'
p55231
sS'SB'
p55232
S'IM'
p55233
sS'PMID'
p55234
S'22845835'
p55235
sS'OT'
p55236
(lp55237
S'HIV'
p55238
aS'Terapia antirretroviral'
p55239
aS'VIH/SIDA'
p55240
aS'antiretroviral therapy'
p55241
aS'cuidados de enfermeria'
p55242
aS'decentralization'
p55243
aS'descentralizacion de los servicios sanitarios'
p55244
aS'decentralisation des services de sante'
p55245
aS'delegation des taches'
p55246
aS'soins bases sur les infirmieres'
p55247
aS'task shifting, quality of care'
p55248
aS'therapie antiretrovirale du VIH/SIDA'
p55249
asS'PST'
p55250
S'ppublish'
p55251
stRp55252
ag2
(g3
g4
(dp55253
S'LID'
p55254
S'10.3851/IMP2231 [doi]'
p55255
sS'STAT'
p55256
S'MEDLINE'
p55257
sS'DEP'
p55258
S'20120718'
p55259
sS'MID'
p55260
(lp55261
S'NIHMS515494'
p55262
asS'DA'
p55263
S'20130221'
p55264
sS'AID'
p55265
(lp55266
S'10.3851/IMP2231 [doi]'
p55267
asS'CRDT'
p55268
(lp55269
S'2012/07/20 06:00'
p55270
asS'DP'
p55271
S'2013'
p55272
sS'AD'
p55273
S'University of Bordeaux, ISPED, Bordeaux, France. Xavier.Anglaret@isped.u-bordeaux2.fr'
p55274
sS'OWN'
p55275
S'NLM'
p55276
sS'PT'
p55277
(lp55278
S'Journal Article'
p55279
aS"Research Support, Non-U.S. Gov't"
p55280
asS'LA'
p55281
(lp55282
S'eng'
p55283
asS'FAU'
p55284
(lp55285
S'Anglaret, Xavier'
p55286
aS'Scott, Callie A'
p55287
aS'Walensky, Rochelle P'
p55288
aS'Ouattara, Eric'
p55289
aS'Losina, Elena'
p55290
aS'Moh, Raoul'
p55291
aS'Becker, Jessica E'
p55292
aS'Uhler, Lauren'
p55293
aS'Danel, Christine'
p55294
aS'Messou, Eugene'
p55295
aS'Eholie, Serge'
p55296
aS'Freedberg, Kenneth A'
p55297
asS'JT'
p55298
S'Antiviral therapy'
p55299
sS'LR'
p55300
S'20150224'
p55301
sS'PG'
p55302
S'45-55'
p55303
sS'TI'
p55304
S'Could early antiretroviral therapy entail more risks than benefits in sub-Saharan African HIV-infected adults? A model-based analysis.'
p55305
sS'RN'
p55306
(lp55307
S'0 (Anti-HIV Agents)'
p55308
asS'PL'
p55309
S'England'
p55310
sS'TA'
p55311
S'Antivir Ther'
p55312
sS'JID'
p55313
S'9815705'
p55314
sS'AB'
p55315
S"BACKGROUND: Initiation of antiretroviral therapy (ART) in all HIV-infected adults, regardless of CD4(+) T-cell count, is a proposed strategy for reducing HIV transmission. We investigated the conditions under which starting ART early could entail more risks than benefits for patients with high CD4(+) T-cell counts. METHODS: We used a simulation model to compare ART initiation upon entry to care ('immediate ART') to initiation at CD4(+) T-cell count </= 350 cells/mul ('WHO 2010 ART') in African adults with CD4(+) T-cell counts >500 cells/mul. We varied inputs to determine the combination of parameters (population characteristics, conditions of care, treatment outcomes) that would result in higher 15-year mortality with immediate ART. RESULTS: The 15-year mortality was 56.7% for WHO 2010 ART and 51.8% for immediate ART. In one-way sensitivity analysis, lower 15-year mortality was consistently achieved with immediate ART unless the rate of fatal ART toxicity was >1.0/100 person-years, the rate of withdrawal from care was >1.2-fold higher or the rate of ART failure due to poor adherence was >4.3-fold higher on immediate than on WHO 2010 ART. In multi-way sensitivity analysis, immediate ART led to higher mortality when moderate rates of fatal ART toxicity (0.25/100 person-years) were combined with rates of withdrawal from care >1.1-fold higher and rates of treatment failure >2.1-fold higher on immediate than on WHO 2010 ART. CONCLUSIONS: In sub-Saharan Africa, ART initiation at entry into care would improve long-term survival of patients with high CD4(+) T-cell counts, unless it is associated with increased withdrawal from care and decreased adherence. In early ART trials, a focus on retention and adherence will be crucial."
p55316
sS'GR'
p55317
(lp55318
S'K24 AI062476/AI/NIAID NIH HHS/United States'
p55319
aS'R01 AI058736/AI/NIAID NIH HHS/United States'
p55320
asS'IP'
p55321
S'1'
sS'IS'
p55322
S'2040-2058 (Electronic) 1359-6535 (Linking)'
p55323
sS'PMC'
p55324
S'PMC3893045'
p55325
sS'DCOM'
p55326
S'20130729'
p55327
sS'AU'
p55328
(lp55329
S'Anglaret X'
p55330
aS'Scott CA'
p55331
aS'Walensky RP'
p55332
aS'Ouattara E'
p55333
aS'Losina E'
p55334
aS'Moh R'
p55335
aS'Becker JE'
p55336
aS'Uhler L'
p55337
aS'Danel C'
p55338
aS'Messou E'
p55339
aS'Eholie S'
p55340
aS'Freedberg KA'
p55341
asS'VI'
p55342
S'18'
p55343
sS'MHDA'
p55344
S'2013/07/31 06:00'
p55345
sS'PHST'
p55346
(lp55347
S'2012/05/19 [accepted]'
p55348
aS'2012/07/18 [aheadofprint]'
p55349
asS'OID'
p55350
(lp55351
S'NLM: NIHMS515494'
p55352
aS'NLM: PMC3893045'
p55353
asS'MH'
p55354
(lp55355
S'Adult'
p55356
aS'Africa South of the Sahara'
p55357
aS'Anti-HIV Agents/*administration & dosage/therapeutic use'
p55358
aS'Antiretroviral Therapy, Highly Active/*methods'
p55359
aS'CD4 Lymphocyte Count'
p55360
aS'CD4-Positive T-Lymphocytes'
p55361
aS'Drug Administration Schedule'
p55362
aS'Female'
p55363
aS'HIV Infections/*drug therapy/mortality/transmission'
p55364
aS'Humans'
p55365
aS'Male'
p55366
aS'*Models, Biological'
p55367
aS'*Secondary Prevention/methods/statistics & numerical data'
p55368
aS'Survival Rate'
p55369
asS'EDAT'
p55370
S'2012/07/20 06:00'
p55371
sS'SO'
p55372
S'Antivir Ther. 2013;18(1):45-55. doi: 10.3851/IMP2231. Epub 2012 Jul 18.'
p55373
sS'SB'
p55374
S'IM'
p55375
sS'PMID'
p55376
S'22809695'
p55377
sS'PST'
p55378
S'ppublish'
p55379
stRp55380
ag2
(g3
g4
(dp55381
S'LID'
p55382
S'10.1097/OLQ.0b013e31825725ad [doi]'
p55383
sS'STAT'
p55384
S'MEDLINE'
p55385
sS'JT'
p55386
S'Sexually transmitted diseases'
p55387
sS'MID'
p55388
(lp55389
S'NIHMS372790'
p55390
asS'DA'
p55391
S'20120716'
p55392
sS'AID'
p55393
(lp55394
S'10.1097/OLQ.0b013e31825725ad [doi]'
p55395
aS'00007435-201208000-00011 [pii]'
p55396
asS'CRDT'
p55397
(lp55398
S'2012/07/17 06:00'
p55399
asS'DP'
p55400
S'2012 Aug'
p55401
sS'AD'
p55402
S'Department of Obstetrics and Gynecology, Women & Infants Hospital/Alpert Medical School at Brown University, Providence, RI 02905, USA. banderson@wihri.org'
p55403
sS'OWN'
p55404
S'NLM'
p55405
sS'PT'
p55406
(lp55407
S'Journal Article'
p55408
aS'Research Support, N.I.H., Extramural'
p55409
aS"Research Support, Non-U.S. Gov't"
p55410
asS'LA'
p55411
(lp55412
S'eng'
p55413
asS'FAU'
p55414
(lp55415
S'Anderson, Brenna L'
p55416
aS'Firnhaber, Cynthia'
p55417
aS'Liu, Tao'
p55418
aS'Swarts, Avril'
p55419
aS'Siminya, Maureen'
p55420
aS'Ingersoll, Jessica'
p55421
aS'Caliendo, Angela M'
p55422
aS'Cu-Uvin, Susan'
p55423
asS'LR'
p55424
S'20150227'
p55425
sS'PG'
p55426
S'638-42'
p55427
sS'TI'
p55428
S'Effect of trichomoniasis therapy on genital HIV viral burden among African women.'
p55429
sS'RN'
p55430
(lp55431
S'0 (Antiprotozoal Agents)'
p55432
aS'140QMO216E (Metronidazole)'
p55433
asS'PL'
p55434
S'United States'
p55435
sS'TA'
p55436
S'Sex Transm Dis'
p55437
sS'JID'
p55438
S'7705941'
p55439
sS'AB'
p55440
S'BACKGROUND: Our objective was to test the hypothesis that treatment for trichomoniasis among HIV-infected women not taking antiretrovirals in South Africa would be associated with decreased HIV genital shedding. METHODS: HIV-infected women presenting for routine HIV care were screened for trichomoniasis using self-collected vaginal swabs with a rapid point-of-care immunochromatographic antigen test. Women testing positive were offered enrollment into a prospective cohort study, if they had documented HIV infection, were aged 18 to 50 years, and were not receiving antiretroviral therapy. Recent use of postexposure prophylaxis or antibiotic therapy, active genital ulcers, or systemic illness were exclusion criteria. Cervical swabs were collected for gonococcal and chlamydial testing, and those testing positive were excluded. Women were treated with directly observed oral therapy with 2 g of oral metronidazole. A follow-up visit was scheduled 1 month after therapy, and partner letters were provided. Paired cervical wicks and plasma were collected for viral load measurement. RESULTS: In all, 557 women were screened. Sixty tested positive for trichomoniasis, 10 subsequently met exclusion criteria, and 4 were lost to follow-up. Of 46 women evaluated at follow-up, 37 (80.4%) were cured. Plasma viral load was not significantly different after therapy (P = 0.93). Genital tract viral load decreased by 0.5 log10 (P < 0.01). The mean genital tract viral load (log10) decreased from 4.66 (<3.52-6.46) to 4.18 (<3.52-6.48) (P < 0.01) after therapy. CONCLUSIONS: Screening and treatment of vaginal trichomoniasis decrease genital shedding of HIV among South African women not receiving antiretrovirals at 1 month after therapy.'
p55441
sS'GR'
p55442
(lp55443
S'K12 HD050108/HD/NICHD NIH HHS/United States'
p55444
aS'K23 HD062340/HD/NICHD NIH HHS/United States'
p55445
aS'K24 AI066884/AI/NIAID NIH HHS/United States'
p55446
aS'NICHD K23 HD062340-01AS/AS/ASC OASH HHS/United States'
p55447
aS'P30AI042853/AI/NIAID NIH HHS/United States'
p55448
asS'IP'
p55449
S'8'
sS'IS'
p55450
S'1537-4521 (Electronic) 0148-5717 (Linking)'
p55451
sS'PMC'
p55452
S'PMC3398383'
p55453
sS'DCOM'
p55454
S'20121204'
p55455
sS'AU'
p55456
(lp55457
S'Anderson BL'
p55458
aS'Firnhaber C'
p55459
aS'Liu T'
p55460
aS'Swarts A'
p55461
aS'Siminya M'
p55462
aS'Ingersoll J'
p55463
aS'Caliendo AM'
p55464
aS'Cu-Uvin S'
p55465
asS'VI'
p55466
S'39'
p55467
sS'MHDA'
p55468
S'2012/12/10 06:00'
p55469
sS'OID'
p55470
(lp55471
S'NLM: NIHMS372790'
p55472
aS'NLM: PMC3398383'
p55473
asS'MH'
p55474
(lp55475
S'Adolescent'
p55476
aS'Adult'
p55477
aS'Antiprotozoal Agents/*administration & dosage'
p55478
aS'Cohort Studies'
p55479
aS'Female'
p55480
aS'HIV Seropositivity/*complications'
p55481
aS'Humans'
p55482
aS'Metronidazole/*administration & dosage'
p55483
aS'Middle Aged'
p55484
aS'Prospective Studies'
p55485
aS'South Africa/epidemiology'
p55486
aS'Trichomonas Vaginitis/diagnosis/*drug therapy'
p55487
aS'Trichomonas vaginalis/*pathogenicity'
p55488
aS'Vagina/immunology/*virology'
p55489
aS'Viral Load/*drug effects'
p55490
aS'Virus Shedding/*drug effects'
p55491
aS'Young Adult'
p55492
asS'EDAT'
p55493
S'2012/07/17 06:00'
p55494
sS'SO'
p55495
S'Sex Transm Dis. 2012 Aug;39(8):638-42. doi: 10.1097/OLQ.0b013e31825725ad.'
p55496
sS'SB'
p55497
S'IM'
p55498
sS'PMID'
p55499
S'22797689'
p55500
sS'PST'
p55501
S'ppublish'
p55502
stRp55503
ag2
(g3
g4
(dp55504
S'LID'
p55505
S'10.7448/IAS.15.4.17389 [doi]'
p55506
sS'STAT'
p55507
S'MEDLINE'
p55508
sS'DEP'
p55509
S'20120711'
p55510
sS'DA'
p55511
S'20120713'
p55512
sS'AID'
p55513
(lp55514
S'17389 [pii]'
p55515
asS'CRDT'
p55516
(lp55517
S'2012/07/14 06:00'
p55518
asS'DP'
p55519
S'2012'
p55520
sS'AD'
p55521
S"Baylor College of Medicine International Pediatric AIDS Initiative at Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA. mhkim@bcm.edu"
p55522
sS'OWN'
p55523
S'NLM'
p55524
sS'PT'
p55525
(lp55526
S'Journal Article'
p55527
aS"Research Support, Non-U.S. Gov't"
p55528
aS"Research Support, U.S. Gov't, Non-P.H.S."
p55529
asS'LA'
p55530
(lp55531
S'eng'
p55532
asS'DCOM'
p55533
S'20121119'
p55534
sS'JT'
p55535
S'Journal of the International AIDS Society'
p55536
sS'LR'
p55537
S'20150721'
p55538
sS'FAU'
p55539
(lp55540
S'Kim, Maria H'
p55541
aS'Ahmed, Saeed'
p55542
aS'Buck, W Chris'
p55543
aS'Preidis, Geoffrey A'
p55544
aS'Hosseinipour, Mina C'
p55545
aS'Bhalakia, Avni'
p55546
aS'Nanthuru, Debora'
p55547
aS'Kazembe, Peter N'
p55548
aS'Chimbwandira, Frank'
p55549
aS'Giordano, Thomas P'
p55550
aS'Chiao, Elizabeth Y'
p55551
aS'Schutze, Gordon E'
p55552
aS'Kline, Mark W'
p55553
asS'TI'
p55554
S'The Tingathe programme: a pilot intervention using community health workers to create a continuum of care in the prevention of mother to child transmission of HIV (PMTCT) cascade of services in Malawi.'
p55555
sS'RN'
p55556
(lp55557
S'0 (Anti-HIV Agents)'
p55558
asS'PL'
p55559
S'Switzerland'
p55560
sS'PG'
p55561
S'17389'
p55562
sS'JID'
p55563
S'101478566'
p55564
sS'AB'
p55565
S'INTRODUCTION: Loss to follow-up is a major challenge in the prevention of mother to child transmission of HIV (PMTCT) programme in Malawi with reported loss to follow-up of greater than 70%. Tingathe-PMTCT is a pilot intervention that utilizes dedicated community health workers (CHWs) to create a complete continuum of care within the PMTCT cascade, improving service utilization and retention of mothers and infants. We describe the impact of the intervention on longitudinal care starting with diagnosis of the mother at antenatal care (ANC) through final diagnosis of the infant. METHODS: PMTCT service utilization, programme retention and outcomes were evaluated for pregnant women living with HIV and their exposed infants enrolled in the Tingathe-PMTCT programme between March 2009 and March 2011. Multivariate logistic regression was done to evaluate maternal factors associated with failure to complete the cascade. RESULTS: Over 24 months, 1688 pregnant women living with HIV were enrolled. Median maternal age was 27 years (IQR, 23.8 to 30.8); 333 (19.7%) were already on ART. Among the remaining women, 1328/1355 (98%) received a CD4 test, with 1243/1328 (93.6%) receiving results. Of the 499 eligible for ART, 363 (72.8%) were successfully initiated. Prior to, delivery there were 93 (5.7%) maternal/foetal deaths, 137 (8.1%) women transferred/moved, 51 (3.0%) were lost and 58 (3.4%) refused ongoing PMTCT services. Of the 1318 live births to date, 1264 (95.9%) of the mothers and 1285 (97.5%) of the infants received ARV prophylaxis; 1064 (80.7%) infants were tested for HIV by PCR and started on cotrimoxazole. Median age at PCR was 1.7 months (IQR, 1.5 to 2.5). Overall transmission at first PCR was 43/1047 (4.1%). Of the 43 infants with positive PCR results, 36 (83.7%) were enrolled in ART clinic and 33 (76.7%) were initiated on ART. CONCLUSIONS: Case management and support by dedicated CHWs can create a continuum of longitudinal care in the PMTCT cascade and result in improved outcomes.'
p55566
sS'GR'
p55567
(lp55568
S'P30 AI036211/AI/NIAID NIH HHS/United States'
p55569
asS'VI'
p55570
S'15 Suppl 2'
p55571
sS'IS'
p55572
S'1758-2652 (Electronic) 1758-2652 (Linking)'
p55573
sS'PMC'
p55574
S'PMC3499848'
p55575
sS'AU'
p55576
(lp55577
S'Kim MH'
p55578
aS'Ahmed S'
p55579
aS'Buck WC'
p55580
aS'Preidis GA'
p55581
aS'Hosseinipour MC'
p55582
aS'Bhalakia A'
p55583
aS'Nanthuru D'
p55584
aS'Kazembe PN'
p55585
aS'Chimbwandira F'
p55586
aS'Giordano TP'
p55587
aS'Chiao EY'
p55588
aS'Schutze GE'
p55589
aS'Kline MW'
p55590
asS'MHDA'
p55591
S'2012/12/10 06:00'
p55592
sS'PHST'
p55593
(lp55594
S'2011/12/17 [received]'
p55595
aS'2012/05/16 [accepted]'
p55596
asS'OID'
p55597
(lp55598
S'NLM: PMC3499848'
p55599
asS'MH'
p55600
(lp55601
S'Adult'
p55602
aS'Anti-HIV Agents/therapeutic use'
p55603
aS'Community Health Workers'
p55604
aS'Community Networks'
p55605
aS'Female'
p55606
aS'HIV Infections/drug therapy/*prevention & control/*transmission'
p55607
aS'Humans'
p55608
aS'Infant'
p55609
aS'Infectious Disease Transmission, Vertical/*prevention & control'
p55610
aS'Longitudinal Studies'
p55611
aS'Malawi'
p55612
aS'Male'
p55613
aS'Pilot Projects'
p55614
aS'Pregnancy'
p55615
aS'Pregnancy Complications/*prevention & control'
p55616
aS'Prenatal Care'
p55617
aS'Program Evaluation'
p55618
aS'Young Adult'
p55619
asS'EDAT'
p55620
S'2012/07/14 06:00'
p55621
sS'SO'
p55622
S'J Int AIDS Soc. 2012 Jul 11;15 Suppl 2:17389. doi: 10.7448/IAS.15.4.17389.'
p55623
sS'SB'
p55624
S'IM X'
p55625
sS'PMID'
p55626
S'22789644'
p55627
sS'TA'
p55628
S'J Int AIDS Soc'
p55629
sS'PST'
p55630
S'epublish'
p55631
stRp55632
ag2
(g3
g4
(dp55633
S'LID'
p55634
S'10.1155/2012/956145 [doi]'
p55635
sS'STAT'
p55636
S'MEDLINE'
p55637
sS'DEP'
p55638
S'20120624'
p55639
sS'DA'
p55640
S'20120710'
p55641
sS'AID'
p55642
(lp55643
S'10.1155/2012/956145 [doi]'
p55644
asS'CRDT'
p55645
(lp55646
S'2012/07/11 06:00'
p55647
asS'DP'
p55648
S'2012'
p55649
sS'OWN'
p55650
S'NLM'
p55651
sS'PT'
p55652
(lp55653
S'Journal Article'
p55654
asS'LA'
p55655
(lp55656
S'eng'
p55657
asS'DCOM'
p55658
S'20121004'
p55659
sS'JT'
p55660
S'Infectious diseases in obstetrics and gynecology'
p55661
sS'LR'
p55662
S'20151119'
p55663
sS'FAU'
p55664
(lp55665
S'Todd, Catherine S'
p55666
aS'Jones, Heidi E'
p55667
aS'Garber, Tracy C'
p55668
aS'Afnan-Holmes, Hoviyeh'
p55669
aS'Woolgar, Helen'
p55670
aS'Bekker, Linda-Gail'
p55671
aS'Myer, Landon'
p55672
asS'TI'
p55673
S'Awareness and interest in intrauterine contraceptive device use among HIV-positive women in Cape Town, South Africa.'
p55674
sS'PL'
p55675
S'Egypt'
p55676
sS'PG'
p55677
S'956145'
p55678
sS'JID'
p55679
S'9318481'
p55680
sS'AB'
p55681
S'OBJECTIVE: To assess awareness of and interest in intrauterine contraceptive device (IUCD) use among HIV-positive women in Cape Town, South Africa. DESIGN: Cross-sectional survey. METHODS: HIV-positive women aged 18 through 45 years presenting for care at a primary health care clinic in Cape Town, South Africa participated in this study. Consented participants completed a staff-administered questionnaire in a private setting. Descriptive statistics were generated. Comparisons between demographic and reproductive health-related variables and IUCD awareness and interest were performed with multiple logistic regression. Analyses for IUCD interest excluded women with prior surgical sterilization. RESULTS: Of 277 HIV-positive women, 37% were aware of the IUCD; awareness was independently associated with greater age (adjusted odds ratio (AOR)=1.15, 95%; confidence interval (CI): 1.10-1.20) and not switching contraceptive methods in the last year (AOR=2.45, 95% CI: 1.03-5.83). Following an IUCD information session, 86% of women (n=206/240) were interested in IUCD use. IUCD interest was inversely associated with age (AOR=0.91, 95% CI: 0.86-0.97) and marginally positively associated with current menstrual bleeding pattern complaints (AOR=2.14, 95% CI: 0.98-4.68). CONCLUSIONS: Despite low levels of method awareness, HIV-positive women in this setting are frequently interested in IUCD use, indicating need for programming to expand method access.'
p55682
sS'AD'
p55683
S'Department of Obstetrics and Gynecology, Columbia University, PH16-69, New York, NY 10032, USA. cst2121@columbia.edu'
p55684
sS'VI'
p55685
S'2012'
p55686
sS'IS'
p55687
S'1098-0997 (Electronic) 1064-7449 (Linking)'
p55688
sS'PMC'
p55689
S'PMC3388580'
p55690
sS'AU'
p55691
(lp55692
S'Todd CS'
p55693
aS'Jones HE'
p55694
aS'Garber TC'
p55695
aS'Afnan-Holmes H'
p55696
aS'Woolgar H'
p55697
aS'Bekker LG'
p55698
aS'Myer L'
p55699
asS'MHDA'
p55700
S'2012/10/05 06:00'
p55701
sS'PHST'
p55702
(lp55703
S'2012/01/20 [received]'
p55704
aS'2012/04/14 [accepted]'
p55705
aS'2012/06/24 [epublish]'
p55706
asS'OID'
p55707
(lp55708
S'NLM: PMC3388580'
p55709
asS'MH'
p55710
(lp55711
S'Adolescent'
p55712
aS'Adult'
p55713
aS'Age Factors'
p55714
aS'Contraception Behavior/statistics & numerical data'
p55715
aS'Cross-Sectional Studies'
p55716
aS'Female'
p55717
aS'*HIV Seropositivity'
p55718
aS'*Health Knowledge, Attitudes, Practice'
p55719
aS'Humans'
p55720
aS'*Intrauterine Devices/utilization'
p55721
aS'Logistic Models'
p55722
aS'Middle Aged'
p55723
aS'South Africa'
p55724
aS'Surveys and Questionnaires'
p55725
aS'Young Adult'
p55726
asS'EDAT'
p55727
S'2012/07/11 06:00'
p55728
sS'SO'
p55729
S'Infect Dis Obstet Gynecol. 2012;2012:956145. doi: 10.1155/2012/956145. Epub 2012 Jun 24.'
p55730
sS'SB'
p55731
S'IM'
p55732
sS'PMID'
p55733
S'22778537'
p55734
sS'TA'
p55735
S'Infect Dis Obstet Gynecol'
p55736
sS'PST'
p55737
S'ppublish'
p55738
stRp55739
ag2
(g3
g4
(dp55740
S'LID'
p55741
S'10.1371/journal.pone.0039894 [doi]'
p55742
sS'STAT'
p55743
S'MEDLINE'
p55744
sS'DEP'
p55745
S'20120626'
p55746
sS'DA'
p55747
S'20120704'
p55748
sS'AID'
p55749
(lp55750
S'10.1371/journal.pone.0039894 [doi]'
p55751
aS'PONE-D-12-04542 [pii]'
p55752
asS'CRDT'
p55753
(lp55754
S'2012/07/05 06:00'
p55755
asS'DP'
p55756
S'2012'
p55757
sS'AD'
p55758
S'Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America. msiedner@partners.org'
p55759
sS'OWN'
p55760
S'NLM'
p55761
sS'PT'
p55762
(lp55763
S'Journal Article'
p55764
aS'Research Support, N.I.H., Extramural'
p55765
aS"Research Support, Non-U.S. Gov't"
p55766
asS'LA'
p55767
(lp55768
S'eng'
p55769
asS'FAU'
p55770
(lp55771
S'Siedner, Mark J'
p55772
aS'Lankowski, Alexander'
p55773
aS'Haberer, Jessica E'
p55774
aS'Kembabazi, Annet'
p55775
aS'Emenyonu, Nneka'
p55776
aS'Tsai, Alexander C'
p55777
aS'Muzoora, Conrad'
p55778
aS'Geng, Elvin'
p55779
aS'Martin, Jeffrey N'
p55780
aS'Bangsberg, David R'
p55781
asS'JT'
p55782
S'PloS one'
p55783
sS'LR'
p55784
S'20160701'
p55785
sS'PG'
p55786
S'e39894'
p55787
sS'TI'
p55788
S'Rethinking the "pre" in pre-therapy counseling: no benefit of additional visits prior to therapy on adherence or viremia in Ugandans initiating ARVs.'
p55789
sS'RN'
p55790
(lp55791
S'0 (Anti-HIV Agents)'
p55792
asS'PL'
p55793
S'United States'
p55794
sS'TA'
p55795
S'PLoS One'
p55796
sS'JID'
p55797
S'101285081'
p55798
sS'AB'
p55799
S'BACKGROUND: Many guidelines recommend adherence counseling prior to initiating antiretrovirals (ARVs), however the additional benefit of pre-therapy counseling visits on early adherence is not known. We sought to assess for a benefit of adherence counseling visits prior to ARV initiation versus adherence counseling during the early treatment period. METHODS: We performed a secondary analysis of data from a prospective cohort of HIV-infected patients in Mbarara, Uganda. Adults were enrolled upon initiation of ARVs. Our primary exposure of interest was ARV adherence counseling prior to initiating therapy (versus concurrent with initiation of therapy). Our outcomes of interest were: 1) average adherence >90% in first three months; 2) absence of treatment interruptions >72 hours in first three months; and 3) Viral load >400 copies/ml at the three month visit. We fit univariable and multivariable regression models, adjusted for predictors of ARV adherence, to estimate the association between additional pre-therapy counseling visits and our outcomes. RESULTS: 300 participants had records of counseling, of whom 231 (77%) completed visits prior to initiation of ARVs and 69 (23%) on or shortly after initiation. Median age was 33, 71% were female, and median CD4 was 133 cell/ml. Median 90-day adherence was 95%. Participants who completed pre-therapy counseling visits had longer delays from ARV eligibility to initiation (median 49 vs 14 days, p<0.01). In multivariable analyses, completing adherence counseling prior to ARV initiation was not associated with average adherence >90% (AOR 0.8, 95%CI 0.4-1.5), absence of treatment gaps (AOR 0.7, 95%CI 0.2-1.9), or HIV viremia (AOR 1.1, 95%CI 0.4-3.1). CONCLUSIONS: Completion of adherence counseling visits prior to ARV therapy was not associated with higher adherence in this cohort of HIV-infected patients in Uganda. Because mortality and loss-to-follow-up remain high in the pre-ARV period, policy makers should reconsider whether counseling can be delivered with ARV initiation, especially in patients with advanced disease.'
p55800
sS'GR'
p55801
(lp55802
S'K23 MH087228/MH/NIMH NIH HHS/United States'
p55803
aS'K24 MH087227/MH/NIMH NIH HHS/United States'
p55804
aS'K24 MH87227/MH/NIMH NIH HHS/United States'
p55805
aS'P30 AI027763/AI/NIAID NIH HHS/United States'
p55806
aS'P30 AI027793/AI/NIAID NIH HHS/United States'
p55807
aS'P30 AI060354/AI/NIAID NIH HHS/United States'
p55808
aS'R01 MH054907/MH/NIMH NIH HHS/United States'
p55809
aS'R01 MH054907/MH/NIMH NIH HHS/United States'
p55810
aS'R24 TW007988/TW/FIC NIH HHS/United States'
p55811
asS'IP'
p55812
S'6'
sS'IS'
p55813
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p55814
sS'PMC'
p55815
S'PMC3383698'
p55816
sS'DCOM'
p55817
S'20130104'
p55818
sS'AU'
p55819
(lp55820
S'Siedner MJ'
p55821
aS'Lankowski A'
p55822
aS'Haberer JE'
p55823
aS'Kembabazi A'
p55824
aS'Emenyonu N'
p55825
aS'Tsai AC'
p55826
aS'Muzoora C'
p55827
aS'Geng E'
p55828
aS'Martin JN'
p55829
aS'Bangsberg DR'
p55830
asS'VI'
p55831
S'7'
sS'MHDA'
p55832
S'2013/01/05 06:00'
p55833
sS'PHST'
p55834
(lp55835
S'2012/02/09 [received]'
p55836
aS'2012/05/28 [accepted]'
p55837
aS'2012/06/26 [epublish]'
p55838
asS'OID'
p55839
(lp55840
S'NLM: PMC3383698'
p55841
asS'MH'
p55842
(lp55843
S'Adult'
p55844
aS'Anti-HIV Agents/*therapeutic use'
p55845
aS'*Counseling'
p55846
aS'Female'
p55847
aS'HIV Infections/*drug therapy/psychology'
p55848
aS'Humans'
p55849
aS'Male'
p55850
aS'*Patient Compliance'
p55851
aS'Uganda'
p55852
asS'EDAT'
p55853
S'2012/07/05 06:00'
p55854
sS'SO'
p55855
S'PLoS One. 2012;7(6):e39894. doi: 10.1371/journal.pone.0039894. Epub 2012 Jun 26.'
p55856
sS'SB'
p55857
S'IM'
p55858
sS'PMID'
p55859
S'22761924'
p55860
sS'PST'
p55861
S'ppublish'
p55862
stRp55863
ag2
(g3
g4
(dp55864
S'LID'
p55865
S'10.1186/1744-8603-8-20 [doi]'
p55866
sS'STAT'
p55867
S'MEDLINE'
p55868
sS'DEP'
p55869
S'20120629'
p55870
sS'DA'
p55871
S'20120808'
p55872
sS'AID'
p55873
(lp55874
S'1744-8603-8-20 [pii]'
p55875
aS'10.1186/1744-8603-8-20 [doi]'
p55876
asS'CRDT'
p55877
(lp55878
S'2012/07/04 06:00'
p55879
asS'DP'
p55880
S'2012'
p55881
sS'OWN'
p55882
S'NLM'
p55883
sS'PT'
p55884
(lp55885
S'Journal Article'
p55886
aS"Research Support, Non-U.S. Gov't"
p55887
asS'LA'
p55888
(lp55889
S'eng'
p55890
asS'DCOM'
p55891
S'20121203'
p55892
sS'JT'
p55893
S'Globalization and health'
p55894
sS'LR'
p55895
S'20150224'
p55896
sS'FAU'
p55897
(lp55898
S'Wilson, Kinsley Rose'
p55899
aS'Kohler, Jillian Clare'
p55900
aS'Ovtcharenko, Natalia'
p55901
asS'TI'
p55902
S'The make or buy debate: considering the limitations of domestic production in Tanzania.'
p55903
sS'RN'
p55904
(lp55905
S'0 (Anti-Retroviral Agents)'
p55906
asS'PL'
p55907
S'England'
p55908
sS'PG'
p55909
S'20'
p55910
sS'JID'
p55911
S'101245734'
p55912
sS'AB'
p55913
S'BACKGROUND: In order to ensure their population\'s regular access to essential medicines, many least developed countries and developing countries are faced with the policy question of whether to import or manufacture drugs locally, in particular for life-saving antiretroviral medicines for HIV/AIDS patients. In order for domestic manufacturing to be viable and cost-effective, the local industry must be able to compete with international suppliers of medicines by producing sufficiently low cost ARVs. METHODS: This paper considers the \'make-or-buy\' dilemma by using Tanzania as a case study. Key informant interviews, event-driven observation, and purposive sampling of documents were used to evaluate the case study. The case study focused on Tanzania\'s imitation technology transfer agreement to locally manufacture a first-line ARV (3TC + d4T + NVP), reverse engineering the ARV. RESULTS: Tanzania is limited by weak political support for the use of TRIPS flexibilities, limited production capacity for ARVs and limited competitiveness in both domestic and regional markets. The Ministry of Health and Social Welfare encourages the use of flexibilities while others push for increased IP protection. Insufficient production capacity and lack of access to donor-financed tenders make it difficult to obtain economies of scale and provide competitive prices. CONCLUSIONS: Within the "make-or-buy" context, it was determined that there are significant limitations in domestic manufacturing for developing countries. The case study highlights the difficulty of governments to make use of economies of scale and produce low-cost medicines, attract technology transfer, and utilize the flexibilities of the WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). The results demonstrate the importance of evaluating barriers to the use of TRIPS flexibilities and long-term planning across sectors in future technology transfer and manufacturing initiatives.'
p55914
sS'AD'
p55915
S'Leslie Dan Faculty of Pharmacy and Munk School of Global Affairs, University of Toronto, 144 College Street, Toronto, M5S 3M2, Canada.'
p55916
sS'VI'
p55917
S'8'
sS'IS'
p55918
S'1744-8603 (Electronic) 1744-8603 (Linking)'
p55919
sS'PMC'
p55920
S'PMC3413540'
p55921
sS'AU'
p55922
(lp55923
S'Wilson KR'
p55924
aS'Kohler JC'
p55925
aS'Ovtcharenko N'
p55926
asS'MHDA'
p55927
S'2012/12/10 06:00'
p55928
sS'PHST'
p55929
(lp55930
S'2011/10/29 [received]'
p55931
aS'2012/06/29 [accepted]'
p55932
aS'2012/06/29 [aheadofprint]'
p55933
asS'OID'
p55934
(lp55935
S'NLM: PMC3413540'
p55936
asS'MH'
p55937
(lp55938
S'Anti-Retroviral Agents/*economics/*supply & distribution/therapeutic use'
p55939
aS'Commerce'
p55940
aS'Cost-Benefit Analysis'
p55941
aS'*Developing Countries'
p55942
aS'Drug Costs'
p55943
aS'Drug Industry'
p55944
aS'Economic Competition'
p55945
aS'HIV Infections/drug therapy'
p55946
aS'Humans'
p55947
aS'Organizational Case Studies'
p55948
aS'Tanzania'
p55949
aS'Technology Transfer'
p55950
asS'EDAT'
p55951
S'2012/07/04 06:00'
p55952
sS'SO'
p55953
S'Global Health. 2012 Jun 29;8:20. doi: 10.1186/1744-8603-8-20.'
p55954
sS'SB'
p55955
S'IM'
p55956
sS'PMID'
p55957
S'22747578'
p55958
sS'TA'
p55959
S'Global Health'
p55960
sS'PST'
p55961
S'epublish'
p55962
stRp55963
ag2
(g3
g4
(dp55964
S'STAT'
p55965
S'MEDLINE'
p55966
sS'AB'
p55967
S'Non-adherence is one of the major causes of treatment failure which leads to increased morbidity and mortality caused by opportunistic infections. Optimal anti-retroviral therapy (ART) adherence is essential for maximal suppression of viral replication and long term survival of patients. In order to develop effective public health interventions in the context of scaling ART services to peripheral areas, it is important to evaluate factors associated with non-adherence among HIV-infected individuals in Pwani Region. The purpose of this study was to identify factors related to non-adherence to ART among HIV infected people in Pwani Region eastern of Tanzania. A case-control study was carried out at Tumbi Hospital and Chalinze Health Centre in Pwani Region in eastern Tanzania. A structured questionnaire was used to assess non-adherence and adherence to doses instruction and time schedule. Patients with less than 95% adherence were defined as cases while those with more than 95% adherence became controls. A structured questionnaire containing factors known to be associated with non-adherence to ART in similar settings was administered. Univariate and multivariate conditional logistic regression was performed to identify factors associated with non-adherence. A total of 79 cases and 237 controls matched by age and sex were studied. A high proportion of cases and controls (77.2% and 84.8%) had good knowledge ofART benefits, adherence and eligibility. Majority of cases (73.3%) and controls (69.2%) used public transport to access ART services. More than half of cases (53.2%) missed clinic appointments due to lack of bus fare or other reasons and was associated with ART non adherence (mOR 4.2, 95%CI, 2.2-8.1 and 2.1,95%CI 1.2-4.2). Disclosure to confidants only and failure to disclose HIV-test positive status were associated with non adherence (mOR 3.3, 95%CI 1.3-8.5 and 2.3, 95%CI 1.2-7.1). Alcohol use was associated with non adherence to ART (mOR 1.9, 95%CI 1.4-3.7). Patients who were not satisfied with providers were more likely to be non adherence to ART (mOR 2.0, 95%CI 1.2-3.8). In conclusion, these findings show that adherence is a process which is depended on local specific adherence factors. Adherence improvement strategies need to consider site specific adherence determinants, patient experiences and concerns.'
p55968
sS'JID'
p55969
S'101479163'
p55970
sS'AD'
p55971
S'Swiss Tropical and Public Health Institute, Socinstrasse 57, 4002 Basel, Switzerland. bidindili@ihi.or.tz'
p55972
sS'JT'
p55973
S'Tanzania journal of health research'
p55974
sS'IP'
p55975
S'3'
sS'IS'
p55976
S'1821-6404 (Print)'
p55977
sS'DCOM'
p55978
S'20151217'
p55979
sS'DA'
p55980
S'20151120'
p55981
sS'AU'
p55982
(lp55983
S'Idindil B'
p55984
aS'Jullu B'
p55985
aS'Mugusi F'
p55986
aS'Tanner M'
p55987
asS'CRDT'
p55988
(lp55989
S'2015/11/24 06:00'
p55990
asS'VI'
p55991
S'14'
p55992
sS'PMID'
p55993
S'26591757'
p55994
sS'DP'
p55995
S'2012 Jul'
p55996
sS'MHDA'
p55997
S'2015/12/19 06:00'
p55998
sS'OWN'
p55999
S'NLM'
p56000
sS'PT'
p56001
(lp56002
S'Journal Article'
p56003
aS"Research Support, Non-U.S. Gov't"
p56004
asS'LA'
p56005
(lp56006
S'eng'
p56007
asS'MH'
p56008
(lp56009
S'Adolescent'
p56010
aS'Adult'
p56011
aS'Anti-Retroviral Agents/*therapeutic use'
p56012
aS'Case-Control Studies'
p56013
aS'Female'
p56014
aS'HIV Infections/*drug therapy'
p56015
aS'Humans'
p56016
aS'Male'
p56017
aS'Medication Adherence/*psychology'
p56018
aS'Risk Factors'
p56019
aS'Surveys and Questionnaires'
p56020
aS'Tanzania'
p56021
asS'FAU'
p56022
(lp56023
S'Idindil, Boniphace'
p56024
aS'Jullu, Boniphace'
p56025
aS'Mugusi, Ferdinand'
p56026
aS'Tanner, Marcel'
p56027
asS'EDAT'
p56028
S'2012/07/01 00:00'
p56029
sS'PST'
p56030
S'ppublish'
p56031
sS'SO'
p56032
S'Tanzan J Health Res. 2012 Jul;14(3):194-203.'
p56033
sS'PG'
p56034
S'194-203'
p56035
sS'TI'
p56036
S'A case-control study of factors associated with non-adherent to antiretroviral therapy among HIV infected people in Pwani Region, eastern Tanzania.'
p56037
sS'SB'
p56038
S'IM'
p56039
sS'RN'
p56040
(lp56041
S'0 (Anti-Retroviral Agents)'
p56042
asS'PL'
p56043
S'Tanzania'
p56044
sS'TA'
p56045
S'Tanzan J Health Res'
p56046
stRp56047
ag2
(g3
g4
(dp56048
S'STAT'
p56049
S'MEDLINE'
p56050
sS'AB'
p56051
S'BACKGROUND: Growth failure is common among children infected with HIV. The degree of growth recovery and its determinants in children initiating combination antiretroviral therapy (cART) are not well understood. METHODS: We conducted a cohort study of children who initiated cART between 2004 and 2008 at a pediatric HIV clinic in Johannesburg, South Africa. To determine the effect of severe immunodeficiency at cART initiation on growth recovery (defined as attaining a z-score > -2), we generated Kaplan-Meier survival functions and fit a Cox proportional hazards model. In sensitivity analyses, we assessed selection bias due to loss to follow-up or death. RESULTS: Of the 2399 children who initiated cART, 71% presented with growth failure. Within 2 years of cART, only 81% of underweight children achieved normal weight, and 64% of stunted children achieved length/height recovery. Severe immunodeficiency at cART initiation was not associated with weight recovery [hazards ratio: 1.05, 95% CI: 0.83 to 1.32] or length/height recovery (hazards ratio: 1.06, 95% CI: 0.83 to 1.34) in overall analyses, and modification by baseline growth failure and age were modest. Older children and those with severe growth failure were less likely to achieve growth recovery, regardless of baseline immunodeficiency status. CONCLUSIONS: A substantial proportion of children fail to achieve growth recovery despite 2 years of cART. Our analysis did not support an association between baseline immunodeficiency and growth recovery. Younger age and less-severe growth failure at cART initiation are strong predictors of achieving growth recovery. These findings support early initiation of cART, before the presence of growth failure, and independent of level of immunodeficiency.'
p56052
sS'JID'
p56053
S'100892005'
p56054
sS'AD'
p56055
S'Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. lfeinst@email.unc.edu'
p56056
sS'JT'
p56057
S'Journal of acquired immune deficiency syndromes (1999)'
p56058
sS'IP'
p56059
S'2'
sS'IS'
p56060
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p56061
sS'DCOM'
p56062
S'20121204'
p56063
sS'DA'
p56064
S'20120925'
p56065
sS'AU'
p56066
(lp56067
S'Feinstein L'
p56068
aS'Yotebieng M'
p56069
aS'Moultrie H'
p56070
aS'Meyers T'
p56071
aS'Van Rie A'
p56072
asS'AID'
p56073
(lp56074
S'10.1097/QAI.0b013e3182634e09 [doi]'
p56075
asS'CRDT'
p56076
(lp56077
S'2012/06/30 06:00'
p56078
asS'VI'
p56079
S'61'
p56080
sS'PMID'
p56081
S'22743597'
p56082
sS'DP'
p56083
S'2012 Oct 1'
p56084
sS'MHDA'
p56085
S'2012/12/10 06:00'
p56086
sS'OWN'
p56087
S'NLM'
p56088
sS'PT'
p56089
(lp56090
S'Journal Article'
p56091
asS'LA'
p56092
(lp56093
S'eng'
p56094
asS'MH'
p56095
(lp56096
S'Adolescent'
p56097
aS'Anti-HIV Agents/*administration & dosage'
p56098
aS'*Antiretroviral Therapy, Highly Active'
p56099
aS'Child'
p56100
aS'Child, Preschool'
p56101
aS'Cohort Studies'
p56102
aS'Female'
p56103
aS'Growth Disorders/*epidemiology'
p56104
aS'HIV Infections/*complications/*drug therapy/immunology'
p56105
aS'Humans'
p56106
aS'Infant'
p56107
aS'Infant, Newborn'
p56108
aS'Male'
p56109
aS'South Africa'
p56110
asS'FAU'
p56111
(lp56112
S'Feinstein, Lydia'
p56113
aS'Yotebieng, Marcel'
p56114
aS'Moultrie, Harry'
p56115
aS'Meyers, Tammy'
p56116
aS'Van Rie, Annelies'
p56117
asS'EDAT'
p56118
S'2012/06/30 06:00'
p56119
sS'PST'
p56120
S'ppublish'
p56121
sS'SO'
p56122
S'J Acquir Immune Defic Syndr. 2012 Oct 1;61(2):235-42.'
p56123
sS'PG'
p56124
S'235-42'
p56125
sS'TI'
p56126
S'Effect of baseline immune suppression on growth recovery in HIV positive South African children receiving antiretroviral treatment.'
p56127
sS'SB'
p56128
S'IM X'
p56129
sS'RN'
p56130
(lp56131
S'0 (Anti-HIV Agents)'
p56132
asS'PL'
p56133
S'United States'
p56134
sS'TA'
p56135
S'J Acquir Immune Defic Syndr'
p56136
stRp56137
ag2
(g3
g4
(dp56138
S'STAT'
p56139
S'MEDLINE'
p56140
sS'JT'
p56141
S'AIDS (London, England)'
p56142
sS'MID'
p56143
(lp56144
S'NIHMS446173'
p56145
asS'DA'
p56146
S'20121031'
p56147
sS'AID'
p56148
(lp56149
S'10.1097/QAD.0b013e328357058a [doi]'
p56150
asS'CRDT'
p56151
(lp56152
S'2012/06/29 06:00'
p56153
asS'DP'
p56154
S'2012 Sep 10'
p56155
sS'AD'
p56156
S'Center for Global Health and Development, School of Public Health, Boston University, Boston, Massachusetts, USA. mfox@bu.edu'
p56157
sS'OWN'
p56158
S'NLM'
p56159
sS'PT'
p56160
(lp56161
S'Journal Article'
p56162
aS'Research Support, N.I.H., Extramural'
p56163
aS"Research Support, Non-U.S. Gov't"
p56164
aS"Research Support, U.S. Gov't, Non-P.H.S."
p56165
asS'LA'
p56166
(lp56167
S'eng'
p56168
asS'FAU'
p56169
(lp56170
S'Fox, Matthew P'
p56171
aS'Shearer, Kate'
p56172
aS'Maskew, Mhairi'
p56173
aS'Macleod, William'
p56174
aS'Majuba, Pappie'
p56175
aS'Macphail, Patrick'
p56176
aS'Sanne, Ian'
p56177
asS'LR'
p56178
S'20150224'
p56179
sS'PG'
p56180
S'1823-8'
p56181
sS'TI'
p56182
S'Treatment outcomes after 7 years of public-sector HIV treatment.'
p56183
sS'RN'
p56184
(lp56185
S'0 (Anti-HIV Agents)'
p56186
asS'PL'
p56187
S'England'
p56188
sS'TA'
p56189
S'AIDS'
p56190
sS'JID'
p56191
S'8710219'
p56192
sS'AB'
p56193
S'OBJECTIVES: To assess outcomes over the first 7 years of antiretroviral therapy (ART) at Themba Lethu Clinic, Johannesburg, South Africa. DESIGN: Observational cohort study. METHODS: Patients are managed according to South African National Treatment Guidelines. Mortality is ascertained through linkage with the national vital registration system. Loss to follow-up is defined as at least 3 months late for the last scheduled appointment. RESULTS: Between April 2004 and March 2010, 13 227 patients initiated ART, increasing from 1794 in the year 2004/2005 to 2481 in 2009/2010. Median CD4 cell count at ART initiation increased 39% between 2004 and 2009 (82 vs. 114 cells/ml). The proportion who died within 1 year on ART was below 11% at all time points, whereas the proportion lost by 1 year increased from 8.5% in 2004 to 12.1% in 2009 [risk ratio (RR) 1.42, 95% confidence interval (CI) 1.18-1.71]. We followed the 1794 patients initiated in April 2004 and March 2005 through August 2011 for 8172 person-years. We estimated 25% of patients were lost and 16% died. The overall mortality rate was 3.59 per 100 person-years (95% CI 3.20-4.02). Of the 1577 who completed at least 6 months of follow-up, 213 (13.5%) failed first-line treatment in a median (interquartile range) of 25.9 (15.8-41.4) months on treatment. Of those who failed, 141 (66.2%) switched to second-line for a rate of 48.5 per 100 person-years (95% CI 41.1-57.2). CONCLUSION: Despite some improvements over 7 years, more intervention is needed in the first year on treatment to reduce overall attrition.'
p56194
sS'GR'
p56195
(lp56196
S'K01 AI083097/AI/NIAID NIH HHS/United States'
p56197
aS'K01AI083097/AI/NIAID NIH HHS/United States'
p56198
asS'IP'
p56199
S'14'
p56200
sS'IS'
p56201
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p56202
sS'PMC'
p56203
S'PMC3600649'
p56204
sS'DCOM'
p56205
S'20130116'
p56206
sS'AU'
p56207
(lp56208
S'Fox MP'
p56209
aS'Shearer K'
p56210
aS'Maskew M'
p56211
aS'Macleod W'
p56212
aS'Majuba P'
p56213
aS'Macphail P'
p56214
aS'Sanne I'
p56215
asS'VI'
p56216
S'26'
p56217
sS'MHDA'
p56218
S'2013/01/17 06:00'
p56219
sS'OID'
p56220
(lp56221
S'NLM: NIHMS446173'
p56222
aS'NLM: PMC3600649'
p56223
asS'MH'
p56224
(lp56225
S'Acquired Immunodeficiency Syndrome/*drug therapy/economics/epidemiology'
p56226
aS'Adult'
p56227
aS'Anti-HIV Agents/*administration & dosage/economics'
p56228
aS'CD4 Lymphocyte Count'
p56229
aS'Cohort Studies'
p56230
aS'Female'
p56231
aS'Government Programs'
p56232
aS'Guidelines as Topic'
p56233
aS'Humans'
p56234
aS'Male'
p56235
aS'Medical Record Linkage'
p56236
aS'Program Evaluation'
p56237
aS'Public Sector'
p56238
aS'Registries'
p56239
aS'South Africa/epidemiology'
p56240
aS'Treatment Outcome'
p56241
aS'Viral Load'
p56242
asS'EDAT'
p56243
S'2012/06/29 06:00'
p56244
sS'SO'
p56245
S'AIDS. 2012 Sep 10;26(14):1823-8.'
p56246
sS'SB'
p56247
S'IM X'
p56248
sS'PMID'
p56249
S'22739391'
p56250
sS'PST'
p56251
S'ppublish'
p56252
stRp56253
ag2
(g3
g4
(dp56254
S'LID'
p56255
S'10.1097/QAD.0b013e328356886d [doi]'
p56256
sS'STAT'
p56257
S'MEDLINE'
p56258
sS'JT'
p56259
S'AIDS (London, England)'
p56260
sS'CI'
p56261
(lp56262
S'(c) 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins'
p56263
asS'DA'
p56264
S'20120810'
p56265
sS'AID'
p56266
(lp56267
S'10.1097/QAD.0b013e328356886d [doi]'
p56268
asS'CRDT'
p56269
(lp56270
S'2012/06/29 06:00'
p56271
asS'DP'
p56272
S'2012 Aug 24'
p56273
sS'AD'
p56274
S'McCord Hospital, Durban, South Africa. henrysunpath@yebo.co.za'
p56275
sS'OWN'
p56276
S'NLM'
p56277
sS'PT'
p56278
(lp56279
S'Journal Article'
p56280
aS'Research Support, N.I.H., Extramural'
p56281
aS"Research Support, Non-U.S. Gov't"
p56282
aS"Research Support, U.S. Gov't, P.H.S."
p56283
asS'LA'
p56284
(lp56285
S'eng'
p56286
asS'FAU'
p56287
(lp56288
S'Sunpath, Henry'
p56289
aS'Wu, Baohua'
p56290
aS'Gordon, Michelle'
p56291
aS'Hampton, Jane'
p56292
aS'Johnson, Brent'
p56293
aS'Moosa, Mahomed-Yunus S'
p56294
aS'Ordonez, Claudia'
p56295
aS'Kuritzkes, Daniel R'
p56296
aS'Marconi, Vincent C'
p56297
asS'LR'
p56298
S'20151119'
p56299
sS'PG'
p56300
S'1679-84'
p56301
sS'TI'
p56302
S'High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen.'
p56303
sS'RN'
p56304
(lp56305
S'0 (Organophosphonates)'
p56306
aS'0 (Reverse Transcriptase Inhibitors)'
p56307
aS'2T8Q726O95 (Lamivudine)'
p56308
aS'94ZLA3W45F (Arginine)'
p56309
aS'99YXE507IL (Tenofovir)'
p56310
aS'BO9LE4QFZF (Stavudine)'
p56311
aS'EC 2.7.7.49 (HIV Reverse Transcriptase)'
p56312
aS'JAC85A2161 (Adenine)'
p56313
aS'K3Z4F929H6 (Lysine)'
p56314
asS'PL'
p56315
S'England'
p56316
sS'TA'
p56317
S'AIDS'
p56318
sS'JID'
p56319
S'8710219'
p56320
sS'AB'
p56321
S'OBJECTIVE: We sought to determine the rate of the K65R mutation in patients receiving tenofovir (TDF)-based antiretroviral therapy (ART) with subtype C HIV infection. DESIGN: Retrospective cohort study. METHODS: All patients initiated on stavudine (d4T) with lamivudine (3TC) or TDF with 3TC and a nonnucleoside reverse transcriptase inhibitor at McCord Hospital in Durban, South Africa had their charts reviewed. All patients with virologic failure, defined as a viral load more than 1000 copies/ml after 5 months of a first ART regimen, had genotypic resistance testing performed prospectively using a validated in-house assay. Important resistance mutations were selected based upon published mutations in subtype B virus in the Stanford HIV Drug Resistance database. RESULTS: A total of 585 patients were initiated on TDF-containing first-line ART from 3 August 2010 to 17 March 2011. Thirty-five (6.0%) of these patients had virologic failure and 23 of 33 (69.7%) of the virologic failure patients had the K65R mutation. The median (interquartile range) for the baseline CD4 cell count was 105 cells/mul (49-209) and viral load at virologic failure was 47 571 copies/ml (20 708-202 000). During the same period, 53 patients were initiated on d4T-containing regimens. Two (3.8%) of these patients had virologic failure and one of the virologic failure patients had the K65R mutation. CONCLUSION: Preliminary data show very high rates (>65%) of K65R for patients failing TDF-based first-line regimens at McCord Hospital with few additional nucleoside reverse transcriptase inhibitor mutations compared with subtype B. These rates may reflect faster in-vivo selection, longer time on a failing regimen or transmitted drug resistance.'
p56322
sS'GR'
p56323
(lp56324
S'K24 RR016482/RR/NCRR NIH HHS/United States'
p56325
aS'K24 RR16482/RR/NCRR NIH HHS/United States'
p56326
aS'P30 AI050409/AI/NIAID NIH HHS/United States'
p56327
aS'P30 AI060354/AI/NIAID NIH HHS/United States'
p56328
aS'P30 AI60354/AI/NIAID NIH HHS/United States'
p56329
aS'U62/CCU123541-01/PHS HHS/United States'
p56330
asS'IP'
p56331
S'13'
p56332
sS'IS'
p56333
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p56334
sS'PMC'
p56335
S'PMC3757561'
p56336
sS'DCOM'
p56337
S'20130306'
p56338
sS'MID'
p56339
(lp56340
S'NIHMS506992'
p56341
asS'AU'
p56342
(lp56343
S'Sunpath H'
p56344
aS'Wu B'
p56345
aS'Gordon M'
p56346
aS'Hampton J'
p56347
aS'Johnson B'
p56348
aS'Moosa MY'
p56349
aS'Ordonez C'
p56350
aS'Kuritzkes DR'
p56351
aS'Marconi VC'
p56352
asS'VI'
p56353
S'26'
p56354
sS'MHDA'
p56355
S'2013/03/07 06:00'
p56356
sS'OID'
p56357
(lp56358
S'NLM: NIHMS506992'
p56359
aS'NLM: PMC3757561'
p56360
asS'MH'
p56361
(lp56362
S'Adenine/*analogs & derivatives/therapeutic use'
p56363
aS'Adult'
p56364
aS'Arginine'
p56365
aS'CD4 Lymphocyte Count'
p56366
aS'Cohort Studies'
p56367
aS'Drug Resistance, Viral/*drug effects/genetics/immunology'
p56368
aS'Female'
p56369
aS'HIV Reverse Transcriptase/*antagonists & inhibitors'
p56370
aS'HIV Seropositivity/*drug therapy/genetics/immunology'
p56371
aS'HIV-1/*genetics/isolation & purification'
p56372
aS'Humans'
p56373
aS'Lamivudine/therapeutic use'
p56374
aS'Lysine'
p56375
aS'Male'
p56376
aS'*Mutation'
p56377
aS'Organophosphonates/*therapeutic use'
p56378
aS'Retrospective Studies'
p56379
aS'Reverse Transcriptase Inhibitors/*therapeutic use'
p56380
aS'South Africa'
p56381
aS'Stavudine/therapeutic use'
p56382
aS'Tenofovir'
p56383
aS'Treatment Failure'
p56384
aS'Viral Load'
p56385
asS'EDAT'
p56386
S'2012/06/29 06:00'
p56387
sS'SO'
p56388
S'AIDS. 2012 Aug 24;26(13):1679-84. doi: 10.1097/QAD.0b013e328356886d.'
p56389
sS'SB'
p56390
S'IM X'
p56391
sS'PMID'
p56392
S'22739389'
p56393
sS'PST'
p56394
S'ppublish'
p56395
stRp56396
ag2
(g3
g4
(dp56397
S'LID'
p56398
S'10.1371/journal.pone.0039187 [doi]'
p56399
sS'STAT'
p56400
S'MEDLINE'
p56401
sS'DEP'
p56402
S'20120618'
p56403
sS'DA'
p56404
S'20120622'
p56405
sS'AID'
p56406
(lp56407
S'10.1371/journal.pone.0039187 [doi]'
p56408
aS'PONE-D-12-03868 [pii]'
p56409
asS'CRDT'
p56410
(lp56411
S'2012/06/23 06:00'
p56412
asS'DP'
p56413
S'2012'
p56414
sS'AD'
p56415
S'Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda. ymanabe@jhmi.edu'
p56416
sS'OWN'
p56417
S'NLM'
p56418
sS'PT'
p56419
(lp56420
S'Journal Article'
p56421
aS'Research Support, N.I.H., Extramural'
p56422
aS"Research Support, Non-U.S. Gov't"
p56423
asS'LA'
p56424
(lp56425
S'eng'
p56426
asS'FAU'
p56427
(lp56428
S'Manabe, Yukari C'
p56429
aS'Hermans, Sabine M'
p56430
aS'Lamorde, Mohammed'
p56431
aS'Castelnuovo, Barbara'
p56432
aS'Mullins, C Daniel'
p56433
aS'Kuznik, Andreas'
p56434
asS'JT'
p56435
S'PloS one'
p56436
sS'LR'
p56437
S'20150808'
p56438
sS'PG'
p56439
S'e39187'
p56440
sS'TI'
p56441
S'Rifampicin for continuation phase tuberculosis treatment in Uganda: a cost-effectiveness analysis.'
p56442
sS'RN'
p56443
(lp56444
S'0 (Antitubercular Agents)'
p56445
aS'V83O1VOZ8L (Isoniazid)'
p56446
aS'VJT6J7R4TR (Rifampin)'
p56447
asS'PL'
p56448
S'United States'
p56449
sS'TA'
p56450
S'PLoS One'
p56451
sS'JID'
p56452
S'101285081'
p56453
sS'AB'
p56454
S'BACKGROUND: In Uganda, isoniazid plus ethambutol is used for 6 months (6HE) during the continuation treatment phase of new tuberculosis (TB) cases. However, the World Health Organization (WHO) recommends using isoniazid plus rifampicin for 4 months (4HR) instead of 6HE. We compared the impact of a continuation phase using 6HE or 4HR on total cost and expected mortality from the perspective of the Ugandan national health system. METHODOLOGY/PRINCIPAL FINDINGS: Treatment costs and outcomes were determined by decision analysis. Median daily drug price was US$0.115 for HR and US$0.069 for HE. TB treatment failure or relapse and mortality rates associated with 6HE vs. 4HR were obtained from randomized trials and systematic reviews for HIV-negative (46% of TB cases; failure/relapse -6HE: 10.4% vs. 4HR: 5.2%; mortality -6HE: 5.6% vs. 4HR: 3.5%) and HIV-positive patients (54% of TB cases; failure or relapse -6HE: 13.7% vs. 4HR: 12.4%; mortality -6HE: 16.6% vs. 4HR: 10.5%). When the initial treatment is not successful, retreatment involves an additional 8-month drug-regimen at a cost of $110.70. The model predicted a mortality rate of 13.3% for patients treated with 6HE and 8.8% for 4HR; average treatment cost per patient was predicted at $26.07 for 6HE and $23.64 for 4HR. These results were robust to the inclusion of MDR-TB as an additional outcome after treatment failure or relapse. CONCLUSIONS/SIGNIFICANCE: Combination therapy with 4HR in the continuation phase dominates 6HE as it is associated with both lower expected costs and lower expected mortality. These data support the WHO recommendation to transition to a continuation phase comprising 4HR.'
p56455
sS'GR'
p56456
(lp56457
S'1R25TW009340-01/TW/FIC NIH HHS/United States'
p56458
aS'IR24TW008886-02/TW/FIC NIH HHS/United States'
p56459
aS'N01AI90500C/AI/NIAID NIH HHS/United States'
p56460
aS'R24 TW008886/TW/FIC NIH HHS/United States'
p56461
asS'IP'
p56462
S'6'
sS'IS'
p56463
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p56464
sS'PMC'
p56465
S'PMC3377630'
p56466
sS'DCOM'
p56467
S'20121212'
p56468
sS'AU'
p56469
(lp56470
S'Manabe YC'
p56471
aS'Hermans SM'
p56472
aS'Lamorde M'
p56473
aS'Castelnuovo B'
p56474
aS'Mullins CD'
p56475
aS'Kuznik A'
p56476
asS'VI'
p56477
S'7'
sS'MHDA'
p56478
S'2012/12/13 06:00'
p56479
sS'PHST'
p56480
(lp56481
S'2012/02/07 [received]'
p56482
aS'2012/05/18 [accepted]'
p56483
aS'2012/06/18 [epublish]'
p56484
asS'OID'
p56485
(lp56486
S'NLM: PMC3377630'
p56487
asS'MH'
p56488
(lp56489
S'Antitubercular Agents/*therapeutic use'
p56490
aS'Cost-Benefit Analysis'
p56491
aS'Drug Therapy, Combination'
p56492
aS'Humans'
p56493
aS'Isoniazid/economics/*therapeutic use'
p56494
aS'Rifampin/economics/*therapeutic use'
p56495
aS'Treatment Outcome'
p56496
aS'Tuberculosis/*drug therapy/*economics'
p56497
aS'Tuberculosis, Multidrug-Resistant/drug therapy/economics'
p56498
aS'Uganda'
p56499
asS'EDAT'
p56500
S'2012/06/23 06:00'
p56501
sS'SO'
p56502
S'PLoS One. 2012;7(6):e39187. doi: 10.1371/journal.pone.0039187. Epub 2012 Jun 18.'
p56503
sS'SB'
p56504
S'IM'
p56505
sS'PMID'
p56506
S'22723960'
p56507
sS'PST'
p56508
S'ppublish'
p56509
stRp56510
ag2
(g3
g4
(dp56511
S'LID'
p56512
S'10.1371/journal.pmed.1001236 [doi]'
p56513
sS'STAT'
p56514
S'MEDLINE'
p56515
sS'DEP'
p56516
S'20120612'
p56517
sS'DA'
p56518
S'20120621'
p56519
sS'AID'
p56520
(lp56521
S'10.1371/journal.pmed.1001236 [doi]'
p56522
aS'PMEDICINE-D-11-02381 [pii]'
p56523
asS'CRDT'
p56524
(lp56525
S'2012/06/22 06:00'
p56526
asS'DP'
p56527
S'2012'
p56528
sS'GR'
p56529
(lp56530
S'3U01AI32775-13S5/AI/NIAID NIH HHS/United States'
p56531
aS'5 U01 AI069518/AI/NIAID NIH HHS/United States'
p56532
aS'5U01AI069455-03/AI/NIAID NIH HHS/United States'
p56533
aS'5U01AI069456-03/AI/NIAID NIH HHS/United States'
p56534
aS'AI-069501/AI/NIAID NIH HHS/United States'
p56535
aS'AI38838/AI/NIAID NIH HHS/United States'
p56536
aS'AI68634/AI/NIAID NIH HHS/United States'
p56537
aS'AI69426/AI/NIAID NIH HHS/United States'
p56538
aS'AI69453/AI/NIAID NIH HHS/United States'
p56539
aS'IAAY1AI8374/AI/NIAID NIH HHS/United States'
p56540
aS'K24 AI056933/AI/NIAID NIH HHS/United States'
p56541
aS'K24 AI56933/AI/NIAID NIH HHS/United States'
p56542
aS'P30 AI027763/AI/NIAID NIH HHS/United States'
p56543
aS'U01 AI69463-03/AI/NIAID NIH HHS/United States'
p56544
aS'U01AI068636/AI/NIAID NIH HHS/United States'
p56545
aS'U01AI069436/AI/NIAID NIH HHS/United States'
p56546
asS'OWN'
p56547
S'NLM'
p56548
sS'PT'
p56549
(lp56550
S'Comparative Study'
p56551
aS'Journal Article'
p56552
aS'Randomized Controlled Trial'
p56553
aS'Research Support, N.I.H., Extramural'
p56554
aS"Research Support, Non-U.S. Gov't"
p56555
asS'LA'
p56556
(lp56557
S'eng'
p56558
asS'FAU'
p56559
(lp56560
S'Lockman, Shahin'
p56561
aS'Hughes, Michael'
p56562
aS'Sawe, Fred'
p56563
aS'Zheng, Yu'
p56564
aS'McIntyre, James'
p56565
aS'Chipato, Tsungai'
p56566
aS'Asmelash, Aida'
p56567
aS'Rassool, Mohammed'
p56568
aS'Kimaiyo, Sylvester'
p56569
aS'Shaffer, Douglas'
p56570
aS'Hosseinipour, Mina'
p56571
aS'Mohapi, Lerato'
p56572
aS'Ssali, Francis'
p56573
aS'Chibowa, Margret'
p56574
aS'Amod, Farida'
p56575
aS'Halvas, Elias'
p56576
aS'Hogg, Evelyn'
p56577
aS'Alston-Smith, Beverly'
p56578
aS'Smith, Laura'
p56579
aS'Schooley, Robert'
p56580
aS'Mellors, John'
p56581
aS'Currier, Judith'
p56582
asS'JT'
p56583
S'PLoS medicine'
p56584
sS'LR'
p56585
S'20160708'
p56586
sS'PG'
p56587
S'e1001236'
p56588
sS'TI'
p56589
S'Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial.'
p56590
sS'RN'
p56591
(lp56592
S'0 (Anti-HIV Agents)'
p56593
aS'2494G1JF75 (Lopinavir)'
p56594
aS'99DK7FVK1H (Nevirapine)'
p56595
aS'O3J8G9O825 (Ritonavir)'
p56596
asS'PL'
p56597
S'United States'
p56598
sS'TA'
p56599
S'PLoS Med'
p56600
sS'FIR'
p56601
(lp56602
S'Conradie, Francesca'
p56603
aS'Dangaiso, Elizabeth'
p56604
aS'Stringer, Elizabeth'
p56605
aS'Siika, Abraham'
p56606
aS'Wools-Kaloustian, Kara'
p56607
aS'Purcelle-Smith, Eva'
p56608
aS'Walawander, Ann'
p56609
aS'Nair, Apsara'
p56610
aS'Zwickl, Beth'
p56611
aS'Mutuluuza, Cissy Kityo'
p56612
aS'Rwambuya, Sandra'
p56613
aS'Kaseba, Christine'
p56614
aS'Maponga, Charles'
p56615
aS'Watts, Heather'
p56616
aS'Kuritzkes, Daniel'
p56617
aS'Campbell, Thomas B'
p56618
aS'Kidd-Freeman, Lynn'
p56619
aS'Carten, Monica'
p56620
aS'Hitti, Jane'
p56621
aS'Marovich, Mary'
p56622
aS'Mugyenyi, Peter'
p56623
aS'Rwambuya, Sandra'
p56624
aS'Sanne, Ian'
p56625
aS'Putnam, Beverly'
p56626
aS'Marcus, Cheryl'
p56627
aS'Wester, Carolyn'
p56628
aS'DiFrancesco, Robin'
p56629
aS'Beddison, Annie'
p56630
aS'Lehrman, Sandra'
p56631
aS'Aweeka, Francesca'
p56632
aS'Dong, Betty'
p56633
aS'Ziba, Peter Ndhleni'
p56634
aS'Saag, Michael'
p56635
aS'Holmes, William'
p56636
aS'Hammer, Scott'
p56637
aS'Potani, Charity'
p56638
aS'Mwausegha, Regina'
p56639
aS'Laher, Fatima'
p56640
aS'Hen-Boisen, Reinet'
p56641
aS'Nzioka, Agnes'
p56642
aS'Moko, Evans'
p56643
aS'Amod, Farida'
p56644
aS'Lalloo, Umesh'
p56645
aS'Pillay, Sandy'
p56646
aS'Nair, Apsara'
p56647
aS'Smith, Laura M'
p56648
aS'Tutko, James'
p56649
aS'Lee, Christine'
p56650
aS'Smith, Eva Purcelle'
p56651
aS'Ferguson, Elaine'
p56652
aS'Martinez, Ana'
p56653
aS'Delph, Yvette'
p56654
aS'Gettinger, Nikki'
p56655
aS'Berman, Linda'
p56656
aS'Boone, Linda'
p56657
aS'Adedeji, Bola'
p56658
aS'Chipato, Tsungai'
p56659
asS'JID'
p56660
S'101231360'
p56661
sS'AB'
p56662
S'BACKGROUND: Nevirapine (NVP) is widely used in antiretroviral treatment (ART) of HIV-1 globally. The primary objective of the AA5208/OCTANE trial was to compare the efficacy of NVP-based versus lopinavir/ritonavir (LPV/r)-based initial ART. METHODS AND FINDINGS: In seven African countries (Botswana, Kenya, Malawi, South Africa, Uganda, Zambia, and Zimbabwe), 500 antiretroviral-naive HIV-infected women with CD4<200 cells/mm(3) were enrolled into a two-arm randomized trial to initiate open-label ART with tenofovir (TDF)/emtricitabine (FTC) once/day plus either NVP (n = 249) or LPV/r (n = 251) twice/day, and followed for >/=48 weeks. The primary endpoint was time from randomization to death or confirmed virologic failure ([VF]) (plasma HIV RNA<1 log(10) below baseline 12 weeks after treatment initiation, or >/=400 copies/ml at or after 24 weeks), with comparison between treatments based on hazard ratios (HRs) in intention-to-treat analysis. Equivalence of randomized treatments was defined as finding the 95% CI for HR for virological failure or death in the range 0.5 to 2.0. Baseline characteristics were (median): age = 34 years, CD4 = 121 cells/mm(3), HIV RNA = 5.2 log(10)copies/ml. Median follow-up = 118 weeks; 29 (6%) women were lost to follow-up. 42 women (37 VFs, five deaths; 17%) in the NVP and 50 (43 VFs, seven deaths; 20%) in the LPV/r arm reached the primary endpoint (HR 0.85, 95% CI 0.56-1.29). During initial assigned treatment, 14% and 16% of women receiving NVP and LPV/r experienced grade 3/4 signs/symptoms and 26% and 22% experienced grade 3/4 laboratory abnormalities. However, 35 (14%) women discontinued NVP because of adverse events, most in the first 8 weeks, versus none for LPV/r (p<0.001). VF, death, or permanent treatment discontinuation occurred in 80 (32%) of NVP and 54 (22%) of LPV/r arms (HR = 1.7, 95% CI 1.2-2.4), with the difference primarily due to more treatment discontinuation in the NVP arm. 13 (45%) of 29 women tested in the NVP versus six (15%) of 40 in the LPV/r arm had any drug resistance mutation at time of VF. CONCLUSIONS: Initial ART with NVP+TDF/FTC demonstrated equivalent virologic efficacy but higher rates of treatment discontinuation and new drug resistance compared with LPV/r+TDF/FTC in antiretroviral-naive women with CD4<200 cells/mm(3). TRIAL REGISTRATION: ClinicalTrials.gov NCT00089505.'
p56663
sS'AD'
p56664
S"Brigham and Women's Hospital, Boston, Massachusetts, United States of America. slockman@hsph.harvard.edu"
p56665
sS'CN'
p56666
(lp56667
S'OCTANE (Optimal Combination Therapy After Nevirapine Exposure) ACTG A5208/OCTANE'
p56668
aS'Study Team'
p56669
asS'IP'
p56670
S'6'
sS'IS'
p56671
S'1549-1676 (Electronic) 1549-1277 (Linking)'
p56672
sS'IR'
p56673
(lp56674
S'Conradie F'
p56675
aS'Dangaiso E'
p56676
aS'Stringer E'
p56677
aS'Siika A'
p56678
aS'Wools-Kaloustian K'
p56679
aS'Purcelle-Smith E'
p56680
aS'Walawander A'
p56681
aS'Nair A'
p56682
aS'Zwickl B'
p56683
aS'Mutuluuza CK'
p56684
aS'Rwambuya S'
p56685
aS'Kaseba C'
p56686
aS'Maponga C'
p56687
aS'Watts H'
p56688
aS'Kuritzkes D'
p56689
aS'Campbell TB'
p56690
aS'Kidd-Freeman L'
p56691
aS'Carten M'
p56692
aS'Hitti J'
p56693
aS'Marovich M'
p56694
aS'Mugyenyi P'
p56695
aS'Rwambuya S'
p56696
aS'Sanne I'
p56697
aS'Putnam B'
p56698
aS'Marcus C'
p56699
aS'Wester C'
p56700
aS'DiFrancesco R'
p56701
aS'Beddison A'
p56702
aS'Lehrman S'
p56703
aS'Aweeka F'
p56704
aS'Dong B'
p56705
aS'Ziba PN'
p56706
aS'Saag M'
p56707
aS'Holmes W'
p56708
aS'Hammer S'
p56709
aS'Potani C'
p56710
aS'Mwausegha R'
p56711
aS'Laher F'
p56712
aS'Hen-Boisen R'
p56713
aS'Nzioka A'
p56714
aS'Moko E'
p56715
aS'Amod F'
p56716
aS'Lalloo U'
p56717
aS'Pillay S'
p56718
aS'Nair A'
p56719
aS'Smith LM'
p56720
aS'Tutko J'
p56721
aS'Lee C'
p56722
aS'Smith EP'
p56723
aS'Ferguson E'
p56724
aS'Martinez A'
p56725
aS'Delph Y'
p56726
aS'Gettinger N'
p56727
aS'Berman L'
p56728
aS'Boone L'
p56729
aS'Adedeji B'
p56730
aS'Chipato T'
p56731
asS'DCOM'
p56732
S'20121119'
p56733
sS'AU'
p56734
(lp56735
S'Lockman S'
p56736
aS'Hughes M'
p56737
aS'Sawe F'
p56738
aS'Zheng Y'
p56739
aS'McIntyre J'
p56740
aS'Chipato T'
p56741
aS'Asmelash A'
p56742
aS'Rassool M'
p56743
aS'Kimaiyo S'
p56744
aS'Shaffer D'
p56745
aS'Hosseinipour M'
p56746
aS'Mohapi L'
p56747
aS'Ssali F'
p56748
aS'Chibowa M'
p56749
aS'Amod F'
p56750
aS'Halvas E'
p56751
aS'Hogg E'
p56752
aS'Alston-Smith B'
p56753
aS'Smith L'
p56754
aS'Schooley R'
p56755
aS'Mellors J'
p56756
aS'Currier J'
p56757
asS'VI'
p56758
S'9'
sS'MHDA'
p56759
S'2012/12/10 06:00'
p56760
sS'PHST'
p56761
(lp56762
S'2011/09/29 [received]'
p56763
aS'2012/05/03 [accepted]'
p56764
aS'2012/06/12 [epublish]'
p56765
asS'OID'
p56766
(lp56767
S'NLM: PMC3373629'
p56768
asS'MH'
p56769
(lp56770
S'Adult'
p56771
aS'Africa'
p56772
aS'Anti-HIV Agents/adverse effects/pharmacology/*therapeutic use'
p56773
aS'CD4 Lymphocyte Count'
p56774
aS'Death'
p56775
aS'Drug Resistance, Viral/drug effects/genetics'
p56776
aS'Endpoint Determination'
p56777
aS'Female'
p56778
aS'HIV Infections/diagnosis/*drug therapy/immunology/*virology'
p56779
aS'HIV-1/drug effects/*physiology'
p56780
aS'Humans'
p56781
aS'Kaplan-Meier Estimate'
p56782
aS'Lopinavir/adverse effects/pharmacology/*therapeutic use'
p56783
aS'Medication Adherence'
p56784
aS'Mutation/genetics'
p56785
aS'Nevirapine/adverse effects/pharmacology/*therapeutic use'
p56786
aS'Ritonavir/adverse effects/pharmacology/*therapeutic use'
p56787
asS'EDAT'
p56788
S'2012/06/22 06:00'
p56789
sS'PMC'
p56790
S'PMC3373629'
p56791
sS'SI'
p56792
(lp56793
S'ClinicalTrials.gov/NCT00089505'
p56794
asS'SO'
p56795
S'PLoS Med. 2012;9(6):e1001236. doi: 10.1371/journal.pmed.1001236. Epub 2012 Jun 12.'
p56796
sS'SB'
p56797
S'IM'
p56798
sS'PMID'
p56799
S'22719231'
p56800
sS'PST'
p56801
S'ppublish'
p56802
stRp56803
ag2
(g3
g4
(dp56804
S'LID'
p56805
S'10.1080/13557858.2012.694068 [doi]'
p56806
sS'STAT'
p56807
S'MEDLINE'
p56808
sS'DEP'
p56809
S'20120620'
p56810
sS'MID'
p56811
(lp56812
S'NIHMS391666'
p56813
asS'DA'
p56814
S'20130328'
p56815
sS'AID'
p56816
(lp56817
S'10.1080/13557858.2012.694068 [doi]'
p56818
asS'CRDT'
p56819
(lp56820
S'2012/06/22 06:00'
p56821
asS'DP'
p56822
S'2013'
p56823
sS'AD'
p56824
S'Pacific Institute for Research and Evaluation, Chapel Hill, NC, USA. Hallfors@pire.org'
p56825
sS'OWN'
p56826
S'NLM'
p56827
sS'PT'
p56828
(lp56829
S'Journal Article'
p56830
aS'Research Support, N.I.H., Extramural'
p56831
asS'LA'
p56832
(lp56833
S'eng'
p56834
asS'FAU'
p56835
(lp56836
S'Hallfors, Denise D'
p56837
aS'Cho, Hyunsan'
p56838
aS'Iritani, Bonita J'
p56839
aS'Mapfumo, John'
p56840
aS'Mpofu, Elias'
p56841
aS'Luseno, Winnie K'
p56842
aS'January, James'
p56843
asS'JT'
p56844
S'Ethnicity & health'
p56845
sS'LR'
p56846
S'20150224'
p56847
sS'PG'
p56848
S'53-65'
p56849
sS'TI'
p56850
S'Preventing HIV by providing support for orphan girls to stay in school: does religion matter?'
p56851
sS'PL'
p56852
S'England'
p56853
sS'TA'
p56854
S'Ethn Health'
p56855
sS'JID'
p56856
S'9608374'
p56857
sS'AB'
p56858
S'OBJECTIVE: The paper examines the influence of religion on attitudes, behaviors, and HIV infection among rural adolescent women in Zimbabwe. DESIGN: We analyzed data from a 2007 to 2010 randomized controlled trial in rural eastern Zimbabwe testing whether school support can prevent HIV risk behaviors and related attitudes among rural adolescent orphan girls; supplementary data from the 2006 Zimbabwe Demographic and Health Survey (ZDHS) were also analyzed. The present study design is largely cross-sectional, using the most recent available survey data from the clinical trial to examine the association between religious affiliation and religiosity on school dropout, marriage, and related attitudes, controlling for intervention condition, age and orphan type. The ZDHS data examined the effect of religious denomination on marriage and HIV status among young rural women, controlling for age. RESULTS: Apostolic Church affiliation greatly increased the likelihood of early marriage compared to reference Methodist Church affiliation (odds ratio = 4.5). Greater religiosity independently reduced the likelihood of school dropout, increased gender equity attitudes and disagreement with early sex, and marginally reduced early marriage. Young rural Apostolic women in the ZDHS were nearly four times as likely to marry as teenagers compared to Protestants, and marriage doubled the likelihood of HIV infection. CONCLUSIONS: Findings contradict an earlier seminal study that Apostolics are relatively protected from HIV compared to other Christian denominations. Young Apostolic women are at increased risk of HIV infection through early marriage. The Apostolic Church is a large and growing denomination in sub-Saharan Africa and many Apostolic sects discourage medical testing and treatment in favor of faith healing. Since this can increase the risk of undiagnosed HIV infection for young married women and their infants in high prevalence areas, further study is urgently needed to confirm this emerging public health problem, particularly among orphan girls. Although empirical evidence suggests that keeping orphan girls in school can reduce HIV risk factors, further study of the religious context and the implications for prevention are needed.'
p56859
sS'GR'
p56860
(lp56861
S'R01 HD055838/HD/NICHD NIH HHS/United States'
p56862
aS'R01HD055838/HD/NICHD NIH HHS/United States'
p56863
asS'IP'
p56864
S'1'
sS'IS'
p56865
S'1465-3419 (Electronic) 1355-7858 (Linking)'
p56866
sS'PMC'
p56867
S'PMC3496833'
p56868
sS'DCOM'
p56869
S'20130913'
p56870
sS'AU'
p56871
(lp56872
S'Hallfors DD'
p56873
aS'Cho H'
p56874
aS'Iritani BJ'
p56875
aS'Mapfumo J'
p56876
aS'Mpofu E'
p56877
aS'Luseno WK'
p56878
aS'January J'
p56879
asS'VI'
p56880
S'18'
p56881
sS'MHDA'
p56882
S'2013/09/14 06:00'
p56883
sS'PHST'
p56884
(lp56885
S'2012/06/20 [aheadofprint]'
p56886
asS'OID'
p56887
(lp56888
S'NLM: NIHMS391666'
p56889
aS'NLM: PMC3496833'
p56890
asS'MH'
p56891
(lp56892
S'Adolescent'
p56893
aS'Age Factors'
p56894
aS'Child, Orphaned/education/*statistics & numerical data'
p56895
aS'Cross-Sectional Studies'
p56896
aS'Female'
p56897
aS'HIV Infections/ethnology/etiology/*prevention & control'
p56898
aS'Health Knowledge, Attitudes, Practice/*ethnology'
p56899
aS'Humans'
p56900
aS'Marital Status/*ethnology/statistics & numerical data'
p56901
aS'Randomized Controlled Trials as Topic'
p56902
aS'*Religion and Medicine'
p56903
aS'*Religion and Sex'
p56904
aS'Risk-Taking'
p56905
aS'Rural Population/statistics & numerical data'
p56906
aS'Schools/economics'
p56907
aS'Social Support'
p56908
aS'Student Dropouts/statistics & numerical data'
p56909
aS'Training Support'
p56910
aS"Women's Rights"
p56911
aS'Young Adult'
p56912
aS'Zimbabwe/epidemiology'
p56913
asS'EDAT'
p56914
S'2012/06/22 06:00'
p56915
sS'SO'
p56916
S'Ethn Health. 2013;18(1):53-65. doi: 10.1080/13557858.2012.694068. Epub 2012 Jun 20.'
p56917
sS'SB'
p56918
S'IM'
p56919
sS'PMID'
p56920
S'22715988'
p56921
sS'PST'
p56922
S'ppublish'
p56923
stRp56924
ag2
(g3
g4
(dp56925
S'LID'
p56926
S'10.7448/IAS.15.2.17381 [doi]'
p56927
sS'STAT'
p56928
S'MEDLINE'
p56929
sS'DEP'
p56930
S'20120531'
p56931
sS'DA'
p56932
S'20120620'
p56933
sS'AID'
p56934
(lp56935
S'17381 [pii]'
p56936
asS'CRDT'
p56937
(lp56938
S'2012/06/21 06:00'
p56939
asS'DP'
p56940
S'2012'
p56941
sS'OWN'
p56942
S'NLM'
p56943
sS'PT'
p56944
(lp56945
S'Comparative Study'
p56946
aS'Journal Article'
p56947
aS'Multicenter Study'
p56948
asS'LA'
p56949
(lp56950
S'eng'
p56951
asS'FAU'
p56952
(lp56953
S'Grimwood, Ashraf'
p56954
aS'Fatti, Geoffrey'
p56955
aS'Mothibi, Eula'
p56956
aS'Malahlela, Mokgadi'
p56957
aS'Shea, Jawaya'
p56958
aS'Eley, Brian'
p56959
asS'JT'
p56960
S'Journal of the International AIDS Society'
p56961
sS'LR'
p56962
S'20150224'
p56963
sS'PG'
p56964
S'17381'
p56965
sS'TI'
p56966
S'Community adherence support improves programme retention in children on antiretroviral treatment: a multicentre cohort study in South Africa.'
p56967
sS'RN'
p56968
(lp56969
S'0 (Anti-Retroviral Agents)'
p56970
asS'PL'
p56971
S'Switzerland'
p56972
sS'TA'
p56973
S'J Int AIDS Soc'
p56974
sS'JID'
p56975
S'101478566'
p56976
sS'AB'
p56977
S"BACKGROUND: HIV-positive children in low-income settings face many challenges to adherence to antiretroviral treatment (ART) and have increased mortality on treatment compared to children in developed countries. Adult ART programmes have demonstrated benefit from community support to improve treatment outcomes; however, there are no empirical data on the effectiveness of this intervention in children. This study compared clinical, virological and immunological outcomes between children who received and who did not receive community-based adherence support from patient advocates (PAs) in four South African provinces. METHODS: A multicentre cohort study of ART-naive children was conducted at 47 public ART facilities. Outcome measures were mortality, patient retention, virological suppression and CD4 percentage changes on ART. PAs are lay community health workers who provide adherence and psychosocial support for children's caregivers, and they undertake home visits to ascertain household challenges potentially impacting on adherence in the child. Corrected mortality estimates were calculated, correcting for deaths amongst those lost to follow-up (LTFU) using probability-weighted Kaplan-Meier and Cox functions. RESULTS: Three thousand five hundred and sixty three children were included with a median baseline age of 6.3 years and a median baseline CD4 cell percentage of 12.0%. PA-supported children numbered 323 (9.1%). Baseline clinical status variables were equivalent between the two groups. Amongst children LTFU, 38.7% were known to have died. Patient retention after 3 years of ART was 91.5% (95% CI: 86.8% to 94.7%) vs. 85.6% (95% CI: 83.3% to 87.6%) amongst children with and without PAs, respectively (p = 0.027). Amongst children aged below 2 years at baseline, retention after 3 years was 92.2% (95% CI: 76.7% to 97.6%) vs. 74.2% (95% CI: 65.4% to 81.0%) in children with and without PAs, respectively (p = 0.053). Corrected mortality after 3 years of ART was 3.7% (95% CI: 1.9% to 7.4%) vs. 8.0% (95% CI: 6.5% to 9.8%) amongst children with and without PAs, respectively (p = 0.060). In multivariable analyses, children with PAs had reduced probabilities of both attrition and mortality, adjusted hazard ratio (AHR) 0.57 (95% CI: 0.35 to 0.94) and 0.39 (95% CI: 0.15 to 1.04), respectively. CONCLUSION: Community-based adherence support is an effective way to improve patient retention amongst children on ART. Expanded implementation of this intervention should be considered in order to reach ART programmatic goals in low-income settings as more children access treatment."
p56978
sS'AD'
p56979
S"Kheth'Impilo, Cape Town, South Africa."
p56980
sS'IP'
p56981
S'2'
sS'IS'
p56982
S'1758-2652 (Electronic) 1758-2652 (Linking)'
p56983
sS'PMC'
p56984
S'PMC3499784'
p56985
sS'DCOM'
p56986
S'20121017'
p56987
sS'AU'
p56988
(lp56989
S'Grimwood A'
p56990
aS'Fatti G'
p56991
aS'Mothibi E'
p56992
aS'Malahlela M'
p56993
aS'Shea J'
p56994
aS'Eley B'
p56995
asS'VI'
p56996
S'15'
p56997
sS'MHDA'
p56998
S'2012/10/18 06:00'
p56999
sS'PHST'
p57000
(lp57001
S'2011/09/17 [received]'
p57002
aS'2012/02/06 [revised]'
p57003
aS'2012/03/30 [accepted]'
p57004
asS'OID'
p57005
(lp57006
S'NLM: PMC3499784'
p57007
asS'MH'
p57008
(lp57009
S'Anti-Retroviral Agents/*administration & dosage'
p57010
aS'*Antiretroviral Therapy, Highly Active'
p57011
aS'CD4 Lymphocyte Count'
p57012
aS'Child'
p57013
aS'Child, Preschool'
p57014
aS'Cohort Studies'
p57015
aS'Community Networks/*utilization'
p57016
aS'Female'
p57017
aS'HIV Infections/*drug therapy/immunology/*psychology/virology'
p57018
aS'Humans'
p57019
aS'Infant'
p57020
aS'Male'
p57021
aS'Medication Adherence/*psychology'
p57022
aS'Social Support'
p57023
aS'South Africa'
p57024
aS'Survival Analysis'
p57025
aS'Treatment Outcome'
p57026
aS'Viral Load'
p57027
asS'EDAT'
p57028
S'2012/06/21 06:00'
p57029
sS'SO'
p57030
S'J Int AIDS Soc. 2012 May 31;15(2):17381. doi: 10.7448/IAS.15.2.17381.'
p57031
sS'SB'
p57032
S'IM X'
p57033
sS'PMID'
p57034
S'22713255'
p57035
sS'PST'
p57036
S'epublish'
p57037
stRp57038
ag2
(g3
g4
(dp57039
S'STAT'
p57040
S'MEDLINE'
p57041
sS'JT'
p57042
S'AIDS (London, England)'
p57043
sS'CI'
p57044
(lp57045
S'(c) 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins'
p57046
asS'DA'
p57047
S'20120809'
p57048
sS'AID'
p57049
(lp57050
S'10.1097/QAD.0b013e3283560678 [doi]'
p57051
asS'CRDT'
p57052
(lp57053
S'2012/06/15 06:00'
p57054
asS'DP'
p57055
S'2012 Aug 24'
p57056
sS'AD'
p57057
S'PharmAccess Foundation, Department of Global Health, Academic Medical Center of the University of Amsterdam and Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands. r.hamers@aighd.org'
p57058
sS'OWN'
p57059
S'NLM'
p57060
sS'PT'
p57061
(lp57062
S'Journal Article'
p57063
aS"Research Support, Non-U.S. Gov't"
p57064
asS'LA'
p57065
(lp57066
S'eng'
p57067
asS'FAU'
p57068
(lp57069
S'Hamers, Raph L'
p57070
aS'Sawyer, A W'
p57071
aS'Tuohy, Martin'
p57072
aS'Stevens, Wendy S'
p57073
aS'Rinke de Wit, Tobias F'
p57074
aS'Hill, Andrew M'
p57075
asS'PG'
p57076
S'1663-72'
p57077
sS'TI'
p57078
S'Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis.'
p57079
sS'RN'
p57080
(lp57081
S'0 (Anti-HIV Agents)'
p57082
asS'PL'
p57083
S'England'
p57084
sS'TA'
p57085
S'AIDS'
p57086
sS'JID'
p57087
S'8710219'
p57088
sS'AB'
p57089
S'OBJECTIVE: To compare the cost-effectiveness of three different strategies for long-term monitoring of antiretroviral therapy (ART) failure and regimen switching in sub-Saharan Africa: a symptom-based approach, or monitoring of either CD4 cell counts or plasma viral load (pVL). DESIGN: Markov model. SETTING AND PARTICIPANTS: Hypothetical HIV-infected adult population who began first-line ART and subsequently had up to 6 years of follow-up. MAIN OUTCOME MEASURES: Total cost, life expectancy and incremental cost-effectiveness ratio (ICER). RESULTS: A symptom-based approach yielded a life expectancy of 64.0 months at a total cost of US$ 4028 per person. All laboratory-based strategies, at testing intervals of 6 or 12 months, were cost-saving and improved life expectancy, compared with a symptom-based approach. The life-expectancy gain was larger for pVL than for CD4 strategies at 6-monthly (2.3 and 0.9 months, respectively) and 12-monthly testing (2.0 and 0.8 months, respectively). Cost-savings of 6-monthly pVL or CD4 testing were similar (US$ 630 and 621, respectively), whereas 12-monthly CD4 cell counts were more cost-saving than 12-monthly pVL (US$ 1132 and 880, respectively). Testing every 12 months - rather than every 6 months - decreased the ICER by 102% for CD4 cell count and 67% for pVL. These findings were robust to a wide range of deterministic sensitivity analyses, but were sensitive to the specificity and costs of diagnostic tests. CONCLUSION: Additional diagnostic costs are balanced by cost-savings from avoiding unnecessary switching due to misdiagnosis of ART failure. Routine pVL monitoring may be preferred as a replacement for CD4 cell counts because of its additional public-health advantages in preventing drug-resistance, supporting adherence and reducing HIV transmission.'
p57090
sS'CN'
p57091
(lp57092
S'ART-A Consortium'
p57093
asS'IP'
p57094
S'13'
p57095
sS'IS'
p57096
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p57097
sS'DCOM'
p57098
S'20130306'
p57099
sS'AU'
p57100
(lp57101
S'Hamers RL'
p57102
aS'Sawyer AW'
p57103
aS'Tuohy M'
p57104
aS'Stevens WS'
p57105
aS'Rinke de Wit TF'
p57106
aS'Hill AM'
p57107
asS'VI'
p57108
S'26'
p57109
sS'MHDA'
p57110
S'2013/03/07 06:00'
p57111
sS'MH'
p57112
(lp57113
S'Acquired Immunodeficiency Syndrome/drug therapy/*economics/epidemiology'
p57114
aS'Africa South of the Sahara/epidemiology'
p57115
aS'Anti-HIV Agents/*economics/therapeutic use'
p57116
aS'CD4 Lymphocyte Count/economics'
p57117
aS'Clinical Laboratory Techniques/*economics'
p57118
aS'Cost-Benefit Analysis'
p57119
aS'Female'
p57120
aS'Humans'
p57121
aS'Life Expectancy'
p57122
aS'Male'
p57123
aS'*Markov Chains'
p57124
aS'Quality-Adjusted Life Years'
p57125
aS'Sentinel Surveillance'
p57126
aS'Treatment Failure'
p57127
aS'Viral Load/economics'
p57128
asS'EDAT'
p57129
S'2012/06/15 06:00'
p57130
sS'SO'
p57131
S'AIDS. 2012 Aug 24;26(13):1663-72.'
p57132
sS'SB'
p57133
S'IM X'
p57134
sS'PMID'
p57135
S'22695297'
p57136
sS'PST'
p57137
S'ppublish'
p57138
stRp57139
ag2
(g3
g4
(dp57140
S'LID'
p57141
S'10.1097/INF.0b013e3182638012 [doi]'
p57142
sS'STAT'
p57143
S'MEDLINE'
p57144
sS'JT'
p57145
S'The Pediatric infectious disease journal'
p57146
sS'MID'
p57147
(lp57148
S'EMS52807'
p57149
asS'DA'
p57150
S'20120817'
p57151
sS'AID'
p57152
(lp57153
S'10.1097/INF.0b013e3182638012 [doi]'
p57154
asS'CRDT'
p57155
(lp57156
S'2012/06/14 06:00'
p57157
asS'DP'
p57158
S'2012 Sep'
p57159
sS'AD'
p57160
S'Kenya Medical Research Institute (KEMRI), Centre for Geographic Medicine Research, Kilifi, Kenya.'
p57161
sS'OWN'
p57162
S'NLM'
p57163
sS'PT'
p57164
(lp57165
S'Journal Article'
p57166
aS"Research Support, Non-U.S. Gov't"
p57167
asS'LA'
p57168
(lp57169
S'eng'
p57170
asS'FAU'
p57171
(lp57172
S'Webb, Clare'
p57173
aS'Ngama, Mwanajuma'
p57174
aS'Ngatia, Anthony'
p57175
aS'Shebbe, Mohammed'
p57176
aS'Morpeth, Susan'
p57177
aS'Mwarumba, Salim'
p57178
aS'Bett, Ann'
p57179
aS'Nokes, D James'
p57180
aS'Seale, Anna C'
p57181
aS'Kazungu, Sidi'
p57182
aS'Munywoki, Patrick'
p57183
aS'Hammitt, Laura L'
p57184
aS'Scott, J Anthony G'
p57185
aS'Berkley, James A'
p57186
asS'LR'
p57187
S'20150224'
p57188
sS'PG'
p57189
S'e152-7'
p57190
sS'TI'
p57191
S'Treatment failure among Kenyan children with severe pneumonia--a cohort study.'
p57192
sS'PL'
p57193
S'United States'
p57194
sS'TA'
p57195
S'Pediatr Infect Dis J'
p57196
sS'JID'
p57197
S'8701858'
p57198
sS'AB'
p57199
S'BACKGROUND: Pneumonia is the leading cause of childhood mortality worldwide. The World Health Organization recommends presumptive treatment based on clinical syndromes. Recent studies raise concerns over the frequency of treatment failure in Africa. METHODS: We applied a definition of treatment failure to data prospectively collected from children who were 2-59 months of age with severe, or very severe, pneumonia admitted to Kilifi District Hospital, Kenya, from May 2007 through May 2008 and treated using World Health Organization guidelines. The primary outcome was treatment failure at 48 hours. RESULTS: Of 568 children, median age 11 months, 165 (29%) had very severe pneumonia, 30 (5.3%) a positive HIV test and 62 (11%) severe malnutrition. One hundred eleven (20%; 95% confidence interval: 17-23%) children failed treatment at 48 hours and 34 (6.0%) died; 22 (65%) deaths occurred before 48 hours. Of 353 children with severe pneumonia, without HIV or severe malnutrition, 42 (12%) failed to respond at 48 hours, 15 (4.3%) failed at 5 days and 1 child (0.3%) died. Among 215 children with either severe pneumonia complicated by HIV or severe malnutrition, or very severe pneumonia, 69 (32%) failed to treatment at 48 hours, 47 (22%) failed at 5 days and 33 (16%) died. Treatment failure at 48 hours was associated with shock, bacteremia, very severe pneumonia, oxygen saturation in hemoglobin <95%, severe malnutrition, HIV and age <1 year in multivariable models. CONCLUSIONS: In this setting, few children with uncomplicated severe pneumonia fail treatment or die under current guidelines. Deaths mainly occurred early and may be reduced by improving prevention, prehospital care and treatment of sepsis.'
p57200
sS'GR'
p57201
(lp57202
S'081186/Wellcome Trust/United Kingdom'
p57203
aS'081186/Wellcome Trust/United Kingdom'
p57204
aS'083579/Wellcome Trust/United Kingdom'
p57205
aS'084633/Wellcome Trust/United Kingdom'
p57206
aS'092654/Wellcome Trust/United Kingdom'
p57207
asS'IP'
p57208
S'9'
sS'IS'
p57209
S'1532-0987 (Electronic) 0891-3668 (Linking)'
p57210
sS'PMC'
p57211
S'PMC3691501'
p57212
sS'DCOM'
p57213
S'20130121'
p57214
sS'AU'
p57215
(lp57216
S'Webb C'
p57217
aS'Ngama M'
p57218
aS'Ngatia A'
p57219
aS'Shebbe M'
p57220
aS'Morpeth S'
p57221
aS'Mwarumba S'
p57222
aS'Bett A'
p57223
aS'Nokes DJ'
p57224
aS'Seale AC'
p57225
aS'Kazungu S'
p57226
aS'Munywoki P'
p57227
aS'Hammitt LL'
p57228
aS'Scott JA'
p57229
aS'Berkley JA'
p57230
asS'VI'
p57231
S'31'
p57232
sS'MHDA'
p57233
S'2013/01/23 06:00'
p57234
sS'OID'
p57235
(lp57236
S'NLM: EMS52807'
p57237
aS'NLM: PMC3691501'
p57238
asS'MH'
p57239
(lp57240
S'Child Nutrition Disorders/complications'
p57241
aS'Child, Preschool'
p57242
aS'Female'
p57243
aS'HIV Infections/complications'
p57244
aS'Humans'
p57245
aS'Infant'
p57246
aS'Infant Nutrition Disorders/complications'
p57247
aS'Kenya/epidemiology'
p57248
aS'Male'
p57249
aS'Odds Ratio'
p57250
aS'Pneumonia/complications/epidemiology/physiopathology/*therapy'
p57251
aS'Prospective Studies'
p57252
aS'Risk Factors'
p57253
aS'Treatment Failure'
p57254
asS'EDAT'
p57255
S'2012/06/14 06:00'
p57256
sS'SO'
p57257
S'Pediatr Infect Dis J. 2012 Sep;31(9):e152-7. doi: 10.1097/INF.0b013e3182638012.'
p57258
sS'SB'
p57259
S'IM'
p57260
sS'PMID'
p57261
S'22692700'
p57262
sS'PST'
p57263
S'ppublish'
p57264
stRp57265
ag2
(g3
g4
(dp57266
S'LID'
p57267
S'10.5588/ijtld.11.0753 [doi]'
p57268
sS'STAT'
p57269
S'MEDLINE'
p57270
sS'DEP'
p57271
S'20120612'
p57272
sS'DA'
p57273
S'20120705'
p57274
sS'AID'
p57275
(lp57276
S'ijtld110753 [pii]'
p57277
aS'10.5588/ijtld.11.0753 [doi]'
p57278
asS'CRDT'
p57279
(lp57280
S'2012/06/14 06:00'
p57281
asS'DP'
p57282
S'2012 Aug'
p57283
sS'OWN'
p57284
S'NLM'
p57285
sS'PT'
p57286
(lp57287
S'Comparative Study'
p57288
aS'Journal Article'
p57289
aS"Research Support, Non-U.S. Gov't"
p57290
asS'LA'
p57291
(lp57292
S'eng'
p57293
asS'FAU'
p57294
(lp57295
S'Louwagie, G'
p57296
aS'Girdler-Brown, B'
p57297
aS'Odendaal, R'
p57298
aS'Rossouw, T'
p57299
aS'Johnson, S'
p57300
aS'Van der Walt, M'
p57301
asS'JT'
p57302
S'The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease'
p57303
sS'PG'
p57304
S'1052-8'
p57305
sS'TI'
p57306
S'Missed opportunities for accessing HIV care among Tshwane tuberculosis patients under different models of care.'
p57307
sS'RN'
p57308
(lp57309
S'0 (Anti-Retroviral Agents)'
p57310
aS'0 (Antitubercular Agents)'
p57311
asS'PL'
p57312
S'France'
p57313
sS'TA'
p57314
S'Int J Tuberc Lung Dis'
p57315
sS'JID'
p57316
S'9706389'
p57317
sS'AB'
p57318
S"OBJECTIVE: To compare access to human immunodeficiency virus (HIV) care for tuberculosis (TB) patients in settings with antiretroviral treatment (ART) and TB care under one roof ('semi-integrated sites') and in settings with geographically separately rendered care in Tshwane, South Africa. METHODS: Historical cohort study of patients registered with TB at 46 TB treatment points, with follow-up until the end of anti-tuberculosis treatment. ART initiation for HIV-positive TB patients was established through linkage of TB register patient identifiers to the electronic ART register. Data analysis entailed univariate and multivariate competing risk analysis. RESULTS: The records of 636 and 1297 patients for semi-integrated and separate facilities, respectively, were reviewed. Cotrimoxazole prophylactic therapy and recording of CD4 count were lower in semi-integrated than in separate facilities, but the reverse was true for referral to HIV-related care. A higher percentage of patients started ART in the semi-integrated than in the separate facilities (70.5% vs. 44.6%, P < 0.001). In competing risk analysis (with death and lost to follow-up as competing risks), attending a semi-integrated facility (sub-hazard ratio [SHR] 2.49, 95%CI 1.06-5.88) and TB case load > 401 (SHR 1.45, 95%CI 1.04-2.03) were associated with increased ART initiation. CONCLUSIONS: ART and TB treatment under one roof appears to facilitate ART initiation for HIV-positive TB patients."
p57319
sS'AD'
p57320
S'School of Health Systems and Public Health, University of Pretoria, Pretoria, South Africa. Goedele.louwagie@up.ac.za'
p57321
sS'IP'
p57322
S'8'
sS'IS'
p57323
S'1815-7920 (Electronic) 1027-3719 (Linking)'
p57324
sS'DCOM'
p57325
S'20121112'
p57326
sS'AU'
p57327
(lp57328
S'Louwagie G'
p57329
aS'Girdler-Brown B'
p57330
aS'Odendaal R'
p57331
aS'Rossouw T'
p57332
aS'Johnson S'
p57333
aS'Van der Walt M'
p57334
asS'VI'
p57335
S'16'
p57336
sS'MHDA'
p57337
S'2012/11/13 06:00'
p57338
sS'PHST'
p57339
(lp57340
S'2012/06/12 [aheadofprint]'
p57341
asS'MH'
p57342
(lp57343
S'Adult'
p57344
aS'Anti-Retroviral Agents/*therapeutic use'
p57345
aS'Antitubercular Agents/*therapeutic use'
p57346
aS'Chi-Square Distribution'
p57347
aS'*Coinfection'
p57348
aS'Delivery of Health Care, Integrated/*organization & administration'
p57349
aS'Female'
p57350
aS'HIV Infections/diagnosis/*drug therapy/epidemiology'
p57351
aS'Health Services Accessibility/*organization & administration'
p57352
aS'Humans'
p57353
aS'Logistic Models'
p57354
aS'Male'
p57355
aS'Medical Record Linkage'
p57356
aS'*Models, Organizational'
p57357
aS'Multivariate Analysis'
p57358
aS'Registries'
p57359
aS'Retrospective Studies'
p57360
aS'Risk Assessment'
p57361
aS'Risk Factors'
p57362
aS'South Africa/epidemiology'
p57363
aS'Treatment Outcome'
p57364
aS'Tuberculosis, Pulmonary/diagnosis/*drug therapy/epidemiology'
p57365
asS'EDAT'
p57366
S'2012/06/14 06:00'
p57367
sS'SO'
p57368
S'Int J Tuberc Lung Dis. 2012 Aug;16(8):1052-8. doi: 10.5588/ijtld.11.0753. Epub 2012 Jun 12.'
p57369
sS'SB'
p57370
S'IM'
p57371
sS'PMID'
p57372
S'22691870'
p57373
sS'PST'
p57374
S'ppublish'
p57375
stRp57376
ag2
(g3
g4
(dp57377
S'LID'
p57378
S'10.5588/ijtld.11.0651 [doi]'
p57379
sS'STAT'
p57380
S'MEDLINE'
p57381
sS'AB'
p57382
S'BACKGROUND: We describe the outcomes of a program in which antiretroviral therapy (ART) is offered to human immunodeficiency virus (HIV) infected patients in South Africa admitted with tuberculosis (TB) or other opportunistic infection (OI) as part of in-patient care. METHODS: Patients admitted with HIV and concurrent TB or other OI were initiated on early in-patient ART. The primary and secondary endpoints were respectively 24-week mortality and 24-week virologic suppression. Multivariable logistic regression modeling explored the associations between baseline (i.e., pre-hospital discharge) characteristics and mortality at 24 weeks. RESULTS: A total of 382 patients were prospectively enrolled (48% women, median age 37 years, median CD4 count 33 cells/mm(3)). Acute OIs were pulmonary TB, 39%; extra-pulmonary TB, 25%; cryptococcal meningitis (CM), 10%; and chronic diarrhea, 9%. The median time from admission to ART initiation was 14 days (range 4-32, IQR 11-18). At 24 weeks of follow-up, as-treated and intention-to-treat virologic suppression were respectively 57% and 93%. Median change in CD4 cell count was +100 cells/mm(3), overall 24-week mortality was 25% and loss to follow-up, 5%. Excess mortality was not observed among patients with CM who initiated early ART. A longer interval between admission and ART was associated with mortality (>21 days vs. <21 days after admission OR 2.1, 95%CI 1.2-4.0, P = 0.016). CONCLUSIONS: For HIV-infected in-patients with TB or an acquired immune-deficiency syndrome defining OI, we demonstrate the operational feasibility of early ART initiation in in-patients.'
p57383
sS'JID'
p57384
S'9706389'
p57385
sS'AD'
p57386
S'McCord Hospital, Durban, South Africa. henrysunpath@yebo.co.za'
p57387
sS'JT'
p57388
S'The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease'
p57389
sS'IP'
p57390
S'7'
sS'IS'
p57391
S'1815-7920 (Electronic) 1027-3719 (Linking)'
p57392
sS'DCOM'
p57393
S'20130509'
p57394
sS'DA'
p57395
S'20120612'
p57396
sS'AU'
p57397
(lp57398
S'Sunpath H'
p57399
aS'Edwin C'
p57400
aS'Chelin N'
p57401
aS'Nadesan S'
p57402
aS'Maharaj R'
p57403
aS'Moosa Y'
p57404
aS'Smeaton L'
p57405
aS'Court R'
p57406
aS'Knight S'
p57407
aS'Gwyther E'
p57408
aS'Murphy RA'
p57409
asS'AID'
p57410
(lp57411
S'10.5588/ijtld.11.0651 [doi]'
p57412
asS'CRDT'
p57413
(lp57414
S'2012/06/13 06:00'
p57415
asS'VI'
p57416
S'16'
p57417
sS'PMID'
p57418
S'22687498'
p57419
sS'DP'
p57420
S'2012 Jul'
p57421
sS'MHDA'
p57422
S'2013/05/10 06:00'
p57423
sS'OWN'
p57424
S'NLM'
p57425
sS'PT'
p57426
(lp57427
S'Journal Article'
p57428
asS'LA'
p57429
(lp57430
S'eng'
p57431
asS'MH'
p57432
(lp57433
S'AIDS-Related Opportunistic Infections/*complications'
p57434
aS'Adult'
p57435
aS'Anti-Retroviral Agents/*therapeutic use'
p57436
aS'CD4 Lymphocyte Count'
p57437
aS'Cohort Studies'
p57438
aS'Female'
p57439
aS'Follow-Up Studies'
p57440
aS'HIV'
p57441
aS'HIV Infections/complications/*drug therapy/mortality'
p57442
aS'Humans'
p57443
aS'Logistic Models'
p57444
aS'Male'
p57445
aS'Operations Research'
p57446
aS'Retrospective Studies'
p57447
aS'South Africa'
p57448
aS'Tuberculosis/*complications'
p57449
asS'FAU'
p57450
(lp57451
S'Sunpath, H'
p57452
aS'Edwin, C'
p57453
aS'Chelin, N'
p57454
aS'Nadesan, S'
p57455
aS'Maharaj, R'
p57456
aS'Moosa, Y'
p57457
aS'Smeaton, L'
p57458
aS'Court, R'
p57459
aS'Knight, S'
p57460
aS'Gwyther, E'
p57461
aS'Murphy, R A'
p57462
asS'EDAT'
p57463
S'2012/06/13 06:00'
p57464
sS'PST'
p57465
S'ppublish'
p57466
sS'SO'
p57467
S'Int J Tuberc Lung Dis. 2012 Jul;16(7):917-23. doi: 10.5588/ijtld.11.0651.'
p57468
sS'PG'
p57469
S'917-23'
p57470
sS'TI'
p57471
S'Operationalizing early antiretroviral therapy in HIV-infected in-patients with opportunistic infections including tuberculosis.'
p57472
sS'SB'
p57473
S'IM'
p57474
sS'RN'
p57475
(lp57476
S'0 (Anti-Retroviral Agents)'
p57477
asS'PL'
p57478
S'France'
p57479
sS'TA'
p57480
S'Int J Tuberc Lung Dis'
p57481
stRp57482
ag2
(g3
g4
(dp57483
S'LID'
p57484
S'10.1371/journal.pone.0038443 [doi]'
p57485
sS'STAT'
p57486
S'MEDLINE'
p57487
sS'DEP'
p57488
S'20120607'
p57489
sS'DA'
p57490
S'20120611'
p57491
sS'AID'
p57492
(lp57493
S'10.1371/journal.pone.0038443 [doi]'
p57494
aS'PONE-D-12-00422 [pii]'
p57495
asS'CRDT'
p57496
(lp57497
S'2012/06/12 06:00'
p57498
asS'DP'
p57499
S'2012'
p57500
sS'AD'
p57501
S'International Center for AIDS Care and Treatment Programs (ICAP), Mailman School of Public Health, Columbia University, New York, New York, United States of America. mrl2013@columbia.edu'
p57502
sS'OWN'
p57503
S'NLM'
p57504
sS'PT'
p57505
(lp57506
S'Journal Article'
p57507
aS'Multicenter Study'
p57508
aS"Research Support, Non-U.S. Gov't"
p57509
aS"Research Support, U.S. Gov't, Non-P.H.S."
p57510
aS"Research Support, U.S. Gov't, P.H.S."
p57511
asS'LA'
p57512
(lp57513
S'eng'
p57514
asS'FAU'
p57515
(lp57516
S'Lamb, Matthew R'
p57517
aS'El-Sadr, Wafaa M'
p57518
aS'Geng, Elvin'
p57519
aS'Nash, Denis'
p57520
asS'JT'
p57521
S'PloS one'
p57522
sS'LR'
p57523
S'20150224'
p57524
sS'PG'
p57525
S'e38443'
p57526
sS'TI'
p57527
S'Association of adherence support and outreach services with total attrition, loss to follow-up, and death among ART patients in sub-Saharan Africa.'
p57528
sS'RN'
p57529
(lp57530
S'0 (Anti-HIV Agents)'
p57531
asS'PL'
p57532
S'United States'
p57533
sS'TA'
p57534
S'PLoS One'
p57535
sS'JID'
p57536
S'101285081'
p57537
sS'AB'
p57538
S'BACKGROUND: Loss to follow-up (LTF) after antiretroviral therapy (ART) initiation is common in HIV clinics. We examined the effect of availability of adherence support and active patient outreach services on patient attrition following ART initiation. METHODS AND FINDINGS: This ecologic study examined clinic attrition rates (total attrition, LTF, and death) among 232,389 patients initiating ART at 349 clinics during 2004-2008 in 10 sub-Saharan African countries, and cohort attrition (proportion retained at 6 and 12 months after ART initiation) among a subset of patients with follow-up information (n=83,389). Log-linear regression compared mean rates of attrition, LTF, and death between clinics with and without adherence support and outreach services. Cumulative attrition, LTF, and death rates were 14.2, 9.2, and 4.9 per 100 person-years on ART, respectively. In multivariate analyses, clinic availability of >2 adherence support services was marginally associated with lower attrition rates (RR(adj)=0.59, 95%CI: 0.35-1.0). Clinics with availability of counseling services (RR(adj)=0.62, 95%CI: 0.42-0.92), educational materials (RR(adj)=0.73, 95%CI: 0.63-0.85), reminder tools (RR(adj)=0.79, 95%CI: 0.64-0.97), and food rations (RR(adj)=0.72, 95%CI: 0.58-0.90) had significantly lower attrition, with similar results observed for LTF. Outreach services were not significantly associated with attrition. In cohort analyses, attrition was significantly lower at clinics offering >2 adherence support services (RR(adj,6m)=0.84, 95%CI: 0.73-0.96), dedicated pharmacy services (RR(adj,6m)=0.78, 95%CI: 0.69-0.90), and active patient outreach (RR(adj,6m)=0.85, 95%CI: 0.73-0.99). Availability of food rations was marginally associated with increased retention at 6 (RR(adj,6m) =0.82, 95%CI: 0.64-1.05) but not 12 months (RR(adj,12m) =0.98, 95%CI: 0.78-1.21). CONCLUSIONS: Availability of adherence support services, active patient outreach and food rations at HIV care clinics may improve retention following ART initiation.'
p57539
sS'GR'
p57540
(lp57541
S'K23 AI084544/AI/NIAID NIH HHS/United States'
p57542
aS'PEPFAR/United States'
p57543
asS'IP'
p57544
S'6'
sS'IS'
p57545
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p57546
sS'PMC'
p57547
S'PMC3369888'
p57548
sS'DCOM'
p57549
S'20121207'
p57550
sS'AU'
p57551
(lp57552
S'Lamb MR'
p57553
aS'El-Sadr WM'
p57554
aS'Geng E'
p57555
aS'Nash D'
p57556
asS'VI'
p57557
S'7'
sS'MHDA'
p57558
S'2012/12/12 06:00'
p57559
sS'PHST'
p57560
(lp57561
S'2011/12/30 [received]'
p57562
aS'2012/05/08 [accepted]'
p57563
aS'2012/06/07 [epublish]'
p57564
asS'OID'
p57565
(lp57566
S'NLM: PMC3369888'
p57567
asS'MH'
p57568
(lp57569
S'Adolescent'
p57570
aS'Adult'
p57571
aS'Africa South of the Sahara'
p57572
aS'Anti-HIV Agents/*therapeutic use'
p57573
aS'Child'
p57574
aS'Cohort Studies'
p57575
aS'Delivery of Health Care/*statistics & numerical data'
p57576
aS'Female'
p57577
aS'Follow-Up Studies'
p57578
aS'HIV Infections/*drug therapy/mortality'
p57579
aS'Health Education/statistics & numerical data'
p57580
aS'Humans'
p57581
aS'Linear Models'
p57582
aS'Lost to Follow-Up'
p57583
aS'Male'
p57584
aS'Multivariate Analysis'
p57585
aS'Outcome Assessment (Health Care)/statistics & numerical data'
p57586
aS'Patient Compliance/*statistics & numerical data'
p57587
aS'Survival Rate'
p57588
asS'EDAT'
p57589
S'2012/06/12 06:00'
p57590
sS'SO'
p57591
S'PLoS One. 2012;7(6):e38443. doi: 10.1371/journal.pone.0038443. Epub 2012 Jun 7.'
p57592
sS'SB'
p57593
S'IM'
p57594
sS'PMID'
p57595
S'22685569'
p57596
sS'PST'
p57597
S'ppublish'
p57598
stRp57599
ag2
(g3
g4
(dp57600
S'LID'
p57601
S'10.1111/j.1471-0528.2012.03402.x [doi]'
p57602
sS'STAT'
p57603
S'MEDLINE'
p57604
sS'DEP'
p57605
S'20120607'
p57606
sS'CI'
p57607
(lp57608
S'(c) 2012 World Health Organization BJOG An International Journal of Obstetrics'
p57609
aS'and Gynaecology (c) 2012 RCOG.'
p57610
asS'DA'
p57611
S'20120711'
p57612
sS'AID'
p57613
(lp57614
S'10.1111/j.1471-0528.2012.03402.x [doi]'
p57615
asS'CRDT'
p57616
(lp57617
S'2012/06/09 06:00'
p57618
asS'DP'
p57619
S'2012 Aug'
p57620
sS'OWN'
p57621
S'NLM'
p57622
sS'PT'
p57623
(lp57624
S'Comparative Study'
p57625
aS'Journal Article'
p57626
aS"Research Support, Non-U.S. Gov't"
p57627
asS'LA'
p57628
(lp57629
S'eng'
p57630
asS'FAU'
p57631
(lp57632
S'Rodriguez, M I'
p57633
aS'Reeves, M F'
p57634
aS'Caughey, A B'
p57635
asS'JT'
p57636
S'BJOG : an international journal of obstetrics and gynaecology'
p57637
sS'PG'
p57638
S'1067-73'
p57639
sS'TI'
p57640
S'Evaluating the competing risks of HIV acquisition and maternal mortality in Africa: a decision analysis.'
p57641
sS'RN'
p57642
(lp57643
S'0 (Contraceptive Agents)'
p57644
aS'0 (Drug Implants)'
p57645
aS'0 (Progestins)'
p57646
asS'PL'
p57647
S'England'
p57648
sS'TA'
p57649
S'BJOG'
p57650
sS'JID'
p57651
S'100935741'
p57652
sS'AB'
p57653
S'OBJECTIVE: To model the risk of HIV acquisition and maternal mortality for women in four African countries in the light of previous data on risk of HIV acquisition and hormonal contraceptive use. DESIGN: Decision analysis. SETTING: Chad, Kenya, South Africa and Uganda. POPULATION: Women of reproductive age, at risk of HIV, who do not desire pregnancy. METHODS: A decision analysis model was built to compare the consequences of removing progestin injectables from use, assuming an increased risk of HIV acquisition. Three scenarios were considered in four African countries: replacement of progestin injectables with no method, with combined oral contraceptives (COC) or with an intrauterine device (IUD). Health outcomes measured include: life-years, maternal mortality, HIV acquisition and unsafe abortion. Sensitivity analysis, including Monte Carlo simulation, was performed around all variables. MAIN OUTCOME MEASURES: HIV acquisition, maternal mortality and life-years. RESULTS: If progestin injectables are removed from use, without a minimum of 70-100% of women switching to an IUD or COCs, up to nine additional maternal deaths will occur for every case of HIV averted. Sensitivity analysis demonstrated that this finding persisted across a broad range of variables. CONCLUSIONS: Contraception is critical to preserving life for women in Africa. In the absence of clear evidence regarding hormonal contraception and HIV acquisition, policy decisions must not overlook the very real risk of maternal mortality.'
p57654
sS'AD'
p57655
S'World Health Organization, Geneva, Switzerland. rodriguezmar@who.int'
p57656
sS'IP'
p57657
S'9'
sS'IS'
p57658
S'1471-0528 (Electronic) 1470-0328 (Linking)'
p57659
sS'DCOM'
p57660
S'20120921'
p57661
sS'AU'
p57662
(lp57663
S'Rodriguez MI'
p57664
aS'Reeves MF'
p57665
aS'Caughey AB'
p57666
asS'VI'
p57667
S'119'
p57668
sS'MHDA'
p57669
S'2012/09/22 06:00'
p57670
sS'PHST'
p57671
(lp57672
S'2012/06/07 [aheadofprint]'
p57673
asS'MH'
p57674
(lp57675
S'Abortion, Induced/statistics & numerical data'
p57676
aS'Africa'
p57677
aS'Condoms/utilization'
p57678
aS'Contraceptive Agents/administration & dosage/*adverse effects/supply & distribution'
p57679
aS'Decision Support Techniques'
p57680
aS'Drug Implants'
p57681
aS'Female'
p57682
aS'HIV Infections/*mortality'
p57683
aS'Health Services Accessibility'
p57684
aS'Humans'
p57685
aS'Intrauterine Devices, Medicated'
p57686
aS'Life Expectancy'
p57687
aS'*Maternal Mortality'
p57688
aS'Pregnancy'
p57689
aS'Pregnancy Complications, Infectious/mortality'
p57690
aS'Pregnancy Rate'
p57691
aS'Progestins/administration & dosage/*adverse effects/supply & distribution'
p57692
aS'Risk Factors'
p57693
asS'EDAT'
p57694
S'2012/06/09 06:00'
p57695
sS'SO'
p57696
S'BJOG. 2012 Aug;119(9):1067-73. doi: 10.1111/j.1471-0528.2012.03402.x. Epub 2012 Jun 7.'
p57697
sS'SB'
p57698
S'AIM IM'
p57699
sS'PMID'
p57700
S'22676150'
p57701
sS'PST'
p57702
S'ppublish'
p57703
stRp57704
ag2
(g3
g4
(dp57705
S'LID'
p57706
S'10.1186/1471-2458-12-405 [doi]'
p57707
sS'STAT'
p57708
S'MEDLINE'
p57709
sS'DEP'
p57710
S'20120606'
p57711
sS'DA'
p57712
S'20120823'
p57713
sS'AID'
p57714
(lp57715
S'1471-2458-12-405 [pii]'
p57716
aS'10.1186/1471-2458-12-405 [doi]'
p57717
asS'CRDT'
p57718
(lp57719
S'2012/06/08 06:00'
p57720
asS'DP'
p57721
S'2012'
p57722
sS'OWN'
p57723
S'NLM'
p57724
sS'PT'
p57725
(lp57726
S'Journal Article'
p57727
asS'LA'
p57728
(lp57729
S'eng'
p57730
asS'DCOM'
p57731
S'20121126'
p57732
sS'JT'
p57733
S'BMC public health'
p57734
sS'LR'
p57735
S'20150225'
p57736
sS'FAU'
p57737
(lp57738
S'Mandala, Justin'
p57739
aS'Moyo, Tiwonge'
p57740
aS'Torpey, Kwasi'
p57741
aS'Weaver, Mark'
p57742
aS'Suzuki, Chiho'
p57743
aS'Dirks, Rebecca'
p57744
aS'Hayashi, Chika'
p57745
asS'TI'
p57746
S'Use of service data to inform pediatric HIV-free survival following prevention of mother-to-child transmission programs in rural Malawi.'
p57747
sS'RN'
p57748
(lp57749
S'0 (Anti-HIV Agents)'
p57750
aS'99DK7FVK1H (Nevirapine)'
p57751
asS'PL'
p57752
S'England'
p57753
sS'PG'
p57754
S'405'
p57755
sS'JID'
p57756
S'100968562'
p57757
sS'AB'
p57758
S"BACKGROUND: Recent years have seen rapid and significant progress in science and implementation of programs to prevent mother-to-child transmission of HIV. Programs that support PMTCT routinely monitor service provision but very few have measured their effectiveness. The objective of the study was to use service data to inform HIV-free survival among HIV exposed children that received antiretroviral drugs to prevent mother-to-child transmission (PMTCT) of HIV. The study was conducted in two rural districts in Malawi with support from FHI 360. METHODS: A descriptive observational study of PMTCT outcomes was conducted between June 2005 and June 2009. The dataset included patient-level data of all pregnant women 1) that tested HIV-positive, 2) that were dispensed with antiretroviral prophylaxis, and 3) whose addresses were available for home visits. The data were matched to each woman's corresponding antenatal clinic data from home visit registers. RESULTS: Out of 438 children whose home addresses were available, 33 (8%) were lost to follow-up, 35 (8%) were alive but not tested for HIV by the time home visit was conducted, and 52 (12%) were confirmed deceased. A total of 318 children were alive at the time of the home visit and had an HIV antibody test done at median age 15 months. The resulting estimated 24-month probability of HIV-free survival over all children was 78%. Among children who did not receive nevirapine, the estimated 24-month probability of HIV-free survival was 61%, and among those who did receive NVP syrup the estimate was 82%. CONCLUSIONS: When mothers and newborns received nevirapine, the estimated 24-month probability of HIV-free survival among children was high at 82% (CI: 54% to 99%). However this conclusion should be interpreted cautiously 1) due to the wide confidence interval; and 2) because the confidence interval range includes 55%, which is the natural HIV-free survival rate in the absence of a PMTCT intervention. This analysis highlighted the need of quality data and well-structured home visits to assess PMTCT effectiveness."
p57759
sS'AD'
p57760
S'FHI, Washington, DC, USA. jmandala@fhi360.org'
p57761
sS'VI'
p57762
S'12'
p57763
sS'IS'
p57764
S'1471-2458 (Electronic) 1471-2458 (Linking)'
p57765
sS'PMC'
p57766
S'PMC3425277'
p57767
sS'AU'
p57768
(lp57769
S'Mandala J'
p57770
aS'Moyo T'
p57771
aS'Torpey K'
p57772
aS'Weaver M'
p57773
aS'Suzuki C'
p57774
aS'Dirks R'
p57775
aS'Hayashi C'
p57776
asS'MHDA'
p57777
S'2012/12/10 06:00'
p57778
sS'PHST'
p57779
(lp57780
S'2011/09/15 [received]'
p57781
aS'2012/06/06 [accepted]'
p57782
aS'2012/06/06 [aheadofprint]'
p57783
asS'OID'
p57784
(lp57785
S'NLM: PMC3425277'
p57786
asS'MH'
p57787
(lp57788
S'Adult'
p57789
aS'Anti-HIV Agents/therapeutic use'
p57790
aS'Breast Feeding/statistics & numerical data'
p57791
aS'Disease-Free Survival'
p57792
aS'Female'
p57793
aS'Follow-Up Studies'
p57794
aS'HIV Infections/diagnosis/drug therapy/*prevention & control'
p57795
aS'Health Services Research/*statistics & numerical data'
p57796
aS'Humans'
p57797
aS'Infant, Newborn'
p57798
aS'Infectious Disease Transmission, Vertical/*prevention & control'
p57799
aS'Malawi/epidemiology'
p57800
aS'Maternal-Child Health Centers/utilization'
p57801
aS'Mothers/statistics & numerical data'
p57802
aS'Nevirapine/therapeutic use'
p57803
aS'*Outcome Assessment (Health Care)'
p57804
aS'Parity'
p57805
aS'*Pediatrics/standards'
p57806
aS'Pregnancy'
p57807
aS'Program Evaluation'
p57808
aS'Proportional Hazards Models'
p57809
aS'*Rural Health'
p57810
asS'EDAT'
p57811
S'2012/06/08 06:00'
p57812
sS'SO'
p57813
S'BMC Public Health. 2012 Jun 6;12:405. doi: 10.1186/1471-2458-12-405.'
p57814
sS'SB'
p57815
S'IM'
p57816
sS'PMID'
p57817
S'22672627'
p57818
sS'TA'
p57819
S'BMC Public Health'
p57820
sS'PST'
p57821
S'epublish'
p57822
stRp57823
ag2
(g3
g4
(dp57824
S'LID'
p57825
S'10.1016/j.oooo.2011.09.004 [doi]'
p57826
sS'STAT'
p57827
S'MEDLINE'
p57828
sS'JT'
p57829
S'Oral surgery, oral medicine, oral pathology and oral radiology'
p57830
sS'CI'
p57831
(lp57832
S'Copyright (c) 2012 Elsevier Inc. All rights reserved.'
p57833
asS'DA'
p57834
S'20120606'
p57835
sS'AID'
p57836
(lp57837
S'S2212-4403(11)00682-1 [pii]'
p57838
aS'10.1016/j.oooo.2011.09.004 [doi]'
p57839
asS'CRDT'
p57840
(lp57841
S'2012/06/07 06:00'
p57842
asS'DP'
p57843
S'2012 Mar'
p57844
sS'AD'
p57845
S'Clinical HIV Research Unit, Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. devans@witshealth.co.za'
p57846
sS'OWN'
p57847
S'NLM'
p57848
sS'PT'
p57849
(lp57850
S'Journal Article'
p57851
aS'Research Support, N.I.H., Extramural'
p57852
aS"Research Support, Non-U.S. Gov't"
p57853
aS"Research Support, U.S. Gov't, Non-P.H.S."
p57854
asS'LA'
p57855
(lp57856
S'eng'
p57857
asS'FAU'
p57858
(lp57859
S'Evans, Denise'
p57860
aS'Maskew, Mhairi'
p57861
aS'Sanne, Ian'
p57862
asS'LR'
p57863
S'20150225'
p57864
sS'PG'
p57865
S'362-72'
p57866
sS'TI'
p57867
S'Increased risk of mortality and loss to follow-up among HIV-positive patients with oropharyngeal candidiasis and malnutrition before antiretroviral therapy initiation: a retrospective analysis from a large urban cohort in Johannesburg, South Africa.'
p57868
sS'RN'
p57869
(lp57870
S'0 (Anti-Retroviral Agents)'
p57871
asS'PL'
p57872
S'United States'
p57873
sS'TA'
p57874
S'Oral Surg Oral Med Oral Pathol Oral Radiol'
p57875
sS'JID'
p57876
S'101576782'
p57877
sS'AB'
p57878
S'OBJECTIVE: We investigated the effect of oropharyngeal candidiasis (OC) and body mass index (BMI) before antiretroviral therapy (ART) initiation on treatment outcomes of human immunodeficiency virus (HIV)-positive patients. STUDY DESIGN: Treatment outcomes included failure to increase CD4 count by >/=50 or >/=100 cells/muL or failure to suppress viral load (<400 copies/mL) at 6 or 12 months in addition to loss to follow-up (LTFU) and mortality by 12 months. Risk and hazard ratios (HRs) were estimated with the use of log-binomial regression and Cox proportional hazards models, respectively. RESULTS: Baseline CD4 <100 cells/muL, low BMI (<18.5 kg/m(2)), low hemoglobin, and elevated aspartate transaminase were associated with OC at ART initiation. Patients with low BMI with and without, respectively, OC were at risk of mortality (HR 2.42, 95% CI 1.88-3.12; HR 1.87, 95% CI 1.54-2.28) and LTFU (HR 1.36, 95% CI 1.02-1.82; HR 1.55, 95% CI 1.30-1.85). CONCLUSIONS: Low BMI (with/without OC) at ART initiation was associated with poor treatment outcomes. Conversely, normal BMI with OC was associated with adequate CD4 response and reduced LTFU compared with without OC.'
p57879
sS'GR'
p57880
(lp57881
S'P30 AI027767/AI/NIAID NIH HHS/United States'
p57882
aS'P30 AI027767-23/AI/NIAID NIH HHS/United States'
p57883
aS'P30AI027767/AI/NIAID NIH HHS/United States'
p57884
asS'IP'
p57885
S'3'
sS'IS'
p57886
S'2212-4411 (Electronic)'
p57887
sS'PMC'
p57888
S'PMC3370659'
p57889
sS'DCOM'
p57890
S'20130429'
p57891
sS'MID'
p57892
(lp57893
S'NIHMS345637'
p57894
asS'AU'
p57895
(lp57896
S'Evans D'
p57897
aS'Maskew M'
p57898
aS'Sanne I'
p57899
asS'VI'
p57900
S'113'
p57901
sS'MHDA'
p57902
S'2013/04/30 06:00'
p57903
sS'PHST'
p57904
(lp57905
S'2011/05/13 [received]'
p57906
aS'2011/09/02 [revised]'
p57907
aS'2011/09/07 [accepted]'
p57908
asS'OID'
p57909
(lp57910
S'NLM: NIHMS345637'
p57911
aS'NLM: PMC3370659'
p57912
asS'MH'
p57913
(lp57914
S'Adult'
p57915
aS'Anti-Retroviral Agents/*therapeutic use'
p57916
aS'Body Mass Index'
p57917
aS'CD4 Lymphocyte Count'
p57918
aS'Candidiasis, Oral/*complications/epidemiology'
p57919
aS'Chi-Square Distribution'
p57920
aS'Female'
p57921
aS'HIV Infections/*complications/drug therapy/*mortality'
p57922
aS'Humans'
p57923
aS'Kaplan-Meier Estimate'
p57924
aS'Logistic Models'
p57925
aS'Lost to Follow-Up'
p57926
aS'Male'
p57927
aS'Malnutrition/*complications'
p57928
aS'Prevalence'
p57929
aS'Proportional Hazards Models'
p57930
aS'Retrospective Studies'
p57931
aS'Risk Factors'
p57932
aS'South Africa/epidemiology'
p57933
aS'Statistics, Nonparametric'
p57934
aS'Urban Population'
p57935
asS'EDAT'
p57936
S'2012/06/07 06:00'
p57937
sS'SO'
p57938
S'Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Mar;113(3):362-72. doi: 10.1016/j.oooo.2011.09.004.'
p57939
sS'SB'
p57940
S'D IM'
p57941
sS'PMID'
p57942
S'22669142'
p57943
sS'PST'
p57944
S'ppublish'
p57945
stRp57946
ag2
(g3
g4
(dp57947
S'STAT'
p57948
S'MEDLINE'
p57949
sS'DEP'
p57950
S'20120302'
p57951
sS'MID'
p57952
(lp57953
S'EMS50449'
p57954
asS'DA'
p57955
S'20120606'
p57956
sS'CRDT'
p57957
(lp57958
S'2012/06/07 06:00'
p57959
asS'DP'
p57960
S'2012 Jun'
p57961
sS'AD'
p57962
S'Department of Medicine, Faculty of Health Sciences, University of Cape Town. charlottelouw@discoverymail.co.za'
p57963
sS'OWN'
p57964
S'NLM'
p57965
sS'PT'
p57966
(lp57967
S'Journal Article'
p57968
aS'Research Support, N.I.H., Extramural'
p57969
aS"Research Support, Non-U.S. Gov't"
p57970
asS'LA'
p57971
(lp57972
S'eng'
p57973
asS'FAU'
p57974
(lp57975
S'Schutz, Charlotte'
p57976
aS'Ismail, Zahiera'
p57977
aS'Proxenos, Charles John'
p57978
aS'Marais, Suzaan'
p57979
aS'Burton, Rosie'
p57980
aS'Kenyon, Chris'
p57981
aS'Maartens, Gary'
p57982
aS'Wilkinson, Robert J'
p57983
aS'Meintjes, Graeme'
p57984
asS'JT'
p57985
S'South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde'
p57986
sS'LR'
p57987
S'20150225'
p57988
sS'PG'
p57989
S'506-11'
p57990
sS'TI'
p57991
S'Burden of antituberculosis and antiretroviral drug-induced liver injury at a secondary hospital in South Africa.'
p57992
sS'RN'
p57993
(lp57994
S'0 (Anti-Retroviral Agents)'
p57995
aS'0 (Antitubercular Agents)'
p57996
aS'EC 2.6.1.1 (Aspartate Aminotransferases)'
p57997
aS'EC 2.6.1.2 (Alanine Transaminase)'
p57998
aS'RFM9X3LJ49 (Bilirubin)'
p57999
asS'PL'
p58000
S'South Africa'
p58001
sS'TA'
p58002
S'S Afr Med J'
p58003
sS'JID'
p58004
S'0404520'
p58005
sS'AB'
p58006
S'BACKGROUND: G F Jooste Hospital (GFJH) is a secondary-level referral hospital in a high HIV and tuberculosis (TB) co-infection setting. AIMS: To assess the proportion of significant drug-induced liver injury (DILI) due to tuberculosis treatment (TBT) and/or antiretroviral therapy (ART) among patients presenting with liver dysfunction at GFJH and to describe management and outcomes. METHODS: A retrospective observational study was performed of all cases referred to GFJH with significant liver dysfunction from 1 January to 30 June 2009. Significant liver dysfunction was defined by alanine transaminase (ALT)>/=200 U/l or total bilirubin (TBR)>/=44 micromol/l. TBT- or ART-associated DILI was defined as significant liver dysfunction attributed to TBT and/or ART and which resulted in the halting of treatment or the adjustment thereof. Outcome measures included case numbers, descriptive data, and in-hospital and 3-month mortality. RESULTS: A total of 318/354 cases of significant liver dysfunction were reviewed: 71 were classified as TBT- or ART-associated DILI, while liver dysfunction was attributed to other causes in the remainder. In-hospital and 3-month mortality of TBT- or ART-associated DILI patients was 27% (n=19) and 35% (n=25), respectively. The majority of deaths were related to sepsis or sepsis complicating liver dysfunction. Twenty-three patients (32%) were lost to follow-up; 23 (32%) were alive and in outpatient care 3 months after presentation. CONCLUSIONS: TBT- or ART-associated DILI is a common reason for presentation at a referral hospital in South Africa. In-hospital and 3-month mortality are high. Prospective studies are needed to define optimal management.'
p58007
sS'GR'
p58008
(lp58009
S'084323/Wellcome Trust/United Kingdom'
p58010
aS'088316/Wellcome Trust/United Kingdom'
p58011
aS'1U2RTW007373-01A1/PHS HHS/United States'
p58012
aS'MC_U117588499/Medical Research Council/United Kingdom'
p58013
aS'U2RTW007373/PHS HHS/United States'
p58014
aS'Wellcome Trust/United Kingdom'
p58015
asS'IP'
p58016
S'6'
sS'IS'
p58017
S'0256-9574 (Print)'
p58018
sS'PMC'
p58019
S'PMC3605782'
p58020
sS'DCOM'
p58021
S'20120821'
p58022
sS'AU'
p58023
(lp58024
S'Schutz C'
p58025
aS'Ismail Z'
p58026
aS'Proxenos CJ'
p58027
aS'Marais S'
p58028
aS'Burton R'
p58029
aS'Kenyon C'
p58030
aS'Maartens G'
p58031
aS'Wilkinson RJ'
p58032
aS'Meintjes G'
p58033
asS'VI'
p58034
S'102'
p58035
sS'MHDA'
p58036
S'2012/08/22 06:00'
p58037
sS'PHST'
p58038
(lp58039
S'2012/01/20 [received]'
p58040
aS'2012/01/27 [accepted]'
p58041
asS'OID'
p58042
(lp58043
S'NLM: EMS50449'
p58044
aS'NLM: PMC3605782'
p58045
asS'MH'
p58046
(lp58047
S'Adult'
p58048
aS'Alanine Transaminase/blood'
p58049
aS'Anti-Retroviral Agents/*adverse effects'
p58050
aS'Antitubercular Agents/*adverse effects'
p58051
aS'Aspartate Aminotransferases/blood'
p58052
aS'Bilirubin/blood'
p58053
aS'Drug-Induced Liver Injury/blood/*physiopathology/therapy'
p58054
aS'Female'
p58055
aS'HIV Infections/drug therapy'
p58056
aS'Hospital Mortality'
p58057
aS'Humans'
p58058
aS'Kaplan-Meier Estimate'
p58059
aS'Length of Stay'
p58060
aS'Male'
p58061
aS'Middle Aged'
p58062
aS'Retrospective Studies'
p58063
aS'Sepsis/complications'
p58064
aS'South Africa'
p58065
aS'Tuberculosis, Pulmonary/drug therapy'
p58066
asS'EDAT'
p58067
S'2012/06/07 06:00'
p58068
sS'SO'
p58069
S'S Afr Med J. 2012 Mar 2;102(6):506-11.'
p58070
sS'SB'
p58071
S'IM'
p58072
sS'PMID'
p58073
S'22668951'
p58074
sS'PST'
p58075
S'epublish'
p58076
stRp58077
ag2
(g3
g4
(dp58078
S'STAT'
p58079
S'MEDLINE'
p58080
sS'DEP'
p58081
S'20120601'
p58082
sS'DA'
p58083
S'20120822'
p58084
sS'AID'
p58085
(lp58086
S'cis507 [pii]'
p58087
aS'10.1093/cid/cis507 [doi]'
p58088
asS'CRDT'
p58089
(lp58090
S'2012/06/05 06:00'
p58091
asS'DP'
p58092
S'2012 Sep'
p58093
sS'GR'
p58094
(lp58095
S'5 U01AI069401/AI/NIAID NIH HHS/United States'
p58096
aS'5U01 AI069438-03/AI/NIAID NIH HHS/United States'
p58097
aS'5U01AI069417-03/AI/NIAID NIH HHS/United States'
p58098
aS'5U01AI069426-03/AI/NIAID NIH HHS/United States'
p58099
aS'AI-068634/AI/NIAID NIH HHS/United States'
p58100
aS'AI069399/AI/NIAID NIH HHS/United States'
p58101
aS'AI069432/AI/NIAID NIH HHS/United States'
p58102
aS'AI069450/AI/NIAID NIH HHS/United States'
p58103
aS'AI069518/AI/NIAID NIH HHS/United States'
p58104
aS'AI69476/AI/NIAID NIH HHS/United States'
p58105
aS'P30 AI050410/AI/NIAID NIH HHS/United States'
p58106
aS'U01A1069518/PHS HHS/United States'
p58107
aS'U01AI068636/AI/NIAID NIH HHS/United States'
p58108
asS'OWN'
p58109
S'NLM'
p58110
sS'PT'
p58111
(lp58112
S'Journal Article'
p58113
aS'Randomized Controlled Trial'
p58114
aS'Research Support, N.I.H., Extramural'
p58115
aS"Research Support, Non-U.S. Gov't"
p58116
asS'LA'
p58117
(lp58118
S'eng'
p58119
asS'FAU'
p58120
(lp58121
S'Robertson, K'
p58122
aS'Jiang, H'
p58123
aS'Kumwenda, J'
p58124
aS'Supparatpinyo, K'
p58125
aS'Evans, S'
p58126
aS'Campbell, T B'
p58127
aS'Price, R'
p58128
aS'Tripathy, S'
p58129
aS'Kumarasamy, N'
p58130
aS'La Rosa, A'
p58131
aS'Santos, B'
p58132
aS'Silva, M T'
p58133
aS'Montano, S'
p58134
aS'Kanyama, C'
p58135
aS'Faesen, S'
p58136
aS'Murphy, R'
p58137
aS'Hall, C'
p58138
aS'Marra, C M'
p58139
aS'Marcus, C'
p58140
aS'Berzins, B'
p58141
aS'Allen, R'
p58142
aS'Housseinipour, M'
p58143
aS'Amod, F'
p58144
aS'Sanne, I'
p58145
aS'Hakim, J'
p58146
aS'Walawander, A'
p58147
aS'Nair, A'
p58148
asS'JT'
p58149
S'Clinical infectious diseases : an official publication of the Infectious Diseases Society of America'
p58150
sS'LR'
p58151
S'20150616'
p58152
sS'PG'
p58153
S'868-76'
p58154
sS'TI'
p58155
S'Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study a5199, the International Neurological Study.'
p58156
sS'RN'
p58157
(lp58158
S'0 (Anti-Retroviral Agents)'
p58159
asS'PL'
p58160
S'United States'
p58161
sS'TA'
p58162
S'Clin Infect Dis'
p58163
sS'JID'
p58164
S'9203213'
p58165
sS'AB'
p58166
S'BACKGROUND: AIDS Clinical Trials Group (ACTG) A5199 compared the neurological and neuropsychological (NP) effects of 3 antiretroviral regimens in participants infected with human immunodeficiency virus type 1 (HIV-1) in resource-limited settings. METHODS: Participants from Brazil, India, Malawi, Peru, South Africa, Thailand, and Zimbabwe were randomized to 3 antiretroviral treatment arms: A (lamivudine-zidovudine plus efavirenz, n = 289), B (atazanavir, emtricitabine, and didanosine-EC, n = 293), and C (emtricitabine-tenofovir-disoproxil fumarate plus efavirenz, n = 278) as part of the ACTG PEARLS study (A5175). Standardized neurological and neuropsychological (NP) screening examinations (grooved pegboard, timed gait, semantic verbal fluency, and finger tapping) were administered every 24 weeks from February 2006 to May 2010. Associations with neurological and neuropsychological function were estimated from linear and logistic regression models using generalized estimating equations. RESULTS: The median weeks on study was 168 (Q1 = 96, Q3 = 192) for the 860 participants. NP test scores improved (P < .05) with the exception of semantic verbal fluency. No differences in neurological and neuropsychological functioning between treatment regimens were detected (P > .10). Significant country effects were noted on all NP tests and neurological outcomes (P < .01). CONCLUSIONS: The study detected no significant differences in neuropsychological and neurological outcomes between randomized ART regimens. Significant improvement occurred in neurocognitive and neurological functioning over time after initiation of ARTs. The etiology of these improvements is likely multifactorial, reflecting reduced central nervous system HIV infection, better general health, and practice effects. This study suggests that treatment with either of the World Health Organization -recommended first-line antiretroviral regimens in resource-limited settings will improve neuropsychological functioning and reduce neurological dysfunction. CLINICAL TRIALS REGISTRATION: NCT00096824.'
p58167
sS'AD'
p58168
S'University of North Carolina, Chapel Hill, 27599-7025, USA. kevinr@neurology.unc.edu'
p58169
sS'CN'
p58170
(lp58171
S'5199 study team'
p58172
aS'AIDS Clinical Trials Group'
p58173
asS'IP'
p58174
S'6'
sS'IS'
p58175
S'1537-6591 (Electronic) 1058-4838 (Linking)'
p58176
sS'PMC'
p58177
S'PMC3491853'
p58178
sS'DCOM'
p58179
S'20130108'
p58180
sS'AU'
p58181
(lp58182
S'Robertson K'
p58183
aS'Jiang H'
p58184
aS'Kumwenda J'
p58185
aS'Supparatpinyo K'
p58186
aS'Evans S'
p58187
aS'Campbell TB'
p58188
aS'Price R'
p58189
aS'Tripathy S'
p58190
aS'Kumarasamy N'
p58191
aS'La Rosa A'
p58192
aS'Santos B'
p58193
aS'Silva MT'
p58194
aS'Montano S'
p58195
aS'Kanyama C'
p58196
aS'Faesen S'
p58197
aS'Murphy R'
p58198
aS'Hall C'
p58199
aS'Marra CM'
p58200
aS'Marcus C'
p58201
aS'Berzins B'
p58202
aS'Allen R'
p58203
aS'Housseinipour M'
p58204
aS'Amod F'
p58205
aS'Sanne I'
p58206
aS'Hakim J'
p58207
aS'Walawander A'
p58208
aS'Nair A'
p58209
asS'VI'
p58210
S'55'
p58211
sS'MHDA'
p58212
S'2013/01/09 06:00'
p58213
sS'PHST'
p58214
(lp58215
S'2012/06/01 [aheadofprint]'
p58216
aS'2012/06/22 [aheadofprint]'
p58217
asS'OID'
p58218
(lp58219
S'NLM: PMC3491853'
p58220
asS'MH'
p58221
(lp58222
S'AIDS Dementia Complex/*epidemiology/*prevention & control'
p58223
aS'Acquired Immunodeficiency Syndrome/*complications/*drug therapy/virology'
p58224
aS'Adult'
p58225
aS'Anti-Retroviral Agents/*therapeutic use'
p58226
aS'Antiretroviral Therapy, Highly Active/*methods'
p58227
aS'Female'
p58228
aS'HIV-1/pathogenicity'
p58229
aS'Humans'
p58230
aS'Male'
p58231
aS'Neurologic Examination'
p58232
aS'Psychological Tests'
p58233
aS'Treatment Outcome'
p58234
asS'EDAT'
p58235
S'2012/06/05 06:00'
p58236
sS'SI'
p58237
(lp58238
S'ClinicalTrials.gov/NCT00096824'
p58239
asS'SO'
p58240
S'Clin Infect Dis. 2012 Sep;55(6):868-76. Epub 2012 Jun 1.'
p58241
sS'SB'
p58242
S'IM'
p58243
sS'PMID'
p58244
S'22661489'
p58245
sS'PST'
p58246
S'ppublish'
p58247
stRp58248
ag2
(g3
g4
(dp58249
S'LID'
p58250
S'10.1371/journal.pone.0037114 [doi]'
p58251
sS'STAT'
p58252
S'MEDLINE'
p58253
sS'DEP'
p58254
S'20120522'
p58255
sS'DA'
p58256
S'20120525'
p58257
sS'AID'
p58258
(lp58259
S'10.1371/journal.pone.0037114 [doi]'
p58260
aS'PONE-D-12-02618 [pii]'
p58261
asS'CRDT'
p58262
(lp58263
S'2012/05/26 06:00'
p58264
asS'DP'
p58265
S'2012'
p58266
sS'OWN'
p58267
S'NLM'
p58268
sS'PT'
p58269
(lp58270
S'Journal Article'
p58271
asS'LA'
p58272
(lp58273
S'eng'
p58274
asS'FAU'
p58275
(lp58276
S'Satti, Hind'
p58277
aS'McLaughlin, Megan M'
p58278
aS'Omotayo, David B'
p58279
aS'Keshavjee, Salmaan'
p58280
aS'Becerra, Mercedes C'
p58281
aS'Mukherjee, Joia S'
p58282
aS'Seung, Kwonjune J'
p58283
asS'JT'
p58284
S'PloS one'
p58285
sS'LR'
p58286
S'20150225'
p58287
sS'PG'
p58288
S'e37114'
p58289
sS'TI'
p58290
S'Outcomes of comprehensive care for children empirically treated for multidrug-resistant tuberculosis in a setting of high HIV prevalence.'
p58291
sS'RN'
p58292
(lp58293
S'0 (Antitubercular Agents)'
p58294
asS'PL'
p58295
S'United States'
p58296
sS'TA'
p58297
S'PLoS One'
p58298
sS'JID'
p58299
S'101285081'
p58300
sS'AB'
p58301
S'BACKGROUND: Few studies have examined outcomes for children treated for multidrug-resistant tuberculosis (MDR-TB), including those receiving concomitant treatment for MDR-TB and HIV co-infection. In Lesotho, where the adult HIV seroprevalence is estimated to be 24%, we sought to measure outcomes and adverse events in a cohort of children treated for MDR-TB using a community-based treatment delivery model. METHODS: We reviewed retrospectively the clinical charts of children </=15 years of age treated for culture-confirmed or suspected MDR-TB between July 2007 and January 2011. RESULTS: Nineteen children, ages two to 15, received treatment. At baseline, 74% of patients were co-infected with HIV, 63% were malnourished, 84% had severe radiographic findings, and 21% had extrapulmonary disease. Five (26%) children had culture-confirmed MDR-TB, ten (53%) did not have culture results available, and four (21%) subsequently had results indicating drug-susceptible TB. All children with HIV co-infection who were not already on antiretroviral therapy (ART) were initiated on ART a median of two weeks after the start of the MDR-TB regimen. Among the 17 patients with final outcomes, 15 (88%) patients were cured or completed treatment, two (12%) patients died, and none defaulted or were lost to follow-up. The majority of patients (95%) experienced adverse events; only two required permanent discontinuation of the offending agent, and only one required suspension of MDR-TB treatment for more than one week. CONCLUSIONS: Pediatric MDR-TB and MDR-TB/HIV co-infection can be successfully treated using a combination of social support, close monitoring by community health workers and clinicians, and inpatient care when needed. In this cohort, adverse events were well tolerated and treatment outcomes were comparable to those reported in children with drug-susceptible TB and no HIV infection.'
p58302
sS'AD'
p58303
S'Partners In Health, Maseru, Lesotho. hsatti@pih.org'
p58304
sS'IP'
p58305
S'5'
sS'IS'
p58306
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p58307
sS'PMC'
p58308
S'PMC3358299'
p58309
sS'DCOM'
p58310
S'20121217'
p58311
sS'AU'
p58312
(lp58313
S'Satti H'
p58314
aS'McLaughlin MM'
p58315
aS'Omotayo DB'
p58316
aS'Keshavjee S'
p58317
aS'Becerra MC'
p58318
aS'Mukherjee JS'
p58319
aS'Seung KJ'
p58320
asS'VI'
p58321
S'7'
sS'MHDA'
p58322
S'2012/12/18 06:00'
p58323
sS'PHST'
p58324
(lp58325
S'2012/01/27 [received]'
p58326
aS'2012/04/16 [accepted]'
p58327
aS'2012/05/22 [epublish]'
p58328
asS'OID'
p58329
(lp58330
S'NLM: PMC3358299'
p58331
asS'MH'
p58332
(lp58333
S'Adolescent'
p58334
aS'Antitubercular Agents/*therapeutic use'
p58335
aS'Child'
p58336
aS'Child, Preschool'
p58337
aS'Coinfection'
p58338
aS'Comorbidity'
p58339
aS'*Comprehensive Health Care'
p58340
aS'Female'
p58341
aS'HIV Infections/*epidemiology'
p58342
aS'HIV Seroprevalence'
p58343
aS'Humans'
p58344
aS'Lesotho/epidemiology'
p58345
aS'Male'
p58346
aS'Prevalence'
p58347
aS'Retrospective Studies'
p58348
aS'Treatment Outcome'
p58349
aS'Tuberculosis, Multidrug-Resistant/*drug therapy/epidemiology'
p58350
asS'EDAT'
p58351
S'2012/05/26 06:00'
p58352
sS'SO'
p58353
S'PLoS One. 2012;7(5):e37114. doi: 10.1371/journal.pone.0037114. Epub 2012 May 22.'
p58354
sS'SB'
p58355
S'IM'
p58356
sS'PMID'
p58357
S'22629356'
p58358
sS'PST'
p58359
S'ppublish'
p58360
stRp58361
ag2
(g3
g4
(dp58362
S'LID'
p58363
S'10.1097/FTD.0b013e3182526e6a [doi]'
p58364
sS'STAT'
p58365
S'MEDLINE'
p58366
sS'JT'
p58367
S'Journal of acquired immune deficiency syndromes (1999)'
p58368
sS'MID'
p58369
(lp58370
S'NIHMS536311'
p58371
asS'DA'
p58372
S'20120524'
p58373
sS'AID'
p58374
(lp58375
S'10.1097/FTD.0b013e3182526e6a [doi]'
p58376
aS'00126334-201206010-00013 [pii]'
p58377
asS'CRDT'
p58378
(lp58379
S'2012/05/25 06:00'
p58380
asS'DP'
p58381
S'2012 Jun 1'
p58382
sS'AD'
p58383
S'Medical Department, Reach Out Mbuya Parish HIV/AIDS Initiative, Kampala, Uganda. stellaalamo@gmail.com'
p58384
sS'OWN'
p58385
S'NLM'
p58386
sS'PT'
p58387
(lp58388
S'Journal Article'
p58389
asS'LA'
p58390
(lp58391
S'eng'
p58392
asS'FAU'
p58393
(lp58394
S'Alamo, Stella T'
p58395
aS'Colebunders, Robert'
p58396
aS'Ouma, Joseph'
p58397
aS'Sunday, Pamela'
p58398
aS'Wagner, Glenn'
p58399
aS'Wabwire-Mangen, Fred'
p58400
aS'Laga, Marie'
p58401
asS'LR'
p58402
S'20150225'
p58403
sS'PG'
p58404
S'e36-45'
p58405
sS'TI'
p58406
S'Return to normal life after AIDS as a reason for lost to follow-up in a community-based antiretroviral treatment program.'
p58407
sS'RN'
p58408
(lp58409
S'0 (Anti-HIV Agents)'
p58410
asS'PL'
p58411
S'United States'
p58412
sS'TA'
p58413
S'J Acquir Immune Defic Syndr'
p58414
sS'JID'
p58415
S'100892005'
p58416
sS'AB'
p58417
S'OBJECTIVES: To understand reasons for lost-to-follow-up (LTFU) from a community-based antiretroviral therapy program in Uganda. STUDY DESIGN: Retrospective cohort of patients LTFU between May 31, 2001, to May 31, 2010, was examined. A representative sample of 579 patients traced to ascertain their outcomes. METHODS: Mixed methods were used. Using "stopped care" as the hazard and "self-transferred" as the comparator, we examined using Cox proportional multivariable model risk factors for stopping care. RESULTS: Overall, 2933 of 3954 (74.0%) patients were LTFU. Of 579 of 2933 (19%) patients sampled for tracing, 32 (5.5%) were untraceable, 66(11.4 %) were dead, and 481 (83.0%) found alive. Of those found alive, 232 (40.0%) stopped care, 249 (43.0%) self-transferred, whereas 61 (12.7%) returned to care at Reach Out Mbuya HIV/AIDS Initiative. In adjusted hazards ratios, born-again religion, originating from outside Kampala, resident in Kampala for <5 years but >1 year, having school-age children who were out of school, non-HIV disclosure, CD4 counts >250 cells per cubic millimeter and pre-antiretroviral therapy were associated with increased risk of stopping care. Qualitative interviews revealed return to a normal life as a key reason for LTFU. Of 61 patients who returned to care, their median CD4 count at LTFU was higher than on return into care (401/mm(3) vs. 205/mm(3), P < 0.0001). CONCLUSIONS: Many patients become LTFU during the course of years, necessitating the need for effective mechanisms to identify those in need of close monitoring. Efforts should be made to improve referrals and mechanisms to track patients who transfer to different facilities. Additionally, tracing of patients who become LTFU is required to convince them to return.'
p58418
sS'GR'
p58419
(lp58420
S'R24 HD056651/HD/NICHD NIH HHS/United States'
p58421
asS'IP'
p58422
S'2'
sS'IS'
p58423
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p58424
sS'PMC'
p58425
S'PMC3872063'
p58426
sS'DCOM'
p58427
S'20120725'
p58428
sS'AU'
p58429
(lp58430
S'Alamo ST'
p58431
aS'Colebunders R'
p58432
aS'Ouma J'
p58433
aS'Sunday P'
p58434
aS'Wagner G'
p58435
aS'Wabwire-Mangen F'
p58436
aS'Laga M'
p58437
asS'VI'
p58438
S'60'
p58439
sS'MHDA'
p58440
S'2012/07/26 06:00'
p58441
sS'OID'
p58442
(lp58443
S'NLM: NIHMS536311'
p58444
aS'NLM: PMC3872063'
p58445
asS'MH'
p58446
(lp58447
S'Acquired Immunodeficiency Syndrome/*drug therapy'
p58448
aS'Adolescent'
p58449
aS'Adult'
p58450
aS'Anti-HIV Agents/*administration & dosage'
p58451
aS'Cohort Studies'
p58452
aS'Female'
p58453
aS'Humans'
p58454
aS'*Lost to Follow-Up'
p58455
aS'Male'
p58456
aS'Middle Aged'
p58457
aS'Retrospective Studies'
p58458
aS'Risk Factors'
p58459
aS'Uganda'
p58460
aS'Young Adult'
p58461
asS'EDAT'
p58462
S'2012/05/25 06:00'
p58463
sS'SO'
p58464
S'J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):e36-45. doi: 10.1097/FTD.0b013e3182526e6a.'
p58465
sS'SB'
p58466
S'IM X'
p58467
sS'PMID'
p58468
S'22622076'
p58469
sS'PST'
p58470
S'ppublish'
p58471
stRp58472
ag2
(g3
g4
(dp58473
S'STAT'
p58474
S'MEDLINE'
p58475
sS'DEP'
p58476
S'20120522'
p58477
sS'DA'
p58478
S'20120807'
p58479
sS'AID'
p58480
(lp58481
S'cis501 [pii]'
p58482
aS'10.1093/cid/cis501 [doi]'
p58483
asS'CRDT'
p58484
(lp58485
S'2012/05/24 06:00'
p58486
asS'DP'
p58487
S'2012 Sep'
p58488
sS'GR'
p58489
(lp58490
S'1U19AI53217-01/AI/NIAID NIH HHS/United States'
p58491
aS'5T32 AI065380-04/AI/NIAID NIH HHS/United States'
p58492
aS'P30 AI050410/AI/NIAID NIH HHS/United States'
p58493
aS'R01 AI081571/AI/NIAID NIH HHS/United States'
p58494
aS'R01 AI081571-02S1/AI/NIAID NIH HHS/United States'
p58495
aS'T32-5TL1 RR024155-04/RR/NCRR NIH HHS/United States'
p58496
aS'TL1 RR024155/RR/NCRR NIH HHS/United States'
p58497
aS'Intramural NIH HHS/United States'
p58498
asS'OWN'
p58499
S'NLM'
p58500
sS'PT'
p58501
(lp58502
S'Journal Article'
p58503
aS'Randomized Controlled Trial'
p58504
aS'Research Support, N.I.H., Intramural'
p58505
asS'LA'
p58506
(lp58507
S'eng'
p58508
asS'FAU'
p58509
(lp58510
S'Brehm, Jessica H'
p58511
aS'Koontz, Dianna L'
p58512
aS'Wallis, Carole L'
p58513
aS'Shutt, Kathleen A'
p58514
aS'Sanne, Ian'
p58515
aS'Wood, Robin'
p58516
aS'McIntyre, James A'
p58517
aS'Stevens, Wendy S'
p58518
aS'Sluis-Cremer, Nicolas'
p58519
aS'Mellors, John W'
p58520
asS'JT'
p58521
S'Clinical infectious diseases : an official publication of the Infectious Diseases Society of America'
p58522
sS'LR'
p58523
S'20150813'
p58524
sS'PG'
p58525
S'737-45'
p58526
sS'TI'
p58527
S'Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors.'
p58528
sS'RN'
p58529
(lp58530
S'0 (Reverse Transcriptase Inhibitors)'
p58531
aS'EC 2.7.7.- (reverse transcriptase, Human immunodeficiency virus 1)'
p58532
aS'EC 2.7.7.49 (HIV Reverse Transcriptase)'
p58533
asS'PL'
p58534
S'United States'
p58535
sS'TA'
p58536
S'Clin Infect Dis'
p58537
sS'FIR'
p58538
(lp58539
S'Badal-Faesen, Sharlaa'
p58540
aS'Botile, Mildred'
p58541
aS'Choonilal, Nastassja'
p58542
aS'Conradie, Francesca'
p58543
aS'Gelant, Jennipher'
p58544
aS'Grab, Janet'
p58545
aS'Graham, Veronica'
p58546
aS'Hafejee, Najma'
p58547
aS'Hamber, Lynda'
p58548
aS'Harduth, Sindesh'
p58549
aS'Hendricks, Johean'
p58550
aS'Herman, Colleen'
p58551
aS'Hero, Mellissa'
p58552
aS'Ive, Prudence'
p58553
aS'Kaplan, Richard'
p58554
aS'Killa, Nicola'
p58555
aS'Klemp, Daniella'
p58556
aS'Laher, Faisel'
p58557
aS'Mabiletsa, Thandi'
p58558
aS'Madlala, Zanele'
p58559
aS'Mafukuzela, Ntombekaya'
p58560
aS'Mahlatsi, Bontle'
p58561
aS'Marias, Helgard'
p58562
aS'Mfundisi, Nomakhaya'
p58563
aS'Motloba, Buang'
p58564
aS'Moyo, Cindy'
p58565
aS'Mtshizana, Mcebisi'
p58566
aS'Ncana, Lundi'
p58567
aS'Newell, Kevin'
p58568
aS'Orell, Catherine'
p58569
aS'Palmer, Sean'
p58570
aS'Pearce, Deborah'
p58571
aS'Potts, Mary-Ann'
p58572
aS'Radebe, Daphne'
p58573
aS'Reyneke, Anne'
p58574
aS'Segeneco, Anna'
p58575
aS'Sekgale, Jennifer'
p58576
aS'Steyn, Jan'
p58577
aS'Thebe, Pinky'
p58578
aS'Truter, Handre'
p58579
aS'van, Diederik'
p58580
aS'Verheye-Dua, Frieda'
p58581
aS'Voges, Karlien'
p58582
aS'Woolgar, Helen'
p58583
aS'Zeinecker, Jennifer'
p58584
aS'Maartens, Gary'
p58585
aS'Spencer, David'
p58586
aS'van der Horst, Charles'
p58587
asS'JID'
p58588
S'9203213'
p58589
sS'AB'
p58590
S'BACKGROUND: It is not known how often mutations in the connection and ribonuclease H domains of reverse transcriptase (RT) emerge with failure of first-line antiretroviral therapy (ART) in subtype C human immunodeficiency virus type 1 (HIV-1) infection and how these mutations affect susceptibility to other antiretrovirals. METHODS: We compared full-length RT sequences in plasma obtained before therapy and at virologic failure of initial ART among 63 participants with subtype C HIV-1 infection enrolled in the Comprehensive International Program of Research on AIDS in South Africa (CIPRA-SA) study. Recombinant viruses containing full-length plasma-derived RT sequences from participants with N348I at virologic failure were assayed for drug susceptibility. RESULTS: Y181C and M184V mutations in the RT polymerase domain were associated with failure of stavudine-lamivudine-nevirapine (d4T/3TC/NVP; P < .01), and K103N, V106M, and M184V with failure of d4T/3TC/efavirenz (EFV; P < .01). N348I in the RT connection domain emerged in 45% (P = .002) and 12% (P = .06) of participants receiving failing regimens containing NVP or EFV, respectively. Longitudinal analyses revealed that nonnucleoside RT inhibitor resistance mutations in the polymerase domain generally appeared first. N348I emerged at the same time, or after, M184V. N348I in the context of polymerase domain mutations reduced susceptibility to NVP (8.9-13-fold), EFV (4-56-fold), etravirine (ETV; 1.9-4.7-fold) and decreased hypersusceptibility to zidovudine (AZT; 1.4-2.2-fold). CONCLUSIONS: N348I emerges frequently with virologic failure of first-line ART in subtype C HIV-1 infection and reduces susceptibility to NVP, EFV, ETV, and AZT. Additional studies are warranted to characterize the effects of N348I on virologic response to second- and third-line regimens in resource-limited settings where subtype C predominates.'
p58591
sS'AD'
p58592
S'University of Pittsburgh School of Medicine, S818 Scaife Hall, 3550 Terrace St, Pittsburgh, Pennsylvania 15261, USA.'
p58593
sS'CN'
p58594
(lp58595
S'CIPRA-SA Project 1 Study Team'
p58596
asS'IP'
p58597
S'5'
sS'IS'
p58598
S'1537-6591 (Electronic) 1058-4838 (Linking)'
p58599
sS'IR'
p58600
(lp58601
S'Badal-Faesen S'
p58602
aS'Botile M'
p58603
aS'Choonilal N'
p58604
aS'Conradie F'
p58605
aS'Gelant J'
p58606
aS'Grab J'
p58607
aS'Graham V'
p58608
aS'Hafejee N'
p58609
aS'Hamber L'
p58610
aS'Harduth S'
p58611
aS'Hendricks J'
p58612
aS'Herman C'
p58613
aS'Hero M'
p58614
aS'Ive P'
p58615
aS'Kaplan R'
p58616
aS'Killa N'
p58617
aS'Klemp D'
p58618
aS'Laher F'
p58619
aS'Mabiletsa T'
p58620
aS'Madlala Z'
p58621
aS'Mafukuzela N'
p58622
aS'Mahlatsi B'
p58623
aS'Marias H'
p58624
aS'Mfundisi N'
p58625
aS'Motloba B'
p58626
aS'Moyo C'
p58627
aS'Mtshizana M'
p58628
aS'Ncana L'
p58629
aS'Newell K'
p58630
aS'Orell C'
p58631
aS'Palmer S'
p58632
aS'Pearce D'
p58633
aS'Potts MA'
p58634
aS'Radebe D'
p58635
aS'Reyneke A'
p58636
aS'Segeneco A'
p58637
aS'Sekgale J'
p58638
aS'Steyn J'
p58639
aS'Thebe P'
p58640
aS'Truter H'
p58641
aS'van D'
p58642
aS'Verheye-Dua F'
p58643
aS'Voges K'
p58644
aS'Woolgar H'
p58645
aS'Zeinecker J'
p58646
aS'Maartens G'
p58647
aS'Spencer D'
p58648
aS'van der Horst C'
p58649
asS'DCOM'
p58650
S'20130708'
p58651
sS'AU'
p58652
(lp58653
S'Brehm JH'
p58654
aS'Koontz DL'
p58655
aS'Wallis CL'
p58656
aS'Shutt KA'
p58657
aS'Sanne I'
p58658
aS'Wood R'
p58659
aS'McIntyre JA'
p58660
aS'Stevens WS'
p58661
aS'Sluis-Cremer N'
p58662
aS'Mellors JW'
p58663
asS'VI'
p58664
S'55'
p58665
sS'MHDA'
p58666
S'2013/07/09 06:00'
p58667
sS'PHST'
p58668
(lp58669
S'2012/05/22 [aheadofprint]'
p58670
aS'2012/05/31 [aheadofprint]'
p58671
aS'2012/06/18 [aheadofprint]'
p58672
asS'OID'
p58673
(lp58674
S'NLM: PMC3491849'
p58675
asS'MH'
p58676
(lp58677
S'Drug Resistance, Viral'
p58678
aS'HIV Infections/*drug therapy/*virology'
p58679
aS'HIV Reverse Transcriptase/*genetics'
p58680
aS'HIV-1/*enzymology/genetics'
p58681
aS'Humans'
p58682
aS'Mutation'
p58683
aS'Reverse Transcriptase Inhibitors/*pharmacology/therapeutic use'
p58684
aS'Treatment Failure'
p58685
aS'Viral Load'
p58686
asS'EDAT'
p58687
S'2012/05/24 06:00'
p58688
sS'PMC'
p58689
S'PMC3491849'
p58690
sS'SI'
p58691
(lp58692
S'ClinicalTrials.gov/NCT00255840'
p58693
asS'SO'
p58694
S'Clin Infect Dis. 2012 Sep;55(5):737-45. Epub 2012 May 22.'
p58695
sS'SB'
p58696
S'IM'
p58697
sS'PMID'
p58698
S'22618567'
p58699
sS'PST'
p58700
S'ppublish'
p58701
stRp58702
ag2
(g3
g4
(dp58703
S'LID'
p58704
S'10.1371/journal.pone.0037350 [doi]'
p58705
sS'STAT'
p58706
S'MEDLINE'
p58707
sS'DEP'
p58708
S'20120511'
p58709
sS'DA'
p58710
S'20120518'
p58711
sS'AID'
p58712
(lp58713
S'10.1371/journal.pone.0037350 [doi]'
p58714
aS'PONE-D-11-23240 [pii]'
p58715
asS'CRDT'
p58716
(lp58717
S'2012/05/19 06:00'
p58718
asS'DP'
p58719
S'2012'
p58720
sS'AD'
p58721
S'Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, United States of America. sisanaka@hsph.harvard.edu'
p58722
sS'OWN'
p58723
S'NLM'
p58724
sS'PT'
p58725
(lp58726
S'Journal Article'
p58727
aS'Randomized Controlled Trial'
p58728
aS'Research Support, N.I.H., Extramural'
p58729
aS"Research Support, Non-U.S. Gov't"
p58730
asS'LA'
p58731
(lp58732
S'eng'
p58733
asS'FAU'
p58734
(lp58735
S'Isanaka, Sheila'
p58736
aS'Aboud, Said'
p58737
aS'Mugusi, Ferdinand'
p58738
aS'Bosch, Ronald J'
p58739
aS'Willett, Walter C'
p58740
aS'Spiegelman, Donna'
p58741
aS'Duggan, Christopher'
p58742
aS'Fawzi, Wafaie W'
p58743
asS'JT'
p58744
S'PloS one'
p58745
sS'LR'
p58746
S'20160729'
p58747
sS'PG'
p58748
S'e37350'
p58749
sS'TI'
p58750
S'Iron status predicts treatment failure and mortality in tuberculosis patients: a prospective cohort study from Dar es Salaam, Tanzania.'
p58751
sS'RN'
p58752
(lp58753
S'0 (Micronutrients)'
p58754
aS'9007-73-2 (Ferritins)'
p58755
aS'E1UOL152H7 (Iron)'
p58756
asS'PL'
p58757
S'United States'
p58758
sS'TA'
p58759
S'PLoS One'
p58760
sS'JID'
p58761
S'101285081'
p58762
sS'AB'
p58763
S'BACKGROUND: Experimental data suggest a role for iron in the course of tuberculosis (TB) infection, but there is limited evidence on the potential effects of iron deficiency or iron overload on the progression of TB disease in humans. The aim of the present analysis was to examine the association of iron status with the risk of TB progression and death. METHODOLOGY/PRINCIPAL FINDINGS: We analyzed plasma samples and data collected as part a randomized micronutrient supplementation trial (not including iron) among HIV-infected and HIV-uninfected TB patients in Dar es Salaam, Tanzania. We prospectively related baseline plasma ferritin concentrations from 705 subjects (362 HIV-infected and 343 HIV-uninfected) to the risk of treatment failure at one month after initiation, TB recurrence and death using binomial and Cox regression analyses. Overall, low (plasma ferritin<30 microg/L) and high (plasma ferritin>150 microg/L for women and>200 microg/L for men) iron status were seen in 9% and 48% of patients, respectively. Compared with normal levels, low plasma ferritin predicted an independent increased risk of treatment failure overall (adjusted RR = 1.95, 95% CI: 1.07 to 3.52) and of TB recurrence among HIV-infected patients (adjusted RR = 4.21, 95% CI: 1.22 to 14.55). High plasma ferritin, independent of C-reactive protein concentrations, was associated with an increased risk of overall mortality (adjusted RR = 3.02, 95% CI: 1.95 to 4.67). CONCLUSIONS/SIGNIFICANCE: Both iron deficiency and overload exist in TB patients and may contribute to disease progression and poor clinical outcomes. Strategies to maintain normal iron status in TB patients could be helpful to reduce TB morbidity and mortality.'
p58764
sS'GR'
p58765
(lp58766
S'1K24HD058795/HD/NICHD NIH HHS/United States'
p58767
aS'K24 HD058795/HD/NICHD NIH HHS/United States'
p58768
aS'P30 DK040561/DK/NIDDK NIH HHS/United States'
p58769
aS'U01 AI045441/AI/NIAID NIH HHS/United States'
p58770
aS'U01AI045441/AI/NIAID NIH HHS/United States'
p58771
asS'IP'
p58772
S'5'
sS'IS'
p58773
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p58774
sS'PMC'
p58775
S'PMC3350480'
p58776
sS'DCOM'
p58777
S'20121016'
p58778
sS'AU'
p58779
(lp58780
S'Isanaka S'
p58781
aS'Aboud S'
p58782
aS'Mugusi F'
p58783
aS'Bosch RJ'
p58784
aS'Willett WC'
p58785
aS'Spiegelman D'
p58786
aS'Duggan C'
p58787
aS'Fawzi WW'
p58788
asS'VI'
p58789
S'7'
sS'MHDA'
p58790
S'2012/10/17 06:00'
p58791
sS'PHST'
p58792
(lp58793
S'2011/11/22 [received]'
p58794
aS'2012/04/20 [accepted]'
p58795
aS'2012/05/11 [epublish]'
p58796
asS'OID'
p58797
(lp58798
S'NLM: PMC3350480'
p58799
asS'MH'
p58800
(lp58801
S'Adult'
p58802
aS'Cohort Studies'
p58803
aS'Female'
p58804
aS'Ferritins/blood'
p58805
aS'HIV Infections/complications'
p58806
aS'Humans'
p58807
aS'Iron/deficiency/*metabolism'
p58808
aS'Iron Overload/complications/metabolism'
p58809
aS'Male'
p58810
aS'Micronutrients/administration & dosage'
p58811
aS'Prospective Studies'
p58812
aS'Tanzania/epidemiology'
p58813
aS'Treatment Failure'
p58814
aS'Tuberculosis, Pulmonary/complications/*metabolism/mortality/therapy'
p58815
aS'Young Adult'
p58816
asS'EDAT'
p58817
S'2012/05/19 06:00'
p58818
sS'SO'
p58819
S'PLoS One. 2012;7(5):e37350. doi: 10.1371/journal.pone.0037350. Epub 2012 May 11.'
p58820
sS'SB'
p58821
S'IM'
p58822
sS'PMID'
p58823
S'22606361'
p58824
sS'PST'
p58825
S'ppublish'
p58826
stRp58827
ag2
(g3
g4
(dp58828
S'STAT'
p58829
S'MEDLINE'
p58830
sS'DEP'
p58831
S'20120307'
p58832
sS'DA'
p58833
S'20120517'
p58834
sS'CRDT'
p58835
(lp58836
S'2012/05/18 06:00'
p58837
asS'DP'
p58838
S'2012'
p58839
sS'OWN'
p58840
S'NLM'
p58841
sS'PT'
p58842
(lp58843
S'Evaluation Studies'
p58844
aS'Journal Article'
p58845
aS"Research Support, Non-U.S. Gov't"
p58846
asS'LA'
p58847
(lp58848
S'eng'
p58849
asS'DCOM'
p58850
S'20120823'
p58851
sS'JT'
p58852
S'The Pan African medical journal'
p58853
sS'LR'
p58854
S'20150225'
p58855
sS'FAU'
p58856
(lp58857
S'Dube, Nomathemba Michell'
p58858
aS'Summers, Robert'
p58859
aS'Tint, Khin-San'
p58860
aS'Mayayise, Guistee'
p58861
asS'TI'
p58862
S'A pharmacovigilance study of adults on highly active antiretroviral therapy, South Africa: 2007 - 2011.'
p58863
sS'RN'
p58864
(lp58865
S'0 (Anti-HIV Agents)'
p58866
asS'PL'
p58867
S'Uganda'
p58868
sS'PG'
p58869
S'39'
p58870
sS'JID'
p58871
S'101517926'
p58872
sS'AB'
p58873
S'BACKGROUND: Of the 1.6 million South African people infected with human immunodeficiency virus (HIV), approximately 970,000 (55%) have been initiated on HAART. Despite these numbers, very little has been published about the safety profile of antiretroviral (ARV) medicines in the country. This study was performed at the Medunsa National Pharmacovigilance Centre and aimed to describe the demographic characteristics of patients enrolled in the pharmacovigilance surveillance study; highly active antiretroviral therapy (HAART) initiation regimen patterns; reasons for regimen changes; and adverse effects of ARV medicines. METHODS: A cohort study of HIV-infected individuals aged 15 years or older who were on ARV medicines was conducted at four sentinel sites. RESULTS: After HAART initiation, with an average lapse of 17.8 months (range: 0 - 83.8 months), 2,815 patients were enrolled into the study. Results show that patients were observed for 1,606.2 person-years for pharmacy visits (collection of ARV medicines) and 817.1 person-years for clinical visits (consultation with the doctor). Females constituted 69.6% (1,958/2,815) of the study population. Almost all patients initiated HAART on first-line regimens (2,801/2,815). Some patients (6.7%, 190/2,815) dropped out of the study after HAART initiation. Reasons for regimen changes were not recorded for 2.5% (22/891) of the patients who changed regimens. The primary reason for regimen changes was drug-related toxicity (76.1%, 678/891), mostly evident in patients taking first-line regimens. Adverse effects experienced by patients were polyneuropathy (24.0%, 163/678); lipodystrophy (23.9%, 162/678); neuropathy (10.6%, 72/678); and suspected lactic acidosis (3.8%, 26/678). CONCLUSION: The majority of prescribers complied with the HAART guidelines and initiated most patients on first-line regimens. However, adverse effects are evident in patients taking first-line regimens. We recommend that the Department of Health should introduce less toxic first-line ARV regimens. Future efforts will aim to initiate patients on HAART and enrol them into the study simultaneously to determine early risk profiles of ARV medicines.'
p58874
sS'AD'
p58875
S'School of Health Sciences and Public Health, Faculty of Health Sciences, University of Pretoria, South Africa.'
p58876
sS'VI'
p58877
S'11'
p58878
sS'IS'
p58879
S'1937-8688 (Electronic)'
p58880
sS'PMC'
p58881
S'PMC3343667'
p58882
sS'AU'
p58883
(lp58884
S'Dube NM'
p58885
aS'Summers R'
p58886
aS'Tint KS'
p58887
aS'Mayayise G'
p58888
asS'MHDA'
p58889
S'2012/08/24 06:00'
p58890
sS'PHST'
p58891
(lp58892
S'2011/08/31 [received]'
p58893
aS'2012/02/28 [accepted]'
p58894
aS'2012/03/07 [epublish]'
p58895
asS'OT'
p58896
(lp58897
S'Pharmacovigilance'
p58898
aS'antiretroviral medicines'
p58899
aS'human immunodeficiency virus'
p58900
aS'surveillance'
p58901
asS'OTO'
p58902
(lp58903
S'NOTNLM'
p58904
asS'OID'
p58905
(lp58906
S'NLM: PMC3343667'
p58907
asS'MH'
p58908
(lp58909
S'Adolescent'
p58910
aS'Adult'
p58911
aS'Aged'
p58912
aS'Anti-HIV Agents/adverse effects/therapeutic use'
p58913
aS'Antiretroviral Therapy, Highly Active/*adverse effects/statistics & numerical data'
p58914
aS'Cohort Studies'
p58915
aS'Female'
p58916
aS'HIV Infections/*drug therapy/*epidemiology'
p58917
aS'Humans'
p58918
aS'Male'
p58919
aS'Middle Aged'
p58920
aS'*Pharmacovigilance'
p58921
aS'Retrospective Studies'
p58922
aS'South Africa'
p58923
aS'Time Factors'
p58924
aS'Young Adult'
p58925
asS'EDAT'
p58926
S'2012/05/18 06:00'
p58927
sS'SO'
p58928
S'Pan Afr Med J. 2012;11:39. Epub 2012 Mar 7.'
p58929
sS'SB'
p58930
S'IM'
p58931
sS'PMID'
p58932
S'22593775'
p58933
sS'TA'
p58934
S'Pan Afr Med J'
p58935
sS'PST'
p58936
S'ppublish'
p58937
stRp58938
ag2
(g3
g4
(dp58939
S'LID'
p58940
S'10.5588/ijtld.11.0122 [doi]'
p58941
sS'STAT'
p58942
S'MEDLINE'
p58943
sS'DEP'
p58944
S'20120507'
p58945
sS'DA'
p58946
S'20120612'
p58947
sS'AID'
p58948
(lp58949
S'ijtld110122 [pii]'
p58950
aS'10.5588/ijtld.11.0122 [doi]'
p58951
asS'CRDT'
p58952
(lp58953
S'2012/05/16 06:00'
p58954
asS'DP'
p58955
S'2012 Jul'
p58956
sS'AD'
p58957
S'London School of Hygiene & Tropical Medicine, London, UK. claretaylor@doctors.org.uk'
p58958
sS'OWN'
p58959
S'NLM'
p58960
sS'PT'
p58961
(lp58962
S'Journal Article'
p58963
aS'Research Support, N.I.H., Extramural'
p58964
aS"Research Support, Non-U.S. Gov't"
p58965
asS'LA'
p58966
(lp58967
S'eng'
p58968
asS'FAU'
p58969
(lp58970
S'van Halsema, C L'
p58971
aS'Fielding, K L'
p58972
aS'Chihota, V N'
p58973
aS'Lewis, J J'
p58974
aS'Churchyard, G J'
p58975
aS'Grant, A D'
p58976
asS'JT'
p58977
S'The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease'
p58978
sS'LR'
p58979
S'20140220'
p58980
sS'PG'
p58981
S'967-73'
p58982
sS'TI'
p58983
S'Trends in drug-resistant tuberculosis in a gold-mining workforce in South Africa, 2002-2008.'
p58984
sS'RN'
p58985
(lp58986
S'0 (Antitubercular Agents)'
p58987
aS'7440-57-5 (Gold)'
p58988
aS'V83O1VOZ8L (Isoniazid)'
p58989
aS'VJT6J7R4TR (Rifampin)'
p58990
asS'PL'
p58991
S'France'
p58992
sS'TA'
p58993
S'Int J Tuberc Lung Dis'
p58994
sS'JID'
p58995
S'9706389'
p58996
sS'AB'
p58997
S'SETTING AND OBJECTIVE: To describe trends in drug-resistant tuberculosis (TB) in two gold-mining workforces, South Africa, 2002-2008. DESIGN: TB programme data analysis. RESULTS: TB case notification rates decreased between 2002 and 2008 from 4006 to 3018 per 100,000 and from 3192 to 2468/100,000 for Companies A and B, respectively. Human immunodeficiency virus (HIV) prevalence exceeded 80% in TB episodes with known status. The proportion of TB episodes with multidrug-resistant TB (MDR-TB) increased from 6/129 (4.7%) to 17/85 (20.0%) among previously treated cases, and from 4/38 (10.4%) to 7/28 (25.0%) in Companies A and B, respectively (tests for trend, Company A, P < 0.001; Company B, P = 0.304). Case notifications of MDR-TB increased during 2002-2008 from 39.8 to 122.9/100,000/year in Company A and from 7.8 to 96.8/100,000/year in Company B. Coverage of second-line drug susceptibility testing (DST) among MDR-TB episodes was low. Previous treatment exposure was a strong risk factor for MDR-TB (prevalence ratio 8.78, 95%CI 5.94-12.97 in previously treated vs. untreated individuals). CONCLUSION: Despite decreasing TB notifications overall, MDR-TB notifications and proportions of episodes with MDR-TB increased in the larger company. Cure must be ensured in first episodes to prevent acquired resistance. Improved coverage of culture, DST and HIV testing is required to allow treatment to be optimised.'
p58998
sS'GR'
p58999
(lp59000
S'5U2RTW007370/PHS HHS/United States'
p59001
aS'5U2RTW007373/PHS HHS/United States'
p59002
aS'AI077486/AI/NIAID NIH HHS/United States'
p59003
aS'G0700837/Medical Research Council/United Kingdom'
p59004
aS'Department of Health/United Kingdom'
p59005
asS'IP'
p59006
S'7'
sS'IS'
p59007
S'1815-7920 (Electronic) 1027-3719 (Linking)'
p59008
sS'DCOM'
p59009
S'20130509'
p59010
sS'AU'
p59011
(lp59012
S'van Halsema CL'
p59013
aS'Fielding KL'
p59014
aS'Chihota VN'
p59015
aS'Lewis JJ'
p59016
aS'Churchyard GJ'
p59017
aS'Grant AD'
p59018
asS'VI'
p59019
S'16'
p59020
sS'MHDA'
p59021
S'2013/05/10 06:00'
p59022
sS'PHST'
p59023
(lp59024
S'2012/05/07 [aheadofprint]'
p59025
asS'MH'
p59026
(lp59027
S'Adult'
p59028
aS'Antitubercular Agents/*therapeutic use'
p59029
aS'Gold'
p59030
aS'HIV Infections/drug therapy/*epidemiology'
p59031
aS'Humans'
p59032
aS'Isoniazid/therapeutic use'
p59033
aS'Middle Aged'
p59034
aS'*Mining'
p59035
aS'Mycobacterium tuberculosis/*isolation & purification'
p59036
aS'Prevalence'
p59037
aS'Rifampin/therapeutic use'
p59038
aS'Risk Factors'
p59039
aS'South Africa/epidemiology'
p59040
aS'Tuberculosis, Multidrug-Resistant/drug therapy/*epidemiology'
p59041
asS'EDAT'
p59042
S'2012/05/16 06:00'
p59043
sS'SO'
p59044
S'Int J Tuberc Lung Dis. 2012 Jul;16(7):967-73. doi: 10.5588/ijtld.11.0122. Epub 2012 May 7.'
p59045
sS'SB'
p59046
S'IM'
p59047
sS'PMID'
p59048
S'22584100'
p59049
sS'PST'
p59050
S'ppublish'
p59051
stRp59052
ag2
(g3
g4
(dp59053
S'LID'
p59054
S'10.5588/ijtld.11.0679 [doi]'
p59055
sS'STAT'
p59056
S'MEDLINE'
p59057
sS'DEP'
p59058
S'20120508'
p59059
sS'DA'
p59060
S'20120612'
p59061
sS'AID'
p59062
(lp59063
S'ijtld110679 [pii]'
p59064
aS'10.5588/ijtld.11.0679 [doi]'
p59065
asS'CRDT'
p59066
(lp59067
S'2012/05/16 06:00'
p59068
asS'DP'
p59069
S'2012 Jul'
p59070
sS'OWN'
p59071
S'NLM'
p59072
sS'PT'
p59073
(lp59074
S'Journal Article'
p59075
aS"Research Support, Non-U.S. Gov't"
p59076
aS"Research Support, U.S. Gov't, Non-P.H.S."
p59077
asS'LA'
p59078
(lp59079
S'eng'
p59080
asS'FAU'
p59081
(lp59082
S'Seddon, J A'
p59083
aS'Hesseling, A C'
p59084
aS'Marais, B J'
p59085
aS'Jordaan, A'
p59086
aS'Victor, T'
p59087
aS'Schaaf, H S'
p59088
asS'JT'
p59089
S'The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease'
p59090
sS'LR'
p59091
S'20131121'
p59092
sS'PG'
p59093
S'928-33'
p59094
sS'TI'
p59095
S'The evolving epidemic of drug-resistant tuberculosis among children in Cape Town, South Africa.'
p59096
sS'RN'
p59097
(lp59098
S'0 (Antitubercular Agents)'
p59099
aS'8G167061QZ (Ethambutol)'
p59100
aS'V83O1VOZ8L (Isoniazid)'
p59101
aS'VJT6J7R4TR (Rifampin)'
p59102
asS'PL'
p59103
S'France'
p59104
sS'TA'
p59105
S'Int J Tuberc Lung Dis'
p59106
sS'JID'
p59107
S'9706389'
p59108
sS'AB'
p59109
S"SETTING: Tygerberg Children's Hospital, Cape Town, South Africa. OBJECTIVE: To determine the prevalence and trend of drug resistance and human immunodeficiency virus (HIV) co-infection among children with culture-confirmed tuberculosis (TB). METHOD: Prospective surveillance from March 2007 to February 2009, compared to three previous surveys (1994-1998, 2003-2005, 2005-2007). Drug susceptibility testing (DST) against isoniazid (INH) and rifampicin (RMP) was performed using genotypic and phenotypic testing. If multidrug-resistant TB (MDR-TB) was detected, further DST against ethambutol (EMB) and second-line drugs was performed. RESULTS: A total of 294 children with a median age of 26 months (range 3 days-13 years) were diagnosed with culture-confirmed TB. DST results were available for 292 (99.3%); 41 (14%) were INH-resistant, including 26 (8.9%) with MDR-TB. Four children (1.4%) had RMP monoresistance. EMB resistance was present in 12/24 (50%) MDR-TB cases tested. Two isolates were resistant to ofloxacin; none had extensively drug-resistant TB. Of those tested, 29% (63/217) were HIV-infected. Any resistance to RMP increased between 1994 and 2009 (P < 0.001), as did RMP monoresistance (P = 0.009) and MDR-TB (P < 0.001). Sensitivity was 87.5% and specificity 100% for genotypic compared to phenotypic testing for INH resistance. CONCLUSIONS: RMP, and consequently multidrug, resistance is increasing among children with TB in this setting. EMB resistance is common among children with resistance to RMP and INH."
p59110
sS'AD'
p59111
S'Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Health Sciences, Stellenbosch University, Cape Town, South Africa. jseddon@sun.ac.za'
p59112
sS'IP'
p59113
S'7'
sS'IS'
p59114
S'1815-7920 (Electronic) 1027-3719 (Linking)'
p59115
sS'DCOM'
p59116
S'20130509'
p59117
sS'AU'
p59118
(lp59119
S'Seddon JA'
p59120
aS'Hesseling AC'
p59121
aS'Marais BJ'
p59122
aS'Jordaan A'
p59123
aS'Victor T'
p59124
aS'Schaaf HS'
p59125
asS'VI'
p59126
S'16'
p59127
sS'MHDA'
p59128
S'2013/05/10 06:00'
p59129
sS'PHST'
p59130
(lp59131
S'2012/05/08 [aheadofprint]'
p59132
asS'MH'
p59133
(lp59134
S'AIDS-Related Opportunistic Infections/*epidemiology'
p59135
aS'Adolescent'
p59136
aS'Antitubercular Agents/*therapeutic use'
p59137
aS'Child'
p59138
aS'Child, Preschool'
p59139
aS'Coinfection'
p59140
aS'Epidemics'
p59141
aS'Ethambutol/therapeutic use'
p59142
aS'Female'
p59143
aS'HIV Infections/*epidemiology'
p59144
aS'Humans'
p59145
aS'Infant'
p59146
aS'Infant, Newborn'
p59147
aS'Isoniazid/therapeutic use'
p59148
aS'Male'
p59149
aS'Mycobacterium tuberculosis/*isolation & purification'
p59150
aS'Prevalence'
p59151
aS'Rifampin/therapeutic use'
p59152
aS'South Africa/epidemiology'
p59153
aS'Tuberculosis, Multidrug-Resistant/complications/drug therapy/*epidemiology'
p59154
asS'EDAT'
p59155
S'2012/05/16 06:00'
p59156
sS'SO'
p59157
S'Int J Tuberc Lung Dis. 2012 Jul;16(7):928-33. doi: 10.5588/ijtld.11.0679. Epub 2012 May 8.'
p59158
sS'SB'
p59159
S'IM'
p59160
sS'PMID'
p59161
S'22583610'
p59162
sS'PST'
p59163
S'ppublish'
p59164
stRp59165
ag2
(g3
g4
(dp59166
S'LID'
p59167
S'10.1093/cid/cis438 [doi]'
p59168
sS'STAT'
p59169
S'MEDLINE'
p59170
sS'DEP'
p59171
S'20120509'
p59172
sS'DA'
p59173
S'20120712'
p59174
sS'AID'
p59175
(lp59176
S'cis438 [pii]'
p59177
aS'10.1093/cid/cis438 [doi]'
p59178
asS'CRDT'
p59179
(lp59180
S'2012/05/11 06:00'
p59181
asS'DP'
p59182
S'2012 Aug'
p59183
sS'OWN'
p59184
S'NLM'
p59185
sS'PT'
p59186
(lp59187
S'Journal Article'
p59188
aS"Research Support, Non-U.S. Gov't"
p59189
asS'LA'
p59190
(lp59191
S'eng'
p59192
asS'FAU'
p59193
(lp59194
S'Luebbert, Julia'
p59195
aS'Tweya, Hannock'
p59196
aS'Phiri, Sam'
p59197
aS'Chaweza, Thom'
p59198
aS'Mwafilaso, Johnbosco'
p59199
aS'Hosseinipour, Mina C'
p59200
aS'Ramroth, Heribert'
p59201
aS'Schnitzler, Paul'
p59202
aS'Neuhann, Florian'
p59203
asS'JT'
p59204
S'Clinical infectious diseases : an official publication of the Infectious Diseases Society of America'
p59205
sS'PG'
p59206
S'441-8'
p59207
sS'TI'
p59208
S'Virological failure and drug resistance in patients on antiretroviral therapy after treatment interruption in Lilongwe, Malawi.'
p59209
sS'RN'
p59210
(lp59211
S'0 (Anti-Retroviral Agents)'
p59212
asS'PL'
p59213
S'United States'
p59214
sS'TA'
p59215
S'Clin Infect Dis'
p59216
sS'JID'
p59217
S'9203213'
p59218
sS'AB'
p59219
S'BACKGROUND: Since 2004, Malawi has rapidly scaled up access to antiretroviral therapy (ART) in the national program following a public health approach with limited laboratory monitoring. We examined virological outcomes in patients with treatment interruption at 2 clinics of the Lighthouse Trust, Lilongwe, Malawi. METHODS: We evaluated patients who resumed first-line ART after having at least 1 treatment interruption documented in the electronic data system in 2008-2009. Viral load (VL) was analyzed at least 2 months after resumption of ART. For VL >/=1000 copies/mL, drug-resistance genotype was characterized using the Stanford database. RESULTS: Between June and November 2009, we enrolled 133 patients (58.7% female) with a mean age of 38.4 years. Mean duration of ART prior to treatment interruption was 14.3 months. After a minimum of 2 months following ART resumption, VL was undetectable in 81 (60.9%) patients, was 400-1000 copies/mL in 12 (9.0%) patients, and was >/=1000 copies/mL in 40 (30.1%) patients. Genotyping and drug-resistance testing were successfully performed for 36 of 40 patients, all carrying human immunodeficiency virus type 1 subtype C. Relevant mutations affecting nonnucleoside reverse transcriptase inhibitors were found in 32 of 133 (24.1%) patients and combined with relevant nucleoside reverse transcriptase mutations in 27 of 133 (20.3%) patients. CONCLUSIONS: Virological failure combined with drug resistance after resumption of first-line ART occurred in 24.1% of the patients with treatment interruption, requiring a switch to protease inhibitor-based second-line therapy. Patients with treatment interruption should receive VL assessment after resumption of ART to detect treatment failure and to reduce development and spread of drug resistance.'
p59220
sS'AD'
p59221
S'Institute of Public Health, University of Heidelberg, Germany.'
p59222
sS'IP'
p59223
S'3'
sS'IS'
p59224
S'1537-6591 (Electronic) 1058-4838 (Linking)'
p59225
sS'DCOM'
p59226
S'20121107'
p59227
sS'AU'
p59228
(lp59229
S'Luebbert J'
p59230
aS'Tweya H'
p59231
aS'Phiri S'
p59232
aS'Chaweza T'
p59233
aS'Mwafilaso J'
p59234
aS'Hosseinipour MC'
p59235
aS'Ramroth H'
p59236
aS'Schnitzler P'
p59237
aS'Neuhann F'
p59238
asS'VI'
p59239
S'55'
p59240
sS'MHDA'
p59241
S'2012/11/08 06:00'
p59242
sS'PHST'
p59243
(lp59244
S'2012/05/09 [aheadofprint]'
p59245
aS'2012/05/21 [aheadofprint]'
p59246
asS'MH'
p59247
(lp59248
S'Adult'
p59249
aS'Anti-Retroviral Agents/*administration & dosage'
p59250
aS'Antiretroviral Therapy, Highly Active/*methods'
p59251
aS'*Drug Resistance, Viral'
p59252
aS'Female'
p59253
aS'HIV Infections/*drug therapy/epidemiology/*virology'
p59254
aS'HIV-1/*drug effects/isolation & purification'
p59255
aS'Humans'
p59256
aS'Malawi/epidemiology'
p59257
aS'Male'
p59258
aS'Prevalence'
p59259
aS'Treatment Failure'
p59260
asS'EDAT'
p59261
S'2012/05/11 06:00'
p59262
sS'SO'
p59263
S'Clin Infect Dis. 2012 Aug;55(3):441-8. doi: 10.1093/cid/cis438. Epub 2012 May 9.'
p59264
sS'SB'
p59265
S'IM'
p59266
sS'PMID'
p59267
S'22573849'
p59268
sS'PST'
p59269
S'ppublish'
p59270
stRp59271
ag2
(g3
g4
(dp59272
S'LID'
p59273
S'10.1093/cid/cir987 [doi]'
p59274
sS'STAT'
p59275
S'MEDLINE'
p59276
sS'JT'
p59277
S'Clinical infectious diseases : an official publication of the Infectious Diseases Society of America'
p59278
sS'DA'
p59279
S'20120430'
p59280
sS'AID'
p59281
(lp59282
S'cir987 [pii]'
p59283
aS'10.1093/cid/cir987 [doi]'
p59284
asS'CRDT'
p59285
(lp59286
S'2012/05/01 06:00'
p59287
asS'DP'
p59288
S'2012 May'
p59289
sS'AD'
p59290
S'Department of Preventive Health, Ministry of Health, Lilongwe, Malawi. nelliewadonda@hotmail.com'
p59291
sS'OWN'
p59292
S'NLM'
p59293
sS'PT'
p59294
(lp59295
S'Journal Article'
p59296
aS"Research Support, Non-U.S. Gov't"
p59297
aS"Research Support, U.S. Gov't, P.H.S."
p59298
asS'LA'
p59299
(lp59300
S'eng'
p59301
asS'DCOM'
p59302
S'20121018'
p59303
sS'LR'
p59304
S'20150225'
p59305
sS'FAU'
p59306
(lp59307
S'Wadonda-Kabondo, Nellie'
p59308
aS'Bennett, Diane'
p59309
aS'van Oosterhout, Joep J'
p59310
aS'Moyo, Kundai'
p59311
aS'Hosseinipour, Mina'
p59312
aS'Devos, Josh'
p59313
aS'Zhou, Zhiyong'
p59314
aS'Aberle-Grasse, John'
p59315
aS'Warne, Thomas R'
p59316
aS'Mtika, Clement'
p59317
aS'Chilima, Ben'
p59318
aS'Banda, Richard'
p59319
aS'Pasulani, Olesi'
p59320
aS'Porter, Carol'
p59321
aS'Phiri, Sam'
p59322
aS'Jahn, Andreas'
p59323
aS'Kamwendo, Debbie'
p59324
aS'Jordan, Michael R'
p59325
aS'Kabuluzi, Storn'
p59326
aS'Chimbwandira, Frank'
p59327
aS'Kagoli, Mathew'
p59328
aS'Matatiyo, Blackson'
p59329
aS'Demby, Austin'
p59330
aS'Yang, Chunfu'
p59331
asS'TI'
p59332
S'Prevalence of HIV drug resistance before and 1 year after treatment initiation in 4 sites in the Malawi antiretroviral treatment program.'
p59333
sS'RN'
p59334
(lp59335
S'0 (Anti-Retroviral Agents)'
p59336
asS'PL'
p59337
S'United States'
p59338
sS'PG'
p59339
S'S362-8'
p59340
sS'JID'
p59341
S'9203213'
p59342
sS'AB'
p59343
S'Since 2004, the Malawi antiretroviral treatment (ART) program has provided a public health-focused system based on World Health Organization clinical staging, standardized first-line ART regimens, limited laboratory monitoring, and no patient-level monitoring of human immunodeficiency virus drug resistance (HIVDR). The Malawi Ministry of Health conducts periodic evaluations of HIVDR development in prospective cohorts at sentinel clinics. We evaluated viral load suppression, HIVDR, and factors associated with HIVDR in 4 ART sites at 12-15 months after ART initiation. More than 70% of patients initiating ART had viral suppression at 12 months. HIVDR prevalence (6.1%) after 12 months of ART was low and largely associated with baseline HIVDR. Better follow-up, removal of barriers to on-time drug pickups, and adherence education for patients 16-24 years of age may further prevent HIVDR.'
p59344
sS'GR'
p59345
(lp59346
S'K23 AI074423-05/AI/NIAID NIH HHS/United States'
p59347
aS'PEPFAR/United States'
p59348
asS'VI'
p59349
S'54 Suppl 4'
p59350
sS'IS'
p59351
S'1537-6591 (Electronic) 1058-4838 (Linking)'
p59352
sS'PMC'
p59353
S'PMC3338306'
p59354
sS'AU'
p59355
(lp59356
S'Wadonda-Kabondo N'
p59357
aS'Bennett D'
p59358
aS'van Oosterhout JJ'
p59359
aS'Moyo K'
p59360
aS'Hosseinipour M'
p59361
aS'Devos J'
p59362
aS'Zhou Z'
p59363
aS'Aberle-Grasse J'
p59364
aS'Warne TR'
p59365
aS'Mtika C'
p59366
aS'Chilima B'
p59367
aS'Banda R'
p59368
aS'Pasulani O'
p59369
aS'Porter C'
p59370
aS'Phiri S'
p59371
aS'Jahn A'
p59372
aS'Kamwendo D'
p59373
aS'Jordan MR'
p59374
aS'Kabuluzi S'
p59375
aS'Chimbwandira F'
p59376
aS'Kagoli M'
p59377
aS'Matatiyo B'
p59378
aS'Demby A'
p59379
aS'Yang C'
p59380
asS'MHDA'
p59381
S'2012/10/19 06:00'
p59382
sS'OID'
p59383
(lp59384
S'NLM: PMC3338306'
p59385
asS'MH'
p59386
(lp59387
S'Adolescent'
p59388
aS'Adult'
p59389
aS'Anti-Retroviral Agents/pharmacology/*therapeutic use'
p59390
aS'Drug Resistance, Viral'
p59391
aS'Female'
p59392
aS'HIV/drug effects/genetics'
p59393
aS'HIV Infections/*drug therapy/*epidemiology/virology'
p59394
aS'Humans'
p59395
aS'Malawi/epidemiology'
p59396
aS'Male'
p59397
aS'Medication Adherence'
p59398
aS'National Health Programs'
p59399
aS'Prevalence'
p59400
aS'Prospective Studies'
p59401
aS'Treatment Outcome'
p59402
asS'EDAT'
p59403
S'2012/05/11 06:00'
p59404
sS'SO'
p59405
S'Clin Infect Dis. 2012 May;54 Suppl 4:S362-8. doi: 10.1093/cid/cir987.'
p59406
sS'SB'
p59407
S'IM'
p59408
sS'PMID'
p59409
S'22544204'
p59410
sS'TA'
p59411
S'Clin Infect Dis'
p59412
sS'PST'
p59413
S'ppublish'
p59414
stRp59415
ag2
(g3
g4
(dp59416
S'LID'
p59417
S'10.1093/cid/cis004 [doi]'
p59418
sS'STAT'
p59419
S'MEDLINE'
p59420
sS'JT'
p59421
S'Clinical infectious diseases : an official publication of the Infectious Diseases Society of America'
p59422
sS'DA'
p59423
S'20120430'
p59424
sS'AID'
p59425
(lp59426
S'cis004 [pii]'
p59427
aS'10.1093/cid/cis004 [doi]'
p59428
asS'CRDT'
p59429
(lp59430
S'2012/05/01 06:00'
p59431
asS'DP'
p59432
S'2012 May'
p59433
sS'AD'
p59434
S'Ministry of Health, Lilongwe, Malawi.'
p59435
sS'OWN'
p59436
S'NLM'
p59437
sS'PT'
p59438
(lp59439
S'Journal Article'
p59440
aS'Research Support, N.I.H., Extramural'
p59441
aS"Research Support, Non-U.S. Gov't"
p59442
asS'LA'
p59443
(lp59444
S'eng'
p59445
asS'DCOM'
p59446
S'20121018'
p59447
sS'LR'
p59448
S'20150225'
p59449
sS'FAU'
p59450
(lp59451
S'Wadonda-Kabondo, Nellie'
p59452
aS'Hedt, Bethany L'
p59453
aS'van Oosterhout, Joep J'
p59454
aS'Moyo, Kundai'
p59455
aS'Limbambala, Eddie'
p59456
aS'Bello, George'
p59457
aS'Chilima, Ben'
p59458
aS'Schouten, Erik'
p59459
aS'Harries, Anthony'
p59460
aS'Massaquoi, Moses'
p59461
aS'Porter, Carol'
p59462
aS'Weigel, Ralf'
p59463
aS'Hosseinipour, Mina'
p59464
aS'Aberle-Grasse, John'
p59465
aS'Jordan, Michael R'
p59466
aS'Kabuluzi, Storn'
p59467
aS'Bennett, Diane E'
p59468
asS'TI'
p59469
S'A retrospective survey of HIV drug resistance among patients 1 year after initiation of antiretroviral therapy at 4 clinics in Malawi.'
p59470
sS'RN'
p59471
(lp59472
S'0 (Anti-Retroviral Agents)'
p59473
asS'PL'
p59474
S'United States'
p59475
sS'PG'
p59476
S'S355-61'
p59477
sS'JID'
p59478
S'9203213'
p59479
sS'AB'
p59480
S'In 2004, Malawi began scaling up its national antiretroviral therapy (ART) program. Because of limited treatment options, population-level surveillance of acquired human immunodeficiency virus drug resistance (HIVDR) is critical to ensuring long-term treatment success. The World Health Organization target for clinic-level HIVDR prevention at 12 months after ART initiation is >/= 70%. In 2007, viral load and HIVDR genotyping was performed in a retrospective cohort of 596 patients at 4 ART clinics. Overall, HIVDR prevention (using viral load </= 400 copies/mL) was 72% (95% confidence interval [CI], 67%-77%; range by site, 60%-83%) and detected HIVDR was 3.4% (95% CI, 1.8%-5.8%; range by site, 2.5%-4.7%). Results demonstrate virological suppression and HIVDR consistent with previous reports from sub-Saharan Africa. High rates of attrition because of loss to follow-up were noted and merit attention.'
p59481
sS'GR'
p59482
(lp59483
S'NIH K23 AI074423-05/AI/NIAID NIH HHS/United States'
p59484
aS'T32 AI007358/AI/NIAID NIH HHS/United States'
p59485
asS'VI'
p59486
S'54 Suppl 4'
p59487
sS'IS'
p59488
S'1537-6591 (Electronic) 1058-4838 (Linking)'
p59489
sS'PMC'
p59490
S'PMC3338311'
p59491
sS'AU'
p59492
(lp59493
S'Wadonda-Kabondo N'
p59494
aS'Hedt BL'
p59495
aS'van Oosterhout JJ'
p59496
aS'Moyo K'
p59497
aS'Limbambala E'
p59498
aS'Bello G'
p59499
aS'Chilima B'
p59500
aS'Schouten E'
p59501
aS'Harries A'
p59502
aS'Massaquoi M'
p59503
aS'Porter C'
p59504
aS'Weigel R'
p59505
aS'Hosseinipour M'
p59506
aS'Aberle-Grasse J'
p59507
aS'Jordan MR'
p59508
aS'Kabuluzi S'
p59509
aS'Bennett DE'
p59510
asS'MHDA'
p59511
S'2012/10/19 06:00'
p59512
sS'OID'
p59513
(lp59514
S'NLM: PMC3338311'
p59515
asS'MH'
p59516
(lp59517
S'Adult'
p59518
aS'Anti-Retroviral Agents/*pharmacology/therapeutic use'
p59519
aS'Drug Resistance, Viral'
p59520
aS'Female'
p59521
aS'HIV/drug effects/genetics'
p59522
aS'HIV Infections/*drug therapy/*epidemiology/virology'
p59523
aS'Humans'
p59524
aS'Malawi/epidemiology'
p59525
aS'Male'
p59526
aS'Middle Aged'
p59527
aS'Population Surveillance'
p59528
aS'Retrospective Studies'
p59529
aS'Treatment Outcome'
p59530
aS'Viral Load'
p59531
aS'World Health Organization'
p59532
asS'EDAT'
p59533
S'2012/05/11 06:00'
p59534
sS'SO'
p59535
S'Clin Infect Dis. 2012 May;54 Suppl 4:S355-61. doi: 10.1093/cid/cis004.'
p59536
sS'SB'
p59537
S'IM'
p59538
sS'PMID'
p59539
S'22544203'
p59540
sS'TA'
p59541
S'Clin Infect Dis'
p59542
sS'PST'
p59543
S'ppublish'
p59544
stRp59545
ag2
(g3
g4
(dp59546
S'LID'
p59547
S'10.1093/cid/cir1014 [doi]'
p59548
sS'STAT'
p59549
S'MEDLINE'
p59550
sS'JT'
p59551
S'Clinical infectious diseases : an official publication of the Infectious Diseases Society of America'
p59552
sS'DA'
p59553
S'20120430'
p59554
sS'AID'
p59555
(lp59556
S'cir1014 [pii]'
p59557
aS'10.1093/cid/cir1014 [doi]'
p59558
asS'CRDT'
p59559
(lp59560
S'2012/05/01 06:00'
p59561
asS'DP'
p59562
S'2012 May'
p59563
sS'AD'
p59564
S'Ministry of Health and Child Welfare, Harare, Zimbabwe.'
p59565
sS'OWN'
p59566
S'NLM'
p59567
sS'PT'
p59568
(lp59569
S'Journal Article'
p59570
aS'Research Support, N.I.H., Extramural'
p59571
aS"Research Support, Non-U.S. Gov't"
p59572
asS'LA'
p59573
(lp59574
S'eng'
p59575
asS'DCOM'
p59576
S'20121018'
p59577
sS'LR'
p59578
S'20150225'
p59579
sS'FAU'
p59580
(lp59581
S'Dzangare, J'
p59582
aS'Gonese, E'
p59583
aS'Mugurungi, O'
p59584
aS'Shamu, T'
p59585
aS'Apollo, T'
p59586
aS'Bennett, D E'
p59587
aS'Kelley, K F'
p59588
aS'Jordan, M R'
p59589
aS'Chakanyuka, C'
p59590
aS'Cham, F'
p59591
aS'Banda, R M'
p59592
asS'TI'
p59593
S'Monitoring of early warning indicators for HIV drug resistance in antiretroviral therapy clinics in Zimbabwe.'
p59594
sS'RN'
p59595
(lp59596
S'0 (Anti-Retroviral Agents)'
p59597
asS'PL'
p59598
S'United States'
p59599
sS'PG'
p59600
S'S313-6'
p59601
sS'JID'
p59602
S'9203213'
p59603
sS'AB'
p59604
S"Monitoring human immunodeficiency virus drug resistance (HIVDR) early warning indicators (EWIs) can help national antiretroviral treatment (ART) programs to identify clinic factors associated with HIVDR emergence and provide evidence to support national program and clinic-level adjustments, if necessary. World Health Organization-recommended HIVDR EWIs were monitored in Zimbabwe using routinely available data at selected ART clinics between 2007 and 2009. As Zimbabwe's national ART coverage increases, improved ART information systems are required to strengthen routine national ART monitoring and evaluation and facilitate scale-up of HIVDR EWI monitoring. Attention should be paid to minimizing loss to follow-up, supporting adherence, and ensuring clinic-level drug supply continuity."
p59605
sS'GR'
p59606
(lp59607
S'K23 AI074423-05/AI/NIAID NIH HHS/United States'
p59608
asS'VI'
p59609
S'54 Suppl 4'
p59610
sS'IS'
p59611
S'1537-6591 (Electronic) 1058-4838 (Linking)'
p59612
sS'PMC'
p59613
S'PMC3338304'
p59614
sS'AU'
p59615
(lp59616
S'Dzangare J'
p59617
aS'Gonese E'
p59618
aS'Mugurungi O'
p59619
aS'Shamu T'
p59620
aS'Apollo T'
p59621
aS'Bennett DE'
p59622
aS'Kelley KF'
p59623
aS'Jordan MR'
p59624
aS'Chakanyuka C'
p59625
aS'Cham F'
p59626
aS'Banda RM'
p59627
asS'MHDA'
p59628
S'2012/10/19 06:00'
p59629
sS'OID'
p59630
(lp59631
S'NLM: PMC3338304'
p59632
asS'MH'
p59633
(lp59634
S'Adult'
p59635
aS'Anti-Retroviral Agents/*pharmacology/supply & distribution/therapeutic use'
p59636
aS'Drug Resistance, Viral'
p59637
aS'HIV Infections/*drug therapy/*epidemiology'
p59638
aS'Humans'
p59639
aS'Lost to Follow-Up'
p59640
aS'National Health Programs'
p59641
aS'Patient Compliance/statistics & numerical data'
p59642
aS'Population Surveillance'
p59643
aS'World Health Organization'
p59644
aS'Zimbabwe/epidemiology'
p59645
asS'EDAT'
p59646
S'2012/05/11 06:00'
p59647
sS'SO'
p59648
S'Clin Infect Dis. 2012 May;54 Suppl 4:S313-6. doi: 10.1093/cid/cir1014.'
p59649
sS'SB'
p59650
S'IM'
p59651
sS'PMID'
p59652
S'22544194'
p59653
sS'TA'
p59654
S'Clin Infect Dis'
p59655
sS'PST'
p59656
S'ppublish'
p59657
stRp59658
ag2
(g3
g4
(dp59659
S'STAT'
p59660
S'MEDLINE'
p59661
sS'DEP'
p59662
S'20120308'
p59663
sS'DA'
p59664
S'20120504'
p59665
sS'CRDT'
p59666
(lp59667
S'2012/05/05 06:00'
p59668
asS'DP'
p59669
S'2012 May'
p59670
sS'AD'
p59671
S'Department of Anaesthesiology, University of the Witwatersrand, Johannesburg, South Africa. seanchetty@gmail.com'
p59672
sS'OWN'
p59673
S'NLM'
p59674
sS'PT'
p59675
(lp59676
S'Journal Article'
p59677
aS'Practice Guideline'
p59678
asS'LA'
p59679
(lp59680
S'eng'
p59681
asS'FAU'
p59682
(lp59683
S'Chetty, S'
p59684
aS'Baalbergen, E'
p59685
aS'Bhigjee, A I'
p59686
aS'Kamerman, P'
p59687
aS'Ouma, J'
p59688
aS'Raath, R'
p59689
aS'Raff, M'
p59690
aS'Salduker, S'
p59691
asS'JT'
p59692
S'South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde'
p59693
sS'LR'
p59694
S'20140912'
p59695
sS'PG'
p59696
S'312-25'
p59697
sS'TI'
p59698
S'Clinical practice guidelines for management of neuropathic pain: expert panel recommendations for South Africa.'
p59699
sS'RN'
p59700
(lp59701
S'0 (Analgesics)'
p59702
aS'0 (Antidepressive Agents)'
p59703
aS'0 (Antidepressive Agents, Tricyclic)'
p59704
asS'PL'
p59705
S'South Africa'
p59706
sS'TA'
p59707
S'S Afr Med J'
p59708
sS'JID'
p59709
S'0404520'
p59710
sS'AB'
p59711
S'Neuropathic pain (NeuP) is challenging to diagnose and manage, despite ongoing improved understanding of the underlying mechanisms. Many patients do not respond satisfactorily to existing treatments. There are no published guidelines for diagnosis or management of NeuP in South Africa. A multidisciplinary expert panel critically reviewed available evidence to provide consensus recommendations for diagnosis and management of NeuP in South Africa. Following accurate diagnosis of NeuP, pregabalin, gabapentin, low-dose tricyclic antidepressants (e.g. amitriptyline) and serotonin norepinephrine reuptake inhibitors (duloxetine and venlafaxine) are all recommended as first-line options for the treatment of peripheral NeuP. If the response is insufficient after 2 - 4 weeks, the recommended next step is to switch to a different class, or combine different classes of agent. Opioids should be reserved for use later in the treatment pathway, if switching drugs and combination therapy fails. For central NeuP, pregabalin or amitriptyline are recommended as first-line agents. Companion treatments (cognitive behavioural therapy and physical therapy) should be administered as part of a multidisciplinary approach. Dorsal root entry zone rhizotomy (DREZ) is not recommended to treat NeuP. Given the large population of HIV/AIDS patients in South Africa, and the paucity of positive efficacy data for its management, research in the form of randomised controlled trials in painful HIV-associated sensory neuropathy (HIV-SN) must be prioritised in this country.'
p59712
sS'CN'
p59713
(lp59714
S'South African Expert Panel'
p59715
asS'IP'
p59716
S'5'
sS'IS'
p59717
S'0256-9574 (Print)'
p59718
sS'DCOM'
p59719
S'20121119'
p59720
sS'AU'
p59721
(lp59722
S'Chetty S'
p59723
aS'Baalbergen E'
p59724
aS'Bhigjee AI'
p59725
aS'Kamerman P'
p59726
aS'Ouma J'
p59727
aS'Raath R'
p59728
aS'Raff M'
p59729
aS'Salduker S'
p59730
asS'VI'
p59731
S'102'
p59732
sS'MHDA'
p59733
S'2012/12/10 06:00'
p59734
sS'PHST'
p59735
(lp59736
S'2011/11/23 [received]'
p59737
aS'2011/11/25 [accepted]'
p59738
asS'MH'
p59739
(lp59740
S'Analgesics/*therapeutic use'
p59741
aS'Antidepressive Agents/therapeutic use'
p59742
aS'Antidepressive Agents, Tricyclic/therapeutic use'
p59743
aS'Drug Therapy, Combination'
p59744
aS'Evidence-Based Medicine'
p59745
aS'Humans'
p59746
aS'Neuralgia/*drug therapy'
p59747
aS'Nociceptors/drug effects'
p59748
aS'Pain Measurement/drug effects'
p59749
aS'Pain Threshold'
p59750
aS'Pain, Intractable/drug therapy'
p59751
aS'Peripheral Nervous System Diseases/*drug therapy'
p59752
aS'Practice Guidelines as Topic'
p59753
aS'*Severity of Illness Index'
p59754
aS'South Africa'
p59755
asS'EDAT'
p59756
S'2012/05/05 06:00'
p59757
sS'SO'
p59758
S'S Afr Med J. 2012 Mar 8;102(5):312-25.'
p59759
sS'SB'
p59760
S'IM'
p59761
sS'PMID'
p59762
S'22554341'
p59763
sS'PST'
p59764
S'epublish'
p59765
stRp59766
ag2
(g3
g4
(dp59767
S'LID'
p59768
S'10.1089/AID.2011.0313 [doi]'
p59769
sS'STAT'
p59770
S'MEDLINE'
p59771
sS'DEP'
p59772
S'20120601'
p59773
sS'DA'
p59774
S'20121122'
p59775
sS'AID'
p59776
(lp59777
S'10.1089/AID.2011.0313 [doi]'
p59778
asS'CRDT'
p59779
(lp59780
S'2012/05/02 06:00'
p59781
asS'DP'
p59782
S'2012 Dec'
p59783
sS'OWN'
p59784
S'NLM'
p59785
sS'PT'
p59786
(lp59787
S'Comparative Study'
p59788
aS'Journal Article'
p59789
aS"Research Support, Non-U.S. Gov't"
p59790
asS'LA'
p59791
(lp59792
S'eng'
p59793
asS'FAU'
p59794
(lp59795
S'Musiime, Victor'
p59796
aS'Kayiwa, Joshua'
p59797
aS'Kiconco, Mary'
p59798
aS'Tamale, William'
p59799
aS'Alima, Hillary'
p59800
aS'Mugerwa, Henry'
p59801
aS'Abwola, Mary'
p59802
aS'Apilli, Eunice'
p59803
aS'Ahimbisibwe, Fred'
p59804
aS'Kizito, Hilda'
p59805
aS'Abongomera, George'
p59806
aS'Namusoke, Asia'
p59807
aS'Makabayi, Agnes'
p59808
aS'Kiweewa, Francis'
p59809
aS'Ssali, Francis'
p59810
aS'Kityo, Cissy'
p59811
aS'Colebunders, Robert'
p59812
aS'Mugyenyi, Peter'
p59813
asS'JT'
p59814
S'AIDS research and human retroviruses'
p59815
sS'PG'
p59816
S'1647-57'
p59817
sS'TI'
p59818
S'Response to antiretroviral therapy of HIV type 1-infected children in urban and rural settings of Uganda.'
p59819
sS'RN'
p59820
(lp59821
S'0 (Anti-Retroviral Agents)'
p59822
asS'PL'
p59823
S'United States'
p59824
sS'TA'
p59825
S'AIDS Res Hum Retroviruses'
p59826
sS'JID'
p59827
S'8709376'
p59828
sS'AB'
p59829
S'From 2006 to 2011, a cohort study was conducted among 1000 children resident in urban and rural settings of Uganda to ascertain and compare the response to antiretroviral therapy (ART) among urban versus rural children and the factors associated with this response. Clinical, immunological, and virological parameters were ascertained at baseline and weeks 24, 48, 96, and 144 after ART initiation. Adherence to ART was assessed at enrollment by self-report (SR) and pill counts (PC). Overall, 499/948 (52.6%) children were resident in rural areas, 504/948 (53.1%) were male, and their mean age was 11.9+/-4.4 years (urban children) and 11.4+/-4.1 years (rural children). The urban children were more likely to switch to second-line ART at a rate of 39.9 per 1000 person-years (95% CI: 28.2-56.4) versus 14.9 per 1000 person-years (95% CI: 8.7-25.7), p=0.0038, develop any new WHO 3/4 events at 127/414 (30.7%) versus 108/466 (23.2%), p=0.012, and have a higher cumulative incidence of hospitalization of 54/449 (12.0%) versus 32/499 (6.4%), p=0.003, when compared to rural children. No differences were observed in mean changes in weight, height, CD4 count and percentage, and hemoglobin and viral load between urban and rural children. Adherence of >/=95% was observed in 88.2% of urban versus 91.3% of rural children by SR (p=0.130), and in 78.8% of urban versus 88.8% of rural children by PC (p<0.0001). In this study rural children had more favorable clinical outcomes and were more likely to adhere optimally to ART than urban children.'
p59830
sS'AD'
p59831
S'Joint Clinical Research Centre, Headquarters, Kampala, Uganda. musiimev@yahoo.co.uk'
p59832
sS'IP'
p59833
S'12'
p59834
sS'IS'
p59835
S'1931-8405 (Electronic) 0889-2229 (Linking)'
p59836
sS'DCOM'
p59837
S'20130423'
p59838
sS'AU'
p59839
(lp59840
S'Musiime V'
p59841
aS'Kayiwa J'
p59842
aS'Kiconco M'
p59843
aS'Tamale W'
p59844
aS'Alima H'
p59845
aS'Mugerwa H'
p59846
aS'Abwola M'
p59847
aS'Apilli E'
p59848
aS'Ahimbisibwe F'
p59849
aS'Kizito H'
p59850
aS'Abongomera G'
p59851
aS'Namusoke A'
p59852
aS'Makabayi A'
p59853
aS'Kiweewa F'
p59854
aS'Ssali F'
p59855
aS'Kityo C'
p59856
aS'Colebunders R'
p59857
aS'Mugyenyi P'
p59858
asS'VI'
p59859
S'28'
p59860
sS'MHDA'
p59861
S'2013/04/24 06:00'
p59862
sS'PHST'
p59863
(lp59864
S'2012/06/01 [aheadofprint]'
p59865
asS'MH'
p59866
(lp59867
S'Adolescent'
p59868
aS'Anti-Retroviral Agents/*administration & dosage'
p59869
aS'Antiretroviral Therapy, Highly Active/*methods'
p59870
aS'Child'
p59871
aS'Child, Preschool'
p59872
aS'Cohort Studies'
p59873
aS'Female'
p59874
aS'HIV Infections/*drug therapy/immunology/pathology/virology'
p59875
aS'Humans'
p59876
aS'Male'
p59877
aS'Rural Population'
p59878
aS'Treatment Outcome'
p59879
aS'Uganda'
p59880
aS'Urban Population'
p59881
asS'EDAT'
p59882
S'2012/05/02 06:00'
p59883
sS'SO'
p59884
S'AIDS Res Hum Retroviruses. 2012 Dec;28(12):1647-57. doi: 10.1089/AID.2011.0313. Epub 2012 Jun 1.'
p59885
sS'SB'
p59886
S'IM X'
p59887
sS'PMID'
p59888
S'22545751'
p59889
sS'PST'
p59890
S'ppublish'
p59891
stRp59892
ag2
(g3
g4
(dp59893
S'LID'
p59894
S'10.1016/S0140-6736(12)60321-3 [doi]'
p59895
sS'STAT'
p59896
S'MEDLINE'
p59897
sS'DEP'
p59898
S'20120426'
p59899
sS'MID'
p59900
(lp59901
S'NIHMS465410'
p59902
asS'DA'
p59903
S'20120703'
p59904
sS'AID'
p59905
(lp59906
S'S0140-6736(12)60321-3 [pii]'
p59907
aS'10.1016/S0140-6736(12)60321-3 [doi]'
p59908
asS'CRDT'
p59909
(lp59910
S'2012/05/01 06:00'
p59911
asS'DP'
p59912
S'2012 Jun 30'
p59913
sS'GR'
p59914
(lp59915
S'D43 TW001039/TW/FIC NIH HHS/United States'
p59916
aS'FIC 2-D43 TW01039-06/TW/FIC NIH HHS/United States'
p59917
aS'P30 AI050410/AI/NIAID NIH HHS/United States'
p59918
aS'P30-AI50410/AI/NIAID NIH HHS/United States'
p59919
aS'R24 HD050924/HD/NICHD NIH HHS/United States'
p59920
aS'R24 TW007988/TW/FIC NIH HHS/United States'
p59921
aS'SIP 13-01 U48-CCU409660-09/PHS HHS/United States'
p59922
aS'SIP 22-09 U48-DP001944-01/DP/NCCDPHP CDC HHS/United States'
p59923
aS'SIP 26-04 U48-DP000059-01/DP/NCCDPHP CDC HHS/United States'
p59924
asS'OWN'
p59925
S'NLM'
p59926
sS'PT'
p59927
(lp59928
S'Journal Article'
p59929
aS'Randomized Controlled Trial'
p59930
aS'Research Support, American Recovery and Reinvestment Act'
p59931
aS'Research Support, N.I.H., Extramural'
p59932
aS"Research Support, U.S. Gov't, P.H.S."
p59933
asS'LA'
p59934
(lp59935
S'eng'
p59936
asS'FAU'
p59937
(lp59938
S'Jamieson, Denise J'
p59939
aS'Chasela, Charles S'
p59940
aS'Hudgens, Michael G'
p59941
aS'King, Caroline C'
p59942
aS'Kourtis, Athena P'
p59943
aS'Kayira, Dumbani'
p59944
aS'Hosseinipour, Mina C'
p59945
aS'Kamwendo, Deborah D'
p59946
aS'Ellington, Sascha R'
p59947
aS'Wiener, Jeffrey B'
p59948
aS'Fiscus, Susan A'
p59949
aS'Tegha, Gerald'
p59950
aS'Mofolo, Innocent A'
p59951
aS'Sichali, Dorothy S'
p59952
aS'Adair, Linda S'
p59953
aS'Knight, Rodney J'
p59954
aS'Martinson, Francis'
p59955
aS'Kacheche, Zebrone'
p59956
aS'Soko, Alice'
p59957
aS'Hoffman, Irving'
p59958
aS'van der Horst, Charles'
p59959
asS'JT'
p59960
S'Lancet (London, England)'
p59961
sS'LR'
p59962
S'20150616'
p59963
sS'PG'
p59964
S'2449-58'
p59965
sS'TI'
p59966
S'Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial.'
p59967
sS'RN'
p59968
(lp59969
S'0 (Anti-Retroviral Agents)'
p59970
aS'2T8Q726O95 (Lamivudine)'
p59971
aS'4B9XT59T7S (Zidovudine)'
p59972
aS'99DK7FVK1H (Nevirapine)'
p59973
asS'PL'
p59974
S'England'
p59975
sS'TA'
p59976
S'Lancet'
p59977
sS'FIR'
p59978
(lp59979
S'Adair, Linda'
p59980
aS'Ahmed, Yusuf'
p59981
aS'Ait-Khaled, Mounir'
p59982
aS'Albrecht, Sandra'
p59983
aS'Bangdiwala, Shrikant'
p59984
aS'Bayer, Ronald'
p59985
aS'Bentley, Margaret'
p59986
aS'Bramson, Brian'
p59987
aS'Bobrow, Emily'
p59988
aS'Boyle, Nicola'
p59989
aS'Butera, Sal'
p59990
aS'Chasela, Charles'
p59991
aS'Chavula, Charity'
p59992
aS"Chimerang'ambe, Joseph"
p59993
aS'Chigwenembe, Maggie'
p59994
aS'Chikasema, Maria'
p59995
aS'Chikhungu, Norah'
p59996
aS'Chilongozi, David'
p59997
aS'Chiudzu, Grace'
p59998
aS'Chome, Lenesi'
p59999
aS'Cole, Anne'
p60000
aS'Corbett, Amanda'
p60001
aS'Corneli, Amy'
p60002
aS'Dow, Anna'
p60003
aS'Duerr, Ann'
p60004
aS'Eliya, Henry'
p60005
aS'Ellington, Sascha'
p60006
aS'Eron, Joseph'
p60007
aS'Farr, Sherry'
p60008
aS'Ferguson, Yvonne Owens'
p60009
aS'Fiscus, Susan'
p60010
aS'Flax, Valerie'
p60011
aS'Fokar, Ali'
p60012
aS'Galvin, Shannon'
p60013
aS'Guay, Laura'
p60014
aS'Heilig, Chad'
p60015
aS'Hoffman, Irving'
p60016
aS'Hooten, Elizabeth'
p60017
aS'Hosseinipour, Mina'
p60018
aS'Hudgens, Michael'
p60019
aS'Hurst, Stacy'
p60020
aS'Hyde, Lisa'
p60021
aS'Jamieson, Denise'
p60022
aS'Joaki, George'
p60023
aS'Jones, David'
p60024
aS'Jordan-Bell, Elizabeth'
p60025
aS'Kacheche, Zebrone'
p60026
aS'Kamanga, Esmie'
p60027
aS'Kamanga, Gift'
p60028
aS'Kampani, Coxcilly'
p60029
aS'Kamthunzi, Portia'
p60030
aS'Kamwendo, Deborah'
p60031
aS'Kanyama, Cecilia'
p60032
aS'Kashuba, Angela'
p60033
aS'Kathyola, Damson'
p60034
aS'Kayira, Dumbani'
p60035
aS'Kazembe, Peter'
p60036
aS'King, Caroline C'
p60037
aS'Knight, Rodney'
p60038
aS'Kourtis, Athena P'
p60039
aS'Krysiak, Robert'
p60040
aS'Kumwenda, Jacob'
p60041
aS'Lee, Hana'
p60042
aS'Loeliger, Edde'
p60043
aS'Long, Dustin'
p60044
aS'Luhanga, Misheck'
p60045
aS'Madhlopa, Victor'
p60046
aS'Majawa, Maganizo'
p60047
aS'Maida, Alice'
p60048
aS'Marcus, Cheryl'
p60049
aS'Martinson, Francis'
p60050
aS'Thoofer, Navdeep'
p60051
aS'Matiki, Chrissie'
p60052
aS'Mayers, Douglas'
p60053
aS'Mayuni, Isabel'
p60054
aS'McDonough, Marita'
p60055
aS'Meme, Joyce'
p60056
aS'Merry, Ceppie'
p60057
aS'Mita, Khama'
p60058
aS'Mkomawanthu, Chimwemwe'
p60059
aS'Mndala, Gertrude'
p60060
aS'Mndala, Ibrahim'
p60061
aS'Moses, Agnes'
p60062
aS'Msika, Albans'
p60063
aS'Msungama, Wezi'
p60064
aS'Mtimuni, Beatrice'
p60065
aS'Muita, Jane'
p60066
aS'Mumba, Noel'
p60067
aS'Musis, Bonface'
p60068
aS'Mwansambo, Charles'
p60069
aS'Mwapasa, Gerald'
p60070
aS'Nkhoma, Jacqueline'
p60071
aS'Parker, Megan'
p60072
aS'Pendame, Richard'
p60073
aS'Piwoz, Ellen'
p60074
aS'Raines, Byron'
p60075
aS'Ramdas, Zane'
p60076
aS'Rublein, John'
p60077
aS'Ryan, Mairin'
p60078
aS'Sanne, Ian'
p60079
aS'Sellers, Christopher'
p60080
aS'Shugars, Diane'
p60081
aS'Sichali, Dorothy'
p60082
aS'Snowden, Wendy'
p60083
aS'Soko, Alice'
p60084
aS'Spensley, Allison'
p60085
aS'Steens, Jean-Marc'
p60086
aS'Tegha, Gerald'
p60087
aS'Tembo, Martin'
p60088
aS'Thomas, Roshan'
p60089
aS'Tien, Hsiao-Chuan'
p60090
aS'Tohill, Beth'
p60091
aS'van der Horst, Charles'
p60092
aS'Waalberg, Esther'
p60093
aS'Widen, Elizabeth'
p60094
aS'Wiener, Jeffrey'
p60095
aS'Wilfert, Cathy'
p60096
aS'Wiyo, Patricia'
p60097
aS'Zgambo, Innocent'
p60098
aS'Zimba, Chifundo'
p60099
asS'JID'
p60100
S'2985213R'
p60101
sS'AB'
p60102
S'BACKGROUND: In resource-limited settings where no safe alternative to breastfeeding exists, WHO recommends that antiretroviral prophylaxis be given to either HIV-infected mothers or infants throughout breastfeeding. We assessed the effect of 28 weeks of maternal or infant antiretroviral prophylaxis on postnatal HIV infection at 48 weeks. METHODS: The Breastfeeding, Antiretrovirals, and Nutrition (BAN) Study was undertaken in Lilongwe, Malawi, between April 21, 2004, and Jan 28, 2010. 2369 HIV-infected breastfeeding mothers with a CD4 count of 250 cells per muL or more and their newborn babies were randomly assigned with a variable-block design to one of three, 28-week regimens: maternal triple antiretroviral (n=849); daily infant nevirapine (n=852); or control (n=668). Patients and local clinical staff were not masked to treatment allocation, but other study investigators were. All mothers and infants received one dose of nevirapine (mother 200 mg; infant 2 mg/kg) and 7 days of zidovudine (mother 300 mg; infants 2 mg/kg) and lamivudine (mothers 150 mg; infants 4 mg/kg) twice a day. Mothers were advised to wean between 24 weeks and 28 weeks after birth. The primary endpoint was HIV infection by 48 weeks in infants who were not infected at 2 weeks and in all infants randomly assigned with censoring at loss to follow-up. This trial is registered with ClinicalTrials.gov, number NCT00164736. FINDINGS: 676 mother-infant pairs completed follow-up to 48 weeks or reached an endpoint in the maternal-antiretroviral group, 680 in the infant-nevirapine group, and 542 in the control group. By 32 weeks post partum, 96% of women in the intervention groups and 88% of those in the control group reported no breastfeeding since their 28-week visit. 30 infants in the maternal-antiretroviral group, 25 in the infant-nevirapine group, and 38 in the control group became HIV infected between 2 weeks and 48 weeks of life; 28 (30%) infections occurred after 28 weeks (nine in maternal-antiretroviral, 13 in infant-nevirapine, and six in control groups). The cumulative risk of HIV-1 transmission by 48 weeks was significantly higher in the control group (7%, 95% CI 5-9) than in the maternal-antiretroviral (4%, 3-6; p=0.0273) or the infant-nevirapine (4%, 2-5; p=0.0027) groups. The rate of serious adverse events in infants was significantly higher during 29-48 weeks than during the intervention phase (1.1 [95% CI 1.0-1.2] vs 0.7 [0.7-0.8] per 100 person-weeks; p<0.0001), with increased risk of diarrhoea, malaria, growth faltering, tuberculosis, and death. Nine women died between 2 weeks and 48 weeks post partum (one in maternal-antiretroviral group, two in infant-nevirapine group, six in control group). INTERPRETATION: In resource-limited settings where no suitable alternative to breastfeeding is available, antiretroviral prophylaxis given to mothers or infants might decrease HIV transmission. Weaning at 6 months might increase infant morbidity. FUNDING: US Centers for Disease Control and Prevention.'
p60103
sS'AD'
p60104
S'US Centers for Disease Control and Prevention, Atlanta, GA 30341, USA. djj0@cdc.gov'
p60105
sS'CN'
p60106
(lp60107
S'BAN study team'
p60108
asS'IP'
p60109
S'9835'
p60110
sS'IS'
p60111
S'1474-547X (Electronic) 0140-6736 (Linking)'
p60112
sS'IR'
p60113
(lp60114
S'Adair L'
p60115
aS'Ahmed Y'
p60116
aS'Ait-Khaled M'
p60117
aS'Albrecht S'
p60118
aS'Bangdiwala S'
p60119
aS'Bayer R'
p60120
aS'Bentley M'
p60121
aS'Bramson B'
p60122
aS'Bobrow E'
p60123
aS'Boyle N'
p60124
aS'Butera S'
p60125
aS'Chasela C'
p60126
aS'Chavula C'
p60127
aS"Chimerang'ambe J"
p60128
aS'Chigwenembe M'
p60129
aS'Chikasema M'
p60130
aS'Chikhungu N'
p60131
aS'Chilongozi D'
p60132
aS'Chiudzu G'
p60133
aS'Chome L'
p60134
aS'Cole A'
p60135
aS'Corbett A'
p60136
aS'Corneli A'
p60137
aS'Dow A'
p60138
aS'Duerr A'
p60139
aS'Eliya H'
p60140
aS'Ellington S'
p60141
aS'Eron J'
p60142
aS'Farr S'
p60143
aS'Ferguson YO'
p60144
aS'Fiscus S'
p60145
aS'Flax V'
p60146
aS'Fokar A'
p60147
aS'Galvin S'
p60148
aS'Guay L'
p60149
aS'Heilig C'
p60150
aS'Hoffman I'
p60151
aS'Hooten E'
p60152
aS'Hosseinipour M'
p60153
aS'Hudgens M'
p60154
aS'Hurst S'
p60155
aS'Hyde L'
p60156
aS'Jamieson D'
p60157
aS'Joaki G'
p60158
aS'Jones D'
p60159
aS'Jordan-Bell E'
p60160
aS'Kacheche Z'
p60161
aS'Kamanga E'
p60162
aS'Kamanga G'
p60163
aS'Kampani C'
p60164
aS'Kamthunzi P'
p60165
aS'Kamwendo D'
p60166
aS'Kanyama C'
p60167
aS'Kashuba A'
p60168
aS'Kathyola D'
p60169
aS'Kayira D'
p60170
aS'Kazembe P'
p60171
aS'King CC'
p60172
aS'Knight R'
p60173
aS'Kourtis AP'
p60174
aS'Krysiak R'
p60175
aS'Kumwenda J'
p60176
aS'Lee H'
p60177
aS'Loeliger E'
p60178
aS'Long D'
p60179
aS'Luhanga M'
p60180
aS'Madhlopa V'
p60181
aS'Majawa M'
p60182
aS'Maida A'
p60183
aS'Marcus C'
p60184
aS'Martinson F'
p60185
aS'Thoofer N'
p60186
aS'Matiki C'
p60187
aS'Mayers D'
p60188
aS'Mayuni I'
p60189
aS'McDonough M'
p60190
aS'Meme J'
p60191
aS'Merry C'
p60192
aS'Mita K'
p60193
aS'Mkomawanthu C'
p60194
aS'Mndala G'
p60195
aS'Mndala I'
p60196
aS'Moses A'
p60197
aS'Msika A'
p60198
aS'Msungama W'
p60199
aS'Mtimuni B'
p60200
aS'Muita J'
p60201
aS'Mumba N'
p60202
aS'Musis B'
p60203
aS'Mwansambo C'
p60204
aS'Mwapasa G'
p60205
aS'Nkhoma J'
p60206
aS'Parker M'
p60207
aS'Pendame R'
p60208
aS'Piwoz E'
p60209
aS'Raines B'
p60210
aS'Ramdas Z'
p60211
aS'Rublein J'
p60212
aS'Ryan M'
p60213
aS'Sanne I'
p60214
aS'Sellers C'
p60215
aS'Shugars D'
p60216
aS'Sichali D'
p60217
aS'Snowden W'
p60218
aS'Soko A'
p60219
aS'Spensley A'
p60220
aS'Steens JM'
p60221
aS'Tegha G'
p60222
aS'Tembo M'
p60223
aS'Thomas R'
p60224
aS'Tien HC'
p60225
aS'Tohill B'
p60226
aS'van der Horst C'
p60227
aS'Waalberg E'
p60228
aS'Widen E'
p60229
aS'Wiener J'
p60230
aS'Wilfert C'
p60231
aS'Wiyo P'
p60232
aS'Zgambo I'
p60233
aS'Zimba C'
p60234
asS'DCOM'
p60235
S'20120801'
p60236
sS'CIN'
p60237
(lp60238
S'Lancet. 2012 Jun 30;379(9835):2405-7. PMID: 22541419'
p60239
asS'AU'
p60240
(lp60241
S'Jamieson DJ'
p60242
aS'Chasela CS'
p60243
aS'Hudgens MG'
p60244
aS'King CC'
p60245
aS'Kourtis AP'
p60246
aS'Kayira D'
p60247
aS'Hosseinipour MC'
p60248
aS'Kamwendo DD'
p60249
aS'Ellington SR'
p60250
aS'Wiener JB'
p60251
aS'Fiscus SA'
p60252
aS'Tegha G'
p60253
aS'Mofolo IA'
p60254
aS'Sichali DS'
p60255
aS'Adair LS'
p60256
aS'Knight RJ'
p60257
aS'Martinson F'
p60258
aS'Kacheche Z'
p60259
aS'Soko A'
p60260
aS'Hoffman I'
p60261
aS'van der Horst C'
p60262
asS'VI'
p60263
S'379'
p60264
sS'MHDA'
p60265
S'2012/08/02 06:00'
p60266
sS'PHST'
p60267
(lp60268
S'2012/04/26 [aheadofprint]'
p60269
asS'OID'
p60270
(lp60271
S'NLM: NIHMS465410'
p60272
aS'NLM: PMC3661206'
p60273
asS'CI'
p60274
(lp60275
S'Copyright (c) 2012 Elsevier Ltd. All rights reserved.'
p60276
asS'MH'
p60277
(lp60278
S'Adult'
p60279
aS'Anti-Retroviral Agents/*administration & dosage'
p60280
aS'Breast Feeding'
p60281
aS'Female'
p60282
aS'Follow-Up Studies'
p60283
aS'HIV Infections/drug therapy/*prevention & control/transmission'
p60284
aS'*HIV-1'
p60285
aS'Humans'
p60286
aS'Infant, Newborn'
p60287
aS'Infectious Disease Transmission, Vertical/*prevention & control'
p60288
aS'Lamivudine/administration & dosage'
p60289
aS'Nevirapine/administration & dosage'
p60290
aS'Pregnancy'
p60291
aS'Young Adult'
p60292
aS'Zidovudine/administration & dosage'
p60293
asS'EDAT'
p60294
S'2012/05/01 06:00'
p60295
sS'PMC'
p60296
S'PMC3661206'
p60297
sS'SI'
p60298
(lp60299
S'ClinicalTrials.gov/NCT00164736'
p60300
asS'SO'
p60301
S'Lancet. 2012 Jun 30;379(9835):2449-58. doi: 10.1016/S0140-6736(12)60321-3. Epub 2012 Apr 26.'
p60302
sS'SB'
p60303
S'AIM IM'
p60304
sS'PMID'
p60305
S'22541418'
p60306
sS'PST'
p60307
S'ppublish'
p60308
stRp60309
ag2
(g3
g4
(dp60310
S'LID'
p60311
S'10.1007/s13365-012-0093-2 [doi]'
p60312
sS'STAT'
p60313
S'MEDLINE'
p60314
sS'DEP'
p60315
S'20120420'
p60316
sS'DA'
p60317
S'20120528'
p60318
sS'AID'
p60319
(lp60320
S'10.1007/s13365-012-0093-2 [doi]'
p60321
asS'CRDT'
p60322
(lp60323
S'2012/04/25 06:00'
p60324
asS'DP'
p60325
S'2012 Jun'
p60326
sS'AD'
p60327
S'Health Economics and Epidemiology Research Office, Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, 2041, South Africa. devans@witshealth.co.za'
p60328
sS'OWN'
p60329
S'NLM'
p60330
sS'PT'
p60331
(lp60332
S'Journal Article'
p60333
aS'Research Support, N.I.H., Extramural'
p60334
aS"Research Support, U.S. Gov't, Non-P.H.S."
p60335
asS'LA'
p60336
(lp60337
S'eng'
p60338
asS'FAU'
p60339
(lp60340
S'Evans, Denise'
p60341
aS'Takuva, Simbarashe'
p60342
aS'Rassool, Mohammed'
p60343
aS'Firnhaber, Cindy'
p60344
aS'Maskew, Mhairi'
p60345
asS'JT'
p60346
S'Journal of neurovirology'
p60347
sS'LR'
p60348
S'20140408'
p60349
sS'PG'
p60350
S'162-71'
p60351
sS'TI'
p60352
S'Prevalence of peripheral neuropathy in antiretroviral therapy naive HIV-positive patients and the impact on treatment outcomes--a retrospective study from a large urban cohort in Johannesburg, South Africa.'
p60353
sS'RN'
p60354
(lp60355
S'0 (Anti-HIV Agents)'
p60356
aS'0 (Antitubercular Agents)'
p60357
aS'V83O1VOZ8L (Isoniazid)'
p60358
asS'PL'
p60359
S'United States'
p60360
sS'TA'
p60361
S'J Neurovirol'
p60362
sS'JID'
p60363
S'9508123'
p60364
sS'AB'
p60365
S'Peripheral neuropathy (PN) is associated with advanced HIV disease and may be a complication of antiretroviral therapy (ART) or anti-tuberculosis (TB) drugs, specifically isoniazid (INH). The effect of non-ART-drug-related PN on treatment outcomes is yet to be determined. We analysed prospectively collected cohort data for HIV-infected ART-naive adults initiating ART at the Themba Lethu Clinic, Johannesburg, South Africa from June 2004 to June 2009. Patients who presented with signs and symptoms of numbness or dysesthesia prior to initiation of ART were defined as having PN. Cox proportional hazard models were used to estimate the effect of PN alone (HIV-related PN) or PN with a history of INH use (TB-related PN) on mortality, lost to follow-up (LTFU), persistent and recurrent PN by 12 months of follow-up. Of the 9,399 patients initiating ART, 3.9 % had HIV-related PN while a further 1.8 % had TB-related PN. Patients with PN did not have a significantly higher risk of mortality compared to those without PN (hazard ratio (HR) 1.17 95 % CI 0.92-1.49). Patients with TB-related PN were less likely to be LTFU by 12 months (HR 0.65 95 % CI 0.44-0.97) compared to those without PN. Patients with HIV-related PN were at increased risk of persistent PN at 3 months post-ART initiation. Patients with HIV-related PN had a similar risk of recurrent PN compared to those with TB-related PN (HR 1.28 95 % CI 0.72-2.27). We demonstrate that patients with PN at initiation of ART present with advanced HIV disease. Completion of TB treatment may reduce the risk of persistent PN in patients with TB-related PN. Use of HIV drugs, even neurotoxic ones, may overall limit neuropathy.'
p60366
sS'GR'
p60367
(lp60368
S'P30AI027767/AI/NIAID NIH HHS/United States'
p60369
asS'IP'
p60370
S'3'
sS'IS'
p60371
S'1538-2443 (Electronic) 1355-0284 (Linking)'
p60372
sS'DCOM'
p60373
S'20121212'
p60374
sS'AU'
p60375
(lp60376
S'Evans D'
p60377
aS'Takuva S'
p60378
aS'Rassool M'
p60379
aS'Firnhaber C'
p60380
aS'Maskew M'
p60381
asS'VI'
p60382
S'18'
p60383
sS'MHDA'
p60384
S'2012/12/13 06:00'
p60385
sS'PHST'
p60386
(lp60387
S'2011/11/09 [received]'
p60388
aS'2012/03/12 [accepted]'
p60389
aS'2012/03/07 [revised]'
p60390
aS'2012/04/20 [aheadofprint]'
p60391
asS'MH'
p60392
(lp60393
S'Adult'
p60394
aS'Anti-HIV Agents/administration & dosage/*therapeutic use'
p60395
aS'Antitubercular Agents/adverse effects/*therapeutic use'
p60396
aS'Coinfection'
p60397
aS'Female'
p60398
aS'HIV Infections/complications/drug therapy/*epidemiology'
p60399
aS'HIV-1'
p60400
aS'Humans'
p60401
aS'Isoniazid/adverse effects/*therapeutic use'
p60402
aS'Lost to Follow-Up'
p60403
aS'Male'
p60404
aS'Peripheral Nervous System Diseases/drug therapy/*epidemiology/etiology'
p60405
aS'Prevalence'
p60406
aS'Proportional Hazards Models'
p60407
aS'Retrospective Studies'
p60408
aS'South Africa/epidemiology'
p60409
aS'Survival Analysis'
p60410
aS'Treatment Outcome'
p60411
aS'Tuberculosis, Pulmonary/complications/drug therapy/*epidemiology'
p60412
aS'Urban Population'
p60413
asS'EDAT'
p60414
S'2012/04/25 06:00'
p60415
sS'SO'
p60416
S'J Neurovirol. 2012 Jun;18(3):162-71. doi: 10.1007/s13365-012-0093-2. Epub 2012 Apr 20.'
p60417
sS'SB'
p60418
S'IM'
p60419
sS'PMID'
p60420
S'22528477'
p60421
sS'PST'
p60422
S'ppublish'
p60423
stRp60424
ag2
(g3
g4
(dp60425
S'LID'
p60426
S'10.1097/QAD.0b013e328354bf43 [doi]'
p60427
sS'STAT'
p60428
S'MEDLINE'
p60429
sS'JT'
p60430
S'AIDS (London, England)'
p60431
sS'DA'
p60432
S'20120706'
p60433
sS'AID'
p60434
(lp60435
S'10.1097/QAD.0b013e328354bf43 [doi]'
p60436
asS'CRDT'
p60437
(lp60438
S'2012/04/25 06:00'
p60439
asS'DP'
p60440
S'2012 Jul 17'
p60441
sS'GR'
p60442
(lp60443
S'Canadian Institutes of Health Research/Canada'
p60444
asS'OWN'
p60445
S'NLM'
p60446
sS'PT'
p60447
(lp60448
S'Journal Article'
p60449
aS'Multicenter Study'
p60450
aS"Research Support, Non-U.S. Gov't"
p60451
asS'LA'
p60452
(lp60453
S'eng'
p60454
asS'FAU'
p60455
(lp60456
S'Mills, Edward J'
p60457
aS'Bakanda, Celestin'
p60458
aS'Birungi, Josephine'
p60459
aS'Yaya, Sanni'
p60460
aS'Ford, Nathan'
p60461
asS'PG'
p60462
S'1425-9'
p60463
sS'TI'
p60464
S'The prognostic value of baseline CD4(+) cell count beyond 6 months of antiretroviral therapy in HIV-positive patients in a resource-limited setting.'
p60465
sS'RN'
p60466
(lp60467
S'0 (Anti-HIV Agents)'
p60468
asS'PL'
p60469
S'England'
p60470
sS'TA'
p60471
S'AIDS'
p60472
sS'FIR'
p60473
(lp60474
S'Bray, Sarah'
p60475
aS'Gedeon, Jillian'
p60476
aS'Hadi, Ahsan'
p60477
aS'Kotb, Ahmed'
p60478
aS'Rahman, Tarun'
p60479
aS'Sarwar, Elaha'
p60480
aS'Savelyeva, Anna'
p60481
aS'Sevigny, Marika'
p60482
aS'Cooper, Curtis L'
p60483
aS'Lester, Richard'
p60484
asS'JID'
p60485
S'8710219'
p60486
sS'AB'
p60487
S'OBJECTIVE: The risk of death is highest in the first few months after initiation of antiretroviral therapy (ART). We examined whether initial CD4 cell count maintains a strong prognostic value among patients with at least 6 months follow-up after the initiation of ART. DESIGN: Observational study of HIV patients in Uganda aged 14 years or older enrolled in 10 clinics across Uganda. METHODS: Baseline CD4 cell count of patients with more than 6 months of follow-up were stratified into categories (<50, 50-99, 100-149, 150-249, >250 cells/mul). A Kaplan-Meier survival analysis and Cox proportional hazards regression was used to model the associations between baseline CD4 cell count and mortality. RESULTS: Of 22 315 patients, 20 730 (92.8%) had more than 6 months of follow-up. Six hundred and eleven (2.9%) patients died during follow-up and 737 (3.6%) were lost to follow-up. Relative to a baseline CD4 cell counts of less than 50 cells/mul, the adjusted hazard ratios for death were 0.83 [95% confidence interval (CI) 0.67-1.02], 0.71 (95% CI 0.57-0.88), 0.52 (95% CI 0.42-0.64), and 0.55 (95% CI 0.42-0.70) favouring those with baseline CD4 cell counts of 50-99, 100-149, 150-249, and at least 250 cells/mul, respectively. Differing ages and male sex increased the likelihood of mortality. CONCLUSION: Among patients with more than 6 months of follow-up after initiation of ART, baseline CD4 cell count at initiation still has important prognostic value. This suggests that active engagement and earlier treatment initiation is important for long-term survival.'
p60488
sS'AD'
p60489
S'Faculty of Health Sciences, University of Ottawa, Ottawa, Canada. edward.mills@uottawa.ca'
p60490
sS'CN'
p60491
(lp60492
S'TASO-CAN Writing Group'
p60493
asS'IP'
p60494
S'11'
p60495
sS'IS'
p60496
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p60497
sS'IR'
p60498
(lp60499
S'Bray S'
p60500
aS'Gedeon J'
p60501
aS'Hadi A'
p60502
aS'Kotb A'
p60503
aS'Rahman T'
p60504
aS'Sarwar E'
p60505
aS'Savelyeva A'
p60506
aS'Sevigny M'
p60507
aS'Cooper CL'
p60508
aS'Lester R'
p60509
asS'DCOM'
p60510
S'20121203'
p60511
sS'AU'
p60512
(lp60513
S'Mills EJ'
p60514
aS'Bakanda C'
p60515
aS'Birungi J'
p60516
aS'Yaya S'
p60517
aS'Ford N'
p60518
asS'VI'
p60519
S'26'
p60520
sS'MHDA'
p60521
S'2012/12/10 06:00'
p60522
sS'MH'
p60523
(lp60524
S'Acquired Immunodeficiency Syndrome/*drug therapy/epidemiology/*immunology'
p60525
aS'Adolescent'
p60526
aS'Adult'
p60527
aS'Age Distribution'
p60528
aS'Aged'
p60529
aS'Anti-HIV Agents/*administration & dosage'
p60530
aS'*CD4 Lymphocyte Count'
p60531
aS'Female'
p60532
aS'Follow-Up Studies'
p60533
aS'HIV-1/*immunology'
p60534
aS'Health Resources/supply & distribution'
p60535
aS'Humans'
p60536
aS'Kaplan-Meier Estimate'
p60537
aS'Male'
p60538
aS'Middle Aged'
p60539
aS'Predictive Value of Tests'
p60540
aS'Prognosis'
p60541
aS'Sex Distribution'
p60542
aS'Uganda/epidemiology'
p60543
aS'Viral Load'
p60544
asS'EDAT'
p60545
S'2012/04/25 06:00'
p60546
sS'SO'
p60547
S'AIDS. 2012 Jul 17;26(11):1425-9. doi: 10.1097/QAD.0b013e328354bf43.'
p60548
sS'SB'
p60549
S'IM X'
p60550
sS'PMID'
p60551
S'22526520'
p60552
sS'PST'
p60553
S'ppublish'
p60554
stRp60555
ag2
(g3
g4
(dp60556
S'LID'
p60557
S'10.1128/JCM.00431-12 [doi]'
p60558
sS'STAT'
p60559
S'MEDLINE'
p60560
sS'DEP'
p60561
S'20120418'
p60562
sS'DA'
p60563
S'20120619'
p60564
sS'AID'
p60565
(lp60566
S'JCM.00431-12 [pii]'
p60567
aS'10.1128/JCM.00431-12 [doi]'
p60568
asS'CRDT'
p60569
(lp60570
S'2012/04/21 06:00'
p60571
asS'DP'
p60572
S'2012 Jul'
p60573
sS'AD'
p60574
S'Paediatric HIV Diagnostic Syndicate, Wits Health Consortium, Johannesburg, South Africa.'
p60575
sS'OWN'
p60576
S'NLM'
p60577
sS'PT'
p60578
(lp60579
S'Evaluation Studies'
p60580
aS'Journal Article'
p60581
aS'Research Support, N.I.H., Extramural'
p60582
aS"Research Support, Non-U.S. Gov't"
p60583
asS'LA'
p60584
(lp60585
S'eng'
p60586
asS'FAU'
p60587
(lp60588
S'Lilian, Rivka R'
p60589
aS'Kalk, Emma'
p60590
aS'Bhowan, Kapila'
p60591
aS'Berrie, Leigh'
p60592
aS'Carmona, Sergio'
p60593
aS'Technau, Karl'
p60594
aS'Sherman, Gayle G'
p60595
asS'JT'
p60596
S'Journal of clinical microbiology'
p60597
sS'LR'
p60598
S'20150225'
p60599
sS'PG'
p60600
S'2373-7'
p60601
sS'TI'
p60602
S'Early diagnosis of in utero and intrapartum HIV infection in infants prior to 6 weeks of age.'
p60603
sS'PL'
p60604
S'United States'
p60605
sS'TA'
p60606
S'J Clin Microbiol'
p60607
sS'JID'
p60608
S'7505564'
p60609
sS'AB'
p60610
S'Early initiation of antiretroviral therapy reduces HIV-related infant mortality. The early peak of pediatric HIV-related deaths in South Africa occurs at 3 months of age, coinciding with the earliest age at which treatment is initiated following PCR testing at 6 weeks of age. Earlier diagnosis is necessary to reduce infant mortality. The performances of the Amplicor DNA PCR, COBAS AmpliPrep/COBAS TaqMan (CAP/CTM), and Aptima assays for detecting early HIV infection (acquired in utero and intrapartum) up to 6 weeks of age were compared. Dried blood spots (DBS) were collected at birth and at 2, 4, and 6 weeks from HIV-exposed infants enrolled in an observational cohort study in Johannesburg, South Africa. HIV status was determined at 6 weeks by DNA PCR on whole blood. Serial DBS samples from all HIV-infected infants and two HIV-uninfected, age-matched controls were tested with the 3 assays. Of 710 infants of known HIV status, 38 (5.4%) had in utero (n = 29) or intrapartum (n = 9) infections. By 14 weeks, when treatment should have been initiated, 13 (45%) in utero-infected and 2 (22%) intrapartum-infected infants had died or were lost to follow-up. The CAP/CTM and Aptima assays identified 76.3% of all infants with early HIV infections at birth and by 4 weeks were 96% sensitive. DNA PCR demonstrated lower sensitivities at birth and 4 weeks of 68.4% and 87.5%, respectively. All assays had the lowest sensitivity at 2 weeks of age. CAP/CTM was the only assay with 100% specificity at all ages. Testing at birth versus 6 weeks of age identifies a higher total number of HIV-infected infants, irrespective of the assay.'
p60611
sS'GR'
p60612
(lp60613
S'5U2RTW007370-05/PHS HHS/United States'
p60614
aS'D43TW000010-21S1/TW/FIC NIH HHS/United States'
p60615
asS'IP'
p60616
S'7'
sS'IS'
p60617
S'1098-660X (Electronic) 0095-1137 (Linking)'
p60618
sS'PMC'
p60619
S'PMC3405609'
p60620
sS'DCOM'
p60621
S'20121017'
p60622
sS'AU'
p60623
(lp60624
S'Lilian RR'
p60625
aS'Kalk E'
p60626
aS'Bhowan K'
p60627
aS'Berrie L'
p60628
aS'Carmona S'
p60629
aS'Technau K'
p60630
aS'Sherman GG'
p60631
asS'VI'
p60632
S'50'
p60633
sS'MHDA'
p60634
S'2012/10/18 06:00'
p60635
sS'PHST'
p60636
(lp60637
S'2012/04/18 [aheadofprint]'
p60638
asS'OID'
p60639
(lp60640
S'NLM: PMC3405609'
p60641
asS'MH'
p60642
(lp60643
S'Adult'
p60644
aS'Blood/virology'
p60645
aS'Cohort Studies'
p60646
aS'Early Diagnosis'
p60647
aS'Female'
p60648
aS'Fetal Diseases/*diagnosis'
p60649
aS'HIV/isolation & purification'
p60650
aS'HIV Infections/*diagnosis'
p60651
aS'Humans'
p60652
aS'Infant'
p60653
aS'Infant, Newborn'
p60654
aS'Molecular Diagnostic Techniques/*methods'
p60655
aS'Prospective Studies'
p60656
aS'Sensitivity and Specificity'
p60657
aS'South Africa'
p60658
aS'Virology/*methods'
p60659
aS'Young Adult'
p60660
asS'EDAT'
p60661
S'2012/04/21 06:00'
p60662
sS'SO'
p60663
S'J Clin Microbiol. 2012 Jul;50(7):2373-7. doi: 10.1128/JCM.00431-12. Epub 2012 Apr 18.'
p60664
sS'SB'
p60665
S'IM'
p60666
sS'PMID'
p60667
S'22518871'
p60668
sS'PST'
p60669
S'ppublish'
p60670
stRp60671
ag2
(g3
g4
(dp60672
S'LID'
p60673
S'10.1089/AID.2012.0058 [doi]'
p60674
sS'STAT'
p60675
S'MEDLINE'
p60676
sS'DEP'
p60677
S'20120508'
p60678
sS'DA'
p60679
S'20121122'
p60680
sS'AID'
p60681
(lp60682
S'10.1089/aid.2012.0058 [doi]'
p60683
asS'CRDT'
p60684
(lp60685
S'2012/04/14 06:00'
p60686
asS'DP'
p60687
S'2012 Dec'
p60688
sS'OWN'
p60689
S'NLM'
p60690
sS'PT'
p60691
(lp60692
S'Journal Article'
p60693
aS"Research Support, Non-U.S. Gov't"
p60694
asS'LA'
p60695
(lp60696
S'eng'
p60697
asS'FAU'
p60698
(lp60699
S'Oliveira, Michelli F'
p60700
aS'Ramalho, Dulce B'
p60701
aS'Abreu, Celina M'
p60702
aS'Vubil, Adolfo'
p60703
aS'Mabunda, Nedio'
p60704
aS'Ismael, Nalia'
p60705
aS'Francisco, Cidia'
p60706
aS'Jani, Ilesh V'
p60707
aS'Tanuri, Amilcar'
p60708
asS'JT'
p60709
S'AIDS research and human retroviruses'
p60710
sS'LR'
p60711
S'20150225'
p60712
sS'PG'
p60713
S'1788-92'
p60714
sS'TI'
p60715
S'Genetic diversity and naturally polymorphisms in HIV type 1 integrase isolates from Maputo, Mozambique: implications for integrase inhibitors.'
p60716
sS'RN'
p60717
(lp60718
S'0 (DNA, Viral)'
p60719
aS'0 (HIV Integrase Inhibitors)'
p60720
aS'EC 2.7.7.- (HIV Integrase)'
p60721
asS'PL'
p60722
S'United States'
p60723
sS'TA'
p60724
S'AIDS Res Hum Retroviruses'
p60725
sS'JID'
p60726
S'8709376'
p60727
sS'AB'
p60728
S'HIV proviral DNA integration into the host chromosome is carried out by integrase becoming an important target antiretroviral therapy. Raltegravir was the first integrase inhibitor approved for use in HIV therapy and elvitegravir is in the late phase of clinical development; both show good results in monotherapy studies and may be used worldwide for rescue therapy. In this work we analyzed 57 integrase sequences obtained from samples from drug-naive and first line regime-failing patients from Maputo, Mozambique, to evaluate the presence of natural polymorphisms and resistance mutations associated with raltegravir and elvitegravir. No major mutations conferring resistance to integrase inhibitors were found and polymorphic accessory mutations were solely observed in low frequency among subtype C sequences-L74M (3.4%), T97A (1.8%), and E157Q (1.8%)-suggesting that this new antiretroviral drug class will be effective in Mozambique providing a good perspective to the introduction of this class of drugs in that country.'
p60729
sS'AD'
p60730
S'Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.'
p60731
sS'IP'
p60732
S'12'
p60733
sS'IS'
p60734
S'1931-8405 (Electronic) 0889-2229 (Linking)'
p60735
sS'PMC'
p60736
S'PMC3505052'
p60737
sS'DCOM'
p60738
S'20130423'
p60739
sS'AU'
p60740
(lp60741
S'Oliveira MF'
p60742
aS'Ramalho DB'
p60743
aS'Abreu CM'
p60744
aS'Vubil A'
p60745
aS'Mabunda N'
p60746
aS'Ismael N'
p60747
aS'Francisco C'
p60748
aS'Jani IV'
p60749
aS'Tanuri A'
p60750
asS'VI'
p60751
S'28'
p60752
sS'MHDA'
p60753
S'2013/04/24 06:00'
p60754
sS'PHST'
p60755
(lp60756
S'2012/05/08 [aheadofprint]'
p60757
asS'OID'
p60758
(lp60759
S'NLM: PMC3505052'
p60760
asS'MH'
p60761
(lp60762
S'DNA, Viral/chemistry/genetics'
p60763
aS'Drug Resistance, Viral'
p60764
aS'*Genetic Variation'
p60765
aS'HIV Infections/*virology'
p60766
aS'HIV Integrase/*genetics'
p60767
aS'HIV Integrase Inhibitors/*therapeutic use'
p60768
aS'Humans'
p60769
aS'Molecular Sequence Data'
p60770
aS'Mozambique'
p60771
aS'Mutation, Missense'
p60772
aS'Proviruses/genetics'
p60773
aS'Sequence Analysis, DNA'
p60774
asS'EDAT'
p60775
S'2012/04/14 06:00'
p60776
sS'SI'
p60777
(lp60778
S'GENBANK/JQ670788'
p60779
aS'GENBANK/JQ670789'
p60780
aS'GENBANK/JQ670790'
p60781
aS'GENBANK/JQ670791'
p60782
aS'GENBANK/JQ670792'
p60783
aS'GENBANK/JQ670793'
p60784
aS'GENBANK/JQ670794'
p60785
aS'GENBANK/JQ670795'
p60786
aS'GENBANK/JQ670796'
p60787
aS'GENBANK/JQ670797'
p60788
aS'GENBANK/JQ670798'
p60789
aS'GENBANK/JQ670799'
p60790
aS'GENBANK/JQ670800'
p60791
aS'GENBANK/JQ670801'
p60792
aS'GENBANK/JQ670802'
p60793
aS'GENBANK/JQ670803'
p60794
aS'GENBANK/JQ670804'
p60795
aS'GENBANK/JQ670805'
p60796
aS'GENBANK/JQ670806'
p60797
aS'GENBANK/JQ670807'
p60798
aS'GENBANK/JQ670808'
p60799
aS'GENBANK/JQ670809'
p60800
aS'GENBANK/JQ670810'
p60801
aS'GENBANK/JQ670811'
p60802
aS'GENBANK/JQ670812'
p60803
aS'GENBANK/JQ670813'
p60804
aS'GENBANK/JQ670814'
p60805
aS'GENBANK/JQ670815'
p60806
aS'GENBANK/JQ670816'
p60807
aS'GENBANK/JQ670817'
p60808
asS'SO'
p60809
S'AIDS Res Hum Retroviruses. 2012 Dec;28(12):1788-92. doi: 10.1089/AID.2012.0058. Epub 2012 May 8.'
p60810
sS'SB'
p60811
S'IM X'
p60812
sS'PMID'
p60813
S'22497664'
p60814
sS'PST'
p60815
S'ppublish'
p60816
stRp60817
ag2
(g3
g4
(dp60818
S'STAT'
p60819
S'MEDLINE'
p60820
sS'AB'
p60821
S"Early diagnosis of tuberculosis (TB) and prompt initiation of treatment are essential for an effective tuberculosis control programme. In many resource limited settings microscopic diagnosis is still the pivotal tool in the diagnosis of pulmonary TB. This study aimed at evaluating laboratory microscopic diagnosis of tuberculosis in a tertiary hospital in Mwanza, Tanzania. This retrospective hospital based study reviewed consecutively from TB registry and patients' files a total of 5,922 TB suspects who submitted their sputum for examination between January 2007 and May 2010 at Bugando Medical Centre (BMC). Among TB suspects (mean age=36.1+/-13.6 years) female accounted for 54.1% of the patients. The prevalence of HIV among TB patients was 59.4%. The sputum smear positivity rate among the TB suspects was 6.1%; the rate was higher in HIV positive than in HIV negative patients (9.9 % versus 3.2%, P-value < 0.001). The overall positivity rate for the first smear was 94.2% with an incremental percentage yield of 5.2% and 0.6% for the second and third smears, respectively. The study found that 28.6% of patients who were positive in the first smear did not return for the second smear. The risk factors among smear positive TB patients were co-illness (32.5%), previous history of TB (7.5%) and history of positive TB contact (4.7%). These findings also show that as CD4+ T Cells count increases, the quantity AFB in sputum smear also increase although not statistically significant. The sputum smear positivity rate at Bugando Medical Centre is low and more than a quarter of initial TB suspects who were positive in the first smear were lost to follow up posing a threat of continuous transmission of tuberculosis to the community. The finding of more sputum smear positivity rate among HIV positive than HIV negative patients at BMC requires a prospective study to ascertain whether it is a reality or a coincidence."
p60822
sS'JID'
p60823
S'101479163'
p60824
sS'AD'
p60825
S'Catholic University of Health and Allied Sciences-Bugando, Mwanza, Tanzania. senijj80@gmail.com'
p60826
sS'JT'
p60827
S'Tanzania journal of health research'
p60828
sS'IP'
p60829
S'2'
sS'IS'
p60830
S'1821-6404 (Print)'
p60831
sS'DCOM'
p60832
S'20151217'
p60833
sS'DA'
p60834
S'20151120'
p60835
sS'AU'
p60836
(lp60837
S'Seni J'
p60838
aS'Kidenya BR'
p60839
aS'Obassy E'
p60840
aS'Mirambo M'
p60841
aS'Burushi V'
p60842
aS'Mazigo HD'
p60843
aS'Kapesa A'
p60844
aS'Majigo M'
p60845
aS'Mshana SE'
p60846
asS'CRDT'
p60847
(lp60848
S'2015/11/24 06:00'
p60849
asS'VI'
p60850
S'14'
p60851
sS'DP'
p60852
S'2012 Apr'
p60853
sS'MHDA'
p60854
S'2015/12/19 06:00'
p60855
sS'OWN'
p60856
S'NLM'
p60857
sS'PT'
p60858
(lp60859
S'Journal Article'
p60860
aS"Research Support, Non-U.S. Gov't"
p60861
asS'LA'
p60862
(lp60863
S'eng'
p60864
asS'MH'
p60865
(lp60866
S'Adult'
p60867
aS'Female'
p60868
aS'HIV Infections/epidemiology'
p60869
aS'Humans'
p60870
aS'Male'
p60871
aS'Prevalence'
p60872
aS'Registries'
p60873
aS'Retrospective Studies'
p60874
aS'Sputum/microbiology'
p60875
aS'Tanzania/epidemiology'
p60876
aS'Tertiary Care Centers'
p60877
aS'Tuberculosis, Pulmonary/*epidemiology'
p60878
asS'FAU'
p60879
(lp60880
S'Seni, Jeremiah'
p60881
aS'Kidenya, Benson R'
p60882
aS'Obassy, Emmanuel'
p60883
aS'Mirambo, Mariam'
p60884
aS'Burushi, Venance'
p60885
aS'Mazigo, Humphrey D'
p60886
aS'Kapesa, Antony'
p60887
aS'Majigo, Mtebe'
p60888
aS'Mshana, Stephen E'
p60889
asS'EDAT'
p60890
S'2012/04/01 00:00'
p60891
sS'PST'
p60892
S'ppublish'
p60893
sS'SO'
p60894
S'Tanzan J Health Res. 2012 Apr;14(2):115-20.'
p60895
sS'PG'
p60896
S'115-20'
p60897
sS'TI'
p60898
S'Low sputum smear positive tuberculosis among pulmonary tuberculosis suspects in a tertiary hospital in Mwanza, Tanzania.'
p60899
sS'SB'
p60900
S'IM'
p60901
sS'PMID'
p60902
S'26591732'
p60903
sS'PL'
p60904
S'Tanzania'
p60905
sS'TA'
p60906
S'Tanzan J Health Res'
p60907
stRp60908
ag2
(g3
g4
(dp60909
S'LID'
p60910
S'10.1093/infdis/jis261 [doi]'
p60911
sS'STAT'
p60912
S'MEDLINE'
p60913
sS'DEP'
p60914
S'20120323'
p60915
sS'DA'
p60916
S'20120510'
p60917
sS'AID'
p60918
(lp60919
S'jis261 [pii]'
p60920
aS'10.1093/infdis/jis261 [doi]'
p60921
asS'CRDT'
p60922
(lp60923
S'2012/03/27 06:00'
p60924
asS'DP'
p60925
S'2012 Jun'
p60926
sS'AD'
p60927
S'Department of GlobalHealth, University of Amsterdam, Amsterdam, The Netherlands. k.sigaloff@pharmaccess.org'
p60928
sS'OWN'
p60929
S'NLM'
p60930
sS'PT'
p60931
(lp60932
S'Journal Article'
p60933
aS"Research Support, Non-U.S. Gov't"
p60934
asS'LA'
p60935
(lp60936
S'eng'
p60937
asS'FAU'
p60938
(lp60939
S'Sigaloff, Kim C E'
p60940
aS'Hamers, Raph L'
p60941
aS'Wallis, Carole L'
p60942
aS'Kityo, Cissy'
p60943
aS'Siwale, Margaret'
p60944
aS'Ive, Prudence'
p60945
aS'Botes, Mariette E'
p60946
aS'Mandaliya, Kishor'
p60947
aS'Wellington, Maureen'
p60948
aS'Osibogun, Akin'
p60949
aS'Stevens, Wendy S'
p60950
aS'van Vugt, Michele'
p60951
aS'Rinke de Wit, Tobias F'
p60952
asS'JT'
p60953
S'The Journal of infectious diseases'
p60954
sS'PG'
p60955
S'1739-44'
p60956
sS'TI'
p60957
S'Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan Africa.'
p60958
sS'RN'
p60959
(lp60960
S'0 (Anti-HIV Agents)'
p60961
aS'0 (RNA, Viral)'
p60962
asS'PL'
p60963
S'United States'
p60964
sS'TA'
p60965
S'J Infect Dis'
p60966
sS'JID'
p60967
S'0413675'
p60968
sS'AB'
p60969
S'Little is known about the effect of human immunodeficiency virus type 1 (HIV-1) resistance mutations present at time of regimen switch on the response to second-line antiretroviral therapy in Africa. In adults who switched to boosted protease inhibitor-based regimens after first-line failure, HIV-RNA and genotypic resistance testing was performed at switch and after 12 months. Factors associated with treatment failure were assessed using logistic regression. Of 243 participants, 53% were predicted to receive partially active second-line regimens due to drug resistance. The risk of treatment failure was, however, not increased in these participants. In this African cohort, boosted protease inhibitors successfully resuppressed drug-resistant HIV after first-line failure.'
p60970
sS'CN'
p60971
(lp60972
S'PharmAccess African Studies to Evaluate Resistance (PASER)'
p60973
asS'IP'
p60974
S'11'
p60975
sS'IS'
p60976
S'1537-6613 (Electronic) 0022-1899 (Linking)'
p60977
sS'DCOM'
p60978
S'20120709'
p60979
sS'AU'
p60980
(lp60981
S'Sigaloff KC'
p60982
aS'Hamers RL'
p60983
aS'Wallis CL'
p60984
aS'Kityo C'
p60985
aS'Siwale M'
p60986
aS'Ive P'
p60987
aS'Botes ME'
p60988
aS'Mandaliya K'
p60989
aS'Wellington M'
p60990
aS'Osibogun A'
p60991
aS'Stevens WS'
p60992
aS'van Vugt M'
p60993
aS'Rinke de Wit TF'
p60994
asS'VI'
p60995
S'205'
p60996
sS'MHDA'
p60997
S'2012/07/10 06:00'
p60998
sS'PHST'
p60999
(lp61000
S'2012/03/23 [aheadofprint]'
p61001
aS'2012/04/12 [aheadofprint]'
p61002
asS'MH'
p61003
(lp61004
S'Adult'
p61005
aS'Africa South of the Sahara'
p61006
aS'Anti-HIV Agents/*administration & dosage'
p61007
aS'Antiretroviral Therapy, Highly Active/*methods'
p61008
aS'Cohort Studies'
p61009
aS'Drug Resistance, Viral'
p61010
aS'Female'
p61011
aS'HIV Infections/*drug therapy/*virology'
p61012
aS'HIV-1/drug effects/*isolation & purification'
p61013
aS'Humans'
p61014
aS'Male'
p61015
aS'Middle Aged'
p61016
aS'Mutation, Missense'
p61017
aS'Prospective Studies'
p61018
aS'RNA, Viral/blood/genetics'
p61019
aS'Salvage Therapy/*methods'
p61020
aS'Treatment Outcome'
p61021
aS'*Viral Load'
p61022
asS'EDAT'
p61023
S'2012/03/27 06:00'
p61024
sS'SO'
p61025
S'J Infect Dis. 2012 Jun;205(11):1739-44. doi: 10.1093/infdis/jis261. Epub 2012 Mar 23.'
p61026
sS'SB'
p61027
S'AIM IM'
p61028
sS'PMID'
p61029
S'22448003'
p61030
sS'PST'
p61031
S'ppublish'
p61032
stRp61033
ag2
(g3
g4
(dp61034
S'LID'
p61035
S'10.1089/AID.2011.0352 [doi]'
p61036
sS'STAT'
p61037
S'MEDLINE'
p61038
sS'DEP'
p61039
S'20120426'
p61040
sS'DA'
p61041
S'20121122'
p61042
sS'AID'
p61043
(lp61044
S'10.1089/aid.2011.0352 [doi]'
p61045
asS'CRDT'
p61046
(lp61047
S'2012/03/27 06:00'
p61048
asS'DP'
p61049
S'2012 Dec'
p61050
sS'AD'
p61051
S'Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. sjr@jhmi.edu'
p61052
sS'OWN'
p61053
S'NLM'
p61054
sS'PT'
p61055
(lp61056
S'Journal Article'
p61057
aS'Research Support, N.I.H., Extramural'
p61058
aS'Research Support, N.I.H., Intramural'
p61059
asS'LA'
p61060
(lp61061
S'eng'
p61062
asS'FAU'
p61063
(lp61064
S'Reynolds, Steven J'
p61065
aS'Laeyendecker, Oliver'
p61066
aS'Nakigozi, Gertrude'
p61067
aS'Gallant, Joel E'
p61068
aS'Huang, Wei'
p61069
aS'Hudelson, Sarah E'
p61070
aS'Quinn, Thomas C'
p61071
aS'Newell, Kevin'
p61072
aS'Serwadda, David'
p61073
aS'Gray, Ronald H'
p61074
aS'Wawer, Maria J'
p61075
aS'Eshleman, Susan H'
p61076
asS'JT'
p61077
S'AIDS research and human retroviruses'
p61078
sS'LR'
p61079
S'20150813'
p61080
sS'PG'
p61081
S'1739-44'
p61082
sS'TI'
p61083
S'Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda.'
p61084
sS'RN'
p61085
(lp61086
S'0 (Anti-Retroviral Agents)'
p61087
aS'EC 2.7.7.49 (HIV Reverse Transcriptase)'
p61088
aS'EC 3.4.23.- (HIV Protease)'
p61089
asS'PL'
p61090
S'United States'
p61091
sS'TA'
p61092
S'AIDS Res Hum Retroviruses'
p61093
sS'JID'
p61094
S'8709376'
p61095
sS'AB'
p61096
S'We analyzed antiretroviral drug susceptibility in HIV-infected adults failing first- and second-line antiretroviral treatment (ART) in Rakai, Uganda. Samples obtained from participants at baseline (pretreatment) and at the time of failure on first-line ART and second-line ART were analyzed using genotypic and phenotypic assays for antiretroviral drug resistance. Test results were obtained from 73 samples from 38 individuals (31 baseline samples, 36 first-line failure samples, and six second-line failure samples). Four (13%) of the 31 baseline samples had mutations associated with resistance to nucleoside or nonnucleoside reverse transcriptase inhibitors (NRTIs and NNRTIs, respectively). Among the 36 first-line failure samples, 31 (86%) had NNRTI resistance mutations and 29 (81%) had lamivudine resistance mutations; only eight (22%) had other NRTI resistance mutations. None of the six individuals failing a second-line protease inhibitor (PI)-based regimen had PI resistance mutations. Six (16%) of the participants had discordant genotypic and phenotypic test results. Genotypic resistance to drugs included in first-line ART regimens was detected prior to treatment and among participants failing first-line ART. PI resistance was not detected in individuals failing second-line ART. Surveillance for transmitted and acquired drug resistance remains a priority for scale-up of ART.'
p61097
sS'GR'
p61098
(lp61099
S'HHSN261200800001E/PHS HHS/United States'
p61100
aS'R01 HD050180/HD/NICHD NIH HHS/United States'
p61101
aS'R24 HD042854/HD/NICHD NIH HHS/United States'
p61102
aS'U01-AI068613/AI/NIAID NIH HHS/United States'
p61103
aS'UM1-AI068613/AI/NIAID NIH HHS/United States'
p61104
aS'Intramural NIH HHS/United States'
p61105
asS'IP'
p61106
S'12'
p61107
sS'IS'
p61108
S'1931-8405 (Electronic) 0889-2229 (Linking)'
p61109
sS'PMC'
p61110
S'PMC3505045'
p61111
sS'DCOM'
p61112
S'20130423'
p61113
sS'AU'
p61114
(lp61115
S'Reynolds SJ'
p61116
aS'Laeyendecker O'
p61117
aS'Nakigozi G'
p61118
aS'Gallant JE'
p61119
aS'Huang W'
p61120
aS'Hudelson SE'
p61121
aS'Quinn TC'
p61122
aS'Newell K'
p61123
aS'Serwadda D'
p61124
aS'Gray RH'
p61125
aS'Wawer MJ'
p61126
aS'Eshleman SH'
p61127
asS'VI'
p61128
S'28'
p61129
sS'MHDA'
p61130
S'2013/04/24 06:00'
p61131
sS'PHST'
p61132
(lp61133
S'2012/04/26 [aheadofprint]'
p61134
asS'OID'
p61135
(lp61136
S'NLM: PMC3505045'
p61137
asS'MH'
p61138
(lp61139
S'Adolescent'
p61140
aS'Adult'
p61141
aS'Anti-Retroviral Agents/*administration & dosage'
p61142
aS'Antiretroviral Therapy, Highly Active/*methods'
p61143
aS'*Drug Resistance, Viral'
p61144
aS'Female'
p61145
aS'Genotype'
p61146
aS'HIV/*drug effects/*genetics/isolation & purification'
p61147
aS'HIV Infections/*drug therapy/*virology'
p61148
aS'HIV Protease/genetics'
p61149
aS'HIV Reverse Transcriptase/genetics'
p61150
aS'Humans'
p61151
aS'Male'
p61152
aS'Microbial Sensitivity Tests'
p61153
aS'Molecular Sequence Data'
p61154
aS'Mutation, Missense'
p61155
aS'Sequence Analysis, DNA'
p61156
aS'Treatment Failure'
p61157
aS'Uganda'
p61158
aS'Young Adult'
p61159
asS'EDAT'
p61160
S'2012/03/27 06:00'
p61161
sS'SI'
p61162
(lp61163
S'GENBANK/JN652138'
p61164
aS'GENBANK/JN652139'
p61165
aS'GENBANK/JN652140'
p61166
aS'GENBANK/JN652141'
p61167
aS'GENBANK/JN652142'
p61168
aS'GENBANK/JN652143'
p61169
aS'GENBANK/JN652144'
p61170
aS'GENBANK/JN652145'
p61171
aS'GENBANK/JN652146'
p61172
aS'GENBANK/JN652147'
p61173
aS'GENBANK/JN652148'
p61174
aS'GENBANK/JN652149'
p61175
aS'GENBANK/JN652150'
p61176
aS'GENBANK/JN652151'
p61177
aS'GENBANK/JN652152'
p61178
aS'GENBANK/JN652153'
p61179
aS'GENBANK/JN652154'
p61180
aS'GENBANK/JN652155'
p61181
aS'GENBANK/JN652156'
p61182
aS'GENBANK/JN652157'
p61183
aS'GENBANK/JN652158'
p61184
aS'GENBANK/JN652159'
p61185
aS'GENBANK/JN652160'
p61186
aS'GENBANK/JN652161'
p61187
aS'GENBANK/JN652162'
p61188
aS'GENBANK/JN652163'
p61189
aS'GENBANK/JN652164'
p61190
aS'GENBANK/JN652165'
p61191
aS'GENBANK/JN652166'
p61192
aS'GENBANK/JN652167'
p61193
aS'GENBANK/JN652168'
p61194
aS'GENBANK/JN652169'
p61195
aS'GENBANK/JN652170'
p61196
aS'GENBANK/JN652171'
p61197
aS'GENBANK/JN652172'
p61198
aS'GENBANK/JN652173'
p61199
aS'GENBANK/JN652174'
p61200
aS'GENBANK/JN652175'
p61201
aS'GENBANK/JN652176'
p61202
aS'GENBANK/JN652177'
p61203
aS'GENBANK/JN652178'
p61204
aS'GENBANK/JN652179'
p61205
aS'GENBANK/JN652180'
p61206
aS'GENBANK/JN652181'
p61207
aS'GENBANK/JN652182'
p61208
aS'GENBANK/JN652183'
p61209
aS'GENBANK/JN652184'
p61210
aS'GENBANK/JN652185'
p61211
aS'GENBANK/JN652186'
p61212
aS'GENBANK/JN652187'
p61213
aS'GENBANK/JN652188'
p61214
aS'GENBANK/JN652189'
p61215
aS'GENBANK/JN652190'
p61216
aS'GENBANK/JN652191'
p61217
aS'GENBANK/JN652192'
p61218
aS'GENBANK/JN652193'
p61219
aS'GENBANK/JN652194'
p61220
aS'GENBANK/JN652195'
p61221
aS'GENBANK/JN652196'
p61222
aS'GENBANK/JN652197'
p61223
aS'GENBANK/JN652198'
p61224
aS'GENBANK/JN652199'
p61225
aS'GENBANK/JN652200'
p61226
aS'GENBANK/JN652201'
p61227
aS'GENBANK/JN652202'
p61228
aS'GENBANK/JN652203'
p61229
aS'GENBANK/JN652204'
p61230
aS'GENBANK/JN652205'
p61231
aS'GENBANK/JN652206'
p61232
aS'GENBANK/JN652207'
p61233
aS'GENBANK/JN652208'
p61234
aS'GENBANK/JN652209'
p61235
aS'GENBANK/JN652210'
p61236
asS'SO'
p61237
S'AIDS Res Hum Retroviruses. 2012 Dec;28(12):1739-44. doi: 10.1089/AID.2011.0352. Epub 2012 Apr 26.'
p61238
sS'SB'
p61239
S'IM X'
p61240
sS'PMID'
p61241
S'22443282'
p61242
sS'PST'
p61243
S'ppublish'
p61244
stRp61245
ag2
(g3
g4
(dp61246
S'LID'
p61247
S'10.1371/journal.pone.0032993 [doi]'
p61248
sS'STAT'
p61249
S'MEDLINE'
p61250
sS'DEP'
p61251
S'20120312'
p61252
sS'DA'
p61253
S'20120319'
p61254
sS'AID'
p61255
(lp61256
S'10.1371/journal.pone.0032993 [doi]'
p61257
aS'PONE-D-11-19361 [pii]'
p61258
asS'CRDT'
p61259
(lp61260
S'2012/03/20 06:00'
p61261
asS'DP'
p61262
S'2012'
p61263
sS'AD'
p61264
S'Division of Infectious Disease, Massachusetts General Hospital, Boston, Massachusetts, United States of America. aahonkhai@partners.org'
p61265
sS'OWN'
p61266
S'NLM'
p61267
sS'PT'
p61268
(lp61269
S'Journal Article'
p61270
aS'Research Support, N.I.H., Extramural'
p61271
asS'LA'
p61272
(lp61273
S'eng'
p61274
asS'FAU'
p61275
(lp61276
S'Ahonkhai, Aima A'
p61277
aS'Noubary, Farzad'
p61278
aS'Munro, Alison'
p61279
aS'Stark, Ruth'
p61280
aS'Wilke, Marisa'
p61281
aS'Freedberg, Kenneth A'
p61282
aS'Wood, Robin'
p61283
aS'Losina, Elena'
p61284
asS'JT'
p61285
S'PloS one'
p61286
sS'LR'
p61287
S'20150226'
p61288
sS'PG'
p61289
S'e32993'
p61290
sS'TI'
p61291
S'Not all are lost: interrupted laboratory monitoring, early death, and loss to follow-up (LTFU) in a large South African treatment program.'
p61292
sS'PL'
p61293
S'United States'
p61294
sS'TA'
p61295
S'PLoS One'
p61296
sS'JID'
p61297
S'101285081'
p61298
sS'AB'
p61299
S'BACKGROUND: Many HIV treatment programs in resource-limited settings are plagued by high rates of loss to follow-up (LTFU). Most studies have not distinguished between those who briefly interrupt, but return to care, and those more chronically lost to follow-up. METHODS: We conducted a retrospective cohort study of 11,397 adults initiating antiretroviral therapy (ART) in 71 Southern African Catholic Bishops Conference/Catholic Relief Services HIV treatment clinics between January 2004 and December 2008. We distinguished among patients with early death, within the first 7 months on ART; patients with interruptions in laboratory monitoring (ILM), defined as missing visits in the first 7 months on ART, but returning to care by 12 months; and those LTFU, defined as missing all follow-up visits in the first 12 months on ART. We used multilevel logistic regression models to determine patient and clinic-level characteristics associated with these outcomes. RESULTS: In the first year on ART, 60% of patients remained in care, 30% missed laboratory visits, and 10% suffered early death. Of the 3,194 patients who missed laboratory visits, 40% had ILM, resuming care by 12 months. After 12 months on ART, patients with ILM had a 30% increase in detectable viremia compared to those who remained in care. Risk of LTFU decreased with increasing enrollment year, and was lowest for patients who enrolled in 2008 compared to 2004 [OR 0.49, 95%CI 0.39-0.62]. CONCLUSIONS: In a large community-based cohort in South Africa, nearly 30% of patients miss follow-up visits for CD4 monitoring in the first year after starting ART. Of those, 40% have ILM but return to clinic with worse virologic outcomes than those who remain in care. The risk of chronic LTFU decreased with enrollment year. As ART availability increases, interruptions in care may become more common, and should be accounted for in addressing program LTFU.'
p61300
sS'GR'
p61301
(lp61302
S'P30 AI060354/AI/NIAID NIH HHS/United States'
p61303
aS'R01 AI058736/AI/NIAID NIH HHS/United States'
p61304
aS'R01 AI058736/AI/NIAID NIH HHS/United States'
p61305
aS'T32 A007433/PHS HHS/United States'
p61306
asS'IP'
p61307
S'3'
sS'IS'
p61308
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p61309
sS'PMC'
p61310
S'PMC3299719'
p61311
sS'DCOM'
p61312
S'20120820'
p61313
sS'AU'
p61314
(lp61315
S'Ahonkhai AA'
p61316
aS'Noubary F'
p61317
aS'Munro A'
p61318
aS'Stark R'
p61319
aS'Wilke M'
p61320
aS'Freedberg KA'
p61321
aS'Wood R'
p61322
aS'Losina E'
p61323
asS'VI'
p61324
S'7'
sS'MHDA'
p61325
S'2012/08/21 06:00'
p61326
sS'PHST'
p61327
(lp61328
S'2011/09/29 [received]'
p61329
aS'2012/02/07 [accepted]'
p61330
aS'2012/03/12 [epublish]'
p61331
asS'OID'
p61332
(lp61333
S'NLM: PMC3299719'
p61334
asS'MH'
p61335
(lp61336
S'Antiretroviral Therapy, Highly Active/statistics & numerical data'
p61337
aS'Cohort Studies'
p61338
aS'HIV Infections/*drug therapy/*epidemiology'
p61339
aS'Humans'
p61340
aS'Logistic Models'
p61341
aS'*Lost to Follow-Up'
p61342
aS'Patient Compliance/*statistics & numerical data'
p61343
aS'Retrospective Studies'
p61344
aS'South Africa/epidemiology'
p61345
asS'EDAT'
p61346
S'2012/03/20 06:00'
p61347
sS'SO'
p61348
S'PLoS One. 2012;7(3):e32993. doi: 10.1371/journal.pone.0032993. Epub 2012 Mar 12.'
p61349
sS'SB'
p61350
S'IM'
p61351
sS'PMID'
p61352
S'22427925'
p61353
sS'PST'
p61354
S'ppublish'
p61355
stRp61356
ag2
(g3
g4
(dp61357
S'LID'
p61358
S'10.1371/journal.pone.0032727 [doi]'
p61359
sS'STAT'
p61360
S'MEDLINE'
p61361
sS'DEP'
p61362
S'20120309'
p61363
sS'DA'
p61364
S'20120319'
p61365
sS'AID'
p61366
(lp61367
S'10.1371/journal.pone.0032727 [doi]'
p61368
aS'PONE-D-11-19234 [pii]'
p61369
asS'CRDT'
p61370
(lp61371
S'2012/03/20 06:00'
p61372
asS'DP'
p61373
S'2012'
p61374
sS'OWN'
p61375
S'NLM'
p61376
sS'PT'
p61377
(lp61378
S'Comparative Study'
p61379
aS'Journal Article'
p61380
aS"Research Support, Non-U.S. Gov't"
p61381
asS'LA'
p61382
(lp61383
S'eng'
p61384
asS'FAU'
p61385
(lp61386
S'Achieng, Loice'
p61387
aS'Musangi, Helen'
p61388
aS"Ong'uti, Sharon"
p61389
aS'Ombegoh, Edwin'
p61390
aS'Bryant, Leeann'
p61391
aS'Mwiindi, Jonathan'
p61392
aS'Smith, Nathaniel'
p61393
aS'Keiser, Philip'
p61394
asS'JT'
p61395
S'PloS one'
p61396
sS'LR'
p61397
S'20150225'
p61398
sS'PG'
p61399
S'e32727'
p61400
sS'TI'
p61401
S'An observational cohort comparison of facilitators of retention in care and adherence to anti-eetroviral therapy at an HIV treatment center in Kenya.'
p61402
sS'PL'
p61403
S'United States'
p61404
sS'TA'
p61405
S'PLoS One'
p61406
sS'JID'
p61407
S'101285081'
p61408
sS'AB'
p61409
S'BACKGROUND: Most HIV treatment programs in resource-limited settings utilize multiple facilitators of adherence and retention in care but there is little data on the efficacy of these methods. We performed an observational cohort analysis of a treatment program in Kenya to assess which program components promote adherence and retention in HIV care in East Africa. METHODS: Patients initiating ART at A.I.C. Kijabe Hospital were prospectively enrolled in an observational study. Kijabe has an intensive program to promote adherence and retention in care during the first 6 months of ART that incorporates the following facilitators: home visits by community health workers, community based support groups, pharmacy counseling, and unannounced pill counts by clinicians. The primary endpoint was time to treatment failure, defined as a detectable HIV-1 viral load; discontinuation of ART; death; or loss to follow-up. Time to treatment failure for each facilitator was calculated using Kaplan-Meier analysis. The relative effects of the facilitators were determined by the Cox Proportional Hazards Model. RESULTS: 301 patients were enrolled. Time to treatment failure was longer in patients participating in support groups (448 days vs. 337 days, P<0.001), pharmacy counseling (480 days vs. 386 days, P = 0.002), pill counts (482 days vs. 189 days, P<0.001) and home visits (485 days vs. 426 days, P = 0.024). Better adherence was seen with support groups (89% vs. 82%, P = 0.05) and pill counts (89% vs. 75%, P = 0.02). Multivariate analysis using the Cox Model found significant reductions in risk of treatment failure associated with pill counts (HR = 0.19, P<0.001) and support groups (HR = 0.43, P = 0.003). CONCLUSION: Unannounced pill counts by the clinician and community based support groups were associated with better long term treatment success and with better adherence.'
p61410
sS'AD'
p61411
S'AIC Kijabe Hospital, Kijabe, Kenya.'
p61412
sS'IP'
p61413
S'3'
sS'IS'
p61414
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p61415
sS'PMC'
p61416
S'PMC3302871'
p61417
sS'DCOM'
p61418
S'20120820'
p61419
sS'AU'
p61420
(lp61421
S'Achieng L'
p61422
aS'Musangi H'
p61423
aS"Ong'uti S"
p61424
aS'Ombegoh E'
p61425
aS'Bryant L'
p61426
aS'Mwiindi J'
p61427
aS'Smith N'
p61428
aS'Keiser P'
p61429
asS'VI'
p61430
S'7'
sS'MHDA'
p61431
S'2012/08/21 06:00'
p61432
sS'PHST'
p61433
(lp61434
S'2011/09/30 [received]'
p61435
aS'2012/01/31 [accepted]'
p61436
aS'2012/03/09 [epublish]'
p61437
asS'OID'
p61438
(lp61439
S'NLM: PMC3302871'
p61440
asS'MH'
p61441
(lp61442
S'Antiretroviral Therapy, Highly Active/*statistics & numerical data'
p61443
aS'Cohort Studies'
p61444
aS'Directive Counseling/statistics & numerical data'
p61445
aS'HIV Infections/*drug therapy'
p61446
aS'House Calls/statistics & numerical data'
p61447
aS'Humans'
p61448
aS'Kenya'
p61449
aS'Medication Adherence/*statistics & numerical data'
p61450
aS'*Medication Therapy Management'
p61451
aS'Observation'
p61452
aS'Self-Help Groups/statistics & numerical data'
p61453
asS'EDAT'
p61454
S'2012/03/20 06:00'
p61455
sS'SO'
p61456
S'PLoS One. 2012;7(3):e32727. doi: 10.1371/journal.pone.0032727. Epub 2012 Mar 9.'
p61457
sS'SB'
p61458
S'IM'
p61459
sS'PMID'
p61460
S'22427869'
p61461
sS'PST'
p61462
S'ppublish'
p61463
stRp61464
ag2
(g3
g4
(dp61465
S'LID'
p61466
S'10.1371/journal.pone.0032144 [doi]'
p61467
sS'STAT'
p61468
S'MEDLINE'
p61469
sS'DEP'
p61470
S'20120313'
p61471
sS'DA'
p61472
S'20120319'
p61473
sS'AID'
p61474
(lp61475
S'10.1371/journal.pone.0032144 [doi]'
p61476
aS'PONE-D-11-13024 [pii]'
p61477
asS'CRDT'
p61478
(lp61479
S'2012/03/20 06:00'
p61480
asS'DP'
p61481
S'2012'
p61482
sS'AD'
p61483
S'Division of General Medicine Massachusetts General Hospital, Boston, Massachusetts, United States of America. jlevison@partners.org'
p61484
sS'OWN'
p61485
S'NLM'
p61486
sS'PT'
p61487
(lp61488
S'Journal Article'
p61489
aS'Research Support, N.I.H., Extramural'
p61490
aS"Research Support, Non-U.S. Gov't"
p61491
asS'LA'
p61492
(lp61493
S'eng'
p61494
asS'FAU'
p61495
(lp61496
S'Levison, Julie H'
p61497
aS'Orrell, Catherine'
p61498
aS'Gallien, Sebastien'
p61499
aS'Kuritzkes, Daniel R'
p61500
aS'Fu, Naishin'
p61501
aS'Losina, Elena'
p61502
aS'Freedberg, Kenneth A'
p61503
aS'Wood, Robin'
p61504
asS'JT'
p61505
S'PloS one'
p61506
sS'LR'
p61507
S'20150226'
p61508
sS'PG'
p61509
S'e32144'
p61510
sS'TI'
p61511
S'Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa.'
p61512
sS'RN'
p61513
(lp61514
S'0 (Protease Inhibitors)'
p61515
asS'PL'
p61516
S'United States'
p61517
sS'TA'
p61518
S'PLoS One'
p61519
sS'JID'
p61520
S'101285081'
p61521
sS'AB'
p61522
S'BACKGROUND: We investigated the prevalence of wild-type virus (no major drug resistance) and drug resistance mutations at second-line antiretroviral treatment (ART) failure in a large HIV treatment program in South Africa. METHODOLOGY/ PRINCIPAL FINDINGS: HIV-infected patients >/= 15 years of age who had failed protease inhibitor (PI)-based second-line ART (2 consecutive HIV RNA tests >1000 copies/ml on lopinavir/ritonavir, didanosine, and zidovudine) were identified retrospectively. Patients with virologic failure were continued on second-line ART. Genotypic testing for drug resistance was performed on frozen plasma samples obtained closest to and after the date of laboratory confirmed second-line ART failure. Of 322 HIV-infected patients on second-line ART, 43 were adults with confirmed virologic failure, and 33 had available plasma for viral sequencing. HIV-1 RNA subtype C predominated (n = 32, 97%). Mean duration on ART (SD) prior to initiation of second-line ART was 23 (17) months, and time from second-line ART initiation to failure was 10 (9) months. Plasma samples were obtained 7(9) months from confirmed failure. At second-line failure, 22 patients (67%) had wild-type virus. There was no major resistance to PIs found. Eleven of 33 patients had a second plasma sample taken 8 (5.5) months after the first. Median HIV-1 RNA and the genotypic resistance profile were unchanged. CONCLUSIONS/ SIGNIFICANCE: Most patients who failed second-line ART had wild-type virus. We did not observe evolution of resistance despite continuation of PI-based ART after failure. Interventions that successfully improve adherence could allow patients to continue to benefit from second-line ART therapy even after initial failure.'
p61523
sS'GR'
p61524
(lp61525
S'K24 A1062476/PHS HHS/United States'
p61526
aS'K24 AI062476/AI/NIAID NIH HHS/United States'
p61527
aS'K24 RR016482/RR/NCRR NIH HHS/United States'
p61528
aS'K24 RR016482/RR/NCRR NIH HHS/United States'
p61529
aS'P30 AI060354/AI/NIAID NIH HHS/United States'
p61530
aS'P30-AI060354/AI/NIAID NIH HHS/United States'
p61531
aS'R01 AI058736/AI/NIAID NIH HHS/United States'
p61532
aS'R01AI058736/AI/NIAID NIH HHS/United States'
p61533
aS'T32 AI007433/AI/NIAID NIH HHS/United States'
p61534
aS'U01 AI068636/AI/NIAID NIH HHS/United States'
p61535
aS'U01 AI068636/AI/NIAID NIH HHS/United States'
p61536
asS'IP'
p61537
S'3'
sS'IS'
p61538
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p61539
sS'PMC'
p61540
S'PMC3302781'
p61541
sS'DCOM'
p61542
S'20120820'
p61543
sS'AU'
p61544
(lp61545
S'Levison JH'
p61546
aS'Orrell C'
p61547
aS'Gallien S'
p61548
aS'Kuritzkes DR'
p61549
aS'Fu N'
p61550
aS'Losina E'
p61551
aS'Freedberg KA'
p61552
aS'Wood R'
p61553
asS'VI'
p61554
S'7'
sS'MHDA'
p61555
S'2012/08/21 06:00'
p61556
sS'PHST'
p61557
(lp61558
S'2011/07/08 [received]'
p61559
aS'2012/01/20 [accepted]'
p61560
aS'2012/03/13 [epublish]'
p61561
asS'OID'
p61562
(lp61563
S'NLM: PMC3302781'
p61564
asS'MH'
p61565
(lp61566
S'Adolescent'
p61567
aS'Adult'
p61568
aS'Antiretroviral Therapy, Highly Active/*statistics & numerical data'
p61569
aS'Cross-Sectional Studies'
p61570
aS'Drug Resistance, Viral/*genetics'
p61571
aS'Flow Cytometry'
p61572
aS'HIV Infections/*drug therapy'
p61573
aS'HIV-1/*drug effects/genetics'
p61574
aS'Humans'
p61575
aS'Protease Inhibitors/*pharmacology'
p61576
aS'Reverse Transcriptase Polymerase Chain Reaction'
p61577
aS'Sequence Analysis, RNA'
p61578
aS'South Africa'
p61579
aS'Treatment Failure'
p61580
asS'EDAT'
p61581
S'2012/03/20 06:00'
p61582
sS'SO'
p61583
S'PLoS One. 2012;7(3):e32144. doi: 10.1371/journal.pone.0032144. Epub 2012 Mar 13.'
p61584
sS'SB'
p61585
S'IM'
p61586
sS'PMID'
p61587
S'22427821'
p61588
sS'PST'
p61589
S'ppublish'
p61590
stRp61591
ag2
(g3
g4
(dp61592
S'LID'
p61593
S'10.1016/S1473-3099(12)70051-8 [doi]'
p61594
sS'STAT'
p61595
S'MEDLINE'
p61596
sS'DEP'
p61597
S'20120316'
p61598
sS'MID'
p61599
(lp61600
S'NIHMS367024'
p61601
asS'DA'
p61602
S'20120629'
p61603
sS'AID'
p61604
(lp61605
S'S1473-3099(12)70051-8 [pii]'
p61606
aS'10.1016/S1473-3099(12)70051-8 [doi]'
p61607
asS'CRDT'
p61608
(lp61609
S'2012/03/20 06:00'
p61610
asS'DP'
p61611
S'2012 Jul'
p61612
sS'AD'
p61613
S'Gertrude H Sergievsky Center, College of Physicians and Surgeons, and Department of Epidemiology, Columbia University, New York, NY 10032, USA. lk24@columbia.edu'
p61614
sS'OWN'
p61615
S'NLM'
p61616
sS'PT'
p61617
(lp61618
S'Journal Article'
p61619
aS'Randomized Controlled Trial'
p61620
aS'Research Support, N.I.H., Extramural'
p61621
aS"Research Support, Non-U.S. Gov't"
p61622
asS'LA'
p61623
(lp61624
S'eng'
p61625
asS'FAU'
p61626
(lp61627
S'Kuhn, Louise'
p61628
aS'Coovadia, Ashraf'
p61629
aS'Strehlau, Renate'
p61630
aS'Martens, Leigh'
p61631
aS'Hu, Chih-Chi'
p61632
aS'Meyers, Tammy'
p61633
aS'Sherman, Gayle'
p61634
aS'Hunt, Gillian'
p61635
aS'Persaud, Deborah'
p61636
aS'Morris, Lynn'
p61637
aS'Tsai, Wei-Yann'
p61638
aS'Abrams, Elaine J'
p61639
asS'JT'
p61640
S'The Lancet. Infectious diseases'
p61641
sS'LR'
p61642
S'20150819'
p61643
sS'PG'
p61644
S'521-30'
p61645
sS'TI'
p61646
S'Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial.'
p61647
sS'RN'
p61648
(lp61649
S'0 (Anti-HIV Agents)'
p61650
aS'0 (HIV Protease Inhibitors)'
p61651
aS'2494G1JF75 (Lopinavir)'
p61652
aS'99DK7FVK1H (Nevirapine)'
p61653
aS'EC 2.6.1.2 (Alanine Transaminase)'
p61654
aS'O3J8G9O825 (Ritonavir)'
p61655
asS'PL'
p61656
S'United States'
p61657
sS'TA'
p61658
S'Lancet Infect Dis'
p61659
sS'JID'
p61660
S'101130150'
p61661
sS'AB'
p61662
S'BACKGROUND: Protease-inhibitor-based treatment is recommended as first-line for infants infected with HIV who have been previously exposed to nevirapine prophylaxis. However, long-term use poses adherence challenges, is associated with metabolic toxic effects, restricts second-line options, and is costly. We present the long-term outcomes of switching nevirapine-exposed children to nevirapine-based treatment after effective suppression of virus replication with a protease-inhibitor-based regimen. METHODS: We did a randomised trial to compare long-term viral suppression with nevirapine-based versus protease-inhibitor-based (ritonavir-boosted lopinavir) treatment in children who had achieved suppression with protease-inhibitor-based treatment. Randomisation (1:1) was by cohort blocks of variable size between eight and 12. Eligible children were younger than 24 months who were previously exposed to nevirapine for prevention of mother-to-child transmission, and achieved virological suppression of less than 400 copies per mL when treated with the regimen based on ritonavir-boosted lopinavir in Johannesburg, South Africa. We gave all drugs as liquids and adjusted doses at each visit in accordance with growth. We continued follow-up for a minimum of 90 weeks and maximum of 232 weeks after randomisation. We quantified HIV RNA every 3 months. Our primary endpoint was any viraemia greater than 50 copies per mL. Our analysis was by modified intention to treat. This study is registered with ClinicalTrials.gov, number NCT00117728. FINDINGS: We followed up the children for a median of 156 weeks and there were three deaths in each group. Children in the switch group (Kaplan-Meier probability 0.595) were less likely to experience non-suppression greater than 50 copies per mL than in the control group (0.687; p=0.01) and had better CD4 and growth responses initially after switching (52 children in the switch group vs 66 control group met this endpoint). By 156 weeks after randomisation, more children had virological failure--which we defined as confirmed viraemia of more than 1000 copies per mL--in the switch group (22 children) than in the control group (ten children; p=0.009). We detected all 22 failures in the switch group by 52 weeks compared with five in the control group. Virological failure was related to non-adherence and pretreatment drug resistance. In children without pretreatment drug resistance, we did not identify a significant difference in virological failure between the switch (Kaplan-Meier probability 0.140) and control (0.095) groups (p=0.34; seven failures in the switch group vs five in the control group). Children in the switch group were significantly more likely to develop grade 1-3 alanine aminotransferase abnormalities over the duration of follow-up. INTERPRETATION: Viral-load testing through 52 weeks can identify all children likely to fail this protease-inhibitor-switch strategy. Switching children once suppressed to a nevirapine-based regimen might be a valuable treatment option if adequate viral-load monitoring can be done. FUNDING: National Institutes of Child Health and Human Development and Secure the Future Foundation.'
p61663
sS'GR'
p61664
(lp61665
S'HD 47177/HD/NICHD NIH HHS/United States'
p61666
aS'HD057784/HD/NICHD NIH HHS/United States'
p61667
aS'R01 HD047177/HD/NICHD NIH HHS/United States'
p61668
aS'R01 HD057784/HD/NICHD NIH HHS/United States'
p61669
aS'R01 HD057784-01/HD/NICHD NIH HHS/United States'
p61670
aS'R01 HD057784-02/HD/NICHD NIH HHS/United States'
p61671
aS'R01 HD057784-03/HD/NICHD NIH HHS/United States'
p61672
aS'R01 HD057784-04/HD/NICHD NIH HHS/United States'
p61673
asS'IP'
p61674
S'7'
sS'IS'
p61675
S'1474-4457 (Electronic) 1473-3099 (Linking)'
p61676
sS'PMC'
p61677
S'PMC4539971'
p61678
sS'DCOM'
p61679
S'20120913'
p61680
sS'CIN'
p61681
(lp61682
S'Lancet Infect Dis. 2012 Jul;12(7):498-9. PMID: 22424721'
p61683
asS'AU'
p61684
(lp61685
S'Kuhn L'
p61686
aS'Coovadia A'
p61687
aS'Strehlau R'
p61688
aS'Martens L'
p61689
aS'Hu CC'
p61690
aS'Meyers T'
p61691
aS'Sherman G'
p61692
aS'Hunt G'
p61693
aS'Persaud D'
p61694
aS'Morris L'
p61695
aS'Tsai WY'
p61696
aS'Abrams EJ'
p61697
asS'VI'
p61698
S'12'
p61699
sS'MHDA'
p61700
S'2012/09/14 06:00'
p61701
sS'PHST'
p61702
(lp61703
S'2012/03/16 [aheadofprint]'
p61704
asS'OID'
p61705
(lp61706
S'NLM: NIHMS367024'
p61707
aS'NLM: PMC4539971'
p61708
asS'CI'
p61709
(lp61710
S'Copyright (c) 2012 Elsevier Ltd. All rights reserved.'
p61711
asS'MH'
p61712
(lp61713
S'Alanine Transaminase/blood'
p61714
aS'Anti-HIV Agents/*therapeutic use'
p61715
aS'Body Height'
p61716
aS'Body Weight'
p61717
aS'Chi-Square Distribution'
p61718
aS'Child, Preschool'
p61719
aS'Drug Resistance, Viral'
p61720
aS'Drug Therapy, Combination'
p61721
aS'Female'
p61722
aS'Follow-Up Studies'
p61723
aS'HIV Infections/*drug therapy/enzymology/virology'
p61724
aS'HIV Protease Inhibitors/*therapeutic use'
p61725
aS'Humans'
p61726
aS'Infant'
p61727
aS'Kaplan-Meier Estimate'
p61728
aS'Lopinavir/*therapeutic use'
p61729
aS'Male'
p61730
aS'Medication Adherence'
p61731
aS'Nevirapine/*therapeutic use'
p61732
aS'Ritonavir/*therapeutic use'
p61733
aS'Statistics, Nonparametric'
p61734
aS'Time Factors'
p61735
aS'Viral Load'
p61736
asS'EDAT'
p61737
S'2012/03/20 06:00'
p61738
sS'SI'
p61739
(lp61740
S'ClinicalTrials.gov/NCT00117728'
p61741
asS'SO'
p61742
S'Lancet Infect Dis. 2012 Jul;12(7):521-30. doi: 10.1016/S1473-3099(12)70051-8. Epub 2012 Mar 16.'
p61743
sS'SB'
p61744
S'IM'
p61745
sS'PMID'
p61746
S'22424722'
p61747
sS'PST'
p61748
S'ppublish'
p61749
stRp61750
ag2
(g3
g4
(dp61751
S'LID'
p61752
S'10.1111/j.1468-1293.2012.01006.x [doi]'
p61753
sS'STAT'
p61754
S'MEDLINE'
p61755
sS'DEP'
p61756
S'20120314'
p61757
sS'CI'
p61758
(lp61759
S'(c) 2012 British HIV Association.'
p61760
asS'DA'
p61761
S'20120911'
p61762
sS'AID'
p61763
(lp61764
S'10.1111/j.1468-1293.2012.01006.x [doi]'
p61765
asS'CRDT'
p61766
(lp61767
S'2012/03/16 06:00'
p61768
asS'DP'
p61769
S'2012 Oct'
p61770
sS'AD'
p61771
S'Muhimbili University of Health and Allied Sciences (MUHAS), Dar es Salaam, Tanzania. tnagu@muhas.ac.tz'
p61772
sS'OWN'
p61773
S'NLM'
p61774
sS'PT'
p61775
(lp61776
S'Journal Article'
p61777
aS'Research Support, N.I.H., Extramural'
p61778
aS"Research Support, Non-U.S. Gov't"
p61779
asS'LA'
p61780
(lp61781
S'eng'
p61782
asS'FAU'
p61783
(lp61784
S'Nagu, T J'
p61785
aS'Kanyangarara, M'
p61786
aS'Hawkins, C'
p61787
aS'Hertmark, E'
p61788
aS'Chalamila, G'
p61789
aS'Spiegelman, D'
p61790
aS'Mugusi, F'
p61791
aS'Fawzi, W'
p61792
asS'JT'
p61793
S'HIV medicine'
p61794
sS'LR'
p61795
S'20150225'
p61796
sS'PG'
p61797
S'541-8'
p61798
sS'TI'
p61799
S'Elevated alanine aminotransferase in antiretroviral-naive HIV-infected African patients: magnitude and risk factors.'
p61800
sS'RN'
p61801
(lp61802
S'0 (DNA, Viral)'
p61803
aS'0 (RNA, Viral)'
p61804
aS'EC 2.6.1.2 (Alanine Transaminase)'
p61805
asS'PL'
p61806
S'England'
p61807
sS'TA'
p61808
S'HIV Med'
p61809
sS'JID'
p61810
S'100897392'
p61811
sS'AB'
p61812
S'BACKGROUND: Alanine aminotransferase (ALT) is commonly used to measure liver injury in resource-limited settings. Elevations in ALT are predictive of increased mortality from liver disease and may influence the choice of first-line antiretroviral therapy (ART). METHODS: A cross-sectional analysis of the prevalence and predictors of elevated ALT (defined as >40 IU/L) was conducted. ART-naive, HIV-infected adults with a baseline ALT measurement who were enrolled in any of the 18 HIV Care and Treatment Clinics in Dar es Salaam, Tanzania between November 2004 and December 2009 were included in the study. Median values were calculated and log-binomial regression models were used to examine predictors of elevated ALT. RESULTS: During the study period, 41891 adults had a baseline ALT measurement performed. The prevalence of ALT >40, >120 and >200 IU/L was 13, 1 and 0.3%, respectively. In multivariate analyses, male sex, CD4 T lymphocyte count <200 cells/muL and higher World Health Organization (WHO) clinical stages were associated with a significantly higher risk of ALT >40 IU/L (all P<0.01). Hypertryglyceridaemia, hyperglycaemia and hepatitis B virus (HBV) coinfection (positive for HBV surface antigen) were significantly associated with a higher risk of elevated ALT. Pregnancy, anaemia, low-density lipoprotein cholesterol >130 mg/dL and current tuberculosis treatment were associated with a significantly reduced risk for elevated ALT. CONCLUSIONS: In this HIV-infected, ART-naive Tanzanian population, extreme elevations in ALT were infrequent but minor elevations were not uncommon. Antiretrovirals with potentially hepatotoxic side effects should be initiated with caution in male patients, and in patients with HBV coinfection, advanced immunosuppression and components of the metabolic syndrome.'
p61813
sS'GR'
p61814
(lp61815
S'5R24TW007988/TW/FIC NIH HHS/United States'
p61816
aS'R24 TW007988/TW/FIC NIH HHS/United States'
p61817
aS'R24 TW007988-01/TW/FIC NIH HHS/United States'
p61818
aS'PEPFAR/United States'
p61819
asS'IP'
p61820
S'9'
sS'IS'
p61821
S'1468-1293 (Electronic) 1464-2662 (Linking)'
p61822
sS'PMC'
p61823
S'PMC3391335'
p61824
sS'DCOM'
p61825
S'20121231'
p61826
sS'MID'
p61827
(lp61828
S'NIHMS357394'
p61829
asS'AU'
p61830
(lp61831
S'Nagu TJ'
p61832
aS'Kanyangarara M'
p61833
aS'Hawkins C'
p61834
aS'Hertmark E'
p61835
aS'Chalamila G'
p61836
aS'Spiegelman D'
p61837
aS'Mugusi F'
p61838
aS'Fawzi W'
p61839
asS'VI'
p61840
S'13'
p61841
sS'MHDA'
p61842
S'2013/01/01 06:00'
p61843
sS'PHST'
p61844
(lp61845
S'2012/02/07 [accepted]'
p61846
aS'2012/03/14 [aheadofprint]'
p61847
asS'OID'
p61848
(lp61849
S'NLM: NIHMS357394'
p61850
aS'NLM: PMC3391335'
p61851
asS'MH'
p61852
(lp61853
S'Adult'
p61854
aS'Alanine Transaminase/*blood'
p61855
aS'CD4 Lymphocyte Count'
p61856
aS'Cross-Sectional Studies'
p61857
aS'DNA, Viral/*metabolism'
p61858
aS'Female'
p61859
aS'HIV Seropositivity/*blood/epidemiology'
p61860
aS'Hepatitis, Viral, Human/*blood/epidemiology'
p61861
aS'Humans'
p61862
aS'Male'
p61863
aS'Middle Aged'
p61864
aS'Pregnancy'
p61865
aS'Pregnancy Complications, Infectious/*blood/epidemiology/virology'
p61866
aS'Prevalence'
p61867
aS'RNA, Viral/*metabolism'
p61868
aS'Risk Factors'
p61869
aS'Tanzania/epidemiology'
p61870
aS'Urban Population/statistics & numerical data'
p61871
aS'Viral Load'
p61872
aS'Young Adult'
p61873
asS'EDAT'
p61874
S'2012/03/16 06:00'
p61875
sS'SO'
p61876
S'HIV Med. 2012 Oct;13(9):541-8. doi: 10.1111/j.1468-1293.2012.01006.x. Epub 2012 Mar 14.'
p61877
sS'SB'
p61878
S'IM'
p61879
sS'PMID'
p61880
S'22416813'
p61881
sS'PST'
p61882
S'ppublish'
p61883
stRp61884
ag2
(g3
g4
(dp61885
S'LID'
p61886
S'10.3851/IMP2087 [doi]'
p61887
sS'STAT'
p61888
S'MEDLINE'
p61889
sS'DEP'
p61890
S'20120313'
p61891
sS'MID'
p61892
(lp61893
S'NIHMS364739'
p61894
asS'DA'
p61895
S'20120529'
p61896
sS'AID'
p61897
(lp61898
S'10.3851/IMP2087 [doi]'
p61899
asS'CRDT'
p61900
(lp61901
S'2012/03/15 06:00'
p61902
asS'DP'
p61903
S'2012'
p61904
sS'AD'
p61905
S'Division of Infectious Diseases, Weill Cornell Medical College, New York, NY, USA. mep2002@med.cornell.edu'
p61906
sS'OWN'
p61907
S'NLM'
p61908
sS'PT'
p61909
(lp61910
S'Journal Article'
p61911
aS'Research Support, N.I.H., Extramural'
p61912
asS'LA'
p61913
(lp61914
S'eng'
p61915
asS'FAU'
p61916
(lp61917
S'Pahuja, Meera'
p61918
aS'Grobler, Anneke'
p61919
aS'Glesby, Marshall J'
p61920
aS'Karim, Farina'
p61921
aS'Parker, Gary'
p61922
aS'Gumede, Sizwe'
p61923
aS'Naidoo, Kogieleum'
p61924
asS'JT'
p61925
S'Antiviral therapy'
p61926
sS'LR'
p61927
S'20150225'
p61928
sS'PG'
p61929
S'737-43'
p61930
sS'TI'
p61931
S'Effects of a reduced dose of stavudine on the incidence and severity of peripheral neuropathy in HIV-infected adults in South Africa.'
p61932
sS'RN'
p61933
(lp61934
S'0 (Anti-HIV Agents)'
p61935
aS'BO9LE4QFZF (Stavudine)'
p61936
asS'PL'
p61937
S'England'
p61938
sS'TA'
p61939
S'Antivir Ther'
p61940
sS'JID'
p61941
S'9815705'
p61942
sS'AB'
p61943
S"BACKGROUND: Although recent World Health Organization (WHO) guidelines recommend withdrawing stavudine (d4T) from first-line antiretroviral therapy (ART), it remains commonly used in resource-limited settings. In 2006, WHO recommended decreasing the dose of d4T from 40 mg to 30 mg to mitigate toxicities. We compared the incidence and severity of peripheral neuropathy by d4T dose in a retrospective cohort study. METHODS: Patients' charts from an ART-naive population at a rural clinic in KwaZulu-Natal, South Africa, were retrospectively reviewed for signs and symptoms of incident peripheral neuropathy and were graded for severity using the DAIDS scale. Patients enrolled prior to the WHO guideline change were included in the study if they were on d4T 40 mg for >/=6 months. After the guideline change all patients were initiated on d4T 30 mg. RESULTS: A total of 475 patients were analysed, including 235 in the 40 mg cohort (152.7 person-years [py]) and 240 in the 30 mg cohort (244.7 py). Incidence of peripheral neuropathy was 90.4/100 py (95% CI 75.9, 106.8) in the 40 mg cohort versus 40.5/100 py (95% CI 32.9, 49.3) in the 30 mg group (incidence rate ratio 0.45; P<0.0001). There was no difference in proportion of severe peripheral neuropathy cases (grade 3/4) between the cohorts: 8.3% in the 40 mg group and 8.9% in the 30 mg group (P=1.0). In a multivariate analysis, risk of peripheral neuropathy was associated with increasing age (hazard ratio [HR] 1.65, 95% CI 1.24, 2.19), 40 mg dose (HR 2.1, 95% CI 1.61, 2.74) and concurrent tuberculosis therapy (HR 1.41, 95% CI 1.06, 1.87). CONCLUSIONS: Incidence of peripheral neuropathy in the 40 mg cohort was extremely high and, although lower, the rate in the 30 mg cohort was nonetheless unacceptably high."
p61944
sS'GR'
p61945
(lp61946
S'K24 AI 78884/AI/NIAID NIH HHS/United States'
p61947
aS'K24 AI078884/AI/NIAID NIH HHS/United States'
p61948
aS'K24 AI078884-04/AI/NIAID NIH HHS/United States'
p61949
aS'T32 AI007613/AI/NIAID NIH HHS/United States'
p61950
asS'IP'
p61951
S'4'
sS'IS'
p61952
S'2040-2058 (Electronic) 1359-6535 (Linking)'
p61953
sS'PMC'
p61954
S'PMC3662496'
p61955
sS'DCOM'
p61956
S'20120905'
p61957
sS'AU'
p61958
(lp61959
S'Pahuja M'
p61960
aS'Grobler A'
p61961
aS'Glesby MJ'
p61962
aS'Karim F'
p61963
aS'Parker G'
p61964
aS'Gumede S'
p61965
aS'Naidoo K'
p61966
asS'VI'
p61967
S'17'
p61968
sS'MHDA'
p61969
S'2012/09/06 06:00'
p61970
sS'PHST'
p61971
(lp61972
S'2011/09/14 [accepted]'
p61973
aS'2012/03/13 [aheadofprint]'
p61974
asS'OID'
p61975
(lp61976
S'NLM: NIHMS364739'
p61977
aS'NLM: PMC3662496'
p61978
asS'MH'
p61979
(lp61980
S'Adult'
p61981
aS'Anti-HIV Agents/administration & dosage/*adverse effects/*therapeutic use'
p61982
aS'Dose-Response Relationship, Drug'
p61983
aS'Female'
p61984
aS'HIV Infections'
p61985
aS'Humans'
p61986
aS'Incidence'
p61987
aS'Male'
p61988
aS'Peripheral Nervous System Diseases/*chemically induced'
p61989
aS'Practice Guidelines as Topic'
p61990
aS'Retrospective Studies'
p61991
aS'South Africa'
p61992
aS'Stavudine/administration & dosage/*adverse effects/*therapeutic use'
p61993
aS'Young Adult'
p61994
asS'EDAT'
p61995
S'2012/03/15 06:00'
p61996
sS'SO'
p61997
S'Antivir Ther. 2012;17(4):737-43. doi: 10.3851/IMP2087. Epub 2012 Mar 13.'
p61998
sS'SB'
p61999
S'IM'
p62000
sS'PMID'
p62001
S'22414588'
p62002
sS'PST'
p62003
S'ppublish'
p62004
stRp62005
ag2
(g3
g4
(dp62006
S'LID'
p62007
S'10.1186/1758-2652-15-13 [doi]'
p62008
sS'STAT'
p62009
S'MEDLINE'
p62010
sS'DEP'
p62011
S'20120312'
p62012
sS'DA'
p62013
S'20120328'
p62014
sS'AID'
p62015
(lp62016
S'1758-2652-15-13 [pii]'
p62017
aS'10.1186/1758-2652-15-13 [doi]'
p62018
asS'CRDT'
p62019
(lp62020
S'2012/03/14 06:00'
p62021
asS'DP'
p62022
S'2012'
p62023
sS'AD'
p62024
S'Clinical HIV Research Unit, Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. mmaskew@witshealth.co.za'
p62025
sS'OWN'
p62026
S'NLM'
p62027
sS'PT'
p62028
(lp62029
S'Comparative Study'
p62030
aS'Journal Article'
p62031
aS'Research Support, N.I.H., Extramural'
p62032
aS"Research Support, Non-U.S. Gov't"
p62033
aS"Research Support, U.S. Gov't, Non-P.H.S."
p62034
asS'LA'
p62035
(lp62036
S'eng'
p62037
asS'FAU'
p62038
(lp62039
S'Maskew, Mhairi'
p62040
aS'Westreich, Daniel'
p62041
aS'Fox, Matthew P'
p62042
aS'Maotoe, Thapelo'
p62043
aS'Sanne, Ian M'
p62044
asS'JT'
p62045
S'Journal of the International AIDS Society'
p62046
sS'LR'
p62047
S'20150225'
p62048
sS'PG'
p62049
S'13'
p62050
sS'TI'
p62051
S'Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIV-infected adults initiating HAART in South Africa.'
p62052
sS'RN'
p62053
(lp62054
S'BO9LE4QFZF (Stavudine)'
p62055
asS'PL'
p62056
S'England'
p62057
sS'TA'
p62058
S'J Int AIDS Soc'
p62059
sS'JID'
p62060
S'101478566'
p62061
sS'AB'
p62062
S'BACKGROUND: As stavudine remains an important and widely prescribed drug in resource-limited settings, the effect of a reduced dose of stavudine (from 40 mg to 30 mg) on outcomes of highly active antiretroviral therapy (HAART) remains an important public health question. METHODS: We analyzed prospectively collected data from the Themba Lethu Clinic in Johannesburg, South Africa. We assessed the relationship between stavudine dose and six- and/or 12-month outcomes of stavudine substitution, failure to suppress viral load to below 400 copies/ml, development of peripheral neuropathy, lipoatrophy and hyperlactatemia/lactic acidosis. Since individuals with a baseline weight of less than 60 kg were expected to have received the same dose of stavudine throughout the study period, analysis was restricted to individuals who weighed 60 kg or more at baseline. Data were analyzed using logistic regression. RESULTS: Between 1 April 2004 and 30 September 2009, 3910 patients were initiated on antiretroviral therapy (ART) with a recorded stavudine dose and were included in the analysis. Of these, 2445 (62.5%) received a 40 mg stavudine dose while 1565 (37.5%) received 30 mg. In multivariate analysis, patients receiving a 40 mg dose were more likely to discontinue stavudine use (adjusted odds ratio, OR 1.71; 95% confidence limits, CI 1.13-2.57) than those receiving 30 mg by 12 months on ART. Additionally, patients receiving 40 mg doses of stavudine were more likely to report peripheral neuropathy (OR 3.12; 95% CI 1.86-5.25), lipoatrophy (OR 11.8; 95% CI 3.2-43.8) and hyperlactatemia/lactic acidosis (OR 8.37; 95% CI 3.83-18.29) in the same time period. Failure to suppress HIV viral load within 12 months of HAART initiation was somewhat more common among those given 40 mg doses (OR 1.62; 95% CI 0.88, 2.97) although this result lacked precision. Sensitivity analyses accounting for death and loss to follow up generally supported these estimates. CONCLUSIONS: Lower stavudine dosage is associated with fewer reports of several stavudine-associated adverse events and also a lower risk of stavudine discontinuation within the first year on ART.'
p62063
sS'GR'
p62064
(lp62065
S'2P30 AI064518/AI/NIAID NIH HHS/United States'
p62066
aS'K01 AI083097/AI/NIAID NIH HHS/United States'
p62067
aS'K01AI083097/AI/NIAID NIH HHS/United States'
p62068
aS'P30 AI064518/AI/NIAID NIH HHS/United States'
p62069
asS'IP'
p62070
S'1'
sS'IS'
p62071
S'1758-2652 (Electronic) 1758-2652 (Linking)'
p62072
sS'PMC'
p62073
S'PMC3313885'
p62074
sS'DCOM'
p62075
S'20120724'
p62076
sS'AU'
p62077
(lp62078
S'Maskew M'
p62079
aS'Westreich D'
p62080
aS'Fox MP'
p62081
aS'Maotoe T'
p62082
aS'Sanne IM'
p62083
asS'VI'
p62084
S'15'
p62085
sS'MHDA'
p62086
S'2012/07/25 06:00'
p62087
sS'PHST'
p62088
(lp62089
S'2011/07/29 [received]'
p62090
aS'2012/03/12 [accepted]'
p62091
aS'2012/03/12 [aheadofprint]'
p62092
asS'OID'
p62093
(lp62094
S'NLM: PMC3313885'
p62095
asS'MH'
p62096
(lp62097
S'Adult'
p62098
aS'*Antiretroviral Therapy, Highly Active'
p62099
aS'CD4 Lymphocyte Count'
p62100
aS'Cohort Studies'
p62101
aS'Dose-Response Relationship, Drug'
p62102
aS'Female'
p62103
aS'HIV/drug effects/physiology'
p62104
aS'HIV Infections/*drug therapy/immunology/virology'
p62105
aS'Humans'
p62106
aS'Male'
p62107
aS'Prospective Studies'
p62108
aS'South Africa'
p62109
aS'Stavudine/*administration & dosage/adverse effects'
p62110
asS'EDAT'
p62111
S'2012/03/14 06:00'
p62112
sS'SO'
p62113
S'J Int AIDS Soc. 2012 Mar 12;15(1):13. doi: 10.1186/1758-2652-15-13.'
p62114
sS'SB'
p62115
S'IM X'
p62116
sS'PMID'
p62117
S'22410312'
p62118
sS'PST'
p62119
S'epublish'
p62120
stRp62121
ag2
(g3
g4
(dp62122
S'LID'
p62123
S'10.1111/j.1365-3156.2012.02958.x [doi]'
p62124
sS'STAT'
p62125
S'MEDLINE'
p62126
sS'DEP'
p62127
S'20120307'
p62128
sS'CI'
p62129
(lp62130
S'(c) 2012 Blackwell Publishing Ltd.'
p62131
asS'DA'
p62132
S'20120906'
p62133
sS'AID'
p62134
(lp62135
S'10.1111/j.1365-3156.2012.02958.x [doi]'
p62136
asS'CRDT'
p62137
(lp62138
S'2012/03/08 06:00'
p62139
asS'DP'
p62140
S'2012 May'
p62141
sS'OWN'
p62142
S'NLM'
p62143
sS'PT'
p62144
(lp62145
S'Journal Article'
p62146
aS'Review'
p62147
asS'LA'
p62148
(lp62149
S'eng'
p62150
asS'FAU'
p62151
(lp62152
S'Ferguson, Laura'
p62153
aS'Grant, Alison D'
p62154
aS'Watson-Jones, Deborah'
p62155
aS'Kahawita, Tanya'
p62156
aS"Ong'ech, John O"
p62157
aS'Ross, David A'
p62158
asS'JT'
p62159
S'Tropical medicine & international health : TM & IH'
p62160
sS'PG'
p62161
S'564-80'
p62162
sS'TI'
p62163
S'Linking women who test HIV-positive in pregnancy-related services to long-term HIV care and treatment services: a systematic review.'
p62164
sS'RN'
p62165
(lp62166
S'0 (Anti-HIV Agents)'
p62167
asS'PL'
p62168
S'England'
p62169
sS'TA'
p62170
S'Trop Med Int Health'
p62171
sS'JID'
p62172
S'9610576'
p62173
sS'AB'
p62174
S"OBJECTIVES: To quantify attrition between women testing HIV-positive in pregnancy-related services and accessing long-term HIV care and treatment services in low- or middle-income countries and to explore the reasons underlying client drop-out by synthesising current literature on this topic. METHODS: A systematic search in Medline, EMBASE, Global Health and the International Bibliography of the Social Sciences of literature published 2000-2010. Only studies meeting pre-defined quality criteria were included. RESULTS: Of 2543 articles retrieved, 20 met the inclusion criteria. Sixteen (80%) drew on data from sub-Saharan Africa. The pathway between testing HIV-positive in pregnancy-related services and accessing long-term HIV-related services is complex, and attrition was usually high. There was a failure to initiate highly active antiretroviral therapy (HAART) among 38-88% of known-eligible women. Providing 'family-focused care', and integrating CD4 testing and HAART provision into prevention of mother-to-child HIV transmission services appear promising for increasing women's uptake of HIV-related services. Individual-level factors that need to be addressed include financial constraints and fear of stigma. CONCLUSIONS: Too few women negotiate the many steps between testing HIV-positive in pregnancy-related services and accessing HIV-related services for themselves. Recent efforts to stem patient drop-out, such as the MTCT-Plus Initiative, hold promise. Addressing barriers and enabling factors both within health facilities and at the levels of the individual woman, her family and society will be essential to improve the uptake of services."
p62175
sS'AD'
p62176
S'Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK. laura.ferguson@lshtm.ac.uk'
p62177
sS'IP'
p62178
S'5'
sS'IS'
p62179
S'1365-3156 (Electronic) 1360-2276 (Linking)'
p62180
sS'DCOM'
p62181
S'20121205'
p62182
sS'AU'
p62183
(lp62184
S'Ferguson L'
p62185
aS'Grant AD'
p62186
aS'Watson-Jones D'
p62187
aS'Kahawita T'
p62188
aS"Ong'ech JO"
p62189
aS'Ross DA'
p62190
asS'VI'
p62191
S'17'
p62192
sS'MHDA'
p62193
S'2012/12/10 06:00'
p62194
sS'PHST'
p62195
(lp62196
S'2012/03/07 [aheadofprint]'
p62197
asS'MH'
p62198
(lp62199
S'Africa South of the Sahara'
p62200
aS'Anti-HIV Agents/therapeutic use'
p62201
aS'Antiretroviral Therapy, Highly Active/*methods'
p62202
aS'Female'
p62203
aS'HIV Infections/*drug therapy/*transmission'
p62204
aS'HIV Seropositivity/drug therapy/transmission'
p62205
aS'Health Services Accessibility/*statistics & numerical data'
p62206
aS'Humans'
p62207
aS'Infectious Disease Transmission, Vertical/*prevention & control'
p62208
aS'Long-Term Care/utilization'
p62209
aS'Patient Acceptance of Health Care/statistics & numerical data'
p62210
aS'Patient Dropouts/statistics & numerical data'
p62211
aS'Preconception Care/*utilization'
p62212
aS'Pregnancy'
p62213
aS'Pregnancy Complications, Infectious/*drug therapy'
p62214
asS'EDAT'
p62215
S'2012/03/08 06:00'
p62216
sS'SO'
p62217
S'Trop Med Int Health. 2012 May;17(5):564-80. doi: 10.1111/j.1365-3156.2012.02958.x. Epub 2012 Mar 7.'
p62218
sS'SB'
p62219
S'IM'
p62220
sS'PMID'
p62221
S'22394050'
p62222
sS'PST'
p62223
S'ppublish'
p62224
stRp62225
ag2
(g3
g4
(dp62226
S'LID'
p62227
S'10.1371/journal.pone.0031706 [doi]'
p62228
sS'STAT'
p62229
S'MEDLINE'
p62230
sS'DEP'
p62231
S'20120223'
p62232
sS'DA'
p62233
S'20120302'
p62234
sS'AID'
p62235
(lp62236
S'10.1371/journal.pone.0031706 [doi]'
p62237
aS'PONE-D-11-08069 [pii]'
p62238
asS'CRDT'
p62239
(lp62240
S'2012/03/03 06:00'
p62241
asS'DP'
p62242
S'2012'
p62243
sS'OWN'
p62244
S'NLM'
p62245
sS'PT'
p62246
(lp62247
S'Comparative Study'
p62248
aS'Journal Article'
p62249
aS"Research Support, Non-U.S. Gov't"
p62250
asS'LA'
p62251
(lp62252
S'eng'
p62253
asS'FAU'
p62254
(lp62255
S'Henriques, Julie'
p62256
aS'Pujades-Rodriguez, Mar'
p62257
aS'McGuire, Megan'
p62258
aS'Szumilin, Elisabeth'
p62259
aS'Iwaz, Jean'
p62260
aS'Etard, Jean-Francois'
p62261
aS'Ecochard, Rene'
p62262
asS'JT'
p62263
S'PloS one'
p62264
sS'LR'
p62265
S'20150225'
p62266
sS'PG'
p62267
S'e31706'
p62268
sS'TI'
p62269
S'Comparison of methods to correct survival estimates and survival regression analysis on a large HIV African cohort.'
p62270
sS'RN'
p62271
(lp62272
S'0 (Anti-Retroviral Agents)'
p62273
asS'PL'
p62274
S'United States'
p62275
sS'TA'
p62276
S'PLoS One'
p62277
sS'JID'
p62278
S'101285081'
p62279
sS'AB'
p62280
S'OBJECTIVE: The evaluation of HIV treatment programs is generally based on an estimation of survival among patients receiving antiretroviral treatment (ART). In large HIV programs, loss to follow-up (LFU) rates remain high despite active patient tracing, which is likely to bias survival estimates and survival regression analyses. METHODS: We compared uncorrected survival estimates derived from routine program data with estimates obtained by applying six correction methods that use updated outcome data by a field survey targeting LFU patients in a rural HIV program in Malawi. These methods were based on double-sampling and differed according to the weights given to survival estimates in LFU and non-LFU subpopulations. We then proposed a correction of the survival regression analysis. RESULTS: Among 6,727 HIV-infected adults receiving ART, 9% were LFU after one year. The uncorrected survival estimates from routine data were 91% in women and 84% in men. According to increasing sophistication of the correction methods, the corrected survival estimates ranged from 89% to 85% in women and 82% to 77% in men. The estimates derived from uncorrected regression analyses were highly biased for initial tuberculosis mortality ratios (RR; 95% CI: 1.07; 0.76-1.50 vs. 2.06 to 2.28 with different correction weights), Kaposi sarcoma diagnosis (2.11; 1.61-2.76 vs. 2.64 to 3.9), and year of ART initiation (1.40; 1.17-1.66 vs. 1.29 to 1.34). CONCLUSIONS: In HIV programs with high LFU rates, the use of correction methods based on non-exhaustive double-sampling data are necessary to minimise the bias in survival estimates and survival regressions.'
p62281
sS'AD'
p62282
S'Service de Biostatistique, Hospices Civils de Lyon, Lyon, France.'
p62283
sS'IP'
p62284
S'2'
sS'IS'
p62285
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p62286
sS'PMC'
p62287
S'PMC3285641'
p62288
sS'DCOM'
p62289
S'20120827'
p62290
sS'AU'
p62291
(lp62292
S'Henriques J'
p62293
aS'Pujades-Rodriguez M'
p62294
aS'McGuire M'
p62295
aS'Szumilin E'
p62296
aS'Iwaz J'
p62297
aS'Etard JF'
p62298
aS'Ecochard R'
p62299
asS'VI'
p62300
S'7'
sS'MHDA'
p62301
S'2012/08/28 06:00'
p62302
sS'PHST'
p62303
(lp62304
S'2011/05/10 [received]'
p62305
aS'2012/01/17 [accepted]'
p62306
aS'2012/02/23 [epublish]'
p62307
asS'OID'
p62308
(lp62309
S'NLM: PMC3285641'
p62310
asS'MH'
p62311
(lp62312
S'Adolescent'
p62313
aS'Adult'
p62314
aS'Africa'
p62315
aS'Algorithms'
p62316
aS'Anti-Retroviral Agents/*therapeutic use'
p62317
aS'Cohort Studies'
p62318
aS'Female'
p62319
aS'HIV Infections/epidemiology/*mortality/*therapy'
p62320
aS'Humans'
p62321
aS'Malawi'
p62322
aS'Male'
p62323
aS'Middle Aged'
p62324
aS'Models, Statistical'
p62325
aS'Regression Analysis'
p62326
aS'Survival Analysis'
p62327
aS'Time Factors'
p62328
aS'Treatment Outcome'
p62329
asS'EDAT'
p62330
S'2012/03/03 06:00'
p62331
sS'SO'
p62332
S'PLoS One. 2012;7(2):e31706. doi: 10.1371/journal.pone.0031706. Epub 2012 Feb 23.'
p62333
sS'SB'
p62334
S'IM'
p62335
sS'PMID'
p62336
S'22384061'
p62337
sS'PST'
p62338
S'ppublish'
p62339
stRp62340
ag2
(g3
g4
(dp62341
S'LID'
p62342
S'10.1371/journal.pone.0031078 [doi]'
p62343
sS'STAT'
p62344
S'MEDLINE'
p62345
sS'DEP'
p62346
S'20120217'
p62347
sS'DA'
p62348
S'20120224'
p62349
sS'AID'
p62350
(lp62351
S'10.1371/journal.pone.0031078 [doi]'
p62352
aS'PONE-D-11-12108 [pii]'
p62353
asS'CRDT'
p62354
(lp62355
S'2012/02/25 06:00'
p62356
asS'DP'
p62357
S'2012'
p62358
sS'OWN'
p62359
S'NLM'
p62360
sS'PT'
p62361
(lp62362
S'Journal Article'
p62363
aS'Multicenter Study'
p62364
aS"Research Support, Non-U.S. Gov't"
p62365
asS'LA'
p62366
(lp62367
S'eng'
p62368
asS'FAU'
p62369
(lp62370
S'Maman, David'
p62371
aS'Pujades-Rodriguez, Mar'
p62372
aS'Subtil, Fabien'
p62373
aS'Pinoges, Loretxu'
p62374
aS'McGuire, Megan'
p62375
aS'Ecochard, Rene'
p62376
aS'Etard, Jean-Francois'
p62377
asS'JT'
p62378
S'PloS one'
p62379
sS'LR'
p62380
S'20150225'
p62381
sS'PG'
p62382
S'e31078'
p62383
sS'TI'
p62384
S'Gender differences in immune reconstitution: a multicentric cohort analysis in sub-Saharan Africa.'
p62385
sS'PL'
p62386
S'United States'
p62387
sS'TA'
p62388
S'PLoS One'
p62389
sS'JID'
p62390
S'101285081'
p62391
sS'AB'
p62392
S'BACKGROUND: In sub-Saharan Africa, men living with HIV often start ART at more advanced stages of disease and have higher early mortality than women. We investigated gender difference in long-term immune reconstitution. METHODS/PRINCIPAL FINDINGS: Antiretroviral-naive adults who received ART for at least 9 months in four HIV programs in sub-Saharan Africa were included. Multivariate mixed linear models were used to examine gender differences in immune reconstitution on first line ART. A total of 21,708 patients (68% women) contributed to 61,912 person-years of follow-up. At ART start,. Median CD4 at ART were 149 [IQR 85-206] for women and 125 cells/microL [IQR 63-187] for men. After the first year on ART, immune recovery was higher in women than in men, and gender-based differences increased by 20 CD4 cells/microL per year on average (95% CI 16-23; P<0.001). Up to 6 years after ART start, patients with low initial CD4 levels experienced similar gains compared to patients with high initial levels, including those with CD4>250 cells/microL (difference between patients with <50 cells/microL and those with >250 was 284 cells/microL; 95% CI 272-296; LR test for interaction with time p = 0.63). Among patients with initial CD4 count of 150-200 cells/microL, women reached 500 CD4 cells after 2.4 years on ART (95% CI 2.4-2.5) and men after 4.5 years (95% CI 4.1-4.8) of ART use. CONCLUSION: Women achieved better long-term immune response to ART, reaching CD4 level associated with lower risks of AIDS related morbidity and mortality quicker than men.'
p62393
sS'AD'
p62394
S'Epicentre, Medecins Sans Frontieres, Paris, France. david.maman@epicentre.msf.org'
p62395
sS'IP'
p62396
S'2'
sS'IS'
p62397
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p62398
sS'PMC'
p62399
S'PMC3281917'
p62400
sS'DCOM'
p62401
S'20120629'
p62402
sS'AU'
p62403
(lp62404
S'Maman D'
p62405
aS'Pujades-Rodriguez M'
p62406
aS'Subtil F'
p62407
aS'Pinoges L'
p62408
aS'McGuire M'
p62409
aS'Ecochard R'
p62410
aS'Etard JF'
p62411
asS'VI'
p62412
S'7'
sS'MHDA'
p62413
S'2012/06/30 06:00'
p62414
sS'PHST'
p62415
(lp62416
S'2011/06/28 [received]'
p62417
aS'2012/01/02 [accepted]'
p62418
aS'2012/02/17 [epublish]'
p62419
asS'OID'
p62420
(lp62421
S'NLM: PMC3281917'
p62422
asS'MH'
p62423
(lp62424
S'Adult'
p62425
aS'Africa South of the Sahara'
p62426
aS'Antiretroviral Therapy, Highly Active'
p62427
aS'CD4 Lymphocyte Count'
p62428
aS'Cohort Studies'
p62429
aS'Female'
p62430
aS'HIV Infections/drug therapy/*immunology'
p62431
aS'Humans'
p62432
aS'Male'
p62433
aS'Middle Aged'
p62434
aS'*Sex Characteristics'
p62435
aS'Time Factors'
p62436
asS'EDAT'
p62437
S'2012/03/01 06:00'
p62438
sS'SO'
p62439
S'PLoS One. 2012;7(2):e31078. doi: 10.1371/journal.pone.0031078. Epub 2012 Feb 17.'
p62440
sS'SB'
p62441
S'IM'
p62442
sS'PMID'
p62443
S'22363550'
p62444
sS'PST'
p62445
S'ppublish'
p62446
stRp62447
ag2
(g3
g4
(dp62448
S'LID'
p62449
S'10.1007/s10900-012-9548-x [doi]'
p62450
sS'STAT'
p62451
S'MEDLINE'
p62452
sS'JT'
p62453
S'Journal of community health'
p62454
sS'MID'
p62455
(lp62456
S'NIHMS367699'
p62457
asS'DA'
p62458
S'20120907'
p62459
sS'AID'
p62460
(lp62461
S'10.1007/s10900-012-9548-x [doi]'
p62462
asS'CRDT'
p62463
(lp62464
S'2012/02/22 06:00'
p62465
asS'DP'
p62466
S'2012 Oct'
p62467
sS'AD'
p62468
S'Pacific Institute for Research and Evaluation, 1516 E. Franklin St., Suite 200, Chapel Hill, NC 27154, USA. Hallfors@pire.org'
p62469
sS'OWN'
p62470
S'NLM'
p62471
sS'PT'
p62472
(lp62473
S'Journal Article'
p62474
aS'Randomized Controlled Trial'
p62475
aS'Research Support, N.I.H., Extramural'
p62476
asS'LA'
p62477
(lp62478
S'eng'
p62479
asS'FAU'
p62480
(lp62481
S'Hallfors, Denise D'
p62482
aS'Cho, Hyunsan'
p62483
aS'Mbai, Isabella'
p62484
aS'Milimo, Benson'
p62485
aS'Itindi, Janet'
p62486
asS'LR'
p62487
S'20150225'
p62488
sS'PG'
p62489
S'1101-9'
p62490
sS'TI'
p62491
S'Process and outcome evaluation of a community intervention for orphan adolescents in western Kenya.'
p62492
sS'PL'
p62493
S'Netherlands'
p62494
sS'TA'
p62495
S'J Community Health'
p62496
sS'JID'
p62497
S'7600747'
p62498
sS'AB'
p62499
S"We conducted a 2-year pilot randomized controlled trial (N = 105) in a high HIV-prevalence area in rural western Kenya to test whether providing young orphan adolescents with uniforms, school fees, and community visitors improves school retention and reduces HIV risk factors. The trial was a community intervention, limited to one community. In this paper, we examined intervention implementation and its association with outcomes using longitudinal data. We used both quantitative and qualitative methods to evaluate the community-based model for orphan HIV prevention, with recommendations for future studies. Despite promising effects after 1 year, GEE analyses showed null effects after 2 years. Volunteer community visitors, a key element of the intervention, showed little of the expected effect although qualitative reports documented active assistance to prevent orphans' school absence. For future research, we recommend capturing the transition to high school, a larger sample size, and biomarker data to add strength to the research design. We also recommend a school-based intervention approach to improve implementation and reduce infrastructure costs. Finally, we recommend evaluating nurses as agents for improving school attendance and preventing dropout because of their unique ability to address critical biopsychosocial problems."
p62500
sS'GR'
p62501
(lp62502
S'5R34MH79749-3/MH/NIMH NIH HHS/United States'
p62503
aS'R34 MH079749/MH/NIMH NIH HHS/United States'
p62504
aS'R34 MH079749-03/MH/NIMH NIH HHS/United States'
p62505
asS'IP'
p62506
S'5'
sS'IS'
p62507
S'1573-3610 (Electronic) 0094-5145 (Linking)'
p62508
sS'PMC'
p62509
S'PMC3392443'
p62510
sS'DCOM'
p62511
S'20130115'
p62512
sS'AU'
p62513
(lp62514
S'Hallfors DD'
p62515
aS'Cho H'
p62516
aS'Mbai I'
p62517
aS'Milimo B'
p62518
aS'Itindi J'
p62519
asS'VI'
p62520
S'37'
p62521
sS'MHDA'
p62522
S'2013/01/16 06:00'
p62523
sS'OID'
p62524
(lp62525
S'NLM: NIHMS367699'
p62526
aS'NLM: PMC3392443'
p62527
asS'MH'
p62528
(lp62529
S'Adolescent'
p62530
aS'*Child, Orphaned'
p62531
aS'Female'
p62532
aS'Follow-Up Studies'
p62533
aS'HIV Infections/epidemiology/*prevention & control'
p62534
aS'Health Promotion/*methods'
p62535
aS'Humans'
p62536
aS'Kenya/epidemiology'
p62537
aS'Male'
p62538
aS'*Outcome and Process Assessment (Health Care)'
p62539
aS'Pilot Projects'
p62540
aS'Qualitative Research'
p62541
aS'Risk Factors'
p62542
aS'Rural Population'
p62543
aS'Schools/*economics'
p62544
aS'Student Dropouts/statistics & numerical data'
p62545
asS'EDAT'
p62546
S'2012/02/22 06:00'
p62547
sS'SO'
p62548
S'J Community Health. 2012 Oct;37(5):1101-9. doi: 10.1007/s10900-012-9548-x.'
p62549
sS'SB'
p62550
S'IM'
p62551
sS'PMID'
p62552
S'22350730'
p62553
sS'PST'
p62554
S'ppublish'
p62555
stRp62556
ag2
(g3
g4
(dp62557
S'LID'
p62558
S'http://dx.doi.org/10.4314/ajpsy.v15i1.7 [doi]'
p62559
sS'STAT'
p62560
S'MEDLINE'
p62561
sS'AB'
p62562
S"OBJECTIVE: Research on HIV in South Africa has not reflected the impact of the disease on psychiatric patients. The aims of the study were: to compare the HIV prevalence among patient groups in Weskoppies Hospital; to compare psychiatric diagnoses of infected and non-infected patients; to assess intravenous drug use and high-risk sexual behaviour; to establish HIV-syphilis Association; and to investigate the rapid test performance for screening, compared to the confirmatory ELISA test. METHOD: Onehundred-and-ninety-five patients were grouped into four categories according to their duration of admission and gender. HIV rapid testing, HIV ELISA, syphilis-RPR and TPHA testing were performed. RESULTS: The HIV prevalence of 11% in the sample was significantly associated with 'gender-and-duration-of-admission' categories (p = 0.003). No significant association between HIV infection and psychiatric diagnoses or intravenous drug use was found, but a significant association existed between HIV infection and high-risk sexual behaviour (p = 0.002), and between HIV and syphilis (p = 0.012). The HIV rapid screening test had a sensitivity of 91.7% and a specificity of 98.2%. CONCLUSION: The overall HIV prevalence at Weskoppies Hospital remains lower than the national average, but has increased since a previous local study. The rapid test for HIV had a lower sensitivity than was expected, and it is recommended that HIV ELISA testing be performed as a first line test in the setting of hospitalised patients. Due to the high prevalence of HIV and syphilis in the psychiatric population it is recommended that all patients be tested for both of these diseases."
p62563
sS'JID'
p62564
S'101465030'
p62565
sS'AD'
p62566
S'Department of Psychiatry, University of Pretoria, Weskoppies Hospital, South Africa.'
p62567
sS'JT'
p62568
S'African journal of psychiatry'
p62569
sS'IP'
p62570
S'1'
sS'IS'
p62571
S'1994-8220 (Print)'
p62572
sS'DCOM'
p62573
S'20130103'
p62574
sS'DA'
p62575
S'20120220'
p62576
sS'AU'
p62577
(lp62578
S'Henning MP'
p62579
aS'Kruger C'
p62580
aS'Fletcher L'
p62581
asS'AID'
p62582
(lp62583
S'http://dx.doi.org/10.4314/ajpsy.v15i1.7 [doi]'
p62584
asS'CRDT'
p62585
(lp62586
S'2012/02/21 06:00'
p62587
asS'VI'
p62588
S'15'
p62589
sS'DP'
p62590
S'2012 Jan'
p62591
sS'MHDA'
p62592
S'2013/01/04 06:00'
p62593
sS'PHST'
p62594
(lp62595
S'2010/11/01 [received]'
p62596
aS'2011/03/25 [accepted]'
p62597
asS'OWN'
p62598
S'NLM'
p62599
sS'PT'
p62600
(lp62601
S'Journal Article'
p62602
aS"Research Support, Non-U.S. Gov't"
p62603
asS'LA'
p62604
(lp62605
S'eng'
p62606
asS'MH'
p62607
(lp62608
S'Adult'
p62609
aS'Comorbidity'
p62610
aS'Enzyme-Linked Immunosorbent Assay/methods'
p62611
aS'Female'
p62612
aS'HIV Seropositivity/*diagnosis/*epidemiology/psychology'
p62613
aS'Humans'
p62614
aS'Inpatients/*psychology/statistics & numerical data'
p62615
aS'Male'
p62616
aS'Mental Disorders/*epidemiology/psychology'
p62617
aS'Prevalence'
p62618
aS'Risk-Taking'
p62619
aS'Sensitivity and Specificity'
p62620
aS'Sex Distribution'
p62621
aS'Sexual Behavior/psychology/statistics & numerical data'
p62622
aS'South Africa/epidemiology'
p62623
aS'Substance Abuse, Intravenous/diagnosis/epidemiology/psychology'
p62624
aS'Syphilis/diagnosis/epidemiology/psychology'
p62625
aS'Time'
p62626
asS'FAU'
p62627
(lp62628
S'Henning, M P'
p62629
aS'Kruger, C'
p62630
aS'Fletcher, L'
p62631
asS'EDAT'
p62632
S'2012/02/22 06:00'
p62633
sS'PST'
p62634
S'ppublish'
p62635
sS'SO'
p62636
S'Afr J Psychiatry (Johannesbg). 2012 Jan;15(1):47-53. doi: http://dx.doi.org/10.4314/ajpsy.v15i1.7.'
p62637
sS'PG'
p62638
S'47-53'
p62639
sS'TI'
p62640
S'HIV sero-positivity in recently admitted and long-term psychiatric in-patients: prevalence and diagnostic profile.'
p62641
sS'SB'
p62642
S'IM'
p62643
sS'PMID'
p62644
S'22344763'
p62645
sS'PL'
p62646
S'South Africa'
p62647
sS'TA'
p62648
S'Afr J Psychiatry (Johannesbg)'
p62649
stRp62650
ag2
(g3
g4
(dp62651
S'LID'
p62652
S'10.1097/QAD.0b013e32835221eb [doi]'
p62653
sS'STAT'
p62654
S'MEDLINE'
p62655
sS'JT'
p62656
S'AIDS (London, England)'
p62657
sS'MID'
p62658
(lp62659
S'NIHMS395916'
p62660
asS'DA'
p62661
S'20120517'
p62662
sS'AID'
p62663
(lp62664
S'10.1097/QAD.0b013e32835221eb [doi]'
p62665
asS'CRDT'
p62666
(lp62667
S'2012/02/21 06:00'
p62668
asS'DP'
p62669
S'2012 Jun 1'
p62670
sS'AD'
p62671
S'Division of Infectious Disease, Department of Medicine, Massachusetts General Hospital, and Harvard Medical School, Boston, MA 02114, USA.'
p62672
sS'OWN'
p62673
S'NLM'
p62674
sS'PT'
p62675
(lp62676
S'Journal Article'
p62677
aS'Research Support, N.I.H., Extramural'
p62678
asS'LA'
p62679
(lp62680
S'eng'
p62681
asS'FAU'
p62682
(lp62683
S'Lorenzana, Sarah B'
p62684
aS'Hughes, Michael D'
p62685
aS'Grinsztejn, Beatriz'
p62686
aS'Collier, Ann C'
p62687
aS'Luz, Paula Mendes'
p62688
aS'Freedberg, Kenneth A'
p62689
aS'Wood, Robin'
p62690
aS'Levison, Julie H'
p62691
aS'Mugyenyi, Peter N'
p62692
aS'Salata, Robert'
p62693
aS'Wallis, Carole L'
p62694
aS'Weinstein, Milton C'
p62695
aS'Schooley, Robert T'
p62696
aS'Walensky, Rochelle P'
p62697
asS'LR'
p62698
S'20160819'
p62699
sS'PG'
p62700
S'1083-93'
p62701
sS'TI'
p62702
S'Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial.'
p62703
sS'RN'
p62704
(lp62705
S'0 (Anti-HIV Agents)'
p62706
asS'PL'
p62707
S'England'
p62708
sS'TA'
p62709
S'AIDS'
p62710
sS'JID'
p62711
S'8710219'
p62712
sS'AB'
p62713
S'OBJECTIVES: To project the clinical and economic outcomes of a genotype assay for selection of third-line antiretroviral therapy (ART) in resource-limited settings, as per the planned international A5288 trial (MULTI-OCTAVE). METHODS: We used the Cost-effectiveness of Preventing AIDS Complications (CEPAC)-International Model to compare three strategies for patients who have failed second-line ART in South Africa: sustained second-line: no genotype assay, all patients remain on second-line ART; A5288: genotype to determine the resistance profile and assign an appropriate regimen; or population-based third-line: no genotype, all patients switch to a potent third-line regimen. Model inputs are from published data in South Africa. Resistance profiles, ART regimens, and efficacy data were those used for trial planning. RESULTS: Projected life expectancy for sustained second-line, A5288, and population-based third-line are 61.1, 103.8, and 104.2 months. Compared to sustained second-line ($12 ,460), per person lifetime costs increase for the A5288 ($39, 250) and population-based ($44, 120) strategies. The incremental cost-effectiveness ratio of A5288, compared to sustained second-line, is $7500/year of life saved (YLS), and for population-based third-line, compared to A5288, is $154 ,500/YLS. In the A5288 strategy, very late presentation to care, coupled with lengthy delays to obtain the genotype, dramatically reduces 5-year survival, making the population-based third-line strategy more attractive. CONCLUSIONS: We project that, whereas the public health approach to third-line therapy is unaffordable, genotype assays and third-line ART in resource-limited settings will increase survival and be cost-effective compared to the population-based approach, supporting the value of an efficacy study.'
p62714
sS'GR'
p62715
(lp62716
S'AI069434/AI/NIAID NIH HHS/United States'
p62717
aS'K24 AI062476/AI/NIAID NIH HHS/United States'
p62718
aS'K24 AI062476/AI/NIAID NIH HHS/United States'
p62719
aS'P30 AI060354/AI/NIAID NIH HHS/United States'
p62720
aS'P30 AI060354/AI/NIAID NIH HHS/United States'
p62721
aS'R01 AI058736/AI/NIAID NIH HHS/United States'
p62722
aS'R01 AI058736/AI/NIAID NIH HHS/United States'
p62723
aS'R01 AI093269/AI/NIAID NIH HHS/United States'
p62724
aS'U01 AI068634/AI/NIAID NIH HHS/United States'
p62725
aS'U01 AI068636/AI/NIAID NIH HHS/United States'
p62726
aS'U01 AI068636/AI/NIAID NIH HHS/United States'
p62727
aS'U01 AI069434/AI/NIAID NIH HHS/United States'
p62728
asS'IP'
p62729
S'9'
sS'IS'
p62730
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p62731
sS'PMC'
p62732
S'PMC3424271'
p62733
sS'DCOM'
p62734
S'20120905'
p62735
sS'AU'
p62736
(lp62737
S'Lorenzana SB'
p62738
aS'Hughes MD'
p62739
aS'Grinsztejn B'
p62740
aS'Collier AC'
p62741
aS'Luz PM'
p62742
aS'Freedberg KA'
p62743
aS'Wood R'
p62744
aS'Levison JH'
p62745
aS'Mugyenyi PN'
p62746
aS'Salata R'
p62747
aS'Wallis CL'
p62748
aS'Weinstein MC'
p62749
aS'Schooley RT'
p62750
aS'Walensky RP'
p62751
asS'VI'
p62752
S'26'
p62753
sS'MHDA'
p62754
S'2012/09/06 06:00'
p62755
sS'OID'
p62756
(lp62757
S'NLM: NIHMS395916'
p62758
aS'NLM: PMC3424271'
p62759
asS'MH'
p62760
(lp62761
S'Anti-HIV Agents/*economics/therapeutic use'
p62762
aS'Clinical Trials as Topic/*economics'
p62763
aS'Cost-Benefit Analysis'
p62764
aS'Female'
p62765
aS'Genotype'
p62766
aS'HIV Infections/drug therapy/*economics'
p62767
aS'Humans'
p62768
aS'Life Expectancy'
p62769
aS'Male'
p62770
aS'Middle Aged'
p62771
aS'Models, Biological'
p62772
aS'South Africa'
p62773
aS'Treatment Outcome'
p62774
asS'EDAT'
p62775
S'2012/02/22 06:00'
p62776
sS'SO'
p62777
S'AIDS. 2012 Jun 1;26(9):1083-93. doi: 10.1097/QAD.0b013e32835221eb.'
p62778
sS'SB'
p62779
S'IM X'
p62780
sS'PMID'
p62781
S'22343964'
p62782
sS'PST'
p62783
S'ppublish'
p62784
stRp62785
ag2
(g3
g4
(dp62786
S'LID'
p62787
S'10.1186/1758-2652-15-7 [doi]'
p62788
sS'STAT'
p62789
S'MEDLINE'
p62790
sS'DEP'
p62791
S'20120217'
p62792
sS'DA'
p62793
S'20120309'
p62794
sS'AID'
p62795
(lp62796
S'1758-2652-15-7 [pii]'
p62797
aS'10.1186/1758-2652-15-7 [doi]'
p62798
asS'CRDT'
p62799
(lp62800
S'2012/02/21 06:00'
p62801
asS'DP'
p62802
S'2012'
p62803
sS'AD'
p62804
S'Indiana University, School of Medicine, 1001 West 10th Street, OPW-M200, Indianapolis, IN 46202, USA. pbraitstein@yahoo.com'
p62805
sS'OWN'
p62806
S'NLM'
p62807
sS'PT'
p62808
(lp62809
S'Journal Article'
p62810
aS"Research Support, Non-U.S. Gov't"
p62811
aS"Research Support, U.S. Gov't, Non-P.H.S."
p62812
asS'LA'
p62813
(lp62814
S'eng'
p62815
asS'FAU'
p62816
(lp62817
S'Braitstein, Paula'
p62818
aS'Siika, Abraham'
p62819
aS'Hogan, Joseph'
p62820
aS'Kosgei, Rose'
p62821
aS'Sang, Edwin'
p62822
aS'Sidle, John'
p62823
aS'Wools-Kaloustian, Kara'
p62824
aS'Keter, Alfred'
p62825
aS'Mamlin, Joseph'
p62826
aS'Kimaiyo, Sylvester'
p62827
asS'JT'
p62828
S'Journal of the International AIDS Society'
p62829
sS'LR'
p62830
S'20160206'
p62831
sS'PG'
p62832
S'7'
sS'TI'
p62833
S'A clinician-nurse model to reduce early mortality and increase clinic retention among high-risk HIV-infected patients initiating combination antiretroviral treatment.'
p62834
sS'RN'
p62835
(lp62836
S'0 (Anti-HIV Agents)'
p62837
asS'PL'
p62838
S'England'
p62839
sS'TA'
p62840
S'J Int AIDS Soc'
p62841
sS'JID'
p62842
S'101478566'
p62843
sS'AB'
p62844
S'BACKGROUND: In resource-poor settings, mortality is at its highest during the first 3 months after combination antiretroviral treatment (cART) initiation. A clear predictor of mortality during this period is having a low CD4 count at the time of treatment initiation. The objective of this study was to evaluate the effect on survival and clinic retention of a nurse-based rapid assessment clinic for high-risk individuals initiating cART in a resource-constrained setting. METHODS: The USAID-AMPATH Partnership has enrolled more than 140,000 patients at 25 clinics throughout western Kenya. High Risk Express Care (HREC) provides weekly or bi-weekly rapid contacts with nurses for individuals initiating cART with CD4 counts of </=100 cells/mm3. All HIV-infected individuals aged 14 years or older initiating cART with CD4 counts of </=100 cells/mm3 were eligible for enrolment into HREC and for analysis. Adjusted hazard ratios (AHRs) control for potential confounding using propensity score methods. RESULTS: Between March 2007 and March 2009, 4,958 patients initiated cART with CD4 counts of </=100 cells/mm3. After adjusting for age, sex, CD4 count, use of cotrimoxazole, treatment for tuberculosis, travel time to clinic and type of clinic, individuals in HREC had reduced mortality (AHR: 0.59; 95% confidence interval: 0.45-0.77), and reduced loss to follow up (AHR: 0.62; 95% CI: 0.55-0.70) compared with individuals in routine care. Overall, patients in HREC were much more likely to be alive and in care after a median of nearly 11 months of follow up (AHR: 0.62; 95% CI: 0.57-0.67). CONCLUSIONS: Frequent monitoring by dedicated nurses in the early months of cART can significantly reduce mortality and loss to follow up among high-risk patients initiating treatment in resource-constrained settings.'
p62845
sS'GR'
p62846
(lp62847
S'P30 AI042853/AI/NIAID NIH HHS/United States'
p62848
asS'IP'
p62849
S'1'
sS'IS'
p62850
S'1758-2652 (Electronic) 1758-2652 (Linking)'
p62851
sS'PMC'
p62852
S'PMC3297518'
p62853
sS'DCOM'
p62854
S'20120724'
p62855
sS'AU'
p62856
(lp62857
S'Braitstein P'
p62858
aS'Siika A'
p62859
aS'Hogan J'
p62860
aS'Kosgei R'
p62861
aS'Sang E'
p62862
aS'Sidle J'
p62863
aS'Wools-Kaloustian K'
p62864
aS'Keter A'
p62865
aS'Mamlin J'
p62866
aS'Kimaiyo S'
p62867
asS'VI'
p62868
S'15'
p62869
sS'MHDA'
p62870
S'2012/07/25 06:00'
p62871
sS'PHST'
p62872
(lp62873
S'2011/09/19 [received]'
p62874
aS'2012/02/17 [accepted]'
p62875
aS'2012/02/17 [aheadofprint]'
p62876
asS'OID'
p62877
(lp62878
S'NLM: PMC3297518'
p62879
asS'MH'
p62880
(lp62881
S'Adolescent'
p62882
aS'Adult'
p62883
aS'Ambulatory Care'
p62884
aS'Ambulatory Care Facilities'
p62885
aS'Anti-HIV Agents/therapeutic use'
p62886
aS'CD4 Lymphocyte Count'
p62887
aS'Female'
p62888
aS'Follow-Up Studies'
p62889
aS'HIV Infections/*drug therapy/immunology/*mortality/nursing'
p62890
aS'House Calls'
p62891
aS'Humans'
p62892
aS'Kenya'
p62893
aS'Male'
p62894
aS'Middle Aged'
p62895
aS'*Models, Nursing'
p62896
aS'Nurse Clinicians'
p62897
aS'Patient Compliance'
p62898
aS'Prospective Studies'
p62899
aS'Retrospective Studies'
p62900
aS'Young Adult'
p62901
asS'EDAT'
p62902
S'2012/02/22 06:00'
p62903
sS'SO'
p62904
S'J Int AIDS Soc. 2012 Feb 17;15(1):7. doi: 10.1186/1758-2652-15-7.'
p62905
sS'SB'
p62906
S'IM X'
p62907
sS'PMID'
p62908
S'22340703'
p62909
sS'PST'
p62910
S'epublish'
p62911
stRp62912
ag2
(g3
g4
(dp62913
S'LID'
p62914
S'10.1097/QAI.0b013e31824276e9 [doi]'
p62915
sS'STAT'
p62916
S'MEDLINE'
p62917
sS'AB'
p62918
S'BACKGROUND: HIV RNA monitoring is not available in most antiretroviral treatment (ART) programs in sub-Saharan Africa; switch to second-line therapy is mostly guided by clinical/immunological criteria. This may lead to unnecessary disease progression and drug resistance accumulation. We investigated the prognostic value of virological and immunological status 6 months after ART initiation with respect to death, loss to follow-up, and treatment switch. METHODS: We considered treatment-naive HIV-1-infected patients, starting ART with available 6-month visit and subsequent follow-up, enrolled in a prospective cohort comprising 5 ART sites in 3 sub-Saharan countries. Outcome measures included the time from 6-month visit to death for all causes, loss to follow-up, and switch to second line. RESULTS: Of 2539 patients, 62% were females, their median pre-ART CD4 count was 215 cells per microliter, median HIV RNA 4.6 Log10 copies per milliliter, 30% were on WHO stage 3/4. At 6 months, 85% had HIV RNA <1000 copies per milliliter. During 3112 person-years follow-up after the 6-month visit, 91 patients died. Death was predicted by 6-month HIV RNA >/=10,000 copies per milliliter, adherence, and 6-month CD4 <200 cells per microliter. The 2-year estimated probability of surviving ranged from 0.69 (with 6-month HIV RNA >/=10,000 and CD4 <200) to 0.95 (with HIV RNA <1000 and CD4 >/=200). Loss to follow-up (1.95 per 100 person-years follow-up) was predicted by the 6-month HIV RNA >10,000 copies per milliliter and adherence but not by CD4. Switch to second line (6.94 per 100 person-years follow-up) was predicted by 6-month HIV RNA and CD4. CONCLUSIONS: In patients starting ART in sub-Saharan Africa, 6-month HIV RNA independently predicts subsequent survival, retention to care, and switch to second-line therapy. This measure warrants further evaluation as specific time point monitoring option.'
p62919
sS'JID'
p62920
S'100892005'
p62921
sS'AD'
p62922
S'Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy. deluca.andrea@fastwebnet.it'
p62923
sS'JT'
p62924
S'Journal of acquired immune deficiency syndromes (1999)'
p62925
sS'IP'
p62926
S'3'
sS'IS'
p62927
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p62928
sS'DCOM'
p62929
S'20120613'
p62930
sS'DA'
p62931
S'20120213'
p62932
sS'AU'
p62933
(lp62934
S'De Luca A'
p62935
aS'Marazzi MC'
p62936
aS'Mancinelli S'
p62937
aS'Ceffa S'
p62938
aS'Altan AM'
p62939
aS'Buonomo E'
p62940
aS'Prosperi MC'
p62941
aS'Pedruzzi B'
p62942
aS'Noorjehan AM'
p62943
aS'Scarcella P'
p62944
aS'Liotta G'
p62945
aS'Palombi L'
p62946
asS'AID'
p62947
(lp62948
S'10.1097/QAI.0b013e31824276e9 [doi]'
p62949
aS'00126334-201203010-00003 [pii]'
p62950
asS'CRDT'
p62951
(lp62952
S'2012/02/14 06:00'
p62953
asS'VI'
p62954
S'59'
p62955
sS'PMID'
p62956
S'22327246'
p62957
sS'DP'
p62958
S'2012 Mar 1'
p62959
sS'MHDA'
p62960
S'2012/06/14 06:00'
p62961
sS'OWN'
p62962
S'NLM'
p62963
sS'PT'
p62964
(lp62965
S'Journal Article'
p62966
aS'Multicenter Study'
p62967
aS"Research Support, Non-U.S. Gov't"
p62968
asS'LA'
p62969
(lp62970
S'eng'
p62971
asS'MH'
p62972
(lp62973
S'Adult'
p62974
aS'Africa South of the Sahara/epidemiology'
p62975
aS'Anti-HIV Agents/*administration & dosage'
p62976
aS'CD4 Lymphocyte Count'
p62977
aS'Cohort Studies'
p62978
aS'Drug Administration Schedule'
p62979
aS'Female'
p62980
aS'HIV Infections/*drug therapy/*immunology/mortality/virology'
p62981
aS'HIV-1/genetics/*immunology'
p62982
aS'Humans'
p62983
aS'Kaplan-Meier Estimate'
p62984
aS'Male'
p62985
aS'Patient Compliance'
p62986
aS'Predictive Value of Tests'
p62987
aS'Prospective Studies'
p62988
aS'RNA, Viral/chemistry/genetics'
p62989
aS'Viral Load'
p62990
asS'FAU'
p62991
(lp62992
S'De Luca, Andrea'
p62993
aS'Marazzi, Maria Cristina'
p62994
aS'Mancinelli, Sandro'
p62995
aS'Ceffa, Susanna'
p62996
aS'Altan, Anna Maria Doro'
p62997
aS'Buonomo, Ersilia'
p62998
aS'Prosperi, Mattia Carlo Felice'
p62999
aS'Pedruzzi, Barbara'
p63000
aS'Noorjehan, Abdul Majid'
p63001
aS'Scarcella, Paola'
p63002
aS'Liotta, Giuseppe'
p63003
aS'Palombi, Leonardo'
p63004
asS'EDAT'
p63005
S'2012/02/14 06:00'
p63006
sS'PST'
p63007
S'ppublish'
p63008
sS'SO'
p63009
S'J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):236-44. doi: 10.1097/QAI.0b013e31824276e9.'
p63010
sS'PG'
p63011
S'236-44'
p63012
sS'TI'
p63013
S'Prognostic value of virological and immunological responses after 6 months of antiretroviral treatment in adults with HIV-1 infection in sub-Saharan Africa.'
p63014
sS'SB'
p63015
S'IM X'
p63016
sS'RN'
p63017
(lp63018
S'0 (Anti-HIV Agents)'
p63019
aS'0 (RNA, Viral)'
p63020
asS'PL'
p63021
S'United States'
p63022
sS'TA'
p63023
S'J Acquir Immune Defic Syndr'
p63024
stRp63025
ag2
(g3
g4
(dp63026
S'LID'
p63027
S'10.1093/aje/kwr444 [doi]'
p63028
sS'STAT'
p63029
S'MEDLINE'
p63030
sS'DEP'
p63031
S'20120203'
p63032
sS'DA'
p63033
S'20120517'
p63034
sS'AID'
p63035
(lp63036
S'kwr444 [pii]'
p63037
aS'10.1093/aje/kwr444 [doi]'
p63038
asS'CRDT'
p63039
(lp63040
S'2012/02/07 06:00'
p63041
asS'DP'
p63042
S'2012 May 15'
p63043
sS'AD'
p63044
S'Division of HIV/AIDS and Infectious Diseases, San Francisco General Hospital, Department of Medicine, School of Medicine, University of California, San Francisco, 995 Potrero Avenue, Building 80, Box 0874, San Francisco, CA 94110, USA. genge@php.ucsf.edu'
p63045
sS'OWN'
p63046
S'NLM'
p63047
sS'PT'
p63048
(lp63049
S'Journal Article'
p63050
aS'Research Support, N.I.H., Extramural'
p63051
aS"Research Support, U.S. Gov't, Non-P.H.S."
p63052
asS'LA'
p63053
(lp63054
S'eng'
p63055
asS'FAU'
p63056
(lp63057
S'Geng, Elvin H'
p63058
aS'Glidden, David V'
p63059
aS'Bangsberg, David R'
p63060
aS'Bwana, Mwebesa Bosco'
p63061
aS'Musinguzi, Nicholas'
p63062
aS'Nash, Denis'
p63063
aS'Metcalfe, John Z'
p63064
aS'Yiannoutsos, Constantin T'
p63065
aS'Martin, Jeffrey N'
p63066
aS'Petersen, Maya L'
p63067
asS'JT'
p63068
S'American journal of epidemiology'
p63069
sS'LR'
p63070
S'20160701'
p63071
sS'PG'
p63072
S'1080-7'
p63073
sS'TI'
p63074
S'A causal framework for understanding the effect of losses to follow-up on epidemiologic analyses in clinic-based cohorts: the case of HIV-infected patients on antiretroviral therapy in Africa.'
p63075
sS'RN'
p63076
(lp63077
S'0 (Anti-HIV Agents)'
p63078
asS'PL'
p63079
S'United States'
p63080
sS'TA'
p63081
S'Am J Epidemiol'
p63082
sS'JID'
p63083
S'7910653'
p63084
sS'AB'
p63085
S'Although clinic-based cohorts are most representative of the "real world," they are susceptible to loss to follow-up. Strategies for managing the impact of loss to follow-up are therefore needed to maximize the value of studies conducted in these cohorts. The authors evaluated adult patients starting antiretroviral therapy at an HIV/AIDS clinic in Uganda, where 29% of patients were lost to follow-up after 2 years (January 1, 2004-September 30, 2007). Unweighted, inverse probability of censoring weighted (IPCW), and sampling-based approaches (using supplemental data from a sample of lost patients subsequently tracked in the community) were used to identify the predictive value of sex on mortality. Directed acyclic graphs (DAGs) were used to explore the structural basis for bias in each approach. Among 3,628 patients, unweighted and IPCW analyses found men to have higher mortality than women, whereas the sampling-based approach did not. DAGs encoding knowledge about the data-generating process, including the fact that death is a cause of being classified as lost to follow-up in this setting, revealed "collider" bias in the unweighted and IPCW approaches. In a clinic-based cohort in Africa, unweighted and IPCW approaches-which rely on the "missing at random" assumption-yielded biased estimates. A sampling-based approach can in general strengthen epidemiologic analyses conducted in many clinic-based cohorts, including those examining other diseases.'
p63086
sS'GR'
p63087
(lp63088
S'K23 AI084544/AI/NIAID NIH HHS/United States'
p63089
aS'K23 AI084544/AI/NIAID NIH HHS/United States'
p63090
aS'K23 AI094251/AI/NIAID NIH HHS/United States'
p63091
aS'K24 MH087227/MH/NIMH NIH HHS/United States'
p63092
aS'P30 AI027763/AI/NIAID NIH HHS/United States'
p63093
aS'P30 AI027763/AI/NIAID NIH HHS/United States'
p63094
aS'R01 MH054907/MH/NIMH NIH HHS/United States'
p63095
aS'U01 AI069911/AI/NIAID NIH HHS/United States'
p63096
asS'IP'
p63097
S'10'
p63098
sS'IS'
p63099
S'1476-6256 (Electronic) 0002-9262 (Linking)'
p63100
sS'PMC'
p63101
S'PMC3353135'
p63102
sS'DCOM'
p63103
S'20120727'
p63104
sS'AU'
p63105
(lp63106
S'Geng EH'
p63107
aS'Glidden DV'
p63108
aS'Bangsberg DR'
p63109
aS'Bwana MB'
p63110
aS'Musinguzi N'
p63111
aS'Nash D'
p63112
aS'Metcalfe JZ'
p63113
aS'Yiannoutsos CT'
p63114
aS'Martin JN'
p63115
aS'Petersen ML'
p63116
asS'VI'
p63117
S'175'
p63118
sS'MHDA'
p63119
S'2012/07/28 06:00'
p63120
sS'PHST'
p63121
(lp63122
S'2012/02/03 [aheadofprint]'
p63123
asS'OID'
p63124
(lp63125
S'NLM: PMC3353135'
p63126
asS'MH'
p63127
(lp63128
S'Adult'
p63129
aS'Ambulatory Care Facilities'
p63130
aS'Anti-HIV Agents/*therapeutic use'
p63131
aS'*Bias (Epidemiology)'
p63132
aS'Causality'
p63133
aS'*Cohort Studies'
p63134
aS'Data Interpretation, Statistical'
p63135
aS'Female'
p63136
aS'HIV Infections/*drug therapy/mortality'
p63137
aS'Humans'
p63138
aS'Logistic Models'
p63139
aS'*Lost to Follow-Up'
p63140
aS'Male'
p63141
aS'Multivariate Analysis'
p63142
aS'Patient Selection'
p63143
aS'Selection Bias'
p63144
aS'Sex Factors'
p63145
aS'Uganda'
p63146
asS'EDAT'
p63147
S'2012/02/07 06:00'
p63148
sS'SO'
p63149
S'Am J Epidemiol. 2012 May 15;175(10):1080-7. doi: 10.1093/aje/kwr444. Epub 2012 Feb 3.'
p63150
sS'SB'
p63151
S'IM'
p63152
sS'PMID'
p63153
S'22306557'
p63154
sS'PST'
p63155
S'ppublish'
p63156
stRp63157
ag2
(g3
g4
(dp63158
S'LID'
p63159
S'10.1111/j.1468-1293.2011.00980.x [doi]'
p63160
sS'STAT'
p63161
S'MEDLINE'
p63162
sS'DEP'
p63163
S'20120202'
p63164
sS'CI'
p63165
(lp63166
S'(c) 2012 British HIV Association.'
p63167
asS'DA'
p63168
S'20120601'
p63169
sS'AID'
p63170
(lp63171
S'10.1111/j.1468-1293.2011.00980.x [doi]'
p63172
asS'CRDT'
p63173
(lp63174
S'2012/02/03 06:00'
p63175
asS'DP'
p63176
S'2012 Jul'
p63177
sS'OWN'
p63178
S'NLM'
p63179
sS'PT'
p63180
(lp63181
S'Journal Article'
p63182
aS"Research Support, Non-U.S. Gov't"
p63183
asS'LA'
p63184
(lp63185
S'eng'
p63186
asS'FAU'
p63187
(lp63188
S'Hermans, S M'
p63189
aS'van Leth, F'
p63190
aS'Manabe, Y C'
p63191
aS'Hoepelman, A I M'
p63192
aS'Lange, J M A'
p63193
aS'Kambugu, A'
p63194
asS'JT'
p63195
S'HIV medicine'
p63196
sS'PG'
p63197
S'337-44'
p63198
sS'TI'
p63199
S'Earlier initiation of antiretroviral therapy, increased tuberculosis case finding and reduced mortality in a setting of improved HIV care: a retrospective cohort study.'
p63200
sS'RN'
p63201
(lp63202
S'0 (Anti-HIV Agents)'
p63203
asS'PL'
p63204
S'England'
p63205
sS'TA'
p63206
S'HIV Med'
p63207
sS'JID'
p63208
S'100897392'
p63209
sS'AB'
p63210
S'OBJECTIVES: High early mortality after antiretroviral therapy (ART) initiation in resource-limited settings is associated with low baseline CD4 cell counts and a high burden of opportunistic infections. Our large urban HIV clinic in Uganda has made concerted efforts to initiate ART at higher CD4 cell counts and to improve diagnosis and care of patients coinfected with tuberculosis (TB). We sought to determine associated treatment outcomes. METHODS: Routinely collected data for all patients who initiated ART from 2005 to 2009 were analysed. Median baseline CD4 cell counts by year of ART initiation were compared using the Cuzick test for trend. Mortality and TB incidence rates in the first year of ART were computed. Hazard ratios (HRs) were calculated using multivariable Cox proportional hazards models. RESULTS: First-line ART was initiated in 7659 patients; 64% were women, and the mean age was 37 years (standard deviation 9 years). Median baseline CD4 counts increased from 2005 to 2009 [82 cells/muL (interquartile range (IQR) 24, 153) to 148 cells/muL (IQR 61, 197), respectively; P<0.001]. The mortality rate fell from 6.5/100 person-years at risk (PYAR) [95% confidence interval (CI) 5.5-7.6 PYAR] to 3.6/100 PYAR (95% CI 2.2-5.8 PYAR). TB incidence rates increased from 8.2/100 PYAR (95% CI 7.1-9.5 PYAR) to 15.6/100 PYAR (95% CI 12.4-19.7 PYAR). A later year of ART initiation was independently associated with decreased mortality (HR 0.91; 95% CI 0.83-1.00; P=0.04). CONCLUSIONS: Baseline CD4 cell counts have increased over time and are associated with decreased mortality. Additional reductions in mortality might be a result of a better standard of care and increased TB case finding. Further efforts to initiate ART earlier should be prioritized even in a setting of capped or reduced funding for ART programmes.'
p63211
sS'AD'
p63212
S'Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda. shermans@idi.co.ug'
p63213
sS'IP'
p63214
S'6'
sS'IS'
p63215
S'1468-1293 (Electronic) 1464-2662 (Linking)'
p63216
sS'DCOM'
p63217
S'20120821'
p63218
sS'AU'
p63219
(lp63220
S'Hermans SM'
p63221
aS'van Leth F'
p63222
aS'Manabe YC'
p63223
aS'Hoepelman AI'
p63224
aS'Lange JM'
p63225
aS'Kambugu A'
p63226
asS'VI'
p63227
S'13'
p63228
sS'MHDA'
p63229
S'2012/08/22 06:00'
p63230
sS'PHST'
p63231
(lp63232
S'2011/10/25 [accepted]'
p63233
aS'2012/02/02 [aheadofprint]'
p63234
asS'MH'
p63235
(lp63236
S'AIDS-Related Opportunistic Infections/drug therapy/*epidemiology/immunology'
p63237
aS'Acquired Immunodeficiency Syndrome/*drug therapy/*epidemiology/immunology'
p63238
aS'Adult'
p63239
aS'Anti-HIV Agents/*therapeutic use'
p63240
aS'CD4 Lymphocyte Count'
p63241
aS'Cohort Studies'
p63242
aS'Female'
p63243
aS'Humans'
p63244
aS'Incidence'
p63245
aS'Male'
p63246
aS'Retrospective Studies'
p63247
aS'Tuberculosis/drug therapy/*epidemiology/immunology'
p63248
aS'Uganda/epidemiology'
p63249
aS'Urban Population/statistics & numerical data'
p63250
asS'EDAT'
p63251
S'2012/02/03 06:00'
p63252
sS'SO'
p63253
S'HIV Med. 2012 Jul;13(6):337-44. doi: 10.1111/j.1468-1293.2011.00980.x. Epub 2012 Feb 2.'
p63254
sS'SB'
p63255
S'IM'
p63256
sS'PMID'
p63257
S'22296211'
p63258
sS'PST'
p63259
S'ppublish'
p63260
stRp63261
ag2
(g3
g4
(dp63262
S'LID'
p63263
S'10.3851/IMP1985 [doi]'
p63264
sS'STAT'
p63265
S'MEDLINE'
p63266
sS'DEP'
p63267
S'20111118'
p63268
sS'MID'
p63269
(lp63270
S'NIHMS451046'
p63271
asS'DA'
p63272
S'20120314'
p63273
sS'AID'
p63274
(lp63275
S'10.3851/IMP1985 [doi]'
p63276
asS'CRDT'
p63277
(lp63278
S'2012/02/02 06:00'
p63279
asS'DP'
p63280
S'2012'
p63281
sS'GR'
p63282
(lp63283
S'K01 AI083097/AI/NIAID NIH HHS/United States'
p63284
aS'U19 AI53217-01/AI/NIAID NIH HHS/United States'
p63285
asS'OWN'
p63286
S'NLM'
p63287
sS'PT'
p63288
(lp63289
S'Journal Article'
p63290
aS'Research Support, N.I.H., Extramural'
p63291
asS'LA'
p63292
(lp63293
S'eng'
p63294
asS'FAU'
p63295
(lp63296
S'Wallis, Carole L'
p63297
aS'Papathanasopolous, Maria A'
p63298
aS'Fox, Matthew'
p63299
aS'Conradie, Francesca'
p63300
aS'Ive, Prudence'
p63301
aS'Orrell, Catherine'
p63302
aS'Zeinecker, Jennifer'
p63303
aS'Sanne, Ian'
p63304
aS'Wood, Robin'
p63305
aS'McIntyre, James'
p63306
aS'Stevens, Wendy'
p63307
asS'JT'
p63308
S'Antiviral therapy'
p63309
sS'LR'
p63310
S'20150128'
p63311
sS'PG'
p63312
S'313-20'
p63313
sS'TI'
p63314
S'Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy.'
p63315
sS'RN'
p63316
(lp63317
S'0 (Anti-HIV Agents)'
p63318
aS'0 (Benzoxazines)'
p63319
aS'0 (RNA, Viral)'
p63320
aS'0 (Reverse Transcriptase Inhibitors)'
p63321
aS'2T8Q726O95 (Lamivudine)'
p63322
aS'BO9LE4QFZF (Stavudine)'
p63323
aS'JE6H2O27P8 (efavirenz)'
p63324
asS'PL'
p63325
S'England'
p63326
sS'TA'
p63327
S'Antivir Ther'
p63328
sS'FIR'
p63329
(lp63330
S'Badal-Faesen, Sharlaa'
p63331
aS'Botile, Mildred'
p63332
aS'Choonilal, Nastassja'
p63333
aS'Gelant, Jennipher'
p63334
aS'Grab, Janet'
p63335
aS'Graham, Veronica'
p63336
aS'Hafejee, Najma'
p63337
aS'Hamber, Lynda'
p63338
aS'Harduth, Sindesh'
p63339
aS'Hendricks, Johean'
p63340
aS'Herman, Colleen'
p63341
aS'Hero, Mellissa'
p63342
aS'Kaplan, Richard'
p63343
aS'Killa, Nicola'
p63344
aS'Klemp, Daniella'
p63345
aS'Laher, Faisel'
p63346
aS'Mabiletsa, Thandi'
p63347
aS'Madlala, Zanele'
p63348
aS'Mafukuzela, Ntombekaya'
p63349
aS'Mahlatsi, Bontle'
p63350
aS'Marias, Helgard'
p63351
aS'Mfundisi, Nomakhaya'
p63352
aS'Motloba, Buang'
p63353
aS'Moyo, Cindy'
p63354
aS'Mtshizana, Mcebisi'
p63355
aS'Ncana, Lundi'
p63356
aS'Newell, Kevin'
p63357
aS'Palmer, Sean'
p63358
aS'Pearce, Deborah'
p63359
aS'Potts, Mary-Ann'
p63360
aS'Radebe, Daphne'
p63361
aS'Reyneke, Anne'
p63362
aS'Segeneco, Anna'
p63363
aS'Sekgale, Jennifer'
p63364
aS'Steyn, Jan'
p63365
aS'Thebe, Pinky'
p63366
aS'Truter, Handre'
p63367
aS'van Niekerk, Diederik'
p63368
aS'Verheye-Dua, Frieda'
p63369
aS'Voges, Karlien'
p63370
aS'Woolgar, Helen'
p63371
aS'Maartens, Gary'
p63372
aS'Spencer, David'
p63373
aS'van der Horst, Charles'
p63374
aS'Ingram, Charlotte'
p63375
aS'Glencross, Debbie'
p63376
asS'JID'
p63377
S'9815705'
p63378
sS'AB'
p63379
S"BACKGROUND: The emergence of complex HIV-1 drug resistance mutations has been linked to the duration of time patients are on a failing antiretroviral drug regimen. This study reports on resistance profiles in a closely monitored subtype C infected cohort. METHODS: A total of 812 participants were enrolled into the CIPRA-SA 'safeguard the household' study, viral loads were determined at 12-weekly intervals for 96 weeks. Virological failure was defined as either a <1.5 log decrease in viral load at week 12 or two consecutive viral load measurements of >1,000 RNA copies/ml after week 24. Regimens prescribed were in line with the South African roll-out programme (stavudine, lamivudine, efavirenz or nevirapine). Viral RNA was extracted from patients with virological failure, and pol reverse-transcriptase PCR and sequence analysis were performed to determine drug-resistant mutations. RESULTS: Virological failure was observed in 83 participants on the first-line regimen during the study period, of which 61 (73%) had HIV-1 drug-resistant mutations. The M184V mutation was the most frequent (n=46; 65%), followed by K103N (46%) and Y181C (21%). Thymidine analogue mutations were infrequent (1%) and Q151M was not observed. CONCLUSIONS: Drug resistance profiles were less complex than has been previously reported in South Africa using the same antiretroviral drug regimens. These data suggest that frequent viral load monitoring limits the level and complexity of resistance observed in HIV-1 subtype C, preserving susceptibility to second-line options."
p63380
sS'AD'
p63381
S'University of the Witwatersrand, Johannesburg, South Africa. cwallis@mweb.co.za'
p63382
sS'CN'
p63383
(lp63384
S'CIPRA-SA project 1 study team'
p63385
asS'IP'
p63386
S'2'
sS'IS'
p63387
S'2040-2058 (Electronic) 1359-6535 (Linking)'
p63388
sS'IR'
p63389
(lp63390
S'Badal-Faesen S'
p63391
aS'Botile M'
p63392
aS'Choonilal N'
p63393
aS'Gelant J'
p63394
aS'Grab J'
p63395
aS'Graham V'
p63396
aS'Hafejee N'
p63397
aS'Hamber L'
p63398
aS'Harduth S'
p63399
aS'Hendricks J'
p63400
aS'Herman C'
p63401
aS'Hero M'
p63402
aS'Kaplan R'
p63403
aS'Killa N'
p63404
aS'Klemp D'
p63405
aS'Laher F'
p63406
aS'Mabiletsa T'
p63407
aS'Madlala Z'
p63408
aS'Mafukuzela N'
p63409
aS'Mahlatsi B'
p63410
aS'Marias H'
p63411
aS'Mfundisi N'
p63412
aS'Motloba B'
p63413
aS'Moyo C'
p63414
aS'Mtshizana M'
p63415
aS'Ncana L'
p63416
aS'Newell K'
p63417
aS'Palmer S'
p63418
aS'Pearce D'
p63419
aS'Potts MA'
p63420
aS'Radebe D'
p63421
aS'Reyneke A'
p63422
aS'Segeneco A'
p63423
aS'Sekgale J'
p63424
aS'Steyn J'
p63425
aS'Thebe P'
p63426
aS'Truter H'
p63427
aS'van Niekerk D'
p63428
aS'Verheye-Dua F'
p63429
aS'Voges K'
p63430
aS'Woolgar H'
p63431
aS'Maartens G'
p63432
aS'Spencer D'
p63433
aS'van der Horst C'
p63434
aS'Ingram C'
p63435
aS'Glencross D'
p63436
asS'DCOM'
p63437
S'20120723'
p63438
sS'AU'
p63439
(lp63440
S'Wallis CL'
p63441
aS'Papathanasopolous MA'
p63442
aS'Fox M'
p63443
aS'Conradie F'
p63444
aS'Ive P'
p63445
aS'Orrell C'
p63446
aS'Zeinecker J'
p63447
aS'Sanne I'
p63448
aS'Wood R'
p63449
aS'McIntyre J'
p63450
aS'Stevens W'
p63451
asS'VI'
p63452
S'17'
p63453
sS'MHDA'
p63454
S'2012/07/24 06:00'
p63455
sS'PHST'
p63456
(lp63457
S'2011/05/29 [accepted]'
p63458
aS'2011/11/18 [aheadofprint]'
p63459
asS'OID'
p63460
(lp63461
S'NLM: NIHMS451046'
p63462
aS'NLM: PMC3600633'
p63463
asS'MH'
p63464
(lp63465
S'Adult'
p63466
aS'Anti-HIV Agents/*pharmacology/therapeutic use'
p63467
aS'Antiretroviral Therapy, Highly Active'
p63468
aS'Benzoxazines/pharmacology/therapeutic use'
p63469
aS'CD4 Lymphocyte Count'
p63470
aS'Drug Resistance, Viral/*genetics'
p63471
aS'Female'
p63472
aS'Genotype'
p63473
aS'HIV Infections/*drug therapy/genetics/virology'
p63474
aS'HIV-1/*drug effects/*genetics'
p63475
aS'Humans'
p63476
aS'Lamivudine/pharmacology/therapeutic use'
p63477
aS'Male'
p63478
aS'RNA, Viral/genetics'
p63479
aS'Reverse Transcriptase Inhibitors/*pharmacology/therapeutic use'
p63480
aS'South Africa'
p63481
aS'Stavudine/pharmacology/therapeutic use'
p63482
aS'Viral Load'
p63483
asS'EDAT'
p63484
S'2012/02/02 06:00'
p63485
sS'PMC'
p63486
S'PMC3600633'
p63487
sS'SO'
p63488
S'Antivir Ther. 2012;17(2):313-20. doi: 10.3851/IMP1985. Epub 2011 Nov 18.'
p63489
sS'SB'
p63490
S'IM'
p63491
sS'PMID'
p63492
S'22293461'
p63493
sS'PST'
p63494
S'ppublish'
p63495
stRp63496
ag2
(g3
g4
(dp63497
S'LID'
p63498
S'10.1080/09540121.2011.644233 [doi]'
p63499
sS'STAT'
p63500
S'MEDLINE'
p63501
sS'DEP'
p63502
S'20120131'
p63503
sS'MID'
p63504
(lp63505
S'NIHMS350038'
p63506
asS'DA'
p63507
S'20120515'
p63508
sS'AID'
p63509
(lp63510
S'10.1080/09540121.2011.644233 [doi]'
p63511
asS'CRDT'
p63512
(lp63513
S'2012/02/02 06:00'
p63514
asS'DP'
p63515
S'2012'
p63516
sS'AD'
p63517
S"General Pediatrics, Children's Hospital of Philadelphia, PA, USA. lowenthale@email.chop.edu"
p63518
sS'OWN'
p63519
S'NLM'
p63520
sS'PT'
p63521
(lp63522
S'Journal Article'
p63523
aS'Research Support, N.I.H., Extramural'
p63524
asS'LA'
p63525
(lp63526
S'eng'
p63527
asS'FAU'
p63528
(lp63529
S'Lowenthal, Elizabeth'
p63530
aS'Lawler, Kathy'
p63531
aS'Harari, Nurit'
p63532
aS'Moamogwe, Lesedi'
p63533
aS'Masunge, Japhter'
p63534
aS'Masedi, Motshodi'
p63535
aS'Matome, Bolefela'
p63536
aS'Seloilwe, Esther'
p63537
aS'Gross, Robert'
p63538
asS'JT'
p63539
S'AIDS care'
p63540
sS'LR'
p63541
S'20151119'
p63542
sS'PG'
p63543
S'722-7'
p63544
sS'TI'
p63545
S'Rapid psychosocial function screening test identified treatment failure in HIV+ African youth.'
p63546
sS'RN'
p63547
(lp63548
S'0 (Anti-HIV Agents)'
p63549
asS'PL'
p63550
S'England'
p63551
sS'TA'
p63552
S'AIDS Care'
p63553
sS'JID'
p63554
S'8915313'
p63555
sS'AB'
p63556
S'Psychosocial dysfunction in older children and adolescents is common and may lead to nonadherence to HIV treatments. Poor adherence leads to HIV treatment failure and the development of resistant virus. In resource-limited settings where treatment options are typically limited to only one or two available lines of therapy, identification of individuals at highest risk of failure before failure occurs is of critical importance. Rapid screening tools for psychosocial dysfunction may allow for identification of those children and adolescents who are most likely to benefit from limited psychosocial support services targeted at preventing HIV treatment failure. The Pediatric Symptom Checklist (PSC) is used in high resource settings for rapid identification of at-risk youth. In 692 HIV-infected treated children (ages of 8-< 17 years) in Botswana, having a high score on the PSC was associated with having virologic failure (OR 1.7, 95% CI: 1.1-2.6). The PSC may be a useful screening tool in pediatric HIV.'
p63557
sS'GR'
p63558
(lp63559
S'K23 MH095669/MH/NIMH NIH HHS/United States'
p63560
aS'P30 AI045008/AI/NIAID NIH HHS/United States'
p63561
aS'P30 AI045008/AI/NIAID NIH HHS/United States'
p63562
aS'P30 AI045008-11/AI/NIAID NIH HHS/United States'
p63563
asS'IP'
p63564
S'6'
sS'IS'
p63565
S'1360-0451 (Electronic) 0954-0121 (Linking)'
p63566
sS'PMC'
p63567
S'PMC3345310'
p63568
sS'DCOM'
p63569
S'20120807'
p63570
sS'AU'
p63571
(lp63572
S'Lowenthal E'
p63573
aS'Lawler K'
p63574
aS'Harari N'
p63575
aS'Moamogwe L'
p63576
aS'Masunge J'
p63577
aS'Masedi M'
p63578
aS'Matome B'
p63579
aS'Seloilwe E'
p63580
aS'Gross R'
p63581
asS'VI'
p63582
S'24'
p63583
sS'MHDA'
p63584
S'2012/08/08 06:00'
p63585
sS'PHST'
p63586
(lp63587
S'2012/01/31 [aheadofprint]'
p63588
asS'OID'
p63589
(lp63590
S'NLM: NIHMS350038'
p63591
aS'NLM: PMC3345310'
p63592
asS'MH'
p63593
(lp63594
S'Adolescent'
p63595
aS'Affective Symptoms/*diagnosis/epidemiology'
p63596
aS'African Continental Ancestry Group'
p63597
aS'Anti-HIV Agents'
p63598
aS'Botswana/epidemiology'
p63599
aS'Checklist'
p63600
aS'Child'
p63601
aS'Child Health Services/*organization & administration'
p63602
aS'Female'
p63603
aS'HIV Seropositivity/drug therapy/epidemiology/*psychology'
p63604
aS'Humans'
p63605
aS'Male'
p63606
aS'Mass Screening/*methods'
p63607
aS'Medication Adherence/*psychology/statistics & numerical data'
p63608
aS'Prevalence'
p63609
aS'Psychological Tests'
p63610
aS'Social Behavior Disorders/*diagnosis/epidemiology'
p63611
aS'Surveys and Questionnaires'
p63612
aS'Treatment Failure'
p63613
asS'EDAT'
p63614
S'2012/02/02 06:00'
p63615
sS'SO'
p63616
S'AIDS Care. 2012;24(6):722-7. doi: 10.1080/09540121.2011.644233. Epub 2012 Jan 31.'
p63617
sS'SB'
p63618
S'IM X'
p63619
sS'PMID'
p63620
S'22292411'
p63621
sS'PST'
p63622
S'ppublish'
p63623
stRp63624
ag2
(g3
g4
(dp63625
S'STAT'
p63626
S'MEDLINE'
p63627
sS'AB'
p63628
S'BACKGROUND: Various studies in sub-Saharan Africa have documented high prevalence of HIV infection in children. OBJECTIVE: To determine the prevalence and outcome of paediatric HIV/AIDS in a new Teaching Hospital in the Federal Capital Territory, Abuja, Nigeria. METHODS: A two year retrospective review of patients attending paediatric outpatient unit of the University of Abuja Teaching Hospital, Gwagwalada, was undertaken for the above objective. RESULTS: Out of a total of 3,669 paediatric patients seen in unit of the hospital, 437(11.9%) tested positive for HIV, 234 were males, while 203 were females (m:f = 1.15:1). Children under the age of five years accounted for 81.7% of the HIV positive children, and mother-to-child transmission was the major route of transmission of HIV in 73.7% of cases. Two other common routes of transmission were the use of blood/ hair dressing implements in 4.8% each, and use of non sterile needle in 3.9%. Most mothers of HIV children were either housewives (45.3%), or petty traders (10.4%), while their fathers were either civil servants (26.5%) or long distance drivers (19.7%). A mortality rate of 3.4% was recorded while 6.0% were lost to follow up. CONCLUSION: The prevalence of HIV/AIDS in children is high in the FCT, Abuja, most of which was through mother-to-child transmission. There is an urgent need to scale up PMTCT programmes to many tertiary, secondary and primary health care facilities across the FCT, and the nation at large in view of the enormous burden of the disease in children. Safe blood for African initiative/techniques should be extended to many health care facilities nationwide, and use of unsterile needles by patent medicine dealers to be prohibited.'
p63629
sS'JID'
p63630
S'100888321'
p63631
sS'AD'
p63632
S'Department of Paediatrics, University of Abuja Teaching Hospital, Gwagwalada. nebokest@yahoo.com'
p63633
sS'JT'
p63634
S'Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria'
p63635
sS'IP'
p63636
S'4'
sS'IS'
p63637
S'1115-2613 (Print) 1115-2613 (Linking)'
p63638
sS'DCOM'
p63639
S'20120209'
p63640
sS'DA'
p63641
S'20120131'
p63642
sS'AU'
p63643
(lp63644
S'Okechukwu AA'
p63645
aS'Okechukwu OI'
p63646
asS'CRDT'
p63647
(lp63648
S'2012/02/01 06:00'
p63649
asS'VI'
p63650
S'20'
p63651
sS'DP'
p63652
S'2011 Oct-Dec'
p63653
sS'MHDA'
p63654
S'2012/02/10 06:00'
p63655
sS'OWN'
p63656
S'NLM'
p63657
sS'PT'
p63658
(lp63659
S'Journal Article'
p63660
asS'LA'
p63661
(lp63662
S'eng'
p63663
asS'MH'
p63664
(lp63665
S'Adolescent'
p63666
aS'Child'
p63667
aS'Child, Preschool'
p63668
aS'Female'
p63669
aS'HIV Infections/*epidemiology/transmission'
p63670
aS'Humans'
p63671
aS'Infant'
p63672
aS'Male'
p63673
aS'Nigeria/epidemiology'
p63674
aS'Prevalence'
p63675
aS'Socioeconomic Factors'
p63676
aS'Urban Population/*statistics & numerical data'
p63677
asS'FAU'
p63678
(lp63679
S'Okechukwu, A A'
p63680
aS'Okechukwu, O I'
p63681
asS'EDAT'
p63682
S'2012/02/01 06:00'
p63683
sS'PST'
p63684
S'ppublish'
p63685
sS'SO'
p63686
S'Niger J Med. 2011 Oct-Dec;20(4):409-13.'
p63687
sS'PG'
p63688
S'409-13'
p63689
sS'TI'
p63690
S'Prevalence of paediatric HIV infection in Federal Capital Territory, Abuja.'
p63691
sS'SB'
p63692
S'IM'
p63693
sS'PMID'
p63694
S'22288313'
p63695
sS'PL'
p63696
S'Nigeria'
p63697
sS'TA'
p63698
S'Niger J Med'
p63699
stRp63700
ag2
(g3
g4
(dp63701
S'LID'
p63702
S'10.1186/1471-2334-12-21 [doi]'
p63703
sS'STAT'
p63704
S'MEDLINE'
p63705
sS'DEP'
p63706
S'20120125'
p63707
sS'DA'
p63708
S'20120307'
p63709
sS'AID'
p63710
(lp63711
S'1471-2334-12-21 [pii]'
p63712
aS'10.1186/1471-2334-12-21 [doi]'
p63713
asS'CRDT'
p63714
(lp63715
S'2012/01/26 06:00'
p63716
asS'DP'
p63717
S'2012'
p63718
sS'AD'
p63719
S'The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, and the Department of Medicine, Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory, 7925 Cape Town, South Africa. Mweete.Nglazi@hiv-research.org.za'
p63720
sS'OWN'
p63721
S'NLM'
p63722
sS'PT'
p63723
(lp63724
S'Comparative Study'
p63725
aS'Journal Article'
p63726
aS'Research Support, N.I.H., Extramural'
p63727
aS"Research Support, Non-U.S. Gov't"
p63728
asS'LA'
p63729
(lp63730
S'eng'
p63731
asS'DCOM'
p63732
S'20120517'
p63733
sS'JT'
p63734
S'BMC infectious diseases'
p63735
sS'LR'
p63736
S'20150428'
p63737
sS'FAU'
p63738
(lp63739
S'Nglazi, Mweete D'
p63740
aS'Kranzer, Katharina'
p63741
aS'Holele, Pearl'
p63742
aS'Kaplan, Richard'
p63743
aS'Mark, Daniella'
p63744
aS'Jaspan, Heather'
p63745
aS'Lawn, Stephen D'
p63746
aS'Wood, Robin'
p63747
aS'Bekker, Linda-Gail'
p63748
asS'TI'
p63749
S'Treatment outcomes in HIV-infected adolescents attending a community-based antiretroviral therapy clinic in South Africa.'
p63750
sS'RN'
p63751
(lp63752
S'0 (Anti-HIV Agents)'
p63753
asS'PL'
p63754
S'England'
p63755
sS'PG'
p63756
S'21'
p63757
sS'JID'
p63758
S'100968551'
p63759
sS'AB'
p63760
S'BACKGROUND: Very few data are available on treatment outcomes of adolescents living with HIV infection (whether perinatally acquired or sexually acquired) in sub-Saharan Africa. The present study therefore compared the treatment outcomes in adolescents with those of young adults at a public sector community-based ART programme in Cape Town, South Africa. METHODS: Treatment outcomes of adolescents (9-19 years) were compared with those of young adults (20-28 years), enrolled in a prospective cohort between September 2002 and June 2009. Kaplan-Meier estimates and Cox proportional hazard models were used to assess outcomes and determine associations with age, while adjusting for potential confounders. The treatment outcomes were mortality, loss to follow-up (LTFU), immunological response, virological suppression and virological failure. RESULTS: 883 patients, including 65 adolescents (47 perinatally infected and 17 sexually infected) and 818 young adults, received ART. There was no difference in median baseline CD4 cell count between adolescents and young adults (133.5 vs 116 cells/muL; p = 0.31). Overall mortality rates in adolescents and young adults were 1.2 (0.3-4.8) and 3.1 (2.4-3.9) deaths per 100 person-years, respectively. Adolescents had lower rates of virological suppression (< 400 copies/mL) at 48 weeks (27.3% vs 63.1%; p < 0.001). Despite this, however, the median change in CD4 count from baseline at 48 weeks of ART was significantly greater for adolescents than young adults (373 vs 187 cells/muL; p = 0.0001). Treatment failure rates were 8.2 (4.6-14.4) and 5.0 (4.1-6.1) per 100 person-years in the two groups. In multivariate analyses, there was no significant difference in LTFU and mortality between age groups but increased risk in virological failure [AHR 2.06 (95% CI 1.11-3.81; p = 0.002)] in adolescents. CONCLUSIONS: Despite lower virological suppression rates and higher rates of virological failure, immunological responses were nevertheless greater in adolescents than young adults whereas rates of mortality and LTFU were similar. Further studies to determine the reasons for poorer virological outcomes are needed.'
p63761
sS'GR'
p63762
(lp63763
S'5 R01 AI058736-02/AI/NIAID NIH HHS/United States'
p63764
aS'5U01AI4069519/AI/NIAID NIH HHS/United States'
p63765
aS'U01 AI069519/AI/NIAID NIH HHS/United States'
p63766
aS'Wellcome Trust/United Kingdom'
p63767
asS'VI'
p63768
S'12'
p63769
sS'IS'
p63770
S'1471-2334 (Electronic) 1471-2334 (Linking)'
p63771
sS'PMC'
p63772
S'PMC3295677'
p63773
sS'AU'
p63774
(lp63775
S'Nglazi MD'
p63776
aS'Kranzer K'
p63777
aS'Holele P'
p63778
aS'Kaplan R'
p63779
aS'Mark D'
p63780
aS'Jaspan H'
p63781
aS'Lawn SD'
p63782
aS'Wood R'
p63783
aS'Bekker LG'
p63784
asS'MHDA'
p63785
S'2012/05/18 06:00'
p63786
sS'PHST'
p63787
(lp63788
S'2011/05/28 [received]'
p63789
aS'2012/01/25 [accepted]'
p63790
aS'2012/01/25 [aheadofprint]'
p63791
asS'OID'
p63792
(lp63793
S'NLM: PMC3295677'
p63794
asS'MH'
p63795
(lp63796
S'Adolescent'
p63797
aS'Adult'
p63798
aS'Ambulatory Care Facilities'
p63799
aS'Anti-HIV Agents/*administration & dosage'
p63800
aS'Antiretroviral Therapy, Highly Active/*methods'
p63801
aS'CD4 Lymphocyte Count'
p63802
aS'Child'
p63803
aS'Female'
p63804
aS'HIV Infections/*drug therapy/immunology/mortality/virology'
p63805
aS'Humans'
p63806
aS'Male'
p63807
aS'South Africa'
p63808
aS'Survival Analysis'
p63809
aS'Treatment Outcome'
p63810
aS'Viral Load'
p63811
aS'Young Adult'
p63812
asS'EDAT'
p63813
S'2012/01/26 06:00'
p63814
sS'SO'
p63815
S'BMC Infect Dis. 2012 Jan 25;12:21. doi: 10.1186/1471-2334-12-21.'
p63816
sS'SB'
p63817
S'IM'
p63818
sS'PMID'
p63819
S'22273267'
p63820
sS'TA'
p63821
S'BMC Infect Dis'
p63822
sS'PST'
p63823
S'epublish'
p63824
stRp63825
ag2
(g3
g4
(dp63826
S'LID'
p63827
S'10.1097/QAD.0b013e32835143e3 [doi]'
p63828
sS'STAT'
p63829
S'MEDLINE'
p63830
sS'JT'
p63831
S'AIDS (London, England)'
p63832
sS'MID'
p63833
(lp63834
S'NIHMS518659'
p63835
asS'DA'
p63836
S'20120323'
p63837
sS'AID'
p63838
(lp63839
S'10.1097/QAD.0b013e32835143e3 [doi]'
p63840
asS'CRDT'
p63841
(lp63842
S'2012/01/25 06:00'
p63843
asS'DP'
p63844
S'2012 Mar 27'
p63845
sS'AD'
p63846
S'College of Health Sciences, Infectious Diseases Institute, Uganda. akiragga@idi.co.ug'
p63847
sS'OWN'
p63848
S'NLM'
p63849
sS'PT'
p63850
(lp63851
S'Comparative Study'
p63852
aS'Journal Article'
p63853
aS'Research Support, N.I.H., Extramural'
p63854
aS"Research Support, Non-U.S. Gov't"
p63855
asS'LA'
p63856
(lp63857
S'eng'
p63858
asS'FAU'
p63859
(lp63860
S'Kiragga, Agnes N'
p63861
aS'Castelnuovo, Barbara'
p63862
aS'Kamya, Moses R'
p63863
aS'Moore, Richard'
p63864
aS'Manabe, Yukari C'
p63865
asS'LR'
p63866
S'20150128'
p63867
sS'PG'
p63868
S'768-70'
p63869
sS'TI'
p63870
S'Regional differences in predictive accuracy of WHO immunologic failure criteria.'
p63871
sS'RN'
p63872
(lp63873
S'0 (Reverse Transcriptase Inhibitors)'
p63874
asS'PL'
p63875
S'England'
p63876
sS'TA'
p63877
S'AIDS'
p63878
sS'JID'
p63879
S'8710219'
p63880
sS'AB'
p63881
S'We compared the performance of the WHO immunologic criteria for treatment failure among Uganda and American patients. Antiretroviral treatment-naive patients with a CD4 T-cell count less than 200 cells/mul or AIDS at enrollment on a nonnucleoside reverse transcriptase inhibitors-based regimen for more than 1 year were selected. For all criteria, the positive predictive value was significantly higher in the American compared with the Ugandan patients. Population-specific guidelines should be developed using large African cohorts to identify more specific and sensitive criteria.'
p63882
sS'GR'
p63883
(lp63884
S'K24 DA000432/DA/NIDA NIH HHS/United States'
p63885
aS'K24 DA00432/DA/NIDA NIH HHS/United States'
p63886
aS'P30 AI094189/AI/NIAID NIH HHS/United States'
p63887
aS'R01 AA016893/AA/NIAAA NIH HHS/United States'
p63888
aS'R01 AA16893/AA/NIAAA NIH HHS/United States'
p63889
aS'R01 DA011602/DA/NIDA NIH HHS/United States'
p63890
aS'R01 DA11602/DA/NIDA NIH HHS/United States'
p63891
aS'R21 AA015032/AA/NIAAA NIH HHS/United States'
p63892
aS'U01 AI069918/AI/NIAID NIH HHS/United States'
p63893
asS'IP'
p63894
S'6'
sS'IS'
p63895
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p63896
sS'PMC'
p63897
S'PMC3812797'
p63898
sS'DCOM'
p63899
S'20120627'
p63900
sS'AU'
p63901
(lp63902
S'Kiragga AN'
p63903
aS'Castelnuovo B'
p63904
aS'Kamya MR'
p63905
aS'Moore R'
p63906
aS'Manabe YC'
p63907
asS'VI'
p63908
S'26'
p63909
sS'MHDA'
p63910
S'2012/06/28 06:00'
p63911
sS'OID'
p63912
(lp63913
S'NLM: NIHMS518659'
p63914
aS'NLM: PMC3812797'
p63915
asS'MH'
p63916
(lp63917
S'AIDS-Related Opportunistic Infections/complications'
p63918
aS'Acquired Immunodeficiency Syndrome/complications/drug therapy/immunology'
p63919
aS'Adult'
p63920
aS'CD4 Lymphocyte Count'
p63921
aS'CD4-Positive T-Lymphocytes/*immunology'
p63922
aS'Female'
p63923
aS'HIV Infections/complications/drug therapy/*immunology'
p63924
aS'Humans'
p63925
aS'Male'
p63926
aS'Residence Characteristics'
p63927
aS'Reverse Transcriptase Inhibitors/therapeutic use'
p63928
aS'Treatment Failure'
p63929
aS'Uganda'
p63930
aS'United States'
p63931
aS'Viral Load'
p63932
asS'EDAT'
p63933
S'2012/01/25 06:00'
p63934
sS'SO'
p63935
S'AIDS. 2012 Mar 27;26(6):768-70. doi: 10.1097/QAD.0b013e32835143e3.'
p63936
sS'SB'
p63937
S'IM X'
p63938
sS'PMID'
p63939
S'22269974'
p63940
sS'PST'
p63941
S'ppublish'
p63942
stRp63943
ag2
(g3
g4
(dp63944
S'LID'
p63945
S'10.1093/tropej/fmr112 [doi]'
p63946
sS'STAT'
p63947
S'MEDLINE'
p63948
sS'DEP'
p63949
S'20120119'
p63950
sS'DA'
p63951
S'20121005'
p63952
sS'AID'
p63953
(lp63954
S'fmr112 [pii]'
p63955
aS'10.1093/tropej/fmr112 [doi]'
p63956
asS'CRDT'
p63957
(lp63958
S'2012/01/21 06:00'
p63959
asS'DP'
p63960
S'2012 Oct'
p63961
sS'OWN'
p63962
S'NLM'
p63963
sS'PT'
p63964
(lp63965
S'Journal Article'
p63966
aS"Research Support, Non-U.S. Gov't"
p63967
asS'LA'
p63968
(lp63969
S'eng'
p63970
asS'FAU'
p63971
(lp63972
S'Kurewa, Nyaradzai E'
p63973
aS'Gumbo, Felicity Z'
p63974
aS'Mapingure, Paul M'
p63975
aS'Munjoma, Marshall W'
p63976
aS'Chirenje, Mike Z'
p63977
aS'Rusakaniko, Simbarashe'
p63978
aS'Stray-Pedersen, Babill'
p63979
asS'JT'
p63980
S'Journal of tropical pediatrics'
p63981
sS'LR'
p63982
S'20151119'
p63983
sS'PG'
p63984
S'360-9'
p63985
sS'TI'
p63986
S'Predictors of attrition among children born in a PMTCT programme in Zimbabwe followed up over 5 years.'
p63987
sS'RN'
p63988
(lp63989
S'0 (Anti-HIV Agents)'
p63990
aS'99DK7FVK1H (Nevirapine)'
p63991
asS'PL'
p63992
S'England'
p63993
sS'TA'
p63994
S'J Trop Pediatr'
p63995
sS'JID'
p63996
S'8010948'
p63997
sS'AB'
p63998
S'Eliminating of paediatric HIV within prevention of mother to child transmission (PMTCT) interventions rests on complete follow-up of all children. We report on predictors of child attrition in the PMTCT cascade over 5 years where 1050 pregnant women were enrolled at 36 gestational weeks. Mother and child pairs were followed up at birth, 6 weeks, 4 months, 9 months, and every 6 months thereafter for 60 months. Higher attrition was observed for children of economically advantaged, socially stable mothers regardless of HIV status, whereas compliance was observed for children whose mothers tested positive for HIV-1, HSV-2 and Syphilis. Low birthweight was associated with attrition regardless of maternal HIV status. Five years predictors of attrition did not differ by maternal HIV status, as HIV-exposed children succumbed to mortality and those not exposed were loss to follow-up (LFU). Child follow-up is influenced more by maternal lifestyle and health risks leading to retention of high-risk children in PMTCT programmes.'
p63999
sS'AD'
p64000
S'Letten Foundation Research Center, No. 3 Everrette Close, Avondale, Harare, 263, Zimbabwe. enkurewa@hotmail.com'
p64001
sS'IP'
p64002
S'5'
sS'IS'
p64003
S'1465-3664 (Electronic) 0142-6338 (Linking)'
p64004
sS'DCOM'
p64005
S'20130117'
p64006
sS'AU'
p64007
(lp64008
S'Kurewa NE'
p64009
aS'Gumbo FZ'
p64010
aS'Mapingure PM'
p64011
aS'Munjoma MW'
p64012
aS'Chirenje MZ'
p64013
aS'Rusakaniko S'
p64014
aS'Stray-Pedersen B'
p64015
asS'VI'
p64016
S'58'
p64017
sS'MHDA'
p64018
S'2013/01/18 06:00'
p64019
sS'PHST'
p64020
(lp64021
S'2012/01/19 [aheadofprint]'
p64022
asS'MH'
p64023
(lp64024
S'Adult'
p64025
aS'Anti-HIV Agents/administration & dosage/*therapeutic use'
p64026
aS'Child'
p64027
aS'Child, Preschool'
p64028
aS'Female'
p64029
aS'Follow-Up Studies'
p64030
aS'Forecasting'
p64031
aS'HIV Infections/*drug therapy/prevention & control/transmission'
p64032
aS'Humans'
p64033
aS'Infant'
p64034
aS'Infant, Low Birth Weight'
p64035
aS'Infant, Newborn'
p64036
aS'*Infectious Disease Transmission, Vertical'
p64037
aS'*Lost to Follow-Up'
p64038
aS'Nevirapine/administration & dosage/*therapeutic use'
p64039
aS'*Patient Compliance'
p64040
aS'Pregnancy'
p64041
aS'Pregnancy Complications, Infectious/*drug therapy/prevention & control/virology'
p64042
aS'Program Evaluation/*methods'
p64043
aS'Prospective Studies'
p64044
aS'Socioeconomic Factors'
p64045
aS'Surveys and Questionnaires'
p64046
aS'Urban Population'
p64047
aS'Zimbabwe'
p64048
asS'EDAT'
p64049
S'2012/01/21 06:00'
p64050
sS'SO'
p64051
S'J Trop Pediatr. 2012 Oct;58(5):360-9. doi: 10.1093/tropej/fmr112. Epub 2012 Jan 19.'
p64052
sS'SB'
p64053
S'IM'
p64054
sS'PMID'
p64055
S'22262677'
p64056
sS'PST'
p64057
S'ppublish'
p64058
stRp64059
ag2
(g3
g4
(dp64060
S'LID'
p64061
S'10.1089/AID.2011.0284 [doi]'
p64062
sS'STAT'
p64063
S'MEDLINE'
p64064
sS'DEP'
p64065
S'20120312'
p64066
sS'DA'
p64067
S'20120604'
p64068
sS'AID'
p64069
(lp64070
S'10.1089/aid.2011.0284 [doi]'
p64071
asS'CRDT'
p64072
(lp64073
S'2012/01/19 06:00'
p64074
asS'DP'
p64075
S'2012 Jun'
p64076
sS'GR'
p64077
(lp64078
S'082384/Z/07/Z/Wellcome Trust/United Kingdom'
p64079
aS'097410/Wellcome Trust/United Kingdom'
p64080
asS'OWN'
p64081
S'NLM'
p64082
sS'PT'
p64083
(lp64084
S'Journal Article'
p64085
aS"Research Support, Non-U.S. Gov't"
p64086
aS"Research Support, U.S. Gov't, P.H.S."
p64087
aS'Review'
p64088
asS'LA'
p64089
(lp64090
S'eng'
p64091
asS'FAU'
p64092
(lp64093
S'Manasa, Justen'
p64094
aS'Katzenstein, David'
p64095
aS'Cassol, Sharon'
p64096
aS'Newell, Marie-Louise'
p64097
aS'de Oliveira, Tulio'
p64098
asS'JT'
p64099
S'AIDS research and human retroviruses'
p64100
sS'LR'
p64101
S'20150128'
p64102
sS'PG'
p64103
S'558-65'
p64104
sS'TI'
p64105
S'Primary drug resistance in South Africa: data from 10 years of surveys.'
p64106
sS'RN'
p64107
(lp64108
S'0 (Anti-HIV Agents)'
p64109
asS'PL'
p64110
S'United States'
p64111
sS'TA'
p64112
S'AIDS Res Hum Retroviruses'
p64113
sS'JID'
p64114
S'8709376'
p64115
sS'AB'
p64116
S"HIV-1 transmitted drug resistance (TDR) could reverse the gains of antiretroviral rollout. To ensure that current first-line therapies remain effective, TDR levels in recently infected treatment-naive patients need to be monitored. A literature review and data mining exercise was carried out to determine the temporal trends in TDR in South Africa. In addition, 72 sequences from seroconvertors identified from Africa Centre's 2010 HIV surveillance round were also examined for TDR. Publicly available data on TDR were retrieved from GenBank, curated in RegaDB, and analyzed using the Calibrated Population Resistance Program. There was no evidence of TDR from the 2010 rural KwaZulu Natal samples. Ten datasets with a total of 1618 sequences collected between 2000 and 2010 were pooled to provide a temporal analysis of TDR. The year with the highest TDR rate was 2002 [6.67%, 95% confidence interval (CI): 3.09-13.79%; n=6/90]. After 2002, TDR levels returned to <5% (WHO low-level threshold) and showed no statistically significant increase in the interval between 2002 and 2010. The most common mutations were associated with NNRTI resistance, K103N, followed by Y181C and Y188C/L. Five sequences had multiple resistance mutations associated with NNRTI resistance. There is no evidence of TDR in rural KwaZulu-Natal. TDR levels in South Africa have remained low following a downward trend since 2003. Continuous vigilance in monitoring of TDR is needed as more patients are initiated and maintained onto antiretroviral therapy."
p64117
sS'AD'
p64118
S'Africa Centre for Health and Population Studies, Doris Duke Medical Research Institute, Nelson Mandela School of Medicine, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.'
p64119
sS'CN'
p64120
(lp64121
S'Southern Africa Treatment And Resistance Network (SATuRN)'
p64122
asS'IP'
p64123
S'6'
sS'IS'
p64124
S'1931-8405 (Electronic) 0889-2229 (Linking)'
p64125
sS'PMC'
p64126
S'PMC3358100'
p64127
sS'DCOM'
p64128
S'20120820'
p64129
sS'AU'
p64130
(lp64131
S'Manasa J'
p64132
aS'Katzenstein D'
p64133
aS'Cassol S'
p64134
aS'Newell ML'
p64135
aS'de Oliveira T'
p64136
asS'VI'
p64137
S'28'
p64138
sS'MHDA'
p64139
S'2012/08/21 06:00'
p64140
sS'PHST'
p64141
(lp64142
S'2012/03/12 [aheadofprint]'
p64143
asS'OID'
p64144
(lp64145
S'NLM: PMC3358100'
p64146
asS'MH'
p64147
(lp64148
S'Anti-HIV Agents/pharmacology/*therapeutic use'
p64149
aS'Drug Resistance, Viral/*genetics'
p64150
aS'Female'
p64151
aS'Genotype'
p64152
aS'HIV Seropositivity/*drug therapy/genetics/transmission'
p64153
aS'HIV-1/*genetics'
p64154
aS'Humans'
p64155
aS'Male'
p64156
aS'Molecular Sequence Data'
p64157
aS'Mutation/genetics'
p64158
aS'Polymerase Chain Reaction'
p64159
aS'Population Surveillance'
p64160
aS'Prevalence'
p64161
aS'South Africa/epidemiology'
p64162
aS'Time Factors'
p64163
asS'EDAT'
p64164
S'2012/01/19 06:00'
p64165
sS'SI'
p64166
(lp64167
S'GENBANK/JN664970'
p64168
aS'GENBANK/JN664971'
p64169
aS'GENBANK/JN664972'
p64170
aS'GENBANK/JN664973'
p64171
aS'GENBANK/JN664974'
p64172
aS'GENBANK/JN664975'
p64173
aS'GENBANK/JN664976'
p64174
aS'GENBANK/JN664977'
p64175
aS'GENBANK/JN664978'
p64176
aS'GENBANK/JN664979'
p64177
aS'GENBANK/JN664980'
p64178
aS'GENBANK/JN664981'
p64179
aS'GENBANK/JN664982'
p64180
aS'GENBANK/JN664983'
p64181
aS'GENBANK/JN664984'
p64182
aS'GENBANK/JN664985'
p64183
aS'GENBANK/JN664986'
p64184
aS'GENBANK/JN664987'
p64185
aS'GENBANK/JN664988'
p64186
aS'GENBANK/JN664989'
p64187
aS'GENBANK/JN664990'
p64188
aS'GENBANK/JN664991'
p64189
aS'GENBANK/JN664992'
p64190
aS'GENBANK/JN664993'
p64191
aS'GENBANK/JN664994'
p64192
aS'GENBANK/JN664995'
p64193
aS'GENBANK/JN664996'
p64194
aS'GENBANK/JN664997'
p64195
aS'GENBANK/JN664998'
p64196
aS'GENBANK/JN664999'
p64197
aS'GENBANK/JN665000'
p64198
aS'GENBANK/JN665001'
p64199
aS'GENBANK/JN665002'
p64200
aS'GENBANK/JN665003'
p64201
aS'GENBANK/JN665004'
p64202
aS'GENBANK/JN665005'
p64203
aS'GENBANK/JN665006'
p64204
aS'GENBANK/JN665007'
p64205
aS'GENBANK/JN665008'
p64206
aS'GENBANK/JN665009'
p64207
aS'GENBANK/JN665010'
p64208
aS'GENBANK/JN665011'
p64209
aS'GENBANK/JN665012'
p64210
aS'GENBANK/JN665013'
p64211
aS'GENBANK/JN665014'
p64212
aS'GENBANK/JN665015'
p64213
aS'GENBANK/JN665016'
p64214
aS'GENBANK/JN665017'
p64215
aS'GENBANK/JN665018'
p64216
aS'GENBANK/JN665019'
p64217
aS'GENBANK/JN665020'
p64218
aS'GENBANK/JN665021'
p64219
aS'GENBANK/JN665022'
p64220
aS'GENBANK/JN665023'
p64221
aS'GENBANK/JN665024'
p64222
aS'GENBANK/JN665025'
p64223
aS'GENBANK/JN665026'
p64224
aS'GENBANK/JN665027'
p64225
aS'GENBANK/JN665028'
p64226
aS'GENBANK/JN665029'
p64227
aS'GENBANK/JN665030'
p64228
aS'GENBANK/JN665031'
p64229
aS'GENBANK/JN665032'
p64230
aS'GENBANK/JN665033'
p64231
aS'GENBANK/JN665034'
p64232
aS'GENBANK/JN665035'
p64233
aS'GENBANK/JN665036'
p64234
aS'GENBANK/JN665037'
p64235
aS'GENBANK/JN665038'
p64236
aS'GENBANK/JN665039'
p64237
aS'GENBANK/JN665040'
p64238
aS'GENBANK/JN665041'
p64239
asS'SO'
p64240
S'AIDS Res Hum Retroviruses. 2012 Jun;28(6):558-65. doi: 10.1089/AID.2011.0284. Epub 2012 Mar 12.'
p64241
sS'SB'
p64242
S'IM X'
p64243
sS'PMID'
p64244
S'22251009'
p64245
sS'PST'
p64246
S'ppublish'
p64247
stRp64248
ag2
(g3
g4
(dp64249
S'STAT'
p64250
S'MEDLINE'
p64251
sS'DEP'
p64252
S'20120112'
p64253
sS'DA'
p64254
S'20120113'
p64255
sS'CRDT'
p64256
(lp64257
S'2012/01/14 06:00'
p64258
asS'DP'
p64259
S'2012 Jan'
p64260
sS'OWN'
p64261
S'NLM'
p64262
sS'PT'
p64263
(lp64264
S'Journal Article'
p64265
aS"Research Support, Non-U.S. Gov't"
p64266
asS'LA'
p64267
(lp64268
S'eng'
p64269
asS'FAU'
p64270
(lp64271
S"Ndung'u, Perpetual Wangui"
p64272
aS'Kariuki, Samuel'
p64273
aS"Ng'ang'a, Zipporah"
p64274
aS'Revathi, Gunturu'
p64275
asS'JT'
p64276
S'Journal of infection in developing countries'
p64277
sS'LR'
p64278
S'20151119'
p64279
sS'PG'
p64280
S'33-9'
p64281
sS'TI'
p64282
S'Resistance patterns of Mycobacterium tuberculosis isolates from pulmonary tuberculosis patients in Nairobi.'
p64283
sS'RN'
p64284
(lp64285
S'0 (Antitubercular Agents)'
p64286
aS'V83O1VOZ8L (Isoniazid)'
p64287
aS'VJT6J7R4TR (Rifampin)'
p64288
asS'PL'
p64289
S'Italy'
p64290
sS'TA'
p64291
S'J Infect Dev Ctries'
p64292
sS'JID'
p64293
S'101305410'
p64294
sS'AB'
p64295
S'INTRODUCTION: In Kenya, which ranks thirteenth of 27 high tuberculosis burden countries, diagnosis is based on Ziehl-Neelsen staining alone and patients are treated without information on sensitivity patterns. This study aimed to determine resistance patterns of Mycobacterium tuberculosis isolated from pulmonary samples. METHODOLOGY: Pulmonary tuberculosis patients in Nairobi were randomly sampled after informed consent and recruited into the study using a structured questionnaire. Specimens were cultured in liquid and solid media, and drug susceptibility tests were performed for first-line drugs including (isoniazid, rifampin, streptomycin, ethambutol and pyrazinamide). RESULTS: Eighty-six (30%) of 286 isolates were resistant to at least one of five antibiotics tested. Thirty-seven (30.2%) isolates were resistant to isoniazid; 15 (11.6%) to streptomycin; 13 (4.5%) to ethambutol; four (1.4%) to rifampin ; and 30 (10.4%) to pyrazinamide. Double resistance was seen as follows: four (1.4%) isolates were resistant to both isoniazid and pyrazinamide; four (1.4%) to streptomycin and isoniazid; and one (0.3%) to rifampin and streptomycin. Two isolates (0.7%) were multidrug resistant, and one was triple resistant with an additional resistance to ethambutol. Results also showed 88.7% of patients were below the age of 40 years, while 26.3% were HIV positive. The majority of the patients (66.5%) were unemployed or self-employed in small businesses, with 79.4% earning less than 100 USD per month. CONCLUSION: The high resistance observed in isoniazid, which is a first-line drug, could result in an increase in multidrug resistance unless control programs are strengthened. Poverty should be addressed to reduce infection rates.'
p64296
sS'AD'
p64297
S'Institute of Tropical Medicine and Infectious Diseases (ITROMID), Jomo Kenyatta University of Agriculture and Technology (JKUAT), Nairobi, Kenya. perpetualndungu@yahoo.com'
p64298
sS'IP'
p64299
S'1'
sS'IS'
p64300
S'1972-2680 (Electronic) 1972-2680 (Linking)'
p64301
sS'DCOM'
p64302
S'20120502'
p64303
sS'AU'
p64304
(lp64305
S"Ndung'u PW"
p64306
aS'Kariuki S'
p64307
aS"Ng'ang'a Z"
p64308
aS'Revathi G'
p64309
asS'VI'
p64310
S'6'
sS'MHDA'
p64311
S'2012/05/04 06:00'
p64312
sS'PHST'
p64313
(lp64314
S'2011/08/30 [received]'
p64315
aS'2011/12/01 [accepted]'
p64316
aS'2011/12/01 [revised]'
p64317
asS'MH'
p64318
(lp64319
S'AIDS-Related Opportunistic Infections/epidemiology/microbiology'
p64320
aS'Adult'
p64321
aS'Antitubercular Agents/*pharmacology/therapeutic use'
p64322
aS'Drug Resistance, Bacterial'
p64323
aS'Female'
p64324
aS'HIV Infections/complications/epidemiology/virology'
p64325
aS'Humans'
p64326
aS'Isoniazid/pharmacology/therapeutic use'
p64327
aS'Kenya/epidemiology'
p64328
aS'Male'
p64329
aS'Microbial Sensitivity Tests'
p64330
aS'Middle Aged'
p64331
aS'Mycobacterium tuberculosis/*drug effects/isolation & purification'
p64332
aS'Rifampin/pharmacology/therapeutic use'
p64333
aS'Surveys and Questionnaires'
p64334
aS'Tuberculosis, Multidrug-Resistant/drug therapy/*epidemiology/microbiology'
p64335
aS'Tuberculosis, Pulmonary/drug therapy/*epidemiology/*microbiology'
p64336
asS'EDAT'
p64337
S'2012/01/14 06:00'
p64338
sS'SO'
p64339
S'J Infect Dev Ctries. 2012 Jan 12;6(1):33-9.'
p64340
sS'SB'
p64341
S'IM'
p64342
sS'PMID'
p64343
S'22240426'
p64344
sS'PST'
p64345
S'epublish'
p64346
stRp64347
ag2
(g3
g4
(dp64348
S'LID'
p64349
S'10.1089/apc.2011.0279 [doi]'
p64350
sS'STAT'
p64351
S'MEDLINE'
p64352
sS'DEP'
p64353
S'20120106'
p64354
sS'DA'
p64355
S'20120130'
p64356
sS'AID'
p64357
(lp64358
S'10.1089/apc.2011.0279 [doi]'
p64359
asS'CRDT'
p64360
(lp64361
S'2012/01/10 06:00'
p64362
asS'DP'
p64363
S'2012 Feb'
p64364
sS'OWN'
p64365
S'NLM'
p64366
sS'PT'
p64367
(lp64368
S'Evaluation Studies'
p64369
aS'Journal Article'
p64370
asS'LA'
p64371
(lp64372
S'eng'
p64373
asS'FAU'
p64374
(lp64375
S'Alamo, Stella'
p64376
aS'Wabwire-Mangen, Fred'
p64377
aS'Kenneth, Ekoru'
p64378
aS'Sunday, Pamella'
p64379
aS'Laga, Marie'
p64380
aS'Colebunders, Robert Leon'
p64381
asS'JT'
p64382
S'AIDS patient care and STDs'
p64383
sS'PG'
p64384
S'101-7'
p64385
sS'TI'
p64386
S'Task-shifting to community health workers: evaluation of the performance of a peer-led model in an antiretroviral program in Uganda.'
p64387
sS'RN'
p64388
(lp64389
S'0 (Anti-HIV Agents)'
p64390
asS'PL'
p64391
S'United States'
p64392
sS'TA'
p64393
S'AIDS Patient Care STDS'
p64394
sS'JID'
p64395
S'9607225'
p64396
sS'AB'
p64397
S"Task shifting to community health workers (CHW) has received recognition. We examined the performance of community antiretroviral therapy and tuberculosis treatment supporters (CATTS) in scaling up antiretroviral therapy (ART) in Reach Out, a community-based ART program in Uganda. Retrospective data on home visits made by CATTS were analyzed to examine the CATTS ability to perform home visits to patients based on the model's standard procedures. Qualitative interviews conducted with 347 randomly selected patients and 47 CATTS explored their satisfaction with the model. The CATTS ability to follow-up with patients worsened from patients requiring daily, weekly, monthly, to three-monthly home visits. Only 26% and 15% of them correctly home visited patients with drug side effects and a missed clinic appointment, respectively. Additionally, 83% visited stable pre-ART and ART patients (96%) more frequently than required. Six hundred eighty of the 3650 (18%) patients were lost to follow-up (LTFU) during the study period. The mean number of patients LTFU per CATTS was 40.5. Male (p = 0.005), worked for longer durations (p = 0.02), and had lower education (p = 0.005). An increased number of patients (p = 0.01) were associated with increased LTFU. Ninety-two percent of the CATTS felt the model could be improved by reducing the workload. CATTS who were HIV positive, female, not residing in the same village as their patients, more educated, married, on ART, and spent less time with the patients were rated better by their patients. The Reach-Out CHW model is labor-intensive. Triaged home visits could improve performance and allow CATTS time to focus on patients requiring more intensive follow-up."
p64398
sS'AD'
p64399
S'1 Executive Directors Office, Reach Out Mbuya Parish HIV/AIDS Initiative, Kampala, Uganda. stellaalamo@gmail.com'
p64400
sS'IP'
p64401
S'2'
sS'IS'
p64402
S'1557-7449 (Electronic) 1087-2914 (Linking)'
p64403
sS'DCOM'
p64404
S'20120417'
p64405
sS'AU'
p64406
(lp64407
S'Alamo S'
p64408
aS'Wabwire-Mangen F'
p64409
aS'Kenneth E'
p64410
aS'Sunday P'
p64411
aS'Laga M'
p64412
aS'Colebunders RL'
p64413
asS'VI'
p64414
S'26'
p64415
sS'MHDA'
p64416
S'2012/04/18 06:00'
p64417
sS'PHST'
p64418
(lp64419
S'2012/01/06 [aheadofprint]'
p64420
asS'MH'
p64421
(lp64422
S'Adolescent'
p64423
aS'Adult'
p64424
aS'Ambulatory Care Facilities/manpower/*organization & administration/statistics & numerical data'
p64425
aS'Anti-HIV Agents/*therapeutic use'
p64426
aS'Child'
p64427
aS'*Community Health Workers'
p64428
aS'Female'
p64429
aS'Follow-Up Studies'
p64430
aS'HIV Seropositivity/*drug therapy/epidemiology'
p64431
aS'Home Care Services/manpower/*organization & administration/statistics & numerical data'
p64432
aS'House Calls'
p64433
aS'Humans'
p64434
aS'Lost to Follow-Up'
p64435
aS'Male'
p64436
aS'Middle Aged'
p64437
aS'Program Evaluation'
p64438
aS'Retrospective Studies'
p64439
aS'Uganda/epidemiology'
p64440
aS'Young Adult'
p64441
asS'EDAT'
p64442
S'2012/01/10 06:00'
p64443
sS'SO'
p64444
S'AIDS Patient Care STDS. 2012 Feb;26(2):101-7. doi: 10.1089/apc.2011.0279. Epub 2012 Jan 6.'
p64445
sS'SB'
p64446
S'IM X'
p64447
sS'PMID'
p64448
S'22224411'
p64449
sS'PST'
p64450
S'ppublish'
p64451
stRp64452
ag2
(g3
g4
(dp64453
S'LID'
p64454
S'10.1371/journal.pone.0028691 [doi]'
p64455
sS'STAT'
p64456
S'MEDLINE'
p64457
sS'DEP'
p64458
S'20111229'
p64459
sS'DA'
p64460
S'20120105'
p64461
sS'AID'
p64462
(lp64463
S'10.1371/journal.pone.0028691 [doi]'
p64464
aS'PONE-D-11-12223 [pii]'
p64465
asS'CRDT'
p64466
(lp64467
S'2012/01/06 06:00'
p64468
asS'DP'
p64469
S'2011'
p64470
sS'AD'
p64471
S'School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America. agupta25@jhmi.edu'
p64472
sS'OWN'
p64473
S'NLM'
p64474
sS'PT'
p64475
(lp64476
S'Journal Article'
p64477
aS'Meta-Analysis'
p64478
aS'Research Support, N.I.H., Extramural'
p64479
aS'Review'
p64480
asS'LA'
p64481
(lp64482
S'eng'
p64483
asS'FAU'
p64484
(lp64485
S'Gupta, Amita'
p64486
aS'Nadkarni, Girish'
p64487
aS'Yang, Wei-Teng'
p64488
aS'Chandrasekhar, Aditya'
p64489
aS'Gupte, Nikhil'
p64490
aS'Bisson, Gregory P'
p64491
aS'Hosseinipour, Mina'
p64492
aS'Gummadi, Naveen'
p64493
asS'JT'
p64494
S'PloS one'
p64495
sS'LR'
p64496
S'20150128'
p64497
sS'PG'
p64498
S'e28691'
p64499
sS'TI'
p64500
S'Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis.'
p64501
sS'PL'
p64502
S'United States'
p64503
sS'TA'
p64504
S'PLoS One'
p64505
sS'JID'
p64506
S'101285081'
p64507
sS'AB'
p64508
S'BACKGROUND: We systematically reviewed observational studies of early mortality post-antiretroviral therapy (ART) initiation in low- and middle-income countries (LMIC) in Asia, Africa, and Central and South America, as defined by the World Bank, to summarize what is known. METHODS AND FINDINGS: Studies published in English between January 1996 and December 2010 were searched in Medline and EMBASE. Three independent reviewers examined studies of mortality within one year post-ART. An article was included if the study was conducted in a LMIC, participants were initiating ART in a non-clinical trial setting and were >/=15 years. Fifty studies were included; 38 (76%) from sub-Saharan Africa (SSA), 5 (10%) from Asia, 2 (4%) from the Americas, and 5 (10%) were multi-regional. Median follow-up time and pre-ART CD4 cell count ranged from 3-55 months and 11-192 cells/mm(3), respectively. Loss-to-follow-up, reported in 40 (80%) studies, ranged from 0.3%-27%. Overall, SSA had the highest pooled 12-month mortality probability of 0.17 (95% CI 0.11-0.24) versus 0.11 (95% CI 0.10-0.13) for Asia, and 0.07 (95% CI 0.007-0.20) for the Americas. Of 14 (28%) studies reporting cause-specific mortality, tuberculosis (TB) (5%-44%), wasting (5%-53%), advanced HIV (20%-37%), and chronic diarrhea (10%-25%) were most common. Independent factors associated with early mortality in 30 (60%) studies included: low baseline CD4 cell count, male sex, advanced World Health Organization clinical stage, low body mass index, anemia, age greater than 40 years, and pre-ART quantitative HIV RNA. CONCLUSIONS: Significant heterogeneity in outcomes and in methods of reporting outcomes exist among published studies evaluating mortality in the first year after ART initiation in LMIC. Early mortality rates are highest in SSA, and opportunistic illnesses such as TB and wasting syndrome are the most common reported causes of death. Strategies addressing modifiable risk factors associated with early death are urgently needed.'
p64509
sS'GR'
p64510
(lp64511
S'R01 AI080417/AI/NIAID NIH HHS/United States'
p64512
asS'IP'
p64513
S'12'
p64514
sS'IS'
p64515
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p64516
sS'PMC'
p64517
S'PMC3248405'
p64518
sS'DCOM'
p64519
S'20120425'
p64520
sS'AU'
p64521
(lp64522
S'Gupta A'
p64523
aS'Nadkarni G'
p64524
aS'Yang WT'
p64525
aS'Chandrasekhar A'
p64526
aS'Gupte N'
p64527
aS'Bisson GP'
p64528
aS'Hosseinipour M'
p64529
aS'Gummadi N'
p64530
asS'VI'
p64531
S'6'
sS'MHDA'
p64532
S'2012/04/26 06:00'
p64533
sS'PHST'
p64534
(lp64535
S'2011/06/29 [received]'
p64536
aS'2011/11/14 [accepted]'
p64537
aS'2011/12/29 [epublish]'
p64538
asS'OID'
p64539
(lp64540
S'NLM: PMC3248405'
p64541
asS'MH'
p64542
(lp64543
S'Adult'
p64544
aS'Antiretroviral Therapy, Highly Active/*statistics & numerical data'
p64545
aS'Cause of Death'
p64546
aS'Developing Countries/*economics/*statistics & numerical data'
p64547
aS'HIV Infections/*economics/*mortality'
p64548
aS'Humans'
p64549
aS'Male'
p64550
aS'Odds Ratio'
p64551
aS'Poverty/*economics/*statistics & numerical data'
p64552
aS'Proportional Hazards Models'
p64553
aS'Risk Factors'
p64554
aS'Survival Analysis'
p64555
asS'EDAT'
p64556
S'2012/01/06 06:00'
p64557
sS'SO'
p64558
S'PLoS One. 2011;6(12):e28691. doi: 10.1371/journal.pone.0028691. Epub 2011 Dec 29.'
p64559
sS'SB'
p64560
S'IM'
p64561
sS'PMID'
p64562
S'22220193'
p64563
sS'PST'
p64564
S'ppublish'
p64565
stRp64566
ag2
(g3
g4
(dp64567
S'LID'
p64568
S'10.1371/journal.pone.0027919 [doi]'
p64569
sS'STAT'
p64570
S'MEDLINE'
p64571
sS'DEP'
p64572
S'20111219'
p64573
sS'DA'
p64574
S'20111229'
p64575
sS'AID'
p64576
(lp64577
S'10.1371/journal.pone.0027919 [doi]'
p64578
aS'PONE-D-11-06655 [pii]'
p64579
asS'CRDT'
p64580
(lp64581
S'2011/12/30 06:00'
p64582
asS'DP'
p64583
S'2011'
p64584
sS'GR'
p64585
(lp64586
S'1 U01AI069924-01/AI/NIAID NIH HHS/United States'
p64587
aS'U01 AI069924/AI/NIAID NIH HHS/United States'
p64588
asS'OWN'
p64589
S'NLM'
p64590
sS'PT'
p64591
(lp64592
S'Journal Article'
p64593
aS'Research Support, N.I.H., Extramural'
p64594
aS"Research Support, Non-U.S. Gov't"
p64595
asS'LA'
p64596
(lp64597
S'eng'
p64598
asS'FAU'
p64599
(lp64600
S'Schoni-Affolter, Franziska'
p64601
aS'Keiser, Olivia'
p64602
aS'Mwango, Albert'
p64603
aS'Stringer, Jeffrey'
p64604
aS'Ledergerber, Bruno'
p64605
aS'Mulenga, Lloyd'
p64606
aS'Bucher, Heiner C'
p64607
aS'Westfall, Andrew O'
p64608
aS'Calmy, Alexandra'
p64609
aS'Boulle, Andrew'
p64610
aS'Chintu, Namwinga'
p64611
aS'Egger, Matthias'
p64612
aS'Chi, Benjamin H'
p64613
asS'JT'
p64614
S'PloS one'
p64615
sS'LR'
p64616
S'20150129'
p64617
sS'PG'
p64618
S'e27919'
p64619
sS'TI'
p64620
S'Estimating loss to follow-up in HIV-infected patients on antiretroviral therapy: the effect of the competing risk of death in Zambia and Switzerland.'
p64621
sS'RN'
p64622
(lp64623
S'0 (Anti-HIV Agents)'
p64624
asS'PL'
p64625
S'United States'
p64626
sS'TA'
p64627
S'PLoS One'
p64628
sS'FIR'
p64629
(lp64630
S'Barth, J'
p64631
aS'Battegay, M'
p64632
aS'Bernasconi, E'
p64633
aS'Boni, J'
p64634
aS'Bucher, H C'
p64635
aS'Burgisser, P'
p64636
aS'Burton-Jeangros, C'
p64637
aS'Calmy, A'
p64638
aS'Cavassini, M'
p64639
aS'Egger, M'
p64640
aS'Elzi, L'
p64641
aS'Fehr, J'
p64642
aS'Flepp, M'
p64643
aS'Francioli, P'
p64644
aS'Furrer, H'
p64645
aS'Fux, C A'
p64646
aS'Gorgievski, M'
p64647
aS'Gunthard, H'
p64648
aS'Hasse, B'
p64649
aS'Hirsch, H H'
p64650
aS'Hirschel, B'
p64651
aS'Hosli, I'
p64652
aS'Kahlert, C'
p64653
aS'Kaiser, L'
p64654
aS'Kaiser, O'
p64655
aS'Kind, C'
p64656
aS'Klimkait, T'
p64657
aS'Kovari, H'
p64658
aS'Ledergerber, B'
p64659
aS'Martinetti, G'
p64660
aS'Tejada, B Martinez de'
p64661
aS'Muller, N'
p64662
aS'Nadal, D'
p64663
aS'Pantaleo, G'
p64664
aS'Rauch, A'
p64665
aS'Regenass, S'
p64666
aS'Rickenbach, M'
p64667
aS'Rudin, C'
p64668
aS'Schmid, P'
p64669
aS'Schultze, D'
p64670
aS'Schoni-Affolter, F'
p64671
aS'Schupbach, J'
p64672
aS'Speck, R'
p64673
aS'Taffe, P'
p64674
aS'Telenti, A'
p64675
aS'Trkola, A'
p64676
aS'Vernazza, P'
p64677
aS'Wyl, V von'
p64678
aS'Weber, R'
p64679
aS'Yerly, S'
p64680
asS'JID'
p64681
S'101285081'
p64682
sS'AB'
p64683
S'BACKGROUND: Loss to follow-up (LTFU) is common in antiretroviral therapy (ART) programmes. Mortality is a competing risk (CR) for LTFU; however, it is often overlooked in cohort analyses. We examined how the CR of death affected LTFU estimates in Zambia and Switzerland. METHODS AND FINDINGS: HIV-infected patients aged >/=18 years who started ART 2004-2008 in observational cohorts in Zambia and Switzerland were included. We compared standard Kaplan-Meier curves with CR cumulative incidence. We calculated hazard ratios for LTFU across CD4 cell count strata using cause-specific Cox models, or Fine and Gray subdistribution models, adjusting for age, gender, body mass index and clinical stage. 89,339 patients from Zambia and 1,860 patients from Switzerland were included. 12,237 patients (13.7%) in Zambia and 129 patients (6.9%) in Switzerland were LTFU and 8,498 (9.5%) and 29 patients (1.6%), respectively, died. In Zambia, the probability of LTFU was overestimated in Kaplan-Meier curves: estimates at 3.5 years were 29.3% for patients starting ART with CD4 cells <100 cells/microl and 15.4% among patients starting with >/= 350 cells/microL. The estimates from CR cumulative incidence were 22.9% and 13.6%, respectively. Little difference was found between naive and CR analyses in Switzerland since only few patients died. The results from Cox and Fine and Gray models were similar: in Zambia the risk of loss to follow-up and death increased with decreasing CD4 counts at the start of ART, whereas in Switzerland there was a trend in the opposite direction, with patients with higher CD4 cell counts more likely to be lost to follow-up. CONCLUSIONS: In ART programmes in low-income settings the competing risk of death can substantially bias standard analyses of LTFU. The CD4 cell count and other prognostic factors may be differentially associated with LTFU in low-income and high-income settings.'
p64684
sS'AD'
p64685
S'Division of International and Environmental Health, Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland.'
p64686
sS'CN'
p64687
(lp64688
S'Swiss HIV Cohort Study'
p64689
aS'IeDEA Southern Africa'
p64690
asS'IP'
p64691
S'12'
p64692
sS'IS'
p64693
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p64694
sS'IR'
p64695
(lp64696
S'Barth J'
p64697
aS'Battegay M'
p64698
aS'Bernasconi E'
p64699
aS'Boni J'
p64700
aS'Bucher HC'
p64701
aS'Burgisser P'
p64702
aS'Burton-Jeangros C'
p64703
aS'Calmy A'
p64704
aS'Cavassini M'
p64705
aS'Egger M'
p64706
aS'Elzi L'
p64707
aS'Fehr J'
p64708
aS'Flepp M'
p64709
aS'Francioli P'
p64710
aS'Furrer H'
p64711
aS'Fux CA'
p64712
aS'Gorgievski M'
p64713
aS'Gunthard H'
p64714
aS'Hasse B'
p64715
aS'Hirsch HH'
p64716
aS'Hirschel B'
p64717
aS'Hosli I'
p64718
aS'Kahlert C'
p64719
aS'Kaiser L'
p64720
aS'Kaiser O'
p64721
aS'Kind C'
p64722
aS'Klimkait T'
p64723
aS'Kovari H'
p64724
aS'Ledergerber B'
p64725
aS'Martinetti G'
p64726
aS'Tejada BM'
p64727
aS'Muller N'
p64728
aS'Nadal D'
p64729
aS'Pantaleo G'
p64730
aS'Rauch A'
p64731
aS'Regenass S'
p64732
aS'Rickenbach M'
p64733
aS'Rudin C'
p64734
aS'Schmid P'
p64735
aS'Schultze D'
p64736
aS'Schoni-Affolter F'
p64737
aS'Schupbach J'
p64738
aS'Speck R'
p64739
aS'Taffe P'
p64740
aS'Telenti A'
p64741
aS'Trkola A'
p64742
aS'Vernazza P'
p64743
aS'Wyl Vv'
p64744
aS'Weber R'
p64745
aS'Yerly S'
p64746
asS'DCOM'
p64747
S'20120423'
p64748
sS'AU'
p64749
(lp64750
S'Schoni-Affolter F'
p64751
aS'Keiser O'
p64752
aS'Mwango A'
p64753
aS'Stringer J'
p64754
aS'Ledergerber B'
p64755
aS'Mulenga L'
p64756
aS'Bucher HC'
p64757
aS'Westfall AO'
p64758
aS'Calmy A'
p64759
aS'Boulle A'
p64760
aS'Chintu N'
p64761
aS'Egger M'
p64762
aS'Chi BH'
p64763
asS'VI'
p64764
S'6'
sS'MHDA'
p64765
S'2012/04/24 06:00'
p64766
sS'PHST'
p64767
(lp64768
S'2011/04/13 [received]'
p64769
aS'2011/10/27 [accepted]'
p64770
aS'2011/12/19 [epublish]'
p64771
asS'OID'
p64772
(lp64773
S'NLM: PMC3242760'
p64774
asS'MH'
p64775
(lp64776
S'Adult'
p64777
aS'Anti-HIV Agents/*therapeutic use'
p64778
aS'Cohort Studies'
p64779
aS'Female'
p64780
aS'HIV Infections/*drug therapy/*epidemiology/mortality'
p64781
aS'Humans'
p64782
aS'*Lost to Follow-Up'
p64783
aS'Male'
p64784
aS'Middle Aged'
p64785
aS'Proportional Hazards Models'
p64786
aS'Risk'
p64787
aS'Switzerland/epidemiology'
p64788
aS'Zambia/epidemiology'
p64789
asS'EDAT'
p64790
S'2011/12/30 06:00'
p64791
sS'PMC'
p64792
S'PMC3242760'
p64793
sS'SO'
p64794
S'PLoS One. 2011;6(12):e27919. doi: 10.1371/journal.pone.0027919. Epub 2011 Dec 19.'
p64795
sS'SB'
p64796
S'IM'
p64797
sS'PMID'
p64798
S'22205933'
p64799
sS'PST'
p64800
S'ppublish'
p64801
stRp64802
ag2
(g3
g4
(dp64803
S'LID'
p64804
S'10.1371/journal.pone.0028034 [doi]'
p64805
sS'STAT'
p64806
S'MEDLINE'
p64807
sS'DEP'
p64808
S'20111214'
p64809
sS'DA'
p64810
S'20111223'
p64811
sS'AID'
p64812
(lp64813
S'10.1371/journal.pone.0028034 [doi]'
p64814
aS'PONE-D-11-12062 [pii]'
p64815
asS'CRDT'
p64816
(lp64817
S'2011/12/24 06:00'
p64818
asS'DP'
p64819
S'2011'
p64820
sS'OWN'
p64821
S'NLM'
p64822
sS'PT'
p64823
(lp64824
S'Journal Article'
p64825
aS"Research Support, U.S. Gov't, Non-P.H.S."
p64826
asS'LA'
p64827
(lp64828
S'eng'
p64829
asS'FAU'
p64830
(lp64831
S'Tweya, Hannock'
p64832
aS'Kanyerere, Henry'
p64833
aS'Ben-Smith, Anne'
p64834
aS'Kwanjana, John'
p64835
aS'Jahn, Andreas'
p64836
aS'Feldacker, Caryl'
p64837
aS'Gareta, Dickman'
p64838
aS'Mbetewa, Limbani'
p64839
aS'Kagoli, Mathew'
p64840
aS'Kalulu, Mike Tikhalenawo'
p64841
aS'Weigel, Ralf'
p64842
aS'Phiri, Sam'
p64843
aS'Edginton, Mary'
p64844
asS'JT'
p64845
S'PloS one'
p64846
sS'LR'
p64847
S'20150129'
p64848
sS'PG'
p64849
S'e28034'
p64850
sS'TI'
p64851
S'Re-treatment tuberculosis cases categorised as "other": are they properly managed?'
p64852
sS'PL'
p64853
S'United States'
p64854
sS'TA'
p64855
S'PLoS One'
p64856
sS'JID'
p64857
S'101285081'
p64858
sS'AB'
p64859
S'BACKGROUND: Although the World Health Organization (WHO) provides information on the number of TB patients categorised as "other", there is limited information on treatment regimens or treatment outcomes for "other". Such information is important, as inappropriate treatment can lead to patients remaining infectious and becoming a potential source of drug resistance. Therefore, using a cohort of TB patients from a large registration centre in Lilongwe, Malawi, our study determined the proportion of all TB re-treatment patients who were registered as "other", and described their characteristics and treatment outcomes. METHODS: This retrospective observational study used routine program data to determine the proportion of all TB re-treatment patients who were registered as "other" and describe their characteristics and treatment outcomes between January 2006 and December 2008. RESULTS: 1,384 (12%) of 11,663 TB cases were registered as re-treatment cases. Of these, 898 (65%) were categorised as "other": 707 (79%) had sputum smear-negative pulmonary TB and 191 (21%) had extra pulmonary TB. Compared to the smear-positive relapse, re-treatment after default (RAD) and failure cases, smear-negative "other" cases were older than 34 years and less likely to have their HIV status ascertained. Among those with known HIV status, "other" TB cases were more likely to be HIV positive. Of TB patients categorised as "other", 462 (51%) were managed on the first-line regimen with a treatment success rate of 63%. CONCLUSION: A large proportion of re-treatment patients were categorised as "other". Many of these patients were HIV-infected and over half were treated with a first-line regimen, contrary to national guidelines. Treatment success was low. More attention to recording, diagnosis and management of these patients is warranted as incorrect treatment regimen and poor outcomes could lead to the development of drug resistant forms of TB.'
p64860
sS'AD'
p64861
S'The International Union Against Tuberculosis and Lung Disease, Paris, France. h_tweya@lighthouse.org.mw'
p64862
sS'IP'
p64863
S'12'
p64864
sS'IS'
p64865
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p64866
sS'PMC'
p64867
S'PMC3237425'
p64868
sS'DCOM'
p64869
S'20120827'
p64870
sS'AU'
p64871
(lp64872
S'Tweya H'
p64873
aS'Kanyerere H'
p64874
aS'Ben-Smith A'
p64875
aS'Kwanjana J'
p64876
aS'Jahn A'
p64877
aS'Feldacker C'
p64878
aS'Gareta D'
p64879
aS'Mbetewa L'
p64880
aS'Kagoli M'
p64881
aS'Kalulu MT'
p64882
aS'Weigel R'
p64883
aS'Phiri S'
p64884
aS'Edginton M'
p64885
asS'VI'
p64886
S'6'
sS'MHDA'
p64887
S'2012/08/28 06:00'
p64888
sS'PHST'
p64889
(lp64890
S'2011/06/28 [received]'
p64891
aS'2011/10/30 [accepted]'
p64892
aS'2011/12/14 [epublish]'
p64893
asS'OID'
p64894
(lp64895
S'NLM: PMC3237425'
p64896
asS'MH'
p64897
(lp64898
S'Adolescent'
p64899
aS'Adult'
p64900
aS'Female'
p64901
aS'Humans'
p64902
aS'Incidence'
p64903
aS'Malawi/epidemiology'
p64904
aS'Male'
p64905
aS'Retreatment'
p64906
aS'Treatment Outcome'
p64907
aS'Tuberculosis/*drug therapy/*epidemiology'
p64908
aS'Young Adult'
p64909
asS'EDAT'
p64910
S'2011/12/24 06:00'
p64911
sS'SO'
p64912
S'PLoS One. 2011;6(12):e28034. doi: 10.1371/journal.pone.0028034. Epub 2011 Dec 14.'
p64913
sS'SB'
p64914
S'IM'
p64915
sS'PMID'
p64916
S'22194804'
p64917
sS'PST'
p64918
S'ppublish'
p64919
stRp64920
ag2
(g3
g4
(dp64921
S'LID'
p64922
S'10.1097/QAI.0b013e31824476c4 [doi]'
p64923
sS'STAT'
p64924
S'MEDLINE'
p64925
sS'AB'
p64926
S'BACKGROUND: Access to antiretroviral therapy (ART) has rapidly expanded; as of the end of 2010, an estimated 6.6 million people are receiving ART in low-income and middle-income countries. Few reports have focused on the experiences of rural health centers or the use of community health workers. We report clinical and programatic outcomes at 24 months for a cohort of patients enrolled in a community-based ART program in southeastern Rwanda under collaboration between Partners In Health and the Rwandan Ministry of Health. METHODS AND FINDINGS: A retrospective medical record review was performed for a cohort of 1041 HIV+ adult patients initiating community-based ART between June 1, 2005, and April 30, 2006. Key programatic elements included free ART with direct observation by community health worker, tuberculosis screening and treatment, nutritional support, a transportation allowance, and social support. Among 1041 patients who initiated community-based ART, 961 (92.3%) were retained in care, 52 (5%) died and 28 (2.7%) were lost to follow-up. Median CD4 T-cell count increase was 336 cells per microliter [interquartile range: (IQR): 212-493] from median 190 cells per microliter (IQR: 116-270) at initiation. CONCLUSIONS: A program of intensive community-based treatment support for ART in rural Rwanda had excellent outcomes in 24-month retention in care. Having committed to improving access to HIV treatment in sub-Saharan Africa, the international community, including country HIV programs, should set high programmatic outcome benchmarks.'
p64927
sS'JID'
p64928
S'100892005'
p64929
sS'AD'
p64930
S"Division of Global Health Equity, Brigham and Women's Hospital, Boston, MA, USA."
p64931
sS'JT'
p64932
S'Journal of acquired immune deficiency syndromes (1999)'
p64933
sS'IP'
p64934
S'3'
sS'IS'
p64935
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p64936
sS'DCOM'
p64937
S'20120613'
p64938
sS'DA'
p64939
S'20120215'
p64940
sS'AU'
p64941
(lp64942
S'Rich ML'
p64943
aS'Miller AC'
p64944
aS'Niyigena P'
p64945
aS'Franke MF'
p64946
aS'Niyonzima JB'
p64947
aS'Socci A'
p64948
aS'Drobac PC'
p64949
aS'Hakizamungu M'
p64950
aS'Mayfield A'
p64951
aS'Ruhayisha R'
p64952
aS'Epino H'
p64953
aS'Stulac S'
p64954
aS'Cancedda C'
p64955
aS'Karamaga A'
p64956
aS'Niyonzima S'
p64957
aS'Yarbrough C'
p64958
aS'Fleming J'
p64959
aS'Amoroso C'
p64960
aS'Mukherjee J'
p64961
aS'Murray M'
p64962
aS'Farmer P'
p64963
aS'Binagwaho A'
p64964
asS'AID'
p64965
(lp64966
S'10.1097/QAI.0b013e31824476c4 [doi]'
p64967
asS'CRDT'
p64968
(lp64969
S'2011/12/14 06:00'
p64970
asS'VI'
p64971
S'59'
p64972
sS'PMID'
p64973
S'22156912'
p64974
sS'DP'
p64975
S'2012 Mar 1'
p64976
sS'MHDA'
p64977
S'2012/06/14 06:00'
p64978
sS'OWN'
p64979
S'NLM'
p64980
sS'PT'
p64981
(lp64982
S'Journal Article'
p64983
aS"Research Support, Non-U.S. Gov't"
p64984
asS'LA'
p64985
(lp64986
S'eng'
p64987
asS'MH'
p64988
(lp64989
S'Adolescent'
p64990
aS'Adult'
p64991
aS'Aged'
p64992
aS'Anti-HIV Agents/*therapeutic use'
p64993
aS'CD4 Lymphocyte Count'
p64994
aS'Cohort Studies'
p64995
aS'Female'
p64996
aS'HIV/genetics/*isolation & purification'
p64997
aS'HIV Infections/*drug therapy/immunology/virology'
p64998
aS'Humans'
p64999
aS'Logistic Models'
p65000
aS'Male'
p65001
aS'Middle Aged'
p65002
aS'Patient Compliance'
p65003
aS'Patient Dropouts'
p65004
aS'RNA, Viral/blood'
p65005
aS'Retrospective Studies'
p65006
aS'Rural Population'
p65007
aS'Rwanda'
p65008
aS'Treatment Outcome'
p65009
aS'Young Adult'
p65010
asS'FAU'
p65011
(lp65012
S'Rich, Michael L'
p65013
aS'Miller, Ann C'
p65014
aS'Niyigena, Peter'
p65015
aS'Franke, Molly F'
p65016
aS'Niyonzima, Jean Bosco'
p65017
aS'Socci, Adrienne'
p65018
aS'Drobac, Peter C'
p65019
aS'Hakizamungu, Massudi'
p65020
aS'Mayfield, Alishya'
p65021
aS'Ruhayisha, Robert'
p65022
aS'Epino, Henry'
p65023
aS'Stulac, Sara'
p65024
aS'Cancedda, Corrado'
p65025
aS'Karamaga, Adolph'
p65026
aS'Niyonzima, Saleh'
p65027
aS'Yarbrough, Chase'
p65028
aS'Fleming, Julia'
p65029
aS'Amoroso, Cheryl'
p65030
aS'Mukherjee, Joia'
p65031
aS'Murray, Megan'
p65032
aS'Farmer, Paul'
p65033
aS'Binagwaho, Agnes'
p65034
asS'EDAT'
p65035
S'2011/12/14 06:00'
p65036
sS'PST'
p65037
S'ppublish'
p65038
sS'SO'
p65039
S'J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):e35-42. doi: 10.1097/QAI.0b013e31824476c4.'
p65040
sS'PG'
p65041
S'e35-42'
p65042
sS'TI'
p65043
S'Excellent clinical outcomes and high retention in care among adults in a community-based HIV treatment program in rural Rwanda.'
p65044
sS'SB'
p65045
S'IM X'
p65046
sS'RN'
p65047
(lp65048
S'0 (Anti-HIV Agents)'
p65049
aS'0 (RNA, Viral)'
p65050
asS'PL'
p65051
S'United States'
p65052
sS'TA'
p65053
S'J Acquir Immune Defic Syndr'
p65054
stRp65055
ag2
(g3
g4
(dp65056
S'LID'
p65057
S'10.1016/j.trstmh.2011.10.015 [doi]'
p65058
sS'STAT'
p65059
S'MEDLINE'
p65060
sS'DEP'
p65061
S'20111210'
p65062
sS'CI'
p65063
(lp65064
S'Copyright (c) 2011 Royal Society of Tropical Medicine and Hygiene. Published by'
p65065
aS'Elsevier Ltd. All rights reserved.'
p65066
asS'DA'
p65067
S'20120110'
p65068
sS'AID'
p65069
(lp65070
S'S0035-9203(11)00226-4 [pii]'
p65071
aS'10.1016/j.trstmh.2011.10.015 [doi]'
p65072
asS'CRDT'
p65073
(lp65074
S'2011/12/14 06:00'
p65075
asS'DP'
p65076
S'2012 Feb'
p65077
sS'OWN'
p65078
S'NLM'
p65079
sS'PT'
p65080
(lp65081
S'Journal Article'
p65082
aS"Research Support, Non-U.S. Gov't"
p65083
asS'LA'
p65084
(lp65085
S'eng'
p65086
asS'FAU'
p65087
(lp65088
S'Namuwenge, P M'
p65089
aS'Mukonzo, J K'
p65090
aS'Kiwanuka, N'
p65091
aS'Wanyenze, R'
p65092
aS'Byaruhanga, R'
p65093
aS'Bissell, K'
p65094
aS'Zachariah, R'
p65095
asS'JT'
p65096
S'Transactions of the Royal Society of Tropical Medicine and Hygiene'
p65097
sS'LR'
p65098
S'20131121'
p65099
sS'PG'
p65100
S'84-9'
p65101
sS'TI'
p65102
S'Loss to follow up from isoniazid preventive therapy among adults attending HIV voluntary counseling and testing sites in Uganda.'
p65103
sS'RN'
p65104
(lp65105
S'0 (Antitubercular Agents)'
p65106
aS'V83O1VOZ8L (Isoniazid)'
p65107
asS'PL'
p65108
S'England'
p65109
sS'TA'
p65110
S'Trans R Soc Trop Med Hyg'
p65111
sS'JID'
p65112
S'7506129'
p65113
sS'AB'
p65114
S'Among HIV-infected adults attending non-governmental organization voluntary counseling and testing (VCT) sites in Uganda that provide a nine-month course of isoniazid preventive treatment (IPT), we report on loss to follow-up (LTFU) and its associated risk factors. The design was a retrospective cohort study of program data spanning a three year period (2006-2008). A total of 586 IPT patients were enrolled of whom 335 (57.1%) were females with a mean age of 34 years. Of those starting IPT, 341 (58.1%) were lost to follow-up, 197 (33.6%) completed IPT, 29 (4.9%) were discontinued and 19 (3.2%) died. The return rates at one, three, five and seven months were 78.0% (457), 62.1% (364), 52.9% (310) and 33.6% (197) respectively. Being less than 30 years of age, widowed, separated, or divorced were found to be associated with a higher risk of loss to follow-up. Sudden improvement in retention on IPT was observed between the years 2006 and 2007, although causes of the improvement are poorly understood hence the need for more research. At non-governmental VCT sites in Uganda, six out of ten individuals enrolled on IPT are lost to follow-up and efforts to reduce this attrition including systems strengthening might play a critical role in the success of IPT programs.'
p65115
sS'AD'
p65116
S'Makerere University School of Public Health, Kampala, Uganda. namuwengep@yahoo.com'
p65117
sS'IP'
p65118
S'2'
sS'IS'
p65119
S'1878-3503 (Electronic) 0035-9203 (Linking)'
p65120
sS'DCOM'
p65121
S'20120307'
p65122
sS'AU'
p65123
(lp65124
S'Namuwenge PM'
p65125
aS'Mukonzo JK'
p65126
aS'Kiwanuka N'
p65127
aS'Wanyenze R'
p65128
aS'Byaruhanga R'
p65129
aS'Bissell K'
p65130
aS'Zachariah R'
p65131
asS'VI'
p65132
S'106'
p65133
sS'MHDA'
p65134
S'2012/03/08 06:00'
p65135
sS'PHST'
p65136
(lp65137
S'2010/11/24 [received]'
p65138
aS'2011/10/19 [revised]'
p65139
aS'2011/10/19 [accepted]'
p65140
aS'2011/12/10 [aheadofprint]'
p65141
asS'MH'
p65142
(lp65143
S'AIDS-Related Opportunistic Infections/diagnosis/*drug therapy/epidemiology'
p65144
aS'Adult'
p65145
aS'Antitubercular Agents/*therapeutic use'
p65146
aS'Counseling/*statistics & numerical data'
p65147
aS'Female'
p65148
aS'Humans'
p65149
aS'Isoniazid/*therapeutic use'
p65150
aS'*Lost to Follow-Up'
p65151
aS'Male'
p65152
aS'Retrospective Studies'
p65153
aS'Risk Factors'
p65154
aS'Tuberculin Test'
p65155
aS'Tuberculosis/diagnosis/*drug therapy/epidemiology'
p65156
aS'Uganda/epidemiology'
p65157
asS'EDAT'
p65158
S'2011/12/14 06:00'
p65159
sS'SO'
p65160
S'Trans R Soc Trop Med Hyg. 2012 Feb;106(2):84-9. doi: 10.1016/j.trstmh.2011.10.015. Epub 2011 Dec 10.'
p65161
sS'SB'
p65162
S'IM'
p65163
sS'PMID'
p65164
S'22154974'
p65165
sS'PST'
p65166
S'ppublish'
p65167
stRp65168
ag2
(g3
g4
(dp65169
S'LID'
p65170
S'10.1016/j.jval.2011.06.011 [doi]'
p65171
sS'STAT'
p65172
S'MEDLINE'
p65173
sS'DEP'
p65174
S'20111106'
p65175
sS'CI'
p65176
(lp65177
S'Copyright (c) 2011 International Society for Pharmacoeconomics and Outcomes'
p65178
aS'Research (ISPOR). Published by Elsevier Inc. All rights reserved.'
p65179
asS'DA'
p65180
S'20111214'
p65181
sS'AID'
p65182
(lp65183
S'S1098-3015(11)01566-X [pii]'
p65184
aS'10.1016/j.jval.2011.06.011 [doi]'
p65185
asS'CRDT'
p65186
(lp65187
S'2011/12/14 06:00'
p65188
asS'DP'
p65189
S'2011 Dec'
p65190
sS'OWN'
p65191
S'NLM'
p65192
sS'PT'
p65193
(lp65194
S'Journal Article'
p65195
aS"Research Support, Non-U.S. Gov't"
p65196
asS'LA'
p65197
(lp65198
S'eng'
p65199
asS'FAU'
p65200
(lp65201
S'Simpson, Kit N'
p65202
aS'Baran, Robert W'
p65203
aS'Kirbach, Stephanie E'
p65204
aS'Dietz, Birgitta'
p65205
asS'JT'
p65206
S'Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research'
p65207
sS'LR'
p65208
S'20131121'
p65209
sS'PG'
p65210
S'1048-54'
p65211
sS'TI'
p65212
S'Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya.'
p65213
sS'RN'
p65214
(lp65215
S'0 (Anti-HIV Agents)'
p65216
aS'0 (Drug Combinations)'
p65217
aS'0 (lopinavir-ritonavir drug combination)'
p65218
aS'2494G1JF75 (Lopinavir)'
p65219
aS'O3J8G9O825 (Ritonavir)'
p65220
asS'PL'
p65221
S'United States'
p65222
sS'TA'
p65223
S'Value Health'
p65224
sS'JID'
p65225
S'100883818'
p65226
sS'AB'
p65227
S'BACKGROUND: Substantial immunological improvement has been reported for HIV-infected patients who switch from a failing regimen to a protease inhibitor regimen with Lopinavir/ritonavir (LPV/r). We use decision analysis modeling to estimate health and economic consequences expected from this switch. METHODS: A Markov model combined best evidence for CD4(+) T-cell response, infectious disease events, death rates, and quality of life for African populations with Kenyan and Ugandan data on drug and medical care costs. We estimate the incremental cost-effectiveness ratio of switching to an LPV/r-based regimen versus remaining on a failed first antiretroviral (ARV) regimen or discontinuing all ARV drugs. The model assumes concurrent use of cotrimoxazole, and 4% annual loss to follow-up. Local effects due to prevalence of malaria and tuberculosis are included in the model. Sensitivity analysis examines the effects of varying disease, ARV therapy and CD4(+) T-cell cost, and ART discontinuation assumptions. RESULTS: The base model estimates an improvement of 20 months in average survival for the LPV/r group. The respective LPV/r ICER for Kenya is $1483 per quality-adjusted life year (QALY) compared to $1673/QALY for Uganda. The ICERs increase to $1517 and $1707, respectively, if CD4(+) T-cell tests cost $25. The model comparing switching to LPV/r to discontinuing all ARV drugs decreases both costs and benefits proportionally for the treatment groups. CONCLUSION: The estimates are clearly below the most stringent World Health Organization benchmark for cost-effectiveness for Kenya and within the acceptable range of cost-effectiveness for Uganda. Thus, the switch to second-line therapy with LPV/r in these countries appears to be a cost-effective use of resources.'
p65228
sS'AD'
p65229
S'Department of Health Leadership and Management, Medical University of South Carolina, Charleston, SC 29425, USA. simpsonk@musc.edu'
p65230
sS'IP'
p65231
S'8'
sS'IS'
p65232
S'1524-4733 (Electronic) 1098-3015 (Linking)'
p65233
sS'DCOM'
p65234
S'20120131'
p65235
sS'AU'
p65236
(lp65237
S'Simpson KN'
p65238
aS'Baran RW'
p65239
aS'Kirbach SE'
p65240
aS'Dietz B'
p65241
asS'VI'
p65242
S'14'
p65243
sS'MHDA'
p65244
S'2012/02/01 06:00'
p65245
sS'PHST'
p65246
(lp65247
S'2010/09/13 [received]'
p65248
aS'2011/06/19 [revised]'
p65249
aS'2011/06/20 [accepted]'
p65250
aS'2011/11/06 [aheadofprint]'
p65251
asS'MH'
p65252
(lp65253
S'Anti-HIV Agents/economics/*therapeutic use'
p65254
aS'CD4-Positive T-Lymphocytes/immunology'
p65255
aS'Cost-Benefit Analysis'
p65256
aS'Decision Support Techniques'
p65257
aS'Drug Combinations'
p65258
aS'Drug Costs'
p65259
aS'HIV Infections/*drug therapy/economics'
p65260
aS'Health Care Costs'
p65261
aS'Humans'
p65262
aS'Kenya'
p65263
aS'Lopinavir/economics/*therapeutic use'
p65264
aS'Markov Chains'
p65265
aS'*Models, Economic'
p65266
aS'Quality of Life'
p65267
aS'Quality-Adjusted Life Years'
p65268
aS'Ritonavir/economics/*therapeutic use'
p65269
aS'Uganda'
p65270
asS'EDAT'
p65271
S'2011/12/14 06:00'
p65272
sS'SO'
p65273
S'Value Health. 2011 Dec;14(8):1048-54. doi: 10.1016/j.jval.2011.06.011. Epub 2011 Nov 6.'
p65274
sS'SB'
p65275
S'IM'
p65276
sS'PMID'
p65277
S'22152173'
p65278
sS'PST'
p65279
S'ppublish'
p65280
stRp65281
ag2
(g3
g4
(dp65282
S'LID'
p65283
S'10.1097/QAI.0b013e318243760b [doi]'
p65284
sS'STAT'
p65285
S'MEDLINE'
p65286
sS'JT'
p65287
S'Journal of acquired immune deficiency syndromes (1999)'
p65288
sS'MID'
p65289
(lp65290
S'NIHMS346250'
p65291
asS'DA'
p65292
S'20120709'
p65293
sS'AID'
p65294
(lp65295
S'10.1097/QAI.0b013e318243760b [doi]'
p65296
asS'CRDT'
p65297
(lp65298
S'2011/12/03 06:00'
p65299
asS'DP'
p65300
S'2012 Aug 1'
p65301
sS'AD'
p65302
S'Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital, University of the Witwatersrand, Johannesburg, South Africa.'
p65303
sS'OWN'
p65304
S'NLM'
p65305
sS'PT'
p65306
(lp65307
S'Journal Article'
p65308
aS'Randomized Controlled Trial'
p65309
aS'Research Support, N.I.H., Extramural'
p65310
aS"Research Support, Non-U.S. Gov't"
p65311
asS'LA'
p65312
(lp65313
S'eng'
p65314
asS'FAU'
p65315
(lp65316
S'Strehlau, Renate'
p65317
aS'Coovadia, Ashraf'
p65318
aS'Abrams, Elaine J'
p65319
aS'Martens, Leigh'
p65320
aS'Arpadi, Stephen'
p65321
aS'Meyers, Tammy'
p65322
aS'Kuhn, Louise'
p65323
asS'LR'
p65324
S'20150129'
p65325
sS'PG'
p65326
S'369-76'
p65327
sS'TI'
p65328
S'Lipid profiles in young HIV-infected children initiating and changing antiretroviral therapy.'
p65329
sS'RN'
p65330
(lp65331
S'0 (Anti-HIV Agents)'
p65332
aS'0 (Lipids)'
p65333
aS'2494G1JF75 (Lopinavir)'
p65334
aS'O3J8G9O825 (Ritonavir)'
p65335
asS'PL'
p65336
S'United States'
p65337
sS'TA'
p65338
S'J Acquir Immune Defic Syndr'
p65339
sS'JID'
p65340
S'100892005'
p65341
sS'AB'
p65342
S'BACKGROUND: Both HIV infection and antiretroviral therapy are associated with dyslipidemias in adults, but there are fewer data on outcomes in young children. Here we examined lipid profile changes in a cohort of young children before and after suppression on an initial ritonavir-boosted lopinavir (LPV/r)-based regimen and after switch to a nevirapine (NVP)-based regimen. METHODS: One hundred ninety-five HIV-infected children who initiated LPV/r-based therapy when <24 months of age at 1 site in Johannesburg, South Africa, and who achieved viral suppression (<400 copies/mL sustained for >/= 3 months) were randomized to either continue on the LPV/r-based regimen (n = 99) or to switch to a NVP-based regimen (n = 96). Nonfasting concentrations of total cholesterol (TC), low-density lipoprotein, high-density lipoprotein (HDL), and triglycerides (TG) were measured pretreatment, at randomization when suppressed, and at 9, 20, and 31 months postrandomization. RESULTS: Median age at treatment initiation was 9 months, and the initial regimen was maintained for an average of 9 months before randomization. TC, low-density lipoprotein, and HDL increased from pretreatment to randomization (P < 0.0001) and TC/HDL ratio and TG decreased (P < 0.0001). After switching to NVP, HDL was significantly higher (P < 0.02) and TC/HDL and TG significantly lower (P < 0.0001) through 31 months postswitch relative to remaining on the LPV/r-based regimen. CONCLUSION: Initiating antiretroviral therapy was associated with changes to a more favorable lipid profile in young children. Switching from a LPV/r-based regimen to a NVP-based regimen accentuated and continued these improvements. Investigation of safe and effective methods for managing dyslipidemias in children of different ages in resource-limited settings is warranted.'
p65343
sS'GR'
p65344
(lp65345
S'HD 47177/HD/NICHD NIH HHS/United States'
p65346
aS'R01 HD047177/HD/NICHD NIH HHS/United States'
p65347
aS'R01 HD047177-01A1/HD/NICHD NIH HHS/United States'
p65348
aS'R01 HD047177-02/HD/NICHD NIH HHS/United States'
p65349
aS'R01 HD047177-03/HD/NICHD NIH HHS/United States'
p65350
aS'R01 HD047177-04/HD/NICHD NIH HHS/United States'
p65351
aS'R01 HD047177-05/HD/NICHD NIH HHS/United States'
p65352
aS'R01 HD061255/HD/NICHD NIH HHS/United States'
p65353
aS'R01 HD061255-01A2/HD/NICHD NIH HHS/United States'
p65354
aS'R01 HD061255-02/HD/NICHD NIH HHS/United States'
p65355
aS'R01 HD061255-03/HD/NICHD NIH HHS/United States'
p65356
asS'IP'
p65357
S'4'
sS'IS'
p65358
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p65359
sS'PMC'
p65360
S'PMC3341506'
p65361
sS'DCOM'
p65362
S'20120919'
p65363
sS'AU'
p65364
(lp65365
S'Strehlau R'
p65366
aS'Coovadia A'
p65367
aS'Abrams EJ'
p65368
aS'Martens L'
p65369
aS'Arpadi S'
p65370
aS'Meyers T'
p65371
aS'Kuhn L'
p65372
asS'VI'
p65373
S'60'
p65374
sS'MHDA'
p65375
S'2012/09/20 06:00'
p65376
sS'OID'
p65377
(lp65378
S'NLM: NIHMS346250'
p65379
aS'NLM: PMC3341506'
p65380
asS'MH'
p65381
(lp65382
S'Anti-HIV Agents/*administration & dosage/adverse effects'
p65383
aS'Antiretroviral Therapy, Highly Active/adverse effects/*methods'
p65384
aS'Child, Preschool'
p65385
aS'Cohort Studies'
p65386
aS'Female'
p65387
aS'HIV Infections/*drug therapy/pathology'
p65388
aS'Humans'
p65389
aS'Infant'
p65390
aS'Lipids/*blood'
p65391
aS'Lopinavir/administration & dosage/adverse effects'
p65392
aS'Male'
p65393
aS'Ritonavir/administration & dosage/adverse effects'
p65394
aS'South Africa'
p65395
aS'Treatment Outcome'
p65396
asS'EDAT'
p65397
S'2011/12/03 06:00'
p65398
sS'SO'
p65399
S'J Acquir Immune Defic Syndr. 2012 Aug 1;60(4):369-76. doi: 10.1097/QAI.0b013e318243760b.'
p65400
sS'SB'
p65401
S'IM X'
p65402
sS'PMID'
p65403
S'22134152'
p65404
sS'PST'
p65405
S'ppublish'
p65406
stRp65407
ag2
(g3
g4
(dp65408
S'LID'
p65409
S'10.1097/QAI.0b013e31824206c7 [doi]'
p65410
sS'STAT'
p65411
S'MEDLINE'
p65412
sS'JT'
p65413
S'Journal of acquired immune deficiency syndromes (1999)'
p65414
sS'CIN'
p65415
(lp65416
S'J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):e82-4. PMID: 22330609'
p65417
asS'DA'
p65418
S'20120313'
p65419
sS'AID'
p65420
(lp65421
S'10.1097/QAI.0b013e31824206c7 [doi]'
p65422
asS'CRDT'
p65423
(lp65424
S'2011/12/03 06:00'
p65425
asS'DP'
p65426
S'2012 Apr 15'
p65427
sS'OWN'
p65428
S'NLM'
p65429
sS'PT'
p65430
(lp65431
S'Journal Article'
p65432
aS'Multicenter Study'
p65433
asS'LA'
p65434
(lp65435
S'eng'
p65436
asS'FAU'
p65437
(lp65438
S'Greig, Jane'
p65439
aS"O'Brien, Daniel P"
p65440
aS'Ford, Nathan'
p65441
aS'Spelman, Tim'
p65442
aS'Sabapathy, Kalpana'
p65443
aS'Shanks, Leslie'
p65444
asS'PG'
p65445
S'e92-8'
p65446
sS'TI'
p65447
S'Similar mortality and reduced loss to follow-up in integrated compared with vertical programs providing antiretroviral treatment in sub-saharan Africa.'
p65448
sS'RN'
p65449
(lp65450
S'0 (Anti-HIV Agents)'
p65451
asS'PL'
p65452
S'United States'
p65453
sS'TA'
p65454
S'J Acquir Immune Defic Syndr'
p65455
sS'JID'
p65456
S'100892005'
p65457
sS'AB'
p65458
S'BACKGROUND: Vertical HIV programs have achieved good results but may not be feasible or appropriate in many resource-limited settings. Medecins sans Frontieres has treated HIV in vertical programs since 2000 and over time integrated HIV treatment into general health care services using simplified protocols. We analyzed the survival probability among patients receiving antiretroviral therapy (ART) from 2003 to 2010 in integrated versus vertical programs in 9 countries in sub-Saharan Africa. METHODS AND FINDINGS: Cox regression assessed mortality and program design association, adjusting for baseline age, body mass index, clinical WHO stage, tuberculosis, program age and setting. The analysis included 15,403 HIV-positive adults on ART in 7 vertical (14,124 patients) and 10 integrated (1279 patients) programs. Cox regression including 14,523 patients followed for up to 30 months ART showed similar outcomes for mortality (adjusted hazard ratio (aHR) 1.02; 95% confidence interval (CI): 0.83 to 1.24) and lower risk of loss to follow-up (aHR: 0.71; 95% CI: 0.61 to 0.83) in integrated compared with vertical programs. The greatest risk of death was from initiating ART at WHO stage 4 (aHR 1.99, 95% CI: 1.74 to 2.29), although greater program experience was protective (aHR: 0.77, 95% CI: 0.66 to 0.89). Risk of loss to follow-up was greater in experienced programs (aHR: 3.33; 95% CI: 2.92 to 3.79) and rural settings (aHR: 3.82; 95% CI: 3.49 to 4.20). CONCLUSIONS: ART delivery in integrated general health care programs results in good outcomes. Compared with vertical HIV programs, patients initiated ART in integrated programs at more advanced stages of clinical immunosuppression yet had similar risk of death and lower risk of loss to follow-up.'
p65459
sS'AD'
p65460
S'Manson Unit, Medecins sans Frontieres, Saffron Hill, London, UK. jane.greig@london.msf.org'
p65461
sS'IP'
p65462
S'5'
sS'IS'
p65463
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p65464
sS'DCOM'
p65465
S'20120423'
p65466
sS'AU'
p65467
(lp65468
S'Greig J'
p65469
aS"O'Brien DP"
p65470
aS'Ford N'
p65471
aS'Spelman T'
p65472
aS'Sabapathy K'
p65473
aS'Shanks L'
p65474
asS'VI'
p65475
S'59'
p65476
sS'MHDA'
p65477
S'2012/04/24 06:00'
p65478
sS'MH'
p65479
(lp65480
S'Adult'
p65481
aS'Africa South of the Sahara'
p65482
aS'Anti-HIV Agents/*therapeutic use'
p65483
aS'Cross Infection/*prevention & control'
p65484
aS'Delivery of Health Care, Integrated/*standards'
p65485
aS'Female'
p65486
aS'Follow-Up Studies'
p65487
aS'HIV Infections/*drug therapy/*mortality'
p65488
aS'Humans'
p65489
aS'*Lost to Follow-Up'
p65490
aS'Male'
p65491
aS'Proportional Hazards Models'
p65492
aS'Retrospective Studies'
p65493
aS'Survival Analysis'
p65494
asS'EDAT'
p65495
S'2011/12/03 06:00'
p65496
sS'SO'
p65497
S'J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):e92-8. doi: 10.1097/QAI.0b013e31824206c7.'
p65498
sS'SB'
p65499
S'IM X'
p65500
sS'PMID'
p65501
S'22134144'
p65502
sS'PST'
p65503
S'ppublish'
p65504
stRp65505
ag2
(g3
g4
(dp65506
S'LID'
p65507
S'10.5588/ijtld.10.0625 [doi]'
p65508
sS'STAT'
p65509
S'MEDLINE'
p65510
sS'JT'
p65511
S'The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease'
p65512
sS'DA'
p65513
S'20111128'
p65514
sS'AID'
p65515
(lp65516
S'10.5588/ijtld.10.0625 [doi]'
p65517
asS'CRDT'
p65518
(lp65519
S'2011/11/29 06:00'
p65520
asS'DP'
p65521
S'2011 Dec'
p65522
sS'AD'
p65523
S'Department of Medicine, University of Washington, Seattle, Washington 98104, USA. marentz@u.washington.edu'
p65524
sS'OWN'
p65525
S'NLM'
p65526
sS'PT'
p65527
(lp65528
S'Journal Article'
p65529
aS"Research Support, Non-U.S. Gov't"
p65530
asS'LA'
p65531
(lp65532
S'eng'
p65533
asS'FAU'
p65534
(lp65535
S'Arentz, M'
p65536
aS'Narita, M'
p65537
aS'Sangare, L'
p65538
aS'Kah, J F'
p65539
aS'Low, D'
p65540
aS'Mandaliya, K'
p65541
aS'Amukoye, E'
p65542
aS'Sitienei, J'
p65543
aS'Walson, J L'
p65544
asS'LR'
p65545
S'20150329'
p65546
sS'PG'
p65547
S'1656-63'
p65548
sS'TI'
p65549
S'Impact of smear microscopy results and observed therapy on tuberculosis treatment in Mombasa, Kenya.'
p65550
sS'RN'
p65551
(lp65552
S'0 (Antitubercular Agents)'
p65553
asS'PL'
p65554
S'France'
p65555
sS'TA'
p65556
S'Int J Tuberc Lung Dis'
p65557
sS'JID'
p65558
S'9706389'
p65559
sS'AB'
p65560
S'SETTING: Tuberculosis (TB) treatment center at Coast Provincial General Hospital in Mombasa, Kenya. OBJECTIVES: To describe TB management practices in a facility in coastal Kenya and identify factors associated with poor treatment outcomes. DESIGN: Retrospective review of patient treatment records from January 2008 to June 2009. Treatment outcomes of patients were classified as treatment success (cure or treatment completion) or poor treatment outcome (treatment failure, death or default). Relative risk regression was used to determine the association between exposures of interest and poor treatment outcomes. RESULTS: Records were obtained from a total of 183 patients: 142 (78%) had pulmonary TB, 68 (37%) were human immunodeficiency virus (HIV) infected and 81 (44%) had acid-fast bacilli (AFB) positive smear micros- copy. Most treated individuals (86%) achieved a successful treatment outcome as defined by the World Health Organization. Of those with poor treatment outcomes, 64% defaulted, 32% died, and 4% failed treatment. Initial negative AFB smear and HIV co-infection were associated with poor treatment outcomes (RR 3.32, 95%CI 1.22-8.99 and RR 4.61, 95%CI 1.69- 12.59, respectively). CONCLUSION: Strategies to accelerate accurate diagnosis of smear-negative TB and increase patient retention during treatment, especially in HIV co-infected individuals, are needed to reduce poor treatment outcomes in Kenya.'
p65561
sS'GR'
p65562
(lp65563
S'P30 AI027757/AI/NIAID NIH HHS/United States'
p65564
aS'TL1 RR025016/RR/NCRR NIH HHS/United States'
p65565
asS'IP'
p65566
S'12'
p65567
sS'IS'
p65568
S'1815-7920 (Electronic) 1027-3719 (Linking)'
p65569
sS'DCOM'
p65570
S'20120328'
p65571
sS'AU'
p65572
(lp65573
S'Arentz M'
p65574
aS'Narita M'
p65575
aS'Sangare L'
p65576
aS'Kah JF'
p65577
aS'Low D'
p65578
aS'Mandaliya K'
p65579
aS'Amukoye E'
p65580
aS'Sitienei J'
p65581
aS'Walson JL'
p65582
asS'VI'
p65583
S'15'
p65584
sS'MHDA'
p65585
S'2012/03/29 06:00'
p65586
sS'MH'
p65587
(lp65588
S'Adolescent'
p65589
aS'Adult'
p65590
aS'Antitubercular Agents/administration & dosage/*therapeutic use'
p65591
aS'Directly Observed Therapy/*methods'
p65592
aS'Female'
p65593
aS'HIV Infections/epidemiology'
p65594
aS'Humans'
p65595
aS'Kenya/epidemiology'
p65596
aS'Male'
p65597
aS'Regression Analysis'
p65598
aS'Retrospective Studies'
p65599
aS'Risk'
p65600
aS'Sputum/microbiology'
p65601
aS'Treatment Outcome'
p65602
aS'Tuberculosis/diagnosis/*drug therapy/epidemiology'
p65603
aS'Tuberculosis, Pulmonary/diagnosis/*drug therapy/epidemiology'
p65604
aS'Young Adult'
p65605
asS'EDAT'
p65606
S'2011/11/29 06:00'
p65607
sS'SO'
p65608
S'Int J Tuberc Lung Dis. 2011 Dec;15(12):1656-63. doi: 10.5588/ijtld.10.0625.'
p65609
sS'SB'
p65610
S'IM'
p65611
sS'PMID'
p65612
S'22118174'
p65613
sS'PST'
p65614
S'ppublish'
p65615
stRp65616
ag2
(g3
g4
(dp65617
S'LID'
p65618
S'10.5588/ijtld.10.0698 [doi]'
p65619
sS'STAT'
p65620
S'MEDLINE'
p65621
sS'AB'
p65622
S'BACKGROUND: Data regarding outcomes of tuberculosis (TB) associated cutaneous adverse drug reactions (CADR) are limited. The re-introduction of first-line anti-tuberculosis drugs after CADR is controversial and management poorly defined. METHODS: We retrospectively reviewed the records of 298 patients with CADR admitted to a tertiary dermatology ward in Cape Town, South Africa. RESULTS: TB-associated CADR was diagnosed in 65 of 298 patients. Of these, 60/65 (92%) were human immunodeficiency virus (HIV) infected (median CD4 count 107 cells/mm (3)). Anti-tuberculosis drugs were reintroduced in 46/65 (71%) patients, of whom 23/46 (50%) developed re-introduction reactions. The most frequent re-introduction reactions were itch in 11/23 (48%) and hepatitis in 9/23 (39%) patients. Of the 23 re-introduction reactions, 13 (57%) were mild, six (26%) moderate and four (26%) severe. Among those with reintroduction reactions, rifampicin (RMP) was the offending drug in 13/23 (57%), isoniazid in 5/23(22%), pyrazinamide in 3/23 (13%), and ethambutol, streptomycin and ofloxacin each in 1/23 (4%) cases. Lack of previous TB treatment and re-challenge with RMP were independently associated with the likelihood of reintroduction reactions. CONCLUSIONS: In this high TB burden setting, although re-introduction reactions are common, the majority are non-life-threatening. All first-line anti-tuberculosis drugs can cause CADR, and RMP is more commonly implicated than previously reported. These data guide the management of anti-tuberculosis drug-associated CADR in high HIV prevalence settings.'
p65623
sS'JID'
p65624
S'9706389'
p65625
sS'AD'
p65626
S'Division of Dermatology, Department of Medicine, University of Cape Town, Cape Town, South Africa.'
p65627
sS'JT'
p65628
S'The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease'
p65629
sS'IP'
p65630
S'12'
p65631
sS'IS'
p65632
S'1815-7920 (Electronic) 1027-3719 (Linking)'
p65633
sS'DCOM'
p65634
S'20120328'
p65635
sS'DA'
p65636
S'20111128'
p65637
sS'AU'
p65638
(lp65639
S'Lehloenya RJ'
p65640
aS'Todd G'
p65641
aS'Badri M'
p65642
aS'Dheda K'
p65643
asS'AID'
p65644
(lp65645
S'10.5588/ijtld.10.0698 [doi]'
p65646
asS'CRDT'
p65647
(lp65648
S'2011/11/29 06:00'
p65649
asS'VI'
p65650
S'15'
p65651
sS'PMID'
p65652
S'22118173'
p65653
sS'DP'
p65654
S'2011 Dec'
p65655
sS'MHDA'
p65656
S'2012/03/29 06:00'
p65657
sS'OWN'
p65658
S'NLM'
p65659
sS'PT'
p65660
(lp65661
S'Journal Article'
p65662
aS"Research Support, Non-U.S. Gov't"
p65663
asS'LA'
p65664
(lp65665
S'eng'
p65666
asS'MH'
p65667
(lp65668
S'Adult'
p65669
aS'Antitubercular Agents/administration & dosage/*adverse effects/therapeutic use'
p65670
aS'Drug Eruptions/*etiology/pathology'
p65671
aS'Female'
p65672
aS'HIV Infections/*epidemiology'
p65673
aS'Humans'
p65674
aS'Male'
p65675
aS'Middle Aged'
p65676
aS'Retreatment'
p65677
aS'Retrospective Studies'
p65678
aS'Severity of Illness Index'
p65679
aS'South Africa/epidemiology'
p65680
aS'Tuberculosis/*drug therapy'
p65681
asS'FAU'
p65682
(lp65683
S'Lehloenya, R J'
p65684
aS'Todd, G'
p65685
aS'Badri, M'
p65686
aS'Dheda, K'
p65687
asS'EDAT'
p65688
S'2011/11/29 06:00'
p65689
sS'PST'
p65690
S'ppublish'
p65691
sS'SO'
p65692
S'Int J Tuberc Lung Dis. 2011 Dec;15(12):1649-57. doi: 10.5588/ijtld.10.0698.'
p65693
sS'PG'
p65694
S'1649-57'
p65695
sS'TI'
p65696
S'Outcomes of reintroducing anti-tuberculosis drugs following cutaneous adverse drug reactions.'
p65697
sS'SB'
p65698
S'IM'
p65699
sS'RN'
p65700
(lp65701
S'0 (Antitubercular Agents)'
p65702
asS'PL'
p65703
S'France'
p65704
sS'TA'
p65705
S'Int J Tuberc Lung Dis'
p65706
stRp65707
ag2
(g3
g4
(dp65708
S'LID'
p65709
S'10.1111/j.1468-1293.2011.00949.x [doi]'
p65710
sS'STAT'
p65711
S'MEDLINE'
p65712
sS'DEP'
p65713
S'20111122'
p65714
sS'CI'
p65715
(lp65716
S'(c) 2011 British HIV Association.'
p65717
asS'DA'
p65718
S'20120106'
p65719
sS'AID'
p65720
(lp65721
S'10.1111/j.1468-1293.2011.00949.x [doi]'
p65722
asS'CRDT'
p65723
(lp65724
S'2011/11/24 06:00'
p65725
asS'DP'
p65726
S'2012 Feb'
p65727
sS'AD'
p65728
S'Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.'
p65729
sS'OWN'
p65730
S'NLM'
p65731
sS'PT'
p65732
(lp65733
S'Journal Article'
p65734
aS'Multicenter Study'
p65735
aS"Research Support, Non-U.S. Gov't"
p65736
asS'LA'
p65737
(lp65738
S'eng'
p65739
asS'FAU'
p65740
(lp65741
S'Thierfelder, C'
p65742
aS'Weber, R'
p65743
aS'Elzi, L'
p65744
aS'Furrer, H'
p65745
aS'Cavassini, M'
p65746
aS'Calmy, A'
p65747
aS'Bernasconi, E'
p65748
aS'Gutmann, C'
p65749
aS'Ledergerber, B'
p65750
asS'JT'
p65751
S'HIV medicine'
p65752
sS'PG'
p65753
S'118-26'
p65754
sS'TI'
p65755
S'Participation, characteristics and retention rates of HIV-positive immigrants in the Swiss HIV Cohort Study.'
p65756
sS'PL'
p65757
S'England'
p65758
sS'TA'
p65759
S'HIV Med'
p65760
sS'FIR'
p65761
(lp65762
S'Barth, J'
p65763
aS'Battegay, M'
p65764
aS'Bernasconi, E'
p65765
aS'Boni, J'
p65766
aS'Bucher, H C'
p65767
aS'Burgisser, P'
p65768
aS'Burton-Jeangros, C'
p65769
aS'Calmy, A'
p65770
aS'Cavassini, M'
p65771
aS'M, Egger'
p65772
aS'Elzi, L'
p65773
aS'Fehr, J'
p65774
aS'Flepp, M'
p65775
aS'Francioli, P'
p65776
aS'Furrer, H'
p65777
aS'Fux, C A'
p65778
aS'Gorgievski, M'
p65779
aS'Gunthard, H'
p65780
aS'Hasse, B'
p65781
aS'Hirsch, H H'
p65782
aS'Hirschel, B'
p65783
aS'Hosli, I'
p65784
aS'Kahlert, C'
p65785
aS'Kaiser, L'
p65786
aS'Keiser, O'
p65787
aS'Kind, C'
p65788
aS'Klimkait, T'
p65789
aS'Kovari, H'
p65790
aS'Ledergerber, B'
p65791
aS'Martinetti, G'
p65792
aS'Martinez de Tejada, B'
p65793
aS'Metzner, K'
p65794
aS'Muller, N'
p65795
aS'Nadal, D'
p65796
aS'Pantaleo, G'
p65797
aS'Rauch, A'
p65798
aS'Regenass, S'
p65799
aS'Rickenback, M'
p65800
aS'Rudin, C'
p65801
aS'Schmid, P'
p65802
aS'Schultze, D'
p65803
aS'Schoni-Affolter, F'
p65804
aS'Schupbach, J'
p65805
aS'Speck, R'
p65806
aS'Taffe, P'
p65807
aS'Tarr, P'
p65808
aS'Telenti, A'
p65809
aS'Trkola, A'
p65810
aS'Vernazza, P'
p65811
aS'von Wyl, V'
p65812
aS'Weber, R'
p65813
aS'Yerly, S'
p65814
asS'JID'
p65815
S'100897392'
p65816
sS'AB'
p65817
S'OBJECTIVE: Data from observational cohorts may be influenced by population structure and loss to follow-up (LTFU). Quality of care may be associated with participation in cohort networks. We aimed to study the participation, characteristics and retention rates of immigrants in the Swiss HIV Cohort Study (SHCS). METHODS: We compared enrolment over time (1996-1999, 2000-2003 and 2004-2008) and LTFU between individuals from different geographical regions. In 2008, we performed a cross-sectional survey to investigate the proportion of individuals not participating in the SHCS but who were in care at SHCS institutions. Predictors for LTFU were analysed using Cox proportional hazard models, and those for nonparticipation using logistic regression. RESULTS: A total of 7840 individuals entered the SHCS during the observation period. The proportion of immigrants increased over time, especially the proportion of women from sub-Saharan Africa, which increased from 21 to 48% during the observation period. Overall LTFU was 3.76 [95% confidence interval (CI) 3.58-3.95]/100, with the highest hazard ratio in men from sub-Saharan Africa (2.82/100 patient-years; 95% CI 2.30-3.46/100), compared with men from northwestern countries. Other predictors for LTFU were age <30 years, lower education, injecting drug use, and higher baseline CD4 cell counts. Participants taking antiretroviral therapy had reduced LTFU. The survey showed that 84% of HIV-infected patients in care at SHCS institutions were enrolled in the cohort. Nonparticipation was more likely among men from non-European regions (odds ratio 2.73; 95% CI 2.29-3.24), women from sub-Saharan Africa (odds ratio 3.01; 95% CI 2.40-3.77) and women from Latin America/Caribbean (odds ratio 2.10; 95% CI 1.30-3.39). CONCLUSIONS: Numbers of HIV-infected immigrants are increasing but they are underrepresented in the SHCS, and immigrants are more likely to be lost to follow-up.'
p65818
sS'CN'
p65819
(lp65820
S'Swiss HIV Cohort Study Group'
p65821
asS'IP'
p65822
S'2'
sS'IS'
p65823
S'1468-1293 (Electronic) 1464-2662 (Linking)'
p65824
sS'IR'
p65825
(lp65826
S'Barth J'
p65827
aS'Battegay M'
p65828
aS'Bernasconi E'
p65829
aS'Boni J'
p65830
aS'Bucher HC'
p65831
aS'Burgisser P'
p65832
aS'Burton-Jeangros C'
p65833
aS'Calmy A'
p65834
aS'Cavassini M'
p65835
aS'M E'
p65836
aS'Elzi L'
p65837
aS'Fehr J'
p65838
aS'Flepp M'
p65839
aS'Francioli P'
p65840
aS'Furrer H'
p65841
aS'Fux CA'
p65842
aS'Gorgievski M'
p65843
aS'Gunthard H'
p65844
aS'Hasse B'
p65845
aS'Hirsch HH'
p65846
aS'Hirschel B'
p65847
aS'Hosli I'
p65848
aS'Kahlert C'
p65849
aS'Kaiser L'
p65850
aS'Keiser O'
p65851
aS'Kind C'
p65852
aS'Klimkait T'
p65853
aS'Kovari H'
p65854
aS'Ledergerber B'
p65855
aS'Martinetti G'
p65856
aS'Martinez de Tejada B'
p65857
aS'Metzner K'
p65858
aS'Muller N'
p65859
aS'Nadal D'
p65860
aS'Pantaleo G'
p65861
aS'Rauch A'
p65862
aS'Regenass S'
p65863
aS'Rickenback M'
p65864
aS'Rudin C'
p65865
aS'Schmid P'
p65866
aS'Schultze D'
p65867
aS'Schoni-Affolter F'
p65868
aS'Schupbach J'
p65869
aS'Speck R'
p65870
aS'Taffe P'
p65871
aS'Tarr P'
p65872
aS'Telenti A'
p65873
aS'Trkola A'
p65874
aS'Vernazza P'
p65875
aS'von Wyl V'
p65876
aS'Weber R'
p65877
aS'Yerly S'
p65878
asS'DCOM'
p65879
S'20120315'
p65880
sS'AU'
p65881
(lp65882
S'Thierfelder C'
p65883
aS'Weber R'
p65884
aS'Elzi L'
p65885
aS'Furrer H'
p65886
aS'Cavassini M'
p65887
aS'Calmy A'
p65888
aS'Bernasconi E'
p65889
aS'Gutmann C'
p65890
aS'Ledergerber B'
p65891
asS'VI'
p65892
S'13'
p65893
sS'MHDA'
p65894
S'2012/03/16 06:00'
p65895
sS'PHST'
p65896
(lp65897
S'2011/11/22 [aheadofprint]'
p65898
asS'MH'
p65899
(lp65900
S'Adult'
p65901
aS'Africa South of the Sahara/ethnology'
p65902
aS'Asia, Southeastern/ethnology'
p65903
aS'CD4 Lymphocyte Count/*statistics & numerical data'
p65904
aS'Caribbean Region/ethnology'
p65905
aS'Cohort Studies'
p65906
aS'Cross-Sectional Studies'
p65907
aS'Emigration and Immigration/*statistics & numerical data'
p65908
aS'Europe/ethnology'
p65909
aS'Female'
p65910
aS'Follow-Up Studies'
p65911
aS'HIV Infections/*epidemiology/ethnology'
p65912
aS'*HIV-1'
p65913
aS'Health Services Accessibility'
p65914
aS'Humans'
p65915
aS'Latin America/ethnology'
p65916
aS'Lost to Follow-Up'
p65917
aS'Male'
p65918
aS'Switzerland/epidemiology'
p65919
asS'EDAT'
p65920
S'2011/11/24 06:00'
p65921
sS'SO'
p65922
S'HIV Med. 2012 Feb;13(2):118-26. doi: 10.1111/j.1468-1293.2011.00949.x. Epub 2011 Nov 22.'
p65923
sS'SB'
p65924
S'IM'
p65925
sS'PMID'
p65926
S'22107170'
p65927
sS'PST'
p65928
S'ppublish'
p65929
stRp65930
ag2
(g3
g4
(dp65931
S'LID'
p65932
S'10.1258/ijsa.2009.009145 [doi]'
p65933
sS'STAT'
p65934
S'MEDLINE'
p65935
sS'AB'
p65936
S"Roll-out of combination antiretroviral therapy (cART) in South Africa should impact on AIDS-associated Kaposi's sarcoma (KS). Government provision began in 2003, with 23% coverage for World Health Organization (WHO) stage IV AIDS in 2006. To assess the effect of cART availability on KS management, we evaluated records from 701 KS patients seen at a tertiary oncology centre in KwaZulu-Natal, South Africa, from 1995 to 2006. Associations between cART use and measures of KS care were evaluated. cART availability was 0% prior to 2001, 9.6% (2001-2003) and 44% (2004-2006). Documentation of HIV status increased incrementally from 65% to 92%. cART was associated with chemotherapy administration: 56% on cART versus 17% not on cART (P < 0.001); and less loss to follow-up, 13% on cART versus 38% not on cART (P < 0.001). cART availability improves the care of AIDS-associated KS. Further increases in cART availability for this population are needed in South Africa."
p65937
sS'JID'
p65938
S'9007917'
p65939
sS'AD'
p65940
S'Department of Dermatology, Nelson R Mandela School of Medicine, CAPRISA, University of KwaZulu-Natal, Durban, South Africa. mosama@ukzn.ac.za'
p65941
sS'JT'
p65942
S'International journal of STD & AIDS'
p65943
sS'IP'
p65944
S'11'
p65945
sS'IS'
p65946
S'1758-1052 (Electronic) 0956-4624 (Linking)'
p65947
sS'DCOM'
p65948
S'20120307'
p65949
sS'DA'
p65950
S'20111118'
p65951
sS'AU'
p65952
(lp65953
S'Mosam A'
p65954
aS'Uldrick TS'
p65955
aS'Shaik F'
p65956
aS'Carrara H'
p65957
aS'Aboobaker J'
p65958
aS'Coovadia H'
p65959
asS'AID'
p65960
(lp65961
S'22/11/671 [pii]'
p65962
aS'10.1258/ijsa.2009.009145 [doi]'
p65963
asS'CRDT'
p65964
(lp65965
S'2011/11/19 06:00'
p65966
asS'VI'
p65967
S'22'
p65968
sS'PMID'
p65969
S'22096054'
p65970
sS'DP'
p65971
S'2011 Nov'
p65972
sS'MHDA'
p65973
S'2012/03/08 06:00'
p65974
sS'OWN'
p65975
S'NLM'
p65976
sS'PT'
p65977
(lp65978
S'Journal Article'
p65979
asS'LA'
p65980
(lp65981
S'eng'
p65982
asS'MH'
p65983
(lp65984
S'Acquired Immunodeficiency Syndrome/*drug therapy'
p65985
aS'Adolescent'
p65986
aS'Adult'
p65987
aS'Aged'
p65988
aS'Anti-HIV Agents/*administration & dosage'
p65989
aS'Antiretroviral Therapy, Highly Active/*methods'
p65990
aS'Child, Preschool'
p65991
aS'Female'
p65992
aS'Health Services Accessibility/*statistics & numerical data'
p65993
aS'Humans'
p65994
aS'Male'
p65995
aS'Middle Aged'
p65996
aS'Sarcoma, Kaposi/*therapy'
p65997
aS'South Africa'
p65998
aS'Treatment Outcome'
p65999
aS'Young Adult'
p66000
asS'FAU'
p66001
(lp66002
S'Mosam, A'
p66003
aS'Uldrick, T S'
p66004
aS'Shaik, F'
p66005
aS'Carrara, H'
p66006
aS'Aboobaker, J'
p66007
aS'Coovadia, H'
p66008
asS'EDAT'
p66009
S'2011/11/19 06:00'
p66010
sS'PST'
p66011
S'ppublish'
p66012
sS'SO'
p66013
S'Int J STD AIDS. 2011 Nov;22(11):671-3. doi: 10.1258/ijsa.2009.009145.'
p66014
sS'PG'
p66015
S'671-3'
p66016
sS'TI'
p66017
S"An evaluation of the early effects of a combination antiretroviral therapy programme on the management of AIDS-associated Kaposi's sarcoma in KwaZulu-Natal, South Africa."
p66018
sS'SB'
p66019
S'IM X'
p66020
sS'RN'
p66021
(lp66022
S'0 (Anti-HIV Agents)'
p66023
asS'PL'
p66024
S'England'
p66025
sS'TA'
p66026
S'Int J STD AIDS'
p66027
stRp66028
ag2
(g3
g4
(dp66029
S'LID'
p66030
S'10.1186/1758-2652-14-55 [doi]'
p66031
sS'STAT'
p66032
S'MEDLINE'
p66033
sS'DEP'
p66034
S'20111115'
p66035
sS'DA'
p66036
S'20111202'
p66037
sS'AID'
p66038
(lp66039
S'1758-2652-14-55 [pii]'
p66040
aS'10.1186/1758-2652-14-55 [doi]'
p66041
asS'CRDT'
p66042
(lp66043
S'2011/11/17 06:00'
p66044
asS'DP'
p66045
S'2011'
p66046
sS'OWN'
p66047
S'NLM'
p66048
sS'PT'
p66049
(lp66050
S'Journal Article'
p66051
aS"Research Support, Non-U.S. Gov't"
p66052
asS'LA'
p66053
(lp66054
S'eng'
p66055
asS'DCOM'
p66056
S'20120208'
p66057
sS'JT'
p66058
S'Journal of the International AIDS Society'
p66059
sS'LR'
p66060
S'20150129'
p66061
sS'FAU'
p66062
(lp66063
S'Zyl, Gert U van'
p66064
aS'Rabie, Helena'
p66065
aS'Nuttall, James J'
p66066
aS'Cotton, Mark F'
p66067
asS'TI'
p66068
S'It is time to consider third-line options in antiretroviral-experienced paediatric patients?'
p66069
sS'RN'
p66070
(lp66071
S'0 (Anti-HIV Agents)'
p66072
aS'0 (HIV Protease Inhibitors)'
p66073
aS'O3J8G9O825 (Ritonavir)'
p66074
asS'PL'
p66075
S'England'
p66076
sS'PG'
p66077
S'55'
p66078
sS'JID'
p66079
S'101478566'
p66080
sS'AB'
p66081
S'BACKGROUND: The historic use of full-dose ritonavir as part of an unboosted protease inhibitor (PI)-based antiretroviral therapy regimen in some South African children contributes to the frequent accumulation of major PI resistance mutations. METHODS: In order to describe the prevalence of major PI resistance in children failing antiretroviral therapy and to investigate the clinical, immunological and virological outcomes in children with PI resistance, we conducted a cross-sectional study, with a nested case series, following up those children with major PI resistance. The setting was public health sector antiretroviral clinics in the Western Cape province of South Africa, and the subjects were children failing antiretroviral therapy. The following outcome measures were investigated: CD4 count, viral load and resistance mutations. RESULTS: Fourteen (17%) of 82 patients, referred from tertiary hospitals, had major PI resistance. All these patients were exposed to regimens that included ritonavir as a single PI. Immune reconstitution and clinical benefit were achieved when using a lopinavir/ritonavir-based treatment regimen in these children with prior PI resistance. At first HIV-1 viral load follow up after initial resistance testing (n = 11), only one patient had a viral load of less than 400 copies/ml; at a subsequent follow up (n = 9), the viral loads of five patients were less than 400 copies/ml. Patients retained on LPV/r had lower viral loads than those switched to a non-nucleoside reverse transcriptase inhibitor (NNRTI). However, two of three patients with follow-up resistance tests accumulated additional PI resistance. CONCLUSIONS: In children with pre-existing PI resistance, although initially effective, the long-term durability of a lopinavir/ritonavir-based treatment regimen can be compromised by the accumulation of resistance mutations. Furthermore, a second-line NNRTI regimen is often not durable in these patients. As genotypic resistance testing and third-line treatment regimens are costly and limited in availability, we propose eligibility criteria to identify patients with high risk for resistance and guidance on drug selection for children who would benefit from third-line therapy.'
p66082
sS'AD'
p66083
S'Division of Medical Virology, Stellenbosch University, and National Health Laboratory Service Tygerberg, Parow, Cape Town, South Africa. guvz@sun.ac.za'
p66084
sS'VI'
p66085
S'14'
p66086
sS'IS'
p66087
S'1758-2652 (Electronic) 1758-2652 (Linking)'
p66088
sS'PMC'
p66089
S'PMC3228719'
p66090
sS'AU'
p66091
(lp66092
S'Zyl GU'
p66093
aS'Rabie H'
p66094
aS'Nuttall JJ'
p66095
aS'Cotton MF'
p66096
asS'MHDA'
p66097
S'2012/02/09 06:00'
p66098
sS'PHST'
p66099
(lp66100
S'2011/05/30 [received]'
p66101
aS'2011/11/15 [accepted]'
p66102
aS'2011/11/15 [aheadofprint]'
p66103
asS'OID'
p66104
(lp66105
S'NLM: PMC3228719'
p66106
asS'MH'
p66107
(lp66108
S'Anti-HIV Agents/*administration & dosage'
p66109
aS'Antiretroviral Therapy, Highly Active/*methods'
p66110
aS'CD4 Lymphocyte Count'
p66111
aS'Case-Control Studies'
p66112
aS'Child, Preschool'
p66113
aS'Cross-Sectional Studies'
p66114
aS'*Drug Resistance, Viral'
p66115
aS'Follow-Up Studies'
p66116
aS'HIV Infections/*drug therapy/immunology/*virology'
p66117
aS'HIV Protease Inhibitors/administration & dosage'
p66118
aS'HIV-1/*drug effects/isolation & purification'
p66119
aS'Humans'
p66120
aS'Mutation, Missense'
p66121
aS'Prevalence'
p66122
aS'Ritonavir/administration & dosage'
p66123
aS'South Africa'
p66124
aS'Treatment Failure'
p66125
aS'Viral Load'
p66126
asS'EDAT'
p66127
S'2011/11/17 06:00'
p66128
sS'SO'
p66129
S'J Int AIDS Soc. 2011 Nov 15;14:55. doi: 10.1186/1758-2652-14-55.'
p66130
sS'SB'
p66131
S'IM X'
p66132
sS'PMID'
p66133
S'22085598'
p66134
sS'TA'
p66135
S'J Int AIDS Soc'
p66136
sS'PST'
p66137
S'epublish'
p66138
stRp66139
ag2
(g3
g4
(dp66140
S'LID'
p66141
S'10.1186/1758-2652-14-52 [doi]'
p66142
sS'STAT'
p66143
S'MEDLINE'
p66144
sS'DEP'
p66145
S'20111103'
p66146
sS'DA'
p66147
S'20111121'
p66148
sS'AID'
p66149
(lp66150
S'1758-2652-14-52 [pii]'
p66151
aS'10.1186/1758-2652-14-52 [doi]'
p66152
asS'CRDT'
p66153
(lp66154
S'2011/11/05 06:00'
p66155
asS'DP'
p66156
S'2011'
p66157
sS'AD'
p66158
S'Faculty of Health Sciences, University of Ottawa, Ottawa, Canada. edward.mills@uottawa.ca'
p66159
sS'OWN'
p66160
S'NLM'
p66161
sS'PT'
p66162
(lp66163
S'Journal Article'
p66164
aS"Research Support, Non-U.S. Gov't"
p66165
asS'LA'
p66166
(lp66167
S'eng'
p66168
asS'DCOM'
p66169
S'20120208'
p66170
sS'JT'
p66171
S'Journal of the International AIDS Society'
p66172
sS'LR'
p66173
S'20150129'
p66174
sS'FAU'
p66175
(lp66176
S'Mills, Edward J'
p66177
aS'Bakanda, Celestin'
p66178
aS'Birungi, Josephine'
p66179
aS'Chan, Keith'
p66180
aS'Hogg, Robert S'
p66181
aS'Ford, Nathan'
p66182
aS'Nachega, Jean B'
p66183
aS'Cooper, Curtis L'
p66184
asS'TI'
p66185
S'Male gender predicts mortality in a large cohort of patients receiving antiretroviral therapy in Uganda.'
p66186
sS'RN'
p66187
(lp66188
S'0 (Anti-HIV Agents)'
p66189
asS'PL'
p66190
S'England'
p66191
sS'PG'
p66192
S'52'
p66193
sS'JID'
p66194
S'101478566'
p66195
sS'AB'
p66196
S'BACKGROUND: Because men in Africa are less likely to access HIV/AIDS care than women, we aimed to determine if men have differing outcomes from women across a nationally representative sample of adult patients receiving combination antiretroviral therapy in Uganda. METHODS: We estimated survival distributions for adult male and female patients using Kaplan-Meier, and constructed multivariable regressions to model associations of baseline variables with mortality. We assessed person-years of life lost up to age 55 by sex. To minimize the impact of patient attrition, we assumed a weighted 30% mortality rate among those lost to follow up. RESULTS: We included data from 22,315 adults receiving antiretroviral therapy. At baseline, men tended to be older, had lower CD4 baseline values, more advanced disease, had pulmonary tuberculosis and had received less treatment follow up (all at p < 0.001). Loss to follow up differed between men and women (7.5 versus 5.9%, p < 0.001). Over the period of study, men had a significantly increased risk of death compared with female patients (adjusted hazard ratio 1.43, 95% CI 1.31-1.57, p < 0.001). The crude mortality rate for males differed importantly from females (43.9, 95% CI 40.7-47.0/1000 person-years versus 26.9, 95% CI 25.4-28.5/1000 person years, p < 0.001). The probability of survival was 91.2% among males and 94.1% among females at 12 months. Person-years of life lost was lower for females than males (689.7 versus 995.9 per 1000 person-years, respectively). CONCLUSIONS: In order to maximize the benefits of antiretroviral therapy, treatment programmes need to be gender sensitive to the specific needs of both women and men. Particular efforts are needed to enroll men earlier into care.'
p66197
sS'GR'
p66198
(lp66199
S'Canadian Institutes of Health Research/Canada'
p66200
asS'VI'
p66201
S'14'
p66202
sS'IS'
p66203
S'1758-2652 (Electronic) 1758-2652 (Linking)'
p66204
sS'PMC'
p66205
S'PMC3220631'
p66206
sS'AU'
p66207
(lp66208
S'Mills EJ'
p66209
aS'Bakanda C'
p66210
aS'Birungi J'
p66211
aS'Chan K'
p66212
aS'Hogg RS'
p66213
aS'Ford N'
p66214
aS'Nachega JB'
p66215
aS'Cooper CL'
p66216
asS'MHDA'
p66217
S'2012/02/09 06:00'
p66218
sS'PHST'
p66219
(lp66220
S'2011/06/22 [received]'
p66221
aS'2011/11/03 [accepted]'
p66222
aS'2011/11/03 [aheadofprint]'
p66223
asS'OID'
p66224
(lp66225
S'NLM: PMC3220631'
p66226
asS'MH'
p66227
(lp66228
S'Adolescent'
p66229
aS'Adult'
p66230
aS'Anti-HIV Agents/*administration & dosage'
p66231
aS'*Antiretroviral Therapy, Highly Active'
p66232
aS'Female'
p66233
aS'HIV Infections/drug therapy/*epidemiology/*mortality'
p66234
aS'Humans'
p66235
aS'Male'
p66236
aS'Middle Aged'
p66237
aS'Sex Factors'
p66238
aS'Survival Analysis'
p66239
aS'Uganda/epidemiology'
p66240
aS'Young Adult'
p66241
asS'EDAT'
p66242
S'2011/11/05 06:00'
p66243
sS'SO'
p66244
S'J Int AIDS Soc. 2011 Nov 3;14:52. doi: 10.1186/1758-2652-14-52.'
p66245
sS'SB'
p66246
S'IM X'
p66247
sS'PMID'
p66248
S'22050673'
p66249
sS'TA'
p66250
S'J Int AIDS Soc'
p66251
sS'PST'
p66252
S'epublish'
p66253
stRp66254
ag2
(g3
g4
(dp66255
S'LID'
p66256
S'10.1111/j.1365-3156.2011.02912.x [doi]'
p66257
sS'STAT'
p66258
S'MEDLINE'
p66259
sS'DEP'
p66260
S'20111101'
p66261
sS'CI'
p66262
(lp66263
S'(c) 2011 Blackwell Publishing Ltd.'
p66264
asS'DA'
p66265
S'20120904'
p66266
sS'AID'
p66267
(lp66268
S'10.1111/j.1365-3156.2011.02912.x [doi]'
p66269
asS'CRDT'
p66270
(lp66271
S'2011/11/02 06:00'
p66272
asS'DP'
p66273
S'2012 Feb'
p66274
sS'AD'
p66275
S'UNC Project, Lilongwe, Malawi Lighthouse Trust Clinic, Lilongwe, Malawi.'
p66276
sS'OWN'
p66277
S'NLM'
p66278
sS'PT'
p66279
(lp66280
S'Journal Article'
p66281
aS'Research Support, N.I.H., Extramural'
p66282
asS'LA'
p66283
(lp66284
S'eng'
p66285
asS'FAU'
p66286
(lp66287
S'Vorkas, Charles K'
p66288
aS'Tweya, Hannock'
p66289
aS'Mzinganjira, Dalitso'
p66290
aS'Dickie, George'
p66291
aS'Weigel, Ralf'
p66292
aS'Phiri, Sam'
p66293
aS'Hosseinipour, Mina C'
p66294
asS'JT'
p66295
S'Tropical medicine & international health : TM & IH'
p66296
sS'LR'
p66297
S'20150129'
p66298
sS'PG'
p66299
S'169-76'
p66300
sS'TI'
p66301
S'Practices to improve identification of adult antiretroviral therapy failure at the Lighthouse Trust clinic in Lilongwe, Malawi.'
p66302
sS'RN'
p66303
(lp66304
S'0 (Anti-HIV Agents)'
p66305
asS'PL'
p66306
S'England'
p66307
sS'TA'
p66308
S'Trop Med Int Health'
p66309
sS'JID'
p66310
S'9610576'
p66311
sS'AB'
p66312
S"OBJECTIVES: Evaluating treatment failure is critical when deciding to modify antiretroviral therapy (ART). Virologic Assessment Forms (VAFs) were implemented in July 2008 as a prerequisite for ordering viral load. The form requires assessment of clinical and immunologic status. METHODS: Using the Electronic Medical Record (EMR), we retrospectively evaluated patients who met 2006 WHO guidelines for immunologic failure (>/=15 years old; on ART >/=6 months; CD4 count <baseline OR CD4 count >50% drop from peak OR CD4 persistently <100 cells) at the Lighthouse Trust clinic from December 2007 to December 2009. We compared virologic screening, VAF implementation and ART modification during the same period using Fisher's exact tests and unpaired t-tests as appropriate. RESULTS: Of 7000 enrolled ART patients >/=15 years old with at least two CD4 counts, 10% had immunologic failure with a median follow-up time on ART of 1.4 years (IQR: 0.8-2.3). Forty (6%) viral loads were ordered: 14 (35%) were detectable (>400 HIV RNA copies/mL) and one (7%) patient was switched to second-line therapy. Overall, 259 VAFs were completed: 67% for immunologic failure and 33% for WHO Stage 4 condition. Before VAF implementation, 1% of patients had viral loads drawn during routine care, whereas afterwards, 8% did (P<0.0001; 95% CI: 0.03-0.08). CONCLUSIONS: Clinicians did not identify a large proportion of immunologic failure patients for screening. Implementation of VAFs produced little improvement in virologic screening during routine care. Better training and monitoring systems are needed."
p66313
sS'GR'
p66314
(lp66315
S'P30 AI050410/AI/NIAID NIH HHS/United States'
p66316
aS'P30 AI050410-11/AI/NIAID NIH HHS/United States'
p66317
aS'P30AI50410/AI/NIAID NIH HHS/United States'
p66318
aS'R24 TW007988/TW/FIC NIH HHS/United States'
p66319
aS'R24 TW007988/TW/FIC NIH HHS/United States'
p66320
aS'R24 TW007988-03/TW/FIC NIH HHS/United States'
p66321
asS'IP'
p66322
S'2'
sS'IS'
p66323
S'1365-3156 (Electronic) 1360-2276 (Linking)'
p66324
sS'PMC'
p66325
S'PMC3294101'
p66326
sS'DCOM'
p66327
S'20121119'
p66328
sS'MID'
p66329
(lp66330
S'NIHMS331294'
p66331
asS'AU'
p66332
(lp66333
S'Vorkas CK'
p66334
aS'Tweya H'
p66335
aS'Mzinganjira D'
p66336
aS'Dickie G'
p66337
aS'Weigel R'
p66338
aS'Phiri S'
p66339
aS'Hosseinipour MC'
p66340
asS'VI'
p66341
S'17'
p66342
sS'MHDA'
p66343
S'2012/12/10 06:00'
p66344
sS'PHST'
p66345
(lp66346
S'2011/11/01 [aheadofprint]'
p66347
asS'OID'
p66348
(lp66349
S'NLM: NIHMS331294'
p66350
aS'NLM: PMC3294101'
p66351
asS'MH'
p66352
(lp66353
S'Adolescent'
p66354
aS'Ambulatory Care Facilities'
p66355
aS'Anti-HIV Agents/*therapeutic use'
p66356
aS'*CD4 Lymphocyte Count'
p66357
aS'Electronic Health Records'
p66358
aS'Female'
p66359
aS'Guidelines as Topic'
p66360
aS'HIV Infections/*drug therapy/immunology/virology'
p66361
aS'Humans'
p66362
aS'Malawi'
p66363
aS'Male'
p66364
aS'Retrospective Studies'
p66365
aS'Treatment Failure'
p66366
aS'*Viral Load'
p66367
aS'World Health Organization'
p66368
aS'Young Adult'
p66369
asS'EDAT'
p66370
S'2011/11/02 06:00'
p66371
sS'SO'
p66372
S'Trop Med Int Health. 2012 Feb;17(2):169-76. doi: 10.1111/j.1365-3156.2011.02912.x. Epub 2011 Nov 1.'
p66373
sS'SB'
p66374
S'IM'
p66375
sS'PMID'
p66376
S'22039960'
p66377
sS'PST'
p66378
S'ppublish'
p66379
stRp66380
ag2
(g3
g4
(dp66381
S'LID'
p66382
S'10.1016/S1473-3099(11)70255-9 [doi]'
p66383
sS'STAT'
p66384
S'MEDLINE'
p66385
sS'DEP'
p66386
S'20111027'
p66387
sS'CI'
p66388
(lp66389
S'Copyright (c) 2012 Elsevier Ltd. All rights reserved.'
p66390
asS'DA'
p66391
S'20120330'
p66392
sS'AID'
p66393
(lp66394
S'S1473-3099(11)70255-9 [pii]'
p66395
aS'10.1016/S1473-3099(11)70255-9 [doi]'
p66396
asS'CRDT'
p66397
(lp66398
S'2011/11/01 06:00'
p66399
asS'DP'
p66400
S'2012 Apr'
p66401
sS'AD'
p66402
S'PharmAccess Foundation, Department of Global Health, Amsterdam Institute for Global Health and Development, Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands. r.hamers@aighd.org'
p66403
sS'OWN'
p66404
S'NLM'
p66405
sS'PT'
p66406
(lp66407
S'Clinical Trial'
p66408
aS'Journal Article'
p66409
aS'Multicenter Study'
p66410
aS"Research Support, Non-U.S. Gov't"
p66411
asS'LA'
p66412
(lp66413
S'eng'
p66414
asS'FAU'
p66415
(lp66416
S'Hamers, Raph L'
p66417
aS'Schuurman, Rob'
p66418
aS'Sigaloff, Kim C E'
p66419
aS'Wallis, Carole L'
p66420
aS'Kityo, Cissy'
p66421
aS'Siwale, Margaret'
p66422
aS'Mandaliya, Kishor'
p66423
aS'Ive, Prudence'
p66424
aS'Botes, Mariette E'
p66425
aS'Wellington, Maureen'
p66426
aS'Osibogun, Akin'
p66427
aS'Wit, Ferdinand W'
p66428
aS'van Vugt, Michele'
p66429
aS'Stevens, Wendy S'
p66430
aS'de Wit, Tobias F Rinke'
p66431
asS'JT'
p66432
S'The Lancet. Infectious diseases'
p66433
sS'LR'
p66434
S'20140815'
p66435
sS'PG'
p66436
S'307-17'
p66437
sS'TI'
p66438
S'Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study.'
p66439
sS'RN'
p66440
(lp66441
S'0 (Anti-HIV Agents)'
p66442
aS'0 (RNA, Viral)'
p66443
aS'0 (Reverse Transcriptase Inhibitors)'
p66444
asS'PL'
p66445
S'United States'
p66446
sS'TA'
p66447
S'Lancet Infect Dis'
p66448
sS'JID'
p66449
S'101130150'
p66450
sS'AB'
p66451
S'BACKGROUND: The effect of pretreatment HIV-1 drug resistance on the response to first-line combination antiretroviral therapy (ART) in sub-Saharan Africa has not been assessed. We studied pretreatment drug resistance and virological, immunological, and drug-resistance treatment outcomes in a large prospective cohort. METHODS: HIV-1 infected patients in the PharmAccess African Studies to Evaluate Resistance Monitoring (PASER-M) cohort started non-nucleoside reverse transcriptase inhibitor-based ART at 13 clinical sites in six countries, from 2007 to 2009. We used the International Antiviral Society-USA drug resistance mutation list and the Stanford algorithm to classify participants into three pretreatment drug resistance categories: no pretreatment drug resistance, pretreatment drug resistance with fully active ART prescribed, or pretreatment drug resistance with reduced susceptibility to at least one prescribed drug. We assessed risk factors of virological failure (>/=400 copies per mL) and acquired drug resistance after 12 months of ART by use of multilevel logistic regression with multiple imputations for missing data. CD4 cell count increase was estimated with linear mixed models. FINDINGS: Pretreatment drug resistance results were available for 2579 (94%) of 2733 participants; 2404 (93%) had no pretreatment drug resistance, 123 (5%) had pretreatment drug resistance to at least one prescribed drug, and 52 (2%) had pretreatment drug resistance and received fully active ART. Compared with participants without pretreatment drug resistance, the odds ratio (OR) for virological failure (OR 2.13, 95% CI 1.44-3.14; p<0.0001) and acquired drug-resistance (2.30, 1.55-3.40; p<0.0001) was increased in participants with pretreatment drug resistance to at least one prescribed drug, but not in those with pretreatment drug resistance and fully active ART. CD4 count increased less in participants with pretreatment drug resistance than in those without (35 cells per muL difference after 12 months; 95% CI 13-58; p=0.002). INTERPRETATION: At least three fully active antiretroviral drugs are needed to ensure an optimum response to first-line regimens and to prevent acquisition of drug resistance. Improved access to alternative combinations of antiretroviral drugs in sub-Saharan Africa is warranted. FUNDING: The Netherlands Ministry of Foreign Affairs.'
p66452
sS'CN'
p66453
(lp66454
S'PharmAccess African Studies to Evaluate Resistance (PASER) Investigators'
p66455
asS'IP'
p66456
S'4'
sS'IS'
p66457
S'1474-4457 (Electronic) 1473-3099 (Linking)'
p66458
sS'DCOM'
p66459
S'20120718'
p66460
sS'CIN'
p66461
(lp66462
S'Lancet Infect Dis. 2012 Apr;12(4):261. PMID: 22036232'
p66463
aS'Future Microbiol. 2012 Aug;7(8):929-32. PMID: 22913352'
p66464
aS'Lancet Infect Dis. 2012 Dec;12(12):911. PMID: 23174380'
p66465
asS'AU'
p66466
(lp66467
S'Hamers RL'
p66468
aS'Schuurman R'
p66469
aS'Sigaloff KC'
p66470
aS'Wallis CL'
p66471
aS'Kityo C'
p66472
aS'Siwale M'
p66473
aS'Mandaliya K'
p66474
aS'Ive P'
p66475
aS'Botes ME'
p66476
aS'Wellington M'
p66477
aS'Osibogun A'
p66478
aS'Wit FW'
p66479
aS'van Vugt M'
p66480
aS'Stevens WS'
p66481
aS'de Wit TF'
p66482
asS'VI'
p66483
S'12'
p66484
sS'MHDA'
p66485
S'2012/07/19 06:00'
p66486
sS'PHST'
p66487
(lp66488
S'2011/10/27 [aheadofprint]'
p66489
asS'MH'
p66490
(lp66491
S'Adult'
p66492
aS'Africa South of the Sahara'
p66493
aS'Anti-HIV Agents/*administration & dosage'
p66494
aS'CD4 Lymphocyte Count'
p66495
aS'Cohort Studies'
p66496
aS'Drug Resistance, Viral'
p66497
aS'Female'
p66498
aS'HIV Infections/*drug therapy/immunology/virology'
p66499
aS'HIV-1/genetics/*immunology'
p66500
aS'Humans'
p66501
aS'Logistic Models'
p66502
aS'Male'
p66503
aS'Prospective Studies'
p66504
aS'RNA, Viral/blood'
p66505
aS'Reverse Transcriptase Inhibitors/*administration & dosage'
p66506
asS'EDAT'
p66507
S'2011/11/01 06:00'
p66508
sS'SO'
p66509
S'Lancet Infect Dis. 2012 Apr;12(4):307-17. doi: 10.1016/S1473-3099(11)70255-9. Epub 2011 Oct 27.'
p66510
sS'SB'
p66511
S'IM'
p66512
sS'PMID'
p66513
S'22036233'
p66514
sS'PST'
p66515
S'ppublish'
p66516
stRp66517
ag2
(g3
g4
(dp66518
S'LID'
p66519
S'10.1186/1471-2458-11-828 [doi]'
p66520
sS'STAT'
p66521
S'MEDLINE'
p66522
sS'DEP'
p66523
S'20111026'
p66524
sS'DA'
p66525
S'20111108'
p66526
sS'AID'
p66527
(lp66528
S'1471-2458-11-828 [pii]'
p66529
aS'10.1186/1471-2458-11-828 [doi]'
p66530
asS'CRDT'
p66531
(lp66532
S'2011/10/28 06:00'
p66533
asS'DP'
p66534
S'2011'
p66535
sS'OWN'
p66536
S'NLM'
p66537
sS'PT'
p66538
(lp66539
S'Clinical Trial'
p66540
aS'Journal Article'
p66541
aS"Research Support, Non-U.S. Gov't"
p66542
asS'LA'
p66543
(lp66544
S'eng'
p66545
asS'DCOM'
p66546
S'20120223'
p66547
sS'JT'
p66548
S'BMC public health'
p66549
sS'LR'
p66550
S'20151119'
p66551
sS'FAU'
p66552
(lp66553
S'Chibanda, Dixon'
p66554
aS'Mesu, Petra'
p66555
aS'Kajawu, Lazarus'
p66556
aS'Cowan, Frances'
p66557
aS'Araya, Ricardo'
p66558
aS'Abas, Melanie A'
p66559
asS'TI'
p66560
S'Problem-solving therapy for depression and common mental disorders in Zimbabwe: piloting a task-shifting primary mental health care intervention in a population with a high prevalence of people living with HIV.'
p66561
sS'PL'
p66562
S'England'
p66563
sS'PG'
p66564
S'828'
p66565
sS'JID'
p66566
S'100968562'
p66567
sS'AB'
p66568
S"BACKGROUND: There is limited evidence that interventions for depression and other common mental disorders (CMD) can be integrated sustainably into primary health care in Africa. We aimed to pilot a low-cost multi-component 'Friendship Bench Intervention' for CMD, locally adapted from problem-solving therapy and delivered by trained and supervised female lay workers to learn if was feasible and possibly effective as well as how best to implement it on a larger scale. METHOD: We trained lay workers for 8 days in screening and monitoring CMD and in delivering the intervention. Ten lay workers screened consecutive adult attenders who either were referred or self-referred to the Friendship Bench between July and December 2007. Those scoring above the validated cut-point of the Shona Symptom Questionnaire (SSQ) for CMD were potentially eligible. Exclusions were suicide risk or very severe depression. All others were offered 6 sessions of problem-solving therapy (PST) enhanced with a component of activity scheduling. Weekly nurse-led group supervision and monthly supervision from a mental health specialist were provided. Data on SSQ scores at 6 weeks after entering the study were collected by an independent research nurse. Lay workers completed a brief evaluation on their experiences of delivering the intervention. RESULTS: Of 395 potentially eligible, 33 (8%) were excluded due to high risk. Of the 362 left, 2% (7) declined and 10% (35) were lost to follow-up leaving an 88% response rate (n = 320). Over half (n = 166, 52%) had presented with an HIV-related problem. Mean SSQ score fell from 11.3 (sd 1.4) before treatment to 6.5 (sd 2.4) after 3-6 sessions. The drop in SSQ scores was proportional to the number of sessions attended. Nine of the ten lay workers rated themselves as very able to deliver the PST intervention. CONCLUSION: We have found preliminary evidence of a clinically meaningful improvement in CMD associated with locally adapted problem-solving therapy delivered by lay health workers through routine primary health care in an African setting. There is a need to test the effectiveness of this task-shifting mental health intervention in an appropriately powered randomised controlled trial. TRIAL REGISTRATION: ISRCTN: ISRCTN25476759."
p66569
sS'AD'
p66570
S'Department of Psychiatry, University of Zimbabwe, Harare, Zimbabwe. dichi@zol.co.zw'
p66571
sS'VI'
p66572
S'11'
p66573
sS'IS'
p66574
S'1471-2458 (Electronic) 1471-2458 (Linking)'
p66575
sS'PMC'
p66576
S'PMC3210104'
p66577
sS'AU'
p66578
(lp66579
S'Chibanda D'
p66580
aS'Mesu P'
p66581
aS'Kajawu L'
p66582
aS'Cowan F'
p66583
aS'Araya R'
p66584
aS'Abas MA'
p66585
asS'MHDA'
p66586
S'2012/02/24 06:00'
p66587
sS'PHST'
p66588
(lp66589
S'2010/06/06 [received]'
p66590
aS'2011/10/26 [accepted]'
p66591
aS'2011/10/26 [aheadofprint]'
p66592
asS'OID'
p66593
(lp66594
S'NLM: PMC3210104'
p66595
asS'MH'
p66596
(lp66597
S'Adult'
p66598
aS'*Community Health Workers'
p66599
aS'Depression/psychology/therapy'
p66600
aS'Feasibility Studies'
p66601
aS'Female'
p66602
aS'Follow-Up Studies'
p66603
aS'HIV'
p66604
aS'HIV Infections/epidemiology/therapy'
p66605
aS'Health Promotion/*methods'
p66606
aS'Humans'
p66607
aS'Male'
p66608
aS'Mental Disorders/psychology/*therapy'
p66609
aS'Middle Aged'
p66610
aS'Personnel Staffing and Scheduling'
p66611
aS'Pilot Projects'
p66612
aS'Prevalence'
p66613
aS'*Primary Health Care'
p66614
aS'*Problem Solving'
p66615
aS'Program Evaluation'
p66616
aS'Surveys and Questionnaires'
p66617
aS'Young Adult'
p66618
aS'Zimbabwe/epidemiology'
p66619
asS'EDAT'
p66620
S'2011/10/28 06:00'
p66621
sS'SI'
p66622
(lp66623
S'ISRCTN/ISRCTN25476759'
p66624
asS'SO'
p66625
S'BMC Public Health. 2011 Oct 26;11:828. doi: 10.1186/1471-2458-11-828.'
p66626
sS'SB'
p66627
S'IM'
p66628
sS'PMID'
p66629
S'22029430'
p66630
sS'TA'
p66631
S'BMC Public Health'
p66632
sS'PST'
p66633
S'epublish'
p66634
stRp66635
ag2
(g3
g4
(dp66636
S'LID'
p66637
S'10.1097/QAI.0b013e31823d3aba [doi]'
p66638
sS'STAT'
p66639
S'MEDLINE'
p66640
sS'JT'
p66641
S'Journal of acquired immune deficiency syndromes (1999)'
p66642
sS'MID'
p66643
(lp66644
S'NIHMS338834'
p66645
asS'DA'
p66646
S'20111214'
p66647
sS'AID'
p66648
(lp66649
S'10.1097/QAI.0b013e31823d3aba [doi]'
p66650
asS'CRDT'
p66651
(lp66652
S'2011/10/27 06:00'
p66653
asS'DP'
p66654
S'2012 Jan 1'
p66655
sS'AD'
p66656
S'Division of Infectious Disease, Massachusetts General Hospital, Boston, USA. ibassett@partners.org'
p66657
sS'OWN'
p66658
S'NLM'
p66659
sS'PT'
p66660
(lp66661
S'Journal Article'
p66662
aS'Research Support, N.I.H., Extramural'
p66663
aS"Research Support, Non-U.S. Gov't"
p66664
asS'LA'
p66665
(lp66666
S'eng'
p66667
asS'FAU'
p66668
(lp66669
S'Bassett, Ingrid V'
p66670
aS'Chetty, Senica'
p66671
aS'Wang, Bingxia'
p66672
aS'Mazibuko, Matilda'
p66673
aS'Giddy, Janet'
p66674
aS'Lu, Zhigang'
p66675
aS'Walensky, Rochelle P'
p66676
aS'Freedberg, Kenneth A'
p66677
aS'Losina, Elena'
p66678
asS'LR'
p66679
S'20150129'
p66680
sS'PG'
p66681
S'25-30'
p66682
sS'TI'
p66683
S'Loss to follow-up and mortality among HIV-infected people co-infected with TB at ART initiation in Durban, South Africa.'
p66684
sS'RN'
p66685
(lp66686
S'0 (Anti-HIV Agents)'
p66687
asS'PL'
p66688
S'United States'
p66689
sS'TA'
p66690
S'J Acquir Immune Defic Syndr'
p66691
sS'JID'
p66692
S'100892005'
p66693
sS'AB'
p66694
S'OBJECTIVE: To quantify the impact of tuberculosis (TB) co-infection on death and loss to follow-up (LTFU) 12 months after entry into an ART program. DESIGN: Prospective intervention study. METHODS: From May 2007 to 2008, patients undergoing pre-ART training in Durban, South Africa, were screened for pulmonary TB using mycobacterial culture. Subjects missing appointments for >3 months were phoned. Patients who could not be reached were considered LTFU. Deaths were ascertained by report from family members. We used the Kaplan-Meier method to estimate time to LTFU or death for 3 groups at enrollment as follows: (1) newly diagnosed with TB by sputum culture; (2) on TB treatment (ie, previously diagnosed); and (3) TB free. We evaluated the role of TB on mortality and LTFU using Cox proportional hazards models. RESULTS: Nine hundred fifty-one HIV-infected subjects were enrolled; 59% were female, and median baseline CD4 count was 90 cells per microliter (IQR: 41-148 cells/muL). One hundred forty-four (15%) were newly diagnosed with TB by sputum culture; an additional 199 (21%) were already on TB treatment. By 12 months, 26% newly diagnosed with TB at enrollment died or were LTFU, compared with 19% already on TB treatment, and 14% who were TB free (P = 0.001). Controlling for age, sex, smoking, CD4, and opportunistic infection history, subjects newly diagnosed with pulmonary TB were 76% more likely to die or be LTFU (hazard ratio: 1.76, 95% confidence interval: 1.20 to 2.60) than those without TB. CONCLUSIONS: HIV/TB co-infected individuals are more likely to die or be LTFU within 12 months of ART clinic entry in South Africa. These patients require intensive follow-up during ART initiation.'
p66695
sS'GR'
p66696
(lp66697
S'K23 AI 068458/AI/NIAID NIH HHS/United States'
p66698
aS'K23 AI068458/AI/NIAID NIH HHS/United States'
p66699
aS'K23 AI068458-05/AI/NIAID NIH HHS/United States'
p66700
aS'K24 AI062476/AI/NIAID NIH HHS/United States'
p66701
aS'K24 AI062476/AI/NIAID NIH HHS/United States'
p66702
aS'K24 AR057827/AR/NIAMS NIH HHS/United States'
p66703
aS'K24AR057827/AR/NIAMS NIH HHS/United States'
p66704
aS'P30 AI060354/AI/NIAID NIH HHS/United States'
p66705
aS'P30 AI060354/AI/NIAID NIH HHS/United States'
p66706
aS'R01 AI058736/AI/NIAID NIH HHS/United States'
p66707
aS'R01 AI058736/AI/NIAID NIH HHS/United States'
p66708
aS'R01 AI058736-08/AI/NIAID NIH HHS/United States'
p66709
aS'R01 MH073445/MH/NIMH NIH HHS/United States'
p66710
aS'R01 MH073445/MH/NIMH NIH HHS/United States'
p66711
aS'R01 MH090326/MH/NIMH NIH HHS/United States'
p66712
aS'R01 MH090326/MH/NIMH NIH HHS/United States'
p66713
aS'R01 MH090326-02/MH/NIMH NIH HHS/United States'
p66714
asS'IP'
p66715
S'1'
sS'IS'
p66716
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p66717
sS'PMC'
p66718
S'PMC3237807'
p66719
sS'DCOM'
p66720
S'20120202'
p66721
sS'AU'
p66722
(lp66723
S'Bassett IV'
p66724
aS'Chetty S'
p66725
aS'Wang B'
p66726
aS'Mazibuko M'
p66727
aS'Giddy J'
p66728
aS'Lu Z'
p66729
aS'Walensky RP'
p66730
aS'Freedberg KA'
p66731
aS'Losina E'
p66732
asS'VI'
p66733
S'59'
p66734
sS'MHDA'
p66735
S'2012/02/03 06:00'
p66736
sS'OID'
p66737
(lp66738
S'NLM: NIHMS338834'
p66739
aS'NLM: PMC3237807'
p66740
asS'MH'
p66741
(lp66742
S'Adult'
p66743
aS'Anti-HIV Agents/*therapeutic use'
p66744
aS'Female'
p66745
aS'HIV Infections/*complications/*mortality'
p66746
aS'Humans'
p66747
aS'*Lost to Follow-Up'
p66748
aS'Male'
p66749
aS'Patient Compliance'
p66750
aS'South Africa/epidemiology'
p66751
aS'Tuberculosis/*complications/*mortality'
p66752
asS'EDAT'
p66753
S'2011/10/27 06:00'
p66754
sS'SO'
p66755
S'J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):25-30. doi: 10.1097/QAI.0b013e31823d3aba.'
p66756
sS'SB'
p66757
S'IM X'
p66758
sS'PMID'
p66759
S'22027877'
p66760
sS'PST'
p66761
S'ppublish'
p66762
stRp66763
ag2
(g3
g4
(dp66764
S'LID'
p66765
S'10.1097/QAI.0b013e31823b4448 [doi]'
p66766
sS'STAT'
p66767
S'MEDLINE'
p66768
sS'JT'
p66769
S'Journal of acquired immune deficiency syndromes (1999)'
p66770
sS'DA'
p66771
S'20120117'
p66772
sS'AID'
p66773
(lp66774
S'10.1097/QAI.0b013e31823b4448 [doi]'
p66775
asS'CRDT'
p66776
(lp66777
S'2011/10/27 06:00'
p66778
asS'DP'
p66779
S'2012 Feb 1'
p66780
sS'AD'
p66781
S'Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA. rbs@iupui.edu'
p66782
sS'OWN'
p66783
S'NLM'
p66784
sS'PT'
p66785
(lp66786
S'Journal Article'
p66787
aS'Research Support, N.I.H., Extramural'
p66788
aS"Research Support, U.S. Gov't, Non-P.H.S."
p66789
asS'LA'
p66790
(lp66791
S'eng'
p66792
asS'FAU'
p66793
(lp66794
S'Yoder, Rachel B'
p66795
aS'Nyandiko, Winstone M'
p66796
aS'Vreeman, Rachel C'
p66797
aS'Ayaya, Samwel O'
p66798
aS'Gisore, Peter O'
p66799
aS'Braitstein, Paula'
p66800
aS'Wiehe, Sarah E'
p66801
asS'PG'
p66802
S'199-206'
p66803
sS'TI'
p66804
S'Long-term impact of the Kenya postelection crisis on clinic attendance and medication adherence for HIV-infected children in western Kenya.'
p66805
sS'RN'
p66806
(lp66807
S'0 (Anti-HIV Agents)'
p66808
asS'PL'
p66809
S'United States'
p66810
sS'TA'
p66811
S'J Acquir Immune Defic Syndr'
p66812
sS'JID'
p66813
S'100892005'
p66814
sS'AB'
p66815
S'BACKGROUND: Kenya experienced a political and humanitarian crisis after presidential elections on December 27, 2007. We sought to describe both the immediate and long-term impact of this conflict for HIV-infected children in western Kenya. METHODS: We conducted a retrospective study of a cohort of these children for 3 periods: period 1, before the election (October 26, 2007, to December 25, 2007); period 2, immediately after the election (December 26, 2007, to April 15, 2008); and period 3, long-term postelection (April 16, 2008, to December 31, 2008). Two outcome variables of loss-to-follow-up (LTFU) were assessed: initial LTFU and complete LTFU. We assessed clinic adherence by evaluating the difference between actual visits and expected visits. Among children on antiretroviral therapy (ART), we assessed overall medication adherence and changes in medication adherence. RESULTS: Two thousand five hundred forty-nine HIV-infected children <14 years were seen in period 1. Children on ART had less initial LTFU (3.0% compared with 5.1%, P < 0.01) and less complete LTFU (2.6% compared with 6.8%, P < 0.001) than children not on ART. For children not on ART, clinic adherence improved in period 3 compared with period 2. For children on ART with a more strict measure of clinic adherence, clinic adherence declined over time. Orphans had better clinic adherence than nonorphans. Among children on ART, there were few demographic differences when comparing medication adherence between time. CONCLUSIONS: HIV-infected children are at risk for disruptions in clinic follow-up and medication adherence after a humanitarian crisis. Individual and contextual factors moderate the effects of these disruptions.'
p66816
sS'GR'
p66817
(lp66818
S'1K23MH087225-01/MH/NIMH NIH HHS/United States'
p66819
asS'IP'
p66820
S'2'
sS'IS'
p66821
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p66822
sS'DCOM'
p66823
S'20120308'
p66824
sS'AU'
p66825
(lp66826
S'Yoder RB'
p66827
aS'Nyandiko WM'
p66828
aS'Vreeman RC'
p66829
aS'Ayaya SO'
p66830
aS'Gisore PO'
p66831
aS'Braitstein P'
p66832
aS'Wiehe SE'
p66833
asS'VI'
p66834
S'59'
p66835
sS'MHDA'
p66836
S'2012/03/09 06:00'
p66837
sS'MH'
p66838
(lp66839
S'Adolescent'
p66840
aS'Anti-HIV Agents/*therapeutic use'
p66841
aS'Child'
p66842
aS'Child, Preschool'
p66843
aS'Cohort Studies'
p66844
aS'Female'
p66845
aS'HIV Infections/*drug therapy'
p66846
aS'Humans'
p66847
aS'Infant'
p66848
aS'Kenya'
p66849
aS'Male'
p66850
aS'Medication Adherence'
p66851
aS'*Patient Compliance'
p66852
aS'*Politics'
p66853
aS'Retrospective Studies'
p66854
asS'EDAT'
p66855
S'2011/10/27 06:00'
p66856
sS'SO'
p66857
S'J Acquir Immune Defic Syndr. 2012 Feb 1;59(2):199-206. doi: 10.1097/QAI.0b013e31823b4448.'
p66858
sS'SB'
p66859
S'IM X'
p66860
sS'PMID'
p66861
S'22027872'
p66862
sS'PST'
p66863
S'ppublish'
p66864
stRp66865
ag2
(g3
g4
(dp66866
S'LID'
p66867
S'10.1056/NEJMoa1014181 [doi]'
p66868
sS'STAT'
p66869
S'MEDLINE'
p66870
sS'JT'
p66871
S'The New England journal of medicine'
p66872
sS'CIN'
p66873
(lp66874
S'N Engl J Med. 2011 Oct 20;365(16):1538-40. PMID: 22010921'
p66875
aS'N Engl J Med. 2012 Feb 2;366(5):474; author reply 475-6. PMID: 22296084'
p66876
asS'DA'
p66877
S'20111020'
p66878
sS'AID'
p66879
(lp66880
S'10.1056/NEJMoa1014181 [doi]'
p66881
asS'CRDT'
p66882
(lp66883
S'2011/10/21 06:00'
p66884
asS'DP'
p66885
S'2011 Oct 20'
p66886
sS'AD'
p66887
S'Centre for the AIDS Programme of Research in South Africa, Durban, South Africa. caprisa@ukzn.ac.za'
p66888
sS'OWN'
p66889
S'NLM'
p66890
sS'PT'
p66891
(lp66892
S'Journal Article'
p66893
aS'Randomized Controlled Trial'
p66894
aS'Research Support, N.I.H., Extramural'
p66895
aS"Research Support, Non-U.S. Gov't"
p66896
aS"Research Support, U.S. Gov't, Non-P.H.S."
p66897
asS'LA'
p66898
(lp66899
S'eng'
p66900
asS'FAU'
p66901
(lp66902
S'Abdool Karim, Salim S'
p66903
aS'Naidoo, Kogieleum'
p66904
aS'Grobler, Anneke'
p66905
aS'Padayatchi, Nesri'
p66906
aS'Baxter, Cheryl'
p66907
aS'Gray, Andrew L'
p66908
aS'Gengiah, Tanuja'
p66909
aS'Gengiah, Santhanalakshmi'
p66910
aS'Naidoo, Anushka'
p66911
aS'Jithoo, Niraksha'
p66912
aS'Nair, Gonasagrie'
p66913
aS'El-Sadr, Wafaa M'
p66914
aS'Friedland, Gerald'
p66915
aS'Abdool Karim, Quarraisha'
p66916
asS'LR'
p66917
S'20150129'
p66918
sS'PG'
p66919
S'1492-501'
p66920
sS'TI'
p66921
S'Integration of antiretroviral therapy with tuberculosis treatment.'
p66922
sS'RN'
p66923
(lp66924
S'0 (Anti-Retroviral Agents)'
p66925
aS'0 (Antitubercular Agents)'
p66926
asS'PL'
p66927
S'United States'
p66928
sS'TA'
p66929
S'N Engl J Med'
p66930
sS'JID'
p66931
S'0255562'
p66932
sS'AB'
p66933
S"BACKGROUND: We previously reported that integrating antiretroviral therapy (ART) with tuberculosis treatment reduces mortality. However, the timing for the initiation of ART during tuberculosis treatment remains unresolved. METHODS: We conducted a three-group, open-label, randomized, controlled trial in South Africa involving 642 ambulatory patients, all with tuberculosis (confirmed by a positive sputum smear for acid-fast bacilli), human immunodeficiency virus infection, and a CD4+ T-cell count of less than 500 per cubic millimeter. Findings in the earlier-ART group (ART initiated within 4 weeks after the start of tuberculosis treatment, 214 patients) and later-ART group (ART initiated during the first 4 weeks of the continuation phase of tuberculosis treatment, 215 patients) are presented here. RESULTS: At baseline, the median CD4+ T-cell count was 150 per cubic millimeter, and the median viral load was 161,000 copies per milliliter, with no significant differences between the two groups. The incidence rate of the acquired immunodeficiency syndrome (AIDS) or death was 6.9 cases per 100 person-years in the earlier-ART group (18 cases) as compared with 7.8 per 100 person-years in the later-ART group (19 cases) (incidence-rate ratio, 0.89; 95% confidence interval [CI], 0.44 to 1.79; P=0.73). However, among patients with CD4+ T-cell counts of less than 50 per cubic millimeter, the incidence rates of AIDS or death were 8.5 and 26.3 cases per 100 person-years, respectively (incidence-rate ratio, 0.32; 95% CI, 0.07 to 1.13; P=0.06). The incidence rates of the immune reconstitution inflammatory syndrome (IRIS) were 20.1 and 7.7 cases per 100 person-years, respectively (incidence-rate ratio, 2.62; 95% CI, 1.48 to 4.82; P<0.001). Adverse events requiring a switching of antiretroviral drugs occurred in 10 patients in the earlier-ART group and 1 patient in the later-ART group (P=0.006). CONCLUSIONS: Early initiation of ART in patients with CD4+ T-cell counts of less than 50 per cubic millimeter increased AIDS-free survival. Deferral of the initiation of ART to the first 4 weeks of the continuation phase of tuberculosis therapy in those with higher CD4+ T-cell counts reduced the risks of IRIS and other adverse events related to ART without increasing the risk of AIDS or death. (Funded by the U.S. President's Emergency Plan for AIDS Relief and others; SAPIT ClinicalTrials.gov number, NCT00398996.)."
p66934
sS'GR'
p66935
(lp66936
S'U19 AI051794/AI/NIAID NIH HHS/United States'
p66937
aS'U19 AI051794-05S2/AI/NIAID NIH HHS/United States'
p66938
asS'IP'
p66939
S'16'
p66940
sS'IS'
p66941
S'1533-4406 (Electronic) 0028-4793 (Linking)'
p66942
sS'PMC'
p66943
S'PMC3233684'
p66944
sS'DCOM'
p66945
S'20111102'
p66946
sS'MID'
p66947
(lp66948
S'NIHMS340285'
p66949
asS'AU'
p66950
(lp66951
S'Abdool Karim SS'
p66952
aS'Naidoo K'
p66953
aS'Grobler A'
p66954
aS'Padayatchi N'
p66955
aS'Baxter C'
p66956
aS'Gray AL'
p66957
aS'Gengiah T'
p66958
aS'Gengiah S'
p66959
aS'Naidoo A'
p66960
aS'Jithoo N'
p66961
aS'Nair G'
p66962
aS'El-Sadr WM'
p66963
aS'Friedland G'
p66964
aS'Abdool Karim Q'
p66965
asS'VI'
p66966
S'365'
p66967
sS'MHDA'
p66968
S'2011/11/04 06:00'
p66969
sS'OID'
p66970
(lp66971
S'NLM: NIHMS340285'
p66972
aS'NLM: PMC3233684'
p66973
asS'MH'
p66974
(lp66975
S'AIDS-Related Opportunistic Infections/*drug therapy'
p66976
aS'Adult'
p66977
aS'Anti-Retroviral Agents/*administration & dosage'
p66978
aS'Antitubercular Agents/*therapeutic use'
p66979
aS'CD4 Lymphocyte Count'
p66980
aS'Disease-Free Survival'
p66981
aS'Drug Administration Schedule'
p66982
aS'Female'
p66983
aS'HIV Infections/complications/*drug therapy/mortality'
p66984
aS'Humans'
p66985
aS'Kaplan-Meier Estimate'
p66986
aS'Male'
p66987
aS'Tuberculosis/complications/*drug therapy'
p66988
aS'Viral Load'
p66989
asS'EDAT'
p66990
S'2011/10/21 06:00'
p66991
sS'SI'
p66992
(lp66993
S'ClinicalTrials.gov/NCT00398996'
p66994
asS'SO'
p66995
S'N Engl J Med. 2011 Oct 20;365(16):1492-501. doi: 10.1056/NEJMoa1014181.'
p66996
sS'SB'
p66997
S'AIM IM'
p66998
sS'PMID'
p66999
S'22010915'
p67000
sS'PST'
p67001
S'ppublish'
p67002
stRp67003
ag2
(g3
g4
(dp67004
S'LID'
p67005
S'10.1258/ijsa.2011.010452 [doi]'
p67006
sS'STAT'
p67007
S'MEDLINE'
p67008
sS'AB'
p67009
S'Antiretroviral treatment (ART) has been available in the private sector in Namibia since 1998. National guidelines were developed by the Ministry of Health and clinicians of the public and private sector in 2003 and launched at the start of the public sector ART programme by the Ministry of Health. The Namibian HIV Clinicians Society was established around this period to promote adherence to the national guidelines and to provide comprehensive training for health professionals. To monitor adherence to national ART guidelines, in 2003, the Society requested access to anonymized data on ART dispensing from the medical insurance industry. Dispensing data from all Namibian medical insurance companies were obtained. ART regimens were categorized as recommended (non-nucleoside reverse transcriptase inhibitor-based and boosted protease inhibitor [PI]-based), not recommended (non-boosted PI-based or stavudine/didanosine-containing regimens), ineffective (dual therapy) and second line or salvage regimens. This analysis was repeated in 2004, 2005 and 2008. In 2003, only 2306 adult private patients received ART, of which only 1527 (66%) were recommended regimens. In 2008, 7010 private patients received ART, of which 6372 (91%) were recommended regimens. The private sector covered about 15% of the total number of 46,732 reported ART patients reported in the year 2008. Many of these private patients might not have accessed ART in the public sector.'
p67010
sS'JID'
p67011
S'9007917'
p67012
sS'AD'
p67013
S'Department Epidemiology and Social Medicine, University of Antwerpen, Belgium. fred.vanderveen@telenet.be'
p67014
sS'JT'
p67015
S'International journal of STD & AIDS'
p67016
sS'IP'
p67017
S'10'
p67018
sS'IS'
p67019
S'1758-1052 (Electronic) 0956-4624 (Linking)'
p67020
sS'DCOM'
p67021
S'20120208'
p67022
sS'DA'
p67023
S'20111014'
p67024
sS'AU'
p67025
(lp67026
S'Van der Veen F'
p67027
aS'Mugala-Mukungu F'
p67028
aS'Kangudi M'
p67029
aS'Feris A'
p67030
aS'Katjitae I'
p67031
aS'Colebunders R'
p67032
asS'AID'
p67033
(lp67034
S'22/10/577 [pii]'
p67035
aS'10.1258/ijsa.2011.010452 [doi]'
p67036
asS'CRDT'
p67037
(lp67038
S'2011/10/15 06:00'
p67039
asS'VI'
p67040
S'22'
p67041
sS'PMID'
p67042
S'21998178'
p67043
sS'DP'
p67044
S'2011 Oct'
p67045
sS'MHDA'
p67046
S'2012/02/09 06:00'
p67047
sS'OWN'
p67048
S'NLM'
p67049
sS'PT'
p67050
(lp67051
S'Journal Article'
p67052
asS'LA'
p67053
(lp67054
S'eng'
p67055
asS'MH'
p67056
(lp67057
S'Adolescent'
p67058
aS'Adult'
p67059
aS'Anti-HIV Agents/administration & dosage/*therapeutic use'
p67060
aS'Antiretroviral Therapy, Highly Active'
p67061
aS'Child'
p67062
aS'Child, Preschool'
p67063
aS'Female'
p67064
aS'*Guideline Adherence'
p67065
aS'HIV Infections/*drug therapy'
p67066
aS'HIV Protease Inhibitors/therapeutic use'
p67067
aS'HIV-1/*drug effects'
p67068
aS'Humans'
p67069
aS'Male'
p67070
aS'Namibia'
p67071
aS'*Practice Guidelines as Topic'
p67072
aS'*Private Sector'
p67073
aS'Reverse Transcriptase Inhibitors/therapeutic use'
p67074
asS'FAU'
p67075
(lp67076
S'Van der Veen, F'
p67077
aS'Mugala-Mukungu, F'
p67078
aS'Kangudi, M'
p67079
aS'Feris, A'
p67080
aS'Katjitae, I'
p67081
aS'Colebunders, R'
p67082
asS'EDAT'
p67083
S'2011/10/15 06:00'
p67084
sS'PST'
p67085
S'ppublish'
p67086
sS'SO'
p67087
S'Int J STD AIDS. 2011 Oct;22(10):577-80. doi: 10.1258/ijsa.2011.010452.'
p67088
sS'PG'
p67089
S'577-80'
p67090
sS'TI'
p67091
S'Antiretroviral treatment in the private sector in Namibia.'
p67092
sS'SB'
p67093
S'IM X'
p67094
sS'RN'
p67095
(lp67096
S'0 (Anti-HIV Agents)'
p67097
aS'0 (HIV Protease Inhibitors)'
p67098
aS'0 (Reverse Transcriptase Inhibitors)'
p67099
asS'PL'
p67100
S'England'
p67101
sS'TA'
p67102
S'Int J STD AIDS'
p67103
stRp67104
ag2
(g3
g4
(dp67105
S'LID'
p67106
S'10.1097/QAD.0b013e32834b6480 [doi]'
p67107
sS'STAT'
p67108
S'MEDLINE'
p67109
sS'JT'
p67110
S'AIDS (London, England)'
p67111
sS'MID'
p67112
(lp67113
S'NIHMS446164'
p67114
asS'DA'
p67115
S'20111014'
p67116
sS'AID'
p67117
(lp67118
S'10.1097/QAD.0b013e32834b6480 [doi]'
p67119
aS'00002030-201110230-00012 [pii]'
p67120
asS'CRDT'
p67121
(lp67122
S'2011/10/15 06:00'
p67123
asS'DP'
p67124
S'2011 Oct 23'
p67125
sS'AD'
p67126
S'Health Economics and Epidemiology Research Office, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. abrennan@bu.edu'
p67127
sS'OWN'
p67128
S'NLM'
p67129
sS'PT'
p67130
(lp67131
S'Comparative Study'
p67132
aS'Journal Article'
p67133
aS'Research Support, N.I.H., Extramural'
p67134
aS"Research Support, Non-U.S. Gov't"
p67135
asS'LA'
p67136
(lp67137
S'eng'
p67138
asS'FAU'
p67139
(lp67140
S'Brennan, Alana T'
p67141
aS'Long, Lawrence'
p67142
aS'Maskew, Mhairi'
p67143
aS'Sanne, Ian'
p67144
aS'Jaffray, Imogen'
p67145
aS'MacPhail, Patrick'
p67146
aS'Fox, Matthew P'
p67147
asS'LR'
p67148
S'20150129'
p67149
sS'PG'
p67150
S'2027-36'
p67151
sS'TI'
p67152
S'Outcomes of stable HIV-positive patients down-referred from a doctor-managed antiretroviral therapy clinic to a nurse-managed primary health clinic for monitoring and treatment.'
p67153
sS'RN'
p67154
(lp67155
S'0 (Anti-HIV Agents)'
p67156
asS'PL'
p67157
S'England'
p67158
sS'TA'
p67159
S'AIDS'
p67160
sS'JID'
p67161
S'8710219'
p67162
sS'AB'
p67163
S'OBJECTIVE: To compare clinical, immunologic and virologic outcomes among stable HIV-positive patients down-referred to a nurse-managed primary healthcare clinic (PHC) for treatment maintenance to those who remained at a doctor-managed treatment-initiation site. DESIGN: We conducted a matched cohort analysis among stable HIV patients at the Themba Lethu Clinic in Johannesburg, South Africa. Eligible patients met the criteria for down-referral [undetectable viral load <10 months, antiretroviral therapy (ART) >11 months, CD4 cell count >/=200 cells/mul, stable weight and no opportunistic infections], regardless of whether they were down-referred to a PHC for treatment maintenance between February 2008 and January 2009. Patients were matched 1 : 3 (down-referred : treatment-initiation) using propensity scores. METHODS: We calculated rates and hazard ratios (HRs) for the effect of down-referral on loss to follow-up (LTFU) and mortality and the relative risk of down-referral on viral rebound by 12 months of follow-up. RESULTS: Six hundred and ninety-three down-referred patients were matched to 2079 treatment-initiation patients. Two (0.3%) down-referred and 32 (1.5%) treatment-initiation patients died, 10 (1.4%) down-referred and 87 (4.2%) treatment-initiation patients were lost, and 22 (3.3%) down-referred and 100 (5.6%) treatment-initiation patients experienced viral rebound by 12 months of follow-up. After adjustment, patients down-referred were less likely to die [hazard ratio (HR) 0.2, 95% confidence interval (CI) 0.04-0.8], become LTFU (HR 0.3, 95% CI 0.2-0.6) or experience viral rebound (relative risk 0.6, 95% CI 0.4-0.9) than treatment-initiation patients during follow-up. CONCLUSION: The utilization of nurse-managed PHCs for treatment maintenance of stable patients could decrease the burden on specialized doctor-managed ART clinics. Patient outcomes for down-referred patients at PHCs appear equal, if not better, than those achieved at ART clinics among stable patients.'
p67164
sS'GR'
p67165
(lp67166
S'K01 AI083097/AI/NIAID NIH HHS/United States'
p67167
aS'K01AI083097/AI/NIAID NIH HHS/United States'
p67168
asS'IP'
p67169
S'16'
p67170
sS'IS'
p67171
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p67172
sS'PMC'
p67173
S'PMC3669640'
p67174
sS'DCOM'
p67175
S'20111207'
p67176
sS'AU'
p67177
(lp67178
S'Brennan AT'
p67179
aS'Long L'
p67180
aS'Maskew M'
p67181
aS'Sanne I'
p67182
aS'Jaffray I'
p67183
aS'MacPhail P'
p67184
aS'Fox MP'
p67185
asS'VI'
p67186
S'25'
p67187
sS'MHDA'
p67188
S'2011/12/13 00:00'
p67189
sS'OID'
p67190
(lp67191
S'NLM: NIHMS446164'
p67192
aS'NLM: PMC3669640'
p67193
asS'MH'
p67194
(lp67195
S'Adult'
p67196
aS'Anti-HIV Agents/*therapeutic use'
p67197
aS'CD4 Lymphocyte Count'
p67198
aS'Cohort Studies'
p67199
aS'Female'
p67200
aS'HIV Infections/*drug therapy/immunology/virology'
p67201
aS'*HIV-1'
p67202
aS'Humans'
p67203
aS'Male'
p67204
aS'*Nurse Administrators'
p67205
aS'Primary Health Care/*manpower'
p67206
aS'Proportional Hazards Models'
p67207
aS'*Referral and Consultation'
p67208
aS'South Africa/epidemiology'
p67209
aS'Treatment Outcome'
p67210
aS'*Viral Load'
p67211
asS'EDAT'
p67212
S'2011/10/15 06:00'
p67213
sS'SO'
p67214
S'AIDS. 2011 Oct 23;25(16):2027-36. doi: 10.1097/QAD.0b013e32834b6480.'
p67215
sS'SB'
p67216
S'IM X'
p67217
sS'PMID'
p67218
S'21997488'
p67219
sS'PST'
p67220
S'ppublish'
p67221
stRp67222
ag2
(g3
g4
(dp67223
S'LID'
p67224
S'10.1177/1545109711422273 [doi]'
p67225
sS'STAT'
p67226
S'MEDLINE'
p67227
sS'DEP'
p67228
S'20111004'
p67229
sS'DA'
p67230
S'20120814'
p67231
sS'AID'
p67232
(lp67233
S'1545109711422273 [pii]'
p67234
aS'10.1177/1545109711422273 [doi]'
p67235
asS'CRDT'
p67236
(lp67237
S'2011/10/06 06:00'
p67238
asS'DP'
p67239
S'2012 Jul-Aug'
p67240
sS'OWN'
p67241
S'NLM'
p67242
sS'PT'
p67243
(lp67244
S'Journal Article'
p67245
asS'LA'
p67246
(lp67247
S'eng'
p67248
asS'FAU'
p67249
(lp67250
S'Tolle, Michael'
p67251
aS'Howard, Leigh'
p67252
aS'Kirk, Brianna'
p67253
aS'Gomila, Andres'
p67254
aS'Schwarzwald, Heidi'
p67255
aS'Anabwani, Gabriel'
p67256
asS'JT'
p67257
S'Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)'
p67258
sS'LR'
p67259
S'20140206'
p67260
sS'PG'
p67261
S'260-8'
p67262
sS'TI'
p67263
S'Reverse transcriptase genotypes in pediatric patients failing initial antiretroviral therapy in Gaborone, Botswana.'
p67264
sS'RN'
p67265
(lp67266
S'0 (Anti-HIV Agents)'
p67267
aS'0 (Benzoxazines)'
p67268
aS'0 (Pyridazines)'
p67269
aS'0 (Reverse Transcriptase Inhibitors)'
p67270
aS'0C50HW4FO1 (etravirine)'
p67271
aS'4B9XT59T7S (Zidovudine)'
p67272
aS'99DK7FVK1H (Nevirapine)'
p67273
aS'BO9LE4QFZF (Stavudine)'
p67274
aS'EC 2.7.7.49 (RNA-Directed DNA Polymerase)'
p67275
aS'JE6H2O27P8 (efavirenz)'
p67276
aS'VC2W18DGKR (Thymidine)'
p67277
asS'PL'
p67278
S'United States'
p67279
sS'TA'
p67280
S'J Int Assoc Physicians AIDS Care (Chic)'
p67281
sS'JID'
p67282
S'101185740'
p67283
sS'AB'
p67284
S'BACKGROUND: Limited data are available on patterns of resistance mutations in pediatric patients in southern Africa, where HIV-1 subtype C (HIV-1C) predominates. METHODS: Retrospective chart review of pediatric patients. Nucleoside reverse transcriptase inhibitor (NRTI)- and nonnucleoside reverse transcriptase inhibitor (NNRTI)-associated resistance mutations quantified from population-based sequencing genotypic resistance assay results taken at time of first-line antiretroviral therapy (ART) failure (first-line ART = stavudine [d4T] or zidovudine [ZDV] + lamivudine [3TC] + nevirapine [NVP] or efavirenz [EFV]). RESULTS: Total number of patients with resistance assays analyzed is 45. Nucleoside reverse transcriptase inhibitor-associated mutation frequencies noted were M184V (n = 41; 91.1%); thymidine analogue mutations (TAMs; n = 20; 44.4%); >1 TAM (n = 9; 20%); TAM-2 pathway (n = 10; 22.2%); TAM-1 pathway (n = 7; 15.6%); TAM-1 and TAM-2 pathways (n = 3; 6.7%); K65R (n = 2; 4.4%); Q151M (n = 1; 2.2%); and L74V (n = 0; 0%). Nonnucleoside reverse transcriptase inhibitor-associated mutation frequencies noted were associated with notable resistance to either/both NVP and EFV (n = 40; 88.9%); K103N (n = 15; 33.3%); >/=1 mutations associated with etravirine (ETR) failure (K101E, Y181C, and G190A; n =20; 44.4%); and >/=2 notable NNRTI mutations (n = 12; 26.7%). CONCLUSIONS: In this cohort, low-genetic barrier mutations were common, as were TAMs, including more than 1 TAM. Mutations compromising nonthymidine analogue backbones were rare, suggesting that it is likely that children who fail first-line NRTI backbones containing d4T or ZDV/3TC would still respond to abacavir (ABC), didanosine (ddI), and, for adolescents, tenofovir (TDF). Our data support the empiric continuation of 3TC in second-line regimens.'
p67285
sS'AD'
p67286
S"1Botswana-Baylor Children's Clinical Centre of Excellence, Gaborone, Botswana."
p67287
sS'IP'
p67288
S'4'
sS'IS'
p67289
S'1545-1097 (Print) 1545-1097 (Linking)'
p67290
sS'DCOM'
p67291
S'20140204'
p67292
sS'AU'
p67293
(lp67294
S'Tolle M'
p67295
aS'Howard L'
p67296
aS'Kirk B'
p67297
aS'Gomila A'
p67298
aS'Schwarzwald H'
p67299
aS'Anabwani G'
p67300
asS'VI'
p67301
S'11'
p67302
sS'MHDA'
p67303
S'2014/02/05 06:00'
p67304
sS'PHST'
p67305
(lp67306
S'2011/10/04 [aheadofprint]'
p67307
asS'MH'
p67308
(lp67309
S'Anti-HIV Agents/*therapeutic use'
p67310
aS'Benzoxazines/therapeutic use'
p67311
aS'Botswana'
p67312
aS'Child'
p67313
aS'Child, Preschool'
p67314
aS'Drug Resistance/*genetics'
p67315
aS'Drug Therapy, Combination'
p67316
aS'Female'
p67317
aS'Genotype'
p67318
aS'HIV Infections/*drug therapy/virology'
p67319
aS'HIV-1/*genetics'
p67320
aS'Humans'
p67321
aS'Infant'
p67322
aS'Male'
p67323
aS'Mutation'
p67324
aS'Nevirapine/therapeutic use'
p67325
aS'Pyridazines/therapeutic use'
p67326
aS'RNA-Directed DNA Polymerase/*genetics'
p67327
aS'Retrospective Studies'
p67328
aS'Reverse Transcriptase Inhibitors/*therapeutic use'
p67329
aS'Stavudine/therapeutic use'
p67330
aS'Thymidine/analogs & derivatives/genetics'
p67331
aS'*Treatment Failure'
p67332
aS'Zidovudine/therapeutic use'
p67333
asS'EDAT'
p67334
S'2011/10/06 06:00'
p67335
sS'SO'
p67336
S'J Int Assoc Physicians AIDS Care (Chic). 2012 Jul-Aug;11(4):260-8. doi: 10.1177/1545109711422273. Epub 2011 Oct 4.'
p67337
sS'SB'
p67338
S'IM'
p67339
sS'PMID'
p67340
S'21972264'
p67341
sS'PST'
p67342
S'ppublish'
p67343
stRp67344
ag2
(g3
g4
(dp67345
S'LID'
p67346
S'10.1186/1758-2652-14-S1-S4 [doi]'
p67347
sS'STAT'
p67348
S'MEDLINE'
p67349
sS'DEP'
p67350
S'20110706'
p67351
sS'DA'
p67352
S'20111004'
p67353
sS'AID'
p67354
(lp67355
S'1758-2652-14-S1-S4 [pii]'
p67356
aS'10.1186/1758-2652-14-S1-S4 [doi]'
p67357
asS'CRDT'
p67358
(lp67359
S'2011/10/05 06:00'
p67360
asS'DP'
p67361
S'2011'
p67362
sS'OWN'
p67363
S'NLM'
p67364
sS'PT'
p67365
(lp67366
S'Journal Article'
p67367
aS'Review'
p67368
asS'LA'
p67369
(lp67370
S'eng'
p67371
asS'DCOM'
p67372
S'20120117'
p67373
sS'JT'
p67374
S'Journal of the International AIDS Society'
p67375
sS'LR'
p67376
S'20150129'
p67377
sS'FAU'
p67378
(lp67379
S'Schouten, Erik J'
p67380
aS'Jahn, Andreas'
p67381
aS'Ben-Smith, Anne'
p67382
aS'Makombe, Simon D'
p67383
aS'Harries, Anthony D'
p67384
aS'Aboagye-Nyame, Francis'
p67385
aS'Chimbwandira, Frank'
p67386
asS'TI'
p67387
S'Antiretroviral drug supply challenges in the era of scaling up ART in Malawi.'
p67388
sS'RN'
p67389
(lp67390
S'0 (Anti-HIV Agents)'
p67391
asS'PL'
p67392
S'England'
p67393
sS'PG'
p67394
S'S4'
p67395
sS'JID'
p67396
S'101478566'
p67397
sS'AB'
p67398
S"The number of people receiving antiretroviral treatment (ART) has increased considerably in recent years and is expected to continue to grow in the coming years. A major challenge is to maintain uninterrupted supplies of antiretroviral (ARV) drugs and prevent stock outs. This article discusses issues around the management of ARVs and prevention of stock outs in Malawi, a low-income country with a high HIV/AIDS burden, and a weak procurement and supply chain management system. This system for ARVs, paid for by the Global Fund to Fight AIDS, Tuberculosis and Malaria, and bypassing the government Central Medical Stores, is in place, using the United Nations Children's Fund's (UNICEF's) procurement services. The system, managed by a handful of people who spend limited time on supply management, is characterized by a centrally coordinated quantification based on verified data from all national ART clinics, parallel procurement through UNICEF, and direct distribution to ART clinics. The model worked well in the first years of the ART programme with a single first-line ARV regimen, but with more regimens becoming available (e.g., alternative first-line, second-line and paediatric regimens), it has become more difficult to administer. Managing supplies through a parallel system has the advantage that weaknesses in the national system have limited influence on the ARV procurement and supply chain management system. However, as the current system operates without a central warehouse and national buffer stock capacity, it diminishes the ability to prevent ARV stock outs. The process of ordering ARVs, from the time that estimates are made to the arrival of supplies in health facilities, takes approximately one year. Addressing the challenges involved in maintaining ARVs through an efficient procurement and supply chain management system that prevents ARV stock outs through the establishment of a dedicated procurement team, a central warehouse and/or national buffer stock is a priority."
p67399
sS'AD'
p67400
S'Management Sciences for Health, Lilongwe, Malawi. eschouten@msh.org'
p67401
sS'VI'
p67402
S'14 Suppl 1'
p67403
sS'IS'
p67404
S'1758-2652 (Electronic) 1758-2652 (Linking)'
p67405
sS'PMC'
p67406
S'PMC3194149'
p67407
sS'AU'
p67408
(lp67409
S'Schouten EJ'
p67410
aS'Jahn A'
p67411
aS'Ben-Smith A'
p67412
aS'Makombe SD'
p67413
aS'Harries AD'
p67414
aS'Aboagye-Nyame F'
p67415
aS'Chimbwandira F'
p67416
asS'MHDA'
p67417
S'2012/01/18 06:00'
p67418
sS'PHST'
p67419
(lp67420
S'2011/07/06 [aheadofprint]'
p67421
asS'OID'
p67422
(lp67423
S'NLM: PMC3194149'
p67424
asS'MH'
p67425
(lp67426
S'Anti-HIV Agents/economics/*supply & distribution/therapeutic use'
p67427
aS'HIV Infections/*drug therapy/economics/epidemiology'
p67428
aS'Humans'
p67429
aS'Malawi/epidemiology'
p67430
asS'EDAT'
p67431
S'2011/10/05 06:00'
p67432
sS'SO'
p67433
S'J Int AIDS Soc. 2011 Jul 6;14 Suppl 1:S4. doi: 10.1186/1758-2652-14-S1-S4.'
p67434
sS'SB'
p67435
S'IM X'
p67436
sS'PMID'
p67437
S'21967844'
p67438
sS'TA'
p67439
S'J Int AIDS Soc'
p67440
sS'PST'
p67441
S'epublish'
p67442
stRp67443
ag2
(g3
g4
(dp67444
S'LID'
p67445
S'10.1016/S0140-6736(11)61052-0 [doi]'
p67446
sS'STAT'
p67447
S'MEDLINE'
p67448
sS'DEP'
p67449
S'20110925'
p67450
sS'CI'
p67451
(lp67452
S'Copyright (c) 2011 Elsevier Ltd. All rights reserved.'
p67453
asS'DA'
p67454
S'20111031'
p67455
sS'AID'
p67456
(lp67457
S'S0140-6736(11)61052-0 [pii]'
p67458
aS'10.1016/S0140-6736(11)61052-0 [doi]'
p67459
asS'CRDT'
p67460
(lp67461
S'2011/09/29 06:00'
p67462
asS'DP'
p67463
S'2011 Oct 29'
p67464
sS'OWN'
p67465
S'NLM'
p67466
sS'PT'
p67467
(lp67468
S'Comparative Study'
p67469
aS'Journal Article'
p67470
aS"Research Support, Non-U.S. Gov't"
p67471
asS'LA'
p67472
(lp67473
S'eng'
p67474
asS'FAU'
p67475
(lp67476
S'Jani, Ilesh V'
p67477
aS'Sitoe, Nadia E'
p67478
aS'Alfai, Eunice R'
p67479
aS'Chongo, Patrina L'
p67480
aS'Quevedo, Jorge I'
p67481
aS'Rocha, Beatriz M'
p67482
aS'Lehe, Jonathan D'
p67483
aS'Peter, Trevor F'
p67484
asS'JT'
p67485
S'Lancet (London, England)'
p67486
sS'LR'
p67487
S'20150616'
p67488
sS'PG'
p67489
S'1572-9'
p67490
sS'TI'
p67491
S'Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study.'
p67492
sS'PL'
p67493
S'England'
p67494
sS'TA'
p67495
S'Lancet'
p67496
sS'JID'
p67497
S'2985213R'
p67498
sS'AB'
p67499
S"BACKGROUND: Loss to follow-up of HIV-positive patients before initiation of antiretroviral therapy can exceed 50% in low-income settings and is a challenge to the scale-up of treatment. We implemented point-of-care counting of CD4 cells in Mozambique and assessed the effect on loss to follow-up before immunological staging and treatment initiation. METHODS: In this observational cohort study, data for enrolment into HIV management and initiation of antiretroviral therapy were extracted retrospectively from patients' records at four primary health clinics providing HIV treatment and point-of-care CD4 services. Loss to follow-up and the duration of each preparatory step before treatment initiation were measured and compared with baseline data from before the introduction of point-of-care CD4 testing. FINDINGS: After the introduction of point-of-care CD4 the proportion of patients lost to follow-up before completion of CD4 staging dropped from 57% (278 of 492) to 21% (92 of 437) (adjusted odds ratio [OR] 0.2, 95% CI 0.15-0.27). Total loss to follow-up before initiation of antiretroviral treatment fell from 64% (314 of 492) to 33% (142 of 437) (OR 0.27, 95% CI 0.21-0.36) and the proportion of enrolled patients initiating antiretroviral therapy increased from 12% (57 of 492) to 22% (94 of 437) (OR 2.05, 95% CI 1.42-2.96). The median time from enrolment to antiretroviral therapy initiation reduced from 48 days to 20 days (p<0.0001), primarily because of a reduction in the median time taken to complete CD4 staging, which decreased from 32 days to 3 days (p<0.0001). Loss to follow-up between staging and antiretroviral therapy initiation did not change significantly (OR 0.84, 95% CI 0.49-1.45). INTERPRETATION: Point-of-care CD4 testing enabled clinics to stage patients rapidly on-site after enrolment, which reduced opportunities for pretreatment loss to follow-up. As a result, more patients were identified as eligible for and initiated antiretroviral treatment. Point-of-care testing might therefore be an effective intervention to reduce pretreatment loss to follow-up. FUNDING: Absolute Return for Kids and UNITAID."
p67500
sS'AD'
p67501
S'Instituto Nacional da Saude, Maputo, Mozambique. ilesh.jani@gmail.com'
p67502
sS'IP'
p67503
S'9802'
p67504
sS'IS'
p67505
S'1474-547X (Electronic) 0140-6736 (Linking)'
p67506
sS'DCOM'
p67507
S'20120222'
p67508
sS'CIN'
p67509
(lp67510
S'Lancet. 2011 Oct 29;378(9802):1532-3. PMID: 22035547'
p67511
asS'AU'
p67512
(lp67513
S'Jani IV'
p67514
aS'Sitoe NE'
p67515
aS'Alfai ER'
p67516
aS'Chongo PL'
p67517
aS'Quevedo JI'
p67518
aS'Rocha BM'
p67519
aS'Lehe JD'
p67520
aS'Peter TF'
p67521
asS'VI'
p67522
S'378'
p67523
sS'MHDA'
p67524
S'2012/02/23 06:00'
p67525
sS'PHST'
p67526
(lp67527
S'2011/09/25 [aheadofprint]'
p67528
asS'MH'
p67529
(lp67530
S'Adolescent'
p67531
aS'Adult'
p67532
aS'Age Factors'
p67533
aS'Ambulatory Care/*methods'
p67534
aS'Antiretroviral Therapy, Highly Active/*methods'
p67535
aS'Attitude to Health'
p67536
aS'CD4 Lymphocyte Count'
p67537
aS'Child'
p67538
aS'Child, Preschool'
p67539
aS'Cohort Studies'
p67540
aS'Confidence Intervals'
p67541
aS'Developing Countries'
p67542
aS'Female'
p67543
aS'Follow-Up Studies'
p67544
aS'HIV Infections/*drug therapy/immunology'
p67545
aS'Humans'
p67546
aS'Infant'
p67547
aS'Male'
p67548
aS'Mozambique'
p67549
aS'Odds Ratio'
p67550
aS'Patient Compliance'
p67551
aS'*Point-of-Care Systems'
p67552
aS'Retrospective Studies'
p67553
aS'Risk Assessment'
p67554
aS'Sex Factors'
p67555
aS'Socioeconomic Factors'
p67556
aS'Treatment Outcome'
p67557
aS'Young Adult'
p67558
asS'EDAT'
p67559
S'2011/09/29 06:00'
p67560
sS'SO'
p67561
S'Lancet. 2011 Oct 29;378(9802):1572-9. doi: 10.1016/S0140-6736(11)61052-0. Epub 2011 Sep 25.'
p67562
sS'SB'
p67563
S'AIM IM'
p67564
sS'PMID'
p67565
S'21951656'
p67566
sS'PST'
p67567
S'ppublish'
p67568
stRp67569
ag2
(g3
g4
(dp67570
S'LID'
p67571
S'10.1080/09540121.2011.608789 [doi]'
p67572
sS'STAT'
p67573
S'MEDLINE'
p67574
sS'DEP'
p67575
S'20110921'
p67576
sS'DA'
p67577
S'20120222'
p67578
sS'AID'
p67579
(lp67580
S'10.1080/09540121.2011.608789 [doi]'
p67581
asS'CRDT'
p67582
(lp67583
S'2011/09/22 06:00'
p67584
asS'DP'
p67585
S'2012'
p67586
sS'OWN'
p67587
S'NLM'
p67588
sS'PT'
p67589
(lp67590
S'Journal Article'
p67591
aS"Research Support, Non-U.S. Gov't"
p67592
asS'LA'
p67593
(lp67594
S'eng'
p67595
asS'FAU'
p67596
(lp67597
S'Kaufman, Z A'
p67598
aS'Welsch, R L'
p67599
aS'Erickson, J D'
p67600
aS'Craig, S'
p67601
aS'Adams, L V'
p67602
aS'Ross, D A'
p67603
asS'JT'
p67604
S'AIDS care'
p67605
sS'PG'
p67606
S'377-85'
p67607
sS'TI'
p67608
S'Effectiveness of a sports-based HIV prevention intervention in the Dominican Republic: a quasi-experimental study.'
p67609
sS'PL'
p67610
S'England'
p67611
sS'TA'
p67612
S'AIDS Care'
p67613
sS'JID'
p67614
S'8915313'
p67615
sS'AB'
p67616
S'Previous observational and quasi-experimental studies in sub-Saharan Africa have suggested the effectiveness of youth-targeted HIV prevention interventions using sport as an educational tool. No studies have yet assessed the effect of similar programs in the Caribbean. A quasi-experimental trial was conducted to assess the effectiveness of a sports-based intervention in six migrant settlements in the Puerto Plata Province of the Dominican Republic. A total of 397 structured interviews were conducted with 140 adolescents prior to, immediately following, and four months following 10-hour interventions using the Grassroot Soccer curriculum. Interview responses were coded, aggregated into composite scores, and analyzed using logistic regression, adjusting for baseline differences as well as age, sex, community, and descent. At post-intervention, significant differences were observed between groups in HIV-related knowledge (adjOR = 13.02, 95% CI = 8.26, 20.52), reported attitudes (adjOR = 12.01, 95% CI = 7.61, 18.94), and reported communication (adjOR = 3.13, 95% CI = 1.91, 5.12). These differences remained significant at four-month follow-up, though declines in post-intervention knowledge were observed in the Intervention group while gains in knowledge and reported attitudes were observed in the Control group. Results suggest that this sports-based intervention could play a valuable role in HIV prevention efforts in the Caribbean, particularly those targeting early adolescents. Further evaluation of sports-based interventions should include indicators assessing behavioral and biological outcomes, longer-term follow-up, a larger sample, randomization of study participants, and strenuous efforts to minimize loss-to-follow-up.'
p67617
sS'AD'
p67618
S'Department of Anthropology, Dartmouth College, Hanover, NH, USA. Zachary.Kaufman@lshtm.ac.uk'
p67619
sS'IP'
p67620
S'3'
sS'IS'
p67621
S'1360-0451 (Electronic) 0954-0121 (Linking)'
p67622
sS'DCOM'
p67623
S'20120517'
p67624
sS'AU'
p67625
(lp67626
S'Kaufman ZA'
p67627
aS'Welsch RL'
p67628
aS'Erickson JD'
p67629
aS'Craig S'
p67630
aS'Adams LV'
p67631
aS'Ross DA'
p67632
asS'VI'
p67633
S'24'
p67634
sS'MHDA'
p67635
S'2012/05/18 06:00'
p67636
sS'PHST'
p67637
(lp67638
S'2011/09/21 [aheadofprint]'
p67639
asS'MH'
p67640
(lp67641
S'Acquired Immunodeficiency Syndrome/*prevention & control/transmission'
p67642
aS'Adolescent'
p67643
aS'Africa South of the Sahara'
p67644
aS'Caribbean Region'
p67645
aS'Child'
p67646
aS'Dominican Republic'
p67647
aS'Female'
p67648
aS'Follow-Up Studies'
p67649
aS'HIV Infections/*prevention & control/transmission'
p67650
aS'Health Education/*methods'
p67651
aS'Health Knowledge, Attitudes, Practice'
p67652
aS'Humans'
p67653
aS'Male'
p67654
aS'Risk-Taking'
p67655
aS'Sexual Behavior'
p67656
aS'*Sports'
p67657
aS'Young Adult'
p67658
asS'EDAT'
p67659
S'2011/09/22 06:00'
p67660
sS'SO'
p67661
S'AIDS Care. 2012;24(3):377-85. doi: 10.1080/09540121.2011.608789. Epub 2011 Sep 21.'
p67662
sS'SB'
p67663
S'IM X'
p67664
sS'PMID'
p67665
S'21933038'
p67666
sS'PST'
p67667
S'ppublish'
p67668
stRp67669
ag2
(g3
g4
(dp67670
S'LID'
p67671
S'10.1186/1471-2458-11-696 [doi]'
p67672
sS'STAT'
p67673
S'MEDLINE'
p67674
sS'DEP'
p67675
S'20110909'
p67676
sS'DA'
p67677
S'20110929'
p67678
sS'AID'
p67679
(lp67680
S'1471-2458-11-696 [pii]'
p67681
aS'10.1186/1471-2458-11-696 [doi]'
p67682
asS'CRDT'
p67683
(lp67684
S'2011/09/13 06:00'
p67685
asS'DP'
p67686
S'2011'
p67687
sS'OWN'
p67688
S'NLM'
p67689
sS'PT'
p67690
(lp67691
S'Journal Article'
p67692
asS'LA'
p67693
(lp67694
S'eng'
p67695
asS'DCOM'
p67696
S'20120111'
p67697
sS'JT'
p67698
S'BMC public health'
p67699
sS'LR'
p67700
S'20150204'
p67701
sS'FAU'
p67702
(lp67703
S'Muture, Bernard N'
p67704
aS'Keraka, Margaret N'
p67705
aS'Kimuu, Peter K'
p67706
aS'Kabiru, Ephantus W'
p67707
aS'Ombeka, Victor O'
p67708
aS'Oguya, Francis'
p67709
asS'TI'
p67710
S'Factors associated with default from treatment among tuberculosis patients in Nairobi province, Kenya: a case control study.'
p67711
sS'RN'
p67712
(lp67713
S'0 (Antitubercular Agents)'
p67714
asS'PL'
p67715
S'England'
p67716
sS'PG'
p67717
S'696'
p67718
sS'JID'
p67719
S'100968562'
p67720
sS'AB'
p67721
S'BACKGROUND: Successful treatment of tuberculosis (TB) involves taking anti-tuberculosis drugs for at least six months. Poor adherence to treatment means patients remain infectious for longer, are more likely to relapse or succumb to tuberculosis and could result in treatment failure as well as foster emergence of drug resistant tuberculosis. Kenya is among countries with high tuberculosis burden globally. The purpose of this study was to determine the duration tuberculosis patients stay in treatment before defaulting and factors associated with default in Nairobi. METHODS: A Case-Control study; Cases were those who defaulted from treatment and Controls those who completed treatment course between January 2006 and March 2008. All (945) defaulters and 1033 randomly selected controls from among 5659 patients who completed treatment course in 30 high volume sites were enrolled. Secondary data was collected using a facility questionnaire. From among the enrolled, 120 cases and 154 controls were randomly selected and interviewed to obtain primary data not routinely collected. Data was analyzed using SPSS and Epi Info statistical software. Univariate and multivariate logistic regression analysis to determine association and Kaplan-Meier method to determine probability of staying in treatment over time were applied. RESULTS: Of 945 defaulters, 22.7% (215) and 20.4% (193) abandoned treatment within first and second months (intensive phase) of treatment respectively. Among 120 defaulters interviewed, 16.7% (20) attributed their default to ignorance, 12.5% (15) to traveling away from treatment site, 11.7% (14) to feeling better and 10.8% (13) to side-effects. On multivariate analysis, inadequate knowledge on tuberculosis (OR 8.67; 95% CI 1.47-51.3), herbal medication use (OR 5.7; 95% CI 1.37-23.7), low income (OR 5.57, CI 1.07-30.0), alcohol abuse (OR 4.97; 95% CI 1.56-15.9), previous default (OR 2.33; 95% CI 1.16-4.68), co-infection with Human immune-deficient Virus (HIV) (OR 1.56; 95% CI 1.25-1.94) and male gender (OR 1.43; 95% CI 1.15-1.78) were independently associated with default. CONCLUSION: The rate of defaulting was highest during initial two months, the intensive phase of treatment. Multiple factors were attributed by defaulting patients as cause for abandoning treatment whereas several were independently associated with default. Enhanced patient pre-treatment counseling and education about TB is recommended.'
p67722
sS'AD'
p67723
S'National Public Health Laboratory Services, Ministry of Health, PO Box 20750-00202, Nairobi, Kenya. bnmuture@yahoo.com'
p67724
sS'VI'
p67725
S'11'
p67726
sS'IS'
p67727
S'1471-2458 (Electronic) 1471-2458 (Linking)'
p67728
sS'PMC'
p67729
S'PMC3224095'
p67730
sS'AU'
p67731
(lp67732
S'Muture BN'
p67733
aS'Keraka MN'
p67734
aS'Kimuu PK'
p67735
aS'Kabiru EW'
p67736
aS'Ombeka VO'
p67737
aS'Oguya F'
p67738
asS'MHDA'
p67739
S'2012/01/12 06:00'
p67740
sS'PHST'
p67741
(lp67742
S'2011/02/17 [received]'
p67743
aS'2011/09/09 [accepted]'
p67744
aS'2011/09/09 [aheadofprint]'
p67745
asS'OID'
p67746
(lp67747
S'NLM: PMC3224095'
p67748
asS'MH'
p67749
(lp67750
S'Adolescent'
p67751
aS'Adult'
p67752
aS'Aged'
p67753
aS'Aged, 80 and over'
p67754
aS'Antitubercular Agents/*therapeutic use'
p67755
aS'Case-Control Studies'
p67756
aS'Child'
p67757
aS'Child, Preschool'
p67758
aS'Female'
p67759
aS'Health Knowledge, Attitudes, Practice'
p67760
aS'Humans'
p67761
aS'Infant'
p67762
aS'Kenya'
p67763
aS'Male'
p67764
aS'Medication Adherence/*statistics & numerical data'
p67765
aS'Middle Aged'
p67766
aS'Patient Dropouts/statistics & numerical data'
p67767
aS'Qualitative Research'
p67768
aS'Retrospective Studies'
p67769
aS'Risk Factors'
p67770
aS'Time Factors'
p67771
aS'Tuberculosis/*drug therapy'
p67772
aS'Young Adult'
p67773
asS'EDAT'
p67774
S'2011/09/13 06:00'
p67775
sS'SO'
p67776
S'BMC Public Health. 2011 Sep 9;11:696. doi: 10.1186/1471-2458-11-696.'
p67777
sS'SB'
p67778
S'IM'
p67779
sS'PMID'
p67780
S'21906291'
p67781
sS'TA'
p67782
S'BMC Public Health'
p67783
sS'PST'
p67784
S'epublish'
p67785
stRp67786
ag2
(g3
g4
(dp67787
S'LID'
p67788
S'10.3851/IMP1819 [doi]'
p67789
sS'STAT'
p67790
S'MEDLINE'
p67791
sS'JT'
p67792
S'Antiviral therapy'
p67793
sS'CI'
p67794
(lp67795
S'(c) 2011 International Medical Press'
p67796
asS'DA'
p67797
S'20110908'
p67798
sS'AID'
p67799
(lp67800
S'10.3851/IMP1819 [doi]'
p67801
asS'CRDT'
p67802
(lp67803
S'2011/09/09 06:00'
p67804
asS'DP'
p67805
S'2011'
p67806
sS'AD'
p67807
S'Division of General Medicine, Massachusetts General Hospital, Boston, MA, USA. jlevison@partners.org'
p67808
sS'OWN'
p67809
S'NLM'
p67810
sS'PT'
p67811
(lp67812
S'Journal Article'
p67813
aS'Research Support, N.I.H., Extramural'
p67814
asS'LA'
p67815
(lp67816
S'eng'
p67817
asS'FAU'
p67818
(lp67819
S'Levison, Julie H'
p67820
aS'Orrell, Catherine'
p67821
aS'Losina, Elena'
p67822
aS'Lu, Zhigang'
p67823
aS'Freedberg, Kenneth A'
p67824
aS'Wood, Robin'
p67825
asS'LR'
p67826
S'20150204'
p67827
sS'PG'
p67828
S'853-61'
p67829
sS'TI'
p67830
S'Early outcomes and the virological effect of delayed treatment switching to second-line therapy in an antiretroviral roll-out programme in South Africa.'
p67831
sS'RN'
p67832
(lp67833
S'0 (Anti-HIV Agents)'
p67834
asS'PL'
p67835
S'England'
p67836
sS'TA'
p67837
S'Antivir Ther'
p67838
sS'JID'
p67839
S'9815705'
p67840
sS'AB'
p67841
S'BACKGROUND: More patients in resource-limited settings are starting second-line antiretroviral treatment (ART) following first-line ART failure. We aimed to describe predictors of lack of virological suppression in HIV-infected patients on second-line ART in a roll-out programme in South Africa. METHODS: A retrospective analysis was performed on an adult HIV treatment cohort who started second-line ART (lopinavir/ritonavir, didanosine and zidovudine) after virological failure of first-line ART (two consecutive HIV RNA>1,000 copies/ml). Predictors of week 24 lack of suppression (HIV RNA>400 copies/ml) on second-line ART were determined by bivariate analysis where missing equals failure. A multivariable model that adjusted for gender, age and time to ART switch was used. We tested these findings in sensitivity analyses defining lack of suppression at week 24 as HIV RNA>1,000 and >5,000 copies/ml. RESULTS: Of 6,339 patients on ART, 202 started second-line ART. At week 24, an estimated 41% (95% CI 34-47) did not achieve virological suppression. Female sex (adjusted OR 2.25, 95% CI 1.03-4.88) and time to ART switch (adjusted OR 1.07, 95% CI 1.01-1.14 for each additional month) increased the risk of lack of virological suppression. Age, CD4(+) T-cell count and HIV RNA at second-line ART initiation did not predict this outcome. In multivariate models, these findings were insensitive to the definition of lack of virological suppression. CONCLUSIONS: A substantial number of HIV-infected patients do not achieve virological suppression by week 24 of second-line ART. Women and patients with delayed start of second-line ART after first-line ART failure were at an increased risk of lack of virological suppression.'
p67842
sS'GR'
p67843
(lp67844
S'K24 A1062476/PHS HHS/United States'
p67845
aS'K24 AI062476/AI/NIAID NIH HHS/United States'
p67846
aS'K24 AI062476-04/AI/NIAID NIH HHS/United States'
p67847
aS'P30 AI060354/AI/NIAID NIH HHS/United States'
p67848
aS'P30 AI060354-02/AI/NIAID NIH HHS/United States'
p67849
aS'P30-AI060354/AI/NIAID NIH HHS/United States'
p67850
aS'R01 AI058736/AI/NIAID NIH HHS/United States'
p67851
aS'R01 AI058736-03S1/AI/NIAID NIH HHS/United States'
p67852
aS'R01 AI58072/AI/NIAID NIH HHS/United States'
p67853
aS'T32 AI007433/AI/NIAID NIH HHS/United States'
p67854
aS'T32 AI007433/AI/NIAID NIH HHS/United States'
p67855
aS'T32 AI007433-16/AI/NIAID NIH HHS/United States'
p67856
asS'IP'
p67857
S'6'
sS'IS'
p67858
S'2040-2058 (Electronic) 1359-6535 (Linking)'
p67859
sS'PMC'
p67860
S'PMC3225051'
p67861
sS'DCOM'
p67862
S'20120110'
p67863
sS'MID'
p67864
(lp67865
S'NIHMS336610'
p67866
asS'AU'
p67867
(lp67868
S'Levison JH'
p67869
aS'Orrell C'
p67870
aS'Losina E'
p67871
aS'Lu Z'
p67872
aS'Freedberg KA'
p67873
aS'Wood R'
p67874
asS'VI'
p67875
S'16'
p67876
sS'MHDA'
p67877
S'2012/01/11 06:00'
p67878
sS'OID'
p67879
(lp67880
S'NLM: NIHMS336610'
p67881
aS'NLM: PMC3225051'
p67882
asS'MH'
p67883
(lp67884
S'Adult'
p67885
aS'Anti-HIV Agents/*therapeutic use'
p67886
aS'CD4 Lymphocyte Count'
p67887
aS'Female'
p67888
aS'HIV Infections/*drug therapy/*virology'
p67889
aS'Humans'
p67890
aS'Male'
p67891
aS'Retrospective Studies'
p67892
aS'South Africa'
p67893
aS'Treatment Outcome'
p67894
aS'Viral Load'
p67895
asS'EDAT'
p67896
S'2011/09/09 06:00'
p67897
sS'SO'
p67898
S'Antivir Ther. 2011;16(6):853-61. doi: 10.3851/IMP1819.'
p67899
sS'SB'
p67900
S'IM'
p67901
sS'PMID'
p67902
S'21900717'
p67903
sS'PST'
p67904
S'ppublish'
p67905
stRp67906
ag2
(g3
g4
(dp67907
S'LID'
p67908
S'10.1111/j.1365-3156.2011.02874.x [doi]'
p67909
sS'STAT'
p67910
S'MEDLINE'
p67911
sS'DEP'
p67912
S'20110901'
p67913
sS'CI'
p67914
(lp67915
S'(c) 2011 Blackwell Publishing Ltd.'
p67916
asS'DA'
p67917
S'20120904'
p67918
sS'AID'
p67919
(lp67920
S'10.1111/j.1365-3156.2011.02874.x [doi]'
p67921
asS'CRDT'
p67922
(lp67923
S'2011/09/03 06:00'
p67924
asS'DP'
p67925
S'2011 Dec'
p67926
sS'OWN'
p67927
S'NLM'
p67928
sS'PT'
p67929
(lp67930
S'Journal Article'
p67931
asS'LA'
p67932
(lp67933
S'eng'
p67934
asS'FAU'
p67935
(lp67936
S'Kanapathipillai, Rupa'
p67937
aS'McGuire, Megan'
p67938
aS'Mogha, Robert'
p67939
aS'Szumilin, Elisabeth'
p67940
aS'Heinzelmann, Annette'
p67941
aS'Pujades-Rodriguez, Mar'
p67942
asS'JT'
p67943
S'Tropical medicine & international health : TM & IH'
p67944
sS'PG'
p67945
S'1495-500'
p67946
sS'TI'
p67947
S'Benefit of viral load testing for confirmation of immunological failure in HIV patients treated in rural Malawi.'
p67948
sS'RN'
p67949
(lp67950
S'0 (Anti-Retroviral Agents)'
p67951
asS'PL'
p67952
S'England'
p67953
sS'TA'
p67954
S'Trop Med Int Health'
p67955
sS'JID'
p67956
S'9610576'
p67957
sS'AB'
p67958
S'OBJECTIVE: Viral load testing is used in the HIV programme of Chiradzulu, Malawi, to confirm the diagnosis of immunological failure to prevent unnecessary switching to second-line therapy. Our objective was to quantify the benefit of this strategy for management of treatment failure in a large decentralized HIV programme in Africa. METHODS: Retrospective analysis of monitoring data from adults treated with first-line antiretroviral regimens for >1 year and meeting the WHO immunological failure criteria in an HIV programme in rural Malawi. The positive predictive value of using immunological failure criteria to diagnose virological failure (viral load >5000 copies/ml) was estimated. RESULTS: Of the 227 patients with immunological failure (185 confirmed with a repeat CD4 measurement), 155 (68.2%) had confirmatory viral load testing. Forty-four (28.4%) had viral load >5000 copies/ml and 57 (36.8%) >1000 copies/ml. Positive predictive value was 28.4% (95% CI 21.4-36.2%). Repeat CD4 count testing showed that 41% of patients initially diagnosed with immunological failure did no longer meet failure criteria. CONCLUSIONS: Our results support the need for confirming all cases of immunological failure with viral load testing before switching to second-line ART to optimize the use of resources in developing countries.'
p67959
sS'AD'
p67960
S'Medecins Sans Frontieres, Chiradzulu, Malawi.'
p67961
sS'IP'
p67962
S'12'
p67963
sS'IS'
p67964
S'1365-3156 (Electronic) 1360-2276 (Linking)'
p67965
sS'DCOM'
p67966
S'20121113'
p67967
sS'AU'
p67968
(lp67969
S'Kanapathipillai R'
p67970
aS'McGuire M'
p67971
aS'Mogha R'
p67972
aS'Szumilin E'
p67973
aS'Heinzelmann A'
p67974
aS'Pujades-Rodriguez M'
p67975
asS'VI'
p67976
S'16'
p67977
sS'MHDA'
p67978
S'2012/11/14 06:00'
p67979
sS'PHST'
p67980
(lp67981
S'2011/09/01 [aheadofprint]'
p67982
asS'MH'
p67983
(lp67984
S'Adult'
p67985
aS'Anti-Retroviral Agents/therapeutic use'
p67986
aS'CD4 Lymphocyte Count'
p67987
aS'Female'
p67988
aS'HIV Infections/drug therapy/immunology/*virology'
p67989
aS'Humans'
p67990
aS'Malawi'
p67991
aS'Male'
p67992
aS'Middle Aged'
p67993
aS'Retrospective Studies'
p67994
aS'Rural Health'
p67995
aS'Treatment Failure'
p67996
aS'Viral Load/*methods'
p67997
asS'EDAT'
p67998
S'2011/09/03 06:00'
p67999
sS'SO'
p68000
S'Trop Med Int Health. 2011 Dec;16(12):1495-500. doi: 10.1111/j.1365-3156.2011.02874.x. Epub 2011 Sep 1.'
p68001
sS'SB'
p68002
S'IM'
p68003
sS'PMID'
p68004
S'21883726'
p68005
sS'PST'
p68006
S'ppublish'
p68007
stRp68008
ag2
(g3
g4
(dp68009
S'LID'
p68010
S'10.1097/QAD.0b013e32834c4ac1 [doi]'
p68011
sS'STAT'
p68012
S'MEDLINE'
p68013
sS'JT'
p68014
S'AIDS (London, England)'
p68015
sS'MID'
p68016
(lp68017
S'NIHMS409259'
p68018
asS'DA'
p68019
S'20111024'
p68020
sS'AID'
p68021
(lp68022
S'10.1097/QAD.0b013e32834c4ac1 [doi]'
p68023
asS'CRDT'
p68024
(lp68025
S'2011/09/02 06:00'
p68026
asS'DP'
p68027
S'2011 Nov 13'
p68028
sS'AD'
p68029
S'Department of Medicine, University of California, San Francisco, USA. phunt@php.ucsf.edu'
p68030
sS'OWN'
p68031
S'NLM'
p68032
sS'PT'
p68033
(lp68034
S'Journal Article'
p68035
aS'Research Support, N.I.H., Extramural'
p68036
aS"Research Support, Non-U.S. Gov't"
p68037
asS'LA'
p68038
(lp68039
S'eng'
p68040
asS'FAU'
p68041
(lp68042
S'Hunt, Peter W'
p68043
aS'Cao, Huyen L'
p68044
aS'Muzoora, Conrad'
p68045
aS'Ssewanyana, Isaac'
p68046
aS'Bennett, John'
p68047
aS'Emenyonu, Nneka'
p68048
aS'Kembabazi, Annet'
p68049
aS'Neilands, Torsten B'
p68050
aS'Bangsberg, David R'
p68051
aS'Deeks, Steven G'
p68052
aS'Martin, Jeffrey N'
p68053
asS'LR'
p68054
S'20160701'
p68055
sS'PG'
p68056
S'2123-31'
p68057
sS'TI'
p68058
S'Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy.'
p68059
sS'RN'
p68060
(lp68061
S'0 (Anti-HIV Agents)'
p68062
aS'EC 3.2.2.5 (Antigens, CD38)'
p68063
asS'PL'
p68064
S'England'
p68065
sS'TA'
p68066
S'AIDS'
p68067
sS'JID'
p68068
S'8710219'
p68069
sS'AB'
p68070
S'OBJECTIVES: To assess whether T-cell activation independently predicts the extent of CD4(+) T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy (ART). DESIGN: Prospective cohort study. METHODS: HIV-infected adults starting ART and achieving a plasma HIV RNA level (VL) less than 400 copies/ml by month 6 were sampled from the Uganda AIDS Rural Treatment Outcomes (UARTO) cohort in Mbarara, Uganda. CD4 count, VL, and the percentage-activated (CD38(+)HLA-DR(+)) T cells were measured every 3 months. RESULTS: Of 451 HIV-infected Ugandans starting ART, most were women (70%) with median pre-ART values: age, 34 years; CD4 count, 135 cells/mul; and VL, 5.1 log(10) copies/ml. Of these, 93% achieved a VL less than 400 copies/ml by month 6 and were followed for a median of 24 months, with 8% lost to follow-up at 3 years. Higher pre-ART CD8(+) T-cell activation was associated with diminished CD4 recovery after year 1, after adjustment for pre-ART CD4 count, VL, and sex (P = 0.017). Thirty-four participants died, 15 after month 6. Each 10% point increase in activated CD8(+) T cells at month 6 of suppressive ART was associated with a 1.6-fold increased hazard of subsequent death after adjusting for pretherapy CD4 count (P = 0.048). CONCLUSIONS: Higher pre-ART CD8(+) T-cell activation independently predicts slower CD4(+) T-cell recovery and higher persistent CD8(+) T-cell activation during ART-mediated viral suppression independently predicts increased mortality among HIV-infected Ugandans. Novel therapeutic strategies aimed at preventing or reversing immune activation during ART are needed in this setting.'
p68071
sS'GR'
p68072
(lp68073
S'K23 AI065244/AI/NIAID NIH HHS/United States'
p68074
aS'K24 AI069994/AI/NIAID NIH HHS/United States'
p68075
aS'K24 MH087227/MH/NIMH NIH HHS/United States'
p68076
aS'K24 MH87227/MH/NIMH NIH HHS/United States'
p68077
aS'P30 AI027763/AI/NIAID NIH HHS/United States'
p68078
aS'P30 AI27763/AI/NIAID NIH HHS/United States'
p68079
aS'P30 MH59037/MH/NIMH NIH HHS/United States'
p68080
aS'P30 MH62246/MH/NIMH NIH HHS/United States'
p68081
aS'R01 MH054907/MH/NIMH NIH HHS/United States'
p68082
aS'R01 MH54907/MH/NIMH NIH HHS/United States'
p68083
aS'R21 AI078774/AI/NIAID NIH HHS/United States'
p68084
aS'R21 AI078774/AI/NIAID NIH HHS/United States'
p68085
asS'IP'
p68086
S'17'
p68087
sS'IS'
p68088
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p68089
sS'PMC'
p68090
S'PMC3480326'
p68091
sS'DCOM'
p68092
S'20120110'
p68093
sS'AU'
p68094
(lp68095
S'Hunt PW'
p68096
aS'Cao HL'
p68097
aS'Muzoora C'
p68098
aS'Ssewanyana I'
p68099
aS'Bennett J'
p68100
aS'Emenyonu N'
p68101
aS'Kembabazi A'
p68102
aS'Neilands TB'
p68103
aS'Bangsberg DR'
p68104
aS'Deeks SG'
p68105
aS'Martin JN'
p68106
asS'VI'
p68107
S'25'
p68108
sS'MHDA'
p68109
S'2012/01/11 06:00'
p68110
sS'OID'
p68111
(lp68112
S'NLM: NIHMS409259'
p68113
aS'NLM: PMC3480326'
p68114
asS'MH'
p68115
(lp68116
S'Adult'
p68117
aS'Anti-HIV Agents/*therapeutic use'
p68118
aS'Antigens, CD38/*immunology'
p68119
aS'CD4-CD8 Ratio'
p68120
aS'*CD4-Positive T-Lymphocytes/immunology'
p68121
aS'*CD8-Positive T-Lymphocytes/immunology'
p68122
aS'Cohort Studies'
p68123
aS'Cross-Sectional Studies'
p68124
aS'Female'
p68125
aS'Gene Expression/*immunology'
p68126
aS'HIV Infections/drug therapy/immunology/*mortality'
p68127
aS'*HIV-1/drug effects/immunology/isolation & purification'
p68128
aS'Humans'
p68129
aS'Lymphocyte Activation'
p68130
aS'Male'
p68131
aS'Prospective Studies'
p68132
aS'Treatment Outcome'
p68133
aS'Uganda/epidemiology'
p68134
aS'Viral Load'
p68135
asS'EDAT'
p68136
S'2011/09/02 06:00'
p68137
sS'SO'
p68138
S'AIDS. 2011 Nov 13;25(17):2123-31. doi: 10.1097/QAD.0b013e32834c4ac1.'
p68139
sS'SB'
p68140
S'IM X'
p68141
sS'PMID'
p68142
S'21881481'
p68143
sS'PST'
p68144
S'ppublish'
p68145
stRp68146
ag2
(g3
g4
(dp68147
S'LID'
p68148
S'10.1097/QAI.0b013e318220f016 [doi]'
p68149
sS'STAT'
p68150
S'MEDLINE'
p68151
sS'AB'
p68152
S'Over the last decade, increased funding to support HIV treatment programs has enabled millions of new patients in developing countries to access the medications they need. Today, although demand for antiretrovirals continues to grow, the financial crisis has severely constrained funding leaving countries with difficult choices on program prioritization. Product optimization is one solution countries can pursue to continue to improve patient care while also uncovering savings that can be used for further scale up or other health system needs. Program managers can make procurement decisions that actually reduce program costs by considering additional factors beyond World Health Organization guidelines when making procurement decisions. These include in-country product availability, convenience, price, and logistics such as supply chain implications and laboratory testing requirements. Three immediate product selection opportunities in the HIV space include using boosted atazanavir in place of lopinovir for second-line therapy, lamivudine instead of emtricitabine in both first-line and second-line therapy, and tenofovir + lamivudine over abacavir + didanosine in second-line therapy. If these 3 opportunities were broadly implemented in sub-Saharan Africa and India today, approximately $300 million of savings would be realized over the next 5 years, enabling hundreds of thousands of additional patients to be treated. Although the discussion herein is specific to antriretrovirals, the principles of product selection are generalizable to diseases with multiple treatment options and fungible commodity procurement. Identifying and implementing approaches to overcome health system inefficiencies will help sustain and may expand quality care in resource-limited settings.'
p68153
sS'AD'
p68154
S'Access Programs, Clinton Health Access Initiative, 383 Dorchester Avenue, Boston, MA 02127, USA.'
p68155
sS'JT'
p68156
S'Journal of acquired immune deficiency syndromes (1999)'
p68157
sS'VI'
p68158
S'57 Suppl 2'
p68159
sS'IS'
p68160
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p68161
sS'JID'
p68162
S'100892005'
p68163
sS'DA'
p68164
S'20110822'
p68165
sS'AU'
p68166
(lp68167
S'Amole CD'
p68168
aS'Brisebois C'
p68169
aS'Essajee S'
p68170
aS'Koehler E'
p68171
aS'Levin AD'
p68172
aS'Moore MC'
p68173
aS'Brown Ripin DH'
p68174
aS'Sickler JJ'
p68175
aS'Singh IR'
p68176
asS'SB'
p68177
S'IM X'
p68178
sS'AID'
p68179
(lp68180
S'10.1097/QAI.0b013e318220f016 [doi]'
p68181
aS'00126334-201108012-00012 [pii]'
p68182
asS'CRDT'
p68183
(lp68184
S'2011/08/23 06:00'
p68185
asS'PMID'
p68186
S'21857290'
p68187
sS'DP'
p68188
S'2011 Aug'
p68189
sS'MHDA'
p68190
S'2011/10/18 06:00'
p68191
sS'OWN'
p68192
S'NLM'
p68193
sS'PT'
p68194
(lp68195
S'Journal Article'
p68196
aS"Research Support, Non-U.S. Gov't"
p68197
aS"Research Support, U.S. Gov't, Non-P.H.S."
p68198
asS'LA'
p68199
(lp68200
S'eng'
p68201
asS'MH'
p68202
(lp68203
S'Anti-Retroviral Agents/*economics'
p68204
aS'Atazanavir Sulfate'
p68205
aS'Developing Countries/*economics'
p68206
aS'Didanosine/economics/therapeutic use'
p68207
aS'Dideoxynucleosides/economics/therapeutic use'
p68208
aS'Drug Therapy, Combination'
p68209
aS'HIV Infections/*drug therapy/economics'
p68210
aS'Health Planning/*economics'
p68211
aS'Health Services/*economics'
p68212
aS'Humans'
p68213
aS'Lamivudine/economics/therapeutic use'
p68214
aS'Lopinavir'
p68215
aS'Oligopeptides/economics/therapeutic use'
p68216
aS'Pyridines/economics/therapeutic use'
p68217
aS'Pyrimidinones/economics/therapeutic use'
p68218
aS'Treatment Outcome'
p68219
asS'DCOM'
p68220
S'20111017'
p68221
sS'EDAT'
p68222
S'2011/09/01 06:00'
p68223
sS'PST'
p68224
S'ppublish'
p68225
sS'LR'
p68226
S'20151119'
p68227
sS'FAU'
p68228
(lp68229
S'Amole, Carolyn D'
p68230
aS'Brisebois, Catherine'
p68231
aS'Essajee, Shaffiq'
p68232
aS'Koehler, Erin'
p68233
aS'Levin, Andrew D'
p68234
aS'Moore, Meredith C'
p68235
aS'Brown Ripin, David H'
p68236
aS'Sickler, Joanna J'
p68237
aS'Singh, Inder R'
p68238
asS'TI'
p68239
S'Optimizing antiretroviral product selection: a sample approach to improving patient outcomes, saving money, and scaling-up health services in developing countries.'
p68240
sS'SO'
p68241
S'J Acquir Immune Defic Syndr. 2011 Aug;57 Suppl 2:S100-3. doi: 10.1097/QAI.0b013e318220f016.'
p68242
sS'RN'
p68243
(lp68244
S'0 (Anti-Retroviral Agents)'
p68245
aS'0 (Dideoxynucleosides)'
p68246
aS'0 (Oligopeptides)'
p68247
aS'0 (Pyridines)'
p68248
aS'0 (Pyrimidinones)'
p68249
aS'2494G1JF75 (Lopinavir)'
p68250
aS'2T8Q726O95 (Lamivudine)'
p68251
aS'4MT4VIE29P (Atazanavir Sulfate)'
p68252
aS'K3GDH6OH08 (Didanosine)'
p68253
aS'WR2TIP26VS (abacavir)'
p68254
asS'TA'
p68255
S'J Acquir Immune Defic Syndr'
p68256
sS'PL'
p68257
S'United States'
p68258
sS'PG'
p68259
S'S100-3'
p68260
stRp68261
ag2
(g3
g4
(dp68262
S'LID'
p68263
S'10.1097/QAD.0b013e32834bbbe9 [doi]'
p68264
sS'STAT'
p68265
S'MEDLINE'
p68266
sS'AB'
p68267
S'OBJECTIVES: To evaluate the frequency and progression over time of the WHO-defined transmitted HIV-1 drug resistance mutations (DRMs) among antiretroviral treatment (ART)-naive HIV-1-infected patients in Cameroon. DESIGN: We analyzed HIV-1 DRM data generated from 369 ART-naive individuals consecutively recruited between 1996 and 2007 in urban and rural areas in Cameroon. METHODS: HIV-1 drug resistance genotyping was performed in the pol gene using plasma samples and surveillance DRMs were identified using the 2009 WHO-DRM list. RESULTS: We observed in Yaounde, the capital city, an increasing prevalence of DRMs over time: 0.0% (none of 61 participants) in 1996-1999; 1.9% (one of 53 participants) in 2001; 4.1% (two of 49 participants) in 2002; and 12.3% (10 of 81 participants) in 2007. In the rural areas with more recently implemented ART programs, we found DRMs in six of 125 (4.8%) ART-naive individuals recruited in 2006-2007. DRMs identified in both areas included resistance mutations to protease inhibitors, nucleoside reverse transcriptase inhibitors (NRTIs) and non-NRTIs (NNRTIs) that might impair the efficacy of available first-line and second-line treatments. CONCLUSION: This report showed an increase in transmitted DRMs in areas where antiretroviral drugs were introduced earlier, although other factors such as natural viral polymorphisms and acquired DRMs through exposure to antiretroviral cannot be totally excluded. Further surveillances are needed to confirm this evolution and inform public health policies on adequate actions to help limit the selection and transmission of drug-resistant HIV, while scaling up access to ART in developing countries.'
p68268
sS'JID'
p68269
S'8710219'
p68270
sS'AD'
p68271
S'Virology Laboratory CREMER/IMPM/IRD, Yaounde, Cameroon. avelin.aghokeng@ird.fr'
p68272
sS'JT'
p68273
S'AIDS (London, England)'
p68274
sS'IP'
p68275
S'17'
p68276
sS'IS'
p68277
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p68278
sS'DCOM'
p68279
S'20120110'
p68280
sS'DA'
p68281
S'20111024'
p68282
sS'AU'
p68283
(lp68284
S'Aghokeng AF'
p68285
aS'Kouanfack C'
p68286
aS'Laurent C'
p68287
aS'Ebong E'
p68288
aS'Atem-Tambe A'
p68289
aS'Butel C'
p68290
aS'Montavon C'
p68291
aS'Mpoudi-Ngole E'
p68292
aS'Delaporte E'
p68293
aS'Peeters M'
p68294
asS'AID'
p68295
(lp68296
S'10.1097/QAD.0b013e32834bbbe9 [doi]'
p68297
asS'CRDT'
p68298
(lp68299
S'2011/08/24 06:00'
p68300
asS'VI'
p68301
S'25'
p68302
sS'PMID'
p68303
S'21860346'
p68304
sS'DP'
p68305
S'2011 Nov 13'
p68306
sS'MHDA'
p68307
S'2012/01/11 06:00'
p68308
sS'OWN'
p68309
S'NLM'
p68310
sS'PT'
p68311
(lp68312
S'Journal Article'
p68313
aS"Research Support, Non-U.S. Gov't"
p68314
asS'LA'
p68315
(lp68316
S'eng'
p68317
asS'MH'
p68318
(lp68319
S'Adult'
p68320
aS'Anti-HIV Agents/*pharmacology/therapeutic use'
p68321
aS'Cameroon'
p68322
aS'Drug Resistance, Viral/*genetics'
p68323
aS'Female'
p68324
aS'*Genes, pol/drug effects/genetics'
p68325
aS'Genotype'
p68326
aS'HIV Infections/*drug therapy/genetics'
p68327
aS'HIV-1/*drug effects/*genetics'
p68328
aS'Humans'
p68329
aS'Male'
p68330
aS'Middle Aged'
p68331
aS'*Mutation'
p68332
aS'Treatment Outcome'
p68333
asS'FAU'
p68334
(lp68335
S'Aghokeng, Avelin F'
p68336
aS'Kouanfack, Charles'
p68337
aS'Laurent, Christian'
p68338
aS'Ebong, Eugenie'
p68339
aS'Atem-Tambe, Arrah'
p68340
aS'Butel, Christelle'
p68341
aS'Montavon, Celine'
p68342
aS'Mpoudi-Ngole, Eitel'
p68343
aS'Delaporte, Eric'
p68344
aS'Peeters, Martine'
p68345
asS'EDAT'
p68346
S'2011/08/24 06:00'
p68347
sS'PST'
p68348
S'ppublish'
p68349
sS'SO'
p68350
S'AIDS. 2011 Nov 13;25(17):2183-8. doi: 10.1097/QAD.0b013e32834bbbe9.'
p68351
sS'PG'
p68352
S'2183-8'
p68353
sS'TI'
p68354
S'Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients.'
p68355
sS'SB'
p68356
S'IM X'
p68357
sS'RN'
p68358
(lp68359
S'0 (Anti-HIV Agents)'
p68360
asS'PL'
p68361
S'England'
p68362
sS'TA'
p68363
S'AIDS'
p68364
stRp68365
ag2
(g3
g4
(dp68366
S'LID'
p68367
S'10.1097/QAI.0b013e318230d507 [doi]'
p68368
sS'STAT'
p68369
S'MEDLINE'
p68370
sS'AB'
p68371
S'A retrospective record review was conducted for patients down referred to primary health care facilities between 2007 and 2009 to assess the rate and reported reasons for loss to follow-up among stable antiretroviral patients in a down-referral model of care in Johannesburg, South Africa. Missing patients were traced telephonically. Of 3361 patients down referred, 4.11% were lost to follow-up. Most patients who were lost to follow-up were lost at the transfer stage between initiation and maintenance sites. Decentralization and nurse management of ART should be prioritized to increase access to and retention in HIV/AIDS care.'
p68372
sS'JID'
p68373
S'100892005'
p68374
sS'AD'
p68375
S'Wits Reproductive Health and HIV Institute, Long Beach, CA 90802, USA. caraoc@gmail.com'
p68376
sS'JT'
p68377
S'Journal of acquired immune deficiency syndromes (1999)'
p68378
sS'IP'
p68379
S'4'
sS'IS'
p68380
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p68381
sS'DCOM'
p68382
S'20111222'
p68383
sS'DA'
p68384
S'20111028'
p68385
sS'AU'
p68386
(lp68387
S"O'Connor C"
p68388
aS'Osih R'
p68389
aS'Jaffer A'
p68390
asS'AID'
p68391
(lp68392
S'10.1097/QAI.0b013e318230d507 [doi]'
p68393
asS'CRDT'
p68394
(lp68395
S'2011/08/23 06:00'
p68396
asS'VI'
p68397
S'58'
p68398
sS'PMID'
p68399
S'21857353'
p68400
sS'DP'
p68401
S'2011 Dec 1'
p68402
sS'MHDA'
p68403
S'2011/12/23 06:00'
p68404
sS'OWN'
p68405
S'NLM'
p68406
sS'PT'
p68407
(lp68408
S'Journal Article'
p68409
asS'LA'
p68410
(lp68411
S'eng'
p68412
asS'MH'
p68413
(lp68414
S'Adult'
p68415
aS'Aged'
p68416
aS'Anti-HIV Agents/*therapeutic use'
p68417
aS'Delivery of Health Care/*organization & administration/statistics & numerical data'
p68418
aS'Female'
p68419
aS'Follow-Up Studies'
p68420
aS'HIV Infections/drug therapy/epidemiology'
p68421
aS'Humans'
p68422
aS'Male'
p68423
aS'Middle Aged'
p68424
aS'Patient Compliance/statistics & numerical data'
p68425
aS'*Politics'
p68426
aS'Retrospective Studies'
p68427
aS'Young Adult'
p68428
asS'FAU'
p68429
(lp68430
S"O'Connor, Cara"
p68431
aS'Osih, Regina'
p68432
aS'Jaffer, Ambereen'
p68433
asS'EDAT'
p68434
S'2011/08/23 06:00'
p68435
sS'PST'
p68436
S'ppublish'
p68437
sS'SO'
p68438
S'J Acquir Immune Defic Syndr. 2011 Dec 1;58(4):429-32. doi: 10.1097/QAI.0b013e318230d507.'
p68439
sS'PG'
p68440
S'429-32'
p68441
sS'TI'
p68442
S'Loss to follow-up of stable antiretroviral therapy patients in a decentralized down-referral model of care in Johannesburg, South Africa.'
p68443
sS'SB'
p68444
S'IM X'
p68445
sS'RN'
p68446
(lp68447
S'0 (Anti-HIV Agents)'
p68448
asS'PL'
p68449
S'United States'
p68450
sS'TA'
p68451
S'J Acquir Immune Defic Syndr'
p68452
stRp68453
ag2
(g3
g4
(dp68454
S'LID'
p68455
S'10.1186/1471-2458-11-650 [doi]'
p68456
sS'STAT'
p68457
S'MEDLINE'
p68458
sS'DEP'
p68459
S'20110816'
p68460
sS'DA'
p68461
S'20110914'
p68462
sS'AID'
p68463
(lp68464
S'1471-2458-11-650 [pii]'
p68465
aS'10.1186/1471-2458-11-650 [doi]'
p68466
asS'CRDT'
p68467
(lp68468
S'2011/08/18 06:00'
p68469
asS'DP'
p68470
S'2011'
p68471
sS'OWN'
p68472
S'NLM'
p68473
sS'PT'
p68474
(lp68475
S'Journal Article'
p68476
asS'LA'
p68477
(lp68478
S'eng'
p68479
asS'DCOM'
p68480
S'20120111'
p68481
sS'JT'
p68482
S'BMC public health'
p68483
sS'LR'
p68484
S'20150204'
p68485
sS'FAU'
p68486
(lp68487
S'Groh, Kate'
p68488
aS'Audet, Carolyn M'
p68489
aS'Baptista, Alberto'
p68490
aS'Sidat, Mohsin'
p68491
aS'Vergara, Alfredo'
p68492
aS'Vermund, Sten H'
p68493
aS'Moon, Troy D'
p68494
asS'TI'
p68495
S'Barriers to antiretroviral therapy adherence in rural Mozambique.'
p68496
sS'RN'
p68497
(lp68498
S'0 (Anti-Retroviral Agents)'
p68499
asS'PL'
p68500
S'England'
p68501
sS'PG'
p68502
S'650'
p68503
sS'JID'
p68504
S'100968562'
p68505
sS'AB'
p68506
S'BACKGROUND: HIV is treated as a chronic disease, but high lost-to-follow-up rates and poor adherence to medication result in higher mortality, morbidity, and viral mutation. Within 18 clinical sites in rural Zambezia Province, Mozambique, patient adherence to antiretroviral therapy has been sub-optimal. METHODS: To better understand barriers to adherence, we conducted 18 community and clinic focus groups in six rural districts. We interviewed 76 women and 88 men, of whom 124 were community participants (CP; 60 women, 64 men) and 40 were health care workers (HCW; 16 women, 24 men) who provide care for those living with HIV. RESULTS: While there was some consensus, both CP and HCW provided complementary insights. CP focus groups noted a lack of confidentiality and poor treatment by hospital staff (42% CP vs. 0% HCW), doubt as to the benefits of antiretroviral therapy (75% CP vs. 0% HCW), and sharing medications with family members (66% CP vs. 0%HCW). Men expressed a greater concern about poor treatment by HCW than women (83% men vs. 0% women). Health care workers blamed patient preference for traditional medicine (42% CP vs. 100% HCW) and the side effects of medication for poor adherence (8% CP vs. 83% CHW). CONCLUSIONS: Perspectives of CP and HCW likely reflect differing sociocultural and educational backgrounds. Health care workers must understand community perspectives on causes of suboptimal adherence as a first step toward effective intervention.'
p68507
sS'AD'
p68508
S'Department of Medicine, D-3100, Medical Center North, Nashville, TN 37232-2358, USA.'
p68509
sS'VI'
p68510
S'11'
p68511
sS'IS'
p68512
S'1471-2458 (Electronic) 1471-2458 (Linking)'
p68513
sS'PMC'
p68514
S'PMC3171727'
p68515
sS'AU'
p68516
(lp68517
S'Groh K'
p68518
aS'Audet CM'
p68519
aS'Baptista A'
p68520
aS'Sidat M'
p68521
aS'Vergara A'
p68522
aS'Vermund SH'
p68523
aS'Moon TD'
p68524
asS'MHDA'
p68525
S'2012/01/12 06:00'
p68526
sS'PHST'
p68527
(lp68528
S'2011/04/08 [received]'
p68529
aS'2011/08/16 [accepted]'
p68530
aS'2011/08/16 [aheadofprint]'
p68531
asS'OID'
p68532
(lp68533
S'NLM: PMC3171727'
p68534
asS'MH'
p68535
(lp68536
S'Adult'
p68537
aS'Anti-Retroviral Agents/adverse effects/economics/*therapeutic use'
p68538
aS'Attitude of Health Personnel'
p68539
aS'Attitude to Health'
p68540
aS'Community Health Services'
p68541
aS'Community Health Workers/psychology'
p68542
aS'Community-Based Participatory Research'
p68543
aS'Confidentiality'
p68544
aS'Female'
p68545
aS'Focus Groups'
p68546
aS'HIV Infections/*drug therapy'
p68547
aS'*Health Services Accessibility'
p68548
aS'Humans'
p68549
aS'Male'
p68550
aS'Medication Adherence/*psychology/statistics & numerical data'
p68551
aS'Mozambique'
p68552
aS'*Professional-Patient Relations'
p68553
aS'Qualitative Research'
p68554
aS'*Rural Health Services'
p68555
aS'Socioeconomic Factors'
p68556
asS'EDAT'
p68557
S'2011/08/19 06:00'
p68558
sS'SO'
p68559
S'BMC Public Health. 2011 Aug 16;11:650. doi: 10.1186/1471-2458-11-650.'
p68560
sS'SB'
p68561
S'IM'
p68562
sS'PMID'
p68563
S'21846344'
p68564
sS'TA'
p68565
S'BMC Public Health'
p68566
sS'PST'
p68567
S'epublish'
p68568
stRp68569
ag2
(g3
g4
(dp68570
S'LID'
p68571
S'10.1002/jmv.22189 [doi]'
p68572
sS'STAT'
p68573
S'MEDLINE'
p68574
sS'JT'
p68575
S'Journal of medical virology'
p68576
sS'CI'
p68577
(lp68578
S'Copyright (c) 2011 Wiley-Liss, Inc.'
p68579
asS'DA'
p68580
S'20110812'
p68581
sS'AID'
p68582
(lp68583
S'10.1002/jmv.22189 [doi]'
p68584
asS'CRDT'
p68585
(lp68586
S'2011/08/13 06:00'
p68587
asS'DP'
p68588
S'2011 Oct'
p68589
sS'OWN'
p68590
S'NLM'
p68591
sS'PT'
p68592
(lp68593
S'Journal Article'
p68594
aS"Research Support, Non-U.S. Gov't"
p68595
asS'LA'
p68596
(lp68597
S'eng'
p68598
asS'FAU'
p68599
(lp68600
S'van Zyl, Gert U'
p68601
aS'van der Merwe, Lize'
p68602
aS'Claassen, Mathilda'
p68603
aS'Zeier, Michele'
p68604
aS'Preiser, Wolfgang'
p68605
asS'LR'
p68606
S'20140206'
p68607
sS'PG'
p68608
S'1764-9'
p68609
sS'TI'
p68610
S'Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.'
p68611
sS'RN'
p68612
(lp68613
S'0 (Anti-HIV Agents)'
p68614
aS'0 (Benzoxazines)'
p68615
aS'0 (HIV Protease Inhibitors)'
p68616
aS'0 (Pyridazines)'
p68617
aS'0 (RNA, Viral)'
p68618
aS'0 (Reverse Transcriptase Inhibitors)'
p68619
aS'0C50HW4FO1 (etravirine)'
p68620
aS'4B9XT59T7S (Zidovudine)'
p68621
aS'99DK7FVK1H (Nevirapine)'
p68622
aS'JE6H2O27P8 (efavirenz)'
p68623
asS'PL'
p68624
S'United States'
p68625
sS'TA'
p68626
S'J Med Virol'
p68627
sS'JID'
p68628
S'7705876'
p68629
sS'AB'
p68630
S'Antiretroviral drug resistance in patients failing non-nucleoside reverse transcriptase inhibitor (NNRTI)-based first-line combination antiretroviral treatment (ART) is influenced by: regimen choice, HIV-1 subtype, detection of and response to therapy failure. In order to describe resistance patterns by genotypic testing, at the time of first-line ART failure and to describe associations with having M184I/V, K65R, three or more thymidine analog mutations (TAMs) and etravirine (ETV) resistance, the prevalence of antiretroviral drug resistance associated mutations in a cross-sectional study, at two South African public health clinic settings, at the time of virologic failure (HIV-1 RNA load >400 copies/ml) are described. Also reported are associations of therapy choice, prolonged virologic failure, and concurrent HIV viral load and CD4 count with the presence of M184I/V, TAMs, K65R, and resistance to ETV. Of 167 adult patients with virologic failure on first-line ART, 28 (17%) had no resistance, 137 (82%) had NNRTI resistance, 101 (60%) M184I/V, 20 (12%) TAMs, of which 4 had 3 or more TAMs, and 7 (4%) had K65R, of which 6 were on D4T and one on AZT. A prolonged estimated period of failure was associated with having >/=3 TAMs. Patients treated with nevirapine (NVP) were more likely to have ETV resistance than those treated with efavirenz (EFV). Major protease inhibitor mutations were not detected. A delayed response to ART failure may risk accumulation of TAMs in patients on an NNRTI-based regimen. The use of NVP rather than EFV was associated with ETV resistance.'
p68631
sS'AD'
p68632
S'Division of Medical Virology, Stellenbosch University, Tygerberg, Cape Town, South Africa. guvz@sun.ac.za'
p68633
sS'IP'
p68634
S'10'
p68635
sS'IS'
p68636
S'1096-9071 (Electronic) 0146-6615 (Linking)'
p68637
sS'DCOM'
p68638
S'20120206'
p68639
sS'AU'
p68640
(lp68641
S'van Zyl GU'
p68642
aS'van der Merwe L'
p68643
aS'Claassen M'
p68644
aS'Zeier M'
p68645
aS'Preiser W'
p68646
asS'VI'
p68647
S'83'
p68648
sS'MHDA'
p68649
S'2012/02/07 06:00'
p68650
sS'MH'
p68651
(lp68652
S'Adult'
p68653
aS'Anti-HIV Agents/administration & dosage/*pharmacology/*therapeutic use'
p68654
aS'Benzoxazines/therapeutic use'
p68655
aS'CD4 Lymphocyte Count'
p68656
aS'Cross-Sectional Studies'
p68657
aS'Drug Resistance, Viral/*genetics'
p68658
aS'Female'
p68659
aS'HIV Infections/*drug therapy/epidemiology/virology'
p68660
aS'HIV Protease Inhibitors/administration & dosage/pharmacology/therapeutic use'
p68661
aS'HIV-1/drug effects/genetics/metabolism'
p68662
aS'Humans'
p68663
aS'Male'
p68664
aS'Nevirapine/therapeutic use'
p68665
aS'Pyridazines/therapeutic use'
p68666
aS'RNA, Viral/blood'
p68667
aS'Reverse Transcriptase Inhibitors/administration & dosage/*pharmacology/*therapeutic use'
p68668
aS'South Africa'
p68669
aS'Treatment Failure'
p68670
aS'Viral Load'
p68671
aS'Zidovudine/therapeutic use'
p68672
asS'EDAT'
p68673
S'2011/08/13 06:00'
p68674
sS'SO'
p68675
S'J Med Virol. 2011 Oct;83(10):1764-9. doi: 10.1002/jmv.22189.'
p68676
sS'SB'
p68677
S'IM'
p68678
sS'PMID'
p68679
S'21837793'
p68680
sS'PST'
p68681
S'ppublish'
p68682
stRp68683
ag2
(g3
g4
(dp68684
S'LID'
p68685
S'10.1111/j.1365-3156.2011.02863.x [doi]'
p68686
sS'STAT'
p68687
S'MEDLINE'
p68688
sS'DEP'
p68689
S'20110811'
p68690
sS'CI'
p68691
(lp68692
S'(c) 2011 Blackwell Publishing Ltd.'
p68693
asS'DA'
p68694
S'20120723'
p68695
sS'AID'
p68696
(lp68697
S'10.1111/j.1365-3156.2011.02863.x [doi]'
p68698
asS'CRDT'
p68699
(lp68700
S'2011/08/12 06:00'
p68701
asS'DP'
p68702
S'2011 Nov'
p68703
sS'OWN'
p68704
S'NLM'
p68705
sS'PT'
p68706
(lp68707
S'Journal Article'
p68708
aS"Research Support, Non-U.S. Gov't"
p68709
asS'LA'
p68710
(lp68711
S'eng'
p68712
asS'FAU'
p68713
(lp68714
S'Tayler-Smith, K'
p68715
aS'Zachariah, R'
p68716
aS'Manzi, M'
p68717
aS'Kizito, W'
p68718
aS'Vandenbulcke, A'
p68719
aS'Sitienei, J'
p68720
aS'Chakaya, J'
p68721
aS'Harries, A D'
p68722
asS'JT'
p68723
S'Tropical medicine & international health : TM & IH'
p68724
sS'PG'
p68725
S'1380-3'
p68726
sS'TI'
p68727
S'Antiretroviral treatment uptake and attrition among HIV-positive patients with tuberculosis in Kibera, Kenya.'
p68728
sS'RN'
p68729
(lp68730
S'0 (Anti-Retroviral Agents)'
p68731
asS'PL'
p68732
S'England'
p68733
sS'TA'
p68734
S'Trop Med Int Health'
p68735
sS'JID'
p68736
S'9610576'
p68737
sS'AB'
p68738
S'Using data of human immunodeficiency virus-positive patients with tuberculosis from three primary care clinics in Kibera slums, Nairobi, Kenya, we report on the proportion that started antiretroviral treatment (ART) and attrition (deaths, lost to follow-up and stopped treatment) before and while on ART. Of 427 ART eligible patients, enrolled between January 2004 and December 2008, 70% started ART, 19% were lost to attrition and 11% had not initiated ART. Of those who started ART, 14% were lost to attrition, making a cumulative pre-ART and ART attrition of 33%. ART uptake among patients with TB was relatively good, but programme attrition was high and needs urgent addressing.'
p68739
sS'AD'
p68740
S'Medical Department, Operational Center Brussels, MSF-Luxembourg, Luxembourg.'
p68741
sS'IP'
p68742
S'11'
p68743
sS'IS'
p68744
S'1365-3156 (Electronic) 1360-2276 (Linking)'
p68745
sS'DCOM'
p68746
S'20121016'
p68747
sS'AU'
p68748
(lp68749
S'Tayler-Smith K'
p68750
aS'Zachariah R'
p68751
aS'Manzi M'
p68752
aS'Kizito W'
p68753
aS'Vandenbulcke A'
p68754
aS'Sitienei J'
p68755
aS'Chakaya J'
p68756
aS'Harries AD'
p68757
asS'VI'
p68758
S'16'
p68759
sS'MHDA'
p68760
S'2012/10/17 06:00'
p68761
sS'PHST'
p68762
(lp68763
S'2011/08/11 [aheadofprint]'
p68764
asS'MH'
p68765
(lp68766
S'Adult'
p68767
aS'Anti-Retroviral Agents/*therapeutic use'
p68768
aS'Cross-Sectional Studies'
p68769
aS'Female'
p68770
aS'HIV Seropositivity/complications/*drug therapy'
p68771
aS'Humans'
p68772
aS'Kenya'
p68773
aS'Male'
p68774
aS'*Patient Compliance'
p68775
aS'Patient Dropouts/statistics & numerical data'
p68776
aS'Primary Health Care/methods'
p68777
aS'Retrospective Studies'
p68778
aS'Tuberculosis/*complications'
p68779
aS'Urban Health'
p68780
asS'EDAT'
p68781
S'2011/08/13 06:00'
p68782
sS'SO'
p68783
S'Trop Med Int Health. 2011 Nov;16(11):1380-3. doi: 10.1111/j.1365-3156.2011.02863.x. Epub 2011 Aug 11.'
p68784
sS'SB'
p68785
S'IM'
p68786
sS'PMID'
p68787
S'21831116'
p68788
sS'PST'
p68789
S'ppublish'
p68790
stRp68791
ag2
(g3
g4
(dp68792
S'LID'
p68793
S'10.1371/journal.pone.0022778 [doi]'
p68794
sS'STAT'
p68795
S'MEDLINE'
p68796
sS'DEP'
p68797
S'20110802'
p68798
sS'DA'
p68799
S'20110810'
p68800
sS'AID'
p68801
(lp68802
S'10.1371/journal.pone.0022778 [doi]'
p68803
aS'PONE-D-11-02433 [pii]'
p68804
asS'CRDT'
p68805
(lp68806
S'2011/08/11 06:00'
p68807
asS'DP'
p68808
S'2011'
p68809
sS'AD'
p68810
S'Department of Obstetrics and Gynecology, Duke Global Health Institute, Duke University, Durham, North Carolina, United States of America. daniel.westreich@duke.edu'
p68811
sS'OWN'
p68812
S'NLM'
p68813
sS'PT'
p68814
(lp68815
S'Journal Article'
p68816
aS'Research Support, N.I.H., Extramural'
p68817
aS"Research Support, Non-U.S. Gov't"
p68818
aS"Research Support, U.S. Gov't, Non-P.H.S."
p68819
asS'LA'
p68820
(lp68821
S'eng'
p68822
asS'FAU'
p68823
(lp68824
S'Westreich, Daniel'
p68825
aS'Cole, Stephen R'
p68826
aS'Nagar, Shashi'
p68827
aS'Maskew, Mhairi'
p68828
aS'van der Horst, Charles'
p68829
aS'Sanne, Ian'
p68830
asS'JT'
p68831
S'PloS one'
p68832
sS'LR'
p68833
S'20150204'
p68834
sS'PG'
p68835
S'e22778'
p68836
sS'TI'
p68837
S'Pregnancy and virologic response to antiretroviral therapy in South Africa.'
p68838
sS'RN'
p68839
(lp68840
S'0 (Anti-HIV Agents)'
p68841
asS'PL'
p68842
S'United States'
p68843
sS'TA'
p68844
S'PLoS One'
p68845
sS'JID'
p68846
S'101285081'
p68847
sS'AB'
p68848
S'BACKGROUND: Although women of reproductive age are the largest group of HIV-infected individuals in sub-Saharan Africa, little is known about the impact of pregnancy on response to highly active antiretroviral therapy (HAART) in that setting. We examined the effect of incident pregnancy after HAART initiation on virologic response to HAART. METHODS AND FINDINGS: We evaluated a prospective clinical cohort of adult women who initiated HAART in Johannesburg, South Africa between 1 April 2004 and 30 September 2009, and followed up until an event, death, transfer, drop-out, or administrative end of follow-up on 31 March 2010. Women over age 45 and women who were pregnant at HAART initiation were excluded from the study; final sample size for analysis was 5,494 women. Main exposure was incident pregnancy, experienced by 541 women; main outcome was virologic failure, defined as a failure to suppress virus to </= 400 copies/ml by six months or virologic rebound >400 copies/ml thereafter. We calculated adjusted hazard ratios using marginal structural Cox proportional hazards models and weighted lifetable analysis to calculate adjusted five-year risk differences. The weighted hazard ratio for the effect of pregnancy on time to virologic failure was 1.34 (95% confidence limit [CL] 1.02, 1.78). Sensitivity analyses generally confirmed these main results. CONCLUSIONS: Incident pregnancy after HAART initiation was associated with modest increases in both relative and absolute risks of virologic failure, although uncontrolled confounding cannot be ruled out. Nonetheless, these results reinforce that family planning is an essential part of care for HIV-positive women in sub-Saharan Africa. More work is needed to confirm these findings and to explore specific etiologic pathways by which such effects may operate.'
p68849
sS'GR'
p68850
(lp68851
S'K99 HD063961/HD/NICHD NIH HHS/United States'
p68852
aS'K99-HD-06-3961/HD/NICHD NIH HHS/United States'
p68853
aS'P30-AI-50410/AI/NIAID NIH HHS/United States'
p68854
aS'R00 HD063961/HD/NICHD NIH HHS/United States'
p68855
aS'R00-HD-06-3961-02/HD/NICHD NIH HHS/United States'
p68856
asS'IP'
p68857
S'8'
sS'IS'
p68858
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p68859
sS'PMC'
p68860
S'PMC3149058'
p68861
sS'DCOM'
p68862
S'20111227'
p68863
sS'AU'
p68864
(lp68865
S'Westreich D'
p68866
aS'Cole SR'
p68867
aS'Nagar S'
p68868
aS'Maskew M'
p68869
aS'van der Horst C'
p68870
aS'Sanne I'
p68871
asS'VI'
p68872
S'6'
sS'MHDA'
p68873
S'2011/12/28 06:00'
p68874
sS'PHST'
p68875
(lp68876
S'2011/01/31 [received]'
p68877
aS'2011/07/05 [accepted]'
p68878
aS'2011/08/02 [epublish]'
p68879
asS'OID'
p68880
(lp68881
S'NLM: PMC3149058'
p68882
asS'MH'
p68883
(lp68884
S'Adult'
p68885
aS'Anti-HIV Agents/*therapeutic use'
p68886
aS'Antiretroviral Therapy, Highly Active'
p68887
aS'Female'
p68888
aS'*HIV Infections/complications/drug therapy/virology'
p68889
aS'Humans'
p68890
aS'Middle Aged'
p68891
aS'Pregnancy'
p68892
aS'Pregnancy Complications, Infectious/*drug therapy/virology'
p68893
asS'EDAT'
p68894
S'2011/08/11 06:00'
p68895
sS'SO'
p68896
S'PLoS One. 2011;6(8):e22778. doi: 10.1371/journal.pone.0022778. Epub 2011 Aug 2.'
p68897
sS'SB'
p68898
S'IM'
p68899
sS'PMID'
p68900
S'21829650'
p68901
sS'PST'
p68902
S'ppublish'
p68903
stRp68904
ag2
(g3
g4
(dp68905
S'LID'
p68906
S'10.1089/aid.2011.0136 [doi]'
p68907
sS'STAT'
p68908
S'MEDLINE'
p68909
sS'DEP'
p68910
S'20110805'
p68911
sS'DA'
p68912
S'20120213'
p68913
sS'AID'
p68914
(lp68915
S'10.1089/aid.2011.0136 [doi]'
p68916
asS'CRDT'
p68917
(lp68918
S'2011/08/09 06:00'
p68919
asS'DP'
p68920
S'2012 Feb'
p68921
sS'OWN'
p68922
S'NLM'
p68923
sS'PT'
p68924
(lp68925
S'Journal Article'
p68926
aS"Research Support, Non-U.S. Gov't"
p68927
asS'LA'
p68928
(lp68929
S'eng'
p68930
asS'FAU'
p68931
(lp68932
S'Sigaloff, Kim C E'
p68933
aS'Ramatsebe, Tina'
p68934
aS'Viana, Raquel'
p68935
aS'de Wit, Tobias F Rinke'
p68936
aS'Wallis, Carole L'
p68937
aS'Stevens, Wendy S'
p68938
asS'JT'
p68939
S'AIDS research and human retroviruses'
p68940
sS'LR'
p68941
S'20131121'
p68942
sS'PG'
p68943
S'171-5'
p68944
sS'TI'
p68945
S'Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa.'
p68946
sS'RN'
p68947
(lp68948
S'0 (Anti-HIV Agents)'
p68949
aS'0 (RNA, Viral)'
p68950
aS'VC2W18DGKR (Thymidine)'
p68951
asS'PL'
p68952
S'United States'
p68953
sS'TA'
p68954
S'AIDS Res Hum Retroviruses'
p68955
sS'JID'
p68956
S'8709376'
p68957
sS'AB'
p68958
S'Patients failing antiretroviral treatment for extended periods of time are at risk of accumulating HIV drug resistance mutations (DRMs), which negatively influences second-line treatment. This retrospective study assessed the rate of DRM accumulation among South African patients with continued virological failure. Serial genotypic resistance testing was performed and DRMs were scored according to the 2009 IAS-USA list. Among 43 patients, 38 (88.4%) harbored >/=1 DRM. The median time between two sequential resistance tests was 5 months (IQR: 3-10). Thymidine analogue mutations accumulated at a rate of 0.07 mutation per month of drug exposure, which is faster than previously reported. Routine virological monitoring should be implemented in resource-limited settings to preserve susceptibility to second-line regimens.'
p68959
sS'AD'
p68960
S'PharmAccess Foundation, Amsterdam, The Netherlands. k.sigaloff@pharmaccess.org'
p68961
sS'IP'
p68962
S'2'
sS'IS'
p68963
S'1931-8405 (Electronic) 0889-2229 (Linking)'
p68964
sS'DCOM'
p68965
S'20120522'
p68966
sS'AU'
p68967
(lp68968
S'Sigaloff KC'
p68969
aS'Ramatsebe T'
p68970
aS'Viana R'
p68971
aS'de Wit TF'
p68972
aS'Wallis CL'
p68973
aS'Stevens WS'
p68974
asS'VI'
p68975
S'28'
p68976
sS'MHDA'
p68977
S'2012/05/23 06:00'
p68978
sS'PHST'
p68979
(lp68980
S'2011/08/05 [aheadofprint]'
p68981
asS'MH'
p68982
(lp68983
S'Adult'
p68984
aS'Anti-HIV Agents/*pharmacokinetics'
p68985
aS'Drug Resistance, Viral/drug effects/*genetics'
p68986
aS'Female'
p68987
aS'HIV Seropositivity/*drug therapy/epidemiology/genetics'
p68988
aS'Humans'
p68989
aS'Male'
p68990
aS'Middle Aged'
p68991
aS'Molecular Sequence Data'
p68992
aS'*Mutation'
p68993
aS'RNA, Viral/*drug effects'
p68994
aS'Retrospective Studies'
p68995
aS'South Africa/epidemiology'
p68996
aS'Thymidine/analogs & derivatives/*pharmacokinetics'
p68997
aS'Treatment Failure'
p68998
aS'Viral Load/drug effects'
p68999
asS'EDAT'
p69000
S'2011/08/09 06:00'
p69001
sS'SI'
p69002
(lp69003
S'GENBANK/JN381557'
p69004
aS'GENBANK/JN381558'
p69005
aS'GENBANK/JN381559'
p69006
aS'GENBANK/JN381560'
p69007
aS'GENBANK/JN381561'
p69008
aS'GENBANK/JN381562'
p69009
aS'GENBANK/JN381563'
p69010
aS'GENBANK/JN381564'
p69011
aS'GENBANK/JN381565'
p69012
aS'GENBANK/JN381566'
p69013
aS'GENBANK/JN381567'
p69014
aS'GENBANK/JN381568'
p69015
aS'GENBANK/JN381569'
p69016
aS'GENBANK/JN381570'
p69017
aS'GENBANK/JN381571'
p69018
aS'GENBANK/JN381572'
p69019
aS'GENBANK/JN381573'
p69020
aS'GENBANK/JN381574'
p69021
aS'GENBANK/JN381575'
p69022
aS'GENBANK/JN381576'
p69023
aS'GENBANK/JN381577'
p69024
aS'GENBANK/JN381578'
p69025
aS'GENBANK/JN381579'
p69026
aS'GENBANK/JN381580'
p69027
aS'GENBANK/JN381581'
p69028
aS'GENBANK/JN381582'
p69029
aS'GENBANK/JN381583'
p69030
aS'GENBANK/JN381584'
p69031
aS'GENBANK/JN381585'
p69032
aS'GENBANK/JN381586'
p69033
aS'GENBANK/JN381587'
p69034
aS'GENBANK/JN381588'
p69035
aS'GENBANK/JN381589'
p69036
aS'GENBANK/JN381590'
p69037
aS'GENBANK/JN381591'
p69038
aS'GENBANK/JN381592'
p69039
aS'GENBANK/JN381593'
p69040
aS'GENBANK/JN381594'
p69041
aS'GENBANK/JN381595'
p69042
aS'GENBANK/JN381596'
p69043
aS'GENBANK/JN381597'
p69044
aS'GENBANK/JN381598'
p69045
aS'GENBANK/JN381599'
p69046
aS'GENBANK/JN381600'
p69047
aS'GENBANK/JN381601'
p69048
aS'GENBANK/JN381602'
p69049
aS'GENBANK/JN381603'
p69050
aS'GENBANK/JN381604'
p69051
aS'GENBANK/JN381605'
p69052
aS'GENBANK/JN381606'
p69053
aS'GENBANK/JN381607'
p69054
aS'GENBANK/JN381608'
p69055
aS'GENBANK/JN381609'
p69056
aS'GENBANK/JN381610'
p69057
aS'GENBANK/JN381611'
p69058
aS'GENBANK/JN381612'
p69059
aS'GENBANK/JN381613'
p69060
aS'GENBANK/JN381614'
p69061
aS'GENBANK/JN381615'
p69062
aS'GENBANK/JN381616'
p69063
aS'GENBANK/JN381617'
p69064
aS'GENBANK/JN381618'
p69065
aS'GENBANK/JN381619'
p69066
aS'GENBANK/JN381620'
p69067
aS'GENBANK/JN381621'
p69068
aS'GENBANK/JN381622'
p69069
aS'GENBANK/JN381623'
p69070
aS'GENBANK/JN381624'
p69071
aS'GENBANK/JN381625'
p69072
asS'SO'
p69073
S'AIDS Res Hum Retroviruses. 2012 Feb;28(2):171-5. doi: 10.1089/aid.2011.0136. Epub 2011 Aug 5.'
p69074
sS'SB'
p69075
S'IM X'
p69076
sS'PMID'
p69077
S'21819219'
p69078
sS'PST'
p69079
S'ppublish'
p69080
stRp69081
ag2
(g3
g4
(dp69082
S'LID'
p69083
S'10.1371/journal.pone.0021797 [doi]'
p69084
sS'STAT'
p69085
S'MEDLINE'
p69086
sS'DEP'
p69087
S'20110726'
p69088
sS'DA'
p69089
S'20110805'
p69090
sS'AID'
p69091
(lp69092
S'10.1371/journal.pone.0021797 [doi]'
p69093
aS'PONE-D-10-06208 [pii]'
p69094
asS'CRDT'
p69095
(lp69096
S'2011/08/06 06:00'
p69097
asS'DP'
p69098
S'2011'
p69099
sS'AD'
p69100
S'Division of HIV/AIDS at San Francisco General Hospital, Department of Medicine, University of California San Francisco, San Francisco, California, United States of America. genge@php.ucsf.edu'
p69101
sS'OWN'
p69102
S'NLM'
p69103
sS'PT'
p69104
(lp69105
S'Journal Article'
p69106
aS'Research Support, N.I.H., Extramural'
p69107
aS"Research Support, U.S. Gov't, Non-P.H.S."
p69108
asS'LA'
p69109
(lp69110
S'eng'
p69111
asS'FAU'
p69112
(lp69113
S'Geng, Elvin H'
p69114
aS'Glidden, David V'
p69115
aS'Bwana, Mwebesa Bosco'
p69116
aS'Musinguzi, Nicolas'
p69117
aS'Emenyonu, Nneka'
p69118
aS'Muyindike, Winnie'
p69119
aS'Christopoulos, Katerina A'
p69120
aS'Neilands, Torsten B'
p69121
aS'Yiannoutsos, Constantin T'
p69122
aS'Deeks, Steven G'
p69123
aS'Bangsberg, David R'
p69124
aS'Martin, Jeffrey N'
p69125
asS'JT'
p69126
S'PloS one'
p69127
sS'LR'
p69128
S'20160701'
p69129
sS'PG'
p69130
S'e21797'
p69131
sS'TI'
p69132
S'Retention in care and connection to care among HIV-infected patients on antiretroviral therapy in Africa: estimation via a sampling-based approach.'
p69133
sS'PL'
p69134
S'United States'
p69135
sS'TA'
p69136
S'PLoS One'
p69137
sS'JID'
p69138
S'101285081'
p69139
sS'AB'
p69140
S'INTRODUCTION: Current estimates of retention among HIV-infected patients on antiretroviral therapy (ART) in Africa consider patients who are lost to follow-up (LTF) as well as those who die shortly after their last clinic visit to be no longer in care and to represent limitations in access to care. Yet many lost patients may have "silently" transferred and deaths shortly after the last clinic visit more likely represent limitations in clinical care rather than access to care after initial linkage. METHODS: We evaluated HIV-infected adults initiating ART from 1/1/2004 to 9/30/2007 at a clinic in rural Uganda. A representative sample of lost patients was tracked in the community to obtain updated information about care at other ART sites. Updated outcomes were incorporated with probability weights to obtain "corrected" estimates of retention for the entire clinic population. We used the competing risks approach to estimate "connection to care"--the percentage of patients accessing care over time (including those who died while in care). RESULTS: Among 3,628 patients, 829 became lost, 128 were tracked and in 111, updated information was obtained. Of 111, 79 (71%) were alive and 35/48 (73%) of patients interviewed in person were in care and on ART. Patient retention for the clinic population assuming lost patients were not in care was 82.3%, 68.9%, and 60.1% at 1, 2 and 3 years. Incorporating updated care information from the sample of lost patients increased estimates of patient retention to 85.8% to 90.9%, 78.9% to 86.2% and 75.8% to 84.7% at the same time points. CONCLUSIONS: Accounting for "silent transfers" and early deaths increased estimates of patient retention and connection to care substantially. Deaths soon after the last clinic visit (potentially reflecting limitations in clinical effectiveness) and disconnection from care among patient who were alive each accounted for approximately half of failures of retention.'
p69141
sS'GR'
p69142
(lp69143
S'K23 AI084544/AI/NIAID NIH HHS/United States'
p69144
aS'K23 AI084544/AI/NIAID NIH HHS/United States'
p69145
aS'K23 MH092220/MH/NIMH NIH HHS/United States'
p69146
aS'K24 MH087227/MH/NIMH NIH HHS/United States'
p69147
aS'P30 AI027763/AI/NIAID NIH HHS/United States'
p69148
aS'P30 AI027763/AI/NIAID NIH HHS/United States'
p69149
aS'R01 MH054907/MH/NIMH NIH HHS/United States'
p69150
aS'R01 MH054907/MH/NIMH NIH HHS/United States'
p69151
aS'U01 AI069911/AI/NIAID NIH HHS/United States'
p69152
asS'IP'
p69153
S'7'
sS'IS'
p69154
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p69155
sS'PMC'
p69156
S'PMC3144217'
p69157
sS'DCOM'
p69158
S'20111206'
p69159
sS'AU'
p69160
(lp69161
S'Geng EH'
p69162
aS'Glidden DV'
p69163
aS'Bwana MB'
p69164
aS'Musinguzi N'
p69165
aS'Emenyonu N'
p69166
aS'Muyindike W'
p69167
aS'Christopoulos KA'
p69168
aS'Neilands TB'
p69169
aS'Yiannoutsos CT'
p69170
aS'Deeks SG'
p69171
aS'Bangsberg DR'
p69172
aS'Martin JN'
p69173
asS'VI'
p69174
S'6'
sS'MHDA'
p69175
S'2011/12/13 00:00'
p69176
sS'PHST'
p69177
(lp69178
S'2010/12/08 [received]'
p69179
aS'2011/06/11 [accepted]'
p69180
aS'2011/07/26 [epublish]'
p69181
asS'OID'
p69182
(lp69183
S'NLM: PMC3144217'
p69184
asS'MH'
p69185
(lp69186
S'Adult'
p69187
aS'*Antiretroviral Therapy, Highly Active'
p69188
aS'Confidence Intervals'
p69189
aS'*Delivery of Health Care'
p69190
aS'Female'
p69191
aS'Follow-Up Studies'
p69192
aS'HIV Infections/*drug therapy/*epidemiology'
p69193
aS'Humans'
p69194
aS'Male'
p69195
aS'Sampling Studies'
p69196
aS'Uganda/epidemiology'
p69197
asS'EDAT'
p69198
S'2011/08/06 06:00'
p69199
sS'SO'
p69200
S'PLoS One. 2011;6(7):e21797. doi: 10.1371/journal.pone.0021797. Epub 2011 Jul 26.'
p69201
sS'SB'
p69202
S'IM'
p69203
sS'PMID'
p69204
S'21818265'
p69205
sS'PST'
p69206
S'ppublish'
p69207
stRp69208
ag2
(g3
g4
(dp69209
S'LID'
p69210
S'10.4269/ajtmh.2011.10-0510 [doi]'
p69211
sS'STAT'
p69212
S'MEDLINE'
p69213
sS'JT'
p69214
S'The American journal of tropical medicine and hygiene'
p69215
sS'DA'
p69216
S'20110804'
p69217
sS'AID'
p69218
(lp69219
S'85/2/390 [pii]'
p69220
aS'10.4269/ajtmh.2011.10-0510 [doi]'
p69221
asS'CRDT'
p69222
(lp69223
S'2011/08/05 06:00'
p69224
asS'DP'
p69225
S'2011 Aug'
p69226
sS'OWN'
p69227
S'NLM'
p69228
sS'PT'
p69229
(lp69230
S'Journal Article'
p69231
asS'LA'
p69232
(lp69233
S'eng'
p69234
asS'FAU'
p69235
(lp69236
S'Patel, Premal'
p69237
aS'Davis, Stephanie'
p69238
aS'Tolle, Michael'
p69239
aS'Mabikwa, Vincent'
p69240
aS'Anabwani, Gabriel'
p69241
asS'LR'
p69242
S'20150204'
p69243
sS'PG'
p69244
S'390-4'
p69245
sS'TI'
p69246
S'Prevalence of hepatitis B and hepatitis C coinfections in an adult HIV centre population in Gaborone, Botswana.'
p69247
sS'RN'
p69248
(lp69249
S'0 (Hepatitis B Surface Antigens)'
p69250
aS'0 (Immunoglobulin G)'
p69251
asS'PL'
p69252
S'United States'
p69253
sS'TA'
p69254
S'Am J Trop Med Hyg'
p69255
sS'JID'
p69256
S'0370507'
p69257
sS'AB'
p69258
S"The objective of this study was to assess the prevalence of hepatitis B and hepatitis C coinfections in human immunodeficiency virus (HIV) -infected adults at an HIV center in Gaborone, Botswana. A retrospective review was performed of charts of currently active HIV-infected adult patients in the Family Model Clinic (FMC) of the Botswana-Baylor Children's Clinical Center of Excellence (BCOE) in Gaborone, Botswana, for the results of serum hepatitis B surface antigen (HBsAg) and antihepatitis C IgG tests performed between January 1, 2005 and December 15, 2009. Of 308 active FMC patients, 266 underwent HBsAg serology testing within the period of study. The HBsAg coinfection prevalence was 5.3% (14/266); 2 of 252 patients had at least one positive antihepatitis C IgG serology, a 0.8% prevalence. Hepatitis B coinfection is relatively common in HIV-infected adults at our center in Botswana, whereas hepatitis C coinfection is rare. In this setting, where the diagnosis of hepatitis B coinfection with HIV has implications for choice of first-line antiretroviral therapy and prevention of perinatal hepatitis B transmission, broader sampling to establish the true population prevalence of hepatitis B coinfection and the desirability of adding screening to HIV management should be considered. These findings provide little justification for adding hepatitis C coinfection screening to the management of HIV infection in Botswana."
p69259
sS'AD'
p69260
S"Botswana-Baylor Children's Clinical Centre of Excellence, Gaborone, Botswana. premal33@gmail.com"
p69261
sS'IP'
p69262
S'2'
sS'IS'
p69263
S'1476-1645 (Electronic) 0002-9637 (Linking)'
p69264
sS'PMC'
p69265
S'PMC3144842'
p69266
sS'DCOM'
p69267
S'20111004'
p69268
sS'AU'
p69269
(lp69270
S'Patel P'
p69271
aS'Davis S'
p69272
aS'Tolle M'
p69273
aS'Mabikwa V'
p69274
aS'Anabwani G'
p69275
asS'VI'
p69276
S'85'
p69277
sS'MHDA'
p69278
S'2011/10/05 06:00'
p69279
sS'OID'
p69280
(lp69281
S'NLM: PMC3144842'
p69282
asS'MH'
p69283
(lp69284
S'Adolescent'
p69285
aS'Adult'
p69286
aS'Aged'
p69287
aS'Aged, 80 and over'
p69288
aS'Botswana/epidemiology'
p69289
aS'Female'
p69290
aS'HIV Infections/*complications/epidemiology'
p69291
aS'Hepatitis B/*complications/epidemiology'
p69292
aS'Hepatitis B Surface Antigens/blood'
p69293
aS'Hepatitis C/*complications/epidemiology'
p69294
aS'Humans'
p69295
aS'Immunoglobulin G/blood'
p69296
aS'Male'
p69297
aS'Middle Aged'
p69298
aS'Prevalence'
p69299
aS'Young Adult'
p69300
asS'EDAT'
p69301
S'2011/08/05 06:00'
p69302
sS'SO'
p69303
S'Am J Trop Med Hyg. 2011 Aug;85(2):390-4. doi: 10.4269/ajtmh.2011.10-0510.'
p69304
sS'SB'
p69305
S'AIM IM'
p69306
sS'PMID'
p69307
S'21813864'
p69308
sS'PST'
p69309
S'ppublish'
p69310
stRp69311
ag2
(g3
g4
(dp69312
S'LID'
p69313
S'10.1371/journal.pmed.1001055 [doi]'
p69314
sS'STAT'
p69315
S'MEDLINE'
p69316
sS'DEP'
p69317
S'20110719'
p69318
sS'CIN'
p69319
(lp69320
S'PLoS Med. 2011 Jul;8(7):e1001060. PMID: 21811405'
p69321
asS'DA'
p69322
S'20110803'
p69323
sS'AID'
p69324
(lp69325
S'10.1371/journal.pmed.1001055 [doi]'
p69326
aS'PMEDICINE-D-11-00095 [pii]'
p69327
asS'CRDT'
p69328
(lp69329
S'2011/08/04 06:00'
p69330
asS'DP'
p69331
S'2011 Jul'
p69332
sS'AD'
p69333
S'Health Economics and Epidemiology Research Office, Wits Health Consortium, Johannesburg, South Africa. llong@heroza.org'
p69334
sS'OWN'
p69335
S'NLM'
p69336
sS'PT'
p69337
(lp69338
S'Journal Article'
p69339
aS'Research Support, N.I.H., Extramural'
p69340
aS"Research Support, Non-U.S. Gov't"
p69341
aS"Research Support, U.S. Gov't, Non-P.H.S."
p69342
asS'LA'
p69343
(lp69344
S'eng'
p69345
asS'FAU'
p69346
(lp69347
S'Long, Lawrence'
p69348
aS'Brennan, Alana'
p69349
aS'Fox, Matthew P'
p69350
aS'Ndibongo, Buyiswa'
p69351
aS'Jaffray, Imogen'
p69352
aS'Sanne, Ian'
p69353
aS'Rosen, Sydney'
p69354
asS'JT'
p69355
S'PLoS medicine'
p69356
sS'LR'
p69357
S'20150204'
p69358
sS'PG'
p69359
S'e1001055'
p69360
sS'TI'
p69361
S'Treatment outcomes and cost-effectiveness of shifting management of stable ART patients to nurses in South Africa: an observational cohort.'
p69362
sS'RN'
p69363
(lp69364
S'0 (Anti-Retroviral Agents)'
p69365
asS'PL'
p69366
S'United States'
p69367
sS'TA'
p69368
S'PLoS Med'
p69369
sS'JID'
p69370
S'101231360'
p69371
sS'AB'
p69372
S'BACKGROUND: To address human resource and infrastructure shortages, resource-constrained countries are being encouraged to shift HIV care to lesser trained care providers and lower level health care facilities. This study evaluated the cost-effectiveness of down-referring stable antiretroviral therapy (ART) patients from a doctor-managed, hospital-based ART clinic to a nurse-managed primary health care facility in Johannesburg, South Africa. METHODS AND FINDINGS: Criteria for down-referral were stable ART (>/=11 mo), undetectable viral load within the previous 10 mo, CD4>200 cells/mm(3), <5% weight loss over the last three visits, and no opportunistic infections. All patients down-referred from the treatment-initiation site to the down-referral site between 1 February 2008 and 1 January 2009 were compared to a matched sample of patients eligible for down-referral but not down-referred. Outcomes were assigned based on vital and health status 12 mo after down-referral eligibility and the average cost per outcome estimated from patient medical record data. The down-referral site (n = 712) experienced less death and loss to follow up than the treatment-initiation site (n = 2,136) (1.7% versus 6.2%, relative risk = 0.27, 95% CI 0.15-0.49). The average cost per patient-year for those in care and responding at 12 mo was US$492 for down-referred patients and US$551 for patients remaining at the treatment-initiation site (p<0.0001), a savings of 11%. Down-referral was the cost-effective strategy for eligible patients. CONCLUSIONS: Twelve-month outcomes of stable ART patients who are down-referred to a primary health clinic are as good as, or better than, the outcomes of similar patients who are maintained at a hospital-based ART clinic. The cost of treatment with down-referral is lower across all outcomes and would save 11% for patients who remain in care and respond to treatment. These results suggest that this strategy would increase treatment capacity and conserve resources without compromising patient outcomes.'
p69373
sS'GR'
p69374
(lp69375
S'K01 AI083097/AI/NIAID NIH HHS/United States'
p69376
aS'K01AI083097/AI/NIAID NIH HHS/United States'
p69377
asS'IP'
p69378
S'7'
sS'IS'
p69379
S'1549-1676 (Electronic) 1549-1277 (Linking)'
p69380
sS'PMC'
p69381
S'PMC3139666'
p69382
sS'DCOM'
p69383
S'20111213'
p69384
sS'AU'
p69385
(lp69386
S'Long L'
p69387
aS'Brennan A'
p69388
aS'Fox MP'
p69389
aS'Ndibongo B'
p69390
aS'Jaffray I'
p69391
aS'Sanne I'
p69392
aS'Rosen S'
p69393
asS'VI'
p69394
S'8'
sS'MHDA'
p69395
S'2011/12/14 06:00'
p69396
sS'PHST'
p69397
(lp69398
S'2011/01/14 [received]'
p69399
aS'2011/05/27 [accepted]'
p69400
aS'2011/07/19 [epublish]'
p69401
asS'OID'
p69402
(lp69403
S'NLM: PMC3139666'
p69404
asS'MH'
p69405
(lp69406
S'Adolescent'
p69407
aS'Adult'
p69408
aS'Anti-Retroviral Agents/economics/*therapeutic use'
p69409
aS'Cohort Studies'
p69410
aS'Cost-Benefit Analysis'
p69411
aS'Female'
p69412
aS'HIV Infections/*drug therapy'
p69413
aS'Health Care Costs'
p69414
aS'Humans'
p69415
aS'Male'
p69416
aS'Middle Aged'
p69417
aS'Nursing/*methods'
p69418
aS'Outcome Assessment (Health Care)'
p69419
aS'South Africa'
p69420
aS'Treatment Outcome'
p69421
asS'EDAT'
p69422
S'2011/08/04 06:00'
p69423
sS'SO'
p69424
S'PLoS Med. 2011 Jul;8(7):e1001055. doi: 10.1371/journal.pmed.1001055. Epub 2011 Jul 19.'
p69425
sS'SB'
p69426
S'IM'
p69427
sS'PMID'
p69428
S'21811402'
p69429
sS'PST'
p69430
S'ppublish'
p69431
stRp69432
ag2
(g3
g4
(dp69433
S'LID'
p69434
S'10.1016/S1473-3099(11)70149-9 [doi]'
p69435
sS'STAT'
p69436
S'MEDLINE'
p69437
sS'DEP'
p69438
S'20110727'
p69439
sS'CI'
p69440
(lp69441
S'Copyright (c) 2011 Elsevier Ltd. All rights reserved.'
p69442
asS'DA'
p69443
S'20110930'
p69444
sS'AID'
p69445
(lp69446
S'S1473-3099(11)70149-9 [pii]'
p69447
aS'10.1016/S1473-3099(11)70149-9 [doi]'
p69448
asS'CRDT'
p69449
(lp69450
S'2011/08/02 06:00'
p69451
asS'DP'
p69452
S'2011 Oct'
p69453
sS'GR'
p69454
(lp69455
S'MC_U950080938/Medical Research Council/United Kingdom'
p69456
aS'MC_U950097144/Medical Research Council/United Kingdom'
p69457
asS'OWN'
p69458
S'NLM'
p69459
sS'PT'
p69460
(lp69461
S'Comparative Study'
p69462
aS'Journal Article'
p69463
aS'Multicenter Study'
p69464
aS"Research Support, Non-U.S. Gov't"
p69465
asS'LA'
p69466
(lp69467
S'eng'
p69468
asS'FAU'
p69469
(lp69470
S'Hamers, Raph L'
p69471
aS'Wallis, Carole L'
p69472
aS'Kityo, Cissy'
p69473
aS'Siwale, Margaret'
p69474
aS'Mandaliya, Kishor'
p69475
aS'Conradie, Francesca'
p69476
aS'Botes, Mariette E'
p69477
aS'Wellington, Maureen'
p69478
aS'Osibogun, Akin'
p69479
aS'Sigaloff, Kim C E'
p69480
aS'Nankya, Immaculate'
p69481
aS'Schuurman, Rob'
p69482
aS'Wit, Ferdinand W'
p69483
aS'Stevens, Wendy S'
p69484
aS'van Vugt, Michele'
p69485
aS'de Wit, Tobias F Rinke'
p69486
asS'JT'
p69487
S'The Lancet. Infectious diseases'
p69488
sS'LR'
p69489
S'20140815'
p69490
sS'PG'
p69491
S'750-9'
p69492
sS'TI'
p69493
S'HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study.'
p69494
sS'RN'
p69495
(lp69496
S'0 (Anti-HIV Agents)'
p69497
aS'0 (Anti-Retroviral Agents)'
p69498
aS'VC2W18DGKR (Thymidine)'
p69499
asS'PL'
p69500
S'United States'
p69501
sS'TA'
p69502
S'Lancet Infect Dis'
p69503
sS'FIR'
p69504
(lp69505
S'Mandaliya, K'
p69506
aS'Abdallah, S'
p69507
aS'Jao, I'
p69508
aS'Dolan, M'
p69509
aS'Schuurman, R'
p69510
aS'Wensing, A M'
p69511
aS'Hamers, R L'
p69512
aS'Sigaloff, K C E'
p69513
aS'Straatsma, E'
p69514
aS'Wit, F W'
p69515
aS'van Vugt, M'
p69516
aS'Lange, J M'
p69517
aS'Rinke de Wit, T F'
p69518
aS'Osibogun, A'
p69519
aS'Akanmu, S'
p69520
aS'Botes, M E'
p69521
aS'Conradie, F'
p69522
aS'Ive, P'
p69523
aS'Sanne, I'
p69524
aS'Wallis, C L'
p69525
aS'Letsoalo, E'
p69526
aS'Stevens, W S'
p69527
aS'Hardman, M'
p69528
aS'Kityo, C'
p69529
aS'Namayanja, G'
p69530
aS'Nakatudde, L'
p69531
aS'Nankya, I'
p69532
aS'Kiconco, M'
p69533
aS'Abwola, M'
p69534
aS'Mugyenyi, P'
p69535
aS'Ndembi, N'
p69536
aS'Lyagoba, F'
p69537
aS'Kaleebu, P'
p69538
aS'Siwale, M'
p69539
aS'Njovu, C'
p69540
aS'Labib, M'
p69541
aS'Menke, J'
p69542
aS'Wellington, M'
p69543
aS'Luthy, R'
p69544
asS'JID'
p69545
S'101130150'
p69546
sS'AB'
p69547
S'BACKGROUND: There are few data on the epidemiology of primary HIV-1 drug resistance after the roll-out of antiretroviral treatment (ART) in sub-Saharan Africa. We aimed to assess the prevalence of primary resistance in six African countries after ART roll-out and if wider use of ART in sub-Saharan Africa is associated with rising prevalence of drug resistance. METHODS: We did a cross-sectional study in antiretroviral-naive adults infected with HIV-1 who had not started first-line ART, recruited between 2007 and 2009 from 11 regions in Kenya, Nigeria, South Africa, Uganda, Zambia, and Zimbabwe. We did population-based sequencing of the pol gene on plasma specimens with greater than 1000 copies per mL of HIV RNA. We identified drug-resistance mutations with the WHO list for transmitted resistance. The prevalence of sequences containing at least one drug-resistance mutation was calculated accounting for the sampling weights of the sites. We assessed the risk factors of resistance with multilevel logistic regression with random coefficients. FINDINGS: 2436 (94.1%) of 2590 participants had a pretreatment genotypic resistance result. 1486 participants (57.4%) were women, 1575 (60.8%) had WHO clinical stage 3 or 4 disease, and the median CD4 count was 133 cells per muL (IQR 62-204). Overall sample-weighted drug-resistance prevalence was 5.6% (139 of 2436; 95% CI 4.6-6.7), ranging from 1.1% (two of 176; 0.0-2.7) in Pretoria, South Africa, to 12.3% (22 of 179; 7.5-17.1) in Kampala, Uganda. The pooled prevalence for all three Ugandan sites was 11.6% (66 of 570; 8.9-14.2), compared with 3.5% (73 of 1866; 2.5-4.5) for all other sites. Drug class-specific resistance prevalence was 2.5% (54 of 2436; 1.8-3.2) for nucleoside reverse-transcriptase inhibitors (NRTIs), 3.3% (83 of 2436; 2.5-4.2) for non-NRTIs (NNRTIs), 1.3% (31 of 2436; 0.8-1.8) for protease inhibitors, and 1.2% (25 of 2436; 0.7-1.7) for dual-class resistance to NRTIs and NNRTIs. The most common drug-resistance mutations were K103N (43 [1.8%] of 2436), thymidine analogue mutations (33 [1.6%] of 2436), M184V (25 [1.2%] of 2436), and Y181C/I (19 [0.7%] of 2436). The odds ratio for drug resistance associated with each additional year since the start of the ART roll-out in a region was 1.38 (95% CI 1.13-1.68; p=0.001). INTERPRETATION: The higher prevalence of primary drug resistance in Uganda than in other African countries is probably related to the earlier start of ART roll-out in Uganda. Resistance surveillance and prevention should be prioritised in settings where ART programmes are scaled up. FUNDING: Ministry of Foreign Affairs of the Netherlands.'
p69548
sS'AD'
p69549
S'PharmAccess Foundation, Department of Global Health, Academic Medical Centre of University of Amsterdam, Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands. r.hamers@amc-cpcd.org'
p69550
sS'CN'
p69551
(lp69552
S'PharmAccess African Studies to Evaluate Resistance (PASER)'
p69553
asS'IP'
p69554
S'10'
p69555
sS'IS'
p69556
S'1474-4457 (Electronic) 1473-3099 (Linking)'
p69557
sS'IR'
p69558
(lp69559
S'Mandaliya K'
p69560
aS'Abdallah S'
p69561
aS'Jao I'
p69562
aS'Dolan M'
p69563
aS'Schuurman R'
p69564
aS'Wensing AM'
p69565
aS'Hamers RL'
p69566
aS'Sigaloff KC'
p69567
aS'Straatsma E'
p69568
aS'Wit FW'
p69569
aS'van Vugt M'
p69570
aS'Lange JM'
p69571
aS'Rinke de Wit TF'
p69572
aS'Osibogun A'
p69573
aS'Akanmu S'
p69574
aS'Botes ME'
p69575
aS'Conradie F'
p69576
aS'Ive P'
p69577
aS'Sanne I'
p69578
aS'Wallis CL'
p69579
aS'Letsoalo E'
p69580
aS'Stevens WS'
p69581
aS'Hardman M'
p69582
aS'Kityo C'
p69583
aS'Namayanja G'
p69584
aS'Nakatudde L'
p69585
aS'Nankya I'
p69586
aS'Kiconco M'
p69587
aS'Abwola M'
p69588
aS'Mugyenyi P'
p69589
aS'Ndembi N'
p69590
aS'Lyagoba F'
p69591
aS'Kaleebu P'
p69592
aS'Siwale M'
p69593
aS'Njovu C'
p69594
aS'Labib M'
p69595
aS'Menke J'
p69596
aS'Wellington M'
p69597
aS'Luthy R'
p69598
asS'DCOM'
p69599
S'20111108'
p69600
sS'CIN'
p69601
(lp69602
S'Lancet Infect Dis. 2012 Aug;12(8):585-6. PMID: 22835893'
p69603
aS'Lancet Infect Dis. 2011 Oct;11(10):723-4. PMID: 21958572'
p69604
asS'AU'
p69605
(lp69606
S'Hamers RL'
p69607
aS'Wallis CL'
p69608
aS'Kityo C'
p69609
aS'Siwale M'
p69610
aS'Mandaliya K'
p69611
aS'Conradie F'
p69612
aS'Botes ME'
p69613
aS'Wellington M'
p69614
aS'Osibogun A'
p69615
aS'Sigaloff KC'
p69616
aS'Nankya I'
p69617
aS'Schuurman R'
p69618
aS'Wit FW'
p69619
aS'Stevens WS'
p69620
aS'van Vugt M'
p69621
aS'de Wit TF'
p69622
asS'VI'
p69623
S'11'
p69624
sS'MHDA'
p69625
S'2011/11/09 06:00'
p69626
sS'PHST'
p69627
(lp69628
S'2011/07/27 [aheadofprint]'
p69629
asS'MH'
p69630
(lp69631
S'Adult'
p69632
aS'Africa South of the Sahara/epidemiology'
p69633
aS'Aged'
p69634
aS'Analysis of Variance'
p69635
aS'Anti-HIV Agents/administration & dosage/*pharmacology'
p69636
aS'Anti-Retroviral Agents/administration & dosage'
p69637
aS'Cross-Sectional Studies'
p69638
aS'*Drug Resistance, Viral/drug effects/genetics'
p69639
aS'Female'
p69640
aS'Genotype'
p69641
aS'HIV Infections/*drug therapy/epidemiology/transmission/virology'
p69642
aS'HIV-1/*drug effects'
p69643
aS'Humans'
p69644
aS'Kenya/epidemiology'
p69645
aS'Male'
p69646
aS'Middle Aged'
p69647
aS'Nigeria/epidemiology'
p69648
aS'Population Surveillance'
p69649
aS'Prevalence'
p69650
aS'Prospective Studies'
p69651
aS'South Africa/epidemiology'
p69652
aS'Thymidine/analogs & derivatives/genetics'
p69653
aS'Uganda/epidemiology'
p69654
aS'Viral Load/drug effects'
p69655
aS'Zambia/epidemiology'
p69656
aS'Zimbabwe/epidemiology'
p69657
asS'EDAT'
p69658
S'2011/08/02 06:00'
p69659
sS'SO'
p69660
S'Lancet Infect Dis. 2011 Oct;11(10):750-9. doi: 10.1016/S1473-3099(11)70149-9. Epub 2011 Jul 27.'
p69661
sS'SB'
p69662
S'IM'
p69663
sS'PMID'
p69664
S'21802367'
p69665
sS'PST'
p69666
S'ppublish'
p69667
stRp69668
ag2
(g3
g4
(dp69669
S'LID'
p69670
S'10.1371/journal.pone.0020436 [doi]'
p69671
sS'STAT'
p69672
S'MEDLINE'
p69673
sS'DEP'
p69674
S'20110722'
p69675
sS'DA'
p69676
S'20110729'
p69677
sS'AID'
p69678
(lp69679
S'10.1371/journal.pone.0020436 [doi]'
p69680
aS'PONE-D-11-04324 [pii]'
p69681
asS'CRDT'
p69682
(lp69683
S'2011/07/30 06:00'
p69684
asS'DP'
p69685
S'2011'
p69686
sS'AD'
p69687
S'Johns Hopkins University School of Nursing, Baltimore, Maryland, United States of America. jfarley@son.jhmi.edu'
p69688
sS'OWN'
p69689
S'NLM'
p69690
sS'PT'
p69691
(lp69692
S'Clinical Trial'
p69693
aS'Journal Article'
p69694
aS'Research Support, N.I.H., Extramural'
p69695
aS"Research Support, Non-U.S. Gov't"
p69696
asS'LA'
p69697
(lp69698
S'eng'
p69699
asS'FAU'
p69700
(lp69701
S'Farley, Jason E'
p69702
aS'Ram, Malathi'
p69703
aS'Pan, William'
p69704
aS'Waldman, Stacie'
p69705
aS'Cassell, Gail H'
p69706
aS'Chaisson, Richard E'
p69707
aS'Weyer, Karin'
p69708
aS'Lancaster, Joey'
p69709
aS'Van der Walt, Martie'
p69710
asS'JT'
p69711
S'PloS one'
p69712
sS'LR'
p69713
S'20150204'
p69714
sS'PG'
p69715
S'e20436'
p69716
sS'TI'
p69717
S'Outcomes of multi-drug resistant tuberculosis (MDR-TB) among a cohort of South African patients with high HIV prevalence.'
p69718
sS'PL'
p69719
S'United States'
p69720
sS'TA'
p69721
S'PLoS One'
p69722
sS'JID'
p69723
S'101285081'
p69724
sS'AB'
p69725
S'BACKGROUND: Multidrug-resistant tuberculosis (MDR-TB) is a major clinical challenge, particularly in patients with human immunodeficiency virus (HIV) co-infection. MDR-TB treatment is increasingly available, but outcomes have not been well characterized. South Africa has provided MDR-TB treatment for a decade, and we evaluated outcomes by HIV status for patients enrolled between 2000 and 2004 prior to anti-retroviral access. METHODS: We assessed treatment outcomes in a prospective cohort of patients with MDR-TB from eight provincial programs providing second line drugs. World Health Organization definitions were used. Results were stratified by HIV status. RESULTS: Seven hundred fifty seven patients with known HIV status were included in the final analysis, and HIV infection was documented in 287 (38%). Overall, 348 patients (46.0%) were successfully treated, 74 (9.8%) failed therapy, 177 (23.4%) died and 158 (20.9%) defaulted. Patients with HIV were slightly younger and less likely to be male compared to HIV negative patients. Patients with HIV were less likely to have a successful treatment outcome (40.0 vs. 49.6; P<0.05) and more likely to die (35.2 vs. 16.2; P<0.0001). In a competing risk survival analysis, patients with HIV had a higher hazard of death (HR: 2.33, P<0.0001). Low baseline weight (less than 45 kg and less than 60 kg) was also associated with a higher hazard of death (HR: 2.52, P<0.0001; and HR: 1.50, P<0.0001, respectively, compared to weight greater than 60 kg). Weight less than 45 kg had higher risk of failure (HR: 3.58, P<0.01). Any change in treatment regimen was associated with a higher hazard of default (HR: 2.86; 95% CI 1.55-5.29, P<0.001) and a lower hazard of death (HR: 0.63, P<0.05). CONCLUSIONS: In this MDR-TB treatment program patients with HIV infection and low weight had higher hazards of death. Overall treatment outcomes were poor. Efforts to improve treatment for MDR-TB are urgently needed.'
p69726
sS'GR'
p69727
(lp69728
S'5R25TW007506/TW/FIC NIH HHS/United States'
p69729
aS'K01 HD055415/HD/NICHD NIH HHS/United States'
p69730
asS'IP'
p69731
S'7'
sS'IS'
p69732
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p69733
sS'PMC'
p69734
S'PMC3142109'
p69735
sS'DCOM'
p69736
S'20111206'
p69737
sS'AU'
p69738
(lp69739
S'Farley JE'
p69740
aS'Ram M'
p69741
aS'Pan W'
p69742
aS'Waldman S'
p69743
aS'Cassell GH'
p69744
aS'Chaisson RE'
p69745
aS'Weyer K'
p69746
aS'Lancaster J'
p69747
aS'Van der Walt M'
p69748
asS'VI'
p69749
S'6'
sS'MHDA'
p69750
S'2011/12/13 00:00'
p69751
sS'PHST'
p69752
(lp69753
S'2011/02/25 [received]'
p69754
aS'2011/04/20 [accepted]'
p69755
aS'2011/07/22 [epublish]'
p69756
asS'OID'
p69757
(lp69758
S'NLM: PMC3142109'
p69759
asS'MH'
p69760
(lp69761
S'Adolescent'
p69762
aS'Adult'
p69763
aS'Aged'
p69764
aS'Cohort Studies'
p69765
aS'HIV Infections/*complications/*epidemiology'
p69766
aS'Humans'
p69767
aS'Male'
p69768
aS'Middle Aged'
p69769
aS'Prevalence'
p69770
aS'South Africa/epidemiology'
p69771
aS'Treatment Outcome'
p69772
aS'Tuberculosis, Multidrug-Resistant/*complications/*drug therapy'
p69773
aS'Young Adult'
p69774
asS'EDAT'
p69775
S'2011/07/30 06:00'
p69776
sS'SO'
p69777
S'PLoS One. 2011;6(7):e20436. doi: 10.1371/journal.pone.0020436. Epub 2011 Jul 22.'
p69778
sS'SB'
p69779
S'IM'
p69780
sS'PMID'
p69781
S'21799728'
p69782
sS'PST'
p69783
S'ppublish'
p69784
stRp69785
ag2
(g3
g4
(dp69786
S'LID'
p69787
S'10.1016/j.jcv.2011.06.014 [doi]'
p69788
sS'STAT'
p69789
S'MEDLINE'
p69790
sS'DEP'
p69791
S'20110727'
p69792
sS'CI'
p69793
(lp69794
S'Copyright (c) 2011 Elsevier B.V. All rights reserved.'
p69795
asS'DA'
p69796
S'20110916'
p69797
sS'AID'
p69798
(lp69799
S'S1386-6532(11)00262-9 [pii]'
p69800
aS'10.1016/j.jcv.2011.06.014 [doi]'
p69801
asS'CRDT'
p69802
(lp69803
S'2011/07/30 06:00'
p69804
asS'DP'
p69805
S'2011 Oct'
p69806
sS'OWN'
p69807
S'NLM'
p69808
sS'PT'
p69809
(lp69810
S'Journal Article'
p69811
aS"Research Support, Non-U.S. Gov't"
p69812
asS'LA'
p69813
(lp69814
S'eng'
p69815
asS'FAU'
p69816
(lp69817
S'Lihana, Raphael W'
p69818
aS'Lwembe, Raphael M'
p69819
aS'Bi, Xiuqiong'
p69820
aS'Ochieng, Washingtone'
p69821
aS'Panikulam, Annie'
p69822
aS'Palakudy, Tresa'
p69823
aS'Musoke, Rachel'
p69824
aS'Owens, Mary'
p69825
aS'Ishizaki, Azumi'
p69826
aS'Okoth, Frederick A'
p69827
aS'Songok, Elijah M'
p69828
aS'Ichimura, Hiroshi'
p69829
asS'JT'
p69830
S'Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology'
p69831
sS'PG'
p69832
S'123-8'
p69833
sS'TI'
p69834
S'Efficient monitoring of HIV-1 vertically infected children in Kenya on first-line antiretroviral therapy.'
p69835
sS'RN'
p69836
(lp69837
S'0 (Anti-HIV Agents)'
p69838
asS'PL'
p69839
S'Netherlands'
p69840
sS'TA'
p69841
S'J Clin Virol'
p69842
sS'JID'
p69843
S'9815671'
p69844
sS'AB'
p69845
S'BACKGROUND: Worldwide access to antiretroviral therapy (ART) in low- and middle-income countries has significantly increased. Although this presents better treatment options for HIV-infected individuals, the challenge of monitoring ART in these settings still remains. OBJECTIVE: To investigate efficient and cost-effective criteria for assessing ART failure among HIV-1-infected children on first-line ART in resource-limited settings. STUDY DESIGN: Retrospective analysis of 75 HIV-1 vertically infected Kenyan children with a follow-up period of 24 months after initiating ART. Plasma viral load, peripheral CD4(+)T-cell counts and HIV-1 drug-resistance mutations were monitored biannually. RESULTS: Plasma viral load (VL) was suppressed to undetectable level or more than 1.5 log(10) from baseline levels in 53 (70.7%) children within 24 months. VL in the remaining 22 (29.3%) children was not suppressed significantly. Of the 22 children, 21 were infected with HIV-1 strains that developed drug-resistance mutations; 9 within 12 months and 12 between 12 and 24 months. Among the 53 who were successfully treated, VL was suppressed in 33 within 12 months and in 20 between 12 and 24 months. There was no significant difference in VL at baseline and the change of CD4(+)T-cell counts after initiating ART between those treated successfully and the failure groups. CONCLUSION: After initiating ART, children may require longer times to achieve complete viral suppression. Plasma viral load testing 24 months after initiating ART could be used to differentiate ART failures among HIV-1 vertically infected children in resource-limited settings. Additionally, drug resistance testing, if affordable, would be helpful in identifying those failing therapy and in choosing second-line regimens.'
p69846
sS'AD'
p69847
S'Department of Viral Infection and International Health, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takara-machi, Ishikawa, Kanazawa 920-8640, Japan.'
p69848
sS'IP'
p69849
S'2'
sS'IS'
p69850
S'1873-5967 (Electronic) 1386-6532 (Linking)'
p69851
sS'DCOM'
p69852
S'20120112'
p69853
sS'AU'
p69854
(lp69855
S'Lihana RW'
p69856
aS'Lwembe RM'
p69857
aS'Bi X'
p69858
aS'Ochieng W'
p69859
aS'Panikulam A'
p69860
aS'Palakudy T'
p69861
aS'Musoke R'
p69862
aS'Owens M'
p69863
aS'Ishizaki A'
p69864
aS'Okoth FA'
p69865
aS'Songok EM'
p69866
aS'Ichimura H'
p69867
asS'VI'
p69868
S'52'
p69869
sS'MHDA'
p69870
S'2012/01/13 06:00'
p69871
sS'PHST'
p69872
(lp69873
S'2011/02/28 [received]'
p69874
aS'2011/06/11 [revised]'
p69875
aS'2011/06/28 [accepted]'
p69876
aS'2011/07/27 [aheadofprint]'
p69877
asS'MH'
p69878
(lp69879
S'Anti-HIV Agents/pharmacology/*therapeutic use'
p69880
aS'Antiretroviral Therapy, Highly Active'
p69881
aS'CD4 Lymphocyte Count'
p69882
aS'Child'
p69883
aS'Child, Preschool'
p69884
aS'Drug Resistance, Viral/drug effects/genetics'
p69885
aS'Female'
p69886
aS'Follow-Up Studies'
p69887
aS'Genes, Viral'
p69888
aS'HIV Infections/drug therapy/*transmission'
p69889
aS'HIV-1/*drug effects/*genetics'
p69890
aS'Humans'
p69891
aS'*Infectious Disease Transmission, Vertical'
p69892
aS'Kenya'
p69893
aS'Male'
p69894
aS'Molecular Sequence Data'
p69895
aS'Mutation'
p69896
aS'Retrospective Studies'
p69897
aS'Treatment Failure'
p69898
aS'Viral Load'
p69899
asS'EDAT'
p69900
S'2011/07/30 06:00'
p69901
sS'SI'
p69902
(lp69903
S'GENBANK/HQ586062'
p69904
aS'GENBANK/HQ586063'
p69905
aS'GENBANK/HQ586064'
p69906
aS'GENBANK/HQ586065'
p69907
aS'GENBANK/HQ586066'
p69908
aS'GENBANK/HQ586067'
p69909
aS'GENBANK/HQ586068'
p69910
aS'GENBANK/HQ586069'
p69911
aS'GENBANK/HQ586070'
p69912
aS'GENBANK/HQ586071'
p69913
aS'GENBANK/HQ586072'
p69914
aS'GENBANK/HQ586073'
p69915
aS'GENBANK/HQ586074'
p69916
aS'GENBANK/HQ586075'
p69917
aS'GENBANK/HQ586076'
p69918
aS'GENBANK/HQ586077'
p69919
aS'GENBANK/HQ586078'
p69920
aS'GENBANK/HQ586079'
p69921
aS'GENBANK/HQ586080'
p69922
aS'GENBANK/HQ586081'
p69923
aS'GENBANK/HQ586082'
p69924
aS'GENBANK/HQ586083'
p69925
aS'GENBANK/HQ586084'
p69926
aS'GENBANK/HQ586085'
p69927
aS'GENBANK/HQ586086'
p69928
aS'GENBANK/HQ586087'
p69929
aS'GENBANK/HQ586088'
p69930
aS'GENBANK/HQ586089'
p69931
aS'GENBANK/HQ586090'
p69932
aS'GENBANK/HQ586091'
p69933
aS'GENBANK/HQ586092'
p69934
aS'GENBANK/HQ586093'
p69935
aS'GENBANK/HQ586094'
p69936
aS'GENBANK/HQ586095'
p69937
aS'GENBANK/HQ586096'
p69938
aS'GENBANK/HQ586097'
p69939
aS'GENBANK/HQ586098'
p69940
aS'GENBANK/HQ586099'
p69941
aS'GENBANK/HQ586100'
p69942
aS'GENBANK/HQ586101'
p69943
aS'GENBANK/HQ586102'
p69944
aS'GENBANK/HQ586103'
p69945
aS'GENBANK/HQ586104'
p69946
aS'GENBANK/HQ586105'
p69947
aS'GENBANK/HQ586106'
p69948
aS'GENBANK/HQ586107'
p69949
aS'GENBANK/HQ586108'
p69950
aS'GENBANK/HQ586109'
p69951
aS'GENBANK/HQ586110'
p69952
aS'GENBANK/HQ586111'
p69953
aS'GENBANK/HQ586112'
p69954
aS'GENBANK/HQ586113'
p69955
aS'GENBANK/HQ586114'
p69956
aS'GENBANK/HQ586115'
p69957
aS'GENBANK/HQ586116'
p69958
aS'GENBANK/HQ586117'
p69959
aS'GENBANK/HQ586118'
p69960
aS'GENBANK/HQ586119'
p69961
aS'GENBANK/HQ586120'
p69962
aS'GENBANK/HQ586121'
p69963
aS'GENBANK/HQ586122'
p69964
aS'GENBANK/HQ586123'
p69965
aS'GENBANK/HQ586124'
p69966
aS'GENBANK/HQ586125'
p69967
aS'GENBANK/HQ586126'
p69968
aS'GENBANK/HQ586127'
p69969
aS'GENBANK/HQ586128'
p69970
aS'GENBANK/HQ586129'
p69971
aS'GENBANK/HQ586130'
p69972
aS'GENBANK/HQ586131'
p69973
aS'GENBANK/HQ586132'
p69974
aS'GENBANK/HQ586133'
p69975
aS'GENBANK/HQ586134'
p69976
aS'GENBANK/HQ586135'
p69977
aS'GENBANK/HQ586136'
p69978
aS'GENBANK/HQ586137'
p69979
aS'GENBANK/HQ586138'
p69980
aS'GENBANK/HQ586139'
p69981
aS'GENBANK/HQ586140'
p69982
aS'GENBANK/HQ586141'
p69983
aS'GENBANK/HQ586142'
p69984
aS'GENBANK/HQ586143'
p69985
aS'GENBANK/HQ586144'
p69986
aS'GENBANK/HQ586145'
p69987
aS'GENBANK/HQ586146'
p69988
aS'GENBANK/HQ586147'
p69989
aS'GENBANK/HQ586148'
p69990
aS'GENBANK/HQ586149'
p69991
aS'GENBANK/HQ586150'
p69992
aS'GENBANK/HQ586151'
p69993
aS'GENBANK/HQ586152'
p69994
aS'GENBANK/HQ586153'
p69995
aS'GENBANK/HQ586154'
p69996
aS'GENBANK/HQ586155'
p69997
aS'GENBANK/HQ586156'
p69998
aS'GENBANK/HQ586157'
p69999
aS'GENBANK/HQ586158'
p70000
aS'GENBANK/HQ586159'
p70001
aS'GENBANK/HQ586160'
p70002
aS'GENBANK/HQ586161'
p70003
aS'GENBANK/HQ586162'
p70004
aS'GENBANK/HQ586163'
p70005
aS'GENBANK/HQ586164'
p70006
aS'GENBANK/HQ586165'
p70007
aS'GENBANK/HQ586166'
p70008
aS'GENBANK/HQ586167'
p70009
aS'GENBANK/HQ586168'
p70010
aS'GENBANK/HQ586169'
p70011
aS'GENBANK/HQ586170'
p70012
aS'GENBANK/HQ586171'
p70013
aS'GENBANK/HQ586172'
p70014
aS'GENBANK/HQ586173'
p70015
aS'GENBANK/HQ586174'
p70016
aS'GENBANK/HQ586175'
p70017
aS'GENBANK/HQ586176'
p70018
aS'GENBANK/HQ586177'
p70019
aS'GENBANK/HQ586178'
p70020
aS'GENBANK/HQ586179'
p70021
aS'GENBANK/HQ586180'
p70022
aS'GENBANK/HQ586181'
p70023
aS'GENBANK/HQ586182'
p70024
aS'GENBANK/HQ586183'
p70025
aS'GENBANK/HQ586184'
p70026
aS'GENBANK/HQ586185'
p70027
aS'GENBANK/HQ586186'
p70028
aS'GENBANK/HQ586187'
p70029
aS'GENBANK/HQ586188'
p70030
aS'GENBANK/HQ586189'
p70031
aS'GENBANK/HQ586190'
p70032
aS'GENBANK/HQ586191'
p70033
aS'GENBANK/HQ586192'
p70034
aS'GENBANK/HQ586193'
p70035
aS'GENBANK/HQ586194'
p70036
aS'GENBANK/HQ586195'
p70037
aS'GENBANK/HQ586196'
p70038
aS'GENBANK/HQ586197'
p70039
aS'GENBANK/HQ586198'
p70040
aS'GENBANK/HQ586199'
p70041
aS'GENBANK/HQ586200'
p70042
aS'GENBANK/HQ586201'
p70043
aS'GENBANK/HQ586202'
p70044
aS'GENBANK/HQ586203'
p70045
aS'GENBANK/HQ586204'
p70046
aS'GENBANK/HQ586205'
p70047
aS'GENBANK/HQ586206'
p70048
aS'GENBANK/HQ586207'
p70049
aS'GENBANK/HQ586208'
p70050
aS'GENBANK/HQ586209'
p70051
aS'GENBANK/HQ586210'
p70052
aS'GENBANK/HQ586211'
p70053
aS'GENBANK/HQ586212'
p70054
aS'GENBANK/HQ586213'
p70055
aS'GENBANK/HQ586214'
p70056
aS'GENBANK/HQ586215'
p70057
aS'GENBANK/HQ586216'
p70058
aS'GENBANK/HQ586217'
p70059
aS'GENBANK/HQ586218'
p70060
aS'GENBANK/HQ586219'
p70061
aS'GENBANK/HQ586220'
p70062
aS'GENBANK/HQ586221'
p70063
aS'GENBANK/HQ586222'
p70064
aS'GENBANK/HQ586223'
p70065
aS'GENBANK/HQ586224'
p70066
aS'GENBANK/HQ586225'
p70067
aS'GENBANK/HQ586226'
p70068
aS'GENBANK/HQ586227'
p70069
aS'GENBANK/HQ586228'
p70070
aS'GENBANK/HQ586229'
p70071
aS'GENBANK/HQ586230'
p70072
aS'GENBANK/HQ586231'
p70073
aS'GENBANK/HQ586232'
p70074
aS'GENBANK/HQ586233'
p70075
aS'GENBANK/HQ586234'
p70076
aS'GENBANK/HQ586235'
p70077
aS'GENBANK/HQ586236'
p70078
aS'GENBANK/HQ586237'
p70079
aS'GENBANK/HQ586238'
p70080
aS'GENBANK/HQ586239'
p70081
aS'GENBANK/HQ586240'
p70082
aS'GENBANK/HQ586241'
p70083
aS'GENBANK/HQ586242'
p70084
aS'GENBANK/HQ586243'
p70085
aS'GENBANK/HQ586244'
p70086
aS'GENBANK/HQ586245'
p70087
aS'GENBANK/HQ586246'
p70088
aS'GENBANK/HQ586247'
p70089
aS'GENBANK/HQ586248'
p70090
aS'GENBANK/HQ586249'
p70091
aS'GENBANK/HQ586250'
p70092
aS'GENBANK/HQ586251'
p70093
aS'GENBANK/HQ586252'
p70094
aS'GENBANK/HQ586253'
p70095
aS'GENBANK/HQ586254'
p70096
aS'GENBANK/HQ586255'
p70097
aS'GENBANK/HQ586256'
p70098
aS'GENBANK/HQ586257'
p70099
aS'GENBANK/HQ586258'
p70100
aS'GENBANK/HQ586259'
p70101
aS'GENBANK/HQ586260'
p70102
aS'GENBANK/HQ586261'
p70103
aS'GENBANK/HQ586262'
p70104
aS'GENBANK/HQ586263'
p70105
aS'GENBANK/HQ586264'
p70106
aS'GENBANK/HQ586265'
p70107
aS'GENBANK/HQ586266'
p70108
aS'GENBANK/HQ586267'
p70109
aS'GENBANK/HQ586268'
p70110
aS'GENBANK/HQ586269'
p70111
aS'GENBANK/HQ586270'
p70112
aS'GENBANK/HQ586271'
p70113
aS'GENBANK/HQ586272'
p70114
asS'SO'
p70115
S'J Clin Virol. 2011 Oct;52(2):123-8. doi: 10.1016/j.jcv.2011.06.014. Epub 2011 Jul 27.'
p70116
sS'SB'
p70117
S'IM'
p70118
sS'PMID'
p70119
S'21798798'
p70120
sS'PST'
p70121
S'ppublish'
p70122
stRp70123
ag2
(g3
g4
(dp70124
S'LID'
p70125
S'10.1186/1471-2431-11-67 [doi]'
p70126
sS'STAT'
p70127
S'MEDLINE'
p70128
sS'DEP'
p70129
S'20110726'
p70130
sS'DA'
p70131
S'20110920'
p70132
sS'AID'
p70133
(lp70134
S'1471-2431-11-67 [pii]'
p70135
aS'10.1186/1471-2431-11-67 [doi]'
p70136
asS'CRDT'
p70137
(lp70138
S'2011/07/28 06:00'
p70139
asS'DP'
p70140
S'2011'
p70141
sS'OWN'
p70142
S'NLM'
p70143
sS'PT'
p70144
(lp70145
S'Journal Article'
p70146
asS'LA'
p70147
(lp70148
S'eng'
p70149
asS'DCOM'
p70150
S'20120126'
p70151
sS'JT'
p70152
S'BMC pediatrics'
p70153
sS'LR'
p70154
S'20150204'
p70155
sS'FAU'
p70156
(lp70157
S'Ahoua, Laurence'
p70158
aS'Guenther, Gunar'
p70159
aS'Rouzioux, Christine'
p70160
aS'Pinoges, Loretxu'
p70161
aS'Anguzu, Paul'
p70162
aS'Taburet, Anne-Marie'
p70163
aS'Balkan, Suna'
p70164
aS'Olson, David M'
p70165
aS'Olaro, Charles'
p70166
aS'Pujades-Rodriguez, Mar'
p70167
asS'TI'
p70168
S'Immunovirological response to combined antiretroviral therapy and drug resistance patterns in children: 1- and 2-year outcomes in rural Uganda.'
p70169
sS'RN'
p70170
(lp70171
S'0 (Anti-Retroviral Agents)'
p70172
aS'0 (RNA, Viral)'
p70173
aS'0 (Reverse Transcriptase Inhibitors)'
p70174
asS'PL'
p70175
S'England'
p70176
sS'PG'
p70177
S'67'
p70178
sS'JID'
p70179
S'100967804'
p70180
sS'AB'
p70181
S'BACKGROUND: Children living with HIV continue to be in urgent need of combined antiretroviral therapy (ART). Strategies to scale up and improve pediatric HIV care in resource-poor regions, especially in sub-Saharan Africa, require further research from these settings. We describe treatment outcomes in children treated in rural Uganda after 1 and 2 years of ART start. METHODS: Cross-sectional assessment of all children treated with ART for 12 (M12) and 24 (M24) months was performed. CD4 counts, HIV RNA levels, antiretroviral resistance patterns, and non-nucleoside reverse transcriptase inhibitor (NNRTI) plasma concentrations were determined. Patient adherence and antiretroviral-related toxicity were assessed. RESULTS: Cohort probabilities of retention in care were 0.86 at both M12 and M24. At survey, 71 (83%, M12) and 32 (78%, M24) children remained on therapy, and 84% participated in the survey. At ART start, 39 (45%) were female; median age was 5 years. Median initial CD4 percent was 11% [IQR 9-15] in children < 5 years old (n = 12); CD4 count was 151 cells/mm(3) [IQR 38-188] in those >/= 5 years old (n = 26). At M12, median CD4 gains were 11% [IQR 10-14] in patients < 5 years old, and 206 cells/mm(3) [IQR 98-348] in >/= 5 years old. At M24, median CD4 gains were 11% [IQR 5-17] and 132 cells/mm(3) [IQR 87-443], respectively. Viral suppression (< 400 copies/mL) was achieved in 59% (M12) and 33% (M24) of children. Antiretroviral resistance was found in 25% (M12) and 62% (M24) of children. Overall, 29% of patients had subtherapeutic NNRTI plasma concentrations. CONCLUSIONS: After one year of therapy, satisfactory survival and immunological responses were observed, but nearly 1 in 4 children developed viral resistance and/or subtherapeutic plasma antiretroviral drug levels. Regular weight-adjustment dosing and strategies to reinforce and maintain ART adherence are essential to maximize duration of first-line therapy in children in resource-limited countries.'
p70182
sS'AD'
p70183
S'Clinical Research Department, Epicentre, Paris, France. laurence_ahoua@yahoo.fr'
p70184
sS'VI'
p70185
S'11'
p70186
sS'IS'
p70187
S'1471-2431 (Electronic) 1471-2431 (Linking)'
p70188
sS'PMC'
p70189
S'PMC3176156'
p70190
sS'AU'
p70191
(lp70192
S'Ahoua L'
p70193
aS'Guenther G'
p70194
aS'Rouzioux C'
p70195
aS'Pinoges L'
p70196
aS'Anguzu P'
p70197
aS'Taburet AM'
p70198
aS'Balkan S'
p70199
aS'Olson DM'
p70200
aS'Olaro C'
p70201
aS'Pujades-Rodriguez M'
p70202
asS'MHDA'
p70203
S'2012/01/27 06:00'
p70204
sS'PHST'
p70205
(lp70206
S'2011/05/09 [received]'
p70207
aS'2011/07/26 [accepted]'
p70208
aS'2011/07/26 [aheadofprint]'
p70209
asS'OID'
p70210
(lp70211
S'NLM: PMC3176156'
p70212
asS'MH'
p70213
(lp70214
S'Anti-Retroviral Agents/*therapeutic use'
p70215
aS'CD4 Lymphocyte Count'
p70216
aS'Child'
p70217
aS'Child, Preschool'
p70218
aS'Cohort Studies'
p70219
aS'Cross-Sectional Studies'
p70220
aS'*Drug Resistance, Viral'
p70221
aS'Drug Therapy, Combination'
p70222
aS'Female'
p70223
aS'Follow-Up Studies'
p70224
aS'HIV Infections/*drug therapy/*virology'
p70225
aS'Humans'
p70226
aS'Male'
p70227
aS'RNA, Viral/blood'
p70228
aS'Retrospective Studies'
p70229
aS'Reverse Transcriptase Inhibitors/blood'
p70230
aS'Rural Population'
p70231
aS'Uganda'
p70232
asS'EDAT'
p70233
S'2011/07/28 06:00'
p70234
sS'SO'
p70235
S'BMC Pediatr. 2011 Jul 26;11:67. doi: 10.1186/1471-2431-11-67.'
p70236
sS'SB'
p70237
S'IM'
p70238
sS'PMID'
p70239
S'21791095'
p70240
sS'TA'
p70241
S'BMC Pediatr'
p70242
sS'PST'
p70243
S'epublish'
p70244
stRp70245
ag2
(g3
g4
(dp70246
S'STAT'
p70247
S'MEDLINE'
p70248
sS'JT'
p70249
S'South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde'
p70250
sS'MID'
p70251
(lp70252
S'NIHMS519726'
p70253
asS'DA'
p70254
S'20110726'
p70255
sS'CRDT'
p70256
(lp70257
S'2011/07/27 06:00'
p70258
asS'DP'
p70259
S'2011 Apr'
p70260
sS'AD'
p70261
S'Division of General Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Mass, USA.'
p70262
sS'OWN'
p70263
S'NLM'
p70264
sS'PT'
p70265
(lp70266
S'Journal Article'
p70267
asS'LA'
p70268
(lp70269
S'eng'
p70270
asS'FAU'
p70271
(lp70272
S'Wang, Bingxia'
p70273
aS'Losina, Elena'
p70274
aS'Stark, Ruth'
p70275
aS'Munro, Alison'
p70276
aS'Walensky, Rochelle P'
p70277
aS'Wilke, Marisa'
p70278
aS'Martin, Des'
p70279
aS'Lu, Zhigang'
p70280
aS'Freedberg, Kenneth A'
p70281
aS'Wood, Robin'
p70282
asS'LR'
p70283
S'20150204'
p70284
sS'PG'
p70285
S'253-7'
p70286
sS'TI'
p70287
S'Loss to follow-up in a community clinic in South Africa--roles of gender, pregnancy and CD4 count.'
p70288
sS'RN'
p70289
(lp70290
S'0 (Anti-Retroviral Agents)'
p70291
asS'PL'
p70292
S'South Africa'
p70293
sS'TA'
p70294
S'S Afr Med J'
p70295
sS'JID'
p70296
S'0404520'
p70297
sS'AB'
p70298
S"BACKGROUND: Faith-based organisations have expanded antiretroviral therapy (ART) in community clinics across South Africa. Loss to follow-up (LTFU), however, limits the potential individual and population treatment benefits and optimal care. OBJECTIVE: To identify patient characteristics associated with LTFU 6 months after starting ART in a large community clinic. METHODS: Patients initiating ART between April 2004 and October 2006 in one South African Catholic Bishops' Conference HIV treatment clinic who had at least one follow-up visit were included and routinely monitored every 6 months after ART initiation. Standardised instruments were used to collect data. Rates of LTFU over time were estimated by the Kaplan-Meier method. The Cox proportional hazard regression examined the impact of age, baseline CD4 count, baseline HIV RNA, gender and pregnancy status on LTFU. RESULTS: Data from 925 patients (age >14 years, median age 36 years, 70% female, of whom 16% were pregnant) were included: 51 (6%) were lost to follow-up 6 months after ART initiation. Younger age (< or = 30 years) (hazard ratio (HR) 2.14, 95% confidence interval (CI) 1.05 - 4.38) and pregnancy for women (HR 3.75, 95% CI 1.53 - 9.16) were significantly associated with higher LTFU rates. When stratified by baseline CD4 count, gender and pregnancy status, pregnant women with lower baseline CD4 counts (< or = 200 cells/microl) had 6.06 times the hazard (95% CI 2.20 - 16.71) of LTFU at 6 months compared with men. CONCLUSIONS: HIV-infected pregnant women initiating ART were significantly more likely to be lost to follow-up in a community clinic in South Africa. Urgent interventions to successfully retain pregnant women in care are needed."
p70299
sS'GR'
p70300
(lp70301
S'R01 AI058736/AI/NIAID NIH HHS/United States'
p70302
asS'IP'
p70303
S'4'
sS'IS'
p70304
S'0256-9574 (Print)'
p70305
sS'PMC'
p70306
S'PMC3834586'
p70307
sS'DCOM'
p70308
S'20110811'
p70309
sS'AU'
p70310
(lp70311
S'Wang B'
p70312
aS'Losina E'
p70313
aS'Stark R'
p70314
aS'Munro A'
p70315
aS'Walensky RP'
p70316
aS'Wilke M'
p70317
aS'Martin D'
p70318
aS'Lu Z'
p70319
aS'Freedberg KA'
p70320
aS'Wood R'
p70321
asS'VI'
p70322
S'101'
p70323
sS'MHDA'
p70324
S'2011/08/13 06:00'
p70325
sS'OID'
p70326
(lp70327
S'NLM: NIHMS519726'
p70328
aS'NLM: PMC3834586'
p70329
asS'MH'
p70330
(lp70331
S'Adult'
p70332
aS'Anti-Retroviral Agents/*therapeutic use'
p70333
aS'CD4 Lymphocyte Count'
p70334
aS'*Community Health Services'
p70335
aS'*Continuity of Patient Care/organization & administration'
p70336
aS'Female'
p70337
aS'HIV Infections/blood/*drug therapy/epidemiology'
p70338
aS'Humans'
p70339
aS'Male'
p70340
aS'Pregnancy'
p70341
aS'Pregnancy Complications, Infectious/blood/drug therapy'
p70342
aS'Proportional Hazards Models'
p70343
aS'South Africa'
p70344
asS'EDAT'
p70345
S'2011/07/27 06:00'
p70346
sS'SO'
p70347
S'S Afr Med J. 2011 Apr;101(4):253-7.'
p70348
sS'SB'
p70349
S'IM'
p70350
sS'PMID'
p70351
S'21786730'
p70352
sS'PST'
p70353
S'ppublish'
p70354
stRp70355
ag2
(g3
g4
(dp70356
S'LID'
p70357
S'10.1179/1465328111Y.0000000025 [doi]'
p70358
sS'STAT'
p70359
S'MEDLINE'
p70360
sS'AB'
p70361
S'BACKGROUND: Major obstacles remain in scaling up paediatric HIV treatment, including limited paediatric anti-retroviral drug options for resource-limited settings, challenges with adherence to liquid formulations and treatment fatigue with lifelong therapy. AIM: To determine levels of adherence to HAART in HIV-infected children at 12, 24, 36 and 48 weeks of follow-up and to compare adherence levels before and after switching from syrup to fixed-dose combination (FDC)-tablet anti-retroviral formulations. METHODS: HIV-infected children aged between 6 months and 12 years were initiated on anti-retroviral therapy at Makerere University-Johns Hopkins University Care Clinic, Kampala. Good adherence to HAART was defined as taking >/=95% of prescribed medications. Adherence levels were measured using pharmacy refill data, quarterly unannounced home-visit pill counts and caregiver self-reports. Data were analysed using STATA((R)) version 10.0. RESULTS: A total of 129 HIV-infected children were initiated on HAART with 14.7% on syrups and 85.3% on tablet formulations at enrollment. According to caregiver self-reporting, 99.2%, 100%, 100% and 99.2% achieved >/=95% adherence at 12, 24, 36 and 48 weeks, respectively. Using pharmacy refill data, the proportions were 89.9%, 95.4%, 93.8% and 93.0% and for unannounced home visits were 89.8%, 92.4%, 88.9% and 86.2%, respectively. Median adherence to syrup formulations (97%, IQR 93-98) was significantly lower than for tablets (100%, IQR 97-100, p = 0.012, n = 28) using pharmacy refill data. Viral suppression correlated with home visit and pharmacy refill adherence data. CONCLUSION: The majority of children initiating HAART had good adherence when estimated by caregiver self-report and pharmacy refill data but lower adherence when measured by home-visit pill counts. Adherence to tablet formulation of HAART was significantly better than syrup formulation. Medication formulation did not significantly affect viral suppression.'
p70362
sS'JID'
p70363
S'8210625'
p70364
sS'AD'
p70365
S'Makerere University-Johns Hopkins University Research Collaboration, School of Medicine, College of Health Sciences, Kampala, Uganda. bage311@gmail.com'
p70366
sS'JT'
p70367
S'Annals of tropical paediatrics'
p70368
sS'IP'
p70369
S'3'
sS'IS'
p70370
S'1465-3281 (Electronic) 0272-4936 (Linking)'
p70371
sS'DCOM'
p70372
S'20111115'
p70373
sS'DA'
p70374
S'20110725'
p70375
sS'AU'
p70376
(lp70377
S'Bagenda A'
p70378
aS'Barlow-Mosha L'
p70379
aS'Bagenda D'
p70380
aS'Sakwa R'
p70381
aS'Fowler MG'
p70382
aS'Musoke PM'
p70383
asS'AID'
p70384
(lp70385
S'10.1179/1465328111Y.0000000025 [doi]'
p70386
asS'CRDT'
p70387
(lp70388
S'2011/07/26 06:00'
p70389
asS'VI'
p70390
S'31'
p70391
sS'PMID'
p70392
S'21781419'
p70393
sS'DP'
p70394
S'2011'
p70395
sS'MHDA'
p70396
S'2011/11/16 06:00'
p70397
sS'OWN'
p70398
S'NLM'
p70399
sS'PT'
p70400
(lp70401
S'Journal Article'
p70402
aS"Research Support, Non-U.S. Gov't"
p70403
asS'LA'
p70404
(lp70405
S'eng'
p70406
asS'MH'
p70407
(lp70408
S'Ambulatory Care Facilities'
p70409
aS'Anti-HIV Agents/*administration & dosage'
p70410
aS'Antiretroviral Therapy, Highly Active/*methods'
p70411
aS'Child'
p70412
aS'Child, Preschool'
p70413
aS'Female'
p70414
aS'Follow-Up Studies'
p70415
aS'HIV Infections/*drug therapy'
p70416
aS'Humans'
p70417
aS'Infant'
p70418
aS'Male'
p70419
aS'Medication Adherence/*statistics & numerical data'
p70420
aS'Uganda'
p70421
aS'Urban Population'
p70422
asS'FAU'
p70423
(lp70424
S'Bagenda, A'
p70425
aS'Barlow-Mosha, L'
p70426
aS'Bagenda, D'
p70427
aS'Sakwa, R'
p70428
aS'Fowler, M G'
p70429
aS'Musoke, P M'
p70430
asS'EDAT'
p70431
S'2011/07/26 06:00'
p70432
sS'PST'
p70433
S'ppublish'
p70434
sS'SO'
p70435
S'Ann Trop Paediatr. 2011;31(3):235-45. doi: 10.1179/1465328111Y.0000000025.'
p70436
sS'PG'
p70437
S'235-45'
p70438
sS'TI'
p70439
S'Adherence to tablet and liquid formulations of antiretroviral medication for paediatric HIV treatment at an urban clinic in Uganda.'
p70440
sS'SB'
p70441
S'IM'
p70442
sS'RN'
p70443
(lp70444
S'0 (Anti-HIV Agents)'
p70445
asS'PL'
p70446
S'England'
p70447
sS'TA'
p70448
S'Ann Trop Paediatr'
p70449
stRp70450
ag2
(g3
g4
(dp70451
S'LID'
p70452
S'10.7326/0003-4819-155-4-201108160-00358 [doi]'
p70453
sS'STAT'
p70454
S'MEDLINE'
p70455
sS'DEP'
p70456
S'20110718'
p70457
sS'CIN'
p70458
(lp70459
S'Ann Intern Med. 2011 Aug 16;155(4):265-6. PMID: 21768556'
p70460
asS'DA'
p70461
S'20110816'
p70462
sS'AID'
p70463
(lp70464
S'0003-4819-155-4-201108160-00358 [pii]'
p70465
aS'10.7326/0003-4819-155-4-201108160-00358 [doi]'
p70466
asS'CRDT'
p70467
(lp70468
S'2011/07/20 06:00'
p70469
asS'DP'
p70470
S'2011 Aug 16'
p70471
sS'AD'
p70472
S'University of Ottawa, Ottawa, Ontario, Canada. emills@cfenet.ubc.ca'
p70473
sS'OWN'
p70474
S'NLM'
p70475
sS'PT'
p70476
(lp70477
S'Journal Article'
p70478
aS'Research Support, N.I.H., Extramural'
p70479
aS"Research Support, Non-U.S. Gov't"
p70480
asS'LA'
p70481
(lp70482
S'eng'
p70483
asS'FAU'
p70484
(lp70485
S'Mills, Edward J'
p70486
aS'Bakanda, Celestin'
p70487
aS'Birungi, Josephine'
p70488
aS'Chan, Keith'
p70489
aS'Ford, Nathan'
p70490
aS'Cooper, Curtis L'
p70491
aS'Nachega, Jean B'
p70492
aS'Dybul, Mark'
p70493
aS'Hogg, Robert S'
p70494
asS'JT'
p70495
S'Annals of internal medicine'
p70496
sS'LR'
p70497
S'20130625'
p70498
sS'PG'
p70499
S'209-16'
p70500
sS'TI'
p70501
S'Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda.'
p70502
sS'RN'
p70503
(lp70504
S'0 (Anti-Retroviral Agents)'
p70505
asS'PL'
p70506
S'United States'
p70507
sS'TA'
p70508
S'Ann Intern Med'
p70509
sS'JID'
p70510
S'0372351'
p70511
sS'AB'
p70512
S'BACKGROUND: Little is known about the effect of combination antiretroviral therapy (cART) on life expectancy in sub-Saharan Africa. OBJECTIVE: To estimate life expectancy of patients once they initiate cART in Uganda. DESIGN: Prospective cohort study. SETTING: Public sector HIV and AIDS disease-management program in Uganda. PATIENTS: 22 315 eligible patients initiated cART during the study period, of whom 1943 were considered to have died. MEASUREMENTS: All-cause mortality rates were calculated and abridged life tables were constructed and stratified by sex and baseline CD4 cell count status to estimate life expectancies for patients receiving cART. The average number of years remaining to be lived by patients who received cART at varying age categories was estimated. RESULTS: After adjustment for loss to follow-up, crude mortality rates (deaths per 1000 person-years) ranged from 26.9 (95% CI, 25.4 to 28.5) in women to 43.9 (CI, 40.7 to 47.0) in men. For patients with a baseline CD4 cell count less than 0.050 x 10(9) cells/L, the mortality rate was 67.3 (CI, 62.1 to 72.9) deaths per 1000 person-years, whereas among persons with a baseline CD4 cell count of 0.250 x 10(9) cells/L or more, the mortality rate was 19.1 (CI, 16.0 to 22.7) deaths per 1000 person-years. Life expectancy at age 20 years for the overall cohort was 26.7 (CI, 25.0 to 28.4) additional years and at age 35 years was 27.9 (CI, 26.7 to 29.1) additional years. Life expectancy increased substantially with increasing baseline CD4 cell count. Similar trends are observed for older age groups. LIMITATIONS: A small (6.4%) proportion of patients were lost to follow-up, and it was imputed that 30% of these patients had died. Few patients with a CD4 cell count greater than 0.250 x 10(9) cells/L initiated cART. CONCLUSION: Ugandan patients receiving cART can expect an almost normal life expectancy, although there is considerable variability among subgroups of patients. PRIMARY FUNDING SOURCE: Canadian Institutes of Health Research.'
p70513
sS'GR'
p70514
(lp70515
S'Canadian Institutes of Health Research/Canada'
p70516
asS'IP'
p70517
S'4'
sS'IS'
p70518
S'1539-3704 (Electronic) 0003-4819 (Linking)'
p70519
sS'DCOM'
p70520
S'20111006'
p70521
sS'AU'
p70522
(lp70523
S'Mills EJ'
p70524
aS'Bakanda C'
p70525
aS'Birungi J'
p70526
aS'Chan K'
p70527
aS'Ford N'
p70528
aS'Cooper CL'
p70529
aS'Nachega JB'
p70530
aS'Dybul M'
p70531
aS'Hogg RS'
p70532
asS'VI'
p70533
S'155'
p70534
sS'MHDA'
p70535
S'2011/10/07 06:00'
p70536
sS'PHST'
p70537
(lp70538
S'2011/07/18 [aheadofprint]'
p70539
aS'2011/07/20 [aheadofprint]'
p70540
asS'MH'
p70541
(lp70542
S'Adolescent'
p70543
aS'Adult'
p70544
aS'Anti-Retroviral Agents/*therapeutic use'
p70545
aS'CD4 Lymphocyte Count'
p70546
aS'Cause of Death'
p70547
aS'*Developing Countries'
p70548
aS'Drug Therapy, Combination'
p70549
aS'Female'
p70550
aS'HIV Infections/*drug therapy/immunology/*mortality'
p70551
aS'Humans'
p70552
aS'Kaplan-Meier Estimate'
p70553
aS'*Life Expectancy'
p70554
aS'Male'
p70555
aS'Middle Aged'
p70556
aS'*Poverty'
p70557
aS'Proportional Hazards Models'
p70558
aS'Prospective Studies'
p70559
aS'Uganda/epidemiology'
p70560
aS'Young Adult'
p70561
asS'EDAT'
p70562
S'2011/07/20 06:00'
p70563
sS'SO'
p70564
S'Ann Intern Med. 2011 Aug 16;155(4):209-16. doi: 10.7326/0003-4819-155-4-201108160-00358. Epub 2011 Jul 18.'
p70565
sS'SB'
p70566
S'AIM IM'
p70567
sS'PMID'
p70568
S'21768555'
p70569
sS'PST'
p70570
S'ppublish'
p70571
stRp70572
ag2
(g3
g4
(dp70573
S'LID'
p70574
S'10.1016/S1473-3099(11)70167-0 [doi]'
p70575
sS'STAT'
p70576
S'MEDLINE'
p70577
sS'DEP'
p70578
S'20110719'
p70579
sS'MID'
p70580
(lp70581
S'EMS55881'
p70582
asS'DA'
p70583
S'20111031'
p70584
sS'AID'
p70585
(lp70586
S'S1473-3099(11)70167-0 [pii]'
p70587
aS'10.1016/S1473-3099(11)70167-0 [doi]'
p70588
asS'CRDT'
p70589
(lp70590
S'2011/07/19 06:00'
p70591
asS'DP'
p70592
S'2011 Nov'
p70593
sS'AD'
p70594
S'Division of Medical Microbiology and Institute for Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa. mark.nicol@uct.ac.za'
p70595
sS'OWN'
p70596
S'NLM'
p70597
sS'PT'
p70598
(lp70599
S'Comparative Study'
p70600
aS'Journal Article'
p70601
aS'Multicenter Study'
p70602
aS'Research Support, N.I.H., Extramural'
p70603
aS"Research Support, Non-U.S. Gov't"
p70604
asS'LA'
p70605
(lp70606
S'eng'
p70607
asS'FAU'
p70608
(lp70609
S'Nicol, Mark P'
p70610
aS'Workman, Lesley'
p70611
aS'Isaacs, Washiefa'
p70612
aS'Munro, Jacinta'
p70613
aS'Black, Faye'
p70614
aS'Eley, Brian'
p70615
aS'Boehme, Catharina C'
p70616
aS'Zemanay, Widaad'
p70617
aS'Zar, Heather J'
p70618
asS'JT'
p70619
S'The Lancet. Infectious diseases'
p70620
sS'LR'
p70621
S'20150204'
p70622
sS'PG'
p70623
S'819-24'
p70624
sS'TI'
p70625
S'Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study.'
p70626
sS'RN'
p70627
(lp70628
S'0 (DNA, Bacterial)'
p70629
asS'PL'
p70630
S'United States'
p70631
sS'TA'
p70632
S'Lancet Infect Dis'
p70633
sS'JID'
p70634
S'101130150'
p70635
sS'AB'
p70636
S'BACKGROUND: WHO recommends that Xpert MTB/RIF replaces smear microscopy for initial diagnosis of suspected HIV-associated tuberculosis or multidrug-resistant pulmonary tuberculosis, but no data exist for its use in children. We aimed to assess the accuracy of the test for the diagnosis of pulmonary tuberculosis in children in an area with high tuberculosis and HIV prevalences. METHODS: In this prospective, descriptive study, we enrolled children aged 15 years or younger who had been admitted to one of two hospitals in Cape Town, South Africa, with suspected pulmonary tuberculosis between Feb 19, 2009, and Nov 30, 2010. We compared the diagnostic accuracy of MTB/RIF and concentrated, fluorescent acid-fast smear with a reference standard of liquid culture from two sequential induced sputum specimens (primary analysis). RESULTS: 452 children (median age 19.4 months, IQR 11.1-46.2) had at least one induced sputum specimen; 108 children (24%) had HIV infection. 27 children (6%) had a positive smear result, 70 (16%) had a positive culture result, and 58 (13%) had a positive MTB/RIF test result. With mycobacterial culture as the reference standard, MTB/RIF tests when done on two induced sputum samples detected twice as many cases (75.9%, 95% CI 64.5-87.2) as did smear microscopy (37.9%, 25.1-50.8), detecting all of 22 smear-positive cases and 22 of 36 (61.1%, 44.4-77.8) smear-negative cases. For smear-negative cases, the incremental increase in sensitivity from testing a second specimen was 27.8% for MTB/RIF, compared with 13.8% for culture. The specificity of MTB/RIF was 98.8% (97.6-99.9). MTB/RIF results were available in median 1 day (IQR 0-4) compared with median 12 days (9-17) for culture (p<0.0001). INTERPRETATION: MTB/RIF testing of two induced sputum specimens is warranted as the first-line diagnostic test for children with suspected pulmonary tuberculosis. FUNDING: National Institutes of Health, the National Health Laboratory Service Research Trust, the Medical Research Council of South Africa, and Wellcome Trust.'
p70637
sS'GR'
p70638
(lp70639
S'085251/Wellcome Trust/United Kingdom'
p70640
aS'085251/B/08/Z/Wellcome Trust/United Kingdom'
p70641
aS'1R01HD058971-01/HD/NICHD NIH HHS/United States'
p70642
asS'IP'
p70643
S'11'
p70644
sS'IS'
p70645
S'1474-4457 (Electronic) 1473-3099 (Linking)'
p70646
sS'PMC'
p70647
S'PMC4202386'
p70648
sS'DCOM'
p70649
S'20120206'
p70650
sS'CIN'
p70651
(lp70652
S'Lancet Infect Dis. 2012 Aug;12(8):584-5. PMID: 22835891'
p70653
asS'AU'
p70654
(lp70655
S'Nicol MP'
p70656
aS'Workman L'
p70657
aS'Isaacs W'
p70658
aS'Munro J'
p70659
aS'Black F'
p70660
aS'Eley B'
p70661
aS'Boehme CC'
p70662
aS'Zemanay W'
p70663
aS'Zar HJ'
p70664
asS'VI'
p70665
S'11'
p70666
sS'MHDA'
p70667
S'2012/02/07 06:00'
p70668
sS'PHST'
p70669
(lp70670
S'2011/07/19 [aheadofprint]'
p70671
asS'OID'
p70672
(lp70673
S'NLM: EMS55881'
p70674
aS'NLM: PMC4202386'
p70675
asS'CI'
p70676
(lp70677
S'Copyright (c) 2011 Elsevier Ltd. All rights reserved.'
p70678
asS'MH'
p70679
(lp70680
S'Child, Preschool'
p70681
aS'DNA, Bacterial/chemistry/genetics'
p70682
aS'Drug Resistance, Multiple, Bacterial'
p70683
aS'Female'
p70684
aS'Humans'
p70685
aS'Infant'
p70686
aS'Male'
p70687
aS'Mycobacterium tuberculosis/*isolation & purification'
p70688
aS'Prospective Studies'
p70689
aS'Real-Time Polymerase Chain Reaction/*methods'
p70690
aS'Sensitivity and Specificity'
p70691
aS'South Africa'
p70692
aS'Sputum/microbiology'
p70693
aS'Statistics, Nonparametric'
p70694
aS'Tuberculosis, Pulmonary/*diagnosis/genetics/*microbiology'
p70695
asS'EDAT'
p70696
S'2011/07/19 06:00'
p70697
sS'SO'
p70698
S'Lancet Infect Dis. 2011 Nov;11(11):819-24. doi: 10.1016/S1473-3099(11)70167-0. Epub 2011 Jul 19.'
p70699
sS'SB'
p70700
S'IM'
p70701
sS'PMID'
p70702
S'21764384'
p70703
sS'PST'
p70704
S'ppublish'
p70705
stRp70706
ag2
(g3
g4
(dp70707
S'LID'
p70708
S'10.1007/s10461-011-9996-9 [doi]'
p70709
sS'STAT'
p70710
S'MEDLINE'
p70711
sS'JT'
p70712
S'AIDS and behavior'
p70713
sS'MID'
p70714
(lp70715
S'NIHMS536310'
p70716
asS'DA'
p70717
S'20120208'
p70718
sS'AID'
p70719
(lp70720
S'10.1007/s10461-011-9996-9 [doi]'
p70721
asS'CRDT'
p70722
(lp70723
S'2011/07/09 06:00'
p70724
asS'DP'
p70725
S'2012 Feb'
p70726
sS'AD'
p70727
S'Medical Department, Reach Out Mbuya HIV/AIDS Initiative, Kampala, Uganda. stellaalamo@gmail.com'
p70728
sS'OWN'
p70729
S'NLM'
p70730
sS'PT'
p70731
(lp70732
S'Journal Article'
p70733
aS'Research Support, N.I.H., Extramural'
p70734
asS'LA'
p70735
(lp70736
S'eng'
p70737
asS'FAU'
p70738
(lp70739
S'Alamo, Stella T'
p70740
aS'Wagner, Glenn J'
p70741
aS'Sunday, Pamela'
p70742
aS'Wanyenze, Rhoda K'
p70743
aS'Ouma, Joseph'
p70744
aS'Kamya, Moses'
p70745
aS'Colebunders, Robert'
p70746
aS'Wabwire-Mangen, Fred'
p70747
asS'LR'
p70748
S'20150204'
p70749
sS'PG'
p70750
S'368-74'
p70751
sS'TI'
p70752
S'Electronic medical records and same day patient tracing improves clinic efficiency and adherence to appointments in a community based HIV/AIDS care program, in Uganda.'
p70753
sS'PL'
p70754
S'United States'
p70755
sS'TA'
p70756
S'AIDS Behav'
p70757
sS'JID'
p70758
S'9712133'
p70759
sS'AB'
p70760
S'Patients who miss clinic appointments make unscheduled visits which compromise the ability to plan for and deliver quality care. We implemented Electronic Medical Records (EMR) and same day patient tracing to minimize missed appointments in a community-based HIV clinic in Kampala. Missed, early, on-schedule appointments and waiting times were evaluated before (pre-EMR) and 6 months after implementation of EMR and patient tracing (post-EMR). Reasons for missed appointments were documented pre and post-EMR. The mean daily number of missed appointments significantly reduced from 21 pre-EMR to 8 post-EMR. The main reason for missed appointments was forgetting (37%) but reduced significantly by 30% post-EMR. Loss to follow-up (LTFU) also significantly decreased from 10.9 to 4.8% The total median waiting time to see providers significantly decreased from 291 to 94 min. Our findings suggest that EMR and same day patient tracing can significantly reduce missed appointments, and LTFU and improve clinic efficiency.'
p70761
sS'GR'
p70762
(lp70763
S'1 R24 HD056651-01/HD/NICHD NIH HHS/United States'
p70764
aS'R24 HD056651/HD/NICHD NIH HHS/United States'
p70765
asS'IP'
p70766
S'2'
sS'IS'
p70767
S'1573-3254 (Electronic) 1090-7165 (Linking)'
p70768
sS'PMC'
p70769
S'PMC3872059'
p70770
sS'DCOM'
p70771
S'20120416'
p70772
sS'AU'
p70773
(lp70774
S'Alamo ST'
p70775
aS'Wagner GJ'
p70776
aS'Sunday P'
p70777
aS'Wanyenze RK'
p70778
aS'Ouma J'
p70779
aS'Kamya M'
p70780
aS'Colebunders R'
p70781
aS'Wabwire-Mangen F'
p70782
asS'VI'
p70783
S'16'
p70784
sS'MHDA'
p70785
S'2012/04/17 06:00'
p70786
sS'OID'
p70787
(lp70788
S'NLM: NIHMS536310'
p70789
aS'NLM: PMC3872059'
p70790
asS'MH'
p70791
(lp70792
S'Acquired Immunodeficiency Syndrome/drug therapy/*epidemiology'
p70793
aS'Adult'
p70794
aS'*Appointments and Schedules'
p70795
aS'Community Health Services/*organization & administration'
p70796
aS'Contact Tracing/methods'
p70797
aS'*Electronic Health Records'
p70798
aS'Female'
p70799
aS'Follow-Up Studies'
p70800
aS'Humans'
p70801
aS'Male'
p70802
aS'Office Visits/*statistics & numerical data'
p70803
aS'Outpatient Clinics, Hospital'
p70804
aS'Program Evaluation'
p70805
aS'Reminder Systems'
p70806
aS'Uganda/epidemiology'
p70807
asS'EDAT'
p70808
S'2011/07/09 06:00'
p70809
sS'SO'
p70810
S'AIDS Behav. 2012 Feb;16(2):368-74. doi: 10.1007/s10461-011-9996-9.'
p70811
sS'SB'
p70812
S'IM'
p70813
sS'PMID'
p70814
S'21739285'
p70815
sS'PST'
p70816
S'ppublish'
p70817
stRp70818
ag2
(g3
g4
(dp70819
S'LID'
p70820
S'10.1016/j.trstmh.2011.04.014 [doi]'
p70821
sS'STAT'
p70822
S'MEDLINE'
p70823
sS'DEP'
p70824
S'20110702'
p70825
sS'CI'
p70826
(lp70827
S'Copyright (c) 2011 Royal Society of Tropical Medicine and Hygiene. Published by'
p70828
aS'Elsevier Ltd. All rights reserved.'
p70829
asS'DA'
p70830
S'20110718'
p70831
sS'AID'
p70832
(lp70833
S'S0035-9203(11)00089-7 [pii]'
p70834
aS'10.1016/j.trstmh.2011.04.014 [doi]'
p70835
asS'CRDT'
p70836
(lp70837
S'2011/07/05 06:00'
p70838
asS'DP'
p70839
S'2011 Aug'
p70840
sS'OWN'
p70841
S'NLM'
p70842
sS'PT'
p70843
(lp70844
S'Journal Article'
p70845
aS'Multicenter Study'
p70846
aS"Research Support, Non-U.S. Gov't"
p70847
asS'LA'
p70848
(lp70849
S'eng'
p70850
asS'FAU'
p70851
(lp70852
S'Zachariah, R'
p70853
aS'Tayler-Smith, K'
p70854
aS'Manzi, M'
p70855
aS'Massaquoi, M'
p70856
aS'Mwagomba, B'
p70857
aS'van Griensven, J'
p70858
aS'van Engelgem, I'
p70859
aS'Arnould, L'
p70860
aS'Schouten, E J'
p70861
aS'Chimbwandira, F M'
p70862
aS'Harries, A D'
p70863
asS'JT'
p70864
S'Transactions of the Royal Society of Tropical Medicine and Hygiene'
p70865
sS'PG'
p70866
S'421-30'
p70867
sS'TI'
p70868
S'Retention and attrition during the preparation phase and after start of antiretroviral treatment in Thyolo, Malawi, and Kibera, Kenya: implications for programmes?'
p70869
sS'RN'
p70870
(lp70871
S'0 (Anti-HIV Agents)'
p70872
asS'PL'
p70873
S'England'
p70874
sS'TA'
p70875
S'Trans R Soc Trop Med Hyg'
p70876
sS'JID'
p70877
S'7506129'
p70878
sS'AB'
p70879
S"Among adults eligible for antiretroviral therapy (ART) in Thyolo (rural Malawi) and Kibera (Nairobi, Kenya), this study (a) reports on retention and attrition during the preparation phase and after starting ART and (b) identifies risk factors associated with attrition. 'Retention' implies being alive and on follow-up, whilst 'attrition' implies loss to follow-up, death or stopping treatment (if on ART). There were 11,309 ART-eligible patients from Malawi and 3633 from Kenya, of whom 8421 (74%) and 2792 (77%), respectively, went through the preparation phase and started ART. In Malawi, 2649 patients (23%) were lost to attrition in the preparation phase and 2189 (26%) after starting ART. Similarly, in Kenya 546 patients (15%) were lost to attrition in the ART preparation phase and 647 (23%) while on ART. Overall programme attrition was 43% (4838/11,309) for Malawi and 33% (1193/3633) for Kenya. Restricting cohort evaluation to 'on ART' (as is usually done) underestimates overall programme attrition by 38% in Malawi and 36% in Kenya. Risk factors associated with attrition in the preparation phase included male sex, age <35 years, advanced HIV/AIDS disease and increasing malnutrition. Considerable attrition occurs during the preparation phase of ART, and programme evaluations confined to on-treatment analysis significantly underestimate attrition. This has important operational implications, which are discussed here."
p70880
sS'AD'
p70881
S'Medecins sans Frontieres, Medical Department (Operational Research), Brussels Operational Center, 68 Rue de Gasperich, L-1617, Luxembourg, Luxembourg. zachariah@internet.lu'
p70882
sS'IP'
p70883
S'8'
sS'IS'
p70884
S'1878-3503 (Electronic) 0035-9203 (Linking)'
p70885
sS'DCOM'
p70886
S'20111007'
p70887
sS'AU'
p70888
(lp70889
S'Zachariah R'
p70890
aS'Tayler-Smith K'
p70891
aS'Manzi M'
p70892
aS'Massaquoi M'
p70893
aS'Mwagomba B'
p70894
aS'van Griensven J'
p70895
aS'van Engelgem I'
p70896
aS'Arnould L'
p70897
aS'Schouten EJ'
p70898
aS'Chimbwandira FM'
p70899
aS'Harries AD'
p70900
asS'VI'
p70901
S'105'
p70902
sS'MHDA'
p70903
S'2011/10/08 06:00'
p70904
sS'PHST'
p70905
(lp70906
S'2010/07/08 [received]'
p70907
aS'2011/04/19 [revised]'
p70908
aS'2011/04/19 [accepted]'
p70909
aS'2011/07/02 [aheadofprint]'
p70910
asS'MH'
p70911
(lp70912
S'Adolescent'
p70913
aS'Adult'
p70914
aS'Anti-HIV Agents/*therapeutic use'
p70915
aS'Female'
p70916
aS'HIV Infections/*drug therapy/*epidemiology'
p70917
aS'HIV-1/*drug effects'
p70918
aS'Humans'
p70919
aS'Kenya/epidemiology'
p70920
aS'Malawi/epidemiology'
p70921
aS'Male'
p70922
aS'Middle Aged'
p70923
aS'Patient Dropouts/*statistics & numerical data'
p70924
aS'Program Evaluation'
p70925
aS'Retrospective Studies'
p70926
aS'Risk Factors'
p70927
aS'Survival Analysis'
p70928
aS'Young Adult'
p70929
asS'EDAT'
p70930
S'2011/07/05 06:00'
p70931
sS'SO'
p70932
S'Trans R Soc Trop Med Hyg. 2011 Aug;105(8):421-30. doi: 10.1016/j.trstmh.2011.04.014. Epub 2011 Jul 2.'
p70933
sS'SB'
p70934
S'IM'
p70935
sS'PMID'
p70936
S'21724219'
p70937
sS'PST'
p70938
S'ppublish'
p70939
stRp70940
ag2
(g3
g4
(dp70941
S'LID'
p70942
S'10.1371/journal.pone.0020010 [doi]'
p70943
sS'STAT'
p70944
S'MEDLINE'
p70945
sS'DEP'
p70946
S'20110615'
p70947
sS'DA'
p70948
S'20110623'
p70949
sS'AID'
p70950
(lp70951
S'10.1371/journal.pone.0020010 [doi]'
p70952
aS'PONE-D-11-00516 [pii]'
p70953
asS'CRDT'
p70954
(lp70955
S'2011/06/24 06:00'
p70956
asS'DP'
p70957
S'2011'
p70958
sS'AD'
p70959
S'University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America.'
p70960
sS'OWN'
p70961
S'NLM'
p70962
sS'PT'
p70963
(lp70964
S'Journal Article'
p70965
aS'Research Support, N.I.H., Extramural'
p70966
aS"Research Support, Non-U.S. Gov't"
p70967
asS'LA'
p70968
(lp70969
S'eng'
p70970
asS'FAU'
p70971
(lp70972
S'Steele, Katherine T'
p70973
aS'Steenhoff, Andrew P'
p70974
aS'Newcomb, Craig W'
p70975
aS'Rantleru, Tumelo'
p70976
aS'Nthobatsang, Rudo'
p70977
aS'Lesetedi, Gloria'
p70978
aS'Bellamy, Scarlett L'
p70979
aS'Nachega, Jean B'
p70980
aS'Gross, Robert'
p70981
aS'Bisson, Gregory P'
p70982
asS'JT'
p70983
S'PloS one'
p70984
sS'LR'
p70985
S'20150204'
p70986
sS'PG'
p70987
S'e20010'
p70988
sS'TI'
p70989
S'Early mortality and AIDS progression despite high initial antiretroviral therapy adherence and virologic suppression in Botswana.'
p70990
sS'RN'
p70991
(lp70992
S'0 (Anti-HIV Agents)'
p70993
asS'PL'
p70994
S'United States'
p70995
sS'TA'
p70996
S'PLoS One'
p70997
sS'JID'
p70998
S'101285081'
p70999
sS'AB'
p71000
S'BACKGROUND: Adverse outcomes occurring early after antiretroviral therapy (ART) initiation are common in sub-Saharan Africa, despite reports of high levels of ART adherence in this setting. We sought to determine the relationship between very early ART adherence and early adverse outcomes in HIV-infected adults in Botswana. METHODS: This prospective cohort study of 402 ART-naive, HIV-infected adults initiating ART at a public HIV clinic in Gaborone, Botswana evaluated the relationship between suboptimal early ART adherence and HIV treatment outcomes in the initial months after ART initiation. Early adherence during the interval between initial ART dispensation and first ART refill was calculated using pill counts. In the primary analysis patients not returning to refill and those with adherence <0.95 were considered to have suboptimal early adherence. The primary outcome was death or loss to follow-up during the first 6 months of ART; a secondary composite outcome included the primary outcome plus incident opportunistic illness (OIs) and virologic failure. We also calculated the percent of early adverse outcomes theoretically attributable to suboptimal early adherence using the population attributable risk percent (PAR%). RESULTS: Suboptimal early adherence was independently associated with loss to follow-up and death (adjusted OR 2.3, 95% CI 1.1-4.8) and with the secondary composite outcome including incident OIs and virologic failure (adjusted OR 2.6, 95% CI 1.4-4.7). However, of those with early adverse outcomes, less than one-third had suboptimal adherence and approximately two-thirds achieved virologic suppression. The PAR% relating suboptimal early adherence and primary and secondary outcomes were 14.7% and 17.7%, respectively. CONCLUSIONS: Suboptimal early adherence was associated with poor outcomes, but most early adverse outcomes occurred in patients with optimal early adherence. Clinical care and research efforts should focus on understanding early adverse outcomes that occur despite optimal adherence.'
p71001
sS'GR'
p71002
(lp71003
S'P30 AI 045008/AI/NIAID NIH HHS/United States'
p71004
asS'IP'
p71005
S'6'
sS'IS'
p71006
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p71007
sS'PMC'
p71008
S'PMC3115945'
p71009
sS'DCOM'
p71010
S'20111107'
p71011
sS'AU'
p71012
(lp71013
S'Steele KT'
p71014
aS'Steenhoff AP'
p71015
aS'Newcomb CW'
p71016
aS'Rantleru T'
p71017
aS'Nthobatsang R'
p71018
aS'Lesetedi G'
p71019
aS'Bellamy SL'
p71020
aS'Nachega JB'
p71021
aS'Gross R'
p71022
aS'Bisson GP'
p71023
asS'VI'
p71024
S'6'
sS'MHDA'
p71025
S'2011/11/08 06:00'
p71026
sS'PHST'
p71027
(lp71028
S'2010/12/23 [received]'
p71029
aS'2011/04/20 [accepted]'
p71030
aS'2011/06/15 [epublish]'
p71031
asS'OID'
p71032
(lp71033
S'NLM: PMC3115945'
p71034
asS'MH'
p71035
(lp71036
S'Acquired Immunodeficiency Syndrome/*drug therapy/*mortality/physiopathology/virology'
p71037
aS'Adult'
p71038
aS'Aged'
p71039
aS'Anti-HIV Agents/*therapeutic use'
p71040
aS'Botswana'
p71041
aS'Disease Progression'
p71042
aS'Female'
p71043
aS'Humans'
p71044
aS'Male'
p71045
aS'Middle Aged'
p71046
aS'*Patient Compliance'
p71047
aS'Prospective Studies'
p71048
aS'*Viral Load'
p71049
asS'EDAT'
p71050
S'2011/06/24 06:00'
p71051
sS'SO'
p71052
S'PLoS One. 2011;6(6):e20010. doi: 10.1371/journal.pone.0020010. Epub 2011 Jun 15.'
p71053
sS'SB'
p71054
S'IM'
p71055
sS'PMID'
p71056
S'21698283'
p71057
sS'PST'
p71058
S'ppublish'
p71059
stRp71060
ag2
(g3
g4
(dp71061
S'LID'
p71062
S'10.1371/journal.pone.0021241 [doi]'
p71063
sS'STAT'
p71064
S'MEDLINE'
p71065
sS'DEP'
p71066
S'20110616'
p71067
sS'DA'
p71068
S'20110623'
p71069
sS'AID'
p71070
(lp71071
S'10.1371/journal.pone.0021241 [doi]'
p71072
aS'PONE-D-11-02053 [pii]'
p71073
asS'CRDT'
p71074
(lp71075
S'2011/06/24 06:00'
p71076
asS'DP'
p71077
S'2011'
p71078
sS'AD'
p71079
S'Department of Immunology, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe. mtshabaz@gmail.com'
p71080
sS'OWN'
p71081
S'NLM'
p71082
sS'PT'
p71083
(lp71084
S'Journal Article'
p71085
aS'Research Support, N.I.H., Extramural'
p71086
aS"Research Support, Non-U.S. Gov't"
p71087
asS'LA'
p71088
(lp71089
S'eng'
p71090
asS'FAU'
p71091
(lp71092
S'Tshabalala, Mqondisi'
p71093
aS'Manasa, Justen'
p71094
aS'Zijenah, Lynn S'
p71095
aS'Rusakaniko, Simbarashe'
p71096
aS'Kadzirange, Gerard'
p71097
aS'Mucheche, Mary'
p71098
aS'Kassaye, Seble'
p71099
aS'Johnston, Elizabeth'
p71100
aS'Katzenstein, David'
p71101
asS'JT'
p71102
S'PloS one'
p71103
sS'LR'
p71104
S'20150204'
p71105
sS'PG'
p71106
S'e21241'
p71107
sS'TI'
p71108
S'Surveillance of transmitted antiretroviral drug resistance among HIV-1 infected women attending antenatal clinics in Chitungwiza, Zimbabwe.'
p71109
sS'PL'
p71110
S'United States'
p71111
sS'TA'
p71112
S'PLoS One'
p71113
sS'JID'
p71114
S'101285081'
p71115
sS'AB'
p71116
S'The rapid scale-up of highly active antiretroviral therapy (HAART) and use of single dose Nevirapine (SD NVP) for prevention of mother-to-child transmission (pMTCT) have raised fears about the emergence of resistance to the first line antiretroviral drug regimens. A cross-sectional study was conducted to determine the prevalence of primary drug resistance (PDR) in a cohort of young (<25 yrs) HAART-naive HIV pregnant women attending antenatal clinics in Chitungwiza, Zimbabwe. Whole blood was collected in EDTA for CD4 counts, viral load, serological estimation of duration of infection using the BED Calypte assay and genotyping for drug resistance. Four hundred and seventy-one women, mean age 21 years; SD: 2.1 were enrolled into the study between 2006 and 2007. Their median CD4 count was 371cells/microL; IQR: 255-511 cells/microL. Two hundred and thirty-six samples were genotyped for drug resistance. Based on the BED assay, 27% were recently infected (RI) whilst 73% had long-term infection (LTI). Median CD4 count was higher (p<0.05) in RI than in women with LTI. Only 2 women had drug resistance mutations; protease I85V and reverse transcriptase Y181C. Prevalence of PDR in Chitungwiza, 4 years after commencement of the national ART program remained below WHO threshold limit (5%). Frequency of recent infection BED testing is consistent with high HIV acquisition during pregnancy. With the scale-up of long-term ART programs, maintenance of proper prescribing practices, continuous monitoring of patients and reinforcement of adherence may prevent the acquisition and transmission of PDR.'
p71117
sS'GR'
p71118
(lp71119
S'R01 AI060399/AI/NIAID NIH HHS/United States'
p71120
aS'U2R TW006878/TW/FIC NIH HHS/United States'
p71121
asS'IP'
p71122
S'6'
sS'IS'
p71123
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p71124
sS'PMC'
p71125
S'PMC3116901'
p71126
sS'DCOM'
p71127
S'20111107'
p71128
sS'AU'
p71129
(lp71130
S'Tshabalala M'
p71131
aS'Manasa J'
p71132
aS'Zijenah LS'
p71133
aS'Rusakaniko S'
p71134
aS'Kadzirange G'
p71135
aS'Mucheche M'
p71136
aS'Kassaye S'
p71137
aS'Johnston E'
p71138
aS'Katzenstein D'
p71139
asS'VI'
p71140
S'6'
sS'MHDA'
p71141
S'2011/11/08 06:00'
p71142
sS'PHST'
p71143
(lp71144
S'2011/01/26 [received]'
p71145
aS'2011/05/24 [accepted]'
p71146
aS'2011/06/16 [epublish]'
p71147
asS'OID'
p71148
(lp71149
S'NLM: PMC3116901'
p71150
asS'MH'
p71151
(lp71152
S'Adult'
p71153
aS'CD4 Lymphocyte Count'
p71154
aS'*Drug Resistance, Viral'
p71155
aS'Female'
p71156
aS'HIV Infections/*drug therapy/epidemiology/virology'
p71157
aS'HIV-1/isolation & purification'
p71158
aS'Humans'
p71159
aS'*Population Surveillance'
p71160
aS'Viral Load'
p71161
aS'Zimbabwe/epidemiology'
p71162
asS'EDAT'
p71163
S'2011/06/24 06:00'
p71164
sS'SO'
p71165
S'PLoS One. 2011;6(6):e21241. doi: 10.1371/journal.pone.0021241. Epub 2011 Jun 16.'
p71166
sS'SB'
p71167
S'IM'
p71168
sS'PMID'
p71169
S'21698125'
p71170
sS'PST'
p71171
S'ppublish'
p71172
stRp71173
ag2
(g3
g4
(dp71174
S'LID'
p71175
S'10.1097/QAI.0b013e318227fc34 [doi]'
p71176
sS'STAT'
p71177
S'MEDLINE'
p71178
sS'JT'
p71179
S'Journal of acquired immune deficiency syndromes (1999)'
p71180
sS'DA'
p71181
S'20110822'
p71182
sS'AID'
p71183
(lp71184
S'10.1097/QAI.0b013e318227fc34 [doi]'
p71185
asS'CRDT'
p71186
(lp71187
S'2011/06/23 06:00'
p71188
asS'DP'
p71189
S'2011 Sep 1'
p71190
sS'AD'
p71191
S'PharmAccess Foundation, Amsterdam, The Netherlands. k.sigaloff@pharmaccess.org'
p71192
sS'OWN'
p71193
S'NLM'
p71194
sS'PT'
p71195
(lp71196
S'Clinical Trial'
p71197
aS'Journal Article'
p71198
aS'Multicenter Study'
p71199
aS"Research Support, Non-U.S. Gov't"
p71200
asS'LA'
p71201
(lp71202
S'eng'
p71203
asS'FAU'
p71204
(lp71205
S'Sigaloff, Kim C E'
p71206
aS'Hamers, Raph L'
p71207
aS'Wallis, Carole L'
p71208
aS'Kityo, Cissy'
p71209
aS'Siwale, Margaret'
p71210
aS'Ive, Prudence'
p71211
aS'Botes, Mariette E'
p71212
aS'Mandaliya, Kishor'
p71213
aS'Wellington, Maureen'
p71214
aS'Osibogun, Akin'
p71215
aS'Stevens, Wendy S'
p71216
aS'van Vugt, Michele'
p71217
aS'de Wit, Tobias F Rinke'
p71218
asS'PG'
p71219
S'23-31'
p71220
sS'TI'
p71221
S'Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa.'
p71222
sS'RN'
p71223
(lp71224
S'0 (Anti-HIV Agents)'
p71225
aS'0 (RNA, Viral)'
p71226
asS'PL'
p71227
S'United States'
p71228
sS'TA'
p71229
S'J Acquir Immune Defic Syndr'
p71230
sS'JID'
p71231
S'100892005'
p71232
sS'AB'
p71233
S'OBJECTIVES: This study aimed to investigate the consequences of using clinicoimmunological criteria to detect antiretroviral treatment (ART) failure and guide regimen switches in HIV-infected adults in sub-Saharan Africa. Frequencies of unnecessary switches, patterns of HIV drug resistance, and risk factors for the accumulation of nucleoside reverse transcriptase inhibitor (NRTI)-associated mutations were evaluated. METHODS: Cross-sectional analysis of adults switching ART regimens at 13 clinical sites in 6 African countries was performed. Two types of failure identification were compared: diagnosis of clinicoimmunological failure without viral load testing (CIF only) or CIF with local targeted viral load testing (targeted VL). After study enrollment, reference HIV RNA and genotype were determined retrospectively. Logistic regression assessed factors associated with multiple thymidine analogue mutations (TAMs) and NRTI cross-resistance (>/=2 TAMs or Q151M or K65R/K70E). RESULTS: Of 250 patients with CIF switching to second-line ART, targeted VL was performed in 186. Unnecessary switch at reference HIV RNA <1000 copies per milliliter occurred in 46.9% of CIF only patients versus 12.4% of patients with targeted VL (P < 0.001). NRTI cross-resistance was observed in 48.0% of 183 specimens available for genotypic analysis, comprising >/=2 TAMs (37.7%), K65R (7.1%), K70E (3.3%), or Q151M (3.3%). The presence of NRTI cross-resistance was associated with the duration of ART exposure and zidovudine use. CONCLUSIONS: Clinicoimmunological monitoring without viral load testing resulted in frequent unnecessary regimen switches. Prolonged treatment failure was indicated by extensive NRTI cross-resistance. Access to virological monitoring should be expanded to prevent inappropriate switches, enable early failure detection and preserve second-line treatment options in Africa.'
p71234
sS'CN'
p71235
(lp71236
S'PharmAccess African Studies to Evaluate Resistance (PASER)'
p71237
asS'IP'
p71238
S'1'
sS'IS'
p71239
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p71240
sS'DCOM'
p71241
S'20111102'
p71242
sS'AU'
p71243
(lp71244
S'Sigaloff KC'
p71245
aS'Hamers RL'
p71246
aS'Wallis CL'
p71247
aS'Kityo C'
p71248
aS'Siwale M'
p71249
aS'Ive P'
p71250
aS'Botes ME'
p71251
aS'Mandaliya K'
p71252
aS'Wellington M'
p71253
aS'Osibogun A'
p71254
aS'Stevens WS'
p71255
aS'van Vugt M'
p71256
aS'de Wit TF'
p71257
asS'VI'
p71258
S'58'
p71259
sS'MHDA'
p71260
S'2011/11/04 06:00'
p71261
sS'MH'
p71262
(lp71263
S'Adult'
p71264
aS'Africa/epidemiology'
p71265
aS'Anti-HIV Agents/administration & dosage/*therapeutic use'
p71266
aS'Cohort Studies'
p71267
aS'Cross-Sectional Studies'
p71268
aS'Drug Administration Schedule'
p71269
aS'Drug Resistance, Viral/*genetics'
p71270
aS'*Drug Substitution'
p71271
aS'Female'
p71272
aS'HIV Infections/*drug therapy/epidemiology/virology'
p71273
aS'HIV-1/*drug effects/genetics'
p71274
aS'Humans'
p71275
aS'Male'
p71276
aS'Middle Aged'
p71277
aS'Mutation'
p71278
aS'RNA, Viral/blood'
p71279
aS'Treatment Failure'
p71280
aS'*Viral Load'
p71281
asS'EDAT'
p71282
S'2011/06/23 06:00'
p71283
sS'SO'
p71284
S'J Acquir Immune Defic Syndr. 2011 Sep 1;58(1):23-31. doi: 10.1097/QAI.0b013e318227fc34.'
p71285
sS'SB'
p71286
S'IM X'
p71287
sS'PMID'
p71288
S'21694603'
p71289
sS'PST'
p71290
S'ppublish'
p71291
stRp71292
ag2
(g3
g4
(dp71293
S'LID'
p71294
S'10.3851/IMP1790 [doi]'
p71295
sS'STAT'
p71296
S'MEDLINE'
p71297
sS'JT'
p71298
S'Antiviral therapy'
p71299
sS'DA'
p71300
S'20110620'
p71301
sS'AID'
p71302
(lp71303
S'10.3851/IMP1790 [doi]'
p71304
asS'CRDT'
p71305
(lp71306
S'2011/06/21 06:00'
p71307
asS'DP'
p71308
S'2011'
p71309
sS'AD'
p71310
S'Project PHIDISA, South African Military Health Service, South African National Defence Force, Pretoria, South Africa.'
p71311
sS'OWN'
p71312
S'NLM'
p71313
sS'PT'
p71314
(lp71315
S'Clinical Trial, Phase II'
p71316
aS'Journal Article'
p71317
aS'Randomized Controlled Trial'
p71318
aS'Research Support, N.I.H., Extramural'
p71319
aS'Research Support, N.I.H., Intramural'
p71320
aS"Research Support, Non-U.S. Gov't"
p71321
aS"Research Support, U.S. Gov't, Non-P.H.S."
p71322
asS'LA'
p71323
(lp71324
S'eng'
p71325
asS'FAU'
p71326
(lp71327
S'Dlamini, Judith'
p71328
aS'Ledwaba, Lotty'
p71329
aS'Mokwena, Nthabiseng'
p71330
aS'Mokhathi, Thabo'
p71331
aS'Orsega, Susan'
p71332
aS'Tsoku, Mary'
p71333
aS'Kowo, Hedwig'
p71334
aS'Proschan, Michael'
p71335
aS'Khabo, Paul'
p71336
aS'Maja, Patrick'
p71337
aS'Hadigan, Colleen'
p71338
asS'LR'
p71339
S'20150813'
p71340
sS'PG'
p71341
S'605-9'
p71342
sS'TI'
p71343
S'Lactic acidosis and symptomatic hyperlactataemia in a randomized trial of first-line therapy in HIV-infected adults in South Africa.'
p71344
sS'RN'
p71345
(lp71346
S'0 (Anti-HIV Agents)'
p71347
aS'0 (Benzoxazines)'
p71348
aS'0 (Lactates)'
p71349
aS'0 (Reverse Transcriptase Inhibitors)'
p71350
aS'2T8Q726O95 (Lamivudine)'
p71351
aS'BO9LE4QFZF (Stavudine)'
p71352
aS'JE6H2O27P8 (efavirenz)'
p71353
asS'PL'
p71354
S'England'
p71355
sS'TA'
p71356
S'Antivir Ther'
p71357
sS'JID'
p71358
S'9815705'
p71359
sS'AB'
p71360
S'BACKGROUND: Lactic acidosis (LA) is a potentially life-threatening complication of antiretroviral (ARV) therapy. Few randomized prospective studies have compared LA between different ARV regimens. METHODS: Characterization of cases of LA (serum lactate >5 mmol/l and arterial pH<7.35 or bicarbonate <20 mmol/l) and symptomatic hyperlactataemia (SH; serum lactate >2.2 mmol/l and symptoms) was made in a randomized open-label 2x2 factorial study of stavudine/lamivudine (d4T/3TC)-based versus didanosine/zidovudine-based therapy and lopinavir/ritonavir-based versus efavirenz (EFV)-based therapy in 1,771 HIV-infected adults initiating therapy between 2004 and 2008. RESULTS: The LA incident rate was 3.5/1,000 person-years (95% CI 1.8-5.9), and for combined LA/SH was 11.0/1,000 person-years (95% CI 7.9-14.9). There were two deaths (15% mortality) among 13 LA cases; all 11 survivors experienced symptom resolution and started new ARV regimens. LA cases were more likely to be female (OR 7.19, 95% CI 1.84-40.75; P=0.001) and had a higher body mass index (BMI; P<0.0001) compared with non-cases. There was no increase in LA according to ARV regimen, age or CD4(+) T-cell count at randomization. When combined, LA/SH cases (n=41) were more often female (OR 4.76, 95% CI 2.36-10.08; P<0.0001), had increased BMI (P<0.0001), were more likely to be assigned d4T/3TC (OR 3.17, 95% CI 1.50-7.28; P=0.001) and were more likely to be assigned EFV (OR 2.18, 95% CI 1.08-4.61; P=0.026). CONCLUSIONS: Female sex and increased BMI were associated with severe LA in this large randomized trial of first-line ARV in South Africa. While female sex, increased BMI and d4T are previously described risk factors for the development of clinically significant lactate elevations, the independent risk associated with EFV is a novel observation warranting further investigation.'
p71361
sS'GR'
p71362
(lp71363
S'Intramural NIH HHS/United States'
p71364
asS'IP'
p71365
S'4'
sS'IS'
p71366
S'2040-2058 (Electronic) 1359-6535 (Linking)'
p71367
sS'DCOM'
p71368
S'20111026'
p71369
sS'AU'
p71370
(lp71371
S'Dlamini J'
p71372
aS'Ledwaba L'
p71373
aS'Mokwena N'
p71374
aS'Mokhathi T'
p71375
aS'Orsega S'
p71376
aS'Tsoku M'
p71377
aS'Kowo H'
p71378
aS'Proschan M'
p71379
aS'Khabo P'
p71380
aS'Maja P'
p71381
aS'Hadigan C'
p71382
asS'VI'
p71383
S'16'
p71384
sS'MHDA'
p71385
S'2011/10/27 06:00'
p71386
sS'MH'
p71387
(lp71388
S'Acidosis, Lactic/*epidemiology/mortality'
p71389
aS'Adult'
p71390
aS'Anti-HIV Agents/administration & dosage/*adverse effects/therapeutic use'
p71391
aS'Benzoxazines/administration & dosage/adverse effects/therapeutic use'
p71392
aS'Drug Therapy, Combination'
p71393
aS'Female'
p71394
aS'HIV Infections/*drug therapy'
p71395
aS'Humans'
p71396
aS'Incidence'
p71397
aS'Lactates/*blood'
p71398
aS'Lamivudine/administration & dosage/adverse effects/therapeutic use'
p71399
aS'Male'
p71400
aS'Reverse Transcriptase Inhibitors/administration & dosage/*adverse effects/therapeutic use'
p71401
aS'South Africa/epidemiology'
p71402
aS'Stavudine/administration & dosage/adverse effects/therapeutic use'
p71403
aS'Treatment Outcome'
p71404
asS'EDAT'
p71405
S'2011/06/21 06:00'
p71406
sS'SO'
p71407
S'Antivir Ther. 2011;16(4):605-9. doi: 10.3851/IMP1790.'
p71408
sS'SB'
p71409
S'IM'
p71410
sS'PMID'
p71411
S'21685549'
p71412
sS'PST'
p71413
S'ppublish'
p71414
stRp71415
ag2
(g3
g4
(dp71416
S'LID'
p71417
S'10.1097/CCO.0b013e328349428d [doi]'
p71418
sS'STAT'
p71419
S'MEDLINE'
p71420
sS'JT'
p71421
S'Current opinion in oncology'
p71422
sS'CIN'
p71423
(lp71424
S'Curr Opin Oncol. 2011 Sep;23(5):461-2. PMID: 21788896'
p71425
asS'DA'
p71426
S'20110812'
p71427
sS'AID'
p71428
(lp71429
S'10.1097/CCO.0b013e328349428d [doi]'
p71430
asS'CRDT'
p71431
(lp71432
S'2011/06/18 06:00'
p71433
asS'DP'
p71434
S'2011 Sep'
p71435
sS'AD'
p71436
S'AIDS Malignancy Consortium, c/o The EMMES Corporation, Rockville, Maryland, USA. krowns@mskcc.org'
p71437
sS'OWN'
p71438
S'NLM'
p71439
sS'PT'
p71440
(lp71441
S'Journal Article'
p71442
aS'Research Support, N.I.H., Extramural'
p71443
aS'Review'
p71444
asS'LA'
p71445
(lp71446
S'eng'
p71447
asS'FAU'
p71448
(lp71449
S'Krown, Susan E'
p71450
asS'LR'
p71451
S'20150204'
p71452
sS'PG'
p71453
S'463-8'
p71454
sS'TI'
p71455
S'Treatment strategies for Kaposi sarcoma in sub-Saharan Africa: challenges and opportunities.'
p71456
sS'PL'
p71457
S'United States'
p71458
sS'TA'
p71459
S'Curr Opin Oncol'
p71460
sS'JID'
p71461
S'9007265'
p71462
sS'AB'
p71463
S'PURPOSE OF REVIEW: The purpose of this review is to summarize recent published literature on treatment of AIDS-associated Kaposi sarcoma, the most common HIV-associated malignancy and a leading cancer diagnosis in sub-Saharan Africa (SSA), and to highlight the challenges faced in treating Kaposi sarcoma in this resource-limited environment. RECENT FINDINGS: There are few prospective clinical trials for Kaposi sarcoma treatment in SSA, along with a relatively poor cancer treatment infrastructure, leading to late diagnosis and poor access to therapy. The only prospectively randomized trial of chemotherapy compared antiretroviral therapy (HAART) alone to HAART with combination chemotherapy with doxorubicin, bleomycin and vincristine (ABV), and documented a significantly higher rate of tumor regression for the combination along with improvement in quality of life and no adverse effects on HIV control. Other studies suggest that gemcitabine may be an active second-line chemotherapeutic agent after failure of HAART and ABV and suggest that AIDS-associated Kaposi sarcoma in children may respond well to HAART with chemotherapy. There are also (primarily retrospective) data suggesting a beneficial effect of HAART on Kaposi sarcoma, but some evidence for Kaposi sarcoma as a manifestation of immune reconstitution inflammatory syndrome. SUMMARY: Opportunities and need exist for prospective research to establish evidence-based guidelines for the most effective treatments for Kaposi sarcoma in SSA.'
p71464
sS'GR'
p71465
(lp71466
S'U01 CA121947/CA/NCI NIH HHS/United States'
p71467
aS'UO1 CA121947/CA/NCI NIH HHS/United States'
p71468
asS'IP'
p71469
S'5'
sS'IS'
p71470
S'1531-703X (Electronic) 1040-8746 (Linking)'
p71471
sS'PMC'
p71472
S'PMC3465839'
p71473
sS'DCOM'
p71474
S'20130927'
p71475
sS'MID'
p71476
(lp71477
S'NIHMS408679'
p71478
asS'AU'
p71479
(lp71480
S'Krown SE'
p71481
asS'VI'
p71482
S'23'
p71483
sS'MHDA'
p71484
S'2013/09/28 06:00'
p71485
sS'OID'
p71486
(lp71487
S'NLM: NIHMS408679'
p71488
aS'NLM: PMC3465839'
p71489
asS'MH'
p71490
(lp71491
S'AIDS-Related Opportunistic Infections/*drug therapy/epidemiology'
p71492
aS'Africa South of the Sahara'
p71493
aS'*Antiretroviral Therapy, Highly Active'
p71494
aS'Humans'
p71495
aS'Incidence'
p71496
aS'Randomized Controlled Trials as Topic'
p71497
aS'Sarcoma, Kaposi/*drug therapy/epidemiology'
p71498
asS'EDAT'
p71499
S'2011/06/18 06:00'
p71500
sS'SO'
p71501
S'Curr Opin Oncol. 2011 Sep;23(5):463-8. doi: 10.1097/CCO.0b013e328349428d.'
p71502
sS'SB'
p71503
S'IM'
p71504
sS'PMID'
p71505
S'21681092'
p71506
sS'PST'
p71507
S'ppublish'
p71508
stRp71509
ag2
(g3
g4
(dp71510
S'LID'
p71511
S'10.1097/QAD.0b013e32834957fd [doi]'
p71512
sS'STAT'
p71513
S'MEDLINE'
p71514
sS'JT'
p71515
S'AIDS (London, England)'
p71516
sS'MID'
p71517
(lp71518
S'NIHMS358778'
p71519
asS'DA'
p71520
S'20110804'
p71521
sS'AID'
p71522
(lp71523
S'10.1097/QAD.0b013e32834957fd [doi]'
p71524
asS'CRDT'
p71525
(lp71526
S'2011/06/16 06:00'
p71527
asS'DP'
p71528
S'2011 Aug 24'
p71529
sS'AD'
p71530
S'Department of Global Health, University of Washington, Seattle, 98104, USA. pkohler2@uw.edu'
p71531
sS'OWN'
p71532
S'NLM'
p71533
sS'PT'
p71534
(lp71535
S'Journal Article'
p71536
aS'Research Support, N.I.H., Extramural'
p71537
aS"Research Support, Non-U.S. Gov't"
p71538
aS"Research Support, U.S. Gov't, P.H.S."
p71539
asS'LA'
p71540
(lp71541
S'eng'
p71542
asS'FAU'
p71543
(lp71544
S'Kohler, Pamela K'
p71545
aS'Chung, Michael H'
p71546
aS'McGrath, Christine J'
p71547
aS'Benki-Nugent, Sarah F'
p71548
aS'Thiga, Joan W'
p71549
aS'John-Stewart, Grace C'
p71550
asS'LR'
p71551
S'20151119'
p71552
sS'PG'
p71553
S'1657-61'
p71554
sS'TI'
p71555
S'Implementation of free cotrimoxazole prophylaxis improves clinic retention among antiretroviral therapy-ineligible clients in Kenya.'
p71556
sS'RN'
p71557
(lp71558
S'0 (Anti-Infective Agents)'
p71559
aS'8064-90-2 (Trimethoprim, Sulfamethoxazole Drug Combination)'
p71560
asS'PL'
p71561
S'England'
p71562
sS'TA'
p71563
S'AIDS'
p71564
sS'JID'
p71565
S'8710219'
p71566
sS'AB'
p71567
S'OBJECTIVE: To determine whether implementation of free cotrimoxazole (CTX) provision was associated with improved retention among clients ineligible for antiretroviral therapy (ART) enrolled in an HIV treatment program in Kenya. DESIGN: Data were obtained from a clinical cohort for program evaluation purposes. Twelve-month clinic retention was compared among ART-ineligible clients enrolled in the time period before free CTX versus the time period after. METHODS: Statistical comparisons were made using Kaplan-Meier survival curves, log-rank tests, and multivariate Cox proportional hazards models. To exclude potential temporal program changes that may have influenced retention, ART clients before and after the same cut-off date were compared. FINDINGS: Among adult clients enrolled between 2005 and 2007, 3234 began ART within 1 year of enrollment, and 1024 of those who did not start treatment were defined as ART-ineligible. ART-ineligible clients enrolled in the period following free CTX provision had higher 12-month retention (84%) than those who enrolled prior to free CTX (63%; P < 0.001). Retention did not change significantly during these periods among ART clients (P = 0.55). In multivariate analysis, ART-ineligible clients enrolled prior to free CTX were more than twice as likely to be lost to follow-up compared to those following free CTX [adjusted hazard ratio (aHR) = 2.64, 95% confidence interval 1.95-3.57, P < 0.001]. CONCLUSION: Provision of free CTX was associated with significantly improved retention among ART-ineligible clients. Retention and CD4-monitoring of ART-ineligible clients are essential to promptly identify ART eligibility and provide treatment. Implementation of free CTX may improve retention in sub-Saharan Africa and, via increasing timely ART initiation, provide survival benefit.'
p71568
sS'GR'
p71569
(lp71570
S'K23 AI065222/AI/NIAID NIH HHS/United States'
p71571
aS'K24 HD054314/HD/NICHD NIH HHS/United States'
p71572
aS'K24 HD054314/HD/NICHD NIH HHS/United States'
p71573
aS'K24 HD054314-05/HD/NICHD NIH HHS/United States'
p71574
aS'P30 AI027757/AI/NIAID NIH HHS/United States'
p71575
aS'P30 AI027757/AI/NIAID NIH HHS/United States'
p71576
aS'P30 AI027757-13/AI/NIAID NIH HHS/United States'
p71577
aS'TL1 RR025016/RR/NCRR NIH HHS/United States'
p71578
aS'TL1RR025016/RR/NCRR NIH HHS/United States'
p71579
aS'U62/CCU024512/PHS HHS/United States'
p71580
asS'IP'
p71581
S'13'
p71582
sS'IS'
p71583
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p71584
sS'PMC'
p71585
S'PMC3383052'
p71586
sS'DCOM'
p71587
S'20111019'
p71588
sS'AU'
p71589
(lp71590
S'Kohler PK'
p71591
aS'Chung MH'
p71592
aS'McGrath CJ'
p71593
aS'Benki-Nugent SF'
p71594
aS'Thiga JW'
p71595
aS'John-Stewart GC'
p71596
asS'VI'
p71597
S'25'
p71598
sS'MHDA'
p71599
S'2011/10/20 06:00'
p71600
sS'OID'
p71601
(lp71602
S'NLM: NIHMS358778'
p71603
aS'NLM: PMC3383052'
p71604
asS'MH'
p71605
(lp71606
S'Adult'
p71607
aS'Ambulatory Care Facilities/*utilization'
p71608
aS'Anti-Infective Agents/economics/*therapeutic use'
p71609
aS'*Antibiotic Prophylaxis'
p71610
aS'CD4 Lymphocyte Count'
p71611
aS'Drug Costs'
p71612
aS'Female'
p71613
aS'HIV Infections/*drug therapy'
p71614
aS'Humans'
p71615
aS'Kaplan-Meier Estimate'
p71616
aS'Kenya'
p71617
aS'Male'
p71618
aS'Patient Compliance'
p71619
aS'Program Evaluation'
p71620
aS'Treatment Outcome'
p71621
aS'Trimethoprim, Sulfamethoxazole Drug Combination/economics/*therapeutic use'
p71622
asS'EDAT'
p71623
S'2011/06/16 06:00'
p71624
sS'SO'
p71625
S'AIDS. 2011 Aug 24;25(13):1657-61. doi: 10.1097/QAD.0b013e32834957fd.'
p71626
sS'SB'
p71627
S'IM X'
p71628
sS'PMID'
p71629
S'21673562'
p71630
sS'PST'
p71631
S'ppublish'
p71632
stRp71633
ag2
(g3
g4
(dp71634
S'LID'
p71635
S'10.1097/QAD.0b013e328349a414 [doi]'
p71636
sS'STAT'
p71637
S'MEDLINE'
p71638
sS'JT'
p71639
S'AIDS (London, England)'
p71640
sS'MID'
p71641
(lp71642
S'NIHMS492781'
p71643
asS'DA'
p71644
S'20110804'
p71645
sS'AID'
p71646
(lp71647
S'10.1097/QAD.0b013e328349a414 [doi]'
p71648
asS'CRDT'
p71649
(lp71650
S'2011/06/16 06:00'
p71651
asS'DP'
p71652
S'2011 Aug 24'
p71653
sS'AD'
p71654
S'University of Birmingham, UK.'
p71655
sS'OWN'
p71656
S'NLM'
p71657
sS'PT'
p71658
(lp71659
S'Journal Article'
p71660
aS'Research Support, N.I.H., Extramural'
p71661
aS"Research Support, Non-U.S. Gov't"
p71662
aS'Validation Studies'
p71663
asS'LA'
p71664
(lp71665
S'eng'
p71666
asS'FAU'
p71667
(lp71668
S'Abouyannis, Michael'
p71669
aS'Menten, Joris'
p71670
aS'Kiragga, Agnes'
p71671
aS'Lynen, Lutgarde'
p71672
aS'Robertson, Gavin'
p71673
aS'Castelnuovo, Barbara'
p71674
aS'Manabe, Yukari C'
p71675
aS'Reynolds, Steven J'
p71676
aS'Roberts, Lesley'
p71677
asS'LR'
p71678
S'20150325'
p71679
sS'PG'
p71680
S'1627-35'
p71681
sS'TI'
p71682
S'Development and validation of systems for rational use of viral load testing in adults receiving first-line ART in sub-Saharan Africa.'
p71683
sS'RN'
p71684
(lp71685
S'0 (Anti-Retroviral Agents)'
p71686
asS'PL'
p71687
S'England'
p71688
sS'TA'
p71689
S'AIDS'
p71690
sS'JID'
p71691
S'8710219'
p71692
sS'AB'
p71693
S'BACKGROUND: World Health Organization (WHO) immunological and clinical criteria for monitoring first-line antiretroviral treatment (ART) offer low accuracy for predicting viral failure. Targeting viral load assays to those at high risk has been recommended and a system to do this has been developed in Cambodia. Systems for use in sub-Saharan African populations were evaluated. METHODS: A new Ugandan-based scoring system for targeting viral load assays was developed from data from the first 4 years of a Ugandan cohort (N = 559) receiving first-line ART. The accuracy of this, the Cambodian system and the WHO criteria to predict viral failure, through targeting viral load assays, were compared in a separate population of 496 Ugandans. RESULTS: The new Ugandan scoring system included CD4 cell count, mean cell volume, adherence, and HIV-associated clinical events as predictors of viral failure. In the validation population, the Ugandan system undertook viral load assays in 61 (12.3%) cases offering 20.5% sensitivity and 100% positive predictive value (PPV) to predict viral failure. The Cambodian system undertook viral load assays in 33 (6.7%) cases producing 23.1% sensitivity and 90.0% PPV. WHO criteria recommended viral load assays in 72 (14.5%) cases offering 30.8% sensitivity and 100% PPV. CONCLUSION: Locally developed algorithms based on clinical and immunological criteria may offer little additional accuracy over WHO criteria for targeting viral load assays. When possible, confirming viral load before switching therapy is recommended. Scoring systems are more flexible than WHO criteria in allowing ART providers to choose the proportion of the population that undergo targeted viral load testing.'
p71694
sS'GR'
p71695
(lp71696
S'Z99 AI999999/Intramural NIH HHS/United States'
p71697
asS'IP'
p71698
S'13'
p71699
sS'IS'
p71700
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p71701
sS'PMC'
p71702
S'PMC3725464'
p71703
sS'DCOM'
p71704
S'20111019'
p71705
sS'AU'
p71706
(lp71707
S'Abouyannis M'
p71708
aS'Menten J'
p71709
aS'Kiragga A'
p71710
aS'Lynen L'
p71711
aS'Robertson G'
p71712
aS'Castelnuovo B'
p71713
aS'Manabe YC'
p71714
aS'Reynolds SJ'
p71715
aS'Roberts L'
p71716
asS'VI'
p71717
S'25'
p71718
sS'MHDA'
p71719
S'2011/10/20 06:00'
p71720
sS'OID'
p71721
(lp71722
S'NLM: NIHMS492781'
p71723
aS'NLM: PMC3725464'
p71724
asS'MH'
p71725
(lp71726
S'Adult'
p71727
aS'*Algorithms'
p71728
aS'Anti-Retroviral Agents/*therapeutic use'
p71729
aS'CD4 Lymphocyte Count'
p71730
aS'Cambodia'
p71731
aS'Drug Therapy, Combination'
p71732
aS'Female'
p71733
aS'*HIV Infections/drug therapy/immunology'
p71734
aS'Humans'
p71735
aS'Male'
p71736
aS'Prognosis'
p71737
aS'Sensitivity and Specificity'
p71738
aS'Treatment Failure'
p71739
aS'Uganda'
p71740
aS'Viral Load/*methods'
p71741
aS'World Health Organization'
p71742
asS'EDAT'
p71743
S'2011/06/16 06:00'
p71744
sS'SO'
p71745
S'AIDS. 2011 Aug 24;25(13):1627-35. doi: 10.1097/QAD.0b013e328349a414.'
p71746
sS'SB'
p71747
S'IM X'
p71748
sS'PMID'
p71749
S'21673555'
p71750
sS'PST'
p71751
S'ppublish'
p71752
stRp71753
ag2
(g3
g4
(dp71754
S'STAT'
p71755
S'MEDLINE'
p71756
sS'DEP'
p71757
S'20110614'
p71758
sS'DA'
p71759
S'20121001'
p71760
sS'AID'
p71761
(lp71762
S'1545109711406733 [pii]'
p71763
aS'10.1177/1545109711406733 [doi]'
p71764
asS'CRDT'
p71765
(lp71766
S'2011/06/16 06:00'
p71767
asS'DP'
p71768
S'2012 Sep-Oct'
p71769
sS'AD'
p71770
S'1Harvard School of Public Health, Boston, MA, USA.'
p71771
sS'OWN'
p71772
S'NLM'
p71773
sS'PT'
p71774
(lp71775
S'Journal Article'
p71776
aS'Observational Study'
p71777
aS"Research Support, Non-U.S. Gov't"
p71778
asS'LA'
p71779
(lp71780
S'eng'
p71781
asS'FAU'
p71782
(lp71783
S'Chalamilla, Guerino'
p71784
aS'Hawkins, Claudia'
p71785
aS'Okuma, James'
p71786
aS'Spiegelman, Donna'
p71787
aS'Aveika, Akum'
p71788
aS'Christian, Beatrice'
p71789
aS'Koda, Happiness'
p71790
aS'Kaaya, Sylvia'
p71791
aS'Mtasiwa, Deo'
p71792
aS'Fawzi, Wafaie'
p71793
asS'JT'
p71794
S'Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)'
p71795
sS'PG'
p71796
S'296-304'
p71797
sS'TI'
p71798
S'Mortality and treatment failure among HIV-infected adults in Dar Es Salaam, Tanzania.'
p71799
sS'RN'
p71800
(lp71801
S'0 (Anti-HIV Agents)'
p71802
aS'0 (Hemoglobins)'
p71803
aS'BO9LE4QFZF (Stavudine)'
p71804
asS'PL'
p71805
S'United States'
p71806
sS'TA'
p71807
S'J Int Assoc Physicians AIDS Care (Chic)'
p71808
sS'JID'
p71809
S'101185740'
p71810
sS'AB'
p71811
S'OBJECTIVES: Monitoring antiretroviral treatment (ART) outcomes is essential for assessing the success of HIV care and treatment programs in resource-limited settings (RLS). METHODS: Longitudinal analyses of clinical and immunologic parameters in HIV-infected adults initiated on ART between November 2004 and June 2008 at Management and Development for Health (MDH)-Presidents Emergency Plan For AIDS Relief PEPFAR supported HIV care and treatment clinics in Tanzania. RESULTS: A total of 12 842 patients were analyzed (65.9% female, median baseline CD4 count, 106 cells/mm(3)). Significant improvements in immunologic status were observed with an increase in CD4 count to 298 (interquartile range [IQR] 199-416), 372 (256-490) and 427 (314-580) cells/mm(3), at 1, 2, and 3 years, respectively. Overall mortality was 13.1% (1682 of 12 842). Male sex, World Health Organization (WHO) stage III/IV, CD4 <200 cells/mm(3), hemoglobin (Hgb) <8.5 g/dL, and stavudine (d4T)-containing regimens were independently associated with early and overall mortality. CONCLUSIONS: Closer monitoring of males and patients with advanced HIV disease following ART initiation may improve clinical and immunologic outcomes in these individuals.'
p71812
sS'CN'
p71813
(lp71814
S'MDH Tanzania HIV/AIDS Program'
p71815
asS'IP'
p71816
S'5'
sS'IS'
p71817
S'1545-1097 (Print) 1545-1097 (Linking)'
p71818
sS'DCOM'
p71819
S'20140204'
p71820
sS'AU'
p71821
(lp71822
S'Chalamilla G'
p71823
aS'Hawkins C'
p71824
aS'Okuma J'
p71825
aS'Spiegelman D'
p71826
aS'Aveika A'
p71827
aS'Christian B'
p71828
aS'Koda H'
p71829
aS'Kaaya S'
p71830
aS'Mtasiwa D'
p71831
aS'Fawzi W'
p71832
asS'VI'
p71833
S'11'
p71834
sS'MHDA'
p71835
S'2014/02/05 06:00'
p71836
sS'PHST'
p71837
(lp71838
S'2011/06/14 [aheadofprint]'
p71839
asS'MH'
p71840
(lp71841
S'Adult'
p71842
aS'Anti-HIV Agents/*therapeutic use'
p71843
aS'CD4 Lymphocyte Count'
p71844
aS'*Developing Countries'
p71845
aS'Drug Therapy, Combination'
p71846
aS'Female'
p71847
aS'HIV Infections/*drug therapy/immunology/*mortality'
p71848
aS'Hemoglobins/metabolism'
p71849
aS'Humans'
p71850
aS'Male'
p71851
aS'Middle Aged'
p71852
aS'Prospective Studies'
p71853
aS'Risk Factors'
p71854
aS'Sex Factors'
p71855
aS'Stavudine/therapeutic use'
p71856
aS'Tanzania/epidemiology'
p71857
aS'*Treatment Failure'
p71858
asS'EDAT'
p71859
S'2011/06/16 06:00'
p71860
sS'SO'
p71861
S'J Int Assoc Physicians AIDS Care (Chic). 2012 Sep-Oct;11(5):296-304. Epub 2011 Jun 14.'
p71862
sS'SB'
p71863
S'IM'
p71864
sS'PMID'
p71865
S'21673195'
p71866
sS'PST'
p71867
S'ppublish'
p71868
stRp71869
ag2
(g3
g4
(dp71870
S'LID'
p71871
S'10.1097/QAD.0b013e32834957da [doi]'
p71872
sS'STAT'
p71873
S'MEDLINE'
p71874
sS'JT'
p71875
S'AIDS (London, England)'
p71876
sS'MID'
p71877
(lp71878
S'NIHMS446156'
p71879
asS'DA'
p71880
S'20110804'
p71881
sS'AID'
p71882
(lp71883
S'10.1097/QAD.0b013e32834957da [doi]'
p71884
asS'CRDT'
p71885
(lp71886
S'2011/06/08 06:00'
p71887
asS'DP'
p71888
S'2011 Aug 24'
p71889
sS'AD'
p71890
S'Center for Global Health and Development, Boston University, Massachusetts, USA. abrennan@bu.edu'
p71891
sS'OWN'
p71892
S'NLM'
p71893
sS'PT'
p71894
(lp71895
S'Journal Article'
p71896
aS'Research Support, N.I.H., Extramural'
p71897
aS"Research Support, Non-U.S. Gov't"
p71898
asS'LA'
p71899
(lp71900
S'eng'
p71901
asS'FAU'
p71902
(lp71903
S'Brennan, Alana'
p71904
aS'Evans, Denise'
p71905
aS'Maskew, Mhairi'
p71906
aS'Naicker, Saraladevi'
p71907
aS'Ive, Prudence'
p71908
aS'Sanne, Ian'
p71909
aS'Maotoe, Thapelo'
p71910
aS'Fox, Matthew'
p71911
asS'LR'
p71912
S'20151119'
p71913
sS'PG'
p71914
S'1603-9'
p71915
sS'TI'
p71916
S'Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir.'
p71917
sS'RN'
p71918
(lp71919
S'0 (Anti-HIV Agents)'
p71920
aS'0 (Organophosphonates)'
p71921
aS'99YXE507IL (Tenofovir)'
p71922
aS'AYI8EX34EU (Creatinine)'
p71923
aS'JAC85A2161 (Adenine)'
p71924
asS'PL'
p71925
S'England'
p71926
sS'TA'
p71927
S'AIDS'
p71928
sS'JID'
p71929
S'8710219'
p71930
sS'AB'
p71931
S'OBJECTIVE: In April 2010, the South African government added tenofovir disoproxil fumarate to its first-line antiretroviral therapy (ART) for HIV patients. We analyzed the relationship between renal dysfunction at tenofovir initiation, nephrotoxicity and mortality. DESIGN: Cohort analysis of HIV-infected adults who received tenofovir and had a creatinine clearance done at initiation at the Themba Lethu Clinic, Johannesburg, South Africa, between April 2004 and September 2009. METHODS: We estimated the relationship between renal dysfunction, nephrotoxicity [any decline in kidney function from baseline (acute or chronic) that is secondary to a toxin (including drugs)] and mortality for patients initiated onto tenofovir-containing regimens using marginal structural models and inverse probability of treatment weights to correct estimates for lost to follow-up and confounding. RESULTS: Of 890 patients initiated onto tenofovir, 573 (64.4%) had normal renal function (>/=90 ml/min), 271 (30.4%) had mild renal dysfunction (60-89 ml/min) and 46 (5.2%) had moderate renal dysfunction (30-59 ml/min). A total of 2.4% experienced nephrotoxicity, 7.8% died and 9.7% were lost during 48 months of follow-up. Patients with mild [hazard ratio 4.8; 95% confidence interval (CI) 1.5-15.2] or moderate (hazard ratio 15.0; 95% CI 3.4-66.5) renal dysfunction were at greatest risk of nephrotoxicity, whereas those with mild (hazard ratio 1.2; 95% CI 0.7-2.3) or moderate (hazard ratio 3.2; 95% CI 1.3-7.8) renal dysfunction vs. normal renal function were at highest risk of death by 48 months. CONCLUSION: Much of the incident renal dysfunction in tenofovir patients is likely related to preexisting renal disorder, which may be exacerbated by tenofovir. With expanded use of tenofovir, screening for renal dysfunction prior to initiation and dose adjustment is necessary to help improve ART outcomes.'
p71932
sS'GR'
p71933
(lp71934
S'K01 AI083097/AI/NIAID NIH HHS/United States'
p71935
aS'K01AI083097/AI/NIAID NIH HHS/United States'
p71936
aS'P30 AI50410/AI/NIAID NIH HHS/United States'
p71937
asS'IP'
p71938
S'13'
p71939
sS'IS'
p71940
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p71941
sS'PMC'
p71942
S'PMC3586413'
p71943
sS'DCOM'
p71944
S'20111019'
p71945
sS'AU'
p71946
(lp71947
S'Brennan A'
p71948
aS'Evans D'
p71949
aS'Maskew M'
p71950
aS'Naicker S'
p71951
aS'Ive P'
p71952
aS'Sanne I'
p71953
aS'Maotoe T'
p71954
aS'Fox M'
p71955
asS'VI'
p71956
S'25'
p71957
sS'MHDA'
p71958
S'2011/10/20 06:00'
p71959
sS'OID'
p71960
(lp71961
S'NLM: NIHMS446156'
p71962
aS'NLM: PMC3586413'
p71963
asS'MH'
p71964
(lp71965
S'Adenine/adverse effects/*analogs & derivatives'
p71966
aS'Adult'
p71967
aS'Anti-HIV Agents/*adverse effects'
p71968
aS'Cohort Studies'
p71969
aS'Creatinine/urine'
p71970
aS'Female'
p71971
aS'HIV Infections/*drug therapy'
p71972
aS'Humans'
p71973
aS'Kidney/drug effects/*physiopathology'
p71974
aS'Male'
p71975
aS'Middle Aged'
p71976
aS'Organophosphonates/*adverse effects'
p71977
aS'*Renal Insufficiency/chemically induced/mortality'
p71978
aS'Risk Factors'
p71979
aS'South Africa/epidemiology'
p71980
aS'Tenofovir'
p71981
asS'EDAT'
p71982
S'2011/06/08 06:00'
p71983
sS'SO'
p71984
S'AIDS. 2011 Aug 24;25(13):1603-9. doi: 10.1097/QAD.0b013e32834957da.'
p71985
sS'SB'
p71986
S'IM X'
p71987
sS'PMID'
p71988
S'21646902'
p71989
sS'PST'
p71990
S'ppublish'
p71991
stRp71992
ag2
(g3
g4
(dp71993
S'LID'
p71994
S'10.1097/QAD.0b013e3283492180 [doi]'
p71995
sS'STAT'
p71996
S'MEDLINE'
p71997
sS'JT'
p71998
S'AIDS (London, England)'
p71999
sS'MID'
p72000
(lp72001
S'NIHMS306707'
p72002
asS'DA'
p72003
S'20110712'
p72004
sS'AID'
p72005
(lp72006
S'10.1097/QAD.0b013e3283492180 [doi]'
p72007
asS'CRDT'
p72008
(lp72009
S'2011/06/03 06:00'
p72010
asS'DP'
p72011
S'2011 Jul 31'
p72012
sS'AD'
p72013
S'AIDS Virus Research Unit, National Institute for Communicable Diseases, Johannesburg, South Africa. gillianh@nicd.ac.za'
p72014
sS'OWN'
p72015
S'NLM'
p72016
sS'PT'
p72017
(lp72018
S'Journal Article'
p72019
aS'Research Support, N.I.H., Extramural'
p72020
aS"Research Support, Non-U.S. Gov't"
p72021
asS'LA'
p72022
(lp72023
S'eng'
p72024
asS'FAU'
p72025
(lp72026
S'Hunt, Gillian M'
p72027
aS'Coovadia, Ashraf'
p72028
aS'Abrams, Elaine J'
p72029
aS'Sherman, Gayle'
p72030
aS'Meyers, Tammy'
p72031
aS'Morris, Lynn'
p72032
aS'Kuhn, Louise'
p72033
asS'LR'
p72034
S'20150825'
p72035
sS'PG'
p72036
S'1461-9'
p72037
sS'TI'
p72038
S'HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine.'
p72039
sS'RN'
p72040
(lp72041
S'0 (RNA, Viral)'
p72042
aS'99DK7FVK1H (Nevirapine)'
p72043
asS'PL'
p72044
S'England'
p72045
sS'TA'
p72046
S'AIDS'
p72047
sS'JID'
p72048
S'8710219'
p72049
sS'AB'
p72050
S'OBJECTIVE: To describe the prevalence of HIV-1 drug resistance mutations at the time of treatment initiation in a large cohort of HIV-infected children previously exposed to single-dose nevirapine (sdNVP) for prevention of transmission. DESIGN: Drug resistance mutations were measured pretreatment in 255 infants and young children under 2 years of age in South Africa exposed to sdNVP and initiating ritonavir-boosted lopinavir-based therapy. Those who achieved viral suppression were randomized to either continue the primary regimen or to switch to a nevirapine-based regimen. Pretreatment samples were tested using population sequencing and real time allele-specific PCR (AS-PCR) to detect Y181C and K103N minority variants. Those with confirmed viremia more than 1000 copies/ml by 52 weeks postrandomization in the switch group were defined as having viral failure. RESULTS: Nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations, predominantly Y181C, were detected by either method in 62% of infants less than 6 months of age, in 39% of children 6-12 months of age, 22% 12-18 months, and 16% 18-24 months (P = <0.0001). NNRTI mutations detected by genotyping, but not K103N or Y181C mutations detected only by AS-PCR, were associated with viral failure in the switch group. CONCLUSION: The prevalence of mutations known to compromise primary NNRTI-based therapy is high in sdNVP-exposed children, supporting current guidelines recommending use of protease inhibitor-based regimens for young children. Standard genotyping is adequate to identify children who could benefit from switching to NNRTI-based therapy.'
p72051
sS'GR'
p72052
(lp72053
S'HD 47177/HD/NICHD NIH HHS/United States'
p72054
aS'R01 HD047177/HD/NICHD NIH HHS/United States'
p72055
aS'R01 HD047177-01A1/HD/NICHD NIH HHS/United States'
p72056
aS'R01 HD047177-02/HD/NICHD NIH HHS/United States'
p72057
aS'R01 HD047177-03/HD/NICHD NIH HHS/United States'
p72058
aS'R01 HD047177-04/HD/NICHD NIH HHS/United States'
p72059
aS'R01 HD047177-05/HD/NICHD NIH HHS/United States'
p72060
asS'IP'
p72061
S'12'
p72062
sS'IS'
p72063
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p72064
sS'PMC'
p72065
S'PMC4547386'
p72066
sS'DCOM'
p72067
S'20110914'
p72068
sS'AU'
p72069
(lp72070
S'Hunt GM'
p72071
aS'Coovadia A'
p72072
aS'Abrams EJ'
p72073
aS'Sherman G'
p72074
aS'Meyers T'
p72075
aS'Morris L'
p72076
aS'Kuhn L'
p72077
asS'VI'
p72078
S'25'
p72079
sS'MHDA'
p72080
S'2011/09/15 06:00'
p72081
sS'OID'
p72082
(lp72083
S'NLM: NIHMS306707'
p72084
aS'NLM: PMC4547386'
p72085
asS'MH'
p72086
(lp72087
S'Drug Administration Schedule'
p72088
aS'Drug Resistance, Viral/drug effects/genetics/*immunology'
p72089
aS'Female'
p72090
aS'Genotype'
p72091
aS'HIV Infections/drug therapy/genetics/*immunology/transmission'
p72092
aS'HIV-1/drug effects/*immunology'
p72093
aS'Humans'
p72094
aS'Infant'
p72095
aS'Infectious Disease Transmission, Vertical'
p72096
aS'Male'
p72097
aS'Nevirapine/administration & dosage/*immunology'
p72098
aS'Polymerase Chain Reaction'
p72099
aS'Prevalence'
p72100
aS'RNA, Viral'
p72101
aS'South Africa'
p72102
aS'Treatment Outcome'
p72103
aS'Viral Load'
p72104
asS'EDAT'
p72105
S'2011/06/03 06:00'
p72106
sS'SO'
p72107
S'AIDS. 2011 Jul 31;25(12):1461-9. doi: 10.1097/QAD.0b013e3283492180.'
p72108
sS'SB'
p72109
S'IM X'
p72110
sS'PMID'
p72111
S'21633285'
p72112
sS'PST'
p72113
S'ppublish'
p72114
stRp72115
ag2
(g3
g4
(dp72116
S'LID'
p72117
S'10.1371/journal.pone.0019566 [doi]'
p72118
sS'STAT'
p72119
S'MEDLINE'
p72120
sS'DEP'
p72121
S'20110518'
p72122
sS'DA'
p72123
S'20110525'
p72124
sS'AID'
p72125
(lp72126
S'10.1371/journal.pone.0019566 [doi]'
p72127
aS'PONE-D-10-05380 [pii]'
p72128
asS'CRDT'
p72129
(lp72130
S'2011/05/26 06:00'
p72131
asS'DP'
p72132
S'2011'
p72133
sS'OWN'
p72134
S'NLM'
p72135
sS'PT'
p72136
(lp72137
S'Journal Article'
p72138
aS"Research Support, Non-U.S. Gov't"
p72139
asS'LA'
p72140
(lp72141
S'eng'
p72142
asS'FAU'
p72143
(lp72144
S'Lorent, Natalie'
p72145
aS'Sebatunzi, Osee'
p72146
aS'Mukeshimana, Gloria'
p72147
aS'Van den Ende, Jef'
p72148
aS'Clerinx, Joannes'
p72149
asS'JT'
p72150
S'PloS one'
p72151
sS'LR'
p72152
S'20150204'
p72153
sS'PG'
p72154
S'e19566'
p72155
sS'TI'
p72156
S'Incidence and risk factors of serious adverse events during antituberculous treatment in Rwanda: a prospective cohort study.'
p72157
sS'RN'
p72158
(lp72159
S'0 (Antitubercular Agents)'
p72160
asS'PL'
p72161
S'United States'
p72162
sS'TA'
p72163
S'PLoS One'
p72164
sS'JID'
p72165
S'101285081'
p72166
sS'AB'
p72167
S'BACKGROUND: Tuberculosis (TB) and TB-human immunodeficiency virus infection (HIV) coinfection is a major public health concern in resource-limited settings. Although TB treatment is challenging in HIV-infected patients because of treatment interactions, immunopathological reactions, and concurrent infections, few prospective studies have addressed this in sub-Saharan Africa. In this study we aimed to determine incidence, causes of, and risk factors for serious adverse events among patients on first-line antituberculous treatment, as well as its impact on antituberculous treatment outcome. METHODS AND FINDINGS: Prospective observational cohort study of adults treated for TB at the Internal Medicine department of the Kigali University Hospital from May 2008 through August 2009. Of 263 patients enrolled, 253 were retained for analysis: median age 35 (Interquartile range, IQR 28-40), 55% male, 66% HIV-positive with a median CD4 count 104 cells/mm(3) (IQR 44-248 cells/mm(3)). Forty percent had pulmonary TB, 43% extrapulmonary TB and 17% a mixed form. Sixty-four (26%) developed a serious adverse event; 58/167 (35%) HIV-infected vs. 6/86 (7%) HIV-uninfected individuals. Commonest events were concurrent infection (n = 32), drug-induced hepatitis (n = 24) and paradoxical reactions/TB-IRIS (n = 23). HIV-infection (adjusted Hazard Ratio, aHR 3.4, 95% Confidence Interval, CI 1.4-8.7) and extrapulmonary TB (aHR 2, 95%CI 1.1-3.7) were associated with an increased risk of serious adverse events. For TB/HIV co-infected patients, extrapulmonary TB (aHR 2.0, 95%CI 1.1-3.9) and CD4 count <100 cells/mm3 at TB diagnosis (aHR 1.7, 95%CI 1.0-2.9) were independent predictors. Adverse events were associated with an almost two-fold higher risk of unsuccessful treatment outcome at 6 months (HR 1.89, 95%CI 1.3-3.0). CONCLUSION: Adverse events frequently complicate the course of antituberculous treatment and worsen treatment outcome, particularly in patients with extrapulmonary TB and advanced immunodeficiency. Concurrent infection accounts for most events. Our data suggest that deterioration in a patient already receiving antituberculous treatment should prompt an aggressive search for additional infections.'
p72168
sS'AD'
p72169
S'Internal Medicine Department, Centre Hospitalier Universitaire de Kigali, Kigali, Rwanda. nlorent@itg.be'
p72170
sS'IP'
p72171
S'5'
sS'IS'
p72172
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p72173
sS'PMC'
p72174
S'PMC3097195'
p72175
sS'DCOM'
p72176
S'20110912'
p72177
sS'AU'
p72178
(lp72179
S'Lorent N'
p72180
aS'Sebatunzi O'
p72181
aS'Mukeshimana G'
p72182
aS'Van den Ende J'
p72183
aS'Clerinx J'
p72184
asS'VI'
p72185
S'6'
sS'MHDA'
p72186
S'2011/09/13 06:00'
p72187
sS'PHST'
p72188
(lp72189
S'2010/11/24 [received]'
p72190
aS'2011/04/11 [accepted]'
p72191
aS'2011/05/18 [epublish]'
p72192
asS'OID'
p72193
(lp72194
S'NLM: PMC3097195'
p72195
asS'MH'
p72196
(lp72197
S'Adult'
p72198
aS'Antitubercular Agents/*adverse effects/*therapeutic use'
p72199
aS'Female'
p72200
aS'Follow-Up Studies'
p72201
aS'HIV Infections/complications'
p72202
aS'Humans'
p72203
aS'Incidence'
p72204
aS'Kaplan-Meier Estimate'
p72205
aS'Male'
p72206
aS'Multivariate Analysis'
p72207
aS'Prospective Studies'
p72208
aS'Risk Factors'
p72209
aS'Rwanda/epidemiology'
p72210
aS'Tuberculosis/complications/*drug therapy/*epidemiology'
p72211
asS'EDAT'
p72212
S'2011/05/26 06:00'
p72213
sS'SO'
p72214
S'PLoS One. 2011;6(5):e19566. doi: 10.1371/journal.pone.0019566. Epub 2011 May 18.'
p72215
sS'SB'
p72216
S'IM'
p72217
sS'PMID'
p72218
S'21611117'
p72219
sS'PST'
p72220
S'ppublish'
p72221
stRp72222
ag2
(g3
g4
(dp72223
S'LID'
p72224
S'10.1097/QAI.0b013e318221863f [doi]'
p72225
sS'STAT'
p72226
S'MEDLINE'
p72227
sS'AB'
p72228
S'BACKGROUND: Data on the prevalence of the complications of antiretroviral therapy (ART) (diabetes, central fat accumulation, peripheral fat wasting, and dyslipidemia) in sub-Saharan Africa are sparse. We examined the prevalence and associated risk factors of dysglycemia and insulin sensitivity in HIV-infected South Africans. METHODS: HIV-infected patients, on nonnucleoside reverse transcriptase inhibitor-based ART or ART-naive, had oral glucose tolerance tests and clinical anthropometry. Insulin sensitivity and beta-cell function were assessed. RESULTS: The prevalence of dysglycemia in 406 ART-naive patients and 443 patients on ART was 25.7% and 21.9% (P = 0.193), respectively. Dysglycemic patients on ART had a similar body mass index (P = 0.440), greater waist circumference (P = 0.047), and smaller calf skinfold thickness (P = 0.015) than dysglycemic ART-naive patients but no difference in beta-cell function or insulin sensitivity. Normoglycemic patients on ART had a greater body mass index (P = 0.0009), waist circumference (P = 0.0001), and abdominal skinfold thickness (P = 0.040), similar calf skinfold thickness (P = 0.079), and reduced beta-cell function [lower insulinogenic index (P = 0.027) and oral disposition index (D(o), P = 0.020)] compared with normoglycemic ART-naive patients. In multivariate analysis, older age [odds ratio (OR): 1.04, 95% confidence interval (CI): 1.02 to 1.06], male gender (OR: 1.96, 95% CI: 1.28 to 2.99), higher CD4 count (OR: 1.0, 95% CI: 1.00 to 1.02) and use of efavirenz (OR: 1.70, 95% CI: 1.19 to 2.45) were associated with dysglycemia. CONCLUSIONS: The prevalence of dysglycemia in ART-naive and ART patients was similar. Peripheral fat wasting was more common in dysglycemic patients on ART. The association of efavirenz with dysglycemia is important because first-line ART regimens in the developing world include nonnucleoside reverse transcriptase inhibitors, and increasingly, efavirenz is selected because of its perceived lower toxicity than nevirapine.'
p72229
sS'JID'
p72230
S'100892005'
p72231
sS'AD'
p72232
S'Division of Diabetic Medicine and Endocrinology, Department of Medicine, University of Cape Town, Cape Town, South Africa. joel.dave@uct.ac.za'
p72233
sS'JT'
p72234
S'Journal of acquired immune deficiency syndromes (1999)'
p72235
sS'IP'
p72236
S'4'
sS'IS'
p72237
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p72238
sS'DCOM'
p72239
S'20111024'
p72240
sS'DA'
p72241
S'20110822'
p72242
sS'AU'
p72243
(lp72244
S'Dave JA'
p72245
aS'Lambert EV'
p72246
aS'Badri M'
p72247
aS'West S'
p72248
aS'Maartens G'
p72249
aS'Levitt NS'
p72250
asS'AID'
p72251
(lp72252
S'10.1097/QAI.0b013e318221863f [doi]'
p72253
asS'CRDT'
p72254
(lp72255
S'2011/05/24 06:00'
p72256
asS'VI'
p72257
S'57'
p72258
sS'PMID'
p72259
S'21602696'
p72260
sS'DP'
p72261
S'2011 Aug 1'
p72262
sS'MHDA'
p72263
S'2011/10/25 06:00'
p72264
sS'OWN'
p72265
S'NLM'
p72266
sS'PT'
p72267
(lp72268
S'Journal Article'
p72269
aS"Research Support, Non-U.S. Gov't"
p72270
asS'LA'
p72271
(lp72272
S'eng'
p72273
asS'MH'
p72274
(lp72275
S'Adult'
p72276
aS'Anti-HIV Agents/*adverse effects/therapeutic use'
p72277
aS'Blood Glucose/*drug effects'
p72278
aS'Female'
p72279
aS'HIV Infections/*drug therapy/epidemiology'
p72280
aS'Humans'
p72281
aS'Hyperglycemia/*chemically induced/epidemiology'
p72282
aS'*Insulin Resistance'
p72283
aS'Male'
p72284
aS'Multivariate Analysis'
p72285
aS'Prevalence'
p72286
aS'Reverse Transcriptase Inhibitors/*adverse effects/therapeutic use'
p72287
aS'Risk Factors'
p72288
aS'South Africa/epidemiology'
p72289
asS'FAU'
p72290
(lp72291
S'Dave, Joel A'
p72292
aS'Lambert, Estelle V'
p72293
aS'Badri, Motasim'
p72294
aS'West, Sacha'
p72295
aS'Maartens, Gary'
p72296
aS'Levitt, Naomi S'
p72297
asS'EDAT'
p72298
S'2011/05/24 06:00'
p72299
sS'PST'
p72300
S'ppublish'
p72301
sS'SO'
p72302
S'J Acquir Immune Defic Syndr. 2011 Aug 1;57(4):284-9. doi: 10.1097/QAI.0b013e318221863f.'
p72303
sS'PG'
p72304
S'284-9'
p72305
sS'TI'
p72306
S'Effect of nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy on dysglycemia and insulin sensitivity in South African HIV-infected patients.'
p72307
sS'SB'
p72308
S'IM X'
p72309
sS'RN'
p72310
(lp72311
S'0 (Anti-HIV Agents)'
p72312
aS'0 (Blood Glucose)'
p72313
aS'0 (Reverse Transcriptase Inhibitors)'
p72314
asS'PL'
p72315
S'United States'
p72316
sS'TA'
p72317
S'J Acquir Immune Defic Syndr'
p72318
stRp72319
ag2
(g3
g4
(dp72320
S'LID'
p72321
S'10.1186/1758-2652-14-24 [doi]'
p72322
sS'STAT'
p72323
S'MEDLINE'
p72324
sS'DEP'
p72325
S'20110515'
p72326
sS'DA'
p72327
S'20110621'
p72328
sS'AID'
p72329
(lp72330
S'1758-2652-14-24 [pii]'
p72331
aS'10.1186/1758-2652-14-24 [doi]'
p72332
asS'CRDT'
p72333
(lp72334
S'2011/05/18 06:00'
p72335
asS'DP'
p72336
S'2011'
p72337
sS'AD'
p72338
S'Center for Global Health & Development, Boston University, Boston, MA, USA. sbrosen@bu.edu'
p72339
sS'OWN'
p72340
S'NLM'
p72341
sS'PT'
p72342
(lp72343
S'Journal Article'
p72344
aS'Research Support, N.I.H., Extramural'
p72345
aS"Research Support, U.S. Gov't, Non-P.H.S."
p72346
asS'LA'
p72347
(lp72348
S'eng'
p72349
asS'DCOM'
p72350
S'20111107'
p72351
sS'JT'
p72352
S'Journal of the International AIDS Society'
p72353
sS'LR'
p72354
S'20150204'
p72355
sS'FAU'
p72356
(lp72357
S'Rosen, Sydney'
p72358
aS'Long, Lawrence'
p72359
aS'Sanne, Ian'
p72360
aS'Stevens, Wendy S'
p72361
aS'Fox, Matthew P'
p72362
asS'TI'
p72363
S'The net cost of incorporating resistance testing into HIV/AIDS treatment in South Africa: a Markov model with primary data.'
p72364
sS'RN'
p72365
(lp72366
S'0 (Anti-HIV Agents)'
p72367
asS'PL'
p72368
S'England'
p72369
sS'PG'
p72370
S'24'
p72371
sS'JID'
p72372
S'101478566'
p72373
sS'AB'
p72374
S"BACKGROUND: Current guidelines for providing antiretroviral therapy (ART) in South Africa's public sector programme call for switching patients from first-line to second-line treatment upon virologic failure as indicated by two consecutive viral loads above 5000 copies/ml, but without laboratory evidence of viral resistance. We modelled the net cost of adding resistance testing for patients with virological failure and retaining patients without resistance on first-line therapy, rather than switching all failures to second-line therapy. METHODS: Costs were estimated for three scenarios: routine maintenance (standard care without resistance testing, switch all failures to second line); resistance testing (resistance test for patients with failure, switch those with resistance); and limited testing (resistance test for patients with failure in the first three years, switch those with resistance). A Markov model was used to estimate the cost of each arm over five years after first line initiation. Rates of treatment failure, viral resistance and treatment costs were estimated with primary data from a large HIV treatment cohort at a public facility in Johannesburg. Future costs were discounted at 3%. RESULTS: Virological failure rates over five years were 19.8% in routine maintenance and 20.2% in resistance testing and limited testing; 16.8% and 11.4% of failures in routine and limited testing, respectively, did not have any resistance mutations, resulting in 3.1% and 2.0% fewer patients switching to second-line ART by the end of five years. Treatment costs were estimated at US$526 and $1268 per patient per year on first-line and second-line therapy, respectively; a resistance test cost $242. The total average cost per patient over five years was $2780 in routine maintenance; $2775 in resistance testing; and $2763 in limited testing. CONCLUSIONS: Incorporating resistance testing into treatment guidelines in South Africa is potentially cost-neutral and can identify other reasons for failure, conserve treatment options, and generate information about emerging resistance patterns."
p72375
sS'GR'
p72376
(lp72377
S'K01 AI083097/AI/NIAID NIH HHS/United States'
p72378
aS'K01AI083097/AI/NIAID NIH HHS/United States'
p72379
asS'VI'
p72380
S'14'
p72381
sS'IS'
p72382
S'1758-2652 (Electronic) 1758-2652 (Linking)'
p72383
sS'PMC'
p72384
S'PMC3119176'
p72385
sS'AU'
p72386
(lp72387
S'Rosen S'
p72388
aS'Long L'
p72389
aS'Sanne I'
p72390
aS'Stevens WS'
p72391
aS'Fox MP'
p72392
asS'MHDA'
p72393
S'2011/11/08 06:00'
p72394
sS'PHST'
p72395
(lp72396
S'2010/08/16 [received]'
p72397
aS'2011/05/15 [accepted]'
p72398
aS'2011/05/15 [aheadofprint]'
p72399
asS'OID'
p72400
(lp72401
S'NLM: PMC3119176'
p72402
asS'MH'
p72403
(lp72404
S'Acquired Immunodeficiency Syndrome/drug therapy/economics/virology'
p72405
aS'Anti-HIV Agents/*economics/therapeutic use'
p72406
aS'*Cost of Illness'
p72407
aS'HIV/physiology'
p72408
aS'HIV Infections/drug therapy/*economics/virology'
p72409
aS'Humans'
p72410
aS'Markov Chains'
p72411
aS'South Africa'
p72412
aS'Viral Load'
p72413
asS'EDAT'
p72414
S'2011/05/18 06:00'
p72415
sS'SO'
p72416
S'J Int AIDS Soc. 2011 May 15;14:24. doi: 10.1186/1758-2652-14-24.'
p72417
sS'SB'
p72418
S'IM X'
p72419
sS'PMID'
p72420
S'21575155'
p72421
sS'TA'
p72422
S'J Int AIDS Soc'
p72423
sS'PST'
p72424
S'epublish'
p72425
stRp72426
ag2
(g3
g4
(dp72427
S'STAT'
p72428
S'MEDLINE'
p72429
sS'JT'
p72430
S'African health sciences'
p72431
sS'DA'
p72432
S'20110516'
p72433
sS'CRDT'
p72434
(lp72435
S'2011/05/17 06:00'
p72436
asS'DP'
p72437
S'2011 Mar'
p72438
sS'OWN'
p72439
S'NLM'
p72440
sS'PT'
p72441
(lp72442
S'Journal Article'
p72443
aS"Research Support, Non-U.S. Gov't"
p72444
asS'LA'
p72445
(lp72446
S'eng'
p72447
asS'FAU'
p72448
(lp72449
S'Kalyesubula, R'
p72450
aS'Kagimu, M'
p72451
aS'Opio, K C'
p72452
aS'Kiguba, R'
p72453
aS'Semitala, C F'
p72454
aS'Schlech, W F'
p72455
aS'Katabira, E T'
p72456
asS'LR'
p72457
S'20150204'
p72458
sS'PG'
p72459
S'16-23'
p72460
sS'TI'
p72461
S'Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting.'
p72462
sS'RN'
p72463
(lp72464
S'0 (Anti-HIV Agents)'
p72465
aS'EC 2.6.1.2 (Alanine Transaminase)'
p72466
asS'PL'
p72467
S'Uganda'
p72468
sS'TA'
p72469
S'Afr Health Sci'
p72470
sS'JID'
p72471
S'101149451'
p72472
sS'AB'
p72473
S'BACKGROUND: Highly active antiretroviral therapy (HAART) has been associated with liver toxicity. The role of monitoring for liver toxicity has not been well studied in resource-limited settings (RLS). OBJECTIVES: To determine the background prevalence and incidence of liver injury and describe the associated signs and symptoms of acute hepatitis after initiating HAART; and to determine the role of liver enzyme tests in monitoring hepatotoxicity. METHODS: In this prospective study, in Mulago Hospital AIDS Clinics, we consecutively enrolled adult patients initiated on one of three first line HAART regimens [Stavudine (d4T)-Lamivudine (3TC) and nevirapine (NVP); Zidovudine (AZT)-3TC and Efavirenz (EFV) or d4T-3TC-EFV]. We monitored ALT (alanine aminotransferase) and clinical evidence of acute hepatitis at baseline, 2(nd), 6(th), 10(th) and 14(th) week of therapy. RESULTS: Two hundred and forty HIV-positive HAART- naive patients were enrolled in the study. The baseline prevalence of transaminitis was 1.7% with an incidence of 4.2% at 14 weeks. Grade 3-4 hepatotoxicity was documented in 1.3%. Jaundice was seen in grade 2-4 ALT elevations. Being on concurrent HAART and antituberculous drugs was associated with grade 2-4 toxicity compared to those who were only on HAART [OR; 16.0 (95% CI; 2.4-104.2)]. CONCLUSIONS: Incidence of severe hepatotoxicity within three months of first-line antiretroviral therapy was low, suggesting that routine measurement of transaminases may not be necessary in all patients initiating HAART in RLS. Routine measurement may be important in following patients on HAART and concurrent TB treatment as well as those with jaundice to avoid missing hepatotoxicity.'
p72474
sS'AD'
p72475
S'Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda. rkalyes@yahoo.com'
p72476
sS'IP'
p72477
S'1'
sS'IS'
p72478
S'1729-0503 (Electronic) 1680-6905 (Linking)'
p72479
sS'PMC'
p72480
S'PMC3092323'
p72481
sS'DCOM'
p72482
S'20110728'
p72483
sS'AU'
p72484
(lp72485
S'Kalyesubula R'
p72486
aS'Kagimu M'
p72487
aS'Opio KC'
p72488
aS'Kiguba R'
p72489
aS'Semitala CF'
p72490
aS'Schlech WF'
p72491
aS'Katabira ET'
p72492
asS'VI'
p72493
S'11'
p72494
sS'MHDA'
p72495
S'2011/07/29 06:00'
p72496
sS'OTO'
p72497
(lp72498
S'NOTNLM'
p72499
asS'OID'
p72500
(lp72501
S'NLM: PMC3092323'
p72502
asS'MH'
p72503
(lp72504
S'Adult'
p72505
aS'Alanine Transaminase/blood'
p72506
aS'Anti-HIV Agents/*adverse effects'
p72507
aS'Antiretroviral Therapy, Highly Active/*adverse effects'
p72508
aS'CD4 Lymphocyte Count'
p72509
aS'Drug-Induced Liver Injury/blood/*epidemiology'
p72510
aS'Female'
p72511
aS'Follow-Up Studies'
p72512
aS'HIV Infections/complications/*drug therapy/virology'
p72513
aS'Hepatitis B/complications/epidemiology'
p72514
aS'Hepatitis C/complications/epidemiology'
p72515
aS'Humans'
p72516
aS'Incidence'
p72517
aS'Liver/*drug effects'
p72518
aS'Male'
p72519
aS'Prevalence'
p72520
aS'Proportional Hazards Models'
p72521
aS'Prospective Studies'
p72522
aS'Uganda/epidemiology'
p72523
asS'EDAT'
p72524
S'2011/05/17 06:00'
p72525
sS'SO'
p72526
S'Afr Health Sci. 2011 Mar;11(1):16-23.'
p72527
sS'SB'
p72528
S'IM'
p72529
sS'PMID'
p72530
S'21572852'
p72531
sS'OT'
p72532
(lp72533
S'HAART'
p72534
aS'Hepatotoxicity'
p72535
aS'Uganda'
p72536
asS'PST'
p72537
S'ppublish'
p72538
stRp72539
ag2
(g3
g4
(dp72540
S'LID'
p72541
S'10.1097/QAD.0b013e328348a4b1 [doi]'
p72542
sS'STAT'
p72543
S'MEDLINE'
p72544
sS'JT'
p72545
S'AIDS (London, England)'
p72546
sS'CIN'
p72547
(lp72548
S'AIDS. 2015 Nov 28;29(18):2532-3. PMID: 26558550'
p72549
aS'AIDS. 2015 Nov 28;29(18):2531-2. PMID: 26372486'
p72550
asS'DA'
p72551
S'20110629'
p72552
sS'AID'
p72553
(lp72554
S'10.1097/QAD.0b013e328348a4b1 [doi]'
p72555
asS'CRDT'
p72556
(lp72557
S'2011/05/17 06:00'
p72558
asS'DP'
p72559
S'2011 Jul 17'
p72560
sS'AD'
p72561
S'Weill Bugando University College of Health Sciences, Mwanza, Tanzania.'
p72562
sS'OWN'
p72563
S'NLM'
p72564
sS'PT'
p72565
(lp72566
S'Journal Article'
p72567
aS'Research Support, N.I.H., Extramural'
p72568
aS"Research Support, Non-U.S. Gov't"
p72569
asS'LA'
p72570
(lp72571
S'eng'
p72572
asS'FAU'
p72573
(lp72574
S'Msango, Leonard'
p72575
aS'Downs, Jennifer A'
p72576
aS'Kalluvya, Samuel E'
p72577
aS'Kidenya, Benson R'
p72578
aS'Kabangila, Rodrick'
p72579
aS'Johnson, Warren D Jr'
p72580
aS'Fitzgerald, Daniel W'
p72581
aS'Peck, Robert N'
p72582
asS'LR'
p72583
S'20160212'
p72584
sS'PG'
p72585
S'1421-5'
p72586
sS'TI'
p72587
S'Renal dysfunction among HIV-infected patients starting antiretroviral therapy.'
p72588
sS'RN'
p72589
(lp72590
S'0 (Anti-Retroviral Agents)'
p72591
asS'PL'
p72592
S'England'
p72593
sS'TA'
p72594
S'AIDS'
p72595
sS'JID'
p72596
S'8710219'
p72597
sS'AB'
p72598
S'OBJECTIVE: HIV-related renal dysfunction is associated with high mortality. Data on the prevalence of renal dysfunction among HIV-infected outpatients starting antiretroviral therapy (ART) in sub-Saharan Africa are limited. Recent recommendations to include the nephrotoxic drug tenofovir in first-line ART regimens make clarification of this issue urgent. METHODS: We screened for renal dysfunction by measuring serum creatinine, proteinuria, and microalbuminuria in HIV-positive outpatients initiating ART in Mwanza, Tanzania. We excluded patients with pre-existing renal disease, hypertension, diabetes, or hepatitis C virus co-infection. Estimated glomerular filtration rates (eGFRs) were calculated by Cockroft-Gault and Modification of Diet in Renal Disease equations. RESULTS: Only 129 (36%) of 355 enrolled patients had normal eGFRs (grade 0 or 1) above 90 ml/min per 1.73 m. Grade 2 renal dysfunction (eGFR between 60 and 89 ml/min per 1.73 m) was present in 137 patients (38.6%), and 87 patients (25%) had grade 3 dysfunction (eGFR between 30 and 59 ml/min per 1.73 m). Microalbuminuria and proteinuria were detected in 72 and 36% of patients, respectively. Factors predictive of renal dysfunction in multivariate analysis included female sex [odds ratio (OR) 3.0, 95% confidence interval (1.8-5.1), P < 0.0001], BMI less than 18.5 [OR 2.3 (1.3-4.1), P = 0.004], CD4 T-cell count below 200 cells/mul [OR 2.3 (1.1-4.8), P = 0.04], and WHO clinical stage II or above [OR 1.6 (1.2-2.3), P = 0.001]. CONCLUSION: Renal dysfunction was highly prevalent in this population of HIV-positive outpatients initiating first ART in Tanzania. This highlights the critical and underappreciated need to monitor renal function in HIV-positive patients in sub-Saharan Africa, particularly given the increasing use of tenofovir in first-line ART.'
p72599
sS'GR'
p72600
(lp72601
S'D43 TW000018/TW/FIC NIH HHS/United States'
p72602
aS'TW 00018/TW/FIC NIH HHS/United States'
p72603
asS'IP'
p72604
S'11'
p72605
sS'IS'
p72606
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p72607
sS'PMC'
p72608
S'PMC3631352'
p72609
sS'DCOM'
p72610
S'20110914'
p72611
sS'MID'
p72612
(lp72613
S'NIHMS454918'
p72614
asS'AU'
p72615
(lp72616
S'Msango L'
p72617
aS'Downs JA'
p72618
aS'Kalluvya SE'
p72619
aS'Kidenya BR'
p72620
aS'Kabangila R'
p72621
aS'Johnson WD Jr'
p72622
aS'Fitzgerald DW'
p72623
aS'Peck RN'
p72624
asS'VI'
p72625
S'25'
p72626
sS'MHDA'
p72627
S'2011/09/15 06:00'
p72628
sS'OID'
p72629
(lp72630
S'NLM: NIHMS454918'
p72631
aS'NLM: PMC3631352'
p72632
asS'MH'
p72633
(lp72634
S'Anti-Retroviral Agents/*therapeutic use'
p72635
aS'Cross-Sectional Studies'
p72636
aS'Female'
p72637
aS'Glomerular Filtration Rate'
p72638
aS'HIV Infections/complications/*drug therapy/urine'
p72639
aS'Humans'
p72640
aS'Male'
p72641
aS'Prevalence'
p72642
aS'Renal Insufficiency/*drug therapy/etiology/urine'
p72643
aS'Risk Factors'
p72644
aS'Tanzania'
p72645
asS'EDAT'
p72646
S'2011/05/17 06:00'
p72647
sS'SO'
p72648
S'AIDS. 2011 Jul 17;25(11):1421-5. doi: 10.1097/QAD.0b013e328348a4b1.'
p72649
sS'SB'
p72650
S'IM X'
p72651
sS'PMID'
p72652
S'21572304'
p72653
sS'PST'
p72654
S'ppublish'
p72655
stRp72656
ag2
(g3
g4
(dp72657
S'LID'
p72658
S'10.1371/journal.pone.0019261 [doi]'
p72659
sS'STAT'
p72660
S'MEDLINE'
p72661
sS'DEP'
p72662
S'20110429'
p72663
sS'DA'
p72664
S'20110511'
p72665
sS'AID'
p72666
(lp72667
S'10.1371/journal.pone.0019261 [doi]'
p72668
aS'PONE-D-10-06525 [pii]'
p72669
asS'CRDT'
p72670
(lp72671
S'2011/05/12 06:00'
p72672
asS'DP'
p72673
S'2011'
p72674
sS'OWN'
p72675
S'NLM'
p72676
sS'PT'
p72677
(lp72678
S'Journal Article'
p72679
aS"Research Support, Non-U.S. Gov't"
p72680
asS'LA'
p72681
(lp72682
S'eng'
p72683
asS'FAU'
p72684
(lp72685
S'Bakanda, Celestin'
p72686
aS'Birungi, Josephine'
p72687
aS'Mwesigwa, Robert'
p72688
aS'Nachega, Jean B'
p72689
aS'Chan, Keith'
p72690
aS'Palmer, Alexis'
p72691
aS'Ford, Nathan'
p72692
aS'Mills, Edward J'
p72693
asS'JT'
p72694
S'PloS one'
p72695
sS'LR'
p72696
S'20150204'
p72697
sS'PG'
p72698
S'e19261'
p72699
sS'TI'
p72700
S'Survival of HIV-infected adolescents on antiretroviral therapy in Uganda: findings from a nationally representative cohort in Uganda.'
p72701
sS'RN'
p72702
(lp72703
S'0 (Anti-Retroviral Agents)'
p72704
asS'PL'
p72705
S'United States'
p72706
sS'TA'
p72707
S'PLoS One'
p72708
sS'JID'
p72709
S'101285081'
p72710
sS'AB'
p72711
S'BACKGROUND: Adolescents have been identified as a high-risk group for poor adherence to and defaulting from combination antiretroviral therapy (cART) care. However, data on outcomes for adolescents on cART in resource-limited settings remain scarce. METHODS: We developed an observational study of patients who started cART at The AIDS Service Organization (TASO) in Uganda between 2004 and 2009. Age was stratified into three groups: children (</=10 years), adolescents (11-19 years), and adults (>/=20 years). Kaplan-Meier survival curves were generated to describe time to mortality and loss to follow-up, and Cox regression used to model associations between age and mortality and loss to follow-up. To address loss to follow up, we applied a weighted analysis that assumes 50% of lost patients had died. FINDINGS: A total of 23,367 patients were included in this analysis, including 810 (3.5%) children, 575 (2.5%) adolescents, and 21 982 (94.0%) adults. A lower percentage of children (5.4%) died during their cART treatment compared to adolescents (8.5%) and adults (10%). After adjusting for confounding, other features predicted mortality than age alone. Mortality was higher among males (p<0.001), patients with a low initial CD4 cell count (p<0.001), patients with advanced WHO clinical disease stage (p<0.001), and shorter duration of time receiving cART (p<0.001). The crude mortality rate was lower for children (22.8 per 1000 person-years; 95% CI: 16.1, 29.5), than adolescents (36.5 per 1000 person-years; 95% CI: 26.3, 46.8) and adults (37.5 per 1000 person-years; 95% CI: 35.9, 39.1). INTERPRETATION: This study is the largest assessment of adolescents receiving cART in Africa. Adolescents did not have cART mortality outcomes different from adults or children.'
p72712
sS'AD'
p72713
S'The AIDS Support Organization, Kampala, Uganda.'
p72714
sS'IP'
p72715
S'4'
sS'IS'
p72716
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p72717
sS'PMC'
p72718
S'PMC3084801'
p72719
sS'DCOM'
p72720
S'20111128'
p72721
sS'AU'
p72722
(lp72723
S'Bakanda C'
p72724
aS'Birungi J'
p72725
aS'Mwesigwa R'
p72726
aS'Nachega JB'
p72727
aS'Chan K'
p72728
aS'Palmer A'
p72729
aS'Ford N'
p72730
aS'Mills EJ'
p72731
asS'VI'
p72732
S'6'
sS'MHDA'
p72733
S'2011/12/13 00:00'
p72734
sS'PHST'
p72735
(lp72736
S'2010/12/08 [received]'
p72737
aS'2011/03/25 [accepted]'
p72738
aS'2011/04/29 [epublish]'
p72739
asS'OID'
p72740
(lp72741
S'NLM: PMC3084801'
p72742
asS'MH'
p72743
(lp72744
S'Adolescent'
p72745
aS'Adult'
p72746
aS'Age Factors'
p72747
aS'Anti-Retroviral Agents/*therapeutic use'
p72748
aS'CD4-Positive T-Lymphocytes/cytology/virology'
p72749
aS'Child'
p72750
aS'Cohort Studies'
p72751
aS'Drug Therapy, Combination'
p72752
aS'Female'
p72753
aS'HIV Infections/*drug therapy/mortality'
p72754
aS'Humans'
p72755
aS'Male'
p72756
aS'Proportional Hazards Models'
p72757
aS'Treatment Outcome'
p72758
aS'Uganda'
p72759
asS'EDAT'
p72760
S'2011/05/12 06:00'
p72761
sS'SO'
p72762
S'PLoS One. 2011 Apr 29;6(4):e19261. doi: 10.1371/journal.pone.0019261.'
p72763
sS'SB'
p72764
S'IM'
p72765
sS'PMID'
p72766
S'21559441'
p72767
sS'PST'
p72768
S'epublish'
p72769
stRp72770
ag2
(g3
g4
(dp72771
S'LID'
p72772
S'10.1371/journal.pone.0019201 [doi]'
p72773
sS'STAT'
p72774
S'MEDLINE'
p72775
sS'DEP'
p72776
S'20110503'
p72777
sS'DA'
p72778
S'20110511'
p72779
sS'AID'
p72780
(lp72781
S'10.1371/journal.pone.0019201 [doi]'
p72782
aS'PONE-D-10-06331 [pii]'
p72783
asS'CRDT'
p72784
(lp72785
S'2011/05/12 06:00'
p72786
asS'DP'
p72787
S'2011'
p72788
sS'OWN'
p72789
S'NLM'
p72790
sS'PT'
p72791
(lp72792
S'Journal Article'
p72793
asS'LA'
p72794
(lp72795
S'eng'
p72796
asS'FAU'
p72797
(lp72798
S'Boyles, Tom H'
p72799
aS'Wilkinson, Lynne S'
p72800
aS'Leisegang, Rory'
p72801
aS'Maartens, Gary'
p72802
asS'JT'
p72803
S'PloS one'
p72804
sS'LR'
p72805
S'20150204'
p72806
sS'PG'
p72807
S'e19201'
p72808
sS'TI'
p72809
S'Factors influencing retention in care after starting antiretroviral therapy in a rural South African programme.'
p72810
sS'RN'
p72811
(lp72812
S'0 (Anti-Retroviral Agents)'
p72813
asS'PL'
p72814
S'United States'
p72815
sS'TA'
p72816
S'PLoS One'
p72817
sS'JID'
p72818
S'101285081'
p72819
sS'AB'
p72820
S'INTRODUCTION: The prognosis of patients with HIV in Africa has improved with the widespread use of antiretroviral therapy (ART) but these successes are threatened by low rates of long-term retention in care. There are limited data on predictors of retention in care, particularly from rural sites. METHODS: Prospective cohort analysis of outcome measures in adults from a rural HIV care programme in Madwaleni, Eastern Cape, South Africa. The ART programme operates from Madwaleni hospital and seven primary care feeder clinics with full integration between inpatient and outpatient services. Outreach workers conducted home visits for defaulters. RESULTS: 1803 adults initiated ART from June 2005 to May 2009. At the end of the study period 82.4% were in active care or had transferred elsewhere, 11.1% had died and 6.5% were lost to follow-up (LTFU). Independent predictors associated with an increased risk of LTFU were CD4 nadir >200, initiating ART as an inpatient or while pregnant, and younger age, while being in care for >6 months before initiating ART was associated with a reduced risk. Independent factors associated with an increased risk of mortality were baseline CD4 count <50 and initiating ART as an inpatient, while being in care for >6 months before initiating ART and initiating ART while pregnant were associated with a reduced risk. CONCLUSIONS: Serving a socioeconomically deprived rural population is not a barrier to successful ART delivery. Patients initiating ART while pregnant and inpatients may require additional counselling and support to reduce LTFU. Providing HIV care for patients not yet eligible for ART may be protective against being LTFU and dying after ART initiation.'
p72821
sS'AD'
p72822
S'Madwaleni Hospital, Eastern Cape, South Africa. tomboyles@yahoo.com'
p72823
sS'IP'
p72824
S'5'
sS'IS'
p72825
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p72826
sS'PMC'
p72827
S'PMC3086905'
p72828
sS'DCOM'
p72829
S'20111108'
p72830
sS'AU'
p72831
(lp72832
S'Boyles TH'
p72833
aS'Wilkinson LS'
p72834
aS'Leisegang R'
p72835
aS'Maartens G'
p72836
asS'VI'
p72837
S'6'
sS'MHDA'
p72838
S'2011/11/09 06:00'
p72839
sS'PHST'
p72840
(lp72841
S'2010/12/07 [received]'
p72842
aS'2011/03/28 [accepted]'
p72843
aS'2011/05/03 [epublish]'
p72844
asS'OID'
p72845
(lp72846
S'NLM: PMC3086905'
p72847
asS'MH'
p72848
(lp72849
S'Adult'
p72850
aS'Anti-Retroviral Agents/*therapeutic use'
p72851
aS'CD4-Positive T-Lymphocytes/cytology'
p72852
aS'Cohort Studies'
p72853
aS'Communicable Disease Control/*methods'
p72854
aS'Female'
p72855
aS'HIV Infections/*drug therapy/mortality'
p72856
aS'Humans'
p72857
aS'Male'
p72858
aS'Medication Adherence'
p72859
aS'Middle Aged'
p72860
aS'*Patient Compliance'
p72861
aS'Poverty'
p72862
aS'Pregnancy'
p72863
aS'Pregnancy Complications, Infectious/drug therapy'
p72864
aS'Rural Health Services/organization & administration'
p72865
aS'Rural Population'
p72866
aS'South Africa'
p72867
aS'Treatment Outcome'
p72868
asS'EDAT'
p72869
S'2011/05/12 06:00'
p72870
sS'SO'
p72871
S'PLoS One. 2011 May 3;6(5):e19201. doi: 10.1371/journal.pone.0019201.'
p72872
sS'SB'
p72873
S'IM'
p72874
sS'PMID'
p72875
S'21559280'
p72876
sS'PST'
p72877
S'epublish'
p72878
stRp72879
ag2
(g3
g4
(dp72880
S'LID'
p72881
S'10.1097/COH.0b013e3283479316 [doi]'
p72882
sS'STAT'
p72883
S'MEDLINE'
p72884
sS'AB'
p72885
S'PURPOSE OF REVIEW: In this review, we describe the challenges faced by using clinical cohorts to perform Monitoring and Evaluation (M&E) and the possible solutions for increasing and strengthening health systems in low-income and middle-income countries. RECENT FINDINGS: HIV scale-up has facilitated the transition from paper-based medical records to electronic medical records at hundreds of sites in most of the countries in sub-Saharan Africa and the implementation of national HIV databases. However, National M&E systems in resource-limited settings tend to be chronically challenged by persistently incomplete reporting and inaccurate data, which undermines their usefulness. In low-income and middle-income countries, new information technologies such as Web-based systems and mobile phone networks are expanding rapidly. Their use will improve data quality and, therefore, reduce participant dropout and improve reporting rates. These systems have the potential to allow real time access to summary reports and to integrate data from other settings such as maternal and infant health clinics. SUMMARY: The efforts to address the AIDS pandemic in sub-Saharan Africa will require enhanced information systems. Stronger systems are needed to deliver primary healthcare for those with and without HIV, and it is also essential to build and take advantage of synergies across health information systems.'
p72886
sS'JID'
p72887
S'101264945'
p72888
sS'AD'
p72889
S"Programme PACCI, Abidjan, Cote d'Ivoire. didier.ekouevi@gmail.com"
p72890
sS'JT'
p72891
S'Current opinion in HIV and AIDS'
p72892
sS'IP'
p72893
S'4'
sS'IS'
p72894
S'1746-6318 (Electronic) 1746-630X (Linking)'
p72895
sS'DCOM'
p72896
S'20110926'
p72897
sS'DA'
p72898
S'20110607'
p72899
sS'AU'
p72900
(lp72901
S'Ekouevi DK'
p72902
aS'Karcher S'
p72903
aS'Coffie PA'
p72904
asS'AID'
p72905
(lp72906
S'10.1097/COH.0b013e3283479316 [doi]'
p72907
asS'CRDT'
p72908
(lp72909
S'2011/05/07 06:00'
p72910
asS'VI'
p72911
S'6'
sS'DP'
p72912
S'2011 Jul'
p72913
sS'MHDA'
p72914
S'2011/09/29 06:00'
p72915
sS'OWN'
p72916
S'NLM'
p72917
sS'PT'
p72918
(lp72919
S'Journal Article'
p72920
aS"Research Support, Non-U.S. Gov't"
p72921
aS'Review'
p72922
asS'LA'
p72923
(lp72924
S'eng'
p72925
asS'MH'
p72926
(lp72927
S'Africa South of the Sahara/epidemiology'
p72928
aS'Communicable Disease Control/*methods'
p72929
aS'Developing Countries'
p72930
aS'HIV Infections/*diagnosis/drug therapy/*epidemiology/*prevention & control'
p72931
aS'Humans'
p72932
aS'Information Systems/*organization & administration'
p72933
aS'Primary Health Care/methods'
p72934
asS'FAU'
p72935
(lp72936
S'Ekouevi, Didier K'
p72937
aS'Karcher, Sophie'
p72938
aS'Coffie, Patrick A'
p72939
asS'EDAT'
p72940
S'2011/05/07 06:00'
p72941
sS'PST'
p72942
S'ppublish'
p72943
sS'SO'
p72944
S'Curr Opin HIV AIDS. 2011 Jul;6(4):245-50. doi: 10.1097/COH.0b013e3283479316.'
p72945
sS'PG'
p72946
S'245-50'
p72947
sS'TI'
p72948
S'Strengthening health systems through HIV monitoring and evaluation in Sub-Saharan Africa.'
p72949
sS'SB'
p72950
S'IM X'
p72951
sS'PMID'
p72952
S'21546830'
p72953
sS'PL'
p72954
S'United States'
p72955
sS'TA'
p72956
S'Curr Opin HIV AIDS'
p72957
stRp72958
ag2
(g3
g4
(dp72959
S'LID'
p72960
S'10.1371/journal.pone.0018435 [doi]'
p72961
sS'STAT'
p72962
S'MEDLINE'
p72963
sS'DEP'
p72964
S'20110425'
p72965
sS'DA'
p72966
S'20110504'
p72967
sS'AID'
p72968
(lp72969
S'10.1371/journal.pone.0018435 [doi]'
p72970
asS'CRDT'
p72971
(lp72972
S'2011/05/05 06:00'
p72973
asS'DP'
p72974
S'2011'
p72975
sS'OWN'
p72976
S'NLM'
p72977
sS'PT'
p72978
(lp72979
S'Clinical Trial'
p72980
aS'Journal Article'
p72981
aS"Research Support, U.S. Gov't, Non-P.H.S."
p72982
aS"Research Support, U.S. Gov't, P.H.S."
p72983
asS'LA'
p72984
(lp72985
S'eng'
p72986
asS'FAU'
p72987
(lp72988
S'Gust, Deborah A'
p72989
aS'Mosimaneotsile, Barudi'
p72990
aS'Mathebula, Unami'
p72991
aS'Chingapane, Balladiah'
p72992
aS'Gaul, Zaneta'
p72993
aS'Pals, Sherri L'
p72994
aS'Samandari, Taraz'
p72995
asS'JT'
p72996
S'PloS one'
p72997
sS'LR'
p72998
S'20150204'
p72999
sS'PG'
p73000
S'e18435'
p73001
sS'TI'
p73002
S'Risk factors for non-adherence and loss to follow-up in a three-year clinical trial in Botswana.'
p73003
sS'RN'
p73004
(lp73005
S'V83O1VOZ8L (Isoniazid)'
p73006
asS'PL'
p73007
S'United States'
p73008
sS'TA'
p73009
S'PLoS One'
p73010
sS'JID'
p73011
S'101285081'
p73012
sS'AB'
p73013
S'BACKGROUND: Participant non-adherence and loss to follow-up can compromise the validity of clinical trial results. An assessment of these issues was made in a 3-year tuberculosis prevention trial among HIV-infected adults in Botswana. METHODS AND FINDINGS: Between 11/2004-07/2006, 1995 participants were enrolled at eight public health clinics. They returned monthly to receive bottles of medication and were expected to take daily tablets of isoniazid or placebo for three years. Non-adherence was defined as refusing tablet ingestion but agreeing to quarterly physical examinations. Loss to follow-up was defined as not having returned for appointments in >/=60 days. Between 10/2008-04/2009, survey interviews were conducted with 83 participants identified as lost to follow-up and 127 identified as non-adherent. As a comparison, 252 randomly selected adherent participants were also surveyed. Multivariate logistic regression analysis was used to identify associations with selected risk factors. Men had higher odds of being non-adherent (adjusted odds ratio (AOR), 2.24; 95% confidence interval [95%CI] 1.24-4.04) and lost to follow-up (AOR 3.08; 95%CI 1.50-6.33). Non-adherent participants had higher odds of reporting difficulties taking the regimen or not knowing if they had difficulties (AOR 3.40; 95%CI 1.75-6.60) and lower odds associated with each year of age (AOR 0.95; 95%CI 0.91-0.98), but other variables such as employment, distance from clinic, alcohol use, and understanding study requirements were not significantly different than controls. Among participants who were non-adherent or lost to follow-up, 40/210 (19.0%) reported that they stopped the medication because of work commitments and 33/210 (15.7%) said they thought they had completed the study. CONCLUSIONS: Men had higher odds of non-adherence and loss to follow-up than women. Potential interventions that might improve adherence in trial participants may include:targeting health education for men, reducing barriers, clarifying study expectations, educating employers about HIV/AIDS to help reduce stigma in the workplace, and encouraging employers to support employee health. TRIAL REGISTRATION: ClinicalTrials.gov NCT00164281.'
p73014
sS'AD'
p73015
S'Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America. dgust@cdc.gov'
p73016
sS'IP'
p73017
S'4'
sS'IS'
p73018
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p73019
sS'PMC'
p73020
S'PMC3081815'
p73021
sS'DCOM'
p73022
S'20110823'
p73023
sS'AU'
p73024
(lp73025
S'Gust DA'
p73026
aS'Mosimaneotsile B'
p73027
aS'Mathebula U'
p73028
aS'Chingapane B'
p73029
aS'Gaul Z'
p73030
aS'Pals SL'
p73031
aS'Samandari T'
p73032
asS'VI'
p73033
S'6'
sS'MHDA'
p73034
S'2011/08/24 06:00'
p73035
sS'PHST'
p73036
(lp73037
S'2010/11/02 [received]'
p73038
aS'2011/03/03 [accepted]'
p73039
aS'2011/04/25 [epublish]'
p73040
asS'OID'
p73041
(lp73042
S'NLM: PMC3081815'
p73043
asS'MH'
p73044
(lp73045
S'Adult'
p73046
aS'Botswana'
p73047
aS'Case-Control Studies'
p73048
aS'Female'
p73049
aS'Health Surveys'
p73050
aS'Humans'
p73051
aS'Interviews as Topic'
p73052
aS'Isoniazid/therapeutic use/urine'
p73053
aS'*Lost to Follow-Up'
p73054
aS'Male'
p73055
aS'Multivariate Analysis'
p73056
aS'*Patient Compliance'
p73057
aS'Regression Analysis'
p73058
aS'Risk Factors'
p73059
aS'Self Report'
p73060
asS'EDAT'
p73061
S'2011/05/05 06:00'
p73062
sS'SI'
p73063
(lp73064
S'ClinicalTrials.gov/NCT00164281'
p73065
asS'SO'
p73066
S'PLoS One. 2011 Apr 25;6(4):e18435. doi: 10.1371/journal.pone.0018435.'
p73067
sS'SB'
p73068
S'IM'
p73069
sS'PMID'
p73070
S'21541021'
p73071
sS'PST'
p73072
S'epublish'
p73073
stRp73074
ag2
(g3
g4
(dp73075
S'LID'
p73076
S'10.1371/journal.pone.0018505 [doi]'
p73077
sS'STAT'
p73078
S'MEDLINE'
p73079
sS'DEP'
p73080
S'20110421'
p73081
sS'DA'
p73082
S'20110502'
p73083
sS'AID'
p73084
(lp73085
S'10.1371/journal.pone.0018505 [doi]'
p73086
asS'CRDT'
p73087
(lp73088
S'2011/05/03 06:00'
p73089
asS'DP'
p73090
S'2011'
p73091
sS'AD'
p73092
S'Massachusetts General Hospital Center for Global Health, Boston, Massachusetts, United States of America. jhaberer@partners.org'
p73093
sS'OWN'
p73094
S'NLM'
p73095
sS'PT'
p73096
(lp73097
S'Journal Article'
p73098
aS'Randomized Controlled Trial'
p73099
aS'Research Support, N.I.H., Extramural'
p73100
aS"Research Support, Non-U.S. Gov't"
p73101
asS'LA'
p73102
(lp73103
S'eng'
p73104
asS'FAU'
p73105
(lp73106
S'Haberer, Jessica E'
p73107
aS'Cook, Adrian'
p73108
aS'Walker, A Sarah'
p73109
aS'Ngambi, Marjorie'
p73110
aS'Ferrier, Alex'
p73111
aS'Mulenga, Veronica'
p73112
aS'Kityo, Cissy'
p73113
aS'Thomason, Margaret'
p73114
aS'Kabamba, Desiree'
p73115
aS'Chintu, Chifumbe'
p73116
aS'Gibb, Diana M'
p73117
aS'Bangsberg, David R'
p73118
asS'JT'
p73119
S'PloS one'
p73120
sS'LR'
p73121
S'20150204'
p73122
sS'PG'
p73123
S'e18505'
p73124
sS'TI'
p73125
S'Excellent adherence to antiretrovirals in HIV+ Zambian children is compromised by disrupted routine, HIV nondisclosure, and paradoxical income effects.'
p73126
sS'RN'
p73127
(lp73128
S'0 (Anti-HIV Agents)'
p73129
asS'PL'
p73130
S'United States'
p73131
sS'TA'
p73132
S'PLoS One'
p73133
sS'JID'
p73134
S'101285081'
p73135
sS'AB'
p73136
S'INTRODUCTION: A better understanding of pediatric antiretroviral therapy (ART) adherence in sub-Saharan Africa is necessary to develop interventions to sustain high levels of adherence. METHODOLOGY/PRINCIPAL FINDINGS: Adherence among 96 HIV-infected Zambian children (median age 6, interquartile range [IQR] 2,9) initiating fixed-dose combination ART was measured prospectively (median 23 months; IQR 20,26) with caregiver report, clinic and unannounced home-based pill counts, and medication event monitoring systems (MEMS). HIV-1 RNA was determined at 48 weeks. Child and caregiver characteristics, socio-demographic status, and treatment-related factors were assessed as predictors of adherence. Median adherence was 97.4% (IQR 96.1,98.4%) by visual analog scale, 94.8% (IQR 86,100%) by caregiver-reported last missed dose, 96.9% (IQR 94.5,98.2%) by clinic pill count, 93.4% (IQR 90.2,96.7%) by unannounced home-based pill count, and 94.8% (IQR 87.8,97.7%) by MEMS. At 48 weeks, 72.6% of children had HIV-1 RNA <50 copies/ml. Agreement among adherence measures was poor; only MEMS was significantly associated with viral suppression (p = 0.013). Predictors of poor adherence included changing residence, school attendance, lack of HIV disclosure to children aged nine to 15 years, and increasing household income. CONCLUSIONS/SIGNIFICANCE: Adherence among children taking fixed-dose combination ART in sub-Saharan Africa is high and sustained over two years. However, certain groups are at risk for treatment failure, including children with disrupted routines, no knowledge of their HIV diagnosis among older children, and relatively high household income, possibly reflecting greater social support in the setting of greater poverty.'
p73137
sS'GR'
p73138
(lp73139
S'K23 MH087228/MH/NIMH NIH HHS/United States'
p73140
aS'MC_U122886353/Medical Research Council/United Kingdom'
p73141
aS'NIMH K23-87228/PHS HHS/United States'
p73142
aS'NIMH K24-87227/PHS HHS/United States'
p73143
asS'IP'
p73144
S'4'
sS'IS'
p73145
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p73146
sS'PMC'
p73147
S'PMC3080873'
p73148
sS'DCOM'
p73149
S'20110830'
p73150
sS'AU'
p73151
(lp73152
S'Haberer JE'
p73153
aS'Cook A'
p73154
aS'Walker AS'
p73155
aS'Ngambi M'
p73156
aS'Ferrier A'
p73157
aS'Mulenga V'
p73158
aS'Kityo C'
p73159
aS'Thomason M'
p73160
aS'Kabamba D'
p73161
aS'Chintu C'
p73162
aS'Gibb DM'
p73163
aS'Bangsberg DR'
p73164
asS'VI'
p73165
S'6'
sS'MHDA'
p73166
S'2011/08/31 06:00'
p73167
sS'PHST'
p73168
(lp73169
S'2010/12/20 [received]'
p73170
aS'2011/03/02 [accepted]'
p73171
aS'2011/04/21 [epublish]'
p73172
asS'OID'
p73173
(lp73174
S'NLM: PMC3080873'
p73175
asS'MH'
p73176
(lp73177
S'Anti-HIV Agents/*therapeutic use'
p73178
aS'Child'
p73179
aS'*Disclosure'
p73180
aS'Female'
p73181
aS'HIV Infections/*drug therapy'
p73182
aS'Humans'
p73183
aS'Male'
p73184
aS'*Patient Compliance'
p73185
aS'Zambia'
p73186
asS'EDAT'
p73187
S'2011/05/03 06:00'
p73188
sS'SO'
p73189
S'PLoS One. 2011 Apr 21;6(4):e18505. doi: 10.1371/journal.pone.0018505.'
p73190
sS'SB'
p73191
S'IM'
p73192
sS'PMID'
p73193
S'21533031'
p73194
sS'PST'
p73195
S'epublish'
p73196
stRp73197
ag2
(g3
g4
(dp73198
S'STAT'
p73199
S'MEDLINE'
p73200
sS'AB'
p73201
S'BACKGROUND: The introduction of the highly active antiretroviral therapy in the mid-1990s has significantly reduced morbidities and prolonged the lifespan of people living with HIV. However, the emergence of resistance to the antiretroviral drugs is becoming a major cause of treatment failure. While the problem of drug resistance is being tackled in developed countries, not much seem to be done in this regard in developing countries of Africa, Asia and Latin America. This review looked at the regional distribution of HIV groups and subtypes and how this has affected the pattern of antiretroviral resistance. METHODS: The review was sourced from papers presented at international conferences on HIV/AIDS and rational drug use, relevant journals and Medline search using the keywords--Antiretroviral drugs, drug resistance, HIV subtypes and resistance testing. RESULTS: The types, groups, subtypes, sub-subtypes and recombinant forms of HIV-1 have been identified according to their geographical distributions. The evolution of HIV viral mutations, process (es) involved in development of primary and secondary antiretroviral drug resistance, including the role of HIV genetic polymorphisms, and transmitted resistance have been discussed. CONCLUSION: The pitfalls in the current resistance testing based on HIV-1 subtype B have been highlighted. The design of resistance testing algorithm based on HIV-1 subtype non-B has been suggested for the developing world.'
p73202
sS'JID'
p73203
S'100888321'
p73204
sS'AD'
p73205
S'Department of Medicine, Ahmadu Bello University Teaching Hospital Shika Zaria. reginaldobiako@yahoo.com'
p73206
sS'JT'
p73207
S'Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria'
p73208
sS'IP'
p73209
S'4'
sS'IS'
p73210
S'1115-2613 (Print) 1115-2613 (Linking)'
p73211
sS'DCOM'
p73212
S'20110930'
p73213
sS'DA'
p73214
S'20110429'
p73215
sS'AU'
p73216
(lp73217
S'Obiako OR'
p73218
aS'Murktar HM'
p73219
aS'Ogoina D'
p73220
asS'CRDT'
p73221
(lp73222
S'2011/04/30 06:00'
p73223
asS'VI'
p73224
S'19'
p73225
sS'PMID'
p73226
S'21526620'
p73227
sS'DP'
p73228
S'2010 Oct-Dec'
p73229
sS'MHDA'
p73230
S'2011/10/01 06:00'
p73231
sS'OWN'
p73232
S'NLM'
p73233
sS'PT'
p73234
(lp73235
S'Journal Article'
p73236
aS'Review'
p73237
asS'LA'
p73238
(lp73239
S'eng'
p73240
asS'MH'
p73241
(lp73242
S'Africa South of the Sahara'
p73243
aS'Anti-HIV Agents/*pharmacology/therapeutic use'
p73244
aS'Antiretroviral Therapy, Highly Active'
p73245
aS'Developing Countries'
p73246
aS'*Drug Resistance, Viral/genetics'
p73247
aS'Female'
p73248
aS'Genome'
p73249
aS'HIV Infections/*drug therapy/genetics/virology'
p73250
aS'HIV-1/*drug effects/genetics'
p73251
aS'Humans'
p73252
aS'Male'
p73253
aS'Mutation'
p73254
aS'Polymorphism, Genetic'
p73255
asS'FAU'
p73256
(lp73257
S'Obiako, O R'
p73258
aS'Murktar, H M'
p73259
aS'Ogoina, D'
p73260
asS'EDAT'
p73261
S'2011/04/30 06:00'
p73262
sS'PST'
p73263
S'ppublish'
p73264
sS'SO'
p73265
S'Niger J Med. 2010 Oct-Dec;19(4):352-60.'
p73266
sS'PG'
p73267
S'352-60'
p73268
sS'TI'
p73269
S'Antiretroviral drug resistance--implications for HIV/AIDS reduction in sub-Saharan Africa and other developing countries.'
p73270
sS'SB'
p73271
S'IM'
p73272
sS'RN'
p73273
(lp73274
S'0 (Anti-HIV Agents)'
p73275
asS'PL'
p73276
S'Nigeria'
p73277
sS'TA'
p73278
S'Niger J Med'
p73279
stRp73280
ag2
(g3
g4
(dp73281
S'LID'
p73282
S'10.1016/j.trstmh.2011.02.011 [doi]'
p73283
sS'STAT'
p73284
S'MEDLINE'
p73285
sS'DEP'
p73286
S'20110420'
p73287
sS'CI'
p73288
(lp73289
S'Copyright (c) 2011 Royal Society of Tropical Medicine and Hygiene. Published by'
p73290
aS'Elsevier Ltd. All rights reserved.'
p73291
asS'DA'
p73292
S'20110523'
p73293
sS'AID'
p73294
(lp73295
S'S0035-9203(11)00041-1 [pii]'
p73296
aS'10.1016/j.trstmh.2011.02.011 [doi]'
p73297
asS'CRDT'
p73298
(lp73299
S'2011/04/23 06:00'
p73300
asS'DP'
p73301
S'2011 Jun'
p73302
sS'OWN'
p73303
S'NLM'
p73304
sS'PT'
p73305
(lp73306
S'Journal Article'
p73307
aS'Multicenter Study'
p73308
aS"Research Support, Non-U.S. Gov't"
p73309
asS'LA'
p73310
(lp73311
S'eng'
p73312
asS'FAU'
p73313
(lp73314
S'Thomson, Kerry A'
p73315
aS'Cheti, Erastus O'
p73316
aS'Reid, Tony'
p73317
asS'JT'
p73318
S'Transactions of the Royal Society of Tropical Medicine and Hygiene'
p73319
sS'PG'
p73320
S'320-6'
p73321
sS'TI'
p73322
S'Implementation and outcomes of an active defaulter tracing system for HIV, prevention of mother to child transmission of HIV (PMTCT), and TB patients in Kibera, Nairobi, Kenya.'
p73323
sS'RN'
p73324
(lp73325
S'0 (Anti-Retroviral Agents)'
p73326
asS'PL'
p73327
S'England'
p73328
sS'TA'
p73329
S'Trans R Soc Trop Med Hyg'
p73330
sS'JID'
p73331
S'7506129'
p73332
sS'AB'
p73333
S'Retention of patients in long term care and adherence to treatment regimens are a constant challenge for HIV, prevention of mother to child transmission of HIV (PMTCT), and TB programmes in sub-Saharan Africa. This study describes the implementation and outcomes of an active defaulter tracing system used to reduce loss to follow-up (LTFU) among HIV, PMTCT, TB, and HIV/TB co-infected patients receiving treatment at three Medecins Sans Frontieres clinics in the informal settlement of Kibera, Nairobi, Kenya. Patients are routinely contacted by a social worker via telephone, in-person visit, or both very soon after they miss an appointment. Patient outcomes identified through 1066 tracing activities conducted between 1 April 2008 and 31 March 2009 included: 59.4% returned to the clinic, 9.0% unable to return to clinic, 6.3% died, 4.7% refused to return to clinic, 4.5% went to a different clinic, and 0.8% were hospitalized. Fifteen percent of patients identified for tracing could not be contacted. LTFU among all HIV patients decreased from 21.2% in 2006 to 11.5% in 2009. An active defaulter tracing system is feasible in a resource poor setting, solicits feedback from patients, retains a mobile population of patients in care, and reduces LTFU among HIV, PMTCT, and TB patients.'
p73334
sS'AD'
p73335
S'Medecins Sans Frontieres (MSF) Operational Centre Brussels, PO BOX 38897 Postal Code 00623, Parklands, Nairobi, Kenya. thomson.kerry@gmail.com'
p73336
sS'IP'
p73337
S'6'
sS'IS'
p73338
S'1878-3503 (Electronic) 0035-9203 (Linking)'
p73339
sS'DCOM'
p73340
S'20110913'
p73341
sS'AU'
p73342
(lp73343
S'Thomson KA'
p73344
aS'Cheti EO'
p73345
aS'Reid T'
p73346
asS'VI'
p73347
S'105'
p73348
sS'MHDA'
p73349
S'2011/09/14 06:00'
p73350
sS'PHST'
p73351
(lp73352
S'2010/05/12 [received]'
p73353
aS'2011/02/24 [revised]'
p73354
aS'2011/02/24 [accepted]'
p73355
aS'2011/04/20 [aheadofprint]'
p73356
asS'MH'
p73357
(lp73358
S'Anti-Retroviral Agents/therapeutic use'
p73359
aS'Contact Tracing/methods/statistics & numerical data'
p73360
aS'Female'
p73361
aS'HIV Infections/*epidemiology/prevention & control/transmission'
p73362
aS'Humans'
p73363
aS'Infectious Disease Transmission, Vertical/*prevention & control/statistics & numerical data'
p73364
aS'Kenya/epidemiology'
p73365
aS'Lost to Follow-Up'
p73366
aS'Male'
p73367
aS'Medication Adherence/statistics & numerical data'
p73368
aS'Retrospective Studies'
p73369
aS'Sentinel Surveillance'
p73370
aS'Tuberculosis/*epidemiology/prevention & control/transmission'
p73371
aS'Vital Statistics'
p73372
asS'EDAT'
p73373
S'2011/04/23 06:00'
p73374
sS'SO'
p73375
S'Trans R Soc Trop Med Hyg. 2011 Jun;105(6):320-6. doi: 10.1016/j.trstmh.2011.02.011. Epub 2011 Apr 20.'
p73376
sS'SB'
p73377
S'IM'
p73378
sS'PMID'
p73379
S'21511317'
p73380
sS'PST'
p73381
S'ppublish'
p73382
stRp73383
ag2
(g3
g4
(dp73384
S'LID'
p73385
S'10.1016/S0140-6736(11)60438-8 [doi]'
p73386
sS'STAT'
p73387
S'MEDLINE'
p73388
sS'DEP'
p73389
S'20110418'
p73390
sS'CI'
p73391
(lp73392
S'Copyright (c) 2011 Elsevier Ltd. All rights reserved.'
p73393
asS'DA'
p73394
S'20110502'
p73395
sS'AID'
p73396
(lp73397
S'S0140-6736(11)60438-8 [pii]'
p73398
aS'10.1016/S0140-6736(11)60438-8 [doi]'
p73399
asS'CRDT'
p73400
(lp73401
S'2011/04/22 06:00'
p73402
asS'DP'
p73403
S'2011 Apr 30'
p73404
sS'AD'
p73405
S'Foundation for Innovative New Diagnostics, Geneva, Switzerland. catharina.boehme@finddiagnostics.org'
p73406
sS'OWN'
p73407
S'NLM'
p73408
sS'PT'
p73409
(lp73410
S'Journal Article'
p73411
aS'Multicenter Study'
p73412
aS"Research Support, Non-U.S. Gov't"
p73413
asS'LA'
p73414
(lp73415
S'eng'
p73416
asS'FAU'
p73417
(lp73418
S'Boehme, Catharina C'
p73419
aS'Nicol, Mark P'
p73420
aS'Nabeta, Pamela'
p73421
aS'Michael, Joy S'
p73422
aS'Gotuzzo, Eduardo'
p73423
aS'Tahirli, Rasim'
p73424
aS'Gler, Ma Tarcela'
p73425
aS'Blakemore, Robert'
p73426
aS'Worodria, William'
p73427
aS'Gray, Christen'
p73428
aS'Huang, Laurence'
p73429
aS'Caceres, Tatiana'
p73430
aS'Mehdiyev, Rafail'
p73431
aS'Raymond, Lawrence'
p73432
aS'Whitelaw, Andrew'
p73433
aS'Sagadevan, Kalaiselvan'
p73434
aS'Alexander, Heather'
p73435
aS'Albert, Heidi'
p73436
aS'Cobelens, Frank'
p73437
aS'Cox, Helen'
p73438
aS'Alland, David'
p73439
aS'Perkins, Mark D'
p73440
asS'JT'
p73441
S'Lancet (London, England)'
p73442
sS'LR'
p73443
S'20150616'
p73444
sS'PG'
p73445
S'1495-505'
p73446
sS'TI'
p73447
S'Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study.'
p73448
sS'RN'
p73449
(lp73450
S'0 (Antibiotics, Antitubercular)'
p73451
aS'VJT6J7R4TR (Rifampin)'
p73452
asS'PL'
p73453
S'England'
p73454
sS'TA'
p73455
S'Lancet'
p73456
sS'JID'
p73457
S'2985213R'
p73458
sS'AB'
p73459
S"BACKGROUND: The Xpert MTB/RIF test (Cepheid, Sunnyvale, CA, USA) can detect tuberculosis and its multidrug-resistant form with very high sensitivity and specificity in controlled studies, but no performance data exist from district and subdistrict health facilities in tuberculosis-endemic countries. We aimed to assess operational feasibility, accuracy, and effectiveness of implementation in such settings. METHODS: We assessed adults (>/=18 years) with suspected tuberculosis or multidrug-resistant tuberculosis consecutively presenting with cough lasting at least 2 weeks to urban health centres in South Africa, Peru, and India, drug-resistance screening facilities in Azerbaijan and the Philippines, and an emergency room in Uganda. Patients were excluded from the main analyses if their second sputum sample was collected more than 1 week after the first sample, or if no valid reference standard or MTB/RIF test was available. We compared one-off direct MTB/RIF testing in nine microscopy laboratories adjacent to study sites with 2-3 sputum smears and 1-3 cultures, dependent on site, and drug-susceptibility testing. We assessed indicators of robustness including indeterminate rate and between-site performance, and compared time to detection, reporting, and treatment, and patient dropouts for the techniques used. FINDINGS: We enrolled 6648 participants between Aug 11, 2009, and June 26, 2010. One-off MTB/RIF testing detected 933 (90.3%) of 1033 culture-confirmed cases of tuberculosis, compared with 699 (67.1%) of 1041 for microscopy. MTB/RIF test sensitivity was 76.9% in smear-negative, culture-positive patients (296 of 385 samples), and 99.0% specific (2846 of 2876 non-tuberculosis samples). MTB/RIF test sensitivity for rifampicin resistance was 94.4% (236 of 250) and specificity was 98.3% (796 of 810). Unlike microscopy, MTB/RIF test sensitivity was not significantly lower in patients with HIV co-infection. Median time to detection of tuberculosis for the MTB/RIF test was 0 days (IQR 0-1), compared with 1 day (0-1) for microscopy, 30 days (23-43) for solid culture, and 16 days (13-21) for liquid culture. Median time to detection of resistance was 20 days (10-26) for line-probe assay and 106 days (30-124) for conventional drug-susceptibility testing. Use of the MTB/RIF test reduced median time to treatment for smear-negative tuberculosis from 56 days (39-81) to 5 days (2-8). The indeterminate rate of MTB/RIF testing was 2.4% (126 of 5321 samples) compared with 4.6% (441 of 9690) for cultures. INTERPRETATION: The MTB/RIF test can effectively be used in low-resource settings to simplify patients' access to early and accurate diagnosis, thereby potentially decreasing morbidity associated with diagnostic delay, dropout and mistreatment. FUNDING: Foundation for Innovative New Diagnostics, Bill & Melinda Gates Foundation, European and Developing Countries Clinical Trials Partnership (TA2007.40200.009), Wellcome Trust (085251/B/08/Z), and UK Department for International Development."
p73460
sS'GR'
p73461
(lp73462
S'085251/Wellcome Trust/United Kingdom'
p73463
aS'085251/B/08/Z/Wellcome Trust/United Kingdom'
p73464
asS'IP'
p73465
S'9776'
p73466
sS'IS'
p73467
S'1474-547X (Electronic) 0140-6736 (Linking)'
p73468
sS'PMC'
p73469
S'PMC3085933'
p73470
sS'DCOM'
p73471
S'20110527'
p73472
sS'CIN'
p73473
(lp73474
S'Lancet. 2011 Aug 6;378(9790):481; author reply 482-3. PMID: 21821176'
p73475
aS'Lancet. 2011 Aug 6;378(9790):481-2; author reply 482-3. PMID: 21821177'
p73476
aS'Lancet. 2011 Aug 6;378(9790):482; author reply 482-3. PMID: 21821179'
p73477
aS'Evid Based Med. 2011 Dec;16(6):174-5. PMID: 21990187'
p73478
aS'Lancet. 2011 Apr 30;377(9776):1467-8. PMID: 21507476'
p73479
asS'AU'
p73480
(lp73481
S'Boehme CC'
p73482
aS'Nicol MP'
p73483
aS'Nabeta P'
p73484
aS'Michael JS'
p73485
aS'Gotuzzo E'
p73486
aS'Tahirli R'
p73487
aS'Gler MT'
p73488
aS'Blakemore R'
p73489
aS'Worodria W'
p73490
aS'Gray C'
p73491
aS'Huang L'
p73492
aS'Caceres T'
p73493
aS'Mehdiyev R'
p73494
aS'Raymond L'
p73495
aS'Whitelaw A'
p73496
aS'Sagadevan K'
p73497
aS'Alexander H'
p73498
aS'Albert H'
p73499
aS'Cobelens F'
p73500
aS'Cox H'
p73501
aS'Alland D'
p73502
aS'Perkins MD'
p73503
asS'VI'
p73504
S'377'
p73505
sS'MHDA'
p73506
S'2011/05/28 06:00'
p73507
sS'PHST'
p73508
(lp73509
S'2011/04/18 [aheadofprint]'
p73510
asS'OID'
p73511
(lp73512
S'NLM: PMC3085933'
p73513
asS'MH'
p73514
(lp73515
S'Adolescent'
p73516
aS'Adult'
p73517
aS'Aged'
p73518
aS'Antibiotics, Antitubercular/*pharmacology/therapeutic use'
p73519
aS'Bacteriological Techniques'
p73520
aS'*Developing Countries'
p73521
aS'Drug Resistance, Bacterial'
p73522
aS'Female'
p73523
aS'HIV Seronegativity'
p73524
aS'HIV Seropositivity/complications'
p73525
aS'Humans'
p73526
aS'Male'
p73527
aS'Middle Aged'
p73528
aS'Mycobacterium tuberculosis/*drug effects/isolation & purification'
p73529
aS'Rifampin/*pharmacology/therapeutic use'
p73530
aS'Sensitivity and Specificity'
p73531
aS'Sputum/*microbiology'
p73532
aS'Tuberculosis, Multidrug-Resistant/*diagnosis/drug therapy/virology'
p73533
aS'Tuberculosis, Pulmonary/*diagnosis/drug therapy/virology'
p73534
aS'Young Adult'
p73535
asS'EDAT'
p73536
S'2011/04/22 06:00'
p73537
sS'SO'
p73538
S'Lancet. 2011 Apr 30;377(9776):1495-505. doi: 10.1016/S0140-6736(11)60438-8. Epub 2011 Apr 18.'
p73539
sS'SB'
p73540
S'AIM IM'
p73541
sS'PMID'
p73542
S'21507477'
p73543
sS'PST'
p73544
S'ppublish'
p73545
stRp73546
ag2
(g3
g4
(dp73547
S'LID'
p73548
S'10.1097/QAD.0b013e3283471deb [doi]'
p73549
sS'STAT'
p73550
S'MEDLINE'
p73551
sS'JT'
p73552
S'AIDS (London, England)'
p73553
sS'CIN'
p73554
(lp73555
S'AIDS. 2011 Jun 1;25(9):1225-6. PMID: 21593620'
p73556
asS'DA'
p73557
S'20110519'
p73558
sS'AID'
p73559
(lp73560
S'10.1097/QAD.0b013e3283471deb [doi]'
p73561
asS'CRDT'
p73562
(lp73563
S'2011/04/21 06:00'
p73564
asS'DP'
p73565
S'2011 Jun 1'
p73566
sS'OWN'
p73567
S'NLM'
p73568
sS'PT'
p73569
(lp73570
S'Journal Article'
p73571
aS"Research Support, Non-U.S. Gov't"
p73572
aS"Research Support, U.S. Gov't, Non-P.H.S."
p73573
asS'LA'
p73574
(lp73575
S'eng'
p73576
asS'FAU'
p73577
(lp73578
S'Hawkins, Claudia'
p73579
aS'Chalamilla, Guerino'
p73580
aS'Okuma, James'
p73581
aS'Spiegelman, Donna'
p73582
aS'Hertzmark, Ellen'
p73583
aS'Aris, Eric'
p73584
aS'Ewald, Tarcila'
p73585
aS'Mugusi, Ferdinand'
p73586
aS'Mtasiwa, Deo'
p73587
aS'Fawzi, Wafaie'
p73588
asS'PG'
p73589
S'1189-97'
p73590
sS'TI'
p73591
S'Sex differences in antiretroviral treatment outcomes among HIV-infected adults in an urban Tanzanian setting.'
p73592
sS'RN'
p73593
(lp73594
S'0 (Anti-Retroviral Agents)'
p73595
asS'PL'
p73596
S'England'
p73597
sS'TA'
p73598
S'AIDS'
p73599
sS'JID'
p73600
S'8710219'
p73601
sS'AB'
p73602
S"OBJECTIVE: To determine the relationship between sex and antiretroviral therapy (ART) outcomes in an urban Tanzanian setting. DESIGN: Longitudinal analysis of a cohort of HIV-infected adult men and women on ART enrolled at the Management and Development for Health (MDH)-President's Emergency Plan For AIDS Relief (PEPFAR) HIV care and treatment program in Dar es Salaam, Tanzania. METHODS: Clinical and immunologic responses to ART were compared between HIV-infected men and women enrolled from November 2004 to June 2008. Cox regression analyses were used to study sex differences with regard to mortality, immunologic failure (WHO, 2006) and loss to follow-up, after adjusting for other risk factors for the outcomes. RESULTS: Four thousand, three hundred and eighty-three (34%) men and 8459 (66%) women were analyzed. Men were significantly more immunocompromised than women at enrollment in terms of stage IV disease (27 vs. 23%, P < 0.001) and mean CD4(+) cell count (123 vs. 136 cells/mul, P < 0.001). In multivariate analyses, men had a significantly higher risk of overall mortality [hazard ratio 1.19, 95% confidence interval (CI) 1.05-1.30, P < 0.001], immunologic nonresponse defined as CD4 cell count less than 100 cells/mul after at least 6 months of initiating ART (hazard ratio 1.74, 95% CI 1.44-2.11, P < 0.001) and loss to follow-up (hazard ratio 1.19, 95% CI 1.10-1.30, P < 0.001) than that in women. Associations did not change significantly when restricting analyses to the period of good adherence for all patients. CONCLUSION: Nonadherence to care and advanced immunodeficiency at enrollment explained only 17% of the inferior mortality in HIV-infected men in this resource-limited setting. Additional study of behavioral and biologic factors that may adversely impact treatment outcomes in men is needed to reduce these sex disparities."
p73603
sS'AD'
p73604
S'Division of Infectious Diseases, Northwestern University, Chicago, Illinois 60611, USA. c-hawkins@md.northwestern.edu'
p73605
sS'IP'
p73606
S'9'
sS'IS'
p73607
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p73608
sS'DCOM'
p73609
S'20110913'
p73610
sS'AU'
p73611
(lp73612
S'Hawkins C'
p73613
aS'Chalamilla G'
p73614
aS'Okuma J'
p73615
aS'Spiegelman D'
p73616
aS'Hertzmark E'
p73617
aS'Aris E'
p73618
aS'Ewald T'
p73619
aS'Mugusi F'
p73620
aS'Mtasiwa D'
p73621
aS'Fawzi W'
p73622
asS'VI'
p73623
S'25'
p73624
sS'MHDA'
p73625
S'2011/09/14 06:00'
p73626
sS'MH'
p73627
(lp73628
S'Adolescent'
p73629
aS'Adult'
p73630
aS'Anti-Retroviral Agents/*therapeutic use'
p73631
aS'CD4 Lymphocyte Count'
p73632
aS'Female'
p73633
aS'HIV Infections/*drug therapy/epidemiology/immunology'
p73634
aS'Humans'
p73635
aS'Male'
p73636
aS'Middle Aged'
p73637
aS'Prospective Studies'
p73638
aS'Risk Factors'
p73639
aS'Sex Characteristics'
p73640
aS'Tanzania/epidemiology'
p73641
aS'Treatment Outcome'
p73642
aS'Urban Health/*standards'
p73643
aS'Young Adult'
p73644
asS'EDAT'
p73645
S'2011/04/21 06:00'
p73646
sS'SO'
p73647
S'AIDS. 2011 Jun 1;25(9):1189-97. doi: 10.1097/QAD.0b013e3283471deb.'
p73648
sS'SB'
p73649
S'IM X'
p73650
sS'PMID'
p73651
S'21505309'
p73652
sS'PST'
p73653
S'ppublish'
p73654
stRp73655
ag2
(g3
g4
(dp73656
S'LID'
p73657
S'10.1186/1471-2334-11-98 [doi]'
p73658
sS'STAT'
p73659
S'MEDLINE'
p73660
sS'DEP'
p73661
S'20110419'
p73662
sS'DA'
p73663
S'20110603'
p73664
sS'AID'
p73665
(lp73666
S'1471-2334-11-98 [pii]'
p73667
aS'10.1186/1471-2334-11-98 [doi]'
p73668
asS'CRDT'
p73669
(lp73670
S'2011/04/21 06:00'
p73671
asS'DP'
p73672
S'2011'
p73673
sS'OWN'
p73674
S'NLM'
p73675
sS'PT'
p73676
(lp73677
S'Journal Article'
p73678
aS"Research Support, Non-U.S. Gov't"
p73679
asS'LA'
p73680
(lp73681
S'eng'
p73682
asS'DCOM'
p73683
S'20111201'
p73684
sS'JT'
p73685
S'BMC infectious diseases'
p73686
sS'LR'
p73687
S'20150204'
p73688
sS'FAU'
p73689
(lp73690
S'Mossdorf, Erik'
p73691
aS'Stoeckle, Marcel'
p73692
aS'Mwaigomole, Emmanuel G'
p73693
aS'Chiweka, Evarist'
p73694
aS'Kibatala, Patience L'
p73695
aS'Geubbels, Eveline'
p73696
aS'Urassa, Honoraty'
p73697
aS'Abdulla, Salim'
p73698
aS'Elzi, Luigia'
p73699
aS'Tanner, Marcel'
p73700
aS'Furrer, Hansjakob'
p73701
aS'Hatz, Christoph'
p73702
aS'Battegay, Manuel'
p73703
asS'TI'
p73704
S'Improved antiretroviral treatment outcome in a rural African setting is associated with cART initiation at higher CD4 cell counts and better general health condition.'
p73705
sS'RN'
p73706
(lp73707
S'0 (Anti-HIV Agents)'
p73708
aS'99DK7FVK1H (Nevirapine)'
p73709
asS'PL'
p73710
S'England'
p73711
sS'PG'
p73712
S'98'
p73713
sS'JID'
p73714
S'100968551'
p73715
sS'AB'
p73716
S'BACKGROUND: Data on combination antiretroviral therapy (cART) in remote rural African regions is increasing. METHODS: We assessed prospectively initial cART in HIV-infected adults treated from 2005 to 2008 at St. Francis Designated District Hospital, Ifakara, Tanzania. Adherence was assisted by personal adherence supporters. We estimated risk factors of death or loss to follow-up by Cox regression during the first 12 months of cART. RESULTS: Overall, 1,463 individuals initiated cART, which was nevirapine-based in 84.6%. The median age was 40 years (IQR 34-47), 35.4% were males, 7.6% had proven tuberculosis. Median CD4 cell count was 131 cells/mul and 24.8% had WHO stage 4. Median CD4 cell count increased by 61 and 130 cells/mul after 6 and 12 months, respectively. 215 (14.7%) patients modified their treatment, mostly due to toxicity (56%), in particular polyneuropathy and anemia. Overall, 129 patients died (8.8%) and 189 (12.9%) were lost to follow-up. In a multivariate analysis, low CD4 cells at starting cART were associated with poorer survival and loss to follow-up (HR 1.77, 95% CI 1.15-2.75, p=0.009; for CD4<50 compared to >100 cells/mul). Higher weight was strongly associated with better survival (HR 0.63, 95% CI 0.51-0.76, p<0.001 per 10 kg increase). CONCLUSIONS: cART initiation at higher CD4 cell counts and better general health condition reduces HIV related mortality in a rural African setting. Efforts must be made to promote earlier HIV diagnosis to start cART timely. More research is needed to evaluate effective strategies to follow cART at a peripheral level with limited technical possibilities.'
p73717
sS'AD'
p73718
S'St. Francis Designated District Hospital, Ifakara, United Republic of Tanzania.'
p73719
sS'VI'
p73720
S'11'
p73721
sS'IS'
p73722
S'1471-2334 (Electronic) 1471-2334 (Linking)'
p73723
sS'PMC'
p73724
S'PMC3107177'
p73725
sS'AU'
p73726
(lp73727
S'Mossdorf E'
p73728
aS'Stoeckle M'
p73729
aS'Mwaigomole EG'
p73730
aS'Chiweka E'
p73731
aS'Kibatala PL'
p73732
aS'Geubbels E'
p73733
aS'Urassa H'
p73734
aS'Abdulla S'
p73735
aS'Elzi L'
p73736
aS'Tanner M'
p73737
aS'Furrer H'
p73738
aS'Hatz C'
p73739
aS'Battegay M'
p73740
asS'MHDA'
p73741
S'2011/12/13 00:00'
p73742
sS'PHST'
p73743
(lp73744
S'2010/09/23 [received]'
p73745
aS'2011/04/19 [accepted]'
p73746
aS'2011/04/19 [aheadofprint]'
p73747
asS'OID'
p73748
(lp73749
S'NLM: PMC3107177'
p73750
asS'MH'
p73751
(lp73752
S'Adult'
p73753
aS'Anti-HIV Agents/*therapeutic use'
p73754
aS'CD4 Lymphocyte Count'
p73755
aS'Female'
p73756
aS'Follow-Up Studies'
p73757
aS'HIV Infections/*drug therapy/epidemiology/*immunology/mortality'
p73758
aS'Health Status'
p73759
aS'Humans'
p73760
aS'Lost to Follow-Up'
p73761
aS'Male'
p73762
aS'Middle Aged'
p73763
aS'Nevirapine/therapeutic use'
p73764
aS'Prospective Studies'
p73765
aS'Rural Health/statistics & numerical data'
p73766
aS'Tanzania/epidemiology'
p73767
asS'EDAT'
p73768
S'2011/04/21 06:00'
p73769
sS'SO'
p73770
S'BMC Infect Dis. 2011 Apr 19;11:98. doi: 10.1186/1471-2334-11-98.'
p73771
sS'SB'
p73772
S'IM'
p73773
sS'PMID'
p73774
S'21504595'
p73775
sS'TA'
p73776
S'BMC Infect Dis'
p73777
sS'PST'
p73778
S'epublish'
p73779
stRp73780
ag2
(g3
g4
(dp73781
S'LID'
p73782
S'10.1016/j.jadohealth.2010.08.007 [doi]'
p73783
sS'STAT'
p73784
S'MEDLINE'
p73785
sS'DEP'
p73786
S'20110218'
p73787
sS'CI'
p73788
(lp73789
S'Copyright (c) 2011 Society for Adolescent Health and Medicine. Published by'
p73790
aS'Elsevier Inc. All rights reserved.'
p73791
asS'DA'
p73792
S'20110419'
p73793
sS'AID'
p73794
(lp73795
S'S1054-139X(10)00396-4 [pii]'
p73796
aS'10.1016/j.jadohealth.2010.08.007 [doi]'
p73797
asS'CRDT'
p73798
(lp73799
S'2011/04/20 06:00'
p73800
asS'DP'
p73801
S'2011 May'
p73802
sS'AD'
p73803
S'Pacific Institute for Research and Evaluation, 1516 E. Franklin Street, Chapel Hill, NC 27514, USA. cho@pire.org'
p73804
sS'OWN'
p73805
S'NLM'
p73806
sS'PT'
p73807
(lp73808
S'Journal Article'
p73809
aS'Randomized Controlled Trial'
p73810
aS'Research Support, N.I.H., Extramural'
p73811
asS'LA'
p73812
(lp73813
S'eng'
p73814
asS'FAU'
p73815
(lp73816
S'Cho, Hyunsan'
p73817
aS'Hallfors, Denise D'
p73818
aS'Mbai, Isabella I'
p73819
aS'Itindi, Janet'
p73820
aS'Milimo, Benson W'
p73821
aS'Halpern, Carolyn T'
p73822
aS'Iritani, Bonita J'
p73823
asS'JT'
p73824
S'The Journal of adolescent health : official publication of the Society for Adolescent Medicine'
p73825
sS'LR'
p73826
S'20150204'
p73827
sS'PG'
p73828
S'523-6'
p73829
sS'TI'
p73830
S'Keeping adolescent orphans in school to prevent human immunodeficiency virus infection: evidence from a randomized controlled trial in Kenya.'
p73831
sS'PL'
p73832
S'United States'
p73833
sS'TA'
p73834
S'J Adolesc Health'
p73835
sS'JID'
p73836
S'9102136'
p73837
sS'AB'
p73838
S'PURPOSE: We report the findings from a pilot study in western Kenya, using an experimental design to test whether comprehensive support used to keep adolescent orphans in school can reduce risk factors associated with infection with human immunodeficiency virus. METHODS: Adolescent orphans aged 12-14 years (N = 105) in Nyanza Province were randomized to condition, after stratifying by household, gender, and baseline survey report of sexual behavior. The intervention comprised school fees, uniforms, and a "community visitor" who monitored school attendance and helped to resolve problems that would lead to absence or dropout. Data were analyzed using generalized estimating equations over two time points, controlling for gender and age. RESULTS: Compared with the control group, intervention students were less likely to drop out of school, commence sexual intercourse, or report attitudes supporting early sex. School support also increased prosocial bonding and gender equity attitudes. CONCLUSIONS: After 1 year of exposure to the intervention, we found evidence suggesting that comprehensive school support can prevent school dropout, delay sexual debut, and reduce risk factors associated with infection with human immunodeficiency virus. Further research, with much larger samples, is needed to better understand factors that mediate the association between educational support and delayed sexual debut, and how gender might moderate these relationships.'
p73839
sS'GR'
p73840
(lp73841
S'5R34MH79749-3/MH/NIMH NIH HHS/United States'
p73842
aS'R24 HD050924/HD/NICHD NIH HHS/United States'
p73843
aS'R34 MH079749/MH/NIMH NIH HHS/United States'
p73844
aS'R34 MH079749-03/MH/NIMH NIH HHS/United States'
p73845
asS'IP'
p73846
S'5'
sS'IS'
p73847
S'1879-1972 (Electronic) 1054-139X (Linking)'
p73848
sS'PMC'
p73849
S'PMC3079907'
p73850
sS'DCOM'
p73851
S'20110829'
p73852
sS'MID'
p73853
(lp73854
S'NIHMS231398'
p73855
asS'AU'
p73856
(lp73857
S'Cho H'
p73858
aS'Hallfors DD'
p73859
aS'Mbai II'
p73860
aS'Itindi J'
p73861
aS'Milimo BW'
p73862
aS'Halpern CT'
p73863
aS'Iritani BJ'
p73864
asS'VI'
p73865
S'48'
p73866
sS'MHDA'
p73867
S'2011/08/30 06:00'
p73868
sS'PHST'
p73869
(lp73870
S'2010/03/30 [received]'
p73871
aS'2010/08/10 [revised]'
p73872
aS'2010/08/10 [accepted]'
p73873
aS'2011/02/18 [aheadofprint]'
p73874
asS'OID'
p73875
(lp73876
S'NLM: NIHMS231398'
p73877
aS'NLM: PMC3079907'
p73878
asS'MH'
p73879
(lp73880
S'Adolescent'
p73881
aS'Child'
p73882
aS'*Child, Orphaned'
p73883
aS'Data Collection'
p73884
aS'Female'
p73885
aS'HIV Infections/*prevention & control'
p73886
aS'Humans'
p73887
aS'Kenya'
p73888
aS'Male'
p73889
aS'*Schools'
p73890
aS'Sexual Behavior'
p73891
aS'Student Dropouts'
p73892
asS'EDAT'
p73893
S'2011/04/20 06:00'
p73894
sS'SO'
p73895
S'J Adolesc Health. 2011 May;48(5):523-6. doi: 10.1016/j.jadohealth.2010.08.007. Epub 2011 Feb 18.'
p73896
sS'SB'
p73897
S'IM'
p73898
sS'PMID'
p73899
S'21501814'
p73900
sS'PST'
p73901
S'ppublish'
p73902
stRp73903
ag2
(g3
g4
(dp73904
S'LID'
p73905
S'10.2105/AJPH.2010.300042 [doi]'
p73906
sS'STAT'
p73907
S'MEDLINE'
p73908
sS'DEP'
p73909
S'20110414'
p73910
sS'MID'
p73911
(lp73912
S'NIHMS306716'
p73913
asS'DA'
p73914
S'20110513'
p73915
sS'AID'
p73916
(lp73917
S'AJPH.2010.300042 [pii]'
p73918
aS'10.2105/AJPH.2010.300042 [doi]'
p73919
asS'CRDT'
p73920
(lp73921
S'2011/04/16 06:00'
p73922
asS'DP'
p73923
S'2011 Jun'
p73924
sS'AD'
p73925
S'Pacific Institute for Research and Evaluation, 1516 E Franklin St, Suite 200, Chapel Hill, NC 27514, USA. hallfors@pire.org'
p73926
sS'OWN'
p73927
S'NLM'
p73928
sS'PT'
p73929
(lp73930
S'Journal Article'
p73931
aS'Randomized Controlled Trial'
p73932
asS'LA'
p73933
(lp73934
S'eng'
p73935
asS'FAU'
p73936
(lp73937
S'Hallfors, Denise'
p73938
aS'Cho, Hyunsan'
p73939
aS'Rusakaniko, Simbarashe'
p73940
aS'Iritani, Bonita'
p73941
aS'Mapfumo, John'
p73942
aS'Halpern, Carolyn'
p73943
asS'JT'
p73944
S'American journal of public health'
p73945
sS'LR'
p73946
S'20150204'
p73947
sS'PG'
p73948
S'1082-8'
p73949
sS'TI'
p73950
S'Supporting adolescent orphan girls to stay in school as HIV risk prevention: evidence from a randomized controlled trial in Zimbabwe.'
p73951
sS'PL'
p73952
S'United States'
p73953
sS'TA'
p73954
S'Am J Public Health'
p73955
sS'JID'
p73956
S'1254074'
p73957
sS'AB'
p73958
S'OBJECTIVES: Using a randomized controlled trial in rural eastern Zimbabwe, we tested whether comprehensive support to keep orphan adolescent girls in school could reduce HIV risk. METHODS: All orphan girls in grade 6 in 25 primary schools were invited to participate in the study in fall 2007 (n = 329). Primary schools were randomized to condition. All primary schools received a universal daily feeding program; intervention participants received fees, uniforms, and a school-based helper to monitor attendance and resolve problems. We conducted annual surveys and collected additional information on school dropout, marriage, and pregnancy rates. We analyzed data using generalized estimating equations over 3 time points, controlling for school and age at baseline. RESULTS: The intervention reduced school dropout by 82% and marriage by 63% after 2 years. Compared with control participants, the intervention group reported greater school bonding, better future expectations, more equitable gender attitudes, and more concerns about the consequences of sex. CONCLUSIONS: We found promising evidence that comprehensive school support may reduce HIV risk for orphan girls. Further study, including assessment of dose response, cost benefit, and HIV and herpes simplex virus 2 biomarker measurement, is warranted.'
p73959
sS'GR'
p73960
(lp73961
S'R01 HD055838/HD/NICHD NIH HHS/United States'
p73962
aS'R01 HD055838-01/HD/NICHD NIH HHS/United States'
p73963
aS'R01 HD055838-02/HD/NICHD NIH HHS/United States'
p73964
aS'R01 HD055838-03/HD/NICHD NIH HHS/United States'
p73965
aS'R01 HD055838-04/HD/NICHD NIH HHS/United States'
p73966
aS'R01 HD055838-04S1/HD/NICHD NIH HHS/United States'
p73967
aS'R24 HD050924/HD/NICHD NIH HHS/United States'
p73968
asS'IP'
p73969
S'6'
sS'IS'
p73970
S'1541-0048 (Electronic) 0090-0036 (Linking)'
p73971
sS'PMC'
p73972
S'PMC3093274'
p73973
sS'DCOM'
p73974
S'20110712'
p73975
sS'AU'
p73976
(lp73977
S'Hallfors D'
p73978
aS'Cho H'
p73979
aS'Rusakaniko S'
p73980
aS'Iritani B'
p73981
aS'Mapfumo J'
p73982
aS'Halpern C'
p73983
asS'VI'
p73984
S'101'
p73985
sS'MHDA'
p73986
S'2011/07/13 06:00'
p73987
sS'PHST'
p73988
(lp73989
S'2011/04/14 [aheadofprint]'
p73990
asS'OID'
p73991
(lp73992
S'NLM: NIHMS306716'
p73993
aS'NLM: PMC3093274'
p73994
asS'MH'
p73995
(lp73996
S'Adolescent'
p73997
aS'Child'
p73998
aS'Child, Orphaned/*psychology/statistics & numerical data'
p73999
aS'Evidence-Based Medicine'
p74000
aS'Female'
p74001
aS'Follow-Up Studies'
p74002
aS'HIV Infections/*prevention & control'
p74003
aS'Health Promotion/*methods'
p74004
aS'Humans'
p74005
aS'Pregnancy'
p74006
aS'Risk Factors'
p74007
aS'Rural Health'
p74008
aS'*Schools/statistics & numerical data'
p74009
aS'*Social Support'
p74010
aS'Zimbabwe'
p74011
asS'EDAT'
p74012
S'2011/04/16 06:00'
p74013
sS'SO'
p74014
S'Am J Public Health. 2011 Jun;101(6):1082-8. doi: 10.2105/AJPH.2010.300042. Epub 2011 Apr 14.'
p74015
sS'SB'
p74016
S'AIM IM'
p74017
sS'PMID'
p74018
S'21493943'
p74019
sS'PST'
p74020
S'ppublish'
p74021
stRp74022
ag2
(g3
g4
(dp74023
S'LID'
p74024
S'10.2165/11588240-000000000-00000 [doi]'
p74025
sS'STAT'
p74026
S'MEDLINE'
p74027
sS'JT'
p74028
S'Drug safety'
p74029
sS'MID'
p74030
(lp74031
S'NIHMS804183'
p74032
asS'DA'
p74033
S'20110518'
p74034
sS'AID'
p74035
(lp74036
S'10.2165/11588240-000000000-00000 [doi]'
p74037
asS'CRDT'
p74038
(lp74039
S'2011/04/15 06:00'
p74040
asS'DP'
p74041
S'2011 Jun 1'
p74042
sS'AD'
p74043
S'Department of Emergency Medicine, Mt Sinai School of Medicine, New York, New York 10029, USA. liza.leung@mssm.edu'
p74044
sS'OWN'
p74045
S'NLM'
p74046
sS'PT'
p74047
(lp74048
S'Journal Article'
p74049
asS'LA'
p74050
(lp74051
S'eng'
p74052
asS'FAU'
p74053
(lp74054
S'Leung, Liza'
p74055
aS'Wilson, Douglas'
p74056
aS'Manini, Alex F'
p74057
asS'LR'
p74058
S'20160909'
p74059
sS'PG'
p74060
S'521-7'
p74061
sS'TI'
p74062
S'Fatal toxicity from symptomatic hyperlactataemia: a retrospective cohort study of factors implicated with long-term nucleoside reverse transcriptase inhibitor use in a South African hospital.'
p74063
sS'RN'
p74064
(lp74065
S'0 (Anti-HIV Agents)'
p74066
aS'0 (Nucleosides)'
p74067
aS'0 (Reverse Transcriptase Inhibitors)'
p74068
aS'33X04XA5AT (Lactic Acid)'
p74069
asS'PL'
p74070
S'New Zealand'
p74071
sS'TA'
p74072
S'Drug Saf'
p74073
sS'JID'
p74074
S'9002928'
p74075
sS'AB'
p74076
S'BACKGROUND: In many Sub-Saharan African countries, first-line therapy for HIV may include a nucleoside reverse transcriptase inhibitor (NRTI). Long-term NRTI use is associated with symptomatic hyperlactataemia due to inhibition of mitochondrial DNA polymerase gamma, a potentially fatal complication. OBJECTIVE: The purpose of the study was to evaluate the factors associated with inhospital fatality for HIV inpatients prescribed NRTIs long term who presented with symptomatic hyperlactataemia. METHODS: We performed a retrospective cohort study at a 900-bed university hospital in South Africa over 4 years (2005-2008). We included HIV inpatients prescribed NRTIs long term who presented with symptomatic hyperlactataemia (long-term NRTI use; lactate >4.0 mmol/L; absence of infectious source; symptoms requiring admission). Data included demographics, medical history, NRTI duration, blood pressure, symptom duration and relevant laboratory data. RESULTS: Of 79 patients who met inclusion criteria (mean age 38.2 +/- 10.5 years, 97% female) there were 46 fatalities (58%). Factors significantly associated with fatality were presence of diabetes mellitus (p = 0.04), lactate >/=10 mmol/L (p = 0.003), pH <7.2 (p = 0.002), creatinine >/=200 mumol/L (p = 0.03) and altered mental status (p = 0.03). CONCLUSIONS: In this study, NRTI-related symptomatic hyperlactataemia occurred predominantly in females. Mortality was associated with severely elevated lactate (>/=10 mmol/L), the degree of acidosis, elevated creatinine, history of diabetes and altered mental status on presentation.'
p74077
sS'GR'
p74078
(lp74079
S'K23 DA026476/DA/NIDA NIH HHS/United States'
p74080
asS'IP'
p74081
S'6'
sS'IS'
p74082
S'1179-1942 (Electronic) 0114-5916 (Linking)'
p74083
sS'PMC'
p74084
S'PMC4959600'
p74085
sS'DCOM'
p74086
S'20111003'
p74087
sS'AU'
p74088
(lp74089
S'Leung L'
p74090
aS'Wilson D'
p74091
aS'Manini AF'
p74092
asS'VI'
p74093
S'34'
p74094
sS'MHDA'
p74095
S'2011/10/04 06:00'
p74096
sS'OID'
p74097
(lp74098
S'NLM: NIHMS804183'
p74099
aS'NLM: PMC4959600'
p74100
asS'MH'
p74101
(lp74102
S'Adult'
p74103
aS'Anti-HIV Agents/*administration & dosage/adverse effects'
p74104
aS'Cohort Studies'
p74105
aS'Female'
p74106
aS'HIV Infections/blood/drug therapy'
p74107
aS'Hospital Mortality'
p74108
aS'Humans'
p74109
aS'Lactic Acid/*blood'
p74110
aS'Long-Term Care'
p74111
aS'Male'
p74112
aS'Nucleosides/administration & dosage'
p74113
aS'Retrospective Studies'
p74114
aS'Reverse Transcriptase Inhibitors/*administration & dosage/adverse effects'
p74115
aS'Risk Factors'
p74116
aS'South Africa'
p74117
asS'EDAT'
p74118
S'2011/04/15 06:00'
p74119
sS'SO'
p74120
S'Drug Saf. 2011 Jun 1;34(6):521-7. doi: 10.2165/11588240-000000000-00000.'
p74121
sS'SB'
p74122
S'IM'
p74123
sS'PMID'
p74124
S'21488705'
p74125
sS'PST'
p74126
S'ppublish'
p74127
stRp74128
ag2
(g3
g4
(dp74129
S'STAT'
p74130
S'MEDLINE'
p74131
sS'DEP'
p74132
S'20101201'
p74133
sS'MID'
p74134
(lp74135
S'NIHMS333310'
p74136
asS'DA'
p74137
S'20110318'
p74138
sS'CRDT'
p74139
(lp74140
S'2011/03/19 06:00'
p74141
asS'DP'
p74142
S'2010 Dec'
p74143
sS'AD'
p74144
S'Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town.'
p74145
sS'OWN'
p74146
S'NLM'
p74147
sS'PT'
p74148
(lp74149
S'Comparative Study'
p74150
aS'Journal Article'
p74151
aS'Research Support, N.I.H., Extramural'
p74152
asS'LA'
p74153
(lp74154
S'eng'
p74155
asS'FAU'
p74156
(lp74157
S'Fitzgerald, Felicity C'
p74158
aS'Bekker, Linda-Gail'
p74159
aS'Kaplan, Richard'
p74160
aS'Myer, Landon'
p74161
aS'Lawn, Stephen D'
p74162
aS'Wood, Robin'
p74163
asS'JT'
p74164
S'South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde'
p74165
sS'LR'
p74166
S'20150204'
p74167
sS'PG'
p74168
S'827-31'
p74169
sS'TI'
p74170
S'Mother-to-child transmission of HIV in a community-based antiretroviral clinic in South Africa.'
p74171
sS'RN'
p74172
(lp74173
S'0 (Anti-HIV Agents)'
p74174
asS'PL'
p74175
S'South Africa'
p74176
sS'TA'
p74177
S'S Afr Med J'
p74178
sS'JID'
p74179
S'0404520'
p74180
sS'AB'
p74181
S"OBJECTIVE: To examine the uptake of ART among pregnant women referred to an ART service and the associated rates and risk factors for vertical HIV transmission. METHOD: Retrospective analysis of an observational cohort at a community ART clinic in Cape Town. RESULTS: Between 2002 and 2008, 367 treatment-naive pregnant women accessed the clinic. The median age was 27.5 years, and median gestation at presentation was 28 weeks. The median baseline CD4 count and viral load were 134 cells/microl and 28 282 copies/ml. Two hundred and sixty-five women (72%) commenced ART before giving birth, 73 women (20%) were referred for prevention of mother-to-child transmission therapy (PMTCT), and 29 (8%) received no intervention. Among ART-eligible women, 13% were lost to follow-up. Of those starting ART, median duration of therapy prior to birth was 7.6 weeks (interquartile range (IQR) 4 - 11.9).The HIV transmission rate was 5.1% (95% confidence interval (CI) 2.8 - 9.0%). Factors associated with transmission were advanced maternal WHO disease stage (odds ratio (OR) 9.57, p=0.02), and follow-up viral load above 50 copies/ml (OR 3.64, p=0.03). Each additional week on ART reduced transmission by 20% (p=0.05). There was no HIV transmission among women who received more than 8 weeks' therapy. CONCLUSIONS: The rate of HIV transmission in this study was higher than reported in high-income countries. Prevention of vertical transmission with ART was hindered by women presenting late in pregnancy and with advanced stage of HIV disease. Interventions that facilitate earlier ART commencement and improve programmatic retention of pregnant women are required."
p74182
sS'GR'
p74183
(lp74184
S'1U19AI53217-01/AI/NIAID NIH HHS/United States'
p74185
aS'A1058736-01A1/PHS HHS/United States'
p74186
aS'R01 AI058736/AI/NIAID NIH HHS/United States'
p74187
aS'R01 AI058736-01A1/AI/NIAID NIH HHS/United States'
p74188
aS'U19 AI053217/AI/NIAID NIH HHS/United States'
p74189
asS'IP'
p74190
S'12'
p74191
sS'IS'
p74192
S'0256-9574 (Print)'
p74193
sS'PMC'
p74194
S'PMC3954611'
p74195
sS'DCOM'
p74196
S'20110426'
p74197
sS'AU'
p74198
(lp74199
S'Fitzgerald FC'
p74200
aS'Bekker LG'
p74201
aS'Kaplan R'
p74202
aS'Myer L'
p74203
aS'Lawn SD'
p74204
aS'Wood R'
p74205
asS'VI'
p74206
S'100'
p74207
sS'MHDA'
p74208
S'2011/04/27 06:00'
p74209
sS'PHST'
p74210
(lp74211
S'2010/01/22 [received]'
p74212
aS'2010/05/12 [accepted]'
p74213
asS'OID'
p74214
(lp74215
S'NLM: NIHMS333310'
p74216
aS'NLM: PMC3954611'
p74217
asS'MH'
p74218
(lp74219
S'Adult'
p74220
aS'Anti-HIV Agents/*therapeutic use'
p74221
aS'Female'
p74222
aS'Follow-Up Studies'
p74223
aS'*HIV'
p74224
aS'HIV Infections/epidemiology/prevention & control/*transmission'
p74225
aS'*Hospitals, Special'
p74226
aS'Humans'
p74227
aS'Infant, Newborn'
p74228
aS'Infectious Disease Transmission, Vertical/*prevention & control'
p74229
aS'Pregnancy'
p74230
aS'*Pregnancy Complications, Infectious'
p74231
aS'Pregnancy Outcome'
p74232
aS'Retrospective Studies'
p74233
aS'South Africa/epidemiology'
p74234
aS'Young Adult'
p74235
asS'EDAT'
p74236
S'2011/03/19 06:00'
p74237
sS'SO'
p74238
S'S Afr Med J. 2010 Dec 1;100(12):827-31.'
p74239
sS'SB'
p74240
S'IM'
p74241
sS'PMID'
p74242
S'21414276'
p74243
sS'PST'
p74244
S'epublish'
p74245
stRp74246
ag2
(g3
g4
(dp74247
S'LID'
p74248
S'10.1371/journal.pone.0017518 [doi]'
p74249
sS'STAT'
p74250
S'MEDLINE'
p74251
sS'DEP'
p74252
S'20110309'
p74253
sS'DA'
p74254
S'20110316'
p74255
sS'AID'
p74256
(lp74257
S'10.1371/journal.pone.0017518 [doi]'
p74258
asS'CRDT'
p74259
(lp74260
S'2011/03/17 06:00'
p74261
asS'DP'
p74262
S'2011'
p74263
sS'AD'
p74264
S'Division of Global Health (IHCAR), Karolinska Institutet, Stockholm, Sweden. ziad.khatib@gmail.com'
p74265
sS'OWN'
p74266
S'NLM'
p74267
sS'PT'
p74268
(lp74269
S'Journal Article'
p74270
aS'Research Support, N.I.H., Extramural'
p74271
aS"Research Support, Non-U.S. Gov't"
p74272
asS'LA'
p74273
(lp74274
S'eng'
p74275
asS'FAU'
p74276
(lp74277
S'El-Khatib, Ziad'
p74278
aS'Katzenstein, David'
p74279
aS'Marrone, Gaetano'
p74280
aS'Laher, Fatima'
p74281
aS'Mohapi, Lerato'
p74282
aS'Petzold, Max'
p74283
aS'Morris, Lynn'
p74284
aS'Ekstrom, Anna Mia'
p74285
asS'JT'
p74286
S'PloS one'
p74287
sS'LR'
p74288
S'20150204'
p74289
sS'PG'
p74290
S'e17518'
p74291
sS'TI'
p74292
S'Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa.'
p74293
sS'PL'
p74294
S'United States'
p74295
sS'TA'
p74296
S'PLoS One'
p74297
sS'JID'
p74298
S'101285081'
p74299
sS'AB'
p74300
S'BACKGROUND: Affordable strategies to prevent treatment failure on first-line regimens among HIV patients are essential for the long-term success of antiretroviral therapy (ART) in sub-Saharan Africa. WHO recommends using routinely collected data such as adherence to drug-refill visits as early warning indicators. We examined the association between adherence to drug-refill visits and long-term virologic and immunologic failure among non-nucleoside reverse transcriptase inhibitor (NNRTI) recipients in South Africa. METHODS: In 2008, 456 patients on NNRTI-based ART for a median of 44 months (range 12-99 months; 1,510 person-years) were enrolled in a retrospective cohort study in Soweto. Charts were reviewed for clinical characteristics before and during ART. Multivariable logistic regression and Kaplan-Meier survival analysis assessed associations with virologic (two repeated VL>50 copies/ml) and immunologic failure (as defined by WHO). RESULTS: After a median of 15 months on ART, 19% (n = 88) and 19% (n = 87) had failed virologically and immunologically respectively. A cumulative adherence of <95% to drug-refill visits was significantly associated with both virologic and immunologic failure (p<0.01). In the final multivariable model, risk factors for virologic failure were incomplete adherence (OR 2.8, 95%CI 1.2-6.7), and previous exposure to single-dose nevirapine or any other antiretrovirals (adj. OR 2.1, 95%CI 1.2-3.9), adjusted for age and sex. In Kaplan-Meier analysis, the virologic failure rate by month 48 was 19% vs. 37% among adherent and non-adherent patients respectively (logrank p value = 0.02). CONCLUSION: One in five failed virologically after a median of 15 months on ART. Adherence to drug-refill visits works as an early warning indicator for both virologic and immunologic failure.'
p74301
sS'GR'
p74302
(lp74303
S'2 U2R TW006878/TW/FIC NIH HHS/United States'
p74304
aS'R01 AI066922/AI/NIAID NIH HHS/United States'
p74305
asS'IP'
p74306
S'3'
sS'IS'
p74307
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p74308
sS'PMC'
p74309
S'PMC3052314'
p74310
sS'DCOM'
p74311
S'20110705'
p74312
sS'AU'
p74313
(lp74314
S'El-Khatib Z'
p74315
aS'Katzenstein D'
p74316
aS'Marrone G'
p74317
aS'Laher F'
p74318
aS'Mohapi L'
p74319
aS'Petzold M'
p74320
aS'Morris L'
p74321
aS'Ekstrom AM'
p74322
asS'VI'
p74323
S'6'
sS'MHDA'
p74324
S'2011/07/06 06:00'
p74325
sS'PHST'
p74326
(lp74327
S'2010/11/18 [received]'
p74328
aS'2011/02/04 [accepted]'
p74329
aS'2011/03/09 [epublish]'
p74330
asS'OID'
p74331
(lp74332
S'NLM: PMC3052314'
p74333
asS'MH'
p74334
(lp74335
S'Adolescent'
p74336
aS'Adult'
p74337
aS'*Antiretroviral Therapy, Highly Active'
p74338
aS'CD4 Lymphocyte Count'
p74339
aS'Demography'
p74340
aS'Female'
p74341
aS'HIV Infections/drug therapy/*immunology/*virology'
p74342
aS'Humans'
p74343
aS'Kaplan-Meier Estimate'
p74344
aS'Male'
p74345
aS'Middle Aged'
p74346
aS'*Patient Compliance'
p74347
aS'Self Report'
p74348
aS'South Africa'
p74349
aS'Treatment Failure'
p74350
aS'Young Adult'
p74351
asS'EDAT'
p74352
S'2011/03/17 06:00'
p74353
sS'SO'
p74354
S'PLoS One. 2011 Mar 9;6(3):e17518. doi: 10.1371/journal.pone.0017518.'
p74355
sS'SB'
p74356
S'IM'
p74357
sS'PMID'
p74358
S'21408071'
p74359
sS'PST'
p74360
S'epublish'
p74361
stRp74362
ag2
(g3
g4
(dp74363
S'LID'
p74364
S'10.1097/QAI.0b013e3182167f0d [doi]'
p74365
sS'STAT'
p74366
S'MEDLINE'
p74367
sS'JT'
p74368
S'Journal of acquired immune deficiency syndromes (1999)'
p74369
sS'MID'
p74370
(lp74371
S'NIHMS282833'
p74372
asS'DA'
p74373
S'20110822'
p74374
sS'AID'
p74375
(lp74376
S'10.1097/QAI.0b013e3182167f0d [doi]'
p74377
asS'CRDT'
p74378
(lp74379
S'2011/03/17 06:00'
p74380
asS'DP'
p74381
S'2011 Jul 1'
p74382
sS'AD'
p74383
S'Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA. pbraitstein@yahoo.com'
p74384
sS'OWN'
p74385
S'NLM'
p74386
sS'PT'
p74387
(lp74388
S'Journal Article'
p74389
aS'Research Support, N.I.H., Extramural'
p74390
aS"Research Support, Non-U.S. Gov't"
p74391
asS'LA'
p74392
(lp74393
S'eng'
p74394
asS'FAU'
p74395
(lp74396
S'Braitstein, Paula'
p74397
aS'Songok, Julia'
p74398
aS'Vreeman, Rachel C'
p74399
aS'Wools-Kaloustian, Kara K'
p74400
aS'Koskei, Pamela'
p74401
aS'Walusuna, Leahbell'
p74402
aS'Ayaya, Samwel'
p74403
aS'Nyandiko, Winstone'
p74404
aS'Yiannoutsos, Constantin'
p74405
asS'LR'
p74406
S'20150204'
p74407
sS'PG'
p74408
S'e40-6'
p74409
sS'TI'
p74410
S'"Wamepotea" (they have become lost): outcomes of HIV-positive and HIV-exposed children lost to follow-up from a large HIV treatment program in western Kenya.'
p74411
sS'PL'
p74412
S'United States'
p74413
sS'TA'
p74414
S'J Acquir Immune Defic Syndr'
p74415
sS'JID'
p74416
S'100892005'
p74417
sS'AB'
p74418
S'OBJECTIVE: The objective of this study was to identify the vital status and reasons for children becoming loss to follow-up (LTFU) from a large program in western Kenya. METHODS: This was a prospective evaluation of a random sample of 30% of HIV-exposed and HIV-positive children LTFU from either an urban or rural HIV Academic Model Providing Access to Healthcare clinic. LTFU is defined as absence from clinic for >6 months if on combination antiretroviral therapy and > 12 months if not. Experienced community health workers were engaged to locate them. RESULTS: There were 97 children sampled (78 urban, 19 rural). Of these, 82% were located (78% urban, 100% rural). Among the HIV positive, 16% of the children were deceased, and 16% had not returned to clinic because of disclosure issues/discrimination in the family or community. Among the HIV exposed, 30% never returned to care because their guardians either had not disclosed their own HIV status or were afraid of family/community stigma related to their HIV status or that of the child. Among children whose HIV status was unknown, 29% of those found had actually died, and disclosure/discrimination accounted for 14% of the reasons for becoming LTFU. Other reasons included believing the child was healed by faith or through the use of traditional medicine (7%), transport costs (6%), and transferring care to other programs or clinics (8%). CONCLUSION: After locating >80% of the children in our sample, we identified that mortality and disclosure issues including fear of family or community discrimination were the most important reasons why these children became LTFU.'
p74419
sS'GR'
p74420
(lp74421
S'U01 AI069911/AI/NIAID NIH HHS/United States'
p74422
aS'U01 AI069911-03/AI/NIAID NIH HHS/United States'
p74423
aS'U01-AI0669911/AI/NIAID NIH HHS/United States'
p74424
asS'IP'
p74425
S'3'
sS'IS'
p74426
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p74427
sS'PMC'
p74428
S'PMC3145828'
p74429
sS'DCOM'
p74430
S'20111021'
p74431
sS'AU'
p74432
(lp74433
S'Braitstein P'
p74434
aS'Songok J'
p74435
aS'Vreeman RC'
p74436
aS'Wools-Kaloustian KK'
p74437
aS'Koskei P'
p74438
aS'Walusuna L'
p74439
aS'Ayaya S'
p74440
aS'Nyandiko W'
p74441
aS'Yiannoutsos C'
p74442
asS'VI'
p74443
S'57'
p74444
sS'MHDA'
p74445
S'2011/10/22 06:00'
p74446
sS'OID'
p74447
(lp74448
S'NLM: NIHMS282833'
p74449
aS'NLM: PMC3145828'
p74450
asS'MH'
p74451
(lp74452
S'Child'
p74453
aS'Child, Orphaned'
p74454
aS'Child, Preschool'
p74455
aS'Female'
p74456
aS'HIV Infections/*epidemiology/*therapy'
p74457
aS'Humans'
p74458
aS'Infant'
p74459
aS'Kenya/epidemiology'
p74460
aS'*Lost to Follow-Up'
p74461
aS'Male'
p74462
aS'Prejudice'
p74463
aS'Rural Population'
p74464
aS'Urban Population'
p74465
asS'EDAT'
p74466
S'2011/03/17 06:00'
p74467
sS'SO'
p74468
S'J Acquir Immune Defic Syndr. 2011 Jul 1;57(3):e40-6. doi: 10.1097/QAI.0b013e3182167f0d.'
p74469
sS'SB'
p74470
S'IM X'
p74471
sS'PMID'
p74472
S'21407085'
p74473
sS'PST'
p74474
S'ppublish'
p74475
stRp74476
ag2
(g3
g4
(dp74477
S'LID'
p74478
S'10.1371/journal.pmed.1000422 [doi]'
p74479
sS'STAT'
p74480
S'MEDLINE'
p74481
sS'DEP'
p74482
S'20110301'
p74483
sS'DA'
p74484
S'20110310'
p74485
sS'AID'
p74486
(lp74487
S'10.1371/journal.pmed.1000422 [doi]'
p74488
asS'CRDT'
p74489
(lp74490
S'2011/03/11 06:00'
p74491
asS'DP'
p74492
S'2011 Mar'
p74493
sS'AD'
p74494
S'Department of Global Health, University of Washington, Seattle, Washington, USA. mhchung@uw.edu'
p74495
sS'OWN'
p74496
S'NLM'
p74497
sS'PT'
p74498
(lp74499
S'Comparative Study'
p74500
aS'Journal Article'
p74501
aS'Randomized Controlled Trial'
p74502
aS'Research Support, N.I.H., Extramural'
p74503
aS"Research Support, U.S. Gov't, P.H.S."
p74504
asS'LA'
p74505
(lp74506
S'eng'
p74507
asS'FAU'
p74508
(lp74509
S'Chung, Michael H'
p74510
aS'Richardson, Barbra A'
p74511
aS'Tapia, Kenneth'
p74512
aS'Benki-Nugent, Sarah'
p74513
aS'Kiarie, James N'
p74514
aS'Simoni, Jane M'
p74515
aS'Overbaugh, Julie'
p74516
aS'Attwa, Mena'
p74517
aS'John-Stewart, Grace C'
p74518
asS'JT'
p74519
S'PLoS medicine'
p74520
sS'LR'
p74521
S'20150329'
p74522
sS'PG'
p74523
S'e1000422'
p74524
sS'TI'
p74525
S'A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes.'
p74526
sS'RN'
p74527
(lp74528
S'0 (Anti-Retroviral Agents)'
p74529
aS'0 (Drug Combinations)'
p74530
aS'0 (RNA, Viral)'
p74531
asS'PL'
p74532
S'United States'
p74533
sS'TA'
p74534
S'PLoS Med'
p74535
sS'JID'
p74536
S'101231360'
p74537
sS'AB'
p74538
S'BACKGROUND: Behavioral interventions that promote adherence to antiretroviral medications may decrease HIV treatment failure. Antiretroviral treatment programs in sub-Saharan Africa confront increasing financial constraints to provide comprehensive HIV care, which include adherence interventions. This study compared the impact of counseling and use of an alarm device on adherence and biological outcomes in a resource-limited setting. METHODS AND FINDINGS: A randomized controlled, factorial designed trial was conducted in Nairobi, Kenya. Antiretroviral-naive individuals initiating free highly active antiretroviral therapy (HAART) in the form of fixed-dose combination pills (d4T, 3TC, and nevirapine) were randomized to one of four arms: counseling (three counseling sessions around HAART initiation), alarm (pocket electronic pill reminder carried for 6 months), counseling plus alarm, and neither counseling nor alarm. Participants were followed for 18 months after HAART initiation. Primary study endpoints included plasma HIV-1 RNA and CD4 count every 6 months, mortality, and adherence measured by monthly pill count. Between May 2006 and September 2008, 400 individuals were enrolled, 362 initiated HAART, and 310 completed follow-up. Participants who received counseling were 29% less likely to have monthly adherence <80% (hazard ratio [HR] = 0.71; 95% confidence interval [CI] 0.49-1.01; p = 0.055) and 59% less likely to experience viral failure (HIV-1 RNA >/=5,000 copies/ml) (HR 0.41; 95% CI 0.21-0.81; p = 0.01) compared to those who received no counseling. There was no significant impact of using an alarm on poor adherence (HR 0.93; 95% CI 0.65-1.32; p = 0.7) or viral failure (HR 0.99; 95% CI 0.53-1.84; p = 1.0) compared to those who did not use an alarm. Neither counseling nor alarm was significantly associated with mortality or rate of immune reconstitution. CONCLUSIONS: Intensive early adherence counseling at HAART initiation resulted in sustained, significant impact on adherence and virologic treatment failure during 18-month follow-up, while use of an alarm device had no effect. As antiretroviral treatment clinics expand to meet an increasing demand for HIV care in sub-Saharan Africa, adherence counseling should be implemented to decrease the development of treatment failure and spread of resistant HIV.'
p74539
sS'GR'
p74540
(lp74541
S'1K24HD054314-04/HD/NICHD NIH HHS/United States'
p74542
aS'5K23AI065222-04/AI/NIAID NIH HHS/United States'
p74543
aS'P30 AI027757/AI/NIAID NIH HHS/United States'
p74544
aS'P30AI027757/AI/NIAID NIH HHS/United States'
p74545
aS'U62/CCU024512-04/PHS HHS/United States'
p74546
asS'IP'
p74547
S'3'
sS'IS'
p74548
S'1549-1676 (Electronic) 1549-1277 (Linking)'
p74549
sS'PMC'
p74550
S'PMC3046986'
p74551
sS'DCOM'
p74552
S'20110623'
p74553
sS'AU'
p74554
(lp74555
S'Chung MH'
p74556
aS'Richardson BA'
p74557
aS'Tapia K'
p74558
aS'Benki-Nugent S'
p74559
aS'Kiarie JN'
p74560
aS'Simoni JM'
p74561
aS'Overbaugh J'
p74562
aS'Attwa M'
p74563
aS'John-Stewart GC'
p74564
asS'VI'
p74565
S'8'
sS'MHDA'
p74566
S'2011/06/24 06:00'
p74567
sS'PHST'
p74568
(lp74569
S'2010/08/17 [received]'
p74570
aS'2011/01/19 [accepted]'
p74571
aS'2011/03/01 [epublish]'
p74572
asS'OID'
p74573
(lp74574
S'NLM: PMC3046986'
p74575
asS'MH'
p74576
(lp74577
S'Adult'
p74578
aS'Anti-Retroviral Agents/pharmacology/*therapeutic use'
p74579
aS'Antiretroviral Therapy, Highly Active/*methods'
p74580
aS'CD4 Lymphocyte Count'
p74581
aS'*Counseling'
p74582
aS'Drug Combinations'
p74583
aS'Female'
p74584
aS'HIV Infections/*drug therapy/mortality'
p74585
aS'HIV-1/*drug effects'
p74586
aS'Humans'
p74587
aS'Kenya'
p74588
aS'Male'
p74589
aS'Memory'
p74590
aS'*Patient Compliance'
p74591
aS'Proportional Hazards Models'
p74592
aS'RNA, Viral/blood'
p74593
aS'*Reminder Systems'
p74594
aS'Treatment Outcome'
p74595
asS'EDAT'
p74596
S'2011/03/11 06:00'
p74597
sS'SI'
p74598
(lp74599
S'ClinicalTrials.gov/NCT00273780'
p74600
asS'SO'
p74601
S'PLoS Med. 2011 Mar;8(3):e1000422. doi: 10.1371/journal.pmed.1000422. Epub 2011 Mar 1.'
p74602
sS'SB'
p74603
S'IM'
p74604
sS'PMID'
p74605
S'21390262'
p74606
sS'PST'
p74607
S'ppublish'
p74608
stRp74609
ag2
(g3
g4
(dp74610
S'LID'
p74611
S'10.1371/journal.pone.0016800 [doi]'
p74612
sS'STAT'
p74613
S'MEDLINE'
p74614
sS'DEP'
p74615
S'20110223'
p74616
sS'DA'
p74617
S'20110304'
p74618
sS'AID'
p74619
(lp74620
S'10.1371/journal.pone.0016800 [doi]'
p74621
asS'CRDT'
p74622
(lp74623
S'2011/03/05 06:00'
p74624
asS'DP'
p74625
S'2011'
p74626
sS'GR'
p74627
(lp74628
S'G0800247/Medical Research Council/United Kingdom'
p74629
aS'G0901364/Medical Research Council/United Kingdom'
p74630
asS'OWN'
p74631
S'NLM'
p74632
sS'PT'
p74633
(lp74634
S'Evaluation Studies'
p74635
aS'Journal Article'
p74636
aS"Research Support, Non-U.S. Gov't"
p74637
aS"Research Support, U.S. Gov't, Non-P.H.S."
p74638
asS'LA'
p74639
(lp74640
S'eng'
p74641
asS'FAU'
p74642
(lp74643
S'Kigen, Gabriel'
p74644
aS'Kimaiyo, Sylvester'
p74645
aS'Nyandiko, Winstone'
p74646
aS'Faragher, Brian'
p74647
aS'Sang, Edwin'
p74648
aS'Jakait, Beatrice'
p74649
aS'Owen, Andrew'
p74650
aS'Back, David'
p74651
aS'Gibbons, Sara'
p74652
aS'Seden, Kay'
p74653
aS'Khoo, Saye H'
p74654
asS'JT'
p74655
S'PloS one'
p74656
sS'LR'
p74657
S'20150224'
p74658
sS'PG'
p74659
S'e16800'
p74660
sS'TI'
p74661
S'Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohort.'
p74662
sS'RN'
p74663
(lp74664
S'0 (Anti-HIV Agents)'
p74665
aS'0 (Drug Combinations)'
p74666
asS'PL'
p74667
S'United States'
p74668
sS'TA'
p74669
S'PLoS One'
p74670
sS'FIR'
p74671
(lp74672
S'Nyandiko, W'
p74673
aS'Wools-Kaloustian, K'
p74674
aS'Kimaiyo, S'
p74675
aS'Braitstein, P'
p74676
aS'Sang, E'
p74677
aS'Jakait, B'
p74678
aS'Pastakia, S'
p74679
asS'JID'
p74680
S'101285081'
p74681
sS'AB'
p74682
S"BACKGROUND: Clinically significant drug-drug interactions (CSDIs) involving antiretrovirals are frequent and under-recognized in developed countries, but data are lacking for developing countries. METHODOLOGY AND PRINCIPAL FINDINGS: To investigate the prevalence of CSDIs between antiretrovirals and coadministered drugs, we surveyed prescriptions dispensed in a large HIV clinic in Kenya. Of 1040 consecutive patients screened, 996 were eligible for inclusion. CSDIs were defined as 'major' (capable of causing severe or permanent damage, contraindicated, avoid or not recommended by the manufacturer, or requiring dose modification) or 'moderate' (manufacturers advise caution, or close monitoring, or capable of causing clinical deterioration). A total of 334 patients (33.5%) were at risk for a CSDI, potentially lowering antiretroviral drug concentrations in 120 (12%) patients. Major interactions most frequently involved rifampicin (12.4%, mostly with efavirenz) and azoles (2.7%) whereas moderate interactions were frequently azoles (13%), steroids (11%), and antimalarials (3%). Multivariable analyses suggested that patients at risk for CSDIs had lower CD4 counts (P = 0.006) and baseline weight (P = 0.023) and WHO Stage 3 or 4 disease (P</=0.007). Risk for CSDIs was not associated with particular regimens, although only 116 (11.6%) patients were receiving WHO second line regimens. CONCLUSIONS: One in three patients receiving antiretrovirals in our programme were at risk of CSDIs. Strategies need to be urgently developed to avoid important drug interactions, to identify early markers of toxicity and to manage unavoidable interactions safely in order to reduce risk of harm, and to maximize the effectiveness of mass antiretroviral deployment in Africa."
p74683
sS'AD'
p74684
S'Department of Pharmacology and Toxicology, Moi University School of Medicine, Eldoret, Kenya.'
p74685
sS'CN'
p74686
(lp74687
S'USAID-Academic Model for Prevention Treatment of HIV/AIDS'
p74688
asS'IP'
p74689
S'2'
sS'IS'
p74690
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p74691
sS'IR'
p74692
(lp74693
S'Nyandiko W'
p74694
aS'Wools-Kaloustian K'
p74695
aS'Kimaiyo S'
p74696
aS'Braitstein P'
p74697
aS'Sang E'
p74698
aS'Jakait B'
p74699
aS'Pastakia S'
p74700
asS'DCOM'
p74701
S'20110901'
p74702
sS'AU'
p74703
(lp74704
S'Kigen G'
p74705
aS'Kimaiyo S'
p74706
aS'Nyandiko W'
p74707
aS'Faragher B'
p74708
aS'Sang E'
p74709
aS'Jakait B'
p74710
aS'Owen A'
p74711
aS'Back D'
p74712
aS'Gibbons S'
p74713
aS'Seden K'
p74714
aS'Khoo SH'
p74715
asS'VI'
p74716
S'6'
sS'MHDA'
p74717
S'2011/09/02 06:00'
p74718
sS'PHST'
p74719
(lp74720
S'2010/10/13 [received]'
p74721
aS'2010/12/24 [accepted]'
p74722
aS'2011/02/23 [epublish]'
p74723
asS'OID'
p74724
(lp74725
S'NLM: PMC3044141'
p74726
asS'MH'
p74727
(lp74728
S'Adult'
p74729
aS'Aged'
p74730
aS'Anti-HIV Agents/*administration & dosage/therapeutic use'
p74731
aS'Cohort Studies'
p74732
aS'Drug Combinations'
p74733
aS'Drug Interactions/*physiology'
p74734
aS'Drug-Related Side Effects and Adverse Reactions/*epidemiology'
p74735
aS'Female'
p74736
aS'HIV Infections/*drug therapy/epidemiology'
p74737
aS'Humans'
p74738
aS'Kenya'
p74739
aS'Male'
p74740
aS'Middle Aged'
p74741
aS'Polypharmacy'
p74742
aS'Prevalence'
p74743
aS'Sample Size'
p74744
aS'Young Adult'
p74745
asS'EDAT'
p74746
S'2011/03/05 06:00'
p74747
sS'PMC'
p74748
S'PMC3044141'
p74749
sS'SO'
p74750
S'PLoS One. 2011 Feb 23;6(2):e16800. doi: 10.1371/journal.pone.0016800.'
p74751
sS'SB'
p74752
S'IM'
p74753
sS'PMID'
p74754
S'21373194'
p74755
sS'PST'
p74756
S'epublish'
p74757
stRp74758
ag2
(g3
g4
(dp74759
S'LID'
p74760
S'10.1089/AID.2010.0205 [doi]'
p74761
sS'STAT'
p74762
S'MEDLINE'
p74763
sS'DEP'
p74764
S'20110323'
p74765
sS'DA'
p74766
S'20110824'
p74767
sS'AID'
p74768
(lp74769
S'10.1089/aid.2010.0205 [doi]'
p74770
asS'CRDT'
p74771
(lp74772
S'2011/02/25 06:00'
p74773
asS'DP'
p74774
S'2011 Sep'
p74775
sS'AD'
p74776
S'Division of Infectious Diseases, Department of Medicine, University of Texas Health Sciences Center at San Antonio, USA.'
p74777
sS'OWN'
p74778
S'NLM'
p74779
sS'PT'
p74780
(lp74781
S'Journal Article'
p74782
aS'Research Support, N.I.H., Extramural'
p74783
aS"Research Support, Non-U.S. Gov't"
p74784
asS'LA'
p74785
(lp74786
S'eng'
p74787
asS'FAU'
p74788
(lp74789
S'Taylor, Barbara S'
p74790
aS'Hunt, Gillian'
p74791
aS'Abrams, Elaine J'
p74792
aS'Coovadia, Ashraf'
p74793
aS'Meyers, Tammy'
p74794
aS'Sherman, Gayle'
p74795
aS'Strehlau, Renate'
p74796
aS'Morris, Lynn'
p74797
aS'Kuhn, Louise'
p74798
asS'JT'
p74799
S'AIDS research and human retroviruses'
p74800
sS'LR'
p74801
S'20150204'
p74802
sS'PG'
p74803
S'945-56'
p74804
sS'TI'
p74805
S'Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa.'
p74806
sS'RN'
p74807
(lp74808
S'0 (HIV Protease Inhibitors)'
p74809
aS'0 (RNA, Viral)'
p74810
aS'0 (pol Gene Products, Human Immunodeficiency Virus)'
p74811
aS'2494G1JF75 (Lopinavir)'
p74812
aS'99DK7FVK1H (Nevirapine)'
p74813
aS'EC 3.4.23.- (HIV Protease)'
p74814
aS'O3J8G9O825 (Ritonavir)'
p74815
asS'PL'
p74816
S'United States'
p74817
sS'TA'
p74818
S'AIDS Res Hum Retroviruses'
p74819
sS'JID'
p74820
S'8709376'
p74821
sS'AB'
p74822
S'Data on the development of antiretroviral drug resistance in HIV-1-infected children receiving protease inhibitor (PI)-based antiretroviral therapy (ART) are limited. We examined antiretroviral resistance among a cohort of 323 South African HIV-infected children <2 years old exposed to nevirapine for prevention of mother-to-child transmission. Ritonavir (RTV) was used initially for 138 children who were <6 months old or receiving antimycobacterial therapy; otherwise children received lopinavir/ritonavir (LPV/r)-based ART. HIV-1 population sequencing of the pol gene was conducted on all pretreatment samples and on posttreatment samples for children who did not achieve HIV-1 plasma RNA <400 copies/ml by 52 weeks. Among children in the cohort, 38 died, 22 had <24 weeks follow-up, 209 achieved virologic suppression, and 54 did not. Of 41 children without virologic suppression with posttreatment HIV genotype data available, major resistance mutations were found in 32 (78%): 14 (36%) had PI mutations including V82A, M46I, and L90M; 29 (71%) had M184V/I; and three had NNRTI mutations (K103N, Y181C, and G190A). Among the children who did not achieve virologic suppression, none of the seven children treated exclusively with LPV/r developed PI-related mutations, compared with 14 of 32 (44%) who received RTV-based regimens (p=0.036); PI genotypes were unavailable for two children. Seventy-eight percent of children without virologic suppression developed resistance mutations that impact second-line ART options. Only children who received RTV-based ART developed major PI-related resistance mutations, and use of this regimen should be avoided.'
p74823
sS'GR'
p74824
(lp74825
S'HD 47177/HD/NICHD NIH HHS/United States'
p74826
aS'K23 AI081538/AI/NIAID NIH HHS/United States'
p74827
aS'K23 AI081538-03/AI/NIAID NIH HHS/United States'
p74828
aS'K23AI081538/AI/NIAID NIH HHS/United States'
p74829
aS'R01 HD047177/HD/NICHD NIH HHS/United States'
p74830
aS'R01 HD047177-02/HD/NICHD NIH HHS/United States'
p74831
aS'R01 HD047177-03/HD/NICHD NIH HHS/United States'
p74832
aS'R01 HD047177-04/HD/NICHD NIH HHS/United States'
p74833
aS'R01 HD047177-05/HD/NICHD NIH HHS/United States'
p74834
asS'IP'
p74835
S'9'
sS'IS'
p74836
S'1931-8405 (Electronic) 0889-2229 (Linking)'
p74837
sS'PMC'
p74838
S'PMC3161115'
p74839
sS'DCOM'
p74840
S'20111216'
p74841
sS'AU'
p74842
(lp74843
S'Taylor BS'
p74844
aS'Hunt G'
p74845
aS'Abrams EJ'
p74846
aS'Coovadia A'
p74847
aS'Meyers T'
p74848
aS'Sherman G'
p74849
aS'Strehlau R'
p74850
aS'Morris L'
p74851
aS'Kuhn L'
p74852
asS'VI'
p74853
S'27'
p74854
sS'MHDA'
p74855
S'2011/12/17 06:00'
p74856
sS'PHST'
p74857
(lp74858
S'2011/03/23 [aheadofprint]'
p74859
asS'OID'
p74860
(lp74861
S'NLM: PMC3161115'
p74862
asS'MH'
p74863
(lp74864
S'Amino Acid Substitution'
p74865
aS'Antiretroviral Therapy, Highly Active/*methods'
p74866
aS'Cohort Studies'
p74867
aS'*Drug Resistance, Viral'
p74868
aS'Female'
p74869
aS'HIV Infections/*drug therapy/*virology'
p74870
aS'HIV Protease/*genetics'
p74871
aS'HIV Protease Inhibitors/*administration & dosage/pharmacology'
p74872
aS'HIV-1/*genetics/isolation & purification'
p74873
aS'Humans'
p74874
aS'Infant'
p74875
aS'Lopinavir/administration & dosage/pharmacology'
p74876
aS'Male'
p74877
aS'Mutation, Missense'
p74878
aS'Nevirapine/administration & dosage/pharmacology'
p74879
aS'RNA, Viral/blood'
p74880
aS'Ritonavir/administration & dosage/pharmacology'
p74881
aS'Sequence Analysis, DNA'
p74882
aS'South Africa'
p74883
aS'Viral Load'
p74884
aS'pol Gene Products, Human Immunodeficiency Virus/genetics'
p74885
asS'EDAT'
p74886
S'2011/02/25 06:00'
p74887
sS'SO'
p74888
S'AIDS Res Hum Retroviruses. 2011 Sep;27(9):945-56. doi: 10.1089/AID.2010.0205. Epub 2011 Mar 23.'
p74889
sS'SB'
p74890
S'IM X'
p74891
sS'PMID'
p74892
S'21345162'
p74893
sS'PST'
p74894
S'ppublish'
p74895
stRp74896
ag2
(g3
g4
(dp74897
S'LID'
p74898
S'10.1016/S1473-3099(10)70317-0 [doi]'
p74899
sS'STAT'
p74900
S'MEDLINE'
p74901
sS'DEP'
p74902
S'20110218'
p74903
sS'MID'
p74904
(lp74905
S'EMS57473'
p74906
asS'DA'
p74907
S'20110401'
p74908
sS'AID'
p74909
(lp74910
S'S1473-3099(10)70317-0 [pii]'
p74911
aS'10.1016/S1473-3099(10)70317-0 [doi]'
p74912
asS'CRDT'
p74913
(lp74914
S'2011/02/22 06:00'
p74915
asS'DP'
p74916
S'2011 Apr'
p74917
sS'AD'
p74918
S'Department of Medicine, College of Medicine, Chichiri, Blantyre, Malawi. katherineaz@doctors.org.uk'
p74919
sS'OWN'
p74920
S'NLM'
p74921
sS'PT'
p74922
(lp74923
S'Journal Article'
p74924
aS'Randomized Controlled Trial'
p74925
aS"Research Support, Non-U.S. Gov't"
p74926
asS'LA'
p74927
(lp74928
S'eng'
p74929
asS'FAU'
p74930
(lp74931
S'Ajdukiewicz, Katherine Mb'
p74932
aS'Cartwright, Katharine E'
p74933
aS'Scarborough, Matthew'
p74934
aS'Mwambene, James B'
p74935
aS'Goodson, Patrick'
p74936
aS'Molyneux, Malcolm E'
p74937
aS'Zijlstra, Eduard E'
p74938
aS'French, Neil'
p74939
aS'Whitty, Christopher Jm'
p74940
aS'Lalloo, David G'
p74941
asS'JT'
p74942
S'The Lancet. Infectious diseases'
p74943
sS'LR'
p74944
S'20150205'
p74945
sS'PG'
p74946
S'293-300'
p74947
sS'TI'
p74948
S'Glycerol adjuvant therapy in adults with bacterial meningitis in a high HIV seroprevalence setting in Malawi: a double-blind, randomised controlled trial.'
p74949
sS'RN'
p74950
(lp74951
S'0 (Adjuvants, Pharmaceutic)'
p74952
aS'0 (Anti-Bacterial Agents)'
p74953
aS'0 (Placebos)'
p74954
aS'PDC6A3C0OX (Glycerol)'
p74955
asS'PL'
p74956
S'United States'
p74957
sS'TA'
p74958
S'Lancet Infect Dis'
p74959
sS'JID'
p74960
S'101130150'
p74961
sS'AB'
p74962
S'BACKGROUND: Southern Africa has a high incidence of bacterial meningitis in adults, often associated with HIV co-infection. Mortality exceeds 50%, even with appropriate antibiotic therapy, and is not improved with corticosteroids. Glycerol adjuvant therapy reduces long-term morbidity in bacterial meningitis in children, and its use is being promoted. We aimed to assess the effectiveness of glycerol as an adjuvant therapy for adults with bacterial meningitis in Africa. METHODS: The study was done in two phases. First, in an open-label dose-finding study, 45 adult patients with symptoms, signs, and cerebrospinal fluid findings consistent with bacterial meningitis received either 50 mL, 75 mL, or 100 mL of glycerol four times a day for 4 days. We then did a randomised, double-blind, placebo-controlled trial of oral glycerol in adults with bacterial meningitis. Patients with clinical and cerebrospinal fluid findings suggestive of bacterial meningitis were randomly assigned in blocks of 12 by use of a random number list produced by an independent statistician to receive either glycerol or an equivalent volume of sugar solution. Glycerol and placebo were indistinguishable by colour or taste. The primary outcome was mortality at 40 days, with secondary outcomes including disability and mortality restricted to pneumococcal disease. All patients were analysed for the primary outcome excluding those who were lost to follow-up. This trial is registered at controlled-trials.com, number ISRCTN70121840. FINDINGS: 75 mL glycerol four times a day was the highest tolerated dose, and was used for the main study. 265 patients were assigned treatment: 137 glycerol and 128 placebo. The trial was stopped early on the advice of the data and safety monitoring board after a planned interim analysis. By day 40, 61 (49%) of 125 patients in the placebo group and 86 (63%) of 136 in the glycerol group had died (adjusted odds ratio 2.4, 95% CI 1.3-4.2, p=0.003). There was no benefit from glycerol for death and disability by day 40, and glycerol did not improve death and disability by day 40 or death at day 40 in patients with proven bacterial disease or pneumococcal disease. Two serious adverse events occurred that were possibly due to the study drug. INTERPRETATION: Oral glycerol therapy cannot be recommended as an adjuvant therapy in adults with bacterial meningitis in resource-poor settings with a high HIV prevalence. FUNDING: Meningitis Research Foundation.'
p74963
sS'GR'
p74964
(lp74965
S'087791/Wellcome Trust/United Kingdom'
p74966
aS'Wellcome Trust/United Kingdom'
p74967
asS'IP'
p74968
S'4'
sS'IS'
p74969
S'1474-4457 (Electronic) 1473-3099 (Linking)'
p74970
sS'PMC'
p74971
S'PMC3999512'
p74972
sS'DCOM'
p74973
S'20110531'
p74974
sS'CIN'
p74975
(lp74976
S'Lancet Infect Dis. 2011 Apr;11(4):257-8. PMID: 21334261'
p74977
aS'Lancet Infect Dis. 2011 Dec;11(12):897-8. PMID: 22115069'
p74978
asS'AU'
p74979
(lp74980
S'Ajdukiewicz KM'
p74981
aS'Cartwright KE'
p74982
aS'Scarborough M'
p74983
aS'Mwambene JB'
p74984
aS'Goodson P'
p74985
aS'Molyneux ME'
p74986
aS'Zijlstra EE'
p74987
aS'French N'
p74988
aS'Whitty CJ'
p74989
aS'Lalloo DG'
p74990
asS'VI'
p74991
S'11'
p74992
sS'MHDA'
p74993
S'2011/06/01 06:00'
p74994
sS'PHST'
p74995
(lp74996
S'2011/02/18 [aheadofprint]'
p74997
asS'OID'
p74998
(lp74999
S'NLM: EMS57473'
p75000
aS'NLM: PMC3999512'
p75001
asS'CI'
p75002
(lp75003
S'Copyright (c) 2011 Elsevier Ltd. All rights reserved.'
p75004
asS'MH'
p75005
(lp75006
S'Adjuvants, Pharmaceutic/*administration & dosage'
p75007
aS'Adult'
p75008
aS'Anti-Bacterial Agents/*administration & dosage'
p75009
aS'Double-Blind Method'
p75010
aS'Drug Therapy, Combination/methods'
p75011
aS'Female'
p75012
aS'Glycerol/*administration & dosage'
p75013
aS'HIV Infections/*epidemiology'
p75014
aS'*HIV Seroprevalence'
p75015
aS'Humans'
p75016
aS'Malawi'
p75017
aS'Male'
p75018
aS'Meningitis, Bacterial/complications/*drug therapy/mortality'
p75019
aS'Placebos/administration & dosage'
p75020
aS'Treatment Outcome'
p75021
asS'EDAT'
p75022
S'2011/02/22 06:00'
p75023
sS'SI'
p75024
(lp75025
S'ISRCTN/ISRCTN70121840'
p75026
asS'SO'
p75027
S'Lancet Infect Dis. 2011 Apr;11(4):293-300. doi: 10.1016/S1473-3099(10)70317-0. Epub 2011 Feb 18.'
p75028
sS'SB'
p75029
S'IM'
p75030
sS'PMID'
p75031
S'21334262'
p75032
sS'PST'
p75033
S'ppublish'
p75034
stRp75035
ag2
(g3
g4
(dp75036
S'LID'
p75037
S'10.1097/QAD.0b013e32834564e9 [doi]'
p75038
sS'STAT'
p75039
S'MEDLINE'
p75040
sS'JT'
p75041
S'AIDS (London, England)'
p75042
sS'DA'
p75043
S'20110318'
p75044
sS'AID'
p75045
(lp75046
S'10.1097/QAD.0b013e32834564e9 [doi]'
p75047
asS'CRDT'
p75048
(lp75049
S'2011/02/19 06:00'
p75050
asS'DP'
p75051
S'2011 Mar 27'
p75052
sS'AD'
p75053
S'Faculty of Health Sciences, University of Ottawa, Canada. edward.mills@uottawa.ca'
p75054
sS'OWN'
p75055
S'NLM'
p75056
sS'PT'
p75057
(lp75058
S'Journal Article'
p75059
aS'Multicenter Study'
p75060
aS"Research Support, Non-U.S. Gov't"
p75061
asS'LA'
p75062
(lp75063
S'eng'
p75064
asS'FAU'
p75065
(lp75066
S'Mills, Edward J'
p75067
aS'Bakanda, Celestin'
p75068
aS'Birungi, Josephine'
p75069
aS'Mwesigwa, Robert'
p75070
aS'Chan, Keith'
p75071
aS'Ford, Nathan'
p75072
aS'Hogg, Robert S'
p75073
aS'Cooper, Curtis'
p75074
asS'PG'
p75075
S'851-5'
p75076
sS'TI'
p75077
S'Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda.'
p75078
sS'RN'
p75079
(lp75080
S'0 (Anti-Retroviral Agents)'
p75081
asS'PL'
p75082
S'England'
p75083
sS'TA'
p75084
S'AIDS'
p75085
sS'JID'
p75086
S'8710219'
p75087
sS'AB'
p75088
S'OBJECTIVE: Evaluations of CD4 cell count and other prognostic factors on the survival of HIV patients in sub-Saharan Africa are extremely limited. Funders have been reticent to recommend earlier initiation of treatment. We aimed to examine the effect of baseline CD4 cell count on mortality using data from HIV patients receiving combination antiretroviral therapy (cART) in Uganda. DESIGN: Observational study of patients aged at least 14 years enrolled in 10 clinics across Uganda for which The AIDS Support Organization (TASO) has data. METHODS: CD4 cell count was stratified into categories (<50, 50-99, 100-149, 150-199, 200-249, 250-299, >/=300 cells/mul) and Cox proportional hazards regression was used to model the associations between CD4 cell count and mortality. RESULTS: A total of 22 315 patients were included. 1498 patients died during follow-up (6.7%) and 1433 (6.4%) of patients were lost to follow-up. Crude mortality rates (CMRs) ranged from 53.8 per 1000 patient-years [95% confidence interval (CI) 48.8-58.8] among those with CD4 cell counts of less than 50, to 15.7, (95% CI 12.1-19.3) among those with at least 300 cells/mul. Relative to a baseline CD4 cell count of less than 50 cells/mul, the risk of mortality was 0.75 (95% CI 0.65-0.88), 0.60 (95% CI 0.51-0.70), 0.43 (0.37-0.50), and 0.41 (0.33-0.51) for those with baseline CD4 cell counts of 50-99, 100-149, 150-249, and >/=250 cells/mul, respectively. CONCLUSION: Earlier initiation of cART is associated with increased survival benefits over deferred treatment.'
p75089
sS'GR'
p75090
(lp75091
S'Canadian Institutes of Health Research/Canada'
p75092
asS'IP'
p75093
S'6'
sS'IS'
p75094
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p75095
sS'DCOM'
p75096
S'20110628'
p75097
sS'AU'
p75098
(lp75099
S'Mills EJ'
p75100
aS'Bakanda C'
p75101
aS'Birungi J'
p75102
aS'Mwesigwa R'
p75103
aS'Chan K'
p75104
aS'Ford N'
p75105
aS'Hogg RS'
p75106
aS'Cooper C'
p75107
asS'VI'
p75108
S'25'
p75109
sS'MHDA'
p75110
S'2011/06/29 06:00'
p75111
sS'MH'
p75112
(lp75113
S'Adult'
p75114
aS'Anti-Retroviral Agents/*therapeutic use'
p75115
aS'*CD4 Lymphocyte Count'
p75116
aS'Cohort Studies'
p75117
aS'Female'
p75118
aS'HIV Infections/*drug therapy/mortality/virology'
p75119
aS'HIV-1/*drug effects'
p75120
aS'Humans'
p75121
aS'Male'
p75122
aS'Uganda/epidemiology'
p75123
aS'Viral Load'
p75124
asS'EDAT'
p75125
S'2011/02/19 06:00'
p75126
sS'SO'
p75127
S'AIDS. 2011 Mar 27;25(6):851-5. doi: 10.1097/QAD.0b013e32834564e9.'
p75128
sS'SB'
p75129
S'IM X'
p75130
sS'PMID'
p75131
S'21330903'
p75132
sS'PST'
p75133
S'ppublish'
p75134
stRp75135
ag2
(g3
g4
(dp75136
S'LID'
p75137
S'10.1097/QAI.0b013e3182067d99 [doi]'
p75138
sS'STAT'
p75139
S'MEDLINE'
p75140
sS'JT'
p75141
S'Journal of acquired immune deficiency syndromes (1999)'
p75142
sS'CIN'
p75143
(lp75144
S'J Acquir Immune Defic Syndr. 2011 Aug 1;57(4):e92. PMID: 21860360'
p75145
asS'DA'
p75146
S'20110214'
p75147
sS'AID'
p75148
(lp75149
S'10.1097/QAI.0b013e3182067d99 [doi]'
p75150
aS'00126334-201103010-00016 [pii]'
p75151
asS'CRDT'
p75152
(lp75153
S'2011/02/15 06:00'
p75154
asS'DP'
p75155
S'2011 Mar 1'
p75156
sS'OWN'
p75157
S'NLM'
p75158
sS'PT'
p75159
(lp75160
S'Journal Article'
p75161
asS'LA'
p75162
(lp75163
S'eng'
p75164
asS'FAU'
p75165
(lp75166
S'Klausner, Jeffrey D'
p75167
aS'Serenata, Celicia'
p75168
aS"O'Bra, Heidi"
p75169
aS'Mattson, Christine L'
p75170
aS'Brown, J W'
p75171
aS'Wilson, Melinda'
p75172
aS'Mbengashe, Thobile'
p75173
aS'Goldman, Thurma M'
p75174
asS'LR'
p75175
S'20121228'
p75176
sS'PG'
p75177
S'292-5'
p75178
sS'TI'
p75179
S'Scale-up and continuation of antiretroviral therapy in South African treatment programs, 2005-2009.'
p75180
sS'RN'
p75181
(lp75182
S'0 (Anti-HIV Agents)'
p75183
asS'PL'
p75184
S'United States'
p75185
sS'TA'
p75186
S'J Acquir Immune Defic Syndr'
p75187
sS'JID'
p75188
S'100892005'
p75189
sS'AB'
p75190
S"BACKGROUND: South Africa has the greatest burden of HIV-infection in the world with about 5.2 million HIV-infected adults. In 2003, the South African Government launched a comprehensive HIV and AIDS care treatment program supported by the United States in 2004 through the President's Emergency Plan for AIDS Relief (PEPFAR). METHODS: To describe the scale-up and continuation of antiretroviral therapy in South African Government and PEPFAR-supported sites in South Africa, we conducted a retrospective analysis of routinely collected program reporting data, 2005-2009. RESULTS: From 2005 through 2009, the average rate of persons initiated on antiretroviral therapy in PEPFAR-supported South African Government treatment programs increased nearly four-fold from 6,327 a month in 2005-2006 to 24,622 a month in 2008-2009 resulting in an increase from 33,543 patients on continued treatment in April-June 2005 to 631,985 patients in July-September 2009. Of those 631,985 patients receiving treatment, 65% were women. Men were more likely to be lost to follow-up (9.2% vs. 7.8%, PR 1.18, 95% CI 1.17-1.19) and more likely to die (5.6% vs. 4.1%, PR 1.36, 95% CI 1.35-1.37) than women. CONCLUSIONS: Scale-up and continuation of antiretroviral therapy in South Africa has been a remarkable medical accomplishment. Because more women receive and continue treatment, more efforts are needed to treat and retain men."
p75191
sS'AD'
p75192
S'Centers for Disease Control and Prevention, Global AIDS Program, Atlanta, Georgia, USA. klausnerj@sa.cdc.gov'
p75193
sS'IP'
p75194
S'3'
sS'IS'
p75195
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p75196
sS'DCOM'
p75197
S'20110404'
p75198
sS'AU'
p75199
(lp75200
S'Klausner JD'
p75201
aS'Serenata C'
p75202
aS"O'Bra H"
p75203
aS'Mattson CL'
p75204
aS'Brown JW'
p75205
aS'Wilson M'
p75206
aS'Mbengashe T'
p75207
aS'Goldman TM'
p75208
asS'VI'
p75209
S'56'
p75210
sS'MHDA'
p75211
S'2011/04/05 06:00'
p75212
sS'MH'
p75213
(lp75214
S'Adolescent'
p75215
aS'Adult'
p75216
aS'Aged'
p75217
aS'Aged, 80 and over'
p75218
aS'Anti-HIV Agents/*therapeutic use'
p75219
aS'Antiretroviral Therapy, Highly Active/*methods'
p75220
aS'Child'
p75221
aS'Child, Preschool'
p75222
aS'Female'
p75223
aS'HIV Infections/*drug therapy'
p75224
aS'Humans'
p75225
aS'Infant'
p75226
aS'Infant, Newborn'
p75227
aS'Male'
p75228
aS'Middle Aged'
p75229
aS'Retrospective Studies'
p75230
aS'South Africa'
p75231
aS'Young Adult'
p75232
asS'EDAT'
p75233
S'2011/02/15 06:00'
p75234
sS'SO'
p75235
S'J Acquir Immune Defic Syndr. 2011 Mar 1;56(3):292-5. doi: 10.1097/QAI.0b013e3182067d99.'
p75236
sS'SB'
p75237
S'IM X'
p75238
sS'PMID'
p75239
S'21317587'
p75240
sS'PST'
p75241
S'ppublish'
p75242
stRp75243
ag2
(g3
g4
(dp75244
S'LID'
p75245
S'10.3851/IMP1683 [doi]'
p75246
sS'STAT'
p75247
S'MEDLINE'
p75248
sS'JT'
p75249
S'Antiviral therapy'
p75250
sS'DA'
p75251
S'20110211'
p75252
sS'AID'
p75253
(lp75254
S'10.3851/IMP1683 [doi]'
p75255
asS'CRDT'
p75256
(lp75257
S'2011/02/12 06:00'
p75258
asS'DP'
p75259
S'2011'
p75260
sS'OWN'
p75261
S'NLM'
p75262
sS'PT'
p75263
(lp75264
S'Case Reports'
p75265
aS'Journal Article'
p75266
asS'LA'
p75267
(lp75268
S'eng'
p75269
asS'FAU'
p75270
(lp75271
S'Hamers, Raph L'
p75272
aS'Wensing, Annemarie Mj'
p75273
aS'Back, Nicole Kt'
p75274
aS'Arcilla, Maria S'
p75275
aS'Frissen, Jos Ph'
p75276
asS'LR'
p75277
S'20131121'
p75278
sS'PG'
p75279
S'115-8'
p75280
sS'TI'
p75281
S'Multi-nucleoside reverse transcriptase inhibitor resistant HIV type-1 in a patient from Sierra Leone failing stavudine, lamivudine and nevirapine.'
p75282
sS'RN'
p75283
(lp75284
S'0 (Nucleosides)'
p75285
aS'0 (Reverse Transcriptase Inhibitors)'
p75286
aS'2T8Q726O95 (Lamivudine)'
p75287
aS'99DK7FVK1H (Nevirapine)'
p75288
aS'BO9LE4QFZF (Stavudine)'
p75289
aS'EC 2.7.7.49 (HIV Reverse Transcriptase)'
p75290
asS'PL'
p75291
S'England'
p75292
sS'TA'
p75293
S'Antivir Ther'
p75294
sS'JID'
p75295
S'9815705'
p75296
sS'AB'
p75297
S'We report a 33-year-old HIV type-1 (HIV-1)-infected male from Sierra Leone who harboured extensive drug resistance mutations to all nucleoside reverse transcriptase inhibitors (NRTIs) and non-NRTIs, including the multi-NRTI-resistance Q151M complex, K65R, M184I and Y181I, after using standard first-line generic fixed-dose stavudine, lamivudine and nevirapine (Triomune) for 36 months. In the context of non-B subtypes in resource-limited countries, first-line stavudine-containing regimens have been associated with more extensive and complex mutation patterns, compared with subtype B viruses. Whether the extensive and complex NRTI resistance patterns found among African patients failing first-line antiretroviral therapy is explained by viral genetic diversity or by different patient monitoring strategies remains to be elucidated. Emerging multi-NRTI resistance in sub-Saharan Africa would not only compromise second-line treatment options and the success of antiretroviral rollout, but could also contribute to the spread of drug-resistant variants worldwide.'
p75298
sS'AD'
p75299
S'Department of Internal Medicine, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands. r.hamers@pharmaccess.org'
p75300
sS'IP'
p75301
S'1'
sS'IS'
p75302
S'2040-2058 (Electronic) 1359-6535 (Linking)'
p75303
sS'DCOM'
p75304
S'20110722'
p75305
sS'AU'
p75306
(lp75307
S'Hamers RL'
p75308
aS'Wensing AM'
p75309
aS'Back NK'
p75310
aS'Arcilla MS'
p75311
aS'Frissen JP'
p75312
asS'VI'
p75313
S'16'
p75314
sS'MHDA'
p75315
S'2011/07/23 06:00'
p75316
sS'MH'
p75317
(lp75318
S'Adult'
p75319
aS'Drug Resistance, Multiple, Viral/*drug effects/*genetics'
p75320
aS'Genetic Variation'
p75321
aS'HIV Infections/*drug therapy/*genetics/virology'
p75322
aS'HIV Reverse Transcriptase/antagonists & inhibitors/genetics'
p75323
aS'HIV-1/drug effects/genetics'
p75324
aS'Humans'
p75325
aS'Lamivudine/administration & dosage/therapeutic use'
p75326
aS'Male'
p75327
aS'Monitoring, Physiologic'
p75328
aS'Mutation'
p75329
aS'Nevirapine/administration & dosage/therapeutic use'
p75330
aS'Nucleosides/metabolism'
p75331
aS'Reverse Transcriptase Inhibitors/*administration & dosage/therapeutic use'
p75332
aS'Sierra Leone'
p75333
aS'Stavudine/administration & dosage/therapeutic use'
p75334
aS'Treatment Failure'
p75335
asS'EDAT'
p75336
S'2011/02/12 06:00'
p75337
sS'SO'
p75338
S'Antivir Ther. 2011;16(1):115-8. doi: 10.3851/IMP1683.'
p75339
sS'SB'
p75340
S'IM'
p75341
sS'PMID'
p75342
S'21311115'
p75343
sS'PST'
p75344
S'ppublish'
p75345
stRp75346
ag2
(g3
g4
(dp75347
S'LID'
p75348
S'10.1186/1758-2652-14-7 [doi]'
p75349
sS'STAT'
p75350
S'MEDLINE'
p75351
sS'DEP'
p75352
S'20110209'
p75353
sS'DA'
p75354
S'20110316'
p75355
sS'AID'
p75356
(lp75357
S'1758-2652-14-7 [pii]'
p75358
aS'10.1186/1758-2652-14-7 [doi]'
p75359
asS'DCOM'
p75360
S'20110607'
p75361
sS'DP'
p75362
S'2011'
p75363
sS'EIN'
p75364
(lp75365
S'J Int AIDS Soc. 2011;14. doi:10.1186/1758-2652-14-17'
p75366
asS'OWN'
p75367
S'NLM'
p75368
sS'PT'
p75369
(lp75370
S'Journal Article'
p75371
aS'Research Support, N.I.H., Extramural'
p75372
aS"Research Support, Non-U.S. Gov't"
p75373
asS'LA'
p75374
(lp75375
S'eng'
p75376
asS'CRDT'
p75377
(lp75378
S'2011/02/11 06:00'
p75379
asS'JT'
p75380
S'Journal of the International AIDS Society'
p75381
sS'LR'
p75382
S'20150205'
p75383
sS'PG'
p75384
S'7'
sS'TI'
p75385
S'A biregional survey and review of first-line treatment failure and second-line paediatric antiretroviral access and use in Asia and southern Africa.'
p75386
sS'RN'
p75387
(lp75388
S'0 (Anti-HIV Agents)'
p75389
asS'PL'
p75390
S'England'
p75391
sS'TA'
p75392
S'J Int AIDS Soc'
p75393
sS'FIR'
p75394
(lp75395
S'Saphonn, V'
p75396
aS'Saramony, S'
p75397
aS'Vibol, U'
p75398
aS'Sophan, S'
p75399
aS'Zhang, F J'
p75400
aS'Han, N'
p75401
aS'Kumarasamy, N'
p75402
aS'Saghayam, S'
p75403
aS'Kurniati, N'
p75404
aS'Muktiarti, D'
p75405
aS'Fong, S M'
p75406
aS'Thien, M'
p75407
aS'Nik Yusoff, N K'
p75408
aS'Hai, L C'
p75409
aS'Razali, K'
p75410
aS'Abdul Rahman, N F'
p75411
aS'Nallusamy, R'
p75412
aS'Chan, K C'
p75413
aS'Sirisanthana, V'
p75414
aS'Aurpibul, L'
p75415
aS'Hansudewechakul, R'
p75416
aS'Khongponoi, A'
p75417
aS'Lumbiganon, P'
p75418
aS'Kosalaraksa, P'
p75419
aS'Jourdain, G'
p75420
aS'Ananworanich, J'
p75421
aS'Suwanlerk, T'
p75422
aS'Chokephaibulkit, K'
p75423
aS'Wittawatmongkol, O'
p75424
aS'Truong, H K'
p75425
aS'Mai, D A N'
p75426
aS'Do, C V'
p75427
aS'Ha, M T'
p75428
aS'Bui, H V'
p75429
aS'Nguyen, V L'
p75430
aS'Le, O N'
p75431
aS'Sohn, A H'
p75432
aS'Messerschmidt, L'
p75433
aS'Pang, J'
p75434
aS'Cooper, D A'
p75435
aS'Kariminia, A'
p75436
aS'Davies, Mary-Ann'
p75437
aS'Eley, Brian'
p75438
aS'Giddy, Janet'
p75439
aS'Moultrie, Harry'
p75440
aS'Pascoe, Margaret'
p75441
aS'Rabie, Helena'
p75442
aS'Technau, Karl'
p75443
aS'Van Cutsem, Gilles'
p75444
aS'Vaz, Paula'
p75445
aS'Weigel, Ralf'
p75446
aS'Wood, Robin'
p75447
asS'JID'
p75448
S'101478566'
p75449
sS'AB'
p75450
S'BACKGROUND: To better understand the need for paediatric second-line antiretroviral therapy (ART), an ART management survey and a cross-sectional analysis of second-line ART use were conducted in the TREAT Asia Paediatric HIV Observational Database and the IeDEA Southern Africa (International Epidemiologic Databases to Evaluate AIDS) regional cohorts. METHODS: Surveys were conducted in April 2009. Analysis data from the Asia cohort were collected in March 2009 from 12 centres in Cambodia, India, Indonesia, Malaysia, and Thailand. Data from the IeDEA Southern Africa cohort were finalized in February 2008 from 10 centres in Malawi, Mozambique, South Africa and Zimbabwe. RESULTS: Survey responses reflected inter-regional variations in drug access and national guidelines. A total of 1301 children in the TREAT Asia and 4561 children in the IeDEA Southern Africa cohorts met inclusion criteria for the cross-sectional analysis. Ten percent of Asian and 3.3% of African children were on second-line ART at the time of data transfer. Median age (interquartile range) in months at second-line initiation was 120 (78-145) months in the Asian cohort and 66 (29-112) months in the southern African cohort. Regimens varied, and the then current World Health Organization-recommended nucleoside reverse transcriptase combination of abacavir and didanosine was used in less than 5% of children in each region. CONCLUSIONS: In order to provide life-long ART for children, better use of current first-line regimens and broader access to heat-stable, paediatric second-line and salvage formulations are needed. There will be limited benefit to earlier diagnosis of treatment failure unless providers and patients have access to appropriate drugs for children to switch to.'
p75451
sS'CN'
p75452
(lp75453
S'TREAT Asia Pediatric HIV Observational Database (TApHOD)'
p75454
aS'International Epidemiologic Databases to Evaluate AIDS (IeDEA) Southern Africa'
p75455
aS'Paediatric Group'
p75456
asS'VI'
p75457
S'14'
p75458
sS'IS'
p75459
S'1758-2652 (Electronic) 1758-2652 (Linking)'
p75460
sS'IR'
p75461
(lp75462
S'Saphonn V'
p75463
aS'Saramony S'
p75464
aS'Vibol U'
p75465
aS'Sophan S'
p75466
aS'Zhang FJ'
p75467
aS'Han N'
p75468
aS'Kumarasamy N'
p75469
aS'Saghayam S'
p75470
aS'Kurniati N'
p75471
aS'Muktiarti D'
p75472
aS'Fong SM'
p75473
aS'Thien M'
p75474
aS'Nik Yusoff NK'
p75475
aS'Hai LC'
p75476
aS'Razali K'
p75477
aS'Abdul Rahman NF'
p75478
aS'Nallusamy R'
p75479
aS'Chan KC'
p75480
aS'Sirisanthana V'
p75481
aS'Aurpibul L'
p75482
aS'Hansudewechakul R'
p75483
aS'Khongponoi A'
p75484
aS'Lumbiganon P'
p75485
aS'Kosalaraksa P'
p75486
aS'Jourdain G'
p75487
aS'Ananworanich J'
p75488
aS'Suwanlerk T'
p75489
aS'Chokephaibulkit K'
p75490
aS'Wittawatmongkol O'
p75491
aS'Truong HK'
p75492
aS'Mai DA'
p75493
aS'Do CV'
p75494
aS'Ha MT'
p75495
aS'Bui HV'
p75496
aS'Nguyen VL'
p75497
aS'Le ON'
p75498
aS'Sohn AH'
p75499
aS'Messerschmidt L'
p75500
aS'Pang J'
p75501
aS'Cooper DA'
p75502
aS'Kariminia A'
p75503
aS'Davies MA'
p75504
aS'Eley B'
p75505
aS'Giddy J'
p75506
aS'Moultrie H'
p75507
aS'Pascoe M'
p75508
aS'Rabie H'
p75509
aS'Technau K'
p75510
aS'Van Cutsem G'
p75511
aS'Vaz P'
p75512
aS'Weigel R'
p75513
aS'Wood R'
p75514
asS'AD'
p75515
S'TREAT Asia/amfAR - The Foundation for AIDS Research, Bangkok, Thailand. annette.sohn@treatasia.org'
p75516
sS'MHDA'
p75517
S'2011/06/08 06:00'
p75518
sS'PHST'
p75519
(lp75520
S'2010/11/30 [received]'
p75521
aS'2011/02/09 [accepted]'
p75522
aS'2011/02/09 [aheadofprint]'
p75523
asS'OID'
p75524
(lp75525
S'NLM: PMC3058075'
p75526
asS'MH'
p75527
(lp75528
S'Adolescent'
p75529
aS'Africa, Southern'
p75530
aS'Anti-HIV Agents/*therapeutic use'
p75531
aS'Antiretroviral Therapy, Highly Active/*methods'
p75532
aS'Asia'
p75533
aS'Child'
p75534
aS'Child, Preschool'
p75535
aS'Cross-Sectional Studies'
p75536
aS'Drug Utilization/*statistics & numerical data'
p75537
aS'Female'
p75538
aS'HIV Infections/*drug therapy'
p75539
aS'Health Services Accessibility/*statistics & numerical data'
p75540
aS'*Health Services Research'
p75541
aS'Humans'
p75542
aS'Male'
p75543
aS'Treatment Failure'
p75544
asS'EDAT'
p75545
S'2011/02/11 06:00'
p75546
sS'PMC'
p75547
S'PMC3058075'
p75548
sS'GR'
p75549
(lp75550
S'U01 AI069924/AI/NIAID NIH HHS/United States'
p75551
aS'U01 AI069924-01/AI/NIAID NIH HHS/United States'
p75552
aS'U01-AI069907/AI/NIAID NIH HHS/United States'
p75553
asS'SO'
p75554
S'J Int AIDS Soc. 2011 Feb 9;14:7. doi: 10.1186/1758-2652-14-7.'
p75555
sS'SB'
p75556
S'IM X'
p75557
sS'PMID'
p75558
S'21306608'
p75559
sS'PST'
p75560
S'epublish'
p75561
stRp75562
ag2
(g3
g4
(dp75563
S'LID'
p75564
S'10.1111/j.1365-3156.2011.02740.x [doi]'
p75565
sS'STAT'
p75566
S'MEDLINE'
p75567
sS'DEP'
p75568
S'20110209'
p75569
sS'CI'
p75570
(lp75571
S'(c) 2011 Blackwell Publishing Ltd.'
p75572
asS'DA'
p75573
S'20110415'
p75574
sS'AID'
p75575
(lp75576
S'10.1111/j.1365-3156.2011.02740.x [doi]'
p75577
asS'CRDT'
p75578
(lp75579
S'2011/02/11 06:00'
p75580
asS'DP'
p75581
S'2011 May'
p75582
sS'OWN'
p75583
S'NLM'
p75584
sS'PT'
p75585
(lp75586
S'Journal Article'
p75587
asS'LA'
p75588
(lp75589
S'eng'
p75590
asS'FAU'
p75591
(lp75592
S'Tayler-Smith, K'
p75593
aS'Zachariah, R'
p75594
aS'Manzi, M'
p75595
aS'Kizito, W'
p75596
aS'Vandenbulcke, A'
p75597
aS'Dunkley, S'
p75598
aS'von Rege, D'
p75599
aS'Reid, T'
p75600
aS'Arnould, L'
p75601
aS'Suleh, A'
p75602
aS'Harries, A D'
p75603
asS'JT'
p75604
S'Tropical medicine & international health : TM & IH'
p75605
sS'PG'
p75606
S'579-84'
p75607
sS'TI'
p75608
S'Demographic characteristics and opportunistic diseases associated with attrition during preparation for antiretroviral therapy in primary health centres in Kibera, Kenya.'
p75609
sS'RN'
p75610
(lp75611
S'0 (Anti-HIV Agents)'
p75612
asS'PL'
p75613
S'England'
p75614
sS'TA'
p75615
S'Trop Med Int Health'
p75616
sS'JID'
p75617
S'9610576'
p75618
sS'AB'
p75619
S"Using routine data from HIV-positive adult patients eligible for antiretroviral therapy (ART), we report on routinely collected demographic characteristics and opportunistic diseases associated with pre-ART attrition (deaths and loss to follow-up). Among 2471 ART eligible patients, enrolled between January 2005 and November 2008, 446 (18%) were lost to attrition pre-ART. Adjusted risk factors significantly associated with pre-ART attrition included age <35 years (Odds Ratio, OR 1.4, 95% Confidence Interval, CI 1.1-1.8), severe malnutrition (OR 1.5, 95% CI 1.1-2.0), active pulmonary tuberculosis (OR 1.6, 95% CI 1.1-2.4), severe bacterial infections including severe bacterial pneumonia (OR 1.9, 95% CI 1.2-2.8) and prolonged unexplained fever (>1 month), (OR 2.6, 95% CI 1.3-5.2). This study highlights a number of clinical markers associated with pre-ART attrition that could serve as 'pointers' or screening tools to identify patients who merit fast-tracking onto ART and/or closer clinical attention and follow-up."
p75620
sS'AD'
p75621
S'Medecins sans Frontieres, Medical Department (Operational Research), Brussels Operational Center, Luxembourg, Luxembourg.'
p75622
sS'IP'
p75623
S'5'
sS'IS'
p75624
S'1365-3156 (Electronic) 1360-2276 (Linking)'
p75625
sS'DCOM'
p75626
S'20110628'
p75627
sS'AU'
p75628
(lp75629
S'Tayler-Smith K'
p75630
aS'Zachariah R'
p75631
aS'Manzi M'
p75632
aS'Kizito W'
p75633
aS'Vandenbulcke A'
p75634
aS'Dunkley S'
p75635
aS'von Rege D'
p75636
aS'Reid T'
p75637
aS'Arnould L'
p75638
aS'Suleh A'
p75639
aS'Harries AD'
p75640
asS'VI'
p75641
S'16'
p75642
sS'MHDA'
p75643
S'2011/06/29 06:00'
p75644
sS'PHST'
p75645
(lp75646
S'2011/02/09 [aheadofprint]'
p75647
asS'MH'
p75648
(lp75649
S'AIDS-Related Opportunistic Infections/epidemiology'
p75650
aS'Adolescent'
p75651
aS'Adult'
p75652
aS'Anti-HIV Agents/*therapeutic use'
p75653
aS'Antiretroviral Therapy, Highly Active'
p75654
aS'Female'
p75655
aS'HIV Infections/*drug therapy/epidemiology'
p75656
aS'Humans'
p75657
aS'Kenya/epidemiology'
p75658
aS'Male'
p75659
aS'Patient Dropouts/*statistics & numerical data'
p75660
aS'Patient Selection'
p75661
aS'Pneumonia, Bacterial/epidemiology'
p75662
aS'Primary Health Care'
p75663
aS'Risk Factors'
p75664
aS'Tuberculosis, Pulmonary/epidemiology'
p75665
aS'Young Adult'
p75666
asS'EDAT'
p75667
S'2011/02/11 06:00'
p75668
sS'SO'
p75669
S'Trop Med Int Health. 2011 May;16(5):579-84. doi: 10.1111/j.1365-3156.2011.02740.x. Epub 2011 Feb 9.'
p75670
sS'SB'
p75671
S'IM'
p75672
sS'PMID'
p75673
S'21306485'
p75674
sS'PST'
p75675
S'ppublish'
p75676
stRp75677
ag2
(g3
g4
(dp75678
S'LID'
p75679
S'10.1080/09540121.2010.525615 [doi]'
p75680
sS'STAT'
p75681
S'MEDLINE'
p75682
sS'JT'
p75683
S'AIDS care'
p75684
sS'MID'
p75685
(lp75686
S'NIHMS359021'
p75687
asS'DA'
p75688
S'20110418'
p75689
sS'AID'
p75690
(lp75691
S'933021708 [pii]'
p75692
aS'10.1080/09540121.2010.525615 [doi]'
p75693
asS'CRDT'
p75694
(lp75695
S'2011/02/05 06:00'
p75696
asS'DP'
p75697
S'2011 May'
p75698
sS'AD'
p75699
S'Department of Global Health, University of Washington, Seattle, WA, USA. leepyne@gmail.com'
p75700
sS'OWN'
p75701
S'NLM'
p75702
sS'PT'
p75703
(lp75704
S'Journal Article'
p75705
asS'LA'
p75706
(lp75707
S'eng'
p75708
asS'FAU'
p75709
(lp75710
S'Pyne-Mercier, Lee D'
p75711
aS'John-Stewart, Grace C'
p75712
aS'Richardson, Barbra A'
p75713
aS'Kagondu, Njeri L'
p75714
aS'Thiga, Joan'
p75715
aS'Noshy, Haidy'
p75716
aS'Kist, Nadia'
p75717
aS'Chung, Michael H'
p75718
asS'LR'
p75719
S'20150329'
p75720
sS'PG'
p75721
S'562-8'
p75722
sS'TI'
p75723
S'The consequences of post-election violence on antiretroviral HIV therapy in Kenya.'
p75724
sS'RN'
p75725
(lp75726
S'0 (Anti-HIV Agents)'
p75727
asS'PL'
p75728
S'England'
p75729
sS'TA'
p75730
S'AIDS Care'
p75731
sS'JID'
p75732
S'8915313'
p75733
sS'AB'
p75734
S'Over 1000 individuals were killed and 600,000 were displaced during post-election violence (PEV) in Kenya in 2008. Antiretroviral therapy (ART) depends on continuous access to medications which may have been interrupted due to PEV. In a mixed-methods retrospective review, treatment interruption of ART during PEV was measured among 2534 HIV-positive adults attending the Coptic Hope Center for Infectious Diseases in Nairobi, Kenya. Clients experiencing treatment interruption were compared between the PEV period (30 December 2007 to 28 February 2008) and the same time period one year earlier. Treatment interruption was defined as visiting the pharmacy >/=48 hours after antiretrovirals were calculated to have been completed. Despite clinical services remaining open throughout the PEV period, more clients (16.1%) experienced treatment interruption than during the comparison period (10.2%). Mean daily pharmacy visits were significantly lower (87 vs. 104; p < 0.006) and more variable (p = 0.03) during PEV. Among clients present at both periods (n = 1605), the odds of treatment interruption were 71% higher during PEV (95% confidence interval [CI], 34-118%). In multivariate analysis, men (odds ratio [OR], 1.37; 95% CI, 1.07-1.76) and clients traveling >/=3 hours to clinic (OR, 1.86; 95% CI, 1.28-2.71) were significantly more likely to experience treatment interruption. Clients affected by PEV were interviewed about factors associated with treatment interruption using semi-structured methods. Clients described fear, lack of transportation, and violence as contributing to treatment interruption. Widespread violence associated with the 2007 election in Kenya revealed the dependence of HIV patients on a stable civil society and infrastructure to access medications. Without the ability to maintain consistent HIV therapy, some patients face rapid treatment failure. HIV programs should have appropriate contingency plans wherever political instability may occur. Peace may be one of the most effective and most important public health interventions in Africa.'
p75735
sS'GR'
p75736
(lp75737
S'K24 HD054314/HD/NICHD NIH HHS/United States'
p75738
aS'P30 AI027757/AI/NIAID NIH HHS/United States'
p75739
aS'P30 AI027757-12/AI/NIAID NIH HHS/United States'
p75740
asS'IP'
p75741
S'5'
sS'IS'
p75742
S'1360-0451 (Electronic) 0954-0121 (Linking)'
p75743
sS'PMC'
p75744
S'PMC3372410'
p75745
sS'DCOM'
p75746
S'20110916'
p75747
sS'AU'
p75748
(lp75749
S'Pyne-Mercier LD'
p75750
aS'John-Stewart GC'
p75751
aS'Richardson BA'
p75752
aS'Kagondu NL'
p75753
aS'Thiga J'
p75754
aS'Noshy H'
p75755
aS'Kist N'
p75756
aS'Chung MH'
p75757
asS'VI'
p75758
S'23'
p75759
sS'MHDA'
p75760
S'2011/09/17 06:00'
p75761
sS'OID'
p75762
(lp75763
S'NLM: NIHMS359021'
p75764
aS'NLM: PMC3372410'
p75765
asS'MH'
p75766
(lp75767
S'Adolescent'
p75768
aS'Adult'
p75769
aS'Anti-HIV Agents/supply & distribution/*therapeutic use'
p75770
aS'Female'
p75771
aS'HIV Infections/*drug therapy'
p75772
aS'Health Services Accessibility/statistics & numerical data'
p75773
aS'Humans'
p75774
aS'Kenya'
p75775
aS'Male'
p75776
aS'Middle Aged'
p75777
aS'*Politics'
p75778
aS'Retrospective Studies'
p75779
aS'Violence/*statistics & numerical data'
p75780
aS'Young Adult'
p75781
asS'EDAT'
p75782
S'2011/02/05 06:00'
p75783
sS'SO'
p75784
S'AIDS Care. 2011 May;23(5):562-8. doi: 10.1080/09540121.2010.525615.'
p75785
sS'SB'
p75786
S'IM X'
p75787
sS'PMID'
p75788
S'21293984'
p75789
sS'PST'
p75790
S'ppublish'
p75791
stRp75792
ag2
(g3
g4
(dp75793
S'LID'
p75794
S'10.1097/QAD.0b013e3283428cbe [doi]'
p75795
sS'STAT'
p75796
S'MEDLINE'
p75797
sS'JT'
p75798
S'AIDS (London, England)'
p75799
sS'MID'
p75800
(lp75801
S'NIHMS259953'
p75802
asS'DA'
p75803
S'20110204'
p75804
sS'AID'
p75805
(lp75806
S'10.1097/QAD.0b013e3283428cbe [doi]'
p75807
aS'00002030-201102200-00010 [pii]'
p75808
asS'CRDT'
p75809
(lp75810
S'2011/02/05 06:00'
p75811
asS'DP'
p75812
S'2011 Feb 20'
p75813
sS'GR'
p75814
(lp75815
S'3U01AI32775-13S5/AI/NIAID NIH HHS/United States'
p75816
aS'5 U01 AI069518/AI/NIAID NIH HHS/United States'
p75817
aS'5U01AI069455-03/AI/NIAID NIH HHS/United States'
p75818
aS'5U01AI069456-03/AI/NIAID NIH HHS/United States'
p75819
aS'AI-069501/AI/NIAID NIH HHS/United States'
p75820
aS'AI69453/AI/NIAID NIH HHS/United States'
p75821
aS'K01 AI078754/AI/NIAID NIH HHS/United States'
p75822
aS'K01 AI078754/AI/NIAID NIH HHS/United States'
p75823
aS'K01 AI078754-02/AI/NIAID NIH HHS/United States'
p75824
aS'K24 AI056933/AI/NIAID NIH HHS/United States'
p75825
aS'K24 AI062476/AI/NIAID NIH HHS/United States'
p75826
aS'K24 AI062476/AI/NIAID NIH HHS/United States'
p75827
aS'K24 AI56933/AI/NIAID NIH HHS/United States'
p75828
aS'P30 AI 60354/AI/NIAID NIH HHS/United States'
p75829
aS'P30 AI060354/AI/NIAID NIH HHS/United States'
p75830
aS'R01 AI 69453/AI/NIAID NIH HHS/United States'
p75831
aS'R01 AI058736/AI/NIAID NIH HHS/United States'
p75832
aS'R01 AI058736/AI/NIAID NIH HHS/United States'
p75833
aS'R01 HD044391/HD/NICHD NIH HHS/United States'
p75834
aS'R01 HD044391/HD/NICHD NIH HHS/United States'
p75835
aS'U01 AI032775/AI/NIAID NIH HHS/United States'
p75836
aS'U01 AI068636/AI/NIAID NIH HHS/United States'
p75837
aS'U01 AI068636/AI/NIAID NIH HHS/United States'
p75838
aS'U01 AI069424/AI/NIAID NIH HHS/United States'
p75839
aS'U01 AI069424/AI/NIAID NIH HHS/United States'
p75840
aS'U01 AI069436/AI/NIAID NIH HHS/United States'
p75841
aS'U01 AI069453/AI/NIAID NIH HHS/United States'
p75842
aS'U01 AI069455/AI/NIAID NIH HHS/United States'
p75843
aS'U01 AI069456/AI/NIAID NIH HHS/United States'
p75844
aS'U01 AI069501/AI/NIAID NIH HHS/United States'
p75845
aS'U01 AI069518/AI/NIAID NIH HHS/United States'
p75846
aS'U01 AI68634/AI/NIAID NIH HHS/United States'
p75847
aS'U01 AI69463-03/AI/NIAID NIH HHS/United States'
p75848
aS'U01AI069436/AI/NIAID NIH HHS/United States'
p75849
aS'U19 AI053217/AI/NIAID NIH HHS/United States'
p75850
aS'U19 AI53217/AI/NIAID NIH HHS/United States'
p75851
aS'UM1 AI068632/AI/NIAID NIH HHS/United States'
p75852
asS'OWN'
p75853
S'NLM'
p75854
sS'PT'
p75855
(lp75856
S'Journal Article'
p75857
aS'Research Support, N.I.H., Extramural'
p75858
aS"Research Support, Non-U.S. Gov't"
p75859
asS'LA'
p75860
(lp75861
S'eng'
p75862
asS'FAU'
p75863
(lp75864
S'Ciaranello, Andrea L'
p75865
aS'Lockman, Shahin'
p75866
aS'Freedberg, Kenneth A'
p75867
aS'Hughes, Michael'
p75868
aS'Chu, Jennifer'
p75869
aS'Currier, Judith'
p75870
aS'Wood, Robin'
p75871
aS'Holmes, Charles B'
p75872
aS'Pillay, Sandy'
p75873
aS'Conradie, Francesca'
p75874
aS'McIntyre, James'
p75875
aS'Losina, Elena'
p75876
aS'Walensky, Rochelle P'
p75877
asS'LR'
p75878
S'20160819'
p75879
sS'PG'
p75880
S'479-92'
p75881
sS'TI'
p75882
S'First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial.'
p75883
sS'RN'
p75884
(lp75885
S'0 (Anti-HIV Agents)'
p75886
aS'0 (Pyrimidinones)'
p75887
aS'2494G1JF75 (Lopinavir)'
p75888
aS'99DK7FVK1H (Nevirapine)'
p75889
aS'O3J8G9O825 (Ritonavir)'
p75890
asS'PL'
p75891
S'England'
p75892
sS'TA'
p75893
S'AIDS'
p75894
sS'FIR'
p75895
(lp75896
S'Danel, Christine'
p75897
aS"N'Dri-Yoman, Therese"
p75898
aS'Messou, Eugene'
p75899
aS'Moh, Raoul'
p75900
aS'Ouattara, Eric'
p75901
aS'Seyler, Catherine'
p75902
aS'Toure, Siaka'
p75903
aS'Yazdanpanah, Yazdan'
p75904
aS'Anglaret, Xavier'
p75905
aS'Gabillard, Delphine'
p75906
aS'Toure, Hapsatou'
p75907
aS'Kumarasamy, Nagalingeswaran'
p75908
aS'Ganesh, A K'
p75909
aS'Orrell, Catherine'
p75910
aS'Wood, Robin'
p75911
aS'Martinson, Neil'
p75912
aS'Mohapi, Lerato'
p75913
aS'Cotich, Kara'
p75914
aS'Goldie, Sue J'
p75915
aS'Kimmel, April D'
p75916
aS'Lipsitch, Marc'
p75917
aS'McCormick, Alethea'
p75918
aS'Rydzak, Chara'
p75919
aS'Seage, George R 3rd'
p75920
aS'Weinstein, Milton C'
p75921
aS'Horsburgh, C Robert'
p75922
aS'Hsu, Heather E'
p75923
aS'Flanigan, Timothy'
p75924
aS'Mayer, Kenneth'
p75925
aS'Paltiel, A David'
p75926
aS'Ahonkhai, Aima'
p75927
aS'Andrews, Jason'
p75928
aS'Bassett, Ingrid V'
p75929
aS'Becker, Jessica'
p75930
aS'Bender, Melissa A'
p75931
aS'Chiosi, John'
p75932
aS'Levison, Julie'
p75933
aS'Linas, Benjamin P'
p75934
aS'Lu, Zhigang'
p75935
aS'Lorenzana, Sarah'
p75936
aS'Morris, Bethany'
p75937
aS'Pho, Mai'
p75938
aS'Rhode, Erin'
p75939
aS'Scott, Callie A'
p75940
aS'Sloan, Caroline'
p75941
aS'Stoler, Adam'
p75942
aS'Uhler, Lauren'
p75943
aS'Wang, Bingxia'
p75944
aS'Wong, Angela'
p75945
aS'Chaisson, Richard'
p75946
aS'De Gruttola, Victor'
p75947
aS'Eron, Joseph'
p75948
aS'Gangakhedkar, R R'
p75949
aS'Kaplan, Jonathan'
p75950
aS'Karim, Salim'
p75951
aS"N'Dri-Yoman, Therese"
p75952
aS'Owens, Douglas'
p75953
aS'Wong, John'
p75954
asS'JID'
p75955
S'8710219'
p75956
sS'AB'
p75957
S'BACKGROUND: The OCTANE trial reports superior outcomes of lopinavir/ritonavir vs. nevirapine-based antiretroviral therapy (ART) among women previously exposed to single-dose nevirapine to prevent mother-to-child HIV transmission. However, lopinavir/ritonavir is 12 times costlier than nevirapine. METHODS: We used a computer model, with OCTANE and local data, to simulate HIV-infected, single-dose nevirapine-exposed women in South Africa. Outcomes of three alternative ART sequences were projected: no ART (for comparison), first-line nevirapine, and first-line lopinavir/ritonavir. OCTANE data included mean age (31 years) and CD4 cell count (135/mul); median time since single-dose nevirapine (17 months); and 24-week viral suppression efficacy for first-line ART (nevirapine: 85%, lopinavir/ritonavir: 97%). Outcomes included life expectancy, per-person costs (2008 US$), and incremental cost-effectiveness ratios. RESULTS: With no ART, projected life expectancy was 1.6 years and per-person cost was $2980. First-line nevirapine increased life expectancy (15.2 years) and cost ($13 990; cost-effectiveness ratio: $810/year of life saved versus no ART). First-line lopinavir/ritonavir further increased life expectancy to 16.3 years and cost to $15 630 (cost-effectiveness ratio: $1520/year of life saved versus first-line nevirapine). First-line lopinavir/ritonavir cost-effectiveness was sensitive to prevalence of nevirapine-resistant virus at ART initiation, time from single-dose nevirapine exposure to ART initiation (6-12, 12-24, or >24 months), second-line ART efficacies, and outcomes after 24 weeks on ART. CONCLUSIONS: First-line lopinavir/ritonavir-based ART is very cost-effective in single-dose nevirapine-exposed, South African women similar to OCTANE participants. Lopinavir/ritonavir should be initiated in women with known nevirapine resistance or single-dose nevirapine exposure less than 12 months prior, or in whom such information is unknown.'
p75958
sS'AD'
p75959
S'Division of Infectious Disease, Massachusetts General Hospital, Boston, 02114, USA. aciaranello@partners.org'
p75960
sS'CN'
p75961
(lp75962
S'CEPAC-International and OCTANE Investigators'
p75963
asS'IP'
p75964
S'4'
sS'IS'
p75965
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p75966
sS'IR'
p75967
(lp75968
S'Danel C'
p75969
aS"N'Dri-Yoman T"
p75970
aS'Messou E'
p75971
aS'Moh R'
p75972
aS'Ouattara E'
p75973
aS'Seyler C'
p75974
aS'Toure S'
p75975
aS'Yazdanpanah Y'
p75976
aS'Anglaret X'
p75977
aS'Gabillard D'
p75978
aS'Toure H'
p75979
aS'Kumarasamy N'
p75980
aS'Ganesh AK'
p75981
aS'Orrell C'
p75982
aS'Wood R'
p75983
aS'Martinson N'
p75984
aS'Mohapi L'
p75985
aS'Cotich K'
p75986
aS'Goldie SJ'
p75987
aS'Kimmel AD'
p75988
aS'Lipsitch M'
p75989
aS'McCormick A'
p75990
aS'Rydzak C'
p75991
aS'Seage GR 3rd'
p75992
aS'Weinstein MC'
p75993
aS'Horsburgh CR'
p75994
aS'Hsu HE'
p75995
aS'Flanigan T'
p75996
aS'Mayer K'
p75997
aS'Paltiel AD'
p75998
aS'Ahonkhai A'
p75999
aS'Andrews J'
p76000
aS'Bassett IV'
p76001
aS'Becker J'
p76002
aS'Bender MA'
p76003
aS'Chiosi J'
p76004
aS'Levison J'
p76005
aS'Linas BP'
p76006
aS'Lu Z'
p76007
aS'Lorenzana S'
p76008
aS'Morris B'
p76009
aS'Pho M'
p76010
aS'Rhode E'
p76011
aS'Scott CA'
p76012
aS'Sloan C'
p76013
aS'Stoler A'
p76014
aS'Uhler L'
p76015
aS'Wang B'
p76016
aS'Wong A'
p76017
aS'Chaisson R'
p76018
aS'De Gruttola V'
p76019
aS'Eron J'
p76020
aS'Gangakhedkar RR'
p76021
aS'Kaplan J'
p76022
aS'Karim S'
p76023
aS"N'Dri-Yoman T"
p76024
aS'Owens D'
p76025
aS'Wong J'
p76026
asS'DCOM'
p76027
S'20110606'
p76028
sS'AU'
p76029
(lp76030
S'Ciaranello AL'
p76031
aS'Lockman S'
p76032
aS'Freedberg KA'
p76033
aS'Hughes M'
p76034
aS'Chu J'
p76035
aS'Currier J'
p76036
aS'Wood R'
p76037
aS'Holmes CB'
p76038
aS'Pillay S'
p76039
aS'Conradie F'
p76040
aS'McIntyre J'
p76041
aS'Losina E'
p76042
aS'Walensky RP'
p76043
asS'VI'
p76044
S'25'
p76045
sS'MHDA'
p76046
S'2011/06/07 06:00'
p76047
sS'OID'
p76048
(lp76049
S'NLM: NIHMS259953'
p76050
aS'NLM: PMC3068908'
p76051
asS'MH'
p76052
(lp76053
S'Adult'
p76054
aS'Anti-HIV Agents/*economics/therapeutic use'
p76055
aS'Cost-Benefit Analysis'
p76056
aS'Female'
p76057
aS'HIV Infections/*drug therapy/*economics/epidemiology'
p76058
aS'Humans'
p76059
aS'Infant, Newborn'
p76060
aS'Infectious Disease Transmission, Vertical/*economics/prevention & control'
p76061
aS'Life Expectancy'
p76062
aS'Lopinavir'
p76063
aS'Male'
p76064
aS'Nevirapine/*economics/therapeutic use'
p76065
aS'Pregnancy'
p76066
aS'Pyrimidinones/*economics/therapeutic use'
p76067
aS'Ritonavir/*economics/therapeutic use'
p76068
aS'South Africa/epidemiology'
p76069
aS'Treatment Outcome'
p76070
asS'EDAT'
p76071
S'2011/02/05 06:00'
p76072
sS'PMC'
p76073
S'PMC3068908'
p76074
sS'SO'
p76075
S'AIDS. 2011 Feb 20;25(4):479-92. doi: 10.1097/QAD.0b013e3283428cbe.'
p76076
sS'SB'
p76077
S'IM X'
p76078
sS'PMID'
p76079
S'21293199'
p76080
sS'PST'
p76081
S'ppublish'
p76082
stRp76083
ag2
(g3
g4
(dp76084
S'LID'
p76085
S'10.1186/1471-2334-11-28 [doi]'
p76086
sS'STAT'
p76087
S'MEDLINE'
p76088
sS'DEP'
p76089
S'20110126'
p76090
sS'DA'
p76091
S'20110228'
p76092
sS'AID'
p76093
(lp76094
S'1471-2334-11-28 [pii]'
p76095
aS'10.1186/1471-2334-11-28 [doi]'
p76096
asS'CRDT'
p76097
(lp76098
S'2011/01/29 06:00'
p76099
asS'DP'
p76100
S'2011'
p76101
sS'OWN'
p76102
S'NLM'
p76103
sS'PT'
p76104
(lp76105
S'Journal Article'
p76106
aS"Research Support, U.S. Gov't, Non-P.H.S."
p76107
asS'LA'
p76108
(lp76109
S'eng'
p76110
asS'DCOM'
p76111
S'20110503'
p76112
sS'JT'
p76113
S'BMC infectious diseases'
p76114
sS'LR'
p76115
S'20150205'
p76116
sS'FAU'
p76117
(lp76118
S'Fairlie, Lee'
p76119
aS'Beylis, Natalie C'
p76120
aS'Reubenson, Gary'
p76121
aS'Moore, David P'
p76122
aS'Madhi, Shabir A'
p76123
asS'TI'
p76124
S'High prevalence of childhood multi-drug resistant tuberculosis in Johannesburg, South Africa: a cross sectional study.'
p76125
sS'RN'
p76126
(lp76127
S'0 (Antitubercular Agents)'
p76128
asS'PL'
p76129
S'England'
p76130
sS'PG'
p76131
S'28'
p76132
sS'JID'
p76133
S'100968551'
p76134
sS'AB'
p76135
S'BACKGROUND: There are limited data on the prevalence of multi-drug resistant tuberculosis (MDR-TB), estimated at 0.6-6.7%, in African children with tuberculosis. We undertook a retrospective analysis of the prevalence of MDR-TB in children with Mycobacterium tuberculosis (MTB) at two hospitals in Johannesburg, South Africa. METHODS: Culture-confirmed cases of MTB in children under 14 years, attending two academic hospitals in Johannesburg, South Africa during 2008 were identified and hospital records of children diagnosed with drug-resistant TB were reviewed, including clinical and radiological outcomes at 6 and 12 months post-diagnosis. Culture of Mycobacterium tuberculosis complex (MTB) was performed using the automated liquid broth MGIT 960 method. Drug susceptibility testing (DST) was performed using the MGIT 960 method for both first and second-line anti-TB drugs. RESULTS: 1317 children were treated for tuberculosis in 2008 between the two hospitals where the study was conducted. Drug susceptibility testing was undertaken in 148 (72.5%) of the 204 children who had culture-confirmed tuberculosis. The prevalence of isoniazid-resistance was 14.2% (n = 21) (95%CI, 9.0-20.9%) and the prevalence of MDR-TB 8.8% (n = 13) (95%CI, 4.8-14.6%). The prevalence of HIV co-infection was 52.1% in children with drug susceptible-TB and 53.9% in children with MDR-TB. Ten (76.9%) of the 13 children with MDR-TB received appropriate treatment and four (30.8%) died at a median of 2.8 months (range 0.1-4.0 months) after the date of tuberculosis investigation. CONCLUSIONS: There is a high prevalence of drug-resistant tuberculosis in children in Johannesburg in a setting with a high prevalence of HIV co-infection, although no association between HIV infection and MDR-TB was found in this study. Routine HIV and drug-susceptibility testing is warranted to optimize the management of childhood tuberculosis in settings such as ours.'
p76136
sS'AD'
p76137
S'Faculty of Health Sciences, University of the Witwatersrand, 6 York Street, Parktown, Johannesburg, 2193, South Africa. leef@witsecho.org.za'
p76138
sS'VI'
p76139
S'11'
p76140
sS'IS'
p76141
S'1471-2334 (Electronic) 1471-2334 (Linking)'
p76142
sS'PMC'
p76143
S'PMC3045316'
p76144
sS'AU'
p76145
(lp76146
S'Fairlie L'
p76147
aS'Beylis NC'
p76148
aS'Reubenson G'
p76149
aS'Moore DP'
p76150
aS'Madhi SA'
p76151
asS'MHDA'
p76152
S'2011/05/04 06:00'
p76153
sS'PHST'
p76154
(lp76155
S'2010/09/03 [received]'
p76156
aS'2011/01/26 [accepted]'
p76157
aS'2011/01/26 [aheadofprint]'
p76158
asS'OID'
p76159
(lp76160
S'NLM: PMC3045316'
p76161
asS'MH'
p76162
(lp76163
S'Adolescent'
p76164
aS'Antitubercular Agents/*therapeutic use'
p76165
aS'Child'
p76166
aS'Child, Preschool'
p76167
aS'Cross-Sectional Studies'
p76168
aS'Female'
p76169
aS'Humans'
p76170
aS'Infant'
p76171
aS'Male'
p76172
aS'Mycobacterium/drug effects/genetics/isolation & purification'
p76173
aS'Prevalence'
p76174
aS'Retrospective Studies'
p76175
aS'South Africa/epidemiology'
p76176
aS'Tuberculosis, Multidrug-Resistant/*drug therapy/*epidemiology/microbiology'
p76177
asS'EDAT'
p76178
S'2011/01/29 06:00'
p76179
sS'SO'
p76180
S'BMC Infect Dis. 2011 Jan 26;11:28. doi: 10.1186/1471-2334-11-28.'
p76181
sS'SB'
p76182
S'IM'
p76183
sS'PMID'
p76184
S'21269475'
p76185
sS'TA'
p76186
S'BMC Infect Dis'
p76187
sS'PST'
p76188
S'epublish'
p76189
stRp76190
ag2
(g3
g4
(dp76191
S'LID'
p76192
S'10.1371/journal.pmed.1000390 [doi]'
p76193
sS'STAT'
p76194
S'MEDLINE'
p76195
sS'DEP'
p76196
S'20110118'
p76197
sS'CIN'
p76198
(lp76199
S'PLoS Med. 2011;8(1):e1000392. PMID: 21267064'
p76200
asS'DA'
p76201
S'20110126'
p76202
sS'AID'
p76203
(lp76204
S'10.1371/journal.pmed.1000390 [doi]'
p76205
asS'CRDT'
p76206
(lp76207
S'2011/01/27 06:00'
p76208
asS'DP'
p76209
S'2011'
p76210
sS'GR'
p76211
(lp76212
S'K23 AI084544/AI/NIAID NIH HHS/United States'
p76213
aS'U01 AI069919/AI/NIAID NIH HHS/United States'
p76214
aS'U01 AI069924/AI/NIAID NIH HHS/United States'
p76215
aS'U01-AI069911/AI/NIAID NIH HHS/United States'
p76216
aS'U01-AI069919/AI/NIAID NIH HHS/United States'
p76217
aS'U01-AI069924/AI/NIAID NIH HHS/United States'
p76218
asS'OWN'
p76219
S'NLM'
p76220
sS'PT'
p76221
(lp76222
S'Journal Article'
p76223
aS'Research Support, N.I.H., Extramural'
p76224
aS"Research Support, Non-U.S. Gov't"
p76225
asS'LA'
p76226
(lp76227
S'eng'
p76228
asS'FAU'
p76229
(lp76230
S'Egger, Matthias'
p76231
aS'Spycher, Ben D'
p76232
aS'Sidle, John'
p76233
aS'Weigel, Ralf'
p76234
aS'Geng, Elvin H'
p76235
aS'Fox, Matthew P'
p76236
aS'MacPhail, Patrick'
p76237
aS'van Cutsem, Gilles'
p76238
aS'Messou, Eugene'
p76239
aS'Wood, Robin'
p76240
aS'Nash, Denis'
p76241
aS'Pascoe, Margaret'
p76242
aS'Dickinson, Diana'
p76243
aS'Etard, Jean-Francois'
p76244
aS'McIntyre, James A'
p76245
aS'Brinkhof, Martin W G'
p76246
asS'JT'
p76247
S'PLoS medicine'
p76248
sS'LR'
p76249
S'20150526'
p76250
sS'PG'
p76251
S'e1000390'
p76252
sS'TI'
p76253
S'Correcting mortality for loss to follow-up: a nomogram applied to antiretroviral treatment programmes in sub-Saharan Africa.'
p76254
sS'RN'
p76255
(lp76256
S'0 (Anti-HIV Agents)'
p76257
asS'PL'
p76258
S'United States'
p76259
sS'TA'
p76260
S'PLoS Med'
p76261
sS'JID'
p76262
S'101231360'
p76263
sS'AB'
p76264
S'BACKGROUND: The World Health Organization estimates that in sub-Saharan Africa about 4 million HIV-infected patients had started antiretroviral therapy (ART) by the end of 2008. Loss of patients to follow-up and care is an important problem for treatment programmes in this region. As mortality is high in these patients compared to patients remaining in care, ART programmes with high rates of loss to follow-up may substantially underestimate mortality of all patients starting ART. METHODS AND FINDINGS: We developed a nomogram to correct mortality estimates for loss to follow-up, based on the fact that mortality of all patients starting ART in a treatment programme is a weighted average of mortality among patients lost to follow-up and patients remaining in care. The nomogram gives a correction factor based on the percentage of patients lost to follow-up at a given point in time, and the estimated ratio of mortality between patients lost and not lost to follow-up. The mortality observed among patients retained in care is then multiplied by the correction factor to obtain an estimate of programme-level mortality that takes all deaths into account. A web calculator directly calculates the corrected, programme-level mortality with 95% confidence intervals (CIs). We applied the method to 11 ART programmes in sub-Saharan Africa. Patients retained in care had a mortality at 1 year of 1.4% to 12.0%; loss to follow-up ranged from 2.8% to 28.7%; and the correction factor from 1.2 to 8.0. The absolute difference between uncorrected and corrected mortality at 1 year ranged from 1.6% to 9.8%, and was above 5% in four programmes. The largest difference in mortality was in a programme with 28.7% of patients lost to follow-up at 1 year. CONCLUSIONS: The amount of bias in mortality estimates can be large in ART programmes with substantial loss to follow-up. Programmes should routinely report mortality among patients retained in care and the proportion of patients lost. A simple nomogram can then be used to estimate mortality among all patients who started ART, for a range of plausible mortality rates among patients lost to follow-up.'
p76265
sS'AD'
p76266
S'Institute of Social and Preventive Medicine (ISPM), University of Bern, Switzerland. egger@ispm.unibe.ch'
p76267
sS'CN'
p76268
(lp76269
S'IeDEA East Africa, West Africa and Southern Africa'
p76270
asS'IP'
p76271
S'1'
sS'IS'
p76272
S'1549-1676 (Electronic) 1549-1277 (Linking)'
p76273
sS'PMC'
p76274
S'PMC3022522'
p76275
sS'DCOM'
p76276
S'20110531'
p76277
sS'AU'
p76278
(lp76279
S'Egger M'
p76280
aS'Spycher BD'
p76281
aS'Sidle J'
p76282
aS'Weigel R'
p76283
aS'Geng EH'
p76284
aS'Fox MP'
p76285
aS'MacPhail P'
p76286
aS'van Cutsem G'
p76287
aS'Messou E'
p76288
aS'Wood R'
p76289
aS'Nash D'
p76290
aS'Pascoe M'
p76291
aS'Dickinson D'
p76292
aS'Etard JF'
p76293
aS'McIntyre JA'
p76294
aS'Brinkhof MW'
p76295
asS'VI'
p76296
S'8'
sS'MHDA'
p76297
S'2011/06/01 06:00'
p76298
sS'PHST'
p76299
(lp76300
S'2010/04/01 [received]'
p76301
aS'2010/12/02 [accepted]'
p76302
aS'2011/01/18 [epublish]'
p76303
asS'OID'
p76304
(lp76305
S'NLM: PMC3022522'
p76306
asS'MH'
p76307
(lp76308
S'Adult'
p76309
aS'Africa South of the Sahara/epidemiology'
p76310
aS'*Algorithms'
p76311
aS'Anti-HIV Agents/*therapeutic use'
p76312
aS'Bias (Epidemiology)'
p76313
aS'Child'
p76314
aS'Drug Utilization'
p76315
aS'Follow-Up Studies'
p76316
aS'HIV Infections/drug therapy/*mortality'
p76317
aS'Humans'
p76318
aS'*Nomograms'
p76319
aS'Patient Dropouts/*statistics & numerical data'
p76320
aS'Program Evaluation/statistics & numerical data'
p76321
asS'EDAT'
p76322
S'2011/01/27 06:00'
p76323
sS'SO'
p76324
S'PLoS Med. 2011 Jan 18;8(1):e1000390. doi: 10.1371/journal.pmed.1000390.'
p76325
sS'SB'
p76326
S'IM'
p76327
sS'PMID'
p76328
S'21267057'
p76329
sS'PST'
p76330
S'epublish'
p76331
stRp76332
ag2
(g3
g4
(dp76333
S'LID'
p76334
S'10.1097/QAI.0b013e318207a535 [doi]'
p76335
sS'STAT'
p76336
S'MEDLINE'
p76337
sS'JT'
p76338
S'Journal of acquired immune deficiency syndromes (1999)'
p76339
sS'MID'
p76340
(lp76341
S'NIHMS260178'
p76342
asS'DA'
p76343
S'20110301'
p76344
sS'AID'
p76345
(lp76346
S'10.1097/QAI.0b013e318207a535 [doi]'
p76347
asS'CRDT'
p76348
(lp76349
S'2011/01/27 06:00'
p76350
asS'DP'
p76351
S'2011 Apr'
p76352
sS'AD'
p76353
S'Vanderbilt University Institute for Global Health, Nashville, TN 37203, USA.'
p76354
sS'OWN'
p76355
S'NLM'
p76356
sS'PT'
p76357
(lp76358
S'Journal Article'
p76359
aS'Research Support, N.I.H., Extramural'
p76360
aS"Research Support, Non-U.S. Gov't"
p76361
aS"Research Support, U.S. Gov't, P.H.S."
p76362
asS'LA'
p76363
(lp76364
S'eng'
p76365
asS'FAU'
p76366
(lp76367
S'Cook, Rebecca E'
p76368
aS'Ciampa, Philip J'
p76369
aS'Sidat, Mohsin'
p76370
aS'Blevins, Meridith'
p76371
aS'Burlison, Janeen'
p76372
aS'Davidson, Mario A'
p76373
aS'Arroz, Jorge A'
p76374
aS'Vergara, Alfredo E'
p76375
aS'Vermund, Sten H'
p76376
aS'Moon, Troy D'
p76377
asS'LR'
p76378
S'20150205'
p76379
sS'PG'
p76380
S'e104-9'
p76381
sS'TI'
p76382
S'Predictors of successful early infant diagnosis of HIV in a rural district hospital in Zambezia, Mozambique.'
p76383
sS'PL'
p76384
S'United States'
p76385
sS'TA'
p76386
S'J Acquir Immune Defic Syndr'
p76387
sS'JID'
p76388
S'100892005'
p76389
sS'AB'
p76390
S"BACKGROUND: A key challenge inhibiting the timely initiation of pediatric antiretroviral treatment is the loss to follow-up of mothers and their infants between the time of mothers' HIV diagnoses in pregnancy and return after delivery for early infant diagnosis of HIV. We sought to identify barriers to follow-up of HIV-exposed infants in rural Zambezia Province, Mozambique. METHODS: We determined follow-up rates for early infant diagnosis and age at first test in a retrospective cohort of 443 HIV-infected mothers and their infants. Multivariable logistic regression models were used to identify factors associated with successful follow-up. RESULTS: Of the 443 mother-infant pairs, 217 (49%) mothers enrolled in the adult HIV care clinic, and only 110 (25%) infants were brought for early infant diagnosis. The predictors of follow-up for early infant diagnosis were larger household size (odds ratio [OR], 1.29; 95% confidence interval [CI], 1.09-1.53), independent maternal source of income (OR, 10.8; 95% CI, 3.42-34.0), greater distance from the hospital (OR, 2.14; 95% CI, 1.01-4.51), and maternal receipt of antiretroviral therapy (OR, 3.15; 95% CI, 1.02-9.73). The median age at first test among 105 infants was 5 months (interquartile range, 2-7); 16% of the tested infants were infected. CONCLUSIONS: Three of four HIV-infected women in rural Mozambique did not bring their children for early infant HIV diagnosis. Maternal receipt of antiretroviral therapy has favorable implications for maternal health that will increase the likelihood of early infant diagnosis. We are working with local health authorities to improve the linkage of HIV-infected women to HIV care to maximize early infant diagnosis and care."
p76391
sS'GR'
p76392
(lp76393
S'D43 TW001035/TW/FIC NIH HHS/United States'
p76394
aS'D43 TW001035-13/TW/FIC NIH HHS/United States'
p76395
aS'D43TW001035/TW/FIC NIH HHS/United States'
p76396
aS'U2GPS000631/PHS HHS/United States'
p76397
asS'IP'
p76398
S'4'
sS'IS'
p76399
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p76400
sS'PMC'
p76401
S'PMC3073723'
p76402
sS'DCOM'
p76403
S'20110412'
p76404
sS'AU'
p76405
(lp76406
S'Cook RE'
p76407
aS'Ciampa PJ'
p76408
aS'Sidat M'
p76409
aS'Blevins M'
p76410
aS'Burlison J'
p76411
aS'Davidson MA'
p76412
aS'Arroz JA'
p76413
aS'Vergara AE'
p76414
aS'Vermund SH'
p76415
aS'Moon TD'
p76416
asS'VI'
p76417
S'56'
p76418
sS'MHDA'
p76419
S'2011/04/13 06:00'
p76420
sS'OID'
p76421
(lp76422
S'NLM: NIHMS260178'
p76423
aS'NLM: PMC3073723'
p76424
asS'MH'
p76425
(lp76426
S'Early Diagnosis'
p76427
aS'Female'
p76428
aS'HIV Infections/*diagnosis'
p76429
aS'Hospitals, District'
p76430
aS'Humans'
p76431
aS'Infant'
p76432
aS'Infant, Newborn'
p76433
aS'Male'
p76434
aS'Mozambique'
p76435
aS'Patient Acceptance of Health Care/*statistics & numerical data'
p76436
aS'Pregnancy'
p76437
aS'Retrospective Studies'
p76438
aS'Rural Population'
p76439
asS'EDAT'
p76440
S'2011/01/27 06:00'
p76441
sS'SO'
p76442
S'J Acquir Immune Defic Syndr. 2011 Apr;56(4):e104-9. doi: 10.1097/QAI.0b013e318207a535.'
p76443
sS'SB'
p76444
S'IM X'
p76445
sS'PMID'
p76446
S'21266912'
p76447
sS'PST'
p76448
S'ppublish'
p76449
stRp76450
ag2
(g3
g4
(dp76451
S'LID'
p76452
S'10.1371/journal.pone.0016279 [doi]'
p76453
sS'STAT'
p76454
S'MEDLINE'
p76455
sS'DEP'
p76456
S'20110117'
p76457
sS'DA'
p76458
S'20110125'
p76459
sS'AID'
p76460
(lp76461
S'10.1371/journal.pone.0016279 [doi]'
p76462
asS'CRDT'
p76463
(lp76464
S'2011/01/26 06:00'
p76465
asS'DP'
p76466
S'2011'
p76467
sS'OWN'
p76468
S'NLM'
p76469
sS'PT'
p76470
(lp76471
S'Journal Article'
p76472
asS'LA'
p76473
(lp76474
S'eng'
p76475
asS'FAU'
p76476
(lp76477
S'Bakanda, Celestin'
p76478
aS'Birungi, Josephine'
p76479
aS'Mwesigwa, Robert'
p76480
aS'Zhang, Wendy'
p76481
aS'Hagopian, Amy'
p76482
aS'Ford, Nathan'
p76483
aS'Mills, Edward J'
p76484
asS'JT'
p76485
S'PloS one'
p76486
sS'LR'
p76487
S'20150205'
p76488
sS'PG'
p76489
S'e16279'
p76490
sS'TI'
p76491
S'Density of healthcare providers and patient outcomes: evidence from a nationally representative multi-site HIV treatment program in Uganda.'
p76492
sS'PL'
p76493
S'United States'
p76494
sS'TA'
p76495
S'PLoS One'
p76496
sS'JID'
p76497
S'101285081'
p76498
sS'AB'
p76499
S'OBJECTIVE: We examined the association between density of healthcare providers and patient outcomes using a large nationally representative cohort of patients receiving combination antiretroviral therapy (cART) in Uganda. DESIGN: We obtained data from The AIDS Support Organization (TASO) in Uganda. Patients 18 years of age and older who initiated cART at TASO between 2004 and 2008 contributed to this analysis. The number of healthcare providers per 100 patients, the number of patients lost to follow-up per 100 person years and number of deaths per 100 person years were calculated. Spearman correlation was used to identify associations between patient loss to follow-up and mortality with the healthcare provider-patient ratios. RESULTS: We found no significant associations between the number of patients lost to follow-up and physicians (p = 0.45), nurses (p = 0.93), clinical officers (p = 0.80), field officers (p = 0.56), and healthcare providers overall (p = 0.83). Similarly, no significant associations were observed between mortality and physicians (p = 0.65), nurses (p = 0.49), clinical officers (p = 0.73), field officers (p = 0.78), and healthcare providers overall (p = 0.73). CONCLUSIONS: Patient outcomes, as measured by loss to follow-up and mortality, were not significantly associated with the number of doctors, nurses, clinical officers, field officers, or healthcare providers overall. This may suggest that that other factors, such as the presence of volunteer patient supporters or broader political or socioeconomic influences, may be more closely associated with outcomes of care among patients on cART in Uganda.'
p76500
sS'AD'
p76501
S'The AIDS Support Organization, Headquarters, Kampala, Uganda.'
p76502
sS'IP'
p76503
S'1'
sS'IS'
p76504
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p76505
sS'PMC'
p76506
S'PMC3022029'
p76507
sS'DCOM'
p76508
S'20110802'
p76509
sS'AU'
p76510
(lp76511
S'Bakanda C'
p76512
aS'Birungi J'
p76513
aS'Mwesigwa R'
p76514
aS'Zhang W'
p76515
aS'Hagopian A'
p76516
aS'Ford N'
p76517
aS'Mills EJ'
p76518
asS'VI'
p76519
S'6'
sS'MHDA'
p76520
S'2011/08/04 06:00'
p76521
sS'PHST'
p76522
(lp76523
S'2010/09/15 [received]'
p76524
aS'2010/12/09 [accepted]'
p76525
aS'2011/01/17 [epublish]'
p76526
asS'OID'
p76527
(lp76528
S'NLM: PMC3022029'
p76529
asS'MH'
p76530
(lp76531
S'Adolescent'
p76532
aS'Adult'
p76533
aS'Aged'
p76534
aS'Data Collection'
p76535
aS'HIV Infections/drug therapy/*epidemiology/mortality'
p76536
aS'Health Personnel/*statistics & numerical data'
p76537
aS'Humans'
p76538
aS'Lost to Follow-Up'
p76539
aS'Middle Aged'
p76540
aS'Mortality'
p76541
aS'National Health Programs/statistics & numerical data'
p76542
aS'Treatment Outcome'
p76543
aS'Uganda'
p76544
aS'Young Adult'
p76545
asS'EDAT'
p76546
S'2011/01/26 06:00'
p76547
sS'SO'
p76548
S'PLoS One. 2011 Jan 17;6(1):e16279. doi: 10.1371/journal.pone.0016279.'
p76549
sS'SB'
p76550
S'IM'
p76551
sS'PMID'
p76552
S'21264224'
p76553
sS'PST'
p76554
S'epublish'
p76555
stRp76556
ag2
(g3
g4
(dp76557
S'LID'
p76558
S'10.1136/jme.2010.038570 [doi]'
p76559
sS'STAT'
p76560
S'MEDLINE'
p76561
sS'DEP'
p76562
S'20110124'
p76563
sS'DA'
p76564
S'20110318'
p76565
sS'AID'
p76566
(lp76567
S'jme.2010.038570 [pii]'
p76568
aS'10.1136/jme.2010.038570 [doi]'
p76569
asS'CRDT'
p76570
(lp76571
S'2011/01/26 06:00'
p76572
asS'DP'
p76573
S'2011 Apr'
p76574
sS'OWN'
p76575
S'NLM'
p76576
sS'PT'
p76577
(lp76578
S'Journal Article'
p76579
aS"Research Support, Non-U.S. Gov't"
p76580
asS'LA'
p76581
(lp76582
S'eng'
p76583
asS'FAU'
p76584
(lp76585
S'Johansson, Kjell Arne'
p76586
aS'Miljeteig, Ingrid'
p76587
aS'Kigwangalla, Hamisi'
p76588
aS'Norheim, Ole Frithjof'
p76589
asS'JT'
p76590
S'Journal of medical ethics'
p76591
sS'PG'
p76592
S'221-6'
p76593
sS'TI'
p76594
S'HIV priorities and health distributions in a rural region in Tanzania: a qualitative study.'
p76595
sS'RN'
p76596
(lp76597
S'0 (Anti-Retroviral Agents)'
p76598
asS'PL'
p76599
S'England'
p76600
sS'TA'
p76601
S'J Med Ethics'
p76602
sS'JID'
p76603
S'7513619'
p76604
sS'AB'
p76605
S'BACKGROUND: International and national agencies play a major role in setting HIV care-and-treatment priorities in low-income-countries. Little is known about priority setting at lower health-system levels. The objective of this article is to explore experiences of HIV priority decisions, at what levels these decisions are made and how they might influence the distribution of health benefits in a high-endemic region in Tanzania. METHODS: This is a qualitative study using observations, key documents and semistructured focus-group and individual interviews (43) with health workers, patients and administrators at one regional and one district hospital. The analysis was based on an editing analysis style. RESULTS: Health workers did not perceive themselves as bedside rationing agents and they reported following national recommendations and felt they have little impact on important priority decisions. Health benefit distributions were largely determined by priority decisions made at a national level. External factors, such as eligibility criteria, inadequate funding and barriers to access seemed to play a major role in the actual distribution of health services and benefits in the region. Patient groups who were actually given high priority were the sickest patients, those living near a facility and those who could afford long journeys and frequent visits. Low-priority groups were those experiencing other co-morbidities or treatment failure, children, asymptomatic patients and the poorest. CONCLUSIONS/SIGNIFICANCE: The interaction of priority setting across health-system levels and their impact on distribution of health outcomes in the population has been underestimated. The distributional pattern of health outcomes calls for further normative assessment.'
p76606
sS'AD'
p76607
S'University of Bergen, Department of Public Health and Primary Health Care, PB 7804, 5020 Bergen, Norway. kjell.johansson@isf.uib.no'
p76608
sS'IP'
p76609
S'4'
sS'IS'
p76610
S'1473-4257 (Electronic) 0306-6800 (Linking)'
p76611
sS'DCOM'
p76612
S'20110523'
p76613
sS'AU'
p76614
(lp76615
S'Johansson KA'
p76616
aS'Miljeteig I'
p76617
aS'Kigwangalla H'
p76618
aS'Norheim OF'
p76619
asS'VI'
p76620
S'37'
p76621
sS'MHDA'
p76622
S'2011/05/24 06:00'
p76623
sS'PHST'
p76624
(lp76625
S'2011/01/24 [aheadofprint]'
p76626
asS'MH'
p76627
(lp76628
S'Anti-Retroviral Agents/economics/*therapeutic use'
p76629
aS'Decision Making/*ethics'
p76630
aS'HIV Infections/*drug therapy/economics'
p76631
aS'Health Care Rationing/ethics/*organization & administration'
p76632
aS'Health Priorities/ethics/*organization & administration'
p76633
aS'Health Services Needs and Demand/ethics/*organization & administration'
p76634
aS'Humans'
p76635
aS'Qualitative Research'
p76636
aS'Rural Health'
p76637
aS'Tanzania'
p76638
asS'EDAT'
p76639
S'2011/01/26 06:00'
p76640
sS'SO'
p76641
S'J Med Ethics. 2011 Apr;37(4):221-6. doi: 10.1136/jme.2010.038570. Epub 2011 Jan 24.'
p76642
sS'SB'
p76643
S'E IM'
p76644
sS'PMID'
p76645
S'21262784'
p76646
sS'PST'
p76647
S'ppublish'
p76648
stRp76649
ag2
(g3
g4
(dp76650
S'LID'
p76651
S'10.1371/journal.pone.0015841 [doi]'
p76652
sS'STAT'
p76653
S'MEDLINE'
p76654
sS'DEP'
p76655
S'20110106'
p76656
sS'DA'
p76657
S'20110121'
p76658
sS'AID'
p76659
(lp76660
S'10.1371/journal.pone.0015841 [doi]'
p76661
asS'CRDT'
p76662
(lp76663
S'2011/01/22 06:00'
p76664
asS'DP'
p76665
S'2011'
p76666
sS'AD'
p76667
S'Department of Medicine, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York, United States of America. jcmbrust@gmail.com'
p76668
sS'OWN'
p76669
S'NLM'
p76670
sS'PT'
p76671
(lp76672
S'Journal Article'
p76673
aS'Research Support, N.I.H., Extramural'
p76674
aS"Research Support, Non-U.S. Gov't"
p76675
aS"Research Support, U.S. Gov't, Non-P.H.S."
p76676
asS'LA'
p76677
(lp76678
S'eng'
p76679
asS'FAU'
p76680
(lp76681
S'Brust, James C M'
p76682
aS'Lygizos, Melissa'
p76683
aS'Chaiyachati, Krisda'
p76684
aS'Scott, Michelle'
p76685
aS'van der Merwe, Theo L'
p76686
aS'Moll, Anthony P'
p76687
aS'Li, Xuan'
p76688
aS'Loveday, Marian'
p76689
aS'Bamber, Sheila A'
p76690
aS'Lalloo, Umesh G'
p76691
aS'Friedland, Gerald H'
p76692
aS'Shah, N Sarita'
p76693
aS'Gandhi, Neel R'
p76694
asS'JT'
p76695
S'PloS one'
p76696
sS'LR'
p76697
S'20150205'
p76698
sS'PG'
p76699
S'e15841'
p76700
sS'TI'
p76701
S'Culture conversion among HIV co-infected multidrug-resistant tuberculosis patients in Tugela Ferry, South Africa.'
p76702
sS'RN'
p76703
(lp76704
S'0 (Anti-Retroviral Agents)'
p76705
aS'0 (Antitubercular Agents)'
p76706
asS'PL'
p76707
S'United States'
p76708
sS'TA'
p76709
S'PLoS One'
p76710
sS'JID'
p76711
S'101285081'
p76712
sS'AB'
p76713
S'BACKGROUND: Little is known about the time to sputum culture conversion in MDR-TB patients co-infected with HIV, although such patients have, historically, had poor outcomes. We describe culture conversion rates among MDR-TB patients with and without HIV-co-infection in a TB-endemic, high-HIV prevalent, resource-limited setting. METHODS: Patients with culture-proven MDR-TB were treated with a standardized second-line regimen. Sputum cultures were taken monthly and conversion was defined as two negative cultures taken at least one month apart. Time-to-conversion was measured from the day of initiation of MDR-TB therapy. Subjects with HIV received antiretroviral therapy (ART) regardless of CD4 count. RESULTS: Among 45 MDR-TB patients, 36 (80%) were HIV-co-infected. Overall, 40 (89%) of the 45 patients culture-converted within the first six months and there was no difference in the proportion who converted based on HIV status. Median time-to-conversion was 62 days (IQR 48-111). Among the five patients who did not culture convert, three died, one was transferred to another facility, and one refused further treatment before completing 6 months of therapy. Thus, no patients remained persistently culture-positive at 6 months of therapy. CONCLUSIONS: With concurrent second-line TB and ART medications, MDR-TB/HIV co-infected patients can achieve culture conversion rates and times similar to those reported from HIV-negative patients worldwide. Future studies are needed to examine whether similar cure rates are achieved at the end of MDR-TB treatment and to determine the optimal use and timing of ART in the setting of MDR-TB treatment.'
p76714
sS'GR'
p76715
(lp76716
S'K23 AI083088/AI/NIAID NIH HHS/United States'
p76717
aS'K23AI083088/AI/NIAID NIH HHS/United States'
p76718
aS'P30 AI051519/AI/NIAID NIH HHS/United States'
p76719
asS'IP'
p76720
S'1'
sS'IS'
p76721
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p76722
sS'PMC'
p76723
S'PMC3017058'
p76724
sS'DCOM'
p76725
S'20110802'
p76726
sS'AU'
p76727
(lp76728
S'Brust JC'
p76729
aS'Lygizos M'
p76730
aS'Chaiyachati K'
p76731
aS'Scott M'
p76732
aS'van der Merwe TL'
p76733
aS'Moll AP'
p76734
aS'Li X'
p76735
aS'Loveday M'
p76736
aS'Bamber SA'
p76737
aS'Lalloo UG'
p76738
aS'Friedland GH'
p76739
aS'Shah NS'
p76740
aS'Gandhi NR'
p76741
asS'VI'
p76742
S'6'
sS'MHDA'
p76743
S'2011/08/04 06:00'
p76744
sS'PHST'
p76745
(lp76746
S'2010/09/27 [received]'
p76747
aS'2010/11/26 [accepted]'
p76748
aS'2011/01/06 [epublish]'
p76749
asS'OID'
p76750
(lp76751
S'NLM: PMC3017058'
p76752
asS'MH'
p76753
(lp76754
S'Adult'
p76755
aS'Anti-Retroviral Agents/therapeutic use'
p76756
aS'Antitubercular Agents/therapeutic use'
p76757
aS'Female'
p76758
aS'HIV Infections/*complications/drug therapy'
p76759
aS'Humans'
p76760
aS'Male'
p76761
aS'Remission Induction'
p76762
aS'Retrospective Studies'
p76763
aS'South Africa'
p76764
aS'Sputum/microbiology/virology'
p76765
aS'Time Factors'
p76766
aS'Tuberculosis, Multidrug-Resistant/*complications/drug therapy'
p76767
aS'Young Adult'
p76768
asS'EDAT'
p76769
S'2011/01/22 06:00'
p76770
sS'SO'
p76771
S'PLoS One. 2011 Jan 6;6(1):e15841. doi: 10.1371/journal.pone.0015841.'
p76772
sS'SB'
p76773
S'IM'
p76774
sS'PMID'
p76775
S'21253585'
p76776
sS'PST'
p76777
S'epublish'
p76778
stRp76779
ag2
(g3
g4
(dp76780
S'LID'
p76781
S'10.1097/QAI.0b013e31820dc0cc [doi]'
p76782
sS'STAT'
p76783
S'MEDLINE'
p76784
sS'JT'
p76785
S'Journal of acquired immune deficiency syndromes (1999)'
p76786
sS'MID'
p76787
(lp76788
S'NIHMS268926'
p76789
asS'DA'
p76790
S'20110401'
p76791
sS'AID'
p76792
(lp76793
S'10.1097/QAI.0b013e31820dc0cc [doi]'
p76794
asS'CRDT'
p76795
(lp76796
S'2011/01/18 06:00'
p76797
asS'DP'
p76798
S'2011 Apr'
p76799
sS'AD'
p76800
S'Division of Medical Virology, Department of Pathology, NHLS Tygerberg and Stellenbosch University, Tygerberg, South Africa. guvz@sun.ac.za'
p76801
sS'OWN'
p76802
S'NLM'
p76803
sS'PT'
p76804
(lp76805
S'Journal Article'
p76806
aS'Research Support, N.I.H., Extramural'
p76807
aS"Research Support, Non-U.S. Gov't"
p76808
asS'LA'
p76809
(lp76810
S'eng'
p76811
asS'FAU'
p76812
(lp76813
S'van Zyl, Gert Uves'
p76814
aS'van Mens, Thijs E'
p76815
aS'McIlleron, Helen'
p76816
aS'Zeier, Michele'
p76817
aS'Nachega, Jean B'
p76818
aS'Decloedt, Eric'
p76819
aS'Malavazzi, Carolina'
p76820
aS'Smith, Peter'
p76821
aS'Huang, Yong'
p76822
aS'van der Merwe, Lize'
p76823
aS'Gandhi, Monica'
p76824
aS'Maartens, Gary'
p76825
asS'LR'
p76826
S'20150205'
p76827
sS'PG'
p76828
S'333-9'
p76829
sS'TI'
p76830
S'Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting.'
p76831
sS'RN'
p76832
(lp76833
S'0 (Anti-HIV Agents)'
p76834
aS'0 (Pyrimidinones)'
p76835
aS'0 (RNA, Viral)'
p76836
aS'2494G1JF75 (Lopinavir)'
p76837
asS'PL'
p76838
S'United States'
p76839
sS'TA'
p76840
S'J Acquir Immune Defic Syndr'
p76841
sS'JID'
p76842
S'100892005'
p76843
sS'AB'
p76844
S'BACKGROUND: In resource-limited settings, many patients, with no prior protease inhibitor (PI) treatment on a second-line, high genetic barrier, ritonavir-boosted PI-containing regimen have virologic failure. METHODS: We conducted a cross-sectional survey to investigate the aetiology of virologic failure in 2 public health antiretroviral clinics in South Africa documenting the prevalence of virologic failure (HIV RNA load >500 copies/mL) and genotypic antiretroviral resistance; and lopinavir hair and plasma concentrations in a nested case-control study. RESULTS: Ninety-three patients treated with a second-line regimen including lopinavir boosted with ritonavir were included, of whom 50 (25 cases, with virologic failure and 25 controls) were included in a nested case control study. Of 93 patients, 37 (40%) had virological failure, only 2 of them had had major PI mutations. The negative predictive values: probability of failure with lopinavir plasma concentration >1 microg/mL or hair concentrations >3.63 ng/mg for virologic failure were 86% and 89%, and positive predictive values of low concentrations 73% and 79%, respectively, whereas all virologic failures with HIV RNA loads above 1000 copies per milliliter, of patients without PI resistance, could be explained by either having a low lopinavir concentration in plasma or hair. CONCLUSIONS: Most patients who fail a lopinavir/ritonavir regimen, in our setting, have poor lopinavir exposure. A threshold plasma lopinavir concentration (indicating recent lopinavir/ritonavir use) and/or hair concentration (indicating longer term lopinavir exposure) are valuable in determining the aetiology of virologic failure and identifying patients in need of adherence counselling or resistance testing.'
p76845
sS'GR'
p76846
(lp76847
S'K23 AI 068582-01/AI/NIAID NIH HHS/United States'
p76848
aS'K23 AI068582-01/AI/NIAID NIH HHS/United States'
p76849
aS'T84H21126-01-01/PHS HHS/United States'
p76850
aS'WT087537MA/Wellcome Trust/United Kingdom'
p76851
asS'IP'
p76852
S'4'
sS'IS'
p76853
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p76854
sS'PMC'
p76855
S'PMC3073814'
p76856
sS'DCOM'
p76857
S'20110412'
p76858
sS'AU'
p76859
(lp76860
S'van Zyl GU'
p76861
aS'van Mens TE'
p76862
aS'McIlleron H'
p76863
aS'Zeier M'
p76864
aS'Nachega JB'
p76865
aS'Decloedt E'
p76866
aS'Malavazzi C'
p76867
aS'Smith P'
p76868
aS'Huang Y'
p76869
aS'van der Merwe L'
p76870
aS'Gandhi M'
p76871
aS'Maartens G'
p76872
asS'VI'
p76873
S'56'
p76874
sS'MHDA'
p76875
S'2011/04/13 06:00'
p76876
sS'OID'
p76877
(lp76878
S'NLM: NIHMS268926'
p76879
aS'NLM: PMC3073814'
p76880
asS'MH'
p76881
(lp76882
S'Adult'
p76883
aS'Anti-HIV Agents/*pharmacokinetics/*therapeutic use'
p76884
aS'Case-Control Studies'
p76885
aS'Cross-Sectional Studies'
p76886
aS'Drug Resistance, Viral'
p76887
aS'Female'
p76888
aS'HIV Infections/*drug therapy'
p76889
aS'Hair/*chemistry'
p76890
aS'Humans'
p76891
aS'Lopinavir'
p76892
aS'Male'
p76893
aS'Middle Aged'
p76894
aS'Plasma/*chemistry'
p76895
aS'Pyrimidinones/*pharmacokinetics/*therapeutic use'
p76896
aS'RNA, Viral/blood/genetics'
p76897
aS'South Africa'
p76898
aS'Treatment Failure'
p76899
aS'Viral Load'
p76900
asS'EDAT'
p76901
S'2011/01/18 06:00'
p76902
sS'SO'
p76903
S'J Acquir Immune Defic Syndr. 2011 Apr;56(4):333-9. doi: 10.1097/QAI.0b013e31820dc0cc.'
p76904
sS'SB'
p76905
S'IM X'
p76906
sS'PMID'
p76907
S'21239995'
p76908
sS'PST'
p76909
S'ppublish'
p76910
stRp76911
ag2
(g3
g4
(dp76912
S'LID'
p76913
S'10.1111/j.1365-3156.2010.02724.x [doi]'
p76914
sS'STAT'
p76915
S'MEDLINE'
p76916
sS'DEP'
p76917
S'20110112'
p76918
sS'CI'
p76919
(lp76920
S'(c) 2011 Blackwell Publishing Ltd.'
p76921
asS'DA'
p76922
S'20110307'
p76923
sS'AID'
p76924
(lp76925
S'10.1111/j.1365-3156.2010.02724.x [doi]'
p76926
asS'CRDT'
p76927
(lp76928
S'2011/01/14 06:00'
p76929
asS'DP'
p76930
S'2011 Mar'
p76931
sS'OWN'
p76932
S'NLM'
p76933
sS'PT'
p76934
(lp76935
S'Journal Article'
p76936
asS'LA'
p76937
(lp76938
S'eng'
p76939
asS'FAU'
p76940
(lp76941
S'Thwing, J I'
p76942
aS'Njau, J D'
p76943
aS'Goodman, C'
p76944
aS'Munkondya, J'
p76945
aS'Kahigwa, E'
p76946
aS'Bloland, P B'
p76947
aS'Mkikima, S'
p76948
aS'Mills, A'
p76949
aS'Abdulla, S'
p76950
aS'Kachur, S P'
p76951
asS'JT'
p76952
S'Tropical medicine & international health : TM & IH'
p76953
sS'LR'
p76954
S'20151119'
p76955
sS'PG'
p76956
S'272-9'
p76957
sS'TI'
p76958
S'Drug dispensing practices during implementation of artemisinin-based combination therapy at health facilities in rural Tanzania, 2002-2005.'
p76959
sS'RN'
p76960
(lp76961
S'0 (Antimalarials)'
p76962
aS'0 (Artemisinins)'
p76963
aS'0 (Drug Combinations)'
p76964
aS'37338-39-9 (fanasil, pyrimethamine drug combination)'
p76965
aS'60W3249T9M (artesunate)'
p76966
aS'88463U4SM5 (Sulfadoxine)'
p76967
aS'Z3614QOX8W (Pyrimethamine)'
p76968
asS'PL'
p76969
S'England'
p76970
sS'TA'
p76971
S'Trop Med Int Health'
p76972
sS'JID'
p76973
S'9610576'
p76974
sS'AB'
p76975
S'OBJECTIVE: To assess the degree to which policy changes to artemisinin-based combination therapies (ACTs) as first-line treatment for uncomplicated malaria translate into effective ACT delivery. METHODS: Prospective observational study of drug dispensing practices at baseline and during the 3 years following introduction of ACT with sulfadoxine-pyrimethamine (SP) plus artesunate (AS) in Rufiji District, compared with two neighbouring districts where SP monotherapy remained the first-line treatment, was carried out. Demographic and dispensing data were collected from all patients at the dispensing units of selected facilities for 1 month per quarter, documenting a total of 271, 953 patient encounters in the three districts. RESULTS: In Rufiji, the proportion of patients who received a clinical diagnosis of malaria increased from 47.6% to 57.0%. A majority (75.9%) of these received SP + AS during the intervention period. Of patients who received SP + AS, 94.6% received the correct dose of both. Among patients in Rufiji who received SP, 14.2% received SP monotherapy, and among patients who received AS, 0.3% received AS monotherapy. CONCLUSIONS: The uptake of SP + AS in Rufiji was rapid and sustained. Although some SP monotherapy occurred, AS monotherapy was rare, and most received the correct dose of both drugs. These results suggest that implementation of an artemisinin combination therapy, accompanied by training, job aids and assistance in stock management, can rapidly increase access to effective antimalarial treatment.'
p76976
sS'AD'
p76977
S'Centers for Disease Control, Atlanta, GA, USA. jthwing@cdc.gov'
p76978
sS'IP'
p76979
S'3'
sS'IS'
p76980
S'1365-3156 (Electronic) 1360-2276 (Linking)'
p76981
sS'DCOM'
p76982
S'20110502'
p76983
sS'AU'
p76984
(lp76985
S'Thwing JI'
p76986
aS'Njau JD'
p76987
aS'Goodman C'
p76988
aS'Munkondya J'
p76989
aS'Kahigwa E'
p76990
aS'Bloland PB'
p76991
aS'Mkikima S'
p76992
aS'Mills A'
p76993
aS'Abdulla S'
p76994
aS'Kachur SP'
p76995
asS'VI'
p76996
S'16'
p76997
sS'MHDA'
p76998
S'2011/05/03 06:00'
p76999
sS'PHST'
p77000
(lp77001
S'2011/01/12 [aheadofprint]'
p77002
asS'MH'
p77003
(lp77004
S'Adolescent'
p77005
aS'Age Factors'
p77006
aS'Antimalarials/economics/*therapeutic use'
p77007
aS'Artemisinins/economics/*therapeutic use'
p77008
aS'Case Management/organization & administration'
p77009
aS'Child'
p77010
aS'Child, Preschool'
p77011
aS'Drug Combinations'
p77012
aS'Drug Costs/statistics & numerical data'
p77013
aS'Drug Prescriptions/standards/statistics & numerical data'
p77014
aS'Drug Therapy, Combination'
p77015
aS'Humans'
p77016
aS'Infant'
p77017
aS'Malaria/*drug therapy/epidemiology'
p77018
aS"Practice Patterns, Physicians'/standards/*statistics & numerical data"
p77019
aS'Prospective Studies'
p77020
aS'Pyrimethamine/economics/therapeutic use'
p77021
aS'Rural Health Services/standards/*statistics & numerical data'
p77022
aS'Sulfadoxine/economics/therapeutic use'
p77023
aS'Tanzania/epidemiology'
p77024
asS'EDAT'
p77025
S'2011/01/14 06:00'
p77026
sS'SO'
p77027
S'Trop Med Int Health. 2011 Mar;16(3):272-9. doi: 10.1111/j.1365-3156.2010.02724.x. Epub 2011 Jan 12.'
p77028
sS'SB'
p77029
S'IM'
p77030
sS'PMID'
p77031
S'21226795'
p77032
sS'PST'
p77033
S'ppublish'
p77034
stRp77035
ag2
(g3
g4
(dp77036
S'LID'
p77037
S'10.1002/pbc.22903 [doi]'
p77038
sS'STAT'
p77039
S'MEDLINE'
p77040
sS'DEP'
p77041
S'20101128'
p77042
sS'CI'
p77043
(lp77044
S'Copyright (c) 2010 Wiley-Liss, Inc.'
p77045
asS'DA'
p77046
S'20110112'
p77047
sS'AID'
p77048
(lp77049
S'10.1002/pbc.22903 [doi]'
p77050
asS'CRDT'
p77051
(lp77052
S'2011/01/13 06:00'
p77053
asS'DP'
p77054
S'2011 Mar'
p77055
sS'OWN'
p77056
S'NLM'
p77057
sS'PT'
p77058
(lp77059
S'Journal Article'
p77060
asS'LA'
p77061
(lp77062
S'eng'
p77063
asS'FAU'
p77064
(lp77065
S'Stefan, D Cristina'
p77066
aS'Stones, David K'
p77067
aS'Wainwright, Linda'
p77068
aS'Newton, Robert'
p77069
asS'JT'
p77070
S'Pediatric blood & cancer'
p77071
sS'LR'
p77072
S'20151119'
p77073
sS'PG'
p77074
S'392-6'
p77075
sS'TI'
p77076
S'Kaposi sarcoma in South African children.'
p77077
sS'RN'
p77078
(lp77079
S'0 (Anti-Retroviral Agents)'
p77080
aS'11056-06-7 (Bleomycin)'
p77081
aS'5J49Q6B70F (Vincristine)'
p77082
aS'5V9KLZ54CY (Vinblastine)'
p77083
aS'80168379AG (Doxorubicin)'
p77084
asS'PL'
p77085
S'United States'
p77086
sS'TA'
p77087
S'Pediatr Blood Cancer'
p77088
sS'JID'
p77089
S'101186624'
p77090
sS'AB'
p77091
S"BACKGROUND: The incidence of Kaposi's sarcoma (KS) in sub-Saharan Africa, increased tens of times since the onset of the AIDS epidemic. There is, however, very little literature concerning the clinical features of this disease, its management and outcome in HIV-positive children in Africa. This study describes retrospectively the clinical presentation of the malignancy, its management and outcome, in a series of HIV-positive children. PATIENTS AND METHODS: Seventy children with KS and HIV infection were admitted consecutively from January 1998 to December 2009 in South African hospitals. Clinical data were extracted from tumor registries and patient records and analyzed. RESULTS: The average age in this series was 73 months. The males/females ratio was 1.59:1. Skin lesions were present in 36 out of 63 cases (57.14%), followed by lymph node lesions (28 cases, 44.44%). The mean CD4+ lymphocyte count was 440 (SD = 385). The average CD4+ percentage was 12.20% (SD = 9.13). Only 14 patients (20%) were taking combined antiretrovirals at the time of diagnosis; a further 35 were given HIV treatment after diagnosis. Thirty-two patients (45.71%) survived only 4 months on average; 10 were lost to follow-up; and 28 (40%) were alive, with an average follow-up of 16 months. Antiretrovirals improved survival (P = 0.001). CONCLUSIONS: The often present skin lesions facilitated the diagnosis; lymphadenopathy was less frequently seen than skin lesions. Antiretroviral drugs were associated with higher survival rate. The mortality remains high in spite of antiretrovirals and cytostatics."
p77092
sS'AD'
p77093
S'Department of Paediatrics and Child Health, Tygerberg Hospital, Stellenbosch University, Tygerberg, Cape Town, South Africa. cs@sun.ac.za'
p77094
sS'IP'
p77095
S'3'
sS'IS'
p77096
S'1545-5017 (Electronic) 1545-5009 (Linking)'
p77097
sS'DCOM'
p77098
S'20110301'
p77099
sS'AU'
p77100
(lp77101
S'Stefan DC'
p77102
aS'Stones DK'
p77103
aS'Wainwright L'
p77104
aS'Newton R'
p77105
asS'VI'
p77106
S'56'
p77107
sS'MHDA'
p77108
S'2011/03/02 06:00'
p77109
sS'PHST'
p77110
(lp77111
S'2010/05/04 [received]'
p77112
aS'2010/10/11 [accepted]'
p77113
aS'2010/11/28 [aheadofprint]'
p77114
asS'MH'
p77115
(lp77116
S'Adolescent'
p77117
aS'Adult'
p77118
aS'Aged'
p77119
aS'Aged, 80 and over'
p77120
aS'Anti-Retroviral Agents/therapeutic use'
p77121
aS'Antineoplastic Combined Chemotherapy Protocols/therapeutic use'
p77122
aS'Bleomycin/administration & dosage'
p77123
aS'CD4 Lymphocyte Count'
p77124
aS'Child'
p77125
aS'Cohort Studies'
p77126
aS'Doxorubicin/administration & dosage'
p77127
aS'Drug Therapy, Combination'
p77128
aS'Female'
p77129
aS'HIV Infections/diagnosis/drug therapy/virology'
p77130
aS'Humans'
p77131
aS'Male'
p77132
aS'Middle Aged'
p77133
aS'Prognosis'
p77134
aS'Retrospective Studies'
p77135
aS'Risk Factors'
p77136
aS'Sarcoma, Kaposi/*diagnosis/*drug therapy/mortality'
p77137
aS'South Africa'
p77138
aS'Survival Rate'
p77139
aS'Vinblastine/administration & dosage'
p77140
aS'Vincristine/administration & dosage'
p77141
aS'Viral Load'
p77142
aS'Young Adult'
p77143
asS'EDAT'
p77144
S'2011/01/13 06:00'
p77145
sS'SO'
p77146
S'Pediatr Blood Cancer. 2011 Mar;56(3):392-6. doi: 10.1002/pbc.22903. Epub 2010 Nov 28.'
p77147
sS'SB'
p77148
S'IM'
p77149
sS'PMID'
p77150
S'21225916'
p77151
sS'PST'
p77152
S'ppublish'
p77153
stRp77154
ag2
(g3
g4
(dp77155
S'LID'
p77156
S'10.1080/09540121.2010.498867 [doi]'
p77157
sS'STAT'
p77158
S'MEDLINE'
p77159
sS'JT'
p77160
S'AIDS care'
p77161
sS'DA'
p77162
S'20110110'
p77163
sS'AID'
p77164
(lp77165
S'931916071 [pii]'
p77166
aS'10.1080/09540121.2010.498867 [doi]'
p77167
asS'CRDT'
p77168
(lp77169
S'2011/01/11 06:00'
p77170
asS'DP'
p77171
S'2011 Jan'
p77172
sS'AD'
p77173
S"Unite d'Epidemiologie des Maladies Emergentes, Institut Pasteur, Paris, France."
p77174
sS'OWN'
p77175
S'NLM'
p77176
sS'PT'
p77177
(lp77178
S'Journal Article'
p77179
asS'LA'
p77180
(lp77181
S'eng'
p77182
asS'FAU'
p77183
(lp77184
S'Landier, Jordi'
p77185
aS'Akonde, Alain'
p77186
aS'Pizzocolo, Cecilia'
p77187
aS'Haidara, Ibrahim'
p77188
aS'Drabo, Mahamadou'
p77189
aS'Pizarro, Louis'
p77190
aS'Fontanet, Arnaud'
p77191
aS'Katlama, Christine'
p77192
aS'Madec, Yoann'
p77193
asS'LR'
p77194
S'20110815'
p77195
sS'PG'
p77196
S'75-8'
p77197
sS'TI'
p77198
S'Switch to second-line ART in West African routine care: incidence and reasons for switching.'
p77199
sS'RN'
p77200
(lp77201
S'0 (Anti-HIV Agents)'
p77202
asS'PL'
p77203
S'England'
p77204
sS'TA'
p77205
S'AIDS Care'
p77206
sS'JID'
p77207
S'8915313'
p77208
sS'AB'
p77209
S'In sub-Saharan Africa, while antiretroviral therapy (ART) becomes widely available, access to biological measurements to monitor patients under ART remains scarce, making the management of ART difficult. We described the management of switching to second-line ART where HIV care is provided mainly in secondary health-care structures, in the region of Segou, Mali. Of 865 patients, followed under ART for a median time of 15 months, 40 switched to second-line ART (3.3 switches/100 person years). Reason for switching was failure in 18 patients (after 21 months in median) and severe intolerance in 13 (after three months in median). Switching to second-line ART occurred earlier when motivated by intolerance than by failure. The low rate of switch compares well with other studies, but was low compared to the expected rate of failure, and may indicate that physicians are reluctant to switch ART when treatment options are limited.'
p77210
sS'GR'
p77211
(lp77212
S'R01 HD050176-01A2/HD/NICHD NIH HHS/United States'
p77213
asS'IP'
p77214
S'1'
sS'IS'
p77215
S'1360-0451 (Electronic) 0954-0121 (Linking)'
p77216
sS'DCOM'
p77217
S'20110427'
p77218
sS'AU'
p77219
(lp77220
S'Landier J'
p77221
aS'Akonde A'
p77222
aS'Pizzocolo C'
p77223
aS'Haidara I'
p77224
aS'Drabo M'
p77225
aS'Pizarro L'
p77226
aS'Fontanet A'
p77227
aS'Katlama C'
p77228
aS'Madec Y'
p77229
asS'VI'
p77230
S'23'
p77231
sS'MHDA'
p77232
S'2011/04/28 06:00'
p77233
sS'MH'
p77234
(lp77235
S'Adolescent'
p77236
aS'Adult'
p77237
aS'Anti-HIV Agents/adverse effects/*therapeutic use'
p77238
aS'Antiretroviral Therapy, Highly Active'
p77239
aS'CD4 Lymphocyte Count'
p77240
aS'Drug Substitution/*statistics & numerical data'
p77241
aS'Epidemiologic Methods'
p77242
aS'Female'
p77243
aS'HIV Infections/*drug therapy/immunology'
p77244
aS'Humans'
p77245
aS'Male'
p77246
aS'Middle Aged'
p77247
aS'Treatment Failure'
p77248
asS'EDAT'
p77249
S'2011/01/11 06:00'
p77250
sS'SO'
p77251
S'AIDS Care. 2011 Jan;23(1):75-8. doi: 10.1080/09540121.2010.498867.'
p77252
sS'SB'
p77253
S'IM X'
p77254
sS'PMID'
p77255
S'21218279'
p77256
sS'PST'
p77257
S'ppublish'
p77258
stRp77259
ag2
(g3
g4
(dp77260
S'LID'
p77261
S'10.1007/s10461-010-9877-7 [doi]'
p77262
sS'STAT'
p77263
S'MEDLINE'
p77264
sS'JT'
p77265
S'AIDS and behavior'
p77266
sS'DA'
p77267
S'20120111'
p77268
sS'AID'
p77269
(lp77270
S'10.1007/s10461-010-9877-7 [doi]'
p77271
asS'CRDT'
p77272
(lp77273
S'2011/01/08 06:00'
p77274
asS'DP'
p77275
S'2012 Jan'
p77276
sS'AD'
p77277
S'Centre for Geographic Medicine Research, Kenya Medical Research Institute, Kilifi, Kenya.'
p77278
sS'OWN'
p77279
S'NLM'
p77280
sS'PT'
p77281
(lp77282
S'Journal Article'
p77283
asS'LA'
p77284
(lp77285
S'eng'
p77286
asS'FAU'
p77287
(lp77288
S'Hassan, Amin S'
p77289
aS'Sakwa, Erick M'
p77290
aS'Nabwera, Helen M'
p77291
aS'Taegtmeyer, Miriam M'
p77292
aS'Kimutai, Robert M'
p77293
aS'Sanders, Eduard J'
p77294
aS'Awuondo, Ken K'
p77295
aS'Mutinda, Maureen N'
p77296
aS'Molyneux, Catherine S'
p77297
aS'Berkley, James A'
p77298
asS'LR'
p77299
S'20150205'
p77300
sS'PG'
p77301
S'5-12'
p77302
sS'TI'
p77303
S'Dynamics and constraints of early infant diagnosis of HIV infection in Rural Kenya.'
p77304
sS'PL'
p77305
S'United States'
p77306
sS'TA'
p77307
S'AIDS Behav'
p77308
sS'JID'
p77309
S'9712133'
p77310
sS'AB'
p77311
S'A cohort design was used to determine uptake and drop out of 213 HIV-exposed infants eligible for Early Infant Diagnosis (EID) of HIV. To explore service providers and care givers knowledge, attitudes and perceptions of the EID process, observations and in-depth interviews were conducted. 145 (68%) infants enrolled after 2 months of age. 139 (65%) dropped out before follow up to 18 months old. 60 (43%) drop outs occurred within 2 months of enrolment. Maternal factors associated with infant drop out were maternal loss to follow up (48 [68%] vs. 8 [20%], P < 0.001) and younger maternal age (27.2 vs. 30.1 years, P = 0.033). Service providers and caregivers had inadequate training, knowledge and understanding of EID. Poverty and lack of social support were challenges in accessing EID services. EID should be more closely aligned within PMTCT services, integrated with routine mother and child health (MCH) activities and its implementation more closely monitored.'
p77312
sS'GR'
p77313
(lp77314
S'092654/Wellcome Trust/United Kingdom'
p77315
asS'IP'
p77316
S'1'
sS'IS'
p77317
S'1573-3254 (Electronic) 1090-7165 (Linking)'
p77318
sS'PMC'
p77319
S'PMC3254874'
p77320
sS'DCOM'
p77321
S'20120315'
p77322
sS'AU'
p77323
(lp77324
S'Hassan AS'
p77325
aS'Sakwa EM'
p77326
aS'Nabwera HM'
p77327
aS'Taegtmeyer MM'
p77328
aS'Kimutai RM'
p77329
aS'Sanders EJ'
p77330
aS'Awuondo KK'
p77331
aS'Mutinda MN'
p77332
aS'Molyneux CS'
p77333
aS'Berkley JA'
p77334
asS'VI'
p77335
S'16'
p77336
sS'MHDA'
p77337
S'2012/03/16 06:00'
p77338
sS'OID'
p77339
(lp77340
S'NLM: PMC3254874'
p77341
asS'MH'
p77342
(lp77343
S'Adult'
p77344
aS'Cohort Studies'
p77345
aS'*Early Diagnosis'
p77346
aS'Female'
p77347
aS'Follow-Up Studies'
p77348
aS'HIV Infections/*diagnosis'
p77349
aS'HIV-1/isolation & purification'
p77350
aS'*Health Knowledge, Attitudes, Practice'
p77351
aS'Health Services Accessibility'
p77352
aS'Humans'
p77353
aS'Infant'
p77354
aS'Infant, Newborn'
p77355
aS'Infectious Disease Transmission, Vertical/*prevention & control'
p77356
aS'Interviews as Topic'
p77357
aS'Kenya'
p77358
aS'Male'
p77359
aS'Maternal Age'
p77360
aS'Polymerase Chain Reaction'
p77361
aS'Rural Population'
p77362
aS'Social Support'
p77363
aS'Socioeconomic Factors'
p77364
asS'EDAT'
p77365
S'2011/01/08 06:00'
p77366
sS'SO'
p77367
S'AIDS Behav. 2012 Jan;16(1):5-12. doi: 10.1007/s10461-010-9877-7.'
p77368
sS'SB'
p77369
S'IM'
p77370
sS'PMID'
p77371
S'21213034'
p77372
sS'PST'
p77373
S'ppublish'
p77374
stRp77375
ag2
(g3
g4
(dp77376
S'LID'
p77377
S'10.1371/journal.pone.0015735 [doi]'
p77378
sS'STAT'
p77379
S'MEDLINE'
p77380
sS'DEP'
p77381
S'20101229'
p77382
sS'DA'
p77383
S'20110106'
p77384
sS'AID'
p77385
(lp77386
S'10.1371/journal.pone.0015735 [doi]'
p77387
asS'CRDT'
p77388
(lp77389
S'2011/01/07 06:00'
p77390
asS'DP'
p77391
S'2010'
p77392
sS'OWN'
p77393
S'NLM'
p77394
sS'PT'
p77395
(lp77396
S'Journal Article'
p77397
aS"Research Support, Non-U.S. Gov't"
p77398
asS'LA'
p77399
(lp77400
S'eng'
p77401
asS'FAU'
p77402
(lp77403
S'Andrews, Jason R'
p77404
aS'Shah, N Sarita'
p77405
aS'Weissman, Darren'
p77406
aS'Moll, Anthony P'
p77407
aS'Friedland, Gerald'
p77408
aS'Gandhi, Neel R'
p77409
asS'JT'
p77410
S'PloS one'
p77411
sS'LR'
p77412
S'20150205'
p77413
sS'PG'
p77414
S'e15735'
p77415
sS'TI'
p77416
S'Predictors of multidrug- and extensively drug-resistant tuberculosis in a high HIV prevalence community.'
p77417
sS'PL'
p77418
S'United States'
p77419
sS'TA'
p77420
S'PLoS One'
p77421
sS'JID'
p77422
S'101285081'
p77423
sS'AB'
p77424
S'BACKGROUND: Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) have emerged in high-HIV-prevalence settings, which generally lack laboratory infrastructure for diagnosing TB drug resistance. Even where available, inherent delays with current drug-susceptibility testing (DST) methods result in clinical deterioration and ongoing transmission of MDR and XDR-TB. Identifying clinical predictors of drug resistance may aid in risk stratification for earlier treatment and infection control. METHODS: We performed a retrospective case-control study of patients with MDR (cases), XDR (cases) and drug-susceptible (controls) TB in a high-HIV-prevalence setting in South Africa to identify clinical and demographic risk factors for drug-resistant TB. Controls were selected in a 1:1:1 ratio and were not matched. We calculated odds ratios (OR) and performed multivariate logistic regression to identify independent predictors. RESULTS: We enrolled 116, 123 and 139 patients with drug-susceptible, MDR, and XDR-TB. More than 85% in all three patient groups were HIV-infected. In multivariate analysis, MDR and XDR-TB were each strongly associated with history of TB treatment failure (adjusted OR 51.7 [CI 6.6-403.7] and 51.5 [CI 6.4-414.0], respectively) and hospitalization more than 14 days (aOR 3.8 [CI 1.1-13.3] and 6.1 [CI 1.8-21.0], respectively). Prior default from TB treatment was not a risk factor for MDR or XDR-TB. HIV was a risk factor for XDR (aOR 8.2, CI 1.3-52.6), but not MDR-TB. Comparing XDR with MDR-TB patients, the only significant risk factor for XDR-TB was HIV infection (aOR 5.3, CI 1.0-27.6). DISCUSSION: In this high-HIV-prevalence and drug-resistant TB setting, a history of prolonged hospitalization and previous TB treatment failure were strong risk factors for both MDR and XDR-TB. Given high mortality observed among patients with HIV and drug-resistant TB co-infection, previously treated and hospitalized patients should be considered for empiric second-line TB therapy while awaiting confirmatory DST results in settings with a high-burden of MDR/XDR-TB.'
p77425
sS'AD'
p77426
S'Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.'
p77427
sS'IP'
p77428
S'12'
p77429
sS'IS'
p77430
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p77431
sS'PMC'
p77432
S'PMC3012092'
p77433
sS'DCOM'
p77434
S'20110705'
p77435
sS'AU'
p77436
(lp77437
S'Andrews JR'
p77438
aS'Shah NS'
p77439
aS'Weissman D'
p77440
aS'Moll AP'
p77441
aS'Friedland G'
p77442
aS'Gandhi NR'
p77443
asS'VI'
p77444
S'5'
sS'MHDA'
p77445
S'2011/07/06 06:00'
p77446
sS'PHST'
p77447
(lp77448
S'2010/09/10 [received]'
p77449
aS'2010/11/25 [accepted]'
p77450
aS'2010/12/29 [epublish]'
p77451
asS'OID'
p77452
(lp77453
S'NLM: PMC3012092'
p77454
asS'MH'
p77455
(lp77456
S'Adult'
p77457
aS'Case-Control Studies'
p77458
aS'Communicable Disease Control'
p77459
aS'Extensively Drug-Resistant Tuberculosis/*complications/*diagnosis'
p77460
aS'Female'
p77461
aS'HIV Infections/*complications/*diagnosis'
p77462
aS'Humans'
p77463
aS'Male'
p77464
aS'Odds Ratio'
p77465
aS'Prevalence'
p77466
aS'Retrospective Studies'
p77467
aS'Risk'
p77468
aS'Risk Factors'
p77469
aS'South Africa'
p77470
aS'Tuberculosis, Multidrug-Resistant/*complications/*diagnosis'
p77471
asS'EDAT'
p77472
S'2011/01/07 06:00'
p77473
sS'SO'
p77474
S'PLoS One. 2010 Dec 29;5(12):e15735. doi: 10.1371/journal.pone.0015735.'
p77475
sS'SB'
p77476
S'IM'
p77477
sS'PMID'
p77478
S'21209951'
p77479
sS'PST'
p77480
S'epublish'
p77481
stRp77482
ag2
(g3
g4
(dp77483
S'STAT'
p77484
S'MEDLINE'
p77485
sS'AB'
p77486
S'OBJECTIVE: To evaluate the extent of HIV-1 drug resistance among drug naive Kenyan individuals. DESIGN: Cross-sectional study. SETTING: Kenya Medical Research Institute HIV laboratory Nairobi, Kenya. SUBJECTS: A total of seventy eight HIV-1 positive drug naive subjects randomised from five Kenyan provincial hospitals between April and June 2004. RESULTS: A major non-nucleoside reverse transcriptase (NNRTI) an associated mutation was found in one patient (1.3%). NNRTI associated resistance mutations were present at amino acid codon sites G98A (2.56%); K103E (1.3%) and L100F (3.57%) prevalences. Baseline resistance may compromise the response to standard NNRTI-based first-line ART in 1.3 % of the study subjects. CONCLUSION: This indicates in general, that drug resistance among HIV-1 positive drug naive individual is at low thresholds (1.3%) but the problem could be more serious than reported here. Continuous resistance monitoring is therefore warranted to maintain individual and population-level ART effectiveness.'
p77487
sS'JID'
p77488
S'0372766'
p77489
sS'JT'
p77490
S'East African medical journal'
p77491
sS'IP'
p77492
S'1'
sS'IS'
p77493
S'0012-835X (Print) 0012-835X (Linking)'
p77494
sS'DCOM'
p77495
S'20140724'
p77496
sS'DA'
p77497
S'20140627'
p77498
sS'AU'
p77499
(lp77500
S'Nyamache AK'
p77501
aS'Waihenya R'
p77502
aS"Ng'ang'a ZW"
p77503
aS'Muigai AW'
p77504
aS'Khamadi SA'
p77505
asS'CRDT'
p77506
(lp77507
S'2014/06/28 06:00'
p77508
asS'VI'
p77509
S'88'
p77510
sS'PMID'
p77511
S'24968596'
p77512
sS'DP'
p77513
S'2011 Jan'
p77514
sS'MHDA'
p77515
S'2014/07/25 06:00'
p77516
sS'OWN'
p77517
S'NLM'
p77518
sS'PT'
p77519
(lp77520
S'Journal Article'
p77521
asS'LA'
p77522
(lp77523
S'eng'
p77524
asS'MH'
p77525
(lp77526
S'Adolescent'
p77527
aS'Adult'
p77528
aS'Aged'
p77529
aS'Anti-HIV Agents/*therapeutic use'
p77530
aS'Codon/genetics'
p77531
aS'Drug Resistance, Viral/*genetics'
p77532
aS'Female'
p77533
aS'HIV Reverse Transcriptase/*genetics'
p77534
aS'HIV Seropositivity/*drug therapy'
p77535
aS'HIV-1/*genetics'
p77536
aS'Humans'
p77537
aS'Kenya'
p77538
aS'Male'
p77539
aS'Middle Aged'
p77540
aS'Mutation'
p77541
aS'Reverse Transcriptase Inhibitors/*therapeutic use'
p77542
aS'Young Adult'
p77543
asS'FAU'
p77544
(lp77545
S'Nyamache, A K'
p77546
aS'Waihenya, R'
p77547
aS"Ng'ang'a, Z W"
p77548
aS'Muigai, A W'
p77549
aS'Khamadi, S A'
p77550
asS'EDAT'
p77551
S'2011/01/01 00:00'
p77552
sS'PST'
p77553
S'ppublish'
p77554
sS'SO'
p77555
S'East Afr Med J. 2011 Jan;88(1):4-8.'
p77556
sS'PG'
p77557
S'4-8'
p77558
sS'TI'
p77559
S'Reverse transcriptase inhibitors drug resistance mutations in drug-naive HIV type 1 positive Kenyans.'
p77560
sS'SB'
p77561
S'IM'
p77562
sS'RN'
p77563
(lp77564
S'0 (Anti-HIV Agents)'
p77565
aS'0 (Codon)'
p77566
aS'0 (Reverse Transcriptase Inhibitors)'
p77567
aS'EC 2.7.7.- (reverse transcriptase, Human immunodeficiency virus 1)'
p77568
aS'EC 2.7.7.49 (HIV Reverse Transcriptase)'
p77569
asS'PL'
p77570
S'Kenya'
p77571
sS'TA'
p77572
S'East Afr Med J'
p77573
stRp77574
ag2
(g3
g4
(dp77575
S'LID'
p77576
S'10.1371/journal.pone.0014149 [doi]'
p77577
sS'STAT'
p77578
S'MEDLINE'
p77579
sS'DEP'
p77580
S'20101130'
p77581
sS'DA'
p77582
S'20101214'
p77583
sS'AID'
p77584
(lp77585
S'10.1371/journal.pone.0014149 [doi]'
p77586
asS'CRDT'
p77587
(lp77588
S'2010/12/15 06:00'
p77589
asS'DP'
p77590
S'2010'
p77591
sS'GR'
p77592
(lp77593
S'G0600599/Medical Research Council/United Kingdom'
p77594
aS'U01 AI069919/AI/NIAID NIH HHS/United States'
p77595
aS'U01 AI069924/AI/NIAID NIH HHS/United States'
p77596
aS'U01-AI069911/AI/NIAID NIH HHS/United States'
p77597
aS'U01-AI069919/AI/NIAID NIH HHS/United States'
p77598
aS'U01-AI069924/AI/NIAID NIH HHS/United States'
p77599
asS'OWN'
p77600
S'NLM'
p77601
sS'PT'
p77602
(lp77603
S'Journal Article'
p77604
aS'Research Support, N.I.H., Extramural'
p77605
aS"Research Support, Non-U.S. Gov't"
p77606
asS'LA'
p77607
(lp77608
S'eng'
p77609
asS'FAU'
p77610
(lp77611
S'Brinkhof, Martin W G'
p77612
aS'Spycher, Ben D'
p77613
aS'Yiannoutsos, Constantin'
p77614
aS'Weigel, Ralf'
p77615
aS'Wood, Robin'
p77616
aS'Messou, Eugene'
p77617
aS'Boulle, Andrew'
p77618
aS'Egger, Matthias'
p77619
aS'Sterne, Jonathan A C'
p77620
asS'JT'
p77621
S'PloS one'
p77622
sS'LR'
p77623
S'20150526'
p77624
sS'PG'
p77625
S'e14149'
p77626
sS'TI'
p77627
S'Adjusting mortality for loss to follow-up: analysis of five ART programmes in sub-Saharan Africa.'
p77628
sS'RN'
p77629
(lp77630
S'0 (Antiviral Agents)'
p77631
asS'PL'
p77632
S'United States'
p77633
sS'TA'
p77634
S'PLoS One'
p77635
sS'JID'
p77636
S'101285081'
p77637
sS'AB'
p77638
S"BACKGROUND: Evaluation of antiretroviral treatment (ART) programmes in sub-Saharan Africa is difficult because many patients are lost to follow-up. Outcomes in these patients are generally unknown but studies tracing patients have shown mortality to be high. We adjusted programme-level mortality in the first year of antiretroviral treatment (ART) for excess mortality in patients lost to follow-up. METHODS AND FINDINGS: Treatment-naive patients starting combination ART in five programmes in Cote d'Ivoire, Kenya, Malawi and South Africa were eligible. Patients whose last visit was at least nine months before the closure of the database were considered lost to follow-up. We filled missing survival times in these patients by multiple imputation, using estimates of mortality from studies that traced patients lost to follow-up. Data were analyzed using Weibull models, adjusting for age, sex, ART regimen, CD4 cell count, clinical stage and treatment programme. A total of 15,915 HIV-infected patients (median CD4 cell count 110 cells/microL, median age 35 years, 68% female) were included; 1,001 (6.3%) were known to have died and 1,285 (14.3%) were lost to follow-up in the first year of ART. Crude estimates of mortality at one year ranged from 5.7% (95% CI 4.9-6.5%) to 10.9% (9.6-12.4%) across the five programmes. Estimated mortality hazard ratios comparing patients lost to follow-up with those remaining in care ranged from 6 to 23. Adjusted estimates based on these hazard ratios ranged from 10.2% (8.9-11.6%) to 16.9% (15.0-19.1%), with relative increases in mortality ranging from 27% to 73% across programmes. CONCLUSIONS: Naive survival analysis ignoring excess mortality in patients lost to follow-up may greatly underestimate overall mortality, and bias ART programme evaluations. Adjusted mortality estimates can be obtained based on excess mortality rates in patients lost to follow-up."
p77639
sS'AD'
p77640
S'Division of International and Environmental Health, Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland.'
p77641
sS'CN'
p77642
(lp77643
S'International epidemiological Database to Evaluate AIDS (IeDEA)'
p77644
asS'IP'
p77645
S'11'
p77646
sS'IS'
p77647
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p77648
sS'PMC'
p77649
S'PMC2994756'
p77650
sS'DCOM'
p77651
S'20110427'
p77652
sS'AU'
p77653
(lp77654
S'Brinkhof MW'
p77655
aS'Spycher BD'
p77656
aS'Yiannoutsos C'
p77657
aS'Weigel R'
p77658
aS'Wood R'
p77659
aS'Messou E'
p77660
aS'Boulle A'
p77661
aS'Egger M'
p77662
aS'Sterne JA'
p77663
asS'VI'
p77664
S'5'
sS'MHDA'
p77665
S'2011/04/28 06:00'
p77666
sS'PHST'
p77667
(lp77668
S'2010/04/08 [received]'
p77669
aS'2010/09/24 [accepted]'
p77670
aS'2010/11/30 [epublish]'
p77671
asS'OID'
p77672
(lp77673
S'NLM: PMC2994756'
p77674
asS'MH'
p77675
(lp77676
S'Adult'
p77677
aS'Antiviral Agents/*therapeutic use'
p77678
aS"Cote d'Ivoire/epidemiology"
p77679
aS'Female'
p77680
aS'HIV Infections/*drug therapy/mortality'
p77681
aS'Humans'
p77682
aS'Kaplan-Meier Estimate'
p77683
aS'Kenya/epidemiology'
p77684
aS'Lost to Follow-Up'
p77685
aS'Malawi/epidemiology'
p77686
aS'Male'
p77687
aS'South Africa/epidemiology'
p77688
aS'Survival Rate'
p77689
asS'EDAT'
p77690
S'2010/12/15 06:00'
p77691
sS'SO'
p77692
S'PLoS One. 2010 Nov 30;5(11):e14149. doi: 10.1371/journal.pone.0014149.'
p77693
sS'SB'
p77694
S'IM'
p77695
sS'PMID'
p77696
S'21152392'
p77697
sS'PST'
p77698
S'epublish'
p77699
stRp77700
ag2
(g3
g4
(dp77701
S'LID'
p77702
S'10.1371/journal.pone.0015334 [doi]'
p77703
sS'STAT'
p77704
S'MEDLINE'
p77705
sS'DEP'
p77706
S'20101209'
p77707
sS'DA'
p77708
S'20101214'
p77709
sS'AID'
p77710
(lp77711
S'10.1371/journal.pone.0015334 [doi]'
p77712
asS'CRDT'
p77713
(lp77714
S'2010/12/15 06:00'
p77715
asS'DP'
p77716
S'2010'
p77717
sS'AD'
p77718
S'Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom. judith.glynn@lshtm.ac.uk'
p77719
sS'OWN'
p77720
S'NLM'
p77721
sS'PT'
p77722
(lp77723
S'Journal Article'
p77724
aS"Research Support, Non-U.S. Gov't"
p77725
asS'LA'
p77726
(lp77727
S'eng'
p77728
asS'FAU'
p77729
(lp77730
S'Glynn, Judith R'
p77731
aS'Kayuni, Ndoliwe'
p77732
aS'Floyd, Sian'
p77733
aS'Banda, Emmanuel'
p77734
aS'Francis-Chizororo, Monica'
p77735
aS'Tanton, Clare'
p77736
aS'Molesworth, Anna'
p77737
aS'Hemmings, Joanne'
p77738
aS'Crampin, Amelia C'
p77739
aS'French, Neil'
p77740
asS'JT'
p77741
S'PloS one'
p77742
sS'LR'
p77743
S'20150205'
p77744
sS'PG'
p77745
S'e15334'
p77746
sS'TI'
p77747
S'Age at menarche, schooling, and sexual debut in northern Malawi.'
p77748
sS'PL'
p77749
S'United States'
p77750
sS'TA'
p77751
S'PLoS One'
p77752
sS'JID'
p77753
S'101285081'
p77754
sS'AB'
p77755
S'BACKGROUND: Age at sexual debut is a key behavioural indicator used in HIV behavioural surveillance. Early age at menarche may precipitate early sex through perceived readiness for sex, or through school drop-out, but this is rarely studied. We investigated trends and circumstances of sexual debut in relation to schooling and age at menarche. METHODS AND FINDINGS: A cross-sectional sexual behaviour survey was conducted on all individuals age 15-59 within a demographic surveillance site in Karonga District, Malawi. Time trends were assessed using birth cohorts. Survival analysis was used to estimate the median age at menarche, sexual debut and first marriage. The 25(th) centile was used to define "early" sex, and analyses of risk factors for early sex were restricted to those who had reached that age, and were done using logistic regression. Of the 8232 women and 7338 men resident in the area, 88% and 78%, respectively, were seen, and, 94% and 92% of these were interviewed. The median reported age at first sex was 17.5 for women and 18.8 for men. For women, ages at menarche, sexual debut and first marriage did not differ by birth cohort. For men, age at sexual debut and first marriage decreased slightly in later birth cohorts. For both men and women increased schooling was associated with later sexual debut and a longer delay between sexual debut and first marriage, but the associations were stronger for women. Earlier age at menarche was strongly associated with earlier sexual debut and marriage and lower schooling levels. In women early sexual debut (<16 years) was less likely in those with menarche at age 14-15 (odds ratio (OR) 0.31, 95%CI 0.26-0.36), and >/=16 (OR 0.04, 95%CI 0.02-0.05) compared to those with menarche at <14. The proportion of women who completed primary school was 46% in those with menarche at <14, 60% in those with menarche at 14-15 and 70% in those with menarche at >/=16. The association between age at menarche and schooling was partly explained by age at sexual debut. The association between age at menarche and early sex was not altered by adjusting for schooling. CONCLUSIONS: Women with early menarche start sex and marry early, leading to school drop-out. It is important to find ways to support those who reach menarche early to access the same opportunities as other young women.'
p77756
sS'GR'
p77757
(lp77758
S'079828/Wellcome Trust/United Kingdom'
p77759
aS'079828/Z/06/Z/Wellcome Trust/United Kingdom'
p77760
asS'IP'
p77761
S'12'
p77762
sS'IS'
p77763
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p77764
sS'PMC'
p77765
S'PMC3000342'
p77766
sS'DCOM'
p77767
S'20110705'
p77768
sS'AU'
p77769
(lp77770
S'Glynn JR'
p77771
aS'Kayuni N'
p77772
aS'Floyd S'
p77773
aS'Banda E'
p77774
aS'Francis-Chizororo M'
p77775
aS'Tanton C'
p77776
aS'Molesworth A'
p77777
aS'Hemmings J'
p77778
aS'Crampin AC'
p77779
aS'French N'
p77780
asS'VI'
p77781
S'5'
sS'MHDA'
p77782
S'2011/07/06 06:00'
p77783
sS'PHST'
p77784
(lp77785
S'2010/09/23 [received]'
p77786
aS'2010/11/08 [accepted]'
p77787
aS'2010/12/09 [epublish]'
p77788
asS'OID'
p77789
(lp77790
S'NLM: PMC3000342'
p77791
asS'MH'
p77792
(lp77793
S'Adolescent'
p77794
aS'Adult'
p77795
aS'Age Factors'
p77796
aS'Cross-Sectional Studies'
p77797
aS'*Educational Status'
p77798
aS'Female'
p77799
aS'Humans'
p77800
aS'Malawi'
p77801
aS'Male'
p77802
aS'*Menarche'
p77803
aS'Middle Aged'
p77804
aS'Puberty'
p77805
aS'Risk Factors'
p77806
aS'Sexual Behavior/*statistics & numerical data'
p77807
asS'EDAT'
p77808
S'2010/12/15 06:00'
p77809
sS'SO'
p77810
S'PLoS One. 2010 Dec 9;5(12):e15334. doi: 10.1371/journal.pone.0015334.'
p77811
sS'SB'
p77812
S'IM'
p77813
sS'PMID'
p77814
S'21151570'
p77815
sS'PST'
p77816
S'epublish'
p77817
stRp77818
ag2
(g3
g4
(dp77819
S'LID'
p77820
S'10.1186/1758-2652-13-49 [doi]'
p77821
sS'STAT'
p77822
S'MEDLINE'
p77823
sS'DEP'
p77824
S'20101207'
p77825
sS'DA'
p77826
S'20110103'
p77827
sS'AID'
p77828
(lp77829
S'1758-2652-13-49 [pii]'
p77830
aS'10.1186/1758-2652-13-49 [doi]'
p77831
asS'CRDT'
p77832
(lp77833
S'2010/12/08 06:00'
p77834
asS'DP'
p77835
S'2010'
p77836
sS'AD'
p77837
S'Center for Global Health and Development, Boston University, Boston, MA, USA. abrennan@bu.edu'
p77838
sS'OWN'
p77839
S'NLM'
p77840
sS'PT'
p77841
(lp77842
S'Journal Article'
p77843
aS'Research Support, N.I.H., Extramural'
p77844
aS"Research Support, U.S. Gov't, Non-P.H.S."
p77845
asS'LA'
p77846
(lp77847
S'eng'
p77848
asS'DCOM'
p77849
S'20110408'
p77850
sS'JT'
p77851
S'Journal of the International AIDS Society'
p77852
sS'LR'
p77853
S'20150205'
p77854
sS'FAU'
p77855
(lp77856
S'Brennan, Alana T'
p77857
aS'Maskew, Mhairi'
p77858
aS'Sanne, Ian'
p77859
aS'Fox, Matthew P'
p77860
asS'TI'
p77861
S'The importance of clinic attendance in the first six months on antiretroviral treatment: a retrospective analysis at a large public sector HIV clinic in South Africa.'
p77862
sS'RN'
p77863
(lp77864
S'0 (Anti-HIV Agents)'
p77865
asS'PL'
p77866
S'England'
p77867
sS'PG'
p77868
S'49'
p77869
sS'JID'
p77870
S'101478566'
p77871
sS'AB'
p77872
S'BACKGROUND: Adherence to care and treatment are essential for HIV-infected individuals to benefit from antiretroviral therapy (ART). We sought to quantify the effects on treatment outcomes of missing visits soon after initiating ART. METHODS: We analyzed data from HIV-infected patients initiating ART at Themba Lethu Clinic, Johannesburg, South Africa, from April 2004 to August 2008. We used log-binomial regression to evaluate the relative risk of missing visits during the first six months of ART on immunological response and virologic suppression. Cox models were used to evaluate the relationship between missed visits and mortality and loss to follow up over 12 months. RESULTS: Of 4476 patients, 65% missed no visits, while 26% missed one visit, 7% missed two and 1.6% missed three or more visits during the first six months on treatment. Patients who missed three or more medical or antiretroviral (ARV) visits had a two-fold increased risk of poor CD4 response by six months, while the risk of failing to achieve virologic suppression by six months increased two- to five-fold among patients who missed two and three or more medical or ARV visits. Adjusted Cox models showed that patients who missed two (HR 2.1; 95% CI: 1.0-4.3) and three or more (HR 4.7; 95% CI: 1.4-16.2) medical visits had an increased risk of death, while those who missed two ARV (HR 3.8; 95% CI: 2.5-5.8) or three or more medical (HR 3.0; 95% CI: 1.1-8.1) visits had an increased risk of loss to follow up. CONCLUSIONS: Thirty-five percent of patients missed one or more visits in the first six months on treatment, increasing their risk of poorer outcomes. These patients could be targeted for additional adherence counselling to help improve ART outcomes.'
p77873
sS'GR'
p77874
(lp77875
S'K01 AI083097/AI/NIAID NIH HHS/United States'
p77876
aS'K01AI083097/AI/NIAID NIH HHS/United States'
p77877
asS'VI'
p77878
S'13'
p77879
sS'IS'
p77880
S'1758-2652 (Electronic) 1758-2652 (Linking)'
p77881
sS'PMC'
p77882
S'PMC3012655'
p77883
sS'AU'
p77884
(lp77885
S'Brennan AT'
p77886
aS'Maskew M'
p77887
aS'Sanne I'
p77888
aS'Fox MP'
p77889
asS'MHDA'
p77890
S'2011/04/09 06:00'
p77891
sS'PHST'
p77892
(lp77893
S'2010/08/11 [received]'
p77894
aS'2010/12/07 [accepted]'
p77895
aS'2010/12/07 [aheadofprint]'
p77896
asS'OID'
p77897
(lp77898
S'NLM: PMC3012655'
p77899
asS'MH'
p77900
(lp77901
S'Adult'
p77902
aS'Ambulatory Care Facilities/*utilization'
p77903
aS'Anti-HIV Agents/therapeutic use'
p77904
aS'Female'
p77905
aS'HIV Infections/*drug therapy/immunology/mortality/*psychology'
p77906
aS'Humans'
p77907
aS'Male'
p77908
aS'Middle Aged'
p77909
aS'*Patient Compliance'
p77910
aS'Public Sector'
p77911
aS'Retrospective Studies'
p77912
aS'South Africa'
p77913
aS'Young Adult'
p77914
asS'EDAT'
p77915
S'2010/12/08 06:00'
p77916
sS'SO'
p77917
S'J Int AIDS Soc. 2010 Dec 7;13:49. doi: 10.1186/1758-2652-13-49.'
p77918
sS'SB'
p77919
S'IM X'
p77920
sS'PMID'
p77921
S'21134297'
p77922
sS'TA'
p77923
S'J Int AIDS Soc'
p77924
sS'PST'
p77925
S'epublish'
p77926
stRp77927
ag2
(g3
g4
(dp77928
S'LID'
p77929
S'10.1097/QAD.0b013e328340fdf8 [doi]'
p77930
sS'STAT'
p77931
S'MEDLINE'
p77932
sS'JT'
p77933
S'AIDS (London, England)'
p77934
sS'CI'
p77935
(lp77936
S'2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.'
p77937
asS'DA'
p77938
S'20101221'
p77939
sS'AID'
p77940
(lp77941
S'10.1097/QAD.0b013e328340fdf8 [doi]'
p77942
asS'CRDT'
p77943
(lp77944
S'2010/12/03 06:00'
p77945
asS'DP'
p77946
S'2011 Jan 14'
p77947
sS'AD'
p77948
S'Division of General Internal Medicine, Stanford University, Stanford, USA. ebd@stanford.edu'
p77949
sS'OWN'
p77950
S'NLM'
p77951
sS'PT'
p77952
(lp77953
S'Journal Article'
p77954
asS'LA'
p77955
(lp77956
S'eng'
p77957
asS'FAU'
p77958
(lp77959
S'Bendavid, Eran'
p77960
aS'Grant, Philip'
p77961
aS'Talbot, Annie'
p77962
aS'Owens, Douglas K'
p77963
aS'Zolopa, Andrew'
p77964
asS'LR'
p77965
S'20150205'
p77966
sS'PG'
p77967
S'211-20'
p77968
sS'TI'
p77969
S"Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis."
p77970
sS'PL'
p77971
S'England'
p77972
sS'TA'
p77973
S'AIDS'
p77974
sS'JID'
p77975
S'8710219'
p77976
sS'AB'
p77977
S'OBJECTIVE: the World Health Organization (WHO) recently changed its first-line antiretroviral treatment guidelines in resource-limited settings. The cost-effectiveness of the new guidelines is unknown. DESIGN: comparative effectiveness and cost-effectiveness analysis using a model of HIV disease progression and treatment. METHODS: using a simulation of HIV disease and treatment in South Africa, we compared the life expectancy, quality-adjusted life expectancy, lifetime costs, and cost-effectiveness of five initial regimens. Four are currently recommended by the WHO: tenofovir/lamivudine/efavirenz; tenofovir/lamivudine/nevirapine; zidovudine/lamivudine/efavirenz; and zidovudine/lamivudine/nevirapine. The fifth is the most common regimen in current use: stavudine/lamivudine/nevirapine. Virologic suppression and toxicities determine regimen effectiveness and cost-effectiveness. RESULTS: choice of first-line regimen is associated with a difference of nearly 12 months of quality-adjusted life expectancy, from 135.2 months (tenofovir/lamivudine/efavirenz) to 123.7 months (stavudine/lamivudine/nevirapine). Stavudine/lamivudine/nevirapine is more costly and less effective than zidovudine/lamivudine/nevirapine. Initiating treatment with a regimen containing tenofovir/lamivudine/nevirapine is associated with an incremental cost-effectiveness ratio of $1045 per quality-adjusted life year compared with zidovudine/lamivudine/nevirapine. Using tenofovir/lamivudine/efavirenz was associated with the highest survival, fewest opportunistic diseases, lowest rate of regimen substitution, and an incremental cost-effectiveness ratio of $5949 per quality-adjusted life year gained compared with tenofovir/lamivudine/nevirapine. Zidovudine/lamivudine/efavirenz was more costly and less effective than tenofovir/lamivudine/nevirapine. Results were sensitive to the rates of toxicities and the disutility associated with each toxicity. CONCLUSION: among the options recommended by WHO, we estimate only three should be considered under normal circumstances. Choice among those depends on available resources and willingness to pay. Stavudine/lamivudine/nevirapine is associated with the poorest quality-adjusted survival and higher costs than zidovudine/lamivudine/nevirapine.'
p77978
sS'GR'
p77979
(lp77980
S'K01 AI084582/AI/NIAID NIH HHS/United States'
p77981
aS'K01 AI084582-01/AI/NIAID NIH HHS/United States'
p77982
aS'R01 DA015612/DA/NIDA NIH HHS/United States'
p77983
asS'IP'
p77984
S'2'
sS'IS'
p77985
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p77986
sS'PMC'
p77987
S'PMC3071983'
p77988
sS'DCOM'
p77989
S'20110506'
p77990
sS'MID'
p77991
(lp77992
S'NIHMS252779'
p77993
asS'AU'
p77994
(lp77995
S'Bendavid E'
p77996
aS'Grant P'
p77997
aS'Talbot A'
p77998
aS'Owens DK'
p77999
aS'Zolopa A'
p78000
asS'VI'
p78001
S'25'
p78002
sS'MHDA'
p78003
S'2011/05/07 06:00'
p78004
sS'OID'
p78005
(lp78006
S'NLM: NIHMS252779'
p78007
aS'NLM: PMC3071983'
p78008
asS'MH'
p78009
(lp78010
S'Adolescent'
p78011
aS'Adult'
p78012
aS'Antiretroviral Therapy, Highly Active/*economics/methods'
p78013
aS'CD4 Lymphocyte Count'
p78014
aS'Cost-Benefit Analysis/*economics/statistics & numerical data'
p78015
aS'Female'
p78016
aS'HIV Infections/drug therapy/*economics/mortality'
p78017
aS'Health Resources/*economics/statistics & numerical data'
p78018
aS'Humans'
p78019
aS'Male'
p78020
aS'Middle Aged'
p78021
aS'Models, Theoretical'
p78022
aS'Quality-Adjusted Life Years'
p78023
aS'South Africa/epidemiology'
p78024
aS'Viral Load'
p78025
aS'World Health Organization'
p78026
aS'Young Adult'
p78027
asS'EDAT'
p78028
S'2010/12/03 06:00'
p78029
sS'SO'
p78030
S'AIDS. 2011 Jan 14;25(2):211-20. doi: 10.1097/QAD.0b013e328340fdf8.'
p78031
sS'SB'
p78032
S'IM X'
p78033
sS'PMID'
p78034
S'21124202'
p78035
sS'PST'
p78036
S'ppublish'
p78037
stRp78038
ag2
(g3
g4
(dp78039
S'LID'
p78040
S'10.1093/jac/dkq433 [doi]'
p78041
sS'STAT'
p78042
S'MEDLINE'
p78043
sS'DEP'
p78044
S'20101125'
p78045
sS'DA'
p78046
S'20110311'
p78047
sS'AID'
p78048
(lp78049
S'dkq433 [pii]'
p78050
aS'10.1093/jac/dkq433 [doi]'
p78051
asS'CRDT'
p78052
(lp78053
S'2010/12/01 06:00'
p78054
asS'DP'
p78055
S'2011 Feb'
p78056
sS'OWN'
p78057
S'NLM'
p78058
sS'PT'
p78059
(lp78060
S'Journal Article'
p78061
aS"Research Support, Non-U.S. Gov't"
p78062
asS'LA'
p78063
(lp78064
S'eng'
p78065
asS'FAU'
p78066
(lp78067
S'Johannessen, Asgeir'
p78068
aS'Garrido, Carolina'
p78069
aS'Zahonero, Natalia'
p78070
aS'Naman, Ezra'
p78071
aS'de Mendoza, Carmen'
p78072
asS'JT'
p78073
S'The Journal of antimicrobial chemotherapy'
p78074
sS'LR'
p78075
S'20150205'
p78076
sS'PG'
p78077
S'260-4'
p78078
sS'TI'
p78079
S'HIV-1 drug resistance testing from dried blood spots collected in rural Tanzania using the ViroSeq HIV-1 Genotyping System.'
p78080
sS'RN'
p78081
(lp78082
S'0 (Anti-Retroviral Agents)'
p78083
asS'PL'
p78084
S'England'
p78085
sS'TA'
p78086
S'J Antimicrob Chemother'
p78087
sS'JID'
p78088
S'7513617'
p78089
sS'AB'
p78090
S'OBJECTIVES: To assess whether the commercial ViroSeq HIV-1 Genotyping System (Abbott Molecular, Des Plains, IL, USA) can be used in conjunction with dried blood spots (DBS) for clinical monitoring of drug resistance in patients who fail antiretroviral treatment (ART) in rural Tanzania. PATIENTS AND METHODS: Patients at Haydom Lutheran Hospital with confirmed treatment failure (viral load >1000 copies/mL) of a first-line ART regimen were selected for resistance testing. DBS were stored with desiccant at -20 degrees C for a median of 126 days (range 0-203) and shipped at ambient temperature for 20 days. After manual extraction of nucleic acids, the ViroSeq kit was used for amplification and sequencing. DBS-derived genotypes were compared with those of a plasma-based assay. RESULTS: Seventeen of 36 (47%) DBS specimens were successfully genotyped. Only 2 of 16 (13%) DBS with a viral load <10,000 copies/mL could be amplified, compared with 15 of 20 (75%) DBS with a viral load >10,000 copies/mL (P = 0.001). In samples that yielded a sequence, all 23 clinically significant reverse transcriptase (RT) mutations in plasma were also detected in DBS. One RT mutation was found in DBS only. In the protease region, 77 polymorphisms were found in plasma, of which 70 (91%) were also detected in DBS. Sixteen of 17 (94%) patients had identical resistance profiles to antiretroviral drugs in plasma and DBS. CONCLUSIONS: The ViroSeq kit performed well in patients with a high viral load, but failed to genotype most DBS with a viral load <10,000 copies/mL. In DBS that yielded a genotype, there was high concordance with a plasma-based assay.'
p78091
sS'AD'
p78092
S'Department of Infectious Diseases, Oslo University Hospital, Ulleval, Oslo, Norway.'
p78093
sS'IP'
p78094
S'2'
sS'IS'
p78095
S'1460-2091 (Electronic) 0305-7453 (Linking)'
p78096
sS'PMC'
p78097
S'PMC3019084'
p78098
sS'DCOM'
p78099
S'20111004'
p78100
sS'AU'
p78101
(lp78102
S'Johannessen A'
p78103
aS'Garrido C'
p78104
aS'Zahonero N'
p78105
aS'Naman E'
p78106
aS'de Mendoza C'
p78107
asS'VI'
p78108
S'66'
p78109
sS'MHDA'
p78110
S'2011/10/05 06:00'
p78111
sS'PHST'
p78112
(lp78113
S'2010/11/25 [aheadofprint]'
p78114
asS'MH'
p78115
(lp78116
S'Anti-Retroviral Agents/*therapeutic use'
p78117
aS'Drug Resistance, Viral/*genetics'
p78118
aS'Genotype'
p78119
aS'HIV Infections/blood/*drug therapy/virology'
p78120
aS'HIV-1/*drug effects/*genetics'
p78121
aS'Humans'
p78122
aS'Microbial Sensitivity Tests'
p78123
aS'Molecular Diagnostic Techniques'
p78124
aS'Mutation'
p78125
aS'Polymerase Chain Reaction'
p78126
aS'Polymorphism, Genetic'
p78127
aS'Sequence Analysis, RNA'
p78128
aS'Specimen Handling'
p78129
aS'Tanzania'
p78130
aS'Treatment Failure'
p78131
aS'Viral Load'
p78132
asS'EDAT'
p78133
S'2010/12/01 06:00'
p78134
sS'SO'
p78135
S'J Antimicrob Chemother. 2011 Feb;66(2):260-4. doi: 10.1093/jac/dkq433. Epub 2010 Nov 25.'
p78136
sS'SB'
p78137
S'IM'
p78138
sS'PMID'
p78139
S'21115444'
p78140
sS'PST'
p78141
S'ppublish'
p78142
stRp78143
ag2
(g3
g4
(dp78144
S'LID'
p78145
S'10.1186/1758-2652-13-46 [doi]'
p78146
sS'STAT'
p78147
S'MEDLINE'
p78148
sS'DEP'
p78149
S'20101125'
p78150
sS'DA'
p78151
S'20101216'
p78152
sS'AID'
p78153
(lp78154
S'1758-2652-13-46 [pii]'
p78155
aS'10.1186/1758-2652-13-46 [doi]'
p78156
asS'CRDT'
p78157
(lp78158
S'2010/11/27 06:00'
p78159
asS'DP'
p78160
S'2010'
p78161
sS'OWN'
p78162
S'NLM'
p78163
sS'PT'
p78164
(lp78165
S'Journal Article'
p78166
asS'LA'
p78167
(lp78168
S'eng'
p78169
asS'DCOM'
p78170
S'20110309'
p78171
sS'JT'
p78172
S'Journal of the International AIDS Society'
p78173
sS'LR'
p78174
S'20150205'
p78175
sS'FAU'
p78176
(lp78177
S'Fatti, Geoffrey'
p78178
aS'Bock, Peter'
p78179
aS'Grimwood, Ashraf'
p78180
aS'Eley, Brian'
p78181
asS'TI'
p78182
S'Increased vulnerability of rural children on antiretroviral therapy attending public health facilities in South Africa: a retrospective cohort study.'
p78183
sS'RN'
p78184
(lp78185
S'0 (Anti-HIV Agents)'
p78186
asS'PL'
p78187
S'England'
p78188
sS'PG'
p78189
S'46'
p78190
sS'JID'
p78191
S'101478566'
p78192
sS'AB'
p78193
S'BACKGROUND: A large proportion of the 340,000 HIV-positive children in South Africa live in rural areas, yet there is little sub-Saharan data comparing rural paediatric antiretroviral therapy (ART) programme outcomes with urban facilities. We compared clinical, immunological and virological outcomes between children at seven rural and 37 urban facilities across four provinces in South Africa. METHODS: We conducted a retrospective cohort study of routine data of children enrolled on ART between November 2003 and March 2008 in three settings, namely: urban residence and facility attendance (urban group); rural residence and facility attendance (rural group); and rural residents attending urban facilities (rural/urban group). Outcome measures were: death, loss to follow up (LTFU), virological suppression, and changes in CD4 percentage and weight-for-age-z (WAZ) scores. Kaplan-Meier estimates, logrank tests, multivariable Cox regression and generalized estimating equation models were used to compare outcomes between groups. RESULTS: In total, 2332 ART-naive children were included, (1727, 228 and 377 children in the urban, rural and rural/urban groups, respectively). At presentation, rural group children were older (6.7 vs. 5.6 and 5.8 years), had lower CD4 cell percentages (10.0% vs. 12.8% and 12.7%), lower WAZ scores (-2.06 vs. -1.46 and -1.41) and higher proportions with severe underweight (26% vs.15% and 15%) compared with the urban and rural/urban groups, respectively. Mortality was significantly higher in the rural group and LTFU significantly increased in the rural/urban group. After 24 months of ART, mortality probabilities were 3.4% (CI: 2.4-4.8%), 7.7% (CI: 4.5-13.0%) and 3.1% (CI: 1.7-5.6%) p = 0.0137; LTFU probabilities were 11.5% (CI: 9.3-14.0%), 8.8% (CI: 4.5-16.9%) and 16.6% (CI: 12.4-22.6%), p = 0.0028 in the urban, rural and rural/urban groups, respectively. The rural group had an increased adjusted mortality probability, adjusted hazards ratio 2.41 (CI: 1.25-4.67) and the rural/urban group had an increased adjusted LTFU probability, aHR 2.85 (CI: 1.41-5.79). The rural/urban group had a decreased adjusted probability of virological suppression compared with the urban group at any timepoint on treatment, adjusted odds ratio 0.67 (CI: 0.48-0.93). CONCLUSIONS: Rural HIV-positive children are a vulnerable group, exhibiting delayed access to ART and an increased risk of poor outcomes while on ART. Expansion of rural paediatric ART programmes, with future research exploring improvements to rural health system effectiveness, is required.'
p78194
sS'AD'
p78195
S"Kheth'Impilo, Green Square, 37 Hares Crescent, Woodstock, 7925, Cape Town, South Africa. geoffrey.fatti@khethimpilo.org"
p78196
sS'VI'
p78197
S'13'
p78198
sS'IS'
p78199
S'1758-2652 (Electronic) 1758-2652 (Linking)'
p78200
sS'PMC'
p78201
S'PMC3002304'
p78202
sS'AU'
p78203
(lp78204
S'Fatti G'
p78205
aS'Bock P'
p78206
aS'Grimwood A'
p78207
aS'Eley B'
p78208
asS'MHDA'
p78209
S'2011/03/10 06:00'
p78210
sS'PHST'
p78211
(lp78212
S'2010/08/13 [received]'
p78213
aS'2010/11/25 [accepted]'
p78214
aS'2010/11/25 [aheadofprint]'
p78215
asS'OID'
p78216
(lp78217
S'NLM: PMC3002304'
p78218
asS'MH'
p78219
(lp78220
S'Adolescent'
p78221
aS'Anti-HIV Agents/*therapeutic use'
p78222
aS'Child'
p78223
aS'Child, Preschool'
p78224
aS'Female'
p78225
aS'HIV Infections/*drug therapy/immunology/*mortality'
p78226
aS'Health Facilities/statistics & numerical data'
p78227
aS'Humans'
p78228
aS'Infant'
p78229
aS'Male'
p78230
aS'Retrospective Studies'
p78231
aS'Rural Population'
p78232
aS'South Africa'
p78233
aS'Treatment Outcome'
p78234
asS'EDAT'
p78235
S'2010/11/27 06:00'
p78236
sS'SO'
p78237
S'J Int AIDS Soc. 2010 Nov 25;13:46. doi: 10.1186/1758-2652-13-46.'
p78238
sS'SB'
p78239
S'IM X'
p78240
sS'PMID'
p78241
S'21108804'
p78242
sS'TA'
p78243
S'J Int AIDS Soc'
p78244
sS'PST'
p78245
S'epublish'
p78246
stRp78247
ag2
(g3
g4
(dp78248
S'LID'
p78249
S'10.1371/journal.pone.0013901 [doi]'
p78250
sS'STAT'
p78251
S'MEDLINE'
p78252
sS'DEP'
p78253
S'20101115'
p78254
sS'DA'
p78255
S'20101118'
p78256
sS'AID'
p78257
(lp78258
S'10.1371/journal.pone.0013901 [doi]'
p78259
asS'CRDT'
p78260
(lp78261
S'2010/11/19 06:00'
p78262
asS'DP'
p78263
S'2010'
p78264
sS'OWN'
p78265
S'NLM'
p78266
sS'PT'
p78267
(lp78268
S'Journal Article'
p78269
aS"Research Support, Non-U.S. Gov't"
p78270
asS'LA'
p78271
(lp78272
S'eng'
p78273
asS'FAU'
p78274
(lp78275
S'Cox, Helen S'
p78276
aS'McDermid, Cheryl'
p78277
aS'Azevedo, Virginia'
p78278
aS'Muller, Odelia'
p78279
aS'Coetzee, David'
p78280
aS'Simpson, John'
p78281
aS'Barnard, Marinus'
p78282
aS'Coetzee, Gerrit'
p78283
aS'van Cutsem, Gilles'
p78284
aS'Goemaere, Eric'
p78285
asS'JT'
p78286
S'PloS one'
p78287
sS'LR'
p78288
S'20150205'
p78289
sS'PG'
p78290
S'e13901'
p78291
sS'TI'
p78292
S'Epidemic levels of drug resistant tuberculosis (MDR and XDR-TB) in a high HIV prevalence setting in Khayelitsha, South Africa.'
p78293
sS'RN'
p78294
(lp78295
S'0 (Antibiotics, Antitubercular)'
p78296
aS'8G167061QZ (Ethambutol)'
p78297
aS'V83O1VOZ8L (Isoniazid)'
p78298
aS'VJT6J7R4TR (Rifampin)'
p78299
asS'PL'
p78300
S'United States'
p78301
sS'TA'
p78302
S'PLoS One'
p78303
sS'JID'
p78304
S'101285081'
p78305
sS'AB'
p78306
S'BACKGROUND: Although multidrug-resistant tuberculosis (MDR-TB) is emerging as a significant threat to tuberculosis control in high HIV prevalence countries such as South Africa, limited data is available on the burden of drug resistant tuberculosis and any association with HIV in such settings. We conducted a community-based representative survey to assess the MDR-TB burden in Khayelitsha, an urban township in South Africa with high HIV and TB prevalence. METHODOLOGY/PRINCIPAL FINDINGS: A cross-sectional survey was conducted among adult clinic attendees suspected for pulmonary tuberculosis in two large primary care clinics, together constituting 50% of the tuberculosis burden in Khayelitsha. Drug susceptibility testing (DST) for isoniazid and rifampicin was conducted using a line probe assay on positive sputum cultures, and with culture-based DST for first and second-line drugs. Between May and November 2008, culture positive pulmonary tuberculosis was diagnosed in 271 new and 264 previously treated tuberculosis suspects (sample enriched with previously treated cases). Among those with known HIV status, 55% and 71% were HIV infected respectively. MDR-TB was diagnosed in 3.3% and 7.7% of new and previously treated cases. These figures equate to an estimated case notification rate for MDR-TB of 51/100,000/year, with new cases constituting 55% of the estimated MDR-TB burden. HIV infection was not significantly associated with rifampicin resistance in multivariate analyses. CONCLUSIONS/SIGNIFICANCE: There is an extremely high burden of MDR-TB in this setting, most likely representing ongoing transmission. These data highlight the need to diagnose drug resistance among all TB cases, and for innovative models of case detection and treatment for MDR-TB, in order to interrupt transmission and control this emerging epidemic.'
p78307
sS'AD'
p78308
S'Burnet Institute, Melbourne, Australia. hcox@burnet.edu.au'
p78309
sS'IP'
p78310
S'11'
p78311
sS'IS'
p78312
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p78313
sS'PMC'
p78314
S'PMC2981525'
p78315
sS'DCOM'
p78316
S'20110427'
p78317
sS'AU'
p78318
(lp78319
S'Cox HS'
p78320
aS'McDermid C'
p78321
aS'Azevedo V'
p78322
aS'Muller O'
p78323
aS'Coetzee D'
p78324
aS'Simpson J'
p78325
aS'Barnard M'
p78326
aS'Coetzee G'
p78327
aS'van Cutsem G'
p78328
aS'Goemaere E'
p78329
asS'VI'
p78330
S'5'
sS'MHDA'
p78331
S'2011/04/28 06:00'
p78332
sS'PHST'
p78333
(lp78334
S'2010/06/27 [received]'
p78335
aS'2010/10/19 [accepted]'
p78336
aS'2010/11/15 [epublish]'
p78337
asS'OID'
p78338
(lp78339
S'NLM: PMC2981525'
p78340
asS'MH'
p78341
(lp78342
S'Adolescent'
p78343
aS'Adult'
p78344
aS'Antibiotics, Antitubercular/therapeutic use'
p78345
aS'Comorbidity'
p78346
aS'Cross-Sectional Studies'
p78347
aS'*Epidemics'
p78348
aS'Ethambutol/therapeutic use'
p78349
aS'Female'
p78350
aS'HIV Infections/*epidemiology'
p78351
aS'Humans'
p78352
aS'Isoniazid/therapeutic use'
p78353
aS'Male'
p78354
aS'Multivariate Analysis'
p78355
aS'Prevalence'
p78356
aS'Rifampin/therapeutic use'
p78357
aS'South Africa/epidemiology'
p78358
aS'Tuberculosis, Multidrug-Resistant/diagnosis/drug therapy/*epidemiology'
p78359
aS'Tuberculosis, Pulmonary/diagnosis/drug therapy/epidemiology'
p78360
aS'Young Adult'
p78361
asS'EDAT'
p78362
S'2010/11/19 06:00'
p78363
sS'SO'
p78364
S'PLoS One. 2010 Nov 15;5(11):e13901. doi: 10.1371/journal.pone.0013901.'
p78365
sS'SB'
p78366
S'IM'
p78367
sS'PMID'
p78368
S'21085569'
p78369
sS'PST'
p78370
S'epublish'
p78371
stRp78372
ag2
(g3
g4
(dp78373
S'STAT'
p78374
S'MEDLINE'
p78375
sS'JT'
p78376
S'Current HIV research'
p78377
sS'DA'
p78378
S'20101115'
p78379
sS'AID'
p78380
(lp78381
S'ABS-98 [pii]'
p78382
asS'CRDT'
p78383
(lp78384
S'2010/11/16 06:00'
p78385
asS'DP'
p78386
S'2010 Oct'
p78387
sS'OWN'
p78388
S'NLM'
p78389
sS'PT'
p78390
(lp78391
S'Journal Article'
p78392
aS"Research Support, Non-U.S. Gov't"
p78393
asS'LA'
p78394
(lp78395
S'eng'
p78396
asS'FAU'
p78397
(lp78398
S'Perez Molina, Jose A'
p78399
aS'Rillo, Marta Mora'
p78400
aS'Suarez-Lozano, Ignacio'
p78401
aS'Casado Osorio, Jose L'
p78402
aS'Cobo, Ramon Teira'
p78403
aS'Gonzalez, Pablo Rivas'
p78404
aS'Clotet, Enric Pedrol'
p78405
aS'Jerez, Asuncion Hernando'
p78406
aS'Pedrol, Pere Domingo'
p78407
aS'Royuela, Ana'
p78408
aS'Diaz, Elena Barquilla'
p78409
aS'Esteban, Herminia'
p78410
aS'Gonzalez-Garcia, Juan'
p78411
asS'LR'
p78412
S'20120210'
p78413
sS'PG'
p78414
S'521-30'
p78415
sS'TI'
p78416
S'Do HIV-Infected Immigrants Initiating HAART have Poorer Treatment-Related Outcomes than Autochthonous Patients in Spain? Results of the GESIDA 5808 Study.'
p78417
sS'RN'
p78418
(lp78419
S'0 (Anti-HIV Agents)'
p78420
asS'PL'
p78421
S'Netherlands'
p78422
sS'TA'
p78423
S'Curr HIV Res'
p78424
sS'JID'
p78425
S'101156990'
p78426
sS'AB'
p78427
S'OBJECTIVE: currently, 12% of the Spanish population is foreign-born, and a third of newly diagnosed HIV-infected patients are immigrants. We determined whether being an immigrant was associated with a poorer response to antiretroviral treatment. METHODS: historical multicenter cohort study of naive patients starting HAART. The primary endpoint was time to treatment failure (TTF) defined as virological failure (VF), death, opportunistic disease, treatment discontinuation (D/C), or missing patient. Secondary endpoints were TTF expressed as observed data (TFO; censoring missing patients) and time to virological failure (TVF; censoring missing patients and D/C not due to VF). A multivariate analysis was performed to control for confounders. RESULTS: a total of 1090 treatment-naive HIV-infected patients (387 immigrants and 703 autochthonous) from 33 hospitals were included. Most immigrants were from Sub-Saharan Africa (28.3%) or South-Central America/Caribbean (31%). Immigrants were significantly younger (34 y vs. 39 y), more frequently female (37.5% vs. 24.6%), with less HCV coinfection than autochthonous patients (7% vs. 31.3%). There were no differences in baseline viral load (4.95 Log(10) vs. 4.98 Log(10)), CD4 lymphocyte count (193.5/microL vs. 201.5/microL), late initiation of HAART (56.4% vs. 56.0%), or antiretrovirals used. Cox-regression analysis (HR; 95%CI) did not show differences in TTF (0.89; 0.66-1.20), TFO (0.95; 0.66-1.36), or TVF (1.00; 0.57-1.78) between immigrants and autochthonous patients. Losses to follow-up were more frequent among immigrants (17.8% vs. 12.1; p=0.009). Sub-Saharan African patients and immigrant females had a significantly shorter TTF. CONCLUSIONS: the response to HAART among immigrant patients was similar to that of autochthonous patients, although they had a higher rate of losses to follow-up. Sub-Saharan Africans and immigrant females may need particular measures to avoid barriers hindering antiviral efficacy.'
p78428
sS'AD'
p78429
S'Tropical Medicine Unit, Infectious Diseases Department, Hospital Ramon y Cajal, Carretera de Colmenar Km 9,100, Madrid 28034, Spain. jose.perezmolina@gmail.com'
p78430
sS'IP'
p78431
S'7'
sS'IS'
p78432
S'1873-4251 (Electronic) 1570-162X (Linking)'
p78433
sS'DCOM'
p78434
S'20110718'
p78435
sS'AU'
p78436
(lp78437
S'Perez Molina JA'
p78438
aS'Rillo MM'
p78439
aS'Suarez-Lozano I'
p78440
aS'Casado Osorio JL'
p78441
aS'Cobo RT'
p78442
aS'Gonzalez PR'
p78443
aS'Clotet EP'
p78444
aS'Jerez AH'
p78445
aS'Pedrol PD'
p78446
aS'Royuela A'
p78447
aS'Diaz EB'
p78448
aS'Esteban H'
p78449
aS'Gonzalez-Garcia J'
p78450
asS'VI'
p78451
S'8'
sS'MHDA'
p78452
S'2011/07/19 06:00'
p78453
sS'PHST'
p78454
(lp78455
S'2010/01/12 [received]'
p78456
aS'2010/10/01 [accepted]'
p78457
asS'MH'
p78458
(lp78459
S'Adult'
p78460
aS'Anti-HIV Agents/*therapeutic use'
p78461
aS'*Antiretroviral Therapy, Highly Active'
p78462
aS'CD4 Lymphocyte Count'
p78463
aS'Cohort Studies'
p78464
aS'*Emigrants and Immigrants'
p78465
aS'Endpoint Determination'
p78466
aS'Ethnic Groups'
p78467
aS'Female'
p78468
aS'Geography'
p78469
aS'HIV Infections/*drug therapy/epidemiology/*ethnology/virology'
p78470
aS'Humans'
p78471
aS'Male'
p78472
aS'Middle Aged'
p78473
aS'Spain/epidemiology'
p78474
aS'Treatment Failure'
p78475
aS'Treatment Outcome'
p78476
aS'Viral Load'
p78477
asS'EDAT'
p78478
S'2010/11/16 06:00'
p78479
sS'SO'
p78480
S'Curr HIV Res. 2010 Oct;8(7):521-30.'
p78481
sS'SB'
p78482
S'IM'
p78483
sS'PMID'
p78484
S'21073441'
p78485
sS'PST'
p78486
S'ppublish'
p78487
stRp78488
ag2
(g3
g4
(dp78489
S'LID'
p78490
S'10.1371/journal.pone.0013801 [doi]'
p78491
sS'STAT'
p78492
S'MEDLINE'
p78493
sS'DEP'
p78494
S'20101102'
p78495
sS'DA'
p78496
S'20101112'
p78497
sS'AID'
p78498
(lp78499
S'10.1371/journal.pone.0013801 [doi]'
p78500
asS'CRDT'
p78501
(lp78502
S'2010/11/13 06:00'
p78503
asS'DP'
p78504
S'2010'
p78505
sS'AD'
p78506
S'Department of Medicine, Faculty of Health Sciences, The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa. katharina.kranzer@lshtm.ac.uk'
p78507
sS'OWN'
p78508
S'NLM'
p78509
sS'PT'
p78510
(lp78511
S'Journal Article'
p78512
aS'Research Support, N.I.H., Extramural'
p78513
aS"Research Support, Non-U.S. Gov't"
p78514
asS'LA'
p78515
(lp78516
S'eng'
p78517
asS'FAU'
p78518
(lp78519
S'Kranzer, Katharina'
p78520
aS'Zeinecker, Jennifer'
p78521
aS'Ginsberg, Philip'
p78522
aS'Orrell, Catherine'
p78523
aS'Kalawe, Nosindiso N'
p78524
aS'Lawn, Stephen D'
p78525
aS'Bekker, Linda-Gail'
p78526
aS'Wood, Robin'
p78527
asS'JT'
p78528
S'PloS one'
p78529
sS'LR'
p78530
S'20150205'
p78531
sS'PG'
p78532
S'e13801'
p78533
sS'TI'
p78534
S'Linkage to HIV care and antiretroviral therapy in Cape Town, South Africa.'
p78535
sS'RN'
p78536
(lp78537
S'0 (Anti-Retroviral Agents)'
p78538
asS'PL'
p78539
S'United States'
p78540
sS'TA'
p78541
S'PLoS One'
p78542
sS'JID'
p78543
S'101285081'
p78544
sS'AB'
p78545
S'BACKGROUND: Antiretroviral therapy (ART) has been scaled-up rapidly in Africa. Programme reports typically focus on loss to follow-up and mortality among patients receiving ART. However, little is known about linkage and retention in care of individuals prior to starting ART. METHODOLOGY: Data on adult residents from a periurban community in Cape Town were collected at a primary care clinic and hospital. HIV testing registers, CD4 count results provided by the National Health Laboratory System and ART registers were linked. A random sample (n = 885) was drawn from adults testing HIV positive through antenatal care, sexual transmitted disease and voluntary testing and counseling services between January 2004 and March 2009. All adults (n = 103) testing HIV positive through TB services during the same time period were also included in the study. Linkage to HIV care was defined as attending for a CD4 count measurement within 6 months of HIV diagnosis. Linkage to ART care was defined as initiating ART within 6 months of HIV diagnosis in individuals with a CD4 count </=200 cells/microl taken within 6 months of HIV diagnosis. FINDINGS: Only 62.6% of individuals attended for a CD4 count measurement within 6 months of testing HIV positive. Individuals testing through sexually transmitted infection services had the best (84.1%) and individuals testing on their own initiative (53.5%) the worst linkage to HIV care. One third of individuals with timely CD4 counts were eligible for ART and 66.7% of those were successfully linked to ART care. Linkage to ART care was highest among antenatal care clients. Among individuals not yet eligible for ART only 46.3% had a repeat CD4 count. Linkage to HIV care improved in patients tested in more recent calendar period. CONCLUSION: Linkage to HIV and ART care was low in this poor peri-urban community despite free services available within close proximity. More efforts are needed to link VCT scale-up to subsequent care.'
p78546
sS'GR'
p78547
(lp78548
S'1U19AI53217-01/AI/NIAID NIH HHS/United States'
p78549
aS'R01 A1058736-01A1/PHS HHS/United States'
p78550
aS'R01 AI058736/AI/NIAID NIH HHS/United States'
p78551
aS'U19 AI053217/AI/NIAID NIH HHS/United States'
p78552
aS'Wellcome Trust/United Kingdom'
p78553
asS'IP'
p78554
S'11'
p78555
sS'IS'
p78556
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p78557
sS'PMC'
p78558
S'PMC2970551'
p78559
sS'DCOM'
p78560
S'20110427'
p78561
sS'AU'
p78562
(lp78563
S'Kranzer K'
p78564
aS'Zeinecker J'
p78565
aS'Ginsberg P'
p78566
aS'Orrell C'
p78567
aS'Kalawe NN'
p78568
aS'Lawn SD'
p78569
aS'Bekker LG'
p78570
aS'Wood R'
p78571
asS'VI'
p78572
S'5'
sS'MHDA'
p78573
S'2011/04/28 06:00'
p78574
sS'PHST'
p78575
(lp78576
S'2010/06/16 [received]'
p78577
aS'2010/10/10 [accepted]'
p78578
aS'2010/11/02 [epublish]'
p78579
asS'OID'
p78580
(lp78581
S'NLM: PMC2970551'
p78582
asS'MH'
p78583
(lp78584
S'Adult'
p78585
aS'Anti-Retroviral Agents/*therapeutic use'
p78586
aS'*CD4 Lymphocyte Count'
p78587
aS'Community Health Services/statistics & numerical data'
p78588
aS'Female'
p78589
aS'HIV Infections/*diagnosis/*drug therapy/epidemiology'
p78590
aS'Health Services Accessibility/statistics & numerical data'
p78591
aS'Humans'
p78592
aS'Male'
p78593
aS'Prevalence'
p78594
aS'South Africa/epidemiology'
p78595
aS'Time Factors'
p78596
asS'EDAT'
p78597
S'2010/11/13 06:00'
p78598
sS'SO'
p78599
S'PLoS One. 2010 Nov 2;5(11):e13801. doi: 10.1371/journal.pone.0013801.'
p78600
sS'SB'
p78601
S'IM'
p78602
sS'PMID'
p78603
S'21072191'
p78604
sS'PST'
p78605
S'epublish'
p78606
stRp78607
ag2
(g3
g4
(dp78608
S'LID'
p78609
S'10.1371/journal.pone.0013613 [doi]'
p78610
sS'STAT'
p78611
S'MEDLINE'
p78612
sS'DEP'
p78613
S'20101025'
p78614
sS'DA'
p78615
S'20101104'
p78616
sS'AID'
p78617
(lp78618
S'10.1371/journal.pone.0013613 [doi]'
p78619
asS'CRDT'
p78620
(lp78621
S'2010/11/05 06:00'
p78622
asS'DP'
p78623
S'2010'
p78624
sS'OWN'
p78625
S'NLM'
p78626
sS'PT'
p78627
(lp78628
S'Journal Article'
p78629
asS'LA'
p78630
(lp78631
S'eng'
p78632
asS'FAU'
p78633
(lp78634
S'Unge, Christian'
p78635
aS'Sodergard, Bjorn'
p78636
aS'Marrone, Gaetano'
p78637
aS'Thorson, Anna'
p78638
aS'Lukhwaro, Abigael'
p78639
aS'Carter, Jane'
p78640
aS'Ilako, Festus'
p78641
aS'Ekstrom, Anna Mia'
p78642
asS'JT'
p78643
S'PloS one'
p78644
sS'LR'
p78645
S'20150205'
p78646
sS'PG'
p78647
S'e13613'
p78648
sS'TI'
p78649
S'Long-term adherence to antiretroviral treatment and program drop-out in a high-risk urban setting in sub-Saharan Africa: a prospective cohort study.'
p78650
sS'RN'
p78651
(lp78652
S'0 (Anti-HIV Agents)'
p78653
asS'PL'
p78654
S'United States'
p78655
sS'TA'
p78656
S'PLoS One'
p78657
sS'JID'
p78658
S'101285081'
p78659
sS'AB'
p78660
S'BACKGROUND: Seventy percent of urban populations in sub-Saharan Africa live in slums. Sustaining HIV patients in these high-risk and highly mobile settings is a major future challenge. This study seeks to assess program retention and to find determinants for low adherence to antiretroviral treatment (ART) and drop-out from an established HIV/ART program in Kibera, Nairobi, one of Africa\'s largest informal urban settlements. METHODS AND FINDINGS: A prospective open cohort study of 800 patients was performed at the African Medical Research Foundation (AMREF) clinic in the Kibera slum. Adherence to ART and drop-out from the ART program were independent outcomes. Two different adherence measures were used: (1) "dose adherence" (the proportion of a prescribed dose taken over the past 4 days) and (2) "adherence index" (based on three adherence questions covering dosing, timing and special instructions). Drop-out from the program was calculated based on clinic appointment dates and number of prescribed doses, and a patient was defined as being lost to follow-up if over 90 days had expired since the last prescribed dose. More than one third of patients were non-adherent when all three aspects of adherence--dosing, timing and special instructions--were taken into account. Multivariate logistic regression revealed that not disclosing HIV status, having a low level of education, living below the poverty limit (US$ 2/day) and not having a treatment buddy were significant predictors for non-adherence. Additionally, one quarter of patients dropped out for more than 90 days after the last prescribed ART dose. Not having a treatment buddy was associated with increased risk for drop-out (hazard ratio 1.4, 95% CI = 1.0-1.9). CONCLUSION: These findings point to the dilemma of trying to sustain a growing number of people on life-long ART in conditions where prevailing stigma, poverty and food shortages threatens the long-term success of HIV treatment.'
p78661
sS'AD'
p78662
S'Division of Global Health, IHCAR, Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden. christianunge@gmail.com'
p78663
sS'IP'
p78664
S'10'
p78665
sS'IS'
p78666
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p78667
sS'PMC'
p78668
S'PMC2963610'
p78669
sS'DCOM'
p78670
S'20110307'
p78671
sS'AU'
p78672
(lp78673
S'Unge C'
p78674
aS'Sodergard B'
p78675
aS'Marrone G'
p78676
aS'Thorson A'
p78677
aS'Lukhwaro A'
p78678
aS'Carter J'
p78679
aS'Ilako F'
p78680
aS'Ekstrom AM'
p78681
asS'VI'
p78682
S'5'
sS'MHDA'
p78683
S'2011/03/08 06:00'
p78684
sS'PHST'
p78685
(lp78686
S'2010/07/23 [received]'
p78687
aS'2010/10/01 [accepted]'
p78688
aS'2010/10/25 [epublish]'
p78689
asS'OID'
p78690
(lp78691
S'NLM: PMC2963610'
p78692
asS'MH'
p78693
(lp78694
S'Africa South of the Sahara'
p78695
aS'Anti-HIV Agents/*therapeutic use'
p78696
aS'HIV Infections/*drug therapy'
p78697
aS'Humans'
p78698
aS'Logistic Models'
p78699
aS'*Patient Compliance'
p78700
aS'Prospective Studies'
p78701
aS'Risk Factors'
p78702
aS'Urban Health'
p78703
asS'EDAT'
p78704
S'2010/11/05 06:00'
p78705
sS'SO'
p78706
S'PLoS One. 2010 Oct 25;5(10):e13613. doi: 10.1371/journal.pone.0013613.'
p78707
sS'SB'
p78708
S'IM'
p78709
sS'PMID'
p78710
S'21049045'
p78711
sS'PST'
p78712
S'epublish'
p78713
stRp78714
ag2
(g3
g4
(dp78715
S'LID'
p78716
S'10.1186/1758-2652-13-42 [doi]'
p78717
sS'STAT'
p78718
S'MEDLINE'
p78719
sS'DEP'
p78720
S'20101103'
p78721
sS'DA'
p78722
S'20101125'
p78723
sS'AID'
p78724
(lp78725
S'1758-2652-13-42 [pii]'
p78726
aS'10.1186/1758-2652-13-42 [doi]'
p78727
asS'CRDT'
p78728
(lp78729
S'2010/11/05 06:00'
p78730
asS'DP'
p78731
S'2010'
p78732
sS'OWN'
p78733
S'NLM'
p78734
sS'PT'
p78735
(lp78736
S'Clinical Trial'
p78737
aS'Journal Article'
p78738
aS"Research Support, Non-U.S. Gov't"
p78739
asS'LA'
p78740
(lp78741
S'eng'
p78742
asS'DCOM'
p78743
S'20110309'
p78744
sS'JT'
p78745
S'Journal of the International AIDS Society'
p78746
sS'LR'
p78747
S'20150205'
p78748
sS'FAU'
p78749
(lp78750
S'Kiragga, Agnes N'
p78751
aS'Castelnuovo, Barbara'
p78752
aS'Nakanjako, Damalie'
p78753
aS'Manabe, Yukari C'
p78754
asS'TI'
p78755
S'Baseline severe anaemia should not preclude use of zidovudine in antiretroviral-eligible patients in resource-limited settings.'
p78756
sS'RN'
p78757
(lp78758
S'0 (Anti-HIV Agents)'
p78759
aS'0 (Hemoglobins)'
p78760
aS'4B9XT59T7S (Zidovudine)'
p78761
asS'PL'
p78762
S'England'
p78763
sS'PG'
p78764
S'42'
p78765
sS'JID'
p78766
S'101478566'
p78767
sS'AB'
p78768
S'BACKGROUND: Stavudine is no longer recommended as part of first-line therapy for patients initiating antiretroviral therapy (ART) in Uganda. Most patients are currently initiated on zidovudine-containing regimens, which can induce anaemia. We investigated the risk factors for early severe anaemia in the first six months of ART initiation. METHODS: We defined baseline (ART initiation) anaemia as haemoglobin (Hb) </=9.5 g/dL, baseline severe anaemia as Hb </=8 g/dL, and early severe anaemia as Hb </=8 g/dL within six months of ART initiation. Risk factors for the development of early severe anaemia were analyzed using a multivariable logistic regression model. RESULTS: In total, 5494 patients initiated ART, 821 (15%) had baseline anaemia, and 296 (5%) had baseline severe anaemia. Early severe anaemia occurred in 109 (4%) of 3105 patients who had at least one Hb measurement in the first six months on ART. Patients with baseline anaemia had a larger increase in Hb (median g/dL [IQR]) within the first six months compared with non-anaemic patients (2.9 [1.7, 4.6] vs. 0.7 [-0.2, 1.7], p < 0.0001). Having a new tuberculosis episode OR 3.69 (95% CI 1.64 - 8.32), MCV <80fL OR 1.60 (95% CI 1.01- 2.52) and baseline severe anaemia OR 5.27 (95% CI 3.00 - 9.26) were associated with early severe anaemia. Initiation on a zidovudine-based regimen was not associated with an increased risk of early severe anaemia. CONCLUSIONS: Among patients in an urban HIV clinic in Uganda, severe anaemia is modestly prevalent at ART initiation and improves with ART in the majority of patients. These data suggest that baseline severe anaemia should not be used as a criterion for avoiding the use of zidovudine in patients initiating ART in resource-limited settings.'
p78769
sS'AD'
p78770
S'Infectious Diseases Institute, Makerere University, Kampala, Uganda.'
p78771
sS'VI'
p78772
S'13'
p78773
sS'IS'
p78774
S'1758-2652 (Electronic) 1758-2652 (Linking)'
p78775
sS'PMC'
p78776
S'PMC2991285'
p78777
sS'AU'
p78778
(lp78779
S'Kiragga AN'
p78780
aS'Castelnuovo B'
p78781
aS'Nakanjako D'
p78782
aS'Manabe YC'
p78783
asS'MHDA'
p78784
S'2011/03/10 06:00'
p78785
sS'PHST'
p78786
(lp78787
S'2010/04/07 [received]'
p78788
aS'2010/11/03 [accepted]'
p78789
aS'2010/11/03 [aheadofprint]'
p78790
asS'OID'
p78791
(lp78792
S'NLM: PMC2991285'
p78793
asS'MH'
p78794
(lp78795
S'Adult'
p78796
aS'Anemia/blood/*etiology'
p78797
aS'Anti-HIV Agents/*adverse effects/therapeutic use'
p78798
aS'Female'
p78799
aS'HIV Infections/blood/complications/*drug therapy'
p78800
aS'Hemoglobins/metabolism'
p78801
aS'Humans'
p78802
aS'Male'
p78803
aS'Risk Factors'
p78804
aS'Uganda'
p78805
aS'Zidovudine/*adverse effects/therapeutic use'
p78806
asS'EDAT'
p78807
S'2010/11/05 06:00'
p78808
sS'SO'
p78809
S'J Int AIDS Soc. 2010 Nov 3;13:42. doi: 10.1186/1758-2652-13-42.'
p78810
sS'SB'
p78811
S'IM X'
p78812
sS'PMID'
p78813
S'21047391'
p78814
sS'TA'
p78815
S'J Int AIDS Soc'
p78816
sS'PST'
p78817
S'epublish'
p78818
stRp78819
ag2
(g3
g4
(dp78820
S'LID'
p78821
S'10.1097/QAD.0b013e328340fe76 [doi]'
p78822
sS'STAT'
p78823
S'MEDLINE'
p78824
sS'JT'
p78825
S'AIDS (London, England)'
p78826
sS'MID'
p78827
(lp78828
S'NIHMS252693'
p78829
asS'DA'
p78830
S'20101110'
p78831
sS'AID'
p78832
(lp78833
S'10.1097/QAD.0b013e328340fe76 [doi]'
p78834
asS'CRDT'
p78835
(lp78836
S'2010/11/04 06:00'
p78837
asS'DP'
p78838
S'2010 Nov 27'
p78839
sS'AD'
p78840
S'Department of Medicine, GF Jooste Hospital, Cape Town, South Africa.'
p78841
sS'OWN'
p78842
S'NLM'
p78843
sS'PT'
p78844
(lp78845
S'Journal Article'
p78846
aS'Research Support, N.I.H., Extramural'
p78847
aS"Research Support, Non-U.S. Gov't"
p78848
aS"Research Support, U.S. Gov't, Non-P.H.S."
p78849
asS'LA'
p78850
(lp78851
S'eng'
p78852
asS'FAU'
p78853
(lp78854
S'Asselman, Valerie'
p78855
aS'Thienemann, Friedrich'
p78856
aS'Pepper, Dominique J'
p78857
aS'Boulle, Andrew'
p78858
aS'Wilkinson, Robert J'
p78859
aS'Meintjes, Graeme'
p78860
aS'Marais, Suzaan'
p78861
asS'LR'
p78862
S'20160610'
p78863
sS'PG'
p78864
S'2871-6'
p78865
sS'TI'
p78866
S'Central nervous system disorders after starting antiretroviral therapy in South Africa.'
p78867
sS'RN'
p78868
(lp78869
S'0 (Benzoxazines)'
p78870
aS'JE6H2O27P8 (efavirenz)'
p78871
asS'PL'
p78872
S'England'
p78873
sS'TA'
p78874
S'AIDS'
p78875
sS'JID'
p78876
S'8710219'
p78877
sS'AB'
p78878
S'OBJECTIVE: To describe the spectrum of central nervous system (CNS) disease during the first year of antiretroviral therapy (ART) and to determine the contribution of neurological immune reconstitution inflammatory syndrome (IRIS). DESIGN: A prospective observational cohort study conducted over a 12-month period at a public sector referral hospital in South Africa. METHODS: HIV-seropositive patients who developed new or recurrent neurological or psychiatric symptom(s) or sign(s) within the first year of starting ART were enrolled. We used the number of patients starting ART in the referral area in the preceding year as the denominator to calculate the incidence of referral for neurological deterioration. Patients with delirium and peripheral neuropathy were excluded. Outcome at 6 months was recorded. RESULTS: Seventy-five patients were enrolled. The median nadir CD4(+) cell counts was 64 cells/mul. Fifty-nine percent of the patients were receiving antituberculosis treatment. The incidence of referral for CNS deterioration in the first year of ART was 23.3 cases [95% confidence interval (CI), 18.3-29.2] per 1000 patient-years at risk. CNS tuberculosis (n = 27, 36%), cryptococcal meningitis (n = 18, 24%), intracerebral space occupying lesions (other than tuberculoma) (n = 10, 13%) and psychosis (n = 9, 12%) were the most frequent diagnoses. Paradoxical neurological IRIS was diagnosed in 21 patients (28%), related to tuberculosis in 16 and cryptococcosis in five. At 6 months, 23% of the patients had died and 20% were lost to follow-up. CONCLUSION: Opportunistic infections, notably tuberculosis and cryptococcosis, were the most frequent causes for neurological deterioration after starting ART. Neurological IRIS occurred in over a quarter of patients.'
p78879
sS'GR'
p78880
(lp78881
S'072070/Wellcome Trust/United Kingdom'
p78882
aS'081667/Wellcome Trust/United Kingdom'
p78883
aS'084323/Wellcome Trust/United Kingdom'
p78884
aS'084323/Wellcome Trust/United Kingdom'
p78885
aS'088316/Wellcome Trust/United Kingdom'
p78886
aS'088316/Wellcome Trust/United Kingdom'
p78887
aS'1U2RTW007370/PHS HHS/United States'
p78888
aS'1U2RTW007373-01A1/PHS HHS/United States'
p78889
aS'MC_U117588499/Medical Research Council/United Kingdom'
p78890
aS'U117588499(88499)/Medical Research Council/United Kingdom'
p78891
aS'U2R TW007370/TW/FIC NIH HHS/United States'
p78892
aS'U2R TW007370-01A1/TW/FIC NIH HHS/United States'
p78893
aS'U2R TW007373/TW/FIC NIH HHS/United States'
p78894
aS'U2R TW007373-01A1/TW/FIC NIH HHS/United States'
p78895
asS'IP'
p78896
S'18'
p78897
sS'IS'
p78898
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p78899
sS'PMC'
p78900
S'PMC3077551'
p78901
sS'DCOM'
p78902
S'20110506'
p78903
sS'AU'
p78904
(lp78905
S'Asselman V'
p78906
aS'Thienemann F'
p78907
aS'Pepper DJ'
p78908
aS'Boulle A'
p78909
aS'Wilkinson RJ'
p78910
aS'Meintjes G'
p78911
aS'Marais S'
p78912
asS'VI'
p78913
S'24'
p78914
sS'MHDA'
p78915
S'2011/05/07 06:00'
p78916
sS'OID'
p78917
(lp78918
S'NLM: NIHMS252693'
p78919
aS'NLM: PMC3077551'
p78920
asS'MH'
p78921
(lp78922
S'AIDS-Related Opportunistic Infections/*chemically induced/epidemiology/physiopathology'
p78923
aS'Adolescent'
p78924
aS'Adult'
p78925
aS'Aged'
p78926
aS'Antiretroviral Therapy, Highly Active'
p78927
aS'Benzoxazines/*adverse effects'
p78928
aS'CD4 Lymphocyte Count'
p78929
aS'Female'
p78930
aS'HIV Seropositivity/*drug therapy/epidemiology/physiopathology'
p78931
aS'Humans'
p78932
aS'Immune Reconstitution Inflammatory Syndrome/*chemically induced/epidemiology/physiopathology'
p78933
aS'Male'
p78934
aS'Middle Aged'
p78935
aS'Prospective Studies'
p78936
aS'South Africa/epidemiology'
p78937
aS'Young Adult'
p78938
asS'EDAT'
p78939
S'2010/11/04 06:00'
p78940
sS'SO'
p78941
S'AIDS. 2010 Nov 27;24(18):2871-6. doi: 10.1097/QAD.0b013e328340fe76.'
p78942
sS'SB'
p78943
S'IM X'
p78944
sS'PMID'
p78945
S'21045634'
p78946
sS'PST'
p78947
S'ppublish'
p78948
stRp78949
ag2
(g3
g4
(dp78950
S'LID'
p78951
S'10.3851/IMP1660 [doi]'
p78952
sS'STAT'
p78953
S'MEDLINE'
p78954
sS'AB'
p78955
S'BACKGROUND: HIV type-1 (HIV-1) drug resistance testing is rarely available in resource-limited settings because of high costs and stringent requirements for storage and transport of plasma. Dried blood spots (DBS) can be a convenient alternative to plasma, but the use of DBS needs validation under field conditions. We assessed the performance of DBS in genotypic resistance testing of patients who failed first-line antiretroviral therapy (ART) in rural Tanzania. METHODS: A total of 36 ART-experienced patients with viral loads >1,000 copies/ml (median 15,180 copies/ml [range 1,350-3,683,000]) and with various HIV-1 subtypes were selected for resistance testing. DBS were stored with desiccant at ambient temperature for a median of 29 days (range 8-89). Samples were amplified using an in-house reverse transcriptase-nested PCR method and sequenced using the ViroSeq assay (Abbott Molecular, Des Plaines, IL, USA). DBS-derived genotypes were compared with genotypes from plasma. RESULTS: Overall, 34 of 36 (94%) DBS specimens were successfully genotyped. In the protease region, of 142 polymorphisms found in plasma, 132 (93%) were also detected in DBS. In the reverse transcriptase region, of 57 clinically relevant mutations present in plasma, 51 (89%) were also detected in DBS. A total of 30 of 34 (88%) patients had identical resistance profiles to antiretroviral drugs in plasma and DBS. CONCLUSIONS: Genotyping was successful in the vast majority of DBS specimens stored at ambient temperature for up to 3 months, and there was high concordance between mutations found in DBS and plasma. Our study suggests that DBS can be a feasible and reliable tool to monitor HIV-1 drug resistance in patients on ART in resource-limited settings.'
p78956
sS'JID'
p78957
S'9815705'
p78958
sS'AD'
p78959
S'Department of Infectious Diseases, Oslo University Hospital, Ulleval, Oslo, Norway. asgeir.johannessen@medisin.uio.no'
p78960
sS'JT'
p78961
S'Antiviral therapy'
p78962
sS'IP'
p78963
S'7'
sS'IS'
p78964
S'2040-2058 (Electronic) 1359-6535 (Linking)'
p78965
sS'DCOM'
p78966
S'20110210'
p78967
sS'DA'
p78968
S'20101102'
p78969
sS'AU'
p78970
(lp78971
S'Johannessen A'
p78972
aS'Holberg-Petersen M'
p78973
aS'Lovgaarden G'
p78974
aS'Naman E'
p78975
aS'Ormaasen V'
p78976
aS'Matee MI'
p78977
aS'Gundersen SG'
p78978
aS'Bruun JN'
p78979
asS'AID'
p78980
(lp78981
S'10.3851/IMP1660 [doi]'
p78982
asS'CRDT'
p78983
(lp78984
S'2010/11/03 06:00'
p78985
asS'VI'
p78986
S'15'
p78987
sS'DP'
p78988
S'2010'
p78989
sS'MHDA'
p78990
S'2011/02/11 06:00'
p78991
sS'OWN'
p78992
S'NLM'
p78993
sS'PT'
p78994
(lp78995
S'Comparative Study'
p78996
aS'Journal Article'
p78997
aS"Research Support, Non-U.S. Gov't"
p78998
asS'LA'
p78999
(lp79000
S'eng'
p79001
asS'MH'
p79002
(lp79003
S'Adolescent'
p79004
aS'Adult'
p79005
aS'Aged'
p79006
aS'Antiretroviral Therapy, Highly Active'
p79007
aS'Blood/*virology'
p79008
aS'Child'
p79009
aS'Child, Preschool'
p79010
aS'*Drug Resistance, Multiple, Viral'
p79011
aS'Feasibility Studies'
p79012
aS'Female'
p79013
aS'Genotype'
p79014
aS'HIV Infections/blood'
p79015
aS'HIV-1/*drug effects/genetics/isolation & purification'
p79016
aS'Humans'
p79017
aS'Male'
p79018
aS'Middle Aged'
p79019
aS'Mutation'
p79020
aS'Plasma/*virology'
p79021
aS'Polymerase Chain Reaction'
p79022
aS'Rural Population'
p79023
aS'Specimen Handling/methods'
p79024
aS'Tanzania'
p79025
aS'Viral Load'
p79026
aS'Young Adult'
p79027
asS'FAU'
p79028
(lp79029
S'Johannessen, Asgeir'
p79030
aS'Holberg-Petersen, Mona'
p79031
aS'Lovgaarden, Gunilla'
p79032
aS'Naman, Ezra'
p79033
aS'Ormaasen, Vidar'
p79034
aS'Matee, Mecky I'
p79035
aS'Gundersen, Svein G'
p79036
aS'Bruun, Johan N'
p79037
asS'EDAT'
p79038
S'2010/11/03 06:00'
p79039
sS'PST'
p79040
S'ppublish'
p79041
sS'SO'
p79042
S'Antivir Ther. 2010;15(7):1003-9. doi: 10.3851/IMP1660.'
p79043
sS'PG'
p79044
S'1003-9'
p79045
sS'TI'
p79046
S'HIV type-1 drug resistance testing on dried blood spots is feasible and reliable in patients who fail antiretroviral therapy in rural Tanzania.'
p79047
sS'SB'
p79048
S'IM'
p79049
sS'PMID'
p79050
S'21041915'
p79051
sS'PL'
p79052
S'England'
p79053
sS'TA'
p79054
S'Antivir Ther'
p79055
stRp79056
ag2
(g3
g4
(dp79057
S'LID'
p79058
S'10.1097/QAD.0b013e32833ec5b2 [doi]'
p79059
sS'STAT'
p79060
S'MEDLINE'
p79061
sS'AB'
p79062
S'INTRODUCTION: The latest WHO guidelines recommend initiating antiretroviral therapy (ART) at CD4 cell counts less than 350 cells/mul. However, donors and national governments are reluctant to support implementation owing to uncertainty regarding feasibility and relative benefit. Lesotho has supported earlier initiation since 2008. We assessed outcomes comparing early (CD4 cell counts >200 cells/mul) and late (CD4 cell counts </=200 cells/mul) initiation. METHODS: We describe survival probability among patients initiating ART at CD4 cell counts 200 or less and more than 200 cells/mul and assess associations between baseline CD4 cell counts and mortality, morbidity, loss to follow-up and hospitalization using Cox regression adjusting for confounders identified a priori. RESULTS: Our analysis included 1177 patients; median age was 38 years and the majority (67%) were women. Median time on ART for the overall cohort was 506 days (interquartile range 396-608). Five hundred and thirty eight patients initiated ART at a CD4 cell count 200 cells/mul or less (interquartile range 54-160) and 639 patients initiated at CD4 cell count more than 200 cells/mul (interquartile range 238-321). In multivariate analysis, we found that patients initiating at CD4 cell count more than 200 cells/mul were 68% less likely to die (adjusted hazard ratio 0.32, 95% confidence interval 0.20-0.50), and 39% less likely to be lost to follow-up (adjusted hazard ratio 0.61, 95% confidence interval 0.43-0.87). Initiating ART at CD4 cell count more than 200 cells/mul was also associated with a 27% reduction in the rate of incident morbidity (adjusted hazard ratio 0.73, 95% confidence interval 0.65-0.82) and a 63% decreased rate of hospitalization (adjusted hazard ratio 0.37, 95% confidence interval 0.19-0.73). CONCLUSION: Earlier initiation is feasible in a low resource, high HIV prevalence setting, and provides important benefits in terms of reduced mortality, morbidity, retention and hospitalization. Donors should fully support the implementation of the latest WHO recommendations.'
p79063
sS'JID'
p79064
S'8710219'
p79065
sS'AD'
p79066
S'Medecins Sans Frontieres, University of Cape Town, South Africa. Nathan.ford@msf.org'
p79067
sS'JT'
p79068
S'AIDS (London, England)'
p79069
sS'IP'
p79070
S'17'
p79071
sS'IS'
p79072
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p79073
sS'DCOM'
p79074
S'20110325'
p79075
sS'DA'
p79076
S'20101028'
p79077
sS'AU'
p79078
(lp79079
S'Ford N'
p79080
aS'Kranzer K'
p79081
aS'Hilderbrand K'
p79082
aS'Jouquet G'
p79083
aS'Goemaere E'
p79084
aS'Vlahakis N'
p79085
aS'Trivino L'
p79086
aS'Makakole L'
p79087
aS'Bygrave H'
p79088
asS'AID'
p79089
(lp79090
S'10.1097/QAD.0b013e32833ec5b2 [doi]'
p79091
aS'00002030-201011130-00006 [pii]'
p79092
asS'CRDT'
p79093
(lp79094
S'2010/10/29 06:00'
p79095
asS'VI'
p79096
S'24'
p79097
sS'DP'
p79098
S'2010 Nov 13'
p79099
sS'MHDA'
p79100
S'2011/03/26 06:00'
p79101
sS'OWN'
p79102
S'NLM'
p79103
sS'PT'
p79104
(lp79105
S'Journal Article'
p79106
asS'LA'
p79107
(lp79108
S'eng'
p79109
asS'MH'
p79110
(lp79111
S'Adult'
p79112
aS'Antiretroviral Therapy, Highly Active/methods'
p79113
aS'CD4 Lymphocyte Count'
p79114
aS'Drug Administration Schedule'
p79115
aS'Female'
p79116
aS'HIV Infections/*drug therapy/immunology/mortality'
p79117
aS'Humans'
p79118
aS'Lesotho/epidemiology'
p79119
aS'Male'
p79120
aS'Middle Aged'
p79121
aS'Residence Characteristics'
p79122
aS'Viral Load'
p79123
asS'FAU'
p79124
(lp79125
S'Ford, Nathan'
p79126
aS'Kranzer, Katharina'
p79127
aS'Hilderbrand, Katherine'
p79128
aS'Jouquet, Guillaume'
p79129
aS'Goemaere, Eric'
p79130
aS'Vlahakis, Nathalie'
p79131
aS'Trivino, Laura'
p79132
aS'Makakole, Lipontso'
p79133
aS'Bygrave, Helen'
p79134
asS'EDAT'
p79135
S'2010/10/29 06:00'
p79136
sS'PST'
p79137
S'ppublish'
p79138
sS'SO'
p79139
S'AIDS. 2010 Nov 13;24(17):2645-50. doi: 10.1097/QAD.0b013e32833ec5b2.'
p79140
sS'PG'
p79141
S'2645-50'
p79142
sS'TI'
p79143
S'Early initiation of antiretroviral therapy and associated reduction in mortality, morbidity and defaulting in a nurse-managed, community cohort in Lesotho.'
p79144
sS'SB'
p79145
S'IM X'
p79146
sS'PMID'
p79147
S'20980868'
p79148
sS'PL'
p79149
S'England'
p79150
sS'TA'
p79151
S'AIDS'
p79152
stRp79153
ag2
(g3
g4
(dp79154
S'LID'
p79155
S'10.1371/journal.pone.0013414 [doi]'
p79156
sS'STAT'
p79157
S'MEDLINE'
p79158
sS'DEP'
p79159
S'20101015'
p79160
sS'DA'
p79161
S'20101026'
p79162
sS'AID'
p79163
(lp79164
S'10.1371/journal.pone.0013414 [doi]'
p79165
asS'CRDT'
p79166
(lp79167
S'2010/10/27 06:00'
p79168
asS'DP'
p79169
S'2010'
p79170
sS'AD'
p79171
S'Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, Tourcoing, France. armellepasquet@hotmail.com'
p79172
sS'OWN'
p79173
S'NLM'
p79174
sS'PT'
p79175
(lp79176
S'Journal Article'
p79177
aS'Research Support, N.I.H., Extramural'
p79178
aS"Research Support, Non-U.S. Gov't"
p79179
asS'LA'
p79180
(lp79181
S'eng'
p79182
asS'FAU'
p79183
(lp79184
S'Pasquet, Armelle'
p79185
aS'Messou, Eugene'
p79186
aS'Gabillard, Delphine'
p79187
aS'Minga, Albert'
p79188
aS'Depoulosky, Ayeby'
p79189
aS'Deuffic-Burban, Sylvie'
p79190
aS'Losina, Elena'
p79191
aS'Freedberg, Kenneth A'
p79192
aS'Danel, Christine'
p79193
aS'Anglaret, Xavier'
p79194
aS'Yazdanpanah, Yazdan'
p79195
asS'JT'
p79196
S'PloS one'
p79197
sS'LR'
p79198
S'20150205'
p79199
sS'PG'
p79200
S'e13414'
p79201
sS'TI'
p79202
S"Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Cote d'Ivoire."
p79203
sS'RN'
p79204
(lp79205
S'0 (Anti-HIV Agents)'
p79206
asS'PL'
p79207
S'United States'
p79208
sS'TA'
p79209
S'PLoS One'
p79210
sS'JID'
p79211
S'101285081'
p79212
sS'AB'
p79213
S"BACKGROUND: To evaluate the type and frequency of antiretroviral drug stock-outs, and their impact on death and interruption in care among HIV-infected patients in Abidjan, Cote d'Ivoire. METHODS AND FINDINGS: We conducted a cohort study of patients who initiated combination antiretroviral therapy (cART) in three adult HIV clinics between February 1, 2006 and June 1, 2007. Follow-up ended on February 1, 2008. The primary outcome was cART regimen modification, defined as at least one drug substitution, or discontinuation for at least one month due to drug stock-outs at the clinic pharmacy. The secondary outcome for patients who were on cART for at least six months was interruption in care, or death. A Cox regression model with time-dependent variables was used to assess the impact of antiretroviral drug stock-outs on interruption in care or death. Overall, 1,554 adults initiated cART and were followed for a mean of 13.2 months. During this time, 72 patients discontinued treatment and 98 modified their regimen because of drug stock-outs. Stock-outs involved nevirapine and fixed-dose combination zidovudine/lamivudine in 27% and 51% of cases. Of 1,554 patients, 839 (54%) initiated cART with fixed-dose stavudine/lamivudine/nevirapine and did not face stock-outs during the study period. Among the 975 patients who were on cART for at least six months, stock-out-related cART discontinuations increased the risk of interruption in care or death (adjusted hazard ratio [HR], 2.83; 95%CI, 1.25-6.44) but cART modifications did not (adjusted HR, 1.21; 95%CI, 0.46-3.16). CONCLUSIONS: cART stock-outs affected at least 11% of population on treatment. Treatment discontinuations due to stock-outs were frequent and doubled the risk of interruption in care or death. These stock-outs did not involve the most common first-line regimen. As access to cART continues to increase in sub-Saharan Africa, first-line regimens should be standardized to decrease the probability of drug stock-outs."
p79214
sS'GR'
p79215
(lp79216
S'K24 AI062476/AI/NIAID NIH HHS/United States'
p79217
aS'K24 AI062476/AI/NIAID NIH HHS/United States'
p79218
aS'R01 AI058736/AI/NIAID NIH HHS/United States'
p79219
aS'R01 AI058736/AI/NIAID NIH HHS/United States'
p79220
asS'IP'
p79221
S'10'
p79222
sS'IS'
p79223
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p79224
sS'PMC'
p79225
S'PMC2955519'
p79226
sS'DCOM'
p79227
S'20110307'
p79228
sS'AU'
p79229
(lp79230
S'Pasquet A'
p79231
aS'Messou E'
p79232
aS'Gabillard D'
p79233
aS'Minga A'
p79234
aS'Depoulosky A'
p79235
aS'Deuffic-Burban S'
p79236
aS'Losina E'
p79237
aS'Freedberg KA'
p79238
aS'Danel C'
p79239
aS'Anglaret X'
p79240
aS'Yazdanpanah Y'
p79241
asS'VI'
p79242
S'5'
sS'MHDA'
p79243
S'2011/03/08 06:00'
p79244
sS'PHST'
p79245
(lp79246
S'2010/06/13 [received]'
p79247
aS'2010/09/04 [accepted]'
p79248
aS'2010/10/15 [epublish]'
p79249
asS'OID'
p79250
(lp79251
S'NLM: PMC2955519'
p79252
asS'MH'
p79253
(lp79254
S'Adult'
p79255
aS'Anti-HIV Agents/*supply & distribution/therapeutic use'
p79256
aS"Cote d'Ivoire/epidemiology"
p79257
aS'HIV Infections/*drug therapy/mortality'
p79258
aS'Humans'
p79259
aS'Proportional Hazards Models'
p79260
asS'EDAT'
p79261
S'2010/10/27 06:00'
p79262
sS'SO'
p79263
S'PLoS One. 2010 Oct 15;5(10):e13414. doi: 10.1371/journal.pone.0013414.'
p79264
sS'SB'
p79265
S'IM'
p79266
sS'PMID'
p79267
S'20976211'
p79268
sS'PST'
p79269
S'epublish'
p79270
stRp79271
ag2
(g3
g4
(dp79272
S'LID'
p79273
S'10.1089/aid.2010.0113 [doi]'
p79274
sS'STAT'
p79275
S'MEDLINE'
p79276
sS'DEP'
p79277
S'20101018'
p79278
sS'DA'
p79279
S'20110404'
p79280
sS'AID'
p79281
(lp79282
S'10.1089/aid.2010.0113 [doi]'
p79283
asS'CRDT'
p79284
(lp79285
S'2010/10/20 06:00'
p79286
asS'DP'
p79287
S'2011 Apr'
p79288
sS'OWN'
p79289
S'NLM'
p79290
sS'PT'
p79291
(lp79292
S'Journal Article'
p79293
aS"Research Support, Non-U.S. Gov't"
p79294
asS'LA'
p79295
(lp79296
S'eng'
p79297
asS'FAU'
p79298
(lp79299
S'Mosha, F'
p79300
aS'Urassa, W'
p79301
aS'Aboud, S'
p79302
aS'Lyamuya, E'
p79303
aS'Sandstrom, E'
p79304
aS'Bredell, H'
p79305
aS'Williamson, C'
p79306
asS'JT'
p79307
S'AIDS research and human retroviruses'
p79308
sS'PG'
p79309
S'377-82'
p79310
sS'TI'
p79311
S'Prevalence of genotypic resistance to antiretroviral drugs in treatment-naive youths infected with diverse HIV type 1 subtypes and recombinant forms in Dar es Salaam, Tanzania.'
p79312
sS'RN'
p79313
(lp79314
S'0 (Anti-Retroviral Agents)'
p79315
asS'PL'
p79316
S'United States'
p79317
sS'TA'
p79318
S'AIDS Res Hum Retroviruses'
p79319
sS'JID'
p79320
S'8709376'
p79321
sS'AB'
p79322
S'As human immunodeficiency virus (HIV) diversity may have an impact on both vaccine efficacy and drug resistance, it is important to have knowledge of circulating genetic variants. With widespread use of antiretroviral (ARV) drugs in Africa, one of the major potential challenges is the risk of emergence of ARV drug-resistant HIV strains. This study aimed to determine the circulating HIV subtypes and recombinant forms, as well as the prevalence of ARV drug resistance mutations, among 75 treatment-naive HIV-infected youths in Dar es Salaam, Tanzania. Gag (n = 48), partial pol (n = 44), and partial env (n = 35) sequencing was performed; all three regions were sequenced in 26 samples. Evidence of infection with recombinant viruses was found in 12 (46%) participants; AC recombinants were the most commonly detected and they were identified in six (23%) participants. Of individuals infected with nonrecombinant strains, subtype A was most commonly detected in seven (27%) participants, followed by subtype C detected in six (23%) participants and subtype D detected in one (4%) participant. Among the pol sequences from 44 individuals, three (7%) had resistance to nucleoside reverse transcriptase (RT) inhibitors and four (9%) had nonnucleoside RT inhibitor resistance mutations. Of these, three (7%) individuals were infected with viruses with cross-resistance mutations to both classes of RT inhibitors. These resistant mutations were all associated with drugs currently used in first-line therapy and in the prevention of vertical transmission. This high prevalence of resistance mutations is of considerable concern in apparently drug-naive populations as it may result in treatment failure and the spread of ARV-resistant strains.'
p79323
sS'AD'
p79324
S'Field Epidemiology and Laboratory Training Programme, Ministry of Health and Social Welfare , Dar es Salaam, Tanzania.'
p79325
sS'IP'
p79326
S'4'
sS'IS'
p79327
S'1931-8405 (Electronic) 0889-2229 (Linking)'
p79328
sS'DCOM'
p79329
S'20110718'
p79330
sS'AU'
p79331
(lp79332
S'Mosha F'
p79333
aS'Urassa W'
p79334
aS'Aboud S'
p79335
aS'Lyamuya E'
p79336
aS'Sandstrom E'
p79337
aS'Bredell H'
p79338
aS'Williamson C'
p79339
asS'VI'
p79340
S'27'
p79341
sS'MHDA'
p79342
S'2011/07/19 06:00'
p79343
sS'PHST'
p79344
(lp79345
S'2010/10/18 [aheadofprint]'
p79346
asS'MH'
p79347
(lp79348
S'Adolescent'
p79349
aS'Adult'
p79350
aS'Anti-Retroviral Agents/*pharmacology'
p79351
aS'*Drug Resistance, Viral'
p79352
aS'Female'
p79353
aS'Genetic Variation'
p79354
aS'Genotype'
p79355
aS'HIV/*drug effects/*genetics/isolation & purification'
p79356
aS'HIV Infections/*epidemiology/*virology'
p79357
aS'Humans'
p79358
aS'Male'
p79359
aS'Mutation, Missense'
p79360
aS'Prevalence'
p79361
aS'Recombination, Genetic'
p79362
aS'Tanzania/epidemiology'
p79363
aS'Young Adult'
p79364
asS'EDAT'
p79365
S'2010/10/20 06:00'
p79366
sS'SO'
p79367
S'AIDS Res Hum Retroviruses. 2011 Apr;27(4):377-82. doi: 10.1089/aid.2010.0113. Epub 2010 Oct 18.'
p79368
sS'SB'
p79369
S'IM X'
p79370
sS'PMID'
p79371
S'20954839'
p79372
sS'PST'
p79373
S'ppublish'
p79374
stRp79375
ag2
(g3
g4
(dp79376
S'LID'
p79377
S'10.1086/656718 [doi]'
p79378
sS'STAT'
p79379
S'MEDLINE'
p79380
sS'DEP'
p79381
S'20101013'
p79382
sS'CIN'
p79383
(lp79384
S'J Infect Dis. 2010 Nov 15;202(10):1467-9. PMID: 20942649'
p79385
asS'DA'
p79386
S'20101019'
p79387
sS'AID'
p79388
(lp79389
S'10.1086/656718 [doi]'
p79390
asS'CRDT'
p79391
(lp79392
S'2010/10/15 06:00'
p79393
asS'DP'
p79394
S'2010 Nov 15'
p79395
sS'CN'
p79396
(lp79397
S'Phidisa II Writing Team for Project Phidisa'
p79398
asS'OWN'
p79399
S'NLM'
p79400
sS'PT'
p79401
(lp79402
S'Journal Article'
p79403
aS'Randomized Controlled Trial'
p79404
aS'Research Support, N.I.H., Extramural'
p79405
aS"Research Support, U.S. Gov't, Non-P.H.S."
p79406
asS'LA'
p79407
(lp79408
S'eng'
p79409
asS'FAU'
p79410
(lp79411
S'Ratsela, Andrew'
p79412
aS'Polis, Michael'
p79413
aS'Dhlomo, Sibongiseni'
p79414
aS'Emery, Sean'
p79415
aS'Grandits, Greg'
p79416
aS'Khabo, Paul'
p79417
aS'Khanyile, Thandeka'
p79418
aS'Komati, Stephanus'
p79419
aS'Neaton, James D'
p79420
aS'Naidoo, Lionel Chris David'
p79421
aS'Magongoa, Daphne'
p79422
aS'Qolohle, Duma'
p79423
asS'JT'
p79424
S'The Journal of infectious diseases'
p79425
sS'LR'
p79426
S'20160622'
p79427
sS'PG'
p79428
S'1529-37'
p79429
sS'TI'
p79430
S'A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/muL in South Africa.'
p79431
sS'RN'
p79432
(lp79433
S'0 (Anti-HIV Agents)'
p79434
aS'0 (Benzoxazines)'
p79435
aS'0 (Pyrimidinones)'
p79436
aS'0 (RNA, Viral)'
p79437
aS'2494G1JF75 (Lopinavir)'
p79438
aS'2T8Q726O95 (Lamivudine)'
p79439
aS'4B9XT59T7S (Zidovudine)'
p79440
aS'BO9LE4QFZF (Stavudine)'
p79441
aS'JE6H2O27P8 (efavirenz)'
p79442
aS'K3GDH6OH08 (Didanosine)'
p79443
aS'O3J8G9O825 (Ritonavir)'
p79444
asS'PL'
p79445
S'United States'
p79446
sS'TA'
p79447
S'J Infect Dis'
p79448
sS'FIR'
p79449
(lp79450
S'Brodine, S'
p79451
aS'Lane, H C'
p79452
aS'Motumi, N'
p79453
aS'Radebe, M'
p79454
aS'Jamuna, A'
p79455
aS'Oelofse, P J'
p79456
aS'Ngqakayi, S'
p79457
aS'Siwisa, L'
p79458
aS'Swanapoel, S'
p79459
aS'Levin, J'
p79460
aS'Rida, W N'
p79461
aS'Morodi, T'
p79462
aS'Leeuw, Y'
p79463
aS'Hassim, S'
p79464
aS'Malan, L'
p79465
aS'Somarro, H'
p79466
aS'Mokhathi, T'
p79467
aS'Mokwena, N'
p79468
aS'Coangae, N'
p79469
aS'Khanyile, T'
p79470
aS'Yokwana, Z'
p79471
aS'Mabindla, B'
p79472
aS'Manqola, G'
p79473
aS'Maluleke, M'
p79474
aS'Tseka, T'
p79475
aS'Dlamini, J'
p79476
aS'Ledwaba, L'
p79477
aS'Maja, P'
p79478
aS'Marumo, M'
p79479
aS'Matchaba, U'
p79480
aS'Mthethwa, J'
p79481
aS'Sangweni, P'
p79482
aS'Baseler, B'
p79483
aS'Eckes, R'
p79484
aS'Masur, H'
p79485
aS'Grace, B'
p79486
aS'Morgan, G'
p79487
aS'McNay, L'
p79488
aS'Metcalf, J'
p79489
aS'Orsega, S'
p79490
aS'Pau, A'
p79491
aS'Tavel, J'
p79492
aS'Zuckerman, J'
p79493
aS'Simpson, S'
p79494
aS'Highbarger, H'
p79495
aS'Dewar, R'
p79496
asS'JID'
p79497
S'0413675'
p79498
sS'AB'
p79499
S'BACKGROUND: Few randomized trials comparing antiretroviral therapy (ART) regimens have been conducted in resource-limited settings. METHODS: In the Republic of South Africa, antiretroviral-naive human immunodeficiency virus (HIV)-infected individuals >14 years old with a CD4 cell count <200 cells/muL or a prior AIDS diagnosis were randomized to receive efavirenz (EFV) or lopinavir/ritonavir (LPV/r) with either zidovudine (ZDV) plus didanosine (ddI) or stavudine (d4T) plus lamivudine (3TC) in an open-label, 2-by-2 factorial study and followed up for the primary outcome of AIDS or death and prespecified secondary outcomes, including CD4 cell count and viral load changes, treatment discontinuation, and grade 4 events. RESULTS: In total, 1771 persons were randomized and followed up for a median of 24.7 months. AIDS or death occurred in (1) 163 participants assigned EFV and 157 assigned LPV/r (hazard ratio [HR], 1.04 [95% confidence interval {CI}, 0.84-1.30]) and in (2) 170 participants assigned ZDV+ddI and 150 assigned d4T+3TC (HR, 1.15 [95% CI, 0.93-1.44]). HIV RNA levels were lower (P < .001) and CD4 cell counts were greater (P < .01) over follow-up for d4T+3TC versus ZDV+ddI. Rates of potentially life-threatening adverse events and overall treatment discontinuation were similar for d4T+3TC and ZDV+ddI; however, more participants discontinued d4T because of toxicity (12.6%) than other treatments (<5%). CONCLUSION: EFV and LPV/r are effective components of first-line ART. The poorer viral and immune responses with ZDV+ddI and the greater toxicity-associated discontinuation rate with d4T+3TC suggest that these treatments be used cautiously as initial therapy. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00342355.'
p79500
sS'GR'
p79501
(lp79502
S'Z99 AI999999/Intramural NIH HHS/United States'
p79503
aS'ZID AI009004-01/Intramural NIH HHS/United States'
p79504
asS'IP'
p79505
S'10'
p79506
sS'IS'
p79507
S'1537-6613 (Electronic) 0022-1899 (Linking)'
p79508
sS'IR'
p79509
(lp79510
S'Brodine S'
p79511
aS'Lane HC'
p79512
aS'Motumi N'
p79513
aS'Radebe M'
p79514
aS'Jamuna A'
p79515
aS'Oelofse PJ'
p79516
aS'Ngqakayi S'
p79517
aS'Siwisa L'
p79518
aS'Swanapoel S'
p79519
aS'Levin J'
p79520
aS'Rida WN'
p79521
aS'Morodi T'
p79522
aS'Leeuw Y'
p79523
aS'Hassim S'
p79524
aS'Malan L'
p79525
aS'Somarro H'
p79526
aS'Mokhathi T'
p79527
aS'Mokwena N'
p79528
aS'Coangae N'
p79529
aS'Khanyile T'
p79530
aS'Yokwana Z'
p79531
aS'Mabindla B'
p79532
aS'Manqola G'
p79533
aS'Maluleke M'
p79534
aS'Tseka T'
p79535
aS'Dlamini J'
p79536
aS'Ledwaba L'
p79537
aS'Maja P'
p79538
aS'Marumo M'
p79539
aS'Matchaba U'
p79540
aS'Mthethwa J'
p79541
aS'Sangweni P'
p79542
aS'Baseler B'
p79543
aS'Eckes R'
p79544
aS'Masur H'
p79545
aS'Grace B'
p79546
aS'Morgan G'
p79547
aS'McNay L'
p79548
aS'Metcalf J'
p79549
aS'Orsega S'
p79550
aS'Pau A'
p79551
aS'Tavel J'
p79552
aS'Zuckerman J'
p79553
aS'Simpson S'
p79554
aS'Highbarger H'
p79555
aS'Dewar R'
p79556
asS'DCOM'
p79557
S'20101122'
p79558
sS'MID'
p79559
(lp79560
S'NIHMS228914'
p79561
asS'AU'
p79562
(lp79563
S'Ratsela A'
p79564
aS'Polis M'
p79565
aS'Dhlomo S'
p79566
aS'Emery S'
p79567
aS'Grandits G'
p79568
aS'Khabo P'
p79569
aS'Khanyile T'
p79570
aS'Komati S'
p79571
aS'Neaton JD'
p79572
aS'Naidoo LC'
p79573
aS'Magongoa D'
p79574
aS'Qolohle D'
p79575
asS'VI'
p79576
S'202'
p79577
sS'MHDA'
p79578
S'2010/12/14 06:00'
p79579
sS'PHST'
p79580
(lp79581
S'2010/10/13 [aheadofprint]'
p79582
asS'OID'
p79583
(lp79584
S'NLM: NIHMS228914'
p79585
aS'NLM: PMC3008165'
p79586
asS'MH'
p79587
(lp79588
S'Acquired Immunodeficiency Syndrome/complications/*drug therapy/immunology/virology'
p79589
aS'Adult'
p79590
aS'Anti-HIV Agents/adverse effects/*therapeutic use'
p79591
aS'Benzoxazines/*therapeutic use'
p79592
aS'CD4 Lymphocyte Count'
p79593
aS'Didanosine/adverse effects/*therapeutic use'
p79594
aS'Drug Therapy, Combination'
p79595
aS'Female'
p79596
aS'HIV/genetics'
p79597
aS'Humans'
p79598
aS'Lamivudine/adverse effects/*therapeutic use'
p79599
aS'Lopinavir'
p79600
aS'Male'
p79601
aS'Pyrimidinones/*therapeutic use'
p79602
aS'RNA, Viral/blood'
p79603
aS'Ritonavir/*therapeutic use'
p79604
aS'South Africa'
p79605
aS'Stavudine/adverse effects/*therapeutic use'
p79606
aS'Treatment Outcome'
p79607
aS'Zidovudine/adverse effects/*therapeutic use'
p79608
asS'EDAT'
p79609
S'2010/10/15 06:00'
p79610
sS'PMC'
p79611
S'PMC3008165'
p79612
sS'SI'
p79613
(lp79614
S'ClinicalTrials.gov/NCT00342355'
p79615
asS'SO'
p79616
S'J Infect Dis. 2010 Nov 15;202(10):1529-37. doi: 10.1086/656718. Epub 2010 Oct 13.'
p79617
sS'SB'
p79618
S'AIM IM'
p79619
sS'PMID'
p79620
S'20942650'
p79621
sS'PST'
p79622
S'ppublish'
p79623
stRp79624
ag2
(g3
g4
(dp79625
S'LID'
p79626
S'10.2471/BLT.09.063982 [doi]'
p79627
sS'STAT'
p79628
S'MEDLINE'
p79629
sS'DEP'
p79630
S'20100903'
p79631
sS'DA'
p79632
S'20101008'
p79633
sS'AID'
p79634
(lp79635
S'10.2471/BLT.09.063982 [doi]'
p79636
asS'CRDT'
p79637
(lp79638
S'2010/10/09 06:00'
p79639
asS'DP'
p79640
S'2010 Oct 1'
p79641
sS'OWN'
p79642
S'NLM'
p79643
sS'PT'
p79644
(lp79645
S'Journal Article'
p79646
aS"Research Support, Non-U.S. Gov't"
p79647
asS'LA'
p79648
(lp79649
S'eng'
p79650
asS'FAU'
p79651
(lp79652
S'Dube, Christopher'
p79653
aS'Nozaki, Ikuma'
p79654
aS'Hayakawa, Tadao'
p79655
aS'Kakimoto, Kazuhiro'
p79656
aS'Yamada, Norio'
p79657
aS'Simpungwe, James B'
p79658
asS'JT'
p79659
S'Bulletin of the World Health Organization'
p79660
sS'LR'
p79661
S'20141202'
p79662
sS'PG'
p79663
S'788-91'
p79664
sS'TI'
p79665
S'Expansion of antiretroviral treatment to rural health centre level by a mobile service in Mumbwa district, Zambia.'
p79666
sS'RN'
p79667
(lp79668
S'0 (Anti-HIV Agents)'
p79669
asS'PL'
p79670
S'Switzerland'
p79671
sS'TA'
p79672
S'Bull World Health Organ'
p79673
sS'JID'
p79674
S'7507052'
p79675
sS'AB'
p79676
S'PROBLEM: Despite the Government\'s effort to expand services to district level, it is still hard for people living with HIV to access antiretroviral treatment (ART) in rural Zambia. Strong demands for expanding ART services at the rural health centre level face challenges of resource shortages. APPROACH: The Mumbwa district health management team introduced mobile ART services using human resources and technical support from district hospitals, and community involvement at four rural health centres in the first quarter of 2007. This paper discusses the uptake of the mobile ART services in rural Mumbwa. LOCAL SETTING: Mumbwa is a rural district with an area of 23 000 km(2) and a population of 167 000. Before the introduction of mobile services, ART services were provided only at Mumbwa District Hospital. RELEVANT CHANGES: The mobile services improved accessibility to ART, especially for clients in better functional status, i.e. still able to work. In addition, these mobile services may reduce the number of cases "lost to follow-up". This might be due to the closer involvement of the community and the better support offered by these services to rural clients. LESSONS LEARNT: These mobile ART services helped expand services to rural health facilities where resources are limited, bringing them as close as possible to where clients live.'
p79677
sS'AD'
p79678
S'Mumbwa District Health Office, Mumbwa, Zambia.'
p79679
sS'IP'
p79680
S'10'
p79681
sS'IS'
p79682
S'1564-0604 (Electronic) 0042-9686 (Linking)'
p79683
sS'PMC'
p79684
S'PMC2947034'
p79685
sS'DCOM'
p79686
S'20110217'
p79687
sS'AU'
p79688
(lp79689
S'Dube C'
p79690
aS'Nozaki I'
p79691
aS'Hayakawa T'
p79692
aS'Kakimoto K'
p79693
aS'Yamada N'
p79694
aS'Simpungwe JB'
p79695
asS'VI'
p79696
S'88'
p79697
sS'MHDA'
p79698
S'2011/02/18 06:00'
p79699
sS'PHST'
p79700
(lp79701
S'2009/02/09 [received]'
p79702
aS'2010/01/14 [revised]'
p79703
aS'2010/02/24 [accepted]'
p79704
aS'2010/09/03 [epublish]'
p79705
asS'OID'
p79706
(lp79707
S'NLM: PMC2947034'
p79708
asS'MH'
p79709
(lp79710
S'Adult'
p79711
aS'Anti-HIV Agents/*therapeutic use'
p79712
aS'Female'
p79713
aS'HIV Infections/*drug therapy'
p79714
aS'Health Services Accessibility'
p79715
aS'Health Services Needs and Demand'
p79716
aS'Health Status Disparities'
p79717
aS'Humans'
p79718
aS'Male'
p79719
aS'Mobile Health Units/*organization & administration'
p79720
aS'Rural Health Services/*organization & administration'
p79721
aS'Zambia'
p79722
asS'EDAT'
p79723
S'2010/10/12 06:00'
p79724
sS'SO'
p79725
S'Bull World Health Organ. 2010 Oct 1;88(10):788-91. doi: 10.2471/BLT.09.063982. Epub 2010 Sep 3.'
p79726
sS'SB'
p79727
S'IM'
p79728
sS'PMID'
p79729
S'20931065'
p79730
sS'PST'
p79731
S'ppublish'
p79732
stRp79733
ag2
(g3
g4
(dp79734
S'LID'
p79735
S'10.1136/thx.2010.134767 [doi]'
p79736
sS'STAT'
p79737
S'MEDLINE'
p79738
sS'DEP'
p79739
S'20101001'
p79740
sS'CIN'
p79741
(lp79742
S'Thorax. 2010 Dec;65(12):1036-8. PMID: 20965924'
p79743
asS'DA'
p79744
S'20101122'
p79745
sS'AID'
p79746
(lp79747
S'thx.2010.134767 [pii]'
p79748
aS'10.1136/thx.2010.134767 [doi]'
p79749
asS'CRDT'
p79750
(lp79751
S'2010/10/05 06:00'
p79752
asS'DP'
p79753
S'2010 Dec'
p79754
sS'OWN'
p79755
S'NLM'
p79756
sS'PT'
p79757
(lp79758
S'Journal Article'
p79759
aS"Research Support, Non-U.S. Gov't"
p79760
asS'LA'
p79761
(lp79762
S'eng'
p79763
asS'FAU'
p79764
(lp79765
S'Jeremiah, Kidola'
p79766
aS'Praygod, George'
p79767
aS'Faurholt-Jepsen, Daniel'
p79768
aS'Range, Nyagosya'
p79769
aS'Andersen, Aase B'
p79770
aS'Grewal, Harleen M S'
p79771
aS'Friis, Henrik'
p79772
asS'JT'
p79773
S'Thorax'
p79774
sS'PG'
p79775
S'1072-6'
p79776
sS'TI'
p79777
S'BCG vaccination status may predict sputum conversion in patients with pulmonary tuberculosis: a new consideration for an old vaccine?'
p79778
sS'RN'
p79779
(lp79780
S'0 (Adjuvants, Immunologic)'
p79781
aS'0 (BCG Vaccine)'
p79782
asS'PL'
p79783
S'England'
p79784
sS'TA'
p79785
S'Thorax'
p79786
sS'JID'
p79787
S'0417353'
p79788
sS'AB'
p79789
S'BACKGROUND: Failure to convert (persistent sputum and/or culture positivity) while on antituberculosis (anti-TB) treatment at the end of the second month of anti-TB therapy has been reported to be a predictor of treatment failure. Factors that could be associated with persistent bacillary positivity at the end of the second month after initiation of anti-TB treatment were assessed. METHODS: A prospective cohort study was conducted in 754 patients with sputum culture positive pulmonary TB in Mwanza, Tanzania. Information on social demographic characteristics, anthropometric measurements, BCG scar status, HIV status, CD4+ count, white blood cell count, haemoglobin and sputum culture status was obtained. RESULTS: Factors associated with sputum culture non-conversion at the end of the second month of anti-TB treatment were initial acid-fast bacilli (AFB) culture grading of 3+ (OR 5.70, 95% CI 1.34 to 24.31, p=0.02) and absence of a BCG scar (OR 3.35, 95% CI 1.48 to 7.58, p=0.004). CONCLUSION: Patients with pulmonary TB with no BCG scar and high initial AFB sputum intensity are at risk of remaining sputum culture positive at the end of the second month of anti-TB treatment. These findings reflect a beneficial role for BCG vaccination on sputum conversion which should also be examined in large studies in other areas. The finding of a beneficial role for BCG vaccination on the treatment of pulmonary TB is important for TB control and vaccination programmes.'
p79790
sS'AD'
p79791
S'The Gade Institute, Section for Microbiology and Immunology, University of Bergen, Department of Microbiology and Immunology, Haukeland University Hospital, Norway .'
p79792
sS'IP'
p79793
S'12'
p79794
sS'IS'
p79795
S'1468-3296 (Electronic) 0040-6376 (Linking)'
p79796
sS'DCOM'
p79797
S'20110111'
p79798
sS'AU'
p79799
(lp79800
S'Jeremiah K'
p79801
aS'Praygod G'
p79802
aS'Faurholt-Jepsen D'
p79803
aS'Range N'
p79804
aS'Andersen AB'
p79805
aS'Grewal HM'
p79806
aS'Friis H'
p79807
asS'VI'
p79808
S'65'
p79809
sS'MHDA'
p79810
S'2011/01/12 06:00'
p79811
sS'PHST'
p79812
(lp79813
S'2010/10/01 [aheadofprint]'
p79814
asS'MH'
p79815
(lp79816
S'*Adjuvants, Immunologic'
p79817
aS'Adolescent'
p79818
aS'Adult'
p79819
aS'Age Distribution'
p79820
aS'*BCG Vaccine'
p79821
aS'CD4 Lymphocyte Count'
p79822
aS'Cicatrix'
p79823
aS'Drug Resistance, Bacterial'
p79824
aS'Female'
p79825
aS'HIV/isolation & purification'
p79826
aS'Humans'
p79827
aS'Male'
p79828
aS'Middle Aged'
p79829
aS'Mycobacterium tuberculosis/*isolation & purification'
p79830
aS'Prospective Studies'
p79831
aS'Sex Distribution'
p79832
aS'Sputum/*microbiology'
p79833
aS'Tuberculosis, Pulmonary/drug therapy/*microbiology/prevention & control'
p79834
aS'Young Adult'
p79835
asS'EDAT'
p79836
S'2010/10/05 06:00'
p79837
sS'SO'
p79838
S'Thorax. 2010 Dec;65(12):1072-6. doi: 10.1136/thx.2010.134767. Epub 2010 Oct 1.'
p79839
sS'SB'
p79840
S'IM'
p79841
sS'PMID'
p79842
S'20889521'
p79843
sS'PST'
p79844
S'ppublish'
p79845
stRp79846
ag2
(g3
g4
(dp79847
S'LID'
p79848
S'10.1016/j.trstmh.2010.08.015 [doi]'
p79849
sS'STAT'
p79850
S'MEDLINE'
p79851
sS'JT'
p79852
S'Transactions of the Royal Society of Tropical Medicine and Hygiene'
p79853
sS'CI'
p79854
(lp79855
S'Copyright (c) 2010 Royal Society of Tropical Medicine and Hygiene. Published by'
p79856
aS'Elsevier Ltd. All rights reserved.'
p79857
asS'DA'
p79858
S'20101203'
p79859
sS'AID'
p79860
(lp79861
S'S0035-9203(10)00201-4 [pii]'
p79862
aS'10.1016/j.trstmh.2010.08.015 [doi]'
p79863
asS'CRDT'
p79864
(lp79865
S'2010/10/05 06:00'
p79866
asS'DP'
p79867
S'2011 Jan'
p79868
sS'OWN'
p79869
S'NLM'
p79870
sS'PT'
p79871
(lp79872
S'Journal Article'
p79873
asS'LA'
p79874
(lp79875
S'eng'
p79876
asS'FAU'
p79877
(lp79878
S'Kizito, Kibango Walter'
p79879
aS'Dunkley, Sophie'
p79880
aS'Kingori, Magdalene'
p79881
aS'Reid, Tony'
p79882
asS'PG'
p79883
S'52-7'
p79884
sS'TI'
p79885
S'Lost to follow up from tuberculosis treatment in an urban informal settlement (Kibera), Nairobi, Kenya: what are the rates and determinants?'
p79886
sS'PL'
p79887
S'England'
p79888
sS'TA'
p79889
S'Trans R Soc Trop Med Hyg'
p79890
sS'JID'
p79891
S'7506129'
p79892
sS'AB'
p79893
S"Patients lost to follow up (LTFU) from treatment are a major concern for tuberculosis (TB) programmes. It is even more challenging in programmes in urban informal settlements (slums) with large, highly mobile, impoverished populations. Kibera, on the outskirts of Nairobi, Kenya is such a community with an estimated population of 500,000 to 700,000. Medecins Sans Frontieres (MSF), in collaboration with the Kenyan Ministry of Public Health and Sanitation (MPHS), operate three clinics providing integrated TB, HIV and primary health care. We undertook a retrospective study between July 2006 and December 2008 to determine the rate of LTFU from the TB programme in Kibera and to assess associated clinical and socio-demographic factors. Thanks to an innovative 'Defaulter Tracing Programme', patients who missed their appointments were routinely traced and encouraged to return for treatment. Where possible, reasons for missed appointments were recorded. LTFU occurred in 146 (13%) of the 1094 patients registered, with male gender, no salaried employment, lack of family support and positive TB smear at diagnosis found to be significant associations (P value </= 0.05). The most commonly cited reasons for LTFU were relocation from Kibera to 'up-country' rural homes and work commitments."
p79894
sS'AD'
p79895
S'Medecins Sans Frontieres - Operational Centre Belgium, Kenya Mission, Kileleshwa, Nairobi, Kenya. kwalta@gmail.com'
p79896
sS'IP'
p79897
S'1'
sS'IS'
p79898
S'1878-3503 (Electronic) 0035-9203 (Linking)'
p79899
sS'DCOM'
p79900
S'20110411'
p79901
sS'AU'
p79902
(lp79903
S'Kizito KW'
p79904
aS'Dunkley S'
p79905
aS'Kingori M'
p79906
aS'Reid T'
p79907
asS'VI'
p79908
S'105'
p79909
sS'MHDA'
p79910
S'2011/04/13 06:00'
p79911
sS'PHST'
p79912
(lp79913
S'2010/04/02 [received]'
p79914
aS'2010/08/25 [revised]'
p79915
aS'2010/08/25 [accepted]'
p79916
asS'MH'
p79917
(lp79918
S'Adult'
p79919
aS'Female'
p79920
aS'Humans'
p79921
aS'Kenya/epidemiology'
p79922
aS'*Lost to Follow-Up'
p79923
aS'Male'
p79924
aS'Medication Adherence/*statistics & numerical data'
p79925
aS'Retrospective Studies'
p79926
aS'Sentinel Surveillance'
p79927
aS'Tuberculosis/drug therapy/*epidemiology'
p79928
aS'Urban Health'
p79929
asS'EDAT'
p79930
S'2010/10/05 06:00'
p79931
sS'SO'
p79932
S'Trans R Soc Trop Med Hyg. 2011 Jan;105(1):52-7. doi: 10.1016/j.trstmh.2010.08.015.'
p79933
sS'SB'
p79934
S'IM'
p79935
sS'PMID'
p79936
S'20889176'
p79937
sS'PST'
p79938
S'ppublish'
p79939
stRp79940
ag2
(g3
g4
(dp79941
S'LID'
p79942
S'10.1097/QAD.0b013e32833ff58c [doi]'
p79943
sS'STAT'
p79944
S'MEDLINE'
p79945
sS'JT'
p79946
S'AIDS (London, England)'
p79947
sS'DA'
p79948
S'20101110'
p79949
sS'AID'
p79950
(lp79951
S'10.1097/QAD.0b013e32833ff58c [doi]'
p79952
asS'CRDT'
p79953
(lp79954
S'2010/10/02 06:00'
p79955
asS'DP'
p79956
S'2010 Nov 27'
p79957
sS'OWN'
p79958
S'NLM'
p79959
sS'PT'
p79960
(lp79961
S'Journal Article'
p79962
aS"Research Support, Non-U.S. Gov't"
p79963
aS"Research Support, U.S. Gov't, Non-P.H.S."
p79964
asS'LA'
p79965
(lp79966
S'eng'
p79967
asS'FAU'
p79968
(lp79969
S'Marazzi, Maria C'
p79970
aS'Liotta, Giuseppe'
p79971
aS'Nielsen-Saines, Karin'
p79972
aS'Haswell, Jere'
p79973
aS'Magid, Nurja A'
p79974
aS'Buonomo, Ersilia'
p79975
aS'Scarcella, Paola'
p79976
aS'Doro Altan, Anna M'
p79977
aS'Mancinelli, Sandro'
p79978
aS'Palombi, Leonardo'
p79979
asS'LR'
p79980
S'20131121'
p79981
sS'PG'
p79982
S'2819-26'
p79983
sS'TI'
p79984
S'Extended antenatal antiretroviral use correlates with improved infant outcomes throughout the first year of life.'
p79985
sS'RN'
p79986
(lp79987
S'99DK7FVK1H (Nevirapine)'
p79988
asS'PL'
p79989
S'England'
p79990
sS'TA'
p79991
S'AIDS'
p79992
sS'JID'
p79993
S'8710219'
p79994
sS'AB'
p79995
S'OBJECTIVES: To evaluate the effect of extended antenatal triple antiretroviral therapy (ART) on infant outcomes. DESIGN: Retrospective cohort study using pooled data from health clinics in Malawi and Mozambique from July 2005 to December 2009. METHODS: Computerized records of 3273 HIV-infected pregnant women accessing Drug Resource Enhancement Against AIDS and Malnutrition centers were reviewed. ART regimens consisted of nevirapine-based HAART as of 14-25 weeks gestation until 6 months postpartum. Infant infection was determined at 1, 6 and 12 months of age by branched DNA. RESULTS: A total of 3071 pregnancies resulted in 3148 live births. Lost to follow-up, infant deaths and HIV-1 infection rates at 1 and 12 months were 1.3 and 11.5, 0.8 and 6.7 and 0.8 and 2.0, respectively. Infant HIV-1-free survival at 12 months was 92.5%. Mother-to-child transmission and/or infant deaths correlated with length of maternal antenatal ART by multivariate analysis at 1, 6 and 12 months: 14% in women with more than 30 days of triple antenatal ART and 6.9% in mothers receiving at least 90 days of antenatal ART, P = 0.001. Fifty percent of 54 episodes of transmission occurred in women with higher CD4 cell counts (>350 cells/mul). Infant mortality was 67/1000, lower than background rates (78-100/1000). Growth failure (weight-for-age Z score <-2) was present in 8% of infants around birth, 6% at 6 months, 23% at 12 months (lower than country-specific rates). CONCLUSION: Extended antenatal ART is protective against adverse infant outcomes up to 12 months of age even in children born to mothers with higher CD4 cell counts.'
p79996
sS'AD'
p79997
S'Division of Infectious Diseases, David Geffen UCLA School of Medicine, Los Angeles, California 90095, USA.'
p79998
sS'IP'
p79999
S'18'
p80000
sS'IS'
p80001
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p80002
sS'DCOM'
p80003
S'20110506'
p80004
sS'AU'
p80005
(lp80006
S'Marazzi MC'
p80007
aS'Liotta G'
p80008
aS'Nielsen-Saines K'
p80009
aS'Haswell J'
p80010
aS'Magid NA'
p80011
aS'Buonomo E'
p80012
aS'Scarcella P'
p80013
aS'Doro Altan AM'
p80014
aS'Mancinelli S'
p80015
aS'Palombi L'
p80016
asS'VI'
p80017
S'24'
p80018
sS'MHDA'
p80019
S'2011/05/07 06:00'
p80020
sS'MH'
p80021
(lp80022
S'Adult'
p80023
aS'Breast Feeding'
p80024
aS'CD4 Lymphocyte Count'
p80025
aS'Cohort Studies'
p80026
aS'Drug Administration Schedule'
p80027
aS'Female'
p80028
aS'HIV Infections/*drug therapy/immunology/transmission'
p80029
aS'*HIV-1'
p80030
aS'Humans'
p80031
aS'Infant'
p80032
aS'Infant Mortality'
p80033
aS'Infant, Newborn'
p80034
aS'Infectious Disease Transmission, Vertical/*prevention & control'
p80035
aS'Kaplan-Meier Estimate'
p80036
aS'Malawi'
p80037
aS'Male'
p80038
aS'Mozambique'
p80039
aS'Nevirapine/*administration & dosage'
p80040
aS'Pregnancy'
p80041
aS'Retrospective Studies'
p80042
aS'Treatment Outcome'
p80043
asS'EDAT'
p80044
S'2010/10/05 06:00'
p80045
sS'SO'
p80046
S'AIDS. 2010 Nov 27;24(18):2819-26. doi: 10.1097/QAD.0b013e32833ff58c.'
p80047
sS'SB'
p80048
S'IM X'
p80049
sS'PMID'
p80050
S'20885282'
p80051
sS'PST'
p80052
S'ppublish'
p80053
stRp80054
ag2
(g3
g4
(dp80055
S'LID'
p80056
S'10.2471/BLT.09.064329 [doi]'
p80057
sS'STAT'
p80058
S'MEDLINE'
p80059
sS'DEP'
p80060
S'20100416'
p80061
sS'DA'
p80062
S'20100924'
p80063
sS'AID'
p80064
(lp80065
S'10.2471/BLT.09.064329 [doi]'
p80066
asS'CRDT'
p80067
(lp80068
S'2010/09/25 06:00'
p80069
asS'DP'
p80070
S'2010 Sep 1'
p80071
sS'AD'
p80072
S'United States Agency for International Development, Academic Model Providing Access To Healthcare Partnership, Eldoret, Kenya.'
p80073
sS'OWN'
p80074
S'NLM'
p80075
sS'PT'
p80076
(lp80077
S'Journal Article'
p80078
aS'Research Support, N.I.H., Extramural'
p80079
aS"Research Support, Non-U.S. Gov't"
p80080
asS'LA'
p80081
(lp80082
S'eng'
p80083
asS'FAU'
p80084
(lp80085
S'Ochieng-Ooko, Vincent'
p80086
aS'Ochieng, Daniel'
p80087
aS'Sidle, John E'
p80088
aS'Holdsworth, Margaret'
p80089
aS'Wools-Kaloustian, Kara'
p80090
aS'Siika, Abraham M'
p80091
aS'Yiannoutsos, Constantin T'
p80092
aS'Owiti, Michael'
p80093
aS'Kimaiyo, Sylvester'
p80094
aS'Braitstein, Paula'
p80095
asS'JT'
p80096
S'Bulletin of the World Health Organization'
p80097
sS'LR'
p80098
S'20141202'
p80099
sS'PG'
p80100
S'681-8'
p80101
sS'TI'
p80102
S'Influence of gender on loss to follow-up in a large HIV treatment programme in western Kenya.'
p80103
sS'RN'
p80104
(lp80105
S'0 (Anti-Retroviral Agents)'
p80106
asS'PL'
p80107
S'Switzerland'
p80108
sS'TA'
p80109
S'Bull World Health Organ'
p80110
sS'JID'
p80111
S'7507052'
p80112
sS'AB'
p80113
S'OBJECTIVE: To determine the incidence of loss to follow-up in a treatment programme for people living with human immunodeficiency virus (HIV) infection in Kenya and to investigate how loss to follow-up is affected by gender. METHODS: Between November 2001 and November 2007, 50 275 HIV-positive individuals aged >/= 14 years (69% female; median age: 36.2 years) were enrolled in the study. An individual was lost to follow-up when absent from the HIV treatment clinic for > 3 months if on combination antiretroviral therapy (cART) or for > 6 months if not. The incidence of loss to follow-up was calculated using Kaplan-Meier methods and factors associated with loss to follow-up were identified by logistic and Cox multivariate regression analysis. FINDINGS: Overall, 8% of individuals attended no follow-up visits, and 54% of them were lost to follow-up. The overall incidence of loss to follow-up was 25.1 per 100 person-years. Among the 92% who attended at least one follow-up visit, the incidence of loss to follow-up before and after starting cART was 27.2 and 14.0 per 100 person-years, respectively. Baseline factors associated with loss to follow-up included younger age, a long travel time to the clinic, patient disclosure of positive HIV status, high CD4+ lymphocyte count, advanced-stage HIV disease, and rural clinic location. Men were at an increased risk overall and before and after starting cART. CONCLUSION: The risk of being lost to follow-up was high, particularly before starting cART. Men were more likely to become lost to follow-up, even after adjusting for baseline sociodemographic and clinical characteristics. Interventions designed for men and women separately could improve retention.'
p80114
sS'GR'
p80115
(lp80116
S'U01-AI0669911/AI/NIAID NIH HHS/United States'
p80117
asS'IP'
p80118
S'9'
sS'IS'
p80119
S'1564-0604 (Electronic) 0042-9686 (Linking)'
p80120
sS'PMC'
p80121
S'PMC2930357'
p80122
sS'DCOM'
p80123
S'20110106'
p80124
sS'AU'
p80125
(lp80126
S'Ochieng-Ooko V'
p80127
aS'Ochieng D'
p80128
aS'Sidle JE'
p80129
aS'Holdsworth M'
p80130
aS'Wools-Kaloustian K'
p80131
aS'Siika AM'
p80132
aS'Yiannoutsos CT'
p80133
aS'Owiti M'
p80134
aS'Kimaiyo S'
p80135
aS'Braitstein P'
p80136
asS'VI'
p80137
S'88'
p80138
sS'MHDA'
p80139
S'2011/01/07 06:00'
p80140
sS'PHST'
p80141
(lp80142
S'2009/10/20 [received]'
p80143
aS'2010/01/13 [revised]'
p80144
aS'2010/01/18 [accepted]'
p80145
aS'2010/04/16 [epublish]'
p80146
asS'OID'
p80147
(lp80148
S'NLM: PMC2930357'
p80149
asS'MH'
p80150
(lp80151
S'Adult'
p80152
aS'Anti-Retroviral Agents/administration & dosage/*therapeutic use'
p80153
aS'Female'
p80154
aS'HIV Infections/*drug therapy/*epidemiology'
p80155
aS'Humans'
p80156
aS'Incidence'
p80157
aS'Kenya'
p80158
aS'*Lost to Follow-Up'
p80159
aS'Male'
p80160
aS'Middle Aged'
p80161
aS'Retrospective Studies'
p80162
aS'Risk Factors'
p80163
aS'Sex Factors'
p80164
aS'Socioeconomic Factors'
p80165
aS'Time Factors'
p80166
asS'EDAT'
p80167
S'2010/09/25 06:00'
p80168
sS'SO'
p80169
S'Bull World Health Organ. 2010 Sep 1;88(9):681-8. doi: 10.2471/BLT.09.064329. Epub 2010 Apr 16.'
p80170
sS'SB'
p80171
S'IM'
p80172
sS'PMID'
p80173
S'20865073'
p80174
sS'PST'
p80175
S'ppublish'
p80176
stRp80177
ag2
(g3
g4
(dp80178
S'LID'
p80179
S'10.1097/QAI.0b013e3181f5bd03 [doi]'
p80180
sS'STAT'
p80181
S'MEDLINE'
p80182
sS'JT'
p80183
S'Journal of acquired immune deficiency syndromes (1999)'
p80184
sS'DA'
p80185
S'20101214'
p80186
sS'AID'
p80187
(lp80188
S'10.1097/QAI.0b013e3181f5bd03 [doi]'
p80189
asS'CRDT'
p80190
(lp80191
S'2010/09/24 06:00'
p80192
asS'DP'
p80193
S'2011 Jan 1'
p80194
sS'OWN'
p80195
S'NLM'
p80196
sS'PT'
p80197
(lp80198
S'Journal Article'
p80199
asS'LA'
p80200
(lp80201
S'eng'
p80202
asS'FAU'
p80203
(lp80204
S'Castelnuovo, Barbara'
p80205
aS'Kiragga, Agnes'
p80206
aS'Kamya, Moses R'
p80207
aS'Manabe, Yukari'
p80208
asS'LR'
p80209
S'20140206'
p80210
sS'PG'
p80211
S'59-63'
p80212
sS'TI'
p80213
S'Stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda.'
p80214
sS'RN'
p80215
(lp80216
S'0 (Anti-HIV Agents)'
p80217
aS'0 (Benzoxazines)'
p80218
aS'2T8Q726O95 (Lamivudine)'
p80219
aS'4B9XT59T7S (Zidovudine)'
p80220
aS'99DK7FVK1H (Nevirapine)'
p80221
aS'BO9LE4QFZF (Stavudine)'
p80222
aS'JE6H2O27P8 (efavirenz)'
p80223
asS'PL'
p80224
S'United States'
p80225
sS'TA'
p80226
S'J Acquir Immune Defic Syndr'
p80227
sS'JID'
p80228
S'100892005'
p80229
sS'AB'
p80230
S'PURPOSE: In resource-limited settings, there are only a few antiretroviral treatment (ART) options. Our objective was to evaluate the reasons for first-line ART changes in resource-limited settings. METHODS: Prospective research cohort of patients initiating ART between April 2004 and April 2005 in Kampala, Uganda. The main endpoint was the substitution of at least 1 drug included in the initial combination. RESULTS: Five hundred Fifty-nine patients initiated on ART, 70% were female, median CD4+ count 98 (21-163) cells per microliter, median HIV RNA log(1)(0) 5.4 (5.0-5.8). 413 (74%) patients were started on stavudine, lamivudine, and nevirapine, and 146 (36%) on zidovudine, lamivudine and efavirenz. One hundred Forty-eight (26.5%) had at least one treatment change (incidence rate 14.3 per 100 person-years; confidence interval: 12.2 to 16.9). The main reason for first treatment change was drug toxicity (n = 91, 61.5%). Stavudine accounted for the majority of the toxicities that led to drug substitution (n = 76, 84%). In the multivariate analysis, being female (P = 0.011) and being stage 3-4 as compared with 1-2 at ART initiation were predictive of stavudine substitution (P = 0.05). There was no difference in virologic outcome in patients who changed due to toxicity compared with those who did not. CONCLUSIONS: The majority of the treatment changes were due to stavudine-related toxicity. Long-term stavudine use is less well tolerated in women.'
p80231
sS'AD'
p80232
S'Research Department, Infectious Diseases Institute, Makerere University, Kampala Uganda. bcastelnuovo@idi.co.ug'
p80233
sS'IP'
p80234
S'1'
sS'IS'
p80235
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p80236
sS'DCOM'
p80237
S'20110111'
p80238
sS'AU'
p80239
(lp80240
S'Castelnuovo B'
p80241
aS'Kiragga A'
p80242
aS'Kamya MR'
p80243
aS'Manabe Y'
p80244
asS'VI'
p80245
S'56'
p80246
sS'MHDA'
p80247
S'2011/01/12 06:00'
p80248
sS'MH'
p80249
(lp80250
S'Adult'
p80251
aS'Anti-HIV Agents/administration & dosage/*adverse effects/therapeutic use'
p80252
aS'Antiretroviral Therapy, Highly Active/adverse effects'
p80253
aS'Benzoxazines/administration & dosage/therapeutic use'
p80254
aS'Female'
p80255
aS'HIV Infections/*drug therapy'
p80256
aS'Humans'
p80257
aS'Kaplan-Meier Estimate'
p80258
aS'Lamivudine/administration & dosage/therapeutic use'
p80259
aS'Male'
p80260
aS'Multivariate Analysis'
p80261
aS'Nevirapine/administration & dosage/therapeutic use'
p80262
aS'Prospective Studies'
p80263
aS'Risk Factors'
p80264
aS'Sex Factors'
p80265
aS'Stavudine/administration & dosage/*adverse effects/therapeutic use'
p80266
aS'Uganda/epidemiology'
p80267
aS'Zidovudine/administration & dosage/therapeutic use'
p80268
asS'EDAT'
p80269
S'2010/09/24 06:00'
p80270
sS'SO'
p80271
S'J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):59-63. doi: 10.1097/QAI.0b013e3181f5bd03.'
p80272
sS'SB'
p80273
S'IM X'
p80274
sS'PMID'
p80275
S'20861741'
p80276
sS'PST'
p80277
S'ppublish'
p80278
stRp80279
ag2
(g3
g4
(dp80280
S'LID'
p80281
S'10.1186/1475-2875-9-261 [doi]'
p80282
sS'STAT'
p80283
S'MEDLINE'
p80284
sS'DEP'
p80285
S'20100918'
p80286
sS'DA'
p80287
S'20101013'
p80288
sS'AID'
p80289
(lp80290
S'1475-2875-9-261 [pii]'
p80291
aS'10.1186/1475-2875-9-261 [doi]'
p80292
asS'CRDT'
p80293
(lp80294
S'2010/09/21 06:00'
p80295
asS'DP'
p80296
S'2010'
p80297
sS'AD'
p80298
S'Malaria Public Health and Epidemiology Group, KEMRI/Wellcome Trust Research Programme, Centre for Geographic Medicine Research-Coast (CGMRC), Nairobi, Kenya Nairobi, Kenya. bwasunna@nairobi.kemri-wellcome.org'
p80299
sS'OWN'
p80300
S'NLM'
p80301
sS'PT'
p80302
(lp80303
S'Journal Article'
p80304
aS"Research Support, Non-U.S. Gov't"
p80305
asS'LA'
p80306
(lp80307
S'eng'
p80308
asS'DCOM'
p80309
S'20101221'
p80310
sS'JT'
p80311
S'Malaria journal'
p80312
sS'LR'
p80313
S'20141202'
p80314
sS'FAU'
p80315
(lp80316
S'Wasunna, Beatrice'
p80317
aS'Zurovac, Dejan'
p80318
aS'Bruce, Jane'
p80319
aS'Jones, Caroline'
p80320
aS'Webster, Jayne'
p80321
aS'Snow, Robert W'
p80322
asS'TI'
p80323
S'Health worker performance in the management of paediatric fevers following in-service training and exposure to job aids in Kenya.'
p80324
sS'RN'
p80325
(lp80326
S'0 (Antimalarials)'
p80327
aS'0 (Artemisinins)'
p80328
aS'0 (Drug Combinations)'
p80329
aS'0 (Ethanolamines)'
p80330
aS'0 (Fluorenes)'
p80331
aS'0 (artemether-lumefantrine combination)'
p80332
asS'PL'
p80333
S'England'
p80334
sS'PG'
p80335
S'261'
p80336
sS'JID'
p80337
S'101139802'
p80338
sS'AB'
p80339
S'BACKGROUND: Improving the way artemether-lumefantrine (AL) is provided to patients attending clinics is critical to maximize the benefit of this new medicine. In 2007, a new initiative was launched in one part of Kenya to improve malaria case-management through enhanced in-service training and provision of job aids. METHODS: An evaluation of the intervention using pre- and post-intervention cross sectional health facility surveys was conducted in Bondo district. The surveys included: audit of government health facilities, health worker structured interviews and exit interviews with caretakers of sick children below five years of age. The outcome indicators were the proportions of febrile children who had AL prescribed, AL dispensed, and four different dispensing and counseling tasks performed. RESULTS: At baseline 33 government health facilities, 48 health workers and 386 febrile child consultations were evaluated. At follow-up the same health facilities were surveyed and 36 health workers and 390 febrile child consultations evaluated. The findings show: 1) no health facility or health worker was exposed to all components of the intervention; 2) the proportion of health workers who received the enhanced in-service training was 67%; 3) the proportion of febrile children with uncomplicated malaria treated with the first-line anti-malarial drug, artemether-lumefantrine (AL), at health facilities where AL was in stock increased from 76.9% (95%CI: 69.4, 83.1) to 87.6% (95% CI: 82.5, 91.5); 4) there were modest but non-significant improvements in dispensing and counseling practices; and 5) when the analyses were restricted to health workers who received the enhanced in-service training and/or had received new guidelines and job aids, no significant improvements in reported case-management tasks were observed compared to baseline. CONCLUSION: In-service training and provision of job aids alone may not be adequate to improve the prescribing, dispensing and counseling tasks necessary to change malaria case-management practices and the inclusion of supervision and post-training follow-up should be considered in future clinical practice change initiatives.'
p80340
sS'GR'
p80341
(lp80342
S'079080/Wellcome Trust/United Kingdom'
p80343
aS'084253/Wellcome Trust/United Kingdom'
p80344
asS'VI'
p80345
S'9'
sS'IS'
p80346
S'1475-2875 (Electronic) 1475-2875 (Linking)'
p80347
sS'PMC'
p80348
S'PMC2955674'
p80349
sS'AU'
p80350
(lp80351
S'Wasunna B'
p80352
aS'Zurovac D'
p80353
aS'Bruce J'
p80354
aS'Jones C'
p80355
aS'Webster J'
p80356
aS'Snow RW'
p80357
asS'MHDA'
p80358
S'2010/12/22 06:00'
p80359
sS'PHST'
p80360
(lp80361
S'2010/06/25 [received]'
p80362
aS'2010/09/18 [accepted]'
p80363
aS'2010/09/18 [aheadofprint]'
p80364
asS'OID'
p80365
(lp80366
S'NLM: PMC2955674'
p80367
asS'MH'
p80368
(lp80369
S'Antimalarials/*therapeutic use'
p80370
aS'Artemisinins/*therapeutic use'
p80371
aS'Child, Preschool'
p80372
aS'Cross-Sectional Studies'
p80373
aS'Drug Combinations'
p80374
aS'Ethanolamines/*therapeutic use'
p80375
aS'Fever of Unknown Origin/diagnosis/*etiology'
p80376
aS'Fluorenes/*therapeutic use'
p80377
aS'Health Personnel/*education'
p80378
aS'Health Services Research'
p80379
aS'Humans'
p80380
aS'Infant'
p80381
aS'Infant, Newborn'
p80382
aS'Kenya'
p80383
aS'Malaria/*diagnosis/*drug therapy'
p80384
aS'Professional Competence/*statistics & numerical data'
p80385
asS'EDAT'
p80386
S'2010/09/21 06:00'
p80387
sS'SO'
p80388
S'Malar J. 2010 Sep 18;9:261. doi: 10.1186/1475-2875-9-261.'
p80389
sS'SB'
p80390
S'IM'
p80391
sS'PMID'
p80392
S'20849650'
p80393
sS'TA'
p80394
S'Malar J'
p80395
sS'PST'
p80396
S'epublish'
p80397
stRp80398
ag2
(g3
g4
(dp80399
S'STAT'
p80400
S'MEDLINE'
p80401
sS'AB'
p80402
S'BACKGROUND: The introduction of the highly active antiretroviral therapy in the mid-1990s has significantly reduced morbidities and prolonged the lifespan of people living with HIV However, the emergence of resistance to the antiretroviral drugs is becoming a major cause of treatment failure. While the problem of drug resistance is being tackled in developed countries, not much seem to be done in this regard in developing countries of Africa, Asia and Latin America. This review looked at the regional distribution of HIV groups and subtypes and how this has affected the pattern of antiretroviral resistance. METHODS: The review was sourced from papers presented at international conferences on HIV/AIDS and rational drug use, relevant journals and Medline search using the keywords-Antiretroviral drugs, drug resistance, HIV subtypes and resistance testing. RESULTS: The types, groups, subtypes, sub-subtypes and recombinant forms of HIV-1 have been identified according to their geographical distributions. The evolution of HIV viral mutations, process (es) involved in development of primary and secondary antiretroviral drug resistance, including the role of HIV genetic polymorphisms, and transmitted resistance have been discussed. CONCLUSION: The pitfalls in the current resistance testing based on HIV-1 subtype B have been highlighted. The design of resistance testing algorithm based on HIV-1 subtype non-B has been suggested for the developing world.'
p80403
sS'JID'
p80404
S'100888321'
p80405
sS'AD'
p80406
S'Department of Medicine, Ahmadu Bello University Teaching Hospital Shika Zaria. reginaldobiako@yahoo.com'
p80407
sS'JT'
p80408
S'Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria'
p80409
sS'IP'
p80410
S'3'
sS'IS'
p80411
S'1115-2613 (Print) 1115-2613 (Linking)'
p80412
sS'DCOM'
p80413
S'20100928'
p80414
sS'DA'
p80415
S'20100917'
p80416
sS'AU'
p80417
(lp80418
S'Obiako OR'
p80419
aS'Murktar HM'
p80420
aS'Ogoina D'
p80421
asS'SB'
p80422
S'IM'
p80423
sS'CRDT'
p80424
(lp80425
S'2010/09/18 06:00'
p80426
asS'VI'
p80427
S'19'
p80428
sS'PMID'
p80429
S'20845636'
p80430
sS'DP'
p80431
S'2010 Jul-Sep'
p80432
sS'MHDA'
p80433
S'2010/09/30 06:00'
p80434
sS'OWN'
p80435
S'NLM'
p80436
sS'PT'
p80437
(lp80438
S'Journal Article'
p80439
aS'Review'
p80440
asS'LA'
p80441
(lp80442
S'eng'
p80443
asS'MH'
p80444
(lp80445
S'Africa South of the Sahara'
p80446
aS'Anti-HIV Agents/therapeutic use'
p80447
aS'Developing Countries'
p80448
aS'*Drug Resistance, Viral'
p80449
aS'Female'
p80450
aS'*HIV Infections/drug therapy'
p80451
aS'HIV Reverse Transcriptase/genetics'
p80452
aS'*HIV-1/drug effects/genetics'
p80453
aS'Humans'
p80454
aS'Male'
p80455
aS'Polymorphism, Genetic'
p80456
asS'FAU'
p80457
(lp80458
S'Obiako, O R'
p80459
aS'Murktar, H M'
p80460
aS'Ogoina, D'
p80461
asS'EDAT'
p80462
S'2010/09/18 06:00'
p80463
sS'PST'
p80464
S'ppublish'
p80465
sS'RF'
p80466
S'71'
p80467
sS'LR'
p80468
S'20101022'
p80469
sS'PG'
p80470
S'302-10'
p80471
sS'TI'
p80472
S'Antiretroviral drug resistance--implications for HIV/AIDS reduction in sub-Saharan Africa and other developing countries.'
p80473
sS'SO'
p80474
S'Niger J Med. 2010 Jul-Sep;19(3):302-10.'
p80475
sS'RN'
p80476
(lp80477
S'0 (Anti-HIV Agents)'
p80478
aS'EC 2.7.7.49 (HIV Reverse Transcriptase)'
p80479
asS'PL'
p80480
S'Nigeria'
p80481
sS'TA'
p80482
S'Niger J Med'
p80483
stRp80484
ag2
(g3
g4
(dp80485
S'STAT'
p80486
S'MEDLINE'
p80487
sS'AB'
p80488
S'HIV care and antiretroviral treatment (ART) provision is largely hospital-based with an over-reliance on doctors. Existing ART sites are reaching capacity and are increasingly unable to initiate new patients and also see follow up patients. In response, the Reproductive Health and HIV Research Unit (RHRU), has supported the KwaZulu-Natal provincial Department of Health with developing a model to decentralise services to primary health care (PHC) level. The programme has been in operation since 2006, and currently nine ART initiation sites down refer stable patients to 24 PHC clinics. Data on patient numbers, treatment outcomes and patient retention rates were collected through a file audit of 2071 adult patient files and analyzed. Results indicate that a file audit is a feasible mechanism to provide this data and can be used to identify gaps and improve quality of care. PHC sites in resource-constrained settings are able to manage stable patients on ART; however, sites need support with monitoring and evaluation and with tracking patients that have been down referred. In terms of quality of care, PHC sites need to ensure that clients receive CD4 count tests and viral load monitoring at six monthly intervals to ensure that treatment failure does not go undetected. Patients suspected of experiencing adverse events or treatment failure appear to be managed according to standard operating procedures, but there is a need to ensure that adverse events are clearly documented in patient files.'
p80489
sS'JID'
p80490
S'9214582'
p80491
sS'AD'
p80492
S'Reproductive Health & HIV Research Unit, University of Witwatersrand, Johannesburg, South Africa. csearle@rhru.co.za'
p80493
sS'JT'
p80494
S'Studies in health technology and informatics'
p80495
sS'IP'
p80496
S'Pt 1'
p80497
sS'IS'
p80498
S'0926-9630 (Print) 0926-9630 (Linking)'
p80499
sS'DCOM'
p80500
S'20101231'
p80501
sS'DA'
p80502
S'20100915'
p80503
sS'AU'
p80504
(lp80505
S'Searle C'
p80506
aS'Ramkissoon A'
p80507
aS'Govender T'
p80508
asS'CRDT'
p80509
(lp80510
S'2010/09/16 06:00'
p80511
asS'VI'
p80512
S'160'
p80513
sS'PMID'
p80514
S'20841732'
p80515
sS'DP'
p80516
S'2010'
p80517
sS'MHDA'
p80518
S'2011/01/01 06:00'
p80519
sS'OWN'
p80520
S'NLM'
p80521
sS'PT'
p80522
(lp80523
S'Journal Article'
p80524
aS"Research Support, U.S. Gov't, Non-P.H.S."
p80525
asS'LA'
p80526
(lp80527
S'eng'
p80528
asS'MH'
p80529
(lp80530
S'Adult'
p80531
aS'Anti-Retroviral Agents/*therapeutic use'
p80532
aS'Clinical Audit/*methods'
p80533
aS'*Database Management Systems'
p80534
aS'*Databases, Factual'
p80535
aS'HIV Infections/*drug therapy/epidemiology'
p80536
aS'Humans'
p80537
aS'Outcome Assessment (Health Care)/*methods'
p80538
aS'Patient Dropouts/statistics & numerical data'
p80539
aS'Politics'
p80540
aS'Prevalence'
p80541
aS'Primary Health Care/methods'
p80542
aS'*Sentinel Surveillance'
p80543
aS'South Africa/epidemiology'
p80544
asS'FAU'
p80545
(lp80546
S'Searle, Catherine'
p80547
aS'Ramkissoon, Arthi'
p80548
aS'Govender, Thamandrie'
p80549
asS'EDAT'
p80550
S'2010/09/16 06:00'
p80551
sS'PST'
p80552
S'ppublish'
p80553
sS'SO'
p80554
S'Stud Health Technol Inform. 2010;160(Pt 1):476-80.'
p80555
sS'PG'
p80556
S'476-80'
p80557
sS'TI'
p80558
S'Using a file audit to evaluate retention in care and patient outcomes in a programme to decentralise antiretroviral treatment to primary health care facilities in a high prevalence setting in KwaZulu-Natal, South Africa.'
p80559
sS'SB'
p80560
S'T'
sS'RN'
p80561
(lp80562
S'0 (Anti-Retroviral Agents)'
p80563
asS'PL'
p80564
S'Netherlands'
p80565
sS'TA'
p80566
S'Stud Health Technol Inform'
p80567
stRp80568
ag2
(g3
g4
(dp80569
S'LID'
p80570
S'10.1097/QAI.0b013e3181f5376d [doi]'
p80571
sS'STAT'
p80572
S'MEDLINE'
p80573
sS'JT'
p80574
S'Journal of acquired immune deficiency syndromes (1999)'
p80575
sS'MID'
p80576
(lp80577
S'NIHMS237365'
p80578
asS'DA'
p80579
S'20101105'
p80580
sS'AID'
p80581
(lp80582
S'10.1097/QAI.0b013e3181f5376d [doi]'
p80583
asS'CRDT'
p80584
(lp80585
S'2010/09/15 06:00'
p80586
asS'DP'
p80587
S'2010 Dec'
p80588
sS'AD'
p80589
S'Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, MA 02111, USA. shong@tuftsmedicalcenter.org'
p80590
sS'OWN'
p80591
S'NLM'
p80592
sS'PT'
p80593
(lp80594
S'Journal Article'
p80595
aS'Research Support, N.I.H., Extramural'
p80596
aS"Research Support, Non-U.S. Gov't"
p80597
aS"Research Support, U.S. Gov't, Non-P.H.S."
p80598
asS'LA'
p80599
(lp80600
S'eng'
p80601
asS'FAU'
p80602
(lp80603
S'Hong, Steven Y'
p80604
aS'Jonas, Anna'
p80605
aS'Dumeni, Efraim'
p80606
aS'Badi, Alfons'
p80607
aS'Pereko, Dawn'
p80608
aS'Blom, Abraham'
p80609
aS'Muthiani, Victor S'
p80610
aS'Shiningavamwe, Andreas N'
p80611
aS'Mukamba, James'
p80612
aS'Andemichael, Ghirmay'
p80613
aS'Barbara, Rony'
p80614
aS'Bennett, Diane E'
p80615
aS'Jordan, Michael R'
p80616
asS'LR'
p80617
S'20141202'
p80618
sS'PG'
p80619
S'27-31'
p80620
sS'TI'
p80621
S'Population-based monitoring of HIV drug resistance in Namibia with early warning indicators.'
p80622
sS'RN'
p80623
(lp80624
S'0 (Anti-Retroviral Agents)'
p80625
asS'PL'
p80626
S'United States'
p80627
sS'TA'
p80628
S'J Acquir Immune Defic Syndr'
p80629
sS'JID'
p80630
S'100892005'
p80631
sS'AB'
p80632
S'INTRODUCTION: HIV drug resistance (HIVDR) testing is not routinely available in many resource-limited settings, therefore, antiretroviral therapy (ART) program and site factors known to be associated with HIVDR should be monitored to optimize the quality of patient care and minimize the emergence of preventable HIVDR. METHODS: In 2009, Namibia selected 5 World Health Organization Early Warning Indicators (EWIs) and piloted abstraction at 9 ART sites: "ART prescribing practices, patients lost to follow-up at 12 months, patient retention on first-line ART at 12 months, on-time antiretroviral drug pick-up, and antiretroviral drug-supply continuity". RESULTS: Records supported monitoring of 3 of 5 selected EWIs. Nine of 9 (100%) sites met the target of 100% initiated on appropriate first-line regimens. Eight of 9 (89%) sites met the target of </=20% lost to follow-up, although 20.8% of ART starters (range: 4.6%-44.6%) had a period of absence without documented ART coverage of 2.3 months (range: 1.5-3.9 months). Six of 9 (67%) sites met the target of 0% switched to a second-line regimen. CONCLUSIONS: EWI monitoring directly resulted in public health action which will optimize the quality of care, specifically the strengthening of ART record systems permitting monitoring of 5 EWIs in future years and protocols for improved ART patient defaulter tracing.'
p80633
sS'GR'
p80634
(lp80635
S'K23 AI074423/AI/NIAID NIH HHS/United States'
p80636
aS'K23 AI074423-04/AI/NIAID NIH HHS/United States'
p80637
aS'K23 AI074423-04/AI/NIAID NIH HHS/United States'
p80638
aS'L30 AI080268-02/AI/NIAID NIH HHS/United States'
p80639
aS'L30 AI080268-02/AI/NIAID NIH HHS/United States'
p80640
aS'T32 AI007438/AI/NIAID NIH HHS/United States'
p80641
aS'T32 AI007438-17/AI/NIAID NIH HHS/United States'
p80642
aS'T32 AI007438-17/AI/NIAID NIH HHS/United States'
p80643
asS'IP'
p80644
S'4'
sS'IS'
p80645
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p80646
sS'PMC'
p80647
S'PMC2974796'
p80648
sS'DCOM'
p80649
S'20110104'
p80650
sS'AU'
p80651
(lp80652
S'Hong SY'
p80653
aS'Jonas A'
p80654
aS'Dumeni E'
p80655
aS'Badi A'
p80656
aS'Pereko D'
p80657
aS'Blom A'
p80658
aS'Muthiani VS'
p80659
aS'Shiningavamwe AN'
p80660
aS'Mukamba J'
p80661
aS'Andemichael G'
p80662
aS'Barbara R'
p80663
aS'Bennett DE'
p80664
aS'Jordan MR'
p80665
asS'VI'
p80666
S'55'
p80667
sS'MHDA'
p80668
S'2011/01/05 06:00'
p80669
sS'OID'
p80670
(lp80671
S'NLM: NIHMS237365'
p80672
aS'NLM: PMC2974796'
p80673
asS'MH'
p80674
(lp80675
S'Anti-Retroviral Agents/*therapeutic use'
p80676
aS'*Developing Countries'
p80677
aS'*Drug Resistance, Viral'
p80678
aS'Environmental Monitoring/*statistics & numerical data'
p80679
aS'Epidemiological Monitoring'
p80680
aS'HIV/*drug effects'
p80681
aS'HIV Infections/*drug therapy/*epidemiology'
p80682
aS'Humans'
p80683
aS'Namibia/epidemiology'
p80684
aS'National Health Programs/standards'
p80685
aS'Pilot Projects'
p80686
asS'EDAT'
p80687
S'2010/09/15 06:00'
p80688
sS'SO'
p80689
S'J Acquir Immune Defic Syndr. 2010 Dec;55(4):27-31. doi: 10.1097/QAI.0b013e3181f5376d.'
p80690
sS'SB'
p80691
S'IM X'
p80692
sS'PMID'
p80693
S'20838224'
p80694
sS'PST'
p80695
S'ppublish'
p80696
stRp80697
ag2
(g3
g4
(dp80698
S'LID'
p80699
S'10.1001/jama.2010.1278 [doi]'
p80700
sS'STAT'
p80701
S'MEDLINE'
p80702
sS'JT'
p80703
S'JAMA'
p80704
sS'CIN'
p80705
(lp80706
S'JAMA. 2010 Dec 15;304(23):2589; author reply 2589-90. PMID: 21156944'
p80707
asS'DA'
p80708
S'20100908'
p80709
sS'AID'
p80710
(lp80711
S'304/10/1082 [pii]'
p80712
aS'10.1001/jama.2010.1278 [doi]'
p80713
asS'CRDT'
p80714
(lp80715
S'2010/09/09 06:00'
p80716
asS'DP'
p80717
S'2010 Sep 8'
p80718
sS'AD'
p80719
S'Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital, Johannesburg, South Africa.'
p80720
sS'OWN'
p80721
S'NLM'
p80722
sS'PT'
p80723
(lp80724
S'Journal Article'
p80725
aS'Randomized Controlled Trial'
p80726
aS'Research Support, N.I.H., Extramural'
p80727
aS"Research Support, Non-U.S. Gov't"
p80728
asS'LA'
p80729
(lp80730
S'eng'
p80731
asS'FAU'
p80732
(lp80733
S'Coovadia, Ashraf'
p80734
aS'Abrams, Elaine J'
p80735
aS'Stehlau, Renate'
p80736
aS'Meyers, Tammy'
p80737
aS'Martens, Leigh'
p80738
aS'Sherman, Gayle'
p80739
aS'Hunt, Gillian'
p80740
aS'Hu, Chih-Chi'
p80741
aS'Tsai, Wei-Yann'
p80742
aS'Morris, Lynn'
p80743
aS'Kuhn, Louise'
p80744
asS'LR'
p80745
S'20150819'
p80746
sS'PG'
p80747
S'1082-90'
p80748
sS'TI'
p80749
S'Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.'
p80750
sS'RN'
p80751
(lp80752
S'0 (Anti-HIV Agents)'
p80753
aS'0 (Protease Inhibitors)'
p80754
aS'0 (Pyrimidinones)'
p80755
aS'0 (RNA, Viral)'
p80756
aS'2494G1JF75 (Lopinavir)'
p80757
aS'2T8Q726O95 (Lamivudine)'
p80758
aS'99DK7FVK1H (Nevirapine)'
p80759
aS'BO9LE4QFZF (Stavudine)'
p80760
asS'PL'
p80761
S'United States'
p80762
sS'TA'
p80763
S'JAMA'
p80764
sS'JID'
p80765
S'7501160'
p80766
sS'AB'
p80767
S'CONTEXT: Protease inhibitor (PI)-based therapy is recommended for infants infected with human immunodeficiency virus (HIV) who were exposed to nevirapine for prevention of mother-to-child HIV transmission. However, there are limitations of continuing PI-based therapy indefinitely and reuse of nevirapine has many advantages. OBJECTIVE: To test whether nevirapine-exposed infants who initially achieve viral suppression with PI-based therapy can maintain viral suppression when switched to nevirapine-based therapy. DESIGN, SETTING, AND PATIENTS: Randomized trial conducted between April 2005 and May 2009 at a hospital in Johannesburg, South Africa, among 195 children who achieved viral suppression less than 400 copies/mL for 3 or more months from a cohort of 323 nevirapine-exposed children who initiated PI-based therapy before 24 months of age. INTERVENTIONS: Control group children continued to receive ritonavir-boosted lopinavir, stavudine, and lamivudine (n = 99). Switch group children substituted nevirapine for ritonavir-boosted lopinavir (n = 96). MAIN OUTCOME MEASURES: Children were followed up for 52 weeks after randomization. Plasma HIV-1 RNA of greater than 50 copies/mL was the primary end point. Confirmed viremia greater than 1000 copies/mL was used as a criterion to consider regimen changes for children in either group (safety end point). RESULTS: Plasma viremia greater than 50 copies/mL occurred less frequently in the switch group (Kaplan-Meier probability, 0.438; 95% CI, 0.334-0.537) than in the control group (0.576; 95% CI, 0.470-0.668) (P = .02). Confirmed viremia greater than 1000 copies/mL occurred more frequently in the switch group (0.201; 95% CI, 0.125-0.289) than in the control group (0.022; 95% CI, 0.004-0.069) (P < .001). CD4 cell response was better in the switch group (median CD4 percentage at 52 weeks, 34.7) vs the control group (CD4 percentage, 31.3) (P = .004). Older age (relative hazard [RH], 1.71; 95% CI, 1.08-2.72) was associated with viremia greater than 50 copies/mL in the control group. Inadequate adherence (RH, 4.14; 95% CI, 1.18-14.57) and drug resistance (RH, 4.04; 95% CI, 1.40-11.65) before treatment were associated with confirmed viremia greater than 1000 copies/mL in the switch group. CONCLUSION: Among HIV-infected children previously exposed to nevirapine, switching to nevirapine-based therapy after achieving viral suppression with a ritonavir-boosted lopinavir regimen resulted in lower rates of viremia greater than 50 copies/mL than maintaining the primary ritonavir-boosted lopinavir regimen. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00117728.'
p80768
sS'GR'
p80769
(lp80770
S'HD 47177/HD/NICHD NIH HHS/United States'
p80771
aS'R01 HD047177/HD/NICHD NIH HHS/United States'
p80772
asS'IP'
p80773
S'10'
p80774
sS'IS'
p80775
S'1538-3598 (Electronic) 0098-7484 (Linking)'
p80776
sS'PMC'
p80777
S'PMC4540068'
p80778
sS'DCOM'
p80779
S'20100910'
p80780
sS'MID'
p80781
(lp80782
S'NIHMS552502'
p80783
asS'AU'
p80784
(lp80785
S'Coovadia A'
p80786
aS'Abrams EJ'
p80787
aS'Stehlau R'
p80788
aS'Meyers T'
p80789
aS'Martens L'
p80790
aS'Sherman G'
p80791
aS'Hunt G'
p80792
aS'Hu CC'
p80793
aS'Tsai WY'
p80794
aS'Morris L'
p80795
aS'Kuhn L'
p80796
asS'VI'
p80797
S'304'
p80798
sS'MHDA'
p80799
S'2010/09/11 06:00'
p80800
sS'OID'
p80801
(lp80802
S'NLM: NIHMS552502'
p80803
aS'NLM: PMC4540068'
p80804
asS'MH'
p80805
(lp80806
S'Anti-HIV Agents/*therapeutic use'
p80807
aS'Child, Preschool'
p80808
aS'Drug Therapy, Combination'
p80809
aS'Female'
p80810
aS'HIV Infections/*drug therapy/virology'
p80811
aS'*HIV-1'
p80812
aS'Humans'
p80813
aS'Infant'
p80814
aS'Infectious Disease Transmission, Vertical'
p80815
aS'Lamivudine/therapeutic use'
p80816
aS'Lopinavir'
p80817
aS'Male'
p80818
aS'*Maternal Exposure'
p80819
aS'Nevirapine/*therapeutic use'
p80820
aS'Protease Inhibitors/*therapeutic use'
p80821
aS'Pyrimidinones/therapeutic use'
p80822
aS'RNA, Viral/blood'
p80823
aS'Stavudine/therapeutic use'
p80824
aS'Treatment Outcome'
p80825
aS'Viremia'
p80826
asS'EDAT'
p80827
S'2010/09/09 06:00'
p80828
sS'SI'
p80829
(lp80830
S'ClinicalTrials.gov/NCT00117728'
p80831
asS'SO'
p80832
S'JAMA. 2010 Sep 8;304(10):1082-90. doi: 10.1001/jama.2010.1278.'
p80833
sS'SB'
p80834
S'AIM IM'
p80835
sS'PMID'
p80836
S'20823434'
p80837
sS'PST'
p80838
S'ppublish'
p80839
stRp80840
ag2
(g3
g4
(dp80841
S'LID'
p80842
S'10.1016/j.healthpol.2010.05.004 [doi]'
p80843
sS'STAT'
p80844
S'MEDLINE'
p80845
sS'DEP'
p80846
S'20100608'
p80847
sS'CI'
p80848
(lp80849
S'Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.'
p80850
asS'DA'
p80851
S'20100902'
p80852
sS'AID'
p80853
(lp80854
S'S0168-8510(10)00128-4 [pii]'
p80855
aS'10.1016/j.healthpol.2010.05.004 [doi]'
p80856
asS'CRDT'
p80857
(lp80858
S'2010/09/03 06:00'
p80859
asS'DP'
p80860
S'2010 Oct'
p80861
sS'OWN'
p80862
S'NLM'
p80863
sS'PT'
p80864
(lp80865
S'Journal Article'
p80866
aS"Research Support, Non-U.S. Gov't"
p80867
asS'LA'
p80868
(lp80869
S'eng'
p80870
asS'FAU'
p80871
(lp80872
S"Olang'o, Charles Omondi"
p80873
aS'Nyamongo, Isaac K'
p80874
aS'Aagaard-Hansen, Jens'
p80875
asS'JT'
p80876
S'Health policy (Amsterdam, Netherlands)'
p80877
sS'LR'
p80878
S'20131121'
p80879
sS'PG'
p80880
S'232-7'
p80881
sS'TI'
p80882
S'Staff attrition among community health workers in home-based care programmes for people living with HIV and AIDS in western Kenya.'
p80883
sS'PL'
p80884
S'Ireland'
p80885
sS'TA'
p80886
S'Health Policy'
p80887
sS'JID'
p80888
S'8409431'
p80889
sS'AB'
p80890
S"OBJECTIVES: This paper examines trends and underlying causes of attrition among volunteer community health workers in home-based care for people living with HIV and AIDS in western Kenya. METHODS: Ethnographic data were collected between January and November 2006 through participant observation, focus group discussions and in-depth interviews with 30 CHWs, NGO staff and health care providers and 70 PLWHA. RESULTS: An attrition rate of 33% was observed among the CHWs. The reasons for dropout included: the cultural environment within which CHWs operated; lack of adequate support from area NGOs; poor selection criteria for CHWs; and power differences between NGO officials and CHWs which fostered lack of transparency in the NGOs' operations. CONCLUSIONS: In order to achieve well functioning and sustainable HBC services, factors which influence retention/dropout of CHWs should be addressed taking into account the socio-cultural, programmatic and economic contexts within which CHW activities are implemented."
p80891
sS'AD'
p80892
S'Institute of Anthropology, Gender and African Studies, University of Nairobi, Nairobi, Kenya. kolango2003@yahoo.com'
p80893
sS'IP'
p80894
S'2-3'
p80895
sS'IS'
p80896
S'1872-6054 (Electronic) 0168-8510 (Linking)'
p80897
sS'DCOM'
p80898
S'20101228'
p80899
sS'AU'
p80900
(lp80901
S"Olang'o CO"
p80902
aS'Nyamongo IK'
p80903
aS'Aagaard-Hansen J'
p80904
asS'VI'
p80905
S'97'
p80906
sS'MHDA'
p80907
S'2010/12/29 06:00'
p80908
sS'PHST'
p80909
(lp80910
S'2009/12/10 [received]'
p80911
aS'2010/05/05 [revised]'
p80912
aS'2010/05/08 [accepted]'
p80913
aS'2010/06/08 [aheadofprint]'
p80914
asS'MH'
p80915
(lp80916
S'Adult'
p80917
aS'Community Health Workers/*supply & distribution'
p80918
aS'Female'
p80919
aS'Focus Groups'
p80920
aS'HIV Infections/*therapy'
p80921
aS'Health Policy'
p80922
aS'Home Care Services/*manpower/organization & administration'
p80923
aS'Humans'
p80924
aS'Kenya'
p80925
aS'Male'
p80926
aS'Personnel Selection'
p80927
aS'Social Support'
p80928
aS'*Volunteers'
p80929
asS'EDAT'
p80930
S'2010/09/03 06:00'
p80931
sS'SO'
p80932
S'Health Policy. 2010 Oct;97(2-3):232-7. doi: 10.1016/j.healthpol.2010.05.004. Epub 2010 Jun 8.'
p80933
sS'SB'
p80934
S'H'
sS'PMID'
p80935
S'20807685'
p80936
sS'PST'
p80937
S'ppublish'
p80938
stRp80939
ag2
(g3
g4
(dp80940
S'LID'
p80941
S'10.1089/aid.2009.0309 [doi]'
p80942
sS'STAT'
p80943
S'MEDLINE'
p80944
sS'JT'
p80945
S'AIDS research and human retroviruses'
p80946
sS'DA'
p80947
S'20100903'
p80948
sS'AID'
p80949
(lp80950
S'10.1089/aid.2009.0309 [doi]'
p80951
asS'CRDT'
p80952
(lp80953
S'2010/08/17 06:00'
p80954
asS'DP'
p80955
S'2010 Sep'
p80956
sS'GR'
p80957
(lp80958
S'R01 AI058736/AI/NIAID NIH HHS/United States'
p80959
asS'OWN'
p80960
S'NLM'
p80961
sS'PT'
p80962
(lp80963
S'Journal Article'
p80964
aS"Research Support, Non-U.S. Gov't"
p80965
aS"Research Support, U.S. Gov't, Non-P.H.S."
p80966
asS'LA'
p80967
(lp80968
S'eng'
p80969
asS'FAU'
p80970
(lp80971
S'Minga, Albert'
p80972
aS'Lewden, Charlotte'
p80973
aS'Dohoun, Lambert'
p80974
aS'Abo, Yao'
p80975
aS'Emieme, Arlette'
p80976
aS'Coulibaly, Ali'
p80977
aS'Salamon, Roger'
p80978
aS'Eholie, Serge'
p80979
aS'Anglaret, Xavier'
p80980
aS'Danel, Christine'
p80981
asS'LR'
p80982
S'20141203'
p80983
sS'PG'
p80984
S'991-5'
p80985
sS'TI'
p80986
S"Short communication: Severe symptomatic hyperlactatemia among HIV type 1-infected adults on antiretroviral therapy in Cote d'Ivoire."
p80987
sS'RN'
p80988
(lp80989
S'0 (Anti-HIV Agents)'
p80990
aS'0 (Lactates)'
p80991
aS'BO9LE4QFZF (Stavudine)'
p80992
asS'PL'
p80993
S'United States'
p80994
sS'TA'
p80995
S'AIDS Res Hum Retroviruses'
p80996
sS'FIR'
p80997
(lp80998
S'Anglaret, Xavier'
p80999
aS'Dabis, Francois'
p81000
aS'Danel, Christine'
p81001
aS'Deveau, Christiane'
p81002
aS'Goujard, Cecile'
p81003
aS'Lewden, Charlotte'
p81004
aS'Meyer, Laurence'
p81005
aS'Minga, Albert'
p81006
aS'Thiebaut, Rodolphe'
p81007
aS'Chaix, Marie-Laure'
p81008
aS'Rouzioux, Christine'
p81009
aS"Toni, Thomas d'Aquin"
p81010
aS'Inwoley, Andre'
p81011
aS'Sinet, Martine'
p81012
aS'Bazin, Brigitte'
p81013
aS'Quinty, Laurence'
p81014
aS'Abo, Yao'
p81015
aS'Dohoun, Lambert'
p81016
aS'Minga, Albert'
p81017
aS'Anini, Emma'
p81018
aS'Drowa, Yah'
p81019
aS'Bades, Isidore Bohouo'
p81020
aS'Kouame, Tatiana'
p81021
aS"N'Dri, Marie Julie"
p81022
aS'Ouattara, Minata'
p81023
aS'Sidibe, Abdelh'
p81024
aS'Afi, Roseline'
p81025
aS'Emieme, Arlette'
p81026
aS'Inwoley, Andre'
p81027
aS"Thomas d'Aquin, Toni"
p81028
aS'Coulibaly, Ali'
p81029
aS'Bomisso, Germain'
p81030
aS'Konate, Mamadou'
p81031
asS'JID'
p81032
S'8709376'
p81033
sS'AB'
p81034
S"Stavudine is no longer recommended for use in first-line antiretroviral therapy (ART), but it remains in high demand worldwide because it is affordable. We report the clinical presentation and incidence of severe hyperlactatemia (SL) in HIV-infected adults who initiated ART between April 2005 and May 2009 in Cote d'Ivoire, West Africa. In a prospective cohort study at the HIV care center affiliated with the National Centre for Blood Transfusion, we used standardized forms to record baseline and follow-up data. We measured serum lactate levels for all adults on ART who showed signs of hyperlactatemia. SL was defined as serum lactate >2.5 mmol/liter. Overall, 806 adults initiated ART. Among the 591 patients (73%) on stavudine-containing regimens, 394 were women (67%); the median pre-ART CD4 count was 150/mm3 and the median body mass index was 20.9 kg/m2. These patients were followed for a median of 28 months. We detected SL only among patients taking stavudine. The incidence of SL was 0.55/100 person-years (PY) (95% CI 0.47-0.63) overall and 0.85/100 PY among women (95% CI 0.75-0.95). Among the eight patients with SL, 100% lost >9% of body weight before diagnosis, 100% had serum lactate >4 mmol/liter (range 4.2-12.1), 50% had pre-ART BMI >25 kg/m2, and three patients died (38%), accounting for 6.4% of deaths among patients taking stavudine. As long as HIV clinicians continue to use stavudine in sub-Saharan Africa, they should watch out for acute unexplained weight loss in patients taking ART, particularly among women and patients with high pre-ART BMI."
p81035
sS'AD'
p81036
S"Programme PAC-CI, Abidjan, Cote d'Ivoire. minga.albert@yahoo.fr"
p81037
sS'CN'
p81038
(lp81039
S'ANRS 1220 Primo-CI Study Group'
p81040
asS'IP'
p81041
S'9'
sS'IS'
p81042
S'1931-8405 (Electronic) 0889-2229 (Linking)'
p81043
sS'IR'
p81044
(lp81045
S'Anglaret X'
p81046
aS'Dabis F'
p81047
aS'Danel C'
p81048
aS'Deveau C'
p81049
aS'Goujard C'
p81050
aS'Lewden C'
p81051
aS'Meyer L'
p81052
aS'Minga A'
p81053
aS'Thiebaut R'
p81054
aS'Chaix ML'
p81055
aS'Rouzioux C'
p81056
aS'Toni Td'
p81057
aS'Inwoley A'
p81058
aS'Sinet M'
p81059
aS'Bazin B'
p81060
aS'Quinty L'
p81061
aS'Abo Y'
p81062
aS'Dohoun L'
p81063
aS'Minga A'
p81064
aS'Anini E'
p81065
aS'Drowa Y'
p81066
aS'Bades IB'
p81067
aS'Kouame T'
p81068
aS"N'Dri MJ"
p81069
aS'Ouattara M'
p81070
aS'Sidibe A'
p81071
aS'Afi R'
p81072
aS'Emieme A'
p81073
aS'Inwoley A'
p81074
aS"Thomas d'Aquin T"
p81075
aS'Coulibaly A'
p81076
aS'Bomisso G'
p81077
aS'Konate M'
p81078
asS'DCOM'
p81079
S'20101109'
p81080
sS'AU'
p81081
(lp81082
S'Minga A'
p81083
aS'Lewden C'
p81084
aS'Dohoun L'
p81085
aS'Abo Y'
p81086
aS'Emieme A'
p81087
aS'Coulibaly A'
p81088
aS'Salamon R'
p81089
aS'Eholie S'
p81090
aS'Anglaret X'
p81091
aS'Danel C'
p81092
asS'VI'
p81093
S'26'
p81094
sS'MHDA'
p81095
S'2010/11/10 06:00'
p81096
sS'OID'
p81097
(lp81098
S'NLM: PMC3531999'
p81099
asS'MH'
p81100
(lp81101
S'Adult'
p81102
aS'Anti-HIV Agents/*therapeutic use'
p81103
aS'CD4 Lymphocyte Count'
p81104
aS"Cote d'Ivoire/epidemiology"
p81105
aS'Female'
p81106
aS'HIV Infections/drug therapy/*epidemiology'
p81107
aS'HIV-1/drug effects/immunology'
p81108
aS'Humans'
p81109
aS'Incidence'
p81110
aS'Lactates/*blood'
p81111
aS'Male'
p81112
aS'Prospective Studies'
p81113
aS'Stavudine/*therapeutic use'
p81114
asS'EDAT'
p81115
S'2010/08/17 06:00'
p81116
sS'PMC'
p81117
S'PMC3531999'
p81118
sS'SO'
p81119
S'AIDS Res Hum Retroviruses. 2010 Sep;26(9):991-5. doi: 10.1089/aid.2009.0309.'
p81120
sS'SB'
p81121
S'IM X'
p81122
sS'PMID'
p81123
S'20707728'
p81124
sS'PST'
p81125
S'ppublish'
p81126
stRp81127
ag2
(g3
g4
(dp81128
S'LID'
p81129
S'10.1001/archinternmed.2010.249 [doi]'
p81130
sS'STAT'
p81131
S'MEDLINE'
p81132
sS'JT'
p81133
S'Archives of internal medicine'
p81134
sS'MID'
p81135
(lp81136
S'NIHMS201527'
p81137
asS'DA'
p81138
S'20100810'
p81139
sS'AID'
p81140
(lp81141
S'170/15/1347 [pii]'
p81142
aS'10.1001/archinternmed.2010.249 [doi]'
p81143
asS'CRDT'
p81144
(lp81145
S'2010/08/11 06:00'
p81146
asS'DP'
p81147
S'2010 Aug 9'
p81148
sS'CON'
p81149
(lp81150
S'Arch Intern Med. 2010 Aug 9;170(15):1354-6. PMID: 20696961'
p81151
asS'OWN'
p81152
S'NLM'
p81153
sS'PT'
p81154
(lp81155
S'Comment'
p81156
aS'Comparative Study'
p81157
aS'Journal Article'
p81158
aS'Research Support, N.I.H., Extramural'
p81159
aS"Research Support, U.S. Gov't, Non-P.H.S."
p81160
asS'LA'
p81161
(lp81162
S'eng'
p81163
asS'FAU'
p81164
(lp81165
S'Bendavid, Eran'
p81166
aS'Brandeau, Margaret L'
p81167
aS'Wood, Robin'
p81168
aS'Owens, Douglas K'
p81169
asS'LR'
p81170
S'20141203'
p81171
sS'PG'
p81172
S'1347-54'
p81173
sS'TI'
p81174
S'Comparative effectiveness of HIV testing and treatment in highly endemic regions.'
p81175
sS'PL'
p81176
S'United States'
p81177
sS'TA'
p81178
S'Arch Intern Med'
p81179
sS'JID'
p81180
S'0372440'
p81181
sS'AB'
p81182
S'BACKGROUND: Universal testing and treatment holds promise for reducing the burden of human immunodeficiency virus (HIV) in sub-Saharan Africa, but linkage from testing to treatment sites and retention in care are inadequate. METHODS: We developed a simulation of the HIV epidemic and HIV disease progression in South Africa to compare the outcomes of the present HIV treatment campaign (status quo) with 4 HIV testing and treating strategies that increase access to antiretroviral therapy: (1) universal testing and treatment without changes in linkage to care and loss to follow-up; (2) universal testing and treatment with improved linkage to care; (3) universal testing and treatment with reduced loss to follow-up; and (4) comprehensive HIV care with universal testing and treatment, improved linkage to care, and reduced loss to follow-up. The main outcome measures were survival benefits, new HIV infections, and HIV prevalence. RESULTS: Compared with the status quo strategy, universal testing and treatment (1) was associated with a mean (95% uncertainty bounds) life expectancy gain of 12.0 months (11.3-12.2 months), and 35.3% (32.7%-37.5%) fewer HIV infections over a 10-year time horizon. Improved linkage to care (2), prevention of loss to follow-up (3), and comprehensive HIV care (4) provided substantial additional benefits: life expectancy gains compared with the status quo strategy were 16.1, 18.6, and 22.2 months, and new infections were 55.5%, 51.4%, and 73.2% lower, respectively. In sensitivity analysis, comprehensive HIV care reduced new infections by 69.7% to 76.7% under a broad set of assumptions. CONCLUSIONS: Universal testing and treatment with current levels of linkage to care and loss to follow-up could substantially reduce the HIV death toll and new HIV infections. However, increasing linkage to care and preventing loss to follow-up provides nearly twice the benefits of universal testing and treatment alone.'
p81183
sS'GR'
p81184
(lp81185
S'K01-AI084582/AI/NIAID NIH HHS/United States'
p81186
aS'R01 DA015612/DA/NIDA NIH HHS/United States'
p81187
aS'R01 DA015612-08/DA/NIDA NIH HHS/United States'
p81188
aS'R01 DA15612/DA/NIDA NIH HHS/United States'
p81189
asS'IP'
p81190
S'15'
p81191
sS'IS'
p81192
S'1538-3679 (Electronic) 0003-9926 (Linking)'
p81193
sS'PMC'
p81194
S'PMC2921232'
p81195
sS'DCOM'
p81196
S'20100901'
p81197
sS'AU'
p81198
(lp81199
S'Bendavid E'
p81200
aS'Brandeau ML'
p81201
aS'Wood R'
p81202
aS'Owens DK'
p81203
asS'AD'
p81204
S'Division of General Internal Medicine, Center for Health Policy, Department of Management Science and Engineering, Stanford University, 117 Encina Commons, Stanford, CA 94305-8526, USA. ebd@stanford.edu'
p81205
sS'VI'
p81206
S'170'
p81207
sS'MHDA'
p81208
S'2010/09/02 06:00'
p81209
sS'OID'
p81210
(lp81211
S'NLM: NIHMS201527'
p81212
aS'NLM: PMC2921232'
p81213
asS'MH'
p81214
(lp81215
S'Adolescent'
p81216
aS'Adult'
p81217
aS'Endemic Diseases'
p81218
aS'Female'
p81219
aS'HIV Infections/*diagnosis/*drug therapy/mortality'
p81220
aS'Humans'
p81221
aS'Male'
p81222
aS'*Mass Screening'
p81223
aS'*Medical Record Linkage'
p81224
aS'Prevalence'
p81225
aS'South Africa/epidemiology'
p81226
aS'Young Adult'
p81227
asS'EDAT'
p81228
S'2010/08/11 06:00'
p81229
sS'SO'
p81230
S'Arch Intern Med. 2010 Aug 9;170(15):1347-54. doi: 10.1001/archinternmed.2010.249.'
p81231
sS'SB'
p81232
S'AIM IM'
p81233
sS'PMID'
p81234
S'20696960'
p81235
sS'PST'
p81236
S'ppublish'
p81237
stRp81238
ag2
(g3
g4
(dp81239
S'LID'
p81240
S'10.1097/QAI.0b013e3181ea0df8 [doi]'
p81241
sS'STAT'
p81242
S'MEDLINE'
p81243
sS'JT'
p81244
S'Journal of acquired immune deficiency syndromes (1999)'
p81245
sS'DA'
p81246
S'20100922'
p81247
sS'AID'
p81248
(lp81249
S'10.1097/QAI.0b013e3181ea0df8 [doi]'
p81250
asS'CRDT'
p81251
(lp81252
S'2010/08/06 06:00'
p81253
asS'DP'
p81254
S'2010 Oct'
p81255
sS'GR'
p81256
(lp81257
S'G0600044/Medical Research Council/United Kingdom'
p81258
aS'G0600344/Medical Research Council/United Kingdom'
p81259
aS'MC_U122886351/Medical Research Council/United Kingdom'
p81260
aS'MC_U122886352/Medical Research Council/United Kingdom'
p81261
aS'MC_U950080931/Medical Research Council/United Kingdom'
p81262
aS'MC_U950080938/Medical Research Council/United Kingdom'
p81263
aS'Medical Research Council/United Kingdom'
p81264
asS'OWN'
p81265
S'NLM'
p81266
sS'PT'
p81267
(lp81268
S'Journal Article'
p81269
aS"Research Support, Non-U.S. Gov't"
p81270
asS'LA'
p81271
(lp81272
S'eng'
p81273
asS'FAU'
p81274
(lp81275
S'Lyagoba, Fred'
p81276
aS'Dunn, David T'
p81277
aS'Pillay, Deenan'
p81278
aS'Kityo, Cissy'
p81279
aS'Robertson, Val'
p81280
aS'Tugume, Stephano'
p81281
aS'Hakim, James'
p81282
aS'Munderi, Paula'
p81283
aS'Chirara, Mike'
p81284
aS'Ndembi, Nicaise'
p81285
aS'Goodall, Ruth L'
p81286
aS'Yirrell, David L'
p81287
aS'Burke, Andy'
p81288
aS'Gilks, Charles F'
p81289
aS'Kaleebu, Pontiano'
p81290
asS'LR'
p81291
S'20151119'
p81292
sS'PG'
p81293
S'277-83'
p81294
sS'TI'
p81295
S'Evolution of drug resistance during 48 weeks of zidovudine/lamivudine/tenofovir in the absence of real-time viral load monitoring.'
p81296
sS'RN'
p81297
(lp81298
S'0 (Anti-HIV Agents)'
p81299
aS'0 (Organophosphonates)'
p81300
aS'2T8Q726O95 (Lamivudine)'
p81301
aS'4B9XT59T7S (Zidovudine)'
p81302
aS'99YXE507IL (Tenofovir)'
p81303
aS'JAC85A2161 (Adenine)'
p81304
asS'PL'
p81305
S'United States'
p81306
sS'TA'
p81307
S'J Acquir Immune Defic Syndr'
p81308
sS'FIR'
p81309
(lp81310
S'Grosskurth, H'
p81311
aS'Munderi, P'
p81312
aS'Kabuye, G'
p81313
aS'Nsibambi, D'
p81314
aS'Kasirye, R'
p81315
aS'Zalwango, E'
p81316
aS'Nakazibwe, M'
p81317
aS'Kikaire, B'
p81318
aS'Nassuna, G'
p81319
aS'Massa, R'
p81320
aS'Fadhiru, K'
p81321
aS'Namyalo, M'
p81322
aS'Zalwango, A'
p81323
aS'Generous, L'
p81324
aS'Khauka, P'
p81325
aS'Rutikarayo, N'
p81326
aS'Nakahima, W'
p81327
aS'Mugisha, A'
p81328
aS'Todd, J'
p81329
aS'Levin, J'
p81330
aS'Muyingo, S'
p81331
aS'Ruberantwari, A'
p81332
aS'Kaleebu, P'
p81333
aS'Yirrell, D'
p81334
aS'Ndembi, N'
p81335
aS'Lyagoba, F'
p81336
aS'Hughes, P'
p81337
aS'Aber, M'
p81338
aS'Medina Lara, A'
p81339
aS'Foster, S'
p81340
aS'Amurwon, J'
p81341
aS'Nyanzi Wakholi, B'
p81342
aS'Wangati, K'
p81343
aS'Amuron, B'
p81344
aS'Kajungu, D'
p81345
aS'Nakiyingi, J'
p81346
aS'Omony, W'
p81347
aS'Nsibambi, D'
p81348
aS'Khauka, P'
p81349
aS'Mugyenyi, P'
p81350
aS'Kityo, C'
p81351
aS'Ssali, F'
p81352
aS'Tumukunde, D'
p81353
aS'Otim, T'
p81354
aS'Kabanda, J'
p81355
aS'Musana, H'
p81356
aS'Akao, J'
p81357
aS'Kyomugisha, H'
p81358
aS'Byamukama, A'
p81359
aS'Sabiiti, J'
p81360
aS'Komugyena, J'
p81361
aS'Wavamunno, P'
p81362
aS'Mukiibi, S'
p81363
aS'Drasiku, A'
p81364
aS'Byaruhanga, R'
p81365
aS'Labeja, O'
p81366
aS'Katundu, P'
p81367
aS'Tugume, S'
p81368
aS'Awio, P'
p81369
aS'Namazzi, A'
p81370
aS'Bakeinyaga, G T'
p81371
aS'Katabira, H'
p81372
aS'Abaine, D'
p81373
aS'Tukamushaba, J'
p81374
aS'Anywar, W'
p81375
aS'Ojiambo, W'
p81376
aS'Angweng, E'
p81377
aS'Murungi, S'
p81378
aS'Haguma, W'
p81379
aS'Atwiine, S'
p81380
aS'Kigozi, J'
p81381
aS'Namale, L'
p81382
aS'Mukose, A'
p81383
aS'Mulindwa, G'
p81384
aS'Atwiine, D'
p81385
aS'Muhwezi, A'
p81386
aS'Nimwesiga, E'
p81387
aS'Barungi, G'
p81388
aS'Takubwa, J'
p81389
aS'Murungi, S'
p81390
aS'Mwebesa, D'
p81391
aS'Kagina, G'
p81392
aS'Mulindwa, M'
p81393
aS'Ahimbisibwe, F'
p81394
aS'Mwesigwa, P'
p81395
aS'Akuma, S'
p81396
aS'Zawedde, C'
p81397
aS'Nyiraguhirwa, D'
p81398
aS'Tumusiime, C'
p81399
aS'Bagaya, L'
p81400
aS'Namara, W'
p81401
aS'Kigozi, J'
p81402
aS'Karungi, J'
p81403
aS'Kankunda, R'
p81404
aS'Enzama, R'
p81405
aS'Latif, A'
p81406
aS'Hakim, J'
p81407
aS'Robertson, V'
p81408
aS'Reid, A'
p81409
aS'Chidziva, E'
p81410
aS'Bulaya-Tembo, R'
p81411
aS'Musoro, G'
p81412
aS'Taziwa, F'
p81413
aS'Chimbetete, C'
p81414
aS'Chakonza, L'
p81415
aS'Mawora, A'
p81416
aS'Muvirimi, C'
p81417
aS'Tinago, G'
p81418
aS'Svovanapasis, P'
p81419
aS'Simango, M'
p81420
aS'Chirema, O'
p81421
aS'Machingura, J'
p81422
aS'Mutsai, S'
p81423
aS'Phiri, M'
p81424
aS'Bafana, T'
p81425
aS'Chirara, M'
p81426
aS'Muchabaiwa, L'
p81427
aS'Muzambi, M'
p81428
aS'Chigwedere, E'
p81429
aS'Pascoe, M'
p81430
aS'Warambwa, C'
p81431
aS'Zengeza, E'
p81432
aS'Mapinge, F'
p81433
aS'Makota, S'
p81434
aS'Jamu, A'
p81435
aS'Ngorima, N'
p81436
aS'Chirairo, H'
p81437
aS'Chitsungo, S'
p81438
aS'Chimanzi, J'
p81439
aS'Maweni, C'
p81440
aS'Warara, R'
p81441
aS'Matongo, M'
p81442
aS'Mudzingwa, S'
p81443
aS'Jangano, M'
p81444
aS'Moyo, K'
p81445
aS'Vere, L'
p81446
aS'Machingura, I'
p81447
aS'Katabira, E'
p81448
aS'Ronald, A'
p81449
aS'Kambungu, A'
p81450
aS'Lutwama, F'
p81451
aS'Mambule, I'
p81452
aS'Nanfuka, A'
p81453
aS'Walusimbi, J'
p81454
aS'Nabankema, E'
p81455
aS'Nalumenya, R'
p81456
aS'Namuli, T'
p81457
aS'Kulume, R'
p81458
aS'Namata, I'
p81459
aS'Nyachwo, L'
p81460
aS'Florence, A'
p81461
aS'Kusiima, A'
p81462
aS'Lubwama, E'
p81463
aS'Nairuba, R'
p81464
aS'Oketta, F'
p81465
aS'Buluma, E'
p81466
aS'Waita, R'
p81467
aS'Ojiambo, H'
p81468
aS'Sadik, F'
p81469
aS'Wanyama, J'
p81470
aS'Nabongo, P'
p81471
aS'Oyugi, J'
p81472
aS'Sematala, F'
p81473
aS'Muganzi, A'
p81474
aS'Twijukye, C'
p81475
aS'Byakwaga, H'
p81476
aS'Ochai, R'
p81477
aS'Muhweezi, D'
p81478
aS'Coutinho, A'
p81479
aS'Etukoit, B'
p81480
aS'Gilks, C'
p81481
aS'Boocock, K'
p81482
aS'Puddephatt, C'
p81483
aS'Grundy, C'
p81484
aS'Bohannon, J'
p81485
aS'Winogron, D'
p81486
aS'Darbyshire, J'
p81487
aS'Gibb, D M'
p81488
aS'Burke, A'
p81489
aS'Bray, D'
p81490
aS'Babiker, A'
p81491
aS'Walker, A S'
p81492
aS'Wilkes, H'
p81493
aS'Rauchenberger, M'
p81494
aS'Sheehan, S'
p81495
aS'Spencer-Drake, C'
p81496
aS'Taylor, K'
p81497
aS'Spyer, M'
p81498
aS'Ferrier, A'
p81499
aS'Naidoo, B'
p81500
aS'Dunn, D'
p81501
aS'Goodall, R'
p81502
aS'Nanfuka, R'
p81503
aS'Mufuka-Kapuya, C'
p81504
aS'Weller, I'
p81505
aS'Babiker, A'
p81506
aS'Bahendeka, S'
p81507
aS'Bassett, M'
p81508
aS'Chogo Wapakhabulo, A'
p81509
aS'Darbyshire, J'
p81510
aS'Gazzard, B'
p81511
aS'Gilks, C'
p81512
aS'Grosskurth, H'
p81513
aS'Hakim, J'
p81514
aS'Latif, A'
p81515
aS'Mapuchere, C'
p81516
aS'Mugurungi, O'
p81517
aS'Mugyenyi, P'
p81518
aS'Burke, C'
p81519
aS'Distel, M'
p81520
aS'Jones, S'
p81521
aS'Loeliger, E'
p81522
aS'Naidoo, P'
p81523
aS'Newland, C'
p81524
aS'Pearce, G'
p81525
aS'Rahim, S'
p81526
aS'Rooney, J'
p81527
aS'Smith, M'
p81528
aS'Snowden, W'
p81529
aS'Steens, J M'
p81530
aS'Breckenridge, A'
p81531
aS'McLaren, A'
p81532
aS'Hill, C'
p81533
aS'Matenga, J'
p81534
aS'Pozniak, A'
p81535
aS'Serwadda, D'
p81536
aS'Peto, T'
p81537
aS'Palfreeman, A'
p81538
aS'Borok, M'
p81539
aS'Katabira, E'
p81540
aS'Awio, P'
p81541
aS'Burke, A'
p81542
aS'Chirara, M'
p81543
aS'Dunn, D'
p81544
aS'Gibb, D'
p81545
aS'Gilks, C'
p81546
aS'Goodall, R'
p81547
aS'Grosskurth, H'
p81548
aS'Hakim, J'
p81549
aS'Kaleebu, P'
p81550
aS'Katundu, P'
p81551
aS'Kityo, C'
p81552
aS'Lyagoba, F'
p81553
aS'McCormick, A'
p81554
aS'Mugyenyi, P'
p81555
aS'Munderi, P'
p81556
aS'Ndembi, N'
p81557
aS'Pillay, D'
p81558
aS'Reid, A'
p81559
aS'Robertson, V'
p81560
aS'Spyer, M'
p81561
aS'Tugume, S'
p81562
aS'Yirrell, D'
p81563
asS'JID'
p81564
S'100892005'
p81565
sS'AB'
p81566
S'OBJECTIVES: To describe the resistance mutations selected by a first-line regimen of zidovudine/lamivudine/tenofovir in the absence of real-time viral load monitoring. DESIGN: A substudy of 300 participants from the Development of Antiretroviral Therapy in Africa trial in Uganda and Zimbabwe, which compared managing antiretroviral therapy with and without laboratory monitoring. METHODS: Stored plasma samples from selected time points were assayed retrospectively for HIV-1 RNA. The pol gene in all baseline samples and those with HIV RNA >1000 copies per milliliter at weeks 24 and 48 were sequenced. RESULTS: The proportion with HIV RNA >1000 copies per milliliter increased from 15% at 24 weeks to 24% at 48 weeks. Eighteen of 31 (58%) genotyped samples at 24 weeks had >/= 1 major nucleoside reverse transcriptase inhibitor-associated mutations compared with 41 of 47 (87%) at 48 weeks. Excluding 1 nonadherent patient, a mean of 2.0 (95% confidence interval: 1.3 to 2.8) thymidine analogue mutations (TAMs) developed between weeks 24 and 48 among 14 patients with HIV RNA >1000 copies per milliliter at both time points. K65R was detected in 8 of 63 (13%) patients and was negatively associated with number of TAMs (P = 0.01) but not viral subtype (P = 0.30). CONCLUSIONS: A high rate of acquisition of TAMs, but not of K65R, among patients with prolonged viraemia was observed. However, most patients were virologically suppressed at 48 weeks, and long-term clinical and immunological outcomes in the Development of Antiretroviral Therapy in Africa trial were favorable.'
p81567
sS'AD'
p81568
S'MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda.'
p81569
sS'CN'
p81570
(lp81571
S'DART Virology and Trial Team'
p81572
asS'IP'
p81573
S'2'
sS'IS'
p81574
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p81575
sS'IR'
p81576
(lp81577
S'Grosskurth H'
p81578
aS'Munderi P'
p81579
aS'Kabuye G'
p81580
aS'Nsibambi D'
p81581
aS'Kasirye R'
p81582
aS'Zalwango E'
p81583
aS'Nakazibwe M'
p81584
aS'Kikaire B'
p81585
aS'Nassuna G'
p81586
aS'Massa R'
p81587
aS'Fadhiru K'
p81588
aS'Namyalo M'
p81589
aS'Zalwango A'
p81590
aS'Generous L'
p81591
aS'Khauka P'
p81592
aS'Rutikarayo N'
p81593
aS'Nakahima W'
p81594
aS'Mugisha A'
p81595
aS'Todd J'
p81596
aS'Levin J'
p81597
aS'Muyingo S'
p81598
aS'Ruberantwari A'
p81599
aS'Kaleebu P'
p81600
aS'Yirrell D'
p81601
aS'Ndembi N'
p81602
aS'Lyagoba F'
p81603
aS'Hughes P'
p81604
aS'Aber M'
p81605
aS'Medina Lara A'
p81606
aS'Foster S'
p81607
aS'Amurwon J'
p81608
aS'Nyanzi Wakholi B'
p81609
aS'Wangati K'
p81610
aS'Amuron B'
p81611
aS'Kajungu D'
p81612
aS'Nakiyingi J'
p81613
aS'Omony W'
p81614
aS'Nsibambi D'
p81615
aS'Khauka P'
p81616
aS'Mugyenyi P'
p81617
aS'Kityo C'
p81618
aS'Ssali F'
p81619
aS'Tumukunde D'
p81620
aS'Otim T'
p81621
aS'Kabanda J'
p81622
aS'Musana H'
p81623
aS'Akao J'
p81624
aS'Kyomugisha H'
p81625
aS'Byamukama A'
p81626
aS'Sabiiti J'
p81627
aS'Komugyena J'
p81628
aS'Wavamunno P'
p81629
aS'Mukiibi S'
p81630
aS'Drasiku A'
p81631
aS'Byaruhanga R'
p81632
aS'Labeja O'
p81633
aS'Katundu P'
p81634
aS'Tugume S'
p81635
aS'Awio P'
p81636
aS'Namazzi A'
p81637
aS'Bakeinyaga GT'
p81638
aS'Katabira H'
p81639
aS'Abaine D'
p81640
aS'Tukamushaba J'
p81641
aS'Anywar W'
p81642
aS'Ojiambo W'
p81643
aS'Angweng E'
p81644
aS'Murungi S'
p81645
aS'Haguma W'
p81646
aS'Atwiine S'
p81647
aS'Kigozi J'
p81648
aS'Namale L'
p81649
aS'Mukose A'
p81650
aS'Mulindwa G'
p81651
aS'Atwiine D'
p81652
aS'Muhwezi A'
p81653
aS'Nimwesiga E'
p81654
aS'Barungi G'
p81655
aS'Takubwa J'
p81656
aS'Murungi S'
p81657
aS'Mwebesa D'
p81658
aS'Kagina G'
p81659
aS'Mulindwa M'
p81660
aS'Ahimbisibwe F'
p81661
aS'Mwesigwa P'
p81662
aS'Akuma S'
p81663
aS'Zawedde C'
p81664
aS'Nyiraguhirwa D'
p81665
aS'Tumusiime C'
p81666
aS'Bagaya L'
p81667
aS'Namara W'
p81668
aS'Kigozi J'
p81669
aS'Karungi J'
p81670
aS'Kankunda R'
p81671
aS'Enzama R'
p81672
aS'Latif A'
p81673
aS'Hakim J'
p81674
aS'Robertson V'
p81675
aS'Reid A'
p81676
aS'Chidziva E'
p81677
aS'Bulaya-Tembo R'
p81678
aS'Musoro G'
p81679
aS'Taziwa F'
p81680
aS'Chimbetete C'
p81681
aS'Chakonza L'
p81682
aS'Mawora A'
p81683
aS'Muvirimi C'
p81684
aS'Tinago G'
p81685
aS'Svovanapasis P'
p81686
aS'Simango M'
p81687
aS'Chirema O'
p81688
aS'Machingura J'
p81689
aS'Mutsai S'
p81690
aS'Phiri M'
p81691
aS'Bafana T'
p81692
aS'Chirara M'
p81693
aS'Muchabaiwa L'
p81694
aS'Muzambi M'
p81695
aS'Chigwedere E'
p81696
aS'Pascoe M'
p81697
aS'Warambwa C'
p81698
aS'Zengeza E'
p81699
aS'Mapinge F'
p81700
aS'Makota S'
p81701
aS'Jamu A'
p81702
aS'Ngorima N'
p81703
aS'Chirairo H'
p81704
aS'Chitsungo S'
p81705
aS'Chimanzi J'
p81706
aS'Maweni C'
p81707
aS'Warara R'
p81708
aS'Matongo M'
p81709
aS'Mudzingwa S'
p81710
aS'Jangano M'
p81711
aS'Moyo K'
p81712
aS'Vere L'
p81713
aS'Machingura I'
p81714
aS'Katabira E'
p81715
aS'Ronald A'
p81716
aS'Kambungu A'
p81717
aS'Lutwama F'
p81718
aS'Mambule I'
p81719
aS'Nanfuka A'
p81720
aS'Walusimbi J'
p81721
aS'Nabankema E'
p81722
aS'Nalumenya R'
p81723
aS'Namuli T'
p81724
aS'Kulume R'
p81725
aS'Namata I'
p81726
aS'Nyachwo L'
p81727
aS'Florence A'
p81728
aS'Kusiima A'
p81729
aS'Lubwama E'
p81730
aS'Nairuba R'
p81731
aS'Oketta F'
p81732
aS'Buluma E'
p81733
aS'Waita R'
p81734
aS'Ojiambo H'
p81735
aS'Sadik F'
p81736
aS'Wanyama J'
p81737
aS'Nabongo P'
p81738
aS'Oyugi J'
p81739
aS'Sematala F'
p81740
aS'Muganzi A'
p81741
aS'Twijukye C'
p81742
aS'Byakwaga H'
p81743
aS'Ochai R'
p81744
aS'Muhweezi D'
p81745
aS'Coutinho A'
p81746
aS'Etukoit B'
p81747
aS'Gilks C'
p81748
aS'Boocock K'
p81749
aS'Puddephatt C'
p81750
aS'Grundy C'
p81751
aS'Bohannon J'
p81752
aS'Winogron D'
p81753
aS'Darbyshire J'
p81754
aS'Gibb DM'
p81755
aS'Burke A'
p81756
aS'Bray D'
p81757
aS'Babiker A'
p81758
aS'Walker AS'
p81759
aS'Wilkes H'
p81760
aS'Rauchenberger M'
p81761
aS'Sheehan S'
p81762
aS'Spencer-Drake C'
p81763
aS'Taylor K'
p81764
aS'Spyer M'
p81765
aS'Ferrier A'
p81766
aS'Naidoo B'
p81767
aS'Dunn D'
p81768
aS'Goodall R'
p81769
aS'Nanfuka R'
p81770
aS'Mufuka-Kapuya C'
p81771
aS'Weller I'
p81772
aS'Babiker A'
p81773
aS'Bahendeka S'
p81774
aS'Bassett M'
p81775
aS'Chogo Wapakhabulo A'
p81776
aS'Darbyshire J'
p81777
aS'Gazzard B'
p81778
aS'Gilks C'
p81779
aS'Grosskurth H'
p81780
aS'Hakim J'
p81781
aS'Latif A'
p81782
aS'Mapuchere C'
p81783
aS'Mugurungi O'
p81784
aS'Mugyenyi P'
p81785
aS'Burke C'
p81786
aS'Distel M'
p81787
aS'Jones S'
p81788
aS'Loeliger E'
p81789
aS'Naidoo P'
p81790
aS'Newland C'
p81791
aS'Pearce G'
p81792
aS'Rahim S'
p81793
aS'Rooney J'
p81794
aS'Smith M'
p81795
aS'Snowden W'
p81796
aS'Steens JM'
p81797
aS'Breckenridge A'
p81798
aS'McLaren A'
p81799
aS'Hill C'
p81800
aS'Matenga J'
p81801
aS'Pozniak A'
p81802
aS'Serwadda D'
p81803
aS'Peto T'
p81804
aS'Palfreeman A'
p81805
aS'Borok M'
p81806
aS'Katabira E'
p81807
aS'Awio P'
p81808
aS'Burke A'
p81809
aS'Chirara M'
p81810
aS'Dunn D'
p81811
aS'Gibb D'
p81812
aS'Gilks C'
p81813
aS'Goodall R'
p81814
aS'Grosskurth H'
p81815
aS'Hakim J'
p81816
aS'Kaleebu P'
p81817
aS'Katundu P'
p81818
aS'Kityo C'
p81819
aS'Lyagoba F'
p81820
aS'McCormick A'
p81821
aS'Mugyenyi P'
p81822
aS'Munderi P'
p81823
aS'Ndembi N'
p81824
aS'Pillay D'
p81825
aS'Reid A'
p81826
aS'Robertson V'
p81827
aS'Spyer M'
p81828
aS'Tugume S'
p81829
aS'Yirrell D'
p81830
asS'DCOM'
p81831
S'20101008'
p81832
sS'AU'
p81833
(lp81834
S'Lyagoba F'
p81835
aS'Dunn DT'
p81836
aS'Pillay D'
p81837
aS'Kityo C'
p81838
aS'Robertson V'
p81839
aS'Tugume S'
p81840
aS'Hakim J'
p81841
aS'Munderi P'
p81842
aS'Chirara M'
p81843
aS'Ndembi N'
p81844
aS'Goodall RL'
p81845
aS'Yirrell DL'
p81846
aS'Burke A'
p81847
aS'Gilks CF'
p81848
aS'Kaleebu P'
p81849
asS'VI'
p81850
S'55'
p81851
sS'MHDA'
p81852
S'2010/10/12 06:00'
p81853
sS'MH'
p81854
(lp81855
S'Adenine/administration & dosage/*analogs & derivatives/therapeutic use'
p81856
aS'Anti-HIV Agents/administration & dosage/*therapeutic use'
p81857
aS'Antiretroviral Therapy, Highly Active'
p81858
aS'Drug Resistance, Viral/genetics'
p81859
aS'Genotype'
p81860
aS'HIV-1/drug effects/genetics'
p81861
aS'Humans'
p81862
aS'Lamivudine/administration & dosage/*therapeutic use'
p81863
aS'Mutation'
p81864
aS'Organophosphonates/administration & dosage/*therapeutic use'
p81865
aS'Tenofovir'
p81866
aS'Time Factors'
p81867
aS'Viral Load'
p81868
aS'Zidovudine/administration & dosage/*therapeutic use'
p81869
asS'EDAT'
p81870
S'2010/08/06 06:00'
p81871
sS'SO'
p81872
S'J Acquir Immune Defic Syndr. 2010 Oct;55(2):277-83. doi: 10.1097/QAI.0b013e3181ea0df8.'
p81873
sS'SB'
p81874
S'IM X'
p81875
sS'PMID'
p81876
S'20686411'
p81877
sS'PST'
p81878
S'ppublish'
p81879
stRp81880
ag2
(g3
g4
(dp81881
S'LID'
p81882
S'10.2471/BLT.09.069419 [doi]'
p81883
sS'STAT'
p81884
S'MEDLINE'
p81885
sS'DEP'
p81886
S'20100510'
p81887
sS'DA'
p81888
S'20100803'
p81889
sS'AID'
p81890
(lp81891
S'10.2471/BLT.09.069419 [doi]'
p81892
asS'CRDT'
p81893
(lp81894
S'2010/08/04 06:00'
p81895
asS'DP'
p81896
S'2010 Aug 1'
p81897
sS'AD'
p81898
S'Africa Centre for Health and Population Studies, Mtubatuba, South Africa. pmutevedzi@africacentre.ac.za'
p81899
sS'OWN'
p81900
S'NLM'
p81901
sS'PT'
p81902
(lp81903
S'Journal Article'
p81904
aS"Research Support, Non-U.S. Gov't"
p81905
aS"Research Support, U.S. Gov't, Non-P.H.S."
p81906
asS'LA'
p81907
(lp81908
S'eng'
p81909
asS'FAU'
p81910
(lp81911
S'Mutevedzi, Portia C'
p81912
aS'Lessells, Richard J'
p81913
aS'Heller, Tom'
p81914
aS'Barnighausen, Till'
p81915
aS'Cooke, Graham S'
p81916
aS'Newell, Marie-Louise'
p81917
asS'JT'
p81918
S'Bulletin of the World Health Organization'
p81919
sS'LR'
p81920
S'20141203'
p81921
sS'PG'
p81922
S'593-600'
p81923
sS'TI'
p81924
S'Scale-up of a decentralized HIV treatment programme in rural KwaZulu-Natal, South Africa: does rapid expansion affect patient outcomes?'
p81925
sS'RN'
p81926
(lp81927
S'0 (Anti-Retroviral Agents)'
p81928
asS'PL'
p81929
S'Switzerland'
p81930
sS'TA'
p81931
S'Bull World Health Organ'
p81932
sS'JID'
p81933
S'7507052'
p81934
sS'AB'
p81935
S'OBJECTIVE: To describe the scale-up of a decentralized HIV treatment programme delivered through the primary health care system in rural KwaZulu-Natal, South Africa, and to assess trends in baseline characteristics and outcomes in the study population. METHODS: The programme started delivery of antiretroviral therapy (ART) in October 2004. Information on all patients initiated on ART was captured in the programme database and follow-up status was updated monthly. All adult patients (> or = 16 years) who initiated ART between October 2004 and September 2008 were included and stratified into 6-month groups. Clinical and sociodemographic characteristics were compared between the groups. Retention in care, mortality, loss to follow-up and virological outcomes were assessed at 12 months post-ART initiation. FINDINGS: A total of 5719 adults initiated on ART were included (67.9% female). Median baseline CD4+ lymphocyte count was 116 cells/microl (interquartile range, IQR: 53-173). There was an increase in the proportion of women who initiated ART while pregnant but no change in other baseline characteristics over time. Overall retention in care at 12 months was 84.0% (95% confidence interval, CI: 82.6-85.3); 10.9% died (95% CI: 9.8-12.0); 3.7% were lost to follow-up (95% CI: 3.0-4.4). Mortality was highest in the first 3 months after ART initiation: 30.1 deaths per 100 person-years (95% CI: 26.3-34.5). At 12 months 23.0% had a detectable viral load (> 25 copies/ml) (95% CI: 19.5-25.5). CONCLUSION: Outcomes were not affected by rapid expansion of this decentralized HIV treatment programme. The relatively high rates of detectable viral load highlight the need for further efforts to improve the quality of services.'
p81936
sS'GR'
p81937
(lp81938
S'Wellcome Trust/United Kingdom'
p81939
asS'IP'
p81940
S'8'
sS'IS'
p81941
S'1564-0604 (Electronic) 0042-9686 (Linking)'
p81942
sS'PMC'
p81943
S'PMC2908968'
p81944
sS'DCOM'
p81945
S'20101130'
p81946
sS'AU'
p81947
(lp81948
S'Mutevedzi PC'
p81949
aS'Lessells RJ'
p81950
aS'Heller T'
p81951
aS'Barnighausen T'
p81952
aS'Cooke GS'
p81953
aS'Newell ML'
p81954
asS'VI'
p81955
S'88'
p81956
sS'MHDA'
p81957
S'2010/12/14 06:00'
p81958
sS'PHST'
p81959
(lp81960
S'2009/07/03 [received]'
p81961
aS'2009/12/09 [revised]'
p81962
aS'2009/12/11 [accepted]'
p81963
aS'2010/05/10 [epublish]'
p81964
asS'OID'
p81965
(lp81966
S'NLM: PMC2908968'
p81967
asS'MH'
p81968
(lp81969
S'Adult'
p81970
aS'Anti-Retroviral Agents/therapeutic use'
p81971
aS'Female'
p81972
aS'HIV Infections/*drug therapy/physiopathology'
p81973
aS'Humans'
p81974
aS'Longitudinal Studies'
p81975
aS'Male'
p81976
aS'Medical Audit'
p81977
aS'*Quality of Health Care'
p81978
aS'Rural Health Services/*organization & administration'
p81979
aS'South Africa'
p81980
asS'EDAT'
p81981
S'2010/08/04 06:00'
p81982
sS'SO'
p81983
S'Bull World Health Organ. 2010 Aug 1;88(8):593-600. doi: 10.2471/BLT.09.069419. Epub 2010 May 10.'
p81984
sS'SB'
p81985
S'IM'
p81986
sS'PMID'
p81987
S'20680124'
p81988
sS'PST'
p81989
S'ppublish'
p81990
stRp81991
ag2
(g3
g4
(dp81992
S'LID'
p81993
S'10.1186/1471-2431-10-54 [doi]'
p81994
sS'STAT'
p81995
S'MEDLINE'
p81996
sS'DEP'
p81997
S'20100730'
p81998
sS'DA'
p81999
S'20100811'
p82000
sS'AID'
p82001
(lp82002
S'1471-2431-10-54 [pii]'
p82003
aS'10.1186/1471-2431-10-54 [doi]'
p82004
asS'CRDT'
p82005
(lp82006
S'2010/08/03 06:00'
p82007
asS'DP'
p82008
S'2010'
p82009
sS'OWN'
p82010
S'NLM'
p82011
sS'PT'
p82012
(lp82013
S'Journal Article'
p82014
aS"Research Support, Non-U.S. Gov't"
p82015
asS'LA'
p82016
(lp82017
S'eng'
p82018
asS'DCOM'
p82019
S'20101019'
p82020
sS'JT'
p82021
S'BMC pediatrics'
p82022
sS'LR'
p82023
S'20141203'
p82024
sS'FAU'
p82025
(lp82026
S'Sutcliffe, Catherine G'
p82027
aS'Bolton-Moore, Carolyn'
p82028
aS'van Dijk, Janneke H'
p82029
aS'Cotham, Matt'
p82030
aS'Tambatamba, Bushimbwa'
p82031
aS'Moss, William J'
p82032
asS'TI'
p82033
S'Secular trends in pediatric antiretroviral treatment programs in rural and urban Zambia: a retrospective cohort study.'
p82034
sS'RN'
p82035
(lp82036
S'0 (Anti-Retroviral Agents)'
p82037
asS'PL'
p82038
S'England'
p82039
sS'PG'
p82040
S'54'
p82041
sS'JID'
p82042
S'100967804'
p82043
sS'AB'
p82044
S'BACKGROUND: Since 2003 pediatric antiretroviral treatment (ART) programs have scaled-up in sub-Saharan Africa and should be evaluated to assess progress and identify areas for improvement. We evaluated secular trends in the characteristics and treatment outcomes of children in three pediatric ART clinics in urban and rural areas in Zambia. METHODS: Routinely collected data were analyzed from three ART programs in rural (Macha and Mukinge) and urban (Lusaka) Zambia between program implementation and July 2008. Data were obtained from electronic medical record systems and medical record abstraction, and were categorized by year of program implementation. Characteristics of all HIV-infected and exposed children enrolled in the programs and all children initiating treatment were compared by year of implementation. RESULTS: Age decreased and immunologic characteristics improved in all groups over time in both urban and rural clinics, with greater improvement observed in the rural clinics. Among children both eligible and ineligible for ART at clinic enrollment, the majority started treatment within a year. A high proportion of children, particularly those ineligible for ART at clinic enrollment, were lost to follow-up prior to initiating ART. Among children initiating ART, clinical and immunologic outcomes after six months of treatment improved in both urban and rural clinics. In the urban clinics, mortality after six months of treatment declined with program duration, and in the rural clinics, the proportion of children defaulting by six months increased with program duration. CONCLUSIONS: Treatment programs are showing signs of progress in the care of HIV-infected children, particularly in the rural clinics where scale-up increased rapidly over the first three years of program implementation. However, continued efforts to optimize care are needed as many children continue to enroll in ART programs at a late stage of disease and thus are not receiving the full benefits of treatment.'
p82045
sS'AD'
p82046
S'Bloomberg School of Public Health, Johns Hopkins University, 615 North Wolfe Street, Baltimore, MD 21205, USA. csutclif@jhsph.edu'
p82047
sS'VI'
p82048
S'10'
p82049
sS'IS'
p82050
S'1471-2431 (Electronic) 1471-2431 (Linking)'
p82051
sS'PMC'
p82052
S'PMC2919522'
p82053
sS'AU'
p82054
(lp82055
S'Sutcliffe CG'
p82056
aS'Bolton-Moore C'
p82057
aS'van Dijk JH'
p82058
aS'Cotham M'
p82059
aS'Tambatamba B'
p82060
aS'Moss WJ'
p82061
asS'MHDA'
p82062
S'2010/10/20 06:00'
p82063
sS'PHST'
p82064
(lp82065
S'2010/01/16 [received]'
p82066
aS'2010/07/30 [accepted]'
p82067
aS'2010/07/30 [aheadofprint]'
p82068
asS'OID'
p82069
(lp82070
S'NLM: PMC2919522'
p82071
asS'MH'
p82072
(lp82073
S'Anti-Retroviral Agents/*therapeutic use'
p82074
aS'Child'
p82075
aS'Child, Preschool'
p82076
aS'Cohort Studies'
p82077
aS'Female'
p82078
aS'HIV Infections/*drug therapy'
p82079
aS'Humans'
p82080
aS'Infant'
p82081
aS'Male'
p82082
aS'Rural Health Services'
p82083
aS'Treatment Outcome'
p82084
aS'Urban Health Services'
p82085
aS'Zambia'
p82086
asS'EDAT'
p82087
S'2010/08/03 06:00'
p82088
sS'SO'
p82089
S'BMC Pediatr. 2010 Jul 30;10:54. doi: 10.1186/1471-2431-10-54.'
p82090
sS'SB'
p82091
S'IM'
p82092
sS'PMID'
p82093
S'20673355'
p82094
sS'TA'
p82095
S'BMC Pediatr'
p82096
sS'PST'
p82097
S'epublish'
p82098
stRp82099
ag2
(g3
g4
(dp82100
S'LID'
p82101
S'10.1128/JCM.00564-10 [doi]'
p82102
sS'STAT'
p82103
S'MEDLINE'
p82104
sS'DEP'
p82105
S'20100721'
p82106
sS'DA'
p82107
S'20100831'
p82108
sS'AID'
p82109
(lp82110
S'JCM.00564-10 [pii]'
p82111
aS'10.1128/JCM.00564-10 [doi]'
p82112
asS'CRDT'
p82113
(lp82114
S'2010/07/28 06:00'
p82115
asS'DP'
p82116
S'2010 Sep'
p82117
sS'OWN'
p82118
S'NLM'
p82119
sS'PT'
p82120
(lp82121
S'Evaluation Studies'
p82122
aS'Journal Article'
p82123
aS"Research Support, Non-U.S. Gov't"
p82124
aS"Research Support, U.S. Gov't, P.H.S."
p82125
asS'LA'
p82126
(lp82127
S'eng'
p82128
asS'FAU'
p82129
(lp82130
S'Yang, Chunfu'
p82131
aS'McNulty, Amanda'
p82132
aS'Diallo, Karidia'
p82133
aS'Zhang, Jing'
p82134
aS'Titanji, Boghuma'
p82135
aS'Kassim, Sidibe'
p82136
aS'Wadonda-Kabondo, Nellie'
p82137
aS'Aberle-Grasse, John'
p82138
aS'Kibuka, Tabitha'
p82139
aS'Ndumbe, Peter M'
p82140
aS'Vedapuri, Shanmugam'
p82141
aS'Zhou, Zhiyong'
p82142
aS'Chilima, Benson'
p82143
aS'Nkengasong, John N'
p82144
asS'JT'
p82145
S'Journal of clinical microbiology'
p82146
sS'LR'
p82147
S'20141203'
p82148
sS'PG'
p82149
S'3158-64'
p82150
sS'TI'
p82151
S'Development and application of a broadly sensitive dried-blood-spot-based genotyping assay for global surveillance of HIV-1 drug resistance.'
p82152
sS'PL'
p82153
S'United States'
p82154
sS'TA'
p82155
S'J Clin Microbiol'
p82156
sS'JID'
p82157
S'7505564'
p82158
sS'AB'
p82159
S'As antiretroviral therapy (ART) is scaled up in resource-limited countries, surveillance for HIV drug resistance (DR) is vital to ensure sustained effectiveness of first-line ART. We have developed and applied a broadly sensitive dried-blood-spot (DBS)-based genotyping assay for surveillance of HIV-1 DR in international settings. In 2005 and 2006, 171 DBS samples were collected under field conditions from newly diagnosed HIV-1-infected individuals from Malawi (n = 58), Tanzania (n = 60), and China (n =53). In addition, 30 DBS and 40 plasma specimens collected from ART patients in China and Cameroon, respectively, were also tested. Of the 171 DBS analyzed at the protease and RT regions, 149 (87.1%) could be genotyped, including 49 (81.7%) from Tanzania, 47 (88.7%) from China, and 53 (91.4%) from Malawi. Among the 70 ART patient samples analyzed, 100% (30/30) of the Chinese DBS and 90% (36/40) of the Cameroonian plasma specimens were genotyped, including 8 samples with a viral load of <400 copies/ml. The results of phylogenetic analyses indicated that the subtype, circulating recombinant form (CRF), and unique recombinant form (URF) distribution was as follows: 73 strains were subtype C (34%), 37 were subtype B (17.2%), 24 each were CRF01_AE or CRF02_AG (11.2% each), 22 were subtype A1 (10.2%), and 9 were unclassifiable (UC) (4.2%). The remaining samples were minor strains comprised of 6 that were CRF07_BC (2.8%), 5 that were CRF10_CD (2.3%), 3 each that were URF_A1C and CRF08_BC (1.4%), 2 each that were G, URF_BC, and URF_D/UC (0.9%), and 1 each that were subtype F1, subtype F2, and URF_A1D (0.5%). Our results indicate that this broadly sensitive genotyping assay can be used to genotype DBS collected from areas with diverse HIV-1 group M subtypes and CRFs. Thus, the assay is likely to become a useful screening tool in the global resistance surveillance and monitoring of HIV-1 where multiple subtypes and CRFs are found.'
p82160
sS'AD'
p82161
S'Division of Global AIDS, International Laboratory Branch, DGHA, NCHHSTP, CDC, Mail Stop A-11, 1600 Clifton Road, Atlanta, GA 30333, USA. cxy0@cdc.gov'
p82162
sS'IP'
p82163
S'9'
sS'IS'
p82164
S'1098-660X (Electronic) 0095-1137 (Linking)'
p82165
sS'PMC'
p82166
S'PMC2937690'
p82167
sS'DCOM'
p82168
S'20101208'
p82169
sS'AU'
p82170
(lp82171
S'Yang C'
p82172
aS'McNulty A'
p82173
aS'Diallo K'
p82174
aS'Zhang J'
p82175
aS'Titanji B'
p82176
aS'Kassim S'
p82177
aS'Wadonda-Kabondo N'
p82178
aS'Aberle-Grasse J'
p82179
aS'Kibuka T'
p82180
aS'Ndumbe PM'
p82181
aS'Vedapuri S'
p82182
aS'Zhou Z'
p82183
aS'Chilima B'
p82184
aS'Nkengasong JN'
p82185
asS'VI'
p82186
S'48'
p82187
sS'MHDA'
p82188
S'2010/12/14 06:00'
p82189
sS'PHST'
p82190
(lp82191
S'2010/07/21 [aheadofprint]'
p82192
asS'OID'
p82193
(lp82194
S'NLM: PMC2937690'
p82195
asS'MH'
p82196
(lp82197
S'Blood/*virology'
p82198
aS'Cameroon'
p82199
aS'China'
p82200
aS'*Desiccation'
p82201
aS'Genotype'
p82202
aS'HIV Infections/*virology'
p82203
aS'HIV-1/classification/*drug effects/genetics/isolation & purification'
p82204
aS'Humans'
p82205
aS'Malawi'
p82206
aS'Microbial Sensitivity Tests/methods'
p82207
aS'Molecular Sequence Data'
p82208
aS'Phylogeny'
p82209
aS'Sequence Analysis, DNA'
p82210
aS'Specimen Handling/*methods'
p82211
aS'Tanzania'
p82212
asS'EDAT'
p82213
S'2010/07/28 06:00'
p82214
sS'SI'
p82215
(lp82216
S'GENBANK/HQ009559'
p82217
aS'GENBANK/HQ009560'
p82218
aS'GENBANK/HQ009561'
p82219
aS'GENBANK/HQ009562'
p82220
aS'GENBANK/HQ009563'
p82221
aS'GENBANK/HQ009564'
p82222
aS'GENBANK/HQ009565'
p82223
aS'GENBANK/HQ009566'
p82224
aS'GENBANK/HQ009567'
p82225
aS'GENBANK/HQ009568'
p82226
aS'GENBANK/HQ009569'
p82227
aS'GENBANK/HQ009570'
p82228
aS'GENBANK/HQ009571'
p82229
aS'GENBANK/HQ009572'
p82230
aS'GENBANK/HQ009573'
p82231
aS'GENBANK/HQ009574'
p82232
aS'GENBANK/HQ009575'
p82233
aS'GENBANK/HQ009576'
p82234
aS'GENBANK/HQ009577'
p82235
aS'GENBANK/HQ009578'
p82236
aS'GENBANK/HQ009579'
p82237
aS'GENBANK/HQ009580'
p82238
aS'GENBANK/HQ009581'
p82239
aS'GENBANK/HQ009582'
p82240
aS'GENBANK/HQ009583'
p82241
aS'GENBANK/HQ009584'
p82242
aS'GENBANK/HQ009585'
p82243
aS'GENBANK/HQ009586'
p82244
aS'GENBANK/HQ009587'
p82245
aS'GENBANK/HQ009588'
p82246
aS'GENBANK/HQ009589'
p82247
aS'GENBANK/HQ009590'
p82248
aS'GENBANK/HQ009591'
p82249
aS'GENBANK/HQ009592'
p82250
aS'GENBANK/HQ009593'
p82251
aS'GENBANK/HQ009594'
p82252
aS'GENBANK/HQ009595'
p82253
aS'GENBANK/HQ009596'
p82254
aS'GENBANK/HQ009597'
p82255
aS'GENBANK/HQ009598'
p82256
aS'GENBANK/HQ009599'
p82257
aS'GENBANK/HQ009600'
p82258
aS'GENBANK/HQ009601'
p82259
aS'GENBANK/HQ009602'
p82260
aS'GENBANK/HQ009603'
p82261
aS'GENBANK/HQ009604'
p82262
aS'GENBANK/HQ009605'
p82263
aS'GENBANK/HQ009606'
p82264
aS'GENBANK/HQ009607'
p82265
aS'GENBANK/HQ009608'
p82266
aS'GENBANK/HQ009609'
p82267
aS'GENBANK/HQ009610'
p82268
aS'GENBANK/HQ009611'
p82269
aS'GENBANK/HQ009612'
p82270
aS'GENBANK/HQ009613'
p82271
aS'GENBANK/HQ009614'
p82272
aS'GENBANK/HQ009615'
p82273
aS'GENBANK/HQ009616'
p82274
aS'GENBANK/HQ009617'
p82275
aS'GENBANK/HQ009618'
p82276
aS'GENBANK/HQ009619'
p82277
aS'GENBANK/HQ009620'
p82278
aS'GENBANK/HQ009621'
p82279
aS'GENBANK/HQ009622'
p82280
aS'GENBANK/HQ009623'
p82281
aS'GENBANK/HQ009624'
p82282
aS'GENBANK/HQ009625'
p82283
aS'GENBANK/HQ009626'
p82284
aS'GENBANK/HQ009627'
p82285
aS'GENBANK/HQ009628'
p82286
aS'GENBANK/HQ009629'
p82287
aS'GENBANK/HQ009630'
p82288
aS'GENBANK/HQ009631'
p82289
aS'GENBANK/HQ009632'
p82290
aS'GENBANK/HQ009633'
p82291
aS'GENBANK/HQ009634'
p82292
aS'GENBANK/HQ009635'
p82293
aS'GENBANK/HQ009636'
p82294
aS'GENBANK/HQ009637'
p82295
aS'GENBANK/HQ009638'
p82296
aS'GENBANK/HQ009639'
p82297
aS'GENBANK/HQ009640'
p82298
aS'GENBANK/HQ009641'
p82299
aS'GENBANK/HQ009642'
p82300
aS'GENBANK/HQ009643'
p82301
aS'GENBANK/HQ009644'
p82302
aS'GENBANK/HQ009645'
p82303
aS'GENBANK/HQ009646'
p82304
aS'GENBANK/HQ009647'
p82305
aS'GENBANK/HQ009648'
p82306
aS'GENBANK/HQ009649'
p82307
aS'GENBANK/HQ009650'
p82308
aS'GENBANK/HQ009651'
p82309
aS'GENBANK/HQ009652'
p82310
aS'GENBANK/HQ009653'
p82311
aS'GENBANK/HQ009654'
p82312
aS'GENBANK/HQ009655'
p82313
aS'GENBANK/HQ009656'
p82314
aS'GENBANK/HQ009657'
p82315
aS'GENBANK/HQ009658'
p82316
aS'GENBANK/HQ009659'
p82317
aS'GENBANK/HQ009660'
p82318
aS'GENBANK/HQ009661'
p82319
aS'GENBANK/HQ009662'
p82320
aS'GENBANK/HQ009663'
p82321
aS'GENBANK/HQ009664'
p82322
aS'GENBANK/HQ009665'
p82323
aS'GENBANK/HQ009666'
p82324
aS'GENBANK/HQ009667'
p82325
aS'GENBANK/HQ009668'
p82326
aS'GENBANK/HQ009669'
p82327
aS'GENBANK/HQ009670'
p82328
aS'GENBANK/HQ009671'
p82329
aS'GENBANK/HQ009672'
p82330
aS'GENBANK/HQ009673'
p82331
aS'GENBANK/HQ009674'
p82332
aS'GENBANK/HQ009675'
p82333
aS'GENBANK/HQ009676'
p82334
aS'GENBANK/HQ009677'
p82335
aS'GENBANK/HQ009678'
p82336
aS'GENBANK/HQ009679'
p82337
aS'GENBANK/HQ009680'
p82338
aS'GENBANK/HQ009681'
p82339
aS'GENBANK/HQ009682'
p82340
aS'GENBANK/HQ009683'
p82341
aS'GENBANK/HQ009684'
p82342
aS'GENBANK/HQ009685'
p82343
aS'GENBANK/HQ009686'
p82344
aS'GENBANK/HQ009687'
p82345
aS'GENBANK/HQ009688'
p82346
aS'GENBANK/HQ009689'
p82347
aS'GENBANK/HQ009690'
p82348
asS'SO'
p82349
S'J Clin Microbiol. 2010 Sep;48(9):3158-64. doi: 10.1128/JCM.00564-10. Epub 2010 Jul 21.'
p82350
sS'SB'
p82351
S'IM'
p82352
sS'PMID'
p82353
S'20660209'
p82354
sS'PST'
p82355
S'ppublish'
p82356
stRp82357
ag2
(g3
g4
(dp82358
S'LID'
p82359
S'10.1016/S0140-6736(10)60666-6 [doi]'
p82360
sS'STAT'
p82361
S'MEDLINE'
p82362
sS'DEP'
p82363
S'20100715'
p82364
sS'MID'
p82365
(lp82366
S'NIHMS227856'
p82367
asS'DA'
p82368
S'20100809'
p82369
sS'AID'
p82370
(lp82371
S'S0140-6736(10)60666-6 [pii]'
p82372
aS'10.1016/S0140-6736(10)60666-6 [doi]'
p82373
asS'CRDT'
p82374
(lp82375
S'2010/07/20 06:00'
p82376
asS'DP'
p82377
S'2010 Aug 7'
p82378
sS'GR'
p82379
(lp82380
S'1U01AI069924/AI/NIAID NIH HHS/United States'
p82381
aS'5U01AI069919/AI/NIAID NIH HHS/United States'
p82382
aS'G0700820/Medical Research Council/United Kingdom'
p82383
aS'U01 AI069919/AI/NIAID NIH HHS/United States'
p82384
aS'U01 AI069924/AI/NIAID NIH HHS/United States'
p82385
aS'U01 AI069924-04/AI/NIAID NIH HHS/United States'
p82386
asS'OWN'
p82387
S'NLM'
p82388
sS'PT'
p82389
(lp82390
S'Journal Article'
p82391
aS'Research Support, N.I.H., Extramural'
p82392
aS"Research Support, Non-U.S. Gov't"
p82393
asS'LA'
p82394
(lp82395
S'eng'
p82396
asS'FAU'
p82397
(lp82398
S'May, Margaret'
p82399
aS'Boulle, Andrew'
p82400
aS'Phiri, Sam'
p82401
aS'Messou, Eugene'
p82402
aS'Myer, Landon'
p82403
aS'Wood, Robin'
p82404
aS'Keiser, Olivia'
p82405
aS'Sterne, Jonathan A C'
p82406
aS'Dabis, Francois'
p82407
aS'Egger, Matthias'
p82408
asS'JT'
p82409
S'Lancet (London, England)'
p82410
sS'LR'
p82411
S'20150616'
p82412
sS'PG'
p82413
S'449-57'
p82414
sS'TI'
p82415
S'Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes.'
p82416
sS'RN'
p82417
(lp82418
S'0 (Anti-Retroviral Agents)'
p82419
asS'PL'
p82420
S'England'
p82421
sS'TA'
p82422
S'Lancet'
p82423
sS'JID'
p82424
S'2985213R'
p82425
sS'AB'
p82426
S"BACKGROUND: Prognostic models have been developed for patients infected with HIV-1 who start combination antiretroviral therapy (ART) in high-income countries, but not for patients in sub-Saharan Africa. We developed two prognostic models to estimate the probability of death in patients starting ART in sub-Saharan Africa. METHODS: We analysed data for adult patients who started ART in four scale-up programmes in Cote d'Ivoire, South Africa, and Malawi from 2004 to 2007. Patients lost to follow-up in the first year were excluded. We used Weibull survival models to construct two prognostic models: one with CD4 cell count, clinical stage, bodyweight, age, and sex (CD4 count model); and one that replaced CD4 cell count with total lymphocyte count and severity of anaemia (total lymphocyte and haemoglobin model), because CD4 cell count is not routinely measured in many African ART programmes. Death from all causes in the first year of ART was the primary outcome. FINDINGS: 912 (8.2%) of 11 153 patients died in the first year of ART. 822 patients were lost to follow-up and not included in the main analysis; 10 331 patients were analysed. Mortality was strongly associated with high baseline CD4 cell count (>/=200 cells per muL vs <25; adjusted hazard ratio 0.21, 95% CI 0.17-0.27), WHO clinical stage (stages III-IV vs I-II; 3.45, 2.43-4.90), bodyweight (>/=60 kg vs <45 kg; 0.23, 0.18-0.30), and anaemia status (none vs severe: 0.27, 0.20-0.36). Other independent risk factors for mortality were low total lymphocyte count, advanced age, and male sex. Probability of death at 1 year ranged from 0.9% (95% CI 0.6-1.4) to 52.5% (43.8-61.7) with the CD4 model, and from 0.9% (0.5-1.4) to 59.6% (48.2-71.4) with the total lymphocyte and haemoglobin model. Both models accurately predict early mortality in patients starting ART in sub-Saharan Africa compared with observed data. INTERPRETATION: Prognostic models should be used to counsel patients, plan health services, and predict outcomes for patients with HIV-1 infection in sub-Saharan Africa. FUNDING: US National Institute of Allergy And Infectious Diseases, Eunice Kennedy Shriver National Institute of Child Health and Human Development, and National Cancer Institute."
p82427
sS'AD'
p82428
S'Department of Social Medicine, University of Bristol, Bristol, UK.'
p82429
sS'CN'
p82430
(lp82431
S'IeDEA Southern Africa and West Africa'
p82432
asS'IP'
p82433
S'9739'
p82434
sS'IS'
p82435
S'1474-547X (Electronic) 0140-6736 (Linking)'
p82436
sS'PMC'
p82437
S'PMC3138328'
p82438
sS'DCOM'
p82439
S'20100824'
p82440
sS'CIN'
p82441
(lp82442
S'Lancet. 2010 Oct 16;376(9749):1302. PMID: 20951892'
p82443
aS'Lancet. 2010 Aug 7;376(9739):396-8. PMID: 20638119'
p82444
asS'AU'
p82445
(lp82446
S'May M'
p82447
aS'Boulle A'
p82448
aS'Phiri S'
p82449
aS'Messou E'
p82450
aS'Myer L'
p82451
aS'Wood R'
p82452
aS'Keiser O'
p82453
aS'Sterne JA'
p82454
aS'Dabis F'
p82455
aS'Egger M'
p82456
asS'VI'
p82457
S'376'
p82458
sS'MHDA'
p82459
S'2010/08/25 06:00'
p82460
sS'PHST'
p82461
(lp82462
S'2010/07/15 [aheadofprint]'
p82463
asS'OID'
p82464
(lp82465
S'NLM: NIHMS227856'
p82466
aS'NLM: PMC3138328'
p82467
asS'CI'
p82468
(lp82469
S'Copyright 2010 Elsevier Ltd. All rights reserved.'
p82470
asS'MH'
p82471
(lp82472
S'Adolescent'
p82473
aS'Adult'
p82474
aS'Africa South of the Sahara/epidemiology'
p82475
aS'Anti-Retroviral Agents/*therapeutic use'
p82476
aS'Developing Countries'
p82477
aS'Female'
p82478
aS'HIV Infections/*drug therapy/epidemiology/mortality/virology'
p82479
aS'*HIV-1'
p82480
aS'Humans'
p82481
aS'Male'
p82482
aS'Middle Aged'
p82483
aS'Models, Statistical'
p82484
aS'Prognosis'
p82485
aS'Survival Rate'
p82486
aS'Viral Load'
p82487
aS'Young Adult'
p82488
asS'EDAT'
p82489
S'2010/07/20 06:00'
p82490
sS'SO'
p82491
S'Lancet. 2010 Aug 7;376(9739):449-57. doi: 10.1016/S0140-6736(10)60666-6. Epub 2010 Jul 15.'
p82492
sS'SB'
p82493
S'AIM IM'
p82494
sS'PMID'
p82495
S'20638120'
p82496
sS'PST'
p82497
S'ppublish'
p82498
stRp82499
ag2
(g3
g4
(dp82500
S'LID'
p82501
S'10.1097/INF.0b013e3181ed2af3 [doi]'
p82502
sS'STAT'
p82503
S'MEDLINE'
p82504
sS'AB'
p82505
S'BACKGROUND: Long-term (>12 months follow-up) virologic data of children receiving antiretroviral therapy (ART) in Sub-Saharan Africa are limited. Data from rural areas are especially scarce. The aim of this study was to evaluate the long-term virologic outcome of a pediatric cohort in rural South Africa. METHODS: We performed a retrospective, observational cohort study, including children who initiated ART at least 1 year before data-analysis. Regular monitoring, including HIV-RNA testing, was performed. Genotypic resistance testing was done for children with virologic failure (HIV-RNA >1000 copies/mL). Logistic regression analysis was used to determine predictors of virologic failure. RESULTS: A total of 101 children were included. Median duration since beginning ART was 31 months. Overall patient retention-rate was 76% (77/101), with early mortality being the main cause of attrition (13/24, 54%). Initial immunologic and virologic responses were excellent. However, 38% (31/81) of children subsequently experienced virologic failure. Correlation between virologic failure and immunologic decline was nearly absent. At the time of failure, multiple non-nucleoside reverse transcription inhibitor-associated mutations were observed in 52% (12/23) of children. No definite predictors of virologic failure could be determined. CONCLUSIONS: ART provides significant benefits for children in this rural African setting, but the finding that a large proportion of children had virologic failure and developed major drug-resistance mutations on first-line ART is worrying. Causes of failure need to be analyzed and effective prevention strategies are needed. Because of the lack of a correlation between immunologic and virologic failure, treatment failure generally stays unnoticed in settings where HIV-RNA testing is not available.'
p82506
sS'JID'
p82507
S'8701858'
p82508
sS'AD'
p82509
S'Department of Internal Medicine and Infectious Diseases, University Medical Centre Utrecht, Utrecht, The Netherlands. r.e.barth@umcutrecht.nl'
p82510
sS'JT'
p82511
S'The Pediatric infectious disease journal'
p82512
sS'IP'
p82513
S'1'
sS'IS'
p82514
S'1532-0987 (Electronic) 0891-3668 (Linking)'
p82515
sS'DCOM'
p82516
S'20110714'
p82517
sS'DA'
p82518
S'20110420'
p82519
sS'AU'
p82520
(lp82521
S'Barth RE'
p82522
aS'Tempelman HA'
p82523
aS'Smelt E'
p82524
aS'Wensing AM'
p82525
aS'Hoepelman AI'
p82526
aS'Geelen SP'
p82527
asS'AID'
p82528
(lp82529
S'10.1097/INF.0b013e3181ed2af3 [doi]'
p82530
asS'CRDT'
p82531
(lp82532
S'2010/07/16 06:00'
p82533
asS'VI'
p82534
S'30'
p82535
sS'PMID'
p82536
S'20631647'
p82537
sS'DP'
p82538
S'2011 Jan'
p82539
sS'MHDA'
p82540
S'2011/07/16 06:00'
p82541
sS'OWN'
p82542
S'NLM'
p82543
sS'PT'
p82544
(lp82545
S'Journal Article'
p82546
asS'LA'
p82547
(lp82548
S'eng'
p82549
asS'MH'
p82550
(lp82551
S'Adolescent'
p82552
aS'Anti-Retroviral Agents/*therapeutic use'
p82553
aS'CD4 Lymphocyte Count'
p82554
aS'Chi-Square Distribution'
p82555
aS'Child'
p82556
aS'Child, Preschool'
p82557
aS'Drug Resistance, Viral'
p82558
aS'HIV Infections/*drug therapy/virology'
p82559
aS'HIV-1/genetics'
p82560
aS'Humans'
p82561
aS'Infant'
p82562
aS'Logistic Models'
p82563
aS'Longitudinal Studies'
p82564
aS'Lost to Follow-Up'
p82565
aS'Medication Adherence'
p82566
aS'Mutation'
p82567
aS'Retrospective Studies'
p82568
aS'Rural Population'
p82569
aS'South Africa'
p82570
aS'Treatment Outcome'
p82571
asS'FAU'
p82572
(lp82573
S'Barth, Roos E'
p82574
aS'Tempelman, Hugo A'
p82575
aS'Smelt, Elbert'
p82576
aS'Wensing, Annemarie M J'
p82577
aS'Hoepelman, Andy I'
p82578
aS'Geelen, Sibyl P'
p82579
asS'EDAT'
p82580
S'2010/07/16 06:00'
p82581
sS'PST'
p82582
S'ppublish'
p82583
sS'SO'
p82584
S'Pediatr Infect Dis J. 2011 Jan;30(1):52-6. doi: 10.1097/INF.0b013e3181ed2af3.'
p82585
sS'PG'
p82586
S'52-6'
p82587
sS'TI'
p82588
S'Long-term outcome of children receiving antiretroviral treatment in rural South Africa: substantial virologic failure on first-line treatment.'
p82589
sS'SB'
p82590
S'IM'
p82591
sS'RN'
p82592
(lp82593
S'0 (Anti-Retroviral Agents)'
p82594
asS'PL'
p82595
S'United States'
p82596
sS'TA'
p82597
S'Pediatr Infect Dis J'
p82598
stRp82599
ag2
(g3
g4
(dp82600
S'STAT'
p82601
S'MEDLINE'
p82602
sS'JT'
p82603
S'The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease'
p82604
sS'CIN'
p82605
(lp82606
S'Int J Tuberc Lung Dis. 2010 Aug;14(8):935-6. PMID: 20626933'
p82607
asS'DA'
p82608
S'20100714'
p82609
sS'CRDT'
p82610
(lp82611
S'2010/07/15 06:00'
p82612
asS'DP'
p82613
S'2010 Aug'
p82614
sS'AD'
p82615
S'Department of Community Health, Nelson R Mandela School of Medicine, Centre for AIDS Programme of Research in South Africa, Durban, South Africa.'
p82616
sS'OWN'
p82617
S'NLM'
p82618
sS'PT'
p82619
(lp82620
S'Comparative Study'
p82621
aS'Journal Article'
p82622
aS'Research Support, N.I.H., Extramural'
p82623
aS"Research Support, Non-U.S. Gov't"
p82624
asS'LA'
p82625
(lp82626
S'eng'
p82627
asS'FAU'
p82628
(lp82629
S'Padayatchi, N'
p82630
aS'Daftary, A'
p82631
aS'Moodley, T'
p82632
aS'Madansein, R'
p82633
aS'Ramjee, A'
p82634
asS'LR'
p82635
S'20151119'
p82636
sS'PG'
p82637
S'960-6'
p82638
sS'TI'
p82639
S'Case series of the long-term psychosocial impact of drug-resistant tuberculosis in HIV-negative medical doctors.'
p82640
sS'RN'
p82641
(lp82642
S'0 (Antitubercular Agents)'
p82643
asS'PL'
p82644
S'France'
p82645
sS'TA'
p82646
S'Int J Tuberc Lung Dis'
p82647
sS'JID'
p82648
S'9706389'
p82649
sS'AB'
p82650
S'BACKGROUND: Health care workers (HCWs) are at greater risk for tuberculosis (TB), including multidrug-resistant TB (MDR-TB), compared to the general population. The psychosocial impact of nosocomial TB on HCWs has received little attention in the literature. METHODS: A retrospective medical record review from 1999 to 2003 found 15 HCWs who were treated for drug-resistant TB at a specialist hospital in South Africa. Five human immunodeficiency virus (HIV) negative doctors with no predisposing factors for drug resistance are included in this case series. We collectively present their clinical case histories based on medical records from 2000 to 2005, and explore the long-term psychosocial impact of TB from interviews conducted in 2009. RESULTS: Four doctors had primary MDR-TB and one had primary resistance to multiple first-line drugs. Time from symptom onset to commencement of effective treatment ranged from 8 to 39 weeks. Time for bacteriological confirmation of drug-resistant TB ranged from 6 to 24 weeks. All were cured within 3 years of initial presentation. Content analysis of follow-up interviews revealed five main themes: 1) prolonged morbidity, 2) psychological impact, 3) poor infection control, 4) weak support structures and 5) attrition from the field. CONCLUSION: Themes emergent from this case series encourage prioritisation of TB infection control education and practice to minimise HCW morbidity and prevent HCW attrition from high-burden resource-constrained settings.'
p82651
sS'GR'
p82652
(lp82653
S'AI51794/AI/NIAID NIH HHS/United States'
p82654
aS'Canadian Institutes of Health Research/Canada'
p82655
asS'IP'
p82656
S'8'
sS'IS'
p82657
S'1815-7920 (Electronic) 1027-3719 (Linking)'
p82658
sS'DCOM'
p82659
S'20101019'
p82660
sS'AU'
p82661
(lp82662
S'Padayatchi N'
p82663
aS'Daftary A'
p82664
aS'Moodley T'
p82665
aS'Madansein R'
p82666
aS'Ramjee A'
p82667
asS'VI'
p82668
S'14'
p82669
sS'MHDA'
p82670
S'2010/10/20 06:00'
p82671
sS'MH'
p82672
(lp82673
S'Adult'
p82674
aS'Antitubercular Agents/*therapeutic use'
p82675
aS'*Attitude to Health'
p82676
aS'Drug Resistance, Bacterial'
p82677
aS'Female'
p82678
aS'Follow-Up Studies'
p82679
aS'*HIV Seronegativity'
p82680
aS'Humans'
p82681
aS'Incidence'
p82682
aS'Infectious Disease Transmission, Patient-to-Professional/*prevention & control'
p82683
aS'Male'
p82684
aS'Mental Disorders/epidemiology/*etiology/psychology'
p82685
aS'Physicians/*psychology'
p82686
aS'Prognosis'
p82687
aS'Retrospective Studies'
p82688
aS'Risk Factors'
p82689
aS'South Africa/epidemiology'
p82690
aS'Surveys and Questionnaires'
p82691
aS'Time Factors'
p82692
aS'Tuberculosis, Multidrug-Resistant/complications/*psychology/transmission'
p82693
asS'EDAT'
p82694
S'2010/07/16 06:00'
p82695
sS'SO'
p82696
S'Int J Tuberc Lung Dis. 2010 Aug;14(8):960-6.'
p82697
sS'SB'
p82698
S'IM'
p82699
sS'PMID'
p82700
S'20626939'
p82701
sS'PST'
p82702
S'ppublish'
p82703
stRp82704
ag2
(g3
g4
(dp82705
S'LID'
p82706
S'10.1089/aid.2009.0229 [doi]'
p82707
sS'STAT'
p82708
S'MEDLINE'
p82709
sS'JT'
p82710
S'AIDS research and human retroviruses'
p82711
sS'DA'
p82712
S'20100719'
p82713
sS'AID'
p82714
(lp82715
S'10.1089/aid.2009.0229 [doi]'
p82716
asS'CRDT'
p82717
(lp82718
S'2010/07/14 06:00'
p82719
asS'DP'
p82720
S'2010 Jul'
p82721
sS'OWN'
p82722
S'NLM'
p82723
sS'PT'
p82724
(lp82725
S'Journal Article'
p82726
aS"Research Support, Non-U.S. Gov't"
p82727
asS'LA'
p82728
(lp82729
S'eng'
p82730
asS'FAU'
p82731
(lp82732
S'Lihana, Raphael W'
p82733
aS'Khamadi, Samoel A'
p82734
aS'Lubano, Kizito'
p82735
aS'Mwangi, Joseph'
p82736
aS'Kinyua, Joyceline G'
p82737
aS'Okoth, Vincent O'
p82738
aS'Lagat, Nancy J'
p82739
aS'Okoth, Fredrick A'
p82740
aS'Songok, Elijah M'
p82741
aS'Makokha, Ernest P'
p82742
asS'PG'
p82743
S'833-8'
p82744
sS'TI'
p82745
S'Genetic characterization of HIV type 1 among patients with suspected immune reconstitution inflammatory syndrome after initiation of antiretroviral therapy in Kenya.'
p82746
sS'RN'
p82747
(lp82748
S'0 (Anti-HIV Agents)'
p82749
aS'0 (env Gene Products, Human Immunodeficiency Virus)'
p82750
aS'0 (pol Gene Products, Human Immunodeficiency Virus)'
p82751
asS'PL'
p82752
S'United States'
p82753
sS'TA'
p82754
S'AIDS Res Hum Retroviruses'
p82755
sS'JID'
p82756
S'8709376'
p82757
sS'AB'
p82758
S'Antiretroviral therapy (ART) has improved the survival of HIV patients but is also associated with unique manifestations of disease in some subjects during the initial months of therapy. Immune reconstitution inflammatory syndrome (IRIS) is a disorder among individuals starting ART, with no evidence-based treatment and management guidelines. We characterized HIV-1 and determined drug resistance among 14 Kenyan patients with suspected IRIS after ART initiation in 2005. Polymerase chain reaction, sequencing, and phylogenetic analysis of viral pol and env showed the following HIV-1 subtypes: A1/A1/A1 (pol-RT/gp41/C2V3), 5; A1/C/A1, 1; A1/D/A1, 2; D/A1/A1, 1; D/C/A1, 1; D/D/A1, 2; D/D/D, 1; and D/A1/A2, 1. Three patients had viruses with major drug resistance-associated mutations. These included nucleoside reverse transcriptase inhibitor (RTI) mutations: M41L, K65R, D67N, K70R, M184V, and K219Q, and nonnucleoside RTI mutations: K101P, L100I, K103N, and Y181C. Twelve patients harbored viruses that are predicted to use chemokine coreceptor 5 (CCR5) whereas two had variant viruses predicted to use the CXCR4 coreceptor. Drug resistance may not be the only cause of ART adverse events. HIV-1 characterization would be important before and during HIV therapy to avoid treatment failure.'
p82759
sS'AD'
p82760
S'Center for Virus Research, Kenya Medical Research Institute, Nairobi, Kenya. Rlihana@kemri.org'
p82761
sS'IP'
p82762
S'7'
sS'IS'
p82763
S'1931-8405 (Electronic) 0889-2229 (Linking)'
p82764
sS'DCOM'
p82765
S'20101019'
p82766
sS'AU'
p82767
(lp82768
S'Lihana RW'
p82769
aS'Khamadi SA'
p82770
aS'Lubano K'
p82771
aS'Mwangi J'
p82772
aS'Kinyua JG'
p82773
aS'Okoth VO'
p82774
aS'Lagat NJ'
p82775
aS'Okoth FA'
p82776
aS'Songok EM'
p82777
aS'Makokha EP'
p82778
asS'VI'
p82779
S'26'
p82780
sS'MHDA'
p82781
S'2010/10/20 06:00'
p82782
sS'MH'
p82783
(lp82784
S'Adult'
p82785
aS'Aged'
p82786
aS'Amino Acid Substitution/genetics'
p82787
aS'Anti-HIV Agents/adverse effects/*therapeutic use'
p82788
aS'Antiretroviral Therapy, Highly Active/*adverse effects'
p82789
aS'Drug Resistance, Viral'
p82790
aS'Female'
p82791
aS'HIV Infections/*complications/drug therapy/*virology'
p82792
aS'HIV-1/*classification/*genetics/isolation & purification'
p82793
aS'Humans'
p82794
aS'Immune Reconstitution Inflammatory Syndrome/*virology'
p82795
aS'Kenya'
p82796
aS'Male'
p82797
aS'Middle Aged'
p82798
aS'Molecular Sequence Data'
p82799
aS'Mutation, Missense'
p82800
aS'Sequence Analysis, DNA'
p82801
aS'env Gene Products, Human Immunodeficiency Virus/genetics'
p82802
aS'pol Gene Products, Human Immunodeficiency Virus/genetics'
p82803
asS'EDAT'
p82804
S'2010/07/14 06:00'
p82805
sS'SI'
p82806
(lp82807
S'GENBANK/FJ599374'
p82808
aS'GENBANK/FJ599375'
p82809
aS'GENBANK/FJ599376'
p82810
aS'GENBANK/FJ599377'
p82811
aS'GENBANK/FJ599378'
p82812
aS'GENBANK/FJ599381'
p82813
aS'GENBANK/FJ599382'
p82814
aS'GENBANK/FJ599383'
p82815
aS'GENBANK/FJ599384'
p82816
aS'GENBANK/FJ599385'
p82817
aS'GENBANK/FJ599386'
p82818
aS'GENBANK/FJ599387'
p82819
aS'GENBANK/FJ599388'
p82820
aS'GENBANK/FJ599389'
p82821
aS'GENBANK/FJ599390'
p82822
aS'GENBANK/FJ599391'
p82823
aS'GENBANK/FJ599392'
p82824
aS'GENBANK/FJ599393'
p82825
aS'GENBANK/FJ599394'
p82826
aS'GENBANK/FJ599395'
p82827
aS'GENBANK/FJ599396'
p82828
aS'GENBANK/FJ599397'
p82829
aS'GENBANK/FJ599398'
p82830
aS'GENBANK/FJ599399'
p82831
aS'GENBANK/FJ599482'
p82832
aS'GENBANK/FJ599483'
p82833
aS'GENBANK/FJ599484'
p82834
aS'GENBANK/FJ599485'
p82835
aS'GENBANK/FJ599486'
p82836
aS'GENBANK/FJ599487'
p82837
aS'GENBANK/FJ599488'
p82838
aS'GENBANK/FJ599489'
p82839
aS'GENBANK/FJ599490'
p82840
aS'GENBANK/FJ599491'
p82841
aS'GENBANK/FJ599492'
p82842
aS'GENBANK/FJ599493'
p82843
aS'GENBANK/FJ599494'
p82844
aS'GENBANK/FJ599495'
p82845
aS'GENBANK/FJ599496'
p82846
aS'GENBANK/FJ599497'
p82847
aS'GENBANK/FJ599498'
p82848
asS'SO'
p82849
S'AIDS Res Hum Retroviruses. 2010 Jul;26(7):833-8. doi: 10.1089/aid.2009.0229.'
p82850
sS'SB'
p82851
S'IM X'
p82852
sS'PMID'
p82853
S'20624074'
p82854
sS'PST'
p82855
S'ppublish'
p82856
stRp82857
ag2
(g3
g4
(dp82858
S'LID'
p82859
S'10.1111/j.1365-3156.2010.02503.x [doi]'
p82860
sS'STAT'
p82861
S'MEDLINE'
p82862
sS'AB'
p82863
S'OBJECTIVE: To assess the effect of decentralization (DC) of antiretroviral therapy (ART) provision in a rural district of Malawi using an integrated primary care model. METHODS: Between October 2004 and December 2008, 8093 patients (63% women) were registered for ART. Of these, 3440 (43%) were decentralized to health centres for follow-up ART care. We applied multivariate regression analysis that adjusted for sex, age, clinical stage at initiation, type of regimen, presence of side effects because of ART, and duration of treatment and follow-up at site of analysis. RESULTS: Patients managed at health centres had lower mortality [adjusted OR 0.19 (95% C.I. 0.15-0.25)] and lower loss to follow-up (defaulted from treatment) [adjusted OR 0.48 (95% C.I. 0.40-0.58)]. During the first 10 months of follow-up, those decentralized to health centres were approximately 60% less likely to default than those not decentralized; and after 10 months of follow-up, 40% less likely to default. DC was significantly associated with a reduced risk of death from 0 to 25 months of follow-up. The lower mortality may be explained by the selection of stable patients for DC, and the mentorship and supportive supervision of lower cadre health workers to identify and refer complicated cases. CONCLUSION: Decentralization of follow-up ART care to rural health facilities, using an integrated primary care model, appears a safe and effective way to rapidly scale-up ART and improves both geographical equity in access to HIV-related services and adherence to ART.'
p82864
sS'AD'
p82865
S'Dignitas International, Zomba, Malawi.'
p82866
sS'JT'
p82867
S'Tropical medicine & international health : TM & IH'
p82868
sS'VI'
p82869
S'15 Suppl 1'
p82870
sS'IS'
p82871
S'1365-3156 (Electronic) 1360-2276 (Linking)'
p82872
sS'JID'
p82873
S'9610576'
p82874
sS'DA'
p82875
S'20100630'
p82876
sS'AU'
p82877
(lp82878
S'Chan AK'
p82879
aS'Mateyu G'
p82880
aS'Jahn A'
p82881
aS'Schouten E'
p82882
aS'Arora P'
p82883
aS'Mlotha W'
p82884
aS'Kambanji M'
p82885
aS'van Lettow M'
p82886
asS'AID'
p82887
(lp82888
S'TMI2503 [pii]'
p82889
aS'10.1111/j.1365-3156.2010.02503.x [doi]'
p82890
asS'CRDT'
p82891
(lp82892
S'2010/07/01 06:00'
p82893
asS'PMID'
p82894
S'20586966'
p82895
sS'DP'
p82896
S'2010 Jun'
p82897
sS'MHDA'
p82898
S'2011/05/03 06:00'
p82899
sS'OWN'
p82900
S'NLM'
p82901
sS'PT'
p82902
(lp82903
S'Journal Article'
p82904
aS'Multicenter Study'
p82905
asS'LA'
p82906
(lp82907
S'eng'
p82908
asS'MH'
p82909
(lp82910
S'Adolescent'
p82911
aS'Adult'
p82912
aS'Anti-HIV Agents/administration & dosage'
p82913
aS'*Antiretroviral Therapy, Highly Active'
p82914
aS'Child'
p82915
aS'Child, Preschool'
p82916
aS'Delivery of Health Care/*organization & administration'
p82917
aS'Drug Administration Schedule'
p82918
aS'Epidemiologic Methods'
p82919
aS'Female'
p82920
aS'HIV Infections/*drug therapy/mortality'
p82921
aS'Humans'
p82922
aS'Infant'
p82923
aS'Infant, Newborn'
p82924
aS'Long-Term Care/organization & administration'
p82925
aS'Malawi/epidemiology'
p82926
aS'Male'
p82927
aS'Medication Adherence/statistics & numerical data'
p82928
aS'Models, Organizational'
p82929
aS'Outcome Assessment (Health Care)'
p82930
aS'Primary Health Care/organization & administration'
p82931
aS'Rural Health Services/*organization & administration'
p82932
aS'Young Adult'
p82933
asS'DCOM'
p82934
S'20110502'
p82935
sS'EDAT'
p82936
S'2010/07/14 06:00'
p82937
sS'PST'
p82938
S'ppublish'
p82939
sS'SO'
p82940
S'Trop Med Int Health. 2010 Jun;15 Suppl 1:90-7. doi: 10.1111/j.1365-3156.2010.02503.x.'
p82941
sS'FAU'
p82942
(lp82943
S'Chan, Adrienne K'
p82944
aS'Mateyu, Gabriel'
p82945
aS'Jahn, Andreas'
p82946
aS'Schouten, Erik'
p82947
aS'Arora, Paul'
p82948
aS'Mlotha, William'
p82949
aS'Kambanji, Marion'
p82950
aS'van Lettow, Monique'
p82951
asS'TI'
p82952
S'Outcome assessment of decentralization of antiretroviral therapy provision in a rural district of Malawi using an integrated primary care model.'
p82953
sS'SB'
p82954
S'IM'
p82955
sS'RN'
p82956
(lp82957
S'0 (Anti-HIV Agents)'
p82958
asS'TA'
p82959
S'Trop Med Int Health'
p82960
sS'PL'
p82961
S'England'
p82962
sS'PG'
p82963
S'90-7'
p82964
stRp82965
ag2
(g3
g4
(dp82966
S'LID'
p82967
S'10.1111/j.1365-3156.2010.02507.x [doi]'
p82968
sS'STAT'
p82969
S'MEDLINE'
p82970
sS'JT'
p82971
S'Tropical medicine & international health : TM & IH'
p82972
sS'MID'
p82973
(lp82974
S'NIHMS270616'
p82975
asS'DA'
p82976
S'20100630'
p82977
sS'AID'
p82978
(lp82979
S'TMI2507 [pii]'
p82980
aS'10.1111/j.1365-3156.2010.02507.x [doi]'
p82981
asS'CRDT'
p82982
(lp82983
S'2010/07/01 06:00'
p82984
asS'DP'
p82985
S'2010 Jun'
p82986
sS'AD'
p82987
S'Division of HIV/AIDS, Department of Medicine, San Francisco General Hospital, San Francisco, CA, USA. genge@php.ucsf.edu'
p82988
sS'OWN'
p82989
S'NLM'
p82990
sS'PT'
p82991
(lp82992
S'Journal Article'
p82993
asS'LA'
p82994
(lp82995
S'eng'
p82996
asS'DCOM'
p82997
S'20110502'
p82998
sS'LR'
p82999
S'20141203'
p83000
sS'FAU'
p83001
(lp83002
S'Geng, Elvin H'
p83003
aS'Glidden, David V'
p83004
aS'Emenyonu, Nneka'
p83005
aS'Musinguzi, Nicolas'
p83006
aS'Bwana, Mwebwesa Bosco'
p83007
aS'Neilands, Torsten B'
p83008
aS'Muyindike, Winnie'
p83009
aS'Yiannoutsos, Constantin T'
p83010
aS'Deeks, Steven G'
p83011
aS'Bangsberg, David R'
p83012
aS'Martin, Jeffrey N'
p83013
asS'TI'
p83014
S'Tracking a sample of patients lost to follow-up has a major impact on understanding determinants of survival in HIV-infected patients on antiretroviral therapy in Africa.'
p83015
sS'PL'
p83016
S'England'
p83017
sS'PG'
p83018
S'63-9'
p83019
sS'JID'
p83020
S'9610576'
p83021
sS'AB'
p83022
S"OBJECTIVE: To date, data regarding the determinants of mortality in HIV-infected patients starting antiretroviral therapy (ART) in Africa have been primarily derived from routine clinical care settings practicing the public health approach. Losses to follow-up, however, are high in these settings and may lead to bias in understanding the determinants of mortality. METHODS: We evaluated HIV-infected adults initiating ART between January 1, 2004 and September 30th, 2007 in an ART clinic in southwestern Uganda. Clinical and demographic characteristics were obtained through routine clinical care. In evaluating determinants of mortality, a 'naive' analysis used only deaths known through routine processes. A 'sample-corrected' approach incorporated, through probability weights, outcomes from a representative sample of patients lost to follow-up whose vital status was ascertained through tracking in the community. RESULTS: In 3,628 patients followed for up to 3.75 years after ART initiation, the 'naive' approach identified male sex and lower pre-ART CD4 count as independent determinants of mortality. The 'sample-corrected' approach found lower pre-ART CD4 count, older age, lower weight and calendar year of ART initiation, but not male sex, to be independent determinants of mortality. CONCLUSIONS: Analyses to identify determinants of mortality in HIV-infected patients on ART in Africa that do not account for losses to follow-up can identify spurious associations and miss actual relationships - both with the potential to mislead public health efforts. A sampling-based approach to account for losses to follow-up represents a feasible and potentially scalable method to strengthen the evidence available for implementation of ART delivery in Africa."
p83023
sS'GR'
p83024
(lp83025
S'K23 AI084544/AI/NIAID NIH HHS/United States'
p83026
aS'K23 AI084544-01/AI/NIAID NIH HHS/United States'
p83027
aS'K23 AI084544-02/AI/NIAID NIH HHS/United States'
p83028
aS'K23 AI084544-03/AI/NIAID NIH HHS/United States'
p83029
aS'K24 MH087227/MH/NIMH NIH HHS/United States'
p83030
aS'R01 MH054907/MH/NIMH NIH HHS/United States'
p83031
asS'VI'
p83032
S'15 Suppl 1'
p83033
sS'IS'
p83034
S'1365-3156 (Electronic) 1360-2276 (Linking)'
p83035
sS'PMC'
p83036
S'PMC3038920'
p83037
sS'AU'
p83038
(lp83039
S'Geng EH'
p83040
aS'Glidden DV'
p83041
aS'Emenyonu N'
p83042
aS'Musinguzi N'
p83043
aS'Bwana MB'
p83044
aS'Neilands TB'
p83045
aS'Muyindike W'
p83046
aS'Yiannoutsos CT'
p83047
aS'Deeks SG'
p83048
aS'Bangsberg DR'
p83049
aS'Martin JN'
p83050
asS'MHDA'
p83051
S'2011/05/03 06:00'
p83052
sS'OID'
p83053
(lp83054
S'NLM: NIHMS270616'
p83055
aS'NLM: PMC3038920'
p83056
asS'MH'
p83057
(lp83058
S'Adult'
p83059
aS'*Antiretroviral Therapy, Highly Active'
p83060
aS'CD4 Lymphocyte Count'
p83061
aS'Female'
p83062
aS'Follow-Up Studies'
p83063
aS'HIV Infections/*drug therapy/immunology/mortality'
p83064
aS'Humans'
p83065
aS'Lost to Follow-Up'
p83066
aS'Male'
p83067
aS'Medication Adherence/statistics & numerical data'
p83068
aS'Patient Dropouts/*statistics & numerical data'
p83069
aS'Sex Factors'
p83070
aS'Treatment Outcome'
p83071
aS'Uganda/epidemiology'
p83072
asS'EDAT'
p83073
S'2010/07/14 06:00'
p83074
sS'SO'
p83075
S'Trop Med Int Health. 2010 Jun;15 Suppl 1:63-9. doi: 10.1111/j.1365-3156.2010.02507.x.'
p83076
sS'SB'
p83077
S'IM'
p83078
sS'PMID'
p83079
S'20586962'
p83080
sS'TA'
p83081
S'Trop Med Int Health'
p83082
sS'PST'
p83083
S'ppublish'
p83084
stRp83085
ag2
(g3
g4
(dp83086
S'LID'
p83087
S'10.1111/j.1365-3156.2010.02514.x [doi]'
p83088
sS'STAT'
p83089
S'MEDLINE'
p83090
sS'JT'
p83091
S'Tropical medicine & international health : TM & IH'
p83092
sS'DA'
p83093
S'20100630'
p83094
sS'AID'
p83095
(lp83096
S'TMI2514 [pii]'
p83097
aS'10.1111/j.1365-3156.2010.02514.x [doi]'
p83098
asS'CRDT'
p83099
(lp83100
S'2010/07/01 06:00'
p83101
asS'DP'
p83102
S'2010 Jun'
p83103
sS'OWN'
p83104
S'NLM'
p83105
sS'PT'
p83106
(lp83107
S'Journal Article'
p83108
aS"Research Support, Non-U.S. Gov't"
p83109
asS'LA'
p83110
(lp83111
S'eng'
p83112
asS'DCOM'
p83113
S'20110502'
p83114
sS'LR'
p83115
S'20141203'
p83116
sS'FAU'
p83117
(lp83118
S'Miller, Candace M'
p83119
aS'Ketlhapile, Mpefe'
p83120
aS'Rybasack-Smith, Heather'
p83121
aS'Rosen, Sydney'
p83122
asS'TI'
p83123
S'Why are antiretroviral treatment patients lost to follow-up? A qualitative study from South Africa.'
p83124
sS'RN'
p83125
(lp83126
S'0 (Anti-HIV Agents)'
p83127
asS'PL'
p83128
S'England'
p83129
sS'PG'
p83130
S'48-54'
p83131
sS'JID'
p83132
S'9610576'
p83133
sS'AB'
p83134
S'OBJECTIVES: To better understand the reasons why patients default from antiretroviral treatment (ART) programmes to help design interventions that improve treatment retention and ultimately, patient outcomes. METHODS: Prospective cohort study at two treatment sites in South Africa followed by qualitative interviews with patients that had defaulted. RESULTS: Respondents overwhelmingly reported that ART improved their health status and quality of life. Nevertheless, despite improved health from taking ART and worse health when treatment is stopped, serious barriers to treatment remained: transport costs, time needed for treatment, and logistical challenges were barriers to treatment, whereas stigma around HIV/AIDS, and side effects associated with ART were less influential. CONCLUSION: With a better understanding of the reasons for defaulting, interventions can be designed that improve treatment retention and ultimately, patient outcomes. This study argues for realistic interventions and policy changes designed to reduce the financial and time burden of ART and to reduce logistical barriers, such as simplifying the referral and transfer process, employing patient advocates, and adopting extended and weekend clinic hours.'
p83135
sS'AD'
p83136
S'Center for Global Health and Development, Boston University, Boston, MA 02118, USA. Candace@bu.edu'
p83137
sS'VI'
p83138
S'15 Suppl 1'
p83139
sS'IS'
p83140
S'1365-3156 (Electronic) 1360-2276 (Linking)'
p83141
sS'PMC'
p83142
S'PMC3060335'
p83143
sS'AU'
p83144
(lp83145
S'Miller CM'
p83146
aS'Ketlhapile M'
p83147
aS'Rybasack-Smith H'
p83148
aS'Rosen S'
p83149
asS'MHDA'
p83150
S'2011/05/03 06:00'
p83151
sS'OID'
p83152
(lp83153
S'NLM: PMC3060335'
p83154
asS'MH'
p83155
(lp83156
S'Adult'
p83157
aS'Anti-HIV Agents/administration & dosage'
p83158
aS'Antiretroviral Therapy, Highly Active/psychology/*statistics & numerical data'
p83159
aS'Drug Administration Schedule'
p83160
aS'Epidemiologic Methods'
p83161
aS'Female'
p83162
aS'HIV Infections/*drug therapy/psychology'
p83163
aS'Health Knowledge, Attitudes, Practice'
p83164
aS'Health Status'
p83165
aS'Humans'
p83166
aS'Lost to Follow-Up'
p83167
aS'Male'
p83168
aS'Medication Adherence/psychology/*statistics & numerical data'
p83169
aS'Patient Dropouts/psychology/statistics & numerical data'
p83170
aS'South Africa'
p83171
asS'EDAT'
p83172
S'2010/07/14 06:00'
p83173
sS'SO'
p83174
S'Trop Med Int Health. 2010 Jun;15 Suppl 1:48-54. doi: 10.1111/j.1365-3156.2010.02514.x.'
p83175
sS'SB'
p83176
S'IM'
p83177
sS'PMID'
p83178
S'20586960'
p83179
sS'TA'
p83180
S'Trop Med Int Health'
p83181
sS'PST'
p83182
S'ppublish'
p83183
stRp83184
ag2
(g3
g4
(dp83185
S'LID'
p83186
S'10.1111/j.1365-3156.2010.02511.x [doi]'
p83187
sS'STAT'
p83188
S'MEDLINE'
p83189
sS'JT'
p83190
S'Tropical medicine & international health : TM & IH'
p83191
sS'MID'
p83192
(lp83193
S'NIHMS237472'
p83194
asS'DA'
p83195
S'20100630'
p83196
sS'AID'
p83197
(lp83198
S'TMI2511 [pii]'
p83199
aS'10.1111/j.1365-3156.2010.02511.x [doi]'
p83200
asS'CRDT'
p83201
(lp83202
S'2010/07/01 06:00'
p83203
asS'DP'
p83204
S'2010 Jun'
p83205
sS'AD'
p83206
S'Center for Global Health and Development, Boston University School of Public Health, Boston, MA 02118, USA. blarson@bu.edu'
p83207
sS'OWN'
p83208
S'NLM'
p83209
sS'PT'
p83210
(lp83211
S'Journal Article'
p83212
aS'Research Support, N.I.H., Extramural'
p83213
aS"Research Support, Non-U.S. Gov't"
p83214
aS"Research Support, U.S. Gov't, Non-P.H.S."
p83215
asS'LA'
p83216
(lp83217
S'eng'
p83218
asS'DCOM'
p83219
S'20110502'
p83220
sS'LR'
p83221
S'20141203'
p83222
sS'FAU'
p83223
(lp83224
S'Larson, Bruce A'
p83225
aS'Brennan, Alana'
p83226
aS'McNamara, Lynne'
p83227
aS'Long, Lawrence'
p83228
aS'Rosen, Sydney'
p83229
aS'Sanne, Ian'
p83230
aS'Fox, Matthew P'
p83231
asS'TI'
p83232
S'Early loss to follow up after enrolment in pre-ART care at a large public clinic in Johannesburg, South Africa.'
p83233
sS'PL'
p83234
S'England'
p83235
sS'PG'
p83236
S'43-7'
p83237
sS'JID'
p83238
S'9610576'
p83239
sS'AB'
p83240
S'OBJECTIVE: To estimate loss to follow up (LTFU) between initial enrollment and the first scheduled return medical visit of a pre-antiretroviral therapy (ART) care program for patients not eligible for ART. METHODS: The study was conducted at a public-sector HIV clinic in Johannesburg. We reviewed records of all patients newly enrolled in the pre-ART care program and not yet eligible for ART between January 2007 and February 2008. Crude proportions of patients completing their first return medical visit stratified by patient characteristics were calculated. A modified-Poisson approach was used to estimate directly relative risks of returning for their first return medical visit within 1 year adjusting for patient characteristics as potential confounders. RESULTS: A total of 356 patients were identified. Two-thirds had a CD4 count > 350 cells/microl (median [IQR] CD4 = 458 [394, 585]) and were scheduled to return in 6 months for a first medical visit. Seventy-four percent of these patients did not return within one year for this visit. The remaining 36% of all patients had a baseline CD4 count 251-350 cells/microl and were scheduled to return in 3 months. Only 6% of these patients returned within 4 months; 41% returned within one year. Relative risks were positively associated with a patient being employed and negatively associated with the baseline CD4 count. CONCLUSIONS: Given the high rate of LTFU immediately after enrolling in pre-ART care, it is clear that care programs are not expediting the timely initiation of ART. Significantly improved adherence to pre-ART care and monitoring for patients not yet eligible for ART is required for South Africa to achieve its AIDS strategy goals and reduce the problem of late presentation and initiation of ART.'
p83241
sS'GR'
p83242
(lp83243
S'K01 AI083097/AI/NIAID NIH HHS/United States'
p83244
aS'K01 AI083097-01/AI/NIAID NIH HHS/United States'
p83245
aS'K01AI083097/AI/NIAID NIH HHS/United States'
p83246
asS'VI'
p83247
S'15 Suppl 1'
p83248
sS'IS'
p83249
S'1365-3156 (Electronic) 1360-2276 (Linking)'
p83250
sS'PMC'
p83251
S'PMC2954490'
p83252
sS'AU'
p83253
(lp83254
S'Larson BA'
p83255
aS'Brennan A'
p83256
aS'McNamara L'
p83257
aS'Long L'
p83258
aS'Rosen S'
p83259
aS'Sanne I'
p83260
aS'Fox MP'
p83261
asS'MHDA'
p83262
S'2011/05/03 06:00'
p83263
sS'OID'
p83264
(lp83265
S'NLM: NIHMS237472'
p83266
aS'NLM: PMC2954490'
p83267
asS'MH'
p83268
(lp83269
S'Adult'
p83270
aS'Antiretroviral Therapy, Highly Active'
p83271
aS'CD4 Lymphocyte Count'
p83272
aS'Female'
p83273
aS'Follow-Up Studies'
p83274
aS'HIV Infections/immunology/psychology/*therapy'
p83275
aS'Humans'
p83276
aS'Long-Term Care'
p83277
aS'Lost to Follow-Up'
p83278
aS'Male'
p83279
aS'Patient Compliance/statistics & numerical data'
p83280
aS'Patient Dropouts/*statistics & numerical data'
p83281
aS'Program Evaluation'
p83282
aS'South Africa'
p83283
asS'EDAT'
p83284
S'2010/07/14 06:00'
p83285
sS'SO'
p83286
S'Trop Med Int Health. 2010 Jun;15 Suppl 1:43-7. doi: 10.1111/j.1365-3156.2010.02511.x.'
p83287
sS'SB'
p83288
S'IM'
p83289
sS'PMID'
p83290
S'20586959'
p83291
sS'TA'
p83292
S'Trop Med Int Health'
p83293
sS'PST'
p83294
S'ppublish'
p83295
stRp83296
ag2
(g3
g4
(dp83297
S'LID'
p83298
S'10.1111/j.1365-3156.2010.02508.x [doi]'
p83299
sS'STAT'
p83300
S'MEDLINE'
p83301
sS'JT'
p83302
S'Tropical medicine & international health : TM & IH'
p83303
sS'CIN'
p83304
(lp83305
S'Trop Med Int Health. 2011 Mar;16(3):390-1; author reply 392. PMID: 21143352'
p83306
asS'DA'
p83307
S'20100630'
p83308
sS'AID'
p83309
(lp83310
S'TMI2508 [pii]'
p83311
aS'10.1111/j.1365-3156.2010.02508.x [doi]'
p83312
asS'CRDT'
p83313
(lp83314
S'2010/07/01 06:00'
p83315
asS'DP'
p83316
S'2010 Jun'
p83317
sS'AD'
p83318
S'Center for Global Health and Development, Boston University, Boston, MA 02118, USA. mfox@bu.edu'
p83319
sS'OWN'
p83320
S'NLM'
p83321
sS'PT'
p83322
(lp83323
S'Journal Article'
p83324
aS'Research Support, N.I.H., Extramural'
p83325
aS"Research Support, Non-U.S. Gov't"
p83326
aS"Research Support, U.S. Gov't, Non-P.H.S."
p83327
aS'Review'
p83328
asS'LA'
p83329
(lp83330
S'eng'
p83331
asS'DCOM'
p83332
S'20110502'
p83333
sS'LR'
p83334
S'20141203'
p83335
sS'FAU'
p83336
(lp83337
S'Fox, Matthew P'
p83338
aS'Rosen, Sydney'
p83339
asS'TI'
p83340
S'Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review.'
p83341
sS'PL'
p83342
S'England'
p83343
sS'PG'
p83344
S'1-15'
p83345
sS'JID'
p83346
S'9610576'
p83347
sS'AB'
p83348
S'OBJECTIVES: To estimate the proportion of all-cause adult patient attrition from antiretroviral therapy (ART) programs in service delivery settings in sub-Saharan Africa through 36 months on treatment. METHODS: We identified cohorts within Ovid Medline, ISI Web of Knowledge, Cochrane Database of Systematic Reviews and four conference abstract archives. We summarized retention rates from studies describing observational cohorts from sub-Saharan Africa reporting on adult HIV 1- infected patients initiating first-line three-drug ART. We estimated all-cause attrition rates for 6, 12, 18, 24, or 36 months after ART initiation including patients who died or were lost to follow-up (as defined by the author), but excluding transferred patients. RESULTS: We analysed 33 sources describing 39 cohorts and 226 307 patients. Patients were more likely to be female (median 65%) and had a median age at initiation of 37 (range 34-40). Median starting CD4 count was 109 cells/mm(3). Loss to follow-up was the most common cause of attrition (59%), followed by death (41%). Median attrition at 12, 24 and 36 months was 22.6% (range 7%-45%), 25% (range 11%-32%) and 29.5% (range 13%-36.1%) respectively. After pooling data in a random-effects meta-analysis, retention declined from 86.1% at 6 months to 80.2% at 12 months, 76.8% at 24 months and 72.3% at 36 months. Adjusting for variable follow-up time in a sensitivity analysis, 24 month retention was 70.0% (range: 66.7%-73.3%), while 36 month retention was 64.6% (range: 57.5%-72.1%). CONCLUSIONS: Our findings document the difficulties in retaining patients in care for lifelong treatment, and the progress being made in raising overall retention rates.'
p83349
sS'GR'
p83350
(lp83351
S'K01 AI083097/AI/NIAID NIH HHS/United States'
p83352
aS'K01 AI083097-01/AI/NIAID NIH HHS/United States'
p83353
aS'K01AI083097/AI/NIAID NIH HHS/United States'
p83354
asS'VI'
p83355
S'15 Suppl 1'
p83356
sS'IS'
p83357
S'1365-3156 (Electronic) 1360-2276 (Linking)'
p83358
sS'PMC'
p83359
S'PMC2948795'
p83360
sS'MID'
p83361
(lp83362
S'NIHMS237422'
p83363
asS'AU'
p83364
(lp83365
S'Fox MP'
p83366
aS'Rosen S'
p83367
asS'MHDA'
p83368
S'2011/05/03 06:00'
p83369
sS'OID'
p83370
(lp83371
S'NLM: NIHMS237422'
p83372
aS'NLM: PMC2948795'
p83373
asS'MH'
p83374
(lp83375
S'Adult'
p83376
aS'Africa South of the Sahara'
p83377
aS'Antiretroviral Therapy, Highly Active/*statistics & numerical data'
p83378
aS'Female'
p83379
aS'Follow-Up Studies'
p83380
aS'HIV Infections/*drug therapy'
p83381
aS'Humans'
p83382
aS'Male'
p83383
aS'Medication Adherence/*statistics & numerical data'
p83384
aS'Patient Dropouts/statistics & numerical data'
p83385
asS'EDAT'
p83386
S'2010/07/14 06:00'
p83387
sS'SO'
p83388
S'Trop Med Int Health. 2010 Jun;15 Suppl 1:1-15. doi: 10.1111/j.1365-3156.2010.02508.x.'
p83389
sS'SB'
p83390
S'IM'
p83391
sS'PMID'
p83392
S'20586956'
p83393
sS'TA'
p83394
S'Trop Med Int Health'
p83395
sS'PST'
p83396
S'ppublish'
p83397
stRp83398
ag2
(g3
g4
(dp83399
S'LID'
p83400
S'10.1186/1758-2652-13-23 [doi]'
p83401
sS'STAT'
p83402
S'MEDLINE'
p83403
sS'DEP'
p83404
S'20100708'
p83405
sS'DA'
p83406
S'20100804'
p83407
sS'AID'
p83408
(lp83409
S'1758-2652-13-23 [pii]'
p83410
aS'10.1186/1758-2652-13-23 [doi]'
p83411
asS'CRDT'
p83412
(lp83413
S'2010/07/10 06:00'
p83414
asS'DP'
p83415
S'2010'
p83416
sS'OWN'
p83417
S'NLM'
p83418
sS'PT'
p83419
(lp83420
S'Journal Article'
p83421
asS'LA'
p83422
(lp83423
S'eng'
p83424
asS'DCOM'
p83425
S'20101213'
p83426
sS'JT'
p83427
S'Journal of the International AIDS Society'
p83428
sS'LR'
p83429
S'20141203'
p83430
sS'FAU'
p83431
(lp83432
S'Chu, Kathryn M'
p83433
aS'Mahlangeni, Gcina'
p83434
aS'Swannet, Sarah'
p83435
aS'Ford, Nathan P'
p83436
aS'Boulle, Andrew'
p83437
aS'Van Cutsem, Gilles'
p83438
asS'TI'
p83439
S"AIDS-associated Kaposi's sarcoma is linked to advanced disease and high mortality in a primary care HIV programme in South Africa."
p83440
sS'PL'
p83441
S'England'
p83442
sS'PG'
p83443
S'23'
p83444
sS'JID'
p83445
S'101478566'
p83446
sS'AB'
p83447
S"BACKGROUND: AIDS-associated Kaposi's sarcoma is an important, life-threatening opportunistic infection among people living with HIV/AIDS in resource-limited settings. In western countries, the introduction of combination antiretroviral therapy (cART) and new chemotherapeutic agents has resulted in decreased incidence and improved prognosis of AIDS-associated Kaposi's sarcoma. In African cohorts, however, mortality remains high. In this study, we describe disease characteristics and risk factors for mortality in a public sector HIV programme in South Africa. METHODS: We analysed data from an observational cohort study of HIV-infected adults with AIDS-associated Kaposi's sarcoma, enrolled between May 2001 and January 2007 in three primary care clinics. Paper records from primary care and tertiary hospital oncology clinics were reviewed to determine the site of Kaposi's sarcoma lesions, immune reconstitution inflammatory syndrome stage, and treatment. Baseline characteristics, cART use and survival outcomes were extracted from an electronic database maintained for routine monitoring and evaluation. Cox regression was used to model associations with mortality. RESULTS: Of 6292 patients, 215 (3.4%) had AIDS-associated Kaposi's sarcoma. Lesions were most commonly oral (65%) and on the lower extremities (56%). One quarter of patients did not receive cART. The mortality and lost-to-follow-up rates were, respectively, 25 (95% CI 19-32) and eight (95% CI 5-13) per 100 person years for patients who received cART, and 70 (95% CI 42-117) and 119 (80-176) per 100 person years for patients who did not receive cART. Advanced T stage (adjusted HR, AHR = 5.3, p < 0.001), advanced S stage (AHR = 5.1, p = 0.008), and absence of chemotherapy (AHR = 2.4, p = 0.012) were associated with mortality. Patients with AIDS-associated Kaposi's sarcoma presented with advanced disease and high rates of mortality and loss to follow up. Risk factors for mortality included advanced Kaposi's sarcoma disease and lack of chemotherapy use. Contributing factors to the high mortality for patients with AIDS-associated Kaposi's sarcoma likely included late diagnosis of HIV disease, late accessibility to cART, and sub-optimal treatment of advanced Kaposi's sarcoma. CONCLUSIONS: These findings confirm the importance of early access to both cART and chemotherapy for patients with AIDS-associated Kaposi's sarcoma. Early diagnosis and improved treatment protocols in resource-poor settings are essential."
p83448
sS'AD'
p83449
S'Medecins Sans Frontieres, Braamfontein, Johannesburg, South Africa. kathryn.chu@joburg.msf.org'
p83450
sS'VI'
p83451
S'13'
p83452
sS'IS'
p83453
S'1758-2652 (Electronic) 1758-2652 (Linking)'
p83454
sS'PMC'
p83455
S'PMC2914751'
p83456
sS'AU'
p83457
(lp83458
S'Chu KM'
p83459
aS'Mahlangeni G'
p83460
aS'Swannet S'
p83461
aS'Ford NP'
p83462
aS'Boulle A'
p83463
aS'Van Cutsem G'
p83464
asS'MHDA'
p83465
S'2010/12/14 06:00'
p83466
sS'PHST'
p83467
(lp83468
S'2009/10/25 [received]'
p83469
aS'2010/07/08 [accepted]'
p83470
aS'2010/07/08 [aheadofprint]'
p83471
asS'OID'
p83472
(lp83473
S'NLM: PMC2914751'
p83474
asS'MH'
p83475
(lp83476
S'AIDS-Related Opportunistic Infections/drug therapy/epidemiology/etiology/*mortality'
p83477
aS'Acquired Immunodeficiency Syndrome/*complications/drug therapy/mortality'
p83478
aS'Adult'
p83479
aS'Cohort Studies'
p83480
aS'Female'
p83481
aS'Humans'
p83482
aS'Male'
p83483
aS'Middle Aged'
p83484
aS'Primary Health Care'
p83485
aS'Risk Factors'
p83486
aS'Sarcoma, Kaposi/drug therapy/epidemiology/etiology/*mortality'
p83487
aS'South Africa/epidemiology'
p83488
asS'EDAT'
p83489
S'2010/07/10 06:00'
p83490
sS'SO'
p83491
S'J Int AIDS Soc. 2010 Jul 8;13:23. doi: 10.1186/1758-2652-13-23.'
p83492
sS'SB'
p83493
S'IM X'
p83494
sS'PMID'
p83495
S'20615222'
p83496
sS'TA'
p83497
S'J Int AIDS Soc'
p83498
sS'PST'
p83499
S'epublish'
p83500
stRp83501
ag2
(g3
g4
(dp83502
S'LID'
p83503
S'10.1097/QAD.0b013e32833c703e [doi]'
p83504
sS'STAT'
p83505
S'MEDLINE'
p83506
sS'JT'
p83507
S'AIDS (London, England)'
p83508
sS'CIN'
p83509
(lp83510
S'AIDS. 2010 Aug 24;24(13):2123-4. PMID: 20639727'
p83511
asS'DA'
p83512
S'20100803'
p83513
sS'AID'
p83514
(lp83515
S'10.1097/QAD.0b013e32833c703e [doi]'
p83516
asS'CRDT'
p83517
(lp83518
S'2010/07/09 06:00'
p83519
asS'DP'
p83520
S'2010 Aug 24'
p83521
sS'AD'
p83522
S'Center for Global Health and Development, Boston University, Boston, Massachusetts 02118, USA. mfox@bu.edu'
p83523
sS'OWN'
p83524
S'NLM'
p83525
sS'PT'
p83526
(lp83527
S'Journal Article'
p83528
aS'Multicenter Study'
p83529
aS'Randomized Controlled Trial'
p83530
aS'Research Support, N.I.H., Extramural'
p83531
aS"Research Support, U.S. Gov't, Non-P.H.S."
p83532
asS'LA'
p83533
(lp83534
S'eng'
p83535
asS'FAU'
p83536
(lp83537
S'Fox, Matthew P'
p83538
aS'Sanne, Ian M'
p83539
aS'Conradie, Francesca'
p83540
aS'Zeinecker, Jennifer'
p83541
aS'Orrell, Catherine'
p83542
aS'Ive, Prudence'
p83543
aS'Rassool, Mohammed'
p83544
aS'Dehlinger, Marjorie'
p83545
aS'van der Horst, Charles'
p83546
aS'McIntyre, James'
p83547
aS'Wood, Robin'
p83548
asS'LR'
p83549
S'20141203'
p83550
sS'PG'
p83551
S'2041-50'
p83552
sS'TI'
p83553
S'Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa.'
p83554
sS'PL'
p83555
S'England'
p83556
sS'TA'
p83557
S'AIDS'
p83558
sS'JID'
p83559
S'8710219'
p83560
sS'AB'
p83561
S'OBJECTIVES: To compare treatment outcomes by starting CD4 cell counts using data from the Comprehensive International Program of Research on AIDS-South Africa trial. DESIGN: An observational cohort study. METHODS: Patients presenting to primary care clinics with CD4 cell counts below 350 cells/microl were randomized to either doctor or nurse-managed HIV care and followed for at least 2 years after antiretroviral therapy (ART) initiation. Clinical and laboratory outcomes were compared by baseline CD4 cell counts. RESULTS: Eight hundred and twelve patients were followed for a median of 27.5 months and 36% initiated ART with a CD4 cell count above 200 cells/microl. Although 10% of patients failed virologically, the risk was nearly double among those with a CD4 cell count of 200 cells/microl or less vs. above 200 cells/microl (12.2 vs. 6.8%). Twenty-one deaths occurred, with a five-fold increased risk for the low CD4 cell count group (3.7 vs. 0.7%). After adjustment, those with a CD4 cell count of 200 cells/microl had twice the risk of death/virologic failure [hazard ratio 1.9; 95% confidence interval (CI), 1.1-3.3] and twice the risk of incident tuberculosis (hazard ratio 1.90; 95% CI, 0.89-4.04) as those above 200 cells/microl. Those with either a CD4 cell count of 200 cells/microl or less (hazard ratio 2.1; 95% CI, 1.2-3.8) or a WHO IV condition (hazard ratio 2.9; 95% CI, 0.93-8.8) alone had a two-to-three-fold increased risk of death/virologic failure vs. those with neither, but those with both conditions had a four-fold increased risk (hazard ratio 3.9; 95% CI, 1.9-8.1). We observed some decreased loss to follow-up among those initiating ART at less than 200 cells/microl (hazard ratio 0.79; 95% CI, 0.50-1.25). CONCLUSION: Patients initiating ART with higher CD4 cell counts had reduced mortality, tuberculosis and less virologic failure than those initiated at lower CD4 cell counts. Our data support increasing CD4 cell count eligibility criteria for ART initiation.'
p83562
sS'GR'
p83563
(lp83564
S'5U2RTW007373-03/PHS HHS/United States'
p83565
aS'K01 AI083097/AI/NIAID NIH HHS/United States'
p83566
aS'K01 AI083097-02/AI/NIAID NIH HHS/United States'
p83567
aS'K01AI083097/AI/NIAID NIH HHS/United States'
p83568
aS'P30-AI50410/AI/NIAID NIH HHS/United States'
p83569
aS'U19 AI53217/AI/NIAID NIH HHS/United States'
p83570
asS'IP'
p83571
S'13'
p83572
sS'IS'
p83573
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p83574
sS'PMC'
p83575
S'PMC2914833'
p83576
sS'DCOM'
p83577
S'20110325'
p83578
sS'MID'
p83579
(lp83580
S'NIHMS221845'
p83581
asS'AU'
p83582
(lp83583
S'Fox MP'
p83584
aS'Sanne IM'
p83585
aS'Conradie F'
p83586
aS'Zeinecker J'
p83587
aS'Orrell C'
p83588
aS'Ive P'
p83589
aS'Rassool M'
p83590
aS'Dehlinger M'
p83591
aS'van der Horst C'
p83592
aS'McIntyre J'
p83593
aS'Wood R'
p83594
asS'VI'
p83595
S'24'
p83596
sS'MHDA'
p83597
S'2011/03/26 06:00'
p83598
sS'OID'
p83599
(lp83600
S'NLM: NIHMS221845'
p83601
aS'NLM: PMC2914833'
p83602
asS'MH'
p83603
(lp83604
S'AIDS-Related Opportunistic Infections/*drug therapy/immunology/mortality'
p83605
aS'Adult'
p83606
aS'Antiretroviral Therapy, Highly Active'
p83607
aS'CD4 Lymphocyte Count'
p83608
aS'Cohort Studies'
p83609
aS'Drug Administration Schedule'
p83610
aS'Female'
p83611
aS'HIV Infections/*drug therapy/immunology/mortality'
p83612
aS'Humans'
p83613
aS'Male'
p83614
aS'South Africa/epidemiology'
p83615
aS'Treatment Outcome'
p83616
aS'Tuberculosis/*drug therapy/immunology/mortality'
p83617
aS'Viral Load'
p83618
asS'EDAT'
p83619
S'2010/07/09 06:00'
p83620
sS'SO'
p83621
S'AIDS. 2010 Aug 24;24(13):2041-50. doi: 10.1097/QAD.0b013e32833c703e.'
p83622
sS'SB'
p83623
S'IM X'
p83624
sS'PMID'
p83625
S'20613459'
p83626
sS'PST'
p83627
S'ppublish'
p83628
stRp83629
ag2
(g3
g4
(dp83630
S'LID'
p83631
S'10.1097/QAI.0b013e3181e0c4cf [doi]'
p83632
sS'STAT'
p83633
S'MEDLINE'
p83634
sS'JT'
p83635
S'Journal of acquired immune deficiency syndromes (1999)'
p83636
sS'MID'
p83637
(lp83638
S'NIHMS203689'
p83639
asS'DA'
p83640
S'20100721'
p83641
sS'AID'
p83642
(lp83643
S'10.1097/QAI.0b013e3181e0c4cf [doi]'
p83644
asS'CRDT'
p83645
(lp83646
S'2010/07/01 06:00'
p83647
asS'DP'
p83648
S'2010 Aug'
p83649
sS'GR'
p83650
(lp83651
S'1 U01 AI069924-01/AI/NIAID NIH HHS/United States'
p83652
aS'U01 AI069924/AI/NIAID NIH HHS/United States'
p83653
aS'U01 AI069924-03/AI/NIAID NIH HHS/United States'
p83654
asS'OWN'
p83655
S'NLM'
p83656
sS'PT'
p83657
(lp83658
S'Journal Article'
p83659
aS'Research Support, N.I.H., Extramural'
p83660
asS'LA'
p83661
(lp83662
S'eng'
p83663
asS'FAU'
p83664
(lp83665
S'Fenner, Lukas'
p83666
aS'Brinkhof, Martin W G'
p83667
aS'Keiser, Olivia'
p83668
aS'Weigel, Ralf'
p83669
aS'Cornell, Morna'
p83670
aS'Moultrie, Harry'
p83671
aS'Prozesky, Hans'
p83672
aS'Technau, Karl'
p83673
aS'Eley, Brian'
p83674
aS'Vaz, Paula'
p83675
aS'Pascoe, Margaret'
p83676
aS'Giddy, Janet'
p83677
aS'Van Cutsem, Gilles'
p83678
aS'Wood, Robin'
p83679
aS'Egger, Matthias'
p83680
aS'Davies, Mary-Ann'
p83681
asS'LR'
p83682
S'20141203'
p83683
sS'PG'
p83684
S'524-32'
p83685
sS'TI'
p83686
S'Early mortality and loss to follow-up in HIV-infected children starting antiretroviral therapy in Southern Africa.'
p83687
sS'RN'
p83688
(lp83689
S'0 (Anti-HIV Agents)'
p83690
asS'PL'
p83691
S'United States'
p83692
sS'TA'
p83693
S'J Acquir Immune Defic Syndr'
p83694
sS'FIR'
p83695
(lp83696
S'Pascoe, Margaret'
p83697
aS'Wood, Robin'
p83698
aS'Moultrie, Harry'
p83699
aS'Technau, Karl'
p83700
aS'van Cutsem, Gilles'
p83701
aS'Vaz, Paula'
p83702
aS'Giddy, Janet'
p83703
aS'Eley, Brian'
p83704
aS'Prozesky, Hans'
p83705
asS'JID'
p83706
S'100892005'
p83707
sS'AB'
p83708
S'BACKGROUND: Many HIV-infected children in Southern Africa have been started on antiretroviral therapy (ART), but loss to follow up (LTFU) can be substantial. We analyzed mortality in children retained in care and in all children starting ART, taking LTFU into account. PATIENTS AND METHODS: Children who started ART before the age of 16 years in 10 ART programs in South Africa, Malawi, Mozambique, and Zimbabwe were included. Risk factors for death in the first year of ART were identified in Weibull models. A meta-analytic approach was used to estimate cumulative mortality at 1 year. RESULTS: Eight thousand two hundred twenty-five children (median age 49 months, median CD4 cell percent 11.6%) were included; 391 (4.8%) died and 523 (7.0%) were LTFU in the first year. Mortality at 1 year was 4.5% [95% confidence interval (CI): 2.8% to 7.4%] in children remaining in care, but 8.7% (5.4% to 12.1%) at the program level, after taking mortality in children and LTFU into account. Factors associated with mortality in children remaining in care included age [adjusted hazard ratio (HR) 0.37; 95% CI: 0.25 to 0.54 comparing > or =120 months with <18 months], CD4 cell percent (HR: 0.56; 95% CI: 0.39 to 0.78 comparing > or =20% with <10%), and clinical stage (HR: 0.12; 95% CI: 0.03 to 0.45 comparing World Health Organization stage I with III/IV). CONCLUSIONS: In children starting ART and remaining in care in Southern Africa mortality at 1 year is <5% but almost twice as high at the program level, when taking LTFU into account. Age, CD4 percentage, and clinical stage are important predictors of mortality at the individual level.'
p83709
sS'AD'
p83710
S'Institute of Social and Preventive Medicine, University of Bern, Switzerland. lfenner@ispm.unibe.ch'
p83711
sS'CN'
p83712
(lp83713
S'International epidemiologic Databases to Evaluate AIDS in Southern Africa'
p83714
asS'IP'
p83715
S'5'
sS'IS'
p83716
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p83717
sS'IR'
p83718
(lp83719
S'Pascoe M'
p83720
aS'Wood R'
p83721
aS'Moultrie H'
p83722
aS'Technau K'
p83723
aS'van Cutsem G'
p83724
aS'Vaz P'
p83725
aS'Giddy J'
p83726
aS'Eley B'
p83727
aS'Prozesky H'
p83728
asS'DCOM'
p83729
S'20100812'
p83730
sS'AU'
p83731
(lp83732
S'Fenner L'
p83733
aS'Brinkhof MW'
p83734
aS'Keiser O'
p83735
aS'Weigel R'
p83736
aS'Cornell M'
p83737
aS'Moultrie H'
p83738
aS'Prozesky H'
p83739
aS'Technau K'
p83740
aS'Eley B'
p83741
aS'Vaz P'
p83742
aS'Pascoe M'
p83743
aS'Giddy J'
p83744
aS'Van Cutsem G'
p83745
aS'Wood R'
p83746
aS'Egger M'
p83747
aS'Davies MA'
p83748
asS'VI'
p83749
S'54'
p83750
sS'MHDA'
p83751
S'2010/08/13 06:00'
p83752
sS'OID'
p83753
(lp83754
S'NLM: NIHMS203689'
p83755
aS'NLM: PMC2925143'
p83756
asS'MH'
p83757
(lp83758
S'Africa, Southern/epidemiology'
p83759
aS'Age Factors'
p83760
aS'Anti-HIV Agents/*therapeutic use'
p83761
aS'*Antiretroviral Therapy, Highly Active'
p83762
aS'CD4 Lymphocyte Count'
p83763
aS'Child'
p83764
aS'Child, Preschool'
p83765
aS'Female'
p83766
aS'HIV Infections/drug therapy/*epidemiology/*mortality'
p83767
aS'Humans'
p83768
aS'Infant'
p83769
aS'Male'
p83770
aS'Prognosis'
p83771
aS'Risk Factors'
p83772
aS'Severity of Illness Index'
p83773
asS'EDAT'
p83774
S'2010/07/01 06:00'
p83775
sS'PMC'
p83776
S'PMC2925143'
p83777
sS'SO'
p83778
S'J Acquir Immune Defic Syndr. 2010 Aug;54(5):524-32. doi: 10.1097/QAI.0b013e3181e0c4cf.'
p83779
sS'SB'
p83780
S'IM X'
p83781
sS'PMID'
p83782
S'20588185'
p83783
sS'PST'
p83784
S'ppublish'
p83785
stRp83786
ag2
(g3
g4
(dp83787
S'LID'
p83788
S'10.1097/QAI.0b013e3181e544e0 [doi]'
p83789
sS'STAT'
p83790
S'MEDLINE'
p83791
sS'JT'
p83792
S'Journal of acquired immune deficiency syndromes (1999)'
p83793
sS'DA'
p83794
S'20100824'
p83795
sS'AID'
p83796
(lp83797
S'10.1097/QAI.0b013e3181e544e0 [doi]'
p83798
asS'CRDT'
p83799
(lp83800
S'2010/06/30 06:00'
p83801
asS'DP'
p83802
S'2010 Sep'
p83803
sS'AD'
p83804
S'PharmAccess Foundation, Amsterdam, The Netherlands. r.hamers@pharmaccess.org'
p83805
sS'OWN'
p83806
S'NLM'
p83807
sS'PT'
p83808
(lp83809
S'Journal Article'
p83810
aS"Research Support, Non-U.S. Gov't"
p83811
asS'LA'
p83812
(lp83813
S'eng'
p83814
asS'FAU'
p83815
(lp83816
S'Hamers, Raph L'
p83817
aS'Siwale, Margaret'
p83818
aS'Wallis, Carole L'
p83819
aS'Labib, Moheb'
p83820
aS'van Hasselt, Robbert'
p83821
aS'Stevens, Wendy S'
p83822
aS'Schuurman, Rob'
p83823
aS'Wensing, Annemarie M J'
p83824
aS'Van Vugt, Michele'
p83825
aS'Rinke de Wit, Tobias F'
p83826
asS'LR'
p83827
S'20110906'
p83828
sS'PG'
p83829
S'95-101'
p83830
sS'TI'
p83831
S'HIV-1 drug resistance mutations are present in six percent of persons initiating antiretroviral therapy in Lusaka, Zambia.'
p83832
sS'RN'
p83833
(lp83834
S'0 (Anti-HIV Agents)'
p83835
aS'0 (RNA, Viral)'
p83836
aS'0 (pol Gene Products, Human Immunodeficiency Virus)'
p83837
asS'PL'
p83838
S'United States'
p83839
sS'TA'
p83840
S'J Acquir Immune Defic Syndr'
p83841
sS'JID'
p83842
S'100892005'
p83843
sS'AB'
p83844
S'OBJECTIVE: To assess the mutational patterns and factors associated with baseline drug-resistant HIV-1 present at initiation of first-line antiretroviral therapy (ART) at 3 sites in Lusaka, Zambia, in 2007-2008. METHODS: Population sequencing of the HIV-1 pol gene was performed in the PharmAccess African Studies to Evaluate Resistance Monitoring cohort. Drug resistance-associated mutations (DRMs) were identified using the WHO 2009 Surveillance DRM list. Multiple logistic regression was used to assess factors associated with baseline resistance. RESULTS: The overall prevalence of baseline resistance was 5.7% [31 of 548 participants; 95% confidence interval (CI): 3.9 to 7.9]; the prevalence of DRMs associated with nucleoside reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors was 1.1%, 4.0%, and 1.1%, respectively. Resistance prevalence was 5.2% (27 of 523) in antiretroviral-naive and 16.0% (4 of 25) in antiretroviral-experienced (ie, previous use of ART or antiretroviral prophylaxis for prevention of mother-to-child transmission) participants (P = 0.022). Dual-class resistance to NRTIs and NNRTIs was observed in 0.6% of participants. HIV-1 subtype C was identified in 98.0% (537 of 548) of participants. Prior antiretroviral experience (odds ratio: 4.32, CI: 1.34 to 14.0, P = 0.015) and hemoglobin level (highest tertile versus lowest tertile odds ratio: 2.74, CI: 1.09 to 6.89, P = 0.033) were independently associated with baseline resistance. CONCLUSIONS: Baseline resistance may compromise the response to standard NNRTI-based first-line ART in 6% of patients in Lusaka, Zambia. Continuous resistance monitoring is warranted to maintain individual and population-level ART effectiveness.'
p83845
sS'CN'
p83846
(lp83847
S'PharmAccess African Studies to Evaluate Resistance'
p83848
asS'IP'
p83849
S'1'
sS'IS'
p83850
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p83851
sS'DCOM'
p83852
S'20100916'
p83853
sS'AU'
p83854
(lp83855
S'Hamers RL'
p83856
aS'Siwale M'
p83857
aS'Wallis CL'
p83858
aS'Labib M'
p83859
aS'van Hasselt R'
p83860
aS'Stevens WS'
p83861
aS'Schuurman R'
p83862
aS'Wensing AM'
p83863
aS'Van Vugt M'
p83864
aS'Rinke de Wit TF'
p83865
asS'VI'
p83866
S'55'
p83867
sS'MHDA'
p83868
S'2010/09/18 06:00'
p83869
sS'MH'
p83870
(lp83871
S'Adult'
p83872
aS'Anti-HIV Agents/*pharmacology'
p83873
aS'Antiretroviral Therapy, Highly Active'
p83874
aS'*Drug Resistance, Viral'
p83875
aS'Female'
p83876
aS'HIV Infections/drug therapy/*virology'
p83877
aS'HIV-1/*drug effects/genetics/isolation & purification'
p83878
aS'Humans'
p83879
aS'Male'
p83880
aS'Middle Aged'
p83881
aS'Molecular Sequence Data'
p83882
aS'*Mutation, Missense'
p83883
aS'Prevalence'
p83884
aS'RNA, Viral/genetics'
p83885
aS'Sequence Analysis, DNA'
p83886
aS'Zambia'
p83887
aS'pol Gene Products, Human Immunodeficiency Virus/genetics'
p83888
asS'EDAT'
p83889
S'2010/06/30 06:00'
p83890
sS'SI'
p83891
(lp83892
S'GENBANK/HM119603'
p83893
aS'GENBANK/HM119604'
p83894
aS'GENBANK/HM119605'
p83895
aS'GENBANK/HM119606'
p83896
aS'GENBANK/HM119607'
p83897
aS'GENBANK/HM119608'
p83898
aS'GENBANK/HM119609'
p83899
aS'GENBANK/HM119610'
p83900
aS'GENBANK/HM119611'
p83901
aS'GENBANK/HM119612'
p83902
aS'GENBANK/HM119613'
p83903
aS'GENBANK/HM119614'
p83904
aS'GENBANK/HM119615'
p83905
aS'GENBANK/HM119616'
p83906
aS'GENBANK/HM119617'
p83907
aS'GENBANK/HM119618'
p83908
aS'GENBANK/HM119619'
p83909
aS'GENBANK/HM119620'
p83910
aS'GENBANK/HM119621'
p83911
aS'GENBANK/HM119622'
p83912
aS'GENBANK/HM119623'
p83913
aS'GENBANK/HM119624'
p83914
aS'GENBANK/HM119625'
p83915
aS'GENBANK/HM119626'
p83916
aS'GENBANK/HM119627'
p83917
aS'GENBANK/HM119628'
p83918
aS'GENBANK/HM119629'
p83919
aS'GENBANK/HM119630'
p83920
aS'GENBANK/HM119631'
p83921
aS'GENBANK/HM119632'
p83922
aS'GENBANK/HM119633'
p83923
aS'GENBANK/HM119634'
p83924
aS'GENBANK/HM119635'
p83925
aS'GENBANK/HM119636'
p83926
aS'GENBANK/HM119637'
p83927
aS'GENBANK/HM119638'
p83928
aS'GENBANK/HM119639'
p83929
aS'GENBANK/HM119640'
p83930
aS'GENBANK/HM119641'
p83931
aS'GENBANK/HM119642'
p83932
aS'GENBANK/HM119643'
p83933
aS'GENBANK/HM119644'
p83934
aS'GENBANK/HM119645'
p83935
aS'GENBANK/HM119646'
p83936
aS'GENBANK/HM119647'
p83937
aS'GENBANK/HM119648'
p83938
aS'GENBANK/HM119649'
p83939
aS'GENBANK/HM119650'
p83940
aS'GENBANK/HM119651'
p83941
aS'GENBANK/HM119652'
p83942
aS'GENBANK/HM119653'
p83943
aS'GENBANK/HM119654'
p83944
aS'GENBANK/HM119655'
p83945
aS'GENBANK/HM119656'
p83946
aS'GENBANK/HM119657'
p83947
aS'GENBANK/HM119658'
p83948
aS'GENBANK/HM119659'
p83949
aS'GENBANK/HM119660'
p83950
aS'GENBANK/HM119661'
p83951
aS'GENBANK/HM119662'
p83952
aS'GENBANK/HM119663'
p83953
aS'GENBANK/HM119664'
p83954
aS'GENBANK/HM119665'
p83955
aS'GENBANK/HM119666'
p83956
aS'GENBANK/HM119667'
p83957
aS'GENBANK/HM119668'
p83958
aS'GENBANK/HM119669'
p83959
aS'GENBANK/HM119670'
p83960
aS'GENBANK/HM119671'
p83961
aS'GENBANK/HM119672'
p83962
aS'GENBANK/HM119673'
p83963
aS'GENBANK/HM119674'
p83964
aS'GENBANK/HM119675'
p83965
aS'GENBANK/HM119676'
p83966
aS'GENBANK/HM119677'
p83967
aS'GENBANK/HM119678'
p83968
aS'GENBANK/HM119679'
p83969
aS'GENBANK/HM119680'
p83970
aS'GENBANK/HM119681'
p83971
aS'GENBANK/HM119682'
p83972
aS'GENBANK/HM119683'
p83973
aS'GENBANK/HM119684'
p83974
aS'GENBANK/HM119685'
p83975
aS'GENBANK/HM119686'
p83976
aS'GENBANK/HM119687'
p83977
aS'GENBANK/HM119688'
p83978
aS'GENBANK/HM119689'
p83979
aS'GENBANK/HM119690'
p83980
aS'GENBANK/HM119691'
p83981
aS'GENBANK/HM119692'
p83982
aS'GENBANK/HM119693'
p83983
aS'GENBANK/HM119694'
p83984
aS'GENBANK/HM119695'
p83985
aS'GENBANK/HM119696'
p83986
aS'GENBANK/HM119697'
p83987
aS'GENBANK/HM119698'
p83988
aS'GENBANK/HM119699'
p83989
aS'GENBANK/HM119700'
p83990
aS'GENBANK/HM119701'
p83991
aS'GENBANK/HM119702'
p83992
aS'GENBANK/HM119703'
p83993
aS'GENBANK/HM119704'
p83994
aS'GENBANK/HM119705'
p83995
aS'GENBANK/HM119706'
p83996
aS'GENBANK/HM119707'
p83997
aS'GENBANK/HM119708'
p83998
aS'GENBANK/HM119709'
p83999
aS'GENBANK/HM119710'
p84000
aS'GENBANK/HM119711'
p84001
aS'GENBANK/HM119712'
p84002
aS'GENBANK/HM119713'
p84003
aS'GENBANK/HM119714'
p84004
aS'GENBANK/HM119715'
p84005
aS'GENBANK/HM119716'
p84006
aS'GENBANK/HM119717'
p84007
aS'GENBANK/HM119718'
p84008
aS'GENBANK/HM119719'
p84009
aS'GENBANK/HM119720'
p84010
aS'GENBANK/HM119721'
p84011
aS'GENBANK/HM119722'
p84012
aS'GENBANK/HM119723'
p84013
aS'GENBANK/HM119724'
p84014
aS'GENBANK/HM119725'
p84015
aS'GENBANK/HM119726'
p84016
aS'GENBANK/HM119727'
p84017
aS'GENBANK/HM119728'
p84018
aS'GENBANK/HM119729'
p84019
aS'GENBANK/HM119730'
p84020
aS'GENBANK/HM119731'
p84021
aS'GENBANK/HM119732'
p84022
aS'GENBANK/HM119733'
p84023
aS'GENBANK/HM119734'
p84024
aS'GENBANK/HM119735'
p84025
aS'GENBANK/HM119736'
p84026
aS'GENBANK/HM119737'
p84027
aS'GENBANK/HM119738'
p84028
aS'GENBANK/HM119739'
p84029
aS'GENBANK/HM119740'
p84030
aS'GENBANK/HM119741'
p84031
aS'GENBANK/HM119742'
p84032
aS'GENBANK/HM119743'
p84033
aS'GENBANK/HM119744'
p84034
aS'GENBANK/HM119745'
p84035
aS'GENBANK/HM119746'
p84036
aS'GENBANK/HM119747'
p84037
aS'GENBANK/HM119748'
p84038
aS'GENBANK/HM119749'
p84039
aS'GENBANK/HM119750'
p84040
aS'GENBANK/HM119751'
p84041
aS'GENBANK/HM119752'
p84042
aS'GENBANK/HM119753'
p84043
aS'GENBANK/HM119754'
p84044
aS'GENBANK/HM119755'
p84045
aS'GENBANK/HM119756'
p84046
aS'GENBANK/HM119757'
p84047
aS'GENBANK/HM119758'
p84048
aS'GENBANK/HM119759'
p84049
aS'GENBANK/HM119760'
p84050
aS'GENBANK/HM119761'
p84051
aS'GENBANK/HM119762'
p84052
aS'GENBANK/HM119763'
p84053
aS'GENBANK/HM119764'
p84054
aS'GENBANK/HM119765'
p84055
aS'GENBANK/HM119766'
p84056
aS'GENBANK/HM119767'
p84057
aS'GENBANK/HM119768'
p84058
aS'GENBANK/HM119769'
p84059
aS'GENBANK/HM119770'
p84060
aS'GENBANK/HM119771'
p84061
aS'GENBANK/HM119772'
p84062
aS'GENBANK/HM119773'
p84063
aS'GENBANK/HM119774'
p84064
aS'GENBANK/HM119775'
p84065
aS'GENBANK/HM119776'
p84066
aS'GENBANK/HM119777'
p84067
aS'GENBANK/HM119778'
p84068
aS'GENBANK/HM119779'
p84069
aS'GENBANK/HM119780'
p84070
aS'GENBANK/HM119781'
p84071
aS'GENBANK/HM119782'
p84072
aS'GENBANK/HM119783'
p84073
aS'GENBANK/HM119784'
p84074
aS'GENBANK/HM119785'
p84075
aS'GENBANK/HM119786'
p84076
aS'GENBANK/HM119787'
p84077
aS'GENBANK/HM119788'
p84078
aS'GENBANK/HM119789'
p84079
aS'GENBANK/HM119790'
p84080
aS'GENBANK/HM119791'
p84081
aS'GENBANK/HM119792'
p84082
aS'GENBANK/HM119793'
p84083
aS'GENBANK/HM119794'
p84084
aS'GENBANK/HM119795'
p84085
aS'GENBANK/HM119796'
p84086
aS'GENBANK/HM119797'
p84087
aS'GENBANK/HM119798'
p84088
aS'GENBANK/HM119799'
p84089
aS'GENBANK/HM119800'
p84090
aS'GENBANK/HM119801'
p84091
aS'GENBANK/HM119802'
p84092
aS'GENBANK/HM119803'
p84093
aS'GENBANK/HM119804'
p84094
aS'GENBANK/HM119805'
p84095
aS'GENBANK/HM119806'
p84096
aS'GENBANK/HM119807'
p84097
aS'GENBANK/HM119808'
p84098
aS'GENBANK/HM119809'
p84099
aS'GENBANK/HM119810'
p84100
aS'GENBANK/HM119811'
p84101
aS'GENBANK/HM119812'
p84102
aS'GENBANK/HM119813'
p84103
aS'GENBANK/HM119814'
p84104
aS'GENBANK/HM119815'
p84105
aS'GENBANK/HM119816'
p84106
aS'GENBANK/HM119817'
p84107
aS'GENBANK/HM119818'
p84108
aS'GENBANK/HM119819'
p84109
aS'GENBANK/HM119820'
p84110
aS'GENBANK/HM119821'
p84111
aS'GENBANK/HM119822'
p84112
aS'GENBANK/HM119823'
p84113
aS'GENBANK/HM119824'
p84114
aS'GENBANK/HM119825'
p84115
aS'GENBANK/HM119826'
p84116
aS'GENBANK/HM119827'
p84117
aS'GENBANK/HM119828'
p84118
aS'GENBANK/HM119829'
p84119
aS'GENBANK/HM119830'
p84120
aS'GENBANK/HM119831'
p84121
aS'GENBANK/HM119832'
p84122
aS'GENBANK/HM119833'
p84123
aS'GENBANK/HM119834'
p84124
aS'GENBANK/HM119835'
p84125
aS'GENBANK/HM119836'
p84126
aS'GENBANK/HM119837'
p84127
aS'GENBANK/HM119838'
p84128
aS'GENBANK/HM119839'
p84129
aS'GENBANK/HM119840'
p84130
aS'GENBANK/HM119841'
p84131
aS'GENBANK/HM119842'
p84132
aS'GENBANK/HM119843'
p84133
aS'GENBANK/HM119844'
p84134
aS'GENBANK/HM119845'
p84135
aS'GENBANK/HM119846'
p84136
aS'GENBANK/HM119847'
p84137
aS'GENBANK/HM119848'
p84138
aS'GENBANK/HM119849'
p84139
aS'GENBANK/HM119850'
p84140
aS'GENBANK/HM119851'
p84141
aS'GENBANK/HM119852'
p84142
aS'GENBANK/HM119853'
p84143
aS'GENBANK/HM119854'
p84144
aS'GENBANK/HM119855'
p84145
aS'GENBANK/HM119856'
p84146
aS'GENBANK/HM119857'
p84147
aS'GENBANK/HM119858'
p84148
aS'GENBANK/HM119859'
p84149
aS'GENBANK/HM119860'
p84150
aS'GENBANK/HM119861'
p84151
aS'GENBANK/HM119862'
p84152
aS'GENBANK/HM119863'
p84153
aS'GENBANK/HM119864'
p84154
aS'GENBANK/HM119865'
p84155
aS'GENBANK/HM119866'
p84156
aS'GENBANK/HM119867'
p84157
aS'GENBANK/HM119868'
p84158
aS'GENBANK/HM119869'
p84159
aS'GENBANK/HM119870'
p84160
aS'GENBANK/HM119871'
p84161
aS'GENBANK/HM119872'
p84162
aS'GENBANK/HM119873'
p84163
aS'GENBANK/HM119874'
p84164
aS'GENBANK/HM119875'
p84165
aS'GENBANK/HM119876'
p84166
aS'GENBANK/HM119877'
p84167
aS'GENBANK/HM119878'
p84168
aS'GENBANK/HM119879'
p84169
aS'GENBANK/HM119880'
p84170
aS'GENBANK/HM119881'
p84171
aS'GENBANK/HM119882'
p84172
aS'GENBANK/HM119883'
p84173
aS'GENBANK/HM119884'
p84174
aS'GENBANK/HM119885'
p84175
aS'GENBANK/HM119886'
p84176
aS'GENBANK/HM119887'
p84177
aS'GENBANK/HM119888'
p84178
aS'GENBANK/HM119889'
p84179
aS'GENBANK/HM119890'
p84180
aS'GENBANK/HM119891'
p84181
aS'GENBANK/HM119892'
p84182
aS'GENBANK/HM119893'
p84183
aS'GENBANK/HM119894'
p84184
aS'GENBANK/HM119895'
p84185
aS'GENBANK/HM119896'
p84186
aS'GENBANK/HM119897'
p84187
aS'GENBANK/HM119898'
p84188
aS'GENBANK/HM119899'
p84189
aS'GENBANK/HM119900'
p84190
aS'GENBANK/HM119901'
p84191
aS'GENBANK/HM119902'
p84192
aS'GENBANK/HM119903'
p84193
aS'GENBANK/HM119904'
p84194
aS'GENBANK/HM119905'
p84195
aS'GENBANK/HM119906'
p84196
aS'GENBANK/HM119907'
p84197
aS'GENBANK/HM119908'
p84198
aS'GENBANK/HM119909'
p84199
aS'GENBANK/HM119910'
p84200
aS'GENBANK/HM119911'
p84201
aS'GENBANK/HM119912'
p84202
aS'GENBANK/HM119913'
p84203
aS'GENBANK/HM119914'
p84204
aS'GENBANK/HM119915'
p84205
aS'GENBANK/HM119916'
p84206
aS'GENBANK/HM119917'
p84207
aS'GENBANK/HM119918'
p84208
aS'GENBANK/HM119919'
p84209
aS'GENBANK/HM119920'
p84210
aS'GENBANK/HM119921'
p84211
aS'GENBANK/HM119922'
p84212
aS'GENBANK/HM119923'
p84213
aS'GENBANK/HM119924'
p84214
aS'GENBANK/HM119925'
p84215
aS'GENBANK/HM119926'
p84216
aS'GENBANK/HM119927'
p84217
aS'GENBANK/HM119928'
p84218
aS'GENBANK/HM119929'
p84219
aS'GENBANK/HM119930'
p84220
aS'GENBANK/HM119931'
p84221
aS'GENBANK/HM119932'
p84222
aS'GENBANK/HM119933'
p84223
aS'GENBANK/HM119934'
p84224
aS'GENBANK/HM119935'
p84225
aS'GENBANK/HM119936'
p84226
aS'GENBANK/HM119937'
p84227
aS'GENBANK/HM119938'
p84228
aS'GENBANK/HM119939'
p84229
aS'GENBANK/HM119940'
p84230
aS'GENBANK/HM119941'
p84231
aS'GENBANK/HM119942'
p84232
aS'GENBANK/HM119943'
p84233
aS'GENBANK/HM119944'
p84234
aS'GENBANK/HM119945'
p84235
aS'GENBANK/HM119946'
p84236
aS'GENBANK/HM119947'
p84237
aS'GENBANK/HM119948'
p84238
aS'GENBANK/HM119949'
p84239
aS'GENBANK/HM119950'
p84240
aS'GENBANK/HM119951'
p84241
aS'GENBANK/HM119952'
p84242
aS'GENBANK/HM119953'
p84243
aS'GENBANK/HM119954'
p84244
aS'GENBANK/HM119955'
p84245
aS'GENBANK/HM119956'
p84246
aS'GENBANK/HM119957'
p84247
aS'GENBANK/HM119958'
p84248
aS'GENBANK/HM119959'
p84249
aS'GENBANK/HM119960'
p84250
aS'GENBANK/HM119961'
p84251
aS'GENBANK/HM119962'
p84252
aS'GENBANK/HM119963'
p84253
aS'GENBANK/HM119964'
p84254
aS'GENBANK/HM119965'
p84255
aS'GENBANK/HM119966'
p84256
aS'GENBANK/HM119967'
p84257
aS'GENBANK/HM119968'
p84258
aS'GENBANK/HM119969'
p84259
aS'GENBANK/HM119970'
p84260
aS'GENBANK/HM119971'
p84261
aS'GENBANK/HM119972'
p84262
aS'GENBANK/HM119973'
p84263
aS'GENBANK/HM119974'
p84264
aS'GENBANK/HM119975'
p84265
aS'GENBANK/HM119976'
p84266
aS'GENBANK/HM119977'
p84267
aS'GENBANK/HM119978'
p84268
aS'GENBANK/HM119979'
p84269
aS'GENBANK/HM119980'
p84270
aS'GENBANK/HM119981'
p84271
aS'GENBANK/HM119982'
p84272
aS'GENBANK/HM119983'
p84273
aS'GENBANK/HM119984'
p84274
aS'GENBANK/HM119985'
p84275
aS'GENBANK/HM119986'
p84276
aS'GENBANK/HM119987'
p84277
aS'GENBANK/HM119988'
p84278
aS'GENBANK/HM119989'
p84279
aS'GENBANK/HM119990'
p84280
aS'GENBANK/HM119991'
p84281
aS'GENBANK/HM119992'
p84282
aS'GENBANK/HM119993'
p84283
aS'GENBANK/HM119994'
p84284
aS'GENBANK/HM119995'
p84285
aS'GENBANK/HM119996'
p84286
aS'GENBANK/HM119997'
p84287
aS'GENBANK/HM119998'
p84288
aS'GENBANK/HM119999'
p84289
aS'GENBANK/HM120000'
p84290
aS'GENBANK/HM120001'
p84291
aS'GENBANK/HM120002'
p84292
aS'GENBANK/HM120003'
p84293
aS'GENBANK/HM120004'
p84294
aS'GENBANK/HM120005'
p84295
aS'GENBANK/HM120006'
p84296
aS'GENBANK/HM120007'
p84297
aS'GENBANK/HM120008'
p84298
aS'GENBANK/HM120009'
p84299
aS'GENBANK/HM120010'
p84300
aS'GENBANK/HM120011'
p84301
aS'GENBANK/HM120012'
p84302
aS'GENBANK/HM120013'
p84303
aS'GENBANK/HM120014'
p84304
aS'GENBANK/HM120015'
p84305
aS'GENBANK/HM120016'
p84306
aS'GENBANK/HM120017'
p84307
aS'GENBANK/HM120018'
p84308
aS'GENBANK/HM120019'
p84309
aS'GENBANK/HM120020'
p84310
aS'GENBANK/HM120021'
p84311
aS'GENBANK/HM120022'
p84312
aS'GENBANK/HM120023'
p84313
aS'GENBANK/HM120024'
p84314
aS'GENBANK/HM120025'
p84315
aS'GENBANK/HM120026'
p84316
aS'GENBANK/HM120027'
p84317
aS'GENBANK/HM120028'
p84318
aS'GENBANK/HM120029'
p84319
aS'GENBANK/HM120030'
p84320
aS'GENBANK/HM120031'
p84321
aS'GENBANK/HM120032'
p84322
aS'GENBANK/HM120033'
p84323
aS'GENBANK/HM120034'
p84324
aS'GENBANK/HM120035'
p84325
aS'GENBANK/HM120036'
p84326
aS'GENBANK/HM120037'
p84327
aS'GENBANK/HM120038'
p84328
aS'GENBANK/HM120039'
p84329
aS'GENBANK/HM120040'
p84330
aS'GENBANK/HM120041'
p84331
aS'GENBANK/HM120042'
p84332
aS'GENBANK/HM120043'
p84333
aS'GENBANK/HM120044'
p84334
aS'GENBANK/HM120045'
p84335
aS'GENBANK/HM120046'
p84336
aS'GENBANK/HM120047'
p84337
aS'GENBANK/HM120048'
p84338
aS'GENBANK/HM120049'
p84339
aS'GENBANK/HM120050'
p84340
aS'GENBANK/HM120051'
p84341
aS'GENBANK/HM120052'
p84342
aS'GENBANK/HM120053'
p84343
aS'GENBANK/HM120054'
p84344
aS'GENBANK/HM120055'
p84345
aS'GENBANK/HM120056'
p84346
aS'GENBANK/HM120057'
p84347
aS'GENBANK/HM120058'
p84348
aS'GENBANK/HM120059'
p84349
aS'GENBANK/HM120060'
p84350
aS'GENBANK/HM120061'
p84351
aS'GENBANK/HM120062'
p84352
aS'GENBANK/HM120063'
p84353
aS'GENBANK/HM120064'
p84354
aS'GENBANK/HM120065'
p84355
aS'GENBANK/HM120066'
p84356
aS'GENBANK/HM120067'
p84357
aS'GENBANK/HM120068'
p84358
aS'GENBANK/HM120069'
p84359
aS'GENBANK/HM120070'
p84360
aS'GENBANK/HM120071'
p84361
aS'GENBANK/HM120072'
p84362
aS'GENBANK/HM120073'
p84363
aS'GENBANK/HM120074'
p84364
aS'GENBANK/HM120075'
p84365
aS'GENBANK/HM120076'
p84366
aS'GENBANK/HM120077'
p84367
aS'GENBANK/HM120078'
p84368
aS'GENBANK/HM120079'
p84369
aS'GENBANK/HM120080'
p84370
aS'GENBANK/HM120081'
p84371
aS'GENBANK/HM120082'
p84372
aS'GENBANK/HM120083'
p84373
aS'GENBANK/HM120084'
p84374
aS'GENBANK/HM120085'
p84375
aS'GENBANK/HM120086'
p84376
aS'GENBANK/HM120087'
p84377
aS'GENBANK/HM120088'
p84378
aS'GENBANK/HM120089'
p84379
aS'GENBANK/HM120090'
p84380
aS'GENBANK/HM120091'
p84381
aS'GENBANK/HM120092'
p84382
aS'GENBANK/HM120093'
p84383
aS'GENBANK/HM120094'
p84384
aS'GENBANK/HM120095'
p84385
aS'GENBANK/HM120096'
p84386
aS'GENBANK/HM120097'
p84387
aS'GENBANK/HM120098'
p84388
aS'GENBANK/HM120099'
p84389
aS'GENBANK/HM120100'
p84390
aS'GENBANK/HM120101'
p84391
aS'GENBANK/HM120102'
p84392
aS'GENBANK/HM120103'
p84393
aS'GENBANK/HM120104'
p84394
aS'GENBANK/HM120105'
p84395
aS'GENBANK/HM120106'
p84396
aS'GENBANK/HM120107'
p84397
aS'GENBANK/HM120108'
p84398
aS'GENBANK/HM120109'
p84399
aS'GENBANK/HM120110'
p84400
aS'GENBANK/HM120111'
p84401
aS'GENBANK/HM120112'
p84402
aS'GENBANK/HM120113'
p84403
aS'GENBANK/HM120114'
p84404
aS'GENBANK/HM120115'
p84405
aS'GENBANK/HM120116'
p84406
aS'GENBANK/HM120117'
p84407
aS'GENBANK/HM120118'
p84408
aS'GENBANK/HM120119'
p84409
aS'GENBANK/HM120120'
p84410
aS'GENBANK/HM120121'
p84411
aS'GENBANK/HM120122'
p84412
aS'GENBANK/HM120123'
p84413
aS'GENBANK/HM120124'
p84414
aS'GENBANK/HM120125'
p84415
aS'GENBANK/HM120126'
p84416
aS'GENBANK/HM120127'
p84417
aS'GENBANK/HM120128'
p84418
aS'GENBANK/HM120129'
p84419
aS'GENBANK/HM120130'
p84420
aS'GENBANK/HM120131'
p84421
aS'GENBANK/HM120132'
p84422
aS'GENBANK/HM120133'
p84423
aS'GENBANK/HM120134'
p84424
aS'GENBANK/HM120135'
p84425
aS'GENBANK/HM120136'
p84426
aS'GENBANK/HM120137'
p84427
aS'GENBANK/HM120138'
p84428
aS'GENBANK/HM120139'
p84429
aS'GENBANK/HM120140'
p84430
aS'GENBANK/HM120141'
p84431
aS'GENBANK/HM120142'
p84432
aS'GENBANK/HM120143'
p84433
aS'GENBANK/HM120144'
p84434
aS'GENBANK/HM120145'
p84435
aS'GENBANK/HM120146'
p84436
aS'GENBANK/HM120147'
p84437
aS'GENBANK/HM120148'
p84438
aS'GENBANK/HM120149'
p84439
aS'GENBANK/HM120150'
p84440
asS'SO'
p84441
S'J Acquir Immune Defic Syndr. 2010 Sep;55(1):95-101. doi: 10.1097/QAI.0b013e3181e544e0.'
p84442
sS'SB'
p84443
S'IM X'
p84444
sS'PMID'
p84445
S'20585262'
p84446
sS'PST'
p84447
S'ppublish'
p84448
stRp84449
ag2
(g3
g4
(dp84450
S'LID'
p84451
S'10.1128/AAC.01409-09 [doi]'
p84452
sS'STAT'
p84453
S'MEDLINE'
p84454
sS'DEP'
p84455
S'20100628'
p84456
sS'DA'
p84457
S'20100818'
p84458
sS'AID'
p84459
(lp84460
S'AAC.01409-09 [pii]'
p84461
aS'10.1128/AAC.01409-09 [doi]'
p84462
asS'CRDT'
p84463
(lp84464
S'2010/06/30 06:00'
p84465
asS'DP'
p84466
S'2010 Sep'
p84467
sS'AD'
p84468
S'University Teaching Hospital, Lusaka, Zambia.'
p84469
sS'OWN'
p84470
S'NLM'
p84471
sS'PT'
p84472
(lp84473
S'Journal Article'
p84474
aS'Randomized Controlled Trial'
p84475
asS'LA'
p84476
(lp84477
S'eng'
p84478
asS'FAU'
p84479
(lp84480
S'Mwenya, Darlington M'
p84481
aS'Charalambous, Bambos M'
p84482
aS'Phillips, Patrick P J'
p84483
aS'Mwansa, James C L'
p84484
aS'Batt, Sarah L'
p84485
aS'Nunn, Andrew J'
p84486
aS'Walker, Sarah'
p84487
aS'Gibb, Diana M'
p84488
aS'Gillespie, Stephen H'
p84489
asS'JT'
p84490
S'Antimicrobial agents and chemotherapy'
p84491
sS'LR'
p84492
S'20151119'
p84493
sS'PG'
p84494
S'3756-62'
p84495
sS'TI'
p84496
S'Impact of cotrimoxazole on carriage and antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae in HIV-infected children in Zambia.'
p84497
sS'RN'
p84498
(lp84499
S'0 (Anti-Infective Agents)'
p84500
aS'8064-90-2 (Trimethoprim, Sulfamethoxazole Drug Combination)'
p84501
asS'PL'
p84502
S'United States'
p84503
sS'TA'
p84504
S'Antimicrob Agents Chemother'
p84505
sS'JID'
p84506
S'0315061'
p84507
sS'AB'
p84508
S'This is a substudy of a larger randomized controlled trial on HIV-infected Zambian children, which revealed that cotrimoxazole prophylaxis reduced morbidity and mortality despite a background of high cotrimoxazole resistance. The impact of cotrimoxazole on the carriage and antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae as major causes of childhood mortality in HIV-infected children was investigated since these are unclear. Representative nasopharyngeal swabs were taken prior to randomization for 181 of 534 children (92 on cotrimoxazole and 89 on placebo). Bacterial identification and antibiotic susceptibility were performed by routine methods. Due to reduced mortality, prophylactic cotrimoxazole increased the median time from randomization to the last specimen from 48 to 56 months (P = 0.001). The carriage of H. influenzae was unaltered by cotrimoxazole. Carriage of S. pneumoniae increased slightly in both arms but was not statistically significant in the placebo arm. In S. pneumoniae switching between carriage and no carriage in consecutive pairs of samples was unaffected by cotrimoxazole (P = 0.18) with a suggestion that the probability of remaining carriage free was lower (P = 0.10). In H. influenzae cotrimoxazole decreased switching from carriage to no carriage (P = 0.02). Cotrimoxazole resistance levels were higher in postbaseline samples in the cotrimoxazole arm than in the placebo arm (S. pneumoniae, P < 0.0001; H. influenzae, P = 0.005). Cotrimoxazole decreased switching from cotrimoxazole resistance to cotrimoxazole sensitivity in S. pneumoniae (P = 0.002) and reduced the chance of H. influenzae remaining cotrimoxazole sensitive (P = 0.05). No associations were observed between the percentage of CD4 (CD4%), the change in CD4% from baseline, child age at date of specimen, child gender, or sampling month with carriage of either pathogen.'
p84509
sS'GR'
p84510
(lp84511
S'MC_U122886353/Medical Research Council/United Kingdom'
p84512
asS'IP'
p84513
S'9'
sS'IS'
p84514
S'1098-6596 (Electronic) 0066-4804 (Linking)'
p84515
sS'PMC'
p84516
S'PMC2934996'
p84517
sS'DCOM'
p84518
S'20101201'
p84519
sS'AU'
p84520
(lp84521
S'Mwenya DM'
p84522
aS'Charalambous BM'
p84523
aS'Phillips PP'
p84524
aS'Mwansa JC'
p84525
aS'Batt SL'
p84526
aS'Nunn AJ'
p84527
aS'Walker S'
p84528
aS'Gibb DM'
p84529
aS'Gillespie SH'
p84530
asS'VI'
p84531
S'54'
p84532
sS'MHDA'
p84533
S'2010/12/14 06:00'
p84534
sS'PHST'
p84535
(lp84536
S'2010/06/28 [aheadofprint]'
p84537
asS'OID'
p84538
(lp84539
S'NLM: PMC2934996'
p84540
asS'MH'
p84541
(lp84542
S'Anti-Infective Agents/therapeutic use'
p84543
aS'Child, Preschool'
p84544
aS'Drug Resistance, Bacterial/*drug effects'
p84545
aS'Female'
p84546
aS'HIV Infections/*microbiology'
p84547
aS'Haemophilus Infections/complications/drug therapy/*microbiology'
p84548
aS'Haemophilus influenzae/*drug effects/physiology'
p84549
aS'Humans'
p84550
aS'Male'
p84551
aS'Pneumococcal Infections/complications/drug therapy/*microbiology'
p84552
aS'Streptococcus pneumoniae/*drug effects/physiology'
p84553
aS'Trimethoprim, Sulfamethoxazole Drug Combination/*therapeutic use'
p84554
aS'Zambia'
p84555
asS'EDAT'
p84556
S'2010/06/30 06:00'
p84557
sS'SO'
p84558
S'Antimicrob Agents Chemother. 2010 Sep;54(9):3756-62. doi: 10.1128/AAC.01409-09. Epub 2010 Jun 28.'
p84559
sS'SB'
p84560
S'IM'
p84561
sS'PMID'
p84562
S'20585110'
p84563
sS'PST'
p84564
S'ppublish'
p84565
stRp84566
ag2
(g3
g4
(dp84567
S'LID'
p84568
S'10.1371/journal.pmed.1000296 [doi]'
p84569
sS'STAT'
p84570
S'MEDLINE'
p84571
sS'DEP'
p84572
S'20100622'
p84573
sS'CIN'
p84574
(lp84575
S'Future Microbiol. 2010 Nov;5(11):1641-3. PMID: 21133686'
p84576
asS'DA'
p84577
S'20100628'
p84578
sS'AID'
p84579
(lp84580
S'10.1371/journal.pmed.1000296 [doi]'
p84581
asS'CRDT'
p84582
(lp84583
S'2010/06/29 06:00'
p84584
asS'DP'
p84585
S'2010 Jun'
p84586
sS'AD'
p84587
S"Division of Global Health Equity, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America."
p84588
sS'OWN'
p84589
S'NLM'
p84590
sS'PT'
p84591
(lp84592
S'Journal Article'
p84593
aS'Research Support, N.I.H., Extramural'
p84594
aS"Research Support, Non-U.S. Gov't"
p84595
asS'LA'
p84596
(lp84597
S'eng'
p84598
asS'FAU'
p84599
(lp84600
S'Cohen, Ted'
p84601
aS'Murray, Megan'
p84602
aS'Wallengren, Kristina'
p84603
aS'Alvarez, Gonzalo G'
p84604
aS'Samuel, Elizabeth Y'
p84605
aS'Wilson, Douglas'
p84606
asS'JT'
p84607
S'PLoS medicine'
p84608
sS'LR'
p84609
S'20141203'
p84610
sS'PG'
p84611
S'e1000296'
p84612
sS'TI'
p84613
S'The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study.'
p84614
sS'RN'
p84615
(lp84616
S'0 (Antitubercular Agents)'
p84617
aS'V83O1VOZ8L (Isoniazid)'
p84618
aS'VJT6J7R4TR (Rifampin)'
p84619
asS'PL'
p84620
S'United States'
p84621
sS'TA'
p84622
S'PLoS Med'
p84623
sS'JID'
p84624
S'101231360'
p84625
sS'AB'
p84626
S"BACKGROUND: Tuberculosis is the leading cause of death in South Africa by death notification, but accurate diagnosis of tuberculosis is challenging in this setting of high HIV prevalence. We conducted limited autopsies on young adults dying in a single public hospital in the province of KwaZulu-Natal between October 2008 and August 2009 in order to estimate the magnitude of deaths attributable to tuberculosis. METHODS AND FINDINGS: We studied a representative sample of 240 adult inpatients (aged 20-45 years) dying after admission to Edendale Hospital. Limited autopsies included collection of respiratory tract secretions and tissue by needle core biopsies of lung, liver, and spleen. Specimens were examined by fluorescent microscopy for acid-fast bacilli and cultured in liquid media; cultures positive for M. tuberculosis were tested for drug susceptibility to first- and second-line antibiotics. Ninety-four percent of our study cohort was HIV seropositive and 50% of decedents had culture-positive tuberculosis at the time of death. Fifty percent of the participants were on treatment for tuberculosis at the time of death and 58% of these treated individuals remained culture positive at the time of death. Of the 50% not receiving tuberculosis treatment, 42% were culture positive. Seventeen percent of all positive cultures were resistant to both isoniazid and rifampin (i.e., multidrug resistant); 16% of patients dying during the initiation phase of their first ever course of tuberculosis treatment were infected with multidrug-resistant bacilli. CONCLUSIONS: Our findings reveal the immense toll of tuberculosis among HIV-positive individuals in KwaZulu-Natal. The majority of decedents who remained culture positive despite receiving tuberculosis treatment were infected with pan-susceptible M. tuberculosis, suggesting that the diagnosis of tuberculosis was made too late to alter the fatal course of the infection. There is also a significant burden of undetected multidrug-resistant tuberculosis among HIV-coinfected individuals dying in this setting. New public health approaches that improve early diagnosis of tuberculosis and accelerate the initiation of treatment are urgently needed in this setting. Please see later in the article for the Editors' Summary."
p84627
sS'GR'
p84628
(lp84629
S'DP2 OD006663/OD/NIH HHS/United States'
p84630
aS'DP2 OD006663-01/OD/NIH HHS/United States'
p84631
aS'DP2OD006663/OD/NIH HHS/United States'
p84632
asS'IP'
p84633
S'6'
sS'IS'
p84634
S'1549-1676 (Electronic) 1549-1277 (Linking)'
p84635
sS'PMC'
p84636
S'PMC2889914'
p84637
sS'DCOM'
p84638
S'20101203'
p84639
sS'AU'
p84640
(lp84641
S'Cohen T'
p84642
aS'Murray M'
p84643
aS'Wallengren K'
p84644
aS'Alvarez GG'
p84645
aS'Samuel EY'
p84646
aS'Wilson D'
p84647
asS'VI'
p84648
S'7'
sS'MHDA'
p84649
S'2010/12/14 06:00'
p84650
sS'PHST'
p84651
(lp84652
S'2010/01/08 [received]'
p84653
aS'2010/05/13 [accepted]'
p84654
aS'2010/06/22 [epublish]'
p84655
asS'OID'
p84656
(lp84657
S'NLM: PMC2889914'
p84658
asS'MH'
p84659
(lp84660
S'AIDS-Related Opportunistic Infections/drug therapy/microbiology/*mortality'
p84661
aS'Adult'
p84662
aS'Antitubercular Agents/*therapeutic use'
p84663
aS'Autopsy'
p84664
aS'Drug Resistance, Bacterial'
p84665
aS'Female'
p84666
aS'*HIV'
p84667
aS'HIV Seropositivity/complications/*mortality/virology'
p84668
aS'Hospitals'
p84669
aS'Humans'
p84670
aS'Isoniazid/therapeutic use'
p84671
aS'Male'
p84672
aS'Middle Aged'
p84673
aS'*Mycobacterium tuberculosis'
p84674
aS'Prevalence'
p84675
aS'Rifampin/therapeutic use'
p84676
aS'South Africa/epidemiology'
p84677
aS'Tuberculosis, Multidrug-Resistant/drug therapy/microbiology/*mortality'
p84678
aS'Young Adult'
p84679
asS'EDAT'
p84680
S'2010/06/29 06:00'
p84681
sS'SO'
p84682
S'PLoS Med. 2010 Jun 22;7(6):e1000296. doi: 10.1371/journal.pmed.1000296.'
p84683
sS'SB'
p84684
S'IM'
p84685
sS'PMID'
p84686
S'20582324'
p84687
sS'PST'
p84688
S'epublish'
p84689
stRp84690
ag2
(g3
g4
(dp84691
S'LID'
p84692
S'10.1093/jac/dkq234 [doi]'
p84693
sS'STAT'
p84694
S'MEDLINE'
p84695
sS'DEP'
p84696
S'20100624'
p84697
sS'CIN'
p84698
(lp84699
S'J Antimicrob Chemother. 2011 Apr;66(4):956-7; author reply 957-8. PMID: 21393221'
p84700
asS'DA'
p84701
S'20100812'
p84702
sS'AID'
p84703
(lp84704
S'dkq234 [pii]'
p84705
aS'10.1093/jac/dkq234 [doi]'
p84706
asS'CRDT'
p84707
(lp84708
S'2010/06/26 06:00'
p84709
asS'DP'
p84710
S'2010 Sep'
p84711
sS'OWN'
p84712
S'NLM'
p84713
sS'PT'
p84714
(lp84715
S'Journal Article'
p84716
aS"Research Support, Non-U.S. Gov't"
p84717
asS'LA'
p84718
(lp84719
S'eng'
p84720
asS'FAU'
p84721
(lp84722
S'Bratholm, Clara'
p84723
aS'Johannessen, Asgeir'
p84724
aS'Naman, Ezra'
p84725
aS'Gundersen, Svein G'
p84726
aS'Kivuyo, Sokoine L'
p84727
aS'Holberg-Petersen, Mona'
p84728
aS'Ormaasen, Vidar'
p84729
aS'Bruun, Johan N'
p84730
asS'JT'
p84731
S'The Journal of antimicrobial chemotherapy'
p84732
sS'LR'
p84733
S'20141203'
p84734
sS'PG'
p84735
S'1996-2000'
p84736
sS'TI'
p84737
S'Drug resistance is widespread among children who receive long-term antiretroviral treatment at a rural Tanzanian hospital.'
p84738
sS'RN'
p84739
(lp84740
S'0 (Anti-Retroviral Agents)'
p84741
asS'PL'
p84742
S'England'
p84743
sS'TA'
p84744
S'J Antimicrob Chemother'
p84745
sS'JID'
p84746
S'7513617'
p84747
sS'AB'
p84748
S'OBJECTIVES: To assess long-term virological efficacy and the emergence of drug resistance in children who receive antiretroviral treatment (ART) in rural Tanzania. PATIENTS AND METHODS: Haydom Lutheran Hospital has provided ART to HIV-infected individuals since 2003. From February through May 2009, a cross-sectional virological efficacy survey was conducted among children (<15 years) who had completed >or=6 months of first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based ART. Genotypic resistance was determined in those with a viral load of >200 copies/mL. RESULTS: Virological response was measured in 19 of 23 eligible children; 8 of 19 were girls and median age at ART initiation was 5 years (range 2-14 years). Median duration of ART at the time of the survey was 40 months (range 11-61 months). Only 8 children were virologically suppressed (<or=40 copies/mL), whereas 11 children had clinically relevant resistance mutations in the reverse transcriptase gene. The most frequent mutations were M184V (n = 11), conferring resistance to lamivudine and emtricitabine, and Y181C (n = 4), G190A/S (n = 4) and K103N (n = 4), conferring resistance to NNRTIs. Of concern, three children had thymidine analogue mutations, associated with cross-resistance to all nucleoside reverse transcriptase inhibitors. Despite widespread resistance, however, only one child experienced a new WHO stage 4 event and none had a CD4 cell count of <200 cells/mm(3). CONCLUSIONS: Among children on long-term ART in rural Tanzania, >50% harboured drug resistance. Results for children were markedly poorer than for adults attending the same programme, underscoring the need for improved treatment strategies for children in resource-limited settings.'
p84749
sS'AD'
p84750
S'Department of Infectious Diseases, Oslo University Hospital, Ulleval, Oslo, Norway.'
p84751
sS'IP'
p84752
S'9'
sS'IS'
p84753
S'1460-2091 (Electronic) 0305-7453 (Linking)'
p84754
sS'PMC'
p84755
S'PMC2920178'
p84756
sS'DCOM'
p84757
S'20101116'
p84758
sS'AU'
p84759
(lp84760
S'Bratholm C'
p84761
aS'Johannessen A'
p84762
aS'Naman E'
p84763
aS'Gundersen SG'
p84764
aS'Kivuyo SL'
p84765
aS'Holberg-Petersen M'
p84766
aS'Ormaasen V'
p84767
aS'Bruun JN'
p84768
asS'VI'
p84769
S'65'
p84770
sS'MHDA'
p84771
S'2010/11/17 06:00'
p84772
sS'PHST'
p84773
(lp84774
S'2010/06/24 [aheadofprint]'
p84775
asS'OID'
p84776
(lp84777
S'NLM: PMC2920178'
p84778
asS'MH'
p84779
(lp84780
S'Adolescent'
p84781
aS'Anti-Retroviral Agents/*therapeutic use'
p84782
aS'Child'
p84783
aS'Child, Preschool'
p84784
aS'Cross-Sectional Studies'
p84785
aS'*Drug Resistance, Viral'
p84786
aS'Female'
p84787
aS'Genotype'
p84788
aS'HIV/drug effects/*genetics/*isolation & purification'
p84789
aS'HIV Infections/*drug therapy'
p84790
aS'Hospitals'
p84791
aS'Humans'
p84792
aS'Male'
p84793
aS'Prevalence'
p84794
aS'Rural Population'
p84795
aS'Tanzania'
p84796
aS'*Viral Load'
p84797
asS'EDAT'
p84798
S'2010/06/26 06:00'
p84799
sS'SO'
p84800
S'J Antimicrob Chemother. 2010 Sep;65(9):1996-2000. doi: 10.1093/jac/dkq234. Epub 2010 Jun 24.'
p84801
sS'SB'
p84802
S'IM'
p84803
sS'PMID'
p84804
S'20576637'
p84805
sS'PST'
p84806
S'ppublish'
p84807
stRp84808
ag2
(g3
g4
(dp84809
S'LID'
p84810
S'10.1086/654800 [doi]'
p84811
sS'STAT'
p84812
S'MEDLINE'
p84813
sS'JT'
p84814
S'Clinical infectious diseases : an official publication of the Infectious Diseases Society of America'
p84815
sS'DA'
p84816
S'20100705'
p84817
sS'AID'
p84818
(lp84819
S'10.1086/654800 [doi]'
p84820
asS'CRDT'
p84821
(lp84822
S'2010/06/25 06:00'
p84823
asS'DP'
p84824
S'2010 Aug 1'
p84825
sS'AD'
p84826
S'Departments of Medicine, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe. mborok@mweb.co.zw'
p84827
sS'OWN'
p84828
S'NLM'
p84829
sS'PT'
p84830
(lp84831
S'Journal Article'
p84832
aS'Research Support, N.I.H., Extramural'
p84833
aS"Research Support, Non-U.S. Gov't"
p84834
asS'LA'
p84835
(lp84836
S'eng'
p84837
asS'FAU'
p84838
(lp84839
S'Borok, Margaret'
p84840
aS'Fiorillo, Suzanne'
p84841
aS'Gudza, Ivy'
p84842
aS'Putnam, Beverly'
p84843
aS'Ndemera, Buxton'
p84844
aS'White, Irene E'
p84845
aS'Gwanzura, Lovemore'
p84846
aS'Schooley, Robert T'
p84847
aS'Campbell, Thomas B'
p84848
asS'LR'
p84849
S'20151119'
p84850
sS'PG'
p84851
S'342-9'
p84852
sS'TI'
p84853
S'Evaluation of plasma human herpesvirus 8 DNA as a marker of clinical outcomes during antiretroviral therapy for AIDS-related Kaposi sarcoma in Zimbabwe.'
p84854
sS'RN'
p84855
(lp84856
S'0 (Anti-HIV Agents)'
p84857
aS'0 (Biomarkers)'
p84858
aS'0 (DNA, Viral)'
p84859
asS'PL'
p84860
S'United States'
p84861
sS'TA'
p84862
S'Clin Infect Dis'
p84863
sS'JID'
p84864
S'9203213'
p84865
sS'AB'
p84866
S'BACKGROUND: The usefulness of plasma human herpesvirus 8 (HHV-8) DNA as a marker of response to treatment for acquired immunodeficiency syndrome-associated Kaposi sarcoma (AIDS-KS) in an African setting is unknown. METHODS: We conducted a prospective pilot study at the Parirenyatwa Hospital Kaposi Sarcoma Clinic (Harare, Zimbabwe) to investigate the hypothesis that the clinical response of AIDS-KS is associated with suppression of HHV-8 DNA. Antiretroviral therapy (ART) was provided as coformulation of abacavir, lamivudine, and zidovudine. Clinical response was defined as survival to week 96 with either complete or partial resolution of KS disease. RESULTS: Ninety ART-naive participants (62 men and 28 women) aged >18 years who had human immunodeficiency virus type 1 (HIV-1) infection and biopsy-confirmed KS were studied; 82% had stage T1 disease. Fifty participants received adjunctive chemotherapy. The median CD4(+) lymphocyte count increased from 124 cells/microL at baseline to 281 cells/microL, the plasma HIV-1 RNA level decreased from 4.69 to <2.60 log(10) copies/mL, the plasma HHV-8 DNA level decreased from 660 to <25 copies/mL, and HHV-8 DNA level in peripheral blood mononuclear cells decreased from 2790 to 37 copies/10(6) cells (P < .001 for each comparison). There were 14 deaths (16%) and 13 patients (15%) lost to follow-up. The most common cause of death was infection. Clinical response of KS occurred in 17 participants (19%). Pretreatment plasma HHV-8 DNA levels of <660 copies/mL were associated with greater survival (odds ratio, 2.83; 95% confidence interval, 1.07-7.53; P = .04) and a better clinical response (odds ratio, 6.38; 95% confidence interval, 1.68-24.19; P = .006). CONCLUSIONS: AIDS-KS tumor responses after ART initiation were limited. Pretreatment plasma HHV-8 DNA level may be a surrogate for KS disease that is in need of intensive clinical management.'
p84867
sS'GR'
p84868
(lp84869
S'AA054907/AA/NIAAA NIH HHS/United States'
p84870
asS'IP'
p84871
S'3'
sS'IS'
p84872
S'1537-6591 (Electronic) 1058-4838 (Linking)'
p84873
sS'DCOM'
p84874
S'20101104'
p84875
sS'AU'
p84876
(lp84877
S'Borok M'
p84878
aS'Fiorillo S'
p84879
aS'Gudza I'
p84880
aS'Putnam B'
p84881
aS'Ndemera B'
p84882
aS'White IE'
p84883
aS'Gwanzura L'
p84884
aS'Schooley RT'
p84885
aS'Campbell TB'
p84886
asS'VI'
p84887
S'51'
p84888
sS'MHDA'
p84889
S'2010/11/05 06:00'
p84890
sS'MH'
p84891
(lp84892
S'Acquired Immunodeficiency Syndrome/complications/*drug therapy'
p84893
aS'Adult'
p84894
aS'Aged'
p84895
aS'Anti-HIV Agents/*therapeutic use'
p84896
aS'Antiretroviral Therapy, Highly Active/methods'
p84897
aS'Biomarkers'
p84898
aS'DNA, Viral/*blood'
p84899
aS'Drug Monitoring/*methods'
p84900
aS'Female'
p84901
aS'Herpesvirus 8, Human/*genetics/isolation & purification'
p84902
aS'Humans'
p84903
aS'Male'
p84904
aS'Middle Aged'
p84905
aS'Pilot Projects'
p84906
aS'Plasma/*virology'
p84907
aS'Prospective Studies'
p84908
aS'Sarcoma, Kaposi/*drug therapy'
p84909
aS'Survival Analysis'
p84910
aS'Treatment Outcome'
p84911
aS'Viral Load'
p84912
aS'Zimbabwe'
p84913
asS'EDAT'
p84914
S'2010/06/25 06:00'
p84915
sS'SO'
p84916
S'Clin Infect Dis. 2010 Aug 1;51(3):342-9. doi: 10.1086/654800.'
p84917
sS'SB'
p84918
S'IM'
p84919
sS'PMID'
p84920
S'20572760'
p84921
sS'PST'
p84922
S'ppublish'
p84923
stRp84924
ag2
(g3
g4
(dp84925
S'STAT'
p84926
S'MEDLINE'
p84927
sS'JT'
p84928
S'The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease'
p84929
sS'MID'
p84930
(lp84931
S'NIHMS330295'
p84932
asS'DA'
p84933
S'20100616'
p84934
sS'CRDT'
p84935
(lp84936
S'2010/06/17 06:00'
p84937
asS'DP'
p84938
S'2010 Jul'
p84939
sS'AD'
p84940
S'Doctors Without Borders USA, New York, New York, USA. ramurphy@gmail.com'
p84941
sS'OWN'
p84942
S'NLM'
p84943
sS'PT'
p84944
(lp84945
S'Journal Article'
p84946
aS'Research Support, N.I.H., Extramural'
p84947
aS"Research Support, Non-U.S. Gov't"
p84948
asS'LA'
p84949
(lp84950
S'eng'
p84951
asS'FAU'
p84952
(lp84953
S'Murphy, R A'
p84954
aS'Sunpath, H'
p84955
aS'Taha, B'
p84956
aS'Kappagoda, S'
p84957
aS'Maphasa, K T M'
p84958
aS'Kuritzkes, D R'
p84959
aS'Smeaton, L'
p84960
asS'LR'
p84961
S'20141203'
p84962
sS'PG'
p84963
S'903-8'
p84964
sS'TI'
p84965
S'Low uptake of antiretroviral therapy after admission with human immunodeficiency virus and tuberculosis in KwaZulu-Natal, South Africa.'
p84966
sS'RN'
p84967
(lp84968
S'0 (Anti-HIV Agents)'
p84969
asS'PL'
p84970
S'France'
p84971
sS'TA'
p84972
S'Int J Tuberc Lung Dis'
p84973
sS'JID'
p84974
S'9706389'
p84975
sS'AB'
p84976
S'OBJECTIVES: A prospective cohort study was conducted among human immunodeficiency virus (HIV) infected in-patients with tuberculosis (TB) or other opportunistic infections (OIs) in South Africa to estimate subsequent antiretroviral therapy (ART) uptake and survival. METHODS: Logistic regression modeling explored associations between baseline characteristics and starting ART, and ART exposure-adjusted incidence of death was estimated over 6 months of follow-up. RESULTS: Among 49 participants enrolled, median CD4 cell count at hospital discharge was 42 cells/microl and the most common presenting OIs were TB (76%), Pneumocystis pneumonia (8%), chronic diarrhea (8%), cryptococcal meningitis (6%), and Toxoplasma gondii (4%). By 6 months, only 20 (45%) patients had initiated ART, and four (8%) were lost to follow-up. ART uptake was independently associated with previous use of traditional medicine (OR 7.2, 95%CI 1.4-55.1) and with less advanced HIV infection (baseline CD4 count per 50 cells/microl increase OR 1.4, 95%CI 0.9-2.2). A total of 14 (31%) patients died before initiating ART; the monthly incidence of death did not decrease over the 6-month interval. CONCLUSION: The high mortality observed within the 6 months following hospitalization with TB or other acute OIs indicate that mechanisms are needed to expedite ART for patients after an acquired immune-deficiency syndrome defining illness.'
p84977
sS'GR'
p84978
(lp84979
S'K24 RR016482/RR/NCRR NIH HHS/United States'
p84980
aS'K24-RR016482/RR/NCRR NIH HHS/United States'
p84981
aS'P30 AI060354/AI/NIAID NIH HHS/United States'
p84982
aS'P30 AI060354/AI/NIAID NIH HHS/United States'
p84983
asS'IP'
p84984
S'7'
sS'IS'
p84985
S'1815-7920 (Electronic) 1027-3719 (Linking)'
p84986
sS'PMC'
p84987
S'PMC3207641'
p84988
sS'DCOM'
p84989
S'20100920'
p84990
sS'AU'
p84991
(lp84992
S'Murphy RA'
p84993
aS'Sunpath H'
p84994
aS'Taha B'
p84995
aS'Kappagoda S'
p84996
aS'Maphasa KT'
p84997
aS'Kuritzkes DR'
p84998
aS'Smeaton L'
p84999
asS'VI'
p85000
S'14'
p85001
sS'MHDA'
p85002
S'2010/09/21 06:00'
p85003
sS'OID'
p85004
(lp85005
S'NLM: NIHMS330295'
p85006
aS'NLM: PMC3207641'
p85007
asS'MH'
p85008
(lp85009
S'AIDS-Related Opportunistic Infections/*epidemiology'
p85010
aS'Adolescent'
p85011
aS'Adult'
p85012
aS'Anti-HIV Agents/*therapeutic use'
p85013
aS'CD4 Lymphocyte Count'
p85014
aS'Child'
p85015
aS'Child, Preschool'
p85016
aS'Cohort Studies'
p85017
aS'Female'
p85018
aS'Follow-Up Studies'
p85019
aS'HIV Infections/complications/*drug therapy/mortality'
p85020
aS'Hospitalization'
p85021
aS'Humans'
p85022
aS'Infant'
p85023
aS'Logistic Models'
p85024
aS'Male'
p85025
aS'Prospective Studies'
p85026
aS'South Africa'
p85027
aS'Tuberculosis/*complications'
p85028
aS'Young Adult'
p85029
asS'EDAT'
p85030
S'2010/06/17 06:00'
p85031
sS'SO'
p85032
S'Int J Tuberc Lung Dis. 2010 Jul;14(7):903-8.'
p85033
sS'SB'
p85034
S'IM'
p85035
sS'PMID'
p85036
S'20550776'
p85037
sS'PST'
p85038
S'ppublish'
p85039
stRp85040
ag2
(g3
g4
(dp85041
S'LID'
p85042
S'10.1097/OLQ.0b013e3181e212e5 [doi]'
p85043
sS'STAT'
p85044
S'MEDLINE'
p85045
sS'JT'
p85046
S'Sexually transmitted diseases'
p85047
sS'CIN'
p85048
(lp85049
S'Sex Transm Dis. 2011 Feb;38(2):150. PMID: 21209599'
p85050
aS'Sex Transm Dis. 2010 Aug;37(8):494-6. PMID: 20539259'
p85051
asS'DA'
p85052
S'20100728'
p85053
sS'AID'
p85054
(lp85055
S'10.1097/OLQ.0b013e3181e212e5 [doi]'
p85056
asS'CRDT'
p85057
(lp85058
S'2010/06/12 06:00'
p85059
asS'DP'
p85060
S'2010 Aug'
p85061
sS'OWN'
p85062
S'NLM'
p85063
sS'PT'
p85064
(lp85065
S'Journal Article'
p85066
aS"Research Support, Non-U.S. Gov't"
p85067
asS'LA'
p85068
(lp85069
S'eng'
p85070
asS'FAU'
p85071
(lp85072
S'Corbell, Catherine'
p85073
aS'Stergachis, Andy'
p85074
aS'Ndowa, Francis'
p85075
aS'Ndase, Patrick'
p85076
aS'Barnes, Linda'
p85077
aS'Celum, Connie'
p85078
asS'LR'
p85079
S'20131121'
p85080
sS'PG'
p85081
S'488-93'
p85082
sS'TI'
p85083
S'Genital ulcer disease treatment policies and access to acyclovir in eight sub-Saharan African countries.'
p85084
sS'RN'
p85085
(lp85086
S'0 (Antiviral Agents)'
p85087
aS'X4HES1O11F (Acyclovir)'
p85088
asS'PL'
p85089
S'United States'
p85090
sS'TA'
p85091
S'Sex Transm Dis'
p85092
sS'JID'
p85093
S'7705941'
p85094
sS'AB'
p85095
S'BACKGROUND: Herpes simplex virus-2, the most common cause of genital ulcer disease (GUD) globally, is a cofactor in human immunodeficiency virus type-1 (HIV-1) acquisition and transmission. Current World Health Organization guidelines for sexually transmitted infections recommend acyclovir as first-line syndromic treatment of GUD in countries with high herpes simplex virus-2 prevalence (> or =30%). OBJECTIVE: To assess the extent of adoption of acyclovir as syndromic treatment for GUD, and describe procurement, distribution, and cost of acyclovir in the public and private sectors of 8 sub-Saharan African countries. METHODS: We conducted standardized interviews with Ministry of Health (MoH) officials, pharmacists, and other pharmacy workers based in the public and private sectors. Interviews were conducted in Botswana, Kenya, Malawi, South Africa, Tanzania, Uganda, Zambia, and Zimbabwe. Price comparisons were conducted using the 2007 median international reference price (IRP) for acyclovir. RESULTS: Of the 8 African countries, 4 surveyed had adopted acyclovir as first-line syndromic GUD treatment in both their essential medical lists and sexually transmitted infection guidelines. Country-specific acquisition prices for acyclovir 200 mg were comparable to the median IRP and ranged from 0.74 to 1.95 times the median IRP. The median retail cost of acyclovir in the private sector ranged from 5.85 to 9.76 times the median IRP. Public health facilities faced cost and regulatory barriers that impeded the requisitioning of acyclovir from the central medical stores. CONCLUSIONS: Systems for drug procurement, distribution, and access in sub-Saharan African countries need strengthening for a GUD treatment policy using acyclovir to be effective.'
p85096
sS'AD'
p85097
S'Department of Pharmacy, University of Washington, Seattle, WA 98195, USA.'
p85098
sS'IP'
p85099
S'8'
sS'IS'
p85100
S'1537-4521 (Electronic) 0148-5717 (Linking)'
p85101
sS'DCOM'
p85102
S'20110418'
p85103
sS'AU'
p85104
(lp85105
S'Corbell C'
p85106
aS'Stergachis A'
p85107
aS'Ndowa F'
p85108
aS'Ndase P'
p85109
aS'Barnes L'
p85110
aS'Celum C'
p85111
asS'VI'
p85112
S'37'
p85113
sS'MHDA'
p85114
S'2011/04/19 06:00'
p85115
sS'MH'
p85116
(lp85117
S'Acyclovir/economics/*therapeutic use'
p85118
aS'Africa South of the Sahara/epidemiology'
p85119
aS'Antiviral Agents/economics/*therapeutic use'
p85120
aS'Female'
p85121
aS'Genital Diseases, Female/drug therapy/virology'
p85122
aS'Genital Diseases, Male/drug therapy/virology'
p85123
aS'*Health Policy'
p85124
aS'*Health Services Accessibility'
p85125
aS'Herpes Genitalis/*drug therapy/virology'
p85126
aS'Herpesvirus 2, Human'
p85127
aS'Humans'
p85128
aS'Interviews as Topic'
p85129
aS'Male'
p85130
aS'Practice Guidelines as Topic'
p85131
aS'Private Sector'
p85132
aS'Public Sector'
p85133
aS'Ulcer/*drug therapy/virology'
p85134
asS'EDAT'
p85135
S'2010/06/12 06:00'
p85136
sS'SO'
p85137
S'Sex Transm Dis. 2010 Aug;37(8):488-93. doi: 10.1097/OLQ.0b013e3181e212e5.'
p85138
sS'SB'
p85139
S'IM'
p85140
sS'PMID'
p85141
S'20539260'
p85142
sS'PST'
p85143
S'ppublish'
p85144
stRp85145
ag2
(g3
g4
(dp85146
S'LID'
p85147
S'10.1007/s10461-010-9720-1 [doi]'
p85148
sS'STAT'
p85149
S'MEDLINE'
p85150
sS'JT'
p85151
S'AIDS and behavior'
p85152
sS'MID'
p85153
(lp85154
S'NIHMS230970'
p85155
asS'DA'
p85156
S'20101108'
p85157
sS'AID'
p85158
(lp85159
S'10.1007/s10461-010-9720-1 [doi]'
p85160
asS'CRDT'
p85161
(lp85162
S'2010/06/10 06:00'
p85163
asS'DP'
p85164
S'2010 Dec'
p85165
sS'AD'
p85166
S'Department of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA. jhaberer@partners.org'
p85167
sS'OWN'
p85168
S'NLM'
p85169
sS'PT'
p85170
(lp85171
S'Journal Article'
p85172
aS'Research Support, N.I.H., Extramural'
p85173
asS'LA'
p85174
(lp85175
S'eng'
p85176
asS'FAU'
p85177
(lp85178
S'Haberer, Jessica E'
p85179
aS'Kiwanuka, Julius'
p85180
aS'Nansera, Denis'
p85181
aS'Wilson, Ira B'
p85182
aS'Bangsberg, David R'
p85183
asS'LR'
p85184
S'20141203'
p85185
sS'PG'
p85186
S'1294-301'
p85187
sS'TI'
p85188
S'Challenges in using mobile phones for collection of antiretroviral therapy adherence data in a resource-limited setting.'
p85189
sS'PL'
p85190
S'United States'
p85191
sS'TA'
p85192
S'AIDS Behav'
p85193
sS'JID'
p85194
S'9712133'
p85195
sS'AB'
p85196
S'Frequent antiretroviral therapy adherence monitoring could detect incomplete adherence before viral rebound develops and thus potentially prevent treatment failure. Mobile phone technologies make frequent, brief adherence interviews possible in resource-limited settings; however, feasibility and acceptability are unknown. Interactive voice response (IVR) and short message service (SMS) text messaging were used to collect adherence data from 19 caregivers of HIV-infected children in Uganda. IVR calls or SMS quantifying missed doses were sent in the local language once weekly for 3-4 weeks. Qualitative interviews were conducted to assess participant impressions of the technologies. Participant interest and participation rates were high; however, weekly completion rates for adherence queries were low (0-33%), most commonly due to misunderstanding of personal identification numbers. Despite near ubiquity of mobile phone technology in resource-limited settings, individual level collection of healthcare data presents challenges. Further research is needed for effective training and incentive methods.'
p85197
sS'GR'
p85198
(lp85199
S'K23 MH087228/MH/NIMH NIH HHS/United States'
p85200
aS'K24 MH087227/MH/NIMH NIH HHS/United States'
p85201
aS'K24 MH092242/MH/NIMH NIH HHS/United States'
p85202
aS'R01 MH054907/MH/NIMH NIH HHS/United States'
p85203
aS'R21 MH083306/MH/NIMH NIH HHS/United States'
p85204
aS'R21 MH083306-01/MH/NIMH NIH HHS/United States'
p85205
aS'R21MH083306/MH/NIMH NIH HHS/United States'
p85206
asS'IP'
p85207
S'6'
sS'IS'
p85208
S'1573-3254 (Electronic) 1090-7165 (Linking)'
p85209
sS'PMC'
p85210
S'PMC2975780'
p85211
sS'DCOM'
p85212
S'20110217'
p85213
sS'AU'
p85214
(lp85215
S'Haberer JE'
p85216
aS'Kiwanuka J'
p85217
aS'Nansera D'
p85218
aS'Wilson IB'
p85219
aS'Bangsberg DR'
p85220
asS'VI'
p85221
S'14'
p85222
sS'MHDA'
p85223
S'2011/02/18 06:00'
p85224
sS'OID'
p85225
(lp85226
S'NLM: NIHMS230970'
p85227
aS'NLM: PMC2975780'
p85228
asS'MH'
p85229
(lp85230
S'Adult'
p85231
aS'*Antiretroviral Therapy, Highly Active'
p85232
aS'Caregivers'
p85233
aS'*Cell Phones'
p85234
aS'Child'
p85235
aS'Child, Preschool'
p85236
aS'Data Collection/*methods'
p85237
aS'Feasibility Studies'
p85238
aS'Female'
p85239
aS'HIV Infections/diagnosis/*drug therapy'
p85240
aS'Humans'
p85241
aS'Interviews as Topic'
p85242
aS'Male'
p85243
aS'*Medication Adherence'
p85244
aS'Prospective Studies'
p85245
aS'Qualitative Research'
p85246
aS'Reminder Systems'
p85247
aS'Uganda'
p85248
asS'EDAT'
p85249
S'2010/06/10 06:00'
p85250
sS'SO'
p85251
S'AIDS Behav. 2010 Dec;14(6):1294-301. doi: 10.1007/s10461-010-9720-1.'
p85252
sS'SB'
p85253
S'IM'
p85254
sS'PMID'
p85255
S'20532605'
p85256
sS'PST'
p85257
S'ppublish'
p85258
stRp85259
ag2
(g3
g4
(dp85260
S'LID'
p85261
S'10.1111/j.1365-3156.2010.02539.x [doi]'
p85262
sS'STAT'
p85263
S'MEDLINE'
p85264
sS'DEP'
p85265
S'20100514'
p85266
sS'MID'
p85267
(lp85268
S'NIHMS223971'
p85269
asS'DA'
p85270
S'20100713'
p85271
sS'AID'
p85272
(lp85273
S'TMI2539 [pii]'
p85274
aS'10.1111/j.1365-3156.2010.02539.x [doi]'
p85275
asS'CRDT'
p85276
(lp85277
S'2010/05/22 06:00'
p85278
asS'DP'
p85279
S'2010 Jul'
p85280
sS'AD'
p85281
S'Moi University School of Medicine, Eldoret, Kenya. pbraitstein@yahoo.com'
p85282
sS'OWN'
p85283
S'NLM'
p85284
sS'PT'
p85285
(lp85286
S'Journal Article'
p85287
aS'Multicenter Study'
p85288
aS'Research Support, N.I.H., Extramural'
p85289
aS"Research Support, Non-U.S. Gov't"
p85290
aS"Research Support, U.S. Gov't, Non-P.H.S."
p85291
asS'LA'
p85292
(lp85293
S'eng'
p85294
asS'FAU'
p85295
(lp85296
S'Braitstein, Paula'
p85297
aS'Katshcke, Adrian'
p85298
aS'Shen, Changyu'
p85299
aS'Sang, Edwin'
p85300
aS'Nyandiko, Winstone'
p85301
aS'Ochieng, Vincent Ooko'
p85302
aS'Vreeman, Rachel'
p85303
aS'Yiannoutsos, Constantin T'
p85304
aS'Wools-Kaloustian, Kara'
p85305
aS'Ayaya, Samwel'
p85306
asS'JT'
p85307
S'Tropical medicine & international health : TM & IH'
p85308
sS'LR'
p85309
S'20141203'
p85310
sS'PG'
p85311
S'833-41'
p85312
sS'TI'
p85313
S'Retention of HIV-infected and HIV-exposed children in a comprehensive HIV clinical care programme in Western Kenya.'
p85314
sS'RN'
p85315
(lp85316
S'0 (Anti-HIV Agents)'
p85317
asS'PL'
p85318
S'England'
p85319
sS'TA'
p85320
S'Trop Med Int Health'
p85321
sS'JID'
p85322
S'9610576'
p85323
sS'AB'
p85324
S'BACKGROUND: To describe incidence rates (IR) and risk factors for loss-to-follow-up (LTFU) among HIV-infected and HIV-exposed children in a large HIV treatment programme in Western Kenya. METHODS: The USAID-AMPATH Partnership has enrolled >100,000 patients (20% children) at 23 clinic sites throughout western Kenya. LTFU is defined as being absent from the clinic for >3 months if on combination antiretroviral treatment (cART) and >6 months if not. Included in this analysis were children aged <14 years, HIV exposed or infected at enrollment, and enrolled between April 2002 and March 2009. The IR for LTFU are presented per 100 child-years (CY) of follow-up. Proportional hazards models with time-independent and time-dependent covariates were used to model factors associated with LTFU. Weight for height Z-scores were calculated using EpiInfo, with severe malnutrition being defined as a Z-score <or=-3.0. Immune suppression was defined as per WHO age-specific categories. RESULTS: There were 13,510 children eligible for analysis, comprising 3106 children who at enrollment were HIV infected and 10,404 children who were HIV exposed. The overall IR of LTFU was 18.4 (17.8-18.9) per 100 CY. Among HIV-infected children, 15.2 (13.8-16.7) and 14.1 (13.1-15.8) per 100 CY became LTFU, pre- and post-cART initiation, respectively. The only independent risk factor for becoming LTFU among the HIV-infected children was severe immune suppression (AHR: 2.17, 95% CI: 1.51-3.12). Among the HIV-exposed children, 20.1 per 100 (19.4-20.7) became LTFU. Independent risk factors for LTFU among them were being severely low weight for height (AHR: 1.69, 95% CI: 1.25-2.28), being orphaned at enrollment (AHR: 1.57, 95% CI: 1.23-1.64), being CDC Class B or C (AHR: 1.41, 95% CI: 1.14-1.74), and having received cART (AHR: 1.56, 95% CI: 1.23-1.99). Protective against becoming LTFU among the HIV exposed were testing HIV positive (AHR: 0.26, 95% CI: 0.21-0.32), older age (AHR: 0.90, 95% CI: 0.85-0.96), enrolling in later time periods, and receiving food supplementation (AHR: 0.58, 95% CI: 0.32-1.04). CONCLUSIONS: There is a high rate of LTFU among these highly vulnerable children, particularly among the HIV exposed. These data suggest that HIV-infected and HIV-exposed children are at especially high risk for LTFU if they are sick or malnourished.'
p85325
sS'GR'
p85326
(lp85327
S'U01 AI069911/AI/NIAID NIH HHS/United States'
p85328
aS'U01 AI069911-01/AI/NIAID NIH HHS/United States'
p85329
aS'U01-AI0669911/AI/NIAID NIH HHS/United States'
p85330
asS'IP'
p85331
S'7'
sS'IS'
p85332
S'1365-3156 (Electronic) 1360-2276 (Linking)'
p85333
sS'PMC'
p85334
S'PMC2929358'
p85335
sS'DCOM'
p85336
S'20100730'
p85337
sS'AU'
p85338
(lp85339
S'Braitstein P'
p85340
aS'Katshcke A'
p85341
aS'Shen C'
p85342
aS'Sang E'
p85343
aS'Nyandiko W'
p85344
aS'Ochieng VO'
p85345
aS'Vreeman R'
p85346
aS'Yiannoutsos CT'
p85347
aS'Wools-Kaloustian K'
p85348
aS'Ayaya S'
p85349
asS'VI'
p85350
S'15'
p85351
sS'MHDA'
p85352
S'2010/07/31 06:00'
p85353
sS'PHST'
p85354
(lp85355
S'2010/05/14 [aheadofprint]'
p85356
asS'OID'
p85357
(lp85358
S'NLM: NIHMS223971'
p85359
aS'NLM: PMC2929358'
p85360
asS'MH'
p85361
(lp85362
S'Adolescent'
p85363
aS'Age Factors'
p85364
aS'Anti-HIV Agents/therapeutic use'
p85365
aS'Child'
p85366
aS'Child, Preschool'
p85367
aS'Dietary Supplements/utilization'
p85368
aS'Epidemiologic Methods'
p85369
aS'Female'
p85370
aS'HIV Infections/drug therapy/*epidemiology/prevention & control'
p85371
aS'Humans'
p85372
aS'Infant'
p85373
aS'Kenya/epidemiology'
p85374
aS'Male'
p85375
aS'Patient Dropouts/*statistics & numerical data'
p85376
aS'Program Evaluation'
p85377
asS'EDAT'
p85378
S'2010/05/22 06:00'
p85379
sS'SO'
p85380
S'Trop Med Int Health. 2010 Jul;15(7):833-41. doi: 10.1111/j.1365-3156.2010.02539.x. Epub 2010 May 14.'
p85381
sS'SB'
p85382
S'IM'
p85383
sS'PMID'
p85384
S'20487430'
p85385
sS'PST'
p85386
S'ppublish'
p85387
stRp85388
ag2
(g3
g4
(dp85389
S'LID'
p85390
S'10.1111/j.1365-3156.2010.02540.x [doi]'
p85391
sS'STAT'
p85392
S'MEDLINE'
p85393
sS'DEP'
p85394
S'20100507'
p85395
sS'MID'
p85396
(lp85397
S'NIHMS225029'
p85398
asS'DA'
p85399
S'20100713'
p85400
sS'AID'
p85401
(lp85402
S'TMI2540 [pii]'
p85403
aS'10.1111/j.1365-3156.2010.02540.x [doi]'
p85404
asS'CRDT'
p85405
(lp85406
S'2010/05/22 06:00'
p85407
asS'DP'
p85408
S'2010 Jul'
p85409
sS'AD'
p85410
S'Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.'
p85411
sS'OWN'
p85412
S'NLM'
p85413
sS'PT'
p85414
(lp85415
S'Journal Article'
p85416
aS'Research Support, N.I.H., Extramural'
p85417
aS"Research Support, Non-U.S. Gov't"
p85418
aS"Research Support, U.S. Gov't, P.H.S."
p85419
asS'LA'
p85420
(lp85421
S'eng'
p85422
asS'FAU'
p85423
(lp85424
S'Chintu, Namwinga'
p85425
aS'Giganti, Mark J'
p85426
aS'Putta, Nande B'
p85427
aS'Sinkala, Moses'
p85428
aS'Sadoki, Ebedy'
p85429
aS'Stringer, Elizabeth M'
p85430
aS'Stringer, Jeffrey S A'
p85431
aS'Chi, Benjamin H'
p85432
asS'JT'
p85433
S'Tropical medicine & international health : TM & IH'
p85434
sS'LR'
p85435
S'20141203'
p85436
sS'PG'
p85437
S'842-7'
p85438
sS'TI'
p85439
S'Peripartum nevirapine exposure and subsequent clinical outcomes among HIV-infected women receiving antiretroviral therapy for at least 12 months.'
p85440
sS'RN'
p85441
(lp85442
S'0 (Anti-HIV Agents)'
p85443
aS'0 (Reverse Transcriptase Inhibitors)'
p85444
aS'99DK7FVK1H (Nevirapine)'
p85445
asS'PL'
p85446
S'England'
p85447
sS'TA'
p85448
S'Trop Med Int Health'
p85449
sS'JID'
p85450
S'9610576'
p85451
sS'AB'
p85452
S'OBJECTIVE: Prior exposure to intrapartum/neonatal nevirapine (NVP) is associated with compromised virologic treatment outcomes once non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy (ART) is initiated. We examined the longer-term clinical outcomes in a programmatic setting. METHODS: We compared post-12 month mortality and clinical treatment failure (defined by WHO clinical and immunologic criteria) among women with and without prior NVP exposure in Lusaka, Zambia. RESULTS: Between April 2004 and July 2006, 6740 women initiated an NNRTI-containing regimen. At 12 months, 5172 (78%) remained active and were included in this analysis. Of these, 596 (12%) reported prior NVP exposure, whose time from exposure to ART initiation was: <6 months for 11%, 6-12 months for 13%, >12 months for 37%, unknown for 39%. Overall, women with prior NVP exposure trended towards increased survival (adjusted hazard ratio [AHR]: 0.53; 95% confidence interval [CI]: 0.27-1.06, P = 0.07) and towards increased hazard of clinical treatment failure (AHR: 1.18; 95% CI: 0.95-1.47, P = 0.14), particularly those with exposure for <6 months (AHR: 1.52; 95% CI: 0.94-2.45, P = 0.09). CONCLUSIONS: Prior NVP exposure appeared to increase risk for clinical treatment failure after 12 months of follow-up, but this finding did not reach statistical significance. With growing evidence linking recent NVP exposure to virologic failure, optimized monitoring algorithms should be considered for women with starting NNRTI-based ART. The association between prior NVP exposure and improved survival has not been previously shown and may be a result of residual confounding around health-seeking behaviours.'
p85453
sS'GR'
p85454
(lp85455
S'D43 TW001035/TW/FIC NIH HHS/United States'
p85456
aS'D43 TW001035-11/TW/FIC NIH HHS/United States'
p85457
aS'D43-TW001035/TW/FIC NIH HHS/United States'
p85458
aS'K01 TW006670/TW/FIC NIH HHS/United States'
p85459
aS'K01 TW006670-01A1/TW/FIC NIH HHS/United States'
p85460
aS'K01-TW06670/TW/FIC NIH HHS/United States'
p85461
aS'P30 AI027767/AI/NIAID NIH HHS/United States'
p85462
aS'P30 AI027767-23/AI/NIAID NIH HHS/United States'
p85463
aS'P30-AI027767/AI/NIAID NIH HHS/United States'
p85464
aS'U62/CCU12354/PHS HHS/United States'
p85465
asS'IP'
p85466
S'7'
sS'IS'
p85467
S'1365-3156 (Electronic) 1360-2276 (Linking)'
p85468
sS'PMC'
p85469
S'PMC2921548'
p85470
sS'DCOM'
p85471
S'20100730'
p85472
sS'AU'
p85473
(lp85474
S'Chintu N'
p85475
aS'Giganti MJ'
p85476
aS'Putta NB'
p85477
aS'Sinkala M'
p85478
aS'Sadoki E'
p85479
aS'Stringer EM'
p85480
aS'Stringer JS'
p85481
aS'Chi BH'
p85482
asS'VI'
p85483
S'15'
p85484
sS'MHDA'
p85485
S'2010/07/31 06:00'
p85486
sS'PHST'
p85487
(lp85488
S'2010/05/07 [aheadofprint]'
p85489
asS'OID'
p85490
(lp85491
S'NLM: NIHMS225029'
p85492
aS'NLM: PMC2921548'
p85493
asS'MH'
p85494
(lp85495
S'Adult'
p85496
aS'Anti-HIV Agents/administration & dosage/*therapeutic use'
p85497
aS'Antiretroviral Therapy, Highly Active/methods'
p85498
aS'Drug Administration Schedule'
p85499
aS'Epidemiologic Methods'
p85500
aS'Female'
p85501
aS'HIV Infections/*drug therapy/transmission'
p85502
aS'Humans'
p85503
aS'Infectious Disease Transmission, Vertical/prevention & control'
p85504
aS'Nevirapine/administration & dosage/*therapeutic use'
p85505
aS'Pregnancy'
p85506
aS'Pregnancy Complications, Infectious/*drug therapy'
p85507
aS'Reverse Transcriptase Inhibitors/administration & dosage/therapeutic use'
p85508
aS'Treatment Failure'
p85509
aS'Treatment Outcome'
p85510
asS'EDAT'
p85511
S'2010/05/22 06:00'
p85512
sS'SO'
p85513
S'Trop Med Int Health. 2010 Jul;15(7):842-7. doi: 10.1111/j.1365-3156.2010.02540.x. Epub 2010 May 7.'
p85514
sS'SB'
p85515
S'IM'
p85516
sS'PMID'
p85517
S'20487418'
p85518
sS'PST'
p85519
S'ppublish'
p85520
stRp85521
ag2
(g3
g4
(dp85522
S'LID'
p85523
S'10.1086/653119 [doi]'
p85524
sS'STAT'
p85525
S'MEDLINE'
p85526
sS'JT'
p85527
S'Clinical infectious diseases : an official publication of the Infectious Diseases Society of America'
p85528
sS'MID'
p85529
(lp85530
S'NIHMS192949'
p85531
asS'DA'
p85532
S'20100603'
p85533
sS'AID'
p85534
(lp85535
S'10.1086/653119 [doi]'
p85536
asS'CRDT'
p85537
(lp85538
S'2010/05/21 06:00'
p85539
asS'DP'
p85540
S'2010 Jul 1'
p85541
sS'AD'
p85542
S'Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. rwalensky@partners.org'
p85543
sS'OWN'
p85544
S'NLM'
p85545
sS'PT'
p85546
(lp85547
S'Journal Article'
p85548
aS'Research Support, N.I.H., Extramural'
p85549
aS"Research Support, Non-U.S. Gov't"
p85550
aS'Review'
p85551
asS'LA'
p85552
(lp85553
S'eng'
p85554
asS'FAU'
p85555
(lp85556
S'Walensky, Rochelle P'
p85557
aS'Ciaranello, Andrea L'
p85558
aS'Park, Ji-Eun'
p85559
aS'Freedberg, Kenneth A'
p85560
asS'RF'
p85561
S'30'
p85562
sS'LR'
p85563
S'20141203'
p85564
sS'PG'
p85565
S'85-92'
p85566
sS'TI'
p85567
S'Cost-effectiveness of laboratory monitoring in sub-Saharan Africa: a review of the current literature.'
p85568
sS'RN'
p85569
(lp85570
S'0 (RNA, Viral)'
p85571
asS'PL'
p85572
S'United States'
p85573
sS'TA'
p85574
S'Clin Infect Dis'
p85575
sS'JID'
p85576
S'9203213'
p85577
sS'AB'
p85578
S'As the global community evaluates the unprecedented investment in the scale-up of human immunodeficiency virus (HIV) therapy and considers future investments in HIV care, it is crucial to identify those HIV interventions that maximize the benefit realized from each dollar spent. The use of laboratory monitoring assays--CD4 cell count and HIV RNA level--in decisions about when to initiate and switch antiretroviral therapy may offer substantial clinical benefit, but their economic value remains controversial. Cost-effectiveness analysis can be used to evaluate the value for money of strategies for HIV care, including alternative approaches to laboratory monitoring. Five published cost-effectiveness analyses address the question of CD4 cell count and HIV RNA level monitoring for HIV-infected patients in Africa, with differing conclusions. We describe the use of cost-effectiveness analysis in resource-limited settings and review the cost-effectiveness literature with regard to monitoring the CD4 cell count and HIV RNA level in Africa, highlighting some of the most critical issues in this debate.'
p85579
sS'GR'
p85580
(lp85581
S'K01 AI078754/AI/NIAID NIH HHS/United States'
p85582
aS'K01 AI078754/AI/NIAID NIH HHS/United States'
p85583
aS'K01 AI078754-01A1/AI/NIAID NIH HHS/United States'
p85584
aS'K24 AI062476/AI/NIAID NIH HHS/United States'
p85585
aS'K24 AI062476/AI/NIAID NIH HHS/United States'
p85586
aS'K24 AI062476-05/AI/NIAID NIH HHS/United States'
p85587
aS'P30 AI060354/AI/NIAID NIH HHS/United States'
p85588
aS'P30 AI060354/AI/NIAID NIH HHS/United States'
p85589
aS'P30 AI060354-04/AI/NIAID NIH HHS/United States'
p85590
aS'P30 AI060354-06/AI/NIAID NIH HHS/United States'
p85591
aS'R01 AI058736/AI/NIAID NIH HHS/United States'
p85592
aS'R01 AI058736/AI/NIAID NIH HHS/United States'
p85593
aS'R01 AI058736-06S1/AI/NIAID NIH HHS/United States'
p85594
asS'IP'
p85595
S'1'
sS'IS'
p85596
S'1537-6591 (Electronic) 1058-4838 (Linking)'
p85597
sS'PMC'
p85598
S'PMC2880656'
p85599
sS'DCOM'
p85600
S'20100810'
p85601
sS'AU'
p85602
(lp85603
S'Walensky RP'
p85604
aS'Ciaranello AL'
p85605
aS'Park JE'
p85606
aS'Freedberg KA'
p85607
asS'VI'
p85608
S'51'
p85609
sS'MHDA'
p85610
S'2010/08/11 06:00'
p85611
sS'OID'
p85612
(lp85613
S'NLM: NIHMS192949'
p85614
aS'NLM: PMC2880656'
p85615
asS'MH'
p85616
(lp85617
S'Africa South of the Sahara'
p85618
aS'CD4 Lymphocyte Count/economics'
p85619
aS'Clinical Laboratory Techniques/*economics'
p85620
aS'Cost-Benefit Analysis'
p85621
aS'Developing Countries/economics'
p85622
aS'Drug Monitoring/*economics'
p85623
aS'HIV Infections/*economics/therapy/virology'
p85624
aS'Humans'
p85625
aS'RNA, Viral/blood'
p85626
asS'EDAT'
p85627
S'2010/05/21 06:00'
p85628
sS'SO'
p85629
S'Clin Infect Dis. 2010 Jul 1;51(1):85-92. doi: 10.1086/653119.'
p85630
sS'SB'
p85631
S'IM'
p85632
sS'PMID'
p85633
S'20482371'
p85634
sS'PST'
p85635
S'ppublish'
p85636
stRp85637
ag2
(g3
g4
(dp85638
S'LID'
p85639
S'10.1371/journal.pone.0010527 [doi]'
p85640
sS'STAT'
p85641
S'MEDLINE'
p85642
sS'DEP'
p85643
S'20100507'
p85644
sS'DA'
p85645
S'20100518'
p85646
sS'AID'
p85647
(lp85648
S'10.1371/journal.pone.0010527 [doi]'
p85649
asS'CRDT'
p85650
(lp85651
S'2010/05/19 06:00'
p85652
asS'DP'
p85653
S'2010'
p85654
sS'OWN'
p85655
S'NLM'
p85656
sS'PT'
p85657
(lp85658
S'Journal Article'
p85659
aS"Research Support, Non-U.S. Gov't"
p85660
asS'LA'
p85661
(lp85662
S'eng'
p85663
asS'FAU'
p85664
(lp85665
S'Hermans, Sabine M'
p85666
aS'Kiragga, Agnes N'
p85667
aS'Schaefer, Petra'
p85668
aS'Kambugu, Andrew'
p85669
aS'Hoepelman, Andy I M'
p85670
aS'Manabe, Yukari C'
p85671
asS'JT'
p85672
S'PloS one'
p85673
sS'LR'
p85674
S'20141203'
p85675
sS'PG'
p85676
S'e10527'
p85677
sS'TI'
p85678
S'Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan Africa.'
p85679
sS'PL'
p85680
S'United States'
p85681
sS'TA'
p85682
S'PLoS One'
p85683
sS'JID'
p85684
S'101285081'
p85685
sS'AB'
p85686
S'BACKGROUND: Antiretroviral therapy (ART) effectively decreases tuberculosis (TB) incidence long-term, but is associated with high TB incidence rates in the first 6 months. We sought to determine the incidence and the long-term effects of TB during ART on HIV treatment outcome, and the risk factors for incident TB during ART in a large urban HIV clinic in Uganda. METHODOLOGY/PRINCIPAL FINDINGS: Routinely collected longitudinal clinical data from all patients initiated on first-line ART was retrospectively analysed. 5,982 patients were included with a median baseline CD4+ T cell count (CD4 count) of 117 cells/mm(3) (interquartile range [IQR]; 42, 182). In the first 2 years, there were 336 (5.6%) incident TB events in 10,710 person-years (py) of follow-up (3.14 cases/100 pyar [95% CI 2.82-3.49]); incidence rates at 0-3, 3-6, 6-12 and 12-24 months were 11.25 (9.58-13.21), 6.27 (4.99-7.87), 2.47 (1.87-3.36) and 1.02 (0.80-1.31), respectively. Incident TB during ART was independently associated with baseline CD4 count of <50 cells/mm(3) (hazard ratio [HR] 1.84 [1.25-2.70], P = 0.002) and male gender (HR 1.68 [1.34-2.11], P<0.001). After two years on ART, the patients who had developed TB in the first 12 months had a significantly lower median CD4 count increase (184 cells/mm(3) [IQR; 107, 258, n = 118] vs 209 cells/mm(3) [124, 309, n = 2166], P = 0.01), a larger proportion of suboptimal immune reconstitution according to two definitions (increase in CD4 count <200 cells/mm(3): 57.4% vs 46.9%, P = 0.03, and absolute CD4 count <200 cells/mm(3): 30.4 vs 19.9%, P = 0.006), and a higher percentage of immunological failure according to the WHO criteria (13.6% vs 6.5%, P = 0.003). Incident TB during ART was independently associated with poor CD4 count recovery and fulfilling WHO immunological failure definitions. CONCLUSIONS/SIGNIFICANCE: Incident TB during ART occurs most often within 3 months and in patients with CD4 counts less than 50 cells/mm(3). Incident TB during ART is associated with long-term impairment in immune recovery.'
p85687
sS'AD'
p85688
S'Department of Internal Medicine and Infectious Diseases, University Medical Center Utrecht, Utrecht, The Netherlands. shermans@idi.co.ug'
p85689
sS'IP'
p85690
S'5'
sS'IS'
p85691
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p85692
sS'PMC'
p85693
S'PMC2866328'
p85694
sS'DCOM'
p85695
S'20100907'
p85696
sS'AU'
p85697
(lp85698
S'Hermans SM'
p85699
aS'Kiragga AN'
p85700
aS'Schaefer P'
p85701
aS'Kambugu A'
p85702
aS'Hoepelman AI'
p85703
aS'Manabe YC'
p85704
asS'VI'
p85705
S'5'
sS'MHDA'
p85706
S'2010/09/08 06:00'
p85707
sS'PHST'
p85708
(lp85709
S'2009/12/21 [received]'
p85710
aS'2010/04/02 [accepted]'
p85711
aS'2010/05/07 [epublish]'
p85712
asS'OID'
p85713
(lp85714
S'NLM: PMC2866328'
p85715
asS'MH'
p85716
(lp85717
S'Adult'
p85718
aS'*Ambulatory Care Facilities'
p85719
aS'Antiretroviral Therapy, Highly Active/*adverse effects'
p85720
aS'CD4 Lymphocyte Count'
p85721
aS'Female'
p85722
aS'Follow-Up Studies'
p85723
aS'HIV/*immunology'
p85724
aS'HIV Infections/*drug therapy/epidemiology/*immunology/mortality'
p85725
aS'Humans'
p85726
aS'Incidence'
p85727
aS'Logistic Models'
p85728
aS'Male'
p85729
aS'Multivariate Analysis'
p85730
aS'Risk Factors'
p85731
aS'Tuberculosis/complications/*epidemiology/*etiology'
p85732
aS'Uganda/epidemiology'
p85733
aS'Urban Population/statistics & numerical data'
p85734
asS'EDAT'
p85735
S'2010/05/19 06:00'
p85736
sS'SO'
p85737
S'PLoS One. 2010 May 7;5(5):e10527. doi: 10.1371/journal.pone.0010527.'
p85738
sS'SB'
p85739
S'IM'
p85740
sS'PMID'
p85741
S'20479873'
p85742
sS'PST'
p85743
S'epublish'
p85744
stRp85745
ag2
(g3
g4
(dp85746
S'LID'
p85747
S'10.1016/j.jinf.2010.04.009 [doi]'
p85748
sS'STAT'
p85749
S'MEDLINE'
p85750
sS'DEP'
p85751
S'20100512'
p85752
sS'DA'
p85753
S'20100726'
p85754
sS'AID'
p85755
(lp85756
S'S0163-4453(10)00129-5 [pii]'
p85757
aS'10.1016/j.jinf.2010.04.009 [doi]'
p85758
asS'CRDT'
p85759
(lp85760
S'2010/05/18 06:00'
p85761
asS'DP'
p85762
S'2010 Jul'
p85763
sS'OWN'
p85764
S'NLM'
p85765
sS'PT'
p85766
(lp85767
S'Journal Article'
p85768
aS"Research Support, Non-U.S. Gov't"
p85769
asS'LA'
p85770
(lp85771
S'eng'
p85772
asS'FAU'
p85773
(lp85774
S'Moore, E'
p85775
aS'Beadsworth, M B J'
p85776
aS'Chaponda, M'
p85777
aS'Mhango, B'
p85778
aS'Faragher, B'
p85779
aS'Njala, J'
p85780
aS'Hofland, H W C'
p85781
aS'Davies, J'
p85782
aS'Hart, I J'
p85783
aS'Beeching, N J'
p85784
aS'Zijlstra, E E'
p85785
aS'van Oosterhout, J J'
p85786
asS'JT'
p85787
S'The Journal of infection'
p85788
sS'PG'
p85789
S'155-63'
p85790
sS'TI'
p85791
S'Favourable one-year ART outcomes in adult Malawians with hepatitis B and C co-infection.'
p85792
sS'RN'
p85793
(lp85794
S'0 (Anti-HIV Agents)'
p85795
asS'PL'
p85796
S'England'
p85797
sS'TA'
p85798
S'J Infect'
p85799
sS'JID'
p85800
S'7908424'
p85801
sS'AB'
p85802
S'BACKGROUND: Few studies have investigated the impact of chronic hepatitis B and C infection on antiretroviral therapy (ART) outcomes in sub-Saharan Africa. Hepatotoxicity may be a particular concern in co-infected patients taking nevirapine-stavudine-lamivudine. METHODS: We conducted a prospective cohort study of 300 Malawian adults starting ART and describe one-year ART outcomes according to viral hepatitis status. RESULTS: At baseline, patients had advanced HIV disease (29.3% were in WHO stage 4; mean CD4 = 157 cells/microL; mean log(10)HIV-1 RNA = 5.24 copies/ml). Co-infection with hepatitis B, C and B + C were present in 6.7%, 5.7% and 1.7% respectively. At 50 weeks, all-cause mortality was 43 (14.3%). Sixteen (5.3%) had transferred to another unit. Eight (2.7%) were lost to follow up. Sixteen (5.3%) had stopped ART. 217 (72.3%) were alive on ART, of whom 82.5% had an HIV-1 RNA <400 copies/ml at week 50. During the first 50 weeks of ART, severe hepatotoxicity (liver enzyme values >5 times upper level of normal) occurred in 9%, but did not result in any ART discontinuations. Clinical hepatitis or jaundice was not observed. There were no significant differences in occurrence of hepatotoxicity, other side effects, mortality, severe morbidity, immune reconstitution or virological failure between hepatitis B and/or C co-infected patients and those who were not. Viral hepatitis co-infection was not associated with severe hepatotoxicity, mortality, severe morbidity or virological failure in multivariate analyses. CONCLUSION: Our data suggest that screening for viral hepatitis B and C and liver enzyme monitoring may not require high priority in ART programmes in sub-Saharan Africa.'
p85803
sS'AD'
p85804
S'Department of Medicine, College of Medicine, University of Malawi, Blantyre, Malawi.'
p85805
sS'IP'
p85806
S'2'
sS'IS'
p85807
S'1532-2742 (Electronic) 0163-4453 (Linking)'
p85808
sS'DCOM'
p85809
S'20101101'
p85810
sS'AU'
p85811
(lp85812
S'Moore E'
p85813
aS'Beadsworth MB'
p85814
aS'Chaponda M'
p85815
aS'Mhango B'
p85816
aS'Faragher B'
p85817
aS'Njala J'
p85818
aS'Hofland HW'
p85819
aS'Davies J'
p85820
aS'Hart IJ'
p85821
aS'Beeching NJ'
p85822
aS'Zijlstra EE'
p85823
aS'van Oosterhout JJ'
p85824
asS'VI'
p85825
S'61'
p85826
sS'MHDA'
p85827
S'2010/11/03 06:00'
p85828
sS'PHST'
p85829
(lp85830
S'2010/01/25 [received]'
p85831
aS'2010/03/29 [revised]'
p85832
aS'2010/04/22 [accepted]'
p85833
aS'2010/05/12 [aheadofprint]'
p85834
asS'MH'
p85835
(lp85836
S'Adult'
p85837
aS'Anti-HIV Agents/*administration & dosage/adverse effects'
p85838
aS'Antiretroviral Therapy, Highly Active/adverse effects/*methods'
p85839
aS'Cohort Studies'
p85840
aS'Female'
p85841
aS'HIV Infections/*complications/*drug therapy'
p85842
aS'HIV-1'
p85843
aS'Hepatitis B, Chronic/*complications'
p85844
aS'Hepatitis C, Chronic/*complications'
p85845
aS'Humans'
p85846
aS'Malawi'
p85847
aS'Male'
p85848
aS'Pregnancy'
p85849
aS'Prospective Studies'
p85850
aS'Treatment Outcome'
p85851
asS'EDAT'
p85852
S'2010/05/18 06:00'
p85853
sS'SO'
p85854
S'J Infect. 2010 Jul;61(2):155-63. doi: 10.1016/j.jinf.2010.04.009. Epub 2010 May 12.'
p85855
sS'SB'
p85856
S'IM'
p85857
sS'PMID'
p85858
S'20470823'
p85859
sS'PST'
p85860
S'ppublish'
p85861
stRp85862
ag2
(g3
g4
(dp85863
S'LID'
p85864
S'10.1186/1471-2458-10-249 [doi]'
p85865
sS'STAT'
p85866
S'MEDLINE'
p85867
sS'DEP'
p85868
S'20100514'
p85869
sS'DA'
p85870
S'20100526'
p85871
sS'AID'
p85872
(lp85873
S'1471-2458-10-249 [pii]'
p85874
aS'10.1186/1471-2458-10-249 [doi]'
p85875
asS'CRDT'
p85876
(lp85877
S'2010/05/18 06:00'
p85878
asS'DP'
p85879
S'2010'
p85880
sS'OWN'
p85881
S'NLM'
p85882
sS'PT'
p85883
(lp85884
S'Comparative Study'
p85885
aS'Journal Article'
p85886
aS"Research Support, U.S. Gov't, Non-P.H.S."
p85887
asS'LA'
p85888
(lp85889
S'eng'
p85890
asS'DCOM'
p85891
S'20120601'
p85892
sS'JT'
p85893
S'BMC public health'
p85894
sS'LR'
p85895
S'20151119'
p85896
sS'FAU'
p85897
(lp85898
S'Torpey, Kwasi'
p85899
aS'Mwenda, Lona'
p85900
aS'Kabaso, Mushota'
p85901
aS'Malebe, Thierry'
p85902
aS'Makelele, Patrick'
p85903
aS'Mwema, Francis'
p85904
aS'Phiri, Henry'
p85905
aS'Mukundu, Jonathan'
p85906
aS'Weaver, Mark A'
p85907
aS'Stanback, John'
p85908
asS'TI'
p85909
S'Excluding pregnancy among women initiating antiretroviral therapy: efficacy of a family planning job aid.'
p85910
sS'RN'
p85911
(lp85912
S'0 (Anti-Retroviral Agents)'
p85913
aS'0 (Reagent Strips)'
p85914
asS'PL'
p85915
S'England'
p85916
sS'PG'
p85917
S'249'
p85918
sS'JID'
p85919
S'100968562'
p85920
sS'AB'
p85921
S"BACKGROUND: Guidelines for initiating ART recommend pregnancy testing, typically a urine test, as part of the basic laboratory package. The principal reason for this recommendation is that Efavirenz, a first-line antiretroviral medication, has the potential of causing birth defects when used in the first trimester of pregnancy and is therefore contraindicated for use by pregnant women. Unfortunately, in many African countries pregnancy tests are not routinely provided or available in ART clinics, and, when available outside clinics, are often not affordable for clients.Recently, the World Health Organization added a family planning job aid called the 'pregnancy checklist,' developed by researchers at Family Health International, as a recommended tool for screening new ART clients to exclude pregnancy. Although the checklist has been validated for excluding pregnancy among family planning clients, there are no data on its efficacy among ART clients.This study was conducted to assess the clinical performance of a job aid to exclude pregnancy among HIV positive women initiating ART. METHODS: Non-menstruating women eligible for ART were enrolled from 20 sites in four provinces in Zambia. The pregnancy checklist was administered followed by a urine pregnancy test as a reference standard. Sensitivity, specificity, and positive and negative predictive values were estimated. RESULTS: Of the 200 women for whom the checklist ruled out pregnancy, 198 were not pregnant, for an estimated negative predictive value of 99%. The sensitivity of the checklist was 90.0%, and specificity was 38.7%. Among the women, 416 out of 534 (77.9%) did not abstain from sex since their last menses. Only 72 out of the 534 women (13.4%) reported using reliable contraception. Among the 416 women who did not abstain, 376 (90.4%) did not use reliable contraception. CONCLUSION: The pregnancy checklist is effective for excluding pregnancy in many women initiating ART, but its moderate sensitivity and specificity precludes its use to completely replace pregnancy testing. Its use should be encouraged in low resource settings where pregnancy tests are unavailable or must be rationed. Family planning methods should be available and integrated into ART clinics."
p85922
sS'AD'
p85923
S'Family Health International/Zambia Plot 2055 Nasser Road, Lusaka, Zambia. ktorpey@fhi.org'
p85924
sS'VI'
p85925
S'10'
p85926
sS'IS'
p85927
S'1471-2458 (Electronic) 1471-2458 (Linking)'
p85928
sS'PMC'
p85929
S'PMC2876108'
p85930
sS'AU'
p85931
(lp85932
S'Torpey K'
p85933
aS'Mwenda L'
p85934
aS'Kabaso M'
p85935
aS'Malebe T'
p85936
aS'Makelele P'
p85937
aS'Mwema F'
p85938
aS'Phiri H'
p85939
aS'Mukundu J'
p85940
aS'Weaver MA'
p85941
aS'Stanback J'
p85942
asS'MHDA'
p85943
S'2012/06/02 06:00'
p85944
sS'PHST'
p85945
(lp85946
S'2009/11/23 [received]'
p85947
aS'2010/05/14 [accepted]'
p85948
aS'2010/05/14 [aheadofprint]'
p85949
asS'OID'
p85950
(lp85951
S'NLM: PMC2876108'
p85952
asS'MH'
p85953
(lp85954
S'Adult'
p85955
aS'Anti-Retroviral Agents/*therapeutic use'
p85956
aS'Family Planning Services/*standards'
p85957
aS'Female'
p85958
aS'Humans'
p85959
aS'Menstruation'
p85960
aS'Pregnancy'
p85961
aS'Pregnancy Tests/*methods'
p85962
aS'Reagent Strips'
p85963
aS'*Surveys and Questionnaires'
p85964
aS'World Health Organization'
p85965
aS'Zambia'
p85966
asS'EDAT'
p85967
S'2010/05/18 06:00'
p85968
sS'SO'
p85969
S'BMC Public Health. 2010 May 14;10:249. doi: 10.1186/1471-2458-10-249.'
p85970
sS'SB'
p85971
S'IM'
p85972
sS'PMID'
p85973
S'20470367'
p85974
sS'TA'
p85975
S'BMC Public Health'
p85976
sS'PST'
p85977
S'epublish'
p85978
stRp85979
ag2
(g3
g4
(dp85980
S'LID'
p85981
S'10.1111/j.1365-4632.2009.04279.x [doi]'
p85982
sS'STAT'
p85983
S'MEDLINE'
p85984
sS'JT'
p85985
S'International journal of dermatology'
p85986
sS'DA'
p85987
S'20100514'
p85988
sS'AID'
p85989
(lp85990
S'IJD4279 [pii]'
p85991
aS'10.1111/j.1365-4632.2009.04279.x [doi]'
p85992
asS'CRDT'
p85993
(lp85994
S'2010/05/15 06:00'
p85995
asS'DP'
p85996
S'2010 Jan'
p85997
sS'OWN'
p85998
S'NLM'
p85999
sS'PT'
p86000
(lp86001
S'Journal Article'
p86002
asS'LA'
p86003
(lp86004
S'eng'
p86005
asS'FAU'
p86006
(lp86007
S'Navarini, Alexander A'
p86008
aS'Stoeckle, Marcel'
p86009
aS'Navarini, Susanne'
p86010
aS'Mossdorf, Erik'
p86011
aS'Jullu, Boniphace S'
p86012
aS'Mchomvu, Rehema'
p86013
aS'Mbata, Marco'
p86014
aS'Kibatala, Patience'
p86015
aS'Tanner, Marcel'
p86016
aS'Hatz, Christoph'
p86017
aS'Schmid-Grendelmeier, Peter'
p86018
asS'LR'
p86019
S'20151119'
p86020
sS'PG'
p86021
S'83-6'
p86022
sS'TI'
p86023
S'Antihistamines are superior to topical steroids in managing human immunodeficiency virus (HIV)-associated papular pruritic eruption.'
p86024
sS'RN'
p86025
(lp86026
S'0 (Histamine Antagonists)'
p86027
aS'0 (Histamine H1 Antagonists)'
p86028
aS'0 (Steroids)'
p86029
aS'FF28EJQ494 (Promethazine)'
p86030
asS'PL'
p86031
S'United States'
p86032
sS'TA'
p86033
S'Int J Dermatol'
p86034
sS'JID'
p86035
S'0243704'
p86036
sS'AB'
p86037
S'Papular pruritic eruption (PPE) is a frequent HIV-comorbidity in tropical countries. Because of constant itching and social stigma, effective treatment is highly valued. In our HIV cohort in rural Tanzania with 12% prevalence of PPE, we have retrospectively analyzed responses to available treatments. Oral promethazine improved itching (P < 0.0058) and clinical scores (P < 0.032) significantly more than topical steroids. Disease activity did not correlate with CD4+ and CD8+ T cell counts and was independent of anti-retroviral medication. Therefore, oral antihistamines are an effective first-line treatment for PPE.'
p86038
sS'AD'
p86039
S'Ifakara Health Institute, Ifakara, Kilombero, Tanzania. alexander.navarini@usz.ch'
p86040
sS'IP'
p86041
S'1'
sS'IS'
p86042
S'1365-4632 (Electronic) 0011-9059 (Linking)'
p86043
sS'DCOM'
p86044
S'20100820'
p86045
sS'AU'
p86046
(lp86047
S'Navarini AA'
p86048
aS'Stoeckle M'
p86049
aS'Navarini S'
p86050
aS'Mossdorf E'
p86051
aS'Jullu BS'
p86052
aS'Mchomvu R'
p86053
aS'Mbata M'
p86054
aS'Kibatala P'
p86055
aS'Tanner M'
p86056
aS'Hatz C'
p86057
aS'Schmid-Grendelmeier P'
p86058
asS'VI'
p86059
S'49'
p86060
sS'MHDA'
p86061
S'2010/08/21 06:00'
p86062
sS'MH'
p86063
(lp86064
S'Administration, Oral'
p86065
aS'Administration, Topical'
p86066
aS'Antiretroviral Therapy, Highly Active'
p86067
aS'CD4-CD8 Ratio'
p86068
aS'Exanthema/*drug therapy/pathology/virology'
p86069
aS'HIV Infections/*complications/drug therapy/immunology'
p86070
aS'Histamine Antagonists/*administration & dosage'
p86071
aS'Histamine H1 Antagonists/administration & dosage'
p86072
aS'Humans'
p86073
aS'Promethazine/administration & dosage'
p86074
aS'Pruritus/*drug therapy/pathology/virology'
p86075
aS'Retrospective Studies'
p86076
aS'Steroids/*administration & dosage'
p86077
aS'Surveys and Questionnaires'
p86078
aS'Tanzania'
p86079
aS'Treatment Outcome'
p86080
asS'EDAT'
p86081
S'2010/05/15 06:00'
p86082
sS'SO'
p86083
S'Int J Dermatol. 2010 Jan;49(1):83-6. doi: 10.1111/j.1365-4632.2009.04279.x.'
p86084
sS'SB'
p86085
S'IM'
p86086
sS'PMID'
p86087
S'20465620'
p86088
sS'PST'
p86089
S'ppublish'
p86090
stRp86091
ag2
(g3
g4
(dp86092
S'LID'
p86093
S'10.1089/aid.2009.0123 [doi]'
p86094
sS'STAT'
p86095
S'MEDLINE'
p86096
sS'JT'
p86097
S'AIDS research and human retroviruses'
p86098
sS'DA'
p86099
S'20100518'
p86100
sS'AID'
p86101
(lp86102
S'10.1089/aid.2009.0123 [doi]'
p86103
asS'CRDT'
p86104
(lp86105
S'2010/05/12 06:00'
p86106
asS'DP'
p86107
S'2010 May'
p86108
sS'OWN'
p86109
S'NLM'
p86110
sS'PT'
p86111
(lp86112
S'Clinical Trial'
p86113
aS'Journal Article'
p86114
asS'LA'
p86115
(lp86116
S'eng'
p86117
asS'FAU'
p86118
(lp86119
S'Landman, Roland'
p86120
aS'Diallo, M B'
p86121
aS'Gueye, N F Ngom'
p86122
aS'Kane, C Toure'
p86123
aS'Mboup, S'
p86124
aS'Fall, M B Koita'
p86125
aS'Ndiaye, B'
p86126
aS'Peytavin, G'
p86127
aS'Bennai, Y'
p86128
aS'Benalycherif, A'
p86129
aS'Girard, P M'
p86130
aS'Sow, P S'
p86131
asS'LR'
p86132
S'20151119'
p86133
sS'PG'
p86134
S'519-25'
p86135
sS'TI'
p86136
S'Efficacy and safety of unboosted atazanavir in combination with lamivudine and didanosine in naive HIV type 1 patients in Senegal.'
p86137
sS'RN'
p86138
(lp86139
S'0 (Anti-HIV Agents)'
p86140
aS'0 (Oligopeptides)'
p86141
aS'0 (Pyridines)'
p86142
aS'0 (RNA, Viral)'
p86143
aS'0 (Reverse Transcriptase Inhibitors)'
p86144
aS'2T8Q726O95 (Lamivudine)'
p86145
aS'4MT4VIE29P (Atazanavir Sulfate)'
p86146
aS'K3GDH6OH08 (Didanosine)'
p86147
asS'PL'
p86148
S'United States'
p86149
sS'TA'
p86150
S'AIDS Res Hum Retroviruses'
p86151
sS'JID'
p86152
S'8709376'
p86153
sS'AB'
p86154
S'The use of ritonavir as a protease inhibitor boost is rare in sub-Saharan Africa because a heat-stable formula is not available. We report the results of an open-label pilot trial with unboosted atazanavir in combination with lamivudine and didanosine as first-line therapy conducted in Senegal. Treatment-naive HIV-1 infected adult patients without active opportunistic disease were included. The primary endpoint was the proportion of patients with plasma HIV-1 RNA <400 copies/ml at week 48. Forty patients (12 men and 28 women; mean age +/- SD: 40 +/- 9 years) were included. Treatment was changed during the study for two patients (pregnancy, tuberculosis); one patient was lost to follow-up and one patient died (gastroenteritis with cachexia). At week 48, 78% [95% confidence interval (CI): 65-90%] and 68% (95% CI: 53-82%) of the patients had HIV-1 RNA <400 and <50 copies/ml, respectively (intent-to-treat analysis; not completer = failure). Among the seven patients with HIV-1 RNA >or=400 copies/ml at week 48, five were not compliant; genotyping analysis (n = 4) did not reveal a major mutation for protease inhibitors. The mean CD4 cell count change from baseline to week 48 was +238 +/- 79 cells/mm(3). The combination of unboosted atazanavir with lamivudine and didanosine was efficient and well tolerated in HIV-1-infected patients with results similar to those observed in Northern countries. These results suggest that unboosted atazanavir with its high genetic barrier could be a valuable alternative to NNRTIs in resource-limited countries in some HIV-1-infected patients in case of compliance issues with NNRTIs, intolerance to NNRTIs, resistance mutations to NNRTIs, in women with childbearing potential, or as a maintenance therapy in patients with virological suppression.'
p86155
sS'AD'
p86156
S"Institut de Medecine et d'Epidemiologie Appliquee, Service des Maladies Infectieuses et Tropicales, Bichat Claude-Bernard Hospital, Paris Cedex 18, France. roland.landman@univ-paris-diderot.fr"
p86157
sS'IP'
p86158
S'5'
sS'IS'
p86159
S'1931-8405 (Electronic) 0889-2229 (Linking)'
p86160
sS'DCOM'
p86161
S'20100824'
p86162
sS'AU'
p86163
(lp86164
S'Landman R'
p86165
aS'Diallo MB'
p86166
aS'Gueye NF'
p86167
aS'Kane CT'
p86168
aS'Mboup S'
p86169
aS'Fall MB'
p86170
aS'Ndiaye B'
p86171
aS'Peytavin G'
p86172
aS'Bennai Y'
p86173
aS'Benalycherif A'
p86174
aS'Girard PM'
p86175
aS'Sow PS'
p86176
asS'VI'
p86177
S'26'
p86178
sS'MHDA'
p86179
S'2010/08/25 06:00'
p86180
sS'MH'
p86181
(lp86182
S'Adult'
p86183
aS'*Anti-HIV Agents/administration & dosage/adverse effects/therapeutic use'
p86184
aS'Atazanavir Sulfate'
p86185
aS'*Didanosine/administration & dosage/adverse effects/therapeutic use'
p86186
aS'Drug Administration Schedule'
p86187
aS'Drug Therapy, Combination'
p86188
aS'Female'
p86189
aS'HIV Infections/*drug therapy/immunology/virology'
p86190
aS'HIV-1/drug effects/physiology'
p86191
aS'Humans'
p86192
aS'*Lamivudine/administration & dosage/adverse effects/therapeutic use'
p86193
aS'Male'
p86194
aS'Middle Aged'
p86195
aS'*Oligopeptides/administration & dosage/adverse effects/therapeutic use'
p86196
aS'Pilot Projects'
p86197
aS'*Pyridines/administration & dosage/adverse effects/therapeutic use'
p86198
aS'RNA, Viral/blood'
p86199
aS'Reverse Transcriptase Inhibitors/administration & dosage/adverse effects/therapeutic use'
p86200
aS'Senegal'
p86201
aS'Treatment Outcome'
p86202
asS'EDAT'
p86203
S'2010/05/12 06:00'
p86204
sS'SO'
p86205
S'AIDS Res Hum Retroviruses. 2010 May;26(5):519-25. doi: 10.1089/aid.2009.0123.'
p86206
sS'SB'
p86207
S'IM X'
p86208
sS'PMID'
p86209
S'20455760'
p86210
sS'PST'
p86211
S'ppublish'
p86212
stRp86213
ag2
(g3
g4
(dp86214
S'LID'
p86215
S'10.1097/QAD.0b013e32833a097b [doi]'
p86216
sS'STAT'
p86217
S'MEDLINE'
p86218
sS'JT'
p86219
S'AIDS (London, England)'
p86220
sS'MID'
p86221
(lp86222
S'NIHMS198948'
p86223
asS'DA'
p86224
S'20100630'
p86225
sS'AID'
p86226
(lp86227
S'10.1097/QAD.0b013e32833a097b [doi]'
p86228
asS'CRDT'
p86229
(lp86230
S'2010/05/11 06:00'
p86231
asS'DP'
p86232
S'2010 Jul 17'
p86233
sS'AD'
p86234
S'Division of Global Health (IHCAR), Karolinska Institutet, Stockholm, Sweden. ziad.el-khatib@ki.se'
p86235
sS'OWN'
p86236
S'NLM'
p86237
sS'PT'
p86238
(lp86239
S'Journal Article'
p86240
aS'Multicenter Study'
p86241
aS'Research Support, N.I.H., Extramural'
p86242
aS"Research Support, Non-U.S. Gov't"
p86243
asS'LA'
p86244
(lp86245
S'eng'
p86246
asS'FAU'
p86247
(lp86248
S'El-Khatib, Ziad'
p86249
aS'Ekstrom, Anna Mia'
p86250
aS'Ledwaba, Johanna'
p86251
aS'Mohapi, Lerato'
p86252
aS'Laher, Fatima'
p86253
aS'Karstaedt, Alan'
p86254
aS'Charalambous, Salome'
p86255
aS'Petzold, Max'
p86256
aS'Katzenstein, David'
p86257
aS'Morris, Lynn'
p86258
asS'LR'
p86259
S'20141203'
p86260
sS'PG'
p86261
S'1679-87'
p86262
sS'TI'
p86263
S'Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa.'
p86264
sS'RN'
p86265
(lp86266
S'0 (Anti-HIV Agents)'
p86267
asS'PL'
p86268
S'England'
p86269
sS'TA'
p86270
S'AIDS'
p86271
sS'JID'
p86272
S'8710219'
p86273
sS'AB'
p86274
S'BACKGROUND: We assessed risk factors for viremia and drug resistance among long-term recipients of antiretroviral therapy (ART) in South Africa. METHODS: In 2008, we conducted a cross-sectional study among patients receiving ART for 12 months or more. Genotypic resistance testing was performed on individuals with a viral load higher than 400 RNA copies/ml. Multiple logistic regression analysis was used to assess associations. RESULTS: Of 998 participants, 75% were women with a median age of 41 years. Most (64%) had been on treatment for more than 3 years. The prevalence of viremia was 14% (n = 139): 12% (102/883) on first-line [i.e. nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based regimen] and 33% (37/115) on second-line (i.e. protease inhibitor (PI)-based regimen) ART. Of viremic patients, 78% had drug resistance mutations. For NRTIs, NNRTIs and PIs, the prevalence of mutations was 64, 81 and 2%, respectively, among first-line failures and 29, 54 and 6%, respectively, among second-line failures. M184V/I, K103N and V106A/M were the most common mutations. Significant risk factors associated with viremia on first-line regimen included concurrent tuberculosis treatment [odds ratio (OR) 6.4, 95% confidence interval (CI) 2.2-18.8, P < 0.01] and a recent history of poor adherence (OR 2.7, 1.3-5.6, P = 0.01). Among second-line failures, attending a public clinic (OR 4.6, 95% CI 1.8-11.3, P < 0.01) and not having a refrigerator at home (OR 6.7, 95% CI 1.2-37.5, P = 0.03) were risk factors for virological failure. CONCLUSION: Risk factors for viral failure were line regimen dependent. Second-line ART recipients had a higher rate of viremia, albeit with infrequent PI drug resistance mutations. Measures to maintain effective virologic suppression should include increased adherence counseling, attention to concomitant tuberculosis treatment and heat-stable formulations of second-line ART regimens.'
p86275
sS'GR'
p86276
(lp86277
S'2 U2R TW006878/TW/FIC NIH HHS/United States'
p86278
aS'U2R TW006878/TW/FIC NIH HHS/United States'
p86279
aS'U2R TW006878-01A1/TW/FIC NIH HHS/United States'
p86280
asS'IP'
p86281
S'11'
p86282
sS'IS'
p86283
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p86284
sS'PMC'
p86285
S'PMC2894994'
p86286
sS'DCOM'
p86287
S'20100819'
p86288
sS'AU'
p86289
(lp86290
S'El-Khatib Z'
p86291
aS'Ekstrom AM'
p86292
aS'Ledwaba J'
p86293
aS'Mohapi L'
p86294
aS'Laher F'
p86295
aS'Karstaedt A'
p86296
aS'Charalambous S'
p86297
aS'Petzold M'
p86298
aS'Katzenstein D'
p86299
aS'Morris L'
p86300
asS'VI'
p86301
S'24'
p86302
sS'MHDA'
p86303
S'2010/08/20 06:00'
p86304
sS'OID'
p86305
(lp86306
S'NLM: NIHMS198948'
p86307
aS'NLM: PMC2894994'
p86308
asS'MH'
p86309
(lp86310
S'Adult'
p86311
aS'Anti-HIV Agents/*therapeutic use'
p86312
aS'Antiretroviral Therapy, Highly Active/methods'
p86313
aS'*Drug Resistance, Viral'
p86314
aS'Epidemiologic Methods'
p86315
aS'Female'
p86316
aS'HIV Infections/*drug therapy/epidemiology/virology'
p86317
aS'HIV-1/*drug effects/isolation & purification'
p86318
aS'Humans'
p86319
aS'Male'
p86320
aS'Middle Aged'
p86321
aS'Patient Compliance'
p86322
aS'Socioeconomic Factors'
p86323
aS'South Africa/epidemiology'
p86324
aS'Treatment Failure'
p86325
aS'Viral Load'
p86326
aS'Viremia/*drug therapy/epidemiology/virology'
p86327
asS'EDAT'
p86328
S'2010/05/11 06:00'
p86329
sS'SO'
p86330
S'AIDS. 2010 Jul 17;24(11):1679-87. doi: 10.1097/QAD.0b013e32833a097b.'
p86331
sS'SB'
p86332
S'IM X'
p86333
sS'PMID'
p86334
S'20453629'
p86335
sS'PST'
p86336
S'ppublish'
p86337
stRp86338
ag2
(g3
g4
(dp86339
S'LID'
p86340
S'10.1136/sti.2009.038372 [doi]'
p86341
sS'STAT'
p86342
S'MEDLINE'
p86343
sS'DEP'
p86344
S'20100505'
p86345
sS'DA'
p86346
S'20100604'
p86347
sS'AID'
p86348
(lp86349
S'sti.2009.038372 [pii]'
p86350
aS'10.1136/sti.2009.038372 [doi]'
p86351
asS'CRDT'
p86352
(lp86353
S'2010/05/07 06:00'
p86354
asS'DP'
p86355
S'2010 Jun'
p86356
sS'AD'
p86357
S'MRC Uganda/UVRI Research Unit on AIDS, Entebbe, Uganda.'
p86358
sS'OWN'
p86359
S'NLM'
p86360
sS'PT'
p86361
(lp86362
S'Clinical Trial, Phase II'
p86363
aS'Journal Article'
p86364
aS'Randomized Controlled Trial'
p86365
aS"Research Support, Non-U.S. Gov't"
p86366
asS'LA'
p86367
(lp86368
S'eng'
p86369
asS'FAU'
p86370
(lp86371
S'Kamali, Anatoli'
p86372
aS'Byomire, Helen'
p86373
aS'Muwonge, Catherine'
p86374
aS'Bakobaki, Julie'
p86375
aS'Rutterford, Clare'
p86376
aS'Okong, Pius'
p86377
aS'Profy, Albert'
p86378
aS'Byaruhanga, Romano'
p86379
aS'Namukwaya, Stella'
p86380
aS'McCormack, Sheena'
p86381
aS'Grosskurth, Heiner'
p86382
aS'Nunn, Andrew J'
p86383
aS'Lacey, Charles J N'
p86384
asS'JT'
p86385
S'Sexually transmitted infections'
p86386
sS'LR'
p86387
S'20140219'
p86388
sS'PG'
p86389
S'222-6'
p86390
sS'TI'
p86391
S'A randomised placebo-controlled safety and acceptability trial of PRO 2000 vaginal microbicide gel in sexually active women in Uganda.'
p86392
sS'RN'
p86393
(lp86394
S'0 (Anti-Infective Agents, Local)'
p86395
aS'0 (Naphthalenesulfonates)'
p86396
aS'0 (PRO 2000)'
p86397
aS'0 (Polymers)'
p86398
aS'0 (Vaginal Creams, Foams, and Jellies)'
p86399
asS'PL'
p86400
S'England'
p86401
sS'TA'
p86402
S'Sex Transm Infect'
p86403
sS'JID'
p86404
S'9805554'
p86405
sS'AB'
p86406
S'OBJECTIVES: To determine the safety of 0.5% and 2% PRO 2000 gel in terms of local and systemic adverse events (AE) and the acceptability of gel use. DESIGN: A randomised placebo-controlled trial among healthy, sexually active African women aged 18-45 years. Between June 2003 and September 2004, 180 consenting women were randomly assigned to one of four groups: PRO 2000 gel (0.5% or 2%), placebo gel, or condom use only. Participants were screened for sexually transmitted infections, with HIV counselling and testing. Women randomly assigned to gel used this intravaginally twice a day for 28 days. Follow-up visits were fortnightly up to 6 weeks from enrolment, and comprised a physical examination including colposcopy, laboratory testing and questionnaire interviews. RESULTS: Ten women were lost to follow-up, none due to AE. Adherence with total gel doses was 69%. Observed rates of the primary toxicity endpoints, ulceration greater than 2 x 1 cm and clinically relevant coagulation abnormalities were, for PRO 2000 0.5%: 1.6% (95% CI 0.04% to 8.5%) and 0% (97.5% CI 0% to 5.7%), and for PRO 2000 2%: 0% and 0% (97.5% CI 0% to 5.9%). Women randomly assigned to active gels did not show an increased rate of AE. Gel use had no significant effect on haematology and biochemistry results. Women found gel use highly acceptable. CONCLUSIONS: Both concentrations of PRO 2000 gel were found to be safe and well tolerated. These data justified testing the gels in large-scale effectiveness trials.'
p86407
sS'GR'
p86408
(lp86409
S'G0100137/Medical Research Council/United Kingdom'
p86410
aS'MC_U950080930/Medical Research Council/United Kingdom'
p86411
aS'Medical Research Council/United Kingdom'
p86412
asS'IP'
p86413
S'3'
sS'IS'
p86414
S'1472-3263 (Electronic) 1368-4973 (Linking)'
p86415
sS'DCOM'
p86416
S'20100728'
p86417
sS'AU'
p86418
(lp86419
S'Kamali A'
p86420
aS'Byomire H'
p86421
aS'Muwonge C'
p86422
aS'Bakobaki J'
p86423
aS'Rutterford C'
p86424
aS'Okong P'
p86425
aS'Profy A'
p86426
aS'Byaruhanga R'
p86427
aS'Namukwaya S'
p86428
aS'McCormack S'
p86429
aS'Grosskurth H'
p86430
aS'Nunn AJ'
p86431
aS'Lacey CJ'
p86432
asS'VI'
p86433
S'86'
p86434
sS'MHDA'
p86435
S'2010/07/29 06:00'
p86436
sS'PHST'
p86437
(lp86438
S'2010/05/05 [aheadofprint]'
p86439
asS'MH'
p86440
(lp86441
S'Adolescent'
p86442
aS'Adult'
p86443
aS'Anti-Infective Agents, Local/*administration & dosage/adverse effects'
p86444
aS'Condoms/utilization'
p86445
aS'Female'
p86446
aS'HIV Infections/prevention & control'
p86447
aS'Humans'
p86448
aS'Medication Adherence'
p86449
aS'Middle Aged'
p86450
aS'Naphthalenesulfonates/*administration & dosage/adverse effects'
p86451
aS'*Patient Satisfaction'
p86452
aS'Polymers/*administration & dosage/adverse effects'
p86453
aS'Sexually Transmitted Diseases/*prevention & control/psychology'
p86454
aS'Uganda'
p86455
aS'Vaginal Creams, Foams, and Jellies'
p86456
aS'Young Adult'
p86457
asS'EDAT'
p86458
S'2010/05/07 06:00'
p86459
sS'SO'
p86460
S'Sex Transm Infect. 2010 Jun;86(3):222-6. doi: 10.1136/sti.2009.038372. Epub 2010 May 5.'
p86461
sS'SB'
p86462
S'IM'
p86463
sS'PMID'
p86464
S'20444744'
p86465
sS'PST'
p86466
S'ppublish'
p86467
stRp86468
ag2
(g3
g4
(dp86469
S'LID'
p86470
S'10.1371/journal.pone.0010307 [doi]'
p86471
sS'STAT'
p86472
S'MEDLINE'
p86473
sS'DEP'
p86474
S'20100422'
p86475
sS'DA'
p86476
S'20100505'
p86477
sS'AID'
p86478
(lp86479
S'10.1371/journal.pone.0010307 [doi]'
p86480
asS'CRDT'
p86481
(lp86482
S'2010/05/06 06:00'
p86483
asS'DP'
p86484
S'2010'
p86485
sS'AD'
p86486
S'National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America. sjr@jhmi.edu'
p86487
sS'OWN'
p86488
S'NLM'
p86489
sS'PT'
p86490
(lp86491
S'Journal Article'
p86492
aS'Randomized Controlled Trial'
p86493
aS'Research Support, N.I.H., Intramural'
p86494
asS'LA'
p86495
(lp86496
S'eng'
p86497
asS'FAU'
p86498
(lp86499
S'Reynolds, Steven J'
p86500
aS'Kityo, Cissy'
p86501
aS'Hallahan, Claire W'
p86502
aS'Kabuye, Geoffrey'
p86503
aS'Atwiine, Diana'
p86504
aS'Mbamanya, Frank'
p86505
aS'Ssali, Francis'
p86506
aS'Dewar, Robin'
p86507
aS'Daucher, Marybeth'
p86508
aS'Davey, Richard T Jr'
p86509
aS'Mugyenyi, Peter'
p86510
aS'Fauci, Anthony S'
p86511
aS'Quinn, Thomas C'
p86512
aS'Dybul, Mark R'
p86513
asS'JT'
p86514
S'PloS one'
p86515
sS'LR'
p86516
S'20150813'
p86517
sS'PG'
p86518
S'e10307'
p86519
sS'TI'
p86520
S'A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in Uganda.'
p86521
sS'RN'
p86522
(lp86523
S'0 (Anti-Retroviral Agents)'
p86524
aS'0 (RNA, Viral)'
p86525
asS'PL'
p86526
S'United States'
p86527
sS'TA'
p86528
S'PLoS One'
p86529
sS'JID'
p86530
S'101285081'
p86531
sS'AB'
p86532
S'BACKGROUND: Short cycle treatment interruption could reduce toxicity and drug costs and contribute to further expansion of antiretroviral therapy (ART) programs. METHODS: A 72 week, non-inferiority trial enrolled one hundred forty six HIV positive persons receiving ART (CD4+ cell count > or =125 cells/mm(3) and HIV RNA plasma levels <50 copies/ml) in one of three arms: continuous, 7 days on/7 days off and 5 days on/2 days off treatment. Primary endpoint was ART treatment failure determined by plasma HIV RNA level, CD4+ cell count decrease, death attributed to study participation, or opportunistic infection. RESULTS: Following enrollment of 32 participants, the 7 days on/7 days off arm was closed because of a failure rate of 31%. Six of 52 (11.5%) participants in the 5 days on/2 days off arm failed. Five had virologic failure and one participant had immunologic failure. Eleven of 51 (21.6%) participants in the continuous treatment arm failed. Nine had virologic failure with 1 death (lactic acidosis) and 1 clinical failure (extra-pulmonary TB). The upper 97.5% confidence boundary for the difference between the percent of non-failures in the 5 days on/2 days off arm (88.5% non-failure) compared to continuous treatment (78.4% non failure) was 4.8% which is well within the preset non-inferiority margin of 15%. No significant difference was found in time to failure in the 2 study arms (p = 0.39). CONCLUSIONS: Short cycle 5 days on/2 days off intermittent ART was at least as effective as continuous therapy. TRIAL REGISTRATION: ClinicalTrials.gov NCT00339456.'
p86533
sS'GR'
p86534
(lp86535
S'Intramural NIH HHS/United States'
p86536
asS'IP'
p86537
S'4'
sS'IS'
p86538
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p86539
sS'PMC'
p86540
S'PMC2860845'
p86541
sS'DCOM'
p86542
S'20110616'
p86543
sS'AU'
p86544
(lp86545
S'Reynolds SJ'
p86546
aS'Kityo C'
p86547
aS'Hallahan CW'
p86548
aS'Kabuye G'
p86549
aS'Atwiine D'
p86550
aS'Mbamanya F'
p86551
aS'Ssali F'
p86552
aS'Dewar R'
p86553
aS'Daucher M'
p86554
aS'Davey RT Jr'
p86555
aS'Mugyenyi P'
p86556
aS'Fauci AS'
p86557
aS'Quinn TC'
p86558
aS'Dybul MR'
p86559
asS'VI'
p86560
S'5'
sS'MHDA'
p86561
S'2011/06/17 06:00'
p86562
sS'PHST'
p86563
(lp86564
S'2009/10/19 [received]'
p86565
aS'2010/03/22 [accepted]'
p86566
aS'2010/04/22 [epublish]'
p86567
asS'OID'
p86568
(lp86569
S'NLM: PMC2860845'
p86570
asS'MH'
p86571
(lp86572
S'Adult'
p86573
aS'Anti-Retroviral Agents/*administration & dosage'
p86574
aS'CD4 Lymphocyte Count'
p86575
aS'Drug Administration Schedule'
p86576
aS'Female'
p86577
aS'HIV Infections/complications/*drug therapy/mortality'
p86578
aS'Humans'
p86579
aS'Male'
p86580
aS'Middle Aged'
p86581
aS'Opportunistic Infections'
p86582
aS'RNA, Viral/blood'
p86583
aS'Treatment Failure'
p86584
aS'Treatment Outcome'
p86585
aS'Uganda'
p86586
aS'Viral Load/drug effects/methods'
p86587
asS'EDAT'
p86588
S'2010/05/06 06:00'
p86589
sS'SI'
p86590
(lp86591
S'ClinicalTrials.gov/NCT00339456'
p86592
asS'SO'
p86593
S'PLoS One. 2010 Apr 22;5(4):e10307. doi: 10.1371/journal.pone.0010307.'
p86594
sS'SB'
p86595
S'IM'
p86596
sS'PMID'
p86597
S'20442758'
p86598
sS'PST'
p86599
S'epublish'
p86600
stRp86601
ag2
(g3
g4
(dp86602
S'STAT'
p86603
S'MEDLINE'
p86604
sS'AB'
p86605
S'OBJECTIVE: An audit of outcomes of cervical cancer screening and prevention services for HIV-positive women in Cape Town, South Africa. DESIGN: Retrospective review of clinic registers, patient records and pathology databases at three HIV primary health clinics and a tertiary colposcopy referral centre. SUBJECTS: Women recently diagnosed with HIV at three primary health clinics between 2006 and 2008 (N=2 240); new patients seen for colposcopy at a tertiary referral centre between 2006 and 2009 (N=2 031). OUTCOME MEASURES: The proportion of women undergoing cervical cancer screening after HIV diagnosis at primary health clinics, demographic characteristics of women referred for colposcopy at a tertiary centre, and outcomes of therapy for precancerous lesions of the cervix. RESULTS: The proportion of women undergoing at least one Pap smear at HIV primary health clinics after HIV diagnosis was low (13.1%). Women referred for colposcopy tended to be HIV-positive and over the age of 30 years, and in most (70.2%) cytological examination revealed high-grade cervical dysplasia. HIV-positive women treated with excision for precancerous lesions of the cervix were significantly more likely than their HIV-negative counterparts to undergo incomplete excision, experience persistent cervical disease after treatment, and be lost to follow-up. CONCLUSION: Cervical cancer screening efforts must be scaled up for women with HIV. Treatment and surveillance guidelines for cervical intraepithelial neoplasia in HIV-positive women may need to be revised and new interventions developed to reduce incomplete treatment and patient default.'
p86606
sS'JID'
p86607
S'0404520'
p86608
sS'AD'
p86609
S'College of Physicians and Surgeons, Columbia University, New York, NY, USA. priya.batra@gmail.com'
p86610
sS'JT'
p86611
S'South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde'
p86612
sS'IP'
p86613
S'1'
sS'IS'
p86614
S'0256-9574 (Print)'
p86615
sS'DCOM'
p86616
S'20100518'
p86617
sS'DA'
p86618
S'20100430'
p86619
sS'AU'
p86620
(lp86621
S'Batra P'
p86622
aS'Kuhn L'
p86623
aS'Denny L'
p86624
asS'SB'
p86625
S'IM'
p86626
sS'CRDT'
p86627
(lp86628
S'2010/05/01 06:00'
p86629
asS'VI'
p86630
S'100'
p86631
sS'DP'
p86632
S'2010 Jan'
p86633
sS'MHDA'
p86634
S'2010/05/19 06:00'
p86635
sS'OWN'
p86636
S'NLM'
p86637
sS'PT'
p86638
(lp86639
S'Journal Article'
p86640
aS"Research Support, Non-U.S. Gov't"
p86641
asS'LA'
p86642
(lp86643
S'eng'
p86644
asS'MH'
p86645
(lp86646
S'Adult'
p86647
aS'Cohort Studies'
p86648
aS'Colposcopy/utilization'
p86649
aS'Female'
p86650
aS'HIV Infections/pathology/prevention & control/*psychology'
p86651
aS'Humans'
p86652
aS'Middle Aged'
p86653
aS'Papanicolaou Test'
p86654
aS'*Patient Acceptance of Health Care'
p86655
aS'Preventive Health Services/*utilization'
p86656
aS'Retrospective Studies'
p86657
aS'South Africa'
p86658
aS'Uterine Cervical Neoplasms/diagnosis/*prevention & control/virology'
p86659
aS'Vaginal Smears/utilization'
p86660
aS"Women's Health Services/*utilization"
p86661
aS'Young Adult'
p86662
asS'FAU'
p86663
(lp86664
S'Batra, Priya'
p86665
aS'Kuhn, Louise'
p86666
aS'Denny, Lynette'
p86667
asS'EDAT'
p86668
S'2010/05/01 06:00'
p86669
sS'PST'
p86670
S'ppublish'
p86671
sS'LR'
p86672
S'20140912'
p86673
sS'PG'
p86674
S'39-44'
p86675
sS'TI'
p86676
S'Utilisation and outcomes of cervical cancer prevention services among HIV-infected women in Cape Town.'
p86677
sS'SO'
p86678
S'S Afr Med J. 2010 Jan;100(1):39-44.'
p86679
sS'PMID'
p86680
S'20429487'
p86681
sS'PL'
p86682
S'South Africa'
p86683
sS'TA'
p86684
S'S Afr Med J'
p86685
stRp86686
ag2
(g3
g4
(dp86687
S'LID'
p86688
S'10.1097/QAD.0b013e3283333639 [doi]'
p86689
sS'STAT'
p86690
S'MEDLINE'
p86691
sS'JT'
p86692
S'AIDS (London, England)'
p86693
sS'MID'
p86694
(lp86695
S'NIHMS190101'
p86696
asS'DA'
p86697
S'20100415'
p86698
sS'CRDT'
p86699
(lp86700
S'2010/04/17 06:00'
p86701
asS'DP'
p86702
S'2010 Apr 24'
p86703
sS'GR'
p86704
(lp86705
S'K24 RR016482/RR/NCRR NIH HHS/United States'
p86706
aS'K24 RR016482-01/RR/NCRR NIH HHS/United States'
p86707
aS'K24 RR016482-02/RR/NCRR NIH HHS/United States'
p86708
aS'K24 RR016482-03/RR/NCRR NIH HHS/United States'
p86709
aS'K24 RR016482-04/RR/NCRR NIH HHS/United States'
p86710
aS'K24 RR016482-05/RR/NCRR NIH HHS/United States'
p86711
aS'K24 RR016482-06/RR/NCRR NIH HHS/United States'
p86712
aS'K24 RR016482-07/RR/NCRR NIH HHS/United States'
p86713
aS'K24 RR016482-08/RR/NCRR NIH HHS/United States'
p86714
aS'K24 RR016482-09/RR/NCRR NIH HHS/United States'
p86715
aS'K24 RR16482/RR/NCRR NIH HHS/United States'
p86716
aS'P30 AI060354/AI/NIAID NIH HHS/United States'
p86717
aS'P30 AI60354/AI/NIAID NIH HHS/United States'
p86718
aS'U62/CCU123541-01/PHS HHS/United States'
p86719
asS'OWN'
p86720
S'NLM'
p86721
sS'PT'
p86722
(lp86723
S'Journal Article'
p86724
aS'Research Support, N.I.H., Extramural'
p86725
aS"Research Support, Non-U.S. Gov't"
p86726
aS"Research Support, U.S. Gov't, P.H.S."
p86727
asS'LA'
p86728
(lp86729
S'eng'
p86730
asS'FAU'
p86731
(lp86732
S'Murphy, Richard A'
p86733
aS'Sunpath, Henry'
p86734
aS'Lu, Zhigang'
p86735
aS'Chelin, Neville'
p86736
aS'Losina, Elena'
p86737
aS'Gordon, Michelle'
p86738
aS'Ross, Douglas'
p86739
aS'Ewusi, Aba D'
p86740
aS'Matthews, Lynn T'
p86741
aS'Kuritzkes, Daniel R'
p86742
aS'Marconi, Vincent C'
p86743
asS'LR'
p86744
S'20141203'
p86745
sS'PG'
p86746
S'1007-12'
p86747
sS'TI'
p86748
S'Outcomes after virologic failure of first-line ART in South Africa.'
p86749
sS'RN'
p86750
(lp86751
S'0 (Anti-HIV Agents)'
p86752
aS'0 (Anti-Retroviral Agents)'
p86753
asS'PL'
p86754
S'England'
p86755
sS'TA'
p86756
S'AIDS'
p86757
sS'FIR'
p86758
(lp86759
S'Walker, Bruce D'
p86760
aS'Holst, Helga'
p86761
aS'Giddy, Janet'
p86762
aS'Hampton, Jane'
p86763
aS'Maharaj, Roma'
p86764
aS'Reddi, Anand'
p86765
aS'Khumalo, Nokuthula'
p86766
aS'Carpenter, Steve'
p86767
aS'Koranteng-Apeagyei, Kofi'
p86768
aS'Dube, Lorraine Simangele'
p86769
aS'Daily, Jennifer'
p86770
aS'Padayachi, Nagavelli'
p86771
aS'Smith, Alan'
p86772
asS'JID'
p86773
S'8710219'
p86774
sS'AB'
p86775
S'OBJECTIVE: To determine initial 24-week outcomes among prospectively enrolled patients with failure of initial antiretroviral therapy (ART). METHODS: Baseline virologic failure was defined as HIV-1 viral load greater than 1000 copies/ml. Second-line ART was informed by results of genotype testing and selected from agents in the South-African public sector. Twenty-four week endpoints included virologic suppression and mortality. RESULTS: The cohort consisted of 141 patients (median CD4 cell count and viral load at failure of 173 cells/microl and 17 500 copies/ml). The median prior duration of initial ART was 12.0 months. At least one major resistance mutation was found in 87% of patients. After 24 weeks of follow-up, intent-to-treat virologic suppression (<50 copies/ml) was 65%, as-treated virologic suppression was 78%, the median CD4 cell count improvement was 88 cells/microl and the mortality was 6%. The median CD4 cell count at initial virologic failure among those who died was 70 cells/microl, compared to 182 cells/microl among patients who survived (P = 0.01). Patients with wild-type virus at initial failure (N = 19) had inferior outcomes after switch. The presence of nucleoside analogue resistance mutations at failure did not affect early efficacy of boosted-protease inhibitor regimens. CONCLUSIONS: Virologic monitoring linked to resistance testing helped demonstrate the efficacy of lopinavir/ritonavir-containing second-line regimens in South Africa. A switch to second-line regimens in patients with virologic failure and drug resistance has substantial and rapid immunological and clinical benefits. Resistance testing identified a high-risk group without resistance who might benefit from increased medication access and/or adherence support.'
p86776
sS'AD'
p86777
S'Operational Support Unit, Doctors Without Borders, New York, New York 10001, USA. ramurphy@gmail.com'
p86778
sS'CN'
p86779
(lp86780
S'South Africa Resistance Cohort Study Team'
p86781
asS'IP'
p86782
S'7'
sS'IS'
p86783
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p86784
sS'IR'
p86785
(lp86786
S'Walker BD'
p86787
aS'Holst H'
p86788
aS'Giddy J'
p86789
aS'Hampton J'
p86790
aS'Maharaj R'
p86791
aS'Reddi A'
p86792
aS'Khumalo N'
p86793
aS'Carpenter S'
p86794
aS'Koranteng-Apeagyei K'
p86795
aS'Dube LS'
p86796
aS'Daily J'
p86797
aS'Padayachi N'
p86798
aS'Smith A'
p86799
asS'DCOM'
p86800
S'20110121'
p86801
sS'AU'
p86802
(lp86803
S'Murphy RA'
p86804
aS'Sunpath H'
p86805
aS'Lu Z'
p86806
aS'Chelin N'
p86807
aS'Losina E'
p86808
aS'Gordon M'
p86809
aS'Ross D'
p86810
aS'Ewusi AD'
p86811
aS'Matthews LT'
p86812
aS'Kuritzkes DR'
p86813
aS'Marconi VC'
p86814
asS'VI'
p86815
S'24'
p86816
sS'MHDA'
p86817
S'2011/01/22 06:00'
p86818
sS'OID'
p86819
(lp86820
S'NLM: NIHMS190101'
p86821
aS'NLM: PMC2902159'
p86822
asS'MH'
p86823
(lp86824
S'Adult'
p86825
aS'Anti-HIV Agents/*therapeutic use'
p86826
aS'Anti-Retroviral Agents/therapeutic use'
p86827
aS'CD4 Lymphocyte Count'
p86828
aS'Drug Resistance, Viral/genetics'
p86829
aS'Female'
p86830
aS'Genotype'
p86831
aS'HIV Infections/*drug therapy/immunology/mortality/virology'
p86832
aS'HIV-1/drug effects/*genetics/immunology'
p86833
aS'Humans'
p86834
aS'Male'
p86835
aS'Middle Aged'
p86836
aS'Mutation'
p86837
aS'Prospective Studies'
p86838
aS'South Africa'
p86839
aS'Treatment Failure'
p86840
aS'*Viral Load'
p86841
asS'EDAT'
p86842
S'2010/04/17 06:00'
p86843
sS'PMC'
p86844
S'PMC2902159'
p86845
sS'SO'
p86846
S'AIDS. 2010 Apr 24;24(7):1007-12. doi: 10.1097/QAD.0b013e3283333639.'
p86847
sS'SB'
p86848
S'IM X'
p86849
sS'PMID'
p86850
S'20397305'
p86851
sS'PST'
p86852
S'ppublish'
p86853
stRp86854
ag2
(g3
g4
(dp86855
S'LID'
p86856
S'10.1097/QAI.0b013e3181d91788 [doi]'
p86857
sS'STAT'
p86858
S'MEDLINE'
p86859
sS'JT'
p86860
S'Journal of acquired immune deficiency syndromes (1999)'
p86861
sS'DA'
p86862
S'20100721'
p86863
sS'AID'
p86864
(lp86865
S'10.1097/QAI.0b013e3181d91788 [doi]'
p86866
asS'CRDT'
p86867
(lp86868
S'2010/04/17 06:00'
p86869
asS'DP'
p86870
S'2010 Aug'
p86871
sS'OWN'
p86872
S'NLM'
p86873
sS'PT'
p86874
(lp86875
S'Journal Article'
p86876
asS'LA'
p86877
(lp86878
S'eng'
p86879
asS'FAU'
p86880
(lp86881
S'Datay, Mohammed Ishaaq'
p86882
aS'Boulle, Andrew'
p86883
aS'Mant, David'
p86884
aS'Yudkin, Patricia'
p86885
asS'LR'
p86886
S'20131121'
p86887
sS'PG'
p86888
S'489-95'
p86889
sS'TI'
p86890
S'Associations with virologic treatment failure in adults on antiretroviral therapy in South Africa.'
p86891
sS'RN'
p86892
(lp86893
S'0 (Anti-HIV Agents)'
p86894
aS'99DK7FVK1H (Nevirapine)'
p86895
asS'PL'
p86896
S'United States'
p86897
sS'TA'
p86898
S'J Acquir Immune Defic Syndr'
p86899
sS'JID'
p86900
S'100892005'
p86901
sS'AB'
p86902
S'OBJECTIVES: Highly active antiretroviral therapy (HAART) has been available in government facilities in the Western Cape Province of South Africa since 2001. We aimed to investigate factors associated with virologic treatment failure in this setting. DESIGN: Case-control study, matched on facility and on starting date and duration of HAART. METHODS: Cases and controls were identified from clinic registers from May 2001 to June 2006. Cases were patients who switched to second-line therapy after confirmed virologic failure (2 consecutive viral loads above 1000 copies/mL). Controls were on first-line treatment with viral load <400 copies per milliliter at the time of case incidence. RESULTS: One hundred thirty cases and 238 controls were selected from 8 clinics (median 16.6 months on HAART, interquartile range: 12.2-24.6). Treatment interruptions [adjusted odds ratio (AOR) 8.6, 95% confidence interval: 3.6 to 20.8], prior nevirapine-based prevention of mother-to-child transmission (PMTCT) treatment (AOR: 9.6, 95% confidence interval: 2.9 to 32.2), a baseline CD4 count less than 50 cells per microliter or from 50-150 cells per microliter (AOR: 6.6, 95% confidence interval: 2.3 to 18.8 and AOR: 5.8, 95% confidence interval: 2.1 to 16.3 compared with a baseline CD4 count of more than 150 cells/microL), and the use of nevirapine in the initial regimen (AOR: 2.5, 95% confidence interval: 1.4 to 4.7) were all independently associated with virologic treatment failure. CONCLUSIONS: In this setting, nevirapine in the initial HAART regimen or for PMTCT treatment is associated with virologic treatment failure, together with low CD4 count at ART initiation. Earlier initiation of HAART and access to improved triple therapy and PMTCT regimens are priorities for HIV programs in Southern Africa.'
p86903
sS'AD'
p86904
S'Department of Primary Health Care, University of Oxford, Oxford, UK.'
p86905
sS'IP'
p86906
S'5'
sS'IS'
p86907
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p86908
sS'DCOM'
p86909
S'20100812'
p86910
sS'AU'
p86911
(lp86912
S'Datay MI'
p86913
aS'Boulle A'
p86914
aS'Mant D'
p86915
aS'Yudkin P'
p86916
asS'VI'
p86917
S'54'
p86918
sS'MHDA'
p86919
S'2010/08/13 06:00'
p86920
sS'MH'
p86921
(lp86922
S'Adult'
p86923
aS'Anti-HIV Agents/*therapeutic use'
p86924
aS'Antiretroviral Therapy, Highly Active/*methods'
p86925
aS'CD4 Lymphocyte Count'
p86926
aS'Case-Control Studies'
p86927
aS'Female'
p86928
aS'HIV Infections/*drug therapy/prevention & control'
p86929
aS'Humans'
p86930
aS'Infectious Disease Transmission, Vertical/prevention & control'
p86931
aS'Male'
p86932
aS'Nevirapine/therapeutic use'
p86933
aS'Risk Factors'
p86934
aS'South Africa'
p86935
aS'Time Factors'
p86936
aS'Treatment Failure'
p86937
asS'EDAT'
p86938
S'2010/04/17 06:00'
p86939
sS'SO'
p86940
S'J Acquir Immune Defic Syndr. 2010 Aug;54(5):489-95. doi: 10.1097/QAI.0b013e3181d91788.'
p86941
sS'SB'
p86942
S'IM X'
p86943
sS'PMID'
p86944
S'20395870'
p86945
sS'PST'
p86946
S'ppublish'
p86947
stRp86948
ag2
(g3
g4
(dp86949
S'LID'
p86950
S'10.1007/s10461-010-9687-y [doi]'
p86951
sS'STAT'
p86952
S'MEDLINE'
p86953
sS'JT'
p86954
S'AIDS and behavior'
p86955
sS'MID'
p86956
(lp86957
S'NIHMS515159'
p86958
asS'DA'
p86959
S'20100924'
p86960
sS'AID'
p86961
(lp86962
S'10.1007/s10461-010-9687-y [doi]'
p86963
asS'CRDT'
p86964
(lp86965
S'2010/04/01 06:00'
p86966
asS'DP'
p86967
S'2010 Oct'
p86968
sS'AD'
p86969
S'Population Studies and Training Center, Brown University, Providence, RI 02912, USA. abigail_harrison@brown.edu'
p86970
sS'OWN'
p86971
S'NLM'
p86972
sS'PT'
p86973
(lp86974
S'Journal Article'
p86975
aS'Research Support, N.I.H., Extramural'
p86976
aS"Research Support, Non-U.S. Gov't"
p86977
asS'LA'
p86978
(lp86979
S'eng'
p86980
asS'FAU'
p86981
(lp86982
S'Harrison, Abigail'
p86983
aS"O'Sullivan, Lucia F"
p86984
asS'LR'
p86985
S'20141204'
p86986
sS'PG'
p86987
S'991-1000'
p86988
sS'TI'
p86989
S'In the absence of marriage: long-term concurrent partnerships, pregnancy, and HIV risk dynamics among South African young adults.'
p86990
sS'PL'
p86991
S'United States'
p86992
sS'TA'
p86993
S'AIDS Behav'
p86994
sS'JID'
p86995
S'9712133'
p86996
sS'AB'
p86997
S"In KwaZulu/Natal, South Africa, where HIV prevalence is among the world's highest, a longitudinal qualitative study of partnership dynamics and HIV preventive behaviors was conducted. 47 young adults aged 18-24 participated in in-depth interviews, and 29 were re-interviewed 2 years later. Five analytical domains emerged: primary partnerships, love and romance; secondary partnerships; pregnancy/parenthood; condom use/prevention; and contextual influences, including schooling and future aspirations. Primary relationships were long-lasting, with most men and women in the same relationship at 2-year follow-up. Secondary, casual partnerships were common for men and women, although these were shorter and changed frequently. Love and marriage aspirations were not viewed as incompatible with secondary partners. Condom use increased over time in some primary relationships, but decreased in others, and was nearly universal with non-primary partners. Pregnancy, school drop-out, and economic need strongly influence young people's lifecourse. These findings suggest the need to focus prevention efforts on the partnership context, including partner reduction, and structural factors that impede or enhance prevention success."
p86998
sS'GR'
p86999
(lp87000
S'R01 HD041721/HD/NICHD NIH HHS/United States'
p87001
aS'R01-HD41721/HD/NICHD NIH HHS/United States'
p87002
aS'R24 HD041020/HD/NICHD NIH HHS/United States'
p87003
asS'IP'
p87004
S'5'
sS'IS'
p87005
S'1573-3254 (Electronic) 1090-7165 (Linking)'
p87006
sS'PMC'
p87007
S'PMC3848496'
p87008
sS'DCOM'
p87009
S'20101220'
p87010
sS'AU'
p87011
(lp87012
S'Harrison A'
p87013
aS"O'Sullivan LF"
p87014
asS'VI'
p87015
S'14'
p87016
sS'MHDA'
p87017
S'2010/12/21 06:00'
p87018
sS'OID'
p87019
(lp87020
S'NLM: NIHMS515159'
p87021
aS'NLM: PMC3848496'
p87022
asS'MH'
p87023
(lp87024
S'Adolescent'
p87025
aS'African Continental Ancestry Group'
p87026
aS'Female'
p87027
aS'HIV Infections/epidemiology/*prevention & control/transmission'
p87028
aS'Humans'
p87029
aS'Interpersonal Relations'
p87030
aS'Interviews as Topic'
p87031
aS'Longitudinal Studies'
p87032
aS'Male'
p87033
aS'*Marriage'
p87034
aS'Pregnancy'
p87035
aS'Prevalence'
p87036
aS'Qualitative Research'
p87037
aS'Risk-Taking'
p87038
aS'Sexual Behavior/*psychology'
p87039
aS'Sexual Partners/*psychology'
p87040
aS'Socioeconomic Factors'
p87041
aS'South Africa/epidemiology'
p87042
aS'Time Factors'
p87043
aS'Young Adult'
p87044
asS'EDAT'
p87045
S'2010/04/01 06:00'
p87046
sS'SO'
p87047
S'AIDS Behav. 2010 Oct;14(5):991-1000. doi: 10.1007/s10461-010-9687-y.'
p87048
sS'SB'
p87049
S'IM'
p87050
sS'PMID'
p87051
S'20354777'
p87052
sS'PST'
p87053
S'ppublish'
p87054
stRp87055
ag2
(g3
g4
(dp87056
S'LID'
p87057
S'10.1111/j.1468-1293.2010.00825.x [doi]'
p87058
sS'STAT'
p87059
S'MEDLINE'
p87060
sS'DEP'
p87061
S'20100319'
p87062
sS'MID'
p87063
(lp87064
S'NIHMS768407'
p87065
asS'DA'
p87066
S'20100810'
p87067
sS'AID'
p87068
(lp87069
S'HIV825 [pii]'
p87070
aS'10.1111/j.1468-1293.2010.00825.x [doi]'
p87071
asS'CRDT'
p87072
(lp87073
S'2010/03/30 06:00'
p87074
asS'DP'
p87075
S'2010 Sep'
p87076
sS'AD'
p87077
S'University of North Carolina Project, Lilongwe, Malawi. mina_hosseinipour@med.unc.edu'
p87078
sS'OWN'
p87079
S'NLM'
p87080
sS'PT'
p87081
(lp87082
S'Journal Article'
p87083
aS'Multicenter Study'
p87084
aS"Research Support, Non-U.S. Gov't"
p87085
asS'LA'
p87086
(lp87087
S'eng'
p87088
asS'FAU'
p87089
(lp87090
S'Hosseinipour, M C'
p87091
aS'Kumwenda, J J'
p87092
aS'Weigel, R'
p87093
aS'Brown, L B'
p87094
aS'Mzinganjira, D'
p87095
aS'Mhango, B'
p87096
aS'Eron, J J'
p87097
aS'Phiri, S'
p87098
aS'van Oosterhout, J J'
p87099
asS'JT'
p87100
S'HIV medicine'
p87101
sS'LR'
p87102
S'20160417'
p87103
sS'PG'
p87104
S'510-8'
p87105
sS'TI'
p87106
S'Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline.'
p87107
sS'RN'
p87108
(lp87109
S'0 (Anti-Retroviral Agents)'
p87110
aS'0 (Organophosphonates)'
p87111
aS'0 (RNA, Viral)'
p87112
aS'4B9XT59T7S (Zidovudine)'
p87113
aS'99YXE507IL (Tenofovir)'
p87114
aS'JAC85A2161 (Adenine)'
p87115
asS'PL'
p87116
S'England'
p87117
sS'TA'
p87118
S'HIV Med'
p87119
sS'JID'
p87120
S'100897392'
p87121
sS'AB'
p87122
S'OBJECTIVES: The Malawi antiretroviral therapy (ART) programme uses the public health approach to identify ART failure. Advanced disease progression may occur before switching to second-line ART. We report outcomes for patients evaluated and initiated on second-line treatment in Malawi. METHODS: Patients meeting Malawi immunological or clinical criteria for ART failure in two large urban ART clinics were evaluated for virological failure (viral load >400 HIV-1 RNA copies/mL) and, if failure was confirmed, initiated on second-line ART (zidovudine/lamivudine/tenofovir/lopinavir/ritonavir). Patients were seen monthly and laboratory evaluations were performed quarterly and as needed. We performed logistic regression modelling to identify factors associated with mortality, mortality or new HIV illnesses, and virological suppression at 12 months. RESULTS: Of the 109 patients with confirmed virological failure, five patients died prior to initiation, three declined switching and 101 patients initiated second-line treatment. Over 12 months, 10 additional patients died, 34 patients experienced 45 HIV-related events, and 19 patients experienced grade 3 or 4 toxicities. Among survivors, 85.2% had HIV-1 RNA<400 copies/mL at 12 months. While power to distinguish differences was limited, response rates were similar regardless of baseline resistance level. The median CD4 count increase was 142 cells/microL. World Health Organization clinical failure at baseline [odds ratio (OR) 3.47; 95% confidence interval (CI) 1.14-10.59] and body mass index <18.5 (OR 4.43; 95% CI 1.15-17.12) were risk factors for death. Baseline CD4 count <50 cells/microL was associated with increased risk for death or morbidity at 12 months (OR 2.57; 95% CI 1.01-6.52). CONCLUSIONS: Second-line treatment in Malawi was associated with substantial mortality, morbidity and toxicity but, among survivors, virological outcomes were favourable.'
p87123
sS'GR'
p87124
(lp87125
S'P30 AI050410/AI/NIAID NIH HHS/United States'
p87126
asS'IP'
p87127
S'8'
sS'IS'
p87128
S'1468-1293 (Electronic) 1464-2662 (Linking)'
p87129
sS'PMC'
p87130
S'PMC4833877'
p87131
sS'DCOM'
p87132
S'20110105'
p87133
sS'AU'
p87134
(lp87135
S'Hosseinipour MC'
p87136
aS'Kumwenda JJ'
p87137
aS'Weigel R'
p87138
aS'Brown LB'
p87139
aS'Mzinganjira D'
p87140
aS'Mhango B'
p87141
aS'Eron JJ'
p87142
aS'Phiri S'
p87143
aS'van Oosterhout JJ'
p87144
asS'VI'
p87145
S'11'
p87146
sS'MHDA'
p87147
S'2011/01/06 06:00'
p87148
sS'PHST'
p87149
(lp87150
S'2010/03/19 [aheadofprint]'
p87151
asS'OID'
p87152
(lp87153
S'NLM: NIHMS768407'
p87154
aS'NLM: PMC4833877'
p87155
asS'MH'
p87156
(lp87157
S'Adenine/adverse effects/analogs & derivatives'
p87158
aS'Adolescent'
p87159
aS'Adult'
p87160
aS'Anti-Retroviral Agents/adverse effects/*therapeutic use'
p87161
aS'Body Mass Index'
p87162
aS'CD4 Lymphocyte Count'
p87163
aS'Developing Countries'
p87164
aS'*Drug Resistance, Viral'
p87165
aS'Drug Therapy, Combination/methods'
p87166
aS'Drug-Related Side Effects and Adverse Reactions/chemically induced/*epidemiology'
p87167
aS'Female'
p87168
aS'Genotype'
p87169
aS'HIV Infections/*drug therapy/etiology/mortality'
p87170
aS'HIV-1/*genetics'
p87171
aS'Humans'
p87172
aS'Malawi/epidemiology'
p87173
aS'Male'
p87174
aS'Medication Adherence'
p87175
aS'Middle Aged'
p87176
aS'National Health Programs'
p87177
aS'Organophosphonates/adverse effects'
p87178
aS'Prospective Studies'
p87179
aS'RNA, Viral/*analysis'
p87180
aS'Statistics as Topic'
p87181
aS'Tenofovir'
p87182
aS'Treatment Failure'
p87183
aS'Tuberculosis/complications'
p87184
aS'Urban Population'
p87185
aS'Viral Load'
p87186
aS'Zidovudine/adverse effects'
p87187
asS'EDAT'
p87188
S'2010/03/30 06:00'
p87189
sS'SO'
p87190
S'HIV Med. 2010 Sep;11(8):510-8. doi: 10.1111/j.1468-1293.2010.00825.x. Epub 2010 Mar 19.'
p87191
sS'SB'
p87192
S'IM'
p87193
sS'PMID'
p87194
S'20345885'
p87195
sS'PST'
p87196
S'ppublish'
p87197
stRp87198
ag2
(g3
g4
(dp87199
S'LID'
p87200
S'10.1186/1472-6963-10-73 [doi]'
p87201
sS'STAT'
p87202
S'MEDLINE'
p87203
sS'DEP'
p87204
S'20100322'
p87205
sS'DA'
p87206
S'20100409'
p87207
sS'AID'
p87208
(lp87209
S'1472-6963-10-73 [pii]'
p87210
aS'10.1186/1472-6963-10-73 [doi]'
p87211
asS'CRDT'
p87212
(lp87213
S'2010/03/24 06:00'
p87214
asS'DP'
p87215
S'2010'
p87216
sS'OWN'
p87217
S'NLM'
p87218
sS'PT'
p87219
(lp87220
S'Journal Article'
p87221
asS'LA'
p87222
(lp87223
S'eng'
p87224
asS'DCOM'
p87225
S'20120620'
p87226
sS'JT'
p87227
S'BMC health services research'
p87228
sS'LR'
p87229
S'20141204'
p87230
sS'FAU'
p87231
(lp87232
S'Wolpaw, Benjamin J'
p87233
aS'Mathews, Catherine'
p87234
aS'Chopra, Mickey'
p87235
aS'Hardie, Diana'
p87236
aS'de Azevedo, Virginia'
p87237
aS'Jennings, Karen'
p87238
aS'Lurie, Mark N'
p87239
asS'TI'
p87240
S'The failure of routine rapid HIV testing: a case study of improving low sensitivity in the field.'
p87241
sS'RN'
p87242
(lp87243
S'0 (Reagent Kits, Diagnostic)'
p87244
asS'PL'
p87245
S'England'
p87246
sS'PG'
p87247
S'73'
p87248
sS'JID'
p87249
S'101088677'
p87250
sS'AB'
p87251
S'BACKGROUND: The rapid HIV antibody test is the diagnostic tool of choice in low and middle-income countries. Previous evidence suggests that rapid HIV diagnostic tests may underperform in the field, failing to detect a substantial number of infections. A research study inadvertently discovered that a clinic rapid HIV testing process was failing to detect cases of established (high antibody titer) infection, exhibiting an estimated 68.7% sensitivity (95% CI [41.3%-89.0%]) over the course of the first three weeks of observation. The setting is a public service clinic that provides STI diagnosis and treatment in an impoverished, peri-urban community outside of Cape Town, South Africa. METHODS: The researchers and local health administrators collaborated to investigate the cause of the poor test performance and make necessary corrections. The clinic changed the brand of rapid test being used and later introduced quality improvement measures. Observations were made of the clinic staff as they administered rapid HIV tests to real patients. Estimated testing sensitivity was calculated as the number of rapid HIV test positive individuals detected by the clinic divided by this number plus the number of PCR positive, highly reactive 3rd generation ELISA patients identified among those who were rapid test negative at the clinic. RESULTS: In the period of five months after the clinic made the switch of rapid HIV tests, estimated sensitivity improved to 93.5% (95% CI [86.5%-97.6%]), during which time observations of counselors administering tests at the clinic found poor adherence to the recommended testing protocol. Quality improvement measures were implemented and estimated sensitivity rose to 95.1% (95% CI [83.5%-99.4%]) during the final two months of full observation. CONCLUSIONS: Poor testing procedure in the field can lead to exceedingly low levels of rapid HIV test sensitivity, making it imperative that stringent quality control measures are implemented where they do not already exist. Certain brands of rapid-testing kits may perform better than others when faced with sub-optimal use.'
p87252
sS'AD'
p87253
S'Health Systems Research Unit, South African Medical Research Council, Cape Town, South Africa. ben.wolpaw@gmail.com'
p87254
sS'VI'
p87255
S'10'
p87256
sS'IS'
p87257
S'1472-6963 (Electronic) 1472-6963 (Linking)'
p87258
sS'PMC'
p87259
S'PMC2851712'
p87260
sS'AU'
p87261
(lp87262
S'Wolpaw BJ'
p87263
aS'Mathews C'
p87264
aS'Chopra M'
p87265
aS'Hardie D'
p87266
aS'de Azevedo V'
p87267
aS'Jennings K'
p87268
aS'Lurie MN'
p87269
asS'MHDA'
p87270
S'2012/06/21 06:00'
p87271
sS'PHST'
p87272
(lp87273
S'2009/11/13 [received]'
p87274
aS'2010/03/22 [accepted]'
p87275
aS'2010/03/22 [aheadofprint]'
p87276
asS'OID'
p87277
(lp87278
S'NLM: PMC2851712'
p87279
asS'MH'
p87280
(lp87281
S'Adult'
p87282
aS'HIV Infections/*diagnosis/virology'
p87283
aS'HIV-1/immunology/isolation & purification'
p87284
aS'Humans'
p87285
aS'Mass Screening/*standards'
p87286
aS'Poverty'
p87287
aS'Quality Control'
p87288
aS'Reagent Kits, Diagnostic/*standards'
p87289
aS'Sensitivity and Specificity'
p87290
aS'South Africa'
p87291
asS'EDAT'
p87292
S'2010/03/24 06:00'
p87293
sS'SO'
p87294
S'BMC Health Serv Res. 2010 Mar 22;10:73. doi: 10.1186/1472-6963-10-73.'
p87295
sS'SB'
p87296
S'IM'
p87297
sS'PMID'
p87298
S'20307310'
p87299
sS'TA'
p87300
S'BMC Health Serv Res'
p87301
sS'PST'
p87302
S'epublish'
p87303
stRp87304
ag2
(g3
g4
(dp87305
S'LID'
p87306
S'10.1371/journal.pone.0009680 [doi]'
p87307
sS'STAT'
p87308
S'MEDLINE'
p87309
sS'DEP'
p87310
S'20100312'
p87311
sS'DA'
p87312
S'20100319'
p87313
sS'AID'
p87314
(lp87315
S'10.1371/journal.pone.0009680 [doi]'
p87316
asS'CRDT'
p87317
(lp87318
S'2010/03/20 06:00'
p87319
asS'DP'
p87320
S'2010'
p87321
sS'EIN'
p87322
(lp87323
S'PLoS One. 2010; 5(3) doi: 10.1371/annotation/dbc3ee9b-dab4-494b-87d1-7c32b8d684b5'
p87324
asS'OWN'
p87325
S'NLM'
p87326
sS'PT'
p87327
(lp87328
S'Journal Article'
p87329
aS'Randomized Controlled Trial'
p87330
aS"Research Support, Non-U.S. Gov't"
p87331
asS'LA'
p87332
(lp87333
S'eng'
p87334
asS'FAU'
p87335
(lp87336
S'Koethe, John R'
p87337
aS'Westfall, Andrew O'
p87338
aS'Luhanga, Dora K'
p87339
aS'Clark, Gina M'
p87340
aS'Goldman, Jason D'
p87341
aS'Mulenga, Priscilla L'
p87342
aS'Cantrell, Ronald A'
p87343
aS'Chi, Benjamin H'
p87344
aS'Zulu, Isaac'
p87345
aS'Saag, Michael S'
p87346
aS'Stringer, Jeffrey S A'
p87347
asS'JT'
p87348
S'PloS one'
p87349
sS'LR'
p87350
S'20141204'
p87351
sS'PG'
p87352
S'e9680'
p87353
sS'TI'
p87354
S'A cluster randomized trial of routine HIV-1 viral load monitoring in Zambia: study design, implementation, and baseline cohort characteristics.'
p87355
sS'RN'
p87356
(lp87357
S'0 (Anti-Retroviral Agents)'
p87358
asS'PL'
p87359
S'United States'
p87360
sS'TA'
p87361
S'PLoS One'
p87362
sS'JID'
p87363
S'101285081'
p87364
sS'AB'
p87365
S'BACKGROUND: The benefit of routine HIV-1 viral load (VL) monitoring of patients on antiretroviral therapy (ART) in resource-constrained settings is uncertain because of the high costs associated with the test and the limited treatment options. We designed a cluster randomized controlled trial to compare the use of routine VL testing at ART-initiation and at 3, 6, 12, and 18 months, versus our local standard of care (which uses immunological and clinical criteria to diagnose treatment failure, with discretionary VL testing when the two do not agree). METHODOLOGY: Dedicated study personnel were integrated into public-sector ART clinics. We collected participant information in a dedicated research database. Twelve ART clinics in Lusaka, Zambia constituted the units of randomization. Study clinics were stratified into pairs according to matching criteria (historical mortality rate, size, and duration of operation) to limit the effect of clustering, and independently randomized to the intervention and control arms. The study was powered to detect a 36% reduction in mortality at 18 months. PRINCIPAL FINDINGS: From December 2006 to May 2008, we completed enrollment of 1973 participants. Measured baseline characteristics did not differ significantly between the study arms. Enrollment was staggered by clinic pair and truncated at two matched sites. CONCLUSIONS: A large clinical trial of routing VL monitoring was successfully implemented in a dynamic and rapidly growing national ART program. Close collaboration with local health authorities and adequate reserve staff were critical to success. Randomized controlled trials such as this will likely prove valuable in determining long-term outcomes in resource-constrained settings. TRIAL REGISTRATION: Clinicaltrials.gov NCT00929604.'
p87366
sS'AD'
p87367
S'Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.'
p87368
sS'IP'
p87369
S'3'
sS'IS'
p87370
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p87371
sS'PMC'
p87372
S'PMC2837376'
p87373
sS'DCOM'
p87374
S'20110111'
p87375
sS'AU'
p87376
(lp87377
S'Koethe JR'
p87378
aS'Westfall AO'
p87379
aS'Luhanga DK'
p87380
aS'Clark GM'
p87381
aS'Goldman JD'
p87382
aS'Mulenga PL'
p87383
aS'Cantrell RA'
p87384
aS'Chi BH'
p87385
aS'Zulu I'
p87386
aS'Saag MS'
p87387
aS'Stringer JS'
p87388
asS'VI'
p87389
S'5'
sS'MHDA'
p87390
S'2011/01/12 06:00'
p87391
sS'PHST'
p87392
(lp87393
S'2009/09/02 [received]'
p87394
aS'2010/02/23 [accepted]'
p87395
aS'2010/03/12 [epublish]'
p87396
asS'OID'
p87397
(lp87398
S'NLM: PMC2837376'
p87399
asS'MH'
p87400
(lp87401
S'Adult'
p87402
aS'Anti-Retroviral Agents/*pharmacology'
p87403
aS'Antiretroviral Therapy, Highly Active/methods'
p87404
aS'Cohort Studies'
p87405
aS'Female'
p87406
aS'HIV Infections/*drug therapy'
p87407
aS'HIV-1/*metabolism'
p87408
aS'Humans'
p87409
aS'Male'
p87410
aS'Middle Aged'
p87411
aS'Research Design'
p87412
aS'Time Factors'
p87413
aS'Treatment Outcome'
p87414
aS'*Viral Load'
p87415
aS'Zambia'
p87416
asS'EDAT'
p87417
S'2010/03/20 06:00'
p87418
sS'SI'
p87419
(lp87420
S'ClinicalTrials.gov/NCT00929604'
p87421
asS'SO'
p87422
S'PLoS One. 2010 Mar 12;5(3):e9680. doi: 10.1371/journal.pone.0009680.'
p87423
sS'SB'
p87424
S'IM'
p87425
sS'PMID'
p87426
S'20300631'
p87427
sS'PST'
p87428
S'epublish'
p87429
stRp87430
ag2
(g3
g4
(dp87431
S'LID'
p87432
S'10.1186/1758-2652-13-10 [doi]'
p87433
sS'STAT'
p87434
S'MEDLINE'
p87435
sS'DEP'
p87436
S'20100315'
p87437
sS'DA'
p87438
S'20100409'
p87439
sS'AID'
p87440
(lp87441
S'1758-2652-13-10 [pii]'
p87442
aS'10.1186/1758-2652-13-10 [doi]'
p87443
asS'CRDT'
p87444
(lp87445
S'2010/03/17 06:00'
p87446
asS'DP'
p87447
S'2010'
p87448
sS'AD'
p87449
S'Emory University, Atlanta, Georgia, USA. mconkl2@emory.edu'
p87450
sS'OWN'
p87451
S'NLM'
p87452
sS'PT'
p87453
(lp87454
S'Journal Article'
p87455
aS'Research Support, N.I.H., Extramural'
p87456
aS"Research Support, Non-U.S. Gov't"
p87457
asS'LA'
p87458
(lp87459
S'eng'
p87460
asS'DCOM'
p87461
S'20101213'
p87462
sS'JT'
p87463
S'Journal of the International AIDS Society'
p87464
sS'LR'
p87465
S'20141204'
p87466
sS'FAU'
p87467
(lp87468
S'Conkling, Martha'
p87469
aS'Shutes, Erin L'
p87470
aS'Karita, Etienne'
p87471
aS'Chomba, Elwyn'
p87472
aS'Tichacek, Amanda'
p87473
aS'Sinkala, Moses'
p87474
aS'Vwalika, Bellington'
p87475
aS'Iwanowski, Melissa'
p87476
aS'Allen, Susan A'
p87477
asS'TI'
p87478
S"Couples' voluntary counselling and testing and nevirapine use in antenatal clinics in two African capitals: a prospective cohort study."
p87479
sS'RN'
p87480
(lp87481
S'99DK7FVK1H (Nevirapine)'
p87482
asS'PL'
p87483
S'England'
p87484
sS'PG'
p87485
S'10'
p87486
sS'JID'
p87487
S'101478566'
p87488
sS'AB'
p87489
S"BACKGROUND: With the accessibility of prevention of mother to child transmission (PMTCT) services in sub-Saharan Africa, more women are being tested for HIV in antenatal care settings. Involving partners in the counselling and testing process could help prevent horizontal and vertical transmission of HIV. This study was conducted to assess the feasibility of couples' voluntary counseling and testing (CVCT) in antenatal care and to measure compliance with PMTCT. METHODS: A prospective cohort study was conducted over eight months at two public antenatal clinics in Kigali, Rwanda, and Lusaka, Zambia. A convenience sample of 3625 pregnant women was enrolled. Of these, 1054 women were lost to follow up. The intervention consisted of same-day individual voluntary counselling and testing (VCT) and weekend CVCT; HIV-positive participants received nevirapine tablets. In Kigali, nevirapine syrup was provided in the labour and delivery ward; in Lusaka, nevirapine syrup was supplied in pre-measured single-dose syringes. The main outcome measures were nurse midwife-recorded deliveries and reported nevirapine use. RESULTS: In eight months, 1940 women enrolled in Kigali (984 VCT, 956 CVCT) and 1685 women enrolled in Lusaka (1022 VCT, 663 CVCT). HIV prevalence was 14% in Kigali, and 27% in Lusaka. Loss to follow up was more common in Kigali than Lusaka (33% vs. 24%, p = 0.000). In Lusaka, HIV-positive and HIV-negative women had significantly different loss-to-follow-up rates (30% vs. 22%, p = 0.002). CVCT was associated with reduced loss to follow up: in Kigali, 31% of couples versus 36% of women testing alone (p = 0.011); and in Lusaka, 22% of couples versus 25% of women testing alone (p = 0.137). Among HIV-positive women with follow up, CVCT had no impact on nevirapine use (86-89% in Kigali; 78-79% in Lusaka). CONCLUSIONS: Weekend CVCT, though new, was feasible in both capital cities. The beneficial impact of CVCT on loss to follow up was significant, while nevirapine compliance was similar in women tested alone or with their partners. Pre-measured nevirapine syrup syringes provided flexibility to HIV-positive mothers in Lusaka, but may have contributed to study loss to follow up. These two prevention interventions remain a challenge, with CVCT still operating without supportive government policy in Zambia."
p87490
sS'GR'
p87491
(lp87492
S'2D43 TW001042/TW/FIC NIH HHS/United States'
p87493
aS'AI050409/AI/NIAID NIH HHS/United States'
p87494
aS'R01 MH66767/MH/NIMH NIH HHS/United States'
p87495
asS'VI'
p87496
S'13'
p87497
sS'IS'
p87498
S'1758-2652 (Electronic) 1758-2652 (Linking)'
p87499
sS'PMC'
p87500
S'PMC2851580'
p87501
sS'AU'
p87502
(lp87503
S'Conkling M'
p87504
aS'Shutes EL'
p87505
aS'Karita E'
p87506
aS'Chomba E'
p87507
aS'Tichacek A'
p87508
aS'Sinkala M'
p87509
aS'Vwalika B'
p87510
aS'Iwanowski M'
p87511
aS'Allen SA'
p87512
asS'MHDA'
p87513
S'2010/12/14 06:00'
p87514
sS'PHST'
p87515
(lp87516
S'2009/09/30 [received]'
p87517
aS'2010/03/15 [accepted]'
p87518
aS'2010/03/15 [aheadofprint]'
p87519
asS'OID'
p87520
(lp87521
S'NLM: PMC2851580'
p87522
asS'MH'
p87523
(lp87524
S'Adult'
p87525
aS'Cohort Studies'
p87526
aS'*Counseling'
p87527
aS'Family Characteristics'
p87528
aS'Female'
p87529
aS'HIV Infections/*drug therapy/prevention & control/*psychology'
p87530
aS'Humans'
p87531
aS'Infectious Disease Transmission, Vertical/prevention & control'
p87532
aS'Male'
p87533
aS'Nevirapine/*therapeutic use'
p87534
aS'*Patient Compliance'
p87535
aS'Pregnancy'
p87536
aS'Prospective Studies'
p87537
aS'Rwanda'
p87538
aS'Young Adult'
p87539
aS'Zambia'
p87540
asS'EDAT'
p87541
S'2010/03/17 06:00'
p87542
sS'SO'
p87543
S'J Int AIDS Soc. 2010 Mar 15;13:10. doi: 10.1186/1758-2652-13-10.'
p87544
sS'SB'
p87545
S'IM X'
p87546
sS'PMID'
p87547
S'20230628'
p87548
sS'TA'
p87549
S'J Int AIDS Soc'
p87550
sS'PST'
p87551
S'epublish'
p87552
stRp87553
ag2
(g3
g4
(dp87554
S'LID'
p87555
S'10.1086/650383 [doi]'
p87556
sS'STAT'
p87557
S'MEDLINE'
p87558
sS'AB'
p87559
S'The South African antiretroviral treatment guidelines recommend the use of human immunodeficiency virus type 1 (HIV-1) load testing for patient monitoring and, in particular, to assist in switching to second-line treatment regimens. There are significant challenges to implementing HIV load testing on the scale that is required in South Africa. To put this in context, approximately 560,000 HIV-infected individuals are receiving antiretroviral therapy, and program recommendations include viral load testing twice per year. Currently, a 3-tiered laboratory infrastructure exists with tertiary facilities and, to some extent, secondary laboratories able to implement quantitative HIV nucleic acid testing. Challenges include high sample volumes, transportation logistics from remote sites, costs, phlebotomy in children, a national skills shortage, and sample throughput of technology platforms. Several approaches are thus being explored simultaneously: (1) the feasibility of establishing higher throughput and more automated central laboratories; (2) improvement of current sample collection, transportation, and storage techniques; (3) alternative viral load technologies, including flow-based marker screening approaches to reduce testing volumes, and (4) point-of-care viral load testing strategies for clinics. The development of appropriate solutions for each laboratory tier in South Africa will require close collaboration between researchers in the field and partners in industry.'
p87560
sS'AD'
p87561
S'Department of Molecular Medicine and Haematology, National Health Laboratory Service and University of the Witwatersrand, Johannesburg, South Africa. wendy.stevens@nhls.ac.za'
p87562
sS'JT'
p87563
S'The Journal of infectious diseases'
p87564
sS'VI'
p87565
S'201 Suppl 1'
p87566
sS'IS'
p87567
S'1537-6613 (Electronic) 0022-1899 (Linking)'
p87568
sS'JID'
p87569
S'0413675'
p87570
sS'DA'
p87571
S'20100315'
p87572
sS'AU'
p87573
(lp87574
S'Stevens WS'
p87575
aS'Marshall TM'
p87576
asS'SB'
p87577
S'AIM IM'
p87578
sS'AID'
p87579
(lp87580
S'10.1086/650383 [doi]'
p87581
asS'CRDT'
p87582
(lp87583
S'2010/03/16 06:00'
p87584
asS'DP'
p87585
S'2010 Apr 15'
p87586
sS'MHDA'
p87587
S'2010/04/20 06:00'
p87588
sS'OWN'
p87589
S'NLM'
p87590
sS'PT'
p87591
(lp87592
S'Journal Article'
p87593
aS"Research Support, Non-U.S. Gov't"
p87594
aS'Review'
p87595
asS'LA'
p87596
(lp87597
S'eng'
p87598
asS'MH'
p87599
(lp87600
S'HIV Infections/drug therapy/epidemiology/*virology'
p87601
aS'HIV-1/*isolation & purification'
p87602
aS'Humans'
p87603
aS'Medical Laboratory Science/*organization & administration'
p87604
aS'South Africa'
p87605
aS'Viral Load/*methods'
p87606
asS'DCOM'
p87607
S'20100419'
p87608
sS'EDAT'
p87609
S'2010/03/17 06:00'
p87610
sS'PST'
p87611
S'ppublish'
p87612
sS'RF'
p87613
S'28'
p87614
sS'LR'
p87615
S'20111117'
p87616
sS'FAU'
p87617
(lp87618
S'Stevens, Wendy S'
p87619
aS'Marshall, Theresa M'
p87620
asS'TI'
p87621
S'Challenges in implementing HIV load testing in South Africa.'
p87622
sS'SO'
p87623
S'J Infect Dis. 2010 Apr 15;201 Suppl 1:S78-84. doi: 10.1086/650383.'
p87624
sS'PMID'
p87625
S'20225952'
p87626
sS'TA'
p87627
S'J Infect Dis'
p87628
sS'PL'
p87629
S'United States'
p87630
sS'PG'
p87631
S'S78-84'
p87632
stRp87633
ag2
(g3
g4
(dp87634
S'LID'
p87635
S'10.1097/QAI.0b013e3181d8ad51 [doi]'
p87636
sS'STAT'
p87637
S'MEDLINE'
p87638
sS'AB'
p87639
S'OBJECTIVES: To compare rates of mother to child transmission of HIV and infant survival in women-infant dyads receiving different interventions in a prevention of Mother to Child Transmission (pMTCT) program in western Kenya. DESIGN: Retrospective cohort study using prospectively collected data stored in an electronic medical record system. SETTING: Eighteen HIV clinics in western Kenya. POPULATION: HIV-exposed infants enrolled between February 2002 and July 2007, at any of the United States Agency for International Development-Academic Model Providing Access To Healthcare partnership clinics. MAIN OUTCOME MEASURES: Combined endpoint (CE) of infant HIV status and mortality at 3 and 18 months. ANALYSIS: Descriptive statistics, chi Fisher exact test, and multivariable modeling. RESULTS: Between February 2002 and July 2007, 2477 HIV-exposed children were registered for care by the United States Agency for International Development-Academic Model Providing Access To Healthcare partnership pMTCT program before 3 months of age. Median age at enrollment was 6.1 weeks; 50.4% infants were male. By 3 months, 31 of 2477 infants (1.3%) were dead and 183 (7.4%) were lost to follow-up. One thousand (40%) underwent HIV DNA Polymerase Chain Reaction virologic test at a median age of 8.3 weeks: 5% were HIV infected, 89% uninfected, and 6% were indeterminate. Of the 968 infants with specific test results or mortality data at 3 months, the CE of HIV infection or death was reached in 84 of 968 (8.7%) infants. The 3-month CE was significantly impacted (A) by maternal prophylaxis [51 of 752 (6.8%) combination antiretroviral therapy (cART); 8 of 69 (11.6%) single-dose nevirapine (sdNVP); and 25 of 147 (17%) no prophylaxis (P < 0.001)] and (B) by feeding method for the 889 of 968 (91.8%) mother-infant pairs for which feeding choice was documented [5 of 29 (17.2%) exclusive breastfeeding; 13 of 110 (11.8%) mixed feeding; and 54 of 750 (7.2%) formula feeding (P = 0.041)]. Of the 1201 infants > or = 18 months of age: 41 (3.4%) were deceased and 329 (27.4%) were lost to follow-up. Of 621 of 831 (74.7%) infants tested, 65 (10.5%) were infected resulting in a CE of 103 of 659 (15.6%). CE differed significantly by maternal prophylaxis [52 of 441 (11.8%) for cART; 13 of 96 (13.5%) for sdNVP; and 38 of 122 (31.2%) no therapy group (P < 0.001)] but not by feeding method for the 638 of 659 (96.8%) children with documented feeding choice [7 of 35 (20%) exclusive breastfeeding, 14 of 63 (22.2%) mixed, and 74 of 540 (13.7%) formula (P = 0.131)]. On multivariate analysis, sdNVP (odds ratio: 0.4; 95% confidence interval: 0.2 to 0.8) and cART (odds ratio: 0.3; 95% confidence interval: 0.2 to 0.6) were associated with fewer CE. At 18 months, feeding method was not significantly associated with the CE. CONCLUSIONS: Though ascertainment bias is likely, results strongly suggest a benefit of antiretroviral prophylaxis in reducing infant death and HIV infection, but do not show a benefit at 18-months from the use of formula. There was a high rate of loss to follow up, and adherence to the HIV infant testing protocol was less than 50% indicating the need to address barriers related to infant HIV testing, and to improve outreach and follow-up services.'
p87640
sS'JID'
p87641
S'100892005'
p87642
sS'GR'
p87643
(lp87644
S'U01 AI069911/AI/NIAID NIH HHS/United States'
p87645
asS'JT'
p87646
S'Journal of acquired immune deficiency syndromes (1999)'
p87647
sS'IP'
p87648
S'1'
sS'IS'
p87649
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p87650
sS'DCOM'
p87651
S'20100504'
p87652
sS'DA'
p87653
S'20100426'
p87654
sS'AU'
p87655
(lp87656
S'Nyandiko WM'
p87657
aS'Otieno-Nyunya B'
p87658
aS'Musick B'
p87659
aS'Bucher-Yiannoutsos S'
p87660
aS'Akhaabi P'
p87661
aS'Lane K'
p87662
aS'Yiannoutsos CT'
p87663
aS'Wools-Kaloustian K'
p87664
asS'AID'
p87665
(lp87666
S'10.1097/QAI.0b013e3181d8ad51 [doi]'
p87667
asS'CRDT'
p87668
(lp87669
S'2010/03/13 06:00'
p87670
asS'VI'
p87671
S'54'
p87672
sS'DP'
p87673
S'2010 May 1'
p87674
sS'AD'
p87675
S'Department of Child Health and Pediatrics, Moi University School of Medicine, Eldoret, Kenya.'
p87676
sS'MHDA'
p87677
S'2010/05/05 06:00'
p87678
sS'OWN'
p87679
S'NLM'
p87680
sS'PT'
p87681
(lp87682
S'Journal Article'
p87683
aS'Research Support, N.I.H., Extramural'
p87684
aS"Research Support, U.S. Gov't, Non-P.H.S."
p87685
asS'LA'
p87686
(lp87687
S'eng'
p87688
asS'MH'
p87689
(lp87690
S'Animals'
p87691
aS'Antiretroviral Therapy, Highly Active/*methods'
p87692
aS'Cohort Studies'
p87693
aS'Developing Countries'
p87694
aS'Female'
p87695
aS'HIV Infections/*drug therapy/*transmission'
p87696
aS'Humans'
p87697
aS'Incidence'
p87698
aS'Infant'
p87699
aS'Infectious Disease Transmission, Vertical/*prevention & control'
p87700
aS'Kenya'
p87701
aS'Male'
p87702
aS'Pregnancy'
p87703
aS'Pregnancy Complications, Infectious/*drug therapy'
p87704
aS'Retrospective Studies'
p87705
aS'Survival Analysis'
p87706
aS'Treatment Outcome'
p87707
asS'FAU'
p87708
(lp87709
S'Nyandiko, Winstone M'
p87710
aS'Otieno-Nyunya, Boaz'
p87711
aS'Musick, Beverly'
p87712
aS'Bucher-Yiannoutsos, Sherri'
p87713
aS'Akhaabi, Pamela'
p87714
aS'Lane, Karin'
p87715
aS'Yiannoutsos, Constantin T'
p87716
aS'Wools-Kaloustian, Kara'
p87717
asS'EDAT'
p87718
S'2010/03/13 06:00'
p87719
sS'PST'
p87720
S'ppublish'
p87721
sS'SO'
p87722
S'J Acquir Immune Defic Syndr. 2010 May 1;54(1):42-50. doi: 10.1097/QAI.0b013e3181d8ad51.'
p87723
sS'PG'
p87724
S'42-50'
p87725
sS'TI'
p87726
S'Outcomes of HIV-exposed children in western Kenya: efficacy of prevention of mother to child transmission in a resource-constrained setting.'
p87727
sS'SB'
p87728
S'IM X'
p87729
sS'PMID'
p87730
S'20224420'
p87731
sS'PL'
p87732
S'United States'
p87733
sS'TA'
p87734
S'J Acquir Immune Defic Syndr'
p87735
stRp87736
ag2
(g3
g4
(dp87737
S'LID'
p87738
S'10.1093/aje/kwq008 [doi]'
p87739
sS'STAT'
p87740
S'MEDLINE'
p87741
sS'DEP'
p87742
S'20100310'
p87743
sS'DA'
p87744
S'20100409'
p87745
sS'AID'
p87746
(lp87747
S'kwq008 [pii]'
p87748
aS'10.1093/aje/kwq008 [doi]'
p87749
asS'CRDT'
p87750
(lp87751
S'2010/03/12 06:00'
p87752
asS'DP'
p87753
S'2010 Apr 15'
p87754
sS'AD'
p87755
S'Centre for Infectious Disease Research in Zambia, Box 34681, 1275 Lubuto Road, Lusaka, Zambia. bchi@cidrz.org'
p87756
sS'OWN'
p87757
S'NLM'
p87758
sS'PT'
p87759
(lp87760
S'Journal Article'
p87761
aS'Research Support, N.I.H., Extramural'
p87762
aS"Research Support, Non-U.S. Gov't"
p87763
aS"Research Support, U.S. Gov't, P.H.S."
p87764
asS'LA'
p87765
(lp87766
S'eng'
p87767
asS'FAU'
p87768
(lp87769
S'Chi, Benjamin H'
p87770
aS'Cantrell, Ronald A'
p87771
aS'Mwango, Albert'
p87772
aS'Westfall, Andrew O'
p87773
aS'Mutale, Wilbroad'
p87774
aS'Limbada, Mohammed'
p87775
aS'Mulenga, Lloyd B'
p87776
aS'Vermund, Sten H'
p87777
aS'Stringer, Jeffrey S A'
p87778
asS'JT'
p87779
S'American journal of epidemiology'
p87780
sS'LR'
p87781
S'20141204'
p87782
sS'PG'
p87783
S'924-31'
p87784
sS'TI'
p87785
S'An empirical approach to defining loss to follow-up among patients enrolled in antiretroviral treatment programs.'
p87786
sS'RN'
p87787
(lp87788
S'0 (Anti-HIV Agents)'
p87789
asS'PL'
p87790
S'United States'
p87791
sS'TA'
p87792
S'Am J Epidemiol'
p87793
sS'JID'
p87794
S'7910653'
p87795
sS'AB'
p87796
S'In many programs providing antiretroviral therapy (ART), clinicians report substantial patient attrition; however, there are no consensus criteria for defining patient loss to follow-up (LTFU). Data on a multisite human immunodeficiency virus (HIV) treatment cohort in Lusaka, Zambia, were used to determine an empirical "days-late" definition of LTFU among patients on ART. Cohort members were classified as either "in care" or LTFU as of December 31, 2007, according to a range of days-late intervals. The authors then looked forward in the database to determine which patients actually returned to care at any point over the following year. The interval that best minimized LTFU misclassification was described as "best-performing." Overall, 33,704 HIV-infected adults on ART were included. Nearly one-third (n = 10,196) were at least 1 day late for an appointment. The best-performing LTFU definition was 56 days after a missed visit, which had a sensitivity of 84.1% (95% confidence interval (CI): 83.2, 85.0), specificity of 97.5% (95% CI: 97.3, 97.7), and misclassification of 5.1% (95% CI: 4.8, 5.3). The 60-day threshold performed similarly well, with only a marginal difference (<0.1%) in misclassification. This analysis suggests that > or =60 days since the last appointment is a reasonable definition of LTFU. Standardization to empirically derived definitions of LTFU will permit more reliable comparisons within and across programs.'
p87797
sS'GR'
p87798
(lp87799
S'D43-TW001035/TW/FIC NIH HHS/United States'
p87800
aS'K01 TW06670/TW/FIC NIH HHS/United States'
p87801
aS'P30-AI027767/AI/NIAID NIH HHS/United States'
p87802
aS'U62/CCU12354/PHS HHS/United States'
p87803
asS'IP'
p87804
S'8'
sS'IS'
p87805
S'1476-6256 (Electronic) 0002-9262 (Linking)'
p87806
sS'PMC'
p87807
S'PMC2850972'
p87808
sS'DCOM'
p87809
S'20100423'
p87810
sS'AU'
p87811
(lp87812
S'Chi BH'
p87813
aS'Cantrell RA'
p87814
aS'Mwango A'
p87815
aS'Westfall AO'
p87816
aS'Mutale W'
p87817
aS'Limbada M'
p87818
aS'Mulenga LB'
p87819
aS'Vermund SH'
p87820
aS'Stringer JS'
p87821
asS'VI'
p87822
S'171'
p87823
sS'MHDA'
p87824
S'2010/04/24 06:00'
p87825
sS'PHST'
p87826
(lp87827
S'2010/03/10 [aheadofprint]'
p87828
aS'2010/04/07 [aheadofprint]'
p87829
asS'OID'
p87830
(lp87831
S'NLM: PMC2850972'
p87832
asS'MH'
p87833
(lp87834
S'Adult'
p87835
aS'Anti-HIV Agents/*therapeutic use'
p87836
aS'Appointments and Schedules'
p87837
aS'Cohort Studies'
p87838
aS'*Data Interpretation, Statistical'
p87839
aS'Drug Monitoring/statistics & numerical data'
p87840
aS'HIV Infections/*drug therapy/mortality'
p87841
aS'Humans'
p87842
aS'Medical Records Systems, Computerized'
p87843
aS'Medication Adherence/statistics & numerical data'
p87844
aS'*Patient Dropouts/classification/statistics & numerical data'
p87845
aS'ROC Curve'
p87846
aS'Sensitivity and Specificity'
p87847
aS'Time Factors'
p87848
aS'Zambia/epidemiology'
p87849
asS'EDAT'
p87850
S'2010/03/12 06:00'
p87851
sS'SO'
p87852
S'Am J Epidemiol. 2010 Apr 15;171(8):924-31. doi: 10.1093/aje/kwq008. Epub 2010 Mar 10.'
p87853
sS'SB'
p87854
S'IM'
p87855
sS'PMID'
p87856
S'20219765'
p87857
sS'PST'
p87858
S'ppublish'
p87859
stRp87860
ag2
(g3
g4
(dp87861
S'LID'
p87862
S'10.1097/QAI.0b013e3181cf4882 [doi]'
p87863
sS'STAT'
p87864
S'MEDLINE'
p87865
sS'JT'
p87866
S'Journal of acquired immune deficiency syndromes (1999)'
p87867
sS'MID'
p87868
(lp87869
S'NIHMS181145'
p87870
asS'DA'
p87871
S'20100708'
p87872
sS'AID'
p87873
(lp87874
S'10.1097/QAI.0b013e3181cf4882 [doi]'
p87875
asS'CRDT'
p87876
(lp87877
S'2010/03/11 06:00'
p87878
asS'DP'
p87879
S'2010 Aug'
p87880
sS'AD'
p87881
S'Duke University Medical Center, Durham, North Carolina, USA.'
p87882
sS'OWN'
p87883
S'NLM'
p87884
sS'PT'
p87885
(lp87886
S'Journal Article'
p87887
aS'Research Support, N.I.H., Extramural'
p87888
aS"Research Support, Non-U.S. Gov't"
p87889
asS'LA'
p87890
(lp87891
S'eng'
p87892
asS'FAU'
p87893
(lp87894
S'Emmett, Susan D'
p87895
aS'Cunningham, Coleen K'
p87896
aS'Mmbaga, Blandina T'
p87897
aS'Kinabo, Grace D'
p87898
aS'Schimana, Werner'
p87899
aS'Swai, Mark E'
p87900
aS'Bartlett, John A'
p87901
aS'Crump, John A'
p87902
aS'Reddy, Elizabeth A'
p87903
asS'LR'
p87904
S'20141204'
p87905
sS'PG'
p87906
S'368-75'
p87907
sS'TI'
p87908
S'Predicting virologic failure among HIV-1-infected children receiving antiretroviral therapy in Tanzania: a cross-sectional study.'
p87909
sS'RN'
p87910
(lp87911
S'0 (Anti-HIV Agents)'
p87912
aS'0 (Anti-Retroviral Agents)'
p87913
aS'0 (Antigens, CD4)'
p87914
aS'0 (Benzoxazines)'
p87915
aS'0 (RNA, Viral)'
p87916
aS'99DK7FVK1H (Nevirapine)'
p87917
aS'JE6H2O27P8 (efavirenz)'
p87918
asS'PL'
p87919
S'United States'
p87920
sS'TA'
p87921
S'J Acquir Immune Defic Syndr'
p87922
sS'JID'
p87923
S'100892005'
p87924
sS'AB'
p87925
S'BACKGROUND: Many HIV care and treatment programs in resource-limited settings rely on clinical and immunologic monitoring of antiretroviral therapy (ART), but accuracy of this strategy to detect virologic failure (VF) among children has not been evaluated. METHODS: A cross-sectional sample of HIV-infected children aged 1-16 years on ART >or=6 months receiving care at a Tanzanian referral center underwent clinical staging, CD4 lymphocyte measurement, plasma HIV-1 RNA level, and complete blood count. Associations with VF (HIV-1 RNA >or=400 copies/mL) were determined utilizing bivariable and multivariate analyses; accuracy of current clinical and immunologic guidelines in identifying children with VF was assessed. FINDINGS: Of 206 children (median age 8.7 years, ART duration 2.4 years), 65 (31.6%) demonstrated VF at enrollment. Clinical and immunological criteria identified 2 (3.5%) of 57 children with VF on first-line therapy, exhibiting 3.5% sensitivity and 100% specificity. VF was associated with younger age, receipt of nevirapine vs. efavirenz-based regimen, CD4% < 25%, and physician documentation of maladherence (P < 0.05 on bivariable analysis); the latter 2 factors remained significant on multivariate logistic regression. INTERPRETATION: This study demonstrates poor performance of clinical and immunologic criteria in identifying children with virologic failure. Affordable techniques for measuring HIV-1 RNA level applicable in resource-limited settings are urgently needed.'
p87926
sS'GR'
p87927
(lp87928
S'D43 PA-03-018/PHS HHS/United States'
p87929
aS'D43 TW006732/TW/FIC NIH HHS/United States'
p87930
aS'P30 AI 64518/AI/NIAID NIH HHS/United States'
p87931
aS'P30 AI051445/AI/NIAID NIH HHS/United States'
p87932
aS'P30 AI064518/AI/NIAID NIH HHS/United States'
p87933
aS'T32 AI007392-18/AI/NIAID NIH HHS/United States'
p87934
aS'U01 AI-03-036/AI/NIAID NIH HHS/United States'
p87935
aS'U01 AI069484/AI/NIAID NIH HHS/United States'
p87936
aS'U01 AI06984-01/AI/NIAID NIH HHS/United States'
p87937
aS'Howard Hughes Medical Institute/United States'
p87938
asS'IP'
p87939
S'4'
sS'IS'
p87940
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p87941
sS'PMC'
p87942
S'PMC4185279'
p87943
sS'DCOM'
p87944
S'20100810'
p87945
sS'AU'
p87946
(lp87947
S'Emmett SD'
p87948
aS'Cunningham CK'
p87949
aS'Mmbaga BT'
p87950
aS'Kinabo GD'
p87951
aS'Schimana W'
p87952
aS'Swai ME'
p87953
aS'Bartlett JA'
p87954
aS'Crump JA'
p87955
aS'Reddy EA'
p87956
asS'VI'
p87957
S'54'
p87958
sS'MHDA'
p87959
S'2010/08/11 06:00'
p87960
sS'OID'
p87961
(lp87962
S'NLM: NIHMS181145'
p87963
aS'NLM: PMC4185279'
p87964
asS'MH'
p87965
(lp87966
S'Adolescent'
p87967
aS'Anti-HIV Agents/*therapeutic use'
p87968
aS'Anti-Retroviral Agents/*therapeutic use'
p87969
aS'Antigens, CD4/blood'
p87970
aS'Benzoxazines/therapeutic use'
p87971
aS'CD4 Lymphocyte Count'
p87972
aS'Child'
p87973
aS'Child, Preschool'
p87974
aS'Cross-Sectional Studies'
p87975
aS'Female'
p87976
aS'Follow-Up Studies'
p87977
aS'HIV Infections/*drug therapy'
p87978
aS'HIV-1/genetics'
p87979
aS'Humans'
p87980
aS'Infant'
p87981
aS'Male'
p87982
aS'Nevirapine/therapeutic use'
p87983
aS'Predictive Value of Tests'
p87984
aS'RNA, Viral/blood'
p87985
aS'Recurrence'
p87986
aS'Severity of Illness Index'
p87987
aS'Tanzania'
p87988
aS'*Treatment Failure'
p87989
asS'EDAT'
p87990
S'2010/03/11 06:00'
p87991
sS'SO'
p87992
S'J Acquir Immune Defic Syndr. 2010 Aug;54(4):368-75. doi: 10.1097/QAI.0b013e3181cf4882.'
p87993
sS'SB'
p87994
S'IM X'
p87995
sS'PMID'
p87996
S'20216225'
p87997
sS'PST'
p87998
S'ppublish'
p87999
stRp88000
ag2
(g3
g4
(dp88001
S'LID'
p88002
S'10.1159/000292356 [doi]'
p88003
sS'STAT'
p88004
S'MEDLINE'
p88005
sS'DEP'
p88006
S'20100306'
p88007
sS'CI'
p88008
(lp88009
S'Copyright 2010 S. Karger AG, Basel.'
p88010
asS'DA'
p88011
S'20100319'
p88012
sS'AID'
p88013
(lp88014
S'000292356 [pii]'
p88015
aS'10.1159/000292356 [doi]'
p88016
asS'CRDT'
p88017
(lp88018
S'2010/03/11 06:00'
p88019
asS'DP'
p88020
S'2010'
p88021
sS'OWN'
p88022
S'NLM'
p88023
sS'PT'
p88024
(lp88025
S'Journal Article'
p88026
aS"Research Support, Non-U.S. Gov't"
p88027
aS"Research Support, U.S. Gov't, Non-P.H.S."
p88028
asS'LA'
p88029
(lp88030
S'eng'
p88031
asS'FAU'
p88032
(lp88033
S'Strother, R Matthew'
p88034
aS'Gregory, Kelly M'
p88035
aS'Pastakia, Sonak D'
p88036
aS'Were, Pamela'
p88037
aS'Tenge, Constance'
p88038
aS'Busakhala, Naftali'
p88039
aS'Jakait, Beatrice'
p88040
aS'Schellhase, Ellen M'
p88041
aS'Rosmarin, Alan G'
p88042
aS'Loehrer, Patrick J'
p88043
asS'JT'
p88044
S'Oncology'
p88045
sS'LR'
p88046
S'20131121'
p88047
sS'PG'
p88048
S'5-11'
p88049
sS'TI'
p88050
S"Retrospective analysis of the efficacy of gemcitabine for previously treated AIDS-associated Kaposi's sarcoma in western Kenya."
p88051
sS'RN'
p88052
(lp88053
S'0 (Antimetabolites, Antineoplastic)'
p88054
aS'0W860991D6 (Deoxycytidine)'
p88055
aS'11056-06-7 (Bleomycin)'
p88056
aS'5V9KLZ54CY (Vinblastine)'
p88057
aS'80168379AG (Doxorubicin)'
p88058
aS'B76N6SBZ8R (gemcitabine)'
p88059
aS'VBA protocol'
p88060
asS'PL'
p88061
S'Switzerland'
p88062
sS'TA'
p88063
S'Oncology'
p88064
sS'JID'
p88065
S'0135054'
p88066
sS'AB'
p88067
S"OBJECTIVES: Evaluation of outcomes in the use of single-agent gemcitabine for the treatment of AIDS-associated Kaposi's sarcoma (KS) in a western Kenyan cancer treatment program. METHODS: Retrospective chart review of all patients with KS treated with single agent gemcitabine following failure of first-line Adriamycin, bleomycin, and vincristine (ABV). Baseline demographics were collected, and clinicians' assessments of response were utilized to fill out objective criteria for both response as well as symptom benefit assessment. RESULTS: Twenty-three patients with KS who had previously failed first-line therapy with ABV were evaluated. Following treatment, 22 of the 23 patients responded positively to treatment with stable disease or better. Of the 18 patients who had completed therapy, with a median follow-up of 5 months, 12 patients had no documented progression. CONCLUSIONS: Treatment options in the resource-constrained setting are limited, both by financial constraints as well as the need to avoid myelotoxicity, which is associated with high morbidity in this treatment setting. This work shows that gemcitabine has promising activity in KS, with both objective responses and clinical benefit observed in this care setting. Gemcitabine as a single agent merits further investigation for AIDS-associated KS."
p88068
sS'AD'
p88069
S'Indiana University School of Medicine, IU Simon Cancer Center, 535 Barnhill Drive, Indianapolis, IN 46202, USA. rstrothe@gmail.com'
p88070
sS'IP'
p88071
S'1'
sS'IS'
p88072
S'1423-0232 (Electronic) 0030-2414 (Linking)'
p88073
sS'DCOM'
p88074
S'20100427'
p88075
sS'AU'
p88076
(lp88077
S'Strother RM'
p88078
aS'Gregory KM'
p88079
aS'Pastakia SD'
p88080
aS'Were P'
p88081
aS'Tenge C'
p88082
aS'Busakhala N'
p88083
aS'Jakait B'
p88084
aS'Schellhase EM'
p88085
aS'Rosmarin AG'
p88086
aS'Loehrer PJ'
p88087
asS'VI'
p88088
S'78'
p88089
sS'MHDA'
p88090
S'2010/04/28 06:00'
p88091
sS'PHST'
p88092
(lp88093
S'2009/11/09 [received]'
p88094
aS'2009/12/12 [accepted]'
p88095
aS'2010/03/06 [aheadofprint]'
p88096
asS'MH'
p88097
(lp88098
S'Acquired Immunodeficiency Syndrome/*complications'
p88099
aS'Adult'
p88100
aS'Antimetabolites, Antineoplastic/*therapeutic use'
p88101
aS'Antineoplastic Combined Chemotherapy Protocols/therapeutic use'
p88102
aS'Bleomycin/therapeutic use'
p88103
aS'Deoxycytidine/*analogs & derivatives/therapeutic use'
p88104
aS'Doxorubicin/therapeutic use'
p88105
aS'Female'
p88106
aS'Humans'
p88107
aS'Kenya'
p88108
aS'Male'
p88109
aS'Middle Aged'
p88110
aS'Neoplasm Recurrence, Local'
p88111
aS'Retrospective Studies'
p88112
aS'Sarcoma, Kaposi/*drug therapy/etiology'
p88113
aS'Treatment Failure'
p88114
aS'Treatment Outcome'
p88115
aS'Vinblastine/therapeutic use'
p88116
asS'EDAT'
p88117
S'2010/03/11 06:00'
p88118
sS'SO'
p88119
S'Oncology. 2010;78(1):5-11. doi: 10.1159/000292356. Epub 2010 Mar 6.'
p88120
sS'SB'
p88121
S'IM'
p88122
sS'PMID'
p88123
S'20215784'
p88124
sS'PST'
p88125
S'ppublish'
p88126
stRp88127
ag2
(g3
g4
(dp88128
S'LID'
p88129
S'10.1371/journal.pone.0009538 [doi]'
p88130
sS'STAT'
p88131
S'MEDLINE'
p88132
sS'DEP'
p88133
S'20100304'
p88134
sS'DA'
p88135
S'20100308'
p88136
sS'AID'
p88137
(lp88138
S'10.1371/journal.pone.0009538 [doi]'
p88139
asS'CRDT'
p88140
(lp88141
S'2010/03/09 06:00'
p88142
asS'DP'
p88143
S'2010'
p88144
sS'AD'
p88145
S'Division of General Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States of America. elosina@partners.org'
p88146
sS'OWN'
p88147
S'NLM'
p88148
sS'PT'
p88149
(lp88150
S'Journal Article'
p88151
aS'Multicenter Study'
p88152
aS'Research Support, N.I.H., Extramural'
p88153
aS"Research Support, Non-U.S. Gov't"
p88154
asS'LA'
p88155
(lp88156
S'eng'
p88157
asS'FAU'
p88158
(lp88159
S'Losina, Elena'
p88160
aS'Bassett, Ingrid V'
p88161
aS'Giddy, Janet'
p88162
aS'Chetty, Senica'
p88163
aS'Regan, Susan'
p88164
aS'Walensky, Rochelle P'
p88165
aS'Ross, Douglas'
p88166
aS'Scott, Callie A'
p88167
aS'Uhler, Lauren M'
p88168
aS'Katz, Jeffrey N'
p88169
aS'Holst, Helga'
p88170
aS'Freedberg, Kenneth A'
p88171
asS'JT'
p88172
S'PloS one'
p88173
sS'LR'
p88174
S'20141204'
p88175
sS'PG'
p88176
S'e9538'
p88177
sS'TI'
p88178
S'The "ART" of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa.'
p88179
sS'RN'
p88180
(lp88181
S'0 (Anti-Retroviral Agents)'
p88182
asS'PL'
p88183
S'United States'
p88184
sS'TA'
p88185
S'PLoS One'
p88186
sS'JID'
p88187
S'101285081'
p88188
sS'AB'
p88189
S'BACKGROUND: Although loss to follow-up after antiretroviral therapy (ART) initiation is increasingly recognized, little is known about pre-treatment losses to care (PTLC) after an initial positive HIV test. Our objective was to determine PTLC in newly identified HIV-infected individuals in South Africa. METHODOLOGY/PRINCIPAL FINDINGS: We assembled the South African Test, Identify and Link (STIAL) Cohort of persons presenting for HIV testing at two sites offering HIV and CD4 count testing and HIV care in Durban, South Africa. We defined PTLC as failure to have a CD4 count within 8 weeks of HIV diagnosis. We performed multivariate analysis to identify factors associated with PTLC. From November 2006 to May 2007, of 712 persons who underwent HIV testing and received their test result, 454 (64%) were HIV-positive. Of those, 206 (45%) had PTLC. Infected patients were significantly more likely to have PTLC if they lived > or = 10 kilometers from the testing center (RR = 1.37; 95% CI: 1.11-1.71), had a history of tuberculosis treatment (RR = 1.26; 95% CI: 1.00-1.58), or were referred for testing by a health care provider rather than self-referred (RR = 1.61; 95% CI: 1.22-2.13). Patients with one, two or three of these risks for PTLC were 1.88, 2.50 and 3.84 times more likely to have PTLC compared to those with no risk factors. CONCLUSIONS/SIGNIFICANCE: Nearly half of HIV-infected persons at two high prevalence sites in Durban, South Africa, failed to have CD4 counts following HIV diagnosis. These high rates of pre-treatment loss to care highlight the urgent need to improve rates of linkage to HIV care after an initial positive HIV test.'
p88190
sS'GR'
p88191
(lp88192
S'K23 AI068458/AI/NIAID NIH HHS/United States'
p88193
aS'K23 AI068458/AI/NIAID NIH HHS/United States'
p88194
aS'K24 AI062476/AI/NIAID NIH HHS/United States'
p88195
aS'K24 AI062476/AI/NIAID NIH HHS/United States'
p88196
aS'K24 AR 02123/AR/NIAMS NIH HHS/United States'
p88197
aS'K24 AR002123/AR/NIAMS NIH HHS/United States'
p88198
aS'P30 AI042851/AI/NIAID NIH HHS/United States'
p88199
aS'P30 AI060354/AI/NIAID NIH HHS/United States'
p88200
aS'R01 AI058736/AI/NIAID NIH HHS/United States'
p88201
aS'R01 AI058736/AI/NIAID NIH HHS/United States'
p88202
asS'IP'
p88203
S'3'
sS'IS'
p88204
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p88205
sS'PMC'
p88206
S'PMC2832018'
p88207
sS'DCOM'
p88208
S'20110111'
p88209
sS'AU'
p88210
(lp88211
S'Losina E'
p88212
aS'Bassett IV'
p88213
aS'Giddy J'
p88214
aS'Chetty S'
p88215
aS'Regan S'
p88216
aS'Walensky RP'
p88217
aS'Ross D'
p88218
aS'Scott CA'
p88219
aS'Uhler LM'
p88220
aS'Katz JN'
p88221
aS'Holst H'
p88222
aS'Freedberg KA'
p88223
asS'VI'
p88224
S'5'
sS'MHDA'
p88225
S'2011/01/12 06:00'
p88226
sS'PHST'
p88227
(lp88228
S'2009/09/03 [received]'
p88229
aS'2010/02/11 [accepted]'
p88230
aS'2010/03/04 [epublish]'
p88231
asS'OID'
p88232
(lp88233
S'NLM: PMC2832018'
p88234
asS'MH'
p88235
(lp88236
S'Adult'
p88237
aS'Anti-Retroviral Agents/*therapeutic use'
p88238
aS'Cohort Studies'
p88239
aS'Continuity of Patient Care'
p88240
aS'Demography/methods'
p88241
aS'Female'
p88242
aS'Geography'
p88243
aS'HIV Infections/epidemiology/*mortality/*therapy'
p88244
aS'HIV Seropositivity'
p88245
aS'Humans'
p88246
aS'Male'
p88247
aS'Middle Aged'
p88248
aS'Patient Acceptance of Health Care'
p88249
aS'Patient Compliance'
p88250
aS'Prospective Studies'
p88251
aS'South Africa'
p88252
aS'Time Factors'
p88253
aS'Treatment Outcome'
p88254
asS'EDAT'
p88255
S'2010/03/09 06:00'
p88256
sS'SO'
p88257
S'PLoS One. 2010 Mar 4;5(3):e9538. doi: 10.1371/journal.pone.0009538.'
p88258
sS'SB'
p88259
S'IM'
p88260
sS'PMID'
p88261
S'20209059'
p88262
sS'PST'
p88263
S'epublish'
p88264
stRp88265
ag2
(g3
g4
(dp88266
S'STAT'
p88267
S'MEDLINE'
p88268
sS'JT'
p88269
S'The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease'
p88270
sS'MID'
p88271
(lp88272
S'NIHMS254519'
p88273
asS'DA'
p88274
S'20100305'
p88275
sS'CRDT'
p88276
(lp88277
S'2010/03/06 06:00'
p88278
asS'DP'
p88279
S'2010 Apr'
p88280
sS'AD'
p88281
S'Divisions of General Internal Medicine and Infectious Diseases, Department of Medicine, Montefiore Medical Center & Albert Einstein College of Medicine, Bronx, New York 10467, USA. jcb26@columbia.edu'
p88282
sS'OWN'
p88283
S'NLM'
p88284
sS'PT'
p88285
(lp88286
S'Journal Article'
p88287
aS'Research Support, N.I.H., Extramural'
p88288
asS'LA'
p88289
(lp88290
S'eng'
p88291
asS'FAU'
p88292
(lp88293
S'Brust, J C M'
p88294
aS'Gandhi, N R'
p88295
aS'Carrara, H'
p88296
aS'Osburn, G'
p88297
aS'Padayatchi, N'
p88298
asS'LR'
p88299
S'20141204'
p88300
sS'PG'
p88301
S'413-9'
p88302
sS'TI'
p88303
S'High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003.'
p88304
sS'RN'
p88305
(lp88306
S'0 (Antitubercular Agents)'
p88307
asS'PL'
p88308
S'France'
p88309
sS'TA'
p88310
S'Int J Tuberc Lung Dis'
p88311
sS'JID'
p88312
S'9706389'
p88313
sS'AB'
p88314
S'SETTING: Multidrug-resistant tuberculosis (MDR-TB) has emerged as a significant public health threat in South Africa. OBJECTIVE: To describe treatment outcomes and determine risk factors associated with unfavorable outcomes among MDR-TB patients admitted to the provincial TB referral hospital in KwaZulu-Natal Province, South Africa. DESIGN: Retrospective observational study of MDR-TB patients admitted from 2000 to 2003. RESULTS: Of 1209 MDR-TB patients with documented treatment outcomes, 491 (41%) were cured, 35 (3%) completed treatment, 208 (17%) failed treatment, 223 (18%) died and 252 (21%) defaulted. Of the total number of patients with known human immunodeficiency virus (HIV) status, 52% were HIV-infected. Treatment failure, death and default each differed in their risk factors. Greater baseline resistance (aOR 2.3-3.0), prior TB (aOR 1.7), and diagnosis in 2001, 2002 or 2003 (aOR 1.9-2.3) were independent risk factors for treatment failure. HIV co-infection was a risk factor for death (aOR 5.6), and both HIV (aOR 2.0) and male sex (aOR 1.9) were risk factors for treatment default. CONCLUSION: MDR-TB treatment outcomes in KwaZulu-Natal were substantially worse than those published from other MDR-TB cohorts. Interventions such as concurrent antiretroviral therapy and decentralized MDR-TB treatment should be considered to improve MDR-TB outcomes in this high HIV prevalence setting.'
p88315
sS'GR'
p88316
(lp88317
S'AI51794/AI/NIAID NIH HHS/United States'
p88318
aS'U19 AI051794/AI/NIAID NIH HHS/United States'
p88319
aS'U19 AI051794-05/AI/NIAID NIH HHS/United States'
p88320
asS'IP'
p88321
S'4'
sS'IS'
p88322
S'1815-7920 (Electronic) 1027-3719 (Linking)'
p88323
sS'PMC'
p88324
S'PMC3005763'
p88325
sS'DCOM'
p88326
S'20100520'
p88327
sS'AU'
p88328
(lp88329
S'Brust JC'
p88330
aS'Gandhi NR'
p88331
aS'Carrara H'
p88332
aS'Osburn G'
p88333
aS'Padayatchi N'
p88334
asS'VI'
p88335
S'14'
p88336
sS'MHDA'
p88337
S'2010/05/21 06:00'
p88338
sS'OID'
p88339
(lp88340
S'NLM: NIHMS254519'
p88341
aS'NLM: PMC3005763'
p88342
asS'MH'
p88343
(lp88344
S'Adult'
p88345
aS'Antitubercular Agents/*therapeutic use'
p88346
aS'Chi-Square Distribution'
p88347
aS'*Developing Countries/statistics & numerical data'
p88348
aS'Female'
p88349
aS'HIV Infections/mortality'
p88350
aS'Humans'
p88351
aS'Logistic Models'
p88352
aS'Male'
p88353
aS'*Medication Adherence/statistics & numerical data'
p88354
aS'Middle Aged'
p88355
aS'Odds Ratio'
p88356
aS'Prevalence'
p88357
aS'Program Evaluation'
p88358
aS'Retrospective Studies'
p88359
aS'Risk Assessment'
p88360
aS'Risk Factors'
p88361
aS'Sex Factors'
p88362
aS'South Africa/epidemiology'
p88363
aS'Time Factors'
p88364
aS'Treatment Failure'
p88365
aS'Tuberculosis, Multidrug-Resistant/*drug therapy/mortality'
p88366
aS'Young Adult'
p88367
asS'EDAT'
p88368
S'2010/03/06 06:00'
p88369
sS'SO'
p88370
S'Int J Tuberc Lung Dis. 2010 Apr;14(4):413-9.'
p88371
sS'SB'
p88372
S'IM'
p88373
sS'PMID'
p88374
S'20202298'
p88375
sS'PST'
p88376
S'ppublish'
p88377
stRp88378
ag2
(g3
g4
(dp88379
S'LID'
p88380
S'10.1016/S1473-3099(09)70328-7 [doi]'
p88381
sS'STAT'
p88382
S'MEDLINE'
p88383
sS'JT'
p88384
S'The Lancet. Infectious diseases'
p88385
sS'CI'
p88386
(lp88387
S'2010 Elsevier Ltd. All rights reserved.'
p88388
asS'DA'
p88389
S'20100226'
p88390
sS'AID'
p88391
(lp88392
S'S1473-3099(09)70328-7 [pii]'
p88393
aS'10.1016/S1473-3099(09)70328-7 [doi]'
p88394
asS'CRDT'
p88395
(lp88396
S'2010/02/27 06:00'
p88397
asS'DP'
p88398
S'2010 Mar'
p88399
sS'OWN'
p88400
S'NLM'
p88401
sS'PT'
p88402
(lp88403
S'Journal Article'
p88404
aS'Review'
p88405
asS'LA'
p88406
(lp88407
S'eng'
p88408
asS'FAU'
p88409
(lp88410
S'Barth, Roos E'
p88411
aS'van der Loeff, Maarten F Schim'
p88412
aS'Schuurman, Rob'
p88413
aS'Hoepelman, Andy I M'
p88414
aS'Wensing, Annemarie M J'
p88415
asS'RF'
p88416
S'107'
p88417
sS'LR'
p88418
S'20140815'
p88419
sS'PG'
p88420
S'155-66'
p88421
sS'TI'
p88422
S'Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review.'
p88423
sS'RN'
p88424
(lp88425
S'0 (Anti-HIV Agents)'
p88426
aS'0 (Anti-Retroviral Agents)'
p88427
asS'PL'
p88428
S'United States'
p88429
sS'TA'
p88430
S'Lancet Infect Dis'
p88431
sS'JID'
p88432
S'101130150'
p88433
sS'AB'
p88434
S'Following large-scale roll-out of antiretroviral therapy in sub-Saharan Africa, the non-clinical efficacy of antiretroviral therapy has received little attention. We aimed to systematically review virological efficacy and drug-resistance outcomes of programmes of antiretroviral therapy in sub-Saharan Africa. 89 studies with heterogeneous design, definitions, and methods were identified. Overall, in on-treatment analysis, 10 351 (78%) of 13 288 patients showed virological suppression after 6 months of antiretroviral therapy, 7413 (76%) of 9794 after 12 months, and 3840 (67%) of 5690 after 24 months. Long-term virological data are scarce. Genotyping results were available for patients with virological failure (HIV-1 RNA greater than 1000 copies per mL). Most patients (839 of 849; 99%) were infected with a non-B HIV-1 subtype. However, drug-resistance patterns were largely similar to those in subtype B. Resistance profiles were associated with the antiretroviral drugs commonly used: the lamivudine-associated M184V mutation was most common, followed by K103N which is associated with non-nucleoside reverse transcriptase inhibitors. Thymidine-analogue mutations and the K65R mutation were less common. First-line antiretroviral therapy regimens used in sub-Saharan Africa are effective. Profiles of drug resistance suggest that a second-line treatment regimen based on protease inhibitors, with a backbone of nucleoside reverse transcriptase inhibitors, is a reasonable option for patients with HIV in sub-Saharan Africa who experience first-line treatment failure.'
p88435
sS'AD'
p88436
S'University Medical Centre Utrecht, Department of Internal Medicine and Infectious Diseases, Netherlands. r.e.barth@umcutrecht.nl'
p88437
sS'IP'
p88438
S'3'
sS'IS'
p88439
S'1474-4457 (Electronic) 1473-3099 (Linking)'
p88440
sS'DCOM'
p88441
S'20100323'
p88442
sS'AU'
p88443
(lp88444
S'Barth RE'
p88445
aS'van der Loeff MF'
p88446
aS'Schuurman R'
p88447
aS'Hoepelman AI'
p88448
aS'Wensing AM'
p88449
asS'VI'
p88450
S'10'
p88451
sS'MHDA'
p88452
S'2010/03/24 06:00'
p88453
sS'MH'
p88454
(lp88455
S'Acquired Immunodeficiency Syndrome/*drug therapy/epidemiology'
p88456
aS'Adult'
p88457
aS'Africa South of the Sahara/epidemiology'
p88458
aS'Anti-HIV Agents/therapeutic use'
p88459
aS'Anti-Retroviral Agents/*therapeutic use'
p88460
aS'Antiretroviral Therapy, Highly Active'
p88461
aS'Female'
p88462
aS'HIV Infections/*drug therapy/epidemiology'
p88463
aS'HIV-1/drug effects/pathogenicity'
p88464
aS'Humans'
p88465
aS'Male'
p88466
aS'Retroviridae Infections/*drug therapy/epidemiology'
p88467
aS'Viral Load'
p88468
asS'EDAT'
p88469
S'2010/02/27 06:00'
p88470
sS'SO'
p88471
S'Lancet Infect Dis. 2010 Mar;10(3):155-66. doi: 10.1016/S1473-3099(09)70328-7.'
p88472
sS'SB'
p88473
S'IM'
p88474
sS'PMID'
p88475
S'20185094'
p88476
sS'PST'
p88477
S'ppublish'
p88478
stRp88479
ag2
(g3
g4
(dp88480
S'LID'
p88481
S'10.1186/1758-2652-13-3 [doi]'
p88482
sS'STAT'
p88483
S'MEDLINE'
p88484
sS'DEP'
p88485
S'20100120'
p88486
sS'DA'
p88487
S'20100301'
p88488
sS'AID'
p88489
(lp88490
S'1758-2652-13-3 [pii]'
p88491
aS'10.1186/1758-2652-13-3 [doi]'
p88492
asS'CRDT'
p88493
(lp88494
S'2010/02/26 06:00'
p88495
asS'DP'
p88496
S'2010'
p88497
sS'AD'
p88498
S'University of Washington Department of Global Health, Harborview Medical Center, Seattle, 98104, USA. jamespf@u.washington.edu'
p88499
sS'OWN'
p88500
S'NLM'
p88501
sS'PT'
p88502
(lp88503
S'Journal Article'
p88504
aS"Research Support, Non-U.S. Gov't"
p88505
asS'LA'
p88506
(lp88507
S'eng'
p88508
asS'DCOM'
p88509
S'20101213'
p88510
sS'JT'
p88511
S'Journal of the International AIDS Society'
p88512
sS'LR'
p88513
S'20150329'
p88514
sS'FAU'
p88515
(lp88516
S'Pfeiffer, James'
p88517
aS'Montoya, Pablo'
p88518
aS'Baptista, Alberto J'
p88519
aS'Karagianis, Marina'
p88520
aS'Pugas, Marilia de Morais'
p88521
aS'Micek, Mark'
p88522
aS'Johnson, Wendy'
p88523
aS'Sherr, Kenneth'
p88524
aS'Gimbel, Sarah'
p88525
aS'Baird, Shelagh'
p88526
aS'Lambdin, Barrot'
p88527
aS'Gloyd, Stephen'
p88528
asS'TI'
p88529
S'Integration of HIV/AIDS services into African primary health care: lessons learned for health system strengthening in Mozambique - a case study.'
p88530
sS'RN'
p88531
(lp88532
S'0 (Anti-HIV Agents)'
p88533
asS'PL'
p88534
S'England'
p88535
sS'PG'
p88536
S'3'
sS'JID'
p88537
S'101478566'
p88538
sS'AB'
p88539
S'INTRODUCTION: In 2004, Mozambique, supported by large increases in international disease-specific funding, initiated a national rapid scale-up of antiretroviral treatment (ART) and HIV care through a vertical "Day Hospital" approach. Though this model showed substantial increases in people receiving treatment, it diverted scarce resources away from the primary health care (PHC) system. In 2005, the Ministry of Health (MOH) began an effort to use HIV/AIDS treatment and care resources as a means to strengthen their PHC system. The MOH worked closely with a number of NGOs to integrate HIV programs more effectively into existing public-sector PHC services. CASE DESCRIPTION: In 2005, the Ministry of Health and Health Alliance International initiated an effort in two provinces to integrate ART into the existing primary health care system through health units distributed across 23 districts. Integration included: a) placing ART services in existing units; b) retraining existing workers; c) strengthening laboratories, testing, and referral linkages; e) expanding testing in TB wards; f) integrating HIV and antenatal services; and g) improving district-level management. DISCUSSION: By 2008, treatment was available in nearly 67 health facilities in 23 districts. Nearly 30,000 adults were on ART. Over 80,000 enrolled in the HIV/AIDS program. Loss to follow-up from antenatal and TB testing to ART services has declined from 70% to less than 10% in many integrated sites. Average time from HIV testing to ART initiation is significantly faster and adherence to ART is better in smaller peripheral clinics than in vertical day hospitals. Integration has also improved other non-HIV aspects of primary health care. CONCLUSION: The integration approach enables the public sector PHC system to test more patients for HIV, place more patients on ART more quickly and efficiently, reduce loss-to-follow-up, and achieve greater geographic HIV care coverage compared to the vertical model. Through the integration process, HIV resources have been used to rehabilitate PHC infrastructure (including laboratories and pharmacies), strengthen supervision, fill workforce gaps, and improve patient flow between services and facilities in ways that can benefit all programs. Using aid resources to integrate and better link HIV care with existing services can strengthen wider PHC systems.'
p88540
sS'GR'
p88541
(lp88542
S'P30 AI027757/AI/NIAID NIH HHS/United States'
p88543
aS'T32 AI007140/AI/NIAID NIH HHS/United States'
p88544
asS'VI'
p88545
S'13'
p88546
sS'IS'
p88547
S'1758-2652 (Electronic) 1758-2652 (Linking)'
p88548
sS'PMC'
p88549
S'PMC2828398'
p88550
sS'AU'
p88551
(lp88552
S'Pfeiffer J'
p88553
aS'Montoya P'
p88554
aS'Baptista AJ'
p88555
aS'Karagianis M'
p88556
aS'Pugas Mde M'
p88557
aS'Micek M'
p88558
aS'Johnson W'
p88559
aS'Sherr K'
p88560
aS'Gimbel S'
p88561
aS'Baird S'
p88562
aS'Lambdin B'
p88563
aS'Gloyd S'
p88564
asS'MHDA'
p88565
S'2010/12/14 06:00'
p88566
sS'PHST'
p88567
(lp88568
S'2009/07/04 [received]'
p88569
aS'2010/01/20 [accepted]'
p88570
aS'2010/01/20 [aheadofprint]'
p88571
asS'OID'
p88572
(lp88573
S'NLM: PMC2828398'
p88574
asS'MH'
p88575
(lp88576
S'Acquired Immunodeficiency Syndrome/*drug therapy'
p88577
aS'Anti-HIV Agents/*therapeutic use'
p88578
aS'Delivery of Health Care'
p88579
aS'HIV Infections/*drug therapy'
p88580
aS'Humans'
p88581
aS'Mozambique'
p88582
aS'*Primary Health Care'
p88583
asS'EDAT'
p88584
S'2010/02/26 06:00'
p88585
sS'SO'
p88586
S'J Int AIDS Soc. 2010 Jan 20;13:3. doi: 10.1186/1758-2652-13-3.'
p88587
sS'SB'
p88588
S'IM X'
p88589
sS'PMID'
p88590
S'20180975'
p88591
sS'TA'
p88592
S'J Int AIDS Soc'
p88593
sS'PST'
p88594
S'epublish'
p88595
stRp88596
ag2
(g3
g4
(dp88597
S'LID'
p88598
S'10.1111/j.1365-3156.2010.02473.x [doi]'
p88599
sS'STAT'
p88600
S'MEDLINE'
p88601
sS'DEP'
p88602
S'20100217'
p88603
sS'MID'
p88604
(lp88605
S'NIHMS236472'
p88606
asS'DA'
p88607
S'20100422'
p88608
sS'AID'
p88609
(lp88610
S'TMI2473 [pii]'
p88611
aS'10.1111/j.1365-3156.2010.02473.x [doi]'
p88612
asS'CRDT'
p88613
(lp88614
S'2010/02/26 06:00'
p88615
asS'DP'
p88616
S'2010 Apr'
p88617
sS'AD'
p88618
S'Center for Global Health and Development, Boston University, MA, USA.'
p88619
sS'OWN'
p88620
S'NLM'
p88621
sS'PT'
p88622
(lp88623
S'Journal Article'
p88624
aS'Research Support, N.I.H., Extramural'
p88625
aS"Research Support, U.S. Gov't, Non-P.H.S."
p88626
asS'LA'
p88627
(lp88628
S'eng'
p88629
asS'FAU'
p88630
(lp88631
S'Fox, Matthew P'
p88632
aS'Brennan, Alana'
p88633
aS'Maskew, Mhairi'
p88634
aS'MacPhail, Patrick'
p88635
aS'Sanne, Ian'
p88636
asS'JT'
p88637
S'Tropical medicine & international health : TM & IH'
p88638
sS'LR'
p88639
S'20141204'
p88640
sS'PG'
p88641
S'405-13'
p88642
sS'TI'
p88643
S'Using vital registration data to update mortality among patients lost to follow-up from ART programmes: evidence from the Themba Lethu Clinic, South Africa.'
p88644
sS'RN'
p88645
(lp88646
S'0 (Anti-Retroviral Agents)'
p88647
asS'PL'
p88648
S'England'
p88649
sS'TA'
p88650
S'Trop Med Int Health'
p88651
sS'JID'
p88652
S'9610576'
p88653
sS'AB'
p88654
S"OBJECTIVE: To estimate the rates of mortality in patients lost to follow-up (LTFU) from a large urban public sector HIV clinic in South Africa. METHODS: We compared vital status using the clinic's database to vital status verified against the Vital Registration system at the South African Department of Home Affairs. We compared rates of mortality before and after updating mortality data. Predictors of mortality were estimated using Kaplan-Meier curves and proportional hazard regression. RESULTS: Of the 7097 total patients who initiated highly active antiretroviral therapy at Themba Lethu Clinic by October 1st, 2008 and had an ID number, 6205 were included. 2453 patients (21%) were LTFU, of whom 1037 (42.3%) could be included in the analysis. After matching to the vital registration system, mortality more than doubled from 4.2% (258/6205) to 10.9% (676/6205). Overall 37% of those LTFU died by life-table analysis the probability of survival amongst those LTFU was 69% (95% CI: 66-72%), 64% (95% CI: 61-67%) and 59% (95% CI: 55-62%) by years 1, 2 and 3 since being lost, respectively. Those at highest risk of death after being lost were patients with a history of tuberculosis, CD4 count < 100 cells/microl, BMI < 17.5, haemoglobin < 10 and on <6 months of treatment. CONCLUSION: Mortality was substantially underestimated among patients lost from a South African HIV treatment programme despite limited active tracing. Linking to vital registration systems can provide more accurate assessments of programme effectiveness and target lost patients most at risk for mortality."
p88655
sS'GR'
p88656
(lp88657
S'K01 AI083097/AI/NIAID NIH HHS/United States'
p88658
aS'K01 AI083097-03/AI/NIAID NIH HHS/United States'
p88659
aS'K01AI083097/AI/NIAID NIH HHS/United States'
p88660
asS'IP'
p88661
S'4'
sS'IS'
p88662
S'1365-3156 (Electronic) 1360-2276 (Linking)'
p88663
sS'PMC'
p88664
S'PMC2951133'
p88665
sS'DCOM'
p88666
S'20100610'
p88667
sS'AU'
p88668
(lp88669
S'Fox MP'
p88670
aS'Brennan A'
p88671
aS'Maskew M'
p88672
aS'MacPhail P'
p88673
aS'Sanne I'
p88674
asS'VI'
p88675
S'15'
p88676
sS'MHDA'
p88677
S'2010/06/11 06:00'
p88678
sS'PHST'
p88679
(lp88680
S'2010/02/17 [aheadofprint]'
p88681
asS'OID'
p88682
(lp88683
S'NLM: NIHMS236472'
p88684
aS'NLM: PMC2951133'
p88685
asS'MH'
p88686
(lp88687
S'Adult'
p88688
aS'Anti-Retroviral Agents/*therapeutic use'
p88689
aS'Cohort Studies'
p88690
aS'Data Collection/*methods'
p88691
aS'Female'
p88692
aS'HIV Infections/drug therapy/*mortality'
p88693
aS'Humans'
p88694
aS'Kaplan-Meier Estimate'
p88695
aS'Male'
p88696
aS'Patient Dropouts/statistics & numerical data'
p88697
aS'Proportional Hazards Models'
p88698
aS'*Registries'
p88699
aS'Risk Factors'
p88700
aS'South Africa/epidemiology'
p88701
aS'Urban Population'
p88702
asS'EDAT'
p88703
S'2010/02/26 06:00'
p88704
sS'SO'
p88705
S'Trop Med Int Health. 2010 Apr;15(4):405-13. doi: 10.1111/j.1365-3156.2010.02473.x. Epub 2010 Feb 17.'
p88706
sS'SB'
p88707
S'IM'
p88708
sS'PMID'
p88709
S'20180931'
p88710
sS'PST'
p88711
S'ppublish'
p88712
stRp88713
ag2
(g3
g4
(dp88714
S'LID'
p88715
S'10.1371/journal.pone.0009183 [doi]'
p88716
sS'STAT'
p88717
S'MEDLINE'
p88718
sS'DEP'
p88719
S'20100217'
p88720
sS'DA'
p88721
S'20100222'
p88722
sS'AID'
p88723
(lp88724
S'10.1371/journal.pone.0009183 [doi]'
p88725
asS'CRDT'
p88726
(lp88727
S'2010/02/23 06:00'
p88728
asS'DP'
p88729
S'2010'
p88730
sS'OWN'
p88731
S'NLM'
p88732
sS'PT'
p88733
(lp88734
S'Journal Article'
p88735
asS'LA'
p88736
(lp88737
S'eng'
p88738
asS'FAU'
p88739
(lp88740
S'Chu, Kathryn M'
p88741
aS'Boulle, Andrew M'
p88742
aS'Ford, Nathan'
p88743
aS'Goemaere, Eric'
p88744
aS'Asselman, Valerie'
p88745
aS'Van Cutsem, Gilles'
p88746
asS'JT'
p88747
S'PloS one'
p88748
sS'LR'
p88749
S'20141204'
p88750
sS'PG'
p88751
S'e9183'
p88752
sS'TI'
p88753
S'Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in South Africa.'
p88754
sS'RN'
p88755
(lp88756
S'0 (Reverse Transcriptase Inhibitors)'
p88757
aS'99DK7FVK1H (Nevirapine)'
p88758
aS'EC 2.6.1.2 (Alanine Transaminase)'
p88759
asS'PL'
p88760
S'United States'
p88761
sS'TA'
p88762
S'PLoS One'
p88763
sS'JID'
p88764
S'101285081'
p88765
sS'AB'
p88766
S'BACKGROUND: The majority of antiretroviral treatment programmes in sub-Saharan Africa are scaling up antiretroviral treatment using a fixed dose first-line antiretroviral regimen containing stavudine, lamivudine, and nevirapine. One of the primary concerns with the use of this regimen is nevirapine-associated hepatotoxicity. METHODOLOGY/PRINCIPAL FINDINGS: Study participants were 1809 HIV-infected, antiretroviral naive adults initiating nevirapine-based antiretroviral therapy between November 2002 and December 2006. The primary outcome was early hepatotoxicity. Secondary outcomes were associations with hepatotoxicity and mortality at six months. The cumulative proportion of early hepatotoxicity ranged from 1.0-2.0% giving an incidence-rate at 102 days of 3.6-7.6 per 100 person-years. Median time to hepatotoxicity was 32 (IQR 28-58) days. At 12 weeks, only 8% of patients had alanine aminotransferase monitoring at all the time-points recommended by national guidelines. No association was found between age, gender, baseline CD4 count, concurrent tuberculosis infection, prior participation in a prevention of mother-to-child-transmission program, or baseline weight and early hepatotoxicity. There was no association between early hepatotoxicity and mortality. CONCLUSIONS: The cumulative proportion of early hepatotoxicity in nevirapine based antiretroviral therapy was low in this resource-constrained setting. Hepatotoxicity was not associated with mortality. Frequent routine monitoring of alanine aminotransferase proved difficult to implement in this public sector primary care programme. Focused monitoring in the first month may be a more cost-effective and pragmatic option in settings with limited resources. Correlation with clinical signs and symptoms may allow future alanine aminotransferase testing to be dictated by clinical criteria.'
p88767
sS'AD'
p88768
S'South African Medical Unit, Medecins Sans Frontieres, Johannesburg, South Africa. kathryn.chu@joburg.msf.org'
p88769
sS'IP'
p88770
S'2'
sS'IS'
p88771
S'1932-6203 (Electronic) 1932-6203 (Linking)'
p88772
sS'PMC'
p88773
S'PMC2822855'
p88774
sS'DCOM'
p88775
S'20100930'
p88776
sS'AU'
p88777
(lp88778
S'Chu KM'
p88779
aS'Boulle AM'
p88780
aS'Ford N'
p88781
aS'Goemaere E'
p88782
aS'Asselman V'
p88783
aS'Van Cutsem G'
p88784
asS'VI'
p88785
S'5'
sS'MHDA'
p88786
S'2010/10/01 06:00'
p88787
sS'PHST'
p88788
(lp88789
S'2009/07/28 [received]'
p88790
aS'2010/01/18 [accepted]'
p88791
aS'2010/02/17 [epublish]'
p88792
asS'OID'
p88793
(lp88794
S'NLM: PMC2822855'
p88795
asS'MH'
p88796
(lp88797
S'Adult'
p88798
aS'Alanine Transaminase/blood'
p88799
aS'Antiretroviral Therapy, Highly Active/adverse effects'
p88800
aS'CD4 Lymphocyte Count'
p88801
aS'Drug-Induced Liver Injury/blood/*etiology/mortality'
p88802
aS'Female'
p88803
aS'Follow-Up Studies'
p88804
aS'HIV Infections/*drug therapy'
p88805
aS'Humans'
p88806
aS'Incidence'
p88807
aS'Liver/*drug effects/pathology'
p88808
aS'Male'
p88809
aS'Multivariate Analysis'
p88810
aS'Nevirapine/*adverse effects/therapeutic use'
p88811
aS'Primary Health Care/methods'
p88812
aS'Reverse Transcriptase Inhibitors/adverse effects/therapeutic use'
p88813
aS'Risk Factors'
p88814
aS'South Africa/epidemiology'
p88815
aS'Survival Rate'
p88816
aS'Time Factors'
p88817
asS'EDAT'
p88818
S'2010/02/23 06:00'
p88819
sS'SO'
p88820
S'PLoS One. 2010 Feb 17;5(2):e9183. doi: 10.1371/journal.pone.0009183.'
p88821
sS'SB'
p88822
S'IM'
p88823
sS'PMID'
p88824
S'20174653'
p88825
sS'PST'
p88826
S'epublish'
p88827
stRp88828
ag2
(g3
g4
(dp88829
S'LID'
p88830
S'10.1371/journal.pmed.1000233 [doi]'
p88831
sS'STAT'
p88832
S'MEDLINE'
p88833
sS'DEP'
p88834
S'20100216'
p88835
sS'DA'
p88836
S'20100219'
p88837
sS'AID'
p88838
(lp88839
S'10.1371/journal.pmed.1000233 [doi]'
p88840
asS'CRDT'
p88841
(lp88842
S'2010/02/20 06:00'
p88843
asS'DP'
p88844
S'2010 Feb'
p88845
sS'AD'
p88846
S'University of Alabama at Birmingham Centre for Infectious Disease Research in Zambia, Lusaka, Zambia. stringer@cidrz.org'
p88847
sS'OWN'
p88848
S'NLM'
p88849
sS'PT'
p88850
(lp88851
S'Journal Article'
p88852
aS"Research Support, U.S. Gov't, P.H.S."
p88853
asS'LA'
p88854
(lp88855
S'eng'
p88856
asS'FAU'
p88857
(lp88858
S'Stringer, Jeffrey S A'
p88859
aS'McConnell, Michelle S'
p88860
aS'Kiarie, James'
p88861
aS'Bolu, Omotayo'
p88862
aS'Anekthananon, Thanomsak'
p88863
aS'Jariyasethpong, Tavatchai'
p88864
aS'Potter, Dara'
p88865
aS'Mutsotso, Winnie'
p88866
aS'Borkowf, Craig B'
p88867
aS'Mbori-Ngacha, Dorothy'
p88868
aS'Muiruri, Peter'
p88869
aS"Ong'ech, John Odero"
p88870
aS'Zulu, Isaac'
p88871
aS'Njobvu, Lungowe'
p88872
aS'Jetsawang, Bongkoch'
p88873
aS'Pathak, Sonal'
p88874
aS'Bulterys, Marc'
p88875
aS'Shaffer, Nathan'
p88876
aS'Weidle, Paul J'
p88877
asS'JT'
p88878
S'PLoS medicine'
p88879
sS'LR'
p88880
S'20141204'
p88881
sS'PG'
p88882
S'e1000233'
p88883
sS'TI'
p88884
S'Effectiveness of non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: a multi-country, prospective cohort study.'
p88885
sS'RN'
p88886
(lp88887
S'0 (Reverse Transcriptase Inhibitors)'
p88888
aS'99DK7FVK1H (Nevirapine)'
p88889
asS'PL'
p88890
S'United States'
p88891
sS'TA'
p88892
S'PLoS Med'
p88893
sS'JID'
p88894
S'101231360'
p88895
sS'AB'
p88896
S'BACKGROUND: Intrapartum and neonatal single-dose nevirapine (NVP) reduces the risk of mother-to-child HIV transmission but also induces viral resistance to non-nucleoside reverse transcriptase inhibitor (NNRTI) drugs. This drug resistance largely fades over time. We hypothesized that women with a prior single-dose NVP exposure would have no more than a 10% higher cumulative prevalence of failure of their NNRTI-containing antiretroviral therapy (ART) over the first 48 wk of therapy than would women without a prior exposure. METHODS AND FINDINGS: We enrolled 355 NVP-exposed and 523 NVP-unexposed women at two sites in Zambia, one site in Kenya, and two sites in Thailand into a prospective, non-inferiority cohort study and followed them for 48 wk on ART. Those who died, discontinued NNRTI-containing ART, or had a plasma viral load >or=400 copies/ml at either the 24 wk or 48 wk study visits and confirmed on repeat testing were characterized as having failed therapy. Overall, 114 of 355 NVP-exposed women (32.1%) and 132 of 523 NVP-unexposed women (25.2%) met criteria for treatment failure. The difference in failure rates between the exposure groups was 6.9% (95% confidence interval [CI] 0.8%-13.0%). The failure rates of women stratified by our predefined exposure interval categories were as follows: 47 of 116 women in whom less than 6 mo elapsed between exposure and starting ART failed therapy (40%; p<0.001 compared to unexposed women); 25 of 67 women in whom 7-12 mo elapsed between exposure and starting ART failed therapy (37%; p = 0.04 compared to unexposed women); and 42 of 172 women in whom more than 12 mo elapsed between exposure and starting ART failed therapy (24%; p = 0.82 compared to unexposed women). Locally weighted regression analysis also indicated a clear inverse relationship between virologic failure and the exposure interval. CONCLUSIONS: Prior exposure to single-dose NVP was associated with an increased risk of treatment failure; however, this risk seems largely confined to women with a more recent exposure. Women requiring ART within 12 mo of NVP exposure should not be prescribed an NNRTI-containing regimen as first-line therapy.'
p88897
sS'GR'
p88898
(lp88899
S'U62/CCU024526/PHS HHS/United States'
p88900
aS'U62/CCU12354/PHS HHS/United States'
p88901
asS'IP'
p88902
S'2'
sS'IS'
p88903
S'1549-1676 (Electronic) 1549-1277 (Linking)'
p88904
sS'PMC'
p88905
S'PMC2821896'
p88906
sS'DCOM'
p88907
S'20100507'
p88908
sS'AU'
p88909
(lp88910
S'Stringer JS'
p88911
aS'McConnell MS'
p88912
aS'Kiarie J'
p88913
aS'Bolu O'
p88914
aS'Anekthananon T'
p88915
aS'Jariyasethpong T'
p88916
aS'Potter D'
p88917
aS'Mutsotso W'
p88918
aS'Borkowf CB'
p88919
aS'Mbori-Ngacha D'
p88920
aS'Muiruri P'
p88921
aS"Ong'ech JO"
p88922
aS'Zulu I'
p88923
aS'Njobvu L'
p88924
aS'Jetsawang B'
p88925
aS'Pathak S'
p88926
aS'Bulterys M'
p88927
aS'Shaffer N'
p88928
aS'Weidle PJ'
p88929
asS'VI'
p88930
S'7'
sS'MHDA'
p88931
S'2010/05/08 06:00'
p88932
sS'PHST'
p88933
(lp88934
S'2009/10/08 [received]'
p88935
aS'2010/01/14 [accepted]'
p88936
aS'2010/02/16 [epublish]'
p88937
asS'OID'
p88938
(lp88939
S'NLM: PMC2821896'
p88940
asS'MH'
p88941
(lp88942
S'Adult'
p88943
aS'Cohort Studies'
p88944
aS'Female'
p88945
aS'HIV Infections/*drug therapy'
p88946
aS'Humans'
p88947
aS'Infectious Disease Transmission, Vertical/*prevention & control'
p88948
aS'Kenya'
p88949
aS'Nevirapine/*therapeutic use'
p88950
aS'Pregnancy'
p88951
aS'Prospective Studies'
p88952
aS'Reverse Transcriptase Inhibitors/*therapeutic use'
p88953
aS'Thailand'
p88954
aS'Treatment Outcome'
p88955
aS'Zambia'
p88956
asS'EDAT'
p88957
S'2010/02/20 06:00'
p88958
sS'SO'
p88959
S'PLoS Med. 2010 Feb 16;7(2):e1000233. doi: 10.1371/journal.pmed.1000233.'
p88960
sS'SB'
p88961
S'IM'
p88962
sS'PMID'
p88963
S'20169113'
p88964
sS'PST'
p88965
S'epublish'
p88966
stRp88967
ag2
(g3
g4
(dp88968
S'LID'
p88969
S'10.1016/S1473-3099(09)70321-4 [doi]'
p88970
sS'STAT'
p88971
S'MEDLINE'
p88972
sS'JT'
p88973
S'The Lancet. Infectious diseases'
p88974
sS'CI'
p88975
(lp88976
S'2010 Elsevier Ltd. All rights reserved.'
p88977
asS'DA'
p88978
S'20100204'
p88979
sS'AID'
p88980
(lp88981
S'S1473-3099(09)70321-4 [pii]'
p88982
aS'10.1016/S1473-3099(09)70321-4 [doi]'
p88983
asS'CRDT'
p88984
(lp88985
S'2010/02/05 06:00'
p88986
asS'DP'
p88987
S'2010 Jan'
p88988
sS'OWN'
p88989
S'NLM'
p88990
sS'PT'
p88991
(lp88992
S'Journal Article'
p88993
asS'LA'
p88994
(lp88995
S'eng'
p88996
asS'FAU'
p88997
(lp88998
S'Harries, Anthony D'
p88999
aS'Zachariah, Rony'
p89000
aS'van Oosterhout, Joep J'
p89001
aS'Reid, Steven D'
p89002
aS'Hosseinipour, Mina C'
p89003
aS'Arendt, Vic'
p89004
aS'Chirwa, Zengani'
p89005
aS'Jahn, Andreas'
p89006
aS'Schouten, Erik J'
p89007
aS'Kamoto, Kelita'
p89008
asS'LR'
p89009
S'20140815'
p89010
sS'PG'
p89011
S'60-5'
p89012
sS'TI'
p89013
S'Diagnosis and management of antiretroviral-therapy failure in resource-limited settings in sub-Saharan Africa: challenges and perspectives.'
p89014
sS'RN'
p89015
(lp89016
S'0 (Anti-HIV Agents)'
p89017
aS'0 (RNA, Viral)'
p89018
asS'PL'
p89019
S'United States'
p89020
sS'TA'
p89021
S'Lancet Infect Dis'
p89022
sS'JID'
p89023
S'101130150'
p89024
sS'AB'
p89025
S'Despite the enormous progress made in scaling up antiretroviral therapy (ART) in sub-Saharan Africa, many challenges remain, not least of which are the identification and management of patients who have failed first-line therapy. Less than 3% of patients are receiving second-line treatment at present, whereas 15-25% of patients have detectable viral loads 12 months or more into treatment, of whom a substantial proportion might have virological failure. We discuss the reasons why virological ART failure is likely to be under-diagnosed in the routine health system, and address the current difficulties with standard recommended second-line ART regimens. The development of new diagnostic tools for ART failure, in particular a point-of-care HIV viral-load test, combined with simple and inexpensive second-line therapy, such as boosted protease-inhibitor monotherapy, could revolutionise the management of ART failure in resource-limited settings.'
p89026
sS'AD'
p89027
S'International Union against Tuberculosis and Lung Disease, Paris, France. adharries@theunion.org'
p89028
sS'IP'
p89029
S'1'
sS'IS'
p89030
S'1474-4457 (Electronic) 1473-3099 (Linking)'
p89031
sS'DCOM'
p89032
S'20100302'
p89033
sS'AU'
p89034
(lp89035
S'Harries AD'
p89036
aS'Zachariah R'
p89037
aS'van Oosterhout JJ'
p89038
aS'Reid SD'
p89039
aS'Hosseinipour MC'
p89040
aS'Arendt V'
p89041
aS'Chirwa Z'
p89042
aS'Jahn A'
p89043
aS'Schouten EJ'
p89044
aS'Kamoto K'
p89045
asS'VI'
p89046
S'10'
p89047
sS'MHDA'
p89048
S'2010/03/03 06:00'
p89049
sS'MH'
p89050
(lp89051
S'Africa South of the Sahara/epidemiology'
p89052
aS'Anti-HIV Agents/*administration & dosage/economics/*therapeutic use'
p89053
aS'HIV Infections/*economics/epidemiology/*therapy'
p89054
aS'Health Care Costs'
p89055
aS'Humans'
p89056
aS'RNA, Viral'
p89057
aS'Treatment Failure'
p89058
aS'Viral Load'
p89059
asS'EDAT'
p89060
S'2010/02/05 06:00'
p89061
sS'SO'
p89062
S'Lancet Infect Dis. 2010 Jan;10(1):60-5. doi: 10.1016/S1473-3099(09)70321-4.'
p89063
sS'SB'
p89064
S'IM'
p89065
sS'PMID'
p89066
S'20129150'
p89067
sS'PST'
p89068
S'ppublish'
p89069
stRp89070
ag2
(g3
g4
(dp89071
S'LID'
p89072
S'10.1097/01.aids.0000366083.75945.07 [doi]'
p89073
sS'STAT'
p89074
S'MEDLINE'
p89075
sS'JT'
p89076
S'AIDS (London, England)'
p89077
sS'MID'
p89078
(lp89079
S'NIHMS359022'
p89080
asS'DA'
p89081
S'20091221'
p89082
sS'AID'
p89083
(lp89084
S'10.1097/01.aids.0000366083.75945.07 [doi]'
p89085
aS'00002030-201001001-00007 [pii]'
p89086
asS'CRDT'
p89087
(lp89088
S'2009/12/22 06:00'
p89089
asS'DP'
p89090
S'2010 Jan'
p89091
sS'AD'
p89092
S'Department of Global Health, University of Washington, Seattle, Washington, USA. ksherr@u.washington.edu'
p89093
sS'OWN'
p89094
S'NLM'
p89095
sS'PT'
p89096
(lp89097
S'Journal Article'
p89098
aS'Multicenter Study'
p89099
aS"Research Support, Non-U.S. Gov't"
p89100
asS'LA'
p89101
(lp89102
S'eng'
p89103
asS'DCOM'
p89104
S'20110506'
p89105
sS'LR'
p89106
S'20151119'
p89107
sS'FAU'
p89108
(lp89109
S'Sherr, Kenneth H'
p89110
aS'Micek, Mark A'
p89111
aS'Gimbel, Sarah O'
p89112
aS'Gloyd, Stephen S'
p89113
aS'Hughes, James P'
p89114
aS'John-Stewart, Grace C'
p89115
aS'Manjate, Rosa M'
p89116
aS'Pfeiffer, James'
p89117
aS'Weiss, Noel S'
p89118
asS'TI'
p89119
S'Quality of HIV care provided by non-physician clinicians and physicians in Mozambique: a retrospective cohort study.'
p89120
sS'PL'
p89121
S'England'
p89122
sS'PG'
p89123
S'S59-66'
p89124
sS'JID'
p89125
S'8710219'
p89126
sS'AB'
p89127
S'OBJECTIVES: To compare HIV care quality provided by non-physician clinicians (NPC) and physicians. DESIGN: Retrospective cohort study assessing the relationship between provider cadre and HIV care quality among non-pregnant adult patients initiating antiretroviral therapy (ART) in the national HIV care programme. METHODS: Computerized medical records from patients initiating ART between July 2004 and October 2007 at two HIV public HIV clinics in central Mozambique were used to develop multivariate analyses evaluating differences in process and care continuity measures for patients whose initial provider was a NPC or physician. RESULTS: A total of 5892 patients was included in the study, including 4093 (69.5%) with NPC and 1799 (30.5%) with physicians as initial providers. Those whose initial provider was a NPC were more likely to have a CD4 cell count 90-210 days [risk ratio (RR) 1.13, 1.04<RR<1.23] and 330-390 days (RR 1.12, 0.96<RR<1.31) after initiating ART. A large majority of patients adhered well to care, although patients whose initial provider was a NPC had more frequent clinical visits in the first year post-ART initiation (RR 1.02, 1.00<RR<1.05) and higher levels of adherence to antiretroviral medicines in the first 6 months after initiating ART (RR1.05, 1.02<RR<1.09). Patients of NPC were less likely to be lost to follow-up than those seen by physicians (RR 0.86, 0.73<RR<1.02). CONCLUSION: NPC performance was similar to or better than that of physicians for the HIV care quality study measures. Our results highlight the important role of NPC in scaling up ART in Mozambique, and argue for using all relevant clinical resources to meet the large demands for care in countries with high HIV burdens.'
p89128
sS'GR'
p89129
(lp89130
S'K24 HD054314/HD/NICHD NIH HHS/United States'
p89131
aS'K24 HD054314-02/HD/NICHD NIH HHS/United States'
p89132
aS'P30 AI027757/AI/NIAID NIH HHS/United States'
p89133
aS'P30 AI027757-13/AI/NIAID NIH HHS/United States'
p89134
aS'T32 AI007140/AI/NIAID NIH HHS/United States'
p89135
asS'VI'
p89136
S'24 Suppl 1'
p89137
sS'IS'
p89138
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p89139
sS'PMC'
p89140
S'PMC3372417'
p89141
sS'AU'
p89142
(lp89143
S'Sherr KH'
p89144
aS'Micek MA'
p89145
aS'Gimbel SO'
p89146
aS'Gloyd SS'
p89147
aS'Hughes JP'
p89148
aS'John-Stewart GC'
p89149
aS'Manjate RM'
p89150
aS'Pfeiffer J'
p89151
aS'Weiss NS'
p89152
asS'MHDA'
p89153
S'2011/05/07 06:00'
p89154
sS'OID'
p89155
(lp89156
S'NLM: NIHMS359022'
p89157
aS'NLM: PMC3372417'
p89158
asS'MH'
p89159
(lp89160
S'Adult'
p89161
aS'Antiretroviral Therapy, Highly Active'
p89162
aS'CD4 Lymphocyte Count'
p89163
aS'Female'
p89164
aS'HIV Infections/epidemiology/*therapy'
p89165
aS'Humans'
p89166
aS'Male'
p89167
aS'Mozambique/epidemiology'
p89168
aS'Physician Assistants/*standards'
p89169
aS'Physicians/*standards'
p89170
aS"Practice Patterns, Physicians'"
p89171
aS'Quality of Health Care/*standards'
p89172
aS'Retrospective Studies'
p89173
asS'EDAT'
p89174
S'2010/01/20 06:00'
p89175
sS'SO'
p89176
S'AIDS. 2010 Jan;24 Suppl 1:S59-66. doi: 10.1097/01.aids.0000366083.75945.07.'
p89177
sS'SB'
p89178
S'IM X'
p89179
sS'PMID'
p89180
S'20023441'
p89181
sS'TA'
p89182
S'AIDS'
p89183
sS'PST'
p89184
S'ppublish'
p89185
stRp89186
ag2
(g3
g4
(dp89187
S'LID'
p89188
S'10.1097/QAD.0b013e3283360976 [doi]'
p89189
sS'STAT'
p89190
S'MEDLINE'
p89191
sS'AB'
p89192
S'OBJECTIVE: The present article estimates the cost and outcomes of second-line antiretroviral therapy. The cost of second-line drugs is generally higher than that of first-line drugs and it is expected that the absolute number of patients on second-line antiretroviral therapy will increase over time. This information is crucial for planning and budgeting. METHODS: Resource utilization and outcome data were extracted for patients who initiated standard second-line therapy. Resource usage was measured from second-line initiation for 12 months and outcomes were determined at 12 months. Unit costs were applied to resource usage using standard costing techniques. Costs were classified into drug, laboratory, visit, and fixed costs. Outcomes at 12 months were determined using attendance status, diagnostic results, and treatment status. Average cost per patient and average cost per outcome were reported. RESULTS: Of the 293 participants in the study cohort, 58% remained in care and responding, 15% were in care but not responding, and 26% were no longer in care. During the 12 months following second-line initiation, the average cost per participant was $1037. Most of the cost per patient was attributable to drugs (71%), 13% to laboratory tests, 10% to clinic and pharmacy visits, and 6% to infrastructure and other fixed costs. Second-line therapy was 2.4 times more expensive per year in care than first-line therapy. CONCLUSION: The gradual increase in second-line numbers that can be expected as treatment programs mature may cause a meaningful increase in the overall average cost per patient treated.'
p89193
sS'JID'
p89194
S'8710219'
p89195
sS'AD'
p89196
S'Health Economics and Epidemiology Research Office, Wits Health Consortium, University of the Witwatersrand, Johannesburg, South Africa. llong@heroza.org'
p89197
sS'JT'
p89198
S'AIDS (London, England)'
p89199
sS'IP'
p89200
S'6'
sS'IS'
p89201
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p89202
sS'DCOM'
p89203
S'20110325'
p89204
sS'DA'
p89205
S'20100317'
p89206
sS'AU'
p89207
(lp89208
S'Long L'
p89209
aS'Fox M'
p89210
aS'Sanne I'
p89211
aS'Rosen S'
p89212
asS'AID'
p89213
(lp89214
S'10.1097/QAD.0b013e3283360976 [doi]'
p89215
asS'CRDT'
p89216
(lp89217
S'2010/01/01 06:00'
p89218
asS'VI'
p89219
S'24'
p89220
sS'DP'
p89221
S'2010 Mar 27'
p89222
sS'MHDA'
p89223
S'2011/03/26 06:00'
p89224
sS'OWN'
p89225
S'NLM'
p89226
sS'PT'
p89227
(lp89228
S'Journal Article'
p89229
aS"Research Support, U.S. Gov't, Non-P.H.S."
p89230
asS'LA'
p89231
(lp89232
S'eng'
p89233
asS'MH'
p89234
(lp89235
S'Antiretroviral Therapy, Highly Active/*economics'
p89236
aS'CD4 Lymphocyte Count/*economics'
p89237
aS'Cost-Benefit Analysis'
p89238
aS'HIV Infections/drug therapy/*economics'
p89239
aS'*HIV-1'
p89240
aS'Health Services/*economics'
p89241
aS'Humans'
p89242
aS'South Africa/epidemiology'
p89243
asS'FAU'
p89244
(lp89245
S'Long, Lawrence'
p89246
aS'Fox, Matthew'
p89247
aS'Sanne, Ian'
p89248
aS'Rosen, Sydney'
p89249
asS'EDAT'
p89250
S'2010/01/01 06:00'
p89251
sS'PST'
p89252
S'ppublish'
p89253
sS'SO'
p89254
S'AIDS. 2010 Mar 27;24(6):915-9. doi: 10.1097/QAD.0b013e3283360976.'
p89255
sS'PG'
p89256
S'915-9'
p89257
sS'TI'
p89258
S'The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa.'
p89259
sS'SB'
p89260
S'IM X'
p89261
sS'PMID'
p89262
S'20042849'
p89263
sS'PL'
p89264
S'England'
p89265
sS'TA'
p89266
S'AIDS'
p89267
stRp89268
ag2
(g3
g4
(dp89269
S'LID'
p89270
S'10.2190/IQ.31.1.b [doi]'
p89271
sS'STAT'
p89272
S'MEDLINE'
p89273
sS'AB'
p89274
S'Studies of factors influencing tuberculosis (TB) care-seeking and treatment adherence in high TB/HIV co-burden African countries have typically surveyed urban patients\' sociodemographic characteristics. To understand community perceptions and guide rapid assessment interviews, we interviewed key informants (nurses, tribal leaders, n = 9) and local researchers (n = 3) in poor, rural areas of South Africa. HIV-related stigma and misperceptions about TB causes and symptoms were cited as barriers. Key informants said older people preferred traditional healers; local researchers heard a preference for "western" care and suggested supporting clinic staff travel to remote villages with health education and diagnostic services. Key informants said not understanding the consequences of incomplete treatment and reluctance to relinquish disability grants decreased adherence. All reported that nonfamily DOTS supporters provided invaluable support. Rapid assessment should include drop-outs, re-treated, and co-infected patients and ask questions examining origins of misperceptions, stigma of testing, and pre-test messages to improve community perceptions about TB care-seeking and treatment adherence.'
p89275
sS'JID'
p89276
S'8010942'
p89277
sS'AD'
p89278
S'School of Public Health, University of Texas, Houston, USA. rfinnie@asu.edu'
p89279
sS'JT'
p89280
S'International quarterly of community health education'
p89281
sS'IP'
p89282
S'1'
sS'IS'
p89283
S'0272-684X (Print) 0272-684X (Linking)'
p89284
sS'DCOM'
p89285
S'20110804'
p89286
sS'DA'
p89287
S'20110517'
p89288
sS'AU'
p89289
(lp89290
S'Finnie RK'
p89291
aS'Mabunda T'
p89292
aS'Khoza LB'
p89293
aS'van den Borne B'
p89294
aS'Selwyn B'
p89295
aS'Mullen PD'
p89296
asS'AID'
p89297
(lp89298
S'A8321Q7818702727 [pii]'
p89299
aS'10.2190/IQ.31.1.b [doi]'
p89300
asS'CRDT'
p89301
(lp89302
S'2011/05/18 06:00'
p89303
asS'VI'
p89304
S'31'
p89305
sS'DP'
p89306
S'2010-2011'
p89307
sS'MHDA'
p89308
S'2011/08/05 06:00'
p89309
sS'OWN'
p89310
S'NLM'
p89311
sS'PT'
p89312
(lp89313
S'Journal Article'
p89314
asS'LA'
p89315
(lp89316
S'eng'
p89317
asS'MH'
p89318
(lp89319
S'Adolescent'
p89320
aS'Adult'
p89321
aS'Aged'
p89322
aS'Comorbidity'
p89323
aS'Female'
p89324
aS'HIV Infections/epidemiology/*psychology/therapy'
p89325
aS'*Health Knowledge, Attitudes, Practice'
p89326
aS'Health Services Research/methods'
p89327
aS'Humans'
p89328
aS'Interviews as Topic'
p89329
aS'Male'
p89330
aS'Middle Aged'
p89331
aS'Patient Acceptance of Health Care/*psychology'
p89332
aS'Pilot Projects'
p89333
aS'Rural Health'
p89334
aS'Social Stigma'
p89335
aS'South Africa'
p89336
aS'Tuberculosis/epidemiology/*psychology/therapy'
p89337
aS'Young Adult'
p89338
asS'FAU'
p89339
(lp89340
S'Finnie, Ramona K C'
p89341
aS'Mabunda, Tiyane'
p89342
aS'Khoza, Lunic Base'
p89343
aS'van den Borne, Bart'
p89344
aS'Selwyn, Beatrice'
p89345
aS'Mullen, Patricia Dolan'
p89346
asS'EDAT'
p89347
S'2010/01/01 00:00'
p89348
sS'PST'
p89349
S'ppublish'
p89350
sS'SO'
p89351
S'Int Q Community Health Educ. 2010-2011;31(1):3-19. doi: 10.2190/IQ.31.1.b.'
p89352
sS'PG'
p89353
S'3-19'
p89354
sS'TI'
p89355
S'Pilot study to develop a rapid assessment of tuberculosis care-seeking and adherence practices in rural Limpopo Province, South Africa.'
p89356
sS'SB'
p89357
S'IM'
p89358
sS'PMID'
p89359
S'21576064'
p89360
sS'PL'
p89361
S'United States'
p89362
sS'TA'
p89363
S'Int Q Community Health Educ'
p89364
stRp89365
ag2
(g3
g4
(dp89366
S'LID'
p89367
S'10.1016/j.healthpol.2009.11.021 [doi]'
p89368
sS'STAT'
p89369
S'MEDLINE'
p89370
sS'JT'
p89371
S'Health policy (Amsterdam, Netherlands)'
p89372
sS'CI'
p89373
(lp89374
S'Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.'
p89375
asS'DA'
p89376
S'20100407'
p89377
sS'AID'
p89378
(lp89379
S'S0168-8510(09)00306-6 [pii]'
p89380
aS'10.1016/j.healthpol.2009.11.021 [doi]'
p89381
asS'CRDT'
p89382
(lp89383
S'2009/12/22 06:00'
p89384
asS'DP'
p89385
S'2010 May'
p89386
sS'OWN'
p89387
S'NLM'
p89388
sS'PT'
p89389
(lp89390
S'Journal Article'
p89391
aS"Research Support, Non-U.S. Gov't"
p89392
asS'LA'
p89393
(lp89394
S'eng'
p89395
asS'FAU'
p89396
(lp89397
S'Lubega, Muhamadi'
p89398
aS'Nsabagasani, Xavier'
p89399
aS'Tumwesigye, Nazarius M'
p89400
aS'Wabwire-Mangen, Fred'
p89401
aS'Ekstrom, Anna Mia'
p89402
aS'Pariyo, George'
p89403
aS'Peterson, Stefan'
p89404
asS'LR'
p89405
S'20151119'
p89406
sS'PG'
p89407
S'153-8'
p89408
sS'TI'
p89409
S'Policy and practice, lost in transition: Reasons for high drop-out from pre-antiretroviral care in a resource-poor setting of eastern Uganda.'
p89410
sS'RN'
p89411
(lp89412
S'0 (Anti-HIV Agents)'
p89413
asS'PL'
p89414
S'Ireland'
p89415
sS'TA'
p89416
S'Health Policy'
p89417
sS'JID'
p89418
S'8409431'
p89419
sS'AB'
p89420
S'OBJECTIVE: This study explores reasons for drop-out from pre-ARV care in a resource-poor setting where premature death is a common consequence of delayed ARV initiation. METHODS: In Iganga, Uganda, we conducted key informant interviews with staff at the pre-ARV clinic, focus group discussions with persons who looked after people living with HIV (PLWH) and in-depth interviews with PLWH half of whom had dropped out of pre-ARV care. Content data analysis was done to identify recurrent themes. RESULTS: Reasons cited for dropping out of pre-ARV care include: inadequate post-test counseling due to staff work overload, competition from the holistic and less stigmatizing traditional/spiritual healers. Others were transportation costs, long waiting time lack of incentives to seek pre-ARV care by healthy looking PLWH and gender inequalities. CONCLUSIONS: Pre-ARV adherence counseling should be improved through recruitment of counselors or multi-skilling in counseling skills for the available staff to reduce on the work load. Traditional/ spiritual healers should be integrated and supervised to offer pre-ARV care. Door step supply of cotrimoxazole using agents could reduce transport costs, waiting time and increase access to pre-ARV. Women should be sensitized on comprehensive HIV care through the local media and local leaders to address gender inequalities.'
p89421
sS'AD'
p89422
S'District Health Office, Iganga District Administration, PO Box 358, Iganga, Uganda. dlmuhamadi@yahoo.co.uk'
p89423
sS'IP'
p89424
S'2-3'
p89425
sS'IS'
p89426
S'1872-6054 (Electronic) 0168-8510 (Linking)'
p89427
sS'DCOM'
p89428
S'20100706'
p89429
sS'AU'
p89430
(lp89431
S'Lubega M'
p89432
aS'Nsabagasani X'
p89433
aS'Tumwesigye NM'
p89434
aS'Wabwire-Mangen F'
p89435
aS'Ekstrom AM'
p89436
aS'Pariyo G'
p89437
aS'Peterson S'
p89438
asS'VI'
p89439
S'95'
p89440
sS'MHDA'
p89441
S'2010/07/07 06:00'
p89442
sS'PHST'
p89443
(lp89444
S'2009/08/01 [received]'
p89445
aS'2009/11/14 [revised]'
p89446
aS'2009/11/22 [accepted]'
p89447
asS'MH'
p89448
(lp89449
S'Adult'
p89450
aS'Aged'
p89451
aS'Anti-HIV Agents/*therapeutic use'
p89452
aS'*Attitude of Health Personnel'
p89453
aS'Counseling'
p89454
aS'Female'
p89455
aS'Focus Groups'
p89456
aS'HIV Infections/drug therapy/epidemiology/*psychology'
p89457
aS'Health Resources'
p89458
aS'Humans'
p89459
aS'Integrative Medicine'
p89460
aS'Male'
p89461
aS'Medication Adherence/*psychology/statistics & numerical data'
p89462
aS'Medicine, African Traditional'
p89463
aS'Middle Aged'
p89464
aS'*Motivation'
p89465
aS'Patient Dropouts/education/*psychology/statistics & numerical data'
p89466
aS'Qualitative Research'
p89467
aS'Stereotyping'
p89468
aS'Surveys and Questionnaires'
p89469
aS'Transportation'
p89470
aS'Uganda/epidemiology'
p89471
aS"Women's Rights"
p89472
aS'Workload'
p89473
asS'EDAT'
p89474
S'2009/12/22 06:00'
p89475
sS'SO'
p89476
S'Health Policy. 2010 May;95(2-3):153-8. doi: 10.1016/j.healthpol.2009.11.021.'
p89477
sS'SB'
p89478
S'H'
sS'PMID'
p89479
S'20022131'
p89480
sS'PST'
p89481
S'ppublish'
p89482
stRp89483
ag2
(g3
g4
(dp89484
S'LID'
p89485
S'10.1016/S0140-6736(09)62067-5 [doi]'
p89486
sS'STAT'
p89487
S'MEDLINE'
p89488
sS'DEP'
p89489
S'20091208'
p89490
sS'CI'
p89491
(lp89492
S'Copyright 2010 Elsevier Ltd. All rights reserved.'
p89493
asS'DA'
p89494
S'20100129'
p89495
sS'AID'
p89496
(lp89497
S'S0140-6736(09)62067-5 [pii]'
p89498
aS'10.1016/S0140-6736(09)62067-5 [doi]'
p89499
asS'CRDT'
p89500
(lp89501
S'2009/12/17 06:00'
p89502
asS'DP'
p89503
S'2010 Jan 9'
p89504
sS'GR'
p89505
(lp89506
S'G0600344/Medical Research Council/United Kingdom'
p89507
aS'MC_U122886352/Medical Research Council/United Kingdom'
p89508
aS'MC_U950080931/Medical Research Council/United Kingdom'
p89509
aS'Medical Research Council/United Kingdom'
p89510
asS'OWN'
p89511
S'NLM'
p89512
sS'PT'
p89513
(lp89514
S'Journal Article'
p89515
aS'Multicenter Study'
p89516
aS'Randomized Controlled Trial'
p89517
aS"Research Support, Non-U.S. Gov't"
p89518
asS'LA'
p89519
(lp89520
S'eng'
p89521
asS'FAU'
p89522
(lp89523
S'Mugyenyi, P'
p89524
aS'Walker, A S'
p89525
aS'Hakim, J'
p89526
aS'Munderi, P'
p89527
aS'Gibb, D M'
p89528
aS'Kityo, C'
p89529
aS'Reid, A'
p89530
aS'Grosskurth, H'
p89531
aS'Darbyshire, J H'
p89532
aS'Ssali, F'
p89533
aS'Bray, D'
p89534
aS'Katabira, E'
p89535
aS'Babiker, A G'
p89536
aS'Gilks, C F'
p89537
aS'Grosskurth, H'
p89538
aS'Munderi, P'
p89539
aS'Kabuye, G'
p89540
aS'Nsibambi, D'
p89541
aS'Kasirye, R'
p89542
aS'Zalwango, E'
p89543
aS'Nakazibwe, M'
p89544
aS'Kikaire, B'
p89545
aS'Nassuna, G'
p89546
aS'Massa, R'
p89547
aS'Fadhiru, K'
p89548
aS'Namyalo, M'
p89549
aS'Zalwango, A'
p89550
aS'Generous, L'
p89551
aS'Khauka, P'
p89552
aS'Rutikarayo, N'
p89553
aS'Nakahima, W'
p89554
aS'Mugisha, A'
p89555
aS'Todd, J'
p89556
aS'Levin, J'
p89557
aS'Muyingo, S'
p89558
aS'Ruberantwari, A'
p89559
aS'Kaleebu, P'
p89560
aS'Yirrell, D'
p89561
aS'Ndembi, N'
p89562
aS'Lyagoba, F'
p89563
aS'Hughes, P'
p89564
aS'Aber, M'
p89565
aS'Lara, A Medina'
p89566
aS'Foster, S'
p89567
aS'Amurwon, J'
p89568
aS'Wakholi, B Nyanzi'
p89569
aS'Whitworth, J'
p89570
aS'Wangati, K'
p89571
aS'Amuron, B'
p89572
aS'Kajungu, D'
p89573
aS'Nakiyingi, J'
p89574
aS'Omony, W'
p89575
aS'Fadhiru, K'
p89576
aS'Nsibambi, D'
p89577
aS'Khauka, P'
p89578
aS'Mugyenyi, P'
p89579
aS'Kityo, C'
p89580
aS'Ssali, F'
p89581
aS'Tumukunde, D'
p89582
aS'Otim, T'
p89583
aS'Kabanda, J'
p89584
aS'Musana, H'
p89585
aS'Akao, J'
p89586
aS'Kyomugisha, H'
p89587
aS'Byamukama, A'
p89588
aS'Sabiiti, J'
p89589
aS'Komugyena, J'
p89590
aS'Wavamunno, P'
p89591
aS'Mukiibi, S'
p89592
aS'Drasiku, A'
p89593
aS'Byaruhanga, R'
p89594
aS'Labeja, O'
p89595
aS'Katundu, P'
p89596
aS'Tugume, S'
p89597
aS'Awio, P'
p89598
aS'Namazzi, A'
p89599
aS'Bakeinyaga, G T'
p89600
aS'Katabira, H'
p89601
aS'Abaine, D'
p89602
aS'Tukamushaba, J'
p89603
aS'Anywar, W'
p89604
aS'Ojiambo, W'
p89605
aS'Angweng, E'
p89606
aS'Murungi, S'
p89607
aS'Haguma, W'
p89608
aS'Atwiine, S'
p89609
aS'Kigozi, J'
p89610
aS'Namale, L'
p89611
aS'Mukose, A'
p89612
aS'Mulindwa, G'
p89613
aS'Atwiine, D'
p89614
aS'Muhwezi, A'
p89615
aS'Nimwesiga, E'
p89616
aS'Barungi, G'
p89617
aS'Takubwa, J'
p89618
aS'Murungi, S'
p89619
aS'Mwebesa, D'
p89620
aS'Kagina, G'
p89621
aS'Mulindwa, M'
p89622
aS'Ahimbisibwe, F'
p89623
aS'Mwesigwa, P'
p89624
aS'Akuma, S'
p89625
aS'Zawedde, C'
p89626
aS'Nyiraguhirwa, D'
p89627
aS'Tumusiime, C'
p89628
aS'Bagaya, L'
p89629
aS'Namara, W'
p89630
aS'Kigozi, J'
p89631
aS'Karungi, J'
p89632
aS'Kankunda, R'
p89633
aS'Enzama, R'
p89634
aS'Latif, A'
p89635
aS'Hakim, J'
p89636
aS'Robertson, V'
p89637
aS'Reid, A'
p89638
aS'Chidziva, E'
p89639
aS'Bulaya-Tembo, R'
p89640
aS'Musoro, G'
p89641
aS'Taziwa, F'
p89642
aS'Chimbetete, C'
p89643
aS'Chakonza, L'
p89644
aS'Mawora, A'
p89645
aS'Muvirimi, C'
p89646
aS'Tinago, G'
p89647
aS'Svovanapasis, P'
p89648
aS'Simango, M'
p89649
aS'Chirema, O'
p89650
aS'Machingura, J'
p89651
aS'Mutsai, S'
p89652
aS'Phiri, M'
p89653
aS'Bafana, T'
p89654
aS'Chirara, M'
p89655
aS'Muchabaiwa, L'
p89656
aS'Muzambi, M'
p89657
aS'Mutowo, J'
p89658
aS'Chivhunga, T'
p89659
aS'Chigwedere, E'
p89660
aS'Pascoe, M'
p89661
aS'Warambwa, C'
p89662
aS'Zengeza, E'
p89663
aS'Mapinge, F'
p89664
aS'Makota, S'
p89665
aS'Jamu, A'
p89666
aS'Ngorima, N'
p89667
aS'Chirairo, H'
p89668
aS'Chitsungo, S'
p89669
aS'Chimanzi, J'
p89670
aS'Maweni, C'
p89671
aS'Warara, R'
p89672
aS'Matongo, M'
p89673
aS'Mudzingwa, S'
p89674
aS'Jangano, M'
p89675
aS'Moyo, K'
p89676
aS'Vere, L'
p89677
aS'Mdege, N'
p89678
aS'Machingura, I'
p89679
aS'Katabira, E'
p89680
aS'Ronald, A'
p89681
aS'Kambungu, A'
p89682
aS'Lutwama, F'
p89683
aS'Mambule, I'
p89684
aS'Nanfuka, A'
p89685
aS'Walusimbi, J'
p89686
aS'Nabankema, E'
p89687
aS'Nalumenya, R'
p89688
aS'Namuli, T'
p89689
aS'Kulume, R'
p89690
aS'Namata, I'
p89691
aS'Nyachwo, L'
p89692
aS'Florence, A'
p89693
aS'Kusiima, A'
p89694
aS'Lubwama, E'
p89695
aS'Nairuba, R'
p89696
aS'Oketta, F'
p89697
aS'Buluma, E'
p89698
aS'Waita, R'
p89699
aS'Ojiambo, H'
p89700
aS'Sadik, F'
p89701
aS'Wanyama, J'
p89702
aS'Nabongo, P'
p89703
aS'Oyugi, J'
p89704
aS'Sematala, F'
p89705
aS'Muganzi, A'
p89706
aS'Twijukye, C'
p89707
aS'Byakwaga, H'
p89708
aS'Ochai, R'
p89709
aS'Muhweezi, D'
p89710
aS'Coutinho, A'
p89711
aS'Etukoit, B'
p89712
aS'Gilks, C'
p89713
aS'Boocock, K'
p89714
aS'Puddephatt, C'
p89715
aS'Grundy, C'
p89716
aS'Bohannon, J'
p89717
aS'Winogron, D'
p89718
aS'Gibb, D M'
p89719
aS'Burke, A'
p89720
aS'Bray, D'
p89721
aS'Babiker, A'
p89722
aS'Walker, A S'
p89723
aS'Wilkes, H'
p89724
aS'Rauchenberger, M'
p89725
aS'Sheehan, S'
p89726
aS'Spencer-Drake, C'
p89727
aS'Taylor, K'
p89728
aS'Spyer, M'
p89729
aS'Ferrier, A'
p89730
aS'Naidoo, B'
p89731
aS'Dunn, D'
p89732
aS'Goodall, R'
p89733
aS'Darbyshire, J H'
p89734
aS'Peto, L'
p89735
aS'Nanfuka, R'
p89736
aS'Mufuka-Kapuya, C'
p89737
aS'Kaleebu, P'
p89738
aS'Pillay, D'
p89739
aS'Robertson, V'
p89740
aS'Yirrell, D'
p89741
aS'Tugume, S'
p89742
aS'Chirara, M'
p89743
aS'Katundu, P'
p89744
aS'Ndembi, N'
p89745
aS'Lyagoba, F'
p89746
aS'Dunn, D'
p89747
aS'Goodall, R'
p89748
aS'McCormick, A'
p89749
aS'Lara, A Medina'
p89750
aS'Foster, S'
p89751
aS'Amurwon, J'
p89752
aS'Wakholi, B Nyanzi'
p89753
aS'Kigozi, J'
p89754
aS'Muchabaiwa, L'
p89755
aS'Muzambi, M'
p89756
aS'Weller, I'
p89757
aS'Babiker, A'
p89758
aS'Bahendeka, S'
p89759
aS'Bassett, M'
p89760
aS'Wapakhabulo, A Chogo'
p89761
aS'Darbyshire, J H'
p89762
aS'Gazzard, B'
p89763
aS'Gilks, C'
p89764
aS'Grosskurth, H'
p89765
aS'Hakim, J'
p89766
aS'Latif, A'
p89767
aS'Mapuchere, C'
p89768
aS'Mugurungi, O'
p89769
aS'Mugyenyi, P'
p89770
aS'Burke, C'
p89771
aS'Jones, S'
p89772
aS'Newland, C'
p89773
aS'Pearce, G'
p89774
aS'Rahim, S'
p89775
aS'Rooney, J'
p89776
aS'Smith, M'
p89777
aS'Snowden, W'
p89778
aS'Steens, J-M'
p89779
aS'Breckenridge, A'
p89780
aS'McLaren, A'
p89781
aS'Hill, C'
p89782
aS'Matenga, J'
p89783
aS'Pozniak, A'
p89784
aS'Serwadda, D'
p89785
aS'Peto, T'
p89786
aS'Palfreeman, A'
p89787
aS'Borok, M'
p89788
aS'Katabira, E'
p89789
asS'JT'
p89790
S'Lancet (London, England)'
p89791
sS'LR'
p89792
S'20151119'
p89793
sS'PG'
p89794
S'123-31'
p89795
sS'TI'
p89796
S'Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.'
p89797
sS'RN'
p89798
(lp89799
S'0 (Anti-Retroviral Agents)'
p89800
aS'0 (Dideoxynucleosides)'
p89801
aS'0 (Hemoglobins)'
p89802
aS'0 (Organophosphonates)'
p89803
aS'0 (RNA, Viral)'
p89804
aS'2T8Q726O95 (Lamivudine)'
p89805
aS'4B9XT59T7S (Zidovudine)'
p89806
aS'8W8T17847W (Urea)'
p89807
aS'99DK7FVK1H (Nevirapine)'
p89808
aS'99YXE507IL (Tenofovir)'
p89809
aS'AYI8EX34EU (Creatinine)'
p89810
aS'JAC85A2161 (Adenine)'
p89811
aS'WR2TIP26VS (abacavir)'
p89812
asS'PL'
p89813
S'England'
p89814
sS'TA'
p89815
S'Lancet'
p89816
sS'FIR'
p89817
(lp89818
S'Gilks, C F'
p89819
aS'Mugyenyi, P'
p89820
aS'Hakim, J'
p89821
aS'Reid, A'
p89822
aS'Bray, D'
p89823
aS'Darbyshire, J H'
p89824
aS'Gibb, D M'
p89825
aS'Babiker, A G'
p89826
aS'Mugyenyi, P'
p89827
aS'Grosskurth, H'
p89828
aS'Katabira, E'
p89829
aS'Kityo, C'
p89830
aS'Munderi, P'
p89831
aS'Ssali, F'
p89832
aS'Hakim, J'
p89833
aS'Reid, A'
p89834
aS'Gibb, D M'
p89835
aS'Gilks, C F'
p89836
aS'Babiker, A G'
p89837
aS'Walker, A S'
p89838
asS'JID'
p89839
S'2985213R'
p89840
sS'AB'
p89841
S"BACKGROUND: HIV antiretroviral therapy (ART) is often managed without routine laboratory monitoring in Africa; however, the effect of this approach is unknown. This trial investigated whether routine toxicity and efficacy monitoring of HIV-infected patients receiving ART had an important long-term effect on clinical outcomes in Africa. METHODS: In this open, non-inferiority trial in three centres in Uganda and one in Zimbabwe, 3321 symptomatic, ART-naive, HIV-infected adults with CD4 counts less than 200 cells per microL starting ART were randomly assigned to laboratory and clinical monitoring (LCM; n=1659) or clinically driven monitoring (CDM; n=1662) by a computer-generated list. Haematology, biochemistry, and CD4-cell counts were done every 12 weeks. In the LCM group, results were available to clinicians; in the CDM group, results (apart from CD4-cell count) could be requested if clinically indicated and grade 4 toxicities were available. Participants switched to second-line ART after new or recurrent WHO stage 4 events in both groups, or CD4 count less than 100 cells per microL (LCM only). Co-primary endpoints were new WHO stage 4 HIV events or death, and serious adverse events. Non-inferiority was defined as the upper 95% confidence limit for the hazard ratio (HR) for new WHO stage 4 events or death being no greater than 1.18. Analyses were by intention to treat. This study is registered, number ISRCTN13968779. FINDINGS: Two participants assigned to CDM and three to LCM were excluded from analyses. 5-year survival was 87% (95% CI 85-88) in the CDM group and 90% (88-91) in the LCM group, and 122 (7%) and 112 (7%) participants, respectively, were lost to follow-up over median 4.9 years' follow-up. 459 (28%) participants receiving CDM versus 356 (21%) LCM had a new WHO stage 4 event or died (6.94 [95% CI 6.33-7.60] vs 5.24 [4.72-5.81] per 100 person-years; absolute difference 1.70 per 100 person-years [0.87-2.54]; HR 1.31 [1.14-1.51]; p=0.0001). Differences in disease progression occurred from the third year on ART, whereas higher rates of switch to second-line treatment occurred in LCM from the second year. 283 (17%) participants receiving CDM versus 260 (16%) LCM had a new serious adverse event (HR 1.12 [0.94-1.32]; p=0.19), with anaemia the most common (76 vs 61 cases). INTERPRETATION: ART can be delivered safely without routine laboratory monitoring for toxic effects, but differences in disease progression suggest a role for monitoring of CD4-cell count from the second year of ART to guide the switch to second-line treatment. FUNDING: UK Medical Research Council, the UK Department for International Development, the Rockefeller Foundation, GlaxoSmithKline, Gilead Sciences, Boehringer-Ingelheim, and Abbott Laboratories."
p89842
sS'CN'
p89843
(lp89844
S'DART Trial Team'
p89845
asS'IP'
p89846
S'9709'
p89847
sS'IS'
p89848
S'1474-547X (Electronic) 0140-6736 (Linking)'
p89849
sS'IR'
p89850
(lp89851
S'Gilks CF'
p89852
aS'Mugyenyi P'
p89853
aS'Hakim J'
p89854
aS'Reid A'
p89855
aS'Bray D'
p89856
aS'Darbyshire JH'
p89857
aS'Gibb DM'
p89858
aS'Babiker AG'
p89859
aS'Mugyenyi P'
p89860
aS'Grosskurth H'
p89861
aS'Katabira E'
p89862
aS'Kityo C'
p89863
aS'Munderi P'
p89864
aS'Ssali F'
p89865
aS'Hakim J'
p89866
aS'Reid A'
p89867
aS'Gibb DM'
p89868
aS'Gilks CF'
p89869
aS'Babiker AG'
p89870
aS'Walker AS'
p89871
asS'DCOM'
p89872
S'20100304'
p89873
sS'CIN'
p89874
(lp89875
S'Lancet. 2010 Jan 9;375(9709):96-8. PMID: 20004465'
p89876
aS'Lancet. 2010 Feb 20;375(9715):622-3. PMID: 20171386'
p89877
aS'Lancet. 2010 Mar 20;375(9719):979; author reply 979-80. PMID: 20304235'
p89878
aS'Lancet. 2010 Mar 20;375(9719):979. PMID: 20304233'
p89879
asS'AU'
p89880
(lp89881
S'Mugyenyi P'
p89882
aS'Walker AS'
p89883
aS'Hakim J'
p89884
aS'Munderi P'
p89885
aS'Gibb DM'
p89886
aS'Kityo C'
p89887
aS'Reid A'
p89888
aS'Grosskurth H'
p89889
aS'Darbyshire JH'
p89890
aS'Ssali F'
p89891
aS'Bray D'
p89892
aS'Katabira E'
p89893
aS'Babiker AG'
p89894
aS'Gilks CF'
p89895
aS'Grosskurth H'
p89896
aS'Munderi P'
p89897
aS'Kabuye G'
p89898
aS'Nsibambi D'
p89899
aS'Kasirye R'
p89900
aS'Zalwango E'
p89901
aS'Nakazibwe M'
p89902
aS'Kikaire B'
p89903
aS'Nassuna G'
p89904
aS'Massa R'
p89905
aS'Fadhiru K'
p89906
aS'Namyalo M'
p89907
aS'Zalwango A'
p89908
aS'Generous L'
p89909
aS'Khauka P'
p89910
aS'Rutikarayo N'
p89911
aS'Nakahima W'
p89912
aS'Mugisha A'
p89913
aS'Todd J'
p89914
aS'Levin J'
p89915
aS'Muyingo S'
p89916
aS'Ruberantwari A'
p89917
aS'Kaleebu P'
p89918
aS'Yirrell D'
p89919
aS'Ndembi N'
p89920
aS'Lyagoba F'
p89921
aS'Hughes P'
p89922
aS'Aber M'
p89923
aS'Lara AM'
p89924
aS'Foster S'
p89925
aS'Amurwon J'
p89926
aS'Wakholi BN'
p89927
aS'Whitworth J'
p89928
aS'Wangati K'
p89929
aS'Amuron B'
p89930
aS'Kajungu D'
p89931
aS'Nakiyingi J'
p89932
aS'Omony W'
p89933
aS'Fadhiru K'
p89934
aS'Nsibambi D'
p89935
aS'Khauka P'
p89936
aS'Mugyenyi P'
p89937
aS'Kityo C'
p89938
aS'Ssali F'
p89939
aS'Tumukunde D'
p89940
aS'Otim T'
p89941
aS'Kabanda J'
p89942
aS'Musana H'
p89943
aS'Akao J'
p89944
aS'Kyomugisha H'
p89945
aS'Byamukama A'
p89946
aS'Sabiiti J'
p89947
aS'Komugyena J'
p89948
aS'Wavamunno P'
p89949
aS'Mukiibi S'
p89950
aS'Drasiku A'
p89951
aS'Byaruhanga R'
p89952
aS'Labeja O'
p89953
aS'Katundu P'
p89954
aS'Tugume S'
p89955
aS'Awio P'
p89956
aS'Namazzi A'
p89957
aS'Bakeinyaga GT'
p89958
aS'Katabira H'
p89959
aS'Abaine D'
p89960
aS'Tukamushaba J'
p89961
aS'Anywar W'
p89962
aS'Ojiambo W'
p89963
aS'Angweng E'
p89964
aS'Murungi S'
p89965
aS'Haguma W'
p89966
aS'Atwiine S'
p89967
aS'Kigozi J'
p89968
aS'Namale L'
p89969
aS'Mukose A'
p89970
aS'Mulindwa G'
p89971
aS'Atwiine D'
p89972
aS'Muhwezi A'
p89973
aS'Nimwesiga E'
p89974
aS'Barungi G'
p89975
aS'Takubwa J'
p89976
aS'Murungi S'
p89977
aS'Mwebesa D'
p89978
aS'Kagina G'
p89979
aS'Mulindwa M'
p89980
aS'Ahimbisibwe F'
p89981
aS'Mwesigwa P'
p89982
aS'Akuma S'
p89983
aS'Zawedde C'
p89984
aS'Nyiraguhirwa D'
p89985
aS'Tumusiime C'
p89986
aS'Bagaya L'
p89987
aS'Namara W'
p89988
aS'Kigozi J'
p89989
aS'Karungi J'
p89990
aS'Kankunda R'
p89991
aS'Enzama R'
p89992
aS'Latif A'
p89993
aS'Hakim J'
p89994
aS'Robertson V'
p89995
aS'Reid A'
p89996
aS'Chidziva E'
p89997
aS'Bulaya-Tembo R'
p89998
aS'Musoro G'
p89999
aS'Taziwa F'
p90000
aS'Chimbetete C'
p90001
aS'Chakonza L'
p90002
aS'Mawora A'
p90003
aS'Muvirimi C'
p90004
aS'Tinago G'
p90005
aS'Svovanapasis P'
p90006
aS'Simango M'
p90007
aS'Chirema O'
p90008
aS'Machingura J'
p90009
aS'Mutsai S'
p90010
aS'Phiri M'
p90011
aS'Bafana T'
p90012
aS'Chirara M'
p90013
aS'Muchabaiwa L'
p90014
aS'Muzambi M'
p90015
aS'Mutowo J'
p90016
aS'Chivhunga T'
p90017
aS'Chigwedere E'
p90018
aS'Pascoe M'
p90019
aS'Warambwa C'
p90020
aS'Zengeza E'
p90021
aS'Mapinge F'
p90022
aS'Makota S'
p90023
aS'Jamu A'
p90024
aS'Ngorima N'
p90025
aS'Chirairo H'
p90026
aS'Chitsungo S'
p90027
aS'Chimanzi J'
p90028
aS'Maweni C'
p90029
aS'Warara R'
p90030
aS'Matongo M'
p90031
aS'Mudzingwa S'
p90032
aS'Jangano M'
p90033
aS'Moyo K'
p90034
aS'Vere L'
p90035
aS'Mdege N'
p90036
aS'Machingura I'
p90037
aS'Katabira E'
p90038
aS'Ronald A'
p90039
aS'Kambungu A'
p90040
aS'Lutwama F'
p90041
aS'Mambule I'
p90042
aS'Nanfuka A'
p90043
aS'Walusimbi J'
p90044
aS'Nabankema E'
p90045
aS'Nalumenya R'
p90046
aS'Namuli T'
p90047
aS'Kulume R'
p90048
aS'Namata I'
p90049
aS'Nyachwo L'
p90050
aS'Florence A'
p90051
aS'Kusiima A'
p90052
aS'Lubwama E'
p90053
aS'Nairuba R'
p90054
aS'Oketta F'
p90055
aS'Buluma E'
p90056
aS'Waita R'
p90057
aS'Ojiambo H'
p90058
aS'Sadik F'
p90059
aS'Wanyama J'
p90060
aS'Nabongo P'
p90061
aS'Oyugi J'
p90062
aS'Sematala F'
p90063
aS'Muganzi A'
p90064
aS'Twijukye C'
p90065
aS'Byakwaga H'
p90066
aS'Ochai R'
p90067
aS'Muhweezi D'
p90068
aS'Coutinho A'
p90069
aS'Etukoit B'
p90070
aS'Gilks C'
p90071
aS'Boocock K'
p90072
aS'Puddephatt C'
p90073
aS'Grundy C'
p90074
aS'Bohannon J'
p90075
aS'Winogron D'
p90076
aS'Gibb DM'
p90077
aS'Burke A'
p90078
aS'Bray D'
p90079
aS'Babiker A'
p90080
aS'Walker AS'
p90081
aS'Wilkes H'
p90082
aS'Rauchenberger M'
p90083
aS'Sheehan S'
p90084
aS'Spencer-Drake C'
p90085
aS'Taylor K'
p90086
aS'Spyer M'
p90087
aS'Ferrier A'
p90088
aS'Naidoo B'
p90089
aS'Dunn D'
p90090
aS'Goodall R'
p90091
aS'Darbyshire JH'
p90092
aS'Peto L'
p90093
aS'Nanfuka R'
p90094
aS'Mufuka-Kapuya C'
p90095
aS'Kaleebu P'
p90096
aS'Pillay D'
p90097
aS'Robertson V'
p90098
aS'Yirrell D'
p90099
aS'Tugume S'
p90100
aS'Chirara M'
p90101
aS'Katundu P'
p90102
aS'Ndembi N'
p90103
aS'Lyagoba F'
p90104
aS'Dunn D'
p90105
aS'Goodall R'
p90106
aS'McCormick A'
p90107
aS'Lara AM'
p90108
aS'Foster S'
p90109
aS'Amurwon J'
p90110
aS'Wakholi BN'
p90111
aS'Kigozi J'
p90112
aS'Muchabaiwa L'
p90113
aS'Muzambi M'
p90114
aS'Weller I'
p90115
aS'Babiker A'
p90116
aS'Bahendeka S'
p90117
aS'Bassett M'
p90118
aS'Wapakhabulo AC'
p90119
aS'Darbyshire JH'
p90120
aS'Gazzard B'
p90121
aS'Gilks C'
p90122
aS'Grosskurth H'
p90123
aS'Hakim J'
p90124
aS'Latif A'
p90125
aS'Mapuchere C'
p90126
aS'Mugurungi O'
p90127
aS'Mugyenyi P'
p90128
aS'Burke C'
p90129
aS'Jones S'
p90130
aS'Newland C'
p90131
aS'Pearce G'
p90132
aS'Rahim S'
p90133
aS'Rooney J'
p90134
aS'Smith M'
p90135
aS'Snowden W'
p90136
aS'Steens JM'
p90137
aS'Breckenridge A'
p90138
aS'McLaren A'
p90139
aS'Hill C'
p90140
aS'Matenga J'
p90141
aS'Pozniak A'
p90142
aS'Serwadda D'
p90143
aS'Peto T'
p90144
aS'Palfreeman A'
p90145
aS'Borok M'
p90146
aS'Katabira E'
p90147
asS'AD'
p90148
S'MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK.'
p90149
sS'VI'
p90150
S'375'
p90151
sS'MHDA'
p90152
S'2010/03/05 06:00'
p90153
sS'PHST'
p90154
(lp90155
S'2009/12/08 [aheadofprint]'
p90156
asS'OID'
p90157
(lp90158
S'NLM: PMC2805723'
p90159
asS'MH'
p90160
(lp90161
S'Adenine/analogs & derivatives/therapeutic use'
p90162
aS'Adolescent'
p90163
aS'Adult'
p90164
aS'Africa/epidemiology'
p90165
aS'Aged'
p90166
aS'Anemia/epidemiology'
p90167
aS'Anti-Retroviral Agents/*therapeutic use'
p90168
aS'CD4 Lymphocyte Count'
p90169
aS'Creatinine/analysis'
p90170
aS'Dideoxynucleosides/therapeutic use'
p90171
aS'Disease Progression'
p90172
aS'*Drug Monitoring'
p90173
aS'Female'
p90174
aS'Glomerular Filtration Rate'
p90175
aS'HIV Infections/classification/*drug therapy/mortality'
p90176
aS'HIV-1/genetics'
p90177
aS'HIV-Associated Lipodystrophy Syndrome/epidemiology'
p90178
aS'Hemoglobins/analysis'
p90179
aS'Humans'
p90180
aS'Lamivudine/therapeutic use'
p90181
aS'Male'
p90182
aS'Middle Aged'
p90183
aS'Neutropenia/epidemiology'
p90184
aS'Neutrophils/metabolism'
p90185
aS'Nevirapine/therapeutic use'
p90186
aS'Organophosphonates/therapeutic use'
p90187
aS'RNA, Viral/metabolism'
p90188
aS'Tenofovir'
p90189
aS'Urea/analysis'
p90190
aS'Viral Load'
p90191
aS'Zidovudine/therapeutic use'
p90192
asS'EDAT'
p90193
S'2009/12/17 06:00'
p90194
sS'PMC'
p90195
S'PMC2805723'
p90196
sS'SI'
p90197
(lp90198
S'ISRCTN/ISRCTN13968779'
p90199
asS'SO'
p90200
S'Lancet. 2010 Jan 9;375(9709):123-31. doi: 10.1016/S0140-6736(09)62067-5. Epub 2009 Dec 8.'
p90201
sS'SB'
p90202
S'AIM IM'
p90203
sS'PMID'
p90204
S'20004464'
p90205
sS'PST'
p90206
S'ppublish'
p90207
stRp90208
ag2
(g3
g4
(dp90209
S'LID'
p90210
S'10.1097/QAD.0b013e328332d5ca [doi]'
p90211
sS'STAT'
p90212
S'MEDLINE'
p90213
sS'JT'
p90214
S'AIDS (London, England)'
p90215
sS'MID'
p90216
(lp90217
S'NIHMS202927'
p90218
asS'DA'
p90219
S'20091202'
p90220
sS'AID'
p90221
(lp90222
S'10.1097/QAD.0b013e328332d5ca [doi]'
p90223
asS'CRDT'
p90224
(lp90225
S'2009/11/27 06:00'
p90226
asS'DP'
p90227
S'2010 Jan 2'
p90228
sS'AD'
p90229
S'Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. yotebieng@unc.edu'
p90230
sS'OWN'
p90231
S'NLM'
p90232
sS'PT'
p90233
(lp90234
S'Journal Article'
p90235
aS'Research Support, N.I.H., Extramural'
p90236
aS"Research Support, Non-U.S. Gov't"
p90237
aS"Research Support, U.S. Gov't, Non-P.H.S."
p90238
asS'LA'
p90239
(lp90240
S'eng'
p90241
asS'FAU'
p90242
(lp90243
S'Yotebieng, Marcel'
p90244
aS'Van Rie, Annelies'
p90245
aS'Moultrie, Harry'
p90246
aS'Meyers, Tammy'
p90247
asS'LR'
p90248
S'20141204'
p90249
sS'PG'
p90250
S'139-46'
p90251
sS'TI'
p90252
S'Six-month gain in weight, height, and CD4 predict subsequent antiretroviral treatment responses in HIV-infected South African children.'
p90253
sS'PL'
p90254
S'England'
p90255
sS'TA'
p90256
S'AIDS'
p90257
sS'JID'
p90258
S'8710219'
p90259
sS'AB'
p90260
S"OBJECTIVES: Construct percentile curves for 6-month gain in weight, height, CD4 cell count, and CD4 percentage (CD4%) in children initiating ART, and to assess the association between lower percentiles and subsequent ART responses. DESIGN: Cohort of 1394 HIV-infected children initiating ART between April 2004 and March 2008, Johannesburg, South Africa METHODS: The generalized additive model for location, scale, and shape was used to construct percentile curves for 6-month gain in weight, height, CD4 cell count, and CD4%. Cox proportional models were used to assess the association between lower percentiles of each distribution and death, virological suppression, and treatment failure between 6 to 36 months post-ART initiation. RESULTS: Lower percentiles for gain in weight, CD4, and CD4% count after 6 months of ART, but not height, were associated with poor subsequent treatment outcomes independent of baseline characteristics, with increasing strength of association as percentiles decreased. Age-specific 6-month post-ART weight gain in our cohort was substantially higher compared with 6-month weight gain in non-HIV-infected American children of the Fels Institute cohort and the attained weight-for-age at 6 months post-ART plotted on WHO weight-for-age growth charts were not associated with subsequent treatment outcomes. CONCLUSION: Gain in CD4% in the first 6 months of ART was the best predictor of poor subsequent ART outcomes. In areas with limited access to CD4%, weight gain post-ART using our newly developed reference distributions for HIV-infected children on ART is a good alternative to CD4%, and clearly superior to the commonly used 'Road-to-Health' weight-for-age charts."
p90261
sS'GR'
p90262
(lp90263
S'5 D43 TW01039-08/TW/FIC NIH HHS/United States'
p90264
aS'D43 TW001039/TW/FIC NIH HHS/United States'
p90265
aS'D43 TW001039-08/TW/FIC NIH HHS/United States'
p90266
asS'IP'
p90267
S'1'
sS'IS'
p90268
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p90269
sS'PMC'
p90270
S'PMC2939835'
p90271
sS'DCOM'
p90272
S'20101228'
p90273
sS'AU'
p90274
(lp90275
S'Yotebieng M'
p90276
aS'Van Rie A'
p90277
aS'Moultrie H'
p90278
aS'Meyers T'
p90279
asS'VI'
p90280
S'24'
p90281
sS'MHDA'
p90282
S'2010/12/29 06:00'
p90283
sS'OID'
p90284
(lp90285
S'NLM: NIHMS202927'
p90286
aS'NLM: PMC2939835'
p90287
asS'MH'
p90288
(lp90289
S'Adolescent'
p90290
aS'Antiretroviral Therapy, Highly Active'
p90291
aS'Body Height/*drug effects'
p90292
aS'Body Mass Index'
p90293
aS'Body Weight/*drug effects'
p90294
aS'CD4 Lymphocyte Count'
p90295
aS'Child'
p90296
aS'Child, Preschool'
p90297
aS'Female'
p90298
aS'HIV Infections/complications/*drug therapy/mortality'
p90299
aS'*HIV-1'
p90300
aS'Humans'
p90301
aS'Infant'
p90302
aS'Male'
p90303
aS'South Africa/epidemiology'
p90304
aS'Viral Load'
p90305
aS'Weight Gain/drug effects'
p90306
asS'EDAT'
p90307
S'2009/11/27 06:00'
p90308
sS'SO'
p90309
S'AIDS. 2010 Jan 2;24(1):139-46. doi: 10.1097/QAD.0b013e328332d5ca.'
p90310
sS'SB'
p90311
S'IM X'
p90312
sS'PMID'
p90313
S'19940744'
p90314
sS'PST'
p90315
S'ppublish'
p90316
stRp90317
ag2
(g3
g4
(dp90318
S'LID'
p90319
S'10.1097/QAD.0b013e32832ec1c3 [doi]'
p90320
sS'STAT'
p90321
S'MEDLINE'
p90322
sS'JT'
p90323
S'AIDS (London, England)'
p90324
sS'CIN'
p90325
(lp90326
S'AIDS. 2010 Jan 2;24(1):101-2. PMID: 19734773'
p90327
asS'DA'
p90328
S'20091202'
p90329
sS'AID'
p90330
(lp90331
S'10.1097/QAD.0b013e32832ec1c3 [doi]'
p90332
asS'CRDT'
p90333
(lp90334
S'2009/11/26 06:00'
p90335
asS'DP'
p90336
S'2010 Jan 2'
p90337
sS'AD'
p90338
S'INSERM U897, Universite Victor Segalen Bordeaux 2, Bordeaux, France.'
p90339
sS'OWN'
p90340
S'NLM'
p90341
sS'PT'
p90342
(lp90343
S'Journal Article'
p90344
aS"Research Support, Non-U.S. Gov't"
p90345
asS'LA'
p90346
(lp90347
S'eng'
p90348
asS'FAU'
p90349
(lp90350
S'Messou, Eugene'
p90351
aS'Anglaret, Xavier'
p90352
aS'Duvignac, Julien'
p90353
aS"Konan-N'dri, Eric"
p90354
aS'Komena, Eric'
p90355
aS'Gnokoro, Joachim'
p90356
aS'Karcher, Sophie'
p90357
aS'Tanoh, Anthony'
p90358
aS"N'dri-Yoman, Therese"
p90359
aS'Seyler, Catherine'
p90360
asS'LR'
p90361
S'20141204'
p90362
sS'PG'
p90363
S'93-9'
p90364
sS'TI'
p90365
S"Antiretroviral treatment changes in adults from Cote d'Ivoire: the roles of tuberculosis and pregnancy."
p90366
sS'RN'
p90367
(lp90368
S'0 (Anti-HIV Agents)'
p90369
asS'PL'
p90370
S'England'
p90371
sS'TA'
p90372
S'AIDS'
p90373
sS'JID'
p90374
S'8710219'
p90375
sS'AB'
p90376
S"OBJECTIVE: To determine the rates and causes of first antiretroviral treatment changes in HIV-infected adults in Cote d'Ivoire. METHODS: We evaluated adults who initiated antiretroviral treatment in an outpatient clinic in Abidjan. We recorded baseline and follow-up data, including drug prescriptions and reasons for changing to alternative first-line regimens (drug substitution for any reason but failure) or second-line regimens (switch for failure). RESULTS: Two thousand and twelve HIV-infected adults (73% women) initiated antiretroviral treatment. At baseline, 9% of all patients were on treatment for tuberculosis and 3% of women were pregnant. First-line antiretroviral treatment consisted of two nucleoside reverse transcriptase inhibitors (58% stavudine-lamivudine, 42% zidovudine-lamivudine) and efavirenz (63%), nevirapine (32%) or indinavir (5%). Median follow-up time was 16.9 months. During this time, 205 (10%) patients died and 261 (13%) were lost to follow-up. Overall, the rate of treatment modifications was 20.7/100 patient-years. The most common modifications were drug substitutions for intolerance (12.4/100 patient-years), pregnancy (4.5/100 patient-years) and tuberculosis (2.5/100 patient-years). The rates of intolerance-related substitutions were 17.9/100 patient-years for stavudine, 6.3/100 patient-years for nevirapine, 3.9/100 patient-years for zidovudine and 0.1/100 patient-years for efavirenz. Twenty percent of efavirenz substitutions resulted from pregnancy and 18% of nevirapine substitutions were related to tuberculosis treatment. CONCLUSION: During the first months following antiretroviral treatment initiation, a third of all treatment changes occurred for reasons other than intolerance to the drug or treatment failure. In Africa, drug forecasting is crucial to ensuring the success of HIV treatment programmes. Drugs that do not require interruptions during pregnancy or tuberculosis treatment should be made more readily available as first-line drugs in sub-Saharan Africa."
p90377
sS'GR'
p90378
(lp90379
S'R01 AI058736/AI/NIAID NIH HHS/United States'
p90380
asS'IP'
p90381
S'1'
sS'IS'
p90382
S'1473-5571 (Electronic) 0269-9370 (Linking)'
p90383
sS'PMC'
p90384
S'PMC3936254'
p90385
sS'DCOM'
p90386
S'20101228'
p90387
sS'MID'
p90388
(lp90389
S'NIHMS517976'
p90390
asS'AU'
p90391
(lp90392
S'Messou E'
p90393
aS'Anglaret X'
p90394
aS'Duvignac J'
p90395
aS"Konan-N'dri E"
p90396
aS'Komena E'
p90397
aS'Gnokoro J'
p90398
aS'Karcher S'
p90399
aS'Tanoh A'
p90400
aS"N'dri-Yoman T"
p90401
aS'Seyler C'
p90402
asS'VI'
p90403
S'24'
p90404
sS'MHDA'
p90405
S'2010/12/29 06:00'
p90406
sS'OID'
p90407
(lp90408
S'NLM: NIHMS517976'
p90409
aS'NLM: PMC3936254'
p90410
asS'MH'
p90411
(lp90412
S'Anti-HIV Agents/adverse effects/*therapeutic use'
p90413
aS'Antiretroviral Therapy, Highly Active/adverse effects'
p90414
aS"Cote d'Ivoire/epidemiology"
p90415
aS'*Drug Substitution/statistics & numerical data'
p90416
aS'Female'
p90417
aS'HIV Infections/*drug therapy/immunology/virology'
p90418
aS'*HIV-1/immunology'
p90419
aS'Humans'
p90420
aS'Male'
p90421
aS'Pregnancy'
p90422
aS'Pregnancy Complications, Infectious/*drug therapy/virology'
p90423
aS'Tuberculosis/*drug therapy/immunology/virology'
p90424
aS'Viral Load'
p90425
asS'EDAT'
p90426
S'2009/11/26 06:00'
p90427
sS'SO'
p90428
S'AIDS. 2010 Jan 2;24(1):93-9. doi: 10.1097/QAD.0b013e32832ec1c3.'
p90429
sS'SB'
p90430
S'IM X'
p90431
sS'PMID'
p90432
S'19935382'
p90433
sS'PST'
p90434
S'ppublish'
p90435
stRp90436
ag2
(g3
g4
(dp90437
S'LID'
p90438
S'10.1016/j.jviromet.2009.11.011 [doi]'
p90439
sS'STAT'
p90440
S'MEDLINE'
p90441
sS'DEP'
p90442
S'20091114'
p90443
sS'CI'
p90444
(lp90445
S'2009 Elsevier B.V. All rights reserved.'
p90446
asS'DA'
p90447
S'20100201'
p90448
sS'AID'
p90449
(lp90450
S'S0166-0934(09)00481-9 [pii]'
p90451
aS'10.1016/j.jviromet.2009.11.011 [doi]'
p90452
asS'CRDT'
p90453
(lp90454
S'2009/11/18 06:00'
p90455
asS'DP'
p90456
S'2010 Feb'
p90457
sS'AD'
p90458
S'Department of Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg, South Africa. cwallis@mweb.co.za'
p90459
sS'OWN'
p90460
S'NLM'
p90461
sS'PT'
p90462
(lp90463
S'Evaluation Studies'
p90464
aS'Journal Article'
p90465
aS'Research Support, N.I.H., Extramural'
p90466
aS"Research Support, Non-U.S. Gov't"
p90467
aS'Validation Studies'
p90468
asS'LA'
p90469
(lp90470
S'eng'
p90471
asS'FAU'
p90472
(lp90473
S'Wallis, Carole L'
p90474
aS'Papathanasopoulos, Maria A'
p90475
aS'Lakhi, Shabir'
p90476
aS'Karita, Etienne'
p90477
aS'Kamali, Anatoli'
p90478
aS'Kaleebu, Pontiano'
p90479
aS'Sanders, Eduard'
p90480
aS'Anzala, Omu'
p90481
aS'Bekker, Linda-Gail'
p90482
aS'Stevens, Gwynn'
p90483
aS'de Wit, Tobias F Rinke'
p90484
aS'Stevens, Wendy'
p90485
asS'JT'
p90486
S'Journal of virological methods'
p90487
sS'LR'
p90488
S'20141204'
p90489
sS'PG'
p90490
S'505-8'
p90491
sS'TI'
p90492
S'Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1.'
p90493
sS'RN'
p90494
(lp90495
S'0 (Anti-Retroviral Agents)'
p90496
aS'0 (DNA Primers)'
p90497
aS'0 (RNA, Viral)'
p90498
asS'PL'
p90499
S'Netherlands'
p90500
sS'TA'
p90501
S'J Virol Methods'
p90502
sS'JID'
p90503
S'8005839'
p90504
sS'AB'
p90505
S'The introduction of antiretroviral (ARV) therapy in resource-poor settings is effective in suppressing HIV-1 replication and prolonging life of infected individuals. This has led to a demand for affordable HIV-1 drug resistance assays, since treatment failure due to development of drug resistance is common. This study developed and evaluated an affordable "in-house" genotyping assay to monitor HIV-1 drug resistance in Africa, particularly South Africa. An "in-house" assay using automated RNA extraction, and subtype C specific PCR and sequencing primers was developed and successfully evaluated 396 patient samples (viral load ranges 1000-1.6 million RNA copies/ml). The "in-house" assay was validated by comparing sequence data and drug resistance profiles from 90 patient and 10 external quality control samples to data from the ViroSeq HIV-1 Genotyping kit. The "in-house" assay was more efficient, amplifying all 100 samples, compared to 91 samples using Viroseq. The "in house" sequences were 99.2% homologous to the ViroSeq sequences, and identical drug resistance mutation profiles were observed in 96 samples. Furthermore, the "in-house" assay genotyped 260 of 295 samples from seven African sites, where 47% were non-subtype C. Overall, the newly validated "in-house" drug resistance assay is suited for use in Africa as it overcomes the obstacle of subtype diversity.'
p90506
sS'GR'
p90507
(lp90508
S'1U19 AI53217-01/AI/NIAID NIH HHS/United States'
p90509
aS'GPH-G-00-01-0004-00/PHS HHS/United States'
p90510
aS'MC_U950080930/Medical Research Council/United Kingdom'
p90511
aS'MC_U950080938/Medical Research Council/United Kingdom'
p90512
aS'U19 AI053217/AI/NIAID NIH HHS/United States'
p90513
aS'U19 AI053217-08/AI/NIAID NIH HHS/United States'
p90514
asS'IP'
p90515
S'2'
sS'IS'
p90516
S'1879-0984 (Electronic) 0166-0934 (Linking)'
p90517
sS'PMC'
p90518
S'PMC2932961'
p90519
sS'DCOM'
p90520
S'20100217'
p90521
sS'MID'
p90522
(lp90523
S'NIHMS228566'
p90524
asS'AU'
p90525
(lp90526
S'Wallis CL'
p90527
aS'Papathanasopoulos MA'
p90528
aS'Lakhi S'
p90529
aS'Karita E'
p90530
aS'Kamali A'
p90531
aS'Kaleebu P'
p90532
aS'Sanders E'
p90533
aS'Anzala O'
p90534
aS'Bekker LG'
p90535
aS'Stevens G'
p90536
aS'de Wit TF'
p90537
aS'Stevens W'
p90538
asS'VI'
p90539
S'163'
p90540
sS'MHDA'
p90541
S'2010/02/18 06:00'
p90542
sS'PHST'
p90543
(lp90544
S'2009/04/03 [received]'
p90545
aS'2009/10/20 [revised]'
p90546
aS'2009/11/05 [accepted]'
p90547
aS'2009/11/14 [aheadofprint]'
p90548
asS'OID'
p90549
(lp90550
S'NLM: NIHMS228566'
p90551
aS'NLM: PMC2932961'
p90552
asS'MH'
p90553
(lp90554
S'Anti-Retroviral Agents/*pharmacology'
p90555
aS'Automation'
p90556
aS'DNA Primers/genetics'
p90557
aS'*Drug Resistance, Viral'
p90558
aS'*Genes, Viral'
p90559
aS'Genotype'
p90560
aS'HIV-1/*drug effects/genetics/isolation & purification'
p90561
aS'Humans'
p90562
aS'Microbial Sensitivity Tests/*economics/*methods'
p90563
aS'RNA, Viral/*genetics/isolation & purification'
p90564
aS'Reverse Transcriptase Polymerase Chain Reaction/methods'
p90565
aS'Sensitivity and Specificity'
p90566
aS'South Africa'
p90567
asS'EDAT'
p90568
S'2009/11/18 06:00'
p90569
sS'SO'
p90570
S'J Virol Methods. 2010 Feb;163(2):505-8. doi: 10.1016/j.jviromet.2009.11.011. Epub 2009 Nov 14.'
p90571
sS'SB'
p90572
S'IM'
p90573
sS'PMID'
p90574
S'19917318'
p90575
sS'PST'
p90576
S'ppublish'
p90577
stRp90578
ag2
(g3
g4
(dp90579
S'LID'
p90580
S'10.1164/rccm.200907-0989OC [doi]'
p90581
sS'STAT'
p90582
S'MEDLINE'
p90583
sS'DEP'
p90584
S'20091015'
p90585
sS'CIN'
p90586
(lp90587
S'Am J Respir Crit Care Med. 2010 Dec 15;182(12):1567; author reply 1568-9. PMID:'
p90588
aS'21159908'
p90589
asS'DA'
p90590
S'20091222'
p90591
sS'AID'
p90592
(lp90593
S'200907-0989OC [pii]'
p90594
aS'10.1164/rccm.200907-0989OC [doi]'
p90595
asS'CRDT'
p90596
(lp90597
S'2009/10/17 06:00'
p90598
asS'DP'
p90599
S'2010 Jan 1'
p90600
sS'GR'
p90601
(lp90602
S'Howard Hughes Medical Institute/United States'
p90603
asS'OWN'
p90604
S'NLM'
p90605
sS'PT'
p90606
(lp90607
S'Journal Article'
p90608
aS"Research Support, Non-U.S. Gov't"
p90609
asS'LA'
p90610
(lp90611
S'eng'
p90612
asS'FAU'
p90613
(lp90614
S'Gandhi, Neel R'
p90615
aS'Shah, N Sarita'
p90616
aS'Andrews, Jason R'
p90617
aS'Vella, Venanzio'
p90618
aS'Moll, Anthony P'
p90619
aS'Scott, Michelle'
p90620
aS'Weissman, Darren'
p90621
aS'Marra, Claudio'
p90622
aS'Lalloo, Umesh G'
p90623
aS'Friedland, Gerald H'
p90624
asS'JT'
p90625
S'American journal of respiratory and critical care medicine'
p90626
sS'LR'
p90627
S'20101230'
p90628
sS'PG'
p90629
S'80-6'
p90630
sS'TI'
p90631
S'HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality.'
p90632
sS'PL'
p90633
S'United States'
p90634
sS'TA'
p90635
S'Am J Respir Crit Care Med'
p90636
sS'JID'
p90637
S'9421642'
p90638
sS'AB'
p90639
S'RATIONALE: The multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) epidemics are rapidly expanding in South Africa. Our initial report of HIV-associated XDR TB in South Africa revealed rapid and near complete mortality. Lower mortality has been described in the literature, but few of these patients have been HIV coinfected. OBJECTIVES: To characterize mortality from MDR and XDR TB in a setting with high HIV-coinfection rates. METHODS: We conducted a retrospective observational study among 654 MDR and XDR TB cases diagnosed in Tugela Ferry, South Africa, from 2005 to 2007. Demographics and HIV status were abstracted from available medical records. MEASUREMENTS AND MAIN RESULTS: Survival was determined from the date of sputum collection until October 2008 and correlated with year of diagnosis and drug-susceptibility test results. From 2005 to 2007, 272 MDR TB and 382 XDR TB cases were diagnosed; HIV-coinfection rates were 90 and 98%, respectively. One-year mortality was 71% for MDR and 83% for XDR TB patients; 40% of MDR TB and 51% of XDR TB cases died within 30 days of sputum collection. One-year mortality among both MDR and XDR TB patients improved from 2005 to 2007; however, the majority of deaths still occurred within the first 30 days. One-year and 30-day mortality rates were worse with greater degree of drug resistance (P < 0.001). CONCLUSIONS: Mortality from MDR and XDR TB in this high HIV-prevalence region is extraordinarily high, particularly within the first 30 days. Efforts to reduce mortality must focus on earlier diagnosis and early initiation of second-line TB and antiretroviral therapy.'
p90640
sS'AD'
p90641
S'Departments of Medicine and Epidemiology & Population Health, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York 10467, USA. neelgandhi@alumni.williams.edu'
p90642
sS'CN'
p90643
(lp90644
S'Tugela Ferry Care and Research (TF CARES) Collaboration'
p90645
asS'IP'
p90646
S'1'
sS'IS'
p90647
S'1535-4970 (Electronic) 1073-449X (Linking)'
p90648
sS'DCOM'
p90649
S'20100111'
p90650
sS'AU'
p90651
(lp90652
S'Gandhi NR'
p90653
aS'Shah NS'
p90654
aS'Andrews JR'
p90655
aS'Vella V'
p90656
aS'Moll AP'
p90657
aS'Scott M'
p90658
aS'Weissman D'
p90659
aS'Marra C'
p90660
aS'Lalloo UG'
p90661
aS'Friedland GH'
p90662
asS'VI'
p90663
S'181'
p90664
sS'MHDA'
p90665
S'2010/01/12 06:00'
p90666
sS'PHST'
p90667
(lp90668
S'2009/10/15 [aheadofprint]'
p90669
asS'MH'
p90670
(lp90671
S'Adult'
p90672
aS'Extensively Drug-Resistant Tuberculosis/*complications/mortality'
p90673
aS'Female'
p90674
aS'HIV Infections/*complications/mortality'
p90675
aS'Humans'
p90676
aS'Kaplan-Meier Estimate'
p90677
aS'Male'
p90678
aS'South Africa/epidemiology'
p90679
asS'EDAT'
p90680
S'2009/10/17 06:00'
p90681
sS'SO'
p90682
S'Am J Respir Crit Care Med. 2010 Jan 1;181(1):80-6. doi: 10.1164/rccm.200907-0989OC. Epub 2009 Oct 15.'
p90683
sS'SB'
p90684
S'AIM IM'
p90685
sS'PMID'
p90686
S'19833824'
p90687
sS'PST'
p90688
S'ppublish'
p90689
stRp90690
ag2
(g3
g4
(dp90691
S'LID'
p90692
S'10.1097/QAI.0b013e3181bc478b [doi]'
p90693
sS'STAT'
p90694
S'MEDLINE'
p90695
sS'JT'
p90696
S'Journal of acquired immune deficiency syndromes (1999)'
p90697
sS'DA'
p90698
S'20100311'
p90699
sS'AID'
p90700
(lp90701
S'10.1097/QAI.0b013e3181bc478b [doi]'
p90702
asS'CRDT'
p90703
(lp90704
S'2009/10/06 06:00'
p90705
asS'DP'
p90706
S'2010 Apr 1'
p90707
sS'AD'
p90708
S'Department of Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg, South Africa. cwallis@mweb.co.za'
p90709
sS'OWN'
p90710
S'NLM'
p90711
sS'PT'
p90712
(lp90713
S'Journal Article'
p90714
aS'Research Support, N.I.H., Extramural'
p90715
aS"Research Support, Non-U.S. Gov't"
p90716
asS'LA'
p90717
(lp90718
S'eng'
p90719
asS'FAU'
p90720
(lp90721
S'Wallis, Carole L'
p90722
aS'Mellors, John W'
p90723
aS'Venter, Willem D F'
p90724
aS'Sanne, Ian'
p90725
aS'Stevens, Wendy'
p90726
asS'PG'
p90727
S'480-4'
p90728
sS'TI'
p90729
S'Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa.'
p90730
sS'RN'
p90731
(lp90732
S'0 (Anti-HIV Agents)'
p90733
aS'0 (Viral Proteins)'
p90734
asS'PL'
p90735
S'United States'
p90736
sS'TA'
p90737
S'J Acquir Immune Defic Syndr'
p90738
sS'JID'
p90739
S'100892005'
p90740
sS'AB'
p90741
S'BACKGROUND: The South African national antiretroviral therapy roll-out program is entering its sixth year, with over 570,000 adults accessing treatment. HIV-1 drug resistance is a potential consequence of therapy. This study determined the pattern of HIV-1 drug resistance mutations after failure of first-line treatment regimens in South Africa. METHODS: Two hundred and twenty-six patients virologically failing first-line regimens were studied to determine resistance patterns. RESULTS: The most common reverse transcriptase mutation was M184V/I (72%; n = 163); 11% of patients (n = 25) had only nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations and 17% (n = 38) had no known resistance mutations. The K65R mutation was detected in 4%. The frequency of thymidine analog mutations was significantly higher with azidothymidine-containing (31 of 57) than stavudine-containing regimens (39 of 169; P < 0.001). The Y181C mutation was more frequent with failure of nevirapine (NVP)-containing (26%) than efavirenz (EFV)-containing therapy (3%; P < 0.001). The V106M mutation was more frequent with EFV (30%) than NVP (4%; P = 0.012). CONCLUSIONS: HIV-1 drug resistance patterns varied broadly after failure of first-line therapy, ranging from no known resistance mutations (17%) to multinucleoside reverse transcriptase inhibitor and NNRTI resistance (23%). NNRTI mutation profiles differed for patients on EFV- compared with NVP-containing regimens. Overall, these findings suggest that HIV-1 drug resistance testing would be useful in identifying most appropriate second-line regimens.'
p90742
sS'GR'
p90743
(lp90744
S'U01AI38858/AI/NIAID NIH HHS/United States'
p90745
asS'IP'
p90746
S'4'
sS'IS'
p90747
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p90748
sS'DCOM'
p90749
S'20100329'
p90750
sS'AU'
p90751
(lp90752
S'Wallis CL'
p90753
aS'Mellors JW'
p90754
aS'Venter WD'
p90755
aS'Sanne I'
p90756
aS'Stevens W'
p90757
asS'VI'
p90758
S'53'
p90759
sS'MHDA'
p90760
S'2010/03/30 06:00'
p90761
sS'MH'
p90762
(lp90763
S'Adolescent'
p90764
aS'Adult'
p90765
aS'Aged'
p90766
aS'Anti-HIV Agents/pharmacology/*therapeutic use'
p90767
aS'*Antiretroviral Therapy, Highly Active'
p90768
aS'Child'
p90769
aS'*Drug Resistance, Viral'
p90770
aS'Female'
p90771
aS'HIV Infections/*drug therapy/*virology'
p90772
aS'HIV-1/*drug effects'
p90773
aS'Humans'
p90774
aS'Male'
p90775
aS'Middle Aged'
p90776
aS'Mutation, Missense/genetics'
p90777
aS'South Africa'
p90778
aS'Treatment Failure'
p90779
aS'Viral Proteins/genetics'
p90780
aS'Young Adult'
p90781
asS'EDAT'
p90782
S'2009/10/06 06:00'
p90783
sS'SO'
p90784
S'J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):480-4. doi: 10.1097/QAI.0b013e3181bc478b.'
p90785
sS'SB'
p90786
S'IM X'
p90787
sS'PMID'
p90788
S'19801944'
p90789
sS'PST'
p90790
S'ppublish'
p90791
stRp90792
ag2
(g3
g4
(dp90793
S'LID'
p90794
S'10.1097/QAI.0b013e3181b843f0 [doi]'
p90795
sS'STAT'
p90796
S'MEDLINE'
p90797
sS'JT'
p90798
S'Journal of acquired immune deficiency syndromes (1999)'
p90799
sS'MID'
p90800
(lp90801
S'NIHMS447662'
p90802
asS'DA'
p90803
S'20100302'
p90804
sS'AID'
p90805
(lp90806
S'10.1097/QAI.0b013e3181b843f0 [doi]'
p90807
asS'CRDT'
p90808
(lp90809
S'2009/09/12 06:00'
p90810
asS'DP'
p90811
S'2010 Mar'
p90812
sS'AD'
p90813
S'Division of HIV/AIDS at San Francisco General Hospital, 995 Potrero Avenue, Building 80, San Francisco, CA 94110, USA. genge@php.ucsf.edu'
p90814
sS'OWN'
p90815
S'NLM'
p90816
sS'PT'
p90817
(lp90818
S'Journal Article'
p90819
aS'Research Support, N.I.H., Extramural'
p90820
aS"Research Support, Non-U.S. Gov't"
p90821
asS'LA'
p90822
(lp90823
S'eng'
p90824
asS'FAU'
p90825
(lp90826
S'Geng, Elvin H'
p90827
aS'Bangsberg, David R'
p90828
aS'Musinguzi, Nicolas'
p90829
aS'Emenyonu, Nneka'
p90830
aS'Bwana, Mwebesa Bosco'
p90831
aS'Yiannoutsos, Constantin T'
p90832
aS'Glidden, David V'
p90833
aS'Deeks, Steven G'
p90834
aS'Martin, Jeffrey N'
p90835
asS'LR'
p90836
S'20141207'
p90837
sS'PG'
p90838
S'405-11'
p90839
sS'TI'
p90840
S'Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach.'
p90841
sS'RN'
p90842
(lp90843
S'0 (Anti-HIV Agents)'
p90844
asS'PL'
p90845
S'United States'
p90846
sS'TA'
p90847
S'J Acquir Immune Defic Syndr'
p90848
sS'JID'
p90849
S'100892005'
p90850
sS'AB'
p90851
S'OBJECTIVES: Losses to follow-up after initiation of antiretroviral therapy (ART) are common in Africa and are a considerable obstacle to understanding the effectiveness of nascent treatment programs. We sought to characterize, through a sampling-based approach, reasons for and outcomes of patients who become lost to follow-up. DESIGN: Cohort study. METHODS: We searched for and interviewed a representative sample of lost patients or close informants in the community to determine reasons for and outcomes among lost patients. RESULTS: Three thousand six hundred twenty-eight HIV-infected adults initiated ART between January 1, 2004 and September 30, 2007 in Mbarara, Uganda. Eight hundred twenty-nine became lost to follow-up (cumulative incidence at 1, 2, and 3 years of 16%, 30%, and 39%). We sought a representative sample of 128 lost patients in the community and ascertained vital status in 111 (87%). Top reasons for loss included lack of transportation or money and work/child care responsibilities. Among the 111 lost patients who had their vital status ascertained through tracking, 32 deaths occurred (cumulative 1-year incidence 36%); mortality was highest shortly after the last clinic visit. Lower pre-ART CD4 T-cell count, older age, low blood pressure, and a central nervous system syndrome at the last clinic visit predicted deaths. Of patients directly interviewed, 83% were in care at another clinic and 71% were still using ART. CONCLUSIONS: Sociostructural factors are the primary reasons for loss to follow-up. Outcomes among the lost are heterogeneous: both deaths and transfers to other clinics were common. Tracking a sample of lost patients is an efficient means for programs to understand site-specific reasons for and outcomes among patients lost to follow-up.'
p90852
sS'GR'
p90853
(lp90854
S'K23 AI084544/AI/NIAID NIH HHS/United States'
p90855
aS'P30 AI027763/AI/NIAID NIH HHS/United States'
p90856
aS'R01 MH054907/MH/NIMH NIH HHS/United States'
p90857
aS'R01 MH054907/MH/NIMH NIH HHS/United States'
p90858
aS'T32 AI06530/AI/NIAID NIH HHS/United States'
p90859
aS'U01 AI069911/AI/NIAID NIH HHS/United States'
p90860
asS'IP'
p90861
S'3'
sS'IS'
p90862
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p90863
sS'PMC'
p90864
S'PMC3606953'
p90865
sS'DCOM'
p90866
S'20100326'
p90867
sS'AU'
p90868
(lp90869
S'Geng EH'
p90870
aS'Bangsberg DR'
p90871
aS'Musinguzi N'
p90872
aS'Emenyonu N'
p90873
aS'Bwana MB'
p90874
aS'Yiannoutsos CT'
p90875
aS'Glidden DV'
p90876
aS'Deeks SG'
p90877
aS'Martin JN'
p90878
asS'VI'
p90879
S'53'
p90880
sS'MHDA'
p90881
S'2010/03/27 06:00'
p90882
sS'OID'
p90883
(lp90884
S'NLM: NIHMS447662'
p90885
aS'NLM: PMC3606953'
p90886
asS'MH'
p90887
(lp90888
S'Adult'
p90889
aS'Anti-HIV Agents/*therapeutic use'
p90890
aS'*Antiretroviral Therapy, Highly Active'
p90891
aS'Female'
p90892
aS'HIV Infections/*drug therapy'
p90893
aS'Humans'
p90894
aS'Male'
p90895
aS'Medication Adherence/*statistics & numerical data'
p90896
aS'Patient Dropouts/*statistics & numerical data'
p90897
aS'Treatment Outcome'
p90898
aS'Uganda'
p90899
asS'EDAT'
p90900
S'2009/09/12 06:00'
p90901
sS'SO'
p90902
S'J Acquir Immune Defic Syndr. 2010 Mar;53(3):405-11. doi: 10.1097/QAI.0b013e3181b843f0.'
p90903
sS'SB'
p90904
S'IM X'
p90905
sS'PMID'
p90906
S'19745753'
p90907
sS'PST'
p90908
S'ppublish'
p90909
stRp90910
ag2
(g3
g4
(dp90911
S'LID'
p90912
S'10.1097/QAI.0b013e3181b8f26e [doi]'
p90913
sS'STAT'
p90914
S'MEDLINE'
p90915
sS'JT'
p90916
S'Journal of acquired immune deficiency syndromes (1999)'
p90917
sS'DA'
p90918
S'20100128'
p90919
sS'AID'
p90920
(lp90921
S'10.1097/QAI.0b013e3181b8f26e [doi]'
p90922
asS'CRDT'
p90923
(lp90924
S'2009/09/12 06:00'
p90925
asS'DP'
p90926
S'2010 Feb'
p90927
sS'OWN'
p90928
S'NLM'
p90929
sS'PT'
p90930
(lp90931
S'Journal Article'
p90932
aS"Research Support, U.S. Gov't, Non-P.H.S."
p90933
asS'LA'
p90934
(lp90935
S'eng'
p90936
asS'FAU'
p90937
(lp90938
S'Braitstein, Paula'
p90939
aS'Ayuo, Paul'
p90940
aS'Mwangi, Ann'
p90941
aS'Wools-Kaloustian, Kara'
p90942
aS'Musick, Beverly'
p90943
aS'Siika, Abraham'
p90944
aS'Kimaiyo, Sylvester'
p90945
asS'LR'
p90946
S'20110906'
p90947
sS'PG'
p90948
S'254-9'
p90949
sS'TI'
p90950
S'Sustainability of first-line antiretroviral regimens: findings from a large HIV treatment program in western Kenya.'
p90951
sS'RN'
p90952
(lp90953
S'0 (Anti-HIV Agents)'
p90954
asS'PL'
p90955
S'United States'
p90956
sS'TA'
p90957
S'J Acquir Immune Defic Syndr'
p90958
sS'JID'
p90959
S'100892005'
p90960
sS'AB'
p90961
S'OBJECTIVE: To describe first change or discontinuation in combination antiretroviral treatment (cART) among previously treatment naive, HIV-infected adults in a resource-constrained setting. METHODS: The United States Agency for International Development-Academic Model Providing Access to Healthcare Partnership has enrolled >90,000 HIV-infected patients at 18 clinics throughout western Kenya. Patients in this analysis were aged > or =18 years, previously antiretroviral treatment naive, and initiated to cART between January 2006 and November 2007, with at least 1 follow-up visit. A treatment change or discontinuation was defined as change of regimen including single drug substitutions or a complete halting of cART. RESULTS: There were 14,162 patients eligible for analysis and 10,313 person-years of follow-up, of whom 1376 changed or stopped their cART. Among these, 859 (62%) changed their regimen (including 514 patients who had a single drug substitution) and 517 (38%) completely discontinued cART. The overall incidence rate (IR) of cART changes or stops per 100 person-years was 13.3 [95% confidence interval (CI): 12.7-14.1]. The incidence was much higher in the first year of post-cART initiation (IR: 25.0, 95% CI: 23.6-26.3) compared with the second year (IR: 2.4, 95% CI: 2.0-2.8). The most commonly cited reason was toxicity (46%). In multivariate regression, individuals were more likely to discontinue cART if they were World Health Organization stage III/IV [adjusted hazard ratio (AHR): 1.37, 95% CI: 1.11-1.69] or were receiving a zidovudine-containing regimen (AHR: 4.44, 95% CI: 3.35-5.88). Individuals were more likely to change their regimen if they were aged > or =38 years (AHR: 1.44, 95% CI: 1.23-1.69), had to travel more than 1 hour to clinic (AHR: 1.34, 95% CI: 1.15-1.57), had a CD4 at cART initiation < or =111 cells/mm3 (AHR: 1.51, 95% CI: 1.29-1.77), or had been receiving a zidovudine-containing regimen (AHR: 3.73, 95% CI: 2.81-4.95). Those attending urban clinics and those receiving stavudine-containing regimens were less likely to experience either a discontinuation or a change of their cART. CONCLUSIONS: These data suggest a moderate incidence of cART changes and discontinuations among this large population of adults in western Kenya. Mostly occurring within 12 months of cART initiation, and primarily due to toxicity, older individuals, those with more advanced disease, and those using zidovudine are at higher risk of experiencing a change or a discontinuation in their cART.'
p90962
sS'AD'
p90963
S'Department of Medicine, Indiana University, School of Medicine, Indianapolis, IN, USA. pbraitstein@yahoo.com'
p90964
sS'IP'
p90965
S'2'
sS'IS'
p90966
S'1944-7884 (Electronic) 1525-4135 (Linking)'
p90967
sS'DCOM'
p90968
S'20100217'
p90969
sS'AU'
p90970
(lp90971
S'Braitstein P'
p90972
aS'Ayuo P'
p90973
aS'Mwangi A'
p90974
aS'Wools-Kaloustian K'
p90975
aS'Musick B'
p90976
aS'Siika A'
p90977
aS'Kimaiyo S'
p90978
asS'VI'
p90979
S'53'
p90980
sS'MHDA'
p90981
S'2010/02/18 06:00'
p90982
sS'MH'
p90983
(lp90984
S'Adult'
p90985
aS'Anti-HIV Agents/*administration & dosage/*therapeutic use'
p90986
aS'Drug Therapy, Combination'
p90987
aS'Female'
p90988
aS'HIV Infections/*drug therapy'
p90989
aS'Humans'
p90990
aS'Kenya/epidemiology'
p90991
aS'Male'
p90992
aS'Middle Aged'
p90993
aS'Multivariate Analysis'
p90994
aS'Proportional Hazards Models'
p90995
aS'Retrospective Moral Judgment'
p90996
aS'Travel'
p90997
asS'EDAT'
p90998
S'2009/09/12 06:00'
p90999
sS'SO'
p91000
S'J Acquir Immune Defic Syndr. 2010 Feb;53(2):254-9. doi: 10.1097/QAI.0b013e3181b8f26e.'
p91001
sS'SB'
p91002
S'IM X'
p91003
sS'PMID'
p91004
S'19745752'
p91005
sS'PST'
p91006
S'ppublish'
p91007
stRp91008
ag2
(g3
g4
(dp91009
S'LID'
p91010
S'10.1093/tropej/fmp054 [doi]'
p91011
sS'STAT'
p91012
S'MEDLINE'
p91013
sS'DEP'
p91014
S'20090713'
p91015
sS'DA'
p91016
S'20100125'
p91017
sS'AID'
p91018
(lp91019
S'fmp054 [pii]'
p91020
aS'10.1093/tropej/fmp054 [doi]'
p91021
asS'CRDT'
p91022
(lp91023
S'2009/07/16 09:00'
p91024
asS'DP'
p91025
S'2010 Feb'
p91026
sS'OWN'
p91027
S'NLM'
p91028
sS'PT'
p91029
(lp91030
S'Evaluation Studies'
p91031
aS'Journal Article'
p91032
aS"Research Support, Non-U.S. Gov't"
p91033
asS'LA'
p91034
(lp91035
S'eng'
p91036
asS'FAU'
p91037
(lp91038
S'Ahoua, Laurence'
p91039
aS'Ayikoru, Harriet'
p91040
aS'Gnauck, Katherine'
p91041
aS'Odaru, Grace'
p91042
aS'Odar, Emmanuel'
p91043
aS'Ondoa-Onama, Christine'
p91044
aS'Pinoges, Loretxu'
p91045
aS'Balkan, Suna'
p91046
aS'Olson, David'
p91047
aS'Pujades-Rodriguez, Mar'
p91048
asS'JT'
p91049
S'Journal of tropical pediatrics'
p91050
sS'LR'
p91051
S'20101118'
p91052
sS'PG'
p91053
S'43-52'
p91054
sS'TI'
p91055
S'Evaluation of a 5-year programme to prevent mother-to-child transmission of HIV infection in Northern Uganda.'
p91056
sS'RN'
p91057
(lp91058
S'0 (Anti-HIV Agents)'
p91059
asS'PL'
p91060
S'England'
p91061
sS'TA'
p91062
S'J Trop Pediatr'
p91063
sS'JID'
p91064
S'8010948'
p91065
sS'AB'
p91066
S'Prevention of mother-to-child transmission (PMTCT) is essential in HIV/AIDS control. We analysed 2000-05 data from mother-infant pairs in our PMTCT programme in rural Uganda, examining programme utilization and outcomes, HIV transmission rates and predictors of death or loss to follow-up (LFU). Out of 19,017 women, 1,037 (5.5%) attending antenatal care services tested HIV positive. Of these, 517 (50%) enrolled in the PMTCT programme and gave birth to 567 infants. Before tracing, 303 (53%) mother-infant pairs were LFU. Reasons for dropout were infant death and lack of understanding of importance of follow-up. Risk of death or LFU was higher among infants with no or incomplete intrapartum prophylaxis (OR = 1.90, 95% CI 1.07-3.36) and of weaning age <6 months (OR 2.55, 95% CI 1.42-4.58), and lower in infants with diagnosed acute illness (OR 0.30, 95% CI 0.16-0.55). Mother-to-child HIV cumulative transmission rate was 8.3%, and 15.5% when HIV-related deaths were considered. Improved tracking of HIV-exposed infants is needed in PMTCT programmes where access to early infant diagnosis is still limited.'
p91067
sS'AD'
p91068
S'Epicentre, Paris, France. laurence.ahoua@epicentre.msf.org'
p91069
sS'IP'
p91070
S'1'
sS'IS'
p91071
S'1465-3664 (Electronic) 0142-6338 (Linking)'
p91072
sS'DCOM'
p91073
S'20100330'
p91074
sS'AU'
p91075
(lp91076
S'Ahoua L'
p91077
aS'Ayikoru H'
p91078
aS'Gnauck K'
p91079
aS'Odaru G'
p91080
aS'Odar E'
p91081
aS'Ondoa-Onama C'
p91082
aS'Pinoges L'
p91083
aS'Balkan S'
p91084
aS'Olson D'
p91085
aS'Pujades-Rodriguez M'
p91086
asS'VI'
p91087
S'56'
p91088
sS'MHDA'
p91089
S'2010/03/31 06:00'
p91090
sS'PHST'
p91091
(lp91092
S'2009/07/13 [aheadofprint]'
p91093
asS'MH'
p91094
(lp91095
S'Adult'
p91096
aS'Anti-HIV Agents/*therapeutic use'
p91097
aS'Counseling'
p91098
aS'Female'
p91099
aS'HIV Infections/drug therapy/prevention & control/*transmission'
p91100
aS'HIV-1'
p91101
aS'Humans'
p91102
aS'Infectious Disease Transmission, Vertical/*prevention & control/statistics & numerical data'
p91103
aS'Kaplan-Meier Estimate'
p91104
aS'Male'
p91105
aS'Middle Aged'
p91106
aS'Mothers'
p91107
aS'Postnatal Care/utilization'
p91108
aS'Pregnancy'
p91109
aS'Pregnancy Complications, Infectious/*drug therapy/epidemiology'
p91110
aS'Prenatal Care'
p91111
aS'Retrospective Studies'
p91112
aS'Rural Population'
p91113
aS'Treatment Outcome'
p91114
aS'Uganda/epidemiology'
p91115
aS'Young Adult'
p91116
asS'EDAT'
p91117
S'2009/07/16 09:00'
p91118
sS'SO'
p91119
S'J Trop Pediatr. 2010 Feb;56(1):43-52. doi: 10.1093/tropej/fmp054. Epub 2009 Jul 13.'
p91120
sS'SB'
p91121
S'IM'
p91122
sS'PMID'
p91123
S'19602489'
p91124
sS'PST'
p91125
S'ppublish'
p91126
stRp91127
a.